Admission	O
Date	O
:	O
[	O
**	O
2192-2-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2192-3-6	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2122-6-18	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
ICU	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
a	O
69	O
year	O
-	O
old	O
gentleman	O
with	O
an	O
extensive	O
tobacco	O
history	O
complaining	O
of	O
fever	O
to	O
102	O
,	O
productive	O
cough	O
and	O
progressive	O
shortness	O
of	O
breath	O
for	O
two	O
to	O
three	O
days	O
.	O
The	O
patient	O
also	O
commented	O
on	O
associated	O
malaise	O
and	O
diarrhea	O
for	O
two	O
episodes	O
.	O
The	O
patient	O
denied	O
sick	O
contacts	O
,	O
chest	O
pain	O
,	O
did	O
report	O
receiving	O
the	O
flu	O
vaccine	O
this	O
year	O
and	O
has	O
no	O
history	O
of	O
prior	O
hospitalizations	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
flares	O
,	O
pneumonias	O
or	O
any	O
other	O
pulmonary	O
complications	O
.	O
The	O
patient	O
denies	O
recent	O
travel	O
,	O
lower	O
extremity	O
trauma	O
,	O
calf	O
pain	O
or	O
any	O
other	O
risk	O
factors	O
for	O
pulmonary	O
embolus	O
.	O
Review	O
of	O
systems	O
was	O
otherwise	O
negative	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Hypertension	O
.	O
2	O
.	O
Fast	O
heart	O
rate	O
.	O
3	O
.	O
Increased	O
cholesterol	O
.	O
4	O
.	O
Benign	O
prostatic	O
hypertrophy	O
.	O
5	O
.	O
Status	O
post	O
appendectomy	O
.	O
6	O
.	O
Emphysema	O
without	O
steroid	O
or	O
inhaler	O
use	O
.	O
ALLERGIES	O
:	O
Penicillin	I-Drug
,	O
which	O
produces	O
a	O
rash	I-Ade
.	O
MEDICATIONS	O
;	O
1	O
.	O
Toprol	I-Drug
100	O
.	O
2	O
.	O
Lipitor	I-Drug
10	O
q.d.	O
3	O
.	O
Cardura	I-Drug
2	O
q.d.	O
SOCIAL	O
HISTORY	O
:	O
Significant	O
for	O
greater	O
then	O
100	O
pack	O
years	O
tobacco	O
history	O
.	O
Occasional	O
ethanol	O
use	O
.	O
PHYSICAL	O
EXAMINATION	O
ON	O
ADMISSION	O
:	O
Temperature	O
101.8	O
.	O
Heart	O
rate	O
95	O
.	O
Blood	O
pressure	O
175/76	O
.	O
Respiratory	O
rate	O
23	O
.	O
Satting	O
88	O
%	O
on	O
room	O
air	O
.	O
97	O
%	O
on	O
2	O
liters	O
.	O
In	O
general	O
,	O
alert	O
and	O
oriented	O
times	O
three	O
,	O
mild	O
distress	O
,	O
shortness	O
of	O
breath	O
with	O
speech	O
.	O
HEENT	O
pupils	O
are	O
equal	O
,	O
round	O
and	O
reactive	O
to	O
light	O
.	O
Bilateral	O
injected	O
sclera	O
.	O
Flat	O
JVP	O
.	O
Lungs	O
with	O
diffuse	O
rhonchi	O
,	O
expiratory	O
wheeze	O
and	O
delayed	O
expiration	O
.	O
Cardiovascular	O
regular	O
rate	O
and	O
rhythm	O
.	O
S1	O
and	O
S2	O
with	O
distant	O
heart	O
sounds	O
.	O
Abdomen	O
was	O
soft	O
,	O
obese	O
,	O
nontender	O
,	O
nondistended	O
with	O
normoactive	O
bowel	O
sounds	O
.	O
Extremities	O
were	O
without	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
and	O
were	O
warm	O
,	O
dry	O
and	O
pink	O
.	O
PERTINENT	O
DIAGNOSTIC	O
STUDIES	O
ON	O
ADMISSION	O
:	O
Normal	O
CBC	O
with	O
normal	O
differential	O
with	O
white	O
blood	O
cell	O
count	O
.	O
Normal	O
electrolytes	O
.	O
Blood	O
cultures	O
that	O
were	O
sent	O
remain	O
negative	O
.	O
Chest	O
x-ray	O
with	O
emphysematous	O
changes	O
without	O
evidence	O
of	O
acute	O
cardiopulmonary	O
disease	O
.	O
CT	O
angiogram	O
with	O
diffuse	O
emphysematous	O
changes	O
without	O
evidence	O
of	O
infiltrate	O
,	O
effusion	O
or	O
pulmonary	O
embolus	O
.	O
Initial	O
electrocardiogram	O
normal	O
sinus	O
rhythm	O
without	O
evidence	O
of	O
acute	O
ischemic	O
changes	O
.	O
HOSPITAL	O
COURSE	O
:	O
1	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
exacerbation	O
:	O
The	O
patient	O
was	O
initially	O
admitted	O
to	O
the	O
General	O
Medical	O
Service	O
for	O
a	O
presumed	O
chronic	O
obstructive	O
pulmonary	O
disease	O
exacerbation	O
in	O
the	O
setting	O
of	O
a	O
upper	O
respiratory	O
infection	O
with	O
negative	O
DFAs	O
for	O
influenza	O
A	O
and	O
B.	O
Subsequently	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Intensive	O
Care	O
Unit	O
and	O
intubated	O
for	O
hypercapnic	O
respiratory	O
failure	O
and	O
was	O
continually	O
treated	O
with	O
Levofloxacin	I-Drug
,	O
steroids	I-Drug
and	O
nebulized	O
Albuterol	I-Drug
and	O
Atrovent	I-Drug
for	O
this	O
chronic	B-Reason
obstructive	I-Reason
pulmonary	O
disease	O
exacerbation	O
with	O
full	O
ventilatory	O
support	O
.	O
Several	O
days	O
into	O
the	O
Intensive	O
Care	O
Unit	O
course	O
bile	O
cultures	O
for	O
influenza	O
came	O
back	O
positive	O
.	O
The	O
patient	O
completed	O
a	O
course	O
of	O
Levofloxacin	I-Drug
and	O
was	O
briefly	O
extubated	O
for	O
two	O
to	O
three	O
days	O
with	O
recurrent	O
respiratory	O
failure	O
,	O
reintubated	O
and	O
eventually	O
underwent	O
tracheostomy	O
.	O
On	O
the	O
day	O
of	O
discharge	O
the	O
patient	O
's	O
chest	O
x-ray	O
remained	O
clear	O
.	O
The	O
patient	O
was	O
afebrile	O
and	O
tolerating	O
recurrent	O
spontaneous	O
breathing	O
trials	O
on	O
trach	O
mask	O
with	O
intermittent	O
requirement	O
of	O
pressure	O
support	O
ventilation	O
.	O
Sputum	O
samples	O
sent	O
from	O
the	O
day	O
of	O
discharge	O
revealed	O
gram	O
positive	O
cocci	O
without	O
evidence	O
of	O
infiltrate	O
on	O
chest	O
x-ray	O
,	O
evidence	O
of	O
a	O
fever	O
,	O
stable	O
white	O
blood	O
cell	O
count	O
and	O
improved	O
respiratory	O
status	O
.	O
2	O
.	O
Cardiovascular	O
:	O
The	O
patient	O
developed	O
positive	O
intubation	O
hypotension	O
and	O
intermittently	O
required	O
pressures	O
for	O
support	O
of	O
his	O
blood	O
pressure	O
throughout	O
his	O
Intensive	O
Care	O
Unit	O
course	O
.	O
The	O
patient	O
also	O
developed	O
rapid	O
atrial	I-Reason
fibrillation	O
during	O
his	O
Emergency	O
Department	O
course	O
that	O
was	O
initially	O
treated	O
with	O
Diltiazem	I-Drug
.	O
The	O
patient	O
was	O
placed	O
on	O
Diltiazem	I-Drug
drip	O
and	O
required	O
intermittent	O
boluses	O
of	O
Diltiazem	I-Drug
throughout	O
his	O
Intensive	O
Care	O
Unit	O
course	O
.	O
After	O
extubation	O
the	O
patient	O
was	O
switched	O
to	O
po	O
Metoprolol	I-Drug
of	O
which	O
he	O
was	O
maintained	O
as	O
an	O
outpatient	O
for	O
his	O
known	O
history	O
of	O
paroxysmal	B-Reason
atrial	I-Reason
fibrillation	I-Reason
and	O
supraventricular	I-Reason
tachycardia	O
.	O
At	O
the	O
time	O
of	O
discharge	O
the	O
patient	O
had	O
been	O
without	O
pressers	I-Drug
for	O
several	O
days	O
and	O
had	O
his	O
heart	O
rate	O
well	O
controlled	O
on	O
b.i.d.	O
Metoprolol	I-Drug
.	O
The	O
patient	O
's	O
outpatient	O
cardiologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1147	O
**	O
]	O
was	O
involved	O
in	O
the	O
care	O
of	O
this	O
patient	O
on	O
a	O
day	O
to	O
day	O
basis	O
and	O
frequently	O
added	O
input	O
to	O
the	O
care	O
of	O
his	O
supraventricular	O
tachycardia	O
.	O
3	O
.	O
Gastrointestinal	O
bleed	O
:	O
After	O
intubation	O
and	O
placement	O
of	O
a	O
nasogastric	O
tube	O
the	O
patient	O
was	O
noted	O
to	O
have	O
evidence	O
of	O
an	O
upper	O
gastrointestinal	O
bleed	O
.	O
The	O
Gastroenterology	O
Service	O
was	O
consulted	O
and	O
performed	O
an	O
endoscopy	O
and	O
discovered	O
events	O
of	O
trauma	O
from	O
the	O
nasogastric	O
tube	O
that	O
was	O
thought	O
to	O
be	O
the	O
cause	O
of	O
this	O
self	O
limited	O
upper	O
gastrointestinal	O
bleed	O
while	O
on	O
anticoagulation	I-Drug
for	O
the	O
paroxysmal	B-Reason
atrial	I-Reason
fibrillation	I-Reason
.	O
The	O
patient	O
was	O
without	O
evidence	O
of	O
gastrointestinal	O
bleed	O
throughout	O
the	O
remainder	O
of	O
his	O
hospitalization	O
.	O
4	O
.	O
Hematuria	O
:	O
During	O
the	O
patient	O
's	O
Intensive	O
Care	O
Unit	O
course	O
the	O
patient	O
developed	O
gross	O
hematuria	O
in	O
the	O
setting	O
of	O
continuous	O
indwelling	O
Foley	O
catheters	O
.	O
This	O
hematuria	O
was	O
associated	O
with	O
a	O
brief	O
drop	O
in	O
the	O
patient	O
's	O
hematocrit	O
,	O
which	O
required	O
2	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
for	O
transfusion	O
.	O
After	O
continuous	O
bladder	O
irrigation	O
the	O
hematuria	O
resolved	O
and	O
the	O
patient	O
was	O
without	O
such	O
findings	O
throughout	O
the	O
remainder	O
of	O
his	O
hospital	O
course	O
.	O
5	O
.	O
Fluid	O
,	O
electrolytes	O
and	O
nutrition	O
:	O
The	O
patient	O
was	O
maintained	O
on	O
tube	O
feeds	O
throughout	O
his	O
Intensive	O
Care	O
Unit	O
stay	O
and	O
received	O
a	O
percutaneous	O
feeding	O
tube	O
placement	O
and	O
was	O
tolerating	O
tube	O
feeds	O
at	O
goal	O
at	O
the	O
time	O
of	O
discharge	O
.	O
CONDITION	O
ON	O
DISCHARGE	O
:	O
Fair	O
.	O
DISCHARGE	O
STATUS	O
:	O
To	O
rehab	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Respiratory	O
failure	O
.	O
2	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
exacerbation	O
.	O
3	O
.	O
Influenza	O
.	O
4	O
.	O
Paroxysmal	O
supraventricular	O
tachycardia	O
.	O
5	O
.	O
Atrial	O
fibrillation	O
.	O
6	O
.	O
Hematuria	O
.	O
7	O
.	O
Emphysema	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
1	O
.	O
Metoprolol	I-Drug
.	O
2	O
.	O
Colace	I-Drug
.	O
3	O
.	O
Bisacodyl	I-Drug
.	O
4	O
.	O
Nicotine	I-Drug
patch	O
.	O
5	O
.	O
Doxazosin	I-Drug
.	O
6	O
.	O
Albuterol	I-Drug
.	O
7	O
.	O
Atrovent	I-Drug
8	O
.	O
Fluticasone	I-Drug
FOLLOW	O
UP	O
PLANS	O
:	O
The	O
patient	O
is	O
to	O
contact	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1147	O
**	O
]	O
for	O
follow	O
up	O
within	O
one	O
to	O
two	O
weeks	O
of	O
discharge	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
12175	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
37596	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Name8	O
(	O
MD	O
)	O
28700	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2192-3-6	O
**	O
]	O
12:24	O
T	O
:	O
[	O
**	O
2192-3-6	O
**	O
]	O
12:31	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
97945	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2198-9-5	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2198-9-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2129-6-11	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Ciprofloxacin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3507	O
**	O
]	O
Chief	O
Complaint	O
:	O
Respiratory	O
Distress	O
,	O
Fever	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
HPI	O
-	O
This	O
is	O
a	O
69	O
y	O
/	O
o	O
Russian	O
-	O
speaking	O
male	O
with	O
PMH	O
significant	O
for	O
metastatic	O
renal	O
CA	O
to	O
brain	O
and	O
lungs	O
,	O
s	O
/	O
p	O
LLL	O
lobectomy	O
,	O
s	O
/	O
p	O
TURP	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
prostate	O
CA	O
,	O
colon	O
CA	O
s	O
/	O
p	O
colectomy	O
,	O
who	O
presents	O
to	O
the	O
ED	O
from	O
NH	O
with	O
respiratory	O
distress	O
.	O
History	O
is	O
limited	O
by	O
patient	O
's	O
non-verbal	O
state	O
and	O
wife	O
's	O
limited	O
English	O
.	O
Per	O
wife	O
,	O
patient	O
has	O
been	O
in	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
since	O
[	O
**	O
5	O
-	O
22	O
**	O
]	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
CVA	O
involving	O
the	O
right	O
extremities	O
.	O
His	O
mental	O
status	O
has	O
been	O
poor	O
at	O
baseline	O
and	O
has	O
increasingly	O
worsened	O
to	O
a	O
non-verbal	O
state	O
approx	O
one	O
month	O
ago	O
.	O
Beginning	O
two	O
nights	O
ago	O
,	O
the	O
patient	O
was	O
noted	O
to	O
have	O
some	O
respiratory	O
distress	O
,	O
requiring	O
oxygen	I-Drug
and	O
was	O
started	O
on	O
Augmentin	I-Drug
for	O
a	B-Reason
presumed	I-Reason
PNA	I-Reason
.	O
However	O
,	O
his	O
respiratory	O
status	O
did	O
not	O
improve	O
and	O
was	O
noted	O
to	O
have	O
a	O
low	O
-	O
grade	O
temp	O
of	O
100.9	O
,	O
RR	O
30	O
,	O
HR	O
140	O
,	O
BP	O
155/88	O
,	O
SaO2	O
94	O
%	O
on	O
supplemental	O
O2	I-Drug
(	O
unknown	O
amount	O
)	O
,	O
prompting	O
the	O
NH	O
to	O
send	O
the	O
patient	O
to	O
the	O
ED	O
early	O
this	O
morning	O
.	O
.	O
In	O
the	O
ED	O
,	O
he	O
was	O
noted	O
to	O
have	O
a	O
Tc	O
of	O
103.8	O
(	O
rectally	O
)	O
,	O
HR	O
134	O
,	O
BP	O
124/74	O
,	O
RR	O
42	O
,	O
SaO2	O
88	O
%	O
/	O
NRB	O
.	O
His	O
labs	O
were	O
notable	O
for	O
a	O
WBC	O
of	O
27.9	O
(	O
97	O
%	O
N	O
,	O
no	O
bands	O
)	O
and	O
lactate	O
of	O
2	O
.	O
He	O
received	O
combivent	I-Drug
nebs	O
,	O
1	O
gm	O
tylenol	I-Drug
pr	O
,	O
500	O
cc	O
of	O
NS	I-Drug
bolus	O
,	O
1	O
gm	O
ceftaz	I-Drug
,	O
500	O
mg	O
IV	O
flagyl	I-Drug
,	O
and	O
1	O
gm	O
of	O
vanc	I-Drug
.	O
His	O
sats	O
improved	O
while	O
in	O
the	O
ED	O
and	O
he	O
was	O
weaned	O
down	O
to	O
4	O
L	O
NC	O
.	O
ABG	O
on	O
4L	O
was	O
7.49	O
/	O
34/82/31	O
.	O
Patient	O
was	O
admitted	O
to	O
the	O
MICU	O
and	O
admitted	O
on	O
broad	O
spectrum	O
antibiotics	I-Drug
.	O
Discussion	O
was	O
held	O
with	O
family	O
and	O
patient	O
was	O
made	O
DNR	O
/	O
DNI	O
/	O
no	O
pressors	I-Drug
.	O
Past	O
Medical	O
History	O
:	O
PMH	O
-	O
1	O
.	O
Metastatic	B-Reason
renal	I-Reason
CA	I-Reason
-	O
s	O
/	O
p	O
right	O
nephrectomy	O
17	O
yrs	O
ago	O
;	O
s	O
/	O
p	O
immunotherapy	I-Drug
in	O
[	O
**	O
2193	O
**	O
]	O
,	O
followed	O
at	O
[	O
**	O
Hospital1	O
336	O
**	O
]	O
.	O
Mets	O
to	O
b	O
/	O
l	O
lungs	O
and	O
brain	O
,	O
follows	O
with	O
neuro	O
-	O
onc	O
at	O
[	O
**	O
Hospital1	O
336	O
**	O
]	O
.	O
2	O
.	O
s	O
/	O
p	O
LLL	O
lobectomy	O
-	O
?	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
mets	O
from	O
renal	O
CA	O
3	O
.	O
s	O
/	O
p	O
prostate	O
resection	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
prostate	O
CA	O
-	O
[	O
**	O
2191	O
**	O
]	O
4	O
.	O
s	O
/	O
p	O
CVA	O
[	O
**	O
5	O
-	O
22	O
**	O
]	O
,	O
affecting	O
right	O
side	O
5	O
.	O
NIDDM	O
6	O
.	O
COPD	O
7	O
.	O
A	O
fib	O
8	O
.	O
Colon	O
ca	O
,	O
dx	O
[	O
**	O
2197	O
**	O
]	O
-	O
s	O
/	O
p	O
colectomy	O
Social	O
History	O
:	O
SH	O
-	O
Lives	O
at	O
[	O
**	O
Location	O
**	O
]	O
since	O
CVA	O
[	O
**	O
5	O
-	O
22	O
**	O
]	O
.	O
Russian	O
-	O
speaking	O
only	O
.	O
Former	O
smoker	O
,	O
quit	O
in	O
[	O
**	O
2191	O
**	O
]	O
.	O
Occasional	O
EtOH	O
,	O
no	O
illicits	O
.	O
Wife	O
lives	O
in	O
area	O
,	O
has	O
children	O
living	O
outside	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
.	O
.	O
Family	O
History	O
:	O
.	O
FH	O
-	O
NC	O
Physical	O
Exam	O
:	O
VS	O
:	O
Tc	O
,	O
BP	O
,	O
HR	O
,	O
RR	O
,	O
SaO2	O
98	O
%	O
/	O
3L	O
NC	O
General	O
:	O
Non-verbal	O
elderly	O
male	O
in	O
NAD	O
.	O
Unable	O
to	O
clear	O
secretions	O
and	O
copious	O
secretions	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
food	O
noted	O
.	O
HEENT	O
:	O
NC	O
/	O
AT	O
,	O
PERRL	O
,	O
able	O
to	O
track	O
movements	O
with	O
eyes	O
.	O
Anicteric	O
sclerae	O
.	O
MM	O
dry	O
.	O
Food	O
noted	O
in	O
mouth	O
.	O
Neck	O
:	O
supple	O
,	O
no	O
JVD	O
noted	O
Chest	O
:	O
Diffuse	O
rhonchi	O
b	O
/	O
l	O
,	O
with	O
rales	O
in	O
RLL	O
.	O
CV	O
:	O
RRR	O
,	O
s1	O
s2	O
normal	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
Abd	O
:	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
minimal	O
BS	O
.	O
Midline	O
abdominal	O
scar	O
noted	O
.	O
Ext	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
,	O
cool	O
extremities	O
.	O
Pulses	O
2	O
+	O
b	O
/	O
l	O
Neuro	O
:	O
Non-verbal	O
,	O
moves	O
left	O
side	O
freely	O
,	O
withdraws	O
to	O
pain	O
,	O
tracks	O
movements	O
purposefully	O
with	O
eyes	O
.	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2198-9-8	O
**	O
]	O
12:28	O
AM	O
BLOOD	O
calTIBC	O
-	O
144	O
*	O
Ferritn	O
-	O
1183	O
*	O
TRF	O
-	O
111	O
*	O
[	O
**	O
2198-9-5	O
**	O
]	O
06:15	O
AM	O
BLOOD	O
Glucose	O
-	O
135	O
*	O
UreaN	O
-	O
22	O
*	O
Creat	O
-	O
0.5	O
Na	O
-	O
147	O
*	O
K	O
-	O
3.3	O
Cl	O
-	O
106	O
HCO3	O
-	O
29	O
AnGap	O
-	O
15	O
[	O
**	O
2198-9-11	O
**	O
]	O
04:40	O
AM	O
BLOOD	O
Glucose	O
-	O
118	O
*	O
UreaN	O
-	O
44	O
*	O
Creat	O
-	O
2.2	O
*	O
Na	O
-	O
145	O
K	O
-	O
4.2	O
Cl	O
-	O
109	O
*	O
HCO3	O
-	O
27	O
AnGap	O
-	O
13	O
[	O
**	O
2198-9-13	O
**	O
]	O
04:58	O
AM	O
BLOOD	O
Glucose	O
-	O
187	O
*	O
UreaN	O
-	O
53	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
141	O
K	O
-	O
4.0	O
Cl	O
-	O
102	O
HCO3	O
-	O
27	O
AnGap	O
-	O
16	O
[	O
**	O
2198-9-13	O
**	O
]	O
04:58	O
AM	O
BLOOD	O
WBC	O
-	O
19.0	O
*	O
RBC	O
-	O
3.32	O
*	O
Hgb	O
-	O
8.7	O
*	O
Hct	O
-	O
27.0	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
26.3	O
*	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
580	O
*	O
[	O
**	O
2198-9-5	O
**	O
]	O
06:15	O
AM	O
WBC	O
-	O
27.9	O
*	O
RBC	O
-	O
4.40	O
*	O
HGB	O
-	O
12.0	O
*	O
HCT	O
-	O
36.4	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
27.4	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
17.1	O
*	O
.	O
[	O
**	O
2198-9-9	O
**	O
]	O
URINE	O
URINE	O
CULTURE	O
-	O
FINAL	O
{	O
YEAST	O
}	O
INPATIENT	O
[	O
**	O
2198-9-6	O
**	O
]	O
SPUTUM	O
GRAM	O
STAIN	O
-	O
FINAL	O
;	O
RESPIRATORY	O
CULTURE	O
-	O
FINAL	O
{	O
YEAST	O
,	O
STAPH	O
AUREUS	O
COAG	O
+	O
}	O
INPATIENT	O
[	O
**	O
2198-9-5	O
**	O
]	O
BLOOD	O
CULTURE	O
AEROBIC	O
BOTTLE	O
-	O
FINAL	O
;	O
ANAEROBIC	O
BOTTLE	O
-	O
FINAL	O
INPATIENT	O
[	O
**	O
2198-9-5	O
**	O
]	O
BLOOD	O
CULTURE	O
AEROBIC	O
BOTTLE	O
-	O
FINAL	O
{	O
STAPHYLOCOCCUS	O
,	O
COAGULASE	O
NEGATIVE	O
}	O
;	O
ANAEROBIC	O
BOTTLE	O
-	O
FINAL	O
INPATIENT	O
[	O
**	O
2198-9-5	O
**	O
]	O
URINE	O
URINE	O
CULTURE	O
-	O
FINAL	O
EMERGENCY	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
RENAL	O
ULTRASOUND	O
:	O
The	O
patient	O
is	O
status	O
post	O
right	O
nephrectomy	O
.	O
The	O
left	O
kidney	O
measures	O
13.4	O
cm	O
.	O
The	O
calyces	O
are	O
mildly	O
prominent	O
throughout	O
the	O
left	O
kidney	O
,	O
however	O
,	O
there	O
is	O
no	O
frank	O
evidence	O
of	O
hydronephrosis	O
.	O
No	O
stones	O
or	O
masses	O
are	O
identified	O
.	O
The	O
bladder	O
is	O
catheterized	O
and	O
empty	O
.	O
.	O
Video	O
Swallow	O
:	O
FINDINGS	O
:	O
Video	O
oropharyngeal	O
fluoroscopic	O
swallowing	O
evaluation	O
was	O
performed	O
in	O
conjunction	O
with	O
speech	O
and	O
swallow	O
pathology	O
.	O
Patient	O
was	O
administered	O
various	O
consistencies	O
of	O
barium	O
including	O
thin	O
,	O
nectar	O
,	O
thick	O
,	O
and	O
ground	O
cookie	O
.	O
Posterior	O
oral	O
transit	O
was	O
moderately	O
delayed	O
.	O
In	O
addition	O
,	O
swallowing	O
initiation	O
was	O
severely	O
impaired	O
with	O
significantly	O
delayed	O
swallowing	O
initiation	O
to	O
large	O
boluses	O
.	O
When	O
swallow	O
was	O
initiated	O
,	O
there	O
was	O
some	O
adequate	O
epiglottic	O
deflection	O
,	O
and	O
laryngeal	O
valve	O
closure	O
.	O
However	O
,	O
there	O
was	O
silent	O
aspiration	O
to	O
thin	O
liquids	O
.	O
The	O
patient	O
had	O
difficulties	O
following	O
commands	O
during	O
the	O
examination	O
,	O
and	O
would	O
not	O
take	O
cookie	O
or	O
straw	O
.	O
IMPRESSION	O
:	O
Severe	O
swallow	O
initiation	O
delay	O
with	O
aspiration	O
to	O
thins	O
.	O
For	O
further	O
details	O
,	O
please	O
consult	O
the	O
speech	O
and	O
swallow	O
pathology	O
note	O
.	O
.	O
CT	O
Head	O
:	O
CLINICAL	O
INDICATION	O
:	O
Metastatic	O
renal	O
cell	O
carcinoma	O
with	O
somnolence	O
,	O
assess	O
for	O
intracranial	O
hemorrhage	O
.	O
There	O
is	O
a	O
large	O
hyperdense	O
lesion	O
involving	O
the	O
left	O
frontal	O
lobe	O
near	O
the	O
convexity	O
measuring	O
4.2	O
x	O
4	O
cm	O
and	O
surrounded	O
by	O
vasogenic	O
edema	O
,	O
with	O
mass	O
effect	O
seen	O
over	O
the	O
left	O
lateral	O
ventricle	O
.	O
There	O
is	O
minimal	O
midline	O
shift	O
to	O
the	O
right	O
.	O
The	O
edema	O
extends	O
inferiorly	O
into	O
the	O
left	O
frontoparietal	O
white	O
matter	O
and	O
the	O
left	O
temporal	O
lobe	O
.	O
The	O
ventricular	O
system	O
is	O
not	O
dilated	O
.	O
There	O
is	O
no	O
intraparenchymal	O
or	O
subdural	O
hemorrhage	O
.	O
The	O
fourth	O
ventricle	O
remains	O
in	O
the	O
midline	O
.	O
There	O
is	O
heterogeneous	O
hyperdense	O
lesion	O
abutting	O
the	O
right	O
frontal	O
aspect	O
of	O
the	O
calvarium	O
along	O
the	O
midline	O
.	O
This	O
could	O
represent	O
volume	O
averaging	O
.	O
No	O
lytic	O
lesions	O
are	O
identified	O
.	O
Chronic	O
mucosal	O
thickening	O
is	O
seen	O
within	O
the	O
paranasal	O
sinuses	O
.	O
.	O
IMPRESSION	O
:	O
4	O
-	O
cm	O
hyperdense	O
necrotic	O
mass	O
lesion	O
involving	O
the	O
left	O
frontal	O
lobe	O
surrounded	O
by	O
significant	O
vasogenic	O
edema	O
and	O
associated	O
with	O
sulcal	O
effacement	O
and	O
surrounding	O
mass	O
effect	O
as	O
noted	O
above	O
.	O
This	O
is	O
most	O
likely	O
metastatic	O
in	O
nature	O
given	O
the	O
history	O
of	O
renal	O
cell	O
cancer	O
.	O
No	O
intraparenchymal	O
hemorrhage	O
was	O
seen	O
.	O
.	O
CT	O
Chest	O
:	O
Multidetector	O
CT	O
of	O
the	O
chest	O
was	O
performed	O
without	O
intravenous	O
or	O
oral	O
contrast	O
administration	O
.	O
Images	O
are	O
presented	O
for	O
display	O
in	O
the	O
axial	O
plane	O
at	O
both	O
5	O
-	O
mm	O
and	O
1.25	O
-	O
mm	O
collimation	O
.	O
.	O
There	O
is	O
near	O
complete	O
opacification	O
of	O
the	O
remaining	O
portion	O
of	O
the	O
left	O
lung	O
with	O
only	O
a	O
small	O
amount	O
of	O
residual	O
aerated	O
lung	O
at	O
the	O
apical	O
portion	O
.	O
Assessment	O
of	O
the	O
central	O
airways	O
demonstrates	O
complete	O
obstruction	O
of	O
the	O
left	O
main	O
bronchus	O
just	O
beyond	O
its	O
origin	O
.	O
The	O
contents	O
within	O
the	O
obstructed	O
bronchus	O
range	O
from	O
fluid	O
to	O
soft	O
tissue	O
attenuation	O
.	O
Superiorly	O
,	O
there	O
are	O
some	O
areas	O
of	O
consolidation	O
and	O
ground	O
-	O
glass	O
superimposed	O
upon	O
underlying	O
areas	O
of	O
emphysema	O
,	O
but	O
beginning	O
in	O
the	O
mid	O
portion	O
of	O
the	O
left	O
lung	O
,	O
opacified	O
lung	O
is	O
relatively	O
homogeneous	O
without	O
air	O
bronchograms	O
.	O
An	O
area	O
of	O
curvilinear	O
calcification	O
is	O
present	O
in	O
the	O
lower	O
left	O
hemithorax	O
posteriorly	O
and	O
there	O
are	O
surgical	O
clips	O
present	O
in	O
the	O
paraaortic	O
and	O
perihilar	O
regions	O
.	O
.	O
The	O
left	O
lobe	O
of	O
the	O
thyroid	O
gland	O
is	O
markedly	O
enlarged	O
and	O
heterogeneous	O
.	O
The	O
superior	O
portion	O
of	O
the	O
enlarged	O
lobe	O
is	O
not	O
completely	O
imaged	O
on	O
this	O
scan	O
,	O
and	O
it	O
is	O
difficult	O
to	O
exclude	O
adjacent	O
areas	O
of	O
lymphadenopathy	O
in	O
the	O
left	O
neck	O
as	O
well	O
.	O
The	O
enlarged	O
thyroid	O
gland	O
results	O
in	O
rightward	O
displacement	O
and	O
coronal	O
narrowing	O
of	O
the	O
trachea	O
which	O
is	O
narrowed	O
to	O
approximately	O
8	O
mm	O
at	O
the	O
thoracic	O
inlet	O
level	O
.	O
There	O
is	O
bulky	O
mediastinal	O
lymphadenopathy	O
on	O
both	O
sides	O
of	O
midline	O
,	O
with	O
the	O
right	O
paratracheal	O
lymph	O
node	O
measuring	O
up	O
to	O
3.6	O
x	O
2.7	O
cm	O
and	O
a	O
left	O
prevascular	O
node	O
measuring	O
up	O
to	O
2.5	O
x	O
3.0	O
cm	O
.	O
A	O
bulky	O
left	O
lower	O
paratracheal	O
lymph	O
node	O
measures	O
3.1	O
x	O
2.0	O
cm	O
.	O
The	O
left	O
hilum	O
is	O
difficult	O
to	O
assess	O
without	O
intravenous	O
contrast	O
but	O
there	O
is	O
probable	O
left	O
hilar	O
lymphadenopathy	O
as	O
well	O
.	O
.	O
There	O
is	O
left	O
-	O
sided	O
pleural	O
thickening	O
contiguous	O
with	O
the	O
area	O
of	O
homogeneous	O
opacification	O
in	O
the	O
left	O
lower	O
lung	O
region	O
.	O
This	O
is	O
contiguous	O
with	O
an	O
area	O
of	O
chest	O
wall	O
destruction	O
involving	O
a	O
lower	O
left	O
lateral	O
rib	O
which	O
is	O
partially	O
destroyed	O
by	O
the	O
mass	O
.	O
Enlarged	O
nodes	O
are	O
also	O
present	O
in	O
the	O
lower	O
left	O
paraaortic	O
region	O
and	O
in	O
the	O
left	O
extrapleural	O
space	O
.	O
.	O
Within	O
the	O
imaged	O
portion	O
of	O
the	O
upper	O
abdomen	O
,	O
there	O
are	O
bulky	O
lymph	O
node	O
masses	O
which	O
are	O
incompletely	O
imaged	O
on	O
this	O
study	O
.	O
These	O
are	O
in	O
the	O
region	O
of	O
the	O
celiac	O
axis	O
anterior	O
to	O
the	O
aorta	O
,	O
measuring	O
up	O
to	O
approximately	O
5.5	O
and	O
6.4	O
cm	O
in	O
greatest	O
dimension	O
.	O
A	O
left	O
anterior	O
peridiaphragmatic	O
enlarged	O
node	O
is	O
present	O
as	O
well	O
as	O
left	O
retroperitoneal	O
node	O
enlargement	O
.	O
The	O
adrenal	O
glands	O
are	O
incompletely	O
imaged	O
on	O
this	O
study	O
.	O
Calcified	O
gallstone	O
is	O
observed	O
within	O
the	O
gallbladder	O
.	O
No	O
definite	O
lesions	O
are	O
seen	O
within	O
the	O
liver	O
but	O
lack	O
of	O
intravenous	O
contrast	O
limits	O
assessment	O
.	O
.	O
As	O
noted	O
,	O
the	O
trachea	O
is	O
compressed	O
and	O
displaced	O
by	O
the	O
thyroid	O
mass	O
.	O
Fluid	O
level	O
within	O
the	O
intrathoracic	O
trachea	O
is	O
probably	O
due	O
to	O
retained	O
secretions	O
.	O
Within	O
the	O
right	O
lung	O
,	O
there	O
are	O
several	O
small	O
pulmonary	O
nodules	O
present	O
,	O
some	O
of	O
which	O
are	O
well	O
circumscribed	O
,	O
and	O
others	O
of	O
which	O
are	O
more	O
poorly	O
defined	O
.	O
The	O
largest	O
individual	O
nodule	O
is	O
a	O
poorly	O
defined	O
lateral	O
segment	O
right	O
middle	O
lobe	O
nodule	O
measuring	O
10	O
mm	O
on	O
image	O
31	O
of	O
series	O
3	O
.	O
Respiratory	O
motion	O
limits	O
assessment	O
of	O
the	O
right	O
lower	O
lobe	O
and	O
right	O
middle	O
lobe	O
.	O
.	O
Skeletal	O
structures	O
reveal	O
partial	O
destruction	O
of	O
the	O
left	O
seventh	O
lateral	O
rib	O
as	O
described	O
above	O
.	O
Post-thoracotomy	O
changes	O
are	O
present	O
just	O
above	O
this	O
level	O
.	O
Healed	O
lower	O
right	O
anterior	O
rib	O
fractures	O
are	O
noted	O
without	O
definite	O
associated	O
lytic	O
lesions	O
.	O
.	O
Finally	O
,	O
incidental	O
note	O
is	O
made	O
of	O
a	O
calcified	O
granuloma	O
in	O
the	O
periphery	O
of	O
the	O
right	O
middle	O
lobe	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Complete	O
obstruction	O
left	O
main	O
bronchus	O
.	O
Although	O
possibly	O
due	O
to	O
retained	O
secretions	O
,	O
obstructing	O
endobronchial	O
lesion	O
is	O
likely	O
in	O
this	O
patient	O
with	O
history	O
of	O
renal	O
cell	O
carcinoma	O
.	O
Correlative	O
bronchoscopy	O
would	O
be	O
helpful	O
.	O
2	O
.	O
Postobstructive	O
collapse	O
/	O
consolidation	O
in	O
left	O
upper	O
lobe	O
(	O
status	O
post	O
left	O
lower	O
lobectomy	O
)	O
.	O
Associated	O
soft	O
tissue	O
mass	O
with	O
dystrophic	O
calcifications	O
,	O
contiguous	O
or	O
adjacent	O
to	O
chest	O
wall	O
mass	O
with	O
destruction	O
of	O
the	O
left	O
lateral	O
seventh	O
rib	O
.	O
3	O
.	O
Bulky	O
mediastinal	O
and	O
upper	O
abdominal	O
lymphadenopathy	O
consistent	O
with	O
metastatic	O
disease	O
.	O
Dedicated	O
contrast	I-Drug
-	O
enhanced	O
CT	O
torso	O
could	O
be	O
considered	O
to	O
more	O
completely	O
characterize	O
the	O
extent	O
of	O
metastatic	O
disease	O
if	O
warranted	O
clinically	O
.	O
4	O
.	O
Marked	O
enlargement	O
of	O
left	O
lobe	O
of	O
thyroid	O
gland	O
with	O
displacement	O
and	O
compression	O
of	O
trachea	O
.	O
It	O
is	O
difficult	O
to	O
exclude	O
adjacent	O
lymphadenopathy	O
in	O
the	O
left	O
neck	O
.	O
5	O
.	O
Left	O
-	O
sided	O
pleural	O
thickening	O
and	O
small	O
amount	O
of	O
pleural	O
fluid	O
.	O
6	O
.	O
Scattered	O
nodules	O
in	O
the	O
right	O
lung	O
,	O
some	O
of	O
which	O
are	O
well	O
defined	O
and	O
likely	O
reflect	O
metastatic	O
foci	O
and	O
others	O
of	O
which	O
are	O
poorly	O
defined	O
and	O
likely	O
are	O
related	O
to	O
the	O
infection	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Hospital	O
course	O
,	O
by	O
Problem	O
:	O
#Respiratory	O
Distress	O
:	O
initially	O
thought	O
to	O
be	O
d	O
/	O
t	O
aspiration	I-Reason
PNA	O
.	O
Was	O
intially	O
treated	O
with	O
broad	O
spectum	O
abx	I-Drug
(	O
Vanc	I-Drug
,	O
CTX	I-Drug
,	O
Flagyl	I-Drug
)	O
.	O
Blood	O
and	O
Urine	O
Cx	O
negative	O
but	O
sputum	O
did	O
grow	O
MRSA	O
.	O
To	O
sort	O
out	O
whether	O
the	O
patient	O
simply	O
had	O
aspiration	O
pnuemonitis	O
vs	O
PNA	O
,	O
a	O
CT	O
scan	O
of	O
the	O
chest	O
was	O
obtained	O
.	O
This	O
showed	O
almost	O
complete	O
collapse	O
of	O
the	O
remaining	O
portion	O
of	O
his	O
left	O
lung	O
from	O
a	O
L	O
mainstem	O
bronchus	O
lesion	O
,	O
concerning	O
for	O
metastatic	O
disease	O
.	O
It	O
also	O
showed	O
narrowing	O
of	O
the	O
trachea	O
to	O
approx	O
8	O
mm	O
from	O
an	O
enlarged	O
left	O
lobe	O
of	O
the	O
thyroid	O
,	O
which	O
is	O
stable	O
in	O
size	O
according	O
to	O
his	O
outside	O
oncologists	O
.	O
Because	O
of	O
renal	O
failure	O
(	O
see	O
below	O
)	O
,	O
the	O
patient	O
was	O
switched	O
to	O
Linezolid	I-Drug
to	O
cover	O
MRSA	I-Reason
;	O
CTX	I-Drug
/	O
Flagyl	I-Drug
were	O
continued	O
to	O
cover	O
for	O
?	O
post-obstructive	O
process	O
.	O
He	O
will	O
complete	O
a	O
today	O
of	O
a	O
10	O
day	O
course	O
of	O
antitiotics	I-Drug
to	O
end	O
on	O
[	O
**	O
9	O
-	O
15	O
**	O
]	O
.	O
.	O
#Acute	O
Renal	O
Failure	O
:	O
during	O
his	O
hosptial	O
course	O
,	O
his	O
Cr	O
rose	O
from	O
a	O
baseline	O
of	O
0.3	O
-	O
0.4	O
to	O
a	O
peak	O
of	O
2.2	O
.	O
Renal	O
U	O
/	O
S	O
negative	O
.	O
Urine	O
indicies	O
not	O
c	O
/	O
w	O
pre-renal	O
state	O
,	O
Urine	O
Eos	O
neagtive	O
.	O
Renal	O
team	O
consulted	O
;	O
felt	O
to	O
be	O
secondary	O
to	O
ATN	I-Ade
,	O
most	O
likely	O
from	O
vancomycin	I-Drug
.	O
Cr	O
now	O
starting	O
to	O
improve	O
(	O
2.0	O
on	O
day	O
of	O
discharge	O
)	O
.	O
.	O
#Cerebral	O
Mets	O
:	O
on	O
CT	O
scan	O
,	O
there	O
was	O
noted	O
to	O
me	O
marked	O
vasogenic	B-Reason
edmema	I-Reason
.	O
The	O
patients	O
DMS	I-Drug
was	O
increased	O
to	O
4	O
mg	O
IV	O
q	O
8	O
hours	O
and	O
should	O
be	O
continued	O
indefinatley	O
as	O
the	O
patient	O
appears	O
to	O
be	O
more	O
awake	O
when	O
on	O
the	O
higher	O
dose	O
.	O
They	O
can	O
be	O
decreased	O
should	O
the	O
patient	O
develop	O
agitation	O
.	O
.	O
#ONC	O
issues	O
/	O
goals	O
of	O
care	O
:	O
after	O
the	O
Left	O
mainstem	O
lesion	O
was	O
discovered	O
,	O
both	O
interventional	O
pulmonary	O
team	O
and	O
radiation	O
team	O
were	O
consulted	O
.	O
Both	O
felt	O
that	O
bronchoscopy	O
and	O
radition	O
therapy	O
would	O
add	O
little	O
to	O
his	O
quality	O
/	O
quantity	O
of	O
life	O
,	O
given	O
his	O
extremely	O
poor	O
performance	O
status	O
and	O
prognosis	O
.	O
His	O
wife	O
was	O
in	O
agreement	O
that	O
he	O
should	O
not	O
receive	O
any	O
invasive	O
procedures	O
in	O
the	O
future	O
.	O
She	O
understood	O
that	O
should	O
the	O
patient	O
develop	O
subsequent	O
respiratory	O
distress	O
,	O
she	O
should	O
not	O
be	O
brought	O
back	O
to	O
the	O
hospital	O
but	O
should	O
be	O
given	O
morphine	I-Drug
and	O
ativan	I-Drug
for	O
comfort	I-Reason
.	O
.	O
#Anemia	O
:	O
high	O
ferrtin	O
c	O
/	O
w	O
Anemia	O
of	O
Chronic	O
Disease	O
.	O
Stable	O
.	O
.	O
#FEN	O
:	O
the	O
patient	O
had	O
speech	O
/	O
swallow	O
evaluation	O
which	O
showed	O
moderate	O
-	O
severe	O
oropharyngeal	O
dysphagia	O
characterized	O
by	O
reduced	O
bolus	O
control	O
and	O
formation	O
as	O
well	O
as	O
a	O
significant	O
pharyngeal	O
swallow	O
initiation	O
delay	O
with	O
mild	O
silent	O
aspiration	O
of	O
thin	O
liquids	O
.	O
The	O
speech	O
/	O
swallow	O
team	O
recommended	O
Nectar	O
thick	O
liquids	O
and	O
pureed	O
solids	O
,	O
PO	O
meds	O
crushed	O
in	O
purees	O
,	O
along	O
with	O
1:1	O
assistance	O
for	O
meals	O
,	O
strict	O
aspiration	O
precautions	O
.	O
Medications	O
on	O
Admission	O
:	O
MEDS	O
(	O
per	O
NH	O
record	O
)	O
1	O
.	O
Lantus	I-Drug
40	O
units	O
qHS	O
,	O
Novolin	I-Drug
SS	O
2	O
.	O
Omeprazole	B-Drug
20	O
mg	O
qd	O
3	O
.	O
Senna	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
4	O
.	O
Klonopin	I-Drug
0.25	O
mg	O
qd	O
5	O
.	O
Percocet	I-Drug
prn	O
6	O
.	O
Augmentin	I-Drug
500	O
mg	O
tid	O
7	O
.	O
Decadron	I-Drug
1	O
mg	O
qod	O
(	O
taper	O
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
inhalation	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
qs	O
inhalation	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
(	O
65	O
)	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Lansoprazole	B-Drug
30	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Ceftazidime	I-Drug
-	O
Dextrose	O
(	O
Iso	O
-	O
osm	O
)	O
1	O
g	O
/	O
50	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
GM	O
Intravenous	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
:	O
course	O
to	O
end	O
[	O
**	O
9	O
-	O
15	O
**	O
]	O
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Metronidazole	I-Drug
in	O
NaCl	O
(	O
Iso	O
-	O
os	O
)	O
500	O
mg	O
/	O
100	O
mL	O
Piggyback	O
Sig	O
:	O
Five	O
Hundred	O
(	O
500	O
)	O
mg	O
Intravenous	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
:	O
course	O
to	O
end	O
[	O
**	O
9	O
-	O
15	O
**	O
]	O
.	O
Disp	O
:	O
*	O
qs	O
mg	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Linezolid	I-Drug
600	O
mg	O
/	O
300	O
mL	O
Parenteral	O
Solution	O
Sig	O
:	O
Six	O
Hundred	O
(	O
600	O
)	O
mg	O
Intravenous	O
every	O
twelve	O
(	O
12	O
)	O
hours	O
:	O
course	O
to	O
end	O
[	O
**	O
9	O
-	O
15	O
**	O
]	O
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
Dexamethasone	B-Drug
Sodium	I-Drug
Phosphate	I-Drug
4	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
gm	O
Injection	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
qs	O
gm	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Insulin	I-Drug
Glargine	O
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Forty	O
Two	O
(	O
42	O
)	O
units	O
Subcutaneous	O
at	O
bedtime	O
:	O
titrate	O
accordingly	O
.	O
Disp	O
:	O
*	O
qs	O
units	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Morphine	I-Drug
Concentrate	O
20	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
cc	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Ativan	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
Respiratory	B-Reason
distress	I-Reason
or	O
anxiety	I-Reason
.	O
Disp	O
:	O
*	O
qs	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnoses	O
:	O
1	O
.	O
Post-obstructive	O
PNA	O
vs	O
Aspiration	O
PNA	O
2	O
.	O
Acute	B-Ade
Renal	I-Ade
Failure	I-Ade
,	O
likely	O
secondary	O
to	O
Vancomycin	I-Drug
3	O
.	O
8	O
mm	O
Tracheal	O
Narrowing	O
secondary	O
to	O
thyroid	O
enlargement	O
4	O
.	O
Complete	O
obstruction	O
left	O
mainstem	O
bronchus	O
;	O
retained	O
secretions	O
vs	O
obstructing	O
endobronchial	O
lesion	O
5	O
.	O
Metastatic	O
chest	O
wall	O
mass	O
with	O
destruction	O
of	O
the	O
left	O
lateral	O
seventh	O
rib	O
6	O
.	O
Renal	O
cell	O
carcinoma	O
with	O
4	O
-	O
cm	O
hyperdense	O
necrotic	O
mass	O
lesion	O
involving	O
the	O
left	O
frontal	O
lobe	O
surrounded	O
by	O
significant	O
vasogenic	O
edema	O
Secondary	O
Diagnoses	O
1	O
.	O
Metastatic	O
renal	O
CA	O
2	O
.	O
s	O
/	O
p	O
LLL	O
lobectomy	O
-	O
?	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
mets	O
from	O
renal	O
CA	O
3	O
.	O
s	O
/	O
p	O
prostate	O
resection	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
prostate	O
CA	O
-	O
[	O
**	O
2191	O
**	O
]	O
4	O
.	O
s	O
/	O
p	O
CVA	O
[	O
**	O
5	O
-	O
22	O
**	O
]	O
,	O
affecting	O
right	O
side	O
5	O
.	O
NIDDM	O
6	O
.	O
COPD	O
7	O
.	O
A	O
fib	O
8	O
.	O
Colon	O
ca	O
,	O
dx	O
[	O
**	O
2197	O
**	O
]	O
-	O
s	O
/	O
p	O
colectomy	O
Discharge	O
Condition	O
:	O
DNR	O
/	O
DNI	O
/	O
DNH	O
Discharge	O
Instructions	O
:	O
Please	O
make	O
sure	O
that	O
the	O
patient	O
is	O
as	O
comfortable	O
as	O
possible	O
.	O
Please	O
,	O
note	O
,	O
the	O
patient	O
is	O
DO	O
NOT	O
HOSPITALIZE	O
(	O
DNH	O
)	O
per	O
discussion	O
with	O
his	O
wife	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
should	O
be	O
treated	O
for	O
his	O
pneumonia	O
until	O
[	O
**	O
9	O
-	O
15	O
**	O
]	O
and	O
receive	O
steroids	I-Drug
indefinatley	O
for	O
his	O
cerebral	B-Reason
mets	I-Reason
.	O
Should	O
he	O
develop	O
respiratory	O
distress	O
,	O
he	O
should	O
not	O
to	O
be	O
brought	O
back	O
to	O
the	O
hospital	O
(	O
per	O
Wife	O
's	O
wishes	O
)	O
.	O
In	O
this	O
case	O
,	O
should	O
be	O
given	O
Morphine	I-Drug
and	O
Ativan	I-Drug
prn	O
,	O
titrated	O
to	O
comfort	O
.	O
.	O
He	O
can	O
continue	O
to	O
receive	O
his	O
blood	B-Drug
pressure	I-Drug
meds	I-Drug
and	O
his	O
insulin	I-Drug
can	O
be	O
titrated	O
accordingly	O
.	O
Followup	O
Instructions	O
:	O
None	O

Admission	O
Date	O
:	O
[	O
**	O
2152-8-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2152-8-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2078-11-30	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Coumadin	I-Drug
/	O
Quinidine	B-Drug
Sulfate	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
922	O
**	O
]	O
Chief	O
Complaint	O
:	O
chest	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
cabg	O
x4	O
/	O
cryoMaze	O
/	O
ASD	O
closure	O
/	O
rem	O
.	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
1916	O
**	O
]	O
[	O
**	O
2152-8-21	O
**	O
]	O
(	O
LIMA	O
to	O
LAD	O
,	O
SVG	O
to	O
PDA	O
,	O
SVG	O
to	O
DIAG	O
,	O
sequenced	O
to	O
OM	O
)	O
History	O
of	O
Present	O
Illness	O
:	O
73	O
M	O
with	O
h	O
/	O
o	O
AF	O
not	O
on	O
anticoaggulation	I-Drug
presented	O
to	O
PCP	O
with	O
constant	O
chest	O
pressure	O
,	O
worse	O
with	O
eating	O
or	O
exertion	O
.	O
Gets	O
minimal	O
relief	O
from	O
TUMS	I-Drug
.	O
His	O
PCP	O
referred	O
him	O
for	O
ETT	O
which	O
was	O
stopped	O
after	O
5	O
min	O
due	O
to	O
chest	O
pain	O
.	O
MIBI	O
revealed	O
inferior	O
ischemia	O
,	O
posterior	O
wall	O
infarct	O
,	O
and	O
LVEF	O
47	O
%	O
with	O
inferobasal	O
hypokinesis	O
.	O
He	O
had	O
catheterization	O
on	O
[	O
**	O
2152-8-14	O
**	O
]	O
which	O
showed	O
severe	O
3VD	O
(	O
occluded	O
RCA	O
,	O
90	O
%	O
LCx	O
,	O
80	O
%	O
LAD	O
)	O
.	O
He	O
has	O
had	O
intermittent	B-Reason
CP	I-Reason
,	O
especially	O
at	O
night	O
,	O
and	O
a	O
nitro	I-Drug
drip	O
was	O
started	O
.	O
He	O
was	O
set	O
to	O
get	O
CABG	O
today	O
(	O
[	O
**	O
2152-8-18	O
**	O
]	O
)	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
914	O
**	O
]	O
,	O
but	O
his	O
creatinine	O
rose	O
to	O
1.8	O
over	O
baseline	O
of	O
1.2	O
.	O
CABG	O
was	O
delayed	O
to	O
allow	O
pt	O
's	O
renal	O
function	O
to	O
improve	O
.	O
Pain	O
free	O
currently	O
.	O
Past	O
Medical	O
History	O
:	O
A	O
fib	O
s	O
/	O
p	O
unsuccessful	O
EP	O
ablation	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
in	O
4/97	O
b	O
/	O
l	O
hernia	O
repair	O
AAA	O
restless	O
leg	O
syndrome	O
Social	O
History	O
:	O
Married	O
and	O
lives	O
with	O
wife	O
.	O
15	O
pack	O
year	O
smoking	O
history	O
.	O
Quit	O
30	O
years	O
ago	O
.	O
Denies	O
ETOH	O
and	O
illicit	O
drugs	O
.	O
Retired	O
.	O
Family	O
History	O
:	O
No	O
premature	O
CAD	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
117/64	O
HR	O
59	O
RR	O
18	O
93	O
-	O
97	O
%	O
RA	O
Gen	O
:	O
comfortable	O
,	O
nad	O
HEENT	O
:	O
perrl	O
,	O
eomi	O
Neck	O
:	O
no	O
JVD	O
CV	O
:	O
RRR	O
nl	O
S1S2	O
no	O
m	O
/	O
r	O
/	O
g	O
Abd	O
:	O
+	O
BS	O
,	O
soft	O
,	O
ND	O
/	O
NT	O
EXT	O
:	O
no	O
edema	O
,	O
2	O
+	O
pp	O
Pertinent	O
Results	O
:	O
[	O
**	O
2152-8-28	O
**	O
]	O
6:25	O
A	O
95	O
32	O
*	O
1.5	O
*	O
137	O
4.0	O
98	O
32	O
11	O
[	O
**	O
2152-8-25	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
WBC	O
-	O
8.9	O
RBC	O
-	O
3.98	O
*	O
Hgb	O
-	O
9.4	O
*	O
Hct	O
-	O
27.7	O
*	O
MCV	O
-	O
70	O
*	O
MCH	O
-	O
23.5	O
*	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
21.9	O
*	O
Plt	O
Ct	O
-	O
113	O
*	O
[	O
**	O
2152-8-25	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
113	O
*	O
[	O
**	O
2152-8-24	O
**	O
]	O
02:22	O
AM	O
BLOOD	O
PT	O
-	O
13.2	O
*	O
PTT	O
-	O
28.8	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2152-8-25	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Glucose	O
-	O
96	O
UreaN	O
-	O
30	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
132	O
*	O
K	O
-	O
4.4	O
Cl	O
-	O
96	O
HCO3	O
-	O
29	O
AnGap	O
-	O
11	O
[	O
**	O
2152-8-17	O
**	O
]	O
09:20	O
AM	O
BLOOD	O
ALT	O
-	O
23	O
AST	O
-	O
25	O
CK	O
(	O
CPK	O
)	O
-	O
76	O
AlkPhos	O
-	O
82	O
Amylase	O
-	O
53	O
TotBili	O
-	O
0.8	O
[	O
**	O
2152-8-17	O
**	O
]	O
09:20	O
AM	O
BLOOD	O
Lipase	O
-	O
17	O
[	O
**	O
2152-8-25	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Calcium	O
-	O
7.7	O
*	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.0	O
[	O
**	O
2152-8-16	O
**	O
]	O
09:35	O
AM	O
BLOOD	O
%	O
HbA1c	O
-	O
5.7	O
[	O
Hgb	O
]	O
-	O
DONE	O
[	O
A1c	O
]	O
-	O
DONE	O
[	O
**	O
2152-8-14	O
**	O
]	O
01:16	O
PM	O
BLOOD	O
HDL	O
-	O
42	O
CHOL	O
/	O
HD	O
-	O
3.0	O
LDLmeas	O
-	O
72	O
FINAL	O
REPORT	O
PORTABLE	O
CHEST	O
10:11	O
A.M.	O
ON	O
[	O
**	O
8	O
-	O
23	O
**	O
]	O
.	O
INDICATION	O
:	O
Status	O
post	O
CABG	O
and	O
ASD	O
closure	O
.	O
Evaluate	O
for	O
pneumothorax	O
,	O
status	O
post	O
chest	O
tube	O
removal	O
.	O
FINDINGS	O
:	O
Compared	O
with	O
9/19	O
,	O
ETT	O
,	O
NGT	O
,	O
mediastinal	O
and	O
left	O
chest	O
tubes	O
have	O
been	O
removed	O
.	O
The	O
tip	O
of	O
the	O
Swan	O
-	O
Ganz	O
catheter	O
remains	O
at	O
the	O
level	O
of	O
the	O
right	O
main	O
PA.	O
.	O
No	O
pneumothorax	O
identified	O
.	O
Persistent	O
left	O
lower	O
lobe	O
atelectasis	O
/	O
effusion	O
.	O
DR.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
Approved	O
:	O
WED	O
[	O
**	O
2152-8-23	O
**	O
]	O
10:20	O
PM	O
Procedure	O
Date	O
:[	O
**	O
2152-8-23	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
29488	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
29489	O
**	O
]	O
(	O
Complete	O
)	O
Done	O
[	O
**	O
2152-8-21	O
**	O
]	O
at	O
9:08:04	O
AM	O
PRELIMINARY	O
Referring	O
Physician	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
**	O
]	O
Information	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
177	O
**	O
]	O
[	O
**	O
Hospital	O
Unit	O
Name	O
927	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
718	O
**	O
]	O
Status	O
:	O
Inpatient	O
DOB	O
:	O
[	O
**	O
2078-11-30	O
**	O
]	O
Age	O
(	O
years	O
)	O
:	O
73	O
M	O
Hgt	O
(	O
in	O
)	O
:	O
BP	O
(	O
mm	O
Hg	O
)	O
:	O
/	O
Wgt	O
(	O
lb	O
)	O
:	O
HR	O
(	O
bpm	O
)	O
:	O
BSA	O
(	O
m2	O
)	O
:	O
Indication	O
:	O
Aortic	O
valve	O
disease	O
.	O
Coronary	O
artery	O
disease	O
.	O
Left	O
ventricular	O
function	O
.	O
Valvular	O
heart	O
disease	O
.	O
ICD	O
-	O
9	O
Codes	O
:	O
427.31	O
,	O
440.0	O
,	O
424.1	O
,	O
424.0	O
,	O
424.2	O
Test	O
Information	O
Date	O
/	O
Time	O
:	O
[	O
**	O
2152-8-21	O
**	O
]	O
at	O
09:08	O
Interpret	O
MD	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
168	O
**	O
]	O
,	O
MD	O
Test	O
Type	O
:	O
TEE	O
(	O
Complete	O
)	O
Son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
930	O
**	O
]	O
:	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
168	O
**	O
]	O
,	O
MD	O
Doppler	O
:	O
Full	O
Doppler	O
and	O
color	O
Doppler	O
Test	O
Location	O
:	O
Anesthesia	O
West	O
OR	O
cardiac	O
Contrast	O
:	O
None	O
Tech	O
Quality	O
:	O
Adequate	O
Tape	O
#	O
:	O
2006AW1	O
-	O
:	O
Machine	O
:	O
Echocardiographic	O
Measurements	O
Results	O
Measurements	O
Normal	O
Range	O
Left	O
Atrium	O
-	O
Long	O
Axis	O
Dimension	O
:	O
*	O
5.5	O
cm	O
<	O
=	O
4.0	O
cm	O
Left	O
Atrium	O
-	O
Four	O
Chamber	O
Length	O
:	O
*	O
7.3	O
cm	O
<	O
=	O
5.2	O
cm	O
Right	O
Atrium	O
-	O
Four	O
Chamber	O
Length	O
:	O
*	O
6.3	O
cm	O
<	O
=	O
5.0	O
cm	O
Left	O
Ventricle	O
-	O
Diastolic	O
Dimension	O
:	O
*	O
6.3	O
cm	O
<	O
=	O
5.6	O
cm	O
Aorta	O
-	O
Valve	O
Level	O
:	O
2.5	O
cm	O
<	O
=	O
3.6	O
cm	O
Aortic	O
Valve	O
-	O
Pressure	O
Half	O
Time	O
:	O
744	O
ms	O
Findings	O
LEFT	O
ATRIUM	O
:	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
LA	O
enlargement	O
.	O
Elongated	O
LA	O
.	O
No	O
mass	O
/	O
thrombus	O
in	O
the	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
LAA	O
.	O
RIGHT	O
ATRIUM	O
/	O
INTERATRIAL	O
SEPTUM	O
:	O
Moderately	O
dilated	O
RA	O
.	O
PFO	O
is	O
present	O
.	O
Left	O
-	O
to	O
-	O
right	O
shunt	O
across	O
the	O
interatrial	O
septum	O
at	O
rest	O
.	O
LEFT	O
VENTRICLE	O
:	O
Moderately	O
dilated	O
LV	O
cavity	O
.	O
Normal	O
regional	O
LV	O
systolic	O
function	O
.	O
Low	O
normal	O
LVEF	O
.	O
RIGHT	O
VENTRICLE	O
:	O
Normal	O
RV	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
.	O
AORTA	O
:	O
Normal	O
ascending	O
aorta	O
diameter	O
.	O
Mildly	O
dilated	O
descending	O
aorta	O
.	O
There	O
are	O
complex	O
(	O
>	O
4	O
mm	O
)	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
AORTIC	O
VALVE	O
:	O
Mildly	O
thickened	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
.	O
Mild	O
to	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
1192	O
**	O
]	O
(	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
+	O
)	O
AR	O
.	O
MITRAL	O
VALVE	O
:	O
Mildly	O
thickened	O
mitral	O
valve	O
leaflets	O
.	O
Mild	O
(	O
1	O
+	O
)	O
MR.	O
Eccentric	O
MR	O
jet	O
.	O
TRICUSPID	O
VALVE	O
:	O
Normal	O
tricuspid	O
valve	O
leaflets	O
.	O
Mild	O
to	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
1192	O
**	O
]	O
[	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
+	O
]	O
TR	O
.	O
PULMONIC	O
VALVE	O
/	O
PULMONARY	O
ARTERY	O
:	O
Normal	O
pulmonic	O
valve	O
leaflets	O
.	O
Physiologic	O
(	O
normal	O
)	O
PR	O
.	O
GENERAL	O
COMMENTS	O
:	O
A	O
TEE	O
was	O
performed	O
in	O
the	O
location	O
listed	O
above	O
.	O
I	O
certify	O
I	O
was	O
present	O
in	O
compliance	O
with	O
HCFA	O
regulations	O
.	O
No	O
TEE	O
related	O
complications	O
.	O
The	O
patient	O
was	O
under	O
general	O
anesthesia	I-Drug
throughout	O
the	O
procedure	O
.	O
Results	O
were	O
REGIONAL	O
LEFT	O
VENTRICULAR	O
WALL	O
MOTION	O
:	O
N	O
=	O
Normal	O
,	O
H	O
=	O
Hypokinetic	O
,	O
A	O
=	O
Akinetic	O
,	O
D	O
=	O
Dyskinetic	O
Conclusions	O
PREBYPASS	O
1	O
.	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
No	O
mass	O
/	O
thrombus	O
is	O
seen	O
in	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
A	O
patent	O
foramen	O
ovale	O
is	O
present	O
.	O
A	O
left	O
-	O
to	O
-	O
right	O
shunt	O
across	O
the	O
interatrial	O
septum	O
is	O
seen	O
at	O
rest	O
by	O
color	O
flow	O
Doppler	O
and	O
with	O
agitated	O
saline	O
contrast	O
during	O
a	O
modified	O
Valsalva	O
maneuver	O
.	O
2	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
low	O
normal	O
(	O
LVEF	O
50	O
-	O
55	O
%	O
)	O
.	O
3	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
4	O
.	O
The	O
descending	O
thoracic	O
aorta	O
is	O
mildly	O
dilated	O
.	O
There	O
are	O
complex	O
(	O
>	O
4	O
mm	O
)	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
5	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
Mild	O
to	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
1192	O
**	O
]	O
(	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
6	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
to	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
1192	O
**	O
]	O
(	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
regurgitation	O
jet	O
is	O
eccentric	O
and	O
directed	O
posteriorly	O
.	O
MR	O
increased	O
to	O
the	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
1192	O
**	O
]	O
range	O
with	O
increasing	O
of	O
SBP	O
to	O
160	O
mm	O
Hg	O
.	O
POSTBYPASS	O
1	O
.	O
Biventricular	O
systolic	O
function	O
remains	O
normal	O
.	O
2	O
.	O
The	O
AI	O
remains	O
unchanged	O
.	O
3	O
.	O
No	O
flow	O
is	O
seen	O
across	O
the	O
interatrial	O
septum	O
by	O
color	O
flow	O
doppler	O
interrogation	O
.	O
Bubble	O
study	O
with	O
valsalva	O
is	O
negative	O
.	O
4	O
.	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
9807	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1192	O
**	O
]	O
on	O
coming	O
off	O
CPB	O
,	O
subsequently	O
improved	O
to	O
mild	O
-	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1192	O
**	O
]	O
.	O
5	O
.	O
Aorta	O
is	O
intact	O
post	O
decannulation	O
I	O
certify	O
that	O
I	O
was	O
present	O
for	O
this	O
procedure	O
in	O
compliance	O
with	O
HCFA	O
regulations	O
.	O
Interpretation	O
assigned	O
to	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
168	O
**	O
]	O
,	O
MD	O
,	O
Interpreting	O
physician	O
??????	O
[	O
**	O
2148	O
**	O
]	O
CareGroup	O
IS	O
.	O
All	O
rights	O
reserved	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Admitted	O
on	O
[	O
**	O
2152-8-14	O
**	O
]	O
for	O
cardiac	O
cath	O
and	O
referred	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
914	O
**	O
]	O
for	O
cabg	O
/	O
Maze	O
.	O
Surgery	O
delayed	O
for	O
rising	O
creatinine	O
and	O
plavix	I-Drug
washout	O
,	O
and	O
right	O
femoral	O
pseudoaneurysm	O
post-cath	O
.	O
Renal	O
consult	O
done	O
.	O
Ultimately	O
underwent	O
cabg	O
x4	O
/	O
cryo	O
Maze	O
/	O
ASD	O
closure	O
/	O
ligation	O
of	O
left	O
atrial	O
appendage	O
on	O
[	O
**	O
8	O
-	O
21	O
**	O
]	O
.	O
Transferred	O
to	O
the	O
CSRU	O
in	O
stable	O
condition	O
on	O
neosynephrine	I-Drug
and	O
propofol	I-Drug
drips	O
.	O
Transfused	I-Drug
for	O
postop	B-Reason
anemia	I-Reason
and	O
on	O
epinephrine	I-Drug
,	O
amiodarone	I-Drug
,	O
neo	I-Drug
and	O
insulin	I-Drug
drips	O
.	O
TEE	O
/	O
cardioversion	O
done	O
for	O
Afib	O
.	O
Extubated	O
later	O
that	O
morning	O
.	O
Epinephrine	I-Drug
weaned	O
off	O
on	O
POD	O
#	O
2	O
and	O
transferred	O
to	O
the	O
floor	O
on	O
POD	O
#	O
3	O
to	O
begin	O
increasing	O
his	O
activity	O
level	O
.	O
Central	O
line	O
and	O
foley	O
removed	O
on	O
POD	O
#	O
3	O
.	O
Pacing	O
wires	O
removed	O
without	O
incident	O
on	O
POD	O
#	O
4	O
.	O
Some	O
serosanguineous	O
sternal	O
drainage	O
started	O
on	O
Friday	O
and	O
was	O
observed	O
with	O
abx	I-Drug
started	O
on	O
POD	O
#	O
6	O
and	O
discontinued	O
on	O
POD	O
#	O
7	O
.	O
Will	O
monitor	O
with	O
a	O
wound	O
check	O
in	O
4	O
days	O
here	O
on	O
[	O
**	O
Hospital	O
Ward	O
Name	O
121	O
**	O
]	O
2	O
.	O
Creatinine	O
1.5	O
(	O
roughly	O
baseline	O
)	O
on	O
POD	O
#	O
7	O
and	O
cleared	O
for	O
discharge	O
to	O
home	O
with	O
services.Patient	O
to	O
make	O
all	O
follow	O
-	O
up	O
appts	O
.	O
as	O
per	O
discharge	O
instructions	O
.	O
Medications	O
on	O
Admission	O
:	O
Amiodarone	I-Drug
200	O
mg	O
every	O
AM	O
,	O
100	O
mg	O
every	O
evening	O
Aspirin	I-Drug
81	O
mg	O
daily	O
Plavix	I-Drug
75	O
mg	O
daily	O
Imdur	I-Drug
30	O
mg	O
daily	O
NG	I-Drug
SL	O
PRN	O
MVI	O
Discharge	O
Medications	O
:	O
1	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
for	O
1	O
months	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
40	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
2	O
weeks	O
.	O
Disp	O
:	O
*	O
14	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
1	O
tab	O
,	O
200	O
mg	O
Q	O
AM	O
,	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
tab	O
,	O
100	O
mg	O
Q	O
PM	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Captopril	I-Drug
12.5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
45	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
9	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Furosemide	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
7	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Potassium	B-Drug
Chloride	I-Drug
10	O
mEq	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
14	O
Capsule	O
,	O
Sustained	O
Release	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital1	O
1474	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
s	O
/	O
p	O
cabg	O
x4	O
/	O
cryo	O
Maze	O
/	O
ASD	O
closure	O
/	O
removal	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
1916	O
**	O
]	O
Afib	O
(	O
unsuccessful	O
ablation	O
)	O
AAA	O
restless	O
leg	O
syndrome	O
mild	O
CRI	O
Discharge	O
Condition	O
:	O
good	O
Discharge	O
Instructions	O
:	O
may	O
shower	O
over	O
incisions	O
and	O
pat	O
dry	O
no	O
lotions	O
,	O
creams	O
or	O
powders	O
on	O
any	O
incision	O
no	O
driving	O
for	O
one	O
month	O
no	O
lifting	O
greater	O
than	O
10	O
pounds	O
for	O
10	O
weeks	O
call	O
for	O
fever	O
greater	O
than	O
101.5	O
,	O
redness	O
or	O
drainage	O
RETURN	O
for	O
wound	O
check	O
on	O
[	O
**	O
Hospital	O
Ward	O
Name	O
121	O
**	O
]	O
2	O
on	O
Friday	O
[	O
**	O
9	O
-	O
1	O
**	O
]	O
Followup	O
Instructions	O
:	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
16004	O
**	O
]	O
in	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
weeks	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
weeks	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
914	O
**	O
]	O
in	O
4	O
weeks	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
RETURN	O
for	O
wound	O
check	O
on	O
[	O
**	O
Hospital	O
Ward	O
Name	O
121	O
**	O
]	O
2	O
on	O
Friday	O
[	O
**	O
9	O
-	O
1	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2152-8-28	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2120-6-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2120-6-25	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1515	O
**	O
]	O
Chief	O
Complaint	O
:	O
worsening	O
shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
percutaneouos	O
aortic	O
valve	O
replacement	O
(	O
CoreValve	O
)	O
pacemaker	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
prior	O
CABG	O
has	O
been	O
experiencing	O
fatigue	O
and	O
severe	O
shortness	O
of	O
breath	O
with	O
minimal	O
activity	O
,	O
which	O
is	O
new	O
over	O
the	O
last	O
few	O
months	O
.	O
He	O
denies	O
any	O
symptoms	O
occurring	O
at	O
rest	O
.	O
He	O
denies	O
any	O
chest	O
pain	O
.	O
He	O
denies	O
claudication	O
,	O
orthopnea	O
,	O
pnd	O
,	O
lightheadedness	O
or	O
lower	O
extremity	O
edema	O
.	O
He	O
was	O
seen	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
59323	O
**	O
]	O
who	O
referred	O
him	O
for	O
an	O
echocardiogram	O
.	O
This	O
revealed	O
worsening	O
of	O
his	O
aortic	O
stenosis	O
.	O
He	O
was	O
seen	O
and	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
6349	O
**	O
]	O
and	O
was	O
deemed	O
appropriate	O
for	O
TAVI	O
/	O
CoreValve	O
placement	O
.	O
NYHA	O
Class	O
:	O
II	O
Past	O
Medical	O
History	O
:	O
PMH	O
:	O
CAD	O
,	O
s	O
/	O
p	O
inferior	O
,	O
posterior	O
MI	O
,	O
s	O
/	O
p	O
CABG	O
x	O
4	O
in	O
[	O
**	O
8	O
-	O
/	O
2113	O
**	O
]	O
(	O
SVG	O
/	O
OM	O
,	O
Diag	O
,	O
PLB	O
,	O
and	O
LIMA	O
to	O
LAD	O
)	O
Pancreatitis	O
post	O
CABG	O
S	O
/	O
P	O
Cholescystectomy	O
in	O
[	O
**	O
10/2113	O
**	O
]	O
S	O
/	O
P	O
cataract	O
extraction	O
OD	O
S	O
/	O
P	O
right	O
carpal	O
tunnel	O
release	O
S	O
/	O
P	O
right	O
knee	O
arthroscopy	O
S	O
/	O
P	O
Upper	O
GI	O
scope	O
with	O
gastric	O
biopsy	O
,	O
esophageal	O
biopsy	O
,	O
and	O
balloon	O
dilatation	O
in	O
[	O
**	O
4	O
-	O
/	O
2116	O
**	O
]	O
H	O
/	O
O	O
diverticulosis	O
H	O
/	O
O	O
GIB	O
S	O
/	O
P	O
right	O
hemicolectomy	O
(	O
17	O
units	O
of	O
blood	O
)	O
H	O
/	O
O	O
right	O
carotid	O
bruit	O
H	O
/	O
O	O
NSVT	O
Hypertension	O
Hyperlipidemia	O
Chronic	O
renal	O
failure	O
Mitral	O
regurgitation	O
Depression	O
Insomnia	O
Hearing	O
impaired	O
Polymyalgia	O
rheumatica	O
-	O
on	O
Prednisone	O
Arthritis	O
BPH	O
s	O
/	O
p	O
TURP	O
Past	O
Surgical	O
History	O
:	O
S	O
/	O
P	O
Cholescystectomy	O
in	O
[	O
**	O
10/2113	O
**	O
]	O
S	O
/	O
P	O
cataract	O
extraction	O
OD	O
S	O
/	O
P	O
right	O
carpal	O
tunnel	O
release	O
S	O
/	O
P	O
right	O
knee	O
arthroscopy	O
s	O
/	O
p	O
TURP	O
s	O
/	O
p	O
R	O
hemicolectomy	O
s	O
/	O
p	O
CABGx4	O
(	O
SVG	O
/	O
OM	O
,	O
Diag	O
,	O
PLB	O
,	O
and	O
LIMA	O
to	O
LAD	O
)	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
Social	O
History	O
:	O
SOCIAL	O
HISTORY	O
:	O
Pt	O
lives	O
alone	O
independently	O
in	O
a	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
house	O
in	O
NH	O
.	O
He	O
plans	O
to	O
stay	O
with	O
his	O
daughter	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
after	O
discharge	O
.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
37190	O
**	O
]	O
(	O
dtr	O
)	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
82471	O
**	O
]	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
(	O
dtr	O
-	O
in	O
-	O
law	O
)	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
82472	O
**	O
]	O
Lives	O
with	O
:	O
lives	O
alone	O
Occupation	O
:	O
retired	O
GE	O
tester	O
(	O
jet	O
engines	O
)	O
Tobacco	O
:	O
1	O
/	O
2ppd	O
x	O
15	O
yrs	O
-	O
quit	O
60	O
yrs	O
ago	O
ETOH	O
:	O
none	O
Family	O
History	O
:	O
Longevity	O
(	O
sisters	O
x	O
2	O
deceased	O
age	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
)	O
Physical	O
Exam	O
:	O
ADMISSION	O
EXAM	O
Pulse	O
:	O
65	O
B	O
/	O
P	O
:	O
146/65	O
Resp	O
:	O
18	O
O2	O
Sat	O
:	O
Temp	O
:	O
97.1	O
General	O
:	O
Alert	O
hard	O
of	O
hearing	O
pleasant	O
elderly	O
gentleman	O
in	O
NAD	O
at	O
rest	O
,	O
spleaking	O
comfortably	O
.	O
Skin	O
:	O
Color	O
pale	O
pink	O
,	O
turgor	O
fair	O
.	O
No	O
ulcerations	O
,	O
no	O
lesions	O
.	O
HEENT	O
:	O
Normocephalic	O
,	O
anicteric	O
.	O
Oropharynx	O
moist	O
.	O
Conjunctiva	O
pale	O
pink	O
.	O
Lower	O
partials	O
.	O
Neck	O
:	O
Neck	O
supple	O
,	O
trachea	O
midline	O
.	O
Bilat	O
carotid	O
bruit	O
vs.	O
referred	O
murmer	O
.	O
JVD	O
.	O
Chest	O
:	O
Well	O
healed	O
sternal	O
incision	O
.	O
No	O
obvious	O
deformity	O
.	O
Heart	O
:	O
RRR	O
.	O
V	O
/	O
VI	O
murmer	O
throughout	O
Abdomen	O
:	O
soft	O
,	O
nontender	O
,	O
nondistended	O
,	O
(	O
+	O
)	O
bowel	O
sounds	O
all	O
quad	O
Extremities	O
:	O
No	O
hair	O
growth	O
below	O
knees	O
.	O
Trace	O
pedal	O
edema	O
bilat	O
.	O
Neuro	O
:	O
Alert	O
and	O
oriented	O
,	O
mildly	O
anxious	O
.	O
Gross	O
FROM	O
.	O
OOB	O
,	O
gait	O
steady	O
.	O
Pulses	O
:	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
+	O
palpable	O
peripheral	O
pulses	O
throughout	O
DISCHARGE	O
EXAM	O
VITALS	O
:	O
Temp	O
current	O
:	O
98.7	O
HR	O
:	O
75	O
-	O
95	O
RR	O
:	O
18	O
BP	O
:	O
126-147/60	O
s	O
O2	O
Sat	O
:	O
100	O
%	O
RA	O
General	O
:	O
resting	O
comfortably	O
in	O
bed	O
,	O
NAD	O
HEENT	O
:	O
Oropharynx	O
moist	O
.	O
Neck	O
:	O
Neck	O
supple	O
.	O
Chest	O
:	O
Well	O
healed	O
sternal	O
incision	O
.	O
No	O
obvious	O
deformity	O
.	O
Skin	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
1994	O
**	O
]	O
from	O
tape	O
removal	O
center	O
chest	O
,	O
dressing	O
not	O
removed	O
for	O
exam	O
.	O
Lungs	O
CTA	O
bilaterally	O
with	O
good	O
air	O
entry	O
.	O
Heart	O
:	O
RRR	O
,	O
paradoxical	O
split	O
S2	O
.	O
Abdomen	O
:	O
soft	O
,	O
nontender	O
,	O
nondistended	O
,	O
(	O
+	O
)	O
bowel	O
sounds	O
all	O
quad	O
.	O
Well	O
healed	O
surgical	O
scar	O
.	O
Extremities	O
:	O
No	O
hair	O
growth	O
below	O
knees	O
.	O
No	O
pedal	O
edema	O
.	O
Small	O
(	O
nickel	O
-	O
sized	O
)	O
right	O
groin	O
hematoma	O
,	O
mildly	O
TTP	O
.	O
Palpable	O
DP	O
pulses	O
.	O
Neuro	O
:	O
Alert	O
and	O
oriented	O
,	O
mildly	O
anxious	O
.	O
Gross	O
FROM	O
.	O
OOB	O
,	O
gait	O
steady	O
.	O
Skin	O
:	O
Color	O
pink	O
,	O
skin	O
warm	O
and	O
dry	O
.	O
Heels	O
and	O
sacrum	O
intact	O
.	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
[	O
**	O
2120-6-17	O
**	O
]	O
WBC	O
-	O
7.8	O
RBC	O
-	O
3.19	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
31.4	O
*	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
35.1	O
*	O
MCHC	O
-	O
35.7	O
*	O
RDW	O
-	O
16.3	O
*	O
Plt	O
Ct	O
-	O
189	O
PT	O
-	O
13.7	O
*	O
PTT	O
-	O
22.6	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
Glucose	O
-	O
121	O
*	O
UreaN	O
-	O
34	O
*	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
143	O
K	O
-	O
4.7	O
Cl	O
-	O
109	O
*	O
HCO3	O
-	O
26	O
AnGap	O
-	O
13	O
Albumin	O
-	O
4.0	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
2.9	O
Mg	O
-	O
2.0	O
%	O
HbA1c	O
-	O
5.7	O
eAG	O
-	O
117	O
ALT	O
-	O
18	O
AST	O
-	O
37	O
CK	O
(	O
CPK	O
)	O
-	O
29	O
*	O
AlkPhos	O
-	O
40	O
TotBili	O
-	O
0.9	O
CK	O
-	O
MB	O
-	O
3	O
proBNP	O
-	O
2320	O
*	O
Discharge	O
labs	O
:	O
[	O
**	O
2120-6-25	O
**	O
]	O
WBC	O
-	O
9.4	O
RBC	O
-	O
2.78	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
27.6	O
*	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
33.1	O
*	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
240	O
PT	O
-	O
13.5	O
*	O
PTT	O
-	O
25.0	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
Glucose	O
-	O
92	O
UreaN	O
-	O
29	O
*	O
Creat	O
-	O
1.4	O
*	O
Na	O
-	O
142	O
K	O
-	O
4.1	O
Cl	O
-	O
108	O
HCO3	O
-	O
24	O
AnGap	O
-	O
14	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
2.5	O
*	O
Mg	O
-	O
1.9	O
proBNP	O
-	O
2338	O
*	O
Imaging	O
ECG	O
:	O
(	O
[	O
**	O
6	O
-	O
17	O
**	O
]	O
)	O
Sinus	O
rhythm	O
.	O
Right	O
bundle	O
-	O
branch	O
block	O
.	O
Left	O
anterior	O
fascicular	O
block	O
.	O
Inferolateral	O
lead	O
ST	O
-	O
T	O
wave	O
changes	O
are	O
primary	O
and	O
non-specific	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2120-5-17	O
**	O
]	O
inferolateral	O
lead	O
ST	O
-	O
T	O
wave	O
changes	O
appear	O
less	O
prominent	O
.	O
.	O
ECHO	O
(	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
)	O
PRE	O
VALVE	O
DEPLOYMENT	O
The	O
left	O
atrium	O
is	O
dilated	O
.	O
No	O
spontaneous	O
echo	O
contrast	O
or	O
thrombus	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
A	O
patent	O
foramen	O
ovale	O
is	O
present	O
.	O
A	O
left	O
-	O
to	O
-	O
right	O
shunt	O
across	O
the	O
interatrial	O
septum	O
is	O
seen	O
at	O
rest	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
There	O
is	O
moderate	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
severe	O
inferior	O
,	O
inferolateral	O
,	O
and	O
inferoseptal	O
hypokinesis	O
.	O
The	O
remaining	O
myocardial	O
segments	O
are	O
mildly	O
,	O
globally	O
depressed	O
.	O
The	O
right	O
ventricle	O
displays	O
mild	O
global	O
free	O
wall	O
hypokinesis	O
.	O
The	O
descending	O
thoracic	O
aorta	O
is	O
mildly	O
dilated	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
There	O
are	O
three	O
aortic	O
valve	O
leaflets	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
severely	O
thickened	O
/	O
deformed	O
.	O
There	O
is	O
critical	O
aortic	O
valve	O
stenosis	O
(	O
valve	O
area	O
<	O
0.8	O
cm2	O
)	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
more	O
significant	O
calcification	O
of	O
the	O
base	O
of	O
the	O
posterior	O
mitral	O
leaflet	O
and	O
posterior	O
mitral	O
annulus	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
.	O
POST	O
VALVE	O
DEPLOYMENT	O
At	O
initail	O
deployment	O
,	O
the	O
patient	O
developed	O
near	O
cardiac	O
arrest	O
with	O
right	O
ventricular	O
akinesis	O
.	O
The	O
aortic	O
valve	O
was	O
quickly	O
replaced	O
and	O
epinephrine	O
was	O
given	O
with	O
resolution	O
of	O
right	O
ventricular	O
failure	O
.	O
The	O
right	O
ventriclular	O
function	O
then	O
returned	O
to	O
the	O
pre-deployment	O
state	O
.	O
The	O
mitral	O
regurgitation	O
was	O
worsened	O
and	O
severe	O
immediately	O
after	O
this	O
event	O
but	O
after	O
valve	O
replacement	O
returned	O
to	O
baseline	O
(	O
mild	O
to	O
moderate	O
)	O
.	O
The	O
aortic	O
valve	O
and	O
supporting	O
structure	O
is	O
in	O
situ	O
.	O
The	O
leaflets	O
can	O
be	O
seen	O
moving	O
.	O
The	O
maximum	O
gradient	O
across	O
the	O
valve	O
was	O
7	O
mmHg	O
with	O
a	O
mean	O
of	O
4	O
mmHg	O
.	O
There	O
is	O
mild	O
aortic	O
regurgitation	O
with	O
two	O
paravalvular	O
jets	O
seen	O
.	O
.	O
ECG	O
(	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
)	O
Sinus	O
rhythm	O
with	O
atrial	O
sensed	O
and	O
ventricular	O
paced	O
rhythm	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
the	O
same	O
date	O
ventricular	O
paced	O
rhythm	O
is	O
now	O
present	O
.	O
TRACING	O
#	O
2	O
.	O
CXR	O
(	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
)	O
A	O
CoreValve	O
is	O
in	O
place	O
.	O
The	O
left	O
-	O
sided	O
pacemaker	O
with	O
the	O
leads	O
terminating	O
at	O
right	O
atrium	O
and	O
right	O
ventricle	O
is	O
noted	O
.	O
Lungs	O
are	O
essentially	O
clear	O
.	O
Heart	O
size	O
and	O
mediastinal	O
silhouette	O
are	O
stable	O
.	O
There	O
is	O
no	O
pleural	O
effusion	O
or	O
pneumothorax	O
noted	O
.	O
.	O
ECHO	O
(	O
[	O
**	O
6	O
-	O
20	O
**	O
]	O
)	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
moderately	O
depressed	O
(	O
LVEF	O
=	O
35	O
%	O
)	O
secondary	O
to	O
jypokinesis	O
of	O
the	O
inferior	O
septum	O
,	O
inferior	O
free	O
wall	O
,	O
and	O
posterior	O
wall	O
.	O
The	O
right	O
ventricular	O
free	O
wall	O
is	O
hypertrophied	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
with	O
borderline	O
normal	O
free	O
wall	O
function	O
.	O
An	O
aortic	O
CoreValve	O
prosthesis	O
is	O
present	O
.	O
A	O
paravalvular	O
aortic	O
valve	O
leak	O
(	O
trace	O
-	O
to	O
-	O
mild	O
)	O
is	O
probably	O
present	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
There	O
is	O
borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
CXR	O
(	O
[	O
**	O
6	O
-	O
20	O
**	O
]	O
)	O
IMPRESSION	O
:	O
Very	O
satisfactory	O
postoperative	O
situation	O
.	O
Permanent	O
pacer	O
with	O
two	O
intracavitary	O
electrodes	O
in	O
unremarkable	O
position	O
.	O
No	O
pneumothorax	O
identified	O
.	O
.	O
ECHO	O
(	O
[	O
**	O
6	O
-	O
25	O
**	O
]	O
)	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
There	O
is	O
moderate	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
basal	O
inferoseptal	O
,	O
inferior	O
,	O
and	O
inferolateral	O
akinesis	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
An	O
aortic	O
CoreValve	O
prosthesis	O
is	O
present	O
and	O
appears	O
well	O
-	O
seated	O
.	O
The	O
transaortic	O
gradient	O
is	O
normal	O
for	O
this	O
prosthesis	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
(	O
probably	O
paravalvular	O
)	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2120-6-20	O
**	O
]	O
,	O
left	O
ventricular	O
systolic	O
function	O
appears	O
similar	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
may	O
have	O
been	O
slightly	O
underestimated	O
in	O
the	O
prior	O
report	O
.	O
Estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
now	O
higher	O
.	O
Mitral	O
regurgitation	O
is	O
now	O
more	O
prominent	O
.	O
Tricuspid	O
regurgitation	O
is	O
now	O
more	O
prominent	O
.	O
.	O
ECG	O
(	O
[	O
**	O
6	O
-	O
25	O
**	O
]	O
)	O
Ventricular	O
paced	O
rhythm	O
at	O
a	O
rate	O
of	O
80	O
beats	O
per	O
minute	O
.	O
No	O
diagnostic	O
change	O
compared	O
to	O
previous	O
tracing	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Pt	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
M	O
with	O
a	O
PMH	O
significant	O
for	O
critical	O
AS	O
,	O
CABG	O
x4	O
and	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
82473	O
**	O
]	O
for	O
percutaneous	O
aortic	O
valve	O
replacement	O
with	O
CoreValve	O
device	O
.	O
#	O
1	O
Severe	O
symptomatic	O
aortic	O
stenosis	O
s	O
/	O
p	O
CoreValve	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
:	O
At	O
initail	O
deployment	O
,	O
the	O
patient	O
developed	O
near	O
cardiac	B-Reason
arrest	I-Reason
with	O
right	O
ventricular	O
akinesis	O
.	O
The	O
aortic	O
valve	O
was	O
quickly	O
replaced	O
and	O
epinephrine	I-Drug
was	O
given	O
with	O
resolution	O
of	O
right	O
ventricular	O
failure	O
.	O
The	O
right	O
ventriclular	O
function	O
then	O
returned	O
to	O
the	O
pre-deployment	O
state	O
.	O
The	O
mitral	O
regurgitation	O
was	O
worsened	O
and	O
severe	O
immediately	O
after	O
this	O
event	O
but	O
after	O
valve	O
replacement	O
returned	O
to	O
baseline	O
(	O
mild	O
to	O
moderate	O
)	O
.	O
Perioperative	O
permanent	O
pacemaker	O
placed	O
following	O
occlusion	O
of	O
RCA	O
,	O
has	O
right	O
BBB	O
and	O
paced	O
beats	O
.	O
ECHO	O
shows	O
good	O
valve	O
placement	O
and	O
mild	O
perivalvular	O
leak	O
.	O
One	O
unit	O
PRBC	I-Drug
given	O
post	O
procedure	O
for	O
low	B-Reason
hct	I-Reason
.	O
Pt	O
will	O
need	O
aspirin	I-Drug
and	O
Plavix	I-Drug
for	O
a	O
total	O
of	O
3	O
months	O
and	O
will	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
1022	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
32655	O
**	O
]	O
NP	O
for	O
routine	O
post	O
procedure	O
care	O
.	O
.	O
#	O
2	O
Complete	O
Heart	O
Block	O
during	O
CoreValve	O
placement	O
:	O
common	O
occurance	O
in	O
patients	O
with	O
right	O
bundle	O
branch	O
block	O
.	O
A	O
[	O
**	O
Company	O
1543	O
**	O
]	O
DDD	O
pacemaker	O
model	O
Sensia	O
SEDR01	O
,	O
serial	O
number	O
[	O
**	O
Serial	O
Number	O
82474	O
**	O
]	O
.	O
One	O
week	O
wound	O
check	O
and	O
interrogation	O
occurred	O
while	O
pt	O
was	O
still	O
hospitalized	O
and	O
pt	O
will	O
need	O
to	O
f	O
/	O
u	O
every	O
6	O
months	O
for	O
a	O
pacemaker	O
check	O
.	O
#	O
3	O
CAD	I-Reason
:	O
s	O
/	O
p	O
CABG	O
x	O
4	O
(	O
[	O
**	O
2112	O
**	O
]	O
)	O
.	O
Bypass	O
graft	O
angiography	O
demonstrates	O
the	O
vein	O
graft	O
to	O
the	O
obtuse	O
marginal	O
and	O
the	O
LIMA	O
to	O
LAD	O
to	O
be	O
patent	O
,	O
however	O
during	O
CoreValve	O
procedure	O
the	O
RCA	O
graft	O
was	O
TO	O
.	O
Pt	O
had	O
no	O
significant	O
chest	O
pain	O
during	O
hospitalization	O
and	O
was	O
discharged	O
on	O
home	O
aspirin	I-Drug
,	O
plavix	I-Drug
,	O
metoprolol	I-Drug
and	O
Lipitor	I-Drug
.	O
.	O
#	O
4	O
Chronic	B-Reason
Systolic	I-Reason
Dysfunction	I-Reason
:	O
EF	O
35	O
%	O
.	O
Appeared	O
euvolemic	O
at	O
discharge	O
.	O
Had	O
not	O
been	O
on	O
ACEi	I-Drug
[	O
**	O
1	O
-	O
24	O
**	O
]	O
AS	O
and	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
.	O
Would	O
consider	O
starting	O
low	O
dose	O
ACEi	I-Drug
as	O
outpatient	O
.	O
Started	O
Lasix	I-Drug
20	O
mg	O
PO	O
for	O
inc	B-Reason
TR	I-Reason
gradient	O
.	O
.	O
#	O
Diarrhea	I-Ade
.	O
Possibly	O
due	O
to	O
antibiotics	I-Drug
and	O
bowel	O
regimen	O
.	O
No	O
fever	O
or	O
leukocytosis	O
.	O
Resolved	O
at	O
discharge	O
.	O
.	O
#	O
Skin	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
1994	O
**	O
]	O
.	O
Likely	O
secondary	O
to	O
prednisone	I-Drug
.	O
Mild	O
serosanguinous	I-Ade
oozing	O
at	O
site	O
.	O
Wound	O
nurse	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
6349	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1994	O
**	O
]	O
and	O
wrote	O
recommendations	O
to	O
VNA	O
for	O
dressing	O
.	O
.	O
#	O
.	O
Polymyalgia	B-Reason
Rheumatica	I-Reason
:	O
On	O
chronic	O
steroids	I-Drug
at	O
home	O
,	O
continued	O
in	O
hospital	O
.	O
.	O
#	O
.	O
CKD	O
:	O
baseline	O
creatinine	O
1.5	O
.	O
Increased	O
to	O
1.6	O
,	O
possibly	O
secondary	O
to	O
intravascular	O
depletion	O
from	O
diuresis	O
/	O
diarrhea	O
.	O
Pt	O
will	O
have	O
his	O
labs	O
rechecked	O
as	O
an	O
outpatient	O
.	O
Medications	O
on	O
Admission	O
:	O
atenolol	I-Drug
25	O
mg	O
daily	O
aspirin	I-Drug
81	O
mg	O
daily	O
lipitor	I-Drug
10	O
mg	O
QOD	O
(	O
every	O
other	O
am	O
)	O
prednisone	I-Drug
10	O
mg	O
daily	O
tamulosiin	B-Drug
SR	I-Drug
0.4	O
mg	O
qevening	O
multivitamin	I-Drug
1	O
tab	O
daily	O
fish	B-Drug
oil	I-Drug
capsule	O
1000	O
mg	O
twice	O
a	O
day	O
systane	B-Drug
lubricant	I-Drug
eye	I-Drug
drops	O
1gtt	O
TID	O
Discharge	O
Medications	O
:	O
1	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
check	O
Chem	O
-	O
7	O
and	O
CBC	O
on	O
Thursday	O
[	O
**	O
6	O
-	O
27	O
**	O
]	O
with	O
results	O
to	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
1022	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
32655	O
**	O
]	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
32656	O
**	O
]	O
fax	O
and	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
79809	O
**	O
]	O
phone	O
2	O
.	O
metoprolol	B-Drug
succinate	I-Drug
50	O
mg	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
Sig	O
:	O
1.5	O
Tablet	O
Extended	O
Release	O
24	O
hrs	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
45	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QODHS	O
(	O
every	O
other	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
5	O
.	O
prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Ext	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Ext	O
Release	O
24	O
hr	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
7	O
.	O
multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
omega	B-Drug
-	I-Drug
3	I-Drug
fatty	I-Drug
acids	I-Drug
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Company	O
1519	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Aortic	O
Stenosis	O
Acute	O
Systolic	O
Dysfunction	O
,	O
no	O
ACE	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
[	O
**	O
1	O
-	O
24	O
**	O
]	O
acute	O
kidney	O
injury	O
Hypertension	O
Anemia	O
Complete	O
heart	O
block	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
You	O
had	O
a	O
percutaneous	O
replacement	O
of	O
your	O
aortic	O
valve	O
with	O
a	O
CoreValve	O
bioprosthetic	B-Reason
valve	I-Reason
.	O
You	O
will	O
need	O
to	O
take	O
asprin	I-Drug
and	O
Plavix	I-Drug
for	O
3	O
months	O
to	B-Reason
prevent	I-Reason
blood	I-Reason
clots	I-Reason
around	I-Reason
the	I-Reason
valve	I-Reason
.	O
Do	O
not	O
stop	O
taking	O
aspirin	I-Drug
and	O
Plavix	I-Drug
unless	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
tells	O
you	O
it	O
is	O
OK	O
to	O
do	O
so	O
.	O
You	O
also	O
needed	O
a	O
pacemaker	O
after	O
the	O
procedure	O
for	O
a	O
slow	O
heart	O
rhythm	O
,	O
you	O
will	O
need	O
to	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
11250	O
**	O
]	O
and	O
an	O
electrophysiology	O
doctor	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
3844	O
**	O
]	O
to	O
have	O
the	O
pacemaker	O
checked	O
every	O
6	O
months	O
.	O
No	O
lifting	O
more	O
than	O
5	O
pounds	O
with	O
your	O
left	O
arm	O
or	O
lift	O
your	O
left	O
arm	O
over	O
your	O
head	O
for	O
6	O
weeks	O
.	O
There	O
are	O
no	O
activity	O
restrictions	O
for	O
your	O
right	O
arm	O
.	O
You	O
can	O
shower	O
when	O
you	O
get	O
home	O
.	O
You	O
needed	O
a	O
blood	B-Drug
transfusion	I-Drug
for	O
anemia	I-Reason
,	O
your	O
blood	O
count	O
is	O
better	O
now	O
.	O
You	O
heart	O
is	O
slightly	O
weaker	O
now	O
than	O
before	O
.	O
You	O
need	O
to	O
watch	O
your	O
salt	O
intake	O
and	O
take	O
all	O
of	O
your	O
medicines	O
daily	O
.	O
Information	O
regarding	O
your	O
medicines	O
and	O
diet	O
was	O
discussed	O
with	O
you	O
before	O
discharge	O
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
11250	O
**	O
]	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
in	O
1	O
day	O
or	O
5	O
pounds	O
in	O
3	O
days	O
.	O
.	O
We	O
made	O
the	O
following	O
changes	O
to	O
your	O
medicines	O
:	O
1	O
.	O
Stop	O
taking	O
Atenolol	I-Drug
,	O
take	O
metoprolol	I-Drug
instead	O
to	O
lower	B-Reason
your	I-Reason
heart	O
rate	O
and	O
help	B-Reason
your	I-Reason
heart	I-Reason
pump	I-Reason
better	I-Reason
2	O
.	O
Start	O
taking	O
plavix	I-Drug
every	O
day	O
to	B-Reason
prevent	I-Reason
blood	I-Reason
clots	I-Reason
on	O
the	O
new	O
valve	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
THURSDAY	O
[	O
**	O
2120-7-18	O
**	O
]	O
at	O
3:00	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
You	O
will	O
have	O
an	O
Echocardiogram	O
at	O
the	O
same	O
time	O
as	O
this	O
appt	O
.	O
.	O
PCP	O
Name	O
:	O
AUNG	O
,	O
THET	O
H	O
Address	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
77486	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
77350	O
**	O
]	O
Appointment	O
:	O
Thursday	O
[	O
**	O
2120-6-27	O
**	O
]	O
11:30	O
am	O
Completed	O
by	O
:[	O
**	O
2120-6-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2200-2-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2200-2-19	O
**	O
]	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
No	O
Drug	O
Allergy	O
Information	O
on	O
File	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3227	O
**	O
]	O
Chief	O
Complaint	O
:	O
consulted	O
for	O
SDH	O
found	O
on	O
head	O
CT	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
85	O
male	O
sent	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ER	O
with	O
mental	O
status	O
changes	O
from	O
the	O
nursing	O
home	O
.	O
There	O
is	O
no	O
report	O
of	O
a	O
fall	O
or	O
any	O
other	O
trauma	O
.	O
The	O
patient	O
is	O
unable	O
to	O
provide	O
a	O
history	O
at	O
this	O
time	O
and	O
his	O
health	O
care	O
proxies	O
are	O
unavailable	O
.	O
He	O
had	O
a	O
head	O
CT	O
which	O
revealed	O
a	O
SDH	O
and	O
small	O
SAH	O
.	O
Neurosurgery	O
was	O
consulted	O
for	O
evaluation	O
.	O
Past	O
Medical	O
History	O
:	O
prostate	O
cancer	O
Social	O
History	O
:	O
lives	O
at	O
nursing	O
home	O
with	O
wife	O
Family	O
History	O
:	O
non-contributory	O
Physical	O
Exam	O
:	O
Upon	O
admission	O
:	O
T	O
:	O
98.6	O
BP	O
:	O
119/76	O
HR	O
:	O
117	O
RR	O
:	O
18	O
O2Sats	O
:	O
100	O
%	O
RA	O
Gen	O
:	O
WD	O
/	O
WN	O
,	O
comfortable	O
,	O
NAD	O
.	O
HEENT	O
:	O
Pupils	O
:	O
Pupils	O
surgical	O
bilaterally	O
.	O
EOMs	O
-	O
intact	O
Ears	O
:	O
Patient	O
is	O
nearly	O
deaf	O
.	O
Neck	O
:	O
Supple	O
.	O
Lungs	O
:	O
CTA	O
bilaterally	O
.	O
Cardiac	O
:	O
RRR	O
.	O
S1	O
/	O
S2	O
.	O
Abd	O
:	O
Soft	O
,	O
NT	O
,	O
BS	O
+	O
Extrem	O
:	O
Warm	O
and	O
well	O
-	O
perfused	O
.	O
Neuro	O
:	O
Mental	O
status	O
:	O
Awake	O
and	O
alert	O
,	O
cooperative	O
with	O
exam	O
,	O
normal	O
affect	O
.	O
Orientation	O
:	O
Oriented	O
to	O
person	O
.	O
Language	O
:	O
+	O
dysarthria	O
,	O
speech	O
is	O
not	O
fluent	O
Cranial	O
Nerves	O
:	O
I	O
:	O
Not	O
tested	O
II	O
:	O
Pupils	O
surgical	O
bilaterally	O
.	O
Visual	O
fields	O
are	O
full	O
to	O
confrontation	O
.	O
III	O
,	O
IV	O
,	O
VI	O
:	O
Extraocular	O
movements	O
intact	O
bilaterally	O
without	O
nystagmus	O
.	O
V	O
,	O
VII	O
:	O
Facial	O
strength	O
and	O
sensation	O
intact	O
and	O
symmetric	O
.	O
VIII	O
:	O
Hearing	O
intact	O
to	O
voice	O
.	O
IX	O
,	O
X	O
:	O
Palatal	O
elevation	O
symmetrical	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
Sternocleidomastoid	O
and	O
trapezius	O
normal	O
bilaterally	O
.	O
XII	O
:	O
Tongue	O
midline	O
without	O
fasciculations	O
.	O
Motor	O
:	O
Normal	O
bulk	O
and	O
tone	O
bilaterally	O
.	O
No	O
abnormal	O
movements	O
,	O
tremors	O
.	O
Strength	O
full	O
power	O
[	O
**	O
5	O
-	O
20	O
**	O
]	O
in	O
the	O
uppers	O
and	O
[	O
**	O
4	O
-	O
20	O
**	O
]	O
in	O
the	O
lowers	O
.	O
He	O
did	O
not	O
participate	O
with	O
all	O
muscle	O
groups	O
in	O
the	O
lowers	O
.	O
Did	O
not	O
participate	O
with	O
pronator	O
drift	O
testing	O
.	O
Sensation	O
:	O
Intact	O
to	O
light	O
touch	O
bilaterally	O
.	O
Toes	O
downgoing	O
bilaterally	O
Upon	O
discharge	O
:	O
Patient	O
is	O
oriented	O
x	O
1	O
upon	O
discharge	O
.	O
His	O
pupils	O
are	O
surgical	O
bilaterally	O
.	O
He	O
is	O
following	O
commands	O
.	O
He	O
appears	O
to	O
have	O
some	O
neglect	O
on	O
the	O
right	O
side	O
but	O
does	O
move	O
the	O
right	O
side	O
somewhat	O
.	O
His	O
left	O
side	O
is	O
strong	O
,	O
purposeful	O
.	O
He	O
has	O
a	O
foley	O
catheter	O
in	O
place	O
.	O
Pertinent	O
Results	O
:	O
CT	O
head	O
[	O
**	O
2200-2-17	O
**	O
]	O
:	O
FINDINGS	O
:	O
The	O
study	O
is	O
compared	O
with	O
the	O
initial	O
NECT	O
of	O
[	O
**	O
2	O
-	O
14	O
**	O
]	O
and	O
the	O
interval	O
unenhanced	O
and	O
enhanced	O
MR	O
examinations	O
of	O
[	O
**	O
2200-2-15	O
**	O
]	O
.	O
Over	O
the	O
three	O
-	O
day	O
interval	O
,	O
there	O
has	O
been	O
little	O
change	O
in	O
the	O
overall	O
appearance	O
of	O
the	O
heterogeneous	O
but	O
predominantly	O
hyperattenuating	O
lobulated	O
process	O
centered	O
in	O
the	O
extra-axial	O
space	O
of	O
the	O
left	O
parietovertex	O
.	O
This	O
appears	O
to	O
"	O
mold	O
"	O
to	O
the	O
contour	O
of	O
the	O
subjacent	O
convexity	O
,	O
where	O
there	O
is	O
focal	O
low	O
-	O
attenuation	O
in	O
the	O
immediate	O
subcortical	O
white	O
matter	O
,	O
corresponding	O
to	O
the	O
FLAIR	O
-	O
signal	O
abnormality	O
in	O
this	O
region	O
,	O
which	O
may	O
represent	O
edema	O
secondary	O
to	O
venous	O
congestion	O
,	O
gliosis	O
,	O
or	O
both	O
.	O
The	O
overall	O
appearance	O
is	O
most	O
suggestive	O
of	O
a	O
partially	O
calcified	O
en	O
plaque	O
meningioma	O
,	O
though	O
there	O
is	O
no	O
specific	O
evidence	O
of	O
"	O
reactive	O
change	O
"	O
in	O
the	O
suprajacent	O
inner	O
table	O
of	O
the	O
skull	O
.	O
There	O
has	O
been	O
no	O
other	O
short	O
-	O
interval	O
change	O
.	O
IMPRESSION	O
:	O
No	O
short	O
-	O
interval	O
change	O
in	O
the	O
overall	O
appearance	O
,	O
with	O
the	O
lobulated	O
,	O
predominantly	O
hyperdense	O
,	O
process	O
,	O
in	O
the	O
extra-axial	O
space	O
at	O
the	O
left	O
parietovertex	O
,	O
given	O
its	O
stability	O
and	O
MR	O
[	O
**	O
Date	O
Range	O
**	O
]	O
more	O
likely	O
an	O
en	O
plaque	O
meningioma	O
,	O
partially	O
calcified	O
,	O
accounting	O
for	O
the	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
16313	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
.	O
Moreover	O
,	O
the	O
findings	O
on	O
both	O
this	O
exam	O
and	O
the	O
recent	O
enhanced	O
MR	O
study	O
raise	O
the	O
serious	O
possibility	O
of	O
at	O
least	O
partial	O
invasion	O
of	O
the	O
immediately	O
subjacent	O
superior	O
sagittal	O
sinus	O
,	O
without	O
definite	O
thrombosis	O
,	O
and	O
possible	O
venous	O
obstruction	O
-	O
related	O
edema	O
in	O
local	O
white	O
matter	O
.	O
If	O
this	O
will	O
affect	O
therapeutic	O
decision	O
,	O
dedicated	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
venography	O
might	O
be	O
considered	O
.	O
MRI	O
Brain	O
[	O
**	O
2200-2-15	O
**	O
]	O
:	O
FINDINGS	O
:	O
The	O
study	O
is	O
significantly	O
limited	O
due	O
to	O
patient	O
motion	O
artifacts	O
.	O
There	O
is	O
enhancement	O
noted	O
in	O
the	O
area	O
of	O
known	O
hemorrhage	O
in	O
the	O
left	O
parieto	O
-	O
occipital	O
region	O
,	O
compared	O
to	O
the	O
pre-contrast	O
sequences	O
done	O
on	O
the	O
prior	O
study	O
.	O
However	O
,	O
the	O
etiology	O
of	O
enhancement	O
is	O
not	O
clear	O
as	O
there	O
is	O
significant	O
amount	O
of	O
hemorrhage	O
in	O
this	O
location	O
,	O
as	O
seen	O
on	O
the	O
prior	O
CT	O
and	O
MR	O
studies	O
.	O
Mildly	O
dilated	O
ventricles	O
are	O
visualized	O
,	O
not	O
adequately	O
assessed	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Study	O
significantly	O
limited	O
due	O
to	O
motion	O
artifacts	O
.	O
Enhancement	O
noted	O
in	O
the	O
left	O
parieto	O
-	O
occipital	O
region	O
,	O
partly	O
extending	O
along	O
the	O
dura	O
,	O
the	O
etiology	O
of	O
which	O
is	O
uncertain	O
,	O
as	O
this	O
is	O
in	O
the	O
region	O
of	O
the	O
known	O
hemorrhage	O
.	O
Repeat	O
evaluation	O
,	O
after	O
resolution	O
of	O
the	O
hemorrhage	O
can	O
be	O
considered	O
,	O
to	O
evaluate	O
for	O
any	O
underlying	O
vascular	O
or	O
space	O
-	O
occupying	O
lesion	O
.	O
Close	O
followup	O
with	O
CT	O
scan	O
can	O
also	O
be	O
considered	O
as	O
clinically	O
indicated	O
.	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
admitted	O
on	O
[	O
**	O
2200-2-14	O
**	O
]	O
to	O
the	O
neurosurgery	O
service	O
after	O
a	O
mental	O
status	O
change	O
at	O
the	O
nursing	O
home	O
.	O
He	O
was	O
admitted	O
with	O
a	O
presumed	O
SDH	O
on	O
the	O
CT	O
scan	O
.	O
However	O
,	O
the	O
patient	O
had	O
an	O
MRI	O
which	O
revealed	O
a	O
mass	O
resembling	O
a	O
meningioma	O
.	O
There	O
was	O
no	O
hemorrhage	O
there	O
.	O
The	O
patient	O
was	O
transferred	O
out	O
of	O
the	O
ICU	O
on	O
[	O
**	O
2200-2-18	O
**	O
]	O
.	O
He	O
was	O
evaluated	O
by	O
PT	O
and	O
a	O
speech	O
/	O
swallowing	O
therapist	O
.	O
PT	O
felt	O
that	O
he	O
was	O
safe	O
to	O
be	O
discharged	O
back	O
the	O
his	O
nursing	O
home	O
on	O
[	O
**	O
2200-2-19	O
**	O
]	O
.	O
On	O
[	O
**	O
2	O
-	O
19	O
**	O
]	O
he	O
was	O
also	O
able	O
to	O
take	O
in	O
thin	O
liquids	O
and	O
pureed	O
solids	O
without	O
difficulty	O
.	O
He	O
had	O
his	O
foley	O
catheter	O
removed	O
on	O
[	O
**	O
2	O
-	O
18	O
**	O
]	O
but	O
had	O
urinary	O
retention	O
.	O
A	O
Coud	O
??????	O
catheter	O
was	O
placed	O
that	O
night	O
and	O
he	O
was	O
discharged	O
with	O
it	O
in	O
place	O
.	O
Flomax	I-Drug
was	O
started	O
as	O
well	O
and	O
bladder	O
training	O
was	O
begun	O
.	O
He	O
may	O
be	O
able	O
to	O
have	O
it	O
removed	O
in	O
a	O
day	O
or	O
so	O
at	O
the	O
nursing	O
home	O
.	O
The	O
patient	O
should	O
follow	O
up	O
with	O
a	O
urologist	O
.	O
The	O
patient	O
was	O
made	O
DNR	O
/	O
DNI	O
in	O
the	O
hospital	O
by	O
his	O
health	O
care	O
proxy	O
as	O
well	O
as	O
for	O
the	O
ambulance	O
ride	O
.	O
Palliative	O
care	O
and	O
medical	O
consults	O
were	O
obtained	O
to	O
assist	O
in	O
management	O
of	O
the	O
patient	O
.	O
His	O
medications	O
were	O
optimized	O
due	O
to	O
his	O
mental	O
status	O
changes	O
.	O
Additionally	O
a	O
family	O
meeting	O
with	O
all	O
3	O
teams	O
occurred	O
.	O
It	O
was	O
felt	O
that	O
surgery	O
would	O
not	O
benefit	O
the	O
patient	O
and	O
that	O
quality	O
of	O
life	O
was	O
important	O
.	O
We	O
all	O
agreed	O
that	O
being	O
at	O
the	O
nursing	O
home	O
with	O
his	O
wife	O
would	O
be	O
the	O
best	O
for	O
him	O
at	O
this	O
time	O
.	O
The	O
nursing	O
home	O
staff	O
may	O
want	O
to	O
consider	O
a	O
"	O
Do	O
not	O
hospitalize	O
"	O
policy	O
with	O
this	O
patient	O
and	O
his	O
health	O
care	O
proxy	O
.	O
Medications	O
on	O
Admission	O
:	O
Lisinopril	B-Drug
10	O
mg	O
PO	O
DAILY	O
Atenolol	I-Drug
25	O
mg	O
PO	O
DAILY	O
Omeprazole	I-Drug
10	O
mg	O
PO	O
DAILY	O
Hydrochlorothiazide	I-Drug
12.5	O
mg	O
PO	O
DAILY	O
Vesicare	I-Drug
5	O
mg	O
Oral	O
daily	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
PO	O
DAILY	O
Meclizine	I-Drug
25	O
mg	O
PO	O
QID	O
Mirtazapine	B-Drug
7.5	O
mg	O
PO	O
HS	O
Cholestyramine	I-Drug
4	O
gm	O
PO	O
DAILY	O
Trazadone	I-Drug
25	O
mg	O
PO	O
HS	O
Oxycodone	B-Drug
SR	I-Drug
(	I-Drug
OxyconTIN	O
)	O
10	O
mg	O
PO	O
Q12H	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
PO	O
BID	O
Senna	I-Drug
1	O
TAB	O
PO	O
BID	O
Bisacodyl	B-Drug
10	O
mg	O
PO	O
/	O
PR	O
DAILY	O
Discharge	O
Medications	O
:	O
1	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
Cyanocobalamin	I-Drug
1,000	O
mcg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
DAILY	O
(	O
Daily	O
)	O
for	O
3	O
days	O
.	O
3	O
.	O
Vitamin	B-Drug
B	I-Drug
-	I-Drug
12	I-Drug
1,000	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
4	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
5	O
.	O
Lisinopril	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Atenolol	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
10	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
-	O
1.0	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
:	O
pain	I-Reason
.	O
*****	O
The	O
PO	O
vitamin	B-Drug
B12	I-Drug
should	O
begin	O
after	O
the	O
injections	O
are	O
completed	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
Academy	O
Manor	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
7658	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
7658	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
meningioma	O
Discharge	O
Condition	O
:	O
neurologically	O
improved	O
compared	O
to	O
admission	O
Discharge	O
Instructions	O
:	O
??????	O
Take	O
your	O
pain	I-Drug
medicine	O
as	O
prescribed	O
.	O
??????	O
Exercise	O
should	O
be	O
limited	O
to	O
walking	O
;	O
no	O
lifting	O
,	O
straining	O
,	O
or	O
excessive	O
bending	O
.	O
??????	O
Increase	O
your	O
intake	O
of	O
fluids	O
and	O
fiber	O
,	O
as	O
narcotic	B-Drug
pain	I-Drug
medicine	O
can	O
cause	O
constipation	I-Ade
.	O
We	O
generally	O
recommend	O
taking	O
an	O
over	B-Drug
the	I-Drug
counter	I-Drug
stool	I-Drug
softener	I-Drug
,	O
such	O
as	O
Docusate	I-Drug
(	O
Colace	O
)	O
while	O
taking	O
narcotic	B-Drug
pain	I-Drug
medication	I-Drug
.	O
??????	O
Unless	O
directed	O
by	O
your	O
doctor	O
,	O
do	O
not	O
take	O
any	O
anti-inflammatory	B-Drug
medicines	I-Drug
such	O
as	O
Motrin	I-Drug
,	O
Aspirin	I-Drug
,	O
Advil	I-Drug
,	O
or	O
Ibuprofen	I-Drug
etc.	O
.	O
CALL	O
YOUR	O
SURGEON	O
IMMEDIATELY	O
IF	O
YOU	O
EXPERIENCE	O
ANY	O
OF	O
THE	O
FOLLOWING	O
??????	O
New	O
onset	O
of	O
tremors	O
or	O
seizures	O
.	O
??????	O
Any	O
confusion	O
,	O
lethargy	O
or	O
change	O
in	O
mental	O
status	O
.	O
??????	O
Any	O
numbness	O
,	O
tingling	O
,	O
weakness	O
in	O
your	O
extremities	O
.	O
??????	O
Pain	O
or	O
headache	O
that	O
is	O
continually	O
increasing	O
,	O
or	O
not	O
relieved	O
by	O
pain	I-Drug
medication	O
.	O
??????	O
New	O
onset	O
of	O
the	O
loss	O
of	O
function	O
,	O
or	O
decrease	O
of	O
function	O
on	O
one	O
whole	O
side	O
of	O
your	O
body	O
.	O
Followup	O
Instructions	O
:	O
No	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
needed	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1669	O
**	O
]	O
with	O
questions	O
.	O
Your	O
medications	O
were	O
adjusted	O
while	O
in	O
the	O
hospital	O
.	O
Please	O
take	O
as	O
directed	O
in	O
the	O
following	O
pages	O
.	O
You	O
had	O
a	O
foley	O
catheter	O
placed	O
on	O
[	O
**	O
2	O
-	O
18	O
**	O
]	O
due	O
to	O
urinary	O
retention	O
.	O
Follow	O
up	O
with	O
a	O
urologist	O
at	O
the	O
nursing	O
home	O
or	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
-	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
164	O
**	O
]	O
for	O
an	O
appointment	O
in	O
the	O
urology	O
office	O
on	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
.	O
Completed	O
by	O
:[	O
**	O
2200-2-19	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2148-1-11	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2148-1-16	O
**	O
]	O
Service	O
:	O
NEUROLOGY	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Amoxicillin	I-Drug
/	O
Banana	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2569	O
**	O
]	O
Chief	O
Complaint	O
:	O
code	O
stroke	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
-	O
IV	O
-	O
tPA	I-Drug
given	O
for	O
stroke	I-Reason
,	O
with	O
minimal	O
improvement	O
-	O
Right	O
thigh	O
fasciotomy	O
for	O
hematoma	O
/	O
compartment	O
syndrome	O
-	O
Made	O
CMO	O
-	O
Deceased	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
86	O
yo	O
W	O
with	O
h	O
/	O
o	O
AF	O
not	O
on	O
coumadin	I-Drug
,	O
MVR	O
and	O
recent	O
hip	O
fracture	O
s	O
/	O
p	O
ORIF	O
[	O
**	O
2147-12-20	O
**	O
]	O
who	O
presents	O
with	O
acute	O
onset	O
L	O
sided	O
weakness	O
and	O
facial	O
droop	O
at	O
rehab	O
.	O
The	O
patient	O
was	O
noticed	O
by	O
rehab	O
staff	O
to	O
acutely	O
develop	O
left	O
facial	O
droop	O
and	O
left	O
arm	O
and	O
leg	O
weakness	O
at	O
13:45	O
today	O
.	O
There	O
is	O
no	O
other	O
collateral	O
history	O
available	O
.	O
Per	O
patient	O
's	O
daugther	O
,	O
she	O
has	O
been	O
declining	O
since	O
[	O
**	O
2147-9-13	O
**	O
]	O
with	O
more	O
confusion	O
,	O
falls	O
and	O
finally	O
the	O
hip	O
fracture	O
for	O
which	O
she	O
remained	O
hospitalized	O
for	O
3	O
weeks	O
with	O
complications	O
including	O
delirium	O
.	O
She	O
is	O
intermitently	O
confused	O
,	O
but	O
usually	O
oriented	O
x	O
2	O
,	O
she	O
is	O
able	O
to	O
feed	O
herself	O
.	O
She	O
has	O
not	O
walked	O
since	O
the	O
surgery	O
,	O
but	O
was	O
previously	O
using	O
a	O
walker	O
.	O
Before	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
,	O
she	O
was	O
living	O
alone	O
and	O
independent	O
.	O
On	O
arrival	O
in	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
,	O
NIHSS	O
8	O
for	O
L	O
facial	O
droop	O
,	O
L	O
hemiparesis	O
,	O
answers	O
name	O
but	O
not	O
age	O
correctly	O
,	O
dysarthria	O
.	O
Head	O
CT	O
showed	O
hypodensity	O
of	O
the	O
R	O
MCA	O
territory	O
,	O
no	O
cut	O
-	O
off	O
seen	O
,	O
no	O
ICH	O
.	O
Patient	O
was	O
deemed	O
candidate	O
for	O
t	B-Drug
-	I-Drug
PA	I-Drug
with	O
no	O
absolute	O
contraindications	O
(	O
surgery	O
was	O
>	O
14	O
days	O
ago	O
)	O
.	O
She	O
was	O
given	O
t	B-Drug
-	I-Drug
PA	I-Drug
with	O
no	O
immediate	O
improvement	O
.	O
After	O
30	O
minutes	O
,	O
L	O
arm	O
was	O
antigravity	O
,	O
she	O
was	O
opening	O
eyes	O
more	O
and	O
answering	O
yes	O
/	O
no	O
questions	O
with	O
nodding	O
head	O
.	O
Denies	O
pain	O
or	O
headache	O
.	O
Upon	O
completion	O
of	O
t	B-Drug
-	I-Drug
PA	I-Drug
(	O
1	O
hour	O
)	O
,	O
patient	O
was	O
lifting	O
L	O
hand	O
antigravity	O
to	O
command	O
,	O
proximal	O
strength	O
better	O
than	O
distal	O
strength	O
(	O
still	O
not	O
squeezing	O
hand	O
)	O
.	O
She	O
was	O
indicating	O
she	O
had	O
pain	O
in	O
the	O
right	O
lower	O
back	O
and	O
right	O
thigh	O
.	O
Inspection	O
of	O
the	O
right	O
thigh	O
revealed	O
swollen	O
,	O
hard	O
area	O
c	O
/	O
w	O
hematoma	O
.	O
Ortho	O
was	O
consulted	O
for	O
possible	O
compartment	O
syndrome	O
.	O
CT	O
scan	O
of	O
the	O
thigh	O
was	O
ordered	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
MVR	O
for	O
prolapse	O
-	O
chronic	O
Afib	O
-	O
HTN	O
-	O
hyperlipidemia	O
-	O
hypothyroidism	O
-	O
UTIs	O
Social	O
History	O
:	O
Had	O
been	O
@Rehab	O
Facility	O
.	O
Had	O
been	O
living	O
alone	O
until	O
[	O
**	O
9	O
-	O
/	O
2147	O
**	O
]	O
,	O
then	O
went	O
to	O
rehab	O
due	O
to	O
falls	O
,	O
then	O
[	O
**	O
Hospital3	O
**	O
]	O
(	O
[	O
**	O
Hospital	O
**	O
]	O
)	O
,	O
and	O
then	O
fell	O
again	O
prompting	O
recent	O
hospitalization	O
and	O
discharge	O
to	O
rehab	O
.	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
<<	O
on	O
admission	O
>>	O
VS	O
:	O
T	O
AF	O
HR	O
84	O
BP	O
123/65	O
RR	O
19	O
02	O
100	O
/	O
face	O
mask	O
GEN	O
:	O
cachectic	O
elderly	O
woman	O
,	O
moderate	O
distress	O
HEENT	O
:	O
sclera	O
anicteric	O
CV	O
:	O
irregular	O
PULM	O
:	O
CTAB	O
AB	O
:	O
ND	O
/	O
NT	O
EXT	O
:	O
no	O
edema	O
NEURO	O
:	O
MS	O
:	O
Eyes	O
closed	O
,	O
do	O
not	O
open	O
to	O
command	O
,	O
open	O
slightly	O
to	O
noxious	O
stimuli	O
.	O
Answers	O
name	O
,	O
says	O
age	O
is	O
61	O
.	O
Speech	O
dysarthria	O
,	O
also	O
moaning	O
,	O
difficult	O
to	O
assess	O
language	O
further	O
.	O
CN	O
:	O
PERRL	O
2.5	O
to	O
2	O
mm	O
.	O
EOMI	O
.	O
Blinks	O
to	O
threat	O
bilaterally	O
.	O
L	O
facial	O
droop	O
at	O
rest	O
.	O
Tongue	O
midline	O
MOTOR	O
:	O
moving	O
R	O
side	O
spontaneously	O
and	O
to	O
command	O
(	O
can	O
not	O
lift	O
RLE	O
to	O
command	O
s	O
/	O
p	O
hip	O
surgery	O
)	O
,	O
moving	O
LLE	O
to	O
command	O
antigravity	O
for	O
8	O
seconds	O
,	O
no	O
movement	O
of	O
LUE	O
to	O
command	O
.	O
Withdraws	O
and	O
localizes	O
pain	O
in	O
all	O
4	O
extremities	O
.	O
SENSATION	O
:	O
withdraws	O
to	O
pain	O
in	O
all	O
4	O
extremities	O
.	O
COORDINATION	O
:	O
intact	O
finger	O
to	O
nose	O
on	O
RUE	O
Pertinent	O
Results	O
:	O
[	O
**	O
2148-1-12	O
**	O
]	O
04:52	O
AM	O
BLOOD	O
WBC	O
-	O
10.9	O
RBC	O
-	O
2.95	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
26.9	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
19.9	O
*	O
Plt	O
Ct	O
-	O
243	O
[	O
**	O
2148-1-11	O
**	O
]	O
09:34	O
PM	O
BLOOD	O
WBC	O
-	O
15.1	O
*	O
RBC	O
-	O
2.44	O
*	O
Hgb	O
-	O
7.8	O
*	O
Hct	O
-	O
23.6	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
32.1	O
*	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
19.5	O
*	O
Plt	O
Ct	O
-	O
285	O
[	O
**	O
2148-1-11	O
**	O
]	O
02:44	O
PM	O
BLOOD	O
WBC	O
-	O
10.1	O
RBC	O
-	O
2.60	O
*	O
Hgb	O
-	O
8.8	O
*	O
Hct	O
-	O
26.3	O
*	O
MCV	O
-	O
101	O
*	O
MCH	O
-	O
33.9	O
*	O
MCHC	O
-	O
33.5	O
RDW	O
-	O
16.9	O
*	O
Plt	O
Ct	O
-	O
359	O
[	O
**	O
2148-1-11	O
**	O
]	O
09:34	O
PM	O
BLOOD	O
PT	O
-	O
14.4	O
*	O
PTT	O
-	O
27.3	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2148-1-11	O
**	O
]	O
02:44	O
PM	O
BLOOD	O
PT	O
-	O
13.2	O
PTT	O
-	O
24.9	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2148-1-12	O
**	O
]	O
04:52	O
AM	O
BLOOD	O
Glucose	O
-	O
99	O
UreaN	O
-	O
28	O
*	O
Creat	O
-	O
0.6	O
Na	O
-	O
138	O
K	O
-	O
4.8	O
Cl	O
-	O
105	O
HCO3	O
-	O
26	O
AnGap	O
-	O
12	O
[	O
**	O
2148-1-11	O
**	O
]	O
09:34	O
PM	O
BLOOD	O
Glucose	O
-	O
101	O
*	O
UreaN	O
-	O
28	O
*	O
Creat	O
-	O
0.6	O
Na	O
-	O
135	O
K	O
-	O
5.0	O
Cl	O
-	O
106	O
HCO3	O
-	O
24	O
AnGap	O
-	O
10	O
[	O
**	O
2148-1-11	O
**	O
]	O
02:44	O
PM	O
BLOOD	O
Glucose	O
-	O
91	O
UreaN	O
-	O
29	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
138	O
K	O
-	O
4.7	O
Cl	O
-	O
104	O
HCO3	O
-	O
27	O
AnGap	O
-	O
12	O
[	O
**	O
2148-1-11	O
**	O
]	O
09:34	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
42	O
[	O
**	O
2148-1-11	O
**	O
]	O
09:34	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
4	O
cTropnT	O
-	O
0.04	O
*	O
[	O
**	O
2148-1-11	O
**	O
]	O
02:44	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
5	O
[	O
**	O
2148-1-11	O
**	O
]	O
02:44	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.04	O
*	O
[	O
**	O
2148-1-12	O
**	O
]	O
04:52	O
AM	O
BLOOD	O
Calcium	O
-	O
7.9	O
*	O
Phos	O
-	O
4.1	O
Mg	O
-	O
2.4	O
[	O
**	O
2148-1-11	O
**	O
]	O
09:34	O
PM	O
BLOOD	O
Calcium	O
-	O
7.9	O
*	O
Phos	O
-	O
4.3	O
#	O
Mg	O
-	O
1.8	O
[	O
**	O
2148-1-11	O
**	O
]	O
ECG	O
:	O
<<	O
a.flutter	O
>>	O
Cardiology	O
Report	O
ECG	O
Study	O
Date	O
of	O
[	O
**	O
2148-1-11	O
**	O
]	O
2:35:06	O
PM	O
Possible	O
atrial	O
flutter	O
with	O
multiple	O
premature	O
ventricular	O
complexes	O
.	O
Right	O
axis	O
deviation	O
.	O
Left	O
ventricular	O
hypertrophy	O
with	O
secondary	O
repolarization	O
abnormalities	O
.	O
Inferolateral	O
ST	O
segment	O
changes	O
secondary	O
to	O
left	O
ventricular	O
hypertrophy	O
versus	O
myocardial	O
ischemia	O
.	O
Clinical	O
correlation	O
is	O
suggested	O
.	O
Extensive	O
baseline	O
artifact	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2148-1-3	O
**	O
]	O
the	O
rhythm	O
now	O
appears	O
to	O
be	O
more	O
consistent	O
with	O
atrial	O
flutter	O
versus	O
atrial	O
fibrillation	O
and	O
multiple	O
premature	O
ventricular	O
complexes	O
are	O
now	O
seen	O
.	O
TRACING	O
#	O
1	O
Read	O
by	O
:	O
FISH	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
E.	O
Intervals	O
Axes	O
Rate	O
PR	O
QRS	O
QT	O
/	O
QTc	O
P	O
QRS	O
T	O
87	O
0	O
122364/411	O
0	O
69	O
35	O
[	O
**	O
2148-1-11	O
**	O
]	O
HCT	O
/	O
CTA	O
/	O
CT	O
-	O
perfusion	O
(	O
@presentation	O
to	O
our	O
ED	O
)	O
:	O
FINDINGS	O
:	O
HEAD	O
CT	O
:	O
An	O
extensive	O
region	O
of	O
the	O
right	O
MCA	O
distribution	O
demonstrates	O
loss	O
of	O
the	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
and	O
is	O
diffusely	O
hypodense	O
.	O
There	O
is	O
minimal	O
sulcal	O
effacement	O
.	O
There	O
is	O
no	O
associated	O
intracranial	O
hemorrhage	O
.	O
Elsewhere	O
in	O
the	O
brain	O
,	O
there	O
is	O
no	O
edema	O
,	O
hemorrhage	O
,	O
mass	O
effect	O
,	O
or	O
evidence	O
of	O
infarction	O
.	O
Ventricles	O
and	O
sulci	O
are	O
otherwise	O
normal	O
in	O
size	O
and	O
configuration	O
for	O
the	O
patient	O
's	O
age	O
.	O
No	O
fractures	O
are	O
identified	O
.	O
The	O
right	O
maxillary	O
sinus	O
is	O
again	O
atelectatic	O
and	O
completely	O
opacified	O
.	O
Remaining	O
paranasal	O
sinuses	O
and	O
mastoid	O
air	O
cells	O
are	O
well	O
aerated	O
.	O
The	O
configuration	O
of	O
the	O
calvarium	O
is	O
again	O
unusual	O
,	O
with	O
thinning	O
of	O
the	O
posterior	O
calvarium	O
bilaterally	O
,	O
with	O
a	O
congenital	O
appearance	O
.	O
CT	O
PERFUSION	O
:	O
The	O
perfusion	O
maps	O
demonstrate	O
an	O
extensive	O
region	O
of	O
prolonged	O
transit	O
time	O
and	O
reduced	O
blood	O
flow	O
and	O
blood	O
volume	O
throughout	O
the	O
right	O
MCA	O
distribution	O
,	O
compatible	O
with	O
infarct	O
.	O
There	O
is	O
no	O
mismatch	O
to	O
indicate	O
a	O
penumbra	O
.	O
HEAD	O
AND	O
NECK	O
CTA	O
:	O
There	O
is	O
an	O
abrupt	O
cutoff	O
of	O
the	O
superior	O
division	O
of	O
the	O
right	O
M2	O
segment	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
.	O
The	O
inferior	O
division	O
arises	O
early	O
from	O
the	O
M1	O
segment	O
on	O
the	O
right	O
.	O
There	O
is	O
a	O
relative	O
paucity	O
of	O
distal	O
opacification	O
within	O
the	O
MCA	O
territory	O
on	O
the	O
right	O
.	O
However	O
,	O
a	O
few	O
opacified	O
vessels	O
are	O
present	O
,	O
the	O
result	O
of	O
collateral	O
flow	O
.	O
The	O
remainder	O
of	O
the	O
circle	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
431	O
**	O
]	O
is	O
patent	O
without	O
other	O
area	O
of	O
occlusion	O
.	O
The	O
anterior	O
communicating	O
artery	O
has	O
a	O
slightly	O
bulbous	O
appearance	O
.	O
The	O
cervical	O
carotid	O
and	O
vertebral	O
arteries	O
and	O
major	O
branches	O
are	O
patent	O
with	O
no	O
high	O
-	O
grade	O
stenoses	O
.	O
However	O
,	O
the	O
entire	O
right	O
cervical	O
ICA	O
is	O
slightly	O
diminutive	O
in	O
caliber	O
relative	O
to	O
the	O
left	O
,	O
and	O
slightly	O
irregular	O
suggesting	O
a	O
long	O
segment	O
of	O
atherosclerosis	O
.	O
Both	O
carotid	O
bulbs	O
demonstrate	O
atheromatous	O
irregularity	O
without	O
high	O
-	O
grade	O
stenosis	O
.	O
There	O
is	O
atherosclerotic	O
calcification	O
of	O
the	O
cavernous	O
carotids	O
bilaterally	O
as	O
well	O
.	O
Lung	O
apices	O
demonstrate	O
scarring	O
and	O
high	O
-	O
density	O
material	O
bilaterally	O
,	O
with	O
bronchiectasis	O
at	O
the	O
right	O
lung	O
apex	O
.	O
The	O
aortic	O
arch	O
and	O
origin	O
of	O
the	O
major	O
vessels	O
demonstrate	O
dense	O
atherosclerotic	O
calcification	O
.	O
The	O
right	O
internal	O
carotid	O
artery	O
measures	O
8.3	O
mm	O
at	O
the	O
bulb	O
,	O
3	O
mm	O
just	O
above	O
the	O
bulb	O
,	O
and	O
3	O
mm	O
at	O
its	O
upper	O
portion	O
.	O
The	O
left	O
internal	O
carotid	O
artery	O
measures	O
9	O
mm	O
at	O
the	O
bulb	O
,	O
5	O
mm	O
just	O
above	O
the	O
bulb	O
,	O
and	O
3.3	O
mm	O
along	O
the	O
upper	O
segment	O
.	O
IMPRESSIONS	O
:	O
1	O
.	O
Large	O
acute	O
infarct	O
in	O
the	O
right	O
MCA	O
distribution	O
,	O
with	O
no	O
perfusion	O
mismatch	O
.	O
2	O
.	O
Abrupt	O
occlusion	O
of	O
the	O
superior	O
division	O
of	O
the	O
right	O
M2	O
segment	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
,	O
with	O
decreased	O
filling	O
of	O
distal	O
branches	O
.	O
Otherwise	O
,	O
patent	O
circle	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
431	O
**	O
]	O
.	O
3	O
.	O
Atheromatous	O
irregularity	O
at	O
the	O
carotid	O
bulb	O
bilaterally	O
,	O
with	O
slightly	O
diminutive	O
right	O
cervical	O
ICA	O
along	O
its	O
entire	O
length	O
,	O
suggesting	O
long	O
segment	O
atherosclerosis	O
versus	O
vasculitis	O
.	O
However	O
,	O
no	O
high	O
-	O
grade	O
stenosis	O
of	O
either	O
side	O
.	O
4	O
.	O
Slightly	O
bulbous	O
appearance	O
of	O
the	O
anterior	O
communicating	O
artery	O
.	O
Please	O
correlate	O
with	O
angiography	O
.	O
5	O
.	O
Complete	O
opacification	O
and	O
atelectasis	O
of	O
the	O
right	O
maxillary	O
sinus	O
as	O
seen	O
previously	O
.	O
[	O
**	O
2148-1-11	O
**	O
]	O
NCHCT	O
:	O
FINDINGS	O
:	O
Again	O
noted	O
is	O
loss	O
of	O
the	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
in	O
the	O
right	O
insula	O
.	O
Sulcal	O
effacement	O
and	O
loss	O
of	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
differentiation	O
extends	O
to	O
the	O
right	O
frontal	O
and	O
parietal	O
lobes	O
in	O
a	O
right	O
MCA	O
distribution	O
.	O
No	O
evidence	O
of	O
acute	O
hemorrhage	O
is	O
seen	O
.	O
There	O
is	O
some	O
compression	O
of	O
the	O
right	O
lateral	O
ventricle	O
,	O
not	O
significantly	O
changed	O
from	O
the	O
prior	O
examination	O
.	O
General	O
prominence	O
of	O
the	O
ventricles	O
and	O
sulci	O
is	O
compatible	O
with	O
generalized	O
atrophy	O
,	O
age	O
related	O
.	O
Areas	O
of	O
periventricular	O
and	O
subcortical	O
white	O
matter	O
hypodensity	O
likely	O
reflect	O
sequela	O
of	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
.	O
No	O
concerning	O
osseous	O
lesion	O
is	O
seen	O
.	O
There	O
are	O
vascular	O
calcifications	O
of	O
the	O
bilateral	O
carotid	O
siphons	O
.	O
Complete	O
opacification	O
of	O
the	O
right	O
maxillary	O
sinus	O
is	O
unchanged	O
.	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
hemorrhage	O
.	O
2	O
.	O
Infarction	O
in	O
right	O
MCA	O
distribution	O
as	O
previously	O
seen	O
.	O
No	O
shift	O
of	O
midline	O
structures	O
.	O
[	O
**	O
2148-1-12	O
**	O
]	O
NCHCT	O
:	O
FINDINGS	O
:	O
Again	O
seen	O
is	O
a	O
large	O
right	O
MCA	O
territory	O
infarct	O
with	O
expected	O
evolution	O
.	O
There	O
is	O
no	O
evidence	O
of	O
hemorrhage	O
within	O
the	O
infarct	O
.	O
No	O
significant	O
mass	O
effect	O
or	O
shift	O
of	O
midline	O
structures	O
is	O
seen	O
.	O
The	O
ventricles	O
and	O
sulci	O
are	O
mildly	O
dilated	O
,	O
consistent	O
with	O
age	O
-	O
related	O
involutional	O
changes	O
.	O
The	O
basal	O
cisterns	O
are	O
normal	O
.	O
Calcification	O
of	O
the	O
cavernous	O
portion	O
of	O
bilateral	O
carotid	O
arteries	O
is	O
present	O
.	O
The	O
mastoid	O
air	O
cells	O
and	O
imaged	O
paranasal	O
sinuses	O
are	O
clear	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Expected	O
evolution	O
of	O
the	O
large	O
right	O
MCA	O
territory	O
infarct	O
.	O
No	O
significant	O
mass	O
effect	O
or	O
shift	O
of	O
midline	O
structures	O
is	O
seen	O
.	O
2	O
.	O
No	O
evidence	O
of	O
hemorrhage	O
within	O
the	O
infarct	O
.	O
Brief	O
Hospital	O
Course	O
:	O
86y	O
F	O
with	O
atrial	O
flutter	O
and	O
recently	O
worsening	O
dementia	O
(	O
undiagnosed	O
)	O
,	O
who	O
was	O
not	O
taking	O
anti-coagulation	I-Drug
for	O
her	O
afib	O
,	O
recently	O
s	O
/	O
p	O
right	O
Femur	O
repair	O
[	O
**	O
2147-12-20	O
**	O
]	O
.	O
Returned	O
from	O
Rehab	O
to	O
our	O
ED	O
as	O
a	O
code	O
stroke	O
due	O
to	O
Left	O
-	O
sided	O
weakness	O
,	O
and	O
was	O
found	O
to	O
have	O
a	O
Right	O
-	O
M2	O
(	O
superior	O
division	O
)	O
occlusion	O
,	O
presumably	O
due	O
to	O
cardioembolic	B-Reason
clot	I-Reason
given	O
her	O
aflutter	O
without	O
A	O
/	O
C.	O
Given	O
IV	O
-	O
tPA	I-Drug
in	O
the	O
ED	O
,	O
with	O
some	O
improvement	O
in	O
her	O
LUE	O
(	O
anti-gravity	O
strength	O
)	O
,	O
but	O
this	O
was	O
c	O
/	O
b	O
a	O
large	O
and	O
painful	O
hematoma	O
in	O
the	O
region	O
of	O
her	O
recent	O
surgery	O
,	O
which	O
required	O
that	O
she	O
go	O
to	O
OR	O
urgently	O
with	O
Orthopedics	O
for	O
fasciotomy	O
to	O
relieve	O
pressure	O
from	O
compartment	O
syndrome	O
(	O
70mmHg	O
pressure	O
measured	O
by	O
Ortho	O
)	O
.	O
Her	O
H&H	O
dropped	O
,	O
but	O
improved	O
appopriately	O
after	O
transfusion	O
of	O
2U	O
PRBCs	I-Drug
.	O
Her	O
family	O
decided	O
to	O
stop	O
pursuing	O
aggressive	O
care	O
measures	O
;	O
fasciotomy	O
and	O
transfusion	O
were	O
performed	O
due	O
to	O
their	O
palliative	O
value	O
(	O
pt	O
.	O
in	O
severe	O
pain	O
from	O
pressure	O
/	O
compartment	O
syndrome	O
)	O
.	O
Pt	O
was	O
made	O
CMO	O
by	O
family	O
and	O
transferred	O
to	O
the	O
floor	O
,	O
with	O
removal	O
of	O
tubes	O
,	O
lines	O
,	O
and	O
invasive	O
interventions	O
and	O
testing	O
measures	O
.	O
She	O
remained	O
comfortable	O
,	O
but	O
minimally	O
responsive	O
,	O
with	O
PRN	O
sublingual	O
morphine	I-Drug
and	O
with	O
scopolamine	I-Drug
patch	O
.	O
She	O
died	O
[	O
**	O
2147-1-16	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
3	O
.	O
aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
levothyroxine	I-Drug
100	O
mcg	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
5	O
.	O
lisinopril	I-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
0.03	O
%	O
Drops	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
drop	O
Ophthalmic	O
at	O
bedtime	O
.	O
7	O
.	O
megestrol	I-Drug
400	O
mg	O
/	O
10	O
mL	O
(	O
40	O
mg	O
/	O
mL	O
)	O
Suspension	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
pill	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
cholecalciferol	B-Drug
(	I-Drug
vitamin	I-Drug
D3	I-Drug
)	I-Drug
400	O
unit	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
calcium	B-Drug
carbonate	I-Drug
200	O
mg	O
(	O
500	O
mg	O
)	O
Tablet	O
,	O
Chewable	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
sertraline	I-Drug
50	O
mg	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
digoxin	I-Drug
125	O
mcg	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
EVERY	O
OTHER	O
DAY	O
(	O
Every	O
Other	O
Day	O
)	O
.	O
12	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
packet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
13	O
.	O
bisacodyl	I-Drug
10	O
mg	O
Suppository	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
14	O
.	O
olanzapine	I-Drug
5	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
0.5	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
cyanocobalamin	B-Drug
(	I-Drug
vitamin	I-Drug
B	I-Drug
-	I-Drug
12	I-Drug
)	I-Drug
250	O
mcg	O
Tablet	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
16	O
.	O
lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
17	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	B-Reason
fever	I-Reason
.	O
18	O
.	O
enoxaparin	I-Drug
30	O
mg	O
/	O
0.3	O
mL	O
Syringe	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
syringe	O
Subcutaneous	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
for	O
10	O
days	O
:	O
Last	O
day	O
=	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
.	O
19	O
.	O
mirtazapine	I-Drug
15	O
mg	O
Tablet	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
20	O
.	O
metoprolol	B-Drug
succinate	I-Drug
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
:	O
1.5	O
Tablet	O
Sustained	O
Release	O
24	O
hrs	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Medications	O
:	O
deceased	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
deceased	O
Discharge	O
Condition	O
:	O
deceased	O
Discharge	O
Instructions	O
:	O
deceased	O
Followup	O
Instructions	O
:	O
deceased	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
162	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2575	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2148-1-23	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2133-6-12	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2133-7-1	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2073-11-10	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
9569	O
**	O
]	O
Chief	O
Complaint	O
:	O
Lower	O
Back	O
Pain	O
with	O
LE	O
weakness	O
beginning	O
[	O
**	O
2133-6-8	O
**	O
]	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Laminectomy	O
T12	O
-	O
L2	O
Single	O
wire	O
pacemaker	O
placed	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
a	O
59	O
y	O
/	O
o	O
Cantonese	O
female	O
with	O
a	O
h	O
/	O
o	O
Atrial	O
fibrillation	O
and	O
mechanical	O
MVR	O
(	O
Bjork	O
-	O
Shiley	O
)	O
secondary	O
to	O
RHD	O
experienced	O
low	O
back	O
pain	O
and	O
LE	O
weakness	O
beginning	O
on	O
[	O
**	O
2133-6-8	O
**	O
]	O
.	O
MRI	O
of	O
the	O
lumbar	O
spine	O
revealed	O
a	O
cystic	O
mass	O
at	O
the	O
T12	O
-	O
L2	O
,	O
which	O
was	O
found	O
to	O
be	O
a	O
hematoma	O
upon	O
surgical	O
exploration	O
on	O
[	O
**	O
2133-6-12	O
**	O
]	O
and	O
was	O
subsequently	O
evacuated	O
.	O
Pt	O
has	O
been	O
on	O
Coumadin	I-Drug
and	O
digoxin	I-Drug
due	O
to	O
her	O
cardiac	O
hx	O
and	O
initially	O
her	O
INR	O
was	O
3.5	O
.	O
During	O
the	O
operation	O
the	O
pt	O
experienced	O
episodes	O
of	O
bradycardia	O
with	O
right	O
neck	O
manipulation	O
and	O
swan	O
-	O
ganz	O
catheter	O
placement	O
c	O
/	O
w	O
vagal	O
etiology	O
,	O
however	O
bradycardia	O
and	O
pauses	O
continued	O
for	O
following	O
the	O
surgery	O
.	O
Permanent	O
v	O
-	O
lead	O
pacemaker	O
was	O
placed	O
on	O
[	O
**	O
2133-6-14	O
**	O
]	O
.	O
Pt	O
demonstrated	O
NSVT	I-Ade
believed	O
to	O
be	O
d	O
/	O
t	O
digoxin	I-Drug
toxicity	O
(	O
1.1	O
)	O
.	O
Currently	O
pt	O
c	O
/	O
o	O
pain	O
in	O
right	O
leg	O
from	O
the	O
buttock	O
down	O
to	O
the	O
ankle	O
on	O
the	O
lateral	O
calf	O
,	O
diminishing	O
distally	O
.	O
No	O
c	O
/	O
o	O
CP	O
other	O
than	O
at	O
the	O
incision	O
site	O
for	O
the	O
pacemaker	O
,	O
no	O
SOB	O
,	O
no	O
LH	O
.	O
Difficulty	O
with	O
using	O
bedside	O
commode	O
due	O
to	O
pain	O
and	O
reports	O
no	O
BM	O
,	O
but	O
positive	O
flatus	O
.	O
Past	O
Medical	O
History	O
:	O
MVR	O
secondary	O
to	O
RHD	O
with	O
Bjork	O
-	O
Shiley	O
valve	O
in	O
[	O
**	O
3	O
-	O
/	O
2108	O
**	O
]	O
Atrial	O
fibrillation	O
HTN	O
Social	O
History	O
:	O
Visiting	O
brother	O
in	O
US	O
,	O
lives	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
651	O
**	O
]	O
,	O
speaks	O
predominantly	O
Cantonese	O
and	O
some	O
English	O
.	O
No	O
tobacco	O
,	O
alcohol	O
,	O
or	O
recreational	O
drugs	O
.	O
Family	O
History	O
:	O
Mother	O
with	O
HTN	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
HR	O
-	O
103	O
RR	O
-	O
20	O
T	O
-	O
98.8	O
BP	O
-	O
124/78	O
O2	O
sat	O
-	O
95	O
%	O
on	O
RA	O
Pain	O
-	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
Gen	O
:	O
WN	O
,	O
WD	O
thin	O
woman	O
who	O
appears	O
her	O
age	O
.	O
Appears	O
to	O
be	O
uncomfortable	O
and	O
is	O
diaphoretic	O
.	O
HEENT	O
:	O
EOMI	O
NECK	O
:	O
JVP	O
noted	O
b	O
/	O
l	O
,	O
no	O
JVD	O
CV	O
:	O
Irregularly	O
irregular	O
,	O
tachycardic	O
;	O
Loud	O
S1	O
,	O
S2	O
,	O
no	O
M	O
/	O
R	O
/	O
G	O
/	O
C	O
noted	O
;	O
heart	O
beat	O
noted	O
visibly	O
across	O
the	O
chest	O
and	O
by	O
palpation	O
.	O
No	O
carotid	O
bruits	O
.	O
Resp	O
:	O
CTA	O
b	O
/	O
l	O
A	O
/	O
P	O
,	O
no	O
W	O
/	O
R	O
/	O
R	O
Abd	O
:	O
+	O
BSx4	O
,	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
no	O
HSM	O
Ext	O
:	O
PP	O
present	O
and	O
symmetric	O
,	O
except	O
dorsalis	O
pedis	O
R	O
>	O
L.	O
Ext	O
warm	O
,	O
with	O
no	O
cyanosis	O
or	O
edema	O
.	O
No	O
right	O
leg	O
tenderness	O
.	O
Neuro	O
:	O
AOx3	O
;	O
observed	O
exam	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1022	O
**	O
]	O
(	O
ortho	O
)	O
-	O
weakness	O
in	O
right	O
hallux	O
extension	O
;	O
left	O
LE	O
weakness	O
improving	O
,	O
left	O
knee	O
extension	O
at	O
2/5	O
strength	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2133-6-12	O
**	O
]	O
12:20	O
AM	O
DIGOXIN	I-Drug
-	O
1.1	O
[	O
**	O
2133-6-12	O
**	O
]	O
12:20	O
AM	O
PT	O
-	O
23.0	O
*	O
PTT	O
-	O
31.6	O
INR	O
(	O
PT	O
)	O
-	O
3.5	O
[	O
**	O
2133-6-12	O
**	O
]	O
12:20	O
AM	O
WBC	O
-	O
8.8	O
RBC	O
-	O
4.13	O
*	O
HGB	O
-	O
13.6	O
HCT	O
-	O
39.2	O
MCV	O
-	O
95	O
MCH	O
-	O
33.0	O
*	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
13.4	O
[	O
**	O
2133-6-12	O
**	O
]	O
12:20	O
AM	O
GLUCOSE	O
-	O
137	O
*	O
UREA	O
N	O
-	O
18	O
CREAT	O
-	O
0.6	O
SODIUM	O
-	O
135	O
POTASSIUM	O
-	O
3.8	O
CHLORIDE	O
-	O
96	O
TOTAL	O
CO2	O
-	O
28	O
ANION	O
GAP	O
-	O
15	O
MRI	O
L	O
-	O
Spine	O
[	O
**	O
2133-6-12	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Extramedullary	O
hematoma	O
,	O
which	O
may	O
be	O
intradural	O
or	O
epidural	O
,	O
compressing	O
the	O
conus	O
and	O
cauda	O
equina	O
from	O
T11	O
/	O
12	O
through	O
L1	O
/	O
2	O
.	O
Associated	O
large	O
veins	O
are	O
suggestive	O
of	O
a	O
vascular	O
malformation	O
.	O
If	O
the	O
hematoma	O
is	O
intradural	O
,	O
a	O
spinal	O
cord	O
arteriovenous	O
malformation	O
is	O
likely	O
.	O
A	O
conventional	O
angiogram	O
is	O
recommended	O
for	O
assessment	O
of	O
vascular	O
malformation	O
.	O
Follow	O
-	O
up	O
lumbar	O
spine	O
MRI	O
is	O
also	O
recommended	O
to	O
evaluate	O
the	O
surgical	O
decompression	O
.	O
MRI	O
L	O
-	O
Spine	O
[	O
**	O
2133-6-13	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Status	O
post	O
decompression	O
of	O
a	O
large	O
dorsal	O
epidural	O
hematoma	O
,	O
there	O
is	O
soft	O
tissue	O
swelling	O
which	O
continues	O
to	O
impress	O
the	O
distal	O
cord	O
and	O
proximal	O
cauda	O
equina	O
.	O
CXR	O
[	O
**	O
2133-6-15	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Pacing	O
leads	O
in	O
the	O
expected	O
position	O
of	O
the	O
right	O
ventricle	O
.	O
No	O
evidence	O
of	O
pneumothorax	O
.	O
2	O
.	O
Massive	O
enlargement	O
of	O
the	O
left	O
atrium	O
Echo	O
[	O
**	O
2133-6-16	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Normal	O
functioning	O
mitral	O
valve	O
prosthesis	O
.	O
Mild	O
aortic	O
stenosis	O
.	O
Mild	O
aortic	O
regurgitation	O
.	O
Severe	O
biatrial	O
enlargement	O
.	O
Preserved	O
biventricular	O
systolic	O
function	O
.	O
Pulmonary	O
artery	O
hypertension	O
.	O
PM	O
Interrogation	O
[	O
**	O
2133-6-24	O
**	O
]	O
:	O
PM	O
functioning	O
properly	O
Brief	O
Hospital	O
Course	O
:	O
59	O
yo	O
Cantonese	O
F	O
with	O
history	O
of	O
Atrial	O
fibrillation	O
,	O
Mitral	O
valve	O
replacement	O
presented	O
with	O
epidural	O
hematoma	O
and	O
lower	O
extremity	O
weakness	O
.	O
Patient	O
is	O
s	O
/	O
p	O
epidural	O
hematoma	O
evacuation	O
on	O
[	O
**	O
2133-6-12	O
**	O
]	O
and	O
s	O
/	O
p	O
single	O
wire	O
pacer	O
placement	O
on	O
[	O
**	O
2133-6-14	O
**	O
]	O
sceondary	O
to	O
periop	O
brady	O
/	O
pause	O
.	O
Patient	O
was	O
found	O
to	O
have	O
NSVT	I-Ade
/	O
?	O
junctional	B-Ade
tachycardia	I-Ade
likely	O
secondary	O
to	O
digoxin	I-Drug
toxicity	O
.	O
.	O
The	O
patient	O
p	O
/	O
w	O
spontaneous	O
epidural	O
hematoma	O
and	O
LE	O
weakness	O
on	O
[	O
**	O
2133-6-12	O
**	O
]	O
.	O
Following	O
diagnositic	O
evaluation	O
,	O
the	O
patient	O
was	O
taken	O
to	O
surgery	O
for	O
a	O
T12	O
-	O
L2	O
laminectomy	O
and	O
subsequent	O
evacuation	O
of	O
the	O
hematoma	O
.	O
At	O
the	O
time	O
of	O
admission	O
the	O
patient	O
's	O
INR	O
was	O
3.5	O
as	O
she	O
was	O
taking	O
3.5	O
mg	O
coumadin	I-Drug
PO	O
Qhs	O
for	O
prophylactic	I-Reason
anticoagulation	O
due	O
to	O
her	O
h	O
/	O
o	O
afib	I-Reason
and	O
MVR	I-Reason
.	O
Her	O
coumadin	I-Drug
was	O
held	O
and	O
her	O
INR	O
monitored	O
following	O
surgery	O
.	O
She	O
was	O
placed	O
on	O
coumadin	I-Drug
3.0	O
mg	O
Qhs	O
once	O
her	O
INR	O
dropped	O
below	O
2.0	O
and	O
she	O
was	O
bridged	O
with	O
a	O
heparin	I-Drug
drip	O
.	O
Coumadin	I-Drug
was	O
increased	O
to	O
4.0	O
mg	O
on	O
[	O
**	O
2133-6-17	O
**	O
]	O
and	O
as	O
her	O
INR	O
rose	O
to	O
2.8	O
on	O
[	O
**	O
6	O
-	O
22	O
**	O
]	O
,	O
decreased	O
to	O
3.0	O
mg	O
.	O
Subsequent	O
to	O
her	O
INR	O
dropping	O
from	O
2.5	O
to	O
2.1	O
on	O
[	O
**	O
6	O
-	O
25	O
**	O
]	O
and	O
then	O
to	O
1.9	O
on	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
the	O
coumadin	I-Drug
dose	O
was	O
increased	O
to	O
4.0	O
mg	O
and	O
5.0	O
mg	O
repectively	O
.	O
Coumadin	I-Drug
continued	O
to	O
be	O
titrated	O
to	O
a	O
dose	O
of	O
3.5	O
mg	O
(	O
her	O
dose	O
PTA	O
)	O
giving	O
an	O
INR	O
of	O
2.4	O
at	O
discharge	O
.	O
In	O
the	O
perioperative	O
period	O
the	O
patient	O
began	O
having	O
episodes	O
of	O
bradycardia	O
and	O
pauses	O
for	O
which	O
a	O
single	O
wire	O
pacemaker	O
was	O
placed	O
on	O
[	O
**	O
2133-6-14	O
**	O
]	O
,	O
with	O
confirmation	O
of	O
proper	O
lead	O
placement	O
by	O
CXR	O
.	O
The	O
PM	O
was	O
interrogated	O
on	O
[	O
**	O
2133-6-24	O
**	O
]	O
and	O
found	O
to	O
be	O
functioning	O
properly	O
.	O
Additionally	O
in	O
this	O
time	O
she	O
developed	O
mild	O
anemia	O
likely	O
due	O
to	O
the	O
spontaneous	O
hematoma	O
and	O
surgical	O
blood	O
loss	O
for	O
which	O
she	O
received	O
a	O
total	O
of	O
2	O
units	O
of	O
PRBCs	I-Drug
and	O
has	O
since	O
resolved	O
.	O
During	O
this	O
time	O
the	O
patient	O
was	O
continued	O
on	O
Lanoxin	I-Drug
for	O
her	O
atrial	B-Reason
fibrillation	I-Reason
and	O
developed	O
a	O
NSVT	I-Ade
/	O
?	O
junctional	I-Ade
tachycardia	O
likely	O
due	O
to	O
digoxin	I-Drug
toxicity	O
.	O
Her	O
digoxin	I-Drug
was	O
discontinued	O
and	O
per	O
EP	O
's	O
recommendations	O
was	O
not	O
restarted	O
and	O
will	O
be	O
held	O
indefinitely	O
.	O
In	O
order	O
to	O
maintain	O
K	O
levels	O
above	O
4.0	O
to	O
avoid	O
potential	O
dysrhytmias	O
from	O
hypokalemia	O
,	O
spironolactone	I-Drug
25	O
mg	O
PO	O
daily	O
was	O
started	O
.	O
On	O
this	O
regimen	O
the	O
patient	O
required	O
40mEq	O
of	O
KCl	I-Drug
PO	O
daily	O
to	O
maintain	O
her	O
K	O
levels	O
and	O
this	O
was	O
reduced	O
to	O
20mEq	O
daily	O
as	O
the	O
K	O
level	O
on	O
the	O
day	O
prior	O
to	O
discharge	O
was	O
4.5	O
.	O
On	O
discharge	O
the	O
K	O
level	O
was	O
4.3	O
.	O
For	O
heartrate	B-Reason
control	I-Reason
metoprolol	I-Drug
was	O
increased	O
over	O
time	O
to	O
an	O
eventual	O
dose	O
of	O
75	O
mg	O
PO	O
BID	O
the	O
day	O
prior	O
to	O
discharge	O
,	O
during	O
which	O
time	O
the	O
patient	O
's	O
BP	O
was	O
stable	O
at	O
SBP	O
=	O
110s	O
to	O
130s	O
.	O
On	O
the	O
day	O
of	O
discharge	O
metoprolol	I-Drug
75	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
was	O
increased	O
to	O
Toprol	I-Drug
XL	O
200	O
mg	O
to	O
help	O
control	B-Reason
SBP	I-Reason
that	O
were	O
in	O
the	O
upper	O
120s	O
.	O
Following	O
evacuation	O
of	O
her	O
epidural	O
hematoma	O
she	O
developed	O
right	O
LE	O
pain	O
,	O
which	O
was	O
attributed	O
to	O
a	O
radiculpathy	I-Reason
and	O
was	O
successfully	O
treated	O
with	O
Neurontin	I-Drug
100	O
mg	O
TID	O
.	O
Due	O
to	O
predominately	O
left	O
LE	O
weakness	O
,	O
PT	O
was	O
consulted	O
and	O
recommended	O
that	O
the	O
pt	O
be	O
discharged	O
to	O
an	O
extended	O
care	O
factility	O
where	O
she	O
could	O
receive	O
further	O
care	O
from	O
PT	O
.	O
The	O
patient	O
continued	O
to	O
improve	O
during	O
the	O
course	O
of	O
her	O
stay	O
,	O
but	O
was	O
it	O
was	O
still	O
considered	O
necessary	O
that	O
the	O
pt	O
receive	O
rehab	O
upon	O
d	O
/	O
c.	O
Prior	O
to	O
discharge	O
the	O
patient	O
was	O
prescribed	O
an	O
AFO	O
left	O
foot	O
splint	O
.	O
In	O
addition	O
she	O
spiked	O
a	O
temperature	O
to	O
100.3	O
,	O
for	O
which	O
an	O
infection	O
work	O
-	O
up	O
was	O
began	O
.	O
Urine	O
Cx	O
showed	O
Proteus	O
Mirabilis	O
,	O
Bld	O
Cx	O
negative	O
.	O
She	O
was	O
treated	O
impirically	O
on	O
Vacnomycin	I-Drug
,	O
which	O
was	O
d	O
/	O
c	O
after	O
the	O
Bld	O
Cx	O
came	O
back	O
negative	O
,	O
and	O
Ciprofloxacin	I-Drug
.	O
P.	O
mirabilis	O
was	O
found	O
to	O
be	O
intermediately	O
sensitive	O
to	O
ciprofloxacin	I-Drug
and	O
Tx	O
was	O
switched	O
to	O
a	O
sensitive	O
antibiotic	O
,	O
Ceftriaxone	I-Drug
500	O
mg	O
po	O
Q12H	O
for	O
10	O
days	O
.	O
Ceftriaxone	I-Drug
was	O
stopped	O
on	O
[	O
**	O
2133-6-29	O
**	O
]	O
and	O
the	O
patient	O
remained	O
afebrile	O
and	O
asymptomatic	O
.	O
Both	O
incisions	O
healed	O
well	O
without	O
current	O
drainage	O
,	O
erythema	O
,	O
edema	O
,	O
or	O
tenderness	O
.	O
Lastly	O
during	O
her	O
hospital	O
course	O
she	O
developed	O
some	O
bladder	I-Reason
irritation	O
/	O
spasms	O
and	O
hematuria	O
likely	O
due	O
to	O
foley	O
catheter	O
trauma	O
.	O
The	O
catheter	O
was	O
d	O
/	O
c	O
'	O
ed	O
and	O
she	O
was	O
treated	O
with	O
Detrol	I-Drug
for	O
a	O
couple	O
of	O
days	O
.	O
She	O
has	O
since	O
been	O
asymmptomatic	O
and	O
without	O
hematuria	O
.	O
Medications	O
on	O
Admission	O
:	O
Lanoxin	I-Drug
0.25	O
mg	O
po	O
daily	O
Coumadin	I-Drug
Flexeril	I-Drug
Vicodin	I-Drug
Mehtylprednislone	I-Drug
dose	O
back	O
Apo	B-Drug
-	I-Drug
amilizide	I-Drug
50/5	O
mg	O
po	O
daily	O
Tensiomin	I-Drug
(	O
Chinese	O
med	O
)	O
25	O
mg	O
po	O
daily	O
Take	O
chinese	O
herbs	O
and	O
teas	O
Discharge	O
Medications	O
:	O
1	O
.	O
Spironolactone	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Warfarin	B-Drug
Sodium	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
3.5	O
Tablets	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
3	O
.	O
Gabapentin	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
4	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
5	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
6	O
.	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
packet	O
PO	O
once	O
a	O
day	O
.	O
7	O
.	O
Toprol	B-Drug
XL	I-Drug
200	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
85	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Epidural	O
hematoma	O
s	O
/	O
p	O
evacuation	O
,	O
periop	O
brady	O
/	O
pause	O
s	O
/	O
p	O
single	O
wire	O
pacemaker	O
placement	O
,	O
non-sustained	B-Ade
ventricular	I-Ade
tachycardia	I-Ade
secondary	O
to	O
digoxin	I-Drug
toxicity	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
Contact	O
primary	O
care	O
physician	O
or	O
return	O
to	O
hospital	O
if	O
experience	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpitations	O
,	O
worsening	O
lower	O
extremity	O
weakness	O
,	O
or	O
other	O
concerns	O
.	O
Followup	O
Instructions	O
:	O
The	O
following	O
appointments	O
have	O
been	O
scheduled	O
for	O
you	O
:	O
1	O
.	O
[	O
**	O
Company	O
191	O
**	O
]	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Name12	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
MD	O
Where	O
:	O
[	O
**	O
Hospital	O
273	O
**	O
]	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2133-7-24	O
**	O
]	O
3:00	O
2	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
900	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
901	O
**	O
]	O
,	O
M.D.	O
Where	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
CARDIAC	O
SERVICES	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
902	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2133-8-10	O
**	O
]	O
11:30	O
Completed	O
by	O
:[	O
**	O
2133-7-1	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2192-9-23	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2192-9-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2140-7-8	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
Diarrhea	O
for	O
6	O
weeks	O
,	O
anuric	O
x3	O
days	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
's	O
history	O
and	O
hospital	O
course	O
reviewed	O
.	O
Briefly	O
,	O
this	O
is	O
a	O
52M	O
w	O
/	O
h	O
/	O
o	O
HIV	O
who	O
p	O
/	O
w	O
3	O
days	O
of	O
anuria	O
and	O
general	O
malaise	O
.	O
He	O
had	O
been	O
having	O
diarrhea	O
for	O
the	O
past	O
6	O
weeks	O
and	O
on	O
presentation	O
to	O
the	O
ED	O
for	O
his	O
anuria	O
,	O
he	O
was	O
found	O
to	O
be	O
hypotensive	O
to	O
84/60	O
and	O
in	O
ARF	O
with	O
Cr	O
5.7	O
(	O
baseline	O
1.0	O
)	O
.	O
He	O
also	O
complained	O
of	O
left	O
-	O
sided	O
chest	O
discomfort	O
,	O
a	O
substernal	O
pressure	O
radiating	O
across	O
his	O
chest	O
that	O
had	O
been	O
ongoing	O
for	O
2	O
-	O
3	O
weeks	O
.	O
Sepsis	O
protocol	O
was	O
initiated	O
and	O
RSC	O
CVL	O
was	O
placed	O
.	O
BP	I-Reason
improved	O
to	O
SBP	O
of	O
100	O
with	O
4L	O
IVF	I-Drug
and	O
IV	O
heparin	I-Drug
was	O
started	O
for	O
troponin	O
leak	O
of	O
0.11	O
.	O
He	O
was	O
transferred	O
to	O
the	O
MICU	O
.	O
.	O
While	O
in	O
the	O
MICU	O
,	O
the	O
patient	O
's	O
ARF	I-Reason
responded	O
well	O
to	O
IVF	I-Drug
,	O
with	O
his	O
Cr	O
decreasing	O
to	O
1.8	O
on	O
transfer	O
to	O
the	O
floor	O
.	O
TnT	O
decreased	O
from	O
0.11	O
to	O
0.02	O
.	O
However	O
,	O
TTE	O
showed	O
a	O
markedly	O
dilated	O
RV	O
cavity	O
and	O
moderate	O
global	O
RV	O
free	O
wall	O
hypokinesis	O
consistent	O
with	O
RV	O
pressure	O
/	O
volume	O
overload	O
.	O
The	O
patient	O
's	O
pretest	O
probability	O
for	O
PE	O
was	O
considered	O
high	O
given	O
his	O
HIV	O
status	O
,	O
chest	O
pain	O
,	O
and	O
TTE	O
results	O
,	O
but	O
a	O
V	O
/	O
Q	O
scan	O
showed	O
low	O
probability	O
.	O
Given	O
his	O
post-test	O
estimated	O
probability	O
of	O
PE	O
was	O
20	O
%	O
,	O
he	O
was	O
continued	O
on	O
anticoagulation	O
.	O
Hct	O
drop	O
from	O
33.8	O
on	O
admission	O
to	O
26.1	O
after	O
fluid	O
resuscitation	O
with	O
guaiac	O
positive	O
stool	O
,	O
hypovolemia	O
,	O
likely	O
demand	O
ischemia	O
,	O
and	O
h	O
/	O
o	O
abnormal	O
EGD	O
raised	O
strong	O
suspicion	O
for	O
GIB	O
,	O
but	O
his	O
Hct	O
returned	O
to	O
33.3	O
by	O
time	O
of	O
transfer	O
to	O
floor	O
.	O
His	O
platelets	O
dropped	O
from	O
160	O
on	O
admission	O
to	O
97	O
,	O
and	O
HIT	O
antibody	O
test	O
was	O
positive	O
[	O
**	O
9	O
-	O
25	O
**	O
]	O
,	O
so	O
he	O
was	O
switched	O
to	O
argatroban	I-Drug
.	O
On	O
the	O
day	O
of	O
transfer	O
,	O
the	O
pt	O
spiked	O
a	O
low	O
-	O
grade	O
temperature	O
to	O
100.7	O
.	O
He	O
was	O
pan-cultured	O
but	O
no	O
antibiotics	O
were	O
started	O
as	O
there	O
was	O
no	O
clear	O
infectious	O
source	O
.	O
Past	O
Medical	O
History	O
:	O
HIV	O
-	O
dx	O
[	O
**	O
2179	O
**	O
]	O
,	O
CD4	O
<	O
100	O
on	O
[	O
**	O
2192-9-11	O
**	O
]	O
,	O
on	O
HAART	O
HIV	O
neuropathy	O
Vacuolar	O
Myelopathy	O
-	O
impaired	O
sensation	O
from	O
neck	O
down	O
Spastic	O
Bladder	O
Muscle	O
Spasticity	O
of	O
Leg	O
CAD	O
s	O
/	O
p	O
cypher	O
times	O
3	O
(	O
mid-RCA	O
,	O
prox	O
-	O
RCA	O
,	O
and	O
mid-LAD	O
)	O
+	O
PPD	O
but	O
negative	O
CXR	O
and	O
sputum	O
s	O
/	O
p	O
Appy	O
Social	O
History	O
:	O
Lives	O
with	O
wife	O
,	O
son	O
,	O
and	O
father	O
,	O
smokes	O
1.5	O
ppd	O
x	O
35	O
years	O
,	O
occ	O
etoh	O
,	O
no	O
drugs	O
,	O
previously	O
worked	O
as	O
manager	O
,	O
now	O
on	O
disability	O
Family	O
History	O
:	O
Father	O
alive	O
at	O
86	O
and	O
healthy	O
,	O
mother	O
deceased	O
at	O
age	O
85	O
from	O
breast	O
cancer	O
,	O
one	O
sister	O
and	O
one	O
brother	O
both	O
healthy	O
Physical	O
Exam	O
:	O
VS	O
:	O
100.6	O
,	O
139/95	O
,	O
85	O
,	O
20	O
,	O
100	O
%	O
RA	O
,	O
83.3	O
kg	O
Gen	O
-	O
sitting	O
comfortably	O
in	O
bed	O
,	O
NAD	O
HEENT	O
-	O
PERRL	O
,	O
EOMI	O
,	O
sl	O
thrush	O
,	O
MMM	O
NECK	O
-	O
supple	O
,	O
LAD	O
(	O
old	O
)	O
,	O
no	O
JVD	O
Lungs	O
:	O
CTAB	O
CV	O
-	O
RRR	O
,	O
nl	O
S1S2	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
Abd	O
-	O
soft	O
,	O
ND	O
,	O
NT	O
,	O
no	O
reb	O
/	O
gaurd	O
,	O
NABS	O
Ext	O
-	O
no	O
c	O
/	O
c	O
/	O
e	O
,	O
dry	O
skin	O
over	O
lower	O
extremities	O
Neuro	O
-	O
CN	O
II	O
-	O
XII	O
intact	O
,	O
spastic	O
lower	O
extremities	O
with	O
3/5	O
weakness	O
,	O
nl	O
strength	O
in	O
upper	O
ext.	O
.	O
AAO	O
X3	O
,	O
no	O
focal	O
deficits	O
Pertinent	O
Results	O
:	O
[	O
**	O
2192-9-23	O
**	O
]	O
12:35	O
PM	O
GLUCOSE	O
-	O
98	O
UREA	O
N	O
-	O
41	O
*	O
CREAT	O
-	O
5.7	O
*	O
#	O
SODIUM	O
-	O
135	O
POTASSIUM	O
-	O
4.2	O
CHLORIDE	O
-	O
100	O
TOTAL	O
CO2	O
-	O
19	O
*	O
ANION	O
GAP	O
-	O
20	O
[	O
**	O
2192-9-23	O
**	O
]	O
12:35	O
PM	O
WBC	O
-	O
8.1	O
#	O
RBC	O
-	O
3.91	O
*	O
HGB	O
-	O
11.9	O
*	O
HCT	O
-	O
33.8	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
30.3	O
MCHC	O
-	O
35.1	O
*	O
RDW	O
-	O
17.9	O
*	O
[	O
**	O
2192-9-23	O
**	O
]	O
12:35	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
16	O
AST	O
(	O
SGOT	O
)	O
-	O
37	O
CK	O
(	O
CPK	O
)	O
-	O
264	O
*	O
ALK	O
PHOS	O
-	O
115	O
TOT	O
BILI	O
-	O
0.5	O
[	O
**	O
2192-9-23	O
**	O
]	O
12:35	O
PM	O
LIPASE	O
-	O
180	O
*	O
[	O
**	O
2192-9-23	O
**	O
]	O
08:13	O
PM	O
URINE	O
BLOOD	O
-	O
LG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
30	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
MOD	O
[	O
**	O
2192-9-23	O
**	O
]	O
08:13	O
PM	O
URINE	O
RBC	O
-	O
[	O
**	O
5	O
-	O
12	O
**	O
]	O
*	O
WBC	O
-	O
[	O
**	O
2	O
-	O
5	O
**	O
]	O
BACTERIA	O
-	O
OCC	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
[	O
**	O
2192-9-23	O
**	O
]	O
10:58	O
PM	O
CORTISOL	O
-	O
3.6	O
[	O
**	O
2192-9-23	O
**	O
]	O
10:58	O
PM	O
CORTISOL	O
-	O
24.5	O
*	O
[	O
**	O
2192-9-23	O
**	O
]	O
10:58	O
PM	O
CALCIUM	O
-	O
6.4	O
*	O
PHOSPHATE	O
-	O
3.7	O
MAGNESIUM	O
-	O
1.9	O
URIC	O
ACID	O
-	O
7.4	O
*	O
.	O
[	O
**	O
9	O
-	O
23	O
**	O
]	O
CXR	O
:	O
PORTABLE	O
AP	O
CHEST	O
RADIOGRAPH	O
:	O
The	O
right	O
subclavian	O
venous	O
line	O
is	O
terminating	O
in	O
mid	O
SVC	O
.	O
There	O
is	O
no	O
evidence	O
of	O
pneumothorax	O
.	O
Cardiac	O
and	O
mediastinal	O
contours	O
are	O
within	O
normal	O
limits	O
,	O
and	O
there	O
is	O
no	O
consolidation	O
or	O
effusion	O
.	O
.	O
[	O
**	O
9	O
-	O
23	O
**	O
]	O
CT	O
OF	O
THE	O
ABDOMEN	O
WITHOUT	O
IV	O
CONTRAST	I-Drug
.	O
Dependent	O
changes	O
are	O
seen	O
at	O
the	O
lung	O
bases	O
.	O
Allowing	O
for	O
limitations	O
of	O
a	O
non-contrast	O
study	O
,	O
the	O
liver	O
,	O
gallbladder	O
,	O
pancreas	O
,	O
spleen	O
,	O
and	O
kidneys	O
appear	O
unremarkable	O
.	O
Again	O
seen	O
is	O
a	O
rounded	O
hypodensity	O
in	O
the	O
right	O
adrenal	O
likely	O
representing	O
adrenal	O
adenoma	O
,	O
not	O
significantly	O
changed	O
in	O
appearance	O
from	O
prior	O
study	O
.	O
Visualized	O
portions	O
of	O
bowel	O
appear	O
unremarkable	O
.	O
There	O
is	O
no	O
evidence	O
of	O
free	O
air	O
or	O
free	O
fluid	O
within	O
the	O
abdomen	O
.	O
Scattered	O
lymph	O
nodes	O
are	O
seenthroughout	O
the	O
mesentery	O
and	O
retroperitoneum	O
,	O
however	O
,	O
none	O
appear	O
to	O
meet	O
CT	O
criteria	O
for	O
pathological	O
enlargement	O
.	O
.	O
-	O
CT	O
OF	O
THE	O
PELVIS	O
WITHOUT	O
IV	O
CONTRAST	I-Drug
:	O
The	O
rectum	O
,	O
sigmoid	O
appear	O
unremarkable	O
.	O
Air	O
is	O
seen	O
within	O
the	O
bladder	O
,	O
likely	O
secondary	O
to	O
Foley	O
catheterization	O
.	O
No	O
evidence	O
of	O
free	O
air	O
or	O
free	O
fluid	O
within	O
the	O
pelvis	O
.	O
.	O
-	O
ECHO	O
(	O
[	O
**	O
5	O
-	O
8	O
**	O
]	O
)	O
:	O
EF	O
55	O
%	O
,	O
no	O
regional	O
wall	O
abnormaliites	O
,	O
mild	O
pulmonary	O
HTN	O
.	O
.	O
-	O
ECHO	O
[	O
**	O
2192-9-24	O
**	O
]	O
:	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
markedly	O
dilated	O
with	O
moderate	O
global	O
free	O
wall	O
hypokinesis	O
.	O
There	O
is	O
abnormal	O
septal	O
motion	O
/	O
position	O
consistent	O
with	O
right	O
ventricular	O
pressure	O
/	O
volume	O
overload	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
minimal	O
mitral	O
regurgitation	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
.	O
[	O
**	O
2192-9-24	O
**	O
]	O
LENIs	O
:	O
no	O
DVT	O
.	O
[	O
**	O
2192-9-24	O
**	O
]	O
V	O
/	O
Q	O
scan	O
:	O
low	O
probability	O
for	O
PE	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
52	O
y.o.	O
HIV	O
positive	O
male	O
(	O
[	O
**	O
2192-9-11	O
**	O
]	O
:	O
CD4	O
72	O
,	O
VL	O
>	O
100,000	O
)	O
with	O
a	O
6	O
week	O
history	O
of	O
diarrhea	O
and	O
low	O
-	O
grade	O
temp	O
who	O
was	O
initially	O
admitted	O
to	O
the	O
MICU	O
for	O
hypotension	O
and	O
ARF	O
,	O
improved	O
after	O
volume	O
resuscitation	O
.	O
.	O
#	O
Diarrhea	I-Reason
.	O
Likely	O
the	O
patient	O
was	O
hypotensive	O
and	O
in	O
renal	O
failure	O
secondary	O
to	O
hypovolemia	O
precipitating	O
ARF	O
.	O
The	O
patient	O
had	O
a	O
small	O
amount	O
of	O
outpatient	O
work	O
-	O
up	O
for	O
this	O
,	O
negative	O
to	O
date	O
,	O
including	O
:	O
Stool	O
C.	O
Diff	O
,	O
culture	O
and	O
CMV	O
viral	O
load	O
undetectable	O
.	O
The	O
patient	O
was	O
given	O
symptomatic	O
treatment	O
,	O
including	O
imodium	I-Drug
and	O
his	O
diarrhea	O
improved	O
dramatically	O
.	O
He	O
was	O
unable	O
to	O
provide	O
a	O
stool	O
sample	O
while	O
on	O
the	O
floor	O
.	O
The	O
patient	O
was	O
given	O
a	O
prescription	O
for	O
an	O
outpatient	O
stool	O
sample	O
for	O
repeat	O
stool	O
culture	O
(	O
including	O
viral	O
and	O
bacterial	O
)	O
,	O
DFA	O
for	O
crytosporidium	O
and	O
giardia	O
,	O
ova	O
&	O
parasites	O
,	O
microsporidium	O
.	O
The	O
GI	O
team	O
was	O
consulted	O
on	O
the	O
patient	O
.	O
It	O
was	O
their	O
recommendation	O
that	O
the	O
patient	O
have	O
an	O
infectious	O
work	O
-	O
up	O
.	O
If	O
negative	O
and	O
diarrhea	O
persists	O
,	O
the	O
patient	O
should	O
have	O
a	O
colonoscopy	O
at	O
a	O
later	O
date	O
when	O
aspirin	I-Drug
and	O
plavix	I-Drug
can	O
be	O
held	O
(	O
at	O
least	O
9	O
months	O
from	O
the	O
time	O
of	O
drug	O
eluting	O
stent	O
placement	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
's	O
diarrhea	I-Reason
was	O
well	O
-	O
controlled	O
with	O
loperamide	I-Drug
and	O
the	O
patient	O
was	O
tolerating	O
fluids	O
PO	O
.	O
He	O
was	O
encouraged	O
to	O
have	O
aggressive	O
PO	O
fluid	O
intake	O
whenever	O
diarrhea	O
occurs	O
.	O
.	O
#	O
Fevers	I-Reason
.	O
The	O
patient	O
had	O
a	O
low	O
-	O
grade	O
(	O
100	O
)	O
fever	O
after	O
coming	O
to	O
the	O
floor	O
from	O
the	O
MICU	O
.	O
This	O
may	O
be	O
secondary	O
to	O
the	O
same	O
process	O
as	O
the	O
diarrhea	O
.	O
However	O
,	O
the	O
patient	O
has	O
poorly	O
controlled	O
HIV	O
and	O
therefore	O
is	O
at	O
risk	O
for	O
numerous	O
sources	O
.	O
Empiric	O
antibiotics	I-Drug
were	O
deferred	O
as	O
no	O
source	O
of	O
infection	O
was	O
found	O
.	O
.	O
#	O
Hypotension	I-Reason
.	O
Likely	O
secondary	O
to	O
persistent	O
diarrhea	O
.	O
The	O
patient	O
was	O
aggressively	O
hydrated	O
with	O
IV	O
NS	I-Drug
in	O
the	O
MICU	O
.	O
He	O
came	O
to	O
the	O
floor	O
normotensive	O
and	O
maintained	O
this	O
volume	O
status	O
for	O
the	O
remainder	O
of	O
his	O
time	O
in	O
the	O
hospital	O
.	O
.	O
#	O
Acute	O
renal	O
failure	O
.	O
Likely	O
pre-renal	O
secondary	O
to	O
persistent	O
diarrhea	O
and	O
volume	O
depletion	O
.	O
The	O
patient	O
's	O
Cr	O
improved	O
to	O
normal	O
range	O
after	O
volume	O
resuscitation	O
.	O
.	O
#	O
Chest	O
pain	O
.	O
The	O
patient	O
had	O
a	O
CTA	O
that	O
was	O
negative	O
for	O
PE	O
.	O
He	O
had	O
a	O
slight	O
troponin	O
elevation	O
thought	O
consistent	O
with	O
demand	O
ischemia	O
in	O
the	O
setting	O
of	O
hypotension	O
and	O
poor	O
troponin	O
excretion	O
in	O
the	O
setting	O
of	O
renal	O
failure	O
.	O
The	O
patient	O
's	O
troponin	O
trended	O
downward	O
throughout	O
his	O
admission	O
and	O
he	O
never	O
showed	O
CK	O
elevations	O
.	O
.	O
#	O
CAD	I-Reason
.	O
No	O
signs	O
of	O
acute	O
ischemia	O
.	O
Troponin	O
leak	O
with	O
normal	O
CK	O
likely	O
secondary	O
to	O
demand	O
ischemia	O
and	O
ARF	O
.	O
The	O
patient	O
was	O
continued	O
on	O
ASA	I-Drug
,	O
plavix	I-Drug
,	O
beta	B-Drug
blocker	I-Drug
,	O
statin	I-Drug
.	O
His	O
ACEi	I-Drug
was	O
held	O
for	O
renal	O
failure	O
and	O
then	O
restarted	O
prior	O
to	O
discharge	O
.	O
On	O
echo	O
,	O
the	O
patient	O
had	O
new	O
mechanical	O
dysfunction	O
.	O
The	O
patient	O
should	O
have	O
outpatient	O
p	O
-	O
MIBI	O
to	O
assess	O
for	O
perfusion	O
deficits	O
.	O
.	O
#	O
HIV	I-Reason
.	O
On	O
[	O
**	O
2192-9-11	O
**	O
]	O
,	O
CD4	O
72	O
,	O
VL	O
>	O
100,000	O
.	O
The	O
patient	O
's	O
HAART	I-Drug
has	O
been	O
held	O
while	O
in	O
the	O
MICU	O
for	O
renal	O
failure	O
.	O
These	O
medications	O
were	O
restarted	O
prior	O
to	O
discharge	O
.	O
The	O
patient	O
's	O
PCP	O
will	O
consider	O
initiating	O
prophylactic	O
antibiotics	O
as	O
an	O
outpatient	O
.	O
.	O
#	O
Anemia	I-Reason
.	O
Patient	O
's	O
baseline	O
appears	O
29	O
-	O
30	O
.	O
Patient	O
with	O
drop	O
in	O
Hct	O
likely	O
in	O
part	O
secondary	O
to	O
dilution	O
.	O
The	O
patient	O
had	O
guaiac	O
positive	O
stool	O
with	O
known	O
abnormal	O
colonoscopy	O
and	O
EGD	O
in	O
past	O
is	O
concerning	O
for	O
GI	O
bleed	O
.	O
The	O
patient	O
had	O
multiple	O
units	O
of	O
blood	I-Drug
transfusion	O
while	O
in	O
the	O
MICU	O
.	O
His	O
Hct	O
normalized	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
Thrombocytopenia	I-Ade
.	O
The	O
patient	O
's	O
platelets	O
declined	O
to	O
90	O
while	O
in	O
the	O
MICU	O
and	O
he	O
was	O
found	O
to	O
be	O
HIT	I-Ade
antibody	O
positive	O
.	O
Heparin	I-Drug
products	O
were	O
held	O
and	O
the	O
patient	O
's	O
platelet	O
count	O
stabilized	O
.	O
Medications	O
on	O
Admission	O
:	O
Ritonavir	I-Drug
100	O
qd	O
3TC	I-Drug
300	O
mg	O
qd	O
DDI	I-Drug
400	O
mg	O
qd	O
Atazanavir	I-Drug
300	O
mg	O
qd	O
Lisinopril	I-Drug
5	O
mg	O
qd	O
ASA	I-Drug
325	O
qd	O
Plavix	I-Drug
75	O
qd	O
Atenolol	B-Drug
25	O
mg	O
qd	O
Lipitor	I-Drug
20	O
qd	O
Famotidine	B-Drug
20	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Gabapentin	I-Drug
300	O
mg	O
qhs	O
Sucralfate	I-Drug
1	O
g	O
qid	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Ritonavir	B-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Didanosine	B-Drug
400	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Lamivudine	I-Drug
150	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Atazanavir	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Loperamide	I-Drug
2	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
9	O
.	O
Lisinopril	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Atenolol	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
11	O
.	O
Famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
12	O
.	O
Gabapentin	B-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
13	O
.	O
Sucralfate	I-Drug
1	O
g	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
four	O
times	O
a	O
day	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
14	O
.	O
Outpatient	O
Lab	O
Work	O
Stool	O
sample	O
:	O
Please	O
send	O
for	O
C.	O
Diff	O
toxin	O
assay	O
,	O
DFA	O
for	O
Cryptosporidium	O
/	O
Giardia	O
,	O
routine	O
stool	O
cx	O
,	O
Microsporidium	O
,	O
Yersinia	O
,	O
Vibrio	O
,	O
Ova	O
and	O
Parasites	O
.	O
Give	O
this	O
sample	O
at	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
12103	O
**	O
]	O
office	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Diarrhea	O
.	O
Secondary	O
:	O
HIV	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Take	O
all	O
medications	O
as	O
prescribed	O
.	O
.	O
Attend	O
all	O
follow	O
-	O
up	O
appointment	O
.	O
.	O
You	O
must	O
give	O
a	O
stool	O
sample	O
for	O
analysis	O
at	O
your	O
primary	O
care	O
physician	O
's	O
office	O
.	O
.	O
It	O
is	O
recommmended	O
that	O
you	O
have	O
an	O
outpatient	O
colonoscopy	O
.	O
Please	O
have	O
your	O
primary	O
care	O
physician	O
help	O
you	O
schedule	O
this	O
study	O
.	O
.	O
If	O
you	O
have	O
recurrent	O
diarrhea	O
you	O
must	O
drink	O
a	O
large	O
amount	O
of	O
water	O
to	O
replace	O
what	O
is	O
lost	O
in	O
your	O
stool	O
.	O
.	O
If	O
you	O
develop	O
nausea	O
,	O
vomiting	O
,	O
fevers	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
or	O
decreased	O
urine	O
output	O
please	O
call	O
your	O
doctor	O
or	O
return	O
to	O
the	O
hospital	O
.	O
Followup	O
Instructions	O
:	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3308	O
**	O
]	O
)	O
,	O
Monday	O
[	O
**	O
2192-10-8	O
**	O
]	O
10:30	O
AM	O
.	O
Give	O
a	O
stool	O
sample	O
at	O
this	O
office	O
visit	O
to	O
look	O
for	O
possible	O
causes	O
of	O
your	O
diarrhea	O
.	O
Please	O
make	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
aware	O
that	O
it	O
is	O
recommended	O
for	O
you	O
to	O
have	O
a	O
colonoscopy	O
when	O
it	O
is	O
safe	O
to	O
hold	O
your	O
aspirin	I-Drug
plavix	I-Drug
(	O
9	O
months	O
after	O
your	O
coronary	O
stent	O
was	O
placed	O
)	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2197-9-16	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2197-12-27	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2197-9-16	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
Neonatology	O
HISTORY	O
:	O
Baby	O
boy	O
[	O
**	O
Known	O
lastname	O
68869	O
**	O
]	O
,	O
twin	O
No.	O
1	O
,	O
was	O
born	O
weighing	O
718	O
grams	O
,	O
the	O
product	O
of	O
a	O
24	O
and	O
6/7	O
weeks	O
gestation	O
pregnancy	O
.	O
He	O
was	O
born	O
to	O
a	O
34	O
-	O
year	O
-	O
old	O
G2	O
,	O
P0	O
,	O
now	O
2	O
mother	O
.	O
Maternal	O
history	O
was	O
notable	O
for	O
short	O
cervix	O
with	O
cerclage	O
placement	O
prenatally	O
.	O
Prenatal	O
screens	O
-	O
blood	O
type	O
O	O
positive	O
,	O
antibody	O
negative	O
,	O
HbSAg	O
negative	O
,	O
RPR	O
nonreactive	O
,	O
rubella	O
immune	O
,	O
GBS	O
unknown	O
.	O
This	O
infant	O
was	O
born	O
by	O
cesarean	O
section	O
after	O
unstoppable	O
preterm	O
labor	O
.	O
The	O
infant	O
emerged	O
with	O
a	O
weak	O
cry	O
,	O
was	O
brought	O
to	O
the	O
warmer	O
,	O
given	O
some	O
positive	O
pressure	O
ventilation	O
and	O
intubated	O
in	O
the	O
delivery	O
room	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
Anterior	O
fontanel	O
open	O
and	O
flat	O
.	O
Coarse	O
breath	O
sounds	O
bilaterally	O
with	O
good	O
breaths	O
bilaterally	O
.	O
Positive	O
red	O
reflexes	O
bilaterally	O
.	O
No	O
murmur	O
.	O
normal	O
S1S2	O
.	O
Normal	O
pulses	O
.	O
Soft	O
,	O
nondistended	O
,	O
no	O
masses	O
.	O
Moved	O
all	O
extremities	O
equally	O
.	O
Pink	O
and	O
well	O
perfused	O
.	O
Three	O
-	O
vessel	O
cord	O
,	O
patent	O
anus	O
.	O
SUMMARY	O
OF	O
HOSPITAL	O
COURSE	O
BY	O
SYSTEMS	O
:	O
RESPIRATORY	O
:	O
The	O
infant	O
had	O
respiratory	O
distress	O
syndrome	O
on	O
admission	O
to	O
the	O
NICU	O
and	O
was	O
intubated	O
and	O
received	O
surfactant	O
therapy	O
x2	O
.	O
He	O
remained	O
ventilated	O
with	O
conventional	O
ventilation	O
until	O
[	O
**	O
2197-10-11	O
**	O
]	O
,	O
which	O
is	O
day	O
of	O
life	O
25	O
when	O
he	O
required	O
high	O
frequency	O
ventilation	O
at	O
that	O
time	O
for	O
sepsis	O
issues	O
.	O
Within	O
24	O
hours	O
he	O
returned	O
to	O
conventional	O
ventilation	O
.	O
In	O
the	O
setting	O
of	O
his	O
chronic	B-Reason
lung	I-Reason
disease	I-Reason
,	O
he	O
was	O
started	O
on	O
Lasix	I-Drug
on	O
DOL	O
#	O
42	O
(	O
[	O
**	O
10	O
-	O
28	O
**	O
]	O
)	O
,	O
receiving	O
Lasix	I-Drug
every	O
Monday	O
,	O
Wednesday	O
and	O
Friday	O
.	O
He	O
extubated	O
to	O
CPAP	O
on	O
[	O
**	O
2197-11-7	O
**	O
]	O
,	O
day	O
of	O
life	O
52	O
,	O
successfully	O
weaned	O
to	O
nasal	O
cannula	O
on	O
[	O
**	O
2197-11-27	O
**	O
]	O
,	O
which	O
is	O
day	O
of	O
life	O
73	O
.	O
He	O
weaned	O
to	O
room	O
air	O
on	O
[	O
**	O
2197-12-17	O
**	O
]	O
,	O
and	O
has	O
remained	O
stable	O
on	O
room	O
air	O
since	O
that	O
time	O
.	O
He	O
has	O
had	O
no	O
apnea	O
or	O
bradycardia	O
issues	O
for	O
well	O
over	O
a	O
week	O
.	O
He	O
was	O
given	O
caffeine	I-Drug
citrate	O
from	O
[	O
**	O
2197-11-19	O
**	O
]	O
,	O
through	O
till	O
[	O
**	O
2197-10-17	O
**	O
]	O
,	O
at	O
which	O
time	O
caffeine	I-Drug
was	O
discontinued	O
due	O
to	O
increased	B-Ade
heart	I-Ade
rate	I-Ade
.	O
Caffeine	I-Drug
was	O
never	O
restarted	O
thereafter	O
.	O
Currently	O
,	O
he	O
is	O
receiving	O
Lasix	I-Drug
every	O
Monday	O
,	O
Wednesday	O
and	O
Friday	O
.	O
He	O
had	O
been	O
receiving	O
KCl	I-Drug
as	O
well	O
but	O
this	O
was	O
discontinued	O
on	O
[	O
**	O
12	O
-	O
20	O
**	O
]	O
and	O
his	O
most	O
recent	O
Cl	O
on	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
was	O
106	O
with	O
a	O
K	O
of	O
5.5	O
.	O
The	O
infant	O
will	O
be	O
followed	O
for	O
chronic	O
lung	O
disease	O
by	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
487	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
37305	O
**	O
]	O
at	O
[	O
**	O
Hospital3	O
1810	O
**	O
]	O
and	O
has	O
a	O
follow	O
-	O
up	O
appointment	O
on	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
.	O
CARDIOVASCULAR	O
:	O
The	O
infant	O
presented	O
with	O
symptoms	O
of	O
PDA	I-Reason
on	O
[	O
**	O
2197-9-17	O
**	O
]	O
,	O
at	O
which	O
time	O
indomethacin	I-Drug
was	O
given	O
.	O
A	O
post-indomethacin	O
echocardiogram	O
on	O
[	O
**	O
2197-9-19	O
**	O
]	O
showed	O
that	O
that	O
the	O
ductus	O
was	O
closed	O
.	O
Followup	O
echocardiogram	O
was	O
done	O
on	O
[	O
**	O
2197-10-3	O
**	O
]	O
,	O
due	O
to	O
re-presentation	O
,	O
which	O
showed	O
a	O
small	O
1	O
mm	O
PDA	O
.	O
No	O
indomethacin	I-Drug
was	O
given	O
at	O
that	O
time	O
.	O
Two	O
further	O
echocardiograms	O
have	O
been	O
done	O
,	O
both	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
359	O
**	O
]	O
(	O
23	O
and	O
26th	O
)	O
due	O
to	O
persistent	O
murmurs	O
.	O
Both	O
of	O
those	O
showed	O
a	O
very	O
tiny	O
PDA	O
,	O
neither	O
of	O
which	O
was	O
treated	O
with	O
Indocin	I-Drug
.	O
The	O
infant	O
has	O
been	O
hemodynamically	O
stable	O
and	O
at	O
this	O
time	O
does	O
not	O
have	O
a	O
murmur	O
and	O
has	O
normal	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O
No	O
further	O
issues	O
.	O
He	O
does	O
not	O
have	O
a	O
murmur	O
at	O
the	O
time	O
of	O
discharge	O
.	O
The	O
infant	O
did	O
present	O
with	O
a	O
brief	O
period	O
of	O
supraventricular	I-Ade
tachycardia	O
on	O
[	O
**	O
2197-10-17	O
**	O
]	O
,	O
at	O
which	O
time	O
caffeine	I-Drug
citrate	O
was	O
discontinued	O
and	O
no	O
urther	O
episodes	O
have	O
been	O
observed	O
.	O
FLUIDS	O
,	O
ELECTROLYTES	O
AND	O
NUTRITION	O
:	O
IV	O
fluids	I-Drug
were	O
initiated	O
on	O
admission	O
to	O
the	O
NICU	O
and	O
changed	O
to	O
total	O
parental	O
nutrition	O
over	O
the	O
next	O
few	O
days	O
.	O
An	O
umbilical	O
arterial	O
catheter	O
was	O
placed	O
and	O
a	O
double	O
lumen	O
umbilical	O
venous	O
line	O
was	O
also	O
placed	O
on	O
admission	O
.	O
The	O
infant	O
was	O
started	O
on	O
enteral	O
feedings	O
on	O
[	O
**	O
2197-9-21	O
**	O
]	O
,	O
with	O
a	O
slow	O
feeding	O
advance	O
and	O
achieved	O
full	O
enteral	O
feedings	O
.	O
A	O
PICC	O
line	O
was	O
placed	O
on	O
[	O
**	O
2197-9-23	O
**	O
]	O
.	O
The	O
double	O
lumen	O
UVC	O
was	O
discontinued	O
at	O
that	O
time	O
.	O
Enteral	O
feedings	O
were	O
advanced	O
and	O
the	O
infant	O
achieved	O
full	O
enteral	O
feedings	O
by	O
[	O
**	O
2197-9-30	O
**	O
]	O
.	O
Enteral	O
feedings	O
were	O
then	O
further	O
concentrated	O
to	O
caloric	O
density	O
of	O
breast	O
milk	O
30	O
calorie	O
per	O
ounce	O
with	O
Beneprotein	O
.	O
The	O
infant	O
had	O
an	O
episode	O
of	O
abdominal	O
distention	O
with	O
an	O
abnormal	O
KUB	O
and	O
was	O
treated	O
for	O
14	O
days	O
for	O
medical	O
necrotizing	O
enterocolitis	O
which	O
was	O
started	O
on	O
[	O
**	O
2197-10-10	O
**	O
]	O
.	O
The	O
KUB	O
subsequently	O
normalized	O
and	O
the	O
infant	O
was	O
restarted	O
on	O
enteral	O
feedings	O
on	O
[	O
**	O
2197-10-27	O
**	O
]	O
.	O
Feedings	O
advanced	O
without	O
an	O
incident	O
.	O
Currently	O
,	O
he	O
is	O
feeding	O
PO	O
ad	O
lib	O
of	O
26	O
calorie	O
breast	O
milk	O
mixed	O
as	O
breast	O
milk	O
with	O
4	O
calories	O
of	O
Similac	O
powder	O
per	O
ounce	O
and	O
2	O
calories	O
of	O
corn	O
oil	O
per	O
ounce	O
.	O
The	O
infant	O
's	O
most	O
recent	O
weight	O
is	O
2810	O
grams	O
.	O
He	O
is	O
gaining	O
well	O
.	O
He	O
is	O
taking	O
approximately	O
3	O
ounces	O
every	O
4	O
hours	O
enterally	O
.	O
Most	O
recent	O
set	O
of	O
electrolytes	O
were	O
done	O
on	O
[	O
**	O
2197-12-26	O
**	O
]	O
,	O
and	O
the	O
results	O
are	O
Na	O
=	O
138	O
,	O
K	O
=	O
5.5	O
,	O
Cl	O
=	O
106	O
,	O
HCO3	O
=	O
23	O
.	O
His	O
most	O
recent	O
head	O
circumference	O
is	O
34	O
cm	O
,	O
most	O
recent	O
length	O
is	O
48	O
cm	O
,	O
both	O
done	O
on	O
[	O
**	O
2197-12-26	O
**	O
]	O
;	O
at	O
present	O
he	O
is	O
10	O
to	O
25th	O
percentile	O
for	O
weight	O
,	O
50	O
to	O
75th	O
percentile	O
for	O
head	O
circumference	O
,	O
and	O
25th	O
to	O
50th	O
percentile	O
for	O
length	O
.	O
He	O
is	O
on	O
daily	O
multivitamins	I-Drug
,	O
1	O
ml	O
per	O
day	O
.	O
Renal	O
:	O
On	O
[	O
**	O
2197-12-26	O
**	O
]	O
,	O
renal	O
ultrasound	O
was	O
performed	O
which	O
showed	O
bilateral	B-Ade
calcifications	I-Ade
in	I-Ade
both	I-Ade
kidneys	I-Ade
,	O
consistent	O
with	O
chronic	O
lasix	I-Drug
use	O
.	O
GASTROINTESTINAL	O
:	O
The	O
infant	O
did	O
have	O
a	O
period	O
of	O
medical	O
necrotizing	O
enterocolitis	O
that	O
was	O
discussed	O
under	O
fluid	O
,	O
electrolytes	O
and	O
nutrition	O
as	O
above	O
,	O
treatment	O
from	O
[	O
**	O
2197-10-10	O
**	O
]	O
,	O
through	O
[	O
**	O
2197-10-27	O
**	O
]	O
.	O
The	O
infant	O
did	O
have	O
hyperbilirubinemia	O
with	O
a	O
peak	O
bilirubin	O
level	O
of	O
3.8	O
/	O
0.3	O
and	O
did	O
receive	O
a	O
total	O
of	O
8	O
days	O
of	O
phototherapy	O
.	O
HEMATOLOGY	O
:	O
The	O
patient	O
's	O
blood	O
type	O
is	O
A	O
positive	O
,	O
DAT	O
negative	O
.	O
The	O
infant	O
has	O
received	O
numerous	O
blood	B-Drug
product	I-Drug
transfusions	O
,	O
and	O
in	O
total	O
has	O
received	O
5	O
transfusions	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
with	O
the	O
most	O
recent	O
transfusion	O
being	O
on	O
[	O
**	O
2197-10-28	O
**	O
]	O
.	O
The	O
infant	O
is	O
on	O
elemental	B-Drug
iron	I-Drug
,	I-Drug
ferrous	I-Drug
sulfate	O
at	O
0.5	O
ml	O
PO	O
daily	O
.	O
Most	O
recent	O
hematocrit	O
was	O
36	O
on	O
[	O
**	O
2197-12-12	O
**	O
]	O
,	O
with	O
a	O
reticulocyte	O
count	O
of	O
8.1	O
%	O
.	O
INFECTIOUS	O
DISEASE	O
:	O
CBC	O
and	O
blood	O
culture	O
were	O
screened	O
on	O
admission	O
to	O
the	O
NICU	O
.	O
The	O
infant	O
had	O
a	O
white	O
blood	O
cell	O
count	O
of	O
5.1	O
with	O
29	O
polys	O
,	O
yielding	O
an	O
ANC	O
of	O
1479	O
.	O
There	O
was	O
no	O
left	O
shift	O
.	O
The	O
infant	O
received	O
48	O
hours	O
of	O
ampicillin	I-Drug
and	O
gentamycin	I-Drug
initially	O
which	O
were	O
subsequently	O
discontinued	O
when	O
the	O
blood	O
culture	O
remained	O
negative	O
at	O
that	O
time	O
.	O
The	O
infant	O
had	O
a	O
sepsis	O
evaluation	O
done	O
on	O
[	O
**	O
2197-9-29	O
**	O
]	O
,	O
at	O
13	O
days	O
of	O
life	O
due	O
to	O
clinical	O
instability	O
.	O
CBC	O
at	O
that	O
time	O
was	O
normal	O
but	O
the	O
blood	O
culture	O
grew	O
staph	B-Reason
epidermidis	I-Reason
bacteremia	O
.	O
The	O
infant	O
was	O
started	O
on	O
vancomycin	I-Drug
and	O
gentamycin	I-Drug
and	O
given	O
a	O
7	O
-	O
day	O
course	O
of	O
antibiotics	I-Drug
at	O
that	O
time	O
.	O
At	O
the	O
end	O
of	O
that	O
course	O
of	O
antibiotics	I-Drug
,	O
the	O
infant	O
presented	O
with	O
medical	O
necrotizing	O
enterocolitis	O
and	O
that	O
was	O
on	O
[	O
**	O
2197-10-10	O
**	O
]	O
.	O
The	O
antibiotic	I-Drug
therapy	O
was	O
switched	O
to	O
Zosyn	I-Drug
to	O
treat	O
for	O
medical	B-Reason
necrotizing	I-Reason
enterocolitis	I-Reason
at	O
that	O
time	O
.	O
The	O
infant	O
received	O
12	O
days	O
of	O
Zosyn	I-Drug
therapy	O
which	O
was	O
changed	O
on	O
[	O
**	O
2197-10-21	O
**	O
]	O
,	O
to	O
vancomycin	I-Drug
,	O
gentamycin	I-Drug
and	O
clindamycin	I-Drug
when	O
a	O
blood	O
culture	O
grew	O
positive	O
at	O
that	O
time	O
for	O
gram	B-Reason
positive	I-Reason
cocci	I-Reason
.	O
CBC	O
at	O
that	O
time	O
was	O
not	O
shifted	O
on	O
[	O
**	O
2197-10-10	O
**	O
]	O
.	O
The	O
infant	O
received	O
an	O
additional	O
7	O
days	O
of	O
antibiotics	I-Drug
which	O
were	O
subsequently	O
discontinued	O
on	O
[	O
**	O
2197-10-27	O
**	O
]	O
.	O
The	O
infant	O
had	O
a	O
yeast	B-Reason
diaper	I-Reason
rash	I-Reason
and	O
was	O
treated	O
with	O
miconazole	I-Drug
powder	O
from	O
[	O
**	O
2197-10-21	O
**	O
]	O
,	O
through	O
till	O
[	O
**	O
2197-10-29	O
**	O
]	O
.	O
There	O
have	O
been	O
no	O
further	O
infectious	O
disease	O
issues	O
.	O
NEUROLOGY	O
:	O
The	O
infant	O
has	O
had	O
numerous	O
cranial	O
ultrasounds	O
done	O
on	O
[	O
**	O
2197-9-18	O
**	O
]	O
,	O
[	O
**	O
2197-9-25	O
**	O
]	O
,	O
[	O
**	O
2197-10-16	O
**	O
]	O
,	O
[	O
**	O
2197-12-21	O
**	O
]	O
,	O
all	O
within	O
normal	O
limits	O
.	O
SENSORY	O
:	O
Hearing	O
screen	O
was	O
performed	O
and	O
the	O
infant	O
passed	O
in	O
both	O
ears	O
.	O
OPHTHALMOLOGY	O
:	O
The	O
infant	O
has	O
had	O
numerous	O
ophthalmological	O
examinations	O
.	O
The	O
initial	O
examination	O
was	O
done	O
on	O
[	O
**	O
2197-10-30	O
**	O
]	O
,	O
and	O
the	O
most	O
recent	O
ophthalmologic	O
examination	O
was	O
[	O
**	O
2197-10-26	O
**	O
]	O
.	O
The	O
infant	O
did	O
have	O
mild	O
ROP	O
but	O
has	O
progressed	O
to	O
mature	O
eyes	O
on	O
[	O
**	O
2197-10-26	O
**	O
]	O
,	O
and	O
the	O
plan	O
is	O
for	O
follow	O
up	O
with	O
ophthalmology	O
in	O
9	O
months	O
after	O
discharge	O
.	O
PSYCHOSOCIAL	O
:	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
social	O
worker	O
has	O
been	O
involved	O
with	O
the	O
family	O
.	O
If	O
there	O
are	O
any	O
concerns	O
,	O
she	O
can	O
be	O
reached	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
56048	O
**	O
]	O
.	O
CONDITION	O
ON	O
DISCHARGE	O
:	O
Good	O
.	O
DISCHARGE	O
DISPOSITION	O
:	O
Home	O
with	O
the	O
parents	O
.	O
NAME	O
OF	O
PRIMARY	O
PEDIATRICIAN	O
:	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
from	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
.	O
CARE	O
RECOMMENDATIONS	O
:	O
1	O
.	O
Ad	O
lib	O
PO	O
feedings	O
of	O
breast	O
milk	O
26	O
calorie	O
per	O
ounce	O
made	O
as	O
breast	O
milk	O
with	O
4	O
calorie	O
per	O
ounce	O
of	O
Similac	O
powder	O
and	O
2	O
calories	O
per	O
ounce	O
of	O
corn	O
oil	O
.	O
2	O
.	O
Medications	O
:	O
Elemental	B-Drug
iron	I-Drug
0.5	O
ml	O
per	O
day	O
.	O
Daily	O
multivitamin	I-Drug
drops	O
1	O
ml	O
per	O
day	O
,	O
Lasix	I-Drug
5.5	O
mg	O
which	O
equals	O
0.6	O
ml	O
once	O
daily	O
on	O
Mondays	O
,	O
Wednesdays	O
and	O
Fridays	O
.	O
3	O
.	O
Car	O
seat	O
positioning	O
.	O
The	O
infant	O
was	O
tested	O
in	O
the	O
infant	O
car	O
seat	O
and	O
did	O
not	O
pass	O
in	O
an	O
upright	O
position	O
.	O
It	O
was	O
recommended	O
that	O
the	O
infant	O
be	O
discharged	O
in	O
an	O
infant	O
car	O
bed	O
in	O
a	O
supine	O
position	O
.	O
4	O
.	O
State	O
newborn	O
screens	O
:	O
Numerous	O
state	O
newborn	O
screens	O
have	O
been	O
sent	O
and	O
the	O
most	O
recent	O
screen	O
is	O
normal	O
.	O
5	O
.	O
Immunizations	O
received	O
:	O
The	O
infant	O
received	O
Pediarix	I-Drug
vaccine	O
on	O
[	O
**	O
2197-11-19	O
**	O
]	O
,	O
pneumococcal	I-Drug
vaccine	O
on	O
[	O
**	O
2197-11-20	O
**	O
]	O
,	O
Synagis	I-Drug
on	O
[	O
**	O
2197-12-25	O
**	O
]	O
.	O
6	O
.	O
Immunizations	O
Recommended	O
:	O
Synagis	I-Drug
RSV	O
prophylaxis	I-Reason
should	O
be	O
continued	O
monthly	O
through	O
[	O
**	O
Month	O
(	O
only	O
)	O
958	O
**	O
]	O
.	O
Influenza	I-Drug
immunization	O
is	O
recommended	O
annually	O
in	O
the	O
fall	O
for	O
all	O
infants	O
once	O
they	O
reach	O
6	O
months	O
of	O
age	O
.	O
Before	O
this	O
age	O
and	O
for	O
the	O
first	O
24	O
months	O
of	O
the	O
child	O
's	O
life	O
,	O
immunization	O
against	O
influenza	O
is	O
recommended	O
for	O
household	O
contacts	O
and	O
out	O
of	O
home	O
caregivers	O
.	O
Follow	O
up	O
appointment	O
is	O
recommended	O
with	O
the	O
pediatrician	O
on	O
[	O
**	O
2187-12-29	O
**	O
]	O
.	O
Also	O
followup	O
appointment	O
on	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
at	O
1	O
p.m.	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
37305	O
**	O
]	O
,	O
from	O
pediatric	O
pulmonology	O
at	O
[	O
**	O
Hospital3	O
18242	O
**	O
]	O
.	O
VNA	O
referral	O
after	O
discharge	O
.	O
Early	O
intervention	O
follow	O
up	O
and	O
Infant	O
[	O
**	O
Hospital	O
**	O
]	O
Clinic	O
at	O
[	O
**	O
Hospital3	O
1810	O
**	O
]	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Prematurity	O
born	O
at	O
24	O
and	O
6/7	O
weeks	O
gestation	O
.	O
2	O
.	O
Twin	O
No.	O
1	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
resolved	O
3	O
.	O
Rule	O
out	O
sepsis	O
.	O
4	O
.	O
Patent	O
ductus	O
arteriosus	O
,	O
resolved	O
5	O
.	O
Necrotizing	O
enterocolitis	O
,	O
resolved	O
6	O
.	O
Staph	O
epidermidis	O
bacteremia	O
,	O
resolved	O
7	O
.	O
Chronic	O
lung	O
disease	O
.	O
8	O
.	O
Hyperbilirubinemia	O
,	O
resolved	O
9	O
.	O
Anemia	O
of	O
prematurity	O
.	O
10	O
.	O
Retinopathy	O
of	O
prematurity	O
,	O
resolved	O
.	O
11	O
.	O
Left	O
hydrocele	O
.	O
12	O
.	O
Bilateral	B-Ade
renal	I-Ade
calcifications	I-Ade
Lasix	I-Drug
-	O
induced	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
56662	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Name8	O
(	O
MD	O
)	O
68870	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2197-12-26	O
**	O
]	O
22:22:26	O
T	O
:	O
[	O
**	O
2197-12-27	O
**	O
]	O
02:27:30	O
Job	O
#	O
:	O
[	O
**	O
Job	O
Number	O
68871	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2144-7-31	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2144-8-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2090-5-20	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Bactrim	I-Drug
/	O
Prilosec	I-Drug
/	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
6088	O
**	O
]	O
Chief	O
Complaint	O
:	O
cold	O
,	O
painful	O
right	O
foot	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
Insertion	O
of	O
Gunther	O
-	O
Tulip	O
IVC	O
filter	O
,	O
jugular	O
approach	O
.	O
2	O
.	O
Venous	O
iliofemoral	O
and	O
femoral	O
popliteal	O
thrombectomy	O
.	O
3	O
.	O
Right	O
groin	O
AV	O
fistula	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
54F	O
s	O
/	O
p	O
right	O
total	O
knee	O
replacement	O
[	O
**	O
2144-7-16	O
**	O
]	O
.	O
Presented	O
to	O
[	O
**	O
Hospital3	O
17031	O
**	O
]	O
on	O
[	O
**	O
2144-7-29	O
**	O
]	O
with	O
3	O
-	O
4	O
day	O
h	O
/	O
o	O
shortness	O
of	O
breath	O
,	O
new	O
RLE	O
swelling	O
,	O
and	O
right	O
foot	O
pain	O
.	O
CTA	O
chest	O
at	O
that	O
time	O
demonstrated	O
PE	O
.	O
BLE	O
US	O
demonstrated	O
DVT	O
in	O
right	O
comomon	O
femoral	O
vein	O
,	O
superficial	O
femoral	O
vein	O
,	O
and	O
proximal	O
greater	O
saphenous	O
vein	O
;	O
popliteal	O
vein	O
was	O
not	O
assessed	O
.	O
Prior	O
to	O
presentation	O
,	O
she	O
was	O
on	O
Lovenox	I-Drug
for	O
DVT	B-Reason
prophylaxis	I-Reason
;	O
platelet	O
count	O
was	O
41,000	O
on	O
presentation	O
.	O
Given	O
suspicion	B-Reason
of	I-Reason
HIT	I-Ade
,	O
she	O
was	O
started	O
on	O
an	O
argatroban	I-Drug
drip	O
and	O
coumadin	I-Drug
for	O
her	B-Reason
DVT	I-Reason
.	O
Since	O
admission	O
,	O
her	O
foot	O
has	O
become	O
progressively	O
more	O
cyanotic	O
,	O
painful	O
,	O
and	O
swollen	O
.	O
Report	O
from	O
transferring	O
ICU	O
physician	O
was	O
that	O
right	O
foot	O
DP	O
and	O
PT	O
pulses	O
were	O
dopplerable	O
.	O
She	O
is	O
transferred	O
here	O
for	O
further	O
management	O
.	O
Past	O
Medical	O
History	O
:	O
OSA	O
,	O
fentanyl	I-Drug
usage	O
,	O
mitral	O
regurgitation	O
/	O
valve	O
prolapse	O
,	O
HTN	O
,	O
obesity	O
,	O
hyperlipidemia	O
,	O
asthma	O
,	O
h	O
/	O
o	O
palpitations	O
and	O
unifocal	O
premature	O
ventricular	O
beats	O
(	O
followed	O
by	O
cardiology	O
here	O
)	O
,	O
GERD	O
Social	O
History	O
:	O
Denies	O
EtOH	O
and	O
tobacco	O
use	O
.	O
Former	O
nurse	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Hospital3	O
**	O
]	O
Hospital	O
.	O
Currently	O
disabled	O
.	O
Family	O
History	O
:	O
family	O
cardiovascular	O
illness	O
,	O
o	O
/	O
w	O
noncontributory	O
Physical	O
Exam	O
:	O
Vital	O
:	O
Tm99	O
.2	O
Tc98	O
.9	O
P80	O
BP102	O
/	O
60	O
RR98	O
%	O
RA	O
Gen	O
:	O
NAD	O
,	O
AAOx3	O
CV	O
:	O
RRR	O
,	O
+	O
s1	O
,	O
s2	O
Lung	O
:	O
CTAB	O
Abd	O
:	O
+	O
BS	O
,	O
Soft	O
,	O
NT	O
/	O
ND	O
Right	O
foot	O
:	O
no	O
drainage	O
,	O
less	O
edematous	O
,	O
dressed	O
with	O
silvadine	O
ointment	O
and	O
gauze	O
.	O
Palpable	O
pulses	O
on	O
right	O
LE	O
Pertinent	O
Results	O
:	O
[	O
**	O
2144-8-10	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
WBC	O
-	O
6.1	O
RBC	O
-	O
3.45	O
*	O
Hgb	O
-	O
9.4	O
*	O
Hct	O
-	O
28.9	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
27.3	O
MCHC	O
-	O
32.6	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
300	O
[	O
**	O
2144-8-9	O
**	O
]	O
05:33	O
AM	O
BLOOD	O
WBC	O
-	O
5.3	O
RBC	O
-	O
3.39	O
*	O
Hgb	O
-	O
9.1	O
*	O
Hct	O
-	O
28.5	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
27.0	O
MCHC	O
-	O
32.1	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
234	O
[	O
**	O
2144-8-8	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
WBC	O
-	O
6.2	O
RBC	O
-	O
3.41	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
28.2	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
26.8	O
*	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
213	O
[	O
**	O
2144-8-7	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
WBC	O
-	O
8.2	O
RBC	O
-	O
3.55	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
29.2	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
27.5	O
MCHC	O
-	O
33.4	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
194	O
[	O
**	O
2144-8-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
WBC	O
-	O
8.2	O
RBC	O
-	O
3.54	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
29.3	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
26.9	O
*	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
15.5	O
Plt	O
Ct	O
-	O
166	O
[	O
**	O
2144-8-5	O
**	O
]	O
03:24	O
AM	O
BLOOD	O
WBC	O
-	O
10.2	O
RBC	O
-	O
3.56	O
*	O
Hgb	O
-	O
9.9	O
*	O
Hct	O
-	O
29.3	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
27.9	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
15.6	O
*	O
Plt	O
Ct	O
-	O
128	O
*	O
[	O
**	O
2144-8-4	O
**	O
]	O
01:54	O
AM	O
BLOOD	O
WBC	O
-	O
8.8	O
RBC	O
-	O
3.46	O
*	O
Hgb	O
-	O
9.7	O
*	O
Hct	O
-	O
28.6	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
28.1	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
112	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
06:02	O
PM	O
BLOOD	O
WBC	O
-	O
9.8	O
RBC	O
-	O
3.60	O
*	O
Hgb	O
-	O
10.2	O
*	O
Hct	O
-	O
29.5	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
28.3	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
15.4	O
Plt	O
Ct	O
-	O
109	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:15	O
AM	O
BLOOD	O
WBC	O
-	O
7.5	O
RBC	O
-	O
3.67	O
*	O
Hgb	O
-	O
10.2	O
*	O
Hct	O
-	O
30.4	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
27.8	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
15.3	O
Plt	O
Ct	O
-	O
89	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
WBC	O
-	O
6.6	O
RBC	O
-	O
3.85	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
31.7	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
27.9	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
101	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
02:10	O
PM	O
BLOOD	O
WBC	O
-	O
4.7	O
RBC	O
-	O
3.81	O
*	O
Hgb	O
-	O
10.2	O
*	O
Hct	O
-	O
31.0	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
26.7	O
*	O
MCHC	O
-	O
32.8	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
119	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
09:27	O
AM	O
BLOOD	O
Hct	O
-	O
30.6	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
WBC	O
-	O
5.5	O
RBC	O
-	O
3.27	O
*	O
Hgb	O
-	O
8.8	O
*	O
Hct	O
-	O
26.4	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
27.0	O
MCHC	O
-	O
33.4	O
RDW	O
-	O
14.9	O
Plt	O
Ct	O
-	O
120	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
01:11	O
AM	O
BLOOD	O
Hct	O
-	O
28.2	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
10:19	O
AM	O
BLOOD	O
Hct	O
-	O
26.6	O
*	O
Plt	O
Ct	O
-	O
82	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:44	O
AM	O
BLOOD	O
WBC	O
-	O
7.3	O
RBC	O
-	O
3.41	O
*	O
Hgb	O
-	O
9.1	O
*	O
Hct	O
-	O
26.8	O
*	O
MCV	O
-	O
79	O
*	O
MCH	O
-	O
26.8	O
*	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
91	O
*	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
WBC	O
-	O
11.1	O
*	O
RBC	O
-	O
4.11	O
*	O
Hgb	O
-	O
10.7	O
*	O
Hct	O
-	O
33.6	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
26.1	O
*	O
MCHC	O
-	O
31.9	O
RDW	O
-	O
15.3	O
Plt	O
Ct	O
-	O
91	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
06:02	O
PM	O
BLOOD	O
Neuts	O
-	O
87	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
6.0	O
*	O
Monos	O
-	O
5	O
Eos	O
-	O
2	O
Baso	O
-	O
0	O
[	O
**	O
2144-8-2	O
**	O
]	O
02:10	O
PM	O
BLOOD	O
Neuts	O
-	O
67.5	O
Lymphs	O
-	O
18.8	O
Monos	O
-	O
7.0	O
Eos	O
-	O
6.4	O
*	O
Baso	O
-	O
0.4	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
Neuts	O
-	O
78	O
*	O
Bands	O
-	O
2	O
Lymphs	O
-	O
7	O
*	O
Monos	O
-	O
10	O
Eos	O
-	O
3	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
1	O
+	O
Poiklo	O
-	O
OCCASIONAL	O
Macrocy	O
-	O
OCCASIONAL	O
Microcy	O
-	O
OCCASIONAL	O
Polychr	O
-	O
1	O
+	O
Ovalocy	O
-	O
OCCASIONAL	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
1	O
+	O
Poiklo	O
-	O
OCCASIONAL	O
Macrocy	O
-	O
OCCASIONAL	O
Microcy	O
-	O
OCCASIONAL	O
Polychr	O
-	O
1	O
+	O
Ovalocy	O
-	O
OCCASIONAL	O
[	O
**	O
2144-8-10	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
300	O
[	O
**	O
2144-8-10	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
PT	O
-	O
39.8	O
*	O
PTT	O
-	O
54.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.3	O
*	O
[	O
**	O
2144-8-9	O
**	O
]	O
05:33	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
234	O
[	O
**	O
2144-8-9	O
**	O
]	O
05:33	O
AM	O
BLOOD	O
PT	O
-	O
41.9	O
*	O
PTT	O
-	O
54.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.6	O
*	O
[	O
**	O
2144-8-8	O
**	O
]	O
12:15	O
PM	O
BLOOD	O
PT	O
-	O
38.4	O
*	O
PTT	O
-	O
52.1	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.1	O
*	O
[	O
**	O
2144-8-8	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
213	O
[	O
**	O
2144-8-8	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
PT	O
-	O
36.4	O
*	O
PTT	O
-	O
48.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.9	O
*	O
[	O
**	O
2144-8-8	O
**	O
]	O
02:58	O
AM	O
BLOOD	O
PT	O
-	O
37.4	O
*	O
PTT	O
-	O
52.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.0	O
*	O
[	O
**	O
2144-8-7	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
PT	O
-	O
34.7	O
*	O
PTT	O
-	O
47.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.7	O
*	O
[	O
**	O
2144-8-7	O
**	O
]	O
12:47	O
PM	O
BLOOD	O
PT	O
-	O
36.8	O
*	O
PTT	O
-	O
67.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.9	O
*	O
[	O
**	O
2144-8-7	O
**	O
]	O
09:50	O
AM	O
BLOOD	O
PT	O
-	O
39.4	O
*	O
PTT	O
-	O
76.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.3	O
*	O
[	O
**	O
2144-8-7	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
194	O
[	O
**	O
2144-8-7	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
PT	O
-	O
46.0	O
*	O
PTT	O
-	O
91.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
5.2	O
*	O
[	O
**	O
2144-8-6	O
**	O
]	O
11:45	O
PM	O
BLOOD	O
PT	O
-	O
44.1	O
*	O
PTT	O
-	O
90.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.9	O
*	O
[	O
**	O
2144-8-6	O
**	O
]	O
04:55	O
PM	O
BLOOD	O
PTT	O
-	O
85.9	O
*	O
[	O
**	O
2144-8-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
166	O
[	O
**	O
2144-8-5	O
**	O
]	O
05:48	O
PM	O
BLOOD	O
PT	O
-	O
34.2	O
*	O
PTT	O
-	O
89.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.6	O
*	O
[	O
**	O
2144-8-5	O
**	O
]	O
03:24	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
128	O
*	O
[	O
**	O
2144-8-5	O
**	O
]	O
03:24	O
AM	O
BLOOD	O
PT	O
-	O
34.1	O
*	O
PTT	O
-	O
99.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.6	O
*	O
[	O
**	O
2144-8-4	O
**	O
]	O
08:42	O
AM	O
BLOOD	O
PT	O
-	O
32.8	O
*	O
PTT	O
-	O
77.1	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.4	O
*	O
[	O
**	O
2144-8-4	O
**	O
]	O
01:54	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
112	O
*	O
[	O
**	O
2144-8-4	O
**	O
]	O
01:54	O
AM	O
BLOOD	O
PT	O
-	O
36.6	O
*	O
PTT	O
-	O
107.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.9	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
08:07	O
PM	O
BLOOD	O
PT	O
-	O
32.5	O
*	O
PTT	O
-	O
81.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.4	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
06:02	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
109	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:56	O
PM	O
BLOOD	O
PT	O
-	O
35.5	O
*	O
PTT	O
-	O
90.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.8	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
08:55	O
AM	O
BLOOD	O
PT	O
-	O
37.0	O
*	O
PTT	O
-	O
82.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.0	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:15	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
89	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
08:46	O
PM	O
BLOOD	O
PTT	O
-	O
82.9	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
101	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
PT	O
-	O
43.4	O
*	O
PTT	O
-	O
103	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.8	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
02:10	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
119	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
02:10	O
PM	O
BLOOD	O
PT	O
-	O
42.8	O
*	O
PTT	O
-	O
92.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.7	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
09:27	O
AM	O
BLOOD	O
PTT	O
-	O
80.1	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
120	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
PTT	O
-	O
95.1	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
12:04	O
AM	O
BLOOD	O
PTT	O
-	O
81.5	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:29	O
PM	O
BLOOD	O
PT	O
-	O
34.1	O
*	O
PTT	O
-	O
78.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.6	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
10:19	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
82	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
10:19	O
AM	O
BLOOD	O
PT	O
-	O
34.2	O
*	O
PTT	O
-	O
87.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.6	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:44	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
91	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:44	O
AM	O
BLOOD	O
PT	O
-	O
31.7	O
*	O
PTT	O
-	O
87.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.3	O
*	O
[	O
**	O
2144-8-1	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
PTT	O
-	O
94.6	O
*	O
[	O
**	O
2144-7-31	O
**	O
]	O
05:06	O
PM	O
BLOOD	O
PT	O
-	O
33.1	O
*	O
PTT	O
-	O
93.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.4	O
*	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
Plt	O
Smr	O
-	O
LOW	O
Plt	O
Ct	O
-	O
91	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Fibrino	O
-	O
280	O
[	O
**	O
2144-8-9	O
**	O
]	O
05:33	O
AM	O
BLOOD	O
Glucose	O
-	O
111	O
*	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.6	O
Na	O
-	O
142	O
K	O
-	O
4.0	O
Cl	O
-	O
109	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2144-8-8	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
Glucose	O
-	O
103	O
UreaN	O
-	O
9	O
Creat	O
-	O
0.6	O
Na	O
-	O
144	O
K	O
-	O
4.0	O
Cl	O
-	O
111	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2144-8-7	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Glucose	O
-	O
114	O
*	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
3.9	O
Cl	O
-	O
107	O
HCO3	O
-	O
26	O
AnGap	O
-	O
12	O
[	O
**	O
2144-8-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
Glucose	O
-	O
114	O
*	O
UreaN	O
-	O
9	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
3.4	O
Cl	O
-	O
106	O
HCO3	O
-	O
26	O
AnGap	O
-	O
12	O
[	O
**	O
2144-8-5	O
**	O
]	O
03:24	O
AM	O
BLOOD	O
Glucose	O
-	O
104	O
UreaN	O
-	O
9	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
3.6	O
Cl	O
-	O
108	O
HCO3	O
-	O
24	O
AnGap	O
-	O
13	O
[	O
**	O
2144-8-4	O
**	O
]	O
01:54	O
AM	O
BLOOD	O
Glucose	O
-	O
120	O
*	O
UreaN	O
-	O
8	O
Creat	O
-	O
0.7	O
Na	O
-	O
143	O
K	O
-	O
4.4	O
Cl	O
-	O
113	O
*	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
13	O
[	O
**	O
2144-8-3	O
**	O
]	O
08:07	O
PM	O
BLOOD	O
K	O
-	O
3.8	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:15	O
AM	O
BLOOD	O
Glucose	O
-	O
117	O
*	O
UreaN	O
-	O
7	O
Creat	O
-	O
0.7	O
Na	O
-	O
144	O
K	O
-	O
4.0	O
Cl	O
-	O
114	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
9	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Glucose	O
-	O
114	O
*	O
UreaN	O
-	O
8	O
Creat	O
-	O
0.6	O
Na	O
-	O
140	O
K	O
-	O
4.1	O
Cl	O
-	O
110	O
*	O
HCO3	O
-	O
23	O
AnGap	O
-	O
11	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
Glucose	O
-	O
308	O
*	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.7	O
Na	O
-	O
137	O
K	O
-	O
4.0	O
Cl	O
-	O
103	O
HCO3	O
-	O
26	O
AnGap	O
-	O
12	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:44	O
AM	O
BLOOD	O
Glucose	O
-	O
127	O
*	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.6	O
Na	O
-	O
137	O
K	O
-	O
4.1	O
Cl	O
-	O
103	O
HCO3	O
-	O
26	O
AnGap	O
-	O
12	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
Glucose	O
-	O
112	O
*	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.9	O
Na	O
-	O
138	O
K	O
-	O
5.0	O
Cl	O
-	O
100	O
HCO3	O
-	O
26	O
AnGap	O
-	O
17	O
[	O
**	O
2144-8-8	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:15	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
865	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
929	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
716	O
*	O
TotBili	O
-	O
0.7	O
DirBili	O
-	O
0.3	O
IndBili	O
-	O
0.4	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:44	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
87	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
53	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2144-8-9	O
**	O
]	O
05:33	O
AM	O
BLOOD	O
Calcium	O
-	O
8.2	O
*	O
Phos	O
-	O
3.7	O
Mg	O
-	O
2.4	O
[	O
**	O
2144-8-8	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.6	O
Mg	O
-	O
2.2	O
[	O
**	O
2144-8-7	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Calcium	O
-	O
8.2	O
*	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.1	O
[	O
**	O
2144-8-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
3.5	O
Mg	O
-	O
2.1	O
[	O
**	O
2144-8-5	O
**	O
]	O
03:24	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.8	O
Mg	O
-	O
1.9	O
[	O
**	O
2144-8-4	O
**	O
]	O
01:54	O
AM	O
BLOOD	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
3.7	O
Mg	O
-	O
2.2	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:15	O
AM	O
BLOOD	O
Calcium	O
-	O
7.6	O
*	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.1	O
[	O
**	O
2144-8-2	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Calcium	O
-	O
7.4	O
*	O
Phos	O
-	O
4.2	O
Mg	O
-	O
2.1	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
4.2	O
Mg	O
-	O
2.3	O
[	O
**	O
2144-8-1	O
**	O
]	O
04:44	O
AM	O
BLOOD	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.1	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
Calcium	O
-	O
9.9	O
Phos	O
-	O
4.3	O
Mg	O
-	O
2.5	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
Hapto	O
-	O
137	O
[	O
**	O
2144-8-4	O
**	O
]	O
07:55	O
AM	O
BLOOD	O
Vanco	O
-	O
6.8	O
*	O
[	O
**	O
2144-8-4	O
**	O
]	O
02:25	O
AM	O
BLOOD	O
Type	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
pH	O
-	O
7.42	O
[	O
**	O
2144-8-3	O
**	O
]	O
10:22	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
91	O
pCO2	O
-	O
43	O
pH	O
-	O
7.37	O
calTCO2	O
-	O
26	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2144-8-3	O
**	O
]	O
09:08	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
82	O
*	O
pCO2	O
-	O
44	O
pH	O
-	O
7.39	O
calTCO2	O
-	O
28	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:29	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
86	O
pCO2	O
-	O
42	O
pH	O
-	O
7.42	O
calTCO2	O
-	O
28	O
Base	O
XS	O
-	O
2	O
[	O
**	O
2144-8-2	O
**	O
]	O
07:09	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
101	O
pCO2	O
-	O
44	O
pH	O
-	O
7.40	O
calTCO2	O
-	O
28	O
Base	O
XS	O
-	O
1	O
[	O
**	O
2144-8-2	O
**	O
]	O
05:08	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
86	O
pCO2	O
-	O
42	O
pH	O
-	O
7.39	O
calTCO2	O
-	O
26	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:43	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
Rates	O
-	O
/	O
10	O
Tidal	O
V	O
-	O
700	O
FiO2	O
-	O
58	O
pO2	O
-	O
186	O
*	O
pCO2	O
-	O
41	O
pH	O
-	O
7.41	O
calTCO2	O
-	O
27	O
Base	O
XS	O
-	O
1	O
Intubat	O
-	O
INTUBATED	O
[	O
**	O
2144-8-2	O
**	O
]	O
01:49	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
Rates	O
-	O
/	O
11	O
Tidal	O
V	O
-	O
700	O
FiO2	O
-	O
59	O
pO2	O
-	O
198	O
*	O
pCO2	O
-	O
36	O
pH	O
-	O
7.47	O
*	O
calTCO2	O
-	O
27	O
Base	O
XS	O
-	O
3	O
Intubat	O
-	O
INTUBATED	O
[	O
**	O
2144-8-2	O
**	O
]	O
11:06	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
Rates	O
-	O
/	O
10	O
Tidal	O
V	O
-	O
700	O
FiO2	O
-	O
86	O
pO2	O
-	O
235	O
*	O
pCO2	O
-	O
40	O
pH	O
-	O
7.46	O
*	O
calTCO2	O
-	O
29	O
Base	O
XS	O
-	O
5	O
AADO2	O
-	O
356	O
REQ	O
O2	O
-	O
62	O
Intubat	O
-	O
INTUBATED	O
Vent	O
-	O
CONTROLLED	O
[	O
**	O
2144-8-3	O
**	O
]	O
03:10	O
PM	O
BLOOD	O
K	O
-	O
3.8	O
[	O
**	O
2144-8-3	O
**	O
]	O
09:08	O
AM	O
BLOOD	O
Glucose	O
-	O
115	O
*	O
K	O
-	O
3.5	O
[	O
**	O
2144-8-2	O
**	O
]	O
01:49	O
PM	O
BLOOD	O
Glucose	O
-	O
99	O
Lactate	O
-	O
0.9	O
Na	O
-	O
139	O
K	O
-	O
4.0	O
Cl	O
-	O
106	O
calHCO3	O
-	O
27	O
[	O
**	O
2144-8-2	O
**	O
]	O
11:06	O
AM	O
BLOOD	O
Glucose	O
-	O
104	O
Lactate	O
-	O
0.9	O
Na	O
-	O
139	O
K	O
-	O
4.6	O
Cl	O
-	O
102	O
calHCO3	O
-	O
29	O
[	O
**	O
2144-8-3	O
**	O
]	O
10:22	O
AM	O
BLOOD	O
O2	O
Sat	O
-	O
95	O
[	O
**	O
2144-8-3	O
**	O
]	O
09:08	O
AM	O
BLOOD	O
O2	O
Sat	O
-	O
94	O
[	O
**	O
2144-8-2	O
**	O
]	O
07:09	O
PM	O
BLOOD	O
O2	O
Sat	O
-	O
96	O
[	O
**	O
2144-8-2	O
**	O
]	O
03:43	O
PM	O
BLOOD	O
Hgb	O
-	O
11.0	O
*	O
calcHCT	O
-	O
33	O
[	O
**	O
2144-8-2	O
**	O
]	O
01:49	O
PM	O
BLOOD	O
Hgb	O
-	O
10.4	O
*	O
calcHCT	O
-	O
31	O
[	O
**	O
2144-8-2	O
**	O
]	O
11:06	O
AM	O
BLOOD	O
Hgb	O
-	O
11.0	O
*	O
calcHCT	O
-	O
33	O
[	O
**	O
2144-8-4	O
**	O
]	O
02:25	O
AM	O
BLOOD	O
freeCa	O
-	O
1.08	O
*	O
[	O
**	O
2144-8-3	O
**	O
]	O
09:08	O
AM	O
BLOOD	O
freeCa	O
-	O
1.12	O
[	O
**	O
2144-8-3	O
**	O
]	O
02:29	O
AM	O
BLOOD	O
freeCa	O
-	O
1.11	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
01:49	O
PM	O
BLOOD	O
freeCa	O
-	O
1.10	O
*	O
[	O
**	O
2144-8-2	O
**	O
]	O
11:06	O
AM	O
BLOOD	O
freeCa	O
-	O
1.12	O
[	O
**	O
2144-7-31	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
HEPARIN	I-Drug
DEPENDENT	O
ANTIBODIES	O
-	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
is	O
a	O
54	O
-	O
year	O
-	O
old	O
female	O
who	O
had	O
a	O
total	O
knee	O
repair	O
2	O
weeks	O
ago	O
and	O
subsequently	O
developed	O
heparin	I-Drug
induced	I-Ade
thrombocytopenia	O
with	O
a	O
large	O
right	O
iliofemoral	O
DVT	O
and	O
over	O
the	O
past	O
3	O
days	O
.	O
Progressive	O
signs	O
of	O
phlegmasia	O
cerulea	O
dolens	O
.	O
Despite	O
aggressive	O
anticoagulation	I-Reason
with	O
direct	I-Drug
thrombin	O
inhibitors	O
and	O
elevation	O
,	O
the	O
toes	O
were	O
progressively	O
gangrenous	O
and	O
venous	O
thrombectomy	O
was	O
required	O
to	O
prevent	O
limb	O
loss	O
.	O
She	O
was	O
not	O
a	O
candidate	O
for	O
thrombolysis	I-Drug
,	O
due	O
to	O
her	O
recent	O
knee	O
replacement	O
.	O
Patient	O
was	O
admitted	O
and	O
placed	O
on	O
argatroban	I-Drug
for	O
anticoagulation	I-Reason
and	O
diltiazem	I-Drug
.	O
Patient	O
was	O
transfused	O
2units	O
x2	O
for	O
low	O
hct	O
.	O
Patient	O
was	O
taken	O
to	O
the	O
OR	O
venous	O
thrombectomy	O
to	O
salvage	O
limb	O
.	O
In	O
the	O
OR	O
the	O
patient	O
was	O
found	O
to	O
have	O
a	O
patent	O
left	O
iliac	O
venous	O
system	O
and	O
patent	O
inferior	O
vena	O
cava	O
.	O
Uneventful	O
deployment	O
of	O
a	O
Tulip	O
IVC	O
filter	O
.	O
Successful	O
thrombectomy	O
of	O
the	O
femoral	O
vein	O
of	O
the	O
thigh	O
and	O
profunda	O
veins	O
along	O
with	O
large	O
amount	O
of	O
thrombus	O
removed	O
from	O
the	O
right	O
iliac	O
system	O
.	O
The	O
resultant	O
clearing	O
was	O
quite	O
good	O
.	O
AV	O
fistula	O
was	O
placed	O
from	O
the	O
branch	O
of	O
the	O
anterior	O
saphenous	O
vein	O
to	O
the	O
superficial	O
femoral	O
artery	O
.	O
Patient	O
tolerated	O
the	O
procedure	O
well	O
and	O
was	O
transferred	O
in	O
stable	O
condition	O
to	O
CVICU	O
intubated	O
and	O
given	O
argatatroban	I-Drug
.	O
POD1	O
:	O
swelling	O
on	O
right	O
leg	O
was	O
much	O
improved	O
.	O
Patient	O
was	O
extubated	O
.	O
SW	O
was	O
consulted	O
and	O
saw	O
the	O
patient	O
several	O
times	O
for	O
emotional	O
suppor	O
and	O
to	O
help	O
cope	O
with	O
her	O
illness	O
.	O
Patient	O
was	O
continued	O
tx	O
of	O
vanco	I-Drug
/	O
flagyl	I-Drug
for	O
prophylaxis	I-Reason
.	O
POD2	O
:	O
Physical	O
therapy	O
cleared	O
for	O
rehab	O
.	O
POD3	O
:	O
Patient	O
was	O
started	O
on	O
coumadin	I-Drug
anticoagulation	I-Reason
.	O
Was	O
encouraged	O
to	O
be	O
OOB	O
for	O
short	O
periods	O
.	O
Physical	O
therapy	O
was	O
c	O
/	O
s	O
for	O
dx	O
&	O
tx	O
.	O
POD4	O
:	O
psychiatry	O
was	O
consulted	O
for	O
assessment	O
and	O
management	O
of	O
anxiety	O
.	O
Pt	O
was	O
assessed	O
with	O
dx	O
c	O
/	O
w	O
adjustment	B-Reason
d	I-Reason
/	I-Reason
o	I-Reason
with	I-Reason
mixed	I-Reason
anxiety	O
/	O
depression	O
and	O
recommended	O
ativan	I-Drug
0.5	O
mg	O
PO	O
TID	O
PRN	O
anxiety	I-Reason
.	O
Psychiatry	O
continued	O
to	O
follow	O
during	O
her	O
stay	O
.	O
POD5	O
:	O
Argatroban	I-Drug
was	O
stopped	O
(	O
PTT	O
was	O
102.0	O
and	O
INR	O
was	O
5.1	O
)	O
and	O
INR	O
checked	O
four	O
hours	O
later	O
to	O
allow	O
the	O
effects	O
of	O
argatroban	I-Drug
to	O
wear	O
off	O
(	O
PTT90	O
.8	O
,	O
INR4	O
.9	O
at	O
that	O
time	O
)	O
.	O
Due	O
to	O
therapeutic	O
INR	O
,	O
argatroban	I-Drug
remained	O
off	O
and	O
patient	O
was	O
anticoagulated	I-Reason
with	O
coumadin	I-Drug
only	O
with	O
target	O
INR	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
.	O
Silvadine	I-Drug
was	O
applied	O
to	O
right	B-Reason
foot	I-Reason
wound	I-Reason
.	O
And	O
activity	O
was	O
increased	O
to	O
touchdown	O
weight	O
bearing	O
of	O
right	O
heel	O
.	O
POD6	O
:	O
INR	O
3.7	O
and	O
PTT	O
45.9	O
and	O
coumadin	I-Drug
7.5	O
mg	O
given	O
and	O
PTT	O
/	O
INR	O
cont	O
to	O
followed	O
.	O
POD8	O
:	O
INR	O
4.3	O
and	O
PTT	O
54.3	O
,	O
last	O
INR	O
prior	O
to	O
D	O
/	O
C	O
Medications	O
on	O
Admission	O
:	O
Advair	I-Drug
,	O
Protonix	I-Drug
,	O
verapamil	I-Drug
240	O
,	O
baby	O
aspirin	I-Drug
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
2	O
.	O
Fluticasone	I-Drug
-	O
Salmeterol	O
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Diltiazem	I-Drug
HCl	O
60	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Ipratropium	I-Drug
Bromide	O
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
6	O
.	O
Atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
.	O
8	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
9	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
11	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
13	O
.	O
Menthol	B-Drug
-	I-Drug
Cetylpyridinium	I-Drug
3	O
mg	O
Lozenge	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Lozenge	O
Mucous	O
membrane	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
14	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
15	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
16	O
.	O
Silver	B-Drug
Sulfadiazine	I-Drug
1	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
17	O
.	O
Hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
.	O
18	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
19	O
.	O
Lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
.	O
20	O
.	O
Magnesium	I-Drug
Hydroxide	O
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
21	O
.	O
Warfarin	I-Drug
3	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
:	O
goal	O
INR	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
.	O
22	O
.	O
Bisacodyl	I-Drug
10	O
mg	O
Suppository	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O
23	O
.	O
Insulin	I-Drug
Insulin	I-Drug
SC	O
(	O
per	O
Insulin	I-Drug
Flowsheet	O
)	O
Sliding	O
Scale	O
Fingerstick	O
QACHSInsulin	O
SC	O
Sliding	O
Scale	O
Q6H	O
Regular	O
Glucose	O
Insulin	I-Drug
Dose	O
0	B-Reason
-	I-Reason
60	I-Reason
mg	I-Reason
/	I-Reason
dL	I-Reason
[	O
**	O
1	O
-	O
29	O
**	O
]	O
amp	O
D50	I-Drug
61	O
-	O
120	O
mg	O
/	O
dL	O
0	O
Units	O
121	O
-	O
140	O
mg	O
/	O
dL	O
2	O
Units	O
141	O
-	O
160	O
mg	O
/	O
dL	O
3	O
Units	O
161	O
-	O
180	O
mg	O
/	O
dL	O
4	O
Units	O
181	O
-	O
200	O
mg	O
/	O
dL	O
5	O
Units	O
201	O
-	O
220	O
mg	O
/	O
dL	O
6	O
Units	O
221	O
-	O
240	O
mg	O
/	O
dL	O
7	O
Units	O
241	O
-	O
260	O
mg	O
/	O
dL	O
8	O
Units	O
261	O
-	O
280	O
mg	O
/	O
dL	O
9	O
Units	O
281	O
-	O
300	O
mg	O
/	O
dL	O
10	O
Units	O
301	O
-	O
320	O
mg	O
/	O
dL	O
11	O
Units	O
321	O
-	O
340	O
mg	O
/	O
dL	O
12	O
Units	O
341	O
-	O
360	O
mg	O
/	O
dL	O
13	O
Units	O
>	O
360	O
mg	O
/	O
dL	O
Notify	O
M.D.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
**	O
]	O
Hospital	O
[	O
**	O
Hospital1	O
189	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Phlegmasia	O
,	O
venous	O
gangrene	O
R	O
lower	O
extremity	O
OSA	O
fentanyl	I-Drug
usage	O
,	O
mitral	O
regurgitation	O
/	O
valve	O
prolapse	O
HTN	O
obesity	O
hyperlipidemia	O
asthma	O
h	O
/	O
o	O
palpitations	O
and	O
unifocal	O
premature	O
ventricular	O
beats	O
(	O
followed	O
by	O
cardiology	O
here	O
)	O
GERD	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
-	O
You	O
had	O
-	O
Insertion	O
of	O
Gunther	O
-	O
Tulip	O
IVC	O
filter	O
,	O
jugular	O
approach	O
,	O
Venous	O
iliofemoral	O
and	O
femoral	O
popliteal	O
thrombectomy	O
,	O
Right	O
groin	O
AV	O
fistula	O
.	O
-	O
You	O
will	O
resume	O
activities	O
per	O
your	O
prescribed	O
activity	O
limitations	O
.	O
-	O
Your	O
R	O
foot	O
wound	O
care	O
per	O
orders	O
.	O
-	O
FU	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
as	O
scheduled	O
.	O
-	O
Keep	O
your	O
other	O
FU	O
as	O
scheduled	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
251	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1490	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1237	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2144-8-19	O
**	O
]	O
10:00	O
Provider	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
16827	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2144-12-2	O
**	O
]	O
8:40	O
Completed	O
by	O
:[	O
**	O
2144-8-10	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2134-5-28	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2134-6-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2070-2-22	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Tetracycline	I-Drug
/	O
Dicloxacillin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1377	O
**	O
]	O
Chief	O
Complaint	O
:	O
UTI	O
and	O
urolithiasis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Lithotripsy	O
PICC	O
line	O
placement	O
/	O
removal	O
History	O
of	O
Present	O
Illness	O
:	O
64	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
nephrolithiasis	O
,	O
recurrent	O
UTIs	O
,	O
DVT	O
/	O
PE	O
,	O
HIV	O
,	O
HBV	O
cirrhosis	O
&	O
HCC	O
s	O
/	O
p	O
orthotopic	O
liver	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
in	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
,	O
who	O
presented	O
on	O
[	O
**	O
5	O
-	O
28	O
**	O
]	O
for	O
a	O
direct	O
admission	O
to	O
be	O
bridged	O
from	O
coumadin	I-Drug
to	O
heparin	I-Drug
for	O
a	O
lithotripsy	O
procedure	O
.	O
As	O
the	O
patient	O
was	O
being	O
admitted	O
,	O
an	O
outpatient	O
urine	O
culture	O
was	O
reported	O
as	O
growing	O
Vancomycin	B-Reason
Resistant	I-Reason
Enterococcus	O
,	O
and	O
daptomycin	I-Drug
therapy	O
was	O
begun	O
.	O
Patient	O
was	O
stable	O
and	O
without	O
complaint	O
.	O
Past	O
Medical	O
History	O
:	O
*	O
s	O
/	O
p	O
Liver	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
on	O
[	O
**	O
2133-5-30	O
**	O
]	O
for	O
Hep	O
B	O
cirrhosis	O
c	O
/	O
b	O
HCC	O
s	O
/	O
p	O
RFA	O
*	O
HIV	O
diagnosed	O
in	O
[	O
**	O
2111	O
**	O
]	O
with	O
undetectable	O
viral	O
load	O
(	O
CD4	O
159	O
[	O
**	O
2133-11-10	O
**	O
]	O
,	O
HIV	O
VL	O
274	O
[	O
**	O
2133-11-10	O
**	O
]	O
)	O
*	O
Hepatitis	O
B	O
diagnosed	O
in	O
[	O
**	O
2093	O
**	O
]	O
with	O
undetectable	O
viral	O
load	O
(	O
[	O
**	O
2133-5-13	O
**	O
]	O
HBVL	O
<	O
40	O
)	O
*	O
h	O
/	O
o	O
PE	I-Reason
in	O
[	O
**	O
5	O
-	O
5	O
**	O
]	O
s	O
/	O
p	O
5.5	O
months	O
of	O
coumadin	I-Drug
*	O
Herpes	O
simplex	O
*	O
HPV	O
*	O
Peripheral	B-Ade
neuropathy	I-Ade
(	O
feet	O
)	O
secondary	O
to	O
Stavudine	I-Drug
*	O
Nephrolithiasis	O
*	O
Left	O
sided	O
kidney	O
stones	O
surgical	O
removal	O
in	O
the	O
early	O
[	O
**	O
2103	O
**	O
]	O
's	O
and	O
had	O
lithotrypsy	O
3	O
times	O
in	O
the	O
[	O
**	O
2103	O
**	O
]	O
's	O
.	O
*	O
Pancytopenia	O
*	O
Depression	O
*	O
Benign	O
prostatic	O
hypertrophy	O
*	O
Basal	O
cell	O
carcinoma	O
with	O
Moh	O
??????	O
s	O
surgery	O
*	O
Gonorrhea	O
*	O
Hypogonadism	O
Social	O
History	O
:	O
Patient	O
is	O
retired	O
restaurant	O
/	O
bar	O
manager	O
(	O
on	O
disability	O
since	O
[	O
**	O
2126	O
**	O
]	O
due	O
to	O
neuropathy	O
)	O
.	O
Homosexual	O
male	O
.	O
He	O
is	O
the	O
primary	O
caregiver	O
for	O
his	O
mother	O
who	O
has	O
dementia	O
.	O
Patient	O
is	O
not	O
married	O
.	O
Never	O
smoked	O
and	O
no	O
current	O
alcohol	O
.	O
No	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
with	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
499	O
**	O
]	O
cancer	O
.	O
Father	O
had	O
brain	O
tumor	O
.	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
General	O
Appearance	O
:	O
No	O
acute	O
distress	O
Eyes	O
/	O
Conjunctiva	O
:	O
PERRL	O
,	O
Pupils	O
dilated	O
Head	O
,	O
Ears	O
,	O
Nose	O
,	O
Throat	O
:	O
Normocephalic	O
,	O
Poor	O
dentition	O
Cardiovascular	O
:	O
(	O
S1	O
:	O
Normal	O
)	O
,	O
(	O
S2	O
:	O
Normal	O
)	O
,	O
(	O
Murmur	O
:	O
Systolic	O
)	O
Peripheral	O
Vascular	O
:	O
(	O
Right	O
radial	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Left	O
radial	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Right	O
DP	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Left	O
DP	O
pulse	O
:	O
Present	O
)	O
Respiratory	O
/	O
Chest	O
:	O
(	O
Breath	O
Sounds	O
:	O
Clear	O
:	O
,	O
Crackles	O
:	O
at	O
bilateral	O
bases	O
)	O
Abdominal	O
:	O
Soft	O
,	O
Non-tender	O
,	O
Bowel	O
sounds	O
present	O
Extremities	O
:	O
Right	O
lower	O
extremity	O
edema	O
:	O
3	O
+	O
,	O
Left	O
lower	O
extremity	O
edema	O
:	O
3	O
+	O
Musculoskeletal	O
:	O
Unable	O
to	O
stand	O
Skin	O
:	O
Not	O
assessed	O
Neurologic	O
:	O
Attentive	O
,	O
Responds	O
to	O
:	O
Not	O
assessed	O
,	O
Movement	O
:	O
Not	O
assessed	O
,	O
Tone	O
:	O
Not	O
assessed	O
,	O
hemiplegia	O
and	O
aphasia	O
On	O
Discharge	O
:	O
Vitals	O
:	O
97.9	O
120/69	O
63	O
18	O
98	O
%	O
RA	O
GENERAL	O
-	O
Sitting	O
up	O
in	O
bed	O
,	O
cachectic	O
HEENT	O
-	O
sclerae	O
anicteric	O
,	O
MMM	O
NECK	O
-	O
no	O
JVD	O
LUNGS	O
-	O
CTA	O
bilat	O
,	O
no	O
rales	O
/	O
rhonchi	O
/	O
wheezes	O
,	O
HEART	O
-	O
RRR	O
,	O
no	O
MRG	O
ABDOMEN	O
-	O
BS	O
+	O
,	O
moderately	O
distended	O
,	O
increased	O
from	O
prior	O
exam	O
,	O
nontender	O
GU	O
-	O
Foley	O
in	O
place	O
,	O
no	O
CVA	O
tenderness	O
EXTREMITIES	O
-	O
WWP	O
,	O
2	O
+	O
DP	O
b	O
/	O
l	O
SKIN	O
-	O
no	O
rashes	O
/	O
lesions	O
,	O
no	O
bruising	O
NEURO	O
-	O
AOx3	O
,	O
awake	O
,	O
no	O
asterixis	O
Pertinent	O
Results	O
:	O
[	O
**	O
2134-5-28	O
**	O
]	O
11:34	O
PM	O
URINE	O
COLOR	O
-	O
Straw	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.015	O
[	O
**	O
2134-5-28	O
**	O
]	O
11:34	O
PM	O
URINE	O
BLOOD	O
-	O
SM	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
75	O
GLUCOSE	O
-	O
100	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
MOD	O
[	O
**	O
2134-5-28	O
**	O
]	O
11:34	O
PM	O
URINE	O
RBC	O
-	O
0	O
WBC	O
-21-50	O
*	O
BACTERIA	O
-	O
OCC	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
0	O
[	O
**	O
2134-5-27	O
**	O
]	O
11:30	O
AM	O
FREE	O
TEST	O
-	O
2.3	O
*	O
[	O
**	O
2134-5-27	O
**	O
]	O
11:30	O
AM	O
PT	O
-	O
14.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
.	O
LIVER	O
and	O
Gallbladder	O
U	O
/	O
S	O
[	O
**	O
2134-6-2	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Small	O
amount	O
of	O
ascitic	O
fluid	O
in	O
the	O
lower	O
quadrants	O
.	O
2	O
.	O
Splenomegaly	O
.	O
3	O
.	O
Distended	O
bladder	O
with	O
echogenic	O
foci	O
most	O
likely	O
representing	O
patient	O
's	O
known	O
bladder	O
stones	O
.	O
.	O
Portal	O
Abdominal	O
Xray	O
-	O
[	O
**	O
2134-6-2	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Fragmentation	O
of	O
left	O
renal	O
stones	O
and	O
clearance	O
of	O
bladder	O
stones	O
.	O
2	O
.	O
Left	O
ureteral	O
stent	O
placement	O
.	O
Brief	O
Hospital	O
Course	O
:	O
64yo	O
M	O
with	O
HIV	O
,	O
HBV	O
,	O
HCV	O
,	O
HCC	O
,	O
cirrhosis	O
status	O
post	O
orthotopic	O
liver	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
(	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
)	O
,	O
a	O
history	O
of	O
DVT	O
/	O
PE	O
and	O
nephrolithiasis	O
,	O
who	O
was	O
admitted	O
on	O
[	O
**	O
5	O
-	O
28	O
**	O
]	O
for	O
antibiotic	I-Drug
treatment	O
of	O
a	O
VRE	B-Reason
UTI	I-Reason
and	O
bridge	O
from	O
coumadin	I-Drug
to	O
heparin	I-Drug
for	O
lithotripsy	B-Reason
procedure	I-Reason
[	O
**	O
6	O
-	O
1	O
**	O
]	O
.	O
His	O
post-operative	O
course	O
was	O
complicated	O
by	O
fevers	O
,	O
confusion	O
,	O
unstable	O
vitals	O
consistent	O
with	O
urosepsis	O
/	O
shock	O
,	O
requiring	O
transfer	O
to	O
the	O
MICU	O
and	O
broad	O
antibiotic	I-Drug
therapy	O
,	O
now	O
transferred	O
back	O
to	O
the	O
[	O
**	O
Doctor	O
Last	O
Name	O
3271	O
**	O
]	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
679	O
**	O
]	O
service	O
,	O
stable	O
,	O
and	O
ready	O
for	O
discharge	O
.	O
.	O
#	O
UTI	O
/	O
Urosepsis	O
/	O
Urolithiasis	O
:	O
On	O
admission	O
,	O
an	O
oupatient	O
culture	O
was	O
reported	O
as	O
growing	O
Vancomycin	I-Drug
Resistant	O
Enterococcus	O
.	O
Treatment	O
of	O
a	O
VRE	B-Reason
UTI	I-Reason
infection	I-Reason
with	O
daptomycin	I-Drug
was	O
initated	O
on	O
[	O
**	O
5	O
-	O
28	O
**	O
]	O
,	O
with	O
a	O
documented	O
negative	O
urine	O
culture	O
on	O
[	O
**	O
5	O
-	O
31	O
**	O
]	O
.	O
On	O
[	O
**	O
6	O
-	O
1	O
**	O
]	O
patient	O
underwent	O
lithotripsy	O
and	O
placement	O
of	O
a	O
stent	O
.	O
During	O
the	O
middle	O
of	O
the	O
night	O
,	O
he	O
was	O
noted	O
to	O
have	O
altered	O
mental	O
status	O
.	O
He	O
had	O
taken	O
off	O
his	O
heparin	I-Drug
gtt	O
and	O
was	O
walking	O
around	O
saying	O
that	O
he	O
was	O
ready	O
to	O
go	O
home	O
.	O
They	O
continued	O
to	O
hold	O
his	O
heparin	I-Drug
gtt	O
at	O
that	O
time	O
.	O
He	O
was	O
placed	O
back	O
in	O
bed	O
,	O
and	O
noted	O
to	O
be	O
febrile	O
with	O
a	O
Tm	O
of	O
102.7	O
at	O
0030	O
this	O
morning	O
.	O
His	O
BP	O
was	O
80	O
/	O
d	O
at	O
the	O
time	O
,	O
HR	O
in	O
the	O
50s	O
.	O
He	O
received	O
1L	O
bolus	O
without	O
effect	O
in	O
his	O
BP	O
.	O
At	O
530	O
this	O
morning	O
,	O
his	O
BP	O
was	O
104	O
/	O
d	O
and	O
HR	O
88	O
.	O
After	O
the	O
1L	O
of	O
IVFs	I-Drug
,	O
his	O
O2	O
sat	O
was	O
noted	O
to	O
be	O
87	O
%	O
on	O
RA	O
.	O
He	O
was	O
placed	O
on	O
2L	O
NC	I-Drug
and	O
improved	O
.	O
He	O
received	O
a	O
second	O
L	O
bolus	O
and	O
at	O
8	O
am	O
this	O
morning	O
,	O
was	O
rigoring	O
again	O
with	O
T	O
102.6	O
,	O
BP	O
110/50	O
,	O
P	O
100	O
,	O
R	O
36	O
and	O
97	O
%	O
on	O
2L	O
.	O
The	O
MICU	O
was	O
called	O
for	O
transfer	O
.	O
A	O
urine	O
culture	O
drawn	O
at	O
this	O
time	O
grew	O
out	O
polymicrobial	I-Reason
(	O
klebsiella	O
,	O
enterobacter	O
,	O
nonpsuedomonas	O
nonfermenter	O
)	O
and	O
the	O
patient	O
was	O
appropriately	O
started	O
on	O
meropenem	I-Drug
on	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
.	O
Urology	O
confirmed	O
placement	O
and	O
draining	O
of	O
stent	O
on	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
.	O
A	O
larger	O
foley	O
was	O
placed	O
to	O
aid	O
in	O
the	O
drainage	O
of	O
the	O
stones	O
.	O
On	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
the	O
patient	O
had	O
a	O
PICC	O
line	O
placed	O
for	O
outpatient	O
antibiotic	I-Drug
administration	O
.	O
On	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
,	O
per	O
ID	O
recommendations	O
relating	O
to	O
culture	O
sensitivies	O
,	O
the	O
meropenem	I-Drug
was	O
switched	O
to	O
Cipro	I-Drug
.	O
The	O
patient	O
completed	O
his	O
course	O
of	O
daptomycin	I-Drug
on	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
.	O
The	O
patient	O
will	O
continue	O
PO	O
Cipro	I-Drug
until	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
.	O
He	O
will	O
follow	O
up	O
with	O
the	O
[	O
**	O
Hospital	O
159	O
**	O
]	O
clinic	O
as	O
an	O
outpatient	O
.	O
He	O
will	O
follow	O
up	O
with	O
ID	O
as	O
an	O
outpatient	O
.	O
.	O
Hospital	O
Acquired	O
Pneumonia	O
:	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
MICU	O
with	O
hypoxia	O
thought	O
to	O
be	O
secondary	O
to	O
an	O
aspiration	O
.	O
Other	O
etiologies	O
considered	O
were	O
hypoxia	I-Ade
secondary	O
to	O
volume	O
overload	O
from	O
IV	O
fluid	I-Drug
boluses	O
(	O
last	O
echo	O
in	O
[	O
**	O
2132	O
**	O
]	O
was	O
normal	O
)	O
and	O
pneumonia	O
.	O
Antibiotic	I-Drug
coverage	O
for	O
hospital	B-Reason
acquired	I-Reason
pneumonia	I-Reason
with	O
meropenem	I-Drug
was	O
started	O
on	O
[	O
**	O
6	O
-	O
2	O
**	O
]	O
and	O
vancomycin	I-Drug
was	O
added	O
on	O
[	O
**	O
6	O
-	O
3	O
**	O
]	O
to	O
provide	O
better	O
coverage	O
for	O
MRSA	I-Reason
.	O
CXR	O
on	O
[	O
**	O
6	O
-	O
3	O
**	O
]	O
showed	O
a	O
stable	O
left	O
lower	O
lobe	O
consolidation	O
with	O
new	O
opacity	O
and	O
air	O
bronchograms	O
in	O
the	O
right	O
middle	O
lobe	O
that	O
could	O
possible	O
be	O
atelectasis	O
.	O
Respiratory	O
aspirate	O
cultures	O
were	O
without	O
growth	O
.	O
On	O
transfer	O
to	O
the	O
floors	O
,	O
the	O
patient	O
was	O
continued	O
on	O
meropenem	I-Drug
for	O
possible	O
hospital	I-Reason
acquired	O
pneumonia	O
.	O
Vancomycin	I-Drug
was	O
stopped	O
as	O
per	O
ID	O
's	O
recommendations	O
.	O
Antibiotics	I-Drug
were	O
continued	O
as	O
discussed	O
above	O
.	O
.	O
History	O
of	O
DVT	O
/	O
PE	O
:	O
The	O
patient	O
had	O
a	O
PE	I-Reason
in	O
[	O
**	O
2132	O
**	O
]	O
and	O
was	O
placed	O
on	O
heparin	I-Drug
.	O
On	O
arrival	O
to	O
the	O
hospital	O
,	O
a	O
heparin	I-Drug
bridge	O
was	O
initiated	O
to	O
prepare	O
for	O
the	O
lithotripsy	B-Reason
procedure	I-Reason
.	O
On	O
[	O
**	O
6	O
-	O
1	O
**	O
]	O
the	O
heparin	I-Drug
was	O
held	O
,	O
the	O
patient	O
underwent	O
the	O
lithotripsy	O
,	O
and	O
the	O
heparin	I-Drug
gtt	O
was	O
restarted	O
after	O
the	O
procedure	O
.	O
The	O
heparin	I-Drug
was	O
held	O
during	O
the	O
events	O
leading	O
up	O
the	O
[	O
**	O
Hospital	O
228	O
**	O
]	O
transfer	O
to	O
the	O
MICU	O
,	O
resulting	O
in	O
subtherapeutic	O
PTTs	O
.	O
He	O
was	O
restarted	O
on	O
heparin	I-Drug
in	O
the	O
MICU	O
and	O
bridged	O
to	O
coumadin	I-Drug
.	O
On	O
transfer	O
to	O
the	O
floors	O
,	O
his	O
INR	O
was	O
supratherapeutic	O
,	O
requiring	O
adjustment	O
of	O
the	O
coumadin	I-Drug
to	O
5	O
mg	O
.	O
When	O
the	O
patient	O
was	O
transitioned	O
to	O
cipro	I-Drug
,	O
his	O
coumadin	I-Drug
was	O
empirically	O
lowered	O
to	O
3	O
mg	O
.	O
His	O
INR	O
trended	O
downwards	O
and	O
his	O
coumadin	I-Drug
was	O
increased	O
to	O
5	O
mg	O
.	O
He	O
will	O
have	O
his	O
INR	O
checked	O
with	O
this	O
labs	O
on	O
Monday	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
and	O
reviewed	O
at	O
his	O
clinic	O
appointment	O
on	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
.	O
.	O
S	O
/	O
P	O
OLT	O
:	O
The	O
patient	O
has	O
a	O
hx	O
of	O
hepatitis	O
B	O
,	O
HCC	O
,	O
and	O
is	O
s	O
/	O
p	O
OLT	O
one	O
year	O
prior	O
to	O
presentation	O
.	O
On	O
admission	O
he	O
had	O
stable	O
LFTs	O
and	O
no	O
signs	O
of	O
encephalopathy	O
on	O
tacrolimus	I-Drug
,	O
cellcept	I-Drug
,	O
and	O
bactrim	I-Drug
prophyllaxis	O
.	O
Following	O
his	O
lithotripsy	O
,	O
the	O
patient	O
developed	O
with	O
abdominal	O
distension	O
concerning	O
for	O
ascites	O
,	O
confirmed	O
by	O
ultrasound	O
,	O
along	O
with	O
positive	O
asterixis	O
.	O
In	O
combination	O
with	O
his	O
altered	O
mental	O
status	O
,	O
this	O
was	O
concerning	O
for	O
hepatic	O
encephalopathy	O
.	O
On	O
[	O
**	O
6	O
-	O
2	O
**	O
]	O
the	O
patient	O
was	O
started	O
on	O
lactulose	I-Drug
for	O
treatment	O
of	O
hepatic	B-Reason
encephalopathy	I-Reason
,	O
then	O
transitioned	O
to	O
rifaxamin	I-Drug
on	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
.	O
The	O
patient	O
was	O
continued	O
on	O
his	O
tacrolimus	I-Drug
and	O
cellcept	I-Drug
.	O
He	O
will	O
follow	O
up	O
in	O
[	O
**	O
Month	O
/	O
Day	O
(	O
4	O
)	O
**	O
]	O
clinic	O
,	O
where	O
he	O
will	O
be	O
assessed	O
for	O
future	O
liver	O
biopsy	O
.	O
He	O
will	O
require	O
an	O
INPATIENT	O
stay	O
for	O
this	O
biopsy	O
so	O
that	O
he	O
can	O
bridged	O
from	O
coumadin	I-Drug
to	O
heparin	I-Drug
prior	O
to	O
the	O
procedure	O
.	O
.	O
Pancytopenia	O
:	O
Patient	O
has	O
a	O
longstanding	O
history	O
of	O
pancytopenia	O
.	O
WBC	O
was	O
1.9	O
on	O
admission	O
and	O
ranged	O
from	O
1.5	O
-	O
3.1	O
over	O
his	O
hospital	O
course	O
.	O
HCT	O
was	O
in	O
the	O
low	O
20s	O
and	O
required	O
1	O
transfusion	O
of	O
pRBCs	I-Drug
.	O
This	O
is	O
of	O
uncertain	O
origin	O
,	O
likely	O
multifactorial	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
infection	O
,	O
medication	O
(	O
HIV	O
,	O
antibiotics	I-Drug
,	O
etc	O
)	O
.	O
In	O
setting	O
of	O
increasing	O
splenomegaly	O
,	O
we	O
have	O
considered	O
a	O
hem	O
/	O
onc	O
process	O
.	O
As	O
per	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2148	O
**	O
]	O
,	O
this	O
is	O
already	O
being	O
worked	O
up	O
in	O
the	O
outpatient	O
setting	O
.	O
.	O
HIV	O
:	O
Stable	O
,	O
CD4	O
65	O
,	O
VL	O
120	O
,	O
immunosuppressed	O
on	O
anti-rejection	O
medications	O
.	O
No	O
modifications	O
were	O
made	O
to	O
his	O
HAART	O
regimen	O
(	O
RiTONAvir	I-Drug
,	O
Raltegravir	I-Drug
)	O
and	O
bactrim	I-Drug
ppx	O
.	O
Lyrica	I-Drug
(	O
for	O
HIV	I-Reason
neuropathy	O
)	O
was	O
held	O
while	O
in	O
MICU	O
,	O
but	O
restarted	O
on	O
the	O
floors	O
.	O
.	O
DM	I-Reason
:	O
Stable	O
,	O
continue	O
insulin	I-Drug
sliding	O
scale	O
.	O
.	O
Depression	I-Reason
:	O
Continued	O
mirtazapine	I-Drug
and	O
lexapro	I-Drug
.	O
.	O
BPH	I-Reason
:	O
Continue	O
terazosin	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
DARUNAVIR	I-Drug
[	O
PREZISTA	I-Drug
]	O
600	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
EMTRICITABINE	B-Drug
-	I-Drug
TENOFOVIR	I-Drug
[	O
TRUVADA	I-Drug
]	O
200	O
mg	O
-	O
300	O
mg	O
QOD	O
ESCITALOPRAM	I-Drug
[	O
LEXAPRO	I-Drug
]	O
20	O
mg	O
daily	O
FENOFIBRATE	B-Drug
NANOCRYSTALLIZED	I-Drug
[	O
TRICOR	I-Drug
]	O
48	O
mg	O
Tablet	O
daily	O
HEPATITIS	B-Drug
B	I-Drug
IMMUNE	I-Drug
GLOBULIN	I-Drug
[	O
NABI	O
-	O
HB	O
]	O
10,000	O
units	O
q	O
month	O
INSULIN	B-Drug
GLARGINE	I-Drug
[	O
LANTUS	I-Drug
]	O
20	O
u	O
qAM	O
INSULIN	B-Drug
LISPRO	I-Drug
[	O
HUMALOG	I-Drug
]	O
sliding	O
scale	O
LEVOFLOXACIN	I-Drug
[	O
LEVAQUIN	I-Drug
]	O
250	O
mg	O
x7	O
day	O
?	O
MIRTAZAPINE	I-Drug
-	O
15	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
at	O
bedtime	O
MYCOPHENOLATE	B-Drug
MOFETIL	I-Drug
250	O
mg	O
Capsule	O
[	O
**	O
Hospital1	O
**	O
]	O
PREGABALIN	B-Drug
[	I-Drug
LYRICA	I-Drug
]	O
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
RALTEGRAVIR	I-Drug
[	O
ISENTRESS	I-Drug
]	O
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
RITONAVIR	I-Drug
[	O
NORVIR	I-Drug
]	O
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
SULFAMETHOXAZOLE	B-Drug
-	I-Drug
TRIMETHOPRIM	I-Drug
800	O
mg	O
-	O
160	O
mg	O
qMWF	O
TACROLIMUS	I-Drug
0.5	O
mg	O
qMonday	O
TERAZOSIN	I-Drug
2	O
mg	O
qHS	O
WARFARIN	I-Drug
6	O
mg	O
daily	O
CALCIUM	B-Drug
CARBONATE	I-Drug
-	I-Drug
VIT	I-Drug
D3	I-Drug
-	I-Drug
MIN	I-Drug
600	O
mg	O
-	O
400	O
unit	O
[	O
**	O
Hospital1	O
**	O
]	O
FERROUS	B-Drug
SULFATE	I-Drug
325	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
Darunavir	I-Drug
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Ritonavir	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Tacrolimus	I-Drug
0.5	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
1X	O
/	O
WEEK	O
(	O
MO	O
)	O
.	O
4	O
.	O
Sulfamethoxazole	B-Drug
-	I-Drug
Trimethoprim	I-Drug
800	O
-	O
160	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
3X	O
/	O
WEEK	O
(	O
MO	O
,	O
WE	O
,	O
FR	O
)	O
.	O
5	O
.	O
Mirtazapine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
6	O
.	O
Raltegravir	I-Drug
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Mycophenolate	B-Drug
Mofetil	I-Drug
250	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Ciprofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
3	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Tricor	I-Drug
48	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
Lantus	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
20	O
U	O
Subcutaneous	O
qAM	O
.	O
11	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Sliding	O
Scale	O
Subcutaneous	O
qmeal	O
.	O
12	O
.	O
Outpatient	O
Lab	O
Work	O
PLEASE	O
DRAW	O
LABS	O
:	O
COMPLETE	O
BLOOD	O
COUNT	O
AND	O
CHEMISTRY	O
PANEL	O
(	O
ELECTROLYTES	O
,	O
BUN	O
/	O
CREATININE	O
)	O
AND	O
FAX	O
RESULTS	O
TO	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
,	O
MD	O
-	O
INFECTIOUS	O
DISEASES	O
FAX	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1419	O
**	O
]	O
13	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
14	O
.	O
Truvada	I-Drug
200	O
-	O
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QOD	O
.	O
15	O
.	O
Nabi	B-Drug
-	I-Drug
HB	I-Drug
>	O
1,560	O
unit	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
[	O
**	O
Numeric	O
Identifier	O
961	O
**	O
]	O
Intramuscular	O
once	O
a	O
month	O
.	O
16	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
-	I-Drug
Vitamin	I-Drug
D3	I-Drug
600	O
mg	O
(	O
1,500	O
mg	O
)	O
-400	O
unit	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
17	O
.	O
Lyrica	I-Drug
150	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
18	O
.	O
Lexapro	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
19	O
.	O
Terazosin	I-Drug
2	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
at	O
bedtime	O
.	O
20	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
Iron	O
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
:	O
urosepsis	O
,	O
VRE	O
urinary	O
tract	O
infection	O
,	O
bladder	O
stones	O
SECONDARY	O
:	O
HIV	O
,	O
HBV	O
,	O
HCV	O
s	O
/	O
p	O
OLT	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
It	O
was	O
a	O
pleasure	O
to	O
participate	O
in	O
your	O
care	O
Mr.	O
[	O
**	O
Known	O
lastname	O
26080	O
**	O
]	O
.	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
anticoagulation	I-Reason
with	O
heparin	I-Drug
prior	O
to	O
your	O
lithotripsy	B-Reason
procedure	I-Reason
.	O
Following	O
your	O
procedure	O
,	O
you	O
had	O
an	O
infection	O
that	O
caused	O
you	O
to	O
have	O
low	O
blood	O
pressure	O
.	O
You	O
have	O
now	O
completed	O
intravenous	O
antibiotic	I-Drug
therapy	O
for	O
that	O
infection	I-Reason
and	O
have	O
three	O
days	O
remaining	O
of	O
an	O
oral	O
antibiotic	I-Drug
(	O
see	O
below	O
)	O
.	O
Please	O
see	O
below	O
for	O
your	O
follow	O
-	O
up	O
appointments	O
.	O
Your	O
medications	O
have	O
CHANGED	O
as	O
follows	O
:	O
1	O
.	O
We	O
ADDED	O
Ciprofloxacin	I-Drug
500	O
mg	O
daily	O
to	O
treat	O
the	O
serious	O
infection	I-Reason
you	O
had	O
during	O
your	O
hospital	O
stay	O
.	O
The	O
course	O
of	O
this	O
medications	O
will	O
be	O
complete	O
on	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
.	O
2	O
.	O
We	O
DECREASED	O
your	O
Coumadin	I-Drug
dose	O
to	O
5	O
mg	O
daily	O
.	O
Please	O
continue	O
to	O
take	O
your	O
other	O
medications	O
as	O
you	O
have	O
been	O
,	O
and	O
keep	O
your	O
follow	O
up	O
appointments	O
.	O
BECAUSE	O
OF	O
YOUR	O
CONDITION	O
CALLED	O
HEPATIC	O
ENCEPHALOPATHY	O
WHICH	O
CAN	O
OCCUR	O
AT	O
ANY	O
TIME	O
,	O
YOU	O
ABSOLUTELY	O
[	O
**	O
Street	O
Address	O
(	O
1	O
)	O
56354	O
**	O
]	O
!!!	O
DRIVING	O
CAN	O
CAUSE	O
SERIOUS	O
INJURY	O
OR	O
DEATH	O
TO	O
YOU	O
AND	O
OTHERS	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2088	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2134-6-14	O
**	O
]	O
3:00	O
PM	O
2	O
.	O
Please	O
follow	O
-	O
up	O
in	O
Infectious	O
Disease	O
clinic	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
724	O
**	O
]	O
.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
28019	O
**	O
]	O
Call	O
to	O
schedule	O
an	O
appointment	O
.	O
You	O
will	O
need	O
labs	O
drawn	O
next	O
week	O
and	O
faxed	O
to	O
the	O
ID	O
doctors	O
(	O
see	O
below	O
)	O
.	O
3	O
.	O
Please	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
27027	O
**	O
]	O
in	O
the	O
[	O
**	O
Hospital	O
159	O
**	O
]	O
clinic	O
within	O
1	O
month	O
.	O
The	O
number	O
is	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
164	O
**	O
]	O
4	O
.	O
Please	O
follow	O
-	O
up	O
in	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
hepatology	O
(	O
liver	O
)	O
clinic	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
on	O
Weds	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
at	O
2	O
PM	O
as	O
you	O
may	O
need	O
to	O
discuss	O
inpatient	O
liver	O
biopsy	O
.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
1379	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2138-9-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2138-10-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2068-3-23	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Iodine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
6169	O
**	O
]	O
Chief	O
Complaint	O
:	O
Bright	O
Red	O
Blood	O
per	O
rectum	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
70	O
yo	O
female	O
with	O
myelodysplastic	O
syndrome	O
,	O
chronic	B-Ade
renal	I-Ade
insufficiency	O
secondary	O
to	O
cyclosporine	I-Drug
,	O
extensive	B-Reason
GI	I-Reason
bleeding	I-Reason
over	O
the	O
past	O
several	O
years	O
,	O
presenting	O
with	O
multiple	O
episodes	O
of	O
BRBPR	O
starting	O
on	O
the	O
morning	O
of	O
admission	O
.	O
Pt	O
was	O
initially	O
admitted	O
to	O
the	O
OMED	O
service	O
with	O
a	O
hct	O
drop	O
of	O
4	O
points	O
and	O
was	O
transfused	O
2U	O
PRBC	I-Drug
and	O
3U	O
pf	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
for	O
a	O
platelet	B-Reason
count	I-Reason
of	I-Reason
14	I-Reason
.	O
She	O
was	O
also	O
given	O
DDAVP	I-Drug
for	O
presumed	O
dysfunctional	B-Reason
platelets	I-Reason
.	O
She	O
was	O
hemodynamically	O
stable	O
.	O
Last	O
night	O
she	O
was	O
also	O
found	O
to	O
be	O
febrile	I-Reason
and	O
was	O
started	O
on	O
Cefepime	I-Drug
and	O
Flagyl	I-Drug
and	O
then	O
changed	O
over	O
to	O
Zosyn	I-Drug
as	O
she	O
complained	O
of	O
severe	B-Ade
nausea	I-Ade
on	O
Flagyl	I-Drug
.	O
This	O
am	O
the	O
patient	O
developed	O
worsening	O
BRBPR	O
and	O
again	O
had	O
one	O
bloody	B-Reason
stool	I-Reason
with	O
associated	O
abdominal	O
pain	O
as	O
well	O
as	O
hypotension	O
with	O
a	O
systolic	O
BP	O
of	O
90	O
and	O
tachycardia	O
.	O
She	O
was	O
transfused	O
another	O
3U	O
PRBC	I-Drug
and	O
her	O
BP	O
and	O
HR	O
normalized	O
again	O
.	O
The	O
patient	O
then	O
went	O
to	O
nuclear	O
medicine	O
and	O
subsequently	O
was	O
transferred	O
to	O
the	O
ICU	O
for	O
closer	O
monitoring	O
.	O
.	O
ROS	O
:	O
negative	O
for	O
lightheadedness	O
,	O
chest	O
pain	O
,	O
palpitations	O
,	O
SOB	O
,	O
dysuria	O
or	O
altered	O
mental	O
status	O
.	O
She	O
reports	O
fatigue	O
,	O
mild	O
cramping	O
abdominal	O
pain	O
,	O
and	O
increased	O
number	O
of	O
echymoses	O
across	O
her	O
abdomen	O
,	O
arms	O
,	O
and	O
legs	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
)	O
Aplastic	O
anemia	O
/	O
Hypocellular	O
myelodysplastic	O
syndrome	O
with	O
trisomy	O
8	O
and	O
21	O
.	O
s	O
/	O
p	O
high	O
dose	O
prednisone	I-Drug
and	O
gamma	B-Drug
globulin	I-Drug
,	O
s	O
/	O
p	O
Anti-thymocyte	O
globulin	O
therapy	O
[	O
**	O
2126	O
**	O
]	O
,	O
on	O
cyclosporine	I-Drug
since	O
with	O
renal	B-Ade
insufficiency	I-Ade
;	O
started	O
IVIG	I-Drug
q3	O
weeks	O
[	O
**	O
2138-7-10	O
**	O
]	O
2	O
)	O
s	O
/	O
p	O
terminal	O
ileum	O
resection	O
[	O
**	O
3	O
-	O
26	O
**	O
]	O
for	O
multiple	O
bleeding	O
ulcers	O
3	O
)	O
h	O
/	O
o	O
candidemia	O
with	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
parapsilosis	O
4	O
)	O
Renal	O
insufficiency	O
(	O
recent	O
baseline	O
Cr	O
1.2	O
-	O
1.6	O
)	O
5	O
)	O
Hypertension	O
6	O
)	O
h	O
/	O
o	O
hypercholesterolemia	O
Past	O
Surgical	O
History	O
:	O
-	O
TAH	O
/	O
BSO	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
fibroids	O
-	O
Appendectomy	O
-	O
Venous	O
stripping	O
LLE	O
Social	O
History	O
:	O
Married	O
,	O
5	O
children	O
.	O
Does	O
not	O
smoke	O
,	O
drink	O
alcohol	O
or	O
coffee	O
Family	O
History	O
:	O
Mother	O
died	O
of	O
scleroderma	O
,	O
father	O
died	O
of	O
CAD	O
Physical	O
Exam	O
:	O
Vital	O
signs	O
:	O
T	O
:	O
100.4	O
,	O
HR	O
80	O
,	O
RR	O
20	O
,	O
Sats	O
94	O
%	O
ra	O
General	O
:	O
Awake	O
,	O
alert	O
,	O
NAD	O
.	O
HEENT	O
:	O
NC	O
/	O
AT	O
,	O
PERRL	O
,	O
EOMI	O
,	O
no	O
scleral	O
icterus	O
noted	O
,	O
MMM	O
,	O
white	O
patches	O
on	O
oropharynx	O
consistent	O
with	O
thrush	O
.	O
Neck	O
:	O
supple	O
,	O
no	O
JVD	O
no	O
lymphadenopathy	O
Pulmonary	O
:	O
Lungs	O
CTA	O
bilaterally	O
,	O
no	O
crackles	O
or	O
wheezes	O
.	O
equal	O
aeration	O
bilaterally	O
.	O
Cardiac	O
:	O
RRR	O
,	O
nl	O
.	O
S1S2	O
,	O
no	O
M	O
/	O
R	O
/	O
G	O
noted	O
Abdomen	O
:	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
normoactive	O
bowel	O
sounds	O
,	O
no	O
masses	O
or	O
organomegaly	O
noted	O
.	O
purpura	O
across	O
her	O
abdomen	O
Extremities	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
bilaterally	O
,	O
2	O
+	O
radial	O
,	O
DP	O
and	O
PT	O
pulses	O
b	O
/	O
l.	O
Lymphatics	O
:	O
No	O
cervical	O
,	O
supraclavicular	O
,	O
axillary	O
or	O
inguinal	O
lymphadenopathy	O
noted	O
.	O
Skin	O
:	O
purpura	O
and	O
echymoses	O
across	O
arms	O
,	O
legs	O
and	O
abdomen	O
.	O
Neurologic	O
:	O
-	O
mental	O
status	O
:	O
Alert	O
,	O
oriented	O
x	O
3	O
.	O
Able	O
to	O
relate	O
history	O
without	O
difficulty	O
.	O
-	O
cranial	O
nerves	O
:	O
II	O
-	O
XII	O
intact	O
-	O
motor	O
:	O
normal	O
bulk	O
,	O
strength	O
and	O
tone	O
throughout	O
.	O
No	O
abnormal	O
movements	O
noted	O
.	O
-	O
sensory	O
:	O
No	O
deficits	O
to	O
light	O
touch	O
throughout	O
.	O
-	O
cerebellar	O
:	O
No	O
nystagmus	O
,	O
dysarthria	O
,	O
intention	O
or	O
action	O
tremor	O
-	O
DTRs	O
:	O
Plantar	O
response	O
was	O
flexor	O
bilaterally	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2138-9-17	O
**	O
]	O
09:31	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
SlHazy	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.018	O
[	O
**	O
2138-9-17	O
**	O
]	O
09:31	O
PM	O
URINE	O
BLOOD	O
-	O
SM	O
NITRITE	O
-	O
POS	O
PROTEIN	O
-	O
TR	O
GLUCOSE	O
-	O
TR	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
TR	O
[	O
**	O
2138-9-17	O
**	O
]	O
09:31	O
PM	O
URINE	O
RBC	O
-	O
2	O
WBC	O
-	O
6	O
*	O
BACTERIA	O
-	O
MOD	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
3	O
[	O
**	O
2138-9-17	O
**	O
]	O
07:31	O
PM	O
WBC	O
-	O
2.1	O
*	O
RBC	O
-	O
2.68	O
*	O
HGB	O
-	O
9.5	O
*	O
HCT	O
-	O
26.9	O
*	O
MCV	O
-	O
101	O
*	O
MCH	O
-	O
35.3	O
*	O
MCHC	O
-	O
35.1	O
*	O
RDW	O
-	O
21.0	O
*	O
[	O
**	O
2138-9-17	O
**	O
]	O
07:31	O
PM	O
PLT	O
COUNT	O
-	O
19	O
*	O
[	O
**	O
2138-9-17	O
**	O
]	O
02:05	O
PM	O
PLT	O
COUNT	O
-	O
36	O
*	O
#	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
GLUCOSE	O
-	O
129	O
*	O
UREA	O
N	O
-	O
42	O
*	O
CREAT	O
-	O
1.7	O
*	O
SODIUM	O
-	O
131	O
*	O
POTASSIUM	O
-	O
4.2	O
CHLORIDE	O
-	O
101	O
TOTAL	O
CO2	O
-	O
21	O
*	O
ANION	O
GAP	O
-	O
13	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
81	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
39	O
LD	O
(	O
LDH	O
)	O
-	O
265	O
*	O
ALK	O
PHOS	O
-	O
38	O
*	O
TOT	O
BILI	O
-	O
1.0	O
DIR	O
BILI	O
-	O
0.5	O
*	O
INDIR	O
BIL	O
-	O
0.5	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
ALBUMIN	O
-	O
3.1	O
*	O
CALCIUM	O
-	O
8.0	O
*	O
PHOSPHATE	O
-	O
2.2	O
*	O
MAGNESIUM	O
-	O
1.5	O
*	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
WBC	O
-	O
2.5	O
*	O
#	O
RBC	O
-	O
2.35	O
*	O
HGB	O
-	O
8.4	O
*	O
HCT	O
-	O
24.8	O
*	O
MCV	O
-	O
105	O
*	O
MCH	O
-	O
35.7	O
*	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
20.3	O
*	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
NEUTS	O
-	O
93	O
*	O
BANDS	O
-	O
0	O
LYMPHS	O
-	O
4	O
*	O
MONOS	O
-	O
3	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
1	O
+	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
1	O
+	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
NORMAL	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
PLT	O
SMR	O
-	O
RARE	O
PLT	O
COUNT	O
-	O
14	O
*	O
#	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
PT	O
-	O
11.6	O
PTT	O
-	O
20.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2138-9-17	O
**	O
]	O
11:50	O
AM	O
GRAN	O
CT	O
-	O
2325	O
.	O
Imaging	O
:	O
CXR	O
:	O
Single	O
AP	O
view	O
of	O
the	O
chest	O
reveals	O
the	O
tip	O
of	O
a	O
port	O
line	O
in	O
the	O
SVC	O
in	O
satisfactory	O
position	O
.	O
The	O
mediastinum	O
is	O
midline	O
.	O
There	O
is	O
peribronchial	O
thickening	O
and	O
increased	O
markings	O
in	O
both	O
lung	O
bases	O
without	O
gross	O
consolidation	O
however	O
early	O
pneumonitis	O
in	O
the	O
left	O
lower	O
lobe	O
can	O
not	O
be	O
excluded	O
.	O
.	O
Nuclear	O
bleeding	O
scan	O
:	O
negative	O
per	O
oral	O
report	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
Reason	O
:	O
progression	O
of	O
opacities	O
,	O
likely	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
1064	O
**	O
]	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
70	O
year	O
old	O
woman	O
with	O
myelodysplastic	O
syndrome	O
,	O
with	O
fever	O
and	O
neutropenia	O
,	O
with	O
decreased	O
o2	O
sats	O
and	O
SOB	O
.	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
progression	O
of	O
opacities	O
,	O
likely	O
PCP	O
pneumonia	O
HISTORY	O
:	O
Fever	O
.	O
Shortness	O
of	O
breath	O
.	O
Single	O
portable	O
radiograph	O
of	O
the	O
chest	O
demonstrates	O
similar	O
cardiomediastinal	O
contour	O
to	O
that	O
seen	O
on	O
[	O
**	O
2138-10-15	O
**	O
]	O
.	O
Right	O
-	O
sided	O
Port	O
-	O
A-Cath	O
remains	O
unchanged	O
.	O
Increased	O
opacity	O
involving	O
the	O
bilateral	O
lungs	O
remains	O
similar	O
in	O
appearance	O
.	O
There	O
is	O
very	O
mild	O
blunting	O
of	O
the	O
bilateral	O
costophrenic	O
angles	O
.	O
Trachea	O
is	O
midline	O
.	O
IMPRESSION	O
:	O
No	O
interval	O
change	O
.	O
CT	O
CHEST	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2138-9-28	O
**	O
]	O
3:47	O
PM	O
CT	O
CHEST	O
W	O
/	O
O	O
CONTRAST	O
Reason	O
:	O
please	O
evaluate	O
for	O
infiltrates	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
70	O
year	O
old	O
woman	O
with	O
MDS	O
fevers	O
,	O
acute	O
hypoxia	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
please	O
evaluate	O
for	O
infiltrates	O
CONTRAINDICATIONS	O
for	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
STUDY	O
:	O
CT	O
of	O
the	O
chest	O
without	O
contrast	O
.	O
INDICATION	O
:	O
70	O
-	O
year	O
-	O
old	O
female	O
with	O
history	O
of	O
myelodysplastic	O
syndrome	O
presenting	O
with	O
fevers	O
,	O
acute	O
hypoxia	O
.	O
Assess	O
for	O
infiltrates	O
.	O
COMPARISONS	O
:	O
[	O
**	O
2138-9-24	O
**	O
]	O
.	O
TECHNIQUE	O
:	O
MDCT	O
axial	O
images	O
of	O
the	O
lungs	O
are	O
acquired	O
.	O
Coronal	O
and	O
sagittal	O
reformatted	O
images	O
were	O
then	O
obtained	O
.	O
CT	O
OF	O
THE	O
CHEST	O
WITHOUT	O
INTRAVENOUS	O
CONTRAST	O
:	O
There	O
are	O
several	O
,	O
subcentimeter	O
mediastinal	O
lymph	O
nodes	O
.	O
No	O
pathologically	O
enlarged	O
axillary	O
or	O
hilar	O
lymph	O
nodes	O
are	O
present	O
.	O
A	O
small	O
pericardial	O
effusion	O
is	O
relatively	O
unchanged	O
in	O
size	O
compared	O
to	O
the	O
examination	O
four	O
days	O
prior	O
.	O
A	O
moderate	O
-	O
to	O
large	O
-	O
sized	O
hiatal	O
hernia	O
is	O
also	O
again	O
noted	O
.	O
Lung	O
windows	O
demonstrate	O
dramatic	O
interval	O
change	O
with	O
diffuse	O
,	O
ground	O
-	O
glass	O
opacities	O
present	O
throughout	O
both	O
lungs	O
,	O
mostly	O
new	O
compared	O
to	O
the	O
previous	O
examination	O
.	O
A	O
few	O
pulmonary	O
nodules	O
within	O
the	O
right	O
lung	O
are	O
again	O
noted	O
and	O
unchanged	O
compared	O
to	O
the	O
previous	O
examination	O
.	O
Incidental	O
note	O
is	O
also	O
made	O
of	O
bibasilar	O
atelectasis	O
.	O
No	O
lytic	O
or	O
blastic	O
lesions	O
within	O
the	O
osseous	O
structures	O
are	O
noted	O
.	O
Limited	O
views	O
of	O
the	O
upper	O
abdomen	O
are	O
unremarkable	O
.	O
IMPRESSION	O
:	O
Multifocal	O
air	O
-	O
space	O
process	O
throughout	O
both	O
lungs	O
dramatically	O
new	O
compared	O
to	O
examination	O
from	O
four	O
days	O
prior	O
.	O
Given	O
the	O
non-pathologic	O
but	O
prominent	O
mediastinal	O
lymphadenopathy	O
,	O
infectious	O
etiologies	O
including	O
atypical	O
infections	O
if	O
the	O
patient	O
is	O
immunocompromised	O
should	O
be	O
considered	O
.	O
ARDS	O
given	O
the	O
timing	O
of	O
these	O
findings	O
is	O
also	O
a	O
diagnostic	O
consideration	O
.	O
Clinical	O
correlation	O
is	O
advised	O
.	O
No	O
pleural	O
effusion	O
.	O
Findings	O
were	O
discussed	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
at	O
4:55	O
pm	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
7747	O
**	O
]	O
over	O
the	O
telephone	O
on	O
[	O
**	O
2138-9-28	O
**	O
]	O
.	O
[	O
**	O
2138-10-28	O
**	O
]	O
HCT	O
28.8	O
platelet	O
67	O
wbc	O
3.5	O
Na	O
130	O
creat	O
1.9	O
BUN	O
25	O
K	O
4.5	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
70	O
y.o.	O
woman	O
with	O
myelodysplastic	O
syndrome	O
and	O
resultant	O
pancytopenia	O
and	O
recurrent	O
GIB	O
associated	O
with	O
ulcerations	O
in	O
her	O
small	O
intestine	O
.	O
.	O
#	O
GI	O
Bleeding	O
:	O
Likely	O
due	O
from	O
previously	O
discovered	O
small	O
intestinal	O
ulcerations	O
,	O
with	O
increased	O
propensity	O
for	O
bleeding	O
given	O
thrombocytopenia	O
.	O
No	O
evidence	O
of	O
UGIB	O
.	O
Baseline	O
hct	O
32	O
,	O
was	O
22	O
on	O
admission	O
.	O
On	O
the	O
second	O
day	O
of	O
hospitalization	O
the	O
patient	O
had	O
further	O
bleeding	O
per	O
rectum	O
,	O
became	O
hypotensive	O
,	O
and	O
had	O
sinus	O
tachycardia	O
to	O
140	O
.	O
She	O
was	O
soon	O
transferred	O
to	O
the	O
MICU	O
.	O
While	O
in	O
the	O
ICU	O
,	O
Angiography	O
did	O
not	O
show	O
active	O
bleed	O
,	O
although	O
unable	O
to	O
catheterize	O
the	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
899	O
**	O
]	O
.	O
Tagged	O
RBC	O
study	O
also	O
did	O
not	O
show	O
site	O
of	O
bleed	O
.	O
At	O
present	O
,	O
there	O
are	O
no	O
surgical	O
or	O
endoscopic	O
options	O
,	O
so	O
will	O
continue	O
with	O
supportive	O
care	O
.	O
NG	O
lavage	O
was	O
negative	O
.	O
The	O
patient	O
received	O
numerous	O
PRBC	I-Drug
transfusions	O
.	O
Platelets	O
remain	O
above	O
50	O
after	O
many	O
platelent	O
transufsions	O
.	O
After	O
stabilization	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
floor	O
where	O
she	O
remained	O
hemodynamically	O
stable	O
for	O
the	O
remainder	O
of	O
her	O
hospitalization	O
.	O
She	O
did	O
have	O
occasional	O
BRBPR	O
,	O
and	O
always	O
remained	O
guaiac	O
positive	O
.	O
She	O
continued	O
to	O
receive	O
prbc	B-Drug
's	I-Drug
nearly	O
every	O
other	O
day	O
to	O
maintain	B-Reason
a	I-Reason
stable	I-Reason
hematocrit	O
,	O
and	O
she	O
received	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
on	O
nearly	O
a	O
daily	O
basis	O
to	O
maintain	B-Reason
her	I-Reason
platelet	I-Reason
count	I-Reason
over	I-Reason
50	I-Reason
.	O
.	O
#	O
Neutropenic	B-Ade
fever	I-Ade
:	O
The	O
patient	O
finished	O
her	O
5th	O
day	O
of	O
decitabine	I-Drug
for	O
MDS	B-Reason
treatment	I-Reason
on	O
[	O
**	O
9	O
-	O
12	O
**	O
]	O
.	O
Previous	O
to	O
decitabine	I-Drug
therapy	O
the	O
patient	O
had	O
adequate	O
cell	O
counts	O
,	O
and	O
after	O
decitabine	I-Drug
the	O
patient	O
became	O
progressively	O
neutropenic	I-Ade
.	O
On	O
return	O
to	O
the	O
floor	O
form	O
the	O
MICU	O
the	O
patient	O
proceeded	O
to	O
spike	O
daily	O
fevers	O
as	O
high	O
as	O
103.0	O
,	O
with	O
associated	O
rigors	O
.	O
The	O
source	O
of	O
fever	I-Reason
was	O
not	O
identified	O
.	O
Daily	O
blood	O
cultures	O
were	O
negative	O
.	O
stool	O
was	O
C.Diff	O
negative	O
.	O
The	O
patient	O
placed	O
on	O
several	O
antibiotics	I-Drug
,	O
including	O
vancomycin	I-Drug
,	O
Zosyn	I-Drug
,	O
Flagyl	I-Drug
,	O
and	O
fluconazole	I-Drug
,	O
and	O
continued	O
to	O
spike	O
.	O
CT	O
chest	O
/	O
Abdomen	O
/	O
Pelvis	O
on	O
[	O
**	O
9	O
-	O
24	O
**	O
]	O
did	O
not	O
reveal	O
a	O
source	O
of	O
fevers	O
.	O
CT	O
Pelvis	O
revealed	O
fat	O
stranding	O
and	O
questionable	O
external	O
iliac	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
thrombus	O
,	O
followup	O
MRI	O
showed	O
fat	O
stranding	O
but	O
no	O
thrombus	O
.	O
Antibiotics	I-Drug
eventually	O
switched	O
to	O
Vanc	I-Drug
/	O
Cefepime	I-Drug
/	O
Flagyl	I-Drug
(	O
cefepime	I-Drug
was	O
discontinued	O
secondary	O
to	O
drug	O
rash	I-Ade
)	O
,	O
to	O
Vanc	I-Drug
/	O
Aztreonam	I-Drug
/	O
Caspofungin	I-Drug
.	O
The	O
patient	O
desaturated	O
on	O
[	O
**	O
9	O
-	O
28	O
**	O
]	O
to	O
78	O
%	O
,	O
and	O
CT	O
chest	O
showed	O
extensive	O
infiltrates	O
.	O
Clinical	O
suspicion	O
for	O
PCP	I-Reason
was	O
high	O
,	O
and	O
after	O
consulting	O
ID	O
,	O
the	O
patient	O
was	O
maintained	O
on	O
Vanc	I-Drug
/	O
Caspo	I-Drug
/	O
Meropenem	I-Drug
,	O
and	O
the	O
patient	O
was	O
begun	O
on	O
Bactrim	I-Drug
and	O
steroids	I-Drug
empirically	O
,	O
unable	O
to	O
perform	O
bronchoscopy	O
with	O
the	O
high	O
likelihood	O
of	O
being	O
unable	O
to	O
extubate	O
her	O
.	O
Soon	O
after	O
Bactrim	I-Drug
administration	O
her	O
fevers	I-Reason
stopped	O
.	O
She	O
was	O
continued	O
with	O
a	O
full	O
14	O
day	O
course	O
of	O
IV	O
Bactrim	I-Drug
.	O
After	O
completing	O
this	O
course	O
she	O
was	O
transitioned	O
to	O
Bactrim	I-Drug
DS	O
3	O
times	O
weekly	O
.	O
.	O
#O2	O
desaturation	O
-	O
Patient	O
began	O
to	O
desat	O
on	O
[	O
**	O
9	O
-	O
26	O
**	O
]	O
.	O
Thought	O
initially	O
to	O
be	O
due	O
to	O
fluid	B-Ade
overload	I-Ade
in	O
setting	O
of	O
increased	O
platelet	I-Drug
and	O
prbc	I-Drug
transfusions	O
,	O
and	O
CT	O
on	O
[	O
**	O
9	O
-	O
24	O
**	O
]	O
showing	O
bibasilar	O
atelectasis	O
.	O
Oxygen	O
improved	O
with	O
lasix	I-Drug
on	O
[	O
**	O
9	O
-	O
26	O
**	O
]	O
and	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
,	O
and	O
patient	O
was	O
saturating	O
at	O
94	O
%	O
on	O
room	O
air	O
on	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
.	O
Patient	O
desaturated	O
to	O
78	O
%	O
on	O
[	O
**	O
9	O
-	O
28	O
**	O
]	O
.	O
CT	O
chest	O
showed	O
extensive	O
infiltrates	O
.	O
ID	O
reccomended	O
broad	O
antibiotic	I-Drug
coverage	O
,	O
and	O
biggest	O
concern	O
was	O
for	O
PCP	I-Reason
in	O
the	O
setting	O
of	O
an	O
immunocompromised	O
patient	O
.	O
She	O
was	O
subsequently	O
begun	O
on	O
Bactrim	I-Drug
and	O
steroids	I-Drug
.	O
Soon	O
after	O
bactrim	I-Drug
administration	O
the	O
patient	O
stopped	O
spiking	O
fevers	O
,	O
however	O
she	O
persisted	O
with	O
low	I-Reason
oxygen	O
saturation	O
and	O
required	O
6L	O
O2	I-Drug
by	O
nasal	O
cannula	O
.	O
The	O
patient	O
's	O
O2	O
saturation	O
ranged	O
from	O
89	O
-	O
94	O
%	O
,	O
and	O
appeared	O
to	O
improve	O
with	O
lasix	I-Drug
administration	O
.	O
She	O
occasionally	O
required	O
masked	O
ventilation	O
to	O
maintain	O
O2	O
saturation	O
over	O
90	O
%	O
.	O
After	O
six	O
days	O
of	O
bactrim	I-Drug
therapy	O
,	O
her	O
bactrim	I-Drug
was	O
discontinued	O
out	O
of	O
concern	O
that	O
it	O
was	O
contributing	O
to	O
the	O
patient	O
's	O
neutropenia	I-Ade
.	O
Primaquine	I-Drug
and	O
clindamycin	I-Drug
were	O
begun	O
instead	O
.	O
Her	O
neutrophil	O
count	O
slowly	O
increased	O
over	O
a	O
period	O
of	O
four	O
days	O
from	O
40	O
to	O
170	O
,	O
she	O
remained	O
afebrile	O
,	O
but	O
her	O
oxygenation	O
did	O
not	O
improve	O
.	O
On	O
[	O
**	O
10	O
-	O
12	O
**	O
]	O
the	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
ICU	O
after	O
having	O
another	O
acute	O
oxygen	O
desaturation	O
of	O
78	O
%	O
on	O
6LNC	O
.	O
Patient	O
was	O
stabilized	O
and	O
transeferred	O
back	O
to	O
the	O
floor	O
on	O
NRB	O
100	O
%	O
,	O
she	O
continued	O
on	O
IV	O
antibiotic	I-Drug
regimen	O
of	O
meropenem	I-Drug
and	O
Bactrim	I-Drug
.	O
She	O
remained	O
afebrile	I-Reason
and	O
was	O
continued	O
on	O
Bactrim	I-Drug
and	O
voriconazole	I-Drug
.	O
She	O
was	O
able	O
to	O
be	O
weaned	O
to	O
99	O
%	O
on	O
3L	O
nasal	O
cannula	O
prior	O
to	O
discharge	O
.	O
Her	O
prednisone	I-Drug
dose	O
was	O
tapered	O
,	O
she	O
was	O
discharge	O
on	O
Prednisone	I-Drug
30	O
mg	O
AM	O
,	O
10	O
mg	O
PM	O
per	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1557	O
**	O
]	O
who	O
will	O
follow	O
her	O
at	O
the	O
rehabilitation	O
facility	O
.	O
Given	O
her	O
risk	O
of	O
GIB	O
it	O
was	O
very	O
important	O
to	O
taper	O
her	O
steroid	I-Drug
dose	O
.	O
#	O
MDS	I-Reason
:	O
The	O
patient	O
is	O
s	O
/	O
p	O
decitabine	I-Drug
treatment	O
from	O
[	O
**	O
9	O
-	O
12	O
**	O
]	O
,	O
and	O
gradually	O
became	O
neutropenic	I-Ade
.	O
While	O
in	O
the	O
hospital	O
her	O
cyclosporine	I-Drug
was	O
discontinued	O
.	O
She	O
was	O
administered	O
neupogen	I-Drug
and	O
her	O
counts	O
eventually	O
recovered	O
slowly	O
.	O
Her	O
last	O
ANC	O
on	O
the	O
day	O
of	O
discharge	O
was	O
3100	O
.	O
Further	O
treatment	O
for	O
underlying	O
disease	O
at	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
6168	O
**	O
]	O
discretion	O
.	O
#	O
Hyponatremia	O
:	O
Urine	O
electrolytes	O
consistent	O
with	O
SIADH	O
,	O
likely	O
from	O
the	O
pulmonary	O
process	O
.	O
She	O
was	O
fluid	O
restricted	O
to	O
1L	O
,	O
it	O
was	O
diffucult	O
to	O
mantain	O
this	O
restriction	O
given	O
the	O
IV	O
medications	I-Drug
.	O
Once	O
she	O
was	O
taken	O
off	O
the	O
IV	O
meds	I-Drug
her	O
sodium	O
level	O
rose	O
,	O
130	O
upon	O
dishcharge	O
.	O
She	O
was	O
continued	O
on	O
salt	O
tabs	O
.	O
#Sundowning	O
:	O
Her	O
mental	O
status	O
would	O
wax	O
and	O
wane	O
at	O
nighttime	O
,	O
multifactorial	O
etiology	O
of	O
undrlying	O
infection	O
,	O
hypoxia	O
,	O
hyponatremia	O
and	O
medications	O
.	O
Her	O
medication	O
list	O
was	O
reviewed	O
and	O
with	O
treatment	O
of	O
her	O
underlying	O
disease	O
her	O
mental	O
status	O
improved	O
.	O
She	O
was	O
alert	O
and	O
oriented	O
at	O
discharge	O
.	O
Medications	O
on	O
Admission	O
:	O
Home	O
Medications	O
:	O
1	O
.	O
Cyclosporine	I-Drug
50	O
mg	O
twice	O
daily	O
2	O
.	O
IVIG	I-Drug
finished	O
9	O
week	O
therapy	O
3	O
weeks	O
ago	O
.	O
3	O
.	O
Prednisone	I-Drug
20	O
mg	O
daily	O
,	O
15	O
mg	O
qam	O
,	O
5	O
mg	O
qpm	O
4	O
.	O
Decitabine	I-Drug
c1	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
51772	O
**	O
]	O
5	O
.	O
Metoprolol	I-Drug
50	O
mg	O
twice	O
daily	O
6	O
.	O
Aranesp	I-Drug
PRN	O
7	O
.	O
Vitamin	B-Drug
B6	I-Drug
8	O
.	O
Folic	B-Drug
Acid	I-Drug
9	O
.	O
Danazol	I-Drug
200g	O
Daily	O
10	O
.	O
Protonix	I-Drug
40	O
mg	O
Daily	O
11	O
.	O
Potassium	I-Drug
20mEq	O
twice	O
daily	O
12	O
.	O
Mg	B-Drug
supplements	I-Drug
.	O
.	O
Medications	O
on	O
transfer	O
:	O
Meperidine	I-Drug
25	O
-	O
50	O
mg	O
IV	O
Q6H	O
:	O
PRN	O
Acetaminophen	I-Drug
325	O
-	O
650	O
mg	O
PO	O
Q6H	O
:	O
PRN	O
Nystatin	I-Drug
Oral	O
Suspension	O
5	O
ml	O
PO	O
QID	O
:	O
PRN	O
CycloSPORINE	I-Drug
(	O
Sandimmune	I-Drug
)	O
50	O
mg	O
PO	O
Q12H	O
Pantoprazole	I-Drug
40	O
mg	O
PO	O
Q12H	O
Danazol	I-Drug
200	O
mg	O
PO	O
QD	O
DiphenhydrAMINE	I-Drug
25	O
mg	O
PO	O
Q6H	O
:	O
PRN	O
FoLIC	B-Drug
Acid	I-Drug
1	O
mg	O
PO	O
DAILY	O
HYDROmorphone	B-Drug
(	I-Drug
Dilaudid	I-Drug
)	I-Drug
0.5	O
mg	O
IV	O
Q4H	O
:	O
PRN	O
pain	I-Reason
Zolpidem	B-Drug
Tartrate	I-Drug
10	O
mg	O
PO	O
HS	O
:	O
PRN	O
Hydrocortisone	I-Drug
Na	O
Succ	O
.	O
100	O
mg	O
IV	O
Q8H	O
Lorazepam	I-Drug
0.5	O
mg	O
PO	O
Q8H	O
:	O
PRN	O
Zosyn	I-Drug
2.25	O
mg	O
Q6h	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
/	O
fever	I-Reason
.	O
2	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
(	O
0.83	O
mg	O
/	O
mL	O
)	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q2H	O
(	O
every	O
2	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
3	O
.	O
Danazol	I-Drug
200	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Guaifenesin	I-Drug
100	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
5	O
-	O
10	O
MLs	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
cough	I-Reason
.	O
5	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
6	O
.	O
Isosorbide	B-Drug
Dinitrate	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Mupirocin	B-Drug
Calcium	I-Drug
2	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
9	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
10	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
13	O
.	O
Lactulose	I-Drug
10	O
gram	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
14	O
.	O
Voriconazole	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
15	O
.	O
Sodium	B-Drug
Chloride	I-Drug
0.65	O
%	O
Aerosol	O
,	O
Spray	O
Sig	O
:	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
Sprays	O
Nasal	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
dry	B-Reason
nose	I-Reason
.	O
16	O
.	O
Sodium	B-Drug
Chloride	I-Drug
1	O
gram	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
hyponatremia	I-Reason
.	O
17	O
.	O
Trimethoprim	B-Drug
-	I-Drug
Sulfamethoxazole	I-Drug
160	O
-	O
800	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
MWF	O
(	O
Monday	O
-	O
Wednesday	O
-	O
Friday	O
)	O
.	O
18	O
.	O
Ondansetron	B-Drug
HCl	I-Drug
(	I-Drug
PF	I-Drug
)	I-Drug
4	O
mg	O
/	O
2	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
19	O
.	O
Prednisone	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
QPM	O
for	O
5	O
days	O
.	O
20	O
.	O
Prednisone	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
QAM	O
for	O
5	O
days	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
NE	O
[	O
**	O
Hospital1	O
41724	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Aplastic	O
anemia	O
/	O
Hypocellular	O
myelodysplastic	O
syndrome	O
with	O
trisomy	O
8	O
and	O
21	O
.	O
s	O
/	O
p	O
high	O
dose	O
prednisone	I-Drug
and	O
gamma	I-Drug
globulin	O
,	O
s	O
/	O
p	O
Anti-thymocyte	O
globulin	O
therapy	O
[	O
**	O
2126	O
**	O
]	O
,	O
on	O
cyclosporine	I-Drug
since	O
with	O
renal	B-Ade
insufficiency	I-Ade
;	O
started	O
IVIG	I-Drug
q3	O
weeks	O
[	O
**	O
2138-7-10	O
**	O
]	O
Empiric	O
tx	O
for	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
1064	O
**	O
]	O
s	O
/	O
p	O
terminal	O
ileum	O
resection	O
[	O
**	O
3	O
-	O
26	O
**	O
]	O
for	O
multiple	O
bleeding	O
ulcers	O
h	O
/	O
o	O
candidemia	O
with	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
parapsilosis	O
Renal	O
insufficiency	O
(	O
recent	O
baseline	O
Cr	O
1.2	O
-	O
1.6	O
)	O
Hypertension	O
h	O
/	O
o	O
hypercholesterolemia	O
Past	O
Surgical	O
History	O
:	O
-	O
TAH	O
/	O
BSO	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
fibroids	O
-	O
Appendectomy	O
-	O
Venous	O
stripping	O
LLE	O
Discharge	O
Condition	O
:	O
Stable	O
,	O
ambulating	O
with	O
assistance	O
,	O
alert	O
and	O
oriented	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
GI	O
bleeding	O
,	O
you	O
were	O
in	O
the	O
ICU	O
and	O
transfused	O
.	O
Your	O
hospital	O
course	O
was	O
further	O
complicated	O
by	O
hypoxia	O
which	O
was	O
treated	O
as	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
1064	O
**	O
]	O
.	O
This	O
led	O
to	O
2	O
transfers	O
to	O
the	O
ICU	O
for	O
problems	O
[	O
**	O
Name	O
(	O
NI	O
)	O
51773	O
**	O
]	O
your	O
oxygen	O
status	O
.	O
You	O
completed	O
treatment	O
for	O
PCP	O
pneumonia	O
and	O
your	O
oxygen	I-Drug
was	O
weaned	O
to	O
3	O
liter	O
by	O
nasal	O
canula	O
.	O
You	O
have	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1557	O
**	O
]	O
on	O
[	O
**	O
2138-10-31	O
**	O
]	O
at	O
11	O
am	O
for	O
follow	O
up	O
.	O
Take	O
all	O
of	O
your	O
medications	O
as	O
prescribed	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
M.D.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1983	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2138-11-28	O
**	O
]	O
12:30	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
1730	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
6175	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2138-10-31	O
**	O
]	O
11:00	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
5255	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2189-9-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2189-9-25	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2154-12-25	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
Gynecologic	O
Oncology	O
ADDENDUM	O
:	O
1	O
.	O
Left	B-Reason
leg	I-Reason
pain	I-Reason
:	O
Additionally	O
,	O
the	O
patient	O
was	O
also	O
on	O
Doxepin	I-Drug
10	O
mg	O
daily	O
per	O
recommendation	O
of	O
the	O
pain	O
service	O
.	O
This	O
was	O
discontinued	O
after	O
the	O
patient	O
had	O
had	O
her	O
narcotic	I-Drug
overdose	I-Ade
episode	O
.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
4784	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Name8	O
(	O
MD	O
)	O
5256	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2189-9-29	O
**	O
]	O
11:33	O
T	O
:	O
[	O
**	O
2189-9-29	O
**	O
]	O
12:08	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
5257	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2105-7-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2105-7-28	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
330	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Central	O
Venous	O
line	O
(	O
Right	O
IJ	O
)	O
Arterial	O
line	O
(	O
Left	O
)	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
atrial	O
fibrillation	O
,	O
systolic	O
heart	O
failure	O
,	O
chronic	O
kidney	O
disease	O
who	O
presents	O
from	O
NH	O
with	O
altered	O
mental	O
status	O
.	O
Per	O
report	O
,	O
pt	O
was	O
noted	O
by	O
staff	O
at	O
NH	O
yesterday	O
to	O
be	O
difficult	O
to	O
arouse	O
and	O
having	O
labored	O
breathing	O
.	O
His	O
vitals	O
at	O
the	O
time	O
included	O
BP	O
112/57	O
,	O
and	O
O2	O
sats	O
and	O
temperature	O
were	O
not	O
obtainable	O
due	O
likely	O
to	O
hypothermia	O
.	O
He	O
was	O
sent	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
for	O
further	O
revaluation	O
.	O
Of	O
note	O
,	O
per	O
his	O
daughter	O
,	O
he	O
was	O
recently	O
hospitalized	O
(	O
[	O
**	O
2015-7-16	O
**	O
]	O
)	O
from	O
[	O
**	O
Hospital3	O
**	O
]	O
Hospital	O
with	O
congestive	O
heart	O
failure	O
.	O
During	O
this	O
hospitalization	O
he	O
was	O
noted	O
to	O
have	O
deteriorating	O
mental	O
status	O
and	O
delirium	O
,	O
which	O
is	O
why	O
he	O
had	O
been	O
discharged	O
to	O
NH	O
.	O
In	O
the	O
ED	O
,	O
VS	O
T	O
92.1	O
axillary	O
,	O
BP	O
100/50	O
,	O
HR	O
50	O
,	O
RR	O
21	O
88	O
%	O
6L	O
initially	O
then	O
placed	O
99	O
%	O
NRB	O
.	O
He	O
received	O
vancomycin	I-Drug
,	O
ceftriaxone	I-Drug
,	O
and	O
flagyl	I-Drug
for	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
Also	O
received	O
vitamin	B-Drug
K	I-Drug
IV	O
10	O
mg	O
for	O
coagulopathy	I-Reason
with	O
INR	O
to	O
7.2	O
.	O
With	O
CT	O
head	O
negative	O
for	O
acute	O
intracranial	O
process	O
.	O
Also	O
received	O
1	O
L	O
IVF	I-Drug
total	O
in	O
ED	O
.	O
On	O
arrival	O
to	O
MICU	O
,	O
he	O
was	O
noteedd	O
to	O
be	O
bradycardic	I-Reason
to	O
HRs	O
to	O
30s	O
and	O
hypotensive	O
to	O
SBP	O
80s	O
with	O
MAPS	O
50s	O
.	O
He	O
was	O
given	O
1	O
mg	O
atropine	I-Drug
with	O
HR	O
to	O
50s	O
.	O
He	O
was	O
given	O
500	O
cc	O
fluid	I-Drug
bolus	O
x	O
2	O
and	O
SBP	O
came	O
up	O
to	O
90s	O
.	O
Past	O
Medical	O
History	O
:	O
Systolic	O
Heart	O
Failure	O
with	O
EF	O
30	O
%	O
Hypertension	O
Atrial	O
Fibrillation	O
Hypothyrodism	O
Chronic	O
kidney	O
disease	O
,	O
stage	O
III	O
Dysphagia	O
Dementia	O
?	O
Social	O
History	O
:	O
Currently	O
lives	O
in	O
a	O
nursing	O
home	O
.	O
Has	O
a	O
daughter	O
and	O
son	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
3003	O
**	O
]	O
to	O
being	O
in	O
the	O
nursing	O
home	O
,	O
he	O
lived	O
with	O
his	O
daugther	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
VS	O
:	O
HR	O
46	O
96/49	O
RR	O
18	O
100	O
%	O
NRB	O
GEN	O
:	O
On	O
NRB	O
,	O
difficult	O
to	O
arouse	O
,	O
non-verbal	O
,	O
opens	O
eyes	O
to	O
painful	O
stimuli	O
,	O
unable	O
to	O
follow	O
commands	O
HEENT	O
:	O
AT	O
,	O
NC	O
,	O
EOMI	O
,	O
no	O
conjuctival	O
injection	O
,	O
anicteric	O
,	O
MM	O
dry	O
,	O
right	O
pupil	O
reactive	O
3	O
to	O
2	O
mm	O
,	O
left	O
pupil	O
unreactive	O
CV	O
:	O
Irreg	O
irreg	O
,	O
nl	O
s1	O
s2	O
PULM	O
:	O
Diffuse	O
crackles	O
anteriorly	O
ABD	O
:	O
soft	O
,	O
mild	O
distension	O
,	O
+	O
BS	O
,	O
no	O
HSM	O
EXT	O
:	O
cool	O
,	O
b	O
/	O
l	O
lateral	O
malleolus	O
venous	O
stasis	O
ulcers	O
NEURO	O
:	O
Unable	O
to	O
assess	O
due	O
to	O
mental	O
status	O
Pertinent	O
Results	O
:	O
[	O
**	O
2105-7-26	O
**	O
]	O
10:40	O
PM	O
BLOOD	O
WBC	O
-	O
4.8	O
RBC	O
-	O
3.30	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
32.1	O
*	O
MCV	O
-	O
98	O
MCH	O
-	O
32.0	O
MCHC	O
-	O
32.8	O
RDW	O
-	O
17.6	O
*	O
Plt	O
Ct	O
-	O
124	O
*	O
[	O
**	O
2105-7-27	O
**	O
]	O
05:10	O
PM	O
BLOOD	O
WBC	O
-	O
5.9	O
RBC	O
-	O
3.06	O
*	O
Hgb	O
-	O
10.0	O
*	O
Hct	O
-	O
30.5	O
*	O
MCV	O
-	O
100	O
*	O
MCH	O
-	O
32.7	O
*	O
MCHC	O
-	O
32.8	O
RDW	O
-	O
17.2	O
*	O
Plt	O
Ct	O
-	O
100	O
*	O
[	O
**	O
2105-7-26	O
**	O
]	O
10:40	O
PM	O
BLOOD	O
Neuts	O
-	O
85.0	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
9.2	O
*	O
Monos	O
-	O
4.7	O
Eos	O
-	O
0.6	O
Baso	O
-	O
0.5	O
[	O
**	O
2105-7-26	O
**	O
]	O
10:40	O
PM	O
BLOOD	O
PT	O
-	O
60.4	O
*	O
PTT	O
-	O
67.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
7.2	O
*	O
[	O
**	O
2105-7-27	O
**	O
]	O
04:49	O
AM	O
BLOOD	O
Fibrino	O
-	O
405	O
*	O
D	O
-	O
Dimer	O
-	O
686	O
*	O
[	O
**	O
2105-7-26	O
**	O
]	O
10:40	O
PM	O
BLOOD	O
Glucose	O
-	O
61	O
*	O
UreaN	O
-	O
50	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
137	O
K	O
-	O
4.8	O
Cl	O
-	O
100	O
HCO3	O
-	O
27	O
AnGap	O
-	O
15	O
[	O
**	O
2105-7-26	O
**	O
]	O
10:40	O
PM	O
BLOOD	O
ALT	O
-	O
23	O
AST	O
-	O
40	O
CK	O
(	O
CPK	O
)	O
-	O
175	O
*	O
AlkPhos	O
-	O
164	O
*	O
TotBili	O
-	O
0.8	O
[	O
**	O
2105-7-26	O
**	O
]	O
10:40	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
17	O
*	O
MB	O
Indx	O
-	O
9.7	O
*	O
cTropnT	O
-	O
0.12	O
*	O
proBNP	O
-	O
5749	O
*	O
[	O
**	O
2105-7-27	O
**	O
]	O
03:32	O
AM	O
BLOOD	O
Albumin	O
-	O
2.8	O
*	O
Calcium	O
-	O
7.5	O
*	O
Phos	O
-	O
4.1	O
Mg	O
-	O
1.9	O
[	O
**	O
2105-7-27	O
**	O
]	O
03:32	O
AM	O
BLOOD	O
TSH	O
-	O
20	O
*	O
[	O
**	O
2105-7-27	O
**	O
]	O
04:55	O
PM	O
BLOOD	O
T4	O
-	O
5.9	O
calcTBG	O
-	O
0.82	O
TUptake	O
-	O
1.22	O
T4Index	O
-	O
7.2	O
[	O
**	O
2105-7-26	O
**	O
]	O
11:01	O
PM	O
BLOOD	O
Lactate	O
-	O
1.4	O
Relevant	O
Imaging	O
:	O
CT	O
Head	O
FINDINGS	O
:	O
There	O
is	O
no	O
intra	O
-	O
or	O
extra-axial	O
hemorrhage	O
,	O
mass	O
effect	O
,	O
or	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
Extensive	O
bilateral	O
periventricular	O
as	O
well	O
as	O
subcortical	O
white	O
matter	O
hypoattenuation	O
related	O
to	O
chronic	O
microangiopathic	O
ischemic	O
changes	O
is	O
evident	O
.	O
The	O
ventricles	O
and	O
sulci	O
are	O
moderately	O
prominent	O
,	O
appropriate	O
for	O
age	O
-	O
associated	O
involutionary	O
changes	O
.	O
Bilateral	O
basal	O
ganglia	O
calcification	O
and	O
extensive	O
calcification	O
along	O
the	O
tentorium	O
and	O
falx	O
cerebri	O
are	O
evident	O
.	O
The	O
osseous	O
and	O
soft	O
tissue	O
structures	O
are	O
unremarkable	O
.	O
A	O
nonspecific	O
focus	O
of	O
hyperdense	O
focus	O
is	O
noted	O
in	O
the	O
left	O
pre-zygomatic	O
soft	O
tissue	O
.	O
Clinical	O
correlation	O
is	O
advised	O
.	O
IMPRESSION	O
:	O
No	O
acute	O
intracranial	O
process	O
.	O
A	O
small	O
hyperdense	O
focus	O
in	O
the	O
left	O
pre-zygomatic	O
soft	O
tissue	O
could	O
represent	O
calcification	O
and	O
clinical	O
correlation	O
is	O
advised	O
.	O
ECHO	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
markedly	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
severe	O
hypokinesis	O
of	O
the	O
basal	O
half	O
of	O
the	O
inferior	O
and	O
inferolateral	O
walls	O
.	O
The	O
remaining	O
segments	O
contract	O
normally	O
(	O
LVEF	O
=	O
40	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
ascending	O
aorta	O
is	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
descending	O
thoracic	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
severely	O
thickened	O
/	O
deformed	O
.	O
Significant	O
aortic	O
stenosis	O
is	O
present	O
(	O
not	O
quantified	O
)	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
regional	O
systolic	O
dysfunction	O
c	O
/	O
w	O
CAD	O
.	O
Aortic	O
stenosis	O
.	O
Dilated	O
ascending	O
aorta	O
.	O
If	O
clinically	O
indicated	O
,	O
a	O
follow	O
-	O
up	O
study	O
to	O
assess	O
aortic	O
stenosis	O
is	O
suggested	O
when	O
the	O
patient	O
can	O
be	O
transported	O
to	O
the	O
Echo	O
laboratory	O
.	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
systolic	O
congestive	O
heart	O
failure	O
,	O
atrial	O
fibrillation	O
,	O
who	O
presented	O
with	O
hypoxia	O
,	O
hypotension	O
,	O
and	O
hypothermia	O
.	O
Upon	O
admission	O
to	O
the	O
MICU	O
,	O
agressive	O
therapy	O
was	O
initiated	O
keeping	O
a	O
broad	O
differential	O
diagnosis	O
.	O
Patient	O
however	O
continued	O
to	O
deteriorate	O
and	O
abruptly	O
became	O
profoundly	O
bradycardic	I-Reason
,	O
unresponsive	O
to	O
atropine	I-Drug
or	O
increasing	O
doses	O
of	O
pressors	I-Drug
,	O
culminating	O
in	O
asystole	O
;	O
patient	O
was	O
pronounced	O
dead	O
at	O
1:05	O
am	O
on	O
[	O
**	O
2105-7-28	O
**	O
]	O
.	O
Below	O
are	O
the	O
details	O
leading	O
to	O
these	O
events	O
,	O
arranged	O
by	O
problem	O
:	O
1	O
)	O
Hypotension	O
/	O
Hypothermia	O
:	O
On	O
initial	O
presentation	O
on	O
the	O
floor	O
SBP	B-Reason
80s	I-Reason
,	O
given	O
500cc	O
fluid	I-Drug
bolus	O
x	O
2	O
with	O
SBP	O
to	O
90s	O
.	O
Meets	O
SIRS	O
criteria	O
with	O
hypothermia	O
and	O
tachpnea	O
and	O
hypotension	O
concerning	O
for	O
sepsis	O
,	O
with	O
pneumonia	O
as	O
the	O
most	O
likely	O
source	O
.	O
Also	O
on	O
differential	O
was	O
hypovolemic	O
hypotension	O
for	O
occult	O
blood	O
loss	O
,	O
cardiogenic	O
shock	O
,	O
adrenal	O
insuffiency	O
and	O
myxedema	O
coma	O
.	O
Cooling	O
blanket	O
placed	O
on	O
patient	O
upon	O
arrival	O
.	O
Patient	O
was	O
given	O
fluid	I-Drug
boluses	O
and	O
central	O
access	O
was	O
obtained	O
.	O
Echocardiogram	O
was	O
obtained	O
and	O
revealed	O
mildly	O
depressed	O
ejection	O
fraction	O
(	O
40	O
%	O
)	O
with	O
inferolateral	O
wall	O
hypokinesis	O
and	O
moderate	O
tricuspid	O
regurgitation	O
.	O
Central	O
venous	O
pressure	O
was	O
measured	O
and	O
found	O
to	O
be	O
elvated	O
to	O
24mmHg	O
,	O
which	O
even	O
in	O
the	O
setting	O
of	O
TR	O
was	O
felt	O
to	O
rule	O
out	O
hypovolemia	O
.	O
Patient	O
was	O
initiated	O
on	O
Dopamine	I-Drug
in	O
hopes	O
of	O
supporting	B-Reason
both	I-Reason
blood	I-Reason
pressure	I-Reason
and	O
heart	O
rate	O
.	O
Arterial	O
line	O
was	O
placed	O
for	O
accurate	O
assessment	O
of	O
arterial	O
pressure	O
.	O
Hematocrit	O
remained	O
stable	O
and	O
pressure	O
responded	O
to	O
pressor	I-Drug
support	O
.	O
Patient	O
started	O
on	O
stress	O
dose	O
steroids	I-Drug
for	O
possible	O
adrenal	I-Reason
insufficiency	O
.	O
2	O
)	O
Hypoxia	O
:	O
With	O
bilateral	O
infiltrates	O
and	O
likely	O
superimposed	O
fluid	O
overlaod	O
.	O
Given	O
recent	O
hospitalization	O
and	O
extent	O
of	O
O2	O
requirement	O
,	O
high	O
suspicion	O
for	O
Hospital	B-Reason
Acquired	I-Reason
Pneumonia	I-Reason
(	O
HAP	O
)	O
with	O
vancomycin	I-Drug
and	O
zosyn	I-Drug
.	O
This	O
was	O
later	O
changed	O
to	O
Vancomycin	I-Drug
and	O
Cefepime	I-Drug
.	O
Patients	O
blood	O
gas	O
was	O
concerning	O
for	O
hypercarbia	O
,	O
and	O
after	O
re-discussing	O
goals	O
of	O
care	O
with	O
family	O
and	O
confirming	O
patient	O
did	O
not	O
want	O
to	O
be	O
intubated	O
,	O
non	O
invasive	O
ventillation	O
was	O
initiated	O
.	O
Patient	O
tolerated	O
NIPPV	O
well	O
and	O
hypoxia	O
/	O
hypercarbia	O
/	O
respiratory	O
acidosis	O
improved	O
until	O
his	O
sudden	O
decompensation	O
.	O
3	O
)	O
Bradycardia	I-Reason
:	O
With	O
baseline	O
bradycardia	O
per	O
history	O
,	O
unclear	O
etiology	O
.	O
On	O
arrival	O
to	O
MICU	O
,	O
bradycardic	O
to	O
HR	O
in	O
30s	O
,	O
gave	O
1	O
mg	O
atropine	I-Drug
with	O
HR	O
to	O
50s	O
.	O
All	O
nodal	O
agents	O
were	O
stopped	O
and	O
heart	O
rate	O
improved	O
with	O
Dopamine	I-Drug
administration	O
.	O
4	O
)	O
Meningitis	I-Reason
:	O
Given	O
patients	O
poor	O
baseline	O
mental	O
status	O
and	O
findings	O
of	O
significant	O
nuchal	O
rigidity	O
,	O
concern	O
for	O
meningitis	O
was	O
raised	O
.	O
Given	O
patients	O
decompensated	O
status	O
,	O
lumbar	O
puncture	O
was	O
not	O
pursued	O
and	O
empiric	O
coverage	O
with	O
Ampicillin	I-Drug
for	O
listeria	I-Reason
,	O
Vancomycin	I-Drug
/	O
Cefepime	I-Drug
for	O
Staph	I-Reason
/	O
Strep	I-Reason
were	O
initiated	O
.	O
5	O
)	O
Hypothyroidism	I-Reason
:	O
TSH	O
of	O
20	O
,	O
difficult	O
to	O
interpret	O
in	O
this	O
setting	O
as	O
sick	O
euthyroid	O
may	O
have	O
impacted	O
laboratory	O
results	O
.	O
Given	O
decompensated	O
state	O
,	O
endocrine	O
consult	O
was	O
placed	O
and	O
thyroid	B-Drug
hormone	I-Drug
was	O
supplemented	O
intravenously	O
at	O
higher	O
doses	O
than	O
per	O
outpatient	O
regimen	O
.	O
Free	O
T3	O
,	O
T4	O
and	O
Thyroid	O
binding	O
protein	O
were	O
ordered	O
but	O
were	O
not	O
available	O
before	O
patient	O
decompensated	O
.	O
Per	O
endocrine	O
team	O
recommendations	O
,	O
T3	O
was	O
not	O
given	O
due	O
to	O
concerns	O
for	O
arrythmia	O
and	O
cardiac	O
side	O
effects	O
,	O
and	O
given	O
very	O
poor	O
level	O
of	O
evidence	O
for	O
its	O
efficacy	O
.	O
6	O
)	O
Coagulopathy	I-Reason
:	O
INR	O
7.2	O
on	O
admission	O
in	O
setting	O
of	O
anticoagulation	I-Drug
.	O
Given	O
vitamin	B-Drug
K	I-Drug
and	O
FFP	I-Drug
.	O
DIC	O
labs	O
negative	O
.	O
7	O
)	O
Chronic	O
kidney	O
disease	O
:	O
With	O
known	O
baseline	O
CKD	O
stage	O
III	O
,	O
likely	O
exacerbated	O
in	O
the	O
setting	O
of	O
hypotension	O
.	O
Medications	O
on	O
Admission	O
:	O
Acetaminophen	I-Drug
325	O
mg	O
PRN	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
Milk	B-Drug
of	I-Drug
Magnesia	I-Drug
PRN	O
Dulcolax	I-Drug
10	O
mg	O
Rectal	O
Suppository	O
PRN	O
Fleet	B-Drug
Enema	I-Drug
PRN	O
Albuterol	I-Drug
INH	O
PRN	O
Coumadin	I-Drug
2.5	O
mg	O
DAILY	O
Flomax	I-Drug
0.4	O
mg	O
DAILY	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
DAILY	O
Levothyroxine	I-Drug
125	O
mcg	O
DAILY	O
Lasix	I-Drug
20	O
mg	O
DAILY	O
Lisinopril	I-Drug
2.5	O
mg	O
DAILY	O
Magnesium	B-Drug
Oxide	I-Drug
400	O
mg	O
DAILY	O
Calcium	I-Drug
500	O
with	O
Vitamin	B-Drug
D	I-Drug
DAILY	O
Proscar	I-Drug
5	O
mg	O
DAILY	O
Ranitidine	I-Drug
150	O
mg	O
DAILY	O
Zyprexa	I-Drug
2.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Patient	O
expired	O
Discharge	O
Condition	O
:	O
Patient	O
expired	O
Discharge	O
Instructions	O
:	O
Patient	O
expired	O
Followup	O
Instructions	O
:	O
Patient	O
expired	O

Admission	O
Date	O
:	O
[	O
**	O
2163-1-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2163-1-9	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2111-9-9	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
7539	O
**	O
]	O
Chief	O
Complaint	O
:	O
SOB	O
,	O
lightheadedness	O
,	O
weakness	O
,	O
leg	O
heaviness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Placement	O
of	O
Right	O
Interior	O
Jugular	O
central	O
line	O
Transesophageal	O
Echocardiogram	O
DC	O
Cardioversion	O
with	O
conscious	O
sedation	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
51yo	O
M	O
w	O
/	O
PMH	O
of	O
HTN	O
and	O
afib	O
dx	O
one	O
week	O
ago	O
who	O
presented	O
to	O
his	O
PCP	O
today	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
/	O
SOB	O
,	O
leg	O
heaviness	O
,	O
lightheadedness	O
,	O
weakness	O
and	O
fatigue	O
.	O
Found	O
to	O
be	O
hypotensive	O
(	O
SBP	O
in	O
60s	O
)	O
and	O
bradycardic	O
(	O
HR	O
30s	O
)	O
.	O
EMS	O
was	O
called	O
and	O
transported	O
him	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ER	O
.	O
In	O
the	O
ER	O
,	O
he	O
was	O
given	O
atropine	I-Drug
x2	O
,	O
glucagon	I-Drug
,	O
calcium	I-Drug
and	O
1.5	O
L	O
NS	I-Drug
.	O
EKGs	O
showed	O
bradycardia	O
at	O
rate	O
of	O
~	O
30	O
,	O
with	O
no	O
definite	O
P	O
waves	O
,	O
but	O
a	O
baseline	O
suggestive	O
of	O
afib	O
/	O
flutter	O
.	O
No	O
qwaves	O
,	O
no	O
ST	O
or	O
T	O
wave	O
changes	O
.	O
He	O
was	O
still	O
hypotensive	O
so	O
a	O
R	O
IJ	O
was	O
placed	O
and	O
he	O
was	O
started	O
on	O
a	O
dopamine	I-Drug
gtt	O
at	O
15	O
mcg	O
/	O
hr	O
.	O
.	O
Was	O
diagnosed	O
w	O
/	O
afib	O
about	O
a	O
week	O
ago	O
.	O
Had	O
a	O
persistent	O
chest	O
cold	O
for	O
approx.	O
3	O
weeks	O
,	O
went	O
to	O
see	O
his	O
PCP	O
who	O
examined	O
him	O
and	O
found	O
him	O
to	O
be	O
in	O
rapid	O
afib	O
w	O
/	O
HR	O
of	O
170s	O
by	O
EKG	O
.	O
From	O
his	O
PCP	O
's	O
office	O
,	O
he	O
was	O
sent	O
to	O
the	O
ER	O
at	O
[	O
**	O
Hospital6	O
**	O
]	O
.	O
He	O
was	O
admitted	O
and	O
was	O
finally	O
rate	B-Reason
controlled	I-Reason
in	O
the	O
ED	O
(	O
to	O
HR	O
of	O
96	O
)	O
after	O
35	O
mg	O
IV	O
diltiazem	I-Drug
and	O
60	O
mg	O
PO	O
diltiazem	I-Drug
.	O
Was	O
d	O
/	O
c	O
on	O
atenolol	I-Drug
and	O
diltiazem	I-Drug
on	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
and	O
represented	O
to	O
the	O
ER	O
on	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
via	O
EMS	O
because	O
of	O
SOB	O
,	O
lightheadedness	O
,	O
and	O
3	O
episodes	O
of	O
chest	O
pressure	O
at	O
home	O
.	O
He	O
was	O
observed	O
overnight	O
,	O
r	O
/	O
o	O
MI	O
by	O
3	O
sets	O
of	O
neg	O
CE	O
and	O
had	O
a	O
stress	O
test	O
which	O
was	O
negative	O
.	O
He	O
was	O
then	O
sent	O
home	O
on	O
[	O
**	O
1	O
-	O
1	O
**	O
]	O
.	O
He	O
decided	O
at	O
that	O
point	O
that	O
perhaps	O
his	O
symptoms	O
were	O
due	O
to	O
his	O
warfarin	I-Drug
so	O
he	O
started	O
taking	O
2	O
mg	O
QHS	O
instead	O
of	O
5	O
mg	O
QHS	O
as	O
instructed	O
.	O
He	O
continued	O
to	O
take	O
the	O
atenolol	I-Drug
and	O
diltiazem	I-Drug
as	O
instructed	O
.	O
Today	O
,	O
he	O
felt	O
well	O
when	O
he	O
woke	O
up	O
but	O
began	O
to	O
have	O
symptoms	O
of	O
lightheadedness	O
,	O
SOB	O
,	O
and	O
leg	O
heaviness	O
about	O
an	O
hour	O
after	O
he	O
took	O
his	O
medications	O
.	O
He	O
went	O
to	O
his	O
PCP	O
's	O
office	O
,	O
as	O
he	O
had	O
a	O
previously	O
scheduled	O
appointment	O
,	O
and	O
she	O
called	O
EMS	O
who	O
brought	O
him	O
here	O
.	O
.	O
ROS	O
:	O
denies	O
CP	O
,	O
palpitations	O
,	O
headache	O
,	O
nausea	O
,	O
vomiting	O
or	O
any	O
sort	O
of	O
pain	O
associated	O
w	O
/	O
these	O
episodes	O
;	O
no	O
PND	O
,	O
orthopnea	O
currently	O
(	O
though	O
did	O
complain	O
of	O
those	O
a	O
week	O
ago	O
)	O
;	O
no	O
f	O
/	O
c	O
,	O
no	O
further	O
symptoms	O
of	O
his	O
chest	O
cold	O
(	O
no	O
cough	O
,	O
rhinorrhea	O
or	O
sore	O
throat	O
)	O
;	O
no	O
diarrhea	O
,	O
constipation	O
or	O
BRBPR	O
,	O
no	O
urinary	O
sx	O
Past	O
Medical	O
History	O
:	O
Atrial	O
fibrillation	O
HTN	O
Hypercholesterolemia	O
Social	O
History	O
:	O
Lives	O
alone	O
.	O
Works	O
as	O
a	O
caterer	O
,	O
but	O
took	O
last	O
week	O
and	O
this	O
week	O
off	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
newly	O
dx	O
afib	O
and	O
generally	O
not	O
feeling	O
well	O
.	O
No	O
tob	O
,	O
occ	O
EtOH	O
(	O
had	O
been	O
taking	O
shots	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
help	O
w	O
/	O
his	O
cold	O
)	O
,	O
occ	O
marijuana	O
,	O
no	O
IVDU	O
,	O
no	O
cocaine	O
.	O
Has	O
two	O
brothers	O
,	O
one	O
of	O
whom	O
is	O
his	O
legal	O
next	O
of	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
(	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
#	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
107905	O
**	O
]	O
)	O
.	O
Family	O
History	O
:	O
+	O
CAD	O
.	O
M	O
has	O
a	O
pacermaker	O
,	O
F	O
had	O
a	O
CABG	O
around	O
age	O
60	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
96.5	O
,	O
BP	O
115/69	O
(	O
on	O
dopa	O
gtt	O
)	O
,	O
HR	O
70s	O
,	O
RR	O
14	O
,	O
sats	O
98	O
%	O
on	O
2L	O
Gen	O
:	O
WDWN	O
,	O
middle	O
aged	O
male	O
,	O
lying	O
in	O
bed	O
,	O
in	O
NAD	O
.	O
Ruddy	O
complexion	O
.	O
HEENT	O
:	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
OP	O
clear	O
,	O
no	O
exudates	O
or	O
lesions	O
.	O
MM	O
dry	O
.	O
Neck	O
:	O
R	O
IJ	O
line	O
in	O
,	O
can	O
not	O
assess	O
for	O
JVD	O
CV	O
:	O
RR	O
,	O
with	O
some	O
premature	O
beats	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
Lungs	O
:	O
few	O
scattered	O
insp	O
crackles	O
,	O
but	O
otherwise	O
CTAB	O
.	O
Abd	O
:	O
Soft	O
,	O
NTND	O
.	O
+	O
BS	O
.	O
No	O
masses	O
.	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
.	O
2	O
+	O
DP	O
,	O
radial	O
pulses	O
bilaterally	O
.	O
No	O
c	O
/	O
c	O
/	O
e.	O
Toes	O
w	O
/	O
onychomycosis	O
.	O
Skin	O
:	O
Warm	O
,	O
dry	O
.	O
Back	O
is	O
pink	O
,	O
blanching	O
,	O
but	O
pt	O
denies	O
that	O
it	O
's	O
pruritic	O
.	O
Does	O
not	O
extend	O
to	O
chest	O
or	O
abdomen	O
.	O
Neuro	O
:	O
CN	O
II	O
-	O
XII	O
grossly	O
intact	O
.	O
Pertinent	O
Results	O
:	O
Labs	O
on	O
admission	O
:	O
WBC	O
10.9	O
,	O
Hgb	O
17.0	O
,	O
Hct	O
47.5	O
,	O
MCV	O
88	O
,	O
Plt	O
360	O
(	O
DIFF	O
:	O
Neuts	O
-	O
74.2	O
*	O
Lymphs	O
-	O
18.6	O
Monos	O
-	O
5.2	O
Eos	O
-	O
0.9	O
Baso	O
-	O
1.1	O
)	O
PT	O
13.6	O
*	O
,	O
PTT	O
25.0	O
,	O
INR	O
(	O
PT	O
)	O
1.2	O
*	O
Na	O
138	O
,	O
K	O
5.8	O
,	O
Cl	O
102	O
,	O
HCO3	O
28	O
,	O
BUN	O
32	O
,	O
Cr	O
1.5	O
,	O
Glu	O
114	O
Ca	O
9.9	O
,	O
Ph	O
3.8	O
,	O
Mg	O
1.9	O
ALT	O
51	O
,	O
AST	O
34	O
,	O
AlkPhos	O
80	O
,	O
TBili	O
0.5	O
repeat	O
:	O
ALT	O
58	O
*	O
,	O
AST	O
31	O
TSH	O
1.7	O
.	O
Cardiac	O
enzymes	O
:	O
[	O
**	O
2163-1-3	O
**	O
]	O
11:55	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
52	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2163-1-3	O
**	O
]	O
05:45	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
49	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
.	O
Urinalysis	O
:	O
[	O
**	O
2163-1-3	O
**	O
]	O
09:40	O
PM	O
URINE	O
Color	O
-	O
Straw	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.006	O
Blood	O
-	O
NEG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
NEG	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.0	O
Leuks	O
-	O
NEG	O
RBC	O
-0-2	O
WBC	O
-	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
Bacteri	O
-	O
FEW	O
Yeast	O
-	O
NONE	O
Epi	O
-0-2	O
[	O
**	O
2163-1-3	O
**	O
]	O
09:40	O
PM	O
URINE	O
Hours	O
-	O
RANDOM	O
Creat	O
-	O
15	O
Na	O
-	O
98	O
.	O
Labs	O
on	O
discharge	O
:	O
WBC	O
10.4	O
,	O
Hgb	O
14.5	O
,	O
Hct	O
39.4	O
*	O
,	O
MCV	O
84	O
,	O
Plt	O
244	O
PT	O
24.0	O
*	O
,	O
INR	O
(	O
PT	O
)	O
2.4	O
*	O
Na	O
138	O
,	O
K	O
4.3	O
,	O
Cl	O
103	O
,	O
HCO3	O
25	O
,	O
BUN	O
21	O
,	O
Cr	O
1.2	O
,	O
Glu	O
102	O
,	O
Ca	O
9.2	O
,	O
Mg	O
1.9	O
,	O
Phos	O
4.3	O
.	O
Imaging	O
:	O
[	O
**	O
1	O
-	O
3	O
**	O
]	O
CXR	O
-	O
There	O
are	O
no	O
prior	O
studies	O
available	O
for	O
comparison	O
.	O
There	O
is	O
a	O
right	O
internal	O
jugular	O
vein	O
line	O
,	O
with	O
its	O
tip	O
at	O
the	O
superior	O
vena	O
cava	O
/	O
right	O
atrial	O
junction	O
.	O
No	O
pneumothorax	O
is	O
seen	O
.	O
The	O
heart	O
size	O
is	O
at	O
the	O
upper	O
limits	O
of	O
normal	O
for	O
technique	O
.	O
The	O
pulmonary	O
vascularity	O
is	O
normal	O
in	O
appearance	O
without	O
redistribution	O
.	O
No	O
pleural	O
effusions	O
are	O
seen	O
,	O
though	O
the	O
extreme	O
right	O
costophrenic	O
angle	O
has	O
been	O
excluded	O
from	O
the	O
study	O
.	O
There	O
are	O
no	O
focal	O
consolidations	O
.	O
.	O
[	O
**	O
2163-1-5	O
**	O
]	O
TEE	O
-	O
1	O
.	O
The	O
left	O
atrium	O
is	O
dilated	O
.	O
No	O
spontaneous	O
echo	O
contrast	O
or	O
thrombus	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
/	O
left	O
atrial	O
appendage	O
or	O
the	O
body	O
of	O
the	O
right	O
atrium	O
/	O
right	O
atrial	O
appendage	O
.	O
The	O
right	O
atrium	O
is	O
dilated	O
.	O
2	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
The	O
left	O
ventricular	O
function	O
is	O
hard	O
to	O
assess	O
given	O
that	O
the	O
ventricular	O
rate	O
is	O
very	O
rapid	O
but	O
there	O
is	O
probably	O
moderate	O
global	O
left	O
ventricular	O
hypokinesis	O
with	O
an	O
EF	O
of	O
35	O
-	O
40	O
%	O
.	O
3	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
Right	O
ventricular	O
systolic	O
function	O
is	O
borderline	O
normal	O
.	O
4	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
5	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
6	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
IMPRESSION	O
:	O
No	O
thrombus	O
in	O
the	O
left	O
or	O
right	O
atria	O
.	O
Moderate	O
global	O
left	O
ventricular	O
hypokinesis	O
.	O
Brief	O
Hospital	O
Course	O
:	O
51yo	O
M	O
w	O
/	O
hypotension	I-Ade
and	O
bradycardia	I-Ade
,	O
likely	O
in	O
setting	O
of	O
CCB	I-Drug
and	O
BB	I-Drug
for	O
his	O
newly	O
diagnosed	O
afib	I-Reason
.	O
.	O
#	O
CV	O
:	O
*	O
Rhythm	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
107906	O
**	O
]	O
bradycardia	I-Ade
was	O
likely	O
due	O
to	O
excessive	O
nodal	B-Drug
blockade	I-Drug
from	O
CCB	I-Drug
and	O
BB	I-Drug
since	O
he	O
recovered	O
his	O
rate	O
and	O
BP	O
off	O
all	O
nodal	O
blocking	O
agents	O
.	O
He	O
then	O
went	O
back	O
into	O
rapid	O
afib	O
,	O
with	O
HR	O
up	O
to	O
160s	O
despite	O
the	O
addition	O
of	O
BB	I-Drug
.	O
His	O
BP	O
remained	O
stable	O
so	O
the	O
decision	O
was	O
made	O
to	O
attempt	O
cardioversion	O
.	O
TEE	O
showed	O
no	O
clot	O
and	O
DCCV	O
was	O
attempted	O
but	O
he	O
was	O
only	O
able	O
to	O
maintain	O
NSR	O
for	O
~	O
30	O
sec	O
.	O
He	O
continued	O
to	O
be	O
in	O
afib	B-Reason
w	I-Reason
/	I-Reason
RVR	I-Reason
,	O
with	O
a	O
rate	O
as	O
high	O
as	O
160	O
-	O
170	O
.	O
Diltiazem	I-Drug
30	O
mg	O
PO	O
QID	O
was	O
added	O
,	O
still	O
with	O
insufficient	O
control	O
of	O
his	O
rate	O
.	O
The	O
diltiazem	I-Drug
dose	O
was	O
then	O
increased	O
to	O
60	O
mg	O
TID	O
on	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
due	O
to	O
persistent	B-Reason
tachycardia	I-Reason
with	O
good	O
effect	O
on	O
his	O
rate	O
.	O
EP	O
was	O
consulted	O
to	O
help	O
guide	O
the	O
management	O
of	O
his	O
arrhythmia	O
and	O
they	O
recommended	O
discontinuing	O
his	O
diltiazem	I-Drug
and	O
instead	O
attempting	O
to	O
control	B-Reason
his	I-Reason
rhythm	I-Reason
(	I-Reason
and	I-Reason
rate	I-Reason
)	I-Reason
with	O
amiodarone	I-Drug
.	O
He	O
was	O
started	O
on	O
400	O
mg	O
PO	O
TID	O
x1	O
week	O
,	O
with	O
the	O
plan	O
to	O
decrease	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
dosing	O
x1	O
week	O
then	O
QD	O
dosing	O
.	O
Once	O
he	O
had	O
received	O
an	O
adequate	O
amiodarone	I-Drug
load	O
,	O
the	O
plan	O
was	O
to	O
attempt	O
another	O
DCCV	O
as	O
an	O
outpatient	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
discussed	O
this	O
plan	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
73	O
**	O
]	O
who	O
also	O
wanted	O
him	O
to	O
wear	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
of	O
Hearts	O
monitor	O
upon	O
discharge	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
instructed	O
in	O
the	O
use	O
of	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
of	O
Hearts	O
monitor	O
and	O
was	O
told	O
to	O
send	O
in	O
rhythm	O
strips	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
73	O
**	O
]	O
daily	O
,	O
so	O
his	O
rate	O
and	O
his	O
intervals	O
could	O
be	O
monitored	O
daily	O
.	O
Despite	O
the	O
initiation	O
of	O
amiodarone	I-Drug
,	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
also	O
needed	O
a	O
beta	B-Drug
-	I-Drug
blocker	I-Drug
to	O
keep	O
his	B-Reason
rate	I-Reason
under	I-Reason
control	O
.	O
His	O
beta	B-Drug
-	I-Drug
blocker	I-Drug
was	O
slowly	O
increased	O
up	O
to	O
75	O
mg	O
PO	O
QID	O
and	O
was	O
then	O
switched	O
to	O
Toprol	I-Drug
XL	O
300	O
mg	O
PO	O
QD	O
prior	O
to	O
discharge	O
.	O
The	O
Toprol	I-Drug
XL	O
and	O
amiodarone	I-Drug
allowed	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
to	O
achieve	B-Reason
a	I-Reason
resting	I-Reason
heart	I-Reason
rate	I-Reason
of	I-Reason
90	I-Reason
-	I-Reason
100s	I-Reason
.	O
Coumadin	I-Drug
was	O
started	O
on	O
[	O
**	O
1	O
-	O
4	O
**	O
]	O
with	O
a	O
goal	O
INR	O
of	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
.	O
He	O
was	O
kept	O
on	O
a	O
heparin	I-Drug
gtt	O
until	O
his	O
INR	O
was	O
therapeutic	O
.	O
He	O
was	O
discharged	O
on	O
3	O
mg	O
of	O
coumadin	I-Drug
daily	O
,	O
and	O
his	O
INR	O
on	O
discharge	O
was	O
2.4	O
.	O
.	O
*	O
Pump	O
:	O
Although	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
had	O
no	O
evidence	O
of	O
heart	O
failure	O
by	O
exam	O
(	O
lungs	O
were	O
CTAB	O
and	O
his	O
JVP	O
was	O
flat	O
)	O
,	O
his	O
OSH	O
ECHO	O
and	O
TEE	O
here	O
showed	O
a	O
depressed	O
EF	O
.	O
After	O
receiving	O
IVF	I-Drug
in	O
the	O
ER	O
,	O
he	O
had	O
some	O
swelling	O
in	O
his	O
hands	O
and	O
feet	O
which	O
resolved	O
on	O
its	O
own	O
.	O
He	O
never	O
required	O
diuresis	I-Reason
with	O
lasix	I-Drug
.	O
.	O
*	O
Ischemia	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
has	O
no	O
evidence	O
of	O
ischemia	O
.	O
His	O
CE	O
enzymes	O
were	O
negative	O
x2	O
.	O
EKG	O
has	O
no	O
evidence	O
of	O
ST	O
or	O
T	O
wave	O
changes	O
.	O
.	O
#	O
ARF	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
in	O
mild	O
ARF	O
on	O
admission	O
,	O
w	O
/	O
Cr	O
of	O
1.5	O
and	O
K	O
of	O
5.8	O
.	O
It	O
resolved	O
after	O
receiving	O
several	O
liters	O
of	O
IVF	I-Drug
in	O
the	O
ER	O
.	O
It	O
was	O
most	O
likely	O
prerenal	O
+	O
/	O
-	O
ATN	O
from	O
hypotension	O
.	O
His	O
Cr	O
was	O
1.2	O
on	O
discharge	O
(	O
lowest	O
value	O
was	O
1.0	O
during	O
his	O
stay	O
)	O
.	O
.	O
#	O
FEN	O
:	O
He	O
follwed	O
a	O
regular	O
heart	O
-	O
healthy	O
diet	O
.	O
No	O
IVF	I-Drug
were	O
needed	O
.	O
His	O
electrolytes	O
were	O
checked	O
daily	O
and	O
were	O
repleted	O
prn	O
to	O
keep	O
K	O
>	O
4	O
and	O
Mg	O
>	O
2	O
.	O
.	O
#	O
ACCESS	O
:	O
He	O
had	O
a	O
centrail	O
line	O
(	O
R	O
IJ	O
)	O
placed	O
in	O
the	O
ER	O
initially	O
,	O
but	O
it	O
was	O
pulled	O
after	O
TEE	O
/	O
DCCV	O
.	O
He	O
then	O
had	O
peripheral	O
IVs	O
for	O
IV	O
access	O
.	O
.	O
#	O
PPX	I-Reason
:	O
He	O
was	O
on	O
heparin	I-Drug
gtt	O
as	O
a	O
bridge	O
to	O
coumadin	I-Drug
until	O
his	O
INR	O
was	O
therapeutic	O
.	O
He	O
had	O
a	O
bowel	O
regimen	O
.	O
No	O
PPI	I-Drug
was	O
indicated	O
.	O
.	O
#	O
CODE	O
:	O
FULL	O
.	O
#	O
DISPO	O
:	O
To	O
home	O
,	O
with	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
of	O
Hearts	O
monitor	O
.	O
Will	O
follow	O
up	O
in	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
107907	O
**	O
]	O
office	O
for	O
INR	O
checks	O
.	O
.	O
#	O
COMMUNICATION	O
:	O
brother	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
=	O
ph	O
#	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
107905	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
Atenolol	I-Drug
50	O
mg	O
PO	O
QD	O
Diltiazem	I-Drug
CD	O
240	O
mg	O
PO	O
QD	O
Warfarin	I-Drug
5	O
mg	O
PO	O
QHS	O
Discharge	O
Medications	O
:	O
1	O
.	O
Coumadin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
:	O
Please	O
take	O
400	O
mg	O
(	O
2	O
tablets	O
)	O
three	O
times	O
a	O
day	O
for	O
4	O
more	O
days	O
.	O
Starting	O
on	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
,	O
take	O
2	O
tablets	O
(	O
400	O
mg	O
)	O
twice	O
a	O
day	O
for	O
one	O
week	O
.	O
Starting	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
,	O
please	O
take	O
2	O
tablets	O
(	O
400	O
mg	O
)	O
once	O
a	O
day	O
.	O
.	O
Disp	O
:	O
*	O
100	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Metoprolol	I-Drug
Succinate	O
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
diagnosis	O
:	O
Symptomatic	B-Ade
bradycardia	I-Ade
and	O
hypotension	I-Ade
secondary	O
to	O
high	O
dose	O
atenolol	I-Drug
and	O
diltiazem	I-Drug
therapy	O
Acute	O
renal	O
failure	O
.	O
Secondary	O
diagnoses	O
:	O
Atrial	O
fibrillation	O
Hypertension	O
Hypercholesterolemia	O
Discharge	O
Condition	O
:	O
Good	O
.	O
HR	O
100s	O
,	O
BP	O
123/98	O
,	O
RR	O
20	O
,	O
sats	O
97	O
%	O
on	O
RA	O
.	O
Discharge	O
Instructions	O
:	O
1	O
.	O
Please	O
call	O
your	O
PCP	O
or	O
go	O
to	O
the	O
nearest	O
ER	O
if	O
if	O
you	O
develop	O
symptoms	O
of	O
dizziness	O
,	O
lightheadedness	O
,	O
weakness	O
,	O
malaise	O
,	O
chest	O
pain	O
/	O
pressure	O
,	O
shortness	O
of	O
breath	O
,	O
leg	O
heaviness	O
,	O
nausea	O
,	O
vomiting	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
2	O
.	O
Please	O
take	O
all	O
your	O
medications	O
as	O
prescribed	O
.	O
3	O
.	O
Please	O
send	O
in	O
a	O
transmission	O
from	O
your	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
of	O
Hearts	O
monitor	O
every	O
day	O
.	O
4	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
weeks	O
for	O
follow	O
-	O
up	O
from	O
your	O
hospitalization	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
You	O
will	O
require	O
blood	O
work	O
to	O
be	O
completed	O
at	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
107907	O
**	O
]	O
office	O
in	O
2	O
to	O
3	O
days	O
(	O
no	O
later	O
than	O
Wednesday	O
)	O
to	O
ensure	O
your	O
INR	O
is	O
therapeutic	O
with	O
your	O
current	O
coumadin	I-Drug
(	O
warfarin	I-Drug
)	O
dosing	O
.	O
2	O
.	O
You	O
should	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
weeks	O
.	O
Please	O
call	O
her	O
office	O
on	O
Monday	O
to	O
make	O
an	O
appointment	O
at	O
your	O
convenience	O
.	O
You	O
should	O
have	O
hepatitis	O
serologies	O
drawn	O
to	O
insure	O
that	O
your	O
elevated	O
liver	O
enzymes	O
are	O
not	O
due	O
to	O
hepatitis	O
infection	O
.	O
You	O
should	O
also	O
have	O
PFTs	O
scheduled	O
since	O
you	O
are	O
starting	O
on	O
amiodarone	I-Drug
.	O
3	O
.	O
Please	O
contact	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
73	O
**	O
]	O
,	O
phone	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1920	O
**	O
]	O
,	O
to	O
schedule	O
a	O
follow	O
up	O
appointment	O
in	O
4	O
weeks	O
for	O
further	O
management	O
of	O
your	O
atrial	O
fibrillation	O
.	O
4	O
.	O
Please	O
send	O
in	O
a	O
tracing	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
73	O
**	O
]	O
every	O
day	O
from	O
your	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
of	O
Hearts	O
monitor	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2173-8-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2173-8-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2114-1-5	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
clindamycin	B-Drug
HCl	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
23497	O
**	O
]	O
Chief	O
Complaint	O
:	O
Weakness	O
and	O
fatigue	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
59M	O
w	O
/	O
pmhx	O
CHF	O
(	O
last	O
EF	O
55	O
-	O
60	O
%	O
)	O
,	O
afib	O
,	O
elevated	O
LFTs	O
,	O
chronic	O
LE	O
wounds	O
(	O
recent	O
admission	O
for	O
cellulitis	O
on	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
)	O
,	O
hx	O
of	O
PE	O
and	O
atrial	O
thrombus	O
,	O
presented	O
to	O
clinic	O
today	O
for	O
F	O
/	O
U.	O
Pt	O
had	O
hx	O
of	O
multiple	O
missed	O
appointments	O
and	O
F	O
/	O
U	O
labs	O
were	O
drawn	O
today	O
.	O
Reported	O
losing	O
~	O
20	O
lbs	O
within	O
the	O
past	O
month	O
.	O
Pt	O
appeared	O
euvolemic	O
and	O
had	O
extensive	B-Reason
chronic	I-Reason
LE	I-Reason
ulcerations	I-Reason
(	O
pt	O
was	O
seen	O
in	O
vascular	O
clinic	O
immediately	O
prior	O
to	O
general	O
medicine	O
appointment	O
and	O
was	O
started	O
on	O
Keflex	I-Drug
)	O
.	O
Referred	O
to	O
ED	O
due	O
to	O
hyponatremia	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
found	O
on	O
labs	O
.	O
On	O
presentation	O
to	O
the	O
emergency	O
Department	O
the	O
patient	O
reports	O
that	O
he	O
has	O
had	O
occasional	O
exertional	O
shortness	O
of	O
breath	O
,	O
reports	O
no	O
symptoms	O
at	O
rest	O
.	O
He	O
denies	O
chest	O
pain	O
at	O
any	O
point	O
.	O
He	O
reports	O
that	O
due	O
to	O
neuropathy	O
he	O
has	O
n't	O
felt	O
any	O
pain	O
in	O
his	O
leg	O
ulcers	O
but	O
notices	O
that	O
they	O
are	O
significantly	O
more	O
erythematous	O
and	O
draining	O
more	O
fluid	O
.	O
Additionally	O
he	O
reports	O
that	O
he	O
has	O
not	O
taken	O
any	O
of	O
his	O
A.	O
fib	O
medications	O
for	O
several	O
days	O
.	O
In	O
the	O
ED	O
his	O
initial	O
vitals	O
were	O
98.4	O
13090/52	O
18	O
100	O
.	O
An	O
EKG	O
showed	O
afib	O
@	O
115	O
,	O
NA	O
,	O
lateral	O
minimal	O
stdep	O
likely	O
demand	O
related	O
.	O
no	O
STE	O
.	O
He	O
recieved	O
1L	O
NS	I-Drug
and	O
was	O
restarted	O
on	O
his	O
metorolol	I-Drug
and	O
diltiazem	I-Drug
.	O
His	O
digoxin	I-Drug
was	O
held	O
.	O
Past	O
Medical	O
History	O
:	O
CARDIAC	O
HISTORY	O
:	O
-	O
Afib	O
-	O
noted	O
first	O
during	O
admission	O
[	O
**	O
1	O
-	O
/	O
2171	O
**	O
]	O
;	O
initial	O
TEE	O
CV	O
aborted	O
due	O
to	O
left	O
atrial	O
thrombus	O
;	O
s	O
/	O
p	O
DCCV	O
[	O
**	O
2171-4-11	O
**	O
]	O
.	O
-	O
Systolic	O
CHF	O
/	O
nonischemic	O
dilated	O
cardiomyopathy	O
-	O
thought	O
due	O
to	O
tachymyopathy	O
.	O
Recent	O
EF	O
40	O
%	O
(	O
[	O
**	O
3	O
-	O
/	O
2171	O
**	O
]	O
)	O
-	O
PFO	O
(	O
noted	O
on	O
TEE	O
)	O
-	O
HTN	O
Other	O
Past	O
History	O
:	O
-	O
Pulmonary	O
embolus	O
(	O
noted	O
on	O
CT	O
[	O
**	O
1	O
-	O
/	O
2171	O
**	O
]	O
)	O
-	O
Anxiety	O
-	O
S	O
/	O
p	O
hernia	O
repair	O
,	O
pt	O
describes	O
complicated	O
course	O
of	O
what	O
sounds	O
like	O
dehiscence	O
and	O
redo	O
x2	O
with	O
mesh	O
placement	O
,	O
last	O
in	O
12	O
/	O
[	O
**	O
2168	O
**	O
]	O
.	O
-	O
Seasonal	O
allergies	O
Social	O
History	O
:	O
He	O
is	O
single	O
and	O
lives	O
alone	O
.	O
He	O
worked	O
as	O
a	O
painter	O
at	O
[	O
**	O
Hospital1	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
620	O
**	O
]	O
,	O
still	O
out	O
of	O
work	O
.	O
He	O
is	O
a	O
lifetime	O
nonsmoker	O
and	O
denies	O
illicit	O
drug	O
use	O
.	O
he	O
does	O
drink	O
approximately	O
[	O
**	O
12	O
-	O
28	O
**	O
]	O
bottle	O
of	O
wine	O
about	O
3	O
times	O
weekly	O
and	O
"	O
a	O
few	O
beers	O
"	O
from	O
time	O
to	O
time	O
with	O
friends	O
.	O
Family	O
History	O
:	O
Father	O
:	O
h	O
/	O
o	O
CVA	O
Mother	O
:	O
h	O
/	O
o	O
heart	O
disease	O
,	O
arrythmia	O
and	O
had	O
a	O
pacer	O
.	O
Deceased	O
82yo	O
.	O
Physical	O
Exam	O
:	O
ADMIT	O
EXAM	O
:	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
EOMI	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
s	O
/	O
p	O
DP	O
amutation	O
of	O
left	O
great	O
toe	O
,	O
venous	O
stasis	O
dermatitis	O
with	O
possible	O
super	O
infection	O
bilaterally	O
Neuro	O
:	O
CNII	O
-	O
XII	O
intact	O
,	O
5/5	O
strength	O
upper	O
/	O
lower	O
extremities	O
,	O
grossly	O
normal	O
sensation	O
,	O
2	O
+	O
reflexes	O
bilaterally	O
,	O
gait	O
deferred	O
.	O
DISCHARGE	O
EXAM	O
:	O
VS	O
:	O
99.7	O
112/62	O
100	O
18	O
96	O
%	O
RA	O
Gen	O
:	O
awake	O
,	O
alert	O
,	O
resting	O
comfortably	O
in	O
chair	O
,	O
NAD	O
HEENT	O
:	O
sclera	O
anicteric	O
,	O
MMM	O
CV	O
:	O
RRR	O
Lungs	O
:	O
CTAB	O
,	O
no	O
wheezes	O
/	O
rales	O
/	O
rhonchi	O
Abd	O
:	O
bowel	O
sounds	O
present	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
Ext	O
:	O
bilateral	O
pedal	O
edema	O
,	O
venous	O
stasis	O
changes	O
,	O
legs	O
wrapped	O
in	O
ACE	O
bandages	O
Pertinent	O
Results	O
:	O
IMAGING	O
:	O
CXR	O
[	O
**	O
2173-8-3	O
**	O
]	O
-	O
FINDINGS	O
AND	O
IMPRESSION	O
:	O
The	O
lungs	O
are	O
clear	O
.	O
No	O
pleural	O
effusion	O
,	O
pulmonary	O
edema	O
or	O
pneumothorax	O
is	O
present	O
.	O
Mild	O
cardiomegaly	O
is	O
unchanged	O
.	O
MICRO	O
/	O
PATH	O
:	O
[	O
**	O
2173-8-3	O
**	O
]	O
BLOOD	O
CULTURES	O
X	O
2	O
-	O
no	O
growth	O
to	O
date	O
after	O
5	O
days	O
.	O
ADMIT	O
LABS	O
:	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
WBC	O
-	O
15.1	O
*	O
RBC	O
-	O
3.29	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
30.6	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.9	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
15.6	O
*	O
Plt	O
Ct	O
-	O
289	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
Neuts	O
-	O
93	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
5	O
*	O
Monos	O
-	O
1	O
*	O
Eos	O
-	O
1	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
NORMAL	O
Poiklo	O
-	O
NORMAL	O
Macrocy	O
-	O
1	O
+	O
Microcy	O
-	O
NORMAL	O
Polychr	O
-	O
NORMAL	O
[	O
**	O
2173-8-2	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
PT	O
-	O
15.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.5	O
*	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
UreaN	O
-	O
60	O
*	O
Creat	O
-	O
3.4	O
*	O
#	O
Na	O
-	O
120	O
*	O
K	O
-	O
4.6	O
Cl	O
-	O
80	O
*	O
HCO3	O
-	O
24	O
AnGap	O
-	O
21	O
*	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
Glucose	O
-	O
102	O
*	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
ALT	O
-	O
33	O
AST	O
-	O
36	O
CK	O
(	O
CPK	O
)	O
-	O
46	O
*	O
AlkPhos	O
-	O
162	O
*	O
TotBili	O
-	O
0.9	O
[	O
**	O
2173-8-2	O
**	O
]	O
04:15	O
PM	O
BLOOD	O
Albumin	O
-	O
3.6	O
Calcium	O
-	O
9.1	O
Cholest	O
-	O
141	O
RELEVANT	O
LABS	O
:	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
WBC	O
-	O
12.7	O
*	O
RBC	O
-	O
3.08	O
*	O
Hgb	O
-	O
10.0	O
*	O
Hct	O
-	O
28.8	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
32.5	O
*	O
MCHC	O
-	O
34.7	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
272	O
[	O
**	O
2173-8-3	O
**	O
]	O
05:13	O
AM	O
BLOOD	O
WBC	O
-	O
10.7	O
RBC	O
-	O
2.99	O
*	O
Hgb	O
-	O
10.0	O
*	O
Hct	O
-	O
28.1	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
33.3	O
*	O
MCHC	O
-	O
35.5	O
*	O
RDW	O
-	O
15.7	O
*	O
Plt	O
Ct	O
-	O
224	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
Neuts	O
-	O
82.3	O
*	O
Lymphs	O
-	O
10.2	O
*	O
Monos	O
-	O
6.3	O
Eos	O
-	O
0.9	O
Baso	O
-	O
0.3	O
[	O
**	O
2173-8-3	O
**	O
]	O
05:13	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
224	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
Glucose	O
-	O
104	O
*	O
UreaN	O
-	O
58	O
*	O
Creat	O
-	O
3.0	O
*	O
Na	O
-	O
118	O
*	O
K	O
-	O
4.6	O
Cl	O
-	O
85	O
*	O
HCO3	O
-	O
20	O
*	O
AnGap	O
-	O
18	O
[	O
**	O
2173-8-3	O
**	O
]	O
05:13	O
AM	O
BLOOD	O
Glucose	O
-	O
91	O
UreaN	O
-	O
55	O
*	O
Creat	O
-	O
2.5	O
*	O
Na	O
-	O
119	O
*	O
K	O
-	O
4.5	O
Cl	O
-	O
86	O
*	O
HCO3	O
-	O
24	O
AnGap	O
-	O
14	O
[	O
**	O
2173-8-3	O
**	O
]	O
07:00	O
AM	O
BLOOD	O
Glucose	O
-	O
132	O
*	O
UreaN	O
-	O
58	O
*	O
Creat	O
-	O
2.8	O
*	O
Na	O
-	O
120	O
*	O
K	O
-	O
4.0	O
Cl	O
-	O
85	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
17	O
[	O
**	O
2173-8-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
Glucose	O
-	O
131	O
*	O
UreaN	O
-	O
55	O
*	O
Creat	O
-	O
2.3	O
*	O
Na	O
-	O
124	O
*	O
K	O
-	O
4.1	O
Cl	O
-	O
89	O
*	O
HCO3	O
-	O
23	O
AnGap	O
-	O
16	O
[	O
**	O
2173-8-3	O
**	O
]	O
07:53	O
PM	O
BLOOD	O
Glucose	O
-	O
136	O
*	O
UreaN	O
-	O
52	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
123	O
*	O
K	O
-	O
5.6	O
*	O
Cl	O
-	O
91	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
16	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
ALT	O
-	O
33	O
AST	O
-	O
35	O
LD	O
(	O
LDH	O
)	O
-	O
333	O
*	O
AlkPhos	O
-	O
163	O
*	O
TotBili	O
-	O
0.8	O
[	O
**	O
2173-8-3	O
**	O
]	O
05:13	O
AM	O
BLOOD	O
ALT	O
-	O
29	O
AST	O
-	O
32	O
LD	O
(	O
LDH	O
)	O
-	O
283	O
*	O
AlkPhos	O
-	O
146	O
*	O
TotBili	O
-	O
0.9	O
[	O
**	O
2173-8-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
ALT	O
-	O
25	O
AST	O
-	O
25	O
LD	O
(	O
LDH	O
)	O
-	O
265	O
*	O
AlkPhos	O
-	O
137	O
*	O
TotBili	O
-	O
0.7	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
proBNP	O
-	O
1588	O
*	O
[	O
**	O
2173-8-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
proBNP	O
-	O
1666	O
*	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
ALT	O
-	O
33	O
AST	O
-	O
35	O
LD	O
(	O
LDH	O
)	O
-	O
333	O
*	O
AlkPhos	O
-	O
163	O
*	O
TotBili	O
-	O
0.8	O
[	O
**	O
2173-8-3	O
**	O
]	O
05:13	O
AM	O
BLOOD	O
ALT	O
-	O
29	O
AST	O
-	O
32	O
LD	O
(	O
LDH	O
)	O
-	O
283	O
*	O
AlkPhos	O
-	O
146	O
*	O
TotBili	O
-	O
0.9	O
[	O
**	O
2173-8-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
ALT	O
-	O
25	O
AST	O
-	O
25	O
LD	O
(	O
LDH	O
)	O
-	O
265	O
*	O
AlkPhos	O
-	O
137	O
*	O
TotBili	O
-	O
0.7	O
[	O
**	O
2173-8-3	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
proBNP	O
-	O
1588	O
*	O
[	O
**	O
2173-8-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
proBNP	O
-	O
1666	O
*	O
[	O
**	O
2173-8-3	O
**	O
]	O
07:00	O
AM	O
BLOOD	O
Calcium	O
-	O
8.3	O
*	O
Phos	O
-	O
3.8	O
Mg	O
-	O
1.5	O
*	O
[	O
**	O
2173-8-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
Albumin	O
-	O
3.2	O
*	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
3.6	O
Mg	O
-	O
2.6	O
[	O
**	O
2173-8-3	O
**	O
]	O
07:53	O
PM	O
BLOOD	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
3.6	O
Mg	O
-	O
2.5	O
DISCHARGE	O
LABS	O
:	O
[	O
**	O
2173-8-8	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
WBC	O
-	O
10.0	O
RBC	O
-	O
2.65	O
*	O
Hgb	O
-	O
8.4	O
*	O
Hct	O
-	O
25.6	O
*	O
MCV	O
-	O
97	O
MCH	O
-	O
31.9	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
252	O
[	O
**	O
2173-8-8	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Glucose	O
-	O
99	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.9	O
Na	O
-	O
134	O
K	O
-	O
4.2	O
Cl	O
-	O
97	O
HCO3	O
-	O
27	O
AnGap	O
-	O
14	O
[	O
**	O
2173-8-8	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
3.6	O
Mg	O
-	O
1.6	O
[	O
**	O
2173-8-8	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
PT	O
-	O
15.0	O
*	O
PTT	O
-	O
28.2	O
INR	O
(	O
PT	O
)	O
-	O
1.4	O
*	O
Brief	O
Hospital	O
Course	O
:	O
59	O
year	O
old	O
male	O
with	O
a	O
past	O
medical	O
history	O
of	O
systolic	O
congestive	O
heart	O
failure	O
(	O
last	O
EF	O
55	O
-	O
60	O
%	O
)	O
,	O
atrial	B-Reason
fibrillation	I-Reason
on	O
coumadin	I-Drug
,	O
transaminitis	O
secondary	O
to	O
cirrhosis	O
,	O
chronic	O
lower	O
extremity	O
stasis	O
dermatitis	O
(	O
recent	O
admission	O
for	O
cellulitis	O
on	O
[	O
**	O
2173-6-14	O
**	O
]	O
)	O
,	O
history	O
of	O
pulmonary	O
embolus	O
and	O
atrial	O
thrombus	O
who	O
presented	O
from	O
clinic	O
with	O
with	O
a	O
significant	O
hyponatremia	O
,	O
elevated	O
lactate	O
,	O
and	O
acute	O
kidney	O
injury	O
.	O
#	O
.	O
HYPONATREMIA	O
:	O
Etiology	O
was	O
likely	O
hypovolemic	B-Ade
hyponatremia	I-Ade
in	O
the	O
setting	O
of	O
over-aggressive	O
diuretic	I-Drug
use	O
and	O
decreased	O
dietary	O
intake	O
of	O
sodium	O
.	O
Patient	O
had	O
started	O
dieting	O
,	O
eating	O
less	O
salt	O
and	O
drinking	O
more	O
water	O
.	O
He	O
presented	O
with	O
hypotension	O
and	O
tachycardia	O
.	O
Patient	O
also	O
presented	O
with	O
acute	O
kidney	O
injury	O
,	O
elevated	O
lactate	O
,	O
fractional	O
excretion	O
of	O
sodium	O
less	O
than	O
1	O
,	O
low	O
urine	O
sodium	O
,	O
and	O
elevated	O
creatinine	O
and	O
BUN	O
all	O
suggesting	O
hypovolemic	B-Reason
hyponatremia	I-Reason
as	O
the	O
etiology	O
.	O
While	O
in	O
the	O
MICU	O
his	O
sodium	O
was	O
corrected	O
with	O
normal	B-Drug
saline	I-Drug
and	O
his	O
urine	O
and	O
serum	O
sodium	O
trended	O
.	O
Once	O
his	O
sodium	O
was	O
trending	O
upward	O
he	O
was	O
transferred	O
to	O
the	O
medicine	O
floor	O
.	O
His	O
torsemide	I-Drug
was	O
held	O
and	O
then	O
restarted	O
on	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
on	O
an	O
every	O
other	O
day	O
dosing	O
schedule	O
,	O
and	O
he	O
should	O
follow	O
up	O
with	O
his	O
PCP	O
for	O
repeat	O
lab	O
testing	O
.	O
#	O
HYPOTENSION	O
/	O
TACHYCARDIA	O
-	O
Though	O
initially	O
concerned	O
for	O
SIRS	O
/	O
sepsis	O
because	O
of	O
leukocytosis	O
on	O
admission	O
,	O
and	O
possible	O
source	O
of	O
infection	O
being	O
cellulitis	O
from	O
chronic	O
venous	O
stasis	O
ulcers	O
.	O
CXR	O
,	O
UA	O
,	O
blood	O
cultures	O
were	O
all	O
negative	O
for	O
signs	O
of	O
infection	O
.	O
He	O
did	O
not	O
have	O
fever	O
of	O
systemic	O
signs	O
of	O
infection	O
.	O
Initially	O
he	O
met	O
systemic	B-Reason
inflammatory	I-Reason
response	I-Reason
syndrome	O
criteria	O
with	O
a	O
possible	O
source	O
.	O
He	O
was	O
started	O
on	O
vancomycin	I-Drug
and	O
unasyn	I-Drug
empirically	O
.	O
On	O
re-evaluation	O
he	O
remained	O
afebrile	O
with	O
no	O
constitutional	O
symptoms	O
concerning	O
for	O
sepsis	O
.	O
His	O
vancomycin	I-Drug
and	O
unysin	I-Drug
was	O
discontinued	O
and	O
keflex	I-Drug
was	O
kept	O
on	O
per	O
his	O
vascular	O
physicians	O
prescription	O
.	O
Hypotension	O
was	O
likely	O
a	O
result	O
of	O
extracellular	O
volume	O
depletion	O
in	O
the	O
setting	O
of	O
overdiuresis	O
and	O
salt	O
restriction	O
as	O
above	O
,	O
with	O
a	O
reactive	O
tachycardia	O
.	O
Metoprolol	I-Drug
,	O
digoxin	I-Drug
,	O
and	O
diltiazem	I-Drug
were	O
held	O
for	O
hypotension	I-Ade
but	O
restarted	O
as	O
his	O
pressures	O
tolerated	O
them	O
.	O
He	O
was	O
monitored	O
on	O
telemetry	O
and	O
was	O
not	O
shown	O
to	O
have	O
any	O
atrial	O
fibrillation	O
with	O
RVR	O
.	O
However	O
,	O
he	O
had	O
asymptomatic	O
sinus	O
tachycardia	O
to	O
the	O
130	O
-	O
160s	O
during	O
physical	O
therapy	O
.	O
This	O
was	O
likely	O
because	O
his	O
home	O
medications	O
were	O
held	O
,	O
and	O
his	O
tachycardia	I-Reason
improved	O
upon	O
restarting	O
digoxin	I-Drug
,	O
metoprolol	I-Drug
,	O
and	O
diltiazem	I-Drug
at	O
his	O
home	O
doses	O
.	O
Torsemide	I-Drug
was	O
restarted	O
on	O
an	O
every	O
other	O
day	O
dosing	O
schedule	O
.	O
#	O
.	O
ATRIAL	B-Reason
FIBRILLATION	I-Reason
:	O
Chronic	O
issue	O
.	O
On	O
coumadin	I-Drug
,	O
metoprolol	I-Drug
,	O
diltizem	I-Drug
,	O
and	O
digoxin	I-Drug
at	O
home	O
.	O
In	O
the	O
MICU	O
,	O
he	O
became	O
mildly	O
hypotensive	I-Ade
(	O
sbp	O
in	O
90s	O
,	O
not	O
requiring	O
pressors	I-Drug
)	O
so	O
his	O
metoprolol	I-Drug
and	O
diltiazem	I-Drug
were	O
reduced	O
in	O
dose	O
.	O
Upon	O
trasnfer	O
to	O
floor	O
,	O
blood	O
pressure	O
was	O
stable	O
after	O
resuming	O
home	O
meidcations	O
and	O
metoprolol	I-Drug
was	O
uptitrates	O
in	O
setting	O
of	O
tachycardia	O
,	O
particularly	O
with	O
exertion	O
with	O
PT	O
.	O
He	O
should	O
follow	O
up	O
with	O
his	O
PCP	O
regarding	O
titration	O
of	O
his	B-Reason
rate	I-Reason
control	I-Reason
.	O
His	O
INR	B-Reason
was	I-Reason
subtherapeutic	O
,	O
so	O
his	O
warfarin	I-Drug
was	O
increased	O
to	O
6	O
mg	O
.	O
Digoxin	I-Drug
was	O
continued	O
and	O
level	O
was	O
not	O
toxic	O
.	O
#	O
.	O
Acute	B-Reason
kidney	I-Reason
injury	I-Reason
:	O
Likely	O
prerenal	O
and	O
related	O
to	O
hypoperfusion	O
in	O
the	O
setting	O
of	O
hypotension	I-Reason
.	O
creatinine	O
improved	O
with	O
holding	O
torsemide	I-Drug
and	O
administration	O
of	O
IVF	I-Drug
.	O
His	O
creatine	O
and	O
BUN	O
were	O
trended	O
and	O
his	O
creatine	O
trended	O
downward	O
with	O
IV	O
fluids	I-Drug
.	O
#	O
.	O
STASIS	B-Reason
DERMATITIS	I-Reason
WITH	O
POSSIBLE	O
SUPER	B-Reason
IMPOSED	I-Reason
CELLULITIS	I-Reason
:	O
While	O
in	O
the	O
MICU	O
he	O
did	O
not	O
spike	O
a	O
fever	O
or	O
appear	O
overtly	O
septic	O
by	O
exam	O
or	O
review	O
of	O
systems	O
.	O
His	O
leukocytosis	O
normalized	O
.	O
The	O
decision	O
was	O
made	O
to	O
leave	O
him	O
on	O
his	O
outpatient	O
dose	O
of	O
keflex	I-Drug
however	O
pending	O
follow	O
-	O
up	O
with	O
his	O
vascular	O
physician	O
.	O
#	O
.	O
CIRRHOSIS	O
:	O
This	O
is	O
a	O
diagnosis	O
that	O
is	O
currently	O
undergoing	O
outpatient	O
workup	O
.	O
He	O
did	O
not	O
appear	O
hypervolemic	O
and	O
this	O
was	O
not	O
likely	O
related	O
to	O
the	O
etiology	O
of	O
his	O
hyponatremia	O
.	O
He	O
denies	O
alcohol	O
abuse	O
and	O
is	O
reportedly	O
planning	O
on	O
undergoing	O
a	O
liver	O
biopsy	O
to	O
further	O
characterize	O
his	O
liver	O
disease	O
.	O
His	O
liver	O
function	O
was	O
monitored	O
while	O
in	O
the	O
MICU	O
and	O
remained	O
stable	O
,	O
and	O
no	O
further	O
management	O
of	O
his	O
possible	O
cirrhosis	O
was	O
performed	O
.	O
TRANSITIONAL	O
ISSUES	O
:	O
-	O
Vascular	O
,	O
renal	O
,	O
and	O
hepatic	O
follow	O
-	O
up	O
.	O
-	O
Should	O
f	O
/	O
u	O
with	O
PCP	O
regarding	O
torsemide	I-Drug
dosing	O
which	O
was	O
decreased	O
to	O
every	O
other	O
day	O
.	O
He	O
should	O
be	O
evaluated	O
for	O
less	O
aggressive	O
diuresis	O
if	O
has	O
bump	O
in	O
creatinine	O
.	O
-	O
He	O
should	O
follow	O
up	O
with	O
his	O
PCP	O
and	O
cardiology	O
regarding	O
titration	O
of	O
his	O
metoprolol	I-Drug
and	O
diltiazem	I-Drug
for	O
rate	B-Reason
control	I-Reason
.	O
-	O
Warfarin	I-Drug
increased	O
to	O
6	O
mg	O
at	O
discharge	O
as	O
his	O
INR	O
was	O
1.4	O
Medications	O
on	O
Admission	O
:	O
Preadmission	O
medications	O
listed	O
are	O
correct	O
and	O
complete	O
.	O
Information	O
was	O
obtained	O
from	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
581	O
**	O
]	O
.	O
1	O
.	O
Warfarin	I-Drug
2	O
mg	O
PO	O
DAILY16	O
2	O
.	O
Torsemide	I-Drug
50	O
mg	O
PO	O
DAILY	O
3	O
.	O
OxycoDONE	I-Drug
(	O
Immediate	O
Release	O
)	O
5	O
mg	O
PO	O
BID	O
:	O
PRN	O
pain	I-Reason
4	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
XL	I-Drug
50	O
mg	O
PO	O
DAILY	O
5	O
.	O
Latanoprost	I-Drug
0.005	O
%	O
Ophth	O
.	O
Soln	O
.	O
1	O
DROP	O
LEFT	O
EYE	O
HS	O
6	O
.	O
Diltiazem	I-Drug
Extended	O
-	O
Release	O
180	O
mg	O
PO	O
DAILY	O
7	O
.	O
Digoxin	I-Drug
0.125	O
mg	O
PO	O
DAILY	O
8	O
.	O
Cephalexin	I-Drug
500	O
mg	O
PO	O
Q6H	O
Discharge	O
Medications	O
:	O
1	O
.	O
Cephalexin	I-Drug
500	O
mg	O
PO	O
Q6H	O
2	O
.	O
Digoxin	I-Drug
0.125	O
mg	O
PO	O
DAILY	O
3	O
.	O
Latanoprost	I-Drug
0.005	O
%	O
Ophth	O
.	O
Soln	O
.	O
1	O
DROP	O
BOTH	O
EYES	O
HS	O
4	O
.	O
OxycoDONE	I-Drug
(	O
Immediate	O
Release	O
)	O
5	O
mg	O
PO	O
BID	O
:	O
PRN	O
pain	I-Reason
5	O
.	O
Oxycodone	B-Drug
SR	I-Drug
(	I-Drug
OxyconTIN	I-Drug
)	I-Drug
20	O
mg	O
PO	O
Q12H	O
6	O
.	O
Torsemide	I-Drug
20	O
mg	O
PO	O
EVERY	O
OTHER	O
DAY	O
please	O
hold	O
for	O
SBP	B-Ade
<	I-Ade
100	I-Ade
RX	O
*	O
Demadex	I-Drug
20	O
mg	O
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
every	O
other	O
day	O
Disp	O
#	O
*	O
15	O
Tablet	O
Refills	O
:	O
*	O
0	O
7	O
.	O
Warfarin	I-Drug
6	O
mg	O
PO	O
DAILY16	O
8	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
XL	I-Drug
100	O
mg	O
PO	O
DAILY	O
RX	O
*	O
metoprolol	B-Drug
succinate	I-Drug
100	O
mg	O
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Disp	O
#	O
*	O
30	O
Tablet	O
Refills	O
:	O
*	O
0	O
9	O
.	O
Diltiazem	I-Drug
Extended	O
-	O
Release	O
180	O
mg	O
PO	O
DAILY	O
10	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
check	O
INR	O
[	O
**	O
2173-8-9	O
**	O
]	O
and	O
send	O
results	O
to	O
[	O
**	O
Company	O
191	O
**	O
]	O
[	O
**	O
Hospital	O
3052	O
**	O
]	O
.	O
Phone	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2173	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Allcare	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Hyponatremia	O
,	O
acute	O
kidney	O
injury	O
Secondary	O
:	O
Atrial	O
fibrillation	O
,	O
chronic	O
systolic	O
congestive	O
heart	O
failure	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
10840	O
**	O
]	O
,	O
You	O
were	O
treated	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
low	O
sodium	O
and	O
decreased	O
kidney	O
function	O
.	O
Your	O
low	O
sodium	O
and	O
decreased	O
kidney	O
function	O
were	O
likely	O
caused	O
by	O
a	O
combination	O
of	O
not	O
eating	O
and	O
drinking	O
as	O
much	O
as	O
you	O
used	O
to	O
,	O
as	O
well	O
as	O
your	O
torsemide	I-Drug
diuretic	I-Drug
.	O
As	O
we	O
gave	O
you	O
fluid	O
and	O
discontinued	O
your	O
torsemide	I-Drug
,	O
your	O
sodium	O
level	O
improved	O
.	O
Please	O
restart	O
your	O
torsemide	I-Drug
,	O
but	O
at	O
a	O
lower	O
dose	O
.	O
Take	O
20	O
mg	O
every	O
other	O
day	O
until	O
you	O
see	O
your	O
cardiologist	O
and	O
primary	O
care	O
doctor	O
.	O
You	O
should	O
take	O
your	O
next	O
dose	O
on	O
Monday	O
[	O
**	O
2173-8-9	O
**	O
]	O
.	O
Your	O
kidney	O
function	O
also	O
improved	O
with	O
IV	O
fluids	I-Drug
,	O
and	O
is	O
now	O
normal	O
.	O
Please	O
have	O
your	O
INR	O
checked	O
on	O
Tuesday	O
[	O
**	O
2173-8-10	O
**	O
]	O
.	O
You	O
may	O
need	O
adjustment	O
in	O
your	O
coumadin	I-Drug
dose	O
.	O
For	O
now	O
,	O
you	O
should	O
take	O
6	O
mg	O
per	O
day	O
as	O
your	O
INR	O
is	O
low	O
.	O
Please	O
keep	O
the	O
appointments	O
listed	O
below	O
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
FRIDAY	O
[	O
**	O
2173-8-13	O
**	O
]	O
at	O
11:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2003	O
**	O
]	O
,	O
NP	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
VASCULAR	O
SURGERY	O
When	O
:	O
MONDAY	O
[	O
**	O
2173-9-13	O
**	O
]	O
at	O
10:45	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
20205	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
20206	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Bldg	O
(	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Department	O
:	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2173-8-18	O
**	O
]	O
at	O
1:30	O
PM	O
With	O
:	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
2184	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2185	O
**	O
]	O
in	O
the	O
[	O
**	O
Company	O
191	O
**	O
]	O
POST	O
[	O
**	O
Hospital	O
894	O
**	O
]	O
CLINIC	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2010	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
South	O
[	O
**	O
Hospital	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Notes	O
:	O
This	O
appointment	O
is	O
with	O
a	O
hospital	O
-	O
based	O
doctor	O
as	O
part	O
of	O
your	O
transition	O
from	O
the	O
hospital	O
back	O
to	O
your	O
primary	O
care	O
provider	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
616	O
**	O
]	O
this	O
visit	O
,	O
you	O
will	O
see	O
your	O
regular	O
primary	O
care	O
doctor	O
in	O
follow	O
up	O
.	O
Completed	O
by	O
:[	O
**	O
2173-8-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2154-5-30	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2154-6-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2089-4-30	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Levofloxacin	I-Drug
/	O
ceftriaxone	I-Drug
/	O
Keflex	I-Drug
/	O
Flagyl	I-Drug
/	O
vancomycin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2279	O
**	O
]	O
Chief	O
Complaint	O
:	O
fevers	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
65	O
yo	O
female	O
with	O
no	O
significant	O
PMHx	O
recently	O
s	O
/	O
p	O
excisional	O
biopsy	O
of	O
salivary	O
gland	O
tumor	O
on	O
[	O
**	O
2154-5-16	O
**	O
]	O
(	O
did	O
not	O
have	O
a	O
parotid	O
dissection	O
)	O
.	O
Two	O
days	O
later	O
she	O
presented	O
to	O
the	O
ED	O
with	O
dysphagia	O
and	O
found	O
to	O
have	O
cellulitis	I-Reason
of	O
surgical	O
wound	O
.	O
She	O
was	O
hospitalized	O
for	O
5	O
days	O
,	O
treated	O
with	O
antibiotics	I-Drug
and	O
discharged	O
on	O
Keflex	I-Drug
.	O
She	O
had	O
been	O
doing	O
well	O
until	O
Tuesday	O
/	O
Wed	O
when	O
she	O
began	O
experiencing	O
fevers	O
with	O
associated	O
generalized	O
malaise	O
,	O
fatigue	I-Reason
and	O
weakness	I-Reason
.	O
These	O
symptoms	O
persisted	O
,	O
did	O
improve	O
with	O
Tylenol	I-Drug
or	O
Advil	I-Drug
,	O
until	O
she	O
saw	O
her	O
OTL	O
surgeon	O
this	O
morning	O
for	O
follow	O
up	O
.	O
She	O
was	O
found	O
to	O
be	O
febrile	O
to	O
103	O
and	O
with	O
hypotension	O
to	O
mid-80s	O
systolic	O
.	O
She	O
was	O
sent	O
to	O
the	O
ED	O
with	O
evaluation	O
.	O
On	O
review	O
of	O
systems	O
the	O
patient	O
is	O
completely	O
asymptomatic	O
aside	O
from	O
weakness	O
and	O
malaise	O
.	O
No	O
sore	O
throat	O
,	O
no	O
runny	O
nose	O
,	O
eye	O
pain	O
or	O
discharge	O
,	O
sinus	O
pain	O
,	O
no	O
neck	O
pain	O
or	O
stiffness	O
,	O
no	O
redness	O
,	O
swelling	O
or	O
pain	O
at	O
site	O
of	O
incision	O
.	O
No	O
cough	O
,	O
SOB	O
,	O
chest	O
pain	O
,	O
no	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
or	O
diarrhea	O
.	O
Patient	O
does	O
endorse	O
increased	O
urinary	O
frequency	O
but	O
no	O
dysuria	O
.	O
No	O
rashes	O
or	O
joint	O
pain	O
,	O
no	O
leg	O
swelling	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vitals	O
were	O
99	O
10193/49	O
16	O
96	O
%	O
.	O
CBC	O
showed	O
white	O
blood	O
cell	O
count	O
of	O
5.1	O
K.	O
Sodium	O
was	O
128	O
on	O
Chem7	O
.	O
Lactate	O
was	O
1.0	O
.	O
Urinalysis	O
was	O
negative	O
and	O
blood	O
cultures	O
were	O
sent	O
.	O
Patient	O
was	O
administered	O
1	O
liter	O
NS	I-Drug
.	O
Chest	O
X-ray	O
showed	O
no	O
focal	O
consolidation	O
or	O
effusion	O
,	O
no	O
acute	O
process	O
.	O
ENT	O
was	O
consulted	O
and	O
initially	O
did	O
not	O
think	O
there	O
was	O
anything	O
going	O
on	O
with	O
the	O
surgical	O
site	O
.	O
CT	O
neck	O
was	O
performed	O
which	O
showed	O
fat	O
stranding	O
at	O
site	O
of	O
right	O
posterior	O
submandibular	O
node	O
resection	O
,	O
with	O
no	O
drainable	O
fluid	O
collection	O
.	O
Overall	O
there	O
was	O
an	O
improved	O
post-op	O
appearance	O
compared	O
to	O
recent	O
imaging	O
in	O
[	O
**	O
4	O
-	O
/	O
2154	O
**	O
]	O
,	O
with	O
less	O
mass	O
effect	O
upon	O
the	O
parapharyngeal	O
space	O
and	O
stable	O
edema	O
of	O
the	O
right	O
sternocleidomastoid	O
.	O
CTA	O
chest	O
was	O
also	O
performed	O
with	O
no	O
pulmonary	O
emboli	O
noted	O
,	O
but	O
scattered	O
mediastinal	B-Reason
lymph	I-Reason
nodes	I-Reason
measuring	I-Reason
up	I-Reason
to	I-Reason
9	I-Reason
mm	I-Reason
.	O
Initially	O
,	O
cephalexin	I-Drug
and	O
trimethoprim	B-Drug
/	I-Drug
sulfamethoxazole	I-Drug
were	O
administered	O
PO	O
.	O
Patient	O
was	O
admitted	O
to	O
observation	O
with	O
plan	O
for	O
likely	O
discharge	O
in	O
the	O
morning	O
.	O
Around	O
0230	O
,	O
patient	O
dropped	O
systolic	O
blood	O
pressures	O
to	O
70s	O
,	O
was	O
tachycardic	O
to	O
the	O
130s	O
,	O
with	O
a	O
temperature	O
of	O
104.8	O
F	O
,	O
RR	O
40s	O
,	O
with	O
O2	O
sat	O
77	O
%	O
on	O
RA	O
,	O
but	O
improved	O
to	O
mid-90s	O
with	O
nasal	O
cannula	O
O2	I-Drug
administration	O
.	O
She	O
was	O
reported	O
to	O
have	O
skin	O
mottling	O
of	O
the	O
extremities	O
.	O
A	O
left	O
external	O
jugular	O
peripheral	O
line	O
was	O
inserted	O
and	O
administration	O
of	O
2	O
liters	O
NS	B-Drug
IVF	I-Drug
was	O
bolused	O
.	O
Patient	O
was	O
administed	O
vancomycin	I-Drug
,	O
ceftriaxone	I-Drug
and	O
metronidazole	I-Drug
IV	O
.	O
ENT	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
and	O
recommended	O
MICU	O
admission	O
,	O
and	O
thought	O
there	O
was	O
no	O
surgical	O
intervention	O
needed	O
.	O
Past	O
Medical	O
History	O
:	O
s	O
/	O
p	O
excisional	O
biopsy	O
of	O
salivary	O
gland	O
tumor	O
on	O
[	O
**	O
2154-5-16	O
**	O
]	O
hx	O
of	O
pneumonia	O
Social	O
History	O
:	O
She	O
has	O
smoked	O
for	O
eight	O
to	O
ten	O
years	O
,	O
a	O
half	O
pack	O
per	O
day	O
.	O
She	O
smokes	O
generally	O
in	O
intervals	O
of	O
years	O
and	O
is	O
not	O
currently	O
smoking	O
.	O
From	O
the	O
standpoint	O
of	O
alcohol	O
,	O
she	O
rarely	O
drinks	O
it	O
.	O
Family	O
History	O
:	O
Her	O
mother	O
had	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
499	O
**	O
]	O
cancer	O
,	O
and	O
her	O
daughter	O
had	O
a	O
brain	O
tumor	O
.	O
There	O
is	O
also	O
a	O
history	O
of	O
hearing	O
loss	O
,	O
and	O
migraines	O
.	O
Physical	O
Exam	O
:	O
Admission	O
Exam	O
:	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
EOMI	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
,	O
no	O
tenderness	O
to	O
palpation	O
,	O
no	O
rebound	O
or	O
guarding	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
CNII	O
-	O
XII	O
intact	O
,	O
5/5	O
strength	O
upper	O
/	O
lower	O
extremities	O
,	O
grossly	O
normal	O
sensation	O
,	O
2	O
+	O
reflexes	O
bilaterally	O
,	O
gait	O
deferred	O
.	O
Discharge	O
Exam	O
:	O
VITALS	O
:	O
98.4	O
79125/84	O
20	O
97RA	O
GENERAL	O
:	O
awake	O
,	O
alert	O
,	O
NAD	O
NECK	O
:	O
Surgical	O
scar	O
on	O
right	O
submandibular	O
region	O
is	O
C	O
/	O
D	O
/	O
I	O
without	O
erythema	O
.	O
LUNGS	O
:	O
CTAB	O
HEART	O
:	O
RRR	O
,	O
normal	O
S1	O
S2	O
,	O
no	O
MRG	O
ABDOMEN	O
:	O
Soft	O
,	O
NT	O
/	O
ND	O
,	O
NABS	O
EXTREMITIES	O
:	O
WWP	O
no	O
c	O
/	O
c	O
/	O
e.	O
SKIN	O
:	O
scattered	O
pink	O
papules	O
worst	O
on	O
back	O
and	O
upper	O
arms	O
,	O
thighs	O
,	O
non-pruritic	O
.	O
no	O
vesicles	O
,	O
no	O
ulceration	O
Pertinent	O
Results	O
:	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
GR	O
HOLD	O
-	O
HOLD	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Hazy	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.016	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
TR	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.5	O
LEUK	O
-	O
NEG	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
RBC	O
-	O
1	O
WBC	O
-	O
4	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
1	O
RENAL	O
EPI	O
-	O
<	O
1	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
HYALINE	O
-	O
5	O
*	O
[	O
**	O
2154-5-30	O
**	O
]	O
06:12	O
PM	O
URINE	O
MUCOUS	O
-	O
FEW	O
[	O
**	O
2154-5-30	O
**	O
]	O
05:14	O
PM	O
PT	O
-	O
11.9	O
PTT	O
-	O
29.3	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2154-5-30	O
**	O
]	O
04:57	O
PM	O
LACTATE	O
-	O
1.0	O
[	O
**	O
2154-5-30	O
**	O
]	O
04:50	O
PM	O
GLUCOSE	O
-	O
109	O
*	O
UREA	O
N	O
-	O
12	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
128	O
*	O
POTASSIUM	O
-	O
5.1	O
CHLORIDE	O
-	O
98	O
TOTAL	O
CO2	O
-	O
23	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2154-5-30	O
**	O
]	O
04:50	O
PM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2154-5-30	O
**	O
]	O
04:50	O
PM	O
WBC	O
-	O
5.1	O
RBC	O
-	O
4.82	O
HGB	O
-	O
13.3	O
HCT	O
-	O
39.3	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
27.5	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
13.6	O
[	O
**	O
2154-5-30	O
**	O
]	O
04:50	O
PM	O
NEUTS	O
-	O
87.4	O
*	O
LYMPHS	O
-	O
8.0	O
*	O
MONOS	O
-	O
1.6	O
*	O
EOS	O
-	O
2.8	O
BASOS	O
-	O
0.1	O
[	O
**	O
2154-5-30	O
**	O
]	O
04:50	O
PM	O
PLT	O
COUNT	O
-	O
217	O
Brief	O
Hospital	O
Course	O
:	O
65	O
yo	O
female	O
with	O
no	O
significant	O
PMHx	O
recently	O
s	O
/	O
p	O
excisional	O
biopsy	O
of	O
salivary	O
gland	O
tumor	O
on	O
[	O
**	O
2154-5-16	O
**	O
]	O
with	O
a	O
postop	O
course	O
complicated	O
by	O
cellulitis	I-Reason
,	O
now	O
presenting	O
with	O
fevers	O
and	O
hypotension	O
.	O
Treatment	O
with	O
fluids	I-Drug
and	O
Abx	I-Drug
in	O
ICU	O
resolved	O
hypotension	I-Reason
and	O
fever	I-Reason
,	O
but	O
she	O
developed	O
a	O
rash	I-Ade
which	O
is	O
most	O
likely	O
drug	O
-	O
induced	O
.	O
Abx	I-Drug
discontinued	O
and	O
she	O
was	O
transfered	O
to	O
the	O
floor	O
where	O
she	O
has	O
remained	O
stable	O
.	O
Discharged	O
on	O
hospital	O
stay	O
day	O
4	O
.	O
Active	O
issues	O
:	O
#	O
Cellulitis	I-Reason
:	O
Pt	O
admitted	O
with	O
hypotension	I-Ade
occurring	O
during	O
treatment	O
for	O
cellulitis	I-Reason
on	O
Keflex	I-Drug
.	O
Pt	O
received	O
approximately	O
13days	O
of	O
Keflex	I-Drug
prior	O
to	O
admission	O
to	O
ICU	O
.	O
While	O
in	O
the	O
ICU	O
pt	O
received	O
Vanc	I-Drug
/	O
CTX	I-Drug
/	O
Flagyl	I-Drug
IV	O
and	O
ICU	O
stay	O
was	O
complicated	O
by	O
drug	O
eruption	O
(	O
see	O
below	O
)	O
.	O
IV	O
abx	I-Drug
were	O
discontinued	O
and	O
pt	O
remained	O
afebrile	O
and	O
stable	O
for	O
>	O
36	O
hrs	O
prior	O
to	O
discharge	O
.	O
Pt	O
was	O
transferred	O
to	O
the	O
floor	O
where	O
she	O
continued	O
to	O
do	O
well	O
with	O
no	O
evidence	O
of	O
recurrence	O
of	O
cellulitis	O
.	O
We	O
discussed	O
with	O
ENT	O
and	O
they	O
agreed	O
that	O
she	O
does	O
not	O
need	O
to	O
be	O
sent	O
home	O
on	O
antibiotics	I-Drug
.	O
#	O
Drug	O
Eruption	O
:	O
Pt	O
.	O
was	O
febrile	I-Ade
,	O
tachycardic	I-Ade
and	O
hypotensive	I-Ade
with	O
pruritic	B-Ade
pink	I-Ade
papules	I-Ade
over	O
her	O
back	O
and	O
arms	O
that	O
developed	O
after	O
taking	O
a	O
cephalosporin	I-Drug
for	O
post-op	B-Reason
cellulitis	I-Reason
.	O
There	O
was	O
no	O
infectious	O
etiology	O
determined	O
as	O
CXR	O
,	O
UA	O
,	O
Ucx	O
were	O
negative	O
and	O
CT	O
of	O
neck	O
did	O
not	O
reveal	O
a	O
fluid	O
collection	O
around	O
surgical	O
site	O
.	O
Pt	O
was	O
fluid	O
resuscitated	O
and	O
received	O
benadryl	I-Drug
and	O
famotidine	I-Drug
for	O
drug	B-Reason
rxn	I-Reason
and	O
topical	O
steroid	I-Drug
for	O
pruritis	I-Reason
.	O
Eruption	O
slowly	O
faded	O
and	O
became	O
non-pruritic	O
.	O
#Hyponatremia	O
:	O
Most	O
likely	O
hypovolemic	O
hyponatremia	O
that	O
resolved	O
with	O
fluid	O
resuscitation	O
.	O
#	O
Anemia	O
:	O
unknown	O
etiology	O
with	O
HH	O
11.4	O
&	O
35	O
.	O
H&H	O
remained	O
stable	O
over	O
admission	O
and	O
eventually	O
recovered	O
to	O
12.4	O
on	O
day	O
of	O
discharge	O
.	O
Chronic	O
issues	O
:	O
None	O
Transitional	O
issues	O
:	O
f	O
/	O
u	O
excisional	O
salivary	O
tumor	O
bx	O
Infectious	O
workup	O
:	O
f	O
/	O
u	O
viral	O
Cx	O
[	O
**	O
2154-5-1	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
OXYCODONE	B-Drug
-	I-Drug
ACETAMINOPHEN	I-Drug
-	O
5	O
mg	O
-	O
325	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
Every	O
4	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
Discharge	O
Medications	O
:	O
none	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Cellulitis	O
Drug	O
Eruption	O
Discharge	O
Condition	O
:	O
Stable	O
.	O
Incision	O
c	O
/	O
d	O
/	O
i.	O
No	O
erythema	O
.	O
Drug	O
eruption	O
fading	O
and	O
non-pruritic	O
.	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
Thank	O
you	O
for	O
choosing	O
us	O
for	O
your	O
care	O
.	O
You	O
were	O
admitted	O
with	O
cellulitis	I-Reason
(	O
a	O
skin	O
infection	O
)	O
and	O
hypotension	I-Reason
(	O
low	O
blood	O
pressure	O
)	O
.	O
In	O
the	O
ICU	O
you	O
received	O
IV	O
fluids	I-Drug
and	O
antibiotics	I-Drug
.	O
You	O
developed	O
a	O
rash	I-Ade
that	O
was	O
likely	O
a	O
response	O
to	O
the	O
antibiotics	I-Drug
you	O
recieved	O
.	O
In	O
this	O
context	O
,	O
we	O
stopped	O
the	O
antibiotics	I-Drug
.	O
You	O
have	O
been	O
off	O
antibiotics	I-Drug
for	O
3	O
days	O
and	O
your	O
skin	O
infection	O
has	O
resolved	O
.	O
We	O
are	O
not	O
sure	O
which	O
of	O
the	O
antibiotics	I-Drug
contributed	O
to	O
your	O
rash	I-Ade
,	O
but	O
in	O
the	O
future	O
,	O
please	O
just	O
be	O
on	O
alert	O
when	O
using	O
any	O
of	O
the	O
following	O
:	O
Vancomycin	I-Drug
,	O
Ceftriaxone	I-Drug
,	O
Flagyl	I-Drug
,	O
Keflex	I-Drug
,	O
Bactrim	I-Drug
.	O
There	O
are	O
no	O
changes	O
to	O
your	O
medications	O
.	O
Please	O
continue	O
to	O
take	O
the	O
medicines	O
you	O
had	O
been	O
on	O
at	O
home	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
OTOLARYNGOLOGY	O
-	O
AUDIOLOGY	O
When	O
:	O
TUESDAY	O
[	O
**	O
2154-6-11	O
**	O
]	O
at	O
8:45	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
177	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
41	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Bldg	O
(	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Department	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
MEDICAL	O
GROUP	O
When	O
:	O
THURSDAY	O
[	O
**	O
2154-6-13	O
**	O
]	O
at	O
10:45	O
AM	O
With	O
:	O
DR.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2400	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
133	O
**	O
]	O
Building	O
:	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
3375	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
MA	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
858	O
**	O
]	O
Campus	O
:	O
OFF	O
CAMPUS	O
Best	O
Parking	O
:	O
On	O
Street	O
Parking	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2285	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2154-6-3	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2156-11-24	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2156-11-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2086-2-27	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3619	O
**	O
]	O
Chief	O
Complaint	O
:	O
RUQ	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
70	O
-	O
year	O
-	O
old	O
female	O
with	O
stage	O
IIIC	O
ovarian	O
cancer	O
.	O
She	O
is	O
status	O
post	O
one	O
cycle	O
of	O
carboplatin	I-Drug
and	O
Taxol	I-Drug
chemotherapy	O
alone	O
.	O
She	O
is	O
status	O
post	O
5	O
doses	O
of	O
IV	O
chemotherapy	I-Drug
with	O
intraperitoneal	O
cisplatin	I-Drug
given	O
on	O
day	O
#	O
2	O
and	O
status	O
post	O
4	O
doses	O
of	O
intraperitoneal	O
Taxol	I-Drug
given	O
on	O
day	O
#	O
8	O
.	O
She	O
has	O
just	O
received	O
her	O
last	O
dose	O
of	O
chemotherapy	I-Drug
last	O
Thursday	O
.	O
Today	O
is	O
cycle	O
#	O
6	O
,	O
day	O
#	O
13	O
of	O
chemotherapy	I-Drug
.	O
She	O
was	O
seen	O
in	O
clinic	O
today	O
for	O
an	O
acute	O
complaint	O
of	O
RUQ	O
pain	O
.	O
[	O
**	O
Known	O
firstname	O
2429	O
**	O
]	O
states	O
that	O
she	O
has	O
a	O
deep	O
right	O
upper	O
quadrant	O
pain	O
on	O
palpation	O
,	O
movement	O
,	O
and	O
inspiration	O
.	O
She	O
rated	O
this	O
pain	O
a	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
.	O
No	O
actual	O
chest	O
pain	O
,	O
no	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
.	O
She	O
is	O
moving	O
her	O
bowels	O
and	O
going	O
to	O
the	O
bathroom	O
without	O
problems	O
.	O
She	O
is	O
eating	O
well	O
as	O
well	O
.	O
Patient	O
was	O
tachycardic	O
in	O
clinic	O
.	O
given	O
pleuritic	O
pain	O
and	O
hyprecoagulable	O
state	O
,	O
she	O
was	O
sent	O
to	O
ED	O
for	O
evaluation	O
.	O
IN	O
ED	O
patient	O
had	O
CT	O
Torso	O
which	O
revealed	O
a	O
saddle	O
embolus	O
and	O
right	O
sided	O
saddle	O
embolus	O
with	O
near	O
complete	O
occlusion	O
of	O
RLL	O
pulm	O
.	O
artery	O
,	O
with	O
wedge	O
shaped	O
consolidation	O
in	O
RLL	O
likely	O
representing	O
infarction	O
as	O
well	O
as	O
a	O
Left	O
common	O
femoral	O
vein	O
acute	O
DVT	I-Reason
,	O
as	O
well	O
as	O
left	O
gonadal	O
vein	O
thrombus	O
.	O
Patient	O
wAs	O
started	O
on	O
IV	O
heparin	I-Drug
and	O
remained	O
hemodynamically	O
statble	O
throught	O
her	O
9	O
hour	O
emergency	O
room	O
visit	O
.	O
Given	O
fever	I-Reason
,	O
patient	O
also	O
cultured	O
and	O
given	O
dose	O
of	O
cefepime	I-Drug
in	O
ED	O
.	O
Upon	O
arrival	O
to	O
the	O
floor	O
:	O
Patient	O
VS	O
:	O
100.1	O
150/100110	O
20	O
100	O
%	O
RA	O
.	O
[	O
**	O
Known	O
firstname	O
2429	O
**	O
]	O
continues	O
to	O
experience	O
RUQ	O
pain	O
,	O
R	O
sided	O
pleuritic	O
chest	O
pain	O
and	O
mild	O
shortness	O
of	O
breath	O
with	O
exertion	O
.	O
She	O
denies	O
any	O
chest	O
pain	O
at	O
rest	O
,	O
denies	O
any	O
lightheadness	O
,	O
dizziness	O
or	O
palpitations	O
.	O
ROS	O
is	O
otherwise	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
HTN	O
-	O
Hypercholesterolemia	O
Past	O
Surgical	O
History	O
:	O
-	O
Removal	O
rectal	O
polyp	O
-	O
Biopsy	O
of	O
left	O
breast	O
mass	O
-	O
Bilateral	O
tubal	O
ligation	O
Past	O
Gynecologic	O
History	O
:	O
-	O
LMP	O
age	O
47	O
.	O
h	O
/	O
o	O
uterine	O
fibroids	O
.	O
No	O
h	O
/	O
o	O
abnormal	O
paps	O
.	O
Past	O
Obstetric	O
History	O
:	O
-	O
G6P4	O
Social	O
History	O
:	O
Pt	O
used	O
to	O
work	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Pt	O
is	O
married	O
.	O
Denies	O
tob	O
/	O
etoh	O
/	O
drug	O
use	O
.	O
Family	O
History	O
:	O
No	O
family	O
h	O
/	O
o	O
cancer	O
Physical	O
Exam	O
:	O
GEN	O
:	O
chronically	O
ill	O
appearing	O
female	O
in	O
mild	O
resp	O
distress	O
VS	O
:	O
100.1	O
150/100110	O
20	O
100	O
%	O
RA	O
HEENT	O
:	O
PERRL	O
,	O
OP	O
-	O
clear	O
,	O
no	O
erythema	O
,	O
no	O
exudates	O
NECK	O
:	O
CVS	O
:	O
?	O
split	O
S1	O
S2	O
tachy	O
Chest	O
:	O
rales	O
1	O
/	O
2way	O
up	O
on	O
Right	O
side	O
;	O
+	O
splinting	O
Abd	O
:	O
obese	O
;	O
soft	O
;	O
Non-tender	O
ext	O
:	O
+2	O
edemia	O
b	O
/	O
l	O
Pertinent	O
Results	O
:	O
[	O
**	O
2156-11-24	O
**	O
]	O
02:40	O
PM	O
WBC	O
-	O
3.7	O
*	O
RBC	O
-	O
3.95	O
*	O
HGB	O
-	O
11.0	O
*	O
HCT	O
-	O
31.7	O
*	O
MCV	O
-	O
80	O
*	O
MCH	O
-	O
27.7	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
19.4	O
*	O
[	O
**	O
2156-11-24	O
**	O
]	O
02:40	O
PM	O
NEUTS	O
-	O
43.6	O
*	O
LYMPHS	O
-	O
51.1	O
*	O
MONOS	O
-	O
4.2	O
EOS	O
-	O
0.8	O
BASOS	O
-	O
0.3	O
[	O
**	O
2156-11-24	O
**	O
]	O
02:40	O
PM	O
ANISOCYT	O
-	O
2	O
+	O
MICROCYT	O
-	O
2	O
+	O
[	O
**	O
2156-11-24	O
**	O
]	O
02:40	O
PM	O
PLT	O
COUNT	O
-	O
138	O
*	O
[	O
**	O
2156-11-24	O
**	O
]	O
11:54	O
AM	O
UREA	O
N	O
-	O
19	O
CREAT	O
-	O
1.0	O
SODIUM	O
-	O
135	O
POTASSIUM	O
-	O
3.3	O
CHLORIDE	O
-	O
94	O
*	O
TOTAL	O
CO2	O
-	O
31	O
ANION	O
GAP	O
-	O
13	O
[	O
**	O
2156-11-24	O
**	O
]	O
11:54	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
73	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
53	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
315	O
*	O
ALK	O
PHOS	O
-	O
100	O
AMYLASE	O
-	O
79	O
TOT	O
BILI	O
-	O
0.5	O
[	O
**	O
2156-11-24	O
**	O
]	O
11:54	O
AM	O
LIPASE	O
-	O
23	O
[	O
**	O
2156-11-24	O
**	O
]	O
11:54	O
AM	O
ALBUMIN	O
-	O
4.0	O
MAGNESIUM	O
-	O
1.7	O
[	O
**	O
2156-11-24	O
**	O
]	O
03:15	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
7.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2156-11-24	O
**	O
]	O
03:15	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.008	O
[	O
**	O
2156-11-24	O
**	O
]	O
03:57	O
PM	O
LACTATE	O
-	O
1.3	O
CXR	O
:	O
IMPRESSION	O
:	O
Low	O
lung	O
volumes	O
.	O
Opacities	O
in	O
both	O
bases	O
are	O
likely	O
secondary	O
to	O
atelectasis	O
.	O
Followup	O
PA	O
and	O
lateral	O
examinations	O
may	O
be	O
helpful	O
when	O
the	O
patient	O
is	O
clinically	O
able	O
.	O
CTA	O
CHEST	O
:	O
The	O
heart	O
,	O
pericardium	O
,	O
and	O
great	O
vessels	O
are	O
unremarkable	O
.	O
There	O
is	O
no	O
evidence	O
of	O
pleural	O
or	O
pericardial	O
effusion	O
.	O
No	O
significant	O
axillary	O
,	O
hilar	O
,	O
or	O
mediastinal	O
lymphadenopathy	O
is	O
identified	O
.	O
The	O
central	O
airways	O
are	O
patent	O
bilaterally	O
.	O
There	O
is	O
a	O
large	O
saddle	O
embolus	O
in	O
the	O
right	O
main	O
pulmonary	O
artery	O
,	O
which	O
nearly	O
completely	O
occludes	O
the	O
right	O
lower	O
lobe	O
pulmonary	O
artery	O
,	O
and	O
there	O
is	O
evidence	O
of	O
wedge	O
shaped	O
,	O
parenchymal	O
opacity	O
localized	O
to	O
the	O
right	O
lower	O
lobe	O
,	O
which	O
may	O
represent	O
pulmonary	O
infarction	O
.	O
Some	O
contrast	O
passes	O
the	O
embolism	O
to	O
the	O
right	O
middle	O
and	O
right	O
upper	O
lobe	O
pulmonary	O
arteries	O
,	O
and	O
the	O
lung	O
parenchyma	O
in	O
these	O
areas	O
is	O
unremarkable	O
.	O
There	O
is	O
no	O
evidence	O
of	O
pulmonary	O
embolism	O
on	O
the	O
left	O
side	O
.	O
The	O
left	O
lung	O
fields	O
are	O
clear	O
.	O
CT	O
OF	O
THE	O
ABDOMEN	O
WITH	O
IV	O
CONTRAST	I-Drug
:	O
The	O
liver	O
enhances	O
homogeneously	O
,	O
without	O
evidence	O
of	O
focal	O
intrahepatic	O
lesion	O
.	O
There	O
is	O
no	O
evidence	O
of	O
ascites	O
.	O
There	O
is	O
no	O
evidence	O
of	O
intra	O
-	O
or	O
extra-hepatic	O
biliary	O
ductal	O
dilatation	O
.	O
The	O
gallbladder	O
,	O
pancreas	O
,	O
spleen	O
,	O
and	O
adrenal	O
glands	O
are	O
unremarkable	O
.	O
There	O
is	O
evidence	O
of	O
a	O
subcutaneous	O
Chemo	O
-	O
Port	O
in	O
the	O
left	O
abdominal	O
wall	O
,	O
with	O
a	O
peritoneal	O
catheter	O
extending	O
into	O
the	O
left	O
lower	O
quadrant	O
.	O
The	O
kidneys	O
enhance	O
symmetrically	O
and	O
excrete	O
contrast	O
normally	O
bilaterally	O
.	O
The	O
ureters	O
are	O
normal	O
in	O
appearance	O
,	O
without	O
evidence	O
of	O
hydronephrosis	O
.	O
Within	O
the	O
midpole	O
of	O
the	O
right	O
kidney	O
,	O
there	O
is	O
a	O
low	O
attenuation	O
focus	O
measuring	O
1.4	O
x	O
1.8	O
cm	O
,	O
which	O
contains	O
low	O
-	O
density	O
fluid	O
,	O
consistent	O
with	O
a	O
simple	O
cyst	O
.	O
Smaller	O
hypodensities	O
are	O
seen	O
throughout	O
both	O
kidneys	O
,	O
but	O
are	O
too	O
small	O
to	O
definitively	O
characterize	O
.	O
The	O
stomach	O
and	O
opacified	O
loops	O
of	O
intraabdominal	O
bowel	O
are	O
unremarkable	O
.	O
There	O
is	O
no	O
free	O
air	O
,	O
free	O
fluid	O
,	O
or	O
pathologic	O
mesenteric	O
or	O
retroperitoneal	O
lymphadenopathy	O
.	O
Expansile	O
,	O
centrally	O
located	O
thrombus	O
is	O
seen	O
within	O
the	O
left	O
gonadal	O
vein	O
,	O
beginning	O
inferiorly	O
at	O
the	O
level	O
of	O
the	O
mid	O
psoas	O
muscle	O
and	O
extending	O
proximally	O
up	O
to	O
and	O
involving	O
the	O
confluence	O
at	O
the	O
superior	O
mesenteric	O
vein	O
.	O
No	O
thrombus	O
is	O
seen	O
more	O
proximally	O
than	O
the	O
SMV	O
.	O
Expansile	O
,	O
acute	O
thrombus	O
is	O
also	O
seen	O
within	O
the	O
left	O
common	O
femoral	O
vein	O
,	O
extending	O
proximally	O
to	O
the	O
level	O
of	O
the	O
pubic	O
symphysis	O
.	O
CT	O
OF	O
THE	O
PELVIS	O
WITH	O
IV	O
CONTRAST	I-Drug
:	O
The	O
rectum	O
,	O
sigmoid	O
colon	O
,	O
pelvic	O
loops	O
of	O
bowel	O
,	O
urinary	O
bladder	O
,	O
and	O
distal	O
ureters	O
are	O
unremarkable	O
.	O
The	O
patient	O
is	O
status	O
post	O
hysterectomy	O
.	O
No	O
free	O
fluid	O
is	O
seen	O
within	O
the	O
pelvis	O
,	O
and	O
no	O
abnormal	O
pelvic	O
or	O
inguinal	O
lymphadenopathy	O
is	O
identified	O
.	O
CT	O
head	O
:	O
1	O
.	O
No	O
evidence	O
of	O
intracranial	O
hemorrhage	O
or	O
mass	O
effect	O
.	O
2	O
.	O
No	O
enhancing	O
lesions	O
identified	O
.	O
3	O
.	O
Mottled	O
appearance	O
of	O
the	O
calvarium	O
,	O
suggesting	O
possible	O
renal	O
osteodystrophy	O
.	O
EKG	O
:	O
nl	O
sinus	O
;	O
Left	O
axis	O
deviation	O
;	O
t	O
wave	O
inversion	O
III	O
;	O
.5	O
mm	O
st	O
depression	O
V5	O
-	O
6	O
Brief	O
Hospital	O
Course	O
:	O
.	O
A	O
/	O
P	O
:	O
70	O
y.o.	O
woman	O
with	O
a	O
history	O
of	O
metastatic	O
ovarian	O
CA	O
presenting	O
with	O
chest	O
pain	O
,	O
found	O
to	O
have	O
large	O
pulmonary	O
embolus	O
with	O
significant	O
DVT	O
clot	O
burden	O
,	O
hemodynamically	O
stable	O
,	O
saturating	O
well	O
on	O
RA	O
,	O
now	O
on	O
lovenox	I-Drug
.	O
.	O
#	O
PE	O
with	O
large	B-Reason
DVT	I-Reason
clot	I-Reason
burden	I-Reason
.	O
The	O
patient	O
presented	O
with	O
chest	O
pain	O
and	O
was	O
found	O
on	O
CT	O
scan	O
to	O
have	O
a	O
large	O
saddle	O
embolus	O
with	O
near	O
complete	O
occlusion	O
of	O
the	O
RLL	O
pulmonary	O
artery	O
and	O
a	O
likely	O
infarct	O
of	O
the	O
RLL	O
.	O
CT	O
scan	O
also	O
revealed	O
left	O
common	O
femoral	O
vein	O
DVT	O
and	O
Left	O
gonadal	O
vein	O
thrombus	O
.	O
It	O
is	O
likely	O
that	O
these	O
clots	O
occurred	O
secondary	O
to	O
hypercoaguability	O
of	O
malignancy	O
.	O
The	O
patient	O
was	O
hemodynamically	O
stable	O
.	O
EKG	O
showed	O
sinus	O
tachycardia	O
without	O
clear	O
signs	O
of	O
Right	O
heart	O
strain	O
.	O
The	O
patient	O
was	O
initiated	O
on	O
IV	O
heparin	I-Drug
and	O
briefly	O
sent	O
to	O
the	O
ICU	O
out	O
of	O
concern	O
for	O
her	O
considerable	O
clot	I-Reason
burden	O
and	O
potential	O
hemodynamic	O
complications	O
.	O
The	O
patient	O
had	O
a	O
fever	O
,	O
likely	O
secondary	O
to	O
her	O
clot	O
burden	O
.	O
The	O
patient	O
was	O
changed	O
to	O
lovenox	I-Drug
for	O
long	B-Reason
-	I-Reason
term	I-Reason
anticoagulation	I-Reason
.	O
She	O
remained	O
hemodynamically	O
stable	O
throughout	O
her	O
admission	O
,	O
saturating	O
well	O
(	O
>	O
95	O
%	O
)	O
on	O
RA	O
and	O
with	O
improved	O
chest	O
pain	O
.	O
Lower	O
extremity	O
ultrasound	O
was	O
ordered	O
to	O
further	O
assess	O
clot	O
burden	O
.	O
However	O
,	O
the	O
ultrasound	O
tech	O
was	O
not	O
available	O
to	O
complete	O
the	O
study	O
and	O
after	O
discussion	O
with	O
radiology	O
it	O
was	O
felt	O
that	O
the	O
CT	O
scan	O
provided	O
adequate	O
imaging	O
of	O
the	O
deep	O
veins	O
.	O
There	O
was	O
no	O
change	O
of	O
management	O
to	O
be	O
made	O
based	O
upon	O
the	O
Lower	O
extremity	O
ultrasound	O
study	O
.	O
The	O
patient	O
will	O
likely	O
require	O
life	O
-	O
long	O
lovenox	I-Drug
vs.	O
coumadin	I-Drug
therapy	O
.	O
.	O
#	O
Anemia	O
.	O
On	O
admission	O
,	O
the	O
patient	O
's	O
Hct	O
dropped	O
from	O
34.4	O
to	O
a	O
nadir	O
of	O
26.4	O
in	O
the	O
setting	O
of	O
new	O
anticoagulation	O
.	O
The	O
patient	O
had	O
no	O
obvious	O
source	O
of	O
bleeding	O
.	O
The	O
patient	O
's	O
Hct	O
stabilized	O
and	O
trended	O
upward	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
Ovarian	O
CA	O
.	O
Intravenous	O
and	O
intraperitoneal	O
chemotherapy	I-Drug
per	O
primary	O
oncologist	O
.	O
.	O
#	O
HTN	I-Reason
.	O
Well	O
controlled	O
on	O
CCB	I-Drug
and	O
diuretic	I-Drug
.	O
.	O
#	O
Leukopenia	I-Ade
.	O
Likely	O
secondary	O
to	O
chemotherapy	I-Drug
.	O
Not	O
neutropenic	O
by	O
numbers	O
.	O
.	O
#	O
Fever	O
.	O
Resolved	O
.	O
Likely	O
secondary	O
to	O
clot	O
burden	O
.	O
Cultures	O
without	O
growth	O
to	O
date	O
.	O
.	O
#	O
Hyperlipidemia	I-Reason
.	O
The	O
patient	O
's	O
statin	I-Drug
therapy	O
was	O
held	O
while	O
LFT	B-Ade
's	I-Ade
were	I-Ade
elevated	I-Ade
,	O
likely	O
secondary	O
to	O
recent	O
chemotherapy	I-Drug
.	O
This	O
therapy	O
was	O
re-instated	O
prior	O
to	O
discharge	O
as	O
her	O
LFT	O
's	O
normalized	O
.	O
Medications	O
on	O
Admission	O
:	O
MEDICATIONS	O
:	O
Norvasc	I-Drug
5	O
mg	O
po	O
QD	O
,	O
this	O
is	O
dose	O
reduced	O
from	O
her	O
primary	O
care	O
doctor	O
from	O
10	O
mg	O
po	O
QD	O
.	O
Lipitor	I-Drug
10	O
mg	O
p.o.	O
once	O
daily	O
,	O
Compazine	I-Drug
,	O
hydrochlorothiazide	I-Drug
12.5	O
mg	O
p.o.	O
once	O
daily	O
,	O
milk	B-Drug
of	I-Drug
magnesia	I-Drug
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Hydrochlorothiazide	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Magnesium	B-Drug
Hydroxide	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
5	O
.	O
Enoxaparin	I-Drug
80	O
mg	O
/	O
0.8	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
60	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
119	O
**	O
]	O
Homecare	O
Discharge	O
Diagnosis	O
:	O
Pulmonary	O
embolism	O
with	O
large	O
deep	O
vein	O
thrombosis	O
clot	O
burden	O
.	O
Metastatic	O
ovarian	O
cancer	O
Hypertension	O
Hypercholesterolemia	O
Discharge	O
Condition	O
:	O
Good	O
,	O
saturating	O
well	O
on	O
room	O
air	O
with	O
decreased	O
chest	O
pain	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
chest	O
pain	O
.	O
This	O
was	O
likely	O
due	O
to	O
blood	O
clots	O
in	O
your	O
lungs	O
.	O
These	O
clots	O
came	O
from	O
the	O
blood	O
vessels	O
in	O
your	O
legs	O
and	O
abdomen	O
.	O
This	O
is	O
likely	O
a	O
complication	O
from	O
your	O
ovarian	O
cancer	O
.	O
You	O
were	O
started	O
on	O
a	O
medication	O
,	O
called	O
lovenox	I-Drug
(	O
also	O
called	O
enoxaparin	O
)	O
,	O
to	O
thin	O
your	O
blood	O
and	O
prevent	B-Reason
further	I-Reason
clotting	O
.	O
Please	O
inject	O
this	O
medication	O
as	O
you	O
have	O
been	O
taught	O
twice	O
a	O
day	O
.	O
.	O
Follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2244	O
**	O
]	O
in	O
the	O
oncology	O
clinic	O
on	O
[	O
**	O
2156-12-2	O
**	O
]	O
for	O
further	O
management	O
of	O
your	O
ovarian	O
cancer	O
and	O
blood	I-Reason
clot	O
complications	O
.	O
.	O
Take	O
all	O
medications	O
as	O
prescribed	O
.	O
The	O
only	O
change	O
in	O
your	O
medications	O
is	O
the	O
addition	O
of	O
Lovenox	I-Drug
(	O
also	O
called	O
enoxaparin	O
)	O
.	O
.	O
Call	O
your	O
doctor	O
or	O
return	O
to	O
the	O
hospital	O
for	O
any	O
new	O
or	O
worsening	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
or	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2156-12-2	O
**	O
]	O
9:30	O
Provider	O
:	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
5558	O
**	O
]	O
,	O
[	O
**	O
Name12	O
(	O
NameIs	O
)	O
5557	O
**	O
]	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
-	O
CC9	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2156-12-2	O
**	O
]	O
9:30	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
3621	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2125-9-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2125-9-18	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2055-6-5	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Ampicillin	I-Drug
/	O
Aspirin	I-Drug
Attending	O
:[	O
**	O
Doctor	O
First	O
Name	O
2080	O
**	O
]	O
Chief	O
Complaint	O
:	O
Diarrhea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
70	O
y	O
/	O
o	O
lady	O
with	O
h	O
/	O
o	O
recurrent	O
C.diff	O
colitis	O
since	O
[	O
**	O
Month	O
(	O
only	O
)	O
958	O
**	O
]	O
of	O
[	O
**	O
2124	O
**	O
]	O
presenting	O
worsening	O
diarrhea	O
.	O
Patient	O
has	O
noticed	O
increased	O
amount	O
of	O
bowel	O
movements	O
>	O
10	O
per	O
day	O
in	O
the	O
last	O
two	O
days	O
.	O
She	O
has	O
noticed	O
some	O
bright	O
blood	O
and	O
dark	O
colored	O
stool	O
occasionally	O
.	O
She	O
has	O
a	O
hard	O
time	O
explaining	O
the	O
quality	O
and	O
quantitiy	O
of	O
stool	O
.	O
Her	O
appetite	O
was	O
very	O
poor	O
and	O
did	O
not	O
eat	O
in	O
the	O
last	O
two	O
days	O
.	O
Denies	O
nausea	O
/	O
vomitting	O
.	O
She	O
had	O
mild	O
abdominal	O
pain	O
prior	O
to	O
bowel	O
movement	O
yesterday	O
.	O
She	O
felt	O
very	O
tired	O
and	O
decided	O
to	O
come	O
to	O
the	O
ED	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
T97	O
.4	O
P95	O
BP128	O
/	O
65	O
R20	O
O292	O
%	O
sat	O
in	O
RA	O
.	O
She	O
spiked	O
a	O
temp	B-Reason
to	I-Reason
102.4	I-Reason
approx	O
5	O
hours	O
after	O
presentation	O
.	O
Patient	O
recieved	O
1	O
gram	O
of	O
tylenol	I-Drug
and	O
became	O
afebrile	O
.	O
She	O
initially	O
recieved	O
1	O
L	O
NS	I-Drug
.	O
Her	O
SBP	B-Reason
dropped	I-Reason
to	I-Reason
80s	I-Reason
(	O
per	O
verbal	O
signout	O
)	O
and	O
she	O
was	O
started	O
on	O
peripheral	O
levophed	I-Drug
and	O
additional	O
2	O
L	O
NS	I-Drug
were	O
given	O
.	O
Patient	O
refused	O
central	O
line	O
.	O
She	O
had	O
2	O
PIV	O
(	O
18G	O
)	O
placed	O
in	O
ED	O
per	O
verbal	O
signout	O
.	O
CXR	O
was	O
concerning	O
LLL	B-Reason
PNA	I-Reason
.	O
Patient	O
was	O
also	O
given	O
1	O
gram	O
of	O
IV	O
vancomycin	I-Drug
,	O
500	O
mg	O
IV	O
flagyl	I-Drug
,	O
750	O
mg	O
IV	O
levofloxacin	I-Drug
and	O
2	O
grams	O
of	O
IV	O
calcium	I-Drug
.	O
.	O
On	O
the	O
floor	O
,	O
patient	O
was	O
comfortable	O
.	O
.	O
Review	O
of	O
sytems	O
:	O
Denies	O
fevers	O
at	O
home	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
headache	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denied	O
cough	O
,	O
shortness	O
of	O
breath	O
.	O
Denied	O
chest	O
pain	O
or	O
tightness	O
,	O
palpitations	O
.	O
Denied	O
arthralgias	O
or	O
myalgias	O
,	O
new	O
weakness	O
or	O
numbness	O
.	O
Has	O
chronic	O
right	O
shoulder	O
weakness	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Recurrent	O
C	O
Diff	O
colitis	O
beginning	O
[	O
**	O
1	O
-	O
/	O
2125	O
**	O
]	O
,	O
last	O
episode	O
and	O
hospitalization	O
[	O
**	O
2125-8-1	O
**	O
]	O
to	O
[	O
**	O
2125-8-10	O
**	O
]	O
,	O
confirmed	O
colitis	I-Reason
on	O
CT	O
and	O
flex	O
-	O
sig	O
without	O
pseudomembranes	O
and	O
patient	O
refused	O
biopsy	O
,	O
was	O
treated	O
with	O
a	O
pulse	O
and	O
taper	O
dose	O
of	O
vancomycin	I-Drug
(	O
completed	O
on	O
[	O
**	O
2125-9-2	O
**	O
]	O
)	O
,	O
Florastor	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
,	O
and	O
was	O
started	O
on	O
rifaximin	I-Drug
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
on	O
[	O
**	O
2125-9-3	O
**	O
]	O
.	O
-	O
RUE	B-Reason
DVT	I-Reason
following	O
PICC	O
Placement	O
in	O
[	O
**	O
2125-7-20	O
**	O
]	O
,	O
on	O
coumadin	I-Drug
-	O
Anxiety	O
-	O
HTN	O
-	O
CAD	O
s	O
/	O
p	O
NSTEMI	O
in	O
the	O
setting	O
of	O
demand	O
ischemia	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
958	O
**	O
]	O
of	O
[	O
**	O
2124	O
**	O
]	O
-	O
s	O
/	O
p	O
ORIF	O
of	O
R	O
wrist	O
in	O
[	O
**	O
1	O
-	O
/	O
2125	O
**	O
]	O
-	O
Anemia	O
Social	O
History	O
:	O
Usually	O
lives	O
alone	O
and	O
is	O
able	O
to	O
do	O
activities	O
of	O
daily	O
living	O
including	O
driving	O
herself	O
but	O
since	O
her	O
MI	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
958	O
**	O
]	O
she	O
has	O
been	O
afraid	O
to	O
leave	O
the	O
house	O
and	O
her	O
son	O
has	O
been	O
living	O
with	O
her	O
to	O
help	O
with	O
activities	O
around	O
the	O
house	O
.	O
She	O
has	O
a	O
neice	O
who	O
works	O
in	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
13042	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Quit	O
tobacco	O
in	O
[	O
**	O
2	O
-	O
5	O
**	O
]	O
but	O
smoked	O
for	O
50	O
years	O
[	O
**	O
12	O
-	O
1	O
**	O
]	O
ppd	O
before	O
that	O
.	O
No	O
alcohol	O
or	O
other	O
drug	O
use	O
.	O
Family	O
History	O
:	O
One	O
brother	O
with	O
kidney	O
tumor	O
,	O
CHF	O
,	O
OA	O
,	O
obesity	O
.	O
Dad	O
had	O
DM	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
97.3	O
BP	O
:	O
101/44	O
P	O
:	O
84	O
R	O
:	O
18	O
O2	O
:	O
96	O
%	O
on	O
2LNC	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
7	O
cm	O
Lungs	O
:	O
distant	O
BS	O
diffusely	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Heart	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
I	O
/	O
VI	O
holosystolic	O
murmur	O
at	O
left	O
lower	O
sternal	O
border	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Guaic	O
negative	O
in	O
ED	O
Pertinent	O
Results	O
:	O
Admission	O
Labs	O
:	O
[	O
**	O
2125-9-13	O
**	O
]	O
03:09	O
PM	O
GLUCOSE	O
-	O
109	O
*	O
UREA	O
N	O
-	O
18	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
134	O
POTASSIUM	O
-	O
4.5	O
CHLORIDE	O
-	O
106	O
TOTAL	O
CO2	O
-	O
19	O
*	O
ANION	O
GAP	O
-	O
14	O
[	O
**	O
2125-9-13	O
**	O
]	O
03:09	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
29	O
AST	O
(	O
SGOT	O
)	O
-	O
30	O
LD	O
(	O
LDH	O
)	O
-	O
183	O
ALK	O
PHOS	O
-	O
170	O
*	O
TOT	O
BILI	O
-	O
0.4	O
[	O
**	O
2125-9-13	O
**	O
]	O
03:09	O
PM	O
GGT	O
-	O
153	O
*	O
[	O
**	O
2125-9-13	O
**	O
]	O
08:41	O
AM	O
GLUCOSE	O
-	O
109	O
*	O
UREA	O
N	O
-	O
20	O
CREAT	O
-	O
0.9	O
SODIUM	O
-	O
135	O
POTASSIUM	O
-	O
5.0	O
CHLORIDE	O
-	O
106	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2125-9-13	O
**	O
]	O
08:41	O
AM	O
ALBUMIN	O
-	O
3.1	O
*	O
CALCIUM	O
-	O
7.6	O
*	O
PHOSPHATE	O
-	O
3.5	O
MAGNESIUM	O
-	O
1.6	O
[	O
**	O
2125-9-13	O
**	O
]	O
08:41	O
AM	O
WBC	O
-	O
4.5	O
#	O
RBC	O
-	O
3.04	O
*	O
HGB	O
-	O
9.2	O
*	O
HCT	O
-	O
28.2	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
30.1	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
14.8	O
[	O
**	O
2125-9-13	O
**	O
]	O
04:35	O
AM	O
LACTATE	O
-	O
1.4	O
K	O
+	O
-	O
5.0	O
[	O
**	O
2125-9-12	O
**	O
]	O
11:08	O
PM	O
CALCIUM	O
-	O
9.6	O
PHOSPHATE	O
-	O
3.4	O
MAGNESIUM	O
-	O
1.8	O
[	O
**	O
2125-9-12	O
**	O
]	O
11:08	O
PM	O
NEUTS	O
-	O
84	O
*	O
BANDS	O
-	O
9	O
*	O
LYMPHS	O
-	O
3	O
*	O
MONOS	O
-	O
3	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
1	O
*	O
MYELOS	O
-	O
0	O
.	O
CT	O
Abd	O
/	O
Pelvis	O
:	O
IMPRESSIONS	O
:	O
1	O
.	O
Wall	O
thickening	O
and	O
stranding	O
along	O
the	O
colon	O
from	O
the	O
splenic	O
flexure	O
through	O
the	O
sigmoid	O
colon	O
,	O
similar	O
to	O
that	O
seen	O
on	O
[	O
**	O
2125-8-1	O
**	O
]	O
.	O
Findings	O
again	O
represent	O
nonspecific	O
colitis	O
,	O
possibly	O
ischemic	O
,	O
infectious	O
or	O
inflammatory	O
in	O
etiology	O
.	O
No	O
free	O
air	O
,	O
definite	O
abscess	O
,	O
pneumatosis	O
,	O
or	O
portal	O
gas	O
seen	O
.	O
2	O
.	O
Left	O
kidney	O
with	O
hyperdense	O
cyst	O
and	O
other	O
subcentimeter	O
hypodensities	O
.	O
3	O
.	O
Atherosclerotic	O
disease	O
.	O
.	O
Stool	O
cx	O
:	O
/	O
15/09	O
1:55	O
am	O
STOOL	O
CONSISTENCY	O
:	O
SOFT	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2125-9-17	O
**	O
]	O
**	O
FECAL	O
CULTURE	O
(	O
Final	O
[	O
**	O
2125-9-14	O
**	O
]	O
)	O
:	O
NO	O
SALMONELLA	O
OR	O
SHIGELLA	O
FOUND	O
.	O
CAMPYLOBACTER	O
CULTURE	O
(	O
Final	O
[	O
**	O
2125-9-15	O
**	O
]	O
)	O
:	O
NO	O
CAMPYLOBACTER	O
FOUND	O
.	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST	O
(	O
Final	O
[	O
**	O
2125-9-13	O
**	O
]	O
)	O
:	O
REPORTED	O
BY	O
PHONE	O
TO	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
KITCHEN	O
ON	O
[	O
**	O
2125-9-13	O
**	O
]	O
AT	O
1:10	O
PM	O
.	O
CLOSTRIDIUM	O
DIFFICILE	O
.	O
FECES	O
POSITIVE	O
FOR	O
C.	O
DIFFICILE	O
TOXIN	O
BY	O
EIA	O
.	O
(	O
Reference	O
Range	O
-	O
Negative	O
)	O
.	O
A	O
positive	O
result	O
in	O
a	O
recently	O
treated	O
patient	O
is	O
of	O
uncertain	O
significance	O
unless	O
the	O
patient	O
is	O
currently	O
symptomatic	O
(	O
relapse	O
)	O
.	O
Brief	O
Hospital	O
Course	O
:	O
C.	B-Reason
difficile	I-Reason
colitis	I-Reason
/	O
Sepsis	I-Reason
:	O
Given	O
history	O
of	O
recurrent	O
C.	O
difficile	O
colitis	O
,	O
diarrhea	O
,	O
and	O
sepsis	O
,	O
etiology	O
was	O
presumed	O
to	O
be	O
CDAD	O
,	O
confirmed	O
on	O
stool	O
cx	O
.	O
She	O
was	O
started	O
on	O
PO	O
vanco	I-Drug
,	O
IV	O
flagyl	I-Drug
empirically	O
.	O
CT	O
scan	O
demonstrated	O
colitis	O
.	O
Patient	O
was	O
admitted	O
to	O
the	O
ICU	O
for	O
aggressive	O
IVF	I-Drug
,	O
though	O
patient	O
refused	O
central	O
line	O
.	O
She	O
was	O
briefly	O
on	O
peripheral	O
levophed	I-Drug
.	O
ID	O
and	O
GI	O
were	O
consulted	O
.	O
After	O
adequate	O
resuscitation	O
,	O
she	O
stabilized	O
clinically	O
and	O
was	O
transferred	O
to	O
the	O
medical	O
floor	O
.	O
Her	O
diarrhea	O
improved	O
,	O
though	O
her	O
flagyl	I-Drug
was	O
stopped	O
after	O
she	O
developed	O
parasthesias	I-Ade
.	O
Reviewing	O
the	O
record	O
,	O
it	O
appeared	O
that	O
she	O
stopped	O
her	O
previous	O
taper	O
early	O
.	O
Therefore	O
,	O
a	O
more	O
aggressive	O
taper	O
was	O
pursued	O
,	O
deferring	O
possible	O
fecal	O
transplantation	O
to	O
the	O
outpatient	O
setting	O
,	O
as	O
well	O
as	O
rifamixin	I-Drug
.	O
.	O
ARF	I-Reason
:	O
Likely	O
pre-renal	O
.	O
Resolved	O
with	O
IVF	I-Drug
resusitation	O
.	O
h	B-Reason
/	I-Reason
o	I-Reason
DVT	I-Reason
:	O
Coumadin	I-Drug
was	O
reversed	O
initially	O
.	O
However	O
,	O
once	O
she	O
stabilized	O
it	O
was	O
restarted	O
with	O
lovenox	I-Drug
bridge	O
.	O
She	O
will	O
need	O
close	O
follow	O
up	O
to	O
ensure	O
her	O
coumadin	I-Drug
returns	O
to	O
therapeutic	O
range	O
2	O
-	O
3	O
and	O
was	O
dicharged	O
on	O
warfarin	I-Drug
4	O
mg	O
daily	O
and	O
lovenox	I-Drug
40	O
mg	O
SC	O
q12	O
to	O
bridge	O
.	O
Plexopathy	I-Reason
:	O
Continued	O
coumadin	I-Drug
.	O
HTN	B-Reason
,	I-Reason
benign	I-Reason
:	O
will	O
restart	O
home	O
antihypertensives	I-Drug
on	O
discharge	O
.	O
Chronic	O
diastolic	O
CHF	O
:	O
was	O
euvolemic	O
on	O
exam	O
.	O
Continued	O
home	O
medications	O
Medications	O
on	O
Admission	O
:	O
Citalopram	I-Drug
40	O
mg	O
daily	O
Gabapentin	B-Drug
100	O
mg	O
TID	O
Alprazolam	I-Drug
1	O
mg	O
TID	O
prn	O
Lisinopril	I-Drug
10	O
mg	O
daily	O
Metoprolol	I-Drug
Tartrate	O
12.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Pantoprazole	I-Drug
40	O
mg	O
daily	O
Oxycodone	I-Drug
5	O
mg	O
q6h	O
prn	O
pain	I-Reason
Trazodone	I-Drug
50	O
mg	O
qhs	O
prn	O
Vitamin	B-Drug
D	I-Drug
-	O
3	O
800	O
units	O
daily	O
Calcium	I-Drug
Carbonate	O
500	O
mg	O
(	O
1,250	O
mg	O
)	O
2tabs	O
daily	O
Multivitamin	I-Drug
daily	O
Lidocaine	B-Drug
HCl	I-Drug
5	O
%	O
Ointment	O
topical	O
TID	O
prn	O
rectal	B-Reason
pain	I-Reason
Warfarin	I-Drug
6	O
mg	O
for	O
the	O
first	O
day	O
follwed	O
by	O
4	O
mg	O
in	O
the	O
next	O
two	O
days	O
Discharge	O
Medications	O
:	O
1	O
.	O
Vancomycin	I-Drug
125	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
as	O
directed	O
:	O
125	O
mg	O
4	O
times	O
per	O
day	O
through	O
[	O
**	O
2125-9-26	O
**	O
]	O
,	O
14	O
days	O
,	O
then	O
125	O
mg	O
2	O
times	O
per	O
day	O
through	O
[	O
**	O
2125-10-3	O
**	O
]	O
,	O
7	O
days	O
,	O
then	O
125	O
mg	O
1	O
time	O
per	O
day	O
through	O
[	O
**	O
2125-10-10	O
**	O
]	O
,	O
7	O
days	O
,	O
then	O
125	O
mg	O
every	O
other	O
day	O
through	O
[	O
**	O
2125-10-18	O
**	O
]	O
,	O
8	O
days	O
,	O
then	O
125	O
mg	O
every	O
3rd	O
day	O
through	O
[	O
**	O
2125-11-2	O
**	O
]	O
,	O
15	O
days	O
.	O
Disp	O
:	O
*	O
90	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Citalopram	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Gabapentin	B-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
5	O
.	O
Cholecalciferol	I-Drug
(	O
Vitamin	O
D3	O
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Calcium	I-Drug
Carbonate	O
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Acetaminophen	B-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
9	O
.	O
Alprazolam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
11	O
.	O
Warfarin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
:	O
please	O
have	O
INR	O
checked	O
2	O
days	O
after	O
discharge	O
and	O
adjust	O
according	O
to	O
your	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
18303	O
**	O
]	O
INR	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
.	O
12	O
.	O
Outpatient	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
Work	O
PT	O
/	O
INR	O
on	O
[	O
**	O
2125-9-20	O
**	O
]	O
,	O
[	O
**	O
2125-9-22	O
**	O
]	O
.	O
to	O
fax	O
to	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
20561	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
26190	O
**	O
]	O
Fax	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
81080	O
**	O
]	O
13	O
.	O
Enoxaparin	I-Drug
40	O
mg	O
/	O
0.4	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
injection	O
Subcutaneous	O
Q12	O
HR	O
(	O
)	O
:	O
subcutaneously	O
until	O
INR	O
2	O
.	O
Disp	O
:	O
*	O
10	O
injection	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital3	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
#	O
C	O
-	O
diff	O
colitis	O
,	O
protracted	O
#	O
Sepsis	O
due	O
to	O
c	O
-	O
diff	O
colitis	O
#	O
acute	O
exacerbation	O
of	O
diastolic	O
heart	O
failure	O
#	O
Acute	O
renal	O
failure	O
#	O
Right	O
brachial	O
plexopathy	O
#	O
Peripheral	B-Ade
neuropathy	I-Ade
,	O
new	O
;	O
likely	O
d	O
/	O
t	O
Flagyl	I-Drug
#	O
Anticoagulation	I-Reason
on	O
coumadin	I-Drug
Discharge	O
Condition	O
:	O
stable	O
,	O
diarrhea	O
,	O
improved	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
recurrent	O
diarrhea	O
due	O
to	O
your	O
c	B-Reason
-	I-Reason
diff	I-Reason
infection	O
.	O
Please	O
take	O
your	O
medications	O
as	O
prescribed	O
.	O
It	O
will	O
be	O
very	O
important	O
to	O
complete	O
the	O
full	O
course	O
of	O
vancomycin	I-Drug
,	O
even	O
if	O
you	O
start	O
feeling	O
better	O
.	O
You	O
will	O
be	O
tapered	O
off	O
this	O
medication	O
.	O
Please	O
seek	O
medical	O
attention	O
if	O
you	O
develop	O
worsened	O
diarrhea	O
,	O
abdominal	O
pain	O
,	O
blood	O
in	O
your	O
stools	O
,	O
fevers	O
,	O
chills	O
,	O
or	O
any	O
other	O
concerns	O
.	O
Also	O
,	O
your	O
coumadin	I-Drug
is	O
not	O
in	O
the	O
desired	O
range	O
.	O
You	O
will	O
need	O
to	O
take	O
Lovenox	I-Drug
injections	O
until	O
your	O
coumadin	I-Drug
level	O
is	O
therapeutic	O
.	O
.	O
New	O
medication	O
:	O
Vancomycin	I-Drug
,	O
oral	O
:	O
125	O
mg	O
4	O
times	O
per	O
day	O
through	O
[	O
**	O
2125-9-26	O
**	O
]	O
,	O
14	O
days	O
,	O
then	O
125	O
mg	O
2	O
times	O
per	O
day	O
through	O
[	O
**	O
2125-10-3	O
**	O
]	O
,	O
7	O
days	O
,	O
then	O
125	O
mg	O
1	O
time	O
per	O
day	O
through	O
[	O
**	O
2125-10-10	O
**	O
]	O
,	O
7	O
days	O
,	O
then	O
125	O
mg	O
every	O
other	O
day	O
through	O
[	O
**	O
2125-10-18	O
**	O
]	O
,	O
8	O
days	O
,	O
then	O
125	O
mg	O
every	O
3rd	O
day	O
through	O
[	O
**	O
2125-11-2	O
**	O
]	O
,	O
15	O
days	O
.	O
Lovenox	I-Drug
40	O
mg	O
subcutaneously	O
twice	O
daily	O
until	O
INR	O
is	O
2	O
.	O
.	O
Appointments	O
have	O
been	O
made	O
for	O
you	O
.	O
Please	O
return	O
to	O
the	O
hospital	O
if	O
you	O
experience	O
fevers	O
/	O
chills	O
,	O
worsening	O
abdominal	O
pain	O
,	O
lightheadedness	O
,	O
or	O
any	O
other	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Appointment	O
#	O
1	O
MD	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
20561	O
**	O
]	O
Specialty	O
:	O
Internal	O
Medicine	O
/	O
PCP	O
Date	O
and	O
time	O
:	O
Monday	O
,	O
[	O
**	O
10	O
-	O
1	O
**	O
]	O
,	O
1:20	O
pm	O
Location	O
:	O
One	O
Pearl	O
St	O
,	O
[	O
**	O
Hospital1	O
1474	O
**	O
]	O
MA	O
Phone	O
number	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
26190	O
**	O
]	O
Special	O
instructions	O
if	O
applicable	O
:	O
.	O
Appointment	O
#	O
2	O
MD	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2643	O
**	O
]	O
Specialty	O
:	O
Gastroenterology	O
Date	O
and	O
time	O
:	O
Monday	O
,	O
[	O
**	O
10	O
-	O
15	O
**	O
]	O
,	O
11	O
am	O
Location	O
:	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Buidling	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Phone	O
number	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
463	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2120-12-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2121-1-4	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Benzodiazepines	I-Drug
/	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
348	O
**	O
]	O
Chief	O
Complaint	O
:	O
respiratory	O
distress	O
,	O
hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Endotracheal	O
intubation	O
Swan	O
-	O
ganz	O
catheter	O
placement	O
Blood	O
component	O
transfusions	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
an	O
88	O
yo	O
male	O
h	O
/	O
o	O
CAD	O
,	O
MI	O
,	O
AAA	O
(	O
s	O
/	O
p	O
repair	O
,	O
no	O
leak	O
)	O
recent	O
AICD	O
for	O
syncopal	O
episode	O
NOS	O
(	O
[	O
**	O
11	O
-	O
11	O
**	O
]	O
)	O
,	O
severe	O
cardiomyopathy	O
EF	O
10	O
%	O
,	O
who	O
originally	O
presented	O
to	O
OSH	O
with	O
epigastric	O
pain	O
found	O
to	O
be	O
hypotensive	O
there	O
to	O
60s	O
systolic	O
.	O
He	O
was	O
then	O
intubated	O
for	O
hypoxic	O
respiratory	O
failure	O
with	O
ABG	O
7.26	O
/	O
52/41	O
(	O
was	O
DNR	O
/	O
DNI	O
)	O
.	O
He	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital1	O
**	O
]	O
CCU	O
.	O
A	O
CTA	O
was	O
done	O
to	O
rule	O
out	O
AAA	O
and	O
did	O
not	O
show	O
any	O
leak	O
but	O
aneurysm	O
of	O
6.5	O
cm	O
and	O
stable	O
.	O
.	O
Pt	O
was	O
treated	O
for	O
his	O
shock	I-Reason
which	O
was	O
of	O
unclear	O
etiology	O
.	O
He	O
was	O
started	O
on	O
Zosyn	I-Drug
and	O
Vancomycin	I-Drug
on	O
[	O
**	O
2120-12-13	O
**	O
]	O
and	O
vancomycin	I-Drug
was	O
d	O
/	O
cd	O
as	O
sputum	O
from	O
[	O
**	O
2120-12-14	O
**	O
]	O
grew	O
GNR	O
not	O
further	O
speciated	O
.	O
There	O
was	O
not	O
found	O
to	O
be	O
any	O
other	O
source	O
of	O
infection	O
.	O
In	O
the	O
CCU	O
,	O
pressors	O
were	O
weaned	O
off	O
[	O
**	O
2120-12-17	O
**	O
]	O
.	O
Pt	O
was	O
started	O
on	O
steroids	I-Drug
on	O
[	O
**	O
2120-12-14	O
**	O
]	O
for	O
inappropriate	B-Reason
cortisol	I-Reason
stimulation	I-Reason
test	I-Reason
though	O
it	O
appears	O
not	O
drawn	O
correctly	O
.	O
.	O
Called	O
by	O
floor	O
team	O
today	O
as	O
pt	O
with	O
"	O
[	O
**	O
10	O
-	O
15	O
**	O
]	O
"	O
abdominal	O
pain	O
that	O
was	O
sharp	O
and	O
radiated	O
to	O
his	O
back	O
x	O
10	O
minutes	O
.	O
Their	O
exam	O
revealed	O
pain	O
out	O
of	O
proportion	O
to	O
it	O
and	O
concern	O
was	O
for	O
mesenteric	O
ischemia	O
.	O
Lactate	O
on	O
a	O
VBG	O
was	O
noted	O
to	O
be	O
up	O
to	O
2.4	O
but	O
repeat	O
with	O
ABG	O
is	O
1.7	O
.	O
Pt	O
says	O
that	O
he	O
vomited	O
x	O
1	O
today	O
,	O
did	O
not	O
notice	O
the	O
color	O
.	O
+	O
mild	O
sob	O
.	O
+	O
dry	O
cough	O
that	O
started	O
today	O
.	O
+	O
abdominal	O
pain	O
[	O
**	O
9	O
-	O
15	O
**	O
]	O
when	O
I	O
saw	O
pt	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
s	O
/	O
p	O
CABG	O
PAF	O
AAA	O
(	O
s	O
/	O
p	O
repair	O
)	O
severe	O
cardiomyopathy	O
-	O
EF	O
10	O
%	O
s	O
/	O
p	O
AICD	O
for	O
sick	O
sinus	O
syndrome	O
(	O
[	O
**	O
11	O
-	O
11	O
**	O
]	O
)	O
s	O
/	O
p	O
biV	O
pacer	O
HTN	O
GERD	O
hypercholesterolemia	O
PVD	O
s	O
/	O
p	O
iliac	O
stent	O
placement	O
bilaterally	O
h	O
/	O
o	O
DVT	O
/	O
PE	O
in	O
past	O
Social	O
History	O
:	O
wife	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
former	O
smoker	O
Family	O
History	O
:	O
non-contributory	O
Physical	O
Exam	O
:	O
T	O
:	O
97	O
(	O
r	O
)	O
;	O
BP	O
:	O
106/70	O
;	O
HR	O
:	O
88	O
;	O
RR	O
:	O
22	O
;	O
O2	O
98	O
2L	O
Gen	O
:	O
Sitting	O
up	O
in	O
bed	O
tachypnic	O
speaking	O
in	O
full	O
sentences	O
HEENT	O
:	O
EOMI	O
;	O
sclera	O
anicteric	O
;	O
OP	O
clear	O
Neck	O
:	O
No	O
LAD	O
.	O
JVD	O
not	O
appreciated	O
at	O
80	O
degrees	O
CV	O
:	O
Irregularly	O
irregular	O
,	O
S1S2	O
.	O
I	O
-	O
II	O
/	O
VI	O
systolic	O
murmur	O
at	O
LUSB	O
and	O
apex	O
Lungs	O
:	O
Good	O
air	O
flow	O
.	O
Crackles	O
at	O
left	O
base	O
.	O
No	O
change	O
to	O
percussion	O
Abd	O
:	O
NABS	O
.	O
Soft	O
,	O
ND	O
.	O
Mild	O
tenderness	O
to	O
deep	O
palpation	O
in	O
epigastric	O
area	O
.	O
No	O
rebound	O
or	O
guarding	O
Back	O
:	O
No	O
spinal	O
,	O
paraspinal	O
,	O
CVA	O
tenderness	O
Ext	O
:	O
No	O
edema	O
.	O
DP	O
2	O
+	O
Neuro	O
:	O
CN	O
II	O
-	O
XII	O
tested	O
and	O
intact	O
.	O
"	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
"	O
"	O
[	O
**	O
2110	O
**	O
]	O
"	O
.	O
Knew	O
he	O
was	O
at	O
a	O
hospital	O
,	O
though	O
not	O
which	O
one	O
.	O
Pertinent	O
Results	O
:	O
CTA	O
[	O
**	O
2120-12-13	O
**	O
]	O
-	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
for	O
aortic	O
dissection	O
or	O
pulmonary	O
embolus	O
.	O
2	O
.	O
6.5	O
-	O
cm	O
infrarenal	O
abdominal	O
aortic	O
aneurysm	O
with	O
evidence	O
of	O
graft	O
repair	O
distally	O
.	O
No	O
evidence	O
of	O
aneurysm	O
rupture	O
or	O
leak	O
.	O
3	O
.	O
Pulmonary	O
vascular	O
congestion	O
,	O
intra-abdominal	O
ascites	O
,	O
periportal	O
edema	O
,	O
and	O
anasarca	O
suggest	O
congestive	O
heart	O
failure	O
versus	O
volume	O
overload	O
or	O
both	O
.	O
4	O
.	O
Cardiomegaly	O
.	O
5	O
.	O
Bibasilar	O
subsegmental	O
atelectasis	O
with	O
small	O
bilateral	O
pleural	O
effusions	O
.	O
.	O
Echo	O
[	O
**	O
2120-12-13	O
**	O
]	O
-	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
.	O
There	O
is	O
severe	O
global	O
left	O
ventricular	O
hypokinesis	O
,	O
EF	O
10	O
-	O
15	O
%	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
mild	O
global	O
right	O
ventricular	O
free	O
wall	O
hypokinesis	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
CXR	O
AP	O
(	O
not	O
official	O
read	O
)	O
-	O
enlarged	O
heart	O
s	O
/	O
p	O
sternotomy	O
wires	O
.	O
There	O
are	O
b	O
/	O
l	O
pleural	O
effusions	O
.	O
?	O
left	O
retrocardiac	O
opacity	O
.	O
.	O
CTA	O
wet	O
read	O
from	O
radiology	O
:	O
SMA	O
is	O
patent	O
.	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
899	O
**	O
]	O
cant	O
see	O
[	O
**	O
2	O
-	O
8	O
**	O
]	O
graft	O
.	O
No	O
post-ischemic	O
changes	O
.	O
Free	O
fluid	O
in	O
abdomen	O
and	O
anasarca	O
,	O
all	O
unchanged	O
.	O
No	O
change	O
from	O
prior	O
.	O
Brief	O
Hospital	O
Course	O
:	O
In	O
Brief	O
,	O
the	O
patient	O
is	O
an	O
88	O
year	O
old	O
man	O
with	O
severe	O
ischemic	O
cardiomyopathy	O
s	O
/	O
p	O
BiV	O
-	O
ICD	O
placement	O
,	O
atrial	O
flutter	O
,	O
CAD	O
,	O
chronic	O
kidney	O
disease	O
who	O
presented	O
with	O
hypoxic	O
respiratory	O
failure	O
and	O
shock	O
which	O
was	O
stablized	O
.	O
His	O
course	O
was	O
further	O
complicated	O
by	O
acute	O
abdomial	O
pain	O
,	O
psoas	O
muscle	O
hematoma	O
,	O
upper	O
GI	O
bleed	O
,	O
acute	O
on	O
chronic	O
renal	O
failure	O
,	O
heparin	I-Drug
induced	O
thrombocytopenia	I-Ade
with	O
upper	O
extremity	O
DVT	O
,	O
intermittent	O
hypoxia	O
,	O
and	O
urinary	O
retention	O
.	O
.	O
1	O
)	O
Shock	I-Reason
-	O
Patient	O
intially	O
presented	O
in	O
shock	O
requiring	O
vasopressors	I-Drug
.	O
Cardiac	O
index	O
was	O
normal	O
with	O
decreased	O
SVR	O
which	O
were	O
not	O
consistent	O
with	O
cardiogenic	O
shock	O
.	O
The	O
likely	O
cause	O
of	O
was	O
distributive	B-Reason
/	I-Reason
septic	I-Reason
shock	I-Reason
of	O
unclear	O
source	O
of	O
infection	O
.	O
He	O
completed	O
a	O
full	O
course	O
of	O
empiric	O
antibiotics	I-Drug
.	O
He	O
completed	O
7	O
days	O
of	O
hydrocortisone	I-Drug
/	O
fludrocort	O
for	O
sub-optimal	B-Reason
response	I-Reason
to	I-Reason
ACTH	O
.	O
BP	O
stablized	O
by	O
time	O
of	O
discharge	O
.	O
.	O
2	O
)	O
Respiratory	O
Failure	O
:	O
The	O
patient	O
initially	O
presented	O
in	O
hypoxic	O
respiratory	O
failure	O
likely	O
secondary	O
to	O
CHF	O
,	O
hypoventilation	O
and	O
decreased	O
mental	O
status	O
.	O
He	O
was	O
intubated	O
prior	O
to	O
transfer	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
He	O
was	O
weaned	O
from	O
the	O
ventilator	O
successfully	O
.	O
He	O
did	O
have	O
intermittent	O
hypoxia	O
largely	O
secondary	O
to	O
pulmonary	B-Reason
edema	I-Reason
from	O
inadequate	O
diuresis	O
.	O
He	O
was	O
stabilized	O
on	O
standing	O
twice	O
daily	O
lasix	I-Drug
.	O
He	O
was	O
started	O
on	O
BiPaP	O
at	O
night	O
for	O
hypoventilation	O
.	O
.	O
3	O
)	O
Abdominal	O
pain	O
-	O
During	O
the	O
hospital	O
stay	O
he	O
developed	O
acute	O
severe	O
epigastric	O
pain	O
.	O
He	O
was	O
transfered	O
to	O
the	O
MICU	O
for	O
concern	O
for	O
mesenteric	O
ischemia	O
.	O
An	O
abominal	O
CTA	O
was	O
negative	O
for	O
this	O
.	O
A	O
surgery	O
consult	O
was	O
obtained	O
and	O
recommended	O
no	O
surgical	O
intervention	O
.	O
The	O
pain	O
resolved	O
without	O
specific	O
intervention	O
.	O
He	O
was	O
subsequently	O
found	O
to	O
have	O
an	O
psoas	O
muscle	O
hematoma	O
and	O
required	O
several	O
blood	O
transfusions	O
with	O
appropriate	O
response	O
in	O
his	O
hematocrit	O
.	O
4	O
)	O
Cardiovascular	O
:	O
a.	O
CAD	I-Reason
-	O
history	O
of	O
MI	O
s	O
/	O
p	O
CABG	O
.	O
will	O
continue	O
ASA	I-Drug
,	O
simvastatin	I-Drug
,	O
beta	B-Drug
-	I-Drug
blocker	I-Drug
.	O
.	O
b.	O
Pump	O
-	O
Severe	O
ischemic	O
cardiomyopathy	O
with	O
EF	O
10	O
-	O
15	O
%	O
s	O
/	O
p	O
BiV	O
-	O
ICD	O
placement	O
.	O
No	O
evidence	O
of	O
cardiogenic	O
shock	O
upon	O
initial	O
presenation	O
as	O
C.I.	O
was	O
normal	O
.	O
Medically	O
managed	O
CHF	I-Reason
with	O
ACEi	I-Drug
,	O
beta	B-Drug
-	I-Drug
blocker	I-Drug
,	O
digoxin	I-Drug
,	O
spironolactone	I-Drug
,	O
furosemide	I-Drug
.	O
.	O
c.	O
rhythm	O
-	O
[	O
**	O
Hospital1	O
**	O
]	O
-	O
V	O
paced	O
with	O
underlying	O
rhythm	O
is	O
atrial	I-Reason
flutter	O
/	O
fibrillation	O
.	O
Started	O
on	O
amiodarone	I-Drug
for	O
maintenance	B-Reason
of	I-Reason
sinus	O
rhythm	O
to	O
maximize	O
likelihood	O
of	O
atrial	O
kick	O
.	O
Also	O
,	O
amiodarone	I-Drug
to	O
decrease	O
in	O
-	O
appropriate	O
shocks	O
from	O
ICD	O
.	O
5	O
)	O
Upper	B-Ade
GI	I-Ade
bleed	I-Ade
-	O
The	O
patient	O
did	O
develop	O
guaiac	O
positive	O
stools	O
in	O
the	O
setting	O
of	O
anticoagulation	I-Drug
for	O
the	O
atrial	I-Reason
fibrillation	O
.	O
The	O
hematocrit	O
drop	O
was	O
largely	O
due	O
to	O
the	O
psoas	O
hematoma	O
as	O
above	O
.	O
The	O
patient	O
refused	O
EGD	O
.	O
If	O
the	O
patient	O
develops	O
recurrent	O
melenotic	O
stools	O
he	O
could	O
be	O
referred	O
to	O
GI	O
for	O
endoscopy	O
.	O
He	O
will	O
continue	O
on	O
a	O
PPI	I-Drug
.	O
.	O
6	O
)	O
Acute	O
on	O
Chronic	O
Renal	O
failure	O
-	O
Initial	O
creatinine	O
down	O
from	O
admission	O
to	O
peak	O
2.5	O
this	O
was	O
likely	O
from	O
pre-renal	O
secondary	O
to	O
shock	O
state	O
;	O
no	O
evidence	O
of	O
ATN	O
.	O
By	O
time	O
of	O
discharge	O
,	O
the	O
creatinine	O
had	O
resolved	O
to	O
baseline	O
.	O
.	O
7	O
)	O
Anemia	O
-	O
In	O
addition	O
the	O
the	O
acute	O
blood	O
loss	O
anemia	O
as	O
described	O
above	O
.	O
The	O
patient	O
has	O
a	O
chronic	O
microcytic	O
anemia	O
.	O
Iron	O
studies	O
were	O
consistent	O
with	O
anemia	O
of	O
chronic	O
disease	O
(	O
labs	O
drawn	O
before	O
blood	O
transfusions	O
were	O
given	O
)	O
.	O
Also	O
with	O
regard	O
to	O
the	O
significant	O
microcytosis	O
and	O
his	O
Italian	O
extraction	O
,	O
hemoglobin	O
electrophoresis	O
was	O
performed	O
to	O
evaluate	O
for	O
thallasemia	O
.	O
These	O
results	O
were	O
pending	O
at	O
time	O
of	O
discharge	O
.	O
.	O
8	O
)	O
Thrombocytopenia	B-Reason
-	I-Reason
HIT	I-Reason
type	I-Reason
II	I-Reason
.	O
PF4	O
positive	O
on	O
[	O
**	O
2120-12-27	O
**	O
]	O
,	O
Platelets	O
stable	O
at	O
around	O
70K	O
with	O
subsequent	O
recovery	O
to	O
greater	O
than	O
150K	O
.	O
He	O
did	O
have	O
a	O
left	O
upper	O
extremity	O
venous	O
clot	O
although	O
the	O
developement	O
of	O
this	O
was	O
after	O
his	O
platelets	O
had	O
stabilized	O
.	O
Started	O
argatroban	I-Drug
on	O
[	O
**	O
2120-12-27	O
**	O
]	O
with	O
transition	O
to	O
coumadin	I-Drug
.	O
He	O
continued	O
on	O
argatroban	I-Drug
until	O
his	O
INR	O
on	O
combined	O
anti-coagulation	I-Drug
was	O
>	O
4	O
.	O
At	O
which	O
time	O
he	O
was	O
maintained	O
on	O
coumadin	I-Drug
alone	O
.	O
.	O
9	O
)	O
Urinary	B-Reason
retention	I-Reason
:	O
-	O
The	O
patient	O
has	O
no	O
prior	O
history	O
of	O
urinary	O
retention	O
,	O
nocturia	O
,	O
frequency	O
or	O
related	O
BPH	O
symptoms	O
.	O
During	O
one	O
attempt	O
at	O
removing	O
the	O
foley	O
catheter	O
he	O
had	O
decreased	O
urine	O
output	O
with	O
a	O
large	O
volume	O
detected	O
on	O
bladder	O
scan	O
.	O
The	O
foley	O
was	O
replaced	O
.	O
He	O
was	O
started	O
on	O
finasteride	I-Drug
,	O
not	O
wanting	O
to	O
use	O
an	O
alpha	B-Drug
-	I-Drug
blocker	I-Drug
that	O
would	O
likely	O
cause	O
hypotension	I-Ade
when	O
added	O
to	O
his	O
extensive	O
cardiac	O
regimen	O
.	O
The	O
catheter	O
was	O
left	O
in	O
at	O
discharge	O
.	O
This	O
should	O
be	O
removed	O
in	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
days	O
followed	O
by	O
confirmation	O
that	O
the	O
patient	O
can	O
urinate	O
.	O
.	O
10	O
)	O
Code	O
Status	O
:	O
DNR	O
/	O
DNI	O
confirmed	O
with	O
patient	O
and	O
HCP	O
.	O
.	O
11	O
)	O
Dispo	O
:	O
the	O
patient	O
was	O
discharged	O
to	O
rehab	O
Medications	O
on	O
Admission	O
:	O
Hydrocortisone	I-Drug
Na	O
50	O
mg	O
IV	O
q6	O
RISS	I-Drug
Ipratropium	I-Drug
MDI	O
prn	O
Tylenol	I-Drug
prn	O
Albuterol	I-Drug
prn	O
Lactulose	I-Drug
30	O
mg	O
po	O
q8	O
prn	O
Pantoprazole	I-Drug
40	O
mg	O
po	O
q24	O
hr	O
Amiodarone	I-Drug
200	O
mg	O
po	O
qday	O
ASA	I-Drug
81	O
mg	O
po	O
qday	O
Colace	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Senna	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
Fludrocortisone	I-Drug
0.05	O
mg	O
po	O
qday	O
Simvastatin	I-Drug
40	O
mg	O
po	O
qday	O
Heparin	I-Drug
gtt	O
Zosyn	I-Drug
2.25	O
mg	O
IV	O
q6	O
Discharge	O
Medications	O
:	O
1	O
.	O
Simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
4	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Lactulose	I-Drug
10	O
g	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
:	O
to	O
maintain	O
at	O
least	O
1BM	O
per	O
day	O
.	O
7	O
.	O
Digoxin	I-Drug
125	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
EVERY	O
OTHER	O
DAY	O
(	O
Every	O
Other	O
Day	O
)	O
.	O
8	O
.	O
Metoprolol	I-Drug
Succinate	O
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
sleep	I-Reason
.	O
10	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Spironolactone	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
hold	O
for	O
sbp	O
<	O
95	O
.	O
13	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
,	O
dyspnea	I-Reason
.	O
14	O
.	O
Furosemide	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
:	O
titrate	O
to	O
INR	O
goal	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
.	O
16	O
.	O
Finasteride	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
17	O
.	O
Compazine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
18	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
draw	O
PT	O
/	O
INR	O
daily	O
for	O
3	O
days	O
and	O
thereafter	O
per	O
protocol	O
for	O
INR	O
goal	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
19	O
.	O
Aluminum	B-Drug
-	I-Drug
Magnesium	I-Drug
Hydroxide	I-Drug
225	O
-	O
200	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15	O
-	O
30	O
MLs	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
20	O
.	O
BiPaP	O
BiPAP	O
with	O
mask	O
at	O
night	O
10cmH2O	O
PS	O
,	O
5	O
cmH2O	O
PEEP	O
.	O
Titrate	O
FIO2	O
to	O
keep	O
O2sat	O
>	O
95	O
%	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
700	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
701	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Septic	O
Shock	O
Hypoxic	O
respiratory	O
failure	O
Secondary	O
:	O
Heparin	I-Drug
induced	O
thrombocytopenia	I-Reason
Acute	B-Ade
blood	I-Ade
loss	I-Ade
anemia	I-Ade
from	I-Ade
Psoas	I-Ade
muscle	I-Ade
hematoma	I-Ade
Urinary	O
retention	O
Upper	O
extremity	O
venous	O
clot	O
Ischemic	O
cardiomyopathy	O
Atrial	O
fibrillation	O
/	O
Atrial	O
flutter	O
Congestive	O
heart	O
failure	O
-	O
systolic	O
,	O
compensated	O
Microcytic	O
Anemia	O
Discharge	O
Condition	O
:	O
good	O
.	O
stable	O
vital	O
signs	O
.	O
tolerating	O
oral	O
medications	O
and	O
nutrition	O
.	O
ambulating	O
with	O
minimal	O
assist	O
.	O
Discharge	O
Instructions	O
:	O
You	O
have	O
been	O
evaluated	O
for	O
respiratory	O
distress	O
,	O
and	O
very	O
low	O
blood	O
blood	O
pressure	O
.	O
These	O
resolved	O
with	O
time	O
,	O
antibiotics	I-Drug
,	O
and	O
close	O
management	O
of	O
your	O
chronic	O
heart	O
disease	O
.	O
Your	O
course	O
was	O
complicated	O
by	O
a	B-Ade
bleed	I-Ade
into	I-Ade
a	I-Ade
hip	I-Ade
muscle	I-Ade
,	O
a	O
reaction	O
to	O
a	O
medication	O
called	O
heparin	I-Drug
,	O
and	O
difficulty	O
urinating	O
.	O
These	O
were	O
all	O
stablized	O
over	O
the	O
course	O
of	O
the	O
hospital	O
stay	O
.	O
Please	O
take	O
the	O
medications	O
as	O
prescribed	O
.	O
Please	O
make	O
and	O
attend	O
your	O
recommended	O
follow	O
-	O
up	O
appointments	O
.	O
If	O
you	O
develop	O
any	O
concerning	O
symptom	O
particularly	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
bloody	O
or	O
tarry	O
stools	O
please	O
seek	O
medical	O
attention	O
.	O
Followup	O
Instructions	O
:	O
Please	O
contact	O
your	O
primary	O
doctor	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
58623	O
**	O
]	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
58624	O
**	O
]	O
to	O
be	O
seen	O
within	O
the	O
next	O
1	O
-	O
2	O
weeks	O
.	O
In	O
the	O
meantime	O
you	O
will	O
be	O
evaluated	O
by	O
the	O
physicians	O
at	O
the	O
rehab	O
facility	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2136-8-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2136-8-21	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2064-3-15	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1167	O
**	O
]	O
Chief	O
Complaint	O
:	O
nausea	O
/	O
vomiting	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Attempted	O
temporary	O
pacing	O
wire	O
placement	O
(	O
unsuccessful	O
)	O
Foley	O
catheter	O
History	O
of	O
Present	O
Illness	O
:	O
72	O
year	O
old	O
female	O
with	O
h	O
/	O
o	O
severe	O
ventricular	O
dysfunction	O
(	O
EF	O
10	O
%	O
)	O
secondary	O
to	O
polysubstance	O
abuse	O
and	O
HIV	O
(	O
dx	O
[	O
**	O
2116	O
**	O
]	O
on	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
2775	O
**	O
]	O
,	O
last	O
CD4	O
359	O
)	O
,	O
2	O
+	O
MR	O
,	O
on	O
methadone	I-Drug
maintenance	O
who	O
presents	O
with	O
nausea	O
,	O
bradycardia	O
,	O
acute	O
on	O
chronic	O
renal	O
failure	O
with	O
potassium	O
of	O
6.0	O
.	O
Patient	O
states	O
she	O
has	O
been	O
fatigued	O
recently	O
but	O
denies	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
orthopnea	O
and	O
leg	O
swelling	O
.	O
On	O
day	O
of	O
presentation	O
to	O
ED	O
,	O
she	O
began	O
vomiting	O
,	O
non-bloody	O
non-bilious	O
.	O
.	O
Patient	O
was	O
recently	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
105348	O
**	O
]	O
/	O
07	O
with	O
CHF	O
exacerbation	O
,	O
swan	O
was	O
placed	O
that	O
admission	O
and	O
she	O
was	O
diuresed	O
.	O
Elevated	O
troponin	O
at	O
the	O
time	O
thought	O
secondary	O
to	O
demand	O
.	O
She	O
was	O
started	O
on	O
amiodarone	I-Drug
for	O
runs	B-Reason
of	I-Reason
VTach	I-Reason
and	O
continued	O
on	O
digoxin	I-Drug
.	O
She	O
states	O
she	O
has	O
been	O
compliant	O
with	O
her	O
medications	O
.	O
.	O
ED	O
:	O
sbp	O
80's	O
,	O
which	O
is	O
baseline	O
.	O
Given	O
insulin	I-Drug
,	O
1amp	O
D50	I-Drug
,	O
atropine	I-Drug
,	O
calcium	B-Drug
gluconate	I-Drug
1g	O
,	O
sodium	B-Drug
bicarbonate	I-Drug
50mEq	O
for	O
potassium	B-Reason
6.0	I-Reason
.	O
Given	O
ondansetron	I-Drug
.	O
EKG	O
likely	O
junctional	O
brady	O
with	O
retrograde	O
p	O
waves	O
.	O
.	O
On	O
review	O
of	O
symptoms	O
,	O
she	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
,	O
hemoptysis	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
She	O
denies	O
recent	O
fevers	O
,	O
chills	O
or	O
rigors	O
.	O
Other	O
review	O
of	O
symptoms	O
negative	O
aside	O
from	O
above	O
.	O
.	O
In	O
the	O
ED	O
,	O
the	O
patient	O
was	O
afebrile	O
with	O
SBP	O
in	O
the	O
80	O
-	O
90s	O
.	O
She	O
had	O
nausea	O
and	O
was	O
noted	O
to	O
have	O
HR	O
in	O
the	O
30s	O
junctional	O
vs	O
av	O
delay	O
.	O
Now	O
being	O
transferred	O
to	O
floor	O
for	O
further	O
mgmt	O
.	O
.	O
On	O
arrival	O
to	O
the	O
CCU	O
,	O
she	O
was	O
feeling	O
tired	O
(	O
had	O
n't	O
slept	O
all	O
night	O
)	O
but	O
no	O
CP	O
,	O
shortness	O
of	O
breath	O
,	O
dizziness	O
or	O
LH	O
.	O
.	O
On	O
review	O
of	O
symptoms	O
,	O
she	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
,	O
hemoptysis	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
She	O
denies	O
recent	O
fevers	O
,	O
chills	O
or	O
rigors	O
.	O
Other	O
review	O
of	O
symptoms	O
negative	O
aside	O
from	O
above	O
.	O
.	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
absence	O
of	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
HIV	O
-	O
Diagnosed	O
in	O
[	O
**	O
2116	O
**	O
]	O
,	O
has	O
taken	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
2775	O
**	O
]	O
therapy	O
intermittently	O
.	O
Stopped	O
taking	O
her	O
pills	O
three	O
months	O
ago	O
because	O
stated	O
she	O
had	O
foamy	O
vomit	O
every	O
time	O
she	O
took	O
them	O
.	O
CD4	O
274	O
,	O
VL	O
<	O
50	O
in	O
[	O
**	O
12	O
-	O
10	O
**	O
]	O
2	O
.	O
CHF	O
-	O
EF	O
10	O
%	O
7/07	O
followed	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
437	O
**	O
]	O
3	O
.	O
HCV	O
-	O
VL	O
>	O
700K	O
in	O
[	O
**	O
12	O
-	O
9	O
**	O
]	O
,	O
not	O
a	O
good	O
candidate	O
for	O
interferon	O
therapy	O
or	O
liver	O
biopsy	O
per	O
gi	O
note	O
in	O
04	O
.	O
4	O
.	O
mild	O
COPD	O
-	O
PFTs	O
[	O
**	O
7	O
-	O
/	O
2129	O
**	O
]	O
showed	O
a	O
normal	O
study	O
5	O
.	O
IVDU	O
--	O
last	O
abuse	O
heroin	O
several	O
days	O
ago	O
,	O
skin	O
popping	O
6	O
.	O
Arthritis	O
7	O
.	O
chronic	O
pancreatitis	O
8	O
.	O
ventricular	O
tachycardia	O
Social	O
History	O
:	O
Has	O
20	O
grandchildren	O
,	O
tobacco	O
:	O
[	O
**	O
4	O
-	O
8	O
**	O
]	O
cig	O
/	O
day	O
,	O
40	O
py	O
Heavy	O
EtOH	O
in	O
past	O
.	O
States	O
that	O
last	O
used	O
heroin	O
in	O
the	O
past	O
few	O
days	O
(	O
skin	O
popping	O
)	O
and	O
also	O
used	O
cocaine	O
in	O
the	O
last	O
month	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
VS	O
:	O
96.2	O
F	O
HR	O
30	O
BP	O
86/50	O
RR	O
16	O
100	O
%	O
/	O
2Ln.c	O
.	O
Gen	O
:	O
Cachectic	O
female	O
in	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Mood	O
,	O
affect	O
appropriate	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
Neck	O
:	O
Supple	O
,	O
thin	O
.	O
CV	O
:	O
PMI	O
located	O
in	O
7th	O
intercostal	O
space	O
,	O
midclavicular	O
line	O
.	O
Distant	O
heart	O
sounds	O
,	O
regular	O
rhythm	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
[	O
**	O
3	O
-	O
13	O
**	O
]	O
holosystolic	O
murmur	O
at	O
apex	O
.	O
Chest	O
:	O
No	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
Crackles	O
at	O
right	O
base	O
,	O
left	O
base	O
clear	O
.	O
Abd	O
:	O
Soft	O
,	O
ND	O
,	O
mild	O
TTP	O
epigastrium	O
and	O
RUQ	O
with	O
hepatomegaly	O
.	O
No	O
abdominal	O
bruits	O
.	O
Ext	O
:	O
no	O
LE	O
edema	O
bilaterally	O
.	O
Skin	O
:	O
Multiple	O
well	O
healed	O
lesions	O
from	O
h	O
/	O
o	O
drug	O
abuse	O
Pulses	O
:	O
Right	O
:	O
1	O
+	O
DP	O
Left	O
:	O
1	O
+	O
DP	O
Pertinent	O
Results	O
:	O
7	O
/	O
13/7	O
.	O
CXR	O
.	O
Stable	O
severe	O
cardiomegaly	O
.	O
New	O
mild	O
-	O
to	O
-	O
moderate	O
pulmonary	O
edema	O
accompanied	O
by	O
small	O
bilateral	O
new	O
pleural	O
effusion	O
.	O
[	O
**	O
2136-8-14	O
**	O
]	O
.	O
Digoxin	I-Drug
level	O
3.8	O
[	O
**	O
2136-8-16	O
**	O
]	O
.	O
Dig	I-Drug
level	O
2.5	O
[	O
**	O
2136-8-17	O
**	O
]	O
.	O
Dig	I-Drug
level	O
2.1	O
[	O
**	O
2136-8-18	O
**	O
]	O
.	O
Dig	I-Drug
level	O
1.5	O
Brief	O
Hospital	O
Course	O
:	O
72	O
yo	O
female	O
with	O
severe	O
ventricular	O
dysfunction	O
(	O
EF	O
10	O
%	O
)	O
secondary	O
to	O
polysubstance	O
abuse	O
and	O
HIV	O
(	O
last	O
CD4	O
359	O
)	O
who	O
presented	O
with	O
bradycardia	I-Ade
secondary	O
to	O
digoxin	I-Drug
and	O
amiodarone	I-Drug
toxicity	I-Ade
.	O
.	O
#	O
Rhythm	O
:	O
Found	O
to	O
be	O
bradycardic	I-Ade
to	O
30's	O
in	O
ED	O
in	O
setting	O
of	O
digoxin	I-Drug
toxicity	I-Ade
with	O
amiodarone	I-Drug
and	O
hyperkalemia	O
contributing	O
.	O
Patient	O
had	O
been	O
started	O
on	O
amiodarone	I-Drug
at	O
her	O
last	O
hospitalization	O
due	O
to	O
runs	B-Reason
of	I-Reason
VTach	I-Reason
.	O
Pacer	O
pads	O
were	O
placed	O
but	O
she	O
did	O
not	O
require	O
transcutaneous	O
pacing	O
.	O
An	O
isoproterenol	I-Drug
drip	O
was	O
started	O
which	O
increased	B-Reason
her	I-Reason
Heart	I-Reason
rates	I-Reason
to	I-Reason
50's	I-Reason
-	I-Reason
60's	I-Reason
(	O
although	O
initially	O
remained	O
in	O
junctional	O
rhythm	O
)	O
.	O
Digoxin	I-Drug
and	O
amiodarone	I-Drug
were	O
held	O
.	O
An	O
attempt	O
was	O
made	O
to	O
place	O
a	O
temporary	O
pacing	O
wire	O
,	O
but	O
this	O
attempt	O
was	O
unsuccessful	O
because	O
of	O
thrombosed	O
veins	O
.	O
The	O
isoprotenenol	I-Drug
drip	O
was	O
stopped	O
on	O
[	O
**	O
8	O
-	O
18	O
**	O
]	O
.	O
Patient	O
will	O
not	O
go	O
home	O
on	O
amiodarone	I-Drug
and	O
will	O
go	O
home	O
on	O
Digoxin	I-Drug
0.125	O
mg	O
qod	O
.	O
.	O
#	O
Pump	O
:	O
EF	O
10	O
%	O
on	O
last	O
echo	O
(	O
[	O
**	O
2136-8-3	O
**	O
]	O
)	O
.	O
She	O
appeared	O
euvolemic	O
on	O
admission	O
so	O
lasix	I-Drug
was	O
held	O
.	O
She	O
developed	O
increased	O
shortness	O
of	O
breath	O
and	O
CXR	O
was	O
consistent	O
with	O
pulmonary	B-Reason
edema	I-Reason
,	O
so	O
patient	O
was	O
diuresed	I-Reason
with	O
lasix	I-Drug
.	O
A	O
foley	O
catheter	O
was	O
placed	O
to	O
monitor	O
accurate	O
I	O
/	O
Os	O
.	O
Digoxin	I-Drug
and	O
ACEI	I-Drug
were	O
held	O
.	O
ACEI	I-Drug
will	O
be	O
held	O
until	O
she	O
follows	O
up	O
in	O
clinic	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
437	O
**	O
]	O
.	O
#	O
CAD	O
:	O
No	O
evidence	O
of	O
active	O
ischemia	O
during	O
admission	O
.	O
Normal	O
perfusion	O
images	O
in	O
[	O
**	O
2133	O
**	O
]	O
.	O
#	O
HIV	O
:	O
Last	O
CD4	O
359	O
in	O
04	O
/	O
[	O
**	O
2136	O
**	O
]	O
.	O
Patient	O
requested	O
that	O
her	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
2775	O
**	O
]	O
therapy	O
be	O
stopped	O
as	O
she	O
felt	O
that	O
this	O
made	O
her	O
nauseated	O
and	O
gave	O
her	O
abdominal	O
discomfort	O
.	O
Her	O
PCP	O
was	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
and	O
made	O
aware	O
that	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2775	O
**	O
]	O
was	O
stopped	O
.	O
Her	O
bactrim	I-Drug
prophylaxis	I-Reason
was	O
continued	O
.	O
She	O
will	O
follow	O
-	O
up	O
with	O
her	O
PCP	O
[	O
**	O
2136-8-23	O
**	O
]	O
to	O
discuss	O
further	O
treatment	O
options	O
.	O
#	O
Polysubstance	B-Reason
abuse	I-Reason
:	O
Last	O
use	O
[	O
**	O
6	O
-	O
10	O
**	O
]	O
mos	O
PTA	O
.	O
Continued	O
with	O
methadone	I-Drug
90	O
mg	O
.	O
#	O
ARF	O
on	O
CRI	O
:	O
Baseline	O
creatinine	O
1.3	O
-	O
1.5	O
.	O
Now	O
ARF	O
on	O
CRI	O
;	O
likely	O
secondary	O
to	O
bradycardia	I-Ade
and	O
low	B-Ade
EF	I-Ade
in	O
setting	O
of	O
digoxin	I-Drug
toxicity	O
.	O
Held	O
lasix	I-Drug
and	O
ACEI	I-Drug
initially	O
.	O
Creatine	O
continues	O
to	O
trend	O
towards	O
baseline	O
with	O
return	O
of	O
home	O
lasix	I-Drug
dose	O
.	O
#	O
)	O
Hyperkalemia	I-Reason
:	O
likely	O
[	O
**	O
3	O
-	O
9	O
**	O
]	O
ARF	O
on	O
CRI	O
.	O
Held	O
ACEI	I-Drug
.	O
Avoided	O
Calcium	I-Drug
in	O
setting	O
of	O
digoxin	I-Drug
toxicity	I-Ade
.	O
Monitored	O
frequent	O
electrolytes	O
.	O
Treated	O
with	O
kayxalate	I-Drug
as	O
needed	O
.	O
She	O
will	O
have	O
her	O
potassium	O
monitored	O
on	O
[	O
**	O
8	O
-	O
22	O
**	O
]	O
at	O
the	O
rehab	O
facility	O
.	O
#	O
)	O
Anticoagulation	I-Reason
:	O
Patient	O
started	O
on	O
coumadin	I-Drug
given	O
poor	O
LV	O
function	O
and	O
risk	B-Reason
of	I-Reason
clot	O
formation	O
.	O
Continued	O
coumadin	I-Drug
at	O
decreased	O
dose	O
with	O
sub-therapeutic	O
INR	O
.	O
Prior	O
to	O
discharge	O
to	O
rehab	O
,	O
coumadin	I-Drug
was	O
increased	O
to	O
5	O
mg	O
daily	O
.	O
Her	O
INR	O
will	O
be	O
checked	O
on	O
[	O
**	O
8	O
-	O
22	O
**	O
]	O
at	O
rehab	O
and	O
coumadin	I-Drug
will	O
be	O
adjusted	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
437	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Amiodarone	I-Drug
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
2	O
.	O
Digoxin	I-Drug
0.125	O
mcg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
3	O
.	O
Emtricitabine	B-Drug
-	I-Drug
Tenofovir	O
200	O
-	O
300	O
mg	O
po	O
daily	O
4	O
.	O
Furosemide	I-Drug
100	O
mg	O
po	O
bid	O
5	O
.	O
Lansoprazole	I-Drug
Oral	O
Disintegrating	O
Tab	O
30	O
mg	O
PO	O
DAILY	O
6	O
.	O
Lisinopril	B-Drug
20	O
mg	O
PO	O
DAILY	O
7	O
.	O
Methadone	I-Drug
HCl	O
90	O
mg	O
PO	O
DAILY	O
8	O
.	O
Sulfameth	B-Drug
/	I-Drug
Trimethoprim	O
DS	O
1	O
TAB	O
PO	O
BID	O
9	O
.	O
Warfarin	I-Drug
2	O
mg	O
PO	O
HS	O
Discharge	O
Medications	O
:	O
1	O
.	O
Methadone	I-Drug
10	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Nine	O
(	O
9	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Lansoprazole	B-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Trimethoprim	B-Drug
-	I-Drug
Sulfamethoxazole	O
160	O
-	O
800	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Furosemide	I-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Five	O
(	O
5	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Digoxin	I-Drug
125	O
mcg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
other	O
day	O
:	O
Start	O
on	O
Tuesday	O
,	O
[	O
**	O
2136-8-21	O
**	O
]	O
.	O
6	O
.	O
Coumadin	I-Drug
2.5	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
have	O
your	O
INR	O
checked	O
on	O
[	O
**	O
2136-8-22	O
**	O
]	O
.	O
Results	O
faxed	O
to	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
401	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
437	O
**	O
]	O
.	O
7	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
have	O
your	O
PT	O
/	O
PTT	O
/	O
INR	O
as	O
well	O
as	O
a	O
chem	O
7	O
(	O
electrolytes	O
,	O
creatinine	O
,	O
BUN	O
)	O
checked	O
on	O
Wednesday	O
,	O
[	O
**	O
2136-8-22	O
**	O
]	O
.	O
Fax	O
results	O
to	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
401	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
437	O
**	O
]	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
49261	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
1186	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
538	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Digoxin	I-Drug
toxicity	I-Ade
resulting	O
in	O
bradycardia	I-Ade
Congestive	O
heart	O
failure	O
Coronary	O
artery	O
disease	O
Discharge	O
Condition	O
:	O
afebrile	O
,	O
comfortable	O
on	O
room	O
air	O
Discharge	O
Instructions	O
:	O
Your	O
foley	O
catheter	O
was	O
removed	O
just	O
prior	O
to	O
discharge	O
to	O
rehab	O
.	O
Please	O
perform	O
a	O
voiding	O
trial	O
on	O
the	O
day	O
of	O
admission	O
to	O
rehab	O
.	O
.	O
Please	O
stop	O
taking	O
Amiodarone	I-Drug
and	O
lisinopril	I-Drug
.	O
Please	O
resume	O
taking	O
digoxin	B-Drug
0.125	O
mg	O
every	O
other	O
day	O
starting	O
on	O
Tuesday	O
,	O
[	O
**	O
2136-8-21	O
**	O
]	O
.	O
.	O
Please	O
take	O
coumadin	I-Drug
at	O
5	O
mg	O
daily	O
.	O
Your	O
INR	O
will	O
be	O
checked	O
on	O
Wednesday	O
,	O
[	O
**	O
8	O
-	O
22	O
**	O
]	O
.	O
Results	O
will	O
be	O
faxed	O
to	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
3536	O
**	O
]	O
office	O
.	O
.	O
Please	O
resume	O
the	O
rest	O
of	O
the	O
medications	O
you	O
were	O
on	O
prior	O
to	O
admission	O
,	O
including	O
lasix	I-Drug
100	O
mg	O
twice	O
per	O
day	O
.	O
Please	O
call	O
your	O
primary	O
physician	O
or	O
return	O
to	O
the	O
emergency	O
room	O
should	O
you	O
develop	O
any	O
of	O
the	O
following	O
symptoms	O
:	O
nausea	O
/	O
vomiting	O
,	O
chest	O
pain	O
,	O
difficulty	O
breathing	O
,	O
or	O
any	O
other	O
concerns	O
.	O
Followup	O
Instructions	O
:	O
Please	O
keep	O
your	O
appointment	O
to	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
Thursday	O
,	O
[	O
**	O
2136-8-23	O
**	O
]	O
at	O
2:30	O
pm	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3581	O
**	O
]	O
if	O
there	O
is	O
a	O
problem	O
with	O
this	O
appointment	O
.	O
You	O
should	O
discuss	O
restarting	O
your	O
HIV	O
medications	O
at	O
this	O
appointment	O
.	O
Please	O
see	O
DR.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
on	O
[	O
**	O
2136-8-27	O
**	O
]	O
at	O
3:30	O
PM	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3512	O
**	O
]	O
if	O
there	O
is	O
a	O
problem	O
with	O
this	O
appointment	O
.	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
3874	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
M	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
3875	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2124-9-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2124-9-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2048-7-14	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Codeine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
391	O
**	O
]	O
Addendum	O
:	O
Discharge	O
Medications	O
accidentally	O
left	O
out	O
of	O
Discharge	O
summary	O
.	O
They	O
are	O
as	O
follows	O
:	O
.	O
-	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
-	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
-	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
-	O
Calcium	I-Drug
Acetate	O
667	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
-	O
Acetaminophen	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
-	O
B	B-Drug
Complex	I-Drug
-	I-Drug
Vitamin	I-Drug
C	I-Drug
-	I-Drug
Folic	O
Acid	O
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
-	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
(	O
0.83	O
mg	O
/	O
mL	O
)	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q2H	O
(	O
every	O
2	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	B-Reason
.	I-Reason
-	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
-	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
:	O
On	O
Tu	O
/	O
Th	O
/	O
Sa	O
,	O
hold	O
for	O
sbp	O
<	O
100	O
and	O
hr	O
<	O
60	O
.	O
-	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
on	O
M	O
/	O
W	O
/	O
F	O
/	O
Sunday	O
Hold	O
for	O
SBP	O
<	O
100	O
or	O
HR	O
<	O
60	O
.	O
-	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
-	O
Metronidazole	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
11	O
days	O
.	O
-	O
Clarithromycin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
11	O
days	O
.	O
-	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
-	O
Simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
-	O
Aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
-	O
NPH	I-Drug
16/3	O
and	O
HISS	I-Drug
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
3876	O
**	O
]	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
116	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
117	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
392	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2124-9-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2160-12-7	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2160-12-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2083-2-25	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Ativan	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
290	O
**	O
]	O
Chief	O
Complaint	O
:	O
fatigue	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
77M	O
with	O
inoperable	O
NSCLC	B-Reason
adenocarcinoma	I-Reason
stage	O
IIIA	O
(	O
T1N2M0	O
)	O
s	O
/	O
p	O
carboplatin	I-Drug
paclitaxel	I-Drug
x6	O
as	O
a	O
sensitizing	O
regmen	O
with	O
definitive	O
XRT	O
.	O
Also	O
CAD	O
and	O
CHF	O
(	O
EF	O
35	O
-	O
40	O
%	O
)	O
His	O
last	O
dose	O
of	O
chemotherapy	I-Drug
was	O
on	O
[	O
**	O
2160-10-23	O
**	O
]	O
C6	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
and	O
completed	O
XRT	O
with	O
6660	O
cGy	O
to	O
the	O
tumor	O
and	O
nodes	O
on	O
[	O
**	O
2160-11-5	O
**	O
]	O
.	O
He	O
was	O
admitted	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
47017	O
**	O
]	O
for	O
hemoptysis	O
,	O
nausea	O
,	O
odynophagia	O
.	O
CTA	O
negative	O
for	O
PE	O
but	O
found	O
evidence	O
of	O
radiation	B-Reason
-	I-Reason
induced	I-Reason
mid-esophagitis	I-Reason
.	O
He	O
was	O
managed	O
conservatively	O
with	O
magic	B-Drug
mouthwash	I-Drug
.	O
His	O
odynophagia	O
had	O
resolved	O
swiftly	O
.	O
His	O
Aspirin	I-Drug
was	O
held	O
at	O
time	O
of	O
discharge	O
.	O
He	O
now	O
p	O
/	O
w	O
weakness	O
and	O
n	O
/	O
v	O
x5	O
days	O
.	O
Not	O
tolerating	O
POs	O
secondary	O
to	O
dysguesia	O
and	O
vomitting	O
after	O
eating	O
.	O
no	O
F	O
/	O
C	O
/	O
NS	O
.	O
minimal	O
cough	O
with	O
new	O
(	O
in	O
last	O
10	O
days	O
)	O
"	O
gorilla	O
snot	O
"	O
sputum	O
,	O
DOE	O
worsened	O
since	O
radiation	O
.	O
Minimal	O
constant	O
non	O
radiating	O
CP	O
since	O
radiation	O
.	O
Patient	O
has	O
been	O
receiving	O
regular	O
fluid	I-Drug
boluses	O
and	O
has	O
gone	O
longer	O
than	O
he	O
had	O
previously	O
tolerated	O
.	O
In	O
the	O
ED	O
,	O
comfortable	O
,	O
pale	O
,	O
CTA	O
,	O
RRR	O
,	O
Abd	O
soft	O
NT	O
ND	O
,	O
Rectal	O
,	O
external	O
hemmorhoids	O
,	O
guiac	O
neg	O
.	O
1l	O
ns	O
Past	O
Medical	O
History	O
:	O
Past	O
Oncologic	O
History	O
:	O
NSCLC	O
adenocarcinoma	O
stage	O
IIIA	O
(	O
T1N2M0	O
)	O
-	O
[	O
**	O
2160-7-4	O
**	O
]	O
Presented	O
with	O
cough	O
and	O
unintentional	O
weight	O
loss	O
of	O
30	O
lbs	O
-	O
[	O
**	O
2160-7-24	O
**	O
]	O
CT	O
chest	O
ordered	O
given	O
symptoms	O
,	O
ongoing	O
tobacco	O
abuse	O
revealed	O
2	O
spiculated	O
nodules	O
and	O
necrotic	O
mediastinal	O
adenopathy	O
-	O
[	O
**	O
2160-7-29	O
**	O
]	O
PET	O
CT	O
showed	O
that	O
the	O
2	O
pulmonary	O
nodules	O
were	O
FDG	O
avid	O
with	O
lymphadenopathy	O
of	O
at	O
least	O
two	O
nodes	O
in	O
the	O
left	O
paratracheal	O
station	O
-	O
[	O
**	O
2160-8-4	O
**	O
]	O
Brain	O
MRI	O
w	O
/	O
o	O
evidence	O
of	O
metastatic	O
disease	O
-	O
[	O
**	O
2160-8-18	O
**	O
]	O
Bronchoscopic	O
Bx	O
of	O
the	O
mediastinal	O
nodes	O
revealed	O
NSCLC	O
adenocarcinoma	O
-	O
[	O
**	O
2160-9-4	O
**	O
]	O
Met	O
with	O
Medical	O
Oncology	O
and	O
Radiation	O
Oncology	O
.	O
Given	O
cardiac	O
comorbidities	O
,	O
planned	O
to	O
proceed	O
with	O
XRT	O
with	O
concomitant	O
carboplatin	I-Drug
paclitaxel	I-Drug
-	O
[	O
**	O
2160-9-18	O
**	O
]	O
C1	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
with	O
concomitant	O
XRT	O
-	O
[	O
**	O
2160-9-25	O
**	O
]	O
C2	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
with	O
concomitant	O
XRT	O
-	O
[	O
**	O
2160-10-2	O
**	O
]	O
C3	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
with	O
concomitant	O
XRT	O
-	O
[	O
**	O
2160-10-9	O
**	O
]	O
C4	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
with	O
concomitant	O
XRT	O
-	O
[	O
**	O
2160-10-16	O
**	O
]	O
C6	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
with	O
concomitant	O
XRT	O
-	O
[	O
**	O
2160-10-23	O
**	O
]	O
C6	O
Carboplatin	I-Drug
2	O
AUC	O
paclitaxel	I-Drug
50	O
mg	O
/	O
m2	O
with	O
concomitant	O
XRT	O
-	O
[	O
**	O
2160-11-5	O
**	O
]	O
Completed	O
XRT	O
with	O
6660	O
cGy	O
to	O
the	O
tumor	O
and	O
nodes	O
Other	O
Past	O
Medical	O
History	O
:	O
-	O
Ongoing	O
tobacco	O
abuse	O
-	O
CAD	O
s	O
/	O
p	O
MI	O
in	O
[	O
**	O
2124	O
**	O
]	O
,	O
[	O
**	O
2129	O
**	O
]	O
and	O
[	O
**	O
2134	O
**	O
]	O
-	O
87	O
-	O
CABG	O
[	O
**	O
2135	O
**	O
]	O
-	O
Stress	O
test	O
[	O
**	O
8	O
-	O
/	O
2160	O
**	O
]	O
with	O
mild	O
ischemic	O
disease	O
-	O
Distant	O
CVA	O
with	O
some	O
redisual	O
left	O
-	O
sided	O
weakness	O
-	O
s	O
/	O
p	O
CEA	O
-	O
Depression	O
-	O
HTN	O
-	O
Hyperlipidemia	O
-	O
Hypothyroidism	O
-	O
Right	O
macular	O
degeneration	O
on	O
an	O
intraoccular	O
injection	O
clinical	O
trial	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
which	O
has	O
improved	O
his	O
disease	O
-	O
s	O
/	O
p	O
right	O
hip	O
replacement	O
Social	O
History	O
:	O
-	O
Tobacco	O
:	O
age	O
10	O
to	O
50	O
4	O
PPD	O
,	O
since	O
age	O
50	O
1	O
PPD	O
,	O
>	O
100	O
pack	I-Drug
years	O
-	O
Alcohol	O
:	O
Social	O
-	O
Illicit	O
:	O
Denies	O
-	O
Occupation	O
:	O
DOD	O
driver	O
-	O
Exposures	O
:	O
Denies	O
-	O
Living	O
situation	O
:	O
Lives	O
with	O
wife	O
Family	O
History	O
:	O
-	O
Mother	O
:	O
CAD	O
-	O
Father	O
:	O
CAD	O
-	O
Grandmother	O
:	O
Breast	O
cancer	O
Physical	O
Exam	O
:	O
Admission	O
Physical	O
Exam	O
:	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
VS	O
:	O
T97	O
.5	O
bp	O
120/82	O
HR	O
102	O
SaO2	O
98RA	O
RR	O
17	O
SaO2	O
98	O
RA	O
Triage	O
[	O
**	O
12	O
-	O
7	O
**	O
]	O
:	O
99.3	O
88107/53	O
22	O
95	O
%	O
Admit	O
:	O
2159	O
-	O
hr	O
84-108/56	O
-18-93	O
%	O
,	O
GEN	O
:	O
Elderly	O
man	O
in	O
NAD	O
,	O
awake	O
,	O
alert	O
,	O
talkative	O
HEENT	O
:	O
EOMI	O
,	O
sclera	O
anicteric	O
,	O
conjunctivae	O
clear	O
,	O
OP	O
dry	O
and	O
without	O
lesion	O
NECK	O
:	O
Supple	O
,	O
no	O
JVD	O
appreciated	O
CV	O
:	O
RRR	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
Somewhat	O
musical	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
complex	O
systolic	O
murmur	O
heard	O
best	O
at	O
apex	O
.	O
No	O
r	O
/	O
g	O
appreciated	O
CHEST	O
:	O
Resp	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
decreased	O
breath	O
sounds	O
on	O
the	O
right	O
side	O
;	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
ABD	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
,	O
no	O
HSM	O
,	O
bowel	O
sounds	O
present	O
MSK	O
:	O
normal	O
muscle	O
tone	O
and	O
bulk	O
EXT	O
:	O
No	O
c	O
/	O
c	O
/	O
e	O
,	O
2	O
+	O
DP	O
/	O
PT	O
bilaterally	O
SKIN	O
:	O
No	O
rash	O
,	O
warm	O
skin	O
PSYCH	O
:	O
appropriate	O
Discharge	O
Physical	O
Exam	O
:	O
No	O
corneal	O
reflex	O
No	O
response	O
to	O
painful	O
stimuli	O
No	O
heart	O
beat	O
or	O
breath	O
sounds	O
with	O
auscultation	O
of	O
chest	O
for	O
1	O
minute	O
Time	O
of	O
death	O
07:11	O
on	O
[	O
**	O
2160-12-11	O
**	O
]	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
WBC	O
-	O
3.1	O
*	O
RBC	O
-	O
2.10	O
*	O
HGB	O
-	O
7.1	O
*	O
HCT	O
-	O
19.9	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
34.0	O
*	O
MCHC	O
-	O
35.9	O
*	O
RDW	O
-	O
15.7	O
*	O
NEUTS	O
-	O
80.6	O
*	O
LYMPHS	O
-	O
9.4	O
*	O
MONOS	O
-	O
8.6	O
EOS	O
-	O
1.0	O
BASOS	O
-	O
0.3	O
RET	O
AUT	O
-	O
2.9	O
HAPTOGLOB	O
-	O
338	O
*	O
FERRITIN	O
-	O
455	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
499	O
*	O
TOT	O
BILI	O
-	O
0.5	O
GLUCOSE	O
-	O
138	O
*	O
UREA	O
N	O
-	O
20	O
CREAT	O
-	O
1.0	O
SODIUM	O
-	O
129	O
*	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
97	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
14	O
Imaging	O
:	O
CXR	O
[	O
**	O
2160-12-7	O
**	O
]	O
-	O
Frontal	O
and	O
lateral	O
views	O
of	O
the	O
chest	O
were	O
obtained	O
.	O
Please	O
note	O
per	O
history	O
,	O
the	O
patient	O
has	O
history	O
of	O
lung	O
cancer	O
.	O
Comparison	O
is	O
also	O
made	O
to	O
scout	O
radiograph	O
from	O
CT	O
from	O
[	O
**	O
2160-11-12	O
**	O
]	O
.	O
Large	O
area	O
of	O
opacity	O
projecting	O
over	O
the	O
left	O
lung	O
is	O
worrisome	O
for	O
infectious	O
process	O
,	O
alternatively	O
progression	O
of	O
malignancy	O
/	O
lymphangitic	O
spread	O
.	O
Opacity	O
is	O
seen	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
right	O
lung	O
.	O
There	O
may	O
be	O
superimposed	O
pulmonary	O
edema	O
.	O
No	O
large	O
pleural	O
effusion	O
or	O
pneumothorax	O
is	O
seen	O
.	O
Again	O
seen	O
,	O
the	O
upper	O
two	O
sternal	O
wires	O
are	O
fractured	O
.	O
Cardiac	O
and	O
mediastinal	O
silhouettes	O
are	O
stable	O
.	O
CXR	O
[	O
**	O
2160-12-8	O
**	O
]	O
-	O
As	O
compared	O
to	O
the	O
previous	O
radiograph	O
,	O
there	O
is	O
a	O
minimal	O
increase	O
in	O
extent	O
of	O
the	O
pre-existing	O
parenchymal	O
opacities	O
.	O
This	O
increase	O
is	O
most	O
noticeable	O
in	O
the	O
right	O
upper	O
lobe	O
.	O
No	O
other	O
relevant	O
changes	O
.	O
Status	O
post	O
sternotomy	O
,	O
CABG	O
,	O
moderate	O
cardiomegaly	O
,	O
the	O
presence	O
of	O
a	O
small	O
left	O
pleural	O
effusion	O
can	O
not	O
be	O
excluded	O
.	O
Transthoracic	O
echocardiogram	O
[	O
**	O
2160-12-9	O
**	O
]	O
-	O
Poor	O
image	O
quality.The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
A	O
small	O
secundum	O
atrial	O
septal	O
defect	O
is	O
present	O
.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
0	O
-	O
5	O
mmHg	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
There	O
is	O
moderate	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
inferior	O
and	O
infero	O
-	O
lateral	O
akinesis	O
and	O
distal	O
septal	O
,	O
distal	O
anterior	O
and	O
apical	O
hypokinesis	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
diameters	O
of	O
aorta	O
at	O
the	O
sinus	O
,	O
ascending	O
and	O
arch	O
levels	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
to	O
severe	O
(	O
3	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2160-8-28	O
**	O
]	O
,	O
the	O
degree	O
of	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
seen	O
has	O
increased	O
slightly	O
(	O
degree	O
of	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
12314	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
102625	O
**	O
]	O
on	O
prior	O
report	O
)	O
.	O
CT	O
Head	O
[	O
**	O
2160-12-10	O
**	O
]	O
-	O
WET	O
READ	O
-	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
hemorrhage	O
,	O
edema	O
,	O
mass	O
effect	O
,	O
or	O
major	O
vascular	O
territory	O
infarction	O
.	O
Evaluation	O
of	O
small	O
mass	O
,	O
however	O
,	O
is	O
limited	O
in	O
the	O
absence	O
of	O
IV	O
contrast	I-Drug
.	O
2	O
.	O
Remote	O
right	O
middle	O
cerebral	O
artery	O
infarction	O
.	O
Brief	O
Hospital	O
Course	O
:	O
77	O
M	O
with	O
history	O
of	O
stage	O
IIIa	O
NSCLC	O
,	O
sCHF	O
with	O
EF	O
35	O
-	O
40	O
%	O
,	O
CAD	O
s	O
/	O
p	O
CABG	O
presenting	O
initially	O
for	O
n	O
/	O
v	O
/	O
[	O
**	O
Hospital	O
**	O
]	O
transferred	O
to	O
ICU	O
for	O
hypotension	O
,	O
hypoxia	O
,	O
and	O
fever	O
.	O
#	O
Respiratory	O
distress	O
:	O
Patient	O
transferred	O
to	O
ICU	O
on	O
HD	O
1	O
due	O
to	O
episode	O
of	O
hypotension	O
and	O
hypoxia	O
while	O
receiving	O
blood	O
transfusion	O
.	O
Patient	O
continued	O
to	O
be	O
hypotensive	O
and	O
hypoxic	O
throughout	O
the	O
day	O
with	O
an	O
increasing	O
O2	O
requirement	O
.	O
He	O
spiked	O
a	O
fever	O
and	O
CXR	O
was	O
concerning	O
for	O
new	O
pneumonia	I-Reason
,	O
so	O
vancomycin	I-Drug
,	O
cefepime	I-Drug
and	O
levofloxacin	I-Drug
were	O
started	O
.	O
Patient	O
was	O
transferred	O
to	O
the	O
ICU	O
for	O
close	O
monitoring	O
.	O
His	O
blood	O
pressure	O
remained	O
stable	O
with	O
normal	O
mentation	O
and	O
good	O
urine	O
output	O
,	O
and	O
he	O
did	O
not	O
require	O
any	O
fluid	O
boluses	O
or	O
pressors	O
.	O
He	O
continued	O
to	O
require	O
a	O
non	O
rebreather	O
to	O
maintain	O
oxygen	O
saturations	O
,	O
and	O
de-sat	O
'	O
ed	O
to	O
70s	O
without	O
the	O
facemask	O
.	O
Concerns	O
were	O
for	O
bacterial	O
pneumonia	O
vs	O
PCP	O
pneumonia	O
vs	O
radiation	O
pneumonitis	O
vs	O
worsening	O
of	O
underlying	O
malignancy	O
.	O
Patient	O
was	O
initially	O
put	O
on	O
steroids	I-Drug
to	O
treat	O
radiation	I-Reason
pneumonitis	O
in	O
addition	O
the	O
antibiotics	O
as	O
above	O
to	O
cover	O
hospital	O
acquired	O
bacterial	O
pneumonia	O
.	O
Patient	O
's	O
oxygen	O
requirement	O
increased	O
overnight	O
on	O
HD	O
3	O
and	O
so	O
treatment	O
for	O
PCP	I-Reason
pneumonia	O
was	O
started	O
with	O
high	O
dose	O
bactrim	I-Drug
.	O
Steroids	I-Drug
were	O
altered	O
to	O
treat	O
PCP	I-Reason
rather	O
than	O
radiation	O
pneumonitis	O
.	O
Beta	I-Drug
glucan	O
and	O
galactomannan	O
were	O
also	O
sent	O
on	O
HD	O
2	O
.	O
Once	O
patient	O
was	O
made	O
comfort	O
measures	O
only	O
,	O
antibiotics	O
and	O
steroids	I-Drug
were	O
discontinued	O
,	O
and	O
focus	O
was	O
turned	O
towards	O
controlling	B-Reason
tachypnea	I-Reason
and	I-Reason
dyspnea	I-Reason
with	O
morphine	I-Drug
and	O
albuterol	B-Drug
/	I-Drug
ipratropium	I-Drug
nebulizers	O
.	O
Patient	O
was	O
kept	O
on	O
shovel	O
mask	O
and	O
nasal	O
cannula	O
and	O
was	O
given	O
morphine	I-Drug
as	O
needed	O
for	O
assistance	B-Reason
with	I-Reason
breathing	I-Reason
.	O
Family	O
requested	O
to	O
have	O
oxygen	O
removed	O
,	O
and	O
start	O
morphine	I-Drug
drip	O
.	O
Drip	O
started	O
,	O
and	O
nasal	O
cannula	O
/	O
shovel	O
mask	O
removed	O
and	O
patient	O
expired	O
within	O
30	O
minutes	O
.	O
#	O
Right	O
MCA	O
stroke	O
:	O
On	O
HD	O
3	O
,	O
housestaff	O
was	O
called	O
to	O
bedside	O
for	O
acute	O
change	O
in	O
patient	O
's	O
breathing	O
.	O
Patient	O
was	O
noted	O
to	O
have	O
left	O
sided	O
neglect	O
in	O
addition	O
to	O
complete	O
left	O
sided	O
hemiplegia	O
.	O
A	O
code	O
stroke	O
was	O
called	O
and	O
a	O
CT	O
of	O
the	O
head	O
showed	O
a	O
non-hemorrhagic	O
stroke	O
in	O
the	O
right	O
MCA	O
,	O
adjacent	O
to	O
prior	O
stroke	O
.	O
TPA	I-Drug
was	O
not	O
given	O
as	O
neurology	O
felt	O
that	O
it	O
was	O
high	O
risk	O
for	O
re-bleed	O
of	O
prior	O
stroke	O
.	O
Patient	O
was	O
started	O
on	O
aspirin	I-Drug
325	O
mg	O
,	O
however	O
,	O
once	O
decision	O
was	O
made	O
to	O
make	O
patient	O
comfort	O
measures	O
only	O
,	O
aspirin	I-Drug
was	O
discontinued	O
.	O
#	O
Insomnia	I-Reason
:	O
Patient	O
struggled	O
with	O
insomnia	O
throughout	O
admission	O
.	O
He	O
was	O
prescribed	O
olanzapine	I-Drug
in	O
the	O
outpatient	O
setting	O
which	O
helped	O
him	O
sleep	I-Reason
at	O
doses	O
of	O
15	O
mg	O
qHS	O
.	O
With	O
the	O
assistance	O
of	O
palliative	O
care	O
,	O
patient	O
was	O
continued	O
on	O
olanzapine	I-Drug
10	O
mg	O
qHS	O
.	O
He	O
was	O
also	O
given	O
morphine	I-Drug
as	O
needed	O
for	O
comfort	I-Reason
as	O
part	O
of	O
his	O
difficulty	O
sleeping	O
was	O
secondary	O
to	O
his	O
tachypnea	O
.	O
#	O
Goals	O
of	O
care	O
:	O
Several	O
goals	O
of	O
care	O
discussions	O
occurred	O
during	O
hospitalization	O
.	O
Following	O
patient	O
's	O
stroke	O
,	O
he	O
and	O
his	O
family	O
decided	O
that	O
they	O
wanted	O
him	O
to	O
be	O
comfort	O
measures	O
only	O
and	O
to	O
go	O
home	O
with	O
hospice	O
.	O
However	O
,	O
patient	O
developed	O
increased	B-Reason
work	I-Reason
of	I-Reason
breathing	I-Reason
and	O
family	O
requested	O
morphine	I-Drug
boluses	O
.	O
Patient	O
was	O
made	O
comfortable	O
with	O
morphine	I-Drug
boluses	O
,	O
then	O
morphine	I-Drug
drip	O
and	O
expired	O
at	O
07:11	O
am	O
on	O
[	O
**	O
2160-12-11	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
atenolol	I-Drug
100	O
mg	O
qd	O
2	O
.	O
atorvastatin	I-Drug
20	O
mg	O
qd	O
3	O
.	O
doxazosin	B-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
fluoxetine	I-Drug
40	O
mg	O
qd	O
5	O
.	O
levothyroxine	I-Drug
175	O
mcg	O
qd	O
6	O
.	O
nitroglycerin	B-Drug
0.3	O
mg	O
Tablet	O
prn	O
7	O
.	O
olanzapine	I-Drug
[	O
**	O
5	O
-	O
6	O
**	O
]	O
qHS	O
8	O
.	O
prochlorperazine	B-Drug
maleate	I-Drug
10	O
mg	O
Tablet	O
q6	O
PRN	O
9	O
.	O
triamcinolone	B-Drug
acetonide	I-Drug
0.1	O
%	O
Ointment	O
[	O
**	O
Hospital1	O
**	O
]	O
10	O
.	O
multivitamin	I-Drug
qd	O
11	O
.	O
lidocaine	B-Drug
-	I-Drug
diphenhyd	I-Drug
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
mag	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
200	O
-25-400-40	O
mg	O
/	O
30	O
mL	O
Mouthwash	O
Sig	O
:	O
One	O
(	O
1	O
)	O
teaspoon	O
Mucous	O
membrane	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Discharge	O
Medications	O
:	O
expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Non-small	O
cell	O
lung	O
cancer	O
Right	O
MCA	O
stroke	O
Discharge	O
Condition	O
:	O
Patient	O
expired	O
Discharge	O
Instructions	O
:	O
Patient	O
expired	O
Followup	O
Instructions	O
:	O
Patient	O
expired	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
292	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2188-2-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2188-3-4	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Hydralazine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3151	O
**	O
]	O
Chief	O
Complaint	O
:	O
"	O
I	O
could	O
n't	O
breathe	O
"	O
x	O
1	O
day	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Angiogram	O
Embolization	O
of	O
L3	O
Lumbar	O
Artery	O
History	O
of	O
Present	O
Illness	O
:	O
86	O
-	O
year	O
-	O
old	O
woman	O
w	O
/	O
HTN	O
,	O
hypothyroidism	O
,	O
AAA	O
presents	O
w	O
/	O
shortness	O
of	O
breath	O
x	O
1	O
day	O
.	O
She	O
was	O
in	O
her	O
USOH	O
until	O
3	O
days	O
ago	O
,	O
when	O
she	O
developed	O
insidious	O
onset	O
of	O
nasal	O
congestion	O
,	O
runny	O
nose	O
,	O
and	O
cough	O
occasionally	O
productive	O
of	O
scant	O
yellow	O
sputum	O
.	O
She	O
reports	O
minor	O
subjective	O
fever	O
initially	O
that	O
has	O
resolved	O
.	O
These	O
symptoms	O
have	O
persisted	O
until	O
now	O
.	O
Over	O
the	O
past	O
2	O
days	O
,	O
she	O
has	O
developed	O
increased	O
dyspnea	O
on	O
exertion	O
.	O
There	O
is	O
no	O
dyspnea	O
at	O
rest	O
,	O
orthopnea	O
,	O
or	O
PND	O
.	O
This	O
morning	O
,	O
she	O
had	O
a	O
prolonged	O
episode	O
of	O
coughing	O
which	O
caused	O
significant	O
dyspnea	O
,	O
prompting	O
her	O
to	O
call	O
her	O
PCP	O
for	O
advice	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
665	O
**	O
]	O
was	O
concerned	O
about	O
her	O
dyspnea	O
and	O
advised	O
her	O
to	O
present	O
to	O
the	O
ED	O
for	O
evaluation	O
.	O
She	O
denies	O
any	O
weight	O
loss	O
,	O
chills	O
,	O
myalgias	O
,	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
hematochezia	O
,	O
black	O
stools	O
,	O
dysuria	O
,	O
chest	O
pain	O
,	O
or	O
palpitations	O
.	O
She	O
does	O
report	O
difficulty	O
w	O
/	O
balance	O
over	O
past	O
months	O
requiring	O
her	O
to	O
use	O
a	O
cane	O
for	O
walking	O
.	O
In	O
the	O
ED	O
,	O
she	O
was	O
observed	O
to	O
have	O
a	O
large	O
melanic	O
stool	O
without	O
any	O
associated	O
symptoms	O
.	O
Vital	O
signs	O
were	O
stable	O
.	O
She	O
was	O
treated	O
w	O
/	O
ceftriaxone	I-Drug
1gm	O
and	O
azithromycin	I-Drug
500	O
mg	O
for	O
possible	O
PNA	I-Reason
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Pacemaker	O
DDD	O
for	O
sick	O
sinus	O
syndrome	O
2	O
.	O
Thoracic	O
aortic	O
aneurysm	O
s	O
/	O
p	O
aortic	O
arch	O
graft	O
and	O
AVR	O
3	O
.	O
s	O
/	O
p	O
AVR	O
w	O
/	O
St.	O
Jude	O
's	O
valve	O
[	O
**	O
2178	O
**	O
]	O
4	O
.	O
Hypertension	O
5	O
.	O
Hypothyroidism	O
6	O
.	O
Lower	O
back	O
pain	O
7	O
.	O
Colonic	O
polyps	O
8	O
.	O
Iron	O
deficiency	O
anemia	O
9	O
.	O
Abdominal	O
aortic	O
aneurysm	O
10	O
.	O
h	O
/	O
o	O
gallstone	O
pancreatitis	O
11	O
.	O
s	O
/	O
p	O
open	O
cholecystectomy	O
[	O
**	O
7	O
-	O
/	O
2183	O
**	O
]	O
Social	O
History	O
:	O
Divorced	O
;	O
former	O
stock	O
broker	O
,	O
lives	O
alone	O
in	O
apt	O
in	O
[	O
**	O
Hospital1	O
1426	O
**	O
]	O
Towers	O
;	O
smoked	O
20	O
pack	O
-	O
years	O
but	O
quit	O
years	O
ago	O
;	O
no	O
alcohol	O
or	O
recreational	O
drug	O
use	O
;	O
walks	O
w	O
/	O
cane	O
at	O
baseline	O
.	O
Family	O
History	O
:	O
1	O
.	O
DM2	O
:	O
brother	O
Physical	O
Exam	O
:	O
VS	O
T	O
98.2	O
F	O
,	O
BP	O
119/58	O
,	O
HR	O
82	O
,	O
RR	O
18	O
,	O
O2	O
sat	O
99	O
%	O
4L	O
/	O
m	O
Gen	O
:	O
awake	O
,	O
alert	O
,	O
NAD	O
HEENT	O
:	O
anicteric	O
,	O
EOMI	O
,	O
PERRL	O
,	O
pink	O
conjunctivae	O
,	O
OP	O
clear	O
w	O
/	O
MMM	O
,	O
no	O
JVD	O
,	O
neck	O
supple	O
CV	O
:	O
reg	O
s1	O
/	O
s2	O
,	O
no	O
s3	O
/	O
s4	O
/	O
m	O
/	O
r	O
Pulm	O
:	O
crackles	O
at	O
left	O
base	O
cleared	O
w	O
/	O
cough	O
,	O
no	O
wheezes	O
Abd	O
:	O
+	O
BS	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
Ext	O
:	O
warm	O
,	O
2	O
+	O
DP	O
B	O
,	O
no	O
edema	O
Neuro	O
:	O
alert	O
and	O
oriented	O
x	O
3	O
,	O
CN	O
2	O
-	O
12	O
intact	O
,	O
strength	O
5/5	O
throughout	O
UE	O
/	O
LE	O
B	O
,	O
sensation	O
to	O
fine	O
touch	O
intact	O
throughout	O
Pertinent	O
Results	O
:	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
WBC	O
-	O
4.5	O
RBC	O
-	O
3.98	O
*	O
HGB	O
-	O
11.2	O
*	O
HCT	O
-	O
32.9	O
*	O
MCV	O
-	O
83	O
#	O
MCH	O
-	O
28.2	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
14.9	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
PLT	O
COUNT	O
-	O
127	O
*	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
NEUTS	O
-	O
81.2	O
*	O
LYMPHS	O
-	O
11.0	O
*	O
MONOS	O
-	O
7.4	O
EOS	O
-	O
0.2	O
BASOS	O
-	O
0.2	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
GLUCOSE	O
-	O
86	O
UREA	O
N	O
-	O
25	O
*	O
CREAT	O
-	O
0.9	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
3.8	O
CHLORIDE	O
-	O
100	O
TOTAL	O
CO2	O
-	O
29	O
ANION	O
GAP	O
-	O
14	O
[	O
**	O
2188-2-8	O
**	O
]	O
08:15	O
AM	O
CALCIUM	O
-	O
8.5	O
PHOSPHATE	O
-	O
3.0	O
MAGNESIUM	O
-	O
1.8	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
221	O
*	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
CK	O
-	O
MB	O
-	O
6	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2188-2-8	O
**	O
]	O
08:15	O
AM	O
CK	O
(	O
CPK	O
)	O
-	O
372	O
*	O
[	O
**	O
2188-2-8	O
**	O
]	O
08:15	O
AM	O
CK	O
-	O
MB	O
-	O
7	O
[	O
**	O
2188-2-8	O
**	O
]	O
08:15	O
AM	O
cTropnT	O
-	O
0.02	O
*	O
[	O
**	O
2188-2-8	O
**	O
]	O
12:24	O
PM	O
CK	O
-	O
MB	O
-	O
8	O
[	O
**	O
2188-2-8	O
**	O
]	O
12:24	O
PM	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
URINE	O
COLOR	O
-	O
Straw	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.018	O
[	O
**	O
2188-2-7	O
**	O
]	O
06:30	O
PM	O
URINE	O
RBC	O
-0-2	O
WBC	O
-0-2	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
CXR	O
:	O
Left	O
basilar	O
opacity	O
that	O
may	O
represent	O
atelectasis	O
altho	O
pneumonia	O
not	O
excluded	O
.	O
Probable	O
emphysema	O
.	O
CTA	O
chest	O
:	O
1	O
.	O
Slightly	O
limited	O
examination	O
for	O
evaluation	O
for	O
pulmonary	O
embolus	O
,	O
although	O
no	O
large	O
central	O
pulmonary	O
embolus	O
is	O
present	O
and	O
no	O
definite	O
evidence	O
of	O
more	O
distal	O
pulmonary	O
embolus	O
is	O
visualized	O
.	O
2	O
.	O
Mediastinal	O
and	O
hilar	O
lymphadenopathy	O
,	O
including	O
multiple	O
subcentimeter	O
pretracheal	O
and	O
precarinal	O
nodes	O
,	O
and	O
enlarged	O
right	O
hilar	O
and	O
subcarinal	O
nodal	O
masses	O
.	O
3	O
.	O
Four	O
millimeter	O
nodule	O
within	O
the	O
left	O
upper	O
lobe	O
laterally	O
.	O
Comparison	O
with	O
any	O
possibly	O
available	O
prior	O
imaging	O
is	O
recommended	O
.	O
Short	O
-	O
term	O
CT	O
follow	O
-	O
up	O
is	O
recommended	O
.	O
4	O
.	O
Bronchiectatic	O
changes	O
predominantly	O
in	O
the	O
lower	O
lobes	O
bilaterally	O
.	O
5	O
.	O
Large	O
hiatal	O
hernia	O
.	O
[	O
**	O
2188-2-22	O
**	O
]	O
:	O
Angiogram	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
active	O
extravasation	O
of	O
the	O
contrast	O
material	O
as	O
above	O
.	O
2	O
.	O
Embolization	O
of	O
the	O
left	O
L3	O
lumbar	O
artery	O
per	O
surgical	O
team	O
request	O
.	O
Brief	O
Hospital	O
Course	O
:	O
1	O
.	O
Dyspnea	O
:	O
she	O
was	O
admitted	O
w	O
/	O
dyspnea	O
in	O
setting	O
of	O
URI	O
symptoms	O
that	O
was	O
most	O
consistent	O
w	O
/	O
viral	O
URI	O
,	O
as	O
there	O
was	O
no	O
fever	O
and	O
no	O
infiltrative	O
process	O
on	O
chest	O
CT.	O
.	O
She	O
was	O
tested	O
for	O
influenza	O
w	O
/	O
DFA	O
of	O
nasal	O
aspirate	O
.	O
Meanwhile	O
,	O
she	O
was	O
treated	O
w	O
/	O
ceftriaxone	I-Drug
and	O
azithromycin	I-Drug
to	O
cover	O
possible	O
CAP	I-Reason
.	O
On	O
HD	O
#	O
2	O
,	O
DFA	O
returned	O
as	O
positive	O
for	O
influenza	O
A	O
.	O
As	O
the	O
pt	O
had	O
been	O
afebrile	O
w	O
/	O
no	O
signs	O
of	O
infxn	O
,	O
pneumonia	O
was	O
thought	O
to	O
be	O
unlikely	O
and	O
abx	O
were	O
d	O
/	O
c	O
at	O
that	O
time	O
.	O
She	O
remained	O
dyspnic	O
w	O
/	O
upper	O
and	O
lower	O
airway	O
wheezing	O
throughout	O
her	O
early	O
hospital	O
course	O
,	O
which	O
was	O
thought	O
to	O
be	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
viral	O
bronchitis	I-Reason
.	O
She	O
was	O
treated	O
w	O
/	O
prednisone	I-Drug
taper	O
and	O
nebulized	O
albuterol	I-Drug
and	O
atrovent	I-Drug
,	O
w	O
/	O
good	O
symptom	O
control	O
.	O
However	O
,	O
she	O
required	O
continued	O
O2	I-Drug
by	O
NC	O
to	O
maintain	O
O2	O
sats	O
>	O
93	O
%	O
throughout	O
the	O
first	O
half	O
of	O
her	O
admission	O
.	O
By	O
d	O
/	O
c	O
,	O
she	O
was	O
weaned	O
off	O
O2	I-Drug
and	O
was	O
breathing	O
comfortably	O
on	O
room	O
air	O
without	O
requirement	O
for	O
albuterol	I-Drug
or	O
atrovent	I-Drug
.	O
At	O
d	O
/	O
c	O
,	O
she	O
is	O
maintaining	O
good	O
O2	O
sat	O
on	O
room	O
air	O
and	O
is	O
not	O
dyspnic	O
.	O
2	O
.	O
GI	O
bleed	O
:	O
she	O
was	O
observed	O
to	O
have	O
melanic	O
stool	O
in	O
the	O
ED	O
,	O
without	O
any	O
GI	O
symptoms	O
.	O
She	O
was	O
guaiac	O
positive	O
at	O
that	O
time	O
.	O
This	O
was	O
most	O
likely	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
indolent	O
upper	O
GI	O
bleed	O
.	O
On	O
admission	O
,	O
coumadin	I-Drug
was	O
held	O
and	O
heparin	I-Drug
was	O
started	O
for	O
anticoagulation	I-Reason
given	O
her	O
AVR	O
.	O
Treatment	O
was	O
started	O
w	O
/	O
IV	O
protonix	I-Drug
.	O
Plans	O
were	O
made	O
for	O
EGD	O
/	O
colonoscopy	O
to	O
evaluate	O
for	O
source	O
of	O
bleeding	O
,	O
but	O
these	O
procedures	O
were	O
delayed	O
due	O
to	O
the	O
pt	O
's	O
dyspnea	O
and	O
relative	O
risk	O
of	O
sedation	O
.	O
Her	O
HCT	O
was	O
observed	O
to	O
drop	O
significantly	O
,	O
which	O
was	O
likely	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
retroperitoneal	O
bleed	O
as	O
below	O
,	O
and	O
not	O
related	O
to	O
GI	O
bleed	O
.	O
After	O
her	O
admission	O
,	O
she	O
had	O
no	O
further	O
melena	O
or	O
hematochezia	O
.	O
After	O
stabilization	O
of	O
retroperitoneal	O
bleed	O
,	O
she	O
underwent	O
EGD	O
and	O
colonoscopy	O
,	O
which	O
demonstrated	O
evidence	O
of	O
esophagitis	O
w	O
/	O
no	O
active	O
bleeding	O
.	O
Protonix	I-Drug
was	O
changed	O
to	O
oral	O
formulation	O
,	O
and	O
sucralfate	I-Drug
was	O
added	O
for	O
improved	O
treatment	O
of	O
esophagitis	I-Reason
.	O
She	O
had	O
no	O
further	O
evidence	O
of	O
active	O
GI	O
bleeding	O
during	O
her	O
admission	O
.	O
Her	O
sucralfate	I-Drug
was	O
stopped	O
.	O
She	O
will	O
need	O
to	O
continue	O
protonix	I-Drug
twice	O
daily	O
after	O
d	O
/	O
c.	O
3	O
.	O
Retroperitoneal	O
hemorrhage	O
:	O
on	O
HD	O
#	O
4	O
,	O
her	O
HCT	O
was	O
observed	O
to	O
have	O
dropped	O
overnight	O
from	O
27	O
to	O
21	O
.	O
This	O
was	O
concerning	O
for	O
active	O
GI	O
bleed	O
.	O
She	O
was	O
transfused	O
w	O
/	O
2units	O
PRBCs	I-Drug
,	O
w	O
/	O
appropriate	O
HCT	O
increase	O
to	O
29	O
after	O
transfusion	O
.	O
However	O
,	O
her	O
HCT	O
again	O
decreased	O
overnight	O
from	O
29	O
to	O
22	O
with	O
no	O
melena	O
or	O
hematochezia	O
to	O
explain	O
the	O
blood	O
loss	O
.	O
Lab	O
workup	O
showed	O
no	O
evidence	O
of	O
hemolysis	O
.	O
Abd	O
CT	O
demonstrated	O
large	O
left	O
retroperitoneal	O
hemorrhage	O
,	O
11x5	O
cm	O
in	O
size	O
,	O
w	O
/	O
radiographic	O
evidence	O
of	O
acute	O
on	O
chronic	O
bleeding	O
.	O
Heparin	I-Drug
was	O
d	O
/	O
c	O
,	O
she	O
was	O
transfused	O
w	O
/	O
an	O
additional	O
2units	O
PRBCs	I-Drug
,	O
and	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
close	O
monitoring	O
.	O
Surgery	O
was	O
consulted	O
,	O
and	O
recommended	O
holding	O
anticoagulation	O
with	O
close	O
monitoring	O
of	O
HCT	O
.	O
The	O
pt	O
had	O
appropriate	O
response	O
of	O
HCT	O
w	O
/	O
PRBC	I-Drug
transfusion	O
,	O
and	O
HCT	O
remained	O
stable	O
for	O
3	O
days	O
off	O
anticoagulation	O
.	O
As	O
HCT	O
had	O
stabilized	O
,	O
she	O
was	O
transferred	O
back	O
to	O
the	O
Medicine	O
floor	O
and	O
Surgery	O
recommended	O
resuming	O
heparin	I-Drug
for	O
anticoagulation	I-Reason
.	O
Heparin	I-Drug
was	O
resumed	O
w	O
/	O
close	O
monitoring	O
of	O
PTT	O
,	O
and	O
HCT	O
was	O
monitored	O
closely	O
.	O
However	O
,	O
after	O
resuming	O
heparin	I-Drug
the	O
pt	O
had	O
another	O
decrease	O
in	O
HCT	O
concerning	O
for	O
active	O
bleeding	O
.	O
Heparin	I-Drug
was	O
stopped	O
immediately	O
.	O
Repeat	O
CT	O
scan	O
showed	O
enlarging	O
left	O
retroperitoneal	O
bleed	O
tracking	O
down	O
into	O
pelvis	O
and	O
left	O
thigh	O
.	O
CTA	O
was	O
done	O
to	O
localize	O
source	O
of	O
bleed	O
,	O
and	O
showed	O
active	O
contrast	O
extravasation	O
from	O
the	O
left	O
L3	O
lumbar	O
artery	O
.	O
IR	O
was	O
consulted	O
,	O
and	O
performed	O
embolization	O
of	O
left	O
L3	O
lumbar	O
artery	O
,	O
though	O
there	O
was	O
no	O
evidence	O
of	O
active	O
bleeding	O
from	O
the	O
artery	O
at	O
the	O
time	O
of	O
the	O
procedure	O
.	O
She	O
tolerated	O
the	O
procedure	O
well	O
.	O
HCT	O
was	O
follow	O
closely	O
after	O
embolization	O
,	O
and	O
remained	O
stable	O
for	O
3	O
days	O
.	O
Repeat	O
CTA	O
showed	O
no	O
active	O
bleeding	O
from	O
the	O
L3	O
lumbar	O
artery	O
,	O
which	O
indicated	O
a	O
successful	O
embolization	O
.	O
Given	O
this	O
confirmation	O
and	O
stable	O
HCT	O
,	O
heparin	I-Drug
was	O
resumed	O
w	O
/	O
initial	O
goal	O
PTT	O
of	O
40	O
.	O
HCT	O
was	O
stable	O
on	O
this	O
level	O
of	O
heparin	I-Drug
,	O
so	O
heparin	I-Drug
was	O
increased	O
to	O
goal	O
PTT	O
of	O
60	O
-	O
70	O
.	O
The	O
pt	O
received	O
1	O
dose	O
of	O
coumadin	I-Drug
5	O
mg	O
to	O
begin	O
long	O
-	O
term	O
anticoagulation	I-Reason
.	O
A	O
PTT	O
of	O
60	O
was	O
achieved	O
and	O
was	O
stable	O
for	O
12	O
hours	O
w	O
/	O
stable	O
HCT	O
,	O
but	O
the	O
pt	O
then	O
developed	O
abdominal	O
distention	O
and	O
pain	O
,	O
w	O
/	O
significant	O
LLQ	O
/	O
LUQ	O
tenderness	O
on	O
exam	O
.	O
This	O
was	O
concerning	O
for	O
additional	O
bleeding	O
.	O
Heparin	I-Drug
was	O
once	O
again	O
d	O
/	O
c	O
,	O
and	O
repeat	O
CT	O
showed	O
markedly	O
enlarged	O
retroperitoneal	O
bleed	O
displacing	O
the	O
left	O
kidney	O
and	O
bowels	O
to	O
the	O
right	O
abdomen	O
.	O
Surgery	O
,	O
IR	O
,	O
and	O
Vascular	O
Surgery	O
were	O
all	O
consulted	O
for	O
recommendations	O
on	O
how	O
to	O
stop	O
her	O
bleeding	O
.	O
The	O
consulting	O
services	O
all	O
agreed	O
that	O
intervention	O
was	O
ill	O
-	O
advised	O
,	O
as	O
surgical	O
treatment	O
was	O
often	O
inneffective	O
and	O
repeated	O
arterial	O
embolization	O
in	O
this	O
setting	O
might	O
result	O
in	O
embolization	O
of	O
the	O
wrong	O
vessel	O
,	O
w	O
/	O
possible	O
bowel	O
infarction	O
or	O
other	O
complication	O
.	O
Thus	O
,	O
the	O
pt	O
was	O
given	O
2units	O
FFP	I-Drug
to	O
reverse	O
her	O
INR	O
of	O
1.3	O
,	O
and	O
was	O
transfused	O
w	O
/	O
2units	O
of	O
PRBCs	I-Drug
.	O
Her	O
HCT	O
did	O
not	O
respond	O
appropriately	O
to	O
PRBC	I-Drug
transfusion	O
,	O
so	O
she	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
close	O
monitoring	O
and	O
continued	O
transfusion	O
.	O
While	O
in	O
MICU	O
,	O
anticoagulation	O
continued	O
to	O
be	O
held	O
,	O
and	O
patient	O
remained	O
stable	O
during	O
MICU	O
course	O
.	O
Indeed	O
,	O
it	O
was	O
felt	O
that	O
risks	O
of	O
bleeding	O
outweighed	O
need	O
to	O
anti-coagulation	O
benefits	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
floor	O
with	O
no	O
further	O
episodes	O
of	O
bleeding	O
and	O
a	O
stable	O
hematocrit	O
for	O
>	O
72	O
hours	O
by	O
discharge	O
.	O
4	O
.	O
HTN	O
:	O
BP	O
was	O
acceptable	O
on	O
admission	O
.	O
BP	O
meds	O
were	O
held	O
initially	O
given	O
concern	O
for	O
GI	O
bleed	O
and	O
subsequent	O
retroperitoneal	O
hemorrhage	O
.	O
However	O
,	O
BP	O
was	O
elevated	O
within	O
a	O
few	O
days	O
of	O
admission	O
.	O
When	O
retroperitoneal	O
bleed	O
had	O
initially	O
stabilized	O
,	O
her	O
outpt	O
meds	O
were	O
resumed	O
including	O
diovan	I-Drug
,	O
HCTZ	I-Drug
,	O
and	O
clonidine	I-Drug
,	O
resulting	O
in	O
good	O
BP	B-Reason
control	I-Reason
.	O
When	O
her	O
hematocrit	O
began	O
to	O
drop	O
for	O
a	O
second	O
time	O
and	O
the	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
MICU	O
,	O
her	O
antihypertensives	I-Drug
were	O
again	O
held	O
.	O
As	O
her	O
bleed	O
stabilized	O
,	O
her	O
blood	O
pressures	O
trended	O
upward	O
and	O
she	O
was	O
restarted	O
on	O
diovan	I-Drug
at	O
1/2	O
her	O
home	O
dose	O
.	O
Her	O
blood	O
pressures	O
should	O
be	O
followed	O
at	O
rehab	O
.	O
5	O
.	O
Anemia	O
:	O
she	O
has	O
h	O
/	O
o	O
iron	O
deficiency	O
anemia	O
,	O
w	O
/	O
prior	O
EGD	O
showing	O
gastritis	O
.	O
HCT	O
on	O
admission	O
was	O
slightly	O
below	O
baseline	O
of	O
32	O
-	O
33	O
.	O
HCT	O
remained	O
stable	O
for	O
initial	O
hospital	O
days	O
,	O
but	O
dropped	O
w	O
/	O
retroperitoneal	O
bleed	O
as	O
above	O
.	O
Her	O
HCT	O
was	O
labile	O
throughout	O
her	O
admission	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
intermittent	O
bleeding	O
.	O
At	O
d	O
/	O
c	O
,	O
there	O
is	O
no	O
evidence	O
of	O
active	O
bleeding	O
.	O
She	O
will	O
require	O
f	O
/	O
u	O
of	O
HCT	O
after	O
d	O
/	O
c	O
to	O
watch	O
for	O
further	O
bleeding	O
.	O
6	O
.	O
Hypothyroidism	I-Reason
:	O
stable	O
on	O
synthroid	I-Drug
during	O
her	O
admission	O
.	O
7	O
.	O
AVR	O
:	O
she	O
has	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
1525	O
**	O
]	O
artificial	O
aortic	O
valve	O
;	O
requires	O
anticoagulation	O
w	O
/	O
goal	O
INR	O
2.5	O
-	O
3.5	O
.	O
INR	O
subtherapeutic	O
on	O
admission	O
.	O
Given	O
melanic	O
stool	O
,	O
we	O
held	O
coumadin	I-Drug
on	O
admission	O
and	O
started	O
heparin	I-Drug
for	O
anticoagulation	I-Reason
.	O
She	O
had	O
intermittent	O
retroperitoneal	O
bleeding	O
during	O
her	O
admission	O
,	O
requiring	O
d	O
/	O
c	O
and	O
resumption	O
of	O
heparin	I-Drug
multiple	O
times	O
as	O
above	O
.	O
Given	O
her	O
repeated	O
spontaneous	O
bleeding	O
after	O
embolization	O
of	O
L3	O
lumber	O
artery	O
,	O
we	O
do	O
not	O
want	O
to	O
restart	O
anticoagulation	O
in	O
the	O
near	O
future	O
as	O
the	O
risk	O
of	O
ongoing	O
bleeding	O
is	O
too	O
great	O
.	O
8	O
.	O
Mediastinal	O
LAD	O
:	O
she	O
has	O
mediastinal	O
LAD	O
,	O
w	O
/	O
largest	O
node	O
3	O
x	O
2	O
cm	O
by	O
CT.	O
.	O
This	O
may	O
represent	O
lung	O
CA	O
given	O
pulm	O
nodule	O
and	O
smoking	O
history	O
.	O
However	O
,	O
the	O
pt	O
wishes	O
to	O
defer	O
further	O
evaluation	O
until	O
active	O
issues	O
resolved	O
.	O
Will	O
follow	O
w	O
/	O
repeat	O
CT	O
2	O
months	O
after	O
d	O
/	O
c.	O
9	O
.	O
Cystitis	I-Reason
:	O
she	O
developed	O
cystitis	O
from	O
yeast	O
while	O
using	O
foley	O
catheter	O
,	O
likely	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
,	O
as	O
supported	O
by	O
pyuria	O
and	O
yeast	O
in	O
ucx	O
.	O
Foley	O
catheter	O
was	O
changed	O
on	O
discovery	O
of	O
yeast	I-Reason
in	O
urine	O
,	O
and	O
she	O
was	O
treated	O
w	O
/	O
7	O
day	O
course	O
of	O
fluconazole	I-Drug
.	O
At	O
d	O
/	O
c	O
,	O
there	O
is	O
no	O
evidence	O
of	O
active	O
infection	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
coumadin	I-Drug
6	O
mg	O
6	O
days	O
per	O
week	O
,	O
7	O
mg	O
1	O
day	O
per	O
week	O
2	O
.	O
diovan	I-Drug
160	O
mg	O
qam	O
3	O
.	O
HCTZ	I-Drug
12.5	O
mg	O
q	O
day	O
4	O
.	O
Prevacid	I-Drug
5	O
.	O
Synthroid	I-Drug
175mcg	O
q	O
day	O
6	O
.	O
clonidine	I-Drug
0.1	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
Levothyroxine	B-Drug
Sodium	I-Drug
175	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Zolpidem	B-Drug
Tartrate	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O
3	O
.	O
Valsartan	I-Drug
80	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
and	O
pain	I-Reason
.	O
5	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
6	O
.	O
Simethicone	I-Drug
80	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Lidocaine	B-Drug
HCl	I-Drug
2	O
%	O
Gel	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Urethral	O
Q4	O
-	O
6	O
PRN	O
(	O
)	O
as	O
needed	O
for	O
rectal	B-Reason
discomfort	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
1	O
.	O
Retroperitoneal	O
Bleed	O
.	O
2	O
.	O
Influenza	O
A	O
3	O
.	O
Mediastinal	O
Lymphadenopathy	O
.	O
4	O
.	O
4	O
mm	O
nodule	O
within	O
the	O
left	O
upper	O
lobe	O
laterally	O
with	O
hazy	O
spiculated	O
margins	O
.	O
5	O
.	O
Bronchiectasis	O
.	O
6	O
.	O
Hiatal	O
Hernia	O
.	O
7	O
.	O
GI	O
bleed	O
.	O
Secondary	O
/	O
PMH	O
:	O
1	O
.	O
Ascending	O
thoracic	O
aortic	O
aneurysm	O
s	O
/	O
p	O
valve	O
conduit	O
replacement	O
with	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
923	O
**	O
]	O
MVR	O
and	O
hemi	O
-	O
Cabrol	O
and	O
hemi	O
-	O
Rhemi	O
arch	O
replacement	O
.	O
2	O
.	O
Hypertension	O
.	O
3	O
.	O
Hypothyroidism	O
.	O
4	O
.	O
Iron	O
Deficiency	O
Anemia	O
.	O
5	O
.	O
Abdominal	O
Aortic	O
Aneurysm	O
.	O
3.1	O
x	O
3.6	O
cm	O
6	O
.	O
Gallstone	O
Pancreatitis	O
.	O
7	O
.	O
Perforated	O
hemorrhagic	O
gallbladder	O
s	O
/	O
p	O
Cholecystectomy	O
.	O
Discharge	O
Condition	O
:	O
Stable	O
to	O
go	O
to	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
.	O
No	O
evidence	O
of	O
active	O
bleeding	O
or	O
infection	O
.	O
Tolerating	O
diet	O
well	O
.	O
Discharge	O
Instructions	O
:	O
You	O
are	O
being	O
discharged	O
after	O
treatment	O
for	O
influenza	O
,	O
GI	O
bleed	O
,	O
and	O
retroperitoneal	O
bleeding	O
.	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
We	O
restarted	O
your	O
diovan	I-Drug
at	O
half	O
of	O
your	O
previous	O
dose	O
.	O
Your	O
blood	O
pressures	O
should	O
be	O
followed	O
closely	O
at	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
.	O
Call	O
your	O
doctor	O
or	O
present	O
to	O
the	O
ED	O
if	O
you	O
have	O
shortness	O
of	O
breath	O
,	O
dizziness	O
,	O
chest	O
pain	O
,	O
confusion	O
,	O
abdominal	O
pain	O
,	O
nausea	O
and	O
vomiting	O
,	O
fever	O
,	O
bleeding	O
,	O
black	O
stools	O
,	O
or	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
665	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
)	O
after	O
you	O
have	O
been	O
discharged	O
from	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
.	O
Call	O
to	O
make	O
an	O
appointment	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1947	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
3152	O
**	O
]	O
[	O
**	O
Hospital	O
1947	O
**	O
]	O
CLINIC	O
Where	O
:	O
CC	O
-	O
2	O
[	O
**	O
Hospital	O
1947	O
**	O
]	O
UNIT	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3153	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2188-4-15	O
**	O
]	O
2:10	O

Admission	O
Date	O
:	O
[	O
**	O
2125-11-9	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2125-11-24	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2050-1-26	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Demerol	I-Drug
/	O
Codeine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2279	O
**	O
]	O
Chief	O
Complaint	O
:	O
altered	O
mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
chest	O
tube	O
placement	O
intubation	O
History	O
of	O
Present	O
Illness	O
:	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
75	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
Afib	O
s	O
/	O
p	O
ablation	O
,	O
HTN	O
,	O
DM	O
,	O
spinal	O
stenosis	O
,	O
with	O
recent	O
hospitalization	O
for	O
osteomyelitis	O
who	O
presents	O
with	O
altered	O
mental	O
status	O
and	O
worsening	O
tremor	O
.	O
She	O
had	O
been	O
discharged	O
from	O
[	O
**	O
Hospital1	O
**	O
]	O
following	O
hospitalization	O
from	O
presumed	O
sepsis	O
and	O
hypotension	O
on	O
[	O
**	O
2125-11-5	O
**	O
]	O
to	O
rehab	O
.	O
On	O
the	O
evening	O
of	O
[	O
**	O
11	O
-	O
9	O
**	O
]	O
a	O
moonlighter	O
was	O
called	O
for	O
increasing	O
agitation	O
.	O
It	O
is	O
unclear	O
at	O
what	O
point	O
she	O
received	O
0.5	O
mg	O
of	O
ativan	I-Drug
.	O
The	O
patient	O
was	O
confused	O
(	O
oriented	O
x1	O
)	O
with	O
a	O
question	O
of	O
increasing	O
tremor	O
and	O
possibly	O
slurred	O
speech	O
and	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
concern	O
of	O
seizures	O
v.	O
sepsis	O
with	O
AMS	O
.	O
.	O
In	O
ED	O
tachy	O
to	O
110s	O
,	O
SBP	O
110s	O
and	O
required	O
a	O
0.7	O
L	O
fluid	I-Drug
bolus	O
with	O
resolution	O
of	O
BP	O
to	O
130s	O
,	O
but	O
remained	O
tachy	O
to	O
low	O
100s	O
.	O
A	O
CT	O
ab	O
/	O
pelvis	O
revealed	O
a	O
fluid	O
collection	O
on	O
her	O
left	O
flank	O
.	O
No	O
PE	O
was	O
noted	O
.	O
She	O
continued	O
to	O
receive	O
Vanc	I-Drug
/	O
flagyl	I-Drug
and	O
got	O
a	O
dose	O
of	O
zosyn	I-Drug
,	O
with	O
admission	O
for	O
further	O
work	O
up	O
.	O
.	O
ROS	O
was	O
negative	O
for	O
chest	O
pain	O
,	O
syncope	O
or	O
presyncope	O
,	O
myalgias	O
,	O
joint	O
pains	O
,	O
cough	O
,	O
hemoptysis	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
Patient	O
did	O
not	O
have	O
any	O
other	O
complaints	O
.	O
She	O
reported	O
that	O
her	O
tremor	O
has	O
been	O
present	O
since	O
she	O
was	O
in	O
her	O
20s	O
,	O
related	O
to	O
a	O
medication	O
effect	O
.	O
.	O
This	O
am	O
on	O
the	O
floor	O
she	O
was	O
intermittently	O
oriented	O
to	O
place	O
and	O
month	O
but	O
sometimes	O
thinking	O
she	O
was	O
stranded	O
without	O
her	O
car	O
and	O
needing	O
help	O
.	O
She	O
did	O
complain	O
of	O
anxiety	O
once	O
,	O
calling	O
for	O
help	O
,	O
and	O
was	O
verbally	O
calmed	O
down	O
then	O
noted	O
to	O
be	O
tachycardic	O
to	O
the	O
140s	O
.	O
Cardiology	O
was	O
consulted	O
,	O
with	O
carotid	O
massage	O
x	O
2	O
performed	O
,	O
with	O
return	O
to	O
normal	O
sinus	O
rythm	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
son	O
notes	O
that	O
her	O
speech	O
is	O
significantly	O
more	O
garbled	O
in	O
the	O
last	O
two	O
to	O
three	O
days	O
than	O
previously	O
.	O
She	O
began	O
to	O
have	O
difficulty	O
speaking	O
status	O
post	O
extubation	O
during	O
the	O
previous	O
ICU	O
stay	O
,	O
but	O
her	O
speech	O
has	O
become	O
progressively	O
worse	O
.	O
He	O
confirms	O
that	O
the	O
patient	O
has	O
had	O
a	O
baseline	O
tremor	O
,	O
thought	O
to	O
be	O
due	O
to	O
a	O
medication	O
effect	O
20	O
years	O
ago	O
.	O
By	O
the	O
time	O
the	O
son	O
visited	O
the	O
patient	O
in	O
the	O
late	O
morning	O
,	O
her	O
tremor	O
had	O
improved	O
,	O
though	O
it	O
did	O
intermittently	O
worsen	O
when	O
the	O
patient	O
became	O
more	O
anxious	O
.	O
Son	O
also	O
noted	O
that	O
pt	O
had	O
intermittently	O
stared	O
off	O
into	O
space	O
and	O
been	O
less	O
responsive	O
for	O
a	O
few	O
minutes	O
,	O
then	O
would	O
return	O
to	O
conversation	O
.	O
Past	O
Medical	O
History	O
:	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
Atrial	O
fibrillation	O
s	O
/	O
p	O
ablation	O
,	O
not	O
on	O
coumadin	I-Drug
Iron	O
-	O
deficiency	O
anemia	O
Gastritis	O
per	O
EGD	O
,	O
[	O
**	O
2124	O
**	O
]	O
Insulin	I-Drug
-	O
dependent	O
diabetes	B-Reason
mellitus	I-Reason
c	O
/	O
b	O
neuropathy	O
,	O
retinopathy	O
Lumbar	O
stenosis	O
,	O
s	O
/	O
p	O
L5	O
-	O
S1	O
laminectomy	O
(	O
age	O
40	O
)	O
Hypertension	O
Hyperlipidemia	O
DJD	O
Tremor	O
Steatohepatitis	O
Depression	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
Cataract	O
surgery	O
Carpal	O
tunnel	O
release	O
bilaterally	O
Tonsillectomy	O
Appendectomy	O
Cholecystectomy	O
Social	O
History	O
:	O
Patient	O
currently	O
lives	O
in	O
a	O
house	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
Mass.	O
.	O
She	O
lives	O
with	O
her	O
husband	O
.	O
She	O
is	O
now	O
retired	O
but	O
formerly	O
worked	O
in	O
medical	O
records	O
at	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
.	O
She	O
denies	O
EtOH	O
,	O
tobacco	O
,	O
and	O
other	O
drugs	O
.	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
reports	O
attempting	O
to	O
maintain	O
a	O
diabetic	O
diet	O
,	O
but	O
admits	O
to	O
not	O
being	O
as	O
good	O
about	O
it	O
as	O
she	O
should	O
be	O
.	O
She	O
reports	O
exercising	O
by	O
doing	O
chores	O
around	O
the	O
house	O
.	O
Family	O
History	O
:	O
Diabetes	O
II	O
Physical	O
Exam	O
:	O
On	O
admission	O
VS	O
-	O
97.5	O
(	O
98.8	O
rectally	O
)	O
,	O
120/60	O
,	O
110	O
,	O
24	O
,	O
100	O
%	O
2L	O
Gen	O
:	O
Tremor	O
worse	O
with	O
movement	O
.	O
HEENT	O
:	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
CV	O
:	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
No	O
thrills	O
,	O
lifts	O
.	O
No	O
S3	O
or	O
S4	O
.	O
Chest	O
:	O
Decreased	O
BS	O
,	O
worse	O
on	O
L.	O
Abd	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
Ext	O
:	O
+	O
edema	O
b	O
/	O
l	O
,	O
pitting	O
.	O
Skin	O
:	O
midline	O
surgical	O
scar	O
on	O
back	O
.	O
At	O
the	O
bottom	O
of	O
scar	O
,	O
small	O
opening	O
,	O
small	O
amount	O
of	O
bleeding	O
when	O
instpected	O
with	O
Q	O
-	O
tip	O
,	O
no	O
tracking	O
noted	O
.	O
Neuro	O
:	O
CNII	O
-	O
XII	O
intact	O
.	O
Strength	O
diffusly	O
[	O
**	O
2	O
-	O
25	O
**	O
]	O
.	O
Sensation	O
intact	O
.	O
She	O
is	O
awake	O
,	O
alert	O
,	O
oriented	O
to	O
self	O
only	O
.	O
Responds	O
to	O
questions	O
and	O
some	O
long	O
term	O
memory	O
intact	O
.	O
Patient	O
able	O
to	O
recal	O
1	O
object	O
at	O
5	O
minutes	O
.	O
Difficulty	O
with	O
finger	O
to	O
nose	O
b	O
/	O
l.	O
Changes	O
at	O
discharge	O
:	O
1	O
+	O
bilateral	O
foot	O
edema	O
,	O
trace	O
bilateral	O
lower	O
extremity	O
edema	O
,	O
alert	O
and	O
oriented	O
x	O
3	O
,	O
answering	O
questions	O
appropriately	O
Pertinent	O
Results	O
:	O
============	O
Radiology	O
============	O
CT	O
Torso	O
[	O
**	O
11	O
-	O
9	O
**	O
]	O
1	O
.	O
No	O
pulmonary	O
embolus	O
or	O
acute	O
aortic	O
abnormality	O
.	O
2	O
.	O
2.2	O
x	O
2.0	O
cm	O
fluid	O
and	O
air	O
collection	O
in	O
the	O
subcutaneous	O
tissues	O
of	O
the	O
left	O
lateral	O
abdominal	O
wall	O
that	O
could	O
reflect	O
post-operative	O
seroma	O
,	O
but	O
abscess	O
can	O
not	O
be	O
excluded	O
.	O
3	O
.	O
No	O
evidence	O
large	O
fluid	O
collection	O
surrounding	O
spinal	O
fixation	O
hardware	O
in	O
the	O
lumbar	O
spine	O
,	O
although	O
artifact	O
obscures	O
fine	O
detail	O
and	O
evaluation	O
is	O
suboptimal	O
.	O
4	O
.	O
Cirrhotic	O
liver	O
with	O
ascites	O
.	O
5	O
.	O
Bilateral	O
pleural	O
effusions	O
,	O
moderate	O
on	O
the	O
left	O
and	O
small	O
on	O
the	O
right	O
with	O
adjacent	O
atelectasis	O
.	O
6	O
.	O
Atherosclerotic	O
disease	O
.	O
CT	O
Head	O
[	O
**	O
11	O
-	O
10	O
**	O
]	O
IMPRESSION	O
:	O
Limited	O
study	O
due	O
to	O
patient	O
motion	O
.	O
Within	O
this	O
limitation	O
,	O
no	O
acute	O
intracranial	O
abnormalities	O
identified	O
.	O
Repeat	O
study	O
[	O
**	O
11	O
-	O
10	O
**	O
]	O
Several	O
rounded	O
areas	O
of	O
hypodensity	O
are	O
seen	O
within	O
the	O
left	O
frontal	O
region	O
seen	O
on	O
axial	O
images	O
only	O
that	O
are	O
likely	O
areas	O
of	O
volume	O
averaging	O
,	O
however	O
,	O
peripheral	O
areas	O
of	O
infarction	O
can	O
not	O
be	O
entirely	O
excluded	O
,	O
and	O
if	O
of	O
clinical	O
concern	O
,	O
a	O
repeat	O
examination	O
or	O
MR	O
can	O
be	O
performed	O
.	O
No	O
evidence	O
of	O
hemorrhage	O
.	O
MR	O
[	O
**	O
Name13	O
(	O
STitle	O
)	O
430	O
**	O
]	O
[	O
**	O
11	O
-	O
11	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
No	O
definite	O
acute	O
infarction	O
.	O
2	O
.	O
Mild	O
-	O
to	O
-	O
moderate	O
dilatation	O
of	O
the	O
lateral	O
ventricles	O
,	O
with	O
features	O
as	O
described	O
above	O
and	O
slightly	O
out	O
of	O
proportion	O
to	O
the	O
prominence	O
of	O
the	O
cerebral	O
sulci	O
;	O
while	O
this	O
can	O
relate	O
to	O
volume	O
loss	O
,	O
associated	O
communicating	O
hydrocephalus	O
/	O
NPH	O
can	O
not	O
be	O
completely	O
excluded	O
.	O
To	O
correlate	O
clinically	O
============	O
Neurology	O
============	O
EEG	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
This	O
is	O
a	O
normal	O
routine	O
EEG	O
in	O
the	O
waking	O
and	O
drowsy	O
states	O
.	O
Note	O
is	O
made	O
by	O
technician	O
of	O
intermittent	O
left	O
leg	O
shaking	O
without	O
obvious	O
epileptiform	O
discharges	O
or	O
EEG	O
correlate	O
seen	O
during	O
that	O
time	O
.	O
Due	O
to	O
technical	O
difficulties	O
,	O
video	O
was	O
unavailable	O
for	O
review	O
.	O
No	O
focal	O
,	O
lateralized	O
,	O
or	O
epileptiform	O
features	O
were	O
noted	O
during	O
this	O
recording	O
.	O
Note	O
is	O
made	O
of	O
a	O
tachycardia	O
of	O
108	O
bpm	O
in	O
a	O
single	O
EKG	O
channel	O
.	O
24	O
hour	O
EEG	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
This	O
24	O
hour	O
video	O
EEG	O
telemetry	O
capture	O
no	O
electrographic	O
seizures	O
.	O
There	O
were	O
no	O
clear	O
focal	O
or	O
lateralizing	O
epileptiform	O
features	O
.	O
The	O
background	O
showed	O
a	O
slightly	O
disorganized	O
alpha	O
theta	O
rhythm	O
which	O
would	O
be	O
normal	O
for	O
advanced	O
age	O
.	O
===========	O
Cytology	O
============	O
Pleural	O
fluids	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS	O
.	O
============	O
Cardiology	O
============	O
Stress	B-Reason
test	I-Reason
[	O
**	O
11	O
-	O
12	O
**	O
]	O
No	O
anginal	O
symptoms	O
or	O
ischemic	O
ST	O
segment	O
changes	O
to	O
pharmacologic	O
stress	O
.	O
Appropriate	O
blood	O
pressure	O
response	O
with	O
flat	O
heart	O
rate	O
response	O
to	O
Persantine	I-Drug
infusion	O
.	O
Nuclear	O
report	O
sent	O
separately	O
.	O
TTE	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
focal	O
hypokinesis	O
of	O
the	O
basal	O
half	O
of	O
the	O
inferior	O
wall	O
and	O
mid-inferior	O
septum	O
and	O
inferolateral	O
walls	O
.	O
The	O
remaining	O
segments	O
contract	O
normally	O
(	O
LVEF	O
=	O
50	O
%	O
)	O
.	O
The	O
estimated	O
cardiac	O
index	O
is	O
normal	O
(	O
>	O
=	O
2.5	O
L	O
/	O
min	O
/	O
m2	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
diameters	O
of	O
aorta	O
at	O
the	O
sinus	O
,	O
ascending	O
and	O
arch	O
levels	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
fat	O
pad	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2125-11-5	O
**	O
]	O
,	O
regional	O
left	O
ventricular	O
systolic	O
function	O
is	O
now	O
improved	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
now	O
higher	O
.	O
===========	O
Micro	O
===========	O
[	O
**	O
2125-11-13	O
**	O
]	O
7:38	O
pm	O
MRSA	O
SCREEN	O
:	O
No	O
MRSA	O
isolated	O
.	O
[	O
**	O
2125-11-24	O
**	O
]	O
Urine	O
culture	O
:	O
YEAST	O
.	O
10,000	O
-	O
100,000	O
ORGANISMS	O
/	O
ML	O
==============	O
Labs	O
==============	O
Admission	O
Labs	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
WBC	O
-	O
8.5	O
RBC	O
-	O
3.35	O
*	O
Hgb	O
-	O
9.3	O
*	O
Hct	O
-	O
30.2	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
27.9	O
MCHC	O
-	O
30.9	O
*	O
RDW	O
-	O
18.7	O
*	O
Plt	O
Ct	O
-	O
366	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
Neuts	O
-	O
83.5	O
*	O
Lymphs	O
-	O
9.4	O
*	O
Monos	O
-	O
6.4	O
Eos	O
-	O
0.5	O
Baso	O
-	O
0.2	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
PT	O
-	O
16.0	O
*	O
PTT	O
-	O
31.4	O
INR	O
(	O
PT	O
)	O
-	O
1.4	O
*	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
Glucose	O
-	O
109	O
*	O
UreaN	O
-	O
13	O
Creat	O
-	O
1.2	O
*	O
Na	O
-	O
145	O
K	O
-	O
3.7	O
Cl	O
-	O
108	O
HCO3	O
-	O
29	O
AnGap	O
-	O
12	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
ALT	O
-	O
20	O
AST	O
-	O
32	O
CK	O
(	O
CPK	O
)	O
-	O
54	O
TotBili	O
-	O
0.5	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.04	O
*	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.04	O
*	O
[	O
**	O
2125-11-9	O
**	O
]	O
06:00	O
PM	O
BLOOD	O
Albumin	O
-	O
3.1	O
*	O
Calcium	O
-	O
8.3	O
*	O
Mg	O
-	O
1.3	O
*	O
Discharge	O
labs	O
:	O
WBC	O
-	O
7.2	O
RBC	O
-	O
3.59	O
*	O
Hgb	O
-	O
10.6	O
*	O
Hct	O
-	O
33.2	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
29.4	O
MCHC	O
-	O
31.8	O
RDW	O
-	O
18.0	O
*	O
Plt	O
Ct	O
-	O
324	O
Glucose	O
-	O
179	O
*	O
UreaN	O
-	O
17	O
Creat	O
-	O
1.1	O
Na	O
-	O
141	O
K	O
-	O
4.3	O
Cl	O
-	O
99	O
HCO3	O
-	O
33	O
*	O
AnGap	O
-	O
13	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
3.7	O
Mg	O
-	O
1.8	O
Brief	O
Hospital	O
Course	O
:	O
75	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
Afib	O
s	O
/	O
p	O
ablation	O
,	O
HTN	O
,	O
DM	O
,	O
spinal	O
stenosis	O
,	O
with	O
recent	O
hospitalization	O
for	O
osteomyelitis	O
who	O
presents	O
with	O
altered	O
mental	O
status	O
and	O
worsening	O
tremor	O
.	O
She	O
had	O
been	O
discharged	O
from	O
[	O
**	O
Hospital1	O
**	O
]	O
following	O
hospitalization	O
from	O
presumed	O
sepsis	O
and	O
hypotension	O
on	O
[	O
**	O
2125-11-5	O
**	O
]	O
to	O
rehab	O
.	O
On	O
the	O
evening	O
of	O
[	O
**	O
11	O
-	O
9	O
**	O
]	O
a	O
moonlighter	O
was	O
called	O
for	O
increasing	I-Reason
agitation	O
.	O
It	O
is	O
unclear	O
at	O
what	O
point	O
she	O
received	O
0.5	O
mg	O
of	O
ativan	I-Drug
.	O
The	O
patient	O
was	O
confused	O
(	O
oriented	O
x1	O
)	O
with	O
a	O
question	O
of	O
increasing	O
tremor	O
and	O
possibly	O
slurred	O
speech	O
and	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
concern	O
of	O
seizures	O
v.	O
sepsis	O
with	O
AMS	O
.	O
On	O
the	O
day	O
of	O
admission	O
,	O
patient	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
an	O
episode	O
of	O
unresponsiveness	O
on	O
the	O
floor	O
.	O
The	O
patient	O
rapidly	O
improved	O
in	O
regards	O
to	O
her	O
mental	O
status	O
upon	O
admission	O
to	O
the	O
MICU	O
.	O
CT	O
head	O
and	O
MRI	O
were	O
negative	O
,	O
and	O
Neuro	O
felt	O
this	O
event	O
was	O
likely	O
toxic	O
/	O
metabolic	O
in	O
nature	O
.	O
She	O
was	O
called	O
out	O
to	O
the	O
floor	O
where	O
an	O
EEG	O
was	O
performed	O
and	O
negative	O
.	O
She	O
underwent	O
diagnosistc	O
thoracentesis	O
which	O
was	O
transudative	O
in	O
nature	O
on	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
.	O
Post-thoracentesis	O
CXR	O
detected	O
a	O
left	O
hemidiaphagm	O
and	O
repeat	O
film	O
several	O
hours	O
later	O
was	O
performed	O
while	O
the	O
patient	O
was	O
having	O
another	O
episode	O
of	O
shaking	O
.	O
She	O
became	O
unresponsive	O
and	O
was	O
noted	O
to	O
have	O
shallow	O
breathing	O
.	O
The	O
xray	O
technicians	O
at	O
the	O
patient	O
's	O
side	O
were	O
unable	O
to	O
palpate	O
a	O
pulse	O
so	O
CPR	O
was	O
initiated	O
and	O
a	O
code	O
was	O
called	O
.	O
Code	O
team	O
immediately	O
noted	O
that	O
patient	O
was	O
in	O
A	O
fib	O
,	O
and	O
CPR	O
was	O
stopped	O
.	O
Patient	O
at	O
this	O
time	O
was	O
awake	O
but	O
delirious	O
.	O
Her	O
oxygen	O
saturation	O
began	O
to	O
plummet	O
and	O
decreased	O
breath	O
sounds	O
were	O
noted	O
on	O
the	O
left	O
side	O
.	O
CXR	O
revealed	O
a	O
large	O
hydrothorax	O
,	O
and	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
MICU	O
.	O
A	O
chest	O
tube	O
was	O
placed	O
and	O
blood	O
tinged	O
sanguinous	O
fluid	O
returned	O
.	O
Patient	O
was	O
intubated	O
for	O
airway	O
protection	O
.	O
Patient	O
remained	O
in	O
the	O
MICU	O
from	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
through	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
.	O
While	O
in	O
the	O
MICU	O
she	O
was	O
extubated	O
on	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
.	O
She	O
required	O
pressors	O
from	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
through	O
[	O
**	O
11	O
-	O
15	O
**	O
]	O
.	O
Her	O
hypotension	O
was	O
felt	O
to	O
be	O
due	O
to	O
hypovolemia	O
secondary	O
to	O
dramatic	O
chest	O
tube	O
fluid	O
output	O
.	O
Chest	O
tube	O
drained	O
between	O
2	O
and	O
4	O
L	O
per	O
day	O
of	O
ascitic	O
fluid	O
from	O
presumed	O
hepatic	O
hydrothorax	O
.	O
Cardiac	O
enzymes	O
were	O
slightly	O
elevated	O
,	O
but	O
consistent	O
with	O
her	O
level	O
of	O
renal	O
dysfunction	O
and	O
was	O
felt	O
not	O
to	O
have	O
ACS	O
.	O
She	O
had	O
several	O
TTEs	O
which	O
showed	O
improving	O
systolic	O
function	O
from	O
EF	O
35	O
to	O
50	O
%	O
.	O
The	O
patient	O
required	O
2	O
untis	O
of	O
PRBC	I-Drug
transfusion	O
in	O
the	O
unit	O
and	O
multiple	O
albumin	I-Drug
bags	O
for	O
resuscitation	I-Reason
.	O
Thoracic	O
surgery	O
was	O
consulted	O
on	O
[	O
**	O
11	O
-	O
16	O
**	O
]	O
for	O
assistance	O
on	O
hydrothorax	O
management	O
,	O
and	O
they	O
advised	O
no	O
surgical	O
intervention	O
.	O
Instead	O
the	O
chest	O
tube	O
was	O
placed	O
to	O
waterseal	O
on	O
[	O
**	O
11	O
-	O
17	O
**	O
]	O
and	O
diuresis	I-Reason
was	O
initiated	O
with	O
lasix	I-Drug
drip	O
per	O
thoracic	O
surgery	O
recommendations	O
.	O
A	O
diaphragmatic	O
defect	O
was	O
not	O
felt	O
to	O
be	O
responsible	O
.	O
The	O
patient	O
was	O
able	O
to	O
maintain	O
her	O
pressures	O
,	O
and	O
she	O
tolerated	O
diuresis	O
with	O
these	O
maneuvers	O
.	O
Her	O
course	O
in	O
the	O
MICU	O
was	O
also	O
complicated	O
by	O
intermittent	O
episodes	O
of	O
sinus	O
tachycardia	O
to	O
has	O
high	O
as	O
140s	O
bpm	O
which	O
responded	O
transiently	O
to	O
carotid	O
massage	O
.	O
Her	O
sinus	O
tach	O
was	O
felt	O
to	O
be	O
due	O
to	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
3041	O
**	O
]	O
shifts	O
and	O
anxiety	O
.	O
She	O
was	O
transferred	O
out	O
of	O
the	O
MICU	O
on	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
.	O
No	O
clear	O
cause	O
for	O
her	O
change	O
in	O
mental	O
status	O
was	O
found	O
while	O
in	O
the	O
MICU	O
.	O
A	O
repeat	O
EEG	O
was	O
again	O
negative	O
,	O
and	O
Neurology	O
once	O
again	O
felt	O
that	O
this	O
was	O
likely	O
multifactorial	O
toxic	O
/	O
metabolic	O
insults	O
in	O
the	O
setting	O
of	O
acute	O
on	O
chronic	O
renal	O
failure	O
,	O
liver	O
disease	O
,	O
chf	O
,	O
dm	O
and	O
hypoxia	O
from	O
chronic	O
pleural	O
effusions	O
.	O
Back	O
on	O
the	O
medical	O
floor	O
,	O
she	O
continued	O
to	O
improve	O
.	O
#	O
Altered	O
mental	O
status	O
:	O
Her	O
altered	O
mental	O
status	O
was	O
likely	O
related	O
to	O
medication	O
side	O
effects	O
or	O
hepatic	O
encephalopathy	O
.	O
Her	O
Elavil	I-Drug
was	O
decreased	O
for	O
possible	O
anticholinergic	B-Ade
side	I-Ade
effects	O
.	O
If	O
her	O
mental	O
status	O
worsens	O
,	O
suggest	O
changing	O
patient	O
over	O
to	O
nortripytline	O
and	O
checking	O
levels	O
.	O
#	O
Tachycardia	I-Reason
:	O
Her	O
sinus	O
tachycardia	O
improved	O
after	O
adding	O
metoprolol	I-Drug
back	O
to	O
her	O
medication	O
regimen	O
.	O
#	O
Anemia	I-Reason
:	O
She	O
had	O
a	O
hematocrit	O
drop	O
while	O
in	O
the	O
MICU	O
without	O
clear	O
source	O
and	O
was	O
guaiac	O
negative	O
.	O
After	O
2	O
units	O
pRBCs	I-Drug
on	O
[	O
**	O
11	O
-	O
15	O
**	O
]	O
,	O
her	O
hematocrit	O
was	O
stable	O
.	O
#	O
Osteomyelitis	I-Reason
:	O
Patient	O
is	O
on	O
long	O
term	O
vanco	I-Drug
/	O
metronidazole	I-Drug
since	O
previous	O
hospitalization	O
for	O
L2	O
osteo	O
and	O
is	O
followed	O
by	O
ID	O
as	O
an	O
outpatient	O
.	O
She	O
is	O
to	O
continue	O
vancomycin	I-Drug
until	O
[	O
**	O
2125-12-16	O
**	O
]	O
and	O
flagyl	I-Drug
until	O
[	O
**	O
2125-12-20	O
**	O
]	O
.	O
#	O
Mild	O
systolic	O
congestive	O
heart	O
failure	O
:	O
She	O
was	O
diuresed	O
as	O
above	O
.	O
Patient	O
's	O
most	O
recent	O
EF	O
50	O
%	O
.	O
#	O
NASH	B-Reason
Cirrhosis	I-Reason
:	O
She	O
was	O
seen	O
by	O
hepatology	O
during	O
this	O
admission	O
.	O
She	O
had	O
a	O
low	O
MELD	O
.	O
Patient	O
was	O
started	O
on	O
aldactone	I-Drug
and	O
diuresed	O
as	O
above	O
.	O
She	O
is	O
to	O
follow	O
-	O
up	O
with	O
the	O
liver	O
center	O
as	O
an	O
outpatient	O
.	O
#	O
Inverted	O
nipple	O
noted	O
on	O
exam	O
:	O
Patient	O
will	O
need	O
follow	O
up	O
with	O
PCP	O
for	O
this	O
issue	O
.	O
#	O
DM	I-Reason
:	O
She	O
was	O
continued	O
on	O
an	O
insulin	I-Drug
sliding	O
scale	O
.	O
#	O
Communication	O
:	O
daughter	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
40153	O
**	O
]	O
,	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
40152	O
**	O
]	O
,	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
40154	O
**	O
]	O
Full	O
code	O
Medications	O
on	O
Admission	O
:	O
Per	O
last	O
D	O
/	O
C	O
sum	O
:	O
Acetaminophen	I-Drug
325	O
mg	O
prn	O
q6	O
Amitriptyline	I-Drug
75	O
mg	O
qHS	O
Bisacodyl	I-Drug
10	O
mg	O
dailr	O
prn	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
Iron	I-Drug
)	O
daily	O
Furosemide	I-Drug
40	O
mg	O
daily	O
Heparin	I-Drug
SC	O
5,000	O
Units	O
TID	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
daily	O
prn	O
Megestrol	I-Drug
40	O
mg	O
TID	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Metronidazole	I-Drug
500	O
mg	O
q8	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
[	O
**	O
Hospital1	O
**	O
]	O
Pantoprazole	B-Drug
40	O
mg	O
Daily	O
Sennosides	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
Simvastatin	B-Drug
40	O
mg	O
daily	O
Trifluoperazine	I-Drug
2	O
mg	O
daily	O
Vancomycin	I-Drug
500	O
mg	O
IV	O
Q	O
24H	O
Insulin	I-Drug
SS	O
Discharge	O
Medications	O
:	O
1	O
.	O
Bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
2	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
3	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
:	O
12	O
hours	O
on	O
and	O
12	O
hours	O
off	O
.	O
5	O
.	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
Hold	O
for	O
SBP	O
<	O
100	O
,	O
HR	O
<	O
60	O
.	O
6	O
.	O
Lactulose	I-Drug
10	O
gram	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
:	O
Hold	O
for	O
>	O
4	O
BM	O
per	O
day	O
.	O
7	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
skin	B-Reason
irritation	I-Reason
.	O
8	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
9	O
.	O
Simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Metronidazole	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
:	O
Continue	O
until	O
[	O
**	O
2125-12-20	O
**	O
]	O
.	O
11	O
.	O
Vancomycin	I-Drug
750	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
dose	O
Intravenous	O
once	O
a	O
day	O
:	O
Until	O
[	O
**	O
2125-12-16	O
**	O
]	O
.	O
12	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
13	O
.	O
Amitriptyline	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
14	O
.	O
Trifluoperazine	B-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
Spironolactone	B-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Hold	O
for	O
SBP	O
<	O
100	O
.	O
16	O
.	O
Furosemide	I-Drug
10	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
Sixty	O
(	O
60	O
)	O
milligrams	O
Injection	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
17	O
.	O
Aspirin	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
18	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
:	O
Do	O
not	O
exceed	O
2grams	O
daily	O
.	O
19	O
.	O
Lantus	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Ten	O
(	O
10	O
)	O
units	O
Subcutaneous	O
at	O
bedtime	O
.	O
20	O
.	O
Insulin	I-Drug
Please	O
continue	O
humalog	I-Drug
insulin	O
sliding	O
scale	O
as	O
attached	O
.	O
21	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Syringe	O
Sig	O
:	O
5000	O
(	O
5000	O
)	O
units	O
Injection	O
three	O
times	O
a	O
day	O
.	O
22	O
.	O
Fluconazole	B-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
last	O
day	O
[	O
**	O
2125-12-8	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
700	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
701	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Altered	O
mental	O
status	O
Urinary	O
tract	O
infection	O
Hydrothorax	O
Osteomyelitis	O
Cirrhosis	O
Discharge	O
Condition	O
:	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
(	O
but	O
intermittent	O
as	O
patient	O
may	O
wx	O
and	O
wane	O
)	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
(	O
waxes	O
and	O
wanes	O
but	O
alert	O
and	O
oriented	O
currently	O
)	O
Questionable	O
hospitalization	O
delirium	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
confusion	O
.	O
During	O
your	O
hospital	O
stay	O
,	O
you	O
had	O
2	O
episodes	O
of	O
decreased	O
responsiveness	O
prompting	O
stays	O
in	O
the	O
intensive	O
care	O
unit	O
.	O
We	O
suspect	O
your	O
first	O
episode	O
was	O
from	O
medications	O
causing	O
sedation	O
and	O
that	O
your	O
second	O
episode	O
was	O
from	O
difficulty	O
breathing	O
because	O
you	O
had	O
fluid	O
accumulating	O
around	O
your	O
left	O
lung	O
.	O
You	O
improved	O
after	O
draining	O
the	O
fluid	O
with	O
a	O
cathether	O
and	O
taking	O
medications	O
to	O
clear	O
the	O
fluid	O
from	O
your	O
body	O
.	O
You	O
were	O
stable	O
to	O
be	O
discharged	O
to	O
a	O
rehab	O
facility	O
to	O
work	O
on	O
regaining	O
your	O
strength	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
40075	O
**	O
]	O
.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
medications	O
:	O
Decreased	O
Elavil	I-Drug
from	O
75	O
mg	O
to	O
25	O
mg	O
as	O
it	O
may	O
have	O
worsened	O
your	O
confusion	I-Ade
Increased	O
lasix	I-Drug
to	O
60	O
mg	O
IV	O
twice	O
a	O
day	O
.	O
This	O
will	O
be	O
tapered	O
to	O
meet	O
your	O
goal	O
Ins	O
and	O
Outs	O
Increased	O
vancomycin	I-Drug
to	O
750	O
mg	O
for	O
therapeutic	O
level	O
Decreased	O
metoprolol	I-Drug
from	O
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
12.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Started	O
fluconazole	I-Drug
200	O
mg	O
daily	O
for	O
fungus	B-Reason
in	I-Reason
your	I-Reason
urine	I-Reason
for	O
14	O
days	O
(	O
last	O
day	O
[	O
**	O
2125-12-8	O
**	O
]	O
)	O
Started	O
Lactulose	I-Drug
30	O
mg	O
TID	O
and	O
aldactone	I-Drug
to	O
help	O
control	O
your	O
liver	B-Reason
cirrhosis	I-Reason
.	O
Started	O
full	O
dose	O
aspirin	I-Drug
for	O
your	B-Reason
atrial	I-Reason
fibrillation	I-Reason
Stopped	O
megace	I-Drug
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
40075	O
**	O
]	O
.	O
You	O
can	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
40076	O
**	O
]	O
to	O
schedule	O
an	O
appointment	O
.	O
Please	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
497	O
**	O
]	O
in	O
the	O
liver	O
center	O
.	O
You	O
will	O
be	O
called	O
about	O
appointment	O
scheduling	O
but	O
if	O
you	O
do	O
not	O
hear	O
from	O
them	O
,	O
please	O
call	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1582	O
**	O
]	O
.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2285	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2137-9-19	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2137-10-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2075-12-7	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Iodine	I-Drug
;	O
Iodine	I-Drug
Containing	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
922	O
**	O
]	O
Chief	O
Complaint	O
:	O
chest	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
s	O
/	O
p	O
CABGx5	O
(	O
LIMA	O
-	O
>	O
LAD	O
,	O
SVG	O
-	O
.	O
pLAD	O
,	O
Ramus	O
,	O
PDA	O
,	O
LCX	O
)	O
[	O
**	O
2137-9-19	O
**	O
]	O
Reexploration	O
for	O
bleeding	O
.	O
Cardiac	O
catherization	O
History	O
of	O
Present	O
Illness	O
:	O
61	O
year	O
old	O
male	O
with	O
angina	O
over	O
last	O
year	O
relieved	O
with	O
rest	O
.	O
Presented	O
to	O
OSH	O
when	O
angina	O
did	O
not	O
relieve	O
with	O
rest	O
and	O
ruled	O
in	O
for	O
NSTEMI	O
.	O
Transferred	O
for	O
cardiac	O
catherization	O
Past	O
Medical	O
History	O
:	O
Hypertension	O
Angina	O
Heart	O
Failure	O
Atrial	O
Fibrillation	O
Skin	O
Cancer	O
Social	O
History	O
:	O
Works	O
at	O
[	O
**	O
Company	O
**	O
]	O
globe	O
,	O
is	O
married	O
Tobacco	O
-	O
denies	O
ETOH	O
-	O
[	O
**	O
2	O
-	O
16	O
**	O
]	O
/	O
day	O
Family	O
History	O
:	O
Non	O
contributory	O
Physical	O
Exam	O
:	O
Discharge	O
Neuro	O
:	O
alert	O
,	O
oriented	O
x3	O
,	O
strength	O
R	O
=	O
L	O
[	O
**	O
3	O
-	O
20	O
**	O
]	O
,	O
no	O
vision	O
left	O
eye	O
,	O
normal	O
vision	O
right	O
eye	O
Pulmonary	O
:	O
lungs	O
clear	O
to	O
auscultation	O
bilaterally	O
Cardiac	O
:	O
RRR	O
+	O
murmur	O
2/6	O
SEM	O
,	O
no	O
rub	O
/	O
gallop	O
Sternal	O
incision	O
:	O
healing	O
no	O
erythema	O
,	O
no	O
drainage	O
,	O
sternum	O
stable	O
Abdomen	O
:	O
soft	O
,	O
nontender	O
,	O
nondistended	O
,	O
+	O
bowel	O
sounds	O
last	O
BM	O
[	O
**	O
10	O
-	O
12	O
**	O
]	O
Extremeties	O
:	O
warm	O
,	O
edema	O
+1	O
nonpitting	O
,	O
pulses	O
palpable	O
Leg	O
incision	O
:	O
endovascular	O
harvest	O
,	O
healing	O
,	O
no	O
drainage	O
,	O
no	O
erythema	O
Pertinent	O
Results	O
:	O
RENAL	O
U.S.	O
;	O
DUPLEX	O
DOP	O
ABD	O
/	O
PEL	O
LIMITED	O
Reason	O
:	O
r	O
/	O
o	O
RAS	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
61	O
year	O
old	O
man	O
s	O
/	O
p	O
CABGx5	O
with	O
acutely	O
increased	O
creatinine	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
r	O
/	O
o	O
RAS	O
INDICATION	O
:	O
Status	O
post	O
CABG	O
with	O
acutely	O
increased	O
creatinine	O
.	O
Rule	O
out	O
renal	O
artery	O
stenosis	O
.	O
RENAL	O
ULTRASOUND	O
:	O
No	O
prior	O
examinations	O
.	O
The	O
kidneys	O
are	O
normal	O
in	O
size	O
and	O
appearance	O
.	O
The	O
right	O
kidney	O
measures	O
13.6	O
cm	O
and	O
left	O
kidney	O
measures	O
13.2	O
cm	O
.	O
There	O
are	O
normal	O
arterial	O
waveforms	O
in	O
the	O
parenchyma	O
bilaterally	O
.	O
The	O
maximum	O
RI	O
on	O
the	O
right	O
is	O
0.76	O
and	O
on	O
the	O
left	O
is	O
0.8	O
(	O
both	O
of	O
which	O
are	O
minimally	O
elevated	O
)	O
.	O
There	O
is	O
no	O
evidence	O
of	O
renal	O
artery	O
stenosis	O
.	O
No	O
hydronephrosis	O
,	O
stone	O
,	O
or	O
mass	O
.	O
The	O
bladder	O
is	O
filled	O
with	O
fluid	O
and	O
shows	O
no	O
wall	O
thickening	O
or	O
focal	O
masses	O
.	O
IMPRESSION	O
:	O
Minimally	O
elevated	O
resistive	O
indices	O
in	O
both	O
kidneys	O
,	O
with	O
no	O
evidence	O
of	O
renal	O
artery	O
stenosis	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
18394	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
18395	O
**	O
]	O
CHEST	O
(	O
PA	O
&	O
LAT	O
)	O
[	O
**	O
2137-10-11	O
**	O
]	O
6:30	O
PM	O
CHEST	O
(	O
PA	O
&	O
LAT	O
)	O
Reason	O
:	O
evaluate	O
pleural	O
effusion	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
61	O
year	O
old	O
man	O
s	O
/	O
p	O
CABG	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
evaluate	O
pleural	O
effusion	O
INDICATION	O
:	O
Status	O
post	O
CABG	O
,	O
evaluate	O
pleural	O
effusion	O
.	O
PA	O
AND	O
LATERAL	O
CHEST	O
:	O
Compared	O
to	O
[	O
**	O
2137-10-10	O
**	O
]	O
.	O
Left	O
-	O
sided	O
PICC	O
line	O
is	O
unchanged	O
in	O
position	O
with	O
its	O
tip	O
in	O
the	O
distal	O
SVC	O
.	O
There	O
is	O
no	O
pneumothorax	O
.	O
There	O
remains	O
a	O
small	O
left	O
pleural	O
effusion	O
not	O
significantly	O
changed	O
and	O
a	O
small	O
amount	O
of	O
linear	O
atelectasis	O
at	O
the	O
left	O
mid	O
lung	O
base	O
.	O
Calcified	O
left	O
hilar	O
adenopathy	O
again	O
seen	O
.	O
Heart	O
remains	O
upper	O
limits	O
of	O
normal	O
in	O
size	O
.	O
No	O
significant	O
short	O
interval	O
change	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
DR.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
GENERAL	O
COMMENTS	O
:	O
Suboptimal	O
image	O
quality	O
-	O
poor	O
echo	O
windows	O
.	O
Conclusions	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
moderately	O
depressed	O
(	O
EF	O
35	O
-	O
40	O
%	O
)	O
.	O
Due	O
to	O
the	O
suboptimal	O
image	O
quality	O
,	O
a	O
regional	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
excluded	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
There	O
is	O
mild	O
global	O
right	O
ventricular	O
free	O
wall	O
hypokinesis	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
a	O
small	O
pericardial	O
effusion	O
.	O
The	O
effusion	O
is	O
echo	O
dense	O
,	O
consistent	O
with	O
blood	O
,	O
inflammation	O
or	O
other	O
cellular	O
elements	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
IMPRESSION	O
:	O
Small	O
echodense	O
pericardial	O
effusion	O
without	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
Moderate	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O
Mild	O
aortic	O
regurgitation	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2137-10-3	O
**	O
]	O
,	O
the	O
pericardial	O
effusion	O
is	O
smaller	O
.	O
The	O
other	O
findings	O
are	O
similar	O
.	O
Electronically	O
signed	O
by	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
171	O
**	O
]	O
,	O
MD	O
on	O
[	O
**	O
2137-10-10	O
**	O
]	O
14:51	O
.	O
MRA	O
head	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
orbital	O
abnormality	O
on	O
limited	O
sections	O
through	O
the	O
orbits	O
.	O
2	O
.	O
Evidence	O
of	O
atherosclerotic	O
disease	O
,	O
but	O
without	O
marked	O
stenoses	O
or	O
occlusion	O
among	O
the	O
major	O
arteries	O
of	O
the	O
circle	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
431	O
**	O
]	O
.	O
Because	O
of	O
the	O
limitations	O
of	O
the	O
study	O
,	O
the	O
ophthalmic	O
arteries	O
are	O
not	O
well	O
visualized	O
on	O
either	O
side	O
.	O
3	O
.	O
Multiple	O
small	O
foci	O
of	O
T2	O
hyperintensity	O
suggestive	O
of	O
prior	O
tiny	O
infarcts	O
in	O
the	O
cerebral	O
white	O
matte	O
bilaterally	O
.	O
A	O
few	O
of	O
these	O
demonstrate	O
faintly	O
increased	O
signal	O
also	O
on	O
diffusion	O
-	O
weighted	O
imaging	O
,	O
suggesting	O
that	O
they	O
may	O
be	O
either	O
subacute	O
or	O
chronic	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Transferred	O
in	O
from	O
OSH	O
and	O
underwent	O
cardiac	O
catherization	O
that	O
resulted	O
in	O
intra	O
aortic	O
balloon	O
pump	O
placement	O
and	O
transferred	O
to	O
operating	O
room	O
emergently	O
[	O
**	O
9	O
-	O
19	O
**	O
]	O
.	O
Please	O
see	O
catherization	O
report	O
for	O
further	O
details	O
.	O
He	O
underwent	O
coronary	B-Reason
artery	I-Reason
bypass	I-Reason
graft	O
x5	O
,	O
please	O
see	O
operative	O
report	O
for	O
further	O
details	O
.	O
He	O
was	O
transferred	O
to	O
the	O
CSRU	O
on	O
Neo	I-Drug
and	O
propofol	I-Drug
with	O
IABP	O
.	O
He	O
received	O
FFP	I-Drug
,	O
protamine	I-Drug
,	O
and	O
platlets	I-Drug
for	O
post	B-Reason
operative	I-Reason
bleeding	O
,	O
and	O
then	O
returned	O
to	O
operating	O
room	O
for	O
reexploration	O
,	O
please	O
see	O
operative	O
report	O
for	O
further	O
details	O
.	O
He	O
was	O
transferred	O
to	O
CSRU	O
for	O
continued	O
management	O
.	O
He	O
continued	O
with	O
tachycardia	I-Reason
not	O
responsive	O
to	O
esmolol	I-Drug
was	O
changed	O
to	O
cardizem	I-Drug
with	O
better	O
control	O
,	O
required	O
vasopressors	I-Drug
for	O
hypotension	I-Reason
.	O
On	O
postoperative	O
day	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
the	O
IABP	O
was	O
weaned	O
and	O
removed	O
,	O
he	O
continued	O
on	O
vasopressors	I-Drug
,	O
cardizem	I-Drug
was	O
discontinued	O
and	O
he	O
was	O
started	O
on	O
beta	B-Drug
blockers	I-Drug
.	O
He	O
remained	O
intubated	O
due	O
to	O
hemodynamics	O
and	O
agitation	O
.	O
Agitation	O
continued	O
with	O
weaning	O
of	O
sedation	I-Drug
,	O
diuresed	I-Drug
,	O
and	O
betablocker	I-Drug
increased	O
.	O
Postoperative	O
day	O
[	O
**	O
4	O
-	O
18	O
**	O
]	O
tolerated	O
CPAP	O
and	O
was	O
extubated	O
but	O
was	O
confused	O
moving	O
all	O
extremeties	O
.	O
Blood	B-Reason
pressure	I-Reason
and	I-Reason
heart	I-Reason
rate	I-Reason
labile	I-Reason
,	O
labetolol	I-Drug
started	O
.	O
Postoperative	O
[	O
**	O
6	O
-	O
20	O
**	O
]	O
he	O
went	O
into	O
atrial	B-Reason
fibrillation	I-Reason
and	O
treated	O
with	O
Amiodarone	I-Drug
and	O
beta	B-Drug
blockers	I-Drug
.	O
He	O
remained	O
in	O
the	O
CSRU	O
due	O
to	O
agitation	I-Reason
on	O
CIWA	O
d	O
/	O
t	O
ETOH	O
withdrawal	O
,	O
hemodynamic	O
,	O
and	O
respiratory	O
management	O
.	O
Psychiatry	O
consulted	O
due	O
to	O
continued	O
delirium	O
and	O
medications	O
adjusted	O
.	O
Anticoagulation	O
was	O
started	O
for	O
atrial	B-Reason
fibrillation	I-Reason
with	O
coumadin	I-Drug
on	O
POD	O
[	O
**	O
11	O
-	O
25	O
**	O
]	O
.	O
On	O
postoperative	O
14/13	O
he	O
was	O
ready	O
for	O
transfer	O
to	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
2	O
with	O
a	O
sitter	O
,	O
he	O
continued	O
with	O
confusion	O
at	O
times	O
,	O
in	O
/	O
out	O
atrial	O
fibrillation	O
.	O
He	O
continued	O
to	O
progress	O
and	O
physical	O
activity	O
increased	O
,	O
he	O
became	O
more	O
oriented	O
,	O
and	O
was	O
able	O
to	O
wean	O
off	O
ativan	I-Drug
and	O
sitter	O
.	O
On	O
posterative	O
day	O
20/19	O
he	O
complained	O
of	O
not	O
being	O
able	O
to	O
see	O
out	O
of	O
left	O
eye	O
-	O
opthamology	O
evaluated	O
with	O
question	O
of	O
posterior	O
ischemic	O
optic	O
neuropathy	O
which	O
is	O
diagnosis	O
by	O
exclusion	O
and	O
he	O
underwent	O
MRI	O
.	O
Plan	O
for	O
follow	O
up	O
with	O
opthamology	O
in	O
clinic	O
no	O
medical	O
intervention	O
at	O
this	O
time	O
.	O
On	O
postoperative	O
day	O
21/20	O
creatinine	O
elevated	O
with	O
decreased	O
sodium	O
.	O
Fluid	O
intake	O
was	O
increased	O
,	O
renal	O
consulted	O
,	O
echocardiogram	O
(	O
EF	O
35	O
-	O
40	O
%	O
)	O
.	O
All	O
diuretics	I-Drug
,	O
ACE	B-Drug
inhibitors	I-Drug
,	O
and	O
NSAID	I-Drug
discontinued	O
.	O
Creatinine	O
decreased	O
on	O
Postoperative	O
day	O
23/22	O
but	O
sodium	O
remained	O
decreased	O
and	O
placed	O
on	O
free	O
water	O
restriction	O
with	O
plan	O
for	O
chemistry	O
to	O
be	O
rechecked	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
at	O
rehab	O
.	O
He	O
was	O
ready	O
for	O
discharge	O
to	O
rehab	O
with	O
plan	O
for	O
lab	O
checks	O
.	O
Medications	O
on	O
Admission	O
:	O
lopressor	I-Drug
,	O
lipitor	I-Drug
,	O
ASA	I-Drug
,	O
pepcid	I-Drug
,	O
Solumedrol	I-Drug
,	O
Plavix	I-Drug
,	O
Discharge	O
Medications	O
:	O
1	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
.	O
5	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Hexavitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
8	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Thiamine	B-Drug
HCl	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Fluticasone	I-Drug
110	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Diltiazem	B-Drug
HCl	I-Drug
180	O
mg	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
Haloperidol	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
15	O
.	O
Ferrous	B-Drug
Gluconate	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
16	O
.	O
Outpatient	O
Lab	O
Work	O
please	O
check	O
SMA	O
7	O
and	O
HCT	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
17	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
please	O
give	O
0.5	O
mg	O
[	O
**	O
10	O
-	O
13	O
**	O
]	O
and	O
check	O
INR	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
459	O
**	O
]	O
for	O
the	O
Aged	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
550	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Coronary	O
artery	O
disease	O
.	O
HTN	O
Delirium	O
.	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Follow	O
medications	O
on	O
discharge	O
instructions	O
.	O
Do	O
not	O
drive	O
for	O
4	O
weeks	O
.	O
Do	O
not	O
lift	O
more	O
than	O
10	O
lbs	O
for	O
2	O
months	O
.	O
Shower	O
daily	O
,	O
let	O
water	O
flow	O
over	O
wounds	O
,	O
pat	O
dry	O
with	O
a	O
towel	O
.	O
Do	O
not	O
use	O
lotions	O
,	O
powders	O
,	O
or	O
creams	O
on	O
wounds	O
.	O
Call	O
our	O
office	O
for	O
sternal	O
drainage	O
,	O
temp	O
>	O
101.5	O
.	O
Please	O
have	O
SMA	O
7	O
,	O
HCT	O
,	O
INR	O
checked	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
Free	O
water	O
restriction	O
for	O
hyponatremia	O
Followup	O
Instructions	O
:	O
Make	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
131	O
**	O
]	O
for	O
1	O
-	O
2	O
weeks	O
.	O
Make	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
4469	O
**	O
]	O
for	O
2	O
-	O
3	O
weeks	O
.	O
Make	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
914	O
**	O
]	O
for	O
4	O
weeks	O
.	O
Make	O
an	O
appointment	O
to	O
see	O
your	O
local	O
opthamologist	O
after	O
discharge	O
.	O
Make	O
an	O
appointment	O
to	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
22897	O
**	O
]	O
with	O
Neuro	O
-	O
opthamology	O
after	O
discharge	O
.	O
Phone	O
#	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
253	O
**	O
]	O
.	O
Please	O
have	O
SMA	O
7	O
,	O
HCT	O
,	O
and	O
INR	O
drawn	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2137-10-12	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2153-1-20	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2153-2-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2084-11-24	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
Heparin	I-Drug
Agents	O
/	O
Motrin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1835	O
**	O
]	O
Chief	O
Complaint	O
:	O
shoulder	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
S	O
/	O
P	O
ACD	O
S	O
/	O
P	O
POSTERIOR	O
CERVICAL	O
RECONSTRUCTION	O
History	O
of	O
Present	O
Illness	O
:	O
68	O
M	O
PMH	O
thyroid	O
ca	O
with	O
mets	O
to	O
bone	O
and	O
liver	O
,	O
history	O
of	O
intrathecal	O
narcotics	I-Drug
requirement	O
,	O
who	O
p	O
/	O
w	O
increased	O
pain	O
.	O
The	O
pain	O
is	O
located	O
in	O
the	O
L	O
shoulder	O
scapular	O
to	O
humoral	O
region	O
,	O
with	O
no	O
obvious	O
radation	O
,	O
and	O
was	O
[	O
**	O
2156-9-14	O
**	O
]	O
in	O
severity	O
.	O
He	O
also	O
describes	O
other	O
chronic	O
pains	O
,	O
including	O
leg	O
and	O
some	O
chest	O
pain	O
with	O
heavy	O
coughing	O
,	O
but	O
these	O
have	O
been	O
stable	O
.	O
He	O
was	O
seen	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
19	O
**	O
]	O
on	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
,	O
where	O
he	O
was	O
also	O
noted	O
to	O
have	O
some	O
L	O
sided	O
weakness	O
,	O
and	O
was	O
sent	O
for	O
an	O
MRI	O
to	O
evaluate	O
for	O
metastatic	O
disease	O
,	O
which	O
as	O
noted	O
below	O
showed	O
no	O
new	O
changes	O
.	O
He	O
was	O
attempting	O
to	O
increase	O
his	O
decadron	I-Drug
as	O
indicated	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
19	O
**	O
]	O
,	O
when	O
he	O
could	O
n't	O
handle	O
the	O
pain	O
this	O
AM	O
,	O
and	O
came	O
to	O
the	O
ED	O
.	O
He	O
has	O
also	O
described	O
some	O
diffuse	O
paresthesias	O
of	O
both	O
fingertips	O
,	O
although	O
primarily	O
on	O
the	O
L	O
--	O
no	O
apparent	O
pattern	O
.	O
Otherwise	O
,	O
he	O
denies	O
focal	O
weakness	O
,	O
numbness	O
,	O
incontinence	O
of	O
stool	O
or	O
urine	O
,	O
urinary	O
retention	O
,	O
HA	O
,	O
as	O
well	O
as	O
any	O
F	O
/	O
C	O
/	O
NS	O
,	O
LH	O
,	O
appetite	O
changes	O
,	O
SOB	O
,	O
N	O
/	O
V	O
,	O
or	O
abdominal	O
pain	O
.	O
He	O
has	O
a	O
chronic	O
cough	O
[	O
**	O
3	O
-	O
9	O
**	O
]	O
radiation	O
,	O
and	O
also	O
noted	O
poor	O
fluid	O
intake	O
over	O
the	O
past	O
few	O
days	O
,	O
although	O
no	O
apparent	O
reason	O
.	O
He	O
requires	O
a	O
walker	O
to	O
ambulate	O
,	O
but	O
notes	O
no	O
change	O
over	O
the	O
past	O
few	O
days	O
.	O
.	O
In	O
the	O
ED	O
,	O
given	O
dilaudid	I-Drug
4	O
mg	O
IV	O
x	O
2	O
,	O
with	O
pain	I-Reason
that	O
was	O
not	O
completely	O
revolved	O
,	O
but	O
"	O
tolerable	O
.	O
"	O
Past	O
Medical	O
History	O
:	O
Thyroid	O
ca	O
s	O
/	O
p	O
thyroidectomy	O
[	O
**	O
2147	O
**	O
]	O
,	O
with	O
mets	O
to	O
bone	O
and	O
liver	O
-	O
s	O
/	O
p	O
implanted	O
epidural	O
narcotics	I-Drug
on	O
prior	O
admission	O
;	O
hx	O
of	O
infected	O
Port	O
-	O
A-Cath	O
system	O
S	O
/	O
p	O
carboplatin	I-Drug
[	O
**	O
1	O
-	O
9	O
**	O
]	O
S	O
/	O
p	O
cyperknife	O
to	O
T1	O
[	O
**	O
7	O
-	O
10	O
**	O
]	O
Clear	O
cell	O
ca	O
of	O
L	O
kidney	O
s	O
/	O
p	O
L	O
nephrectomy	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
S	O
/	O
p	O
appy	O
Social	O
History	O
:	O
History	O
of	O
smoking	O
cigarettes	O
,	O
1	O
pack	O
-	O
per	O
-	O
day	O
,	O
for	O
10	O
years	O
--	O
stopped	O
in	O
[	O
**	O
2126	O
**	O
]	O
.	O
Occasional	O
alcohol	O
,	O
1	O
-	O
2	O
drinks	O
per	O
week	O
.	O
He	O
does	O
not	O
use	O
any	O
illicit	O
drugs	O
.	O
Family	O
History	O
:	O
His	O
mother	O
died	O
of	O
tuberculosis	O
at	O
age	O
36	O
in	O
[	O
**	O
2085	O
**	O
]	O
.	O
His	O
father	O
died	O
at	O
age	O
73	O
from	O
coronary	O
artery	O
disease	O
.	O
His	O
brother	O
died	O
of	O
smoking	O
-	O
related	O
lung	O
cancer	O
.	O
His	O
sister	O
and	O
his	O
children	O
are	O
healthy	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
98.8	O
BP	O
150/91	O
HR	O
93	O
R	O
20	O
Sat	O
97	O
%	O
RA	O
*	O
PE	O
:	O
G	O
:	O
NAD	O
,	O
WN	O
,	O
WD	O
HEENT	O
:	O
Clear	O
OP	O
,	O
MMM	O
Neck	O
:	O
Supple	O
,	O
No	O
LAD	O
,	O
No	O
JVD	O
Lungs	O
:	O
BS	O
BL	O
,	O
No	O
W	O
/	O
R	O
/	O
C	O
Cardiac	O
:	O
RR	O
,	O
NL	O
rate	O
.	O
NL	O
S1S2	O
.	O
No	O
murmurs	O
Abd	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
.	O
NL	O
BS	O
.	O
No	O
HSM	O
.	O
Ext	O
:	O
No	O
edema	O
.	O
2	O
+	O
DP	O
pulses	O
BL	O
.	O
Neuro	O
:	O
A&O	O
x3	O
.	O
Appropriate	O
.	O
CN	O
2	O
-	O
12	O
grossly	O
intact	O
.	O
Preserved	O
sensation	O
throughout	O
.	O
Strength	O
UE	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
R	O
,	O
4/5	O
L	O
throughout	O
--	O
no	O
pattern	O
and	O
pt	O
denies	O
pain	O
limiting	O
,	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
BL	O
LE	O
.	O
2	O
+	O
reflexes	O
,	O
equal	O
BL	O
.	O
Ungoing	O
toes	O
BL	O
.	O
Past	O
-	O
pointing	O
on	O
L	O
UE	O
,	O
NL	O
on	O
R.	O
Pertinent	O
Results	O
:	O
MR	O
[	O
**	O
Name13	O
(	O
STitle	O
)	O
2853	O
**	O
]	O
[	O
**	O
2153-1-17	O
**	O
]	O
:	O
There	O
is	O
no	O
change	O
from	O
[	O
**	O
2152-2-12	O
**	O
]	O
.	O
There	O
is	O
metastatic	O
disease	O
at	O
C7	O
-	O
T1	O
and	O
T2	O
with	O
collapse	O
of	O
T1	O
and	O
resultant	O
kyphosis	O
.	O
There	O
is	O
stable	O
epidural	O
disease	O
.	O
There	O
have	O
been	O
posterior	O
laminectomies	O
and	O
there	O
is	O
no	O
spinal	O
cord	O
compression	O
,	O
although	O
there	O
is	O
probably	O
some	O
myelomalacia	O
and	O
atrophy	O
at	O
the	O
level	O
of	O
the	O
surgery	O
,	O
unchanged	O
.	O
*	O
L	O
Shoulder	O
/	O
humerus	O
Plain	O
film	O
:	O
Read	O
pending	O
;	O
no	O
obvious	O
fracture	O
,	O
?	O
metastatic	O
involvement	O
.	O
.	O
CXR	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
:	O
Patchy	O
opacities	O
most	O
prominent	O
in	O
the	O
right	O
lower	O
lobe	O
,	O
worrisome	O
for	O
pneumonia	O
.	O
.	O
CT	O
spine	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
:	O
Progression	O
of	O
the	O
lytic	O
osseous	O
and	O
epidural	O
metastases	O
,	O
with	O
progressed	O
malalignment	O
.	O
Fracture	O
through	O
the	O
T2	O
pedicle	O
screws	O
bilaterally	O
.	O
CTA	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
:	O
1	O
)	O
Right	O
lower	O
and	O
right	O
middle	O
lobe	O
air	O
space	O
consolidation	O
consistent	O
with	O
pneumonia	O
.	O
There	O
appears	O
to	O
be	O
narrowing	O
of	O
the	O
bronchus	O
intermedius	O
.	O
2	O
)	O
Left	O
lower	O
lobe	O
atelectasis	O
and	O
patchy	O
multifocal	O
bilateral	O
generalized	O
foci	O
of	O
air	O
space	O
disease	O
most	O
likely	O
reflecting	O
consolidations	O
though	O
metastases	O
are	O
not	O
excluded	O
.	O
3	O
)	O
Progression	O
of	O
osseous	O
vertebral	O
and	O
hepatic	O
metastasis	O
.	O
4	O
)	O
No	O
evidence	O
of	O
PE	O
.	O
5	O
)	O
Possible	O
cervical	O
instability	O
.	O
.	O
Bone	O
scan	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
:	O
1	O
)	O
No	O
abnormal	O
uptake	O
in	O
the	O
left	O
upper	O
extremity	O
.	O
2	O
)	O
Uptakecorresponding	O
to	O
known	O
metastases	O
in	O
the	O
sternum	O
,	O
cervical	O
spine	O
as	O
above	O
.	O
The	O
new	O
uptake	O
in	O
the	O
left	O
11th	O
and	O
12th	O
rib	O
ends	O
likely	O
post-traumatic	O
.	O
Brief	O
Hospital	O
Course	O
:	O
68M	O
thyroid	O
ca	O
to	O
bone	O
+	O
liver	O
p	O
/	O
w	O
increased	O
pain	O
L	O
shoulder	O
/	O
humerus	O
.	O
Pt	O
was	O
admitted	O
to	O
the	O
Medicine	O
service	O
and	O
treated	O
for	O
the	O
following	O
problems	O
:	O
.	O
#	O
pneumonia	I-Reason
:	O
Patient	O
had	O
altered	O
MS	O
and	O
low	O
grade	O
fevers	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
and	O
CXR	O
performed	O
which	O
suggested	O
pna	O
.	O
Started	O
on	O
levo	I-Drug
/	O
flagyl	I-Drug
with	O
concern	O
for	O
aspiration	O
.	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
,	O
patient	O
had	O
new	O
hypoxia	O
and	O
hemoptysis	O
.	O
Hematocrit	O
has	O
remained	O
stable	O
.	O
CTA	O
negative	O
for	O
PE	O
but	O
did	O
confirm	O
significant	O
pneumonia	O
.	O
No	O
fevers	O
since	O
starting	O
levo	I-Drug
/	O
flagyl	I-Drug
.	O
.	O
#	O
L	B-Reason
shoulder	I-Reason
/	I-Reason
humerus	I-Reason
pain	I-Reason
:	O
Evaluated	O
by	O
radiation	O
oncology	O
who	O
felt	O
that	O
risks	O
of	O
radiation	O
in	O
setting	O
of	O
multiple	O
prior	O
episodes	O
was	O
quite	O
high	O
especially	O
given	O
instability	O
.	O
Neurosurgery	O
consulted	O
for	O
cervical	O
spine	O
.	O
His	O
pain	O
was	O
initially	O
difficult	O
to	O
control	O
,	O
but	O
was	O
ultimately	O
dramatically	O
improved	O
when	O
he	O
was	O
changed	O
to	O
a	O
dilaudid	I-Drug
PCA	O
--	O
he	O
did	O
not	O
have	O
relief	O
from	O
fentanyl	I-Drug
patch	O
,	O
likely	O
b	O
/	O
c	O
of	O
soft	O
tissue	O
wasting	O
and	O
future	O
efforts	O
at	O
long	O
acting	O
medications	O
should	O
be	O
PO	O
.	O
.	O
#thyroid	O
ca	I-Reason
,	O
metastatic	B-Reason
disease	I-Reason
:	O
progressive	O
in	O
spine	O
and	O
likely	O
contributing	O
to	O
current	O
complaints	O
.	O
Levothyroxine	I-Drug
was	O
continued	O
.	O
consider	O
neupogen	I-Drug
.	O
Will	O
d	O
/	O
w	O
attending	O
Oncologist	O
.	O
#	O
thrush	I-Reason
:	O
The	O
patient	O
was	O
admitted	O
with	O
thrush	O
which	O
was	O
succesfully	O
treated	O
with	O
nystatin	I-Drug
S&S	O
.	O
Neurosurgery	O
team	O
asked	O
to	O
eval	O
this	O
pt	O
on	O
[	O
**	O
2153-1-23	O
**	O
]	O
and	O
was	O
transferred	O
to	O
our	O
service	O
for	O
spinal	O
deformity	O
which	O
was	O
noted	O
on	O
upper	O
level	O
of	O
images	O
(	O
CT	O
chest	O
)	O
to	O
r	O
/	O
o	O
PE	O
.	O
CT	O
of	O
cervical	O
thoracic	O
spine	O
was	O
obtained	O
and	O
results	O
of	O
T1	O
collapse	O
noted	O
.	O
Pts	O
family	O
,	O
at	O
that	O
time	O
wanted	O
to	O
continue	O
care	O
with	O
prior	O
Neurosurgeon	O
/	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1327	O
**	O
]	O
.	O
This	O
was	O
communicated	O
to	O
this	O
neurosurgery	O
team	O
.	O
Some	O
short	O
time	O
later	O
the	O
family	O
wished	O
against	O
transfer	O
out	O
to	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1334	O
**	O
]	O
care	O
and	O
decided	O
that	O
they	O
would	O
want	O
surgery	O
to	O
correct	O
spinal	O
deformity	O
/	O
kyphosis	O
here	O
.	O
The	O
pt	O
was	O
placed	O
in	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
20482	O
**	O
]	O
Halo	O
traction	O
at	O
30	O
lbs	O
of	O
traction	O
.	O
This	O
was	O
in	O
attempt	O
to	O
reduce	O
kyphotic	O
deformity	O
for	O
pre-operative	O
optimization	O
.	O
A	O
CT	O
scan	O
of	O
the	O
spine	O
was	O
obtained	O
in	O
traction	O
and	O
good	O
reduction	O
of	O
the	O
deformity	O
was	O
noted	O
.	O
The	O
pt	O
was	O
then	O
medically	O
optimized	O
and	O
pre-op	O
'd	O
and	O
taken	O
to	O
the	O
OR	O
on	O
[	O
**	O
2153-2-8	O
**	O
]	O
for	O
C7	O
T1	O
T2	O
corpectomies	O
/	O
anterior	O
approach	O
.	O
There	O
was	O
a	O
lot	O
of	O
bleeding	O
during	O
the	O
initial	O
anterior	O
approach	O
/	O
the	O
case	O
lasting	O
approximately	O
7	O
hours	O
.	O
It	O
was	O
decided	O
that	O
the	O
pt	O
would	O
remain	O
intubated	O
and	O
return	O
to	O
the	O
OR	O
on	O
the	O
5th	O
(	O
the	O
next	O
day	O
for	O
continuation	O
of	O
the	O
case	O
.	O
The	O
second	O
portion	O
of	O
the	O
case	O
was	O
completed	O
that	O
day	O
(	O
the	O
5th	O
)	O
.	O
Thoracic	O
surgery	O
assisted	O
because	O
of	O
mediastinal	O
mass	O
/	O
we	O
needed	O
sternotomy	O
to	O
control	O
bleeding	O
and	O
complete	O
ant	O
.	O
approach	O
.	O
The	O
total	O
EBL	O
was	O
7.5	O
liters	O
with	O
the	O
pt	O
being	O
given	O
22	O
units	O
of	O
PRBC	B-Drug
's	I-Drug
.	O
He	O
had	O
a	O
chest	O
tube	O
placed	O
on	O
the	O
left	O
side	O
intraoperatively	O
.	O
This	O
was	O
removed	O
on	O
approx	O
1	O
/	O
7/7	O
.	O
Postoperatively	O
he	O
was	O
started	O
on	O
Fondiparinox	I-Drug
on	O
[	O
**	O
2	O
-	O
13	O
**	O
]	O
as	O
he	O
is	O
HIT	B-Reason
positive	I-Reason
.	O
On	O
[	O
**	O
2153-2-14	O
**	O
]	O
he	O
had	O
a	O
peg	O
tube	O
place	O
.	O
His	O
postoperative	O
head	O
CT	O
and	O
spine	O
CT	O
's	O
were	O
stable	O
.	O
His	O
neurological	O
status	O
postoperatively	O
was	O
stable	O
.	O
All	O
extremeties	O
are	O
antigravity	O
and	O
his	O
mentation	O
is	O
intact	O
.	O
His	O
course	O
complicated	O
by	O
intermittent	O
low	O
HCT	O
's	O
for	O
which	O
he	O
was	O
transfused	O
.	O
Temps	B-Reason
as	I-Reason
high	I-Reason
as	I-Reason
102	I-Reason
.	O
+	O
for	O
which	O
he	O
was	O
started	O
on	O
Zosyn	I-Drug
.	O
On	O
[	O
**	O
2153-2-16	O
**	O
]	O
his	O
left	O
upper	O
extremity	O
was	O
noted	O
to	O
be	O
swollen	O
and	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
noted	O
LUE	O
DVT	O
.	O
On	O
the	O
14th	O
,	O
the	O
halo	O
ring	O
that	O
was	O
initially	O
placed	O
for	O
use	O
of	O
cervical	O
traction	O
and	O
for	O
potential	O
halo	O
vest	O
placement	O
was	O
removed	O
.	O
He	O
remains	O
in	O
a	O
cervical	O
collar	O
and	O
had	O
been	O
OOB	O
to	O
chair	O
.	O
The	O
patient	O
required	O
prolonged	O
ventilation	O
he	O
had	O
difficulty	O
clearing	O
his	O
secretions	O
.	O
His	O
family	O
was	O
offered	O
a	O
trach	O
but	O
they	O
felt	O
the	O
patient	O
had	O
a	O
difficult	O
post	O
operative	O
course	O
and	O
was	O
suffering	O
they	O
did	O
not	O
want	O
to	O
the	O
patient	O
to	O
under	O
go	O
further	O
procedures	O
.	O
The	O
patient	O
had	O
made	O
his	O
wishes	O
clear	O
to	O
his	O
family	O
not	O
to	O
be	O
dependent	O
or	O
on	O
a	O
ventilator	O
for	O
a	O
prolonged	O
period	O
.	O
After	O
a	O
long	O
discussion	O
with	O
the	O
family	O
and	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
they	O
decided	O
to	O
extubate	O
the	O
patient	O
and	O
see	O
if	O
he	O
could	O
tolerate	O
being	O
extubated	O
,	O
he	O
quickly	O
passed	O
away	O
in	O
a	O
few	O
minutes	O
with	O
his	O
family	O
at	O
his	O
side	O
.	O
Medications	O
on	O
Admission	O
:	O
gabapentin	I-Drug
300	O
/	O
300/900	O
,	O
hydromorphone	I-Drug
4	O
-	O
8	O
mg	O
Q8H	O
PRN	O
,	O
tizanidine	I-Drug
2	O
mg	O
t.i.d.	O
,	O
fentanyl	I-Drug
patch	O
75	O
mcg	O
per	O
hour	O
every	O
three	O
days	O
,	O
lidoderm	I-Drug
patch	O
50	O
,	O
3	O
patches	O
a	O
day	O
lorazepam	I-Drug
0.5	O
mg	O
Q4	O
-	O
6H	O
PRN	O
levothyroxine	I-Drug
0.125	O
qd	O
protonix	I-Drug
40	O
qd	O
folic	B-Drug
acid	I-Drug
decadron	I-Drug
2	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
incr	O
to	O
4	O
mg	O
in	O
AM	O
today	O
)	O
Discharge	O
Medications	O
:	O
N	O
/	O
A	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Discharge	O
Diagnosis	O
:	O
cervical	O
spine	O
harware	O
failure	O
s	O
/	O
p	O
cervical	O
spine	O
stabilization	O
metestatic	O
disease	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
N	O
/	O
A	O
Followup	O
Instructions	O
:	O
N	O
/	O
A	O
Completed	O
by	O
:[	O
**	O
2153-2-19	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2190-9-26	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2190-9-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2121-12-29	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1115	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fatigue	O
,	O
weakness	O
,	O
and	O
dizziness	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Esophagogastroduodenoscopy	O
Blood	O
transfusion	O
History	O
of	O
Present	O
Illness	O
:	O
68	O
year	O
old	O
male	O
with	O
BPH	O
,	O
CAD	O
(	O
IMI	O
[	O
**	O
2185	O
**	O
]	O
w	O
/	O
BMS	O
to	O
RCA	O
)	O
who	O
presented	O
with	O
fatigue	O
,	O
lightheadedness	O
and	O
shortness	O
of	O
breath	O
.	O
He	O
first	O
began	O
feeling	O
fatigued	O
two	O
days	O
ago	O
.	O
The	O
day	O
before	O
admission	O
,	O
he	O
was	O
weak	O
in	O
the	O
morning	O
,	O
feeling	O
short	O
of	O
breath	O
and	O
lightheaded	O
while	O
walking	O
up	O
stairs	O
.	O
That	O
day	O
he	O
also	O
noted	O
thick	O
tarry	O
stool	O
.	O
At	O
5AM	O
this	O
morning	O
sat	O
down	O
on	O
the	O
tiolet	O
to	O
urinate	O
around	O
felt	O
lightheaded	O
,	O
flushed	O
,	O
and	O
chills	O
.	O
Called	O
911	O
.	O
Felt	O
similar	O
to	O
when	O
had	O
stents	O
placed	O
in	O
[	O
**	O
2185	O
**	O
]	O
except	O
then	O
had	O
chest	O
pain	O
.	O
This	O
time	O
he	O
reports	O
no	O
chest	O
pain	O
,	O
pressure	O
,	O
or	O
tightness	O
.	O
He	O
denied	O
any	O
shortness	O
of	O
breath	O
at	O
rest	O
.	O
He	O
denies	O
abdominal	O
pain	O
or	O
diarrhea	O
.	O
Denies	O
focal	O
weakness	O
or	O
tingling	O
.	O
The	O
patient	O
has	O
been	O
taking	O
ibuprofen	I-Drug
and	O
naproxen	I-Drug
in	O
addition	O
to	O
his	O
prescribed	O
ASA	I-Drug
325	O
mg	O
,	O
increased	O
recently	O
after	O
completing	O
a	O
bike	O
trip	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
216	O
**	O
]	O
.	O
Found	O
by	O
EMS	O
pale	O
,	O
cool	O
,	O
diaphoretic	O
.	O
Orthostatics	O
with	O
SBP	O
seated	O
102	O
-	O
>	O
92	O
when	O
standing	O
with	O
increased	O
symptoms	O
.	O
More	O
pale	O
and	O
diaphoretic	O
.	O
EKG	O
in	O
field	O
reported	O
as	O
unremarkable	O
.	O
150cc	O
NS	I-Drug
given	O
en	O
route	O
.	O
In	O
the	O
ED	O
,	O
initial	O
VS	O
were	O
:	O
96.8	O
6395/70	O
18	O
98	O
%	O
2L	O
Crit	O
46.6	O
-	O
>	O
36.3	O
,	O
BUN	O
/	O
Cr	O
62/0	O
.9	O
Rectal	O
exam	O
showed	O
dark	O
black	O
stool	O
,	O
Guaiac	O
pos	O
.	O
Troponin	O
<	O
0.01	O
,	O
EKG	O
sinus	O
rhythm	O
,	O
rate	O
65	O
,	O
nl	O
axis	O
,	O
non-specific	O
st	O
-	O
t	O
changes	O
,	O
consistent	O
w	O
/	O
prior	O
from	O
[	O
**	O
7	O
-	O
/	O
2189	O
**	O
]	O
unchanged	O
.	O
BPs	O
80s	O
-	O
100s	O
,	O
baseline	O
BPs	O
are	O
110	O
-	O
120s	O
.	O
NG	O
lavage	O
was	O
negative	O
no	O
withdrawal	O
of	O
clots	O
or	O
red	O
return	O
with	O
350cc	O
fluids	O
.	O
He	O
was	O
given	O
1L	O
IVF	I-Drug
,	O
two	O
peripheral	O
IV	O
's	O
were	O
placed	O
,	O
type	O
and	O
cross	O
sent	O
,	O
and	O
was	O
started	O
on	O
protonix	I-Drug
gtt	O
.	O
On	O
arrival	O
to	O
the	O
MICU	O
,	O
the	O
patient	O
still	O
feels	O
lightheaded	O
when	O
stands	O
to	O
use	O
bathroom	O
but	O
otherwise	O
feels	O
like	O
his	O
regular	O
self	O
.	O
Denies	O
SOB	O
,	O
chest	O
pain	O
/	O
pressure	O
/	O
tightness	O
.	O
Review	O
of	O
systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheezing	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
,	O
or	O
weakness	O
.	O
Denies	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
abdominal	O
pain	O
,	O
or	O
changes	O
in	O
bowel	O
habits	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
:	O
MI	O
[	O
**	O
2185	O
**	O
]	O
,	O
cath	O
with	O
2	O
vessel	O
disease	O
and	O
stent	O
placement	O
Stress	O
MIBI	O
in	O
[	O
**	O
2	O
-	O
/	O
2187	O
**	O
]	O
showed	O
EF	O
of	O
53	O
%	O
with	O
small	O
inferobasal	O
infarct	O
.	O
Hyperlipidemia	O
Sacral	O
Osteomyelitis	O
BPH	O
s	O
/	O
p	O
TURP	O
Inguinal	O
hernia	O
repair	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
Colonoscopy	O
[	O
**	O
2189	O
**	O
]	O
:	O
Polyp	O
in	O
the	O
proximal	O
ascending	O
colon	O
(	O
polypectomy	O
)	O
Polyp	O
in	O
the	O
transverse	O
colon	O
(	O
polypectomy	O
)	O
Tattoo	O
in	O
the	O
transverse	O
colon	O
from	O
previous	O
polypectomy	O
Otherwise	O
normal	O
colonoscopy	O
to	O
cecum	O
Social	O
History	O
:	O
married	O
,	O
lives	O
with	O
wife	O
+	O
ETOH	O
,	O
denies	O
Tobacco	O
,	O
recreational	O
drug	O
use	O
Family	O
History	O
:	O
Father	O
deceased	O
from	O
"	O
old	O
age	O
"	O
in	O
his	O
90's	O
,	O
mother	O
deceased	O
60	O
years	O
ago	O
from	O
rheumatic	O
fever	O
.	O
One	O
brother	O
,	O
healthy	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
known	O
family	O
history	O
of	O
sudden	O
death	O
or	O
premature	O
cardiac	O
disease	O
.	O
Physical	O
Exam	O
:	O
Admission	O
physical	O
exam	O
Vitals	O
:	O
T	O
:	O
98.2	O
65114/70	O
13	O
97	O
%	O
RA	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
Neck	O
:	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
DISCHARGE	O
PHYSICAL	O
EXAM	O
:	O
VS	O
:	O
98.5	O
77121/76	O
15	O
98	O
%	O
RA	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
EOMI	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
grossly	O
intact	O
Pertinent	O
Results	O
:	O
[	O
**	O
2190-9-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
WBC	O
-	O
6.9	O
RBC	O
-	O
3.68	O
*	O
#	O
Hgb	O
-	O
11.9	O
*	O
#	O
Hct	O
-	O
36.3	O
*	O
#	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
32.4	O
*	O
MCHC	O
-	O
32.8	O
RDW	O
-	O
12.4	O
Plt	O
Ct	O
-	O
207	O
[	O
**	O
2190-9-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
Neuts	O
-	O
69.7	O
Lymphs	O
-	O
21.4	O
Monos	O
-	O
6.9	O
Eos	O
-	O
1.5	O
Baso	O
-	O
0.6	O
[	O
**	O
2190-9-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
207	O
[	O
**	O
2190-9-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
Glucose	O
-	O
99	O
UreaN	O
-	O
62	O
*	O
Creat	O
-	O
0.9	O
Na	O
-	O
143	O
K	O
-	O
4.4	O
Cl	O
-	O
110	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2190-9-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
ALT	O
-	O
18	O
AST	O
-	O
18	O
LD	O
(	O
LDH	O
)	O
-	O
117	O
AlkPhos	O
-	O
46	O
TotBili	O
-	O
0.3	O
[	O
**	O
2190-9-26	O
**	O
]	O
05:43	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2190-9-26	O
**	O
]	O
10:44	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2190-9-27	O
**	O
]	O
03:05	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2190-9-27	O
**	O
]	O
03:05	O
AM	O
BLOOD	O
Calcium	O
-	O
8.3	O
*	O
Phos	O
-	O
2.4	O
*	O
Mg	O
-	O
2.1	O
[	O
**	O
2190-9-26	O
**	O
]	O
08:30	O
AM	O
BLOOD	O
Lactate	O
-	O
2.0	O
Studies	O
CXR	O
[	O
**	O
2190-9-26	O
**	O
]	O
FINDINGS	O
:	O
The	O
lungs	O
are	O
clear	O
.	O
Cardiomediastinal	O
silhouette	O
and	O
hilar	O
contours	O
are	O
unremarkable	O
.	O
No	O
effusion	O
or	O
pneumothorax	O
.	O
Aorta	O
is	O
tortuous	O
.	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
acute	O
cardiopulmonary	O
process	O
.	O
EGD	O
Impression	O
:	O
Mucosa	O
suggestive	O
of	O
short	O
segment	O
Barrett	O
's	O
esophagus	O
.	O
Normal	O
mucosa	O
in	O
the	O
duodenum	O
.	O
Ulcers	O
in	O
the	O
antrum	O
.	O
Otherwise	O
normal	O
EGD	O
to	O
third	O
part	O
of	O
the	O
duodenum	O
.	O
Micro	O
:	O
None	O
DISCHARGE	O
LABS	O
[	O
**	O
2190-9-28	O
**	O
]	O
08:20	O
AM	O
BLOOD	O
WBC	O
-	O
5.2	O
RBC	O
-	O
3.72	O
*	O
Hgb	O
-	O
12.0	O
*	O
Hct	O
-	O
35.6	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
180	O
[	O
**	O
2190-9-27	O
**	O
]	O
03:05	O
AM	O
BLOOD	O
WBC	O
-	O
6.8	O
RBC	O
-	O
3.70	O
*	O
Hgb	O
-	O
11.9	O
*	O
Hct	O
-	O
35.3	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
32.1	O
*	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
13.9	O
Plt	O
Ct	O
-	O
172	O
Brief	O
Hospital	O
Course	O
:	O
68yoM	O
with	O
history	O
of	O
CAD	O
s	O
/	O
p	O
IMI	O
in	O
[	O
**	O
2185	O
**	O
]	O
with	O
BMS	O
to	O
RCA	O
and	O
BPH	O
presenting	O
with	O
dizziness	O
/	O
LH	O
and	O
low	O
Hct	O
,	O
found	O
to	O
have	O
GI	O
Bleed	O
with	O
antral	O
ulcers	O
.	O
#	O
GI	O
Bleed	O
:	O
The	O
patient	O
presented	O
with	O
melena	O
,	O
with	O
low	O
Hct	O
and	O
orthostasis	O
.	O
The	O
patient	O
had	O
a	O
history	O
of	O
active	O
NSAID	I-Drug
use	O
,	O
and	O
also	O
uses	O
Etoh	O
socially	O
.	O
He	O
was	O
admitted	O
to	O
the	O
MICU	O
.	O
He	O
got	O
2	O
units	O
PRBCs	I-Drug
without	O
Hct	O
response	O
to	O
the	O
first	O
unit	O
,	O
but	O
with	O
good	O
Hct	O
response	O
to	O
the	O
second	O
unit	O
.	O
EGD	O
showed	O
non-bleeding	O
antral	O
ulcers	O
and	O
possible	O
Barretts	O
esophanus	O
.	O
The	O
patient	O
was	O
stable	O
with	O
no	O
further	O
Hct	O
drop	O
,	O
so	O
he	O
was	O
transfered	O
to	O
the	O
floor	O
.	O
He	O
was	O
counseled	O
to	O
avoid	O
all	O
NSAIDs	I-Drug
indefinently	O
,	O
unless	O
told	O
otherwise	O
by	O
GI	O
in	O
the	O
future	O
.	O
GI	O
saw	O
the	O
patient	O
in	O
house	O
and	O
will	O
follow	O
outpatient	O
,	O
with	O
repeat	O
EGD	O
in	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
weeks	O
to	O
eval	O
for	O
healing	O
of	O
antral	O
ulcers	O
and	O
possible	O
esophagus	O
biopsy	O
.	O
H	O
pylori	O
blood	O
test	O
was	O
sent	O
and	O
was	O
pending	O
at	O
time	O
of	O
discharge	O
.	O
#	O
CAD	O
:	O
s	O
/	O
p	O
BMS	O
placement	O
in	O
[	O
**	O
2185	O
**	O
]	O
.	O
No	O
active	O
signs	O
of	O
ischemia	O
now	O
,	O
Troponins	O
negative	O
,	O
EKG	O
unchanged	O
,	O
no	O
chest	O
pain	O
.	O
Dizziness	O
and	O
diaphoresis	O
likely	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
anemia	O
from	O
acute	O
blood	O
loss	O
from	O
GI	O
bleed	O
,	O
and	O
does	O
not	O
represent	O
anginal	O
equivalent	O
at	O
this	O
time	O
.	O
ASA	I-Drug
325	O
was	O
initially	O
held	O
on	O
admission	O
for	O
acute	O
GI	O
bleed	O
.	O
On	O
discussion	O
with	O
outpatient	O
cardiologist	O
,	O
it	O
was	O
decided	O
to	O
decrease	O
ASA	I-Drug
to	O
81	O
daily	O
.	O
ASA	I-Drug
was	O
restarted	O
the	O
morning	O
of	O
discharge	O
since	O
it	O
was	O
felt	O
that	O
the	O
patient	O
was	O
not	O
actively	O
bleeding	O
.	O
#	O
HTN	I-Reason
-	O
cont	O
metoprolol	I-Drug
,	O
DCed	O
lisinopril	I-Drug
per	O
outpatient	O
cardiologist	O
since	O
BP	O
well	O
controlled	O
without	O
it	O
and	O
has	O
normal	O
LV	O
function	O
.	O
#	O
HLD	I-Reason
-	O
cont	O
atorvastatin	I-Drug
#	O
BPH	O
:	O
no	O
active	O
issues	O
#	O
PPX	O
:	O
pneumatic	O
boots	O
,	O
bowel	O
regimen	O
#	O
CODE	O
STATUS	O
:	O
Full	O
,	O
confirmed	O
#	O
CONTACT	O
:	O
Wife	O
[	O
**	O
Name	O
(	O
NI	O
)	O
107117	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
107118	O
**	O
]	O
home	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
107119	O
**	O
]	O
cell	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
107120	O
**	O
]	O
Transitional	O
issues	O
-	O
F	O
/	O
U	O
H	O
pylori	O
,	O
which	O
was	O
pending	O
at	O
time	O
of	O
DC	O
.	O
Medications	O
on	O
Admission	O
:	O
Preadmission	O
medications	O
listed	O
are	O
correct	O
and	O
complete	O
.	O
Information	O
was	O
obtained	O
from	O
PatientwebOMR	O
.	O
1	O
.	O
Lisinopril	I-Drug
5	O
mg	O
PO	O
DAILY	O
2	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
XL	I-Drug
25	O
mg	O
PO	O
DAILY	O
3	O
.	O
Atorvastatin	I-Drug
40	O
mg	O
PO	O
DAILY	O
4	O
.	O
Aspirin	I-Drug
325	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications	O
:	O
1	O
.	O
Atorvastatin	I-Drug
40	O
mg	O
PO	O
DAILY	O
2	O
.	O
Aspirin	I-Drug
81	O
mg	O
PO	O
DAILY	O
RX	O
*	O
aspirin	I-Drug
81	O
mg	O
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Disp	O
#	O
*	O
30	O
Tablet	O
Refills	O
:	O
*	O
0	O
3	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
XL	I-Drug
25	O
mg	O
PO	O
DAILY	O
4	O
.	O
Omeprazole	I-Drug
40	O
mg	O
PO	O
BID	O
RX	O
*	O
omeprazole	I-Drug
40	O
mg	O
1	O
capsule	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#	O
*	O
60	O
Capsule	O
Refills	O
:	O
*	O
0	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Peptic	O
Ulcer	O
Disease	O
Upper	O
GI	O
bleed	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
you	O
were	O
feeling	O
lightheaded	O
and	O
had	O
were	O
not	O
feeling	O
well	O
.	O
Your	O
symptoms	O
were	O
explained	O
by	O
a	O
bleed	O
in	O
your	O
stomach	O
.	O
The	O
gastroenterologists	O
performed	O
an	O
endoscopy	O
which	O
showed	O
an	O
ulcer	I-Ade
in	O
your	O
stomach	O
.	O
This	O
is	O
likely	O
related	O
to	O
the	O
ibuprofen	I-Drug
and	O
naproxen	I-Drug
use	O
.	O
It	O
is	O
very	O
important	O
that	O
you	O
avoid	O
such	O
medications	O
in	O
the	O
future	O
.	O
You	O
will	O
need	O
a	O
follow	O
up	O
endoscopy	O
in	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
weeks	O
.	O
Also	O
,	O
at	O
discharge	O
there	O
is	O
a	O
lab	O
test	O
(	O
which	O
tests	O
if	O
there	O
is	O
bacteria	O
in	O
your	O
stomach	O
causing	O
the	O
ulcers	O
)	O
that	O
is	O
still	O
pending	O
.	O
We	O
will	O
arrive	O
for	O
someone	O
to	O
contact	O
you	O
with	O
the	O
results	O
.	O
Followup	O
Instructions	O
:	O
Please	O
be	O
sure	O
to	O
keep	O
the	O
following	O
appointments	O
:	O
Name	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
2539	O
**	O
]	O
,	O
[	O
**	O
First	O
Name7	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
Location	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
HOSPITAL	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Address	O
:	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
3002	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
49151	O
**	O
]	O
*	O
Appointment	O
Thursday	O
[	O
**	O
2190-10-7	O
**	O
]	O
2:30	O
pm	O
*	O
Gastroenterology	O
:	O
will	O
call	O
you	O
with	O
an	O
appointment	O
.	O
If	O
you	O
do	O
n't	O
hear	O
from	O
their	O
office	O
by	O
Friday	O
,	O
please	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
463	O
**	O
]	O
.	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
MONDAY	O
[	O
**	O
2191-8-15	O
**	O
]	O
at	O
12:40	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1523	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O

Admission	O
Date	O
:	O
[	O
**	O
2125-9-12	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2125-9-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2044-5-25	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
10842	O
**	O
]	O
Chief	O
Complaint	O
:	O
altered	O
mental	O
status	O
,	O
hypoxia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Transesophageal	O
echocardiogram	O
[	O
**	O
2125-9-18	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
an	O
81	O
yo	O
M	O
with	O
rheumatic	O
heart	O
disease	O
(	O
c	O
/	O
b	O
aortic	O
stenosis	O
s	O
/	O
p	O
recent	O
[	O
**	O
Known	O
lastname	O
1291	O
**	O
]	O
/	O
MVR	O
on	O
[	O
**	O
2125-7-3	O
**	O
]	O
)	O
and	O
atrial	O
fibrillation	O
who	O
presents	O
from	O
his	O
rehabilitation	O
center	O
with	O
altered	O
mental	O
status	O
.	O
.	O
The	O
patient	O
was	O
recently	O
admitted	O
to	O
the	O
cardiothoracic	O
service	O
from	O
[	O
**	O
2125-7-2	O
**	O
]	O
-	O
[	O
**	O
2125-7-26	O
**	O
]	O
for	O
worsening	O
shortness	O
of	O
breath	O
thought	O
to	O
be	O
due	O
to	O
worsening	O
AS	O
,	O
MR	O
,	O
and	O
worsening	O
heart	O
failure	O
(	O
EF	O
40	O
%	O
)	O
.	O
He	O
was	O
taken	O
to	O
the	O
OR	O
on	O
[	O
**	O
7	O
-	O
3	O
**	O
]	O
for	O
aortic	O
valve	O
replacement	O
with	O
a	O
St.	O
Jude	O
's	O
valve	O
,	O
aortic	O
endarterectomy	O
,	O
and	O
MVR	O
with	O
a	O
[	O
**	O
Company	O
1543	O
**	O
]	O
mosaic	O
tissue	O
valve	O
.	O
His	O
hospital	O
course	O
was	O
complicated	O
by	O
hypotension	I-Reason
requiring	O
pressor	I-Drug
support	O
and	O
eventual	O
failure	O
to	O
extubate	O
due	O
to	O
altered	O
mental	O
status	O
/	O
encephalopathy	O
and	O
inability	O
to	O
handle	O
secretions	O
.	O
He	O
received	O
trach	O
and	O
PEG	O
on	O
[	O
**	O
2125-7-17	O
**	O
]	O
.	O
He	O
also	O
received	O
7	O
days	O
of	O
Vancomycin	I-Drug
and	O
Cefepime	I-Drug
for	O
the	O
secretions	B-Reason
(	I-Reason
presumably	I-Reason
for	I-Reason
emperic	O
treatment	O
of	O
VAP	O
)	O
.	O
Of	O
note	O
,	O
he	O
did	O
have	O
some	O
delerium	I-Reason
noted	O
at	O
night	O
--	O
seroquel	I-Drug
was	O
attempted	O
but	O
discontinued	O
due	O
to	O
somnolence	I-Ade
.	O
He	O
was	O
tolerated	O
trach	O
collar	O
,	O
PM	O
valve	O
,	O
and	O
tube	O
feeds	O
prior	O
to	O
discharge	O
to	O
[	O
**	O
Hospital6	O
1293	O
**	O
]	O
.	O
.	O
His	O
daughter	O
reports	O
that	O
at	O
baseline	O
,	O
he	O
has	O
baseline	O
dementia	O
but	O
has	O
some	O
baseline	O
cognitive	O
function	O
,	O
including	O
being	O
alert	O
,	O
interactive	O
,	O
and	O
talkative	O
.	O
Of	O
note	O
,	O
trach	O
was	O
also	O
removed	O
at	O
rehab	O
.	O
However	O
,	O
his	O
mental	O
status	O
at	O
rehab	O
has	O
been	O
waxing	O
and	O
[	O
**	O
Doctor	O
Last	O
Name	O
688	O
**	O
]	O
during	O
his	O
rehab	O
stay	O
(	O
documented	O
in	O
multiple	O
cardiothoracic	O
NP	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
29639	O
**	O
]	O
as	O
having	O
confusion	O
at	O
rehab	O
occasionally	O
requiring	O
restraints	O
and	O
wandering	O
)	O
,	O
but	O
noted	O
by	O
his	O
dtr	O
to	O
be	O
worsening	O
over	O
the	O
past	O
week	O
since	O
he	O
was	O
transferred	O
to	O
a	O
new	O
[	O
**	O
Hospital1	O
1501	O
**	O
]	O
.	O
He	O
has	O
had	O
episodes	O
of	O
jerking	O
movements	O
of	O
his	O
fingers	O
or	O
a	O
'	O
kick	O
'	O
of	O
the	O
legs	O
.	O
Independently	O
,	O
he	O
also	O
has	O
episodes	O
of	O
lethargy	O
,	O
where	O
he	O
falls	O
"	O
asleep	O
"	O
mid-sentence	O
,	O
is	O
unresponsive	O
to	O
tactile	O
or	O
verbal	O
stimuli	O
,	O
then	O
returns	O
to	O
his	O
baseline	O
but	O
appears	O
drowsy	O
/	O
confused	O
.	O
These	O
unresponsive	O
episodes	O
were	O
occurring	O
[	O
**	O
2	O
-	O
28	O
**	O
]	O
times	O
a	O
day	O
,	O
but	O
were	O
also	O
increasing	O
in	O
frequency	O
during	O
the	O
week	O
prior	O
to	O
admission	O
.	O
Haldol	I-Drug
and	O
Trazodone	I-Drug
have	O
been	O
attempted	O
at	O
rehab	O
without	O
good	O
effect	O
and	O
were	O
discontinued	O
due	O
the	O
drowsiness	I-Ade
as	O
well	O
as	O
(	O
per	O
ED	O
report	O
)	O
some	O
symptoms	O
of	O
lip	I-Ade
smacking	O
that	O
were	O
thought	O
to	O
be	O
[	O
**	O
2	O
-	O
27	O
**	O
]	O
tardive	B-Ade
dyskinesia	I-Ade
.	O
He	O
was	O
originally	O
discharged	O
on	O
tube	O
feeds	O
,	O
but	O
per	O
report	O
has	O
been	O
tolerating	O
a	O
PO	O
diet	O
.	O
He	O
was	O
brought	O
into	O
the	O
ED	O
today	O
for	O
further	O
evaluation	O
of	O
these	O
symptoms	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
98.5	O
90130/102	O
18	O
99	O
%	O
on	O
room	O
air	O
Patient	O
was	O
given	O
ativan	I-Drug
2	O
mg	O
IV	O
x1	O
,	O
Vancomyin	I-Drug
1	O
gram	O
IV	O
x1	O
,	O
CFTX	I-Drug
2	O
grams	O
IV	O
x1	O
,	O
and	O
Dexamethasone	I-Drug
10	O
mg	O
IV	O
x1	O
.	O
Labs	O
significant	O
for	O
a	O
WBC	O
of	O
14.0	O
,	O
ALT	O
of	O
41	O
,	O
AST	O
of	O
47	O
,	O
INR	O
of	O
3.8	O
,	O
and	O
chemistries	O
WNL	O
.	O
No	O
formal	O
ABG	O
performed	O
,	O
but	O
pH	O
noted	O
to	O
be	O
7.40	O
at	O
4:46	O
PM	O
.	O
He	O
was	O
noted	O
multiple	O
times	O
by	O
the	O
ED	O
attendings	O
and	O
residents	O
to	O
have	O
multiple	O
(	O
>	O
3	O
)	O
lethargic	O
episodes	O
and	O
multiple	O
episodes	O
of	O
myoclonic	O
jerks	O
.	O
The	O
patient	O
would	O
be	O
responsive	O
afterwards	O
,	O
but	O
somewhat	O
confused	O
per	O
report	O
,	O
stating	O
he	O
was	O
'	O
in	O
Brookline	O
'	O
.	O
He	O
got	O
2	O
mg	O
of	O
Ativan	I-Drug
for	O
presumed	O
seizure	B-Reason
activity	I-Reason
and	O
became	O
unresponsive	I-Ade
with	O
slight	O
desaturation	I-Ade
requiring	O
BiPAP	O
.	O
Neurology	O
was	O
consulted	O
in	O
the	O
ED	O
and	O
thought	O
the	O
patient	O
was	O
having	O
myoclonic	I-Reason
jerks	O
/	O
encephalopathy	I-Reason
,	O
but	O
exam	O
was	O
clouded	O
by	O
recently	O
receiving	O
Ativan	I-Drug
.	O
Head	O
CT	O
with	O
no	O
acute	O
intracranial	O
process	O
.	O
CTA	O
demonstrated	O
no	O
PE	O
,	O
LLL	O
aspiration	O
pneumonitis	O
,	O
and	O
a	O
stable	O
AAA	O
.	O
He	O
was	O
initially	O
going	O
to	O
be	O
taken	O
onto	O
the	O
neurology	O
service	O
,	O
but	O
due	O
to	O
concern	O
for	O
his	O
unresponsiveness	O
and	O
possible	O
respiratory	O
compromise	O
,	O
he	O
was	O
admitted	O
to	O
the	O
MICU	O
for	O
further	O
monitoring	O
.	O
His	O
VS	O
were	O
afebrile	O
110	O
25125/86	O
100	O
%	O
on	O
NRB	O
prior	O
to	O
transfer	O
.	O
.	O
On	O
the	O
floor	O
,	O
the	O
patient	O
is	O
lethargic	O
and	O
minimally	O
responsive	O
to	O
vocal	O
or	O
tactile	O
stimuli	O
.	O
IV	O
metoprolol	I-Drug
5	O
mg	O
q5	O
min	O
given	O
upon	O
admission	O
to	O
the	O
floor	O
for	O
AF	B-Reason
w	I-Reason
/	I-Reason
RVR	I-Reason
.	O
Past	O
Medical	O
History	O
:	O
Past	O
Medical	O
History	O
:	O
Hypertension	O
Hyperlipidemia	O
Atrial	O
fibrillation	O
Rheumatic	O
Heart	O
Disease	O
complicated	O
by	O
aortic	O
stenosis	O
:	O
s	O
/	O
p	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
1291	O
**	O
]	O
/	O
MVR	O
on	O
[	O
**	O
2125-7-3	O
**	O
]	O
[	O
**	O
2089	O
**	O
]	O
SBE	O
after	O
dental	O
procedure	O
[	O
**	O
2095	O
**	O
]	O
's	O
:	O
colon	O
cancer	O
s	O
/	O
p	O
colectomy	O
Tonsillectomy	O
Hypoacusis	O
,	O
bilateral	O
hearing	O
aids	O
Colon	O
polyps	O
s	O
/	O
p	O
polypectomy	O
.	O
Past	O
Surgical	O
History	O
:	O
[	O
**	O
2125-7-17	O
**	O
]	O
Trach	O
/	O
PEG	O
,	O
[	O
**	O
2125-7-3	O
**	O
]	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
1291	O
**	O
]	O
(	O
tissue	O
)	O
/	O
MVR	O
(	O
tissue	O
)	O
/	O
aortic	O
endarterectomy	O
Social	O
History	O
:	O
Patient	O
is	O
widowed	O
with	O
three	O
children	O
.	O
He	O
lives	O
alone	O
.	O
He	O
worked	O
in	O
sales	O
.	O
Tobacco	O
:	O
Denies	O
ETOH	O
:	O
None	O
since	O
[	O
**	O
2085	O
**	O
]	O
Family	O
History	O
:	O
Non-contributory	O
.	O
No	O
family	O
history	O
of	O
premature	O
CAD	O
.	O
Physical	O
Exam	O
:	O
Physical	O
Exam	O
on	O
Admission	O
to	O
ICU	O
:	O
Vitals	O
:	O
T	O
:	O
96.3	O
BP	O
:	O
130/85	O
P	O
:	O
106	O
R	O
:	O
24	O
18	O
O2	O
:	O
97	O
%	O
face	O
tent	O
oxygen	O
mask	O
General	O
:	O
elderly	O
M	O
lethargic	O
not	O
responsive	O
to	O
sternal	O
or	O
vocal	O
stimuli	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MM	O
dry	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
elevated	O
10	O
cm	O
at	O
35	O
'	O
Lungs	O
:	O
crackles	O
at	O
bases	O
,	O
LLL	O
>	O
RLL	O
CV	O
:	O
tachycardic	O
,	O
irregularly	O
irregular	O
,	O
normal	O
S1	O
+	O
S2	O
with	O
metallic	O
heart	O
sounds	O
;	O
unable	O
to	O
appreciate	O
murmurs	O
given	O
tachycardia	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
;	O
PEG	O
c	O
/	O
d	O
/	O
i	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neurologic	O
:	O
depressed	O
LOC	O
,	O
not	O
following	O
commands	O
;	O
normal	O
tone	O
in	O
all	O
extremities	O
.	O
1	O
+	O
reflexes	O
in	O
biceps	O
,	O
0	O
+	O
reflexes	O
in	O
achilles	O
/	O
patellar	O
tendons	O
BL	O
(	O
symmetric	O
)	O
Pertinent	O
Results	O
:	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
GLUCOSE	O
-	O
117	O
*	O
UREA	O
N	O
-	O
20	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
4.1	O
CHLORIDE	O
-	O
100	O
TOTAL	O
CO2	O
-	O
32	O
ANION	O
GAP	O
-	O
10	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
28	O
*	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
CK	O
-	O
MB	O
-	O
2	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
CALCIUM	O
-	O
8.6	O
PHOSPHATE	O
-	O
4.5	O
MAGNESIUM	O
-	O
2.3	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
VIT	O
B12	O
-	O
1060	O
*	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
TSH	O
-	O
0.96	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
WBC	O
-	O
14.0	O
*	O
RBC	O
-	O
4.28	O
*	O
#	O
HGB	O
-	O
12.3	O
*	O
HCT	O
-	O
38.4	O
*	O
MCV	O
-	O
90	O
#	O
MCH	O
-	O
28.7	O
MCHC	O
-	O
32.0	O
RDW	O
-	O
15.5	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
PLT	O
COUNT	O
-	O
206	O
[	O
**	O
2125-9-12	O
**	O
]	O
06:48	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
[	O
**	O
2125-9-12	O
**	O
]	O
06:48	O
PM	O
URINE	O
bnzodzpn	O
-	O
NEG	O
opiates	O
-	O
NEG	O
cocaine	O
-	O
NEG	O
mthdone	O
-	O
NEG	O
[	O
**	O
2125-9-12	O
**	O
]	O
05:34	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.025	O
[	O
**	O
2125-9-12	O
**	O
]	O
05:34	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
25	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
TR	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
1	O
PH	O
-	O
6.5	O
LEUK	O
-	O
NEG	O
[	O
**	O
2125-9-12	O
**	O
]	O
05:34	O
PM	O
URINE	O
RBC	O
-0-2	O
WBC	O
-0-2	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
[	O
**	O
2125-9-12	O
**	O
]	O
05:34	O
PM	O
URINE	O
HYALINE	O
-	O
[	O
**	O
7	O
-	O
5	O
**	O
]	O
*	O
[	O
**	O
2125-9-12	O
**	O
]	O
05:34	O
PM	O
URINE	O
CA	O
OXAL	O
-	O
OCC	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:46	O
PM	O
PH	O
-	O
7.40	O
COMMENTS	O
-	O
GREEN	O
TOP	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:46	O
PM	O
GLUCOSE	O
-	O
108	O
*	O
LACTATE	O
-	O
1.2	O
NA	O
+	O
-	O
140	O
K	O
+	O
-	O
4.1	O
CL	O
--	O
97	O
*	O
TCO2	O
-	O
36	O
*	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:46	O
PM	O
freeCa	O
-	O
1.08	O
*	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:42	O
PM	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
0.8	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:42	O
PM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:42	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
41	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
47	O
*	O
ALK	O
PHOS	O
-	O
85	O
TOT	O
BILI	O
-	O
0.9	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:42	O
PM	O
LIPASE	O
-	O
23	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:42	O
PM	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2125-9-12	O
**	O
]	O
04:42	O
PM	O
ALBUMIN	O
-	O
3.2	O
*	O
CALCIUM	O
-	O
8.8	O
PHOSPHATE	O
-	O
4.1	O
MAGNESIUM	O
-	O
2.3	O
.	O
Other	O
Notable	O
Labs	O
:	O
[	O
**	O
2125-9-14	O
**	O
]	O
02:22	O
AM	O
BLOOD	O
ALT	O
-	O
33	O
AST	O
-	O
34	O
LD	O
(	O
LDH	O
)	O
-	O
294	O
*	O
AlkPhos	O
-	O
65	O
TotBili	O
-	O
0.3	O
[	O
**	O
2125-9-13	O
**	O
]	O
09:33	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
25	O
*	O
[	O
**	O
2125-9-13	O
**	O
]	O
09:33	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2125-9-14	O
**	O
]	O
02:22	O
AM	O
BLOOD	O
Albumin	O
-	O
2.7	O
*	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.1	O
Mg	O
-	O
2.2	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
BLOOD	O
VitB12	O
-	O
1060	O
*	O
[	O
**	O
2125-9-12	O
**	O
]	O
08:50	O
PM	O
BLOOD	O
TSH	O
-	O
0.96	O
[	O
**	O
2125-9-14	O
**	O
]	O
02:32	O
AM	O
BLOOD	O
freeCa	O
-	O
1.19	O
.	O
Discharge	O
Labs	O
:	O
[	O
**	O
2125-9-19	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
WBC	O
-	O
9.8	O
RBC	O
-	O
3.95	O
*	O
Hgb	O
-	O
11.0	O
*	O
Hct	O
-	O
34.7	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
27.9	O
MCHC	O
-	O
31.9	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
158	O
[	O
**	O
2125-9-19	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
PT	O
-	O
26.1	O
*	O
PTT	O
-	O
33.8	O
INR	O
(	O
PT	O
)	O
-	O
2.5	O
*	O
[	O
**	O
2125-9-19	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
Glucose	O
-	O
104	O
*	O
UreaN	O
-	O
13	O
Creat	O
-	O
0.6	O
Na	O
-	O
138	O
K	O
-	O
4.0	O
Cl	O
-	O
100	O
HCO3	O
-	O
33	O
*	O
AnGap	O
-	O
9	O
[	O
**	O
2125-9-19	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.1	O
Mg	O
-	O
2.2	O
.	O
ECG	O
[	O
**	O
2125-9-12	O
**	O
]	O
:	O
Atrial	O
fibrillation	O
with	O
a	O
mean	O
ventricular	O
rate	O
of	O
110	O
.	O
Non-specific	O
intraventricular	O
conduction	O
delay	O
.	O
Left	O
axis	O
deviation	O
with	O
probable	O
left	O
ventricular	O
hypertrophy	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2125-7-3	O
**	O
]	O
multiple	O
abnormalities	O
as	O
previously	O
noted	O
persist	O
without	O
major	O
change	O
.	O
.	O
CT	O
Head	O
w	O
/	O
o	O
contrast	O
[	O
**	O
2125-9-12	O
**	O
]	O
:	O
No	O
acute	O
intracranial	O
process	O
.	O
Low	O
-	O
attenuating	O
lesions	O
in	O
the	O
periventricular	O
white	O
matter	O
,	O
most	O
likely	O
represent	O
sequelae	O
of	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
.	O
.	O
Chest	O
CTA	O
[	O
**	O
2125-9-12	O
**	O
]	O
:	O
1	O
.	O
Bilateral	O
pleural	O
effusions	O
with	O
perifissural	O
consolidation	O
/	O
atelectasis	O
.	O
Peribronchovascular	O
thickening	O
extending	O
into	O
the	O
posterior	O
segment	O
to	O
the	O
left	O
lower	O
lobe	O
is	O
concerning	O
for	O
aspiration	O
.	O
2	O
.	O
Stable	O
ascending	O
aortic	O
aneurysm	O
.	O
Stable	O
dilation	O
of	O
the	O
aortic	O
arch	O
as	O
well	O
as	O
the	O
distal	O
aspect	O
of	O
the	O
thoracic	O
aorta	O
.	O
3	O
.	O
Cardiomegaly	O
with	O
biatrial	O
enlargement	O
.	O
4	O
.	O
No	O
pulmonary	O
embolism	O
.	O
.	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
5283	O
**	O
]	O
US	O
[	O
**	O
2125-9-13	O
**	O
]	O
:	O
1	O
.	O
No	O
evidence	O
of	O
cholecystitis	O
or	O
biliary	O
obstruction	O
.	O
2	O
.	O
Bilateral	O
,	O
right	O
greater	O
than	O
left	O
small	O
pleural	O
effusions	O
.	O
3	O
.	O
Multiple	O
bilateral	O
renal	O
cyst	O
again	O
seen	O
.	O
.	O
TTE	O
[	O
**	O
2125-9-14	O
**	O
]	O
:	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
moderately	O
depressed	O
(	O
LVEF	O
=	O
30	O
-	O
35	O
%	O
)	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
mildly	O
dilated	O
with	O
borderline	O
normal	O
free	O
wall	O
function	O
.	O
A	O
bioprosthetic	O
aortic	O
valve	O
prosthesis	O
is	O
present	O
.	O
The	O
prosthetic	O
aortic	O
valve	O
leaflets	O
appear	O
normal	O
The	O
transaortic	O
gradient	O
is	O
normal	O
for	O
this	O
prosthesis	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
A	O
bioprosthetic	O
mitral	O
valve	O
prosthesis	O
is	O
present	O
.	O
The	O
prosthetic	O
mitral	O
valve	O
leaflets	O
are	O
thickened	O
.	O
The	O
transmitral	O
gradient	O
is	O
normal	O
for	O
this	O
prosthesis	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
No	O
vegetations	O
seen	O
,	O
but	O
current	O
study	O
can	O
not	O
exclude	O
prosthetic	O
valve	O
endocarditis	O
.	O
Depressed	O
left	O
ventricular	O
systolic	O
function	O
.	O
.	O
TEE	O
[	O
**	O
2125-9-18	O
**	O
]	O
:	O
Moderate	O
to	O
severe	O
spontaneous	O
echo	O
contrast	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
.	O
No	O
mass	O
/	O
thrombus	O
is	O
seen	O
in	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
LV	O
systolic	O
function	O
appears	O
depressed	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
A	O
bioprosthetic	O
aortic	O
valve	O
prosthesis	O
is	O
present	O
.	O
The	O
aortic	O
valve	O
prosthesis	O
appears	O
well	O
seated	O
,	O
with	O
normal	O
leaflet	O
/	O
disc	O
motion	O
and	O
transvalvular	O
gradients	O
.	O
No	O
masses	O
or	O
vegetations	O
are	O
seen	O
on	O
the	O
aortic	O
valve	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
A	O
bioprosthetic	O
mitral	O
valve	O
prosthesis	O
is	O
present	O
.	O
The	O
prosthetic	O
mitral	O
leaflets	O
appear	O
normal	O
.	O
The	O
transmitral	O
gradient	O
is	O
normal	O
for	O
this	O
prosthesis	O
.	O
No	O
mass	O
or	O
vegetation	O
is	O
seen	O
on	O
the	O
mitral	O
valve	O
.	O
There	O
is	O
a	O
moderate	O
sized	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
No	O
valvular	O
vegetations	O
seen	O
.	O
Normally	O
-	O
functioning	O
bioprosthetic	O
aortic	O
and	O
mitral	O
valves	O
.	O
Brief	O
Hospital	O
Course	O
:	O
81yo	O
male	O
with	O
history	O
of	O
rheumatic	O
heart	O
disease	O
s	O
/	O
p	O
St.	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
1525	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1291	O
**	O
]	O
and	O
tissue	O
MVR	O
in	O
[	O
**	O
6	O
-	O
/	O
2125	O
**	O
]	O
,	O
afib	I-Reason
on	O
coumadin	I-Drug
,	O
and	O
systolic	O
heart	O
failure	O
who	O
presented	O
to	O
ED	O
from	O
rehab	O
with	O
lethargy	O
/	O
altered	O
mental	O
status	O
.	O
#	O
.	O
Respiratory	O
Failure	O
:	O
Patient	O
developed	O
acute	B-Ade
hypercarbic	I-Ade
respiratory	O
failure	O
secondary	O
to	O
lorazepam	I-Drug
administration	O
in	O
ED	O
.	O
He	O
was	O
transferred	O
to	O
ICU	O
for	O
further	O
care	O
,	O
but	O
did	O
not	O
require	O
intubation	O
.	O
He	O
has	O
severe	O
OSA	O
,	O
and	O
was	O
seen	O
by	O
sleep	O
medicine	O
while	O
in	O
ICU	O
.	O
Unable	O
to	O
complete	O
study	O
as	O
patient	O
could	O
not	O
tolerate	O
BiPAP	O
,	O
but	O
patient	O
will	O
need	O
sleep	O
medicine	O
follow	O
-	O
up	O
and	O
repeat	O
sleep	O
study	O
as	O
outpatient	O
.	O
The	O
patient	O
's	O
respiratory	O
status	O
improved	O
,	O
and	O
he	O
was	O
stable	O
for	O
transfer	O
to	O
the	O
floor	O
on	O
[	O
**	O
2125-9-14	O
**	O
]	O
.	O
The	O
patient	O
was	O
unable	O
to	O
tolerate	O
CPAP	O
,	O
and	O
therefore	O
was	O
kept	O
on	O
oxygen	I-Drug
via	O
nasal	O
cannula	O
at	O
night	O
.	O
He	O
was	O
not	O
given	O
any	O
further	O
sedating	O
medications	O
except	O
in	O
the	O
setting	O
of	O
his	O
TEE	O
.	O
All	O
sedating	O
meds	O
in	O
the	O
outpatient	O
setting	O
should	O
be	O
avoided	O
or	O
minimized	O
as	O
possible	O
.	O
.	O
#	O
.	O
Enterococcal	B-Reason
bacteremia	I-Reason
:	O
Blood	O
cultures	O
drawn	O
on	O
admission	O
positive	O
for	O
enterococcus	O
sensitive	O
to	O
vancomycin	I-Drug
and	O
ampicilin	I-Drug
.	O
He	O
was	O
initially	O
on	O
vancomycin	I-Drug
,	O
then	O
switched	O
to	O
ampicillin	I-Drug
/	O
gentamicin	I-Drug
per	O
ID	O
consult	O
recommendations	O
.	O
He	O
required	O
ampicillin	I-Drug
desensitization	O
in	O
ICU	O
setting	O
given	O
his	O
h	O
/	O
o	O
penicillin	I-Drug
allergy	O
.	O
A	O
TEE	O
on	O
[	O
**	O
2125-9-18	O
**	O
]	O
did	O
not	O
reveal	O
the	O
presence	O
of	O
any	O
valvular	O
vegetations	O
.	O
However	O
,	O
per	O
ID	O
recs	O
the	O
patient	O
should	O
still	O
complete	O
a	O
course	O
of	O
antibiotics	I-Drug
that	O
would	O
treat	O
endocarditis	I-Reason
,	O
especially	O
given	O
his	O
[	O
**	O
Date	O
Range	O
1291	O
**	O
]	O
/	O
MVR	O
.	O
CT	O
surgery	O
was	O
following	O
,	O
and	O
there	O
was	O
no	O
need	O
for	O
surgical	O
intervention	O
given	O
the	O
TEE	O
findings	O
.	O
The	O
patient	O
will	O
be	O
on	O
ampicillin	I-Drug
until	O
[	O
**	O
2125-10-28	O
**	O
]	O
,	O
and	O
gentamicin	I-Drug
for	O
synergy	I-Reason
until	O
[	O
**	O
2125-9-29	O
**	O
]	O
.	O
He	O
had	O
a	O
PICC	O
placed	O
on	O
[	O
**	O
2125-9-19	O
**	O
]	O
for	O
continued	O
antibiotic	I-Drug
therapy	O
.	O
All	O
surveillance	O
blood	O
cultures	O
drawn	O
since	O
[	O
**	O
2125-9-12	O
**	O
]	O
were	O
negative	O
to	O
date	O
at	O
time	O
of	O
discharge	O
.	O
The	O
patient	O
remained	O
afebrile	O
and	O
was	O
hemodynamically	O
stable	O
.	O
.	O
#	O
.	O
Altered	O
mental	O
status	O
:	O
The	O
patient	O
was	O
found	O
to	O
have	O
enterococcal	O
bacteremia	O
,	O
and	O
delirium	O
in	O
setting	O
of	O
infection	O
was	O
likely	O
the	O
primary	O
contributing	O
factor	O
to	O
his	O
altered	O
mental	O
status	O
.	O
Also	O
probable	O
contributing	O
factors	O
include	O
chronic	O
CO2	O
retention	O
,	O
severe	O
OSA	O
,	O
medication	O
effects	O
,	O
and	O
prolonged	O
hospital	O
course	O
.	O
Head	O
CT	O
on	O
admission	O
did	O
not	O
show	O
any	O
acute	O
intracranial	O
process	O
.	O
No	O
other	O
source	O
of	O
infection	O
,	O
including	O
PNA	O
or	O
UTI	O
,	O
was	O
identified	O
.	O
At	O
time	O
of	O
discharge	O
,	O
patient	O
's	O
mental	O
status	O
continued	O
to	O
wax	O
and	O
wane	O
.	O
He	O
was	O
oriented	O
to	O
person	O
and	O
place	O
,	O
and	O
able	O
to	O
follow	O
some	O
commands	O
.	O
.	O
#	O
.	O
s	O
/	O
p	O
St.	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
1525	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1291	O
**	O
]	O
and	O
tissue	O
MVR	O
:	O
Given	O
valves	O
,	O
goal	O
INR	O
is	O
2.5	O
-	O
3.5	O
.	O
The	O
patient	O
's	O
INR	O
was	O
trended	O
and	O
coumadin	I-Drug
dose	O
was	O
adjusted	O
accordingly	O
.	O
Coumadin	I-Drug
held	O
for	O
period	O
in	O
setting	O
of	O
supratherapeutic	O
INR	O
,	O
then	O
restarted	O
.	O
INR	O
was	O
also	O
briefly	O
subtherapeutic	O
,	O
and	O
patient	O
was	O
placed	O
on	O
heparin	I-Drug
gtt	O
during	O
this	O
time	O
to	O
bridge	O
back	O
to	O
a	O
therapeutic	O
INR	O
on	O
coumadin	I-Drug
.	O
INR	O
was	O
at	O
goal	O
(	O
2.5	O
)	O
on	O
day	O
of	O
discharge	O
,	O
and	O
heparin	I-Drug
gtt	O
had	O
been	O
stopped	O
.	O
INR	O
should	O
continue	O
to	O
be	O
monitored	O
,	O
and	O
coumadin	I-Drug
dose	O
adjusted	O
accordinly	O
.	O
As	O
above	O
,	O
no	O
evidence	O
of	O
valvular	O
vegetations	O
was	O
seen	O
on	O
TEE	O
[	O
**	O
2125-9-18	O
**	O
]	O
.	O
.	O
#	O
.	O
Atrial	B-Reason
fibrillation	I-Reason
:	O
Patient	O
's	O
home	O
dose	O
of	O
metoprolol	I-Drug
was	O
titrated	O
up	O
to	O
100	O
mg	O
PO	O
TID	O
,	O
given	O
frequent	O
episodes	O
of	O
tachycardia	I-Reason
to	O
120s	O
.	O
Patient	O
was	O
asymptomatic	O
and	O
hemodynamically	O
stable	O
during	O
these	O
episodes	O
.	O
He	O
was	O
continued	O
on	O
coumadin	I-Drug
as	O
above	O
for	O
both	O
his	O
a	B-Reason
fib	I-Reason
and	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
1291	O
**	O
]	O
/	O
MVR	I-Reason
.	O
.	O
#	O
.	O
Chronic	B-Reason
systolic	I-Reason
heart	I-Reason
failure	I-Reason
:	O
TTE	O
on	O
[	O
**	O
2125-9-14	O
**	O
]	O
showed	O
LVEF	O
of	O
30	O
-	O
35	O
%	O
.	O
Patient	O
appeared	O
euvolemic	O
for	O
much	O
of	O
hospital	O
course	O
.	O
He	O
was	O
on	O
furosemide	I-Drug
20	O
mg	O
daily	O
prior	O
to	O
admission	O
,	O
and	O
this	O
medication	O
should	O
be	O
restarted	O
in	O
outpatient	O
setting	O
if	O
patient	O
develops	O
hypervolemia	I-Reason
and	O
pulmonary	B-Reason
edema	I-Reason
.	O
Patient	O
was	O
continued	O
on	O
ACE	B-Drug
inhibitor	I-Drug
and	O
beta	B-Drug
blocker	I-Drug
.	O
Lisinopril	I-Drug
dose	O
is	O
currently	O
5	O
mg	O
daily	O
,	O
this	O
can	O
be	O
up	O
-	O
titrated	O
if	O
BP	O
will	O
allow	O
in	O
outpatient	O
setting	O
.	O
.	O
#	O
.	O
Hypertension	I-Reason
:	O
The	O
patient	O
was	O
continued	O
on	O
metoprolol	I-Drug
,	O
lisinopril	I-Drug
as	O
above	O
.	O
Furosemide	I-Drug
may	O
be	O
restarted	O
as	O
outpatient	O
if	O
patient	O
develops	O
hypervolemia	I-Reason
or	O
becomes	O
more	O
hypertensive	O
.	O
.	O
#	O
.	O
Hyperlidipemia	I-Reason
:	O
The	O
patient	O
was	O
on	O
simvastatin	I-Drug
10	O
mg	O
daily	O
prior	O
to	O
admission	O
,	O
and	O
this	O
was	O
re-started	O
prior	O
to	O
discharge	O
.	O
This	O
medication	O
was	O
briefly	O
held	O
in	O
setting	O
of	O
elevated	O
transaminases	O
,	O
however	O
was	O
resumed	O
as	O
transaminases	O
trended	O
down	O
to	O
normal	O
levels	O
.	O
Etiology	O
of	O
elevation	O
in	O
transaminases	O
unclear	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
5283	O
**	O
]	O
US	O
on	O
[	O
**	O
2125-9-13	O
**	O
]	O
was	O
unremarkable	O
.	O
.	O
#	O
.	O
Nutrition	O
:	O
Patient	O
has	O
PEG	O
tube	O
in	O
place	O
,	O
but	O
has	O
not	O
been	O
using	O
since	O
prior	O
to	O
admission	O
.	O
He	O
is	O
able	O
to	O
tolerate	O
PO	O
intake	O
,	O
but	O
should	O
be	O
monitored	O
on	O
aspiration	O
precautions	O
.	O
Medications	O
on	O
Admission	O
:	O
ATORVASTATIN	I-Drug
10	O
mg	O
PO	O
QHS	O
FUROSEMIDE	I-Drug
20	O
mg	O
PO	O
daily	O
IPRATROPIUM	B-Drug
BROMIDE	I-Drug
[	O
ATROVENT	I-Drug
HFA	O
]	O
17	O
mcg	O
INH	O
2	O
puffs	O
QID	O
:	O
PRN	O
LANSOPRAZOLE	I-Drug
30	O
mg	O
PO	O
daily	O
LISINOPRIL	I-Drug
5	O
mg	O
PO	O
daily	O
METOPROLOL	B-Drug
TARTRATE	I-Drug
75	O
mg	O
PO	O
BID	O
POTASSIUM	B-Drug
CHLORIDE	I-Drug
10	O
mEq	O
PO	O
once	O
a	O
day	O
WARFARIN	I-Drug
[	O
COUMADIN	I-Drug
]	O
4	O
mg	O
PO	O
daily	O
(	O
dosed	O
based	O
on	O
INR	O
-	O
held	O
since	O
[	O
**	O
2125-9-11	O
**	O
]	O
due	O
to	O
elevated	O
INR	O
of	O
4.0	O
)	O
ASPIRIN	I-Drug
81	O
mg	O
PO	O
daily	O
MULTIVITAMIN	I-Drug
1	O
tablet	O
PO	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Ampicillin	B-Drug
Sodium	I-Drug
2	O
gram	O
Recon	O
Soln	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Recon	O
Soln	O
Injection	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
for	O
39	O
days	O
:	O
last	O
day	O
[	O
**	O
2125-10-28	O
**	O
]	O
.	O
2	O
.	O
Warfarin	I-Drug
2	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
3	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Gentamicin	B-Drug
in	I-Drug
NaCl	I-Drug
(	I-Drug
Iso	I-Drug
-	I-Drug
osm	I-Drug
)	I-Drug
80	O
mg	O
/	O
50	O
mL	O
Piggyback	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
every	O
twelve	O
(	O
12	O
)	O
hours	O
for	O
10	O
days	O
:	O
last	O
day	O
[	O
**	O
2125-9-29	O
**	O
]	O
.	O
5	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
7	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
,	O
hypoxia	I-Reason
.	O
11	O
.	O
Simvastatin	I-Drug
10	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
1293	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1294	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
1	O
.	O
Bacteremia	O
.	O
Secondary	O
Diagnoses	O
:	O
1	O
.	O
Delirium	O
2	O
.	O
Atrial	O
fibrillation	O
3	O
.	O
Chronic	O
systolic	O
heart	O
failure	O
4	O
.	O
Hypertension	O
5	O
.	O
Hyperlipidemia	O
6	O
.	O
Aortic	O
valve	O
and	O
mitral	O
valve	O
replacements	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
always	O
.	O
Level	O
of	O
Consciousness	O
:	O
Lethargic	O
but	O
arousable	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
increased	O
tiredness	O
and	O
confusion	O
.	O
We	O
found	O
you	O
have	O
an	O
infection	B-Reason
in	I-Reason
your	I-Reason
blood	I-Reason
.	O
You	O
were	O
initially	O
admitted	O
to	O
the	O
ICU	O
because	O
you	O
were	O
having	O
trouble	O
breathing	O
,	O
but	O
your	O
breathing	O
improved	O
and	O
you	O
were	O
stable	O
to	O
be	O
on	O
the	O
general	O
medicine	O
floor	O
.	O
An	O
ultrasound	O
of	O
your	O
heart	O
did	O
not	O
show	O
any	O
infection	O
on	O
your	O
heart	O
valves	O
.	O
We	O
treated	O
you	O
with	O
antibiotics	I-Drug
,	O
and	O
you	O
will	O
need	O
to	O
continue	O
these	O
antibiotics	O
after	O
you	O
leave	O
the	O
hospital	O
.	O
.	O
Please	O
take	O
all	O
medications	O
as	O
directed	O
.	O
Please	O
keep	O
follow	O
-	O
up	O
appointments	O
as	O
scheduled	O
.	O
You	O
should	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1147	O
**	O
]	O
,	O
and	O
also	O
follow	O
-	O
up	O
with	O
sleep	B-Drug
medicine	I-Drug
about	O
repeating	O
a	O
sleep	O
study	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1147	O
**	O
]	O
after	O
you	O
leave	O
rehab	O
.	O
.	O
Department	O
:	O
GENERAL	O
SURGERY	O
/	O
[	O
**	O
Hospital	O
Unit	O
Name	O
2193	O
**	O
]	O
When	O
:	O
THURSDAY	O
[	O
**	O
2125-9-27	O
**	O
]	O
at	O
9:45	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2359	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
.	O
GARAGE	O

Admission	O
Date	O
:	O
[	O
**	O
2172-8-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2172-9-6	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2114-3-8	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3984	O
**	O
]	O
Chief	O
Complaint	O
:	O
dyspnea	O
,	O
hoarseness	O
,	O
and	O
cough	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Bronchoscopy	O
x2	O
Tracheal	O
Y	O
-	O
stent	O
placement	O
[	O
**	O
2172-8-25	O
**	O
]	O
Pigtail	O
catheter	O
placement	O
(	O
right	O
)	O
[	O
**	O
2172-8-25	O
**	O
]	O
for	O
pleural	O
effusion	O
Intubation	O
[	O
**	O
2172-8-25	O
**	O
]	O
,	O
re-intubated	O
[	O
**	O
2172-8-26	O
**	O
]	O
after	O
attempted	O
extubation	O
Chest	O
tube	O
placement	O
(	O
right	O
)	O
[	O
**	O
2172-8-26	O
**	O
]	O
for	O
pneumothorax	O
Radiation	O
therapy	O
x2	O
Chemotherapy	I-Drug
x3days	O
Lumbar	O
puncture	O
[	O
**	O
2172-9-3	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
58	O
year	O
-	O
old	O
female	O
,	O
60	O
pack	O
-	O
year	O
smoker	O
,	O
with	O
dyspnea	O
,	O
hoarseness	O
,	O
and	O
cough	O
x1	O
month	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
SICU	O
[	O
**	O
2172-8-25	O
**	O
]	O
after	O
found	O
to	O
have	O
large	O
mediastinal	O
mass	O
,	O
today	O
found	O
to	O
be	O
poorly	O
-	O
differentiated	O
carcinoma	O
,	O
suspected	O
small	O
cell	O
.	O
On	O
initial	O
evaluation	O
,	O
patient	O
was	O
found	O
to	O
have	O
3	O
mm	O
opening	O
of	O
distal	O
trachea	O
secondary	O
to	O
external	O
compression	O
from	O
mediastinal	O
mass	O
,	O
RUL	O
mass	O
,	O
RUL	O
collapse	O
,	O
and	O
clinical	O
findings	O
consistent	O
with	O
SVC	O
sydrome	O
.	O
Y	O
-	O
stent	O
was	O
placed	O
that	O
evening	O
,	O
in	O
addition	O
to	O
Pigtail	O
catheter	O
for	O
right	O
-	O
sided	O
effusion	O
.	O
Patient	O
remained	O
intubated	O
following	O
surgery	O
,	O
on	O
paralytics	O
due	O
to	O
low	O
-	O
lying	O
ET	O
tube	O
and	O
small	O
volume	O
bleeding	O
after	O
endobronchial	O
biopsy	O
.	O
On	O
[	O
**	O
2172-8-26	O
**	O
]	O
,	O
extubated	O
was	O
attempted	O
.	O
Patient	O
was	O
reintubated	O
within	O
10	O
minutes	O
due	O
to	O
neurological	O
unresponsiveness	O
,	O
hypoxia	O
(	O
O2	O
saturation	O
80s	O
)	O
,	O
and	O
hemodynamic	O
instability	O
.	O
She	O
was	O
found	O
to	O
have	O
a	O
right	O
pneumothorax	O
,	O
which	O
improved	O
with	O
subsequent	O
placement	O
of	O
chest	O
tube	O
.	O
Patient	O
was	O
also	O
noted	O
to	O
have	O
pericardial	O
effusion	O
;	O
given	O
absence	O
of	O
physiologic	O
tamponade	O
,	O
cardiology	O
decided	O
against	O
pericardiocentesis	O
.	O
.	O
Hospital	O
course	O
also	O
complicated	O
by	O
hyponatremia	O
on	O
admission	O
(	O
Na	O
118	O
)	O
attributed	O
to	O
SIADH	O
and	O
improved	O
with	O
fluid	O
restriction	O
(	O
Na	O
126	O
)	O
.	O
Also	O
with	O
hypotension	O
(	O
sBP	O
90s	O
)	O
following	O
reintubation	O
on	O
[	O
**	O
2172-8-26	O
**	O
]	O
.	O
Given	O
hyperkalemia	O
,	O
hyponatremia	O
adrenal	O
insufficiency	O
was	O
suspected	O
;	O
evaluated	O
by	O
endocrine	O
team	O
who	O
recommended	O
stress	O
dose	O
steroids	I-Drug
pending	O
further	O
evaluation	O
of	O
etiology	O
of	O
hypotension	O
.	O
Also	O
with	O
non-anion	O
gap	O
metabolic	O
acidosis	O
,	O
transient	O
hypothermia	O
(	O
T	O
95	O
[	O
**	O
2172-8-26	O
**	O
]	O
)	O
of	O
unknown	O
etiology	O
.	O
.	O
Per	O
report	O
,	O
patient	O
has	O
done	O
well	O
today	O
.	O
She	O
remains	O
intubated	O
,	O
on	O
pressure	O
support	O
.	O
Given	O
the	O
above	O
pathology	O
results	O
,	O
patient	O
is	O
transferred	O
to	O
the	O
medical	O
ICU	O
(	O
[	O
**	O
Hospital	O
Ward	O
Name	O
332	O
**	O
]	O
)	O
for	O
radiation	O
therapy	O
.	O
.	O
On	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
332	O
**	O
]	O
medical	O
ICU	O
,	O
patient	O
is	O
intubated	O
,	O
sedated	O
,	O
and	O
unable	O
to	O
provide	O
history	O
.	O
Past	O
Medical	O
History	O
:	O
Hypertension	O
s	O
/	O
p	O
cerebral	O
sneurysm	O
repair	O
x3	O
GERD	O
Social	O
History	O
:	O
Per	O
review	O
of	O
records	O
,	O
60	O
pack	O
-	O
year	O
history	O
Family	O
History	O
:	O
Unable	O
to	O
obtain	O
.	O
Physical	O
Exam	O
:	O
On	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
admission	O
[	O
**	O
2172-8-27	O
**	O
]	O
:	O
96.0	O
,	O
103	O
,	O
120/68	O
,	O
13	O
,	O
97	O
%	O
[	O
PS	O
14/5	O
50	O
%	O
]	O
General	O
:	O
Intubated	O
,	O
sedated	O
,	O
not	O
responsive	O
to	O
verbal	O
stimuli	O
;	O
swelling	O
of	O
head	O
,	O
neck	O
,	O
and	O
upper	O
extremities	O
;	O
wasting	O
of	O
lower	O
extremities	O
Skin	O
:	O
Mottled	O
at	O
arms	O
and	O
superior	O
to	O
nipple	O
line	O
;	O
telangiectasias	O
on	O
chest	O
wall	O
HEENT	O
:	O
Temporal	O
wasting	O
;	O
pupils	O
symmetric	O
,	O
minimal	O
reactivity	O
to	O
light	O
;	O
sclerae	O
anicetric	O
;	O
scleral	O
edema	O
;	O
dry	O
mucous	O
membranes	O
Neck	O
:	O
Large	O
;	O
unable	O
to	O
appreciate	O
neck	O
veins	O
secondary	O
to	O
swelling	O
;	O
right	O
anterior	O
chain	O
palpable	O
lymph	O
node	O
Chest	O
:	O
Right	O
chest	O
tube	O
,	O
pigtail	O
catheter	O
in	O
place	O
Lungs	O
:	O
Upper	O
airway	O
noise	O
;	O
by	O
anterior	O
ausculation	O
,	O
few	O
expiratory	O
wheezes	O
diffusely	O
;	O
breath	O
sounds	O
appreciable	O
in	O
all	O
lung	O
fields	O
CV	O
:	O
Tachycardic	O
;	O
regular	O
rhythm	O
;	O
pronounced	O
S2	O
at	O
apex	O
;	O
I	O
/	O
VI	O
early	O
systolic	O
murmur	O
at	O
left	O
LLSB	O
;	O
unable	O
to	O
assess	O
pulsus	O
paradoxus	O
given	O
quiet	O
Korsakoff	O
sounds	O
Abdomen	O
:	O
Hypoactive	O
bowel	O
sounds	O
;	O
soft	O
,	O
non-distended	O
GU	O
:	O
Foley	O
Ext	O
:	O
Right	O
DP	O
1	O
+	O
,	O
left	O
DP	O
appreciated	O
with	O
Doppler	O
;	O
no	O
lower	O
extremity	O
edema	O
;	O
upper	O
extremity	O
nonpitting	O
edema	O
Pertinent	O
Results	O
:	O
On	O
admission	O
[	O
**	O
2172-8-26	O
**	O
]	O
:	O
WBC	O
-	O
11.1	O
*	O
RBC	O
-	O
3.47	O
*	O
Hgb	O
-	O
10.9	O
*	O
Hct	O
-	O
31.9	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
12.5	O
Plt	O
Ct	O
-	O
393	O
Glucose	O
-	O
112	O
*	O
UreaN	O
-	O
9	O
Creat	O
-	O
0.8	O
Na	O
-	O
118	O
*	O
K	O
-	O
4.8	O
Cl	O
-	O
82	O
*	O
HCO3	O
-	O
24	O
AnGap	O
-	O
17	O
ALT	O
-	O
7	O
AST	O
-	O
21	O
LD	O
(	O
LDH	O
)	O
-	O
584	O
*	O
AlkPhos	O
-	O
75	O
TotBili	O
-	O
0.2	O
Cortsol	O
-	O
25.7	O
*	O
Hgb	O
-	O
13.5	O
calcHCT	O
-	O
41	O
O2	O
Sat	O
-	O
82	O
.	O
Imaging	O
:	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
CT	O
Chest	O
without	O
contrast	O
:	O
1	O
.	O
Large	O
mediastinal	O
mass	O
causes	O
narrowing	O
of	O
the	O
right	O
pulmonary	O
artery	O
,	O
superior	O
vena	O
cava	O
,	O
and	O
trachea	O
and	O
occlusion	O
of	O
the	O
pulmonary	O
artery	O
supplying	O
the	O
right	O
upper	O
lobe	O
in	O
addition	O
to	O
the	O
right	O
upper	O
lobe	O
bronchus	O
.	O
These	O
findings	O
are	O
most	O
concerning	O
for	O
a	O
primary	O
lung	O
carcinoma	O
.	O
2	O
.	O
Right	O
upper	O
lobe	O
collapse	O
with	O
nonenhancing	O
lung	O
parenchyma	O
.	O
Tumor	O
involvement	O
can	O
not	O
be	O
excluded	O
.	O
Atelectasis	O
of	O
the	O
right	O
lower	O
and	O
middle	O
lobe	O
.	O
3	O
.	O
Large	O
right	O
pleural	O
effusion	O
.	O
.	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
Tracheal	O
mass	O
tissue	O
pathology	O
:	O
Immunohistochemical	O
studies	O
show	O
that	O
tumor	O
cells	O
are	O
positively	O
stained	O
by	O
TTF	O
-	O
1	O
and	O
CK7	O
;	O
they	O
are	O
negative	O
for	O
CK20	O
,	O
chromogranin	O
,	O
and	O
synaptophysin	O
.	O
The	O
tumor	O
shows	O
areas	O
of	O
necrosis	O
,	O
extensive	O
apoptosis	O
and	O
focal	O
lymphatic	O
vascular	O
invasion	O
;	O
some	O
areas	O
the	O
tumor	O
cell	O
size	O
approaching	O
that	O
of	O
a	O
small	O
cell	O
carcinoma	O
,	O
but	O
much	O
of	O
the	O
tumor	O
has	O
larger	O
nuclei	O
.	O
Overall	O
,	O
the	O
tumor	O
probably	O
fits	O
into	O
the	O
spectrum	O
of	O
a	O
small	O
cell	O
carcinoma	O
of	O
lung	O
.	O
.	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
Pleural	O
fluid	O
cytology	O
:	O
Rare	O
groups	O
of	O
epithelioid	O
cells	O
,	O
too	O
few	O
to	O
characterize	O
further	O
.	O
By	O
immunohistochemistry	O
:	O
mesothelial	O
cells	O
stain	O
for	O
calretinin	O
and	O
WT	O
-	O
1	O
.	O
Epithelial	O
markers	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
31	O
,	O
CEA	O
,	O
and	O
B72	O
.3	O
are	O
negative	O
.	O
Rare	O
cells	O
are	O
highlighted	O
by	O
TTF	O
-	O
1	O
;	O
however	O
,	O
these	O
cells	O
are	O
not	O
cytologically	O
atypical	O
and	O
may	O
represent	O
non-specific	O
reactivity	O
.	O
.	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
EKG	O
:	O
Sinus	O
tachycardia	O
.	O
Low	O
QRS	O
voltage	O
in	O
limb	O
leads	O
.	O
No	O
previous	O
tracing	O
available	O
for	O
comparison	O
.	O
.	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
Echo	O
:	O
The	O
left	O
atrium	O
and	O
right	O
atrium	O
are	O
normal	O
in	O
cavity	O
size	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
a	O
small	O
to	O
moderate	O
sized	O
,	O
primarily	O
anterior	O
pericardial	O
effusion	O
without	O
right	O
ventricular	O
diastolic	O
collapse	O
.	O
IMPRESSION	O
:	O
Suboptimal	O
image	O
quality	O
.	O
Mild	O
-	O
moderate	O
,	O
primarily	O
anterior	O
pericardial	O
effusion	O
.	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function	O
.	O
If	O
clinically	O
indicated	O
,	O
a	O
follow	O
-	O
up	O
study	O
is	O
suggested	O
.	O
.	O
[	O
**	O
8	O
-	O
27	O
**	O
]	O
CT	O
chest	O
/	O
abdomen	O
/	O
pelvis	O
with	O
and	O
without	O
contrast	O
:	O
1	O
.	O
Vascular	O
findings	O
unchanged	O
from	O
[	O
**	O
2172-8-25	O
**	O
]	O
.	O
Narrowing	O
of	O
SVC	O
and	O
left	O
brachiocephalic	O
vein	O
by	O
large	O
mediastinal	O
mass	O
.	O
The	O
SVC	O
is	O
narrowed	O
to	O
approximately	O
5	O
mm	O
over	O
a	O
region	O
extending	O
3	O
cm	O
in	O
craniocaudal	O
dimension	O
.	O
Indirect	O
evidence	O
of	O
right	O
brachiocephalic	O
vein	O
occlusion	O
,	O
likely	O
complete	O
.	O
Unchanged	O
narrowing	O
of	O
right	O
pulmonary	O
artery	O
.	O
Splayed	O
but	O
patent	O
aortic	O
arch	O
branches	O
.	O
2	O
.	O
Interval	O
decrease	O
in	O
large	O
right	O
pleural	O
effusion	O
,	O
with	O
small	O
anterior	O
pneumothorax	O
.	O
Right	O
chest	O
tube	O
terminating	O
at	O
apex	O
.	O
3	O
.	O
No	O
interval	O
change	O
in	O
large	O
infiltrative	O
hypoattenuating	O
right	O
hilar	O
/	O
mediastinal	O
mass	O
.	O
4	O
.	O
No	O
evidence	O
of	O
metastases	O
in	O
the	O
abdomen	O
or	O
pelvis	O
.	O
Slightly	O
bulky	O
left	O
adrenal	O
gland	O
without	O
discrete	O
nodule	O
or	O
mass	O
.	O
5	O
.	O
Anasarca	O
and	O
small	O
amount	O
of	O
peritoneal	O
fluid	O
collecting	O
in	O
the	O
pelvis	O
,	O
likely	O
related	O
to	O
edema	O
.	O
6	O
.	O
Interval	O
tracheal	O
stenting	O
with	O
improved	O
caliber	O
of	O
airway	O
.	O
.	O
[	O
**	O
2172-8-27	O
**	O
]	O
ECHO	O
:	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2172-8-26	O
**	O
]	O
,	O
the	O
size	O
of	O
the	O
pericardial	O
effusion	O
is	O
unchanged	O
with	O
no	O
signs	O
of	O
tamponade	O
.	O
The	O
left	O
ventricle	O
seems	O
to	O
be	O
underfilled	O
.	O
.	O
[	O
**	O
8	O
-	O
28	O
**	O
]	O
CT	O
Head	O
:	O
1	O
.	O
Within	O
limits	O
of	O
this	O
modality	O
,	O
no	O
evidence	O
of	O
enhancing	O
mass	O
or	O
edema	O
to	O
suggest	O
metastatic	O
disease	O
.	O
2	O
.	O
Status	O
post	O
bilateral	O
frontal	O
craniotomy	O
and	O
probable	O
aneurysm	O
clipping	O
with	O
encephalomalacic	O
changes	O
in	O
the	O
right	O
frontotemporal	O
and	O
left	O
temporal	O
lobes	O
.	O
No	O
evidence	O
of	O
acute	O
hemorrhage	O
or	O
infarct	O
.	O
3	O
.	O
Probable	O
chronic	O
bifrontal	O
subdural	O
hygromas	O
with	O
minimal	O
mass	O
effect	O
on	O
the	O
subjacent	O
frontal	O
gyri	O
;	O
these	O
may	O
relate	O
to	O
the	O
extensive	O
remote	O
surgery	O
.	O
[	O
**	O
2172-9-2	O
**	O
]	O
CT	O
Head	O
(	O
performed	O
due	O
to	O
worsened	O
mental	O
status	O
)	O
:	O
1	O
.	O
Unchanged	O
examination	O
from	O
recent	O
exam	O
of	O
[	O
**	O
2172-8-28	O
**	O
]	O
.	O
2	O
.	O
Status	O
post	O
bilateral	O
frontal	O
craniotomies	O
with	O
aneurysm	O
clipping	O
and	O
encephalomalcia	O
,	O
as	O
described	O
above	O
.	O
No	O
evidence	O
of	O
acute	O
hemorrhage	O
or	O
infarct	O
.	O
.	O
[	O
**	O
2172-9-3	O
**	O
]	O
Renal	O
US	O
:	O
1	O
.	O
Mildly	O
echogenic	O
kidneys	O
consistent	O
with	O
medical	O
renal	O
disease	O
.	O
There	O
is	O
no	O
evidence	O
of	O
hydronephrosis	O
,	O
stone	O
,	O
or	O
mass	O
.	O
2	O
.	O
The	O
left	O
kidney	O
remains	O
atrophic	O
and	O
lobulated	O
,	O
similar	O
to	O
[	O
**	O
2172-8-27	O
**	O
]	O
.	O
.	O
[	O
**	O
2172-9-4	O
**	O
]	O
CT	O
Chest	O
w	O
/	O
o	O
contrast	O
(	O
to	O
evaluate	O
tumor	O
s	O
/	O
p	O
XRT	O
and	O
chemo	O
for	O
future	O
XRT	O
sessions	O
)	O
:	O
1	O
.	O
Right	O
anterior	O
pneumothorax	O
has	O
resolved	O
.	O
2	O
.	O
Mixed	O
response	O
of	O
the	O
tumor	O
to	O
radiotherapy	O
with	O
a	O
decrease	O
of	O
the	O
central	O
component	O
of	O
the	O
tumor	O
and	O
a	O
mixed	O
response	O
of	O
the	O
peripheral	O
tumor	O
components	O
:	O
3	O
.	O
The	O
peripheral	O
consolidations	O
in	O
the	O
right	O
upper	O
lobe	O
have	O
overall	O
decreased	O
in	O
size	O
,	O
however	O
,	O
a	O
new	O
cavitary	O
lesion	O
has	O
formed	O
measuring	O
11	O
x	O
19	O
mm	O
.	O
4	O
.	O
The	O
peripheral	O
consolidations	O
in	O
the	O
right	O
lower	O
lobe	O
and	O
left	O
lower	O
lobe	O
have	O
increased	O
in	O
size	O
,	O
number	O
and	O
density	O
and	O
may	O
be	O
part	O
of	O
post	O
-	O
obstructive	O
,	O
post-radiotherapy	O
,	O
post-infectious	O
,	O
or	O
acute	O
inflammatory	O
changes	O
.	O
5	O
.	O
Lymphangio	O
-	O
carcinomatosis	O
in	O
the	O
right	O
upper	O
lobe	O
.	O
6	O
.	O
There	O
is	O
new	O
small	O
right	O
pleural	O
effusion	O
and	O
increased	O
moderate	O
left	O
pleural	O
effusion	O
.	O
7	O
.	O
Left	O
adrenal	O
gland	O
mass	O
is	O
only	O
partially	O
visualized	O
in	O
this	O
study	O
.	O
.	O
[	O
**	O
2172-9-3	O
**	O
]	O
EEG	O
:	O
Markedly	O
abnormal	O
portable	O
EEG	O
due	O
to	O
the	O
very	O
disorganized	O
and	O
slow	O
background	O
rhythms	O
.	O
This	O
suggests	O
a	O
widespread	O
and	O
moderately	O
severe	O
encephalopathy	O
in	O
both	O
cortical	O
and	O
subcortical	O
structures	O
.	O
Medications	O
,	O
metabolic	O
disturbances	O
,	O
and	O
infection	O
are	O
among	O
the	O
most	O
common	O
causes	O
.	O
Although	O
there	O
were	O
fleeting	O
asymmetries	O
,	O
there	O
was	O
no	O
reliable	O
area	O
of	O
focal	O
slowing	O
.	O
Encephalopathies	O
may	O
obscure	O
focal	O
findings	O
.	O
There	O
are	O
some	O
sharp	O
features	O
,	O
but	O
no	O
clearly	O
epileptiform	O
abnormalities	O
and	O
no	O
electrographic	O
seizures	O
.	O
.	O
[	O
**	O
2172-9-5	O
**	O
]	O
LENI	O
:	O
no	O
DVT	O
.	O
[	O
**	O
2172-9-5	O
**	O
]	O
ECHO	O
:	O
final	O
read	O
pending	O
.	O
Micro	O
:	O
[	O
**	O
2172-8-26	O
**	O
]	O
Pleural	O
fluid	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2172-8-26	O
**	O
]	O
)	O
:	O
3	O
+	O
(	O
5	O
-	O
10	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2172-8-29	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2172-9-1	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2172-8-27	O
**	O
]	O
)	O
:	O
no	O
AFB	O
seen	O
on	O
direct	O
smear	O
ACID	O
FAST	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
PENDING	O
Cytology	O
:	O
Atypical	O
cells	O
,	O
non-specific	O
findings	O
.	O
[	O
**	O
2172-9-4	O
**	O
]	O
BAL	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2172-9-4	O
**	O
]	O
)	O
:	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
NEGATIVE	O
ROD	O
(	O
S	O
)	O
.	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
BUDDING	O
YEAST	O
WITH	O
PSEUDOHYPHAE	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
FUNGAL	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
.	O
[	O
**	O
2172-9-3	O
**	O
]	O
CSF	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2172-9-3	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
Cytology	O
:	O
no	O
malignant	O
cells	O
.	O
C.	O
diff	O
negative	O
.	O
[	O
**	O
8	O
-	O
30	O
**	O
]	O
Blood	O
Cx	O
??????	O
NGTD	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
Blooc	O
cx	O
-	O
pending	O
.	O
Bronchoscopy	O
[	O
**	O
2172-9-4	O
**	O
]	O
:	O
lots	O
of	O
necrotic	O
tissue	O
noted	O
,	O
ETT	O
tube	O
dislodged	O
between	O
stent	O
and	O
tracheal	O
wall	O
,	O
repositioned	O
during	O
bronch	O
.	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
Course	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
84902	O
**	O
]	O
58F	O
with	O
likely	O
small	O
cell	O
carcinoma	O
complicated	O
by	O
SVC	O
syndrome	O
,	O
airway	O
compromise	O
requiring	O
Y	O
-	O
stent	O
,	O
pericardial	O
effusion	O
,	O
resolved	O
pleural	O
effusion	O
and	O
pneumothorax	O
,	O
and	O
electrolytes	O
disturbances	O
admitted	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
radiation	O
decompression	O
therapy	O
and	O
chemotherapy	I-Drug
.	O
Pt	O
developed	O
respiratory	O
failure	O
and	O
renal	O
failure	O
.	O
.	O
#	O
.	O
Hypoxic	O
respiratory	O
failure	O
:	O
Pt	O
was	O
initially	O
transferred	O
from	O
SICU	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
on	O
CPAP	O
/	O
PS	O
.	O
She	O
developed	O
increasing	O
respiratory	O
failure	O
and	O
was	O
changed	O
to	O
AC	O
mode	O
.	O
In	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
,	O
she	O
underwent	O
XRT	O
x2	O
and	O
then	O
chemotherapy	I-Drug
for	O
3	O
days	O
.	O
Increased	O
hypoxia	O
may	O
have	O
been	O
due	O
to	O
pneumothorax	O
,	O
which	O
resolved	O
,	O
pleural	O
effusions	O
,	O
atelectasis	O
,	O
possible	O
VAP	O
,	O
tumor	O
compression	O
.	O
During	O
hypoxic	O
episodes	O
,	O
pt	O
underwent	O
bronchoscopy	O
twice	O
,	O
both	O
times	O
of	O
which	O
demonstrated	O
the	O
ETT	O
lodged	O
between	O
tracheal	O
wall	O
and	O
stent	O
.	O
Pt	O
's	O
saturation	O
improved	O
with	O
repositioning	O
.	O
Respiratory	O
status	O
also	O
complicated	O
by	O
possible	O
underlying	O
COPD	O
given	O
smoking	O
history	O
with	O
possible	O
air	O
stacking	O
/	O
trapping	O
.	O
Pt	O
was	O
started	O
on	O
vancomycin	I-Drug
,	O
cefepime	I-Drug
and	O
ciprofloxacin	I-Drug
(	O
started	O
[	O
**	O
2172-8-31	O
**	O
]	O
for	O
8	O
day	O
course	O
)	O
for	O
VAP	I-Reason
.	O
Vanco	I-Drug
was	O
later	O
held	O
as	O
the	O
level	O
was	O
elevated	O
in	O
the	O
setting	O
of	O
renal	O
failure	O
.	O
Patient	O
's	O
family	O
decided	O
to	O
persue	O
comfort	O
only	O
care	O
on	O
[	O
**	O
2172-9-6	O
**	O
]	O
,	O
and	O
she	O
was	O
terminally	O
extubated	O
.	O
Patient	O
expired	O
15	O
minutes	O
later	O
from	O
respiratory	O
failure	O
and	O
asystole	O
secondary	O
to	O
lung	O
cancer	O
.	O
.	O
#	O
Altered	O
Mental	O
Status	O
:	O
Pt	O
had	O
decline	O
in	O
mental	O
status	O
over	O
time	O
.	O
She	O
initially	O
withdrew	O
from	O
noxious	O
stimuli	O
but	O
later	O
was	O
less	O
responsive	O
.	O
AMS	O
continued	O
despite	O
sedation	O
being	O
off	O
.	O
AMS	O
most	O
likely	O
due	O
to	O
toxic	O
metabolic	O
syndrome	O
in	O
setting	O
of	O
uremia	O
and	O
multi-system	O
organ	O
failure	O
.	O
Differential	O
also	O
included	O
seizure	O
(	O
given	O
hx	O
of	O
cerebral	O
aneurysm	O
repair	O
,	O
on	O
anti-epileptics	O
presumably	O
prophylactically	O
)	O
although	O
EEG	O
did	O
not	O
demonstrate	O
focal	O
abnormalities	O
.	O
LP	O
did	O
not	O
demonstrate	O
infection	O
or	O
spread	O
of	O
malignancy	O
.	O
CT	O
head	O
[	O
**	O
2172-9-2	O
**	O
]	O
negative	O
for	O
acute	O
process	O
.	O
.	O
#	O
.	O
Small	O
cell	O
lung	O
carcinoma	O
:	O
per	O
pathology	O
,	O
the	O
tumor	O
probably	O
fits	O
into	O
the	O
spectrum	O
of	O
a	O
small	O
cell	O
carcinoma	O
of	O
lung	O
.	O
Given	O
associated	O
SVC	O
syndrome	O
,	O
prognosis	O
poor	O
.	O
CT	O
head	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
103	O
**	O
]	O
/	O
pelvis	O
negative	O
for	O
metastases	O
.	O
Pt	O
underwent	O
3	O
days	O
of	O
chemotherapy	I-Drug
and	O
2	O
sessions	O
of	O
XRT	O
.	O
Initially	O
,	O
XRT	O
was	O
clinical	O
emergency	O
-	O
normal	O
and	O
pathologic	O
tissue	O
was	O
likely	O
treated	O
;	O
necrotic	O
tissue	O
noted	O
on	O
bronchoscopy	O
[	O
**	O
2172-9-4	O
**	O
]	O
.	O
Pt	O
was	O
to	O
undergo	O
formal	O
tissue	O
planning	O
session	O
on	O
[	O
**	O
2172-9-8	O
**	O
]	O
to	O
better	O
delineate	O
area	O
of	O
radiation	O
however	O
family	O
decided	O
to	O
persue	O
comfort	O
only	O
care	O
on	O
[	O
**	O
2172-9-6	O
**	O
]	O
.	O
.	O
#	O
Acute	B-Ade
Renal	I-Ade
failure	I-Ade
:	O
In	O
setting	O
of	O
chemo	I-Drug
with	O
carboplatin	I-Drug
.	O
Urine	O
casts	O
consistent	O
with	O
ATN	O
.	O
Uric	O
acid	O
and	O
electrolytes	O
elevated	O
4	O
-	O
5d	O
post	O
chemotherapy	I-Drug
concerning	O
for	O
tumor	B-Ade
lysis	I-Ade
syndrome	O
.	O
The	O
next	O
therapeutic	O
step	O
was	O
dialysis	O
as	O
patient	O
became	O
oliguric	O
despite	O
volume	O
overload	O
but	O
the	O
family	O
wished	O
for	O
comfort	O
only	O
care	O
given	O
dismal	O
prognosis	O
of	O
her	O
lung	O
cancer	O
.	O
.	O
#	O
.	O
Metabolic	O
acidosis	O
:	O
Originally	O
thought	O
to	O
be	O
non-gap	O
metabolic	O
acidosis	O
due	O
to	O
hypoaldosteronism	O
and	O
type	O
IV	O
RTA	O
.	O
With	O
low	O
albumin	O
,	O
however	O
,	O
this	O
is	O
a	O
gap	O
metabolic	O
acidosis	O
,	O
most	O
likely	O
due	O
to	O
uremia	O
.	O
Unable	O
to	O
increase	O
RR	O
to	O
compensate	O
due	O
to	O
concern	O
for	O
auto	O
-	O
peeping	O
in	O
setting	O
of	O
possible	O
COPD	O
.	O
Goal	O
pH	O
is	O
7.3	O
-	O
7.35	O
.	O
On	O
[	O
**	O
2172-9-5	O
**	O
]	O
,	O
pt	O
's	O
acidosis	O
worsened	O
with	O
pH	O
7.16	O
-	O
7.18	O
.	O
Despite	O
adjusting	O
ETT	O
placement	O
and	O
decreasing	O
RR	O
to	O
reduce	O
auto	O
-	O
peep	O
,	O
pt	O
's	O
acidosis	O
worsened	O
.	O
Bicarbonate	O
was	O
given	O
.	O
.	O
#	O
Tachycardia	O
/	O
Hypotension	O
??????	O
Pt	O
with	O
tachycardia	O
to	O
140s	O
and	O
episodes	O
of	O
hypotension	O
to	O
SBP	O
low	O
80s	O
.	O
Pt	O
with	O
new	O
A-fib	O
on	O
telemetry	O
and	O
EKG	O
.	O
DDx	O
includes	O
possible	O
enlarging	O
pericardial	O
effusion	O
/	O
tamponade	O
but	O
pulsus	O
paradoxus	O
was	O
normal	O
and	O
ECHO	O
[	O
**	O
2172-9-5	O
**	O
]	O
was	O
unchanged	O
from	O
prior	O
.	O
No	O
pneumothorax	O
seen	O
on	O
CXR	O
.	O
Unable	O
to	O
assess	O
for	O
PE	O
by	O
CTA	O
as	O
pt	O
in	O
renal	O
failure	O
and	O
VQ	O
would	O
not	O
be	O
helpful	O
in	O
setting	O
of	O
other	O
lung	O
pathology	O
.	O
LENI	O
's	O
negative	O
for	O
DVT	O
.	O
PE	O
likely	O
given	O
malignancy	O
and	O
prolonged	O
bed	O
rest	O
but	O
unable	O
to	O
do	O
CTA	O
given	O
renal	O
failure	O
and	O
VQ	O
scan	O
not	O
helpful	O
in	O
setting	O
of	O
lung	O
changes	O
.	O
Even	O
if	O
it	O
had	O
been	O
positive	O
,	O
heme	O
/	O
onc	O
recommended	O
against	O
anti-coagulation	I-Drug
in	O
setting	O
of	O
possible	O
tumor	O
necrosis	O
/	O
hemorrhage	O
.	O
Pt	O
remained	O
tachycardic	O
to	O
130s	O
despite	O
numerous	O
fluid	I-Drug
boluses	O
.	O
.	O
#	O
.	O
Electrolyte	O
disturbances	O
:	O
Pt	O
developed	O
hypernatremia	O
on	O
[	O
**	O
2172-9-4	O
**	O
]	O
most	O
likley	O
due	O
to	O
dehydration	B-Reason
with	I-Reason
free	I-Reason
water	I-Reason
deficit	I-Reason
of	O
1.4	O
L	O
,	O
started	O
on	O
D5W	I-Drug
.	O
Pt	O
had	O
hyponatremia	O
and	O
hyperkalemia	O
on	O
admission	O
,	O
both	O
resolved	O
.	O
Unclear	O
etiology	O
of	O
electrolyte	O
disturbances	O
on	O
admission	O
-	O
hyponatremia	O
thought	O
to	O
be	O
secondary	O
to	O
possible	O
adrenal	O
insufficency	O
(	O
now	O
discarded	O
)	O
or	O
possibly	O
SIADH	O
.	O
Low	O
UNa	O
does	O
not	O
exclude	O
SIADH	O
;	O
renal	O
recommended	O
rechecking	O
urine	O
lytes	O
with	O
saline	O
load	O
,	O
whcih	O
was	O
not	O
done	O
in	O
setting	O
of	O
pt	O
??????	O
s	O
other	O
medical	O
issues	O
.	O
Hyperkalemia	O
originally	O
attributed	O
to	O
hypoaldosteronism	O
and	O
Type	O
IV	O
RTA	O
,	O
but	O
unlikely	O
per	O
endocrine	O
because	O
of	O
low	O
urine	O
sodium	O
.	O
.	O
#	O
.	O
SVC	O
syndrome	O
:	O
Incomplete	O
occlusion	O
of	O
SVC	O
;	O
near	O
complete	O
occlusion	O
of	O
brachiocephalic	O
veins	O
.	O
Clinically	O
identified	O
by	O
upper	O
extremity	O
and	O
facial	O
swelling	O
/	O
plethora	O
and	O
mottled	O
skin	O
.	O
Also	O
with	O
scleral	O
edema	O
.	O
Unable	O
to	O
assess	O
jugular	O
venous	O
distension	O
given	O
considerable	O
swelling	O
.	O
Seen	O
in	O
appoximately	O
10	O
%	O
cases	O
of	O
SSLC	O
.	O
Improved	O
edema	O
on	O
exam	O
compared	O
to	O
admission	O
.	O
SVC	O
syndrome	O
occurred	O
after	O
Y	O
-	O
stent	O
placed	O
.	O
Possible	O
that	O
tumor	O
pushing	O
into	O
trachea	O
shifted	O
to	O
compress	O
SVC	O
after	O
stent	O
placement	O
.	O
She	O
underwent	O
radiation	O
therapy	O
and	O
chemotherapy	I-Drug
for	O
decompression	I-Reason
.	O
.	O
#	O
.	O
Pleural	O
effusion	O
:	O
s	O
/	O
p	O
right	O
pigtail	O
catheter	O
placement	O
[	O
**	O
2172-8-25	O
**	O
]	O
,	O
removed	O
[	O
**	O
2172-8-31	O
**	O
]	O
.	O
LDH	O
effusion	O
/	O
serum	O
0.68	O
(	O
exudate	O
by	O
Light	O
??????	O
s	O
criteria	O
)	O
.	O
Greatest	O
concern	O
for	O
malignant	O
effusion	O
however	O
cytology	O
was	O
nonspecific	O
.	O
Cultures	O
of	O
fluid	O
all	O
preliminary	O
negative	O
.	O
.	O
#	O
.	O
Pneumothorax	O
:	O
Developed	O
pneumothorax	O
in	O
setting	O
of	O
re-intubation	O
that	O
resolved	O
after	O
chest	O
tube	O
placement	O
.	O
.	O
#	O
.	O
Pericardial	O
effusion	O
:	O
Suspected	O
by	O
cardiology	O
to	O
be	O
malignant	O
effusion	O
.	O
Felt	O
not	O
to	O
be	O
large	O
enough	O
for	O
percutaneous	O
drainage	O
.	O
EKG	O
without	O
signs	O
of	O
electrical	O
alternans	O
but	O
does	O
have	O
low	O
voltages	O
.	O
Repeat	O
ECHO	O
done	O
[	O
**	O
2172-9-5	O
**	O
]	O
in	O
setting	O
of	O
hypotension	O
demonstrated	O
no	O
change	O
in	O
pericardial	O
effusion	O
.	O
.	O
#	O
Sinus	O
Pause	O
on	O
telemetry	O
:	O
Pt	O
had	O
episodes	O
of	O
sinus	O
pauses	O
on	O
tele	O
night	O
of	O
[	O
**	O
8	O
-	O
30	O
**	O
]	O
with	O
turning	O
to	O
right	O
side	O
.	O
Occurred	O
again	O
[	O
**	O
2172-9-4	O
**	O
]	O
again	O
with	O
re-positioning	O
.	O
Metoprolol	I-Drug
was	O
held	O
and	O
glucagon	I-Drug
given	O
in	O
case	O
this	O
was	O
due	O
to	O
beta	B-Ade
blocker	I-Ade
toxicity	I-Ade
,	O
but	O
pauses	O
decreased	O
in	O
frequency	O
and	O
duration	O
on	O
their	O
own	O
without	O
intervention	O
.	O
Cardiology	O
consulted	O
who	O
felt	O
it	O
was	O
vagally	O
mediated	O
.	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
have	O
been	O
due	O
to	O
ETT	O
tube	O
displacement	O
pressing	O
on	O
carotid	O
when	O
pt	O
was	O
turned	O
.	O
.	O
#	O
Leukopenia	I-Ade
/	O
thrombocytopenia	I-Ade
??????	O
Most	O
likely	O
due	O
to	O
chemotherapy	I-Drug
and	O
no	O
improvement	O
in	O
counts	O
on	O
neupogen	I-Drug
.	O
She	O
was	O
repeatedly	O
pan-cultured	O
with	O
negative	O
results	O
.	O
.	O
#	O
.	O
Anemia	O
:	O
Normocytic	O
and	O
likely	O
due	O
to	O
anemia	O
of	O
chronic	O
disease	O
given	O
malignancy	O
.	O
Hemolysis	O
labs	O
were	O
negative	O
.	O
.	O
#	O
s	O
/	O
p	O
cerebral	O
aneurysm	O
repair	O
:	O
History	O
of	O
cerebral	O
aneurysm	O
repair	O
with	O
a	O
number	O
of	O
chronic	O
changes	O
on	O
head	O
CT.	O
.	O
Her	O
antiepileptic	B-Drug
medications	I-Drug
were	O
continued	O
.	O
Medications	O
on	O
Admission	O
:	O
Home	O
medications	O
:	O
Metoprolol	I-Drug
Omeprazole	I-Drug
Levetiracetam	I-Drug
Carbatrol	I-Drug
Medications	O
on	O
transfer	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
[	O
**	O
2172-8-27	O
**	O
]	O
:	O
Furosemide	I-Drug
10	O
mg	O
IV	O
ONCE	O
Duration	O
:	O
1	O
Doses	O
Carbamazepine	I-Drug
900	O
mg	O
PO	O
QPM	O
Carbamazepine	I-Drug
400	O
mg	O
PO	O
QAM	O
Artificial	B-Drug
Tears	I-Drug
Preserv	I-Drug
.	I-Drug
Free	I-Drug
1	O
-	O
2	O
DROP	O
BOTH	O
EYES	O
PRN	O
dry	B-Reason
eyes	I-Reason
Potassium	B-Drug
Phosphate	I-Drug
IV	O
Sliding	O
Scale	O
Insulin	I-Drug
SC	O
Sliding	O
Scale	O
Insulin	B-Drug
Regular	I-Drug
10	O
UNIT	O
IV	O
ONCE	O
,	O
Dextrose	I-Drug
50	O
%	O
25	O
gm	O
IV	O
ONCE	O
Duration	O
:	O
1	O
Doses	O
08/20	O
@	O
0608	O
Propofol	I-Drug
20	O
-	O
50	O
mcg	O
/	O
kg	O
/	O
min	O
IV	O
DRIP	O
TITRATE	O
TO	O
moderate	B-Reason
/	I-Reason
heavy	I-Reason
sedation	O
Chlorhexidine	B-Drug
Gluconate	I-Drug
0.12	O
%	O
Oral	O
Rinse	O
15	O
mL	O
ORAL	O
[	O
**	O
Hospital1	O
**	O
]	O
Hydrocortisone	I-Drug
Na	O
Succ	O
.	O
100	O
mg	O
IV	O
Q8H	O
Nicotine	I-Drug
Patch	O
14	O
mg	O
TD	O
DAILY	O
LeVETiracetam	I-Drug
500	O
mg	O
IV	O
BID	O
Magnesium	B-Drug
Sulfate	I-Drug
IV	O
Sliding	O
Scale	O
Calcium	B-Drug
Gluconate	I-Drug
IV	O
Sliding	O
Scale	O
Potassium	B-Drug
Chloride	I-Drug
IV	O
Sliding	O
Scale	O
Albuterol	B-Drug
-	I-Drug
Ipratropium	I-Drug
[	O
**	O
1	O
-	O
10	O
**	O
]	O
PUFF	O
IH	O
Q6H	O
Pantoprazole	I-Drug
40	O
mg	O
IV	O
Q24H	O
Heparin	I-Drug
5000	O
UNIT	O
SC	O
TID	O
Fentanyl	B-Drug
Citrate	I-Drug
25	O
-	O
100	O
mcg	O
IV	O
Q6H	O
:	O
PRN	O
Sedation	I-Reason
Discharge	O
Medications	O
:	O
Expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Expired	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
Expired	O
Followup	O
Instructions	O
:	O
Expired	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2437	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
2438	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2153-5-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2153-5-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2116-6-9	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Erythromycin	I-Drug
/	O
Latex	O
/	O
Bactrim	I-Drug
/	O
Penicillins	I-Drug
/	O
Adhesive	O
Bandage	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
668	O
**	O
]	O
Chief	O
Complaint	O
:	O
fevers	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
sigmoidoscopy	O
[	O
**	O
2153-5-10	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
36f	O
s	O
/	O
p	O
pancreas	O
transplant	O
[	O
**	O
2	O
-	O
13	O
**	O
]	O
notes	O
3	O
weeks	O
of	O
loose	O
,	O
watery	O
stools	O
,	O
food	O
and	O
medication	O
intolerance	O
,	O
and	O
,	O
more	O
recently	O
,	O
BRBPR	O
.	O
She	O
presented	O
today	O
to	O
Dr	O
[	O
**	O
Name	O
(	O
NI	O
)	O
8584	O
**	O
]	O
clinic	O
,	O
at	O
which	O
time	O
she	O
was	O
noted	O
to	O
be	O
pale	O
,	O
hypotensive	O
to	O
the	O
80's	O
,	O
tachycardic	O
,	O
and	O
feeling	O
very	O
week	O
.	O
She	O
was	O
directly	O
sent	O
to	O
the	O
ER	O
for	O
further	O
evaluation	O
.	O
Here	O
she	O
notes	O
no	O
abdominal	O
pain	O
,	O
recent	O
melena	O
,	O
no	O
further	O
continued	O
vomiting	O
,	O
no	O
fevers	O
,	O
chills	O
or	O
other	O
constitutional	O
symptoms	O
.	O
She	O
appears	O
with	O
substantial	O
pallor	O
,	O
poor	O
skin	O
turgor	O
,	O
dry	O
eyes	O
and	O
mucous	O
membranes	O
,	O
and	O
states	O
that	O
she	O
feels	O
exhausted	O
.	O
Additionally	O
,	O
she	O
is	O
neutropenic	O
,	O
acidotic	O
with	O
a	O
HCO3	O
of	O
9	O
,	O
and	O
anemic	O
--	O
these	O
laboratory	O
values	O
are	O
all	O
substantial	O
deviations	O
from	O
her	O
prior	O
baseline	O
.	O
Also	O
,	O
her	O
blood	O
sugars	O
have	O
been	O
noted	O
by	O
the	O
patient	O
as	O
being	O
in	O
the	O
170s	O
,	O
fasting	O
,	O
but	O
she	O
is	O
found	O
to	O
have	O
a	O
quick	O
-	O
fingerstick	O
of	O
142	O
and	O
a	O
chemistry	O
-	O
glucose	O
of	O
157	O
.	O
Past	O
Medical	O
History	O
:	O
DM1	O
,	O
hyperlipidemia	O
,	O
exploratory	O
laparotomy	O
for	O
endometriosis	O
,	O
C	O
-	O
section	O
,	O
left	O
frozen	O
shoulder	O
s	O
/	O
p	O
multiple	O
surgeries	O
,	O
and	O
migraines	O
.	O
Social	O
History	O
:	O
Denies	O
ETOH	O
,	O
smoking	O
,	O
recreational	O
drugs	O
.	O
Currently	O
on	O
disability	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
her	O
left	O
shoulder	O
pain	O
.	O
Family	O
History	O
:	O
Significant	O
for	O
diabetes	O
.	O
Father	O
had	O
melanoma	O
.	O
Physical	O
Exam	O
:	O
Physical	O
exam	O
on	O
discharge	O
:	O
AF	O
,	O
VSS	O
General	O
:	O
NAD	O
,	O
alert	O
and	O
oriented	O
x	O
3	O
CV	O
:	O
RRR	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
Pulm	O
:	O
CTAB	O
,	O
no	O
rales	O
/	O
rhonchi	O
/	O
wheezes	O
Abd	O
:	O
soft	O
,	O
non-distended	O
,	O
mild	O
tenderness	O
to	O
palpation	O
in	O
RLQ	O
.	O
Well	O
-	O
healed	O
vertical	O
midline	O
incision	O
.	O
Ext	O
:	O
wwp	O
,	O
no	O
edema	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
WBC	O
-	O
0.6	O
*	O
#	O
RBC	O
-	O
4.25	O
Hgb	O
-	O
12.3	O
Hct	O
-	O
36.8	O
MCV	O
-	O
87	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
33.5	O
RDW	O
-	O
13.6	O
Plt	O
Ct	O
-	O
358	O
[	O
**	O
2153-5-3	O
**	O
]	O
01:10	O
PM	O
BLOOD	O
Neuts	O
-	O
91	O
*	O
Bands	O
-	O
1	O
Lymphs	O
-	O
4	O
*	O
Monos	O
-	O
3	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
1	O
*	O
Myelos	O
-	O
0	O
[	O
**	O
2153-5-3	O
**	O
]	O
01:10	O
PM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
NORMAL	O
Poiklo	O
-	O
1	O
+	O
Macrocy	O
-	O
NORMAL	O
Microcy	O
-	O
NORMAL	O
Polychr	O
-	O
NORMAL	O
Ovalocy	O
-	O
1	O
+	O
Burr	O
-	O
OCCASIONAL	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
358	O
[	O
**	O
2153-5-3	O
**	O
]	O
01:10	O
PM	O
BLOOD	O
PT	O
-	O
14.0	O
*	O
PTT	O
-	O
29.4	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2153-5-3	O
**	O
]	O
01:10	O
PM	O
BLOOD	O
Plt	O
Smr	O
-	O
NORMAL	O
Plt	O
Ct	O
-	O
277	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
UreaN	O
-	O
87	O
*	O
Creat	O
-	O
5.7	O
*	O
#	O
Na	O
-	O
131	O
*	O
K	O
-	O
4.1	O
Cl	O
-	O
98	O
HCO3	O
-	O
14	O
*	O
AnGap	O
-	O
23	O
*	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
Glucose	O
-	O
190	O
*	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
ALT	O
-	O
12	O
AST	O
-	O
24	O
Amylase	O
-	O
123	O
*	O
TotBili	O
-	O
0.3	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
Lipase	O
-	O
62	O
*	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
Albumin	O
-	O
4.6	O
Calcium	O
-	O
9.8	O
Phos	O
-	O
7.0	O
*	O
#	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
%	O
HbA1c	O
-	O
4.8	O
eAG	O
-	O
91	O
[	O
**	O
2153-5-3	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
tacroFK	O
-	O
GREATER	O
TH	O
[	O
**	O
2153-5-3	O
**	O
]	O
04:55	O
PM	O
BLOOD	O
Type	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
pO2	O
-	O
49	O
*	O
pCO2	O
-	O
32	O
*	O
pH	O
-	O
7.24	O
*	O
calTCO2	O
-	O
14	O
*	O
Base	O
XS	O
--	O
12	O
Comment	O
-	O
GREEN	O
TOP	O
[	O
**	O
2153-5-3	O
**	O
]	O
01:17	O
PM	O
BLOOD	O
Lactate	O
-	O
1.3	O
K	O
-	O
3.7	O
[	O
**	O
2153-5-3	O
**	O
]	O
01:17	O
PM	O
BLOOD	O
Hgb	O
-	O
10.8	O
*	O
calcHCT	O
-	O
32	O
Discharge	O
labs	O
:	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
WBC	O
-	O
4.6	O
RBC	O
-	O
3.32	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
28.0	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
28.5	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
168	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
168	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Glucose	O
-	O
103	O
*	O
UreaN	O
-	O
2	O
*	O
Creat	O
-	O
0.8	O
Na	O
-	O
140	O
K	O
-	O
4.5	O
Cl	O
-	O
114	O
*	O
HCO3	O
-	O
23	O
AnGap	O
-	O
8	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Amylase	O
-	O
55	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Lipase	O
-	O
14	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Calcium	O
-	O
7.5	O
*	O
Phos	O
-	O
2.9	O
Mg	O
-	O
1.5	O
*	O
[	O
**	O
2153-5-11	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
tacroFK	O
-	O
8.7	O
Micro	O
:	O
[	O
**	O
2153-5-3	O
**	O
]	O
:	O
BLOOD	O
/	O
FUNGAL	O
CULTURE	O
(	O
Final	O
[	O
**	O
2153-5-7	O
**	O
]	O
)	O
:	O
DUE	O
TO	O
OVERGROWTH	O
OF	O
BACTERIA	O
,	O
.	O
UNABLE	O
TO	O
CONTINUE	O
MONITORING	O
FOR	O
FUNGUS	O
.	O
CORYNEBACTERIUM	O
SPECIES	O
(	O
DIPHTHEROIDS	O
)	O
.	O
ISOLATED	O
FROM	O
ONE	O
SET	O
ONLY	O
.	O
BLOOD	O
/	O
AFB	O
CULTURE	O
(	O
Final	O
[	O
**	O
2153-5-6	O
**	O
]	O
)	O
:	O
DUE	O
TO	O
OVERGROWTH	O
OF	O
BACTERIA	O
,	O
.	O
UNABLE	O
TO	O
CONTINUE	O
MONITORING	O
FOR	O
AFB	O
.	O
Myco	O
-	O
F	O
Bottle	O
Gram	O
Stain	O
(	O
Final	O
[	O
**	O
2153-5-5	O
**	O
]	O
)	O
:	O
GRAM	O
POSITIVE	O
ROD	O
(	O
S	O
)	O
CONSISTENT	O
WITH	O
CORYNEBACTERIUM	O
OR	O
PROPIONIBACTERIUM	O
SPECIES	O
.	O
REPORTED	O
BY	O
PHONE	O
TO	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
9604	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
41183	O
**	O
]	O
AT	O
2103	O
ON	O
[	O
**	O
2153-5-5	O
**	O
]	O
.	O
[	O
**	O
2153-5-3	O
**	O
]	O
5:30	O
pm	O
MRSA	O
SCREEN	O
Source	O
:	O
Nasal	O
swab	O
.	O
MRSA	O
SCREEN	O
(	O
Final	O
[	O
**	O
2153-5-5	O
**	O
]	O
)	O
:	O
POSITIVE	O
FOR	O
METHICILLIN	O
RESISTANT	O
STAPH	O
AUREUS	O
.	O
[	O
**	O
2153-5-10	O
**	O
]	O
11:47	O
am	O
BIOPSY	O
Site	O
:	O
COLON	O
VIRAL	O
CULTURE	O
:	O
R	O
/	O
O	O
CYTOMEGALOVIRUS	O
(	O
Preliminary	O
)	O
:	O
No	O
Virus	O
isolated	O
so	O
far	O
.	O
Fecal	O
culture	O
negative	O
x	O
2	O
,	O
ova	O
and	O
parasites	O
negative	O
x	O
3	O
.	O
Blood	O
cultures	O
negative	O
x	O
2	O
,	O
urine	O
culture	O
negative	O
x	O
1	O
.	O
All	O
other	O
cultures	O
negative	O
or	O
pending	O
.	O
Please	O
refer	O
to	O
the	O
online	O
medical	O
record	O
for	O
details	O
.	O
Brief	O
Hospital	O
Course	O
:	O
36	O
y	O
/	O
o	O
female	O
aditted	O
through	O
the	O
ED	O
with	O
loose	O
stools	O
and	O
most	O
recently	O
BRBPR	O
.	O
She	O
was	O
admitted	O
directly	O
from	O
the	O
ED	O
to	O
the	O
SICU	O
.	O
A	O
CT	O
was	O
obtained	O
but	O
without	O
contrast	O
there	O
was	O
no	O
large	O
fluid	O
collection	O
or	O
hematoma	O
visualized	O
.	O
The	O
assessment	O
of	O
the	O
pancreatic	O
transplant	O
is	O
limited	O
;	O
however	O
,	O
there	O
are	O
no	O
gross	O
fluid	O
collections	O
or	O
inflammatory	O
changes	O
present	O
.	O
Also	O
seen	O
is	O
abdominal	O
rectus	O
diastasis	O
with	O
paraumbilical	O
hernia	O
containing	O
a	O
single	O
loop	O
of	O
herniated	O
bowel	O
,	O
with	O
no	O
evidence	O
of	O
bowel	O
obstruction	O
.	O
She	O
received	O
large	O
volume	O
resuscitation	O
,	O
and	O
2	O
units	O
of	O
RBC	B-Drug
's	I-Drug
on	O
[	O
**	O
5	O
-	O
3	O
**	O
]	O
for	O
hct	O
21	O
%	O
and	O
then	O
2	O
units	O
RBCs	I-Drug
on	O
[	O
**	O
5	O
-	O
4	O
**	O
]	O
for	O
26	O
%	O
.	O
Following	O
these	O
transfusions	O
her	O
hematocrit	O
remained	O
stable	O
and	O
the	O
rectal	O
bleeding	O
had	O
ceased	O
.	O
On	O
[	O
**	O
5	O
-	O
4	O
**	O
]	O
a	O
tagged	O
Red	O
cell	O
scan	O
was	O
performed	O
,	O
and	O
this	O
did	O
not	O
show	O
evidence	O
of	O
active	O
bleeding	O
.	O
Blood	O
cultures	O
collected	O
on	O
admission	O
and	O
then	O
during	O
the	O
hospitalization	O
were	O
all	O
negative	O
.	O
CMV	O
viral	O
load	O
and	O
CMV	O
antibody	O
are	O
both	O
negative	O
.	O
Stool	O
culture	O
,	O
O&P	O
and	O
C	O
diff	O
x	O
3	O
were	O
collected	O
and	O
were	O
all	O
negative	O
.	O
The	O
patient	O
continued	O
to	O
have	O
multiple	O
loose	O
stools	O
.	O
She	O
was	O
consulted	O
to	O
the	O
GI	O
service	O
who	O
performed	O
a	O
colonoscopy	O
.	O
The	O
results	O
were	O
:	O
Normal	O
mucosa	O
in	O
the	O
colon	O
and	O
terminal	O
ileum	O
with	O
cold	O
forceps	O
biopsies	O
taken	O
wich	O
were	O
not	O
finalized	O
at	O
discharge	O
.	O
She	O
also	O
had	O
Grade	O
3	O
internal	O
hemorrhoids	O
Otherwise	O
normal	O
colonoscopy	O
to	O
terminal	O
ileum	O
.	O
She	O
was	O
started	O
on	O
immodium	O
which	O
helped	O
decrease	O
number	O
of	O
stools	O
.	O
Immunosuppression	I-Reason
was	O
changed	O
during	O
this	O
hopsitalization	O
.	O
She	O
was	O
discontinued	O
off	O
Cellcept	I-Drug
,	O
and	O
after	O
a	O
few	O
days	O
of	O
monotherapy	O
on	O
Prograf	I-Drug
,	O
she	O
was	O
started	O
on	O
imuran	I-Drug
,	O
for	O
which	O
she	O
received	O
a	O
script	O
for	O
home	O
.	O
She	O
was	O
taken	O
off	O
valcyte	I-Drug
after	O
it	O
was	O
determined	O
her	O
CMV	O
status	O
was	O
negative	O
,	O
and	O
she	O
is	O
out	O
approximately	O
3	O
months	O
from	O
transplant	O
.	O
ID	O
consult	O
had	O
been	O
obtained	O
early	O
in	O
hospital	O
course	O
.	O
They	O
followed	O
with	O
antibiotic	I-Drug
recommendations	O
,	O
and	O
suggestions	O
regarding	O
neutropenia	O
.	O
She	O
was	O
initially	O
covered	O
with	O
Levaquin	I-Drug
,	O
Vanco	I-Drug
and	O
Flagyl	I-Drug
,	O
this	O
was	O
eventually	O
trimmed	O
to	O
Flagyl	I-Drug
only	O
and	O
then	O
no	O
antibiotics	I-Drug
for	O
home	O
were	O
recommended	O
.	O
She	O
was	O
also	O
profoundly	O
neutropenic	O
,	O
and	O
part	O
of	O
adjusting	O
medications	O
was	O
goal	O
of	O
increasing	O
WBCs	O
as	O
well	O
as	O
7	O
days	O
of	O
Filgrastim	I-Drug
.	O
WBC	O
nadir	O
was	O
0.2	O
.	O
Upon	O
discharge	O
her	O
stools	O
had	O
been	O
mnimized	O
,	O
immunosuppression	O
was	O
adjusted	O
and	O
she	O
was	O
tolerating	O
diet	O
.	O
She	O
has	O
also	O
been	O
followed	O
by	O
social	O
work	O
who	O
will	O
also	O
be	O
following	O
her	O
as	O
an	O
outpatient	O
due	O
to	O
concerns	O
that	O
she	O
needs	O
encouragement	O
to	O
call	O
earlier	O
when	O
not	O
feeling	O
well	O
.	O
Medications	O
on	O
Admission	O
:	O
FAMOTIDINE	I-Drug
-	O
20	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
FEXOFENADINE	I-Drug
[	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
]	O
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
180	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
METOCLOPRAMIDE	B-Drug
[	I-Drug
REGLAN	I-Drug
]	O
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
5	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
three	O
times	O
a	O
day	O
MYCOPHENOLATE	B-Drug
MOFETIL	I-Drug
-	O
500	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
four	O
times	O
a	O
day	O
PENTAMIDINE	B-Drug
[	I-Drug
NEBUPENT	I-Drug
]	O
-	O
300	O
mg	O
Recon	O
Soln	O
-	O
300	O
mg	O
ih	O
monthly	O
dilute	O
in	O
6	O
ml	O
of	O
sterile	B-Drug
water	I-Drug
SODIUM	B-Drug
POLYSTYRENE	I-Drug
SULFONATE	I-Drug
-	O
Powder	O
-	O
Take	O
15	O
gms	O
as	O
directed	O
prn	O
for	O
high	B-Reason
k	I-Reason
dispense	O
464	O
gms	O
TACROLIMUS	I-Drug
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
1	O
mg	O
Capsule	O
-	O
3	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
take	O
up	O
to	O
4	O
capsules	O
[	O
**	O
Hospital1	O
**	O
]	O
TACROLIMUS	I-Drug
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
0.5	O
mg	O
Capsule	O
-	O
1	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
VALGANCICLOVIR	B-Drug
[	I-Drug
VALCYTE	I-Drug
]	O
-	O
450	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
Discharge	O
Medications	O
:	O
1	O
.	O
Famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
2	O
.	O
Fexofenadine	I-Drug
180	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
Metoclopramide	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
4	O
.	O
Pentamidine	I-Drug
300	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
inhalation	O
Inhalation	O
once	O
a	O
month	O
.	O
5	O
.	O
Tacrolimus	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Capsule	O
PO	O
every	O
twelve	O
(	O
12	O
)	O
hours	O
:	O
Please	O
have	O
your	O
tacrolimus	I-Drug
levels	O
drawn	O
weekly	O
and	O
follow	O
up	O
for	O
dose	O
changes	O
.	O
6	O
.	O
Azathioprine	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Myfortic	I-Drug
Oral	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Dehydration	O
Diarrhea	O
fever	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Please	O
have	O
your	O
tacrolimus	I-Drug
levels	O
drawn	O
weekly	O
and	O
follow	O
up	O
for	O
dosage	O
changes	O
.	O
Please	O
call	O
the	O
Transplant	O
office	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
41184	O
**	O
]	O
if	O
you	O
experience	O
any	O
of	O
the	O
warning	O
signs	O
listed	O
below	O
:	O
*	O
You	O
experience	O
new	O
chest	O
pain	O
,	O
pressure	O
,	O
squeezing	O
or	O
tightness	O
.	O
*	O
New	O
or	O
worsening	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheeze	O
.	O
*	O
If	O
you	O
are	O
vomiting	O
and	O
can	O
not	O
keep	O
down	O
fluids	O
or	O
your	O
medications	O
.	O
*	O
You	O
are	O
getting	O
dehydrated	O
due	O
to	O
continued	O
vomiting	O
,	O
diarrhea	O
,	O
or	O
other	O
reasons	O
.	O
Signs	O
of	O
dehydration	O
include	O
dry	O
mouth	O
,	O
rapid	O
heartbeat	O
,	O
or	O
feeling	O
dizzy	O
or	O
faint	O
when	O
standing	O
.	O
*	O
You	O
see	O
blood	O
or	O
dark	O
/	O
black	O
material	O
when	O
you	O
vomit	O
or	O
have	O
a	O
bowel	O
movement	O
.	O
*	O
You	O
experience	O
burning	O
when	O
you	O
urinate	O
,	O
have	O
blood	O
in	O
your	O
urine	O
,	O
or	O
experience	O
a	O
discharge	O
.	O
*	O
You	O
have	O
shaking	O
chills	O
,	O
or	O
fever	O
greater	O
than	O
101.5	O
degrees	O
Fahrenheit	O
or	O
38	O
degrees	O
Celsius	O
.	O
*	O
Any	O
change	O
in	O
your	O
symptoms	O
,	O
or	O
any	O
new	O
symptoms	O
that	O
concern	O
you	O
.	O
Please	O
resume	O
all	O
regular	O
home	O
medications	O
except	O
for	O
cellcept	I-Drug
and	O
valcyte	I-Drug
.	O
Also	O
,	O
please	O
take	O
any	O
new	O
medications	O
as	O
prescribed	O
.	O
Please	O
get	O
plenty	O
of	O
rest	O
,	O
continue	O
to	O
ambulate	O
several	O
times	O
per	O
day	O
,	O
and	O
drink	O
enough	O
fluid	O
to	O
keep	O
your	O
urine	O
pale	O
yellow	O
Followup	O
Instructions	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
[	O
**	O
2153-5-18	O
**	O
]	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
971	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
970	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2153-6-8	O
**	O
]	O
9:50	O
Completed	O
by	O
:[	O
**	O
2153-5-14	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2196-1-28	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2196-2-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2148-11-11	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1257	O
**	O
]	O
Chief	O
Complaint	O
:	O
Pericardial	O
effusion	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
vagus	O
nerve	O
stimulator	O
generator	O
replacement	O
[	O
**	O
2196-1-28	O
**	O
]	O
pericardiocentesis	O
with	O
pericardial	O
drain	O
[	O
**	O
2196-1-29	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
Please	O
see	O
original	O
Neurology	O
Admission	O
Note	O
and	O
MICU	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Transfer	O
Note	O
for	O
details	O
.	O
.	O
Briefly	O
,	O
47	O
y	O
/	O
o	O
man	O
with	O
long	O
standing	O
history	O
of	O
epilepsy	O
s	O
/	O
p	O
right	O
temporal	O
lobectomy	O
(	O
at	O
age	O
19	O
)	O
and	O
VNS	O
placement	O
(	O
7	O
years	O
ago	O
)	O
,	O
h	O
/	O
o	O
EtOH	B-Reason
and	I-Reason
cocaine	I-Reason
abuse	I-Reason
who	O
was	O
having	O
increased	O
seizure	O
frequency	O
in	O
the	O
setting	O
of	O
VNS	O
malfunction	O
.	O
He	O
was	O
admitted	O
on	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
for	O
elective	O
replacement	O
of	O
the	O
vagus	O
nerve	O
stimulator	O
generator	O
.	O
The	O
procedure	O
went	O
without	O
complication	O
.	O
Overnight	O
he	O
developed	O
AF	O
with	O
RVR	O
to	O
the	O
180s	O
with	O
hypotension	O
to	O
the	O
80s	O
.	O
CIWA	O
was	O
17	O
with	O
last	O
drink	O
approximately	O
72	O
hours	O
prior	O
.	O
Patient	O
was	O
also	O
noted	O
to	O
be	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
with	O
a	O
CIWA	O
of	O
17	O
and	O
is	O
thought	O
that	O
last	O
EtOH	O
drink	O
was	O
72	O
hours	O
ago	O
.	O
He	O
received	O
2	O
mg	O
IV	O
ativan	I-Drug
with	O
somnolence	I-Ade
and	O
apenea	I-Ade
afterwards	O
.	O
He	O
was	O
subsequently	O
transferred	O
to	O
the	O
MICU	O
.	O
.	O
His	O
MICU	O
course	O
was	O
notable	O
for	O
an	O
echocardiogram	O
which	O
showed	O
a	O
large	O
pericardial	O
effusion	O
on	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
.	O
He	O
was	O
seen	O
by	O
the	O
cardiology	O
fellow	O
and	O
subsequently	O
underwent	O
pericardial	O
window	O
.	O
450cc	O
of	O
bloody	O
pericardial	O
fluid	O
was	O
drained	O
.	O
Patient	O
developed	O
SVT	I-Reason
in	O
the	O
cath	O
lab	O
and	O
was	O
treated	O
with	O
9	O
mg	O
IV	O
metoprolol	I-Drug
.	O
He	O
was	O
transferred	O
to	O
CCU	O
postprocedurally	O
for	O
monitoring	O
.	O
.	O
On	O
arrival	O
,	O
patient	O
complained	O
of	O
spinal	O
back	O
pain	O
from	O
lying	O
on	O
the	O
operating	O
table	O
.	O
He	O
also	O
reports	O
that	O
his	O
lungs	O
feel	O
"	O
collapsed	O
"	O
but	O
denied	O
shortness	O
of	O
breath	O
.	O
.	O
Review	O
of	O
systems	O
was	O
otherwise	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
epilepsy	O
and	O
nonelectrographic	O
seizures	O
(	O
petite	O
mal	O
with	O
rare	O
secondary	O
generalization	O
)	O
-	O
s	O
/	O
p	O
right	O
temporal	O
lobectomy	O
-	O
s	O
/	O
p	O
VNS	O
placement	O
-	O
Mood	O
disorder	O
and	O
likely	O
borderline	O
personality	O
organization	O
-	O
Multiple	O
suicide	O
attempts	O
in	O
past	O
(	O
largely	O
overdose	O
)	O
-	O
DM	O
due	O
to	O
medication	O
,	O
now	O
apparently	O
resolved	O
-	O
cervical	O
strain	O
-	O
Rosacea	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
865	O
**	O
]	O
esophagus	O
-	O
Polysubstance	O
abuse	O
:	O
EtOH	O
,	O
MJ	O
,	O
cocaine	O
/	O
crack	O
binges	O
with	O
resultant	O
unsafe	O
sexual	O
practices	O
-	O
h	O
/	O
o	O
atrial	O
fibrillation	O
(	O
not	O
on	O
medication	O
)	O
Social	O
History	O
:	O
Unemployed	O
,	O
lives	O
alone	O
.	O
Smokes	O
1pk	O
/	O
day	O
,	O
occasional	O
ETOH	O
and	O
OMR	O
records	O
indicate	O
some	O
history	O
of	O
Crack	O
Cocaine	O
use	O
.	O
Family	O
History	O
:	O
States	O
has	O
FH	O
of	O
diabetes	O
and	O
'	O
cancer	O
in	O
everyone	O
'	O
but	O
no	O
FH	O
of	O
CAD	O
,	O
HTN	O
,	O
sudden	O
death	O
or	O
cardiac	O
dysrhythmias	O
Physical	O
Exam	O
:	O
ON	O
TRANSFER	O
TO	O
CCU	O
:	O
VS	O
:	O
HR	O
:	O
90	O
BP	O
:	O
128/82	O
O2sat	B-Drug
:	O
93	O
%	O
2L	O
(	O
NC	O
)	O
GEN	O
:	O
agitated	O
,	O
in	O
fetal	O
position	O
,	O
not	O
tachypneic	O
HEENT	O
:	O
PERRL	O
.	O
MM	O
dry	O
.	O
NECK	O
:	O
neck	O
supple	O
.	O
Left	O
neck	O
dressing	O
with	O
dried	O
blood	O
.	O
No	O
active	O
bleeding	O
or	O
discharge	O
.	O
Mild	O
tenderness	O
on	O
palpation	O
.	O
PULM	O
:	O
Moving	O
air	O
appropriately	O
,	O
diffuse	O
crackles	O
.	O
Left	O
upper	O
chest	O
(	O
VNS	O
)	O
site	O
c	O
/	O
d	O
/	O
i.	O
CARD	O
:	O
Soft	O
heart	O
sound	O
,	O
RRR	O
,	O
s1	O
/	O
s2	O
present	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
,	O
with	O
pericardial	O
window	O
draining	O
frank	O
blood	O
ABD	O
:	O
+	O
bs	O
,	O
soft	O
,	O
NT	O
/	O
ND	O
EXT	O
:	O
wwp	O
,	O
no	O
edema	O
,	O
2	O
+	O
PD	O
bilaterally	O
SKIN	O
:	O
warm	O
BACK	O
:	O
tenderness	O
to	O
palpation	O
along	O
the	O
spine	O
NEURO	O
:	O
AOx3	O
,	O
agitated	O
,	O
but	O
agreeable	O
.	O
On	O
discharge	O
:	O
VS	O
:	O
96.6	O
118/62	O
(	O
94-130/64	O
-	O
90	O
)	O
64	O
16	O
97	O
%	O
RA	O
Tele	O
:	O
HR	O
in	O
160s	O
yesterday	O
afternoon	O
,	O
otherwise	O
60s	O
,	O
sinus	O
this	O
morning	O
,	O
short	O
runs	O
of	O
SVT	O
to	O
130s	O
<	O
30	O
seconds	O
GEN	O
:	O
AOx3	O
,	O
NAD	O
HEENT	O
:	O
PERRLA	O
,	O
MMM	O
NECK	O
:	O
neck	O
supple	O
PULM	O
:	O
CTAB	O
CARD	O
:	O
RRR	O
,	O
normal	O
s1	O
/	O
s2	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
ABD	O
:	O
soft	O
,	O
nontender	O
,	O
nondistended	O
EXT	O
:	O
wwp	O
no	O
edema	O
.	O
L	O
calf	O
TTP	O
,	O
no	O
swelling	O
or	O
cords	O
noted	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
.	O
[	O
**	O
2196-1-28	O
**	O
]	O
07:11	O
PM	O
BLOOD	O
WBC	O
-	O
9.3	O
#	O
RBC	O
-	O
4.12	O
*	O
Hgb	O
-	O
13.3	O
*	O
Hct	O
-	O
40.2	O
MCV	O
-	O
98	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
14.2	O
Plt	O
Ct	O
-	O
189	O
[	O
**	O
2196-1-28	O
**	O
]	O
07:11	O
PM	O
BLOOD	O
Glucose	O
-	O
115	O
*	O
UreaN	O
-	O
25	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
138	O
K	O
-	O
4.4	O
Cl	O
-	O
102	O
HCO3	O
-	O
27	O
AnGap	O
-	O
13	O
[	O
**	O
2196-1-28	O
**	O
]	O
07:11	O
PM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
4.7	O
*	O
Mg	O
-	O
2.2	O
[	O
**	O
2196-1-29	O
**	O
]	O
06:27	O
AM	O
BLOOD	O
T4	O
-	O
4.7	O
[	O
**	O
2196-1-29	O
**	O
]	O
06:27	O
AM	O
BLOOD	O
TSH	O
-	O
5.8	O
*	O
CARDIAC	O
BIOMARKERS	O
.	O
[	O
**	O
2196-1-29	O
**	O
]	O
05:55	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
2	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2196-1-29	O
**	O
]	O
06:27	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
2	O
cTropnT	O
-	O
<	O
0.01	O
.	O
MICRO	O
:	O
.	O
-	O
Urine	O
cx	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
:	O
neg	O
-	O
Pericardial	O
fluid	O
culture	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
:	O
NGTD	O
,	O
but	O
pending	O
as	O
of	O
transfer	O
to	O
MICU	O
-	O
Pericardial	O
fluid	O
cytology	O
:	O
PND	O
STUDIES	O
:	O
.	O
ECHO	O
[	O
**	O
2196-1-28	O
**	O
]	O
:	O
.	O
LEFT	O
ATRIUM	O
:	O
Normal	O
LA	O
size	O
.	O
RIGHT	O
ATRIUM	O
/	O
INTERATRIAL	O
SEPTUM	O
:	O
Increased	O
IVC	O
diameter	O
(	O
>	O
2.1	O
cm	O
)	O
with	O
35	O
-	O
50	O
%	O
decrease	O
during	O
respiration	O
(	O
estimated	O
RA	O
pressure	O
(	O
10	O
-	O
15mmHg	O
)	O
.	O
LEFT	O
VENTRICLE	O
:	O
Normal	O
LV	O
wall	O
thickness	O
.	O
Normal	O
LV	O
cavity	O
size	O
.	O
Suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
LV	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Depressed	O
LVEF	O
.	O
No	O
resting	O
LVOT	O
gradient	O
.	O
No	O
VSD	O
.	O
RIGHT	O
VENTRICLE	O
:	O
Borderline	O
normal	O
RV	O
systolic	O
function	O
.	O
AORTIC	O
VALVE	O
:	O
No	O
AS	O
.	O
MITRAL	O
VALVE	O
:	O
No	O
MS.	O
[	O
**	O
Name13	O
(	O
STitle	O
)	O
**	O
]	O
MR.	O
TRICUSPID	O
VALVE	O
:	O
Indeterminate	O
PA	O
systolic	O
pressure	O
.	O
PERICARDIUM	O
:	O
Moderate	O
to	O
large	O
pericardial	O
effusion	O
.	O
No	O
RA	O
diastolic	O
collapse	O
.	O
No	O
RV	O
diastolic	O
collapse	O
.	O
GENERAL	O
COMMENTS	O
:	O
Suboptimal	O
image	O
quality	O
-	O
poor	O
echo	O
windows	O
.	O
The	O
rhythm	O
appears	O
to	O
be	O
atrial	O
flutter	O
.	O
Echocardiographic	O
patient	O
.	O
Poor	O
image	O
quality.The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
10	O
-	O
15mmHg	O
with	O
IVC	O
dilation	O
(	O
2.5	O
cm	O
)	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
LV	O
systolic	O
function	O
appears	O
mildly	O
depressed	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
RV	O
with	O
borderline	O
normal	O
free	O
wall	O
function	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
No	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
a	O
moderate	O
to	O
large	O
sized	O
pericardial	O
effusion	O
(	O
greatest	O
anteriorly	O
and	O
best	O
seen	O
in	O
the	O
subcostal	O
view	O
)	O
.	O
No	O
right	O
atrial	O
diastolic	O
collapse	O
is	O
seen	O
.	O
No	O
right	O
ventricular	O
diastolic	O
collapse	O
is	O
seen	O
(	O
mild	O
RV	O
compression	O
in	O
the	O
subcostal	O
view	O
is	O
suggestive	O
of	O
elevated	O
intrapericardial	O
pressure	O
)	O
.	O
.	O
Cardiac	O
cath	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
:	O
COMMENTS	O
:	O
Under	O
fluoroscopic	O
guidance	O
,	O
450	O
CC	O
of	O
bloody	O
pericardial	O
fluid	O
was	O
obtained	O
through	O
subxiphoid	O
approach	O
.	O
Intrapericardial	O
origin	O
of	O
fluid	O
was	O
confirmed	O
with	O
contrast	O
injection	O
and	O
intrapericardial	O
pressure	O
measurement	O
.	O
Initial	O
pericardial	O
pressure	O
was	O
elevated	O
at	O
21	O
mm	O
Hg	O
and	O
dropped	O
to	O
3	O
mm	O
Hg	O
after	O
remorval	O
of	O
fluid	O
.	O
Pericaridal	O
drain	O
was	O
sutured	O
in	O
place	O
for	O
24	O
hours	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
1	O
.	O
Successful	O
urgent	O
pericardiocentesis	O
through	O
subxiphoid	O
approach	O
for	O
impending	O
pericardial	O
temponade	O
.	O
ECHO	O
[	O
**	O
2196-1-30	O
**	O
]	O
IMPRESSION	O
:	O
Small	O
amount	O
of	O
echodense	O
pericardial	O
material	O
/	O
fluid	O
is	O
seen	O
.	O
No	O
evidence	O
of	O
tamponade	O
.	O
Probable	O
regional	O
LV	O
systolic	O
dysfunction	O
.	O
Moderately	O
dilated	O
and	O
hypokinetic	O
right	O
ventricle	O
.	O
Compared	O
with	O
the	O
prior	O
studies	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2196-1-29	O
**	O
]	O
and	O
[	O
**	O
2194-7-23	O
**	O
]	O
,	O
the	O
appearance	O
of	O
the	O
pericardium	O
is	O
similar	O
to	O
that	O
of	O
the	O
post-tap	O
echo	O
yesterday	O
.	O
The	O
basal	O
to	O
mid	O
inferior	O
/	O
inferolateral	O
hypokinesis	O
was	O
probably	O
present	O
in	O
[	O
**	O
2194	O
**	O
]	O
but	O
image	O
quality	O
is	O
poor	O
on	O
all	O
studies	O
.	O
The	O
right	O
ventricle	O
appears	O
dilated	O
on	O
studies	O
from	O
yesterday	O
and	O
today	O
-	O
it	O
was	O
probably	O
normal	O
in	O
[	O
**	O
2194	O
**	O
]	O
.	O
.	O
LENI	O
'S	O
[	O
**	O
2196-2-1	O
**	O
]	O
BILATERAL	O
LOWER	O
EXTREMITY	O
ULTRASOUND	O
:	O
Grayscale	O
,	O
color	O
,	O
and	O
Doppler	O
images	O
of	O
the	O
bilateral	O
common	O
femoral	O
,	O
superficial	O
and	O
deep	O
femoral	O
,	O
and	O
popliteal	O
veins	O
were	O
obtained	O
.	O
There	O
is	O
non-occlusive	O
thrombus	O
in	O
the	O
mid	O
left	O
popliteal	O
vein	O
and	O
left	O
peroneal	O
veins	O
,	O
as	O
well	O
as	O
the	O
right	O
posterior	O
tibial	O
vein	O
.	O
The	O
bilateral	O
common	O
femoral	O
,	O
superficial	O
femoral	O
,	O
and	O
right	O
popliteal	O
veins	O
demonstrated	O
normal	O
compressibility	O
and	O
wall	O
-	O
to	O
-	O
wall	O
color	O
flow	O
.	O
IMPRESSION	O
:	O
Non-occlusive	O
thrombus	O
in	O
left	O
popliteal	O
,	O
left	O
peroneal	O
,	O
and	O
right	O
posterior	O
tibial	O
veins	O
.	O
.	O
CT	O
TORSO	O
[	O
**	O
2196-2-1	O
**	O
]	O
(	O
PRELIM	O
)	O
1	O
.	O
Pulmonary	O
embolism	O
involving	O
right	O
lower	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3630	O
**	O
]	O
posterior	O
basal	O
segmental	O
and	O
subsegmental	O
branches	O
,	O
and	O
subsegmental	O
branch	O
of	O
left	O
lower	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3630	O
**	O
]	O
anterior	O
basal	O
pulmonary	O
artery	O
.	O
2	O
.	O
Bilateral	O
moderate	O
-	O
sized	O
pleural	O
effusions	O
with	O
adjacent	O
atelectasis	O
.	O
3	O
.	O
Evidence	O
of	O
right	O
heart	O
strain	O
,	O
manifest	O
as	O
reflux	O
of	O
IV	O
contrast	I-Drug
into	O
the	O
IVC	O
and	O
hepatic	O
veins	O
.	O
4	O
.	O
Mediastinal	O
and	O
right	O
hilar	O
adenopathy	O
with	O
right	O
hilar	O
soft	O
tissue	O
causing	O
some	O
narrowing	O
of	O
the	O
airways	O
and	O
vessels	O
,	O
concerning	O
for	O
malignancy	O
.	O
Bronchial	O
wall	O
thickening	O
noted	O
,	O
particularly	O
along	O
right	O
middle	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3630	O
**	O
]	O
and	O
right	O
lower	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3630	O
**	O
]	O
bronchi	O
.	O
5	O
.	O
Perifissural	O
consolidation	O
in	O
posteromedial	O
right	O
middle	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
3630	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
represent	O
atelectasis	O
or	O
infection	O
;	O
however	O
,	O
underlying	O
tumor	O
or	O
extension	O
of	O
right	O
hilar	O
mass	O
not	O
excluded	O
.	O
6	O
.	O
11	O
mm	O
spiculated	O
nodule	O
in	O
the	O
right	O
upper	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3630	O
**	O
]	O
is	O
suspicious	O
for	O
malignancy	O
.	O
7	O
.	O
Predominantly	O
paraseptal	O
emphysema	O
in	O
the	O
right	O
upper	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3630	O
**	O
]	O
with	O
largest	O
bulla	O
measuring	O
3.5	O
x	O
5.9	O
cm	O
.	O
8	O
.	O
Tiny	O
pericardial	O
fluid	O
and	O
possible	O
pericardial	O
thickening	O
.	O
9	O
.	O
No	O
evidence	O
of	O
malignancy	O
in	O
the	O
abdomen	O
and	O
pelvis	O
.	O
10	O
.	O
Intraabdominal	O
findings	O
include	O
aortic	O
and	O
iliac	O
artery	O
calcifications	O
,	O
colonic	O
diverticulosis	O
,	O
and	O
tiny	O
bubble	O
of	O
gas	O
within	O
the	O
urinary	O
bladder	O
,	O
which	O
could	O
be	O
due	O
to	O
recent	O
catheterization	O
(	O
correlate	O
clinically	O
)	O
.	O
11	O
.	O
No	O
bony	O
destruction	O
concerning	O
for	O
malignancy	O
.	O
12	O
.	O
Evidence	O
of	O
right	O
femoral	O
head	O
avascular	O
necrosis	O
,	O
without	O
significant	O
collapse	O
.	O
.	O
CT	O
HEAD	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
No	O
evidence	O
of	O
an	O
acute	O
intracranial	O
process	O
.	O
Postoperative	O
changes	O
of	O
right	O
temporal	O
lobectomy	O
.	O
.	O
Pathology	O
,	O
pericardial	O
effusion	O
:	O
POSITIVE	O
FOR	O
MALIGNANT	O
CELLS	O
,	O
Consistent	O
with	O
metastatic	O
adenocarcinoma	O
.	O
Repeat	O
echo	O
,	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
:	O
LV	O
systolic	O
function	O
appears	O
depressed	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
borderline	O
dilated	O
with	O
mild	O
global	O
free	O
wall	O
hypokinesis	O
.	O
There	O
is	O
a	O
small	O
pericardial	O
effusion	O
.	O
The	O
effusion	O
is	O
echo	O
dense	O
,	O
consistent	O
with	O
blood	O
,	O
inflammation	O
or	O
other	O
cellular	O
elements	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
Brief	O
Hospital	O
Course	O
:	O
47	O
yo	O
M	O
with	O
history	O
of	O
epilepsy	O
admitted	O
for	O
elective	O
vagal	O
nerve	O
stimulator	O
replacement	O
,	O
transferred	O
to	O
MICU	O
for	O
management	O
of	O
tachycardia	O
,	O
hypotension	O
,	O
and	O
hypoxia	O
,	O
found	O
to	O
have	O
pericardial	O
effusion	O
,	O
now	O
s	O
/	O
p	O
pericardiocentiesis	O
with	O
drain	O
in	O
place	O
,	O
transferred	O
to	O
CCU	O
for	O
post-operative	O
monitoring	O
,	O
with	O
frequent	O
agitation	O
,	O
now	O
found	O
to	O
have	O
bilateral	O
PEs	O
.	O
#	O
Pericardial	O
effusion	O
:	O
In	O
the	O
MICU	O
,	O
pt	O
noted	O
to	O
be	O
tachycardic	O
with	O
hypotension	O
,	O
and	O
found	O
to	O
have	O
pericardial	O
effusion	O
.	O
He	O
underwent	O
pericardiocentesis	O
with	O
drain	O
placement	O
with	O
drainage	O
of	O
bloody	O
fluid	O
.	O
Hct	O
stable	O
despite	O
profuse	O
bloody	O
drainage	O
.	O
Etiology	O
is	O
likely	O
malignancy	O
given	O
that	O
CT	O
torso	O
showing	O
RUL	O
lung	O
spiculated	O
nodule	O
.	O
Effusion	O
cytology	O
and	O
micro	O
showed	O
cells	O
c	O
/	O
w	O
metastatic	O
lung	O
adenocarcinoma	O
.	O
Drain	O
was	O
eventually	O
pulled	O
without	O
complication	O
and	O
without	O
any	O
further	O
hemodynamic	O
instability	O
.	O
Pulsus	O
checked	O
for	O
several	O
days	O
after	O
drain	O
pulled	O
and	O
resolved	O
effusion	O
on	O
Echo	O
,	O
was	O
~	O
8	O
mmHg	O
on	O
discharge	O
.	O
.	O
#	O
PE	O
/	O
DVT	O
:	O
Pt	O
noted	O
to	O
have	O
enlarged	O
RV	O
on	O
repeat	O
echo	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
,	O
so	O
CTA	O
was	O
obtained	O
for	O
concern	O
of	O
PEs	O
which	O
confirmed	O
b	B-Reason
/	I-Reason
l	I-Reason
subsegmental	O
PEs	O
.	O
LENIs	O
also	O
positive	O
for	O
b	B-Reason
/	I-Reason
l	I-Reason
DVTs	I-Reason
.	O
He	O
was	O
started	O
on	O
heparin	I-Drug
ggt	O
in	O
house	O
and	O
transitioned	O
to	O
an	O
anticoagulation	B-Drug
regimen	I-Drug
of	O
coumadin	I-Drug
,	O
with	O
a	O
lovenox	I-Drug
bridge	O
.	O
He	O
will	O
f	O
/	O
u	O
with	O
his	O
PCP	O
on	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
2974	O
**	O
]	O
[	O
**	O
2	O
-	O
12	O
**	O
]	O
after	O
discharge	O
.	O
.	O
#	O
Agitation	O
:	O
Patient	O
with	O
history	O
of	O
EtOH	O
,	O
marijuana	O
,	O
cocaine	O
/	O
crack	O
binges	O
.	O
He	O
was	O
significantly	O
agitated	I-Reason
throughout	O
admission	O
which	O
was	O
initially	O
thought	O
to	O
be	O
secondary	O
to	O
ETOH	I-Reason
withdrawal	O
.	O
He	O
was	O
maintained	O
on	O
a	O
valium	I-Drug
CIWA	O
and	O
klonipin	I-Drug
1	O
mg	O
TID	O
.	O
However	O
,	O
agitation	O
persisted	O
despite	O
being	O
well	O
out	O
of	O
the	O
acute	O
withdrawal	O
window	O
.	O
He	O
had	O
several	O
code	O
purples	O
called	O
for	O
him	O
and	O
was	O
often	O
violent	O
towards	O
nurses	O
.	O
Of	O
note	O
,	O
pt	O
would	O
be	O
lucid	O
and	O
engaging	O
often	O
during	O
the	O
day	O
with	O
decompensation	O
at	O
night	O
.	O
Psych	O
was	O
consulted	O
who	O
felt	O
that	O
this	O
was	O
less	O
likely	O
to	O
be	O
withdrawal	O
and	O
instead	O
a	O
behavioral	B-Ade
issue	I-Ade
/	O
delerium	I-Ade
,	O
likely	O
in	O
setting	O
of	O
supratherapeutic	O
valproate	I-Drug
level	O
.	O
They	O
recommended	O
haldol	I-Drug
for	O
his	O
agitation	I-Reason
which	O
was	O
continued	O
5	O
mg	O
PRN	O
along	O
with	O
10	O
mg	O
QHS	O
standing	O
,	O
these	O
were	O
discontinued	O
on	O
discharge	O
,	O
takes	O
no	O
psych	O
meds	O
at	O
home	O
and	O
delirium	O
apparently	O
cleared	O
.	O
Evaluated	O
by	O
psychiatry	O
prior	O
to	O
discharge	O
,	O
appeared	O
to	O
understand	O
importance	O
of	O
f	O
/	O
u	O
.	O
He	O
was	O
started	O
on	O
MVI	I-Drug
,	O
thiamine	I-Drug
,	O
folate	I-Drug
.	O
.	O
#	O
Afib	B-Reason
with	I-Reason
RVR	I-Reason
:	O
Patient	O
oscillates	O
between	O
HR	O
of	O
70s	O
??????	O
170s	O
with	O
frequent	O
episodes	O
of	O
RVR	O
on	O
tele	O
,	O
asymptomatic	O
.	O
Based	O
on	O
old	O
records	O
,	O
has	O
a	O
history	O
of	O
Afib	O
with	O
RVR	O
,	O
a	O
flutter	O
,	O
was	O
treated	O
with	O
diltiazem	I-Drug
and	O
flecainide	I-Drug
,	O
and	O
was	O
supposed	O
to	O
be	O
on	O
Metoprolol	I-Drug
.	O
Increased	O
metoprolol	I-Drug
to	O
75	O
mg	O
po	O
qid	O
standing	O
which	O
has	O
controlled	O
rate	O
well	O
,	O
though	O
still	O
with	O
frequent	O
episodes	O
of	O
rapid	B-Reason
ventricular	I-Reason
response	I-Reason
that	O
respond	O
to	O
IV	O
lopressor	I-Drug
5	O
mg	O
x	O
1	O
.	O
Because	O
of	O
continued	O
episodes	B-Reason
of	I-Reason
RVR	I-Reason
(	O
likely	O
in	O
the	O
setting	O
of	O
pericardial	O
effusion	O
and	O
multiple	O
PEs	O
)	O
pt	O
started	O
on	O
diltiazem	I-Drug
drip	O
,	O
weaned	O
off	O
and	O
started	O
on	O
diltiazem	I-Drug
ER	O
120	O
mg	O
daily	O
,	O
and	O
metoprolol	I-Drug
changed	O
to	O
200	O
mg	O
of	O
metoprolol	B-Drug
succinate	I-Drug
on	O
discharge	O
.	O
HR	O
in	O
the	O
60s	O
with	O
these	O
changes	O
,	O
with	O
short	O
bursts	O
of	O
SVT	O
to	O
130s	O
prior	O
to	O
discharge	O
.	O
Would	O
consider	O
uptitrating	O
rate	O
control	O
as	O
an	O
outpatient	O
.	O
.	O
#	O
.	O
h	O
/	O
o	O
epilepsy	O
and	O
seizure	O
activity	O
:	O
VNS	O
placed	O
and	O
was	O
re-activated	O
about	O
1	O
week	O
after	O
placement	O
.	O
He	O
was	O
continued	O
home	O
AEDs	O
.	O
Depakote	I-Drug
ER	O
1250	O
/	O
1500/1500	O
and	O
Oxcarbazepine	I-Drug
600	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
which	O
was	O
often	O
given	O
IV	O
due	O
to	O
inability	O
to	O
take	O
POs	O
from	O
agitation	O
.	O
Depakote	I-Drug
level	O
was	O
found	O
to	O
be	O
elevated	O
in	O
setting	O
of	O
delirium	I-Ade
,	O
however	O
unclear	O
if	O
this	O
was	O
true	O
trough	O
.	O
Was	O
discharged	O
on	O
home	O
meds	O
and	O
advised	O
to	O
f	O
/	O
u	O
with	O
his	O
outpatient	O
neurologist	O
for	O
management	O
of	O
his	O
depakote	I-Drug
.	O
.	O
#	O
Foley	O
self	O
-	O
d	O
/	O
c	O
:	O
Pt	O
pulled	O
own	O
foley	O
overnight	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
.	O
Of	O
note	O
there	O
was	O
blood	O
around	O
the	O
uerethral	O
meatus	O
after	O
he	O
pulled	O
it	O
.	O
Urine	O
output	O
was	O
monitored	O
and	O
foley	O
ended	O
up	O
being	O
replaced	O
on	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
given	O
that	O
he	O
was	O
put	O
back	O
into	O
4	O
pt	O
restraints	O
.	O
Foley	O
dc	O
'	O
ed	O
and	O
was	O
able	O
to	O
void	O
on	O
his	O
own	O
with	O
no	O
hematuria	O
for	O
remaineder	O
of	O
admission	O
.	O
Medications	O
on	O
Admission	O
:	O
-	O
Clonazepam	I-Drug
1	O
mg	O
QID	O
-	O
Divalproex	I-Drug
250	O
mg	O
Sustained	O
Release	O
qAM	O
-	O
Depakote	I-Drug
ER	O
500	O
mg	O
tab	O
-	O
tabs	O
qAM	O
,	O
3	O
tabs	O
in	O
the	O
afternoon	O
and	O
3	O
tabs	O
qPM	O
-	O
Omeprazole	I-Drug
20	O
mg	O
delayed	O
release	O
daily	O
-	O
Oxcarbazepine	I-Drug
600	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
-	O
ASA	I-Drug
81	O
mg	O
daily	O
(	O
not	O
taking	O
as	O
prescribed	O
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
Lovenox	I-Drug
100	O
mg	O
/	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
twice	O
a	O
day	O
for	O
10	O
days	O
.	O
Disp	O
:	O
*	O
20	O
syringe	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
oxcarbazepine	I-Drug
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
clonazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
four	O
times	O
a	O
day	O
.	O
4	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
diltiazem	B-Drug
HCl	I-Drug
120	O
mg	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
,	O
Sustained	O
Release	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
divalproex	I-Drug
250	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
QAM	O
:	O
use	O
in	O
addition	O
to	O
the	O
depakote	I-Drug
500	O
mg	O
strength	O
tabs	O
for	O
total	O
dose	O
of	O
1250	O
/	O
1500/1500	O
mg	O
.	O
8	O
.	O
divalproex	I-Drug
500	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
QAFTERNOON	O
(	O
)	O
.	O
9	O
.	O
divalproex	I-Drug
500	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
10	O
.	O
divalproex	I-Drug
500	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
QAM	O
:	O
take	O
in	O
addition	O
to	O
250	O
mg	O
dose	O
for	O
a	O
total	O
1250	O
mg	O
every	O
morning	O
.	O
11	O
.	O
nicotine	I-Drug
14	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
24	O
hr	O
Transdermal	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Patch	O
24	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
12	O
.	O
metoprolol	B-Drug
succinate	I-Drug
200	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
13	O
.	O
aspirin	I-Drug
81	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Seizure	O
disorder	O
Atrial	O
fibrillation	O
Lung	O
adenocarcinoma	O
,	O
pericardial	O
effusion	O
Deep	O
vein	O
thrombosis	O
,	O
pulmonary	O
embolism	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
seen	O
in	O
the	O
hospital	O
to	O
have	O
your	O
vagal	O
nerve	O
stimulator	O
replaced	O
,	O
which	O
has	O
been	O
turned	O
on	O
again	O
,	O
for	O
your	O
seizures	O
.	O
You	O
were	O
also	O
found	O
to	O
have	O
a	O
very	O
fast	O
heart	O
rate	O
from	O
your	O
atrial	B-Reason
fibrillation	I-Reason
(	I-Reason
irregular	I-Reason
heart	I-Reason
rate	I-Reason
)	I-Reason
and	O
for	O
this	O
we	O
started	O
diltiazem	I-Drug
and	O
metoprolol	I-Drug
,	O
which	O
slow	O
your	O
heart	O
rate	O
.	O
In	O
addition	O
,	O
you	O
were	O
found	O
to	O
have	O
a	O
pericardial	O
effusion	O
(	O
fluid	O
around	O
your	O
heart	O
)	O
which	O
is	O
likely	O
due	O
to	O
spreading	O
of	O
lung	O
cancer	O
,	O
which	O
was	O
discovered	O
on	O
a	O
CT	O
scan	O
.	O
You	O
were	O
seen	O
by	O
the	O
oncologists	O
here	O
who	O
recommended	O
that	O
you	O
go	O
to	O
clinic	O
for	O
follow	O
up	O
to	O
discuss	O
further	O
workup	O
and	O
treatment	O
.	O
You	O
were	O
also	O
found	O
to	O
have	O
a	O
pulmonary	O
embolism	O
and	O
deep	B-Reason
vein	I-Reason
thrombosis	O
(	O
blood	O
clots	O
in	O
your	O
lung	O
and	O
legs	O
)	O
for	O
which	O
you	O
were	O
started	O
a	O
blood	O
thinner	O
.	O
You	O
will	O
be	O
taking	O
a	O
blood	O
thinner	O
called	O
Coumadin	I-Drug
to	O
prevent	B-Reason
more	I-Reason
clots	I-Reason
from	I-Reason
forming	I-Reason
and	O
to	O
treat	O
the	O
ones	O
you	O
already	O
have	O
,	O
and	O
you	O
should	O
take	O
this	O
medication	O
every	O
day	O
.	O
You	O
will	O
be	O
taking	O
Lovenox	I-Drug
,	O
another	O
blood	I-Reason
thinner	O
which	O
works	O
immediately	O
,	O
temporarily	O
until	O
your	O
blood	O
level	O
of	O
Coumadin	I-Drug
reaches	O
the	O
therapeutic	O
range	O
.	O
Changes	O
to	O
your	O
medications	O
:	O
START	O
diltiazem	I-Drug
120	O
mg	O
every	O
day	O
START	O
taking	O
metoprolol	I-Drug
200	O
mg	O
daily	O
START	O
taking	O
warfarin	I-Drug
5	O
mg	O
daily	O
START	O
taking	O
lovenox	I-Drug
shots	O
twice	O
a	O
day	O
until	O
you	O
are	O
told	O
to	O
stop	O
by	O
your	O
doctor	O
Followup	O
Instructions	O
:	O
In	O
addition	O
to	O
the	O
appointments	O
below	O
,	O
the	O
oncologists	O
are	O
trying	O
to	O
schedule	O
you	O
an	O
appointment	O
in	O
clinic	O
.	O
The	O
phone	O
number	O
to	O
call	O
with	O
questions	O
is	O
[	O
**	O
0	O
-	O
0	O
-	O
**	O
]	O
.	O
Department	O
:	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
When	O
:	O
FRIDAY	O
[	O
**	O
2196-2-12	O
**	O
]	O
at	O
4:00	O
PM	O
With	O
:	O
MARK	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
LICSW	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
When	O
:	O
FRIDAY	O
[	O
**	O
2196-2-19	O
**	O
]	O
at	O
3:00	O
PM	O
With	O
:	O
MARK	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
LICSW	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
When	O
:	O
THURSDAY	O
[	O
**	O
2196-3-17	O
**	O
]	O
at	O
4:50	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
1980	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1981	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Completed	O
by	O
:[	O
**	O
2196-2-7	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2125-9-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2125-9-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2078-2-8	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Iodine	I-Drug
Containing	O
Agents	O
Classifier	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2186	O
**	O
]	O
Chief	O
Complaint	O
:	O
flushing	O
,	O
periorbital	O
edema	O
,	O
and	O
hives	O
during	O
CT	O
scan	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
ERCP	O
History	O
of	O
Present	O
Illness	O
:	O
47	O
YO	O
Caucasian	O
male	O
with	O
Hx	O
of	O
chronic	O
pancreatitis	O
admitted	O
following	O
an	O
anaphylactoid	O
reaction	O
in	O
CT	O
scan	O
.	O
Today	O
,	O
the	O
patient	O
went	O
for	O
ERCP	O
to	O
further	O
evaluate	O
his	O
pancreatitis	O
.	O
The	O
ventral	O
pancreatic	O
duct	O
was	O
normal	O
in	O
caliber	O
.	O
The	O
pancreastic	O
duct	O
in	O
the	O
area	O
of	O
the	O
head	O
of	O
the	O
pancreas	O
was	O
very	O
dilated	O
,	O
and	O
contained	O
multiple	O
stones	O
.	O
There	O
was	O
no	O
filling	O
of	O
the	O
pancreatic	O
duct	O
beyond	O
the	O
head	O
.	O
There	O
were	O
no	O
lesions	O
amenable	O
to	O
endoscopic	O
therapy	O
.	O
The	O
patient	O
went	O
for	O
a	O
CTA	O
pancreas	O
to	O
rule	O
out	O
pancreatic	O
neoplasm	O
b	O
/	O
c	O
of	O
elevated	O
CEA	O
and	O
CA19	O
-	O
9	O
.	O
The	O
patient	O
received	O
IV	O
contrast	I-Drug
and	O
developed	O
flushing	I-Ade
,	O
periorbital	B-Ade
/	I-Ade
facial	I-Ade
edema	I-Ade
and	O
hives	I-Ade
.	O
Code	O
Blue	O
was	O
called	O
and	O
the	O
patient	O
was	O
given	O
IV	O
benadryl	I-Drug
,	O
solumedrol	I-Drug
,	O
and	O
H2	B-Drug
blocker	I-Drug
.	O
The	O
patient	O
maintained	O
his	O
O2	I-Drug
sats	O
>	O
100	O
%	O
on	O
a	O
100	O
%	O
NRB	O
,	O
and	O
BP	O
had	O
MAP	O
>	O
60	O
.	O
The	O
patient	O
was	O
able	O
to	O
speak	O
without	O
difficulty	O
and	O
was	O
x-ferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
monitoring	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
?	O
hypertriglyceridemia	O
in	O
the	O
past	O
,	O
but	O
reports	O
triglycerides	O
levels	O
have	O
been	O
much	O
lower	O
in	O
recent	O
years	O
2	O
.	O
Chronic	O
pancreatitis	O
Mr.	O
[	O
**	O
Known	O
lastname	O
64313	O
**	O
]	O
has	O
never	O
undergone	O
any	O
surgery	O
.	O
Social	O
History	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
64313	O
**	O
]	O
previously	O
worked	O
as	O
a	O
painting	O
contractor	O
but	O
has	O
not	O
worked	O
for	O
the	O
last	O
3	O
years	O
.	O
He	O
is	O
still	O
drinking	O
a	O
few	O
beers	O
per	O
week	O
but	O
did	O
not	O
quantify	O
exactly	O
his	O
alcohol	O
intake	O
.	O
He	O
used	O
to	O
smoke	O
2	O
packs	O
per	O
day	O
but	O
currently	O
smokes	O
about	O
1	O
pack	O
per	O
day	O
.	O
He	O
is	O
divorced	O
with	O
3	O
children	O
ages	O
14	O
,	O
12	O
,	O
and	O
11	O
.	O
Family	O
History	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
64313	O
**	O
]	O
has	O
3	O
children	O
age	O
14	O
,	O
12	O
and	O
11	O
.	O
They	O
are	O
healthy	O
.	O
There	O
is	O
no	O
family	O
history	O
of	O
pancreatic	O
diseases	O
.	O
His	O
mother	O
has	O
diabetes	O
mellitus	O
but	O
no	O
symptoms	O
of	O
chronic	O
abdominal	O
pain	O
,	O
steatorrhea	O
,	O
or	O
pancreas	O
problems	O
.	O
His	O
father	O
died	O
of	O
a	O
myocardial	O
infarction	O
at	O
age	O
49	O
.	O
Physical	O
Exam	O
:	O
General	O
:	O
thin	O
man	O
appearing	O
his	O
stated	O
age	O
at	O
times	O
very	O
uncomfortable	O
with	O
changes	O
in	O
position	O
.	O
Skin	O
had	O
no	O
jaundice	O
.	O
HEENT	O
:	O
no	O
scleral	O
icterus	O
,	O
mucus	O
membranes	O
were	O
moist	O
.	O
There	O
was	O
no	O
oral	O
thrush	O
and	O
no	O
oropharyngeal	O
erythema	O
and	O
no	O
oropharyngeal	O
exudates	O
.	O
His	O
neck	O
was	O
supple	O
without	O
lymphadenopathy	O
.	O
The	O
lungs	O
were	O
clear	O
to	O
auscultation	O
,	O
bilaterally	O
.	O
Cardiac	O
regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
and	O
S2	O
with	O
no	O
murmurs	O
,	O
gallops	O
or	O
rubs	O
.	O
The	O
abdomen	O
had	O
normoactive	O
bowel	O
sounds	O
,	O
soft	O
with	O
tenderness	O
in	O
the	O
right	O
upper	O
quadrant	O
,	O
right	O
midabdomen	O
and	O
right	O
lower	O
quadrant	O
with	O
voluntary	O
guarding	O
but	O
no	O
rebound	O
.	O
There	O
were	O
focal	O
mass	O
.	O
There	O
was	O
no	O
hepatosplenomegaly	O
.	O
The	O
extremities	O
had	O
2	O
+	O
distal	O
pulses	O
without	O
edema	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
WBC	O
-	O
15.4	O
*	O
#	O
RBC	O
-	O
4.27	O
*	O
HGB	O
-	O
14.0	O
HCT	O
-	O
40.6	O
MCV	O
-	O
95	O
MCH	O
-	O
32.7	O
*	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
12.6	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
PLT	O
COUNT	O
-	O
279	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
GLUCOSE	O
-	O
102	O
UREA	O
N	O
-	O
9	O
CREAT	O
-	O
0.7	O
SODIUM	O
-	O
135	O
POTASSIUM	O
-	O
3.5	O
CHLORIDE	O
-	O
101	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
16	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
CALCIUM	O
-	O
8.0	O
*	O
PHOSPHATE	O
-	O
3.8	O
MAGNESIUM	O
-	O
1.6	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
17	O
AST	O
(	O
SGOT	O
)	O
-	O
31	O
LD	O
(	O
LDH	O
)	O
-	O
158	O
ALK	O
PHOS	O
-	O
67	O
AMYLASE	O
-	O
59	O
TOT	O
BILI	O
-	O
0.5	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
LIPASE	O
-	O
67	O
*	O
[	O
**	O
2125-9-3	O
**	O
]	O
05:54	O
PM	O
PT	O
-	O
13.7	O
*	O
PTT	O
-	O
27.1	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
Abd	O
CT	O
:	O
Area	O
of	O
atelectasis	O
is	O
seen	O
in	O
the	O
right	O
lung	O
base	O
.	O
There	O
is	O
no	O
pleural	O
effusion	O
.	O
The	O
liver	O
and	O
spleen	O
are	O
not	O
enlarged	O
.	O
Ther	O
is	O
mild	O
intrahepatic	O
biliary	O
duct	O
dilatation	O
.	O
The	O
CBD	O
measures	O
up	O
to	O
10	O
mm	O
.	O
The	O
gallbladder	O
,	O
kidneys	O
,	O
and	O
both	O
adrenals	O
are	O
unremarkable	O
.	O
There	O
are	O
multiple	O
coarse	O
calcifications	O
throughout	O
the	O
head	O
and	O
body	O
of	O
the	O
pancreas	O
.	O
Mild	O
dilatation	O
of	O
the	O
pancreatic	O
main	O
duct	O
.	O
In	O
the	O
head	O
of	O
the	O
pancreas	O
,	O
there	O
is	O
a	O
septated	O
cystic	O
region	O
measuring	O
12	O
x	O
15	O
mm	O
that	O
could	O
correspond	O
with	O
dilated	O
side	O
branches	O
of	O
the	O
duct	O
,	O
or	O
IPMT	O
.	O
This	O
region	O
does	O
n't	O
enhance	O
following	O
the	O
administration	O
of	O
the	O
IV	O
contrast	I-Drug
.	O
The	O
pancreas	O
appears	O
irregular	O
.	O
There	O
is	O
no	O
free	O
fluid	O
or	O
free	O
air	O
within	O
the	O
abdomen	O
.	O
The	O
aorta	O
is	O
normal	O
in	O
caliber	O
.	O
The	O
bowel	O
loops	O
appear	O
unremarkable	O
.	O
ERCP	O
:	O
1	O
.	O
The	O
distal	O
pancreatic	O
duct	O
within	O
the	O
head	O
and	O
neck	O
of	O
the	O
pancreas	O
is	O
markedly	O
dilated	O
with	O
multiple	O
filling	O
defects	O
consistent	O
with	O
stones	O
.	O
The	O
pancreatic	O
duct	O
proximally	O
within	O
the	O
body	O
and	O
tail	O
of	O
the	O
pancreas	O
can	O
not	O
be	O
opacified	O
.	O
2	O
.	O
Normal	O
-	O
appearing	O
ventral	O
pancreatic	O
duct	O
.	O
Brief	O
Hospital	O
Course	O
:	O
1	O
.	O
Anaphylaxis	I-Reason
:	O
the	O
pt	O
had	O
anaphylactoid	B-Ade
reaction	I-Ade
to	O
IV	O
contrast	B-Drug
dye	I-Drug
during	O
CT	O
as	O
evidenced	O
by	O
acute	O
onset	O
of	O
flushing	I-Ade
,	O
periorbital	B-Ade
/	I-Ade
facial	I-Ade
edema	I-Ade
,	O
and	O
hives	I-Ade
.	O
He	O
was	O
treated	O
in	O
the	O
CT	O
suite	O
with	O
IV	O
benadryl	I-Drug
,	O
and	O
was	O
observed	O
to	O
maintain	O
O2	I-Drug
sat	O
100	O
%	O
on	O
NRB	O
and	O
had	O
MAP	O
>	O
60	O
at	O
all	O
times	O
.	O
He	O
was	O
admitted	O
to	O
the	O
ICU	O
for	O
ongoing	O
care	O
,	O
and	O
was	O
treated	O
with	O
standing	O
doses	O
of	O
IV	O
benadryl	I-Drug
,	O
famotidine	I-Drug
,	O
and	O
solumedrol	I-Drug
overnight	O
.	O
The	O
pt	O
had	O
stable	O
respiratory	O
status	O
and	O
BP	O
throughout	O
his	O
admission	O
.	O
By	O
HD	O
#	O
2	O
,	O
his	O
facial	O
edema	O
and	O
hives	O
had	O
resolved	O
,	O
and	O
he	O
was	O
transferred	O
to	O
the	O
medical	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
ongoing	O
care	O
.	O
On	O
the	O
medical	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
he	O
was	O
asymptomatic	O
and	O
tolerated	O
regular	O
diet	O
for	O
lunch	O
well	O
.	O
After	O
lunch	O
,	O
he	O
was	O
d	O
/	O
c	O
home	O
with	O
instructions	O
to	O
take	O
benadryl	I-Drug
prn	O
for	O
itching	I-Reason
or	O
rash	I-Reason
.	O
The	O
pt	O
was	O
instructed	O
to	O
present	O
to	O
the	O
ED	O
if	O
he	O
developed	O
repeated	O
hives	O
,	O
dyspnea	O
,	O
weakness	O
,	O
or	O
confusion	O
.	O
.	O
2	O
.	O
Chronic	O
pancreatitis	O
:	O
his	O
pacreatitis	O
has	O
been	O
long	O
-	O
standing	O
,	O
with	O
evidence	O
of	O
pancreatic	O
calcification	O
on	O
CT	O
and	O
ERCP	O
consistent	O
with	O
pancreatic	O
ductal	O
stones	O
.	O
These	O
stones	O
were	O
not	O
amenable	O
to	O
removal	O
by	O
ERCP	O
,	O
and	O
as	O
they	O
are	O
contributing	O
to	O
inflammation	O
and	O
pain	O
,	O
the	O
pt	O
was	O
referred	O
for	O
consultation	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
468	O
**	O
]	O
for	O
surgical	O
treatment	O
.	O
During	O
his	O
admission	O
,	O
he	O
was	O
treated	O
with	O
pancreatic	O
enzyme	O
replacement	O
before	O
meals	O
.	O
His	O
pain	I-Reason
was	O
controlled	O
with	O
IV	O
dilaudid	I-Drug
initially	O
,	O
and	O
on	O
the	O
day	O
of	O
d	O
/	O
c	O
the	O
pt	O
was	O
transition	O
to	O
his	O
usual	O
regimen	O
of	O
oral	O
morphine	I-Drug
,	O
with	O
good	O
results	O
.	O
He	O
will	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
468	O
**	O
]	O
for	O
surgical	O
consultation	O
after	O
d	O
/	O
c.	O
.	O
3	O
.	O
Code	O
status	O
was	O
FULL	O
CODE	O
during	O
this	O
admission	O
.	O
Medications	O
on	O
Admission	O
:	O
Protonix	I-Drug
40	O
mg	O
before	O
breakfast	O
multivitamin	I-Drug
1	O
tablet	O
per	O
day	O
thiamine	B-Drug
100	O
mg	O
per	O
day	O
folate	I-Drug
1	O
mg	O
per	O
day	O
Viokase	I-Drug
2	O
tablets	O
with	O
meals	O
morphine	I-Drug
sulfate	O
15	O
mg	O
tablets	O
(	O
approximately	O
6	O
tablets	O
per	O
day	O
)	O
prn	O
for	O
abdominal	B-Reason
pain	I-Reason
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
Headache	I-Reason
.	O
2	O
.	O
Zolpidem	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
sleep	I-Reason
.	O
3	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
4	O
.	O
Morphine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
.	O
5	O
.	O
Benadryl	I-Drug
50	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
allergy	B-Reason
symptoms	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Anaphylaxis	I-Ade
secondary	O
to	O
IV	O
contrast	B-Drug
dye	I-Drug
2	O
.	O
Chronic	O
pancreatitis	O
Discharge	O
Condition	O
:	O
Stable	O
to	O
go	O
home	O
.	O
Vital	O
signs	O
normal	O
;	O
no	O
dyspnea	O
,	O
itching	O
,	O
or	O
other	O
evidence	O
of	O
active	O
anaphylaxis	O
.	O
Discharge	O
Instructions	O
:	O
You	O
have	O
been	O
hospitalized	O
after	O
having	O
an	O
allergic	B-Ade
reaction	I-Ade
to	O
IV	O
contrast	B-Drug
dye	I-Drug
.	O
Your	O
vital	O
signs	O
and	O
symptoms	O
have	O
all	O
returned	O
to	O
[	O
**	O
Location	O
64314	O
**	O
]	O
.	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
Call	O
your	O
PCP	O
or	O
present	O
to	O
the	O
ED	O
if	O
you	O
develop	O
fevers	O
,	O
chills	O
,	O
wheezing	O
,	O
shortness	O
of	O
breath	O
,	O
hives	O
,	O
swelling	O
,	O
uncontrolled	O
itching	O
,	O
uncontrolled	O
pain	O
,	O
or	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
468	O
**	O
]	O
in	O
[	O
**	O
12	O
-	O
10	O
**	O
]	O
weeks	O
for	O
evaluation	O
of	O
further	O
treatment	O
options	O
for	O
your	O
chronic	O
pancreatitis	O
.	O
Follow	O
-	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
weeks	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2154-12-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2155-1-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2074-11-21	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Sulfa	B-Drug
(	I-Drug
Sulfonamides	I-Drug
)	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1973	O
**	O
]	O
Chief	O
Complaint	O
:	O
Delta	O
MS	O
,	O
respiratory	O
distress	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
R	O
chest	O
tube	O
place	O
Intubation	O
and	O
mechanical	O
ventilation	O
R	O
IJ	O
central	O
line	O
placed	O
L	O
SC	O
central	O
line	O
placed	O
PICC	O
line	O
placed	O
History	O
of	O
Present	O
Illness	O
:	O
80yo	O
M	O
with	O
h	O
/	O
o	O
hyperlipidemia	O
,	O
RA	O
,	O
new	O
diagnosis	O
of	O
glioblastoma	B-Reason
multiforme	I-Reason
(	O
grade	O
4	O
)	O
p	O
/	O
w	O
altered	O
mental	O
status	O
and	O
respiratory	O
distress	O
.	O
He	O
was	O
diagnosed	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
1096	O
**	O
]	O
with	O
GBM	O
(	O
by	O
biopsy	O
)	O
in	O
the	O
setting	O
of	O
increasing	O
confusion	O
,	O
memory	O
loss	O
.	O
He	O
was	O
started	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
1096	O
**	O
]	O
on	O
high	B-Reason
dose	I-Reason
radiation	I-Reason
therapy	I-Reason
at	O
which	O
time	O
he	O
was	O
also	O
started	O
on	O
high	O
dose	O
decadron	I-Drug
w	O
/	O
q3day	O
taper	O
(	O
most	O
recently	O
on	O
3	O
mg	O
)	O
;	O
last	O
radiation	O
session	O
was	O
late	O
[	O
**	O
Month	O
(	O
only	O
)	O
1096	O
**	O
]	O
.	O
He	O
also	O
recently	O
had	O
a	O
port	O
placed	O
through	O
which	O
he	O
was	O
receiving	O
avastin	I-Drug
(	O
last	O
2	O
weeks	O
ago	O
)	O
.	O
His	O
family	O
reports	O
mildly	O
productive	O
cough	O
(	O
cold	O
sx	O
)	O
beginning	O
approximately	O
1	O
week	O
ago	O
;	O
he	O
had	O
a	O
CXR	O
3	O
-	O
4	O
days	O
ago	O
which	O
reportedly	O
was	O
negative	O
for	O
pneumonia	I-Reason
and	O
took	O
atovaquone	I-Drug
.	O
.	O
After	O
the	O
onset	O
of	O
these	O
pulmonary	O
symptoms	O
,	O
he	O
later	O
developed	O
left	B-Reason
knee	I-Reason
"	I-Reason
bursitis	I-Reason
"	O
last	O
week	O
for	O
which	O
he	O
received	O
injection	O
most	O
recently	O
yesterday	O
by	O
PCP	O
(	O
presumably	O
steroid	I-Drug
injection	O
)	O
.	O
He	O
had	O
largely	O
been	O
bed	O
bound	O
over	O
the	O
last	O
few	O
days	O
[	O
**	O
1	O
-	O
4	O
**	O
]	O
to	O
left	O
knee	O
pain	O
.	O
Beginning	O
this	O
morning	O
,	O
he	O
was	O
very	O
exhausted	O
.	O
He	O
took	O
a	O
nap	O
this	O
morning	O
and	O
when	O
he	O
awoke	O
,	O
he	O
was	O
confused	O
,	O
somnolent	O
,	O
lethargic	O
.	O
His	O
wife	O
called	O
EMS	O
and	O
he	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
.	O
En	O
route	O
to	O
the	O
ED	O
,	O
he	O
was	O
noted	O
to	O
be	O
in	O
a.fib	B-Reason
with	I-Reason
RVR	I-Reason
for	O
which	O
he	O
received	O
diltiazem	I-Drug
.	O
.	O
In	O
the	O
ED	O
initial	O
vitals	O
were	O
T	O
96.7	O
HR	O
112	O
BP	O
105/67	O
RR	O
28	O
O2	O
sat	O
85	O
%	O
RA	O
.	O
CXR	O
showed	O
multifocal	B-Reason
PNA	I-Reason
at	O
RUL	O
,	O
RLL	O
,	O
LLL	O
.	O
He	O
was	O
placed	O
on	O
NRB	O
and	O
shortly	O
thereafter	O
O2	O
sats	O
again	O
dropped	O
to	O
the	O
80s	O
,	O
thus	O
he	O
was	O
intubated	O
4:30	O
pm	O
.	O
Blood	O
cultures	O
were	O
drawn	O
and	O
he	O
received	O
levofloxacin	I-Drug
750g	O
IV	O
x1	O
,	O
vancomycin	I-Drug
1g	O
IV	O
x1	O
,	O
ceftriaxone	I-Drug
1g	O
IV	O
x1	O
,	O
and	O
azithromycin	I-Drug
500	O
mg	O
x1	O
.	O
He	O
also	O
received	O
10	O
mg	O
IV	O
decadron	I-Drug
.	O
He	O
was	O
initially	O
normotensive	O
,	O
but	O
dropped	B-Reason
pressure	I-Reason
at	O
6:30	O
pm	O
into	O
70s	O
requiring	O
initiation	O
of	O
phenylephrine	I-Drug
gtt	O
.	O
Over	O
his	O
entire	O
ED	O
course	O
,	O
received	O
total	O
5L	O
NS	I-Drug
.	O
.	O
Head	O
CT	O
demonstrated	O
"	O
no	O
new	O
findings	O
"	O
and	O
was	O
reportedly	O
reviewed	O
by	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
neurosurgery	O
however	O
there	O
is	O
no	O
note	O
in	O
chart	O
/	O
OMR	O
.	O
Additionally	O
he	O
was	O
seen	O
by	O
his	O
neurologist	O
who	O
follows	O
him	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
,	O
however	O
there	O
is	O
no	O
documentation	O
of	O
this	O
.	O
Past	O
Medical	O
History	O
:	O
#	O
Grade	O
4	O
glioblastoma	B-Reason
multiforme	I-Reason
left	O
temporal	O
lobe	O
;	O
s	O
/	O
p	O
high	I-Reason
dose	O
radiotherapy	O
,	O
previously	O
on	O
high	O
dose	O
steroids	I-Drug
,	O
recently	O
tapered	O
.	O
Recently	O
placed	O
Portacath	O
with	O
steristrips	O
still	O
present	O
.	O
#	O
Rheumatoid	B-Reason
arthritis	I-Reason
;	O
on	O
remicade	I-Drug
until	O
recently	O
#	O
L	O
knee	O
bursitis	O
#	O
Hyperlipidemia	O
Social	O
History	O
:	O
Lives	O
at	O
home	O
with	O
wife	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
and	O
daughter	O
-	O
in	O
-	O
law	O
(	O
who	O
is	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
)	O
live	O
locally	O
.	O
Smoking	O
,	O
Etoh	O
history	O
unknown	O
.	O
Family	O
History	O
:	O
nc	O
Physical	O
Exam	O
:	O
S	O
:	O
Temp	O
:	O
97.2	O
BP	O
:	O
99/69	O
HR	O
:	O
138	O
a.	O
fib	O
RR	O
:	O
22	O
O2sat	O
92	O
%	O
AC	O
500/19	O
PEEP	O
14	O
FiO2	O
1.0	O
GEN	O
:	O
Intubated	O
,	O
unresponsive	O
on	O
minimal	O
sedation	O
HEENT	O
:	O
Pupils	O
pinpoint	O
,	O
symmetric	O
,	O
unresponsive	O
to	O
light	O
,	O
scleral	O
mildy	O
icteric	O
,	O
dry	O
MM	O
,	O
Multiple	O
pinpoint	O
white	O
plaques	O
on	O
roof	O
of	O
mouth	O
NECK	O
:	O
no	O
supraclavicular	O
or	O
cervical	O
lymphadenopathy	O
,	O
no	O
jvd	O
,	O
no	O
carotid	O
bruits	O
,	O
no	O
thyromegaly	O
or	O
thyroid	O
nodules	O
CHEST	O
:	O
Portacath	O
site	O
right	O
anterior	O
chest	O
with	O
steri	O
strips	O
in	O
place	O
,	O
mildly	O
erythematous	O
,	O
no	O
significant	O
increase	O
warmth	O
/	O
induration	O
/	O
fluctuance	O
RESP	O
:	O
Clear	O
anteriorly	O
,	O
decrease	O
BS	O
right	O
laterally	O
,	O
no	O
wheezing	O
/	O
rales	O
CV	O
:	O
irreg	O
irreg	O
,	O
no	O
mrg	O
appreciated	O
ABD	O
:	O
nd	O
,	O
+	O
b	O
/	O
s	O
,	O
soft	O
,	O
nt	O
,	O
no	O
masses	O
or	O
hepatosplenomegaly	O
EXT	O
:	O
1	O
+	O
pedal	O
edema	O
b	O
/	O
l	O
,	O
right	O
foot	O
cooler	O
than	O
left	O
1	O
+	O
DP	O
on	O
right	O
,	O
2	O
+	O
DP	O
on	O
left	O
,	O
palpable	O
PT	O
pulses	O
b	O
/	O
l	O
,	O
left	O
knee	O
with	O
small	O
effusion	O
,	O
increased	O
warmth	O
without	O
significant	O
increased	O
erythema	O
SKIN	O
:	O
appears	O
mildly	O
jaundiced	O
NEURO	O
:	O
Downgoing	O
toes	O
b	O
/	O
l.	O
DTRs	O
[	O
**	O
Name	O
(	O
NI	O
)	O
20772	O
**	O
]	O
throughout	O
including	O
biceps	O
,	O
patellar	O
,	O
achilles	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
WBC	O
-	O
6.0	O
RBC	O
-	O
3.78	O
*	O
Hgb	O
-	O
11.7	O
*	O
Hct	O
-	O
34.3	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
34.1	O
RDW	O
-	O
13.6	O
Plt	O
Ct	O
-	O
74	O
*	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
Neuts	O
-	O
80	O
*	O
Bands	O
-	O
6	O
*	O
Lymphs	O
-	O
9	O
*	O
Monos	O
-	O
3	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
2	O
*	O
Myelos	O
-	O
0	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
NORMAL	O
Poiklo	O
-	O
NORMAL	O
Macrocy	O
-	O
NORMAL	O
Microcy	O
-	O
NORMAL	O
Polychr	O
-	O
NORMAL	O
[	O
**	O
2155-1-2	O
**	O
]	O
02:38	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
179	O
[	O
**	O
2155-1-2	O
**	O
]	O
02:38	O
AM	O
BLOOD	O
PT	O
-	O
14.6	O
*	O
PTT	O
-	O
35.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
PT	O
-	O
13.3	O
PTT	O
-	O
31.5	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
Plt	O
Smr	O
-	O
VERY	O
LOW	O
Plt	O
Ct	O
-	O
74	O
*	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
Glucose	O
-	O
98	O
UreaN	O
-	O
44	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
138	O
K	O
-	O
5.3	O
*	O
Cl	O
-	O
105	O
HCO3	O
-	O
23	O
AnGap	O
-	O
15	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
52	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
[	O
**	O
2154-12-14	O
**	O
]	O
04:45	O
PM	O
BLOOD	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
3.7	O
Mg	O
-	O
2.7	O
*	O
UricAcd	O
-	O
3.4	O
[	O
**	O
2154-12-14	O
**	O
]	O
10:47	O
PM	O
BLOOD	O
calTIBC	O
-	O
146	O
*	O
VitB12	O
-	O
1418	O
*	O
Folate	O
-	O
3.5	O
Ferritn	O
-	O
1409	O
*	O
TRF	O
-	O
112	O
*	O
[	O
**	O
2154-12-14	O
**	O
]	O
10:47	O
PM	O
BLOOD	O
TSH	O
-	O
0.69	O
[	O
**	O
2154-12-15	O
**	O
]	O
06:26	O
AM	O
BLOOD	O
Cortsol	O
-	O
26.9	O
*	O
[	O
**	O
2154-12-14	O
**	O
]	O
06:50	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
60	O
*	O
pCO2	O
-	O
50	O
*	O
pH	O
-	O
7.30	O
*	O
calTCO2	O
-	O
26	O
Base	O
XS	O
--	O
1	O
Intubat	O
-	O
INTUBATED	O
Vent	O
-	O
CONTROLLED	O
[	O
**	O
2154-12-14	O
**	O
]	O
07:15	O
PM	O
BLOOD	O
Lactate	O
-	O
2.2	O
*	O
[	O
**	O
2154-12-15	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
O2	O
Sat	O
-	O
98	O
[	O
**	O
2154-12-15	O
**	O
]	O
12:25	O
AM	O
BLOOD	O
freeCa	O
-	O
1.10	O
*	O
Brief	O
Hospital	O
Course	O
:	O
Note	O
:	O
the	O
majority	O
of	O
this	O
hospital	O
course	O
refers	O
to	O
the	O
patient	O
's	O
ICU	O
course	O
.	O
He	O
was	O
on	O
the	O
medical	O
floor	O
for	O
16	O
hours	O
prior	O
to	O
discharge	O
and	O
was	O
stable	O
during	O
this	O
time	O
.	O
.	O
#	O
Septic	O
Shock	O
:	O
Met	O
criteria	O
for	O
septic	O
shock	O
.	O
On	O
presentation	O
had	O
clear	O
pulmonary	O
source	O
of	O
infection	O
.	O
Initial	O
sputums	O
grew	O
out	O
pneumococci	O
.	O
Patient	O
relatively	O
immunocompromised	I-Ade
due	O
both	O
to	O
cancer	O
diagnosis	O
and	O
chronic	O
steroid	I-Drug
use	O
secondary	O
to	O
brain	I-Reason
tumor	O
.	O
On	O
admission	O
patient	O
had	O
central	O
line	O
placed	O
,	O
CVPs	O
maintained	O
[	O
**	O
7	O
-	O
15	O
**	O
]	O
.	O
Patient	O
needed	O
pressors	I-Drug
to	O
maintain	B-Reason
BP	I-Reason
initially	O
.	O
On	O
levophed	I-Drug
,	O
but	O
developed	O
some	O
tachyarrhythmnias	B-Ade
(	I-Ade
Afib	I-Ade
with	I-Ade
RVR	I-Ade
)	I-Ade
so	O
was	O
switched	O
to	O
neo	I-Drug
.	O
Initially	O
covered	O
with	O
Zosyn	I-Drug
,	O
levoflox	I-Drug
and	O
vanco	I-Drug
.	O
Patient	O
was	O
continued	O
on	O
atovaquone	I-Drug
for	O
PCP	I-Reason
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
6187	O
**	O
]	O
.	O
Patient	O
was	O
also	O
intubated	O
on	O
presentation	O
,	O
and	O
maintained	O
on	O
AC	O
.	O
Patient	O
had	O
EKGs	O
without	O
signs	O
of	O
ischemia	O
,	O
and	O
multiple	O
sets	O
of	O
normal	O
cardiac	O
enzymes	O
.	O
Pressors	O
were	O
largely	O
weaned	O
by	O
HD	O
#	O
3	O
.	O
He	O
did	O
rarely	O
require	O
brief	O
periods	O
of	O
neosynepherine	I-Drug
,	O
due	O
to	O
too	B-Reason
-	I-Reason
rapid	I-Reason
diuresis	I-Reason
.	O
The	O
patient	O
had	O
a	O
normal	O
cortisol	O
stim	O
test	O
.	O
Historically	O
,	O
it	O
was	O
noted	O
that	O
the	O
patient	O
had	O
a	O
red	O
left	O
knee	O
a	O
few	O
days	O
prior	O
to	O
admission	O
.	O
This	O
knee	O
was	O
tapped	O
by	O
ortho	O
and	O
found	O
to	O
be	O
floridly	O
septic	O
.	O
He	O
was	O
taken	O
to	O
the	O
OR	O
and	O
washed	O
out	O
by	O
Ortho	O
(	O
please	O
see	O
seperate	O
op	O
note	O
for	O
full	O
accounting	O
of	O
this	O
procedure	O
)	O
.	O
This	O
infection	O
was	O
found	O
to	O
be	O
MSSA	O
,	O
which	O
also	O
grew	O
out	O
of	O
his	O
blood	O
and	O
eventually	O
out	O
of	O
his	O
R	O
chest	O
chemo	O
-	O
port	O
,	O
which	O
was	O
removed	O
by	O
surgery	O
.	O
He	O
was	O
maintained	O
on	O
a	O
6week	O
course	O
of	O
Nafcillin	I-Drug
for	O
this	O
staph	I-Reason
infection	O
.	O
A	O
TEE	O
demonstrated	O
no	O
signs	O
of	O
endocarditis	O
.	O
Infectious	O
disease	O
was	O
consulted	O
and	O
assisted	O
with	O
his	O
antibiotic	I-Drug
regimen	O
.	O
The	O
patient	O
completed	O
a	O
full	O
14d	O
course	O
of	O
Levoflox	I-Drug
for	O
pneumonia	I-Reason
.	O
The	O
patient	O
also	O
had	O
a	O
full	O
course	O
of	O
Clinda	I-Drug
for	O
a	O
question	O
of	O
toxic	B-Reason
shock	I-Reason
syndrome	I-Reason
or	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
His	O
Vanco	I-Drug
was	O
d	O
/	O
c	O
'd	O
after	O
5d	O
due	O
to	O
only	O
MSSA	O
growing	O
out	O
.	O
On	O
[	O
**	O
12	O
-	O
20	O
**	O
]	O
his	O
pre-existing	O
R	O
chest	O
chemo	O
port	O
was	O
noted	O
to	O
be	O
purulent	O
and	O
was	O
removed	O
by	O
surgery	O
.	O
This	O
grew	O
out	O
MSSA	O
.	O
Once	O
more	O
,	O
the	O
nafcillin	I-Drug
was	O
continued	O
for	O
6week	O
total	O
course	O
.	O
A	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
culture	O
grew	O
out	O
yeast	I-Reason
and	O
he	O
was	O
started	O
on	O
a	O
course	O
of	O
fluconisol	I-Drug
as	O
per	O
ID	O
.	O
He	O
recieved	O
a	O
full	O
Ophtho	O
eval	O
which	O
demonstrated	O
no	O
ocular	O
involvment	O
.	O
Planned	O
course	O
of	O
treatment	O
is	O
for	O
nafcillin	I-Drug
for	O
total	O
of	O
6	O
weeks	O
to	O
end	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
,	O
fluconazole	I-Drug
for	O
2	O
weeks	O
total	O
to	O
end	O
[	O
**	O
1	O
-	O
9	O
**	O
]	O
,	O
and	O
ceftriaxone	I-Drug
to	O
end	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
.	O
.	O
#	O
Afib	B-Reason
c	I-Reason
RvR	I-Reason
:	O
New	O
-	O
onset	O
afib	O
in	O
the	O
face	O
of	O
sepsis	I-Reason
,	O
hypotension	I-Reason
,	O
infection	I-Reason
.	O
Patient	O
initially	O
controlled	O
with	O
boluses	O
of	O
Diltiazem	I-Drug
or	O
Lopressor	I-Drug
.	O
Often	O
returned	O
into	O
Afib	I-Reason
during	O
times	O
of	O
increased	O
activity	O
or	O
stress	O
.	O
Used	O
neosynepharine	I-Drug
which	O
seemed	O
less	O
arrhythmagenic	O
.	O
Amiodarone	I-Drug
was	O
tried	O
initially	O
for	O
control	I-Reason
,	O
but	O
the	O
patient	O
became	O
to	O
bradycardic	I-Ade
on	O
this	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
.	O
As	O
patient	O
was	O
weaned	O
from	O
pressors	I-Drug
he	O
was	O
begun	O
on	O
a	O
regimen	O
of	O
metoprolol	I-Drug
which	O
seemed	O
to	O
control	I-Reason
his	O
rate	O
well	O
.	O
He	O
did	O
ocassionally	O
return	O
to	O
RVR	I-Reason
,	O
which	O
was	O
treated	O
with	O
boluses	O
of	O
dilt	I-Drug
or	O
lopressor	I-Drug
with	O
good	O
effect	O
.	O
He	O
was	O
then	O
restarted	O
on	O
amiodarone	I-Drug
[	O
**	O
1	O
-	O
1	O
**	O
]	O
and	O
responded	O
to	O
it	O
well	O
.	O
Due	O
to	O
his	O
brain	O
tumor	O
he	O
was	O
note	O
anticoagulated	O
during	O
his	O
time	O
in	O
the	O
ICU	O
.	O
The	O
risks	O
and	O
benefits	O
were	O
discussed	O
.	O
It	O
was	O
felt	O
that	O
the	O
risks	O
of	O
ICH	O
outweighed	O
the	O
benefits	O
of	O
stroke	O
prevention	O
at	O
this	O
time	O
.	O
Plans	O
were	O
made	O
to	O
readdress	O
this	O
issue	O
once	O
the	O
patient	O
's	O
mental	O
status	O
improved	O
.	O
.	O
#	O
Septic	B-Reason
Arthritis	I-Reason
:	O
As	O
above	O
,	O
had	O
septic	O
arthritis	O
of	O
L	O
knee	O
treated	O
via	O
washout	O
by	O
ortho	O
on	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
.	O
Nafcillin	I-Drug
x6weeks	O
per	O
ID	O
started	O
on	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
.	O
Nafcillin	I-Drug
is	O
scheduled	O
to	O
finish	O
on	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
.	O
Patient	O
did	O
have	O
a	O
swollen	O
L	O
wrist	O
later	O
in	O
his	O
course	O
,	O
but	O
this	O
was	O
tapped	O
by	O
Ortho	O
and	O
never	O
grew	O
out	O
any	O
bacteria	O
.	O
Plastics	O
-	O
hand	O
was	O
consulted	O
and	O
felt	O
clinically	O
that	O
this	O
was	O
not	O
a	O
septic	O
joint	O
,	O
instead	O
just	O
a	O
manifestation	O
of	O
his	O
chronic	O
RA	O
.	O
Ortho	O
also	O
felt	O
it	O
was	O
not	O
prudent	O
to	O
washout	O
his	O
R	O
knee	O
,	O
which	O
was	O
clinically	O
asymptomatic	O
during	O
his	O
ICU	O
course	O
.	O
His	O
L	O
knee	O
healed	O
well	O
and	O
the	O
staples	O
and	O
drain	O
were	O
removed	O
without	O
incidence	O
.	O
He	O
has	O
been	O
signed	O
off	O
from	O
direct	O
ortho	O
care	O
,	O
and	O
is	O
weight	O
-	O
bearing	O
as	O
tolerated	O
at	O
time	O
of	O
ICU	O
discharge	O
.	O
.	O
#Respiratory	O
status	O
:	O
Patient	O
was	O
maintained	O
on	O
ARDS	O
-	O
style	O
ventilation	O
while	O
on	O
the	O
ventilator	O
.	O
He	O
has	O
a	O
bronchoscopy	O
on	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
which	O
showed	O
diffuse	O
thick	O
bloody	O
sputum	O
greatest	O
in	O
the	O
R	O
LL	O
.	O
By	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
the	O
patient	O
was	O
changed	O
to	O
pressure	O
support	O
ventilation	O
.	O
The	O
patient	O
was	O
activily	O
diuresed	O
at	O
this	O
time	O
,	O
with	O
good	O
effect	O
and	O
improving	O
respiratory	O
status	O
.	O
The	O
patient	O
tested	O
negative	O
for	O
legionella	O
and	O
influenza	O
.	O
The	O
patient	O
was	O
quickly	O
weaned	O
to	O
CPAP+PS	O
of	O
[	O
**	O
4	O
-	O
7	O
**	O
]	O
,	O
but	O
was	O
difficult	O
to	O
wean	O
fully	O
from	O
the	O
vent	O
due	O
mainly	O
to	O
his	O
mental	O
status	O
.	O
He	O
was	O
extubated	O
on	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
with	O
great	O
success	O
.	O
On	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
the	O
patient	O
was	O
noted	O
to	O
have	O
an	O
increasing	O
o2	O
requirement	O
and	O
a	O
CXR	O
demonstrated	O
a	O
moderate	O
-	O
sized	O
R	O
pneumothorax	O
.	O
Thoracic	O
surgery	O
was	O
consulted	O
and	O
placed	O
a	O
chest	O
tube	O
.	O
This	O
tube	O
was	O
intermittantly	O
to	O
wall	O
-	O
suction	O
,	O
water	O
-	O
seal	O
or	O
clamped	O
.	O
On	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
it	O
was	O
d	O
/	O
c	O
'd	O
,	O
with	O
the	O
pneumothoax	O
smaller	O
in	O
size	O
.	O
.	O
#GBM	O
:	O
Head	O
CTs	O
compared	O
to	O
his	O
baseline	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
scans	O
showed	O
no	O
interval	O
change	O
.	O
He	O
was	O
maintained	O
on	O
his	O
baseline	O
3	O
mg	O
of	O
Dexamethasone	I-Drug
while	O
inpatient	O
here	O
.	O
It	O
appears	O
that	O
neurooncs	O
original	O
plans	O
were	O
to	O
taper	O
the	O
dexamethasone	I-Drug
.	O
We	O
were	O
unable	O
to	O
contact	O
primary	O
neuro	O
-	O
oncoligist	O
to	O
discuss	O
steroid	I-Drug
taper	O
but	O
this	O
should	O
be	O
discussed	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
when	O
he	O
becomes	O
available	O
.	O
.	O
#Anemia	O
/	O
thrombocytopenia	O
:	O
Had	O
anemia	O
of	O
chronic	O
disease	O
,	O
admitted	O
with	O
thrombocytopenia	I-Ade
attributed	O
to	O
Avastin	I-Drug
and	O
timador	I-Drug
.	O
His	O
thrombocytopenia	O
was	O
asymptomatic	O
during	O
his	O
hospital	O
course	O
,	O
and	O
steadily	O
improved	O
.	O
His	O
anemia	O
was	O
mild	O
,	O
and	O
did	O
require	O
occasional	O
transfusion	O
.	O
.	O
#	O
Hyperglycemia	I-Reason
:	O
Intitally	O
hyperglycemic	O
in	O
face	O
of	O
sepsis	O
,	O
controlled	O
with	O
SS	O
insulin	I-Drug
and	O
resolved	O
on	O
its	O
own	O
.	O
.	O
#	O
R	O
Chest	B-Reason
wound	I-Reason
:	O
Co	O
n't	O
to	O
drain	O
purulent	O
material	O
s	O
/	O
p	O
removal	O
of	O
port	O
.	O
Surgery	O
recommended	O
QID	O
dilute	O
(	O
[	O
**	O
12	O
-	O
6	O
**	O
]	O
)	O
Dakin	B-Drug
's	I-Drug
solution	I-Drug
and	O
close	O
f	O
/	O
u.	O
Any	O
fluctuant	O
areas	O
must	O
be	O
debrided	O
.	O
.	O
#Mental	O
Status	O
:	O
The	O
patient	O
presented	O
with	O
altered	O
mental	O
status	O
felt	O
to	O
be	O
due	O
to	O
sepsis	O
.	O
He	O
did	O
take	O
some	O
days	O
to	O
awaken	O
from	O
his	O
intubated	O
and	O
sedated	O
state	O
.	O
He	O
continued	O
to	O
be	O
Aox1	O
-	O
2	O
in	O
the	O
MICU	O
,	O
with	O
symptoms	O
consistent	O
with	O
delerium	O
.	O
A	O
repeat	O
head	O
CT	O
showed	O
no	O
change	O
;	O
his	O
delerium	O
was	O
felt	O
to	O
be	O
mainly	O
post-septic	O
and	O
ICU	O
related	O
and	O
appeared	O
to	O
be	O
slowly	O
intervally	O
improving	O
each	O
day	O
.	O
.	O
#Prophylaxis	O
:	O
Patient	O
was	O
initially	O
on	O
pneumoboots	O
and	O
then	O
Heparin	I-Drug
SC	O
,	O
a	O
bowel	O
regmimen	O
and	O
a	O
Gi	O
prophlyaxsis	O
throughout	O
his	O
hospital	O
course	O
.	O
.	O
#	O
Electrolytes	O
:	O
The	O
patient	O
required	O
extensive	O
repletion	O
of	O
his	O
potassium	O
during	O
his	O
ICU	O
course	O
,	O
often	O
requiring	O
q6hr	O
lyte	O
checks	O
and	O
100	O
-	O
200meq	O
of	O
K	O
+	O
per	O
day	O
.	O
This	O
was	O
felt	O
to	O
be	O
mostly	O
due	O
to	O
a	O
diarrhea	O
and	O
thus	O
GI	O
loss	O
,	O
and	O
was	O
resolving	O
at	O
the	O
end	O
of	O
his	O
hospital	O
course	O
as	O
diarrhea	O
resolved	O
.	O
.	O
#	O
Nutrition	O
:	O
The	O
patient	O
was	O
maintained	O
on	O
TF	O
while	O
intubated	O
,	O
and	O
also	O
s	O
/	O
p	O
intubation	O
as	O
he	O
failed	O
his	O
initial	O
speech	O
and	O
swallow	O
exams	O
.	O
On	O
[	O
**	O
1	O
-	O
3	O
**	O
]	O
he	O
passed	O
his	O
speech	O
and	O
swallow	O
bedside	O
test	O
.	O
.	O
#LFTs	O
:	O
Patient	O
had	O
elevated	O
LFTs	O
on	O
presentation	O
which	O
were	O
attributed	O
to	O
sepsis	O
.	O
This	O
abnormality	O
resolved	O
as	O
the	O
patient	O
's	O
clinical	O
picture	O
improved	O
.	O
He	O
should	O
continue	O
on	O
weekly	O
LFT	O
checks	O
due	O
to	O
his	O
continuing	O
nafcillin	I-Drug
.	O
.	O
#	O
PT	O
/	O
OT	O
:	O
after	O
extubation	O
the	O
patient	O
was	O
followed	O
actively	O
by	O
PT	O
and	O
OT	O
.	O
Medications	O
on	O
Admission	O
:	O
#	O
Naproxen	I-Drug
prn	O
#	O
Mepron	I-Drug
(	O
prophylaxis	I-Reason
)	O
#	O
Hydrocodone	I-Drug
#	O
Dexamethasone	I-Drug
3	O
mg	O
#	O
Avastin	I-Drug
(	O
last	O
received	O
2wks	O
ago	O
,	O
due	O
on	O
Monday	O
[	O
**	O
2154-12-16	O
**	O
]	O
)	O
#	O
Lipid	O
lowering	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
(	O
wife	O
unsure	O
of	O
name	O
)	O
#	O
Timador	I-Drug
(	O
was	O
previously	O
on	O
this	O
,	O
but	O
was	O
stopped	O
[	O
**	O
1	O
-	O
4	O
**	O
]	O
to	O
thrombocytopenia	I-Ade
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
5000	O
(	O
5000	O
)	O
units	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ml	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Atovaquone	I-Drug
750	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Seven	O
[	O
**	O
Age	O
over	O
90	O
1230	O
**	O
]	O
y	O
(	O
750	O
)	O
mg	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
6	O
.	O
Dexamethasone	I-Drug
1.5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
8	O
.	O
Guaifenesin	I-Drug
100	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
Fifteen	O
(	O
15	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
cough	I-Reason
.	O
9	O
.	O
Fluconazole	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
2	O
weeks	O
:	O
last	O
day	O
[	O
**	O
1	O
-	O
9	O
**	O
]	O
.	O
10	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
:	O
hold	O
for	O
HR	O
<	O
50	O
and	O
SBP	O
<	O
100	O
.	O
11	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
until	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
then	O
400	O
mg	O
daily	O
.	O
12	O
.	O
Famotidine	I-Drug
10	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
Twenty	O
(	O
20	O
)	O
mg	O
Intravenous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
13	O
.	O
Ceftriaxone	B-Drug
-	I-Drug
Dextrose	I-Drug
(	I-Drug
Iso	I-Drug
-	I-Drug
osm	I-Drug
)	I-Drug
1	O
gram	O
/	O
50	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
gram	O
Intravenous	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
14	O
.	O
Nafcillin	B-Drug
in	I-Drug
D2	I-Drug
.4	I-Drug
W	I-Drug
2	O
gram	O
/	O
100	O
mL	O
Piggyback	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
grams	O
Intravenous	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
for	O
6	O
weeks	O
:	O
last	O
day	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
.	O
15	O
.	O
Heparin	B-Drug
Lock	I-Drug
Flush	I-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
100	O
unit	O
/	O
mL	O
Syringe	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
ML	O
Intravenous	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
16	O
.	O
Insulin	B-Drug
NPH	I-Drug
Human	I-Drug
Recomb	I-Drug
100	O
unit	O
/	O
mL	O
Cartridge	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
units	O
Subcutaneous	O
twice	O
a	O
day	O
.	O
17	O
.	O
Insulin	B-Drug
Regular	I-Drug
Human	I-Drug
300	O
unit	O
/	O
3	O
mL	O
Insulin	I-Drug
Pen	O
Sig	O
:	O
sliding	O
scale	O
Subcutaneous	O
four	O
times	O
a	O
day	O
:	O
sliding	O
scale	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Septic	O
Shock	O
Community	O
Aquired	O
Pneumonia	O
Respiratory	O
Failure	O
Acute	O
Renal	O
Failure	O
Septic	O
Arthritis	O
(	O
L	O
Knee	O
)	O
Bacteremia	O
Infected	O
R	O
Chest	O
Catheter	O
Afib	O
with	O
RVR	O
Delerium	O
Anemia	O
Thrombocytopenia	O
Hyperglycemia	O
Pneumothorax	O
(	O
R	O
)	O
Hypokalemia	O
Transaminitis	O
Secondary	O
:	O
#	O
Grade	O
4	O
glioblastoma	O
multiforme	O
left	O
temporal	O
lobe	O
;	O
s	O
/	O
p	O
high	O
dose	O
radiotherapy	O
,	O
previously	O
on	O
high	O
dose	O
steroids	I-Drug
,	O
recently	O
tapered	O
.	O
Recently	O
placed	O
Portacath	O
with	O
steristrips	O
still	O
present	O
.	O
#	O
Rheumatoid	B-Reason
arthritis	I-Reason
;	O
on	O
remicade	I-Drug
until	O
recently	O
#	O
L	O
knee	O
bursitis	O
#	O
Hyperlipidemia	O
Discharge	O
Condition	O
:	O
fair	O
-	O
multifactorial	O
delirium	O
with	O
waxing	O
and	O
[	O
**	O
Doctor	O
Last	O
Name	O
688	O
**	O
]	O
mental	O
status	O
A+O	O
x1	O
-	O
2	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
for	O
pneumonia	I-Reason
and	O
multiple	B-Reason
infections	I-Reason
including	O
of	O
your	O
knee	O
and	O
blood	O
stream	O
.	O
you	O
were	O
treated	O
with	O
several	O
antibiotics	I-Drug
and	O
had	O
a	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
which	O
required	O
intubation	O
.	O
Currently	O
you	O
are	O
being	O
treated	O
for	O
these	O
infections	O
and	O
are	O
on	O
tube	O
feedings	O
and	O
slowly	O
eating	O
again	O
.	O
Regarding	O
your	O
brain	O
tumor	O
,	O
we	O
felt	O
that	O
this	O
issue	O
,	O
while	O
serious	O
,	O
was	O
stable	O
during	O
your	O
stay	O
here	O
.	O
It	O
is	O
very	O
important	O
that	O
you	O
followup	O
with	O
your	O
neuro	O
-	O
oncologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
.	O
You	O
need	O
to	O
discuss	O
with	O
him	O
whether	O
you	O
should	O
be	O
on	O
blood	B-Drug
thinners	I-Drug
.	O
.	O
Followup	O
Instructions	O
:	O
f	O
/	O
u	O
with	O
Dr.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1005	O
**	O
]	O
of	O
orthopedic	O
surgery	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
15940	O
**	O
]	O
to	O
schedule	O
a	O
followup	O
appointment	O
in	O
1	O
month	O
.	O
f	O
/	O
u	O
with	O
your	O
outpatient	O
rheumatologist	O
in	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
weeks	O
.	O
f	O
/	O
u	O
with	O
your	O
outpatient	O
neurooncologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
Monday	O
by	O
phone	O
-	O
he	O
should	O
be	O
involved	O
in	O
deciding	O
steroid	O
taper	O
and	O
deciding	O
about	O
anticoagulation	O
.	O
Some	O
of	O
your	O
labs	O
will	O
be	O
faxed	O
to	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
of	O
infectious	O
disease	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1353	O
**	O
]	O
(	O
phone	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
17490	O
**	O
]	O
)	O
,	O
she	O
will	O
contact	O
you	O
regarding	O
followup	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2178-12-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2179-1-9	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2111-4-12	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
148	O
**	O
]	O
Chief	O
Complaint	O
:	O
Abdominal	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2178-12-17	O
**	O
]	O
:	O
1	O
.	O
Exploratory	O
laparotomy	O
.	O
2	O
.	O
Reduction	O
of	O
internal	O
volvulus	O
of	O
the	O
small	O
bowel	O
.	O
3	O
.	O
Small	O
-	O
bowel	O
resection	O
with	O
primary	O
anastomosis	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
67	O
year	O
old	O
man	O
with	O
[	O
**	O
Hospital	O
100256	O
**	O
]	O
medical	O
problems	O
including	O
DM	O
type	O
2	O
,	O
[	O
**	O
Hospital3	O
9642	O
**	O
]	O
mechanical	O
[	O
**	O
Hospital3	O
1291	O
**	O
]	O
,	O
Ascending	O
aorta	O
repair	O
with	O
graft	O
CAD	O
s	O
/	O
p	O
CABG	O
,	O
hx	O
of	O
VF	O
arrest	O
s	O
/	O
p	O
AICD	O
[	O
**	O
2175	O
**	O
]	O
who	O
presents	O
with	O
acute	O
onset	O
severe	O
abdominal	O
pain	O
at	O
10	O
am	O
yesterday	O
AM	O
.	O
States	O
was	O
previosly	O
feeling	O
well	O
,	O
tolerating	O
POs	O
and	O
having	O
regular	O
BMs	O
when	O
this	O
started	O
.	O
Never	O
had	O
pain	O
like	O
this	O
before	O
,	O
[	O
**	O
10	O
-	O
3	O
**	O
]	O
diffuse	O
,	O
crampy	O
.	O
+	O
nausea	O
,	O
no	O
vomiting	O
.	O
Last	O
BM	O
yesterday	O
,	O
normal	O
,	O
no	O
blood	O
.	O
Denies	O
Diarrhea	O
.	O
No	O
fevers	O
or	O
chills	O
.	O
In	O
the	O
Emergency	O
Department	O
,	O
he	O
was	O
noted	O
to	O
be	O
hypotensive	O
,	O
started	O
on	O
vasopressors	O
,	O
received	O
3L	O
IVF	O
with	O
labored	O
breathing	O
and	O
thus	O
intubated	O
in	O
ED	O
.	O
He	O
was	O
admitted	O
to	O
to	O
the	O
SICU	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
s	O
/	O
p	O
CABGx3	O
[	O
**	O
2168	O
**	O
]	O
-	O
h	O
/	O
o	O
VF	O
arrest	O
[	O
**	O
6	O
-	O
30	O
**	O
]	O
s	O
/	O
p	O
ICD	O
placement	O
;	O
required	O
explantation	O
for	O
MRSA	O
pocket	O
infection	O
with	O
reimplantation	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
,	O
s	O
/	O
p	O
lead	O
removal	O
[	O
**	O
4	O
-	O
2	O
**	O
]	O
-	O
mechanical	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
1291	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
1525	O
**	O
]	O
,	O
[	O
**	O
2168	O
**	O
]	O
-	O
ascending	O
aorta	O
repair	O
c	O
graft	O
[	O
**	O
4	O
-	O
/	O
2169	O
**	O
]	O
-	O
CHF	O
(	O
EF	O
20	O
%	O
per	O
TTE	O
[	O
**	O
2178-8-19	O
**	O
]	O
)	O
-	O
high	O
grade	O
CoNS	O
bacteremia	I-Reason
in	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
c	O
/	O
b	O
high	O
grade	O
CoNS	O
,	O
VRE	O
bactermia	I-Reason
while	O
on	O
vancomycin	I-Drug
[	O
**	O
3	O
-	O
2	O
**	O
]	O
,	O
s	O
/	O
p	O
4	O
weeks	O
daptomycin	I-Drug
and	O
explantation	O
of	O
ICD	O
leads	O
-	O
pseudomonas	B-Reason
UTI	I-Reason
[	O
**	O
6	O
-	O
2	O
**	O
]	O
s	O
/	O
p	O
cefepime	I-Drug
x	O
14	O
days	O
,	O
now	O
pseudomonas	I-Reason
UTI	O
[	O
**	O
8	O
-	O
2	O
**	O
]	O
s	O
/	O
p	O
meropenem	I-Drug
x	O
14	O
days	O
-	O
R	O
lateral	O
foot	O
ulcer	O
s	O
/	O
p	O
debridement	O
s	O
/	O
p	O
zosyn	I-Drug
x	O
14	O
days	O
-	O
DM2	O
c	O
/	O
b	O
neuropathy	O
-	O
Hep	B-Reason
C	I-Reason
(	O
dx	O
[	O
**	O
4	O
-	O
2	O
**	O
]	O
,	O
2.38	O
million	O
IU	O
/	O
ml	O
.	O
Seen	O
by	O
Hepatology	O
,	O
[	O
**	O
2178-7-30	O
**	O
]	O
note	O
emphasizes	O
deferring	O
IFN	I-Drug
/	O
ribavirin	I-Drug
tx	O
for	O
now	O
given	O
infections	O
,	O
etc.	O
)	O
-	O
HTN	O
-	O
HLP	O
-	O
PVD	O
s	O
/	O
p	O
L	O
BKA	O
[	O
**	O
7	O
-	O
27	O
**	O
]	O
-	O
hypothyroidism	O
-	O
h	O
/	O
o	O
opiate	I-Drug
dependence	O
,	O
?	O
benzo	I-Drug
dependence	O
-	O
acute	O
on	O
chronic	O
SDH	O
,	O
[	O
**	O
8	O
-	O
30	O
**	O
]	O
-	O
h	O
/	O
o	O
R	O
scapula	O
fx	O
-	O
h	O
/	O
o	O
MRSA	O
elbow	O
bursitis	O
,	O
[	O
**	O
5	O
-	O
1	O
**	O
]	O
-	O
h	O
/	O
o	O
closed	O
bimalleolar	O
fx	O
s	O
/	O
p	O
repair	O
,	O
removal	O
of	O
hardware	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
Social	O
History	O
:	O
Lives	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
though	O
has	O
been	O
in	O
rehab	O
for	O
much	O
of	O
the	O
past	O
few	O
months	O
.	O
Former	O
cab	O
driver	O
.	O
Social	O
history	O
is	O
significant	O
for	O
the	O
current	O
tobacco	O
use	O
of	O
40	O
pack	O
years	O
.	O
There	O
is	O
no	O
history	O
of	O
alcohol	O
abuse	O
or	O
recreational	O
drug	O
use	O
.	O
Lives	O
with	O
common	O
-	O
law	O
wife	O
of	O
35	O
years	O
who	O
is	O
a	O
home	O
health	O
aid	O
.	O
Family	O
History	O
:	O
No	O
family	O
history	O
of	O
early	O
MI	O
,	O
arrhythmia	O
,	O
cardiomyopathies	O
,	O
or	O
sudden	O
cardiac	O
death	O
;	O
otherwise	O
non-contributory	O
.	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
VS	O
:	O
T96	O
.0	O
6680/50	O
24	O
100	O
%	O
facemask	O
GEN	O
:	O
ill	O
appearing	O
man	O
,	O
sleepy	O
,	O
answering	O
questions	O
with	O
difficulty	O
HEENT	O
:	O
Sclera	O
anicteric	O
.	O
MMdry	O
CV	O
:	O
irregular	O
irregular	O
LUNGS	O
:	O
Labored	O
breathing	O
.	O
Diffuse	O
bilateral	O
rales	O
ABDOMEN	O
:	O
distended	O
,	O
diffusely	O
tender	O
with	O
rebound	O
and	O
guarding	O
RECTAL	O
:	O
trace	O
guaiac	O
pos	O
.	O
At	O
Discharge	O
:	O
AVSS	O
/	O
afebrile	O
.	O
GEN	O
:	O
Well	O
in	O
NAD	O
.	O
HEENT	O
:	O
Sclerae	O
anicteric	O
.	O
O	O
-	O
P	O
clear	O
.	O
NECK	O
:	O
Supple	O
.	O
LUNGS	O
:	O
CTA	O
(	O
B	O
)	O
COR	O
:	O
Irregularly	O
irregular	O
ABD	O
:	O
Midline	O
incision	O
with	O
steri	O
-	O
strips	O
c	O
/	O
d	O
/	O
i.	O
Lower	O
aspect	O
incisional	O
wound	O
5	O
cm	O
x	O
3	O
cm	O
x	O
2	O
cm	O
granulating	O
,	O
clean	O
.	O
Wet	O
-	O
to	O
-	O
dry	O
packing	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
BSX4	O
.	O
Appopriately	O
tender	O
to	O
palpation	O
along	O
wound	O
,	O
otherwise	O
soft	O
/	O
NT	O
/	O
ND	O
.	O
EXTREM	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
NEURO	O
:	O
A+O	O
x3	O
.	O
Pertinent	O
Results	O
:	O
On	O
Admission	O
:	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
PT	O
-	O
48.6	O
*	O
PTT	O
-	O
61.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
5.2	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
PLT	O
COUNT	O
-	O
158	O
#	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
NEUTS	O
-	O
90.2	O
*	O
LYMPHS	O
-	O
5.2	O
*	O
MONOS	O
-	O
4.0	O
EOS	O
-	O
0.4	O
BASOS	O
-	O
0.2	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
WBC	O
-	O
8.2	O
RBC	O
-	O
3.68	O
*	O
HGB	O
-	O
8.5	O
*	O
HCT	O
-	O
28.7	O
*	O
MCV	O
-	O
78	O
*	O
MCH	O
-	O
23.1	O
*	O
MCHC	O
-	O
29.7	O
*	O
RDW	O
-	O
19.7	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
URINE	O
GR	O
HOLD	O
-	O
HOLD	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
CALCIUM	O
-	O
6.7	O
*	O
PHOSPHATE	O
-	O
2.6	O
*	O
MAGNESIUM	O
-	O
1.7	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
LIPASE	O
-	O
15	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
25	O
AST	O
(	O
SGOT	O
)	O
-	O
33	O
LD	O
(	O
LDH	O
)	O
-	O
196	O
ALK	O
PHOS	O
-	O
59	O
TOT	O
BILI	O
-	O
0.4	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:15	O
AM	O
GLUCOSE	O
-	O
228	O
*	O
UREA	O
N	O
-	O
40	O
*	O
CREAT	O
-	O
1.2	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
3.6	O
CHLORIDE	O
-	O
106	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
15	O
[	O
**	O
2178-12-17	O
**	O
]	O
12:44	O
AM	O
LACTATE	O
-	O
2.2	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
04:30	O
AM	O
PT	O
-	O
21.6	O
*	O
PTT	O
-	O
41.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.0	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
04:38	O
AM	O
LACTATE	O
-	O
2.9	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
04:45	O
AM	O
PT	O
-	O
24.2	O
*	O
PTT	O
-	O
43.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.3	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
06:11	O
AM	O
freeCa	O
-	O
1.04	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
06:11	O
AM	O
HGB	O
-	O
9.2	O
*	O
calcHCT	O
-	O
28	O
[	O
**	O
2178-12-17	O
**	O
]	O
06:11	O
AM	O
GLUCOSE	O
-	O
223	O
*	O
LACTATE	O
-	O
3.9	O
*	O
NA	O
+	O
-	O
137	O
K	O
+	O
-	O
4.2	O
CL	O
--	O
103	O
[	O
**	O
2178-12-17	O
**	O
]	O
07:58	O
AM	O
PT	O
-	O
19.1	O
*	O
PTT	O
-	O
42.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.7	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
07:58	O
AM	O
PLT	O
COUNT	O
-	O
212	O
[	O
**	O
2178-12-17	O
**	O
]	O
07:58	O
AM	O
WBC	O
-	O
14.8	O
*	O
#	O
RBC	O
-	O
3.85	O
*	O
HGB	O
-	O
9.3	O
*	O
HCT	O
-	O
30.6	O
*	O
MCV	O
-	O
80	O
*	O
MCH	O
-	O
24.1	O
*	O
MCHC	O
-	O
30.4	O
*	O
RDW	O
-	O
19.2	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
07:58	O
AM	O
CALCIUM	O
-	O
7.6	O
*	O
PHOSPHATE	O
-	O
2.4	O
*	O
MAGNESIUM	O
-	O
2.2	O
[	O
**	O
2178-12-17	O
**	O
]	O
07:58	O
AM	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2178-12-17	O
**	O
]	O
07:58	O
AM	O
GLUCOSE	O
-	O
230	O
*	O
UREA	O
N	O
-	O
43	O
*	O
CREAT	O
-	O
1.6	O
*	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
3.6	O
CHLORIDE	O
-	O
106	O
TOTAL	O
CO2	O
-	O
21	O
*	O
ANION	O
GAP	O
-	O
17	O
.	O
Prior	O
to	O
Discharge	O
:	O
[	O
**	O
2179-1-7	O
**	O
]	O
06:29	O
AM	O
BLOOD	O
WBC	O
-	O
4.4	O
RBC	O
-	O
3.21	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
27.7	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
28.0	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
22.5	O
*	O
Plt	O
Ct	O
-	O
119	O
*	O
[	O
**	O
2179-1-7	O
**	O
]	O
06:29	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
119	O
*	O
[	O
**	O
2179-1-7	O
**	O
]	O
06:29	O
AM	O
BLOOD	O
Glucose	O
-	O
157	O
*	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.8	O
Na	O
-	O
132	O
*	O
K	O
-	O
4.3	O
Cl	O
-	O
91	O
*	O
HCO3	O
-	O
34	O
*	O
AnGap	O
-	O
11	O
[	O
**	O
2179-1-7	O
**	O
]	O
06:29	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
2.8	O
Mg	O
-	O
1.8	O
[	O
**	O
2179-1-8	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
PT	O
-	O
26.4	O
*	O
PTT	O
-	O
48.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.6	O
*	O
.	O
IMAGING	O
:	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
CXR	O
Interval	O
worsening	O
of	O
mild	O
pulmonary	O
edema	O
.	O
Moderate	O
bibasilar	O
atelectasis	O
in	O
the	O
setting	O
of	O
low	O
lung	O
volumes	O
.	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
CT	O
abd	O
:	O
Findings	O
concerning	O
for	O
mesenteric	O
ischemia	O
with	O
portal	O
venous	O
air	O
,	O
with	O
focus	O
of	O
air	O
seen	O
in	O
mesentery	O
centered	O
about	O
loops	O
of	O
small	O
bowel	O
in	O
the	O
right	O
mid	O
abdomen	O
with	O
air	O
circumferentially	O
surrounding	O
the	O
lumen	O
suggestive	O
of	O
pneumatosis	O
and	O
associated	O
mesenteric	O
stranding	O
(	O
301B	O
:	O
18	O
-	O
27	O
)	O
.	O
Vascular	O
event	O
may	O
represent	O
etiology	O
,	O
though	O
swirling	O
configuration	O
suggests	O
internal	O
hernia	O
.	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
CXR	O
improved	O
basilar	O
aeration	O
.	O
CVl	O
well	O
placed	O
[	O
**	O
12	O
-	O
20	O
**	O
]	O
CXR	O
New	O
b	O
/	O
l	O
poorly	O
defined	O
pulmonary	O
opacities	O
,	O
some	O
w	O
/	O
nodular	O
configuration	O
.	O
[	O
**	O
12	O
-	O
20	O
**	O
]	O
CXR	O
Interval	O
increase	O
in	O
diffuse	O
widespread	O
airspace	O
consolidation	O
,	O
?	O
ARDS	O
.	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
multifocal	O
pneumonia	O
.	O
Co-existing	O
ARDS	O
is	O
also	O
possible	O
.	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
lung	O
CT	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
Head	O
CT	O
[	O
**	O
12	O
-	O
28	O
**	O
]	O
:	O
Echo	O
:	O
EF	O
20	O
-	O
25	O
%	O
,	O
PCWP	O
>	O
18	O
,	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
+	O
MR	O
,	O
dilated	O
LV	O
,	O
global	O
hypokinesis	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
CXR	O
:	O
Worsening	O
pulmonary	O
edema	O
.	O
Evidence	O
for	O
bilateral	O
pleural	O
effusions	O
,	O
which	O
may	O
have	O
increased	O
as	O
well	O
.	O
[	O
**	O
1	O
-	O
4	O
**	O
]	O
CXR	O
:	O
Mild	O
-	O
to	O
-	O
moderate	O
pulmonary	O
edema	O
has	O
improved	O
since	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
CXR	O
:	O
Cardiomegaly	O
,	O
bilateral	O
pleural	O
effusions	O
and	O
atelectasis	O
,	O
overall	O
appearing	O
minimally	O
changed	O
.	O
.	O
MICROBIOLOGY	O
:	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
Sputum	O
MRSA	O
Mod	O
growth	O
.	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
Bcx	O
:	O
Staph	O
coag	O
neg	O
1/2	O
bottles	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
BAL	O
MRSA	O
[	O
**	O
12	O
-	O
20	O
**	O
]	O
Sputum	O
:	O
MRSA	O
,	O
sparse	O
GNR	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
BAL	O
:	O
MRSA	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
BAL	O
:	O
Negative	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
C	O
diff	O
neg	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
Catheter	O
tip	O
neg	O
.	O
PATHOLOGY	O
:	O
[	O
**	O
2178-12-17	O
**	O
]	O
SPECIMEN	O
SUBMITTED	O
:	O
ILEUM	O
.	O
DIAGNOSIS	O
:	O
Ileum	O
,	O
Segmental	O
resection	O
:	O
1	O
.	O
Ischemic	O
enteritis	O
with	O
focally	O
transmural	O
necrosis	O
and	O
associated	O
serositis	O
.	O
2	O
.	O
One	O
unremarkable	O
resection	O
margin	O
;	O
opposite	O
resection	O
margin	O
with	O
mucosal	O
ischemic	O
changes	O
and	O
acute	O
inflammation	O
of	O
the	O
superficial	O
submucosa	O
.	O
Clinical	O
:	O
Ischemic	O
bowel	O
,	O
acute	O
abdomen	O
.	O
Gross	O
:	O
The	O
specimen	O
is	O
received	O
fresh	O
labeled	O
with	O
the	O
patient	O
's	O
name	O
,	O
"	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
"	O
,	O
the	O
medical	O
record	O
number	O
and	O
"	O
ileum	O
.	O
"	O
It	O
consists	O
of	O
a	O
segment	O
of	O
small	O
bowel	O
measuring	O
92	O
cm	O
in	O
length	O
and	O
3	O
cm	O
in	O
average	O
diameter	O
.	O
A	O
portion	O
of	O
mesentery	O
is	O
attached	O
to	O
the	O
small	O
bowel	O
that	O
measures	O
2	O
x	O
4	O
x	O
3	O
cm	O
.	O
The	O
specimen	O
is	O
not	O
oriented	O
.	O
The	O
mesentery	O
is	O
unremarkable	O
.	O
The	O
serosa	O
of	O
the	O
bowel	O
is	O
focally	O
erythematous	O
and	O
dusky	O
looking	O
.	O
There	O
are	O
two	O
staples	O
measuring	O
3.7	O
and	O
5.2	O
cm	O
.	O
The	O
specimen	O
is	O
opened	O
along	O
the	O
antimesenteric	O
surface	O
to	O
reveal	O
fecal	O
material	O
and	O
blood	O
within	O
the	O
lumen	O
.	O
The	O
mucosa	O
in	O
the	O
central	O
portion	O
of	O
the	O
bowel	O
measuring	O
34	O
cm	O
in	O
length	O
is	O
erythematous	O
,	O
brown	O
and	O
dusky	O
looking	O
.	O
No	O
masses	O
or	O
polyps	O
are	O
identified	O
.	O
No	O
perforation	O
site	O
is	O
identified	O
.	O
The	O
bowel	O
wall	O
within	O
the	O
affected	O
area	O
measures	O
up	O
to	O
0.2	O
cm	O
in	O
thickness	O
.	O
Normal	O
looking	O
bowel	O
measures	O
up	O
to	O
0.4	O
cm	O
in	O
thickness	O
.	O
The	O
specimen	O
is	O
represented	O
in	O
cassettes	O
as	O
follows	O
:	O
A	O
=	O
5.2	O
cm	O
stapled	O
margin	O
,	O
B	O
=	O
3.7	O
cm	O
staple	O
margin	O
,	O
C	O
=	O
section	O
of	O
affected	O
bowel	O
,	O
D	O
=	O
transition	O
between	O
effected	O
and	O
normal	O
bowel	O
,	O
E-G	O
=	O
fat	O
.	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
with	O
multiple	O
medical	O
problems	O
was	O
admitted	O
to	O
the	O
General	O
Surgical	O
Service	O
on	O
[	O
**	O
2178-12-17	O
**	O
]	O
for	O
evaluation	O
of	O
an	O
acute	O
abdomen	O
likely	O
from	O
ischemic	B-Reason
bowel	I-Reason
.	O
He	O
was	O
admitted	O
to	O
the	O
SICU	O
.	O
He	O
was	O
made	O
NPO	O
,	O
started	O
on	O
IV	O
fluids	I-Drug
,	O
a	O
foley	O
catheter	O
and	O
CVL	O
were	O
placed	O
,	O
empiric	O
IV	O
Vancomycin	I-Drug
and	O
Zosyn	I-Drug
were	O
started	O
,	O
and	O
he	O
was	O
given	O
Fentanyl	I-Drug
IV	O
PRN	O
for	O
pain	I-Reason
and	O
Valium	I-Drug
for	O
sedation	I-Reason
.	O
He	O
was	O
emergently	O
brought	O
to	O
the	O
Operating	O
Room	O
,	O
where	O
he	O
underwent	O
exploratory	O
laparotomy	O
,	O
reduction	O
of	O
internal	O
volvulus	O
of	O
the	O
small	O
bowel	O
,	O
and	O
small	O
-	O
bowel	O
resection	O
with	O
primary	O
anastomosis	O
(	O
reader	O
referred	O
to	O
the	O
Operative	O
Note	O
for	O
details	O
)	O
.	O
He	O
was	O
found	O
to	O
have	O
ischemic	O
bowel	O
with	O
obstruction	O
,	O
peritonitis	O
,	O
and	O
an	O
internal	O
volvulus	O
of	O
the	O
small	O
bowel	O
.	O
He	O
was	O
returned	O
to	O
the	O
SICU	O
for	O
post-operative	O
care	O
.	O
.	O
SICU	O
/	O
TICU	O
EVENTS	O
[	O
**	O
2178-1-17	O
**	O
]	O
-	O
[	O
**	O
2178-12-29	O
**	O
]	O
:	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
1	O
u	O
PRBC	O
,	O
750	O
LR	O
intraop	O
,	O
to	O
ICU	O
post	O
op	O
.	O
On	O
neo	O
and	O
epi	O
.	O
Transfused	O
1	O
u	O
for	O
hct	O
28	O
.	O
Febrile	O
to	O
101	O
.	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
pm	O
-	O
spike	O
to	O
101.2	O
,	O
decreasing	O
pressor	O
requirements	O
and	O
lactate	O
.	O
Pan-Cxs	O
sent	O
.	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
Left	O
subclavian	O
placed	O
.	O
Bloody	O
guiac	O
+	O
BM	O
overnight	O
.	O
HCT	O
drifting	O
down	O
.	O
GPC	O
on	O
blood	O
culture	O
1/2	O
bottles	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
.	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
:	O
Bronch	O
and	O
BAL.Abx	O
started	O
after	O
BAL	O
[	O
**	O
12	O
-	O
20	O
**	O
]	O
:	O
Low	O
uop	O
.	O
Large	O
heparin	I-Drug
requirement	O
given	O
FFP	I-Drug
2	O
untis	O
for	O
?	O
atIII	O
def	O
.	O
PS	O
trial	O
failed	O
changed	O
back	O
to	O
rate	O
.	O
TPN	O
started	O
.	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
:	O
Concern	O
for	O
depressed	O
mental	O
status	O
in	O
AM	O
.	O
Concern	O
for	O
septic	O
emboli	O
to	O
brain	O
/	O
eyes	O
/	O
lungs	O
.	O
Mental	O
status	O
improved	O
in	O
PM	O
w	O
/	O
o	O
intervention	O
except	O
for	O
holding	O
of	O
propofol	I-Drug
.	O
Also	O
concern	O
for	O
pt	O
's	O
high	O
need	O
of	O
heparin	I-Drug
to	O
stay	O
in	O
therapeutic	O
level	O
.	O
Peripheral	O
smear	O
sent.LENI	O
negative	O
.	O
[	O
**	O
2178-12-22	O
**	O
]	O
:	O
Bedside	O
TTE	O
w	O
/	O
hyperdynamic	O
LV	O
,	O
FeNa	O
0.2	O
%	O
,	O
given	O
3	O
Unit	O
of	O
Blood	O
,	O
He	O
Had	O
melanotic	O
stool	O
,	O
but	O
HD	O
stable	O
,	O
started	O
on	O
D5W	I-Drug
at	O
30cc	O
/	O
h	O
,	O
Creatine	O
improving	O
.	O
acutely	O
became	O
diaphoretic	O
sat	O
down	O
to	O
88	O
%	O
pt	O
labored	O
and	O
desynchronous	O
with	O
ventilator	O
,	O
tachycadic	O
high	O
BP	O
w	O
/	O
Map	O
110	O
,	O
tachycardic	O
120	O
,	O
CVP	O
26	O
.	O
Patient	O
had	O
flush	O
PE	O
lasix	I-Drug
bolus	O
given	O
,	O
patient	O
sedated	O
,	O
ABG	O
improved	O
[	O
**	O
12	O
-	O
27	O
**	O
]	O
-	O
Extubated	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
PM	O
,	O
started	O
on	O
BiPAP	O
.	O
Back	O
on	O
Lasix	I-Drug
gtt	O
,	O
started	O
Carvedilol	I-Drug
,	O
started	O
bridge	O
to	O
Coumadin	I-Drug
.	O
Re-intubated	O
due	O
to	O
fluid	O
reaccumulation	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
:	O
Extubated	O
.	O
Doing	O
well	O
.	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
PICC	O
placed	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
:	O
to	O
TICU	O
for	O
resp	O
distress	O
,	O
Bipap	O
responsive	O
,	O
cardiac	O
diet	O
now	O
,	O
restarted	O
carvedilol	I-Drug
,	O
ace	I-Drug
,	O
aldactone	I-Drug
,	O
required	O
bipap	O
o	O
/	O
n	O
after	O
brief	O
desat	O
[	O
**	O
1	O
-	O
3	O
**	O
]	O
Bipap	O
during	O
the	O
day	O
and	O
extra	O
Lasix	I-Drug
20	O
mg	O
IV	O
x1	O
,	O
negative	O
for	O
the	O
day	O
,	O
Bipap	O
overnight	O
,	O
held	O
coumadin	I-Drug
x	O
1	O
for	O
INR	O
5.8	O
[	O
**	O
1	O
-	O
4	O
**	O
]	O
:	O
Opening	O
of	O
abdominal	O
wound	O
.	O
Held	O
coumadin	I-Drug
for	O
INR	O
5.7	O
.	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
:	O
started	O
glargine	I-Drug
,	O
removed	O
foley	O
,	O
restarted	O
coumadin	I-Drug
3	O
mg	O
.	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
:	O
Coumadin	I-Drug
reduced	O
to	O
2	O
mg	O
.	O
.	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
9	O
EVENTS	O
:	O
On	O
[	O
**	O
2179-1-6	O
**	O
]	O
,	O
the	O
patient	O
was	O
transfered	O
to	O
the	O
inpatient	O
floor	O
.	O
He	O
arrived	O
on	O
a	O
Diabetic	O
/	O
low	O
sodium	O
regular	O
diet	O
,	O
oral	O
medications	O
,	O
voiding	O
without	O
assitance	O
,	O
with	O
IV	O
Linezolid	I-Drug
and	O
Meropenem	I-Drug
continued	O
.	O
Coumadin	I-Drug
was	O
continued	O
,	O
and	O
monitored	O
closely	O
to	O
maintain	O
a	O
therapeutic	O
goal	O
range	O
of	O
2.5	O
-	O
3.5	O
.	O
The	O
INR	O
on	O
[	O
**	O
2179-1-8	O
**	O
]	O
was	O
2.6	O
.	O
.	O
During	O
this	O
hospitalization	O
,	O
the	O
patient	O
ambulated	O
early	O
and	O
frequently	O
,	O
was	O
adherent	O
with	O
respiratory	O
toilet	O
and	O
incentive	O
spirrometry	O
,	O
and	O
actively	O
participated	O
in	O
the	O
plan	O
of	O
care	O
.	O
The	O
patient	O
's	O
blood	O
sugar	O
was	O
monitored	O
regularly	O
throughout	O
the	O
stay	O
;	O
Lantus	I-Drug
and	O
sliding	O
scale	O
insulin	I-Drug
was	O
administered	O
as	O
indicated	O
.	O
Labwork	O
was	O
routinely	O
followed	O
;	O
electrolytes	O
were	O
repleted	O
when	O
indicated	O
.	O
.	O
At	O
the	O
time	O
of	O
discharge	O
on	O
,	O
the	O
patient	O
was	O
doing	O
well	O
,	O
afebrile	O
with	O
stable	O
vital	O
signs	O
.	O
The	O
patient	O
was	O
tolerating	O
a	O
diabetic	O
/	O
low	O
sodium	O
regular	O
diet	O
,	O
ambulating	O
with	O
assistance	O
,	O
voiding	O
without	O
assistance	O
,	O
and	O
pain	O
was	O
well	O
controlled	O
.	O
He	O
was	O
discharged	O
to	O
an	O
extended	O
care	O
facility	O
for	O
rehabilitation	O
and	O
nursing	O
care	O
.	O
The	O
patient	O
received	O
discharge	O
teaching	O
and	O
follow	O
-	O
up	O
instructions	O
with	O
understanding	O
verbalized	O
and	O
agreement	O
with	O
the	O
discharge	O
plan	O
.	O
.	O
Services	O
Consulted	O
during	O
admission	O
:	O
Infectious	O
Disease	O
,	O
Otolaryngology	O
,	O
Cardiology	O
,	O
Pulmonary	O
,	O
Social	O
Work	O
,	O
Physical	O
Therapy	O
,	O
and	O
Occupational	O
Therapy	O
.	O
Medications	O
on	O
Admission	O
:	O
Amiodarone	I-Drug
200	O
mg	O
DAILY	O
Atorvastatin	I-Drug
40	O
mg	O
DAILY	O
Polyethylene	B-Drug
Glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
[	O
**	O
Hospital1	O
**	O
]	O
Amitriptyline	I-Drug
10	O
mg	O
HS	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Senna	I-Drug
8.6	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Captopril	I-Drug
25	O
mg	O
TID	O
Lactulose	I-Drug
30	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Aspirin	I-Drug
81	O
mg	O
Daily	O
Lorazepam	I-Drug
0.5	O
mg	O
Q4H	O
as	O
needed	O
for	O
anxiety	I-Reason
Levetiracetam	I-Drug
500	O
mg	O
QHS	O
Gabapentin	I-Drug
400	O
mg	O
Q8H	O
(	O
Warfarin	I-Drug
5	O
mg	O
Daily	O
Oxycodone	I-Drug
5	O
mg	O
Q4H	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Acetaminophen	I-Drug
500	O
mg	O
q8	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
Bisacodyl	I-Drug
10	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
Albuterol	B-Drug
Sulfate	I-Drug
90	O
mcg	O
2	O
Puffs	O
IH	O
Q6H	O
prn	O
Ipratropium	B-Drug
Bromide	I-Drug
17	O
mcg	O
/	O
Actuation	O
QID	O
(	O
Meropenem	I-Drug
500	O
mg	O
q6	O
Spironolactone	I-Drug
25	O
mg	O
DAILY	O
Torsemide	I-Drug
20	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Metolazone	I-Drug
5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Metoprolol	I-Drug
12.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
once	O
a	O
day	O
Insulin	B-Drug
Glargine	I-Drug
40	O
units	O
Subcutaneous	O
at	O
bedtime	O
Insulin	B-Drug
Lispro	I-Drug
per	O
sliding	O
scale	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
.	O
2	O
.	O
Spironolactone	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
4	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
5	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
6	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
7	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
8	O
.	O
Warfarin	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
at	O
16:00	O
:	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
1525	O
**	O
]	O
mechanical	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
1291	O
**	O
]	O
;	O
INR	O
goal	O
2.5	O
-	O
3.5	O
.	O
9	O
.	O
Ondansetron	I-Drug
4	O
mg	O
IV	O
Q8H	O
:	O
PRN	O
nausea	I-Reason
10	O
.	O
Oxycodone	I-Drug
5	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
5	O
-	O
10	O
mg	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
11	O
.	O
Ativan	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
Tablet	O
(	O
s	O
)	O
(	O
give	O
SL	O
)	O
PO	O
every	O
6	O
-	O
8	O
hours	O
as	O
needed	O
for	O
Anxiety	I-Reason
.	O
12	O
.	O
Atorvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
13	O
.	O
Torsemide	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
14	O
.	O
Metolazone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
15	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
16	O
.	O
Potassium	B-Drug
Chloride	I-Drug
10	O
mEq	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
once	O
a	O
day	O
.	O
17	O
.	O
Levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
18	O
.	O
Neurontin	I-Drug
400	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
three	O
times	O
a	O
day	O
.	O
19	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
20	O
.	O
Amitriptyline	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
21	O
.	O
Captopril	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
22	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
4	O
-	O
22	O
units	O
Subcutaneous	O
As	O
directed	O
per	O
Humalog	B-Drug
Insulin	I-Drug
Sliding	O
Scale	O
.	O
23	O
.	O
Lantus	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Forty	O
(	O
40	O
)	O
units	O
Subcutaneous	O
at	O
bedtime	O
.	O
24	O
.	O
Medication	O
:	O
Morphine	B-Drug
Sulfate	I-Drug
2	O
-	O
4	O
mg	O
IV	O
Q6H	O
:	O
PRN	O
Breakthrough	B-Reason
Pain	I-Reason
Only	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
1	O
.	O
Ischemic	O
bowel	O
.	O
2	O
.	O
Bowel	O
obstruction	O
.	O
3	O
.	O
Peritonitis	O
.	O
4	O
.	O
Internal	O
volvulus	O
of	O
small	O
bowel	O
.	O
5	O
.	O
Multifocal	O
pneumonia	O
.	O
Secondary	O
:	O
1	O
.	O
CAD	O
2	O
.	O
History	O
of	O
VF	O
arrest	O
[	O
**	O
6	O
-	O
30	O
**	O
]	O
s	O
/	O
p	O
ICD	O
placement	O
3	O
.	O
Mechanical	O
St.	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
1525	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1291	O
**	O
]	O
on	O
Coumadin	I-Drug
prophylaxis	I-Reason
INR	O
Goal	O
2.5	O
-	O
3.5	O
)	O
4	O
.	O
CHF	O
(	O
EF	O
20	O
%	O
)	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
Discharge	O
Instructions	O
:	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
.	O
Please	O
resume	O
all	O
regular	O
home	O
medications	O
,	O
unless	O
specifically	O
advised	O
not	O
to	O
take	O
a	O
particular	O
medication	O
.	O
Also	O
,	O
please	O
take	O
any	O
new	O
medications	O
as	O
prescribed	O
.	O
Please	O
get	O
plenty	O
of	O
rest	O
,	O
continue	O
to	O
ambulate	O
several	O
times	O
per	O
day	O
,	O
and	O
drink	O
adequate	O
amounts	O
of	O
fluids	O
.	O
Avoid	O
lifting	O
weights	O
greater	O
than	O
[	O
**	O
5	O
-	O
3	O
**	O
]	O
lbs	O
until	O
you	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
,	O
who	O
will	O
instruct	O
you	O
further	O
regarding	O
activity	O
restrictions	O
.	O
Avoid	O
driving	O
or	O
operating	O
heavy	O
machinery	O
while	O
taking	O
pain	O
medications	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
and	O
Primary	O
Care	O
Provider	O
(	O
PCP	O
)	O
as	O
advised	O
.	O
Incision	O
Care	O
:	O
*	O
Please	O
call	O
your	O
doctor	O
or	O
nurse	O
practitioner	O
if	O
you	O
have	O
increased	O
pain	O
,	O
swelling	O
,	O
redness	O
,	O
or	O
drainage	O
from	O
the	O
incision	O
site	O
.	O
*	O
Avoid	O
swimming	O
and	O
baths	O
until	O
your	O
follow	O
-	O
up	O
appointment	O
.	O
*	O
You	O
may	O
shower	O
,	O
and	O
wash	O
surgical	O
incisions	O
with	O
a	O
mild	O
soap	O
and	O
warm	O
water	O
.	O
Gently	O
pat	O
the	O
area	O
dry	O
.	O
*	O
If	O
you	O
have	O
steri	O
-	O
strips	O
,	O
they	O
will	O
fall	O
off	O
on	O
their	O
own	O
.	O
Please	O
remove	O
any	O
remaining	O
strips	O
7	O
-	O
10	O
days	O
after	O
surgery	O
.	O
*	O
The	O
lower	O
incision	O
wound	O
will	O
be	O
cared	O
for	O
by	O
your	O
nurse	O
.	O
Car	O
is	O
a	O
wet	O
-	O
to	O
-	O
dry	O
dressing	O
changed	O
twice	O
daily	O
.	O
.	O
Coumadin	I-Drug
(	O
Warfarin	I-Drug
)	O
:	O
What	O
is	O
this	O
medicine	O
used	O
for	O
?	O
This	O
medicine	O
is	O
used	O
to	O
thin	B-Reason
the	I-Reason
blood	I-Reason
so	O
that	O
clots	O
will	O
not	O
form	O
.	O
How	O
does	O
it	O
work	O
?	O
Warfarin	I-Drug
changes	O
the	O
body	O
's	O
clotting	O
system	O
.	O
It	O
thins	B-Reason
the	I-Reason
blood	I-Reason
to	O
prevent	O
clots	O
from	O
forming	O
.	O
What	O
you	O
should	O
contact	O
your	O
healthcare	O
provider	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
:	O
Signs	O
of	O
a	O
life	O
-	O
threatening	O
reaction	O
.	O
These	O
include	O
wheezing	O
;	O
chest	O
tightness	O
;	O
fever	O
;	O
itching	O
;	O
bad	O
cough	O
;	O
blue	O
skin	O
color	O
;	O
fits	O
;	O
or	O
swelling	O
of	O
face	O
,	O
lips	O
,	O
tongue	O
,	O
or	O
throat	O
,	O
severe	O
dizziness	O
or	O
passing	O
out	O
,	O
falls	O
or	O
accidents	O
,	O
especially	O
if	O
you	O
hit	O
your	O
head	O
.	O
Talk	O
with	O
healthcare	O
provider	O
even	O
if	O
you	O
feel	O
fine	O
,	O
significant	O
change	O
in	O
thinking	O
clearly	O
and	O
logically	O
,	O
severe	O
headache	O
,	O
severe	O
back	O
pain	O
,	O
severe	O
belly	O
pain	O
,	O
black	O
,	O
tarry	O
,	O
or	O
bloody	O
stools	O
,	O
blood	O
in	O
the	O
urine	O
,	O
nosebleeds	O
,	O
coughing	O
up	O
blood	O
,	O
vomiting	O
blood	O
,	O
unusual	O
bruising	O
or	O
bleeding	O
,	O
severe	O
menstrual	O
bleedin	O
,	O
or	O
rash	O
.	O
Call	O
your	O
doctor	O
if	O
you	O
are	O
unable	O
to	O
eat	O
for	O
several	O
days	O
,	O
for	O
whatever	O
reason	O
.	O
Also	O
call	O
if	O
you	O
have	O
stomach	O
problems	O
,	O
vomiting	O
,	O
or	O
diarrhea	O
that	O
lasts	O
more	O
than	O
1	O
day	O
.	O
These	O
problems	O
could	O
affect	O
your	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
dosage	O
.	O
Coumadin	I-Drug
(	O
Warfarin	I-Drug
)	O
and	O
diet	O
:	O
Certain	O
foods	O
and	O
beverages	O
can	O
impair	O
the	O
effect	O
of	O
warfarin	I-Drug
.	O
For	O
this	O
reason	O
,	O
it	O
's	O
important	O
to	O
pay	O
attention	O
to	O
what	O
you	O
eat	O
while	O
taking	O
this	O
medication	O
.	O
Until	O
recently	O
,	O
doctors	O
advised	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
taking	O
warfarin	I-Drug
to	O
avoid	O
foods	O
high	O
in	O
vitamin	B-Drug
K	I-Drug
.	O
This	O
is	O
because	O
large	O
amounts	O
of	O
vitamin	B-Drug
K	I-Drug
can	O
counteract	O
the	O
benefits	O
of	O
warfarin	I-Drug
.	O
However	O
,	O
recent	O
research	O
shows	O
that	O
rather	O
than	O
eliminating	O
vitamin	B-Drug
K	I-Drug
from	O
your	O
diet	O
,	O
it	O
is	O
more	O
important	O
to	O
be	O
consistent	O
in	O
your	O
dietary	O
vitamin	B-Drug
K	I-Drug
intake	O
.	O
These	O
foods	O
contain	O
vitamin	B-Drug
K	I-Drug
:	O
Fruits	O
and	O
vegetables	O
,	O
such	O
as	O
:	O
Kiwi	O
,	O
Blueberries	O
,	O
Broccoli	O
,	O
Cabbage	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
2831	O
**	O
]	O
sprouts	O
,	O
Green	O
onions	O
,	O
Asparagus	O
,	O
Cauliflower	O
,	O
Peas	O
,	O
Lettuce	O
,	O
Spinach	O
,	O
Turnip	O
,	O
collard	O
,	O
and	O
mustard	O
greens	O
,	O
Parsley	O
,	O
Kale	O
,	O
Endive	O
.	O
Meats	O
,	O
such	O
as	O
:	O
Beef	O
liver	O
,	O
Pork	O
liver	O
.	O
Other	O
:	O
Mayonnaise	O
,	O
Margarine	O
,	O
Canola	O
oil	O
,	O
Soybean	O
oil	O
,	O
Vitamins	O
,	O
Soybeans	O
and	O
Cashews	O
.	O
Limit	O
alcohol	O
.	O
Alcohol	O
can	O
affect	O
your	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
dosage	O
but	O
it	O
does	O
not	O
mean	O
you	O
must	O
avoid	O
all	O
alcohol	O
.	O
Serious	O
problems	O
can	O
occur	O
with	O
alcohol	O
and	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
when	O
you	O
drink	O
more	O
than	O
2	O
drinks	O
a	O
day	O
or	O
when	O
you	O
change	O
your	O
usual	O
pattern	O
.	O
Binge	O
drinking	O
is	O
not	O
good	O
for	O
you	O
.	O
Be	O
careful	O
on	O
special	O
occasions	O
or	O
holidays	O
,	O
and	O
drink	O
only	O
what	O
you	O
usually	O
would	O
on	O
any	O
regular	O
day	O
of	O
the	O
week	O
.	O
Monitoring	O
:	O
The	O
doctor	O
decides	O
how	O
much	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
you	O
need	O
by	O
testing	O
your	O
blood	O
.	O
The	O
test	O
measures	O
how	O
fast	O
your	O
blood	O
is	O
clotting	O
and	O
lets	O
the	O
doctor	O
know	O
if	O
your	O
dosage	O
should	O
change	O
.	O
If	O
your	O
blood	O
test	O
is	O
too	O
high	O
,	O
you	O
might	O
be	O
at	O
risk	O
for	O
bleeding	O
problems	O
.	O
If	O
it	O
is	O
too	O
low	O
,	O
you	O
might	O
be	O
at	O
risk	O
for	O
forming	O
clots	O
.	O
Your	O
doctor	O
has	O
decided	O
on	O
a	O
range	O
on	O
the	O
blood	O
test	O
that	O
is	O
right	O
for	O
you	O
.	O
The	O
blood	O
test	O
used	O
for	O
monitoring	O
is	O
called	O
an	O
INR	O
.	O
Use	O
of	O
Other	O
medications	O
:	O
When	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
is	O
taken	O
with	O
other	O
medicines	O
it	O
can	O
change	O
the	O
way	O
other	O
medicines	O
work	O
.	O
Other	O
medicines	O
can	O
also	O
change	O
the	O
way	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
works	O
.	O
It	O
is	O
very	O
important	O
to	O
talk	O
with	O
your	O
doctor	O
about	O
all	O
of	O
the	O
other	O
medicines	O
that	O
you	O
are	O
taking	O
,	O
including	O
over-the-counter	O
medicines	O
,	O
antibiotics	I-Drug
,	O
vitamins	O
,	O
or	O
herbal	O
products	O
.	O
Followup	O
Instructions	O
:	O
Please	O
call	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2828	O
**	O
]	O
to	O
schedule	O
a	O
follow	O
-	O
up	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
Surgery	O
)	O
in	O
2	O
weeks	O
.	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
3688	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2422	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2179-1-27	O
**	O
]	O
1:10	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
544	O
**	O
]	O
,	O
M.D.	O
(	O
PCP	O
)	O
Date	O
/	O
Time	O
:[	O
**	O
2179-1-29	O
**	O
]	O
11:50	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1244	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1237	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2179-2-23	O
**	O
]	O
10:15	O
Completed	O
by	O
:[	O
**	O
2179-1-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2141-6-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2141-7-6	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2070-6-26	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3256	O
**	O
]	O
Chief	O
Complaint	O
:	O
Transfer	O
from	O
[	O
**	O
Hospital1	O
**	O
]	O
with	O
necrotizing	O
pancreatitis	O
and	O
ARDS	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Mechanical	O
ventilation	O
/	O
intubation	O
x2	O
History	O
of	O
Present	O
Illness	O
:	O
EAST	O
HOSPITAL	O
MEDICINE	O
ATTENDING	O
ADMISSION	O
NOTE	O
Date	O
:	O
[	O
**	O
2141-7-3	O
**	O
]	O
Time	O
:	O
04:13	O
The	O
patient	O
is	O
a	O
Pt	O
is	O
a	O
70F	O
with	O
PMH	O
of	O
HTN	O
,	O
PVD	O
and	O
[	O
**	O
Hospital	O
**	O
]	O
transferred	O
from	O
outside	O
hospital	O
with	O
severe	O
pancreatitis	O
and	O
respiratory	O
failure	O
requiring	O
intubation	O
.	O
History	O
was	O
obtained	O
from	O
family	O
and	O
the	O
medical	O
record	O
.	O
Two	O
days	O
prior	O
to	O
admission	O
,	O
pt	O
began	O
experiencing	O
sharp	O
RUQ	O
pain	O
,	O
nausea	O
,	O
nonbloody	O
,	O
nonbilious	O
vomitus	O
and	O
diarrhea	O
.	O
The	O
family	O
denies	O
any	O
fevers	O
,	O
cough	O
or	O
chills	O
and	O
states	O
she	O
was	O
in	O
her	O
normal	O
state	O
of	O
health	O
prior	O
to	O
developing	O
pain	O
.	O
She	O
did	O
not	O
want	O
to	O
go	O
see	O
her	O
MD	O
,	O
but	O
one	O
day	O
prior	O
to	O
transfer	O
her	O
pain	O
worsened	O
and	O
she	O
finally	O
went	O
to	O
[	O
**	O
Hospital6	O
**	O
]	O
.	O
At	O
LGH	O
intital	O
labs	O
were	O
notable	O
for	O
a	O
lipase	O
of	O
2254	O
which	O
trended	O
upward	O
to	O
8117	O
,	O
normal	O
Cr	O
and	O
WBC	O
of	O
22	O
.	O
Initial	O
BUN	O
was	O
22	O
but	O
subsequently	O
trended	O
upward	O
to	O
30	O
.	O
RUQ	O
US	O
revealed	O
common	B-Reason
bile	I-Reason
duct	O
dilitation	O
and	O
an	O
abnormal	O
appearance	O
of	O
her	O
pancreas	O
.	O
She	O
was	O
given	O
metronidazole	I-Drug
and	O
levofloxacin	I-Drug
and	O
admitted	O
to	O
the	O
general	O
medical	O
floor	O
where	O
she	O
was	O
kept	O
NPO	O
and	O
given	O
IVF	I-Drug
.	O
CT	O
scan	O
of	O
her	O
abdomen	O
and	O
pelvis	O
was	O
performed	O
and	O
was	O
concerning	O
for	O
necrosis	O
,	O
therefore	O
were	O
was	O
transferred	O
to	O
the	O
ICU	O
where	O
aggressive	O
fluid	B-Reason
repletion	I-Reason
was	O
initiated	O
(	O
at	O
the	O
time	O
of	O
transfer	O
she	O
has	O
recieved	O
7	O
L.	O
HCT	O
demonstrated	O
hemoconcentration	O
(	O
54	O
)	O
which	O
remained	O
stable	O
despite	O
fluids	I-Drug
.	O
Antitbiotics	I-Drug
were	O
broadened	O
to	O
imipenem	I-Drug
.	O
She	O
remained	O
hemodynamically	O
stable	O
,	O
afebrile	O
,	O
with	O
UOP	O
of	O
60	O
cc	O
/	O
hr	O
overnight	O
.	O
Initial	O
plan	O
was	O
for	O
ERCP	O
however	O
the	O
afternoon	O
of	O
transfer	O
the	O
patient	O
developed	O
an	O
acute	O
desaturation	O
event	O
to	O
88	O
%	O
on	O
5L	O
NC	O
.	O
Saturations	O
improved	O
to	O
96	O
%	O
with	O
50	O
%	O
FiO2	O
via	O
a	O
venti	O
mask	O
.	O
ABG	O
at	O
that	O
time	O
was	O
7.17	O
/	O
46.2	O
/	O
81.7	O
bicarb	O
of	O
17	O
.	O
She	O
was	O
intubated	O
prior	O
to	O
transfer	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
On	O
transport	O
she	O
was	O
noted	O
to	O
be	O
transiently	O
hypotensive	I-Reason
to	O
the	O
80s	O
requiring	O
peripheral	O
levophed	I-Drug
which	O
was	O
weaned	O
off	O
on	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
.	O
No	O
ROS	O
was	O
obtained	O
due	O
to	O
the	O
patient	O
being	O
unconcious	O
.	O
Of	O
note	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
records	O
the	O
patient	O
has	O
a	O
history	O
of	O
chronic	O
nausea	O
and	O
intolerance	O
of	O
greasy	O
food	O
,	O
however	O
the	O
family	O
denies	O
any	O
previous	O
diagnosis	O
of	O
gallbladder	O
disease	O
.	O
The	O
patient	O
does	O
not	O
drink	O
alcohol	O
,	O
has	O
no	O
new	O
medication	O
but	O
does	O
have	O
HL	I-Reason
for	O
which	O
she	O
has	O
been	O
on	O
pravastatin	I-Drug
.	O
On	O
arrival	O
to	O
the	O
MICU	O
on	O
[	O
**	O
2141-6-14	O
**	O
]	O
,	O
patient	O
's	O
VS	O
157/79	O
105	O
18	O
95	O
%	O
on	O
CMV	O
with	O
RR	O
16	O
,	O
Vt	O
400	O
,	O
FiO2	O
60	O
%	O
.	O
The	O
patient	O
was	O
intubated	O
and	O
sedated	O
due	O
to	O
ARDS	O
.	O
LIJ	O
central	O
venous	O
catheter	O
was	O
placed	O
given	O
access	O
issues	O
.	O
She	O
was	O
extubated	O
on	O
[	O
**	O
2141-6-20	O
**	O
]	O
and	O
was	O
transfered	O
to	O
the	O
medicine	O
floor	O
and	O
was	O
treated	O
for	O
VAP	I-Reason
from	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
112125	O
**	O
]	O
with	O
zosyn	I-Drug
and	O
vancomycin	I-Drug
(	O
cipro	I-Drug
was	O
started	O
initially	O
,	O
but	O
subsequently	O
discontinued	O
)	O
.	O
On	O
[	O
**	O
2141-6-23	O
**	O
]	O
,	O
she	O
was	O
transfered	O
back	O
to	O
the	O
ICU	O
,	O
re-intubated	O
for	O
hypoxia	O
thought	O
to	O
be	O
due	O
to	O
atelectasis	O
,	O
bilateral	O
pleural	O
effusions	O
and	O
a	O
questionable	O
infarct	O
in	O
the	O
[	O
**	O
Date	O
Range	O
**	O
]	O
without	O
thrombus	O
,	O
which	O
was	O
not	O
anticoagulated	I-Drug
.	O
On	O
[	O
**	O
2141-6-24	O
**	O
]	O
,	O
she	O
was	O
noted	O
to	O
have	O
ARF	B-Ade
with	I-Ade
rare	I-Ade
eos	O
(	O
AIN	O
)	O
,	O
which	O
was	O
thought	O
to	O
be	O
due	O
to	O
medications	O
/	O
contrast	I-Drug
dye	O
exposure	O
.	O
Several	O
potential	O
offending	O
agents	O
were	O
discontinued	O
.	O
On	O
ECHO	O
on	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
was	O
wnl	O
.	O
Her	O
initial	O
tachycardia	I-Reason
later	O
improved	O
with	O
verapamil	I-Drug
.	O
A	O
LUQ	O
u	O
/	O
s	O
showed	O
no	O
gallstones	O
and	O
minimal	O
sludge	O
.	O
Past	O
Medical	O
History	O
:	O
Type	O
II	O
DM	O
HTN	O
HL	O
PVD	O
Chronic	O
low	O
back	O
pain	O
Social	O
History	O
:	O
Patient	O
is	O
married	O
,	O
former	O
smoker	O
,	O
but	O
not	O
currently	O
.	O
She	O
does	O
not	O
drink	O
and	O
does	O
not	O
do	O
drugs	O
.	O
She	O
lives	O
with	O
her	O
husband	O
and	O
has	O
three	O
children	O
.	O
Family	O
History	O
:	O
Skin	O
cancer	O
in	O
a	O
grandfather	O
Physical	O
Exam	O
:	O
VS	O
:	O
98.6	O
132/68	O
107	O
22	O
95	O
%	O
RA	O
;	O
0/10	O
pain	O
GEN	O
:	O
No	O
apparent	O
distress	O
,	O
somnolent	O
HEENT	O
:	O
no	O
trauma	O
,	O
pupils	O
round	O
and	O
reactive	O
to	O
light	O
and	O
accommodation	O
,	O
no	O
LAD	O
,	O
oropharynx	O
clear	O
,	O
no	O
exudates	O
CV	O
:	O
regular	O
rate	O
and	O
rhythm	O
,	O
no	O
murmurs	O
/	O
gallops	O
/	O
rubs	O
PULM	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
rales	O
/	O
crackles	O
/	O
rhonchi	O
GI	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
;	O
no	O
guarding	O
/	O
rebound	O
EXT	O
:	O
no	O
clubbing	O
/	O
cyanosis	O
/	O
edema	O
;	O
2	O
+	O
distal	O
pulses	O
;	O
peripheral	O
IV	O
present	O
NEURO	O
:	O
Alert	O
to	O
person	O
and	O
situation	O
;	O
CN	O
II	O
-	O
XII	O
grossly	O
intact	O
,	O
global	O
muscle	O
weakness	O
DERM	O
:	O
no	O
lesions	O
appreciated	O
Pertinent	O
Results	O
:	O
[	O
**	O
2141-6-14	O
**	O
]	O
Na	O
146	O
K	O
4.6	O
Cl	O
116	O
C02	O
20	O
BUN	O
30	O
Cr	O
0.7	O
Alb	O
2.6	O
Alk	O
Phos	O
91	O
Bilirubin	O
0.7	O
(	O
direct	O
0.1	O
)	O
AST	O
171	O
ALT	O
286	O
Tpro	O
6.3	O
Lipase	O
8117	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
1434	O
WBC	O
20.7	O
HgB	O
17.2	O
HCT	O
53.7	O
PLT	O
168	O
ABG	O
BiPAP	O
(	O
PEEP	O
5	O
,	O
PS	O
5	O
)	O
7.20	O
/	O
41/85	O
Venti	O
mask	O
10L	O
7.17	O
/	O
47/82	O
Micro	O
:	O
urine	O
cx	O
[	O
**	O
Hospital1	O
487	O
**	O
]	O
[	O
**	O
2141-6-13	O
**	O
]	O
>	O
100,000	O
colonies	O
of	O
beta	O
hemolytic	O
group	O
B	O
strep	O
[	O
**	O
Hospital3	O
**	O
]	O
Imaging	O
CT	O
Abdomen	O
Pelvis	O
with	O
contrast	I-Drug
Severe	O
acute	O
pancreatitis	O
with	O
suggestion	O
of	O
early	O
pancreatic	O
necrosis	O
Mildly	O
distended	O
gallbladder	O
containing	O
sludge	O
and	O
stones	O
no	O
definite	O
CBD	O
stone	O
identified	O
US	O
Gallbladder	O
:	O
Markedly	O
abnormal	O
appearance	O
of	O
the	O
pancreas	O
and	O
gallbladder	O
with	O
prominent	O
common	O
bile	O
duct	O
.	O
CT	O
Abdomen	O
/	O
Pelvis	O
CXR	O
[	O
**	O
Hospital1	O
487	O
**	O
]	O
:	O
Bilateral	O
lower	O
lobe	O
infiltrates	O
R	O
>	O
L	O
No	O
effusions	O
,	O
No	O
pneumothroax	O
CXR	O
(	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
my	O
read	O
)	O
Bilateral	O
pleural	O
effusions	O
,	O
some	O
vasular	O
prominence	O
no	O
focal	O
consolidations	O
EKG	O
:	O
sinus	O
at	O
137	O
Bpm	O
LAD	O
,	O
isolated	O
Q	O
in	O
V1	O
Admission	O
labs	O
:	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
WBC	O
-	O
16.8	O
*	O
RBC	O
-	O
5.27	O
Hgb	O
-	O
15.1	O
Hct	O
-	O
48.1	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
28.6	O
MCHC	O
-	O
31.3	O
RDW	O
-	O
14.4	O
Plt	O
Ct	O
-	O
214	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
Neuts	O
-	O
75	O
*	O
Bands	O
-	O
10	O
*	O
Lymphs	O
-	O
3	O
*	O
Monos	O
-	O
8	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
1	O
*	O
Metas	O
-	O
3	O
*	O
Myelos	O
-	O
0	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
PT	O
-	O
14.4	O
*	O
PTT	O
-	O
64.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
Glucose	O
-	O
229	O
*	O
UreaN	O
-	O
35	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
3.8	O
Cl	O
-	O
112	O
*	O
HCO3	O
-	O
17	O
*	O
AnGap	O
-	O
16	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
ALT	O
-	O
176	O
*	O
AST	O
-	O
87	O
*	O
AlkPhos	O
-	O
68	O
TotBili	O
-	O
0.7	O
[	O
**	O
2141-6-15	O
**	O
]	O
04:55	O
AM	O
BLOOD	O
ALT	O
-	O
154	O
*	O
AST	O
-	O
71	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
793	O
*	O
AlkPhos	O
-	O
65	O
TotBili	O
-	O
0.7	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
Lipase	O
-	O
980	O
*	O
[	O
**	O
2141-6-15	O
**	O
]	O
12:05	O
AM	O
BLOOD	O
Albumin	O
-	O
2.7	O
*	O
Calcium	O
-	O
6.7	O
*	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
1.5	O
*	O
[	O
**	O
2141-6-15	O
**	O
]	O
01:23	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
Temp	O
-	O
37.4	O
Rates	O
-	O
/	O
16	O
Tidal	O
V	O
-	O
400	O
PEEP	O
-	O
5	O
FiO2	O
-	O
60	O
pO2	O
-	O
96	O
pCO2	O
-	O
41	O
pH	O
-	O
7.23	O
*	O
calTCO2	O
-	O
18	O
*	O
Base	O
XS	O
--	O
9	O
-	O
ASSIST	O
/	O
CON	O
Intubat	O
-	O
INTUBATED	O
[	O
**	O
2141-6-14	O
**	O
]	O
11:23	O
PM	O
TYPE	O
-	O
ART	O
TEMP	O
-	O
37.4	O
[	O
**	O
2141-6-14	O
**	O
]	O
11:23	O
PM	O
LACTATE	O
-	O
1.5	O
[	O
**	O
2141-6-14	O
**	O
]	O
CT	O
abdomen	O
/	O
pelvis	O
IMPRESSION	O
:	O
1	O
.	O
Extensive	O
necrotizing	O
pancreatitis	O
without	O
gas	O
formation	O
.	O
2	O
.	O
Peripancreatic	O
inflammatory	O
fat	O
stranding	O
and	O
free	O
fluid	O
in	O
the	O
retroperitoneum	O
,	O
pelvis	O
and	O
perihepatic	O
locations	O
.	O
Distended	O
gallbladder	O
with	O
sludge	O
and	O
possibly	O
stones	O
,	O
though	O
no	O
ductal	O
dilatation	O
is	O
seen	O
.	O
3	O
.	O
Patent	O
portal	O
venous	O
system	O
,	O
though	O
the	O
splenic	O
artery	O
is	O
attenuated	O
.	O
RUQ	O
U	O
/	O
S	O
[	O
**	O
2141-6-15	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Gallbladder	O
filled	O
with	O
sludge	O
and	O
gallstones	O
.	O
No	O
evidence	O
of	O
choledocholithiasis	O
or	O
definite	O
cholecystitis	O
at	O
this	O
time	O
.	O
2	O
.	O
Rounded	O
heterogeneous	O
segment	O
II	O
liver	O
lesion	O
without	O
correlation	O
to	O
CT	O
two	O
days	O
prior	O
.	O
This	O
could	O
be	O
focal	O
fatty	O
sparing	O
but	O
other	O
lesions	O
such	O
as	O
FNH	O
could	O
be	O
missed	O
on	O
CT	O
in	O
equilibrium	O
phase	O
.	O
When	O
the	O
patient	O
's	O
condition	O
improves	O
,	O
a	O
repeat	O
ultrasound	O
should	O
be	O
obtained	O
.	O
3	O
.	O
Echogenic	O
liver	O
is	O
most	O
consistent	O
with	O
fatty	O
deposition	O
.	O
More	O
advanced	O
liver	O
disease	O
such	O
as	O
fibrosis	O
or	O
cirrhosis	O
can	O
not	O
be	O
excluded	O
on	O
this	O
study	O
.	O
CT	O
abdomen	O
and	O
pelvis	O
[	O
**	O
2141-6-18	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Redemonstration	O
of	O
necrotizing	O
pancreatitis	O
with	O
unchanged	O
distribution	O
of	O
pancreatic	O
necrosis	O
.	O
Interval	O
increase	O
in	O
peripancreatic	O
fluid	O
around	O
on	O
the	O
tail	O
of	O
the	O
pancreas	O
and	O
gastric	O
greater	O
curvature	O
,	O
but	O
fluid	O
collections	O
do	O
not	O
appear	O
organized	O
.	O
2	O
.	O
Moderate	O
nonhemorrhagic	O
pleural	O
effusions	O
with	O
associated	O
atelectasis	O
.	O
Echo	O
[	O
**	O
2141-6-26	O
**	O
]	O
The	O
left	O
atrium	O
and	O
right	O
atrium	O
are	O
normal	O
in	O
cavity	O
size	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Doppler	O
parameters	O
are	O
indeterminate	O
for	O
left	O
ventricular	O
diastolic	O
function	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
LENIs	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
The	O
visualized	O
vessels	O
are	O
patent	O
and	O
compressible	O
with	O
normal	O
flow	O
and	O
augmentation	O
.	O
No	O
thrombus	O
is	O
identified	O
.	O
There	O
is	O
normal	O
phasicity	O
within	O
the	O
common	O
femoral	O
veins	O
bilaterally	O
.	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
bilateral	O
lower	O
extremity	O
DVT	O
.	O
[	O
**	O
2141-6-27	O
**	O
]	O
:	O
renal	O
US	O
:	O
IMPRESSION	O
:	O
No	O
hydronephrosis	O
.	O
CT	O
chest	O
from	O
[	O
**	O
6	O
-	O
25	O
**	O
]	O
Pulmonary	O
nodules	O
measuring	O
up	O
to	O
7	O
mm	O
,	O
for	O
which	O
a	O
followup	O
CT	O
in	O
three	O
to	O
six	O
months	O
is	O
recommended	O
if	O
the	O
patient	O
is	O
high	O
risk	O
for	O
malignancy	O
and	O
6	O
to	O
12	O
months	O
if	O
low	O
risk	O
for	O
malignancy	O
based	O
on	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
8773	O
**	O
]	O
study	O
guidance	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
.	O
Severe	B-Reason
,	I-Reason
necrotizing	I-Reason
gallstone	I-Reason
pancreatitis	I-Reason
:	O
Resolved	O
.	O
Most	O
likely	O
gallstone	O
pancreatitis	O
though	O
LFT	O
pattern	O
not	O
c	O
/	O
w	O
prolonged	O
obstruction	O
.	O
Imaging	O
at	O
outside	O
hospital	O
demonstrated	O
the	O
presence	O
of	O
stones	O
in	O
addition	O
to	O
common	O
bile	O
duct	O
dilitation	O
.	O
She	O
was	O
initially	O
treated	O
with	O
meropenem	I-Drug
which	O
was	O
discontinued	O
after	O
several	O
days	O
.	O
Surgery	O
and	O
ERCP	O
services	O
were	O
consulted	O
and	O
suggested	O
supportive	O
medical	O
management	O
of	O
pancreatitis	O
.	O
ERCP	O
was	O
deferred	O
during	O
acute	O
disease	O
state	O
given	O
that	O
no	O
obstructing	O
stones	O
were	O
identified	O
on	O
CT	O
and	O
RUQ	O
U	O
/	O
S	O
.	O
After	O
acute	O
disease	O
state	O
resolves	O
,	O
she	O
will	O
require	O
lap	O
cholecystectomy	O
or	O
ERCP	O
with	O
sphincterotomy	O
(	O
in	O
2	O
-	O
3	O
months	O
)	O
.	O
#	O
.	O
Hypoxemic	B-Reason
/	I-Reason
hypercarbic	I-Reason
Respiratory	I-Reason
Failure	I-Reason
:	O
Resolved	O
.	O
Initial	O
episode	O
of	O
respiratory	O
failure	O
was	O
thought	O
to	O
be	O
due	O
to	O
ARDS	O
,	O
as	O
well	O
as	O
bilateral	O
effusions	O
and	O
some	O
vascular	O
congestion	O
,	O
suggesting	O
volume	O
overload	O
in	O
the	O
setting	O
of	O
aggressive	O
volume	O
resuscitation	O
.	O
After	O
pt	O
's	O
pancreatitis	O
started	O
to	O
improve	O
,	O
she	O
was	O
aggressively	O
diuresed	O
and	O
weaned	O
off	O
of	O
sedation	O
and	O
the	O
ventilator	O
.	O
She	O
did	O
not	O
have	O
a	O
cuff	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
3564	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
she	O
was	O
given	O
steroids	I-Drug
for	O
24	O
hrs	O
and	O
was	O
ultimately	O
extubated	O
.	O
After	O
extubation	O
,	O
pt	O
was	O
called	O
out	O
to	O
general	O
medical	O
floor	O
on	O
[	O
**	O
6	O
-	O
23	O
**	O
]	O
.	O
Within	O
24	O
hrs	O
,	O
she	O
developed	O
worsening	O
mental	O
status	O
and	O
increased	O
work	O
of	O
breathing	O
.	O
She	O
was	O
found	O
to	O
be	O
hypercarbic	O
on	O
ABG	O
.	O
Despite	O
aggressive	O
diuresis	O
and	O
a	O
trial	O
of	O
bipap	O
,	O
pt	O
's	O
CO2	O
did	O
not	O
improve	O
,	O
so	O
she	O
was	O
re-intubated	O
in	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
.	O
After	O
intubation	O
,	O
a	O
bronchoscopy	O
was	O
performed	O
that	O
did	O
not	O
reveal	O
any	O
evidence	O
of	O
lobar	O
infiltrate	O
consistent	O
with	O
aspiration	O
or	O
pna	O
.	O
BAL	O
cx	O
was	O
negative	O
.	O
A	O
CTA	O
was	O
performed	O
that	O
revealed	O
relative	O
[	O
**	O
Name	O
(	O
NI	O
)	O
20534	O
**	O
]	O
of	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
consistent	O
with	O
ischemic	O
changes	O
,	O
but	O
no	O
thrombus	O
was	O
identified	O
.	O
LENIs	O
were	O
performed	O
and	O
did	O
not	O
demonstrate	O
any	O
evidence	O
of	O
clot	O
and	O
echo	O
did	O
not	O
show	O
right	O
heart	O
strain	O
.	O
She	O
was	O
also	O
noted	O
to	O
have	O
persistent	O
bilateral	O
pleural	O
effusions	O
.	O
Due	O
to	O
the	O
fact	O
that	O
no	O
definitive	O
clot	O
was	O
found	O
and	O
she	O
clinically	O
improved	O
,	O
a	O
decision	O
was	O
made	O
to	O
not	O
anticoagulate	I-Drug
.	O
She	O
was	O
extubated	O
on	O
[	O
**	O
2141-6-28	O
**	O
]	O
,	O
and	O
approximately	O
15	O
min	O
after	O
,	O
she	O
developed	O
stridor	O
and	O
increased	O
wob	O
.	O
She	O
was	O
treated	O
with	O
steroids	I-Drug
,	O
racemic	I-Drug
epinephrine	O
and	O
heliox	I-Drug
for	O
presumed	O
laryngeal	B-Reason
edema	I-Reason
.	O
After	O
several	O
hours	O
her	O
respiratory	O
status	O
improved	O
and	O
within	O
24	O
hrs	O
she	O
was	O
weaned	O
to	O
nasal	O
cannula	O
.	O
Chest	O
X-ray	O
showed	O
improvement	O
in	O
bilateral	O
effusion	O
despite	O
persistent	O
ataelectasis	O
.	O
On	O
discharge	O
she	O
was	O
comfortable	O
at	O
rest	O
and	O
with	O
ambulation	O
on	O
room	O
air	O
.	O
#	O
.	O
Ventilator	O
associated	O
pneumonia	O
:	O
On	O
[	O
**	O
2141-6-20	O
**	O
]	O
,	O
she	O
developed	O
worsening	O
fevers	O
and	O
increased	O
sputum	O
production	O
.	O
Other	O
sources	O
of	O
infection	O
were	O
investigated	O
(	O
normal	O
U	O
/	O
A	O
,	O
abdomen	O
imaging	O
unchanged	O
,	O
no	O
diarrhea	O
)	O
,	O
so	O
she	O
was	O
empirically	O
treated	O
for	O
VAP	I-Reason
with	O
vancomycin	I-Drug
,	O
zosyn	I-Drug
and	O
ciprofloxicin	I-Drug
.	O
Pt	O
completed	O
a	O
8	O
day	O
treatment	O
course	O
for	O
VAP	O
.	O
No	O
current	O
evidence	O
of	O
infectious	O
process	O
#	O
.	O
Acute	O
renal	O
failure	O
:	O
Thought	O
to	O
be	O
AIN	I-Ade
after	O
being	O
exposed	O
to	O
cipro	I-Drug
and	O
zosyn	I-Drug
,	O
both	O
of	O
which	O
can	O
cause	O
AIN	O
.	O
Renal	O
U	O
/	O
S	O
was	O
performed	O
and	O
did	O
not	O
reveal	O
any	O
signs	O
of	O
hydronephrosis	O
.	O
Pt	O
's	O
cr	O
continued	O
to	O
improve	O
(	O
last	O
1.2	O
)	O
and	O
she	O
continued	O
to	O
have	O
good	O
urine	O
output	O
.	O
#	O
.	O
Tachycardia	I-Reason
:	O
Improved	O
with	O
treatment	O
of	O
acute	O
disease	O
and	O
with	O
restarting	O
her	O
home	O
verapamil	I-Drug
and	O
metoprolol	I-Drug
(	O
PCP	O
confirmed	O
that	O
both	O
are	O
for	O
hypertension	I-Reason
)	O
.	O
#	O
.	O
Insomnia	I-Reason
/	O
delerium	I-Reason
:	O
Was	O
previously	O
on	O
olanzapine	I-Drug
for	O
steroid	I-Drug
vs.	O
ICU	O
induced	O
delerium	I-Ade
.	O
She	O
responded	O
well	O
however	O
complained	O
of	O
increased	O
insomnia	I-Ade
.	O
Olanzapine	I-Drug
was	O
discontinued	O
and	O
Trazodone	I-Drug
was	O
ordered	O
.	O
#	O
.	O
Diabetes	O
:	O
She	O
has	O
had	O
fluctuating	O
blood	O
sugars	O
.	O
Initial	O
hyperglycemia	I-Reason
treated	O
with	O
SSI	I-Drug
and	O
lantus	I-Drug
resulted	O
in	O
next	O
day	O
hypoglycemia	I-Ade
.	O
Resolution	O
of	O
hypoglycemia	I-Reason
achieved	O
with	O
D5W	I-Drug
and	O
holding	O
insulin	I-Drug
.	O
Hyperglycemic	I-Reason
again	O
on	O
[	O
**	O
2141-7-2	O
**	O
]	O
with	O
glucose	O
in	O
400s	O
.	O
She	O
was	O
continued	O
on	O
gentle	O
HISS	I-Drug
while	O
NPO	O
.	O
She	O
was	O
ultimately	O
transition	O
back	O
to	O
glargine	I-Drug
and	O
HISS	I-Drug
.	O
The	O
diabetes	O
service	O
saw	O
the	O
patient	O
and	O
also	O
adjusted	O
her	O
insulin	I-Drug
dosing	O
.	O
#	O
.	O
Hypertension	B-Reason
,	I-Reason
benign	I-Reason
:	O
Held	O
home	O
amlodpine	I-Drug
,	O
lisinopril	I-Drug
and	O
verapamil	I-Drug
initially	O
on	O
admission	O
.	O
She	O
was	O
restarted	O
on	O
verapamil	I-Drug
and	O
metoprolol	I-Drug
.	O
#	O
.	O
Peripheral	B-Reason
Vascular	I-Reason
Disease	I-Reason
:	O
-	O
Continue	O
home	O
dose	O
of	O
ASA	I-Drug
#	O
Anemia	O
:	O
Hct	O
on	O
admission	O
in	O
the	O
40's	O
,	O
now	O
23	O
.	O
Improved	O
from	O
yesterday	O
.	O
Iron	O
studies	O
c	O
/	O
w	O
anemia	O
of	O
CD	O
with	O
ferritin	O
of	O
859	O
.	O
Normocytic	O
.	O
LDH	O
is	O
elevated	O
,	O
but	O
bili	O
is	O
normal	O
and	O
coags	O
are	O
normal	O
so	O
hemolysis	O
and	O
DIC	O
seem	O
less	O
likely	O
causes	O
.	O
-	O
consider	O
transfusion	O
if	O
hct	O
<	O
21	O
#	O
Leukocytosis	O
,	O
thrombocytosis	O
:	O
Peaked	O
on	O
[	O
**	O
6	O
-	O
30	O
**	O
]	O
.	O
UA	O
negative	O
.	O
Afebrile	O
.	O
Suspect	O
that	O
this	O
may	O
have	O
been	O
related	O
to	O
aspiration	O
as	O
her	O
WBC	O
and	O
platelets	O
are	O
now	O
improving	O
.	O
.	O
Access	O
:	O
PIV	O
.	O
Prophylaxis	O
:	O
Heparin	I-Drug
sub-Q	O
5000	O
Units	O
TID	O
for	O
VTE	B-Reason
prophylaxis	I-Reason
.	O
.	O
Precautions	O
:	O
None	O
.	O
Communication	O
:	O
Patient	O
,	O
daughter	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1787	O
**	O
]	O
and	O
Husband	O
[	O
**	O
Name	O
(	O
NI	O
)	O
24039	O
**	O
]	O
.	O
Dispo	O
:	O
Pending	O
clinical	O
improvement	O
.	O
CODE	O
:	O
Full	O
(	O
confirmed	O
on	O
this	O
admission	O
)	O
Transitional	O
:	O
-	O
cholecystectomy	O
or	O
ERCP	O
with	O
sphincterotomy	O
in	O
the	O
future	O
-	O
aspiration	O
:	O
on	O
a	O
dysphagia	O
diet	O
of	O
ground	O
solids	O
and	O
nectar	O
-	O
thick	O
liquids	O
-	O
nutrition	O
:	O
continue	O
tube	O
feeds	O
pending	O
re-eval	O
by	O
nutritionist	O
-	O
CT	O
chest	O
:	O
Pulmonary	O
nodules	O
measuring	O
up	O
to	O
7	O
mm	O
,	O
for	O
which	O
a	O
followup	O
CT	O
in	O
three	O
to	O
six	O
months	O
is	O
recommended	O
if	O
the	O
patient	O
is	O
high	O
risk	O
for	O
malignancy	O
and	O
6	O
to	O
12	O
months	O
if	O
low	O
risk	O
for	O
malignancy	O
based	O
on	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
8773	O
**	O
]	O
study	O
guidance	O
.	O
-	O
please	O
uptitrate	O
metoprolol	I-Drug
to	O
home	O
dose	O
(	O
100	O
mg	O
)	O
-	O
uptitrate	O
lisinopril	I-Drug
to	O
40	O
mg	O
as	O
tolerated	O
-	O
once	O
diet	O
is	O
stable	O
(	O
and	O
off	O
TF	O
)	O
restart	O
pt	O
's	O
outpatient	O
diabetes	I-Reason
regimen	O
(	O
actos	I-Drug
and	O
metformin	I-Drug
)	O
Medications	O
on	O
Admission	O
:	O
Actos	I-Drug
15	O
mg	O
daily	O
Amlodipine	I-Drug
2.5	O
mg	O
daily	O
Aspirin	I-Drug
81	O
mg	O
daily	O
Galantamine	I-Drug
8	O
mg	O
daily	O
with	O
food	O
Lasix	I-Drug
20	O
mg	O
PO	O
daily	O
lisinopril	I-Drug
40	O
mg	O
daily	O
Loratadine	I-Drug
10	O
mg	O
daily	O
metformin	I-Drug
500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Metoprolol	I-Drug
tartrate	O
100	O
mg	O
daily	O
omeprazole	I-Drug
40	O
mg	O
daily	O
Pravastain	I-Drug
40	O
mg	O
daily	O
Verapamil	I-Drug
240	O
mg	O
daily	O
Medications	O
on	O
Transfer	O
Acetaminophen	I-Drug
650	O
PR	O
q	O
4	O
PRN	O
Calcium	I-Drug
gluconate	O
1,000	O
q	O
6	O
PRN	O
Heparin	I-Drug
subQ	O
insulin	I-Drug
aspart	O
meropenam	I-Drug
1	O
gram	O
q	O
8	O
day	O
1	O
=[	O
**	O
6	O
-	O
14	O
**	O
]	O
levofloxacin	I-Drug
750	O
mg	O
IV	O
daily	O
day	O
1	O
=	O
[	O
**	O
2141-6-14	O
**	O
]	O
metoprolol	I-Drug
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
morphine	I-Drug
4	O
mg	O
q	O
4	O
hr	O
PRN	O
pain	I-Reason
ondansetron	I-Drug
4	O
mf	O
q	O
8	O
PRN	O
nausea	I-Reason
Pantoprazole	B-Drug
40	O
mg	O
IV	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
galantamine	B-Drug
8	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
Lasix	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
4	O
.	O
lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
5	O
.	O
loratadine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
allergy	B-Reason
symptoms	I-Reason
.	O
6	O
.	O
metoprolol	I-Drug
tartrate	O
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
8	O
.	O
omeprazole	B-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
9	O
.	O
pravastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
verapamil	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
11	O
.	O
ipratropium	B-Drug
bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
.	O
12	O
.	O
senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
13	O
.	O
docusate	I-Drug
sodium	O
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
14	O
.	O
simethicone	I-Drug
80	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
gas	I-Reason
.	O
15	O
.	O
bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
16	O
.	O
insulin	B-Drug
glargine	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Twenty	O
Five	O
(	O
25	O
)	O
u	O
Subcutaneous	O
once	O
a	O
day	O
.	O
17	O
.	O
insulin	B-Drug
lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
see	O
attached	O
sliding	O
scale	O
Subcutaneous	O
four	O
times	O
a	O
day	O
.	O
18	O
.	O
lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
19	O
.	O
heparin	I-Drug
(	O
porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
:	O
Please	O
administer	O
until	O
patient	O
is	O
ambulation	O
tid	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
85	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Pancreatitis	O
Cholelithiasis	O
Aspiration	O
pneumonitis	O
Pneumonia	O
,	O
ventilator	O
associated	O
Diabetes	O
mellitus	O
,	O
type	O
II	O
Hypertension	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
severe	O
pancreatitis	O
from	O
gallstones	O
.	O
You	O
were	O
treated	O
supportively	O
during	O
this	O
and	O
you	O
improved	O
.	O
You	O
required	O
intubation	O
(	O
breathing	O
tube	O
)	O
twice	O
to	O
support	O
your	O
breathing	O
.	O
You	O
were	O
treated	O
for	O
pneumonia	O
,	O
acute	O
kidney	O
failure	O
and	O
aspiration	O
.	O
You	O
are	O
now	O
improving	O
and	O
being	O
sent	O
to	O
an	O
acute	O
rehabilitation	O
facility	O
.	O
In	O
the	O
future	O
it	O
will	O
be	O
important	O
for	O
you	O
to	O
have	O
a	O
cholecystectomy	O
(	O
gall	O
bladder	O
removal	O
)	O
in	O
[	O
**	O
2	O
-	O
10	O
**	O
]	O
months	O
,	O
once	O
you	O
have	O
completely	O
recovered	O
from	O
this	O
hospitalization	O
.	O
You	O
will	O
also	O
need	O
to	O
have	O
follow	O
up	O
imaging	O
(	O
CT	O
scan	O
)	O
of	O
your	O
lungs	O
in	O
6	O
months	O
given	O
the	O
pulmonary	O
nodules	O
found	O
during	O
this	O
admission	O
.	O
Some	O
of	O
your	O
medications	O
have	O
changed	O
:	O
We	O
have	O
stopped	O
actos	I-Drug
and	O
metformin	I-Drug
.	O
These	O
were	O
changed	O
to	O
insulin	I-Drug
while	O
you	O
were	O
sick	O
.	O
Once	O
you	O
go	O
home	O
you	O
can	O
restart	O
these	O
.	O
We	O
have	O
stopped	O
amlodipine	I-Drug
.	O
We	O
have	O
halved	O
your	O
lisinopril	I-Drug
.	O
We	O
have	O
started	O
trazodone	I-Drug
,	O
simethicone	I-Drug
,	O
senna	I-Drug
,	O
colace	I-Drug
,	O
bisacodyl	I-Drug
,	O
insulin	I-Drug
and	O
lidocaine	I-Drug
patch	O
.	O
Followup	O
Instructions	O
:	O
Please	O
schedule	O
a	O
follow	O
up	O
appointment	O
with	O
your	O
primary	O
care	O
doctor	O
within	O
2	O
weeks	O
of	O
leaving	O
rehab	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2193-5-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2193-5-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2149-9-12	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Iodine	I-Drug
/	O
Platinum	B-Drug
Complexes	I-Drug
/	O
Aspirin	I-Drug
/	O
Shellfish	O
Derived	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1253	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fever	O
,	O
chills	O
,	O
nausea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
43	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
pmhx	O
.	O
of	O
recurrent	O
ovarian	O
carcinoma	O
(	O
s	O
/	O
p	O
TAH	O
-	O
BSO	O
,	O
IV	O
and	O
intraperitoneal	O
chemotherapy	I-Drug
,	O
radiation	O
,	O
and	O
microperforation	O
of	O
simoid	O
colon	O
requiring	O
sigmoid	O
resection	O
with	O
end	O
-	O
colostomy	O
)	O
who	O
presents	O
from	O
home	O
with	O
fevers	O
,	O
chills	O
,	O
and	O
nausea	O
of	O
one	O
day	O
.	O
Patient	O
recently	O
began	O
ixabepilone	I-Drug
chemotherapy	O
on	O
[	O
**	O
2193-5-2	O
**	O
]	O
and	O
since	O
that	O
time	O
reports	O
increased	O
vaginal	O
discharge	O
,	O
which	O
she	O
describes	O
as	O
"	O
yellow	O
and	O
brown	O
debris	O
.	O
"	O
States	O
that	O
she	O
has	O
been	O
using	O
about	O
2	O
pads	O
per	O
day	O
,	O
soaking	O
through	O
each	O
,	O
and	O
that	O
discharge	O
is	O
"	O
liquidy	O
"	O
in	O
character	O
.	O
This	O
is	O
an	O
entirely	O
new	O
symptom	O
for	O
her	O
.	O
Also	O
about	O
one	O
week	O
ago	O
patient	O
noticed	O
that	O
her	O
stoma	O
"	O
looked	O
different	O
.	O
"	O
It	O
seemed	O
retracted	O
into	O
her	O
abdominal	O
wall	O
,	O
and	O
there	O
was	O
increased	O
"	O
light	O
pink	O
bubbles	O
"	O
at	O
the	O
opening	O
.	O
She	O
went	O
to	O
see	O
her	O
ostomy	O
nurse	O
on	O
day	O
prior	O
to	O
admission	O
who	O
told	O
her	O
to	O
come	O
into	O
the	O
hospital	O
if	O
she	O
developed	O
fevers	O
,	O
chills	O
,	O
or	O
increased	O
abdominal	O
pain	O
.	O
Ms.	O
[	O
**	O
Known	O
lastname	O
45419	O
**	O
]	O
woke	O
up	O
with	O
these	O
symptoms	O
on	O
day	O
of	O
admission	O
and	O
came	O
to	O
the	O
ED	O
.	O
At	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
,	O
patient	O
had	O
a	O
CT	O
which	O
showed	O
a	O
small	O
rectal	O
stump	O
leak	O
,	O
locule	O
of	O
air	O
near	O
staple	O
line	O
of	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
pouch	O
,	O
and	O
a	O
colovaginal	O
fistula	O
,	O
which	O
had	O
likely	O
been	O
developing	O
over	O
the	O
course	O
of	O
weeks	O
(	O
and	O
was	O
not	O
likely	O
the	O
cause	O
of	O
her	O
current	O
symptoms	O
)	O
.	O
Surgery	O
was	O
consulted	O
and	O
they	O
felt	O
that	O
given	O
the	O
contained	O
leak	O
and	O
proximity	O
of	O
likely	O
residual	O
tumor	O
,	O
there	O
were	O
no	O
good	O
(	O
or	O
safe	O
)	O
surgical	O
options	O
.	O
It	O
was	O
recommended	O
that	O
patient	O
be	O
treated	O
with	O
antibiotic	I-Drug
coverage	O
and	O
remain	O
NPO	O
for	O
the	O
time	O
being	O
.	O
In	O
the	O
ED	O
initial	O
vitals	O
were	O
:	O
100136134	O
/	O
77	O
20	O
100	O
.	O
Patient	O
was	O
given	O
vancomycin	I-Drug
1g	O
,	O
cefepime	I-Drug
and	O
metronidazole	I-Drug
500	O
mg	O
.	O
Mag	I-Drug
was	O
noted	O
to	O
be	O
1.2	O
and	O
patient	O
given	O
2g	O
.	O
Na	O
was	O
128	O
(	O
131	O
on	O
repeat	O
)	O
and	O
k	O
was	O
5.6	O
(	O
4.2	O
on	O
repeat	O
)	O
.	O
WBC	O
23	O
.	O
Also	O
given	O
6L	O
of	O
fluid	I-Drug
.	O
Patient	O
remained	O
tachy	O
into	O
the	O
130	O
,	O
SBP	O
97	O
-	O
120	O
.	O
A	O
U	O
/	O
A	O
revealed	O
trace	O
modertate	O
blood	O
,	O
trace	O
leuks	O
and	O
glucosuria	O
.	O
Zofran	I-Drug
and	O
tylenol	I-Drug
were	O
given	O
symptomatically	O
.	O
On	O
transfer	O
,	O
BP	O
was	O
125/80	O
,	O
HR	O
120	O
,	O
and	O
she	O
was	O
satting	O
99	O
%	O
RA	O
.	O
ROS	O
:	O
Chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
in	O
LLQ	O
.	O
Negative	O
for	O
headache	O
,	O
trouble	O
swallowing	O
,	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
palpitations	O
,	O
dysuria	O
,	O
or	O
any	O
other	O
concerning	O
signs	O
or	O
symptoms	O
.	O
Past	O
Medical	O
History	O
:	O
Past	O
Oncologic	O
history	O
:	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
is	O
43	O
yo	O
woman	O
with	O
advanced	O
ovarian	O
ca	O
.	O
She	O
is	O
s	O
/	O
p	O
debulking	O
surgery	O
and	O
hysterectomy	O
and	O
bilateral	O
salpingo	O
-	O
oopherectomy	O
.	O
She	O
received	O
iv	O
and	O
intraperitoneal	O
chemotherapy	I-Drug
as	O
part	O
of	O
her	O
adjuvant	O
chemotherapy	O
ending	O
in	O
[	O
**	O
2193	O
**	O
]	O
7	O
.	O
She	O
was	O
enrolled	O
in	O
study	O
getting	O
oral	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
AZD2171	O
until	O
[	O
**	O
12	O
-	O
11	O
**	O
]	O
.	O
She	O
resumed	O
tx	O
with	O
single	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
as	O
of	O
[	O
**	O
2191-5-12	O
**	O
]	O
;	O
but	O
had	O
reaction	O
with	O
dose	O
6/08	O
.	O
Started	O
doxil	I-Drug
[	O
**	O
2191-7-21	O
**	O
]	O
.	O
Had	O
evidence	O
of	O
disease	O
progression	O
so	O
tx	O
changed	O
to	O
Alimta	I-Drug
on	O
[	O
**	O
2191-11-17	O
**	O
]	O
till	O
[	O
**	O
2	O
-	O
12	O
**	O
]	O
.	O
Tx	O
changed	O
to	O
Weekly	O
taxol	I-Drug
with	O
Avastin	I-Drug
on	O
[	O
**	O
2192-3-8	O
**	O
]	O
.	O
Due	O
to	O
neuropathy	I-Ade
from	O
taxol	I-Drug
;	O
tx	O
changed	O
to	O
weekly	O
taxotere	I-Drug
on	O
[	O
**	O
2192-6-28	O
**	O
]	O
.	O
She	O
had	O
sigmoid	O
colon	O
perforation	O
and	O
had	O
colon	O
ressection	O
and	O
colonostomy	O
on	O
[	O
**	O
2192-7-6	O
**	O
]	O
.	O
She	O
has	O
been	O
slow	O
to	O
heal	O
and	O
resummed	O
chemo	O
with	O
gemzar	I-Drug
on	O
[	O
**	O
2192-10-11	O
**	O
]	O
.	O
Tx	O
changed	O
to	O
Topotecan	I-Drug
on	O
[	O
**	O
2192-12-14	O
**	O
]	O
.	O
.	O
Past	O
Medical	O
History	O
:	O
Diabetes	O
Hypothyroidism	O
HTN	O
(	O
improved	O
-	O
no	O
meds	O
since	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
)	O
Clear	O
cell	O
ovarian	O
Cancer	O
s	O
/	O
p	O
TAH	O
-	O
BSO	O
,	O
appendectomy	O
,	O
omentectomy	O
[	O
**	O
2189	O
**	O
]	O
s	O
/	O
p	O
sigmoid	O
resection	O
[	O
**	O
7	O
-	O
12	O
**	O
]	O
Social	O
History	O
:	O
Patient	O
lives	O
alone	O
and	O
is	O
in	O
the	O
middle	O
of	O
a	O
divorce	O
.	O
Her	O
father	O
is	O
her	O
HCP	O
.	O
Does	O
not	O
smoke	O
or	O
drink	O
.	O
Continues	O
to	O
work	O
in	O
fundraising	O
at	O
WGBH	O
(	O
send	O
the	O
flyers	O
,	O
does	O
n't	O
do	O
the	O
radio	O
commercials	O
)	O
.	O
Family	O
History	O
:	O
Mother	O
with	O
NHL	O
,	O
tongue	O
CA	O
,	O
died	O
of	O
"	O
strep	O
throat	O
.	O
"	O
Father	O
has	O
a	O
pacemaker	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
Temp	O
:	O
101.7	O
,	O
BP	O
:	O
98/53	O
,	O
HR	O
:	O
108	O
,	O
SPO2	O
:	O
97	O
%	O
RA	O
GENERAL	O
:	O
Thin	O
,	O
chronically	O
ill	O
appearing	O
woman	O
,	O
no	O
acute	O
distress	O
,	O
lying	O
in	O
bed	O
CHEST	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
CARDIAC	O
:	O
RRR	O
,	O
II	O
/	O
VI	O
systolic	O
murmur	O
throughout	O
precordium	O
ABDOMEN	O
:	O
+	O
BS	O
,	O
ostomy	O
bag	O
in	O
place	O
with	O
gas	O
,	O
tenderness	O
in	O
LLQ	O
near	O
ostomy	O
site	O
EXTREMITIES	O
:	O
No	O
edema	O
bilaterally	O
SKIN	O
:	O
Warm	O
,	O
diaphoretic	O
NEURO	O
:	O
Alert	O
and	O
oriented	O
to	O
person	O
,	O
place	O
,	O
time	O
,	O
and	O
event	O
Pertinent	O
Results	O
:	O
[	O
**	O
2193-5-22	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
WBC	O
-	O
23.2	O
*	O
#	O
RBC	O
-	O
3.71	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
31.1	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
28.3	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
15.7	O
*	O
Plt	O
Ct	O
-	O
573	O
*	O
[	O
**	O
2193-5-27	O
**	O
]	O
07:30	O
AM	O
BLOOD	O
WBC	O
-	O
15.6	O
*	O
RBC	O
-	O
2.75	O
*	O
Hgb	O
-	O
7.3	O
*	O
Hct	O
-	O
23.4	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
26.5	O
*	O
MCHC	O
-	O
31.3	O
RDW	O
-	O
15.6	O
*	O
Plt	O
Ct	O
-	O
500	O
*	O
[	O
**	O
2193-5-22	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
Glucose	O
-	O
412	O
*	O
UreaN	O
-	O
12	O
Creat	O
-	O
0.9	O
Na	O
-	O
128	O
*	O
K	O
-	O
5.6	O
*	O
Cl	O
-	O
86	O
*	O
HCO3	O
-	O
26	O
AnGap	O
-	O
22	O
*	O
[	O
**	O
2193-5-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
Glucose	O
-	O
96	O
UreaN	O
-	O
8	O
Creat	O
-	O
0.6	O
Na	O
-	O
135	O
K	O
-	O
4.3	O
Cl	O
-	O
102	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2193-5-22	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
ALT	O
-	O
11	O
AST	O
-	O
32	O
AlkPhos	O
-	O
140	O
*	O
TotBili	O
-	O
0.4	O
[	O
**	O
2193-5-26	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
Phos	O
-	O
2.5	O
*	O
Mg	O
-	O
1.7	O
[	O
**	O
2193-5-22	O
**	O
]	O
02:15	O
PM	O
URINE	O
Color	O
-	O
Straw	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.024	O
[	O
**	O
2193-5-22	O
**	O
]	O
02:15	O
PM	O
URINE	O
Blood	O
-	O
MOD	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
NEG	O
Glucose	O
-	O
1000	O
Ketone	O
-	O
TR	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.0	O
Leuks	O
-	O
TR	O
[	O
**	O
2193-5-22	O
**	O
]	O
03:05	O
PM	O
URINE	O
UCG	O
-	O
NEG	O
Micro	O
:	O
[	O
**	O
2193-5-25	O
**	O
]	O
BLOOD	O
CULTURE	O
Blood	O
Culture	O
,	O
Routine	O
-	O
PENDING	O
INPATIENT	O
[	O
**	O
2193-5-24	O
**	O
]	O
BLOOD	O
CULTURE	O
Blood	O
Culture	O
,	O
Routine	O
-	O
PENDING	O
INPATIENT	O
[	O
**	O
2193-5-24	O
**	O
]	O
BLOOD	O
CULTURE	O
Blood	O
Culture	O
,	O
Routine	O
-	O
PENDING	O
INPATIENT	O
[	O
**	O
2193-5-24	O
**	O
]	O
BLOOD	O
CULTURE	O
Blood	O
Culture	O
,	O
Routine	O
-	O
PENDING	O
INPATIENT	O
[	O
**	O
2193-5-22	O
**	O
]	O
Blood	O
Culture	O
,	O
Routine	O
-	O
{	O
STREPTOCOCCUS	O
ANGINOSUS	O
(	O
MILLERI	O
)	O
GROUP	O
}	O
;	O
Anaerobic	O
Bottle	O
Gram	O
Stain	O
-	O
[	O
**	O
2193-5-22	O
**	O
]	O
Blood	O
Culture	O
,	O
Routine	O
-	O
{	O
STREPTOCOCCUS	O
ANGINOSUS	O
(	O
MILLERI	O
)	O
GROUP	O
}	O
;	O
Anaerobic	O
Bottle	O
Gram	O
Stain	O
STREPTOCOCCUS	O
ANGINOSUS	O
(	O
MILLERI	O
)	O
GROUP	O
CLINDAMYCIN	I-Drug
-----------	O
S	O
ERYTHROMYCIN	I-Drug
----------	O
<	O
=	O
0.25	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
1	O
S	O
PENICILLIN	B-Drug
G	I-Drug
----------	O
<	O
=	O
0.06	O
S	O
VANCOMYCIN	I-Drug
------------	O
<	O
=	O
1	O
S	O
Radiology	O
:	O
[	O
**	O
5	O
-	O
22	O
**	O
]	O
CT	O
ABDOMEN	O
W	O
/	O
O	O
CONTRAST	I-Drug
IMPRESSION	O
:	O
(	O
pt	O
reports	O
hx	O
of	O
allergy	O
to	O
contrast	O
)	O
1	O
.	O
Interval	O
increase	O
of	O
left	O
pelvic	O
mass	O
with	O
close	O
association	O
with	O
the	O
bowel	O
.	O
2	O
.	O
Enterovaginal	O
fistula	O
.	O
3	O
.	O
Locules	O
of	O
gas	O
near	O
the	O
staple	O
line	O
of	O
the	O
Hartmann	O
's	O
pouch	O
;	O
it	O
is	O
unclear	O
if	O
it	O
is	O
intra	O
-	O
or	O
extra-luminal	O
,	O
infectious	O
process	O
at	O
this	O
site	O
not	O
excluded	O
.	O
No	O
evidence	O
of	O
parastomal	O
collection	O
.	O
4	O
.	O
Gallbladder	O
sludge	O
without	O
evidence	O
of	O
acute	O
cholecystitis	O
.	O
5	O
.	O
Bilateral	O
hydronephrosis	O
,	O
stable	O
from	O
previous	O
study	O
.	O
6	O
.	O
Hepatic	O
hypodensity	O
,	O
concerning	O
for	O
metastasis	O
.	O
[	O
**	O
5	O
-	O
26	O
**	O
]	O
KUB	O
FINDINGS	O
:	O
Gas	O
and	O
stool	O
are	O
seen	O
throughout	O
the	O
colon	O
to	O
the	O
region	O
of	O
the	O
splenic	O
flexure	O
.	O
Gas	O
is	O
seen	O
in	O
some	O
mildly	O
dilated	O
loops	O
of	O
small	O
bowel	O
measuring	O
up	O
to	O
4	O
cm	O
,	O
without	O
air	O
-	O
fluid	O
level	O
.	O
This	O
likely	O
represents	O
an	O
ileus	O
.	O
UNILAT	O
LOWER	O
EXT	O
VEINS	O
LEFT	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
DVT	O
.	O
Brief	O
Hospital	O
Course	O
:	O
43	O
yo	O
femaled	O
with	O
advanced	O
ovarian	O
cancer	O
,	O
was	O
admitted	O
with	O
complaints	O
of	O
fever	O
,	O
chills	O
,	O
and	O
was	O
found	O
to	O
have	O
SIRS	I-Reason
/	O
septic	I-Reason
shock	O
,	O
and	O
was	O
initially	O
managed	O
in	O
the	O
ICU	O
.	O
She	O
was	O
started	O
on	O
empiric	O
coverage	O
with	O
broad	O
spectrum	O
antibiotics	I-Drug
.	O
She	O
was	O
found	O
to	O
be	O
bacteremic	O
with	O
strep	O
anginosus	O
,	O
which	O
is	O
likely	O
d	O
/	O
t	O
intrabdominal	O
fisulization	O
/	O
abscesses	O
.	O
A	O
CT	O
of	O
her	O
abdomen	O
and	O
pelvis	O
(	O
without	O
contrast	O
due	O
to	O
allergy	O
)	O
showed	O
significantly	O
worsening	O
ovarian	O
cancer	O
,	O
colovaginal	O
fistulization	O
,	O
and	O
possible	O
microperforation	O
vs	O
infection	O
at	O
her	O
[	O
**	O
Doctor	O
Last	O
Name	O
3379	O
**	O
]	O
pouch	O
.	O
She	O
clinically	O
stabilized	O
,	O
however	O
further	O
discussion	O
with	O
her	O
oncologist	O
and	O
surgeon	O
revealed	O
that	O
there	O
are	O
no	O
further	O
therapeutic	O
options	O
to	O
offer	O
,	O
and	O
she	O
is	O
not	O
a	O
candidate	O
for	O
surgery	O
.	O
Her	O
primary	O
oncologist	O
is	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
She	O
was	O
transitioned	O
to	O
DNR	O
/	O
DNI	O
,	O
and	O
she	O
elected	O
to	O
go	O
home	O
with	O
hospice	O
care	O
.	O
Her	O
blood	O
cultures	O
later	O
revealed	O
strep	O
anginosus	O
(	O
milleri	O
)	O
,	O
and	O
her	O
antibiotics	I-Drug
were	O
changed	O
to	O
oral	O
flagyl	I-Drug
and	O
levofloxacin	I-Drug
,	O
as	O
she	O
prefered	O
an	O
oral	O
regimen	O
for	O
palliation	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
she	O
was	O
still	O
having	O
low	O
-	O
grade	O
temps	O
,	O
but	O
seh	O
was	O
not	O
symptomatic	O
from	O
them	O
.	O
She	O
will	O
complete	O
a	O
2	O
week	O
course	O
of	O
antibiotics	I-Drug
on	O
[	O
**	O
2193-6-5	O
**	O
]	O
.	O
.	O
*	O
Colovaginal	O
fistula	O
-	O
She	O
has	O
a	O
known	O
colovaginal	O
fistula	O
,	O
however	O
there	O
are	O
no	O
surgical	O
options	O
per	O
GynOnc	O
discussion	O
.	O
It	O
does	O
appear	O
that	O
her	O
vaginal	O
discharge	O
may	O
be	O
improving	O
slightly	O
with	O
antibiotic	I-Drug
treatment	O
.	O
.	O
*	O
LLE	O
Edema	O
-	O
She	O
was	O
noted	O
to	O
have	O
some	O
left	O
sided	O
edema	O
(	O
LLE	O
/	O
LUE	O
)	O
.	O
THere	O
was	O
intially	O
concern	O
for	O
possible	O
DVT	O
,	O
however	O
LENI	O
;	O
s	O
were	O
negative	O
.	O
The	O
edema	O
is	O
most	O
likely	O
related	O
to	O
=	O
tumor	O
blocking	O
lymphatic	O
drainage	O
.	O
Elevation	O
and	O
LLE	O
compression	O
hose	O
were	O
recommended	O
for	O
comfort	O
.	O
.	O
*	O
Ovarian	O
cancer	O
-	O
Per	O
primary	O
oncologist	O
,	O
pt	O
has	O
no	O
further	O
chemotherapy	O
options	O
.	O
Transitioned	O
to	O
DNR	O
/	O
DNI	O
and	O
palliative	O
care	O
consulted	O
and	O
assisted	O
throughout	O
the	O
hospitalization	O
.	O
--	O
Patient	O
is	O
being	O
discharged	O
to	O
home	O
with	O
hospice	O
.	O
*	O
DM	I-Reason
-	O
Pt	O
had	O
several	O
episodes	O
of	O
hypoglycemia	I-Ade
on	O
lantus	I-Drug
due	O
to	O
decreasing	O
oral	O
intake	O
.	O
Her	O
lantus	I-Drug
dose	O
was	O
serially	O
downtitrated	O
.	O
Tight	O
glucose	O
control	O
not	O
necessary	O
at	O
this	O
time	O
,	O
but	O
would	O
like	O
to	O
avoid	O
extreme	O
highs	O
that	O
may	O
produce	O
symptoms	O
.	O
-	O
Pt	O
discharged	O
on	O
reduced	O
lantus	I-Drug
dose	O
without	O
sliding	O
scale	O
.	O
.	O
*	O
Hypothyroidism	I-Reason
-	O
continue	O
synthroid	I-Drug
.	O
*	O
Hyperlipdemia	I-Reason
-	O
Hold	O
statin	I-Drug
and	O
Tricor	I-Drug
.	O
*	O
Ostomy	O
Retraction	O
-	O
Ostomy	O
is	O
retracted	O
as	O
per	O
ostomy	O
nurse	O
and	O
surgery	O
consult	O
.	O
Now	O
with	O
resuming	O
stool	O
output	O
.	O
KUB	O
showed	O
some	O
stool	O
c	O
/	O
w	O
constipation	I-Reason
.	O
She	O
was	O
treated	O
with	O
Miralax	I-Drug
with	O
some	O
improvement	O
in	O
her	O
stool	O
output	O
.	O
She	O
was	O
recommened	O
to	O
continue	O
to	O
take	O
stool	B-Drug
softeners	I-Drug
and	O
Miralax	I-Drug
and	O
to	O
stay	O
well	O
hydrated	O
to	O
prevent	O
constipation	I-Reason
in	O
the	O
future	O
.	O
She	O
may	O
also	O
use	O
milk	B-Drug
of	I-Drug
magnesia	I-Drug
as	O
well	O
as	O
needed	O
.	O
.	O
PPX	O
:	O
Pt	O
is	O
at	O
high	O
risk	O
for	O
DVT	O
given	O
ovarian	O
cancer	O
.	O
Pt	O
will	O
be	O
discharged	O
on	O
daily	O
dosing	O
of	O
lovenox	I-Drug
to	O
prevent	B-Reason
DVT	I-Reason
for	O
palliative	O
benefit	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
home	O
today	O
with	O
hospice	O
.	O
She	O
is	O
DNR	O
/	O
DNI	O
.	O
Her	O
oncologist	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
will	O
be	O
the	O
contact	O
person	O
for	O
the	O
Hospice	O
agency	O
.	O
Medications	O
on	O
Admission	O
:	O
Tricor	I-Drug
145	O
QD	O
Crestor	I-Drug
40	O
QD	O
Lantus	I-Drug
80units	O
QHS	O
and	O
Humalog	I-Drug
sliding	O
scale	O
Levothyroxine	I-Drug
100mcg	O
QD	O
Discharge	O
Medications	O
:	O
1	O
.	O
Levothyroxine	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Enoxaparin	I-Drug
40	O
mg	O
/	O
0.4	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
inj	O
Subcutaneous	O
once	O
a	O
day	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
30	O
inj	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Polyethylene	B-Drug
Glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
packet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
30	O
packet	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Magnesium	B-Drug
Hydroxide	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
7	O
.	O
Levofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
8	O
days	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
8	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
Metronidazole	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
for	O
8	O
days	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
24	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
10	O
.	O
Acetaminophen	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
four	O
times	O
a	O
day	O
as	O
needed	O
for	O
pain	I-Reason
.	O
11	O
.	O
Insulin	B-Drug
Glargine	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Thirty	O
Five	O
(	O
35	O
)	O
units	O
Subcutaneous	O
once	O
a	O
day	O
:	O
please	O
continue	O
to	O
follow	O
your	O
blood	O
sugars	O
.	O
Decrease	O
your	O
dose	O
if	O
you	O
have	O
low	O
sugars	O
,	O
and	O
call	O
your	O
PCP	O
.	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
:	O
*	O
1	O
vial	O
*	O
Refills	O
:	O
*	O
1	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Company	O
1519	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
#	O
Recurrent	O
ovarian	O
cancer	O
#	O
Bacteremia	O
;	O
Strep	O
Anginosus	O
#	O
Colovaginal	O
fistula	O
#	O
Diabetes	B-Reason
,	I-Reason
Type	I-Reason
2	I-Reason
on	O
insulin	I-Drug
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
fevers	O
,	O
chills	O
,	O
and	O
nausea	O
,	O
and	O
you	O
were	O
found	O
to	O
have	O
bacteria	B-Reason
in	I-Reason
your	I-Reason
blood	I-Reason
,	O
which	O
is	O
being	O
treated	O
with	O
antibiotics	I-Drug
.	O
After	O
discussion	O
with	O
GYN	O
-	O
Oncology	O
and	O
surgery	O
,	O
there	O
are	O
no	O
further	O
treatment	O
options	O
for	O
your	O
ovarian	O
cancer	O
.	O
You	O
will	O
be	O
followed	O
at	O
home	O
by	O
Hospice	O
,	O
who	O
will	O
make	O
sure	O
that	O
any	O
symptoms	O
remain	O
well	O
managed	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2193-5-30	O
**	O
]	O
at	O
2:00	O
PM	O
With	O
:	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2193-5-30	O
**	O
]	O
at	O
3:00	O
PM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
5338	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
5339	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2193-6-6	O
**	O
]	O
at	O
2:00	O
PM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
5338	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
5339	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
447	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
940	O
**	O
]	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
941	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2193-10-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2193-10-20	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2110-4-2	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
ORTHOPAEDICS	O
Allergies	O
:	O
Percocet	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
942	O
**	O
]	O
Addendum	O
:	O
Please	O
note	O
that	O
patient	O
was	O
discharged	O
on	O
metoprolol	I-Drug
50	O
mg	O
QID	O
and	O
not	O
her	O
home	O
dose	O
of	O
propanolol	I-Drug
.	O
Patient	O
also	O
given	O
1	O
unit	O
pRBCs	I-Drug
on	O
[	O
**	O
10	O
-	O
19	O
**	O
]	O
for	O
hct	B-Reason
of	I-Reason
27	I-Reason
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
3	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
4	O
.	O
Multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Cholecalciferol	B-Drug
(	I-Drug
Vitamin	I-Drug
D3	I-Drug
)	I-Drug
400	O
unit	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Levothyroxine	I-Drug
75	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
Pain	I-Reason
.	O
10	O
.	O
Warfarin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
:	O
INR	O
[	O
**	O
3	O
-	O
12	O
**	O
]	O
.	O
11	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
12	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
13	O
.	O
Quetiapine	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
distress	I-Reason
.	O
14	O
.	O
Lorazepam	I-Drug
0.25	O
mg	O
IV	O
BID	O
:	O
PRN	O
distress	I-Reason
15	O
.	O
Metoprolol	I-Drug
Tartrate	O
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
41	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
42	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Left	O
hip	O
post	O
traumatic	O
OA	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
DISCHARGE	O
INSTRUCTIONS	O
1	O
.	O
Please	O
return	O
to	O
the	O
emergency	O
department	O
or	O
notify	O
MD	O
if	O
you	O
experience	O
severe	O
pain	O
not	O
relieved	O
by	O
medication	O
,	O
increased	O
swelling	O
,	O
decreased	O
sensation	O
,	O
difficulty	O
with	O
movement	O
,	O
fevers	O
>	O
101.5	O
,	O
shaking	O
chills	O
,	O
redness	O
or	O
drainage	O
from	O
the	O
incision	O
site	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
or	O
any	O
other	O
concerns	O
.	O
2	O
.	O
Please	O
follow	O
up	O
with	O
your	O
PCP	O
regarding	O
this	O
admission	O
and	O
any	O
new	O
medications	O
and	O
refills	O
.	O
3	O
.	O
Resume	O
your	O
home	O
medications	O
unless	O
otherwise	O
instructed	O
.	O
4	O
.	O
You	O
have	O
been	O
given	O
medications	O
for	O
pain	O
control	O
.	O
Please	O
do	O
not	O
operate	O
heavy	O
machinery	O
or	O
drink	O
alcohol	O
when	O
taking	O
these	O
medications	O
.	O
As	O
your	O
pain	O
improves	O
,	O
please	O
decrease	O
the	O
amount	O
of	O
pain	B-Drug
medication	I-Drug
.	O
This	O
medication	O
can	O
cause	O
constipation	I-Reason
,	O
so	O
you	O
should	O
drink	O
plenty	O
of	O
water	O
daily	O
and	O
take	O
a	O
stool	B-Drug
softener	I-Drug
(	O
e.g.	O
,	O
colace	O
)	O
as	O
needed	O
to	O
prevent	O
this	O
side	O
effect	O
.	O
5	O
.	O
You	O
may	O
not	O
drive	O
a	O
car	O
until	O
cleared	O
to	O
do	O
so	O
by	O
your	O
surgeon	O
or	O
your	O
primary	O
physician	O
.	O
6	O
.	O
Please	O
keep	O
your	O
wounds	O
clean	O
.	O
You	O
may	O
get	O
the	O
wound	O
wet	O
or	O
take	O
a	O
shower	O
starting	O
5	O
days	O
after	O
surgery	O
,	O
but	O
no	O
baths	O
or	O
swimming	O
for	O
at	O
least	O
4	O
weeks	O
.	O
No	O
dressing	O
is	O
needed	O
if	O
wound	O
continues	O
to	O
be	O
non-draining	O
.	O
Any	O
stitches	O
or	O
staples	O
that	O
need	O
to	O
be	O
removed	O
will	O
be	O
taken	O
out	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
2	O
weeks	O
after	O
your	O
surgery	O
.	O
7	O
.	O
Please	O
call	O
your	O
surgeon	O
's	O
office	O
to	O
schedule	O
or	O
confirm	O
your	O
follow	O
-	O
up	O
appointment	O
at	O
2	O
weeks	O
.	O
8	O
.	O
Please	O
DO	O
NOT	O
take	O
any	O
NSAIDs	I-Drug
(	O
i.e.	O
celebrex	I-Drug
,	O
ibuprofen	I-Drug
,	O
advil	I-Drug
,	O
motrin	I-Drug
,	O
etc	O
)	O
.	O
9	O
.	O
ANTICOAGULATION	I-Reason
:	O
Please	O
continue	O
coumadin	I-Drug
.	O
10	O
.	O
WOUND	O
CARE	O
:	O
Please	O
keep	O
your	O
incision	O
clean	O
and	O
dry	O
.	O
It	O
is	O
okay	O
to	O
shower	O
after	O
POD	O
#	O
5	O
but	O
do	O
not	O
take	O
a	O
tub	O
-	O
bath	O
or	O
submerge	O
your	O
incision	O
until	O
4	O
weeks	O
after	O
surgery	O
.	O
Please	O
place	O
a	O
dry	O
sterile	O
dressing	O
on	O
the	O
wound	O
each	O
day	O
if	O
there	O
is	O
drainage	O
,	O
otherwise	O
leave	O
it	O
open	O
to	O
air	O
.	O
Check	O
wound	O
regularly	O
for	O
signs	O
of	O
infection	O
such	O
as	O
redness	O
or	O
thick	O
yellow	O
drainage	O
.	O
Staples	O
will	O
be	O
removed	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
at	O
2	O
weeks	O
post	O
op.	O
11	O
.	O
VNA	O
(	O
once	O
at	O
home	O
)	O
:	O
Home	O
PT	O
/	O
OT	O
,	O
dressing	O
changes	O
as	O
instructed	O
,	O
wound	O
checks	O
.	O
12	O
.	O
ACTIVITY	O
:	O
Weight	O
bearing	O
as	O
tolerated	O
on	O
the	O
operative	O
leg	O
.	O
No	O
strenuous	O
exercise	O
or	O
heavy	O
lifting	O
until	O
follow	O
up	O
appointment	O
.	O
Physical	O
Therapy	O
:	O
WBAT	O
LLE	O
with	O
posterior	O
precautions	O
Treatments	O
Frequency	O
:	O
Dry	O
sterile	O
dressing	O
to	O
incision	O
daily	O
.	O
Staples	O
out	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
at	O
2	O
week	O
post	O
op	O
visit	O
.	O
Coumadin	I-Drug
daily	O
for	O
INR	O
[	O
**	O
3	O
-	O
12	O
**	O
]	O
Followup	O
Instructions	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
809	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2193-10-30	O
**	O
]	O
10:15	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
943	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
944	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2193-12-6	O
**	O
]	O
9:00	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
945	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2193-10-20	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2107-11-1	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2107-12-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2047-8-17	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
6169	O
**	O
]	O
Chief	O
Complaint	O
:	O
presenting	O
for	O
elective	O
surgery	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
total	O
abdominal	O
hysterectomy	O
and	O
bilateral	O
salpingo	O
-	O
oopherectomy	O
endotracheal	O
intubation	O
central	O
venous	O
catheter	O
placement	O
arterial	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
The	O
patient	O
is	O
a	O
60	O
year	O
old	O
female	O
,	O
with	O
no	O
significant	O
past	O
medical	O
history	O
,	O
recently	O
referred	O
to	O
gynecology	O
-	O
oncology	O
for	O
a	O
diagnosis	O
of	O
ovarian	O
cancer	O
.	O
She	O
initially	O
presented	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
with	O
a	O
complaint	O
of	O
progressive	O
shortness	O
of	O
breath	O
.	O
She	O
also	O
reported	O
a	O
20	O
-	O
30	O
pound	O
weight	O
loss	O
,	O
gradual	O
abdominal	O
distention	O
and	O
bilateral	O
lower	O
extremity	O
swelling	O
.	O
She	O
was	O
found	O
to	O
have	O
a	O
large	O
right	O
pleural	O
effusion	O
and	O
underwent	O
a	O
2.5	O
L	O
thoracentesis	O
,	O
with	O
negative	O
cytology	O
.	O
The	O
patient	O
also	O
had	O
a	O
paracentesis	O
with	O
negative	O
cytology	O
at	O
the	O
OSH	O
.	O
CT	O
torso	O
on	O
[	O
**	O
10	O
-	O
20	O
**	O
]	O
showed	O
bilateral	O
pulmonary	O
opacities	O
,	O
diffuse	O
lymphadenopathy	O
,	O
ascities	O
,	O
and	O
ovarian	O
masses	O
.	O
Ultrasound	O
on	O
[	O
**	O
2107-10-21	O
**	O
]	O
showed	O
bilateral	O
pelvic	O
soft	O
tissue	O
masses	O
with	O
ascites	O
and	O
normal	O
uterus	O
.	O
CA	O
-	O
125	O
was	O
elevated	O
at	O
greater	O
than	O
2500	O
.	O
She	O
was	O
then	O
transferred	O
to	O
the	O
gyn	O
-	O
onc	O
service	O
for	O
further	O
management	O
.	O
.	O
Patient	O
underwent	O
TAH	O
/	O
BSO	O
,	O
and	O
ascites	O
drainage	O
.	O
Right	O
pelvic	O
lymph	O
node	O
was	O
sent	O
for	O
frozen	O
section	O
which	O
was	O
found	O
to	O
be	O
consistent	O
with	O
lymphoma	O
.	O
The	O
right	O
ovarian	O
mass	O
was	O
found	O
to	O
be	O
benign	O
.	O
Multiple	O
enlarged	O
lymph	O
noes	O
were	O
found	O
,	O
the	O
largest	O
was	O
over	O
5	O
cm	O
.	O
Intraoperatively	O
,	O
she	O
received	O
1	O
L	O
IVF	I-Drug
and	O
was	O
bolused	O
subsequently	O
for	O
low	B-Reason
UOP	I-Reason
and	O
for	O
post-operative	O
hypotension	O
.	O
Patient	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
ongoing	O
treatment	O
.	O
.	O
Upon	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
,	O
patient	O
was	O
intubated	O
and	O
mildly	O
sedated	O
,	O
VS	O
:	O
BP	O
84/52	O
MAP	O
65	O
HR	O
88	O
O2	O
sat	O
95	O
%	O
on	O
AC	O
.	O
Central	O
line	O
was	O
placed	O
under	O
ultrasound	O
guidance	O
in	O
the	O
right	O
IJ	O
.	O
While	O
in	O
the	O
ICU	O
,	O
she	O
was	O
put	O
on	O
up	O
to	O
3	O
pressors	I-Drug
for	O
her	O
hypotension	I-Reason
.	O
She	O
went	O
into	O
acute	B-Reason
renal	I-Reason
failure	I-Reason
(	O
thought	O
to	O
be	O
from	O
hypotension	B-Ade
-	I-Ade
related	I-Ade
ATN	I-Ade
with	O
a	O
possible	O
component	O
of	O
tumor	I-Ade
lysis	O
syndrome	O
from	O
steroid	I-Drug
-	O
induced	O
lysis	I-Ade
)	O
requiring	O
CVVH	O
and	O
rasburicase	I-Drug
.	O
She	O
was	O
successfully	O
taken	O
off	O
CVVH	O
and	O
extubated	O
.	O
She	O
was	O
diuresed	O
aggressively	O
for	O
a	O
20L	O
net	O
positive	O
fluid	O
status	O
since	O
her	O
ICU	O
admission	O
.	O
Her	O
abdominal	O
wound	O
was	O
draining	O
up	O
to	O
1L	O
/	O
day	O
.	O
Also	O
while	O
in	O
the	O
ICU	O
,	O
she	O
was	O
noted	O
to	O
have	O
an	O
EF	O
of	O
20	O
%	O
,	O
;	O
it	O
is	O
unclear	O
if	O
this	O
is	O
from	O
an	O
MI	O
in	O
the	O
setting	O
of	O
hypotension	O
or	O
if	O
it	O
is	O
just	O
"	O
shocked	O
"	O
myocardium	O
.	O
.	O
After	O
her	O
acute	O
issues	O
stabilized	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
7	O
[	O
**	O
Hospital	O
Ward	O
Name	O
1826	O
**	O
]	O
for	O
further	O
management	O
.	O
Past	O
Medical	O
History	O
:	O
none	O
Social	O
History	O
:	O
The	O
patient	O
smoked	O
one	O
pack	O
per	O
day	O
for	O
30	O
years	O
,	O
but	O
currently	O
does	O
not	O
smoke	O
.	O
She	O
drinks	O
occasionally	O
.	O
She	O
is	O
married	O
and	O
has	O
two	O
daughters	O
and	O
one	O
son	O
from	O
a	O
previous	O
marraige	O
.	O
Family	O
History	O
:	O
colon	O
cancer	O
Physical	O
Exam	O
:	O
Upon	O
arrival	O
in	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
:	O
GEN	O
:	O
sedated	O
,	O
intubated	O
.	O
not	O
responsive	O
to	O
voice	O
or	O
noxious	O
stimuli	O
HEENT	O
:	O
PERRL	O
CV	O
:	O
distant	O
heart	O
sounds	O
,	O
nl	O
s1	O
,	O
s2	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
Pulm	O
:	O
CTA	O
anteriorly	O
Abd	O
:	O
midline	O
abdominal	O
dressing	O
clean	O
and	O
intact	O
.	O
obese	O
,	O
nontender	O
,	O
hypoactive	O
bowel	O
sounds	O
.	O
Ext	O
:	O
warm	O
,	O
trace	O
edema	O
,	O
no	O
cyanosis	O
.	O
pedal	O
pulses	O
present	O
neuro	O
:	O
not	O
responsive	O
to	O
voice	O
or	O
noxious	O
stimuli	O
[	O
**	O
3	O
-	O
3	O
**	O
]	O
sedation	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2107-10-31	O
**	O
]	O
09:05	O
AM	O
PT	O
-	O
11.4	O
PTT	O
-	O
23.1	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2107-10-31	O
**	O
]	O
09:05	O
AM	O
WBC	O
-	O
6.5	O
RBC	O
-	O
4.24	O
HGB	O
-	O
11.3	O
*	O
HCT	O
-	O
34.3	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
26.7	O
*	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
14.7	O
[	O
**	O
2107-10-31	O
**	O
]	O
09:05	O
AM	O
PLT	O
COUNT	O
-	O
453	O
*	O
[	O
**	O
2107-10-31	O
**	O
]	O
09:05	O
AM	O
TOT	O
PROT	O
-	O
5.9	O
*	O
ALBUMIN	O
-	O
3.9	O
GLOBULIN	O
-	O
2.0	O
CALCIUM	O
-	O
9.3	O
MAGNESIUM	O
-	O
2.3	O
[	O
**	O
2107-10-31	O
**	O
]	O
09:05	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
6	O
AST	O
(	O
SGOT	O
)	O
-	O
14	O
ALK	O
PHOS	O
-	O
84	O
AMYLASE	O
-	O
87	O
TOT	O
BILI	O
-	O
0.5	O
[	O
**	O
2107-10-31	O
**	O
]	O
09:05	O
AM	O
GLUCOSE	O
-	O
78	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
0.7	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
4.1	O
CHLORIDE	O
-	O
96	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
20	O
[	O
**	O
2107-11-1	O
**	O
]	O
03:52	O
PM	O
PT	O
-	O
12.0	O
PTT	O
-	O
23.7	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2107-11-1	O
**	O
]	O
03:52	O
PM	O
PLT	O
COUNT	O
-	O
390	O
[	O
**	O
2107-11-1	O
**	O
]	O
03:52	O
PM	O
WBC	O
-	O
10.9	O
#	O
RBC	O
-	O
3.56	O
*	O
HGB	O
-	O
9.7	O
*	O
HCT	O
-	O
28.4	O
*	O
MCV	O
-	O
80	O
*	O
MCH	O
-	O
27.2	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
14.9	O
.	O
CT	O
scan	O
[	O
**	O
2107-11-4	O
**	O
]	O
for	O
lymphoma	O
staging	O
:	O
There	O
is	O
mildly	O
heterogeneous	O
and	O
enlarged	O
thyroid	O
gland	O
with	O
a	O
small	O
1	O
-	O
cm	O
hypodense	O
nodule	O
within	O
the	O
right	O
lobe	O
.	O
There	O
are	O
multiple	O
nodes	O
present	O
within	O
the	O
mediastinum	O
,	O
the	O
largest	O
of	O
which	O
is	O
seen	O
within	O
the	O
paraesophageal	O
space	O
measuring	O
16	O
mm	O
in	O
diameter	O
.	O
There	O
are	O
bilateral	O
enlarged	O
hilar	O
lymph	O
nodes	O
which	O
can	O
not	O
be	O
definitely	O
measured	O
given	O
lack	O
of	O
IV	O
contrast	I-Drug
.	O
There	O
is	O
marked	O
axillary	O
lymphadenopathy	O
with	O
a	O
representative	O
node	O
on	O
the	O
right	O
measuring	O
20	O
x	O
18	O
mm	O
and	O
is	O
seen	O
on	O
series	O
2	O
,	O
image	O
6	O
.	O
A	O
representative	O
node	O
within	O
the	O
left	O
axilla	O
is	O
seen	O
on	O
series	O
2	O
,	O
image	O
8	O
,	O
measuring	O
16	O
x	O
12	O
mm	O
.	O
There	O
are	O
multiple	O
tiny	O
nodules	O
seen	O
within	O
the	O
breasts	O
bilaterally	O
,	O
the	O
largest	O
on	O
the	O
left	O
hand	O
side	O
measuring	O
12	O
x	O
15	O
mm	O
,	O
seen	O
on	O
series	O
2	O
,	O
image	O
16	O
.	O
There	O
are	O
bilateral	O
large	O
pleural	O
effusions	O
.	O
The	O
lungs	O
are	O
otherwise	O
clear	O
.	O
Along	O
the	O
right	O
thorax	O
just	O
below	O
the	O
scapula	O
,	O
there	O
is	O
a	O
moderate	O
amount	O
of	O
air	O
within	O
the	O
subcutaneous	O
and	O
intramuscular	O
space	O
,	O
probably	O
sequelae	O
from	O
prior	O
thoracentesis	O
.	O
The	O
heart	O
and	O
great	O
vessels	O
are	O
unremarkable	O
.	O
There	O
is	O
a	O
27	O
x	O
15	O
mm	O
node	O
along	O
the	O
right	O
pericardium	O
measuring	O
15	O
x	O
27	O
mm	O
,	O
seen	O
on	O
series	O
2	O
,	O
image	O
36	O
.	O
The	O
patient	O
is	O
intubated	O
and	O
has	O
a	O
nasogastric	O
tube	O
extending	O
with	O
tip	O
in	O
the	O
post-pyloric	O
region	O
.	O
CT	I-Reason
ABDOMEN	O
WITHOUT	O
IV	O
CONTRAST	I-Drug
:	O
There	O
is	O
a	O
moderate	O
amount	O
of	O
ascites	O
.	O
The	O
liver	O
is	O
unremarkable	O
.	O
The	O
gallbladder	O
wall	O
is	O
thickened	O
likely	O
secondary	O
to	O
third	O
spacing	O
.	O
The	O
pancreas	O
is	O
not	O
clearly	O
defined	O
but	O
appears	O
grossly	O
unremarkable	O
.	O
The	O
spleen	O
is	O
prominent	O
,	O
slightly	O
displacing	O
the	O
stomach	O
medially	O
12	O
x	O
7	O
cm	O
.	O
The	O
adrenal	O
glands	O
are	O
not	O
well	O
visualized	O
secondary	O
to	O
an	O
extensive	O
amount	O
of	O
retroperitoneal	O
lymphadenopathy	O
extending	O
from	O
the	O
level	O
of	O
the	O
SMA	O
inferiorly	O
and	O
encasing	O
the	O
aorta	O
and	O
IVC	O
.	O
A	O
representative	O
size	O
of	O
this	O
conglomeration	O
is	O
seen	O
on	O
series	O
2	O
,	O
image	O
74	O
measuring	O
86	O
x	O
52	O
mm	O
.	O
There	O
is	O
extensive	O
lymphadenopathy	O
within	O
the	O
mesentery	O
with	O
a	O
conglomerate	O
of	O
nodes	O
measuring	O
57	O
x	O
40	O
mm	O
,	O
seen	O
on	O
series	O
2	O
,	O
image	O
85	O
.	O
There	O
is	O
a	O
moderate	O
amount	O
of	O
ascites	O
.	O
The	O
small	O
and	O
large	O
bowel	O
are	O
unremarkable	O
and	O
opacified	O
with	O
oral	O
contrast	O
extending	O
to	O
the	O
rectum	O
.	O
There	O
is	O
no	O
evidence	O
of	O
obstruction	O
.	O
CT	I-Reason
PELVIS	O
WITH	O
IV	O
CONTRAST	I-Drug
:	O
The	O
urinary	O
bladder	O
is	O
catheterized	O
.	O
The	O
rectum	O
is	O
unremarkable	O
.	O
The	O
uterus	O
is	O
not	O
well	O
visualized	O
.	O
There	O
are	O
no	O
adnexal	O
masses	O
with	O
the	O
exception	O
of	O
extensive	O
lymphadenopathy	O
that	O
extends	O
into	O
the	O
deep	O
pelvis	O
bilaterally	O
inferiorly	O
from	O
the	O
above	O
-	O
mentioned	O
retroperitoneal	O
lymphadenopathy	O
along	O
the	O
iliac	O
nodal	O
chains	O
.	O
The	O
largest	O
bulk	O
of	O
this	O
lymphadenopathy	O
measures	O
94	O
x	O
47	O
mm	O
along	O
the	O
left	O
iliac	O
nodal	O
chain	O
seen	O
on	O
series	O
2	O
,	O
image	O
105	O
.	O
There	O
is	O
extensive	O
inguinal	O
lymphadenopathy	O
,	O
the	O
largest	O
nodal	O
conglomerate	O
seen	O
on	O
the	O
left	O
measuring	O
49	O
x	O
62	O
mm	O
.	O
Also	O
noted	O
within	O
the	O
subcutaneous	O
tissue	O
in	O
the	O
midline	O
of	O
the	O
abdomen	O
are	O
a	O
few	O
pockets	O
of	O
air	O
seen	O
along	O
a	O
linear	O
soft	O
tissue	O
defect	O
likely	O
secondary	O
to	O
prior	O
surgical	O
intervention	O
.	O
BONE	O
WINDOWS	O
:	O
No	O
suspicious	O
lytic	O
or	O
sclerotic	O
bony	O
lesions	O
.	O
.	O
Echo	O
(	O
[	O
**	O
2107-11-2	O
**	O
]	O
)	O
:	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
There	O
is	O
severe	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
near	O
akinesis	O
of	O
the	O
distal	O
2	O
/	O
3rds	O
of	O
the	O
ventricle	O
.	O
Basal	O
segments	O
contract	O
well	O
.	O
The	O
apex	O
is	O
milldy	O
aneurysmal	O
and	O
akinetic	O
,	O
but	O
no	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
,	O
though	O
the	O
apex	O
is	O
trabeculated	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
There	O
is	O
focal	O
akinesis	O
of	O
the	O
apical	O
half	O
of	O
the	O
RV	O
free	O
wall	O
.	O
The	O
aortic	O
valve	O
leaflets	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
Repeat	O
echo	O
prior	O
to	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
(	O
[	O
**	O
12	O
-	O
5	O
**	O
]	O
)	O
:	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
There	O
is	O
severe	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
near	O
akinesis	O
of	O
the	O
distal	O
2	O
/	O
3rds	O
of	O
the	O
ventricle	O
.	O
Basal	O
segments	O
contract	O
well	O
.	O
The	O
apex	O
is	O
milldy	O
aneurysmal	O
and	O
akinetic	O
,	O
but	O
no	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
,	O
though	O
the	O
apex	O
is	O
trabeculated	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
There	O
is	O
focal	O
akinesis	O
of	O
the	O
apical	O
half	O
of	O
the	O
RV	O
free	O
wall	O
.	O
The	O
aortic	O
valve	O
leaflets	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
Abdominal	O
Ultrasound	O
(	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
)	O
:	O
There	O
are	O
again	O
identified	O
bilateral	O
pleural	O
effusions	O
,	O
partially	O
imaged	O
.	O
There	O
is	O
a	O
moderate	O
-	O
to	O
-	O
large	O
amount	O
of	O
ascites	O
present	O
in	O
all	O
four	O
quadrants	O
,	O
best	O
appreciated	O
in	O
the	O
left	O
lower	O
quadrant	O
.	O
In	O
the	O
left	O
lobe	O
of	O
the	O
liver	O
there	O
are	O
two	O
uniformly	O
hyperechoic	O
lesions	O
,	O
the	O
largest	O
of	O
which	O
measures	O
2.0	O
x	O
1.6	O
x	O
1.7	O
cm	O
with	O
appearance	O
consistent	O
with	O
hemangiomas	O
.	O
No	O
other	O
focal	O
abnormalities	O
are	O
demonstrated	O
within	O
the	O
liver	O
.	O
The	O
gallbladder	O
is	O
collapsed	O
with	O
likely	O
wall	O
thickening	O
again	O
,	O
which	O
could	O
be	O
secondary	O
to	O
third	O
spacing	O
of	O
fluid	O
.	O
A	O
shadowing	O
gallstone	O
is	O
demonstrated	O
within	O
the	O
gallbladder	O
lumen	O
.	O
The	O
spleen	O
is	O
stable	O
in	O
size	O
measuring	O
11	O
cm	O
in	O
its	O
longest	O
length	O
.	O
A	O
small	O
roughly	O
1	O
cm	O
anechoic	O
lesion	O
,	O
without	O
blood	O
flow	O
is	O
demonstrated	O
within	O
the	O
spleen	O
,	O
not	O
fully	O
characterized	O
on	O
this	O
study	O
,	O
though	O
possibly	O
a	O
cyst	O
.	O
The	O
previously	O
described	O
extensive	O
mesenteric	O
or	O
retroperitoneal	O
adenopathy	O
is	O
not	O
well	O
assessed	O
on	O
this	O
study	O
.	O
Color	O
flow	O
and	O
Doppler	O
evaluation	O
of	O
the	O
hepatic	O
vasculature	O
was	O
performed	O
given	O
history	O
of	O
ascites	O
.	O
The	O
hepatic	O
veins	O
,	O
hepatic	O
arteries	O
main	O
portal	O
vein	O
and	O
its	O
branches	O
are	O
patent	O
with	O
appropriate	O
direction	O
of	O
flow	O
and	O
normal	O
waveforms	O
.	O
The	O
inferior	O
vena	O
cava	O
is	O
generally	O
narrowed	O
without	O
intraluminal	O
filling	O
defects	O
.	O
This	O
appearance	O
could	O
be	O
secondary	O
to	O
fluid	O
status	O
or	O
secondary	O
to	O
ascites	O
.	O
.	O
CTA	O
(	O
[	O
**	O
12	O
-	O
2	O
**	O
]	O
)	O
:	O
1	O
.	O
There	O
is	O
a	O
large	O
right	O
pleural	O
effusion	O
with	O
complete	O
passive	O
collapse	O
of	O
the	O
right	O
lung	O
.	O
There	O
is	O
a	O
small	O
left	O
pleural	O
effusion	O
.	O
2	O
.	O
Again	O
seen	O
is	O
mediastinal	O
and	O
pericardial	O
lymphadenopathy	O
,	O
which	O
is	O
not	O
significantly	O
changed	O
in	O
comparison	O
to	O
the	O
prior	O
study	O
.	O
3	O
.	O
A	O
large	O
amount	O
of	O
ascites	O
.	O
4	O
.	O
Three	O
hypodensities	O
are	O
seen	O
within	O
the	O
visualized	O
portion	O
of	O
the	O
liver	O
which	O
are	O
not	O
completely	O
characterized	O
.	O
.	O
.	O
CYTOLOGY	O
:	O
Pleural	O
Fluid	O
:	O
By	O
immunohistochemical	O
stains	O
,	O
the	O
lymphocytes	O
are	O
a	O
mixture	O
of	O
CD20	O
positive	O
B	O
-	O
cells	O
along	O
with	O
CD3	O
positive	O
(	O
B	O
greater	O
than	O
T	O
)	O
.	O
Although	O
definite	O
co-expression	O
of	O
CD5	O
amongst	O
B	O
-	O
cells	O
could	O
not	O
be	O
discerned	O
,	O
a	O
subset	O
of	O
weak	O
CD5	O
expressing	O
cells	O
is	O
seen	O
amongst	O
the	O
brighter	O
CD5	O
positive	O
T	O
-	O
cells	O
.	O
Scattered	O
CD10	O
positive	O
lymphocytes	O
are	O
seen	O
.	O
Bcl	O
-	O
1	O
/	O
cyclin	O
D1	O
is	O
expressed	O
in	O
a	O
minor	O
subset	O
.	O
Overall	O
,	O
the	O
findings	O
indicate	O
involvement	O
by	O
the	O
patient	O
's	O
known	O
Mantle	O
cell	O
lymphoma	O
.	O
Peritoneal	O
Fluid	O
:	O
Three	O
color	O
gating	O
is	O
performed	O
(	O
light	O
scatter	O
vs.	O
CD45	O
)	O
to	O
optimize	O
lymphocyte	O
yield	O
.	O
Abnormal	O
/	O
lymphoma	O
cells	O
comprise	O
5	O
%	O
of	O
lymphoid	O
gated	O
events	O
.	O
B	O
cells	O
demonstrate	O
a	O
monoclonal	O
Lambda	O
light	O
chain	O
restricted	O
population	O
.	O
They	O
co-express	O
pan-B	O
cell	O
markers	O
CD19	O
along	O
with	O
CD5	O
and	O
FMC	O
-	O
7	O
.	O
They	O
do	O
not	O
express	O
any	O
other	O
characteristic	O
antigens	O
including	O
CD10	O
,	O
CD23	O
.	O
A	O
subset	O
express	O
CD20	O
.	O
T	O
cells	O
express	O
mature	O
lineage	O
antigens	O
.	O
INTERPRETATION	O
Findings	O
are	O
of	O
involvement	O
by	O
a	O
Lambda	O
restricted	O
,	O
CD5	O
-	O
positive	O
B	O
cell	O
lymphoproliferative	O
disorder	O
,	O
immunophenotypically	O
consistent	O
with	O
patient	O
's	O
known	O
mantle	O
cell	O
lymphoma	O
.	O
Given	O
the	O
small	O
percentage	O
of	O
involved	O
B	O
-	O
cells	O
,	O
peripheral	O
blood	O
contamination	O
can	O
not	O
be	O
ruled	O
out	O
.	O
Brief	O
Hospital	O
Course	O
:	O
1	O
.	O
See	O
HPI	O
for	O
MICU	O
course	O
.	O
2	O
.	O
Mantle	B-Reason
Cell	I-Reason
Lymphoma	I-Reason
:	O
Received	O
300mg	O
/	O
m2	O
of	O
Cytoxan	I-Drug
twice	O
a	O
day	O
for	O
six	O
doses	O
,	O
with	O
high	O
-	O
dose	O
Decadron	I-Drug
.	O
The	O
decadron	I-Drug
was	O
discontinued	O
after	O
the	O
patient	O
developed	O
psychotic	B-Ade
paranoia	I-Ade
.	O
She	O
developed	O
tumor	B-Ade
lysis	I-Ade
syndrome	I-Ade
with	O
elevated	B-Ade
uric	I-Ade
acid	I-Ade
,	O
and	O
initially	O
requiring	O
CVVH	O
.	O
Her	O
counts	B-Ade
dropped	I-Ade
in	O
response	O
to	O
chemotherapy	I-Drug
and	O
she	O
was	O
neutropenic	I-Reason
for	O
several	O
days	O
.	O
The	O
patient	O
was	O
treated	O
with	O
neupogen	I-Drug
until	O
her	O
counts	O
normalized	O
,	O
and	O
she	O
remained	O
afebrile	O
.	O
Her	O
effusions	O
(	O
below	O
)	O
continued	O
to	O
re-accumulate	O
after	O
taps	O
,	O
and	O
ultimately	O
the	O
decision	O
was	O
made	O
to	O
treat	O
the	O
patient	O
with	O
the	O
first	O
round	O
of	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
.	O
She	O
tolerated	O
the	O
regimen	O
very	O
well	O
,	O
and	O
had	O
no	O
issues	O
completing	O
the	O
prednisone	I-Drug
portion	O
of	O
the	O
therapy	O
.	O
The	O
patient	O
was	O
transfused	O
to	O
keep	O
her	O
hematocrit	O
above	O
25	O
and	O
platelets	O
above	O
10	O
.	O
.	O
3	O
.	O
Malignant	O
effusion	O
:	O
The	O
patient	O
originally	O
presented	O
with	O
shortness	O
of	O
breath	O
from	O
a	O
right	O
pleural	O
effusion	O
and	O
ascites	O
.	O
Her	O
ascites	O
fluid	O
was	O
drained	O
in	O
the	O
operating	O
room	O
,	O
and	O
not	O
sent	O
for	O
studies	O
.	O
Her	O
right	O
pleural	O
effusion	O
was	O
tapped	O
twice	O
,	O
both	O
large	O
volume	O
.	O
Cytology	O
was	O
positive	O
for	O
lymphoma	O
.	O
The	O
patient	O
had	O
reaccumulation	O
of	O
both	O
fluid	O
collections	O
,	O
which	O
were	O
unintervenable	O
while	O
she	O
was	O
neutropenic	O
.	O
Once	O
her	O
counts	O
recovered	O
,	O
the	O
patient	O
underwent	O
therapeutic	O
paracentesis	O
of	O
3	O
liters	O
,	O
which	O
demonstrated	O
malignant	O
cells	O
.	O
The	O
patient	O
remained	O
short	O
of	O
breath	O
after	O
this	O
procedure	O
and	O
underwent	O
a	O
1.6	O
liter	O
thoracentesis	O
by	O
interventional	O
pulmonary	O
.	O
She	O
tolerated	O
the	O
procedure	O
well	O
with	O
immediate	O
symptomatic	O
improvement	O
.	O
On	O
a	O
post-procedure	O
x-ray	O
,	O
however	O
,	O
her	O
right	O
lung	O
remained	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
57454	O
**	O
]	O
-	O
out	O
.	O
She	O
underwent	O
CTA	O
which	O
demostrated	O
a	O
very	O
large	O
right	O
pleural	O
effusion	O
with	O
right	O
lung	O
collapse	O
.	O
The	O
patient	O
,	O
however	O
,	O
had	O
an	O
improvement	O
in	O
her	O
symptoms	O
and	O
decrease	O
in	O
her	O
oxygen	I-Drug
requirement	O
.	O
She	O
underwent	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
in	O
an	O
effort	O
to	O
treat	O
the	O
underlying	O
cause	O
of	O
her	O
effusions	I-Reason
.	O
She	O
was	O
discharged	O
on	O
40	O
po	O
Lasix	I-Drug
to	O
take	O
daily	O
,	O
to	O
which	O
she	O
responded	O
well	O
in	O
the	O
hospital	O
.	O
.	O
4	O
.	O
s	O
/	O
p	O
TAH	O
-	O
BSO	O
:	O
The	O
patient	O
was	O
originally	O
thought	O
to	O
have	O
ovarian	O
cancer	O
,	O
and	O
she	O
underwent	O
TAH	O
-	O
BSO	O
on	O
[	O
**	O
2107-11-1	O
**	O
]	O
.	O
The	O
diagnosis	O
of	O
lymphoma	O
was	O
made	O
on	O
an	O
intraoperative	O
lymph	O
node	O
biopsy	O
.	O
Her	O
ovarian	O
pathology	O
was	O
cystadenofibroma	O
.	O
.	O
5	O
.	O
Cardiomyopathy	O
:	O
In	O
the	O
ICU	O
,	O
her	O
ejection	O
fraction	O
was	O
found	O
to	O
be	O
20	O
%	O
,	O
which	O
is	O
likely	O
ischemic	O
in	O
origin	O
from	O
"	O
shocked	O
"	O
myocardium	O
.	O
Repeat	O
TTE	O
,	O
when	O
her	O
critical	O
illness	O
resolved	O
revealed	O
an	O
ejection	O
fraction	O
of	O
55	O
%	O
,	O
but	O
persistent	O
right	O
sided	O
failure	O
.	O
Prior	O
to	O
beginning	O
treatment	O
with	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
,	O
the	O
patient	O
again	O
had	O
an	O
echocardiogram	O
which	O
demonstrated	O
resolution	O
of	O
the	O
right	O
heart	O
failure	O
and	O
2	O
+	O
MR.	O
.	O
6	O
.	O
ID	O
:	O
the	O
patient	O
had	O
asymptomatic	O
pyruia	O
on	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
,	O
and	O
was	O
treated	O
for	O
7	O
days	O
with	O
Zosyn	I-Drug
for	O
a	O
Citrobacter	B-Reason
UTI	I-Reason
.	O
Repeat	O
urine	O
culture	O
was	O
negative	O
.	O
She	O
remained	O
afebrile	O
while	O
neutropenic	O
.	O
.	O
7	O
.	O
Chronic	O
back	O
pain	O
:	O
MRI	O
demonstrated	O
no	O
spinal	O
or	O
vertebral	O
involvement	O
of	O
her	O
lymphoma	O
.	O
She	O
was	O
maintained	O
on	O
narcotics	I-Drug
for	O
pain	B-Reason
control	I-Reason
.	O
As	O
her	O
ascites	I-Reason
reaccumulated	O
,	O
her	O
pain	I-Drug
medication	O
requirement	O
increased	O
.	O
She	O
was	O
discharged	O
on	O
10	O
mg	O
Oxycontin	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
and	O
5	O
mg	O
Oxycodone	I-Drug
q4	O
prn	O
.	O
MRI	O
revealed	O
no	O
spinal	O
involvement	O
of	O
her	O
lymphoma	O
.	O
8	O
.	O
Disposition	O
:	O
The	O
patient	O
will	O
go	O
to	O
rehabilitation	O
to	O
assist	O
her	O
after	O
her	O
prolonged	O
hospitalization	O
and	O
very	O
low	O
functional	O
status	O
at	O
this	O
point	O
.	O
Patient	O
had	O
a	O
port	O
placed	O
by	O
surgery	O
on	O
[	O
**	O
2107-11-17	O
**	O
]	O
,	O
which	O
was	O
functional	O
through	O
the	O
hospitalization	O
.	O
She	O
was	O
full	O
code	O
.	O
Medications	O
on	O
Admission	O
:	O
hnone	O
Discharge	O
Medications	O
:	O
1	O
.	O
Calcium	I-Drug
Carbonate	O
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
2	O
.	O
Artificial	B-Drug
Tear	I-Drug
with	I-Drug
Lanolin	O
0.1	O
-	O
0.1	O
%	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Ophthalmic	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
3	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
5	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
,	O
wheeze	I-Reason
.	O
6	O
.	O
Allopurinol	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Simethicone	I-Drug
80	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
bloating	I-Reason
.	O
9	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
10	O
.	O
Olanzapine	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
11	O
.	O
Acyclovir	I-Drug
200	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
12	O
.	O
Aluminum	B-Drug
-	I-Drug
Magnesium	I-Drug
Hydroxide	I-Drug
225	O
-	O
200	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15	O
-	O
30	O
MLs	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
13	O
.	O
Oxycodone	I-Drug
10	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
PO	O
twice	O
a	O
day	O
.	O
14	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
.	O
15	O
.	O
Bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
16	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
17	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
18	O
.	O
Heparin	I-Drug
Lock	O
Flush	O
(	O
Porcine	O
)	O
10	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Ten	O
(	O
10	O
)	O
ML	O
Intravenous	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
19	O
.	O
Lasix	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
Medical	O
Center	O
-	O
[	O
**	O
Hospital1	O
3597	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Mantle	O
cell	O
lymphoma	O
Malignant	O
pleural	O
effusion	O
Malignant	O
ascites	O
s	O
/	O
p	O
TAH	O
/	O
BSO	O
Tumor	O
lysis	O
syndrome	O
Cardiogenic	O
shock	O
Chronic	O
low	O
back	O
pain	O
Discharge	O
Condition	O
:	O
afebrile	O
,	O
hemodynamically	O
stable	O
.	O
On	O
2L	O
NC	O
Discharge	O
Instructions	O
:	O
Please	O
return	O
to	O
the	O
ED	O
with	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
fevers	O
,	O
chills	O
,	O
or	O
vomiting	O
.	O
.	O
Please	O
keep	O
all	O
follow	O
up	O
appointments	O
and	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
1730	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
6175	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3237	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2107-12-13	O
**	O
]	O
10:30	O

Admission	O
Date	O
:	O
[	O
**	O
2145-1-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2145-2-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2068-9-1	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3984	O
**	O
]	O
Chief	O
Complaint	O
:	O
Dyspnea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
endotracheal	O
intubation	O
tracheostomy	O
PEG	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
76	O
yo	O
male	O
with	O
a	O
history	O
of	O
end	O
-	O
stage	O
pulmonary	O
sarcoidosis	O
who	O
presents	O
with	O
increased	O
shortness	O
of	O
breath	O
over	O
last	O
24	O
hrs	O
,	O
tachycardia	O
,	O
general	O
fatigue	O
x	O
1	O
week	O
.	O
Similar	O
prior	O
presentations	O
,	O
felt	O
to	O
be	O
related	O
to	O
sarcoidosis	O
.	O
Denies	O
any	O
increase	O
in	O
cough	O
or	O
sputum	O
production	O
,	O
fevers	O
,	O
chills	O
or	O
sweats	O
.	O
No	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomting	O
or	O
diarrhea	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Pulmonary	O
sarcoidosis	O
with	O
pumonary	O
fibrosis	O
,	O
dx	O
[	O
**	O
2128	O
**	O
]	O
,	O
s	O
/	O
p	O
lung	O
bx	O
2	O
.	O
BPH	O
3	O
.	O
Hypercholesterolemia	O
4	O
.	O
Orthostatic	O
hypotension	O
5	O
.	O
L	O
eye	O
ptosis	O
since	O
birth	O
6	O
.	O
Glucose	O
intolerance	O
7	O
.	O
Chronic	O
Encephalomalacia	O
secondary	O
to	O
head	O
trauma	O
while	O
playing	O
ice	O
hockey	O
in	O
[	O
**	O
2106	O
**	O
]	O
8	O
.	O
h	O
/	O
o	O
"	O
tummy	O
tuck	O
"	O
remotely	O
Social	O
History	O
:	O
Retired	O
from	O
import	O
/	O
export	O
business	O
in	O
plumbing	O
.	O
Ran	O
his	O
own	O
business	O
.	O
Only	O
out	O
of	O
country	O
travel	O
was	O
to	O
Bermuda	O
years	O
ago	O
.	O
Smoking	O
hx	O
1-1/2	O
ppd	O
x	O
15	O
yrs	O
,	O
quit	O
[	O
**	O
2117	O
**	O
]	O
.	O
No	O
etoh	O
or	O
drugs	O
.	O
Lives	O
alone	O
.	O
Brother	O
and	O
his	O
familiy	O
live	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
3146	O
**	O
]	O
.	O
Family	O
History	O
:	O
mother	O
died	O
at	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
y.o.	O
hx	O
[	O
**	O
Name	O
(	O
NI	O
)	O
11964	O
**	O
]	O
,	O
Father	O
died	O
at	O
75	O
yo	O
,	O
stroke	O
/	O
cerebral	O
hemorrhage	O
.	O
Patient	O
has	O
2	O
brothers	O
,	O
healthy	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
4084	O
**	O
]	O
married	O
,	O
no	O
children	O
Physical	O
Exam	O
:	O
PE	O
on	O
admission	O
:	O
GEN	O
:	O
tachypnic	O
appearing	O
male	O
HEENT	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2994	O
**	O
]	O
,	O
ptosis	O
on	O
left	O
,	O
anicteric	O
,	O
dry	O
mucous	O
membranes	O
,	O
op	O
without	O
lesions	O
,	O
no	O
supraclavicular	O
or	O
cervical	O
lymphadenopathy	O
,	O
no	O
jvd	O
,	O
no	O
carotid	O
bruits	O
,	O
no	O
thyromegaly	O
or	O
thyroid	O
nodules	O
RESP	O
:	O
rhonchorous	O
diffusely	O
,	O
poor	O
air	O
movement	O
,	O
using	O
accessory	O
muscles	O
of	O
neck	O
and	O
abdomen	O
to	O
assist	O
with	O
ventilation	O
CV	O
:	O
tachycardic	O
,	O
no	O
murmurs	O
ABD	O
:	O
nd	O
,	O
+	O
b	O
/	O
s	O
,	O
soft	O
though	O
muscles	O
contracted	O
EXT	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
SKIN	O
:	O
no	O
rashes	O
/	O
no	O
jaundice	O
/	O
no	O
splinters	O
NEURO	O
:	O
AAOx3	O
.	O
Cn	O
II	O
-	O
XII	O
intact	O
.	O
5/5	O
strength	O
throughout	O
.	O
No	O
sensory	O
deficits	O
to	O
light	O
touch	O
appreciated	O
.	O
.	O
Exam	O
on	O
Discharge	O
Gen	O
:	O
awake	O
and	O
alert	O
w	O
/	O
trach	O
in	O
place	O
,	O
sitting	O
up	O
in	O
bed	O
,	O
thin	O
frail	O
-	O
appearing	O
man	O
HEENT	O
:	O
PERRLA	O
.	O
EOMI	O
.	O
CV	O
:	O
rrr	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
Lungs	O
:	O
diffuse	O
coarse	O
inspiratory	O
and	O
expiratory	O
sounds	O
.	O
Expiratory	O
wheezing	O
more	O
prominent	O
on	O
right	O
lung	O
fields	O
.	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
:	O
soft	O
nondistended	O
and	O
nontender	O
Ext	O
:	O
no	O
edema	O
,	O
+	O
peripheral	O
pulses	O
bilaterally	O
Neuro	O
:	O
grossly	O
intact	O
,	O
writing	O
notes	O
to	O
communicate	O
Pertinent	O
Results	O
:	O
Admission	O
Labs	O
[	O
**	O
2145-1-13	O
**	O
]	O
11:30	O
AM	O
BLOOD	O
WBC	O
-	O
13.6	O
*	O
#	O
RBC	O
-	O
4.83	O
#	O
Hgb	O
-	O
15.2	O
#	O
Hct	O
-	O
45.7	O
#	O
MCV	O
-	O
95	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
13.0	O
Plt	O
Ct	O
-	O
247	O
[	O
**	O
2145-1-13	O
**	O
]	O
11:30	O
AM	O
BLOOD	O
Neuts	O
-	O
91.1	O
*	O
Lymphs	O
-	O
5.6	O
*	O
Monos	O
-	O
2.7	O
Eos	O
-	O
0.3	O
Baso	O
-	O
0.4	O
[	O
**	O
2145-1-13	O
**	O
]	O
11:30	O
AM	O
BLOOD	O
Glucose	O
-	O
107	O
*	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.8	O
Na	O
-	O
143	O
K	O
-	O
3.8	O
Cl	O
-	O
101	O
HCO3	O
-	O
31	O
AnGap	O
-	O
15	O
[	O
**	O
2145-1-13	O
**	O
]	O
11:30	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2145-1-13	O
**	O
]	O
07:56	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2145-1-14	O
**	O
]	O
06:19	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
[	O
**	O
2145-1-13	O
**	O
]	O
07:56	O
PM	O
BLOOD	O
Calcium	O
-	O
7.1	O
*	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
1.4	O
*	O
[	O
**	O
2145-1-13	O
**	O
]	O
07:56	O
PM	O
BLOOD	O
Cortsol	O
-	O
29.8	O
*	O
[	O
**	O
2145-1-13	O
**	O
]	O
11:33	O
AM	O
BLOOD	O
Lactate	O
-	O
2.1	O
*	O
K	O
-	O
3.7	O
.	O
Pertinent	O
Labs	O
[	O
**	O
2145-1-17	O
**	O
]	O
04:42	O
AM	O
BLOOD	O
WBC	O
-	O
7.0	O
RBC	O
-	O
3.36	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
31.6	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
13.1	O
Plt	O
Ct	O
-	O
196	O
[	O
**	O
2145-1-22	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
WBC	O
-	O
9.1	O
RBC	O
-	O
3.56	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
32.5	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
30.4	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
12.7	O
Plt	O
Ct	O
-	O
341	O
[	O
**	O
2145-1-26	O
**	O
]	O
02:44	O
AM	O
BLOOD	O
WBC	O
-	O
9.3	O
RBC	O
-	O
3.08	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
28.4	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
30.9	O
MCHC	O
-	O
33.5	O
RDW	O
-	O
13.3	O
Plt	O
Ct	O
-	O
399	O
[	O
**	O
2145-2-7	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
WBC	O
-	O
9.5	O
RBC	O
-	O
3.81	O
*	O
Hgb	O
-	O
11.9	O
*	O
Hct	O
-	O
35.9	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
31.3	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
449	O
*	O
[	O
**	O
2145-1-21	O
**	O
]	O
04:06	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
323	O
[	O
**	O
2145-1-26	O
**	O
]	O
02:44	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
399	O
[	O
**	O
2145-2-6	O
**	O
]	O
06:07	O
AM	O
BLOOD	O
PT	O
-	O
12.7	O
PTT	O
-	O
24.9	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2145-2-7	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
PT	O
-	O
12.7	O
PTT	O
-	O
24.9	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2145-1-22	O
**	O
]	O
04:23	O
PM	O
BLOOD	O
Glucose	O
-	O
86	O
UreaN	O
-	O
18	O
Creat	O
-	O
0.4	O
*	O
Na	O
-	O
139	O
K	O
-	O
3.5	O
Cl	O
-	O
94	O
*	O
HCO3	O
-	O
39	O
*	O
AnGap	O
-	O
10	O
[	O
**	O
2145-1-25	O
**	O
]	O
03:01	O
AM	O
BLOOD	O
Glucose	O
-	O
87	O
UreaN	O
-	O
21	O
*	O
Creat	O
-	O
0.4	O
*	O
Na	O
-	O
146	O
*	O
K	O
-	O
3.7	O
Cl	O
-	O
106	O
HCO3	O
-	O
38	O
*	O
AnGap	O
-	O
6	O
*	O
[	O
**	O
2145-2-4	O
**	O
]	O
04:07	O
AM	O
BLOOD	O
Glucose	O
-	O
78	O
UreaN	O
-	O
19	O
Creat	O
-	O
0.4	O
*	O
Na	O
-	O
145	O
K	O
-	O
3.8	O
Cl	O
-	O
98	O
HCO3	O
-	O
40	O
*	O
AnGap	O
-	O
11	O
[	O
**	O
2145-2-7	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
Glucose	O
-	O
101	O
*	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.5	O
Na	O
-	O
148	O
*	O
K	O
-	O
3.9	O
Cl	O
-	O
100	O
HCO3	O
-	O
43	O
*	O
AnGap	O
-	O
9	O
[	O
**	O
2145-1-25	O
**	O
]	O
03:01	O
AM	O
BLOOD	O
ALT	O
-	O
33	O
AST	O
-	O
24	O
LD	O
(	O
LDH	O
)	O
-	O
162	O
AlkPhos	O
-	O
98	O
TotBili	O
-	O
0.2	O
[	O
**	O
2145-1-15	O
**	O
]	O
03:44	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
Temp	O
-	O
36.8	O
Rates	O
-	O
/	O
25	O
PEEP	O
-	O
5	O
FiO2	O
-	O
40	O
pO2	O
-	O
163	O
*	O
pCO2	O
-	O
59	O
*	O
pH	O
-	O
7.33	O
*	O
calTCO2	O
-	O
33	O
*	O
Base	O
XS	O
-	O
3	O
Intubat	O
-	O
INTUBATED	O
Vent	O
-	O
SPONTANEOU	O
[	O
**	O
2145-1-22	O
**	O
]	O
04:34	O
PM	O
BLOOD	O
Type	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
Temp	O
-	O
37.5	O
Rates	O
-	O
/	O
12	O
Tidal	O
V	O
-	O
320	O
PEEP	O
-	O
5	O
FiO2	O
-	O
30	O
pO2	O
-	O
48	O
*	O
pCO2	O
-	O
66	O
*	O
pH	O
-	O
7.43	O
calTCO2	O
-	O
45	O
*	O
Base	O
XS	O
-	O
15	O
Intubat	O
-	O
INTUBATED	O
Vent	O
-	O
SPONTANEOU	O
[	O
**	O
2145-1-27	O
**	O
]	O
03:36	O
AM	O
BLOOD	O
Type	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
Temp	O
-	O
38.2	O
Rates	O
-	O
/	O
28	O
Tidal	O
V	O
-	O
400	O
PEEP	O
-	O
5	O
FiO2	O
-	O
30	O
pO2	O
-	O
32	O
*	O
pCO2	O
-	O
59	O
*	O
pH	O
-	O
7.41	O
calTCO2	O
-	O
39	O
*	O
Base	O
XS	O
-	O
8	O
Intubat	O
-	O
INTUBATED	O
Vent	O
-	O
SPONTANEOU	O
[	O
**	O
2145-2-4	O
**	O
]	O
12:07	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
127	O
*	O
pCO2	O
-	O
73	O
*	O
pH	O
-	O
7.39	O
calTCO2	O
-	O
46	O
*	O
Base	O
XS	O
-	O
15	O
Intubat	O
-	O
INTUBATED	O
.	O
Microbiology	O
[	O
**	O
2145-1-13	O
**	O
]	O
12:00	O
PM	O
URINE	O
Blood	O
-	O
MOD	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
150	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
7.0	O
Leuks	O
-	O
NEG	O
[	O
**	O
2145-1-18	O
**	O
]	O
03:34	O
PM	O
URINE	O
Blood	O
-	O
TR	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
TR	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
7.0	O
Leuks	O
-	O
NEG	O
[	O
**	O
2145-2-6	O
**	O
]	O
02:12	O
PM	O
URINE	O
Blood	O
-	O
NEG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
TR	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
7.0	O
Leuks	O
-	O
SM	O
.	O
Blood	O
cultures	O
(	O
[	O
**	O
2145-1-13	O
**	O
]	O
)	O
:	O
No	O
growth	O
Urine	O
culture	O
(	O
[	O
**	O
2145-1-13	O
**	O
]	O
)	O
:	O
No	O
growth	O
Sputum	O
(	O
[	O
**	O
2145-1-13	O
**	O
]	O
)	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2145-1-13	O
**	O
]	O
)	O
:	O
>	O
25	O
PMNs	O
and	O
<	O
10	O
epithelial	O
cells	O
/	O
100X	O
field	O
.	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
MULTIPLE	O
ORGANISMS	O
CONSISTENT	O
WITH	O
OROPHARYNGEAL	O
FLORA	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Final	O
[	O
**	O
2145-1-15	O
**	O
]	O
)	O
:	O
SPARSE	O
GROWTH	O
Commensal	O
Respiratory	O
Flora	O
.	O
DIRECT	O
INFLUENZA	O
A	O
ANTIGEN	O
TEST	O
(	O
Final	O
[	O
**	O
2145-1-14	O
**	O
]	O
)	O
:	O
Negative	O
for	O
Influenza	O
A.	O
DIRECT	O
INFLUENZA	O
B	O
ANTIGEN	O
TEST	O
(	O
Final	O
[	O
**	O
2145-1-14	O
**	O
]	O
)	O
:	O
Negative	O
for	O
Influenza	O
B.	O
Blood	O
cultures	O
(	O
[	O
**	O
2145-1-15	O
**	O
]	O
)	O
:	O
No	O
growth	O
Blood	O
cultures	O
(	O
[	O
**	O
2145-1-18	O
**	O
]	O
)	O
:	O
No	O
growth	O
Blood	O
cultures	O
(	O
[	O
**	O
2145-1-27	O
**	O
]	O
)	O
:	O
No	O
growth	O
CXR	O
(	O
[	O
**	O
2145-1-13	O
**	O
]	O
)	O
:	O
Aside	O
from	O
slightly	O
lower	O
lung	O
volumes	O
,	O
there	O
is	O
no	O
significant	O
interval	O
change	O
in	O
the	O
appearance	O
of	O
the	O
end	O
-	O
stage	O
sarcoidosis	O
as	O
previously	O
documented	O
.	O
.	O
CXR	O
(	O
[	O
**	O
2145-1-24	O
**	O
]	O
)	O
:	O
Comparison	O
with	O
the	O
previous	O
study	O
done	O
[	O
**	O
2145-1-20	O
**	O
]	O
.	O
There	O
are	O
extensive	O
parenchymal	O
and	O
pleural	O
changes	O
consistent	O
with	O
end	O
-	O
stage	O
sarcoidosis	O
as	O
before	O
.	O
An	O
endotracheal	O
tube	O
and	O
nasogastric	O
tube	O
remain	O
in	O
place	O
.	O
Allowing	O
for	O
differences	O
in	O
technique	O
,	O
there	O
is	O
no	O
significant	O
change	O
.	O
No	O
significant	O
interval	O
change	O
.	O
.	O
CXR	O
(	O
[	O
**	O
2145-2-3	O
**	O
]	O
)	O
:	O
Previously	O
questioned	O
retrocardiac	O
nodular	O
infection	O
has	O
cleared	O
,	O
presumably	O
representing	O
secretions	O
resolved	O
from	O
a	O
region	O
of	O
cystic	O
lung	O
.	O
In	O
all	O
other	O
respects	O
the	O
radiographic	O
appearance	O
of	O
these	O
severely	O
scarred	O
and	O
bronchiectatic	O
lungs	O
,	O
as	O
well	O
as	O
bilateral	O
pleural	O
abnormalities	O
are	O
unchanged	O
over	O
the	O
long	O
-	O
term	O
.	O
There	O
are	O
no	O
findings	O
to	O
suggest	O
acute	O
pneumonia	O
or	O
pulmonary	O
edema	O
.	O
Brief	O
Hospital	O
Course	O
:	O
76	O
yo	O
male	O
with	O
end	O
stage	O
sarcoidosis	O
presenting	O
with	O
dyspnea	O
.	O
.	O
#	O
HYPERCARBIC	O
RESPIRATORY	O
FAILURE	O
:	O
Pt	O
presented	O
to	O
the	O
ER	O
with	O
increased	O
shortness	O
of	O
breath	O
over	O
24	O
hrs	O
,	O
tachycardia	O
,	O
and	O
generalized	O
fatigue	O
.	O
Similar	O
prior	O
presentations	O
were	O
felt	O
to	O
be	O
related	O
to	O
sarcoid	O
flares	O
.	O
CXR	O
showed	O
end	O
stage	O
pulmonary	O
fibrosis	O
but	O
no	O
other	O
abnormalities	O
.	O
It	O
was	O
felt	O
his	O
sx	O
likely	O
represented	O
pneumonia	O
in	O
setting	O
of	O
severe	O
underlying	O
fibrotic	O
lung	O
disease	O
.	O
Pt	O
was	O
unable	O
to	O
sustain	O
high	O
minute	O
ventilatory	O
rate	O
,	O
evidenced	O
by	O
a	O
rising	O
pCO2	O
and	O
thus	O
required	O
emergent	O
intubation	O
shortly	O
after	O
arrival	O
to	O
ICU	O
.	O
The	O
patient	O
was	O
treated	O
for	O
presumed	B-Reason
pneumonia	I-Reason
with	O
levofloxacin	I-Drug
and	O
meropenem	I-Drug
given	O
leukocytosis	I-Reason
and	O
dyspnea	O
.	O
Infectious	O
work	O
-	O
up	O
including	O
multiple	O
blood	O
cultures	O
and	O
viral	O
cultures	O
were	O
negative	O
.	O
The	O
patient	O
was	O
not	O
given	O
steroids	I-Drug
since	O
it	O
was	O
felt	O
that	O
his	O
sx	O
were	O
related	O
to	O
an	O
infectious	O
process	O
rather	O
than	O
a	O
flair	O
of	O
his	O
sarcoid	O
lung	O
disease	O
.	O
The	O
patient	O
was	O
made	O
DNR	O
after	O
talking	O
with	O
the	O
son	O
.	O
IP	O
consult	O
was	O
sought	O
for	O
trach	O
placement	O
given	O
the	O
patient	O
's	O
inability	O
to	O
wean	O
off	O
the	O
ventilator	O
with	O
subsequent	O
placement	O
of	O
tracheostomy	O
and	O
PEG	O
on	O
[	O
**	O
1	O
-	O
26	O
**	O
]	O
and	O
[	O
**	O
1	O
-	O
27	O
**	O
]	O
respectively	O
.	O
Pt	O
tolerated	O
trach	O
mask	O
well	O
.	O
He	O
was	O
transferred	O
to	O
the	O
floor	O
on	O
[	O
**	O
2	O
-	O
3	O
**	O
]	O
.	O
Later	O
that	O
afternoon	O
he	O
was	O
noted	O
to	O
desat	O
into	O
the	O
50's	O
with	O
increased	O
work	O
of	O
breathing	O
and	O
was	O
requiring	O
high	O
levels	O
of	O
nursing	O
care	O
.	O
He	O
was	O
transferred	O
back	O
to	O
the	O
MICU	O
where	O
he	O
again	O
experienced	O
agitation	O
and	O
increased	O
work	O
of	O
breathing	O
.	O
He	O
was	O
placed	O
back	O
on	O
the	O
vent	O
on	O
PS	O
overnight	O
and	O
tolerated	O
this	O
well	O
and	O
eventually	O
was	O
able	O
to	O
transition	O
to	O
trach	O
mask	O
throughtout	O
the	O
day	O
and	O
night	O
.	O
Clinical	O
decompensation	O
attributed	O
to	O
mucus	O
plugging	O
.	O
#	O
CHRONIC	B-Reason
ORTHOSTATIC	I-Reason
HYPOTENSION	I-Reason
:	O
Pt	O
normotensive	O
on	O
admission	O
to	O
ICU	O
.	O
His	O
home	O
medications	O
of	O
midodrine	I-Drug
and	O
fludricortisone	I-Drug
were	O
continued	O
while	O
admitted	O
.	O
#	O
Agitation	I-Reason
:	O
The	O
patient	O
had	O
issues	O
with	O
agitation	O
especially	O
at	O
night	O
.	O
Geriatrics	O
was	O
consulted	O
and	O
a	O
regimen	O
of	O
Seroquel	I-Drug
was	O
initiated	O
as	O
well	O
as	O
efforts	O
to	O
limit	O
lines	O
and	O
to	O
orient	O
him	O
frequently	O
.	O
His	O
mental	O
status	O
waxed	O
and	O
waned	O
and	O
he	O
fell	O
out	O
of	O
bed	O
twice	O
but	O
sustained	O
no	O
injuries	O
.	O
By	O
[	O
**	O
2	O
-	O
1	O
**	O
]	O
his	O
delirium	I-Reason
had	O
improved	O
on	O
a	O
regimen	O
of	O
seroquel	I-Drug
to	O
12.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
seroquel	I-Drug
25	O
mg	O
QHS	O
and	O
Seroquel	I-Drug
25	O
mg	O
prn	O
.	O
Upon	O
readmission	O
to	O
the	O
MICU	O
,	O
however	O
,	O
he	O
again	O
became	O
significantly	O
agitated	I-Reason
and	O
required	O
IV	O
haldol	I-Drug
in	O
addition	O
to	O
his	O
scheduled	O
seroquel	I-Drug
.	O
EKG	O
the	O
following	O
morning	O
did	O
not	O
show	O
any	O
eveidence	O
of	O
prolonged	O
QT	O
.	O
Per	O
geriatric	O
recommendations	O
the	O
pt	O
's	O
seroquel	I-Drug
was	O
increased	O
to	O
50	O
mg	O
qhs	O
and	O
his	O
sundowning	O
improved	O
.	O
QTc	O
was	O
noted	O
to	O
419	O
on	O
discharge	O
dose	O
of	O
seroquel	I-Drug
.	O
.	O
The	O
patient	O
was	O
on	O
SubQ	O
heparin	I-Drug
for	O
DVT	B-Reason
prophylaxis	I-Reason
and	O
PPI	I-Drug
for	O
stress	B-Reason
ulcer	I-Reason
prophylaxis	I-Reason
.	O
Communication	O
was	O
with	O
the	O
patient	O
and	O
his	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
802	O
**	O
]	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2013	O
**	O
]	O
(	O
[	O
**	O
Name	O
(	O
NI	O
)	O
802	O
**	O
]	O
)	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
97950	O
**	O
]	O
.	O
Code	O
status	O
was	O
DNR	O
/	O
DNI	O
,	O
confirmed	O
with	O
HCP	O
.	O
.	O
#	O
Malnutrition	O
:	O
He	O
failed	O
swallowing	O
test	O
twice	O
with	O
concern	O
for	O
aspiration	O
.	O
PEG	O
tube	O
was	O
placed	O
and	O
his	O
tube	O
feeds	O
were	O
advanced	O
to	O
goal	O
rate	O
of	O
35	O
cc	O
/	O
hr	O
.	O
Medium	O
chain	O
trigylcerides	O
were	O
added	O
for	O
coloric	O
help	O
.	O
.	O
Follow	O
up	O
at	O
Rehab	O
1	O
.	O
Sundowning	I-Reason
:	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
increase	O
his	O
schedule	O
dose	O
of	O
seroquel	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
and	O
qhs	O
.	O
His	O
QTc	O
on	O
current	O
dose	O
is	O
only	O
419	O
.	O
Please	O
check	O
EKG	O
after	O
increasing	O
his	O
dose	O
to	O
ensure	O
there	O
is	O
no	O
significant	O
QTc	O
prolongation	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Fludrocortisone	B-Drug
0.1	O
mg	O
DAILY	O
2	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
HS	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
as	O
needed	O
for	O
constipation	I-Reason
4	O
.	O
Midodrine	I-Drug
1.25	O
mg	O
PO	O
BID	O
5	O
.	O
Acetaminophen	I-Drug
1000	O
mg	O
PO	O
Q6H	O
as	O
needed	O
for	O
pain	I-Reason
Discharge	O
Medications	O
:	O
1	O
.	O
heparin	I-Drug
(	O
porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
docusate	B-Drug
sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
5	O
.	O
midodrine	I-Drug
2.5	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
beclomethasone	B-Drug
dipropionate	I-Drug
80	O
mcg	O
/	O
Actuation	O
Aerosol	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
fludrocortisone	B-Drug
0.1	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
quetiapine	B-Drug
25	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
9	O
.	O
lansoprazole	B-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
quetiapine	B-Drug
25	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
thrush	I-Reason
.	O
12	O
.	O
acetylcysteine	I-Drug
20	O
%	O
(	O
200	O
mg	O
/	O
mL	O
)	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
ML	O
Miscellaneous	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
.	O
13	O
.	O
oxycodone	I-Drug
-	O
acetaminophen	O
5	O
-	O
325	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
14	O
.	O
ipratropium	B-Drug
-	I-Drug
albuterol	O
18	O
-	O
103	O
mcg	O
/	O
Actuation	O
Aerosol	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Six	O
(	O
6	O
)	O
Puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
15	O
.	O
quetiapine	B-Drug
25	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
16	O
.	O
acetaminophen	I-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
17	O
.	O
medium	B-Drug
chain	I-Drug
triglycerides	I-Drug
7.7	O
kcal	O
/	O
mL	O
Oil	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
ML	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
105	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1121	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1456	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
1	O
.	O
Hypercarbic	O
respiratory	O
failure	O
2	O
.	O
Pneumonia	O
3	O
.	O
Sarcoidosis	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
because	O
you	O
had	O
shortness	O
of	O
breath	O
which	O
was	O
thought	O
to	O
be	O
due	O
to	O
a	O
pneumonia	I-Reason
in	O
setting	O
of	O
your	O
underlying	O
sarcoidosis	O
.	O
You	O
were	O
treated	O
with	O
antibiotics	I-Drug
called	O
MEROPENEM	I-Drug
and	O
VANCOMCYIN	I-Drug
.	O
You	O
needed	O
help	O
with	O
mechanical	O
ventilation	O
to	O
breathe	O
.	O
A	O
tracheostomy	O
was	O
performed	O
as	O
you	O
required	O
prolong	O
ventilatory	O
support	O
.	O
You	O
were	O
removed	O
off	O
of	O
mechanical	O
ventilation	O
and	O
were	O
breathing	O
on	O
trach	O
collar	O
mask	O
prior	O
to	O
transfer	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
rehab	O
.	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
PULMONARY	O
FUNCTION	O
LAB	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2145-3-10	O
**	O
]	O
at	O
3:40	O
PM	O
With	O
:	O
PULMONARY	O
FUNCTION	O
LAB	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
609	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
MEDICAL	O
SPECIALTIES	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2145-3-10	O
**	O
]	O
at	O
4:00	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
612	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
PFT	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2145-3-10	O
**	O
]	O
at	O
4:00	O
PM	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2437	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
2438	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2114-11-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2114-11-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2039-8-6	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Aspirin	I-Drug
/	O
Hydralazine	I-Drug
/	O
Ace	B-Drug
Inhibitors	I-Drug
/	O
Diovan	I-Drug
/	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
826	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypoxia	O
/	O
tachypnea	O
,	O
fever	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Left	O
subclavain	O
line	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
349	O
**	O
]	O
is	O
a	O
75yo	O
woman	O
with	O
h	O
/	O
o	O
ESRD	O
on	O
HD	O
,	O
DM2	O
,	O
CHF	O
,	O
afib	O
and	O
CAD	O
who	O
presented	O
to	O
the	O
ER	O
today	O
from	O
her	O
NH	O
with	O
complaint	O
of	O
fever	O
to	O
103.8	O
,	O
chills	O
,	O
diaphoresis	O
and	O
confusion	O
.	O
On	O
arrival	O
to	O
the	O
ER	O
she	O
was	O
found	O
to	O
have	O
temp	O
101.0	O
,	O
HR	O
126	O
,	O
bp	O
180/86	O
,	O
and	O
to	O
be	O
satting	O
82	O
%	O
on	O
RA	O
which	O
improved	O
to	O
mid-90s	O
on	O
4LNC	O
.	O
Chest	O
XR	O
showed	O
continued	O
and	O
possibly	O
increased	O
R	O
pleural	O
effusion	O
.	O
She	O
complained	O
of	O
midl	O
abdominal	O
pain	O
,	O
and	O
CT	O
abd	O
/	O
pelvis	O
was	O
unremarkable	O
except	O
for	O
known	O
enlarged	O
gallbladder	O
.	O
She	O
was	O
given	O
1LNS	O
,	O
vanco	I-Drug
and	O
levo	I-Drug
and	O
was	O
sent	O
to	O
HD	O
where	O
they	O
were	O
able	O
to	O
remove	O
1.2	O
L	O
.	O
While	O
at	O
HD	O
,	O
the	O
patient	O
spontaneously	O
desaturated	O
to	O
the	O
80s	O
on	O
4LNC	O
and	O
required	O
50	O
%	O
face	O
mask	O
to	O
regain	O
sats	O
of	O
the	O
mid-90s	O
.	O
ABG	O
at	O
that	O
time	O
showed	O
7.36	O
/	O
58/271	O
.	O
Stat	O
CXR	O
showed	O
R	O
pleural	O
effusion	O
but	O
no	O
clear	O
pna	O
.	O
She	O
received	O
nebs	I-Drug
and	O
zosyn	I-Drug
and	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
further	O
care	O
.	O
.	O
In	O
the	O
MICU	O
the	O
patient	O
had	O
a	O
bedside	O
ultrasound	O
to	O
evaluate	O
her	O
effusion	O
which	O
showed	O
no	O
safe	O
area	O
for	O
diagnostic	O
tap	O
.	O
After	O
a	O
few	O
hours	O
in	O
the	O
MICU	O
she	O
dropped	O
her	O
pressures	O
to	O
as	O
low	O
as	O
sbp78	I-Reason
.	O
She	O
was	O
given	O
1500cc	O
total	O
of	O
NS	I-Drug
.	O
Central	O
line	O
was	O
placed	O
in	O
a	O
sterile	O
fashion	O
(	O
LIJ	O
)	O
and	O
she	O
was	O
started	O
on	O
levophed	I-Drug
.	O
Her	O
blood	O
cultures	O
returned	O
4/4	O
bottles	O
GPC	O
in	O
clusters	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
R	O
pleural	O
effusion	O
tapped	O
in	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
neg	O
for	O
malignant	O
cells	O
or	O
infection	O
(	O
attempted	O
tap	O
x	O
3	O
without	O
success	O
,	O
on	O
fourth	O
attempt	O
were	O
able	O
to	O
remove	O
200cc	O
only	O
)	O
-	O
CAD	O
:	O
cath	O
[	O
**	O
11	O
-	O
26	O
**	O
]	O
with	O
3VD	O
,	O
s	O
/	O
p	O
cypher	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
2	O
to	O
RCA	O
.	O
-	O
atrial	O
fibrillation	O
-	O
pulmonary	O
HTN	O
-	O
hypertension	O
-	O
hyperlipidemia	O
-	O
DM2	O
-	O
Severe	O
lumbar	O
spondylosis	O
and	O
spinal	O
stenosis	O
s	O
/	O
p	O
laminectomy	O
in	O
[	O
**	O
2110	O
**	O
]	O
-	O
basal	O
cell	O
carcinoma	O
-	O
CHF	O
:	O
echo	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
shows	O
55	O
%	O
EF	O
-	O
hyperkalemia	O
-	O
ESRD	I-Ade
on	O
HD	O
since	O
[	O
**	O
2111	O
**	O
]	O
after	O
IV	O
contrast	I-Drug
for	O
cath	O
-	O
Osteomyelitis	I-Reason
T5	O
-	O
T6	O
on	O
suppressive	O
vancomycin	I-Drug
for	O
3	O
months	O
(	O
[	O
**	O
2113-4-13	O
**	O
]	O
was	O
day	O
1	O
)	O
-	O
MRSA	O
bacteremia	O
from	O
HD	O
line	O
infection	O
-	O
mild	O
-	O
to	O
-	O
moderate	O
cord	O
compression	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
3046	O
**	O
]	O
/	O
05	O
and	O
evaluated	O
by	O
neurosurgery	O
felt	O
mild	O
and	O
did	O
not	O
put	O
patient	O
at	O
risk	O
for	O
cauda	O
equina	O
syndrome	O
.	O
-	O
urosepsis	O
-	O
several	O
HD	O
line	O
changes	O
Social	O
History	O
:	O
Lives	O
at	O
[	O
**	O
Hospital	O
**	O
]	O
[	O
**	O
Hospital	O
**	O
]	O
Nursing	O
Home	O
since	O
[	O
**	O
2111	O
**	O
]	O
and	O
has	O
been	O
bedridden	O
since	O
that	O
time	O
[	O
**	O
1	O
-	O
25	O
**	O
]	O
spinal	O
stenosis	O
.	O
Past	O
tobacco	O
(	O
quit	O
[	O
**	O
2111	O
**	O
]	O
10py	O
)	O
.	O
Has	O
three	O
children	O
-	O
daughter	O
nad	O
son	O
both	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
86	O
**	O
]	O
area	O
and	O
split	O
her	O
HCP	O
.	O
Widowed	O
in	O
[	O
**	O
2108	O
**	O
]	O
.	O
Retired	O
-	O
worked	O
in	O
retail	O
clothing	O
.	O
Family	O
History	O
:	O
Father	O
died	O
of	O
CVA	O
at	O
64yo	O
.	O
Mother	O
died	O
of	O
MI	O
at	O
86yo	O
.	O
Brother	O
had	O
CAD	O
.	O
Grandmother	O
had	O
T2DM	O
Physical	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
102.0	O
,	O
92	O
,	O
150/40	O
,	O
100	O
%	O
on	O
50	O
%	O
face	O
mask	O
,	O
28	O
gen	O
:	O
responds	O
appropriately	O
to	O
questions	O
,	O
increased	O
work	O
of	O
breathing	O
,	O
quite	O
tachypneic	O
,	O
diaphoretic	O
,	O
severe	O
kyphosis	O
heent	O
:	O
PERRL	O
(	O
constricted	O
)	O
,	O
NCAT	O
neck	O
:	O
unable	O
to	O
estimate	O
jvp	O
given	O
pt	O
inability	O
to	O
turn	O
head	O
cor	O
:	O
rrr	O
,	O
s1s2	O
,	O
no	O
r	O
/	O
g	O
/	O
m	O
pulm	O
:	O
scattered	O
wheezes	O
,	O
decreased	O
BS	O
at	O
right	O
base	O
abd	O
:	O
soft	O
,	O
ntnd	O
,	O
+	O
bs	O
,	O
no	O
hsm	O
ext	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
,	O
w	O
/	O
w	O
/	O
p	O
Pertinent	O
Results	O
:	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:30	O
PM	O
LACTATE	O
-	O
2.1	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
GLUCOSE	O
-	O
142	O
*	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
1.9	O
*	O
SODIUM	O
-	O
141	O
POTASSIUM	O
-	O
3.8	O
CHLORIDE	O
-	O
104	O
TOTAL	O
CO2	O
-	O
31	O
ANION	O
GAP	O
-	O
10	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
CALCIUM	O
-	O
7.0	O
*	O
PHOSPHATE	O
-	O
2.1	O
*	O
MAGNESIUM	O
-	O
1.4	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
VANCO	O
-	O
7.6	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
WBC	O
-	O
9.5	O
RBC	O
-	O
3.43	O
*	O
HGB	O
-	O
11.3	O
*	O
#	O
HCT	O
-	O
32.3	O
*	O
#	O
MCV	O
-	O
94	O
MCH	O
-	O
32.8	O
*	O
MCHC	O
-	O
34.9	O
RDW	O
-	O
14.4	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
PLT	O
COUNT	O
-	O
83	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
PT	O
-	O
16.6	O
*	O
PTT	O
-	O
27.6	O
INR	O
(	O
PT	O
)	O
-	O
1.5	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:20	O
PM	O
FDP	O
-10-40	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
GLUCOSE	O
-	O
194	O
*	O
UREA	O
N	O
-	O
21	O
*	O
CREAT	O
-	O
2.0	O
*	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
95	O
*	O
TOTAL	O
CO2	O
-	O
36	O
*	O
ANION	O
GAP	O
-	O
13	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
CALCIUM	O
-	O
8.7	O
PHOSPHATE	O
-	O
2.7	O
MAGNESIUM	O
-	O
1.6	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
CORTISOL	O
-	O
43.6	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
WBC	O
-	O
12.5	O
*	O
RBC	O
-	O
4.47	O
HGB	O
-	O
14.4	O
HCT	O
-	O
42.6	O
MCV	O
-	O
95	O
MCH	O
-	O
32.1	O
*	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
14.5	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
PLT	O
COUNT	O
-	O
92	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
PT	O
-	O
14.6	O
*	O
PTT	O
-	O
25.8	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
06:41	O
PM	O
FIBRINOGE	O
-	O
654	O
*	O
D	O
-	O
DIMER	O
-	O
4952	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
05:40	O
PM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
271	O
*	O
PCO2	O
-	O
58	O
*	O
PH	O
-	O
7.36	O
TOTAL	O
CO2	O
-	O
34	O
*	O
BASE	O
XS	O
-	O
5	O
[	O
**	O
2114-11-13	O
**	O
]	O
05:40	O
PM	O
LACTATE	O
-	O
2.2	O
*	O
K	O
+	O
-	O
4.5	O
[	O
**	O
2114-11-13	O
**	O
]	O
05:40	O
PM	O
HGB	O
-	O
15.2	O
calcHCT	O
-	O
46	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:11	O
AM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.021	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:11	O
AM	O
URINE	O
BLOOD	O
-	O
LG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
500	O
GLUCOSE	O
-	O
100	O
KETONE	O
-	O
15	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
7.0	O
LEUK	O
-	O
SM	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:11	O
AM	O
URINE	O
RBC	O
-	O
[	O
**	O
2	O
-	O
25	O
**	O
]	O
*	O
WBC	O
-	O
[	O
**	O
2	O
-	O
25	O
**	O
]	O
BACTERIA	O
-	O
NONE	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
GLUCOSE	O
-	O
168	O
*	O
UREA	O
N	O
-	O
35	O
*	O
CREAT	O
-	O
2.8	O
*	O
SODIUM	O
-	O
137	O
POTASSIUM	O
-	O
5.7	O
*	O
CHLORIDE	O
-	O
98	O
TOTAL	O
CO2	O
-	O
29	O
ANION	O
GAP	O
-	O
16	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
25	O
AST	O
(	O
SGOT	O
)	O
-	O
32	O
LD	O
(	O
LDH	O
)	O
-	O
244	O
CK	O
(	O
CPK	O
)	O
-	O
20	O
*	O
ALK	O
PHOS	O
-	O
205	O
*	O
AMYLASE	O
-	O
45	O
TOT	O
BILI	O
-	O
0.4	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
CK	O
(	O
CPK	O
)	O
-	O
22	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
LIPASE	O
-	O
20	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
CK	O
-	O
MB	O
-	O
2	O
cTropnT	O
-	O
0.07	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.08	O
*	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
ALBUMIN	O
-	O
3.5	O
[	O
**	O
2114-11-13	O
**	O
]	O
10:00	O
AM	O
CALCIUM	O
-	O
9.1	O
PHOSPHATE	O
-	O
3.2	O
MAGNESIUM	O
-	O
1.7	O
[	O
**	O
2114-11-13	O
**	O
]	O
09:45	O
AM	O
LACTATE	O
-	O
1.3	O
[	O
**	O
2114-11-13	O
**	O
]	O
09:35	O
AM	O
WBC	O
-	O
12.0	O
*	O
RBC	O
-	O
4.48	O
#	O
HGB	O
-	O
14.4	O
#	O
HCT	O
-	O
42.5	O
#	O
MCV	O
-	O
95	O
MCH	O
-	O
32.2	O
*	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
14.4	O
[	O
**	O
2114-11-13	O
**	O
]	O
09:35	O
AM	O
NEUTS	O
-	O
85	O
*	O
BANDS	O
-	O
10	O
*	O
LYMPHS	O
-	O
0	O
MONOS	O
-	O
5	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2114-11-13	O
**	O
]	O
09:35	O
AM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
NORMAL	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
1	O
+	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
NORMAL	O
[	O
**	O
2114-11-13	O
**	O
]	O
09:35	O
AM	O
PLT	O
COUNT	O
-	O
89	O
*	O
.	O
.	O
ECHO	O
:	O
[	O
**	O
2114-11-14	O
**	O
]	O
Conclusions	O
:	O
1	O
.	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
2	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
>	O
75	O
%	O
)	O
.	O
3	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
Right	O
ventricular	O
systolic	O
function	O
is	O
normal	O
.	O
4	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
5	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
6	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
7	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Impression	O
:	O
No	O
echocardiographic	O
evidence	O
of	O
endocarditis	O
seen	O
.	O
.	O
CXXR	O
[	O
**	O
2114-11-14	O
**	O
]	O
IMPRESSION	O
:	O
No	O
change	O
is	O
demonstrated	O
in	O
large	O
right	O
pleural	O
effusion	O
and	O
atelectasis	O
of	O
the	O
right	O
lower	O
lobe	O
.	O
An	O
infectious	O
process	O
can	O
not	O
be	O
excluded	O
.	O
The	O
left	O
lung	O
is	O
unremarkable	O
.	O
The	O
left	O
subclavian	O
line	O
tip	O
terminates	O
in	O
the	O
left	O
brachiocephalic	O
vein	O
.	O
.	O
.	O
Discharge	O
Labs	O
:	O
Hct	O
31	O
WBC	O
7.6	O
Plt	O
180	O
;	O
Na	O
137	O
K	O
4.3	O
BUN	O
15	O
Crt	O
2.6	O
Brief	O
Hospital	O
Course	O
:	O
#MRSA	O
sepsis	I-Reason
:	O
Pt	O
was	O
admitted	O
to	O
the	O
MICU	O
and	O
started	O
on	O
vancomycin	I-Drug
and	O
zosyn	I-Drug
for	O
antibiotic	I-Drug
coverage	O
.	O
Once	O
sensitivities	O
returned	O
as	O
MRSA	O
,	O
the	O
zosyn	I-Drug
was	O
discontinued	O
.	O
Her	O
blood	B-Reason
pressures	I-Reason
were	I-Reason
low	I-Reason
on	O
initial	O
presentation	O
so	O
the	O
patient	O
was	O
given	O
bolus	O
IV	O
fluids	I-Drug
and	O
levophed	I-Drug
.	O
Her	O
CVP	I-Reason
was	O
maintained	O
above	O
8	O
.	O
She	O
was	O
eventually	O
weaned	O
off	O
of	O
the	O
levophed	I-Drug
.	O
An	O
extensive	O
workup	O
for	O
the	O
source	O
of	O
infection	O
was	O
limited	O
by	O
patient	O
's	O
wishes	O
.	O
She	O
had	O
a	O
TTE	O
which	O
was	O
negative	O
but	O
refused	O
an	O
MRI	O
of	O
the	O
spine	O
.	O
The	O
patient	O
was	O
afebrile	O
during	O
the	O
ICU	O
course	O
.	O
Surveillance	O
cultures	O
were	O
negative	O
after	O
[	O
**	O
2114-11-14	O
**	O
]	O
.	O
She	O
will	O
receive	O
long	O
duration	O
therapy	O
with	O
6wks	O
of	O
Vancomycin	I-Drug
to	O
cover	O
for	O
osteomyelitis	I-Reason
,	O
as	O
she	O
has	O
had	O
this	O
in	O
the	O
past	O
.	O
Her	O
most	O
recent	O
vanco	I-Drug
level	O
was	O
pending	O
at	O
time	O
of	O
discharge	O
.	O
.	O
#Heparin	O
Induced	O
Thrombocytopenia	I-Ade
:	O
The	O
patients	O
platlet	O
count	O
continued	O
to	O
fall	O
during	O
her	O
ICU	O
stay	O
.	O
Heparin	I-Drug
products	O
were	O
held	O
and	O
sent	O
off	O
HIT	I-Ade
Ab	O
labs	O
which	O
eventually	O
came	O
back	O
positive	O
.	O
Her	O
central	O
line	O
was	O
also	O
discontinued	O
which	O
was	O
pre-treated	O
with	O
heparin	I-Drug
.	O
.	O
#ESRD	O
:	O
The	O
patient	O
has	O
ESRD	O
and	O
received	O
dialysis	O
through	O
her	O
fistula	O
while	O
in	O
the	O
MICU	O
.	O
No	O
complications	O
.	O
Last	O
dialysis	O
was	O
on	O
[	O
**	O
2114-11-22	O
**	O
]	O
.	O
Pt	O
required	O
extra	O
sessions	O
of	O
dialysis	O
because	O
of	O
HD	O
-	O
related	O
hypotension	O
,	O
which	O
limited	O
the	O
extent	O
of	O
dialysis	O
that	O
could	O
be	O
done	O
in	O
one	O
session	O
.	O
She	O
was	O
started	O
on	O
EPO	I-Drug
4000units	O
with	O
dialysis	O
for	O
CKD	B-Reason
-	I-Reason
related	I-Reason
anemia	I-Reason
.	O
.	O
#CAD	O
:	O
continue	O
pt	O
's	O
BB	I-Drug
and	O
plavix	I-Drug
.	O
allergy	I-Ade
to	O
asa	I-Drug
and	O
ace	I-Drug
.	O
.	O
#Chronic	O
back	I-Reason
pain	I-Reason
w	I-Reason
/	I-Reason
spinal	I-Reason
stenosis	I-Reason
:	O
continue	O
outpt	O
morphine	I-Drug
SR	O
30	O
qMon	O
-	O
Wed	O
-	O
Fri	O
,	O
and	O
IR	O
15	O
q6h	O
prn	O
,	O
as	O
well	O
as	O
lidoderm	I-Drug
patch	O
.	O
pt	O
appears	O
to	O
be	O
at	O
her	O
baseline	O
back	O
pain	O
,	O
however	O
we	O
wanted	O
to	O
do	O
an	O
MRI	O
to	O
rule	O
out	O
osteomyletis	O
or	O
epidural	O
abscess	O
but	O
the	O
patient	O
refused	O
.	O
#	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
UTI	O
:	O
Ms	O
[	O
**	O
Known	O
lastname	O
349	O
**	O
]	O
had	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
**	O
]	O
in	O
her	O
urine	O
and	O
was	O
started	O
on	O
a	O
7d	O
course	O
of	O
fluconazole	I-Drug
200	O
mg	O
daily	O
.	O
This	O
will	O
completed	O
on	O
[	O
**	O
2114-11-22	O
**	O
]	O
.	O
She	O
does	O
not	O
have	O
a	O
foley	O
catheter	O
and	O
makes	O
20	O
-	O
30cc	O
urine	O
/	O
day	O
.	O
.	O
#DM	O
:	O
pt	O
was	O
continued	O
on	O
humalog	I-Drug
sliding	O
scale	O
.	O
Her	O
glucose	O
was	O
well	O
controlled	O
with	O
this	O
.	O
.	O
#	O
H	O
/	O
o	O
Afib	O
:	O
pt	O
was	O
in	O
sinus	O
rhythm	O
throughout	O
her	O
hospital	O
stay	O
.	O
.	O
#CAD	O
:	O
no	O
evidence	O
of	O
ischemia	O
during	O
hospital	O
stay	O
.	O
Pt	O
continued	O
on	O
outpatient	O
CAD	O
regimen	O
.	O
Medications	O
on	O
Admission	O
:	O
metoprolol	I-Drug
12.5	O
mg	O
po	O
bid	O
prilosec	I-Drug
20	O
mg	O
po	O
qday	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
po	O
qday	O
plavix	I-Drug
75	O
mg	O
po	O
qday	O
lidoderm	I-Drug
patch	O
on	O
8	O
am	O
off	O
8	O
pm	O
vitamin	B-Drug
C	I-Drug
500	O
mg	O
po	O
bid	O
ms	B-Drug
contin	I-Drug
30	O
mg	O
po	O
qMWF	O
calcium	B-Drug
carbonate	I-Drug
500	O
mg	O
po	O
tid	O
calcitriol	I-Drug
0.5	O
mg	O
qmwf	O
celexa	I-Drug
20	O
mg	O
po	O
qday	O
klonopin	I-Drug
0.5	O
mg	O
po	O
bid	O
duonebs	I-Drug
prn	O
morphine	B-Drug
IR	I-Drug
15	O
mg	O
po	O
q4	O
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Calcitriol	I-Drug
0.25	O
mcg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
EVERY	O
OTHER	O
DAY	O
(	O
Every	O
Other	O
Day	O
)	O
.	O
2	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
Q8AM	O
-	O
8PM	O
(	O
)	O
.	O
3	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Vancomycin	B-Drug
in	I-Drug
Dextrose	I-Drug
1	O
g	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
QHD	O
(	O
each	O
hemodialysis	O
)	O
:	O
Continue	O
until	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
,	O
[	O
**	O
2114	O
**	O
]	O
.	O
5	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
7	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Morphine	I-Drug
30	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
QMOWEFR	O
(	O
Monday	O
-	O
Wednesday	O
-	O
Friday	O
)	O
.	O
10	O
.	O
Morphine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
11	O
.	O
Klonopin	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
12	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q3	O
-	O
4H	O
(	O
Every	O
3	O
to	O
4	O
Hours	O
)	O
as	O
needed	O
.	O
13	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
14	O
.	O
Lactulose	I-Drug
10	O
g	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
15	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
16	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
17	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
18	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
19	O
.	O
Epoetin	B-Drug
Alfa	I-Drug
10,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
ml	O
Injection	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
:	O
TO	O
BE	O
GIVEN	O
WITH	O
DIALYSIS	O
(	O
4000units	O
QHD	O
)	O
.	O
20	O
.	O
Insulin	B-Drug
Lispro	I-Drug
(	I-Drug
Human	I-Drug
)	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
2	O
-	O
10	O
units	O
Subcutaneous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
:	O
sliding	O
scale	O
151	O
-	O
200	O
give	O
2u	O
,	O
201	O
-	O
250	O
give	O
4u	O
,	O
251	O
-	O
300	O
give	O
6u	O
,	O
301	O
-	O
350	O
give	O
8u	O
,	O
351	O
-	O
400	O
give	O
10u	O
,	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
[	O
**	O
Hospital	O
**	O
]	O
Nursing	O
Home	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
MRSA	O
Sepsis	O
End	O
stage	O
renal	O
disease	O
on	O
Hemodialysis	O
Heparin	I-Drug
Induced	O
thrombocytopenia	I-Ade
.	O
Secondary	O
:	O
Diabetes	O
mellitus	O
type	O
II	O
Spinal	O
stenosis	O
Congestive	O
heart	O
failure	O
Hypertension	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
Please	O
continue	O
to	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
You	O
will	O
need	O
to	O
have	O
a	O
long	O
course	O
of	O
vancomycin	B-Drug
(	I-Drug
an	I-Drug
antibiotic	I-Drug
)	I-Drug
for	O
your	O
blood	B-Reason
infection	I-Reason
,	O
this	O
will	O
likely	O
be	O
for	O
6	O
weeks	O
.	O
.	O
If	O
you	O
have	O
chest	O
pain	O
/	O
pressure	O
,	O
fevers	O
/	O
chills	O
,	O
shortness	O
of	O
breath	O
,	O
nausea	O
/	O
vomiting	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
please	O
call	O
your	O
PCP	O
or	O
come	O
to	O
the	O
ED	O
.	O
.	O
1	O
.	O
Take	O
medications	O
as	O
directed	O
.	O
2	O
.	O
Attend	O
all	O
follow	O
up	O
appointments	O
.	O
.	O
Your	O
last	O
Hemodialysis	O
was	O
on	O
Thursday	O
[	O
**	O
2114-11-22	O
**	O
]	O
.	O
Please	O
**	O
AVOID	O
HEPARIN	I-Drug
PRODUCTS	O
**	O
you	O
had	O
a	O
reaction	O
to	O
it	O
that	O
caused	O
your	O
platelet	B-Ade
count	I-Ade
to	I-Ade
drop	I-Ade
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
your	O
PCP	O
/	O
NH	O
physician	O
--	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
2113	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2114	O
**	O
]	O
R.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
608	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2184-5-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2184-6-9	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2139-8-7	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
5119	O
**	O
]	O
Chief	O
Complaint	O
:	O
Nausea	O
and	O
Vomiting	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
:	O
Stereotactic	O
brain	O
biopsy	O
History	O
of	O
Present	O
Illness	O
:	O
44yo	O
F	O
with	O
recent	O
dx	O
of	O
lung	O
lesion	O
(	O
3wks	O
ago	O
...	O
currently	O
undergoing	O
outpt	O
w	O
/	O
u	O
)	O
admitted	O
for	O
nausea	O
&	O
vomiting	O
.	O
Per	O
patient	O
she	O
has	O
not	O
been	O
feeling	O
quite	O
herself	O
recently	O
(	O
mentally	O
)	O
and	O
it	O
got	O
to	O
a	O
point	O
on	O
[	O
**	O
5	O
-	O
27	O
**	O
]	O
where	O
she	O
soughtmedical	O
treatment	O
.	O
Does	O
not	O
report	O
any	O
difficulty	O
with	O
motor	O
skills	O
,	O
gait	O
,	O
sensation	O
,	O
or	O
vision	O
at	O
the	O
time	O
of	O
presentation	O
.	O
She	O
reports	O
her	O
current	O
state	O
in	O
very	O
vague	O
terms	O
as	O
"	O
not	O
feeling	O
right	O
"	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Asthma	O
-	O
Recent	O
tooth	O
infection	O
/	O
extractions	O
(	O
[	O
**	O
2184-2-15	O
**	O
]	O
.	O
)	O
-	O
metaphalangeal	O
subluxation	O
following	O
an	O
injury	O
on	O
[	O
**	O
2178-6-17	O
**	O
]	O
-	O
Obesity	O
Social	O
History	O
:	O
Lives	O
with	O
three	O
children	O
and	O
Fiancee	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
1411	O
**	O
]	O
.	O
Originally	O
from	O
Sicily	O
,	O
[	O
**	O
Country	O
2559	O
**	O
]	O
.	O
Moved	O
to	O
US	O
in	O
60s	O
.	O
Travels	O
include	O
[	O
**	O
Country	O
2559	O
**	O
]	O
,	O
Caribbean	O
and	O
US	O
.	O
US	O
travels	O
(	O
[	O
**	O
State	O
108	O
**	O
]	O
,	O
NC	O
,	O
[	O
**	O
State	O
350	O
**	O
]	O
.	O
)	O
TB	O
risk	O
factors	O
:	O
prior	O
incarceration	O
for	O
one	O
day	O
during	O
teens	O
.	O
Hx	O
of	O
homelesness	O
during	O
teens	O
.	O
Hx	O
+	O
BCG	O
,	O
has	O
had	O
negative	O
PPDs	O
in	O
past	O
(	O
used	O
to	O
work	O
in	O
health	O
care	O
facility	O
.	O
)	O
Recurrently	O
on	O
disability	O
after	O
injury	O
at	O
work	O
.	O
Used	O
to	O
work	O
in	O
health	O
care	O
field	O
.	O
Tob	O
:	O
One	O
pack	O
daily	O
x	O
30	O
years	O
.	O
EtOH	O
:	O
N	O
IVDU	O
:	O
past	O
cocaine	O
(	O
snorting	O
)	O
and	O
IVDU	O
in	O
teens	O
.	O
None	O
recent	O
.	O
Sexual	O
history	O
:	O
3	O
lifetime	O
sexual	O
partners	O
.	O
Genital	O
warts	O
.	O
HIV	O
neg	O
in	O
[	O
**	O
2177	O
**	O
]	O
.	O
Exposures	O
:	O
+	O
sick	O
contact	O
.	O
Fiance	O
with	O
cold	O
symptoms	O
.	O
Pets	O
:	O
+	O
dog	O
Family	O
History	O
:	O
-	O
No	O
hx	O
htn	O
,	O
cad	O
/	O
mi	O
,	O
cancer	O
-	O
Diabetes	O
--	O
mother	O
,	O
grandfather	O
,	O
grandmother	O
-	O
Father	O
passed	O
away	O
at	O
76	O
due	O
to	O
"	O
natural	O
causes	O
'	O
-	O
Mother	O
is	O
76	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
Vitals	O
:	O
T	O
99.5	O
BP	O
187/79	O
(	O
180-217/70	O
-	O
85	O
)	O
HR	O
68	O
RR	O
18	O
SaO2	O
96	O
%	O
ra	O
General	O
:	O
no	O
acute	O
distress	O
,	O
sitting	O
in	O
bed	O
talking	O
on	O
phone	O
,	O
comfortable	O
and	O
appropriate	O
HEENT	O
:	O
NC	O
/	O
AT	O
,	O
sclerae	O
anicteric	O
,	O
MMM	O
,	O
no	O
exudates	O
in	O
oropharynx	O
Neck	O
:	O
supple	O
,	O
no	O
nuchal	O
rigidity	O
,	O
no	O
bruits	O
Lungs	O
:	O
clear	O
to	O
auscultation	O
CV	O
:	O
regular	O
rate	O
and	O
rhythm	O
,	O
no	O
MMRG	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
Ext	O
:	O
warm	O
,	O
no	O
edema	O
,	O
pedal	O
pulses	O
appreciated	O
Skin	O
:	O
no	O
rashes	O
Neurologic	O
Examination	O
:	O
Mental	O
Status	O
:	O
Awake	O
and	O
alert	O
,	O
following	O
all	O
commands	O
,	O
slightly	O
odd	O
affect	O
Oriented	O
to	O
person	O
,	O
place	O
,	O
time	O
Language	O
:	O
Speech	O
fluent	O
with	O
good	O
comprehension	O
and	O
repetition	O
.	O
Naming	O
intact	O
.	O
No	O
dysarthria	O
or	O
paraphasic	O
errors	O
.	O
Cranial	O
Nerves	O
:	O
I	O
:	O
Not	O
tested	O
II	O
:	O
Pupils	O
equally	O
round	O
and	O
reactive	O
to	O
light	O
,	O
to	O
mm	O
bilaterally	O
.	O
Visual	O
fields	O
are	O
full	O
to	O
confrontation	O
.	O
III	O
,	O
IV	O
,	O
VI	O
:	O
Extraocular	O
movements	O
intact	O
bilaterally	O
without	O
nystagmus	O
.	O
V	O
,	O
VII	O
:	O
Facial	O
strength	O
and	O
sensation	O
intact	O
and	O
symmetric	O
.	O
VIII	O
:	O
Hearing	O
intact	O
to	O
voice	O
.	O
IX	O
,	O
X	O
:	O
Palatal	O
elevation	O
symmetrical	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
Sternocleidomastoid	O
and	O
trapezius	O
normal	O
bilaterally	O
.	O
XII	O
:	O
Tongue	O
midline	O
without	O
fasciculations	O
.	O
Motor	O
:	O
Normal	O
bulk	O
and	O
tone	O
bilaterally	O
.	O
No	O
abnormal	O
movements	O
,	O
tremors	O
,	O
or	O
asterixis	O
.	O
Strength	O
full	O
power	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
throughout	O
.	O
No	O
pronator	O
drift	O
Sensation	O
:	O
Intact	O
to	O
light	O
touch	O
bilaterally	O
.	O
Reflexes	O
:	O
B	O
T	O
Br	O
Pa	O
Ac	O
Right	O
1	O
1	O
1	O
3	O
1	O
Left	O
2	O
2	O
2	O
3	O
2	O
Coordination	O
:	O
normal	O
on	O
finger	O
-	O
nose	O
-	O
finger	O
,	O
rapid	O
alternating	O
movements	O
,	O
heel	O
to	O
shin	O
Exam	O
on	O
Discharge	O
:	O
XXXXXXXXXXXXXXXXX	O
Pertinent	O
Results	O
:	O
Labs	O
on	O
Admission	O
:	O
[	O
**	O
2184-5-27	O
**	O
]	O
11:00	O
PM	O
BLOOD	O
WBC	O
-	O
10.3	O
RBC	O
-	O
3.95	O
*	O
Hgb	O
-	O
11.5	O
*	O
Hct	O
-	O
34.2	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
14.0	O
Plt	O
Ct	O
-	O
425	O
[	O
**	O
2184-5-27	O
**	O
]	O
11:00	O
PM	O
BLOOD	O
Neuts	O
-	O
71.6	O
*	O
Lymphs	O
-	O
19.4	O
Monos	O
-	O
3.2	O
Eos	O
-	O
5.1	O
*	O
Baso	O
-	O
0.8	O
[	O
**	O
2184-5-28	O
**	O
]	O
05:20	O
AM	O
BLOOD	O
PT	O
-	O
14.9	O
*	O
PTT	O
-	O
33.1	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2184-5-27	O
**	O
]	O
11:00	O
PM	O
BLOOD	O
Glucose	O
-	O
89	O
UreaN	O
-	O
7	O
Creat	O
-	O
0.7	O
Na	O
-	O
143	O
K	O
-	O
3.4	O
Cl	O
-	O
103	O
HCO3	O
-	O
28	O
AnGap	O
-	O
15	O
[	O
**	O
2184-5-27	O
**	O
]	O
11:00	O
PM	O
BLOOD	O
ALT	O
-	O
17	O
AST	O
-	O
14	O
LD	O
(	O
LDH	O
)	O
-	O
281	O
*	O
AlkPhos	O
-	O
80	O
Amylase	O
-	O
29	O
TotBili	O
-	O
0.5	O
.	O
Imaging	O
:	O
EKG	O
[	O
**	O
5	O
-	O
27	O
**	O
]	O
:	O
Sinus	O
bradycardia	O
.	O
Poor	O
R	O
wave	O
progression	O
.	O
Can	O
not	O
rule	O
out	O
prior	O
anteroseptal	O
myocardial	O
infarction	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2184-5-14	O
**	O
]	O
there	O
is	O
no	O
significant	O
diagnostic	O
change	O
.	O
Intervals	O
Axes	O
Rate	O
PR	O
QRS	O
QT	O
/	O
QTc	O
P	O
QRS	O
T	O
56	O
142	O
82	O
468/461	O
56	O
75	O
59	O
.	O
CXR	O
4.17	O
:	O
FINDINGS	O
:	O
Heart	O
size	O
unchanged	O
.	O
Right	O
upper	O
lobe	O
opacification	O
and	O
right	O
mediatinal	O
fullness	O
corresponds	O
to	O
thick	O
walled	O
upper	O
lobe	O
cavity	O
and	O
mediastinal	O
lymphadenopathy	O
with	O
differential	O
including	O
Wegener	O
's	O
,	O
SCC	O
/	O
cancer	O
,	O
and	O
fungal	O
infection	O
.	O
No	O
new	O
focus	O
of	O
consolidation	O
is	O
seen	O
.	O
There	O
is	O
no	O
effusion	O
or	O
pneumothorax	O
.	O
IMPRESSION	O
:	O
Unchanged	O
highly	O
abnormal	O
chest	O
radiograph	O
.	O
.	O
MRI	O
Head	O
[	O
**	O
5	O
-	O
29	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Multiple	O
enhancing	O
lesions	O
are	O
identified	O
in	O
the	O
brain	O
as	O
described	O
above	O
.	O
Although	O
metastatic	O
disease	O
is	O
a	O
consideration	O
,	O
given	O
the	O
restricted	O
diffusion	O
on	O
the	O
diffusion	O
-	O
weighted	O
images	O
,	O
infection	O
needs	O
to	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
.	O
The	O
appearances	O
could	O
also	O
be	O
secondary	O
to	O
multiple	O
tuberculomas	O
given	O
a	O
cavitary	O
lesion	O
in	O
the	O
lung	O
.	O
.	O
CT	O
Torso	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Findings	O
consistent	O
with	O
extensive	O
metastatic	O
disease	O
,	O
including	O
pulmonary	O
nodules	O
,	O
bilateral	O
adrenal	O
masses	O
,	O
and	O
bilateral	O
renal	O
masses	O
.	O
Lymphadenopathy	O
in	O
mediastinal	O
,	O
right	O
greater	O
than	O
left	O
hilar	O
,	O
retroperitoneal	O
,	O
and	O
mesenteric	O
locations	O
,	O
consistent	O
with	O
nodal	O
spread	O
of	O
neoplastic	O
disease	O
.	O
Bronchoscopic	O
biopsy	O
is	O
recommended	O
.	O
2	O
.	O
Cavitary	O
pulmonary	O
nodule	O
in	O
the	O
posterior	O
segment	O
of	O
the	O
right	O
upper	O
lobe	O
,	O
suspicious	O
for	O
primary	O
lung	O
carcinoma	O
.	O
Please	O
see	O
the	O
differential	O
discussion	O
in	O
the	O
prior	O
chest	O
CTA	O
report	O
for	O
less	O
likely	O
considerations	O
.	O
3	O
.	O
Right	O
upper	O
lobe	O
pulmonary	O
interstitial	O
thickening	O
,	O
suspicious	O
for	O
lymphangetic	O
spread	O
.	O
4	O
.	O
Subtle	O
sclerosis	O
in	O
the	O
T4	O
vertebral	O
body	O
.	O
While	O
indeterminate	O
,	O
osseous	O
metastasis	O
is	O
not	O
excluded	O
.	O
If	O
there	O
will	O
be	O
a	O
change	O
in	O
clinical	O
management	O
,	O
then	O
a	O
bone	O
scan	O
may	O
be	O
helpful	O
.	O
5	O
.	O
Wedge	O
-	O
shaped	O
peripheral	O
opacity	O
in	O
the	O
right	O
middle	O
lobe	O
,	O
evolving	O
since	O
the	O
prior	O
chest	O
CTA	O
.	O
Second	O
evolving	O
process	O
in	O
the	O
right	O
upper	O
.	O
While	O
these	O
may	O
be	O
secondary	O
to	O
infection	O
,	O
the	O
morphology	O
of	O
the	O
right	O
middle	O
lobe	O
opacity	O
raises	O
the	O
possibility	O
of	O
a	O
pulmonary	O
infarct	O
.	O
6	O
.	O
Aberrant	O
right	O
subclavian	O
artery	O
.	O
.	O
Head	O
CT	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
(	O
post-bx	O
)	O
:	O
IMPRESSION	O
:	O
Post-surgical	O
changes	O
from	O
recent	O
resection	O
of	O
the	O
left	O
frontal	O
lesion	O
with	O
minimal	O
high	O
attenuation	O
in	O
the	O
resection	O
bed	O
and	O
moderate	O
perilesional	O
vasogenic	O
edema	O
causing	O
effacement	O
of	O
the	O
left	O
frontal	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
of	O
the	O
left	O
lateral	O
ventricle	O
without	O
shift	O
of	O
midline	O
structures	O
.	O
.	O
ECHO	O
[	O
**	O
2184-6-1	O
**	O
]	O
Conclusions	O
The	O
left	O
atrium	O
and	O
right	O
atrium	O
are	O
normal	O
in	O
cavity	O
size	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
The	O
estimated	O
cardiac	O
index	O
is	O
normal	O
(	O
>	O
=	O
2.5	O
L	O
/	O
min	O
/	O
m2	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
No	O
valveular	O
pathology	O
or	O
pathologic	O
flow	O
identified	O
.	O
Normal	O
biventricular	O
cavity	O
sizes	O
and	O
regiona	O
/	O
global	O
systolic	O
function	O
.	O
.	O
[	O
**	O
2184-6-4	O
**	O
]	O
CT	O
head	O
IMPRESSION	O
:	O
Extensive	O
bilateral	O
areas	O
of	O
vasogenic	O
edema	O
,	O
from	O
known	O
brain	O
metastasis	O
.	O
Compared	O
to	O
[	O
**	O
2184-5-30	O
**	O
]	O
,	O
the	O
overall	O
appearance	O
is	O
not	O
significantly	O
changed	O
.	O
.	O
Labs	O
on	O
discharge	O
:	O
***************	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
was	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
after	O
complaints	O
of	O
nausea	O
,	O
vomiting	O
,	O
and	O
not	O
"	O
feeling	O
herself	O
"	O
.	O
Of	O
significance	O
,	O
she	O
is	O
status	O
post	O
diagnosis	O
of	O
lung	O
mass	O
for	O
which	O
she	O
was	O
being	O
worked	O
up	O
on	O
an	O
outpatient	O
basis	O
.	O
.	O
1	O
.	O
NSCLC	O
,	O
metastatic	O
to	O
brain	O
/	O
nausea	O
/	O
vomiting	O
/	O
headache	O
--	O
Upon	O
admission	O
a	O
head	O
CT	O
was	O
performed	O
which	O
identified	O
multiple	O
infra	O
and	O
supra	O
tentorial	O
brain	O
lesions	O
,	O
including	O
the	O
brain	O
stem	O
.	O
High	O
dose	O
steroid	I-Drug
therapy	O
was	O
initiated	O
to	O
treat	O
associated	O
vasogenic	B-Reason
edema	I-Reason
.	O
A	O
left	O
stereotactic	O
brain	O
biopsy	O
was	O
performed	O
on	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
.	O
Post-operatively	O
a	O
head	O
CT	O
was	O
done	O
,	O
and	O
determined	O
to	O
be	O
stable	O
.	O
She	O
was	O
then	O
returned	O
to	O
the	O
ICU	O
pending	O
diagnosis	O
and	O
further	O
management	O
.	O
She	O
was	O
initiated	O
on	O
whole	O
brain	O
radiation	O
on	O
[	O
**	O
2184-6-2	O
**	O
]	O
and	O
was	O
monitored	O
in	O
the	O
ICU	O
for	O
signs	O
and	O
symptoms	O
of	O
increased	O
ICP	O
.	O
She	O
was	O
subsequently	O
transferred	O
to	O
the	O
hospitalist	O
service	O
for	O
the	O
remainder	O
of	O
her	O
course	O
.	O
During	O
initiation	O
of	O
her	O
brain	O
radiation	O
treatments	O
,	O
patient	O
had	O
intractable	O
nausea	O
,	O
vomiting	O
,	O
headache	O
,	O
and	O
hypertension	O
,	O
but	O
repeat	O
CT	O
head	O
did	O
not	O
show	O
increased	O
edema	O
.	O
She	O
continued	O
on	O
IV	O
dexamethasone	I-Drug
6	O
mg	O
q6	O
hours	O
,	O
IV	O
keppra	I-Drug
1000	O
mg	O
q12	O
hours	O
,	O
and	O
IV	O
hydralazine	I-Drug
for	O
blood	B-Reason
pressure	I-Reason
control	I-Reason
(	O
see	O
below	O
)	O
.	O
For	O
nausea	B-Reason
control	I-Reason
,	O
she	O
was	O
kept	O
on	O
compazine	I-Drug
,	O
zofran	I-Drug
,	O
ativan	I-Drug
,	O
phenergen	I-Drug
PRN	O
.	O
Oncology	O
,	O
neuro	O
-	O
oncology	O
,	O
and	O
neurosurgery	O
was	O
involved	O
throughout	O
her	O
hospital	O
course	O
.	O
Her	O
symptoms	O
gradually	O
subsided	O
and	O
she	O
was	O
transitioned	O
to	O
po	O
meds	O
.	O
She	O
will	O
complete	O
the	O
remainder	O
of	O
her	O
radiation	O
treatments	O
as	O
an	O
outpatient	O
.	O
She	O
has	O
follow	O
up	O
scheduled	O
with	O
thorcaic	O
oncology	O
and	O
neuro	O
-	O
oncology	O
.	O
.	O
2	O
.	O
Hypertension	I-Reason
--	O
While	O
unable	O
to	O
tolerate	O
po	O
,	O
she	O
was	O
treated	O
with	O
IV	O
hydralazine	I-Drug
for	O
goal	O
SBP	O
of	O
less	O
than	O
130	O
mmHg	O
.	O
When	O
able	O
to	O
tolerate	O
po	O
,	O
she	O
was	O
transitioned	O
to	O
Lisinopril	I-Drug
.	O
The	O
patient	O
was	O
instructed	O
to	O
followup	O
with	O
her	O
PCP	O
regarding	O
her	O
blood	O
pressure	O
.	O
.	O
3	O
.	O
Asthma	I-Reason
--	O
remained	O
stable	O
throughout	O
her	O
course	O
,	O
continued	O
prn	O
albuterol	I-Drug
.	O
.	O
4	O
.	O
Hyperglycemia	I-Ade
--	O
associated	O
with	O
high	O
dose	O
steroids	I-Drug
and	O
managed	O
with	O
a	O
sliding	O
scale	O
without	O
difficulty	O
.	O
.	O
5	O
.	O
Dispo	O
:	O
The	O
patient	O
ambulated	O
without	O
difficulty	O
and	O
was	O
discharged	O
home	O
in	O
stable	O
conition	O
.	O
Medications	O
on	O
Admission	O
:	O
albuterol	I-Drug
,	O
percocet	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Levetiracetam	I-Drug
1,000	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Dexamethasone	I-Drug
6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
for	O
20	O
days	O
.	O
Disp	O
:	O
*	O
80	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Lorazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Tylenol	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
.	O
6	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
.	O
7	O
.	O
Percocet	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
q6h	O
prn	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
20	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Non-small	O
cell	O
lung	O
cancer	O
with	O
multiple	O
brain	O
metastases	O
2	O
.	O
Hypertension	O
Discharge	O
Condition	O
:	O
Neurologically	O
Stable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
altered	O
mental	O
status	O
secondary	O
to	O
your	O
newly	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
106995	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
metastasis	O
.	O
You	O
underwent	O
brain	O
biopsy	O
and	O
whole	O
brain	O
radiation	O
.	O
You	O
should	O
attend	O
follow	O
up	O
appointments	O
with	O
the	O
thoracic	O
oncologist	O
and	O
neuro	O
-	O
oncolgist	O
.	O
.	O
-	O
Take	O
lisinopril	I-Drug
for	O
high	B-Reason
blood	I-Reason
pressure	I-Reason
.	O
Your	O
PCP	O
should	O
follow	O
up	O
on	O
your	O
blood	O
pressure	O
.	O
-	O
Take	O
lorazepam	I-Drug
at	O
night	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
.	O
General	O
Instructions	O
/	O
Information	O
??????	O
Have	O
a	O
friend	O
/	O
family	O
member	O
check	O
your	O
incision	O
daily	O
for	O
signs	O
of	O
infection	O
.	O
??????	O
Exercise	O
should	O
be	O
limited	O
to	O
walking	O
;	O
no	O
lifting	O
,	O
straining	O
,	O
or	O
excessive	O
bending	O
.	O
??????	O
Use	O
a	O
shower	O
cap	O
to	O
cover	O
your	O
head	O
if	O
you	O
are	O
going	O
to	O
shower	O
.	O
??????	O
You	O
have	O
been	O
prescribed	O
Keppra	I-Drug
for	O
anti-seizure	I-Reason
medicine	O
,	O
take	O
it	O
as	O
prescribed	O
??????	O
You	O
are	O
being	O
sent	O
home	O
on	O
steroid	I-Drug
medication	O
,	O
make	O
sure	O
you	O
are	O
taking	O
a	O
medication	O
to	B-Reason
protect	I-Reason
your	I-Reason
stomach	I-Reason
(	O
Prilosec	I-Drug
,	O
Protonix	I-Drug
,	O
or	O
Pepcid	I-Drug
)	O
,	O
as	O
these	O
medications	O
can	O
cause	O
stomach	I-Ade
irritation	O
.	O
Make	O
sure	O
to	O
take	O
your	O
steroid	I-Drug
medication	O
with	O
meals	O
,	O
or	O
a	O
glass	O
of	O
milk	O
.	O
??????	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
**	O
]	O
NOT	O
DRIVE	O
.	O
Clearance	O
to	O
drive	O
and	O
return	O
to	O
work	O
will	O
be	O
addressed	O
at	O
your	O
post-operative	O
office	O
visit	O
.	O
.	O
CALL	O
YOUR	O
SURGEON	O
IMMEDIATELY	O
IF	O
YOU	O
EXPERIENCE	O
ANY	O
OF	O
THE	O
FOLLOWING	O
??????	O
New	O
onset	O
of	O
tremors	O
or	O
seizures	O
.	O
??????	O
Any	O
confusion	O
or	O
change	O
in	O
mental	O
status	O
.	O
??????	O
Any	O
numbness	O
,	O
tingling	O
,	O
weakness	O
in	O
your	O
extremities	O
.	O
??????	O
Pain	O
or	O
headache	O
that	O
is	O
continually	O
increasing	O
,	O
or	O
not	O
relieved	O
by	O
pain	O
medication	O
.	O
??????	O
Any	O
signs	O
of	O
infection	O
at	O
the	O
wound	O
site	O
:	O
increasing	O
redness	O
,	O
increased	O
swelling	O
,	O
increased	O
tenderness	O
,	O
or	O
drainage	O
.	O
??????	O
Fever	O
greater	O
than	O
or	O
equal	O
to	O
101	O
??????	O
F.	O
Followup	O
Instructions	O
:	O
Follow	O
-	O
Up	O
Appointment	O
Instructions	O
:	O
-	O
Follow	O
up	O
with	O
your	O
PCP	O
on	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
766	O
**	O
]	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
at	O
6	O
pm	O
regarding	O
this	O
hospitalization	O
.	O
Please	O
call	O
and	O
reschedule	O
if	O
you	O
can	O
not	O
make	O
this	O
appointment	O
.	O
-	O
Please	O
call	O
the	O
neurosurgery	O
clinic	O
to	O
arrange	O
an	O
appointment	O
for	O
removal	O
of	O
your	O
sutures	O
and	O
a	O
wound	O
check	O
.	O
This	O
appointment	O
can	O
be	O
made	O
with	O
the	O
Nurse	O
Practitioner	O
.	O
Please	O
make	O
this	O
appointment	O
by	O
calling	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1669	O
**	O
]	O
.	O
If	O
you	O
live	O
quite	O
a	O
distance	O
from	O
that	O
office	O
,	O
please	O
make	O
arrangements	O
for	O
the	O
same	O
,	O
with	O
your	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
106996	O
**	O
]	O
your	O
radiation	O
treatments	O
as	O
scheduled	O
at	O
12	O
pm	O
on	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
,	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
and	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
.	O
-	O
Thoracic	O
oncology	O
clinic	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
831	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
0	O
-	O
0	O
-	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2184-6-22	O
**	O
]	O
-10:30	O
-	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
640	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
4861	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1844	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2184-6-28	O
**	O
]	O
3:00	O
.	O
The	O
Brain	O
[	O
**	O
Hospital	O
341	O
**	O
]	O
Clinic	O
is	O
located	O
on	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
of	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
,	O
in	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Building	O
.	O
Their	O
phone	O
number	O
is	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1844	O
**	O
]	O
.	O
Please	O
call	O
if	O
you	O
need	O
to	O
change	O
your	O
appointment	O
,	O
or	O
require	O
additional	O
directions	O
.	O
[	O
**	O
First	O
Name7	O
(	O
NamePattern1	O
)	O
1569	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
5122	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2184-6-9	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2182-12-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2182-12-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2115-4-23	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Ace	B-Drug
Inhibitors	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1505	O
**	O
]	O
Chief	O
Complaint	O
:	O
Dyspnea	O
on	O
exertion	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2182-12-3	O
**	O
]	O
Aortic	O
Valve	O
Replacement	O
(	O
21	O
mm	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
923	O
**	O
]	O
tissue	O
)	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
67	O
year	O
old	O
female	O
with	O
known	O
history	O
of	O
aortic	O
stenosis	O
that	O
is	O
followed	O
by	O
serial	O
echocardiograms	O
.	O
She	O
complains	O
of	O
progressively	O
worsening	O
dyspnea	O
on	O
exertion	O
.	O
Cardiac	O
cath	O
revealed	O
no	O
coronary	O
artery	O
disease	O
.	O
She	O
is	O
now	O
scheduled	O
for	O
aortic	O
valve	O
replacement	O
this	O
month	O
.	O
Overall	O
she	O
feels	O
well	O
and	O
has	O
no	O
major	O
change	O
in	O
symptoms	O
from	O
[	O
**	O
2182-8-1	O
**	O
]	O
.	O
Past	O
Medical	O
History	O
:	O
Past	O
Medical	O
History	O
:	O
Aotic	O
Stenosis	O
Hypercholesterolemia	O
Hypertension	O
Hyperthyroidism	O
with	O
thyroid	O
nodule	O
Nonspecific	O
Thrombocytopenia	O
(	O
mild	O
)	O
Obesity	O
Depression	O
Meralgia	O
paresthetica	O
Asthma	O
GERD	O
Dysglycemia	O
Thoracic	O
back	O
pain	O
/	O
sciatica	O
SVT	O
(	O
episode	O
during	O
stress	O
test	O
)	O
remote	O
esopagitis	O
Past	O
Surgical	O
History	O
:	O
s	O
/	O
p	O
Tonsillectomy	O
Social	O
History	O
:	O
Race	O
:	O
Caucasian	O
Dental	O
:	O
clearance	O
letter	O
obtained	O
Lives	O
with	O
:	O
Daughter	O
Contact	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
88836	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
Phone	O
#	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
88837	O
**	O
]	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
27057	O
**	O
]	O
tion	O
:	O
Runs	O
coat	O
checking	O
business	O
(	O
has	O
summer	O
off	O
)	O
Cigarettes	O
:	O
Smoked	O
no	O
[	O
]	O
yes	O
[	O
X	O
]	O
last	O
cigarette	O
[	O
**	O
2147	O
**	O
]	O
Hx	O
:	O
1.5	O
ppd	O
Other	O
Tobacco	O
use	O
:	O
no	O
ETOH	O
:	O
<	O
1	O
drink	O
/	O
week	O
[	O
]	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
drinks	O
/	O
week	O
[	O
X	O
]	O
>	O
8	O
drinks	O
/	O
week	O
[	O
]	O
Illicit	O
drug	O
use	O
:	O
Denies	O
Family	O
History	O
:	O
Family	O
History	O
:	O
Denies	O
premature	O
coronary	O
artery	O
disease	O
Physical	O
Exam	O
:	O
VS	O
:	O
B	O
/	O
P	O
Right	O
:	O
118/66	O
Left	O
:	O
116/60	O
Height	O
:	O
5	O
'	O
7	O
[	O
**	O
12	O
-	O
2	O
**	O
]	O
"	O
Weight	O
:	O
190	O
lbs	O
General	O
:	O
WDWN	O
female	O
in	O
NAD	O
Skin	O
:	O
Dry	O
[	O
]	O
x	O
intact	O
[	O
x	O
]	O
HEENT	O
:	O
PERRLA	O
[	O
x	O
]	O
EOMI	O
[	O
x	O
]	O
anicteric	O
sclera	O
;	O
OP	O
unremarkable	O
Neck	O
:	O
Supple	O
[	O
x	O
]	O
Full	O
ROM	O
[	O
]	O
no	O
JVD	O
Chest	O
:	O
Lungs	O
clear	O
bilaterally	O
[	O
x	O
]	O
Heart	O
:	O
RRR	O
[	O
x	O
]	O
Irregular	O
[	O
]	O
Murmur	O
[	O
x	O
]	O
grade	O
___	O
3/6	O
systolic	O
radiates	O
throughout	O
chest	O
to	O
carotids	O
___	O
Abdomen	O
:	O
Soft	O
[	O
x	O
]	O
non-distended	O
[	O
x	O
]	O
non-tender	O
[	O
x	O
]	O
+	O
BS	O
[	O
x	O
]	O
no	O
HSM	O
Extremities	O
:	O
Warm	O
[	O
x	O
]	O
,	O
well	O
-	O
perfused	O
[	O
x	O
]	O
Edema	O
none	O
Varicosities	O
:	O
R	O
lat	O
thigh	O
Neuro	O
:	O
Grossly	O
intact	O
[	O
x	O
]	O
;	O
nonfocal	O
exam	O
;	O
MAE	O
[	O
**	O
4	O
-	O
5	O
**	O
]	O
strengths	O
Pulses	O
:	O
Femoral	O
Right	O
:	O
2	O
+	O
Left	O
:	O
2	O
+	O
DP	O
Right	O
:	O
1	O
+	O
Left	O
:	O
1	O
+	O
PT	O
[	O
**	O
Name	O
(	O
NI	O
)	O
167	O
**	O
]	O
:	O
NP	O
Left	O
:	O
NP	O
Radial	O
Right	O
:	O
2	O
+	O
Left	O
:	O
2	O
+	O
Carotid	O
Bruit	O
-	O
murmur	O
radiates	O
to	O
carotids	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
[	O
**	O
2182-12-3	O
**	O
]	O
10:31	O
AM	O
WBC	O
-	O
8.5	O
#	O
RBC	O
-	O
2.67	O
*	O
#	O
HGB	O
-	O
7.8	O
*	O
#	O
HCT	O
-	O
23.7	O
*	O
#	O
MCV	O
-	O
89	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
32.7	O
RDW	O
-	O
13.7	O
[	O
**	O
2182-12-3	O
**	O
]	O
12:15	O
PM	O
PT	O
-	O
11.6	O
PTT	O
-	O
30.5	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2182-12-3	O
**	O
]	O
12:15	O
PM	O
WBC	O
-	O
7.0	O
RBC	O
-	O
3.02	O
*	O
HGB	O
-	O
9.0	O
*	O
HCT	O
-	O
27.0	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
29.9	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
13.8	O
[	O
**	O
2182-12-3	O
**	O
]	O
12:15	O
PM	O
UREA	O
N	O
-	O
12	O
CREAT	O
-	O
0.6	O
SODIUM	O
-	O
143	O
POTASSIUM	O
-	O
4.0	O
CHLORIDE	O
-	O
114	O
*	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
9	O
Discharge	O
labs	O
:	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ECHOCARDIOGRAPHY	O
REPORT	O
Echocardiographic	O
Measurements	O
Results	O
Measurements	O
Normal	O
Range	O
Left	O
Ventricle	O
-	O
Ejection	O
Fraction	O
:	O
60	O
%	O
to	O
65	O
%	O
>	O
=	O
55	O
%	O
Aorta	O
-	O
Ascending	O
:	O
3.4	O
cm	O
<	O
=	O
3.4	O
cm	O
Aortic	O
Valve	O
-	O
Peak	O
Velocity	O
:	O
*	O
4.2	O
m	O
/	O
sec	O
<	O
=	O
2.0	O
m	O
/	O
sec	O
Aortic	O
Valve	O
-	O
Peak	O
Gradient	O
:	O
*	O
81	O
mm	O
Hg	O
<	O
20	O
mm	O
Hg	O
Aortic	O
Valve	O
-	O
LVOT	O
diam	O
:	O
2.0	O
cm	O
Aortic	O
Valve	O
-	O
Valve	O
Area	O
:	O
*	O
0.9	O
cm2	O
>	O
=	O
3.0	O
cm2	O
Findings	O
LEFT	O
ATRIUM	O
:	O
Mild	O
LA	O
enlargement	O
.	O
No	O
spontaneous	O
echo	O
contrast	O
or	O
thrombus	O
in	O
the	O
body	O
of	O
the	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
LAA	O
.	O
No	O
mass	O
/	O
thrombus	O
in	O
the	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
LAA	O
.	O
Good	O
(	O
>	O
20	O
cm	O
/	O
s	O
)	O
LAA	O
ejection	O
velocity	O
.	O
No	O
thrombus	O
in	O
the	O
LAA	O
.	O
RIGHT	O
ATRIUM	O
/	O
INTERATRIAL	O
SEPTUM	O
:	O
Normal	O
RA	O
size	O
.	O
No	O
ASD	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
LEFT	O
VENTRICLE	O
:	O
Severe	O
symmetric	O
LVH	O
.	O
Normal	O
LV	O
cavity	O
size	O
.	O
Overall	O
normal	O
LVEF	O
(	O
>	O
55	O
%	O
)	O
.	O
RIGHT	O
VENTRICLE	O
:	O
Normal	O
RV	O
free	O
wall	O
thickness	O
.	O
Normal	O
RV	O
chamber	O
size	O
.	O
Normal	O
RV	O
systolic	O
function	O
.	O
AORTA	O
:	O
Normal	O
aortic	O
diameter	O
at	O
the	O
sinus	O
level	O
.	O
Normal	O
ascending	O
aorta	O
diameter	O
.	O
Normal	O
aortic	O
arch	O
diameter	O
.	O
Normal	O
descending	O
aorta	O
diameter	O
.	O
Simple	O
atheroma	O
in	O
descending	O
aorta	O
.	O
AORTIC	O
VALVE	O
:	O
Three	O
aortic	O
valve	O
leaflets	O
.	O
Severely	O
thickened	O
/	O
deformed	O
aortic	O
valve	O
leaflets	O
.	O
No	O
masses	O
or	O
vegetations	O
on	O
aortic	O
valve	O
.	O
Severe	O
AS	O
(	O
area	O
0.8	O
-	O
1.0	O
cm2	O
)	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
AR	O
.	O
MITRAL	O
VALVE	O
:	O
Moderate	O
mitral	O
annular	O
calcification	O
.	O
No	O
MS.	O
Moderate	O
(	O
2	O
+	O
)	O
MR.	O
TRICUSPID	O
VALVE	O
:	O
Normal	O
tricuspid	O
valve	O
leaflets	O
with	O
trivial	O
TR	O
.	O
PULMONIC	O
VALVE	O
/	O
PULMONARY	O
ARTERY	O
:	O
Normal	O
pulmonic	O
valve	O
leaflet	O
.	O
No	O
PS	O
.	O
Physiologic	O
PR	O
.	O
PERICARDIUM	O
:	O
Trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
GENERAL	O
COMMENTS	O
:	O
The	O
patient	O
was	O
under	O
general	O
anesthesia	O
throughout	O
the	O
procedure	O
.	O
The	O
patient	O
received	O
antibiotic	I-Drug
prophylaxis	I-Reason
.	O
The	O
TEE	O
probe	O
was	O
passed	O
with	O
assistance	O
from	O
the	O
anesthesioology	O
staff	O
using	O
a	O
laryngoscope	O
.	O
No	O
TEE	O
related	O
complications	O
.	O
Results	O
were	O
personally	O
reviewed	O
with	O
the	O
MD	O
caring	O
for	O
the	O
patient	O
.	O
REGIONAL	O
LEFT	O
VENTRICULAR	O
WALL	O
MOTION	O
:	O
N	O
=	O
Normal	O
,	O
H	O
=	O
Hypokinetic	O
,	O
A	O
=	O
Akinetic	O
,	O
D	O
=	O
Dyskinetic	O
Conclusions	O
Pre-CPB	O
:	O
1	O
.	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
No	O
spontaneous	O
echo	O
contrast	O
or	O
thrombus	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
No	O
mass	O
/	O
thrombus	O
is	O
seen	O
in	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
No	O
thrombus	O
is	O
seen	O
in	O
the	O
left	O
atrial	O
appendage	O
.	O
2	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
3	O
.	O
There	O
is	O
severe	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
4	O
.	O
The	O
right	O
ventricular	O
free	O
wall	O
thickness	O
is	O
normal	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
with	O
normal	O
free	O
wall	O
contractility	O
.	O
5	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
6	O
.	O
There	O
are	O
three	O
aortic	O
valve	O
leaflets	O
.	O
There	O
was	O
minimal	O
movement	O
of	O
the	O
NCC	O
and	O
RCC	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
severely	O
thickened	O
/	O
deformed	O
.	O
No	O
masses	O
or	O
vegetations	O
are	O
seen	O
on	O
the	O
aortic	O
valve	O
.	O
There	O
is	O
severe	O
aortic	O
valve	O
stenosis	O
(	O
valve	O
area	O
0.8	O
-	O
1.0	O
cm2	O
)	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
7	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
8	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
was	O
notified	O
in	O
person	O
of	O
the	O
results	O
.	O
Post-CPB	O
:	O
On	O
infusion	O
of	O
phenylephrine	O
,	O
AV	O
-	O
pacing	O
for	O
slow	O
CHB	O
(	O
initially	O
)	O
.	O
Well	O
-	O
seated	O
bioprosthetic	O
valve	O
in	O
aortic	O
position	O
with	O
trivial	O
valvular	O
AI	O
,	O
transvalvular	O
gradient	O
measured	O
at	O
15mmHg	O
.	O
Preserved	O
biventricular	O
systolic	O
function	O
,	O
1	O
+	O
MR	O
,	O
aortic	O
contour	O
normal	O
post-decannulation	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Ms	O
[	O
**	O
Known	O
lastname	O
88836	O
**	O
]	O
was	O
a	O
same	O
day	O
admission	O
to	O
the	O
operating	O
room	O
for	O
a	O
scheduled	O
aortic	O
valve	O
replacement	O
.	O
Please	O
see	O
the	O
operative	O
report	O
for	O
details	O
,	O
in	O
summary	O
she	O
had	O
:	O
Aortic	O
valve	O
replacement	O
with	O
a	O
21	O
mm	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
923	O
**	O
]	O
tissue	O
valve	O
.	O
Her	O
cardiopulmonary	O
bypass	O
time	O
was	O
57	O
minutes	O
with	O
a	O
crossclamp	O
time	O
of	O
42	O
minutes	O
.	O
She	O
tolerated	O
the	O
operation	O
well	O
and	O
was	O
transferred	O
from	O
the	O
operating	O
room	O
to	O
the	O
cardiac	O
surgery	O
ICU	O
in	O
stable	O
condition	O
with	O
minimal	O
vasopressor	O
support	O
.	O
She	O
remained	O
hemodynamically	O
stable	O
in	O
the	O
immediate	O
post-op	O
period	O
,	O
her	O
anesthesia	O
was	O
reversed	O
,	O
she	O
woke	O
neurologically	O
intact	O
and	O
was	O
extubated	O
.	O
On	O
POD1	O
she	O
was	O
transferred	O
from	O
the	O
cardiac	O
surgery	O
ICU	O
too	O
the	O
stepdown	O
floor	O
for	O
continued	O
post-op	O
care	O
.	O
All	O
tubes	O
lines	O
and	O
drains	O
were	O
removed	O
per	O
cardiac	O
surgery	O
protocol	O
.	O
She	O
was	O
transfused	O
one	O
unit	O
PRBC	I-Drug
for	O
post-op	B-Reason
anemia	I-Reason
.	O
She	O
reports	O
postoperative	O
intermittent	O
visual	O
changes	O
,	O
lasting	O
only	O
seconds	O
.	O
No	O
focal	O
defecit	O
appreciated	O
.	O
As	O
discussed	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
Ms.	O
[	O
**	O
Known	O
lastname	O
88836	O
**	O
]	O
will	O
alert	O
the	O
cardiac	O
surgery	O
service	O
if	O
these	O
symptoms	O
persist	O
.	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
office	O
will	O
also	O
follow	O
up	O
in	O
1	O
week	O
after	O
discharge	O
to	O
ascertain	O
whether	O
Ms.	O
[	O
**	O
Known	O
lastname	O
88836	O
**	O
]	O
will	O
require	O
an	O
outpatient	O
eval	O
by	O
Neuro	O
and	O
/	O
or	O
Opthamologist	O
.	O
The	O
remainder	O
of	O
her	O
hospital	O
course	O
was	O
uneventful	O
.	O
She	O
worked	O
with	O
nursing	O
and	O
physical	O
therapy	O
to	O
increase	O
her	O
strength	O
and	O
endurance	O
.	O
By	O
POD	O
#	O
5	O
she	O
was	O
ready	O
for	O
discharge	O
home	O
with	O
visiting	O
nurses	O
.	O
She	O
is	O
to	O
follow	O
up	O
with	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
1week	O
at	O
wound	O
clinic	O
and	O
at	O
1	O
month	O
in	O
cardiac	O
surgery	O
clinic	O
.	O
Medications	O
on	O
Admission	O
:	O
METHIMAZOLE	I-Drug
-	O
15	O
mg	O
once	O
a	O
day	O
METOPROLOL	I-Drug
SUCCINATE	O
-50	O
mg	O
Extended	O
Release	O
once	O
a	O
day	O
ROSUVASTATIN	I-Drug
5	O
mg	O
once	O
a	O
day	O
CALCIUM	I-Drug
CARBONATE	O
-	O
500	O
mg	O
calcium	I-Drug
(	O
1,250	O
mg	O
)	O
-	O
1	O
Tablet	O
once	O
a	O
day	O
CHOLECALCIFEROL	I-Drug
1,000	O
unit	O
once	O
a	O
day	O
LYSINE	I-Drug
-500	O
mg	O
once	O
a	O
day	O
Discharge	O
Medications	O
:	O
1	O
.	O
metoprolol	I-Drug
tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
potassium	B-Drug
chloride	I-Drug
10	O
mEq	O
Tablet	O
Extended	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Extended	O
Release	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
5	O
days	O
.	O
Disp	O
:	O
*	O
20	O
Tablet	O
Extended	O
Release	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
furosemide	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
for	O
5	O
days	O
.	O
Disp	O
:	O
*	O
10	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
4	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
ranitidine	I-Drug
HCl	O
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
rosuvastatin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
tramadol	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
45	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
methimazole	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
All	O
Care	O
VNA	O
of	O
Greater	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Aortic	O
Stenosis	O
s	O
/	O
p	O
AVR	O
PMH	O
:	O
Hypercholesterolemia	O
Hypertension	O
Hyperthyroidism	O
with	O
thyroid	O
nodule	O
Nonspecific	O
Thrombocytopenia	O
(	O
mild	O
)	O
Obesity	O
Depression	O
Meralgia	O
paresthetica	O
Asthma	O
GERD	O
Dysglycemia	O
Thoracic	O
back	O
pain	O
/	O
sciatica	O
SVT	O
(	O
episode	O
during	O
stress	O
test	O
)	O
remote	O
esopagitis	O
PSH	O
:	O
Tonsillectomy	O
Discharge	O
Condition	O
:	O
Alert	O
and	O
oriented	O
x3	O
nonfocal	O
Ambulating	O
with	O
steady	O
gait	O
Incisional	B-Reason
pain	I-Reason
managed	O
with	O
oral	O
analgesia	I-Drug
Incisions	O
:	O
Sternal	O
-	O
healing	O
well	O
,	O
no	O
erythema	O
or	O
drainage	O
Leg	O
Edema	O
:	O
Discharge	O
Instructions	O
:	O
Please	O
shower	O
daily	O
including	O
washing	O
incisions	O
gently	O
with	O
mild	O
soap	O
,	O
no	O
baths	O
or	O
swimming	O
until	O
cleared	O
by	O
surgeon	O
.	O
Look	O
at	O
your	O
incisions	O
daily	O
for	O
redness	O
or	O
drainage	O
Please	O
NO	O
lotions	O
,	O
cream	O
,	O
powder	O
,	O
or	O
ointments	O
to	O
incisions	O
Each	O
morning	O
you	O
should	O
weigh	O
yourself	O
and	O
then	O
in	O
the	O
evening	O
take	O
your	O
temperature	O
,	O
these	O
should	O
be	O
written	O
down	O
on	O
the	O
chart	O
No	O
driving	O
for	O
approximately	O
one	O
month	O
and	O
while	O
taking	O
narcotics	I-Drug
,	O
will	O
be	O
discussed	O
at	O
follow	O
up	O
appointment	O
with	O
surgeon	O
when	O
you	O
will	O
be	O
able	O
to	O
drive	O
No	O
lifting	O
more	O
than	O
10	O
pounds	O
for	O
10	O
weeks	O
Please	O
call	O
with	O
any	O
questions	O
or	O
concerns	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
Females	O
:	O
Please	O
wear	O
bra	O
to	O
reduce	O
pulling	O
on	O
incision	O
,	O
avoid	O
rubbing	O
on	O
lower	O
edge	O
**	O
Please	O
call	O
cardiac	O
surgery	O
office	O
with	O
any	O
questions	O
or	O
concerns	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
.	O
Answering	O
service	O
will	O
contact	O
on	O
call	O
person	O
during	O
off	O
hours	O
**	O
Followup	O
Instructions	O
:	O
You	O
are	O
scheduled	O
for	O
the	O
following	O
appointments	O
:	O
Wound	O
Check	O
on	O
[	O
**	O
12	O
-	O
12	O
**	O
]	O
at	O
11:00	O
am	O
[	O
**	O
Hospital	O
**	O
]	O
Medical	O
Office	O
Building	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1504	O
**	O
]	O
Surgeon	O
:	O
Dr	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
at	O
1:15	O
pm	O
[	O
**	O
Hospital	O
**	O
]	O
Medical	O
Office	O
Building	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1504	O
**	O
]	O
Cardiologist	O
:	O
Dr	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
88838	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1923	O
**	O
]	O
on	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
at	O
2:30	O
pm	O
Please	O
call	O
to	O
schedule	O
appointment	O
with	O
:	O
Primary	O
Care	O
:	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
L.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
88839	O
**	O
]	O
in	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
weeks	O
**	O
Please	O
call	O
cardiac	O
surgery	O
office	O
with	O
any	O
questions	O
or	O
concerns	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
.	O
Answering	O
service	O
will	O
contact	O
on	O
call	O
person	O
during	O
off	O
hours	O
**	O
Completed	O
by	O
:[	O
**	O
2182-12-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2109-7-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2109-8-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2053-6-5	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
[	O
**	O
Doctor	O
Last	O
Name	O
1181	O
**	O
]	O
MEDICINE	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
This	O
is	O
a	O
56	O
-	O
year	O
-	O
old	O
white	O
female	O
with	O
a	O
history	O
of	O
right	O
frontal	O
craniotomy	O
on	O
[	O
**	O
2109-7-1	O
**	O
]	O
,	O
for	O
a	O
dysembryoplastic	O
angioneural	O
epithelial	O
lesion	O
with	O
features	O
of	O
an	O
oligodendroglioma	O
who	O
was	O
started	O
on	O
Dilantin	I-Drug
postoperatively	O
for	O
seizure	B-Reason
prophylaxis	I-Reason
and	O
was	O
subsequently	O
developed	O
eye	B-Ade
discharge	I-Ade
and	O
was	O
seen	O
by	O
an	O
optometrist	O
who	O
treated	O
it	O
with	O
sulfate	I-Drug
ophthalmic	O
drops	O
.	O
The	O
patient	O
then	O
developed	O
oral	B-Ade
sores	I-Ade
and	O
rash	I-Ade
in	O
the	O
chest	O
the	O
night	O
before	O
admission	O
which	O
rapidly	O
spread	O
to	O
the	O
face	O
,	O
trunk	O
,	O
and	O
upper	O
extremities	O
within	O
the	O
last	O
24	O
hours	O
.	O
The	O
patient	O
was	O
unable	O
to	O
eat	O
secondary	O
to	O
mouth	O
pain	O
.	O
She	O
had	O
fevers	I-Ade
,	O
weakness	I-Ade
,	O
and	O
diarrhea	I-Ade
.	O
There	O
were	O
no	O
genital	O
the	O
morning	O
of	O
[	O
**	O
7	O
-	O
20	O
**	O
]	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Hypercholesterolemia	O
.	O
2	O
.	O
Benign	O
right	O
frontal	O
cystic	O
tumor	O
status	O
post	O
right	O
frontal	O
craniotomy	O
on	O
[	O
**	O
2109-7-1	O
**	O
]	O
.	O
ALLERGIES	O
:	O
NO	O
KNOWN	O
DRUG	O
ALLERGIES	O
.	O
MEDICATIONS	O
:	O
Lipitor	I-Drug
,	O
Tylenol	B-Drug
with	I-Drug
Codeine	I-Drug
,	O
Dilantin	I-Drug
,	O
previously	O
on	O
Decadron	I-Drug
q.i.d.	O
tapered	O
over	O
one	O
week	O
and	O
discontinued	O
a	O
week	O
ago	O
.	O
SOCIAL	O
HISTORY	O
:	O
The	O
patient	O
lives	O
with	O
her	O
husband	O
,	O
daughter	O
,	O
and	O
son	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
smoking	O
or	O
ethanol	O
use	O
history	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
Vital	O
signs	O
:	O
T	O
-	O
max	O
104.3	O
??????	O
,	O
currently	O
100.8	O
??????	O
,	O
heart	O
rate	O
107	O
-	O
110	O
,	O
blood	O
pressure	O
110/27	O
,	O
respirations	O
15	O
-	O
20	O
,	O
oxygen	O
saturation	O
98	O
%	O
on	O
room	O
air	O
.	O
General	O
:	O
The	O
patient	O
was	O
an	O
alert	O
,	O
ill	O
-	O
appearing	O
woman	O
with	O
postsurgical	O
occiput	O
.	O
Head	O
and	O
neck	O
:	O
Injected	O
conjunctivae	O
,	O
greenish	O
ocular	O
discharge	O
,	O
ulcerative	O
oral	O
lesions	O
.	O
Cardiovascular	O
:	O
Regular	O
rhythm	O
.	O
Rapid	O
rate	O
.	O
No	O
murmurs	O
.	O
Pulmonary	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
.	O
Abdomen	O
:	O
Normoactive	O
bowel	O
sounds	O
.	O
Soft	O
,	O
nontender	O
,	O
nondistended	O
.	O
Extremities	O
:	O
No	O
edema	O
.	O
Skin	O
:	O
Diffuse	O
erythema	O
and	O
pustules	O
on	O
the	O
face	O
.	O
Patulous	O
pustules	O
on	O
the	O
chest	O
,	O
back	O
,	O
and	O
proximal	O
upper	O
extremities	O
.	O
GU	O
:	O
No	O
genital	O
lesions	O
.	O
LABORATORY	O
DATA	O
:	O
Hematocrit	O
34.1	O
,	O
WBC	O
10.3	O
,	O
platelet	O
count	O
291,000	O
,	O
differential	O
of	O
87	O
neutrophils	O
,	O
0	O
bands	O
;	O
sodium	O
133	O
,	O
potassium	O
3.8	O
,	O
chloride	O
93	O
,	O
CO2	O
21	O
,	O
BUN	O
17	O
,	O
creatinine	O
0.9	O
,	O
glucose	O
121	O
;	O
ALT	O
39	O
,	O
AST	O
42	O
,	O
LDH	O
434	O
,	O
amylase	O
63	O
,	O
albumin	O
3.4	O
,	O
total	O
bilirubin	O
0.3	O
;	O
urinalysis	O
with	O
positive	O
ketones	O
,	O
negative	O
nitrites	O
;	O
urine	O
culture	O
pending	O
;	O
blood	O
cultures	O
times	O
two	O
pending	O
;	O
conjunctival	O
culture	O
pending	O
.	O
HOSPITAL	O
COURSE	O
:	O
Given	O
the	O
patient	O
's	O
severe	O
exfoliative	O
skin	O
involvement	O
with	O
rapid	O
progression	O
and	O
extensive	O
involvement	O
of	O
the	O
body	O
,	O
she	O
was	O
admitted	O
to	O
the	O
Medical	O
Intensive	O
Care	O
Unit	O
for	O
close	O
monitoring	O
.	O
She	O
was	O
started	O
on	O
prophylactic	O
Oxacillin	I-Drug
to	O
cover	O
skin	O
flora	O
,	O
and	O
Dermatology	O
was	O
consulted	O
along	O
with	O
Neurology	O
and	O
Ophthalmology	O
for	O
the	O
ophthalmic	I-Reason
involvement	O
.	O
The	O
patient	O
's	O
course	O
in	O
the	O
Intensive	O
Care	O
Unit	O
was	O
uneventful	O
,	O
and	O
she	O
was	O
discharged	O
to	O
the	O
floor	O
with	O
very	O
close	O
monitoring	O
which	O
included	O
q.	O
1	O
hour	O
Pred	B-Drug
Forte	I-Drug
application	O
to	O
the	O
eye	O
and	O
close	O
consultation	O
with	O
Ophthalmology	O
.	O
With	O
regard	O
to	O
her	O
skin	O
lesions	O
,	O
they	O
continued	O
exfoliate	O
over	O
the	O
next	O
couple	O
of	O
days	O
,	O
and	O
her	O
skin	O
care	O
included	O
frequent	O
Vaseline	B-Drug
hydrated	I-Drug
petroleum	I-Drug
application	O
to	O
decrease	B-Reason
insensible	I-Reason
losses	I-Reason
.	O
The	O
patient	O
's	O
intake	O
and	O
output	O
were	O
closely	O
monitored	O
and	O
replaced	O
appropriately	O
;	O
however	O
,	O
the	O
intensive	O
nursing	O
care	O
requirement	O
made	O
it	O
difficult	O
for	O
the	O
patient	O
to	O
receive	O
adequate	O
on	O
the	O
floor	O
,	O
and	O
therefore	O
,	O
she	O
was	O
transferred	O
to	O
the	O
Medical	O
Intensive	O
Care	O
Unit	O
again	O
for	O
frequent	O
ophthalmic	O
applications	O
and	O
skin	O
care	O
.	O
While	O
in	O
the	O
MICU	O
,	O
the	O
patient	O
continued	O
to	O
have	O
meticulous	O
skin	O
care	O
and	O
eye	O
care	O
.	O
The	O
skin	O
lesions	O
continued	O
to	O
desquamate	O
and	O
exfoliate	O
which	O
is	O
the	O
natural	O
progression	O
of	O
this	O
disease	O
.	O
She	O
began	O
to	O
have	O
involvement	O
of	O
the	O
genital	O
area	O
with	O
continued	O
desquamation	O
of	O
the	O
exfoliative	O
lesions	O
.	O
Her	O
course	O
in	O
the	O
Intensive	O
Care	O
Unit	O
within	O
the	O
next	O
8	O
-	O
10	O
days	O
was	O
a	O
slow	O
but	O
gradual	O
improvement	O
from	O
a	O
dermatologic	O
and	O
ophthalmologic	O
standpoint	O
.	O
From	O
a	O
cardiovascular	O
standpoint	O
,	O
she	O
was	O
in	O
sinus	O
tachycardia	O
which	O
was	O
felt	O
to	O
be	O
secondary	O
to	O
her	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
syndrome	O
leading	O
to	O
dehydration	O
and	O
insensible	O
fluid	O
losses	O
.	O
While	O
in	O
the	O
Intensive	O
Care	O
Unit	O
,	O
she	O
was	O
also	O
found	O
to	O
be	O
mildly	O
hypoxic	O
which	O
is	O
likely	O
secondary	O
to	O
atelectasis	O
because	O
of	O
the	O
patient	O
's	O
immobility	O
.	O
Lower	O
extremity	O
Dopplers	O
were	O
also	O
done	O
,	O
and	O
no	O
deep	O
venous	O
thromboses	O
were	O
found	O
.	O
From	O
and	O
Infectious	O
Disease	O
standpoint	O
,	O
the	O
patient	O
was	O
started	O
on	O
intravenous	O
Oxacillin	I-Drug
empirically	O
.	O
Blood	O
cultures	O
on	O
the	O
5th	O
was	O
with	O
no	O
growth	O
times	O
two	O
;	O
however	O
,	O
one	O
bottle	O
from	O
her	O
PICC	O
line	O
grew	O
out	O
gram	O
-	O
positive	O
cocci	O
on	O
[	O
**	O
7	O
-	O
27	O
**	O
]	O
.	O
She	O
was	O
started	O
on	O
a	O
course	O
of	O
Vancomycin	I-Drug
.	O
Subsequently	O
the	O
organism	O
was	O
found	O
to	O
be	O
CNS	O
with	O
Corynebacterium	O
,	O
and	O
Vancomycin	I-Drug
was	O
discontinued	O
prior	O
to	O
transfer	O
to	O
the	O
floor	O
on	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
.	O
The	O
patient	O
's	O
course	O
on	O
the	O
floor	O
was	O
uncomplicated	O
with	O
continued	O
improvement	O
.	O
Dermatology	O
:	O
The	O
patient	O
,	O
as	O
indicated	O
,	O
improved	O
dramatically	O
from	O
her	O
presentation	O
to	O
the	O
time	O
of	O
discharge	O
.	O
Her	O
exfoliative	O
lesions	O
healed	O
over	O
the	O
course	O
of	O
this	O
admission	O
.	O
Her	O
skin	O
care	O
requirements	O
decreased	O
to	O
Petroleum	I-Drug
jelly	O
twice	O
a	O
day	O
at	O
the	O
time	O
of	O
discharge	O
.	O
She	O
was	O
able	O
to	O
take	O
in	O
oral	O
foot	O
without	O
problems	O
.	O
Ophthalmology	O
:	O
The	O
patient	O
's	O
eye	O
care	O
requirement	O
improved	O
markedly	O
.	O
She	O
was	O
able	O
to	O
open	O
her	O
eyes	O
and	O
use	O
her	O
vision	O
without	O
significant	O
problems	O
at	O
the	O
time	O
of	O
discharge	O
.	O
Her	O
Pred	B-Drug
Forte	I-Drug
was	O
discontinued	O
on	O
the	O
day	O
of	O
discharge	O
,	O
and	O
she	O
is	O
to	O
have	O
follow	O
-	O
up	O
with	O
Ophthalmology	O
a	O
couple	O
of	O
days	O
after	O
discharge	O
.	O
Fluid	O
,	O
electrolytes	O
,	O
and	O
nutrition	O
:	O
On	O
admission	O
the	O
patient	O
was	O
begun	O
on	O
TPN	O
for	O
nutritional	O
support	O
.	O
As	O
the	O
patient	O
improved	O
from	O
a	O
medical	O
perspective	O
,	O
her	O
TPN	O
was	O
weaned	O
,	O
and	O
at	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
was	O
taking	O
adequate	O
p.o.	O
with	O
supplementation	O
of	O
Boost	I-Drug
.	O
Infectious	B-Reason
Disease	I-Reason
:	O
At	O
the	O
time	O
of	O
admission	O
,	O
she	O
was	O
started	O
on	O
empiric	O
antibiotics	I-Drug
and	O
placed	O
on	O
contact	O
precautions	O
secondary	O
to	O
her	O
extensive	O
skin	O
lesions	O
;	O
however	O
,	O
as	O
the	O
patient	O
improved	O
throughout	O
the	O
course	O
of	O
this	O
admission	O
,	O
contact	O
precautions	O
were	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
home	O
with	O
services	O
.	O
Cardiology	O
/	O
Pulmonology	O
:	O
The	O
patient	O
was	O
tachycardiac	O
throughout	O
this	O
admission	O
which	O
was	O
attributed	O
to	O
her	O
fluid	O
losses	O
secondary	O
to	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
syndrome	O
;	O
however	O
,	O
given	O
the	O
patient	O
's	O
immobility	O
throughout	O
the	O
course	O
of	O
this	O
admission	O
,	O
a	O
CT	O
angiogram	O
was	O
performed	O
to	O
evaluate	O
for	O
possible	O
pulmonary	O
embolism	O
,	O
and	O
none	O
were	O
found	O
.	O
Neurology	O
:	O
The	O
patient	O
has	O
a	O
history	O
of	O
cystic	B-Reason
tumor	I-Reason
status	I-Reason
post	O
resection	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
205	O
**	O
]	O
of	O
this	O
year	O
and	O
was	O
started	O
on	O
prophylactic	O
Dilantin	I-Drug
leading	O
to	O
presumed	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
syndrome	O
.	O
At	O
the	O
time	O
of	O
this	O
admission	O
,	O
the	O
patient	O
's	O
Dilantin	I-Drug
was	O
discontinued	O
,	O
and	O
no	O
other	O
anticonvulsants	I-Drug
were	O
started	O
,	O
given	O
the	O
patient	O
's	O
risk	O
of	O
seizures	O
several	O
weeks	O
after	O
her	O
surgery	O
was	O
unlikely	O
.	O
This	O
decision	O
was	O
made	O
with	O
the	O
support	O
of	O
her	O
neurosurgeon	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1338	O
**	O
]	O
.	O
Five	O
days	O
before	O
discharge	O
,	O
the	O
patient	O
did	O
have	O
a	O
syncopal	O
event	O
while	O
in	O
the	O
bathroom	O
showering	O
with	O
the	O
help	O
of	O
a	O
nursing	O
aide	O
.	O
The	O
likely	O
etiology	O
of	O
this	O
is	O
orthostatic	O
hypotension	O
from	O
her	O
fluid	O
losses	O
;	O
however	O
,	O
given	O
the	O
patient	O
's	O
neurologic	O
history	O
,	O
Neurology	O
was	O
consulted	O
to	O
evaluate	O
for	O
possible	O
seizure	O
.	O
Neurology	O
's	O
recommendations	O
were	O
to	O
obtain	O
a	O
repeat	O
CT	O
scan	O
which	O
was	O
unchanged	O
from	O
previous	O
showing	O
a	O
right	O
frontal	O
lobe	O
extra-axial	O
hypodensity	O
which	O
was	O
stable	O
.	O
They	O
also	O
recommended	O
repeat	O
MR	O
imaging	O
which	O
was	O
again	O
unremarkable	O
except	O
for	O
a	O
stable	O
extra-axial	O
lesion	O
noted	O
on	O
CT	O
scan	O
.	O
Neurology	O
therefore	O
agrees	O
with	O
the	O
primary	O
team	O
that	O
the	O
syncopal	O
event	O
was	O
likely	O
secondary	O
to	O
a	O
vasovagal	O
reaction	O
.	O
A	O
follow	O
-	O
up	O
MR	O
scan	O
would	O
be	O
recommended	O
with	O
gadolinium	O
to	O
evaluate	O
for	O
the	O
presence	O
of	O
residual	O
tumor	O
.	O
This	O
can	O
be	O
done	O
as	O
an	O
outpatient	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1338	O
**	O
]	O
.	O
Rehabilitation	O
:	O
The	O
patient	O
throughout	O
this	O
admission	O
worked	O
with	O
our	O
physical	O
therapy	O
people	O
and	O
continued	O
to	O
improve	O
with	O
regard	O
to	O
range	O
of	O
motion	O
and	O
strength	O
in	O
the	O
upper	O
and	O
lower	O
extremities	O
,	O
and	O
by	O
the	O
time	O
of	O
discharge	O
,	O
she	O
was	O
ambulating	O
throughout	O
the	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
and	O
around	O
the	O
hospital	O
without	O
problems	O
.	O
She	O
was	O
therefore	O
discharged	O
home	O
without	O
need	O
for	O
Physical	O
Therapy	O
Services	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
has	O
markedly	O
improved	O
from	O
her	O
initial	O
presentation	O
and	O
is	O
to	O
be	O
discharged	O
home	O
with	O
nursing	O
assistance	O
.	O
DISCHARGE	O
STATUS	O
:	O
Markedly	O
improved	O
.	O
DISCHARGE	O
DIAGNOSIS	O
:	O
1	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
syndrome	O
secondary	O
to	O
Dilantin	I-Drug
.	O
2	O
.	O
Status	O
post	O
craniotomy	O
on	O
[	O
**	O
2109-7-1	O
**	O
]	O
,	O
for	O
a	O
cystic	O
cranial	O
lesion	O
,	O
likely	O
dysembryoplastic	O
angioneural	O
epithelial	O
lesion	O
with	O
features	O
consistent	O
with	O
an	O
oligodendroglioma	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
Polysporin	I-Drug
ophthalmology	O
O.U.	O
q.i.d.	O
,	O
hydrated	B-Drug
Petroleum	I-Drug
as	O
needed	O
,	O
Lipitor	I-Drug
10	O
mg	O
p.o.	O
q.d.	O
,	O
Nystatin	I-Drug
,	O
Boost	O
t.i.d.	O
FOLLOW	O
-	O
UP	O
:	O
1	O
.	O
Ophthalmology	O
[	O
**	O
2109-8-20	O
**	O
]	O
,	O
at	O
12:45	O
p.m.	O
2	O
.	O
Primary	O
care	O
physician	O
in	O
two	O
weeks	O
.	O
3	O
.	O
Dermatology	O
as	O
needed	O
.	O
DISCHARGE	O
NOTE	O
:	O
PLEASE	O
NOTE	O
THAT	O
THE	O
PATIENT	O
IS	O
ALLERGIC	O
TO	O
DILANTIN	I-Drug
AND	O
TEGRETOL	I-Drug
GIVEN	O
HER	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
SECONDARY	O
TO	O
DILANTIN	I-Drug
.	O
The	O
patient	O
is	O
recommended	O
to	O
wear	O
an	O
alert	O
bracelet	O
which	O
indicates	O
this	O
reaction	O
.	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
2415	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3474	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
3475	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
40425	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2109-9-3	O
**	O
]	O
12:59	O
T	O
:	O
[	O
**	O
2109-9-3	O
**	O
]	O
12:58	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
99931	O
**	O
]	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
M.D.	O
(	O
cclist	O
)	O

Admission	O
Date	O
:	O
[	O
**	O
2108-2-28	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2108-3-8	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
7333	O
**	O
]	O
Chief	O
Complaint	O
:	O
cardiac	O
arrest	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
PEG	O
,	O
Trach	O
,	O
IR	O
PICC	O
line	O
placeemnt	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
19371	O
**	O
]	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
man	O
with	O
DM2	O
,	O
h	O
/	O
o	O
aortic	O
valve	O
replacement	O
(	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
923	O
**	O
]	O
)	O
,	O
PAD	O
s	O
/	O
p	O
bypass	O
surgery	O
and	O
recurrent	O
LE	O
ulcers	O
who	O
presented	O
to	O
the	O
ED	O
after	O
a	O
cardiac	O
arrest	O
.	O
.	O
Per	O
the	O
family	O
,	O
the	O
pt	O
was	O
eating	O
some	O
pureed	O
foods	O
and	O
complaining	O
of	O
having	O
a	O
choking	O
sensation	O
.	O
The	O
pt	O
's	O
caretaker	O
was	O
on	O
the	O
phone	O
with	O
the	O
pt	O
's	O
primary	O
care	O
doctor	O
when	O
he	O
stopped	O
breathing	O
.	O
The	O
caretaker	O
called	O
EMS	O
,	O
and	O
they	O
arrived	O
within	O
5	O
minutes	O
.	O
He	O
was	O
pulseless	O
and	O
apneic	O
,	O
and	O
CPR	O
was	O
started	O
.	O
He	O
received	O
epinephrine	I-Drug
and	O
atropine	I-Drug
,	O
and	O
his	O
rhythm	O
allegedly	O
converted	O
to	O
PEA	O
.	O
He	O
continued	O
to	O
receive	O
CPR	O
,	O
and	O
an	O
additional	O
round	O
of	O
epinep2hrine	I-Drug
and	O
atropine	I-Drug
were	O
given	O
,	O
and	O
he	O
had	O
ROSC	O
.	O
His	O
rhythm	O
was	O
atrial	O
fibrillation	O
with	O
RVR	O
in	O
the	O
130s	O
.	O
.	O
In	O
the	O
ED	O
,	O
he	O
received	O
vancomycin	I-Drug
,	O
pip	B-Drug
-	I-Drug
tazo	I-Drug
,	O
2.5	O
L	O
NS	I-Drug
,	O
midazolam	I-Drug
,	O
fentanyl	I-Drug
,	O
norepinephrine	I-Drug
and	O
was	O
started	O
on	O
the	O
Arctic	O
Sun	O
therapeutic	O
hypothermia	O
protocol	O
.	O
Of	O
note	O
,	O
he	O
has	O
been	O
on	O
oral	O
antibiotics	I-Drug
for	O
at	O
least	O
the	O
last	O
3	O
weeks	O
,	O
most	O
recently	O
a	O
2	O
-	O
week	O
course	O
of	O
TMP	B-Drug
/	I-Drug
SMX	I-Drug
Past	O
Medical	O
History	O
:	O
Type	O
II	O
Diabetes	O
with	O
neuropathy	O
Coronary	O
artery	O
disease	O
Aortic	O
valve	O
disease	O
,	O
s	O
/	O
p	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
1291	O
**	O
]	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
923	O
**	O
]	O
,	O
anticoagulated	O
Chronic	O
systolic	O
CHF	O
Peripheral	O
arterial	O
disease	O
s	O
/	O
p	O
unsuccessful	O
right	O
fem	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
bypass	O
(	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
)	O
Chronic	O
bilateral	O
foot	O
disease	O
Anemia	O
Social	O
History	O
:	O
Widowed	O
Lives	O
at	O
home	O
with	O
24	O
hr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
care	O
aid	O
s	O
/	O
p	O
discharge	O
from	O
[	O
**	O
Hospital	O
100	O
**	O
]	O
rehab	O
this	O
month	O
Daughter	O
very	O
active	O
in	O
patient	O
's	O
care	O
-	O
Shisa	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
78656	O
**	O
]	O
Denies	O
tobacco	O
or	O
ETOH	O
use	O
Family	O
History	O
:	O
Father	O
died	O
@	O
84	O
yrs	O
Mother	O
died	O
@	O
64	O
complications	O
of	O
DM	O
and	O
CAD	O
Physical	O
Exam	O
:	O
GENERAL	O
:	O
Elderly	O
man	O
,	O
sedated	O
,	O
intubated	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
NECK	O
:	O
JVP	O
of	O
8	O
cm	O
.	O
CARDIAC	O
:	O
II	O
/	O
VI	O
systolic	O
murmur	O
heard	O
best	O
at	O
RUSB	O
,	O
otherwise	O
distant	O
heart	O
sounds	O
LUNGS	O
:	O
slight	O
bilateral	O
ronchi	O
,	O
no	O
wheeze	O
or	O
rales	O
anteriorly	O
ABDOMEN	O
:	O
Soft	O
,	O
NABS	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
No	O
femoral	O
bruits	O
.	O
SKIN	O
:	O
No	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
scars	O
,	O
or	O
xanthomas	O
.	O
NEURO	O
:	O
R	O
pupil	O
5	O
mm	O
and	O
fixed	O
,	O
L	O
pupil	O
3	O
mm	O
and	O
fixed	O
;	O
no	O
corneal	O
reflex	O
;	O
full	O
neuro	O
exam	O
limited	O
by	O
sedation	O
PULSES	O
:	O
Right	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
DP	O
dopplerable	O
Left	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
DP	O
dopplerable	O
Pertinent	O
Results	O
:	O
[	O
**	O
2108-2-28	O
**	O
]	O
10:40	O
AM	O
BLOOD	O
WBC	O
-	O
14.1	O
*	O
RBC	O
-	O
3.72	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
30.5	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
25.5	O
*	O
MCHC	O
-	O
31.1	O
RDW	O
-	O
15.4	O
Plt	O
Ct	O
-	O
280	O
[	O
**	O
2108-2-28	O
**	O
]	O
06:12	O
PM	O
BLOOD	O
WBC	O
-	O
15.6	O
*	O
RBC	O
-	O
3.84	O
*	O
Hgb	O
-	O
9.6	O
*	O
Hct	O
-	O
31.2	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
25.1	O
*	O
MCHC	O
-	O
31.0	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
288	O
[	O
**	O
2108-2-29	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
WBC	O
-	O
11.0	O
RBC	O
-	O
3.48	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
27.3	O
*	O
MCV	O
-	O
78	O
*	O
MCH	O
-	O
26.3	O
*	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
269	O
[	O
**	O
2108-2-29	O
**	O
]	O
01:29	O
PM	O
BLOOD	O
Hct	O
-	O
25.5	O
*	O
[	O
**	O
2108-3-1	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
WBC	O
-	O
11.5	O
*	O
RBC	O
-	O
3.42	O
*	O
Hgb	O
-	O
8.7	O
*	O
Hct	O
-	O
26.6	O
*	O
MCV	O
-	O
78	O
*	O
MCH	O
-	O
25.3	O
*	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
16.1	O
*	O
Plt	O
Ct	O
-	O
253	O
[	O
**	O
2108-3-2	O
**	O
]	O
04:25	O
AM	O
BLOOD	O
WBC	O
-	O
9.9	O
RBC	O
-	O
3.18	O
*	O
Hgb	O
-	O
8.0	O
*	O
Hct	O
-	O
24.7	O
*	O
MCV	O
-	O
78	O
*	O
MCH	O
-	O
25.1	O
*	O
MCHC	O
-	O
32.3	O
RDW	O
-	O
16.4	O
*	O
Plt	O
Ct	O
-	O
264	O
[	O
**	O
2108-3-3	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
WBC	O
-	O
10.9	O
RBC	O
-	O
3.28	O
*	O
Hgb	O
-	O
8.3	O
*	O
Hct	O
-	O
26.0	O
*	O
MCV	O
-	O
79	O
*	O
MCH	O
-	O
25.5	O
*	O
MCHC	O
-	O
32.1	O
RDW	O
-	O
16.1	O
*	O
Plt	O
Ct	O
-	O
267	O
[	O
**	O
2108-2-28	O
**	O
]	O
10:00	O
PM	O
BLOOD	O
PT	O
-	O
23.0	O
*	O
PTT	O
-	O
42.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.2	O
*	O
[	O
**	O
2108-2-29	O
**	O
]	O
10:27	O
PM	O
BLOOD	O
PT	O
-	O
17.2	O
*	O
PTT	O
-	O
66.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.6	O
*	O
[	O
**	O
2108-3-2	O
**	O
]	O
04:25	O
AM	O
BLOOD	O
PT	O
-	O
24.8	O
*	O
PTT	O
-	O
100.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.4	O
*	O
[	O
**	O
2108-3-3	O
**	O
]	O
04:51	O
AM	O
BLOOD	O
PT	O
-	O
31.3	O
*	O
PTT	O
-	O
130.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.2	O
*	O
[	O
**	O
2108-3-4	O
**	O
]	O
01:43	O
AM	O
BLOOD	O
PT	O
-	O
30.9	O
*	O
PTT	O
-	O
88.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.2	O
*	O
[	O
**	O
2108-3-5	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
PT	O
-	O
26.2	O
*	O
PTT	O
-	O
55.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.6	O
*	O
[	O
**	O
2108-3-6	O
**	O
]	O
04:29	O
AM	O
BLOOD	O
PT	O
-	O
18.7	O
*	O
PTT	O
-	O
32.4	O
INR	O
(	O
PT	O
)	O
-	O
1.7	O
*	O
[	O
**	O
2108-2-28	O
**	O
]	O
10:40	O
AM	O
BLOOD	O
Glucose	O
-	O
93	O
UreaN	O
-	O
66	O
*	O
Creat	O
-	O
2.1	O
*	O
Na	O
-	O
138	O
K	O
-	O
6.4	O
*	O
Cl	O
-	O
105	O
HCO3	O
-	O
20	O
*	O
AnGap	O
-	O
19	O
[	O
**	O
2108-2-28	O
**	O
]	O
06:12	O
PM	O
BLOOD	O
Glucose	O
-	O
105	O
UreaN	O
-	O
67	O
*	O
Creat	O
-	O
1.9	O
*	O
Na	O
-	O
137	O
K	O
-	O
5.8	O
*	O
Cl	O
-	O
105	O
HCO3	O
-	O
23	O
AnGap	O
-	O
15	O
[	O
**	O
2108-2-28	O
**	O
]	O
10:00	O
PM	O
BLOOD	O
K	O
-	O
5.9	O
*	O
[	O
**	O
2108-2-29	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
Glucose	O
-	O
84	O
UreaN	O
-	O
71	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
138	O
K	O
-	O
5.6	O
*	O
Cl	O
-	O
106	O
HCO3	O
-	O
23	O
AnGap	O
-	O
15	O
[	O
**	O
2108-3-1	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Glucose	O
-	O
40	O
*	O
UreaN	O
-	O
73	O
*	O
Creat	O
-	O
2.2	O
*	O
Na	O
-	O
140	O
K	O
-	O
4.0	O
Cl	O
-	O
108	O
HCO3	O
-	O
23	O
AnGap	O
-	O
13	O
[	O
**	O
2108-3-2	O
**	O
]	O
04:25	O
AM	O
BLOOD	O
Glucose	O
-	O
0	O
*	O
UreaN	O
-	O
84	O
*	O
Creat	O
-	O
2.6	O
*	O
Na	O
-	O
139	O
K	O
-	O
4.6	O
Cl	O
-	O
106	O
HCO3	O
-	O
24	O
AnGap	O
-	O
14	O
[	O
**	O
2108-3-3	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
Glucose	O
-	O
75	O
UreaN	O
-	O
83	O
*	O
Creat	O
-	O
2.8	O
*	O
Na	O
-	O
142	O
K	O
-	O
3.8	O
Cl	O
-	O
107	O
HCO3	O
-	O
25	O
AnGap	O
-	O
14	O
[	O
**	O
2108-3-4	O
**	O
]	O
01:43	O
AM	O
BLOOD	O
Glucose	O
-	O
101	O
UreaN	O
-	O
85	O
*	O
Creat	O
-	O
2.8	O
*	O
Na	O
-	O
140	O
K	O
-	O
4.1	O
Cl	O
-	O
107	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2108-3-5	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
Glucose	O
-	O
172	O
*	O
UreaN	O
-	O
85	O
*	O
Creat	O
-	O
2.6	O
*	O
Na	O
-	O
139	O
K	O
-	O
4.3	O
Cl	O
-	O
106	O
HCO3	O
-	O
28	O
AnGap	O
-	O
9	O
[	O
**	O
2108-2-28	O
**	O
]	O
10:40	O
AM	O
BLOOD	O
ALT	O
-	O
54	O
*	O
AST	O
-	O
79	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
68	O
AlkPhos	O
-	O
120	O
*	O
Amylase	O
-	O
30	O
TotBili	O
-	O
0.3	O
[	O
**	O
2108-2-28	O
**	O
]	O
06:12	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
226	O
*	O
[	O
**	O
2108-2-29	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
ALT	O
-	O
51	O
*	O
AST	O
-	O
65	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
359	O
*	O
AlkPhos	O
-	O
108	O
TotBili	O
-	O
0.5	O
[	O
**	O
2108-2-29	O
**	O
]	O
05:28	O
PM	O
BLOOD	O
ALT	O
-	O
47	O
*	O
AST	O
-	O
55	O
*	O
AlkPhos	O
-	O
98	O
TotBili	O
-	O
0.3	O
[	O
**	O
2108-2-28	O
**	O
]	O
10:40	O
AM	O
BLOOD	O
cTropnT	O
-	O
0.04	O
*	O
[	O
**	O
2108-2-28	O
**	O
]	O
06:12	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
13	O
*	O
MB	O
Indx	O
-	O
5.8	O
cTropnT	O
-	O
0.07	O
*	O
[	O
**	O
2108-2-28	O
**	O
]	O
06:12	O
PM	O
BLOOD	O
Calcium	O
-	O
7.7	O
*	O
Phos	O
-	O
4.7	O
*	O
#	O
Mg	O
-	O
2.7	O
*	O
[	O
**	O
2108-3-5	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
Calcium	O
-	O
7.6	O
*	O
Phos	O
-	O
4.1	O
Mg	O
-	O
2.7	O
*	O
STUDIES	O
:	O
CT	O
HEAD	O
[	O
**	O
2108-2-28	O
**	O
]	O
:	O
Small	O
vessel	O
ischemic	O
disease	O
and	O
global	O
parenchymal	O
atrophy	O
.	O
No	O
evidence	O
of	O
hemorrhage	O
,	O
edema	O
,	O
mass	O
effect	O
,	O
or	O
acute	O
large	O
vascular	O
territorial	O
infarction	O
.	O
TTE	O
[	O
**	O
2108-2-28	O
**	O
]	O
:	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
(	O
LVEF	O
=	O
20	O
-	O
30	O
%	O
)	O
secondary	O
to	O
extensive	O
akinesis	O
involving	O
the	O
apex	O
and	O
anterior	O
septum	O
;	O
there	O
is	O
severe	O
hypkinesis	O
of	O
the	O
anterior	O
free	O
wall	O
,	O
inferior	O
septum	O
,	O
and	O
inferior	O
free	O
wall	O
.	O
The	O
basal	O
half	O
of	O
the	O
posterior	O
and	O
lateral	O
walls	O
contracts	O
normally	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
with	O
depressed	O
free	O
wall	O
contractility	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
A	O
bileaflet	O
aortic	O
valve	O
prosthesis	O
is	O
present	O
.	O
The	O
aortic	O
valve	O
prosthesis	O
appears	O
well	O
seated	O
,	O
with	O
normal	O
leaflet	O
/	O
disc	O
motion	O
and	O
transvalvular	O
gradients	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Impression	O
:	O
extensive	O
anteroseptal	O
-	O
apical	O
myocardial	O
infarct	O
of	O
unknown	O
acuity	O
;	O
inferior	O
hypokinesis	O
;	O
findings	O
consistent	O
with	O
multivessel	O
obstructive	O
coronary	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
disease	O
EEG	O
[	O
**	O
2108-3-5	O
**	O
]	O
:	O
This	O
telemetry	O
captured	O
no	O
pushbutton	O
activations	O
.	O
Throughout	O
the	O
recording	O
,	O
the	O
background	O
was	O
one	O
of	O
burst	O
suppression	O
alternating	O
between	O
frequent	O
sharp	O
generalized	O
triphasic	O
waves	O
at	O
a	O
maximum	O
frequency	O
of	O
2	O
Hz	O
to	O
a	O
more	O
suppressed	O
pattern	O
of	O
suppression	O
of	O
the	O
background	O
for	O
periods	O
of	O
up	O
to	O
eight	O
seconds	O
alternating	O
with	O
bursts	O
of	O
low	O
amplitude	O
activity	O
.	O
In	O
the	O
recent	O
past	O
those	O
triphasic	O
appearing	O
waves	O
probably	O
represent	O
short	O
electrographic	O
seizures	O
.	O
Brief	O
Hospital	O
Course	O
:	O
In	O
brief	O
this	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
man	O
with	O
DM2	O
,	O
PAD	O
who	O
presented	O
with	O
asystolic	O
cardiac	O
arrest	O
.	O
#	O
Asystolic	O
arrest	O
:	O
Most	O
likely	O
respiratory	O
arrest	O
.	O
Initially	O
started	O
on	O
cooling	O
protocol	O
but	O
this	O
was	O
stopped	O
for	O
elevated	O
INR	O
.	O
Since	O
admission	O
he	O
remained	O
nonresponsive	O
with	O
fixed	O
and	O
dilated	O
pupils	O
.	O
He	O
was	O
intubated	O
and	O
remained	O
so	O
for	O
the	O
duration	O
of	O
the	O
hospitalization	O
.	O
Daily	O
spontaneous	O
breathing	O
trials	O
were	O
negative	O
.	O
Trach	O
was	O
placed	O
and	O
his	O
care	O
was	O
transitioned	O
to	O
a	O
ventilatory	O
rehab	O
facitlity	O
.	O
#	O
Hypotension	I-Reason
:	O
he	O
was	O
noted	O
to	O
be	O
hypotensive	O
in	O
the	O
ED	O
and	O
was	O
given	O
IVF	I-Drug
and	O
started	O
on	O
pressor	I-Drug
support	O
with	O
norepinephrine	I-Drug
.	O
He	O
was	O
waned	O
of	O
this	O
medication	O
and	O
was	O
able	O
to	O
mantain	O
his	O
BP	O
.	O
An	O
ECHO	O
was	O
obtained	O
showing	O
EF20	O
%	O
hypokinetic	O
LV	O
and	O
PCWP	O
elevated	O
.	O
This	O
is	O
suggestive	O
of	O
systolic	O
sysfunction	O
and	O
suggest	O
a	O
cardiac	O
etiology	O
of	O
hypotension	O
.	O
He	O
was	O
gradually	O
weaned	O
off	O
pressors	I-Drug
and	O
maintained	O
a	O
normal	O
BP	O
(	O
90	O
-	O
120	O
systolic	O
)	O
for	O
several	O
days	O
.	O
His	O
tamsulosin	I-Drug
was	O
held	O
.	O
#	O
Coagulopathy	I-Ade
:	O
Likely	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
combination	O
of	O
warfarin	I-Drug
and	O
recent	O
antibiotic	I-Drug
use	O
.	O
No	O
evidence	O
of	O
DIC	O
.	O
This	O
was	O
reversed	O
with	O
vitamin	B-Drug
K	I-Drug
and	O
FFP	I-Drug
.	O
He	O
was	O
then	O
placed	O
on	O
hep	I-Drug
gtt	O
when	O
his	O
inr	O
was	O
subtherapeutic	O
.	O
After	O
the	O
trach	O
and	O
peg	O
he	O
was	O
restarted	O
on	O
coumadin	I-Drug
.	O
He	O
will	O
be	O
bridged	O
back	O
onto	O
coumadin	I-Drug
at	O
the	O
ventilatory	O
rehab	O
center	O
in	O
[	O
**	O
1	O
-	O
3	O
**	O
]	O
days	O
.	O
Goal	O
INR	O
2.5	O
-	O
3.5	O
.	O
#	O
h	O
/	O
o	O
[	O
**	O
Date	O
Range	O
1291	O
**	O
]	O
:	O
on	O
heparin	I-Drug
ggt	O
for	O
thrombus	B-Reason
ppx	I-Reason
.	O
Transition	O
to	O
warfarin	I-Drug
with	O
heparin	I-Drug
bridge	O
for	O
2	O
days	O
at	O
INR	O
>	O
2.5	O
.	O
#	O
Neurological	O
disturbances	O
:	O
As	O
noted	O
he	O
was	O
unrespionsive	O
to	O
verbal	O
and	O
painfull	O
comands	O
.	O
Initially	O
his	O
pupils	O
were	O
fixed	O
and	O
dilated	O
.	O
He	O
was	O
placed	O
on	O
EEG	O
and	O
a	O
head	O
CT	O
showed	O
small	O
vessel	O
ischemic	O
disease	O
and	O
global	O
parenchymal	O
atrophy	O
.	O
No	O
evidence	O
of	O
hemorrhage	O
,	O
edema	O
,	O
mass	O
effect	O
,	O
or	O
acute	O
large	O
vascular	O
territorial	O
infarction	O
.	O
His	O
EEG	O
identified	O
foci	O
of	O
seizure	O
activity	O
,	O
which	O
occurred	O
with	O
concurrent	O
uncontrolled	O
muscle	O
movement	O
suggesting	O
a	O
seizure	O
.	O
Neurology	O
followed	O
the	O
paitent	O
.	O
He	O
was	O
started	O
on	O
Keppra	I-Drug
and	O
this	O
was	O
uptitrated	O
to	O
effect	O
(	O
i.e	O
absence	O
of	O
seizure	I-Reason
activity	O
on	O
exam	O
and	O
EEG	O
)	O
.	O
During	O
his	O
stay	O
he	O
exbited	O
some	O
change	O
in	O
neuro	O
exam	O
,	O
in	O
that	O
he	O
was	O
minimally	O
responsive	O
to	O
pain	O
and	O
pupils	O
more	O
reactive	O
.	O
However	O
this	O
was	O
very	O
short	O
lasted	O
(	O
one	O
day	O
)	O
and	O
subsequently	O
he	O
was	O
again	O
nonresponsive	O
.	O
#	O
Acute	O
renal	O
failure	O
:	O
Initially	O
he	O
was	O
noted	O
to	O
have	O
an	O
elevated	O
creatinine	O
of	O
2.1	O
from	O
1.o	O
in	O
recent	O
months	O
.	O
Also	O
this	O
was	O
associated	O
with	O
oligouria	O
.	O
This	O
improved	O
with	O
pressure	O
support	O
and	O
diuresis	O
,	O
suggestive	O
that	O
the	O
renal	O
failure	O
was	O
related	O
to	O
decreased	O
forward	O
cardiac	O
output	O
.	O
#	O
Longitudinal	O
care	O
:	O
Palliative	O
care	O
consult	O
obtained	O
and	O
several	O
meettings	O
were	O
held	O
with	O
family	O
members	O
and	O
spiritual	O
leader	O
.	O
Decision	O
to	O
mantain	O
ventilatory	O
support	O
unless	O
evidence	O
of	O
worsening	O
multiple	O
organ	O
failure	O
.	O
#	O
Foot	O
Ulceration	O
:	O
Noted	O
severe	O
ulcers	O
on	O
right	O
foot	O
,	O
consistent	O
with	O
prior	O
documented	O
note	O
by	O
vascular	O
surgery	O
(	O
tendons	O
exposed	O
)	O
.	O
Continued	O
wound	O
care	O
.	O
#	O
Nutritional	O
support	O
:	O
provided	O
through	O
tube	O
feeds	O
during	O
his	O
hospitalization	O
.	O
PEG	O
tube	O
placed	O
for	O
future	O
support	O
.	O
#	O
Complicated	O
UTI	I-Reason
:	O
on	O
cefpodoxime	I-Drug
(	O
h	O
/	O
o	O
proteus	O
and	O
enterococcus	O
in	O
urine	O
sensitive	O
to	O
CTX	O
-	O
not	O
cipro	I-Drug
)	O
.	O
End	O
date	O
[	O
**	O
2108-3-11	O
**	O
]	O
.	O
#	O
Access	O
:	O
PICC	O
was	O
placed	O
for	O
administration	O
of	O
IV	O
medications	O
.	O
#	O
Indwelling	O
devices	O
:	O
Trach	O
,	O
PEG	O
,	O
PICC	O
Medications	O
on	O
Admission	O
:	O
Acetaminophen	I-Drug
prn	O
Bisacodyl	I-Drug
prn	O
Oxycodone	I-Drug
prn	O
Glyburide	I-Drug
2.5	O
mg	O
daily	O
Docusate	I-Drug
prn	O
Duloxetine	I-Drug
30	O
mg	O
daily	O
Tramadol	I-Drug
25	O
mg	O
prn	O
Tamsulosin	I-Drug
0.4	O
mg	O
qhs	O
Warfarin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Cefpodoxime	I-Drug
100	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
8	O
days	O
.	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
5	O
.	O
Keppra	I-Drug
750	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
6	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
AS	O
DIR	O
Subcutaneous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
7	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
in	I-Drug
D5W	I-Drug
25,000	O
unit	O
/	O
250	O
mL	O
Parenteral	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
AS	O
DIR	O
Intravenous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
:	O
Goal	O
PTT	O
50	O
-	O
80	O
.	O
8	O
.	O
Polyvinyl	B-Drug
Alcohol	I-Drug
-	I-Drug
Povidone	I-Drug
1.4	O
-	O
0.6	O
%	O
Dropperette	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
[	O
**	O
12	O
-	O
2	O
**	O
]	O
Drops	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
9	O
.	O
White	B-Drug
Petrolatum	I-Drug
-	I-Drug
Mineral	I-Drug
Oil	I-Drug
42.5	O
-	O
56.8	O
%	O
Ointment	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
10	O
.	O
Warfarin	I-Drug
2.5	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
11	O
.	O
Keppra	I-Drug
750	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
105	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Cardiac	O
Arrest	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
your	O
heart	O
stopped	O
beating	O
.	O
You	O
were	O
rescucitated	O
.	O
You	O
had	O
a	O
tube	O
placed	O
in	O
your	O
throat	O
to	O
help	O
you	O
keep	O
breathing	O
.	O
You	O
are	O
now	O
on	O
the	O
machine	O
to	O
keep	O
you	O
breathing	O
.	O
You	O
also	O
had	O
a	O
tube	O
placed	O
in	O
your	O
stomach	O
to	O
feed	O
you	O
.	O
Medication	O
Changes	O
:	O
START	O
:	O
Cefpodoxime	I-Drug
(	O
last	O
dose	O
[	O
**	O
2108-3-15	O
**	O
]	O
)	O
START	O
:	O
Keppra	I-Drug
750	O
mg	O
twice	O
daily	O
START	O
:	O
Lansoprazole	I-Drug
30	O
mg	O
daily	O
STOP	O
:	O
Glyburide	I-Drug
STOP	O
:	O
Duloxetine	I-Drug
STOP	O
:	O
Tramadol	I-Drug
and	O
oxycodone	I-Drug
STOP	O
:	O
Tamsulosin	I-Drug
Followup	O
Instructions	O
:	O
None	O
Completed	O
by	O
:[	O
**	O
2108-3-9	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2110-4-18	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2110-4-26	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Ace	B-Drug
Inhibitors	I-Drug
/	O
Captopril	I-Drug
/	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
30	O
**	O
]	O
Chief	O
Complaint	O
:	O
found	O
unresponsive	O
by	O
daughter	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Intubation	O
History	O
of	O
Present	O
Illness	O
:	O
86	O
yoM	O
with	O
largely	O
unknown	O
past	O
medical	O
history	O
,	O
found	O
down	O
on	O
kitchen	O
floor	O
by	O
daughter	O
[	O
**	O
4	O
-	O
17	O
**	O
]	O
.	O
EMS	O
activated	O
,	O
per	O
records	O
found	O
patient	O
unresponsive	O
with	O
no	O
pulse	O
,	O
WCT	O
?	O
VT	O
noted	O
.	O
Patient	O
was	O
given	O
defibrillation	O
x1	O
,	O
noted	O
"	O
sinus	O
tachycardia	O
"	O
120	O
bpm	O
post	O
cardioversion	O
.	O
Recorded	O
SBP	O
86	O
/	O
p	O
.	O
In	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ER	O
,	O
patient	O
subsequently	O
urgently	O
intubated	O
secondary	O
to	O
respiratory	O
distress	O
.	O
ER	O
concern	O
for	O
sepsis	O
given	O
hypotension	O
,	O
leukocytosis	O
,	O
and	O
possible	O
pneumonia	O
,	O
so	O
"	O
code	O
sepsis	I-Reason
"	O
activated	O
with	O
placement	O
of	O
central	O
venous	O
lines	O
,	O
obtainment	O
of	O
cultures	O
,	O
and	O
administration	O
of	O
antibiotic	I-Drug
(	O
vanc	I-Drug
/	O
levo	I-Drug
/	O
zosyn	I-Drug
)	O
.	O
Patient	O
given	O
total	O
8	O
L	O
IVF	I-Drug
in	O
ER	O
,	O
MAP	O
~	O
65	O
,	O
started	O
on	O
norepinephrine	B-Drug
vasopressor	I-Drug
for	O
hemodynamic	B-Reason
support	I-Reason
.	O
Transferred	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
therapy	O
,	O
arriving	O
intubated	O
and	O
sedated	O
.	O
Per	O
family	O
,	O
patient	O
complained	O
of	O
"	O
cold	O
-	O
like	O
"	O
symptoms	O
for	O
5	O
days	O
prior	O
to	O
admission	O
.	O
Last	O
contact	O
2	O
days	O
before	O
being	O
found	O
down	O
.	O
Meds	O
(	O
in	O
ER	O
)	O
:	O
Vancomycin	I-Drug
1g	O
,	O
Zosyn	I-Drug
,	O
Levofloxacin	I-Drug
,	O
Decadron	I-Drug
6	O
mg	O
IV	O
.	O
Past	O
Medical	O
History	O
:	O
Largely	O
unknown	O
.	O
Per	O
ER	O
,	O
patient	O
living	O
alone	O
,	O
no	O
current	O
medical	O
issues	O
.	O
Social	O
History	O
:	O
Lives	O
alone	O
,	O
fully	O
functional	O
,	O
family	O
in	O
area	O
.	O
Family	O
History	O
:	O
Non	O
contributory	O
Physical	O
Exam	O
:	O
PE	O
:	O
T	O
99.7	O
,	O
BP	O
124/82	O
,	O
P96	O
,	O
R14	O
Gen	O
:	O
Sedated	O
,	O
CV	O
:	O
S1	O
S2	O
with	O
no	O
MRG	O
Lungs	O
:	O
Rare	O
wheezes	O
bilateral	O
anterior	O
fields	O
Abd	O
:	O
Soft	O
,	O
NT	O
/	O
ND	O
Ext	O
:	O
1	O
+	O
bilateral	O
pitting	O
edema	O
Neuro	O
:	O
Moves	O
all	O
extremities	O
,	O
reacts	O
to	O
painful	O
stimuli	O
.	O
No	O
signs	O
of	O
trauma	O
.	O
Pertinent	O
Results	O
:	O
CXR	O
:	O
Endotracheal	O
tube	O
is	O
terminating	O
approximately	O
5	O
cm	O
above	O
the	O
carina	O
.	O
Nasogastric	O
tube	O
is	O
coursing	O
down	O
below	O
the	O
left	O
hemidiaphragm	O
,	O
and	O
terminating	O
in	O
right	O
upper	O
quadrant	O
.	O
Cardiac	O
and	O
mediastinal	O
contours	O
are	O
within	O
normal	O
limits	O
for	O
age	O
,	O
given	O
the	O
positioning	O
.	O
Right	O
costophrenic	O
angle	O
is	O
not	O
included	O
.	O
Patchy	O
opacities	O
are	O
seen	O
in	O
bilateral	O
lower	O
lobes	O
,	O
which	O
may	O
represent	O
atelectasis	O
versus	O
aspiration	O
.	O
IMPRESSION	O
:	O
Tubes	O
and	O
lines	O
as	O
described	O
above	O
.	O
Bibasilar	O
patchy	O
opacities	O
,	O
representing	O
atelectasis	O
or	O
aspiration	O
.	O
.	O
Head	O
CT	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
hemorrhage	O
.	O
2	O
.	O
There	O
is	O
white	O
matter	O
hypodensity	O
near	O
the	O
trigone	O
of	O
the	O
left	O
lateral	O
ventricle	O
without	O
extension	O
to	O
the	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
matter	O
that	O
may	O
represent	O
sequela	O
from	O
chronic	O
small	O
vessel	O
disease	O
.	O
3	O
.	O
Left	O
thalamic	O
and	O
caudate	O
lacunar	O
infarcts	O
.	O
.	O
Repeat	O
CXR	O
:	O
FINDINGS	O
:	O
The	O
cardiomediastinal	O
silhouette	O
is	O
stable	O
.	O
Again	O
seen	O
are	O
bilateral	O
basilar	O
parenchymal	O
opacities	O
,	O
which	O
demonstrate	O
no	O
significant	O
change	O
compared	O
to	O
prior	O
examinations	O
.	O
There	O
are	O
likely	O
small	O
bilateral	O
pleural	O
effusions	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Slight	O
improvement	O
in	O
bilateral	O
basilar	O
pulmonary	O
opacities	O
,	O
right	O
more	O
prominent	O
than	O
left	O
with	O
differential	O
diagnosis	O
including	O
aspiration	O
versus	O
pneumonia	O
.	O
.	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
ASSAY	O
(	O
Final	O
[	O
**	O
2110-4-24	O
**	O
]	O
)	O
:	O
FECES	O
NEGATIVE	O
FOR	O
C.	O
DIFFICILE	O
TOXIN	O
BY	O
EIA	O
.	O
Reference	O
Range	O
:	O
Negative	O
.	O
Blood	O
Cultures	O
:	O
negative	O
Urine	O
Cultures	O
:	O
negative	O
.	O
C1	O
esterase	O
inhibitory	O
assay	O
:	O
pending	O
at	O
time	O
of	O
discharge	O
[	O
**	O
2110-4-17	O
**	O
]	O
08:00	O
PM	O
BLOOD	O
WBC	O
-	O
14.7	O
*	O
RBC	O
-	O
4.51	O
*	O
Hgb	O
-	O
14.6	O
Hct	O
-	O
43.2	O
MCV	O
-	O
96	O
MCH	O
-	O
32.5	O
*	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
13.6	O
Plt	O
Ct	O
-	O
272	O
[	O
**	O
2110-4-23	O
**	O
]	O
05:36	O
AM	O
BLOOD	O
WBC	O
-	O
23.0	O
*	O
#	O
RBC	O
-	O
4.37	O
*	O
Hgb	O
-	O
14.3	O
Hct	O
-	O
40.8	O
MCV	O
-	O
93	O
MCH	O
-	O
32.6	O
*	O
MCHC	O
-	O
35.0	O
RDW	O
-	O
14.3	O
Plt	O
Ct	O
-	O
514	O
*	O
[	O
**	O
2110-4-26	O
**	O
]	O
07:40	O
AM	O
BLOOD	O
WBC	O
-	O
18.8	O
*	O
RBC	O
-	O
4.36	O
*	O
Hgb	O
-	O
14.6	O
Hct	O
-	O
40.9	O
MCV	O
-	O
94	O
MCH	O
-	O
33.4	O
*	O
MCHC	O
-	O
35.7	O
*	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
644	O
*	O
[	O
**	O
2110-4-25	O
**	O
]	O
07:40	O
AM	O
BLOOD	O
Neuts	O
-	O
82	O
*	O
Bands	O
-	O
1	O
Lymphs	O
-	O
12	O
*	O
Monos	O
-	O
1	O
*	O
Eos	O
-	O
1	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
3	O
*	O
[	O
**	O
2110-4-21	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
Ret	O
Aut	O
-	O
0.6	O
*	O
[	O
**	O
2110-4-25	O
**	O
]	O
07:40	O
AM	O
BLOOD	O
Glucose	O
-	O
145	O
*	O
UreaN	O
-	O
33	O
*	O
Creat	O
-	O
1.0	O
Na	O
-	O
142	O
K	O
-	O
4.0	O
Cl	O
-	O
104	O
HCO3	O
-	O
29	O
AnGap	O
-	O
13	O
[	O
**	O
2110-4-20	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
ALT	O
-	O
30	O
AST	O
-	O
54	O
*	O
AlkPhos	O
-	O
52	O
TotBili	O
-	O
0.5	O
[	O
**	O
2110-4-18	O
**	O
]	O
02:12	O
AM	O
BLOOD	O
ALT	O
-	O
29	O
AST	O
-	O
104	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
363	O
*	O
AlkPhos	O
-	O
50	O
TotBili	O
-	O
1.3	O
[	O
**	O
2110-4-17	O
**	O
]	O
08:00	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.35	O
*	O
[	O
**	O
2110-4-18	O
**	O
]	O
06:06	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
124	O
*	O
MB	O
Indx	O
-	O
9.5	O
*	O
cTropnT	O
-	O
3.36	O
*	O
[	O
**	O
2110-4-18	O
**	O
]	O
02:07	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
110	O
*	O
MB	O
Indx	O
-	O
8.8	O
*	O
cTropnT	O
-	O
3.37	O
*	O
[	O
**	O
2110-4-21	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
calTIBC	O
-	O
156	O
*	O
VitB12	O
-	O
406	O
Folate	O
-	O
5.0	O
Hapto	O
-	O
357	O
*	O
Ferritn	O
-	O
1171	O
*	O
TRF	O
-	O
120	O
*	O
[	O
**	O
2110-4-23	O
**	O
]	O
05:36	O
AM	O
BLOOD	O
Triglyc	O
-	O
213	O
*	O
HDL	O
-	O
20	O
CHOL	O
/	O
HD	O
-	O
8.9	O
LDLcalc	O
-	O
115	O
[	O
**	O
2110-4-18	O
**	O
]	O
06:06	O
AM	O
BLOOD	O
TSH	O
-	O
5.4	O
*	O
[	O
**	O
2110-4-22	O
**	O
]	O
04:33	O
AM	O
BLOOD	O
C4	O
-	O
34	O
[	O
**	O
2110-4-17	O
**	O
]	O
08:00	O
PM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
[	O
**	O
2110-4-17	O
**	O
]	O
08:12	O
PM	O
BLOOD	O
Glucose	O
-	O
376	O
*	O
Lactate	O
-	O
5.3	O
*	O
Na	O
-	O
141	O
K	O
-	O
4.1	O
Cl	O
-	O
101	O
calHCO3	O
-	O
21	O
[	O
**	O
2110-4-18	O
**	O
]	O
05:28	O
AM	O
BLOOD	O
Lactate	O
-	O
2.6	O
*	O
[	O
**	O
2110-4-18	O
**	O
]	O
02:24	O
AM	O
BLOOD	O
freeCa	O
-	O
1.03	O
*	O
Brief	O
Hospital	O
Course	O
:	O
86	O
yoM	O
with	O
unknown	O
past	O
medical	O
history	O
presents	O
after	O
being	O
found	O
unresponsive	O
by	O
family	O
member	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
had	O
prodrome	O
of	O
cold	O
-	O
like	O
symptoms	O
per	O
report	O
.	O
It	O
is	O
unclear	O
what	O
was	O
the	O
precipitant	O
of	O
the	O
profound	O
weakness	O
/	O
loss	O
of	O
consciousness	O
,	O
but	O
concern	O
exists	O
for	O
cardiac	O
etiology	O
in	O
addition	O
to	O
infection	O
/	O
sepsis	O
.	O
The	O
patient	O
was	O
not	O
"	O
down	O
"	O
for	O
long	O
(	O
likely	O
<<	O
24h	O
)	O
given	O
absence	O
of	O
profound	O
volume	O
depletion	O
,	O
minimal	O
CK	O
elevation	O
.	O
No	O
evidence	O
of	O
trauma	O
.	O
He	O
was	O
initially	O
transferred	O
to	O
the	O
ICU	O
for	O
treatment	O
.	O
Hospital	O
course	O
is	O
discussed	O
by	O
problem	O
.	O
.	O
ID	O
-	O
Blood	O
cultures	O
were	O
drawn	O
,	O
negative	O
for	O
growth	O
.	O
Given	O
the	O
patient	O
's	O
low	O
grade	O
temperature	O
elevation	O
and	O
leukocytosis	O
,	O
as	O
well	O
as	O
the	O
history	O
of	O
"	O
cold	O
-	O
like	O
"	O
symptoms	O
experienced	O
by	O
patient	O
,	O
pneumonia	O
was	O
thought	O
to	O
be	O
the	O
most	O
likely	O
source	O
of	O
infection	O
.	O
An	O
initial	O
CXR	O
demonstrated	O
an	O
early	O
PNA	I-Reason
consistent	O
with	O
aspiration	O
,	O
so	O
he	O
was	O
started	O
on	O
empiric	B-Reason
coverage	I-Reason
with	O
vancomycin	I-Drug
/	O
levofloxacin	I-Drug
/	O
Flagyl	I-Drug
.	O
The	O
patient	O
went	O
into	O
respiratory	O
distress	O
secondary	O
to	O
sepsis	O
/	O
pneumonia	O
,	O
and	O
the	O
patient	O
required	O
intubation	O
.	O
He	O
was	O
later	O
successfully	O
extubated	O
.	O
The	O
patient	O
rapidly	O
improved	O
and	O
his	O
lactate	O
normalized	O
.	O
His	O
antibiotic	I-Drug
coverage	O
was	O
narrowed	O
to	O
Levofloxacin	I-Drug
only	O
and	O
finished	O
a	O
seven	O
day	O
course	O
prior	O
to	O
discharge	O
.	O
.	O
CV	O
-	O
Possible	O
arrhythmic	O
impetus	O
(	O
VT	O
,	O
less	O
likely	O
VF	O
given	O
period	O
on	O
floor	O
)	O
in	O
setting	O
of	O
unknown	O
history	O
of	O
vascular	O
disease	O
.	O
An	O
EKG	O
demonstrates	O
LBBB	O
,	O
which	O
could	O
be	O
chronic	O
and	O
indicate	O
significant	O
CAD	O
.	O
Given	O
his	O
NSTEMI	O
,	O
with	O
troponin	O
up	O
to	O
>	O
3.0	O
and	O
an	O
index	O
of	O
8	O
,	O
cardiology	O
was	O
consulted	O
for	O
further	O
recommendations	O
.	O
Given	O
that	O
the	O
patient	O
was	O
shocked	O
,	O
hypotensive	O
,	O
and	O
septic	O
;	O
this	O
may	O
have	O
all	O
contributed	O
to	O
the	O
troponin	O
elevation	O
.	O
He	O
underwent	O
an	O
echocardiogram	O
with	O
report	O
as	O
follows	O
:	O
1	O
.	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
2	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
difficult	O
to	O
assess	O
but	O
is	O
probably	O
moderately	O
depressed	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
can	O
not	O
be	O
reliably	O
assessed	O
.	O
3	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
.	O
4	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
severely	O
thickened	O
/	O
deformed	O
.	O
There	O
is	O
probably	O
mild	O
to	O
moderate	O
aortic	O
valve	O
stenosis	O
.	O
5	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
moderate	O
thickening	O
of	O
the	O
mitral	O
valve	O
chordae	O
.	O
At	O
least	O
mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
regurgitation	O
jet	O
is	O
eccentric	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
underestimated	O
.	O
]	O
He	O
was	O
started	O
on	O
a	O
beta	B-Drug
-	I-Drug
blocker	I-Drug
,	O
aspirin	I-Drug
,	O
high	O
dose	O
Statin	I-Drug
,	O
and	O
an	O
ACE	B-Drug
inhibitor	I-Drug
for	O
medical	B-Reason
management	I-Reason
.	O
In	O
addition	O
,	O
a	O
heparin	I-Drug
drip	O
was	O
administered	O
for	O
48	O
hours	O
.	O
However	O
,	O
a	O
few	O
hours	O
after	O
the	O
second	O
dose	O
of	O
Captopril	I-Drug
,	O
the	O
patient	O
developed	O
severe	I-Ade
angioedema	O
with	O
lip	B-Ade
and	I-Ade
tongue	I-Ade
swelling	I-Ade
.	O
The	O
patient	O
was	O
given	O
Epi	I-Drug
,	O
Benadryl	I-Drug
,	O
IV	O
steroids	I-Drug
and	O
ranitidine	I-Drug
immediately	O
,	O
and	O
anesthesia	O
was	O
consulted	O
for	O
possible	O
intubation	O
,	O
as	O
well	O
as	O
the	O
ICU	O
team	O
.	O
The	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
ICU	O
for	O
airway	O
monitoring	O
,	O
but	O
was	O
able	O
to	O
be	O
medically	O
managed	O
without	O
intubation	O
.	O
Allergy	O
service	O
was	O
consulted	O
,	O
and	O
felt	O
that	O
this	O
was	O
consistent	O
with	O
an	O
ACE	B-Drug
-	I-Drug
I	I-Drug
allergy	I-Ade
rather	O
than	O
a	O
C	O
-	O
1	O
deficiency	O
.	O
The	O
C	O
-	O
1	O
assay	O
was	O
sent	O
to	O
rule	O
out	O
deficiency	O
,	O
with	O
the	O
results	O
still	O
pending	O
at	O
the	O
time	O
of	O
discharge	O
.	O
The	O
patient	O
's	O
PCP	O
was	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
,	O
and	O
a	O
follow	O
-	O
up	O
appointment	O
with	O
an	O
outside	O
cardiologist	O
was	O
arranged	O
prior	O
to	O
discharge	O
.	O
He	O
was	O
also	O
started	O
on	O
Norvasc	I-Drug
to	O
help	O
optimize	O
his	O
blood	B-Reason
pressure	I-Reason
control	O
.	O
.	O
Renal	O
-	O
He	O
was	O
initially	O
in	O
acute	O
renal	O
failure	O
,	O
with	O
a	O
creatinine	O
of	O
1.8	O
on	O
admission	O
.	O
Although	O
his	O
baseline	O
was	O
unknown	O
,	O
it	O
resolved	O
to	O
1.1	O
.	O
His	O
Foley	O
was	O
discontinued	O
,	O
and	O
he	O
urinated	O
without	O
difficulty	O
.	O
A	O
microalbumin	O
was	O
sent	O
,	O
which	O
was	O
negative	O
,	O
therefore	O
initiating	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
was	O
deferred	O
by	O
now	O
.	O
According	O
to	O
the	O
allergy	O
service	O
,	O
there	O
is	O
some	O
risk	O
of	O
allergy	O
with	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
,	O
although	O
very	O
low	O
.	O
.	O
Endocrine	O
-	O
Given	O
that	O
he	O
had	O
a	O
history	O
of	O
"	B-Reason
borderline	I-Reason
"	I-Reason
diabetes	I-Reason
,	O
he	O
was	O
monitored	O
with	O
FS	O
QID	O
and	O
covered	O
with	O
an	O
ISS	I-Drug
,	O
particularly	O
in	O
the	O
setting	O
of	O
steroids	I-Drug
for	O
angioedema	I-Reason
.	O
A	O
free	O
T4	O
was	O
normal	O
,	O
and	O
a	O
urine	O
for	O
microalbumin	O
shows	O
alb	O
/	O
creatinine	O
ratio	O
27.6	O
.	O
.	O
Heme	O
-	O
He	O
was	O
found	O
to	O
have	O
anemia	O
,	O
normocytic	O
,	O
hct	O
since	O
admission	O
33	O
-	O
38	O
,	O
then	O
improved	O
to	O
40	O
.	O
He	O
was	O
guaiac	O
negative	O
,	O
and	O
iron	O
studies	O
were	O
consistent	O
with	O
anemia	O
of	O
chronic	O
disease	O
.	O
.	O
He	O
was	O
evaluated	O
by	O
PT	O
and	O
was	O
cleared	O
for	O
a	O
home	O
discharge	O
with	O
services	O
.	O
His	O
PCP	O
was	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
prior	O
to	O
discharge	O
,	O
and	O
the	O
patient	O
was	O
scheduled	O
for	O
a	O
follow	O
-	O
up	O
appointment	O
within	O
one	O
week	O
of	O
discharge	O
.	O
Medications	O
on	O
Admission	O
:	O
excedrin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
vna	O
carenetwork	O
Discharge	O
Diagnosis	O
:	O
Principal	O
:	O
1	O
.	O
Multilobar	O
Pneumonia	O
.	O
2	O
.	O
Septic	O
Shock	O
.	O
3	O
.	O
Wide	O
Complex	O
Tachycardia	O
NOS.	O
4	O
.	O
Non	O
ST	O
Elevation	O
Myocardial	O
Infarction	O
.	O
5	O
.	O
Acute	O
ACE	B-Drug
-	I-Drug
I	I-Drug
Angioedema	I-Ade
with	O
Airway	B-Ade
Compromise	I-Ade
.	O
6	O
.	O
Acute	O
Renal	O
Failure	O
.	O
7	O
.	O
Left	O
Thalamic	O
and	O
Caudate	O
lacunar	O
infarcts	O
-	O
chronic	O
.	O
Secondary	O
:	O
1	O
.	O
Diabetes	O
Mellitus	O
Type	O
II	O
.	O
2	O
.	O
Chronic	O
Kidney	O
Disease	O
Stage	O
I.	O
3	O
.	O
Hypercholesterolemia	O
.	O
4	O
.	O
Hypertension	O
.	O
5	O
.	O
Psoriasis	O
.	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
We	O
have	O
started	O
you	O
on	O
four	O
new	O
medications	O
for	O
your	O
heart	O
.	O
Please	O
continue	O
to	O
take	O
these	O
and	O
all	O
of	O
your	O
medications	O
as	O
instructed	O
.	O
Please	O
call	O
your	O
doctor	O
or	O
return	O
to	O
the	O
hospital	O
if	O
you	O
develop	O
chest	O
pain	O
,	O
difficulty	O
breathing	O
,	O
fevers	O
or	O
chills	O
.	O
You	O
develop	O
a	O
severe	O
allergic	O
reaction	O
called	O
angioedema	I-Ade
when	O
you	O
take	O
a	O
medication	O
called	O
ACE	B-Drug
inhibitors	I-Drug
.	O
Please	O
refrain	O
from	O
ever	O
taking	O
this	O
type	O
of	O
medication	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
You	O
have	O
a	O
scheduled	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
66070	O
**	O
]	O
at	O
[	O
**	O
Hospital	O
1411	O
**	O
]	O
Medical	O
Associates	O
on	O
Monday	O
[	O
**	O
4	O
-	O
28	O
**	O
]	O
at	O
14:15	O
.	O
It	O
is	O
important	O
that	O
you	O
go	O
to	O
this	O
appointment	O
.	O
2	O
.	O
You	O
will	O
also	O
need	O
follow	O
-	O
up	O
with	O
a	O
cardiologist	O
.	O
We	O
have	O
scheduled	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
(	O
cardiologist	O
)	O
at	O
[	O
**	O
Hospital	O
1411	O
**	O
]	O
Medical	O
Associates	O
(	O
his	O
office	O
is	O
next	O
to	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
66071	O
**	O
]	O
office	O
)	O
on	O
[	O
**	O
5	O
-	O
5	O
**	O
]	O
at	O
09:15	O
in	O
the	O
morning	O
.	O
Please	O
call	O
his	O
office	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
66072	O
**	O
]	O
if	O
you	O
have	O
any	O
questions	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2105-12-7	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2105-12-26	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2009	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fevers	O
,	O
desaturation	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Endotracheal	O
Intubation	O
[	O
**	O
Date	O
range	O
(	O
2	O
)	O
98897	O
**	O
]	O
Art	O
-	O
line	O
[	O
**	O
Date	O
range	O
(	O
2	O
)	O
98898	O
**	O
]	O
PICC	O
[	O
**	O
2105-12-10	O
**	O
]	O
-	O
Bronchoscopy	O
[	O
**	O
2105-12-11	O
**	O
]	O
and	O
[	O
**	O
2105-12-13	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
-	O
year	O
-	O
old	O
woman	O
with	O
history	O
of	O
dementia	O
,	O
depression	O
p	O
/	O
w	O
cough	O
,	O
fever	O
,	O
dyspnea	O
from	O
nursing	O
home	O
.	O
At	O
nursing	O
home	O
,	O
patient	O
appeared	O
dyspneic	O
the	O
morning	O
of	O
admission	O
with	O
T	O
100.6	O
,	O
BP	O
147/72	O
,	O
P	O
116	O
,	O
RR	O
17	O
,	O
O2	O
sat	O
in	O
high	O
70s	O
on	O
RA	O
,	O
95	O
%	O
on	O
NRB	O
.	O
Was	O
brought	O
to	O
ED	O
.	O
.	O
On	O
arrival	O
in	O
ED	O
,	O
T	O
103.9	O
,	O
HR	O
110s	O
,	O
SBP	O
150s	O
,	O
RR	O
20s	O
,	O
95	O
-	O
98	O
%	O
NRB	O
.	O
Exam	O
revealed	O
orientation	O
x	O
1	O
(	O
reportedly	O
baseline	O
)	O
,	O
crackles	O
at	O
L	O
base	O
.	O
WBC	O
19.9	O
with	O
94.3	O
%	O
N	O
,	O
3.1	O
%	O
L	O
,	O
no	O
bands	O
.	O
Na	O
152	O
,	O
K	O
2.9	O
,	O
Cl	O
111	O
,	O
HCO3	O
27	O
,	O
BUN	O
29	O
,	O
Cr	O
0.7	O
.	O
CXR	O
showed	O
large	O
LLL	O
infiltrate	O
.	O
ABG	O
7.51	O
/	O
35/60	O
,	O
EKG	O
with	O
no	O
ischemic	O
changes	O
.	O
She	O
received	O
ceftriaxone	B-Drug
,	I-Drug
levoflox	I-Drug
,	O
vanco	I-Drug
,	O
acetaminophen	B-Drug
,	I-Drug
500	O
ml	O
NS	I-Drug
.	O
Of	O
note	O
,	O
patient	O
is	O
full	O
code	O
per	O
NH	O
.	O
.	O
ROS	O
:	O
not	O
obtainable	O
due	O
to	O
dementia	O
.	O
Past	O
Medical	O
History	O
:	O
depression	O
dementia	O
anxiety	O
constipation	O
thrombocytopenia	I-Ade
from	O
valproic	B-Drug
acid	I-Drug
s	O
/	O
p	O
incarcerated	O
inguinal	O
hernia	O
repair	O
.	O
Social	O
History	O
:	O
Lives	O
at	O
nursing	O
home	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
T	O
:	O
98.0	O
oral	O
BP	O
:	O
118/54	O
HR	O
:	O
88	O
RR	O
:	O
34	O
O2Sat	O
:	O
96	O
%	O
on	O
NRB	O
GEN	O
:	O
Tired	O
-	O
appearing	O
elderly	O
woman	O
,	O
tachypneic	O
,	O
with	O
slight	O
use	O
of	O
accessory	O
muscles	O
HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
sclera	O
anicteric	O
,	O
MMM	O
,	O
OP	O
Clear	O
but	O
very	O
poor	O
dentition	O
NECK	O
:	O
No	O
JVD	O
,	O
no	O
bruits	O
,	O
no	O
cervical	O
lymphadenopathy	O
,	O
trachea	O
midline	O
,	O
severe	O
kyphosis	O
COR	O
:	O
Regular	O
rhythm	O
,	O
normal	O
rate	O
,	O
normal	O
S1	O
/	O
S2	O
,	O
3/6	O
systolic	O
murmur	O
>	O
at	O
LUSB	O
,	O
radial	O
pulses	O
+2	O
PULM	O
:	O
Scattered	O
crackles	O
R	O
lung	O
base	O
,	O
otherwise	O
clear	O
on	O
right	O
.	O
Left	O
with	O
decreased	O
BS	O
at	O
base	O
and	O
rhonchi	O
.	O
Pt	O
coughing	O
frequently	O
during	O
exam	O
ABD	O
:	O
Soft	O
,	O
slightly	O
tender	O
to	O
palpation	O
of	O
suprapubic	O
area	O
,	O
otherwise	O
nontender	O
,	O
ND	O
,	O
+	O
BS	O
,	O
no	O
HSM	O
,	O
no	O
masses	O
EXT	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
,	O
1	O
+	O
dp	O
pulses	O
b	O
/	O
l.	O
No	O
ulcers	O
NEURO	O
:	O
Alert	O
,	O
oriented	O
to	O
person	O
only	O
.	O
CN	O
II	O
??????	O
XII	O
grossly	O
intact	O
.	O
Moves	O
all	O
4	O
extremities	O
.	O
SKIN	O
:	O
No	O
jaundice	O
,	O
cyanosis	O
,	O
or	O
gross	O
dermatitis	O
.	O
No	O
ecchymoses	O
.	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
WBC	O
-	O
19.9	O
*	O
#	O
RBC	O
-	O
3.84	O
*	O
HGB	O
-	O
12.1	O
HCT	O
-	O
36.0	O
MCV	O
-	O
94	O
MCH	O
-	O
31.4	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
13.8	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
NEUTS	O
-	O
94.3	O
*	O
LYMPHS	O
-	O
3.1	O
*	O
MONOS	O
-	O
2.3	O
EOS	O
-	O
0.1	O
BASOS	O
-	O
0.2	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
PLT	O
COUNT	O
-	O
287	O
#	O
.	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
PT	O
-	O
15.0	O
*	O
PTT	O
-	O
30.9	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
.	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
GLUCOSE	O
-	O
153	O
*	O
UREA	O
N	O
-	O
29	O
*	O
CREAT	O
-	O
0.7	O
SODIUM	O
-	O
152	O
*	O
POTASSIUM	O
-	O
2.9	O
*	O
CHLORIDE	O
-	O
111	O
*	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
17	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:23	O
AM	O
LACTATE	O
-	O
1.6	O
.	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
CK	O
(	O
CPK	O
)	O
-	O
130	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
cTropnT	O
-	O
0.09	O
*	O
[	O
**	O
2105-12-7	O
**	O
]	O
09:25	O
AM	O
CK	O
-	O
MB	O
-	O
4	O
[	O
**	O
2105-12-7	O
**	O
]	O
05:05	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
237	O
*	O
[	O
**	O
2105-12-7	O
**	O
]	O
05:05	O
PM	O
CK	O
-	O
MB	O
-	O
6	O
cTropnT	O
-	O
0.08	O
*	O
.	O
Admission	O
CXR	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Left	O
basilar	O
consolidation	O
representative	O
of	O
atelectasis	O
or	O
early	O
pneumonia	O
.	O
2	O
.	O
Small	O
left	O
pleural	O
effusion	O
.	O
3	O
.	O
Underlying	O
apical	O
emphysema	O
.	O
Right	O
apical	O
scarring	O
.	O
.	O
[	O
**	O
2105-12-9	O
**	O
]	O
ECHO	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
elongated	O
.	O
No	O
left	O
atrial	O
mass	O
/	O
thrombus	O
seen	O
(	O
best	O
excluded	O
by	O
transesophageal	O
echocardiography	O
)	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
global	O
systolic	O
function	O
.	O
Distal	O
septal	O
hyopkinesis	O
is	O
suggested	O
on	O
some	O
views	O
,	O
but	O
could	O
not	O
be	O
confirmed	O
.	O
Overall	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
60	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
severely	O
thickened	O
/	O
deformed	O
.	O
There	O
is	O
mild	O
aortic	O
valve	O
stenosis	O
(	O
area	O
1.2	O
cm2	O
)	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
very	O
small	O
pericardial	O
effusion	O
without	O
evidence	O
for	O
hemodynamic	O
compromise	O
.	O
IMPRESSION	O
:	O
Mild	O
aortic	O
stenosis	O
.	O
Mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
Normal	O
biventricular	O
cavity	O
sizes	O
with	O
preserved	O
global	O
biventricular	O
systolic	O
function	O
.	O
.	O
[	O
**	O
2105-12-11	O
**	O
]	O
CT	O
CHEST	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Small	O
bilateral	O
pleural	O
effusions	O
,	O
left	O
greater	O
than	O
right	O
.	O
Dense	O
consolidation	O
in	O
the	O
left	O
lower	O
lobe	O
and	O
lingula	O
consistent	O
with	O
atelectasis	O
and	O
pneumonia	O
.	O
Scattered	O
bilateral	O
ground	O
glass	O
nodules	O
likely	O
represent	O
infectious	O
process	O
.	O
Limited	O
evaluation	O
for	O
empyema	O
due	O
to	O
lack	O
of	O
IV	O
contrast	I-Drug
.	O
2	O
.	O
Extensive	O
calcifications	O
of	O
the	O
aorta	O
and	O
its	O
branches	O
.	O
3	O
.	O
Compression	O
fractures	O
of	O
the	O
thoracic	O
spine	O
of	O
indeterminate	O
age	O
.	O
.	O
[	O
**	O
2105-12-15	O
**	O
]	O
REPEAT	O
CT	O
CHEST	O
:	O
IMPRESSION	O
:	O
As	O
compared	O
to	O
the	O
previous	O
examination	O
from	O
[	O
**	O
12	O
-	O
11	O
**	O
]	O
,	O
there	O
is	O
no	O
major	O
overall	O
change	O
in	O
the	O
extent	O
of	O
pleural	O
effusions	O
.	O
Unchanged	O
extensive	O
left	O
lower	O
lobe	O
consolidation	O
.	O
Regression	O
of	O
the	O
pre-existing	O
right	O
than	O
left	O
apical	O
opacities	O
.	O
Unchanged	O
extensive	O
coronary	O
and	O
aortic	O
calcifications	O
.	O
No	O
newly	O
appeared	O
pulmonary	O
changes	O
in	O
the	O
interval	O
.	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
-	O
year	O
-	O
old	O
woman	O
with	O
history	O
of	O
HTN	O
presented	O
with	O
hypoxia	O
,	O
dyspnea	O
,	O
found	O
to	O
have	O
a	O
LLL	O
pneumonia	O
.	O
.	O
#	O
Sepsis	O
/	O
Pneumonia	O
:	O
Patient	O
was	O
admitted	O
to	O
the	O
ICU	O
on	O
non-rebreather	O
and	O
acutely	O
decompensated	O
overnight	O
.	O
She	O
had	O
hypoxemic	O
respiratory	O
failure	O
requiring	O
intubation	O
which	O
was	O
agreeable	O
to	O
her	O
neice	O
and	O
HCP	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
.	O
She	O
became	O
pressor	I-Drug
dependent	O
while	O
intubated	O
for	O
pressures	B-Reason
in	I-Reason
the	I-Reason
60s	I-Reason
/	I-Reason
30s	I-Reason
and	O
went	O
in	O
to	O
A-fib	O
with	O
RVR	O
(	O
see	O
below	O
)	O
.	O
She	O
was	O
started	O
on	O
Vancomycin	I-Drug
and	O
Zosyn	I-Drug
on	O
[	O
**	O
2105-12-7	O
**	O
]	O
for	O
HAP	I-Reason
.	O
Sputum	O
cx	O
and	O
bronchoscopy	O
x2	O
failed	O
to	O
reveal	O
infectious	O
bacteria	O
,	O
but	O
she	O
was	O
kept	O
on	O
these	O
antibiotics	I-Drug
given	O
her	O
respiratory	O
status	O
and	O
pressor	I-Drug
dependence	O
.	O
After	O
much	O
discussion	O
with	O
HCP	O
it	O
was	O
decided	O
that	O
she	O
would	O
not	O
want	O
trachiotomy	O
or	O
PEG	O
tube	O
and	O
would	O
prefer	O
extubation	O
,	O
even	O
if	O
this	O
leads	O
to	O
her	O
demise	O
.	O
The	O
decision	O
has	O
been	O
made	O
to	O
make	O
pt	O
??????	O
s	O
goals	O
of	O
care	O
comfort	O
oriented	O
-	O
no	O
further	O
interventions	O
,	O
no	O
heroic	O
measures	O
.	O
She	O
eventually	O
was	O
weaned	O
off	O
pressors	I-Drug
on	O
[	O
**	O
2105-12-18	O
**	O
]	O
and	O
was	O
extubated	O
.	O
She	O
finished	O
a	O
14	O
day	O
course	O
of	O
Vanc	I-Drug
and	O
Zosyn	I-Drug
on	O
[	O
**	O
2105-12-20	O
**	O
]	O
.	O
Since	O
then	O
has	O
been	O
afebrile	O
.	O
Her	O
code	O
status	O
was	O
changed	O
back	O
to	O
Full	O
code	O
.	O
#	O
Acute	O
Hypoxemic	O
Respiratory	O
Failure	O
:	O
resolved	O
with	O
91	O
-	O
92	O
%	O
/	O
RA	O
.	O
As	O
above	O
,	O
patient	O
was	O
intubated	O
from	O
[	O
**	O
2105-12-8	O
**	O
]	O
to	O
[	O
**	O
2105-12-18	O
**	O
]	O
.	O
SHe	O
continues	O
to	O
have	O
incr	O
plugging	O
which	O
has	O
been	O
treated	O
with	O
aggressive	O
suctioning	O
and	O
chest	O
PT	O
.	O
Was	O
on	O
Vanc	I-Drug
/	O
Zosyn	I-Drug
which	O
ended	O
on	O
[	O
**	O
2105-12-20	O
**	O
]	O
.	O
She	O
does	O
continue	O
to	O
have	O
a	O
large	O
left	O
pleural	O
effusion	O
,	O
and	O
right	O
effusion	O
,	O
without	O
clear	O
infectious	O
etiology	O
.	O
This	O
is	O
most	O
likely	O
from	O
CHF	O
.	O
It	O
was	O
unlikely	O
that	O
doing	O
thoracentesis	O
would	O
help	O
her	O
with	O
improved	O
oxygenation	O
and	O
that	O
the	O
fluid	O
would	O
most	O
likely	O
reaccumulate	O
from	O
CHF	O
.	O
Also	O
given	O
her	O
kyphotic	O
posture	O
,	O
she	O
would	O
unlikely	O
go	O
over	O
her	O
current	O
oxygen	O
saturation	O
level	O
on	O
room	O
air	O
.	O
.	O
#	O
Atrial	B-Reason
fibrillation	I-Reason
with	I-Reason
RVR	I-Reason
:	O
Patient	O
converted	O
to	O
A-fib	O
with	O
RVR	O
during	O
her	O
hypoxic	O
respiratory	O
failure	O
.	O
Her	O
rate	O
was	O
initially	O
controlled	O
with	O
IV	O
diltiazem	B-Drug
.	I-Drug
She	O
was	O
started	O
on	O
amiodarone	I-Drug
gtt	O
and	O
converted	O
to	O
sinus	O
on	O
[	O
**	O
2105-12-9	O
**	O
]	O
.	O
She	O
was	O
transitioned	O
to	O
PO	O
amiodarone	I-Drug
for	O
taper	O
and	O
will	O
be	O
tapered	O
from	O
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
400	O
mg	O
qday	O
on	O
[	O
**	O
2105-12-23	O
**	O
]	O
which	O
should	O
last	O
for	O
1	O
week	O
,	O
then	O
be	O
reduced	O
to	O
200	O
mg	O
daily	O
.	O
.	O
#	O
Acute	O
encephalopathy	O
:	O
She	O
developed	O
change	O
in	O
mental	O
status	O
as	O
a	O
result	O
of	O
her	O
prolonged	O
ICU	O
stay	O
,	O
and	O
gradually	O
cleared	O
post	O
extubation	O
.	O
.	O
#	O
Diastolic	O
CHF	O
,	O
acute	O
:	O
She	O
developed	O
bilateral	O
pleural	O
effusions	O
and	O
interstitial	O
edema	O
with	O
fluid	O
resuscitation	O
.	O
She	O
had	O
an	O
ECHO	O
that	O
showed	O
a	O
preserved	O
EF	O
.	O
Attempts	O
were	O
made	O
at	O
diuresis	O
but	O
were	O
limited	O
by	O
her	O
low	O
intravascular	O
volume	O
.	O
.	O
#	O
Hypernatremia	O
:	O
Sodium	O
went	O
up	O
to	O
almost	O
148	O
after	O
diuresis	O
.	O
Diuresis	O
was	O
then	O
held	O
and	O
she	O
was	O
given	O
back	O
fluid	O
.	O
She	O
can	O
be	O
diuresed	O
at	O
rehab	O
PRN	O
.	O
Also	O
her	O
sodium	O
will	O
need	O
to	O
be	O
checked	O
in	O
[	O
**	O
3	O
-	O
15	O
**	O
]	O
days	O
to	O
monitor	O
.	O
.	O
#	O
Diarrhea	I-Reason
:	O
She	O
developed	O
diarrhea	O
after	O
antibiotic	I-Drug
treatment	O
was	O
completed	O
.	O
She	O
had	O
two	O
negative	O
cdiffs	O
.	O
She	O
was	O
treated	O
empirically	O
with	O
flagyl	B-Drug
,	I-Drug
which	O
was	O
discontinued	O
after	O
the	O
c	O
diff	O
was	O
negative	O
.	O
.	O
#	O
Goals	O
of	O
care	O
:	O
This	O
was	O
discussed	O
repeatedly	O
with	O
her	O
HCP	O
,	O
who	O
originally	O
made	O
her	O
DNR	O
/	O
DNI	O
when	O
she	O
was	O
terminally	O
extubated	O
.	O
However	O
,	O
since	O
she	O
survived	O
extubation	O
,	O
they	O
chose	O
to	O
again	O
make	O
her	O
full	O
code	O
.	O
This	O
should	O
continue	O
to	O
be	O
addressed	O
.	O
Medications	O
on	O
Admission	O
:	O
memantine	I-Drug
10	O
mg	O
PO	O
qam	O
/	O
5	O
mg	O
qpm	O
miralax	I-Drug
sertraline	I-Drug
100	O
mg	O
qday	O
simvastatin	I-Drug
80	O
mg	O
qhs	O
acetaminophen	I-Drug
prn	O
alprazolam	I-Drug
0.25	O
mg	O
PO	O
bid	O
simethicone	I-Drug
1	O
tab	O
qd	O
lidoderm	I-Drug
patch	O
MVI	B-Drug
with	I-Drug
minerals	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
5000	O
(	O
5000	O
)	O
units	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Memantine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
qam	O
(	O
)	O
.	O
3	O
.	O
Memantine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
qpm	O
(	O
)	O
.	O
4	O
.	O
Acetaminophen	I-Drug
160	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
1	O
-	O
2	O
tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
5	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
X	O
1week	O
,	O
then	O
200	O
mg	O
po	O
daily	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
599	O
**	O
]	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
55	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Acute	O
hypoxic	O
respiratory	O
failure	O
.	O
Atrial	O
fibrillation	O
with	O
rapid	O
response	O
.	O
Pneumonia	O
.	O
Encephalopathy	O
Diastolic	O
heart	O
failure	O
exacerbation	O
,	O
acute	O
.	O
Discharge	O
Condition	O
:	O
Stable	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
pneumonia	O
to	O
the	O
ICU	O
.	O
You	O
had	O
a	O
tube	O
to	O
help	O
you	O
breath	O
for	O
almost	O
two	O
weeks	O
,	O
but	O
then	O
it	O
was	O
taken	O
out	O
.	O
You	O
also	O
had	O
a	O
rapid	O
hear	O
trate	O
,	O
that	O
is	O
now	O
improved	O
.	O
You	O
continue	O
to	O
have	O
fluid	O
in	O
your	O
lungs	O
,	O
and	O
have	O
become	O
extremely	O
weak	O
during	O
your	O
hospital	O
stay	O
.	O
.	O
Return	O
to	O
the	O
ER	O
if	O
you	O
develop	O
worsening	O
symptoms	O
,	O
fevers	O
,	O
chills	O
or	O
trouble	O
breathing	O
,	O
or	O
palpitations	O
or	O
chest	O
pain	O
.	O
.	O
Please	O
give	O
Oxygen	I-Drug
by	O
nasal	O
cannula	O
if	O
oxygen	B-Reason
saturation	I-Reason
goes	I-Reason
below	O
92	O
%	O
on	O
room	O
air	O
or	O
is	O
short	B-Reason
of	I-Reason
breath	I-Reason
.	O
.	O
Will	O
need	O
recheck	O
of	O
serum	O
sodium	O
in	O
2	O
days	O
to	O
monitor	O
level	O
.	O
Followup	O
Instructions	O
:	O
BMP	O
on	O
[	O
**	O
2105-12-27	O
**	O
]	O
.	O
Follow	O
up	O
with	O
your	O
PCP	O
at	O
the	O
nursing	O
home	O
when	O
you	O
arrive	O
.	O
.	O
Will	O
need	O
recheck	O
of	O
serum	O
sodium	O
in	O
2	O
days	O
to	O
monitor	O
level	O
.	O
Completed	O
by	O
:[	O
**	O
2105-12-26	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2105-4-28	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2105-5-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2075-11-29	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
NEUROLOGY	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1838	O
**	O
]	O
Chief	O
Complaint	O
:	O
Headache	O
,	O
right	O
-	O
sided	O
weakness	O
and	O
drowsiness	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Intubation	O
.	O
Tracheostomy	O
PEG	O
tube	O
History	O
of	O
Present	O
Illness	O
:	O
Patient	O
admitted	O
from	O
:	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ER	O
History	O
obtained	O
from	O
Medical	O
records	O
,	O
mother	O
and	O
[	O
**	O
Name	O
(	O
NI	O
)	O
6435	O
**	O
]	O
nurse	O
.	O
Patient	O
unable	O
to	O
provide	O
history	O
:	O
Sedated	O
HPI	O
:	O
29	O
yo	O
M	O
with	O
hx	O
HTN	O
(	O
per	O
mother	O
diagnosed	O
at	O
age	O
8	O
,	O
on	O
medications	O
since	O
age	O
17	O
,	O
on	O
four	O
anti-hypertensive	O
agents	O
at	O
home	O
but	O
unsure	O
of	O
meds	O
,	O
and	O
unclear	O
etiology	O
of	O
HTN	O
)	O
,	O
presents	O
with	O
headache	O
,	O
right	O
-	O
sided	O
weakness	O
,	O
and	O
drowsiness	O
.	O
Per	O
mother	O
likely	O
not	O
always	O
compliant	O
with	O
meds	O
listed	O
to	O
the	O
right	O
.	O
He	O
has	O
been	O
hypertensive	O
since	O
8	O
years	O
,	O
with	O
low	O
sodium	O
diet	O
effective	O
until	O
age	O
of	O
17	O
,	O
then	O
medications	O
started	O
.	O
Since	O
that	O
time	O
his	O
PCP	O
has	O
been	O
:	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
89664	O
**	O
]	O
,	O
South	O
JP	O
Health	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
37648	O
**	O
]	O
.	O
Per	O
EMS	O
he	O
was	O
having	O
intercourse	O
and	O
at	O
9:15	O
PM	O
he	O
developed	O
sudden	O
-	O
onset	O
headache	O
and	O
then	O
developed	O
right	O
facial	O
droop	O
and	O
right	O
-	O
sided	O
weakness	O
.	O
He	O
was	O
non-verbal	O
and	O
appeared	O
somnolent	O
.	O
A	O
code	O
-	O
stroke	O
was	O
called	O
.	O
ROS	O
unobtainable	O
.	O
Events	O
Since	O
Admission	O
:	O
Called	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
3726	O
**	O
]	O
.	O
PCP	O
away	O
until	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
766	O
**	O
]	O
,	O
but	O
nurse	O
will	O
call	O
neuro	O
team	O
back	O
.	O
Then	O
:	O
Nurse	O
returned	O
call	O
.	O
No	O
known	O
cause	O
for	O
hypertension	O
.	O
Has	O
seen	O
Cardiology	O
(	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
29204	O
**	O
]	O
,	O
[	O
**	O
Hospital1	O
756	O
**	O
]	O
)	O
,	O
confirmed	O
medications	O
.	O
Last	O
BP	O
on	O
office	O
visit	O
was	O
127/72	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Hypertension	O
as	O
above	O
-	O
Asthma	O
Social	O
History	O
:	O
Occupation	O
:	O
supervisor	O
at	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
89665	O
**	O
]	O
liquor	O
store	O
Drugs	O
:	O
None	O
.	O
Tobacco	O
:	O
None	O
.	O
Alcohol	O
:	O
Rare	O
Family	O
History	O
:	O
-	O
father	O
died	O
at	O
age	O
48	O
from	O
heart	O
disease	O
,	O
mother	O
and	O
sister	O
with	O
hypertension	O
Physical	O
Exam	O
:	O
Vital	O
Signs	O
:	O
Flowsheet	O
Data	O
as	O
of	O
[	O
**	O
2105-4-29	O
**	O
]	O
07:57	O
AM	O
Tmax	O
:	O
36.9	O
??????	O
C	O
(	O
98.4	O
??????	O
F	O
)	O
Tcurrent	O
:	O
36.9	O
??????	O
C	O
(	O
98.4	O
??????	O
F	O
)	O
HR	O
:	O
86	O
(	O
78	O
-	O
96	O
)	O
bpm	O
BP	O
:	O
150/76	O
(	O
93	O
)	O
{	O
123/56	O
(	O
72	O
)	O
-	O
155/96	O
(	O
109	O
)	O
}	O
mmHg	O
RR	O
:	O
24	O
(	O
19	O
-	O
25	O
)	O
insp	O
/	O
min	O
SpO2	O
:	O
99	O
%	O
Heart	O
rhythm	O
:	O
SR	O
(	O
Sinus	O
Rhythm	O
)	O
Wgt	O
(	O
current	O
)	O
:	O
95.9	O
kg	O
(	O
admission	O
)	O
:	O
95.9	O
kg	O
Fluid	O
Balance	O
(	O
24	O
hours	O
;	O
since	O
midnight	O
)	O
0	O
mL	O
;	O
593	O
mL	O
Ventilator	O
-	O
intubated	O
,	O
CPAP	O
O2	O
Delivery	O
Device	O
:	O
Endotracheal	O
tube	O
Ventilator	O
mode	O
:	O
CPAP	O
/	O
PSV	O
Vt	O
(	O
Spontaneous	O
)	O
:	O
428	O
(	O
428	O
-	O
520	O
)	O
mL	O
PS	O
:	O
10	O
cmH2O	O
RR	O
(	O
Spontaneous	O
)	O
:	O
22	O
PEEP	O
:	O
5	O
cmH2O	O
FiO2	O
:	O
60	O
%	O
RSBI	O
Deferred	O
:	O
FiO2	O
>	O
60	O
%	O
,	O
Hemodynamic	O
Instability	O
PIP	O
:	O
16	O
cmH2O	O
SpO2	O
:	O
99	O
%	O
ABG	O
:	O
/	O
/	O
/	O
28	O
/	O
Ve	O
:	O
9	O
L	O
/	O
min	O
Physical	O
Examination	O
:	O
Gen	O
lying	O
in	O
bed	O
,	O
eyes	O
closed	O
,	O
NAD	O
CV	O
:	O
RRR	O
,	O
no	O
murmurs	O
Pulm	O
:	O
CTA	O
anteriorly	O
Abd	O
:	O
soft	O
,	O
nt	O
,	O
nd	O
Extr	O
:	O
no	O
edema	O
Neurologic	O
:	O
Sedated	O
on	O
Propofol	I-Drug
.	O
Awakens	O
with	O
cessation	O
of	O
sedation	O
.	O
Normal	O
breathing	O
pattern	O
.	O
Level	O
of	O
arousal	O
normal	O
,	O
but	O
not	O
alert	O
.	O
Not	O
following	O
commands	O
(	O
but	O
had	O
for	O
nurse	O
with	O
longer	O
break	O
in	O
sedation	O
with	O
squeezing	O
left	O
hand	O
)	O
.	O
Attempted	O
to	O
reach	O
for	O
tube	O
when	O
released	O
from	O
restraint	O
.	O
Mild	O
anisocoria	O
with	O
slightly	O
smaller	O
pupil	O
on	O
right	O
,	O
but	O
otherwise	O
near	O
equal	O
and	O
both	O
react	O
.	O
EOM	O
limited	O
-	O
did	O
not	O
look	O
to	O
left	O
,	O
gaze	O
mildly	O
disconjugate	O
.	O
Right	O
facial	O
droop	O
.	O
Tone	O
flaccid	O
on	O
right	O
.	O
Left	O
arm	O
and	O
leg	O
are	O
antigravity	O
.	O
Reflexes	O
mildly	O
brisker	O
for	O
left	O
arm	O
(	O
brachiradialis	O
only	O
)	O
and	O
Troemner	O
in	O
left	O
hand	O
.	O
Reflexes	O
symmetric	O
for	O
the	O
LE	O
's	O
with	O
upgoing	O
toe	O
on	O
left	O
and	O
equivocal	O
on	O
right	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2105-5-1	O
**	O
]	O
02:23	O
AM	O
BLOOD	O
WBC	O
-	O
9.1	O
RBC	O
-	O
4.61	O
Hgb	O
-	O
13.5	O
*	O
Hct	O
-	O
38.7	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
29.4	O
MCHC	O
-	O
35.0	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
226	O
[	O
**	O
2105-4-29	O
**	O
]	O
03:40	O
AM	O
BLOOD	O
PT	O
-	O
13.2	O
PTT	O
-	O
23.0	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2105-5-1	O
**	O
]	O
02:23	O
AM	O
BLOOD	O
Glucose	O
-	O
116	O
*	O
UreaN	O
-	O
13	O
Creat	O
-	O
0.9	O
Na	O
-	O
137	O
K	O
-	O
3.1	O
*	O
Cl	O
-	O
101	O
HCO3	O
-	O
30	O
AnGap	O
-	O
9	O
[	O
**	O
2105-4-29	O
**	O
]	O
03:40	O
AM	O
BLOOD	O
ALT	O
-	O
41	O
*	O
AST	O
-	O
23	O
CK	O
(	O
CPK	O
)	O
-	O
179	O
AlkPhos	O
-	O
58	O
TotBili	O
-	O
0.3	O
[	O
**	O
2105-4-29	O
**	O
]	O
03:40	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
4	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2105-4-28	O
**	O
]	O
09:35	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
5	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2105-5-1	O
**	O
]	O
02:23	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
4.0	O
Mg	O
-	O
2.0	O
[	O
**	O
2105-4-28	O
**	O
]	O
09:35	O
PM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
[	O
**	O
2105-4-28	O
**	O
]	O
09:43	O
PM	O
BLOOD	O
Lactate	O
-	O
2.4	O
*	O
[	O
**	O
2105-4-30	O
**	O
]	O
07:58	O
PM	O
URINE	O
Color	O
-	O
Straw	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.004	O
[	O
**	O
2105-4-30	O
**	O
]	O
07:58	O
PM	O
URINE	O
Blood	O
-	O
NEG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
NEG	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
10	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
6.5	O
Leuks	O
-	O
NEG	O
[	O
**	O
2105-4-28	O
**	O
]	O
10:45	O
PM	O
URINE	O
RBC	O
-	O
0	O
WBC	O
-	O
<	O
1	O
Bacteri	O
-	O
NONE	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
0	O
[	O
**	O
2105-4-28	O
**	O
]	O
11:00	O
PM	O
URINE	O
bnzodzp	O
-	O
NEG	O
barbitr	O
-	O
NEG	O
opiates	O
-	O
NEG	O
cocaine	O
-	O
NEG	O
amphetm	O
-	O
NEG	O
mthdone	O
-	O
NEG	O
CT	O
(	O
head	O
)	O
[	O
**	O
2105-5-7	O
**	O
]	O
Since	O
the	O
prior	O
study	O
,	O
slight	O
evolution	O
of	O
the	O
blood	O
products	O
seen	O
in	O
the	O
pons	O
without	O
change	O
in	O
the	O
mass	O
effect	O
.	O
No	O
hydrocephalus	O
seen	O
.	O
TTE	O
:	O
[	O
**	O
2105-5-6	O
**	O
]	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
Hyperdynamic	O
left	O
ventricular	O
systolic	O
function	O
with	O
a	O
mild	O
mid	O
cavitary	O
resting	O
gradient	O
.	O
No	O
significant	O
valvular	O
abnormality	O
.	O
CT	O
(	O
head	O
)	O
:	O
[	O
**	O
2105-4-28	O
**	O
]	O
13	O
x	O
16	O
mm	O
left	O
pontine	O
hemorrhage	O
.	O
An	O
MR	O
should	O
be	O
obtained	O
for	O
further	O
evaluation	O
to	O
rule	O
out	O
an	O
underlying	O
mass	O
lesion	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
29	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
hypertension	O
.	O
He	O
has	O
undergone	O
work	O
-	O
up	O
by	O
his	O
primary	O
care	O
doctor	O
,	O
a	O
renal	O
physician	O
and	O
cardiology	O
,	O
without	O
known	O
cause	O
.	O
Hypertension	O
appears	O
to	O
be	O
familial	O
,	O
present	O
in	O
his	O
father	O
and	O
sister	O
,	O
both	O
from	O
a	O
young	O
age	O
.	O
It	O
is	O
possible	O
that	O
whatever	O
underlying	O
predisposition	O
he	O
has	O
is	O
inherited	O
in	O
an	O
autosomally	O
dominant	O
fashion	O
,	O
although	O
this	O
can	O
not	O
be	O
concluded	O
given	O
our	O
limited	O
knowledge	O
of	O
his	O
pedigree	O
.	O
Further	O
outpatient	O
work	O
-	O
up	O
seems	O
warranted	O
.	O
There	O
was	O
no	O
underlying	O
vascular	O
malformation	O
or	O
other	O
lesion	O
from	O
which	O
this	O
hemorrhage	O
has	O
arisen	O
,	O
at	O
least	O
at	O
the	O
resolution	O
of	O
CT.	O
.	O
His	O
compliance	O
has	O
been	O
good	O
but	O
imperfect	O
,	O
so	O
we	O
think	O
that	O
his	O
hemorrhage	O
was	O
most	O
likely	O
hypertensive	O
during	O
the	O
exertions	O
of	O
sexual	O
activity	O
.	O
As	O
such	O
,	O
a	O
primary	O
goal	O
has	O
been	O
to	O
control	O
his	O
blood	O
pressure	O
,	O
which	O
is	O
now	O
quite	O
adequate	O
.	O
The	O
hemorrhage	O
was	O
in	O
the	O
basis	O
pontis	O
on	O
the	O
left	O
,	O
with	O
apparent	O
vasogenic	O
edema	O
of	O
the	O
overlying	O
tegmentum	O
.	O
Although	O
there	O
is	O
not	O
frank	O
hemorrhage	O
into	O
the	O
midline	O
pontine	O
tegmentum	O
,	O
edema	O
and	O
mass	O
effect	O
in	O
this	O
area	O
most	O
likely	O
accounts	O
for	O
drowsiness	O
.	O
He	O
initially	O
demonstrated	O
Troemner	O
's	O
and	O
Babinksi	O
's	O
signs	O
on	O
the	O
left	O
,	O
suggesting	O
some	O
mass	O
effect	O
to	O
the	O
right	O
basis	O
pontis	O
,	O
but	O
this	O
is	O
now	O
resolved	O
.	O
Eye	O
movement	O
abnormality	O
is	O
partially	O
explained	O
by	O
lesion	O
of	O
the	O
tract	O
of	O
the	O
sixth	O
nucleus	O
,	O
with	O
nuclear	O
sparing	O
.	O
In	O
addition	O
,	O
adbuction	O
to	O
the	O
right	O
is	O
incomplete	O
and	O
the	O
reason	O
for	O
this	O
is	O
only	O
speculative	O
.	O
He	O
demonstrates	O
loss	O
of	O
voluntary	O
cough	O
and	O
swallow	O
,	O
with	O
preservation	O
of	O
brisk	O
involuntary	O
cough	O
,	O
likely	O
due	O
to	O
the	O
effect	O
of	O
the	O
lesion	O
on	O
the	O
dorsal	O
midline	O
portion	O
of	O
basis	O
pontis	O
,	O
with	O
preserved	O
nucleus	O
ambiguus	O
and	O
lateral	O
medulla	O
.	O
Drowsiness	O
resulted	O
in	O
intubation	O
while	O
at	O
the	O
scanner	O
after	O
arrival	O
at	O
the	O
ED	O
.	O
He	O
was	O
extubated	O
successfully	O
on	O
[	O
**	O
2105-4-28	O
**	O
]	O
,	O
with	O
some	O
difficult	O
managing	O
secretion	O
,	O
but	O
not	O
oxygenation	O
.	O
When	O
extubated	O
and	O
with	O
controlled	O
pressure	O
he	O
was	O
transferred	O
to	O
the	O
neurology	O
step	O
-	O
down	O
unit	O
.	O
Atenolol	I-Drug
was	O
stopped	O
and	O
replaced	O
with	O
metoprolol	B-Drug
tartrate	I-Drug
given	O
better	O
24	O
hour	O
coverage	O
and	O
conversion	O
to	O
the	O
succinate	O
salt	O
is	O
intended	O
at	O
discharge	O
.	O
After	O
PEG	O
placement	O
he	O
had	O
desaturations	O
to	O
the	O
low	O
80s	O
and	O
was	O
sent	O
back	O
to	O
the	O
ICU	O
.	O
His	O
CXR	O
showed	O
low	O
lung	O
volumes	O
and	O
the	O
etiology	O
was	O
thought	O
to	O
be	O
from	O
the	O
abdominal	O
binder	O
and	O
restrictive	O
lung	O
disease	O
.	O
He	O
was	O
able	O
to	O
be	O
weaned	O
to	O
trach	O
mask	O
with	O
low	O
O2	O
requirements	O
and	O
sent	O
back	O
to	O
the	O
floor	O
.	O
His	O
blood	O
pressure	O
was	O
stable	O
for	O
48	O
hours	O
prior	O
to	O
discharge	O
in	O
the	O
120s	O
-	O
130s	O
systolic	O
.	O
He	O
will	O
follow	O
up	O
in	O
clinic	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
Amlodipine	I-Drug
10	O
mg	O
Atenolol	I-Drug
50	O
mg	O
Lisinopril	B-Drug
/	I-Drug
HCTZ	I-Drug
20/25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Doxazosin	I-Drug
QHS	O
-	O
dose	O
unknown	O
Discharge	O
Medications	O
:	O
1	O
.	O
heparin	B-Drug
(	I-Drug
porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
ml	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QNOON	O
(	O
)	O
.	O
3	O
.	O
hydrochlorothiazide	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
4	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
lisinopril	I-Drug
30	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
6	O
.	O
doxazosin	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
7	O
.	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
8	O
.	O
ipratropium	B-Drug
bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
NEB	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
sob	I-Reason
,	O
wheezing	I-Reason
.	O
9	O
.	O
albuterol	B-Drug
sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
NEB	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
/	O
Wheezing	I-Reason
.	O
10	O
.	O
baclofen	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
11	O
.	O
famotidine	I-Drug
(	O
PF	O
)	O
in	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
(	O
iso	O
-	O
os	O
)	O
20	O
mg	O
/	O
50	O
mL	O
Piggyback	O
Sig	O
:	O
Fifty	O
(	O
50	O
)	O
ml	O
Intravenous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
12	O
.	O
bisacodyl	I-Drug
10	O
mg	O
Suppository	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
13	O
.	O
senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ml	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
14	O
.	O
docusate	B-Drug
sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
Ten	O
(	O
10	O
)	O
ml	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
dose	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
85	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Pontine	O
hemorrhage	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
-	O
unable	O
to	O
speak	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
-	O
unable	O
to	O
speak	O
Activity	O
Status	O
:	O
Bedbound	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
neurology	O
service	O
stroke	O
service	O
after	O
you	O
developed	O
sudden	O
onset	O
of	O
headache	O
and	O
right	O
sided	O
weakness	O
.	O
On	O
examination	O
you	O
had	O
a	O
flaccid	O
paralysis	O
on	O
your	O
right	O
side	O
and	O
your	O
eyes	O
were	O
unable	O
to	O
look	O
to	O
the	O
left	O
.	O
You	O
also	O
had	O
significant	O
bulbar	O
weakness	O
which	O
limited	O
your	O
ability	O
to	O
speak	O
.	O
Your	O
understanding	O
of	O
language	O
was	O
intact	O
.	O
Your	O
imaging	O
showed	O
a	O
left	O
sided	O
pontine	O
hemorrhage	O
.	O
The	O
etiology	O
of	O
the	O
bleed	O
was	O
likely	O
related	O
to	O
longstanding	O
hypertensive	O
which	O
was	O
not	O
always	O
controlled	O
.	O
You	O
were	O
started	O
on	O
several	O
antihypertensives	I-Drug
with	O
a	O
current	O
goal	O
of	O
being	O
normotensive	O
.	O
You	O
had	O
difficulty	O
protecting	O
your	O
airway	O
and	O
eating	O
and	O
had	O
a	O
trach	O
and	O
PEG	O
placed	O
.	O
You	O
are	O
being	O
discharged	O
to	O
rehab	O
with	O
a	O
plan	O
to	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
1	O
.	O
Continue	O
antihypertensive	O
regimen	O
at	O
rehab	O
facilty	O
2	O
.	O
F	O
/	O
U	O
w	O
/	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
in	O
6	O
weeks	O
3	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
after	O
discharge	O
from	O
rehab	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
640	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3445	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2574	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2105-6-29	O
**	O
]	O
2:30	O
Completed	O
by	O
:[	O
**	O
2105-5-13	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2122-1-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2122-2-6	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2057-2-17	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Fentanyl	I-Drug
/	O
Oxycodone	I-Drug
/	O
Meperidine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
11040	O
**	O
]	O
Chief	O
Complaint	O
:	O
ARDS	O
seconrday	O
to	O
septic	O
shock	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Tracheostomy	O
and	O
G	O
-	O
tube	O
placement	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
69940	O
**	O
]	O
is	O
a	O
64	O
year	O
old	O
woman	O
with	O
HTN	O
,	O
RA	O
,	O
Type	O
2	O
DM	O
admitted	O
to	O
OSH	O
on	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
with	O
confusion	O
,	O
chills	O
,	O
fevers	O
to	O
103	O
and	O
a	O
week	O
of	O
green	O
sputum	O
found	O
to	O
have	O
PNA	O
on	O
CXR	O
,	O
hypotension	O
,	O
and	O
hypoxic	O
respiratory	O
failure	O
.	O
She	O
was	O
intubated	O
in	O
ED	O
,	O
started	O
on	O
dopamine	I-Drug
,	O
and	O
transfered	O
to	O
the	O
ICU	O
.	O
She	O
ruled	O
in	O
for	O
NSTEMI	O
.	O
She	O
was	O
switched	O
to	O
Norepinephrine	I-Drug
(	O
per	O
cards	O
)	O
and	O
hydrocort	I-Drug
.	O
She	O
also	O
received	O
Xigris	I-Drug
.	O
Within	O
24	O
hours	O
her	O
HCT	O
dropped	O
from	O
35	O
%	O
to	O
28	O
%	O
and	O
Xigris	I-Drug
was	O
stopped	O
.	O
Pt	O
was	O
initially	O
on	O
Ceftriaxone	I-Drug
and	O
Azithro	I-Drug
which	O
was	O
changed	O
to	O
Levoquin	I-Drug
Vanco	I-Drug
and	O
Clinda	I-Drug
which	O
was	O
stopped	O
on	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
.	O
Due	O
to	O
possible	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
exposure	O
,	O
Doxycycline	I-Drug
was	O
also	O
started	O
.	O
She	O
went	O
into	O
A	O
flutter	O
with	O
RVR	O
and	O
was	O
cardioverted	O
once	O
unsuccessfully	O
at	O
the	O
OSH	O
.	O
She	O
was	O
started	O
on	O
Diltiezem	I-Drug
drip	O
for	O
rate	B-Reason
control	I-Reason
.	O
For	O
?	O
PCP	O
PNA	I-Reason
,	O
she	O
was	O
started	O
on	O
high	O
dose	O
Bactrim	I-Drug
as	O
well	O
.	O
Throughout	O
her	O
OSH	O
course	O
she	O
developed	O
an	O
increasing	O
O2	O
requirment	O
,	O
and	O
there	O
was	O
concern	O
for	O
ARDS	O
with	O
increasing	O
difficulty	O
in	O
ventilation	O
.	O
Her	O
last	O
ABG	O
on	O
transfer	O
was	O
7.30	O
/	O
45/51	O
sating	O
88	O
%	O
on	O
100	O
%	O
FiO2	O
;	O
IMVO	O
14	O
;	O
PEEP	O
8	O
;	O
Tv	O
700	O
.	O
She	O
was	O
transfered	O
here	O
for	O
further	O
management	O
.	O
.	O
PCP	O
:	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Past	O
Medical	O
History	O
:	O
RA	O
-	O
Stopped	O
Methotrexate	I-Drug
5	O
months	O
ago	O
for	O
a	O
"	O
reverse	O
effect	O
"	O
according	O
to	O
notes	O
.	O
Maintained	O
on	O
20	O
mg	O
Prednisone	I-Drug
daily	O
HTN	O
NIDDM	O
GERD	O
Social	O
History	O
:	O
Lives	O
with	O
husband	O
,	O
quit	O
smoking	O
23	O
years	O
ago	O
,	O
occasional	O
wine	O
,	O
no	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
PE	O
:	O
Admitted	O
intubated	O
,	O
on	O
rotating	O
bed	O
T	O
:	O
36.9	O
HR	O
:	O
104	O
BP	O
:	O
133/51	O
(	O
off	O
pressors	O
)	O
RR	O
:	O
19	O
90	O
%	O
O2	O
Sats	O
Wt	O
:	O
98.6	O
kg	O
AC	O
Tv	O
:	O
400	O
FiO2	O
:	O
100	O
%	O
Peep	O
:	O
15	O
PP	O
:	O
24	O
Gen	O
:	O
intubated	O
,	O
sedated	O
HEENT	O
:	O
ET	O
tube	O
in	O
place	O
NECK	O
:	O
unable	O
to	O
asses	O
JVP	O
2/2	O
habitus	O
CV	O
:	O
Regular	O
Rate	O
and	O
rhythym	O
,	O
occasional	O
PVCs	O
.	O
LUNGS	O
:	O
course	O
BS	O
anteriorly	O
/	O
laterally	O
ABD	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
.	O
NL	O
BS	O
.	O
EXT	O
:	O
No	O
edema	O
.	O
2	O
+	O
DP	O
pulses	O
BL	O
SKIN	O
:	O
No	O
lesions	O
Pertinent	O
Results	O
:	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:03	O
PM	O
PT	O
-	O
12.9	O
PTT	O
-	O
27.2	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:03	O
PM	O
PLT	O
COUNT	O
-	O
268	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:03	O
PM	O
WBC	O
-	O
15.9	O
*	O
RBC	O
-	O
3.81	O
*	O
HGB	O
-	O
11.4	O
*	O
HCT	O
-	O
31.7	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
30.1	O
MCHC	O
-	O
36.1	O
*	O
RDW	O
-	O
16.8	O
*	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:03	O
PM	O
CALCIUM	O
-	O
5.9	O
*	O
PHOSPHATE	O
-	O
1.9	O
*	O
MAGNESIUM	O
-	O
2.1	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:03	O
PM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:03	O
PM	O
GLUCOSE	O
-	O
275	O
*	O
UREA	O
N	O
-	O
30	O
*	O
CREAT	O
-	O
0.9	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
3.8	O
CHLORIDE	O
-	O
108	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:09	O
PM	O
freeCa	O
-	O
0.72	O
*	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:09	O
PM	O
LACTATE	O
-	O
2.3	O
*	O
[	O
**	O
2122-1-14	O
**	O
]	O
11:09	O
PM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
69	O
*	O
PCO2	O
-	O
45	O
PH	O
-	O
7.38	O
TOTAL	O
CO2	O
-	O
28	O
BASE	O
XS	O
-	O
0	O
.	O
OSH	O
MICRO	O
DATA	O
:	O
Mycoplasma	O
IgG	O
-	O
posative	O
Blood	O
Cx	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
-	O
Gm	O
posative	O
cocci	O
,	O
speciation	O
/	O
sensis	O
pending	O
Legionella	O
-	O
negative	O
Strep	O
Pneumo	O
antigen	O
-	O
negative	O
RSV	O
-	O
negative	O
Influenza	O
A	O
/	O
B	O
-	O
negative	O
.	O
STUDIES	O
:	O
CXR	O
-	O
has	O
large	O
left	O
pulmonary	O
infiltrate	O
.	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
CT	O
abd	O
/	O
pelvis	O
:	O
1	O
.	O
Uncomplicated	O
pancreatitis	O
with	O
no	O
evidence	O
of	O
abscess	O
or	O
fluid	O
collection	O
.	O
2	O
.	O
Pleural	O
effusions	O
,	O
left	O
greater	O
than	O
right	O
,	O
with	O
consolidation	O
in	O
the	O
right	O
lower	O
lobe	O
consistent	O
with	O
pneumonia	O
.	O
3	O
.	O
Old	O
fractures	O
of	O
the	O
pelvis	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
Hypoxic	O
Respiratory	O
Failure	O
-	O
Secondary	O
to	O
mycoplasma	B-Reason
PNA	I-Reason
for	O
which	O
she	O
completed	O
14	O
day	O
course	O
of	O
levofloxacin	I-Drug
,	O
evolved	O
to	O
ARDS	O
from	O
sepsis	O
.	O
Subsequently	O
complicated	O
by	O
likely	O
ventilator	I-Reason
associated	O
pneumonia	O
,	O
culture	O
and	O
bronchial	O
lavage	O
negative	O
,	O
empirically	O
treated	O
with	O
a	O
course	O
of	O
Vancomycin	I-Drug
and	O
Cefepime	I-Drug
.	O
Also	O
,	O
complicated	O
by	O
severe	O
polyneuropathy	O
from	O
likely	O
critical	O
care	O
neuropathy	O
.	O
NIF	O
was	O
measured	O
and	O
was	O
in	O
the	O
30s	O
range	O
.	O
Pt	O
was	O
weaned	O
to	O
PS	O
5/0	O
on	O
the	O
13th	O
day	O
of	O
hospitalization	O
and	O
extubation	O
was	O
attempted	O
.	O
However	O
the	O
patient	O
became	O
increasingly	O
tachypneic	O
and	O
agitated	O
about	O
12	O
hours	O
after	O
extubation	O
and	O
was	O
reintubated	O
.	O
Failure	O
was	O
thought	O
to	O
be	O
due	O
to	O
respiratory	O
muscle	O
fatigue	O
,	O
poor	O
underlying	O
lung	O
function	O
in	O
the	O
context	O
of	O
pneumonia	O
,	O
possible	O
component	O
of	O
volume	O
overload	O
.	O
A	O
tracheostomy	O
was	O
placed	O
the	O
next	O
day	O
as	O
well	O
as	O
a	O
PEG	O
tube	O
.	O
She	O
was	O
successful	O
with	O
trach	O
mask	O
trials	O
several	O
days	O
after	O
trach	O
placement	O
on	O
high	O
flow	O
O2	O
.	O
She	O
was	O
successful	O
for	O
>	O
12hours	O
daily	O
,	O
but	O
on	O
several	O
occasions	O
became	O
tachypneic	O
in	O
the	O
evening	O
,	O
thought	O
to	O
be	O
influenced	O
largely	O
by	O
anxiety	O
rather	O
than	O
fatigue	O
,	O
requiring	O
placement	O
back	O
on	O
PS	O
overnight	O
.	O
She	O
was	O
,	O
however	O
,	O
trialed	O
for	O
24	O
hours	O
on	O
trach	O
mask	O
and	O
was	O
fatigued	O
the	O
following	O
day	O
requiring	O
full	O
24	O
hours	O
back	O
on	O
PS	O
.	O
This	O
was	O
likely	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
to	O
true	O
respiratory	O
muscle	O
fatigue	O
.	O
.	O
#	O
PNA	I-Reason
:	O
From	O
mycoplasma	O
,	O
treated	O
with	O
14	O
day	O
course	O
of	O
levofloxacin	I-Drug
.	O
Subsequently	O
complicated	O
by	O
likely	O
ventilator	I-Reason
associated	O
pneumonia	O
,	O
culture	O
and	O
bronchial	O
lavage	O
negative	O
,	O
empirically	O
treated	O
with	O
a	O
course	O
of	O
Vancomycin	I-Drug
and	O
Cefepime	I-Drug
.	O
.	O
#	O
Septic	B-Reason
shock	I-Reason
:	O
Lactate	O
on	O
admission	O
2.3	O
,	O
hypotension	O
,	O
elevated	O
WBC	O
with	O
2	O
bands	O
,	O
tachypnea	O
and	O
tachycardia	O
.	O
Initially	O
with	O
pressor	O
requirement	O
.	O
Initial	O
broad	B-Drug
spectrum	I-Drug
Abx	I-Drug
were	O
discontinued	O
once	O
source	O
of	O
sepsis	O
was	O
found	O
to	O
be	O
due	O
to	O
mycoplasma	O
and	O
a	O
course	O
of	O
14	O
days	O
of	O
Levofloxacin	I-Drug
was	O
completed	O
.	O
The	O
patient	O
also	O
was	O
treated	O
with	O
stress	O
dose	O
steroids	I-Drug
initially	O
,	O
which	O
were	O
subsequently	O
weaned	O
to	O
baseline	O
Prednisone	I-Drug
dose	O
for	O
chronic	B-Reason
RA	I-Reason
of	O
20	O
mg	O
.	O
.	O
#	O
Clostridium	B-Reason
difficile	I-Reason
infection	I-Reason
:	O
diagnosed	O
on	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
.	O
Pt	O
.	O
will	O
complete	O
a	O
7	O
day	O
(	O
post	O
other	O
antibiotics	O
)	O
course	O
of	O
flagyl	I-Drug
(	O
flagyl	O
course	O
to	O
be	O
completed	O
on	O
[	O
**	O
2122-2-6	O
**	O
]	O
after	O
receiving	O
her	O
tid	O
dosing	O
that	O
day	O
)	O
.	O
Diarrhea	O
is	O
much	O
improved	O
.	O
.	O
#	O
Pancreatitis	I-Ade
:	O
Thought	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
to	O
propofol	I-Drug
originally	O
with	O
elevated	O
amylase	O
and	O
lipase	O
.	O
Once	O
her	O
propofol	I-Drug
was	O
d	O
/	O
c	O
'd	O
,	O
her	O
amylase	O
normalized	O
.	O
Her	O
lipase	O
decreased	O
,	O
but	O
remained	O
elevated	O
in	O
the	O
150s	O
.	O
Other	O
LFTs	O
were	O
normal	O
.	O
Her	O
tube	O
feeds	O
were	O
held	O
transiently	O
when	O
her	O
lipase	O
failed	O
to	O
completely	O
resolve	O
and	O
she	O
had	O
mild	O
epigastric	O
discomfort	O
.	O
Given	O
that	O
her	O
epigastric	O
discomfort	O
was	O
post	O
G	O
tube	O
placement	O
,	O
it	O
resolved	O
and	O
tube	O
feeds	O
were	O
reinitiated	O
.	O
She	O
did	O
have	O
high	O
residuals	O
so	O
was	O
not	O
originally	O
at	O
goal	O
.	O
Reglan	I-Drug
was	O
started	O
and	O
tube	O
feeds	O
were	O
advanced	O
.	O
She	O
is	O
now	O
tolerating	O
tube	O
feeds	O
at	O
goal	O
without	O
reglan	I-Drug
.	O
.	O
#	O
Critical	O
illness	O
neuropathy	O
:	O
severe	O
distal	O
weakness	O
,	O
slight	O
improvement	O
towards	O
the	O
end	O
of	O
her	O
hospital	O
stay	O
.	O
EMG	O
and	O
nerve	O
conduction	O
studies	O
showed	O
mild	O
,	O
proximal	O
myopathy	O
with	O
a	O
superimposed	O
geneneralized	O
polyneuropathy	O
,	O
predominantly	O
axonal	O
.	O
The	O
picture	O
is	O
consistent	O
with	O
critical	O
illness	O
polyneuropathy	O
and	O
myopathy	O
.	O
Her	O
strength	O
has	O
been	O
consistently	O
increasing	O
,	O
but	O
deficit	O
remains	O
.	O
She	O
will	O
need	O
continued	O
physical	O
therapy	O
for	O
this	O
.	O
.	O
#	O
Rash	I-Ade
,	O
eosinophilia	I-Ade
:	O
During	O
her	O
course	O
of	O
cefepime	I-Drug
and	O
vancomycin	I-Drug
she	O
developed	O
a	O
rash	O
and	O
eosinophilia	O
.	O
Once	O
her	O
7	O
day	O
course	O
of	O
cefepime	I-Drug
and	O
vanco	I-Drug
was	O
complete	O
,	O
her	O
rash	O
resolved	O
although	O
she	O
remained	O
mildly	O
subjectively	O
itchy	I-Reason
requiring	O
fexofenadine	I-Drug
.	O
Her	O
eosinophils	O
remained	O
elevated	O
,	O
but	O
this	O
also	O
started	O
to	O
resolve	O
.	O
There	O
was	O
no	O
other	O
clear	O
drug	O
source	O
and	O
suspiscion	O
for	O
infective	O
cause	O
was	O
very	O
low	O
.	O
.	O
#	O
Low	O
grade	O
fever	O
:	O
Intermittent	O
low	O
grade	O
fever	O
to	O
Tmax	O
of	O
100.2	O
.	O
She	O
has	O
BAL	O
,	O
Urine	O
and	O
blood	O
cultures	O
pending	O
from	O
[	O
**	O
2122-2-5	O
**	O
]	O
,	O
but	O
suspiscion	O
for	O
infection	O
is	O
low	O
given	O
normal	O
WBC	O
count	O
and	O
no	O
left	O
shift	O
on	O
diff	O
.	O
These	O
cultures	O
should	O
be	O
followed	O
up	O
.	O
.	O
#	O
Rheumatoid	B-Reason
arthritis	I-Reason
:	O
Patient	O
was	O
transiently	O
on	O
stress	O
dose	O
steroids	I-Drug
in	O
the	O
setting	O
of	O
sepsis	O
.	O
Steroids	I-Drug
were	O
reduced	O
to	O
her	O
home	O
dose	O
of	O
20	O
mg	O
PO	O
prednisone	I-Drug
with	O
the	O
resolution	O
of	O
sepsis	O
.	O
The	O
need	O
for	O
PCP	B-Reason
prophylaxis	I-Reason
was	O
discussed	O
given	O
chronically	O
on	O
20	O
mg	O
prednisone	I-Drug
daily	O
.	O
The	O
need	O
for	O
this	O
dose	O
in	O
the	O
setting	O
of	O
her	O
RA	I-Reason
and	O
PCP	B-Reason
prophylaxis	I-Reason
was	O
discussed	O
with	O
her	O
rheumatologist	O
and	O
her	O
dose	O
of	O
prednisone	I-Drug
was	O
decreased	O
to	O
15	O
mg	O
po	O
prednisone	I-Drug
as	O
she	O
is	O
not	O
currently	O
complaining	O
of	O
joint	O
symptoms	O
.	O
She	O
was	O
not	O
started	O
on	O
bactrim	I-Drug
while	O
inpatient	O
and	O
if	O
her	O
chronic	O
prednisone	I-Drug
dose	O
requirement	O
increases	O
,	O
this	O
should	O
be	O
readdressed	O
.	O
Additionally	O
,	O
given	O
her	O
age	O
,	O
sex	O
and	O
chronic	O
prednisone	I-Drug
,	O
she	O
was	O
started	O
on	O
vitamin	B-Drug
D	I-Drug
and	O
calcium	I-Drug
.	O
.	O
#	O
Anemia	O
with	O
hct	O
drop	O
:	O
HCT	O
has	O
been	O
stable	O
24	O
-	O
26	O
from	O
original	O
drop	O
from	O
29	O
-	O
31	O
.	O
Anemia	O
w	O
/	O
u	O
included	O
abd	O
CT	O
not	O
revealing	O
for	O
bleed	O
.	O
LDH	O
is	O
elevated	O
,	O
haptoglobin	O
elevated	O
as	O
well	O
,	O
but	O
this	O
is	O
in	O
the	O
setting	O
of	O
inflammation	O
and	O
,	O
thus	O
may	O
not	O
reflect	O
accurately	O
hemolysis	O
.	O
Stools	O
were	O
guaiac	O
negative	O
.	O
Iron	O
revealed	O
normal	O
iron	O
,	O
elevated	O
ferritin	O
,	O
and	O
low	O
TIBC	O
c	O
/	O
w	O
ACD	O
.	O
.	O
#	O
Depression	I-Reason
:	O
Patient	O
has	O
a	O
history	O
of	O
depression	I-Reason
and	O
was	O
on	O
elavil	I-Drug
previously	O
.	O
She	O
is	O
not	O
sure	O
why	O
this	O
was	O
discontinued	O
originally	O
.	O
While	O
hospitalized	O
,	O
she	O
was	O
experiencing	O
low	O
mood	O
and	O
general	O
anxiety	O
.	O
Thus	O
,	O
celexa	I-Drug
was	O
started	O
at	O
20	O
mg	O
daily	O
on	O
[	O
**	O
2122-1-31	O
**	O
]	O
.	O
This	O
can	O
be	O
titrated	O
as	O
appropriate	O
upon	O
discharge	O
.	O
.	O
#	O
Hypertension	I-Reason
:	O
after	O
hypotension	O
in	O
the	O
context	O
of	O
sepsis	O
has	O
resolved	O
,	O
the	O
patient	O
hypertension	I-Reason
which	O
was	O
controlled	O
with	O
Labetalol	I-Drug
and	O
Captopril	I-Drug
.	O
She	O
did	O
require	O
occasional	O
fluid	I-Drug
bolus	O
in	O
setting	O
of	O
negative	B-Reason
fluid	I-Reason
status	I-Reason
and	O
low	B-Reason
UOP	I-Reason
and	O
transient	I-Reason
hypotension	O
,	O
to	O
which	O
her	O
BP	O
responded	O
well	O
.	O
.	O
#	O
A-Flutter	I-Reason
:	O
transient	O
episodes	O
in	O
the	O
context	O
of	O
high	O
adrenergic	O
state	O
after	O
acute	O
sepsis	O
resolved	O
.	O
Hemodynamically	O
stable	O
and	O
was	O
in	O
NSR	O
for	O
>	O
1week	O
prior	O
to	O
discharge	O
,	O
continued	O
on	O
BB	I-Drug
.	O
.	O
#	O
Steroid	I-Drug
induced	I-Reason
hypergylcemia	I-Reason
:	O
transiently	O
on	O
glargine	I-Drug
,	O
then	O
changed	O
to	O
Regular	I-Drug
SS	O
only	O
as	O
steroids	I-Drug
were	O
weaned	O
.	O
Her	O
blood	O
sugars	O
have	O
been	O
well	O
controlled	O
.	O
She	O
has	O
not	O
been	O
requiring	O
SS	O
coverage	O
,	O
but	O
this	O
should	O
be	O
initiated	O
if	O
glucose	O
control	O
worsens	O
.	O
#	O
FEN	O
:	O
PEG	O
tube	O
in	O
place	O
.	O
Tube	O
feeds	O
restarted	O
after	O
PEG	O
tube	O
placement	O
on	O
[	O
**	O
2122-1-29	O
**	O
]	O
.	O
.	O
#	O
PPx	I-Reason
:	O
Heparin	I-Drug
SQ	O
,	O
PPI	I-Drug
.	O
#	O
CODE	O
:	O
Full	O
Code	O
Medications	O
on	O
Admission	O
:	O
MEDS	O
on	O
Transfer	O
:	O
Doxycycline	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Lopressor	I-Drug
2.5	O
mg	O
IV	O
q4	O
'	O
and	O
5	O
mg	O
IV	O
q6	O
'	O
ASA	I-Drug
81	O
mg	O
daily	O
Zithromax	I-Drug
500	O
mg	O
IV	O
Daily	O
(	O
started	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
-	O
one	O
dose	O
given	O
)	O
Bactrim	I-Drug
400	O
mg	O
IV	O
q8	O
'	O
(	O
started	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
-	O
one	O
dose	O
given	O
)	O
Solumedrol	I-Drug
60	O
mg	O
IV	O
q6	O
'	O
(	O
was	O
125	O
mg	O
IV	O
q6hour	O
until	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
)	O
Fludrocortisone	I-Drug
0.1	O
mg	O
NGT	O
Daily	O
Reglan	I-Drug
5	O
mg	O
IV	O
q8	O
'	O
Vancomycin	I-Drug
1gm	O
IV	O
q12	O
'	O
(	O
started	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
-	O
got	O
one	O
dose	O
)	O
Digoxin	I-Drug
0.125	O
mg	O
Daily	O
NG	O
since	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
Lovenox	I-Drug
40	O
mg	O
SC	O
Daily	O
Nexium	I-Drug
40	O
mg	O
Daily	O
Lantus	I-Drug
20u	O
SC	O
daily	O
Lopid	I-Drug
300	O
mg	O
via	O
NG	O
[	O
**	O
Hospital1	O
**	O
]	O
RISS	I-Drug
Ativan	I-Drug
PRN	O
Tylenol	I-Drug
ORN	O
Morphine	I-Drug
PRN	O
Levaquin	I-Drug
500	O
mg	O
IV	O
Daily	O
(	O
started	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
3	O
.	O
Albuterol	B-Drug
-	I-Drug
Ipratropium	I-Drug
103	O
-	O
18	O
mcg	O
/	O
Actuation	O
Aerosol	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Six	O
(	O
6	O
)	O
Puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
when	B-Reason
on	I-Reason
vent	O
.	O
4	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Six	O
(	O
6	O
)	O
Puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
when	B-Reason
on	I-Reason
vent	I-Reason
.	O
5	O
.	O
Insulin	B-Drug
Regular	I-Drug
Human	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
See	O
sliding	O
scale	O
for	O
appropriate	O
dosing	O
Injection	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
6	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O
8	O
.	O
Captopril	I-Drug
12.5	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Labetalol	I-Drug
200	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
11	O
.	O
Acyclovir	I-Drug
5	O
%	O
Ointment	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
6X	O
/	O
D	O
(	O
6	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Citalopram	I-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
[	O
**	O
2	O
-	O
3	O
**	O
]	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
,	O
wheeze	I-Reason
.	O
14	O
.	O
Cholecalciferol	I-Drug
(	O
Vitamin	O
D3	O
)	O
400	O
unit	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
1,250	O
mg	O
/	O
5	O
mL	O
(	O
500	O
mg	O
)	O
Suspension	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
Ten	O
(	O
10	O
)	O
ML	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
16	O
.	O
Metronidazole	I-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
for	O
2	O
doses	O
:	O
to	O
complete	O
3	O
doses	O
on	O
[	O
**	O
2122-2-6	O
**	O
]	O
and	O
then	O
to	O
be	O
discontinued	O
.	O
17	O
.	O
Prednisone	I-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
18	O
.	O
Heparin	B-Drug
Lock	I-Drug
Flush	I-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
100	O
unit	O
/	O
mL	O
Syringe	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
[	O
**	O
2	O
-	O
3	O
**	O
]	O
MLs	O
Intravenous	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
19	O
.	O
Ativan	I-Drug
1	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
0.5	O
-	O
1	O
Tablet	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
Medical	O
Center	O
-	O
[	O
**	O
Hospital1	O
3597	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
1	O
.	O
Hypoxic	O
respiratory	O
failure	O
requiring	O
intubation	O
now	O
s	O
/	O
p	O
tracheostomy	O
and	O
PEG	O
2	O
.	O
Community	O
acquired	O
pneumonia	O
3	O
.	O
Ventilator	O
associated	O
pneumonia	O
4	O
.	O
ARDS	O
5	O
.	O
Pancreatitis	O
6	O
.	O
Depression	O
7	O
.	O
Rheumatoid	O
arthritis	O
8	O
.	O
Polyneuropathy	O
and	O
myopathy	O
of	O
critical	O
illness	O
9	O
.	O
Anemia	O
10	O
.	O
Clostridium	O
difficile	O
colitis	O
Discharge	O
Condition	O
:	O
Stable	O
,	O
had	O
been	O
tolerating	O
trach	O
mask	O
,	O
currently	O
on	O
pressure	O
support	O
and	O
tolerating	O
well	O
.	O
Discharge	O
Instructions	O
:	O
Return	O
to	O
the	O
emergency	O
room	O
if	O
you	O
develop	O
fever	O
,	O
chills	O
,	O
if	O
diarrhea	O
persists	O
or	O
worsens	O
post	O
antibiotic	O
course	O
,	O
worsening	O
abdominal	O
pain	O
,	O
nausea	O
,	O
inability	O
to	O
advance	O
tube	O
feeds	O
.	O
.	O
Please	O
take	O
your	O
medications	O
as	O
prescribed	O
.	O
Please	O
note	O
we	O
have	O
started	O
you	O
on	O
the	O
antidepressant	O
celexa	I-Drug
.	O
Additionally	O
,	O
we	O
have	O
decreased	O
your	O
prednisone	I-Drug
for	O
rheumatoid	B-Reason
arthritis	I-Reason
to	O
15	O
mg	O
daily	O
.	O
If	O
your	O
dose	O
increases	O
chronically	O
from	O
this	O
,	O
you	O
should	O
discuss	O
with	O
your	O
doctor	O
the	O
need	O
for	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
1102	O
**	O
]	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
your	O
primary	O
care	O
doctor	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
69941	O
**	O
]	O
t	O
when	O
appropriate	O
from	O
rehab	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2179-3-31	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2179-4-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2106-5-17	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
78	O
**	O
]	O
Chief	O
Complaint	O
:	O
Headache	O
and	O
instability	O
plus	O
anorexia	O
s	O
/	O
p	O
surgery	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Left	O
sided	O
craniotomy	O
with	O
evacuation	O
SDH	O
History	O
of	O
Present	O
Illness	O
:	O
73	O
year	O
old	O
male	O
who	O
was	O
admitted	O
1	O
week	O
ago	O
and	O
received	O
a	O
burr	O
hole	O
drainage	O
of	O
a	O
left	O
sided	O
SDH	O
.	O
Once	O
discharged	O
,	O
he	O
continued	O
having	O
headaches	O
with	O
the	O
same	O
features	O
as	O
intial	O
presentation	O
.	O
In	O
addition	O
,	O
he	O
had	O
difficulty	O
ambulating	O
(	O
see	O
exam	O
below	O
)	O
although	O
he	O
has	O
had	O
no	O
falls	O
.	O
Today	O
,	O
his	O
wife	O
was	O
concerned	O
because	O
he	O
had	O
remained	O
unsteady	O
,	O
with	O
loss	O
of	O
apetite	O
and	O
continued	O
having	O
headaches	O
.	O
She	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
4662	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
to	O
[	O
**	O
Hospital3	O
60696	O
**	O
]	O
Center	O
where	O
a	O
CT	O
scan	O
showed	O
a	O
chronic	O
SDH	O
with	O
a	O
relevant	O
midline	O
shift	O
(	O
12	O
mm	O
)	O
and	O
greater	O
volume	O
than	O
in	O
the	O
past	O
.	O
He	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Past	O
Medical	O
History	O
:	O
Seasonal	O
allergies	O
.	O
He	O
has	O
on	O
colonoscopy	O
had	O
diverticuli	O
in	O
[	O
**	O
2174	O
**	O
]	O
.	O
He	O
did	O
have	O
a	O
right	O
total	O
knee	O
replacement	O
in	O
[	O
**	O
2174	O
**	O
]	O
.	O
Raynaud	O
's	O
phenomenon	O
.	O
He	O
does	O
have	O
50	O
%	O
carotid	O
blockage	O
on	O
ultrasound	O
in	O
[	O
**	O
2172	O
**	O
]	O
.	O
Recent	O
exercise	O
stress	O
test	O
in	O
which	O
he	O
was	O
only	O
able	O
to	O
perform	O
5	O
minutes	O
of	O
exercise	O
stopping	O
with	O
a	O
maximal	O
heart	O
rate	O
of	O
132	O
with	O
dyspnea	O
and	O
a	O
maximal	O
blood	O
pressure	O
of	O
210/78	O
.	O
No	O
EKG	O
changes	O
with	O
exercise	O
.	O
Emphysema	O
Social	O
History	O
:	O
Social	O
Hx	O
:	O
cigarette	O
smoking	O
but	O
stopped	O
smoking	O
10	O
years	O
ago	O
.	O
He	O
used	O
to	O
work	O
in	O
electronic	O
repair	O
.	O
He	O
is	O
married	O
and	O
lives	O
with	O
his	O
wife	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
does	O
not	O
smoke	O
at	O
present	O
and	O
uses	O
alcohol	O
infrequently	O
.	O
There	O
is	O
a	O
history	O
of	O
mom	O
[	O
**	O
Name	O
(	O
NI	O
)	O
12823	O
**	O
]	O
blindness	O
occurring	O
after	O
being	O
stung	O
with	O
wasps	O
in	O
the	O
past	O
but	O
there	O
is	O
no	O
allergic	O
history	O
.	O
There	O
is	O
no	O
history	O
of	O
allergy	O
to	O
drugs	O
.	O
Family	O
History	O
:	O
FH	O
:	O
His	O
father	O
died	O
prematurely	O
of	O
throat	O
cancer	O
.	O
His	O
father	O
's	O
family	O
died	O
in	O
their	O
70s	O
.	O
His	O
mother	O
died	O
at	O
age	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
with	O
a	O
stroke	O
at	O
age	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
.	O
She	O
did	O
have	O
Alzheimer	O
's	O
disease	O
and	O
carotid	O
vascular	O
disease	O
.	O
He	O
has	O
lost	O
a	O
brother	O
and	O
a	O
sister	O
to	O
trauma.He	O
has	O
a	O
brother	O
and	O
sister	O
who	O
are	O
alive	O
with	O
no	O
history	O
of	O
stroke	O
and	O
no	O
history	O
of	O
coronary	O
disease	O
.	O
He	O
works	O
presently	O
in	O
delicatessen	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
134	O
/	O
74	O
,	O
70	O
bpm	O
,	O
RR	O
12	O
SO2	O
100	O
%	O
RA	O
.	O
GCS	O
15	O
.	O
Gen	O
:	O
Lying	O
in	O
bed	O
,	O
NAD	O
.	O
HEENT	O
:	O
NC	O
/	O
AT	O
,	O
moist	O
oral	O
mucosa	O
Neck	O
:	O
supple	O
,	O
no	O
carotid	O
or	O
vertebral	O
bruit	O
Back	O
:	O
No	O
point	O
tenderness	O
or	O
erythema	O
CV	O
:	O
Nl	O
S1	O
and	O
S2	O
,	O
no	O
murmurs	O
/	O
gallops	O
/	O
rubs	O
Lung	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
Abd	O
:	O
Soft	O
,	O
nontender	O
,	O
non-distended	O
.	O
No	O
masses	O
or	O
megalies	O
.	O
Percussion	O
within	O
normal	O
limits	O
.	O
+	O
BS	O
.	O
Ext	O
:	O
no	O
edema	O
,	O
no	O
DVT	O
data	O
.	O
Pulses	O
+	O
+	O
and	O
symmetric	O
.	O
Neurologic	O
examination	O
:	O
No	O
meningismus	O
.	O
No	O
photophobia	O
.	O
MS	O
:	O
General	O
:	O
alert	O
,	O
awake	O
,	O
normal	O
affect	O
Orientation	O
:	O
oriented	O
to	O
person	O
,	O
place	O
,	O
date	O
,	O
situation	O
Attention	O
:	O
20	O
to	O
1	O
backwards	O
+	O
.	O
Follows	O
simple	O
/	O
complex	O
commands	O
.	O
However	O
digit	O
span	O
backwards	O
is	O
impaired	O
.	O
Speech	O
/	O
Language	O
:	O
fluent	O
w	O
/	O
o	O
paraphasic	O
errors	O
;	O
comprehension	O
,	O
repetition	O
,	O
naming	O
:	O
normal	O
.	O
Prosody	O
:	O
normal	O
.	O
Memory	O
:	O
Registers	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
and	O
Recalls	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
when	O
given	O
choices	O
at	O
5	O
min	O
Praxis	O
/	O
agnosia	O
:	O
Able	O
to	O
brush	O
teeth	O
.	O
No	O
field	O
cuts	O
.	O
CN	O
:	O
I	O
:	O
not	O
tested	O
II	O
,	O
III	O
:	O
VFF	O
to	O
confrontation	O
,	O
PERRL	O
3	O
mm	O
to	O
2	O
mm	O
in	O
the	O
LEFT	O
and	O
4	O
to	O
2	O
mm	O
on	O
the	O
RIGHT	O
to	O
direct	O
and	O
consensual	O
light	O
,	O
fundus	O
w	O
/	O
o	O
papilledema	O
.	O
III	O
,	O
IV	O
,	O
VI	O
:	O
EOMI	O
,	O
no	O
ptosis	O
.	O
No	O
nystagmus	O
V	O
:	O
sensation	O
intact	O
V1	O
-	O
V3	O
to	O
LT	O
VII	O
:	O
Facial	O
strength	O
intact	O
/	O
symmetrical	O
VIII	O
:	O
hears	O
finger	O
rub	O
bilaterally	O
IX	O
,	O
X	O
:	O
palate	O
elevates	O
symmetrically	O
,	O
uvula	O
midline	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
SCM	O
/	O
trapezeii	O
[	O
**	O
5	O
-	O
4	O
**	O
]	O
bilaterally	O
XII	O
:	O
tongue	O
protrudes	O
midline	O
.	O
Rinne	O
:	O
R	O
ear	O
:	O
AC	O
>	O
BC	O
,	O
LEFT	O
ear	O
AC	O
>	O
BC	O
[	O
**	O
Doctor	O
Last	O
Name	O
15716	O
**	O
]	O
:	O
central	O
.	O
Motor	O
:	O
Normal	O
bulk	O
.	O
Tone	O
:	O
mildly	O
increased	O
on	O
the	O
RIGHT	O
hemibody	O
.	O
No	O
tremor	O
,	O
no	O
asterixis	O
or	O
myoclonus	O
.	O
No	O
pronator	O
drift	O
:	O
Delt	O
;	O
C5	O
bic	O
:	O
C6	O
Tri	O
:	O
C7	O
Wr	O
ext	O
:	O
C6	O
Fing	O
ext	O
:	O
C7	O
Left	O
5	O
5	O
5	O
5	O
5	O
Right	O
5	O
5	O
5	O
5	O
5	O
IP	O
:	O
Quad	O
:	O
Hamst	O
:	O
Dorsiflex	O
:	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
938	O
**	O
]	O
:	O
Pl.flex	O
Left	O
5	O
5	O
5	O
5	O
5	O
Right	O
5	O
-	O
5	O
5	O
-	O
5	O
5	O
-	O
Deep	O
tendon	O
Reflexes	O
:	O
Bicip	O
:	O
C5	O
Tric	O
:	O
C7	O
Brachial	O
:	O
C6	O
Patellar	O
:	O
L4	O
Toes	O
:	O
Right	O
2	O
2	O
2	O
2	O
Indifferent	O
Left	O
1	O
1	O
1	O
1	O
DOWNGOING	O
Sensation	O
:	O
Intact	O
to	O
light	O
touch	O
,	O
vibration	O
,	O
and	O
temperature	O
.	O
Propioception	O
:	O
normal	O
.	O
Coordination	O
:	O
*	O
Finger	O
-	O
nose	O
-	O
finger	O
mild	O
dysmetria	O
on	O
the	O
LEFT	O
*	O
Rapid	O
Arm	O
Movements	O
normal	O
.	O
*	O
Fine	O
finger	O
tapping	O
:	O
normal	O
*	O
Heal	O
to	O
shin	O
:	O
normal	O
.	O
Unable	O
to	O
perform	O
heel	O
to	O
toe	O
.	O
Regular	O
gait	O
:	O
narrow	O
based	O
,	O
hemiparetic	O
features	O
,	O
normal	O
arm	O
swing	O
,	O
cadence	O
normal	O
,	O
stride	O
normal	O
.	O
Turns	O
are	O
normal	O
.	O
Trunk	O
is	O
not	O
in	O
flexion	O
.	O
ON	O
DISCHARGE	O
:	O
Pt	O
neurologically	O
intact	O
without	O
focal	O
deficit	O
Incision	O
clean	O
and	O
dry	O
and	O
sutures	O
and	O
staples	O
have	O
been	O
removed	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2179-4-1	O
**	O
]	O
10:34	O
AM	O
BLOOD	O
WBC	O
-	O
7.7	O
RBC	O
-	O
4.59	O
*	O
Hgb	O
-	O
14.9	O
Hct	O
-	O
41.8	O
MCV	O
-	O
91	O
MCH	O
-	O
32.4	O
*	O
MCHC	O
-	O
35.6	O
*	O
RDW	O
-	O
13.3	O
Plt	O
Ct	O
-	O
297	O
[	O
**	O
2179-3-31	O
**	O
]	O
07:30	O
PM	O
BLOOD	O
Neuts	O
-	O
73.3	O
*	O
Lymphs	O
-	O
15.7	O
*	O
Monos	O
-	O
8.6	O
Eos	O
-	O
2.0	O
Baso	O
-	O
0.4	O
[	O
**	O
2179-4-1	O
**	O
]	O
10:34	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
297	O
[	O
**	O
2179-3-31	O
**	O
]	O
07:30	O
PM	O
BLOOD	O
Glucose	O
-	O
94	O
UreaN	O
-	O
19	O
Creat	O
-	O
1.0	O
Na	O
-	O
138	O
K	O
-	O
4.7	O
Cl	O
-	O
105	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
17	O
[	O
**	O
2179-4-1	O
**	O
]	O
05:53	O
AM	O
BLOOD	O
Phenyto	O
-	O
7.9	O
*	O
[	O
**	O
2179-4-1	O
**	O
]	O
05:53	O
AM	O
BLOOD	O
Albumin	O
-	O
3.5	O
[	O
**	O
Hospital1	O
69	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
15701	O
**	O
]	O
Pathology	O
Examination	O
Name	O
Birthdate	O
Age	O
Sex	O
Pathology	O
#	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
80676	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
2106-5-17	O
**	O
]	O
72	O
Male	O
[	O
**	O
Numeric	O
Identifier	O
80677	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
80678	O
**	O
]	O
Report	O
to	O
:	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2093	O
**	O
]	O
Description	O
by	O
:	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
/	O
dif	O
SPECIMEN	O
SUBMITTED	O
:	O
Subdural	O
Membrane	O
.	O
Procedure	O
date	O
Tissue	O
received	O
Report	O
Date	O
Diagnosed	O
by	O
[	O
**	O
2179-4-1	O
**	O
]	O
[	O
**	O
2179-4-2	O
**	O
]	O
[	O
**	O
2179-4-6	O
**	O
]	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
/	O
ttl	O
DIAGNOSIS	O
:	O
Subdural	O
membrane	O
,	O
excision	O
:	O
Dense	O
fibrous	O
tissue	O
with	O
calcifications	O
consistent	O
with	O
dura	O
with	O
hemorrhage	O
,	O
hemosiderin	O
laden	O
macrophages	O
,	O
chronic	O
inflammation	O
,	O
and	O
granulation	O
tissue	O
consistent	O
with	O
subdural	O
hematoma	O
.	O
Clinical	O
:	O
Subdural	O
hematoma	O
.	O
Gross	O
:	O
The	O
specimen	O
is	O
received	O
fresh	O
labeled	O
with	O
the	O
patient	O
's	O
name	O
,	O
"	O
[	O
**	O
Known	O
lastname	O
80675	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
"	O
,	O
the	O
medical	O
record	O
number	O
and	O
"	O
subdural	O
membrane	O
.	O
"	O
It	O
consists	O
of	O
a	O
fragment	O
of	O
pink	O
-	O
tan	O
soft	O
tissue	O
with	O
glistening	O
surfaces	O
measuring	O
2.0	O
x	O
0.3	O
x	O
0.1	O
cm	O
.	O
The	O
specimen	O
is	O
entirely	O
submitted	O
in	O
A.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
80679	O
**	O
]	O
M	O
72	O
[	O
**	O
2106-5-17	O
**	O
]	O
Cardiology	O
Report	O
ECG	O
Study	O
Date	O
of	O
[	O
**	O
2179-4-1	O
**	O
]	O
10:30:38	O
AM	O
Sinus	O
rhythm	O
Normal	O
ECG	O
Since	O
previous	O
tracing	O
of	O
[	O
**	O
2179-3-24	O
**	O
]	O
,	O
no	O
significant	O
change	O
Read	O
by	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
177	O
**	O
]	O
W.	O
Intervals	O
Axes	O
Rate	O
PR	O
QRS	O
QT	O
/	O
QTc	O
P	O
QRS	O
T	O
62	O
138	O
80416/419	O
46	O
-17	O
45	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
80679	O
**	O
]	O
M	O
72	O
[	O
**	O
2106-5-17	O
**	O
]	O
Radiology	O
Report	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
Study	O
Date	O
of	O
[	O
**	O
2179-4-1	O
**	O
]	O
4:29	O
AM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
742	O
**	O
]	O
NSURG	O
SICU	O
-	O
A	O
[	O
**	O
2179-4-1	O
**	O
]	O
4:29	O
AM	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
80680	O
**	O
]	O
Reason	O
:	O
preop	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
72	O
year	O
old	O
man	O
with	O
chronic	O
SDH	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
preop	O
Final	O
Report	O
INDICATION	O
:	O
72	O
-	O
year	O
-	O
old	O
man	O
,	O
preoperative	O
evaluation	O
.	O
Chronic	O
subdural	O
hematoma	O
.	O
COMPARISON	O
:	O
[	O
**	O
2179-3-24	O
**	O
]	O
.	O
SINGLE	O
UPRIGHT	O
VIEW	O
OF	O
THE	O
CHEST	O
AT	O
5:00	O
A.M	O
:	O
The	O
extreme	O
costophrenic	O
angles	O
are	O
excluded	O
from	O
the	O
exam	O
.	O
However	O
,	O
the	O
lungs	O
are	O
well	O
expanded	O
and	O
clear	O
without	O
consolidation	O
,	O
evidence	O
of	O
pleural	O
effusion	O
,	O
or	O
pneumothorax	O
.	O
Tiny	O
pleural	O
effusions	O
can	O
not	O
be	O
excluded	O
.	O
There	O
is	O
no	O
cardiomegaly	O
.	O
The	O
hilar	O
and	O
mediastinal	O
contours	O
are	O
within	O
normal	O
limits	O
.	O
Pulmonary	O
vascularity	O
is	O
normal	O
.	O
Soft	O
tissue	O
and	O
bony	O
structures	O
are	O
unremarkable	O
.	O
IMPRESSION	O
:	O
No	O
acute	O
cardiopulmonary	O
abnormality	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
2671	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
DR.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3891	O
**	O
]	O
Approved	O
:	O
FRI	O
[	O
**	O
2179-4-2	O
**	O
]	O
9:55	O
AM	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
80679	O
**	O
]	O
M	O
72	O
[	O
**	O
2106-5-17	O
**	O
]	O
Radiology	O
Report	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
Study	O
Date	O
of	O
[	O
**	O
2179-4-1	O
**	O
]	O
7:26	O
AM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
742	O
**	O
]	O
NSURG	O
SICU	O
-	O
A	O
[	O
**	O
2179-4-1	O
**	O
]	O
7:26	O
AM	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
80681	O
**	O
]	O
Reason	O
:	O
clinical	O
f	O
/	O
u	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
72	O
year	O
old	O
man	O
with	O
chronic	O
SDH	O
and	O
midline	O
shift	O
(	O
chronic	O
)	O
s	O
/	O
p	O
burr	O
hole	O
drain	O
1	O
week	O
ago	O
.	O
Mild	O
UMN	O
weakness	O
and	O
spasticity	O
in	O
RIGTH	O
inferior	O
extremity	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
clinical	O
f	O
/	O
u	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Provisional	O
Findings	O
Impression	O
:	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
80682	O
**	O
]	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
2179-4-1	O
**	O
]	O
9:54	O
AM	O
Compared	O
to	O
prior	O
exam	O
from	O
[	O
**	O
2179-3-25	O
**	O
]	O
,	O
there	O
is	O
increased	O
size	O
of	O
left	O
cerebral	O
convexity	O
subdural	O
hematoma	O
and	O
mass	O
effect	O
with	O
worsening	O
rightward	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
Final	O
Report	O
INDICATION	O
:	O
72	O
-	O
year	O
-	O
old	O
male	O
with	O
chronic	O
subdural	O
hematoma	O
and	O
midline	O
shift	O
.	O
Patient	O
with	O
mild	O
upper	O
motor	O
neuron	O
weakness	O
and	O
spasticity	O
in	O
the	O
right	O
inferior	O
extremity	O
.	O
NON-CONTRAST	O
HEAD	O
CT	O
:	O
Compared	O
to	O
prior	O
exam	O
from	O
[	O
**	O
2179-3-25	O
**	O
]	O
,	O
there	O
is	O
increased	O
size	O
of	O
left	O
cerebral	O
convexity	O
subdural	O
hematoma	O
although	O
with	O
overall	O
decreased	O
density	O
.	O
There	O
is	O
increased	O
mass	O
effect	O
onto	O
the	O
subjacent	O
brain	O
with	O
increased	O
rightward	O
shift	O
of	O
normally	O
midline	O
structures	O
(	O
13	O
mm	O
)	O
.	O
There	O
is	O
impending	O
left	O
uncal	O
herniation	O
.	O
There	O
is	O
no	O
hydrocephalus	O
,	O
or	O
evidence	O
of	O
major	O
vascular	O
territorial	O
infarct	O
.	O
The	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
is	O
preserved	O
.	O
The	O
visualized	O
paranasal	O
sinuses	O
and	O
mastoid	O
air	O
cells	O
are	O
normally	O
aerated	O
.	O
New	O
left	O
calvarial	O
burr	O
holes	O
are	O
again	O
noted	O
.	O
IMPRESSION	O
:	O
Compared	O
to	O
prior	O
exam	O
from	O
[	O
**	O
2179-3-25	O
**	O
]	O
,	O
there	O
is	O
increased	O
size	O
of	O
left	O
cerebral	O
convexity	O
subdural	O
hematoma	O
and	O
mass	O
effect	O
with	O
worsening	O
rightward	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
DR.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
7410	O
**	O
]	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
3905	O
**	O
]	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3906	O
**	O
]	O
Approved	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
2179-4-1	O
**	O
]	O
12:35	O
PM	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
80679	O
**	O
]	O
M	O
72	O
[	O
**	O
2106-5-17	O
**	O
]	O
Radiology	O
Report	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
Study	O
Date	O
of	O
[	O
**	O
2179-4-5	O
**	O
]	O
6:24	O
PM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
J.	O
NSURG	O
FA11	O
[	O
**	O
2179-4-5	O
**	O
]	O
6:24	O
PM	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
80683	O
**	O
]	O
Reason	O
:	O
assess	O
for	O
any	O
residual	O
blood	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
72	O
year	O
old	O
man	O
with	O
subdural	O
hematoma	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
assess	O
for	O
any	O
residual	O
blood	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Provisional	O
Findings	O
Impression	O
:	O
DMFj	O
MON	O
[	O
**	O
2179-4-5	O
**	O
]	O
8:19	O
PM	O
Persistent	O
left	O
cerebral	O
convexity	O
subdural	O
hematoma	O
with	O
areas	O
of	O
increased	O
density	O
suggestive	O
of	O
ongoing	O
bleeding	O
.	O
Persistent	O
shift	O
of	O
normally	O
midline	O
structures	O
to	O
the	O
right	O
of	O
6	O
mm	O
.	O
Close	O
followup	O
recommended	O
.	O
Final	O
Report	O
STUDY	O
:	O
CT	O
of	O
the	O
head	O
without	O
contrast	O
.	O
HISTORY	O
:	O
72	O
-	O
year	O
-	O
old	O
male	O
with	O
subdural	O
hematoma	O
.	O
Assess	O
for	O
residual	O
blood	O
.	O
COMPARISONS	O
:	O
CT	O
[	O
**	O
2179-4-2	O
**	O
]	O
.	O
TECHNIQUE	O
:	O
MDCT	O
axial	O
images	O
of	O
the	O
head	O
were	O
obtained	O
.	O
FINDINGS	O
:	O
There	O
has	O
been	O
interval	O
removal	O
of	O
an	O
intracranial	O
catheter	O
.	O
The	O
patient	O
is	O
status	O
post	O
left	O
frontal	O
craniotomy	O
.	O
A	O
mixed	O
attenuation	O
collection	O
overlies	O
primarily	O
the	O
left	O
frontoparietal	O
convexity	O
.	O
There	O
are	O
areas	O
of	O
increased	O
attenuation	O
within	O
this	O
collection	O
,	O
which	O
suggest	O
ongoing	O
bleeding	O
.	O
Several	O
areas	O
of	O
pneumocephalus	O
are	O
compatible	O
with	O
recent	O
craniotomy	O
.	O
The	O
total	O
diameter	O
of	O
this	O
collection	O
measures	O
approximately	O
11	O
mm	O
,	O
which	O
is	O
slightly	O
larger	O
compared	O
to	O
the	O
previous	O
measurements	O
of	O
8	O
mm	O
allowing	O
for	O
slight	O
differences	O
in	O
technique	O
.	O
There	O
is	O
persistence	O
of	O
adjacent	O
sulcal	O
enfacement	O
,	O
particularly	O
notable	O
superiorly	O
within	O
the	O
frontal	O
lobe	O
.	O
There	O
is	O
shift	O
of	O
normally	O
midline	O
structures	O
to	O
the	O
right	O
of	O
approximately	O
6	O
mm	O
,	O
which	O
is	O
probably	O
unchanged	O
compared	O
to	O
the	O
previous	O
shift	O
of	O
5	O
mm	O
.	O
The	O
visualized	O
paranasal	O
sinuses	O
and	O
mastoid	O
air	O
cells	O
appear	O
grossly	O
clear	O
.	O
Multiple	O
staples	O
and	O
subcutaneous	O
emphysema	O
are	O
noted	O
along	O
the	O
subcutaneous	O
tissues	O
overlying	O
the	O
left	O
frontal	O
bone	O
and	O
site	O
of	O
craniotomy	O
.	O
IMPRESSION	O
:	O
Persistence	O
of	O
left	O
extra-axial	O
collection	O
status	O
post	O
catheter	O
removal	O
with	O
several	O
areas	O
of	O
increased	O
density	O
suggestive	O
of	O
ongoing	O
hemorrhage	O
.	O
Persistent	O
shift	O
of	O
normally	O
midline	O
structures	O
to	O
the	O
right	O
of	O
approximately	O
6	O
mm	O
.	O
Continued	O
close	O
followup	O
is	O
advised	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
2618	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
DR.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
7415	O
**	O
]	O
Approved	O
:	O
TUE	O
[	O
**	O
2179-4-6	O
**	O
]	O
9:31	O
AM	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
80679	O
**	O
]	O
M	O
72	O
[	O
**	O
2106-5-17	O
**	O
]	O
Neurophysiology	O
Report	O
EEG	O
Study	O
Date	O
of	O
[	O
**	O
2179-4-6	O
**	O
]	O
OBJECT	O
:	O
R	O
/	O
O	O
SEIZURE	O
.	O
REFERRING	O
DOCTOR	O
:	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
742	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
FINDINGS	O
:	O
ABNORMALITY	O
#	O
1	O
:	O
There	O
is	O
diffuse	O
mixed	O
theta	O
/	O
delta	O
frequency	O
slowing	O
seen	O
broadly	O
across	O
the	O
left	O
hemisphere	O
.	O
BACKGROUND	O
:	O
Showed	O
generally	O
a	O
low	O
voltage	O
fast	O
activity	O
across	O
the	O
right	O
hemisphere	O
.	O
The	O
posterior	O
predominant	O
rhythm	O
on	O
the	O
left	O
reached	O
an	O
8	O
Hz	O
maximum	O
.	O
HYPERVENTILATION	O
:	O
Could	O
not	O
be	O
performed	O
.	O
INTERMITTENT	O
PHOTIC	O
STIMULATION	O
:	O
Produced	O
no	O
activation	O
of	O
the	O
record	O
.	O
SLEEP	O
:	O
The	O
patient	O
progressed	O
from	O
wakefulness	O
to	O
drowsiness	O
but	O
did	O
not	O
achieve	O
stage	O
II	O
sleep	O
.	O
CARDIAC	O
MONITOR	O
:	O
Showed	O
a	O
generally	O
regular	O
rhythm	O
with	O
an	O
average	O
rate	O
of	O
60	O
bpm	O
.	O
IMPRESSION	O
:	O
This	O
is	O
an	O
abnormal	O
routine	O
EEG	O
in	O
the	O
waking	O
and	O
drowsy	O
states	O
due	O
to	O
persistent	O
left	O
hemisphere	O
mixed	O
slow	O
wave	O
activity	O
indicative	O
of	O
an	O
area	O
of	O
broad	O
subcortical	O
dysfunction	O
in	O
this	O
region	O
.	O
There	O
are	O
no	O
epileptiform	O
features	O
noted	O
.	O
INTERPRETED	O
BY	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
L.	O
(	O
09	O
-	O
0955J	O
)	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
80679	O
**	O
]	O
M	O
72	O
[	O
**	O
2106-5-17	O
**	O
]	O
Radiology	O
Report	O
MRA	O
NECK	O
W&W	O
/	O
O	O
CONTRAST	O
Study	O
Date	O
of	O
[	O
**	O
2179-4-7	O
**	O
]	O
8:30	O
PM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
J.	O
NSURG	O
FA11	O
[	O
**	O
2179-4-7	O
**	O
]	O
8:30	O
PM	O
MR	O
HEAD	O
W	O
&	O
W	O
/	O
O	O
CONTRAST	O
;	O
MRA	O
NECK	O
W&W	O
/	O
O	O
CONTRAST	O
;	O
MRA	O
BRAIN	O
W	O
/	O
O	O
CONTRAST	O
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
80684	O
**	O
]	O
Reason	O
:	O
evaluate	O
for	O
vascular	O
abnormalities	O
Contrast	O
:	O
MAGNEVIST	I-Drug
Amt	O
:	O
17	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
72	O
year	O
old	O
man	O
with	O
new	O
onset	O
dysarthria	O
several	O
days	O
after	O
crani	O
for	O
sdh	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
evaluate	O
for	O
vascular	O
abnormalities	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Wet	O
Read	O
:	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
80685	O
**	O
]	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
2179-4-8	O
**	O
]	O
11:16	O
AM	O
Noa	O
cute	O
infarction	O
;	O
unchanged	O
left	O
SDH	O
with	O
mass	O
effect	O
on	O
the	O
cerebral	O
hemisphere	O
on	O
the	O
elft	O
.	O
Patent	O
major	O
itnra	O
and	O
extra	O
cranial	O
arteries	O
without	O
focal	O
flow	O
limiting	O
stenosis	O
,	O
occlusion	O
or	O
aneurysm	O
more	O
than	O
3	O
mm	O
within	O
the	O
resolution	O
of	O
MRA	O
.	O
Final	O
Report	O
INDICATION	O
:	O
72	O
-	O
year	O
-	O
old	O
man	O
with	O
new	O
-	O
onset	O
dysarthria	O
several	O
days	O
after	O
craniotomy	O
for	O
SDH	O
,	O
to	O
evaluate	O
for	O
vascular	O
abnormalities	O
.	O
COMPARISON	O
:	O
CT	O
of	O
the	O
head	O
done	O
on	O
[	O
**	O
2179-4-6	O
**	O
]	O
.	O
TECHNIQUE	O
:	O
Multiplanar	O
T1	O
-	O
and	O
T2	O
-	O
weighted	O
imaging	O
of	O
the	O
head	O
was	O
performed	O
without	O
and	O
with	O
IV	O
contrast	I-Drug
.	O
3D	O
TOF	O
MR	O
angiogram	O
of	O
the	O
head	O
,	O
contrast	O
-	O
enhanced	O
MR	O
angiogram	O
of	O
the	O
neck	O
were	O
performed	O
,	O
MIP	O
reformations	O
of	O
the	O
arteries	O
were	O
obtained	O
.	O
FINDINGS	O
:	O
MRI	O
OF	O
THE	O
HEAD	O
:	O
The	O
left	O
-	O
sided	O
convexity	O
based	O
subdural	O
hematoma	O
is	O
again	O
visualized	O
,	O
with	O
small	O
amount	O
of	O
air	O
and	O
mild	O
displacement	O
of	O
the	O
cerebral	O
parenchyma	O
.	O
There	O
is	O
also	O
edema	O
of	O
the	O
left	O
cerebral	O
hemisphere	O
,	O
with	O
decrease	O
in	O
the	O
size	O
of	O
the	O
cerebral	O
sulci	O
,	O
the	O
overall	O
appearance	O
not	O
significantly	O
changed	O
compared	O
to	O
the	O
prior	O
CT	O
study	O
done	O
on	O
[	O
**	O
2179-4-6	O
**	O
]	O
,	O
allowing	O
for	O
the	O
differences	O
in	O
the	O
modalities	O
.	O
There	O
are	O
multiple	O
small	O
FLAIR	O
hyperintense	O
foci	O
noted	O
in	O
the	O
cerebral	O
white	O
matter	O
on	O
both	O
sides	O
,	O
in	O
the	O
frontal	O
and	O
the	O
parietal	O
lobes	O
,	O
periventricular	O
and	O
subcortical	O
in	O
location	O
.	O
There	O
are	O
no	O
areas	O
of	O
restricted	O
diffusion	O
in	O
the	O
brain	O
parenchyma	O
.	O
The	O
visualized	O
portions	O
of	O
the	O
paranasal	O
sinuses	O
are	O
clear	O
.	O
Small	O
areas	O
of	O
increased	O
signal	O
intensity	O
are	O
noted	O
in	O
the	O
left	O
mastoid	O
air	O
cells	O
from	O
mucosal	O
thickening	O
/	O
fluid	O
.	O
3D	O
TOF	O
MR	O
ANGIOGRAM	O
OF	O
THE	O
HEAD	O
:	O
The	O
left	O
vertebral	O
artery	O
is	O
dominant	O
.	O
The	O
right	O
posterior	O
cerebral	O
artery	O
and	O
the	O
P1	O
and	O
P2	O
segments	O
are	O
slightly	O
tortuous	O
with	O
tortuous	O
course	O
of	O
the	O
junction	O
of	O
the	O
P1	O
and	O
P2	O
segments	O
.	O
The	O
P1	O
segment	O
on	O
the	O
left	O
side	O
is	O
not	O
visualized	O
,	O
with	O
a	O
fetal	O
PCA	O
pattern	O
.	O
The	O
A1	O
segment	O
of	O
the	O
left	O
anterior	O
cerebral	O
artery	O
is	O
slightly	O
small	O
in	O
caliber	O
and	O
likely	O
hypoplastic	O
.	O
The	O
anterior	O
communicating	O
artery	O
is	O
faintly	O
visualized	O
.	O
No	O
areas	O
of	O
abnormal	O
enhancement	O
are	O
noted	O
in	O
the	O
brain	O
parenchyma	O
.	O
Enhancement	O
of	O
the	O
meninges	O
,	O
likely	O
relates	O
to	O
the	O
recent	O
surgery	O
in	O
the	O
subdural	O
hematoma	O
on	O
the	O
left	O
side	O
.	O
The	O
tip	O
of	O
the	O
basilar	O
artery	O
is	O
slightly	O
prominent	O
related	O
to	O
the	O
infundibula	O
at	O
the	O
origins	O
of	O
the	O
branch	O
vessels	O
.	O
MR	O
ANGIOGRAM	O
OF	O
THE	O
NECK	O
:	O
The	O
origins	O
of	O
the	O
arch	O
vessels	O
are	O
patent	O
.	O
There	O
is	O
common	O
origin	O
of	O
the	O
brachiocephalic	O
trunk	O
and	O
the	O
left	O
common	O
carotid	O
artery	O
,	O
representing	O
bovine	O
arch	O
variant	O
.	O
There	O
is	O
mild	O
narrowing	O
,	O
at	O
the	O
origin	O
of	O
the	O
left	O
vertebral	O
artery	O
,	O
which	O
may	O
relate	O
to	O
tortuosity	O
or	O
stenosis	O
.	O
However	O
,	O
there	O
is	O
no	O
flow	O
limitation	O
distally	O
.	O
The	O
right	O
vertebral	O
artery	O
is	O
small	O
in	O
caliber	O
diffusely	O
likely	O
related	O
to	O
mild	O
hypoplasia	O
with	O
the	O
left	O
being	O
dominant	O
,	O
the	O
narrowing	O
is	O
more	O
prominent	O
at	O
the	O
origin	O
and	O
v4	O
segment	O
;	O
however	O
,	O
there	O
is	O
no	O
flow	O
limitation	O
.	O
The	O
common	O
carotid	O
arteries	O
are	O
patent	O
,	O
as	O
well	O
as	O
the	O
cervical	O
internal	O
carotid	O
arteries	O
without	O
focal	O
flow	O
-	O
limiting	O
stenosis	O
,	O
occlusion	O
,	O
or	O
aneurysm	O
.	O
There	O
is	O
a	O
short	O
segment	O
of	O
mild	O
-	O
moderate	O
stenosis	O
in	O
the	O
left	O
common	O
carotid	O
artery	O
,	O
seen	O
only	O
on	O
the	O
MIPS	O
and	O
not	O
on	O
the	O
source	O
images	O
and	O
hecne	O
is	O
of	O
doubtful	O
significance	O
-	O
no	O
flow	O
limitation	O
distally	O
.	O
(	O
series	O
106	O
,	O
im	O
6	O
;	O
series	O
108	O
,	O
im	O
5	O
)	O
The	O
delayed	O
phase	O
images	O
are	O
not	O
obtained	O
on	O
the	O
MR	O
angiogram	O
.	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
infarction	O
.	O
2	O
.	O
Small	O
-	O
to	O
-	O
moderate	O
size	O
left	O
-	O
sided	O
subdural	O
hematoma	O
,	O
with	O
small	O
amount	O
of	O
air	O
,	O
and	O
mass	O
effect	O
on	O
the	O
left	O
cerebral	O
hemisphere	O
,	O
with	O
edema	O
,	O
unchanged	O
compared	O
to	O
the	O
most	O
recent	O
CT	O
head	O
study	O
done	O
on	O
[	O
**	O
2179-4-6	O
**	O
]	O
.	O
3	O
.	O
Patent	O
major	O
intra	O
-	O
and	O
extra-cranial	O
arteries	O
,	O
without	O
focal	O
flow	O
-	O
limiting	O
stenosis	O
,	O
occlusion	O
,	O
or	O
aneurysm	O
within	O
the	O
limitations	O
of	O
MR	O
angiogram	O
.	O
Please	O
see	O
the	O
additional	O
details	O
above	O
.	O
4	O
.	O
Narrowing	O
at	O
the	O
origin	O
of	O
the	O
left	O
vertebral	O
artery	O
,	O
question	O
tortuosity	O
,	O
or	O
stenosis	O
,	O
no	O
flow	O
limitation	O
distally	O
;	O
?	O
stenosis	O
in	O
the	O
left	O
common	O
carotid	O
artery	O
-	O
seen	O
only	O
on	O
MIPS	O
but	O
not	O
on	O
source	O
images	O
;	O
no	O
flow	O
limitation	O
distally	O
.	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
10627	O
**	O
]	O
PERI	O
Approved	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
2179-4-8	O
**	O
]	O
10:18	O
PM	O
Imaging	O
Lab	O
EEG	O
[	O
**	O
2179-4-10	O
**	O
]	O
No	O
final	O
read	O
at	O
present	O
-	O
verbal	O
report	O
=	O
NORMAL	O
CT	O
brain	O
[	O
**	O
2179-4-12	O
**	O
]	O
Final	O
report	O
pending	O
Brief	O
Hospital	O
Course	O
:	O
Mr	O
[	O
**	O
Known	O
lastname	O
80675	O
**	O
]	O
was	O
admitted	O
to	O
the	O
SICU	O
for	O
close	O
observation	O
and	O
prepared	O
for	O
a	O
left	O
sided	O
cranitomy	O
for	O
evacuation	O
of	O
subdural	O
hematoma	O
.	O
On	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
he	O
underwent	O
a	O
craniotomy	O
.	O
Post	O
operatively	O
he	O
was	O
monitored	O
for	O
24	O
hours	O
in	O
the	O
SICU	O
his	O
exam	O
improved	O
with	O
no	O
drift	O
or	O
weakness	O
.	O
On	O
his	O
first	O
post	O
operative	O
day	O
he	O
was	O
transferred	O
to	O
the	O
surgical	O
floor	O
.	O
He	O
was	O
tolerating	O
a	O
regular	O
diet	O
,	O
PT	O
eval	O
stated	O
pt	O
was	O
safe	O
to	O
go	O
home	O
.	O
However	O
family	O
was	O
uncomfortable	O
taking	O
pt	O
home	O
and	O
was	O
requesting	O
rehab	O
.	O
During	O
evaluation	O
for	O
re-hab	O
on	O
POD	O
5	O
he	O
then	O
developed	O
severe	O
dysarthria	O
.	O
Repeat	O
head	O
CT	O
was	O
unchanged	O
and	O
MRI	O
/	O
MRA	O
of	O
brain	O
and	O
neck	O
were	O
negative	O
for	O
stroke	O
.	O
His	O
EEG	O
was	O
also	O
negative	O
.	O
Over	O
the	O
next	O
few	O
days	O
his	O
speech	O
/	O
word	O
finding	O
improved	O
.	O
He	O
did	O
wax	O
and	O
wane	O
with	O
periods	O
of	O
aphasia	O
and	O
normal	O
speech	O
.	O
There	O
was	O
concern	O
for	O
seizure	O
so	O
a	O
24	O
hr	O
EEG	O
was	O
done	O
and	O
shows	O
normal	O
activity	O
.	O
CT	O
scan	O
on	O
day	O
of	O
discharge	O
[	O
**	O
2179-4-12	O
**	O
]	O
=	O
stable	O
.	O
Staples	O
and	O
sutures	O
were	O
removed	O
from	O
crani	O
site	O
.	O
Site	O
without	O
erythema	O
.	O
Plan	O
is	O
for	O
discharge	O
home	O
today	O
with	O
[	O
**	O
Name	O
(	O
NI	O
)	O
269	O
**	O
]	O
-	O
pt	O
and	O
family	O
agree	O
with	O
this	O
plan	O
.	O
His	O
exam	O
remains	O
non-focal	O
.	O
Medications	O
on	O
Admission	O
:	O
Phenytoin	I-Drug
Sodium	O
Extended	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Simvastatin	I-Drug
Oral	O
Discharge	O
Medications	O
:	O
1	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Simvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
4	O
.	O
Camphor	B-Drug
-	I-Drug
Menthol	O
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
5	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	O
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
:	O
do	O
not	O
drive	O
while	O
on	O
this	O
medication	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Phenytoin	I-Drug
Sodium	O
Extended	O
100	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
do	O
not	O
stop	O
this	O
medication	O
on	O
your	O
own	O
.	O
Disp	O
:	O
*	O
120	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
do	O
not	O
take	O
at	O
the	O
same	O
time	O
as	O
taking	O
your	O
dilantin	I-Drug
.	O
8	O
.	O
Cholecalciferol	I-Drug
(	O
Vitamin	O
D3	O
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Outpatient	O
Lab	O
Work	O
dilantin	O
level	O
albumin	O
level	O
[	O
**	O
2179-4-20	O
**	O
]	O
please	O
fax	O
results	O
to	O
patients	O
primary	O
care	O
physicians	O
office	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
932	O
**	O
]	O
Area	O
[	O
**	O
Location	O
(	O
un	O
)	O
269	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Left	O
sided	O
subdural	O
hematoma	O
Discharge	O
Condition	O
:	O
Neurologically	O
stable	O
/	O
improved	O
Discharge	O
Instructions	O
:	O
??????	O
Have	O
a	O
friend	O
/	O
family	O
member	O
check	O
your	O
incision	O
daily	O
for	O
signs	O
of	O
infection	O
.	O
??????	O
Take	O
your	O
pain	O
medicine	O
as	O
prescribed	O
.	O
??????	O
Exercise	O
should	O
be	O
limited	O
to	O
walking	O
;	O
no	O
lifting	O
,	O
straining	O
,	O
or	O
excessive	O
bending	O
.	O
??????	O
You	O
may	O
wash	O
your	O
hair	O
??????	O
Increase	O
your	O
intake	O
of	O
fluids	O
and	O
fiber	I-Drug
,	O
as	O
narcotic	O
pain	O
medicine	O
can	O
cause	O
constipation	O
.	O
We	O
generally	O
recommend	O
taking	O
an	O
over	O
the	O
counter	O
stool	O
softener	O
,	O
such	O
as	O
Docusate	I-Drug
(	O
Colace	O
)	O
while	O
taking	O
narcotic	O
pain	O
medication	O
.	O
??????	O
Do	O
not	O
take	O
any	O
anti-inflammatory	O
medicines	O
such	O
as	O
Motrin	I-Drug
,	O
Aspirin	I-Drug
,	O
Advil	I-Drug
,	O
and	O
Ibuprofen	I-Drug
etc.	O
for	O
2	O
weeks	O
.	O
??????	O
Make	O
sure	O
to	O
continue	O
to	O
use	O
your	O
incentive	O
spirometer	O
while	O
at	O
home	O
,	O
unless	O
you	O
have	O
been	O
instructed	O
not	O
to	O
.	O
CALL	O
YOUR	O
SURGEON	O
IMMEDIATELY	O
IF	O
YOU	O
EXPERIENCE	O
ANY	O
OF	O
THE	O
FOLLOWING	O
??????	O
New	O
onset	O
of	O
tremors	O
or	O
seizures	O
.	O
??????	O
Any	O
confusion	O
or	O
change	O
in	O
mental	O
status	O
.	O
??????	O
Any	O
numbness	O
,	O
tingling	O
,	O
weakness	O
in	O
your	O
extremities	O
.	O
??????	O
Pain	O
or	O
headache	O
that	O
is	O
continually	O
increasing	O
,	O
or	O
not	O
relieved	O
by	O
pain	O
medication	O
.	O
??????	O
Any	O
signs	O
of	O
infection	O
at	O
the	O
wound	O
site	O
:	O
redness	O
,	O
swelling	O
,	O
tenderness	O
,	O
or	O
drainage	O
.	O
??????	O
Fever	O
greater	O
than	O
or	O
equal	O
to	O
101	O
??????	O
F.	O
Followup	O
Instructions	O
:	O
Please	O
call	O
to	O
schedule	O
a	O
follow	O
up	O
appointment	O
with	O
Dr	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
to	O
be	O
seen	O
in	O
4	O
weeks	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
/	O
You	O
will	O
need	O
a	O
head	O
CT	O
without	O
contrast	O
at	O
that	O
time	O
Completed	O
by	O
:[	O
**	O
2179-4-12	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2173-10-5	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2173-10-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2120-3-3	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lisinopril	I-Drug
/	O
Oxycodone	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1990	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fevers	O
,	O
chills	O
,	O
sweats	O
,	O
?	O
sepsis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
53	O
y	O
/	O
o	O
F	O
with	O
antiphospholipid	O
syndrome	O
on	O
warfarin	I-Drug
and	O
ESRD	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
lupus	O
nephritis	O
on	O
HD	O
since	O
[	O
**	O
2167	O
**	O
]	O
now	O
s	O
/	O
p	O
renal	O
txp	O
in	O
[	O
**	O
2173-2-8	O
**	O
]	O
on	O
immunosuppression	O
,	O
referred	O
to	O
ED	O
from	O
primary	O
care	O
office	O
where	O
she	O
presented	O
with	O
fevers	O
and	O
chills	O
x	O
three	O
weeks	O
.	O
She	O
also	O
told	O
her	O
providers	O
in	O
the	O
primary	O
care	O
clinic	O
that	O
she	O
has	O
been	O
vomiting	O
and	O
having	O
abdominal	O
pain	O
and	O
urinary	O
frequency	O
.	O
She	O
had	O
reportedly	O
not	O
been	O
eating	O
well	O
,	O
but	O
denied	O
dysuria	O
.	O
In	O
PCP	O
's	O
office	O
today	O
,	O
she	O
was	O
febrile	O
to	O
103.2	O
orally	O
,	O
with	O
HR	O
of	O
116	O
and	O
BP	O
of	O
115/80	O
.	O
She	O
was	O
described	O
as	O
lethargic	O
and	O
sleepy	O
for	O
most	O
of	O
the	O
visit	O
,	O
but	O
easily	O
aroused	O
.	O
Exam	O
was	O
notable	O
for	O
vital	O
signs	O
as	O
above	O
,	O
cool	O
extremities	O
and	O
tenderness	O
over	O
LLQ	O
and	O
RLQ	O
over	O
her	O
transplanted	O
kidney	O
.	O
She	O
was	O
sent	O
to	O
the	O
ED	O
to	O
evaluate	O
for	O
an	O
intra-abdominal	O
,	O
genitourinary	O
,	O
or	O
respiratory	O
source	O
of	O
SIRS	O
/	O
sepsis	O
.	O
In	O
the	O
ED	O
,	O
triage	O
vital	O
signs	O
were	O
100.5	O
,	O
116	O
,	O
125/74	O
,	O
18	O
,	O
97	O
%	O
RA	O
.	O
Exam	O
notable	O
for	O
rigoring	O
,	O
tachycardia	O
,	O
2/6	O
systolic	O
murmur	O
,	O
+	O
RLQ	O
TTP	O
without	O
rebound	O
tenderness	O
or	O
guarding	O
.	O
She	O
was	O
reportedly	O
AAO	O
x2	O
.	O
Labs	O
notable	O
for	O
INR	O
2.9	O
,	O
lactate	O
1.1	O
.	O
Non-contrast	O
CT	O
abd	O
/	O
pelvis	O
showed	O
a	O
malpositioned	O
foley	O
catheter	O
but	O
no	O
explanation	O
for	O
fevers	O
.	O
There	O
was	O
no	O
perinephric	O
stranding	O
or	O
abscess	O
.	O
Ultrasound	O
of	O
the	O
transplanted	O
kidney	O
showed	O
increased	O
resistive	O
indices	O
but	O
no	O
hydronephrosis	O
or	O
perinephric	O
fluid	O
collections	O
.	O
The	O
patient	O
was	O
given	O
two	O
liters	O
of	O
IVF	I-Drug
,	O
and	O
one	O
amp	O
of	O
D50	I-Drug
for	O
hypoglycemia	I-Reason
.	O
She	O
was	O
given	O
1g	O
each	O
of	O
vancomycin	I-Drug
,	O
cefepime	I-Drug
,	O
and	O
acetaminophen	I-Drug
.	O
A	O
third	O
liter	O
of	O
NS	I-Drug
was	O
started	O
prior	O
to	O
transfer	O
to	O
the	O
MICU	O
.	O
Transplant	O
surgery	O
was	O
consulted	O
,	O
and	O
did	O
not	O
feel	O
she	O
needed	O
urgent	O
surgical	O
intervention	O
.	O
Transfer	O
VS	O
per	O
verbal	O
report	O
were	O
temp	O
102	O
,	O
HR	O
120	O
,	O
RR	O
19	O
,	O
99	O
%	O
RA	O
,	O
96/59	O
.	O
Upon	O
arrival	O
to	O
the	O
MICU	O
,	O
the	O
patient	O
had	O
a	O
low	O
-	O
grade	O
fever	O
to	O
100.2	O
.	O
She	O
says	O
she	O
is	O
feeling	O
much	O
better	O
than	O
earlier	O
,	O
and	O
her	O
shaking	O
and	O
chills	O
have	O
stopped	O
.	O
She	O
denies	O
ever	O
having	O
had	O
a	O
cough	O
or	O
dyspnea	O
.	O
Denies	O
urinary	O
frequency	O
,	O
polyuria	O
,	O
or	O
difficulty	O
voiding	O
.	O
Denies	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
or	O
constipation	O
.	O
She	O
was	O
started	O
on	O
D5NS	O
at	O
120	O
cc	O
/	O
hr	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
LUPUS	O
-	O
ANTIPHOSPHOLIPID	O
SYNDROME	O
-	O
ESRD	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
LUPUS	O
NEPHRITIS	O
s	O
/	O
p	O
DCD	O
txp	O
[	O
**	O
2	O
-	O
17	O
**	O
]	O
(	O
recent	O
creat	O
2.3	O
)	O
(	O
Postop	O
course	O
was	O
complicated	O
by	O
SVC	O
syndrome	O
requiring	O
reintubation	O
MRV	O
showed	O
bilateral	O
brachecephalic	O
vein	O
occlusion	O
on	O
[	O
**	O
2173-2-19	O
**	O
]	O
.	O
She	O
underwent	O
venoplasty	O
and	O
stent	O
placement	O
of	O
the	O
Right	O
subclavian	O
vein	O
,	O
brachiocephalic	O
and	O
SVC	O
.	O
Post	O
procedure	O
she	O
was	O
started	O
on	O
heparin	I-Drug
gtts	O
and	O
transitioned	O
to	O
Coumadin	I-Drug
)	O
-	O
THYROID	O
NODULE	O
[	O
**	O
2159	O
**	O
]	O
-	O
ANGIOEDEMA	O
[	O
**	O
2172-10-21	O
**	O
]	O
-	O
HYPERTENSION	O
-	O
HYPERCHOLESTEROLEMIA	O
Social	O
History	O
:	O
Born	O
in	O
[	O
**	O
Country	O
2045	O
**	O
]	O
.	O
She	O
was	O
widowed	O
in	O
6	O
/	O
[	O
**	O
2169	O
**	O
]	O
.	O
She	O
lives	O
alone	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
with	O
1	O
son	O
nearby	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
other	O
3	O
children	O
are	O
still	O
in	O
[	O
**	O
Country	O
2045	O
**	O
]	O
.	O
She	O
denies	O
any	O
tobacco	O
,	O
ethanol	O
or	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Significant	O
for	O
a	O
maternal	O
uncle	O
with	O
hypertension	O
;	O
otherwise	O
denies	O
any	O
family	O
history	O
of	O
heart	O
disease	O
,	O
cancer	O
or	O
diabetes	O
.	O
Mother	O
died	O
of	O
unclear	O
causes	O
when	O
patient	O
was	O
7	O
yo	O
.	O
Father	O
died	O
of	O
unclear	O
causes	O
in	O
[	O
**	O
2152	O
**	O
]	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
Temp	O
:	O
100.2	O
BP	O
:	O
116/51	O
HR	O
:	O
103	O
(	O
regular	O
)	O
RR	O
:	O
17	O
O2sat	O
:	O
100	O
%	O
RA	O
GEN	O
:	O
pleasant	O
,	O
comfortable	O
,	O
NAD	O
.	O
Sitting	O
up	O
in	O
bed	O
.	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
anicteric	O
,	O
MMM	O
,	O
op	O
without	O
lesions	O
,	O
no	O
supraclavicular	O
or	O
cervical	O
lymphadenopathy	O
,	O
no	O
jvd	O
RESP	O
:	O
CTA	O
b	O
/	O
l	O
with	O
good	O
air	O
movement	O
throughout	O
.	O
No	O
wheezes	O
or	O
crackles	O
.	O
CV	O
:	O
RR	O
,	O
S1	O
and	O
S2	O
wnl	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
ABD	O
:	O
Well	O
-	O
healed	O
surgical	O
scar	O
over	O
RLQ	O
.	O
Softly	O
distended	O
,	O
+	O
NABS	O
x4	O
,	O
nt	O
,	O
no	O
masses	O
or	O
hepatosplenomegaly	O
.	O
No	O
TTP	O
over	O
LLQ	O
,	O
RLQ	O
,	O
or	O
elsewhere	O
.	O
No	O
rebound	O
tenderness	O
or	O
guarding	O
.	O
EXT	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
SKIN	O
:	O
+	O
hypopigmented	O
patch	O
over	O
right	O
shoulder	O
extending	O
medially	O
and	O
inferiorly	O
to	O
mid-back	O
,	O
with	O
interspersed	O
hyperpigmented	O
papules	O
(	O
reportedly	O
chronic	O
birthmark	O
)	O
.	O
no	O
rashes	O
/	O
no	O
jaundice	O
/	O
no	O
splinters	O
NEURO	O
:	O
AAOx3	O
.	O
CN	O
II	O
-	O
XII	O
intact	O
.	O
5/5	O
strength	O
throughout	O
.	O
No	O
sensory	O
deficits	O
to	O
light	O
touch	O
appreciated	O
RECTAL	O
:	O
Deferred	O
Pertinent	O
Results	O
:	O
Initial	O
Labs	O
:	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
WBC	O
-	O
5.3	O
#	O
RBC	O
-	O
3.71	O
*	O
HGB	O
-	O
11.1	O
*	O
HCT	O
-	O
32.5	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
29.9	O
MCHC	O
-	O
34.1	O
RDW	O
-	O
15.6	O
*	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
NEUTS	O
-	O
81	O
*	O
BANDS	O
-	O
4	O
LYMPHS	O
-	O
5	O
*	O
MONOS	O
-	O
8	O
EOS	O
-	O
0	O
BASOS	O
-	O
1	O
ATYPS	O
-	O
1	O
*	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
1	O
+	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
NORMAL	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
OCCASIONAL	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
PLT	O
SMR	O
-	O
NORMAL	O
PLT	O
COUNT	O
-	O
195	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
PT	O
-	O
29.0	O
*	O
PTT	O
-	O
31.7	O
INR	O
(	O
PT	O
)	O
-	O
2.9	O
*	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
tacroFK	O
-	O
3.9	O
*	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
ALBUMIN	O
-	O
3.9	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
LIPASE	O
-	O
23	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
13	O
AST	O
(	O
SGOT	O
)	O
-	O
32	O
LD	O
(	O
LDH	O
)	O
-	O
338	O
*	O
ALK	O
PHOS	O
-	O
67	O
AMYLASE	O
-	O
146	O
*	O
TOT	O
BILI	O
-	O
0.6	O
[	O
**	O
2173-10-5	O
**	O
]	O
10:48	O
AM	O
GLUCOSE	O
-	O
38	O
*	O
UREA	O
N	O
-	O
27	O
*	O
CREAT	O
-	O
2.5	O
*	O
SODIUM	O
-	O
133	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
97	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
18	O
[	O
**	O
2173-10-5	O
**	O
]	O
11:49	O
AM	O
LACTATE	O
-	O
1.1	O
[	O
**	O
2173-10-5	O
**	O
]	O
05:20	O
PM	O
URINE	O
COLOR	O
-	O
Straw	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.012	O
[	O
**	O
2173-10-5	O
**	O
]	O
05:20	O
PM	O
URINE	O
BLOOD	O
-	O
MOD	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
75	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
TR	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2173-10-6	O
**	O
]	O
12:00	O
PM	O
BLOOD	O
WBC	O
-	O
3.3	O
*	O
RBC	O
-	O
3.01	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
26.7	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
15.7	O
*	O
Plt	O
Ct	O
-	O
131	O
*	O
[	O
**	O
2173-10-7	O
**	O
]	O
04:55	O
AM	O
BLOOD	O
WBC	O
-	O
2.8	O
*	O
RBC	O
-	O
3.01	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
26.3	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
30.1	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
15.7	O
*	O
Plt	O
Ct	O
-	O
146	O
*	O
[	O
**	O
2173-10-8	O
**	O
]	O
05:55	O
AM	O
BLOOD	O
WBC	O
-	O
2.5	O
*	O
RBC	O
-	O
3.16	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
27.7	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
30.1	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
15.7	O
*	O
Plt	O
Ct	O
-	O
170	O
[	O
**	O
2173-10-9	O
**	O
]	O
07:05	O
AM	O
BLOOD	O
WBC	O
-	O
1.9	O
*	O
RBC	O
-	O
3.16	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
27.6	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
198	O
[	O
**	O
2173-10-10	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
WBC	O
-	O
1.6	O
*	O
RBC	O
-	O
3.30	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
28.8	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
29.8	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
15.5	O
Plt	O
Ct	O
-	O
199	O
Microbiology	O
:	O
blood	O
cx	O
:	O
[	O
**	O
10	O
-	O
5	O
**	O
]	O
Blood	O
Culture	O
,	O
Routine	O
(	O
Preliminary	O
)	O
:	O
e	O
coli	O
GRAM	O
NEGATIVE	O
ROD	O
(	O
S	O
)	O
.	O
PRELIMINARY	O
SENSITIVITY	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_____________________________________________________	O
GRAM	O
NEGATIVE	O
ROD	O
(	O
S	O
)	O
|	O
AMIKACIN	O
--------------	O
S	O
AMPICILLIN	O
------------	O
S	O
AMPICILLIN	O
/	O
SULBACTAM	O
--	O
S	O
CEFEPIME	O
--------------	O
S	O
CEFTAZIDIME	O
-----------	O
S	O
CEFTRIAXONE	O
-----------	O
S	O
CIPROFLOXACIN	O
---------	O
S	O
GENTAMICIN	O
------------	O
S	O
MEROPENEM	O
-------------	O
S	O
PIPERACILLIN	O
/	O
TAZO	O
-----	O
S	O
TOBRAMYCIN	O
------------	O
S	O
stool	O
toxin	O
:	O
[	O
**	O
10	O
-	O
5	O
**	O
]	O
c	O
diff	O
positive	O
Imaging	O
:	O
CXR	O
:	O
[	O
**	O
10	O
-	O
5	O
**	O
]	O
No	O
acute	O
pulmonary	O
process	O
.	O
Stable	O
chest	O
x-ray	O
exam	O
Renal	O
U	O
/	O
S	O
:	O
[	O
**	O
10	O
-	O
5	O
**	O
]	O
No	O
evidence	O
of	O
hydronephrosis	O
or	O
perinephric	O
fluid	O
collection	O
.	O
Increased	O
resistive	O
indices	O
since	O
prior	O
exam	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
216	O
**	O
]	O
,	O
correlate	O
with	O
renal	O
function	O
.	O
CT	O
abdoman	O
/	O
pelvis	O
:	O
[	O
**	O
10	O
-	O
5	O
**	O
]	O
1	O
.	O
No	O
acute	O
findings	O
in	O
the	O
abdomen	O
or	O
pelvis	O
to	O
explain	O
patient	O
's	O
fevers	O
,	O
within	O
the	O
limits	O
of	O
this	O
non-contrast	O
enhanced	O
technique	O
.	O
2	O
.	O
Tip	O
of	O
the	O
Foley	O
catheter	O
within	O
the	O
distal	O
ureter	O
of	O
the	O
transplanted	O
kidney	O
causing	O
mild	O
hydroureteronephrosis	O
.	O
No	O
perinephric	O
collections	O
or	O
masses	O
.	O
No	O
evidence	O
for	O
abscess	O
.	O
3	O
.	O
Fecal	O
loading	O
in	O
the	O
rectum	O
without	O
bowel	O
obstruction	O
Brief	O
Hospital	O
Course	O
:	O
*	O
Please	O
note	O
that	O
pt	O
left	O
against	O
medical	O
advice	O
*	O
.	O
.	O
53	O
y	O
/	O
o	O
immunosuppressed	O
female	O
s	O
/	O
p	O
renal	O
transplant	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
958	O
**	O
]	O
[	O
**	O
2172	O
**	O
]	O
,	O
presenting	O
from	O
PCP	O
's	O
office	O
with	O
three	O
weeks	O
of	O
chills	O
,	O
now	O
with	O
documented	O
fevers	O
tachycardia	O
,	O
borderline	O
hypotension	O
,	O
and	O
hypoglycemia	O
.	O
.	O
1	O
.	O
Sepsis	O
secondary	O
to	O
ecoli	O
bacteremia	O
:	O
On	O
presentation	O
,	O
meet	O
SIRS	O
criteria	O
with	O
fevers	O
,	O
tachycardia	O
and	O
mild	O
bandemia	O
from	O
suspected	O
infectious	O
source	O
especially	O
given	O
immunosuppression	O
.	O
Pancultured	O
in	O
the	O
emergency	O
department	O
and	O
placed	O
on	O
empiric	O
broad	B-Drug
-	I-Drug
spectrum	I-Drug
antibiotics	I-Drug
with	O
vancomycin	I-Drug
and	O
cefepime	I-Drug
.	O
To	O
evaluate	O
for	O
etiology	O
,	O
CXR	O
and	O
CT	O
scan	O
of	O
abdomen	O
was	O
performed	O
with	O
no	O
apparent	O
abnormality	O
besides	O
stool	O
impaction	O
in	O
the	O
rectum	O
.	O
Urinalysis	O
did	O
have	O
minimal	O
blood	O
and	O
white	O
blood	O
cells	O
,	O
but	O
culture	O
returned	O
negative	O
.	O
Stool	O
cx	O
returned	O
positive	O
for	O
cdiff	I-Reason
and	O
patient	O
was	O
started	O
on	O
flagyl	I-Drug
.	O
Blood	O
cx	O
from	O
[	O
**	O
10	O
-	O
5	O
**	O
]	O
grew	O
pansensitive	O
ecoli	O
and	O
antibiotics	I-Drug
were	O
subsequently	O
narrowed	O
to	O
ciprofloxacin	I-Drug
(	O
and	O
flagyl	I-Drug
)	O
.	O
The	O
most	O
likely	O
source	O
of	O
ecoli	O
bacteremia	O
was	O
thought	O
to	O
be	O
translocation	O
from	O
gut	O
in	O
setting	O
of	O
mild	O
colitis	O
.	O
The	O
patient	O
was	O
transiently	O
hypotensive	O
in	O
the	O
emergency	O
department	O
,	O
but	O
responded	O
to	O
fluid	O
boluses	O
.	O
With	O
antibiotic	I-Drug
therapy	O
,	O
she	O
defervesced	O
,	O
tachycardia	O
resolved	O
,	O
and	O
subjective	O
complaints	O
of	O
chills	O
improved	O
.	O
Surveillance	O
blood	O
cx	O
from	O
[	O
**	O
10	O
-	O
6	O
**	O
]	O
were	O
negative	O
for	O
48	O
hrs	O
,	O
pt	O
was	O
continued	O
on	O
cipro	I-Drug
/	O
flagyl	I-Drug
but	O
developed	O
leukopenia	I-Ade
and	O
flagyl	I-Drug
was	O
discontinued	O
(	O
bc	O
can	O
contribute	O
to	O
leukopenia	I-Ade
)	O
and	O
changed	O
to	O
PO	O
vancomycin	I-Drug
.	O
Authorization	O
for	O
PO	O
vanco	I-Drug
could	O
not	O
be	O
obtained	O
over	O
the	O
weekend	O
and	O
pt	O
decided	O
to	O
leave	O
against	O
medical	O
advice	O
in	O
lieu	O
of	O
waiting	O
for	O
vanco	I-Drug
authorization	O
.	O
Pt	O
was	O
advised	O
to	O
continue	O
vanco	I-Drug
for	O
2	O
weeks	O
more	O
after	O
completing	O
2	O
week	O
course	O
of	O
cipro	I-Drug
.	O
She	O
has	O
outpt	O
f	O
/	O
u	O
in	O
transplant	O
clinic	O
to	O
have	O
WBC	O
count	O
checked	O
(	O
in	O
addition	O
to	O
INR	O
and	O
tacro	O
levels	O
,	O
as	O
below	O
)	O
.	O
At	O
time	O
of	O
discharge	O
,	O
pt	O
was	O
abebrile	O
>	O
72	O
hrs	O
,	O
had	O
no	O
diarrhea	O
,	O
no	O
abd	O
pain	O
,	O
no	O
N	O
/	O
V.	O
Of	O
note	O
,	O
mycophenolate	B-Drug
mofetil	I-Drug
was	O
discontinued	O
as	O
well	O
prior	O
to	O
discharge	O
given	O
leukopenia	I-Ade
.	O
Bactrim	I-Drug
and	O
valcyte	I-Drug
,	O
though	O
also	O
can	O
cause	O
leukopenia	I-Ade
,	O
were	O
continued	O
as	O
pt	O
has	O
been	O
on	O
these	O
for	O
a	O
long	O
time	O
without	O
complications	O
.	O
Most	O
likely	O
leukopenia	I-Ade
was	O
due	O
to	O
recent	O
initiation	O
of	O
flagyl	I-Drug
,	O
and	O
should	O
improve	O
on	O
cipro	I-Drug
/	O
vanco	I-Drug
regimen	O
.	O
MMF	I-Drug
was	O
held	O
until	O
follow	O
up	O
as	O
this	O
may	O
have	O
been	O
contributing	O
to	O
her	O
neutropenia	I-Ade
.	O
.	O
2	O
.	O
ESRD	O
s	O
/	O
p	O
transplant	O
:	O
History	O
of	O
lupus	O
nephritis	O
s	O
/	O
p	O
renal	O
transplant	O
on	O
cellcept	I-Drug
,	O
tacrolimus	I-Drug
and	O
prednisone	I-Drug
.	O
Baseline	O
creatinine	I-Drug
is	O
in	O
the	O
1s	O
,	O
but	O
has	O
been	O
slowly	O
increasing	O
since	O
[	O
**	O
Month	O
(	O
only	O
)	O
205	O
**	O
]	O
and	O
has	O
been	O
as	O
high	O
as	O
2.7	O
in	O
the	O
recent	O
past	O
.	O
Etiology	O
of	O
developping	O
renal	O
insufficiency	O
is	O
unclear	O
:	O
CT	O
scan	O
with	O
no	O
evidence	O
of	O
obstruction	O
,	O
urinalysis	O
without	O
active	O
sediment	O
to	O
suggest	O
recurrent	O
lupus	O
nephritis	O
.	O
The	O
patient	O
may	O
have	O
chronic	O
volume	O
depletion	O
,	O
she	O
is	O
on	O
bactrim	I-Drug
for	O
PCP	I-Reason
[	O
**	O
Name9	O
(	O
PRE	O
)	O
**	O
]	O
which	O
may	O
artifactually	O
increase	O
creatinine	I-Drug
.	O
Also	O
,	O
it	O
is	O
unclear	O
whether	O
she	O
is	O
compliant	O
with	O
her	O
immunosuppressants	I-Drug
at	O
home	O
.	O
A	O
renal	O
biopsy	O
may	O
be	O
pursued	O
as	O
an	O
outpatient	O
.	O
During	O
hospitalization	O
,	O
renal	O
function	O
was	O
trended	O
daily	O
and	O
patient	O
continued	O
on	O
immunosuppressants	I-Drug
with	O
bactrim	I-Drug
for	O
PCP	I-Reason
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
.	O
Daily	O
tacrolimus	I-Drug
levels	O
were	O
also	O
followed	O
with	O
level	O
adjusted	O
as	O
needed	O
.	O
Goal	O
level	O
[	O
**	O
7	O
-	O
20	O
**	O
]	O
,	O
tacro	O
level	O
6.4	O
at	O
discharge	O
,	O
per	O
renal	O
consult	O
continued	O
2	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
dosing	O
of	O
tacrolimus	I-Drug
.	O
Cellcept	I-Drug
was	O
discontinued	O
prior	O
to	O
discharge	O
given	O
leukopenia	I-Ade
(	O
as	O
above	O
)	O
.	O
Pt	O
has	O
f	O
/	O
u	O
in	O
renal	O
transplant	O
clinic	O
to	O
have	O
tacro	I-Drug
levels	O
rechecked	O
and	O
to	O
check	O
WBC	O
count	O
,	O
will	O
modulate	O
immunosuppression	I-Drug
regimen	O
based	O
on	O
those	O
results	O
.	O
.	O
3	O
.	O
Antiphospholipid	B-Reason
syndrome	I-Reason
:	O
on	O
longterm	O
anticoagulation	I-Drug
with	O
warfarin	I-Drug
for	O
history	O
of	O
APLS	O
(	O
Anticardiolipin	O
Ab	O
's	O
showing	O
elevated	O
IgG	O
and	O
normal	O
IgM	O
in	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
and	O
[	O
**	O
7	O
-	O
17	O
**	O
]	O
)	O
with	O
multiple	O
prior	O
thrombotic	O
occlusions	O
of	O
dialysis	O
fistula	O
.	O
PT	O
/	O
INR	O
followed	O
daily	O
with	O
warfarin	I-Drug
supratherapeutic	O
on	O
[	O
**	O
10	O
-	O
6	O
**	O
]	O
to	O
4.7	O
.	O
INR	O
at	O
2.9	O
to	O
2.1	O
on	O
discharge	O
(	O
goal	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
)	O
.	O
Coumadin	I-Drug
was	O
restarted	O
at	O
1	O
mg	O
daily	O
with	O
f	O
/	O
u	O
day	O
after	O
discharge	O
to	O
check	O
INR	O
levels	O
and	O
to	O
adjust	O
coumadin	I-Drug
accordingly	O
.	O
.	O
4	O
.	O
SLE	O
:	O
Outpatient	O
rheumatology	O
notes	O
indicate	O
patient	O
diagnosed	O
in	O
[	O
**	O
2165	O
**	O
]	O
and	O
initially	O
seen	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
lupus	O
clinic	O
.	O
Last	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
rheumatology	O
clinic	O
visit	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
,	O
documenting	O
history	O
of	O
lupus	O
nephritis	O
and	O
AVN	O
of	O
ankles	O
with	O
last	O
documented	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
positive	O
1:160	O
in	O
[	O
**	O
2169	O
**	O
]	O
,	O
though	O
dsDNA	O
Ab	O
's	O
have	O
been	O
negative	O
when	O
checked	O
since	O
[	O
**	O
2171	O
**	O
]	O
.	O
No	O
findings	O
on	O
history	O
or	O
physical	O
consistent	O
with	O
lupus	O
flair	O
.	O
.	O
5	O
.	O
Hypertension	O
:	O
Pt	O
has	O
history	O
of	O
hypertension	I-Reason
treated	O
with	O
metoprolol	I-Drug
only	O
,	O
with	O
past	O
systolic	O
blood	O
pressure	O
measurements	O
documented	O
in	O
the	O
110	O
-	O
140	O
range	O
,	O
per	O
OMR	O
.	O
Documented	O
BP	O
's	O
in	O
ED	O
generally	O
in	O
low	O
100s	O
,	O
with	O
IVF	I-Drug
infusion	O
.	O
Given	O
systemic	O
HTN	I-Reason
,	O
home	O
metoprolol	I-Drug
initially	O
held	O
but	O
restarted	O
prior	O
to	O
discharge	O
.	O
.	O
6	O
.	O
Hyperlipidemia	O
:	O
Last	O
lipid	O
panel	O
in	O
[	O
**	O
2172-9-10	O
**	O
]	O
,	O
with	O
TC	O
144	O
,	O
HDL	O
39	O
,	O
LDL	O
81	O
,	O
TG	O
120	O
.	O
Not	O
currently	O
receiving	O
treatment	O
,	O
but	O
was	O
taking	O
simvastatin	I-Drug
through	O
[	O
**	O
2172-3-11	O
**	O
]	O
.	O
.	O
7	O
.	O
Hyponatremia	O
:	O
Mild	O
,	O
without	O
alterations	O
in	O
mental	O
status	O
.	O
Likely	O
poor	O
PO	O
intake	O
over	O
past	O
days	O
-	O
weeks	O
would	O
suggest	O
hypovolemic	O
hyponatremia	O
.	O
Improved	O
following	O
IVF	I-Drug
bolus	O
in	O
emergency	O
department	O
.	O
.	O
8	O
.	O
Osteoporosis	I-Ade
:	O
Last	O
bone	O
densitometry	O
scan	O
in	O
[	O
**	O
2173-4-10	O
**	O
]	O
,	O
consistent	O
with	O
osteoporosis	O
,	O
in	O
setting	O
of	O
chronic	O
glucocorticoid	I-Drug
therapy	O
and	O
hyperparathyroidism	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Mycophenolate	B-Drug
Mofetil	I-Drug
1000	O
mg	O
PO	O
BID	O
2	O
.	O
Acetaminophen	I-Drug
650	O
mg	O
PO	O
/	O
NG	O
Q6H	O
:	O
PRN	O
fever	I-Reason
,	O
pain	I-Reason
3	O
.	O
PredniSONE	I-Drug
5	O
mg	O
PO	O
/	O
NG	O
DAILY	O
4	O
.	O
CefePIME	I-Drug
1	O
g	O
IV	O
Q24H	O
5	O
.	O
Sulfameth	B-Drug
/	I-Drug
Trimethoprim	I-Drug
SS	O
1	O
TAB	O
PO	O
/	O
NG	O
DAILY	O
6	O
.	O
Cinacalcet	I-Drug
30	O
mg	O
PO	O
DAILY	O
7	O
.	O
Tacrolimus	I-Drug
2	O
mg	O
PO	O
Q12H	O
8	O
.	O
Famotidine	I-Drug
20	O
mg	O
PO	O
/	O
NG	O
Q24H	O
9	O
.	O
ValGANCIclovir	I-Drug
450	O
mg	O
PO	O
DAILY	O
10	O
.	O
MetRONIDAZOLE	B-Drug
(	I-Drug
FLagyl	I-Drug
)	O
500	O
mg	O
IV	O
Q8H	O
11	O
.	O
Warfarin	I-Drug
1	O
mg	O
PO	O
/	O
NG	O
DAILY16	O
Discharge	O
Medications	O
:	O
1	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
have	O
your	O
INR	O
checked	O
at	O
[	O
**	O
Hospital3	O
**	O
]	O
(	O
[	O
**	O
Company	O
191	O
**	O
]	O
)	O
on	O
Monday	O
,	O
[	O
**	O
10	O
-	O
11	O
**	O
]	O
.	O
Please	O
fax	O
to	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3534	O
**	O
]	O
.	O
2	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
have	O
your	O
tacrolimus	I-Drug
level	O
,	O
CBC	O
,	O
and	O
INR	O
checked	O
at	O
renal	O
transplant	O
clinic	O
on	O
[	O
**	O
10	O
-	O
18	O
**	O
]	O
.	O
3	O
.	O
cinacalcet	I-Drug
30	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
5	O
.	O
prednisone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
valganciclovir	I-Drug
450	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
EVERY	O
OTHER	O
DAY	O
(	O
Every	O
Other	O
Day	O
)	O
.	O
8	O
.	O
warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
please	O
have	O
your	O
INR	O
checked	O
on	O
[	O
**	O
10	O
-	O
11	O
**	O
]	O
.	O
9	O
.	O
tacrolimus	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
10	O
.	O
sulfamethoxazole	B-Drug
-	I-Drug
trimethoprim	I-Drug
400	O
-	O
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
glipizide	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
12	O
.	O
ciprofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
11	O
days	O
.	O
Disp	O
:	O
*	O
11	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
13	O
.	O
vancomycin	I-Drug
250	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
for	O
25	O
days	O
.	O
Disp	O
:	O
*	O
100	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
E	O
coli	O
bacteremia	O
C	O
diff	O
.	O
Secondary	O
:	O
SLE	O
Antiphospholipid	O
antibody	O
s	O
/	O
p	O
renal	O
transplant	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
are	O
leaving	O
the	O
hospital	O
against	O
medical	O
advice	O
.	O
.	O
You	O
were	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
with	O
fevers	O
and	O
chills	O
.	O
You	O
were	O
found	O
to	O
have	O
bacteria	O
from	O
your	O
blood	O
(	O
E.	O
coli	O
)	O
which	O
likely	O
came	O
from	O
your	O
bowel	O
tract	O
.	O
You	O
have	O
an	O
infection	O
in	O
your	O
bowels	O
called	O
C	B-Ade
diff	I-Ade
which	O
can	O
be	O
contracted	O
while	O
on	O
immunosuppression	I-Drug
and	O
during	O
hospitalizations	O
.	O
You	O
are	O
being	O
treated	O
for	O
both	O
infections	O
with	O
antibiotics	I-Drug
.	O
Your	O
kidney	O
function	O
improved	O
with	O
fluids	O
.	O
Your	O
INR	B-Ade
level	I-Ade
has	I-Ade
been	I-Ade
higher	I-Ade
than	I-Ade
optimal	I-Ade
because	O
your	O
antibiotics	I-Drug
can	O
interfere	O
with	O
coumadin	I-Drug
.	O
We	O
held	O
your	O
coumadin	I-Drug
,	O
but	O
restarted	O
it	O
before	O
your	O
discharge	O
,	O
INR	O
should	O
be	O
closely	O
monitored	O
when	O
you	O
leave	O
the	O
hospital	O
.	O
Please	O
follow	O
up	O
with	O
the	O
coumadin	I-Drug
clinic	O
tomorrow	O
.	O
.	O
We	O
have	O
made	O
the	O
following	O
changes	O
to	O
your	O
medications	O
:	O
Decrease	O
your	O
tacrolimus	I-Drug
to	O
2	O
mg	O
twice	O
a	O
day	O
Take	O
cipro	I-Drug
for	O
11	O
more	O
days	O
(	O
last	O
day	O
=	O
[	O
**	O
10	O
-	O
20	O
**	O
]	O
)	O
Take	O
vancomycin	I-Drug
for	O
25	O
more	O
days	O
(	O
last	O
day	O
=	O
[	O
**	O
11	O
-	O
3	O
**	O
]	O
)	O
Stop	O
taking	O
mycophenolate	B-Drug
mofetil	I-Drug
(	O
cellcept	I-Drug
)	O
until	O
you	O
follow	O
up	O
with	O
the	O
kidney	O
transplant	O
doctors	O
Continue	O
to	O
take	O
coumadin	I-Drug
1	O
mg	O
daily	O
,	O
but	O
have	O
your	O
INR	O
checked	O
at	O
[	O
**	O
Hospital	O
191	O
**	O
]	O
[	O
**	O
Hospital3	O
**	O
]	O
on	O
[	O
**	O
10	O
-	O
11	O
**	O
]	O
to	O
make	O
sure	O
it	O
is	O
therapeutic	O
Followup	O
Instructions	O
:	O
The	O
following	O
appointments	O
have	O
been	O
scheduled	O
for	O
you	O
:	O
.	O
Please	O
have	O
your	O
INR	O
checked	O
at	O
[	O
**	O
Hospital	O
191	O
**	O
]	O
[	O
**	O
Hospital3	O
**	O
]	O
on	O
Monday	O
,	O
[	O
**	O
10	O
-	O
11	O
**	O
]	O
.	O
.	O
Department	O
:	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
When	O
:	O
MONDAY	O
[	O
**	O
2173-10-18	O
**	O
]	O
at	O
9:30	O
AM	O
With	O
:	O
[	O
**	O
Company	O
191	O
**	O
]	O
POST	O
[	O
**	O
Hospital	O
894	O
**	O
]	O
CLINIC	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
.	O
Department	O
:	O
WEST	O
[	O
**	O
Hospital	O
2002	O
**	O
]	O
CLINIC	O
When	O
:	O
MONDAY	O
[	O
**	O
2173-10-18	O
**	O
]	O
at	O
1	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2540	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
721	O
**	O
]	O
Building	O
:	O
De	O
[	O
**	O
Hospital1	O
**	O
]	O
Building	O
(	O
[	O
**	O
Hospital	O
Ward	O
Name	O
121	O
**	O
]	O
Complex	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Street	O
Address	O
(	O
1	O
)	O
592	O
**	O
]	O
Garage	O
Please	O
follow	O
up	O
with	O
the	O
kidney	O
transplant	O
doctors	O
,	O
who	O
will	O
contact	O
you	O
with	O
an	O
appointment	O
.	O
Completed	O
by	O
:[	O
**	O
2173-10-10	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2100-12-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2101-1-7	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Norvasc	I-Drug
/	O
Cipro	I-Drug
I.V.	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
13541	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
PICC	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
22236	O
**	O
]	O
is	O
an	O
89	O
y.o.	O
M	O
with	O
systolic	O
CHF	O
(	O
EF	O
45	O
%	O
in	O
[	O
**	O
9	O
-	O
25	O
**	O
]	O
)	O
,	O
s	O
/	O
p	O
MCA	O
CVA	O
,	O
afib	O
,	O
HTN	O
,	O
and	O
DM	O
II	O
,	O
recently	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
8945	O
**	O
]	O
and	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
22237	O
**	O
]	O
for	O
HAP	O
and	O
UTI	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
transferred	O
from	O
[	O
**	O
Hospital	O
**	O
]	O
hosp	O
for	O
hypotension	O
.	O
History	O
is	O
unclear	O
as	O
obtained	O
from	O
scant	O
OSH	O
records	O
and	O
patient	O
unable	O
to	O
give	O
history	O
.	O
He	O
appears	O
to	O
have	O
been	O
at	O
NH	O
when	O
found	O
to	O
sats	O
81	O
%	O
RA	O
,	O
foley	O
draining	O
dark	O
amber	O
urine	O
.	O
He	O
was	O
noted	O
to	O
have	O
severe	O
peripheral	O
edema	O
and	O
given	O
levoquin	I-Drug
X	O
1	O
and	O
lasix	I-Drug
40	O
mg	O
IV	O
X	O
1	O
at	O
OSH	O
.	O
He	O
became	O
hypotensive	O
to	O
80's	O
at	O
OSH	O
,	O
placed	O
an	O
EJ	O
and	O
started	O
peripheral	O
neo	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
T	O
100	O
,	O
P	O
81	O
,	O
BP	O
107/58	O
,	O
R	O
18	O
,	O
100	O
%	O
NRB	O
O2	O
sat	O
.	O
Patient	O
was	O
given	O
Vanc	I-Drug
/	O
Zosyn	I-Drug
,	O
tylenol	I-Drug
,	O
and	O
1L	O
NS	I-Drug
in	O
ED	O
.	O
Bladder	O
was	O
changed	O
in	O
ED	O
with	O
UCx	O
very	O
positive	O
and	O
sent	O
to	O
ICU	O
.	O
On	O
the	O
floor	O
,	O
he	O
has	O
no	O
complaints	O
.	O
History	O
is	O
obtained	O
mostly	O
from	O
son	O
as	O
patient	O
only	O
answers	O
with	O
single	O
words	O
.	O
Past	O
Medical	O
History	O
:	O
L	O
MCA	O
stroke	O
with	O
right	O
-	O
sided	O
hemiparesis	O
,	O
aphasia	O
[	O
**	O
12/2090	O
**	O
]	O
Systolic	O
CHF	O
with	O
EF	O
45	O
-	O
50	O
%	O
in	O
[	O
**	O
9	O
-	O
/	O
2100	O
**	O
]	O
Mild	O
pulmonary	O
artery	O
hypertension	O
Atrial	O
fibrillation	O
with	O
slow	O
ventricular	O
response	O
Heart	O
block	O
s	O
/	O
p	O
[	O
**	O
Company	O
1543	O
**	O
]	O
Sensia	O
single	O
-	O
chamber	O
pacemaker	O
[	O
**	O
3	O
-	O
25	O
**	O
]	O
Benign	O
Hypertension	O
Hyperlipidemia	O
Type	O
2	O
Diabetes	O
RLE	O
cellulitis	O
RLE	O
DVT	I-Reason
(	O
on	O
coumadin	I-Drug
)	O
s	O
/	O
p	O
IVC	O
filter	O
[	O
**	O
10/2099	O
**	O
]	O
Sleep	O
apnea	O
(	O
intolerant	O
of	O
CPAP	O
)	O
Bladder	O
diverticulum	O
w	O
/	O
?	O
fungal	O
infection	O
,	O
currently	O
inoperable	O
per	O
most	O
recent	O
urology	O
note	O
followed	O
by	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
770	O
**	O
]	O
Recurrent	O
UTIs	O
Social	O
History	O
:	O
He	O
does	O
not	O
drink	O
or	O
smoke	O
.	O
Widower	O
with	O
3	O
children	O
.	O
Former	O
pro-baseball	O
scout	O
for	O
numerous	O
pro-teams	O
.	O
Was	O
one	O
of	O
the	O
first	O
scouts	O
to	O
recruit	O
a	O
minority	O
player	O
(	O
to	O
Philly	O
)	O
,	O
and	O
was	O
then	O
black	O
-	O
listed	O
for	O
this	O
reason	O
for	O
5	O
years	O
.	O
He	O
coached	O
for	O
many	O
many	O
years	O
at	O
[	O
**	O
Location	O
(	O
un	O
)	O
5871	O
**	O
]	O
college	O
,	O
where	O
he	O
boasted	O
a	O
100	O
%	O
graduation	O
rate	O
.	O
Lives	O
in	O
a	O
nursing	O
home	O
,	O
and	O
is	O
visited	O
daily	O
by	O
his	O
sons	O
,	O
who	O
performs	O
many	O
of	O
the	O
tasks	O
of	O
daily	O
care	O
.	O
He	O
does	O
not	O
drink	O
,	O
smoke	O
,	O
nor	O
use	O
recereational	O
drugs	O
.	O
Widower	O
with	O
3	O
children	O
.	O
Family	O
History	O
:	O
Non-Contributory	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
Tm	O
/	O
c	O
97.8	O
,	O
80s	O
,	O
100	O
-	O
120s	O
/	O
50	O
-	O
60s	O
,	O
98	O
%	O
on	O
RA	O
General	O
:	O
sleepy	O
,	O
appears	O
comfortable	O
,	O
responds	O
to	O
a	O
few	O
questions	O
,	O
oriented	O
to	O
[	O
**	O
State	O
350	O
**	O
]	O
&	O
baseball	O
.	O
Does	O
communicate	O
often	O
appropriately	O
.	O
HEENT	O
:	O
Pupils	O
small	O
b	O
/	O
l	O
,	O
but	O
reactive	O
to	O
light	O
.	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
diffuse	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
somewhat	O
firm	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
,	O
multipodus	O
boots	O
on	O
.	O
Skin	O
:	O
Few	O
crusted	O
ulcers	O
on	O
toes	O
GU	O
:	O
swollen	O
scotum	O
Pertinent	O
Results	O
:	O
Discharge	O
Labs	O
:	O
[	O
**	O
2101-1-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
WBC	O
-	O
12.3	O
*	O
RBC	O
-	O
2.62	O
*	O
Hgb	O
-	O
8.4	O
*	O
Hct	O
-	O
25.2	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
31.9	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
15.9	O
*	O
Plt	O
Ct	O
-	O
281	O
[	O
**	O
2101-1-6	O
**	O
]	O
07:00	O
AM	O
BLOOD	O
PT	O
-	O
28.7	O
*	O
PTT	O
-	O
42.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.9	O
*	O
[	O
**	O
2101-1-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
Glucose	O
-	O
68	O
*	O
UreaN	O
-	O
15	O
Creat	O
-	O
1.4	O
*	O
Na	O
-	O
145	O
K	O
-	O
3.7	O
Cl	O
-	O
113	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
11	O
[	O
**	O
2101-1-6	O
**	O
]	O
06:23	O
AM	O
BLOOD	O
Calcium	O
-	O
6.7	O
*	O
Phos	O
-	O
2.7	O
Mg	O
-	O
1.7	O
[	O
**	O
2100-12-28	O
**	O
]	O
11:00	O
PM	O
BLOOD	O
VitB12	O
-	O
1170	O
*	O
Folate	O
-	O
6.5	O
[	O
**	O
2101-1-5	O
**	O
]	O
07:57	O
PM	O
BLOOD	O
Tobra	O
-	O
1.2	O
*	O
Imaging	O
:	O
[	O
**	O
1	O
-	O
3	O
**	O
]	O
CXR	O
:	O
There	O
is	O
increased	O
hazy	O
vasculature	O
bilaterally	O
with	O
bilateral	O
pleural	O
effusions	O
,	O
left	O
greater	O
than	O
right	O
that	O
have	O
increased	O
.	O
Compared	O
to	O
the	O
prior	O
study	O
,	O
there	O
is	O
dense	O
retrocardiac	O
opacification	O
consistent	O
with	O
volume	O
loss	O
/	O
effusion	O
/	O
infiltrate	O
.	O
Compared	O
to	O
the	O
prior	O
study	O
,	O
the	O
amount	O
of	O
pulmonary	O
edema	O
has	O
increased	O
.	O
An	O
underlying	O
infectious	O
infiltrate	O
particularly	O
on	O
the	O
left	O
can	O
not	O
be	O
totally	O
excluded	O
.	O
[	O
**	O
12	O
-	O
28	O
**	O
]	O
Scrotal	O
U	O
/	O
S	O
:	O
Significant	O
subcutaneous	O
scrotal	O
swelling	O
with	O
no	O
hypervascularity	O
and	O
no	O
gas	O
within	O
the	O
tissues	O
identified	O
.	O
This	O
edema	O
may	O
be	O
due	O
to	O
third	O
spacing	O
but	O
ultrasound	O
is	O
unable	O
to	O
further	O
characterize	O
.	O
A	O
clinical	O
evaluation	O
is	O
recommended	O
to	O
exclude	O
a	O
subcutaneous	O
infectious	O
process	O
,	O
and	O
if	O
further	O
imaging	O
is	O
required	O
,	O
a	O
CT	O
could	O
be	O
performed	O
.	O
2	O
)	O
No	O
evidence	O
of	O
an	O
intratesticular	O
mass	O
.	O
No	O
evidence	O
of	O
epididymitis	O
or	O
orchitis	O
.	O
Microbiology	O
:	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2101-1-1	O
**	O
]	O
**	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2101-1-1	O
**	O
]	O
)	O
:	O
PSEUDOMONAS	O
AERUGINOSA	O
.	O
>	O
100,000	O
ORGANISMS	O
/	O
ML	O
.	O
.	O
ESCHERICHIA	O
COLI	O
.	O
>	O
100,000	O
ORGANISMS	O
/	O
ML	O
.	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
PSEUDOMONAS	O
AERUGINOSA	O
|	O
ESCHERICHIA	O
COLI	O
|	O
|	O
AMPICILLIN	O
------------	O
=	O
>	O
32	O
R	O
AMPICILLIN	O
/	O
SULBACTAM	O
--	O
4	O
S	O
CEFAZOLIN	O
-------------	O
32	O
R	O
CEFEPIME	O
--------------	O
8	O
S	O
<	O
=	O
1	O
S	O
CEFTAZIDIME	O
-----------	O
4	O
S	O
<	O
=	O
1	O
S	O
CEFTRIAXONE	O
-----------	O
<	O
=	O
1	O
S	O
CEFUROXIME	O
------------	O
16	O
I	O
CIPROFLOXACIN	O
---------	O
=	O
>	O
4	O
R	O
=	O
>	O
4	O
R	O
GENTAMICIN	O
------------	O
2	O
S	O
<	O
=	O
1	O
S	O
MEROPENEM	O
-------------	O
=	O
>	O
16	O
R	O
<	O
=	O
0.25	O
S	O
NITROFURANTOIN	O
--------	O
<	O
=	O
16	O
S	O
PIPERACILLIN	O
----------	O
16	O
S	O
=	O
>	O
128	O
R	O
PIPERACILLIN	O
/	O
TAZO	O
-----	O
16	O
S	O
<	O
=	O
4	O
S	O
TOBRAMYCIN	O
------------	O
<	O
=	O
1	O
S	O
<	O
=	O
1	O
S	O
TRIMETHOPRIM	O
/	O
SULFA	O
----	O
<	O
=	O
1	O
S	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2101-1-3	O
**	O
]	O
**	O
Blood	O
Culture	O
,	O
Routine	O
(	O
Final	O
[	O
**	O
2101-1-3	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
[	O
**	O
2101-1-4	O
**	O
]	O
6:32	O
am	O
BLOOD	O
CULTURE	O
Source	O
:	O
Line	O
-	O
PICC	O
2	O
OF	O
2	O
.	O
Blood	O
Culture	O
,	O
Routine	O
(	O
Pending	O
)	O
:	O
Brief	O
Hospital	O
Course	O
:	O
An	O
89	O
year	O
old	O
gentleman	O
with	O
systolic	O
CHF	O
,	O
chronic	O
foley	O
who	O
presented	O
from	O
rehab	O
with	O
Psuedomonal	O
/	O
E.	O
Coli	O
urosepsis	O
.	O
#	O
)	O
Urosepsis	O
:	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
for	O
management	O
of	O
urosepsis	I-Reason
.	O
While	O
there	O
he	O
was	O
maintained	O
on	O
neosynephrine	I-Drug
for	O
2	O
days	O
.	O
He	O
was	O
started	O
on	O
Vancomycin	I-Drug
&	O
Zosyn	I-Drug
.	O
The	O
patient	O
was	O
called	O
out	O
to	O
the	O
floor	O
on	O
Zosyn	I-Drug
&	O
Tobramycin	I-Drug
.	O
Further	O
microbiologic	O
data	O
suggested	O
a	O
treatment	O
change	O
to	O
Tobramycin	I-Drug
&	O
Ceftazidime	I-Drug
to	O
be	O
continued	O
until	O
[	O
**	O
2101-1-12	O
**	O
]	O
.	O
Throughout	O
this	O
admission	O
the	O
patient	O
's	O
chronic	O
foley	O
due	O
to	O
bladder	O
diverticulum	O
remained	O
in	O
place	O
and	O
regularly	O
irrigated	O
.	O
-	O
Ceftazidime	I-Drug
2g	O
IV	O
Q12h	O
last	O
dose	O
[	O
**	O
2101-1-12	O
**	O
]	O
-	O
Tobramycin	I-Drug
100	O
mg	O
IV	O
Q24	O
,	O
decrease	O
dose	O
to	O
80	O
mg	O
on	O
[	O
**	O
2101-1-9	O
**	O
]	O
to	O
finish	O
course	O
on	O
[	O
**	O
2101-1-12	O
**	O
]	O
.	O
-	O
Foley	O
requires	O
hand	O
irrigation	O
q4	O
-	O
6	O
hours	O
,	O
no	O
continuous	O
bladder	O
irrigation	O
.	O
#	O
)	O
Atrial	B-Reason
Fibrillation	I-Reason
:	O
The	O
patient	O
has	O
a	O
history	O
of	O
atrial	O
fibrillation	O
for	O
which	O
he	O
is	O
on	O
chronic	O
anti-coagulation	I-Drug
and	O
metoprolol	I-Drug
.	O
Due	O
to	O
his	O
poor	O
PO	O
intake	O
and	O
self	O
-	O
sustained	O
rate	O
control	O
,	O
the	O
patient	O
will	O
not	O
be	O
continued	O
on	O
metoprolol	I-Drug
.	O
His	O
coumadin	I-Drug
was	O
held	O
for	O
much	O
of	O
his	O
admission	O
given	O
a	O
supratherapeutic	B-Ade
INR	I-Ade
.	O
He	O
will	O
be	O
discharged	O
on	O
2	O
mg	O
daily	O
with	O
PT	O
levels	O
to	O
be	O
followed	O
twice	O
weekly	O
,	O
goal	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
.	O
#	O
)	O
Chronic	O
DVTs	O
:	O
Anticoagulated	O
as	O
above	O
.	O
#	O
)	O
Malnutrition	O
/	O
Wound	O
Care	O
(	O
Sacral	O
Decubitus	O
&	O
leg	O
ulcers	O
)	O
:	O
The	O
patient	O
is	O
tolerating	O
limited	O
PO	O
with	O
siginificant	O
aspiration	O
risk	O
&	O
aspiration	O
events	O
.	O
Other	O
feeding	O
options	O
were	O
discussed	O
with	O
the	O
family	O
but	O
they	O
have	O
opted	O
to	O
maintain	O
oral	O
feeding	O
.	O
Of	O
note	O
,	O
the	O
patient	O
has	O
a	O
low	O
Albumin	O
in	O
the	O
1s	O
with	O
significant	O
wound	O
care	O
issues	O
as	O
well	O
as	O
significant	O
scrotal	O
edema	O
.	O
The	O
patient	O
was	O
admitted	O
on	O
Zinc	I-Drug
,	O
Vitamin	B-Drug
C	I-Drug
,	O
&	O
Vitamin	B-Drug
B	I-Drug
but	O
due	O
to	O
his	O
poor	O
ability	O
to	O
consume	O
pills	O
these	O
medicines	O
have	O
not	O
been	O
continued	O
.	O
#	O
)	O
Leukocytosis	O
:	O
The	O
patient	O
has	O
had	O
a	O
maintained	O
elevated	O
white	O
blood	O
cell	O
count	O
while	O
admitted	O
.	O
This	O
is	O
likely	O
due	O
to	O
his	O
ongoing	O
Pseudomonal	O
UTI	O
/	O
chronic	O
foley	O
.	O
An	O
assay	O
for	O
C.	O
diff	O
was	O
sent	O
off	O
and	O
the	O
results	O
will	O
be	O
called	O
to	O
the	O
accepting	O
facility	O
.	O
-	O
If	O
C.	B-Reason
Diff	I-Reason
positive	O
,	O
will	O
begin	O
Flagyl	I-Drug
500	O
mg	O
IV	O
Q8	O
at	O
the	O
discretion	O
of	O
the	O
family	O
.	O
#	O
)	O
CHF	O
:	O
The	O
patient	O
has	O
a	O
history	O
of	O
Congestive	O
Heart	O
failure	O
.	O
Given	O
his	O
renal	O
failure	O
and	O
hypotension	O
his	O
lasix	I-Drug
was	O
initially	O
held	O
.	O
Given	O
his	O
tenuous	O
renal	O
failure	O
we	O
have	O
not	O
restarted	O
Lasix	I-Drug
on	O
discharge	O
.	O
#	O
)	O
Pain	I-Reason
:	O
The	O
patient	O
was	O
maintained	O
on	O
a	O
fentanyl	I-Drug
patch	O
and	O
with	O
tylenol	I-Drug
and	O
morphine	I-Drug
IV	O
.	O
On	O
discharge	O
he	O
will	O
be	O
transitioned	O
to	O
sublingual	O
or	O
liquid	O
morphine	I-Drug
for	O
pain	B-Reason
control	I-Reason
.	O
#	O
ARF	O
:	O
The	O
patient	O
has	O
persistent	O
renal	O
failure	O
with	O
baseline	O
creatinine	O
0.8	O
,	O
1	O
.	O
on	O
discharge	O
.	O
All	O
medicines	O
were	O
renally	O
dosed	O
.	O
#	O
Hypertension	I-Reason
:	O
The	O
patient	O
's	O
beta	B-Drug
blocker	I-Drug
and	O
ace	B-Drug
inhibitor	I-Drug
were	O
not	O
continued	O
.	O
#	O
Type	B-Reason
2	I-Reason
Diabetes	I-Reason
:	O
The	O
patient	O
was	O
continued	O
on	O
an	O
insulin	I-Drug
sliding	O
scale	O
but	O
did	O
not	O
require	O
insulin	I-Drug
.	O
We	O
recommend	O
reducing	O
his	O
finger	O
sticks	O
to	O
once	O
daily	O
only	O
.	O
#	O
Anemia	O
:	O
The	O
patient	O
had	O
fluctuating	O
blood	O
volume	O
without	O
clear	O
blood	O
loss	O
other	O
than	O
phlebotomy	O
.	O
He	O
was	O
not	O
transfused	O
on	O
this	O
admission	O
.	O
#	O
L	O
heel	O
stage	O
II	O
pressure	O
ulcer	O
:	O
Wound	O
care	O
as	O
above	O
.	O
#	O
Dementia	O
:	O
The	O
patient	O
has	O
chronic	O
dementia	O
.	O
He	O
was	O
unable	O
to	O
reliably	O
take	O
food	O
by	O
mouth	O
,	O
however	O
in	O
accordance	O
with	O
the	O
family	O
wishes	O
he	O
was	O
fed	O
but	O
kept	O
on	O
aspiration	O
precautions	O
.	O
Medications	O
on	O
Admission	O
:	O
Medications	O
:	O
1	O
.	O
Fentanyl	I-Drug
12	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
[	O
**	O
Month	O
/	O
Day	O
(	O
3	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
.	O
2	O
.	O
Allopurinol	I-Drug
100	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
3	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Multivitamin,Tx	B-Drug
-	O
Minerals	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
10	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Chlorhexidine	B-Drug
Gluconate	I-Drug
0.12	O
%	O
Mouthwash	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
ML	O
Mucous	O
membrane	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Furosemide	I-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Zinc	B-Drug
Sulfate	I-Drug
220	O
mg	O
Capsule	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
4	O
days	O
.	O
11	O
.	O
Vitamin	B-Drug
A	I-Drug
10,000	O
unit	O
Capsule	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
4	O
doses	O
.	O
12	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
4	O
days	O
.	O
13	O
.	O
Coumadin	I-Drug
1	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Target	O
INR	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
.	O
INR	O
on	O
[	O
**	O
12	O
-	O
16	O
**	O
]	O
was	O
3.9	O
,	O
so	O
hold	O
dose	O
on	O
[	O
**	O
12	O
-	O
16	O
**	O
]	O
and	O
recheck	O
.	O
14	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
qACHS	O
per	O
sliding	O
scale	O
Subcutaneous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
15	O
.	O
Polyvinyl	B-Drug
Alcohol	I-Drug
-	I-Drug
Povidone	I-Drug
1.4	O
-	O
0.6	O
%	O
Dropperette	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
[	O
**	O
11	O
-	O
19	O
**	O
]	O
Drops	O
Ophthalmic	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
16	O
.	O
Oxybutynin	I-Drug
Chloride	O
5	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
17	O
.	O
Metronidazole	I-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
for	O
2	O
weeks	O
.	O
18	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
3	O
.	O
Fentanyl	I-Drug
12	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
.	O
4	O
.	O
Bacitracin	B-Drug
Zinc	I-Drug
500	O
unit	O
/	O
g	O
Ointment	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Acetaminophen	I-Drug
500	O
mg	O
/	O
5	O
mL	O
Liquid	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
:	O
Please	O
mix	O
with	O
patient	O
's	O
pre-thickened	O
water	O
.	O
Patient	O
may	O
refuse	O
.	O
7	O
.	O
Sodium	B-Drug
Chloride	I-Drug
0.9	O
%	O
Flush	O
10	O
mL	O
IV	O
PRN	O
line	B-Reason
flush	I-Reason
PICC	O
,	O
non-heparin	O
dependent	O
:	O
Flush	O
with	O
10	O
mL	O
Normal	B-Drug
Saline	I-Drug
daily	O
and	O
PRN	O
per	O
lumen	O
.	O
8	O
.	O
Ceftazidime	I-Drug
2	O
gram	O
Recon	O
Soln	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Recon	O
Soln	O
Injection	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
5	O
days	O
:	O
Last	O
dose	O
[	O
**	O
2101-1-12	O
**	O
]	O
.	O
9	O
.	O
Tobramycin	B-Drug
Sulfate	I-Drug
40	O
mg	O
/	O
mL	O
Solution	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
:	O
2.5	O
mL	O
Injection	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
5	O
days	O
:	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
to	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
:	O
100	O
mg	O
Q24h	O
Change	O
of	O
Dose	O
:	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
to	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
:	O
80	O
mg	O
Q24	O
.	O
10	O
.	O
Morphine	B-Drug
Sulfate	I-Drug
5	O
mg	O
/	O
0.25	O
mL	O
Solution	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
Ten	O
(	O
10	O
)	O
mg	O
Sublingual	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
11	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
once	O
a	O
day	O
.	O
12	O
.	O
Polyvinyl	B-Drug
Alcohol	I-Drug
-	I-Drug
Povidone	I-Drug
1.4	O
-	O
0.6	O
%	O
Drops	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
gtt	O
Ophthalmic	O
twice	O
a	O
day	O
.	O
13	O
.	O
Warfarin	I-Drug
2	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
Check	O
PT	O
twice	O
weekly	O
and	O
titrate	O
accordingly	O
to	O
goal	O
INR	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
.	O
14	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Month	O
/	O
Day	O
(	O
3	O
)	O
**	O
]	O
:	O
ASDIR	O
Subcutaneous	O
once	O
a	O
day	O
:	O
Please	O
check	O
finger	O
sticks	O
Qam	O
and	O
follow	O
sliding	O
scale	O
as	O
directed	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
582	O
**	O
]	O
Of	O
[	O
**	O
Location	O
(	O
un	O
)	O
5176	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Sepsis	O
due	O
to	O
bacterial	O
UTI	O
(	O
Pseudomonas	O
and	O
E.coli	O
)	O
2	O
.	O
Acute	O
on	O
chronic	O
systolic	O
heart	O
failure	O
3	O
.	O
Acute	O
renal	O
failure	O
4	O
.	O
Severe	O
malnutrition	O
with	O
albumin	O
<	O
1.5	O
5	O
.	O
Stage	O
II	O
decubitus	O
ulcers	O
6	O
.	O
History	O
of	O
DVT	I-Reason
status	O
post	O
IVC	O
filter	O
,	O
on	O
coumadin	I-Drug
7	O
.	O
Atrial	O
Fibrillation	O
8	O
.	O
Dementia	O
9	O
.	O
Bladder	O
diverticulum	O
with	O
chronic	O
indwelling	O
foley	O
catheter	O
Discharge	O
Condition	O
:	O
Vital	O
signs	O
stable	O
,	O
chronically	O
ill	O
.	O
Discharge	O
Instructions	O
:	O
You	O
have	O
been	O
admitted	O
to	O
the	O
hospital	O
with	O
a	O
serious	O
urinary	O
infection	O
.	O
While	O
you	O
were	O
here	O
you	O
were	O
cared	O
for	O
in	O
the	O
Intensive	O
Care	O
Unit	O
and	O
on	O
the	O
medical	O
wards	O
.	O
You	O
will	O
be	O
discharged	O
on	O
IV	O
antibiotics	I-Drug
for	O
this	B-Reason
infection	I-Reason
.	O
Please	O
take	O
all	O
medicines	O
as	O
directed	O
as	O
they	O
have	O
changed	O
.	O
We	O
have	O
stopped	O
many	O
of	O
your	O
medicines	O
so	O
please	O
check	O
carfeully	O
.	O
Followup	O
Instructions	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
22236	O
**	O
]	O
has	O
the	O
following	O
appointment	O
already	O
scheduled	O
prior	O
to	O
this	O
admission	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
676	O
**	O
]	O
CLINIC	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2101-1-21	O
**	O
]	O
4:00	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
will	O
be	O
following	O
Mr.	O
[	O
**	O
Known	O
lastname	O
22236	O
**	O
]	O
after	O
discharge	O
.	O
He	O
can	O
be	O
reached	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22235	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
13546	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2146-3-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2146-4-27	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2117-12-8	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Heparin	I-Drug
Agents	O
/	O
Dilaudid	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
148	O
**	O
]	O
Chief	O
Complaint	O
:	O
Abdominal	O
pain	O
,	O
tachycardia	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2146-3-10	O
**	O
]	O
:	O
Ultrasound	O
-	O
guided	O
pancreatic	O
pseudocyst	O
drainage	O
with	O
drain	O
placement	O
.	O
.	O
[	O
**	O
2146-3-18	O
**	O
]	O
:	O
CT	O
-	O
guided	O
drainage	O
of	O
upper	O
abdominal	O
pseudocyst	O
.	O
[	O
**	O
2146-4-14	O
**	O
]	O
:	O
Ultrasound	O
-	O
guided	O
fluid	O
aspiration	O
of	O
a	O
left	O
flank	O
collection	O
.	O
.	O
[	O
**	O
2146-4-14	O
**	O
]	O
:	O
Ultrasound	O
-	O
guided	O
placement	O
of	O
left	O
pleural	O
pigtail	O
catheter	O
.	O
.	O
[	O
**	O
2146-4-21	O
**	O
]	O
:	O
Ultrasound	O
-	O
guided	O
left	O
flank	O
fluid	O
collection	O
drainage	O
with	O
placement	O
of	O
a	O
8	O
-	O
French	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2823	O
**	O
]	O
pigtail	O
catheter	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
Patient	O
is	O
a	O
28M	O
well	O
-	O
known	O
to	O
the	O
West	O
2	O
surgical	O
service	O
.	O
He	O
was	O
discharged	O
[	O
**	O
2146-3-9	O
**	O
]	O
after	O
a	O
prolonged	O
hospital	O
course	O
for	O
gallstone	O
pancreatitis	O
.	O
This	O
was	O
complicated	O
by	O
DVT	O
,	O
respiratory	O
/	O
renal	O
failure	O
requiring	O
mechanical	O
ventillatory	O
support	O
and	O
CVVHD	O
,	O
and	O
pancreatic	O
necrosis	O
requiring	O
percutaneous	O
drainage	O
.	O
He	O
improved	O
and	O
was	O
discharged	O
yesterday	O
to	O
a	O
rehabilitation	O
facility	O
.	O
Today	O
,	O
he	O
returns	O
with	O
tachycardia	O
and	O
increased	O
abdominal	O
pain	O
.	O
The	O
patient	O
states	O
that	O
he	O
began	O
to	O
experience	O
abdominal	O
pain	O
yesterday	O
afternoon	O
while	O
working	O
with	O
PT	O
.	O
He	O
states	O
that	O
this	O
pain	O
is	O
similar	O
to	O
the	O
epigastric	O
pain	O
he	O
has	O
experienced	O
all	O
along	O
only	O
worse	O
.	O
He	O
rated	O
this	O
as	O
an	O
[	O
**	O
9	O
-	O
6	O
**	O
]	O
though	O
currently	O
[	O
**	O
7	O
-	O
7	O
**	O
]	O
.	O
He	O
states	O
that	O
he	O
was	O
able	O
to	O
eat	O
dinner	O
(	O
grilled	O
chicken	O
)	O
without	O
difficulty	O
.	O
He	O
was	O
eating	O
breakfast	O
this	O
morning	O
and	O
became	O
nauseated	O
while	O
eating	O
grapes	O
.	O
He	O
had	O
several	O
episodes	O
of	O
non-bilious	O
emesis	O
and	O
was	O
brought	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
care	O
given	O
increased	O
abdominal	O
pain	O
and	O
tachycardia	O
.	O
Past	O
Medical	O
History	O
:	O
PMH	O
:	O
Gallstone	O
pancreatitis	O
as	O
above	O
,	O
obesity	O
,	O
congenital	O
blindness	O
in	O
right	O
eye	O
,	O
left	O
common	O
iliac	O
DVT	O
.	O
PSH	O
:	O
Laparoscopic	O
cholecystectomy	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
Social	O
History	O
:	O
Recently	O
married	O
.	O
He	O
lives	O
with	O
his	O
wife	O
and	O
their	O
dog	O
.	O
No	O
kids	O
.	O
Works	O
as	O
an	O
investment	O
manager	O
.	O
Never	O
smoker	O
.	O
Rare	O
alcohol	O
.	O
Smokes	O
marijuana	O
,	O
denies	O
other	O
drugs	O
.	O
Family	O
History	O
:	O
Diverticulosis	O
in	O
both	O
of	O
his	O
parents	O
.	O
DM	O
in	O
grandmother	O
.	O
HTN	O
in	O
father	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
2	O
sisters	O
and	O
one	O
brother	O
.	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
VS	O
:	O
99.4	O
150136/88	O
28	O
100	O
%	O
RA	O
General	O
:	O
awake	O
and	O
alert	O
,	O
diaphoretic	O
and	O
sweaty	O
CV	O
:	O
Tachycardic	O
Lungs	O
:	O
Tachypnic	O
,	O
CTA	O
bilaterally	O
Abdomen	O
:	O
Obese	O
,	O
soft	O
,	O
(	O
+	O
)	O
palpable	O
phlegmon	O
in	O
RUQ	O
,	O
(	O
+	O
)	O
diffuse	O
tenderness	O
greatest	O
in	O
epigastrium	O
,	O
no	O
rebound	O
/	O
guarding	O
,	O
hypoactive	O
BS	O
Ext	O
:	O
warm	O
,	O
no	O
edema	O
.	O
.	O
At	O
Discharge	O
:	O
VS	O
:	O
T	O
99.2	O
HR	O
93	O
BP	O
106/54	O
RR	O
18	O
SaO2	O
98	O
%	O
RA	O
GEN	O
:	O
Deconditioned	O
in	O
NAD	O
.	O
HEENT	O
:	O
Sclerae	O
anicteric	O
.	O
O	O
-	O
P	O
clear	O
.	O
NECK	O
:	O
Supple	O
.	O
No	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
.	O
LUNGS	O
:	O
Slightly	O
decreased	O
at	O
bases	O
,	O
otherwise	O
clear	O
.	O
COR	O
:	O
RRR	O
ABD	O
:	O
Protuberant	O
.	O
(	O
L	O
)	O
LQ	O
abdominal	O
JP	O
drain	O
(	O
into	O
pancreatic	O
pseudocyst	O
)	O
patent	O
/	O
intact	O
.	O
(	O
L	O
)	O
flank	O
drain	O
patent	O
/	O
intact	O
.	O
Both	O
drains	O
with	O
scant	O
output	O
.	O
Prior	O
sub-umbilical	O
drain	O
site	O
clean	O
,	O
healed	O
without	O
drainage	O
.	O
BSx4	O
.	O
Soft	O
/	O
NT	O
/	O
ND	O
.	O
EXTREM	O
:	O
WWP	O
;	O
mild	O
LE	O
edema	O
,	O
no	O
cyanosis	O
,	O
clubbing	O
.	O
NEURO	O
:	O
A+O	O
x3	O
.	O
Very	O
deconditioned	O
.	O
Requires	O
assistance	O
with	O
gait	O
.	O
Pertinent	O
Results	O
:	O
On	O
Admission	O
:	O
[	O
**	O
2146-3-10	O
**	O
]	O
08:28	O
PM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
138	O
*	O
PCO2	O
-	O
42	O
PH	O
-	O
7.55	O
*	O
TOTAL	O
CO2	O
-	O
38	O
*	O
BASE	O
XS	O
-	O
13	O
INTUBATED	O
-	O
NOT	O
INTUBA	O
[	O
**	O
2146-3-10	O
**	O
]	O
08:28	O
PM	O
freeCa	O
-	O
0.98	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
05:10	O
PM	O
OTHER	O
BODY	O
FLUID	O
AMYLASE	O
-	O
[	O
**	O
Numeric	O
Identifier	O
**	O
]	O
[	O
**	O
2146-3-10	O
**	O
]	O
05:10	O
PM	O
PT	O
-	O
20.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.9	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
02:50	O
PM	O
WBC	O
-	O
22.5	O
*	O
RBC	O
-	O
3.31	O
*	O
#	O
HGB	O
-	O
8.5	O
*	O
#	O
HCT	O
-	O
28.0	O
*	O
#	O
MCV	O
-	O
85	O
MCH	O
-	O
25.7	O
*	O
MCHC	O
-	O
30.4	O
*	O
RDW	O
-	O
18.2	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
02:50	O
PM	O
PLT	O
COUNT	O
-	O
511	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
02:07	O
PM	O
GLUCOSE	O
-	O
196	O
*	O
UREA	O
N	O
-	O
19	O
CREAT	O
-	O
1.3	O
*	O
SODIUM	O
-	O
134	O
POTASSIUM	O
-	O
3.7	O
CHLORIDE	O
-	O
93	O
*	O
TOTAL	O
CO2	O
-	O
30	O
ANION	O
GAP	O
-	O
15	O
[	O
**	O
2146-3-10	O
**	O
]	O
02:07	O
PM	O
CALCIUM	O
-	O
7.7	O
*	O
PHOSPHATE	O
-	O
6.2	O
*	O
MAGNESIUM	O
-	O
1.5	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
01:52	O
PM	O
PT	O
-	O
22.6	O
*	O
PTT	O
-	O
33.6	O
INR	O
(	O
PT	O
)	O
-	O
2.1	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
07:29	O
AM	O
WBC	O
-	O
30.7	O
*	O
#	O
RBC	O
-	O
4.67	O
#	O
HGB	O
-	O
11.7	O
*	O
#	O
HCT	O
-	O
39.7	O
*	O
#	O
MCV	O
-	O
85	O
MCH	O
-	O
25.0	O
*	O
MCHC	O
-	O
29.4	O
*	O
RDW	O
-	O
17.4	O
*	O
[	O
**	O
2146-3-10	O
**	O
]	O
07:29	O
AM	O
NEUTS	O
-	O
89	O
*	O
BANDS	O
-	O
3	O
LYMPHS	O
-	O
2	O
*	O
MONOS	O
-	O
4	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
2	O
*	O
MYELOS	O
-	O
0	O
[	O
**	O
2146-3-10	O
**	O
]	O
07:29	O
AM	O
PLT	O
SMR	O
-	O
VERY	O
HIGH	O
PLT	O
COUNT	O
-	O
818	O
*	O
#	O
[	O
**	O
2146-3-10	O
**	O
]	O
05:46	O
AM	O
GLUCOSE	O
-	O
149	O
*	O
LACTATE	O
-	O
2.5	O
*	O
NA	O
+	O
-	O
136	O
K	O
+	O
-	O
4.6	O
CL	O
--	O
99	O
*	O
TCO2	O
-	O
17	O
*	O
.	O
Prior	O
to	O
Discharge	O
:	O
[	O
**	O
2146-4-27	O
**	O
]	O
PT	O
/	O
INR	O
:	O
31.9	O
/	O
3.2	O
.	O
IMAGING	O
:	O
[	O
**	O
2146-3-10	O
**	O
]	O
AP	O
CXR	O
:	O
Low	O
lung	O
volumes	O
with	O
LLL	O
consolidation	O
,	O
could	O
reflect	O
atelectasis	O
,	O
however	O
,	O
pneumonia	O
can	O
not	O
be	O
excluded	O
.	O
.	O
[	O
**	O
2146-3-10	O
**	O
]	O
CTA	O
CHEST	O
W&W	O
/	O
O	O
C&RECONS	O
,	O
ABD	O
/	O
PELVIC	O
CT	O
W	O
/	O
CONTRAST	O
:	O
1	O
.	O
Minimal	O
interval	O
increase	O
in	O
size	O
of	O
right	O
upper	O
quadrant	O
pancreatic	O
pseudocyst	O
.	O
Interval	O
decrease	O
in	O
size	O
of	O
remaining	O
loculated	O
fluid	O
collections	O
.	O
2	O
.	O
No	O
pulmonary	O
embolism	O
present	O
.	O
Large	O
bilateral	O
pleural	O
effusions	O
with	O
associated	O
compression	O
atelectasis	O
.	O
3	O
.	O
Increased	O
amount	O
of	O
abdominal	O
and	O
pelvic	O
free	O
fluid	O
.	O
.	O
[	O
**	O
2146-3-11	O
**	O
]	O
BILAT	O
LOWER	O
EXT	O
VEINS	O
:	O
1	O
.	O
Persistent	O
non-occlusive	O
thrombus	O
in	O
the	O
left	O
common	O
femoral	O
vein	O
.	O
2	O
.	O
No	O
right	O
lower	O
extremity	O
DVT	O
.	O
3	O
.	O
Small	O
right	O
popliteal	O
cyst	O
.	O
.	O
[	O
**	O
2146-3-15	O
**	O
]	O
CXR	O
:	O
Cardiomediastinal	O
silhouette	O
is	O
unchanged	O
as	O
well	O
as	O
there	O
is	O
no	O
change	O
in	O
extremely	O
low	O
lung	O
volumes	O
and	O
bilateral	O
pleural	O
effusions	O
,	O
left	O
more	O
than	O
right	O
.	O
There	O
is	O
mild	O
prominence	O
of	O
the	O
vasculature	O
that	O
appears	O
to	O
be	O
more	O
pronounced	O
than	O
on	O
the	O
prior	O
study	O
and	O
might	O
represent	O
some	O
degree	O
of	O
volume	O
overload	O
.	O
The	O
right	O
internal	O
jugular	O
line	O
tip	O
appears	O
to	O
be	O
atleast	O
at	O
the	O
cavoatrial	O
junction	O
,	O
but	O
also	O
may	O
be	O
present	O
in	O
the	O
proximal	O
right	O
atrium	O
.	O
.	O
[	O
**	O
2146-3-16	O
**	O
]	O
ABD	O
/	O
PELVIC	O
CT	O
W	O
/	O
CONTRAST	O
:	O
1	O
.	O
Enlargement	O
of	O
the	O
previously	O
seen	O
fluid	O
collection	O
and	O
appearance	O
of	O
the	O
numerous	O
new	O
large	O
collections	O
in	O
the	O
peritoneum	O
.	O
The	O
drained	O
collection	O
has	O
significantly	O
decreased	O
in	O
size	O
.	O
2	O
.	O
Increase	O
in	O
pleural	O
effusions	O
:	O
Left	O
moderate	O
and	O
right	O
minimal	O
size	O
,	O
findings	O
are	O
accompanied	O
by	O
compressive	O
atelectasis	O
.	O
3	O
.	O
Minimal	O
residual	O
of	O
the	O
left	O
common	O
femoral	O
vein	O
and	O
left	O
external	O
iliac	O
vein	O
thrombus	O
.	O
.	O
[	O
**	O
2146-3-17	O
**	O
]	O
AP	O
CXR	O
:	O
In	O
comparison	O
with	O
the	O
study	O
of	O
[	O
**	O
3	O
-	O
15	O
**	O
]	O
,	O
there	O
is	O
still	O
extremely	O
low	O
lung	O
volumes	O
.	O
Hazy	O
opacification	O
at	O
the	O
left	O
base	O
is	O
consistent	O
with	O
pleural	O
fluid	O
.	O
Obscuration	O
of	O
the	O
hemidiaphragm	O
suggests	O
volume	O
loss	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
The	O
right	O
lung	O
is	O
essentially	O
clear	O
and	O
there	O
is	O
no	O
evidence	O
of	O
pulmonary	O
vascular	O
congestion	O
.	O
The	O
tip	O
of	O
the	O
right	O
IJ	O
catheter	O
is	O
difficult	O
to	O
see	O
but	O
appears	O
to	O
be	O
in	O
the	O
mid-to-lower	O
portion	O
of	O
the	O
SVC	O
.	O
.	O
1	O
.	O
Markedly	O
decreased	O
size	O
of	O
drained	O
collection	O
anterior	O
to	O
the	O
stomach	O
and	O
surroiunding	O
the	O
left	O
hepatic	O
lobe	O
.	O
New	O
extensive	O
stranding	O
and	O
fluid	O
within	O
the	O
gastrohepatic	O
ligament	O
and	O
porta	O
hepatis	O
,	O
possibly	O
induced	O
by	O
leakage	O
from	O
one	O
of	O
the	O
adjacent	O
collections	O
or	O
recurrent	O
pancreatitis	O
.	O
Slight	O
re-accumulation	O
of	O
fluid	O
within	O
the	O
previously	O
drained	O
collection	O
in	O
the	O
anterior	O
abdomen	O
,	O
now	O
measuring	O
14.3	O
x	O
1.6	O
x	O
5.4	O
cm	O
.	O
Otherwise	O
,	O
overall	O
decrease	O
in	O
multiple	O
remaining	O
peritoneal	O
and	O
extraperitoneal	O
fluid	O
collections	O
compared	O
to	O
the	O
prior	O
study	O
.	O
2	O
.	O
Persistent	O
bile	O
duct	O
dilation	O
likely	O
secondary	O
to	O
pancreatitis	O
.	O
Increased	O
attenuation	O
of	O
patent	O
portal	O
vein	O
from	O
adjacent	O
new	O
inflammation	O
.	O
Persistent	O
marked	O
attenuation	O
of	O
the	O
splenic	O
vein	O
.	O
Smaller	O
splenic	O
infarcts	O
.	O
3	O
.	O
Unchanged	O
bilateral	O
pleural	O
effusions	O
and	O
associated	O
compressive	O
atelectasis	O
.	O
4	O
.	O
Unchanged	O
thrombus	O
within	O
the	O
left	O
external	O
iliac	O
and	O
common	O
iliac	O
veins	O
.	O
.	O
[	O
**	O
2146-3-28	O
**	O
]	O
CXR	O
:	O
Stable	O
size	O
of	O
left	O
pleural	O
effusion	O
with	O
associated	O
consolidation	O
which	O
likely	O
represents	O
atelectasis	O
but	O
superimposed	O
infection	O
can	O
not	O
be	O
excluded	O
.	O
.	O
[	O
**	O
2146-4-13	O
**	O
]	O
ABD	O
/	O
PELVI	O
CT	O
W	O
/	O
CONTRAST	O
:	O
1	O
.	O
In	O
this	O
patient	O
with	O
known	O
history	O
of	O
necrotizing	O
pancreatitis	O
,	O
there	O
is	O
enhancement	O
of	O
the	O
distal	O
body	O
and	O
tail	O
of	O
the	O
pancreas	O
with	O
non	O
visualization	O
of	O
the	O
remainder	O
of	O
the	O
pancreas	O
.	O
Multiple	O
extensive	O
peripancreatic	O
fluid	O
collections	O
have	O
decreased	O
in	O
size	O
since	O
the	O
prior	O
study	O
.	O
2	O
.	O
A	O
small	O
fluid	O
collection	O
adjacent	O
to	O
the	O
inferior	O
edge	O
of	O
right	O
lobe	O
of	O
liver	O
measuring	O
4.9	O
x	O
3.2	O
x	O
2.0	O
cm	O
,	O
is	O
new	O
since	O
the	O
prior	O
study	O
.	O
3	O
.	O
Unchanged	O
left	O
femoral	O
vein	O
thrombosis	O
.	O
Infrarenal	O
IVC	O
filter	O
in	O
place	O
.	O
4	O
.	O
Mild	O
interval	O
improvement	O
in	O
the	O
small	O
-	O
to	O
-	O
moderate	O
left	O
pleural	O
effusion	O
.	O
Compressive	O
atelectasis	O
of	O
the	O
left	O
lower	O
lobe	O
is	O
unchanged	O
.	O
.	O
[	O
**	O
2146-4-15	O
**	O
]	O
CXR	O
:	O
Status	O
after	O
withdrawal	O
of	O
a	O
left	O
-	O
sided	O
chest	O
tube	O
.	O
Minimal	O
apical	O
and	O
lateral	O
basal	O
pneumothorax	O
without	O
evidence	O
of	O
tension	O
.	O
Unchanged	O
minimal	O
atelectasis	O
at	O
the	O
left	O
lung	O
base	O
.	O
No	O
other	O
changes	O
.	O
Normal	O
cardiac	O
silhouette	O
.	O
.	O
[	O
**	O
2146-4-18	O
**	O
]	O
CXR	O
:	O
1	O
.	O
Low	O
lung	O
volumes	O
with	O
left	O
basilar	O
subsegmental	O
atelectasis	O
,	O
likely	O
related	O
to	O
the	O
recent	O
abdominal	O
surgery	O
and	O
ongoing	O
intra-abdominal	O
process	O
.	O
2	O
.	O
No	O
appreciable	O
residual	O
left	O
pneumothorax	O
.	O
3	O
.	O
Left	O
-	O
sided	O
PICC	O
likely	O
at	O
the	O
junction	O
of	O
that	O
axillary	O
and	O
subclavian	O
vein	O
;	O
this	O
may	O
need	O
to	O
be	O
advanced	O
into	O
a	O
more	O
central	O
vein	O
,	O
depending	O
on	O
the	O
indication	O
for	O
its	O
use	O
.	O
.	O
[	O
**	O
2146-4-20	O
**	O
]	O
ABD	O
/	O
PELVIC	O
CT	O
W	O
/	O
O	O
CONTRAST	O
:	O
1	O
.	O
Slightly	O
decreased	O
size	O
of	O
dominant	O
central	O
abdominal	O
fluid	O
collection	O
with	O
left	O
drain	O
in	O
satisfactory	O
position	O
.	O
Right	O
catheter	O
has	O
been	O
removed	O
.	O
2	O
.	O
Other	O
fluid	O
collections	O
are	O
little	O
changed	O
[	O
**	O
2146-4-13	O
**	O
]	O
.	O
3	O
.	O
Resolving	O
left	O
pleural	O
effusion	O
with	O
pleural	O
air	O
secondary	O
to	O
left	O
thoracic	O
drain	O
placement	O
and	O
removal	O
.	O
No	O
new	O
peripancreatic	O
fluid	O
collection	O
.	O
4	O
.	O
Hypodensity	O
of	O
the	O
blood	O
pool	O
relative	O
to	O
the	O
ventricular	O
myocardium	O
is	O
suggestive	O
of	O
anemia	O
.	O
5	O
.	O
Moderate	O
biliary	O
dilatation	O
likely	O
secondary	O
to	O
CBD	O
obstruction	O
by	O
pseudocyst	O
is	O
similar	O
to	O
[	O
**	O
2146-4-13	O
**	O
]	O
.	O
.	O
MICROBIOLOGY	O
:	O
FLUID	O
/	O
WOUND	O
CULTURES	O
:	O
[	O
**	O
2146-4-21	O
**	O
]	O
10:15	O
am	O
FLUID	O
,	O
OTHER	O
LEFT	O
FLANK	O
ABSCESS	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2146-4-25	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-4-21	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
4	O
+	O
(	O
>	O
10	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
.	O
IN	O
PAIRS	O
AND	O
CLUSTERS	O
.	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
NEGATIVE	O
ROD	O
(	O
S	O
)	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-25	O
**	O
]	O
)	O
:	O
Due	O
to	O
mixed	O
bacterial	O
types	O
(	O
>	O
=	O
3	O
)	O
an	O
abbreviated	O
workup	O
is	O
performed	O
;	O
P.aeruginosa	O
,	O
S.aureus	O
and	O
beta	O
strep	O
.	O
are	O
reported	O
if	O
present	O
.	O
Susceptibility	O
will	O
be	O
performed	O
on	O
P.aeruginosa	O
and	O
S.aureus	O
if	O
sparse	O
growth	O
or	O
greater	O
.	O
.	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
MODERATE	O
GROWTH	O
.	O
Oxacillin	I-Drug
RESISTANT	O
Staphylococci	O
MUST	O
be	O
reported	O
as	O
also	O
RESISTANT	O
to	O
other	O
penicillins	I-Drug
,	O
cephalosporins	I-Drug
,	O
carbacephems	I-Drug
,	O
carbapenems	I-Drug
,	O
and	O
beta	B-Drug
-	I-Drug
lactamase	I-Drug
inhibitor	I-Drug
combinations	O
.	O
Rifampin	I-Drug
should	O
not	O
be	O
used	O
alone	O
for	O
therapy	O
.	O
Staphylococcus	O
species	O
may	O
develop	O
resistance	O
during	O
prolonged	O
therapy	O
with	O
quinolones	I-Drug
.	O
Therefore	O
,	O
isolates	O
that	O
are	O
initially	O
susceptible	O
may	O
become	O
resistant	O
within	O
three	O
to	O
four	O
days	O
after	O
initiation	O
of	O
therapy	O
.	O
Testing	O
of	O
repeat	O
isolates	O
may	O
be	O
warranted	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
STAPH	O
AUREUS	O
COAG	O
+	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
=	O
>	O
8	O
R	O
ERYTHROMYCIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
GENTAMICIN	I-Drug
------------	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
0.25	O
S	O
OXACILLIN	I-Drug
-------------	O
=	O
>	O
4	O
R	O
RIFAMPIN	I-Drug
--------------	O
<	O
=	O
0.5	O
S	O
TETRACYCLINE	I-Drug
----------	O
<	O
=	O
1	O
S	O
TRIMETHOPRIM	I-Drug
/	O
SULFA	O
----	O
<	O
=	O
0.5	O
S	O
VANCOMYCIN	I-Drug
------------	O
1	O
S	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-25	O
**	O
]	O
)	O
:	O
NO	O
ANAEROBES	O
ISOLATED	O
.	O
.	O
[	O
**	O
2146-4-16	O
**	O
]	O
4:30	O
pm	O
FLUID	O
,	O
OTHER	O
LEFT	O
JP	O
DRAIN	O
FLUID	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2146-4-19	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-4-16	O
**	O
]	O
)	O
:	O
REPORTED	O
BY	O
PHONE	O
TO	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
@	O
10PM	O
[	O
**	O
2146-4-16	O
**	O
]	O
.	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
4	O
+	O
(	O
>	O
10	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
.	O
IN	O
PAIRS	O
AND	O
CLUSTERS	O
.	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
ROD	O
(	O
S	O
)	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-19	O
**	O
]	O
)	O
:	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
HEAVY	O
GROWTH	O
.	O
Oxacillin	I-Drug
RESISTANT	O
Staphylococci	O
MUST	O
be	O
reported	O
as	O
also	O
RESISTANT	O
to	O
other	O
penicillins	I-Drug
,	O
cephalosporins	I-Drug
,	O
carbacephems	I-Drug
,	O
carbapenems	I-Drug
,	O
and	O
beta	B-Drug
-	I-Drug
lactamase	I-Drug
inhibitor	I-Drug
combinations	O
.	O
Rifampin	I-Drug
should	O
not	O
be	O
used	O
alone	O
for	O
therapy	O
.	O
Staphylococcus	O
species	O
may	O
develop	O
resistance	O
during	O
prolonged	O
therapy	O
with	O
quinolones	I-Drug
.	O
Therefore	O
,	O
isolates	O
that	O
are	O
initially	O
susceptible	O
may	O
become	O
resistant	O
within	O
three	O
to	O
four	O
days	O
after	O
initiation	O
of	O
therapy	O
.	O
Testing	O
of	O
repeat	O
isolates	O
may	O
be	O
warranted	O
.	O
CORYNEBACTERIUM	O
SPECIES	O
(	O
DIPHTHEROIDS	O
)	O
.	O
MODERATE	O
GROWTH	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
STAPH	O
AUREUS	O
COAG	O
+	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
=	O
>	O
8	O
R	O
ERYTHROMYCIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
GENTAMICIN	I-Drug
------------	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
0.25	O
S	O
OXACILLIN	I-Drug
-------------	O
=	O
>	O
4	O
R	O
RIFAMPIN	I-Drug
--------------	O
<	O
=	O
0.5	O
S	O
TETRACYCLINE	I-Drug
----------	O
<	O
=	O
1	O
S	O
TRIMETHOPRIM	I-Drug
/	O
SULFA	O
----	O
<	O
=	O
0.5	O
S	O
VANCOMYCIN	I-Drug
------------	O
1	O
S	O
.	O
[	O
**	O
2146-4-14	O
**	O
]	O
9:51	O
am	O
PERITONEAL	O
FLUID	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-4-14	O
**	O
]	O
)	O
:	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
4	O
+	O
(	O
>	O
10	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
.	O
IN	O
PAIRS	O
AND	O
CLUSTERS	O
.	O
REPORTED	O
BY	O
PHONE	O
TO	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
ON	O
[	O
**	O
2146-4-14	O
**	O
]	O
AT	O
03:50	O
PM	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-17	O
**	O
]	O
)	O
:	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
HEAVY	O
GROWTH	O
.	O
Oxacillin	I-Drug
RESISTANT	O
Staphylococci	O
MUST	O
be	O
reported	O
as	O
also	O
RESISTANT	O
to	O
other	O
penicillins	I-Drug
,	O
cephalosporins	I-Drug
,	O
carbacephems	O
,	O
carbapenems	I-Drug
,	O
and	O
beta	B-Drug
-	I-Drug
lactamase	I-Drug
inhibitor	I-Drug
combinations	O
.	O
Rifampin	I-Drug
should	O
not	O
be	O
used	O
alone	O
for	O
therapy	O
.	O
Staphylococcus	O
species	O
may	O
develop	O
resistance	O
during	O
prolonged	O
therapy	O
with	O
quinolones	I-Drug
.	O
Therefore	O
,	O
isolates	O
that	O
are	O
initially	O
susceptible	O
may	O
become	O
resistant	O
within	O
three	O
to	O
four	O
days	O
after	O
initiation	O
of	O
therapy	O
.	O
Testing	O
of	O
repeat	O
isolates	O
may	O
be	O
warranted	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
STAPH	O
AUREUS	O
COAG	O
+	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
=	O
>	O
8	O
R	O
ERYTHROMYCIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
GENTAMICIN	I-Drug
------------	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
<	O
=	O
0.12	O
S	O
OXACILLIN	I-Drug
-------------	O
=	O
>	O
4	O
R	O
RIFAMPIN	I-Drug
--------------	O
<	O
=	O
0.5	O
S	O
TETRACYCLINE	I-Drug
----------	O
<	O
=	O
1	O
S	O
TRIMETHOPRIM	B-Drug
/	I-Drug
SULFA	I-Drug
----	O
<	O
=	O
0.5	O
S	O
VANCOMYCIN	I-Drug
------------	O
1	O
S	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-18	O
**	O
]	O
)	O
:	O
NO	O
ANAEROBES	O
ISOLATED	O
.	O
FUNGAL	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
FUNGUS	O
ISOLATED	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2146-4-15	O
**	O
]	O
)	O
:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
DIRECT	O
SMEAR	O
.	O
.	O
[	O
**	O
2146-4-14	O
**	O
]	O
9:57	O
am	O
PLEURAL	O
FLUID	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-4-14	O
**	O
]	O
)	O
:	O
3	O
+	O
(	O
5	O
-	O
10	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
This	O
is	O
a	O
concentrated	O
smear	O
made	O
by	O
cytospin	O
method	O
,	O
please	O
refer	O
to	O
hematology	O
for	O
a	O
quantitative	O
white	O
blood	O
cell	O
count	O
.	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-17	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-20	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2146-4-15	O
**	O
]	O
)	O
:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
DIRECT	O
SMEAR	O
.	O
ACID	O
FAST	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
.	O
[	O
**	O
2146-4-5	O
**	O
]	O
SWAB	O
GRAM	O
STAIN	O
-	O
FINAL	O
;	O
FLUID	O
CULTURE	O
-	O
FINAL	O
;	O
ANAEROBIC	O
CULTURE	O
-	O
FINAL	O
:	O
[	O
**	O
2146-4-5	O
**	O
]	O
3:09	O
pm	O
SWAB	O
PSEUDO	O
CYST	O
FLUID	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2146-4-11	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-4-5	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-7	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-11	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
.	O
[	O
**	O
2146-3-28	O
**	O
]	O
9:25	O
am	O
PERITONEAL	O
FLUID	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2146-4-1	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-3-28	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
This	O
is	O
a	O
concentrated	O
smear	O
made	O
by	O
cytospin	O
method	O
,	O
please	O
refer	O
to	O
hematology	O
for	O
a	O
quantitative	O
white	O
blood	O
cell	O
count	O
.	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-1	O
**	O
]	O
)	O
:	O
REPORTED	O
BY	O
PHONE	O
TO	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
6976	O
**	O
]	O
@	O
1:20	O
PM	O
ON	O
[	O
**	O
2146-3-29	O
**	O
]	O
.	O
Due	O
to	O
mixed	O
bacterial	O
types	O
(	O
>	O
=	O
3	O
)	O
an	O
abbreviated	O
workup	O
is	O
performed	O
;	O
P.aeruginosa	O
,	O
S.aureus	O
and	O
beta	O
strep	O
.	O
are	O
reported	O
if	O
present	O
.	O
Susceptibility	O
will	O
be	O
performed	O
on	O
P.aeruginosa	O
and	O
S.aureus	O
if	O
sparse	O
growth	O
or	O
greater	O
.	O
.	O
STAPHYLOCOCCUS	O
,	O
COAGULASE	O
NEGATIVE	O
.	O
RARE	O
GROWTH	O
OF	O
THREE	O
COLONIAL	O
MORPHOLOGIES	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-4-1	O
**	O
]	O
)	O
:	O
NO	O
ANAEROBES	O
ISOLATED	O
.	O
.	O
[	O
**	O
2146-3-23	O
**	O
]	O
10:43	O
pm	O
FLUID	O
,	O
OTHER	O
DRAIN	O
FLUID	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2146-3-28	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-3-24	O
**	O
]	O
)	O
:	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-3-27	O
**	O
]	O
)	O
:	O
Due	O
to	O
mixed	O
bacterial	O
types	O
(	O
>	O
=	O
3	O
)	O
an	O
abbreviated	O
workup	O
is	O
performed	O
;	O
P.aeruginosa	O
,	O
S.aureus	O
and	O
beta	O
strep	O
.	O
are	O
reported	O
if	O
present	O
.	O
Susceptibility	O
will	O
be	O
performed	O
on	O
P.aeruginosa	O
and	O
S.aureus	O
if	O
sparse	O
growth	O
or	O
greater	O
.	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-3-28	O
**	O
]	O
)	O
:	O
NO	O
ANAEROBES	O
ISOLATED	O
.	O
.	O
[	O
**	O
2146-3-10	O
**	O
]	O
FLUID	O
,	O
OTHER	O
GRAM	O
STAIN	O
-	O
FINAL	O
;	O
WOUND	O
CULTURE	O
-	O
FINAL	O
;	O
ANAEROBIC	O
CULTURE	O
-	O
FINAL	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2146-3-10	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
WOUND	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-3-13	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2146-3-16	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
.	O
BLOOD	O
&	O
URINE	O
CULTURES	O
:	O
[	O
**	O
2146-4-18	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-4-15	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-4-14	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-4-13	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-4-12	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-28	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-28	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-23	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-23	O
**	O
]	O
URINE	O
CULTURE	O
-	O
FINAL	O
:	O
NO	O
GROWTH	O
.	O
[	O
**	O
2146-3-23	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-19	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-19	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-18	O
**	O
]	O
FLUID	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-17	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-17	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-13	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-13	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-10	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
[	O
**	O
2146-3-10	O
**	O
]	O
BLOOD	O
CULTURE	O
:	O
NO	O
GROWTH	O
-	O
FINAL	O
.	O
.	O
RESPIRATORY	O
/	O
OTHER	O
CULTURES	O
:	O
[	O
**	O
2146-4-13	O
**	O
]	O
SPUTUM	O
GRAM	O
STAIN	O
-	O
FINAL	O
;	O
RESPIRATORY	O
CULTURE	O
-	O
FINAL	O
:	O
Upper	O
respiratory	O
contamination	O
.	O
[	O
**	O
2146-4-13	O
**	O
]	O
CATHETER	O
TIP	O
-	O
IV	O
WOUND	O
CULTURE	O
-	O
FINAL	O
:	O
NO	O
SIGNIFICANT	O
GROWTH	O
.	O
[	O
**	O
2146-4-12	O
**	O
]	O
SPUTUM	O
GRAM	O
STAIN	O
-	O
FINAL	O
;	O
RESPIRATORY	O
CULTURE	O
-	O
FINAL	O
:	O
Upper	O
Respiratory	O
Contamination	O
.	O
[	O
**	O
2146-3-10	O
**	O
]	O
MRSA	O
SCREEN	O
MRSA	O
:	O
NEGATIVE	O
.	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
re-admitted	O
on	O
[	O
**	O
2146-3-10	O
**	O
]	O
back	O
to	O
the	O
General	O
Surgical	O
Service	O
for	O
evaluation	O
and	O
treatment	O
of	O
abdominal	O
pain	O
and	O
tachycardia	O
.	O
Admission	O
abdominal	O
/	O
pelvic	O
CT	O
revealed	O
minimal	O
interval	O
increase	O
in	O
size	O
of	O
right	O
upper	O
quadrant	O
pancreatic	O
pseudocyst	O
,	O
but	O
decrease	O
in	O
size	O
of	O
remaining	O
loculated	O
fluid	O
collections	O
.	O
Large	O
bilateral	O
pleural	O
effusions	O
with	O
associated	O
compression	O
atelectasis	O
were	O
noted	O
,	O
as	O
well	O
as	O
increased	O
amount	O
of	O
abdominal	O
and	O
pelvic	O
free	O
fluid	O
.	O
He	O
was	O
admitted	O
to	O
the	O
SICU	O
,	O
made	O
NPO	O
,	O
started	O
on	O
vigorous	O
IV	O
fluid	I-Drug
rescusitation	O
,	O
a	O
foley	O
was	O
placed	O
,	O
and	O
he	O
received	O
IV	O
pain	B-Drug
medication	I-Drug
with	O
good	O
effect	O
.	O
He	O
had	O
a	O
very	O
long	O
,	O
and	O
complicated	O
hospital	O
course	O
.	O
.	O
In	O
the	O
process	O
of	O
repairing	O
his	O
florid	O
necrotizing	O
pancreatitis	O
secondary	O
to	O
his	O
history	O
of	O
severe	O
gallstone	O
pancreatitis	O
,	O
he	O
ultimately	O
developed	O
recurrent	O
pseudocyts	O
,	O
which	O
have	O
plagued	O
him	O
throughtout	O
his	O
hospital	O
stays	O
since	O
[	O
**	O
48	O
**	O
]	O
/	O
[	O
**	O
2145	O
**	O
]	O
.	O
To	O
date	O
,	O
these	O
pseudocyts	O
have	O
been	O
managed	O
largely	O
with	O
percutaneous	O
catheter	O
drainage	O
of	O
the	O
pseudocysts	O
.	O
Initially	O
,	O
during	O
this	O
admission	O
,	O
this	O
was	O
the	O
approach	O
to	O
managing	O
the	O
patient	O
's	O
recurring	O
pseudocyts	O
.	O
The	O
patient	O
underwent	O
drainage	O
of	O
pancreatic	O
pseudocysts	O
on	O
[	O
**	O
2146-3-10	O
**	O
]	O
and	O
[	O
**	O
2146-3-18	O
**	O
]	O
,	O
Ultrasound	O
and	O
CT	O
-	O
guided	O
,	O
respectively	O
.	O
However	O
,	O
he	O
developed	O
an	O
accumulating	O
posterior	O
retroperitoneal	O
cyst	O
,	O
which	O
continued	O
to	O
progress	O
,	O
and	O
there	O
was	O
evidence	O
of	O
a	O
disconnected	O
pancreatic	O
remnant	O
within	O
it	O
.	O
The	O
recent	O
drainages	O
of	O
the	O
other	O
satellite	O
lesions	O
have	O
dried	O
them	O
up	O
.	O
The	O
main	O
retroperitoneal	O
cyst	O
continued	O
to	O
grow	O
in	O
size	O
,	O
and	O
became	O
symptomatic	O
for	O
him	O
.	O
He	O
was	O
unable	O
to	O
eat	O
full	O
meals	O
and	O
has	O
a	O
diminished	O
capacity	O
to	O
keep	O
food	O
down	O
,	O
as	O
well	O
as	O
a	O
poor	O
appetite	O
.	O
He	O
also	O
repeatedly	O
spiked	O
temperatures	O
.	O
.	O
Given	O
his	O
history	O
of	O
a	O
left	O
lower	O
extremity	O
acute	O
deep	O
venous	O
thrombosis	O
,	O
Vascular	O
Surgery	O
was	O
consulted	O
.	O
In	O
lieu	O
of	O
planned	O
surgical	O
intervention	O
on	O
[	O
**	O
2146-4-5	O
**	O
]	O
for	O
treatment	O
of	O
the	O
above	O
pseudocyst	O
with	O
adhesions	O
,	O
the	O
patient	O
underwent	O
placement	O
of	O
a	O
Bard	O
G2	O
inferior	O
vena	O
cava	O
filter	O
,	O
which	O
went	O
without	O
complication	O
.	O
Then	O
on	O
[	O
**	O
2146-4-5	O
**	O
]	O
,	O
the	O
patient	O
underwent	O
external	O
drainage	O
of	O
pancreatic	O
pseudocyst	O
and	O
extended	O
adhesiolysis	O
,	O
which	O
also	O
went	O
well	O
without	O
complication	O
(	O
see	O
Operative	O
Note	O
)	O
.	O
After	O
a	O
brief	O
,	O
uneventful	O
stay	O
in	O
the	O
PACU	O
,	O
the	O
patient	O
was	O
returned	O
to	O
the	O
floor	O
NPO	O
with	O
an	O
NG	O
tube	O
,	O
on	O
IV	O
fluids	I-Drug
and	O
TPN	O
,	O
with	O
a	O
foley	O
catheter	O
and	O
two	O
JP	O
drains	O
in	O
place	O
(	O
one	O
in	O
the	O
pseudocyst	O
and	O
one	O
in	O
the	O
abdomen	O
to	O
drain	O
ascites	O
)	O
,	O
he	O
was	O
continued	O
on	O
a	O
Fentanyl	I-Drug
patch	O
and	O
was	O
given	O
a	O
Morphine	I-Drug
PCA	O
with	O
good	O
effect	O
.	O
He	O
was	O
hemodynamically	O
stable	O
.	O
.	O
NEURO	O
:	O
Upon	O
admission	O
,	O
the	O
patient	O
received	O
IV	O
pain	B-Drug
medication	I-Drug
PRN	O
transitioned	O
to	O
a	O
Morphine	I-Drug
PCA	O
with	O
good	O
effect	O
and	O
adequate	O
pain	B-Reason
control	I-Reason
.	O
When	O
tolerating	O
oral	O
intake	O
,	O
he	O
was	O
transitioned	O
to	O
oral	O
pain	B-Drug
medications	I-Drug
.	O
After	O
the	O
surgery	O
on	O
[	O
**	O
2146-4-5	O
**	O
]	O
,	O
the	O
Chronic	O
Pain	O
Service	O
was	O
consulted	O
.	O
His	O
pain	O
was	O
controlled	O
once	O
the	O
Fentanyl	I-Drug
dose	O
was	O
increased	O
to	O
75mcg	O
/	O
72	O
Hr	O
plus	O
the	O
Morphine	I-Drug
PCA	O
.	O
When	O
again	O
tolerating	O
a	O
diet	O
post-operatively	O
,	O
the	O
PCA	O
was	O
discontinued	O
,	O
and	O
he	O
was	O
started	O
on	O
oral	O
pain	B-Drug
medication	I-Drug
in	O
addition	O
to	O
the	O
Fentanyl	I-Drug
patch	O
with	O
continued	O
good	O
effect	O
.	O
He	O
remained	O
neurologically	O
intact	O
.	O
.	O
CV	O
:	O
Upon	O
admission	O
,	O
tachycardia	O
responded	O
to	O
vigorous	O
IV	O
fluid	I-Drug
rescusitation	O
and	O
beta	O
-	O
blockade	O
with	O
Metoprolol	I-Drug
50	O
mg	O
TID	O
.	O
Metoprolol	I-Drug
was	O
increased	O
to	O
75	O
mg	O
TID	O
with	O
eventual	O
excellent	O
rate	B-Reason
and	I-Reason
BP	I-Reason
control	I-Reason
.	O
By	O
discharge	O
,	O
the	O
Metoprolol	I-Drug
was	O
decreased	O
to	O
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
The	O
patient	O
remained	O
stable	O
from	O
a	O
cardiovascular	O
standpoint	O
;	O
vital	O
signs	O
were	O
routinely	O
monitored	O
.	O
.	O
PULMONARY	O
:	O
Tachypnea	I-Reason
on	O
admission	O
.	O
Chest	O
CTA	O
revealed	O
large	O
bilateral	O
pleural	O
effusions	O
with	O
associated	O
compression	O
atelectasis	O
.	O
Tachypnea	I-Reason
resolved	O
with	O
diuresis	I-Reason
with	O
Lasix	I-Drug
and	O
supplemental	O
oxygen	I-Drug
.	O
He	O
was	O
given	O
Albuterol	I-Drug
and	O
Atrovent	I-Drug
nebulizer	O
treatments	O
,	O
good	O
pulmonary	O
toilet	O
and	O
use	O
of	O
the	O
incentive	O
spirrometry	O
were	O
encouraged	O
,	O
and	O
the	O
patient	O
received	O
chest	O
PT	O
with	O
improvement	O
in	O
overall	O
respiratory	O
status	O
.	O
Able	O
to	O
wean	O
off	O
supplemental	O
oxygen	I-Drug
.	O
CXR	O
on	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
revealed	O
still	O
extremely	O
low	O
lung	O
volumes	O
.	O
Hazy	O
opacification	O
at	O
the	O
left	O
base	O
is	O
consistent	O
with	O
pleural	O
fluid	O
.	O
Obscuration	O
of	O
the	O
hemidiaphragm	O
suggests	O
volume	O
loss	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
The	O
right	O
lung	O
was	O
essentially	O
clear	O
and	O
there	O
was	O
no	O
evidence	O
of	O
pulmonary	O
vascular	O
congestion	O
.	O
Starting	O
on	O
[	O
**	O
4	O
-	O
12	O
**	O
]	O
,	O
he	O
spiked	O
a	O
temperature	O
to	O
103	O
PO	O
and	O
his	O
WBC	O
increased	O
from	O
13	O
to	O
23,000	O
.	O
He	O
had	O
a	O
CT	O
abdomen	O
performed	O
which	O
demonstrated	O
a	O
left	O
pleural	O
effusion	O
on	O
the	O
upper	O
cuts	O
of	O
the	O
abdomen	O
.	O
Thoracic	O
surgery	O
was	O
consulted	O
for	O
management	O
of	O
the	O
pleural	O
effusion	O
.	O
On	O
[	O
**	O
2146-4-14	O
**	O
]	O
,	O
he	O
underwent	O
ultrasound	O
-	O
guided	O
thorocentesis	O
and	O
placement	O
of	O
left	O
pleural	O
pigtail	O
catheter	O
.	O
Plural	O
fluid	O
for	O
culture	O
,	O
gram	O
stain	O
,	O
cytology	O
,	O
chemistries	O
,	O
and	O
AFB	O
was	O
sent	O
.	O
The	O
pleural	O
pigtail	O
catheter	O
was	O
removed	O
on	O
[	O
**	O
4	O
-	O
15	O
**	O
]	O
;	O
post-removal	O
CXR	O
revealed	O
minimal	O
apical	O
and	O
lateral	O
basal	O
pneumothorax	O
without	O
evidence	O
of	O
tension	O
.	O
Unchanged	O
minimal	O
atelectasis	O
at	O
the	O
left	O
lung	O
base	O
.	O
A	O
follow	O
-	O
up	O
CXR	O
on	O
[	O
**	O
2146-4-18	O
**	O
]	O
showed	O
continued	O
low	O
lung	O
volumes	O
with	O
left	O
basilar	O
subsegmental	O
atelectasis	O
,	O
likely	O
related	O
to	O
the	O
recent	O
abdominal	O
surgery	O
and	O
ongoing	O
intra-abdominal	O
process	O
.	O
No	O
appreciable	O
residual	O
left	O
pneumothorax	O
was	O
seen	O
.	O
The	O
patient	O
remained	O
stable	O
from	O
a	O
pulmonary	O
standpoitn	O
thereafter	O
.	O
Respiratory	O
toilet	O
,	O
incentive	O
spirrometry	O
,	O
and	O
frequent	O
ambulation	O
was	O
encouraged	O
.	O
.	O
GU	O
/	O
FEN	O
:	O
On	O
admission	O
,	O
the	O
patient	O
was	O
made	O
NPO	O
and	O
he	O
received	O
vigorous	O
IV	O
fluid	I-Drug
rescusitation	O
.	O
A	O
foley	O
catheter	O
was	O
placed	O
.	O
Allowed	O
clears	O
on	O
[	O
**	O
3	O
-	O
11	O
**	O
]	O
and	O
[	O
**	O
3	O
-	O
12	O
**	O
]	O
,	O
but	O
an	O
NG	O
tube	O
was	O
placed	O
on	O
[	O
**	O
3	O
-	O
13	O
**	O
]	O
for	O
increased	O
abdominal	O
distension	O
and	O
emesis	O
resulting	O
with	O
1400mL	O
bilious	O
output	O
.	O
After	O
successful	O
clamp	O
trial	O
overnight	O
,	O
the	O
NG	O
tube	O
was	O
discontinued	O
on	O
[	O
**	O
3	O
-	O
15	O
**	O
]	O
in	O
the	O
morning	O
.	O
Given	O
persistent	O
problems	O
with	O
tolerating	O
oral	O
intake	O
,	O
a	O
PICC	O
was	O
placed	O
,	O
and	O
TPN	O
was	O
started	O
on	O
[	O
**	O
2146-3-14	O
**	O
]	O
.	O
With	O
the	O
decision	O
to	O
proceed	O
to	O
surgery	O
,	O
TPN	O
was	O
continued	O
through	O
[	O
**	O
2146-4-12	O
**	O
]	O
.	O
When	O
not	O
NPO	O
for	O
procedures	O
,	O
his	O
diet	O
was	O
advanced	O
back	O
to	O
low	O
fat	O
regular	O
with	O
good	O
tolerability	O
and	O
intake	O
.	O
When	O
the	O
foley	O
catheter	O
was	O
removed	O
after	O
surgery	O
,	O
he	O
was	O
able	O
to	O
void	O
without	O
problem	O
.	O
Patient	O
's	O
intake	O
and	O
output	O
were	O
closely	O
monitored	O
,	O
and	O
IV	O
fluid	I-Drug
was	O
adjusted	O
when	O
necessary	O
.	O
Electrolytes	O
were	O
routinely	O
followed	O
,	O
and	O
repleted	O
when	O
necessary	O
.	O
.	O
GI	O
:	O
Admission	O
liver	O
and	O
pancreatic	O
enzymes	O
were	O
elevated	O
.	O
Shortly	O
after	O
admission	O
,	O
the	O
patient	O
underwent	O
ultrasound	O
-	O
guided	O
pseudocyst	O
drainage	O
measuring	O
1.7	O
liters	O
of	O
fluid	O
with	O
a	O
drainage	O
catheter	O
left	O
in	O
place	O
to	O
gravity	O
on	O
[	O
**	O
2146-3-10	O
**	O
]	O
.	O
Liver	O
and	O
pancreatic	O
enzymes	O
began	O
trending	O
down	O
.	O
Follow	O
-	O
up	O
abdominal	O
/	O
pelvic	O
CT	O
on	O
[	O
**	O
3	O
-	O
16	O
**	O
]	O
demonstrated	O
enlargement	O
of	O
the	O
previously	O
seen	O
fluid	O
collection	O
and	O
appearance	O
of	O
the	O
numerous	O
new	O
large	O
collections	O
in	O
the	O
peritoneum	O
.	O
The	O
drained	O
collection	O
had	O
significantly	O
decreased	O
in	O
size	O
.	O
On	O
[	O
**	O
3	O
-	O
18	O
**	O
]	O
,	O
the	O
patient	O
returned	O
to	O
Interventional	O
Radiology	O
for	O
drainage	O
of	O
an	O
anterior	O
collection	O
,	O
and	O
placement	O
of	O
a	O
new	O
drainage	O
catheter	O
to	O
gravity	O
.	O
The	O
previous	O
drain	O
was	O
removed	O
,	O
and	O
upper	O
abdominal	O
pseudocyst	O
was	O
succesfully	O
drained	O
with	O
a	O
catheter	O
left	O
in	O
place	O
to	O
gravity	O
.	O
Unfortunately	O
,	O
as	O
noted	O
above	O
,	O
he	O
developed	O
an	O
accumulating	O
posterior	O
retroperitoneal	O
cyst	O
,	O
which	O
continued	O
to	O
progress	O
,	O
and	O
there	O
was	O
evidence	O
of	O
a	O
disconnected	O
pancreatic	O
remnant	O
within	O
it	O
.	O
He	O
underwent	O
external	O
drainage	O
of	O
pancreatic	O
pseudocyst	O
and	O
extended	O
adhesiolysis	O
as	O
described	O
above	O
.	O
A	O
(	O
L	O
)	O
flank	O
drain	O
was	O
left	O
in	O
place	O
.	O
After	O
the	O
surgery	O
,	O
his	O
symptoms	O
improved	O
.	O
.	O
ID	O
:	O
Admission	O
blood	O
cultures	O
were	O
negative	O
.	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
fluid	O
culture	O
had	O
no	O
growth	O
.	O
On	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
after	O
receiving	O
FFPs	I-Drug
,	O
the	O
patient	O
mounted	O
a	O
fever	O
with	O
a	O
Tmax	O
101.5	O
PO	O
.	O
Blood	O
cultures	O
were	O
negative	O
.	O
Fluid	O
cutlure	O
from	O
the	O
[	O
**	O
3	O
-	O
18	O
**	O
]	O
drainage	O
also	O
revealed	O
no	O
growth	O
.	O
The	O
patient	O
's	O
white	O
blood	O
count	O
and	O
fever	O
curves	O
were	O
closely	O
watched	O
for	O
signs	O
of	O
infection	O
.	O
Admission	O
MRSA	O
screen	O
was	O
negative	O
.	O
After	O
the	O
[	O
**	O
2146-4-5	O
**	O
]	O
surgery	O
,	O
cultures	O
from	O
the	O
peritoneal	O
fluid	O
on	O
[	O
**	O
4	O
-	O
14	O
**	O
]	O
,	O
the	O
(	O
L	O
)	O
JP	O
on	O
[	O
**	O
4	O
-	O
19	O
**	O
]	O
,	O
and	O
the	O
flank	O
drain	O
on	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
all	O
grew	O
out	O
MRSA	O
.	O
The	O
patient	O
had	O
been	O
started	O
on	O
empiric	O
IV	O
Vancomycin	I-Drug
,	O
Ciprofloxacin	I-Drug
,	O
and	O
Flagyl	I-Drug
when	O
he	O
spiked	O
a	O
temperature	O
on	O
[	O
**	O
4	O
-	O
14	O
**	O
]	O
.	O
Fluconazole	I-Drug
for	O
empiric	B-Reason
coverage	I-Reason
after	O
the	O
thorocentesis	O
was	O
started	O
on	O
[	O
**	O
4	O
-	O
15	O
**	O
]	O
.	O
Flagyl	I-Drug
,	O
Cipro	I-Drug
,	O
and	O
Fluconazole	I-Drug
were	O
discontinued	O
on	O
[	O
**	O
4	O
-	O
16	O
**	O
]	O
.	O
Cipro	I-Drug
restarted	O
on	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
.	O
Infectious	O
Disease	O
was	O
consulted	O
for	O
discharge	O
antibiotic	I-Drug
recommendations	O
;	O
their	O
input	O
was	O
greatly	O
appreciated	O
.	O
Cipro	I-Drug
was	O
discomntinued	O
,	O
and	O
oral	O
Levofloxacin	I-Drug
and	O
Flagyl	I-Drug
started	O
on	O
[	O
**	O
4	O
-	O
26	O
**	O
]	O
with	O
Vancomycin	I-Drug
continued	O
.	O
At	O
discharge	O
,	O
the	O
patient	O
was	O
sent	O
home	O
on	O
a	O
two	O
week	O
course	O
oral	O
Linezolid	I-Drug
,	O
and	O
a	O
total	O
of	O
four	O
weeks	O
of	O
oral	O
Levofloxacin	I-Drug
and	O
Flagyl	I-Drug
.	O
.	O
ENDOCRINE	O
:	O
The	O
patient	O
's	O
blood	O
sugar	O
was	O
monitored	O
throughout	O
his	O
stay	O
when	O
he	O
was	O
on	O
TPN	O
;	O
sliding	O
scale	O
insulin	I-Drug
was	O
administered	O
accordingly	O
.	O
He	O
did	O
not	O
require	O
exogenous	O
insulin	I-Drug
.	O
.	O
HEMATOLOGY	O
:	O
Upon	O
admission	O
,	O
Coumadin	I-Drug
was	O
stopped	O
,	O
and	O
the	O
patient	O
received	O
5	O
untis	O
of	O
Fresh	B-Drug
Frozen	I-Drug
Plasma	I-Drug
(	I-Drug
FFPs	I-Drug
)	I-Drug
prior	O
to	O
fluid	O
collection	O
drainage	O
in	O
Intervention	O
Radiology	O
.	O
On	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
,	O
FFPs	I-Drug
were	O
again	O
administered	O
in	O
preparation	O
for	O
IR	O
drainage	O
of	O
a	O
large	O
anterior	O
abdominal	O
fluid	O
collection	O
,	O
but	O
was	O
stopped	O
after	O
the	O
patient	O
experienced	O
severe	B-Ade
lower	I-Ade
back	I-Ade
pain	I-Ade
after	O
initiation	O
of	O
the	O
second	O
unit	O
of	O
FFP	I-Drug
.	O
On	O
[	O
**	O
3	O
-	O
18	O
**	O
]	O
,	O
he	O
received	O
a	O
total	O
of	O
4	O
units	O
of	O
FFPs	I-Drug
prior	O
to	O
IR	O
drainage	O
of	O
the	O
aforementioned	O
collection	O
.	O
Prior	O
to	O
[	O
**	O
2146-4-5	O
**	O
]	O
surgery	O
,	O
the	O
patient	O
received	O
2	O
units	O
of	O
PRBCs	I-Drug
for	O
a	O
HCT	O
of	O
22.2	O
.	O
He	O
did	O
not	O
require	O
any	O
further	O
blood	O
products	O
after	O
this	O
date	O
.	O
At	O
discharge	O
,	O
his	O
HCT	O
was	O
23.7	O
.	O
.	O
PROPHYLAXIS	O
:	O
History	O
left	O
common	O
iliac	O
DVT	O
and	O
HITs	O
.	O
Repeat	O
duplex	O
ultra-sound	O
on	O
admission	O
confirmed	O
persistent	O
non-occlusive	O
thrombus	O
in	O
the	O
left	O
common	O
femoral	O
vein	O
;	O
no	O
right	O
DVT	O
was	O
seen	O
.	O
Chest	O
CTA	O
did	O
not	O
reveal	O
a	O
PE	O
.	O
On	O
admission	O
,	O
Coumadin	I-Drug
stopped	O
,	O
and	O
Agatroban	I-Drug
started	O
.	O
After	O
the	O
drainage	O
of	O
the	O
collection	O
on	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
,	O
Agatroban	I-Drug
was	O
stopped	O
,	O
and	O
Coumadin	I-Drug
restarted	O
.	O
Coumadin	I-Drug
also	O
restarted	O
after	O
reversal	O
for	O
second	O
collection	O
drainage	O
.	O
After	O
the	O
surgery	O
on	O
[	O
**	O
2146-4-5	O
**	O
]	O
,	O
the	O
patient	O
was	O
restarted	O
on	O
Argatroban	I-Drug
.	O
He	O
was	O
again	O
converted	O
back	O
to	O
Coumadin	I-Drug
prior	O
to	O
discharge	O
,	O
at	O
which	O
time	O
the	O
INR	O
was	O
therapeutic	O
at	O
3.2	O
on	O
a	O
Coumadin	I-Drug
dose	O
of	O
2.5	O
mg	O
daily	O
.	O
INR	O
goal	O
2.5	O
with	O
a	O
therapeutic	O
range	O
of	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
.	O
.	O
MOBILITY	O
:	O
The	O
patient	O
worked	O
with	O
Physical	O
and	O
Occupation	O
therapy	O
extensively	O
.	O
By	O
discharge	O
,	O
he	O
was	O
able	O
to	O
ambulate	O
independently	O
.	O
He	O
was	O
discharge	O
home	O
with	O
PT	O
and	O
OT	O
services	O
.	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
was	O
doing	O
well	O
,	O
afebrile	O
with	O
stable	O
vital	O
signs	O
.	O
The	O
patient	O
was	O
tolerating	O
a	O
regular	O
diet	O
,	O
ambulating	O
with	O
minimal	O
assistance	O
,	O
voiding	O
without	O
assistance	O
,	O
and	O
pain	O
was	O
well	O
controlled	O
.	O
He	O
was	O
discharged	O
home	O
with	O
VNA	O
and	O
PT	O
services	O
.	O
The	O
patient	O
received	O
discharge	O
teaching	O
and	O
follow	O
-	O
up	O
instructions	O
with	O
understanding	O
verbalized	O
and	O
agreement	O
with	O
the	O
discharge	O
plan	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
2	O
.	O
Senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
3	O
.	O
Polyvinyl	B-Drug
Alcohol	I-Drug
-	I-Drug
Povidone	I-Drug
1.4	O
-	O
0.6	O
%	O
Dropperette	O
Sig	O
:	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
Drops	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
dryness	I-Reason
.	O
4	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
rash	I-Reason
.	O
5	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
.	O
6	O
.	O
Lactulose	I-Drug
10	O
gram	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
7	O
.	O
Methyl	B-Drug
Salicylate	I-Drug
-	I-Drug
Menthol	I-Drug
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
back	B-Reason
pain	I-Reason
.	O
8	O
.	O
Propranolol	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Methadone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
10	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
sliding	O
scale	O
sliding	O
scale	O
Subcutaneous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
11	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q3H	O
(	O
every	O
3	O
hours	O
)	O
as	O
needed	O
for	O
btp	I-Reason
.	O
13	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
14	O
.	O
Lorazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
15	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
ONCE	O
(	O
Once	O
)	O
:	O
Adjust	O
dose	O
according	O
to	O
INR	O
.	O
.	O
16	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
adjust	O
daily	O
dose	O
according	O
to	O
INR	O
.	O
17	O
.	O
Ondansetron	B-Drug
HCl	I-Drug
(	O
PF	O
)	O
4	O
mg	O
/	O
2	O
mL	O
Solution	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
mg	O
Injection	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Colace	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
:	O
Over-the-counter	O
.	O
4	O
.	O
Omeprazole	I-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
30	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
11	O
*	O
5	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
3	O
Tablets	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Fentanyl	I-Drug
75	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
10	O
Patch	O
72	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
.	O
9	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
300	O
mg	O
(	O
60	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Metoclopramide	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QIDACHS	O
(	O
4	O
times	O
a	O
day	O
(	O
before	O
meals	O
and	O
at	O
bedtime	O
)	O
)	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Metronidazole	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
for	O
4	O
weeks	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
84	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
12	O
.	O
Levofloxacin	I-Drug
750	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
4	O
weeks	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
28	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
13	O
.	O
Linezolid	I-Drug
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
14	O
days	O
.	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
*	O
28	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
14	O
.	O
Coumadin	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
daily	O
in	O
the	O
evening	O
or	O
as	O
directed	O
by	O
PCP	O
.	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
15	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
As	O
directed	O
by	O
PCP	O
:	O
**	O
This	O
Prescription	O
should	O
only	O
be	O
used	O
if	O
advised	O
by	O
your	O
PCP	O
.	O
**	O
.	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
119	O
**	O
]	O
homecare	O
VNA	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Necrotizing	O
gallstone	O
pancreatitis	O
.	O
2	O
.	O
Multiple	O
pancreatic	O
pseudocysts	O
.	O
3	O
.	O
Non-occlusive	O
thrombus	O
in	O
the	O
left	O
common	O
femoral	O
vein	O
.	O
4	O
.	O
Left	O
Pleural	O
effusion	O
5	O
.	O
Anemia	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
Discharge	O
Instructions	O
:	O
Please	O
resume	O
all	O
regular	O
home	O
medications	O
,	O
unless	O
specifically	O
advised	O
not	O
to	O
take	O
a	O
particular	O
medication	O
.	O
Also	O
,	O
please	O
take	O
any	O
new	O
medications	O
as	O
prescribed	O
.	O
Please	O
get	O
plenty	O
of	O
rest	O
,	O
continue	O
to	O
ambulate	O
several	O
times	O
per	O
day	O
,	O
and	O
drink	O
adequate	O
amounts	O
of	O
fluids	O
.	O
Avoid	O
lifting	O
weights	O
greater	O
than	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
lbs	O
until	O
you	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
,	O
who	O
will	O
instruct	O
you	O
further	O
regarding	O
activity	O
restrictions	O
.	O
Avoid	O
driving	O
or	O
operating	O
heavy	O
machinery	O
while	O
taking	O
pain	I-Drug
medications	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
and	O
Primary	O
Care	O
Provider	O
(	O
PCP	O
)	O
as	O
advised	O
.	O
.	O
JP	O
Drain	O
Care	O
:	O
*	O
Please	O
look	O
at	O
the	O
site	O
every	O
day	O
for	O
signs	O
of	O
infection	O
(	O
increased	O
redness	O
or	O
pain	O
,	O
swelling	O
,	O
odor	O
,	O
yellow	O
or	O
bloody	O
discharge	O
,	O
warm	O
to	O
touch	O
,	O
fever	O
)	O
.	O
*	O
Maintain	O
suction	O
of	O
the	O
bulb	O
.	O
*	O
Note	O
color	O
,	O
consistency	O
,	O
and	O
amount	O
of	O
fluid	O
in	O
the	O
drain	O
.	O
Call	O
the	O
doctor	O
,	O
nurse	O
practitioner	O
,	O
or	O
VNA	O
nurse	O
if	O
the	O
amount	O
increases	O
significantly	O
or	O
changes	O
in	O
character	O
.	O
*	O
Be	O
sure	O
to	O
empty	O
the	O
drain	O
frequently	O
.	O
Record	O
the	O
output	O
,	O
if	O
instructed	O
to	O
do	O
so	O
.	O
*	O
You	O
may	O
shower	O
;	O
wash	O
the	O
area	O
gently	O
with	O
warm	O
,	O
soapy	O
water	O
.	O
*	O
Keep	O
the	O
insertion	O
site	O
clean	O
and	O
dry	O
otherwise	O
.	O
*	O
Avoid	O
swimming	O
,	O
baths	O
,	O
hot	O
tubs	O
;	O
do	O
not	O
submerge	O
yourself	O
in	O
water	O
.	O
*	O
Make	O
sure	O
to	O
keep	O
the	O
drain	O
attached	O
securely	O
to	O
your	O
body	O
to	O
prevent	O
pulling	O
or	O
dislocation	O
.	O
.	O
General	O
Drain	O
Care	O
:	O
*	O
Please	O
look	O
at	O
the	O
site	O
every	O
day	O
for	O
signs	O
of	O
infection	O
(	O
increased	O
redness	O
or	O
pain	O
,	O
swelling	O
,	O
odor	O
,	O
yellow	O
or	O
bloody	O
discharge	O
,	O
warm	O
to	O
touch	O
,	O
fever	O
)	O
.	O
*	O
If	O
the	O
drain	O
is	O
connected	O
to	O
a	O
collection	O
container	O
,	O
please	O
note	O
color	O
,	O
consistency	O
,	O
and	O
amount	O
of	O
fluid	O
in	O
the	O
drain	O
.	O
Call	O
the	O
doctor	O
,	O
nurse	O
practitioner	O
,	O
or	O
VNA	O
nurse	O
if	O
the	O
amount	O
increases	O
significantly	O
or	O
changes	O
in	O
character	O
.	O
Be	O
sure	O
to	O
empty	O
the	O
drain	O
frequently	O
.	O
Record	O
the	O
output	O
,	O
if	O
instructed	O
to	O
do	O
so	O
.	O
*	O
Wash	O
the	O
area	O
gently	O
with	O
warm	O
,	O
soapy	O
water	O
or	O
1/2	O
strength	O
hydrogen	B-Drug
peroxide	I-Drug
followed	O
by	O
saline	I-Drug
rinse	O
,	O
pat	O
dry	O
,	O
and	O
place	O
a	O
drain	O
sponge	O
.	O
Change	O
daily	O
and	O
as	O
needed	O
.	O
*	O
Keep	O
the	O
insertion	O
site	O
clean	O
and	O
dry	O
otherwise	O
.	O
*	O
Avoid	O
swimming	O
,	O
baths	O
,	O
hot	O
tubs	O
;	O
do	O
not	O
submerge	O
yourself	O
in	O
water	O
.	O
*	O
Make	O
sure	O
to	O
keep	O
the	O
drain	O
attached	O
securely	O
to	O
your	O
body	O
to	O
prevent	O
pulling	O
or	O
dislocation	O
.	O
.	O
Coumadin	I-Drug
(	O
Warfarin	I-Drug
)	O
:	O
What	O
is	O
this	O
medicine	O
used	O
for	O
?	O
This	O
medicine	O
is	O
used	O
to	O
thin	O
the	O
blood	O
so	O
that	O
clots	O
will	O
not	O
form	O
.	O
How	O
does	O
it	O
work	O
?	O
Warfarin	I-Drug
changes	O
the	O
body	O
's	O
clotting	O
system	O
.	O
It	O
thins	O
the	O
blood	O
to	B-Reason
prevent	I-Reason
clots	I-Reason
from	I-Reason
forming	I-Reason
.	O
What	O
you	O
should	O
contact	O
your	O
healthcare	O
provider	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
:	O
Signs	O
of	O
a	O
life	O
-	O
threatening	O
reaction	O
.	O
These	O
include	O
wheezing	O
;	O
chest	O
tightness	O
;	O
fever	O
;	O
itching	O
;	O
bad	O
cough	O
;	O
blue	O
skin	O
color	O
;	O
fits	O
;	O
or	O
swelling	O
of	O
face	O
,	O
lips	O
,	O
tongue	O
,	O
or	O
throat	O
,	O
severe	O
dizziness	O
or	O
passing	O
out	O
,	O
falls	O
or	O
accidents	O
,	O
especially	O
if	O
you	O
hit	O
your	O
head	O
.	O
Talk	O
with	O
healthcare	O
provider	O
even	O
if	O
you	O
feel	O
fine	O
,	O
significant	O
change	O
in	O
thinking	O
clearly	O
and	O
logically	O
,	O
severe	O
headache	O
,	O
severe	O
back	O
pain	O
,	O
severe	O
belly	O
pain	O
,	O
black	O
,	O
tarry	O
,	O
or	O
bloody	O
stools	O
,	O
blood	O
in	O
the	O
urine	O
,	O
nosebleeds	O
,	O
coughing	O
up	O
blood	O
,	O
vomiting	O
blood	O
,	O
unusual	O
bruising	O
or	O
bleeding	O
,	O
severe	O
menstrual	O
bleedin	O
,	O
or	O
rash	O
.	O
Call	O
your	O
doctor	O
if	O
you	O
are	O
unable	O
to	O
eat	O
for	O
several	O
days	O
,	O
for	O
whatever	O
reason	O
.	O
Also	O
call	O
if	O
you	O
have	O
stomach	O
problems	O
,	O
vomiting	O
,	O
or	O
diarrhea	O
that	O
lasts	O
more	O
than	O
1	O
day	O
.	O
These	O
problems	O
could	O
affect	O
your	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
dosage	O
.	O
Coumadin	I-Drug
(	O
Warfarin	I-Drug
)	O
and	O
diet	O
:	O
Certain	O
foods	O
and	O
beverages	O
can	O
impair	O
the	O
effect	O
of	O
warfarin	I-Drug
.	O
For	O
this	O
reason	O
,	O
it	O
's	O
important	O
to	O
pay	O
attention	O
to	O
what	O
you	O
eat	O
while	O
taking	O
this	O
medication	O
.	O
Until	O
recently	O
,	O
doctors	O
advised	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
taking	O
warfarin	I-Drug
to	O
avoid	O
foods	O
high	O
in	O
vitamin	B-Drug
K	I-Drug
.	O
This	O
is	O
because	O
large	O
amounts	O
of	O
vitamin	B-Drug
K	I-Drug
can	O
counteract	O
the	O
benefits	O
of	O
warfarin	I-Drug
.	O
However	O
,	O
recent	O
research	O
shows	O
that	O
rather	O
than	O
eliminating	O
vitamin	B-Drug
K	I-Drug
from	O
your	O
diet	O
,	O
it	O
is	O
more	O
important	O
to	O
be	O
consistent	O
in	O
your	O
dietary	O
vitamin	B-Drug
K	I-Drug
intake	O
.	O
These	O
foods	O
contain	O
vitamin	B-Drug
K	I-Drug
:	O
Fruits	O
and	O
vegetables	O
,	O
such	O
as	O
:	O
Kiwi	O
,	O
Blueberries	O
,	O
Broccoli	O
,	O
Cabbage	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
2831	O
**	O
]	O
sprouts	O
,	O
Green	O
onions	O
,	O
Asparagus	O
,	O
Cauliflower	O
,	O
Peas	O
,	O
Lettuce	O
,	O
Spinach	O
,	O
Turnip	O
,	O
collard	O
,	O
and	O
mustard	O
greens	O
,	O
Parsley	O
,	O
Kale	O
,	O
Endive	O
.	O
Meats	O
,	O
such	O
as	O
:	O
Beef	O
liver	O
,	O
Pork	O
liver	O
.	O
Other	O
:	O
Mayonnaise	O
,	O
Margarine	O
,	O
Canola	O
oil	O
,	O
Soybean	O
oil	O
,	O
Vitamins	O
,	O
Soybeans	O
and	O
Cashews	O
.	O
Limit	O
alcohol	O
.	O
Alcohol	O
can	O
affect	O
your	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
dosage	O
but	O
it	O
does	O
not	O
mean	O
you	O
must	O
avoid	O
all	O
alcohol	O
.	O
Serious	O
problems	O
can	O
occur	O
with	O
alcohol	O
and	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
when	O
you	O
drink	O
more	O
than	O
2	O
drinks	O
a	O
day	O
or	O
when	O
you	O
change	O
your	O
usual	O
pattern	O
.	O
Binge	O
drinking	O
is	O
not	O
good	O
for	O
you	O
.	O
Be	O
careful	O
on	O
special	O
occasions	O
or	O
holidays	O
,	O
and	O
drink	O
only	O
what	O
you	O
usually	O
would	O
on	O
any	O
regular	O
day	O
of	O
the	O
week	O
.	O
Monitoring	O
:	O
The	O
doctor	O
decides	O
how	O
much	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
you	O
need	O
by	O
testing	O
your	O
blood	O
.	O
The	O
test	O
measures	O
how	O
fast	O
your	O
blood	O
is	O
clotting	O
and	O
lets	O
the	O
doctor	O
know	O
if	O
your	O
dosage	O
should	O
change	O
.	O
If	O
your	O
blood	O
test	O
is	O
too	O
high	O
,	O
you	O
might	O
be	O
at	O
risk	O
for	O
bleeding	O
problems	O
.	O
If	O
it	O
is	O
too	O
low	O
,	O
you	O
might	O
be	O
at	O
risk	O
for	O
forming	O
clots	O
.	O
Your	O
doctor	O
has	O
decided	O
on	O
a	O
range	O
on	O
the	O
blood	O
test	O
that	O
is	O
right	O
for	O
you	O
.	O
The	O
blood	O
test	O
used	O
for	O
monitoring	O
is	O
called	O
an	O
INR	O
.	O
Use	O
of	O
Other	O
medications	O
:	O
When	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
is	O
taken	O
with	O
other	O
medicines	O
it	O
can	O
change	O
the	O
way	O
other	O
medicines	O
work	O
.	O
Other	O
medicines	O
can	O
also	O
change	O
the	O
way	O
Coumadin	I-Drug
??????	O
/	O
warfarin	I-Drug
works	O
.	O
It	O
is	O
very	O
important	O
to	O
talk	O
with	O
your	O
doctor	O
about	O
all	O
of	O
the	O
other	O
medicines	O
that	O
you	O
are	O
taking	O
,	O
including	O
over-the-counter	O
medicines	O
,	O
antibiotics	I-Drug
,	O
vitamins	O
,	O
or	O
herbal	O
products	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
6952	O
**	O
]	O
,	O
MD	O
(	O
Hematology	O
)	O
.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3241	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2146-5-18	O
**	O
]	O
2:00	O
.	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
7	O
,	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
.	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
SCAN	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2146-5-26	O
**	O
]	O
2:45	O
.	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
4	O
,	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
.	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
(	O
Infectious	O
Disease	O
)	O
.	O
Phone	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
6732	O
**	O
]	O
.	O
Date	O
/	O
Time	O
:	O
Friday	O
,	O
[	O
**	O
2146-5-27	O
**	O
]	O
at	O
10:00	O
AM	O
.	O
Location	O
:	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
6752	O
**	O
]	O
GB	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
439	O
**	O
]	O
,	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Hospital	O
Ward	O
Name	O
517	O
**	O
]	O
.	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2832	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1231	O
**	O
]	O
Date	O
/	O
Time	O
:	O
Friday	O
,	O
[	O
**	O
2146-5-27	O
**	O
]	O
at	O
11:30	O
AM	O
.	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
3	O
,	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
.	O
.	O
Please	O
call	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
84361	O
**	O
]	O
to	O
arrange	O
a	O
follow	O
-	O
up	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
84362	O
**	O
]	O
(	O
PCP	O
)	O
in	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
weeks	O
.	O
Completed	O
by	O
:[	O
**	O
2146-4-27	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2147-9-16	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2147-9-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2103-7-8	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MED	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
Known	O
firstname	O
943	O
**	O
]	O
Chief	O
Complaint	O
:	O
emesis	O
/	O
melena	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
EGD	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
a	O
44	O
yo	O
male	O
with	O
h	O
/	O
o	O
Hep	O
C	O
/	O
etOH	O
cirrhosis	O
and	O
hepatoma	O
s	O
/	O
p	O
ablation	O
and	O
known	O
esophageal	O
varices	O
who	O
p	O
/	O
w	O
emesis	O
and	O
melena	O
since	O
yesterday	O
.	O
He	O
was	O
given	O
7	O
day	O
course	O
of	O
amoxicillin	I-Drug
and	O
naprosyn	I-Drug
for	O
toothache	I-Reason
and	O
was	O
scheduled	O
to	O
have	O
his	O
extraction	O
today	O
.	O
However	O
,	O
he	O
started	O
to	O
have	O
black	O
stool	O
(	O
X6	O
)	O
and	O
threw	O
up	O
black	O
material	O
(	O
X2	O
)	O
.	O
No	O
BRBPR	O
.	O
Called	O
his	O
liver	O
doctor	O
and	O
referred	O
to	O
ED	O
for	O
evaluation	O
of	O
GIB	O
.	O
Despite	O
known	O
varices	O
,	O
he	O
has	O
no	O
known	O
history	O
of	O
GIB	O
requiring	O
transfusion	O
in	O
the	O
past	O
.	O
Pt	O
denied	O
any	O
CP	O
/	O
SOB	O
/	O
F	O
/	O
C	O
/	O
NS	O
.	O
In	O
ED	O
,	O
afebrile	O
and	O
hemodynamically	O
stable	O
.	O
He	O
was	O
transfused	O
1U	O
plt	I-Drug
in	O
ED	O
for	O
plt	O
count	O
of	O
47	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Cirrhosis	O
(	O
Hep	O
C	O
/	O
etOH	O
)	O
2	O
.	O
hepatoma	O
-	O
s	O
/	O
p	O
ablation	O
now	O
on	O
transplant	O
list	O
/	O
evaluation	O
3	O
.	O
Esophageal	O
varices	O
4	O
.	O
s	O
/	O
p	O
femur	O
/	O
tibia	O
/	O
fib	O
fx	O
5	O
.	O
h	O
/	O
o	O
polysubstance	O
abuse	O
Social	O
History	O
:	O
44	O
yo	O
man	O
,	O
currently	O
unemployed	O
who	O
lives	O
with	O
girlfriend	O
.	O
h	O
/	O
o	O
alcohol	O
use	O
remission	O
for	O
5	O
years	O
tobacco	O
-	O
1ppd	O
X22	O
yrs	O
h	O
/	O
o	O
cocaine	O
,	O
heroine	O
,	O
amphetamine	O
abuse	O
-	O
none	O
since	O
[	O
**	O
2138	O
**	O
]	O
Family	O
History	O
:	O
mother	O
died	O
of	O
MI	O
at	O
65	O
yo	O
Physical	O
Exam	O
:	O
On	O
admission	O
:	O
T	O
:	O
98	O
HR	O
:	O
72	O
BP	O
:	O
102/55	O
RR	O
:	O
20	O
O2	O
sat	O
:	O
99	O
%	O
RA	O
General	O
:	O
mildly	O
juandiced	O
middle	O
aged	O
male	O
,	O
A&OX	O
3	O
,	O
NAD	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
OP	O
-	O
clear	O
,	O
neck	O
supple	O
,	O
no	O
LAD	O
,	O
JVP	O
flat	O
lungs	O
:	O
CTA	O
bilat	O
with	O
good	O
air	O
movt	O
,	O
nml	O
work	O
of	O
breathing	O
cardiac	O
:	O
distant	O
heart	O
sounds	O
,	O
rrr	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
abd	O
:	O
mod	O
distention	O
,	O
non	O
tender	O
+	O
ascites	O
,	O
stool	O
black	O
and	O
guaiac	O
positive	O
no	O
flank	O
/	O
CVA	O
tenderness	O
ext	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
,	O
warm	O
with	O
good	O
capillary	O
refill	O
Pertinent	O
Results	O
:	O
[	O
**	O
2147-9-16	O
**	O
]	O
09:05	O
PM	O
HCT	O
-	O
26.8	O
*	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
GLUCOSE	O
-	O
88	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
0.6	O
SODIUM	O
-	O
137	O
POTASSIUM	O
-	O
4.1	O
CHLORIDE	O
-	O
108	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
9	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
51	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
64	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
210	O
ALK	O
PHOS	O
-	O
84	O
TOT	O
BILI	O
-	O
1.6	O
*	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
ALBUMIN	O
-	O
3.3	O
*	O
CALCIUM	O
-	O
8.8	O
PHOSPHATE	O
-	O
3.1	O
MAGNESIUM	O
-	O
1.7	O
IRON	O
-	O
319	O
*	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
calTIBC	O
-	O
332	O
FERRITIN	O
-	O
237	O
TRF	O
-	O
255	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
ETHANOL	O
-	O
NEG	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
WBC	O
-	O
5.5	O
#	O
RBC	O
-	O
3.00	O
*	O
#	O
HGB	O
-	O
11.0	O
*	O
#	O
HCT	O
-	O
30.1	O
*	O
#	O
MCV	O
-	O
101	O
*	O
MCH	O
-	O
36.6	O
*	O
MCHC	O
-	O
36.4	O
*	O
RDW	O
-	O
15.3	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
NEUTS	O
-	O
60.8	O
LYMPHS	O
-	O
31.7	O
MONOS	O
-	O
5.2	O
EOS	O
-	O
1.9	O
BASOS	O
-	O
0.4	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
MACROCYT	O
-	O
2	O
+	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
PLT	O
COUNT	O
-	O
47	O
*	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
PT	O
-	O
14.5	O
*	O
PTT	O
-	O
29.7	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
[	O
**	O
2147-9-16	O
**	O
]	O
03:47	O
PM	O
RET	O
AUT	O
-	O
4.2	O
*	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
pt	O
is	O
44	O
yo	O
male	O
with	O
hep	O
c	O
cirrhosis	O
,	O
HCC	O
and	O
UGI	B-Ade
bleed	I-Ade
in	O
setting	O
of	O
known	O
varices	O
s	O
/	O
p	O
7	O
days	O
of	O
nsaid	I-Drug
use	O
.	O
1	O
.	O
GI	B-Reason
bleed	I-Reason
:	O
Pt	O
was	O
admitted	O
to	O
the	O
MICU	O
for	O
evaluation	O
and	O
urgent	O
EGD	O
.	O
He	O
was	O
hemodynamically	O
stable	O
throughout	O
admission	O
.	O
GI	B-Ade
bleed	I-Ade
thought	O
more	O
likely	O
due	O
to	O
NSAID	I-Drug
use	O
than	O
esophageal	O
varices	O
as	O
varices	O
noted	O
to	O
be	O
mild	O
in	O
past	O
.	O
On	O
admission	O
,	O
he	O
was	O
started	O
on	O
octreotide	I-Drug
transiently	O
.	O
He	O
was	O
transfused	O
2	O
units	O
of	O
PRBC	B-Drug
's	I-Drug
to	O
keep	O
hct	O
>	O
25	O
prior	O
to	O
transfer	O
to	O
floor	O
.	O
Endoscopy	O
revealed	O
:	O
3	O
cords	O
of	O
grade	O
1	O
varices	O
in	O
lower	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
of	O
esoph	O
but	O
no	O
active	O
bleeding	O
.	O
Stomach	O
:	O
melena	O
seen	O
in	O
body	O
but	O
no	O
sign	O
of	O
active	O
bleeding	O
;	O
antrum	O
with	O
erythema	O
but	O
no	O
bleeding	O
;	O
multiple	O
acute	O
superficial	O
ulcers	O
2	O
-	O
5	O
mm	O
in	O
antrum	O
with	O
pigmented	O
material	O
suggestive	O
of	O
recent	O
bleeding	O
.	O
He	O
was	O
started	O
on	O
carafate	I-Drug
,	O
protonix	I-Drug
,	O
and	O
H	O
pylori	O
serology	O
sentand	O
were	O
negative	O
for	O
H.Pylori	O
.	O
Emesis	O
resolved	O
s	O
/	O
p	O
EGD	O
and	O
advanced	O
to	O
PO	O
diet	O
which	O
he	O
tolerated	O
well	O
.	O
Transferred	O
to	O
floor	O
on	O
[	O
**	O
9	O
-	O
17	O
**	O
]	O
.	O
That	O
evening	O
hct	O
dropped	O
from	O
31	O
to	O
25.1	O
(	O
24.6	O
on	O
repeat	O
)	O
and	O
he	O
was	O
transfused	O
1	O
unit	O
of	O
blood	I-Drug
(	O
3rd	O
during	O
admission	O
)	O
.	O
He	O
responded	O
appropriately	O
with	O
hct	O
inc	O
to	O
27.9	O
.	O
His	O
hct	O
remained	O
stable	O
throughout	O
rest	O
of	O
admission	O
and	O
had	O
increased	O
to	O
30.5	O
by	O
time	O
of	O
discharge	O
.	O
On	O
discharge	O
,	O
reinforced	O
importance	O
of	O
avoiding	O
NSAIDS	I-Drug
to	O
prevent	O
further	O
GI	O
bleeds	O
.	O
2	O
.	O
HEME	O
:	O
Thrombocytopenic	I-Reason
on	O
admission	O
with	O
platelets	O
of	O
47	O
.	O
He	O
has	O
received	O
1	O
Units	O
of	O
platelets	I-Drug
on	O
admission	O
.	O
On	O
the	O
floor	O
,	O
pt	O
was	O
transfused	O
another	O
3	O
units	O
of	O
platelets	I-Drug
to	O
keep	O
plt	O
>	O
75	O
,	O
per	O
hepatology	O
recommendations	O
.	O
Plt	O
on	O
discharge	O
were	O
89	O
.	O
3	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
52965	O
**	O
]	O
Pt	O
is	O
currently	O
undergoing	O
transplant	O
evaluation	O
.	O
He	O
was	O
continued	O
on	O
oupt	O
dose	O
of	O
nadalol	I-Drug
during	O
admission	O
.	O
He	O
received	O
one	O
week	O
of	O
ciprofloxacin	I-Drug
for	O
SBP	B-Reason
prophylaxis	I-Reason
in	O
setting	O
of	O
UGIB	O
.	O
Pt	O
will	O
be	O
in	O
touch	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
497	O
**	O
]	O
for	O
recommendations	O
of	O
oral	O
surgeons	O
to	O
perform	O
his	O
tooth	O
extraction	O
.	O
He	O
will	O
need	O
this	O
procedure	O
to	O
be	O
done	O
in	O
hospital	O
setting	O
where	O
hct	O
and	O
platelets	O
can	O
be	O
monitored	O
.	O
He	O
is	O
also	O
to	O
f	O
/	O
u	O
in	O
liver	O
center	O
on	O
[	O
**	O
9	O
-	O
21	O
**	O
]	O
as	O
previously	O
scheduled	O
.	O
4	O
.	O
Smoking	B-Reason
cessation	I-Reason
-	O
discussed	O
with	O
patient	O
impact	O
of	O
smoking	O
on	O
health	O
and	O
benefits	O
of	O
cessation	O
.	O
He	O
expressed	O
interest	O
in	O
quiting	O
and	O
was	O
successful	O
on	O
nicotine	I-Drug
patch	O
during	O
admission	O
.	O
He	O
was	O
discharged	O
on	O
the	O
patch	O
Medications	O
on	O
Admission	O
:	O
nadolol	I-Drug
60	O
mg	O
po	O
daily	O
lactulose	I-Drug
mvi	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Sucralfate	I-Drug
1	O
g	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Multivitamin	I-Drug
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
4	O
.	O
Nadolol	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
5	O
.	O
Nicotine	I-Drug
21	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
24	O
HR	O
Transdermal	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
6	O
.	O
Ciprofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
3	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Oxycodone	B-Drug
HCl	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
uncontrolled	O
by	O
Tylenol	I-Drug
.	O
Disp	O
:	O
*	O
10	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
GI	O
bleed	O
2	O
.	O
PUD	O
-	O
EGD	O
on	O
[	O
**	O
2147-9-16	O
**	O
]	O
3	O
.	O
cirhhosis	O
4	O
.	O
HCC	O
5	O
.	O
esophageal	O
varices	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
Please	O
call	O
the	O
liver	O
clinic	O
or	O
return	O
to	O
the	O
ER	O
if	O
you	O
experience	O
nausea	O
,	O
vomiting	O
,	O
dizziness	O
,	O
or	O
continued	O
black	O
stools	O
.	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
Complete	O
the	O
remaining	O
3	O
days	O
of	O
Ciprofloxacin	I-Drug
.	O
Please	O
call	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
948	O
**	O
]	O
office	O
tomorrow	O
regarding	O
appointment	O
with	O
the	O
oral	O
surgeon	O
who	O
will	O
be	O
performing	O
your	O
tooth	O
extraction	O
.	O
This	O
should	O
be	O
done	O
in	O
a	O
supervised	O
setting	O
where	O
your	O
blood	O
levels	O
and	O
platelets	O
can	O
be	O
monitored	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
TRANSPLANT	O
,	O
ORIENTATION	O
TRANSPLANT	O
CENTER	O
-	O
MEDICINE	O
Where	O
:	O
TRANSPLANT	O
CENTER	O
-	O
MEDICINE	O
Date	O
/	O
Time	O
:[	O
**	O
2147-9-21	O
**	O
]	O
3:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2424	O
**	O
]	O
,	O
MD	O
Where	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
7129	O
**	O
]	O
CENTER	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2422	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2147-10-12	O
**	O
]	O
9:15	O
Where	O
:	O
PSYCH	O
TRANSPLANT	O
Date	O
/	O
Time	O
:[	O
**	O
2148-2-27	O
**	O
]	O
1:30	O

Admission	O
Date	O
:	O
[	O
**	O
2114-2-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2114-2-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2059-9-16	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
898	O
**	O
]	O
Chief	O
Complaint	O
:	O
Admitted	O
to	O
MICU	O
for	O
GIB	O
,	O
originally	O
c	O
/	O
o	O
dizziness	O
and	O
dark	O
stool	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
EGD	O
with	O
epinephrine	I-Drug
injection	O
and	O
BICAP	O
cautery	O
History	O
of	O
Present	O
Illness	O
:	O
54	O
y	O
/	O
o	O
F	O
with	O
h	O
/	O
o	O
OCD	O
and	O
anemia	O
p	O
/	O
w	O
progressive	O
dizziness	O
,	O
dark	O
stool	O
over	O
past	O
week	O
.	O
She	O
reported	O
having	O
falls	O
at	O
home	O
,	O
no	O
LOC	O
but	O
fell	O
and	O
hit	O
head	O
with	O
head	O
laceration	O
4	O
days	O
prior	O
to	O
admission	O
.	O
She	O
also	O
had	O
been	O
vomiting	O
coffee	O
grounds	O
last	O
2	O
days	O
prior	O
to	O
admission	O
.	O
She	O
reports	O
taking	O
"	O
a	O
lot	O
"	O
of	O
Excedrin	I-Drug
over	O
past	O
week	O
for	O
LBP	O
.	O
She	O
reported	O
no	O
h	O
/	O
o	O
GI	O
bleed	O
.	O
In	O
ED	O
,	O
her	O
initial	O
BP	O
80	O
/	O
50s	O
and	O
the	O
pt	O
was	O
A&O	O
X3	O
able	O
to	O
give	O
hx	O
but	O
sleepy	O
.	O
After	O
20	O
min	O
pt	O
.	O
became	O
unresponsive	I-Reason
and	O
brady	B-Reason
'd	I-Reason
down	I-Reason
to	I-Reason
30	O
-	O
40s	O
.	O
The	O
patient	O
was	O
then	O
intubated	O
,	O
given	O
epinephrine	I-Drug
and	O
atropine	I-Drug
,	O
with	O
IV	O
access	O
difficult	O
to	O
obtain	O
with	O
bilateral	O
unsuccessful	O
groin	O
sticks	O
(	O
possibly	O
a	O
sticks	O
)	O
placed	O
2	O
PIVs	O
and	O
14G	O
R	O
EJ	O
.	O
Hct	O
returned	O
at	O
14	O
%	O
,	O
K	O
was	O
6.7	O
,	O
ABG	O
7.09	O
/	O
34/326	O
on	O
100	O
%	O
intubated	O
.	O
Given	O
Ca	I-Drug
,	O
bicarb	I-Drug
,	O
5	O
U	O
PRBCs	I-Drug
and	O
2L	O
IVF	I-Drug
with	O
improved	O
BP	O
120	O
/	O
70s	O
and	O
HR	O
70s	O
.	O
GI	O
came	O
to	O
do	O
emergent	O
EGD	O
and	O
found	O
gastric	B-Ade
ulcer	I-Ade
and	O
duodenal	B-Ade
bulb	I-Ade
ulcers	I-Ade
c	O
/	O
w	O
NSAID	I-Drug
toxicity	I-Ade
,	O
thought	O
to	O
be	O
source	O
.	O
CT	O
head	O
negative	O
.	O
Abd	O
CT	O
showed	O
?	O
gall	O
bladder	O
sludge	O
with	O
edema	O
otherwise	O
negative	O
.	O
She	O
was	O
admitted	O
then	O
to	O
the	O
MICU	O
for	O
further	O
monitoring	O
and	O
management	O
.	O
Past	O
Medical	O
History	O
:	O
Anemia	O
OCD	O
Depression	O
GERD	O
(	O
but	O
thought	O
Actonel	I-Drug
was	O
for	O
GERD	O
)	O
history	O
of	O
"	O
high	O
white	O
blood	O
cell	O
count	O
"	O
Social	O
History	O
:	O
Lives	O
alone	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
moved	O
from	O
[	O
**	O
Location	O
(	O
un	O
)	O
7349	O
**	O
]	O
in	O
[	O
**	O
2110	O
**	O
]	O
and	O
feels	O
that	O
she	O
left	O
"	O
her	O
city	O
.	O
"	O
Works	O
as	O
administrative	O
assistant	O
at	O
temp	O
firm	O
.	O
SIster	O
lives	O
in	O
[	O
**	O
Location	O
701	O
**	O
]	O
,	O
no	O
children	O
,	O
single	O
.	O
Denies	O
EtOH	O
and	O
IVDA	O
.	O
Family	O
History	O
:	O
Father	O
died	O
at	O
75	O
of	O
MI	O
Mother	O
died	O
at	O
74	O
of	O
colon	O
cancer	O
Sister	O
had	O
ulcers	O
,	O
otherwise	O
healthy	O
Physical	O
Exam	O
:	O
On	O
admission	O
:	O
T	O
98.2	O
/	O
74	O
/	O
/	O
120/80	O
/	O
/	O
19	O
/	O
/	O
100	O
%	O
on	O
NRB	O
Gen	O
:	O
sedated	O
and	O
intubated	O
HEENT	O
:	O
MMM	O
,	O
no	O
JVD	O
Neck	O
:	O
Suple	O
,	O
JVP	O
4	O
cm	O
Heart	O
:	O
RRR	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
Lungs	O
:	O
B	O
/	O
l	O
exp	O
wheezes	O
Abs	O
:	O
s	O
/	O
nt	O
,	O
slight	O
distension	O
,	O
+	O
BS	O
Ext	O
:	O
no	O
edema	O
,	O
2	O
+	O
pulses	O
On	O
transfer	O
from	O
MICU	O
to	O
floor	O
[	O
**	O
2114-2-5	O
**	O
]	O
:	O
AF	O
/	O
96	O
/	O
/	O
168/88	O
/	O
rr22	O
-	O
29	O
/	O
/	O
spo2	O
100	O
%	O
on	O
4L	O
NC	O
Gen	O
:	O
pleasant	O
,	O
a7ox3	O
,	O
NAD	O
,	O
somewhat	O
disheveled	O
middle	O
-	O
aged	O
female	O
sitting	O
in	O
chair	O
,	O
conversant	O
HEENT	O
:	O
MMM	O
,	O
anicteric	O
sclerae	O
,	O
right	O
eyelid	O
erythematous	O
and	O
slightly	O
swollen	O
Neck	O
:	O
Suple	O
,	O
r	O
EJ	O
in	O
place	O
,	O
no	O
jvd	O
Heart	O
:	O
RRR	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
Lungs	O
:	O
CTAB	O
Abs	O
:	O
s	O
/	O
nt	O
,	O
slight	O
distension	O
,	O
no	O
HSM	O
,	O
negative	O
[	O
**	O
Doctor	O
Last	O
Name	O
515	O
**	O
]	O
sign	O
,	O
+	O
BS	O
Ext	O
:	O
1	O
+	O
b	O
/	O
l	O
LE	O
edema	O
,	O
2	O
+	O
DPs	O
b	O
/	O
l	O
Pertinent	O
Results	O
:	O
CBC	O
:	O
[	O
**	O
2114-2-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
WBC	O
-	O
27.4	O
*	O
#	O
RBC	O
-	O
1.55	O
*	O
#	O
Hgb	O
-	O
4.6	O
*	O
#	O
Hct	O
-	O
14.6	O
*	O
#	O
MCV	O
-	O
94	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
31.9	O
RDW	O
-	O
18.1	O
*	O
Plt	O
Ct	O
-	O
367	O
[	O
**	O
2114-2-5	O
**	O
]	O
04:32	O
AM	O
BLOOD	O
WBC	O
-	O
18.3	O
*	O
RBC	O
-	O
3.51	O
*	O
Hgb	O
-	O
10.6	O
*	O
Hct	O
-	O
30.1	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
35.3	O
*	O
RDW	O
-	O
16.7	O
*	O
Plt	O
Ct	O
-	O
167	O
[	O
**	O
2114-2-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
Neuts	O
-	O
86	O
*	O
Bands	O
-	O
4	O
Lymphs	O
-	O
9	O
*	O
Monos	O
-	O
1	O
*	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2114-2-4	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Neuts	O
-	O
85.2	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
11.1	O
*	O
Monos	O
-	O
3.3	O
Eos	O
-	O
0.2	O
Baso	O
-	O
0.1	O
Chemistries	O
:	O
[	O
**	O
2114-2-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
Glucose	O
-	O
86	O
UreaN	O
-	O
67	O
*	O
Creat	O
-	O
1.6	O
*	O
Na	O
-	O
134	O
K	O
-	O
6.7	O
*	O
Cl	O
-	O
95	O
*	O
HCO3	O
-	O
14	O
*	O
AnGap	O
-	O
32	O
*	O
[	O
**	O
2114-2-5	O
**	O
]	O
04:32	O
AM	O
BLOOD	O
Glucose	O
-	O
85	O
UreaN	O
-	O
14	O
Creat	O
-	O
0.4	O
Na	O
-	O
142	O
K	O
-	O
4.0	O
Cl	O
-	O
114	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
10	O
LFTs	O
:	O
[	O
**	O
2114-2-3	O
**	O
]	O
05:33	O
PM	O
BLOOD	O
ALT	O
-	O
399	O
*	O
AST	O
-	O
647	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
1358	O
*	O
AlkPhos	O
-	O
77	O
Amylase	O
-	O
37	O
TotBili	O
-	O
0.9	O
[	O
**	O
2114-2-4	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
ALT	O
-	O
454	O
*	O
AST	O
-	O
966	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
968	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
1050	O
*	O
AlkPhos	O
-	O
78	O
Amylase	O
-	O
37	O
TotBili	O
-	O
0.8	O
Cardiac	O
enzymes	O
:	O
[	O
**	O
2114-2-4	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2114-2-3	O
**	O
]	O
05:33	O
PM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2114-2-3	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
33	O
*	O
MB	O
Indx	O
-	O
1.9	O
cTropnT	O
-	O
<	O
0.01	O
Initial	O
Toxin	O
Screen	O
:	O
[	O
**	O
2114-2-4	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
POS	O
Brief	O
Hospital	O
Course	O
:	O
54	O
y	O
/	O
o	O
f	O
with	O
massive	O
GI	O
Blead	O
and	O
bradycardic	O
arrest	O
in	O
ED	O
,	O
with	O
evidence	O
of	O
active	O
bleeding	O
at	O
gastric	O
and	O
duodenal	O
ulcers	O
.	O
Patient	O
's	O
admission	O
comprised	O
of	O
2	O
day	O
MICU	O
stay	O
with	O
continued	O
hemodynamic	O
stability	O
,	O
followed	O
by	O
several	O
days	O
on	O
the	O
medicine	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
monitoring	O
,	O
physical	O
therapy	O
,	O
treatment	O
for	O
hypoxia	O
and	O
neurologic	O
evaluation	O
.	O
1	O
.	O
Upper	B-Ade
GI	I-Ade
Bleed	I-Ade
:	O
PUD	I-Ade
likely	O
[	O
**	O
3	O
-	O
7	O
**	O
]	O
NSAIDs	I-Drug
.	O
Pt	O
was	O
continued	O
on	O
PPI	I-Drug
,	O
initially	O
IV	O
and	O
transitioned	O
to	O
oral	O
.	O
Her	O
hematocrit	O
was	O
monitored	O
twice	O
daily	O
initially	O
,	O
and	O
then	O
daily	O
.	O
All	O
NSAIDS	I-Drug
and	O
Actonel	I-Drug
were	O
held	O
,	O
with	O
a	O
recommendation	O
to	O
continue	O
to	O
avoid	O
these	O
medications	O
after	O
discharge	O
.	O
Gastrin	B-Ade
level	I-Ade
was	I-Ade
elevated	I-Ade
,	O
but	O
believed	O
secondary	O
to	O
PPI	I-Drug
therapy	O
.	O
Pt	O
will	O
require	O
outpatient	O
GI	O
follow	O
-	O
up	O
.	O
Finally	O
,	O
concern	O
regarding	O
the	O
level	O
of	O
insight	O
underlying	O
the	O
patient	O
's	O
large	O
doses	O
of	O
NSAIDs	I-Drug
,	O
coupled	O
with	O
her	O
family	O
's	O
concerns	O
about	O
her	O
psychiatric	O
history	O
,	O
prompted	O
psychiatric	O
and	O
neurologic	O
evaluations	O
.	O
Both	O
of	O
these	O
services	O
followed	O
the	O
patient	O
through	O
her	O
admission	O
.	O
2	O
)	O
Question	O
of	O
cholescystitis	O
:	O
RUQ	O
U	O
/	O
S	O
for	O
?	O
sludge	O
and	O
GB	O
wall	O
thickening	O
on	O
CT.	O
.	O
U	O
/	O
S	O
equivocal	O
.	O
HIDA	O
scan	O
negative	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
consulted	O
but	O
ascertained	O
that	O
there	O
were	O
no	O
further	O
surgical	O
needs	O
.	O
Cultures	O
and	O
hepatitis	O
serologies	O
were	O
unrevealing	O
,	O
and	O
exam	O
and	O
LFTs	O
normalized	O
.	O
Increased	O
LFTs	O
were	O
likely	O
[	O
**	O
3	O
-	O
7	O
**	O
]	O
hypotension	O
on	O
presentation	O
.	O
3	O
)	O
Elevated	O
LFTS	O
:	O
DDx	O
includes	O
cholecytitis	O
,	O
effect	O
of	O
hypotension	O
,	O
muscle	O
damage	O
.	O
Likely	O
dignosis	O
was	O
hypotension	O
on	O
presentation	O
given	O
negative	O
work	O
-	O
up	O
delineated	O
above	O
.	O
Held	O
Lipitor	I-Drug
given	O
transaminitis	I-Ade
for	O
outpatient	O
review	O
.	O
4	O
)	O
Bradycardia	O
:	O
possibly	O
due	O
to	O
massive	O
GI	O
Bleed	O
,	O
or	O
elev	O
K	O
and	O
acidosis	O
,	O
resolved	O
in	O
ICU	O
5	O
)	O
Metabolic	O
acidosis	O
:	O
-	O
likely	O
lactic	O
acidosis	O
from	O
hypotention	O
and	O
hypovolemic	O
shock	O
,	O
although	O
lactate	O
mildly	O
elevated	O
(	O
but	O
checked	O
after	O
resucitation	O
)	O
,	O
aspirin	I-Drug
negative	O
,	O
resolved	O
in	O
ICU	O
.	O
6	O
)	O
Leukocytosis	O
:	O
some	O
evidence	O
of	O
PNA	O
on	O
CT	O
with	O
4	O
+	O
GPCs	O
on	O
GS	O
,	O
also	O
?	O
gallbladder	O
wall	O
edema	O
on	O
CT.	O
.	O
Evidence	O
lacking	O
for	O
cholecytitis	O
,	O
MICU	O
team	O
hypothesis	O
was	O
that	O
elevation	O
[	O
**	O
3	O
-	O
7	O
**	O
]	O
demargination	O
under	O
stress	O
.	O
Continue	O
to	O
monitor	O
,	O
f	O
/	O
u	O
cultures	O
,	O
d	O
/	O
w	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
was	O
on	O
vanco	B-Drug
/	I-Drug
unasyn	I-Drug
in	O
the	O
ICU	O
,	O
narrowed	O
to	O
levofloxacin	I-Drug
as	O
she	O
had	O
suggestion	O
of	O
pneumonia	I-Reason
but	O
no	O
other	O
infection	O
.	O
7	O
)	O
Wheezing	O
/	O
SOB	O
:	O
Patient	O
with	O
likely	O
COPD	O
as	O
she	O
has	O
smoked	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
PPD	O
x	O
over	O
30	O
years	O
.	O
The	O
patient	O
improved	O
with	O
nebulizer	O
treatments	O
,	O
and	O
will	O
be	O
discharged	O
on	O
bronchodilators	I-Drug
with	O
outpatient	O
follow	O
-	O
up	O
.	O
8	O
)	O
Neuro	O
/	O
Pyschiatric	I-Reason
:	O
Patient	O
on	O
Fluoxetine	I-Drug
,	O
clonazepam	I-Drug
and	O
Anafranil	I-Drug
at	O
home	O
,	O
which	O
were	O
originally	O
held	O
in	O
the	O
ICU	O
.	O
Psychiatry	O
consult	O
was	O
called	O
after	O
discussion	O
with	O
the	O
patient	O
's	O
sister	O
,	O
who	O
was	O
concerned	O
about	O
her	O
inability	O
to	O
work	O
and	O
general	O
lack	O
of	O
ability	O
to	O
care	O
for	O
herself	O
,	O
most	O
clearly	O
manifested	O
financially	O
.	O
The	O
psychiartry	O
consult	O
had	O
no	O
medication	O
recommendations	O
,	O
and	O
her	O
TSH	O
/	O
B12	O
/	O
Folate	O
/	O
RPR	O
were	O
all	O
negative	O
or	O
within	O
normal	O
limits	O
as	O
appropriate	O
.	O
They	O
suspected	O
a	O
cognitive	O
problem	O
and	O
were	O
concerned	O
by	O
her	O
lack	O
of	O
judgement	O
however	O
,	O
and	O
also	O
recommended	O
an	O
MRI	O
.	O
The	O
read	O
of	O
this	O
MRI	O
was	O
notable	O
for	O
multiple	O
T2	O
high	O
-	O
signal	O
-	O
intensity	O
abnormalities	O
in	O
the	O
periventricular	O
white	O
matter	O
and	O
centrum	O
semiovale	O
.	O
The	O
findings	O
suggested	O
a	O
demyelinating	O
disorder	O
,	O
or	O
potentially	O
a	O
microvascular	O
angiopathy	O
.	O
There	O
was	O
also	O
an	O
area	O
of	O
abnormality	O
in	O
the	O
left	O
periatrial	O
white	O
matter	O
,	O
which	O
could	O
represent	O
one	O
of	O
these	O
demyelinating	O
areas	O
or	O
could	O
represent	O
a	O
small	O
subacute	O
infarct	O
.	O
The	O
neurology	O
team	O
recommended	O
an	O
LP	O
for	O
routine	O
analysis	O
,	O
oligoclonal	O
bands	O
,	O
and	O
ACE	O
level	O
to	O
evaluate	O
for	O
multiple	O
sclerosis	O
and	O
sarcoidosis	O
;	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
,	O
ANCA	O
,	O
CRP	O
,	O
and	O
ESR	O
levels	O
to	O
evaluate	O
for	O
vasculitis	O
;	O
formal	O
neuropsych	O
evaluation	O
as	O
an	O
outpatient	O
and	O
follow	O
-	O
up	O
in	O
behavioral	O
neurology	O
clinic	O
.	O
The	O
LP	O
was	O
performed	O
prior	O
to	O
discharge	O
,	O
and	O
the	O
bulk	O
of	O
the	O
serologic	O
testing	O
was	O
performed	O
.	O
The	O
patient	O
's	O
PCP	O
will	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
702	O
**	O
]	O
these	O
studies	O
as	O
an	O
outpatient	O
.	O
In	O
addition	O
,	O
the	O
psychiatry	O
team	O
tried	O
to	O
get	O
in	O
touch	O
with	O
her	O
PCP	O
and	O
psychiatrist	O
as	O
an	O
outpatient	O
,	O
but	O
had	O
been	O
thusfar	O
unsucessful	O
at	O
the	O
time	O
of	O
discharge	O
.	O
9	O
)	O
FEN	O
:	O
Patient	O
was	O
tolerating	O
a	O
normal	O
house	O
diet	O
at	O
the	O
time	O
of	O
discharge	O
.	O
10	O
)	O
follow	O
-	O
up	O
:	O
A	O
follow	O
-	O
up	O
appointment	O
was	O
arranged	O
for	O
the	O
patient	O
with	O
her	O
PCP	O
before	O
discharge	O
.	O
She	O
was	O
also	O
given	O
instructions	O
for	O
neurology	O
,	O
behavioral	O
neurology	O
,	O
psychiatry	O
and	O
neuropsychiatric	O
testing	O
follow	O
-	O
up	O
.	O
Finally	O
,	O
she	O
was	O
recommended	O
to	O
have	O
her	O
hematocrit	O
checked	O
the	O
week	O
following	O
discahrge	O
to	O
ensure	O
continued	O
stability	O
.	O
Medications	O
on	O
Admission	O
:	O
Fluoxetine	I-Drug
20	O
mg	O
po	O
QD	O
Lipitor	I-Drug
20	O
mg	O
po	O
QD	O
Klonipin	I-Drug
1	O
mg	O
up	O
to	O
tid	O
prn	O
Anafranil	I-Drug
250	O
mg	O
po	O
QD	O
Actonel	I-Drug
5	O
mg	O
po	O
QD	O
Discharge	O
Medications	O
:	O
1	O
.	O
Fluoxetine	I-Drug
HCl	O
20	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Sucralfate	I-Drug
1	O
g	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Clonazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
4	O
.	O
Clomipramine	I-Drug
HCl	O
50	O
mg	O
Capsule	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Pantoprazole	I-Drug
Sodium	O
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Salmeterol	I-Drug
Xinafoate	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
inhalation	O
Inhalation	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
inhalation	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Albuterol	B-Drug
-	I-Drug
Ipratropium	O
103	O
-	O
18	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
puffs	O
Inhalation	O
four	O
times	O
a	O
day	O
.	O
Disp	O
:	O
*	O
1	O
MDI	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
119	O
**	O
]	O
Homecare	O
Discharge	O
Diagnosis	O
:	O
Gastric	O
and	O
duodenal	O
ulcers	O
Blood	O
loss	O
anemia	O
Depression	O
Reactive	O
Airway	O
Disease	O
Obsessive	O
-	O
Compulsive	O
Disorder	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
*	O
Return	O
to	O
ER	O
or	O
call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
for	O
any	O
stomach	O
pain	O
,	O
coffee	O
-	O
ground	O
vomit	O
,	O
bloody	O
or	O
black	O
stools	O
,	O
lightheadedness	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
*	O
Avoid	O
all	O
NSAIDs	I-Drug
,	O
aspirin	I-Drug
,	O
Excedrin	I-Drug
or	O
any	O
related	O
symptoms	O
.	O
*	O
Try	O
to	O
avoid	O
smoking	O
as	O
this	O
slows	O
the	O
healing	O
of	O
ulcers	O
.	O
*	O
Take	O
all	O
medications	O
as	O
prescribed	O
.	O
*	O
Follow	O
-	O
up	O
with	O
your	O
doctors	O
as	O
recommended	O
.	O
Followup	O
Instructions	O
:	O
1	O
)	O
Follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
within	O
1	O
week	O
for	O
a	O
blood	O
test	O
.	O
You	O
also	O
have	O
an	O
appointment	O
with	O
her	O
Wednesday	O
[	O
**	O
2	O
-	O
14	O
**	O
]	O
at	O
1:15	O
;	O
the	O
results	O
of	O
your	O
lumbar	O
puncture	O
may	O
be	O
available	O
at	O
that	O
time	O
as	O
well	O
.	O
Her	O
office	O
is	O
at	O
One	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Place	O
,	O
and	O
can	O
be	O
reached	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
6712	O
**	O
]	O
.	O
2	O
)	O
Follow	O
-	O
up	O
with	O
your	O
psychiatrist	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
as	O
soon	O
as	O
possible	O
after	O
discharge	O
,	O
within	O
1	O
-	O
2	O
weeks	O
.	O
3	O
)	O
Follow	O
-	O
up	O
with	O
behavioral	O
neurology	O
in	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
weeks	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
17518	O
**	O
]	O
4	O
)	O
Neurology	O
:	O
Follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1274	O
**	O
]	O
in	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
weeks	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
19252	O
**	O
]	O
.	O
5	O
)	O
Neuropsychiatric	O
testing	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
36355	O
**	O
]	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
can	O
help	O
you	O
arrange	O
this	O
as	O
well	O
.	O
Completed	O
by	O
:[	O
**	O
2114-4-1	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2122-10-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2122-10-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2092-9-22	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MED	O
Allergies	O
:	O
Aspirin	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
290	O
**	O
]	O
Chief	O
Complaint	O
:	O
Shortness	O
of	O
Breath	O
Asthma	O
Attack	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
30	O
yo	O
woman	O
with	O
severe	O
asthma	O
since	O
childhood	O
required	O
multiple	O
intubations	O
(	O
>	O
10x	O
,	O
with	O
last	O
one	O
in	O
[	O
**	O
7	O
-	O
28	O
**	O
]	O
)	O
was	O
admitted	O
due	O
to	O
another	O
episode	O
of	O
asthma	B-Reason
attack	I-Reason
.	O
Pt	O
reported	O
that	O
she	O
has	O
been	O
maintained	O
on	O
prednisone	I-Drug
20	O
mg	O
po	O
qod	O
since	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
,	O
she	O
is	O
followed	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
50575	O
**	O
]	O
of	O
pulmonary	O
and	O
her	O
most	O
recent	O
PFT	O
(	O
[	O
**	O
2122-10-4	O
**	O
]	O
)	O
showed	O
worsening	O
dz	O
(	O
FEV1	O
/	O
FVC	O
=	O
45	O
(	O
56	O
%	O
pred	O
)	O
.	O
Pt	O
reported	O
that	O
around	O
11	O
pm	O
last	O
night	O
she	O
had	O
an	O
asthma	O
attack	O
(	O
she	O
has	O
on	O
avg	O
3	O
attacks	O
per	O
wk	O
)	O
.	O
She	O
feels	O
this	O
was	O
precipitated	O
by	O
here	O
walking	O
between	O
the	O
heat	O
of	O
her	O
home	O
and	O
the	O
cold	O
outside	O
mult	O
times	O
.	O
She	O
took	O
nebs	O
and	O
went	O
to	O
bed	O
at	O
1	O
am	O
and	O
woke	O
up	O
at	O
6	O
am	O
wheezing	O
,	O
nebs	O
did	O
n't	O
help	O
,	O
called	O
EMS	O
.	O
She	O
them	O
collapsed	O
and	O
doesnot	O
remember	O
anything	O
until	O
she	O
woke	O
up	O
in	O
the	O
ED	O
.	O
By	O
report	O
of	O
the	O
family	O
and	O
ambulance	O
,	O
the	O
pt	O
given	O
CPR	O
by	O
brother	O
when	O
she	O
stopped	O
breathing	O
.	O
The	O
EMS	O
gave	O
her	O
O2	I-Drug
,	O
nebs	O
a	O
,	O
and	O
.3	O
sc	O
epi	I-Drug
which	O
brought	O
her	O
sats	O
to	O
95	O
%	O
.	O
In	O
the	O
ED	O
(	O
arrived	O
~	O
7	O
am	O
)	O
she	O
was	O
given	O
solumedrol	I-Drug
125	O
mg	O
x	O
1	O
,	O
heliox	I-Drug
mask	O
vent	O
at	O
10L	O
,	O
and	O
cont	O
nebs	O
to	O
maintain	O
sats	O
.	O
Her	O
symptoms	O
slowly	O
improved	O
as	O
the	O
morning	O
progressed	O
.	O
By	O
the	O
time	O
she	O
arrived	O
at	O
the	O
ICU	O
(	O
12	O
pm	O
)	O
she	O
no	O
longer	O
required	O
nebs	O
to	O
maintain	O
sats	O
or	O
avoid	O
SOB	O
.	O
In	O
the	O
past	O
,	O
pt	O
had	O
been	O
on	O
high	O
dose	O
steroid	I-Drug
for	O
[	O
**	O
1	O
-	O
27	O
**	O
]	O
yrs	O
(	O
~	O
80	O
mg	O
prednisone	I-Drug
daily	O
then	O
decadron	I-Drug
4	O
mg	O
daily	O
)	O
which	O
ended	O
[	O
**	O
2	O
-	O
26	O
**	O
]	O
due	O
to	O
pt	O
developed	O
cushingnoid	O
syndrome	O
.	O
After	O
her	O
last	O
hospitalization	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
,	O
her	O
outpt	O
pulmonogist	O
started	O
her	O
on	O
prednisone	I-Drug
20	O
mg	O
qod	O
.	O
Past	O
Medical	O
History	O
:	O
Asthma	O
eczema	O
Fe	O
Def	O
Anemia	O
Nasal	O
Polyps	O
Social	O
History	O
:	O
No	O
ETOH	O
,	O
No	O
Tob	O
,	O
No	O
drugs	O
.	O
Married	O
,	O
lives	O
with	O
huband	O
and	O
brother	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
Health	O
student	O
at	O
BU	O
Family	O
History	O
:	O
Distant	O
relatives	O
have	O
DM	O
,	O
asthma	O
Physical	O
Exam	O
:	O
Admission	O
exam	O
:	O
T	O
98.8	O
P	O
99	O
RR	O
11	O
BP	O
129/86	O
O2	O
91	O
on	O
10L	O
heliox	O
Gen	O
-	O
A+O	O
x3	O
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
1425	O
**	O
]	O
young	O
woman	O
,	O
spleaking	O
in	O
full	O
sentances	O
,	O
no	O
accessory	O
muscles	O
when	O
breathing	O
,	O
HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
OP	O
clear	O
,	O
no	O
icterus	O
,	O
moon	O
face	O
Neck	O
:	O
supple	O
,	O
posterior	O
hump	O
,	O
acanthosis	O
nigricans	O
,	O
no	O
LAD	O
Cor	O
:	O
RRR	O
no	O
m	O
/	O
r	O
/	O
g	O
Chest	O
:	O
diffuse	O
expiratory	O
wheezes	O
,	O
no	O
rales	O
,	O
no	O
ronchi	O
Abd	O
:	O
obese	O
with	O
striae	O
,	O
NT	O
/	O
ND	O
,	O
+	O
BS	O
,	O
no	O
HSM	O
Ext	O
:	O
nl	O
bulk	O
and	O
tone	O
,	O
+2	O
DP	O
bilat	O
,	O
thickened	O
toenails	O
b	O
/	O
l	O
,	O
no	O
c	O
/	O
c	O
/	O
e	O
Pertinent	O
Results	O
:	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
GLUCOSE	O
-	O
192	O
*	O
UREA	O
N	O
-	O
11	O
CREAT	O
-	O
1.0	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
4.7	O
CHLORIDE	O
-	O
100	O
TOTAL	O
CO2	O
-	O
28	O
ANION	O
GAP	O
-	O
17	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
16	O
AST	O
(	O
SGOT	O
)	O
-	O
15	O
CK	O
(	O
CPK	O
)	O
-	O
103	O
ALK	O
PHOS	O
-	O
136	O
*	O
AMYLASE	O
-	O
107	O
*	O
TOT	O
BILI	O
-	O
0.3	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
CK	O
-	O
MB	O
-	O
3	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
ALBUMIN	O
-	O
3.7	O
CALCIUM	O
-	O
8.8	O
PHOSPHATE	O
-	O
6.8	O
*	O
#	O
MAGNESIUM	O
-	O
2.2	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
WBC	O
-	O
20.1	O
*	O
RBC	O
-	O
4.85	O
HGB	O
-	O
14.1	O
HCT	O
-	O
43.0	O
MCV	O
-	O
89	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
32.7	O
RDW	O
-	O
14.9	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
NEUTS	O
-	O
52.7	O
LYMPHS	O
-	O
32.8	O
MONOS	O
-	O
2.9	O
EOS	O
-	O
10.6	O
*	O
BASOS	O
-	O
1.0	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
PLT	O
COUNT	O
-	O
372	O
[	O
**	O
2122-10-21	O
**	O
]	O
07:10	O
AM	O
PT	O
-	O
13.8	O
*	O
PTT	O
-	O
26.9	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
CXR	O
-	O
no	O
CHF	O
<	O
or	O
focal	O
consolidation	O
PFT	O
[	O
**	O
2122-10-4	O
**	O
]	O
(	O
after	O
albuterol	I-Drug
)	O
FVC	O
2.10	O
/	O
71	O
%	O
pred	O
FEV1	O
0.94	O
/	O
40	O
%	O
pred	O
Fev1	O
/	O
FVC	O
45	O
/	O
56	O
%	O
pred	O
imp	O
:	O
marked	O
obstructive	O
vent	O
def	O
since	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
FVC	O
decreased	O
17	O
%	O
,	O
FEV1	O
decreased	O
27	O
%	O
)	O
Brief	O
Hospital	O
Course	O
:	O
30	O
yo	O
F	O
with	O
a	O
hx	O
of	O
severe	O
asthma	O
who	O
presents	O
with	O
an	O
attack	O
.	O
1	O
)	O
Asthma	I-Reason
-	O
The	O
patient	O
is	O
now	O
recovering	O
from	O
her	O
asthma	O
attack	O
.	O
She	O
is	O
no	O
longer	O
requiring	O
freq	O
nebs	O
and	O
was	O
able	O
to	O
avoid	O
intubation	O
.	O
Home	O
asthma	O
meds	O
including	O
theophylline	I-Drug
,	O
montelukast	I-Drug
,	O
fluticasone	I-Drug
,	O
salumedrol	I-Drug
,	O
and	O
were	O
continued	O
.	O
Also	O
the	O
patient	O
was	O
given	O
125	O
methylprednisolone	I-Drug
q8h	O
.	O
She	O
remained	O
stable	O
overnight	O
without	O
any	O
SOB	O
.	O
Pt	O
placed	O
on	O
insulin	I-Drug
SS	O
w	O
/	O
steroids	I-Drug
.	O
In	O
the	O
morning	O
of	O
the	O
day	O
after	O
abmission	O
the	O
pt	O
was	O
felt	O
stable	O
to	O
go	O
home	O
with	O
pulm	O
follow	O
-	O
up	O
.	O
She	O
was	O
switched	O
to	O
a	O
prednisone	I-Drug
taper	O
starting	O
at	O
60	O
mg	O
qday	O
and	O
going	O
to	O
30	O
mg	O
qday	O
.	O
Also	O
she	O
will	O
be	O
started	O
on	O
protonix	I-Drug
to	O
avoid	O
GERD	I-Reason
which	O
may	O
exacerbate	B-Ade
her	I-Ade
asthma	I-Ade
.	O
As	O
an	O
outpt	O
she	O
should	O
be	O
worked	O
up	O
for	O
OSA	O
2	O
)	O
FEN	O
-	O
house	O
diet	O
3	O
)	O
Access	O
-	O
PIV	O
4	O
)	O
Comm	O
-	O
with	O
pt	O
Full	O
Code	O
Medications	O
on	O
Admission	O
:	O
Theophylline	I-Drug
300	O
mg	O
SR	O
[	O
**	O
Hospital1	O
**	O
]	O
Montelukast	I-Drug
10	O
mg	O
qday	O
Albuterol	I-Drug
1	O
-	O
2	O
puffs	O
q4h	O
Fluticasone	I-Drug
2	O
puffs	O
[	O
**	O
Hospital1	O
**	O
]	O
salmeterol	I-Drug
1	O
puff	O
qday	O
albuterol	I-Drug
nebs	O
[	O
**	O
Hospital1	O
**	O
]	O
prednisone	I-Drug
20	O
mg	O
qod	O
Discharge	O
Medications	O
:	O
1	O
.	O
Montelukast	B-Drug
Sodium	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Theophylline	I-Drug
300	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
12	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
12	O
HR	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Capsule	O
,	O
Sust	O
.	O
Release	O
12	O
HR	O
(	O
s	O
)	O
3	O
.	O
Fluticasone	B-Drug
Propionate	I-Drug
110	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Salmeterol	B-Drug
Xinafoate	I-Drug
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
5	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
Five	O
Hundred	O
(	O
500	O
)	O
mcg	O
Inhalation	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	O
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
60	O
vials	O
*	O
Refills	O
:	O
*	O
6	O
*	O
6	O
.	O
Prednisone	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
see	O
comments	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Take	O
3	O
tabs	O
a	O
day	O
for	O
2	O
days	O
.	O
Then	O
take	O
2	O
tabs	O
a	O
day	O
for	O
2	O
days	O
.	O
Then	O
take	O
1	O
and	O
a	O
half	O
tablets	O
a	O
day	O
until	O
your	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Asthma	O
Exacerbation	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
PLease	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
or	O
return	O
to	O
hospital	O
if	O
you	O
have	O
another	O
attack	O
that	O
is	O
not	O
responsive	O
to	O
your	O
nebulizers	O
.	O
Followup	O
Instructions	O
:	O
Primary	O
Care	O
:	O
Please	O
follow	O
up	O
with	O
your	O
PCP	O
or	O
NP	O
as	O
soon	O
as	O
you	O
are	O
discharged	O
.	O
At	O
the	O
time	O
please	O
mention	O
your	O
prolonged	O
steroid	O
use	O
and	O
possible	O
questions	O
regarding	O
diabetes	O
care	O
.	O
Pulmonary	O
:	O
Please	O
f	O
/	O
u	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
5091	O
**	O
]	O
Thursday	O
[	O
**	O
2122-10-29	O
**	O
]	O
2:30	O
pm	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
292	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2139-4-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2139-5-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2071-1-25	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lisinopril	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
290	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
T4	O
bilateral	O
laminotomy	O
,	O
medial	O
facetectomy	O
.	O
2	O
.	O
T5	O
bilateral	O
laminectomy	O
for	O
removal	O
of	O
extradural	O
lesion	O
.	O
3	O
.	O
T6	O
,	O
T7	O
,	O
T8	O
bilateral	O
laminectomy	O
,	O
medial	O
facetectomy	O
,	O
foraminotomy	O
for	O
extradural	O
mass	O
.	O
4	O
.	O
Biopsy	O
of	O
bone	O
and	O
soft	O
tissue	O
,	O
deep	O
,	O
sent	O
to	O
Pathology	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
68	O
yo	O
M	O
w	O
/	O
HTN	O
,	O
DM	O
,	O
CAD	O
s	O
/	O
p	O
CABG	O
,	O
and	O
recently	O
dx	O
metastatic	I-Reason
poorly	O
differentiated	O
adenocarcinoma	O
,	O
unknown	O
primary	O
possibly	O
lung	O
,	O
w	O
/	O
mets	O
to	O
spine	O
,	O
s	O
/	O
p	O
cycle	O
6	O
of	O
carboplatinum	I-Drug
,	O
taxol	I-Drug
(	O
last	O
[	O
**	O
3	O
-	O
13	O
**	O
]	O
)	O
presented	O
cord	O
compression	O
at	O
T6	O
on	O
MRI	O
spine	O
s	O
/	O
p	O
T5	O
-	O
8	O
laminectomy	O
,	O
transferred	O
to	O
MICU	O
for	O
hypotension	O
and	O
fever	O
.	O
.	O
Pt	O
presented	O
[	O
**	O
4	O
-	O
27	O
**	O
]	O
after	O
MRI	O
as	O
outpt	O
"	O
high	O
-	O
grade	O
spinal	O
canal	O
narrowing	O
at	O
T6	O
,	O
and	O
moderate	O
spinal	O
canal	O
narrowing	O
at	O
T8	O
,	O
"	O
that	O
was	O
concerning	O
for	O
cord	O
compression	O
.	O
He	O
was	O
admitted	O
to	O
OMED	O
service	O
,	O
where	O
ortho	O
and	O
rad	O
onc	O
were	O
consulted	O
.	O
He	O
had	O
MRI	O
c	O
-	O
spine	O
that	O
showed	O
mets	O
involving	O
c4	O
-	O
t2	O
.	O
He	O
was	O
taken	O
to	O
the	O
OR	O
for	O
laminectomy	O
of	O
T5	O
-	O
8	O
,	O
medial	O
facetectomy	O
,	O
foraminotomy	O
for	O
extradural	O
mass	O
on	O
[	O
**	O
4	O
-	O
29	O
**	O
]	O
.	O
On	O
POD	O
#	O
2	O
,	O
pt	O
triggered	O
for	O
hypotension	B-Reason
w	I-Reason
/	I-Reason
BP	I-Reason
90/60	I-Reason
.	O
He	O
also	O
spiked	O
a	O
temperature	O
to	O
100.7	O
.	O
He	O
received	O
total	O
2.5	O
L	O
IVFs	I-Drug
,	O
and	O
was	O
started	O
on	O
vanc	I-Drug
and	O
ceftaz	I-Drug
.	O
His	O
BP	O
did	O
not	O
improve	O
and	O
remained	O
80s	O
-	O
90s	O
/	O
40s	O
,	O
w	O
/	O
HR	O
in	O
100s	O
-	O
110s	O
.	O
He	O
got	O
a	O
CTA	O
that	O
did	O
not	O
show	O
evidence	O
of	O
PE	O
.	O
His	O
urine	O
output	O
was	O
recorded	O
as	O
1125	O
.	O
His	O
vac	O
drained	O
15cc	O
and	O
was	O
d	O
/	O
c	O
'd	O
today	O
.	O
.	O
Currently	O
,	O
pt	O
denies	O
lightheadedness	O
,	O
sob	O
,	O
cp	O
,	O
n	O
/	O
v	O
,	O
abdominal	O
pain	O
,	O
dysuria	O
,	O
cough	O
.	O
He	O
has	O
not	O
had	O
a	O
bowel	O
movement	O
for	O
days	O
,	O
but	O
is	O
passing	O
gas	O
.	O
He	O
does	O
endorse	O
some	O
back	O
pain	O
.	O
.	O
Review	O
of	O
systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheezing	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
,	O
or	O
weakness	O
.	O
Denies	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
abdominal	O
pain	O
,	O
or	O
changes	O
in	O
bowel	O
habits	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
.	O
Past	O
Medical	O
History	O
:	O
HTN	O
DM	O
Hypercholesterolemia	O
ASVD	O
proteinuria	O
CABG	O
Wife	O
[	O
**	O
Name	O
(	O
NI	O
)	O
12808	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
is	O
HCP	O
open	O
angle	O
glaucoma	O
Laminectomy	O
on	O
[	O
**	O
2139-4-29	O
**	O
]	O
Social	O
History	O
:	O
Pt	O
married	O
.	O
-	O
Tobacco	O
:	O
former	O
smoker	O
-	O
Alcohol	O
:	O
infrequent	O
-	O
Illicits	O
:	O
denies	O
Family	O
History	O
:	O
Father	O
passed	O
away	O
of	O
MI	O
at	O
60	O
Physical	O
Exam	O
:	O
VS	O
:	O
100.7	O
,	O
92/52	O
,	O
112	O
,	O
22	O
,	O
91	O
%	O
ra	O
Gen	O
:	O
Mild	O
respiratory	O
distress	O
HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
MMM	O
,	O
OP	O
clear	O
Neck	O
:	O
no	O
JVD	O
,	O
no	O
LAD	O
CV	O
:	O
regular	O
rate	O
and	O
rhythm	O
,	O
no	O
murmurs	O
Resp	O
:	O
CTAB	O
,	O
no	O
wheezes	O
or	O
crackles	O
GI	O
:	O
soft	O
NTND	O
no	O
HSM	O
,	O
+	O
BS	O
Ext	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
,	O
+	O
pneumoboots	O
Neuro	O
:	O
CNII	O
-	O
CNXII	O
intact	O
,	O
strength	O
and	O
sensation	O
intact	O
throughout	O
Psych	O
:	O
A&OX	O
3	O
,	O
appropriate	O
BLE	O
:	O
5/5	O
strength	O
L2	O
-	O
S1	O
Pertinent	O
Results	O
:	O
[	O
**	O
2139-4-27	O
**	O
]	O
04:30	O
PM	O
NEUTS	O
-	O
82.3	O
*	O
LYMPHS	O
-	O
9.9	O
*	O
MONOS	O
-	O
7.6	O
EOS	O
-	O
0.1	O
BASOS	O
-	O
0.1	O
[	O
**	O
2139-4-27	O
**	O
]	O
04:30	O
PM	O
NEUTS	O
-	O
82.3	O
*	O
LYMPHS	O
-	O
9.9	O
*	O
MONOS	O
-	O
7.6	O
EOS	O
-	O
0.1	O
BASOS	O
-	O
0.1	O
[	O
**	O
2139-4-27	O
**	O
]	O
04:30	O
PM	O
WBC	O
-	O
7.5	O
RBC	O
-	O
3.38	O
*	O
HGB	O
-	O
9.8	O
*	O
HCT	O
-	O
30.1	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
28.9	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
15.0	O
.	O
[	O
**	O
2139-5-7	O
**	O
]	O
WBC	O
-	O
10.5	O
RBC	O
-	O
2.95	O
*	O
Hgb	O
-	O
8.7	O
*	O
Hct	O
-	O
26.1	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
29.4	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
277	O
Glucose	O
-	O
160	O
*	O
UreaN	O
-	O
58	O
*	O
Creat	O
-	O
1.6	O
*	O
Na	O
-	O
142	O
K	O
-	O
4.7	O
Cl	O
-	O
112	O
*	O
HCO3	O
-	O
20	O
*	O
AnGap	O
-	O
15	O
ALT	O
-	O
35	O
AST	O
-	O
92	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
890	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
252	O
AlkPhos	O
-	O
362	O
*	O
TotBili	O
-	O
0.6	O
Albumin	O
-	O
2.3	O
*	O
Calcium	O
-	O
7.4	O
*	O
Phos	O
-	O
5.0	O
*	O
Mg	O
-	O
2.2	O
.	O
[	O
**	O
5	O
-	O
7	O
**	O
]	O
SINGLE	O
FRONTAL	O
VIEW	O
OF	O
THE	O
CHEST	O
:	O
The	O
endotracheal	O
tube	O
ends	O
at	O
the	O
level	O
of	O
thoracic	O
inlet	O
,	O
approximately	O
7.5	O
cm	O
above	O
the	O
carina	O
.	O
The	O
entire	O
course	O
of	O
the	O
trachea	O
is	O
not	O
well	O
seen	O
.	O
There	O
is	O
a	O
linear	O
lucency	O
along	O
the	O
right	O
aspect	O
of	O
the	O
superior	O
mediastinum	O
which	O
may	O
represent	O
an	O
angulated	O
deviated	O
trachea	O
versus	O
air	O
within	O
the	O
mediastinum	O
.	O
Other	O
linear	O
lucencies	O
within	O
the	O
mediastinum	O
are	O
consistent	O
with	O
pneumomediastinum	O
.	O
Extensive	O
reticular	O
nodular	O
opacities	O
are	O
again	O
seen	O
bilaterally	O
,	O
consistent	O
with	O
known	O
metastatic	O
disease	O
.	O
Cardiomediastinal	O
contours	O
are	O
unchanged	O
.	O
Gaseous	O
dilation	O
of	O
bowel	O
loops	O
are	O
noted	O
.	O
IMPRESSION	O
:	O
Findings	O
concerning	O
for	O
pneumomediastinum	O
.	O
Endotracheal	O
tube	O
ends	O
at	O
the	O
level	O
of	O
thoracic	O
inlet	O
.	O
Recommend	O
further	O
evaluation	O
with	O
chest	O
CT.	O
.	O
[	O
**	O
5	O
-	O
7	O
**	O
]	O
PORTABLE	O
AP	O
CHEST	O
RADIOGRAPH	O
:	O
There	O
is	O
almost	O
complete	O
white	O
out	O
of	O
the	O
left	O
lung	O
,	O
new	O
compared	O
to	O
prior	O
examination	O
.	O
The	O
acute	O
change	O
is	O
concerning	O
for	O
lobar	O
collapse	O
and	O
a	O
large	O
pleural	O
effusion	O
,	O
possible	O
hemothorax	O
.	O
Multiple	O
reticular	O
nodular	O
opacities	O
throughout	O
the	O
remainder	O
of	O
the	O
aerated	O
lung	O
is	O
unchanged	O
.	O
The	O
tip	O
of	O
the	O
endotracheal	O
tube	O
is	O
at	O
the	O
level	O
of	O
the	O
thoracic	O
inlet	O
,	O
unchanged	O
from	O
prior	O
.	O
No	O
other	O
significant	O
change	O
from	O
prior	O
.	O
IMPRESSION	O
:	O
1	O
.	O
New	O
severe	O
white	O
out	O
of	O
the	O
left	O
lung	O
,	O
probably	O
collapse	O
and	O
large	O
pleural	O
effusion	O
,	O
possible	O
hemothorax	O
.	O
2	O
.	O
Endotracheal	O
tube	O
at	O
thoracic	O
inlet	O
,	O
unchanged	O
.	O
3	O
.	O
Stable	O
reticular	O
nodular	O
opacities	O
in	O
the	O
right	O
lung	O
.	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
initially	O
admitted	O
to	O
the	O
Oncology	O
service	O
and	O
evaluated	O
by	O
the	O
Ortho	O
spine	O
team	O
.	O
He	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
Spine	O
Surgery	O
Service	O
and	O
taken	O
to	O
the	O
Operating	O
Room	O
for	O
the	O
above	O
procedure	O
without	O
complication	O
.	O
For	O
details	O
please	O
refer	O
to	O
the	O
dictated	O
operative	O
note	O
.	O
TEDs	O
/	O
pneumoboots	O
were	O
used	O
for	O
postoperative	O
DVT	O
prophylaxis	O
.	O
Intravenous	O
antibiotics	I-Drug
were	O
continued	O
for	O
24	O
hrs	O
postoperatively	O
per	O
standard	O
protocol	O
.	O
The	B-Reason
patient	I-Reason
's	I-Reason
pain	I-Reason
was	O
controlled	O
with	O
IV	O
pain	B-Drug
medications	I-Drug
followed	O
by	O
oral	O
analgesics	I-Drug
once	O
tolerating	O
POs	O
.	O
The	O
patient	O
's	O
diet	O
was	O
advanced	O
as	O
tolerated	O
.	O
The	O
foley	O
was	O
removed	O
on	O
POD2	O
.	O
Physical	O
therapy	O
was	O
consulted	O
for	O
mobilization	O
.	O
.	O
On	O
POD2	O
the	O
patient	O
was	O
noted	O
to	O
have	O
hypotension	O
to	O
SBPs	O
90's	O
associated	O
with	O
tachycardia	O
to	O
110	O
's	O
and	O
hypoxia	O
90's	O
on	O
RA	O
and	O
a	O
low	O
grade	O
fever	O
.	O
At	O
CT	O
chest	O
was	O
negative	O
for	O
PE	O
.	O
He	O
was	O
transferred	O
to	O
the	O
ICU	O
for	O
closer	O
monitoring	O
given	O
his	O
metastatic	O
CA	O
history	O
and	O
started	O
on	O
empiric	O
IV	O
antibiotics	I-Drug
.	O
He	O
was	O
stable	O
in	O
the	O
ICU	O
and	O
improved	O
with	O
IVF	O
and	O
transferred	O
out	O
to	O
the	O
floor	O
.	O
.	O
On	O
the	O
floor	O
,	O
the	O
pt	O
was	O
persistently	O
febrile	O
,	O
although	O
his	O
fever	O
curve	O
was	O
trending	O
downwards	O
by	O
abx	I-Drug
day	O
6	O
.	O
The	O
plan	O
was	O
to	O
continue	O
an	O
8	O
day	O
empiric	O
course	O
of	O
vanc	I-Drug
/	O
ceftazidime	I-Drug
,	O
although	O
Cx	O
were	O
all	O
negative	O
and	O
even	O
CT	O
torso	O
failed	O
to	O
reveal	O
a	O
source	O
.	O
Pain	O
control	O
became	O
an	O
issue	O
,	O
particularly	O
left	O
shoulder	O
pain	O
.	O
Pt	O
is	O
known	O
to	O
have	O
metastatic	O
disease	O
.	O
He	O
required	O
enough	O
short	O
-	O
acting	O
pain	O
morphine	I-Drug
to	O
warrant	O
starting	O
MS	B-Drug
Contin	I-Drug
,	O
which	O
was	O
uptitrated	O
.	O
However	O
,	O
pt	O
became	O
more	O
somnolent	I-Ade
,	O
but	O
still	O
complained	O
of	O
pain	O
when	O
he	O
was	O
awoke	O
.	O
He	O
had	O
episodes	O
of	O
hypotension	O
to	O
the	O
80s	O
requiring	O
boluses	O
.	O
He	O
ultimately	O
was	O
given	O
Narcan	I-Drug
for	O
his	O
somnolence	I-Reason
.	O
He	O
woke	O
immediately	O
,	O
but	O
began	O
to	O
complain	O
of	O
chest	O
tightness	O
.	O
He	O
was	O
suctioned	O
deeply	O
for	O
suspected	O
mucous	O
plug	O
,	O
but	O
was	O
intermittently	O
desaturating	O
,	O
even	O
on	O
6L	O
NC	O
.	O
He	O
was	O
transferred	O
to	O
the	O
MICU	O
,	O
where	O
he	O
was	O
intubated	O
immediately	O
as	O
was	O
unresponsive	O
and	O
unable	O
to	O
protect	O
his	O
airway	O
.	O
.	O
=====================	O
[	O
**	O
Hospital	O
Unit	O
Name	O
13533	O
**	O
]	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
26511	O
**	O
]	O
=====================	O
.	O
#	O
Acute	O
Hypoxic	O
Respiratory	O
Failure	O
:	O
Initial	O
ABG	O
revealed	O
significant	O
hypercapnia	I-Ade
in	O
setting	O
of	O
narcotics	I-Drug
and	O
altered	I-Ade
mental	O
status	O
,	O
so	O
hypoxic	O
respiratory	O
failure	O
was	O
initially	O
attributed	O
to	O
hypoventilation	I-Ade
.	O
As	O
stated	O
above	O
,	O
he	O
was	O
immediately	O
intubated	O
upon	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
and	O
continued	O
on	O
broad	B-Drug
antibiotics	I-Drug
.	O
He	O
remained	O
on	O
mechanical	O
ventilation	O
.	O
It	O
was	O
then	O
noticed	O
that	O
his	O
endotracheal	O
tube	O
appeared	O
high	O
.	O
On	O
bronchoscopy	O
a	O
new	O
necrotic	O
obstructing	O
mass	O
was	O
noticed	O
in	O
his	O
airway	O
causing	O
tracheal	O
deviation	O
.	O
It	O
was	O
unlikely	O
to	O
be	O
procedure	O
-	O
related	O
trauma	O
,	O
given	O
appearance	O
of	O
the	O
obstruction	O
.	O
Most	O
likely	O
the	O
patient	O
experienced	O
an	O
acute	O
bleed	O
of	O
a	O
necrotic	O
tumor	O
,	O
which	O
compressed	O
his	O
airway	O
and	O
led	O
to	O
inability	O
to	O
provide	O
adequate	O
mechanical	O
ventilation	O
.	O
This	O
ultimately	O
led	O
to	O
his	O
expiration	O
.	O
.	O
#	O
Hypotension	O
:	O
On	O
the	O
evening	O
of	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
the	O
patient	O
began	O
to	O
experience	O
labile	O
blood	O
pressures	O
,	O
dropping	O
to	O
the	O
80s	O
systolic	O
while	O
sleeping	O
and	O
climbing	O
to	O
the	O
140s	O
systolic	O
when	O
awakened	O
.	O
He	O
was	O
given	O
two	O
1L	O
NS	I-Drug
fluid	O
boluses	O
without	O
change	O
in	O
his	O
hemodynamics	O
.	O
Transient	B-Ade
hypotension	I-Ade
was	O
initially	O
attributed	O
to	O
the	O
use	O
of	O
Propofol	I-Drug
for	O
sedation	I-Reason
(	O
subsequently	O
changed	O
to	O
Fentanyl	I-Drug
/	O
Midazolam	I-Drug
)	O
and	O
perhaps	O
large	O
amounts	O
of	O
pain	B-Drug
medication	I-Drug
that	O
were	O
slow	O
to	O
clear	O
secondary	O
to	O
impaired	O
liver	O
and	O
renal	O
function	O
.	O
He	O
was	O
started	O
on	O
peripheral	O
dopamine	I-Drug
for	O
pressure	I-Reason
support	O
.	O
.	O
#	O
Acute	O
Kidney	O
Injury	O
:	O
Thought	O
likely	O
secondary	O
to	O
Contrast	O
Nephropathy	O
based	O
on	O
timing	O
and	O
urine	O
electrolytes	O
.	O
He	O
continued	O
to	O
have	O
adequate	O
urine	O
output	O
and	O
his	O
Creatinine	O
trended	O
down	O
.	O
.	O
#	O
Metastatic	B-Reason
Adenocarcinoma	I-Reason
:	I-Reason
Suspected	I-Reason
lung	I-Reason
primary	I-Reason
and	I-Reason
known	I-Reason
bony	O
and	O
liver	O
mets	O
.	O
The	O
patient	O
had	O
undergone	O
6	O
cycles	O
of	O
taxol	I-Drug
/	O
carboplatin	I-Drug
.	O
He	O
also	O
underwent	O
a	O
T5	O
-	O
8	O
laminectomy	O
for	O
suspected	O
cord	O
compression	O
secondary	O
to	O
a	O
spinal	O
met	O
on	O
[	O
**	O
4	O
-	O
29	O
**	O
]	O
.	O
He	O
suffered	O
tremendous	O
pain	I-Reason
from	O
his	O
extensive	O
disease	O
,	O
which	O
was	O
controlled	O
with	O
Fentanyl	I-Drug
boluses	O
in	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
.	O
.	O
#	O
Coronary	O
Artery	O
Disease	O
:	O
EKGs	O
obtained	O
were	O
consistent	O
with	O
prior	O
and	O
showed	O
no	O
evidence	O
of	O
acute	O
ischemia	O
.	O
He	O
was	O
ruled	O
out	O
for	O
myocardial	O
infarction	O
with	O
two	O
negative	O
sets	O
of	O
cardiac	O
biomarkers	O
.	O
.	O
#	O
Diabetes	O
Mellitus	O
:	O
On	O
oral	O
anti-hyperglycemics	O
at	O
home	O
,	O
which	O
were	O
held	O
.	O
Fingersticks	O
were	O
checked	O
q6h	O
and	O
insulin	I-Drug
provided	O
as	O
needed	O
.	O
.	O
#	O
Anemia	O
:	O
Likely	O
secondary	O
to	O
chronic	O
inflammation	O
from	O
underlying	O
malignancy	O
.	O
Hct	O
remained	O
stable	O
.	O
Medications	O
on	O
Admission	O
:	O
Betimol	I-Drug
0.5	O
%	O
Eye	O
Drops	O
one	O
drop	O
in	O
each	O
eye	O
daily	O
Xalatan	I-Drug
0.005	O
%	O
Eye	O
Drops	O
one	O
drop	O
in	O
each	O
eye	O
at	O
bedtime	O
Lipitor	I-Drug
80	O
mg	O
Tab	O
one	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
in	O
the	O
evening	O
Fish	B-Drug
Oil	I-Drug
1,000	O
mg	O
Cap	O
?	O
frequency	O
Aspirin	I-Drug
325	O
mg	O
Tab	O
one	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
.	O
Metformin	I-Drug
1,000	O
mg	O
Tab	O
one	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Discharge	O
Medications	O
:	O
not	O
applicable	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
-	O
Expired	O
-	O
Metastatic	O
Adenocarcinoma	O
-	O
Respiratory	O
Failure	O
-	O
Hypotension	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
not	O
applicable	O
;	O
patient	O
expired	O
Followup	O
Instructions	O
:	O
not	O
applicable	O
;	O
patient	O
expired	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
292	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2156-1-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2156-1-16	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2090-3-14	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2485	O
**	O
]	O
Chief	O
Complaint	O
:	O
dehydration	O
and	O
?	O
pneumonia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
65	O
year	O
old	O
man	O
with	O
atrial	O
fibrillation	O
and	O
hypothyroidism	O
,	O
who	O
was	O
diagnosed	O
with	O
squamous	B-Reason
cell	I-Reason
CA	I-Reason
of	I-Reason
the	I-Reason
tongue	O
in	O
[	O
**	O
2153	O
**	O
]	O
,	O
s	O
/	O
p	O
chemo	I-Drug
and	O
radiation	O
.	O
Recently	O
,	O
he	O
has	O
biopsy	O
proven	O
mets	O
in	O
the	O
sternum	O
and	O
T3	O
-	O
T7	O
.	O
He	O
presented	O
to	O
clinic	O
on	O
[	O
**	O
2156-1-8	O
**	O
]	O
for	O
evaluation	O
and	O
he	O
was	O
found	O
to	O
be	O
hypoxic	O
and	O
dehydrated	O
.	O
He	O
notes	O
that	O
approximately	O
3	O
weeks	O
ago	O
he	O
presented	O
to	O
his	O
doctor	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
151	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
7186	O
**	O
]	O
of	O
breath	O
and	O
was	O
diagnosed	O
with	O
pneumonia	I-Reason
and	O
given	O
a	O
Z	B-Drug
-	I-Drug
pack	O
.	O
He	O
improved	O
after	O
that	O
but	O
then	O
again	O
felt	O
worse	O
and	O
was	O
given	O
another	O
Z	B-Drug
-	I-Drug
pack	O
.	O
In	O
the	O
last	O
week	O
he	O
has	O
felt	O
progressively	O
short	O
of	O
breath	O
and	O
has	O
been	O
staying	O
on	O
the	O
couch	O
.	O
He	O
denies	O
fever	O
,	O
but	O
says	O
he	O
has	O
sweats	O
on	O
most	O
days	O
.	O
Also	O
denies	O
cough	O
,	O
occasional	O
chest	O
pain	O
,	O
some	O
swelling	O
in	O
his	O
ankles	O
,	O
no	O
blurry	O
vision	O
,	O
confusion	O
.	O
Also	O
,	O
he	O
over	O
the	O
past	O
6	O
months	O
he	O
has	O
had	O
progressive	O
poor	O
appetite	O
he	O
has	O
lost	O
some	O
weight	O
.	O
Otherwise	O
,	O
he	O
complains	O
of	O
xerostomia	O
and	O
difficulty	O
in	O
swallowing	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Squamous	B-Reason
cell	I-Reason
CA	I-Reason
of	I-Reason
the	I-Reason
tongue	I-Reason
:	O
dx	O
[	O
**	O
3	O
-	O
16	O
**	O
]	O
;	O
stage	O
3	O
-	O
4	O
;	O
started	O
cisplatin	I-Drug
and	O
radiation	O
therapy	O
on	O
[	O
**	O
2154-5-27	O
**	O
]	O
-	O
CAD	O
:	O
s	O
/	O
p	O
CABG	O
2	O
vessels	O
in	O
[	O
**	O
2143	O
**	O
]	O
and	O
[	O
**	O
2146	O
**	O
]	O
;	O
NSTEMI	O
in	O
[	O
**	O
3	O
-	O
15	O
**	O
]	O
s	O
/	O
p	O
cardiac	O
catheterization	O
.	O
-	O
CHF	O
:	O
echo	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
w	O
/	O
moderate	O
regional	O
left	O
LV	O
systolic	O
dysfunction	O
with	O
near	O
akinesis	O
of	O
the	O
basal	O
inferior	O
and	O
inferolateral	O
walls	O
,	O
LVEF	O
35	O
%	O
,	O
1	O
+	O
MR.	O
-	O
Atrial	O
fibrillation	O
:	O
s	O
/	O
p	O
DCCV	O
in	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
w	O
/	O
subsequent	O
reversion	O
to	O
AF	O
.	O
-	O
ICD	O
:	O
placed	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
-	O
Hypertension	O
-	O
Hyperlipidemia	O
-	O
Depression	O
Social	O
History	O
:	O
He	O
is	O
a	O
retired	O
salesman	O
who	O
lives	O
with	O
his	O
long	O
-	O
term	O
partner	O
named	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
for	O
30	O
years	O
.	O
He	O
has	O
no	O
children	O
.	O
He	O
smoked	O
greater	O
than	O
30	O
years	O
but	O
quit	O
recently	O
.	O
No	O
alcohol	O
or	O
IV	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
with	O
h	O
/	O
o	O
CAD	O
.	O
Physical	O
Exam	O
:	O
T	O
:	O
97.6	O
BP	O
:	O
129/78	O
RR	O
:	O
24	O
HR	O
:	O
76	O
02:96	O
%	O
on	O
2L	O
Gen	O
:	O
Cachectic	O
male	O
,	O
NAD	O
HEENT	O
:	O
anicteric	O
,	O
EOMI	O
,	O
PERRL	O
,	O
dry	O
mucosa	O
with	O
breakdown	O
of	O
the	O
mucosa	O
.	O
Neck	O
:	O
left	O
sided	O
fullness	O
,	O
palpaple	O
fibrosis	O
.	O
CV	O
:	O
RRR	O
Pulm	O
:	O
Diffuse	O
expiratory	O
wheezing	O
,	O
bilateral	O
crackles	O
at	O
the	O
bases	O
.	O
Abd	O
:	O
soft	O
,	O
non	O
tender	O
,	O
BS	O
+	O
.	O
Ext	O
:	O
1	O
+	O
non-pitting	O
edema	O
.	O
Neuro	O
:	O
Alert	O
and	O
oriented	O
x3	O
,	O
CN	O
2	O
-	O
12	O
intact	O
,	O
strength	O
5/5	O
bilateral	O
and	O
symmetric	O
lower	O
and	O
upper	O
extremities	O
.	O
Pertinent	O
Results	O
:	O
On	O
Admission	O
:	O
[	O
**	O
2156-1-8	O
**	O
]	O
03:35	O
PM	O
BLOOD	O
WBC	O
-	O
18.5	O
*	O
#	O
RBC	O
-	O
4.90	O
Hgb	O
-	O
11.5	O
*	O
Hct	O
-	O
35.9	O
*	O
MCV	O
-	O
73	O
*	O
MCH	O
-	O
23.4	O
*	O
MCHC	O
-	O
32.0	O
RDW	O
-	O
15.3	O
Plt	O
Ct	O
-	O
501	O
*	O
[	O
**	O
2156-1-8	O
**	O
]	O
03:35	O
PM	O
BLOOD	O
PT	O
-	O
22.1	O
*	O
PTT	O
-	O
28.6	O
INR	O
(	O
PT	O
)	O
-	O
2.1	O
*	O
[	O
**	O
2156-1-8	O
**	O
]	O
03:35	O
PM	O
BLOOD	O
Glucose	O
-	O
82	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.5	O
Na	O
-	O
138	O
K	O
-	O
4.4	O
Cl	O
-	O
99	O
HCO3	O
-	O
31	O
AnGap	O
-	O
12	O
[	O
**	O
2156-1-8	O
**	O
]	O
03:35	O
PM	O
BLOOD	O
proBNP	O
-	O
3557	O
*	O
[	O
**	O
2156-1-8	O
**	O
]	O
03:35	O
PM	O
BLOOD	O
Albumin	O
-	O
3.3	O
*	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
3.6	O
Mg	O
-	O
2.2	O
On	O
Day	O
of	O
Demise	O
:	O
[	O
**	O
2156-1-16	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
WBC	O
-	O
14.8	O
*	O
RBC	O
-	O
3.75	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
28.9	O
*	O
MCV	O
-	O
77	O
*	O
MCH	O
-	O
24.0	O
*	O
MCHC	O
-	O
31.1	O
RDW	O
-	O
15.5	O
Plt	O
Ct	O
-	O
405	O
[	O
**	O
2156-1-16	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
PT	O
-	O
42.3	O
*	O
PTT	O
-	O
30.2	O
INR	O
(	O
PT	O
)	O
-	O
4.6	O
*	O
[	O
**	O
2156-1-16	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
Glucose	O
-	O
108	O
*	O
UreaN	O
-	O
11	O
Creat	O
-	O
0.4	O
*	O
Na	O
-	O
145	O
K	O
-	O
3.5	O
Cl	O
-	O
105	O
HCO3	O
-	O
37	O
*	O
AnGap	O
-	O
7	O
*	O
[	O
**	O
2156-1-16	O
**	O
]	O
04:05	O
AM	O
BLOOD	O
ALT	O
-	O
15	O
AST	O
-	O
24	O
LD	O
(	O
LDH	O
)	O
-	O
319	O
*	O
AlkPhos	O
-	O
155	O
*	O
TotBili	O
-	O
0	O
.	O
CT	O
Imaging	O
:	O
----------	O
CT	O
Chest	O
[	O
**	O
2156-1-9	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Multifocal	O
bilateral	O
air	O
space	O
opacities	O
most	O
consistent	O
with	O
acute	O
infection	O
.	O
2	O
.	O
New	O
moderate	O
left	O
pleural	O
effusion	O
.	O
3	O
.	O
Increase	O
in	O
size	O
of	O
several	O
mediastinal	O
lymph	O
nodes	O
may	O
rleate	O
to	O
infection	O
,	O
though	O
attention	O
is	O
recommended	O
on	O
follow	O
-	O
up	O
.	O
Attention	O
should	O
also	O
be	O
again	O
paid	O
to	O
the	O
unchnanged	O
right	O
lower	O
lobe	O
nodule	O
.	O
4	O
.	O
Progression	O
of	O
thoracic	O
spine	O
osseous	O
metastases	O
.	O
CT	O
Head	O
[	O
**	O
2156-1-15	O
**	O
]	O
:	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
hemorrhage	O
,	O
mass	O
effect	O
,	O
midline	O
shift	O
or	O
other	O
acute	O
abnormalities	O
.	O
No	O
evidence	O
of	O
enhancing	O
brain	O
lesions	O
.	O
No	O
significant	O
change	O
on	O
the	O
pre-contrast	O
images	O
compared	O
to	O
[	O
**	O
2154-8-5	O
**	O
]	O
.	O
CXR	O
[	O
**	O
2156-1-16	O
**	O
]	O
:	O
Since	O
yesterday	O
,	O
all	O
tubes	O
and	O
catheters	O
are	O
in	O
unchanged	O
position	O
.	O
Right	O
upper	O
lobe	O
opacity	O
persists	O
,	O
likely	O
due	O
to	O
aspiration	O
.	O
Left	O
lower	O
lobe	O
opacity	O
increased	O
,	O
could	O
be	O
due	O
to	O
worsening	O
atelectasis	O
or	O
superimposed	O
aspiration	O
.	O
Left	O
pleural	O
effusion	O
also	O
increased	O
.	O
There	O
is	O
no	O
other	O
overallchange	O
.	O
Micro	O
and	O
Path	O
:	O
------------------	O
Legionella	O
Urinary	O
antigen	O
[	O
**	O
2156-1-11	O
**	O
]	O
:	O
Negative	O
BAL	O
[	O
**	O
2156-1-12	O
**	O
]	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2156-1-12	O
**	O
]	O
)	O
:	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Final	O
[	O
**	O
2156-1-14	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
,	O
<	O
1000	O
CFU	O
/	O
ml	O
.	O
LEGIONELLA	O
CULTURE	O
(	O
Final	O
[	O
**	O
2156-1-19	O
**	O
]	O
)	O
:	O
NO	O
LEGIONELLA	O
ISOLATED	O
.	O
POTASSIUM	O
HYDROXIDE	O
PREPARATION	O
(	O
Final	O
[	O
**	O
2156-1-13	O
**	O
]	O
)	O
:	O
Test	O
cancelled	O
by	O
laboratory	O
.	O
PATIENT	O
CREDITED	O
.	O
This	O
is	O
a	O
low	O
yield	O
procedure	O
based	O
on	O
our	O
in	O
-	O
house	O
studies	O
.	O
if	O
pulmonary	O
Histoplasmosis	O
,	O
Coccidioidomycosis	O
,	O
Blastomycosis	O
,	O
Aspergillosis	O
or	O
Mucormycosis	O
is	O
strongly	O
suspected	O
,	O
contact	O
the	O
Microbiology	O
Laboratory	O
(	O
7	O
-	O
2306	O
)	O
.	O
Immunoflourescent	O
test	O
for	O
Pneumocystis	O
jirovecii	O
(	O
carinii	O
)	O
(	O
Final	O
[	O
**	O
2156-1-13	O
**	O
]	O
)	O
:	O
NEGATIVE	O
for	O
Pneumocystis	O
jirovecii	O
(	O
carinii	O
)	O
.	O
.	O
FUNGAL	O
CULTURE	O
(	O
Final	O
[	O
**	O
2156-1-25	O
**	O
]	O
)	O
:	O
NO	O
FUNGUS	O
ISOLATED	O
.	O
NOCARDIA	O
CULTURE	O
(	O
Final	O
[	O
**	O
2156-2-1	O
**	O
]	O
)	O
:	O
NO	O
NOCARDIA	O
ISOLATED	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2156-1-13	O
**	O
]	O
)	O
:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
CONCENTRATED	O
SMEAR	O
.	O
Pleural	O
fluid	O
(	O
[	O
**	O
2156-1-13	O
**	O
]	O
)	O
:	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2156-1-13	O
**	O
]	O
)	O
:	O
4	O
+	O
(	O
>	O
10	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
This	O
is	O
a	O
concentrated	O
smear	O
made	O
by	O
cytospin	O
method	O
,	O
please	O
refer	O
to	O
hematology	O
for	O
a	O
quantitative	O
white	O
blood	O
cell	O
count	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
65	O
year	O
old	O
male	O
with	O
squamous	O
cell	O
CA	O
of	O
tongue	O
,	O
with	O
recurrent	O
disease	O
and	O
evidence	O
of	O
metastases	O
and	O
recent	O
spread	O
to	O
spine	O
who	O
presented	O
with	O
worsnening	O
dyspnea	O
on	O
exertion	O
and	O
weight	O
loss	O
.	O
The	O
patient	O
's	O
chief	O
reason	O
for	O
presenting	O
to	O
the	O
ICU	O
was	O
multifactorial	O
hypoxia	O
due	O
to	O
his	O
COPD	O
,	O
CHF	O
,	O
pleural	O
effusion	O
and	O
probable	O
aspiration	O
pneumonia	O
/	O
pneumonitis	O
.	O
On	O
presentation	O
he	O
was	O
started	O
on	O
levofloxacin	I-Drug
for	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
Nevertheless	O
he	O
continued	O
to	O
have	O
worsening	O
of	O
his	O
dyspnea	O
and	O
sputum	O
production	O
and	O
during	O
the	O
day	O
of	O
[	O
**	O
2156-1-11	O
**	O
]	O
he	O
was	O
noted	O
to	O
be	O
increasingly	O
hypoxic	I-Reason
and	O
his	O
oxygen	I-Drug
saturations	O
were	O
dropping	O
to	O
the	O
80's	O
on	O
6L	O
NC	O
.	O
He	O
was	O
switched	O
to	O
100	O
%	O
NRB	O
and	O
maintained	O
sats	O
in	O
the	O
90's	O
on	O
that	O
but	O
appeared	O
to	O
be	O
tiring	O
and	O
was	O
transferred	O
to	O
the	O
ICU	O
on	O
[	O
**	O
2156-1-11	O
**	O
]	O
.	O
At	O
that	O
point	O
a	O
blood	O
gas	O
revealed	O
profound	O
respiratory	O
acidosis	O
and	O
he	O
was	O
then	O
intubated	O
for	O
ventilatory	O
failure	O
.	O
The	O
patient	O
has	O
treated	O
with	O
vancomycin	I-Drug
,	O
cefepime	I-Drug
,	O
metronidazole	I-Drug
for	O
aspiration	I-Reason
/	O
HAP	I-Reason
and	O
was	O
gently	O
diuresed	O
.	O
No	O
microbiologic	O
diagnosis	O
of	O
the	O
patient	O
's	O
pneumonia	O
was	O
ever	O
made	O
and	O
despite	O
BAL	O
no	O
organisms	O
were	O
ever	O
isolated	O
.	O
On	O
[	O
**	O
2156-1-13	O
**	O
]	O
a	O
thoracentesis	O
was	O
performed	O
to	O
evaluate	O
for	O
complicated	O
effusion	O
and	O
this	O
showed	O
sterile	O
inflammatory	O
fluid	O
consistent	O
with	O
parapneumonic	O
effusion	O
.	O
The	O
patient	O
did	O
improve	O
somewhat	O
allowing	O
some	O
weaning	O
of	O
ventilatory	O
settings	O
and	O
acutally	O
self	O
extubated	O
on	O
[	O
**	O
2156-1-14	O
**	O
]	O
.	O
Unfortunately	O
,	O
after	O
extubation	O
mental	O
status	O
remained	O
poor	O
and	O
the	O
patient	O
became	O
progressively	O
more	O
hypercarbic	O
requiring	O
reintubation	O
on	O
[	O
**	O
2156-1-15	O
**	O
]	O
.	O
On	O
the	O
morning	O
of	O
[	O
**	O
2156-1-16	O
**	O
]	O
NIF	O
was	O
checked	O
and	O
was	O
less	O
than	O
30	O
suggesting	O
generalized	O
muscle	O
weakness	O
and	O
high	O
likelihood	O
of	O
ventilatory	O
failure	O
if	O
extubated	O
.	O
With	O
this	O
information	O
,	O
and	O
given	O
the	O
patient	O
had	O
been	O
reluctant	O
to	O
undergo	O
chemotherapy	I-Drug
in	O
the	O
first	O
place	O
and	O
had	O
expressed	O
a	O
desire	O
to	O
not	O
be	O
permanently	O
sustained	O
on	O
artificial	O
means	O
,	O
his	O
husband	O
and	O
family	O
decided	O
to	O
terminally	O
extubate	O
the	O
patient	O
and	O
make	O
him	O
comfortable	O
.	O
He	O
was	O
extubated	O
on	O
the	O
evening	O
of	O
[	O
**	O
2156-1-16	O
**	O
]	O
and	O
gradually	O
became	O
more	O
hypoxic	O
before	O
expiring	O
of	O
respiratory	O
failure	O
.	O
His	O
husband	O
declined	O
autopsy	O
.	O
Medications	O
on	O
Admission	O
:	O
#	O
Maalox	B-Drug
/	I-Drug
Diphenhydramine	I-Drug
/	I-Drug
Lidocaine	O
15	O
-	O
30	O
mL	O
PO	O
15	O
MINUTES	O
BEFORE	O
MEALS	O
AS	O
NEEDED	O
FOR	O
MOUTH	B-Reason
PAIN	I-Reason
#	O
Metoprolol	I-Drug
Succinate	O
XL	O
200	O
mg	O
PO	O
DAILY	O
Please	O
hold	O
for	O
SBP	O
<	O
100	O
or	O
HR	O
<	O
60	O
Order	O
date	O
:	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
@	O
1421	O
#	O
Albuterol	I-Drug
0.083	O
%	O
inhaled	O
Q4H	O
:	O
PRN	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
7186	O
**	O
]	O
of	O
breath	O
#	O
Omeprazole	B-Drug
20	O
mg	O
PO	O
DAILY	O
#	O
Amiodarone	I-Drug
200	O
mg	O
PO	O
DAILY	O
#	O
OxycoDONE	I-Drug
(	O
Immediate	O
Release	O
)	O
10	O
mg	O
PO	O
Q3H	O
:	O
PRN	O
#	O
Digoxin	I-Drug
0.25	O
mg	O
PO	O
DAILY	O
#	O
Furosemide	I-Drug
20	O
mg	O
PO	O
BID	O
#	O
Simvastatin	I-Drug
40	O
mg	O
PO	O
DAILY	O
#	O
Heparin	I-Drug
5000	O
UNIT	O
SC	O
TID	O
#	O
Venlafaxine	I-Drug
200	O
mg	O
PO	O
QAM	O
#	O
Venlafaxine	B-Drug
100	O
mg	O
PO	O
QPM	O
#	O
Isosorbide	B-Drug
Dinitrate	I-Drug
10	O
mg	O
PO	O
TID	O
#	O
Warfarin	I-Drug
7.5	O
mg	O
PO	O
DAYS	O
(	O
MO	O
,	O
TH	O
)	O
Warfarin	I-Drug
5	O
mg	O
PO	O
DAYS	O
(	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
,	O
TU	O
,	O
WE	O
,	O
FR	O
,	O
SA	O
)	O
#	O
Levothyroxine	B-Drug
Sodium	I-Drug
50	O
mcg	O
Order	O
date	O
:	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
@	O
1602	O
#	O
Lisinopril	I-Drug
20	O
mg	O
PO	O
Discharge	O
Medications	O
:	O
Patient	O
expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
Squamous	O
Cell	O
cancer	O
of	O
the	O
head	O
and	O
neck	O
with	O
T	O
-	O
spine	O
involvement	O
Acute	O
Systolic	O
heart	O
failure	O
Deconditioning	O
Dehydration	O
Aspiration	O
pneumonia	O
Hypertension	O
CAD	O
s	O
/	O
p	O
CABGx2	O
Atrial	O
Fibrillation	O
Discharge	O
Condition	O
:	O
Patient	O
expired	O

Admission	O
Date	O
:	O
[	O
**	O
2163-4-20	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2163-5-16	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2092-1-17	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1283	O
**	O
]	O
Chief	O
Complaint	O
:	O
Progressive	O
dyspnea	O
on	O
exertion	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Coronary	O
artery	O
bypass	O
graft	O
x	O
3	O
[	O
**	O
2163-4-22	O
**	O
]	O
.	O
Sternal	O
rewiring	O
[	O
**	O
2163-5-2	O
**	O
]	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
71	O
yo	O
male	O
patient	O
with	O
known	O
history	O
coronary	O
artery	O
disease	O
who	O
was	O
previously	O
turned	O
down	O
for	O
a	O
CABG	O
in	O
[	O
**	O
2143	O
**	O
]	O
due	O
to	O
obesity	O
and	O
was	O
lost	O
to	O
follow	O
-	O
up	O
.	O
He	O
presented	O
recently	O
with	O
complaints	O
of	O
worsening	O
shortness	O
of	O
breath	O
with	O
exertion	O
and	O
was	O
referred	O
for	O
cath	O
showing	O
3VD	O
.	O
At	O
that	O
time	O
he	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
eval	O
for	O
CABG	O
.	O
Past	O
Medical	O
History	O
:	O
Coronary	O
artery	O
disease	O
.	O
Hypertension	O
.	O
Hyperlipidemia	O
.	O
CVA	O
in	O
[	O
**	O
2148	O
**	O
]	O
.	O
Social	O
History	O
:	O
Lives	O
in	O
[	O
**	O
Hospital1	O
10478	O
**	O
]	O
with	O
his	O
wife	O
.	O
Retired	O
engineer	O
.	O
Not	O
very	O
active	O
secondary	O
to	O
severe	O
shortness	O
of	O
breath	O
.	O
Reports	O
that	O
he	O
quit	O
smoking	O
45	O
years	O
ago	O
afetr	O
a	O
415	O
pack	O
year	O
history	O
.	O
Reports	O
very	O
rare	O
ETOH	O
consumption	O
.	O
Family	O
History	O
:	O
Father	O
deceased	O
at	O
age	O
50	O
with	O
MI	O
.	O
Mother	O
deceased	O
at	O
ago	O
72	O
with	O
MI	O
but	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
27185	O
**	O
]	O
MI	O
in	O
her	O
50s	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2163-5-16	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
WBC	O
-	O
14.8	O
*	O
RBC	O
-	O
3.45	O
*	O
Hgb	O
-	O
10.1	O
*	O
Hct	O
-	O
30.7	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
29.3	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
14.1	O
Plt	O
Ct	O
-	O
232	O
[	O
**	O
2163-5-16	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
232	O
[	O
**	O
2163-5-7	O
**	O
]	O
09:55	O
AM	O
BLOOD	O
PT	O
-	O
16.9	O
*	O
PTT	O
-	O
28.2	O
INR	O
(	O
PT	O
)	O
-	O
1.9	O
[	O
**	O
2163-5-15	O
**	O
]	O
04:45	O
AM	O
BLOOD	O
Glucose	O
-	O
80	O
UreaN	O
-	O
12	O
Creat	O
-	O
1.1	O
Na	O
-	O
140	O
K	O
-	O
4.1	O
Cl	O
-	O
103	O
HCO3	O
-	O
29	O
AnGap	O
-	O
12	O
[	O
**	O
2163-5-4	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
ALT	O
-	O
30	O
AST	O
-	O
19	O
AlkPhos	O
-	O
74	O
Amylase	O
-	O
18	O
TotBili	O
-	O
0.5	O
[	O
**	O
2163-5-8	O
**	O
]	O
04:10	O
AM	O
BLOOD	O
Calcium	O
-	O
7.9	O
*	O
Phos	O
-	O
3.0	O
Mg	O
-	O
2.0	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
32993	O
**	O
]	O
was	O
admitted	O
from	O
an	O
OSH	O
on	O
[	O
**	O
2163-4-20	O
**	O
]	O
pre-op	O
for	O
CABG	I-Reason
.	O
Because	O
of	O
his	O
severe	O
3VD	O
he	O
was	O
started	O
on	O
heparin	I-Drug
and	O
nitroglycerine	I-Drug
drips	O
for	O
optimal	O
control	O
of	O
his	O
CAD	I-Reason
.	O
He	O
underwent	O
pre-op	O
workup	O
including	O
pre-op	O
head	O
CT	O
(	O
with	O
hx	O
of	O
CVA	O
)	O
and	O
carotid	O
ultrasound	O
.	O
On	O
[	O
**	O
2163-4-22	O
**	O
]	O
he	O
proceeded	O
to	O
the	O
OR	O
and	O
underwent	O
a	O
CABG	O
x	O
3	O
with	O
LIMA	O
to	O
the	O
LAD	O
,	O
SVG	O
to	O
the	O
OM	O
,	O
and	O
SVG	O
to	O
the	O
Ramus	O
with	O
patch	O
angioplasty	O
and	O
repair	O
of	O
ramus	O
posterior	O
rupture	O
(	O
subacute	O
)	O
.	O
Please	O
see	O
OP	O
note	O
for	O
full	O
details	O
.	O
He	O
was	O
successfully	O
weened	O
and	O
extubated	O
on	O
his	O
operative	O
evening	O
.	O
On	O
POD	O
one	O
he	O
remained	O
in	O
the	O
ICU	O
for	O
ongoing	O
hemodynamic	O
monitoring	O
and	O
on	O
POD	O
two	O
he	O
was	O
transferred	O
to	O
the	O
in	O
-	O
patient	O
telemetry	O
floor	O
for	O
ongoing	O
care	O
.	O
In	O
the	O
early	O
morning	O
hours	O
on	O
POD	O
three	O
,	O
Mr.	O
[	O
**	O
Name14	O
(	O
STitle	O
)	O
32994	O
**	O
]	O
was	O
found	O
to	O
be	O
talking	O
non-sensically	O
and	O
trying	O
to	O
get	O
out	O
of	O
bed	O
.	O
A	O
neuro	O
consult	O
,	O
head	O
CT	O
and	O
MRI	O
were	O
obtained	O
for	O
suspected	O
acute	O
CVA	O
.	O
He	O
was	O
found	O
to	O
have	O
small	O
right	O
parietal	O
,	O
left	O
cerebellar	O
,	O
and	O
right	O
cerebellar	B-Reason
infarcts	I-Reason
thought	O
to	O
be	O
embolic	O
with	O
new	O
post-operative	O
atrial	O
fibrillation	O
.	O
Over	O
PODs	O
four	O
and	O
five	O
Mr.	O
[	O
**	O
Known	O
lastname	O
32993	O
**	O
]	O
continued	O
to	O
wax	O
and	O
waine	O
;	O
he	O
was	O
continued	O
on	O
his	O
heparin	I-Drug
and	O
coumadin	I-Drug
per	O
neuro	O
recs	O
.	O
On	O
POD	O
six	O
his	O
mental	O
status	O
was	O
noted	O
to	O
be	O
significantly	O
improved	O
with	O
neuro	O
recs	O
only	O
for	O
ongoing	O
anticoagulation	I-Drug
for	O
stroke	B-Reason
prevention	I-Reason
.	O
Also	O
on	O
POD	O
six	O
he	O
was	O
noted	O
to	O
have	O
new	O
sternal	O
drainage	O
.	O
His	O
WBC	O
bumped	O
up	O
to	O
18	O
(	O
from	O
13	O
)	O
for	O
which	O
he	O
was	O
pan-cultured	O
.	O
He	O
had	O
continued	O
bursts	O
of	O
atrial	B-Reason
fibrillation	I-Reason
and	O
was	O
started	O
on	O
amiodarone	I-Drug
.	O
On	O
POD	O
seven	O
his	O
sternal	O
drainage	O
significantly	O
increased	O
;	O
due	O
to	O
his	O
elevated	O
INR	O
,	O
he	O
was	O
unable	O
to	O
return	O
immediately	O
to	O
the	O
OR	O
.	O
On	O
POD	O
nine	O
(	O
[	O
**	O
5	O
-	O
2	O
**	O
]	O
)	O
his	O
INR	O
fell	O
below	O
1.7	O
and	O
he	O
returned	O
to	O
the	O
OR	O
for	O
sternal	O
rewiring	O
.	O
On	O
POD	O
eleven	O
he	O
was	O
found	O
to	O
be	O
C.	O
diff	O
positive	O
with	O
multiple	O
loose	O
stools	O
and	O
on	O
POD	O
thirteen	O
he	O
was	O
noted	O
to	O
have	O
guaiac	O
positive	O
stools	O
.	O
An	O
endoscopy	O
showed	O
bleeding	O
ulcers	O
in	O
the	O
duodenal	O
bulb	O
accounting	O
for	O
the	O
patient	O
's	O
GIB	I-Reason
and	O
hemostasis	O
was	O
obtained	O
.	O
He	O
was	O
started	O
on	O
IV	O
protonix	I-Drug
with	O
serial	O
Hcts	O
to	O
monitor	O
progress	O
.	O
He	O
was	O
transfused	O
as	O
necessary	O
and	O
was	O
taken	O
off	O
of	O
his	O
anticoagulation	I-Drug
.	O
After	O
two	O
days	O
in	O
the	O
ICU	O
for	O
close	O
hemodynamic	O
monitoring	O
in	O
light	O
of	O
GIB	O
,	O
he	O
was	O
again	O
transferred	O
to	O
the	O
inpatient	O
floor	O
on	O
PODs	O
16	O
and	O
5	O
.	O
He	O
continued	O
to	O
work	O
with	O
the	O
physical	O
therapy	O
team	O
throughout	O
his	O
stay	O
but	O
it	O
was	O
not	O
felt	O
that	O
he	O
was	O
safe	O
for	O
home	O
.	O
He	O
was	O
screened	O
for	O
rehabilitation	O
.	O
On	O
PODs	O
20	O
and	O
9	O
,	O
a	O
new	O
rash	I-Ade
was	O
noted	O
on	O
trunk	O
and	O
Mr.	O
[	O
**	O
Known	O
lastname	O
32995	O
**	O
]	O
antibiotics	I-Drug
were	O
discontinued	O
.	O
The	O
rash	O
resolved	O
and	O
on	O
PODs	O
24	O
and	O
13	O
,	O
it	O
was	O
decided	O
that	O
he	O
was	O
safe	O
for	O
transfer	O
to	O
a	O
rehabilitation	O
facility	O
for	O
ongoing	O
management	O
,	O
treatment	O
,	O
and	O
rehabilitation	O
.	O
Final	O
recommendations	O
from	O
the	O
neurology	O
service	O
are	O
for	O
coumadin	I-Drug
as	O
soon	O
as	O
cleared	O
by	O
GI	O
with	O
325	O
mg	O
aspirin	I-Drug
daily	O
until	O
then	O
;	O
to	O
follow	O
-	O
up	O
with	O
primary	O
neurologist	O
.	O
GI	O
recommends	O
re-starting	O
Coumadin	I-Drug
14	O
days	O
post	O
bleed	O
:	O
[	O
**	O
2163-5-10	O
**	O
]	O
.	O
Start	O
coumadin	I-Drug
at	O
low	O
dose	O
and	O
keep	O
INR	O
at	O
low	O
-	O
end	O
of	O
theraupetic	O
.	O
Medications	O
on	O
Admission	O
:	O
Aspirin	I-Drug
325	O
daily	O
.	O
Multivitamin	I-Drug
daily	O
.	O
Lipitor	I-Drug
20	O
daily	O
.	O
Nifidipine	B-Drug
XL	I-Drug
30	O
daily	O
.	O
Mirapex	I-Drug
1.5	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
Reminyl	I-Drug
12	O
daily	O
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Furosemide	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
Tab	O
Sust.Rel	O
.	O
Particle	O
/	O
Crystal	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tab	O
Sust.Rel	O
.	O
Particle	O
/	O
Crystal	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
5	O
.	O
Atorvastatin	B-Drug
Calcium	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Zinc	B-Drug
Sulfate	I-Drug
220	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Galantamine	B-Drug
Hydrobromide	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
bid	O
(	O
)	O
.	O
9	O
.	O
Pramipexole	B-Drug
Dihydrochloride	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
bid	O
(	O
)	O
.	O
10	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
twice	O
a	O
day	O
.	O
11	O
.	O
Amiodarone	B-Drug
HCl	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
7	O
days	O
:	O
To	O
be	O
followed	O
by	O
200	O
mg	O
daily	O
dosing	O
.	O
12	O
.	O
Amiodarone	B-Drug
HCl	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Tablet	O
(	O
s	O
)	O
13	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
[	O
**	O
1	O
-	O
9	O
**	O
]	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
14	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
15644	O
**	O
]	O
Long	O
Term	O
Health	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
47	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Coronary	O
artery	O
disease	O
.	O
Cerebral	O
vascular	O
accident	O
.	O
Sternal	O
wound	O
dehissence	O
.	O
Gastrointestinal	O
bleed	O
.	O
Discharge	O
Condition	O
:	O
Stable	O
.	O
Discharge	O
Instructions	O
:	O
Wash	O
incisions	O
daily	O
with	O
soap	O
and	O
water	O
.	O
Rinse	O
well	O
.	O
Do	O
not	O
apply	O
any	O
creams	O
,	O
lotions	O
,	O
powders	O
,	O
lotions	O
,	O
or	O
ointments	O
.	O
No	O
lifting	O
greater	O
than	O
10	O
pounds	O
.	O
Strict	O
sternal	O
precations	O
.	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2138	O
**	O
]	O
p	O
Instructions	O
:	O
Call	O
to	O
schedule	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
in	O
4	O
weeks	O
.	O
Call	O
to	O
schedule	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
32996	O
**	O
]	O
in	O
2	O
weeks	O
.	O
Call	O
to	O
schedule	O
appointment	O
with	O
cardilogist	O
in	O
2	O
weeks	O
.	O
Call	O
to	O
schedule	O
appointment	O
with	O
primary	O
neurologist	O
in	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
weeks	O
.	O
Please	O
check	O
Hct	O
one	O
week	O
post-discharge	O
from	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Low	O
-	O
dose	O
Coumadin	I-Drug
should	O
be	O
started	O
[	O
**	O
2163-5-20	O
**	O
]	O
.	O
Completed	O
by	O
:[	O
**	O
2163-5-16	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2124-2-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2124-3-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2055-8-23	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
9598	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
s	O
/	O
p	O
central	O
line	O
placement	O
x	O
2	O
(	O
HD	O
catheter	O
)	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
2795	O
**	O
]	O
is	O
a	O
68	O
yo	O
with	O
met	O
renal	B-Reason
cell	I-Reason
carc	I-Reason
admitted	O
on	O
[	O
**	O
2124-2-29	O
**	O
]	O
for	O
week	O
2	O
of	O
high	O
dose	O
IL	B-Drug
-	I-Drug
2	I-Drug
therapy	O
.	O
His	O
last	O
dose	O
was	O
complicated	O
by	O
shock	I-Reason
requiring	O
dopamine	I-Drug
and	O
brief	O
atrial	O
fibrillation	O
,	O
spontaneously	O
reverting	O
back	O
when	O
dopamine	I-Drug
was	O
changed	O
to	O
neo	I-Drug
.	O
His	O
current	O
course	O
was	O
given	O
from	O
[	O
**	O
2	O
-	O
29	O
**	O
]	O
to	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
and	O
has	O
been	O
complicated	O
by	O
nausea	O
/	O
vomiting	O
,	O
encephalopathy	O
,	O
diarrhea	O
,	O
rigors	O
,	O
and	O
desquamation	O
,	O
but	O
also	O
by	O
hypotension	I-Reason
in	O
the	O
70s	O
systolic	O
requiring	O
neo	I-Drug
for	O
90	O
min	O
on	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
and	O
restarted	O
again	O
on	O
[	O
**	O
3	O
-	O
5	O
**	O
]	O
,	O
ARF	O
with	O
decreasing	O
UOP	O
(	O
355	O
total	O
cc	O
's	O
on	O
[	O
**	O
3	O
-	O
5	O
**	O
]	O
,	O
none	O
on	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
,	O
+	O
~	O
14L	O
LOC	O
but	O
without	O
detailed	O
recording	O
of	O
his	O
UOP	O
)	O
,	O
and	O
progressive	O
metabolic	O
acidosis	O
despite	O
bicarb	I-Drug
infusion	O
.	O
Vancomycin	I-Drug
was	O
started	O
empirically	O
in	O
the	O
setting	O
of	O
severe	B-Reason
dermatitis	I-Reason
,	O
and	O
he	O
has	O
been	O
on	O
prophylactic	I-Reason
cipro	I-Drug
throughout	O
his	O
stay	O
.	O
His	O
last	O
dose	O
9	O
am	O
on	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
.	O
His	O
Cr	O
has	O
risen	O
progressively	O
from	O
1.9	O
on	O
admission	O
to	O
6.6	O
on	O
the	O
evening	O
of	O
transfer	O
.	O
Because	O
of	O
his	O
progressive	B-Reason
renal	I-Reason
failure	I-Reason
,	O
dopamine	I-Drug
was	O
added	O
to	O
improve	I-Reason
renal	O
perfusion	O
.	O
He	O
was	O
also	O
transiently	O
in	O
afib	O
.	O
His	O
Tmax	O
during	O
his	O
stay	O
has	O
been	O
99.5	O
on	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
with	O
no	O
other	O
elevated	O
temps	O
,	O
though	O
he	O
has	O
been	O
intermittently	O
around	O
95F	O
.	O
.	O
REVIEW	O
OF	O
SYSTEMS	O
:	O
(	O
+	O
)	O
ve	O
:	O
as	O
per	O
HPI	O
(	O
-	O
)	O
ve	O
:	O
chest	O
pain	O
,	O
palpitations	O
,	O
rhinorrhea	O
,	O
nasal	O
congestion	O
,	O
cough	O
,	O
sputum	O
production	O
,	O
hemoptysis	O
,	O
dyspnea	O
,	O
orthopnea	O
,	O
paroxysmal	O
nocturnal	O
dyspnea	O
,	O
constipation	O
,	O
hematochezia	O
,	O
melena	O
,	O
dysuria	O
,	O
urinary	O
frequency	O
,	O
urinary	O
urgency	O
,	O
focal	O
numbness	O
,	O
focal	O
weakness	O
Past	O
Medical	O
History	O
:	O
metastatic	O
renal	O
cell	O
carcinoma	O
,	O
s	O
/	O
p	O
nephrectomy	O
.	O
metastatic	O
to	O
lung	O
,	O
adrenal	O
gland	O
,	O
brain	O
.	O
s	O
/	O
p	O
cyberknife	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
.	O
Bleeding	O
ulcers	O
HTN	O
Hyperlipidemia	O
GERD	O
Diverticulosis	O
Migraines	O
Barrett	O
's	O
esophagus	O
Anemia	O
with	O
folate	O
deficiency	O
Appendectomy	O
in	O
[	O
**	O
2076	O
**	O
]	O
Hemorrhoidectomy	O
[	O
**	O
2094	O
**	O
]	O
Back	O
surgery	O
in	O
[	O
**	O
2113	O
**	O
]	O
Vasectomy	O
Social	O
History	O
:	O
He	O
is	O
a	O
chief	O
of	O
police	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
82875	O
**	O
]	O
Police	O
.	O
He	O
is	O
married	O
and	O
he	O
is	O
seen	O
with	O
his	O
wife	O
today	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
has	O
two	O
adult	O
children	O
.	O
He	O
does	O
not	O
smoke	O
.	O
He	O
has	O
about	O
five	O
to	O
eight	O
glasses	O
of	O
bourbon	O
weekly	O
.	O
Family	O
History	O
:	O
No	O
history	O
of	O
any	O
kidney	O
cancer	O
,	O
but	O
his	O
mother	O
had	O
ovarian	O
cancer	O
,	O
no	O
obvious	O
signs	O
of	O
Burkitt	O
lymphoma	O
,	O
who	O
is	O
now	O
healthy	O
.	O
Physical	O
Exam	O
:	O
97.8	O
119	O
105/44	O
16	O
100	O
%	O
2L	O
.	O
PHYSICAL	O
EXAM	O
GENERAL	O
:	O
dry	O
and	O
desquamated	O
HEENT	O
:	O
Normocephalic	O
,	O
atraumatic	O
.	O
conjunctival	O
erythema	O
.	O
No	O
scleral	O
icterus	O
.	O
PERRLA	O
/	O
EOMI	O
but	O
tracks	O
slowly	O
and	O
incompletely	O
.	O
mucous	O
membranes	O
dry	O
.	O
OP	O
clear	O
.	O
Neck	O
Supple	O
,	O
No	O
LAD	O
,	O
No	O
thyromegaly	O
.	O
CARDIAC	O
:	O
Regular	O
rhythm	O
,	O
tachycardic	O
.	O
Normal	O
S1	O
,	O
S2	O
.	O
2/6	O
SEM	O
in	O
RUSB	O
,	O
rubs	O
or	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
549	O
**	O
]	O
.	O
JVP	O
=	O
flat	O
LUNGS	O
:	O
CTAB	O
,	O
good	O
air	O
movement	O
biaterally	O
anteriorly	O
.	O
ABDOMEN	O
:	O
hypoABS	O
.	O
Soft	O
,	O
NT	O
,	O
ND	O
.	O
No	O
HSM	O
EXTREMITIES	O
:	O
diffuse	O
[	O
**	O
3	O
-	O
15	O
**	O
]	O
+	O
edema	O
,	O
2	O
+	O
dorsalis	O
pedis	O
/	O
posterior	O
tibial	O
pulses	O
.	O
SKIN	O
:	O
diffuse	O
erythema	O
and	O
desquamation	O
.	O
skin	O
breakdown	O
on	O
grown	O
and	O
buttocks	O
.	O
NEURO	O
:	O
A&O	O
x3	O
though	O
with	O
difficulty	O
with	O
word	O
finding	O
.	O
Appropriate	O
.	O
CN	O
2	O
-	O
12	O
intact	O
.	O
Preserved	O
sensation	O
throughout	O
.	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
strength	O
throughout	O
.	O
Gait	O
assessment	O
deferred	O
PSYCH	O
:	O
Listens	O
and	O
responds	O
to	O
questions	O
appropriately	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
21.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
PLT	O
COUNT	O
-	O
386	O
#	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
WBC	O
-	O
8.0	O
RBC	O
-	O
3.21	O
*	O
HGB	O
-	O
9.5	O
*	O
HCT	O
-	O
29.3	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
29.6	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
13.9	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
ALBUMIN	O
-	O
3.4	O
*	O
CALCIUM	O
-	O
8.1	O
*	O
PHOSPHATE	O
-	O
3.2	O
MAGNESIUM	O
-	O
2.0	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
19	O
AST	O
(	O
SGOT	O
)	O
-	O
21	O
LD	O
(	O
LDH	O
)	O
-	O
169	O
CK	O
(	O
CPK	O
)	O
-	O
55	O
TOT	O
BILI	O
-	O
0.6	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2124-2-29	O
**	O
]	O
09:49	O
AM	O
GLUCOSE	O
-	O
121	O
*	O
UREA	O
N	O
-	O
17	O
CREAT	O
-	O
1.6	O
*	O
#	O
SODIUM	O
-	O
144	O
POTASSIUM	O
-	O
4.1	O
CHLORIDE	O
-	O
112	O
*	O
TOTAL	O
CO2	O
-	O
25	O
ANION	O
GAP	O
-	O
11	O
[	O
**	O
2124-3-24	O
**	O
]	O
hand	O
x-ray	O
No	O
previous	O
images	O
.	O
The	O
distal	O
[	O
**	O
Hospital1	O
**	O
]	O
and	O
adjacent	O
soft	O
tissues	O
are	O
essentially	O
within	O
normal	O
limits	O
on	O
the	O
images	O
presented	O
.	O
No	O
evidence	O
of	O
erosions	O
or	O
dystrophic	O
calcification	O
.	O
[	O
**	O
2124-3-23	O
**	O
]	O
CT	O
abd	O
/	O
pelvis	O
1	O
.	O
Small	O
bowel	O
dilation	O
without	O
a	O
clear	O
transition	O
point	O
to	O
suggest	O
mechanical	O
obstruction	O
.	O
A	O
7	O
cm	O
segment	O
of	O
small	O
bowel	O
wall	O
thickening	O
may	O
represent	O
ischemia	O
,	O
infection	O
,	O
or	O
inflammation	O
.	O
A	O
repeated	O
CT	O
with	O
i.v.	O
contrast	O
may	O
help	O
evaluate	O
the	O
transit	O
of	O
oral	O
contrast	O
as	O
well	O
as	O
the	O
mesenteric	O
vasculature	O
2	O
.	O
Nasogastric	O
tube	O
just	O
passed	O
the	O
gastroesophageal	O
junction	O
.	O
Consider	O
reposition	O
of	O
nasogastric	O
tube	O
in	O
the	O
body	O
of	O
the	O
stomach	O
.	O
3	O
.	O
Metastatic	O
disease	O
,	O
incompletely	O
evaluated	O
on	O
this	O
non-contrast	O
study	O
.	O
4	O
.	O
Bibasilar	O
consolidative	O
opacity	O
concerning	O
for	O
pneumonia	O
5	O
.	O
Florid	O
colonic	O
diverticulosis	O
without	O
evidence	O
of	O
diverticulitis	O
.	O
6	O
.	O
Decrease	O
in	O
size	O
of	O
right	O
adrenal	O
nodule	O
suggestive	O
of	O
response	O
to	O
therapy	O
.	O
7	O
.	O
Extensive	O
therosclerotis	O
including	O
coronary	O
artery	O
,	O
abdominal	O
aorta	O
and	O
mesenteric	O
vessels	O
.	O
[	O
**	O
2124-3-23	O
**	O
]	O
MRI	O
head	O
1	O
.	O
Near	O
-	O
complete	O
interval	O
resolution	O
of	O
the	O
enhancing	O
lesion	O
within	O
the	O
left	O
anterior	O
temporal	O
lobe	O
.	O
Only	O
minimal	O
residual	O
enhancement	O
and	O
FLAIR	O
signal	O
hyperintensity	O
persist	O
.	O
No	O
new	O
enhancing	O
lesions	O
are	O
identified	O
.	O
TTE	O
[	O
**	O
2124-3-6	O
**	O
]	O
:	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
a	O
small	O
pericardial	O
effusion	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
TTE	O
[	O
**	O
2124-3-8	O
**	O
]	O
:	O
IMPRESSION	O
:	O
small	O
pericardial	O
effusion	O
located	O
mostly	O
posterior	O
to	O
the	O
left	O
ventricle	O
.	O
There	O
is	O
minimal	O
fluid	O
anterior	O
to	O
the	O
right	O
ventricle	O
.	O
There	O
is	O
significant	O
,	O
accentuated	O
respiratory	O
variation	O
in	O
mitral	O
/	O
tricuspid	O
valve	O
inflows	O
,	O
which	O
can	O
be	O
consistent	O
with	O
impaired	O
ventricular	O
filling	O
but	O
is	O
more	O
likely	O
due	O
to	O
the	O
irregularity	O
of	O
the	O
heart	O
rate	O
.	O
There	O
is	O
no	O
frank	O
tamponade	O
seen	O
.	O
Normal	O
biventricular	O
function	O
.	O
No	O
evidence	O
of	O
endocarditis	O
although	O
the	O
valves	O
are	O
not	O
well	O
seen	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2124-3-6	O
**	O
]	O
,	O
this	O
is	O
a	O
limited	O
study	O
.	O
The	O
valves	O
are	O
not	O
well	O
seen	O
.	O
The	O
patient	O
remains	O
tachycardic	O
but	O
is	O
now	O
in	O
atrial	O
fibrillation	O
.	O
The	O
size	O
of	O
the	O
pericardial	O
effusion	O
is	O
similar	O
Renal	O
Ultrasound	O
[	O
**	O
2124-3-6	O
**	O
]	O
:	O
1	O
.	O
No	O
hydronephrosis	O
of	O
the	O
right	O
kidney	O
.	O
Left	O
kidney	O
is	O
surgically	O
absent	O
.	O
CXR	O
[	O
**	O
2124-3-6	O
**	O
]	O
:	O
Lung	O
volumes	O
are	O
lower	O
,	O
pulmonary	O
vasculature	O
more	O
engorged	O
,	O
and	O
distended	O
mediastinal	O
veins	O
,	O
unchanged	O
,	O
pointing	O
toward	O
volume	O
overload	O
or	O
cardiac	O
decompensation	O
.	O
A	O
more	O
focal	O
opacity	O
at	O
the	O
left	O
lung	O
base	O
laterally	O
would	O
be	O
better	O
evaluated	O
after	O
hemodynamic	O
status	O
is	O
optimized	O
.	O
It	O
could	O
be	O
a	O
small	O
region	O
of	O
infection	O
or	O
infarction	O
,	O
pleural	O
effusion	O
,	O
or	O
transient	O
atelectasis	O
.	O
Heart	O
is	O
top	O
normal	O
size	O
,	O
though	O
increased	O
since	O
yesterday	O
.	O
Right	O
subclavian	O
line	O
ends	O
in	O
the	O
upper	O
SVC	O
.	O
No	O
pneumothorax	O
.	O
CT	O
head	O
/	O
chest	O
non-con	O
[	O
**	O
2124-3-7	O
**	O
]	O
:	O
Slightly	O
decreased	O
vasogenic	O
edema	O
in	O
region	O
of	O
known	O
left	O
temporal	O
lobe	O
metastasis	O
.	O
1	O
.	O
Extensive	O
new	O
strikingly	O
peripheral	O
/	O
subpleural	O
ground	O
-	O
glass	O
opacities	O
with	O
a	O
slight	O
upper	O
lobe	O
predominance	O
is	O
highly	O
suggestive	O
of	O
drug	O
-	O
induced	O
toxicity	O
(	O
likely	O
IL	O
-	O
2	O
drug	O
-	O
induced	O
eosinophilic	O
lung	O
disease	O
)	O
.	O
The	O
more	O
confluent	O
lower	O
lobe	O
opacities	O
are	O
most	O
suggestive	O
of	O
atelectasis	O
,	O
although	O
infection	O
can	O
not	O
be	O
excluded	O
by	O
imaging	O
.	O
2	O
.	O
Persistent	O
findings	O
suggestive	O
of	O
vascular	O
engorgement	O
with	O
mild	O
interstitial	O
edema	O
and	O
small	O
bilateral	O
pleural	O
effusions	O
.	O
3	O
.	O
No	O
significant	O
interval	O
change	O
to	O
some	O
of	O
the	O
previously	O
noted	O
metastatic	O
lesions	O
with	O
many	O
of	O
the	O
previously	O
noted	O
foci	O
obscured	O
by	O
the	O
new	O
lung	O
parenchymal	O
opacities	O
.	O
Slight	O
enlargement	O
of	O
prevascular	O
lymph	O
nodes	O
can	O
be	O
seen	O
in	O
the	O
setting	O
of	O
underlying	O
pulmonary	O
edema	O
/	O
elevated	O
CVP	O
.	O
CXR	O
[	O
**	O
2124-3-8	O
**	O
]	O
:	O
FINDINGS	O
:	O
As	O
compared	O
to	O
the	O
previous	O
examination	O
,	O
a	O
new	O
central	O
venous	O
access	O
line	O
has	O
been	O
inserted	O
over	O
the	O
left	O
anterior	O
jugular	O
vein	O
.	O
The	O
tip	O
of	O
the	O
line	O
projects	O
over	O
the	O
upper	O
SVC	O
.	O
There	O
is	O
no	O
evidence	O
of	O
complication	O
,	O
notably	O
no	O
pneumothorax	O
.	O
The	O
other	O
monitoring	O
and	O
support	O
devices	O
are	O
in	O
unchanged	O
position	O
.	O
Also	O
unchanged	O
is	O
the	O
size	O
of	O
the	O
cardiac	O
silhouette	O
and	O
the	O
bilateral	O
multifocal	O
parenchymal	O
opacities	O
.	O
The	O
retrocardiac	O
opacity	O
could	O
have	O
minimally	O
increased	O
in	O
the	O
interval	O
.	O
Lower	O
Extremity	O
U	O
/	O
S	O
:	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
DVT	O
in	O
either	O
lower	O
extremity	O
.	O
Left	O
peroneal	O
vein	O
not	O
well	O
visualized	O
.	O
BAL	O
:	O
Bronchial	O
lavage	O
,	O
right	O
mid	O
lobe	O
:	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS	O
.	O
Bronchial	O
epithelial	O
cells	O
,	O
pulmonary	O
macrophages	O
,	O
and	O
neutrophils	O
;	O
no	O
viral	O
inclusions	O
noted	O
.	O
CXR	O
[	O
**	O
2124-3-11	O
**	O
]	O
:	O
Tip	O
of	O
the	O
endotracheal	O
tube	O
is	O
no	O
less	O
than	O
48	O
mm	O
from	O
the	O
carina	O
,	O
standard	O
placement	O
for	O
patient	O
of	O
this	O
size	O
.	O
Diffuse	O
infiltrative	O
pulmonary	O
abnormality	O
,	O
more	O
pronounced	O
in	O
the	O
perihilar	O
right	O
lung	O
has	O
progressed	O
could	O
by	O
virtue	O
of	O
asymmetry	O
be	O
pneumonia	O
rather	O
than	O
pulmonary	O
edema	O
,	O
although	O
pulmonary	O
vascular	O
congestion	O
is	O
present	O
.	O
The	O
heart	O
is	O
moderately	O
enlarged	O
.	O
Moderate	O
right	O
pleural	O
effusion	O
is	O
stable	O
.	O
Right	O
jugular	O
line	O
ends	O
in	O
the	O
low	O
SVC	O
,	O
left	O
jugular	O
line	O
in	O
the	O
mid	O
SVC	O
,	O
nasogastric	O
tube	O
passes	O
below	O
the	O
diaphragm	O
and	O
out	O
of	O
view	O
.	O
Mediastinal	O
widening	O
in	O
the	O
right	O
lower	O
paratracheal	O
station	O
is	O
due	O
to	O
a	O
combination	O
of	O
adenopathy	O
and	O
venous	O
engorgement	O
.	O
Portable	O
Abdomen	O
[	O
**	O
2124-3-10	O
**	O
]	O
:	O
FINDINGS	O
:	O
Supine	O
AP	O
abdomen	O
radiograph	O
demonstrates	O
a	O
nasogastric	O
tube	O
following	O
a	O
normal	O
course	O
and	O
terminating	O
in	O
the	O
distal	O
stomach	O
.	O
There	O
is	O
no	O
evidence	O
of	O
pneumoperitoneum	O
.	O
The	O
bowel	O
gas	O
shadow	O
appears	O
unremarkable	O
[	O
**	O
2124-3-6	O
**	O
]	O
7:08	O
am	O
URINE	O
Source	O
:	O
Catheter	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2124-3-8	O
**	O
]	O
**	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2124-3-8	O
**	O
]	O
)	O
:	O
ESCHERICHIA	O
COLI	O
.	O
10,000	O
-	O
100,000	O
ORGANISMS	O
/	O
ML	O
[	O
**	O
2124-3-7	O
**	O
]	O
4:21	O
pm	O
URINE	O
Source	O
:	O
Catheter	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2124-3-8	O
**	O
]	O
**	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2124-3-8	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
DIRECT	O
INFLUENZA	O
A	O
ANTIGEN	O
TEST	O
(	O
Final	O
[	O
**	O
2124-3-7	O
**	O
]	O
)	O
:	O
Negative	O
for	O
Influenza	O
A.	O
DIRECT	O
INFLUENZA	O
B	O
ANTIGEN	O
TEST	O
(	O
Final	O
[	O
**	O
2124-3-7	O
**	O
]	O
)	O
:	O
Negative	O
for	O
Influenza	O
B.	O
[	O
**	O
2124-3-8	O
**	O
]	O
4:22	O
am	O
STOOL	O
CONSISTENCY	O
:	O
SOFT	O
Source	O
:	O
Stool	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2124-3-10	O
**	O
]	O
**	O
FECAL	O
CULTURE	O
(	O
Final	O
[	O
**	O
2124-3-9	O
**	O
]	O
)	O
:	O
NO	O
SALMONELLA	O
OR	O
SHIGELLA	O
FOUND	O
.	O
CAMPYLOBACTER	O
CULTURE	O
(	O
Final	O
[	O
**	O
2124-3-10	O
**	O
]	O
)	O
:	O
NO	O
CAMPYLOBACTER	O
FOUND	O
.	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST	O
(	O
Final	O
[	O
**	O
2124-3-8	O
**	O
]	O
)	O
:	O
Feces	O
negative	O
for	O
C.difficile	O
toxin	O
A	O
&	O
B	O
by	O
EIA	O
.	O
(	O
Reference	O
Range	O
-	O
Negative	O
)	O
.	O
[	O
**	O
2124-3-9	O
**	O
]	O
10:09	O
am	O
BRONCHOALVEOLAR	O
LAVAGE	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2124-3-9	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
.	O
IN	O
PAIRS	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Final	O
[	O
**	O
2124-3-11	O
**	O
]	O
)	O
:	O
~	O
1000	O
/	O
ML	O
Commensal	O
Respiratory	O
Flora	O
.	O
POTASSIUM	O
HYDROXIDE	O
PREPARATION	O
(	O
Final	O
[	O
**	O
2124-3-9	O
**	O
]	O
)	O
:	O
Test	O
cancelled	O
by	O
laboratory	O
.	O
PATIENT	O
CREDITED	O
.	O
This	O
is	O
a	O
low	O
yield	O
procedure	O
based	O
on	O
our	O
in	O
-	O
house	O
studies	O
if	O
pulmonary	O
Histoplasmosis	O
,	O
Coccidioidomycosis	O
,	O
Blastomycosis	O
,	O
Aspergillosis	O
or	O
Mucormycosis	O
is	O
strongly	O
suspected	O
,	O
contact	O
the	O
Microbiology	O
Laboratory	O
(	O
7	O
-	O
2306	O
)	O
.	O
Immunoflourescent	O
test	O
for	O
Pneumocystis	O
jirovecii	O
(	O
carinii	O
)	O
(	O
Final	O
[	O
**	O
2124-3-9	O
**	O
]	O
)	O
:	O
NEGATIVE	O
for	O
Pneumocystis	O
jirovecii	O
(	O
carinii	O
)	O
.	O
.	O
FUNGAL	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
FUNGUS	O
ISOLATED	O
.	O
VIRAL	O
CULTURE	O
:	O
R	O
/	O
O	O
CYTOMEGALOVIRUS	O
(	O
Preliminary	O
)	O
:	O
No	O
Virus	O
isolated	O
so	O
far	O
.	O
[	O
**	O
2124-3-9	O
**	O
]	O
10:09	O
am	O
Rapid	O
Respiratory	O
Viral	O
Screen	O
&	O
Culture	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2124-3-11	O
**	O
]	O
**	O
Respiratory	O
Viral	O
Culture	O
(	O
Final	O
[	O
**	O
2124-3-11	O
**	O
]	O
)	O
:	O
No	O
respiratory	O
viruses	O
isolated	O
.	O
Culture	O
screened	O
for	O
Adenovirus	O
,	O
Influenza	O
A	O
&	O
B	O
,	O
Parainfluenza	O
type	O
1,2	O
&	O
3	O
,	O
and	O
Respiratory	O
Syncytial	O
Virus	O
.	O
.	O
Detection	O
of	O
viruses	O
other	O
than	O
those	O
listed	O
above	O
will	O
only	O
be	O
performed	O
on	O
specific	O
request	O
.	O
Please	O
call	O
Virology	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
6182	O
**	O
]	O
within	O
1	O
week	O
if	O
additional	O
testing	O
is	O
needed	O
.	O
Respiratory	O
Viral	O
Antigen	O
Screen	O
(	O
Final	O
[	O
**	O
2124-3-9	O
**	O
]	O
)	O
:	O
Negative	O
for	O
Respiratory	O
Viral	O
Antigen	O
.	O
Specimen	O
screened	O
for	O
:	O
Adeno	O
,	O
Parainfluenza	O
1	O
,	O
2	O
,	O
3	O
,	O
Influenza	O
A	O
,	O
B	O
,	O
and	O
RSV	O
by	O
immunofluorescence	O
.	O
Refer	O
to	O
respiratory	O
viral	O
culture	O
for	O
further	O
information	O
.	O
[	O
**	O
2124-3-9	O
**	O
]	O
12:11	O
pm	O
SPUTUM	O
Site	O
:	O
ENDOTRACHEAL	O
Source	O
:	O
Endotracheal	O
.	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2124-3-9	O
**	O
]	O
)	O
:	O
>	O
25	O
PMNs	O
and	O
<	O
10	O
epithelial	O
cells	O
/	O
100X	O
field	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Final	O
[	O
**	O
2124-3-11	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
FUNGAL	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
FUNGUS	O
ISOLATED	O
.	O
[	O
**	O
2124-3-6	O
**	O
]	O
2:29	O
am	O
BLOOD	O
CULTURE	O
Source	O
:	O
Line	O
-	O
R	O
SCTL	O
-	O
>	O
MSRA	O
(	O
+	O
)	O
[	O
**	O
2124-3-10	O
**	O
]	O
:	O
VRE	O
blood	O
culture	O
from	O
a-line	O
[	O
**	O
2124-3-11	O
**	O
]	O
,	O
[	O
**	O
2124-3-12	O
**	O
]	O
blood	O
cultures	O
pending	O
Brief	O
Hospital	O
Course	O
:	O
#	O
.	O
Shock	O
:	O
Felt	O
initially	O
most	O
likely	O
due	O
to	O
sepsis	I-Reason
and	O
he	O
was	O
covered	O
broadly	O
with	O
antibiotics	I-Drug
.	O
Initially	O
broadened	O
antibiotics	I-Drug
to	O
vanc	I-Drug
/	O
levo	O
/	O
cefepime	I-Drug
to	O
cover	O
above	O
sources	O
.	O
Goal	O
CVP	O
was	O
[	O
**	O
9	O
-	O
21	O
**	O
]	O
,	O
MAP	O
>	O
65	O
.	O
Initial	O
central	O
venous	O
O2	O
saturation	O
was	O
91	O
%	O
.	O
Patient	O
was	O
transferred	O
from	O
floor	O
to	O
ICU	O
on	O
dopamine	I-Drug
and	O
neo	I-Drug
;	O
dopamine	I-Drug
was	O
converted	O
to	O
levophed	I-Drug
.	O
Pulsus	O
was	O
normal	O
at	O
5	O
.	O
Echocardiogram	O
as	O
above	O
,	O
largely	O
unremarkable	O
.	O
Hypotension	I-Ade
persisted	O
and	O
was	O
thought	O
to	O
be	O
septic	O
in	O
etiology	O
with	O
IL	B-Drug
-	I-Drug
2	I-Drug
distributive	O
physiology	O
contributing	O
.	O
Shock	I-Reason
was	O
refractory	O
to	O
fluid	I-Drug
boluses	O
;	O
received	O
normal	B-Drug
saline	I-Drug
and	O
water	I-Drug
with	O
bicarb	O
given	O
renal	B-Reason
failure	I-Reason
.	O
Blood	O
cultures	O
eventually	O
grew	O
out	O
MRSA	O
,	O
successive	O
cultures	O
negative	O
until	O
[	O
**	O
2124-3-10	O
**	O
]	O
,	O
with	O
[	O
**	O
2124-3-10	O
**	O
]	O
culture	O
growing	O
vancomycin	I-Drug
-	O
resistant	O
Enterococcus	O
.	O
During	O
this	O
time	O
,	O
patient	O
was	O
actually	O
weaned	O
off	O
pressors	I-Drug
.	O
The	O
right	O
subclavian	O
triple	O
lumen	O
was	O
removed	O
and	O
a	O
right	O
internal	O
jugular	O
triple	O
lumen	O
was	O
placed	O
.	O
Goals	O
of	O
care	O
were	O
discussed	O
with	O
family	O
,	O
who	O
requested	O
continued	O
aggressive	O
treatment	O
.	O
Linezolid	I-Drug
replaced	O
vancomycin	I-Drug
for	O
VRE	B-Reason
bacteremia	I-Reason
.	O
The	O
patient	O
's	O
pressures	O
stabilized	O
and	O
pressors	I-Drug
were	O
discontinued	O
.	O
He	O
did	O
not	O
have	O
further	O
hypotension	O
after	O
transfer	O
to	O
the	O
oncology	O
floor	O
.	O
#	O
MRSA	B-Reason
/	I-Reason
VRE	I-Reason
bacteremia	I-Reason
:	O
S	O
/	O
p	O
line	O
removals	O
;	O
Patient	O
completed	O
15	O
day	O
course	O
of	O
linezolid	I-Drug
.	O
Also	O
added	O
Meropenem	I-Drug
on	O
[	O
**	O
3	O
-	O
24	O
**	O
]	O
given	O
MS	O
decline	O
and	O
asterixis	O
.	O
Antibiotics	O
were	O
d	O
/	O
c	O
'd	O
on	O
[	O
**	O
3	O
-	O
25	O
**	O
]	O
and	O
patient	O
has	O
been	O
stable	O
,	O
afebrile	O
without	O
leukocytosis	O
since	O
.	O
Repeat	O
blood	O
and	O
urine	O
cultures	O
have	O
been	O
negative	O
.	O
#	O
partial	O
/	O
early	O
SBO	O
:	O
On	O
[	O
**	O
3	O
-	O
25	O
**	O
]	O
patient	O
developed	O
worsening	O
abdominal	O
distention	O
and	O
confusion	O
.	O
This	O
early	O
SBO	I-Ade
was	O
likely	O
due	O
to	O
narcotics	I-Drug
though	O
concerning	O
that	O
is	O
ongoing	O
and	O
limiting	O
nutrition	O
.	O
MRI	O
head	O
with	O
improved	O
findings	O
.	O
An	O
NGT	O
was	O
placed	O
for	O
24	O
hours	O
and	O
the	O
patient	O
's	O
MS	O
cleared	O
as	O
did	O
his	O
SBO	O
.	O
There	O
was	O
initially	O
some	O
concern	O
for	O
messenteric	O
ischemia	O
given	O
guiaic	O
positive	O
stool	O
,	O
known	O
necrotic	O
fingers	O
and	O
subsequent	O
CT	O
abd	O
findings	O
,	O
so	O
GI	O
and	O
surgery	O
were	O
consulted	O
.	O
Patient	O
however	O
soon	O
improved	O
clinically	O
so	O
further	O
work	O
-	O
up	O
with	O
colonoscopy	O
was	O
not	O
done	O
.	O
He	O
was	O
able	O
to	O
tolerate	O
a	O
regular	O
diet	O
for	O
48H	O
prior	O
to	O
discharge	O
.	O
A	O
PICC	O
had	O
been	O
placed	O
for	O
access	O
and	O
for	O
ability	O
to	O
start	O
TPN	O
if	O
needed	O
,	O
however	O
TPN	O
was	O
never	O
started	O
.	O
#	O
Anemia	I-Reason
:	O
likely	O
multifactorial	O
due	O
to	O
poor	O
nutrition	O
,	O
acute	O
nutrition	O
,	O
and	O
marrow	O
suppression	O
.	O
Patient	O
is	O
also	O
FOB	O
+	O
s	O
/	O
p	O
2U	O
PRBC	I-Drug
since	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
.	O
then	O
another	O
1U	O
[	O
**	O
3	O
-	O
24	O
**	O
]	O
.	O
He	O
was	O
continued	O
on	O
iron	I-Drug
,	O
folate	I-Drug
and	O
B12	I-Drug
on	O
[	O
**	O
3	O
-	O
27	O
**	O
]	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
2795	O
**	O
]	O
did	O
have	O
guiaic	O
positive	O
stools	O
during	O
admission	O
which	O
should	O
be	O
followed	O
-	O
up	O
by	O
gastroenterology	O
as	O
an	O
outpatient	O
.	O
#	O
gangrene	O
:	O
[	O
**	O
3	O
-	O
14	O
**	O
]	O
pressors	O
,	O
shock	O
as	O
below	O
.	O
Patient	O
was	O
treated	O
with	O
wound	O
care	O
and	O
transitioned	O
to	O
a	O
fentanyl	I-Drug
patch	O
with	O
breakthrough	O
morphine	I-Drug
for	O
pain	I-Reason
.	O
#	O
thrombocytopenia	O
:	O
Resolved	O
.	O
Likely	O
due	O
to	O
myelosuppression	O
.	O
#	O
coagulopathy	I-Reason
:	O
Patient	O
was	O
supplemented	O
with	O
vitamin	B-Drug
K	I-Drug
X3	O
days	O
to	O
decrease	O
his	O
INR	O
.	O
#	O
Respiratory	O
failure	O
-	O
Patient	O
was	O
intubated	O
electively	O
in	O
setting	O
of	O
persistent	O
hypervolemia	O
and	O
renal	O
failure	O
.	O
Maintained	O
on	O
minimal	O
ventilatory	O
support	O
during	O
dialysis	O
.	O
Patient	O
received	O
antibiotic	I-Drug
coverage	O
for	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
The	O
patient	O
was	O
extubated	O
on	O
[	O
**	O
2124-3-15	O
**	O
]	O
and	O
continued	O
to	O
improve	O
significantly	O
.	O
The	O
patient	O
was	O
called	O
out	O
to	O
the	O
OMED	O
floor	O
team	O
for	O
further	O
managment	O
.	O
#	O
.	O
ARF	O
:	O
IL	B-Drug
-	I-Drug
2	I-Drug
mediated	O
ARF	I-Ade
most	O
likely	O
,	O
however	O
prerenal	O
or	O
postrenal	O
etiology	O
also	O
possible	O
.	O
K	O
wnl	O
,	O
phos	O
elevated	O
though	O
stable	O
from	O
last	O
draw	O
.	O
Patient	O
likely	O
had	O
IL	B-Drug
-	I-Drug
2	I-Drug
induced	O
renal	I-Ade
injury	O
,	O
with	O
possible	O
ischemic	O
acute	O
tubular	O
necrosis	O
.	O
Despite	O
aggressive	O
fluids	O
,	O
renal	O
function	O
did	O
not	O
improve	O
.	O
Patient	O
was	O
showing	O
signs	O
of	O
uremia	O
and	O
hypervolemia	O
,	O
and	O
continuous	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
venous	O
hemodialysis	O
was	O
started	O
following	O
intubation	O
and	O
placement	O
of	O
HD	O
line	O
.	O
On	O
the	O
last	O
days	O
of	O
admission	O
he	O
did	O
not	O
require	O
diuresis	O
and	O
continued	O
to	O
auto	O
-	O
diurese	O
with	O
a	O
creatinine	O
of	O
1.1	O
-	O
1.3	O
.	O
He	O
was	O
not	O
continued	O
on	O
his	O
anti-hypertensives	O
as	O
his	O
SBPs	O
were	O
130	O
-	O
140	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
2795	O
**	O
]	O
should	O
have	O
his	O
renal	O
function	O
checked	O
as	O
an	O
outpatient	O
in	O
the	O
next	O
1	O
-	O
2	O
weeks	O
.	O
If	O
there	O
are	O
concerns	O
with	O
worsening	O
kidney	O
function	O
as	O
an	O
oupatient	O
,	O
he	O
should	O
be	O
followed	O
by	O
renal	O
.	O
#	O
Atrial	B-Reason
fibrillation	I-Reason
with	I-Reason
rapid	I-Reason
ventricular	I-Reason
response	I-Reason
-	O
Occurred	O
on	O
morning	O
of	O
[	O
**	O
2124-3-7	O
**	O
]	O
.	O
Became	O
more	O
hypotensive	O
,	O
received	O
two	O
attempts	O
at	O
DC	O
cardioversion	O
,	O
transient	O
sinus	O
rhythm	O
restored	O
,	O
then	O
converted	O
back	O
into	O
a.	O
fib	O
.	O
Amiodarone	I-Drug
load	O
and	O
drip	O
was	O
started	O
.	O
Converted	O
to	O
sinus	O
rhythm	O
day	O
later	O
,	O
maintained	O
on	O
amio	I-Drug
drip	O
.	O
Cardiac	O
enzymes	O
were	O
flat	O
,	O
lower	O
extremity	O
ultrasound	O
negative	O
for	O
DVT	O
.	O
Repeat	O
TTE	O
showed	O
no	O
right	O
heart	O
strain	O
.	O
The	O
amiodarone	I-Drug
drip	O
was	O
discontinued	O
and	O
the	O
patient	O
remained	O
in	O
normal	O
sinus	O
rhythm	O
.	O
#	O
.	O
HA	O
/	O
MS	O
changes	O
:	O
Known	O
metastatic	O
disease	O
to	O
brain	O
and	O
IL	B-Drug
-	I-Drug
2	I-Drug
can	O
cause	O
swelling	I-Ade
.	O
He	O
is	O
AOx3	O
,	O
though	O
slightly	O
agitated	O
.	O
Clinical	O
picture	O
not	O
c	O
/	O
w	O
meningitis	O
/	O
encephalitis	O
and	O
most	O
likely	O
toxic	O
-	O
metabolic	O
.	O
CT	O
head	O
showed	O
slight	O
improvement	O
in	O
metastatic	O
disease	O
,	O
less	O
vasogenic	O
edema	O
.	O
Lumbar	O
puncture	O
was	O
deferred	O
given	O
intracranial	O
mass	O
.	O
As	O
patient	O
stayed	O
on	O
the	O
oncology	O
floor	O
his	O
mental	O
status	O
gradually	O
returned	O
to	O
[	O
**	O
Location	O
213	O
**	O
]	O
.	O
He	O
can	O
have	O
a	O
formal	O
neurocognitive	O
outpatient	O
work	O
-	O
up	O
if	O
deemed	O
necessary	O
by	O
his	O
PCP	O
.	O
#	O
skin	O
/	O
eye	O
/	O
mucous	O
membrane	O
breakdown	O
:	O
Patient	O
developed	O
significant	O
skin	B-Ade
breakdown	I-Ade
,	O
particularly	O
on	O
his	O
fingertips	O
likely	O
due	O
to	O
pressors	I-Drug
and	O
IL	B-Drug
-	I-Drug
2	I-Drug
.	O
He	O
was	O
evaluated	O
by	O
plastic	O
surgery	O
and	O
hand	O
x-ray	O
found	O
no	O
need	O
for	O
intervention	O
.	O
He	O
was	O
continued	O
on	O
:	O
nystatin	I-Drug
,	O
miconazole	I-Drug
,	O
benadryl	I-Drug
,	O
sarna	I-Drug
,	O
Hydrocerin	I-Drug
,	O
HydrOXYzine	I-Drug
,	O
eye	B-Drug
drops	O
,	O
Gelclair	I-Drug
.	O
#	O
.	O
RCC	I-Reason
:	O
finished	O
week	O
2	O
of	O
IL	B-Drug
-	I-Drug
2	I-Drug
.	O
Maintained	O
contact	O
with	O
outpatient	O
oncologist	O
.	O
CODE	O
STATUS	O
:	O
Full	O
(	O
confirmed	O
)	O
Medications	O
on	O
Admission	O
:	O
MEDICATIONS	O
upon	O
transfer	O
:	O
Hydrocerin	I-Drug
1	O
Appl	O
TP	O
QID	O
:	O
PRN	O
dry	B-Reason
skin	I-Reason
50	O
mEq	O
Sodium	B-Drug
Bicarbonate	I-Drug
/	O
1000	O
ml	O
D5	B-Drug
1/2	I-Drug
NS	I-Drug
Continuous	O
at	O
75	O
ml	O
/	O
hr	O
HydrOXYzine	I-Drug
25	O
-	O
50	O
mg	O
PO	O
/	O
NG	O
Q6H	O
:	O
PRN	O
pruritis	I-Reason
Lorazepam	I-Drug
0.5	O
-	O
1	O
mg	O
PO	O
/	O
IV	O
Q4H	O
:	O
PRN	O
Acetaminophen	I-Drug
975	O
mg	O
PO	O
Q6H	O
prn	O
Meperidine	I-Drug
25	O
-	O
50	O
mg	O
IV	O
Q2H	O
:	O
PRN	O
Rigors	I-Reason
Artificial	B-Drug
Tears	I-Drug
Preserv	I-Drug
.	I-Drug
Free	O
1	O
-	O
2	O
DROP	O
BOTH	O
EYES	O
PRN	O
Morphine	B-Drug
Sulfate	I-Drug
1	O
-	O
2	O
mg	O
IV	O
Q2H	O
:	O
PRN	O
pain	I-Reason
Ciprofloxacin	I-Drug
HCl	O
250	O
mg	O
PO	O
/	O
NG	O
Q24H	O
Pantoprazole	I-Drug
40	O
mg	O
PO	O
Q24H	O
DOPamine	I-Drug
4	O
mcg	O
/	O
kg	O
/	O
min	O
IV	O
DRIP	O
Phenylephrine	I-Drug
1	O
mcg	O
/	O
kg	O
/	O
min	O
IV	O
DRIP	O
DiphenhydrAMINE	I-Drug
25	O
-	O
50	O
mg	O
PO	O
/	O
IV	O
Q6H	O
:	O
PRN	O
pruritis	I-Reason
Diphenoxylate	B-Drug
-	I-Drug
Atropine	O
[	O
**	O
2	O
-	O
12	O
**	O
]	O
TAB	O
PO	O
PRN	O
after	O
each	O
loose	O
stool	O
Prochlorperazine	I-Drug
10	O
mg	O
PO	O
/	O
IV	O
Q6H	O
:	O
PRN	O
nausea	I-Reason
/	O
vomiting	I-Reason
Erythromycin	I-Drug
*	O
NF	O
*	O
5	O
mg	O
/	O
g	O
OU	O
TID	O
Sarna	I-Drug
Lotion	O
1	O
Appl	O
TP	O
QID	O
:	O
PRN	O
pruritus	I-Reason
Gabapentin	B-Drug
100	O
mg	O
PO	O
/	O
NG	O
TID	O
pruritus	I-Reason
Gelclair	I-Drug
15	O
mL	O
ORAL	O
TID	O
:	O
PRN	O
mucositis	I-Reason
*	O
Stopped	O
*	O
Aldesleukin	I-Drug
47.4	O
Million	O
Units	O
IV	O
Q8H	O
on	O
Days	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
.	O
.	O
Home	O
Medications	O
:	O
lipitor	I-Drug
20	O
mg	O
diltiazem	I-Drug
240	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
folate	I-Drug
1	O
mg	O
qday	O
protonix	I-Drug
40	O
mg	O
qday	O
triamterene	B-Drug
/	I-Drug
hydrochlorothiazide	O
75	O
/	O
50	O
mg	O
qday	O
valsartan	I-Drug
320	O
mg	O
qday	O
vit	B-Drug
C	I-Drug
1g	O
qday	O
citrucel	I-Drug
1g	O
[	O
**	O
Hospital1	O
**	O
]	O
cyanocobalamin	I-Drug
1g	O
sc	O
monthly	O
Discharge	O
Medications	O
:	O
1	O
.	O
Lipitor	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
4	O
.	O
Cyanocobalamin	I-Drug
1,000	O
mcg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
once	O
a	O
month	O
:	O
next	O
due	O
[	O
**	O
4	O
-	O
24	O
**	O
]	O
.	O
5	O
.	O
Vitamin	B-Drug
C	I-Drug
1,000	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
6	O
.	O
Diphenhydramine	I-Drug
HCl	O
25	O
mg	O
Capsule	O
Sig	O
:	O
[	O
**	O
2	O
-	O
12	O
**	O
]	O
Capsules	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pruritis	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Lorazepam	B-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
nausea	B-Reason
/	I-Reason
vomiting	I-Reason
,	O
insomnia	I-Reason
or	O
anxiety	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
White	B-Drug
Petrolatum	I-Drug
-	I-Drug
Mineral	O
Oil	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
dry	B-Reason
skin	I-Reason
.	O
Disp	O
:	O
*	O
QS	O
1	O
month	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Oral	B-Drug
Wound	I-Drug
Care	I-Drug
Products	I-Drug
Gel	O
in	O
Packet	O
Sig	O
:	O
Fifteen	O
(	O
15	O
)	O
ML	O
Mucous	O
membrane	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
mucositis	I-Reason
.	O
Disp	O
:	O
*	O
QS	O
1	O
month	O
*	O
Refills	O
:	O
*	O
0	O
*	O
10	O
.	O
Hydroxyzine	I-Drug
HCl	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pruritis	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Camphor	B-Drug
-	I-Drug
Menthol	O
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
pruritus	I-Reason
.	O
Disp	O
:	O
*	O
QS	O
1	O
month	O
*	O
Refills	O
:	O
*	O
2	O
*	O
12	O
.	O
Acetaminophen	I-Drug
650	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
:	O
do	O
note	O
take	O
more	O
than	O
4	O
grams	O
per	O
day	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
13	O
.	O
Ferrous	B-Drug
Gluconate	I-Drug
325	O
mg	O
(	O
37.5	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
14	O
.	O
Fentanyl	I-Drug
25	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
:	O
remove	O
previous	O
patch	O
before	O
applying	O
.	O
Do	O
not	O
drive	O
while	O
using	O
this	O
.	O
Disp	O
:	O
*	O
20	O
Patch	O
72	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
15	O
.	O
Morphine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
16	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
17	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
18	O
.	O
Polyethylene	B-Drug
Glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
pkt	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
pkt	O
*	O
Refills	O
:	O
*	O
2	O
*	O
19	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
20	O
.	O
ZOFRAN	B-Drug
ODT	I-Drug
8	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Rapid	O
Dissolve	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
health	O
care	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Metastatic	B-Reason
RCCA	I-Reason
-	O
s	O
/	O
p	O
C1W2	O
HD	O
IL	B-Drug
-	I-Drug
2	I-Drug
therapy	O
Secondary	O
:	O
VRE	O
/	O
MRSA	O
sepsis	O
acute	O
renal	O
failure	O
,	O
resolved	O
SBO	O
,	O
resolved	O
peripheral	O
necrosis	O
of	O
digits	O
acute	O
mental	O
status	O
changes	O
,	O
resolved	O
Discharge	O
Condition	O
:	O
Alert	O
,	O
oriented	O
,	O
ambulatory	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
[	O
**	O
Hospital1	O
69	O
**	O
]	O
for	O
IL	B-Drug
-	I-Drug
2	I-Drug
therapy	O
for	O
your	O
Renal	B-Reason
Cell	I-Reason
Carcinoma	I-Reason
.	O
While	O
you	O
were	O
here	O
you	O
had	O
a	O
very	O
complicated	O
hospital	O
course	O
.	O
-	O
You	O
developed	O
bacteria	O
in	O
your	O
blood	O
and	O
you	O
were	O
treated	O
with	O
antibiotics	O
for	O
MRSA	O
and	O
VRE	O
.	O
You	O
have	O
finished	O
your	O
courses	O
of	O
antibiotics	O
and	O
your	O
blood	O
cultures	O
have	O
been	O
normal	O
.	O
-	O
You	O
had	O
a	B-Reason
UTI	I-Reason
with	I-Reason
e-coli	I-Reason
and	O
you	O
were	O
treated	O
with	O
antibiotics	I-Drug
.	O
Your	O
urine	O
cultures	O
have	O
since	O
been	O
normal	O
.	O
-	O
You	O
needed	O
dialysis	O
.	O
Your	O
kidney	O
function	O
has	O
since	O
improved	O
and	O
your	O
creatinine	O
was	O
1.2	O
at	O
discharge	O
.	O
This	O
should	O
be	O
monitored	O
closely	O
and	O
you	O
should	O
see	O
a	O
renal	O
doctor	O
if	O
it	O
worsens	O
.	O
-	O
You	O
were	O
in	O
the	O
intensive	O
care	O
unit	O
and	O
you	O
were	O
intubated	O
for	O
confusion	O
.	O
This	O
improved	O
.	O
You	O
should	O
ask	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
if	O
neurocognitive	O
evaluation	O
is	O
needed	O
.	O
-	O
You	O
had	O
necrosis	O
(	O
damage	O
)	O
to	O
your	O
fingertips	O
from	O
some	O
of	O
the	O
medications	O
in	O
the	O
ICU	O
.	O
Plastic	O
surgery	O
saw	O
you	O
and	O
your	O
finger	O
tips	O
started	O
to	O
improve	O
.	O
-	O
You	O
also	O
had	O
skin	B-Ade
damage	I-Ade
to	O
your	O
sacrum	O
(	O
above	O
your	O
buttocks	O
)	O
from	O
the	O
IL	B-Drug
-	I-Drug
2	I-Drug
.	O
The	O
VNA	O
services	O
should	O
help	O
you	O
change	O
these	O
dressings	O
.	O
While	O
you	O
were	O
here	O
some	O
of	O
your	O
medications	O
were	O
changed	O
.	O
You	O
should	O
CONTINUE	O
taking	O
:	O
lipitor	I-Drug
20	O
mg	O
folate	I-Drug
1	O
mg	O
qday	O
protonix	I-Drug
40	O
mg	O
qday	O
vit	B-Drug
C	I-Drug
1g	O
qday	O
cyanocobalamin	I-Drug
1g	O
sc	O
monthly	O
(	O
you	O
received	O
this	O
on	O
[	O
**	O
3	O
-	O
27	O
**	O
]	O
)	O
You	O
should	O
STOP	O
taking	O
:	O
citrucel	I-Drug
1g	O
[	O
**	O
Hospital1	O
**	O
]	O
diltiazem	I-Drug
240	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
triamterene	B-Drug
/	I-Drug
hydrochlorothiazide	O
75	O
/	O
50	O
mg	O
qday	O
valsartan	I-Drug
320	O
mg	O
qday	O
You	O
should	O
START	O
taking	O
:	O
Benadryl	I-Drug
,	O
hydroxyzine	I-Drug
,	O
camphor	B-Drug
-	I-Drug
methol	I-Drug
,	O
petrolatum	I-Drug
-	O
mineral	O
oil	O
as	O
needed	O
for	O
itching	I-Reason
Lorazepam	I-Drug
as	O
needed	O
for	O
nausea	I-Reason
,	O
vomiting	I-Reason
or	O
anxiety	I-Reason
(	O
do	O
not	O
drive	O
or	O
drink	O
alcohol	O
while	O
taking	O
this	O
)	O
oral	O
care	O
and	O
wound	O
care	O
products	O
tylenol	I-Drug
as	O
needed	O
for	O
pain	I-Reason
ferrous	B-Drug
gluconate	I-Drug
twice	O
a	O
day	O
fentanyl	I-Drug
patch	O
every	O
72	O
hours	O
(	O
do	O
not	O
drive	O
or	O
drink	O
alcohol	O
while	O
taking	O
this	O
)	O
morphine	I-Drug
as	O
needed	O
for	O
pain	I-Reason
(	O
do	O
not	O
drive	O
or	O
drink	O
alcohol	O
while	O
taking	O
this	O
)	O
You	O
should	O
take	O
senna	I-Drug
and	O
colace	I-Drug
every	O
day	O
to	O
prevent	O
constipation	I-Reason
and	O
take	O
miralax	I-Drug
and	O
bisacodyl	I-Drug
if	O
you	O
become	O
constipated	I-Reason
.	O
Notify	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
RN	O
,	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
82663	O
**	O
]	O
for	O
fever	O
,	O
chills	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
inability	O
to	O
take	O
oral	O
fluids	O
Followup	O
Instructions	O
:	O
You	O
have	O
the	O
following	O
appointment	O
's	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1729	O
**	O
]	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
.	O
[	O
**	O
2124-4-25	O
**	O
]	O
02:00	O
p	O
XCT	O
(	O
TCC	O
)	O
[	O
**	O
Apartment	O
Address	O
(	O
1	O
)	O
**	O
]	O
:	O
Catscan	O
appointment	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
[	O
**	O
2124-5-2	O
**	O
]	O
02:30	O
p	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
TUESDAY	O
BIOLOGICS	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
CLINICAL	O
CTR	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
82876	O
**	O
]	O
[	O
**	O
Doctor	O
First	O
Name	O
82877	O
**	O
]	O
PCP	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
82878	O
**	O
]	O
[	O
**	O
4	O
-	O
3	O
**	O
]	O
at	O
2:15	O
pm	O
We	O
will	O
fax	O
a	O
copy	O
of	O
your	O
discharge	O
paperwork	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Visiting	O
Nursing	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
82879	O
**	O
]	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
9601	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
9602	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2128-10-30	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2128-11-16	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2076-2-29	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
Surgery	O
,	O
Purple	O
Team	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
a	O
52	O
-	O
year	O
-	O
old	O
female	O
,	O
status	O
post	O
right	O
cephalic	O
vein	O
port	O
placement	O
and	O
laparoscopic	O
-	O
assisted	O
jejunostomy	O
tube	O
placement	O
on	O
[	O
**	O
2128-10-29	O
**	O
]	O
.	O
The	O
patient	O
presented	O
on	O
[	O
**	O
2128-10-30	O
**	O
]	O
with	O
nausea	O
,	O
vomiting	O
,	O
and	O
abdominal	O
pain	O
.	O
The	O
pain	O
was	O
described	O
as	O
being	O
in	O
the	O
midabdomen	O
and	O
occurs	O
in	O
waves	O
.	O
The	O
pain	I-Reason
began	O
last	O
night	O
.	O
It	O
was	O
only	O
somewhat	O
relieved	O
by	O
Roxicet	I-Drug
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
Past	O
medical	O
history	O
is	O
significant	O
for	O
esophageal	O
cancer	O
which	O
was	O
diagnosed	O
approximately	O
two	O
weeks	O
prior	O
.	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
Past	O
surgical	O
history	O
as	O
described	O
above	O
.	O
MEDICATIONS	O
ON	O
DISCHARGE	O
:	O
Medications	O
included	O
Prevacid	I-Drug
,	O
Roxicet	I-Drug
,	O
multivitamin	I-Drug
,	O
and	O
calcium	I-Drug
.	O
FAMILY	O
HISTORY	O
:	O
Family	O
history	O
is	O
significant	O
for	O
a	O
mom	O
with	O
ovarian	O
cancer	O
.	O
PHYSICAL	O
EXAMINATION	O
ON	O
PRESENTATION	O
:	O
On	O
examination	O
,	O
the	O
patient	O
was	O
noted	O
to	O
have	O
a	O
temperature	O
of	O
98.9	O
,	O
pulse	O
was	O
76	O
,	O
blood	O
pressure	O
was	O
148/70	O
,	O
respiratory	O
rate	O
was	O
16	O
,	O
and	O
was	O
saturating	O
98	O
%	O
on	O
room	O
air	O
.	O
She	O
appeared	O
to	O
be	O
in	O
discomfort	O
and	O
nauseated	O
.	O
Her	O
head	O
,	O
eyes	O
,	O
ears	O
,	O
nose	O
,	O
and	O
throat	O
examination	O
was	O
significant	O
for	O
extraocular	O
movements	O
which	O
were	O
intact	O
.	O
Pupils	O
were	O
equal	O
,	O
round	O
,	O
and	O
reactive	O
to	O
light	O
and	O
accommodation	O
.	O
There	O
was	O
no	O
icterus	O
demonstrated	O
.	O
The	O
oropharynx	O
demonstrated	O
mucous	O
membranes	O
were	O
dry	O
.	O
She	O
was	O
clear	O
to	O
auscultation	O
bilaterally	O
.	O
Heart	O
rate	O
was	O
regular	O
in	O
rate	O
and	O
rhythm	O
without	O
any	O
associated	O
murmurs	O
,	O
rubs	O
,	O
or	O
heart	O
sounds	O
.	O
Her	O
abdomen	O
was	O
distended	O
,	O
tympanitic	O
,	O
with	O
percussion	O
tenderness	O
near	O
the	O
incision	O
.	O
Bowel	O
sounds	O
were	O
hypoactive	O
.	O
Extremities	O
had	O
trace	O
edema	O
bilaterally	O
.	O
PERTINENT	O
LABORATORY	O
DATA	O
ON	O
PRESENTATION	O
:	O
Laboratories	O
obtained	O
at	O
the	O
time	O
indicated	O
white	O
blood	O
cell	O
count	O
was	O
8.5	O
,	O
hematocrit	O
was	O
51.3	O
,	O
platelets	O
were	O
508	O
.	O
Her	O
Chemistry	O
-	O
7	O
demonstrated	O
sodium	O
was	O
138	O
,	O
potassium	O
was	O
4.2	O
,	O
chloride	O
was	O
98	O
,	O
bicarbonate	O
was	O
29	O
,	O
blood	O
urea	O
nitrogen	O
was	O
13	O
,	O
creatinine	O
was	O
0.6	O
,	O
and	O
blood	O
glucose	O
was	O
112	O
.	O
Her	O
liver	O
function	O
tests	O
were	O
normal	O
.	O
RADIOLOGY	O
/	O
IMAGING	O
:	O
A	O
KUB	O
obtained	O
in	O
the	O
Emergency	O
Room	O
indicated	O
free	O
air	O
consistent	O
with	O
her	O
laparoscopic	O
operation	O
.	O
It	O
also	O
demonstrated	O
gastric	O
dilatation	O
and	O
one	O
small	O
air	O
/	O
fluid	O
level	O
in	O
the	O
midabdomen	O
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Purple	O
Surgery	O
Service	O
and	O
treated	O
with	O
antiemetics	I-Drug
,	O
and	O
medication	O
,	O
as	O
well	O
as	O
intravenous	O
hydration	I-Drug
for	O
possible	B-Reason
postoperative	I-Reason
ileus	O
.	O
On	O
hospital	O
day	O
two	O
,	O
she	O
was	O
noted	O
to	O
have	O
increasing	O
amounts	O
of	O
gastric	O
dilatation	O
and	O
increasing	O
amounts	O
of	O
discomfort	O
,	O
starting	O
at	O
approximately	O
11	O
o'clock	O
that	O
afternoon	O
.	O
She	O
was	O
subsequently	O
taken	O
to	O
the	O
operating	O
room	O
for	O
re-exploration	O
and	O
revision	O
of	O
her	O
jejunostomy	O
tube	O
placement	O
.	O
Please	O
see	O
the	O
Operative	O
Note	O
per	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
333	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
for	O
details	O
of	O
this	O
operation	O
.	O
Notably	O
,	O
during	O
the	O
course	O
of	O
this	O
operation	O
her	O
course	O
was	O
complicated	O
by	O
a	O
aspiration	I-Ade
upon	O
anesthesia	I-Drug
induction	O
.	O
Approximately	O
2	O
liters	O
of	O
gastric	O
content	O
was	O
estimated	O
to	O
have	O
entered	O
the	O
lungs	O
and	O
was	O
rapidly	O
suctioned	O
out	O
;	O
however	O
,	O
attempts	O
at	O
extubation	O
failed	O
,	O
and	O
the	O
patient	O
was	O
ultimately	O
transferred	O
to	O
the	O
Intensive	O
Care	O
Unit	O
with	O
a	O
presumed	O
diagnosis	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
her	O
aspiration	O
.	O
On	O
[	O
**	O
2128-10-31	O
**	O
]	O
,	O
the	O
patient	O
was	O
maintained	O
intubated	O
in	O
the	O
Intensive	O
Care	O
Unit	O
.	O
On	O
postoperative	O
day	O
one	O
,	O
the	O
patient	O
was	O
converted	O
to	O
a	O
prone	O
position	O
in	O
the	O
Intensive	O
Care	O
Unit	O
to	O
help	O
improve	O
her	O
respiratory	O
status	O
.	O
This	O
gradually	O
improved	O
.	O
The	O
patient	O
was	O
returned	O
to	O
a	O
supine	O
position	O
on	O
postoperative	O
day	O
two	O
.	O
She	O
was	O
gradually	O
weaned	O
from	O
the	O
ventilator	O
over	O
the	O
next	O
several	O
days	O
until	O
she	O
was	O
extubated	O
on	O
postoperative	O
day	O
eight	O
.	O
On	O
postoperative	O
day	O
seven	O
,	O
Pseudomonas	B-Reason
pneumonia	I-Reason
was	O
grown	O
from	O
her	O
tracheal	O
tube	O
.	O
She	O
was	O
started	O
on	O
ceftazidime	I-Drug
and	O
Zosyn	I-Drug
that	O
was	O
ultimately	O
converted	O
from	O
Zosyn	I-Drug
to	O
ciprofloxacin	I-Drug
.	O
Tube	O
feeds	O
were	O
started	O
on	O
postoperative	O
day	O
eight	O
and	O
were	O
brought	O
to	O
goal	O
by	O
postoperative	O
day	O
thirteen	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
floor	O
on	O
[	O
**	O
2128-11-12	O
**	O
]	O
.	O
Just	O
prior	O
to	O
discharge	O
to	O
the	O
floor	O
,	O
it	O
was	O
noted	O
that	O
she	O
had	O
swelling	O
in	O
her	O
right	O
arm	O
.	O
An	O
ultrasound	O
was	O
undertaken	O
to	O
rule	O
out	O
deep	O
venous	O
thrombosis	O
.	O
A	O
thrombus	I-Reason
was	O
seen	O
within	O
the	O
distal	O
jugular	O
vein	O
;	O
consistent	O
with	O
deep	O
venous	O
thrombosis	O
from	O
the	O
right	O
brachial	O
vein	O
to	O
the	O
subclavian	O
.	O
The	O
patient	O
was	O
started	O
on	O
a	O
heparin	I-Drug
drip	O
at	O
that	O
time	O
,	O
and	O
over	O
the	O
next	O
several	O
days	O
was	O
converted	O
toward	O
Coumadin	I-Drug
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
however	O
,	O
she	O
was	O
not	O
therapeutic	O
on	O
the	O
Coumadin	I-Drug
;	O
potentially	O
from	O
interference	O
from	O
the	O
antibiotics	I-Drug
she	O
was	O
on	O
,	O
so	O
the	O
patient	O
was	O
ultimately	O
discharged	O
on	O
Lovenox	I-Drug
.	O
On	O
the	O
final	O
day	O
of	O
the	O
patient	O
's	O
admission	O
,	O
her	O
port	O
was	O
accessed	O
.	O
She	O
was	O
discharged	O
home	O
on	O
tube	O
feeds	O
at	O
120	O
cc	O
per	O
hour	O
times	O
15	O
hours	O
.	O
She	O
was	O
given	O
oxygen	I-Drug
therapy	O
;	O
predominately	O
because	O
of	O
anxiety	I-Reason
that	O
she	O
was	O
dealing	O
with	O
over	O
feelings	O
of	O
air	O
hunger	O
.	O
She	O
was	O
also	O
given	O
Lovenox	I-Drug
injections	O
.	O
All	O
of	O
this	O
was	O
accomplished	O
through	O
the	O
aid	O
of	O
a	O
visiting	O
nurse	O
who	O
was	O
going	O
to	O
help	O
the	O
patient	O
with	O
delivery	O
of	O
medications	O
,	O
the	O
Lovenox	I-Drug
injections	O
,	O
and	O
the	O
tube	O
feeds	O
,	O
as	O
well	O
as	O
assisting	O
with	O
monitoring	O
Coumadin	I-Drug
in	O
concert	O
with	O
the	O
local	O
physician	O
.	O
CONDITION	O
AT	O
DISCHARGE	O
:	O
Condition	O
on	O
discharge	O
was	O
stable	O
.	O
DISCHARGE	O
STATUS	O
:	O
Discharge	O
status	O
was	O
to	O
home	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Esophageal	O
cancer	O
.	O
2	O
.	O
Status	O
post	O
jejunostomy	O
tube	O
placement	O
and	O
port	O
placement	O
complicated	O
by	O
small	O
-	O
bowel	O
obstruction	O
requiring	O
re-exploration	O
and	O
jejunostomy	O
tube	O
revision	O
,	O
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
subsequent	O
to	O
aspiration	O
.	O
MEDICATIONS	O
ON	O
DISCHARGE	O
:	O
(	O
Discharge	O
medications	O
included	O
)	O
1	O
.	O
Enoxaparin	I-Drug
sodium	O
60	O
mg	O
subcutaneously	O
q.	O
12h	O
.	O
2	O
.	O
Warfarin	I-Drug
5	O
mg	O
q.d.	O
(	O
crushed	O
and	O
given	O
per	O
jejunostomy	O
tube	O
)	O
3	O
.	O
Roxicet	I-Drug
elixir	O
5	O
cc	O
to	O
10	O
cc	O
per	O
jejunostomy	O
tube	O
q.4	O
-	O
6h	O
.	O
as	O
needed	O
.	O
4	O
.	O
Ranitidine	B-Drug
150	O
mg	O
per	O
jejunostomy	O
tube	O
(	O
as	O
an	O
elixir	O
)	O
.	O
5	O
.	O
Sertraline	I-Drug
HCl	O
50	O
mg	O
per	O
jejunostomy	O
tube	O
q.d.	O
6	O
.	O
Colace	I-Drug
elixir	O
100	O
mg	O
per	O
jejunostomy	O
tube	O
b.i.d.	O
7	O
.	O
Albuterol	I-Drug
4	O
puffs	O
inhaled	O
q.4	O
-	O
6h	O
.	O
as	O
needed	O
.	O
8	O
.	O
Tube	O
feeds	O
were	O
also	O
given	O
with	O
Impact	O
full	O
strength	O
with	O
fiber	I-Drug
at	O
120	O
cc	O
per	O
hour	O
.	O
DISCHARGE	O
DISPOSITION	O
/	O
INSTRUCTIONS	O
:	O
Dressing	O
changes	O
were	O
to	O
be	O
done	O
every	O
day	O
on	O
the	O
jejunostomy	O
tube	O
site	O
per	O
[	O
**	O
Hospital6	O
407	O
**	O
]	O
.	O
An	O
oxygen	O
tank	O
was	O
also	O
to	O
be	O
provided	O
to	O
the	O
patient	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
was	O
again	O
receiving	O
tube	O
feeds	O
at	O
the	O
above	O
-	O
mentioned	O
rates	O
over	O
the	O
above	O
-	O
mentioned	O
times	O
and	O
was	O
tolerating	O
this	O
without	O
problems	O
.	O
She	O
was	O
also	O
taking	O
full	O
liquids	O
at	O
the	O
time	O
of	O
discharge	O
.	O
DISCHARGE	O
FOLLOWUP	O
:	O
Follow	O
-	O
up	O
plans	O
included	O
seeing	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
approximately	O
one	O
to	O
two	O
weeks	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
6066	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1752	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2128-11-16	O
**	O
]	O
16:49	O
T	O
:	O
[	O
**	O
2128-11-16	O
**	O
]	O
15:41	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
22150	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2195-9-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2195-9-14	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2121-1-23	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1854	O
**	O
]	O
Chief	O
Complaint	O
:	O
consulted	O
for	O
SDH	O
found	O
on	O
CT	O
at	O
OSH	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
74	O
year	O
old	O
male	O
on	O
coumadin	I-Drug
for	O
ICD	I-Reason
was	O
not	O
feeling	O
well	O
around	O
8	O
pm	O
last	O
night	O
and	O
he	O
went	O
to	O
sleep	O
at	O
that	O
time	O
.	O
This	O
morning	O
at	O
5:30	O
am	O
his	O
wife	O
noticed	O
that	O
he	O
had	O
not	O
moved	O
positions	O
since	O
he	O
went	O
to	O
bed	O
and	O
one	O
of	O
his	O
legs	O
was	O
hanging	O
over	O
the	O
side	O
of	O
the	O
bed	O
.	O
She	O
was	O
unable	O
to	O
arouse	O
him	O
and	O
he	O
went	O
to	O
an	O
OSH	O
.	O
He	O
was	O
intubated	O
and	O
had	O
a	O
head	O
CT	O
which	O
revealed	O
a	O
large	O
right	O
SDH	I-Reason
with	O
midline	O
shift	O
.	O
The	O
patient	O
was	O
given	O
cerebryx	I-Drug
and	O
50	O
mg	O
of	O
mannitol	I-Drug
and	O
sent	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
When	O
neurosurgery	O
was	O
called	O
the	O
patient	O
the	O
ER	O
had	O
ordered	O
another	O
50	O
mg	O
of	O
mannitol	I-Drug
to	O
be	O
given	O
as	O
well	O
as	O
vitamin	B-Drug
K	I-Drug
and	O
Profiline	I-Drug
Past	O
Medical	O
History	O
:	O
Has	O
ICD	I-Reason
-	O
on	O
coumadin	I-Drug
adenocarcinoma	O
of	O
the	O
prostate	O
-	O
s	O
/	O
p	O
brachytherapy	O
Social	O
History	O
:	O
lives	O
with	O
wife	O
,	O
has	O
a	O
daughter	O
,	O
son	O
,	O
and	O
daughter	O
-	O
in	O
-	O
law	O
who	O
are	O
here	O
in	O
the	O
ER	O
with	O
him	O
Family	O
History	O
:	O
non-contributory	O
Physical	O
Exam	O
:	O
PHYSICAL	O
EXAM	O
upon	O
admission	O
:	O
T	O
:	O
99.8	O
BP	O
:	O
109/56	O
HR	O
:	O
74	O
RR	O
:	O
16	O
O2Sats	O
:	O
100	O
%	O
vented	O
Gen	O
:	O
intubated	O
and	O
sedated	O
HEENT	O
:	O
Pupils	O
:	O
5	O
mm	O
,	O
unreactive	O
bilaterally	O
EOMs	O
-	O
unable	O
Neck	O
:	O
Supple	O
.	O
Lungs	O
:	O
CTA	O
bilaterally	O
.	O
Cardiac	O
:	O
RRR	O
.	O
S1	O
/	O
S2	O
.	O
Abd	O
:	O
Soft	O
,	O
NT	O
,	O
BS	O
+	O
Extrem	O
:	O
Warm	O
and	O
well	O
-	O
perfused	O
.	O
Neuro	O
:	O
Mental	O
status	O
:	O
Unresponsive	O
.	O
Cranial	O
Nerves	O
:	O
I	O
:	O
Not	O
tested	O
II	O
:	O
Pupils	O
5	O
mm	O
,	O
unreactive	O
bilaterally	O
.	O
III	O
-	O
XII	O
:	O
unable	O
to	O
test	O
Motor	O
:	O
Upper	O
extremities	O
extending	O
to	O
pain	O
.	O
Lower	O
extremities	O
withdrawing	O
to	O
pain	O
.	O
Toes	O
upgoing	O
bilaterally	O
Pertinent	O
Results	O
:	O
CT	O
Head	O
from	O
OSH	O
[	O
**	O
2195-9-14	O
**	O
]	O
:	O
The	O
patient	O
had	O
a	O
very	O
large	O
right	O
SDH	O
with	O
midline	O
shift	O
and	O
herniation	O
.	O
Formal	O
read	O
is	O
unavailable	O
at	O
this	O
time	O
.	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
after	O
the	O
decision	O
was	O
made	O
to	O
keep	O
him	O
comfortable	O
since	O
he	O
had	O
a	O
devasting	O
hemorrhage	O
with	O
herniation	O
.	O
He	O
was	O
extubated	O
several	O
hours	O
later	O
after	O
the	O
family	O
had	O
a	O
chance	O
to	O
see	O
him	O
and	O
spend	O
some	O
time	O
with	O
him	O
.	O
The	O
patient	O
expired	O
about	O
1	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
after	O
extubation	O
.	O
Medications	O
on	O
Admission	O
:	O
Vytorin	I-Drug
10	O
-	O
80	O
mg	O
PO	O
QHS	O
HCTZ	I-Drug
25	O
mg	O
PO	O
daily	O
Lopressor	I-Drug
200	O
mg	O
PO	O
BID	O
KCL	I-Drug
20	O
mEq	O
PO	O
daily	O
Diovan	I-Drug
320	O
mg	O
PO	O
daily	O
Coumadin	I-Drug
dose	O
changes	O
Tylenol	I-Drug
80	O
-	O
160	O
mg	O
PO	O
PRN	O
pain	I-Reason
Discharge	O
Medications	O
:	O
none	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Right	O
SDH	O
with	O
mass	O
effect	O
and	O
herniation	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
n	O
/	O
a	O
Followup	O
Instructions	O
:	O
n	O
/	O
a	O
Completed	O
by	O
:[	O
**	O
2195-9-14	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2128-8-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2128-8-23	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2064-12-29	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lisinopril	I-Drug
/	O
Shellfish	O
Derived	O
Attending	O
:[	O
**	O
Doctor	O
First	O
Name	O
2080	O
**	O
]	O
Chief	O
Complaint	O
:	O
tongue	O
swelling	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Laryngoscopy	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
63	O
year	O
old	O
male	O
with	O
a	O
PMH	O
significant	O
for	O
hypertension	I-Reason
recently	O
started	O
on	O
lisinopril	I-Drug
who	O
presents	O
with	O
one	O
day	O
of	O
facial	B-Ade
and	I-Ade
tongue	I-Ade
edema	I-Ade
.	O
He	O
states	O
that	O
[	O
**	O
8	O
-	O
22	O
**	O
]	O
after	O
eating	O
some	O
shrimp	O
he	O
woke	O
up	O
around	O
3	O
am	O
and	O
noticed	O
that	O
his	O
face	O
and	O
tongue	O
felt	O
swollen	O
;	O
he	O
tried	O
to	O
go	O
back	O
to	O
sleep	O
but	O
was	O
unable	O
to	O
sleep	O
.	O
When	O
he	O
finally	O
got	O
up	O
in	O
the	O
morning	O
he	O
drank	O
a	O
cup	O
of	O
coffee	O
and	O
showered	O
,	O
but	O
when	O
his	O
face	O
was	O
not	O
improving	O
he	O
called	O
his	O
daughter	O
to	O
come	O
get	O
him	O
and	O
take	O
him	O
to	O
the	O
hospital	O
.	O
He	O
said	O
that	O
he	O
was	O
having	O
some	O
trouble	O
swallowing	O
but	O
denied	O
having	O
any	O
shortness	O
of	O
breath	O
.	O
He	O
says	O
he	O
had	O
a	O
similar	O
episode	O
about	O
two	O
months	O
ago	O
that	O
was	O
not	O
as	O
severe	O
and	O
resolved	O
without	O
intervention	O
.	O
Also	O
,	O
he	O
recently	O
started	O
lisinopril	I-Drug
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
,	O
no	O
other	O
new	O
medications	O
.	O
He	O
says	O
that	O
he	O
has	O
had	O
shrimp	O
multiple	O
times	O
in	O
the	O
past	O
,	O
and	O
that	O
eating	O
shrimp	O
was	O
not	O
associated	O
with	O
his	O
prior	O
episode	O
.	O
In	O
the	O
ER	O
,	O
his	O
initial	O
vitals	O
were	O
:	O
96.6	O
65135/82	O
18	O
100	O
.	O
He	O
was	O
given	O
SQ	O
epinephrine	I-Drug
,	O
125	O
mg	O
solumedrol	I-Drug
,	O
benadryl	I-Drug
and	O
pepcid	I-Drug
.	O
He	O
was	O
evaluated	O
by	O
ENT	O
in	O
the	O
ER	O
,	O
who	O
felt	O
that	O
he	O
had	O
a	O
more	O
impressive	O
exam	O
internally	O
by	O
DL	O
than	O
expected	O
based	O
on	O
his	O
presentation	O
.	O
As	O
a	O
result	O
he	O
was	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
closer	O
monitoring	O
.	O
At	O
the	O
time	O
of	O
transfer	O
his	O
vitals	O
were	O
:	O
71	O
,	O
117/79	O
,	O
16	O
,	O
96	O
%	O
on	O
RA	O
.	O
Upon	O
arrival	O
to	O
the	O
ICU	O
,	O
patient	O
had	O
no	O
complaints	O
,	O
denied	O
any	O
shortness	O
of	O
breath	O
,	O
difficulty	O
swallowing	O
,	O
trouble	O
controlling	O
his	O
own	O
secretions	O
or	O
difficulty	O
speaking	O
in	O
complete	O
sentences	O
;	O
he	O
also	O
denied	O
any	O
rash	O
or	O
pruritus	O
.	O
On	O
review	O
of	O
systems	O
he	O
did	O
note	O
increased	O
frequency	O
of	O
urination	O
in	O
last	O
three	O
days	O
,	O
particularly	O
after	O
lying	O
down	O
.	O
Denies	O
fever	O
,	O
chills	O
.	O
Denies	O
headache	O
,	O
visual	O
changes	O
,	O
sinus	O
pain	O
,	O
rhinorrhea	O
.	O
Denied	O
cough	O
,	O
shortness	O
of	O
breath	O
.	O
Denied	O
chest	O
pain	O
or	O
tightness	O
,	O
palpitations	O
.	O
Denied	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
or	O
abdominal	O
pain	O
.	O
No	O
recent	O
change	O
in	O
bowel	O
or	O
bladder	O
habits	O
.	O
In	O
the	O
ICU	O
he	O
was	O
treated	O
with	O
dexamthasone	I-Drug
,	O
benadryl	I-Drug
,	O
and	O
famotidine	I-Drug
.	O
He	O
was	O
followed	O
by	O
ENT	O
who	O
felt	O
he	O
was	O
stable	O
to	O
transfer	O
to	O
floor	O
.	O
Currently	O
he	O
feels	O
totally	O
back	O
to	O
normal	O
and	O
wants	O
to	O
go	O
home	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Hypertension	O
-	O
Latent	B-Reason
TB	I-Reason
Infection	I-Reason
,	O
s	O
/	O
p	O
9	O
months	O
isoniazid	I-Drug
-	O
H	O
/	O
O	O
Prostatitis	O
-	O
H	O
/	O
O	O
Bladder	O
Stones	O
Social	O
History	O
:	O
The	O
patient	O
is	O
currently	O
living	O
with	O
his	O
wife	O
and	O
two	O
children	O
at	O
home	O
.	O
He	O
is	O
a	O
retired	O
assembly	O
line	O
worker	O
.	O
He	O
walks	O
approximately	O
30	O
-	O
45	O
minutes	O
every	O
day	O
in	O
the	O
morning	O
.	O
He	O
is	O
a	O
lifelong	O
nonsmoker	O
.	O
Drinking	O
approximately	O
zero	O
to	O
one	O
drinks	O
per	O
day	O
of	O
either	O
beer	O
or	O
whisky	O
,	O
generally	O
less	O
than	O
seven	O
in	O
a	O
given	O
week	O
.	O
Denies	O
any	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
The	O
patient	O
denies	O
any	O
knowledge	O
of	O
any	O
family	O
history	O
any	O
illness	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
98.3	O
HR	O
85	O
BP	O
137/70	O
RR	O
20	O
Sat	O
97	O
%	O
RA	O
Gen	O
:	O
Well	O
appearing	O
man	O
in	O
NAD	O
Eye	O
:	O
extra-occular	O
movements	O
intact	O
,	O
pupils	O
equal	O
round	O
,	O
reactive	O
to	O
light	O
,	O
sclera	O
anicteric	O
,	O
not	O
injected	O
,	O
no	O
exudates	O
ENT	O
:	O
mucus	O
membranes	O
moist	O
,	O
no	O
ulcerations	O
or	O
exudates	O
,	O
tongue	O
appears	O
mildly	O
enlarged	O
but	O
per	O
pt	O
is	O
normal	O
Neck	O
:	O
no	O
thyromegally	O
,	O
JVD	O
:	O
flat	O
Cardiovascular	O
:	O
regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
s1	O
,	O
s2	O
,	O
no	O
murmurs	O
,	O
rubs	O
or	O
gallops	O
Respiratory	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
or	O
rhonchi	O
Abd	O
:	O
Soft	O
,	O
non	O
tender	O
,	O
non	O
distended	O
,	O
no	O
heptosplenomegally	O
,	O
bowel	O
sounds	O
present	O
Extremities	O
:	O
No	O
cyanosis	O
,	O
clubbing	O
,	O
edema	O
,	O
joint	O
swelling	O
Neurological	O
:	O
Alert	O
and	O
oriented	O
x3	O
,	O
CN	O
II	O
-	O
XII	O
intact	O
,	O
normal	O
attention	O
,	O
sensation	O
normal	O
,	O
asterixis	O
absent	O
,	O
speech	O
fluent	O
,	O
motor	O
[	O
**	O
3	O
-	O
23	O
**	O
]	O
UE	O
/	O
LE	O
Integument	O
:	O
Warm	O
,	O
moist	O
,	O
no	O
rash	O
or	O
ulceration	O
Psychiatric	O
:	O
appropriate	O
,	O
pleasant	O
,	O
not	O
anxious	O
Hematologic	O
:	O
no	O
cervical	O
or	O
supraclavicular	O
LAD	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
WBC	O
-	O
7.3	O
#	O
RBC	O
-	O
4.69	O
Hgb	O
-	O
13.0	O
*	O
Hct	O
-	O
38.1	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
27.6	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
15.1	O
Plt	O
Ct	O
-	O
296	O
Neuts	O
-	O
68.0	O
Lymphs	O
-	O
27.6	O
Monos	O
-	O
2.7	O
Eos	O
-	O
1.5	O
Baso	O
-	O
0.2	O
Glucose	O
-	O
116	O
*	O
UreaN	O
-	O
19	O
Creat	O
-	O
1.1	O
Na	O
-	O
138	O
K	O
-	O
3.7	O
Cl	O
-	O
99	O
HCO3	O
-	O
30	O
AnGap	O
-	O
13	O
.	O
MRSA	O
screen	O
pending	O
.	O
.	O
Ua	O
negative	O
Brief	O
Hospital	O
Course	O
:	O
63	O
yo	O
man	O
hypertension	O
admitted	O
with	O
angioedema	O
.	O
1	O
.	O
Angioedema	I-Ade
:	O
Likely	O
related	O
to	O
either	O
shellfish	O
/	O
lisinopril	I-Drug
exposure	O
.	O
Was	O
admitted	O
to	O
the	O
MICU	O
for	O
respiratory	O
observation	O
.	O
Patient	O
was	O
evaluated	O
by	O
ENT	O
who	O
saw	O
glottis	O
and	O
soft	O
tissue	O
swelling	O
.	O
He	O
was	O
started	O
on	O
decadron	I-Drug
,	O
famotidine	I-Drug
,	O
and	O
diphenhydramine	I-Drug
with	O
significant	O
improvement	O
in	O
his	O
symptoms	O
.	O
He	O
was	O
transferred	O
to	O
the	O
floor	O
.	O
Over	O
the	O
course	O
of	O
48	O
hrs	O
his	O
symptoms	O
resolved	O
,	O
confirmed	O
on	O
repeat	O
laryngoscopy	O
.	O
He	O
tolerated	O
POs	O
well	O
.	O
He	O
was	O
discharged	O
with	O
specific	O
instructions	O
to	O
avoid	O
shellfish	O
/	O
seafood	O
as	O
well	O
as	O
lisinopril	I-Drug
.	O
He	O
was	O
discharged	O
with	O
a	O
rapid	O
prednisone	I-Drug
taper	O
over	O
5	O
days	O
,	O
as	O
well	O
as	O
famotidine	I-Drug
and	O
diphenhydramine	I-Drug
.	O
JHe	O
has	O
ENT	O
and	O
PCP	O
follow	O
up	O
,	O
and	O
would	O
benefit	O
from	O
allergy	O
follow	O
up	O
to	O
further	O
establish	O
a	O
cause	O
.	O
.	O
2	O
.	O
Hypertension	I-Reason
,	O
benign	O
:	O
Maintained	O
on	O
HCTZ	I-Drug
with	O
good	O
effect	O
.	O
Lisinopril	I-Drug
was	O
stopped	O
.	O
.	O
3	O
.	O
Latent	B-Reason
TB	I-Reason
:	O
Continued	O
pyridoxine	I-Drug
.	O
4	O
.	O
Abnormal	O
CT	O
scan	O
finding	O
:	O
It	O
was	O
noticed	O
that	O
he	O
had	O
a	O
finding	O
on	O
CT	O
Chest	O
which	O
will	O
require	O
3	O
month	O
follow	O
up	O
(	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
321	O
**	O
]	O
)	O
.	O
It	O
was	O
discussed	O
with	O
the	O
patient	O
whp	O
understands	O
.	O
Medications	O
on	O
Admission	O
:	O
Medications	O
at	O
home	O
:	O
-	O
Lisinopril	I-Drug
-	O
HCTZ	O
-	O
Sildenafil	I-Drug
prn	O
-	O
Pyridoxine	I-Drug
originally	O
supposed	O
to	O
be	O
with	O
isoniazid	I-Drug
;	O
he	O
has	O
now	O
completed	O
his	O
course	O
of	O
isoniazid	I-Drug
but	O
has	O
continued	O
to	O
be	O
with	O
pyridoxine	I-Drug
Medications	O
on	O
transfer	O
:	O
Heparin	I-Drug
5000	O
UNIT	O
SC	O
TID	O
Acetaminophen	I-Drug
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1999	O
**	O
]	O
mg	O
PO	O
Q6H	O
:	O
PRN	O
pain	I-Reason
Hydrochlorothiazide	I-Drug
12.5	O
mg	O
PO	O
DAILY	O
Dexamethasone	I-Drug
4	O
mg	O
IV	O
Q6H	O
Duration	O
:	O
6	O
Doses	O
(	O
to	O
complete	O
48	O
hours	O
)	O
DiphenhydrAMINE	B-Drug
25	O
mg	O
PO	O
Q6H	O
Duration	O
:	O
4	O
Days	O
Order	O
date	O
:	O
[	O
**	O
8	O
-	O
22	O
**	O
]	O
@	O
1112	O
Famotidine	I-Drug
20	O
mg	O
PO	O
DAILY	O
Duration	O
:	O
4	O
Doses	O
10/04	O
@	O
1112	O
Discharge	O
Medications	O
:	O
1	O
.	O
Famotidine	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
5	O
days	O
.	O
Disp	O
:	O
*	O
5	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Diphenhydramine	I-Drug
HCl	O
25	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
for	O
5	O
days	O
:	O
may	O
cause	O
drowsiness	I-Ade
.	O
Disp	O
:	O
*	O
20	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
4	O
Tablets	O
PO	O
once	O
a	O
day	O
for	O
4	O
days	O
:	O
[	O
**	O
8	O
-	O
24	O
**	O
]	O
:	O
4	O
pills	O
(	O
40	O
mg	O
)	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
:	O
3	O
pills	O
(	O
30	O
mg	O
)	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
:	O
2	O
pills	O
(	O
20	O
mg	O
)	O
[	O
**	O
8	O
-	O
27	O
**	O
]	O
:	O
1	O
pill	O
(	O
10	O
mg	O
)	O
then	O
STOP	O
.	O
Disp	O
:	O
*	O
10	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
4	O
.	O
Hydrochlorothiazide	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Pyridoxine	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Angioedema	O
/	O
Allergic	O
Reaction	O
Hypertension	O
,	O
benign	O
Discharge	O
Condition	O
:	O
Good	O
,	O
stable	O
respiratory	O
system	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
throat	B-Ade
and	I-Ade
tongue	I-Ade
swelling	I-Ade
called	O
"	O
angioedema	I-Ade
.	O
"	O
This	O
was	O
caused	O
by	O
either	O
shellfish	O
/	O
seafood	O
,	O
or	O
your	O
lisinopril	I-Drug
.	O
You	O
improved	O
with	O
steroids	I-Drug
.	O
Please	O
DO	O
NOT	O
eat	O
any	O
seafood	O
/	O
shellfish	O
or	O
take	O
your	O
lisinopril	I-Drug
for	O
now	O
.	O
.	O
Appointments	O
have	O
been	O
made	O
to	O
follow	O
up	O
with	O
your	O
PCP	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
the	O
ENT	O
doctors	O
.	O
You	O
should	O
also	O
see	O
an	O
allergist	O
to	O
be	O
arranged	O
by	O
your	O
PCP	O
.	O
.	O
You	O
will	O
be	O
given	O
prescriptions	O
for	O
prednisone	I-Drug
to	O
taper	O
each	O
day	O
over	O
5	O
days	O
.	O
You	O
will	O
also	O
be	O
given	O
prescriptions	O
for	O
famotidine	I-Drug
and	O
benadryl	I-Drug
,	O
as	O
well	O
as	O
part	O
of	O
your	O
blood	B-Reason
pressure	I-Reason
pill	O
,	O
hydrochlorothiazide	I-Drug
.	O
.	O
Return	O
to	O
the	O
hospital	O
if	O
you	O
have	O
recurrence	O
of	O
throat	O
/	O
tongue	O
swelling	O
,	O
fevers	O
/	O
chills	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
.	O
Additionally	O
,	O
as	O
we	O
discussed	O
,	O
a	O
chest	O
CT	O
scan	O
performed	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
216	O
**	O
]	O
showed	O
non	O
specific	O
findings	O
.	O
A	O
3	O
month	O
follow	O
up	O
CT	O
was	O
recommended	O
to	O
make	O
sure	O
this	O
finding	O
resolved	O
,	O
and	O
was	O
not	O
part	O
of	O
a	O
concerning	O
process	O
.	O
Followup	O
Instructions	O
:	O
Appointment	O
#	O
1	O
MD	O
:	O
Dr	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1887	O
**	O
]	O
Specialty	O
:	O
Primary	O
Care	O
Date	O
and	O
time	O
:	O
Friday	O
,	O
[	O
**	O
8	O
-	O
27	O
**	O
]	O
at	O
1:45	O
pm	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
,	O
[	O
**	O
Company	O
191	O
**	O
]	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Bldg	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Central	O
Suite	O
Phone	O
number	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Special	O
instructions	O
if	O
applicable	O
:	O
.	O
Appointment	O
#	O
2	O
MD	O
:	O
Dr	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Specialty	O
:	O
Otolaryngology	O
(	O
ENT	O
)	O
Date	O
and	O
time	O
:	O
Wednesday	O
,	O
[	O
**	O
9	O
-	O
22	O
**	O
]	O
at	O
10	O
am	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
517	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
61116	O
**	O
]	O
Phone	O
number	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
41	O
**	O
]	O
.	O
Follow	O
up	O
CT	O
scan	O
of	O
the	O
chest	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2192-12-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2192-12-30	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2130-6-18	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Iodine	I-Drug
;	O
Iodine	I-Drug
Containing	O
/	O
Adhesive	O
Tape	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2279	O
**	O
]	O
Chief	O
Complaint	O
:	O
GIB	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
EGD	O
History	O
of	O
Present	O
Illness	O
:	O
62F	O
with	O
PMH	O
of	O
HTN	O
,	O
renal	O
cell	O
CA	O
s	O
/	O
p	O
nephrectomy	O
[	O
**	O
Numeric	O
Identifier	O
389	O
**	O
]	O
,	O
who	O
presents	O
after	O
syncopizing	O
today	O
at	O
work	O
.	O
She	O
acutely	O
began	O
to	O
feel	O
diaphoretic	O
and	O
lightheaded	O
,	O
so	O
she	O
sat	O
down	O
.	O
Per	O
others	O
'	O
reports	O
she	O
then	O
briefly	O
syncopized	O
and	O
came	O
to	O
immediately	O
afterwards	O
,	O
with	O
no	O
confusion	O
,	O
speech	O
slurring	O
,	O
toic	O
/	O
clonic	O
movements	O
.	O
Endorses	O
associated	O
N	O
/	O
V	O
,	O
but	O
no	O
CP	O
or	O
SOB	O
.	O
No	O
recent	O
F	O
/	O
C	O
.	O
She	O
does	O
note	O
that	O
she	O
has	O
been	O
taking	O
motrin	O
once	O
or	O
twice	O
daily	O
ever	O
since	O
her	O
total	O
hip	O
replacement	O
in	O
[	O
**	O
2192-4-19	O
**	O
]	O
.	O
She	O
also	O
reports	O
that	O
her	O
stools	O
have	O
been	O
darker	O
but	O
not	O
frnakly	O
black	O
for	O
the	O
last	O
few	O
days	O
.	O
In	O
the	O
ED	O
,	O
VS	O
were	O
97.9	O
95113/77	O
16	O
100	O
%	O
RA	O
.	O
NAD	O
.	O
2/6	O
SEM	O
.	O
benign	O
belly	O
.	O
Had	O
1	O
epidose	O
of	O
coffee	O
ground	O
episodes	O
.	O
EKG	O
showed	O
1st	O
degree	O
block	O
,	O
non	O
ischemic	O
.	O
HCT	O
of	O
29.3	O
,	O
baseline	O
40	O
.	O
T+C	O
x	O
4	O
units	O
,	O
no	O
blood	O
given	O
.	O
NG	O
lavage	O
returned	O
coffee	O
grounds	O
,	O
no	O
bright	O
red	O
blood	O
.	O
Self	O
d	O
/	O
c	O
'	O
ed	O
NGT	O
.	O
GI	O
was	O
consulted	O
,	O
will	O
scope	O
tomorrow	O
.	O
Last	O
VS	O
10034/74	O
16	O
99	O
%	O
RA	O
.	O
Access	O
was	O
obtained	O
with	O
2	O
18g	O
PIVs	O
.	O
Got	O
2L	O
NS	I-Drug
and	O
admitted	O
to	O
ICU	O
for	O
monitoring	O
.	O
.	O
Currently	O
feels	O
weak	O
and	O
tired	O
but	O
no	O
other	O
complaints	O
.	O
Past	O
Medical	O
History	O
:	O
HTN	O
RCC	O
s	O
/	O
p	O
partial	O
left	O
nephrectomy	O
[	O
**	O
2183	O
**	O
]	O
-	O
disease	O
free	O
since	O
.	O
high	O
cholesterol	O
s	O
/	O
p	O
total	O
hip	O
replacement	O
[	O
**	O
4	O
-	O
26	O
**	O
]	O
Social	O
History	O
:	O
Works	O
as	O
head	O
of	O
lead	O
prevention	O
program	O
.	O
Denies	O
EtOH	O
/	O
tobacco	O
/	O
drug	O
use	O
.	O
.	O
Family	O
History	O
:	O
non-contributory	O
Physical	O
Exam	O
:	O
VS	O
:	O
afeb	O
103135-153	O
/	O
80	O
-	O
90s	O
21	O
98	O
%	O
RA	O
Gen	O
:	O
middle	O
aged	O
female	O
in	O
NAD	O
HEENT	O
:	O
conjunctival	O
pallor	O
Cor	O
:	O
RRR	O
,	O
2/6	O
systolic	O
murmur	O
LSB	O
Resp	O
:	O
CTAB	O
Abd	O
:	O
obese	O
,	O
S	O
/	O
nt	O
/	O
nd	O
+	O
BS	O
ext	O
:	O
WWP	O
,	O
no	O
c	O
/	O
c	O
/	O
e	O
Pertinent	O
Results	O
:	O
[	O
**	O
2192-12-27	O
**	O
]	O
02:15	O
PM	O
BLOOD	O
WBC	O
-	O
10.5	O
RBC	O
-	O
3.29	O
*	O
Hgb	O
-	O
9.9	O
*	O
Hct	O
-	O
29.3	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
13.5	O
Plt	O
Ct	O
-	O
246	O
[	O
**	O
2192-12-27	O
**	O
]	O
07:37	O
PM	O
BLOOD	O
Hct	O
-	O
29.0	O
*	O
[	O
**	O
2192-12-28	O
**	O
]	O
03:31	O
AM	O
BLOOD	O
WBC	O
-	O
9.2	O
RBC	O
-	O
3.08	O
*	O
Hgb	O
-	O
9.6	O
*	O
Hct	O
-	O
26.4	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
31.1	O
MCHC	O
-	O
36.2	O
*	O
RDW	O
-	O
13.5	O
Plt	O
Ct	O
-	O
293	O
[	O
**	O
2192-12-27	O
**	O
]	O
07:37	O
PM	O
BLOOD	O
PT	O
-	O
13.6	O
*	O
PTT	O
-	O
20.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2192-12-27	O
**	O
]	O
02:15	O
PM	O
BLOOD	O
Glucose	O
-	O
131	O
*	O
UreaN	O
-	O
33	O
*	O
Creat	O
-	O
0.6	O
Na	O
-	O
141	O
K	O
-	O
5.2	O
*	O
Cl	O
-	O
107	O
HCO3	O
-	O
25	O
AnGap	O
-	O
14	O
[	O
**	O
2192-12-28	O
**	O
]	O
03:31	O
AM	O
BLOOD	O
Glucose	O
-	O
94	O
UreaN	O
-	O
23	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
3.8	O
Cl	O
-	O
108	O
HCO3	O
-	O
27	O
AnGap	O
-	O
10	O
ECG	O
Study	O
Date	O
of	O
[	O
**	O
2192-12-27	O
**	O
]	O
1:37:24	O
PM	O
Sinus	O
tachycardia	O
.	O
The	O
P	O
-	O
R	O
interval	O
is	O
short	O
without	O
evidence	O
of	O
pre-excitation	O
.	O
There	O
is	O
an	O
RSR	O
'	O
pattern	O
in	O
lead	O
V1	O
which	O
is	O
probably	O
normal	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
the	O
rate	O
is	O
faster	O
and	O
the	O
P	O
-	O
R	O
interval	O
is	O
shorter	O
.	O
Intervals	O
Axes	O
Rate	O
PR	O
QRS	O
QT	O
/	O
QTc	O
P	O
QRS	O
T	O
103	O
102	O
80342/417	O
50	O
38	O
56	O
EGD	O
Report	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
2974	O
**	O
]	O
,	O
[	O
**	O
2192-12-28	O
**	O
]	O
Impression	O
:	O
Granularity	O
,	O
friability	O
,	O
erythema	O
,	O
congestion	O
and	O
nodularity	O
in	O
the	O
duodenal	O
bulb	O
compatible	O
with	O
duodenitis	O
Granularity	O
,	O
friability	O
,	O
erythema	O
,	O
congestion	O
and	O
erosion	O
in	O
the	O
antrum	O
and	O
stomach	O
body	O
compatible	O
with	O
erosive	O
gastritis	O
Ulcer	O
in	O
the	O
stomach	O
body	O
(	O
injection	O
,	O
endoclip	O
)	O
Otherwise	O
normal	O
EGD	O
to	O
third	O
part	O
of	O
the	O
duodenum	O
Discharge	O
:	O
[	O
**	O
2192-12-30	O
**	O
]	O
12:35	O
PM	O
BLOOD	O
Hct	O
-	O
27.4	O
*	O
Brief	O
Hospital	O
Course	O
:	O
62F	O
with	O
a	O
history	O
of	O
chronic	O
hip	O
pain	O
/	O
NSAID	I-Drug
,	O
s	O
/	O
p	O
right	O
hip	O
replacement	O
this	O
in	O
[	O
**	O
4	O
-	O
26	O
**	O
]	O
who	O
presents	O
with	O
an	O
apparent	O
upper	O
GI	O
bleed	O
.	O
#	O
Upper	B-Ade
Gastrointestinal	I-Ade
Bleed	I-Ade
:	O
The	O
patient	O
presented	O
with	O
syncopy	O
and	O
subsequent	O
Coffee	O
-	O
groud	O
emesis	O
.	O
She	O
was	O
initially	O
admitted	O
to	O
the	O
MICU	O
for	O
monitoring	O
and	O
while	O
her	O
HCT	O
dropped	O
from	O
29	O
--	O
>	O
26	O
,	O
the	O
patient	O
had	O
no	O
evidence	O
of	O
hemodynamic	O
compromise	O
.	O
The	O
patient	O
was	O
started	O
on	O
an	O
IV	O
proton	B-Drug
pump	I-Drug
inhibior	O
and	O
the	O
gastroenterology	O
service	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
.	O
The	O
the	O
patient	O
underwent	O
endoscopy	O
which	O
showed	O
erosive	O
gastritis	O
and	O
deuodenitis	O
.	O
Given	O
the	O
patient	O
's	O
history	O
of	O
chronic	B-Reason
pain	I-Reason
,	O
NSAID	I-Drug
induced	O
gastropathy	I-Ade
was	O
the	O
suscepted	O
underlying	O
cause	O
.	O
Because	O
of	O
the	O
friability	O
of	O
the	O
patient	O
's	O
stomach	O
mucosa	O
,	O
no	O
biopsy	O
was	O
obtained	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
Anti-H	O
.	O
pylori	O
IgG	O
pending	O
.	O
Over	O
the	O
course	O
of	O
hospitalization	O
,	O
the	O
patient	O
recieved	O
1	O
unit	O
of	O
blood	I-Drug
.	O
She	O
continued	O
to	O
have	O
dark	O
stools	O
,	O
but	O
had	O
no	O
further	O
episodes	O
of	O
hematemesis	O
.	O
She	O
was	O
discharged	O
with	O
plans	O
to	O
continue	O
a	O
twice	O
daily	O
proton	B-Drug
pump	I-Drug
inhibior	I-Drug
and	O
a	O
repeat	O
endoscopy	O
in	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
months	O
.	O
She	O
was	O
to	O
have	O
a	O
repeat	O
hematocrit	O
check	O
in	O
1	O
week	O
.	O
She	O
was	O
strictly	O
instructed	O
to	O
avoid	O
NSAIDs	I-Drug
for	O
pain	B-Reason
control	I-Reason
.	O
#	O
HTN	I-Reason
:	O
Home	O
dose	O
of	O
lisinopril	I-Drug
was	O
initially	O
held	O
due	O
to	O
her	O
gastrointestinal	O
bleed	O
.	O
Throughout	O
her	O
stay	O
,	O
she	O
was	O
normotensive	O
.	O
She	O
was	O
instructed	O
to	O
restart	O
her	O
lisinopril	I-Drug
upon	O
discharge	O
at	O
the	O
discretion	O
of	O
her	O
primary	O
care	O
physician	O
.	O
.	O
#	O
Hyperliipidemia	I-Reason
:	O
The	O
patient	O
was	O
continued	O
on	O
her	O
home	O
dose	O
on	O
niacin	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
lisinopril	I-Drug
20	O
mg	O
daily	O
niacin	I-Drug
500	O
[	O
**	O
Hospital1	O
**	O
]	O
flaxseed	B-Drug
oil	I-Drug
MVI	I-Drug
motrin	I-Drug
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Omeprazole	I-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
:	O
Do	O
not	O
exceed	O
4g	O
per	O
day	O
.	O
.	O
3	O
.	O
Multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
do	O
not	O
restart	O
this	O
medication	O
until	O
instructed	O
by	O
your	O
primary	O
care	O
doctor	O
.	O
5	O
.	O
Flaxseed	B-Drug
Oil	I-Drug
Oral	O
6	O
.	O
Niacin	B-Drug
Flush	I-Drug
Free	I-Drug
Oral	O
7	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
Draw	O
:	O
Hematocrit	O
Please	O
ensure	O
results	O
are	O
sent	O
to	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Office	O
Fax	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
104698	O
**	O
]	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Erosive	O
Gastritis	O
Deuodenitis	O
Upper	O
GI	O
bleed	O
Discharge	O
Condition	O
:	O
The	O
patient	O
was	O
hemodynamically	O
stable	O
,	O
afebrile	O
and	O
without	O
pain	O
at	O
the	O
time	O
of	O
discharge	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
for	O
evaluation	O
and	O
treatment	O
of	O
lightheadedness	O
.	O
It	O
was	O
felt	O
that	O
your	O
symptoms	O
were	O
due	O
to	O
blood	O
loss	O
from	O
bleeding	O
in	O
your	O
stomach	O
.	O
During	O
this	O
hospitalization	O
,	O
you	O
underwent	O
an	O
esophagogastroduodenoscopy	O
(	O
EGD	O
)	O
which	O
showed	O
an	O
ulcer	I-Ade
and	O
stomach	B-Ade
irriation	I-Ade
.	O
From	O
your	O
history	O
,	O
this	O
was	O
most	O
likely	O
caused	O
by	O
your	O
daily	O
use	O
of	O
ibuprofen	I-Drug
.	O
.	O
Because	O
of	O
this	O
irriation	O
,	O
you	O
will	O
need	O
to	O
take	O
a	O
medication	O
(	O
Omeprazole	I-Drug
)	O
twice	O
a	O
day	O
for	O
at	O
least	O
8	O
weeks	O
--	O
this	O
will	O
allow	O
your	O
stomach	O
to	O
heal	O
.	O
It	O
is	O
highly	O
recommended	O
that	O
you	O
undergo	O
a	O
repeat	O
EGD	O
in	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
months	O
and	O
that	O
you	O
no	O
longer	O
use	O
ibuprofen	I-Drug
or	O
other	O
types	O
of	O
medications	O
known	O
as	O
NSAIDS	I-Drug
.	O
You	O
may	O
take	O
Tylenol	I-Drug
as	O
needed	O
for	O
pain	I-Reason
but	O
you	O
should	O
let	O
your	O
doctor	O
know	O
if	O
you	O
need	O
to	O
take	O
this	O
on	O
a	O
regular	O
basis	O
.	O
.	O
Because	O
of	O
your	O
bleeding	O
,	O
we	O
also	O
recommend	O
that	O
you	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
as	O
soon	O
as	O
possible	O
for	O
a	O
repeat	O
check	O
of	O
your	O
red	O
blood	O
count	O
(	O
Hematocrit	O
)	O
to	O
make	O
sure	O
you	O
have	O
no	O
further	O
evidence	O
of	O
bleeding	O
.	O
.	O
Your	O
blood	O
pressure	O
was	O
normal	O
this	O
hospitalization	O
,	O
we	O
recommend	O
that	O
you	O
do	O
not	O
continue	O
to	O
take	O
your	O
blood	O
pressure	O
medication	O
(	O
Lisinopril	I-Drug
)	O
until	O
you	O
see	O
your	O
primary	O
care	O
physician	O
.	O
.	O
Please	O
call	O
your	O
doctor	O
or	O
seek	O
immediate	O
medical	O
attention	O
if	O
you	O
develop	O
more	O
lightheadednedd	O
,	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
abdominal	O
pain	O
,	O
increased	O
darkened	O
stools	O
,	O
black	O
or	O
tarry	O
stools	O
or	O
any	O
other	O
symptom	O
of	O
concern	O
.	O
Followup	O
Instructions	O
:	O
Please	O
call	O
your	O
Primary	O
care	O
physician	O
(	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
for	O
an	O
appointment	O
in	O
the	O
next	O
week	O
to	O
10	O
days	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
608	O
**	O
]	O
.	O
Please	O
call	O
the	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
(	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
452	O
**	O
]	O
to	O
arrange	O
for	O
a	O
repeat	O
endoscopy	O
in	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
months	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2233	O
**	O
]	O
Appointments	O
prior	O
to	O
this	O
hospitalization	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
706	O
**	O
]	O
MRI	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2193-1-17	O
**	O
]	O
7:40	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
6781	O
**	O
]	O
,	O
[	O
**	O
Name12	O
(	O
NameIs	O
)	O
280	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1844	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2193-1-17	O
**	O
]	O
9:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
XRAY	O
(	O
SCC	O
2	O
)	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1228	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2193-8-2	O
**	O
]	O
7:35	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2285	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2193-1-1	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2156-12-20	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2156-12-23	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2108-3-22	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
All	O
allergies	O
/	O
adverse	O
drug	O
reactions	O
previously	O
recorded	O
have	O
been	O
deleted	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3984	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypoxemia	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Thoracentesis	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
88321	O
**	O
]	O
is	O
a	O
48	O
year	O
old	O
gentleman	O
with	O
a	O
PMH	O
significant	O
for	O
HCV	O
cirrhosis	O
and	O
a	O
recent	O
admission	O
for	O
a	O
traumatic	O
fall	O
with	O
multiple	O
IPH	O
requiring	O
bolt	O
placement	O
,	O
multiple	O
orthopedic	O
fractures	O
s	O
/	O
p	O
surgeries	O
,	O
trach	O
/	O
PEG	O
with	O
hospital	O
course	O
complicated	O
by	O
Serratia	B-Reason
pneumonia	I-Reason
treated	O
with	O
pip	B-Drug
/	I-Drug
tazo	I-Drug
now	O
admitted	O
for	O
hypoxemia	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
88322	O
**	O
]	O
after	O
a	O
30	O
foot	O
fall	O
from	O
height	O
with	O
multiple	O
IPH	O
s	O
/	O
p	O
intracranial	O
bolt	O
placement	O
for	O
elevated	O
ICP	O
,	O
multiple	O
orthopedic	O
fractures	O
requiring	O
surgical	O
intervention	O
,	O
splenectomy	O
,	O
and	O
trach	O
/	O
PEG	O
.	O
He	O
was	O
noted	O
to	O
develop	O
a	O
VAP	O
that	O
speciated	O
as	O
pan-sensitive	B-Reason
Serratia	I-Reason
and	O
he	O
completed	O
a	O
course	O
of	O
pip	B-Drug
/	I-Drug
tazo	I-Drug
,	O
and	O
also	O
had	O
a	O
right	O
-	O
sided	O
pneumothorax	O
requiring	O
chest	O
tube	O
placement	O
.	O
Per	O
report	O
,	O
the	O
patient	O
was	O
noted	O
at	O
rehab	O
to	O
have	O
been	O
progressively	O
hypoxemic	O
over	O
the	O
past	O
2	O
days	O
with	O
a	O
outpatient	O
CXR	O
concerning	O
for	O
right	O
-	O
sided	O
pneumonia	O
.	O
He	O
did	O
not	O
have	O
increased	O
sputum	O
production	O
or	O
fevers	O
.	O
He	O
was	O
then	O
sent	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
for	O
further	O
evaluation	O
.	O
In	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
,	O
initial	O
VS	O
98.1	O
6292/54	O
18	O
95	O
%	O
40	O
%	O
FM	O
.	O
CXR	O
notable	O
for	O
right	B-Reason
-	I-Reason
sided	I-Reason
complete	I-Reason
opacification	I-Reason
,	O
for	O
which	O
the	O
patient	O
received	O
vanco	I-Drug
and	O
pip	B-Drug
/	I-Drug
tazo	I-Drug
.	O
He	O
was	O
placed	O
on	O
volume	O
cycled	O
assist	O
control	O
,	O
and	O
was	O
sent	O
for	O
a	O
CT	O
chest	O
to	O
rule	O
out	O
diaphragmatic	O
rupture	O
.	O
While	O
at	O
CT	O
,	O
he	O
received	O
5	O
haldol	I-Drug
iv	O
and	O
2	O
iv	O
ativan	I-Drug
for	O
agitation	I-Reason
,	O
after	O
which	O
he	O
was	O
arousable	O
to	O
stimulation	O
.	O
He	O
was	O
then	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
management	O
.	O
Currently	O
,	O
the	O
patient	O
is	O
on	O
mechanical	O
ventilation	O
,	O
minimally	O
responsive	O
to	O
verbal	O
stimuli	O
.	O
ROS	O
:	O
Limited	O
given	O
somnolence	O
.	O
Past	O
Medical	O
History	O
:	O
Admitted	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
88323	O
**	O
]	O
for	O
30	O
foot	O
fall	O
from	O
roof	O
.	O
Multiple	O
IPH	O
(	O
multiple	O
intraparenchymal	O
petechial	O
,	O
hemorrhages	O
at	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
junction	O
,	O
as	O
well	O
as	O
involving	O
the	O
right	O
mid	O
brain	O
,	O
consistent	O
with	O
diffuse	O
axonal	O
injury	O
)	O
,	O
facial	O
fractures	O
,	O
bilateral	O
arm	O
fractures	O
as	O
well	O
as	O
right	O
knee	O
fracture	O
.	O
Underwent	O
splenectomy	O
,	O
multiple	O
orthopedic	O
surgeries	O
.	O
-	O
Surgeries	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
-	O
>	O
ex-lap	O
with	O
splenectomy	O
-	O
Bolt	O
placed	O
on	O
[	O
**	O
11	O
-	O
19	O
**	O
]	O
-	O
Trach	O
/	O
PEG	O
on	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
-	O
Facial	O
ORIF	O
on	O
[	O
**	O
12	O
-	O
1	O
**	O
]	O
-	O
IVC	O
filter	O
placed	O
[	O
**	O
12	O
-	O
7	O
**	O
]	O
-	O
HCAP	I-Reason
treated	O
with	O
vanco	I-Drug
and	O
pip	B-Drug
/	I-Drug
tazo	I-Drug
,	O
speciated	O
as	O
pan-sensitive	B-Reason
Serratia	I-Reason
.	O
-	O
No	O
evidence	O
of	O
seizure	O
activity	O
during	O
admission	O
,	O
EEG	O
demonstrating	O
encephalopathy	O
.	O
Arousable	O
to	O
voice	O
and	O
stimulation	O
with	O
opening	O
of	O
eyes	O
and	O
localization	O
to	O
voice	O
.	O
Intermitently	O
follows	O
commands	O
.	O
-	O
Discharged	O
on	O
35	O
%	O
trach	O
collar	O
.	O
-	O
Received	O
all	O
appropriate	O
vaccinations	O
Social	O
History	O
:	O
Worked	O
as	O
a	O
roofer	O
.	O
Drinks	O
6	O
-	O
12	O
pack	O
of	O
beer	O
daily	O
,	O
quit	O
smoking	O
recently	O
.	O
Family	O
History	O
:	O
Non-contributory	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
97.5	O
6297/66	O
14	O
95	O
%	O
AC	O
550x14	O
,	O
5	O
,	O
50	O
%	O
.	O
Gen	O
:	O
Vented	O
.	O
HEENT	O
:	O
Pupils	O
2	O
-	O
>	O
1	O
mm	O
bilaterally	O
.	O
Sclerae	O
anicteric	O
.	O
MM	O
dry	O
.	O
CV	O
:	O
Nl	O
S1	O
+	O
S2	O
Pulm	O
:	O
Bronchial	O
breath	O
sounds	O
on	O
right	O
,	O
rhonchorous	O
on	O
left	O
anteriorly	O
.	O
Abd	O
:	O
Midline	O
incision	O
healing	O
,	O
no	O
signs	O
of	O
surrounding	O
erythema	O
.	O
G	O
-	O
tube	O
in	O
place	O
.	O
+	O
bs	O
.	O
Ext	O
:	O
Right	O
arm	O
,	O
right	O
knee	O
/	O
RLE	O
,	O
LLE	O
in	O
braces	O
.	O
No	O
c	O
/	O
c	O
/	O
e.	O
Neuro	O
:	O
Opens	O
eyes	O
to	O
verbal	O
stimuli	O
,	O
not	O
following	O
commands	O
.	O
Pertinent	O
Results	O
:	O
Labs	O
at	O
Admission	O
:	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
WBC	O
-	O
15.8	O
*	O
RBC	O
-	O
3.46	O
*	O
Hgb	O
-	O
11.4	O
*	O
Hct	O
-	O
35.7	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
33.0	O
*	O
MCHC	O
-	O
32.0	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
278	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
Neuts	O
-	O
56.4	O
Lymphs	O
-	O
28.2	O
Monos	O
-	O
5.9	O
Eos	O
-	O
8.6	O
*	O
Baso	O
-	O
0.9	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
PT	O
-	O
13.4	O
PTT	O
-	O
35.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
Glucose	O
-	O
93	O
UreaN	O
-	O
17	O
Creat	O
-	O
0.6	O
Na	O
-	O
132	O
*	O
K	O
-	O
7.8	O
*	O
Cl	O
-	O
100	O
HCO3	O
-	O
26	O
AnGap	O
-	O
14	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
ALT	O
-	O
51	O
*	O
AST	O
-	O
139	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
646	O
*	O
AlkPhos	O
-	O
174	O
*	O
TotBili	O
-	O
0.4	O
[	O
**	O
2156-12-20	O
**	O
]	O
10:16	O
PM	O
BLOOD	O
Calcium	O
-	O
8.6	O
Phos	O
-	O
3.9	O
Mg	O
-	O
2.0	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
Albumin	O
-	O
2.7	O
*	O
[	O
**	O
2156-12-20	O
**	O
]	O
10:16	O
PM	O
BLOOD	O
VitB12	O
-	O
1546	O
*	O
Folate	O
-	O
GREATER	O
TH	O
[	O
**	O
2156-12-20	O
**	O
]	O
03:40	O
PM	O
BLOOD	O
Glucose	O
-	O
92	O
Lactate	O
-	O
1.3	O
Na	O
-	O
134	O
*	O
K	O
-	O
7.7	O
*	O
Cl	O
-	O
96	O
*	O
calHCO3	O
-	O
30	O
[	O
**	O
2156-12-20	O
**	O
]	O
09:57	O
PM	O
BLOOD	O
Lactate	O
-	O
1.2	O
Labs	O
at	O
Discharge	O
:	O
[	O
**	O
2156-12-23	O
**	O
]	O
06:04	O
AM	O
BLOOD	O
WBC	O
-	O
14.3	O
*	O
RBC	O
-	O
3.66	O
*	O
Hgb	O
-	O
11.7	O
*	O
Hct	O
-	O
37.6	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
32.1	O
*	O
MCHC	O
-	O
31.3	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
316	O
[	O
**	O
2156-12-23	O
**	O
]	O
06:04	O
AM	O
BLOOD	O
Neuts	O
-	O
51.9	O
Lymphs	O
-	O
29.0	O
Monos	O
-	O
8.5	O
Eos	O
-	O
9.8	O
*	O
Baso	O
-	O
0.8	O
[	O
**	O
2156-12-23	O
**	O
]	O
06:04	O
AM	O
BLOOD	O
Glucose	O
-	O
122	O
*	O
UreaN	O
-	O
11	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
4.1	O
Cl	O
-	O
104	O
HCO3	O
-	O
29	O
AnGap	O
-	O
12	O
[	O
**	O
2156-12-22	O
**	O
]	O
04:40	O
AM	O
BLOOD	O
ALT	O
-	O
53	O
*	O
AST	O
-	O
100	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
242	O
AlkPhos	O
-	O
198	O
*	O
TotBili	O
-	O
0.5	O
[	O
**	O
2156-12-23	O
**	O
]	O
06:04	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
2.7	O
#	O
Mg	O
-	O
2.0	O
Pleural	O
Fluid	O
Analysis	O
:	O
[	O
**	O
2156-12-21	O
**	O
]	O
5:37	O
pm	O
PLEURAL	O
FLUID	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2156-12-21	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2156-12-22	O
**	O
]	O
)	O
:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
DIRECT	O
SMEAR	O
.	O
ACID	O
FAST	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
PLEURAL	O
ANALYSIS	O
WBC	O
RBC	O
Polys	O
Lymphs	O
Monos	O
Eos	O
Meso	O
Macro	O
[	O
**	O
2156-12-21	O
**	O
]	O
17:37	O
850	O
*	O
[	O
**	O
Numeric	O
Identifier	O
3652	O
**	O
]	O
*	O
21	O
*	O
17	O
*	O
3	O
*	O
56	O
*	O
2	O
*	O
1	O
*	O
PLEURAL	O
CHEMISTRY	O
TotProt	O
Glucose	O
LD	O
(	O
LDH	O
)	O
Cholest	O
Triglyc	O
[	O
**	O
2156-12-21	O
**	O
]	O
17:37	O
4.6	O
82	O
272	O
61	O
39	O
OTHER	O
BODY	O
FLUID	O
pH	O
[	O
**	O
2156-12-21	O
**	O
]	O
18:04	O
7.39	O
Pleural	O
Fluid	O
:	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS	O
.	O
Mesothelial	O
cells	O
,	O
histiocytes	O
,	O
lymphocytes	O
,	O
and	O
neutrophils	O
.	O
Imaging	O
Studies	O
:	O
Chest	O
CT	O
without	O
contrast	O
(	O
[	O
**	O
2156-12-20	O
**	O
]	O
)	O
:	O
1	O
.	O
No	O
evidence	O
of	O
diaphragmatic	O
hernia	O
.	O
2	O
.	O
Large	O
right	O
and	O
moderate	O
left	O
simple	O
pleural	O
effusions	O
.	O
Consolidation	O
and	O
volume	O
loss	O
in	O
the	O
lower	O
lobes	O
bilaterally	O
,	O
right	O
greater	O
than	O
left	O
,	O
may	O
represent	O
atelectasis	O
however	O
,	O
aspiration	O
or	O
superimposed	O
infection	O
can	O
not	O
entirely	O
be	O
excluded	O
.	O
3	O
.	O
Healing	O
rib	O
and	O
clavicle	O
fractures	O
,	O
as	O
described	O
above	O
.	O
4	O
.	O
No	O
pneumothorax	O
.	O
Chest	O
x-ray	O
(	O
[	O
**	O
2156-12-21	O
**	O
]	O
)	O
:	O
In	O
comparison	O
with	O
the	O
earlier	O
study	O
of	O
this	O
date	O
,	O
there	O
has	O
been	O
removal	O
of	O
a	O
substantial	O
amount	O
of	O
right	O
pleural	O
effusion	O
with	O
a	O
small	O
residual	O
.	O
No	O
evidence	O
of	O
pneumothorax	O
.	O
Tracheostomy	O
tube	O
remains	O
in	O
place	O
and	O
there	O
is	O
again	O
evidence	O
of	O
volume	O
loss	O
at	O
the	O
left	O
base	O
.	O
Transthoracic	O
echocardiogram	O
(	O
[	O
**	O
2156-12-21	O
**	O
]	O
:	O
The	O
left	O
atrium	O
and	O
right	O
atrium	O
are	O
normal	O
in	O
cavity	O
size	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
global	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
appears	O
bicuspid	O
with	O
mildly	O
thickened	O
leaflets	O
,	O
eccentric	O
closure	O
point	O
and	O
fused	O
right	O
and	O
left	O
raphe	O
.	O
A	O
gradient	O
could	O
not	O
be	O
assessed	O
,	O
but	O
there	O
does	O
not	O
appear	O
to	O
be	O
significant	O
aortic	O
valve	O
stenosis	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
prominent	O
fat	O
pad	O
.	O
IMPRESSION	O
:	O
Probable	O
bicuspid	O
aortic	O
valve	O
with	O
fused	O
right	O
/	O
left	O
raphe	O
and	O
no	O
significant	O
stenosis	O
or	O
regurgitation	O
.	O
Dilated	O
ascending	O
aorta	O
.	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
biventricular	O
systolic	O
function	O
.	O
If	O
there	O
is	O
a	O
clinical	O
suspicion	O
for	O
an	O
aortic	O
dissection	O
-	O
a	O
thoracic	O
CT	O
/	O
MRI	O
or	O
TEE	O
are	O
suggested	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
88321	O
**	O
]	O
is	O
a	O
48	O
year	O
old	O
gentleman	O
with	O
a	O
PMH	O
significant	O
for	O
HCV	O
cirrhosis	O
and	O
a	O
recent	O
admission	O
for	O
a	O
traumatic	O
fall	O
with	O
multiple	O
IPH	O
requiring	O
bolt	O
placement	O
,	O
multiple	O
orthopedic	O
fractures	O
s	O
/	O
p	O
surgeries	O
,	O
trach	O
/	O
PEG	O
with	O
hospital	O
course	O
complicated	O
by	O
Serratia	B-Reason
pneumonia	I-Reason
treated	O
with	O
pip	B-Drug
/	I-Drug
tazo	I-Drug
now	O
admitted	O
for	O
hypoxemia	O
.	O
#	O
Hypoxemia	O
/	O
leukocytosis	O
:	O
CTAP	O
demonstrates	O
a	O
new	O
right	O
-	O
sided	O
pleural	O
effusion	O
with	O
RLL	O
collapse	O
and	O
volume	O
loss	O
throughout	O
right	O
side	O
.	O
Compressive	O
atelectasis	O
was	O
considered	O
,	O
although	O
could	O
not	O
rule	O
out	O
HCAP	O
.	O
With	O
regard	O
to	O
new	O
pleural	O
effusion	O
,	O
LFTs	O
were	O
largely	O
unchanged	O
from	O
prior	O
,	O
making	O
hepatic	O
hydrothorax	O
unlikely	O
.	O
This	O
may	O
be	O
a	O
parapneumonic	O
effusion	O
with	O
underlying	O
pneumonia	O
,	O
or	O
could	O
also	O
be	O
from	O
new	O
heart	O
failure	O
.	O
Would	O
also	O
consider	O
chylothorax	O
given	O
history	O
of	O
trauma	O
.	O
The	O
patient	O
underwent	O
thoracentesis	O
on	O
the	O
first	O
hospital	O
day	O
and	O
1.2	O
liters	O
of	O
exudative	O
fluid	O
were	O
removed	O
from	O
the	O
right	O
pleural	O
space	O
.	O
Cultures	O
from	O
the	O
fluid	O
came	O
back	O
negative	O
,	O
and	O
the	O
antibiotics	O
were	O
stopped	O
.	O
Trauma	O
surgery	O
was	O
consulted	O
who	O
felt	O
that	O
the	O
pleural	O
fluid	O
might	O
be	O
secondary	O
to	O
trauma	O
.	O
They	O
recommended	O
for	O
repeat	O
imaging	O
in	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
days	O
to	O
see	O
if	O
the	O
fluid	O
was	O
reaccumulating	O
.	O
Also	O
,	O
they	O
recommended	O
for	O
repeat	O
imaging	O
if	O
the	O
patient	O
develops	O
any	O
new	O
respiratory	O
symptoms	O
.	O
Interestingly	O
,	O
the	O
fluid	O
from	O
the	O
thoracentesis	O
had	O
an	O
eosinophilic	O
predominance	O
(	O
56	O
%	O
eosinophils	O
)	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
patient	O
was	O
noted	O
to	O
have	O
a	O
peripheral	B-Ade
blood	I-Ade
eosinophilia	I-Ade
.	O
This	O
was	O
all	O
felt	O
to	O
be	O
secondary	O
to	O
Depakote	I-Drug
,	O
which	O
had	O
been	O
recently	O
started	O
.	O
The	O
divalproex	I-Drug
was	O
therefore	O
stopped	O
.	O
Notably	O
,	O
after	O
the	O
thoracentesis	O
,	O
the	O
patient	O
's	O
respiratory	O
status	O
improved	O
markedly	O
and	O
he	O
was	O
able	O
to	O
be	O
weaned	O
back	O
to	O
the	O
trach	O
mask	O
.	O
With	O
regard	O
to	O
work	O
-	O
up	O
for	O
other	O
causes	O
of	O
pleural	O
effusion	O
,	O
a	O
transthoracic	O
echocardiogram	O
did	O
not	O
show	O
any	O
cardiac	O
dysfunction	O
,	O
and	O
infectious	O
studies	O
,	O
as	O
above	O
,	O
all	O
returned	O
negative	O
.	O
Cytologic	O
analysis	O
showed	O
no	O
malignant	O
cells	O
.	O
Antibiotics	O
were	O
stopped	O
after	O
the	O
first	O
hospital	O
day	O
.	O
Due	O
to	O
the	O
calficifications	I-Reason
noted	O
on	O
CT	O
scan	O
,	O
a	O
tuberculin	I-Drug
skin	O
test	O
was	O
placed	O
to	O
the	O
right	O
forearm	O
on	O
[	O
**	O
12	O
-	O
22	O
**	O
]	O
.	O
This	O
should	O
be	O
interpreted	O
on	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
or	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
.	O
The	O
spot	O
of	O
the	O
PPD	I-Drug
placement	O
is	O
marked	O
with	O
a	O
bandaid	O
.	O
#	O
Mental	O
status	O
:	O
His	O
mental	O
status	O
remained	O
at	O
baseline	O
,	O
per	O
family	O
members	O
and	O
rehab	O
facility	O
notes	O
.	O
He	O
was	O
agitated	O
and	O
minimally	O
interactive	O
.	O
He	O
required	O
prn	O
doses	O
of	O
Haldol	I-Drug
and	O
Ativan	I-Drug
for	O
agitation	I-Reason
.	O
With	O
regard	O
to	O
the	O
history	O
of	O
traumatic	O
brain	O
injury	O
,	O
neurosurgery	O
was	O
consulted	O
during	O
this	O
admission	O
and	O
did	O
not	O
feel	O
there	O
was	O
any	O
need	O
for	O
intervention	O
.	O
Head	O
CT	O
was	O
deferred	O
.	O
He	O
was	O
continued	O
on	O
Keppra	I-Drug
for	O
seizure	I-Reason
prophylaxis	O
.	O
Divalproex	I-Drug
,	O
as	O
above	O
,	O
was	O
stopped	O
due	O
to	O
peripheral	I-Ade
blood	O
and	O
pleural	O
fluid	O
eosinophilia	O
.	O
#	O
Anemia	O
:	O
Hematocrit	O
was	O
35.8	O
on	O
admission	O
,	O
baseline	O
during	O
last	O
admission	O
27	O
-	O
33	O
with	O
macrocytosis	O
.	O
His	O
hematocrit	O
remained	O
stable	O
.	O
#	O
Orthopedics	O
:	O
Orthopedics	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
during	O
this	O
admission	O
.	O
Follow	O
-	O
up	O
plans	O
are	O
outlined	O
in	O
the	O
discharge	O
orders	O
.	O
#	O
HCV	O
cirrhosis	O
:	O
LFTs	O
were	O
at	O
baseline	O
.	O
#	O
Depression	O
:	O
Continue	O
home	O
psychotropic	O
regimen	O
.	O
#	O
Ulcerative	O
colitis	O
:	O
Not	O
currently	O
treated	O
.	O
#	O
Nutrition	O
:	O
pnt	O
recieved	O
TF	O
's	O
FEN	O
:	O
TF	O
.	O
.	O
#	O
PPx	I-Reason
:	O
recieved	O
Heparin	I-Drug
SQ.	O
.	O
#	O
Access	O
:	O
Double	O
lumen	O
PICC	O
in	O
LAC	O
;	O
this	O
was	O
removed	O
during	O
the	O
admission	O
as	O
patient	O
was	O
no	O
longer	O
needing	O
antibiotics	I-Drug
or	O
continuous	O
intravenous	O
medicines	O
.	O
.	O
#	O
Code	O
:	O
Confirmed	O
FULL	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
88324	O
**	O
]	O
.	O
.	O
#	O
Contact	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
88325	O
**	O
]	O
(	O
Sister	O
)	O
.	O
#	O
Dispo	O
:	O
ICU	O
level	O
of	O
care	O
,	O
transferred	O
back	O
to	O
rehab	O
after	O
the	O
thoracentesis	O
and	O
improvement	O
in	O
respiratory	O
status	O
.	O
Medications	O
on	O
Admission	O
:	O
Albuterol	I-Drug
nebs	O
Dulcolax	I-Drug
Chlorhexidine	I-Drug
QID	O
citalopram	I-Drug
20	O
mg	O
qam	O
Clonidine	I-Drug
0.1	O
mg	O
Q12H	O
.	O
Clotrimazole	I-Drug
topical	O
tid	O
divalproex	I-Drug
sprinkles	O
250	O
Q8H	O
Erythromycin	I-Drug
eye	O
ointment	O
QID	O
Famotidine	B-Drug
20	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Ferrous	B-Drug
sulfate	I-Drug
300	O
mg	O
QAM	O
Folate	I-Drug
Heparin	I-Drug
SQ	O
Levetiracetam	B-Drug
1000	O
mg	O
Q12H	O
Methadone	I-Drug
5	O
mg	O
Q8H	O
MVI	I-Drug
Quetiapine	B-Drug
25	O
mg	O
QAM	O
,	O
50	O
mg	O
QPM	O
Thiamine	I-Drug
Trazodone	I-Drug
50	O
mg	O
qhs	O
APAP	I-Drug
prn	O
Ativan	I-Drug
0.5	O
mg	O
prn	O
quetiapine	B-Drug
25	O
mg	O
Q6H	O
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
2	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
3	O
.	O
docusate	I-Drug
sodium	O
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Puff	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
5	O
.	O
citalopram	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
levetiracetam	I-Drug
100	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
Ten	O
(	O
10	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
1000	O
mg	O
PO	O
BID	O
.	O
8	O
.	O
thiamine	I-Drug
HCl	O
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
or	O
fever	I-Reason
.	O
10	O
.	O
quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
11	O
.	O
quetiapine	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)	O
)	O
.	O
12	O
.	O
quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
Agitation	I-Reason
.	O
13	O
.	O
trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
14	O
.	O
heparin	I-Drug
(	O
porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
or	O
agitaiton	I-Reason
.	O
16	O
.	O
methadone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
:	O
Hold	O
for	O
sedation	O
/	O
RR	O
<	O
10	O
.	O
17	O
.	O
ferrous	B-Drug
sulfate	I-Drug
300	O
mg	O
(	O
60	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
1107	O
**	O
]	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
38	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Drug	O
induced	O
pulmonary	O
infusion	O
Secondary	O
:	O
Traumatic	O
brain	O
injury	O
secondary	O
to	O
mechanical	O
fall	O
Mutliple	O
skeletal	O
fractures	O
secondary	O
to	O
mechanical	O
fall	O
Hepatitis	O
C	O
Virus	O
Cirrhosis	O
Depression	O
Alcoholic	O
Cirrhosis	O
with	O
history	O
of	O
withdrawal	O
Ulcerative	O
colitis	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
always	O
.	O
Level	O
of	O
Consciousness	O
:	O
Lethargic	O
but	O
arousable	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
due	O
to	O
worsening	O
shortness	O
of	O
breath	O
.	O
You	O
came	O
to	O
the	O
hospital	O
and	O
had	O
a	O
chest	O
xray	O
which	O
showed	O
an	O
accumulation	O
of	O
fluid	O
around	O
the	O
right	O
lung	O
.	O
The	O
fluid	O
around	O
your	O
lung	O
was	O
drained	O
,	O
and	O
your	O
shortness	O
of	O
breath	O
improved	O
.	O
We	O
felt	O
the	O
fluid	B-Ade
accumulation	I-Ade
was	O
due	O
to	O
the	O
new	O
medication	O
you	O
started	O
called	O
"	O
Depakaote	I-Drug
"	O
.	O
As	O
a	O
result	O
,	O
we	O
discontinued	O
this	O
medication	O
.	O
You	O
should	O
follow	O
up	O
with	O
your	O
psychiatrist	O
to	O
make	O
sure	O
your	O
medications	O
are	O
appropriately	O
controlling	O
your	O
agitation	O
.	O
CHANGES	O
TO	O
YOUR	O
MEDICATIONS	O
:	O
DEPAKOTE	I-Drug
---	O
>	O
STOP	O
TAKING	O
THIS	O
MEDICATION	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
at	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
orthopedic	O
hand	O
clinic	O
within	O
2	O
weeks	O
by	O
Tuesday	O
[	O
**	O
2157-1-4	O
**	O
]	O
.	O
Please	O
call	O
to	O
confimr	O
appointment	O
.	O
Hand	O
Clinic	O
-	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
951	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Department	O
:	O
Orthopedics	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
2	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
Phone	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
32269	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2437	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
2438	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2156-12-23	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2135-1-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2135-1-31	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2085-2-3	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
NEUROLOGY	O
Allergies	O
:	O
Hurricaine	O
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1838	O
**	O
]	O
Chief	O
Complaint	O
:	O
Called	O
by	O
Emergency	O
Department	O
as	O
a	O
Code	O
Stroke	O
for	O
Left	O
-	O
sided	O
weakness	O
and	O
aphasia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
IV	O
-	O
tPA	I-Drug
MERCI	O
clot	O
retrieval	O
History	O
of	O
Present	O
Illness	O
:	O
NIH	O
Stroke	O
Scale	O
score	O
was	O
0	O
:	O
17	O
1a	O
.	O
Level	O
of	O
Consciousness	O
:	O
0	O
1b	O
.	O
LOC	O
Question	O
:	O
1	O
1c	O
.	O
LOC	O
Commands	O
:	O
0	O
2	O
.	O
Best	O
gaze	O
:	O
2	O
3	O
.	O
Visual	O
fields	O
:	O
2	O
4	O
.	O
Facial	O
palsy	O
:	O
2	O
5a	O
.	O
Motor	O
arm	O
,	O
left	O
:	O
4	O
5b	O
.	O
Motor	O
arm	O
,	O
right	O
:	O
0	O
6a	O
.	O
Motor	O
leg	O
,	O
left	O
:	O
4	O
6b	O
.	O
Motor	O
leg	O
,	O
right	O
:	O
0	O
7	O
.	O
Limb	O
Ataxia	O
:	O
0	O
8	O
.	O
Sensory	O
:	O
1	O
9	O
.	O
Language	O
:	O
0	O
10	O
.	O
Dysarthria	O
:	O
0	O
11	O
.	O
Extinction	O
and	O
Neglect	O
:	O
1	O
HPI	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
104742	O
**	O
]	O
is	O
a	O
49	O
y	O
/	O
o	O
woman	O
with	O
a	O
PMH	O
significant	O
for	O
myelodysplastic	O
syndrome	O
,	O
HTN	O
and	O
hypothyroidism	O
,	O
who	O
presents	O
with	O
left	O
sided	O
weakness	O
.	O
She	O
reportedly	O
went	O
to	O
bed	O
in	O
her	O
normal	O
state	O
of	O
health	O
at	O
2300	O
.	O
Her	O
partner	O
heard	O
her	O
thrashing	O
in	O
bed	O
at	O
0130	O
and	O
at	O
that	O
time	O
,	O
he	O
noted	O
her	O
speech	O
to	O
be	O
slurred	O
and	O
her	O
left	O
side	O
to	O
be	O
weak	O
,	O
though	O
apparently	O
still	O
able	O
to	O
move	O
.	O
As	O
it	O
seems	O
that	O
the	O
thrashing	O
likely	O
was	O
around	O
the	O
time	O
of	O
onset	O
of	O
the	O
stroke	O
,	O
we	O
considered	O
0130	O
to	O
be	O
the	O
last	O
known	O
well	O
time	O
.	O
She	O
was	O
initially	O
taken	O
to	O
OSH	O
,	O
where	O
she	O
had	O
a	O
CT	O
head	O
that	O
was	O
negative	O
for	O
hemorrhage	O
;	O
it	O
was	O
there	O
determined	O
that	O
she	O
was	O
"	O
out	O
of	O
the	O
tPA	I-Drug
window	O
"	O
and	O
she	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
care	O
.	O
Full	O
ROS	O
unable	O
to	O
be	O
obtained	O
as	O
patient	O
very	O
agitated	O
and	O
seemingly	O
confused	O
when	O
providing	O
her	O
own	O
history	O
.	O
However	O
,	O
she	O
does	O
not	O
appear	O
to	O
have	O
any	O
recent	O
febrile	O
illnesses	O
and	O
there	O
is	O
no	O
current	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpitations	O
or	O
abdominal	O
pain	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
HTN	O
-	O
gout	O
-	O
hypothyroidism	O
-	O
myelodysplastic	O
syndrome	O
-	O
alcohol	O
abuse	O
-	O
lumbar	O
surgery	O
(	O
exact	O
nature	O
of	O
surgery	O
unknown	O
)	O
Social	O
History	O
:	O
She	O
was	O
previously	O
employed	O
as	O
a	O
hairdresser	O
,	O
though	O
says	O
she	O
hasnt	O
worked	O
in	O
4	O
years	O
.	O
Not	O
reported	O
by	O
patient	O
,	O
but	O
there	O
is	O
apparently	O
a	O
history	O
of	O
alochol	O
abuse	O
.	O
Family	O
History	O
:	O
unknown	O
Physical	O
Exam	O
:	O
on	O
admission	O
:	O
Vitals	O
:	O
T	O
:	O
97	O
P	O
:	O
67	O
BP	O
:	O
138/49	O
SaO2	O
:	O
99	O
%	O
NC	O
General	O
:	O
Awake	O
,	O
agitated	O
HEENT	O
:	O
no	O
oral	O
lesions	O
Neck	O
:	O
Supple	O
Pulmonary	O
:	O
Lungs	O
CTA	O
bilaterally	O
Cardiac	O
:	O
RRR	O
,	O
S1S2	O
Abdomen	O
:	O
soft	O
,	O
+	O
BS	O
Extremities	O
:	O
warm	O
,	O
well	O
perfused	O
Neurologic	O
:	O
-	O
Mental	O
Status	O
:	O
Alert	O
,	O
oriented	O
to	O
person	O
,	O
"	O
hospital	O
"	O
,	O
and	O
year	O
but	O
not	O
month	O
.	O
Naming	O
generally	O
intact	O
,	O
with	O
some	O
errors	O
on	O
low	O
frequency	O
objects	O
.	O
Left	O
sided	O
neglect	O
.	O
-	O
Cranial	O
Nerves	O
:	O
PEERL	O
6	O
--	O
>	O
4	O
mm	O
b	O
/	O
l.	O
Gaze	O
deviation	O
to	O
right	O
.	O
Left	O
sided	O
hemianopia	O
.	O
Would	O
not	O
cross	O
midline	O
to	O
commands	O
but	O
is	O
able	O
to	O
track	O
acorss	O
midline	O
.	O
Left	O
facial	O
droop	O
.	O
Sensory	O
loss	O
left	O
face	O
.	O
Motor	O
:	O
L	O
hemiparesis	O
-	O
no	O
antigravity	O
ability	O
at	O
all	O
on	O
left	O
.	O
Right	O
sided	O
strength	O
full	O
.	O
Sensory	O
:	O
Light	O
touch	O
intact	O
at	O
times	O
when	O
testing	O
sensation	O
,	O
but	O
sometimes	O
she	O
would	O
not	O
realize	O
when	O
someone	O
was	O
holding	O
her	O
left	O
arm	O
,	O
indicating	O
a	O
possible	O
sensory	O
componenent	O
.	O
Dimimihed	O
pinprick	O
on	O
left	O
.	O
Reflexex	O
:	O
Patellar	O
reflexes	O
2	O
+	O
b	O
/	O
l.	O
Biceps	O
reflex	O
2	O
+	O
on	O
right	O
,	O
remaining	O
reflexes	O
1	O
+	O
.	O
Toe	O
upgoing	O
on	O
left	O
and	O
mute	O
on	O
right	O
.	O
Coordination	O
:	O
finger	O
-	O
nose	O
intact	O
on	O
right	O
Pertinent	O
Results	O
:	O
[	O
**	O
2135-1-21	O
**	O
]	O
06:20	O
PM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
104	O
PCO2	O
-	O
33	O
*	O
PH	O
-	O
7.45	O
TOTAL	O
CO2	O
-	O
24	O
BASE	O
XS	O
-	O
0	O
[	O
**	O
2135-1-21	O
**	O
]	O
05:02	O
PM	O
TYPE	O
-	O
ART	O
TEMP	O
-	O
37.1	O
RATES	O
-	O
/	O
25	O
TIDAL	O
VOL	O
-	O
500	O
PEEP	O
-	O
5	O
O2	O
-	O
40	O
PO2	O
-	O
148	O
*	O
PCO2	O
-	O
30	O
*	O
PH	O
-	O
7.47	O
*	O
TOTAL	O
CO2	O
-	O
22	O
BASE	O
XS	O
-	O
0	O
INTUBATED	O
-	O
INTUBATED	O
VENT	O
-	O
SPONTANEOU	O
[	O
**	O
2135-1-21	O
**	O
]	O
05:02	O
PM	O
GLUCOSE	O
-	O
82	O
K	O
+	O
-	O
3.7	O
[	O
**	O
2135-1-21	O
**	O
]	O
05:02	O
PM	O
freeCa	O
-	O
1.08	O
*	O
[	O
**	O
2135-1-21	O
**	O
]	O
10:44	O
AM	O
TYPE	O
-	O
ART	O
TEMP	O
-	O
35.0	O
RATES	O
-	O
15	O
/	O
TIDAL	O
VOL	O
-	O
500	O
PEEP	O
-	O
5	O
PO2	O
-	O
139	O
*	O
PCO2	O
-	O
35	O
PH	O
-	O
7.42	O
TOTAL	O
CO2	O
-	O
23	O
BASE	O
XS	O
-	O
0	O
[	O
**	O
2135-1-21	O
**	O
]	O
10:44	O
AM	O
GLUCOSE	O
-	O
124	O
*	O
[	O
**	O
2135-1-21	O
**	O
]	O
10:44	O
AM	O
freeCa	O
-	O
1.07	O
*	O
[	O
**	O
2135-1-21	O
**	O
]	O
08:39	O
AM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
187	O
*	O
PCO2	O
-	O
34	O
*	O
PH	O
-	O
7.44	O
TOTAL	O
CO2	O
-	O
24	O
BASE	O
XS	O
-	O
0	O
INTUBATED	O
-	O
INTUBATED	O
VENT	O
-	O
CONTROLLED	O
[	O
**	O
2135-1-21	O
**	O
]	O
08:39	O
AM	O
HGB	O
-	O
9.5	O
*	O
calcHCT	O
-	O
29	O
[	O
**	O
2135-1-21	O
**	O
]	O
07:38	O
AM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
169	O
*	O
PCO2	O
-	O
36	O
PH	O
-	O
7.44	O
TOTAL	O
CO2	O
-	O
25	O
BASE	O
XS	O
-	O
1	O
INTUBATED	O
-	O
INTUBATED	O
VENT	O
-	O
CONTROLLED	O
[	O
**	O
2135-1-21	O
**	O
]	O
07:38	O
AM	O
GLUCOSE	O
-	O
146	O
*	O
LACTATE	O
-	O
1.5	O
NA	O
+	O
-	O
135	O
K	O
+	O
-	O
3.0	O
*	O
CL	O
--	O
101	O
[	O
**	O
2135-1-21	O
**	O
]	O
07:38	O
AM	O
HGB	O
-	O
10.2	O
*	O
calcHCT	O
-	O
31	O
[	O
**	O
2135-1-21	O
**	O
]	O
07:38	O
AM	O
freeCa	O
-	O
1.10	O
*	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
GLUCOSE	O
-	O
119	O
*	O
UREA	O
N	O
-	O
24	O
*	O
CREAT	O
-	O
1.4	O
*	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
3.7	O
CHLORIDE	O
-	O
99	O
TOTAL	O
CO2	O
-	O
26	O
ANION	O
GAP	O
-	O
17	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
ASA	O
-	O
NEG	O
ETHANOL	O
-	O
NEG	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
URINE	O
HOURS	O
-	O
RANDOM	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
WBC	O
-	O
11.3	O
*	O
RBC	O
-	O
4.08	O
*	O
HGB	O
-	O
11.7	O
*	O
HCT	O
-	O
36.2	O
MCV	O
-	O
89	O
MCH	O
-	O
28.6	O
MCHC	O
-	O
32.3	O
RDW	O
-	O
17.7	O
*	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
PLT	O
COUNT	O
-	O
523	O
*	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
PT	O
-	O
12.2	O
PTT	O
-	O
21.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.017	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
URINE	O
BLOOD	O
-	O
TR	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
25	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
6.5	O
LEUK	O
-	O
NEG	O
[	O
**	O
2135-1-21	O
**	O
]	O
04:35	O
AM	O
URINE	O
RBC	O
-	O
0	O
WBC	O
-	O
0	O
BACTERIA	O
-	O
NONE	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
CTA	O
head	O
/	O
neck	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
:	O
Occlusion	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
near	O
its	O
origin	O
.	O
Likely	O
retrograde	O
collateral	O
flow	O
present	O
,	O
reconstituting	O
more	O
distal	O
branches	O
of	O
this	O
vascular	O
distribution	O
.	O
Evolving	O
infarct	O
within	O
the	O
right	O
basal	O
ganglia	O
region	O
.	O
CT	O
head	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
:	O
Hyperdense	O
regions	O
within	O
the	O
head	O
of	O
the	O
right	O
caudate	O
nucleus	O
and	O
right	O
lentiform	O
nucleus	O
.	O
The	O
findings	O
are	O
of	O
concern	O
for	O
either	O
hemorrhagic	O
transformation	O
of	O
the	O
infarct	O
,	O
versus	O
extravascular	O
accumulation	O
of	O
contrast	O
material	O
.	O
A	O
followup	O
MR	O
study	O
may	O
be	O
of	O
help	O
in	O
differentiating	O
between	O
these	O
two	O
entities	O
.	O
rpt	O
CT	O
head	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
:	O
1	O
.	O
Evolving	O
right	O
basal	O
ganglia	O
hemorrhage	O
with	O
underlying	O
infarct	O
with	O
intraventricular	O
extension	O
of	O
hemorrhage	O
and	O
3	O
mm	O
leftward	O
shift	O
.	O
2	O
.	O
Persistent	O
moderate	O
left	O
subgaleal	O
hematoma	O
,	O
felt	O
to	O
be	O
due	O
to	O
anticoagulants	O
on	O
earlier	O
studies	O
-	O
correlate	O
clinically	O
.	O
3	O
.	O
Paranasal	O
sinus	O
disease	O
.	O
rpt	O
CT	O
head	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
:	O
1	O
.	O
No	O
new	O
foci	O
of	O
acute	O
intracranial	O
hemorrhage	O
.	O
2	O
.	O
Expected	O
interval	O
evolution	O
of	O
the	O
known	O
right	O
basal	O
ganglia	O
hemorrhagic	O
conversion	O
,	O
with	O
interval	O
decreased	O
attenuation	O
of	O
the	O
hyperdense	O
hemorrhagic	O
foci	O
but	O
increase	O
of	O
peri-hemorrhagic	O
edema	O
.	O
3	O
.	O
Essentially	O
unchanged	O
mild	O
leftward	O
shift	O
of	O
normally	O
midline	O
structures	O
,	O
with	O
persistent	O
effacement	O
of	O
the	O
right	O
frontal	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
.	O
4	O
.	O
Unchanged	O
trace	O
intraventricular	O
hemorrhagic	O
extension	O
at	O
the	O
right	O
occipital	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
without	O
developing	O
hydrocephalus	O
.	O
5	O
.	O
Interval	O
decreased	O
soft	O
tissue	O
swelling	O
and	O
hematoma	O
in	O
the	O
left	O
temporal	O
and	O
frontal	O
region	O
.	O
6	O
.	O
Paranasal	O
sinus	O
disease	O
as	O
described	O
above	O
.	O
[	O
**	O
1	O
-	O
26	O
**	O
]	O
:	O
attempted	O
MRI	O
Incomplete	O
examination	O
due	O
to	O
lack	O
of	O
patient	O
cooperation	O
.	O
Right	O
basal	O
ganglia	O
hemorrhage	O
/	O
hematoma	O
is	O
again	O
noted	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Initial	O
Assessment	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
104742	O
**	O
]	O
is	O
a	O
49	O
y	O
/	O
o	O
woman	O
with	O
a	O
PMH	O
significant	O
for	O
myelodysplastic	O
syndrome	O
,	O
HTN	O
and	O
hypothyroidism	O
,	O
who	O
presents	O
with	O
sudden	O
onset	O
left	O
sided	O
weakness	O
.	O
On	O
her	O
exam	O
,	O
her	O
NIHSS	O
is	O
17	O
and	O
she	O
has	O
a	O
dense	O
left	O
sided	O
hemiparesis	O
as	O
well	O
as	O
right	O
gaze	O
deviation	O
,	O
left	O
hemianopia	O
and	O
neglect	O
.	O
Her	O
imaging	O
shows	O
an	O
occlusion	O
of	O
R	O
MCA	O
near	O
its	O
origin	O
.	O
Her	O
history	O
,	O
exam	O
and	O
imaging	O
are	O
consistent	O
with	O
acute	B-Reason
embolic	I-Reason
stroke	I-Reason
in	O
R	O
MCA	O
.	O
The	O
time	O
of	O
onset	O
was	O
taken	O
to	O
be	O
0130	O
;	O
the	O
time	O
of	O
her	O
thrashing	O
,	O
and	O
so	O
when	O
she	O
was	O
seen	O
here	O
,	O
she	O
remained	O
within	O
the	O
window	O
for	O
IV	O
tPA	I-Drug
.	O
The	O
decision	O
was	O
made	O
to	O
proceed	O
with	O
the	O
IV	O
tPA	I-Drug
.	O
The	O
plan	O
at	O
this	O
time	O
is	O
to	O
proceed	O
with	O
tPA	I-Drug
infusion	O
and	O
if	O
clinical	O
exam	O
remains	O
unchanged	O
in	O
30	O
minutes	O
,	O
then	O
plan	O
is	O
to	O
proceed	O
with	O
angio	O
for	O
IA	O
tPA	I-Drug
vs.	O
Merci	O
.	O
Neuro	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
104742	O
**	O
]	O
was	O
admitted	O
to	O
the	O
neurology	O
ICU	O
,	O
attending	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
There	O
was	O
no	O
improvement	O
with	O
tPA	I-Drug
,	O
and	O
she	O
developed	O
hematomas	I-Ade
of	O
the	O
right	O
knee	O
,	O
left	O
scalp	O
,	O
and	O
left	O
clavicular	O
area	O
,	O
so	O
IV	O
TPA	I-Drug
was	O
stopped	O
.	O
The	O
team	O
proceeded	O
with	O
angio	O
and	O
MERCI	O
device	O
was	O
used	O
.	O
This	O
resulted	O
in	O
opening	O
of	O
inferior	O
division	O
of	O
the	O
right	O
MCA	O
,	O
but	O
opening	O
of	O
the	O
superior	O
division	O
was	O
unsuccessful	O
.	O
She	O
was	O
monitored	O
in	O
the	O
ICU	O
and	O
then	O
was	O
transferred	O
to	O
the	O
step	O
down	O
unit	O
,	O
then	O
to	O
the	O
floor	O
for	O
further	O
management	O
.	O
She	O
was	O
started	O
on	O
Aspirin	I-Drug
81	O
mg	O
and	O
Lovenox	I-Drug
40	O
mg	O
daily	O
(	O
given	O
possible	O
MDS	I-Reason
/	O
malignancy	I-Reason
.	O
)	O
Her	O
CT	O
scans	O
showed	O
hemorrhagic	O
conversion	O
in	O
the	O
Right	O
striatum	O
and	O
white	O
matter	O
.	O
An	O
MRI	O
was	O
attempted	O
,	O
but	O
she	O
was	O
unable	O
to	O
tolerate	O
this	O
.	O
There	O
was	O
no	O
need	O
to	O
attempt	O
repeating	O
this	O
MRI	O
,	O
per	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
stroke	O
attending	O
.	O
Imaging	O
otherwise	O
as	O
above	O
.	O
CVR	O
:	O
Blood	B-Reason
pressure	I-Reason
was	O
controlled	O
metoprolol	I-Drug
25	O
mg	O
TID	O
and	O
as	O
needed	O
hydralazine	I-Drug
.	O
Her	O
metoprolol	I-Drug
was	O
increased	O
to	O
50	O
mg	O
TID	O
prior	O
to	O
discharge	O
.	O
She	O
had	O
an	O
transthoracic	O
echocardiogram	O
which	O
showed	O
no	O
ASD	O
or	O
LV	O
thrombus	O
.	O
There	O
was	O
normal	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function	O
.	O
There	O
was	O
mild	O
pulmonary	O
hypertension	O
.	O
A	O
bubble	O
study	O
was	O
not	O
done	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
attempted	O
,	O
however	O
Ms.	O
[	O
**	O
Known	O
lastname	O
104742	O
**	O
]	O
developed	O
methemoglobinemia	I-Ade
(	O
level	O
29	O
)	O
after	O
receiving	O
benzocaine	I-Drug
spray	O
.	O
She	O
received	O
Methylene	B-Drug
blue	I-Drug
140	O
mg	O
IV	O
by	O
anesthesia	O
and	O
had	O
rapid	O
clinical	O
improvement	O
.	O
Her	O
methemoglobinemia	O
level	O
was	O
zero	O
before	O
returning	O
to	O
the	O
neurology	O
floor	O
.	O
A	O
transthoracic	O
echo	O
with	O
bubble	O
was	O
later	O
done	O
which	O
showed	O
No	O
atrial	O
septal	O
defect	O
or	O
patent	O
foramen	O
ovale	O
is	O
seen	O
by	O
2D	O
,	O
color	O
Doppler	O
or	O
saline	O
contrast	O
with	O
maneuvers	O
.	O
She	O
had	O
lower	O
extremity	O
doppler	O
studies	O
which	O
were	O
negative	O
for	O
DVT	O
.	O
Hypercoagulable	O
work	O
up	O
is	O
pending	O
at	O
the	O
time	O
of	O
discharge	O
:	O
antithrombin	O
3	O
,	O
prothrombin	O
gene	O
mutation	O
,	O
factor	O
v	O
leiden	O
.	O
Heme	O
:	O
Due	O
to	O
her	O
myelodysplastic	O
syndrome	O
and	O
bleeding	I-Ade
with	O
tPA	I-Drug
,	O
heme	O
-	O
onc	O
was	O
consulted	O
,	O
and	O
they	O
did	O
not	O
believe	O
there	O
were	O
any	O
restrictions	O
on	O
her	O
stroke	O
management	O
due	O
to	O
her	O
MDS	O
.	O
Additionally	O
,	O
the	O
team	O
spoke	O
with	O
her	O
outpatient	O
hematologist	O
who	O
confirmed	O
no	O
need	O
for	O
epo	I-Drug
or	O
aranesp	I-Drug
while	O
in	O
the	O
hospital	O
.	O
Her	O
HCT	O
was	O
stable	O
during	O
her	O
hospitalization	O
.	O
FEN	O
/	O
GI	O
:	O
She	O
was	O
initially	O
NPO	O
.	O
She	O
was	O
followed	O
closely	O
by	O
speech	O
and	O
language	O
team	O
and	O
was	O
started	O
on	O
NGT	O
feeds	O
.	O
When	O
able	O
,	O
a	O
regular	O
diet	O
was	O
initiated	O
and	O
advanced	O
.	O
At	O
the	O
time	O
of	O
discharge	O
she	O
was	O
tolerating	O
a	O
regular	O
diet	O
with	O
nectar	O
-	O
thick	O
liquids	O
.	O
Her	O
electrolytes	O
were	O
monitored	O
carefully	O
,	O
and	O
repleted	O
as	O
necessary	O
.	O
She	O
received	O
Famotidine	I-Drug
for	O
GI	B-Reason
prophylaxis	I-Reason
.	O
Psych	O
/	O
ETOH	O
:	O
Initially	O
Ms.	O
[	O
**	O
Known	O
lastname	O
104742	O
**	O
]	O
had	O
significant	O
alcohol	I-Reason
withdrawal	O
.	O
She	O
was	O
on	O
a	O
CIWA	O
scale	O
and	O
received	O
multiple	O
doses	O
of	O
Ativan	I-Drug
in	O
addition	O
to	O
Valium	I-Drug
q12	O
.	O
She	O
also	O
received	O
thiamine	I-Drug
and	O
folate	I-Drug
.	O
CIWA	O
was	O
discontinued	O
and	O
she	O
had	O
no	O
further	O
symptoms	O
prior	O
to	O
discharge	O
.	O
She	O
received	O
Trazadone	I-Drug
for	O
sleep	I-Reason
.	O
MSK	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
104742	O
**	O
]	O
had	O
intermittent	O
pain	O
,	O
especially	O
in	O
left	O
shoulder	O
.	O
She	O
had	O
an	O
XR	O
which	O
showed	O
no	O
evidence	O
of	O
cortical	O
disruptions	O
suggestive	O
of	O
fracture	O
or	O
AC	O
separation	O
.	O
Pain	I-Reason
was	O
treated	O
with	O
tylenol	I-Drug
and	O
oxycodone	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
-	O
amlodipine	I-Drug
5	O
mg	O
daily	O
-	O
omeprazole	I-Drug
20	O
mg	O
daily	O
-	O
atenolol	I-Drug
50	O
mg	O
daily	O
-	O
levothyroxine	I-Drug
50mcg	O
daily	O
-	O
vit	B-Drug
B	I-Drug
-	I-Drug
12	I-Drug
1000mcg	O
daily	O
-	O
vit	B-Drug
B1	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
-	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
enoxaparin	I-Drug
40	O
mg	O
/	O
0.4	O
mL	O
Syringe	O
Sig	O
:	O
Forty	O
(	O
40	O
)	O
MG	O
Subcutaneous	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
3	O
.	O
docusate	B-Drug
sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
Ten	O
(	O
10	O
)	O
ML	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
5	O
.	O
aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
7	O
.	O
trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
8	O
.	O
thiamine	B-Drug
HCl	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
85	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
diagnosis	O
:	O
-	O
Stroke	O
(	O
Right	O
PCA+MCA	O
-	O
territory	O
infarction	O
)	O
Secondary	O
diagnoses	O
:	O
-	O
EtOHism	O
/	O
withdrawal	O
-	O
chronic	O
LBP	O
-	O
chronic	O
mild	O
anemia	O
,	O
possible	O
MDS	O
-	O
methemoglobinemia	I-Ade
secondary	O
to	O
benzocaine	I-Drug
spray	O
.	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
after	O
you	O
had	O
a	O
large	O
stroke	I-Reason
.	O
You	O
initially	O
received	O
TPA	I-Drug
in	O
attempt	O
to	O
break	B-Reason
up	I-Reason
the	I-Reason
clot	I-Reason
in	I-Reason
your	I-Reason
brain	O
,	O
however	O
this	O
did	O
not	O
improve	O
your	O
symptoms	O
and	O
you	O
developed	O
bruising	I-Ade
.	O
You	O
then	O
had	O
a	O
MERCI	O
retrieval	O
which	O
was	O
able	O
to	O
open	O
up	O
part	O
of	O
your	O
blood	O
vessels	O
.	O
You	O
were	O
started	O
on	O
medication	O
,	O
Lovenox	I-Drug
,	O
and	O
Aspirin	I-Drug
,	O
to	O
prevent	B-Reason
further	I-Reason
clots	I-Reason
and	I-Reason
strokes	O
.	O
You	O
were	O
also	O
started	O
on	O
a	O
blood	B-Drug
pressure	I-Drug
medication	I-Drug
.	O
You	O
had	O
multiple	O
tests	O
including	O
head	O
CT	O
scans	O
,	O
attempted	O
brain	O
MRI	O
,	O
echocardiograms	O
,	O
and	O
ultrasounds	O
of	O
your	O
legs	O
to	O
determine	O
the	O
cause	O
of	O
your	O
stroke	O
.	O
Additionally	O
,	O
multiple	O
laboratory	O
tests	O
were	O
sent	O
which	O
are	O
still	O
pending	O
.	O
While	O
you	O
were	O
in	O
the	O
hospital	O
you	O
were	O
treated	O
for	O
alcohol	O
withdrawal	O
.	O
You	O
also	O
developed	O
a	O
reaction	O
to	O
benzocaine	I-Drug
spray	O
,	O
called	O
methemoglobinemia	I-Ade
,	O
in	O
which	O
you	O
developed	O
breathing	O
problems	O
requiring	O
treatment	O
in	O
the	O
ICU	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
640	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3445	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2574	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2135-3-14	O
**	O
]	O
1:30	O
The	O
following	O
tests	O
are	O
pending	O
at	O
the	O
time	O
of	O
discharge	O
:	O
antithrombin	O
3	O
,	O
factor	O
v	O
leiden	O
,	O
prothrombin	O
gene	O
mutation	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2106-5-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2106-6-20	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2060-12-28	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Benzodiazepines	I-Drug
/	O
Furosemide	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
330	O
**	O
]	O
Chief	O
Complaint	O
:	O
Evaluation	O
for	O
liver	O
transplant	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
EGD	O
2	O
.	O
Post-pyloric	O
feeding	O
tube	O
x	O
3	O
3	O
.	O
Paracentesis	O
4	O
.	O
PICC	O
line	O
placement	O
x	O
2	O
History	O
of	O
Present	O
Illness	O
:	O
45F	O
with	O
ESLD	O
secondary	O
to	O
EtOH	O
,	O
AIHA	I-Ade
due	O
to	O
lasix	I-Drug
recently	O
on	O
prednisone	I-Drug
who	O
was	O
initially	O
presented	O
to	O
OSH	O
with	O
hepatic	O
encephalopathy	O
transferred	O
from	O
OSH	O
on	O
[	O
**	O
5	O
-	O
27	O
**	O
]	O
for	O
liver	O
transplant	O
evaluation	O
whose	O
course	O
has	O
been	O
complicated	O
by	O
coagulopathy	O
with	O
recurrent	O
epistaxis	O
,	O
VRE	O
bacteremia	O
,	O
new	O
onset	O
Afib	O
with	O
RVR	O
and	O
now	O
with	O
worsening	O
leukocytosis	O
and	O
diffuse	O
bilat	O
pulmonary	O
infiltrates	O
.	O
.	O
To	O
summarize	O
her	O
recent	O
course	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
OSH	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
74368	O
**	O
]	O
for	O
hemolytic	B-Ade
anemia	I-Ade
thought	O
to	O
be	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
lasix	I-Drug
and	O
was	O
started	O
on	O
prednisone	I-Drug
50	O
mg	O
.	O
On	O
[	O
**	O
5	O
-	O
22	O
**	O
]	O
,	O
she	O
represented	O
with	O
hepatic	O
encephalopathy	O
and	O
T	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
F	O
where	O
she	O
underwent	O
paracentesis	O
with	O
negative	O
cultures	O
.	O
CXR	O
showed	O
b	O
/	O
l	O
infiltrates	O
and	O
she	O
received	O
tx	O
with	O
vanco	I-Drug
,	O
levoflox	I-Drug
,	O
and	O
zosyn	I-Drug
and	O
she	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
liver	O
transplant	O
eval	O
.	O
.	O
At	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
,	O
she	O
was	O
noted	O
to	O
have	O
numerous	O
small	O
pulmonary	O
nodules	O
on	O
[	O
**	O
5	O
-	O
29	O
**	O
]	O
chest	O
CT	O
of	O
unclear	O
significance	O
.	O
Pulm	O
consulted	O
for	O
?	O
bronch	O
given	O
concern	O
for	O
infection	O
vs.	O
malignancy	O
.	O
Due	O
to	O
worsening	O
confusion	O
the	O
patient	O
underwent	O
repeat	O
paracentesis	O
with	O
135	O
WBC	O
.	O
Eventually	O
blood	O
cultures	O
from	O
[	O
**	O
6	O
-	O
11	O
**	O
]	O
returned	O
[	O
**	O
12	O
-	O
17	O
**	O
]	O
bottles	O
+	O
ve	O
for	O
VRE	I-Reason
and	O
was	O
started	O
on	O
daptomycin	I-Drug
.	O
Likely	O
source	O
was	O
colonization	O
of	O
urine	O
discovered	O
on	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
.	O
Also	O
on	O
[	O
**	O
6	O
-	O
11	O
**	O
]	O
,	O
the	O
patient	O
was	O
started	O
on	O
CTX	I-Drug
for	O
positive	O
U	O
/	O
A	O
which	O
was	O
then	O
continued	O
per	O
ID	O
to	O
empirically	O
cover	O
possible	O
SBP	I-Reason
.	O
Also	O
treated	O
for	O
hepatorenal	B-Reason
syndrome	I-Reason
(	O
cre	O
1.5	O
which	O
improved	O
to	O
0.4	O
)	O
with	O
albumin	I-Drug
,	O
midodrine	I-Drug
,	O
and	O
octreotide	I-Drug
x	O
4	O
days	O
,	O
which	O
was	O
d	O
/	O
c	O
'd	O
on	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
given	O
improvement	O
in	O
renal	O
function	O
.	O
.	O
On	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
,	O
the	O
patient	O
developed	O
significant	B-Reason
epistaxis	I-Reason
requiring	O
multiple	O
FFP	I-Drug
,	O
platelet	I-Drug
,	O
and	O
RBC	I-Drug
transfusions	O
.	O
There	O
was	O
concern	O
for	O
aspiration	O
given	O
altered	O
mental	O
status	O
.	O
Despite	O
continued	O
G	O
+	O
black	O
stools	O
her	O
Hct	O
has	O
been	O
stable	O
since	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
.	O
On	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
,	O
the	O
medical	O
team	O
repeated	O
her	O
CT	O
chest	O
to	O
eval	O
for	O
progression	O
of	O
pulmonary	O
nodules	O
and	O
found	O
bilateral	O
infiltrates	O
concerning	O
for	O
infection	O
,	O
bleeding	O
,	O
or	O
aspiration	O
.	O
She	O
was	O
started	O
on	O
bactrim	I-Drug
for	O
possible	O
PCP	I-Reason
given	O
her	O
recent	O
prolonged	O
predinsone	I-Drug
course	O
that	O
had	O
been	O
discontinued	O
on	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
.	O
Also	O
on	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
developed	O
new	O
-	O
onset	O
Afib	B-Reason
with	I-Reason
RVR	I-Reason
150s	O
that	O
responded	O
to	O
diltiazem	I-Drug
.	O
Due	O
to	O
increased	O
volume	O
of	O
diarrhea	O
and	O
climbing	O
WBC	O
count	O
she	O
was	O
started	O
on	O
empiric	I-Reason
flagyl	I-Drug
on	O
[	O
**	O
2106-6-17	O
**	O
]	O
.	O
.	O
On	O
transfer	O
to	O
the	O
MICU	O
,	O
the	O
patient	O
denies	O
any	O
complaints	O
including	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
headache	O
,	O
confusion	O
.	O
Past	O
Medical	O
History	O
:	O
EtOH	O
cirrhosis	O
s	O
/	O
p	O
TIPS	O
for	O
varices	O
in	O
[	O
**	O
2102	O
**	O
]	O
with	O
multiple	O
revisions	O
gastric	O
varices	O
hepatic	O
encephalopathy	O
spur	O
cell	O
anemia	O
chronic	O
hyponatremia	O
autoimmune	B-Ade
hemolytic	I-Ade
anemia	I-Ade
(	O
from	O
lasix	I-Drug
?	O
)	O
on	O
prednisone	I-Drug
h	O
/	O
o	O
ovarian	O
cysts	O
Social	O
History	O
:	O
Lives	O
with	O
husband	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
who	O
is	O
very	O
involved	O
in	O
her	O
care	O
.	O
No	O
children	O
.	O
No	O
tobacco	O
use	O
ever	O
.	O
Significant	O
EtOH	O
history	O
,	O
sober	O
since	O
[	O
**	O
2105-11-28	O
**	O
]	O
.	O
Involved	O
in	O
AA	O
.	O
Reported	O
PTSD	O
s	O
/	O
p	O
attack	O
by	O
father	O
as	O
a	O
child	O
/	O
teenager	O
.	O
.	O
Previously	O
worked	O
as	O
a	O
lawyer	O
,	O
studied	O
at	O
[	O
**	O
Name	O
(	O
NI	O
)	O
17448	O
**	O
]	O
Law	O
School	O
.	O
Family	O
History	O
:	O
No	O
liver	O
disease	O
.	O
Alcoholism	O
in	O
father	O
.	O
Physical	O
Exam	O
:	O
Admission	O
Physical	O
Exam	O
Vitals	O
:	O
T	O
:	O
99.3	O
BP	O
:	O
100/60	O
P	O
:	O
74	O
RR	O
:	O
20	O
SpO2	O
:	O
96	O
%	O
RA	O
wt	O
47	O
kg	O
General	O
:	O
Awake	O
,	O
alert	O
,	O
lying	O
flat	O
in	O
bed	O
in	O
NAD	O
.	O
grossly	O
jaundiced	O
,	O
thin	O
.	O
HEENT	O
:	O
EOMI	O
,	O
sclera	O
icteric	O
.	O
MMM	O
,	O
OP	O
without	O
lesions	O
Neck	O
:	O
supple	O
,	O
no	O
JVD	O
appreciated	O
Pulm	O
:	O
mild	O
crackles	O
to	O
b	O
/	O
t	O
bases	O
Cardiac	O
:	O
RRR	O
,	O
nl	O
S1	O
/	O
S2	O
,	O
2/6	O
systolic	O
murmur	O
Abdomen	O
:	O
soft	O
,	O
tender	O
to	O
deep	O
palpation	O
to	O
epigastrum	O
.	O
no	O
rebound	O
/	O
guarding	O
.	O
ND	O
,	O
+	O
BS	O
,	O
no	O
hepatomegaly	O
noted	O
.	O
Rectal	O
:	O
guaiac	O
negative	O
at	O
OSH	O
Ext	O
:	O
No	O
edema	O
b	O
/	O
t	O
,	O
warm	O
.	O
Skin	O
:	O
spider	O
telangiectasias	O
to	O
chest	O
,	O
grossly	O
jaundiced	O
Neurologic	O
:	O
-	O
mental	O
status	O
:	O
Alert	O
&	O
Oriented	O
x	O
3	O
.	O
Able	O
to	O
relate	O
history	O
,	O
but	O
with	O
some	O
memory	O
lapses	O
.	O
-	O
cranial	O
nerves	O
:	O
II	O
-	O
XII	O
intact	O
-	O
motor	O
:	O
[	O
**	O
3	O
-	O
18	O
**	O
]	O
UE	O
strength	O
,	O
[	O
**	O
4	O
-	O
17	O
**	O
]	O
LE	O
.	O
-	O
sensory	O
:	O
No	O
deficits	O
to	O
light	O
touch	O
throughout	O
.	O
-	O
no	O
asterixis	O
.	O
ICU	O
Admission	O
Physical	O
Exam	O
:	O
T	O
96.1	O
HR	O
125	O
BP	O
113/59	O
RR	O
23	O
SaO2	O
98	O
%	O
on	O
RA	O
General	O
:	O
Ill	O
-	O
appearing	O
,	O
jaundiced	O
HEENT	O
:	O
PERRL	O
,	O
EOMi	O
,	O
icteric	O
sclera	O
,	O
mouth	O
and	O
nares	O
with	O
crusted	O
blood	O
,	O
OP	O
clear	O
Neck	O
:	O
supple	O
,	O
trachea	O
midline	O
,	O
no	O
masses	O
,	O
no	O
LAD	O
Cardiac	O
:	O
tachycardic	O
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
3526	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
3526	O
**	O
]	O
,	O
s1s2	O
normal	O
,	O
friction	O
rub	O
noted	O
at	O
LUSB	O
4th	O
intercostal	O
space	O
,	O
no	O
m	O
/	O
g	O
Pulmonary	O
:	O
bilateral	O
crackles	O
(	O
L	O
>	O
R	O
)	O
Abdomen	O
:	O
+	O
BS	O
,	O
soft	O
,	O
nontender	O
,	O
distended	O
,	O
+	O
ascites	O
Extremities	O
:	O
warm	O
,	O
2	O
+	O
bilateral	O
LE	O
edema	O
Neuro	O
:	O
A&O	O
x3	O
,	O
speech	O
clear	O
,	O
CNII	O
-	O
XII	O
intact	O
,	O
no	O
asterixis	O
Pertinent	O
Results	O
:	O
Admission	O
Labs	O
:	O
==============	O
[	O
**	O
2106-5-27	O
**	O
]	O
CBC	O
/	O
DIFF	O
:	O
WBC	O
-	O
19.9	O
*	O
RBC	O
-	O
2.56	O
*	O
HGB	O
-	O
9.3	O
*	O
HCT	O
-	O
24.5	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
36.3	O
*	O
MCHC	O
-	O
37.8	O
PLT	O
39	O
NEUTS	O
-	O
91.4	O
*	O
LYMPHS	O
-	O
4.1	O
*	O
MONOS	O
-	O
4.3	O
EOS	O
-	O
0.1	O
BASOS	O
-	O
0.1	O
[	O
**	O
2106-5-27	O
**	O
]	O
ALBUMIN	O
-	O
2.4	O
*	O
CALCIUM	O
-	O
9.5	O
PHOSPHATE	O
-	O
2.5	O
*	O
MAGNESIUM	O
-	O
2.2	O
IRON	O
-	O
183	O
*	O
CHOLEST	O
-	O
92	O
[	O
**	O
2106-5-27	O
**	O
]	O
LFTs	O
:	O
ALT	O
(	O
SGPT	O
)	O
-	O
51	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
89	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
990	O
*	O
ALK	O
PHOS	O
-	O
114	O
TOT	O
BILI	O
-	O
32.0	O
*	O
DIR	O
BILI	O
-	O
15.2	O
*	O
INDIR	O
BIL	O
-	O
16.8	O
[	O
**	O
2106-5-27	O
**	O
]	O
CHEM	O
7	O
GLUCOSE	O
-	O
101	O
UREA	O
N	O
-	O
38	O
*	O
CREAT	O
-	O
0.6	O
SODIUM	O
-	O
121	O
*	O
POTASSIUM	O
-	O
4.0	O
CHLORIDE	O
-	O
87	O
*	O
TOTAL	O
CO2	O
-	O
29	O
ANION	O
GAP	O
-	O
9	O
[	O
**	O
2106-5-27	O
**	O
]	O
11:40	O
PM	O
PT	O
-	O
23.0	O
*	O
PTT	O
-	O
49.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.3	O
*	O
.	O
Serologies	O
:	O
==========	O
[	O
**	O
2106-5-27	O
**	O
]	O
HCV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2106-5-27	O
**	O
]	O
HBsAg	O
-	O
NEGATIVE	O
HBs	O
Ab	O
-	O
POSITIVE	O
HBc	O
Ab	O
-	O
NEGATIVE	O
HAV	O
Ab	O
-	O
POSITIVE	O
.	O
MICRO	O
:	O
======	O
-	O
Blood	O
Cultures	O
6/15	O
,	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
:	O
Negative	O
-	O
RPR	O
non-reactive	O
-	O
Rubella	O
Immune	O
-	O
Varicella	O
IgG	O
positive	O
.	O
Lipids	O
:	O
======	O
[	O
**	O
2106-5-27	O
**	O
]	O
LIPIDS	O
:	O
TRIGLYCER	O
-	O
87	O
HDL	O
CHOL	O
-	O
45	O
CHOL	O
/	O
HDL	O
-	O
2.0	O
LDL	O
(	O
CALC	O
)	O
-	O
30	O
.	O
IRON	O
STUDIES	O
:	O
TIBC	O
-	O
181	O
*	O
HAPTOGLOB	O
-	O
<	O
20	O
*	O
FERRITIN	O
-	O
1524	O
*	O
TRF	O
-	O
139	O
*	O
.	O
RADIOLOGY	O
:	O
=========	O
[	O
**	O
5	O
-	O
28	O
**	O
]	O
ABD	O
U	O
/	O
S	O
-	O
DOPPLER	O
LIVER	O
ULTRASOUND	O
:	O
No	O
prior	O
studies	O
are	O
available	O
for	O
comparison	O
.	O
The	O
TIPS	O
is	O
patent	O
with	O
wall	O
-	O
to	O
-	O
wall	O
color	O
flow	O
.	O
There	O
is	O
appropriate	O
flow	O
reversal	O
(	O
hepatofugal	O
)	O
within	O
the	O
left	O
portal	O
vein	O
.	O
The	O
assessment	O
of	O
the	O
right	O
anterior	O
and	O
posterior	O
portal	O
veins	O
was	O
limited	O
as	O
the	O
liver	O
is	O
extremely	O
shrunken	O
and	O
nodular	O
.	O
The	O
following	O
velocities	O
were	O
obtained	O
:	O
Main	O
portal	O
vein	O
35	O
cm	O
/	O
sec	O
;	O
proximal	O
TIPS	O
67	O
cm	O
/	O
sec	O
;	O
mid	O
TIPS	O
73	O
cm	O
/	O
sec	O
;	O
distal	O
tips	O
74	O
cm	O
/	O
sec	O
.	O
The	O
receiving	O
hepatic	O
vein	O
is	O
patent	O
.	O
.	O
There	O
is	O
a	O
small	O
amount	O
of	O
ascites	O
surrounding	O
the	O
liver	O
,	O
relatively	O
less	O
in	O
the	O
lower	O
quadrants	O
.	O
The	O
liver	O
is	O
extremely	O
shrunken	O
and	O
nodular	O
with	O
very	O
heterogeneous	O
echotexture	O
.	O
Anterior	O
to	O
the	O
TIPS	O
stent	O
are	O
multiple	O
tubular	O
hypo	O
-	O
to	O
-	O
anechoic	O
structures	O
which	O
could	O
represent	O
dilated	O
ducts	O
or	O
less	O
likely	O
,	O
thrombosed	O
veins	O
.	O
No	O
frank	O
mass	O
lesion	O
is	O
identified	O
but	O
assessment	O
is	O
limited	O
due	O
to	O
the	O
shrunken	O
appearance	O
of	O
the	O
liver	O
.	O
The	O
spleen	O
is	O
within	O
normal	O
limits	O
in	O
size	O
measuring	O
10.7	O
cm	O
.	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Patent	O
TIPS	O
with	O
wall	O
-	O
to	O
-	O
wall	O
flows	O
and	O
appropriate	O
velocities	O
as	O
listed	O
above	O
.	O
2	O
.	O
Shrunken	O
cirrhotic	O
liver	O
without	O
overt	O
hepatic	O
mass	O
.	O
Questionable	O
biliary	O
dilatation	O
anterior	O
to	O
TIPS	O
stent	O
.	O
[	O
**	O
5	O
-	O
29	O
**	O
]	O
CT	O
A	O
/	O
P	O
-	O
IMPRESSION	O
:	O
1	O
.	O
Numerous	O
noncalcified	O
subcentimeter	O
nonspecific	O
pulmonary	O
nodules	O
.	O
Comparison	O
with	O
prior	O
CT	O
scans	O
if	O
available	O
is	O
recommended	O
to	O
evaluate	O
for	O
stability	O
.	O
If	O
no	O
prior	O
examinations	O
are	O
available	O
for	O
comparison	O
,	O
and	O
the	O
patient	O
is	O
a	O
high	O
risk	O
patient	O
i.e.	O
is	O
a	O
smoker	O
or	O
has	O
a	O
known	O
primary	O
malignancy	O
,	O
a	O
followup	O
with	O
CT	O
of	O
the	O
chest	O
in	O
[	O
**	O
5	O
-	O
25	O
**	O
]	O
months	O
is	O
recommended	O
.	O
If	O
the	O
patient	O
is	O
at	O
low	O
risk	O
i.e.	O
,	O
is	O
not	O
a	O
smoker	O
or	O
has	O
no	O
known	O
malignancy	O
,	O
followup	O
with	O
CT	O
of	O
the	O
chest	O
in	O
twelve	O
months	O
is	O
recommended	O
.	O
2	O
.	O
TIPS	O
in	O
the	O
right	O
hepatic	O
lobe	O
.	O
3	O
.	O
Chronic	O
occlusion	O
of	O
the	O
left	O
portal	O
vein	O
and	O
posterior	O
division	O
of	O
the	O
right	O
portal	O
vein	O
with	O
corkscrew	O
hepatic	O
arteries	O
which	O
are	O
patent	O
.	O
There	O
is	O
a	O
tiny	O
left	O
hepatic	O
artery	O
off	O
of	O
the	O
proper	O
hepatic	O
artery	O
with	O
an	O
accessory	O
branch	O
off	O
the	O
left	O
gastric	O
artery	O
.	O
No	O
suspicious	O
hepatic	O
lesions	O
.	O
4	O
.	O
Moderate	O
intraabdominal	O
and	O
intrapelvic	O
ascites	O
with	O
extensive	O
intraabdominal	O
varices	O
as	O
described	O
consistent	O
with	O
portal	O
hypertension	O
.	O
.	O
ECHO	O
(	O
TTE	O
)	O
[	O
**	O
2106-6-1	O
**	O
]	O
-	O
Conclusions	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
>	O
75	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
.	O
There	O
is	O
no	O
valvular	O
aortic	O
stenosis	O
.	O
The	O
increased	O
transaortic	O
gradient	O
is	O
likely	O
related	O
to	O
high	O
cardiac	O
output	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
IMPRESSION	O
:	O
Normal	O
/	O
hyperdynamic	O
biventricular	O
systolic	O
function	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
Trivial	O
aortic	O
regurgitation	O
.	O
.	O
Portable	O
CXR	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
:	O
Cardiomediastinal	O
contour	O
is	O
unchanged	O
.	O
NG	O
tube	O
tip	O
is	O
below	O
the	O
diaphragm	O
out	O
of	O
view	O
.	O
Right	O
PICC	O
line	O
tip	O
is	O
in	O
the	O
mid	O
SVC	O
.	O
There	O
is	O
no	O
pneumothorax	O
.	O
New	O
ill	O
-	O
defined	O
opacity	O
in	O
the	O
left	O
lower	O
lobe	O
in	O
the	O
retrocardiac	O
area	O
is	O
consistent	O
with	O
atelectasis	O
and	O
/	O
or	O
area	O
of	O
aspiration	O
Small	O
left	O
pleural	O
effusion	O
is	O
also	O
new	O
.	O
.	O
CT	O
Chest	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Interim	O
improvement	O
in	O
diffuse	O
predominantly	O
peribronchiolar	O
nodular	O
opacities	O
,	O
though	O
numerous	O
nodular	O
opacities	O
persist	O
on	O
the	O
current	O
study	O
.	O
The	O
coalescing	O
airspace	O
disease	O
adjacent	O
to	O
the	O
minor	O
fissure	O
appears	O
much	O
improved	O
.	O
Given	O
the	O
improved	O
appearance	O
over	O
the	O
short	O
interval	O
,	O
an	O
infectious	O
process	O
is	O
considered	O
likely	O
.	O
Eventual	O
CT	O
followup	O
(	O
three	O
months	O
)	O
is	O
recommended	O
after	O
treatment	O
.	O
2	O
.	O
Small	O
bilateral	O
pleural	O
effusions	O
and	O
moderate	O
-	O
to	O
-	O
large	O
ascites	O
as	O
well	O
as	O
subcutaneous	O
edema	O
are	O
unchanged	O
from	O
the	O
prior	O
exam	O
.	O
.	O
Abdominal	O
U	O
/	O
S	O
[	O
**	O
6	O
-	O
11	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Moderate	O
to	O
large	O
amount	O
of	O
ascites	O
.	O
A	O
spot	O
was	O
marked	O
for	O
paracentesis	O
to	O
be	O
performed	O
by	O
the	O
clinical	O
service	O
.	O
2	O
.	O
_____	O
TIPS	O
unchanged	O
from	O
the	O
prior	O
studies	O
.	O
3	O
.	O
Cirrhotic	O
liver	O
.	O
No	O
focal	O
lesions	O
identified	O
.	O
.	O
Portable	O
CXR	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
:	O
IMPRESSION	O
:	O
AP	O
chest	O
compared	O
to	O
[	O
**	O
2106-6-12	O
**	O
]	O
:	O
Pulmonary	O
vascular	O
congestion	O
has	O
worsened	O
and	O
new	O
opacification	O
at	O
the	O
lung	O
bases	O
is	O
probably	O
a	O
combination	O
of	O
atelectasis	O
and	O
mild	O
edema	O
.	O
Pleural	O
effusion	O
is	O
small	O
,	O
on	O
the	O
left	O
,	O
unchanged	O
acutely	O
.	O
Heart	O
size	O
is	O
top	O
normal	O
.	O
Left	O
PIC	O
catheter	O
ends	O
at	O
the	O
superior	O
cavoatrial	O
junction	O
.	O
Esophageal	O
tube	O
and	O
right	O
PIC	O
line	O
have	O
been	O
removed	O
.	O
.	O
ECHO	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
:	O
Conclusions	O
:	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
>	O
75	O
%	O
)	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
.	O
No	O
masses	O
or	O
vegetations	O
are	O
seen	O
on	O
the	O
aortic	O
valve	O
.	O
There	O
is	O
no	O
valvular	O
aortic	O
stenosis	O
.	O
The	O
increased	O
transaortic	O
gradient	O
is	O
likely	O
related	O
to	O
high	O
cardiac	O
output	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
No	O
mass	O
or	O
vegetation	O
is	O
seen	O
on	O
the	O
mitral	O
valve	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
No	O
vegetation	O
/	O
mass	O
is	O
seen	O
on	O
the	O
pulmonic	O
valve	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
Compared	O
with	O
the	O
findings	O
of	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2106-6-1	O
**	O
]	O
,	O
the	O
tricuspid	O
regurgitation	O
is	O
somewhat	O
increased	O
.	O
.	O
If	O
clinically	O
suggested	O
,	O
the	O
absence	O
of	O
a	O
vegetation	O
by	O
2D	O
echocardiography	O
does	O
not	O
exclude	O
endocarditis	O
.	O
.	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
Chest	O
CT	O
FINDINGS	O
:	O
Since	O
the	O
prior	O
study	O
there	O
has	O
been	O
marked	O
worsening	O
of	O
the	O
alveolar	O
opacities	O
involving	O
both	O
lungs	O
,	O
predominantly	O
in	O
the	O
upper	O
zones	O
.	O
The	O
periphery	O
of	O
the	O
lungs	O
is	O
relatively	O
spared	O
.	O
There	O
are	O
small	O
bilateral	O
pleural	O
effusions	O
.	O
The	O
heart	O
size	O
appears	O
slightly	O
enlarged	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
There	O
are	O
borderline	O
lymph	O
nodes	O
in	O
the	O
paratracheal	O
region	O
measuring	O
up	O
to	O
9	O
mm	O
in	O
short	O
axis	O
.	O
The	O
central	O
airways	O
are	O
patent	O
without	O
endoluminal	O
lesions	O
.	O
A	O
left	O
-	O
sided	O
PICC	O
is	O
seen	O
extending	O
into	O
the	O
superior	O
vena	O
cava	O
.	O
.	O
In	O
the	O
visualized	O
upper	O
abdomen	O
again	O
seen	O
is	O
a	O
cirrhotic	O
liver	O
with	O
the	O
TIPS	O
shunt	O
in	O
place	O
.	O
There	O
is	O
a	O
large	O
amount	O
of	O
ascites	O
noted	O
.	O
Coils	O
are	O
noted	O
in	O
the	O
region	O
of	O
the	O
splenic	O
vessels	O
.	O
The	O
osseous	O
structures	O
appear	O
unremarkable	O
.	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Marked	O
worsening	O
of	O
bilateral	O
extensive	O
alveolar	O
opacities	O
particularly	O
centrally	O
.	O
The	O
rapidity	O
of	O
development	O
and	O
distribution	O
is	O
most	O
concerning	O
for	O
pulmonary	O
edema	O
,	O
however	O
,	O
atypical	O
infection	O
or	O
less	O
likely	O
pulmonary	O
hemorrhage	O
can	O
not	O
be	O
excluded	O
.	O
Small	O
bilateral	O
pleural	O
effusions	O
.	O
2	O
.	O
Cirrhotic	O
liver	O
with	O
a	O
moderate	O
amount	O
of	O
ascites	O
and	O
TIPS	O
shunt	O
in	O
place	O
.	O
.	O
OTHER	O
STUDIES	O
:	O
==============	O
EGD	O
[	O
**	O
2106-6-2	O
**	O
]	O
-	O
Grade	O
1	O
esophageal	O
varices	O
A	O
trans	O
-	O
endoscopic	O
NJ	O
feeding	O
tube	O
(	O
8	O
fr	O
)	O
was	O
placed	O
to	O
120	O
cm	O
.	O
Otherwise	O
normal	O
EGD	O
to	O
second	O
part	O
of	O
duodenum	O
.	O
Brief	O
Hospital	O
Course	O
:	O
45	O
yo	O
female	O
with	O
ESLD	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
EtOH	O
cirrhosis	O
s	O
/	O
p	O
TIPS	O
who	O
presented	O
from	O
OSH	O
for	O
liver	O
transplant	O
evaluation	O
,	O
recent	O
severe	O
bleeding	O
,	O
who	O
developed	O
sepsis	O
,	O
DIC	O
,	O
and	O
multiorgan	O
failure	O
.	O
A	O
brief	O
hospital	O
course	O
by	O
problem	O
is	O
outlined	O
below	O
:	O
.	O
#Sepsis	O
/	O
DIC	I-Reason
:	O
The	O
patient	O
required	O
multiple	O
vasopressors	I-Drug
to	O
maintain	O
SvO2	O
>	O
70	O
and	O
MAP	O
>	O
60s	O
.	O
Lactate	O
continued	O
to	O
rise	O
and	O
she	O
became	O
progressively	O
acidotic	O
.	O
End	O
organ	O
hypoperfusion	O
was	O
demonstrated	O
by	O
anuria	O
.	O
She	O
was	O
treated	O
broadly	O
with	O
antibiotics	I-Drug
and	O
aggressively	O
transfused	O
with	O
blood	B-Drug
products	I-Drug
and	O
albumin	I-Drug
for	O
intravascular	B-Reason
volume	I-Reason
support	I-Reason
and	O
to	O
correct	B-Reason
her	I-Reason
underlying	I-Reason
coagulopathy	O
.	O
HCO3	I-Drug
was	O
utilized	O
prn	O
given	O
worsening	O
acidosis	I-Reason
.	O
The	O
patient	O
was	O
made	O
CMO	O
after	O
an	O
extensive	O
family	O
discussion	O
regarding	O
her	O
poor	O
prognosis	O
and	O
she	O
rapidly	O
expired	O
after	O
removal	O
of	O
vasopressors	I-Drug
and	O
respiratory	O
support	O
.	O
.	O
#	O
Respiratory	O
Failure	O
:	O
Progressively	O
worsening	O
bilateral	O
lung	O
infiltrates	O
resulting	O
in	O
hypoxia	O
requiring	O
intubation	O
.	O
Differential	O
included	O
DAH	O
given	O
coagulopathy	O
,	O
infection	I-Ade
(	O
e.g.	O
PCP	O
/	O
fungal	O
given	O
recent	O
course	O
of	O
steroids	I-Drug
)	O
,	O
or	O
TRALI	O
(	O
though	O
unlikely	O
)	O
.	O
She	O
was	O
afebrile	O
with	O
rapidly	O
progressive	O
leukocytosis	O
.	O
The	O
patient	O
was	O
treated	O
with	O
steroids	I-Drug
and	O
bactrim	I-Drug
for	O
PCP	I-Reason
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
74369	O
**	O
]	O
for	O
fungal	O
coverage	O
,	O
and	O
levaquin	I-Drug
to	O
cover	O
mycoplasma	I-Reason
,	O
and	O
flagyl	I-Drug
for	O
anaerobic	B-Reason
coverage	I-Reason
.	O
Given	O
worsening	O
infiltrates	O
and	O
P	O
/	O
F	O
ratio	O
suggestive	O
of	O
ARDS	O
,	O
she	O
was	O
ventilated	O
on	O
ARDSnet	O
protocol	O
to	O
minimize	O
barotrauma	O
and	O
allowed	O
permissive	O
hypercapnea	O
.	O
.	O
#	O
Acute	O
renal	O
failure	O
:	O
Cr	O
progressively	O
worsened	O
in	O
the	O
setting	O
of	O
sepsis	O
and	O
the	O
patient	O
became	O
anuric	O
.	O
Differential	O
included	O
HRS	O
,	O
ATN	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
renal	O
hypoperfusion	O
,	O
prerenal	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
hypoalbuminemia	O
and	O
3rd	O
spacing	O
.	O
She	O
was	O
unable	O
to	O
take	O
po	O
octreotide	I-Drug
,	O
midodrine	I-Drug
due	O
to	O
increased	B-Ade
GI	I-Ade
secretions	I-Ade
and	O
poor	O
absorption	O
.	O
Attempted	O
to	O
increased	O
intravascular	B-Reason
volume	I-Reason
with	O
albumin	I-Drug
and	O
blood	B-Drug
products	I-Drug
.	I-Drug
Pressors	I-Drug
were	O
utilized	O
to	O
maintain	O
renal	B-Reason
perfusion	I-Reason
.	O
The	O
patient	O
developed	O
a	O
severe	B-Reason
lactic	I-Reason
acid	I-Reason
metabolic	I-Reason
acidosis	I-Reason
due	O
to	O
tissue	O
hypoxia	O
requiring	O
HCO3	I-Drug
pushes	O
.	O
.	O
#	O
ETOH	O
Cirrhosis	O
:	O
Decompensated	O
liver	O
disease	O
s	O
/	O
p	O
TIPS	O
,	O
with	O
hepatic	O
encephalopathy	O
,	O
coagluapathy	O
,	O
elevated	O
Tbili	O
,	O
hyponatremia	O
.	O
On	O
admission	O
,	O
aldactone	I-Drug
held	O
given	O
hyponatremia	I-Ade
and	O
hypotension	I-Ade
.	O
Lasix	I-Drug
held	O
given	O
auto	B-Ade
-	I-Ade
immune	I-Ade
hemolytic	I-Ade
anemia	I-Ade
.	O
She	O
was	O
given	O
lactulose	I-Drug
and	O
rifaxamin	I-Drug
for	O
hepatic	I-Reason
encephalopathy	O
.	O
Ultrasound	O
perfomed	O
on	O
admission	O
and	O
showed	O
patent	O
TIPS	O
,	O
cirrhotic	O
liver	O
,	O
no	O
hepatoma	O
.	O
Diagnostic	O
paracentesis	O
was	O
performed	O
,	O
and	O
was	O
negative	O
for	O
SBP	O
.	O
.	O
During	O
hospitalization	O
,	O
she	O
was	O
evaluated	O
for	O
liver	O
transplant	O
,	O
and	O
was	O
transiently	O
placed	O
on	O
the	O
transplant	O
list	O
but	O
was	O
removed	O
after	O
becoming	O
septic	O
.	O
TTE	O
showed	O
a	O
hyperdynamic	O
EF	O
,	O
with	O
no	O
pulmonary	O
hypertension	O
or	O
significant	O
valvular	O
disease	O
.	O
Liver	O
CT	O
completed	O
.	O
PFT	O
's	O
performed	O
,	O
with	O
noted	O
mild	O
diffusion	O
abnormality	O
.	O
Chest	O
CT	O
demonstrated	O
pulmonary	O
nodules	O
(	O
see	O
below	O
)	O
which	O
were	O
stable	O
on	O
repeat	O
CT	O
chest	O
one	O
week	O
later	O
.	O
Chest	O
CT	O
from	O
[	O
**	O
2106-6-16	O
**	O
]	O
showed	O
marked	O
worsening	O
(	O
see	O
below	O
)	O
.	O
.	O
Hospitalization	O
was	O
complicated	O
by	O
hepatic	O
encephalopathy	O
,	O
hyponatremia	O
and	O
hepatorenal	O
syndrome	O
.	O
HRS	I-Reason
improved	O
after	O
midodrine	I-Drug
and	O
octreotide	I-Drug
,	O
and	O
albumin	I-Drug
steadied	O
hyponatremia	I-Reason
near	O
baseline	O
of	O
127	O
-	O
129	O
.	O
She	O
was	O
fluid	O
restricted	O
,	O
but	O
continued	O
to	O
have	O
worsening	O
peripheral	O
edema	O
;	O
diuretics	O
were	O
held	O
given	O
her	O
recently	O
diagnosed	O
AIHA	I-Ade
[	O
**	O
1	O
-	O
15	O
**	O
]	O
lasix	I-Drug
.	O
.	O
#	O
Arrhythmia	O
:	O
The	O
patient	O
had	O
two	O
asymptomatic	O
episodes	O
of	O
stable	O
Vtach	O
on	O
the	O
floor	O
.	O
On	O
[	O
**	O
2106-6-16	O
**	O
]	O
,	O
pt	O
developed	O
atrial	O
fibrillation	O
to	O
160	O
's	O
.	O
She	O
was	O
converted	O
with	O
lopressor	I-Drug
and	O
diltiazam	I-Drug
,	O
but	O
then	O
reverted	O
to	O
Afib	B-Reason
/	I-Reason
flutter	I-Reason
rate	I-Reason
-	I-Reason
controlled	I-Reason
on	O
diltiazem	I-Drug
.	O
On	O
transfer	O
to	O
the	O
MICU	O
,	O
she	O
had	O
bursts	O
of	O
atrial	O
flutter	O
with	O
variable	O
block	O
and	O
rate	O
-	O
dependent	O
bundle	O
branch	O
block	O
.	O
She	O
remained	O
asymptomatic	O
but	O
nodal	O
agents	O
were	O
held	O
given	O
hypotension	O
.	O
.	O
#	O
Leukocytosis	O
:	O
Initially	O
with	O
nosocomial	O
pneumonia	O
at	O
outside	O
hospital	O
treated	O
with	O
a	O
course	O
of	O
IV	O
antibiotics	I-Drug
.	O
Upon	O
admission	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
,	O
no	O
infectious	O
etiology	O
was	O
found	O
,	O
with	O
negative	O
blood	O
,	O
urine	O
and	O
stool	O
cultures	O
.	O
Although	O
pulmonary	O
nodules	O
were	O
seen	O
on	O
chest	O
CT	O
,	O
this	O
was	O
not	O
felt	O
to	O
represent	O
an	O
acute	O
infectious	O
process	O
given	O
lack	O
of	O
associated	O
signs	O
or	O
symptoms	O
of	O
infection	O
,	O
therefore	O
no	O
further	O
antibiotics	O
were	O
given	O
.	O
Acute	O
alcoholic	O
hepatitis	O
was	O
considered	O
as	O
a	O
possible	O
cause	O
of	O
leukocytosis	O
,	O
however	O
there	O
was	O
no	O
recent	O
alcohol	O
use	O
to	O
go	O
along	O
with	O
this	O
diagnosis	O
.	O
.	O
On	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
,	O
UCx	O
with	O
VRE	O
.	O
On	O
[	O
**	O
6	O
-	O
11	O
**	O
]	O
,	O
pt	O
's	O
blood	O
cultures	O
positive	O
for	O
VRE	I-Reason
.	O
Felt	O
that	O
PICC	O
line	O
was	O
possible	O
source	O
;	O
however	O
,	O
wound	O
tip	O
culture	O
showed	O
no	O
growth	O
.	O
She	O
was	O
started	O
on	O
daptomycin	I-Drug
and	O
ceftriaxone	I-Drug
per	O
ID	O
.	O
Echocardiogram	O
was	O
negative	O
for	O
vegetation	O
.	O
On	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
,	O
a	O
repeat	O
chest	O
CT	O
was	O
performed	O
for	O
further	O
characterization	O
of	O
pulmonary	O
nodules	O
which	O
revealed	O
the	O
interval	O
development	O
of	O
diffuse	O
hazy	O
opacities	O
thought	O
to	O
be	O
consistent	O
with	O
PCP	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
7470	O
**	O
]	O
given	O
that	O
she	O
was	O
weaned	O
off	O
steroids	I-Drug
for	O
AIHA	I-Reason
only	O
days	O
earlier	O
.	O
She	O
was	O
started	O
emperically	O
on	O
treatment	O
doses	O
of	O
bactrim	I-Drug
however	O
she	O
continued	O
to	O
worsen	O
.	O
Diagnostic	O
bronchoscopy	O
was	O
considered	O
upon	O
transfer	O
to	O
the	O
ICU	O
however	O
the	O
patient	O
was	O
too	O
unstable	O
for	O
the	O
procedure	O
.	O
Flagyl	I-Drug
also	O
emperically	O
started	O
for	O
C.	B-Reason
diff	I-Reason
.	O
.	O
#	O
Coagulopathy	I-Reason
:	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
liver	O
disease	O
.	O
Pt	O
has	O
had	O
multiple	O
red	B-Drug
blood	I-Drug
cell	O
transfusions	O
,	O
FFP	I-Drug
,	O
cryo	I-Drug
,	O
and	O
platelets	I-Drug
during	O
admission	O
.	O
Also	O
received	O
ddAVP	I-Drug
for	O
uremic	B-Reason
platelets	I-Reason
.	O
She	O
had	O
an	O
episode	O
of	O
profuse	B-Reason
epistaxis	I-Reason
in	O
the	O
setting	O
of	O
trauma	O
from	O
Doboff	O
feeding	O
tube	O
that	O
could	O
only	O
be	O
controlled	O
with	O
packing	O
,	O
Afrin	I-Drug
and	O
pressure	O
by	O
ENT	O
.	O
She	O
also	O
bled	O
from	O
her	O
paracentesis	O
site	O
,	O
requiring	O
transfusion	O
and	O
sutures	O
.	O
She	O
developed	O
DIC	O
and	O
diffuse	O
mucosal	O
bleeding	O
after	O
becoming	O
septic	O
.	O
.	O
#	O
Auto	B-Ade
-	I-Ade
Immune	I-Ade
Hemolytic	I-Ade
Anemia	I-Ade
:	O
Diagnosed	O
with	O
auto	O
-	O
immune	O
hemolytic	O
anemia	O
at	O
outside	O
hospital	O
,	O
felt	O
to	O
be	O
secondary	O
to	O
lasix	I-Drug
.	O
Re-consulted	O
hematology	O
here	O
who	O
agreed	O
with	O
this	O
diagnosis	O
.	O
Lasix	I-Drug
was	O
held	O
during	O
admission	O
and	O
repeat	O
coombs	O
antibody	O
negative	O
.	O
Reticulocyte	O
count	O
high	O
on	O
admission	O
(	O
29	O
%	O
)	O
,	O
with	O
elevated	O
LDH	O
,	O
tbili	O
,	O
and	O
decreasing	O
hematocrit	O
suggestive	O
of	O
ongoing	O
hemolysis	O
.	O
However	O
,	O
hemolysis	O
indices	O
improved	O
on	O
prednisone	I-Drug
,	O
and	O
slow	O
prednisone	I-Drug
taper	O
initiated	O
as	O
indices	O
stabilized	O
.	O
Blood	O
counts	O
supported	O
as	O
needed	O
with	O
blood	O
transfusions	O
(	O
for	O
hgb	O
<	O
7	O
given	O
difficult	O
crossmatch	O
(	O
she	O
has	O
two	O
antibodies	O
)	O
.	O
.	O
#	O
GI	O
:	O
EGD	O
performed	O
on	O
this	O
admission	O
demonstrated	O
grade	O
1	O
esophageal	O
varices	O
,	O
a	O
trans	O
-	O
endoscopic	O
NJ	O
feeding	O
tube	O
,	O
and	O
otherwise	O
normal	O
EGD	O
to	O
second	O
part	O
of	O
the	O
duodenum	O
.	O
.	O
Medications	O
on	O
Admission	O
:	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
Qday	O
MVI	B-Drug
with	I-Drug
minerals	I-Drug
thiamine	I-Drug
100	O
mg	O
Qday	O
prednisone	I-Drug
45	O
mg	O
Qday	O
spironolactone	I-Drug
50	O
mg	O
Qday	O
lactulose	I-Drug
30	O
ml	O
[	O
**	O
Hospital1	O
**	O
]	O
Mg	B-Drug
oxide	I-Drug
400	O
[	O
**	O
Hospital1	O
**	O
]	O
levoflox	I-Drug
500	O
mg	O
IV	O
Qday	O
(	O
day	O
1	O
:	O
[	O
**	O
5	O
-	O
23	O
**	O
]	O
)	O
vancomycin	I-Drug
750	O
mg	O
IV	O
Qday	O
(	O
day	O
1	O
:	O
[	O
**	O
5	O
-	O
23	O
**	O
]	O
)	O
ceftaz	I-Drug
2g	O
Q8H	O
(	O
day	O
1	O
:	O
[	O
**	O
5	O
-	O
23	O
**	O
]	O
)	O
zofran	I-Drug
4	O
mg	O
PO	O
prn	O
Discharge	O
Medications	O
:	O
none	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnoses	O
:	O
1	O
.	O
Alcoholic	O
Cirrhosis	O
2	O
.	O
Hepatic	O
Encephalopathy	O
3	O
.	O
Nutritional	O
Deficiency	O
Secondary	O
Diagnoses	O
:	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
Expired	O
Followup	O
Instructions	O
:	O
none	O

Admission	O
Date	O
:	O
[	O
**	O
2127-8-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2127-9-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2093-1-14	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Demerol	I-Drug
/	O
Dilaudid	I-Drug
/	O
Ciprofloxacin	I-Drug
/	O
Bacitracin	I-Drug
/	O
Neosporin	I-Drug
/	O
Adhesive	O
Tape	O
/	O
Latex	O
/	O
Optiray	I-Drug
300	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
358	O
**	O
]	O
Chief	O
Complaint	O
:	O
Epigastric	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
34	O
y	O
/	O
o	O
F	O
with	O
h	O
/	O
o	O
autonomic	O
dystonia	O
,	O
gastroparesis	O
,	O
neurocardiogenic	O
syncpoe	O
(	O
pacer	O
[	O
**	O
2121	O
**	O
]	O
)	O
,	O
bladder	O
areflexia	O
with	O
bladder	O
stimulator	O
implant	O
and	O
urostomy	O
,	O
who	O
presents	O
with	O
2	O
days	O
of	O
intermittent	O
,	O
epigastric	O
pain	O
that	O
radiated	O
to	O
flanks	O
and	O
back	O
,	O
exacerbated	O
by	O
eating	O
.	O
Abdominal	O
pain	O
is	O
different	O
in	O
quality	O
from	O
her	O
usual	O
gastroparesis	O
.	O
She	O
has	O
had	O
chills	O
,	O
and	O
low	O
grade	O
fever	O
to	O
99	O
the	O
past	O
2	O
days	O
.	O
+	O
nausea	O
,	O
increased	O
aspirate	O
from	O
g	O
tube	O
,	O
copious	O
,	O
green	O
and	O
black	O
.	O
Pt	O
has	O
also	O
had	O
urinary	O
frequecy	O
and	O
foul	O
smelling	O
urine	O
from	O
urostomy	O
.	O
Pt	O
denies	O
any	O
new	O
meds	O
,	O
no	O
tylenol	I-Drug
and	O
no	O
OTC	O
/	O
supplemental	O
or	O
new	O
therapies	O
.	O
Pt	O
presented	O
to	O
OSH	O
[	O
**	O
8	O
-	O
24	O
**	O
]	O
found	O
to	O
have	O
elevated	O
[	O
**	O
Hospital	O
13550	O
**	O
]	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
work	O
up	O
.	O
.	O
In	O
the	O
ED	O
initial	O
vitals	O
were	O
T	O
99	O
BP	O
99/56	O
AR	O
68	O
RR	O
16	O
O2	O
sat	O
98	O
%	O
RA	O
.	O
Her	O
ALT	O
and	O
AST	O
were	O
found	O
to	O
be	O
1737	O
and	O
2212	O
respectively	O
.	O
.	O
On	O
Medical	O
Floor	O
:	O
Pt	O
was	O
stable	O
,	O
after	O
undergoing	O
Abd	O
CT	O
with	O
IV	O
contrast	B-Drug
pt	O
developed	O
an	O
exacerbation	O
of	O
her	O
dystonia	O
with	O
extensive	O
rigidity	O
,	O
tachycardia	O
HR	O
150s	O
and	O
"	O
unresponsive	O
"	O
.	O
Pt	O
was	O
given	O
Benadryl	I-Drug
25	O
mg	O
IV	O
x1	O
,	O
Valium	I-Drug
10	O
mg	O
IV	O
x1	O
.	O
Per	O
nursing	O
concern	O
pt	O
was	O
transferred	O
to	O
MICU	O
for	O
further	O
monitoring	O
of	O
respiratory	O
status	O
given	O
benzo	I-Drug
requirement	O
to	O
relieve	O
dystonia	O
.	O
Pt	O
was	O
never	O
hypoxic	O
,	O
VSS	O
.	O
Past	O
Medical	O
History	O
:	O
#	O
.	O
generalized	O
dystonia	O
-	O
involving	O
mainly	O
her	O
lower	O
extremities	O
and	O
intermittently	O
her	O
arms	O
,	O
right	O
more	O
than	O
left	O
,	O
occasionally	O
her	O
neck	O
and	O
voice	O
;	O
provoked	O
exacerbations	O
of	O
the	O
symptoms	O
without	O
a	O
clear	O
direct	O
inducer	O
[	O
seen	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
13551	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
13552	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
1774	O
**	O
]	O
]	O
#	O
.	O
dysautonomia	O
with	O
orthostasis	O
,	O
baseline	O
SBP	O
80s	O
-	O
90s	O
-	O
followed	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
#	O
.	O
neuro	O
-	O
cardiogenic	O
syncope	O
s	O
/	O
p	O
pacer	O
in	O
[	O
**	O
12/2120	O
**	O
]	O
#	O
.	O
Parkinsonism	O
-	O
occasional	O
adventitious	O
choreiform	O
movements	O
in	O
both	O
upper	O
extremities	O
induced	O
by	O
action	O
#	O
.	O
gastric	O
dysmotility	O
s	O
/	O
p	O
g	O
-	O
tube	O
placement	O
#	O
.	O
bladder	O
areflexia	O
s	O
/	O
p	O
bladder	O
stimulator	O
implant	O
and	O
urostomy	O
[	O
**	O
2126	O
**	O
]	O
#	O
.	O
depression	O
with	O
h	O
/	O
o	O
suicide	O
attempt	O
#	O
.	O
peripheral	O
neuropathy	O
#	O
.	O
h	O
/	O
o	O
chronic	O
pupillary	O
dilation	O
#	O
.	O
s	O
/	O
p	O
lap	O
CCY	O
Social	O
History	O
:	O
Married	O
and	O
lives	O
with	O
husband	O
,	O
no	O
children	O
.	O
Has	O
a	O
dog	O
.	O
Not	O
working	O
and	O
on	O
disability	O
Family	O
History	O
:	O
Grandfather	O
with	O
frequent	O
syncopy	O
,	O
who	O
has	O
since	O
passed	O
away	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
96.3	O
,	O
BP	O
93/55	O
,	O
HR	O
80	O
,	O
RR	O
18	O
,	O
O2	O
saat	O
98	O
%	O
RA	O
GEN	O
:	O
Pleasant	O
young	O
woman	O
in	O
NAD	O
HEENT	O
:	O
MMM	O
,	O
Dilated	O
Pupils	O
reactive	O
to	O
light	O
5	O
mm	O
--	O
>	O
3	O
mm	O
,	O
EOMI	O
,	O
anicteric	O
sclera	O
RESP	O
:	O
CTA	O
b	O
/	O
l	O
,	O
no	O
stridor	O
CV	O
:	O
Reg	O
Nml	O
S1	O
,	O
S2	O
,	O
no	O
M	O
/	O
R	O
/	O
G	O
ABD	O
:	O
Soft	O
,	O
ND	O
,	O
Tender	O
at	O
RUQ	O
no	O
rebound	O
,	O
no	O
guarding	O
+	O
BS	O
,	O
urostomy	O
in	O
place	O
with	O
pink	O
stomal	O
mucosa	O
-	O
clear	O
urine	O
in	O
bag	O
,	O
GJ	O
tube	O
in	O
place	O
EXT	O
:	O
warm	O
,	O
no	O
peripheral	O
edema	O
,	O
2	O
+	O
DP	O
pulses	O
b	O
/	O
l	O
,	O
legs	O
locked	O
in	O
place	O
crossed	O
at	O
ankles	O
--	O
unable	O
to	O
uncross	O
voluntarily	O
with	O
dorsiflexed	O
ankles	O
,	O
contracture	O
of	O
R	O
hand	O
and	O
flexed	O
at	O
elbow	O
,	O
unable	O
to	O
straighten	O
out	O
NEURO	O
:	O
A&O	O
x3	O
,	O
no	O
focal	O
deficits	O
,	O
unable	O
to	O
assess	O
gait	O
or	O
reflexes	O
as	O
pt	O
's	O
legs	O
and	O
right	O
arm	O
locked	O
in	O
,	O
difficulty	O
sticking	O
out	O
tongue	O
,	O
no	O
facial	O
droop	O
,	O
clear	O
voice	O
Pertinent	O
Results	O
:	O
[	O
**	O
2127-8-24	O
**	O
]	O
10:35	O
PM	O
BLOOD	O
WBC	O
-	O
5.0	O
RBC	O
-	O
3.36	O
*	O
Hgb	O
-	O
10.0	O
*	O
Hct	O
-	O
29.2	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
29.9	O
#	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
115	O
*	O
[	O
**	O
2127-8-25	O
**	O
]	O
06:46	O
AM	O
BLOOD	O
WBC	O
-	O
4.8	O
RBC	O
-	O
3.15	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
27.5	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
30.1	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
101	O
*	O
[	O
**	O
2127-8-26	O
**	O
]	O
03:12	O
AM	O
BLOOD	O
WBC	O
-	O
6.1	O
RBC	O
-	O
3.25	O
*	O
Hgb	O
-	O
9.6	O
*	O
Hct	O
-	O
28.5	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
29.6	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
111	O
*	O
[	O
**	O
2127-8-24	O
**	O
]	O
10:35	O
PM	O
BLOOD	O
Glucose	O
-	O
82	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.5	O
Na	O
-	O
137	O
K	O
-	O
3.9	O
Cl	O
-	O
103	O
HCO3	O
-	O
25	O
AnGap	O
-	O
13	O
[	O
**	O
2127-8-25	O
**	O
]	O
06:46	O
AM	O
BLOOD	O
Glucose	O
-	O
81	O
UreaN	O
-	O
14	O
Creat	O
-	O
0.5	O
Na	O
-	O
137	O
K	O
-	O
3.6	O
Cl	O
-	O
104	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2127-8-26	O
**	O
]	O
03:12	O
AM	O
BLOOD	O
Glucose	O
-	O
110	O
*	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.6	O
Na	O
-	O
137	O
K	O
-	O
3.4	O
Cl	O
-	O
102	O
HCO3	O
-	O
25	O
AnGap	O
-	O
13	O
[	O
**	O
2127-8-24	O
**	O
]	O
10:35	O
PM	O
BLOOD	O
ALT	O
-	O
1737	O
*	O
AST	O
-	O
2212	O
*	O
AlkPhos	O
-	O
436	O
*	O
Amylase	O
-	O
33	O
TotBili	O
-	O
1.8	O
*	O
[	O
**	O
2127-8-25	O
**	O
]	O
06:46	O
AM	O
BLOOD	O
ALT	O
-	O
1443	O
*	O
AST	O
-	O
1502	O
*	O
AlkPhos	O
-	O
432	O
*	O
Amylase	O
-	O
41	O
TotBili	O
-	O
1.7	O
*	O
[	O
**	O
2127-8-26	O
**	O
]	O
03:12	O
AM	O
BLOOD	O
ALT	O
-	O
1053	O
*	O
AST	O
-	O
694	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
233	O
AlkPhos	O
-	O
427	O
*	O
TotBili	O
-	O
0.8	O
[	O
**	O
2127-8-26	O
**	O
]	O
03:12	O
AM	O
BLOOD	O
Calcium	O
-	O
9.1	O
Phos	O
-	O
3.8	O
Mg	O
-	O
2.0	O
[	O
**	O
2127-8-25	O
**	O
]	O
06:46	O
AM	O
BLOOD	O
HBsAg	O
-	O
NEGATIVE	O
HBsAb	O
-	O
POSITIVE	O
HBcAb	O
-	O
NEGATIVE	O
HAV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2127-8-25	O
**	O
]	O
10:41	O
AM	O
BLOOD	O
Smooth	O
-	O
NEGATIVE	O
[	O
**	O
2127-8-25	O
**	O
]	O
12:59	O
PM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
.	O
Imaging	O
:	O
[	O
**	O
2127-8-24	O
**	O
]	O
Liver	O
U	O
/	O
S	O
-	O
Normal	O
-	O
appearing	O
common	O
bile	O
duct	O
,	O
without	O
shadowing	O
stones	O
.	O
Unchanged	O
mild	O
right	O
hydronephrosis	O
.	O
IMPRESSION	O
:	O
Normal	O
Doppler	O
ultrasound	O
.	O
.	O
[	O
**	O
2127-8-25	O
**	O
]	O
ABD	O
CTA	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
portal	O
vein	O
thrombosis	O
.	O
2	O
.	O
Splenomegaly	O
.	O
3	O
.	O
Right	O
complex	O
adnexal	O
structure	O
likely	O
representing	O
hydrosalpinx	O
.	O
Brief	O
Hospital	O
Course	O
:	O
34	O
y	O
/	O
o	O
F	O
with	O
h	O
/	O
o	O
generalized	O
dsytonia	O
,	O
orthostasis	O
,	O
gastroparesis	O
,	O
bladder	O
areflexia	O
s	O
/	O
p	O
urostomy	O
who	O
presented	O
to	O
the	O
hospital	O
with	O
epigastric	O
pain	O
and	O
transaminitis	O
,	O
UTI	O
.	O
.	O
1	O
)	O
Transaminitis	O
:	O
The	O
patient	O
presented	O
to	O
the	O
hospital	O
with	O
sharp	O
epigastric	O
pain	O
and	O
transaminitis	O
on	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
with	O
ALT	O
/	O
AST	O
in	O
the	O
[	O
**	O
1	O
-	O
/	O
2120	O
**	O
]	O
's	O
.	O
During	O
the	O
hospitalization	O
,	O
the	O
ALT	O
and	O
AST	O
trended	O
down	O
.	O
The	O
epigastric	O
pain	O
resolved	O
by	O
the	O
day	O
after	O
admission	O
.	O
Several	O
etiologogies	O
were	O
considered	O
for	O
this	O
acute	O
change	O
in	O
her	O
liver	O
status	O
.	O
Patient	O
denies	O
using	O
tylenol	I-Drug
or	O
NSAIDs	I-Drug
,	O
and	O
tylenol	I-Drug
level	O
was	O
not	O
elevated	O
.	O
The	O
only	O
new	O
medication	O
used	O
was	O
Valtrex	I-Drug
for	O
shingles	I-Reason
in	O
early	O
[	O
**	O
Month	O
(	O
only	O
)	O
596	O
**	O
]	O
,	O
given	O
the	O
time	O
that	O
has	O
passed	O
between	O
using	O
the	O
medication	O
and	O
transaminitis	O
,	O
it	O
is	O
unlikely	O
that	O
this	O
contribued.The	O
patient	O
also	O
had	O
viral	O
serologies	O
,	O
Hep	O
A	O
/	O
B	O
/	O
C	O
were	O
all	O
negative	O
.	O
CMV	O
was	O
negative	O
.	O
EBV	O
showed	O
positive	O
IgG	O
and	O
negative	O
IgM	O
.	O
parvovirus	O
and	O
HSV	O
were	O
negative	O
.	O
Additionally	O
,	O
the	O
patient	O
had	O
autoimmune	O
work	O
up	O
,	O
whcih	O
was	O
negative	O
for	O
RH	O
,	O
alpha	O
1	O
antitrypson	O
,	O
cerruloplasmn	O
.	O
HSV	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
parvo	O
also	O
negative	O
.	O
The	O
patient	O
is	O
status	O
post	O
cholecystectomy	O
,	O
and	O
had	O
a	O
MRCP	O
for	O
the	O
consideration	O
of	O
stone	O
in	O
duct	O
.	O
Sludge	O
was	O
found	O
,	O
pt	O
had	O
sphincerotomy	O
,	O
and	O
sludge	O
was	O
removed	O
.	O
On	O
[	O
**	O
8	O
-	O
31	O
**	O
]	O
,	O
patient	O
complaining	O
of	O
repeat	O
abd	O
pain	O
,	O
now	O
central	O
on	O
right	O
side	O
.	O
Had	O
KUB	O
,	O
was	O
normal	O
,	O
had	O
EGD	O
which	O
was	O
normal	O
,	O
small	O
area	O
of	O
gastritis	O
,	O
Small	O
bowel	O
follow	O
through	O
,	O
normal	O
.	O
Pt	O
has	O
been	O
on	O
TPN	O
for	O
several	O
years	O
,	O
this	O
was	O
discontinued	O
during	O
the	O
beginning	O
of	O
the	O
hospital	O
stay	O
.	O
it	O
was	O
restarted	O
on	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
,	O
and	O
LFTs	O
did	O
not	O
increase	O
at	O
first	O
,	O
but	O
around	O
[	O
**	O
9	O
-	O
1	O
**	O
]	O
they	O
started	O
increasing	O
slightly	O
but	O
consistently	O
.	O
It	O
is	O
likely	O
that	O
patient	O
had	O
a	O
stone	O
that	O
was	O
passed	O
,	O
which	O
caused	O
the	O
initial	O
pain	O
patient	O
felt	O
before	O
coming	O
to	O
the	O
hosptital	O
.	O
Since	O
the	O
Liver	O
enzymes	O
trended	O
up	O
,	O
she	O
got	O
a	O
liver	O
biopsy	O
on	O
[	O
**	O
9	O
-	O
9	O
**	O
]	O
.	O
Pt	O
's	O
liver	O
enzymes	O
have	O
been	O
trending	O
down	O
.	O
.	O
2	O
)	O
Autonomic	O
Dystonia	O
:	O
longstanding	O
since	O
age	O
23	O
,	O
at	O
baseline	O
uses	O
wheelchair	O
,	O
exacerbations	O
in	O
setting	O
of	O
infectious	O
processes	O
or	O
without	O
clear	O
inducing	O
agents	O
noted	O
.	O
Per	O
movement	O
disorder	O
specialists	O
her	O
exam	O
has	O
shown	O
severe	O
dystonia	O
with	O
some	O
atypical	O
features	O
that	O
raise	O
a	O
question	O
of	O
a	O
psychogenic	O
component	O
as	O
well	O
.	O
During	O
her	O
first	O
week	O
here	O
,	O
while	O
she	O
had	O
the	O
UTI	O
,	O
she	O
had	O
about	O
3	O
episodes	O
of	O
acute	O
dystonia	O
during	O
which	O
she	O
could	O
not	O
speak	O
.	O
The	O
first	O
was	O
her	O
first	O
night	O
in	O
the	O
hospital	O
(	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
)	O
.	O
When	O
contrast	I-Drug
for	O
CT	O
scan	O
was	O
done	O
,	O
she	O
became	O
acutely	O
dystonic	O
.	O
She	O
got	O
5	O
mg	O
IV	O
valium	I-Drug
,	O
and	O
then	O
10	O
mg	O
IV	O
valium	I-Drug
plus	O
25	O
mg	O
IV	O
benedryl	I-Drug
.	O
She	O
became	O
unresponsive	O
,	O
and	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
closer	O
monitoring	O
.	O
She	O
was	O
transferred	O
back	O
to	O
the	O
floor	O
the	O
next	O
day	O
.	O
She	O
had	O
another	O
episode	O
overnight	O
,	O
which	O
resolved	O
with	O
10	O
mg	O
IV	O
valium	I-Drug
x2	O
and	O
25	O
benedryl	I-Drug
x2	O
.	O
This	O
regimen	O
has	O
been	O
working	O
for	O
during	O
the	O
hospitization	O
.	O
For	O
less	O
sever	O
dystonia	O
,	O
she	O
takes	O
valium	I-Drug
5	O
mg	O
IV	O
.	O
Also	O
during	O
this	O
hospitalization	O
,	O
with	O
neurologies	O
approval	O
,	O
Sinemet	I-Drug
was	O
restarted	O
.	O
she	O
was	O
taken	O
of	O
this	O
medication	O
a	O
few	O
months	O
back	O
.	O
Pt	O
will	O
be	O
d	O
/	O
cd	O
with	O
PO	O
valium	I-Drug
5	O
mg	O
Q8	O
prn	O
severe	B-Reason
dystonia	I-Reason
and	O
25	O
mg	O
benedryl	I-Drug
po	O
.	O
She	O
must	O
not	O
take	O
these	O
medications	O
in	O
combination	O
with	O
her	O
narcotic	B-Drug
pain	I-Drug
medications	I-Drug
or	O
other	O
sedating	O
medications	O
.	O
She	O
will	O
be	O
following	O
up	O
with	O
hepatology	O
and	O
neurology	O
as	O
outpatient	O
for	O
further	O
care	O
.	O
.	O
2	O
.	O
Ileoconduit	O
infection	O
:	O
patient	O
found	O
to	O
have	O
pan	O
resistent	O
klebsiella	O
in	O
urine	O
in	O
outside	O
hospital	O
.	O
Put	O
on	O
7	O
days	O
of	O
meropenem	I-Drug
.	O
Showing	O
signs	O
of	O
infection	O
again	O
on	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
,	O
but	O
Cx	O
was	O
contaminated	O
.	O
started	O
on	O
meropenem	I-Drug
again	O
.	O
Patient	O
has	O
outpatient	O
follow	O
up	O
appt	O
with	O
ID	O
,	O
who	O
saw	O
her	O
in	O
the	O
hospital	O
.	O
Also	O
seen	O
by	O
Urology	O
,	O
she	O
should	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
neurourologist	O
for	O
issues	O
concerning	O
ileoconduit	O
,	O
and	O
removal	O
of	O
badder	O
stimulator	O
that	O
is	O
no	O
longer	O
in	O
use	O
.	O
She	O
will	O
be	O
following	O
up	O
with	O
ID	O
and	O
urology	O
as	O
outpatient	O
.	O
.	O
3	O
.	O
Diarrhea	O
:	O
since	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
patient	O
has	O
been	O
complaining	O
of	O
blood	O
in	O
stool	O
and	O
diarrhea	O
.	O
She	O
has	O
had	O
3	O
episodes	O
of	O
fecal	O
incontinence	O
.	O
Stool	O
studies	O
were	O
negative	O
.	O
Diarrhea	O
has	O
resolved	O
.	O
.	O
4	O
.	O
Pain	B-Reason
control	I-Reason
:	O
patient	O
prescribed	O
Methadone	I-Drug
5	O
mg	O
q8h	O
at	O
home	O
,	O
but	O
says	O
she	O
rarely	O
takes	O
it	O
.	O
She	O
had	O
significant	O
RUQ	O
pain	O
during	O
her	O
second	O
week	O
here	O
,	O
requiring	O
4	O
mg	O
morphine	I-Drug
every	O
4	O
hours	O
.	O
I	O
started	O
her	O
on	O
methadone	I-Drug
2.5	O
Q8h	O
,	O
and	O
changed	O
her	O
morphine	I-Drug
to	O
2	O
mg	O
q2h	O
.	O
She	O
is	O
requiring	O
less	O
PRN	O
morphine	I-Drug
since	O
starting	O
the	O
methadone	I-Drug
.	O
She	O
will	O
be	O
discharged	O
home	O
on	O
methadone	I-Drug
2.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
and	O
morphine	B-Drug
IR	I-Drug
15	O
mg	O
Q8	O
prn	O
as	O
needed	O
for	O
severe	I-Reason
pain	O
.	O
4	O
.	O
Depression	I-Reason
,	O
hx	O
of	O
suicide	O
attempt	O
in	O
past	O
-	O
continue	O
zoloft	I-Drug
.	O
.	O
5	O
.	O
FEN	O
:	O
Patient	O
on	O
TPN	O
.	O
Will	O
continue	O
at	O
home	O
with	O
the	O
reinitiation	O
of	O
lipids	O
.	O
Medications	O
on	O
Admission	O
:	O
Midodrine	I-Drug
5	O
mg	O
PO	O
TID	O
Nadolol	I-Drug
80	O
mg	O
PO	O
daily	O
Trihexyphenidyl	I-Drug
3	O
mg	O
PO	O
TID	O
Prilosec	I-Drug
20	O
mg	O
PO	O
daily	O
Zoloft	I-Drug
75	O
mg	O
PO	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Midodrine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Baclofen	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Trihexyphenidyl	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Sertraline	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Nadolol	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Carbidopa	B-Drug
-	I-Drug
Levodopa	I-Drug
25	O
-	O
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
TPN	O
Volume	O
=	O
1500	O
ml	O
/	O
d	O
;	O
amino	O
acid	O
=	O
65	O
g	O
/	O
d	O
;	O
branched	O
chain	O
AA	O
=	O
zero	O
;	O
dextrose	O
=	O
345	O
g	O
/	O
d	O
;	O
fat	O
=	O
50g	O
lipids	O
;	O
trace	O
elements	O
;	O
standard	O
adult	O
multivitamins	I-Drug
,	O
Electrolytes	O
:	O
NaCl	O
=	O
95	O
;	O
NaAc	O
=	O
0	O
;	O
NaPO4	O
=	O
25	O
;	O
KCL	O
=	O
30	O
;	O
KAc	O
=	O
0	O
;	O
KPO4	O
=	O
0	O
;	O
MgSO4	O
=	O
10	O
;	O
CaGluc	O
=	O
10	O
.	O
Add	O
1g	O
carnitine	I-Drug
.	O
Cycle	O
over	O
12hours	O
-	O
9pm	O
-	O
9	O
am	O
.	O
10	O
.	O
Methadone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
45	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Diazepam	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
prn	O
as	O
needed	O
for	O
pain	I-Reason
from	O
dystonia	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
12	O
.	O
Morphine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
q8H	O
prn	O
as	O
needed	O
for	O
severe	B-Reason
pain	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
13	O
.	O
Diphenhydramine	B-Drug
HCl	I-Drug
25	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
q6H	O
prn	O
as	O
needed	O
for	O
acute	B-Reason
dystonia	I-Reason
:	O
may	O
take	O
valium	I-Drug
and	O
benedryl	I-Drug
together	O
for	O
severe	B-Reason
/	I-Reason
painful	I-Reason
dystonia	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
14	O
.	O
Prilosec	I-Drug
OTC	O
20	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
All	O
Care	O
VNA	O
of	O
Greater	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Transaminitis	O
Dystonia	O
gastritis	O
complicated	O
urinary	O
tract	O
infection	O
.	O
Secondary	O
:	O
dysautonomia	O
with	O
orthostasis	O
neuro	O
-	O
cardiogenic	O
syncope	O
s	O
/	O
p	O
pacer	O
in	O
[	O
**	O
2121	O
**	O
]	O
gastric	O
dysmotility	O
bladder	O
areflexia	O
depression	O
peripheral	O
neuropathy	O
Discharge	O
Condition	O
:	O
stable	O
.	O
Discharge	O
Instructions	O
:	O
You	O
came	O
to	O
the	O
hospital	O
with	O
abdominal	O
pain	O
.	O
Your	O
liver	O
enzymes	O
were	O
found	O
to	O
be	O
elevated	O
,	O
and	O
they	O
have	O
been	O
trending	O
down	O
since	O
you	O
have	O
been	O
here	O
.	O
You	O
had	O
a	O
ERCP	O
done	O
,	O
and	O
it	O
is	O
likely	O
that	O
this	O
liver	O
problem	O
was	O
caused	O
by	O
a	O
passed	O
gallstone	O
.	O
You	O
also	O
underwent	O
a	O
liver	O
biopsy	O
.	O
You	O
will	O
follow	O
up	O
the	O
results	O
with	O
the	O
liver	O
specialist	O
.	O
.	O
While	O
you	O
were	O
here	O
you	O
had	O
several	O
episodes	O
of	O
acute	B-Reason
dystonia	I-Reason
.	O
We	O
treated	O
these	O
with	O
IV	O
valium	I-Drug
10	O
mg	O
and	O
25	O
mg	O
of	O
IV	O
benadryl	I-Drug
.	O
We	O
reassessed	O
after	O
1	O
-	O
2	O
hours	O
,	O
and	O
repeated	O
this	O
when	O
necessary	O
.	O
Additionally	O
,	O
we	O
pretreated	O
you	O
prior	O
to	O
procedures	O
with	O
the	O
same	O
regimen	O
.	O
We	O
also	O
gave	O
Valium	I-Drug
you	O
started	O
having	O
a	O
tonic	I-Reason
reaction	O
,	O
treating	O
the	O
contraction	O
rather	O
than	O
the	O
pain	O
.	O
Your	O
symptoms	O
improved	O
with	O
this	O
regimen	O
.	O
At	O
home	O
you	O
may	O
take	O
valium	I-Drug
5	O
mg	O
by	O
mouth	O
every	O
6	O
hours	O
for	O
acute	B-Reason
dystonia	I-Reason
as	O
well	O
as	O
25	O
mg	O
of	O
benedryl	I-Drug
by	O
mouth	O
.	O
You	O
must	O
be	O
careful	O
not	O
to	O
take	O
these	O
medications	O
and	O
your	O
pain	B-Drug
medication	I-Drug
,	O
morphine	I-Drug
at	O
the	O
same	O
time	O
.	O
However	O
,	O
you	O
make	O
take	O
valium	I-Drug
and	O
benedryl	I-Drug
for	O
severe	B-Reason
/	I-Reason
painful	I-Reason
dystonia	O
.	O
Do	O
not	O
take	O
these	O
medications	O
if	O
you	O
feel	O
drowsy	O
or	O
confused	O
.	O
If	O
you	O
develop	O
fevers	O
,	O
worsening	O
abdominal	O
pain	O
,	O
or	O
any	O
other	O
concerning	O
symptom	O
please	O
contact	O
your	O
doctors	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
to	O
the	O
emergency	O
room	O
.	O
.	O
You	O
were	O
restarted	O
on	O
TPN	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
ID	O
:	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
4020	O
**	O
]	O
/	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
Basement	O
suite	O
G.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
457	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2127-10-16	O
**	O
]	O
11:00	O
.	O
New	O
patient	O
visit	O
.	O
.	O
2	O
.	O
Urology	O
:	O
With	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
4376	O
**	O
]	O
for	O
management	O
of	O
your	O
diverting	O
ileal	O
loop	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
161	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
162	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
163	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
921	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2127-9-19	O
**	O
]	O
10:30	O
3	O
.	O
BENIGN	O
HEMATOLOGY	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2127-10-3	O
**	O
]	O
3:00	O
.	O
4	O
.	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
PCP	O
Wed	O
[	O
**	O
9	O
-	O
17	O
**	O
]	O
at	O
11:45	O
am	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
13553	O
**	O
]	O
.	O
5	O
.	O
Dr.	O
[	O
**	O
Doctor	O
Last	O
Name	O
13554	O
**	O
]	O
.	O
[	O
**	O
10	O
-	O
8	O
**	O
]	O
at	O
9:30	O
am	O
.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
3	O
)	O
**	O
]	O
.	O
6	O
.	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
13555	O
**	O
]	O
.	O
[	O
**	O
10	O
-	O
8	O
**	O
]	O
at	O
9:30	O
am	O
.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1040	O
**	O
]	O
-	O
this	O
may	O
be	O
a	O
conflict	O
with	O
above	O
appointment	O
.	O
You	O
may	O
call	O
the	O
hepatology	O
and	O
neurology	O
numbers	O
to	O
reschedule	O
at	O
your	O
convenience	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2118-8-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2118-8-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2063-5-16	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Prochlorperazine	I-Drug
/	O
Iodine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3016	O
**	O
]	O
Chief	O
Complaint	O
:	O
Altered	O
mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
79353	O
**	O
]	O
is	O
a	O
55	O
yo	O
man	O
w	O
/	O
metastatic	O
melanoma	O
and	O
known	O
mets	O
to	O
brain	O
(	O
incl	O
cerebellum	O
)	O
,	O
who	O
presents	O
with	O
one	O
day	O
of	O
headache	O
and	O
altered	O
mental	O
status	O
.	O
History	O
is	O
obtained	O
by	O
the	O
patient	O
's	O
wife	O
due	O
to	O
the	O
patient	O
being	O
sedated	O
from	O
the	O
ED	O
.	O
Over	O
the	O
past	O
few	O
days	O
prior	O
to	O
admission	O
,	O
the	O
pt	O
's	O
wife	O
notes	O
that	O
he	O
had	O
not	O
been	O
sleeping	O
well	O
at	O
night	O
due	O
to	O
increased	O
urinary	O
frequency	O
.	O
However	O
,	O
other	O
than	O
feeling	O
more	O
tired	O
during	O
the	O
day	O
he	O
had	O
been	O
overall	O
doing	O
well	O
.	O
On	O
the	O
morning	O
prior	O
to	O
admission	O
,	O
the	O
patient	O
developed	O
a	O
severe	O
headache	O
,	O
associated	O
with	O
nausea	O
and	O
several	O
episodes	O
of	O
bilious	O
vomiting	O
.	O
He	O
was	O
unable	O
to	O
keep	O
down	O
any	O
POs	O
.	O
Additionally	O
,	O
he	O
had	O
increasing	O
confusion	O
and	O
agitation	O
and	O
so	O
was	O
taken	O
to	O
[	O
**	O
Hospital3	O
12748	O
**	O
]	O
.	O
In	O
the	O
ED	O
there	O
,	O
head	O
CT	O
revealed	O
hemorrhage	O
of	O
some	O
of	O
his	O
brain	O
mets	O
with	O
2	O
mm	O
midline	O
shift	O
and	O
mild	O
hydrocephalus	O
.	O
He	O
received	O
8	O
mg	O
IV	O
dexamethasone	I-Drug
,	O
4	O
mg	O
IV	O
morphine	I-Drug
x	O
2	O
,	O
and	O
zofran	I-Drug
.	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
oncology	O
fellow	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
and	O
transfer	O
was	O
arranged	O
.	O
Of	O
note	O
,	O
pt	O
has	O
had	O
2	O
recent	O
admissions	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
with	O
nausea	I-Ade
,	O
vomiting	I-Ade
,	O
dizziness	I-Ade
and	O
dehydration	I-Ade
.	O
This	O
was	O
felt	O
to	O
be	O
due	O
to	O
combination	O
of	O
Taxol	I-Drug
and	O
progression	O
of	O
CNS	O
disease	O
.	O
During	O
admission	O
Mr.	O
[	O
**	O
Known	O
lastname	O
79353	O
**	O
]	O
was	O
made	O
aware	O
that	O
surgical	O
resection	O
of	O
the	O
cerebellar	O
metastasis	O
may	O
relieve	O
these	O
symptoms	O
,	O
however	O
,	O
he	O
has	O
refused	O
any	O
kind	O
of	O
surgery	O
on	O
more	O
than	O
one	O
occasion	O
on	O
review	O
of	O
the	O
medial	O
record	O
.	O
He	O
was	O
placed	O
on	O
4	O
mg	O
every	O
8	O
hours	O
of	O
dexamethasone	I-Drug
and	O
was	O
discharged	O
with	O
home	O
IV	O
fluids	I-Drug
and	O
PICC	O
line	O
on	O
[	O
**	O
2118-7-19	O
**	O
]	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
T	O
97.5	O
,	O
P	O
60	O
,	O
BP	O
166/90	O
,	O
R	O
15	O
,	O
O2	O
sat	O
98	O
%	O
RA	O
.	O
Patient	O
was	O
agitated	I-Reason
,	O
but	O
not	O
talking	O
or	O
answering	O
questions	O
.	O
He	O
was	O
given	O
3	O
mg	O
of	O
ativan	I-Drug
for	O
sedation	I-Reason
to	O
obtain	O
a	O
repeat	O
CT	O
head	O
.	O
He	O
brady	B-Ade
'd	I-Ade
to	I-Ade
the	I-Ade
30s	I-Ade
after	O
receiving	O
sedation	O
,	O
but	O
HR	O
improved	O
up	O
to	O
low	O
100s	O
spontaneously	O
.	O
Repeat	O
CT	O
head	O
was	O
reviewed	O
by	O
neurosurgery	O
and	O
showed	O
no	O
change	O
from	O
OSH	O
imaging	O
,	O
without	O
hydrocephalus	O
or	O
risk	O
for	O
herniation	O
.	O
Additionally	O
,	O
it	O
was	O
felt	O
there	O
was	O
no	O
significant	O
change	O
since	O
his	O
last	O
imaging	O
2	O
months	O
ago	O
.	O
Family	O
declined	O
surgical	O
intervention	O
,	O
per	O
his	O
prior	O
wishes	O
.	O
He	O
was	O
given	O
decadron	I-Drug
10	O
mg	O
IV	O
and	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
close	O
monitoring	O
.	O
On	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
,	O
the	O
patient	O
is	O
somnolent	O
and	O
unarousable	O
but	O
appears	O
comfortable	O
.	O
His	O
wife	O
is	O
at	O
the	O
bedside	O
.	O
Past	O
Medical	O
History	O
:	O
PMH	O
:	O
1	O
.	O
Metastatic	B-Reason
melanoma	I-Reason
:	O
Onc	O
hx	O
adapted	O
from	O
recent	O
onc	O
clinic	O
note	O
by	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
79353	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1834	O
**	O
]	O
wide	O
local	O
excision	O
and	O
left	O
parotid	O
neck	O
node	O
dissection	O
for	O
a	O
6	O
mm	O
thick	O
melanoma	O
of	O
his	O
left	O
parietal	O
scalp	O
in	O
[	O
**	O
2116-7-3	O
**	O
]	O
,	O
with	O
3	O
of	O
27	O
nodes	O
being	O
positive	O
.	O
He	O
received	O
adjuvant	O
interferon	O
,	O
but	O
had	O
a	O
soft	O
tissue	O
recurrence	O
in	O
the	O
left	O
neck	O
a	O
few	O
months	O
into	O
therapy	O
.	O
This	O
was	O
resected	O
and	O
interferon	I-Drug
therapy	O
was	O
resumed	O
post	O
surgery	O
until	O
[	O
**	O
Month	O
(	O
only	O
)	O
404	O
**	O
]	O
of	O
[	O
**	O
2117	O
**	O
]	O
,	O
when	O
he	O
developed	O
contralateral	O
neck	O
soft	O
tissue	O
recurrence	O
treated	O
with	O
surgical	O
resection	O
and	O
parotidectomy	O
in	O
[	O
**	O
2117-4-3	O
**	O
]	O
.	O
Pathology	O
revealed	O
4	O
of	O
8	O
nodes	O
positive	O
,	O
and	O
a	O
large	O
lymph	O
node	O
measuring	O
1.7	O
cm	O
in	O
the	O
parotid	O
.	O
His	O
interferon	O
therapy	O
was	O
discontinued	O
at	O
this	O
time	O
.	O
A	O
PET	O
CT	O
scan	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
216	O
**	O
]	O
of	O
[	O
**	O
2117	O
**	O
]	O
revealed	O
lung	O
nodules	O
and	O
a	O
3.3	O
cm	O
left	O
inguinal	O
mass	O
.	O
Head	O
MRI	O
revealed	O
a	O
single	O
brain	O
metastasis	O
in	O
the	O
right	O
corona	O
radiata	O
.	O
He	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
1834	O
**	O
]	O
CyberKnife	O
radiosurgery	O
to	O
this	O
lesion	O
in	O
[	O
**	O
2117-11-3	O
**	O
]	O
.	O
He	O
began	O
high	O
dose	O
IL2	O
in	O
[	O
**	O
2117-12-4	O
**	O
]	O
,	O
without	O
response	O
.	O
He	O
developed	O
deep	B-Reason
vein	I-Reason
thrombosis	I-Reason
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
404	O
**	O
]	O
of	O
[	O
**	O
2118	O
**	O
]	O
,	O
requiring	O
Lovenox	I-Drug
.	O
Followup	O
head	O
MRI	O
revealed	O
disease	O
progression	O
in	O
the	O
CNS	O
.	O
He	O
was	O
begun	O
on	O
CTLA4	O
antibody	O
protocol	O
on	O
[	O
**	O
2118-3-1	O
**	O
]	O
,	O
with	O
6	O
week	O
scan	O
showing	O
disease	O
progression	O
,	O
particularly	O
in	O
the	O
CNS	O
,	O
and	O
he	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
1834	O
**	O
]	O
whole	O
brain	O
radiation	O
therapy	O
started	O
on	O
[	O
**	O
2118-4-12	O
**	O
]	O
.	O
He	O
completed	O
a	O
4	O
-	O
week	O
course	O
of	O
radiation	O
on	O
[	O
**	O
2118-4-22	O
**	O
]	O
.	O
Repeat	O
CT	O
scan	O
showed	O
evidence	O
of	O
disease	O
progression	O
,	O
particularly	O
in	O
the	O
left	O
inguinal	O
area	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
79353	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1834	O
**	O
]	O
surgical	O
resection	O
of	O
a	O
mass	O
in	O
his	O
left	O
groin	O
area	O
in	O
[	O
**	O
2118-5-4	O
**	O
]	O
.	O
Surgery	O
was	O
able	O
to	O
remove	O
the	O
mass	O
.	O
Ventriculostomy	O
[	O
**	O
2118-6-23	O
**	O
]	O
for	O
occlusive	O
hydrocephalus	O
.	O
Had	O
first	O
dose	O
of	O
taxol	I-Drug
[	O
**	O
2118-6-28	O
**	O
]	O
.	O
2	O
.	O
s	O
/	O
p	O
appendectomy	O
as	O
a	O
child	O
3	O
.	O
Degenerative	O
joint	O
disease	O
in	O
the	O
L5	O
area	O
4	O
.	O
Cervical	O
neck	O
surgery	O
[	O
**	O
2112	O
**	O
]	O
5	O
.	O
DVT	O
as	O
above	O
.	O
Social	O
History	O
:	O
Married	O
,	O
2	O
children	O
.	O
Lives	O
with	O
wife	O
and	O
has	O
pet	O
dog	O
.	O
Formerly	O
worked	O
as	O
a	O
commercial	O
fisherman	O
,	O
a	O
construction	O
worker	O
,	O
and	O
other	O
odd	O
jobs	O
.	O
Quit	O
smoking	O
15	O
years	O
ago	O
after	O
20	O
pack	O
-	O
year	O
history	O
.	O
Very	O
occasional	O
EtOH	O
.	O
Family	O
History	O
:	O
Mother	O
passed	O
away	O
with	O
metastatic	O
uterine	O
CA	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
99.8	O
,	O
BP	O
:	O
149/69	O
,	O
P	O
:	O
87	O
,	O
R	O
:	O
15	O
,	O
O2	O
:	O
97	O
%	O
RA	O
General	O
:	O
Somnolent	O
,	O
moving	O
all	O
extremities	O
spontaneously	O
but	O
is	O
not	O
responsive	O
to	O
painful	O
stimuli	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Well	O
-	O
healed	O
surgical	O
scar	O
on	O
the	O
superior	O
aspect	O
of	O
the	O
head	O
,	O
sclera	O
anicteric	O
,	O
pupils	O
2	O
mm	O
and	O
minimally	O
responsive	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
surgical	O
scar	O
in	O
the	O
left	O
neck	O
,	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
coarse	O
upper	O
airway	O
sounds	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
;	O
10	O
cm	O
subcutaneous	O
mass	O
in	O
the	O
left	O
axilla	O
,	O
6	O
-	O
8	O
cm	O
subcutaneous	O
mass	O
in	O
the	O
left	O
groin	O
near	O
his	O
surgical	O
excision	O
site	O
,	O
and	O
5	O
cm	O
subcutaneous	O
mass	O
at	O
the	O
internal	O
aspect	O
of	O
the	O
right	O
calf	O
Skin	O
:	O
pinpoint	B-Ade
echymoses	I-Ade
on	O
his	O
abdomen	O
[	O
**	O
3	O
-	O
7	O
**	O
]	O
lovenox	I-Drug
injections	O
Pertinent	O
Results	O
:	O
LABS	O
ON	O
ADMISSION	O
:	O
[	O
**	O
2118-8-13	O
**	O
]	O
07:00	O
PM	O
BLOOD	O
WBC	O
-	O
9.6	O
RBC	O
-	O
3.97	O
*	O
Hgb	O
-	O
11.8	O
*	O
Hct	O
-	O
34.4	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
29.7	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
326	O
[	O
**	O
2118-8-13	O
**	O
]	O
07:00	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
326	O
[	O
**	O
2118-8-13	O
**	O
]	O
07:00	O
PM	O
BLOOD	O
Glucose	O
-	O
112	O
*	O
UreaN	O
-	O
23	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
137	O
K	O
-	O
4.2	O
Cl	O
-	O
101	O
HCO3	O
-	O
23	O
AnGap	O
-	O
17	O
[	O
**	O
2118-8-13	O
**	O
]	O
07:00	O
PM	O
BLOOD	O
TSH	O
-	O
2.0	O
LABS	O
ON	O
DISCHARGE	O
:	O
[	O
**	O
2118-8-17	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
WBC	O
-	O
6.3	O
RBC	O
-	O
3.41	O
*	O
Hgb	O
-	O
9.9	O
*	O
Hct	O
-	O
29.8	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
29.1	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
15.9	O
*	O
Plt	O
Ct	O
-	O
232	O
[	O
**	O
2118-8-17	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
232	O
[	O
**	O
2118-8-17	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Glucose	O
-	O
119	O
*	O
UreaN	O
-	O
32	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
144	O
K	O
-	O
4.0	O
Cl	O
-	O
111	O
*	O
HCO3	O
-	O
23	O
AnGap	O
-	O
14	O
[	O
**	O
2118-8-17	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
2.3	O
CXR	O
[	O
**	O
2118-8-13	O
**	O
]	O
:	O
New	O
opacification	O
at	O
the	O
right	O
lung	O
base	O
accompanied	O
by	O
a	O
greater	O
elevation	O
of	O
the	O
right	O
hemidiaphragm	O
could	O
be	O
atelectasis	O
alone	O
or	O
combination	O
of	O
atelectasis	O
and	O
pneumonia	O
,	O
particularly	O
aspiration	O
.	O
Large	O
nodule	O
in	O
the	O
right	O
mid	O
lung	O
unchanged	O
since	O
[	O
**	O
Month	O
(	O
only	O
)	O
547	O
**	O
]	O
.	O
Heart	O
size	O
normal	O
.	O
No	O
appreciable	O
pleural	O
effusion	O
.	O
No	O
pneumothorax	O
.	O
EKG	O
[	O
**	O
2118-8-14	O
**	O
]	O
:	O
Sinus	O
tachycardia	O
,	O
rate	O
140	O
.	O
Vertical	O
axis	O
.	O
Can	O
not	O
exclude	O
inferior	O
myocardial	O
infarction	O
of	O
indeterminate	O
age	O
.	O
S1	O
-	O
Q3	O
-	O
T3	O
pattern	O
.	O
Consider	O
acute	O
pulmonary	O
embolism	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2118-8-14	O
**	O
]	O
sinus	O
bradycardia	O
has	O
given	O
way	O
to	O
sinus	O
tachycardia	O
and	O
axis	O
is	O
now	O
vertical	O
.	O
Also	O
,	O
non-specific	O
inferolateral	O
repolarization	O
changes	O
have	O
appeared	O
.	O
HEAD	O
CT	O
[	O
**	O
2118-8-14	O
**	O
]	O
:	O
No	O
new	O
focus	O
of	O
hemorrhage	O
.	O
Overall	O
unchanged	O
picture	O
of	O
hemorrhagic	O
metastases	O
.	O
Brief	O
Hospital	O
Course	O
:	O
1	O
.	O
ALTERED	B-Ade
MENTAL	I-Ade
STATUS	I-Ade
:	O
Most	O
likely	O
multifactorial	O
but	O
primarily	O
from	O
leptomeningeal	O
involvement	O
and	O
hemorrhagic	O
brain	O
metastases	O
with	O
contributions	O
from	O
over-sedation	I-Ade
from	O
home	O
benzodiazepines	I-Drug
,	O
PNA	O
and	O
UTI	O
.	O
On	O
admission	O
to	O
the	O
ICU	O
patient	O
was	O
quite	O
sedated	O
and	O
only	O
minimally	O
responsive	O
.	O
Across	O
his	O
stay	O
he	O
became	O
more	O
responsive	O
and	O
was	O
able	O
to	O
follow	O
commands	O
,	O
move	O
all	O
extremities	O
,	O
and	O
at	O
times	O
speak	O
quite	O
coherently	O
,	O
although	O
his	O
mental	O
status	O
continued	O
to	O
wax	O
and	O
wane	O
.	O
During	O
his	O
hospitalization	O
he	O
also	O
developed	O
a	O
left	O
sided	O
facial	O
droop	O
thought	O
likely	O
due	O
to	O
evolving	O
brain	O
metastases	O
and	O
leptomeningeal	O
involvement	O
.	O
2	O
.	O
GOALS	O
OF	O
CARE	O
/	O
CODE	O
STATUS	O
:	O
The	O
patient	O
code	O
status	O
was	O
made	O
DNR	O
/	O
DNI	O
during	O
this	O
admission	O
and	O
this	O
was	O
confirmed	O
with	O
the	O
patient	O
's	O
wife	O
.	O
A	O
family	O
meeting	O
was	O
held	O
to	O
discuss	O
goals	O
of	O
care	O
,	O
and	O
it	O
was	O
decided	O
to	O
move	O
towards	O
hospice	O
care	O
after	O
discharge	O
.	O
The	O
patient	O
's	O
wife	O
,	O
however	O
,	O
appeared	O
to	O
hold	O
out	O
ongoing	O
hope	O
for	O
the	O
patient	O
's	O
recovery	O
,	O
and	O
the	O
patient	O
himself	O
expressed	O
the	O
desire	O
to	O
attempt	O
one	O
more	O
round	O
of	O
Taxol	I-Drug
.	O
Discharged	O
with	O
home	O
VNA	O
and	O
bridge	O
to	O
hospice	O
.	O
3	O
.	O
METASTATIC	O
MELANOMA	O
WITH	O
HEMORRHAGIC	O
BRAIN	O
METS	O
:	O
Known	O
mets	O
to	O
scalp	O
,	O
neck	O
,	O
groin	O
,	O
brain	O
s	O
/	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
16859	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
mass	O
resection	O
and	O
ventriculostomy	O
for	O
obstructive	O
hydrocephalus	O
.	O
On	O
Taxol	I-Drug
at	O
admission	O
,	O
first	O
dose	O
5/26	O
.	O
In	O
previous	O
discussions	O
,	O
patient	O
has	O
been	O
clear	O
that	O
he	O
did	O
not	O
desire	O
further	O
surgical	O
intervention	O
for	O
control	O
of	O
his	O
brain	B-Reason
mets	I-Reason
.	O
He	O
repeatedly	O
stated	O
his	O
desire	O
for	O
one	O
more	O
attempt	O
at	O
treatment	O
with	O
Taxol	I-Drug
,	O
which	O
was	O
decided	O
against	O
given	O
the	O
patient	O
's	O
disease	O
progression	O
despite	O
taxol	I-Drug
therapy	O
.	O
Dexamethasone	I-Drug
was	O
continued	O
for	O
cerebral	I-Reason
edema	O
and	O
all	O
anticoagulation	I-Drug
was	O
held	O
.	O
4	O
.	O
FEVERS	I-Reason
/	O
PNA	I-Reason
/	O
UTI	I-Reason
:	O
Fever	O
and	O
CXR	O
on	O
admission	O
with	O
consolidation	O
at	O
right	O
base	O
concerning	O
for	O
aspiration	B-Reason
pneumonia	I-Reason
,	O
as	O
well	O
as	O
WBCs	B-Reason
in	I-Reason
U	I-Reason
/	I-Reason
A.	O
No	O
elevation	O
of	O
WBC	O
.	O
Started	O
on	O
Vanc	I-Drug
/	O
Zosyn	I-Drug
later	O
changed	O
to	O
Vanc	I-Drug
/	O
Cefapime	I-Drug
after	O
blood	O
cultures	O
remained	O
negative	O
.	O
Urine	O
Cx	O
grew	O
out	O
enterococcus	I-Reason
which	O
was	O
sensitive	O
to	O
ampicillin	I-Drug
,	O
nitrofurantoin	I-Drug
and	O
vancomycin	I-Drug
.	O
5	O
.	O
NAUSEA	I-Reason
/	O
VOMITING	I-Ade
:	O
Likely	O
related	O
to	O
leptomeningeal	O
involvement	O
and	O
metastatic	O
impingement	O
on	O
fourth	O
ventricle	O
versus	O
recent	O
chemo	I-Drug
.	O
No	O
evidence	O
of	O
increased	O
intracranial	O
pressure	O
on	O
head	O
CT	O
but	O
during	O
stay	O
patient	O
did	O
develop	O
left	O
sided	O
facial	O
droop	O
.	O
Could	O
be	O
related	O
to	O
vertigo	O
in	O
setting	O
of	O
additional	O
brain	O
edema	O
as	O
in	O
recent	O
admission	O
.	O
He	O
also	O
has	O
had	O
dizziness	O
and	O
lighthededness	O
with	O
standing	O
and	O
sitting	O
up	O
,	O
and	O
on	O
previous	O
admission	O
patient	O
had	O
orthostatic	O
hypotension	O
.	O
Patient	O
was	O
treated	O
with	O
Ondansetron	I-Drug
and	O
Decadron	I-Drug
.	O
6	O
.	O
h	B-Reason
/	I-Reason
o	I-Reason
DVT	I-Reason
:	O
Dx	O
in	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
.	O
Lovenox	I-Drug
stopped	O
on	O
admission	O
given	O
hemorrhagic	B-Ade
brain	I-Ade
mets	I-Ade
.	O
Medications	O
on	O
Admission	O
:	O
Dexamethasone	I-Drug
4	O
mg	O
PO	O
q8	O
Lovenox	I-Drug
80	O
mg	O
SQ	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
held	O
since	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
)	O
Ativan	I-Drug
0.5	O
mg	O
PO	O
TID	O
Vicodin	I-Drug
1	O
-	O
2	O
tabs	O
q6	O
-	O
8	O
prn	O
Olanzapine	I-Drug
2.5	O
mg	O
PO	O
BID	O
prn	O
Zofran	I-Drug
8	O
mg	O
PO	O
TID	O
prn	O
Colace	I-Drug
100	O
-	O
200	O
mg	O
PO	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
.	O
2	O
.	O
Oxycodone	I-Drug
5	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
5	O
-	O
10	O
mg	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
500	O
ml	O
*	O
Refills	O
:	O
*	O
4	O
*	O
3	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
40	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
3	O
*	O
4	O
.	O
Mirtazapine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
Disp	O
:	O
*	O
40	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ml	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
300	O
ml	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Haloperidol	B-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
agitation	I-Reason
,	O
hallucinations	I-Reason
:	O
Please	O
take	O
1	O
tablet	O
up	O
to	O
3	O
times	O
per	O
day	O
as	O
needed	O
for	O
agitation	I-Reason
or	O
hallucinations	I-Reason
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Ondansetron	I-Drug
4	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
Tablet	O
,	O
Rapid	O
Dissolves	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
:	O
please	O
take	O
1	O
-	O
2	O
tablets	O
up	O
to	O
every	O
4	O
hours	O
,	O
as	O
needed	O
,	O
to	O
control	O
nausea	I-Reason
and	O
vomiting	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
,	O
Rapid	O
Dissolve	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
IVF	I-Drug
Resumption	O
of	O
hydration	O
and	O
line	O
per	O
critical	O
care	O
systems	O
.	O
Normal	B-Drug
saline	I-Drug
as	O
needed	O
for	O
hydration	I-Reason
.	O
9	O
.	O
Keppra	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Dexamethasone	I-Drug
Intensol	O
1	O
mg	O
/	O
mL	O
Drops	O
Sig	O
:	O
Six	O
(	O
6	O
)	O
ml	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
.	O
Disp	O
:	O
*	O
qs	O
2	O
weeks	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Company	O
1519	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
:	O
1	O
.	O
Melanoma	O
,	O
metestatic	O
2	O
.	O
Leptomeningeal	O
invovlement	O
3	O
.	O
Mental	O
status	O
changes	O
4	O
.	O
UTI	O
5	O
.	O
PNA	O
Discharge	O
Condition	O
:	O
clinicall	O
stable	O
,	O
moderately	O
alert	O
,	O
pain	O
controlled	O
,	O
patient	O
and	O
family	O
aware	O
of	O
diagnosis	O
,	O
on	O
comfort	O
measures	O
and	O
IVF	I-Drug
only	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
for	O
change	O
in	O
mental	O
status	O
thought	O
to	O
be	O
secondary	O
to	O
progression	O
of	O
your	O
cancer	O
.	O
Your	O
symptoms	O
are	O
consistent	O
with	O
tumor	O
involvement	O
of	O
the	O
fluid	O
in	O
your	O
spinal	O
cord	O
(	O
called	O
leptomeningeal	O
invovlement	O
)	O
.	O
We	O
had	O
a	O
family	O
meeting	O
with	O
palliative	O
care	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
79354	O
**	O
]	O
team	O
and	O
discussed	O
goals	O
of	O
care	O
.	O
You	O
will	O
be	O
discharged	O
home	O
with	O
VNA	O
services	O
with	O
bridge	O
to	O
hospice	O
.	O
You	O
will	O
have	O
a	O
PICC	O
line	O
with	O
IV	O
fluids	I-Drug
.	O
.	O
We	O
have	O
made	O
changes	O
to	O
your	O
medication	O
.	O
Please	O
follow	O
the	O
discharge	O
instruction	O
.	O
.	O
Call	O
your	O
doctor	O
if	O
you	O
have	O
worsening	O
pain	O
or	O
agitation	O
or	O
any	O
other	O
questions	O
.	O
Followup	O
Instructions	O
:	O
Call	O
your	O
doctor	O
if	O
you	O
have	O
worsening	O
pain	O
or	O
agitation	O
or	O
any	O
other	O
questions	O
.	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
831	O
**	O
]	O
MD	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
3018	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2130-7-28	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2130-8-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2056-5-8	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1515	O
**	O
]	O
Chief	O
Complaint	O
:	O
Syncope	O
?	O
cardiac	O
arrest	O
-	O
cooled	O
as	O
per	O
protocol	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Pulmonary	O
Intubation	O
History	O
of	O
Present	O
Illness	O
:	O
74	O
yo	O
M	O
with	O
unknown	O
past	O
medical	O
history	O
suffered	O
an	O
episode	O
on	O
unresponsiveness	O
at	O
a	O
casino	O
,	O
underwent	O
5	O
minutes	O
of	O
chest	O
compressions	O
prior	O
to	O
regaining	O
a	O
pulse	O
without	O
defibrillation	O
,	O
and	O
was	O
ultimately	O
started	O
on	O
a	O
cooling	O
protocol	O
at	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
prior	O
to	O
transfer	O
to	O
our	O
ED	O
.	O
.	O
Records	O
of	O
the	O
event	O
and	O
his	O
initial	O
treatment	O
are	O
limited	O
.	O
We	O
know	O
that	O
he	O
was	O
standing	O
when	O
he	O
collapsed	O
and	O
suffered	O
a	O
minor	O
laceration	O
to	O
his	O
head	O
.	O
Chest	O
compressions	O
were	O
started	O
immediately	O
and	O
were	O
continued	O
for	O
5	O
minutes	O
prior	O
to	O
rhythm	O
analysis	O
by	O
an	O
AED	O
which	O
did	O
not	O
advise	O
shock	O
.	O
300cc	O
NS	I-Drug
given	O
by	O
EMS	O
and	O
he	O
was	O
intubated	O
prior	O
to	O
transport	O
;	O
unknown	O
if	O
any	O
meds	O
were	O
given	O
by	O
the	O
initial	O
EMS	O
team	O
.	O
.	O
At	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
cooling	O
protocol	O
was	O
started	O
and	O
pt	O
given	O
a	O
dilantin	I-Drug
load	O
for	O
question	O
of	O
seizure	B-Reason
-	I-Reason
like	I-Reason
activity	I-Reason
.	O
NCHCT	O
in	O
OSH	O
ED	O
showed	O
significant	O
chronic	O
microvascular	O
changes	O
,	O
but	O
nothing	O
acute	O
.	O
CT	O
PA	O
showed	O
no	O
PE	O
and	O
borderline	O
aneurysmal	O
dilation	O
of	O
the	O
ascending	O
aorta	O
(	O
4	O
cm	O
)	O
.	O
EKG	O
showed	O
atrial	O
fibrillation	O
with	O
a	O
ventricular	O
response	O
in	O
the	O
120s	O
,	O
occ	O
PVCs	O
,	O
IVCD	O
(	O
QRS	O
120	O
)	O
.	O
.	O
Pt	O
transported	O
by	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Enroute	O
he	O
received	O
350	O
mg	O
fentanyl	I-Drug
,	O
8	O
mg	O
pancuronium	I-Drug
,	O
1	O
mg	O
ativan	I-Drug
,	O
20	O
/	O
kg	O
/	O
min	O
propofol	I-Drug
.	O
Cooling	O
continued	O
.	O
.	O
In	O
our	O
ED	O
,	O
he	O
received	O
4.5	O
g	O
zosyn	I-Drug
IV	O
for	O
possible	B-Reason
LUL	I-Reason
infiltrate	O
,	O
ASA	I-Drug
325	O
,	O
plavix	I-Drug
300	O
,	O
heparin	I-Drug
drip	O
,	O
metoprolol	I-Drug
25	O
po	O
x1	O
and	O
tylenol	I-Drug
1g	O
PR	O
.	O
His	O
EKGs	O
were	O
c	O
/	O
w	O
atypical	O
atrial	O
flutter	O
with	O
2:1	O
conduction	O
.	O
By	O
the	O
time	O
he	O
arrived	O
in	O
the	O
CCU	O
,	O
he	O
had	O
converted	O
to	O
sinus	O
rhythm	O
.	O
.	O
Initial	O
labs	O
were	O
notable	O
for	O
trop	O
0.23	O
,	O
ck	O
288	O
,	O
mb	O
pending	O
,	O
cr	O
1.2	O
,	O
leukocytosis	O
witha	O
left	O
shift	O
,	O
noraml	O
coags	O
.	O
Past	O
Medical	O
History	O
:	O
Pos	O
H	B-Reason
pylori	I-Reason
2	O
weeks	O
before	O
admission	O
,	O
treated	O
with	O
prevacid	I-Drug
pack	O
Hyperlipidemia	O
Hypertension	O
Social	O
History	O
:	O
He	O
and	O
his	O
wife	O
own	O
a	O
frame	O
shop	O
Functionally	O
Independent	O
before	O
admission	O
.	O
pt	O
is	O
usually	O
active	O
at	O
baseline	O
,	O
plays	O
cards	O
after	O
work	O
,	O
goes	O
to	O
casino	O
often	O
WIFE	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
4777	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
85049	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
4047	O
**	O
]	O
,	O
MA	O
(	O
[	O
**	O
Hospital1	O
**	O
]	O
/	O
[	O
**	O
Hospital1	O
3597	O
**	O
]	O
)	O
Family	O
History	O
:	O
positive	O
for	O
early	O
cardiac	O
disease	O
Physical	O
Exam	O
:	O
Gen	O
:	O
alert	O
,	O
oriented	O
x	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
,	O
corrected	O
wrong	O
answers	O
,	O
poor	O
recall	O
of	O
hospital	O
events	O
.	O
HEENT	O
:	O
supple	O
,	O
no	O
JVD	O
CV	O
:	O
RRR	O
,	O
no	O
M	O
/	O
R	O
/	O
G	O
RESP	O
:	O
crackles	O
left	O
base	O
,	O
no	O
wheezes	O
.	O
ABD	O
:	O
soft	O
,	O
NT	O
,	O
pos	O
bs	O
EXTR	O
:	O
feet	O
warm	O
,	O
trace	O
diffuse	O
peripheral	O
edema	O
.	O
NEURO	O
:	O
no	O
focal	O
defects	O
,	O
speech	O
clear	O
,	O
poor	O
short	O
term	O
memory	O
but	O
improving	O
distant	O
memory	O
Extremeties	O
:	O
Groin	O
Pulses	O
:	O
Right	O
:	O
DP	O
1	O
+	O
PT	O
1	O
+	O
Left	O
:	O
DP	O
2	O
+	O
PT	O
1	O
+	O
Skin	O
:	O
intact	O
Access	O
:	O
PIV	O
Tubes	O
:	O
Foley	O
,	O
placed	O
2	O
days	O
ago	O
for	O
urinary	O
retention	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2130-8-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
WBC	O
-	O
14.6	O
*	O
RBC	O
-	O
2.85	O
*	O
Hgb	O
-	O
8.8	O
*	O
Hct	O
-	O
26.1	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
30.7	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
15.4	O
Plt	O
Ct	O
-	O
477	O
*	O
[	O
**	O
2130-8-9	O
**	O
]	O
04:59	O
AM	O
BLOOD	O
WBC	O
-	O
15.4	O
*	O
RBC	O
-	O
3.06	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
27.7	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
15.1	O
Plt	O
Ct	O
-	O
465	O
*	O
[	O
**	O
2130-8-8	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
WBC	O
-	O
15.8	O
*	O
RBC	O
-	O
2.98	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
27.0	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
30.7	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
15.1	O
Plt	O
Ct	O
-	O
346	O
[	O
**	O
2130-7-28	O
**	O
]	O
08:50	O
PM	O
BLOOD	O
WBC	O
-	O
18.4	O
*	O
RBC	O
-	O
5.29	O
Hgb	O
-	O
16.1	O
Hct	O
-	O
49.9	O
MCV	O
-	O
94	O
MCH	O
-	O
30.5	O
MCHC	O
-	O
32.3	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
215	O
[	O
**	O
2130-8-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Glucose	O
-	O
110	O
*	O
UreaN	O
-	O
21	O
*	O
Creat	O
-	O
1.0	O
Na	O
-	O
139	O
K	O
-	O
4.1	O
Cl	O
-	O
103	O
HCO3	O
-	O
29	O
AnGap	O
-	O
11	O
[	O
**	O
2130-8-9	O
**	O
]	O
04:59	O
AM	O
BLOOD	O
Glucose	O
-	O
122	O
*	O
UreaN	O
-	O
18	O
Creat	O
-	O
1.0	O
Na	O
-	O
137	O
K	O
-	O
3.6	O
Cl	O
-	O
99	O
HCO3	O
-	O
28	O
AnGap	O
-	O
14	O
[	O
**	O
2130-7-28	O
**	O
]	O
08:50	O
PM	O
BLOOD	O
Glucose	O
-	O
106	O
*	O
UreaN	O
-	O
17	O
Creat	O
-	O
1.2	O
Na	O
-	O
140	O
K	O
-	O
3.8	O
Cl	O
-	O
107	O
HCO3	O
-	O
23	O
AnGap	O
-	O
14	O
[	O
**	O
2130-8-4	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
ALT	O
-	O
58	O
*	O
AST	O
-	O
93	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
338	O
*	O
AlkPhos	O
-	O
49	O
TotBili	O
-	O
0.3	O
[	O
**	O
2130-7-28	O
**	O
]	O
08:50	O
PM	O
BLOOD	O
ALT	O
-	O
61	O
*	O
AST	O
-	O
87	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
288	O
AlkPhos	O
-	O
69	O
TotBili	O
-	O
0.6	O
[	O
**	O
2130-7-29	O
**	O
]	O
06:07	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
29	O
*	O
MB	O
Indx	O
-	O
9.5	O
*	O
[	O
**	O
2130-7-29	O
**	O
]	O
11:22	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
30	O
*	O
MB	O
Indx	O
-	O
8.7	O
*	O
cTropnT	O
-	O
0.29	O
*	O
[	O
**	O
2130-7-29	O
**	O
]	O
02:03	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
26	O
*	O
MB	O
Indx	O
-	O
6.8	O
*	O
cTropnT	O
-	O
0.44	O
*	O
[	O
**	O
2130-8-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
3.8	O
Mg	O
-	O
2.0	O
Iron	O
-	O
PND	O
.	O
Carotid	O
ultrasound	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
:	O
FINDINGS	O
:	O
Minimal	O
calcific	O
plaque	O
at	O
the	O
origin	O
of	O
both	O
internal	O
carotid	O
arteries	O
.	O
The	O
peak	O
systolic	O
velocities	O
bilaterally	O
are	O
normal	O
as	O
are	O
the	O
ICA	O
/	O
CCA	O
ratios	O
.	O
There	O
is	O
normal	O
antegrade	O
flow	O
involving	O
both	O
vertebral	O
arteries	O
.	O
IMPRESSION	O
:	O
Minimal	O
bilateral	O
ICA	O
plaque	O
,	O
no	O
appreciable	O
associated	O
stenosis	O
,	O
however	O
(	O
graded	O
as	O
less	O
than	O
40	O
%	O
)	O
.	O
.	O
ECHO	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
:	O
The	O
left	O
atrium	O
and	O
right	O
atrium	O
are	O
normal	O
in	O
cavity	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
hypokinesis	O
/	O
dysnnchrony	O
of	O
the	O
inferior	O
and	O
inferiolateral	O
walls	O
.	O
The	O
remaining	O
segments	O
contract	O
normally	O
(	O
LVEF	O
=	O
45	O
-	O
50	O
%	O
)	O
.	O
The	O
estimated	O
cardiac	O
index	O
is	O
normal	O
(	O
>	O
=	O
2.5	O
L	O
/	O
min	O
/	O
m2	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
root	O
is	O
moderately	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2130-7-29	O
**	O
]	O
,	O
biventricular	O
systolic	O
function	O
is	O
much	O
improved	O
with	O
mild	O
residual	O
regional	O
dysfunction	O
.	O
.	O
CT	O
Chest	O
/	O
ABD	O
/	O
Pelvis	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Moderate	O
-	O
sized	O
bilateral	O
psoas	O
hematomas	O
extending	O
into	O
right	O
iliopsoas	O
muscle	O
.	O
2	O
.	O
Minimally	O
displaced	O
fractures	O
involving	O
the	O
right	O
third	O
through	O
eleventh	O
ribs	O
and	O
left	O
third	O
through	O
sixth	O
ribs	O
.	O
3	O
.	O
Cholelithiasis	O
without	O
secondary	O
findings	O
of	O
acute	O
cholecystitis	O
.	O
4	O
.	O
Bilateral	O
predominantly	O
hypoattenuating	O
renal	O
lesions	O
some	O
of	O
which	O
are	O
too	O
small	O
to	O
definitely	O
characterize	O
and	O
others	O
which	O
are	O
clearly	O
simple	O
cysts	O
.	O
Largest	O
3	O
cm	O
lesion	O
on	O
the	O
right	O
appears	O
more	O
solid	O
and	O
can	O
be	O
better	O
assessed	O
with	O
a	O
dedicated	O
renal	O
ultrasound	O
on	O
a	O
non-emergent	O
basis	O
to	O
evaluate	O
for	O
renal	O
cell	O
carcinoma	O
.	O
5	O
.	O
Mild	O
-	O
to	O
-	O
moderate	O
bilateral	O
pleural	O
effusions	O
with	O
probable	O
adjacent	O
compression	O
atelectasis	O
.	O
Superinfection	O
can	O
not	O
be	O
excluded	O
and	O
should	O
be	O
correlated	O
with	O
clinical	O
suspicion	O
for	O
underlying	O
pneumonia	O
.	O
6	O
.	O
Single	O
2	O
-	O
mm	O
left	O
upper	O
lobe	O
pulmonary	O
nodule	O
.	O
If	O
patient	O
is	O
at	O
high	O
risk	O
for	O
intrathoracic	O
malignancy	O
this	O
can	O
be	O
followed	O
with	O
a	O
follow	O
-	O
up	O
chest	O
CT	O
in	O
one	O
year	O
otherwise	O
no	O
further	O
surveillance	O
is	O
necessary	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
8773	O
**	O
]	O
Society	O
guidelines	O
.	O
.	O
ECG	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
:	O
Sinus	O
rhythm	O
.	O
Occasional	O
ventricular	O
premature	O
beats	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2130-8-8	O
**	O
]	O
no	O
definite	O
change	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
74	O
-	O
year	O
-	O
old	O
male	O
was	O
initially	O
admitted	O
following	O
an	O
episode	O
of	O
collapse	O
while	O
at	O
a	O
casino	O
.	O
It	O
is	O
unclear	O
whether	O
this	O
was	O
a	O
cardiac	O
arrest	O
but	O
after	O
5	O
minutes	O
of	O
CPR	O
there	O
was	O
evidence	O
of	O
a	O
pulse	O
and	O
AED	O
showed	O
a	O
viable	O
rhythm	O
with	O
no	O
shock	O
advised	O
.	O
He	O
was	O
never	O
defibrillated	O
.	O
During	O
his	O
fall	O
,	O
he	O
hit	O
his	O
head	O
and	O
sustained	O
a	O
minor	O
laceration	O
to	O
his	O
forehead	O
.	O
At	O
the	O
OSH	O
he	O
was	O
intubated	O
and	O
cooled	O
as	O
per	O
protocol	O
and	O
loaded	O
with	O
phenytoin	I-Drug
for	O
?	O
seizures	I-Reason
,	O
a	O
CT	O
-	O
head	O
showed	O
only	O
small	O
vessel	O
disease	O
with	O
no	O
acute	O
changes	O
.	O
In	O
addition	O
,	O
CT	O
-	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
85050	O
**	O
]	O
OSH	O
showed	O
no	O
evidence	O
of	O
PE	O
and	O
a	O
borderline	O
dilation	O
of	O
the	O
aorta	O
.	O
ECG	O
showed	O
AF	O
in	O
120s	O
.	O
He	O
was	O
tehn	O
transported	O
via	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
to	O
teh	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
and	O
was	O
given	O
a	O
stat	O
dose	O
of	O
Pip	B-Drug
/	I-Drug
Tazo	I-Drug
4.5	O
g	O
IV	O
for	O
LUL	B-Reason
infiltrates	I-Reason
present	O
on	O
CXR	O
,	O
was	O
loaded	O
with	O
aspirin	I-Drug
325	O
mg	O
and	O
clopidogrel	I-Drug
300	O
mg	O
,	O
commenced	O
on	O
a	O
heparin	I-Drug
infusion	O
and	O
metoprolol	I-Drug
was	O
started	O
.	O
At	O
this	O
point	O
ECG	O
shoewd	O
AF	O
/	O
A-flutter	O
w	O
/	O
2:1	O
block	O
and	O
he	O
was	O
transferred	O
to	O
the	O
CCU	O
.	O
Initial	O
cardiac	O
enzymes	O
were	O
TnT	O
0.44	O
CK	O
-	O
MB	O
26	O
.	O
And	O
treatment	O
for	O
possible	O
pneumonia	O
was	O
continued	O
.	O
He	O
was	O
cooled	O
for	O
24	O
-	O
hours	O
and	O
there	O
was	O
no	O
evidence	O
of	O
seizure	O
activity	O
on	O
EEG	O
following	O
neurology	O
review	O
.	O
An	O
echo	O
performed	O
in	O
the	O
context	O
of	O
cooling	O
showed	O
a	O
mildly	O
dilated	O
LA	O
and	O
severe	O
biventricular	O
systolic	O
dysfunction	O
with	O
LVEF	O
<	O
20	O
%	O
.	O
When	O
paralytics	O
were	O
weaned	O
,	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
seen	O
to	O
be	O
shaking	O
and	O
tehre	O
was	O
no	O
EEG	O
correlate	O
to	O
suggest	O
seizures	O
.	O
He	O
was	O
weaned	O
off	O
ventilatory	O
supportand	O
CXR	O
showed	O
resolution	O
of	O
the	O
pulmonary	O
infiltrates	O
.	O
Continued	O
EEG	O
monitoring	O
was	O
discontinued	O
and	O
neurology	O
were	O
happy	O
that	O
there	O
was	O
no	O
evidence	O
of	O
seizures	O
.	O
He	O
was	O
extubated	O
on	O
[	O
**	O
2130-8-1	O
**	O
]	O
and	O
was	O
neurologically	O
appropriate	O
.	O
He	O
required	O
IV	O
hydralazine	I-Drug
for	O
labile	B-Reason
BP	I-Reason
and	O
his	O
metoprolol	I-Drug
was	O
up	O
-	O
titrated	O
.	O
His	O
HB	O
also	O
was	O
noted	O
to	O
trend	O
down	O
and	O
although	O
stool	O
was	O
guaiac	O
-	O
ve	O
it	O
was	O
gastroccult	B-Reason
+	I-Reason
ve	I-Reason
and	O
pepcid	I-Drug
was	O
changed	O
to	O
PPI	I-Drug
.	O
Klebsiella	I-Reason
was	O
grown	O
on	O
sputum	O
from	O
[	O
**	O
2130-8-2	O
**	O
]	O
and	O
IV	O
ceftiaxone	I-Drug
was	O
started	O
.	O
He	O
was	O
weaned	O
off	O
the	O
NG	O
tube	O
and	O
by	O
[	O
**	O
8	O
-	O
4	O
**	O
]	O
passed	O
swallow	O
assessment	O
and	O
was	O
able	O
to	O
eat	O
and	O
drink	O
.	O
He	O
had	O
mild	B-Reason
pulmonary	I-Reason
edema	I-Reason
requiring	O
Iv	O
furosemide	I-Drug
.	O
Labetalol	I-Drug
IV	O
was	O
titrated	O
to	O
BP	O
and	O
weaned	O
.	O
He	O
complained	O
of	O
rib	O
pain	O
and	O
a	O
CT	O
-	O
chest	O
showed	O
bilateral	O
psoas	O
hematomas	O
and	O
minimally	O
displaced	O
rib	O
fractures	O
on	O
3rd	O
to	O
11th	O
ribs	O
on	O
R	O
and	O
3rd	O
to	O
6th	O
ribs	O
on	O
the	O
left	O
.	O
This	O
also	O
demonstrated	O
bilateral	O
renal	O
cysts	O
including	O
the	O
largest	O
on	O
the	O
R	O
which	O
was	O
more	O
solid	O
measuring	O
34x36mm	O
and	O
suggested	O
o	O
/	O
p	O
U	O
/	O
S	O
to	O
visualise	O
.	O
In	O
addition	O
there	O
was	O
evidence	O
of	O
bilateral	O
pleural	O
effusions	O
and	O
a	O
4	O
mm	O
L	O
upper	O
lobe	O
pulmonary	O
nodule	O
which	O
should	O
be	O
followed	O
up	O
with	O
a	O
repeat	O
CT	O
in	O
1	O
year	O
.	O
He	O
subsequently	O
developed	O
delirium	I-Reason
which	O
required	O
PRN	O
haloperidol	I-Drug
and	O
there	O
was	O
no	O
recurrence	O
of	O
his	O
AF	O
.	O
He	O
pulled	O
out	O
his	O
urinary	O
catheter	O
on	O
[	O
**	O
2130-8-7	O
**	O
]	O
and	O
failed	O
trial	O
without	O
catheter	O
resulting	O
in	O
replacement	O
.	O
A	O
repeat	O
echo	O
on	O
[	O
**	O
2130-8-7	O
**	O
]	O
was	O
much	O
improved	O
with	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
hypokinesis	O
/	O
dysnnchrony	O
of	O
the	O
inferior	O
and	O
inferiolateral	O
walls	O
and	O
LVEF	O
45	O
-	O
50	O
%	O
.	O
Due	O
to	O
a	O
rising	O
WBC	O
of	O
14	O
and	O
positive	O
urinalysis	O
he	O
was	O
commenced	O
on	O
oral	O
ciprofloxacin	I-Drug
for	O
a	O
presumed	B-Reason
UTI	I-Reason
.	O
There	O
was	O
evidence	O
of	O
a	O
mild	O
R	O
carotid	O
buit	O
and	O
carotid	O
U	O
/	O
S	O
demonstrated	O
mild	O
bilateral	O
disease	O
.	O
He	O
was	O
commence	O
on	O
amiodarone	I-Drug
and	O
warfarin	I-Drug
and	O
ECG	O
showed	O
persistent	O
SR	O
and	O
PVCs	O
.	O
His	O
confusion	O
improved	O
and	O
he	O
had	O
a	O
trial	O
without	O
catheter	O
on	O
[	O
**	O
8	O
-	O
11	O
**	O
]	O
which	O
was	O
successful	O
and	O
was	O
transferred	O
to	O
rehab	O
.	O
#	O
Neurological	O
??????	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
thought	O
initially	O
to	O
be	O
potentially	O
having	O
seizures	I-Reason
and	O
was	O
loaded	O
with	O
phenytoin	I-Drug
although	O
there	O
was	O
no	O
EEG	O
evidence	O
of	O
this	O
.	O
On	O
neurology	O
review	O
,	O
they	O
were	O
happy	O
that	O
he	O
was	O
not	O
having	O
seizures	O
and	O
one	O
episode	O
of	O
shaking	O
post	O
weaning	O
sedation	O
was	O
felt	O
to	O
represent	O
rigors	O
.	O
Following	O
extubation	O
,	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
improved	O
well	O
neurologically	O
although	O
he	O
developed	O
a	O
delirium	O
picture	O
which	O
was	O
presumed	O
likely	O
secondary	O
to	O
acute	O
illness	O
.	O
Head	O
CT	O
at	O
the	O
outside	O
hospital	O
showed	O
no	O
acute	O
changes	O
and	O
although	O
urinalysis	O
x1	O
was	O
positive	O
,	O
there	O
has	O
been	O
no	O
growth	O
on	O
urine	O
culture	O
.	O
He	O
also	O
had	O
urinary	O
retention	O
and	O
the	O
feeling	O
was	O
that	O
this	O
is	O
likely	O
contributing	O
,	O
as	O
patient	O
??????	O
s	O
mental	O
status	O
significantly	O
improved	O
after	O
Foley	O
was	O
placed	O
.	O
Patient	O
completed	O
course	O
of	O
ceftriaxone	I-Drug
after	O
sputum	O
culture	O
positive	O
for	O
Klebsiella	I-Reason
and	O
CT	O
showed	O
atelectasis	O
but	O
no	O
frank	O
consolidation	O
,	O
in	O
addition	O
patient	O
has	O
no	O
clinical	O
signs	O
and	O
symptoms	O
of	O
pneumonia	O
.	O
Haloperidol	I-Drug
was	O
used	O
PRN	O
and	O
he	O
required	O
minimal	O
doses	O
.	O
On	O
discharge	O
he	O
was	O
only	O
very	O
mildly	O
confused	O
and	O
generally	O
oriented	O
.	O
.	O
#	O
.	O
Cardiac	O
arrest	O
:	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
had	O
a	O
collapse	O
while	O
standing	O
at	O
a	O
casino	O
where	O
he	O
had	O
5	O
minutes	O
of	O
CPR	O
and	O
AED	O
showed	O
no	O
shockable	O
rhythm	O
.	O
It	O
is	O
unknown	O
if	O
pt	O
was	O
truly	O
pulseless	O
or	O
merely	O
unresponsive	O
.	O
He	O
was	O
cooled	O
as	O
per	O
protocol	O
and	O
although	O
initial	O
echo	O
while	O
cooled	O
showed	O
a	O
depressed	O
EF	O
<	O
20	O
%	O
,	O
post-rewarming	O
,	O
this	O
had	O
increased	O
to	O
40	O
-	O
45	O
%	O
which	O
is	O
very	O
reassuring	O
.	O
Cardiac	O
enzymes	O
peaked	O
at	O
0.44	O
on	O
admission	O
and	O
have	O
trended	O
down	O
since	O
.	O
No	O
shocks	O
were	O
given	O
throughout	O
course	O
.	O
Only	O
documented	O
rhythms	O
were	O
AFIB	O
/	O
A-flutter	O
,	O
although	O
has	O
latterly	O
been	O
in	O
sinus	O
.	O
He	O
was	O
given	O
a	O
loading	O
dose	O
of	O
aspirin	I-Drug
and	O
clopidogrel	I-Drug
and	O
has	O
been	O
continued	O
on	O
these	O
.	O
He	O
was	O
commenced	O
on	O
warfarin	I-Drug
and	O
will	O
be	O
slowly	O
increased	O
with	O
INR	O
as	O
of	O
[	O
**	O
8	O
-	O
11	O
**	O
]	O
1.3	O
.	O
.	O
#HTN	O
:	O
Very	O
good	O
BP	O
control	O
latterly	O
although	O
required	O
IV	O
labetalol	I-Drug
/	O
hydralazine	I-Drug
as	O
above	O
for	O
labile	B-Reason
BP	I-Reason
.	O
We	O
will	O
continue	O
on	O
HCTZ	I-Drug
,	O
Lisinopril	I-Drug
and	O
toprol	I-Drug
.	O
.	O
#	O
Afib	B-Reason
/	I-Reason
A-flutter	I-Reason
.	O
On	O
presentation	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
found	O
to	O
be	O
in	O
AF	O
/	O
A-Flutter	O
and	O
this	O
has	O
not	O
persisted	O
he	O
was	O
started	O
on	O
amiodarone	I-Drug
[	O
**	O
8	O
-	O
9	O
**	O
]	O
and	O
warfarin	I-Drug
was	O
loaded	O
although	O
his	O
INRs	O
latterly	O
have	O
been	O
low	O
and	O
he	O
will	O
likely	O
need	O
an	O
increased	O
dose	O
.	O
He	O
need	O
close	O
INR	O
monitoring	O
and	O
we	O
are	O
aiming	O
for	O
a	O
goal	O
range	O
INR	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
.	O
We	O
will	O
continue	O
Toprol	I-Drug
XL	O
.	O
On	O
discharge	O
he	O
was	O
in	O
SR	O
with	O
PVCs	O
.	O
.	O
#	O
New	O
carotid	O
bruit	O
noted	O
-	O
A	O
new	O
right	O
carotid	O
bruit	O
was	O
noted	O
on	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
and	O
Carotid	O
series	O
revealed	O
minimal	O
bilateral	O
ICA	O
plaque	O
,	O
with	O
no	O
appreciable	O
stenosis	O
(	O
graded	O
as	O
less	O
than	O
40	O
%	O
)	O
and	O
therefore	O
there	O
is	O
no	O
need	O
for	O
intervention	O
at	O
this	O
time	O
.	O
#	O
Rib	O
/	O
hip	O
pain	O
:	O
Pt	O
is	O
s	O
/	O
p	O
CPR	O
and	O
continues	O
to	O
have	O
pain	O
in	O
hip	O
/	O
lower	O
abdominal	O
area	O
.	O
CT	O
scan	O
shows	O
psoas	O
hematomas	O
which	O
may	O
be	O
contributing	O
to	O
pain	O
and	O
multiple	O
minimally	O
displaced	O
bilateral	O
rib	O
fractures	O
.	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
pain	O
has	O
been	O
improving	O
.	O
.	O
#	O
New	O
CT	O
-	O
findings	O
.	O
On	O
CT	O
-	O
C	O
/	O
A	O
/	O
P	O
there	O
was	O
evidence	O
of	O
bilateral	O
renal	O
cysts	O
,	O
the	O
largest	O
on	O
the	O
R	O
which	O
was	O
more	O
solid	O
measuring	O
34x36mm	O
and	O
suggested	O
o	O
/	O
p	O
U	O
/	O
S	O
to	O
which	O
should	O
be	O
arranged	O
.	O
In	O
addition	O
there	O
was	O
evidence	O
of	O
bilateral	O
pleural	O
effusions	O
and	O
a	O
4	O
mm	O
L	O
upper	O
lobe	O
pulmonary	O
nodule	O
which	O
should	O
be	O
followed	O
up	O
with	O
a	O
repeat	O
CT	O
in	O
1	O
year	O
given	O
his	O
smoking	O
history	O
.	O
.	O
#Anemia	O
??????	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
noted	O
to	O
have	O
a	O
small	O
drop	O
in	O
HCt	O
and	O
this	O
was	O
trended	O
and	O
now	O
stable	O
.	O
It	O
is	O
unclear	O
whether	O
this	O
may	O
be	O
due	O
to	O
poor	O
nutritional	O
state	O
and	O
freq	O
phlebotomy	O
although	O
guaiac	O
stool	O
was	O
-	O
ve	O
,	O
there	O
was	O
positive	B-Reason
guiaic	I-Reason
of	I-Reason
gastric	I-Reason
contents	O
while	O
intubated	O
.	O
He	O
has	O
now	O
been	O
started	O
on	O
a	O
PPI	I-Drug
which	O
has	O
been	O
increased	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
Of	O
note	O
he	O
was	O
rrecently	O
treated	O
for	O
H	O
Pylori	O
according	O
to	O
wife	O
so	O
this	O
may	O
also	O
be	O
contributing	O
.	O
.	O
#	O
Leukocytosis	O
:	O
Mr	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
had	O
pulmonary	B-Reason
infiltrates	I-Reason
on	O
CXR	O
and	O
was	O
treated	O
initially	O
with	O
a	O
stat	O
dose	O
of	O
Pip	B-Drug
/	I-Drug
Tazo	I-Drug
and	O
latterly	O
ceftriaxone	I-Drug
when	O
cultures	O
of	O
sputum	O
grew	O
Klebsiella	I-Reason
.	O
He	O
had	O
previously	O
had	O
low	O
grade	O
temps	O
and	O
has	O
now	O
been	O
apyrexial	O
.	O
Most	O
recently	O
CXR	O
showed	O
atelectasis	O
with	O
no	O
frank	O
consolidation	O
.	O
All	O
further	O
cultures	O
and	O
BCs	O
have	O
been	O
negative	O
.	O
He	O
was	O
started	O
on	O
ciprofloxacin	I-Drug
for	O
?	O
UTI	I-Reason
when	O
urinalysis	O
was	O
positive	O
.	O
.	O
#	O
Urinary	B-Reason
retention	I-Reason
:	O
Pt	O
pulled	O
out	O
Foley	O
catheter	O
and	O
subsequent	O
to	O
re-insertion	O
had	O
urinary	O
retention	O
which	O
resolves	O
.	O
He	O
was	O
voiding	O
post	O
trial	O
without	O
catheter	O
on	O
[	O
**	O
8	O
-	O
11	O
**	O
]	O
although	O
if	O
he	O
does	O
go	O
back	O
into	O
retention	O
he	O
will	O
clearly	O
need	O
further	O
catheterisation	O
and	O
urology	O
follow	O
-	O
up	O
.	O
He	O
was	O
commenced	O
on	O
tamsulosin	I-Drug
.	O
.	O
#	O
Dyslipidemia	I-Reason
:	O
continue	O
high	O
dose	O
statin	I-Drug
Medications	O
on	O
Admission	O
:	O
Lisinopril	I-Drug
5	O
mg	O
QD	O
Prevastatin	I-Drug
80	O
mg	O
QD	O
Vitamin	B-Drug
D	I-Drug
unknown	O
dose	O
Discharge	O
Medications	O
:	O
1	O
.	O
Atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Lisinopril	B-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Hold	O
SBP	O
<	O
100	O
.	O
3	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Hydrochlorothiazide	B-Drug
12.5	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
for	O
5	O
days	O
:	O
Last	O
day	O
is	O
[	O
**	O
8	O
-	O
15	O
**	O
]	O
,	O
then	O
decrease	O
to	O
200	O
mg	O
daily	O
on	O
[	O
**	O
2130-8-16	O
**	O
]	O
.	O
6	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
7	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
/	O
fever	I-Reason
.	O
8	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Warfarin	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
10	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
Rehab	O
Hospital	O
@	O
[	O
**	O
Location	O
(	O
un	O
)	O
4047	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Possible	O
cardiac	O
arrest	O
Atrial	O
Fibrillation	O
/	O
Flutter	O
Pneumonia	O
-	O
klebsiella	O
on	O
sputum	O
Urinary	O
Retention	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
You	O
collapsed	O
and	O
received	O
CPR	O
on	O
[	O
**	O
2130-7-28	O
**	O
]	O
.	O
It	O
is	O
unclear	O
if	O
your	O
heart	O
stopped	O
but	O
you	O
did	O
not	O
receive	O
a	O
shock	O
that	O
we	O
know	O
of	O
.	O
some	O
ribs	O
were	O
cracked	O
during	O
the	O
CPR	O
.	O
You	O
had	O
a	O
small	O
heart	O
attack	O
during	O
this	O
episode	O
.	O
We	O
treated	O
you	O
for	O
a	O
pneumonia	I-Reason
with	O
intravenous	O
antibiotics	I-Drug
.	O
You	O
also	O
developed	O
a	O
blood	B-Ade
collection	I-Ade
in	O
your	O
pelvis	O
from	O
the	O
blood	B-Drug
thinners	I-Drug
,	O
this	O
is	O
getting	O
better	O
.	O
Your	O
blood	O
count	O
is	O
low	O
because	O
of	O
the	O
pelvic	O
bleeding	O
and	O
some	O
bleeding	O
in	O
your	O
bowels	O
.	O
You	O
could	O
not	O
urinate	O
after	O
we	O
took	O
the	O
foley	O
catheter	O
out	O
of	O
your	O
bladder	O
so	O
we	O
replaced	O
it	O
and	O
started	O
you	O
on	O
a	O
medicine	O
called	O
Flomax	I-Drug
to	O
help	B-Reason
shrink	I-Reason
your	I-Reason
prostate	I-Reason
.	O
We	O
took	O
the	O
catheter	O
out	O
on	O
[	O
**	O
2130-8-11	O
**	O
]	O
although	O
if	O
you	O
are	O
further	O
unable	O
to	O
pass	O
urine	O
you	O
will	O
have	O
to	O
have	O
the	O
catheter	O
re-inserted	O
and	O
will	O
have	O
to	O
be	O
seen	O
by	O
urology	O
as	O
an	O
outpatient	O
.	O
Medication	O
changes	O
:	O
1	O
.	O
Stop	O
taking	O
Pravastatin	I-Drug
,	O
start	O
Atorvastatin	I-Drug
instead	O
to	O
lower	I-Reason
your	O
cholesterol	O
2	O
.	O
Increase	O
Lisinopril	I-Drug
to	O
40	O
mg	O
to	O
lower	B-Reason
your	I-Reason
blood	I-Reason
pressure	I-Reason
3	O
.	O
Start	O
Hydrchlorothiazide	I-Drug
to	O
lower	B-Reason
your	I-Reason
blood	I-Reason
pressure	I-Reason
4	O
.	O
Metoprolol	I-Drug
Succinate	O
5	O
.	O
Start	O
Amiodarone	I-Drug
6	O
.	O
Start	O
Haldol	I-Drug
to	O
help	B-Reason
you	I-Reason
relax	I-Reason
if	I-Reason
you	I-Reason
feel	I-Reason
anxious	I-Reason
7	O
.	O
Start	O
pantoprazole	I-Drug
to	B-Reason
protect	I-Reason
your	I-Reason
stomach	I-Reason
8	O
.	O
Start	O
Aspirin	I-Drug
to	O
prevent	I-Reason
blood	O
clots	O
9	O
.	O
Start	O
Coumadin	I-Drug
to	O
prevent	B-Reason
a	I-Reason
stroke	I-Reason
from	I-Reason
your	I-Reason
atrial	I-Reason
fibrillation	O
.	O
You	O
will	O
need	O
to	O
have	O
blood	O
drawn	O
frequently	O
to	O
make	O
sure	O
the	O
level	O
is	O
not	O
too	O
high	O
or	O
too	O
low	O
.	O
10	O
.	O
Start	O
Tamulosin	I-Drug
to	B-Reason
help	I-Reason
you	I-Reason
urinate	I-Reason
11	O
.	O
Start	O
tylenol	I-Drug
as	O
needed	O
for	O
the	B-Reason
rib	I-Reason
pain	I-Reason
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
in	O
1	O
day	O
or	O
6	O
pounds	O
in	O
3	O
days	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
TUESDAY	O
[	O
**	O
2130-9-19	O
**	O
]	O
at	O
9:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O

Admission	O
Date	O
:	O
[	O
**	O
2148-7-2	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2148-7-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2080-10-31	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
IV	O
Dye	I-Drug
,	O
Iodine	I-Drug
Containing	O
/	O
Keflex	I-Drug
/	O
Codeine	I-Drug
/	O
Isoniazid	I-Drug
/	O
Indocin	I-Drug
/	O
Percocet	I-Drug
/	O
Vicodin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2763	O
**	O
]	O
Chief	O
Complaint	O
:	O
GI	O
bleed	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
EGD	O
History	O
of	O
Present	O
Illness	O
:	O
67	O
yo	O
F	O
with	O
a	O
PMH	O
of	O
SLE	O
,	O
DMI	O
,	O
HTN	O
,	O
ESRD	O
on	O
HD	O
T	O
,	O
Th	O
,	O
Sat	O
,	O
paroxysmal	O
afib	O
s	O
/	O
p	O
PV	O
isolation	O
x2	O
,	O
tachy	O
-	O
brady	O
syndrome	O
s	O
/	O
p	O
pacer	O
and	O
PVD	O
with	O
SFA	O
stent	O
placement	O
,	O
NSTEMI	O
with	O
DES	O
to	O
LAD	O
and	O
BMS	O
to	O
OM1	O
on	O
[	O
**	O
6	O
-	O
21	O
**	O
]	O
presenting	O
with	O
lightheadedness	O
and	O
bright	O
red	O
blood	O
per	O
rectum	O
.	O
She	O
stated	O
that	O
last	O
night	O
,	O
she	O
noted	O
large	O
red	O
"	O
clots	O
"	O
in	O
her	O
stool	O
,	O
along	O
with	O
BRB	O
with	O
wiping	O
.	O
Of	O
note	O
,	O
she	O
has	O
hemorhoids	O
.	O
She	O
had	O
more	O
bowel	O
movemets	O
with	O
clots	O
this	O
AM	O
and	O
felt	O
lightheaded	O
.	O
Of	O
note	O
,	O
she	O
is	O
on	O
aspirin	I-Drug
,	O
plavix	I-Drug
,	O
and	O
coumadin	I-Drug
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
took	O
none	O
of	O
her	O
meds	O
this	O
AM	O
.	O
.	O
On	O
arrival	O
to	O
the	O
ED	O
,	O
initial	O
vitals	O
were	O
97.9	O
7085/47	O
22	O
96	O
%	O
RA	O
.	O
By	O
the	O
time	O
she	O
got	O
to	O
her	O
room	O
,	O
her	O
SBPs	O
had	O
come	O
up	O
tot	O
he	O
90s	O
/	O
100s	O
without	O
any	O
fluids	O
.	O
Labs	O
were	O
notable	O
for	O
a	O
Hct	O
of	O
23.7	O
down	O
from	O
32.7	O
one	O
week	O
ago	O
on	O
discharge	O
.	O
K	O
+	O
was	O
7.2	O
,	O
she	O
was	O
given	O
insulin	I-Drug
,	O
D50	I-Drug
,	O
calcium	B-Drug
gluconate	I-Drug
.	O
ECG	O
was	O
V	O
paced	O
without	O
any	O
T	O
wave	O
changes	O
.	O
10	O
mg	O
IV	O
Vitamin	B-Drug
K	I-Drug
given	O
,	O
1	O
unit	O
FFP	I-Drug
and	O
PRBCs	I-Drug
ordered	O
(	O
and	O
given	O
in	O
ED	O
)	O
.	O
CTA	O
done	O
in	O
the	O
ED	O
.	O
GI	O
and	O
renal	O
aware	O
.	O
On	O
transfer	O
,	O
vitals	O
were	O
70s	O
paced	O
106/59	O
no	O
fluids	O
RR	O
15	O
98	O
%	O
RA	O
.	O
A	O
left	O
groin	O
cordis	O
was	O
placed	O
.	O
.	O
On	O
arrival	O
to	O
the	O
MICU	O
,	O
patient	O
had	O
large	O
melanotic	O
bowel	O
movement	O
,	O
otherwise	O
HD	O
stable	O
.	O
.	O
Of	O
note	O
,	O
patient	O
states	O
that	O
she	O
had	O
an	O
EGD	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
showing	O
gastritis	O
and	O
healed	O
ulcers	O
,	O
as	O
well	O
as	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
which	O
showed	O
polyps	O
that	O
were	O
removed	O
.	O
Past	O
Medical	O
History	O
:	O
Diabetes	O
Hypertension	O
CAD	O
s	O
/	O
p	O
DES	O
to	O
midLAD	O
and	O
BMS	O
to	O
OM1	O
[	O
**	O
2148-6-20	O
**	O
]	O
Tachy	O
-	O
brady	O
syndrome	O
s	O
/	O
p	O
[	O
**	O
Company	O
1543	O
**	O
]	O
pacemaker	O
implanted	O
[	O
**	O
2143	O
**	O
]	O
for	O
offset	O
pauses	O
Symptomatic	O
paroxysmal	O
atrial	O
fibrillation	O
s	O
/	O
p	O
afib	O
ablation	O
x2	O
last	O
one	O
[	O
**	O
9	O
-	O
/	O
2147	O
**	O
]	O
by	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
.	O
Does	O
not	O
tolerate	O
1C	O
agents	O
due	O
to	O
lightheadedness	O
.	O
PVD	I-Reason
,	O
recent	O
left	O
SFA	O
stent	B-Reason
placement	I-Reason
on	O
plavix	I-Drug
Mohs	O
procedure	O
for	O
SQC	O
carcinoma	O
of	O
leg	O
SLE	O
Type	O
1	O
diabetes	O
mellitus	O
ESRD	O
(	O
end	O
stage	O
renal	O
disease	O
)	O
on	O
dialysis	O
x	O
~	O
2	O
yr	O
(	O
T	O
,	O
TH	O
,	O
Sat	O
)	O
Calcification	O
/	O
fibroadenoma	O
of	O
left	O
breast	O
h	O
/	O
o	O
squamous	O
cell	O
carcinoma	O
,	O
leg	O
and	O
face	O
DJD	O
of	O
knee	O
and	O
hip	O
Anemia	O
in	O
chronic	O
kidney	O
disease	O
Hyperphosphatemia	O
Hyperparathyroidism	O
due	O
to	O
renal	O
insufficiency	O
Cataract	O
Moderate	O
Nonproliferative	O
Diabetic	O
Retinopathy	O
Colonic	O
Adenoma	O
Neuritis	O
/	O
Radiculitis	O
due	O
to	O
Herniated	O
Lumbar	O
Disc	O
OBESITY	O
-	O
MORBID	O
SPINAL	O
STENOSIS	O
-	O
LUMBAR	O
GLOMERULONEPHRITIS	O
-	O
MEMBRANOUS	O
THROMBOCYTOPENIA	O
-	O
IMMUNE	O
ESOPHAGEAL	O
REFLUX	O
ANTICARDIOLIPIN	O
ANTIBODY	O
SYNDROME	O
GLAUCOMA	O
SUSPECT	O
W	O
OPEN	O
ANGLE	O
VARICOSE	O
VEINS	O
ESOTROPIA	O
HISTORY	O
BASAL	O
CELL	O
CARCINOMA	O
POSITIVE	O
PPD	O
PERICARDITIS	O
S	O
/	O
p	O
cholecystectomy	O
,	O
hysterectomy	O
Social	O
History	O
:	O
Used	O
to	O
work	O
as	O
a	O
nurse	O
.	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
1817	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1818	O
**	O
]	O
,	O
quit	O
40	O
yrs	O
ago	O
.	O
Denies	O
ETOH	O
and	O
other	O
drugs	O
.	O
Family	O
History	O
:	O
brother	O
who	O
died	O
of	O
esophageal	O
CA	O
Father	O
-	O
DM	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
Cancer	O
(	O
70s	O
)	O
,	O
Mother	O
-	O
DM	O
,	O
CAD	O
/	O
PVD	O
,	O
Sister	O
-	O
Lupus	O
,	O
Sister	O
-	O
Breast	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
3730	O
**	O
]	O
(	O
age	O
43	O
)	O
,	O
Sister	O
-	O
Bladder	O
[	O
**	O
Name	O
(	O
NI	O
)	O
3730	O
**	O
]	O
.	O
Paternal	O
GF	O
-	O
CRC	O
Physical	O
Exam	O
:	O
ADMISSION	O
EXAM	O
:	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
EOMI	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
CNII	O
-	O
XII	O
intact	O
,	O
5/5	O
strength	O
upper	O
/	O
lower	O
extremities	O
,	O
grossly	O
normal	O
sensation	O
,	O
2	O
+	O
reflexes	O
bilaterally	O
,	O
gait	O
deferred	O
,	O
finger	O
-	O
to	O
-	O
nose	O
intact	O
.	O
DISCHARGE	O
EXAM	O
:	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
EOMI	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
CNII	O
-	O
XII	O
intact	O
,	O
5/5	O
strength	O
upper	O
/	O
lower	O
extremities	O
,	O
grossly	O
normal	O
sensation	O
,	O
2	O
+	O
reflexes	O
bilaterally	O
,	O
gait	O
deferred	O
,	O
finger	O
-	O
to	O
-	O
nose	O
intact	O
,	O
She	O
was	O
able	O
to	O
get	O
out	O
of	O
bed	O
with	O
a	O
two	O
person	O
assist	O
and	O
was	O
able	O
to	O
shuffle	O
herself	O
to	O
a	O
wheelchair	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2148-7-2	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
WBC	O
-	O
12.5	O
*	O
#	O
RBC	O
-	O
2.43	O
*	O
#	O
Hgb	O
-	O
7.5	O
*	O
#	O
Hct	O
-	O
23.7	O
*	O
#	O
MCV	O
-	O
98	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
31.6	O
RDW	O
-	O
18.8	O
*	O
Plt	O
Ct	O
-	O
182	O
[	O
**	O
2148-7-2	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
Neuts	O
-	O
90.6	O
*	O
Lymphs	O
-	O
5.2	O
*	O
Monos	O
-	O
2.3	O
Eos	O
-	O
1.5	O
Baso	O
-	O
0.4	O
[	O
**	O
2148-7-2	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
PT	O
-	O
55.3	O
*	O
PTT	O
-	O
75.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
5.5	O
*	O
[	O
**	O
2148-7-2	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
Glucose	O
-	O
194	O
*	O
UreaN	O
-	O
57	O
*	O
Creat	O
-	O
7.5	O
*	O
#	O
Na	O
-	O
138	O
K	O
-	O
7.2	O
*	O
Cl	O
-	O
100	O
HCO3	O
-	O
23	O
AnGap	O
-	O
22	O
*	O
[	O
**	O
2148-7-2	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
Calcium	O
-	O
7.8	O
*	O
Phos	O
-	O
6.8	O
*	O
Mg	O
-	O
2.0	O
[	O
**	O
2148-7-2	O
**	O
]	O
07:45	O
AM	O
BLOOD	O
Lactate	O
-	O
1.6	O
.	O
PERTINENT	O
LABS	O
:	O
.	O
DISCHARGE	O
LABS	O
:	O
.	O
MICRO	O
:	O
none	O
.	O
IMAGING	O
:	O
[	O
**	O
2148-7-2	O
**	O
]	O
CT	O
abdomen	O
/	O
pelvis	O
w	O
/	O
o	O
con	O
:	O
1	O
.	O
Left	O
femoral	O
venous	O
catheter	O
has	O
an	O
unusually	O
short	O
intra-vascular	O
course	O
.	O
2	O
.	O
4.6	O
-	O
cm	O
rounded	O
structure	O
in	O
the	O
gallbladder	O
fossa	O
contains	O
a	O
dependent	O
calcification	O
and	O
demonstrates	O
no	O
inflammatory	O
change	O
.	O
This	O
potentially	O
represents	O
a	O
post-operative	O
collection	O
without	O
surrounding	O
inflammation	O
or	O
a	O
retained	O
portion	O
of	O
the	O
gallbladder	O
.	O
Correlation	O
with	O
detailed	O
surgical	O
history	O
is	O
suggested	O
.	O
3	O
.	O
Sigmoid	O
diverticulosis	O
without	O
evidence	O
of	O
diverticulitis	O
4	O
.	O
Focus	O
of	O
air	O
within	O
bladder	O
.	O
Please	O
correlate	O
with	O
history	O
for	O
recent	O
instrumentation	O
.	O
5	O
.	O
Severe	O
vascular	O
calcifications	O
.	O
.	O
[	O
**	O
2148-7-2	O
**	O
]	O
GI	O
Bleeding	O
Study	O
:	O
Blood	O
flow	O
images	O
show	O
normal	O
tracer	O
flow	O
through	O
the	O
large	O
vessels	O
of	O
the	O
abdominal	O
and	O
pelvic	O
vasculature	O
.	O
Dynamic	O
images	O
of	O
the	O
abdomen	O
show	O
tracer	O
extravasation	O
in	O
the	O
right	O
upper	O
quadrant	O
likely	O
in	O
the	O
hepatic	O
flexure	O
of	O
the	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
at	O
the	O
onset	O
of	O
the	O
study	O
.	O
Over	O
72	O
minutes	O
,	O
there	O
is	O
relatively	O
little	O
transit	O
of	O
isotope	O
reaching	O
only	O
the	O
region	O
of	O
the	O
mid-transverse	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
;	O
slow	O
transit	O
is	O
typical	O
of	O
bleeding	O
in	O
the	O
large	O
bowel	O
.	O
IMPRESSION	O
:	O
GI	O
bleed	O
likely	O
in	O
the	O
region	O
of	O
the	O
hepatic	O
flexure	O
of	O
the	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
.	O
.	O
[	O
**	O
2148-7-2	O
**	O
]	O
CXR	O
:	O
Exam	O
is	O
limited	O
as	O
the	O
bilateral	O
bases	O
are	O
excluded	O
from	O
the	O
field	O
of	O
view	O
.	O
Where	O
seen	O
the	O
lungs	O
appear	O
clear	O
.	O
Cardiac	O
silhouette	O
is	O
slightly	O
enlarged	O
likely	O
accentuated	O
by	O
positioning	O
however	O
is	O
unchanged	O
.	O
Dense	O
atherosclerotic	O
calcifications	O
noted	O
at	O
the	O
arch	O
.	O
Osseous	O
and	O
soft	O
tissue	O
structures	O
are	O
unchanged	O
.	O
.	O
[	O
**	O
2148-7-2	O
**	O
]	O
Mesenteric	O
angiogram	O
by	O
IR	O
:	O
1	O
.	O
Extensive	O
atherosclerotic	O
disease	O
,	O
with	O
calcification	O
of	O
multiple	O
vessels	O
seen	O
on	O
fluoroscopic	O
images	O
without	O
contrast	O
.	O
2	O
.	O
Right	O
common	O
femoral	O
artery	O
access	O
was	O
obtained	O
.	O
Atherosclerotic	O
disease	O
but	O
patent	O
right	O
common	O
femoral	O
artery	O
with	O
contrast	O
flowing	O
through	O
and	O
around	O
the	O
sheath	O
.	O
3	O
.	O
SMA	O
angiography	O
demonstrated	O
no	O
evidence	O
of	O
active	O
extravasation	O
,	O
specifically	O
within	O
the	O
right	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
or	O
hepatic	O
flexure	O
.	O
Additional	O
selective	O
angiography	O
of	O
the	O
middle	O
colic	O
and	O
right	O
colic	O
arteries	O
demonstrated	O
no	O
active	O
extravasation	O
within	O
the	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
or	O
visualized	O
portions	O
of	O
small	O
bowel	O
branches	O
.	O
4	O
.	O
Celiac	O
artery	O
angiography	O
demonstrated	O
no	O
active	O
extravasation	O
within	O
the	O
right	O
upper	O
quadrant	O
.	O
Specifically	O
,	O
no	O
active	O
extravasation	O
is	O
seen	O
within	O
the	O
GDA	O
.	O
5	O
.	O
Angiography	O
of	O
the	O
hepatic	O
artery	O
demonstrated	O
a	O
5	O
-	O
6	O
mm	O
pseudoaneurysm	O
arising	O
off	O
the	O
right	O
hepatic	O
artery	O
.	O
This	O
is	O
likely	O
an	O
incidental	O
finding	O
.	O
No	O
active	O
extravasation	O
was	O
seen	O
from	O
this	O
into	O
any	O
biliary	O
ducts	O
or	O
outside	O
of	O
the	O
vessel	O
lumen	O
.	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
active	O
extravasation	O
on	O
this	O
mesenteric	O
angiogram	O
.	O
.	O
[	O
**	O
2148-7-3	O
**	O
]	O
CTA	O
abdomen	O
/	O
pelvis	O
:	O
1	O
.	O
Suboptimal	O
bolus	O
limits	O
evaluation	O
for	O
active	O
GI	O
bleeding	O
,	O
although	O
existing	O
high	O
-	O
density	O
intraluminal	O
contents	O
suggests	O
extravasation	O
from	O
prior	O
angiogram	O
.	O
2	O
.	O
Mild	O
bladder	O
wall	O
thickening	O
and	O
surrounding	O
fat	O
stranding	O
is	O
suggestive	O
of	O
cystitis	O
,	O
correlate	O
with	O
urinalysis	O
.	O
Further	O
,	O
air	O
seen	O
within	O
the	O
bladder	O
wall	O
may	O
relate	O
to	O
prior	O
Foley	O
placement	O
but	O
emphysematous	O
cystitis	O
is	O
not	O
excluded	O
.	O
3	O
.	O
Extensive	O
atherosclerosis	O
,	O
without	O
aneurysm	O
.	O
4	O
.	O
Sigmoid	O
diverticulosis	O
without	O
diverticulitis	O
and	O
cholelithiasis	O
in	O
a	O
gallbladder	O
remnant	O
without	O
cholecystitis	O
.	O
5	O
.	O
Left	O
adnexal	O
cystic	O
lesion	O
is	O
not	O
fully	O
characterized	O
on	O
this	O
study	O
.	O
If	O
warranted	O
,	O
a	O
non-urgent	O
pelvic	O
ultrasound	O
may	O
be	O
performed	O
.	O
Brief	O
Hospital	O
Course	O
:	O
67	O
year	O
old	O
female	O
with	O
SLE	O
,	O
DMI	O
,	O
HTN	O
,	O
ESRD	O
on	O
HD	O
,	O
paroxysmal	O
afib	O
s	O
/	O
p	O
PV	O
isolation	O
x2	O
,	O
tachy	O
-	O
brady	O
syndrome	O
s	O
/	O
p	O
pacer	O
,	O
PVD	O
with	O
SFA	O
stent	O
placement	O
,	O
and	O
NSTEMI	O
s	O
/	O
p	O
DES	O
to	O
LAD	O
and	O
BMS	O
to	O
OM1	O
on	O
[	O
**	O
2148-6-21	O
**	O
]	O
on	O
aspirin	I-Drug
,	O
plavix	I-Drug
,	O
and	O
coumadin	I-Drug
who	O
presented	O
with	O
melena	O
and	O
BRBPR	O
.	O
.	O
#	O
GIB	O
:	O
Patient	O
presented	O
with	O
melena	O
and	O
BRBPR	O
,	O
suspicious	O
for	O
either	O
an	O
upper	O
or	O
lower	O
GI	O
source	O
.	O
The	O
EGD	O
showed	O
mild	O
gastritis	O
but	O
no	O
active	O
bleeding	O
.	O
The	O
flex	O
sig	O
was	O
also	O
negative	O
for	O
active	O
bleeding	O
.	O
The	O
tagged	O
RBC	O
scan	O
was	O
positive	O
in	O
the	O
hepatic	O
flexure	O
,	O
however	O
when	O
she	O
was	O
taken	O
to	O
IR	O
for	O
a	O
mesenteric	O
angiogram	O
,	O
there	O
was	O
no	O
active	O
bleeding	O
.	O
She	O
continued	O
to	O
have	O
melena	O
so	O
underwent	O
an	O
abdominal	O
CTA	O
(	O
after	O
prep	O
for	O
her	O
iodine	I-Drug
allergy	O
)	O
,	O
which	O
was	O
also	O
negative	O
for	O
active	O
bleeding	O
.	O
She	O
was	O
scheduled	O
for	O
a	O
colonoscopy	O
which	O
was	O
then	O
cancelled	O
due	O
to	O
her	O
Afib	O
with	O
RVR	O
(	O
see	O
below	O
)	O
.	O
Overall	O
she	O
received	O
8	O
units	O
of	O
PRBCs	I-Drug
,	O
3	O
units	O
of	O
FFP	I-Drug
,	O
and	O
1	O
unit	O
of	O
platelets	I-Drug
while	O
in	O
the	O
ICU	O
.	O
It	O
was	O
determined	O
by	O
the	O
team	O
that	O
the	O
colonoscopy	O
can	O
be	O
deferred	O
to	O
the	O
outpatient	O
setting	O
given	O
her	O
relative	O
stability	O
.	O
.	O
#	O
Atrial	B-Reason
fibrillation	I-Reason
:	O
S	O
/	O
p	O
two	O
ablations	O
in	O
the	O
past	O
,	O
now	O
with	O
pacemaker	O
.	O
We	O
continued	O
her	O
amiodarone	I-Drug
but	O
initially	O
held	O
her	O
home	O
metoprolol	I-Drug
and	O
diltizem	I-Drug
in	O
the	O
setting	O
of	O
the	O
GIB	O
.	O
She	O
went	O
into	O
AFib	I-Reason
with	O
RVR	O
on	O
MICU	O
day	O
#	O
3	O
so	O
she	O
was	O
given	O
IV	O
diltiazem	I-Drug
and	O
metoprolol	I-Drug
and	O
her	O
home	O
metoprolol	I-Drug
and	O
diltiazem	I-Drug
were	O
restarted	O
.	O
However	O
,	O
she	O
continued	O
to	O
have	O
RVR	O
and	O
required	O
a	O
diltiazem	I-Drug
gtt	O
.	O
She	O
was	O
eventually	O
transitioned	O
to	O
her	O
home	O
doses	O
.	O
.	O
#	O
ESRD	O
:	O
On	O
Tues	O
/	O
Thurs	O
/	O
Sat	O
dialysis	O
schedule	O
,	O
which	O
was	O
continued	O
in	O
the	O
MICU	O
.	O
.	O
#	O
CAD	O
:	O
Patient	O
with	O
NSTEMI	O
one	O
week	O
ago	O
s	O
/	O
p	O
DES	O
to	O
LAD	O
and	O
BMS	O
to	O
OM1	O
.	O
We	O
continued	O
aspirin	I-Drug
/	O
plavix	I-Drug
despite	O
the	O
GIB	O
given	O
risk	O
for	O
in	B-Reason
-	I-Reason
stent	I-Reason
thrombosis	I-Reason
one	O
week	O
out	O
.	O
This	O
was	O
discussed	O
with	O
her	O
[	O
**	O
Date	O
Range	O
**	O
]	O
outpatient	O
cardiologist	O
.	O
.	O
#	O
PVD	O
s	O
/	O
p	O
SFA	O
stenting	O
recently	O
:	O
Recent	O
peripheral	O
angiogram	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3407	O
**	O
]	O
with	O
angioplasty	I-Reason
/	O
stenting	I-Reason
of	O
the	O
left	O
SFA	O
and	O
angioplasty	O
of	O
the	O
left	O
tibial	O
artery	O
;	O
had	O
been	O
on	O
plavix	I-Drug
prior	O
to	O
NSTEMI	O
.	O
She	O
has	O
2	O
gangrenous	O
toes	O
,	O
which	O
appear	O
similar	O
to	O
prior	O
.	O
Continued	O
aspirin	I-Drug
/	O
Plavix	I-Drug
.	O
.	O
#	O
Chronic	B-Reason
pain	I-Reason
:	O
Continued	O
home	O
gabapentin	I-Drug
and	O
dilaudid	I-Drug
.	O
.	O
#	O
Depression	I-Reason
:	O
Continued	O
sertraline	I-Drug
.	O
#	O
Goals	O
of	O
Care	O
:	O
Patient	O
expressing	O
interest	O
in	O
rethinking	O
her	O
goals	O
of	O
care	O
.	O
She	O
is	O
considering	O
a	O
do	O
not	O
hospitalize	O
,	O
but	O
would	O
like	O
to	O
talk	O
things	O
over	O
with	O
her	O
family	O
before	O
making	O
these	O
decisions	O
.	O
She	O
will	O
speak	O
to	O
her	O
primary	O
care	O
doctor	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1057	O
**	O
]	O
,	O
about	O
these	O
issues	O
.	O
She	O
had	O
declined	O
rehab	O
while	O
in	O
the	O
MICU	O
and	O
was	O
very	O
insistent	O
on	O
going	O
home	O
.	O
Because	O
she	O
had	O
good	O
family	O
support	O
and	O
very	O
good	O
insight	O
into	O
her	O
condition	O
,	O
she	O
was	O
discharged	O
home	O
with	O
close	O
follow	O
up	O
by	O
the	O
MICU	O
team	O
.	O
She	O
felt	O
weak	O
at	O
home	O
and	O
was	O
not	O
able	O
to	O
navigate	O
her	O
home	O
as	O
well	O
as	O
she	O
would	O
have	O
liked	O
.	O
The	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2287	O
**	O
]	O
case	O
managers	O
arranged	O
for	O
her	O
to	O
go	O
to	O
[	O
**	O
Hospital	O
1785	O
**	O
]	O
Rehab	O
from	O
home	O
the	O
day	O
after	O
admission	O
.	O
The	O
MICU	O
team	O
was	O
in	O
communication	O
with	O
the	O
case	O
manager	O
and	O
primary	O
care	O
doctor	O
during	O
the	O
post-discharge	O
period	O
in	O
order	O
to	O
faciliatate	O
a	O
proper	O
disposition	O
.	O
There	O
is	O
a	O
separate	O
note	O
in	O
OMR	O
detailing	O
this	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
diltiazem	B-Drug
HCl	I-Drug
120	O
mg	O
Capsule	O
,	O
Extended	O
Release	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
,	O
Extended	O
Release	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
Take	O
360	O
mg	O
in	O
morning	O
and	O
night	O
and	O
240	O
mg	O
in	O
afternoon	O
.	O
2	O
.	O
diltiazem	B-Drug
HCl	I-Drug
240	O
mg	O
Capsule	O
,	O
Extended	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Extended	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Take	O
360	O
mg	O
in	O
morning	O
and	O
night	O
and	O
240	O
mg	O
in	O
afternoon	O
.	O
3	O
.	O
metoprolol	B-Drug
succinate	I-Drug
100	O
mg	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
4.5	O
Tablets	O
PO	O
once	O
a	O
day	O
:	O
Take	O
4.5	O
mg	O
daily	O
.	O
5	O
.	O
amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TUES	O
,	O
THURS	O
,	O
SAT	O
(	O
)	O
.	O
6	O
.	O
fluorouracil	I-Drug
0.5	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
application	O
Topical	O
once	O
a	O
day	O
for	O
2	O
weeks	O
:	O
apply	O
to	O
face	O
with	O
bactroban	I-Drug
.	O
7	O
.	O
Bactroban	I-Drug
2	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
application	O
Topical	O
once	O
a	O
day	O
for	O
2	O
weeks	O
:	O
Apply	O
to	O
face	O
with	O
Fluorouracil	I-Drug
.	O
8	O
.	O
gabapentin	I-Drug
300	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
sertraline	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Ferrlecit	I-Drug
62.5	O
mg	O
/	O
5	O
mL	O
Solution	O
Intravenous	O
11	O
.	O
lorazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
12	O
.	O
tramadol	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
13	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
twice	O
a	O
day	O
.	O
14	O
.	O
Voltaren	I-Drug
1	O
%	O
Gel	O
Sig	O
:	O
One	O
(	O
1	O
)	O
application	O
Topical	O
four	O
times	O
a	O
day	O
:	O
Apply	O
to	O
affected	O
area	O
up	O
to	O
4times	O
daily	O
.	O
15	O
.	O
Epogen	I-Drug
Injection	O
16	O
.	O
insulin	B-Drug
aspart	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
injection	O
Subcutaneous	O
four	O
times	O
a	O
day	O
:	O
Take	O
as	O
directed	O
according	O
to	O
home	O
sliding	O
scale	O
.	O
17	O
.	O
hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q3H	O
(	O
every	O
3	O
hours	O
)	O
as	O
needed	O
for	O
Pain	I-Reason
.	O
18	O
.	O
sevelamer	B-Drug
carbonate	I-Drug
800	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
19	O
.	O
B	B-Drug
complex	I-Drug
-	I-Drug
vitamin	I-Drug
C	I-Drug
-	I-Drug
folic	I-Drug
acid	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
20	O
.	O
acetaminophen	I-Drug
650	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
as	O
needed	O
for	O
Pain	I-Reason
.	O
21	O
.	O
aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
22	O
.	O
nitroglycerin	I-Drug
0.3	O
mg	O
Tablet	O
,	O
Sublingual	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Sublingual	O
Sublingual	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
Chest	B-Reason
pain	I-Reason
:	O
Place	O
1	O
tablet	O
under	O
the	O
tongue	O
for	O
chest	B-Reason
pressure	I-Reason
.	O
Take	O
1	O
every	O
5	O
minutes	O
,	O
up	O
to	O
three	O
times	O
in	O
a	O
row	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Sublingual	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
23	O
.	O
atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
24	O
.	O
clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
25	O
.	O
doxercalciferol	I-Drug
Intravenous	O
Discharge	O
Medications	O
:	O
1	O
.	O
Amiodarone	I-Drug
200	O
mg	O
PO	O
QTUTHSA	O
(	O
TU	O
,	O
TH	O
,	O
SA	O
)	O
2	O
.	O
Aspirin	I-Drug
81	O
mg	O
PO	O
DAILY	O
3	O
.	O
Atorvastatin	I-Drug
80	O
mg	O
PO	O
DAILY	O
4	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
PO	O
DAILY	O
5	O
.	O
Gabapentin	I-Drug
300	O
mg	O
PO	O
TID	O
6	O
.	O
HYDROmorphone	I-Drug
(	O
Dilaudid	I-Drug
)	O
2	O
mg	O
PO	O
Q3H	O
:	O
PRN	O
pain	I-Reason
7	O
.	O
Insulin	I-Drug
SC	O
Sliding	O
Scale	O
Fingerstick	O
QACHS	O
Insulin	I-Drug
SC	O
Sliding	O
Scale	O
using	O
HUM	B-Drug
Insulin	I-Drug
8	O
.	O
Lorazepam	I-Drug
1	O
mg	O
PO	O
BID	O
:	O
PRN	O
anxiety	I-Reason
Hold	O
for	O
sedation	O
or	O
RR	O
<	O
12	O
.	O
9	O
.	O
Mupirocin	I-Drug
Cream	O
2	O
%	O
1	O
Appl	O
TP	O
QD	O
10	O
.	O
Nephrocaps	I-Drug
1	O
CAP	O
PO	O
DAILY	O
11	O
.	O
sevelamer	B-Drug
CARBONATE	I-Drug
1200	O
mg	O
PO	O
TID	O
W	O
/	O
MEALS	O
12	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
PO	O
Q12H	O
RX	O
*	O
pantoprazole	I-Drug
40	O
mg	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
Disp	O
#	O
*	O
60	O
Capsule	O
Refills	O
:	O
*	O
0	O
13	O
.	O
Diltiazem	I-Drug
Extended	O
-	O
Release	O
360	O
mg	O
PO	O
QAM	O
14	O
.	O
Diltiazem	I-Drug
Extended	O
-	O
Release	O
240	O
mg	O
PO	O
QPM	O
15	O
.	O
Diltiazem	I-Drug
Extended	O
-	O
Release	O
360	O
mg	O
PO	O
QHS	O
hold	O
for	O
sbp	O
<	O
100	O
,	O
hr	O
<	O
55	O
16	O
.	O
Sertraline	I-Drug
150	O
mg	O
PO	O
DAILY	O
17	O
.	O
TraMADOL	I-Drug
(	O
Ultram	I-Drug
)	O
50	O
mg	O
PO	O
BID	O
:	O
PRN	O
pain	I-Reason
18	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
XL	I-Drug
200	O
mg	O
PO	O
BID	O
19	O
.	O
Nitroglycerin	I-Drug
SL	O
0.3	O
mg	O
SL	O
PRN	O
chest	B-Reason
pain	I-Reason
take	O
one	O
tab	O
under	O
your	O
tongue	O
if	O
you	O
have	O
chest	B-Reason
pain	I-Reason
.	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
repeat	O
up	O
to	O
three	O
times	O
,	O
five	O
minutes	O
apart	O
.	O
Please	O
call	O
9	O
-1-1	O
if	O
your	O
chest	O
pain	O
persists	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
2255	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2256	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Lower	O
GI	O
Bleed	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
21056	O
**	O
]	O
:	O
It	O
was	O
a	O
pleasure	O
to	O
take	O
care	O
of	O
you	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
You	O
were	O
seen	O
in	O
the	O
hospital	O
because	O
of	O
a	O
gastrointestinal	O
bleed	O
,	O
likely	O
secondary	O
to	O
a	O
high	O
INR	O
.	O
Your	O
coumadin	I-Drug
was	O
held	O
and	O
you	O
were	O
transfused	O
with	O
multiple	O
units	O
of	O
blood	O
.	O
Your	O
blood	O
counts	O
then	O
remained	O
stable	O
.	O
You	O
will	O
likely	O
need	O
to	O
follow	O
up	O
with	O
an	O
outpatient	O
gastroenterologist	O
for	O
a	O
colonosocpy	O
at	O
some	O
point	O
in	O
the	O
next	O
several	O
months	O
.	O
We	O
made	O
the	O
following	O
changes	O
to	O
your	O
medications	O
:	O
STOP	O
Coumadin	I-Drug
-	O
You	O
should	O
have	O
a	O
conversation	O
with	O
your	O
primary	O
care	O
doctor	O
about	O
when	O
you	O
should	O
restart	O
this	O
medication	O
given	O
your	O
bleed	O
DECREASE	O
aspirin	I-Drug
to	O
81	O
mg	O
daily	O
START	O
pantoprazole	I-Drug
40	O
mg	O
PO	O
twice	O
a	O
day	O
STOP	O
Omeprazole	I-Drug
Followup	O
Instructions	O
:	O
You	O
need	O
to	O
make	O
an	O
appointment	O
to	O
see	O
your	O
primary	O
care	O
doctor	O
within	O
the	O
next	O
week	O
.	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2764	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2148-7-9	O
**	O
]	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
14949	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2189-11-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2189-11-20	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2105-4-8	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Sulfasalazine	I-Drug
/	O
Percocet	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
954	O
**	O
]	O
Addendum	O
:	O
Pls	O
note	O
under	O
medications	O
:	O
Other	O
should	O
read	O
-	O
NPH	I-Drug
8	O
units	O
sc	O
qAm	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
[	O
**	O
Hospital	O
345	O
**	O
]	O
Nursing	O
Home	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
[	O
**	O
First	O
Name7	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
955	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2189-11-20	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2111-3-26	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2111-3-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2037-1-10	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2186	O
**	O
]	O
Chief	O
Complaint	O
:	O
Transfered	O
for	O
w	O
/	O
u	O
for	O
surgery	O
for	O
thoracic	O
aortic	O
aneurysm	O
.	O
No	O
surgery	O
indicated	O
.	O
Pt	O
tx	O
'd	O
to	O
ICU	O
for	O
syncope	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
74	O
yo	O
c	O
hx	O
of	O
hypertension	O
,	O
hyperlipidemia	O
,	O
CAD	O
s	O
/	O
p	O
RCA	O
stent	O
[	O
**	O
2	O
-	O
26	O
**	O
]	O
,	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
and	O
aortic	O
root	O
aneurysm	O
who	O
developed	O
intermittent	O
periods	O
of	O
lightheadedness	O
over	O
the	O
last	O
month	O
.	O
He	O
reports	O
feeling	O
dizzy	O
with	O
vague	O
symptoms	O
of	O
vertigo	O
;	O
these	O
occured	O
at	O
random	O
without	O
association	O
with	O
positional	O
changes	O
.	O
He	O
does	O
not	O
describe	O
a	O
clear	O
prodrome	O
to	O
these	O
episodes	O
.	O
Had	O
CT	O
of	O
chest	O
to	O
workup	O
these	O
symptoms	O
and	O
noted	O
to	O
have	O
significant	O
coronary	O
calcifications	O
.	O
Catheterization	O
showed	O
distal	O
RCA	O
occlusion	O
stented	O
.	O
Following	O
cath	O
,	O
had	O
episodes	O
of	O
dizziness	O
,	O
now	O
accompanied	O
with	O
some	O
confusion	O
to	O
orientation	O
quickly	O
clearing	O
.	O
Admitted	O
to	O
OSH	O
with	O
persistent	O
symptoms	O
and	O
noted	O
to	O
have	O
orthostatic	O
hypotension	O
;	O
continued	O
to	O
have	O
symptoms	O
c	O
fluid	O
resuscitation	O
and	O
w	O
/	O
u	O
for	O
adrenal	B-Reason
insufficiency	I-Reason
initiated	I-Reason
.	O
Started	O
on	O
fludricortisone	I-Drug
at	O
OSH	O
.	O
Transfered	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
surgical	O
evaluation	O
of	O
aortic	O
root	O
aneursym	O
and	O
medical	O
evaluation	O
of	O
orthostatic	O
hypotension	O
.	O
.	O
In	O
CSRU	O
,	O
had	O
SBP	O
to	O
160s	O
and	O
started	O
on	O
nitroglycerin	I-Drug
drip	O
;	O
no	O
dissection	O
noted	O
and	O
no	O
emergent	O
surgery	O
performed	O
.	O
Morning	O
of	O
transfer	O
,	O
pt	O
.	O
had	O
episode	O
of	O
questionable	O
loss	O
of	O
consciousness	O
while	O
rising	O
from	O
a	O
seated	O
position	O
to	O
urinate	O
.	O
Arose	O
from	O
bed	O
,	O
stood	O
up	O
at	O
side	O
of	O
bed	O
to	O
urinate	O
,	O
had	O
dizziness	O
/	O
vertigo	O
,	O
fell	O
to	O
bed	O
c	O
no	O
trauma	O
to	O
head	O
.	O
Found	O
unresponsive	O
briefly	O
and	O
noted	O
to	O
have	O
decreased	O
respirations	O
;	O
bag	O
valve	O
mask	O
used	O
briefly	O
and	O
pt	O
.	O
returned	O
to	O
[	O
**	O
Location	O
213	O
**	O
]	O
respirations	O
.	O
Nitro	I-Drug
drip	O
stopped	O
.	O
Sinus	O
rhythm	O
in	O
50s	O
and	O
SBP	O
112/60	O
.	O
Underwent	O
ECHO	O
showing	O
normal	O
valvular	O
function	O
and	O
transfered	O
to	O
medical	O
ICU	O
.	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
-	O
s	O
/	O
p	O
cypher	O
stent	O
to	O
RCA	O
[	O
**	O
2111-3-16	O
**	O
]	O
HTN	O
PAF	O
Hypercholesterolemia	O
Aortic	O
root	O
aneurysm	O
-	O
ascending	O
aorta	O
,	O
5.2	O
cm	O
s	O
/	O
p	O
colon	O
resection	O
for	O
benign	O
polyps	O
s	O
/	O
p	O
hernia	O
repair	O
Social	O
History	O
:	O
SOCHX	O
:	O
Lives	O
with	O
wife	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
3844	O
**	O
]	O
.	O
Drinks	O
1	O
-	O
2	O
drinks	O
of	O
scotch	O
a	O
night	O
.	O
25	O
-	O
50	O
pack	O
year	O
smoking	O
history	O
,	O
quit	O
recently	O
.	O
FAMHX	O
:	O
No	O
hx	O
autoimmune	O
disease	O
Family	O
History	O
:	O
N	O
/	O
C	O
Physical	O
Exam	O
:	O
VITALS	O
:	O
Tc	O
97.1	O
,	O
HR	O
64	O
,	O
BP	O
105/61	O
,	O
RR	O
23	O
,	O
94	O
%	O
RA	O
BP	O
Pulse	O
Supine	O
127/65	O
62	O
Sitting	O
104/68	O
69	O
Standing	O
105/61	O
76	O
GEN	O
:	O
Elderly	O
man	O
lying	O
in	O
bed	O
in	O
NAD	O
HEENT	O
:	O
OP	O
clear	O
,	O
MMM	O
,	O
no	O
LAD	O
CV	O
:	O
RRR	O
,	O
S1	O
,	O
S2	O
,	O
distant	O
heart	O
sounds	O
LUNGS	O
:	O
Decrease	O
breath	O
sounds	O
at	O
L	O
base	O
c	O
decrease	O
fremitus	O
and	O
dullness	O
to	O
percussion	O
over	O
area	O
.	O
No	O
wheeze	O
,	O
crackles	O
,	O
rhonchi	O
BACK	O
:	O
Unremarkable	O
ABD	O
:	O
Obese	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
,	O
BS	O
+	O
EXT	O
:	O
WWP	O
,	O
no	O
cce	O
,	O
good	O
capillary	O
refill	O
NEURO	O
:	O
A	O
*	O
O	O
*	O
3	O
,	O
CN	O
2	O
-	O
12	O
fxn	O
intact	O
,	O
[	O
**	O
3	O
-	O
27	O
**	O
]	O
MS	O
throughout	O
.	O
No	O
nystagmus	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2111-3-26	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
WBC	O
-	O
7.4	O
RBC	O
-	O
3.43	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
32.5	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
32.6	O
*	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
13.6	O
Plt	O
Ct	O
-	O
319	O
#	O
[	O
**	O
2111-3-28	O
**	O
]	O
06:02	O
AM	O
BLOOD	O
Neuts	O
-	O
73.4	O
*	O
Lymphs	O
-	O
20.2	O
Monos	O
-	O
4.9	O
Eos	O
-	O
1.1	O
Baso	O
-	O
0.3	O
[	O
**	O
2111-3-26	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
PT	O
-	O
12.1	O
PTT	O
-	O
24.9	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2111-3-26	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
Glucose	O
-	O
91	O
UreaN	O
-	O
12	O
Creat	O
-	O
1.0	O
Na	O
-	O
140	O
K	O
-	O
3.7	O
Cl	O
-	O
107	O
HCO3	O
-	O
24	O
AnGap	O
-	O
13	O
[	O
**	O
2111-3-26	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
ALT	O
-	O
21	O
AST	O
-	O
19	O
AlkPhos	O
-	O
86	O
Amylase	O
-	O
56	O
TotBili	O
-	O
0.3	O
[	O
**	O
2111-3-26	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
Mg	O
-	O
2.0	O
[	O
**	O
2111-3-27	O
**	O
]	O
07:54	O
AM	O
BLOOD	O
Cortsol	O
-	O
9.9	O
[	O
**	O
2111-3-27	O
**	O
]	O
10:01	O
AM	O
BLOOD	O
Cortsol	O
-	O
19.8	O
.	O
OTHER	O
DATA	O
:	O
[	O
**	O
3	O
-	O
27	O
**	O
]	O
ECHO	O
-	O
1	O
.	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
2	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
3	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
4	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
5	O
.	O
The	O
aortic	O
root	O
is	O
moderately	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
6	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
7	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
8	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
[	O
**	O
3	O
-	O
26	O
**	O
]	O
CT	O
1	O
.	O
Right	O
hypodense	O
subcentimeter	O
renal	O
structure	O
,	O
that	O
may	O
represent	O
a	O
cyst	O
,	O
but	O
a	O
comparison	O
with	O
outside	O
CTs	O
is	O
recommended	O
.	O
Alternatively	O
,	O
an	O
MR	O
can	O
be	O
performed	O
to	O
evaluate	O
this	O
lesion	O
.	O
2	O
.	O
Densely	O
atherosclerotic	O
aorta	O
,	O
but	O
no	O
evidence	O
for	O
acute	O
aortic	O
injury	O
.	O
Within	O
the	O
distal	O
aorta	O
is	O
a	O
very	O
small	O
focal	O
area	O
of	O
dilation	O
with	O
a	O
possible	O
ulcerated	O
plaque	O
.	O
Brief	O
Hospital	O
Course	O
:	O
BRIEF	O
OVERVIEW	O
:	O
74	O
-	O
year	O
-	O
old	O
male	O
xfr	O
'd	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
eval	O
for	O
CT	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
for	O
aortic	O
aneurysm	O
but	O
not	O
a	O
current	O
candidate	O
.	O
Had	O
a	O
syncopal	O
episode	O
in	O
the	O
CSRU	O
and	O
transfered	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
.	O
On	O
history	O
,	O
he	O
was	O
found	O
to	O
have	O
had	O
orthostatic	B-Ade
symptoms	I-Ade
at	O
home	O
over	O
the	O
past	O
~	O
1	O
month	O
since	O
starting	O
flomax	I-Drug
.	O
He	O
had	O
self	O
d	O
/	O
c	O
'd	O
this	O
medication	O
and	O
felt	O
better	O
.	O
He	O
was	O
on	O
nitro	I-Drug
gtt	O
in	O
the	O
CSRU	O
and	O
was	O
urinating	O
when	O
his	O
syncope	O
occurred	O
there	O
.	O
On	O
xfr	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
he	O
had	O
mild	O
orthostatic	B-Reason
hypotension	I-Reason
that	O
was	O
symptomatic	O
originally	O
,	O
but	O
asx	O
after	O
a	O
fluid	I-Drug
bolus	O
of	O
1L	O
.	O
The	O
following	O
day	O
he	O
was	O
symptom	O
free	O
.	O
The	O
leading	O
dx	O
for	O
his	O
syncope	I-Ade
was	O
felt	O
to	O
be	O
medication	O
effect	O
from	O
flomax	I-Drug
/	O
nitroglycerin	I-Drug
.	O
Other	O
diagnostic	O
possibilities	O
included	O
bradycardia	I-Ade
(	O
?	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
amiodarone	I-Drug
)	O
,	O
volume	O
depletion	O
,	O
vasovagal	O
syncope	O
(	O
micturition	O
)	O
.	O
Adrenal	O
fxn	O
was	O
found	O
to	O
be	O
normal	O
on	O
a	O
cosyntropin	I-Drug
stim	O
test	O
.	O
He	O
was	O
felt	O
to	O
be	O
stable	O
at	O
this	O
point	O
in	O
the	O
workup	O
and	O
was	O
transferred	O
to	O
the	O
medical	O
floor	O
for	O
further	O
workup	O
.	O
On	O
the	O
floor	O
,	O
the	O
following	O
problems	O
were	O
addressed	O
.	O
.	O
1	O
.	O
Dizziness	O
-	O
His	O
dizziness	O
was	O
worked	O
up	O
as	O
above	O
in	O
the	O
ICU	O
.	O
He	O
had	O
a	O
normal	O
ECHO	O
w	O
/	O
out	O
significant	O
valvular	O
disease	O
and	O
was	O
monitored	O
on	O
telemetry	O
w	O
/	O
out	O
events	O
noted	O
.	O
He	O
was	O
able	O
to	O
ambulate	O
w	O
/	O
out	O
any	O
problems	O
on	O
the	O
floor	O
and	O
was	O
d	O
/	O
c	O
on	O
the	O
day	O
after	O
admission	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
patient	O
request	O
.	O
Further	O
diagnostic	O
possibilities	O
that	O
could	O
be	O
followed	O
up	O
as	O
an	O
outpatient	O
include	O
:	O
1	O
)	O
CT	O
/	O
MRI	O
of	O
head	O
to	O
exclude	O
stroke	O
in	O
setting	O
of	O
stenting	O
of	O
calcific	O
coronary	O
arteries	O
2	O
)	O
tilt	O
table	O
test	O
3	O
)	O
Neurological	O
evaluation	O
for	O
more	O
rare	O
causes	O
such	O
as	O
shy	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
syndrome	O
.	O
.	O
2	O
.	O
CAD	O
-	O
continued	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
4532	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
in	O
setting	O
of	O
recent	O
RCA	O
stenting	O
.	O
held	O
off	O
on	O
bblocker	I-Drug
or	O
ace	I-Drug
considering	O
his	O
orthostatic	O
hypotension	O
but	O
these	O
could	O
be	O
considered	O
as	O
an	O
outpatient	O
if	O
his	O
symptoms	O
resolve	O
.	O
3	O
.	O
Afib	I-Reason
-	O
should	O
be	O
on	O
coumadin	I-Drug
based	O
on	O
ACC	O
recommendations	O
;	O
defer	O
decision	O
to	O
anticoagulate	O
to	O
PCP	O
.	O
4	O
.	O
Aneurysm	O
-	O
evaluated	O
by	O
surgery	O
and	O
decided	O
to	O
not	O
pursue	O
surgery	O
at	O
this	O
time	O
.	O
Medications	O
on	O
Admission	O
:	O
amio	I-Drug
200	O
'	O
zocor	I-Drug
40	O
'	O
mvi	I-Drug
glucosamine	I-Drug
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
ambien	I-Drug
10	O
nexium	I-Drug
75	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4532	O
**	O
]	O
75	O
Discharge	O
Medications	O
:	O
1	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Simvastatin	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Multivitamin	I-Drug
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Zolpidem	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O
7	O
.	O
Nexium	I-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Orthostatic	O
hypotension	O
likely	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
medication	O
side	O
effect	O
.	O
Secondary	O
:	O
CAD	O
,	O
HTN	O
,	O
hypercholesterolemia	O
Discharge	O
Condition	O
:	O
Stable	O
;	O
tolerating	O
PO	O
and	O
ambulating	O
independently	O
Discharge	O
Instructions	O
:	O
Please	O
take	O
your	O
medications	O
as	O
directed	O
Please	O
keep	O
your	O
follow	O
-	O
up	O
appointments	O
Please	O
return	O
to	O
the	O
ER	O
or	O
call	O
your	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
:	O
1	O
.	O
chest	O
pain	O
2	O
.	O
fever	O
to	O
101	O
3	O
.	O
shortness	O
of	O
breath	O
4	O
.	O
fainting	O
/	O
severe	O
dizziness	O
Please	O
make	O
sure	O
to	O
not	O
rise	O
quickly	O
from	O
a	O
sitting	O
or	O
lying	O
position	O
.	O
When	O
awaking	O
in	O
the	O
morning	O
or	O
getting	O
up	O
at	O
night	O
,	O
please	O
remain	O
sitting	O
for	O
1	O
-	O
2	O
minutes	O
before	O
rising	O
to	O
a	O
standing	O
position	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
176	O
**	O
]	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
weeks	O
Completed	O
by	O
:[	O
**	O
2111-3-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2125-10-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2125-12-21	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2047-4-26	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Adhesive	O
Tape	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4679	O
**	O
]	O
Chief	O
Complaint	O
:	O
Esophageal	O
cancer	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2125-10-10	O
**	O
]	O
1	O
.	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
12351	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
esophagectomy	O
.	O
2	O
.	O
Buttressing	O
of	O
intrathoracic	O
anastomosis	O
with	O
thymic	O
fat	O
pad	O
.	O
3	O
.	O
Laparoscopic	O
jejunostomy	O
.	O
4	O
.	O
Therapeutic	O
bronchoscopy	O
.	O
5	O
.	O
Esophagogastroduodenoscopy	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
78	O
year	O
-	O
old	O
male	O
who	O
's	O
recent	O
endoscopic	O
mucosal	O
resection	O
revealed	O
intramucosal	O
adenocarcinoma	O
that	O
was	O
invading	O
into	O
the	O
lamina	O
propria	O
and	O
was	O
focally	O
present	O
at	O
the	O
cauterized	O
margin	O
.	O
He	O
is	O
being	O
admitted	O
for	O
minimal	O
invasive	O
esophagectomy	O
with	O
Laparoscopic	O
jejunostomy	O
.	O
Past	O
Medical	O
History	O
:	O
GERD	O
Sleep	O
apnea	O
on	O
CPAP	O
Arthritis	O
Diverticulosis	O
Prostate	O
CA	O
s	O
/	O
p	O
surgery	O
[	O
**	O
2116	O
**	O
]	O
Back	O
pain	O
/	O
surgies	O
x	O
3	O
over	O
25	O
years	O
Appendectomy	O
Cholecystectomy	O
Social	O
History	O
:	O
Widower	O
lives	O
alone	O
,	O
Tobacco	O
:	O
quit	O
40	O
years	O
ago	O
Family	O
History	O
:	O
non-contributory	O
Physical	O
Exam	O
:	O
VS	O
:	O
Tc	O
99.1	O
,	O
111/74	O
(	O
off	O
pressors	O
since	O
AM	O
)	O
,	O
88	O
,	O
A	O
/	O
c	O
mode	O
(	O
intubated	O
)	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
sclerae	O
anicteric	O
,	O
neck	O
supple	O
,	O
MMM	O
,	O
no	O
ulcers	O
/	O
lesions	O
/	O
thrush	O
.	O
NG	O
tube	O
,	O
small	O
amount	O
of	O
brown	O
fluid	O
(	O
sunction	O
mode	O
)	O
CV	O
:	O
Distant	O
S1	O
/	O
S2	O
,	O
no	O
murmurs	O
,	O
PULM	O
:	O
Decreased	O
BS	O
BL	O
,	O
rhonchi	O
diffuse	O
Chest	O
tube	O
right	O
lower	O
hemithorax	O
and	O
incision	O
site	O
.	O
Appears	O
clean	O
.	O
No	O
d	O
/	O
c	O
GI	O
:	O
Distended	O
Abd	O
,	O
hypoactive	O
sounds	O
,	O
not	O
rigid	O
.	O
Endoscopy	O
incision	O
clean	O
.	O
(	O
4	O
)	O
Scrotal	O
edema	O
EXT	O
:	O
warm	O
and	O
well	O
perfused	O
,	O
2	O
+	O
DP	O
pulses	O
palpable	O
bilaterally	O
LYMPH	O
:	O
no	O
cervical	O
,	O
axillary	O
,	O
or	O
inguinal	O
lymphadenopathy	O
SKIN	O
:	O
no	O
rashes	O
,	O
no	O
jaundice	O
.	O
Pertinent	O
Results	O
:	O
CT	O
chest	O
/	O
abd	O
/	O
pelvis	O
[	O
**	O
2125-11-2	O
**	O
]	O
:	O
CONCLUSION	O
:	O
1	O
.	O
Relatively	O
large	O
rim	O
-	O
enhancing	O
collection	O
in	O
the	O
right	O
thorax	O
wall	O
adjacent	O
to	O
the	O
thoracotomy	O
site	O
.	O
2	O
.	O
No	O
clear	O
sign	O
of	O
ongoing	O
leak	O
.	O
CT	O
Chest	O
[	O
**	O
2125-11-13	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Stable	O
appearance	O
of	O
periesophageal	O
fluid	O
following	O
stent	O
placement	O
.	O
Drains	O
remain	O
within	O
the	O
pleural	O
space	O
,	O
with	O
no	O
interval	O
increase	O
in	O
periesophageal	O
fluid	O
.	O
No	O
periesophageal	O
abscess	O
.	O
Adjacent	O
compressive	O
atelectasis	O
.	O
2	O
.	O
Interval	O
near	O
resolution	O
of	O
left	O
pleural	O
effusion	O
.	O
3	O
.	O
Multifocal	O
atelectasis	O
.	O
4	O
.	O
Exam	O
not	O
optimized	O
for	O
assessment	O
of	O
tracheomalacia	O
.	O
5	O
.	O
Colonic	O
diverticulosis	O
without	O
diverticulitis	O
.	O
CT	O
Chest	O
/	O
Abd	O
/	O
Pelvis	O
[	O
**	O
2125-12-6	O
**	O
]	O
:	O
1	O
.	O
Slightly	O
decreased	O
intrathoracic	O
fluid	O
collection	O
with	O
decreased	O
passive	O
atelectasis	O
.	O
2	O
.	O
Resolution	O
of	O
extrathoracic	O
fluid	O
collection	O
.	O
3	O
.	O
No	O
additional	O
source	O
found	O
to	O
explain	O
the	O
patient	O
's	O
spiking	O
fevers	O
.	O
4	O
.	O
Endotracheal	O
tube	O
3.5	O
cm	O
above	O
the	O
carina	O
.	O
NG	O
tube	O
with	O
the	O
distal	O
tip	O
in	O
a	O
subdiaphragmatic	O
position	O
within	O
the	O
stomach	O
.	O
Jejunostomy	O
tube	O
in	O
the	O
appropriate	O
place	O
with	O
contrast	O
opacifying	O
bowel	O
distal	O
to	O
the	O
tip	O
of	O
this	O
tube	O
.	O
Pathology	O
[	O
**	O
2125-10-10	O
**	O
]	O
:	O
1	O
.	O
Lymph	O
node	O
,	O
level	O
7	O
(	O
A-B	O
)	O
:	O
Fragments	O
of	O
lymph	O
node	O
,	O
no	O
carcinoma	O
seen	O
.	O
2	O
.	O
Esophagus	O
and	O
stomach	O
,	O
esophagogastrectomy	O
(	O
C	O
-	O
X	O
)	O
:	O
Focal	O
intramucosal	O
adenocarcinoma	O
,	O
See	O
Synoptic	O
Report	O
.	O
3	O
.	O
Gastric	O
donut	O
(	O
Y	O
)	O
:	O
No	O
carcinoma	O
seen	O
.	O
4	O
.	O
Esophageal	O
donut	O
(	O
Z	O
)	O
:	O
No	O
carcinoma	O
seen	O
.	O
5	O
.	O
Stomach	O
,	O
gastric	O
fundus	O
(	O
AA	O
)	O
:	O
No	O
carcinoma	O
seen	O
.	O
Echo	O
[	O
**	O
2125-12-7	O
**	O
]	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
(	O
?	O
#	O
)	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Grossly	O
preserved	O
biventricular	O
systolic	O
function	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
Limited	O
study	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
78	O
year	O
-	O
old	O
male	O
admitted	O
following	O
successful	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
12351	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
esophagectomy	O
,	O
Buttressing	O
of	O
intrathoracic	O
anastomosis	O
with	O
thymic	O
fat	O
pad	O
Laparoscopic	O
jejunostomy	O
,	O
Therapeutic	O
bronchoscopy	O
,	O
Esophagogastroduodenoscopy	O
.	O
He	O
was	O
transferred	O
to	O
the	O
SICU	O
intubated	O
and	O
sedated	O
,	O
NGT	O
,	O
right	O
chest	O
tube	O
,	O
JP	O
drain	O
and	O
Epidural	O
for	O
pain	O
.	O
He	O
was	O
extubated	O
on	O
POD1	O
,	O
placed	O
on	O
3L	O
NC	O
and	O
humidified	O
face	O
tent	O
with	O
oxygen	I-Drug
saturations	O
>	O
90	O
%	O
.	O
His	O
oxygen	O
requirement	O
increased	O
requiring	O
aggressive	O
pulmonary	O
toilet	O
,	O
nebs	O
,	O
and	O
chest	O
PT	O
.	O
Initially	O
he	O
was	O
hypovolemic	O
,	O
fluid	O
challenge	O
was	O
given	O
with	O
a	O
good	O
response	O
.	O
Once	O
his	O
respiratory	O
status	O
improved	O
he	O
transferred	O
to	O
the	O
floor	O
on	O
[	O
**	O
2125-10-15	O
**	O
]	O
.	O
On	O
POD	O
6	O
(	O
[	O
**	O
10	O
-	O
16	O
**	O
]	O
)	O
barium	I-Drug
swallow	O
negative	O
for	O
leak	O
and	O
diet	O
advanced	O
to	O
clears	O
which	O
were	O
well	O
tolerated	O
.	O
On	O
POD	O
8	O
(	O
[	O
**	O
10	O
-	O
18	O
**	O
]	O
)	O
,	O
pt	O
experienced	O
acute	O
R	O
sided	O
CP	O
and	O
RUQ	O
abd	O
pain	O
,	O
hypoxia	O
,	O
and	O
diaphoresis	O
.	O
CXR	O
demonstrated	O
ptx	O
.	O
DART	O
placed	O
with	O
bilious	O
drainage	O
,	O
EGD	O
showed	O
necrosis	O
at	O
anastomotic	O
site	O
.	O
Pt	O
returned	O
to	O
OR	O
for	O
debridement	O
gastric	O
conduit	O
and	O
repair	O
POD	O
9	O
(	O
[	O
**	O
10	O
-	O
19	O
**	O
]	O
)	O
and	O
admitted	O
to	O
TSICU	O
postoperatively	O
with	O
CTx3	O
,	O
JPx2	O
.	O
Pt	O
underwent	O
EGD	O
POD	O
14	O
(	O
[	O
**	O
10	O
-	O
24	O
**	O
]	O
)	O
with	O
healthy	O
-	O
appearing	O
anastomosis	O
.	O
On	O
POD	O
19	O
(	O
[	O
**	O
10	O
-	O
29	O
**	O
]	O
)	O
pt	O
undersent	O
percutaneous	O
tracheostomy	O
placement	O
.	O
Pt	O
noted	O
to	O
have	O
persistent	O
JP	O
drainage	O
.	O
On	O
POD	O
30	O
(	O
[	O
**	O
11	O
-	O
9	O
**	O
]	O
)	O
,	O
pt	O
underwent	O
esophageal	O
stenting	O
and	O
NGT	O
was	O
discontinued	O
.	O
JP	O
output	O
transiently	O
decreased	O
but	O
subsequently	O
increased	O
after	O
stent	O
placement	O
.	O
On	O
POD	O
46	O
(	O
[	O
**	O
11	O
-	O
25	O
**	O
]	O
)	O
pt	O
underwent	O
EGD	O
which	O
demonstrated	O
good	O
stent	O
position	O
and	O
endoscopically	O
placed	O
NGT	O
.	O
He	O
continued	O
to	O
have	O
respiratory	O
distress	O
requiring	O
mechanical	O
ventilation	O
,	O
with	O
tachypnea	O
and	O
agitation	O
with	O
any	O
withdrawal	O
of	O
sedation	O
.	O
His	O
hospital	O
course	O
remained	O
stable	O
until	O
[	O
**	O
2125-12-18	O
**	O
]	O
,	O
requiring	O
sedation	O
and	O
mechanical	O
ventilation	O
.	O
On	O
[	O
**	O
2125-12-19	O
**	O
]	O
,	O
the	O
family	O
requested	O
no	O
further	O
interventions	O
,	O
and	O
that	O
he	O
be	O
allowed	O
to	O
pass	O
if	O
he	O
began	O
to	O
worsen	O
.	O
On	O
[	O
**	O
2125-12-21	O
**	O
]	O
,	O
with	O
the	O
family	O
at	O
bedside	O
,	O
his	O
ventilation	O
was	O
turned	O
off	O
,	O
and	O
he	O
expired	O
at	O
11:30	O
am	O
.	O
Medications	O
on	O
Admission	O
:	O
allopurinol	B-Drug
300	O
mg	O
daily	O
,	O
amlodipine	B-Drug
10	O
mg	O
daily	O
,	O
pravastatin	I-Drug
,	O
terazosin	I-Drug
10	O
mg	O
qhs	O
,	O
omeprazole	I-Drug
40	O
mg	O
,	O
ranitidine	I-Drug
,	O
tamsulosin	I-Drug
0.4	O
mg	O
qhs	O
,	O
finasteride	B-Drug
5	O
mg	O
daijly	O
,	O
percocet	I-Drug
,	O
aspirin	B-Drug
81	O
mg	O
daily	O
,	O
CPAP	O
.	O
Discharge	O
Medications	O
:	O
None	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Esophageal	O
cancer	O
.	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
None	O
Followup	O
Instructions	O
:	O
None	O
Completed	O
by	O
:[	O
**	O
2125-12-21	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2129-12-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2130-1-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2085-7-9	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Morphine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1646	O
**	O
]	O
Chief	O
Complaint	O
:	O
OSH	O
transfer	O
for	O
alcoholic	O
pancreatitis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
PICC	O
placement	O
NGT	O
placement	O
post	O
pyloric	O
by	O
floroscopy	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
12130	O
**	O
]	O
is	O
a	O
44	O
year	O
old	O
man	O
with	O
ETOH	O
abuse	O
and	O
Crohns	O
'	O
disease	O
initially	O
admitted	O
to	O
OSH	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
with	O
abdominal	O
pain	O
radiating	O
to	O
back	O
,	O
nausea	O
and	O
vomiting	O
x	O
1	O
week	O
,	O
which	O
became	O
progressively	O
worse	O
over	O
24	O
hours	O
PTA	O
found	O
to	O
have	O
acute	O
pancreatitis	O
with	O
initial	O
amylase	O
>	O
3000	O
and	O
CT	O
with	O
evidence	O
of	O
necrotizing	B-Reason
pancreatitis	I-Reason
.	O
At	O
OSH	O
,	O
he	O
was	O
treated	O
with	O
bowel	O
rest	O
,	O
IVF	I-Drug
and	O
started	O
on	O
primaxin	I-Drug
.	O
Course	O
was	O
complicated	O
by	O
ETOH	O
withdrawal	I-Reason
and	O
DTs	I-Reason
so	O
he	O
was	O
transferred	O
to	O
ICU	O
there	O
and	O
started	O
on	O
an	O
ativan	I-Drug
drip	O
which	O
was	O
uptitrated	O
to	O
15mg	O
/	O
hr	O
.	O
He	O
is	O
being	O
transferred	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
management	O
,	O
?	O
need	O
for	O
surgical	O
intervention	O
.	O
Course	O
also	O
c	O
/	O
b	O
fevers	O
to	O
101	O
and	O
positive	O
blood	O
cx	O
with	O
GPCs	O
in	O
clusters	O
on	O
[	O
**	O
2129-12-28	O
**	O
]	O
(	O
2	O
bottles	O
of	O
coag	O
neg	O
staph	O
,	O
sensitive	O
to	O
cefazolin	I-Drug
,	O
CTX	I-Drug
,	O
cipro	I-Drug
/	O
levo	I-Drug
,	O
clinda	I-Drug
,	O
azithro	I-Drug
,	O
oxacillin	I-Drug
,	O
bactrim	I-Drug
,	O
tetra	I-Drug
,	O
and	O
vanc	I-Drug
)	O
.	O
He	O
reportedly	O
had	O
been	O
started	O
on	O
TPN	I-Drug
day	O
prior	O
to	O
transfer	O
via	O
PICC	O
.	O
.	O
VS	O
prior	O
to	O
transfer	O
:	O
T	O
:	O
101	O
rectal	O
HR	O
:	O
110s	O
BP	O
:	O
120-130/70	O
-	O
80	O
RR	O
:	O
30s	O
O2	I-Drug
sat	O
:	O
99	O
-	O
100	O
%	O
2L	O
.	O
Upon	O
arrival	O
to	O
the	O
ICU	O
a	O
complete	O
ROS	O
could	O
not	O
be	O
obtained	O
.	O
Prior	O
to	O
transfer	O
to	O
the	O
medical	O
floor	O
the	O
patient	O
was	O
able	O
to	O
state	O
that	O
he	O
did	O
not	O
have	O
CP	O
,	O
SOB	O
,	O
dysuria	O
,	O
headache	O
,	O
neurologic	O
changes	O
,	O
visual	O
changes	O
prior	O
to	O
presentation	O
.	O
He	O
had	O
pain	O
in	O
his	O
abdomen	O
with	O
defecation	O
which	O
is	O
consistent	O
with	O
his	O
Crohn	O
's	O
disease	O
.	O
.	O
Per	O
discussion	O
with	O
family	O
,	O
patient	O
had	O
denied	O
any	O
other	O
complaints	O
prior	O
to	O
admission	O
other	O
than	O
right	O
shoulder	O
pain	O
which	O
was	O
attributed	O
to	O
rotator	O
cuff	O
tear	O
and	O
was	O
recently	O
being	O
worked	O
up	O
with	O
MRI	O
.	O
He	O
had	O
approximately	O
1	O
episode	O
of	O
emesis	O
per	O
week	O
for	O
3	O
weeks	O
PTA	O
and	O
had	O
multiple	O
episodes	O
nonbloody	O
bilious	O
emesis	O
on	O
day	O
of	O
admission	O
with	O
epigastric	O
abdominal	O
pain	O
as	O
above	O
.	O
Had	O
denied	O
fevers	O
,	O
chills	O
,	O
diarrhea	O
,	O
joint	O
pains	O
,	O
headache	O
or	O
any	O
other	O
complaints	O
.	O
Denies	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
.	O
While	O
in	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
a	O
rectal	O
tube	O
placed	O
for	O
frequent	O
stooling	O
.	O
Two	O
cidffs	O
have	O
been	O
negative	O
.	O
A	O
post	O
pyloric	O
feeding	O
tube	O
placed	O
and	O
he	O
started	O
tube	O
feeds	O
.	O
His	O
PICCL	O
was	O
d	O
/	O
c	O
'	O
ed	O
and	O
cultured	O
.	O
On	O
[	O
**	O
2129-12-31	O
**	O
]	O
he	O
developed	O
thrush	I-Reason
and	O
was	O
started	O
on	O
nystatin	I-Drug
.	O
While	O
in	O
the	O
ICU	O
his	O
mental	O
status	O
slowly	O
cleared	O
.	O
.	O
ROS	O
:	O
Currently	O
reports	O
[	O
**	O
12	O
-	O
28	O
**	O
]	O
pain	O
in	O
his	O
R	O
shoulder	O
c	O
/	O
w	O
rotator	O
cuff	O
tear	O
.	O
He	O
does	O
not	O
have	O
any	O
abdominal	O
pain	O
.	O
No	O
cp	O
/	O
sob	O
/	O
n	O
/	O
v.	O
+	O
Diarrhea	O
.	O
He	O
is	O
unclear	O
if	O
it	O
is	O
worse	O
than	O
his	O
usual	O
Crohn	O
's	O
but	O
his	O
family	O
does	O
.	O
[	O
**	O
2130-1-26	O
**	O
]	O
back	O
pain	O
.	O
He	O
reports	O
decreased	O
dexterity	O
of	O
his	O
fingers	O
in	O
that	O
he	O
keeps	O
dropping	O
things	O
.	O
No	O
slurred	O
speech	O
or	O
other	O
focal	O
weakness	O
.	O
All	O
other	O
ROS	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
Crohn	O
's	O
Disease	O
ETOH	O
abuse	O
Marijuana	O
abuse	O
Right	O
shoulder	O
pain	O
/	O
rotator	O
cuff	O
tear	O
Social	O
History	O
:	O
Lives	O
with	O
girlfriend	O
.	O
Divorced	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
3	O
children	O
(	O
2	O
sons	O
,	O
one	O
10	O
year	O
old	O
daughter	O
)	O
.	O
Per	O
friends	O
and	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
40764	O
**	O
]	O
,	O
drinks	O
1	O
pint	O
of	O
vodka	O
/	O
hard	O
liquor	O
per	O
day	O
and	O
2	O
glasses	O
-	O
1	O
bottle	O
of	O
wine	O
daily	O
.	O
No	O
prior	O
h	O
/	O
o	O
withdrawal	O
.	O
Also	O
reprots	O
daily	O
marijuana	O
use	O
.	O
No	O
other	O
drug	O
use	O
.	O
Occ	O
cigarettes	O
.	O
No	O
regular	O
tobacco	O
abuse	O
.	O
He	O
works	O
as	O
an	O
electrician	O
.	O
Family	O
History	O
:	O
Father	O
died	O
of	O
a	O
cerebral	O
anneurysm	O
.	O
Mother	O
is	O
good	O
health	O
.	O
MGF	O
had	O
DM	O
.	O
His	O
second	O
cousin	O
has	O
[	O
**	O
Name	O
(	O
NI	O
)	O
4522	O
**	O
]	O
disease	O
.	O
No	O
family	O
h	O
/	O
o	O
pancreatitis	O
.	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
Tm	O
=	O
101	O
,	O
Tc	O
=	O
99.2	O
HRm	O
=	O
91	O
-	O
105	O
:	O
BP	O
:	O
Pc	O
=	O
105	O
:	O
R	O
:	O
18	O
O2	I-Drug
:	O
100	O
%	O
RA	O
Fluid	O
balance	O
:	O
I	O
/	O
O	O
=	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
86327	O
**	O
]	O
LOS	O
=	O
+	O
3.4	O
L	O
.	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
moist	O
MM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
mildly	O
distended	O
,	O
decreased	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
+	O
foley	O
draining	O
clear	O
yellow	O
urine	O
Rectal	O
:	O
rectal	O
tube	O
draining	O
dark	O
liquid	O
stool	O
.	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
R	O
shoulder	O
without	O
erythema	O
or	O
wamth	O
.	O
No	O
pain	O
with	O
active	O
and	O
passive	O
ROM	O
.	O
Neuro	O
:	O
A	O
&	O
O	O
x3	O
.	O
Able	O
to	O
DOW	O
backwards	O
.	O
5/5	O
strength	O
in	O
upper	O
and	O
lower	O
extremities	O
b	O
/	O
l.	O
2	O
+	O
biceps	O
and	O
patella	O
DTRs	O
.	O
**************	O
at	O
discharge	O
:	O
patient	O
awake	O
,	O
alert	O
,	O
mental	O
status	O
clear	O
.	O
still	O
generally	O
weak	O
and	O
walking	O
with	O
a	O
walker	O
.	O
NGT	O
in	O
place	O
.	O
Not	O
tremulous	O
or	O
with	O
any	O
s	O
/	O
s	O
of	O
etoh	O
w	O
/	O
d.	O
abd	O
tender	O
in	O
epigastrim	O
with	O
some	O
firmness	O
,	O
but	O
no	O
r	O
/	O
g.	O
Pertinent	O
Results	O
:	O
OSH	O
Labs	O
:	O
WBC	O
15.2	O
HCT	O
50.4	O
Lipase	O
>	O
3000	O
,	O
AST	O
2	O
ALT	O
249	O
T	O
Bili	O
1.4	O
Na	O
145	O
K	O
3.4	O
BUN	O
5	O
Cr	O
0.8	O
Phos	O
1.9	O
ca	O
7.8	O
WBC	O
30.6	O
HGB	O
12.8	O
PLT	O
168	O
.	O
LDL	O
42	O
TG	O
202	O
Micro	O
:	O
OSH	O
:	O
Blood	O
cx	O
as	O
above	O
.	O
Blood	O
cultures	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
are	O
pending	O
.	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
WBC	O
-	O
16.8	O
*	O
RBC	O
-	O
4.43	O
*	O
Hgb	O
-	O
13.6	O
*	O
Hct	O
-	O
38.8	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
30.7	O
MCHC	O
-	O
35.0	O
RDW	O
-	O
13.1	O
Plt	O
Ct	O
-	O
283	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Neuts	O
-	O
88.5	O
*	O
Lymphs	O
-	O
6.0	O
*	O
Monos	O
-	O
3.3	O
Eos	O
-	O
2.0	O
Baso	O
-	O
0.2	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
PT	O
-	O
14.0	O
*	O
PTT	O
-	O
30.5	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Glucose	O
-	O
144	O
*	O
UreaN	O
-	O
9	O
Creat	O
-	O
0.7	O
Na	O
-	O
139	O
K	O
-	O
4.4	O
Cl	O
-	O
106	O
HCO3	O
-	O
19	O
*	O
AnGap	O
-	O
18	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
ALT	O
-	O
35	O
AST	O
-	O
31	O
LD	O
(	O
LDH	O
)	O
-	O
480	O
*	O
AlkPhos	O
-	O
97	O
TotBili	O
-	O
0.8	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Albumin	O
-	O
3.1	O
*	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
3.6	O
Mg	O
-	O
2.2	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Osmolal	O
-	O
293	O
[	O
**	O
2129-12-29	O
**	O
]	O
04:57	O
PM	O
BLOOD	O
Vanco	O
-	O
4.6	O
*	O
[	O
**	O
2129-12-29	O
**	O
]	O
05:42	O
PM	O
BLOOD	O
Type	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
pO2	O
-	O
64	O
*	O
pCO2	O
-	O
30	O
*	O
pH	O
-	O
7.47	O
*	O
calTCO2	O
-	O
22	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2129-12-29	O
**	O
]	O
05:42	O
PM	O
BLOOD	O
Lactate	O
-	O
1.6	O
REPORTS	O
:	O
CXR	O
[	O
**	O
2129-12-29	O
**	O
]	O
:	O
Lung	O
volumes	O
are	O
extremely	O
low	O
exaggerating	O
vascular	O
congestion	O
in	O
the	O
lungs	O
and	O
mediastinum	O
though	O
there	O
may	O
be	O
volume	O
overload	O
.	O
Discrete	O
opacification	O
at	O
the	O
left	O
lung	O
base	O
is	O
probably	O
atelectasis	O
.	O
Pleural	O
effusions	O
are	O
small	O
if	O
any	O
.	O
Cardiac	O
silhouette	O
is	O
largely	O
obscured	O
by	O
the	O
high	O
diaphragm	O
but	O
not	O
grossly	O
dilated	O
.	O
No	O
pneumothorax	O
.	O
Left	O
PIC	O
catheter	O
passes	O
at	O
least	O
as	O
far	O
as	O
the	O
upper	O
right	O
atrium	O
,	O
obscured	O
beyond	O
that	O
by	O
overlying	O
EKG	O
leads	O
.	O
CXR	O
[	O
**	O
2130-1-1	O
**	O
]	O
:	O
FINDINGS	O
:	O
Radiodense	O
tip	O
of	O
feeding	O
tube	O
is	O
visualized	O
in	O
the	O
upper	O
to	O
mid	O
cervical	O
region	O
as	O
communicated	O
by	O
telephone	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Exam	O
is	O
otherwise	O
similar	O
to	O
recent	O
radiograph	O
of	O
two	O
days	O
earlier	O
.	O
CT	O
head	O
[	O
**	O
2130-1-1	O
**	O
]	O
:	O
FINDINGS	O
:	O
There	O
is	O
no	O
intracranial	O
hemorrhage	O
,	O
edema	O
,	O
mass	O
effect	O
,	O
shift	O
of	O
normally	O
midline	O
structures	O
,	O
or	O
acute	O
major	O
vascular	O
territorial	O
infarction	O
.	O
The	O
ventricles	O
and	O
sulci	O
are	O
prominent	O
,	O
likely	O
reflective	O
of	O
atrophy	O
.	O
Minimal	O
mucosal	O
thickening	O
of	O
the	O
ethmoid	O
air	O
cells	O
are	O
noted	O
bilaterally	O
.	O
Osseous	O
structures	O
reveal	O
no	O
evidence	O
of	O
fracture	O
.	O
IMPRESSION	O
:	O
No	O
acute	O
intracranial	O
process	O
.	O
CXR	O
PA	O
/	O
LAT	O
[	O
**	O
2130-1-1	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Small	O
left	O
pleural	O
effusion	O
with	O
adjacent	O
opacity	O
favoring	O
atelectasis	O
over	O
infectious	O
pneumonia	O
.	O
[	O
**	O
2129-12-29	O
**	O
]	O
ECG	O
Baseline	O
artifact	O
.	O
The	O
rhythm	O
is	O
most	O
likely	O
sinus	O
tachycardia	O
.	O
Non-specific	O
ST	O
-	O
T	O
wave	O
changes	O
.	O
Repeat	O
tracing	O
is	O
recommended	O
.	O
No	O
previous	O
tracing	O
available	O
for	O
comparison	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Assessment	O
and	O
Plan	O
:	O
44	O
year	O
old	O
man	O
with	O
ETOH	O
abuse	O
transferred	O
from	O
OSH	O
with	O
necrotizing	O
pancreatitis	O
,	O
ETOH	O
withdrawal	O
and	O
DTs	O
,	O
fever	O
and	O
GPC	O
bacteremia	O
.	O
.	O
#	O
.	O
Necrotizing	O
Pancreatitis	O
:	O
Patient	O
initially	O
presented	O
with	O
abdominal	O
pain	O
and	O
nausea	O
and	O
vomiting	O
with	O
lipase	O
>	O
3000	O
and	O
evidence	O
of	O
pancreatic	O
20	O
-	O
30	O
%	O
necrosis	O
on	O
CT	O
scan	O
.	O
US	O
without	O
stones	O
.	O
Surgery	O
evaluated	O
him	O
and	O
elected	O
for	O
conservative	O
management	O
.	O
With	O
high	B-Reason
fever	I-Reason
and	O
level	O
of	O
necrosis	I-Reason
,	O
meropenim	I-Drug
was	O
started	O
at	O
the	O
OSH	O
.	O
A	O
7	O
day	O
course	O
of	O
this	O
was	O
completed	O
.	O
His	O
abd	O
pain	O
is	O
now	O
mostly	O
resolved	O
.	O
He	O
has	O
developed	O
an	O
appetite	O
,	O
but	O
given	O
the	O
level	O
of	O
necrosis	O
seen	O
on	O
the	O
CT	O
scan	O
the	O
mild	O
DM	O
that	O
he	O
has	O
developed	O
it	O
was	O
recommended	O
by	O
surgery	O
that	O
he	O
get	O
jejunal	O
tube	O
feedings	O
for	O
at	O
least	O
another	O
week	O
.	O
After	O
that	O
time	O
,	O
clears	O
should	O
be	O
introduced	O
and	O
diet	O
advanced	O
,	O
and	O
if	O
not	O
tolerated	O
,	O
TF	O
resumed	O
.	O
He	O
is	O
followed	O
by	O
gastroenterology	O
,	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2523	O
**	O
]	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
86328	O
**	O
]	O
for	O
his	O
crohn	O
's	O
disease	O
and	O
she	O
will	O
follow	O
him	O
for	O
his	O
pancreatitis	O
as	O
well	O
.	O
Of	O
note	O
,	O
at	O
the	O
time	O
of	O
discharge	O
his	O
LFT	O
's	O
had	O
returned	O
to	O
[	O
**	O
Location	O
213	O
**	O
]	O
and	O
his	O
WBC	O
's	O
had	O
come	O
down	O
to	O
14	O
from	O
a	O
high	O
of	O
22	O
.	O
.	O
#	O
ETOH	B-Reason
Withdrawal	I-Reason
/	O
abuse	O
:	O
Patient	O
reportedly	O
agitated	O
at	O
OSH	O
secondary	O
to	O
ETOH	B-Reason
withdrawal	I-Reason
and	O
has	O
reported	O
heavy	O
daily	O
ETOH	O
intake	O
.	O
No	O
prior	O
h	O
/	O
o	O
withdrawal	O
but	O
has	O
been	O
in	O
active	O
withdrawal	O
there	O
on	O
ativan	I-Drug
drip	O
and	O
also	O
getting	O
haldol	I-Drug
for	O
agitation	I-Reason
.	O
Last	O
ETOH	O
[	O
**	O
12	O
-	O
22	O
**	O
]	O
or	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
.	O
Pt	O
arrived	O
to	O
the	O
ICU	O
with	O
significance	O
somnolence	I-Ade
,	O
minimally	O
responsive	O
but	O
protecting	O
his	O
airway	O
.	O
We	O
d	O
/	O
c	O
'd	O
ativan	I-Drug
drip	O
and	O
changed	O
to	O
valium	I-Drug
PO	O
as	O
tolerated	O
.	O
Pt	O
's	O
mental	O
status	O
significantly	O
improved	O
and	O
patient	O
became	O
more	O
coherent	O
.	O
CT	O
head	O
without	O
acute	O
changes	O
.	O
Continued	O
MVI	I-Drug
,	O
thiamine	I-Drug
,	O
folic	B-Drug
acid	I-Drug
.	O
Strongly	O
encouraged	O
ETOH	O
cessation	O
.	O
At	O
the	O
time	O
of	O
discharge	O
he	O
was	O
AAO	O
x	O
3	O
,	O
awake	O
,	O
alert	O
,	O
and	O
w	O
/	O
o	O
any	O
s	O
/	O
s	O
of	O
withdrawal	O
.	O
.	O
#	O
GPC	B-Reason
bacteremia	I-Reason
:	O
Most	O
likely	O
sources	O
include	O
catheter	O
related	O
bloodstream	O
infection	O
given	O
PICC	O
line	O
given	O
TPN	I-Drug
.	O
Treated	O
with	O
vanco	I-Drug
and	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2830	O
**	O
]	O
for	O
now	O
while	O
awaiting	O
speciation	O
and	O
sensitivities	O
,	O
that	O
returned	O
as	O
pansensative	B-Reason
coag	I-Reason
neg	I-Reason
staph	I-Reason
.	O
He	O
was	O
given	O
ceftriaxone	I-Drug
to	O
complete	O
a	O
2	O
week	O
course	O
to	O
end	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
.	O
A	O
midline	O
was	O
placed	O
for	O
this	O
which	O
should	O
be	O
removed	O
after	O
abx	I-Drug
therapy	O
is	O
complete	O
.	O
.	O
#	O
Fever	O
/	O
leukocytosis	O
:	O
Likely	O
multifactorial	O
secondary	O
to	O
pancreatitis	O
and	O
bacteremia	O
.	O
last	O
check	O
14	O
.	O
.	O
#B12	O
deficiency	I-Reason
:	O
The	O
patient	O
arrived	O
to	O
our	O
institution	O
on	O
daily	O
B12	I-Drug
injections	O
,	O
presumably	O
from	O
a	O
newly	O
diagnosed	O
B12	O
deficiency	O
.	O
he	O
received	O
1	O
week	O
of	O
daily	O
injections	O
,	O
planning	O
for	O
1	O
month	O
of	O
qweek	O
followed	O
by	O
qmonth	O
afterwards	O
.	O
.	O
#Diarrhea	O
:	O
while	O
on	O
zosyn	I-Drug
,	O
the	O
patient	O
had	O
severe	O
diarrhea	O
.	O
infectious	O
w	O
/	O
u	O
neg	O
.	O
diarrhea	O
stopped	O
.	O
.	O
#crohn	O
's	I-Reason
disease	I-Reason
:	O
No	O
issues	O
.	O
His	O
mesalamine	I-Drug
was	O
held	O
while	O
sick	O
,	O
but	O
was	O
restarted	O
.	O
.	O
#Fe	O
deficiency	I-Reason
anemia	I-Reason
:	O
was	O
also	O
noticed	O
to	O
have	O
low	O
Tsat	O
with	O
fe	O
17	O
TIBC	O
190	O
.	O
Ferritin	O
high	O
from	O
inflammation	O
.	O
did	O
not	O
start	O
on	O
iron	I-Drug
tabs	O
given	O
GI	O
issues	O
,	O
but	O
when	O
stable	O
should	O
resume	O
this	O
.	O
Guaic	O
was	O
negative	O
.	O
.	O
#diabetes	O
:	I-Reason
likely	I-Reason
pancreatitis	I-Reason
related	I-Reason
.	O
q6	O
FS	O
while	O
on	O
TF	O
with	O
insulin	I-Drug
SS	O
.	O
Hopefully	O
with	O
not	O
require	O
DM	O
therapy	O
after	O
discharge	O
.	O
Medications	O
on	O
Admission	O
:	O
Home	O
medications	O
:	O
Lialda	I-Drug
1.2	O
g	O
2	O
tablets	O
daily	O
Percocet	I-Drug
prn	O
Medications	O
prior	O
to	O
Transfer	O
:	O
Clonidine	I-Drug
patch	O
0.3	O
mg	O
transdermal	O
q	O
week	O
TPN	B-Drug
with	I-Drug
fat	O
emulsion	O
Heparin	I-Drug
5000	O
units	O
SQ	O
TID	O
Primaxin	I-Drug
500	O
mg	O
IV	O
q	O
day	O
Ativan	I-Drug
drip	O
at	O
15mg	O
/	O
hr	O
Lopressor	I-Drug
5	O
mg	O
IV	O
q6	O
hours	O
Protonix	I-Drug
40	O
mg	O
IV	O
BID	O
Vanco	I-Drug
1g	O
IV	O
q12	O
day	O
1	O
[	O
**	O
2129-12-28	O
**	O
]	O
B12	I-Drug
1000mcg	O
IM	O
q24	O
hours	O
tylenol	I-Drug
,	O
benadryl	I-Drug
,	O
haldol	I-Drug
,	O
dilaudid	I-Drug
,	O
ativan	I-Drug
,	O
reglan	I-Drug
,	O
zofran	I-Drug
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Lialda	I-Drug
1.2	O
g	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Cyanocobalamin	I-Drug
1,000	O
mcg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
dose	O
Injection	O
once	O
a	O
week	O
for	O
4	O
weeks	O
:	O
then	O
1	O
q	O
month	O
.	O
4	O
.	O
Insulin	I-Drug
Regular	O
Human	O
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
regular	I-Drug
insulin	O
SS	O
q6	O
while	O
on	O
Tube	O
feedings	O
Injection	O
every	O
six	O
(	O
6	O
)	O
hours	O
.	O
5	O
.	O
Ceftriaxone	I-Drug
in	O
Dextrose,Iso	O
-	O
os	O
1	O
gram	O
/	O
50	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
GM	O
Intravenous	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
7	O
days	O
.	O
6	O
.	O
Ondansetron	I-Drug
HCl	O
(	O
PF	O
)	O
4	O
mg	O
/	O
2	O
mL	O
Solution	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
mg	O
Injection	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
7	O
.	O
Hydromorphone	I-Drug
(	O
PF	O
)	O
1	O
mg	O
/	O
mL	O
Syringe	O
Sig	O
:	O
0.25	O
-	O
0.5	O
mg	O
Injection	O
Q3H	O
(	O
every	O
3	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
:	O
(	O
patient	O
has	O
not	O
required	O
this	O
medication	O
in	O
>	O
48	O
hrs	O
)	O
.	O
8	O
.	O
Percocet	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
:	O
patient	O
was	O
taking	O
prior	O
to	O
admission	O
to	O
shoulder	B-Reason
injury	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
1293	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1294	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Discharge	O
Worksheet	O
-	O
Discharge	O
Diagnosis	O
-	O
Finalized	O
:[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
on	O
[	O
**	O
2130-1-3	O
**	O
]	O
@	O
1351	O
Primary	O
Diagnosis	O
:	O
577.0	O
PANCREATITIS	O
,	O
ACUTE	O
Secondary	O
Diagnosis	O
:	O
291.81	O
DRUG	O
WITHDRAWAL	O
,	O
ALCOHOL	O
Secondary	O
Diagnosis	O
:	O
303.90	O
DRUG	O
USE	O
/	O
DEPENDENCE	O
,	O
ALCOHOL	O
Secondary	O
Diagnosis	O
:	O
555.9	O
CROHN	O
'S	O
DISEASE	O
Secondary	O
Diagnosis	O
:	O
790.7	O
BACTEREMIA	O
Secondary	O
Diagnosis	O
:	O
787.91	O
DIARRHEA	O
,	O
NOS	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
Discharge	O
Instructions	O
:	O
Patient	O
being	O
transferred	O
to	O
a	O
facility	O
for	O
tube	O
feedings	O
and	O
to	O
complete	O
antibiotic	I-Drug
course	O
.	O
Followup	O
Instructions	O
:	O
with	O
PCP	O
at	O
the	O
time	O
of	O
discharge	O
from	O
rehab	O
Name	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Address	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
35619	O
**	O
]	O
,	O
[	O
**	O
Apartment	O
Address	O
(	O
1	O
)	O
**	O
]	O
,	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
23661	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
35614	O
**	O
]	O
Fax	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
35625	O
**	O
]	O
*	O
Also	O
needs	O
f	O
/	O
u	O
with	O
his	O
gastroenterologist	O
.	O
We	O
believe	O
he	O
should	O
be	O
seen	O
within	O
next	O
2	O
-	O
4	O
weeks	O
,	O
but	O
she	O
had	O
no	O
appts	O
during	O
that	O
time	O
.	O
She	O
was	O
not	O
availible	O
for	O
contact	O
today	O
,	O
but	O
will	O
be	O
in	O
the	O
office	O
tomorrow	O
to	O
schedule	O
f	O
/	O
u.	O
please	O
call	O
their	O
office	O
tomorrow	O
.	O
MD	O
:	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
2523	O
**	O
]	O
Specialty	O
:	O
Gastroenterology	O
Phone	O
number	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
86328	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2133-8-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2133-9-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2069-3-21	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
7934	O
**	O
]	O
Chief	O
Complaint	O
:	O
Weakness	O
,	O
increased	O
abdominal	O
girth	O
,	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
Tracheostomy	O
Placement	O
2	O
.	O
PEG	O
tube	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
a	O
64	O
yo	O
M	O
with	O
h	O
/	O
o	O
DM2	O
,	O
CAD	O
s	O
/	O
p	O
recent	O
hospitalization	O
for	O
rhabdomyolyis	O
and	O
myopathy	O
presenting	O
with	O
weakness	O
.	O
Pt	O
states	O
that	O
since	O
d	O
/	O
c	O
on	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
he	O
has	O
experienced	O
progressively	O
worsening	O
weakness	O
.	O
He	O
states	O
that	O
he	O
has	O
the	O
most	O
difficulty	O
getting	O
out	O
of	O
chair	O
,	O
changing	O
clothes	O
,	O
not	O
as	O
much	O
weakness	O
at	O
the	O
wrists	O
or	O
ankle	O
.	O
No	O
diplopia	O
or	O
blurry	O
vision	O
,	O
no	O
dysphagia	O
,	O
no	O
headache	O
or	O
jaw	O
pain	O
.	O
Pt	O
denies	O
any	O
myalgias	O
,	O
no	O
paraesthesis	O
.	O
On	O
the	O
previous	O
hospitalization	O
his	O
cholesterol	I-Drug
lowering	O
agents	O
were	O
discontinued	O
as	O
it	O
was	O
thought	O
that	O
these	O
could	O
be	O
the	O
possible	O
culprits	O
for	O
rhabdomyolysis	I-Ade
.	O
During	O
that	O
hospitalization	O
neurology	O
was	O
consulted	O
,	O
and	O
work	O
up	O
included	O
nl	O
TSH	O
,	O
elevated	O
ESR	O
,	O
negative	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
.	O
Pt	O
's	O
health	O
has	O
been	O
deteriorating	O
over	O
the	O
past	O
year	O
in	O
the	O
setting	O
of	O
a	O
chronic	I-Reason
post	O
surgical	O
would	O
infection	O
at	O
the	O
left	O
foot	O
requiring	O
most	O
recently	O
vancomycin	I-Drug
.	O
He	O
was	O
started	O
on	O
zyvox	I-Drug
4	O
days	O
prior	O
to	O
this	O
presentation	O
.	O
Of	O
note	O
,	O
during	O
his	O
prior	O
hospitalization	O
he	O
complained	O
of	O
SOB	I-Reason
and	O
had	O
an	O
oxygen	I-Drug
requirement	O
.	O
Echo	O
demonstrated	O
an	O
EF	O
of	O
%	O
and	O
it	O
was	O
felt	O
that	O
he	O
possibly	O
had	O
diastolic	O
heart	O
failure	O
.	O
He	O
responded	O
to	O
gentle	O
diuresis	O
with	O
subjective	O
improvement	O
in	O
symptoms	O
.	O
Pulmonary	O
was	O
consulted	O
at	O
that	O
time	O
and	O
recommended	O
outpt	O
sleep	O
study	O
.	O
His	O
hospital	O
course	O
results	O
were	O
also	O
remarkable	O
for	O
persistently	O
elevated	O
LFTs	O
.	O
An	O
MRI	O
was	O
planned	O
to	O
further	O
evaluate	O
but	O
pt	O
was	O
unable	O
to	O
fit	O
in	O
MRI	O
due	O
to	O
abdominal	O
girth	O
.	O
.	O
In	O
the	O
ED	O
his	O
labs	O
were	O
notable	O
for	O
elevated	O
CK	O
to	O
<	O
[	O
**	O
Numeric	O
Identifier	O
4731	O
**	O
]	O
.	O
This	O
was	O
higher	O
than	O
the	O
CK	O
max	O
at	O
the	O
prior	O
hospitalization	O
.	O
He	O
was	O
given	O
1L	O
NS	I-Drug
.	O
.	O
ROS	O
:	O
positive	O
for	O
mild	O
SOB	I-Reason
which	O
he	O
says	O
is	O
unchanged	O
since	O
discharge	O
-	O
overall	O
improved	O
over	O
the	O
past	O
month	O
since	O
starting	O
diuretics	I-Drug
;	O
denies	O
CP	O
/	O
palp	O
/	O
cough	O
/	O
diarrhea	O
/	O
rash	O
.	O
Past	O
Medical	O
History	O
:	O
IDDM	O
,	O
Htn	O
,	O
Afib	O
w	O
/	O
anticoagulation	O
therapy	O
Gout	O
,	O
hypercholesterolemia	O
,	O
arthritis	O
CAD	O
PSH	O
:	O
s	O
/	O
p	O
L	O
5th	O
ray	O
amputation	O
[	O
**	O
2130	O
**	O
]	O
s	O
/	O
p	O
R	O
inguinal	O
hernia	O
repair	O
[	O
**	O
2128	O
**	O
]	O
s	O
/	O
p	O
cholecystectomy	O
s	O
/	O
p	O
coronary	O
artery	O
by	O
pass	O
surgery	O
x4	O
[	O
**	O
2127	O
**	O
]	O
s	O
/	O
p	O
L	O
TMA	O
[	O
**	O
12/2131	O
**	O
]	O
Social	O
History	O
:	O
retired	O
postal	O
worker	O
,	O
married	O
,	O
4	O
children	O
,	O
no	O
tobacco	O
,	O
no	O
drugs	O
use	O
,	O
ETOH	I-Drug
qweek	O
,	O
wife	O
involved	O
Family	O
History	O
:	O
Mother	O
died	O
of	O
liver	O
cancer	O
in	O
her	O
70's	O
Physical	O
Exam	O
:	O
VS	O
:	O
130/80	O
,	O
HR	O
87	O
,	O
RR	O
16	O
,	O
89	O
%	O
RA	O
,	O
96	O
%	O
2L	O
oxygen	O
Gen	O
-	O
NAD	O
HEENT	O
-	O
PERRL	O
,	O
extraocular	O
motions	O
intact	O
,	O
anicteric	O
,	O
mucous	O
membranes	O
moist	O
Neck	O
-	O
JVP	O
8	O
cm	O
,	O
no	O
cervical	O
lymphadenopathy	O
Chest	O
-	O
CTA	O
bl	O
CV	O
-	O
irrg	O
/	O
irreg	O
nl	O
s1	O
s2	O
no	O
mrg	O
Abd	O
-	O
obese	O
,	O
nt	O
,	O
nd	O
,	O
nabs	O
Back	O
-	O
No	O
costovertebral	O
angle	O
tendernes	O
,	O
no	O
sacral	O
edema	O
Extr	O
-	O
No	O
clubbing	O
,	O
cyanosis	O
,	O
1	O
+	O
edema	O
to	O
mid	O
shin	O
bl	O
Left	O
-	O
foot	O
surgical	O
scar	O
wound	O
Neuro	O
-	O
Alert	O
and	O
oriented	O
x	O
3	O
,	O
cranial	O
nerves	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
intact	O
,	O
UE	O
strength	O
5/5	O
except	O
for	O
deltoid	O
(	O
[	O
**	O
4	O
-	O
29	O
**	O
]	O
)	O
,	O
LE	O
[	O
**	O
5	O
-	O
29	O
**	O
]	O
except	O
for	O
hip	O
extensors	O
(	O
[	O
**	O
4	O
-	O
29	O
**	O
]	O
)	O
;	O
sensation	O
intact	O
Skin	O
-	O
No	O
rash	O
Pertinent	O
Results	O
:	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
GLUCOSE	O
-	O
120	O
*	O
UREA	O
N	O
-	O
43	O
*	O
CREAT	O
-	O
1.4	O
*	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
4.2	O
CHLORIDE	O
-	O
100	O
TOTAL	O
CO2	O
-	O
28	O
ANION	O
GAP	O
-	O
14	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:42	O
PM	O
LACTATE	O
-	O
1.5	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
542	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
573	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
[	O
**	O
Numeric	O
Identifier	O
37476	O
**	O
]	O
*	O
ALK	O
PHOS	O
-	O
63	O
TOT	O
BILI	O
-	O
0.5	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
LIPASE	O
-	O
39	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
WBC	O
-	O
8.5	O
RBC	O
-	O
4.15	O
*	O
HGB	O
-	O
12.3	O
*	O
HCT	O
-	O
35.8	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
29.6	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
16.4	O
*	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
NEUTS	O
-	O
79.3	O
*	O
LYMPHS	O
-	O
14.2	O
*	O
MONOS	O
-	O
4.6	O
EOS	O
-	O
1.6	O
BASOS	O
-	O
0.4	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
ANISOCYT	O
-	O
1	O
+	O
MICROCYT	O
-	O
1	O
+	O
[	O
**	O
2133-8-13	O
**	O
]	O
05:30	O
PM	O
PLT	O
COUNT	O
-	O
192	O
.	O
CXR	O
--	O
Bibasilar	O
atelectasis	O
,	O
cardiomegaly	O
.	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
RIGHT	O
DELTOID	O
MUSCLE	O
BIOPSY	O
(	O
including	O
snap	O
-	O
frozen	O
tissue	O
)	O
:	O
Acute	O
,	O
recent	O
,	O
and	O
chronic	O
myopathy	O
(	O
chronic	O
active	O
myopathy	O
)	O
Acute	O
myofiber	O
necrosis	O
.	O
Scattered	O
degenerating	O
and	O
regenerating	O
myofibers	O
and	O
scattered	O
myophagocytosis	O
,	O
indicative	O
of	O
recent	O
myofiber	O
injury	O
.	O
Increased	O
endomysial	O
connective	O
tissue	O
,	O
increased	O
frequency	O
of	O
internalized	O
nuclei	O
,	O
and	O
scattered	O
split	O
myofibers	O
,	O
indicative	O
of	O
chronic	O
myopathy	O
.	O
Scattered	O
CD4	O
and	O
CD8	O
T	O
-	O
lymphocytes	O
,	O
without	O
direct	O
association	O
with	O
pathologic	O
changes	O
.	O
Coarse	O
lipid	O
and	O
mitochondrial	O
staining	O
in	O
degenerating	O
myofibers	O
.	O
NOTE	O
:	O
In	O
addition	O
to	O
the	O
findings	O
identified	O
in	O
the	O
preliminary	O
report	O
,	O
these	O
special	O
stains	O
identify	O
coarse	O
lipid	O
staining	O
in	O
many	O
of	O
the	O
degenerating	O
myofibers	O
,	O
along	O
with	O
corresponding	O
changes	O
in	O
mitochondria	O
.	O
While	O
not	O
specific	O
,	O
they	O
are	O
consistent	O
with	O
a	O
metabolic	O
myopathy	O
affecting	O
lipid	O
metabolism	O
,	O
as	O
can	O
be	O
induced	O
by	O
toxic	O
agents	O
and	O
several	O
drugs	O
.	O
They	O
are	O
consistent	O
with	O
effects	O
of	O
some	O
cholesterol	B-Drug
lower	I-Drug
agents	I-Drug
,	O
especially	O
combinations	O
of	O
agents	O
in	O
elderly	O
patients	O
.	O
Diagnostic	O
changes	O
of	O
an	O
inflammatory	O
myositis	O
are	O
not	O
identified	O
in	O
this	O
biopsy	O
.	O
MICROSCOPIC	O
DESCRIPTION	O
:	O
H&E	O
stain	O
:	O
increased	O
internalized	O
nuclei	O
and	O
split	O
myofibers	O
;	O
scattered	O
myophagocytosis	O
and	O
frequent	O
degenerating	O
and	O
regenerating	O
myofibers	O
,	O
including	O
atrophic	O
basophilic	O
fibers	O
;	O
moderate	O
to	O
marked	O
variation	O
in	O
myofiber	O
size	O
;	O
frequent	O
small	O
,	O
round	O
or	O
angulated	O
myofibers	O
;	O
scattered	O
acutely	O
necrotic	O
myofibers	O
having	O
pale	O
eosinophilic	O
staining	O
Gomori	O
trichrome	O
stain	O
:	O
increased	O
endomysial	O
connective	O
tissue	O
in	O
sites	O
of	O
greatest	O
degeneration	O
;	O
no	O
ragged	O
red	O
fibers	O
;	O
degenerating	O
myofibers	O
often	O
show	O
coarse	O
staining	O
of	O
sarcoplasmic	O
mitochondria	O
PAS	O
stain	O
:	O
normal	O
distribution	O
of	O
glycogen	O
PAS	O
+	O
diastase	O
stain	O
:	O
no	O
diastase	O
-	O
resistant	O
glycogen	O
Oil	O
red	O
"	O
O	O
"	O
stain	O
:	O
coarse	O
staining	O
of	O
degenerating	O
myofibers	O
NADH	O
histochemistry	O
:	O
coarse	O
staining	O
of	O
degenerating	O
myofibers	O
in	O
a	O
mitochondrial	O
pattern	O
(	O
mitochondrial	O
clumping	O
)	O
ATPase	O
(	O
pH	O
4.3	O
,	O
4.6	O
,	O
9.5	O
)	O
histochemistry	O
:	O
type	O
I	O
myofiber	O
predominant	O
;	O
atrophic	O
myofibers	O
of	O
both	O
types	O
-	O
predominantly	O
type	O
II	O
;	O
no	O
diagnostic	O
type	O
grouping	O
.	O
CD3	O
immunoperoxidase	O
:	O
non-contributory	O
CD4	O
immunoperoxidase	O
:	O
scattered	O
T4	O
lymphocytes	O
throughout	O
specimen	O
;	O
not	O
directly	O
associated	O
with	O
individual	O
myofiber	O
injury	O
CD8	O
immunoperoxidase	O
:	O
scattered	O
T8	O
lymphocytes	O
throughout	O
specimen	O
;	O
not	O
directly	O
associated	O
with	O
individual	O
myofiber	O
injury	O
CD68	O
immunoperoxidase	O
:	O
non-contributory	O
Factor	O
VIII	O
immunoperoxidase	O
:	O
normal	O
numbers	O
of	O
vessels	O
,	O
including	O
endomysial	O
capillaries	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
64yo	O
man	O
with	O
h	O
/	O
o	O
TIIDM	O
,	O
CAD	O
,	O
Afib	O
,	O
and	O
Gout	O
,	O
presenting	O
with	O
myositis	O
vs	O
rhabdomyalysis	O
,	O
transferred	O
now	O
with	O
tachypnea	O
and	O
hypercapnia	O
and	O
acidemia	O
.	O
.	O
#	O
Respiratory	O
failure	O
Poor	O
ventilation	O
due	O
to	O
progressive	O
muscle	O
weakness	O
.	O
Rising	O
PCO2	O
and	O
respiratory	O
acidemia	O
progressed	O
to	O
hypercarbic	O
respiratory	O
failure	O
.	O
No	O
evidence	O
of	O
primary	O
pulmonary	O
process	O
.	O
-	O
Pt	O
intubated	O
for	O
worsening	O
ventilation	O
/	O
oxygenation	O
in	O
setting	O
of	O
worsening	O
weakness	O
-	O
Remained	O
intubated	O
due	O
to	O
poor	O
NIFs	O
.	O
Very	O
brief	O
SBT	O
failed	O
when	O
pt	O
had	O
no	O
respiratory	O
effort	O
.	O
-	O
Given	O
continued	O
poor	O
respiratory	O
muscle	O
strength	O
,	O
likelihood	O
of	O
lengthy	O
intubation	O
,	O
percutaneous	O
tracheostomy	O
performed	O
on	O
[	O
**	O
2133-9-1	O
**	O
]	O
and	O
trach	O
placed	O
.	O
Complicated	O
trach	O
placement	O
due	O
to	O
subcutaneous	O
emphysema	O
on	O
same	O
day	O
of	O
trach	O
placement	O
.	O
Incision	O
site	O
was	O
widened	O
and	O
subcutaneous	O
emphysema	O
and	O
swelling	O
decreased	O
over	O
the	O
next	O
two	O
days	O
.	O
No	O
pneumothorax	O
or	O
pneumomediastinum	O
seen	O
on	O
CXR	O
.	O
.	O
#	O
Myospathy	O
:	O
rhabdomyolysis	O
/	O
myopathy	O
,	O
pathololgy	O
from	O
muscle	O
biopsy	O
suggests	O
myopathic	O
changes	O
,	O
possibly	O
drug	O
-	O
induced	O
.	O
Rheumatology	O
and	O
neurology	O
consulted	O
.	O
Not	O
thought	O
that	O
steroids	I-Drug
will	O
help	O
this	O
disease	O
process	O
.	O
Off	O
statins	I-Drug
,	O
will	O
follow	O
CK	O
and	O
clinical	O
picture	O
,	O
await	O
gradual	O
recovery	O
.	O
.	O
#	O
ARF	O
:	O
contrast	O
nephropathy	O
,	O
ATN	O
on	O
chronic	O
diabetic	O
nephrophathy	O
.	O
patient	O
briefly	O
anuric	O
.	O
Hemodialyzed	O
,	O
but	O
now	O
with	O
improving	O
renal	O
function	O
,	O
increased	O
urine	O
output	O
,	O
no	O
further	O
need	O
for	O
dialysis	O
at	O
this	O
time	O
.	O
.	O
#	O
Transaminitis	O
:	O
LFTs	O
returned	O
to	O
NL	O
;	O
likely	O
due	O
to	O
rhabdo	O
.	O
hepatitis	O
serologies	O
negative	O
.	O
CTA	O
abdomen	O
nondiagnostic	O
.	O
#	O
Foot	B-Reason
wound	I-Reason
:	O
patient	O
completed	O
10days	O
Linezolid	I-Drug
per	O
podiatry	O
recc	O
's	O
.	O
Podiatry	O
following	O
.	O
.	O
#	O
TIIDM	O
:	O
RISS	I-Drug
+	O
NPH	I-Drug
for	O
elevated	B-Reason
blood	I-Reason
sugars	I-Reason
.	O
.	O
#	O
HTN	I-Reason
:	O
metoprolol	I-Drug
.	O
#	O
FEN	O
:	O
diabetic	O
,	O
cardiac	O
diet	O
;	O
PEG	O
placed	O
on	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
.	O
#	O
PPx	O
:	O
SC	O
heparin	I-Drug
,	O
po	O
diet	O
.	O
#	O
Access	O
:	O
PICC	O
.	O
#	O
Full	O
Code	O
Medications	O
on	O
Admission	O
:	O
Allopurinol	I-Drug
200	O
mg	O
PO	O
DAILY	O
Aspirin	I-Drug
81	O
mg	O
PO	O
DAILY	O
Clonidine	I-Drug
0.3	O
mg	O
/	O
24	O
hr	O
Patch	O
Weekly	O
QSAT	O
Irbesartan	I-Drug
300	O
mg	O
PO	O
qd	O
Warfarin	I-Drug
5	O
mg	O
PO	O
6X	O
/	O
WEEK	O
(	O
MO	O
,	O
TU	O
,	O
WE	O
,	O
TH	O
,	O
FR	O
,	O
SA	O
)	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
PO	O
BID	O
Omega	B-Drug
-	I-Drug
3	I-Drug
Fatty	I-Drug
Acids	I-Drug
550	O
mg	O
PO	O
BID	O
Gabapentin	I-Drug
300	O
mg	O
PO	O
BID	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
PO	O
DAILY	O
Cyanocobalamin	I-Drug
1,000	O
mcg	O
/	O
mL	O
for	O
7	O
days	O
.	O
Furosemide	I-Drug
40	O
mg	O
PO	O
DAILY	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
PO	O
BID	O
Insulin	B-Drug
NPH	I-Drug
-	I-Drug
Regular	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
3	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
5	O
.	O
Gabapentin	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Allopurinol	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
EVERY	O
OTHER	O
DAY	O
(	O
Every	O
Other	O
Day	O
)	O
.	O
7	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
9	O
.	O
Lansoprazole	B-Drug
30	O
mg	O
Susp	O
,	O
Delayed	O
Release	O
for	O
Recon	I-Reason
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Acetylcysteine	I-Drug
20	O
%	O
(	O
200	O
mg	O
/	O
mL	O
)	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
ML	O
Miscell	O
.	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
11	O
.	O
Olanzapine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
13	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
14	O
.	O
Citalopram	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
16	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
17	O
.	O
Hydralazine	I-Drug
20	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
SBP	B-Reason
>	I-Reason
155	I-Reason
.	O
18	O
.	O
Vancomycin	I-Drug
HCl	O
1000	O
mg	O
IV	O
Q	O
12H	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Myopathy	O
2	O
.	O
Respiratory	O
Failure	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
-	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
-	O
Return	O
if	O
you	O
have	O
any	O
worsening	O
weakness	O
,	O
any	O
worsening	O
muscle	O
cramping	O
,	O
chest	O
pain	O
,	O
dizziness	O
,	O
faintness	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
176	O
**	O
]	O
1	O
week	O
of	O
discharge	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2166-12-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2167-1-2	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2123-9-19	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Dilantin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
358	O
**	O
]	O
Chief	O
Complaint	O
:	O
vomiting	O
/	O
confused	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1/24	O
L	O
MCA	O
coiling	O
and	O
EVD	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
HPI	O
:	O
(	O
history	O
obtained	O
from	O
boyfriend	O
)	O
43	O
year	O
old	O
female	O
presents	O
to	O
the	O
ER	O
today	O
after	O
feeling	O
sick	O
since	O
Saturday	O
.	O
She	O
vomited	O
on	O
Saturday	O
and	O
the	O
family	O
thought	O
she	O
had	O
a	O
virus	O
.	O
The	O
patient	O
refused	O
to	O
eat	O
and	O
seemed	O
confused	O
today	O
so	O
her	O
boyfriend	O
called	O
911	O
.	O
She	O
was	O
brought	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
where	O
a	O
CT	O
scan	O
shows	O
a	O
left	O
frontal	O
ICH	O
with	O
extension	O
in	O
the	O
ventricles	O
.	O
The	O
patient	O
does	O
report	O
a	O
headache	O
currently	O
.	O
She	O
does	O
not	O
have	O
any	O
dizziness	O
,	O
numbness	O
,	O
tingling	O
anywhere	O
.	O
Past	O
Medical	O
History	O
:	O
PMHx	O
:	O
unknown	O
Social	O
History	O
:	O
Social	O
Hx	O
:	O
works	O
as	O
a	O
tech	O
in	O
this	O
hospital	O
Family	O
History	O
:	O
unknown	O
Physical	O
Exam	O
:	O
PHYSICAL	O
EXAM	O
:	O
T	O
:	O
98.8	O
BP	O
:	O
125/64	O
HR	O
:	O
54	O
RR	O
:	O
20	O
O2Sats	B-Drug
:	O
99	O
%	O
3L	O
NC	O
Gen	O
:	O
Patient	O
is	O
sleepy	O
,	O
confused	O
as	O
to	O
why	O
she	O
is	O
here	O
.	O
HEENT	O
:	O
Pupils	O
:	O
PERRL	O
EOMs	O
-	O
intact	O
Neck	O
:	O
Supple	O
.	O
Lungs	O
:	O
CTA	O
bilaterally	O
.	O
Cardiac	O
:	O
RRR	O
.	O
S1	O
/	O
S2	O
.	O
Abd	O
:	O
Soft	O
,	O
NT	O
,	O
BS	O
+	O
Extrem	O
:	O
Warm	O
and	O
well	O
-	O
perfused	O
.	O
Neuro	O
:	O
Mental	O
status	O
:	O
Awake	O
and	O
alert	O
,	O
cooperative	O
with	O
exam	O
,	O
flat	O
affect	O
.	O
Orientation	O
:	O
Oriented	O
to	O
person	O
,	O
place	O
,	O
and	O
year	O
.	O
She	O
thought	O
is	O
was	O
[	O
**	O
11	O
-	O
6	O
**	O
]	O
.	O
Language	O
:	O
Speech	O
is	O
slowed	O
.	O
Naming	O
intact	O
.	O
No	O
dysarthria	O
or	O
paraphasic	O
errors	O
.	O
Cranial	O
Nerves	O
:	O
I	O
:	O
Not	O
tested	O
II	O
:	O
Pupils	O
equally	O
round	O
and	O
reactive	O
to	O
light	O
,	O
3	O
to	O
1	O
mm	O
bilaterally	O
.	O
Visual	O
fields	O
are	O
full	O
to	O
confrontation	O
.	O
III	O
,	O
IV	O
,	O
VI	O
:	O
Extraocular	O
movements	O
intact	O
bilaterally	O
without	O
nystagmus	O
.	O
V	O
,	O
VII	O
:	O
Facial	O
strength	O
and	O
sensation	O
intact	O
and	O
symmetric	O
.	O
VIII	O
:	O
Hearing	O
intact	O
to	O
voice	O
.	O
IX	O
,	O
X	O
:	O
Palatal	O
elevation	O
symmetrical	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
Sternocleidomastoid	O
and	O
trapezius	O
normal	O
bilaterally	O
.	O
XII	O
:	O
Tongue	O
midline	O
without	O
fasciculations	O
.	O
Motor	O
:	O
Normal	O
bulk	O
and	O
tone	O
bilaterally	O
.	O
No	O
abnormal	O
movements	O
,	O
tremors	O
.	O
Strength	O
full	O
power	O
[	O
**	O
3	O
-	O
23	O
**	O
]	O
throughout	O
except	O
hamstrings	O
on	O
right	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
.	O
No	O
pronator	O
drift	O
.	O
Sensation	O
:	O
Intact	O
to	O
light	O
touch	O
bilaterally	O
.	O
Pertinent	O
Results	O
:	O
CT	O
head	O
:	O
Preliminary	O
Report	O
!!	O
Wet	O
Read	O
!!	O
(	O
Findings	O
just	O
rev	O
'd	O
,	O
w	O
/	O
Drs.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
3271	O
**	O
]	O
,	O
in	O
detail	O
.	O
)	O
Lrg	O
,	O
acute	O
parench	O
bleed	O
,	O
centered	O
L	O
frontal	O
deep	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
4746	O
**	O
]	O
,	O
w	O
/	O
sign	O
assoc	O
vasogen	O
edema	O
.	O
Process	O
appears	O
centered	O
on	O
12	O
mm	O
round	O
,	O
rel	O
hyperdense	O
lesion	O
:	O
?	O
aneurysm	O
/	O
?	O
mass	O
.	O
Bld	O
dissects	O
into	O
ventric	O
chain	O
,	O
w	O
/	O
early	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
hydroceph	O
and	O
dil	O
temp	O
horns	O
.	O
Min	O
shift	O
of	O
midline	O
;	O
no	O
evid	O
herniation	O
.	O
Labs	O
:	O
PT	O
:	O
13.4	O
PTT	O
:	O
23.6	O
INR	O
:	O
1.1	O
Na	O
142	O
Cl	O
106	O
BUN	O
25	O
Glu	O
112	O
K	O
4.0	O
CO2	O
22	O
Cr	O
0.6	O
WBC	O
15.7	O
Hbg	O
14.3	O
Hct	O
39.5	O
Plts	O
323	O
N	O
:	O
83.8	O
L	O
:	O
11.9	O
M	O
:	O
3.6	O
E	O
:	O
0.3	O
Bas	O
:	O
0.4	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
43	O
yo	O
woman	O
with	O
left	O
MCA	O
aneurysm	O
rupture	O
.	O
.	O
Hospital	O
course	O
:	O
.	O
Patient	O
was	O
admitted	O
from	O
ED	O
to	O
Neuro	O
ICU	O
for	O
q1	O
hour	O
neuro	O
checks	O
.	O
She	O
had	O
CTA	O
/	O
MRA	O
/	O
MRI	O
which	O
showed	O
evolving	O
L	O
IPH	O
of	O
L	O
basal	O
ganglia	O
and	O
frontal	O
lobe	O
with	O
IVH	O
and	O
evidence	O
of	O
obstructive	O
hydrocephalus	O
.	O
She	O
had	O
a	O
L	O
MCA	O
coiling	O
performed	O
and	O
an	O
external	O
ventricular	O
drain	O
placed	O
on	O
[	O
**	O
12	O
-	O
11	O
**	O
]	O
.	O
Started	O
on	O
cefazolin	I-Drug
as	O
prophylaxis	B-Reason
for	I-Reason
the	I-Reason
drain	I-Reason
.	O
She	O
remained	O
intubated	O
until	O
POD	O
3	O
.	O
She	O
spiked	O
a	O
temperature	O
on	O
POD3	O
.	O
Pan	O
cultures	O
and	O
CSF	O
sent	O
.	O
CSF	O
was	O
concerning	O
for	O
infection	O
with	O
250	O
WBCs	O
.	O
Started	O
on	O
empiric	O
Vancomycin	I-Drug
and	O
Ceftriaxone	I-Drug
.	O
Infectious	O
disease	O
was	O
consulted	O
and	O
recommended	O
cipro	I-Drug
and	O
c.diff	O
checks	O
.	O
Continued	O
to	O
spike	O
temps	O
over	O
her	O
hospitalization	O
and	O
multiple	O
blood	O
,	O
csf	O
,	O
and	O
urine	O
cx	O
have	O
been	O
negative	O
except	O
for	O
two	O
urine	O
cx	O
's	O
that	O
grew	O
GPR	O
and	O
Lactobacillus	O
.	O
UTI	O
's	O
treated	O
appropriately	O
but	O
continued	O
to	O
spike	O
fevers	O
.	O
MRI	O
was	O
not	O
concerning	O
for	O
infection	O
.	O
Eventually	O
it	O
was	O
decided	O
to	O
hold	O
abx	I-Drug
for	O
a	O
presumed	O
drug	B-Ade
fever	I-Ade
.	O
After	O
stopping	O
antibiotics	I-Drug
patient	O
remained	O
afebrile	O
.	O
She	O
had	O
hyponatremia	O
and	O
leukopenia	O
on	O
labs	O
.	O
Patient	O
was	O
fluid	O
restricted	O
and	O
started	O
on	O
salt	I-Drug
tabs	O
.	O
Patient	O
's	O
hct	O
then	O
steadily	O
declined	O
no	O
source	O
defined	O
-	O
guaiac	O
negative	O
.	O
Her	O
neuro	O
exam	O
markedly	O
improved	O
and	O
was	O
doing	O
very	O
well	O
with	O
physical	O
therapy	O
.	O
Patient	O
was	O
transferred	O
to	O
medicine	O
service	O
for	O
workup	O
of	O
anemia	O
and	O
treatment	O
of	O
metabolic	O
issues	O
.	O
.	O
On	O
the	O
medicine	O
service	O
:	O
.	O
#	O
Leukopenia	O
:	O
The	O
patient	O
had	O
a	O
leukopenia	O
on	O
transfer	O
.	O
An	O
ANC	O
was	O
checked	O
when	O
the	O
WBC	O
dropped	O
to	O
1.8	O
,	O
with	O
an	O
ANC	O
of	O
700	O
.	O
Etiology	O
of	O
leukopenia	O
was	O
likely	O
lab	O
error	O
versus	O
medication	O
effect	O
(	O
Keppra	I-Drug
,	O
vancomycin	I-Drug
)	O
.	O
She	O
will	O
have	O
her	O
WBC	O
monitored	O
as	O
an	O
outpatient	O
.	O
.	O
#	O
Anemia	O
:	O
On	O
the	O
day	O
of	O
transfer	O
from	O
neurosurgery	O
,	O
she	O
was	O
noted	O
to	O
have	O
a	O
10	O
-	O
point	O
hct	O
drop	O
from	O
30	O
to	O
20	O
.	O
This	O
drop	O
was	O
from	O
lab	O
error	O
,	O
as	O
the	O
repeat	O
check	O
was	O
26	O
%	O
.	O
Hemolysis	O
labs	O
were	O
negative	O
and	O
reticulocytes	O
were	O
normal	O
with	O
an	O
retic	O
index	O
of	O
1.8	O
.	O
There	O
was	O
no	O
sign	O
of	O
bleeding	O
and	O
she	O
was	O
guaiac	O
negative	O
.	O
.	O
#	O
Aneurysm	O
rupture	O
:	O
Was	O
stable	O
on	O
transfer	O
.	O
Coil	O
stable	O
without	O
new	O
pathology	O
seen	O
on	O
MRI	O
/	O
MRA	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
.	O
Patient	O
's	O
memory	O
and	O
weakness	O
deficits	O
were	O
improving	O
daily	O
per	O
boyfriend	O
's	O
report	O
.	O
The	O
nimodipine	I-Drug
was	O
discontinued	O
on	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
and	O
the	O
keppra	I-Drug
was	O
continued	O
(	O
will	O
be	O
on	O
this	O
until	O
1	O
month	O
follow	O
-	O
up	O
with	O
neurosurgery	O
.	O
She	O
was	O
discharged	O
on	O
Plavix	I-Drug
75	O
mg	O
po	O
qday	O
and	O
aspirin	I-Drug
for	O
coil	O
per	O
neurosurgery	O
directions	O
.	O
She	O
was	O
asked	O
to	O
arrange	O
a	O
follow	O
-	O
up	O
MRI	O
/	O
MRA	O
in	O
one	O
month	O
and	O
then	O
see	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
after	O
that	O
.	O
.	O
#	O
Right	O
-	O
hand	O
weakness	O
/	O
Cognitive	O
deficits	O
:	O
Improving	O
per	O
patient	O
and	O
boyfriend	O
.	O
Only	O
minimal	O
weakness	O
noted	O
on	O
exam	O
with	O
wrist	O
extensors	O
,	O
all	O
other	O
strength	O
was	O
equal	O
bilaterally	O
.	O
Patient	O
is	O
right	O
handed	O
and	O
was	O
still	O
having	O
significant	O
difficulty	O
writing	O
at	O
the	O
time	O
of	O
discharge	O
.	O
Per	O
OT	O
notes	O
,	O
the	O
patient	O
's	O
RUE	O
function	O
was	O
improving	O
and	O
recommended	O
outpatient	O
rehab	O
as	O
soon	O
as	O
appropriate	O
.	O
Concerning	O
the	O
cognitive	O
function	O
,	O
she	O
was	O
not	O
at	O
baseline	O
at	O
the	O
time	O
of	O
discharge	O
.	O
She	O
had	O
improved	O
during	O
her	O
hospitalization	O
but	O
experienced	O
delayed	O
responses	O
and	O
speech	O
.	O
She	O
was	O
discharged	O
with	O
plans	O
for	O
outpatient	O
OT	O
,	O
PT	O
and	O
speech	O
therapy	O
.	O
.	O
#	O
Anorexia	I-Reason
:	O
Patient	O
reported	O
having	O
no	O
appetite	O
since	O
the	O
aneurysm	O
bleed	O
,	O
but	O
eating	O
because	O
she	O
knows	O
she	O
needs	O
to	O
eat	O
.	O
Likely	O
related	O
to	O
the	O
aneurysm	O
rupture	O
,	O
and	O
should	O
improve	O
with	O
time	O
.	O
Considered	O
an	O
appetite	B-Drug
stimulant	I-Drug
and	O
suggested	O
starting	O
as	O
an	O
outpatient	O
is	O
appetite	O
did	O
not	O
improve	O
.	O
Did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
depression	O
.	O
She	O
was	O
encouraged	O
to	O
take	O
in	O
high	O
calorie	O
,	O
smaller	O
meals	O
supplemented	O
with	O
ensure	O
.	O
Weight	O
was	O
stable	O
.	O
.	O
#	O
DVT	I-Reason
:	O
Right	O
calf	O
vein	O
DVT	O
at	O
the	O
level	O
of	O
the	O
peroneal	O
vein	O
seen	O
on	O
doppler	O
on	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
.	O
On	O
transfer	O
to	O
medicine	O
was	O
on	O
ASA	I-Drug
,	O
plavix	I-Drug
,	O
and	O
SQ	O
heparin	I-Drug
.	O
Neurosurgery	O
requested	O
that	O
she	O
not	O
be	O
started	O
on	O
coumadin	I-Drug
for	O
now	O
,	O
but	O
aggreed	O
to	O
theraputic	O
lovenox	I-Drug
for	O
a	O
course	O
of	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
months	O
.	O
She	O
will	O
continue	O
lovenox	I-Drug
until	O
her	O
neurosurgery	O
follow	O
-	O
up	O
visit	O
and	O
the	O
issue	O
of	O
coumadin	I-Drug
transition	O
can	O
be	O
discussed	O
at	O
that	O
time	O
.	O
Medications	O
on	O
Admission	O
:	O
Medications	O
prior	O
to	O
admission	O
:	O
unknown	O
Discharge	O
Medications	O
:	O
1	O
.	O
Outpatient	O
Occupational	O
Therapy	O
2	O
.	O
Outpatient	O
Physical	O
Therapy	O
3	O
.	O
Outpatient	O
Speech	O
/	O
Swallowing	O
Therapy	O
4	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
7	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
7	O
.	O
Enoxaparin	I-Drug
80	O
mg	O
/	O
0.8	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
80	O
mg	O
syringe	O
Subcutaneous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
80	O
mg	O
syringe	O
*	O
Refills	O
:	O
*	O
1	O
*	O
8	O
.	O
Acetaminophen	B-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
9	O
.	O
Outpatient	O
Lab	O
Work	O
CBC	O
LFTs	O
Within	O
1	O
-	O
2	O
weeks	O
.	O
Have	O
results	O
send	O
to	O
:	O
REYMOND	O
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
76114	O
**	O
]	O
K	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
76115	O
**	O
]	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
1	O
.	O
Left	O
MCA	O
aneurysm	O
rupture	O
2	O
.	O
Deep	O
Vein	O
Thrombosis	O
3	O
.	O
Hyperglycemia	O
4	O
.	O
Hyponatremia	O
5	O
.	O
Adverse	O
reaction	O
to	O
antibiotics	B-Drug
(	I-Drug
cephalosporins	I-Drug
)	I-Drug
6	O
.	O
Anemia	O
7	O
.	O
Leukopenia	O
8	O
.	O
Anorexia	O
Discharge	O
Condition	O
:	O
Improved	O
:	O
Vital	O
signs	O
stable	O
,	O
right	O
hand	O
weakness	O
improving	O
,	O
cognitive	O
function	O
improving	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
a	O
ruptured	O
brain	O
anurysm	O
.	O
The	O
aneurysm	O
was	O
coiled	O
and	O
the	O
bleeding	O
was	O
stopped	O
.	O
You	O
developed	O
post-op	B-Reason
fever	I-Reason
and	O
were	O
treated	O
with	O
antibiotics	I-Drug
for	O
suspected	B-Reason
infection	I-Reason
.	O
These	O
antibiotics	I-Drug
were	O
stopped	O
when	O
you	O
developed	O
a	O
rash	I-Ade
.	O
The	O
rash	I-Ade
was	O
likely	O
due	O
to	O
ceftriaxone	I-Drug
or	O
ceftazidime	I-Drug
,	O
both	O
of	O
which	O
are	O
part	O
of	O
a	O
group	O
of	O
medications	O
called	O
cephalosporins	I-Drug
.	O
You	O
should	O
not	O
take	O
cephalosporins	I-Drug
for	O
infection	O
in	O
the	O
future	O
.	O
Your	O
cognitive	O
deficits	O
have	O
improved	O
since	O
the	O
aneurysm	O
bleeding	O
was	O
stopped	O
and	O
your	O
right	O
arm	O
/	O
hand	O
weakness	O
is	O
improving	O
.	O
You	O
were	O
started	O
on	O
an	O
antiseizure	I-Reason
medication	O
(	O
Keppra	I-Drug
)	O
due	B-Reason
to	I-Reason
the	O
bleed	O
and	O
will	O
need	O
to	O
take	O
this	O
until	O
directed	O
to	O
stop	O
by	O
your	O
neurosurgeon	O
.	O
For	O
the	O
coil	O
,	O
you	O
were	O
also	O
started	O
on	O
aspirin	I-Drug
and	O
plavix	I-Drug
.	O
You	O
will	O
continue	O
to	O
the	O
aspirin	I-Drug
indefinetely	O
.	O
You	O
will	O
take	O
the	O
plavix	I-Drug
for	O
one	O
more	O
week	O
and	O
then	O
can	O
stop	O
this	O
medication	O
.	O
It	O
was	O
discovered	O
that	O
you	O
developed	O
a	O
DVT	B-Reason
in	I-Reason
your	I-Reason
right	I-Reason
leg	I-Reason
.	O
You	O
were	O
started	O
on	O
a	O
blood	O
thinning	O
medication	O
(	O
lovenox	I-Drug
)	O
and	O
will	O
need	O
to	O
take	O
this	O
until	O
directed	O
to	O
stop	O
.	O
DISCHARGE	O
INSTRUCTIONS	O
FOR	O
CRANIOTOMY	O
/	O
HEAD	O
INJURY	O
??????	O
Have	O
a	O
family	O
member	O
check	O
your	O
incision	O
daily	O
for	O
signs	O
of	O
infection	O
??????	O
Take	O
your	O
pain	B-Drug
medicine	I-Drug
as	O
prescribed	O
??????	O
Exercise	O
should	O
be	O
limited	O
to	O
walking	O
;	O
no	O
lifting	O
,	O
straining	O
,	O
excessive	O
bending	O
??????	O
You	O
may	O
wash	O
your	O
hair	O
only	O
after	O
sutures	O
and	O
/	O
or	O
staples	O
have	O
been	O
removed	O
??????	O
You	O
may	O
shower	O
before	O
this	O
time	O
with	O
assistance	O
and	O
use	O
of	O
a	O
shower	O
cap	O
??????	O
Increase	O
your	O
intake	O
of	O
fluids	O
and	O
fiber	O
as	O
pain	I-Reason
medicine	O
(	O
narcotics	I-Drug
)	O
can	O
cause	O
constipation	I-Ade
??????	O
Unless	O
directed	O
by	O
your	O
doctor	O
,	O
do	O
not	O
take	O
any	O
anti-inflammatory	O
medicines	O
such	O
as	O
Motrin	I-Drug
,	O
aspirin	I-Drug
,	O
Advil	I-Drug
,	O
Ibuprofen	I-Drug
etc.	O
??????	O
If	O
you	O
have	O
been	O
prescribed	O
an	O
anti-seizure	O
medicine	O
,	O
take	O
it	O
as	O
prescribed	O
and	O
follow	O
up	O
with	O
laboratory	O
blood	O
drawing	O
as	O
ordered	O
??????	O
Clearance	O
to	O
drive	O
and	O
return	O
to	O
work	O
will	O
be	O
addressed	O
at	O
your	O
post-operative	O
office	O
visit	O
CALL	O
YOUR	O
SURGEON	O
IMMEDIATELY	O
IF	O
YOU	O
EXPERIENCE	O
ANY	O
OF	O
THE	O
FOLLOWING	O
:	O
??????	O
New	O
onset	O
of	O
tremors	O
or	O
seizures	O
??????	O
Any	O
confusion	O
or	O
change	O
in	O
mental	O
status	O
??????	O
Any	O
numbness	O
,	O
tingling	O
,	O
weakness	O
in	O
your	O
extremities	O
??????	O
Pain	O
or	O
headache	O
that	O
is	O
continually	O
increasing	O
or	O
not	O
relieved	O
by	O
pain	B-Drug
medication	I-Drug
??????	O
Any	O
signs	O
of	O
infection	O
at	O
the	O
wound	O
site	O
:	O
redness	O
,	O
swelling	O
,	O
tenderness	O
,	O
drainage	O
??????	O
Fever	O
greater	O
than	O
or	O
equal	O
to	O
101	O
??????	O
F	O
Followup	O
Instructions	O
:	O
PLEASE	O
CALL	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
TO	O
SCHEDULE	O
AN	O
APPOINTMENT	O
WITH	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
TO	O
HAVE	O
AN	O
ANGIOGRAPHIC	O
STUDY	O
PERFORMED	O
IN	O
ONE	O
MONTH	O
TO	O
ASSESS	O
YOUR	O
ANEURYSM	O
.	O
YOU	O
WILL	O
NEED	O
TO	O
SCHEDULE	O
AN	O
APPOINTMENT	O
TO	O
MEET	O
WITH	O
HIM	O
AFTER	O
THIS	O
IMAGING	O
STUDY	O
HAS	O
BEEN	O
PERFORMED	O
.	O
YOU	O
WILL	O
NEED	O
A	O
CAT	O
SCAN	O
OF	O
THE	O
BRAIN	O
WITHOUT	O
CONTRAST	I-Drug
.	O
YOU	O
WILL	O
/	O
WILL	O
NOT	O
NEED	O
AN	O
MRI	O
OF	O
THE	O
BRAIN	O
WITH	O
OR	O
WITHOUT	O
GADOLIDIUM	O
Please	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
doctor	O
in	O
[	O
**	O
11	O
-	O
19	O
**	O
]	O
weeks	O
regarding	O
your	O
hospitalization	O
.	O
You	O
should	O
have	O
a	O
CBC	O
and	O
LFTs	O
drawn	O
at	O
you	O
follow	O
-	O
up	O
appointment	O
with	O
your	O
PCP	O
.	O
Completed	O
by	O
:[	O
**	O
2167-1-10	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2155-12-24	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2156-2-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2106-8-13	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
NEUROLOGY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
618	O
**	O
]	O
Chief	O
Complaint	O
:	O
Headache	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
49	O
year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
bipolar	O
/	O
schizoaffective	O
disorder	O
,	O
hypothyroidism	O
,	O
recent	O
admission	O
to	O
OSH	O
with	O
HA	O
who	O
was	O
transferred	O
with	O
recurrent	O
HA	O
,	O
nausea	O
and	O
new	O
left	O
parietal	O
hemorrhage	O
.	O
At	O
admission	O
,	O
patient	O
was	O
found	O
to	O
be	O
a	O
poor	O
historian	O
and	O
much	O
of	O
the	O
history	O
was	O
apparently	O
taken	O
from	O
medical	O
records	O
per	O
OSH	O
and	O
the	O
pt	O
's	O
sister	O
.	O
Per	O
sister	O
,	O
pt	O
first	O
presented	O
to	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
11	O
-	O
29	O
**	O
]	O
with	O
~	O
8	O
-	O
9	O
days	O
of	O
nearly	O
daily	O
headache	O
,	O
nausea	O
and	O
vomiting	O
.	O
She	O
was	O
unable	O
to	O
provide	O
details	O
of	O
headache	O
.	O
PCP	O
arranged	O
for	O
head	O
CT	O
which	O
was	O
normal	O
,	O
and	O
pt	O
sent	O
home	O
.	O
Sister	O
accompanied	O
him	O
home	O
,	O
and	O
realized	O
that	O
pt	O
having	O
difficulty	O
with	O
tasks	O
such	O
as	O
dialing	O
phone	O
or	O
using	O
spoon	O
.	O
Normally	O
pt	O
lives	O
alone	O
,	O
and	O
sister	O
felt	O
he	O
was	O
unsafe	O
so	O
brought	O
him	O
to	O
[	O
**	O
Hospital3	O
1443	O
**	O
]	O
Hospital	O
,	O
where	O
he	O
was	O
admitted	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
65003	O
**	O
]	O
.	O
While	O
there	O
,	O
he	O
had	O
MRI	O
that	O
per	O
OSH	O
discharge	O
summary	O
showed	O
small	O
bilateral	O
strokes	I-Reason
in	O
postrior	O
parietal	O
parasaggital	O
region	O
near	O
the	O
parieto	O
-	O
occipital	O
fissure	O
,	O
thought	O
to	O
be	O
watershed	O
however	O
this	O
was	O
not	O
observed	O
.	O
Also	O
in	O
differential	O
was	O
possible	O
viral	O
meningoencephalitis	O
.	O
Stroke	O
workup	O
with	O
negative	O
carotid	O
US	O
,	O
echo	O
,	O
normal	O
lipids	O
and	O
A1C	O
,	O
no	O
arrythmias	O
.	O
He	O
was	O
started	O
on	O
ASA	I-Drug
.	O
On	O
discharge	O
he	O
had	O
full	O
strength	O
,	O
was	O
still	O
having	O
difficulty	O
making	O
phone	O
calls	O
.	O
Headache	I-Reason
had	O
improved	O
,	O
though	O
not	O
fully	O
resolved	O
.	O
Sister	O
reports	O
that	O
he	O
was	O
getting	O
percocet	I-Drug
in	O
hospital	O
,	O
though	O
he	O
was	O
not	O
discharged	O
with	O
any	O
.	O
Since	O
discharge	O
,	O
sister	O
reports	O
that	O
pt	O
complaining	O
of	O
slowly	O
worsening	O
headache	O
.	O
Also	O
has	O
been	O
complaining	O
of	O
trouble	O
seeing	O
,	O
"	O
I	O
ca	O
n't	O
see	O
the	O
kitchen	O
sink	O
.	O
"	O
He	O
saw	O
his	O
PCP	O
yesterday	O
who	O
thought	O
headaches	O
might	O
be	O
migraines	I-Reason
,	O
and	O
gave	O
him	O
Zomig	I-Drug
.	O
Today	O
the	O
headache	O
worsened	O
and	O
pt	O
returned	O
to	O
OSH	O
ED	O
.	O
Head	O
CT	O
showed	O
left	O
parieto	O
-	O
occipital	O
bleed	O
and	O
pt	O
transferred	O
for	O
further	O
management	O
.	O
Per	O
sister	O
and	O
brother	O
-	O
in	O
-	O
law	O
,	O
pt	O
"	O
does	O
OK	O
on	O
all	O
your	O
tests	O
,	O
but	O
he	O
still	O
has	O
trouble	O
functioning	O
,	O
such	O
as	O
trouble	O
getting	O
dressed	O
.	O
"	O
At	O
baseline	O
(	O
prior	O
to	O
recent	O
headaches	O
)	O
pt	O
did	O
have	O
some	O
cognitive	O
difficulties	O
,	O
and	O
some	O
trouble	O
articulating	O
.	O
He	O
is	O
worse	O
now	O
,	O
but	O
it	O
is	O
not	O
entirely	O
clear	O
the	O
time	O
course	O
of	O
this	O
.	O
The	O
trouble	O
making	O
phone	O
calls	O
is	O
definitely	O
new	O
.	O
Also	O
of	O
note	O
,	O
he	O
has	O
had	O
some	O
recent	O
med	O
changes	O
after	O
psych	O
hospitalization	O
at	O
[	O
**	O
Hospital1	O
**	O
]	O
~	O
3	O
months	O
ago	O
.	O
Also	O
,	O
while	O
at	O
OSH	O
pt	O
refused	O
risperdal	I-Drug
and	O
was	O
started	O
on	O
seroquel	I-Drug
instead	O
.	O
Currently	O
,	O
pt	O
reports	O
vertex	O
headache	O
,	O
am	O
unable	O
to	O
get	O
any	O
more	O
details	O
.	O
Also	O
reports	O
+	O
nausea	O
,	O
trouble	O
talking	O
and	O
trouble	O
seeing	O
.	O
No	O
chest	O
pain	O
,	O
abdominal	O
pain	O
.	O
Notes	O
some	O
left	O
leg	O
weakness	O
as	O
well	O
.	O
Social	O
History	O
:	O
Lives	O
alone	O
,	O
is	O
own	O
guardian	O
.	O
Sister	O
had	O
been	O
his	O
guardian	O
in	O
the	O
past	O
but	O
apparently	O
a	O
court	O
has	O
determined	O
that	O
she	O
is	O
no	O
longer	O
allowed	O
to	O
hold	O
this	O
position	O
.	O
Family	O
History	O
:	O
Sister	O
with	O
mental	O
illness	O
.	O
Physical	O
Exam	O
:	O
Admission	O
Physical	O
BP	O
135-152/70	O
s	O
-	O
80s	O
HR	O
50s	O
-	O
60s	O
RR	O
18	O
General	O
:	O
Appears	O
stated	O
age	O
,	O
in	O
no	O
acute	O
distress	O
HEENT	O
:	O
NC	O
/	O
AT	O
Sclera	O
anicteric	O
.	O
OP	O
clear	O
Neck	O
:	O
Supple	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
anterolaterally	O
CV	O
:	O
Brady	O
,	O
reg	O
rhythm	O
,	O
nl	O
S1	O
,	O
S2	O
,	O
no	O
murmur	O
.	O
No	O
carotid	O
or	O
vertebral	O
bruit	O
Abd	O
:	O
Soft	O
,	O
overweight	O
,	O
nontender	O
,	O
normoactive	O
bowel	O
sounds	O
Extr	O
:	O
No	O
edema	O
,	O
good	O
dorsalis	O
pedis	O
pulses	O
Neurologic	O
Examination	O
:	O
Mental	O
Status	O
:	O
Awake	O
,	O
oriented	O
to	O
person	O
,	O
place	O
and	O
"	O
[	O
**	O
Month	O
(	O
only	O
)	O
359	O
**	O
]	O
,	O
[	O
**	O
2152	O
**	O
]	O
"	O
,	O
mostly	O
cooperative	O
with	O
exam	O
though	O
got	O
mildly	O
irritable	O
near	O
end	O
Attention	O
:	O
Can	O
say	O
days	O
of	O
week	O
backward	O
,	O
but	O
slow	O
Language	O
:	O
Fluent	O
,	O
maybe	O
slight	O
dysarthria	O
,	O
no	O
paraphasic	O
errors	O
,	O
repetition	O
intact	O
.	O
Does	O
not	O
name	O
"	O
hand	O
"	O
,	O
says	O
"	O
clock	O
"	O
for	O
"	O
watch	O
"	O
,	O
does	O
not	O
name	O
"	O
watchband	O
"	O
but	O
does	O
get	O
"	O
pen	O
"	O
Can	O
name	O
my	O
coat	O
color	O
as	O
"	O
white	O
"	O
but	O
does	O
not	O
name	O
"	O
green	O
"	O
or	O
"	O
blue	O
"	O
No	O
apraxia	O
for	O
combing	O
hair	O
,	O
brushing	O
teeth	O
,	O
salute	O
.	O
However	O
,	O
can	O
not	O
tell	O
me	O
how	O
to	O
make	O
a	O
phone	O
call	O
.	O
No	O
neglect	O
Cranial	O
Nerves	O
:	O
Visual	O
fields	O
with	O
right	O
hemianopsia	O
.	O
Pupils	O
equally	O
round	O
and	O
reactive	O
to	O
light	O
.	O
Extraocular	O
movements	O
intact	O
,	O
no	O
nystagmus	O
.	O
Facial	O
sensation	O
and	O
facial	O
movement	O
normal	O
bilaterally	O
.	O
Hearing	O
intact	O
to	O
finger	O
rub	O
bilaterally	O
.	O
Normal	O
oropharyngeal	O
movement	O
.	O
Tongue	O
midline	O
,	O
no	O
fasciculations	O
.	O
Motor	O
:	O
Normal	O
bulk	O
and	O
tone	O
bilaterally	O
,	O
fasiculations	O
absent	O
in	O
upper	O
and	O
lower	O
extremities	O
.	O
No	O
tremor	O
.	O
No	O
pronator	O
drift	O
.	O
Full	O
strength	O
bilateral	O
deltoid	O
,	O
triceps	O
,	O
finger	O
ext	O
,	O
finger	O
flexion	O
,	O
IP	O
,	O
dorsiflexion	O
Sensation	O
was	O
intact	O
to	O
light	O
touch	O
and	O
temperature	O
(	O
cold	O
)	O
.	O
Reflexes	O
:	O
DTRs	O
decreased	O
and	O
symmetric	O
throughout	O
,	O
except	O
absent	O
at	O
knees	O
.	O
Toes	O
were	O
mute	O
bilaterally	O
Coordination	O
is	O
normal	O
on	O
finger	O
-	O
nose	O
-	O
finger	O
Gait	O
deferred	O
.	O
Pertinent	O
Results	O
:	O
MRI	O
/	O
MRA	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
:	O
1	O
.	O
MR	O
features	O
of	O
a	O
43	O
x	O
34	O
mm	O
intracerebral	O
hematoma	O
at	O
the	O
left	O
parietal	O
/	O
occipital	O
region	O
,	O
with	O
surrounding	O
vasogenic	O
edema	O
,	O
and	O
extension	O
of	O
hemorrhage	O
into	O
the	O
adjacent	O
subarachnoid	O
spaces	O
and	O
ventricular	O
system	O
.	O
2	O
.	O
No	O
obstructive	O
hydrocephalus	O
is	O
seen	O
at	O
present	O
.	O
3	O
.	O
No	O
pathological	O
enhancement	O
to	O
identify	O
an	O
underlying	O
lesion	O
relating	O
to	O
the	O
left	O
parietal	O
-	O
occipital	O
hematoma	O
.	O
4	O
.	O
Normal	O
brain	O
MR	O
angiography	O
.	O
.	O
TTE	O
:	O
No	O
valvular	O
vegetations	O
or	O
intracardiac	O
thrombi	O
seen	O
.	O
EF	O
>	O
55	O
%	O
.	O
No	O
PFO	O
/	O
ASD	O
.	O
.	O
CT	O
head	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
:	O
There	O
has	O
been	O
evolution	O
of	O
the	O
previously	O
noted	O
blood	O
products	O
in	O
the	O
left	O
parieto	O
-	O
occipital	O
region	O
,	O
overall	O
unchanged	O
in	O
extent	O
in	O
the	O
interval	O
.	O
However	O
,	O
new	O
in	O
the	O
interval	O
is	O
hypodensity	O
in	O
the	O
left	O
internal	O
capsule	O
and	O
thalamus	O
,	O
which	O
is	O
exerting	O
slight	O
mass	O
effect	O
on	O
the	O
frontal	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
of	O
the	O
left	O
lateral	O
ventricle	O
.	O
This	O
is	O
concerning	O
for	O
acute	O
or	O
subacute	O
infarction	O
.	O
No	O
new	O
intracranial	O
hemorrhage	O
or	O
other	O
new	O
suspicious	O
areas	O
of	O
hypodensity	O
are	O
noted	O
.	O
There	O
is	O
no	O
hydrocephalus	O
.	O
The	O
basilar	O
cisterns	O
are	O
visible	O
.	O
The	O
mastoid	O
air	O
cells	O
are	O
opacified	O
bilaterally	O
.	O
The	O
remainder	O
of	O
the	O
paranasal	O
sinuses	O
and	O
the	O
orbits	O
are	O
unremarkable	O
.	O
.	O
EEG	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
:	O
IMPRESSION	O
:	O
This	O
is	O
a	O
mildly	O
abnormal	O
EEG	O
due	O
to	O
the	O
presence	O
of	O
a	O
focal	O
area	O
of	O
slowing	O
in	O
the	O
left	O
anterior	O
quadrant	O
suggestive	O
of	O
a	O
subcortical	O
abnormality	O
in	O
this	O
region	O
.	O
Background	O
frequencies	O
were	O
also	O
somewhat	O
slower	O
than	O
normal	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
mild	O
encephalopathy	O
of	O
toxic	O
,	O
metabolic	O
,	O
or	O
anoxic	O
etiology	O
.	O
.	O
CTA	O
neck	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
:	O
1	O
.	O
Left	O
internal	O
jugular	O
vein	O
thrombosis	O
as	O
described	O
.	O
Question	O
of	O
left	O
sigmoid	O
sinus	O
partial	O
thrombosis	O
,	O
versus	O
mixing	O
artifact	O
.	O
2	O
.	O
Mastoid	O
and	O
partial	O
ethmoid	O
and	O
sphenoid	O
sinus	O
opacification	O
.	O
.	O
CT	O
head	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
:	O
1	O
.	O
New	O
hemorrhagic	O
transformation	O
of	O
left	O
caudate	O
nucleus	O
infarction	O
.	O
Blood	O
products	O
within	O
the	O
fourth	O
ventricle	O
.	O
Close	O
clinical	O
followup	O
and	O
followup	O
CT	O
scan	O
recommended	O
.	O
2	O
.	O
Probable	O
superior	O
sagittal	O
sinus	O
thrombosis	O
and	O
possible	O
thrombosis	O
of	O
the	O
left	O
sigmoid	O
sinus	O
,	O
with	O
continued	O
thrombosis	O
of	O
the	O
left	O
internal	O
jugular	O
vein	O
.	O
.	O
CT	O
head	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
(	O
compared	O
to	O
[	O
**	O
1	O
-	O
19	O
**	O
]	O
)	O
:	O
There	O
has	O
been	O
no	O
significant	O
change	O
from	O
[	O
**	O
2156-1-20	O
**	O
]	O
with	O
a	O
stable	O
appearing	O
left	O
frontal	O
hemorrhage	O
with	O
surrounding	O
edema	O
.	O
There	O
is	O
also	O
a	O
resolving	O
region	O
of	O
hypodensity	O
from	O
hemorrhage	O
in	O
the	O
left	O
temporal	O
lobe	O
.	O
There	O
is	O
stable	O
appearance	O
of	O
the	O
effaced	O
frontal	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
of	O
the	O
left	O
lateral	O
ventricle	O
.	O
No	O
new	O
foci	O
of	O
hemorrhage	O
are	O
indicated	O
.	O
There	O
is	O
no	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
There	O
is	O
some	O
left	O
sphenoid	O
sinus	O
mucosal	O
thickening	O
.	O
IMPRESSION	O
:	O
Multiple	O
stable	O
hemorrhages	O
as	O
described	O
above	O
with	O
no	O
new	O
significant	O
change	O
from	O
[	O
**	O
2156-1-20	O
**	O
]	O
.	O
.	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
PT	O
-	O
13.3	O
PTT	O
-	O
20.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
PLT	O
COUNT	O
-	O
170	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
NEUTS	O
-	O
80.4	O
*	O
LYMPHS	O
-	O
15.2	O
*	O
MONOS	O
-	O
3.9	O
EOS	O
-	O
0.4	O
BASOS	O
-	O
0.1	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
WBC	O
-	O
14.8	O
*	O
RBC	O
-	O
4.61	O
HGB	O
-	O
14.6	O
HCT	O
-	O
39.9	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
31.7	O
MCHC	O
-	O
36.6	O
*	O
RDW	O
-	O
12.7	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
VALPROATE	O
-	O
37	O
*	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
CALCIUM	O
-	O
9.5	O
PHOSPHATE	O
-	O
4.6	O
*	O
MAGNESIUM	O
-	O
1.9	O
[	O
**	O
2155-12-23	O
**	O
]	O
06:50	O
PM	O
CK	O
-	O
MB	O
-	O
1	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2155-12-24	O
**	O
]	O
12:00	O
AM	O
URINE	O
BLOOD	O
-	O
TR	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
15	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
6.5	O
LEUK	O
-	O
NEG	O
[	O
**	O
2155-12-24	O
**	O
]	O
06:00	O
AM	O
T3	O
-	O
104	O
FREE	O
T4	O
-	O
1.0	O
[	O
**	O
2155-12-24	O
**	O
]	O
06:00	O
AM	O
TSH	O
-	O
5.7	O
*	O
[	O
**	O
2155-12-24	O
**	O
]	O
06:00	O
AM	O
LIPASE	O
-	O
40	O
[	O
**	O
2155-12-24	O
**	O
]	O
06:00	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
10	O
AST	O
(	O
SGOT	O
)	O
-	O
13	O
CK	O
(	O
CPK	O
)	O
-	O
31	O
*	O
ALK	O
PHOS	O
-	O
101	O
AMYLASE	O
-	O
52	O
TOT	O
BILI	O
-	O
0.3	O
[	O
**	O
2155-12-24	O
**	O
]	O
03:13	O
PM	O
ASA	O
-	O
NEG	O
ETHANOL	O
-	O
NEG	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2155-12-24	O
**	O
]	O
03:13	O
PM	O
AMMONIA	O
-	O
48	O
*	O
[	O
**	O
2155-12-24	O
**	O
]	O
03:13	O
PM	O
ALBUMIN	O
-	O
3.9	O
[	O
**	O
2156-1-12	O
**	O
]	O
09:45	O
AM	O
BLOOD	O
Fibrino	O
-	O
482	O
*	O
D	O
-	O
Dimer	O
-	O
2839	O
*	O
[	O
**	O
2156-1-11	O
**	O
]	O
09:36	O
PM	O
BLOOD	O
FDP	O
-10-40	O
[	O
**	O
2156-1-9	O
**	O
]	O
12:50	O
PM	O
BLOOD	O
ESR	O
-	O
75	O
*	O
[	O
**	O
2156-1-14	O
**	O
]	O
01:55	O
PM	O
BLOOD	O
ESR	O
-	O
47	O
*	O
[	O
**	O
2156-1-26	O
**	O
]	O
01:19	O
PM	O
BLOOD	O
FacVIII	O
-	O
154	O
*	O
[	O
**	O
2156-2-1	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
LMWH	O
-	O
1.06	O
[	O
**	O
2156-1-26	O
**	O
]	O
01:19	O
PM	O
BLOOD	O
ACA	O
IgG	O
-	O
4.6	O
ACA	O
IgM	O
-	O
7.8	O
[	O
**	O
2156-1-21	O
**	O
]	O
11:10	O
AM	O
BLOOD	O
ProtCFn	O
-	O
119	O
ProtCAg	O
-	O
88	O
ProtSFn	O
-	O
96	O
ProtSAg	O
-	O
148	O
*	O
[	O
**	O
2156-1-9	O
**	O
]	O
07:00	O
PM	O
BLOOD	O
Lupus	O
-	O
NEG	O
AT	O
III	O
-	O
74	O
[	O
**	O
2156-1-9	O
**	O
]	O
07:00	O
PM	O
BLOOD	O
ProtCAg	O
-	O
63	O
*	O
ProtSAg	O
-	O
146	O
*	O
[	O
**	O
2156-1-29	O
**	O
]	O
11:00	O
AM	O
BLOOD	O
TSH	O
-	O
4.1	O
[	O
**	O
2155-12-24	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
T3	O
-	O
104	O
Free	O
T4	O
-	O
1.0	O
[	O
**	O
2156-1-12	O
**	O
]	O
11:58	O
AM	O
BLOOD	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
-	O
NEGATIVE	O
[	O
**	O
2156-1-14	O
**	O
]	O
01:55	O
PM	O
BLOOD	O
CRP	O
-	O
11.0	O
*	O
[	O
**	O
2156-1-29	O
**	O
]	O
11:00	O
AM	O
BLOOD	O
Lithium	O
-	O
0.8	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
65004	O
**	O
]	O
is	O
a	O
49	O
yo	O
RHM	O
with	O
h	O
/	O
o	O
bipolar	O
/	O
schizoaffective	O
disorder	O
,	O
hypothyroidism	O
,	O
who	O
was	O
transferred	O
with	O
complaints	O
of	O
headache	O
for	O
about	O
a	O
month	O
and	O
nausea	O
.	O
Upon	O
admission	O
he	O
was	O
found	O
to	O
have	O
a	O
large	O
left	O
parietal	O
hemorrhage	O
.	O
The	O
exam	O
upon	O
admission	O
was	O
notable	O
for	O
inattention	O
,	O
anomia	O
,	O
right	O
field	O
cut	O
,	O
mild	O
-	O
moderate	O
R	O
hemiparesis	O
,	O
and	O
perseveration	O
.	O
.	O
Neuro	O
:	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
Neuro	O
/	O
ICU	O
for	O
telemetry	O
and	O
aggressive	O
blood	O
pressure	O
control	O
.	O
Neurosurgery	O
evaluated	O
him	O
and	O
no	O
surgical	O
intervention	O
was	O
necessary	O
.	O
His	O
MRI	O
/	O
MRA	O
scans	O
revealed	O
a	O
large	O
(	O
~	O
40cc	O
)	O
hemorrhage	O
near	O
the	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
junction	O
in	O
the	O
left	O
parietal	O
lobe	O
.	O
There	O
was	O
no	O
clear	O
underlying	O
mass	O
and	O
there	O
were	O
no	O
underlying	O
vascular	O
abnormalities	O
per	O
MRA	O
(	O
no	O
aneurysms	O
/	O
AVM	O
)	O
.	O
An	O
ECHO	O
,	O
to	O
look	O
for	O
a	O
cardio	O
-	O
embolic	O
etiology	O
,	O
was	O
negative	O
(	O
no	O
valvular	O
vegetations	O
or	O
intracardiac	O
thrombi	O
;	O
no	O
PFO	O
/	O
ASD	O
,	O
but	O
not	O
with	O
certainty	O
as	O
the	O
image	O
quality	O
was	O
poor	O
)	O
.	O
Mr	O
[	O
**	O
Known	O
lastname	O
65004	O
**	O
]	O
then	O
developed	O
a	O
L	O
thalamic	O
infarct	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
,	O
and	O
was	O
less	O
alert	O
,	O
with	O
increased	O
R	O
hemiparesis	O
.	O
An	O
EEG	O
(	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
)	O
showed	O
focal	O
slowing	O
in	O
the	O
L	O
anterior	O
quadrant	O
.	O
A	O
hemorrhagic	O
conversion	O
of	O
the	O
infract	O
was	O
then	O
noted	O
on	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
with	O
some	O
intraventricular	O
blood	O
(	O
found	O
incidentally	O
when	O
getting	O
CTV	O
)	O
.	O
The	O
CTV	O
(	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
)	O
showed	O
a	O
L	O
superior	O
sagittal	O
sinus	O
thrombosis	O
and	O
?	O
L	O
sigmoid	O
sinus	O
thrombosis	O
with	O
extension	O
into	O
the	O
internal	O
jugular	O
vein	O
.	O
A	O
repeat	O
head	O
CT	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
,	O
showed	O
no	O
evidence	O
of	O
hydrocephalus	O
,	O
and	O
no	O
further	O
blood	O
in	O
4th	O
ventricle	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
65004	O
**	O
]	O
was	O
started	O
on	O
anticoagulation	I-Reason
with	O
Lovenox	I-Drug
on	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
.	O
He	O
was	O
also	O
given	O
a	O
short	O
course	O
of	O
Diamox	I-Drug
for	O
L	B-Reason
hemisphere	I-Reason
edema	O
.	O
Neurosurg	O
was	O
re-consulted	O
to	O
monitor	O
the	O
hemorrhage	O
into	O
the	O
4th	O
ventricle	O
given	O
the	O
risk	O
of	O
hydrocephalus	O
.	O
No	O
intervention	O
was	O
necessary	O
.	O
Follow	O
up	O
CT	O
-	O
head	O
series	O
showed	O
a	O
stable	O
picture	O
.	O
.	O
Psychiatry	O
:	O
The	O
patient	O
was	O
maintained	O
on	O
seroquel	I-Drug
.	O
Depakote	I-Drug
was	O
discontinued	O
,	O
and	O
lithium	I-Drug
was	O
started	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
.	O
Lithium	I-Drug
levels	O
should	O
be	O
monitored	O
closely	O
(	O
every	O
2	O
weeks	O
)	O
and	O
the	O
dosing	O
should	O
be	O
adjusted	O
accordingly	O
.	O
The	O
patient	O
has	O
been	O
closely	O
followed	O
by	O
the	O
psychiatry	O
service	O
.	O
Please	O
contact	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
65005	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
65006	O
**	O
]	O
if	O
any	O
questions	O
arise	O
.	O
Close	O
follow	O
up	O
will	O
be	O
arranged	O
.	O
Haldol	I-Drug
was	O
given	O
on	O
a	O
PRN	O
basis	O
.	O
.	O
Cardiovascular	O
:	O
An	O
Echo	O
showed	O
an	O
EF	O
>	O
55	O
%	O
.	O
The	O
patient	O
was	O
ruled	O
out	O
for	O
an	O
MI	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
.	O
Goal	O
SBP	O
<	O
160	O
.	O
Lipids	O
profile	O
was	O
within	O
normal	O
limits	O
.	O
EKG	O
should	O
be	O
checked	O
if	O
the	O
patient	O
receives	O
haldol	I-Drug
on	O
a	O
regular	O
basis	O
(	O
risk	O
for	O
prolonged	B-Ade
QT	I-Ade
)	O
.	O
.	O
FEN	O
/	O
GI	O
:	O
-	O
cardiac	O
prudent	O
diet	O
.	O
Hematology	O
:	O
The	O
patient	O
was	O
noted	O
to	O
be	O
thrombocytopenic	B-Ade
w	I-Ade
/	I-Ade
nadir	I-Ade
in	I-Ade
80s	I-Ade
,	O
likely	O
secondary	O
to	O
Depakote	I-Drug
.	O
Plt	O
normalized	O
after	O
Depakote	I-Drug
was	O
discontinued	O
.	O
As	O
part	O
of	O
a	O
workup	O
related	O
to	O
the	O
sinus	O
thrombosis	O
the	O
following	O
tests	O
were	O
done	O
:	O
-	O
No	O
LE	O
DVT	O
on	O
[	O
**	O
1	O
-	O
11	O
**	O
]	O
U	O
/	O
S.	O
-	O
Hypercoagulable	O
workup	O
:	O
Fibrinogen	O
482	O
,	O
D	O
-	O
dimer	O
2938	O
.	O
Homocysteine	O
wnl	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
neg	O
,	O
Lupus	O
anticoagulant	O
neg	O
,	O
ATIII	O
wnl	O
,	O
FVL	O
neg	O
.	O
Prot	O
C	O
slightly	O
low	O
63	O
,	O
Prot	O
S	O
elevated	O
(	O
?	O
acute	O
phase	O
reactant	O
)	O
.	O
Factor	O
VIII	O
and	O
anticardiolipin	O
normal	O
.	O
Prothrombin	O
gene	O
mutation	O
pending	O
.	O
Please	O
resend	O
hypercoag	O
workup	O
again	O
in	O
the	O
future	O
if	O
Pt	O
ever	O
comes	O
off	O
anticoagulation	I-Drug
.	O
The	O
patient	O
was	O
started	O
on	O
anticoagulation	I-Reason
with	O
lovenox	I-Drug
as	O
he	O
is	O
not	O
a	O
coumadin	I-Drug
candidate	O
.	O
Lovenox	I-Drug
level	O
2.0	O
on	O
[	O
**	O
1	O
-	O
26	O
**	O
]	O
,	O
after	O
which	O
the	O
dose	O
was	O
decreased	O
;	O
level	O
on	O
[	O
**	O
2	O
-	O
1	O
**	O
]	O
:	O
1.06	O
;	O
level	O
on	O
[	O
**	O
2	O
-	O
3	O
**	O
]	O
:	O
0.9	O
(	O
i.e.	O
within	O
goal	O
range	O
)	O
.	O
.	O
Other	O
:	O
The	O
patient	O
has	O
had	O
multiple	O
falls	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
,	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
,	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
x2	O
,	O
all	O
secondary	O
to	O
orthostasis	O
,	O
a	O
R	O
field	O
cut	O
,	O
and	O
impulsivity	O
.	O
Please	O
check	O
orthostatics	O
in	O
case	O
the	O
patient	O
is	O
unsteady	O
.	O
.	O
Endocrine	O
:	O
-	O
TSH	B-Reason
3.4	I-Reason
;	O
Levoxyl	I-Drug
was	O
continued	O
.	O
Please	O
continue	O
to	O
monitor	O
.	O
-	O
HbA1C	O
5.2	O
,	O
no	O
intervention	O
needed	O
.	O
.	O
ID	O
:	O
On	O
Cipro	I-Drug
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
14813	O
**	O
]	O
for	O
E.	B-Reason
coli	I-Reason
UTI	I-Reason
.	O
UA	O
on	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
was	O
negative	O
.	O
.	O
ENT	O
:	O
Sinus	O
opacification	O
upon	O
admission	O
.	O
This	O
has	O
resolved	O
.	O
If	O
patient	O
becomes	O
symptomatic	O
he	O
will	O
need	O
ENT	O
follow	O
up	O
.	O
.	O
Legal	O
:	O
Mr	O
[	O
**	O
Known	O
lastname	O
65004	O
**	O
]	O
has	O
a	O
legal	O
guardian	O
since	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
is	O
incompetent	O
to	O
sign	O
consent	O
for	O
procedures	O
as	O
he	O
can	O
not	O
clearly	O
understand	O
its	O
risks	O
and	O
benefits	O
.	O
His	O
sister	O
who	O
had	O
been	O
his	O
previous	O
guardian	O
was	O
legally	O
not	O
permitted	O
to	O
hold	O
this	O
position	O
any	O
longer	O
.	O
Medications	O
on	O
Admission	O
:	O
Depakote	I-Drug
1	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
65007	O
**	O
]	O
,	O
seroquel	I-Drug
75	O
hs	O
,	O
cogentin	I-Drug
1	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
ASA	I-Drug
325	O
,	O
levoxyl	I-Drug
12.5	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
2	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Acetaminophen	B-Drug
-	I-Drug
Codeine	O
300	O
-	O
30	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
.	O
4	O
.	O
Quetiapine	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)	O
)	O
.	O
5	O
.	O
Quetiapine	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
2.5	O
Tablets	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
6	O
.	O
Lithium	I-Drug
Carbonate	O
300	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)	O
)	O
.	O
7	O
.	O
Haloperidol	B-Drug
Lactate	I-Drug
5	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
mL	O
Injection	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
agitation	I-Reason
.	O
8	O
.	O
Lithium	I-Drug
Carbonate	O
300	O
mg	O
Capsule	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
9	O
.	O
Levothyroxine	I-Drug
25	O
mcg	O
Tablet	O
Sig	O
:	O
0.75	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Enoxaparin	I-Drug
100	O
mg	O
/	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
11	O
.	O
Benztropine	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
Hollywell	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
5110	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Intracranial	O
hemorrhage	O
2	O
.	O
intracranial	O
ischemic	O
stroke	O
3	O
.	O
venous	O
sinus	O
thrombosis	O
4	O
.	O
psychosis	O
5	O
.	O
urinary	O
tract	O
infection	O
6	O
.	O
hypothyroidism	O
Discharge	O
Condition	O
:	O
Stable	O
Impulsivity	O
,	O
very	O
mild	O
residual	O
hemiparesis	O
and	O
subtle	O
R	O
-	O
upper	O
quadrant	O
field	O
cut	O
;	O
Discharge	O
Instructions	O
:	O
Please	O
take	O
your	O
medications	O
as	O
instructed	O
.	O
.	O
Please	O
check	O
Lithium	I-Drug
level	O
every	O
2	O
weeks	O
.	O
.	O
Please	O
f	O
/	O
u	O
with	O
Neurology	O
,	O
Psychiatry	O
,	O
and	O
your	O
PCP	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
at	O
the	O
Neurology	O
/	O
[	O
**	O
Hospital	O
4038	O
**	O
]	O
clinic	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
4267	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
4268	O
**	O
]	O
,	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
13795	O
**	O
]	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
657	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2156-4-6	O
**	O
]	O
1:00	O
.	O
The	O
patient	O
will	O
need	O
cery	O
close	O
follow	O
up	O
with	O
Psychiatry	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
65005	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
65006	O
**	O
]	O
)	O
from	O
the	O
Dept.	O
of	O
Psychiatry	O
will	O
leave	O
instructions	O
for	O
follow	O
up	O
.	O
If	O
you	O
do	O
not	O
hear	O
from	O
him	O
within	O
one	O
week	O
,	O
please	O
call	O
his	O
number	O
.	O
.	O
Please	O
follow	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
176	O
**	O
]	O
1	O
week	O
after	O
discharge	O
from	O
rehab	O
.	O
.	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
632	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2156-2-4	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2157-10-11	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2157-11-30	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2096-8-13	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Diphenhydramine	I-Drug
/	O
Percocet	I-Drug
/	O
Meropenem	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
6169	O
**	O
]	O
Chief	O
Complaint	O
:	O
Recurrent	O
Large	O
B	O
-	O
Cell	O
Lymphoma	O
admitted	O
for	O
autologous	O
stem	O
cell	O
transplant	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
autologous	O
stem	O
cell	O
transplant	O
History	O
of	O
Present	O
Illness	O
:	O
The	O
patient	O
is	O
admitted	O
for	O
an	O
autologous	O
stem	O
cell	O
transplantation	O
s	O
/	O
p	O
BM	O
harvesting	O
as	O
she	O
did	O
not	O
have	O
an	O
adequate	O
peripheral	O
collection	O
.	O
The	O
paitent	O
was	O
diagnosed	O
in	O
[	O
**	O
2156-9-16	O
**	O
]	O
after	O
presenting	O
with	O
abdominal	O
pain	O
.	O
Disease	O
confined	O
to	O
the	O
abdomin	O
,	O
stage	O
IIIB	O
.	O
She	O
is	O
s	O
/	O
p	O
6	O
cycles	O
of	O
R	O
-	O
CHOP	O
(	O
last	O
treatment	O
[	O
**	O
2157-1-6	O
**	O
]	O
)	O
,	O
She	O
relapsed	O
2	O
months	O
following	O
RCHOP.She	B-Drug
was	O
treated	O
with	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
x	O
2	O
with	O
minimal	O
response	O
,	O
s	O
/	O
p	O
ICE	O
in	O
[	O
**	O
6	O
-	O
21	O
**	O
]	O
and	O
[	O
**	O
7	O
-	O
21	O
**	O
]	O
.	O
She	O
also	O
was	O
admitted	O
on	O
[	O
**	O
8	O
-	O
2	O
**	O
]	O
for	O
cytoxan	I-Drug
and	O
neupogen	I-Drug
for	O
stem	B-Reason
cell	I-Reason
mobilization	I-Reason
.	O
Three	O
peripheral	O
collections	O
were	O
attempted	O
without	O
sufficient	O
cells	O
.	O
She	O
ultimately	O
underwent	O
a	O
BM	O
harvest	O
in	O
the	O
OR	O
with	O
successful	O
colelction	O
of	O
sufficient	O
cells	O
for	O
an	O
attempted	O
autologous	O
stem	O
cell	O
transplantation	O
.	O
Past	O
Medical	O
History	O
:	O
Oncology	O
History	O
1	O
.	O
Large	O
cell	O
lymphoma	O
diagnosed	O
in	O
[	O
**	O
8	O
-	O
/	O
2156	O
**	O
]	O
after	O
she	O
presented	O
with	O
abdominal	O
pain	O
.	O
At	O
that	O
time	O
,	O
she	O
was	O
found	O
to	O
have	O
a	O
bulky	O
intraabdominal	O
mass	O
.	O
CT	O
-	O
guided	O
biopsy	O
complicated	O
by	O
intraabdominal	O
bleeding	O
.	O
Disease	O
confined	O
to	O
the	O
abdomen	O
,	O
stage	O
IIIB	O
.	O
Relapsed	O
after	O
initial	O
therapy	O
with	O
6	O
cycles	O
of	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
(	O
last	O
treatment	O
on	O
[	O
**	O
2157-1-6	O
**	O
]	O
,	O
vincristine	I-Drug
held	O
secondary	O
to	O
peripheral	B-Ade
neuropathy	I-Ade
)	O
,	O
s	O
/	O
p	O
Rituxan	I-Drug
x	O
2	O
,	O
s	O
/	O
p	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
x	O
2	O
,	O
and	O
s	O
/	O
p	O
recent	O
ICE	I-Drug
[	O
**	O
6	O
-	O
21	O
**	O
]	O
and	O
[	O
**	O
7	O
-	O
21	O
**	O
]	O
.	O
.	O
Other	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Hypertension	O
,	O
not	O
on	O
any	O
meds	O
2	O
.	O
s	O
/	O
p	O
ovarian	O
cystectomy	O
of	O
7	O
cm	O
benign	O
left	O
ovarian	O
cyst	O
in	O
[	O
**	O
2147	O
**	O
]	O
at	O
[	O
**	O
Hospital	O
189	O
**	O
]	O
Hosp	O
3	O
.	O
s	O
/	O
p	O
D&C	O
for	O
menometrorrhagia	O
[	O
**	O
2147	O
**	O
]	O
4	O
.	O
s	O
/	O
p	O
post-partum	O
tubal	O
ligation	O
Social	O
History	O
:	O
She	O
lives	O
with	O
her	O
husband	O
in	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
MA	O
.	O
They	O
have	O
2	O
grown	O
children	O
.	O
schizophrenia	O
which	O
is	O
well	O
-	O
controlled	O
.	O
She	O
does	O
n't	O
smoke	O
or	O
drink	O
alcohol	O
.	O
Family	O
History	O
:	O
Her	O
sister	O
has	O
recently	O
been	O
diagnosed	O
with	O
metastatic	O
cervical	O
cancer	O
.	O
Great	O
aunt	O
with	O
breast	O
cancer	O
.	O
Son	O
with	O
schizophrenia	O
Physical	O
Exam	O
:	O
VS	O
T	O
:	O
98.2	O
HR	O
:	O
110	O
RR	O
:	O
18	O
BP	O
:	O
108/65	O
O2	O
:	O
100	O
%	O
RA	O
GEN	O
:	O
A	O
/	O
O	O
,	O
pleasant	O
,	O
in	O
NAD	O
HEENT	O
:	O
NCAT	O
,	O
no	O
oral	O
ulcers	O
,	O
no	O
rashes	O
NECK	O
:	O
No	O
LAD	O
CV	O
:	O
RRR	O
s1	O
,	O
s2	O
,	O
no	O
M	O
/	O
G	O
/	O
R	O
RESP	O
:	O
CTA	O
bl	O
ABD	O
:	O
Soft	O
,	O
NT	O
/	O
ND	O
,	O
no	O
masses	O
EXT	O
:	O
no	O
rashes	O
,	O
+	O
pulses	O
distally	O
Pertinent	O
Results	O
:	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
GRAN	O
CT	O
-	O
[	O
**	O
2091	O
**	O
]	O
*	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
PLT	O
COUNT	O
-	O
124	O
*	O
#	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
HYPOCHROM	O
-	O
1	O
+	O
ANISOCYT	O
-	O
2	O
+	O
POIKILOCY	O
-	O
1	O
+	O
MACROCYT	O
-	O
3	O
+	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
NEUTS	O
-	O
69.9	O
LYMPHS	O
-	O
18.5	O
MONOS	O
-	O
9.8	O
EOS	O
-	O
1.5	O
BASOS	O
-	O
0.3	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
WBC	O
-	O
2.8	O
*	O
RBC	O
-	O
3.72	O
*	O
HGB	O
-	O
11.8	O
*	O
HCT	O
-	O
35.0	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
31.6	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
21.8	O
*	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
ALBUMIN	O
-	O
4.6	O
CALCIUM	O
-	O
9.5	O
PHOSPHATE	O
-	O
3.5	O
MAGNESIUM	O
-	O
2.4	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
14	O
AST	O
(	O
SGOT	O
)	O
-	O
21	O
LD	O
(	O
LDH	O
)	O
-	O
216	O
ALK	O
PHOS	O
-	O
108	O
TOT	O
BILI	O
-	O
0.5	O
DIR	O
BILI	O
-	O
0.2	O
INDIR	O
BIL	O
-	O
0.3	O
[	O
**	O
2157-10-11	O
**	O
]	O
11:38	O
AM	O
GLUCOSE	O
-	O
102	O
UREA	O
N	O
-	O
8	O
CREAT	O
-	O
0.6	O
SODIUM	O
-	O
143	O
POTASSIUM	O
-	O
4.0	O
CHLORIDE	O
-	O
105	O
TOTAL	O
CO2	O
-	O
30	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2157-10-11	O
**	O
]	O
03:32	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
7.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2157-10-11	O
**	O
]	O
03:32	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.015	O
.	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
[	O
**	O
2157-10-12	O
**	O
]	O
11:42	O
PM	O
The	O
heart	O
,	O
mediastinal	O
and	O
hilar	O
contours	O
are	O
unchanged	O
when	O
compared	O
to	O
prior	O
study	O
.	O
There	O
is	O
a	O
new	O
right	O
lower	O
lobe	O
patchy	O
opacity	O
that	O
could	O
represent	O
early	O
pneumonia	O
.	O
It	O
is	O
very	O
subtle	O
and	O
was	O
not	O
seen	O
in	O
the	O
prior	O
study	O
.	O
Since	O
it	O
could	O
be	O
from	O
overlying	O
breast	O
,	O
lateral	O
view	O
is	O
recommended	O
.	O
IMPRESSION	O
:	O
Possible	O
right	O
lower	O
lobe	O
pneumonia	O
.	O
Lateral	O
view	O
recommended	O
for	O
further	O
evaluation	O
.	O
.	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
[	O
**	O
2157-10-23	O
**	O
]	O
4:47	O
PM	O
The	O
previously	O
seen	O
patchy	O
density	O
in	O
the	O
right	O
lower	O
lobe	O
is	O
markedly	O
improved	O
and	O
almost	O
completely	O
resolved	O
.	O
On	O
one	O
projection	O
,	O
slight	O
increased	O
density	O
was	O
noted.The	O
bilateral	O
central	O
venous	O
lines	O
remain	O
in	O
place	O
and	O
there	O
is	O
no	O
pneumothorax	O
.	O
Pulmonary	O
vascular	O
markings	O
,	O
cardiac	O
and	O
mediastinal	O
contours	O
are	O
normal	O
.	O
-	O
Marked	O
improvement	O
versus	O
prior	O
with	O
only	O
minimal	O
residual	O
RLL	O
vague	O
density	O
appreciated	O
.	O
.	O
ABDOMEN	O
(	O
SUPINE	O
&	O
ERECT	O
)	O
[	O
**	O
2157-11-4	O
**	O
]	O
10:12	O
AM	O
Supine	O
and	O
upright	O
plain	O
radiograph	O
of	O
the	O
abdomen	O
and	O
pelvis	O
were	O
obtained	O
.	O
The	O
bowel	O
gas	O
pattern	O
is	O
unremarkable	O
and	O
there	O
is	O
no	O
evidence	O
of	O
free	O
air	O
or	O
obstruction	O
.	O
There	O
is	O
no	O
evidence	O
of	O
organomegaly	O
.	O
Rounded	O
calcifications	O
within	O
the	O
pelvis	O
likely	O
represent	O
phleboliths	O
.	O
Osseous	O
structures	O
are	O
unremarkable	O
.	O
-	O
No	O
evidence	O
of	O
obstruction	O
.	O
.	O
CT	O
PELVIS	O
W	O
/	O
CONTRAST	O
[	O
**	O
2157-11-6	O
**	O
]	O
2:24	O
PM	O
CT	O
CHEST	O
W	O
/	O
CONTRAST	O
;	O
CT	O
ABDOMEN	O
W	O
/	O
CONTRAST	O
CHEST	O
:	O
There	O
is	O
no	O
morphologically	O
significant	O
mediastinal	O
or	O
hilar	O
lymphadenopathy	O
.	O
There	O
is	O
no	O
pericardial	O
or	O
pleural	O
effusion	O
.	O
In	O
the	O
lung	O
window	O
,	O
note	O
is	O
made	O
of	O
atelectatic	O
opacities	O
in	O
the	O
lung	O
bases	O
,	O
however	O
,	O
no	O
other	O
consolidation	O
is	O
noted	O
.	O
The	O
central	O
airways	O
are	O
patent	O
.	O
The	O
evaluation	O
of	O
the	O
lung	O
parenchyma	O
is	O
somewhat	O
limited	O
due	O
to	O
a	O
motion	O
artifact	O
.	O
ABDOMEN	O
:	O
Again	O
note	O
is	O
made	O
of	O
1.7	O
cm	O
low	O
-	O
density	O
lesion	O
in	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
,	O
unchanged	O
since	O
prior	O
study	O
,	O
most	O
likely	O
representing	O
liver	O
cyst	O
.	O
Note	O
is	O
made	O
of	O
small	O
amount	O
of	O
gallbladder	O
edema	O
with	O
normal	O
enhancement	O
of	O
the	O
mucosa	O
,	O
with	O
a	O
nondistended	O
gallbladder	O
.	O
Spleen	O
,	O
pancreas	O
,	O
adrenal	O
glands	O
,	O
and	O
the	O
visualized	O
portion	O
of	O
the	O
large	O
and	O
small	O
intestines	O
are	O
within	O
normal	O
limits	O
.	O
No	O
significant	O
lymphadenopathy	O
.	O
No	O
ascites	O
.	O
Again	O
note	O
is	O
made	O
of	O
a	O
low	O
-	O
density	O
lesion	O
in	O
the	O
right	O
kidney	O
,	O
unchanged	O
since	O
prior	O
study	O
.	O
PELVIS	O
:	O
The	O
visualized	O
portion	O
of	O
large	O
and	O
small	O
intestines	O
are	O
within	O
normal	O
limits	O
.	O
There	O
is	O
no	O
ascites	O
or	O
lymphadenopathy	O
.	O
There	O
is	O
no	O
suspicious	O
lytic	O
or	O
blastic	O
lesion	O
in	O
skeletal	O
structures	O
.	O
IMPRESSION	O
:	O
1	O
.	O
NO	O
evidence	O
of	O
pneumonica	O
or	O
abdominal	O
abscess	O
.	O
2	O
.	O
Mild	O
edema	O
surrounding	O
nondistended	O
gallbladder	O
.	O
Clinical	O
correlation	O
is	O
recommended	O
.	O
3	O
.	O
Liver	O
cyst	O
and	O
renal	O
cyst	O
.	O
4	O
.	O
Basilar	O
atelectasis	O
.	O
.	O
CT	O
SINUS	O
/	O
MANDIBLE	O
/	O
MAXILLOFACIAL	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2157-11-9	O
**	O
]	O
3:45	O
PM	O
There	O
are	O
patent	O
nasal	O
-	O
antral	O
ostia	O
,	O
bilaterally	O
.	O
Uncinate	O
processes	O
are	O
intact	O
,	O
however	O
,	O
and	O
there	O
are	O
no	O
signs	O
of	O
post-surgical	O
change	O
.	O
The	O
appearance	O
is	O
smooth	O
and	O
symmetric	O
,	O
suggesting	O
that	O
the	O
appearance	O
may	O
be	O
congenital	O
,	O
or	O
perhaps	O
,	O
related	O
to	O
remote	O
inflammation	O
.	O
There	O
is	O
minimal	O
mucosal	O
thickening	O
in	O
the	O
ethmoid	O
sinuses	O
,	O
with	O
slight	O
circumferential	O
mucosal	O
thickening	O
in	O
the	O
sphenoid	O
sinus	O
.	O
The	O
maxillary	O
and	O
frontal	O
sinuses	O
are	O
clear	O
.	O
There	O
are	O
no	O
air	O
-	O
fluid	O
levels	O
to	O
suggest	O
acute	O
sinusitis	O
.	O
There	O
is	O
a	O
large	O
bony	O
spur	O
associated	O
with	O
mild	O
leftward	O
deviation	O
of	O
the	O
nasal	O
septum	O
,	O
but	O
the	O
middle	O
meatus	O
is	O
widely	O
patent	O
.	O
The	O
orbits	O
and	O
surrounding	O
soft	O
tissue	O
structures	O
are	O
unremarkable	O
.	O
The	O
osseous	O
structures	O
are	O
within	O
normal	O
limits	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Minimal	O
sphenoid	O
and	O
ethmoid	O
sinus	O
mucosal	O
thickening	O
,	O
without	O
air	O
-	O
fluid	O
levels	O
to	O
suggest	O
acute	O
sinusitis	O
.	O
2	O
.	O
Patent	O
maxillary	O
sinus	O
secondary	O
ostia	O
,	O
most	O
likely	O
congenital	O
.	O
.	O
CT	O
CHEST	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2157-11-18	O
**	O
]	O
3:59	O
PM	O
New	O
right	O
middle	O
lobe	O
consolidation	O
.	O
Given	O
the	O
fast	O
appearance	O
during	O
the	O
last	O
10	O
days	O
it	O
most	O
likely	O
represents	O
bacterial	O
pneumonia	O
.	O
Other	O
sources	O
of	O
infection	O
in	O
a	O
neutropenic	O
patient	O
such	O
as	O
fungal	O
infection	O
,	O
for	O
example	O
aspergillosis	O
or	O
mucormycosis	O
can	O
not	O
be	O
excluded	O
.	O
These	O
findings	O
were	O
communicated	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
10351	O
**	O
]	O
during	O
dictation	O
of	O
this	O
exam	O
.	O
.	O
[	O
**	O
11	O
-	O
27	O
**	O
]	O
BAL	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2157-11-27	O
**	O
]	O
)	O
:	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
MODIFIED	O
ACID	O
-	O
FAST	O
STAIN	O
FOR	O
NOCARDIA	O
(	O
Final	O
[	O
**	O
2157-11-29	O
**	O
]	O
)	O
:	O
Test	O
cancelled	O
by	O
laboratory	O
due	O
to	O
lack	O
of	O
branching	O
gram	O
positive	O
rods	O
in	O
the	O
gram	O
stain	O
.	O
Gram	O
stain	O
is	O
an	O
equally	O
sensitive	O
means	O
of	O
detecting	O
Nocardia	O
in	O
a	O
primary	O
specimen	O
.	O
Culture	O
may	O
be	O
a	O
more	O
sensitive	O
means	O
of	O
detecting	O
Nocardia	O
and	O
should	O
be	O
considered	O
.	O
PATIENT	O
CREDITED	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Final	O
[	O
**	O
2157-11-29	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
,	O
<	O
1000	O
CFU	O
/	O
ml	O
.	O
LEGIONELLA	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
LEGIONELLA	O
ISOLATED	O
.	O
IMMUNOFLUORESCENT	O
TEST	O
FOR	O
PNEUMOCYSTIS	O
CARINII	O
(	O
Final	O
[	O
**	O
2157-11-28	O
**	O
]	O
)	O
:	O
PNEUMOCYSTIS	O
CARINII	O
NOT	O
SEEN	O
.	O
FUNGAL	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
FUNGUS	O
ISOLATED	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2157-11-28	O
**	O
]	O
)	O
:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
CONCENTRATED	O
SMEAR	O
.	O
ACID	O
FAST	O
CULTURE	O
(	O
Pending	O
)	O
:	O
NOCARDIA	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
NOCARDIA	O
ISOLATED	O
.	O
Brief	O
Hospital	O
Course	O
:	O
61	O
y	O
/	O
o	O
F	O
admitted	O
for	O
Autologous	O
Bone	O
marrow	O
transplant	O
with	O
CBV	O
regimen	O
for	O
treatment	O
of	O
large	B-Reason
B	I-Reason
-	I-Reason
cell	I-Reason
lymphoma	I-Reason
.	O
She	O
is	O
status	O
post	O
multiple	O
chemotherapy	I-Drug
regimens	O
and	O
a	O
BM	O
harvest	O
in	O
the	O
OR	O
after	O
failed	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
.	O
Lymphoma	I-Reason
:	O
The	O
patient	O
was	O
admitted	O
to	O
undergo	O
autologous	O
stem	O
cell	O
transplantation	O
with	O
high	O
dose	O
chemotherapy	I-Drug
with	O
CBV	O
therapy	O
.	O
Admitted	O
Day	O
-	O
7	O
and	O
began	O
chemotherapy	I-Drug
D	O
-	O
7	O
.	O
Etoposide	I-Drug
,	O
Cytoxan	I-Drug
,	O
MESNA	I-Drug
,	O
BCNU	I-Drug
given	O
with	O
last	O
dose	O
9/30	O
.	O
Day	O
-2	O
started	O
acyclovir	I-Drug
,	O
ursodiol	I-Drug
.	O
PBCS	I-Drug
given	O
during	O
course	O
of	O
chemo	I-Drug
.	O
[	O
**	O
10	O
-	O
17	O
**	O
]	O
-	O
Day	O
-1	O
patient	O
complained	O
of	O
severe	O
nausea	O
with	O
emesis	O
.	O
[	O
**	O
10	O
-	O
18	O
**	O
]	O
,	O
on	O
day	O
0	O
stem	O
cells	O
given	O
with	O
gross	O
hematuria	O
during	O
.	O
Hematuria	O
prior	O
considered	O
hemorrhagic	B-Ade
cystitis	I-Ade
related	O
to	O
cytoxan	I-Drug
.	O
Patient	O
vigorously	O
hydrated	O
.	O
Course	O
complicated	O
by	O
severe	O
nausea	O
,	O
emesis	O
,	O
severe	O
mucositis	O
,	O
and	O
prolonged	O
neutropenia	O
.	O
Mucositis	O
severe	O
with	O
difficulty	O
swallowing	O
secretions	O
,	O
hematocrit	O
and	O
platelets	O
monitored	O
and	O
patient	O
made	O
NPO	O
with	O
TPN	O
and	O
fentanyl	I-Drug
PCA	O
for	O
pain	I-Reason
.	O
Mucositis	O
greatly	O
improved	O
by	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
,	O
but	O
unfortunately	O
patient	O
did	O
not	O
engraft	O
as	O
of	O
day	O
+17	O
,	O
ANC	O
150	O
,	O
with	O
very	O
slow	O
progression	O
of	O
WBC	O
,	O
though	O
given	O
bone	O
marrow	O
would	O
expect	O
slower	O
recovery	O
.	O
.	O
Fever	O
:	O
Pt	O
developed	O
a	O
fever	O
to	O
100.9	O
on	O
[	O
**	O
10	O
-	O
12	O
**	O
]	O
.	O
Cultures	O
sent	O
,	O
Chest	O
x-ray	O
with	O
likely	O
pneumonia	O
.	O
Penicillin	I-Drug
allergy	I-Ade
,	O
pt	O
unsure	O
if	O
cephalasporin	I-Drug
as	O
well	O
.	O
Treated	O
with	O
levofloxacin	I-Drug
and	O
vancomycin	I-Drug
.	O
Continued	O
with	O
chemo	I-Drug
.	O
Concerning	O
given	O
for	O
autologous	O
SCT	O
3	O
days	O
of	O
chemo	I-Drug
with	O
new	O
pneumonia	O
,	O
though	O
patient	O
asymptomatic	O
and	O
not	O
dramatic	O
picture	O
on	O
CXR	O
.	O
With	O
persistence	O
of	O
low	B-Reason
grade	I-Reason
temps	I-Reason
cefepime	I-Drug
also	O
started	O
[	O
**	O
10	O
-	O
15	O
**	O
]	O
.	O
Patient	O
completed	O
seven	O
day	O
course	O
for	O
CAP	I-Reason
on	O
[	O
**	O
10	O
-	O
15	O
**	O
]	O
.	O
line	O
site	O
with	O
erythema	O
,	O
pt	O
still	O
febrile	O
,	O
added	O
flagyl	I-Drug
to	O
already	O
broad	O
coverage	O
of	O
cefepime	I-Drug
,	O
vanc	I-Drug
,	O
caspo	I-Drug
.	O
cefepime	I-Drug
started	O
[	O
**	O
10	O
-	O
19	O
**	O
]	O
,	O
DC	O
[	O
**	O
10	O
-	O
25	O
**	O
]	O
.	O
flagyl	I-Drug
started	O
[	O
**	O
10	O
-	O
24	O
**	O
]	O
,	O
DC	O
[	O
**	O
10	O
-	O
25	O
**	O
]	O
.	O
meropenem	I-Drug
started	O
[	O
**	O
10	O
-	O
25	O
**	O
]	O
,	O
given	O
nausea	I-Reason
.	O
caspo	I-Drug
started	O
[	O
**	O
10	O
-	O
21	O
**	O
]	O
.	O
[	O
**	O
10	O
-	O
26	O
**	O
]	O
pulled	O
subclavian	O
line	O
on	O
right	O
.	O
Pt	O
febrile	O
despite	O
being	O
on	O
meropenem	I-Drug
,	O
vancomycin	I-Drug
,	O
caspofungin	I-Drug
,	O
acyclovir	I-Drug
,	O
with	O
no	O
blood	O
cultures	O
or	O
catheter	O
tip	O
cultures	O
positive	O
to	O
date	O
.	O
Of	O
note	O
patient	O
neutropenic	O
with	O
ANC	O
150	O
day	O
+17	O
.	O
.	O
Dysphagia	O
-	O
onset	O
[	O
**	O
10	O
-	O
18	O
**	O
]	O
in	O
relation	O
to	O
severe	O
mucositis	O
,	O
etiologies	O
to	O
consider	O
primarily	O
musositis	O
,	O
though	O
viral	O
bacterial	O
,	O
fungal	O
infection	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
329	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
tear	O
from	O
severe	O
wretching	O
all	O
possibilities	O
.	O
Patient	O
kept	O
NPO	O
,	O
TPN	O
started	O
,	O
acyclovir	I-Drug
,	O
cefepime	I-Drug
,	O
and	O
fentanyl	I-Drug
PCA	O
.	O
Improved	O
by	O
day	O
+15	O
,	O
and	O
patient	O
able	O
to	O
tolerate	O
PO	O
,	O
though	O
with	O
emesis	O
.	O
.	O
Anemia	I-Reason
,	O
thrombocytopenia	I-Reason
-	O
epistaxis	O
.	O
Platelets	I-Drug
and	O
PRBC	I-Drug
transfusions	O
throughout	O
course	O
of	O
stay	O
.	O
.	O
nausea	I-Reason
-	O
zofran	I-Drug
,	O
ativan	I-Drug
,	O
and	O
anzemet	I-Drug
with	O
chemo	I-Drug
.	O
scopolamine	I-Drug
patch	O
attempted	O
in	O
addition	O
to	O
decadron	I-Drug
4	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
Patient	O
continued	O
to	O
have	O
severe	O
nausea	O
which	O
dissipated	O
one	O
into	O
treatment	O
but	O
returned	O
three	O
weeks	O
into	O
treatment	O
once	O
patient	O
attempted	O
to	O
restart	O
PO	O
intake	O
.	O
Emesis	O
shortly	O
after	O
eating	O
with	O
no	O
associated	O
cramping	O
.	O
Patient	O
with	O
bowel	O
movements	O
and	O
passing	O
flatus	O
.	O
KUB	O
negative	O
for	O
obtruction	O
and	O
patient	O
encouraged	O
to	O
start	O
slow	O
with	O
PO	O
to	O
advance	O
as	O
tolerated	O
.	O
.	O
ICU	O
COURSE	O
:	O
Patient	O
transferred	O
to	O
ICU	O
on	O
[	O
**	O
2157-11-27	O
**	O
]	O
after	O
found	O
to	O
have	O
a	O
worsening	O
RML	O
consolidation	O
,	O
occluded	O
RML	O
bronchus	O
,	O
and	O
bilateral	O
effusions	O
.	O
Pt	O
underwent	O
bronchoscopy	O
,	O
had	O
new	O
O2	O
requirement	O
(	O
94	O
%	O
on	O
6L	O
)	O
after	O
the	O
procedure	O
.	O
She	O
was	O
subsequently	O
placed	O
on	O
BiPAP	O
,	O
progressively	O
worsening	O
SOB	O
and	O
O2	I-Drug
requirement	O
,	O
and	O
became	O
more	O
SOB	O
requiring	O
60	O
%	O
FM	O
with	O
6L	O
NC	O
to	O
maintain	O
O2	O
sat	O
in	O
the	O
90's	O
.	O
Pt	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
closer	O
monitoring	O
.	O
She	O
had	O
repeat	O
bronchoscopy	O
.	O
Large	O
mucous	O
plug	O
noted	O
in	O
RML	O
bronchus	O
,	O
unable	O
to	O
be	O
removed	O
.	O
.	O
Ultimately	O
,	O
her	O
SOB	O
/	O
hypoxia	O
felt	O
possibly	O
an	O
infectious	O
etiology	O
although	O
no	O
identified	O
source	O
after	O
3	O
BALs	O
.	O
Pt	O
with	O
significant	O
lung	O
pathology	O
(	O
RML	O
consolidation	O
,	O
RML	O
bronchus	O
occlusion	O
,	O
and	O
BL	O
pleural	O
effusions	O
)	O
as	O
well	O
as	O
RLL	O
involvment	O
.	O
She	O
had	O
three	O
total	O
bronchs	O
without	O
bug	O
isolated	O
.	O
Abx	I-Drug
regimen	O
:	O
levoflox	I-Drug
,	O
flagyl	I-Drug
,	O
caspo	I-Drug
,	O
Posaconazle	I-Drug
later	O
switched	O
to	O
ambisome	I-Drug
,	O
and	O
Minocylcine	I-Drug
.	O
Minocycline	I-Drug
for	O
coverage	O
of	O
some	O
Nocardia	B-Reason
species	I-Reason
(	O
other	O
options	O
cause	O
marrow	B-Ade
suppression	I-Ade
including	O
Bactrim	I-Drug
,	O
Linezolid	I-Drug
)	O
.	O
Meropenem	I-Drug
was	O
attempted	O
;	O
however	O
,	O
after	O
desensitization	O
,	O
patient	O
developed	O
A-fib	I-Ade
after	O
dose	O
.	O
It	O
was	O
unclear	O
and	O
unlikely	O
that	O
the	O
afib	O
was	O
related	O
to	O
the	O
meropenam	I-Drug
.	O
.	O
During	O
her	O
ICU	O
course	O
,	O
she	O
also	O
developed	O
Afib	B-Reason
with	I-Reason
RVR	I-Reason
.	O
Started	O
on	O
Procainamide	I-Drug
,	O
per	O
cards	O
recs	O
.	O
She	O
continued	O
metoprolol	I-Drug
25	O
mg	O
PO	O
BID	O
,	O
discontinued	O
digoxin	I-Drug
.	O
Her	O
hemondynamic	O
status	O
was	O
unstable	O
and	O
metoprolol	I-Drug
was	O
then	O
stopped	O
.	O
Then	O
,	O
she	O
was	O
noted	O
to	O
have	O
several	O
episodes	O
of	O
V	O
tach	O
,	O
which	O
resolved	O
prior	O
to	O
requiring	O
pads	O
.	O
Her	O
QTc	I-Reason
was	O
monitored	O
while	O
on	O
Procainamide	I-Drug
.	O
.	O
On	O
[	O
**	O
2157-11-30	O
**	O
]	O
,	O
her	O
cardiac	O
status	O
had	O
not	O
improved	O
.	O
She	O
also	O
became	O
hypotensive	I-Reason
and	O
bradycardic	I-Reason
,	O
ultimately	O
requiring	O
dobutamine	I-Drug
and	O
levophed	I-Drug
with	O
minimal	O
improvement	O
in	O
MAP	O
.	O
UOP	O
declined	O
,	O
lactate	O
rose	O
to	O
14	O
.	O
.	O
Family	O
meeting	O
with	O
patients	O
family	O
and	O
oncologists	O
on	O
[	O
**	O
2157-11-30	O
**	O
]	O
.	O
Family	O
ultimately	O
decided	O
that	O
patient	O
should	O
have	O
no	O
further	O
escalation	O
of	O
care	O
.	O
Later	O
that	O
evening	O
,	O
patient	O
's	O
BP	O
and	O
HR	O
began	O
to	O
decline	O
,	O
and	O
she	O
passed	O
away	O
peacefully	O
with	O
family	O
by	O
bedside	O
.	O
Family	O
agreed	O
to	O
an	O
autopsy	O
to	O
shed	O
light	O
on	O
the	O
cause	O
for	O
her	O
hypoxia	O
/	O
pulmonary	O
dysfunction	O
as	O
well	O
as	O
for	O
the	O
subacute	O
worsening	O
of	O
hemodynamic	O
status	O
,	O
decreased	O
UOP	O
,	O
and	O
elevated	O
lactate	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
2	O
.	O
Zofran	I-Drug
8	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
3	O
.	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
Tab	O
Sust.Rel	O
.	O
Particle	O
/	O
Crystal	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tab	O
Sust.Rel	O
.	O
Particle	O
/	O
Crystal	O
PO	O
once	O
a	O
day	O
.	O
4	O
.	O
Allopurinol	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
5	O
.	O
Levofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
deceased	O
hypoxia	O
cardiac	O
arrest	O
acute	O
renal	O
failure	O
Discharge	O
Condition	O
:	O
deceased	O

Admission	O
Date	O
:	O
[	O
**	O
2143-12-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2144-1-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2069-9-2	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Aspirin	I-Drug
/	O
lisinopril	I-Drug
/	O
Nifedipine	I-Drug
/	O
Cephalexin	I-Drug
/	O
Nafcillin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2782	O
**	O
]	O
Chief	O
Complaint	O
:	O
Abnormal	O
labs	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
74	O
-	O
year	O
-	O
old	O
gentleman	O
with	O
a	O
pmhx	O
.	O
significant	O
for	O
dCHF	O
,	O
afib	I-Reason
on	O
coumadin	I-Drug
,	O
CKD	O
,	O
MSSA	O
/	O
GBS	O
bacteremia	O
,	O
and	O
was	O
recently	O
discharged	O
on	O
[	O
**	O
2143-12-19	O
**	O
]	O
for	O
compression	O
fracture	O
of	O
T11	O
vertebrea	O
and	O
afib	O
with	O
RVR	O
who	O
presents	O
to	O
the	O
ED	O
at	O
the	O
request	O
of	O
his	O
nurse	O
practioner	O
for	O
elevated	O
potassium	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
19829	O
**	O
]	O
had	O
been	O
evaluated	O
in	O
the	O
infectious	O
disease	O
clinic	O
on	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
and	O
had	O
routine	O
labs	O
drawn	O
,	O
at	O
which	O
time	O
his	O
potassium	O
was	O
found	O
to	O
be	O
5.7	O
.	O
He	O
was	O
told	O
to	O
go	O
to	O
the	O
ED	O
that	O
night	O
for	O
evaluation	O
,	O
but	O
decided	O
to	O
come	O
in	O
the	O
next	O
day	O
.	O
Patient	O
denies	O
any	O
particular	O
complaints	O
but	O
does	O
complain	O
of	O
fatigue	O
.	O
No	O
headache	O
,	O
fevers	O
,	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
or	O
other	O
concerning	O
signs	O
or	O
symptoms	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vitals	O
were	O
:	O
97.3	O
120105/72	O
22	O
100	O
%	O
RA	O
.	O
Labs	O
were	O
significant	O
for	O
a	O
creatinine	O
of	O
3.3	O
up	O
from	O
a	O
baseline	O
of	O
1.5	O
and	O
a	O
potassium	O
of	O
6.1	O
.	O
Patient	O
complained	O
of	O
wheezing	O
and	O
chest	O
congestion	O
and	O
received	O
a	O
dose	O
of	O
levaquin	I-Drug
for	O
presumed	O
HCAP	I-Reason
.	O
He	O
also	O
received	O
nebs	I-Drug
,	O
15grams	O
of	O
kayexalate	I-Drug
and	O
250cc	O
of	O
fluid	I-Drug
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
19829	O
**	O
]	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
further	O
evaluation	O
and	O
work	O
-	O
up	O
.	O
Past	O
Medical	O
History	O
:	O
--	O
S.	B-Reason
aureus	I-Reason
/	I-Reason
G	I-Reason
-	I-Reason
strep	I-Reason
bacteremia	I-Reason
:	O
Unknown	O
source	O
although	O
left	O
maxillary	O
dental	O
abscess	O
suspected	O
.	O
Was	O
on	O
IV	O
nafcillin	I-Drug
until	O
[	O
**	O
2143-12-16	O
**	O
]	O
,	O
followed	O
in	O
[	O
**	O
Hospital	O
**	O
]	O
[	O
**	O
Hospital	O
4898	O
**	O
]	O
clinic	O
.	O
--	O
Retroperitoneal	O
Hemmorhage	O
[	O
**	O
2143-6-7	O
**	O
]	O
in	O
the	O
setting	O
of	O
INR	O
of	O
8	O
--	O
Diastolic	O
CHF	O
--	O
HTN	O
--	O
Asthma	O
--	O
Atrial	B-Reason
fibrillation	I-Reason
,	O
on	O
warfarin	I-Drug
.	O
s	O
/	O
p	O
multiple	O
cardioversions	O
,	O
last	O
TEE	O
-	O
guided	O
cardioversion	O
on	O
[	O
**	O
2143-11-5	O
**	O
]	O
--	O
Atopic	O
dermatitis	O
--	O
Hypercholesterolemia	O
--	O
CKD	O
(	O
creatine	O
from	O
1.4	O
-	O
2.3	O
in	O
the	O
last	O
2	O
months	O
)	O
--	O
s	O
/	O
p	O
UGI	O
bleed	O
in	O
[	O
**	O
2130	O
**	O
]	O
from	O
two	O
gastric	O
ulcers	O
,	O
H.	O
pylori	O
neg	O
--	O
hx	O
of	O
colonic	O
adenomas	O
on	O
colonoscopy	O
in	O
[	O
**	O
2133	O
**	O
]	O
--	O
s	O
/	O
p	O
appendectomy	O
--	O
Normocytic	O
anemia	O
-	O
recent	O
BM	O
bx	O
on	O
[	O
**	O
5	O
-	O
24	O
**	O
]	O
which	O
showed	O
mild	O
erythroid	O
dyspoiesis	O
suggesting	O
the	O
possibility	O
of	O
an	O
early	O
evolving	O
MDS	O
.	O
Cytogenetics	O
and	O
FISH	O
for	O
MDS	O
were	O
negative	O
.	O
--	O
Herpes	O
Zoster	O
on	O
upper	O
back	O
in	O
[	O
**	O
2143-5-8	O
**	O
]	O
--	O
Gout	O
Social	O
History	O
:	O
Originally	O
from	O
[	O
**	O
Country	O
19828	O
**	O
]	O
;	O
came	O
to	O
US	O
in	O
the	O
[	O
**	O
2091	O
**	O
]	O
.	O
Married	O
,	O
lives	O
with	O
his	O
wife	O
.	O
Three	O
adult	O
daughters	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1403	O
**	O
]	O
as	O
a	O
physicist	O
for	O
radiation	O
oncology	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
/	O
[	O
**	O
Company	O
2860	O
**	O
]	O
.	O
Previously	O
employed	O
by	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Denies	O
tobacco	O
or	O
illicit	O
drug	O
use	O
.	O
Occasional	O
EtOH	O
-	O
1	O
drink	O
several	O
times	O
per	O
week	O
.	O
Family	O
History	O
:	O
Mother	O
died	O
of	O
complications	O
of	O
childbirth	O
.	O
Father	O
died	O
in	O
his	O
90s	O
from	O
complications	O
of	O
an	O
aortic	O
aneurysm	O
.	O
Brother	O
died	O
of	O
cancer	O
of	O
unknown	O
primary	O
.	O
Son	O
died	O
10	O
years	O
ago	O
by	O
drowning	O
during	O
a	O
caving	O
expedition	O
.	O
Three	O
daughters	O
are	O
alive	O
and	O
well	O
.	O
Multiple	O
family	O
members	O
have	O
eczema	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
96.6	O
,	O
83	O
,	O
109/70	O
,	O
16	O
GENERAL	O
:	O
No	O
acute	O
distress	O
,	O
wheezy	O
HEENT	O
:	O
EOMI	O
,	O
very	O
dry	O
mucous	O
membranes	O
NECK	O
:	O
Supple	O
,	O
no	O
cervical	O
LAD	O
LUNGS	O
:	O
Moderate	O
air	O
movement	O
bilaterally	O
,	O
expiratory	O
upper	O
airway	O
wheezes	O
HEART	O
:	O
Irregularly	O
irregular	O
,	O
no	O
MRG	O
ABDOMEN	O
:	O
Obese	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
,	O
no	O
organomegaly	O
,	O
no	O
rebounding	O
or	O
guarding	O
EXTREMITIES	O
:	O
2	O
+	O
edema	O
bilaterally	O
,	O
peripheral	O
pulses	O
intact	O
SKIN	O
:	O
Diffuse	O
blanching	O
erythema	O
over	O
entire	O
body	O
NEURO	O
:	O
Alert	O
and	O
oriented	O
x3	O
PSYCH	O
:	O
Calm	O
,	O
appropriate	O
affect	O
Pertinent	O
Results	O
:	O
[	O
**	O
2143-12-27	O
**	O
]	O
10:18	O
PM	O
GLUCOSE	O
-	O
108	O
*	O
UREA	O
N	O
-	O
90	O
*	O
CREAT	O
-	O
3.3	O
*	O
SODIUM	O
-	O
144	O
POTASSIUM	O
-	O
5.8	O
*	O
CHLORIDE	O
-	O
110	O
*	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
18	O
[	O
**	O
2143-12-27	O
**	O
]	O
10:18	O
PM	O
CALCIUM	O
-	O
8.4	O
PHOSPHATE	O
-	O
8.2	O
*	O
#	O
MAGNESIUM	O
-	O
2.4	O
[	O
**	O
2143-12-27	O
**	O
]	O
10:18	O
PM	O
WBC	O
-	O
7.4	O
RBC	O
-	O
2.48	O
*	O
HGB	O
-	O
8.2	O
*	O
HCT	O
-	O
25.6	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
33.3	O
*	O
MCHC	O
-	O
32.2	O
RDW	O
-	O
16.7	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
10:18	O
PM	O
NEUTS	O
-	O
78.6	O
*	O
LYMPHS	O
-	O
10.9	O
*	O
MONOS	O
-	O
8.5	O
EOS	O
-	O
1.5	O
BASOS	O
-	O
0.5	O
[	O
**	O
2143-12-27	O
**	O
]	O
10:18	O
PM	O
PLT	O
COUNT	O
-	O
409	O
[	O
**	O
2143-12-27	O
**	O
]	O
10:18	O
PM	O
PT	O
-	O
30.4	O
*	O
PTT	O
-	O
42.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.9	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
06:17	O
PM	O
PO2	O
-	O
47	O
*	O
PCO2	O
-	O
52	O
*	O
PH	O
-	O
7.22	O
*	O
TOTAL	O
CO2	O
-	O
22	O
BASE	O
XS	O
--	O
6	O
COMMENTS	O
-	O
GREEN	O
[	O
**	O
2143-12-27	O
**	O
]	O
06:17	O
PM	O
LACTATE	O
-	O
1.7	O
K	O
+	O
-	O
6.1	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
GLUCOSE	O
-	O
131	O
*	O
UREA	O
N	O
-	O
88	O
*	O
CREAT	O
-	O
3.3	O
*	O
#	O
SODIUM	O
-	O
141	O
POTASSIUM	O
-	O
7.6	O
*	O
CHLORIDE	O
-	O
108	O
TOTAL	O
CO2	O
-	O
20	O
*	O
ANION	O
GAP	O
-	O
21	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
81	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
cTropnT	O
-	O
0.08	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
CK	O
-	O
MB	O
-	O
5	O
proBNP	O
-	O
4982	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
WBC	O
-	O
10.4	O
RBC	O
-	O
2.81	O
*	O
HGB	O
-	O
9.3	O
*	O
HCT	O
-	O
29.0	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
33.3	O
*	O
MCHC	O
-	O
32.2	O
RDW	O
-	O
16.7	O
*	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
NEUTS	O
-	O
80.3	O
*	O
LYMPHS	O
-	O
9.0	O
*	O
MONOS	O
-	O
8.4	O
EOS	O
-	O
1.5	O
BASOS	O
-	O
0.8	O
[	O
**	O
2143-12-27	O
**	O
]	O
04:30	O
PM	O
PLT	O
COUNT	O
-	O
532	O
*	O
.	O
TEE	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
aortic	O
arch	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
moderate	O
bileaflet	O
mitral	O
valve	O
prolapse	O
.	O
No	O
mass	O
or	O
vegetation	O
is	O
seen	O
on	O
the	O
mitral	O
valve	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
9	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
IMPRESSION	O
:	O
Mitral	O
and	O
aortic	O
leaflets	O
are	O
thickened	O
but	O
no	O
discrete	O
vegetation	O
is	O
identified	O
.	O
No	O
abscess	O
seen	O
.	O
.	O
TTE	O
:	O
MPRESSION	O
:	O
Aortic	O
leaflet	O
thickened	O
with	O
mild	O
aortic	O
regurgitation	O
but	O
no	O
discrete	O
vegetation	O
.	O
Moderate	O
mitral	O
regurgitation	O
with	O
thickened	O
leaflets	O
but	O
without	O
discrete	O
vegetation	O
.	O
Pulmonary	O
artery	O
hypertension	O
.	O
Minimal	O
aortic	O
valve	O
stenosis	O
.	O
Dilated	O
thoracic	O
aorta	O
.	O
.	O
MRI	O
TSpine	O
/	O
LSpine	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
osteomyelitis	O
,	O
discitis	O
or	O
epidural	O
abscess	O
.	O
2	O
.	O
Interval	O
subacute	O
T11	O
compression	O
fracture	O
without	O
retropulsion	O
.	O
3	O
.	O
Interval	O
progression	O
of	O
the	O
known	O
L1	O
compression	O
fracture	O
,	O
but	O
without	O
retropulsion	O
.	O
4	O
.	O
Low	O
lumbar	O
degenerative	O
changes	O
,	O
without	O
spinal	O
stenosis	O
.	O
.	O
[	O
**	O
2143-12-27	O
**	O
]	O
Chest	O
PA	O
and	O
lateral	O
radiograph	O
demonstrates	O
unremarkable	O
mediastinal	O
and	O
hilar	O
contours	O
.	O
Stable	O
mild	O
cardiomegaly	O
evident	O
.	O
Increased	O
opacity	O
overlying	O
the	O
right	O
diaphragm	O
on	O
background	O
of	O
right	O
lower	O
lung	O
atelectasis	O
,	O
may	O
indicate	O
pneumonia	O
.	O
No	O
pleural	O
effusion	O
or	O
pneumothorax	O
evident	O
.	O
Stable	O
L1	O
and	O
T12	O
compression	O
fractures	O
.	O
Stable	O
degenerative	O
changes	O
of	O
the	O
right	O
shoulder	O
.	O
IMPRESSION	O
:	O
Increased	O
opacity	O
of	O
right	O
lower	O
lung	O
may	O
reflect	O
worsening	O
atelectasis	O
,	O
though	O
in	O
proper	O
clinical	O
setting	O
,	O
pneumonia	O
is	O
a	O
possibility	O
.	O
No	O
pleural	O
effusion	O
evident	O
.	O
.	O
Culture	O
data	O
(	O
organism	O
and	O
susceptibilities	O
)	O
:	O
STAPHYLOCOCCUS	O
EPIDERMIDIS	O
|	O
STAPHYLOCOCCUSEPIDERMIDIS	O
|	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
=	O
>	O
8	O
R	O
=	O
>	O
8	O
R	O
DAPTOMYCIN	I-Drug
------------	O
S	O
S	O
ERYTHROMYCIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
=	O
>	O
8	O
R	O
GENTAMICIN	I-Drug
------------	O
4	O
S	O
4	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
=	O
>	O
8	O
R	O
LINEZOLID	I-Drug
-------------	O
1	O
S	O
2	O
S	O
OXACILLIN	I-Drug
-------------	O
=	O
>	O
4	O
R	O
=	O
>	O
4	O
R	O
RIFAMPIN	I-Drug
--------------	O
=	O
>	O
32	O
R	O
=	O
>	O
32	O
R	O
TETRACYCLINE	I-Drug
----------	O
=	O
>	O
16	O
R	O
=	O
>	O
16	O
R	O
VANCOMYCIN	I-Drug
------------	O
2	O
S	O
2	O
S	O
Brief	O
Hospital	O
Course	O
:	O
BRIEF	O
HOSPITAL	O
COURSE	O
:	O
This	O
is	O
a	O
74	O
-	O
year	O
-	O
old	O
gentleman	O
with	O
a	O
pmhx	O
significant	O
for	O
recent	O
MSSA	O
and	O
group	O
G	O
strep	O
bactremia	O
,	O
dCHF	O
,	O
asthma	O
,	O
and	O
afib	I-Reason
on	O
coumadin	I-Drug
who	O
was	O
admitted	O
after	O
routine	O
lab	O
tests	O
showed	O
an	O
elevated	O
potassium	O
.	O
He	O
was	O
found	O
to	O
be	O
bacteremic	I-Reason
on	O
admission	O
.	O
A	O
work	O
-	O
up	O
for	O
the	O
source	O
was	O
inconclusive	O
.	O
He	O
was	O
discharged	O
with	O
a	O
PICC	O
line	O
for	O
likely	O
6	O
weeks	O
of	O
vancomycin	I-Drug
therapy	O
.	O
.	O
ACTIVE	O
ISSUES	O
:	O
#	O
POSITIVE	B-Reason
BLOOD	I-Reason
CULTURES	I-Reason
:	O
Blood	O
cultures	O
from	O
[	O
**	O
12	O
-	O
27	O
**	O
]	O
to	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
grew	O
methicillin	O
resistant	O
staph	O
.	O
epidermis	O
.	O
Source	O
search	O
included	O
evaluation	O
for	O
valvular	O
vegetations	O
included	O
TTE	O
and	O
TEE	O
which	O
were	O
unrevealing	O
.	O
Given	O
history	O
of	O
compression	O
fractures	O
an	O
MRI	O
T	O
and	O
L	O
spine	O
showed	O
no	O
source	O
.	O
A	O
RUQ	O
ultrasound	O
was	O
obtained	O
in	O
setting	O
of	O
right	O
upper	O
extremity	O
edema	O
and	O
pain	O
on	O
palpation	O
of	O
the	O
axilla	O
revealed	O
evidence	O
of	O
a	O
non	O
occlusive	O
clot	O
.	O
In	O
setting	O
of	O
atopic	O
dermatitis	O
,	O
multiple	O
skin	O
lesions	O
and	O
recent	O
knee	O
injury	O
with	O
slow	O
healing	O
wound	O
,	O
skin	O
source	O
entertained	O
.	O
A	O
picc	O
line	O
was	O
placed	O
and	O
4	O
-	O
6	O
weeks	O
of	O
vancomycin	I-Drug
will	O
be	O
continued	O
at	O
discharge	O
dose	O
of	O
750	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
.	O
#	O
ACUTE	B-Reason
RENAL	I-Reason
FAILURE	I-Reason
:	O
Patient	O
with	O
creatinine	O
of	O
3.3	O
up	O
from	O
a	O
baseline	O
of	O
1.5	O
.	O
On	O
admission	O
,	O
patient	O
was	O
89	O
kg	O
,	O
down	O
from	O
94.9	O
kg	O
on	O
[	O
**	O
2143-12-16	O
**	O
]	O
.	O
He	O
appeared	O
hypovolemic	O
with	O
increased	O
thirst	O
,	O
and	O
BUN	O
/	O
creatinine	O
ratio	O
is	O
>	O
20	O
.	O
Urine	O
lytes	O
demonstrated	O
FeUrea	O
<	O
34	O
(	O
25	O
)	O
consistent	O
with	O
pre-renal	O
etiology	O
.	O
After	O
administration	O
of	O
IVF	I-Drug
,	O
renal	O
function	O
improved	O
with	O
discharge	O
creatinine	O
1.1	O
.	O
AIN	I-Ade
possibly	O
contributed	O
given	O
recent	O
treatment	O
with	O
Nafcillin	I-Drug
.	O
Urine	O
eosinophils	O
were	O
positive	O
.	O
Valsartan	I-Drug
and	O
lasix	I-Drug
were	O
initially	O
held	O
.	O
Valsartan	I-Drug
was	O
restarted	O
prior	O
to	O
discharge	O
and	O
lasix	I-Drug
was	O
restarted	O
at	O
a	O
lower	O
dose	O
40	O
mg	O
.	O
.	O
#	O
HYPERKALEMIA	I-Ade
:	O
Likely	O
in	O
the	O
setting	O
of	O
dehydration	O
,	O
renal	O
failure	O
,	O
and	O
valsartan	I-Drug
.	O
With	O
fluids	I-Drug
and	O
kayexalate	I-Drug
,	O
patient	O
's	O
potassium	O
trended	O
down	O
.	O
.	O
#	O
SHORTNESS	B-Reason
OF	I-Reason
BREATH	I-Reason
:	O
Differential	O
includes	O
asthma	O
exacerbation	O
vs.	O
pneumonia	O
vs.	O
bronchitis	O
vs.	O
volume	O
overload	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
19829	O
**	O
]	O
was	O
given	O
a	O
prednisone	I-Drug
burst	O
(	O
5	O
days	O
of	O
40	O
mg	O
prednisone	I-Drug
)	O
with	O
significant	O
improvement	O
in	O
his	O
symptoms	O
.	O
His	O
Advair	I-Drug
was	O
increased	O
to	O
500/50	O
and	O
he	O
was	O
started	O
on	O
Singulair	I-Drug
.	O
.	O
INACTIVE	O
ISSUES	O
:	O
#	O
AFIB	B-Reason
WITH	I-Reason
RVR	I-Reason
:	O
Metoprolol	I-Drug
,	O
diltiazem	I-Drug
and	O
coumadin	I-Drug
were	O
continued	O
during	O
admission	O
.	O
.	O
#	O
HTN	I-Reason
:	O
Metoprolol	I-Drug
and	O
dlitiazem	I-Drug
was	O
continued	O
.	O
.	O
#	O
ATOPIC	B-Reason
DERMATITIS	I-Reason
:	O
Hydroxyzine	I-Drug
and	O
clobetasol	I-Drug
were	O
continued	O
during	O
admission	O
.	O
.	O
TRANSITIONAL	O
ISSUES	O
:	O
-	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
702	O
**	O
]	O
:	O
basic	O
metabolic	O
panel	O
-	O
OPAT	O
follow	O
-	O
up	O
:	O
Vancomycin	I-Drug
trough	O
at	O
discharge	O
was	O
22	O
-	O
Code	O
Status	O
:	O
Full	O
Medications	O
on	O
Admission	O
:	O
fluticasone	B-Drug
-	I-Drug
salmeterol	O
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
-	O
1	O
puff	O
[	O
**	O
Hospital1	O
**	O
]	O
hydroxyzine	I-Drug
HCl	O
25	O
mg	O
qhs	O
simvastatin	B-Drug
40	O
mg	O
daily	O
clobetasol	I-Drug
0.05	O
%	O
Ointment	O
[	O
**	O
Hospital1	O
**	O
]	O
valsartan	B-Drug
80	O
mg	O
daily	O
ipratropium	B-Drug
bromide	I-Drug
17	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
every	O
6	O
-	O
7	O
hours	O
prn	O
cholecalciferol	I-Drug
400	O
unit	O
daily	O
multivitamin	I-Drug
Tablet	O
daily	O
metoprolol	I-Drug
succinate	O
200	O
mg	O
daily	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
q4h	O
prn	O
Lasix	I-Drug
60	O
mg	O
Tablet	O
daily	O
warfarin	I-Drug
5	O
mg	O
Tablet	O
daily	O
for	O
7	O
days	O
dilt	I-Drug
120	O
mg	O
ER	O
daily	O
oxycodone	B-Drug
-	I-Drug
acetaminophen	O
5	O
-	O
325	O
mg	O
Tablet	O
q6h	O
prn	O
pain	I-Reason
Discharge	O
Medications	O
:	O
1	O
.	O
vancomycin	I-Drug
750	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
twice	O
a	O
day	O
for	O
6	O
weeks	O
.	O
Disp	O
:	O
*	O
qs	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
fluticasone	I-Drug
-	O
salmeterol	O
500	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
hydroxyzine	I-Drug
HCl	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
4	O
.	O
simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
clobetasol	I-Drug
0.05	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
valsartan	B-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
7	O
.	O
ipratropium	B-Drug
bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
8	O
.	O
cholecalciferol	I-Drug
(	O
vitamin	B-Drug
D3	I-Drug
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
9	O
.	O
multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
metoprolol	B-Drug
succinate	I-Drug
200	O
mg	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
11	O
.	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
every	O
four	O
(	O
4	O
)	O
hours	O
.	O
12	O
.	O
furosemide	B-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
13	O
.	O
warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
14	O
.	O
diltiazem	I-Drug
HCl	O
120	O
mg	O
Capsule	O
,	O
Extended	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Extended	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
oxycodone	B-Drug
-	I-Drug
acetaminophen	O
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Primary	O
home	O
care	O
specialists	O
Discharge	O
Diagnosis	O
:	O
Acute	O
on	O
chronic	O
kidney	O
injury	O
Bacteriemia	O
Atrial	O
fibrillation	O
Congestive	O
heart	O
failure	O
Asthma	O
Atopic	O
dermatitis	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
It	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
.	O
You	O
came	O
because	O
of	O
high	O
potassium	O
.	O
Your	O
potassium	O
was	O
high	O
because	O
your	O
kidneys	O
were	O
not	O
functioning	O
as	O
they	O
usually	O
do	O
.	O
We	O
gave	O
you	O
fluid	I-Drug
and	O
held	O
diuretics	I-Drug
for	O
few	O
days	O
and	O
your	O
kidney	O
function	O
came	O
back	O
to	O
the	O
baseline	O
.	O
While	O
you	O
were	O
in	O
the	O
hospital	O
we	O
found	O
a	O
bacteria	B-Reason
in	I-Reason
your	O
blood	O
.	O
Therefore	O
we	O
had	O
to	O
give	O
you	O
intravenous	O
antibiotics	I-Drug
that	O
you	O
have	O
to	O
continue	O
at	O
home	O
for	O
6	O
weeks	O
.	O
We	O
have	O
done	O
the	O
following	O
changes	O
to	O
your	O
medication	O
:	O
TAKE	O
VANCOMYCIN	I-Drug
750	O
mg	O
intarvenously	O
through	O
the	O
PICC	O
line	O
twice	O
a	O
day	O
.	O
Home	O
service	O
will	O
come	O
to	O
help	O
you	O
.	O
CHANGE	O
furosemide	I-Drug
60	O
mg	O
daily	O
to	O
furosemide	I-Drug
40	O
mg	O
daily	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
TUESDAY	O
[	O
**	O
2144-1-7	O
**	O
]	O
at	O
10:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
647	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
.	O
Department	O
:	O
[	O
**	O
Hospital3	O
249	O
**	O
]	O
When	O
:	O
TUESDAY	O
[	O
**	O
2144-1-7	O
**	O
]	O
at	O
2:20	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
198	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
199	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
.	O
Department	O
:	O
INFECTIOUS	O
DISEASE	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2144-1-22	O
**	O
]	O
at	O
10:30	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
1037	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2335	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
457	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Hospital	O
1422	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O

Admission	O
Date	O
:	O
[	O
**	O
2138-3-20	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2138-4-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2091-2-17	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
Medicine	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
a	O
47	O
-	O
year	O
-	O
old	O
gentleman	O
with	O
hepatitis	O
C	O
cirrhosis	O
who	O
is	O
high	O
up	O
on	O
the	O
transplant	O
list	O
,	O
who	O
for	O
the	O
last	O
five	O
days	O
prior	O
to	O
admission	O
had	O
been	O
having	O
decreased	O
appetite	O
,	O
fatigue	O
,	O
nausea	O
,	O
and	O
occasional	O
vomiting	O
.	O
The	O
patient	O
's	O
diuretics	I-Drug
were	O
recently	O
increased	O
prior	O
to	O
admission	O
to	O
Lasix	I-Drug
40	O
and	O
Aldactone	I-Drug
100	O
,	O
but	O
they	O
were	O
decreased	O
to	O
Lasix	I-Drug
20	O
and	O
Aldactone	I-Drug
50	O
for	O
elevated	I-Ade
creatinines	O
.	O
The	O
patient	O
was	O
found	O
to	O
have	O
acute	O
renal	O
insufficiency	O
by	O
laboratories	O
in	O
clinic	O
and	O
was	O
asked	O
to	O
come	O
to	O
the	O
Emergency	O
Department	O
for	O
further	O
evaluation	O
.	O
In	O
the	O
Emergency	O
Department	O
,	O
laboratories	O
revealed	O
a	O
potassium	O
of	O
6.7	O
and	O
a	O
creatinine	O
of	O
4.3	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
(	O
Significant	O
for	O
)	O
1	O
.	O
Hepatitis	O
C	O
cirrhosis	O
;	O
requiring	O
liver	O
transplantation	O
,	O
the	O
patient	O
is	O
currently	O
on	O
liver	O
transplant	O
list	O
.	O
2	O
.	O
Hypertension	O
.	O
3	O
.	O
History	O
of	O
nephrolithiasis	O
.	O
MEDICATIONS	O
ON	O
ADMISSION	O
:	O
1	O
.	O
Aldactone	I-Drug
50	O
mg	O
.	O
2	O
.	O
Lasix	I-Drug
20	O
mg	O
.	O
3	O
.	O
Flagyl	I-Drug
250	O
mg	O
three	O
times	O
per	O
day	O
.	O
4	O
.	O
Quinine	I-Drug
325	O
mg	O
once	O
per	O
day	O
.	O
5	O
.	O
Protonix	I-Drug
40	O
mg	O
once	O
per	O
day	O
.	O
6	O
.	O
Magnesium	I-Drug
oxide	O
800	O
mg	O
twice	O
per	O
day	O
.	O
7	O
.	O
Oxycodone	I-Drug
2	O
mg	O
to	O
4	O
mg	O
as	O
needed	O
.	O
ALLERGIES	O
:	O
The	O
patient	O
has	O
allergies	I-Ade
to	O
CODEINE	I-Drug
(	O
which	O
causes	O
gastrointestinal	B-Ade
upset	I-Ade
)	O
.	O
SOCIAL	O
HISTORY	O
:	O
He	O
lives	O
at	O
home	O
with	O
his	O
wife	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
is	O
a	O
past	O
alcohol	O
abuser	O
who	O
now	O
works	O
as	O
a	O
substance	O
abuse	O
counselor	O
.	O
FAMILY	O
HISTORY	O
:	O
Significant	O
for	O
father	O
who	O
died	O
of	O
a	O
myocardial	O
infarction	O
at	O
the	O
age	O
of	O
38	O
.	O
PHYSICAL	O
EXAMINATION	O
ON	O
PRESENTATION	O
:	O
On	O
admission	O
,	O
the	O
patient	O
was	O
afebrile	O
.	O
He	O
had	O
a	O
blood	O
pressure	O
of	O
130/58	O
,	O
a	O
pulse	O
of	O
70	O
,	O
a	O
respiratory	O
rate	O
of	O
20	O
,	O
and	O
was	O
saturating	O
97	O
%	O
on	O
room	O
air	O
.	O
He	O
was	O
in	O
no	O
apparent	O
distress	O
.	O
He	O
was	O
anicteric	O
.	O
His	O
pupils	O
were	O
reactive	O
.	O
His	O
extraocular	O
movements	O
were	O
intact	O
.	O
The	O
lungs	O
were	O
clear	O
bilaterally	O
.	O
His	O
cardiac	O
examination	O
showed	O
normal	O
first	O
heart	O
sounds	O
and	O
second	O
heart	O
sounds	O
with	O
a	O
2/6	O
systolic	O
murmur	O
at	O
the	O
right	O
upper	O
sternal	O
border	O
.	O
His	O
abdomen	O
was	O
soft	O
,	O
mildly	O
distended	O
,	O
and	O
nontender	O
.	O
He	O
had	O
no	O
peripheral	O
edema	O
.	O
PERTINENT	O
LABORATORY	O
VALUES	O
ON	O
PRESENTATION	O
:	O
He	O
had	O
a	O
white	O
blood	O
cell	O
count	O
of	O
5.6	O
,	O
his	O
hematocrit	O
was	O
28.4	O
,	O
and	O
he	O
had	O
platelets	O
of	O
101	O
.	O
He	O
had	O
an	O
INR	O
of	O
1.9	O
.	O
Chemistry	O
-	O
7	O
showed	O
an	O
initial	O
creatinine	O
of	O
4.2	O
with	O
a	O
potassium	O
of	O
6.7	O
.	O
After	O
gentle	O
fluids	O
and	O
treatment	O
for	O
his	O
potassium	O
,	O
he	O
had	O
a	O
repeat	O
potassium	O
of	O
5.7	O
and	O
a	O
creatinine	O
of	O
3.9	O
.	O
He	O
had	O
an	O
alanine	O
-	O
aminotransferase	O
of	O
57	O
,	O
his	O
aspartate	O
aminotransferase	O
was	O
166	O
,	O
his	O
alkaline	O
phosphatase	O
was	O
101	O
,	O
and	O
his	O
total	O
bilirubin	O
was	O
3.7	O
.	O
PERTINENT	O
RADIOLOGY	O
/	O
IMAGING	O
:	O
An	O
electrocardiogram	O
showed	O
a	O
normal	O
sinus	O
rhythm	O
.	O
There	O
were	O
no	O
peaked	O
T	O
waves	O
.	O
Otherwise	O
,	O
his	O
electrocardiogram	O
was	O
normal	O
.	O
BRIEF	O
SUMMARY	O
OF	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
was	O
admitted	O
for	O
his	O
acute	B-Ade
renal	I-Ade
insufficiency	I-Ade
.	O
His	O
Lasix	I-Drug
and	O
his	O
Aldactone	I-Drug
were	O
held	O
.	O
His	O
hyperkalemia	I-Reason
responded	O
well	O
to	O
his	O
Kayexalate	I-Drug
therapy	O
.	O
The	O
patient	O
was	O
noted	O
to	O
have	O
some	O
mild	O
periorbital	O
erythema	O
and	O
edema	O
on	O
the	O
right	O
side	O
of	O
his	O
face	O
.	O
He	O
was	O
initially	O
started	O
on	O
doxycycline	I-Drug
for	O
this	O
presumed	B-Reason
preseptal	I-Reason
cellulitis	O
.	O
The	O
patient	O
's	O
creatinine	O
did	O
initially	O
improve	O
;	O
however	O
,	O
it	O
started	O
to	O
increase	O
again	O
slowly	O
during	O
the	O
course	O
of	O
his	O
hospital	O
stay	O
.	O
Initially	O
,	O
it	O
was	O
felt	O
that	O
the	O
patient	O
's	O
initial	O
presentation	O
of	O
acute	B-Ade
renal	I-Ade
insufficiency	I-Ade
was	O
secondary	O
to	O
aggressive	O
diuresis	I-Drug
;	O
however	O
,	O
in	O
the	O
setting	O
of	O
his	O
diuretics	O
being	O
held	O
and	O
his	O
continued	O
increase	O
in	O
his	O
creatinine	O
,	O
it	O
was	O
possible	O
that	O
he	O
could	O
have	O
the	O
initial	O
stages	O
of	O
hepatorenal	O
syndrome	O
.	O
The	O
patient	O
has	O
had	O
elevated	O
creatinines	O
on	O
previous	O
hospitalizations	O
,	O
presumed	O
to	O
be	O
related	O
to	O
hepatorenal	B-Reason
syndrome	I-Reason
.	O
The	O
patient	O
was	O
started	O
on	O
octreotide	I-Drug
and	O
midodrine	I-Drug
.	O
Also	O
in	O
the	O
setting	O
of	O
his	O
acute	B-Ade
renal	I-Ade
insufficiency	I-Ade
,	O
his	O
tetracycline	I-Drug
was	O
held	O
as	O
it	O
was	O
possible	O
that	O
this	O
could	O
be	O
a	O
contributing	O
factor	O
.	O
An	O
Ophthalmology	O
consultation	O
was	O
obtained	O
which	O
showed	O
just	O
some	O
very	O
mild	B-Reason
preseptal	I-Reason
cellulitis	I-Reason
with	O
no	O
orbital	O
signs	O
or	O
symptoms	O
suggestive	O
of	O
an	O
orbital	B-Reason
cellulitis	I-Reason
.	O
The	O
patient	O
's	O
doxycycline	I-Drug
was	O
discontinued	O
in	O
favor	O
of	O
Keflex	I-Drug
.	O
The	O
patient	O
did	O
have	O
urine	O
eosinophils	O
and	O
sediment	O
checked	O
.	O
He	O
had	O
bland	O
sediment	O
which	O
was	O
not	O
consistent	O
with	O
an	O
acute	O
tubular	O
necrosis	O
type	O
picture	O
.	O
The	O
patient	O
was	O
also	O
transfused	O
with	O
2	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
for	O
a	O
low	I-Reason
hematocrit	O
early	O
on	O
during	O
the	O
course	O
of	O
his	O
hospital	O
stay	O
.	O
The	O
patient	O
did	O
not	O
have	O
any	O
upper	O
endoscopy	O
as	O
his	O
anemia	O
was	O
not	O
suspected	O
to	O
be	O
secondary	O
to	O
esophageal	O
varices	O
.	O
The	O
patient	O
's	O
creatinine	B-Ade
continued	I-Ade
to	I-Ade
rise	I-Ade
in	O
the	O
setting	O
of	O
his	O
octreotide	I-Drug
and	O
midodrine	I-Drug
therapy	O
.	O
Because	O
of	O
this	O
,	O
albumin	I-Drug
25	O
grams	O
intravenously	O
once	O
per	O
day	O
was	O
also	O
started	O
.	O
On	O
[	O
**	O
2138-3-29	O
**	O
]	O
,	O
the	O
patient	O
became	O
encephalopathic	O
.	O
Blood	O
cultures	O
and	O
urine	O
cultures	O
were	O
sent	O
,	O
and	O
he	O
did	O
have	O
an	O
episode	O
of	O
occult	O
-	O
blood	O
positive	O
stools	O
.	O
In	O
the	O
setting	O
of	O
his	O
encephalopathy	I-Reason
,	O
his	O
renal	O
function	O
did	O
improve	O
;	O
however	O
,	O
he	O
was	O
transferred	O
to	O
the	O
Unit	O
for	O
further	O
observation	O
.	O
A	O
nasogastric	O
lavage	I-Drug
was	O
done	O
in	O
the	O
setting	O
of	O
his	O
occult	B-Reason
-	I-Reason
blood	I-Reason
positive	I-Reason
stool	I-Reason
.	O
The	O
nasogastric	O
lavage	I-Drug
was	O
negative	O
for	O
blood	O
.	O
He	O
did	O
have	O
a	O
STAT	O
head	O
computed	O
tomography	O
which	O
was	O
negative	O
for	O
bleed	O
.	O
All	O
sedatives	I-Drug
were	O
discontinued	O
,	O
and	O
he	O
was	O
started	O
on	O
lactulose	I-Drug
therapy	O
.	O
A	O
chest	O
x-ray	O
there	O
was	O
negative	O
for	O
a	O
pneumonia	O
.	O
The	O
patient	O
did	O
have	O
serial	O
blood	O
cultures	O
done	O
.	O
He	O
did	O
have	O
a	O
total	O
of	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
blood	O
cultures	O
positive	O
for	O
methicillin	O
-	O
resistant	O
coagulase	O
-	O
negative	O
Staphylococcus	O
.	O
His	O
mental	B-Reason
status	I-Reason
did	O
improve	O
on	O
lactulose	I-Drug
therapy	O
.	O
The	O
origin	O
of	O
his	O
staphylococcal	B-Reason
bacteremia	I-Reason
was	O
still	O
uncertain	O
.	O
In	O
this	O
setting	O
,	O
he	O
did	O
have	O
a	O
diagnostic	O
paracentesis	O
done	O
which	O
was	O
negative	O
for	O
spontaneous	O
bacterial	O
peritonitis	O
.	O
The	O
patient	O
was	O
started	O
on	O
vancomycin	I-Drug
for	O
his	O
high	B-Reason
-	I-Reason
grade	I-Reason
bacteremia	I-Reason
.	O
He	O
did	O
have	O
a	O
transesophageal	O
echocardiogram	O
done	O
which	O
was	O
negative	O
for	O
endocarditis	O
.	O
Per	O
the	O
Infectious	O
Disease	O
staff	O
,	O
it	O
was	O
recommended	O
that	O
he	O
be	O
treated	O
with	O
four	O
to	O
six	O
weeks	O
of	O
vancomycin	I-Drug
from	O
the	O
date	O
of	O
his	O
last	O
positive	O
blood	O
cultures	O
which	O
were	O
[	O
**	O
2138-3-30	O
**	O
]	O
.	O
The	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
floor	O
with	O
an	O
improved	O
mental	O
status	O
and	O
improved	O
renal	O
function	O
.	O
He	O
did	O
well	O
on	O
the	O
floor	O
.	O
His	O
hematocrit	O
remained	O
stable	O
.	O
He	O
remained	O
afebrile	O
on	O
vancomycin	I-Drug
.	O
The	O
patient	O
also	O
completed	O
a	O
course	O
of	O
levofloxacin	I-Drug
for	O
his	O
preseptal	B-Reason
cellulitis	I-Reason
.	O
For	O
his	O
preseptal	B-Reason
cellulitis	I-Reason
,	O
he	O
received	O
a	O
total	O
of	O
10	O
days	O
of	O
antibiotics	I-Drug
which	O
included	O
doxycycline	I-Drug
,	O
Keflex	I-Drug
,	O
and	O
levofloxacin	I-Drug
.	O
The	O
patient	O
did	O
have	O
good	O
nutritional	O
intake	O
while	O
on	O
the	O
floor	O
.	O
His	O
creatinine	O
remained	O
in	O
the	O
1.6	O
to	O
1.9	O
range	O
on	O
the	O
floor	O
and	O
stable	O
.	O
His	O
baseline	O
creatinine	O
is	O
around	O
1	O
.	O
He	O
was	O
not	O
started	O
on	O
diuretics	I-Drug
at	O
discharge	O
.	O
A	O
peripherally	O
inserted	O
central	O
catheter	O
line	O
was	O
placed	O
for	O
administration	O
of	O
intravenous	O
vancomycin	I-Drug
for	O
his	O
high	O
-	O
grade	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
epidermitis	O
bacteremia	O
.	O
The	O
patient	O
was	O
seen	O
by	O
Physical	O
Therapy	O
and	O
was	O
discharged	O
from	O
their	O
service	O
as	O
he	O
had	O
no	O
acute	O
physical	O
therapy	O
needs	O
.	O
The	O
patient	O
did	O
have	O
a	O
candidal	B-Reason
infection	I-Reason
of	I-Reason
his	I-Reason
groin	I-Reason
area	I-Reason
which	O
was	O
treated	O
with	O
topical	O
anti-fungal	B-Drug
medications	I-Drug
,	O
to	O
which	O
he	O
responded	O
well	O
to	O
.	O
Toward	O
the	O
end	O
of	O
his	O
hospital	O
stay	O
,	O
the	O
patient	O
did	O
have	O
increased	O
diarrhea	O
.	O
His	O
lactulose	I-Drug
was	O
held	O
which	O
improved	O
his	O
diarrhea	I-Ade
somewhat	O
;	O
however	O
,	O
he	O
did	O
complain	O
of	O
increased	O
diarrhea	O
.	O
He	O
did	O
have	O
Clostridium	O
difficile	O
toxins	O
times	O
three	O
days	O
which	O
were	O
sent	O
.	O
These	O
were	O
negative	O
for	O
Clostridium	O
difficile	O
.	O
The	O
patient	O
was	O
discharged	O
on	O
no	O
diuretics	I-Drug
;	O
however	O
,	O
the	O
possibility	O
of	O
restarting	O
Aldactone	I-Drug
50	O
mg	O
will	O
be	O
considered	O
as	O
an	O
outpatient	O
.	O
He	O
will	O
be	O
discharged	O
with	O
a	O
total	O
course	O
of	O
four	O
to	O
six	O
weeks	O
of	O
vancomycin	I-Drug
.	O
The	O
start	O
date	O
on	O
his	O
vancomycin	I-Drug
was	O
[	O
**	O
2138-3-30	O
**	O
]	O
.	O
CONDITION	O
AT	O
DISCHARGE	O
:	O
Fair	O
.	O
DISCHARGE	O
STATUS	O
:	O
To	O
home	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Hepatitis	O
C	O
cirrhosis	O
;	O
awaiting	O
liver	O
transplantation	O
.	O
2	O
.	O
Acute	O
renal	O
failure	O
.	O
3	O
.	O
Methicillin	B-Reason
-	I-Reason
resistant	I-Reason
coagulase	I-Reason
-	I-Reason
negative	I-Reason
staphylococcal	I-Reason
bacteremia	O
;	O
on	O
vancomycin	I-Drug
.	O
MEDICATIONS	O
ON	O
DISCHARGE	O
:	O
1	O
.	O
Miconazole	I-Drug
nitrate	O
powder	O
applied	O
three	O
times	O
per	O
day	O
as	O
needed	O
to	O
groin	B-Reason
rash	I-Reason
.	O
2	O
.	O
Protonix	I-Drug
40	O
mg	O
q.	O
12h	O
.	O
3	O
.	O
Lactulose	I-Drug
30	O
mL	O
by	O
mouth	O
three	O
times	O
per	O
day	O
(	O
titrated	O
to	O
four	O
to	O
five	O
bowel	O
movements	O
per	O
day	O
)	O
.	O
4	O
.	O
Vancomycin	I-Drug
1	O
gram	O
intravenously	O
q.	O
12h	O
.	O
(	O
for	O
a	O
total	O
of	O
six	O
weeks	O
)	O
;	O
his	O
vancomycin	I-Drug
dose	O
will	O
be	O
changed	O
per	O
trough	O
levels	O
and	O
his	O
renal	O
function	O
.	O
DISCHARGE	O
INSTRUCTIONS	O
/	O
FOLLOWUP	O
:	O
The	O
patient	O
was	O
to	O
follow	O
up	O
in	O
the	O
Liver	O
Clinic	O
in	O
two	O
days	O
from	O
discharge	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
8507	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
22654	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
11207	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2138-4-7	O
**	O
]	O
15:21	O
T	O
:	O
[	O
**	O
2138-4-9	O
**	O
]	O
07:33	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
25451	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2182-6-19	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2182-6-21	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2105-9-9	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
EMERGENCY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2565	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypoxemia	O
,	O
hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
endotracheal	O
intubation	O
,	O
mechanical	O
ventilation	O
arterial	O
/	O
venous	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
76	O
yo	O
F	O
with	O
h	O
/	O
o	O
metastatic	B-Reason
breast	I-Reason
CA	I-Reason
on	O
chemotherapy	I-Drug
who	O
initially	O
was	O
admitted	O
to	O
the	O
OMED	O
service	O
with	O
diarrhea	O
who	O
is	O
now	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
hypotension	O
and	O
hypoxia	O
.	O
Patient	O
states	O
she	O
had	O
been	O
feeling	O
constipated	I-Reason
for	O
1	O
week	O
after	O
chemo	I-Drug
on	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
and	O
then	O
took	O
laxatives	I-Drug
until	O
she	O
had	O
several	O
large	O
BMs	O
.	O
A	O
few	O
days	O
later	O
she	O
develope	O
large	O
volume	O
,	O
non-bloody	O
dairrhea	I-Ade
that	O
was	O
associated	O
with	O
some	O
lightheadedness	O
.	O
She	O
denied	O
fevers	O
,	O
chills	O
,	O
rashes	O
.	O
Reports	O
poor	O
appetite	O
but	O
states	O
she	O
was	O
drinking	O
lot	O
of	O
water	O
and	O
trying	O
to	O
eat	O
salty	O
foods	O
;	O
however	O
this	O
was	O
limited	O
by	O
worsening	O
mucositis	O
over	O
the	O
past	O
few	O
days	O
.	O
Due	O
to	O
concern	O
for	O
dehydration	O
and	O
contniued	O
diarrhea	O
,	O
the	O
patient	O
was	O
admitted	O
directly	O
from	O
the	O
oncology	O
clinic	O
.	O
.	O
Upon	O
arrival	O
to	O
the	O
floor	O
,	O
pt	O
AF	O
with	O
BP	O
120/74	O
,	O
HR	O
116	O
,	O
RR	O
24	O
,	O
O2	I-Drug
sat	O
94	O
%	O
2L	O
NC	O
.	O
She	O
was	O
given	O
2L	O
IVFs	I-Drug
,	O
started	O
on	O
po	O
flagyl	I-Drug
empirically	B-Reason
for	I-Reason
c.	I-Reason
diff	I-Reason
adn	O
had	O
stool	O
cultures	O
sent	O
for	O
possible	O
OIs	O
.	O
Upon	O
vitals	O
check	O
at	O
0400	O
,	O
pt	O
's	O
BP	O
noted	O
to	O
be	O
78/54	O
,	O
HR	O
98	O
,	O
RR	O
20s	O
,	O
O2	I-Drug
sat	O
86	O
%	O
RA	O
--	O
>	O
93	O
%	O
3L	O
NC	O
.	O
Given	O
500	O
cc	O
IVF	I-Drug
bolus	O
X	O
2	O
with	O
response	O
in	O
SBP	O
to	O
86	O
/	O
40s	O
,	O
however	O
,	O
RR	O
rose	O
to	O
upper	O
20	O
-	O
30s	O
with	O
O2	I-Drug
sats	O
90	O
%	O
6L	O
NC	O
--	O
>	O
95	O
%	O
NRB	O
.	O
ABG	O
7.51	O
/	O
25	O
/	O
114/21	O
.	O
CXR	O
revealed	O
likely	O
pulmonary	O
edema	O
with	O
worsening	O
bilateral	O
pleural	O
effusions	O
and	O
possible	O
retrocardiac	O
opacity	O
.	O
She	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
where	O
code	O
status	O
was	O
confirmed	O
as	O
full	O
and	O
pt	O
was	O
intubated	O
.	O
Peri-intubation	I-Reason
required	O
dopamine	I-Drug
at	O
20	O
mcg	O
/	O
kg	O
/	O
min	O
,	O
which	O
was	O
transitioned	O
over	O
to	O
levophed	I-Drug
gtt	O
once	O
triple	O
lumen	O
catheter	O
placed	O
.	O
Past	O
Medical	O
History	O
:	O
PAST	O
ONCOLOGIC	O
HISTORY	O
:	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
1617	O
**	O
]	O
was	O
previously	O
treated	O
for	O
breast	B-Reason
cancer	I-Reason
in	O
the	O
late	O
[	O
**	O
2153	O
**	O
]	O
.	O
At	O
that	O
time	O
she	O
was	O
diagnosed	O
with	O
a	O
left	B-Reason
-	I-Reason
sided	I-Reason
infiltrating	O
ductal	O
carcinoma	O
on	O
[	O
**	O
2160-7-30	O
**	O
]	O
.	O
Repeat	O
biopsy	O
showed	O
persistent	O
DCIS	O
,	O
and	O
she	O
underwent	O
left	O
mastectomy	O
on	O
[	O
**	O
2160-9-20	O
**	O
]	O
.	O
Two	O
of	O
three	O
lymph	O
nodes	O
were	O
involved	O
.	O
She	O
was	O
treated	O
with	O
6	O
cycles	O
of	O
adjuvant	O
oral	O
CMF	I-Drug
chemotherapy	O
,	O
which	O
completed	O
in	O
[	O
**	O
2161	O
**	O
]	O
,	O
and	O
then	O
eight	O
years	O
of	O
tamoxifen	I-Drug
as	O
the	O
tumor	O
was	O
ER	O
positive	O
,	O
PR	O
negative	O
.	O
Since	O
that	O
time	O
Ms.	O
[	O
**	O
Known	O
lastname	O
1617	O
**	O
]	O
was	O
also	O
diagnosed	O
with	O
a	O
left	O
renal	O
cell	O
carcinoma	O
and	O
underwent	O
partial	O
nephrectomy	O
in	O
03	O
/	O
[	O
**	O
2178	O
**	O
]	O
.	O
Her	O
medical	O
course	O
has	O
been	O
complicated	O
by	O
coronary	O
artery	O
disease	O
status	O
post	O
MI	O
in	O
[	O
**	O
9	O
-	O
/	O
2179	O
**	O
]	O
and	O
atrial	O
fibrillation	O
.	O
More	O
recently	O
,	O
a	O
CT	O
of	O
the	O
chest	O
noted	O
ground	O
-	O
glass	O
abnormalities	O
,	O
raising	O
concern	O
for	O
bronchoalveolar	O
carcinoma	O
.	O
This	O
has	O
not	O
been	O
biopsied	O
or	O
formally	O
diagnosed	O
.	O
In	O
[	O
**	O
2	O
-	O
/	O
2182	O
**	O
]	O
liver	O
function	O
studies	O
were	O
noted	O
to	O
be	O
elevated	O
,	O
and	O
liver	O
ultrasound	O
and	O
abdominal	O
CT	O
showed	O
numerous	O
lesions	O
in	O
the	O
liver	O
.	O
CT	O
-	O
guided	O
core	O
liver	O
biopsy	O
on	O
[	O
**	O
2182-2-25	O
**	O
]	O
showed	O
metastatic	O
breast	O
adenocarcinoma	O
staining	O
positive	O
for	O
mammoglobin	O
,	O
negative	O
for	O
GCDFP	O
,	O
ER	O
,	O
and	O
PR	O
.	O
The	O
tumor	O
overexpressed	O
HER	O
-	O
2	O
/	O
neu	O
.	O
Tumor	O
markers	O
drawn	O
on	O
[	O
**	O
2182-2-18	O
**	O
]	O
were	O
elevated	O
with	O
CEA	O
20	O
ng	O
/	O
mL	O
and	O
CA	O
27.29	O
278	O
u	O
/	O
mL	O
.	O
PET	O
scan	O
performed	O
on	O
[	O
**	O
2182-3-6	O
**	O
]	O
showed	O
numerous	O
heterogeneous	O
liver	O
lesions	O
,	O
sclerotic	O
lesions	O
in	O
the	O
left	O
anterior	O
rib	O
and	O
right	O
ilium	O
that	O
were	O
FDG	O
avid	O
and	O
concerning	O
for	O
metastatic	O
foci	O
,	O
and	O
FDG	O
avid	O
left	O
pelvic	O
side	O
wall	O
lymph	O
node	O
.	O
On	O
[	O
**	O
2182-3-20	O
**	O
]	O
mammogram	O
and	O
ultrasound	O
of	O
the	O
right	O
breast	O
showed	O
a	O
1.9	O
-	O
cm	O
right	O
breast	O
nodule	O
.	O
Pathology	O
from	O
a	O
core	O
breast	O
biopsy	O
showed	O
invasive	O
ductal	O
carcinoma	O
grade	O
I	O
that	O
was	O
HER	O
-	O
2	O
/	O
neu	O
negative	O
and	O
ER	O
/	O
PR	O
positive	O
.	O
Ms.	O
[	O
**	O
Known	O
lastname	O
1617	O
**	O
]	O
,	O
therefore	O
,	O
appears	O
to	O
have	O
a	O
new	O
right	B-Reason
breast	I-Reason
tumor	I-Reason
that	I-Reason
is	I-Reason
ER	O
/	O
PRpositive	O
,	O
HER	O
-	O
2	O
/	O
neu	O
negative	O
,	O
and	O
liver	B-Reason
metastases	I-Reason
that	I-Reason
are	I-Reason
ER	O
/	O
PR	O
negative	O
and	O
HER	O
-	O
2	O
/	O
neu	O
positive	O
.	O
She	O
began	O
Herceptin	I-Drug
on	O
[	O
**	O
2182-4-16	O
**	O
]	O
,	O
and	O
Navelbine	I-Drug
was	O
added	O
on	O
[	O
**	O
2182-6-6	O
**	O
]	O
.	O
Also	O
had	O
L	O
thoracocentesis	O
in	O
[	O
**	O
5	O
-	O
11	O
**	O
]	O
with	O
malignant	O
cells	O
(	O
adenocarcinoma	O
)	O
on	O
cytology	O
.	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
History	O
of	O
left	O
-	O
sided	O
breast	O
cancer	O
as	O
discussed	O
above	O
,	O
metastatic	O
to	O
2	O
.	O
History	O
of	O
renal	O
cell	O
carcinoma	O
status	O
post	O
partial	O
left	O
nephrectomy	O
,	O
03	O
/	O
[	O
**	O
2178	O
**	O
]	O
.	O
3	O
.	O
Coronary	O
artery	O
disease	O
status	O
post	O
MI	O
[	O
**	O
2179-9-11	O
**	O
]	O
with	O
PCI	O
x2	O
.	O
4	O
.	O
Atrial	O
fibrillation	O
.	O
5	O
.	O
Diet	O
-	O
controlled	O
diabetes	O
mellitus	O
.	O
6	O
.	O
Hypertension	O
.	O
7	O
.	O
GERD	O
.	O
8	O
.	O
Hyperlipidemia	O
.	O
9	O
.	O
History	O
of	O
lung	O
imaging	O
abnormalities	O
concerning	O
for	O
BAC	O
.	O
10	O
.	O
History	O
of	O
a	O
right	O
ovarian	O
dermoid	O
cyst	O
resected	O
at	O
age	O
32	O
.	O
11	O
.	O
Osteoporosis	O
.	O
12	O
.	O
History	O
of	O
TMJ	O
syndrome	O
.	O
13	O
.	O
Cataracts	O
.	O
14	O
.	O
H	O
/	O
o	O
C.difficile	O
infection	O
.	O
15	O
.	O
H	O
/	O
o	O
Grp	O
A	O
beta	O
-	O
Strep	O
bacteremia	O
.	O
Social	O
History	O
:	O
The	O
patient	O
is	O
married	O
and	O
lives	O
in	O
[	O
**	O
Location	O
745	O
**	O
]	O
,	O
[	O
**	O
State	O
350	O
**	O
]	O
.	O
She	O
was	O
previously	O
a	O
schoolteacher	O
and	O
is	O
now	O
retired	O
.	O
She	O
denies	O
tobacco	O
or	O
alcohol	O
use	O
,	O
although	O
,	O
admits	O
to	O
a	O
history	O
of	O
secondhand	O
tobacco	O
exposure	O
as	O
a	O
child	O
.	O
Family	O
History	O
:	O
There	O
is	O
no	O
family	O
history	O
of	O
breast	O
cancer	O
.	O
The	O
patient	O
's	O
son	O
is	O
currently	O
being	O
treated	O
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O
She	O
has	O
another	O
son	O
who	O
is	O
without	O
health	O
concerns	O
.	O
Her	O
mother	O
died	O
of	O
a	O
stroke	O
at	O
61	O
years	O
and	O
father	O
died	O
of	O
congestive	O
heart	O
failure	O
at	O
78	O
years	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
-	O
98.5	O
120/74	O
116	O
24	O
94	O
%	O
on	O
2L	O
GENERAL	O
:	O
moderate	O
distress	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
tachypnea	O
and	O
SOB	O
,	O
speaking	O
in	O
full	O
sentences	O
without	O
much	O
difficulty	O
,	O
able	O
to	O
lie	O
flat	O
for	O
Foley	O
insertion	O
but	O
with	O
mild	O
difficulty	O
HEENT	O
:	O
Dry	O
MM	O
,	O
+	O
mucositis	O
,	O
no	O
LAD	O
,	O
cracked	O
lips	O
,	O
JVP	O
approximately	O
12	O
cm	O
above	O
sternal	O
notch	O
CARDIAC	O
:	O
Irregular	O
,	O
II	O
/	O
VI	O
SEM	O
LUNG	O
:	O
CTAB	O
with	O
decreased	O
BS	O
at	O
bilateral	O
bases	O
,	O
no	O
wheezes	O
,	O
rhonchi	O
,	O
rales	O
appreciated	O
ABDOMEN	O
:	O
nondistended	O
,	O
+	O
BS	O
,	O
nontender	O
in	O
all	O
quadrants	O
,	O
no	O
rebound	O
/	O
guarding	O
,	O
no	O
hepatosplenomegaly	O
M	O
/	O
S	O
:	O
2	O
+	O
LE	O
edema	O
bilat	O
with	O
L	O
>	O
R	O
LE	O
,	O
moving	O
all	O
extremities	O
well	O
,	O
no	O
cyanosis	O
,	O
clubbing	O
,	O
no	O
obvious	O
deformities	O
NEURO	O
:	O
CN	O
II	O
-	O
XII	O
intact	O
Pertinent	O
Results	O
:	O
LABS	O
ON	O
ADMISSION	O
:	O
[	O
**	O
2182-6-19	O
**	O
]	O
10:57	O
AM	O
BLOOD	O
WBC	O
-	O
0.5	O
*	O
#	O
RBC	O
-	O
3.18	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
29.3	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
33.2	O
*	O
MCHC	O
-	O
36.0	O
*	O
RDW	O
-	O
13.9	O
Plt	O
Ct	O
-	O
374	O
#	O
[	O
**	O
2182-6-19	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
PT	O
-	O
32.1	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.2	O
*	O
[	O
**	O
2182-6-19	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
UreaN	O
-	O
26	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
121	O
*	O
K	O
-	O
4.4	O
Cl	O
-	O
84	O
*	O
HCO3	O
-	O
26	O
AnGap	O
-	O
15	O
[	O
**	O
2182-6-20	O
**	O
]	O
12:15	O
AM	O
BLOOD	O
ALT	O
-	O
21	O
AST	O
-	O
33	O
LD	O
(	O
LDH	O
)	O
-	O
243	O
AlkPhos	O
-	O
130	O
*	O
TotBili	O
-	O
1.1	O
DirBili	O
-	O
0.6	O
*	O
IndBili	O
-	O
0.5	O
[	O
**	O
2182-6-19	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
Albumin	O
-	O
3.4	O
Calcium	O
-	O
8.9	O
Mg	O
-	O
1.5	O
*	O
.	O
URINE	O
:	O
[	O
**	O
2182-6-20	O
**	O
]	O
08:48	O
AM	O
URINE	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.014	O
[	O
**	O
2182-6-20	O
**	O
]	O
08:48	O
AM	O
URINE	O
Blood	O
-	O
NEG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
30	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.5	O
Leuks	O
-	O
NEG	O
[	O
**	O
2182-6-20	O
**	O
]	O
08:48	O
AM	O
URINE	O
RBC	O
-	O
1	O
WBC	O
-	O
4	O
Bacteri	O
-	O
FEW	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
1	O
[	O
**	O
2182-6-20	O
**	O
]	O
08:48	O
AM	O
URINE	O
Hours	O
-	O
RANDOM	O
UreaN	O
-	O
795	O
Creat	O
-	O
89	O
Na-LESS	O
THAN	O
.	O
MICROBIOLOGY	O
:	O
bl	O
cx	O
-	O
GNR	O
in	O
[	O
**	O
4	O
-	O
6	O
**	O
]	O
bottles	O
.	O
CARDIOLOGY	O
:	O
TTE	O
:	O
Conclusions	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
There	O
is	O
moderate	O
to	O
severe	O
global	O
left	O
ventricular	O
hypokinesis	O
(	O
LVEF	O
=	O
30	O
%	O
)	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
with	O
moderate	O
global	O
free	O
wall	O
hypokinesis	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2182-3-19	O
**	O
]	O
,	O
biventricular	O
systolic	O
funciton	O
is	O
now	O
significantly	O
depressed	O
.	O
.	O
RADIOLOGY	O
:	O
LLE	O
U	O
/	O
S	O
:	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
left	O
lower	O
extremity	O
DVT	O
.	O
.	O
CXR	O
:	O
Comparison	O
is	O
made	O
with	O
prior	O
study	O
[	O
**	O
2182-5-10	O
**	O
]	O
.	O
Mild	O
cardiomegaly	O
is	O
unchanged	O
.	O
Mild	O
left	O
pleural	O
effusion	O
has	O
increased	O
.	O
Small	O
right	O
pleural	O
effusion	O
is	O
unchanged	O
.	O
There	O
is	O
mild	O
pulmonary	O
edema	O
.	O
There	O
is	O
atelectasis	O
in	O
the	O
right	O
lower	O
lobe	O
.	O
Multiple	O
surgical	O
clips	O
are	O
in	O
the	O
left	O
upper	O
quadrant	O
abdomen	O
.	O
There	O
is	O
no	O
pneumothorax	O
.	O
Brief	O
Hospital	O
Course	O
:	O
In	O
short	O
,	O
Ms	O
[	O
**	O
Known	O
lastname	O
1617	O
**	O
]	O
is	O
a	O
76F	O
with	O
h	O
/	O
o	O
metastatic	B-Reason
breast	I-Reason
CA	I-Reason
C1D15	I-Reason
of	O
navelbine	I-Drug
/	O
herceptin	I-Drug
admitted	O
with	O
diarrhea	O
and	O
weakness	O
,	O
transferred	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
in	O
septic	O
shock	O
,	O
expired	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
overwhelming	O
GNR	O
bacteremia	O
.	O
.	O
#	O
Septic	B-Reason
shock	I-Reason
:	O
overwhelming	O
GNR	O
bacteremia	O
w	O
cardiogenic	O
/	O
distributive	O
/	O
hypovolemic	O
components	O
in	O
the	O
setting	O
of	O
febrile	O
neutropenia	O
.	O
DDx	O
for	O
the	O
infection	O
included	O
the	O
gut	O
(	O
given	O
diarrhea	O
)	O
vs	O
the	O
lung	O
vs	O
other	O
.	O
Pt	O
treated	O
w	O
aggressive	O
fluid	I-Drug
resuscitation	I-Reason
,	O
dopamine	I-Drug
,	O
norepinepherine	I-Drug
and	O
vasopressin	I-Drug
pressors	O
,	O
broad	B-Drug
-	I-Drug
spectrum	I-Drug
antibiotics	I-Drug
.	O
TTE	O
revealed	O
decreased	O
LVEF	O
confirming	O
the	O
suspicion	O
of	O
acute	O
heart	O
failure	O
in	O
the	O
setting	O
of	O
sepsis	O
.	O
.	O
#	O
Hypoxic	O
respiratory	O
failure	O
:	O
Hypoxia	I-Ade
progressed	O
relatively	O
rapidly	O
in	O
the	O
setting	O
of	O
receiving	O
IVFs	I-Drug
,	O
CXR	O
with	O
evidence	O
supporting	O
pulmonary	O
edema	O
.	O
Furthermore	O
,	O
pt	O
's	O
known	O
malignant	O
pleural	O
effusion	O
appears	O
to	O
be	O
worsening	O
and	O
is	O
also	O
likely	O
contributing	O
.	O
No	O
known	O
aspiration	O
events	O
.	O
Given	O
neutropenia	O
and	O
other	O
vitals	O
concerning	O
for	O
sepsis	O
,	O
infection	O
also	O
remains	O
on	O
differential	O
.	O
PE	O
also	O
considered	O
,	O
but	O
less	O
likely	O
.	O
Treated	O
for	O
sepsis	O
as	O
above	O
.	O
.	O
#	O
Hyponantremia	I-Reason
:	O
Na	O
120	O
,	O
improved	O
to	O
130	O
w	O
fluid	I-Drug
resuscitation	I-Reason
.	O
Does	O
have	O
prior	O
h	O
/	O
o	O
hyponatremia	O
.	O
Suspect	O
that	O
hypovolemia	O
is	O
primary	O
etiology	O
.	O
.	O
#	O
Diarrhea	I-Ade
:	O
Possibly	O
infectious	O
etiology	O
given	O
neutropenia	O
vs	O
could	O
be	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
chemo	I-Drug
.	O
Given	O
refractory	O
hypotension	O
in	O
the	O
setting	O
of	O
sepsis	O
,	O
possibly	O
developing	O
ischemic	O
colitis	O
.	O
.	O
#	O
Pancytopenia	I-Ade
:	O
likely	O
[	O
**	O
2	O
-	O
4	O
**	O
]	O
chemotherapy	I-Drug
-	O
neutropenic	O
,	O
anemic	O
w	O
underlying	O
combined	O
iron	O
-	O
deficiency	O
anemia	O
and	O
anemia	O
of	O
chronic	O
disease	O
.	O
No	O
evidence	O
of	O
hemolysis	O
.	O
Thrombocytopenia	I-Reason
.	O
Transfused	O
w	O
pRBCs	I-Drug
and	O
FFP	I-Drug
.	O
.	O
#	O
Metastatic	O
breast	O
CA	O
:	O
With	O
known	O
mets	O
to	O
liver	O
and	O
likely	O
to	O
lung	O
and	O
bone	O
based	O
off	O
of	O
PET	O
scan	O
and	O
pleural	O
fluid	O
cytology	O
.	O
.	O
#	O
Atrial	O
fibrillation	O
:	O
INR	O
supratherapeutic	O
on	O
admission	O
.	O
Afib	B-Reason
w	I-Reason
RVR	O
on	O
transfer	O
to	O
ICU	O
in	O
the	O
setting	O
of	O
hypovolemia	O
,	O
sepsis	O
and	O
pressors	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Amlodipine	I-Drug
5	O
mg	O
daily	O
.	O
2	O
.	O
Amoxicillin	I-Drug
prior	O
to	O
dental	B-Reason
procedures	I-Reason
.	O
3	O
.	O
Atenolol	I-Drug
50	O
mg	O
b.i.d.	O
4	O
.	O
Furosemide	I-Drug
10	O
mg	O
daily	O
.	O
5	O
.	O
Lisinopril	I-Drug
40	O
mg	O
daily	O
.	O
6	O
.	O
Potassium	I-Drug
chloride	O
20	O
mEq	O
daily	O
.	O
7	O
.	O
Multivitamin	I-Drug
one	O
capsule	O
daily	O
.	O
8	O
.	O
Warfarin	I-Drug
2	O
mg	O
daily	O
.	O
9	O
.	O
Aspirin	I-Drug
81	O
mg	O
daily	O
.	O
10	O
.	O
Calcium	B-Drug
plus	I-Drug
vitamin	O
D	O
b.i.d.	O
11	O
.	O
Glucosamine	I-Drug
chondroitin	O
three	O
capsules	O
daily	O
.	O
Discharge	O
Medications	O
:	O
expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
septic	O
shock	O
cardiogenic	O
shock	O
GNR	O
bacteremia	O
repiratory	O
failure	O
metastatic	O
breast	O
cancer	O
atrial	O
fibrillation	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
expired	O
Followup	O
Instructions	O
:	O
expired	O
Completed	O
by	O
:[	O
**	O
2182-6-21	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2191-3-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2191-3-15	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2110-2-5	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Simvastatin	I-Drug
/	O
Rosuvastatin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1234	O
**	O
]	O
Chief	O
Complaint	O
:	O
Bilateral	O
disabling	O
claudication	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2191-3-3	O
**	O
]	O
:	O
1	O
.	O
Bilateral	O
extensive	O
iliofemoral	O
endarterectomy	O
with	O
bovine	O
pericardial	O
patch	O
angioplasty	O
.	O
2	O
.	O
Bilateral	O
common	O
iliac	O
stent	O
grafts	O
7	O
-	O
37	O
I	O
cast	O
extension	O
of	O
the	O
stent	O
graft	O
in	O
the	O
left	O
common	O
iliac	O
artery	O
of	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
.	O
3	O
.	O
Right	O
exterior	O
iliac	O
stent	O
complete	O
SE	O
780	O
and	O
extension	O
into	O
the	O
common	O
femoral	O
artery	O
with	O
a	O
7	O
x	O
40	O
complete	O
SE	O
on	O
the	O
right	O
.	O
On	O
the	O
left	O
side	O
,	O
an	O
[	O
**	O
7	O
-	O
/	O
2159	O
**	O
]	O
complete	O
SE	O
stent	O
.	O
[	O
**	O
2191-3-10	O
**	O
]	O
:	O
Sigmoidoscopy	O
History	O
of	O
Present	O
Illness	O
:	O
The	O
patient	O
is	O
an	O
elderly	O
female	O
with	O
longstanding	O
claudication	O
that	O
has	O
gotten	O
worse	O
over	O
the	O
last	O
2	O
years	O
to	O
the	O
point	O
where	O
she	O
could	O
barely	O
walk	O
and	O
started	O
to	O
develop	O
pain	O
in	O
the	O
back	O
of	O
her	O
heel	O
on	O
the	O
left	O
.	O
Can	O
barely	O
walk	O
to	O
the	O
bathroom	O
.	O
After	O
clearance	O
by	O
Cardiology	O
and	O
Pulmonology	O
and	O
understanding	O
the	O
risks	O
and	O
benefits	O
,	O
we	O
decided	O
to	O
electively	O
proceed	O
to	O
surgery	O
.	O
Past	O
Medical	O
History	O
:	O
PMHx	O
:	O
1	O
.	O
Chronic	O
atrial	O
fibrillation	O
2	O
.	O
Hypertension	O
3	O
.	O
Hypercholesterolemia	O
4	O
.	O
Aortic	O
regurgitation	O
(	O
mild	O
AR	O
echo	O
[	O
**	O
10	O
-	O
11	O
**	O
]	O
)	O
5	O
.	O
3.1	O
-	O
cm	O
infrarenal	O
abdominal	O
aortic	O
aneurysm	O
,	O
stable	O
since	O
[	O
**	O
2186	O
**	O
]	O
,	O
but	O
requires	O
annual	O
followup	O
.	O
6	O
.	O
Cholelithiasis	O
.	O
7	O
.	O
Emphysema	O
.	O
8	O
.	O
Colonic	O
diverticulosis	O
.	O
9	O
.	O
Stable	O
small	O
left	O
paraovarian	O
cyst	O
,	O
over	O
3	O
years	O
.	O
10	O
.	O
Peripheral	O
Arterial	O
Disease	O
.	O
Social	O
History	O
:	O
-	O
originally	O
from	O
[	O
**	O
Country	O
4754	O
**	O
]	O
,	O
widowed	O
(	O
husband	O
died	O
of	O
a	O
heart	O
attack	O
in	O
[	O
**	O
2167	O
**	O
]	O
)	O
.	O
She	O
used	O
to	O
run	O
figures	O
at	O
an	O
insurance	O
company	O
,	O
but	O
now	O
is	O
retired	O
and	O
lives	O
off	O
of	O
her	O
husbands	O
pension	O
.	O
She	O
says	O
she	O
lives	O
alone	O
and	O
is	O
independent	O
with	O
all	O
of	O
her	O
ADL	O
.	O
She	O
has	O
a	O
30	O
-	O
pack	O
year	O
smoking	O
history	O
and	O
not	O
currently	O
smoking	O
,	O
occasionally	O
drinks	O
wine	O
.	O
Physical	O
Exam	O
:	O
Alert	O
and	O
oriented	O
x	O
3	O
VS	O
:	O
BP128	O
/	O
50	O
HR	O
87	O
atrial	O
fibrillation	O
Resp	O
:	O
Lungs	O
clear	O
Abd	O
:	O
Soft	O
,	O
non	O
tender	O
Ext	O
:	O
Pulses	O
:	O
Left	O
DP	O
dop	O
,	O
PT	O
dop	O
Right	O
DP	O
dop	O
,	O
PT	O
dop	O
Feet	O
warm	O
,	O
well	O
perfused	O
.	O
No	O
open	O
areas	O
Groin	O
incisions	O
:	O
slightly	O
red	O
but	O
no	O
warmth	O
and	O
drainage	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2191-3-15	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
WBC	O
-	O
8.4	O
RBC	O
-	O
3.15	O
*	O
Hgb	O
-	O
8.9	O
*	O
Hct	O
-	O
27.7	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
28.2	O
MCHC	O
-	O
32.1	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
344	O
[	O
**	O
2191-3-15	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
Glucose	O
-	O
79	O
UreaN	O
-	O
16	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
135	O
K	O
-	O
4.0	O
Cl	O
-	O
104	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
14	O
[	O
**	O
2191-3-15	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
Calcium	O
-	O
7.8	O
*	O
Phos	O
-	O
1.7	O
*	O
Mg	O
-	O
1.8	O
[	O
**	O
2191-3-14	O
**	O
]	O
07:10	O
AM	O
BLOOD	O
PT	O
-	O
29.1	O
*	O
PTT	O
-	O
48.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.8	O
*	O
[	O
**	O
2191-3-3	O
**	O
]	O
02:52	O
PM	O
BLOOD	O
Glucose	O
-	O
142	O
*	O
UreaN	O
-	O
40	O
*	O
Creat	O
-	O
2.4	O
*	O
Na	O
-	O
133	O
K	O
-	O
4.5	O
Cl	O
-	O
106	O
HCO3	O
-	O
18	O
*	O
AnGap	O
-	O
14	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
brought	O
to	O
the	O
operating	O
room	O
on	O
[	O
**	O
2191-3-3	O
**	O
]	O
and	O
underwent	O
bilateral	O
ileofemoral	O
endarterectomies	O
with	O
patch	O
angioplasty	O
and	O
bilateral	O
iliac	O
stents	O
.	O
The	O
procedure	O
was	O
without	O
complications	O
.	O
She	O
was	O
closely	O
monitored	O
in	O
the	O
PACU	O
and	O
then	O
transferred	O
to	O
the	O
ICU	O
for	O
ongoing	O
gas	O
exchange	O
issues	O
related	O
to	O
baseline	O
emphysema	O
and	O
diastolic	O
heart	O
failure	O
.	O
She	O
was	O
transferred	O
to	O
the	O
floor	O
for	O
further	O
monitoring	O
on	O
POD	O
#	O
2	O
in	O
stable	O
condition	O
.	O
We	O
continue	O
to	O
monitor	O
her	O
breathing	O
pattern	O
and	O
gas	O
exchange	O
diuresing	I-Reason
her	O
with	O
lasix	I-Drug
to	O
maintain	O
a	O
negative	O
fluid	O
balance	O
to	O
treat	O
her	O
acute	B-Reason
on	I-Reason
chronic	I-Reason
diastolic	I-Reason
CHF	I-Reason
exacerbation	O
post	O
surgery	O
.	O
Her	O
diet	O
was	O
gradually	O
advanced	O
.	O
She	O
worked	O
with	O
physical	O
therapy	O
who	O
recommended	O
rehab	O
.	O
On	O
POD	O
#	O
7	O
she	O
had	O
an	O
episode	O
of	O
hypotensive	O
causing	O
ischemic	O
colitis	O
which	O
was	O
treated	O
with	O
fluid	O
/	O
albumin	O
.	O
By	O
POD	O
#	O
9	O
her	O
abdominal	O
pain	O
resolved	O
and	O
she	O
started	O
to	O
tolerate	O
on	O
a	O
regular	O
diet	O
.	O
She	O
was	O
discharged	O
to	O
rehab	O
on	O
POD	O
#	O
13	O
in	O
stable	O
condition	O
.	O
Follow	O
-	O
up	O
has	O
been	O
arranged	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
one	O
week	O
.	O
1	O
.	O
Peripheral	O
Arterial	O
Disease	O
sp	O
bilateral	O
ileofemoral	O
endarterectomies	O
with	O
patch	O
angioplasty	O
and	O
bilateral	O
iliac	O
stents	O
on	O
[	O
**	O
2191-3-3	O
**	O
]	O
for	O
disabling	O
claudication	O
.	O
Dopplerable	O
LE	O
pulses	O
.	O
Groin	O
incisions	O
are	O
clean	O
,	O
slightly	O
red	O
and	O
should	O
be	O
covered	O
with	O
DSD	O
until	O
removal	O
at	O
followup	O
appointment	O
next	O
week	O
.	O
2	O
.	O
Diastolic	B-Reason
Congestive	I-Reason
Heart	I-Reason
Failure	I-Reason
She	O
had	O
acute	O
exacerbation	O
of	O
her	O
chronic	O
congestive	O
heart	O
failure	O
after	O
her	O
procedure	O
which	O
we	O
closely	O
monitored	O
and	O
treated	O
with	O
lasix	I-Drug
as	O
needed	O
.	O
She	O
is	O
on	O
her	O
home	O
dose	O
of	O
lasix	I-Drug
40	O
mg	O
daily	O
.	O
Her	O
PREOP	O
WEIGHT	O
is	O
77.1	O
kg	O
.	O
TODAY	O
'S	O
WEIGHT	O
is	O
85.7	O
kg	O
.	O
We	O
have	O
been	O
unable	O
to	O
diurese	O
secondary	O
to	O
hypotension	O
and	O
ischemic	O
colitis	O
.	O
3	O
.	O
Ischemic	O
Colitis	O
On	O
POD	O
#	O
7	O
she	O
had	O
an	O
episode	O
of	O
hypotension	O
to	O
the	O
70's	O
after	O
lasix	I-Drug
administration	O
.	O
At	O
that	O
time	O
,	O
our	O
goal	O
was	O
1	O
liter	O
negative	O
a	O
day	O
.	O
Shortly	O
after	O
this	O
episode	O
,	O
she	O
had	O
vomitting	O
with	O
diarrhea	O
with	O
LUQ	O
abdominal	O
pain	O
.	O
Her	O
lactate	O
level	O
was	O
3.1	O
and	O
her	O
wbc	O
rose	O
to	O
23.3	O
from	O
7.6	O
earlier	O
in	O
the	O
day	O
.	O
She	O
was	O
aggressively	O
resusitate	I-Reason
her	O
with	O
fluid	I-Drug
and	O
albumin	I-Drug
.	O
An	O
Abd	O
CT	O
did	O
not	O
show	O
any	O
overt	O
mesenteric	O
ischemia	O
.	O
Flexible	O
sigmoidoscopy	O
,	O
to	O
evaluate	O
mucosa	O
,	O
was	O
negative	O
for	O
ischemia	O
.	O
Cdiff	O
was	O
also	O
negative	O
.	O
She	O
was	O
started	O
on	O
vanco	I-Drug
/	O
cipro	I-Drug
/	O
flagyl	I-Drug
.	O
She	O
had	O
continued	O
improvement	O
with	O
return	O
of	O
her	O
WBC	O
to	O
normal	O
and	O
resumption	O
of	O
a	O
regular	O
diet	O
by	O
POD	O
#	O
9	O
.	O
4	O
.	O
Hypertension	O
BP	O
now	O
120	O
's	O
/	O
80	O
.	O
WE	O
HAVE	O
NOT	O
RESTARTED	O
HER	O
HOME	O
ANTIHYPERTENSIVES	O
/	O
CARDIAC	O
MEDS	O
of	O
amlodipine	I-Drug
5	O
mg	O
,	O
diltiazem	B-Drug
HCl	I-Drug
XR	O
360	O
mg	O
or	O
moexipril	I-Drug
15	O
mg	O
secondary	O
to	O
relative	O
hypotension	O
(	O
90s	O
systolic	O
)	O
in	O
the	O
setting	O
of	O
presumed	O
bowel	O
ischemia	O
.	O
Please	O
contine	O
to	O
monitor	O
and	O
restart	O
medications	O
as	O
tolerated	O
.	O
5	O
.	O
Chronic	O
Kidney	O
Disease	O
Admission	O
Cr	O
.	O
2.4	O
.	O
Today	O
's	O
Cr	O
is	O
1.3	O
,	O
likely	O
related	O
to	O
holding	O
diuresis	O
and	O
ACE	I-Drug
.	O
6	O
.	O
Emphysema	O
02	O
sats	O
are	O
94	O
%	O
on	O
2L	O
which	O
is	O
her	O
baseline	O
at	O
home	O
.	O
7	O
.	O
Atrial	B-Reason
Fibrillation	I-Reason
HR	O
80s	O
.	O
Coumadin	I-Drug
restarted	O
post	O
procedure	O
.	O
INR	O
2.8	O
today	O
.	O
We	O
have	O
held	O
coumadin	I-Drug
for	O
the	O
last	O
several	O
days	O
.	O
Medications	O
on	O
Admission	O
:	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
'	O
;	O
amlodipine	I-Drug
5	O
'	O
;	O
atorvastatin	I-Drug
80	O
'	O
;	O
calcitriol	I-Drug
0.25	O
'	O
M	O
-	O
W	O
-	O
F	O
;	O
cilostazol	I-Drug
100	O
'	O
;	O
diltiazem	B-Drug
HCl	I-Drug
XR	O
360	O
'	O
;	O
fluticasone	B-Drug
-	I-Drug
salmeterol	I-Drug
250	O
mcg	O
-	O
50	O
mcg	O
''	O
;	O
furosemide	I-Drug
40	O
'	O
;	O
moexipril	I-Drug
15	O
'	O
;	O
tiotropium	B-Drug
bromide	I-Drug
18	O
mcg	O
'	O
;	O
warfarin	I-Drug
3	O
'	O
;	O
ascorbic	I-Drug
acid	O
1,000	O
'	O
;	O
aspirin	I-Drug
81	O
'	O
;	O
calcium	B-Drug
carbonate	I-Drug
250	O
'	O
;	O
hexavitamin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
fluticasone	B-Drug
-	I-Drug
salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
4	O
.	O
atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
astma	I-Reason
.	O
6	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
8	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
furosemide	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
warfarin	I-Drug
1	O
mg	O
tonight	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Facility	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
Nursing	O
&	O
Therapy	O
Center	O
-	O
[	O
**	O
Location	O
1268	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Center	O
for	O
Rehabilitation	O
and	O
Sub-Acute	O
Care	O
)	O
Discharge	O
Diagnosis	O
:	O
Bilateral	O
disabling	O
claudication	O
,	O
Acute	O
on	O
chronic	O
diastolic	O
CHF	O
Emphysema	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
Division	O
of	O
Vascular	O
and	O
Endovascular	O
Surgery	O
Discharge	O
Instructions	O
What	O
to	O
expect	O
when	O
you	O
go	O
leave	O
the	O
hospital	O
:	O
1	O
.	O
It	O
is	O
normal	O
to	O
feel	O
tired	O
,	O
this	O
will	O
last	O
for	O
4	O
-	O
6	O
weeks	O
??????	O
You	O
should	O
get	O
up	O
out	O
of	O
bed	O
every	O
day	O
and	O
gradually	O
increase	O
your	O
activity	O
each	O
day	O
??????	O
You	O
may	O
walk	O
and	O
you	O
may	O
go	O
up	O
and	O
down	O
stairs	O
??????	O
Increase	O
your	O
activities	O
as	O
you	O
can	O
tolerate	O
-	O
do	O
not	O
do	O
too	O
much	O
right	O
away	O
!	O
2	O
.	O
It	O
is	O
normal	O
to	O
have	O
swelling	O
of	O
the	O
leg	O
you	O
were	O
operated	O
on	O
:	O
??????	O
Elevate	O
your	O
leg	O
above	O
the	O
level	O
of	O
your	O
heart	O
(	O
use	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
pillows	O
or	O
a	O
recliner	O
)	O
every	O
2	O
-	O
3	O
hours	O
throughout	O
the	O
day	O
and	O
at	O
night	O
??????	O
Avoid	O
prolonged	O
periods	O
of	O
standing	O
or	O
sitting	O
without	O
your	O
legs	O
elevated	O
3	O
.	O
It	O
is	O
normal	O
to	O
have	O
a	O
decreased	O
appetite	O
,	O
your	O
appetite	O
will	O
return	O
with	O
time	O
??????	O
You	O
will	O
probably	O
lose	O
your	O
taste	O
for	O
food	O
and	O
lose	O
some	O
weight	O
??????	O
Eat	O
small	O
frequent	O
meals	O
??????	O
It	O
is	O
important	O
to	O
eat	O
nutritious	O
food	O
options	O
(	O
high	O
fiber	O
,	O
lean	O
meats	O
,	O
vegetables	O
/	O
fruits	O
,	O
low	O
fat	O
,	O
low	O
cholesterol	O
)	O
to	O
maintain	O
your	O
strength	O
and	O
assist	O
in	O
wound	O
healing	O
??????	O
To	O
avoid	O
constipation	O
:	O
eat	O
a	O
high	O
fiber	O
diet	O
and	O
use	O
stool	O
softener	O
while	O
taking	O
pain	O
medication	O
What	O
activities	O
you	O
can	O
and	O
can	O
not	O
do	O
:	O
??????	O
No	O
driving	O
until	O
post-op	O
visit	O
and	O
you	O
are	O
no	O
longer	O
taking	O
pain	O
medications	O
??????	O
Unless	O
you	O
were	O
told	O
not	O
to	O
bear	O
any	O
weight	O
on	O
operative	O
foot	O
:	O
??????	O
You	O
should	O
get	O
up	O
every	O
day	O
,	O
get	O
dressed	O
and	O
walk	O
??????	O
You	O
should	O
gradually	O
increase	O
your	O
activity	O
??????	O
You	O
may	O
up	O
and	O
down	O
stairs	O
,	O
go	O
outside	O
and	O
/	O
or	O
ride	O
in	O
a	O
car	O
??????	O
Increase	O
your	O
activities	O
as	O
you	O
can	O
tolerate	O
-	O
do	O
not	O
do	O
too	O
much	O
right	O
away	O
!	O
??????	O
No	O
heavy	O
lifting	O
,	O
pushing	O
or	O
pulling	O
(	O
greater	O
than	O
5	O
pounds	O
)	O
until	O
your	O
post	O
op	O
visit	O
??????	O
You	O
may	O
shower	O
(	O
unless	O
you	O
have	O
stitches	O
or	O
foot	O
incisions	O
)	O
no	O
direct	O
spray	O
on	O
incision	O
,	O
let	O
the	O
soapy	O
water	O
run	O
over	O
incision	O
,	O
rinse	O
and	O
pat	O
dry	O
??????	O
Your	O
incision	O
may	O
be	O
left	O
uncovered	O
,	O
unless	O
you	O
have	O
small	O
amounts	O
of	O
drainage	O
from	O
the	O
wound	O
,	O
then	O
place	O
a	O
dry	O
dressing	O
over	O
the	O
area	O
that	O
is	O
draining	O
,	O
as	O
needed	O
??????	O
Take	O
all	O
the	O
medications	O
you	O
were	O
taking	O
before	O
surgery	O
,	O
unless	O
otherwise	O
directed	O
??????	O
Take	O
one	O
full	O
strength	O
(	O
325	O
mg	O
)	O
enteric	O
coated	O
aspirin	I-Drug
daily	O
,	O
unless	O
otherwise	O
directed	O
??????	O
Call	O
and	O
schedule	O
an	O
appointment	O
to	O
be	O
seen	O
in	O
2	O
weeks	O
for	O
staple	O
/	O
suture	O
removal	O
What	O
to	O
report	O
to	O
office	O
:	O
??????	O
Redness	O
that	O
extends	O
away	O
from	O
your	O
incision	O
??????	O
A	O
sudden	O
increase	O
in	O
pain	O
that	O
is	O
not	O
controlled	O
with	O
pain	O
medication	O
??????	O
A	O
sudden	O
change	O
in	O
the	O
ability	O
to	O
move	O
or	O
use	O
your	O
leg	O
or	O
the	O
ability	O
to	O
feel	O
your	O
leg	O
??????	O
Temperature	O
greater	O
than	O
100.5	O
F	O
for	O
24	O
hours	O
??????	O
Bleeding	O
,	O
new	O
or	O
increased	O
drainage	O
from	O
incision	O
or	O
white	O
,	O
yellow	O
or	O
green	O
drainage	O
from	O
incisions	O
Followup	O
Instructions	O
:	O
Department	O
:	O
VASCULAR	O
SURGERY	O
When	O
:	O
TUESDAY	O
[	O
**	O
2191-3-22	O
**	O
]	O
at	O
10:00	O
AM	O
With	O
:	O
[	O
**	O
Hospital	O
21926	O
**	O
]	O
CLINIC	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1237	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Bldg	O
(	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Completed	O
by	O
:[	O
**	O
2191-3-15	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2165-4-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2165-5-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2110-4-6	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
348	O
**	O
]	O
Chief	O
Complaint	O
:	O
Acute	O
Renal	O
Failure	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2165-4-21	O
**	O
]	O
Intubation	O
[	O
**	O
2165-4-21	O
**	O
]	O
Right	O
IJ	O
line	O
placement	O
[	O
**	O
2165-4-24	O
**	O
]	O
IR	O
-	O
guided	O
lumbar	O
puncture	O
[	O
**	O
2165-4-25	O
**	O
]	O
TEE	O
[	O
**	O
2165-4-20	O
**	O
]	O
Intubation	O
[	O
**	O
2165-4-23	O
**	O
]	O
Attempted	O
bedside	O
lumbar	O
puncture	O
[	O
**	O
2165-4-24	O
**	O
]	O
IR	O
-	O
guided	O
lumbar	O
puncture	O
[	O
**	O
2165-4-26	O
**	O
]	O
Hemodialysis	O
line	O
placement	O
and	O
hemodialysis	O
initiation	O
[	O
**	O
2165-4-30	O
**	O
]	O
Nasogastric	O
tube	O
placement	O
[	O
**	O
2165-4-30	O
**	O
]	O
Extubation	O
[	O
**	O
2165-5-2	O
**	O
]	O
IR	O
-	O
guided	O
hemodialysis	O
tunneled	O
catheter	O
placement	O
[	O
**	O
2165-5-6	O
**	O
]	O
lumbar	O
puncture	O
[	O
**	O
2165-5-13	O
**	O
]	O
tunnelled	O
HD	O
cath	O
placed	O
[	O
**	O
2165-5-15	O
**	O
]	O
tunnelled	O
HD	O
cath	O
placed	O
History	O
of	O
Present	O
Illness	O
:	O
55	O
y.o.	O
male	O
with	O
PMHx	O
of	O
DM	O
,	O
HTN	O
,	O
CAD	O
s	O
/	O
p	O
IMI	O
with	O
3	O
stents	O
to	O
RCA	O
and	O
recently	O
diagnosed	O
RCC	O
who	O
is	O
transferred	O
from	O
[	O
**	O
Hospital	O
**	O
]	O
for	O
ongoing	O
work	O
-	O
up	O
of	O
acute	O
renal	O
failure	O
and	O
change	O
in	O
mental	O
status	O
.	O
.	O
Patient	O
was	O
admitted	O
to	O
[	O
**	O
Hospital3	O
7571	O
**	O
]	O
Hospital	O
on	O
[	O
**	O
2165-4-16	O
**	O
]	O
for	O
chest	O
and	O
abdominal	O
pain	O
.	O
He	O
ruled	O
out	O
for	O
an	O
MI	O
with	O
cardiac	O
biomarkers	O
and	O
was	O
felt	O
to	O
be	O
constipated	I-Ade
as	O
was	O
illustrated	O
on	O
CT	O
and	O
thought	O
to	O
be	O
due	O
to	O
chronic	O
narcotic	I-Drug
use	O
for	O
lower	B-Reason
back	I-Reason
pain	O
and	O
right	B-Reason
hip	I-Reason
pain	I-Reason
(	O
awaiting	O
hip	O
replacement	O
)	O
.	O
His	O
constipation	O
was	O
treated	O
aggressively	O
with	O
medications	O
and	O
disimpaction	O
with	O
minimal	O
effect	O
.	O
On	O
day	O
4	O
of	O
his	O
hospitalization	O
,	O
he	O
was	O
febrile	B-Reason
to	I-Reason
104	I-Reason
with	O
a	O
leukocytosis	O
to	O
14	O
and	O
was	O
pan-cultured	O
while	O
Vancomycin	I-Drug
and	O
Zosyn	I-Drug
were	O
started	O
empirically	O
with	O
specific	O
concern	O
for	O
a	O
PIV	O
infection	O
suggested	O
by	O
surrounding	O
erythema	O
and	O
edema	O
.	O
Blood	O
cultures	O
later	O
grew	O
GPCs	O
in	O
[	O
**	O
2	O
-	O
23	O
**	O
]	O
bottles	O
and	O
chronic	O
foot	O
ulcers	O
were	O
swabbed	O
and	O
reportedly	O
grew	O
staph	B-Reason
aureus	I-Reason
with	O
pending	O
sensitivities	O
.	O
Zosyn	I-Drug
was	O
thus	O
discontinued	O
.	O
In	O
the	O
setting	O
of	O
infection	O
,	O
patient	O
became	O
delirious	O
,	O
noted	O
to	O
be	O
attempting	O
to	O
grab	O
things	O
from	O
the	O
air	O
and	O
talking	O
to	O
people	O
in	O
the	O
room	O
.	O
Of	O
note	O
,	O
patient	O
was	O
continued	O
on	O
narcotics	I-Drug
,	O
reportedly	O
at	O
the	O
wife	O
's	O
insistence	O
given	O
concern	O
for	O
narcotic	I-Drug
withdrawal	I-Ade
.	O
Neurology	O
was	O
consulted	O
and	O
recommended	O
a	O
head	O
CT	O
which	O
was	O
unremarkable	O
,	O
leaving	O
them	O
to	O
conclude	O
that	O
the	O
mental	O
status	O
was	O
toxic	O
/	O
metabolic	O
in	O
the	O
setting	O
of	O
infection	O
and	O
narcotic	I-Drug
use	O
.	O
He	O
was	O
started	O
on	O
Ceftriaxone	I-Drug
2	O
grams	O
daily	O
for	O
CNS	B-Reason
coverage	I-Reason
though	O
no	O
LP	O
was	O
performed	O
.	O
On	O
day	O
5	O
,	O
patient	O
was	O
noted	O
to	O
develop	O
acute	O
renal	O
failure	O
with	O
a	O
creatinine	O
of	O
3	O
,	O
up	O
from	O
1.3	O
and	O
was	O
also	O
anuric	O
.	O
CKs	O
were	O
checked	O
to	O
evaluate	O
renal	O
failure	O
from	O
rhabdomyolysis	O
and	O
were	O
not	O
likely	O
contributing	O
at	O
a	O
level	O
of	O
361	O
.	O
He	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
concern	O
of	O
his	O
renal	O
failure	O
progressing	O
to	O
the	O
point	O
of	O
needing	O
HD	O
,	O
since	O
[	O
**	O
Hospital3	O
77641	O
**	O
]	O
no	O
HD	O
facilities	O
.	O
.	O
Upon	O
arrival	O
,	O
patient	O
was	O
noted	O
to	O
vomit	O
and	O
had	O
reportedly	O
vomited	O
in	O
route	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
He	O
additionally	O
started	O
experiencing	O
low	O
-	O
amplitude	O
,	O
rhythmic	O
clonus	O
of	O
his	O
hands	O
and	O
legs	O
,	O
became	O
transiently	O
hypoxic	O
and	O
was	O
not	O
verbally	O
responsive	O
.	O
There	O
was	O
concern	O
for	O
seizing	O
and	O
patient	O
was	O
urgently	O
intubated	O
to	O
protect	O
his	O
airway	O
.	O
Discussion	O
with	O
the	O
patient	O
's	O
wife	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
RN	O
,	O
revealed	O
that	O
the	O
patient	O
has	O
never	O
had	O
a	O
seizure	O
disorder	O
and	O
does	O
not	O
drink	O
alcohol	O
.	O
Additionally	O
,	O
he	O
had	O
a	O
CT	O
scan	O
with	O
contrast	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
3	O
days	O
prior	O
to	O
his	O
admission	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
as	O
a	O
part	O
of	O
his	O
RCC	O
work	O
-	O
up	O
and	O
the	O
wife	O
expressed	O
concern	O
for	O
contrast	I-Drug
-	O
induced	O
nephropathy	I-Ade
.	O
Patient	O
was	O
then	O
ordered	O
for	O
a	O
stat	O
head	O
CT	O
given	O
the	O
mental	O
status	O
and	O
neurology	O
was	O
consulted	O
for	O
further	O
assistance	O
with	O
management	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
s	O
/	O
p	O
IMI	O
in	O
'	O
[	O
**	O
60	O
**	O
]	O
with	O
stents	O
in	O
RCA	O
DM	O
HTN	O
Morbid	O
Obesity	O
OA	O
-	O
awaiting	O
right	O
hip	O
replacement	O
Gout	O
Social	O
History	O
:	O
Per	O
wife	O
,	O
no	O
alcohol	O
.	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
98.5	O
,	O
BP	O
:	O
139/110	O
,	O
P	O
:	O
117	O
,	O
R	O
:	O
16	O
O2	O
:	O
93	O
%	O
AC	O
600	O
/	O
14/100	O
%	O
/	O
5	O
General	O
:	O
Awake	O
,	O
but	O
not	O
able	O
to	O
follow	O
commands	O
,	O
responding	O
with	O
one	O
word	O
sentences	O
,	O
occasionally	O
not	O
responsive	O
to	O
sternal	O
rub	O
,	O
noted	O
to	O
have	O
fasiculations	O
of	O
tongue	O
and	O
low	O
-	O
amplitude	O
clonus	O
of	O
hands	O
and	O
legs	O
bilaterally	O
HEENT	O
:	O
NC	O
/	O
AT	O
;	O
PERRLA	O
,	O
EOMI	O
;	O
OP	O
with	O
dry	O
mucous	O
membranes	O
Neck	O
:	O
Obese	O
neck	O
,	O
unable	O
to	O
appreciate	O
JVD	O
Lungs	O
:	O
CTAB	O
CV	O
:	O
S1	O
,	O
S2	O
nl	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
appreciated	O
Abdomen	O
:	O
Markedly	O
distended	O
and	O
tympanic	O
to	O
percussion	O
,	O
bowel	O
sounds	O
not	O
appreciated	O
Ext	O
:	O
No	O
c	O
/	O
c	O
/	O
e	O
;	O
Left	O
foot	O
with	O
2	O
stage	O
3	O
ulcers	O
without	O
surrounding	O
cellulitis	O
and	O
amputation	O
of	O
2	O
toes	O
Neuro	O
:	O
Patient	O
largely	O
unable	O
to	O
cooperate	O
.	O
Downgoing	O
toes	O
bilaterally	O
Pertinent	O
Results	O
:	O
Discharge	O
Labs	O
:	O
COMPLETE	O
BLOOD	O
COUNT	O
WBC	O
RBC	O
Hgb	O
Hct	O
MCV	O
MCH	O
MCHC	O
RDW	O
Plt	O
Ct	O
[	O
**	O
2165-5-22	O
**	O
]	O
05:07	O
AM	O
8.6	O
2.76	O
*	O
7.6	O
*	O
23.1	O
*	O
84	O
27.6	O
32.9	O
16.4	O
*	O
368	O
PT	O
PTT	O
Plt	O
Smr	O
Plt	O
Ct	O
INR	O
(	O
PT	O
)	O
[	O
**	O
2165-5-22	O
**	O
]	O
05:07	O
AM	O
368	O
Source	O
:	O
Line	O
-	O
picc	O
[	O
**	O
2165-5-22	O
**	O
]	O
05:07	O
AM	O
14.7	O
*	O
26.0	O
1.3	O
*	O
ESR	O
[	O
**	O
2165-5-14	O
**	O
]	O
06:30	O
AM	O
150	O
*	O
Source	O
:	O
Line	O
-	O
PICC	O
HEMOLYTIC	O
WORKUP	O
Ret	O
Aut	O
[	O
**	O
2165-5-16	O
**	O
]	O
05:33	O
AM	O
4.9	O
*	O
Glucose	O
UreaN	O
Creat	O
Na	O
K	O
Cl	O
HCO3	O
AnGap	O
[	O
**	O
2165-5-22	O
**	O
]	O
05:07	O
AM	O
79	O
26	O
*	O
2.2	O
*	O
140	O
4.0	O
100	O
28	O
16	O
Calcium	O
Phos	O
Mg	O
UricAcd	O
Iron	O
[	O
**	O
2165-5-22	O
**	O
]	O
05:07	O
AM	O
9.0	O
3.9	O
1.7	O
Source	O
:	O
Line	O
-	O
picc	O
HEMATOLOGIC	O
calTIBC	O
VitB12	O
Folate	O
Hapto	O
Ferritn	O
TRF	O
[	O
**	O
2165-5-6	O
**	O
]	O
05:25	O
AM	O
156	O
*	O
587	O
9.4	O
336	O
*	O
981	O
*	O
120	O
*	O
PITUITARY	O
TSH	O
[	O
**	O
2165-4-21	O
**	O
]	O
07:47	O
PM	O
4.0	O
ADDED	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
AT	O
2040	O
ON	O
[	O
**	O
2165-4-21	O
**	O
]	O
THYROID	O
PTH	O
[	O
**	O
2165-5-21	O
**	O
]	O
07:30	O
AM	O
26	O
[	O
**	O
2165-5-21	O
**	O
]	O
06:30	O
AM	O
41	O
Source	O
:	O
Line	O
-	O
PICC	O
IMMUNOLOGY	O
CRP	O
[	O
**	O
2165-5-14	O
**	O
]	O
06:30	O
AM	O
112.5	O
*	O
1	O
[	O
**	O
2165-4-21	O
**	O
]	O
through	O
discharge	O
-	O
>	O
no	O
growth	O
in	O
blood	O
cultures	O
[	O
**	O
2165-5-21	O
**	O
]	O
cath	O
tip	O
swab	O
-	O
>	O
no	O
growth	O
For	O
complete	O
blood	O
culture	O
results	O
,	O
please	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2756	O
**	O
]	O
and	O
ask	O
for	O
microbiology	O
.	O
[	O
**	O
2165-4-21	O
**	O
]	O
CXR	O
:	O
ET	O
tube	O
tip	O
at	O
the	O
thoracic	O
inlet	O
is	O
approximately	O
45	O
mm	O
from	O
the	O
carina	O
,	O
standard	O
position	O
.	O
Lung	O
volumes	O
are	O
low	O
and	O
there	O
are	O
several	O
areas	O
of	O
plate	O
-	O
like	O
atelectasis	O
.	O
Heart	O
size	O
borderline	O
enlarged	O
.	O
Pleural	O
effusion	O
,	O
if	O
any	O
,	O
is	O
minimal	O
.	O
No	O
pneumothorax	O
.	O
[	O
**	O
2165-4-21	O
**	O
]	O
Abd	O
XR	O
:	O
Diffuse	O
colonic	O
dilatation	O
without	O
air	O
within	O
the	O
rectum	O
.	O
This	O
may	O
represent	O
ileus	O
.	O
Close	O
followup	O
is	O
recommended	O
.	O
[	O
**	O
2165-4-21	O
**	O
]	O
Left	O
foot	O
XR	O
:	O
The	O
patient	O
is	O
status	O
post	O
partial	O
amputation	O
of	O
the	O
first	O
through	O
fifth	O
metatarsals	O
and	O
resection	O
of	O
multiple	O
phalanges	O
.	O
Portions	O
of	O
the	O
1st	O
distal	O
phalanx	O
,	O
the	O
toe	O
of	O
the	O
second	O
(	O
?	O
)	O
digit	O
,	O
and	O
the	O
fifth	O
toe	O
are	O
present	O
.	O
There	O
is	O
a	O
focus	O
of	O
air	O
overlying	O
the	O
surgical	O
bed	O
of	O
the	O
first	O
ray	O
,	O
representing	O
either	O
air	O
within	O
an	O
area	O
of	O
ulceration	O
or	O
subcutaneous	O
emphysema	O
.	O
There	O
is	O
relative	O
lucency	O
of	O
the	O
adjoining	O
portion	O
of	O
the	O
first	O
metatarsal	O
bony	O
remnant	O
suspicious	O
for	O
osteomyelitis	O
.	O
Correlation	O
with	O
any	O
previous	O
(	O
outside	O
)	O
radiographs	O
and	O
history	O
of	O
recent	O
debridement	O
is	O
recommended	O
for	O
full	O
assessment	O
.	O
The	O
posterior	O
calcaneus	O
is	O
obscured	O
by	O
overlying	O
material	O
and	O
not	O
fully	O
evaluated	O
on	O
this	O
examination	O
.	O
[	O
**	O
2165-4-22	O
**	O
]	O
CT	O
head	O
:	O
No	O
intracranial	O
hemorrhage	O
or	O
edema	O
.	O
[	O
**	O
2165-4-22	O
**	O
]	O
EEG	O
:	O
This	O
is	O
an	O
abnormal	O
portable	O
EEG	O
recording	O
due	O
to	O
the	O
pattern	O
of	O
widespread	O
alpha	O
range	O
activity	O
alternating	O
with	O
relative	O
suppression	O
of	O
the	O
background	O
without	O
reactivity	O
which	O
is	O
suggestive	O
of	O
an	O
alpha	O
coma	O
pattern	O
.	O
This	O
abnormality	O
suggests	O
a	O
severe	O
encephalopathy	O
.	O
Medications	O
and	O
metabolic	O
disturbances	O
may	O
be	O
causes	O
but	O
this	O
pattern	O
can	O
also	O
be	O
seen	O
in	O
post-anoxic	O
patients	O
.	O
There	O
were	O
no	O
lateralized	O
or	O
epileptiform	O
features	O
seen	O
and	O
no	O
electrographic	O
seizures	O
were	O
seen	O
in	O
this	O
recording	O
.	O
[	O
**	O
2165-4-22	O
**	O
]	O
Renal	O
U	O
/	O
S	O
:	O
No	O
evidence	O
of	O
hydronephrosis	O
.	O
[	O
**	O
2165-4-22	O
**	O
]	O
TTE	O
:	O
Suboptimal	O
image	O
quality	O
.	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
mild	O
cavity	O
enlargement	O
and	O
preserved	O
global	O
biventricular	O
systolic	O
function	O
.	O
[	O
**	O
2165-4-25	O
**	O
]	O
TEE	O
:	O
No	O
intracardiac	O
mass	O
or	O
vegetations	O
.	O
No	O
significant	O
valvular	O
regurgitation	O
.	O
Complex	O
,	O
mobile	O
atheroma	O
in	O
descending	O
aorta	O
,	O
simple	O
atheroma	O
in	O
the	O
aortic	O
arch	O
.	O
[	O
**	O
2165-4-25	O
**	O
]	O
MRI	O
/	O
MRV	O
Head	O
w	O
/	O
o	O
Contrast	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
infarction	O
.	O
2	O
.	O
Patent	O
major	O
dural	O
venous	O
sinuses	O
.	O
Decreased	O
signal	O
in	O
the	O
posterior	O
part	O
of	O
the	O
superior	O
sagittal	O
sinus	O
,	O
including	O
the	O
torcular	O
herophili	O
and	O
the	O
right	O
sigmoid	O
sinus	O
,	O
likely	O
relates	O
to	O
slow	O
flow	O
rather	O
than	O
thrombosis	O
given	O
the	O
lack	O
of	O
increased	O
signal	O
on	O
the	O
sagittal	O
T1	O
-	O
weighted	O
sequences	O
.	O
If	O
there	O
is	O
continued	O
concern	O
based	O
on	O
the	O
clinical	O
presentation	O
,	O
CTA	O
and	O
CTV	O
,	O
if	O
serum	O
creatinine	O
level	O
is	O
appropriate	O
or	O
a	O
followup	O
MR	O
venogram	O
can	O
be	O
considered	O
.	O
[	O
**	O
2165-4-30	O
**	O
]	O
CT	O
SPINE	O
:	O
IMPRESSION	O
:	O
Limited	O
study	O
due	O
to	O
patient	O
habitus	O
and	O
motion	O
,	O
and	O
non	O
-	O
myelographic	O
technique	O
,	O
with	O
:	O
1	O
.	O
No	O
definite	O
epidural	O
or	O
subdural	O
abscess	O
collection	O
seen	O
in	O
the	O
thoracolumabr	O
spine	O
.	O
2	O
.	O
Apparent	O
hyperdense	O
focus	O
in	O
the	O
ventral	O
epidural	O
space	O
at	O
the	O
T2	O
level	O
,	O
most	O
likely	O
artifactual	O
.	O
If	O
this	O
remains	O
of	O
clinical	O
concern	O
,	O
follow	O
-	O
up	O
CT	O
study	O
,	O
dedicated	O
CT	O
-	O
myelography	O
or	O
MRI	O
,	O
when	O
feasible	O
,	O
might	O
be	O
helpful	O
for	O
further	O
evaluation	O
.	O
N.B.	O
.	O
The	O
patient	O
successfully	O
underwent	O
MRI	O
of	O
the	O
brain	O
(	O
at	O
this	O
institution	O
)	O
as	O
recently	O
as	O
[	O
**	O
2165-4-25	O
**	O
]	O
.	O
3	O
.	O
No	O
fracture	O
or	O
malalignment	O
.	O
4	O
.	O
Mild	O
spondylosis	O
of	O
the	O
thoracolumbar	O
spine	O
,	O
with	O
no	O
canal	O
compromise	O
.	O
5	O
.	O
Small	O
bilateral	O
pleural	O
effusions	O
and	O
moderate	O
bibasilar	O
consolidations	O
;	O
differential	O
diagnosis	O
includes	O
atelectasis	O
,	O
aspiration	O
and	O
bacterial	O
pneumonia	O
.	O
[	O
**	O
2165-5-2	O
**	O
]	O
Renal	O
U	O
/	O
S	O
:	O
IMPRESSION	O
:	O
No	O
hydronephrosis	O
and	O
no	O
perinephric	O
collections	O
seen	O
in	O
this	O
very	O
limited	O
mobile	O
renal	O
ultrasound	O
study	O
.	O
[	O
**	O
2165-5-9	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Definite	O
abnormal	O
focus	O
of	O
tracer	O
accumulation	O
in	O
the	O
left	O
foot	O
correlating	O
with	O
known	O
sites	O
of	O
ulceration	O
/	O
infection	O
.	O
2	O
.	O
Indeterminate	O
foci	O
in	O
the	O
right	O
proximal	O
thigh	O
medially	O
or	O
scrotum	O
and	O
the	O
soft	O
-	O
tissues	O
of	O
the	O
left	O
knee	O
medially	O
,	O
for	O
which	O
clinical	O
correlation	O
is	O
needed	O
.	O
3	O
.	O
Possible	O
nasal	O
infection	O
or	O
ethmoid	O
sinusitis	O
.	O
[	O
**	O
2165-5-13	O
**	O
]	O
EEG	O
:	O
IMPRESSION	O
:	O
This	O
is	O
an	O
abnormal	O
routine	O
EEG	O
due	O
to	O
a	O
slow	O
and	O
poorly	O
modulated	O
background	O
indicative	O
of	O
a	O
mild	O
to	O
moderate	O
encephalopathy	O
.	O
Medications	O
,	O
metabolic	O
disturbances	O
,	O
and	O
infections	O
are	O
among	O
the	O
most	O
common	O
causes	O
.	O
There	O
were	O
no	O
areas	O
of	O
prominent	O
focal	O
slowing	O
although	O
encephalopathies	O
can	O
obscure	O
focal	O
findings	O
.	O
There	O
were	O
no	O
epileptiform	O
discharges	O
noted	O
.	O
Brief	O
Hospital	O
Course	O
:	O
55	O
year	O
old	O
male	O
had	O
prolonged	O
hospital	O
course	O
complicated	O
by	O
multiple	B-Reason
infections	I-Reason
,	O
mental	O
status	O
changes	O
,	O
and	O
renal	O
failure	O
who	O
requires	O
long	O
term	O
antibiotic	I-Drug
therapy	O
.	O
#	O
Sepsis	I-Reason
/	O
Meningitis	I-Reason
:	O
He	O
was	O
transferred	O
from	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
in	O
the	O
setting	O
of	O
high	O
-	O
grade	O
MSSA	O
bacterimia	O
and	O
mental	O
status	O
changes	O
,	O
and	O
intubated	O
on	O
arrival	O
because	O
of	O
question	O
seizures	O
and	O
concern	O
for	O
airway	O
protection	O
.	O
Before	O
speciation	O
returned	O
,	O
he	O
was	O
initially	O
managed	O
with	O
vancomycin	I-Drug
and	O
zosyn	I-Drug
,	O
and	O
then	O
switched	O
to	O
nafcillin	I-Drug
given	O
MSSA	I-Reason
.	O
He	O
also	O
required	O
pressors	I-Drug
intermittently	O
on	O
the	O
day	O
after	O
presenting	O
but	O
this	O
was	O
ultimately	O
thought	O
to	O
represent	O
a	O
low	O
-	O
baseline	O
blood	O
pressure	O
,	O
and	O
pressors	I-Drug
were	O
subsequently	O
discontinued	O
,	O
with	O
MAPs	O
that	O
remained	O
greater	O
than	O
65	O
.	O
The	O
source	O
of	O
his	O
infection	O
was	O
unclear	O
but	O
thought	O
to	O
be	O
secondary	O
to	O
left	O
foot	O
ulcers	O
,	O
which	O
also	O
grew	O
MSSA	O
.	O
This	O
was	O
evaluated	O
by	O
podiatry	O
and	O
vascular	O
,	O
and	O
he	O
was	O
found	O
to	O
have	O
osteomyelitis	O
of	O
the	O
first	O
toe	O
,	O
and	O
would	O
possibly	O
need	O
L	O
BKA	O
for	O
definitive	O
treatment	O
.	O
There	O
was	O
also	O
concern	O
for	O
encephalopathy	O
given	O
his	O
worsening	O
mental	O
status	O
prior	O
to	O
and	O
after	O
transfer	O
,	O
and	O
neurology	O
was	O
consulted	O
.	O
An	O
LP	O
was	O
initially	O
deferred	O
because	O
of	O
the	O
unlikelihood	O
of	O
him	O
developing	O
meningitis	O
during	O
his	O
hospitalization	O
at	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
as	O
he	O
did	O
not	O
initially	O
present	O
with	O
symptoms	O
suggestive	O
of	O
this	O
condition	O
.	O
However	O
,	O
it	O
was	O
later	O
performed	O
and	O
was	O
consistent	O
with	O
bacterial	B-Reason
meningitis	I-Reason
,	O
and	O
antibiotics	I-Drug
were	O
changed	O
to	O
vancomycin	I-Drug
,	O
ceftriaxone	I-Drug
,	O
and	O
acyclovir	I-Drug
.	O
ACV	O
and	O
CTX	O
were	O
then	O
discontinued	O
as	O
CSF	O
culture	O
returned	O
negative	O
and	O
other	O
cultures	O
continued	O
to	O
be	O
MSSA	O
.	O
He	O
was	O
extubated	O
after	O
10	O
days	O
and	O
tolerate	O
this	O
well	O
.	O
Vancomycin	I-Drug
was	O
continued	O
following	O
transfer	O
to	O
floor	O
.	O
A	O
thorough	O
work	O
up	O
for	O
source	O
of	O
infection	O
,	O
including	O
LP	O
and	O
left	O
foot	O
imaging	O
,	O
did	O
not	O
yield	O
a	O
source	O
.	O
As	O
patient	O
continued	O
to	O
improve	O
clinically	O
,	O
the	O
decision	O
was	O
made	O
to	O
treat	O
empirically	O
with	O
vancomycin	I-Drug
until	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
,	O
dosing	O
during	O
HD	O
.	O
#	O
Altered	O
mental	O
status	O
:	O
After	O
extubation	O
,	O
patient	O
was	O
delirious	O
,	O
not	O
responding	O
to	O
commands	O
,	O
and	O
with	O
jerking	O
motions	O
of	O
his	O
head	O
.	O
An	O
MRI	O
/	O
MRV	O
was	O
negative	O
for	O
structural	O
abnormality	O
on	O
[	O
**	O
2165-4-25	O
**	O
]	O
,	O
after	O
EEG	O
showed	O
possible	O
alpha	O
-	O
coma	O
waves	O
.	O
His	O
mental	O
status	O
cleared	O
after	O
4	O
days	O
extubation	O
suggesting	O
ICU	O
narcosis	O
.	O
He	O
began	O
to	O
follow	O
commands	O
on	O
[	O
**	O
2165-5-4	O
**	O
]	O
.	O
Following	O
transfer	O
to	O
floor	O
,	O
fentanyl	I-Drug
patch	O
was	O
discontinued	O
in	O
favor	O
of	O
morphine	I-Drug
PO	O
.	O
The	O
patient	O
's	O
mental	O
status	O
continued	O
to	O
improve	O
without	O
further	O
intervention	O
.	O
At	O
time	O
of	O
discharge	O
,	O
patient	O
was	O
oriented	O
to	O
time	O
,	O
person	O
,	O
and	O
place	O
.	O
#	O
?	O
hypodense	O
region	O
in	O
TT2	O
area	O
of	O
spinal	O
cord	O
:	O
Intial	O
concern	O
was	O
for	O
abscess	O
with	O
cord	O
compression	O
as	O
patient	O
was	O
febrile	O
with	O
MSSA	O
infection	O
and	O
not	O
moving	O
his	O
lower	O
extremities	O
for	O
several	O
days	O
pre-extubation	O
[	O
**	O
2165-4-30	O
**	O
]	O
.	O
Neurosurgery	O
was	O
consulted	O
and	O
recommended	O
CT	O
myelogram	O
or	O
MRI	O
to	O
better	O
define	O
this	O
lesion	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
radiology	O
)	O
stated	O
CT	O
myelogram	O
was	O
not	O
indicated	O
and	O
suggested	O
MRI	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
77642	O
**	O
]	O
was	O
unable	O
to	O
fit	O
in	O
the	O
MRI	O
scanner	O
far	O
enough	O
to	O
scan	O
his	O
spine	O
so	O
he	O
was	O
watched	O
clinically	O
and	O
improved	O
.	O
Consider	O
f	O
/	O
u	O
MRI	O
in	O
open	O
MRI	O
scanner	O
as	O
an	O
outpatient	O
.	O
#	O
Respiratory	O
failure	O
:	O
He	O
was	O
intubated	O
shortly	O
after	O
ariving	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
because	O
of	O
concern	O
for	O
airway	O
protection	O
in	O
the	O
setting	O
of	O
question	O
seizures	O
,	O
as	O
he	O
had	O
low	O
-	O
amplitude	O
clonic	O
movements	O
of	O
his	O
hands	O
and	O
legs	O
.	O
His	O
vent	O
settings	O
were	O
weaned	O
and	O
plan	O
for	O
extubation	O
on	O
[	O
**	O
5	O
-	O
1	O
**	O
]	O
was	O
moved	O
up	O
after	O
he	O
bit	O
through	O
the	O
tubing	O
to	O
inflate	O
the	O
cuff	O
.	O
He	O
was	O
extubated	O
after	O
9	O
days	O
and	O
his	O
respiratory	O
status	O
continue	O
to	O
improve	O
.	O
EEG	O
obtained	O
showed	O
no	O
epileptiform	O
activity	O
.	O
Patient	O
had	O
stable	O
respiratory	O
for	O
the	O
duration	O
of	O
his	O
hospitalization	O
following	O
extubation	O
.	O
#	O
Acute	O
Renal	O
Failure	O
:	O
His	O
creatinine	O
began	O
rising	O
prior	O
to	O
transfer	O
from	O
a	O
baseline	O
of	O
1.3	O
,	O
and	O
he	O
developed	O
oliguric	O
renal	O
failure	O
.	O
Renal	O
was	O
consulted	O
and	O
their	O
analysis	O
of	O
his	O
urine	O
was	O
consistent	O
with	O
ATN	O
secondary	O
to	O
sepsis	O
,	O
though	O
there	O
was	O
no	O
clear	O
documentation	O
of	O
hypotension	O
from	O
the	O
OSH	O
.	O
He	O
had	O
to	O
be	O
started	O
on	O
HD	O
(	O
[	O
**	O
2165-4-26	O
**	O
]	O
)	O
for	O
volume	O
overload	O
and	O
hyperkalemia	O
.	O
At	O
that	O
point	O
his	O
creatinine	O
was	O
9.8	O
.	O
He	O
continued	O
on	O
HD	O
and	O
eventually	O
a	O
temporary	O
dialysis	O
catheter	O
was	O
placed	O
(	O
on	O
[	O
**	O
5	O
-	O
2	O
**	O
]	O
)	O
and	O
the	O
femoral	O
HD	O
catheter	O
was	O
pulled	O
.	O
His	O
urine	O
output	O
improved	O
,	O
although	O
his	O
need	O
for	O
HD	O
continued	O
.	O
The	O
patient	O
had	O
another	O
dialysis	O
catheter	O
placed	O
on	O
[	O
**	O
5	O
-	O
15	O
**	O
]	O
for	O
HD	O
,	O
with	O
subsequent	O
self	O
-	O
removal	O
secondary	O
to	O
agitation	O
.	O
A	O
tunnelled	O
catheter	O
HD	O
line	O
was	O
placed	O
on	O
[	O
**	O
2165-5-17	O
**	O
]	O
for	O
resumption	O
of	O
HD	O
.	O
The	O
patient	O
continued	O
receiving	O
HD	O
3	O
times	O
weekly	O
on	O
the	O
floor	O
,	O
and	O
pt	O
's	O
creatinine	O
was	O
2.2	O
at	O
time	O
of	O
discharge	O
.	O
The	O
patient	O
will	O
continue	O
HD	O
following	O
discharge	O
and	O
will	O
be	O
followed	O
by	O
the	O
nephrology	O
service	O
.	O
#	O
Hypertension	I-Reason
:	O
After	O
septic	O
picture	O
resolved	O
,	O
patient	O
was	O
hypertensive	O
to	O
200s	O
/	O
80s	O
.	O
His	O
losartan	I-Drug
was	O
held	O
for	O
renal	O
protection	O
in	O
hopes	O
that	O
his	O
renal	O
function	O
would	O
recover	O
.	O
He	O
was	O
started	O
on	O
metoprolol	I-Drug
and	O
hydralizine	I-Drug
with	O
better	O
control	O
.	O
Pt	O
's	O
HTN	O
was	O
managed	O
well	O
on	O
the	O
floor	O
following	O
ICU	O
transfer	O
with	O
the	O
current	O
medication	O
regimen	O
at	O
discharge	O
.	O
#	O
L	O
foot	O
ulcer	O
:	O
Likely	O
seeding	O
to	O
blood	O
causing	O
sepsis	O
.	O
ESR	O
and	O
CRP	O
very	O
high	O
and	O
will	O
monitor	O
with	O
Abx	I-Drug
treatment	O
for	O
osteomyelitis	I-Reason
.	O
-	O
Podiatry	O
and	O
vascular	O
surgery	O
were	O
consulted	O
and	O
stated	O
they	O
would	O
defer	O
amputation	O
and	O
await	O
stabilization	O
/	O
abx	O
treatment	O
of	O
patient	O
prior	O
to	O
surgery	O
.	O
-	O
no	O
intervention	O
was	O
pursued	O
,	O
as	O
patient	O
improved	O
clinically	O
on	O
floor	O
on	O
vancomycin	I-Drug
-	O
pt	O
will	O
have	O
ID	O
follow	O
up	O
on	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
#	O
Right	B-Reason
hip	I-Reason
OA	I-Reason
:	O
significant	O
source	O
of	O
pain	O
and	O
had	O
required	O
large	O
doses	O
of	O
narcotics	I-Drug
prior	O
to	O
admission	O
.	O
Per	O
family	O
,	O
the	O
plan	O
was	O
to	O
replace	O
his	O
hip	O
,	O
but	O
he	O
was	O
battling	O
recurrent	O
infections	O
from	O
L	O
toe	O
delaying	O
this	O
.	O
Morphine	I-Drug
PO	O
with	O
scheduled	O
tylenol	I-Drug
proved	O
an	O
effective	O
regimen	O
for	O
his	B-Reason
pain	I-Reason
.	O
#	O
Large	O
bowel	O
obstruction	O
:	O
A	O
KUB	O
demonstrated	O
a	O
distended	O
transverse	O
colon	O
concerning	O
for	O
ileus	I-Ade
in	O
the	O
setting	O
of	O
large	O
narcotic	I-Drug
use	O
for	O
R	O
hip	O
pain	O
.	O
General	O
surgery	O
was	O
consulted	O
and	O
felt	O
that	O
it	O
was	O
improving	O
and	O
did	O
not	O
require	O
surgical	O
intervention	O
.	O
He	O
eventually	O
began	O
stooling	O
again	O
after	O
PO	O
narcan	I-Drug
was	O
started	O
and	O
with	O
an	O
aggressive	O
bowel	O
regimen	O
.	O
Following	O
transfer	O
to	O
floor	O
,	O
constipation	I-Reason
resolved	O
with	O
bowel	B-Drug
regimen	I-Drug
and	O
change	O
in	O
opiate	O
use	O
.	O
#	O
CAD	B-Reason
s	I-Reason
/	I-Reason
p	I-Reason
IMI	I-Reason
:	O
Ruled	O
out	O
for	O
MI	O
at	O
OSH	O
and	O
was	O
continued	O
on	O
ASA	I-Drug
/	O
plavix	I-Drug
.	O
He	O
was	O
not	O
on	O
a	O
beta	B-Drug
blocker	I-Drug
or	O
statin	I-Drug
at	O
home	O
for	O
unclear	O
reasons	O
.	O
#	O
DM	I-Reason
:	O
Managed	O
initially	O
with	O
an	O
insulin	I-Drug
drip	O
because	O
of	O
elevated	O
finger	O
sticks	O
and	O
converted	O
to	O
a	O
sliding	O
scale	O
.	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
consulted	O
and	O
placed	O
patient	O
on	O
a	O
basal	O
bolus	O
regimen	O
with	O
good	O
control	O
at	O
time	O
of	O
discharge	O
.	O
This	O
regimen	O
will	O
be	O
continued	O
at	O
rehab	O
.	O
#	O
Renal	O
Cell	O
Carcinoma	O
:	O
Is	O
seen	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
.	O
Per	O
family	O
,	O
he	O
was	O
recently	O
diagnosed	O
~	O
2	O
cm	O
mass	O
,	O
CT	O
torso	O
without	O
mets	O
.	O
He	O
was	O
scheduled	O
for	O
cryoablation	O
prior	O
to	O
this	O
hospitalization	O
.	O
#	O
Gout	I-Reason
:	O
Renally	O
-	O
dosed	O
Allopurinol	I-Drug
and	O
then	O
d	O
/	O
c	O
'd	O
given	O
renal	O
failure	O
.	O
#	O
Communication	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
wife	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
77643	O
**	O
]	O
-	O
cell	O
#	O
Patient	O
was	O
made	O
DNR	O
,	O
but	O
okay	O
to	O
re-intubate	O
for	O
respiratory	O
failure	O
post-extubation	O
.	O
Medications	O
on	O
Admission	O
:	O
Medications	O
on	O
Transfer	O
:	O
Allopurinol	I-Drug
Aspirin	I-Drug
Plavix	I-Drug
Colchicine	I-Drug
Lasix	I-Drug
Indomethacin	I-Drug
Insulin	I-Drug
Cozaar	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Docusate	I-Drug
Sodium	O
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
4	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
5	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
6	O
.	O
Amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Calcium	B-Drug
Acetate	I-Drug
667	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
11	O
.	O
Acetaminophen	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
12	O
.	O
Morphine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
13	O
.	O
line	O
care	O
Heparin	B-Drug
Flush	I-Drug
(	O
5000	O
Units	O
/	O
mL	O
)	O
4000	O
-	O
[	O
**	O
Numeric	O
Identifier	O
2249	O
**	O
]	O
UNIT	O
DWELL	O
PRN	O
line	O
flush	O
Dialysis	O
Catheter	O
(	O
Tunneled	O
2	O
-	O
Lumen	O
)	O
:	O
DIALYSIS	O
NURSE	O
ONLY	O
:	O
Withdraw	O
4	O
mL	O
prior	O
to	O
flushing	O
with	O
10	O
mL	O
NS	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
according	O
to	O
volume	O
per	O
lumen	O
.	O
14	O
.	O
Vancomycin	I-Drug
in	O
Dextrose	O
1	O
gram	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
gram	O
Intravenous	O
as	O
directed	O
for	O
2	O
weeks	O
:	O
to	O
be	O
administered	O
after	O
each	O
dialysis	O
session	O
three	O
times	O
weekly	O
,	O
until	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
.	O
15	O
.	O
Insulin	I-Drug
Glargine	O
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Forty	O
Eight	O
(	O
48	O
)	O
units	O
Subcutaneous	O
once	O
a	O
day	O
.	O
16	O
.	O
Humalog	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
as	O
directed	O
Subcutaneous	O
QACHS	O
:	O
please	O
see	O
attached	O
sliding	O
scale	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
-	O
MSSA	O
baceremia	O
-	O
MSSA	O
LLE	O
osteomyelitis	O
-	O
Ileus	O
-	O
MRSA	O
pneumonia	O
-	O
MRSA	O
meningitis	O
-	O
Altered	O
mental	O
status	O
-	O
Acute	O
renal	O
failure	O
-	O
Osteoarthritis	O
awaiting	O
R	O
hip	O
replacement	O
Secondary	O
-	O
Coronary	O
artery	O
disease	O
-	O
Diabetes	O
mellitus	O
-	O
Hypertension	O
-	O
Morbid	O
obesity	O
-	O
Gout	O
Discharge	O
Condition	O
:	O
Hemodynamically	O
stable	O
,	O
afebrile	O
,	O
non-ambulatory	O
,	O
able	O
to	O
tolerate	O
PO	O
Discharge	O
Instructions	O
:	O
You	O
were	O
transferred	O
from	O
another	O
hospital	O
for	O
management	O
of	O
your	O
acute	O
kidney	O
failure	O
in	O
the	O
setting	O
of	O
a	O
high	O
-	O
grade	O
blood	O
infection	O
with	O
a	O
bacteria	O
called	O
MSSA	O
,	O
thought	O
to	O
be	O
introduced	O
from	O
our	O
infected	O
left	O
foot	O
ulcer	O
.	O
You	O
were	O
intubated	O
in	O
the	O
ICU	O
in	O
order	O
to	O
protect	O
your	O
airways	O
due	O
to	O
concern	O
for	O
seizure	O
.	O
You	O
also	O
had	O
an	O
ileus	I-Ade
thought	O
to	O
be	O
precipitated	O
by	O
high	O
doses	O
of	O
narcotics	I-Drug
;	O
this	O
has	O
now	O
resolved	O
.	O
You	O
were	O
initiated	O
on	O
hemodialysis	O
for	O
your	O
renal	O
failure	O
with	O
improvement	O
.	O
Your	O
ICU	O
course	O
here	O
was	O
further	O
complicated	O
by	O
MRSA	B-Reason
bacteral	I-Reason
meningitis	I-Reason
and	O
pneumonia	I-Reason
,	O
for	O
which	O
you	O
were	O
treated	O
with	O
antibtioics	I-Drug
.	O
You	O
were	O
able	O
to	O
be	O
weaned	O
off	O
your	O
ventilator	O
.	O
You	O
were	O
transferred	O
from	O
the	O
ICU	O
to	O
the	O
floor	O
.	O
Your	O
medical	O
problems	O
contributed	O
to	O
confusion	O
,	O
which	O
improved	O
with	O
time	O
.	O
Your	O
kidney	O
function	O
declined	O
from	O
your	O
medical	O
issues	O
,	O
and	O
you	O
were	O
started	O
on	O
dialysis	O
for	O
support	O
.	O
When	O
you	O
left	O
the	O
hospital	O
,	O
you	O
still	O
required	O
dialysis	O
,	O
but	O
your	O
kidney	O
function	O
has	O
improved	O
greatly	O
.	O
Your	O
chronic	O
hip	O
pain	O
is	O
being	O
treated	O
well	O
with	O
medication	O
.	O
You	O
are	O
being	O
dischaged	O
to	O
a	O
rehab	O
center	O
,	O
where	O
they	O
will	O
focus	O
on	O
getting	O
you	O
stronger	O
as	O
you	O
continue	O
to	O
recover	O
from	O
your	O
long	O
hospitalization	O
.	O
There	O
were	O
multiple	O
changes	O
made	O
to	O
your	O
medication	O
,	O
your	O
rehab	O
providers	O
will	O
be	O
responsible	O
for	O
your	O
new	O
regimen	O
.	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
Call	O
your	O
doctor	O
or	O
911	O
if	O
you	O
develop	O
chest	O
pain	O
,	O
difficulty	O
breathing	O
,	O
fevers	O
>	O
101	O
,	O
dizziness	O
,	O
bleeding	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Please	O
call	O
your	O
PCP	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
449	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
6955	O
**	O
]	O
,	O
on	O
discharge	O
from	O
Rehab	O
to	O
schedule	O
follow	O
-	O
up	O
.	O
His	O
office	O
number	O
is	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22629	O
**	O
]	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
111	O
**	O
]	O
,	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
.	O
D.	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
457	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2165-6-5	O
**	O
]	O
1:30	O

Admission	O
Date	O
:	O
[	O
**	O
2164-8-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2164-8-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2085-5-29	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lopressor	I-Drug
/	O
Lisinopril	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
facial	O
swelling	O
/	O
laryngeal	O
edema	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Endotrachial	O
Intubation	O
History	O
of	O
Present	O
Illness	O
:	O
See	O
MICU	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
note	O
from	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
for	O
full	O
details	O
.	O
Briefly	O
this	O
is	O
a	O
79yo	O
patient	O
with	O
PMH	O
significant	O
for	O
HTN	O
,	O
CAD	O
,	O
s	O
/	O
p	O
CABG	O
being	O
transferred	O
from	O
the	O
ICU	O
for	O
probable	O
angioedema	I-Ade
after	O
taking	O
lisinopril	I-Drug
.	O
.	O
Patient	O
had	O
been	O
giving	O
script	O
for	O
lisinopril	I-Drug
a	O
while	O
back	O
but	O
only	O
started	O
taking	O
it	O
on	O
Friday	O
[	O
**	O
8	O
-	O
24	O
**	O
]	O
AM	O
.	O
He	O
started	O
to	O
feel	O
his	O
lips	B-Ade
,	I-Ade
tongue	I-Ade
and	I-Ade
face	I-Ade
swelling	I-Ade
and	I-Ade
it	I-Ade
progressivly	I-Ade
worsened	I-Ade
to	I-Ade
include	O
his	O
throat	O
.	O
He	O
was	O
admitted	O
to	O
the	O
ICU	O
and	O
was	O
intubated	O
and	O
sedated	O
.	O
ENT	O
saw	O
patient	O
and	O
recommended	O
keeping	O
tube	O
in	O
place	O
.	O
However	O
,	O
patient	O
self	O
-	O
extubated	O
overnight	O
and	O
actually	O
remained	O
stable	O
.	O
His	O
condition	O
improved	O
and	O
he	O
was	O
transferred	O
to	O
the	O
floor	O
for	O
further	O
care	O
.	O
.	O
On	O
arrival	O
to	O
the	O
medical	O
floor	O
,	O
patient	O
was	O
stable	O
.	O
Vital	O
signs	O
-	O
T	O
96.5	O
,	O
HR	O
74	O
,	O
BP	O
125/64	O
,	O
R	O
14	O
,	O
satting	O
100	O
%	O
on	O
4L	O
.	O
No	O
complaints	O
except	O
for	O
some	O
facial	O
swelling	O
but	O
reduced	O
from	O
admission	O
.	O
Denied	O
any	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
headaches	O
,	O
dizziness	O
.	O
Doing	O
well	O
,	O
comfortable	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
HTN	O
-	O
Psoriasis	O
-	O
Hypercholesterolemia	O
-	O
CKD	O
,	O
baseline	O
Cr	O
2.6	O
-	O
CAD	O
s	O
/	O
p	O
MI	O
(	O
[	O
**	O
2135	O
**	O
]	O
)	O
s	O
/	O
p	O
Cardiac	O
Stress	O
Test	O
(	O
[	O
**	O
5	O
-	O
20	O
**	O
]	O
:	O
Mild	O
Reversible	O
Ischemic	O
Changes	O
)	O
,	O
s	O
/	O
p	O
Cath	O
(	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
:	O
1	O
vessel	O
disease	O
,	O
No	O
stenting	O
required	O
)	O
,	O
Chronic	O
Stable	O
Angina	O
-	O
Cardiomyopathy	O
,	O
EF	O
50	O
%	O
2/09	O
-	O
Mild	O
Dementia	O
(	O
short	O
term	O
memory	O
impairment	O
)	O
-	O
Gout	O
-	O
BPH	O
-	O
Eczema	O
-	O
s	O
/	O
p	O
L	O
hip	O
fx	O
s	O
/	O
p	O
hemiarthroscopy	O
[	O
**	O
3	O
-	O
/	O
2164	O
**	O
]	O
Social	O
History	O
:	O
NA	O
Family	O
History	O
:	O
NA	O
Physical	O
Exam	O
:	O
General	O
:	O
Intubated	O
,	O
sedated	O
HEENT	O
:	O
Conjunctiva	O
injected	O
.	O
Pupils	O
symmetric	O
,	O
constrict	O
equally	O
to	O
light	O
.	O
Lip	O
swelling	O
.	O
Intubated	O
,	O
OGT	O
in	O
place	O
.	O
Neck	O
:	O
supple	O
.	O
No	O
bruit	O
.	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Bradycardic	O
rate	O
,	O
regular	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Skin	O
:	O
No	O
rashes	O
,	O
hives	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2164-8-26	O
**	O
]	O
03:03	O
AM	O
BLOOD	O
WBC	O
-	O
15.8	O
*	O
#	O
RBC	O
-	O
3.50	O
*	O
Hgb	O
-	O
10.6	O
*	O
Hct	O
-	O
31.2	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.4	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
13.3	O
Plt	O
Ct	O
-	O
336	O
[	O
**	O
2164-8-25	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
WBC	O
-	O
8.1	O
RBC	O
-	O
3.68	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
33.4	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
30.3	O
MCHC	O
-	O
33.4	O
RDW	O
-	O
13.1	O
Plt	O
Ct	O
-	O
313	O
[	O
**	O
2164-8-25	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
Neuts	O
-	O
91.2	O
*	O
Lymphs	O
-	O
7.7	O
*	O
Monos	O
-	O
0.9	O
*	O
Eos	O
-	O
0.2	O
Baso	O
-	O
0.1	O
[	O
**	O
2164-8-26	O
**	O
]	O
03:03	O
AM	O
BLOOD	O
PT	O
-	O
12.0	O
PTT	O
-	O
23.5	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2164-8-26	O
**	O
]	O
03:03	O
AM	O
BLOOD	O
Glucose	O
-	O
168	O
*	O
UreaN	O
-	O
65	O
*	O
Creat	O
-	O
2.8	O
*	O
Na	O
-	O
143	O
K	O
-	O
4.9	O
Cl	O
-	O
115	O
*	O
HCO3	O
-	O
18	O
*	O
AnGap	O
-	O
15	O
[	O
**	O
2164-8-26	O
**	O
]	O
03:03	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
5.0	O
*	O
Mg	O
-	O
2.3	O
Brief	O
Hospital	O
Course	O
:	O
79yo	O
male	O
admitted	O
to	O
ICU	O
for	O
probable	O
angioedema	I-Ade
due	O
to	O
lisinopril	I-Drug
injestion	O
.	O
1	O
.	O
Angioedema	I-Reason
Pt	O
was	O
admitted	O
to	O
the	O
ICU	O
and	O
was	O
intubated	O
and	O
sedated	O
.	O
He	O
was	O
also	O
started	O
on	O
IV	O
steroids	I-Drug
,	O
H2	B-Drug
blockers	I-Drug
,	O
and	O
benadryl	I-Drug
.	O
ENT	O
saw	O
patient	O
and	O
recommended	O
keeping	O
6	O
mm	O
tube	O
in	O
place	O
.	O
However	O
,	O
patient	O
self	O
-	O
extubated	O
overnight	O
and	O
actually	O
remained	O
stable	O
.	O
His	O
condition	O
improved	O
and	O
he	O
was	O
transferred	O
to	O
the	O
floor	O
for	O
further	O
care	O
on	O
[	O
**	O
2164-8-26	O
**	O
]	O
.	O
He	O
was	O
initially	O
on	O
4L	O
NC	O
and	O
satting	O
in	O
high	O
90s	O
and	O
this	O
was	O
quickly	O
weaned	O
.	O
He	O
experienced	O
some	O
soreness	O
of	O
the	O
throat	O
and	O
had	O
a	O
difficult	O
time	O
swallowing	O
pills	O
at	O
first	O
.	O
ENT	O
saw	O
him	O
and	O
thought	O
this	O
was	O
due	O
to	O
trauma	O
from	O
the	O
ET	O
tube	O
and	O
not	O
lingering	O
angioedema	O
.	O
As	O
his	O
angioedema	O
improved	O
he	O
was	O
able	O
to	O
tollerate	O
first	O
thick	O
liquids	O
,	O
then	O
a	O
regular	O
diet	O
.	O
He	O
was	O
switched	O
to	O
PO	O
steroids	I-Drug
with	O
a	O
7	O
day	O
taper	O
starting	O
on	O
[	O
**	O
8	O
-	O
27	O
**	O
]	O
.	O
2	O
.	O
Acute	O
on	O
chronic	O
kidney	O
injury	O
-	O
baseline	O
2.6	O
.	O
creatinine	O
was	O
3.2	O
on	O
admission	O
but	O
this	O
trended	O
back	O
down	O
to	O
2.4	O
by	O
D	O
/	O
C.	O
Allopurinol	I-Drug
was	O
held	O
in	O
the	O
ICU	O
given	O
Cr	O
bump	O
.	O
3	O
.	O
HTN	I-Reason
-	O
Antihypertensives	I-Drug
were	O
held	O
in	O
ICU	O
but	O
amlodipine	I-Drug
was	O
restarted	O
once	O
stable	O
on	O
the	O
medicine	O
floor	O
.	O
4	O
.	O
CHF	O
.	O
Known	O
EF	O
[	O
**	O
3	O
-	O
26	O
**	O
]	O
50	O
%	O
with	O
mild	O
reduced	O
systolic	O
function	O
.	O
Appeared	O
euvolemic	O
on	O
exam	O
.	O
5	O
.	O
CAD	I-Reason
-	O
held	O
ASA	I-Drug
as	O
above	O
-	O
continued	O
simvastatin	I-Drug
Medications	O
on	O
Admission	O
:	O
Amlodipine	I-Drug
2.5	O
mg	O
PO	O
daily	O
Aspirin	I-Drug
325	O
mg	O
PO	O
daily	O
Furosemide	I-Drug
20	O
mg	O
daily	O
Lisinopril	I-Drug
40	O
mg	O
daily	O
Oxybutinin	I-Drug
5	O
mg	O
daily	O
Simvastatin	I-Drug
80	O
mg	O
daily	O
Allopur	I-Drug
.	O
inol	O
100	O
mg	O
daily	O
eucerin	I-Drug
cream	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
Angioedema	O
Secondary	O
Diagnosis	O
:	O
Hypertension	O
Chronic	O
Kidney	O
Disease	O
Discharge	O
Condition	O
:	O
Good	O
.	O
Vital	O
Signs	O
stable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
swelling	B-Ade
in	I-Ade
your	I-Ade
face	I-Ade
and	I-Ade
throat	O
after	O
you	O
took	O
lisinopril	I-Drug
.	O
You	O
were	O
taken	O
to	O
the	O
ICU	O
because	O
the	O
swelling	O
in	O
your	O
neck	O
gave	O
you	O
difficulty	O
breathing	O
.	O
After	O
one	O
night	O
in	O
the	O
ICU	O
you	O
actually	O
pulled	O
out	O
your	O
breathing	O
tube	O
but	O
did	O
well	O
without	O
it	O
.	O
You	O
remained	O
stable	O
the	O
next	O
day	O
and	O
was	O
transferred	O
to	O
the	O
regular	O
medicine	O
floor	O
on	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
,	O
where	O
you	O
remained	O
stable	O
.	O
You	O
initially	O
had	O
trouble	O
swallowing	O
pills	O
and	O
food	O
but	O
this	O
has	O
gotten	O
better	O
and	O
you	O
are	O
now	O
able	O
to	O
swallow	O
food	O
.	O
Your	O
facial	O
swelling	O
has	O
also	O
decreased	O
.	O
We	O
have	O
scheduled	O
follow	O
up	O
appointments	O
with	O
your	O
primary	O
care	O
doctor	O
and	O
the	O
allergy	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
357	O
**	O
]	O
go	O
to	O
your	O
scheduled	O
appointments	O
.	O
You	O
were	O
also	O
prescribed	O
prednisone	I-Drug
,	O
famotidine	I-Drug
,	O
and	O
fexofenadine	I-Drug
to	O
decrease	B-Reason
residual	I-Reason
swelling	I-Reason
.	O
Please	O
take	O
the	O
prednisone	I-Drug
as	O
follows	O
:	O
6	O
tablets	O
on	O
day	O
one	O
,	O
5	O
tablets	O
on	O
day	O
two	O
,	O
4	O
tablets	O
on	O
day	O
three	O
,	O
3	O
tablets	O
on	O
day	O
four	O
,	O
2	O
tablets	O
on	O
day	O
five	O
,	O
1	O
tablet	O
on	O
day	O
six	O
,	O
and	O
1	O
tablet	O
on	O
day	O
seven	O
.	O
Please	O
return	O
to	O
the	O
hospital	O
or	O
call	O
your	O
doctor	O
if	O
you	O
have	O
worsening	O
throat	O
/	O
facial	O
swelling	O
,	O
hives	O
or	O
skin	O
rash	O
,	O
or	O
any	O
other	O
symptoms	O
that	O
concern	O
you	O
.	O
Followup	O
Instructions	O
:	O
Please	O
make	O
a	O
follow	O
-	O
up	O
appointment	O
with	O
your	O
primary	O
care	O
doctor	O
,	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
within	O
the	O
next	O
two	O
weeks	O
.	O
His	O
office	O
phone	O
number	O
is	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
12871	O
**	O
]	O
Allergist	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
14583	O
**	O
]	O
Tuesday	O
[	O
**	O
10	O
-	O
2	O
**	O
]	O
,	O
9	O
am	O
1	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
pl	O
[	O
**	O
Apartment	O
Address	O
(	O
1	O
)	O
20447	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2199-8-30	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2199-9-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2121-11-13	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3016	O
**	O
]	O
Chief	O
Complaint	O
:	O
left	O
hemiplegia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
MERCI	O
procedure	O
-	O
(	O
Mechanical	O
Embolus	O
Removal	O
in	O
Cerebral	O
Ischemia	O
)	O
Thoracentesis	O
x2	O
Nephrostomy	O
tube	O
replacement	O
History	O
of	O
Present	O
Illness	O
:	O
77	O
-	O
year	O
-	O
old	O
male	O
with	O
history	O
gastric	O
CA	O
metastatic	O
and	O
atrial	O
fibrillation	O
,	O
who	O
developed	O
acute	O
onset	O
aphasia	O
,	O
eye	O
movement	O
abnormalities	O
and	O
left	O
-	O
sided	O
hemiplegia	O
during	O
an	O
ultrasound	O
-	O
guided	O
thoracentesis	O
on	O
[	O
**	O
2199-8-30	O
**	O
]	O
for	O
malignant	O
pleural	O
effusion	O
.	O
Patient	O
had	O
been	O
off	O
of	O
coumadin	I-Drug
for	O
10	O
days	O
for	O
the	O
thoracentesis	O
.	O
Code	O
stroke	I-Reason
was	O
called	O
and	O
patient	O
was	O
transferred	O
to	O
the	O
ED	O
.	O
A	O
CTA	O
revealed	O
a	O
large	O
thrombus	O
in	O
tip	O
of	O
the	O
basilar	O
artery	O
,	O
not	O
extending	O
into	O
PCA	O
's	O
.	O
He	O
was	O
taken	O
emergently	O
to	O
angio	O
,	O
where	O
embolectomy	O
and	O
intrarterial	O
tPA	I-Drug
injection	O
was	O
performed	O
.	O
Ischemia	O
time	O
was	O
4	O
hours	O
;	O
EBL	O
was	O
minimal	O
,	O
and	O
he	O
received	O
2U	O
plts	I-Drug
for	O
plt	B-Reason
count	I-Reason
of	I-Reason
25	I-Reason
.	O
Patient	O
was	O
transferred	O
to	O
the	O
SICU	O
for	O
postop	O
care	O
.	O
Past	O
Medical	O
History	O
:	O
Stage	O
IV	O
gastric	O
malignancy	O
Atrial	O
Fibrillation	O
Hypertension	O
Hyperlipidemia	O
BPH	O
Depression	O
/	O
Anxiety	O
Osteoarthritis	O
Obstructive	O
Uropathy	O
s	O
/	O
p	O
right	O
percutaneous	O
nephrostomy	O
Social	O
History	O
:	O
His	O
wife	O
died	O
in	O
[	O
**	O
2193	O
**	O
]	O
due	O
to	O
metastatic	O
lung	O
cancer	O
.	O
He	O
previously	O
lived	O
alone	O
but	O
recently	O
moved	O
in	O
with	O
his	O
son	O
&	O
daughter	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
is	O
retired	O
,	O
previously	O
working	O
40	O
years	O
in	O
the	O
airline	O
industry	O
as	O
a	O
maintenance	O
supervisor	O
.	O
Has	O
family	O
nearby	O
who	O
are	O
involved	O
in	O
his	O
care	O
.	O
Smoked	O
1ppd	O
x	O
20	O
years	O
tobacco	O
,	O
quitting	O
in	O
the	O
[	O
**	O
2158	O
**	O
]	O
.	O
Social	O
alcohol	O
.	O
No	O
recreational	O
drugs	O
.	O
Family	O
History	O
:	O
Father	O
died	O
of	O
pneumonia	O
at	O
64	O
years	O
old	O
;	O
unknown	O
other	O
medical	O
issues	O
.	O
Mother	O
died	O
of	O
pneumonia	O
at	O
53	O
and	O
had	O
asthma	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
96.8	O
,	O
BP	O
:	O
116/63	O
,	O
P	O
:	O
81	O
,	O
RR	O
:	O
18	O
,	O
98	O
%	O
on	O
1L	O
GEN	O
:	O
Elderly	O
male	O
in	O
NAD	O
,	O
NC	O
in	O
place	O
CV	O
:	O
normal	O
rate	O
,	O
ireg	O
rhythm	O
,	O
normal	O
s1	O
,	O
s2	O
,	O
no	O
mr	O
/	O
g	O
PULM	O
:	O
decreased	O
breath	O
sounds	O
and	O
dull	O
to	O
percussion	O
over	O
RLL	O
,	O
LLL	O
,	O
clear	O
in	O
other	O
lung	O
fields	O
EXT	O
:	O
2	O
+	O
edema	O
to	O
mid-tibia	O
,	O
DP	O
,	O
PT	O
pulses	O
1	O
+	O
Pertinent	O
Results	O
:	O
Hematology	O
[	O
**	O
2199-9-11	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
WBC	O
-	O
5.7	O
RBC	O
-	O
2.86	O
*	O
Hgb	O
-	O
8.9	O
*	O
Hct	O
-	O
28.0	O
*	O
MCV	O
-	O
98	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
31.8	O
RDW	O
-	O
17.1	O
*	O
Plt	O
Ct	O
-	O
257	O
[	O
**	O
2199-9-10	O
**	O
]	O
12:43	O
AM	O
BLOOD	O
WBC	O
-	O
6.1	O
RBC	O
-	O
2.98	O
*	O
Hgb	O
-	O
9.4	O
*	O
Hct	O
-	O
29.3	O
*	O
MCV	O
-	O
98	O
MCH	O
-	O
31.4	O
MCHC	O
-	O
31.9	O
RDW	O
-	O
16.9	O
*	O
Plt	O
Ct	O
-	O
238	O
[	O
**	O
2199-9-9	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
WBC	O
-	O
4.6	O
RBC	O
-	O
2.92	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
28.4	O
*	O
MCV	O
-	O
97	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
32.3	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
210	O
[	O
**	O
2199-8-31	O
**	O
]	O
03:05	O
AM	O
BLOOD	O
WBC	O
-	O
5.8	O
RBC	O
-	O
2.94	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
27.2	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
30.6	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
14.9	O
Plt	O
Ct	O
-	O
129	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
WBC	O
-	O
7.0	O
RBC	O
-	O
2.89	O
*	O
Hgb	O
-	O
9.3	O
*	O
Hct	O
-	O
25.9	O
*	O
#	O
MCV	O
-	O
90	O
MCH	O
-	O
32.1	O
*	O
#	O
MCHC	O
-	O
35.9	O
*	O
#	O
RDW	O
-	O
14.8	O
Plt	O
Ct	O
-	O
121	O
*	O
#	O
[	O
**	O
2199-8-30	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
WBC	O
-	O
9.3	O
RBC	O
-	O
3.72	O
*	O
Hgb	O
-	O
10.7	O
*	O
Hct	O
-	O
34.8	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
28.8	O
MCHC	O
-	O
30.8	O
*	O
RDW	O
-	O
14.8	O
Plt	O
Ct	O
-	O
34	O
*	O
#	O
[	O
**	O
2199-9-10	O
**	O
]	O
12:43	O
AM	O
BLOOD	O
Neuts	O
-	O
70	O
Bands	O
-	O
0	O
Lymphs	O
-	O
10	O
*	O
Monos	O
-	O
19	O
*	O
Eos	O
-	O
1	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2199-9-9	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
Neuts	O
-	O
62	O
Bands	O
-	O
1	O
Lymphs	O
-	O
18	O
Monos	O
-	O
17	O
*	O
Eos	O
-	O
1	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
1	O
*	O
[	O
**	O
2199-9-5	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Neuts	O
-	O
52	O
Bands	O
-	O
2	O
Lymphs	O
-	O
29	O
Monos	O
-	O
13	O
*	O
Eos	O
-	O
1	O
Baso	O
-	O
0	O
Atyps	O
-	O
1	O
*	O
Metas	O
-	O
0	O
Myelos	O
-	O
2	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
Neuts	O
-	O
81.9	O
*	O
Lymphs	O
-	O
16.2	O
*	O
Monos	O
-	O
0.7	O
*	O
Eos	O
-	O
1.1	O
Baso	O
-	O
0	O
[	O
**	O
2199-9-10	O
**	O
]	O
12:43	O
AM	O
BLOOD	O
PT	O
-	O
13.8	O
*	O
PTT	O
-	O
35.0	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2199-9-9	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
33.5	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2199-9-7	O
**	O
]	O
05:06	O
AM	O
BLOOD	O
PT	O
-	O
13.7	O
*	O
PTT	O
-	O
34.1	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2199-9-6	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
53.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2199-9-4	O
**	O
]	O
02:29	O
AM	O
BLOOD	O
PT	O
-	O
18.0	O
*	O
PTT	O
-	O
142.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.6	O
*	O
[	O
**	O
2199-9-3	O
**	O
]	O
04:30	O
PM	O
BLOOD	O
PT	O
-	O
25.2	O
*	O
PTT	O
-	O
150	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.4	O
*	O
[	O
**	O
2199-9-3	O
**	O
]	O
08:30	O
AM	O
BLOOD	O
PT	O
-	O
28.1	O
*	O
PTT	O
-	O
63.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.8	O
*	O
[	O
**	O
2199-9-3	O
**	O
]	O
02:00	O
AM	O
BLOOD	O
PT	O
-	O
22.8	O
*	O
PTT	O
-	O
56.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.2	O
*	O
[	O
**	O
2199-9-2	O
**	O
]	O
10:30	O
PM	O
BLOOD	O
PT	O
-	O
21.4	O
*	O
PTT	O
-	O
45.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.0	O
*	O
[	O
**	O
2199-9-2	O
**	O
]	O
01:13	O
PM	O
BLOOD	O
PT	O
-	O
23.1	O
*	O
PTT	O
-	O
53.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.2	O
*	O
[	O
**	O
2199-9-2	O
**	O
]	O
08:24	O
AM	O
BLOOD	O
PT	O
-	O
22.0	O
*	O
PTT	O
-	O
57.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.1	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
PT	O
-	O
15.5	O
*	O
PTT	O
-	O
24.6	O
INR	O
(	O
PT	O
)	O
-	O
1.4	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
PT	O
-	O
15.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
FDP	O
-40-80	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
Fibrino	O
-	O
213	O
[	O
**	O
2199-9-4	O
**	O
]	O
02:29	O
AM	O
BLOOD	O
Ret	O
Aut	O
-	O
0.5	O
*	O
Chemistries	O
:	O
[	O
**	O
2199-9-12	O
**	O
]	O
:	O
Creatinine	O
is	O
2.0	O
[	O
**	O
2199-9-11	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Glucose	O
-	O
97	O
UreaN	O
-	O
35	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
140	O
K	O
-	O
4.5	O
Cl	O
-	O
105	O
HCO3	O
-	O
29	O
AnGap	O
-	O
11	O
[	O
**	O
2199-9-10	O
**	O
]	O
12:43	O
AM	O
BLOOD	O
Glucose	O
-	O
92	O
UreaN	O
-	O
29	O
*	O
Creat	O
-	O
1.7	O
*	O
Na	O
-	O
143	O
K	O
-	O
4.6	O
Cl	O
-	O
108	O
HCO3	O
-	O
28	O
AnGap	O
-	O
12	O
[	O
**	O
2199-9-9	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
Glucose	O
-	O
86	O
UreaN	O
-	O
27	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
141	O
K	O
-	O
4.4	O
Cl	O
-	O
106	O
HCO3	O
-	O
28	O
AnGap	O
-	O
11	O
[	O
**	O
2199-9-3	O
**	O
]	O
03:22	O
AM	O
BLOOD	O
Glucose	O
-	O
105	O
*	O
UreaN	O
-	O
35	O
*	O
Creat	O
-	O
1.2	O
Na	O
-	O
139	O
K	O
-	O
4.0	O
Cl	O
-	O
112	O
*	O
HCO3	O
-	O
20	O
*	O
AnGap	O
-	O
11	O
[	O
**	O
2199-9-2	O
**	O
]	O
02:12	O
PM	O
BLOOD	O
Glucose	O
-	O
109	O
*	O
UreaN	O
-	O
41	O
*	O
Creat	O
-	O
1.4	O
*	O
Na	O
-	O
136	O
K	O
-	O
4.2	O
Cl	O
-	O
106	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
13	O
[	O
**	O
2199-8-31	O
**	O
]	O
06:09	O
AM	O
BLOOD	O
Glucose	O
-	O
101	O
*	O
UreaN	O
-	O
49	O
*	O
Creat	O
-	O
1.4	O
*	O
Na	O
-	O
131	O
*	O
K	O
-	O
4.6	O
Cl	O
-	O
99	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2199-8-31	O
**	O
]	O
03:05	O
AM	O
BLOOD	O
Glucose	O
-	O
102	O
*	O
UreaN	O
-	O
48	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
133	O
K	O
-	O
4.6	O
Cl	O
-	O
100	O
HCO3	O
-	O
25	O
AnGap	O
-	O
13	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
Glucose	O
-	O
117	O
*	O
UreaN	O
-	O
49	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
130	O
*	O
K	O
-	O
4.7	O
Cl	O
-	O
98	O
HCO3	O
-	O
26	O
AnGap	O
-	O
11	O
[	O
**	O
2199-8-30	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
Glucose	O
-	O
116	O
*	O
UreaN	O
-	O
53	O
*	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
133	O
K	O
-	O
5.1	O
Cl	O
-	O
97	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
20	O
[	O
**	O
2199-9-11	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
ALT	O
-	O
46	O
*	O
AST	O
-	O
39	O
LD	O
(	O
LDH	O
)	O
-	O
251	O
*	O
AlkPhos	O
-	O
1010	O
*	O
TotBili	O
-	O
0.7	O
[	O
**	O
2199-9-10	O
**	O
]	O
12:43	O
AM	O
BLOOD	O
ALT	O
-	O
60	O
*	O
AST	O
-	O
56	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
274	O
*	O
AlkPhos	O
-	O
1171	O
*	O
TotBili	O
-	O
0.9	O
[	O
**	O
2199-9-1	O
**	O
]	O
03:03	O
AM	O
BLOOD	O
ALT	O
-	O
50	O
*	O
AST	O
-	O
42	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
363	O
*	O
AlkPhos	O
-	O
457	O
*	O
TotBili	O
-	O
0.8	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
ALT	O
-	O
61	O
*	O
AST	O
-	O
45	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
339	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
81	O
AlkPhos	O
-	O
390	O
*	O
TotBili	O
-	O
0.8	O
[	O
**	O
2199-9-6	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
GGT	O
-	O
1139	O
*	O
[	O
**	O
2199-9-10	O
**	O
]	O
12:43	O
AM	O
BLOOD	O
Albumin	O
-	O
2.9	O
*	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.2	O
Mg	O
-	O
1.9	O
[	O
**	O
2199-9-5	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Albumin	O
-	O
2.7	O
*	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
2.5	O
*	O
Mg	O
-	O
1.9	O
[	O
**	O
2199-9-4	O
**	O
]	O
02:29	O
AM	O
BLOOD	O
Albumin	O
-	O
3.0	O
*	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
1.9	O
*	O
Mg	O
-	O
2.1	O
Iron	O
-	O
31	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
Albumin	O
-	O
3.0	O
*	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.3	O
Mg	O
-	O
2.1	O
Cholest	O
-	O
153	O
Cardiac	O
Enzymes	O
:	O
[	O
**	O
2199-9-6	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
0.79	O
*	O
[	O
**	O
2199-9-5	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
4	O
cTropnT	O
-	O
0.84	O
*	O
[	O
**	O
2199-9-3	O
**	O
]	O
03:22	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
9	O
cTropnT	O
-	O
0.59	O
*	O
[	O
**	O
2199-9-2	O
**	O
]	O
02:12	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
10	O
MB	O
Indx	O
-	O
9.6	O
*	O
cTropnT	O
-	O
0.70	O
*	O
[	O
**	O
2199-8-31	O
**	O
]	O
06:09	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
6	O
cTropnT	O
-	O
0.40	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
7	O
cTropnT	O
-	O
0.39	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
03:30	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.35	O
*	O
Other	O
:	O
[	O
**	O
2199-9-4	O
**	O
]	O
02:29	O
AM	O
BLOOD	O
calTIBC	O
-	O
194	O
Ferritn	O
-	O
2235	O
*	O
TRF	O
-	O
149	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
%	O
HbA1c	O
-	O
6.1	O
*	O
eAG	O
-	O
128	O
*	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
Triglyc	O
-	O
186	O
*	O
HDL	O
-	O
44	O
CHOL	O
/	O
HD	O
-	O
3.5	O
LDLcalc	O
-	O
72	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:05	O
PM	O
BLOOD	O
TSH	O
-	O
0.98	O
ABG	O
:	O
[	O
**	O
2199-9-1	O
**	O
]	O
08:57	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
167	O
*	O
pCO2	O
-	O
47	O
*	O
pH	O
-	O
7.32	O
*	O
calTCO2	O
-	O
25	O
Base	O
XS	O
--	O
2	O
[	O
**	O
2199-8-31	O
**	O
]	O
06:05	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
160	O
*	O
pCO2	O
-	O
42	O
pH	O
-	O
7.37	O
calTCO2	O
-	O
25	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2199-8-31	O
**	O
]	O
05:17	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
127	O
*	O
pCO2	O
-	O
45	O
pH	O
-	O
7.37	O
calTCO2	O
-	O
27	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2199-8-30	O
**	O
]	O
10:42	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
202	O
*	O
pCO2	O
-	O
43	O
pH	O
-	O
7.40	O
calTCO2	O
-	O
28	O
Base	O
XS	O
-	O
1	O
Chest	O
X-ray	O
[	O
**	O
2199-9-8	O
**	O
]	O
:	O
IMPRESSION	O
:	O
PA	O
and	O
lateral	O
chest	O
compared	O
to	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
through	O
[	O
**	O
9	O
-	O
3	O
**	O
]	O
:	O
Moderate	O
left	O
pleural	O
effusion	O
is	O
reaccumulating	O
relative	O
to	O
[	O
**	O
9	O
-	O
1	O
**	O
]	O
.	O
There	O
is	O
no	O
pneumothorax	O
.	O
Right	O
pleural	O
effusion	O
including	O
a	O
fissural	O
component	O
is	O
chronic	O
.	O
No	O
pulmonary	O
edema	O
.	O
Heart	O
size	O
is	O
top	O
normal	O
.	O
Right	O
infusion	O
port	O
catheter	O
ends	O
in	O
the	O
mid	O
SVC	O
.	O
Presence	O
of	O
small	O
pulmonary	O
nodules	O
would	O
be	O
obscured	O
by	O
the	O
extensive	O
overlying	O
pleural	O
abnormalities	O
.	O
[	O
**	O
2199-9-6	O
**	O
]	O
Liver	O
/	O
Gallbladder	O
US	O
:	O
1	O
.	O
Mild	O
intrahepatic	O
biliary	O
dilatation	O
,	O
though	O
with	O
common	O
bile	O
duct	O
within	O
normal	O
limits	O
in	O
size	O
.	O
MRCP	O
could	O
be	O
performed	O
to	O
assess	O
for	O
relationship	O
of	O
hepatic	O
metastases	O
to	O
intrahepatic	O
ducts	O
if	O
intervention	O
is	O
planned	O
.	O
2	O
.	O
Multiple	O
known	O
hepatic	O
metastasis	O
is	O
incompletely	O
evaluated	O
on	O
this	O
study	O
.	O
3	O
.	O
Layering	O
sludge	O
within	O
the	O
gallbladder	O
.	O
4	O
.	O
Small	O
amount	O
of	O
intra-abdominal	O
ascites	O
.	O
[	O
**	O
2199-9-6	O
**	O
]	O
:	O
Right	O
Femoral	O
US	O
:	O
Pseudoaneurysm	O
of	O
the	O
right	O
common	O
femoral	O
artery	O
.	O
Size	O
has	O
slightly	O
increased	O
from	O
1.7	O
to	O
1.9	O
mm	O
in	O
the	O
sagittal	O
plane	O
only	O
.	O
[	O
**	O
2199-9-2	O
**	O
]	O
:	O
CT	O
Abdomen	O
/	O
Pelvis	O
:	O
1	O
.	O
No	O
evidence	O
of	O
retroperitoneal	O
hematoma	O
.	O
2	O
.	O
Right	O
nephrostomy	O
tube	O
in	O
stable	O
position	O
.	O
Similar	O
extent	O
of	O
mild	O
left	O
hydronephrosis	O
and	O
hydroureter	O
.	O
Retained	O
contrast	O
within	O
the	O
left	O
kidney	O
,	O
likely	O
from	O
recent	O
CT	O
two	O
days	O
prior	O
,	O
is	O
compatible	O
with	O
obstructive	O
nephropathy	O
.	O
3	O
.	O
Similar	O
extent	O
of	O
bilateral	O
pleural	O
effusions	O
with	O
associated	O
compressive	O
atelectasis	O
and	O
right	O
middle	O
lobe	O
collapse	O
.	O
4	O
.	O
Metastatic	O
gastric	O
adenocarcinoma	O
with	O
unchanged	O
omental	O
and	O
hepatic	O
metastases	O
.	O
5	O
.	O
Increased	O
anasarca	O
,	O
pulmonary	O
edema	O
,	O
and	O
size	O
of	O
abdominal	O
ascites	O
,	O
suggestive	O
of	O
volume	O
overload	O
.	O
[	O
**	O
2199-8-31	O
**	O
]	O
:	O
ECHO	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
global	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
prominent	O
fat	O
pad	O
.	O
IMPRESSION	O
:	O
No	O
left	O
ventricular	O
thrombus	O
seen	O
.	O
Normal	O
global	O
biventricular	O
systolic	O
function	O
.	O
Mild	O
pulmonary	O
hypertension	O
.	O
[	O
**	O
2199-8-30	O
**	O
]	O
MRI	O
HEAD	O
:	O
MPRESSION	O
:	O
Multiple	O
small	O
acute	O
infarcts	O
are	O
identified	O
in	O
both	O
parietooccipital	O
lobes	O
and	O
cerebellar	O
hemispheres	O
without	O
definite	O
acute	O
infarct	O
within	O
the	O
brainstem	O
.	O
Small	O
vessel	O
disease	O
and	O
brain	O
atrophy	O
.	O
[	O
**	O
2199-8-30	O
**	O
]	O
:	O
CT	O
Head	O
and	O
Neck	O
:	O
1	O
.	O
Thrombosis	O
of	O
the	O
basilar	O
artery	O
.	O
Possible	O
perfusion	O
defects	O
concerning	O
for	O
infarct	O
within	O
the	O
brainstem	O
;	O
however	O
,	O
CT	O
perfusion	O
is	O
suboptimal	O
for	O
the	O
evaluation	O
of	O
the	O
posterior	O
circulation	O
.	O
MRI	O
could	O
be	O
performed	O
for	O
further	O
evaluation	O
.	O
2	O
.	O
Extensive	O
focal	O
atherosclerosis	O
with	O
marked	O
narrowing	O
of	O
the	O
left	O
subclavian	O
artery	O
just	O
proximal	O
to	O
the	O
takeoff	O
of	O
the	O
left	O
vertebral	O
artery	O
.	O
No	O
other	O
areas	O
of	O
significant	O
stenosis	O
or	O
aneurysm	O
formation	O
are	O
seen	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
.	O
Basilar	B-Reason
stroke	I-Reason
:	O
Patient	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
on	O
[	O
**	O
2199-8-30	O
**	O
]	O
for	O
acute	O
stroke	O
.	O
He	O
was	O
treated	O
with	O
MERCI	O
and	O
intra-arterial	O
TPA	I-Drug
:	O
The	O
patient	O
's	O
neuro	O
status	O
was	O
closely	O
monitored	O
.	O
He	O
was	O
transitioned	O
from	O
a	O
heparin	I-Drug
gtt	O
to	O
lovenox	I-Drug
given	O
recent	O
embolic	I-Reason
stroke	O
and	O
hypercoaguable	O
state	O
in	O
setting	O
of	O
malignancy	O
.	O
The	O
patient	O
was	O
cleared	O
for	O
a	O
regular	O
diet	O
after	O
a	O
speech	O
and	O
swallow	O
evaluation	O
.	O
#	O
.	O
Right	O
common	O
femoral	O
artery	O
pseudoaneurysm	O
:	O
Patient	O
s	O
/	O
p	O
mechanical	O
and	O
chemical	O
thrombectomy	O
via	O
right	O
common	O
femoral	O
artery	O
puncture	O
,	O
and	O
was	O
found	O
to	O
have	O
small	O
right	O
common	O
femoral	O
artery	O
pseudoaneurysm	O
.	O
He	O
had	O
a	O
repeat	O
ultrasound	O
on	O
[	O
**	O
2199-9-6	O
**	O
]	O
which	O
showed	O
the	O
pseudoaneurysm	O
had	O
slightly	O
increased	O
in	O
size	O
from	O
1.7	O
to	O
1.9	O
mm	O
in	O
the	O
sagittal	O
plane	O
only	O
.	O
Vascular	O
surgery	O
was	O
following	O
,	O
and	O
did	O
not	O
feel	O
there	O
was	O
a	O
need	O
for	O
intervention	O
.	O
The	O
patient	O
's	O
HCT	O
remained	O
stable	O
.	O
#	O
.	O
Hypoxia	O
:	O
Likely	O
secondary	O
to	O
pleural	O
effusions	O
(	O
malignant	O
)	O
.	O
CXR	O
on	O
[	O
**	O
2199-9-3	O
**	O
]	O
had	O
shown	O
stable	O
reticular	O
nodular	O
pattern	O
in	O
right	O
lung	O
likely	O
representing	O
lymphatic	O
obstruction	O
,	O
a	O
stable	O
right	O
pleural	O
effusion	O
,	O
and	O
increased	O
opacification	O
in	O
left	O
lung	O
likely	O
representing	O
increased	O
atelectasis	O
and	O
increased	O
pleural	O
effusion	O
.	O
The	O
patient	O
's	O
supplemental	O
O2	I-Drug
was	O
gradually	O
weaned	O
as	O
tolerated	O
.	O
Repeat	O
CXR	O
on	O
[	O
**	O
2199-9-8	O
**	O
]	O
showed	O
increased	O
pleural	O
effusion	O
and	O
patient	O
had	O
a	O
repeat	O
thoracentesis	O
on	O
[	O
**	O
2199-9-11	O
**	O
]	O
prior	O
to	O
discharge	O
.	O
A	O
post-procedure	O
chest	O
x-ray	O
was	O
done	O
and	O
there	O
were	O
no	O
complications	O
from	O
the	O
procedure	O
.	O
#	O
.	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
:	O
Patient	O
has	O
h	O
/	O
o	O
bilateral	O
hydronephrosis	O
,	O
likely	O
secondary	O
to	O
obstructive	O
uropathy	O
.	O
s	O
/	O
p	O
right	O
nephrostomy	O
tube	O
in	O
08	O
/	O
[	O
**	O
2198	O
**	O
]	O
.	O
Prior	O
to	O
this	O
admission	O
,	O
the	O
patient	O
had	O
been	O
scheduled	O
for	O
bilateraly	O
stent	O
placement	O
on	O
[	O
**	O
2199-9-12	O
**	O
]	O
.	O
His	O
left	O
stent	O
showed	O
hematuria	O
and	O
had	O
poor	O
output	O
in	O
setting	O
of	O
creatinine	O
increase	O
from	O
1.3	O
-	O
>	O
1.7	O
,	O
his	O
left	O
nephrostomy	O
tube	O
was	O
placed	O
.	O
On	O
discharge	O
,	O
his	O
creatinine	O
was	O
2.0	O
.	O
This	O
lab	O
test	O
should	O
be	O
repeated	O
.	O
#	O
.	O
Stage	B-Reason
IV	I-Reason
gastric	I-Reason
CA	I-Reason
:	O
Patient	O
recently	O
diagnosed	O
with	O
gastric	O
cancer	O
,	O
and	O
gastric	O
biopsy	O
returned	O
positive	O
for	O
poorly	O
differentiated	O
adenocarcinoma	O
infiltrating	O
through	O
the	O
deep	O
mucosal	O
layer	O
.	O
Cytology	O
from	O
the	O
peripancreatic	O
lymph	O
nodes	O
was	O
also	O
positive	O
for	O
malignant	O
cells	O
consistent	O
with	O
adenocarcinoma	O
.	O
Patient	O
started	O
first	O
cycle	O
of	O
chemotherapy	I-Drug
with	O
epirubicin	I-Drug
,	O
oxaliplatin	I-Drug
and	O
capecitabine	I-Drug
on	O
[	O
**	O
2199-8-22	O
**	O
]	O
.	O
Given	O
recent	O
complications	O
in	O
course	O
,	O
chemo	I-Drug
currently	O
on	O
hold	O
.	O
His	O
cell	O
counts	O
were	O
monitored	O
closely	O
in	O
setting	O
of	O
recent	O
chemo	I-Drug
.	O
#	O
.	O
Atrial	B-Reason
Fibrillation	I-Reason
:	O
Patient	O
rate	O
-	O
controlled	O
with	O
metoprolol	I-Drug
.	O
Coumadin	I-Drug
had	O
been	O
held	O
initially	O
for	O
thoracentesis	O
,	O
and	O
was	O
not	O
restarted	O
in	O
setting	O
of	O
stroke	O
and	O
low	O
platelet	O
count	O
.	O
Patient	O
was	O
previously	O
on	O
argatroban	I-Drug
gtt	O
,	O
but	O
placed	O
on	O
heparin	I-Drug
gtt	O
after	O
rise	O
in	O
platelets	O
and	O
exclusion	O
of	O
HIT	O
.	O
Patient	O
will	O
need	O
long	O
-	O
term	O
anticoagulation	I-Reason
in	O
setting	O
of	O
recent	O
embolic	I-Reason
stroke	O
and	O
hypercoagulable	O
state	O
.	O
He	O
was	O
started	O
on	O
lovenox	I-Drug
.	O
#	O
.	O
Hypertension	I-Reason
:	O
BP	O
was	O
well	O
-	O
controlled	O
after	O
transfer	O
to	O
medical	O
oncology	O
service	O
.	O
The	O
patient	O
was	O
continued	O
on	O
metoprolol	I-Drug
for	O
both	O
rate	B-Reason
control	I-Reason
and	O
BP	B-Reason
control	I-Reason
.	O
Medications	O
on	O
Admission	O
:	O
Coumadin	I-Drug
5	O
mg	O
daily	O
Digoxin	B-Drug
0.125	O
mg	O
daily	O
Lisinopril	I-Drug
20	O
mg	O
daily	O
Simvastatin	I-Drug
40	O
mg	O
daily	O
Vicodin	I-Drug
1	O
tab	O
Q4	O
-	O
6H	O
PRN	O
Discharge	O
Medications	O
:	O
1	O
.	O
Simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Tablet	O
(	O
s	O
)	O
3	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
5	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Heparin	I-Drug
Flush	O
(	O
10	O
units	O
/	O
ml	O
)	O
5	O
mL	O
IV	O
PRN	O
line	B-Reason
flush	I-Reason
Indwelling	O
Port	O
(	O
e.g.	O
Portacath	O
)	O
,	O
heparin	I-Drug
dependent	O
:	O
Flush	O
with	O
10	O
mL	O
Normal	B-Drug
Saline	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
daily	O
and	O
PRN	O
per	O
lumen	O
.	O
7	O
.	O
Heparin	B-Drug
Flush	I-Drug
(	O
100	O
units	O
/	O
ml	O
)	O
5	O
mL	O
IV	O
PRN	O
DE-ACCESSING	O
port	O
Indwelling	O
Port	O
(	O
e.g.	O
Portacath	O
)	O
,	O
heparin	I-Drug
dependent	O
:	O
When	O
de-accessing	O
port	O
,	O
instill	O
Heparin	I-Drug
as	O
above	O
per	O
lumen	O
.	O
8	O
.	O
Enoxaparin	I-Drug
80	O
mg	O
/	O
0.8	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
10	O
.	O
Alum	B-Drug
-	I-Drug
Mag	I-Drug
Hydroxide	I-Drug
-	I-Drug
Simeth	I-Drug
200	O
-200-20	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15	O
-	O
30	O
MLs	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
indigestion	I-Reason
.	O
11	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
check	O
CBC	O
,	O
Na	O
,	O
K	O
,	O
Cl	O
,	O
HCO3	O
,	O
BUN	O
,	O
Creatinine	O
,	O
Glucose	O
on	O
[	O
**	O
2199-9-13	O
**	O
]	O
.	O
Please	O
fax	O
results	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
Fax	O
#	O
[	O
**	O
0	O
-	O
0	O
-	O
**	O
]	O
)	O
.	O
12	O
.	O
Zofran	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
Life	O
Care	O
Center	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
5165	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Cerebral	O
Vascular	O
Accident	O
Secondary	O
:	O
Metastatic	O
Gastric	O
Cancer	O
w	O
/	O
obstruction	O
of	O
left	O
ureter	O
Atrial	O
Fibrillation	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
It	O
was	O
a	O
pleasure	O
being	O
involved	O
in	O
your	O
care	O
,	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
.	O
1	O
.	O
Stroke	O
:	O
You	O
were	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
management	O
of	O
your	O
acute	O
stoke	O
.	O
You	O
had	O
a	O
procedure	O
to	O
remove	O
a	O
clot	O
from	O
a	O
major	O
artery	O
in	O
your	O
brain	O
.	O
This	O
helped	O
to	O
prevent	O
your	O
stroke	O
from	O
causing	O
more	O
damage	O
to	O
your	O
brain	O
.	O
You	O
were	O
also	O
treated	O
with	O
blood	O
thinners	O
to	O
prevent	O
more	O
clots	O
from	O
forming	O
.	O
2	O
.	O
Cancer	I-Reason
:	O
You	O
have	O
been	O
diagnosed	O
with	O
metastatic	O
gastric	O
cancer	O
.	O
You	O
were	O
not	O
given	O
any	O
cancer	O
treatments	O
during	O
this	O
admission	O
.	O
You	O
should	O
follow	O
-	O
up	O
with	O
your	O
oncologist	O
as	O
an	O
outpatient	O
as	O
to	O
when	O
you	O
should	O
restart	O
chemotherapy	I-Drug
.	O
3	O
.	O
Atrial	B-Reason
Fibrillation	I-Reason
:	O
You	O
have	O
atrial	O
fibrillation	O
,	O
which	O
is	O
an	O
abnormal	O
heart	O
rhythm	O
.	O
The	O
fast	O
rate	O
was	O
controlled	O
with	O
metoprolol	I-Drug
,	O
a	O
drug	O
that	O
slows	O
your	O
heart	O
rate	O
down	O
.	O
4	O
.	O
Pleural	O
effusion	O
:	O
You	O
had	O
a	O
thoracentesis	O
(	O
Draining	O
of	O
fluid	O
from	O
around	O
the	O
lung	O
)	O
on	O
two	O
occasions	O
during	O
your	O
hospital	O
course	O
.	O
5	O
:	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
medications	O
:	O
-	O
ADDED	O
Lovenox	I-Drug
80	O
mg	O
subcutaneous	O
injection	O
twice	O
a	O
day	O
-	O
STOPPED	O
Lisinopril	I-Drug
,	O
Coumadin	I-Drug
,	O
Digoxin	I-Drug
,	O
Vicodin	I-Drug
-	O
ADDED	O
Senna	I-Drug
,	O
Docusate	I-Drug
,	O
Miralax	I-Drug
-	O
ADDED	O
Metoprolol	I-Drug
37.5	O
mg	O
TID	O
(	O
three	O
times	O
per	O
day	O
)	O
Followup	O
Instructions	O
:	O
Please	O
keep	O
the	O
following	O
appointments	O
:	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2199-9-19	O
**	O
]	O
at	O
1	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
10280	O
**	O
]	O
,	O
PA	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2199-9-19	O
**	O
]	O
at	O
1	O
PM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
7634	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2199-9-19	O
**	O
]	O
at	O
2:00	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
4425	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
**	O
please	O
discuss	O
your	O
chemotherapy	O
questions	O
w	O
/	O
your	O
oncologist	O
at	O
this	O
time	O
***	O
Per	O
urology	O
,	O
they	O
would	O
like	O
to	O
reschedule	O
your	O
stent	O
placement	O
for	O
a	O
later	O
time	O
,	O
they	O
are	O
cancelling	O
your	O
appointment	O
for	O
tomorrow	O
as	O
you	O
need	O
to	O
get	O
stronger	O
first	O
.	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
831	O
**	O
]	O
MD	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
3018	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2177-3-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2177-3-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2122-3-1	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1711	O
**	O
]	O
Chief	O
Complaint	O
:	O
Pericardial	O
effusion	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Pericardiocentesis	O
and	O
pericardial	O
drain	O
placement	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
The	O
patient	O
is	O
a	O
52	O
-	O
year	O
old	O
female	O
with	O
a	O
history	O
of	O
metastatic	I-Reason
breast	O
cancer	O
,	O
s	O
/	O
p	O
lt.	O
mastectomy	O
now	O
enrolled	O
in	O
clinical	O
trial	O
"	O
05	O
-	O
395	O
"	O
(	O
lapatinib	I-Drug
monotherapy	O
1500	O
mg	O
)	O
,	O
who	O
noted	O
lt.	O
arm	O
swelling	O
[	O
**	O
2	O
-	O
28	O
**	O
]	O
.	O
Doppler	O
neg	O
for	O
clot	O
,	O
but	O
CT	O
(	O
routine	O
,	O
restaging	O
)	O
revealed	O
pericardial	O
effusion	O
.	O
Echo	O
[	O
**	O
3	O
-	O
3	O
**	O
]	O
revealed	O
:	O
small	O
to	O
moderate	O
sized	O
circumferential	O
pericardial	O
effusion	O
,	O
most	O
prominently	O
inferolateral	O
to	O
the	O
left	O
ventricle	O
and	O
around	O
the	O
right	O
atrium	O
,	O
but	O
~	O
1	O
cm	O
anterior	O
to	O
the	O
right	O
ventricle	O
.	O
There	O
is	O
mild	O
right	O
ventricular	O
diastolic	O
collapse	O
consistent	O
with	O
increased	O
pericardial	O
pressure	O
/	O
early	O
tamponade	O
physiology	O
.	O
.	O
[	O
**	O
3	O
-	O
5	O
**	O
]	O
:	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2177-3-3	O
**	O
]	O
,	O
the	O
pericardial	O
effusion	O
appears	O
similar	O
to	O
slightly	O
larger	O
.	O
There	O
is	O
right	O
ventricular	O
diastolic	O
collapse	O
,	O
consistent	O
with	O
impaired	O
fillling	O
/	O
tamponade	O
physiology	O
.	O
.	O
[	O
**	O
3	O
-	O
7	O
**	O
]	O
:	O
There	O
is	O
subtle	O
RV	O
diastolic	O
compression	O
without	O
collapse	O
(	O
no	O
overt	O
tamponade	O
)	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2177-3-5	O
**	O
]	O
,	O
there	O
is	O
slightly	O
less	O
pericardial	O
fluid	O
anteriorly	O
.	O
Otherwise	O
no	O
change	O
.	O
.	O
A	O
pericardial	O
drain	O
was	O
placed	O
with	O
return	O
of	O
approximately	O
250	O
cc	O
of	O
serosanginous	O
fluid	O
and	O
normalization	O
of	O
right	O
heart	O
pressures	O
.	O
She	O
is	O
admitted	O
to	O
the	O
CCU	O
for	O
further	O
monitoring	O
.	O
Past	O
Medical	O
History	O
:	O
ONCOLOGY	O
HISTORY	O
:	O
She	O
was	O
initially	O
diagnosed	O
in	O
[	O
**	O
2164	O
**	O
]	O
with	O
a	O
3.5	O
cm	O
infiltrating	O
ductal	O
carcinoma	O
,	O
lymph	O
node	O
positive	O
,	O
LVI	O
positive	O
,	O
ER	O
positive	O
.	O
She	O
is	O
status	O
post	O
left	O
mastectomy	O
with	O
reconstruction	O
,	O
CAF	O
followed	O
by	O
tamoxifen	I-Drug
.	O
She	O
recurred	O
in	O
[	O
**	O
7	O
-	O
/	O
2169	O
**	O
]	O
,	O
with	O
metastasis	O
to	O
her	O
left	O
supraclavicular	O
node	O
and	O
lung	O
.	O
Biopsy	O
documented	O
HER	B-Reason
-	I-Reason
2	I-Reason
/	I-Reason
neu	I-Reason
over	O
expression	O
by	O
immunohistochemistry	O
.	O
ER	O
positive	O
.	O
She	O
was	O
treated	O
with	O
Arimidex	I-Drug
for	O
six	O
months	O
,	O
which	O
was	O
followed	O
by	O
Taxol	I-Drug
and	O
Herceptin	I-Drug
.	O
She	O
was	O
then	O
treated	O
with	O
high	O
-	O
dose	O
chemo	I-Drug
and	O
Herceptin	I-Drug
followed	O
by	O
transplant	O
as	O
part	O
of	O
the	O
clinical	O
trial	O
.	O
This	O
chemo	I-Drug
included	O
thiotepa	I-Drug
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
and	O
Taxol	I-Drug
.	O
In	O
[	O
**	O
9	O
-	O
/	O
2173	O
**	O
]	O
,	O
she	O
was	O
treated	O
with	O
letrozole	I-Drug
and	O
Herceptin	I-Drug
and	O
was	O
then	O
switched	O
to	O
Aromasin	I-Drug
and	O
Herceptin	I-Drug
in	O
11	O
/	O
[	O
**	O
2174	O
**	O
]	O
.	O
Upon	O
progression	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
**	O
]	O
was	O
switched	O
to	O
the	O
lapatinib	I-Drug
phase	O
II	O
trial	O
in	O
[	O
**	O
7	O
-	O
28	O
**	O
]	O
,	O
and	O
herceptin	I-Drug
was	O
discontinued	O
.	O
She	O
has	O
received	O
8	O
cycles	O
of	O
lapatinib	I-Drug
.	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Metastatic	O
breast	O
cancer	O
as	O
above	O
.	O
2	O
.	O
Autologous	O
bone	O
marrow	O
transplant	O
in	O
[	O
**	O
2169	O
**	O
]	O
.	O
3	O
.	O
History	O
of	O
meningoceles	O
.	O
4	O
.	O
Hyperlipidemia	O
.	O
Social	O
History	O
:	O
A	O
single	O
parent	O
.	O
She	O
lives	O
with	O
her	O
13	O
-	O
year	O
-	O
old	O
daughter	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
tobacco	O
,	O
alcohol	O
,	O
or	O
drugs	O
.	O
Family	O
History	O
:	O
Father	O
has	O
lymphoma	O
.	O
Physical	O
Exam	O
:	O
Blood	O
pressure	O
was	O
116/66	O
mm	O
Hg	O
while	O
seated	O
.	O
Pulse	O
was	O
73	O
beats	O
/	O
min	O
and	O
regular	O
,	O
respiratory	O
rate	O
was	O
15	O
breaths	O
/	O
min	O
.	O
Generally	O
the	O
patient	O
was	O
well	O
developed	O
,	O
well	O
nourished	O
and	O
well	O
groomed	O
.	O
The	O
patient	O
was	O
oriented	O
to	O
person	O
,	O
place	O
and	O
time	O
.	O
The	O
patient	O
's	O
mood	O
and	O
affect	O
were	O
not	O
inappropriate	O
.	O
.	O
There	O
was	O
no	O
xanthalesma	O
and	O
conjunctiva	O
were	O
pink	O
with	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
The	O
neck	O
was	O
supple	O
with	O
JVP	O
of	O
less	O
than	O
6	O
cm	O
.	O
The	O
carotid	O
waveform	O
was	O
normal	O
.	O
There	O
was	O
no	O
thyromegaly	O
.	O
The	O
were	O
no	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
The	O
respirations	O
were	O
not	O
labored	O
and	O
there	O
were	O
no	O
use	O
of	O
accessory	O
muscles	O
.	O
The	O
lungs	O
were	O
clear	O
to	O
ascultation	O
bilaterally	O
with	O
normal	O
breath	O
sounds	O
and	O
no	O
adventitial	O
sounds	O
or	O
rubs	O
.	O
.	O
Palpation	O
of	O
the	O
heart	O
revealed	O
the	O
PMI	O
to	O
be	O
located	O
in	O
the	O
5th	O
intercostal	O
space	O
,	O
mid	O
clavicular	O
line	O
.	O
There	O
were	O
no	O
thrills	O
,	O
lifts	O
or	O
palpable	O
S3	O
or	O
S4	O
.	O
The	O
heart	O
sounds	O
revealed	O
a	O
normal	O
S1	O
and	O
the	O
S2	O
was	O
normal	O
.	O
There	O
were	O
no	O
rubs	O
,	O
clicks	O
or	O
gallops	O
.	O
There	O
was	O
a	O
slight	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
HSM	O
.	O
.	O
There	O
is	O
a	O
pericardial	O
drain	O
in	O
place	O
in	O
the	O
sub-xiphoid	O
position	O
.	O
Drainage	O
bag	O
connected	O
,	O
contains	O
approx	O
10	O
cc	O
of	O
serosanguinous	O
fluid	O
.	O
.	O
The	O
abdominal	O
aorta	O
was	O
not	O
enlarged	O
by	O
palpation	O
.	O
There	O
was	O
no	O
hepatosplenomegaly	O
or	O
tenderness	O
.	O
The	O
abdomen	O
was	O
soft	O
nontender	O
and	O
nondistended	O
.	O
The	O
extremities	O
had	O
no	O
pallor	O
,	O
cyanosis	O
,	O
clubbing	O
.	O
There	O
is	O
slight	O
(	O
1	O
+	O
)	O
,	O
diffuse	O
,	O
Lt.	O
UE	O
edema	O
.	O
There	O
were	O
no	O
abdominal	O
,	O
femoral	O
or	O
carotid	O
bruits	O
.	O
Inspection	O
and	O
/	O
or	O
palpation	O
of	O
skin	O
and	O
subcutaneous	O
tissue	O
showed	O
no	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
scars	O
,	O
or	O
xanthomas	O
.	O
.	O
Pulses	O
:	O
Right	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
Popliteal	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Left	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
Popliteal	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Pertinent	O
Results	O
:	O
Labwork	O
on	O
admission	O
:	O
[	O
**	O
2177-3-10	O
**	O
]	O
04:15	O
PM	O
WBC	O
-	O
4.2	O
RBC	O
-	O
3.40	O
*	O
HGB	O
-	O
10.8	O
*	O
HCT	O
-	O
31.0	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
31.9	O
MCHC	O
-	O
35.0	O
RDW	O
-	O
14.8	O
[	O
**	O
2177-3-10	O
**	O
]	O
04:15	O
PM	O
PLT	O
COUNT	O
-	O
161	O
[	O
**	O
2177-3-10	O
**	O
]	O
04:15	O
PM	O
GLUCOSE	O
-	O
99	O
UREA	O
N	O
-	O
12	O
CREAT	O
-	O
0.7	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
3.9	O
CHLORIDE	O
-	O
106	O
TOTAL	O
CO2	O
-	O
25	O
ANION	O
GAP	O
-	O
12	O
.	O
Labwork	O
on	O
admission	O
:	O
C.CATH	O
Study	O
Date	O
of	O
[	O
**	O
2177-3-10	O
**	O
]	O
***	O
Not	O
Signed	O
Out	O
***	O
BRIEF	O
HISTORY	O
:	O
This	O
55	O
year	O
old	O
female	O
with	O
known	O
diagnosis	O
of	O
metastatic	O
breast	O
cancer	O
presented	O
with	O
pericardial	O
effusion	O
diagnosed	O
on	O
echocardiogram	O
with	O
significant	O
respiratory	O
mitral	O
flow	O
variation	O
.	O
Patient	O
was	O
therefore	O
referred	O
for	O
pericardiocentesis	O
.	O
INDICATIONS	O
FOR	O
CATHETERIZATION	O
:	O
Pericardial	O
effusion	O
.	O
PROCEDURE	O
:	O
Right	O
Heart	O
Catheterization	O
:	O
was	O
performed	O
by	O
percutaneous	O
entry	O
of	O
the	O
right	O
femoral	O
vein	O
,	O
using	O
a	O
7	O
French	O
pulmonary	O
wedge	O
pressure	O
catheter	O
,	O
advanced	O
to	O
the	O
PCW	O
position	O
through	O
an	O
8	O
French	O
introducing	O
sheath	O
.	O
Cardiac	O
output	O
was	O
measured	O
by	O
the	O
Fick	O
method	O
.	O
Pericardiocentesis	O
:	O
was	O
performed	O
via	O
the	O
subxyphoid	O
approach	O
,	O
using	O
an	O
18	O
gauge	O
thin	O
-	O
wall	O
needle	O
,	O
a	O
guide	O
wire	O
,	O
and	O
a	O
drainage	O
catheter	O
.	O
Conscious	O
Sedation	O
:	O
was	O
provided	O
with	O
appropriate	O
monitoring	O
performed	O
by	O
a	O
member	O
of	O
the	O
nursing	O
staff	O
.	O
HEMODYNAMICS	O
RESULTS	O
BODY	O
SURFACE	O
AREA	O
:	O
m2	O
HEMOGLOBIN	O
:	O
gms	O
%	O
FICK	O
**	O
PRESSURES	O
RIGHT	O
ATRIUM	O
{	O
a	O
/	O
v	O
/	O
m	O
}	O
14/12/10	O
RIGHT	O
VENTRICLE	O
{	O
s	O
/	O
ed	O
}	O
35/12	O
PULMONARY	O
ARTERY	O
{	O
s	O
/	O
d	O
/	O
m	O
}	O
35/15/21	O
PULMONARY	O
WEDGE	O
{	O
a	O
/	O
v	O
/	O
m	O
}	O
16/16/12	O
AORTA	O
{	O
s	O
/	O
d	O
/	O
m	O
}	O
140	O
/	O
65/95	O
PERICARDIUM	O
{	O
m	O
}	O
12	O
**	O
CARDIAC	O
OUTPUT	O
HEART	O
RATE	O
{	O
beats	O
/	O
min	O
}	O
70	O
RHYTHM	O
SINUS	O
OTHER	O
HEMODYNAMIC	O
DATA	O
:	O
The	O
oxygen	O
consumption	O
was	O
assumed	O
.	O
TECHNICAL	O
FACTORS	O
:	O
Total	O
time	O
(	O
Lidocaine	I-Drug
to	O
test	O
complete	O
)	O
=	O
45	O
minutes	O
.	O
Arterial	O
time	O
=	O
45	O
minutes	O
.	O
Fluoro	O
time	O
=	O
2.3	O
minutes	O
.	O
Contrast	I-Drug
injected	O
:	O
Non-ionic	O
low	O
osmolar	O
(	O
isovue	O
,	O
optiray	O
...	O
)	O
,	O
vol	O
20	O
ml	O
,	O
Indications	O
-	O
Renal	O
Anesthesia	I-Reason
:	O
1	O
%	O
Lidocaine	I-Drug
subq	O
.	O
Cardiac	O
Cath	O
Supplies	O
Used	O
:	O
-	O
[	O
**	O
Company	O
**	O
]	O
,	O
PERICARDIOSENTISIS	O
SET	O
-	O
ALLEGIANCE	O
,	O
CUSTOM	O
STERILE	O
PACK	O
COMMENTS	O
:	O
1	O
.	O
Resting	O
hemodynamics	O
were	O
performed	O
.	O
The	O
right	O
sided	O
filling	O
pressures	O
were	O
mildly	O
elevated	O
(	O
mean	O
RA	O
pressure	O
was	O
12mmHg	O
and	O
RVEDP	O
was	O
12mmHg	O
)	O
.	O
The	O
pulmonary	O
artery	O
pressures	O
were	O
mildly	O
elevated	O
measuring	O
35	O
/	O
15mmHg	O
.	O
The	O
left	O
sided	O
filling	O
pressures	O
were	O
equalized	O
to	O
the	O
right	O
(	O
mean	O
PCW	O
pressure	O
was	O
12mmHg	O
)	O
.	O
There	O
was	O
significant	O
respiratory	O
variation	O
of	O
systemic	O
arterial	O
pressure	O
up	O
to	O
20mmHg	O
.	O
There	O
was	O
equalization	O
of	O
RA	O
and	O
pericardial	O
pressures	O
.	O
2	O
.	O
Pericardiocentesis	O
was	O
performed	O
under	O
fluoroscopy	O
guidance	O
.	O
Pericardial	O
drain	O
was	O
subsequently	O
placed	O
with	O
240cc	O
serosanguinous	O
fluid	O
removed	O
.	O
Repeat	O
measurement	O
of	O
pericardial	O
pressure	O
and	O
RA	O
pressure	O
demonstrated	O
clear	O
seperation	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
1	O
.	O
Elevated	O
right	O
sided	O
filling	O
pressures	O
with	O
equlization	O
of	O
RA	O
/	O
LA	O
/	O
pericardial	O
pressures	O
.	O
2	O
.	O
Successful	O
placement	O
of	O
pericardial	O
drain	O
.	O
.	O
ECHO	O
Study	O
Date	O
of	O
[	O
**	O
2177-3-10	O
**	O
]	O
Conclusions	O
:	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
low	O
normal	O
(	O
LVEF	O
50	O
-	O
55	O
%	O
)	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2177-3-7	O
**	O
]	O
,	O
there	O
is	O
now	O
minimal	O
residual	O
pericardial	O
effusion	O
.	O
.	O
ECG	O
Study	O
Date	O
of	O
[	O
**	O
2177-3-10	O
**	O
]	O
1:00:10	O
PM	O
Sinus	O
rhythm	O
Normal	O
ECG	O
Since	O
previous	O
tracing	O
,	O
no	O
significant	O
change	O
.	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
[	O
**	O
2177-3-11	O
**	O
]	O
IMPRESSION	O
:	O
AP	O
chest	O
,	O
small	O
right	O
pleural	O
effusion	O
is	O
present	O
.	O
Right	O
lower	O
lobe	O
atelectasis	O
is	O
new	O
since	O
[	O
**	O
2	O
-	O
28	O
**	O
]	O
.	O
Consolidation	O
in	O
the	O
anterior	O
segment	O
of	O
the	O
right	O
upper	O
lobe	O
and	O
a	O
right	O
apical	O
paramediastinal	O
mass	O
are	O
unchanged	O
.	O
Left	O
lung	O
is	O
clear	O
.	O
Several	O
loops	O
of	O
pericardiocentesis	O
catheter	O
projecting	O
over	O
the	O
subxiphoid	O
midline	O
,	O
the	O
base	O
of	O
the	O
heart	O
and	O
superiorly	O
to	O
the	O
level	O
of	O
the	O
pulmonary	O
outflow	O
tract	O
,	O
are	O
acutely	O
coiled	O
and	O
should	O
be	O
evaluated	O
clinically	O
to	O
see	O
if	O
they	O
are	O
draining	O
properly	O
.	O
No	O
pneumothorax	O
.	O
.	O
ECHO	O
Study	O
Date	O
of	O
[	O
**	O
2177-3-11	O
**	O
]	O
Conclusions	O
:	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
There	O
is	O
a	O
small	O
circumferential	O
pericardial	O
effusion	O
primarily	O
inferolateral	O
to	O
the	O
left	O
ventricle	O
with	O
minimal	O
effusion	O
anterior	O
to	O
the	O
right	O
ventricle	O
.	O
No	O
echocardiographic	O
signs	O
of	O
tamponade	O
physiology	O
are	O
seen	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2177-3-10	O
**	O
]	O
,	O
the	O
inferolateral	O
effusion	O
is	O
more	O
prominent	O
.	O
.	O
Labwork	O
on	O
discharge	O
:	O
[	O
**	O
2177-3-12	O
**	O
]	O
09:25	O
AM	O
BLOOD	O
WBC	O
-	O
5.6	O
RBC	O
-	O
3.67	O
*	O
Hgb	O
-	O
11.9	O
*	O
Hct	O
-	O
36.0	O
MCV	O
-	O
98	O
#	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
32.9	O
RDW	O
-	O
14.2	O
Plt	O
Ct	O
-	O
185	O
[	O
**	O
2177-3-12	O
**	O
]	O
09:25	O
AM	O
BLOOD	O
Glucose	O
-	O
108	O
*	O
UreaN	O
-	O
8	O
Creat	O
-	O
0.7	O
Na	O
-	O
136	O
K	O
-	O
3.7	O
Cl	O
-	O
104	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
15	O
Brief	O
Hospital	O
Course	O
:	O
55	O
year	O
-	O
old	O
female	O
with	O
metastatic	O
breast	O
cancer	O
presenting	O
with	O
pericardial	O
effusion	O
.	O
.	O
1	O
.	O
Pericardial	O
effusion	O
.	O
Likely	O
malignant	O
.	O
Pericardiocentesis	O
was	O
performed	O
with	O
approximately	O
250	O
cc	O
of	O
serosanguinous	O
fluid	O
output	O
and	O
normalization	O
of	O
right	O
heart	O
pressures	O
.	O
A	O
pericardial	O
drain	O
was	O
placed	O
with	O
320	O
cc	O
of	O
serosanguinous	O
fluid	O
output	O
the	O
first	O
12	O
hours	O
,	O
then	O
75	O
cc	O
over	O
6	O
hours	O
,	O
then	O
no	O
output	O
.	O
A	O
repeat	O
echocardiogram	O
showed	O
a	O
small	O
pericardial	O
effusion	O
without	O
evidence	O
of	O
tamponade	O
as	O
above	O
.	O
The	O
pericardial	O
drain	O
was	O
removed	O
.	O
An	O
echocardiogram	O
the	O
next	O
morning	O
showed	O
stable	O
small	O
pericardial	O
effusion	O
.	O
Cultures	O
were	O
negative	O
at	O
the	O
time	O
of	O
discharge	O
and	O
cytology	O
was	O
pending	O
.	O
The	O
patient	O
will	O
have	O
a	O
repeat	O
echocardiogram	O
five	O
days	O
after	O
discharge	O
and	O
will	O
follow	O
-	O
up	O
with	O
her	O
oncologist	O
.	O
The	O
patient	O
may	O
need	O
a	O
pericardial	O
window	O
or	O
balloon	O
pericardiotomy	O
procedure	O
if	O
the	O
effusion	O
increases	O
in	O
size	O
.	O
.	O
2	O
.	O
Infectious	O
disease	O
.	O
The	O
patient	O
had	O
a	O
temperature	O
to	O
100.8	O
the	O
second	O
day	O
of	O
admission	O
.	O
The	O
patient	O
's	O
only	O
localizing	O
symptom	O
was	O
a	O
nonproductive	O
cough	O
the	O
patient	O
has	O
complained	O
of	O
for	O
the	O
past	O
three	O
weeks	O
,	O
overall	O
improved	O
since	O
that	O
time	O
.	O
Chest	O
x-ray	O
showed	O
atelectasis	O
but	O
no	O
new	O
consolidations	O
.	O
Urinalysis	O
negative	O
for	O
infection	O
.	O
Urine	O
,	O
blood	O
,	O
and	O
pericardial	O
fluid	O
cultures	O
without	O
growth	O
at	O
the	O
time	O
of	O
discharge	O
.	O
The	O
fever	O
was	O
likely	O
secondary	O
to	O
atelectasis	O
or	O
the	O
patient	O
's	O
underlying	O
malignancy	O
.	O
.	O
3	O
.	O
Breast	B-Reason
cancer	I-Reason
.	O
The	O
patient	O
is	O
now	O
off	O
the	O
lapatinib	I-Drug
study	O
.	O
The	O
patient	O
is	O
followed	O
by	O
oncology	O
.	O
.	O
4	O
.	O
Anemia	O
.	O
The	O
patient	O
's	O
hematocrit	O
remained	O
stable	O
at	O
31	O
-	O
36	O
during	O
admission	O
.	O
The	O
patient	O
's	O
iron	O
studies	O
showed	O
an	O
iron	O
to	O
TIBC	O
ratio	O
of	O
5	O
%	O
,	O
although	O
ferritin	O
was	O
within	O
normal	O
limits	O
.	O
Folate	O
and	O
B12	O
were	O
within	O
normal	O
limits	O
.	O
Further	O
management	O
deferred	O
to	O
the	O
patient	O
's	O
primary	O
physician	O
.	O
Medications	O
on	O
Admission	O
:	O
Simvastatin	I-Drug
20	O
mg	O
QD	O
Discharge	O
Medications	O
:	O
1	O
.	O
Simvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Pericardial	O
effusion	O
status	O
post	O
pericardiocentesis	O
and	O
pericardial	O
drain	O
placement	O
/	O
removal	O
.	O
Secondary	O
:	O
1	O
.	O
Metastatic	O
breast	O
cancer	O
2	O
.	O
Autologous	O
bone	O
marrow	O
transplant	O
in	O
[	O
**	O
2169	O
**	O
]	O
3	O
.	O
History	O
of	O
meningoceles	O
4	O
.	O
Hyperlipidemia	O
Discharge	O
Condition	O
:	O
Afebrile	O
,	O
vital	O
signs	O
stable	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
hospitalized	O
after	O
a	O
procedure	O
to	O
remove	O
fluid	O
from	O
your	O
pericardial	O
sac	O
.	O
You	O
will	O
need	O
a	O
repeat	O
echocardiogram	O
to	O
assess	O
for	O
fluid	O
reaccumulation	O
.	O
The	O
office	O
of	O
your	O
oncologist	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
contact	O
you	O
regarding	O
scheduling	O
of	O
your	O
repeat	O
echocardiogram	O
and	O
follow	O
-	O
up	O
with	O
oncology	O
.	O
.	O
You	O
spiked	O
a	O
fever	O
during	O
admission	O
without	O
any	O
localizing	O
symptoms	O
.	O
Your	O
oncologist	O
should	O
follow	O
-	O
up	O
the	O
urine	O
,	O
blood	O
,	O
and	O
pericardial	O
fluid	O
cultures	O
drawn	O
during	O
this	O
admission	O
.	O
.	O
Please	O
contact	O
a	O
physician	O
if	O
you	O
experience	O
fevers	O
,	O
chills	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpitations	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
.	O
Please	O
take	O
your	O
medications	O
as	O
prescribed	O
.	O
There	O
were	O
no	O
changes	O
made	O
to	O
your	O
medications	O
.	O
.	O
Please	O
keep	O
your	O
follow	O
-	O
up	O
appointments	O
as	O
below	O
.	O
Followup	O
Instructions	O
:	O
The	O
office	O
of	O
your	O
oncologist	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
contact	O
you	O
regarding	O
scheduling	O
of	O
your	O
repeat	O
echocardiogram	O
and	O
follow	O
-	O
up	O
with	O
oncology	O
on	O
Monday	O
,	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
.	O
Please	O
call	O
the	O
office	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
21188	O
**	O
]	O
with	O
any	O
questions	O
or	O
concerns	O
or	O
if	O
you	O
do	O
not	O
hear	O
from	O
a	O
representative	O
by	O
this	O
Friday	O
.	O
.	O
Previously	O
scheduled	O
appointments	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
706	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2177-3-17	O
**	O
]	O
10:45	O

Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
64973	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2118-2-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2118-3-15	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2047-12-14	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
VSU	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
Briefly	O
,	O
this	O
is	O
a	O
70	O
-	O
year	O
-	O
old	O
female	O
,	O
with	O
a	O
known	O
abdominal	O
aortic	O
aneurysm	O
,	O
transferred	O
from	O
an	O
outside	O
hospital	O
with	O
severe	O
abdominal	O
tenderness	O
and	O
hypotension	O
.	O
A	O
CT	O
scan	O
at	O
the	O
outside	O
hospital	O
showed	O
no	O
extravasation	O
;	O
however	O
,	O
she	O
was	O
hypotensive	O
on	O
evaluation	O
with	O
severe	O
abdominal	O
pain	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
Significant	O
for	O
cryptogenic	O
cirrhosis	O
,	O
mitral	O
valve	O
regurg	O
,	O
lap	O
-	O
chole	O
,	O
total	O
abdominal	O
hysterectomy	O
,	O
status	O
post	O
appendectomy	O
,	O
and	O
status	O
post	O
ventral	O
hernia	O
repair	O
.	O
MEDICATIONS	O
:	O
Included	O
propranolol	I-Drug
,	O
spironolactone	I-Drug
,	O
Lasix	I-Drug
and	O
Levoxyl	I-Drug
.	O
ALLERGIES	O
:	O
She	O
has	O
no	O
known	O
drug	O
allergies	O
.	O
PHYSICAL	O
EXAM	O
:	O
She	O
was	O
afebrile	O
.	O
VITAL	O
SIGNS	O
:	O
Her	O
heart	O
rate	O
was	O
65	O
,	O
blood	O
pressure	O
in	O
the	O
60s	O
,	O
and	O
she	O
was	O
100	O
%	O
on	O
2	O
liters	O
.	O
She	O
had	O
significant	O
abdominal	O
tenderness	O
with	O
guarding	O
.	O
Her	O
white	O
count	O
was	O
normal	O
,	O
INR	O
was	O
1.3	O
,	O
and	O
her	O
PT	O
was	O
30	O
.	O
Her	O
BUN	O
and	O
creatinine	O
were	O
27	O
.	O
and	O
1.5	O
.	O
HOSPITAL	O
COURSE	O
:	O
Patient	O
was	O
taken	O
to	O
the	O
operating	O
room	O
emergently	O
for	O
a	O
question	O
of	O
a	O
ruptured	O
abdominal	O
aortic	O
aneurysm	O
.	O
Intraoperatively	O
,	O
it	O
was	O
found	O
that	O
she	O
had	O
a	O
large	O
aneurysm	O
.	O
There	O
was	O
also	O
extensive	O
bleeding	O
from	O
her	O
cirrhosis	O
and	O
;	O
therefore	O
,	O
she	O
was	O
left	O
packed	O
and	O
open	O
.	O
Please	O
see	O
the	O
operative	O
report	O
for	O
further	O
details	O
.	O
Postoperatively	O
,	O
she	O
was	O
transferred	O
to	O
the	O
surgical	O
intensive	O
care	O
unit	O
,	O
and	O
she	O
was	O
aggressively	O
resuscitated	O
.	O
After	O
this	O
was	O
done	O
,	O
over	O
the	O
next	O
couple	O
of	O
days	O
she	O
stabilized	O
,	O
bladder	O
pressures	O
were	O
followed	O
,	O
and	O
she	O
was	O
treated	O
for	O
ARDS	O
with	O
an	O
esophageal	O
balloon	O
,	O
and	O
ventilatory	O
management	O
,	O
and	O
an	O
echo	O
was	O
done	O
which	O
showed	O
normal	O
EF	O
.	O
The	O
patient	O
was	O
then	O
returned	O
to	O
the	O
operating	O
room	O
for	O
abdominal	O
washout	O
.	O
Transplant	O
surgery	O
was	O
consulted	O
who	O
assisted	O
in	O
the	O
operative	O
intervention	O
.	O
At	O
this	O
time	O
,	O
it	O
was	O
decided	O
that	O
the	O
patient	O
would	O
return	O
to	O
the	O
operating	O
room	O
.	O
During	O
the	O
second	O
washout	O
,	O
a	O
Vicryl	O
mesh	O
was	O
placed	O
,	O
and	O
a	O
VAC	O
dressing	O
was	O
continued	O
.	O
Her	O
LFTs	O
were	O
followed	O
,	O
and	O
her	O
platelet	O
count	O
was	O
also	O
followed	O
,	O
and	O
her	O
platelet	O
count	O
began	O
to	O
slowly	O
fall	O
.	O
Because	O
of	O
this	O
,	O
a	O
HIT	I-Ade
panel	O
was	O
sent	O
,	O
and	O
this	O
was	O
positive	O
.	O
Her	O
heparin	I-Drug
was	O
stopped	O
,	O
her	O
lines	O
were	O
changed	O
,	O
and	O
she	O
was	O
followed	O
from	O
this	O
standpoint	O
.	O
Postoperatively	O
,	O
from	O
the	O
second	O
washout	O
she	O
was	O
continued	O
on	O
ventilatory	O
management	O
,	O
and	O
she	O
was	O
kept	O
on	O
Levophed	I-Drug
for	O
blood	B-Reason
pressure	I-Reason
control	I-Reason
.	O
She	O
continued	O
to	O
require	O
significant	O
fluid	I-Drug
resuscitation	I-Reason
,	O
as	O
she	O
was	O
losing	O
over	O
3	O
-	O
4	O
liters	O
of	O
ascites	O
fluid	O
from	O
her	O
open	O
abdomen	O
.	O
VAC	O
dressings	O
were	O
changed	O
at	O
the	O
bedside	O
multiple	O
times	O
,	O
and	O
there	O
was	O
slow	O
granulation	O
tissue	O
.	O
She	O
was	O
started	O
on	O
TPN	I-Drug
for	O
nutritional	I-Reason
support	O
during	O
this	O
time	O
.	O
After	O
multiple	O
attempts	O
at	O
weaning	O
the	O
ventilator	O
were	O
attempted	O
,	O
it	O
was	O
decided	O
that	O
the	O
patient	O
would	O
proceed	O
to	O
a	O
tracheostomy	O
,	O
as	O
she	O
was	O
not	O
weaning	O
adequately	O
.	O
Because	O
of	O
this	O
,	O
a	O
tracheostomy	O
was	O
performed	O
,	O
and	O
she	O
did	O
well	O
from	O
that	O
standpoint	O
.	O
She	O
slowly	O
began	O
to	O
improve	O
.	O
However	O
,	O
LFTs	O
continued	O
to	O
rise	O
,	O
and	O
her	O
VAC	O
drain	O
output	O
continued	O
to	O
stay	O
high	O
at	O
over	O
5	O
liters	O
.	O
She	O
was	O
continued	O
to	O
be	O
replaced	O
with	O
albumin	I-Drug
,	O
as	O
well	O
as	O
with	O
IV	O
fluid	I-Drug
.	O
During	O
this	O
time	O
,	O
she	O
began	O
spiking	O
fevers	O
.	O
Pancultures	O
were	O
done	O
,	O
and	O
she	O
was	O
found	O
to	O
have	O
Pseudomonas	I-Reason
in	O
her	O
lungs	O
and	O
;	O
therefore	O
,	O
she	O
was	O
changed	O
from	O
Zosyn	I-Drug
to	O
meropenem	I-Drug
.	O
She	O
became	O
afebrile	O
at	O
that	O
point	O
,	O
and	O
she	O
continued	O
to	O
do	O
well	O
from	O
a	O
pulmonary	O
standpoint	O
.	O
However	O
,	O
she	O
continued	O
to	O
require	O
high	O
ventilatory	O
support	O
with	O
high	O
PEEP	O
and	O
high	O
pressure	O
support	O
,	O
and	O
she	O
was	O
intermittently	O
switched	O
back	O
and	O
forth	O
between	O
assist	O
control	O
and	O
CPAP	O
.	O
From	O
a	O
graft	O
standpoint	O
,	O
she	O
had	O
palpable	O
pulses	O
and	O
good	O
distal	O
perfusion	O
throughout	O
.	O
She	O
was	O
attempted	O
on	O
multiple	O
occasions	O
to	O
be	O
given	O
anticoagulation	I-Reason
using	O
argatroban	I-Drug
and	O
lepirudin	I-Drug
.	O
However	O
,	O
her	O
creatinine	O
clearance	O
and	O
primary	O
liver	O
function	O
abnormalities	O
did	O
not	O
allow	O
for	O
adequate	O
anticoagulation	I-Drug
.	O
She	O
had	O
multiple	O
episodes	O
of	O
bleeding	O
,	O
both	O
from	O
her	O
NG	O
tube	O
,	O
as	O
well	O
as	O
from	O
her	O
Foley	O
which	O
required	O
significant	O
blood	O
product	O
resuscitation	O
.	O
As	O
her	O
bilirubin	O
and	O
LFTs	O
began	O
to	O
rise	O
,	O
and	O
her	O
VAC	O
output	O
continued	O
to	O
rise	O
,	O
a	O
hepatology	O
consult	O
was	O
performed	O
,	O
and	O
a	O
liver	O
ultrasound	O
was	O
also	O
done	O
.	O
The	O
liver	O
ultrasound	O
found	O
that	O
she	O
had	O
thrombosed	O
her	O
portal	O
vein	O
,	O
and	O
because	O
of	O
her	O
dropping	O
hematocrit	O
,	O
the	O
hepatology	O
service	O
proceeded	O
with	O
an	O
endoscopy	O
.	O
Multiple	O
esophageal	O
varices	O
were	O
identified	O
,	O
and	O
while	O
no	O
active	O
bleeding	O
was	O
present	O
,	O
these	O
were	O
significant	O
,	O
and	O
felt	O
that	O
they	O
would	O
likely	O
cause	O
bleeding	O
in	O
the	O
future	O
.	O
Therefore	O
,	O
they	O
were	O
banded	O
.	O
Again	O
,	O
she	O
began	O
having	O
high	O
fevers	O
,	O
and	O
she	O
had	O
ventilator	I-Reason
acquired	O
pneumonia	O
with	O
the	O
Pseudomonas	O
,	O
and	O
this	O
had	O
now	O
become	O
resistant	O
to	O
meropenem	I-Drug
.	O
Therefore	O
,	O
she	O
was	O
changed	O
to	O
ciprofloxacin	I-Drug
.	O
At	O
the	O
same	O
time	O
,	O
she	O
had	O
blood	B-Reason
cultures	I-Reason
which	I-Reason
had	O
gram	O
-	O
positive	O
cocci	O
.	O
She	O
was	O
started	O
empirically	O
on	O
vancomycin	I-Drug
.	O
During	O
one	O
of	O
these	O
episodes	O
of	O
hypotension	O
,	O
she	O
had	O
some	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
changes	O
which	O
were	O
concerning	O
for	O
myocardial	O
ischemia	O
.	O
An	O
EKG	O
was	O
done	O
,	O
and	O
cardiology	O
was	O
consulted	O
.	O
They	O
felt	O
that	O
ultimately	O
this	O
was	O
due	O
to	O
demand	O
ischemia	O
from	O
her	O
overwhelming	O
sepsis	O
.	O
They	O
had	O
no	O
further	O
suggestions	O
other	O
than	O
supportive	O
care	O
as	O
tolerable	O
.	O
Multiple	O
family	O
meetings	O
were	O
done	O
,	O
as	O
the	O
patient	O
continued	O
to	O
not	O
improve	O
.	O
The	O
family	O
was	O
present	O
throughout	O
multiple	O
of	O
these	O
decisions	O
,	O
and	O
it	O
was	O
decided	O
ultimately	O
that	O
she	O
would	O
be	O
made	O
DNR	O
pending	O
any	O
further	O
results	O
or	O
deterioration	O
.	O
After	O
proceeding	O
with	O
the	O
ultrasound	O
and	O
finding	O
the	O
thrombosis	O
of	O
her	O
portal	O
vein	O
,	O
a	O
repeat	O
family	O
meeting	O
was	O
held	O
,	O
and	O
it	O
was	O
decided	O
that	O
the	O
patient	O
would	O
be	O
made	O
comfort	O
measures	O
only	O
.	O
She	O
was	O
made	O
comfort	O
measures	O
on	O
[	O
**	O
2118-3-15	O
**	O
]	O
and	O
passed	O
away	O
shortly	O
thereafter	O
.	O
Patient	O
's	O
family	O
was	O
present	O
throughout	O
the	O
entire	O
time	O
,	O
and	O
after	O
the	O
meeting	O
was	O
there	O
at	O
the	O
time	O
when	O
the	O
patient	O
passed	O
away	O
.	O
Patient	O
died	O
at	O
1:15	O
p.m.	O
on	O
[	O
**	O
2118-3-15	O
**	O
]	O
.	O
The	O
patient	O
's	O
family	O
declined	O
a	O
postmortem	O
evaluation	O
at	O
this	O
time	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Liver	O
failure	O
,	O
2	O
.	O
Thrombosed	O
portal	O
vein	O
.	O
3	O
.	O
Esophageal	O
varices	O
.	O
4	O
.	O
Abdominal	O
aortic	O
aneurysm	O
status	O
post	O
abdominal	O
aneurysm	O
repair	O
.	O
5	O
.	O
Status	O
post	O
abdominal	O
washouts	O
.	O
6	O
.	O
Status	O
post	O
Vicryl	O
mesh	O
closure	O
of	O
the	O
abdomen	O
and	O
VAC	O
placement	O
.	O
7	O
.	O
Status	O
post	O
tracheostomy	O
for	O
respiratory	O
failure	O
.	O
8	O
.	O
Ventilator	O
acquired	O
pneumonia	O
.	O
The	O
patient	O
passed	O
away	O
on	O
[	O
**	O
2118-3-15	O
**	O
]	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
5697	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Doctor	O
Last	O
Name	O
11225	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2118-3-15	O
**	O
]	O
14:16:49	O
T	O
:	O
[	O
**	O
2118-3-15	O
**	O
]	O
14:55:46	O
Job	O
#	O
:	O
[	O
**	O
Job	O
Number	O
64974	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2135-7-2	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2135-8-23	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2081-3-20	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Nafcillin	I-Drug
/	O
Vancomycin	I-Drug
Attending	O
:[	O
**	O
Doctor	O
First	O
Name	O
3290	O
**	O
]	O
Chief	O
Complaint	O
:	O
Back	O
pain	O
due	O
to	O
epidural	O
abscesses	O
complicated	O
by	O
bacteremia	O
and	O
acute	O
respiratory	O
distress	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
[	O
**	O
2135-7-3	O
**	O
]	O
.	O
Cervical	O
decompression	O
via	O
laminectomies	O
C2	O
-	O
C6	O
bilaterally	O
,	O
insertion	O
of	O
2	O
epidural	O
drains	O
.	O
Laminectomy	O
T12	O
-	O
L1	O
-	O
L2	O
,	O
insertion	O
of	O
2	O
drains	O
2	O
.	O
[	O
**	O
2135-7-5	O
**	O
]	O
Right	O
knee	O
arthrocentesis	O
and	O
washout	O
3	O
.	O
[	O
**	O
2135-7-13	O
**	O
]	O
Anterior	O
cervical	O
discectomy	O
and	O
fusion	O
as	O
well	O
as	O
epidural	O
abscess	O
evacuation	O
.	O
4	O
.	O
[	O
**	O
2135-7-25	O
**	O
]	O
IR	O
-	O
guided	O
paraspinal	O
abscess	O
drainage	O
History	O
of	O
Present	O
Illness	O
:	O
54	O
yo	O
F	O
presents	O
to	O
ED	O
w	O
/	O
1	O
week	O
of	O
worsening	O
back	O
pain	O
.	O
Pain	O
reportedly	O
started	O
while	O
riding	O
a	O
bike	O
.	O
Began	O
in	O
lower	O
back	O
and	O
has	O
steadily	O
risen	O
up	O
to	O
her	O
neck	O
over	O
the	O
past	O
week	O
.	O
Also	O
reports	O
some	O
shooting	O
pain	O
down	O
right	O
leg	O
.	O
+	O
fevers	O
and	O
chills	O
.	O
For	O
the	O
past	O
3	O
days	O
,	O
her	O
legs	O
have	O
been	O
feeling	O
weak	O
,	O
she	O
has	O
had	O
difficulty	O
urinating	O
.	O
Fevers	O
and	O
chills	O
have	O
resolved	O
.	O
Reports	O
tremors	O
starting	O
two	O
days	O
ago	O
.	O
She	O
denies	O
fecal	O
incontinence	O
although	O
this	O
was	O
reportedly	O
endorsed	O
to	O
ED	O
staff	O
.	O
Denies	O
any	O
numbness	O
or	O
tingling	O
in	O
her	O
extremities	O
.	O
Past	O
Medical	O
History	O
:	O
None	O
Social	O
History	O
:	O
Works	O
for	O
a	O
mission	O
network	O
.	O
No	O
IVDA	O
.	O
Social	O
EtOH	O
Family	O
History	O
:	O
N	O
/	O
C	O
Physical	O
Exam	O
:	O
ADMISSION	O
PHYSICAL	O
EXAM	O
:	O
T	O
:	O
98.7	O
BP	O
:	O
155/100	O
HR	O
:	O
140	O
-	O
150s	O
RR	O
:	O
20	O
O2Sats	O
100	O
%	O
on	O
NRB	O
Gen	O
:	O
Anxious	O
,	O
Uncomfortable	O
HEENT	O
:	O
Pupils	O
:	O
4	O
-	O
>	O
3	O
EOMs	O
-	O
Full	O
Abd	O
:	O
Soft	O
,	O
NT	O
Extrem	O
:	O
Warm	O
and	O
well	O
-	O
perfused	O
.	O
Neuro	O
:	O
Mental	O
status	O
:	O
Awake	O
and	O
alert	O
,	O
cooperative	O
with	O
exam	O
,	O
normal	O
affect	O
.	O
Orientation	O
:	O
Oriented	O
to	O
person	O
,	O
place	O
,	O
and	O
date	O
.	O
Motor	O
:	O
D	O
B	O
T	O
WE	O
WF	O
IP	O
Q	O
H	O
AT	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
938	O
**	O
]	O
G	O
R	O
5	O
5	O
5	O
5	O
5	O
5	O
5	O
5	O
5	O
-	O
L	O
5	O
5	O
5	O
5	O
5	O
5	O
5	O
5	O
5	O
-	O
Sensation	O
:	O
Intact	O
to	O
light	O
touch	O
,	O
propioception	O
,	O
pinprick	O
and	O
vibration	O
bilaterally	O
.	O
Reflexes	O
:	O
Pa	O
Ac	O
Right	O
2	O
+	O
Mute	O
Left	O
2	O
+	O
Mute	O
Rectal	O
exam	O
-	O
normal	O
sphincter	O
control	O
,	O
normal	O
perianal	O
sensation	O
DISCHARGE	O
PHYSICAL	O
EXAM	O
(	O
[	O
**	O
8	O
-	O
17	O
**	O
]	O
)	O
:	O
VS	O
:	O
Afebrile	O
>	O
36	O
hr	O
,	O
Tc	O
:	O
98.1	O
BP	O
:	O
130/76	O
(	O
140-170/80	O
-	O
92	O
)	O
94	O
%	O
2L	O
02	O
saturation	O
yesterday	O
:	O
97	O
--	O
100	O
%	O
on	O
1	O
-	O
2L	O
;	O
94	O
%	O
RA	O
GEN	O
:	O
Sleeping	O
but	O
arousable	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
non-icteric	O
sclera	O
,	O
MMM	O
NECK	O
:	O
Gauze	O
and	O
tegaderm	O
in	O
place	O
over	O
former	O
RIJ	O
,	O
no	O
tenderness	O
HEART	O
:	O
RRR	O
,	O
nl	O
S1	O
S2	O
,	O
3/6	O
systolic	O
murmur	O
,	O
heard	O
best	O
at	O
LUSB	O
,	O
radiating	O
to	O
neck	O
bilaterally	O
,	O
no	O
rubs	O
LUNGS	O
:	O
anterior	O
lung	O
fields	O
clear	O
,	O
slightly	O
decreased	O
bs	O
at	O
bases	O
,	O
no	O
wheezes	O
ABD	O
:	O
ecchymoses	O
on	O
lower	O
abdomen	O
,	O
+	O
NABS	O
,	O
soft	O
,	O
non-distended	O
,	O
non-tender	O
,	O
without	O
rebound	O
or	O
guarding	O
EXT	O
:	O
warm	O
,	O
1	O
+	O
edema	O
to	O
ankle	O
b	O
/	O
l	O
,	O
right	O
knee	O
with	O
healed	O
surgical	O
scar	O
T	O
/	O
L	O
/	O
D	O
-	O
Left	O
PICC	O
line	O
in	O
place	O
;	O
no	O
surrounding	O
tenderness	O
,	O
erythema	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2135-7-2	O
**	O
]	O
01:45	O
PM	O
URINE	O
RBC	O
-	O
[	O
**	O
5	O
-	O
5	O
**	O
]	O
*	O
WBC	O
-	O
>	O
50	O
BACTERIA	O
-	O
MANY	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
[	O
**	O
2135-7-2	O
**	O
]	O
01:50	O
PM	O
WBC	O
-	O
21.2	O
*	O
RBC	O
-	O
4.70	O
HGB	O
-	O
14.2	O
HCT	O
-	O
43.9	O
MCV	O
-	O
93	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
14.4	O
[	O
**	O
2135-7-2	O
**	O
]	O
01:50	O
PM	O
GLUCOSE	O
-	O
287	O
*	O
UREA	O
N	O
-	O
51	O
*	O
CREAT	O
-	O
1.7	O
*	O
SODIUM	O
-	O
136	O
POTASSIUM	O
-	O
3.6	O
CHLORIDE	O
-	O
96	O
TOTAL	O
CO2	O
-	O
21	O
*	O
ANION	O
GAP	O
-	O
23	O
*	O
[	O
**	O
2135-7-2	O
**	O
]	O
02:17	O
PM	O
LACTATE	O
-	O
2.9	O
*	O
DISCHARGE	O
LABS	O
(	O
[	O
**	O
8	O
-	O
17	O
**	O
]	O
)	O
WBC	O
RBC	O
Hgb	O
Hct	O
MCV	O
MCH	O
MCHC	O
RDW	O
Plt	O
Ct	O
16.6	O
*	O
2.87	O
*	O
8.0	O
*	O
24.4	O
*	O
85	O
27.8	O
32.7	O
17.9	O
*	O
227	O
DIFF	O
Neuts	O
Bands	O
Lymphs	O
Monos	O
Eos	O
Baso	O
Atyps	O
Metas	O
Myelos	O
Promyel	O
NRBC	O
59	O
9	O
*	O
8	O
*	O
21	O
*	O
0	O
0	O
1	O
*	O
2	O
*	O
0	O
Glucose	O
UreaN	O
Creat	O
Na	O
K	O
Cl	O
HCO3	O
AnGap	O
96	O
22	O
*	O
0.5	O
141	O
3.7	O
102	O
32	O
11	O
Inflammatory	O
Markers	O
(	O
[	O
**	O
8	O
-	O
16	O
**	O
]	O
)	O
ESR	O
:	O
115	O
*	O
CRP	O
:	O
30.9	O
.	O
MICRO	O
:	O
Micro	O
:	O
[	O
**	O
7	O
-	O
2	O
**	O
]	O
-	O
Blood	O
Cx	O
-	O
[	O
**	O
2	O
-	O
27	O
**	O
]	O
MSSA	O
[	O
**	O
7	O
-	O
3	O
**	O
]	O
-	O
Epidural	O
Swab	O
-	O
MSSA	O
[	O
**	O
7	O
-	O
5	O
**	O
]	O
-	O
Joint	O
Fluid	O
+	O
Swab	O
-	O
MSSA	O
[	O
**	O
7	O
-	O
13	O
**	O
]	O
-	O
Epidural	O
Swab	O
-	O
MSSA	O
[	O
**	O
7	O
-	O
25	O
**	O
]	O
Abscess	O
-	O
MSSA	O
.	O
C.	O
diff	O
-	O
[	O
**	O
8	O
-	O
1	O
**	O
]	O
(	O
-	O
)	O
,	O
[	O
**	O
7	O
-	O
30	O
**	O
]	O
(	O
-	O
)	O
,	O
[	O
**	O
7	O
-	O
26	O
**	O
]	O
(	O
-	O
)	O
,	O
[	O
**	O
8	O
-	O
16	O
**	O
]	O
(	O
-	O
)	O
.	O
Antimicrobial	O
History	O
:	O
Vanco	I-Drug
+	O
Cefepime	I-Drug
[	O
**	O
7	O
-	O
10	O
**	O
]	O
-	O
>	O
[	O
**	O
7	O
-	O
15	O
**	O
]	O
Vanco	I-Drug
[	O
**	O
7	O
-	O
10	O
**	O
]	O
-	O
>	O
[	O
**	O
7	O
-	O
15	O
**	O
]	O
Nafcillin	I-Drug
[	O
**	O
7	O
-	O
15	O
**	O
]	O
-	O
>	O
[	O
**	O
7	O
-	O
19	O
**	O
]	O
Vanco	I-Drug
[	O
**	O
7	O
-	O
19	O
**	O
]	O
-	O
>	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
Cefepime	I-Drug
[	O
**	O
7	O
-	O
26	O
**	O
]	O
-	O
>	O
[	O
**	O
8	O
-	O
2	O
**	O
]	O
Meropenem	I-Drug
1000	O
mg	O
IV	O
Q8	O
(	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
-	O
[	O
**	O
8	O
-	O
14	O
**	O
]	O
)	O
Daptomycin	I-Drug
600	O
mg	O
IV	O
Q24	O
(	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
-	O
present	O
)	O
[	O
**	O
2135-8-17	O
**	O
]	O
10:22	O
am	O
STOOL	O
CONSISTENCY	O
:	O
NOT	O
APPLICABLE	O
Source	O
:	O
Stool	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2135-8-18	O
**	O
]	O
**	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST	O
(	O
Final	O
[	O
**	O
2135-8-18	O
**	O
]	O
)	O
:	O
Feces	O
negative	O
for	O
C.difficile	O
toxin	O
A	O
&	O
B	O
by	O
EIA	O
.	O
(	O
Reference	O
Range	O
-	O
Negative	O
)	O
.	O
IMAGING	O
:	O
MRI	O
Spine	O
[	O
**	O
7	O
-	O
3	O
**	O
]	O
:	O
1	O
.	O
Cervical	O
anterior	O
epidural	O
collection	O
,	O
with	O
severe	O
narrowing	O
of	O
the	O
thecal	O
sac	O
from	O
C2	O
through	O
C5	O
,	O
without	O
evidence	O
of	O
spinal	O
cord	O
edema	O
.	O
Sagittal	O
post-contrast	O
images	O
suggest	O
that	O
this	O
collection	O
contains	O
fluid	O
at	O
the	O
level	O
of	O
C2	O
,	O
which	O
would	O
indicate	O
an	O
abscess	O
rather	O
than	O
a	O
phlegmon	O
.	O
However	O
,	O
axial	O
post-contrast	O
images	O
suggest	O
that	O
the	O
central	O
hypoenhancing	O
portion	O
of	O
the	O
collection	O
at	O
C2	O
may	O
not	O
be	O
fully	O
liquefied	O
,	O
or	O
that	O
the	O
fluid	O
may	O
be	O
highly	O
viscous	O
.	O
2	O
.	O
Anterior	O
epidural	O
collection	O
from	O
T11	O
through	O
the	O
upper	O
sacrum	O
,	O
compressing	O
the	O
thecal	O
sac	O
and	O
crowding	O
the	O
cauda	O
equina	O
.	O
This	O
collection	O
appears	O
to	O
contain	O
fluid	O
from	O
T12	O
through	O
L3	O
,	O
indicative	O
of	O
an	O
abscess	O
rather	O
than	O
a	O
phlegmon	O
.	O
3	O
.	O
No	O
evidence	O
of	O
discitis	O
or	O
osteomyelitis	O
.	O
4	O
.	O
Bilateral	O
posterior	O
paravertebral	O
muscle	O
phlegmon	O
at	O
the	O
level	O
of	O
L4	O
-	O
5	O
with	O
a	O
possible	O
5	O
mm	O
abscess	O
on	O
the	O
right	O
.	O
Contrast	O
enhancement	O
surrounding	O
the	O
L4	O
-	O
5	O
facet	O
joints	O
may	O
represent	O
inflammation	O
secondary	O
to	O
the	O
severe	O
degenerative	O
facet	O
arthropathy	O
,	O
but	O
septic	O
facet	O
arthropathy	O
can	O
not	O
be	O
excluded	O
Echo	O
[	O
**	O
7	O
-	O
4	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Suboptimal	O
image	O
quality	O
.	O
Mild	O
mitral	O
leaflet	O
thickening	O
but	O
without	O
discrete	O
vegetation	O
or	O
pathologic	O
flow	O
.	O
Mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
Normal	O
left	O
ventricular	O
cavity	O
size	O
with	O
preserved	O
global	O
and	O
regional	O
systolic	O
function	O
MRI	O
Spine	O
[	O
**	O
7	O
-	O
4	O
**	O
]	O
:	O
1	O
.	O
Cervical	O
region	O
:	O
No	O
STIR	O
signal	O
abnormality	O
in	O
the	O
cord	O
.	O
No	O
evidence	O
of	O
cord	O
compression	O
.	O
Expected	O
post-op	O
changes	O
.	O
2	O
.	O
Lumbar	O
region	O
:	O
Small	O
epidural	O
signal	O
abnormality	O
,	O
could	O
represent	O
residual	O
abscess	O
collection	O
from	O
debridement	O
or	O
post-surgical	O
changes	O
.	O
XRAY	O
-	O
Knee	O
IMPRESSION	O
:	O
Small	O
to	O
moderate	O
-	O
sized	O
knee	O
joint	O
effusion	O
.	O
CTA	O
[	O
**	O
7	O
-	O
9	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
No	O
pulmonary	O
embolism	O
or	O
acute	O
aortic	O
pathology	O
.	O
2	O
.	O
Moderate	O
bilateral	O
pleural	O
effusions	O
with	O
subtotal	O
lower	O
lobe	O
collapse	O
.	O
Evidence	O
of	O
loculated	O
pleural	O
effusions	O
tracking	O
up	O
in	O
the	O
right	O
upper	O
lateral	O
pleural	O
space	O
.	O
3	O
.	O
Multiple	O
lung	O
nodules	O
likely	O
infectious	O
in	O
this	O
cl	O
inical	O
setting	O
.	O
Follow	O
-	O
up	O
to	O
resolution	O
is	O
recommended	O
4	O
.	O
No	O
pneumothorax	O
.	O
MR	O
[	O
**	O
Name13	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
Significant	O
increase	O
in	O
volume	O
of	O
the	O
epidural	O
fluid	O
collection	O
/	O
abscess	O
extending	O
from	O
the	O
uppermost	O
C1	O
epidural	O
space	O
to	O
the	O
inferior	O
aspect	O
of	O
the	O
study	O
at	O
L1	O
,	O
largest	O
at	O
the	O
upper	O
cervical	O
spine	O
where	O
it	O
measures	O
approximately	O
1	O
cm	O
in	O
greatest	O
thickness	O
.	O
The	O
patient	O
is	O
status	O
post	O
cervical	O
laminectomy	O
from	O
approximately	O
C2	O
-	O
C6	O
but	O
the	O
epidural	O
collection	O
displaces	O
the	O
cervical	O
cord	O
posteriorly	O
and	O
the	O
cervical	O
cord	O
appears	O
compressed	O
against	O
the	O
posterior	O
ring	O
of	O
C1	O
.	O
There	O
is	O
increased	O
signal	O
within	O
the	O
cervical	O
cord	O
from	O
the	O
medulla	O
to	O
C3	O
.	O
2	O
.	O
The	O
epidural	O
collection	O
/	O
abscess	O
within	O
the	O
thoracic	O
spine	O
mildly	O
displaces	O
the	O
thoracic	O
cord	O
without	O
evidence	O
of	O
cord	O
signal	O
abnormality	O
.	O
CT	O
-	O
Thoracentesis	O
(	O
drainage	O
)	O
[	O
**	O
7	O
-	O
13	O
**	O
]	O
IMPRESSION	O
:	O
Successful	O
diagnostic	O
and	O
therapeutic	O
thoracentesis	O
yielding	O
270	O
cc	O
of	O
serosanguineous	O
fluid	O
from	O
the	O
right	O
pleural	O
cavity	O
.	O
An	O
8	O
French	O
pigtail	O
catheter	O
was	O
placed	O
within	O
the	O
pleural	O
cavity	O
and	O
is	O
currently	O
attached	O
to	O
waterseal	O
.	O
Samples	O
were	O
sent	O
for	O
microbiology	O
and	O
chemistry	O
per	O
the	O
ordering	O
team	O
's	O
request	O
.	O
MR	O
C	O
/	O
T	O
/	O
L	O
-	O
Spine	O
[	O
**	O
7	O
-	O
21	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
New	O
soft	O
tissue	O
paraspinal	O
pockets	O
of	O
fluid	O
collection	O
are	O
seen	O
in	O
the	O
lumbar	O
region	O
since	O
the	O
examination	O
of	O
[	O
**	O
2135-7-2	O
**	O
]	O
and	O
[	O
**	O
2135-7-4	O
**	O
]	O
,	O
visualized	O
in	O
the	O
lower	O
lumbar	O
region	O
involving	O
the	O
psoas	O
muscles	O
and	O
the	O
erector	O
spinae	O
muscles	O
.	O
The	O
largest	O
collection	O
in	O
the	O
right	O
erector	O
spinae	O
muscle	O
is	O
approximately	O
3	O
cm	O
and	O
the	O
largest	O
collection	O
in	O
the	O
right	O
psoas	O
muscle	O
is	O
approximately	O
2	O
cm	O
.	O
Additional	O
left	O
psoas	O
muscle	O
fluid	O
pocket	O
measures	O
2.8	O
cm	O
.	O
Smaller	O
foci	O
are	O
also	O
visualized	O
.	O
2	O
.	O
Lumbar	O
epidural	O
fluid	O
collection	O
ventral	O
and	O
dorsal	O
to	O
the	O
thecal	O
sac	O
in	O
the	O
lower	O
lumbar	O
region	O
may	O
be	O
slightly	O
smaller	O
compared	O
to	O
[	O
**	O
2135-7-2	O
**	O
]	O
.	O
3	O
.	O
Epidural	O
collection	O
in	O
the	O
cervical	O
region	O
extending	O
from	O
C2	O
inferiorly	O
is	O
not	O
significantly	O
changed	O
since	O
the	O
MRI	O
of	O
[	O
**	O
2135-7-14	O
**	O
]	O
.	O
Minimal	O
indentation	O
on	O
the	O
spinal	O
cord	O
in	O
cervical	O
region	O
is	O
unchanged	O
.	O
Postoperative	O
changes	O
and	O
laminectomies	O
are	O
seen	O
in	O
this	O
region	O
.	O
4	O
.	O
Thoracic	O
epidural	O
collection	O
has	O
not	O
changed	O
and	O
there	O
is	O
no	O
cord	O
compression	O
in	O
thoracic	O
region	O
.	O
4	O
.	O
Laminectomies	O
are	O
seen	O
in	O
the	O
lower	O
thoracic	O
/	O
upper	O
lumbar	O
region	O
.	O
Thin	O
rim	O
of	O
epidural	O
collection	O
again	O
seen	O
in	O
the	O
thoracic	O
region	O
which	O
is	O
unchanged	O
.	O
No	O
cord	O
compression	O
is	O
identified	O
in	O
the	O
thoracic	O
region	O
.	O
CT	O
-	O
Chest	O
/	O
Abdomen	O
/	O
Pelvis	O
[	O
**	O
7	O
-	O
26	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Overall	O
,	O
stable	O
appearance	O
of	O
multiple	O
small	O
fluid	O
collection	O
seen	O
in	O
the	O
paraspinal	O
muscles	O
along	O
with	O
the	O
erector	O
spinae	O
and	O
psoas	O
muscles	O
,	O
as	O
described	O
above	O
.	O
No	O
new	O
intraabdominal	O
or	O
intrapelvic	O
collections	O
identified	O
.	O
2	O
.	O
Stable	O
bilateral	O
pleural	O
effusion	O
with	O
bibasilar	O
airspace	O
disease	O
.	O
3	O
.	O
Stable	O
appearance	O
of	O
mediastinal	O
and	O
bilateral	O
hilar	O
lymphadenopathy	O
.	O
U	O
/	O
S	O
Abdomen	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Cholelithiasis	O
with	O
edematous	O
and	O
thick	O
walled	O
but	O
contracted	O
gallbladder	O
.	O
No	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
493	O
**	O
]	O
evidence	O
of	O
acute	O
cholecystitis	O
.	O
Gallbladder	O
wall	O
thickening	O
and	O
edema	O
may	O
be	O
caused	O
by	O
multiple	O
factors	O
such	O
as	O
liver	O
disease	O
and	O
hypoalbuminemia	O
,	O
and	O
clinical	O
correlation	O
is	O
recommended	O
.	O
2	O
.	O
Splenomegaly	O
.	O
CT	O
-	O
Chest	O
/	O
Abdomen	O
/	O
Pelvis	O
[	O
**	O
8	O
-	O
1	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Multiple	O
soft	O
tissue	O
abscesses	O
appear	O
similar	O
to	O
prior	O
examination	O
with	O
erector	O
spinae	O
abscess	O
on	O
the	O
right	O
,	O
left	O
iliopsoas	O
abscess	O
,	O
and	O
fluid	O
pockets	O
overlying	O
the	O
lower	O
lumbar	O
spine	O
spinous	O
processes	O
.	O
2	O
.	O
Left	O
posterior	O
rotator	O
cuff	O
region	O
possible	O
new	O
abscess	O
,	O
not	O
well	O
seen	O
on	O
prior	O
studies	O
.	O
3	O
.	O
Bilateral	O
basal	O
pulmonary	O
volume	O
loss	O
and	O
consolidation	O
,	O
similar	O
to	O
prior	O
examination	O
in	O
lesion	O
addition	O
to	O
bilateral	O
pleural	O
effusions	O
,	O
more	O
pronounced	O
and	O
somewhat	O
loculated	O
on	O
the	O
right	O
but	O
similar	O
to	O
prior	O
study	O
.	O
4	O
.	O
Nonspecific	O
gallbladder	O
wall	O
thickening	O
.	O
Cholecystitis	O
is	O
not	O
excluded	O
,	O
although	O
the	O
appearance	O
is	O
stable	O
compared	O
to	O
prior	O
examination	O
and	O
has	O
been	O
previously	O
evaluated	O
with	O
ultrasound	O
.	O
5	O
.	O
Nonspecific	O
lesion	O
in	O
the	O
right	O
renal	O
upper	O
pole	O
.	O
This	O
was	O
not	O
well	O
seen	O
on	O
prior	O
examination	O
.	O
If	O
there	O
is	O
clinical	O
suspicion	O
for	O
renal	O
abscess	O
,	O
targeted	O
ultrasound	O
could	O
be	O
performed	O
to	O
further	O
assess	O
.	O
6	O
.	O
Left	O
proximal	O
thigh	O
abscess	O
,	O
incompletely	O
assessed	O
but	O
similar	O
to	O
prior	O
study	O
allowing	O
for	O
difference	O
in	O
technique	O
.	O
7	O
.	O
Splenomegaly	O
.	O
MRI	O
C	O
-	O
Spine	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
IMPRESSION	O
:	O
Again	O
,	O
epidural	O
enhancement	O
and	O
abscesses	O
identified	O
in	O
the	O
anterior	O
cervical	O
region	O
.	O
As	O
described	O
above	O
,	O
the	O
fluid	O
collection	O
around	O
C2	O
-	O
C3	O
level	O
appears	O
slightly	O
increased	O
in	O
thickness	O
,	O
but	O
the	O
differences	O
in	O
measurements	O
are	O
small	O
and	O
this	O
could	O
also	O
be	O
due	O
to	O
partial	O
volume	O
averaging	O
,	O
but	O
continued	O
followup	O
is	O
recommended	O
.	O
Otherwise	O
,	O
the	O
examination	O
is	O
stable	O
MRI	O
T	O
-	O
Spine	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
IMPRESSION	O
:	O
Overall	O
stable	O
appearance	O
of	O
the	O
thoracic	O
spine	O
compared	O
to	O
the	O
previous	O
MRI	O
of	O
[	O
**	O
2135-7-21	O
**	O
]	O
.	O
Again	O
,	O
lower	O
thoracic	O
and	O
upper	O
lumbar	O
laminectomies	O
and	O
epidural	O
enhancement	O
is	O
seen	O
in	O
the	O
thoracic	O
region	O
without	O
epidural	O
abscess	O
.	O
CT	O
Scan	O
Abd	O
/	O
Pelvis	O
(	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
)	O
:	O
with	O
abdominal	O
pain	O
of	O
unclear	O
etiology	O
,	O
look	O
for	O
possible	O
underlying	O
abdominal	O
abscess	O
.	O
COMPARISON	O
:	O
CT	O
torso	O
from	O
[	O
**	O
2135-8-1	O
**	O
]	O
.	O
TECHNIQUE	O
:	O
Non-contrast	O
MDCT	O
of	O
the	O
abdomen	O
.	O
The	O
patient	O
not	O
received	O
any	O
oral	O
or	O
IV	O
contrast	I-Drug
.	O
FINDINGS	O
:	O
Of	O
note	O
,	O
evaluation	O
of	O
abdominal	O
organs	O
is	O
limited	O
without	O
any	O
intravenous	O
or	O
oral	O
contrast	I-Drug
administered	O
.	O
Once	O
again	O
,	O
there	O
are	O
bilateral	O
pleural	O
effusions	O
with	O
overlying	O
collapse	O
/	O
consolidation	O
that	O
has	O
slightly	O
improved	O
from	O
previous	O
study	O
.	O
Once	O
again	O
,	O
the	O
right	O
is	O
significantly	O
greater	O
than	O
the	O
left	O
and	O
appears	O
loculated	O
.	O
A	O
nodular	O
density	O
previously	O
seen	O
in	O
the	O
right	O
middle	O
lobe	O
is	O
not	O
visualized	O
in	O
the	O
current	O
study	O
.	O
CT	O
ABDOMEN	O
W	O
/	O
O	O
Contrast	I-Drug
:	O
There	O
is	O
no	O
focal	O
liver	O
lesion	O
seen	O
.	O
There	O
is	O
evidence	O
of	O
a	O
large	O
stone	O
within	O
the	O
gallbladder	O
;	O
however	O
,	O
there	O
are	O
no	O
signs	O
of	O
gallbladder	O
wall	O
thickening	O
or	O
other	O
associated	O
signs	O
to	O
suggest	O
inflammation	O
or	O
infection	O
.	O
The	O
spleen	O
is	O
enlarged	O
.	O
There	O
is	O
no	O
focal	O
splenic	O
lesion	O
or	O
abscess	O
seen	O
.	O
Pancreas	O
appears	O
normal	O
.	O
Adrenals	O
appear	O
normal	O
.	O
The	O
kidney	O
is	O
normal	O
in	O
appearance	O
.	O
Right	O
kidney	O
appears	O
normal	O
in	O
appearance	O
.	O
The	O
small	O
area	O
of	O
hypoattenuation	O
seen	O
in	O
the	O
left	O
kidney	O
on	O
the	O
previous	O
study	O
was	O
not	O
appreciated	O
on	O
the	O
current	O
exam	O
.	O
Small	O
periaortic	O
and	O
portacaval	O
lymph	O
nodes	O
are	O
again	O
seen	O
,	O
however	O
,	O
they	O
do	O
not	O
meet	O
CT	O
criteria	O
for	O
lymphadenopathy	O
.	O
There	O
is	O
no	O
bowel	O
obstruction	O
.	O
The	O
appendix	O
is	O
normal	O
.	O
There	O
is	O
no	O
significant	O
mesenteric	O
lymphadenopathy	O
or	O
fluid	O
collection	O
seen	O
.	O
CT	O
PELVIS	O
W	O
/	O
O	O
contrast	I-Drug
:	O
Once	O
again	O
seen	O
is	O
a	O
low	O
-	O
attenuation	O
fluid	O
collection	O
in	O
the	O
left	O
iliopsoas	O
muscle	O
,	O
extending	O
from	O
the	O
lower	O
lumbar	O
-	O
upper	O
pelvic	O
regions	O
along	O
the	O
psoas	O
.	O
This	O
collection	O
appears	O
unchanged	O
,	O
both	O
in	O
size	O
and	O
in	O
character	O
and	O
further	O
characterization	O
is	O
limited	O
without	O
contrast	O
.	O
Once	O
again	O
seen	O
are	O
the	O
small	O
areas	O
of	O
low	O
attenuation	O
,	O
representing	O
fluid	O
in	O
the	O
proximal	O
thigh	O
as	O
well	O
as	O
stranding	O
in	O
the	O
left	O
greater	O
trochanter	O
.	O
This	O
appears	O
unchanged	O
from	O
the	O
previous	O
study	O
of	O
[	O
**	O
2135-8-1	O
**	O
]	O
.	O
There	O
is	O
no	O
epidural	O
abscess	O
seen	O
in	O
the	O
thoracic	O
region	O
.	O
The	O
rectum	O
,	O
sigmoid	O
colon	O
,	O
bladder	O
,	O
and	O
uterus	O
are	O
normal	O
.	O
3D	O
reconstructions	O
,	O
coronal	O
and	O
sagittal	O
reconstructions	O
were	O
essential	O
in	O
delineating	O
the	O
anatomy	O
and	O
pathology	O
.	O
BONES	O
:	O
There	O
is	O
no	O
osseous	O
destruction	O
seen	O
.	O
As	O
mentioned	O
,	O
evidence	O
of	O
priorlaminectomies	O
at	O
the	O
lower	O
thoracic	O
spine	O
and	O
upper	O
lumbar	O
spine	O
are	O
seen.There	O
are	O
no	O
epidural	O
collections	O
suggestive	O
of	O
epidural	O
abscess	O
in	O
the	O
lumbaror	O
visualized	O
thoracic	O
spine	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Unchanged	O
left	O
iliopsoas	O
abscess	O
2	O
.	O
Slight	O
interval	O
decrease	O
in	O
bilateral	O
basal	O
pulmonary	O
volume	O
loss	O
and	O
consolidation	O
and	O
pleural	O
effusions	O
.	O
3	O
.	O
Large	O
gallstone	O
within	O
the	O
gallbladder	O
without	O
sign	O
of	O
gallbladder	O
inflammation	O
.	O
4	O
.	O
Unchanged	O
fluid	O
collection	O
in	O
the	O
left	O
proximal	O
thigh	O
compared	O
to	O
prior	O
.	O
5	O
.	O
This	O
study	O
was	O
discussed	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
1169	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
at	O
4:30	O
p.m.	O
on	O
[	O
**	O
2135-8-9	O
**	O
]	O
.	O
.	O
Unilateral	O
upper	O
extremity	O
venous	O
ultrasound	O
.	O
(	O
[	O
**	O
8	O
-	O
17	O
**	O
]	O
)	O
COMPARISON	O
:	O
Upper	O
extremity	O
venous	O
ultrasound	O
[	O
**	O
2135-7-11	O
**	O
]	O
.	O
FINDINGS	O
:	O
Color	O
and	O
grayscale	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1417	O
**	O
]	O
of	O
bilateral	O
subclavian	O
and	O
left	O
-	O
sided	O
internal	O
jugular	O
,	O
basilic	O
,	O
brachial	O
and	O
cephalic	O
vessels	O
were	O
evaluated	O
.	O
Evaluated	O
vessels	O
demonstrated	O
normal	O
flow	O
,	O
compressibility	O
and	O
augmentation	O
.	O
There	O
is	O
a	O
PICC	O
line	O
in	O
the	O
basilic	O
.	O
There	O
is	O
duplication	O
of	O
the	O
brachial	O
vessels	O
.	O
IMPRESSION	O
:	O
PICC	O
in	O
the	O
basilic	O
vein	O
but	O
no	O
DVT	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Ms	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
54	O
yo	O
female	O
with	O
no	O
significant	O
past	O
medical	O
history	O
who	O
initially	O
presented	O
with	O
back	O
pain	O
,	O
urinary	O
retention	O
on	O
[	O
**	O
7	O
-	O
3	O
**	O
]	O
,	O
found	O
to	O
have	O
multiple	O
epidural	O
abscesses	O
s	O
/	O
p	O
multiple	O
surgical	O
debridements	O
with	O
hospital	O
course	O
complicated	O
by	O
episodes	O
of	O
flash	O
pulmonary	O
/	O
respiratory	O
compromise	O
requiring	O
intubation	O
and	O
febrile	B-Ade
neutropenia	I-Ade
secondary	O
to	O
lasix	I-Drug
and	O
vancomycin	I-Drug
administration	O
.	O
.	O
#	O
Bacteremia	I-Reason
/	O
Abscesses	I-Reason
/	O
Antibiotic	I-Drug
therapy	O
.	O
Patient	O
initially	O
presented	O
with	O
back	O
pain	O
,	O
associated	O
urinary	O
retention	O
and	O
LE	O
weakness	O
.	O
Admission	O
imaging	O
positive	O
for	O
cervical	B-Reason
and	I-Reason
lumbar	I-Reason
epidural	I-Reason
abscesses	I-Reason
(	O
though	O
patient	O
with	O
no	O
known	O
risk	O
factors	O
)	O
.	O
She	O
was	O
empirically	O
started	O
on	O
vancomycin	I-Drug
/	O
cefepime	I-Drug
/	O
levofloxacin	I-Drug
.	O
She	O
underwent	O
C2	O
-	O
C6	O
/	O
T12	O
-	O
L2	O
bilateral	O
laminectomies	O
with	O
insertion	O
of	O
4	O
drains	O
on	O
[	O
**	O
2135-7-3	O
**	O
]	O
.	O
She	O
subsequently	O
developed	O
a	O
septic	O
right	O
knee	O
and	O
returned	O
to	O
the	O
OR	O
on	O
[	O
**	O
2135-7-4	O
**	O
]	O
for	O
right	O
knee	O
washout	O
.	O
Regarding	O
further	O
initial	O
infectious	O
work	O
-	O
up	O
at	O
that	O
time	O
:	O
a	O
TEE	O
was	O
obtained	O
which	O
showed	O
no	O
vegetations	O
;	O
CT	O
head	O
without	O
evidence	O
of	O
intracranial	O
abscess	O
.	O
.	O
On	O
[	O
**	O
2135-7-6	O
**	O
]	O
,	O
antibiotic	I-Drug
coverage	O
was	O
narrowed	O
to	O
nafcillin	I-Drug
when	O
cultures	O
from	O
abscesses	B-Reason
,	I-Reason
right	I-Reason
knee	I-Reason
,	O
and	O
blood	B-Reason
grew	I-Reason
MSSA	I-Reason
.	O
However	O
,	O
due	O
to	O
signs	O
and	O
symptoms	O
of	O
leukocytosis	O
,	O
hypoxia	O
there	O
was	O
concern	O
for	O
hospital	B-Reason
acquired	I-Reason
pneumonia	I-Reason
and	O
antibiotic	I-Drug
coverage	O
was	O
broadened	O
to	O
vancomycin	I-Drug
,	O
cefepime	I-Drug
,	O
and	O
ciprofloxacin	I-Drug
on	O
[	O
**	O
7	O
-	O
10	O
**	O
]	O
.	O
Patient	O
remained	O
febrile	O
.	O
Surveillance	O
imaging	O
obtained	O
on	O
[	O
**	O
7	O
-	O
12	O
**	O
]	O
which	O
demonstrated	O
increased	O
epidural	O
collection	O
within	O
anterior	O
cervical	O
epidural	O
space	O
and	O
displacement	O
of	O
the	O
cervical	O
cord	O
.	O
The	O
patient	O
returned	O
to	O
the	O
OR	O
on	O
[	O
**	O
7	O
-	O
13	O
**	O
]	O
for	O
abscess	O
decompression	O
and	O
evacuation	O
and	O
fusion	O
of	O
C3	O
-	O
4	O
,	O
C4	O
-	O
5	O
,	O
and	O
C5	O
-	O
6	O
.	O
After	O
reviewing	O
microbial	O
date	O
with	O
all	O
cultures	O
+	O
MSSA	I-Reason
,	O
her	O
antibiotic	I-Drug
coverage	O
was	O
again	O
narrowed	O
to	O
nafcillin	I-Drug
.	O
.	O
Patient	O
had	O
been	O
doing	O
well	O
with	O
normalized	O
temperature	O
and	O
WBC	O
however	O
four	O
days	O
after	O
starting	O
nafcillin	I-Drug
,	O
developed	O
a	O
abdominal	B-Ade
rash	I-Ade
.	O
Derm	O
was	O
consulted	O
,	O
biopsies	O
were	O
taken	O
which	O
were	O
c	O
/	O
w	O
drug	B-Ade
rash	I-Ade
secondary	O
to	O
nafcillin	I-Drug
.	O
Nafcillin	I-Drug
was	O
subsequently	O
discontinued	O
and	O
replaced	O
by	O
IV	O
vancomycin	I-Drug
.	O
.	O
Repeat	O
MR	O
spine	O
with	O
new	O
paraspinal	O
fluid	O
collections	O
,	O
and	O
mild	O
epidural	O
fluid	O
collection	O
throughout	O
the	O
spine	O
.	O
Due	O
to	O
concern	O
for	O
continued	B-Reason
infection	I-Reason
cefepime	I-Drug
was	O
added	O
to	O
antibiotic	I-Drug
regimen	O
.	O
On	O
[	O
**	O
7	O
-	O
25	O
**	O
]	O
,	O
the	O
patient	O
underwent	O
paraspinal	O
abscess	O
drainage	O
by	O
interventional	O
radiology	O
.	O
Follow	O
-	O
up	O
CT	O
torso	O
was	O
obtained	O
on	O
[	O
**	O
8	O
-	O
1	O
**	O
]	O
due	O
to	O
persistent	B-Ade
fevers	I-Ade
on	O
cefepime	I-Drug
and	O
vanc	I-Drug
;	O
finding	O
were	O
stable	O
to	O
previous	O
imaging	O
and	O
cefepime	I-Drug
was	O
discontinued	O
.	O
On	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
,	O
her	O
C	O
-	O
collar	O
was	O
removed	O
.	O
Surveilance	O
MR	O
C	O
/	O
T	O
-	O
Spine	O
on	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
showed	O
stable	O
epidural	O
enhancement	O
and	O
abscesses	O
identified	O
in	O
the	O
anterior	O
cervical	O
region	O
,	O
thoracic	O
region	O
without	O
epidural	O
abscess	O
.	O
CT	O
scan	O
on	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
demonstrated	O
left	O
iliopsoas	O
abscess	O
/	O
phlegmen	O
and	O
left	O
thigh	O
fluid	O
collection	O
;	O
both	O
of	O
which	O
were	O
too	O
small	O
to	O
be	O
drained	O
by	O
IR	O
.	O
.	O
Unfortunately	O
side	O
effects	O
necessitated	O
further	O
antibiotic	I-Drug
adjustment	O
.	O
CBC	O
with	O
noted	O
leukopenia	I-Ade
on	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
with	O
progression	O
to	O
neutropenia	I-Ade
[	O
**	O
8	O
-	O
8	O
**	O
]	O
.	O
Out	O
of	O
concern	O
that	O
vancomycin	I-Drug
could	O
be	O
contributing	O
to	O
decreasing	O
counts	O
,	O
vanc	I-Drug
d	O
/	O
c	O
'	O
ed	O
and	O
IV	O
daptomycin	I-Drug
started	O
.	O
Per	O
ID	O
will	O
plan	O
to	O
treat	O
MSSA	I-Reason
bacteremia	O
/	O
abscesses	O
with	O
IV	O
daptomycin	I-Drug
to	O
total	O
of	O
6	O
-	O
8wk	O
course	O
.	O
At	O
time	O
of	O
discharge	O
utility	O
of	O
repeat	O
imaging	O
discussed	O
.	O
Plan	O
to	O
repeat	O
CT	O
abd	O
/	O
pelvis	O
;	O
MRI	O
spine	O
further	O
into	O
antibiotic	O
treatment	O
.	O
.	O
#	O
Febrile	O
Neutropenia	O
.	O
Patient	O
's	O
WBC	O
count	O
began	O
to	O
slowly	O
decline	O
on	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
with	O
progression	O
to	O
neutropenia	O
on	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
.	O
Neutropenia	I-Ade
was	O
felt	O
secondary	O
to	O
medication	O
effect	O
;	O
subsequently	O
omeprazole	I-Drug
,	O
furosemide	I-Drug
,	O
vancomycin	I-Drug
and	O
seroquel	I-Drug
were	O
discontinued	O
.	O
Hematology	O
was	O
consulted	O
,	O
and	O
felt	O
that	O
furosemide	I-Drug
or	O
vancomycin	I-Drug
were	O
likely	O
offending	O
agents	O
.	O
Antibiotic	I-Drug
coverage	O
altered	O
on	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
:	O
vancomycin	I-Drug
discontinued	O
and	O
daptomycin	I-Drug
started	O
for	O
treatment	O
of	O
MSSA	I-Reason
.	O
On	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
she	O
was	O
febrile	O
102.6	O
and	O
meropenem	I-Drug
started	O
for	O
treatment	O
of	O
neutropenic	B-Reason
fever	I-Reason
.	O
GCSF	I-Drug
initiated	O
.	O
After	O
administration	O
of	O
GCSF	I-Drug
counts	O
slowly	O
became	O
to	O
rise	O
and	O
fevers	O
abated	O
.	O
GCSF	I-Drug
was	O
stopped	O
on	O
[	O
**	O
8	O
-	O
14	O
**	O
]	O
when	O
ANC	O
>	O
1000	O
for	O
more	O
than	O
48	O
hrs	O
.	O
.	O
Respiratory	O
Distress	O
.	O
On	O
admission	O
patient	O
found	O
to	O
be	O
tachypnic	O
.	O
LENIs	O
negative	O
.	O
On	O
[	O
**	O
7	O
-	O
8	O
**	O
]	O
,	O
developed	O
worsening	O
tachypnea	O
and	O
hypoxemia	O
(	O
95	O
%	O
on	O
4L	O
by	O
nasal	O
canula	O
)	O
.	O
The	O
patient	O
diureased	I-Reason
500	O
ml	O
on	O
IV	O
Lasix	I-Drug
and	O
improved	O
slightly	O
.	O
CTA	O
ruled	O
out	O
PE	O
,	O
however	O
showed	O
evidence	O
of	O
bilateral	O
loculated	O
pleural	O
effusions	O
and	O
multiple	O
lung	O
nodules	O
.	O
Cardiac	O
enzymes	O
negative	O
.	O
Pro-BNP	O
2777	O
on	O
[	O
**	O
7	O
-	O
8	O
**	O
]	O
.	O
Estimated	O
EF	O
by	O
TEE	O
was	O
>	O
55	O
%	O
;	O
2	O
repeat	O
echos	O
without	O
evidence	O
of	O
valvular	O
pathology	O
.	O
In	O
MICU	O
,	O
IV	O
Lasix	I-Drug
and	O
morphine	I-Drug
lessened	O
respiratory	I-Reason
distress	O
.	O
On	O
[	O
**	O
7	O
-	O
10	O
**	O
]	O
,	O
transferred	O
to	O
the	O
floor	O
;	O
latered	O
became	O
hypoxic	O
and	O
was	O
transfered	O
back	O
to	O
the	O
MICU	O
and	O
started	O
on	O
BiPAP	O
.	O
Pleural	O
effusion	O
studies	O
suggested	O
parapneumonic	O
effusion	O
.	O
Patient	O
intubated	O
and	O
extubated	O
several	O
time	O
while	O
in	O
MICU	O
.	O
On	O
[	O
**	O
7	O
-	O
16	O
**	O
]	O
,	O
the	O
patient	O
was	O
again	O
extubated	O
.	O
She	O
developed	O
hypertension	O
to	O
180	O
SBP	O
and	O
respiratory	B-Reason
distress	I-Reason
secondary	I-Reason
to	I-Reason
pulm	O
edema	O
,	O
which	O
responded	O
to	O
lasix	I-Drug
and	O
labetolol	I-Drug
.	O
On	O
[	O
**	O
7	O
-	O
19	O
**	O
]	O
,	O
she	O
was	O
comfortable	O
oxygenating	O
with	O
only	O
nasal	O
cannula	O
.	O
She	O
was	O
electively	O
intubated	O
on	O
[	O
**	O
7	O
-	O
25	O
**	O
]	O
for	O
paraspinal	O
abscess	O
drainage	O
and	O
extubated	O
post-procedure	O
.	O
Unfortunately	O
,	O
again	O
developed	O
worsening	O
hypercarbic	O
respiratory	O
distress	O
,	O
requiring	O
reintubation	O
on	O
[	O
**	O
7	O
-	O
27	O
**	O
]	O
.	O
She	O
was	O
gently	O
diuresed	O
,	O
in	O
an	O
effort	O
to	O
decrease	O
the	O
work	O
of	O
breathing	O
.	O
On	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
she	O
was	O
succesfully	O
extubated	O
,	O
satting	O
well	O
on	O
face	O
mask	O
.	O
On	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
she	O
was	O
weaned	O
to	O
NC	O
.	O
CT	O
on	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
showed	O
improvement	O
in	O
pleural	O
effusions	O
and	O
basilar	O
consolidations	O
.	O
She	O
continued	O
to	O
do	O
well	O
on	O
supplemental	O
oxygen	I-Drug
by	O
nasal	O
cannula	O
.	O
On	O
the	O
floor	O
her	O
oxygen	O
requirement	O
was	O
weaned	O
.	O
She	O
had	O
one	O
episode	O
of	O
flash	B-Reason
pulmonary	I-Reason
edema	I-Reason
,	O
during	O
which	O
she	O
desaturated	O
to	O
high	O
80s	O
.	O
She	O
was	O
diuresed	I-Reason
with	O
bumex	I-Drug
with	O
good	O
effect	O
.	O
For	O
the	O
remainder	O
of	O
her	O
stay	O
,	O
team	O
allowed	O
for	O
auto	O
-	O
diuresis	O
.	O
At	O
time	O
of	O
discharge	O
patient	O
saturating	O
94	O
%	O
RA	O
,	O
>	O
95	O
%	O
1L	O
.	O
.	O
#	O
Blood	O
Pressure	O
.	O
During	O
MICU	O
stay	O
pt	O
had	O
repeated	O
episodes	O
of	O
transient	O
bradycardia	O
and	O
hypotension	O
as	O
well	O
as	O
episodes	O
of	O
paroxysmal	O
hypertension	O
into	O
the	O
SBP	O
180	O
-	O
200s	O
.	O
Her	O
hypertension	I-Reason
responded	O
to	O
5mg	O
-	O
10	O
mg	O
doses	O
of	O
IV	O
labetalol	I-Drug
.	O
After	O
significiant	O
diuresis	O
,	O
her	O
SBP	O
remained	O
stable	O
in	O
the	O
150	O
-	O
160s	O
.	O
On	O
the	O
floor	O
,	O
BP	B-Reason
ran	I-Reason
consistently	O
high	O
.	O
Patient	O
was	O
started	O
on	O
metoprolol	I-Drug
and	O
amlodipine	I-Drug
.	O
These	O
medications	O
were	O
gradually	O
uptitrated	O
and	O
at	O
time	O
of	O
discharge	O
pressures	O
were	O
better	O
controlled	O
on	O
metoprolol	I-Drug
50	O
mg	O
TID	O
,	O
amlopidine	I-Drug
10	O
mg	O
QD	O
.	O
She	O
was	O
transitioned	O
to	O
toprol	I-Drug
xl	O
150	O
mg	O
daily	O
at	O
the	O
time	O
of	O
discharge	O
.	O
.	O
#	O
Nutrition	O
.	O
Patient	O
underwent	O
severeal	O
video	O
swallowing	O
evaluation	O
due	O
to	O
concern	O
for	O
silent	O
aspiration	O
.	O
In	O
the	O
MICU	O
,	O
several	O
methods	O
of	O
nutrition	O
employed	O
:	O
NG	O
tube	O
feeds	O
as	O
well	O
as	O
PPN	O
.	O
On	O
transfer	O
to	O
floor	O
patient	O
on	O
NG	O
tube	O
feeds	O
.	O
Repeat	O
speech	O
and	O
swallow	O
on	O
[	O
**	O
8	O
-	O
15	O
**	O
]	O
demonstrated	O
improved	O
oral	O
and	O
pharyngeal	O
swallow	O
with	O
continued	O
swallow	O
delay	O
,	O
premature	O
spillover	O
and	O
reduced	O
base	O
of	O
tongue	O
retraction	O
.	O
Patient	O
continued	O
to	O
aspirate	O
thin	O
liquids	O
silently	O
,	O
but	O
speech	O
deemed	O
it	O
safe	O
to	O
initiate	O
a	O
PO	O
diet	O
of	O
nectar	O
thick	O
liquids	O
and	O
moist	O
,	O
ground	O
solids	O
with	O
the	O
aspiration	O
precautions	O
documented	O
below	O
.	O
It	O
is	O
important	O
to	O
note	O
aspiration	O
is	O
silent	O
,	O
and	O
she	O
will	O
need	O
continued	O
speech	O
therapy	O
follow	O
up	O
with	O
likely	O
repeat	O
video	O
swallow	O
before	O
advancing	O
her	O
diet	O
.	O
#	O
Delirium	I-Reason
.	O
In	O
the	O
MICU	O
observed	O
waxing	O
and	O
[	O
**	O
Doctor	O
Last	O
Name	O
688	O
**	O
]	O
mental	O
status	O
worse	O
at	O
night	O
and	O
with	O
spikes	O
in	O
fever	O
.	O
Symptoms	O
improved	O
with	O
zyprexa	I-Drug
at	O
night	O
.	O
The	O
pt	O
became	O
more	O
alert	O
following	O
extubation	O
on	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
,	O
however	O
,	O
she	O
had	O
some	O
disorientation	I-Reason
.	O
She	O
received	O
several	O
doses	O
of	O
seroquel	I-Drug
,	O
which	O
was	O
discontinued	O
when	O
the	O
patient	O
became	O
neutropenic	I-Ade
,	O
as	O
it	O
can	O
be	O
a	O
potential	O
cause	O
of	O
leukopenia	I-Ade
.	O
Over	O
the	O
course	O
of	O
the	O
next	O
few	O
days	O
,	O
her	O
became	O
more	O
alert	O
and	O
interactive	O
.	O
By	O
time	O
of	O
transfer	O
from	O
MICU	O
to	O
floor	O
on	O
[	O
**	O
8	O
-	O
10	O
**	O
]	O
,	O
she	O
was	O
fully	O
oriented	O
and	O
had	O
a	O
good	O
understanding	O
of	O
the	O
medical	O
plan	O
.	O
On	O
the	O
floor	O
,	O
patients	O
mentation	O
continued	O
to	O
improve	O
.	O
At	O
time	O
of	O
discharge	O
patient	O
mental	O
status	O
was	O
clear	O
and	O
coherent	O
.	O
.	O
#	O
Elbow	O
mass	O
.	O
Mass	O
noted	O
on	O
right	O
elbow	O
.	O
Derm	O
consulted	O
;	O
felt	O
to	O
be	O
consistent	O
with	O
lipoma	O
.	O
.	O
#	O
UTI	I-Reason
:	O
She	O
developed	O
low	O
grade	O
fevers	O
on	O
[	O
**	O
8	O
-	O
21	O
**	O
]	O
to	O
100.4	O
,	O
prompting	O
urinalysis	O
,	O
which	O
demonstrated	O
UTI	O
.	O
She	O
will	O
complete	O
a	O
10	O
day	O
course	O
of	O
ciprofloxacin	I-Drug
500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
end	O
[	O
**	O
2135-9-1	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
None	O
Discharge	O
Medications	O
:	O
.	O
1	O
.	O
Fentanyl	I-Drug
25	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
.	O
2	O
.	O
Amlodipine	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Daptomycin	I-Drug
500	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
Six	O
Hundred	O
(	O
600	O
)	O
Recon	O
Soln	O
Intravenous	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
4	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
/	O
pain	I-Reason
.	O
6	O
.	O
Metoprolol	I-Drug
Tartrate	O
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Heparin	I-Drug
Flush	O
(	O
10	O
units	O
/	O
ml	O
)	O
2	O
mL	O
IV	O
PRN	O
line	B-Reason
flush	I-Reason
PICC	O
,	O
heparin	I-Drug
dependent	O
:	O
Flush	O
with	O
10mL	O
Normal	B-Drug
Saline	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
daily	O
and	O
PRN	O
per	O
lumen	O
.	O
8	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
check	O
weekly	O
CBC	O
with	O
differential	O
,	O
BUN	O
/	O
Cr	O
,	O
LFTs	O
,	O
CK	O
,	O
ESR	O
/	O
CRP	O
.	O
All	O
laboratory	O
results	O
should	O
be	O
faxed	O
to	O
Infectious	O
disease	O
R.Ns	O
.	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1353	O
**	O
]	O
9	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
12	O
.	O
OXYGEN	I-Drug
At	O
time	O
of	O
discharge	O
patient	O
requires	O
1L	O
nasal	O
cannula	O
for	O
comfort	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
105	O
**	O
]	O
Northeast	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1110	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
Methicillin	O
Sensitive	O
Staph	O
Aureus	O
Bacteremia	O
SECONDARY	O
Hypertension	O
Anemia	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
it	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
.	O
.	O
You	O
were	O
initially	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
due	O
to	O
symptoms	O
of	O
back	O
pain	O
.	O
Upon	O
imaging	O
it	O
was	O
found	O
that	O
you	O
had	O
several	O
abscesses	O
throughout	O
your	O
spine	O
as	O
well	O
as	O
in	O
your	O
right	O
knee	O
.	O
You	O
underwent	O
several	O
surgeries	O
to	O
evacuate	O
these	O
infection	I-Reason
and	O
you	O
were	O
also	O
started	O
on	O
antibiotics	I-Drug
.	O
Your	O
antibiotic	I-Drug
regimen	O
was	O
altered	O
several	O
times	O
due	O
to	O
significant	O
side	O
effects	O
.	O
You	O
experienced	O
a	O
rash	I-Ade
after	O
Nafcillin	I-Drug
,	O
and	O
Vancomyocin	I-Drug
was	O
thought	O
to	O
contribute	O
to	O
low	B-Ade
cell	I-Ade
counts	I-Ade
.	O
You	O
were	O
placed	O
on	O
Daptomycin	I-Drug
without	O
side	O
effect	O
for	O
a	O
planned	O
8week	O
course	O
.	O
A	O
PICC	O
line	O
was	O
placed	O
prior	O
to	O
discharge	O
to	O
faciliate	O
antibiotic	I-Drug
administration	O
as	O
an	O
outpatient	O
.	O
You	O
will	O
receive	O
repeat	O
imaging	O
after	O
completion	O
of	O
your	O
antibiotic	I-Drug
therapy	O
for	O
interval	O
evaluation	O
of	O
infection	I-Reason
.	O
.	O
Unfortunately	O
,	O
side	O
effects	O
from	O
various	O
medications	O
prolonged	O
your	O
hospital	O
course	O
.	O
It	O
was	O
thought	O
that	O
a	O
combination	O
of	O
vancomycin	I-Drug
and	O
lasix	I-Drug
contributed	O
to	O
decreased	B-Ade
white	I-Ade
blood	I-Ade
cells	I-Ade
(	O
WBC	O
)	O
.	O
While	O
your	O
WBC	B-Reason
counts	I-Reason
were	I-Reason
low	I-Reason
you	O
were	O
placed	O
on	O
broad	O
spectrum	O
antibiotics	I-Drug
to	B-Reason
protect	I-Reason
you	I-Reason
from	I-Reason
infection	I-Reason
.	O
We	O
discontinued	O
the	O
medications	O
we	O
felt	O
responsible	O
for	O
declining	I-Ade
counts	O
(	O
lasix	I-Drug
and	O
vancomycin	I-Drug
)	O
and	O
also	O
administered	O
a	O
medication	O
called	O
Neupogen	I-Drug
to	B-Reason
increase	I-Reason
WBC	I-Reason
production	I-Reason
.	O
After	O
several	O
days	O
of	O
Neupogen	I-Drug
treatment	O
your	O
white	O
cell	O
counts	O
increased	O
and	O
stabilized	O
.	O
Neupogen	I-Drug
as	O
well	O
as	O
broad	O
spectrum	O
antibiotics	I-Drug
were	O
discontinued	O
prior	O
to	O
discharge	O
.	O
.	O
We	O
also	O
found	O
your	O
blood	O
pressures	O
to	O
be	O
elevated	O
at	O
times	O
during	O
your	O
hospitalization	O
.	O
You	O
were	O
started	O
on	O
medications	O
,	O
metoprolol	I-Drug
and	O
amlodipine	I-Drug
,	O
to	B-Reason
better	I-Reason
control	I-Reason
your	I-Reason
blood	I-Reason
pressure	O
.	O
.	O
Regarding	O
nutrition	O
,	O
after	O
extubation	O
you	O
were	O
noted	O
to	O
have	O
difficultly	O
swallowing	O
.	O
Speech	O
and	O
swallow	O
was	O
consulted	O
and	O
after	O
several	O
attempts	O
you	O
completed	O
and	O
passed	O
your	O
evaluation	O
.	O
After	O
completion	O
,	O
you	O
were	O
started	O
on	O
a	O
thickened	O
nectar	O
liquid	O
regimen	O
and	O
a	O
soft	O
,	O
ground	O
solid	O
diet	O
.	O
You	O
will	O
need	O
repeat	O
speech	O
and	O
swallow	O
evaluation	O
at	O
rehab	O
.	O
.	O
CHANGES	O
TO	O
YOUR	O
MEDICATIONS	O
.	O
On	O
arrival	O
to	O
the	O
hospital	O
you	O
were	O
no	O
prescription	O
medications	O
.	O
.	O
MEDICATIONS	O
WE	O
STARTED	O
.	O
--	O
To	O
treat	O
your	O
infection	O
we	O
STARTED	O
Daptomycin	I-Drug
600	O
mg	O
IV	O
Q24	O
(	O
start	O
date	O
:	O
[	O
**	O
2135-7-26	O
**	O
]	O
,	O
stop	O
date	O
:	O
[	O
**	O
2135-9-19	O
**	O
]	O
(	O
total	O
8	O
weeks	O
)	O
)	O
.	O
--	O
To	O
treat	O
PAIN	I-Reason
we	O
STARTED	O
:	O
1	O
.	O
FENTANYL	I-Drug
25	O
mcg	O
/	O
hr	O
Patch	O
,	O
which	O
can	O
be	O
reapplied	O
every	O
72	O
hr	O
;	O
2	O
.	O
Two	O
LIDOCAINE	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patchs	O
,	O
Apply	O
each	O
Adhesive	O
Patch	O
daily	O
to	O
back	O
3	O
.	O
ACETAMINOPHEN	B-Drug
325	O
mg	O
Tablet	O
;	O
you	O
can	O
take	O
1	O
-	O
2	O
tablets	O
by	O
mouth	O
every	O
6	O
hours	O
.	O
.	O
--	O
To	O
treat	O
your	O
high	B-Reason
blood	I-Reason
pressure	I-Reason
we	O
started	O
:	O
1	O
.	O
AMLODIPINE	I-Drug
10	O
mg	O
daily	O
;	O
you	O
will	O
take	O
two	O
5	O
mg	O
tablets	O
daily	O
2	O
.	O
Metoprolol	B-Drug
succinate	I-Drug
(	O
toprol	O
XL	O
)	O
150	O
mg	O
tablet	O
daily	O
.	O
--	O
To	O
prevent	B-Reason
blood	I-Reason
clot	I-Reason
formation	I-Reason
while	O
you	O
heal	O
and	O
are	O
relatively	O
limited	O
in	O
your	O
movement	O
you	O
will	O
continue	O
to	O
receive	O
:	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Injections	O
three	O
times	O
a	O
day	O
.	O
--	O
To	O
help	O
treat	O
your	O
anxiety	I-Reason
we	O
started	O
:	O
1	O
.	O
Lorazepam	B-Drug
0.5	O
mg	O
Tablet	O
,	O
you	O
can	O
take	O
one	O
0.5	O
tablet	O
by	O
mouth	O
at	O
at	O
bedtime	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
.	O
You	O
will	O
need	O
Outpatient	O
Lab	O
Work	O
which	O
your	O
facility	O
can	O
obtain	O
and	O
fax	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
.	O
New	O
allergies	O
:	O
LASIX	I-Drug
-	O
contraindication	O
-	O
neutropenia	I-Ade
NAFCILLIN	I-Drug
-	O
contraindication	O
-	O
rash	I-Ade
VANCOMYCIN	I-Drug
(	O
relative	O
contraindication	O
)	O
-	O
neutropenia	I-Ade
Followup	O
Instructions	O
:	O
Department	O
:	O
INFECTIOUS	O
DISEASE	O
When	O
:	O
FRIDAY	O
[	O
**	O
2135-9-16	O
**	O
]	O
at	O
11:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
27625	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
457	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Bldg	O
(	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
[	O
**	O
Hospital	O
1422	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O

Admission	O
Date	O
:	O
[	O
**	O
2196-7-30	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2196-8-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2140-3-19	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
458	O
**	O
]	O
Chief	O
Complaint	O
:	O
Chest	O
pain	O
,	O
diaphoresis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Cardiac	O
catheterization	O
with	O
thrombectomy	O
and	O
3.0	O
x23	O
mm	O
Cypher	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
to	O
proximal	O
LAD	O
History	O
of	O
Present	O
Illness	O
:	O
56yoF	O
PMH	O
of	O
htn	O
,	O
DMII	O
,	O
dyslipidemia	O
,	O
presented	O
to	O
[	O
**	O
Hospital1	O
6591	O
**	O
]	O
afternoon	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
with	O
a	O
chief	O
complaint	O
of	O
sudden	O
onset	O
substernal	B-Reason
chest	I-Reason
pain	I-Reason
on	I-Reason
extertion	I-Reason
.	O
On	O
arrival	O
,	O
to	O
the	O
OSH	O
,	O
an	O
EKG	O
was	O
performed	O
which	O
deomonstrated	O
ST	O
depressions	O
in	O
II	O
,	O
III	O
,	O
AVF	O
and	O
ST	O
elevations	O
V1	O
-	O
V4	O
.	O
She	O
was	O
given	O
asa	I-Drug
,	O
nitrogliceryn	I-Drug
,	O
integrelin	I-Drug
and	O
heparin	I-Drug
and	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
catheterization	O
.	O
.	O
In	O
the	O
cath	O
lab	O
,	O
the	O
patient	O
was	O
shown	O
to	O
have	O
a	O
thrombotic	O
subtotal	O
occlusion	O
of	O
the	O
LAD	O
at	O
the	O
Septal	O
-	O
1	O
branch	O
.	O
Thrombectomy	O
was	O
performed	O
and	O
a	O
3.0	O
x23mm	O
Cypher	O
[	O
**	O
Hospital1	O
**	O
]	O
was	O
placed	O
in	O
the	O
proximal	O
LAD	O
with	O
good	O
flow	O
documented	O
post	O
procedure	O
.	O
Given	O
40	O
mg	O
IV	O
lasix	I-Drug
for	O
PCWP	O
>	O
30	O
.	O
The	O
patient	O
had	O
been	O
nauseated	O
but	O
this	O
seemed	O
to	O
increase	O
post	O
cath	O
,	O
with	O
several	O
episodes	O
of	O
emesis	O
.	O
The	O
patient	O
was	O
given	O
300	O
mg	O
of	O
plavix	I-Drug
as	O
concern	O
that	O
pt	O
vomited	O
up	O
plavix	I-Drug
load	O
from	O
prior	O
to	O
cath	O
.	O
While	O
initially	O
clear	O
,	O
the	O
emesis	O
was	O
noted	O
to	O
become	O
blood	O
tinged	O
after	O
several	O
bouts	O
in	O
cath	O
lab	O
.	O
.	O
On	O
arrival	O
to	O
CCU	O
post-cath	O
,	O
vitals	O
were	O
BP	O
111/93	O
,	O
hr	O
86	O
and	O
a	O
temp	O
of	O
95.6	O
.	O
The	O
patient	O
was	O
nauseated	O
w	O
/	O
hemoptemesis	O
x2	O
.	O
She	O
was	O
oriented	O
x3	O
.	O
An	O
NGT	O
was	O
placed	O
and	O
gastric	O
lavage	O
with	O
1	O
L	O
of	O
saline	I-Drug
showed	O
blood	O
,	O
which	O
cleared	O
to	O
pink	O
/	O
blood	O
tinged	O
by	O
last	O
aliquot	O
.	O
Past	O
Medical	O
History	O
:	O
Hypertension	O
Dyslipidemia	O
Cerebral	O
Anuresym	O
s	O
/	O
p	O
Clipping	O
?	O
Deaf	O
in	O
right	O
ear	O
.	O
CVA	I-Reason
-	O
~	O
[	O
**	O
2177	O
**	O
]	O
,	O
embolic	O
?	O
,	O
was	O
on	O
coumadin	I-Drug
for	O
"	O
7	O
years	O
"	O
Gastritis	I-Reason
-	O
pt	O
reports	O
"	O
acid	I-Drug
pill	O
"	O
in	O
past	O
,	O
denies	O
EGD	O
Social	O
History	O
:	O
Patient	O
lives	O
at	O
home	O
with	O
husband	O
,	O
semi-retired	O
,	O
worked	O
at	O
[	O
**	O
Name	O
(	O
NI	O
)	O
67736	O
**	O
]	O
.	O
Occassional	O
etoh	O
use	O
,	O
+	O
tobacco	O
1	O
pack	O
per	O
day	O
for	O
20	O
years	O
.	O
Family	O
History	O
:	O
Mother	O
had	O
DM	O
,	O
father	O
had	O
CA	O
,	O
aunt	O
died	O
of	O
MI	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T98	O
,	O
BP	O
98/60	O
,	O
HR	O
90	O
,	O
RR	O
16	O
,	O
98	O
%	O
6l	O
Gen	O
:	O
WDWN	O
middle	O
aged	O
femaile	O
NAD	O
,	O
resp	O
or	O
otherwise	O
.	O
Oriented	O
x3	O
but	O
was	O
intermittently	O
confused	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
CV	O
:	O
PMI	O
located	O
in	O
5th	O
intercostal	O
space	O
,	O
midclavicular	O
line	O
.	O
RR	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
S4	O
,	O
no	O
S3	O
.	O
Chest	O
:	O
mild	O
crackles	O
bil	O
,	O
resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
No	O
crackles	O
,	O
wheeze	O
,	O
rhonchi	O
.	O
Abd	O
:	O
Obese	O
,	O
soft	O
,	O
NTND	O
,	O
No	O
HSM	O
or	O
tenderness	O
.	O
No	O
abdominial	O
bruits	O
.	O
Ext	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
R	O
groin	O
site	O
with	O
oozing	O
,	O
no	O
sig	O
hematoma	O
.	O
Skin	O
:	O
No	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
scars	O
,	O
or	O
xanthomas	O
.	O
Pulses	O
:	O
Right	O
:	O
Carotid	O
2	O
+	O
without	O
bruit	O
;	O
Femoral	O
2	O
+	O
without	O
bruit	O
;	O
2	O
+	O
DP	O
Left	O
:	O
Carotid	O
2	O
+	O
without	O
bruit	O
;	O
Femoral	O
2	O
+	O
without	O
bruit	O
;	O
2	O
+	O
DP	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
WBC	O
-	O
16.1	O
*	O
RBC	O
-	O
3.78	O
*	O
HGB	O
-	O
12.2	O
HCT	O
-	O
35.1	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
12.9	O
PT	O
-	O
14.8	O
*	O
PTT	O
-	O
94.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
706	O
*	O
CALCIUM	O
-	O
8.9	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
GLUCOSE	O
-	O
241	O
*	O
CREAT	O
-	O
1.0	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
3.1	O
*	O
CHLORIDE	O
-	O
103	O
TOTAL	O
CO2	O
-	O
26	O
ANION	O
GAP	O
-	O
14	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
WBC	O
-	O
16.1	O
*	O
RBC	O
-	O
3.78	O
*	O
Hgb	O
-	O
12.2	O
Hct	O
-	O
35.1	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
12.9	O
Plt	O
Ct	O
-	O
84	O
*	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
Neuts	O
-	O
85.2	O
*	O
Lymphs	O
-	O
12.3	O
*	O
Monos	O
-	O
1.5	O
*	O
Eos	O
-	O
0.8	O
Baso	O
-	O
0.2	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
PT	O
-	O
14.8	O
*	O
PTT	O
-	O
94.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
Plt	O
Smr	O
-	O
LOW	O
Plt	O
Ct	O
-	O
84	O
*	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
Glucose	O
-	O
241	O
*	O
Creat	O
-	O
1.0	O
Na	O
-	O
140	O
K	O
-	O
3.1	O
*	O
Cl	O
-	O
103	O
HCO3	O
-	O
26	O
AnGap	O
-	O
14	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
ALT	O
-	O
24	O
AST	O
-	O
77	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
221	O
CK	O
(	O
CPK	O
)	O
-	O
706	O
*	O
AlkPhos	O
-	O
83	O
TotBili	O
-	O
0.3	O
[	O
**	O
2196-7-30	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
362	O
*	O
MB	O
Indx	O
-	O
9.9	O
*	O
cTropnT	O
-	O
6.09	O
*	O
[	O
**	O
2196-7-30	O
**	O
]	O
03:02	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
4.8	O
*	O
Mg	O
-	O
1.6	O
[	O
**	O
2196-7-30	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
Cholest	O
-	O
202	O
*	O
[	O
**	O
2196-7-30	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
Triglyc	O
-	O
113	O
HDL	O
-	O
49	O
CHOL	O
/	O
HD	O
-	O
4.1	O
LDLcalc	O
-	O
130	O
*	O
LDLmeas	O
-	O
131	O
*	O
.	O
.	O
PERTINENT	O
LABS	O
/	O
STUDIES	O
:	O
WBC	O
:	O
16.1	O
(	O
[	O
**	O
7	O
-	O
30	O
**	O
]	O
)	O
-	O
>	O
13.2	O
-	O
>	O
12.0	O
-	O
>	O
10.5	O
-	O
>	O
9.0	O
-	O
>	O
9.1	O
-	O
>	O
8.9	O
(	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
)	O
Hct	O
:	O
35.1	O
(	O
[	O
**	O
7	O
-	O
30	O
**	O
]	O
)	O
-	O
>	O
35.6	O
-	O
>	O
31.4	O
-	O
>	O
28.9	O
-	O
>	O
30.5	O
-	O
>	O
28.7	O
-	O
>	O
28.5	O
(	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
)	O
Glucose	O
:	O
241	O
(	O
[	O
**	O
7	O
-	O
30	O
**	O
]	O
)	O
-	O
>	O
119	O
(	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
)	O
CK	O
:	O
706	O
(	O
[	O
**	O
7	O
-	O
30	O
**	O
]	O
)	O
-	O
>	O
3654	O
-	O
>	O
3306	O
-	O
>	O
1510	O
(	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
)	O
CK	O
-	O
MB	O
:	O
362	O
(	O
[	O
**	O
7	O
-	O
30	O
**	O
]	O
)	O
-	O
>	O
278	O
-	O
>	O
46	O
(	O
[	O
**	O
7	O
-	O
31	O
**	O
]	O
)	O
TnI	O
:	O
6.09	O
-	O
>	O
8.57	O
-	O
>	O
4.50	O
ALT	O
24	O
,	O
AST	O
77	O
,	O
LDH	O
221	O
,	O
AP	O
83	O
,	O
Tbili	O
0.3	O
HbA1c	O
:	O
6.4	O
%	O
Cholesterol	O
202	O
,	O
Triglycerides	O
113	O
,	O
HDL	O
49	O
,	O
LDL	O
130	O
TSH	O
0.66	O
EKG	O
:	O
nsr	O
,	O
rate	O
87	O
,	O
nl	O
axis	O
,	O
nl	O
intervals	O
,	O
p	O
waves	O
enlarged	O
,	O
poor	O
r	O
wave	O
progression	O
precordial	O
leads	O
,	O
st	O
-	O
elevations	O
anterior	O
.	O
.	O
CARDIAC	O
CATH	O
[	O
**	O
2196-7-30	O
**	O
]	O
:	O
R	O
dominant	O
,	O
single	O
vessel	O
coronary	O
artery	O
disease	O
.	O
LMCA	O
no	O
apparent	O
flow	O
-	O
limiting	O
dz	O
.	O
LAD	O
had	O
thrombotic	O
subtotal	O
occlusion	O
near	O
the	O
Septal	O
-	O
1	O
branch	O
,	O
TIMI	O
II	O
flow	O
in	O
LAD	O
.	O
Small	O
D1	O
had	O
80	O
%	O
ostial	O
stenosis	O
.	O
LCx	O
and	O
RCA	O
had	O
minimal	O
luminal	O
irregularities	O
.	O
Mildly	O
elevated	O
R	O
-	O
sided	O
filling	O
pressure	O
with	O
RVEDP	O
15	O
mmHg	O
and	O
elevated	O
left	O
sided	O
filling	O
pressure	O
PCWP	O
35	O
mmHg	O
.	O
Mild	O
pulmonary	O
arterial	O
hypertension	O
with	O
a	O
PA	O
pressure	O
of	O
44/32	O
mmHg	O
.	O
Central	O
aortic	O
pressure	O
was	O
131/89	O
mmHg	O
.	O
The	O
cardiac	O
index	O
was	O
low	O
at	O
1.8	O
L	O
/	O
min	O
/	O
m2	O
.	O
3	O
.	O
Successful	O
manual	O
thrombectomy	O
and	O
placement	O
of	O
a	O
3.0	O
x23mm	O
Cypher	O
drug	O
-	O
eluting	O
stent	O
were	O
performed	O
in	O
the	O
proximal	O
LAD	O
.	O
Final	O
angiography	O
showed	O
TIMI	O
III	O
flow	O
,	O
no	O
apparent	O
dissection	O
,	O
and	O
no	O
residual	O
stenosis	O
.	O
(	O
See	O
PTCA	O
comments	O
)	O
1	O
.	O
Single	O
vessel	O
coronary	O
artery	O
disease	O
.	O
2	O
.	O
Severe	O
left	O
ventricular	O
diastolic	O
dysfunction	O
.	O
3	O
.	O
Mild	O
pulmonary	O
arterial	O
hypertension	O
.	O
4	O
.	O
Mild	O
right	O
ventricular	O
diastolic	O
dysfunction	O
.	O
5	O
.	O
Reduced	O
cardiac	O
index	O
.	O
6	O
.	O
Placement	O
of	O
a	O
drug	O
-	O
eluting	O
stent	O
in	O
the	O
proximal	O
LAD	O
.	O
.	O
ECHO	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
moderate	O
to	O
severe	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
consistent	O
with	O
proximal	O
LAD	O
coronary	O
disease	O
.	O
Depressed	O
cardiac	O
index	O
.	O
Moderate	O
diastolic	O
dysfunction	O
.	O
Preserved	O
right	O
ventricular	O
systolic	O
function	O
.	O
Mild	O
pulmonary	O
hypertension	O
.	O
.	O
.	O
DISCHARGE	O
LABS	O
:	O
CBC	O
:	O
WBC	O
8.9	O
,	O
Hgb	O
10.2	O
,	O
Hct	O
28.7	O
,	O
Plt	O
202	O
Gluc	O
119	O
,	O
Na	O
141	O
,	O
K	O
4.0	O
,	O
Cl	O
107	O
,	O
HCO3	O
25	O
,	O
BUN	O
20	O
,	O
Cr	O
0.9	O
CK	O
1510	O
CK	O
-	O
MB	O
46	O
,	O
TnI	O
4.5	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
is	O
a	O
56	O
year	O
old	O
female	O
with	O
a	O
history	O
of	O
hypertension	O
,	O
dyslipidemia	O
,	O
cerebral	O
aneurysm	O
clip	O
presented	O
with	O
STEMI	O
,	O
had	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
**	O
]	O
placed	O
in	O
[	O
**	O
Hospital	O
54969	O
**	O
]	O
transferred	O
to	O
CCU	O
with	O
course	O
complicated	O
by	O
post-procedure	O
bloody	O
vomitus	O
with	O
need	O
for	O
Plavix	I-Drug
reload	O
,	O
was	O
tachycardic	O
into	O
the	O
100	O
's	O
overnight	O
.	O
.	O
#	O
CAD	O
/	O
ischemia	O
:	O
Patient	O
presented	O
to	O
the	O
hospital	O
with	O
substernal	O
chest	O
pain	O
on	O
exertion	O
.	O
Patient	O
was	O
found	O
to	O
have	O
ST	O
depressions	O
in	O
II	O
,	O
III	O
,	O
AVF	O
and	O
ST	O
elevations	O
V1	O
-	O
V4	O
.	O
Patient	O
was	O
sent	O
to	O
the	O
cath	O
lab	O
,	O
where	O
she	O
had	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
placed	O
in	O
the	O
LAD	O
territory	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
remained	O
persistently	O
tachycardic	I-Reason
.	O
She	O
was	O
given	O
multiple	O
doses	O
of	O
Metoprolol	I-Drug
IV	O
and	O
was	O
started	O
on	O
Toprol	I-Drug
XL	O
50	O
mg	O
,	O
to	O
which	O
her	O
pulse	O
decreased	O
.	O
Patient	O
was	O
started	O
on	O
Atorvastatin	I-Drug
80	O
mg	O
daily	O
,	O
ASA	I-Drug
325	O
mg	O
daily	O
,	O
Captopril	I-Drug
6.25	O
mg	O
TID	O
,	O
and	O
Plavix	I-Drug
75	O
mg	O
daily	O
.	O
She	O
was	O
discharged	O
on	O
2.5	O
mg	O
Lisinopril	I-Drug
daily	O
.	O
Patient	O
did	O
not	O
have	O
any	O
acute	O
events	O
relating	O
to	O
her	O
CAD	O
while	O
she	O
was	O
in	O
the	O
hospital	O
,	O
and	O
she	O
will	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
79466	O
**	O
]	O
on	O
[	O
**	O
2196-8-9	O
**	O
]	O
.	O
Please	O
consider	O
checking	O
homocysteine	O
level	O
as	O
an	O
outpatient	O
.	O
.	O
#	O
Hematemesis	O
:	O
Patient	O
reported	O
nausea	O
at	O
time	O
of	O
chest	O
pain	O
.	O
Upon	O
admission	O
to	O
CCU	O
,	O
patient	O
denied	O
chest	O
pain	O
but	O
had	O
three	O
episodes	O
of	O
bloody	O
vomitus	O
(	O
quantity	O
<	O
40cc	O
each	O
episode	O
)	O
.	O
NG	O
lavage	O
showed	O
red	O
blood	O
on	O
drawback	O
.	O
Integrilin	I-Drug
was	O
held	O
,	O
but	O
the	O
patient	O
continued	O
to	O
receive	O
her	O
Plavix	B-Drug
.	I-Drug
GI	O
was	O
consulted	O
,	O
and	O
the	O
patient	O
did	O
not	O
have	O
any	O
further	O
episodes	O
of	O
hematemesis	O
.	O
The	O
patient	O
's	O
Hct	O
dropped	O
to	O
28.1	O
and	O
remained	O
at	O
that	O
level	O
for	O
the	O
remainder	O
of	O
her	O
hospital	O
stay	O
.	O
.	O
#	O
Type	B-Reason
2	I-Reason
Diabetes	I-Reason
:	O
Patient	O
's	O
glucose	O
was	O
247	O
on	O
admission	O
,	O
though	O
this	O
was	O
in	O
the	O
setting	O
of	O
acute	O
stress	O
.	O
Patient	O
had	O
a	O
HgA1c	O
checked	O
on	O
this	O
admission	O
,	O
which	O
was	O
6.4	O
%	O
.	O
Patient	O
was	O
placed	O
on	O
a	O
sliding	O
scale	O
insulin	I-Drug
while	O
in	O
the	O
hospital	O
.	O
Patient	O
was	O
advised	O
to	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
regarding	O
this	O
issue	O
.	O
.	O
#	O
Smoking	B-Reason
Cessation	I-Reason
:	O
Patient	O
was	O
counseled	O
on	O
smoking	B-Reason
cessation	I-Reason
during	O
this	O
hospital	O
stay	O
.	O
She	O
was	O
given	O
Nicotine	I-Drug
lozenges	O
,	O
but	O
the	O
patient	O
stated	O
that	O
she	O
was	O
interested	O
in	O
waiting	O
until	O
her	O
current	O
cardiac	O
issue	O
had	O
resolved	O
before	O
attempting	O
to	O
quit	O
smoking	O
.	O
Patient	O
was	O
advised	O
to	O
follow	O
-	O
up	O
on	O
this	O
issue	O
with	O
her	O
PCP	O
.	O
.	O
#	O
.	O
Code	O
:	O
Full	O
.	O
Medications	O
on	O
Admission	O
:	O
HCTZ	I-Drug
25	O
mg	O
Propranolol	I-Drug
120	O
mg	O
Omeprazole	I-Drug
20	O
mg	O
Reconciled	O
with	O
Rite	O
-	O
Aid	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
3	O
.	O
Simvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
4	O
.	O
Toprol	I-Drug
XL	O
50	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
5	O
.	O
Lisinopril	B-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
6	O
.	O
Omeprazole	B-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
STEMI	O
GI	O
bleed	O
Secondary	O
:	O
Tobacco	O
abuse	O
Discharge	O
Condition	O
:	O
Stable	O
,	O
on	O
room	O
air	O
,	O
ambulating	O
without	O
difficulty	O
Systolic	O
BP	O
in	O
90's	O
,	O
HR	O
in	O
70's	O
Discharge	O
Instructions	O
:	O
You	O
should	O
return	O
to	O
the	O
Emergency	O
Department	O
if	O
you	O
experience	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
lightheadedness	O
,	O
palpitations	O
,	O
uncontrolled	O
vomiting	O
,	O
black	O
stools	O
,	O
or	O
bright	O
red	O
blood	O
per	O
rectum	O
.	O
.	O
While	O
you	O
were	O
in	O
the	O
hospital	O
,	O
we	O
made	O
the	O
following	O
changes	O
to	O
your	O
medications	O
:	O
1	O
.	O
We	O
started	O
you	O
on	O
Plavix	B-Drug
.	I-Drug
Please	O
do	O
not	O
stop	O
taking	O
this	O
medication	O
until	O
instructed	O
to	O
do	O
so	O
by	O
your	O
cardiologist	O
.	O
Stopping	O
Plavix	I-Drug
may	O
lead	O
to	O
serious	O
adverse	O
effects	O
.	O
2	O
.	O
We	O
started	O
you	O
on	O
Toprol	I-Drug
XL	O
50	O
mg	O
daily	O
3	O
.	O
We	O
started	O
you	O
on	O
Lisinopril	I-Drug
2.5	O
mg	O
daily	O
4	O
.	O
We	O
started	O
you	O
on	O
Simvastatin	I-Drug
daily	O
5	O
.	O
We	O
started	O
you	O
on	O
aspirin	I-Drug
325	O
mg	O
daily	O
.	O
It	O
is	O
very	O
important	O
to	O
your	O
cardiac	O
health	O
that	O
you	O
stop	O
smoking	O
.	O
You	O
should	O
abstain	O
from	O
cigarettes	O
and	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
regarding	O
smoking	O
cessation	O
strategies	O
.	O
.	O
Please	O
return	O
to	O
the	O
ED	O
or	O
your	O
healthcare	O
provider	O
if	O
you	O
experience	O
any	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
fatigue	O
,	O
chills	O
,	O
fevers	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
Primary	O
care	O
)	O
[	O
**	O
2196-8-18	O
**	O
]	O
at	O
12:30	O
PM	O
.	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
79466	O
**	O
]	O
(	O
Cardiologist	O
)	O
[	O
**	O
2196-8-16	O
**	O
]	O
at	O
4	O
PM	O
.	O
.	O
Tests	O
for	O
consideration	O
post-discharge	O
:	O
Homocysteine	O
level	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
.	O
You	O
can	O
call	O
the	O
Smokers	O
??????	O
Quitline	O
at	O
1	O
-800-Try-to-Stop	O
(	O
1	O
-	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
79467	O
**	O
]	O
to	O
obtain	O
a	O
free	O
nicotine	I-Drug
patch	O
kit	O
from	O
the	O
[	O
**	O
State	O
350	O
**	O
]	O
Tobacco	O
Control	O
Program	O
.	O
Completed	O
by	O
:[	O
**	O
2196-8-4	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2101-9-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2101-9-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2055-6-1	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3565	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypotension	O
and	O
ascites	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Abdominal	O
Paracentesis	O
(	O
8.8	O
and	O
8.11	O
)	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
59304	O
**	O
]	O
is	O
a	O
46	O
-	O
year	O
-	O
old	O
male	O
with	O
metastatic	B-Reason
renal	I-Reason
cell	I-Reason
carcinoma	O
now	O
on	O
axitinib	I-Drug
therapy	O
for	O
~	O
5	O
weeks	O
,	O
admitted	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
91600	O
**	O
]	O
with	O
anemia	O
,	O
malignant	O
ascites	O
and	O
treated	O
with	O
3L	O
therapeutic	O
paracentesis	O
2	O
wks	O
ago	O
and	O
noted	O
to	O
have	O
disease	O
progression	O
on	O
CT.	O
.	O
Patient	O
presented	O
from	O
cliic	O
with	O
hypotension	O
(	O
SBP	O
70s	O
)	O
.	O
He	O
had	O
acutely	O
worsening	O
sharp	O
diffuse	O
abdominal	O
pain	O
that	O
is	O
worse	O
with	O
movement	O
the	O
night	O
prior	O
to	O
admission	O
.	O
The	O
morning	O
of	O
admission	O
he	O
felt	O
weak	O
and	O
dizzy	O
.	O
He	O
had	O
two	O
episoes	O
of	O
vomiting	O
;	O
one	O
prior	O
to	O
admission	O
which	O
was	O
bilious	O
and	O
one	O
while	O
in	O
the	O
ED	O
that	O
had	O
small	O
amount	O
of	O
blood	O
.	O
He	O
also	O
reports	O
decreased	O
PO	O
intake	O
over	O
the	O
past	O
several	O
days	O
secondary	O
to	O
feeling	O
consipated	O
and	O
bloated	O
.	O
His	O
last	O
bowel	O
movement	O
was	O
two	O
days	O
prior	O
to	O
admission	O
.	O
He	O
denies	O
any	O
fever	O
,	O
cough	O
,	O
dyspnea	O
,	O
chest	O
pain	O
,	O
rash	O
.	O
Of	O
note	O
,	O
has	O
also	O
been	O
on	O
steroid	I-Drug
taper	O
(	O
previously	O
on	O
dex	I-Drug
1	O
mg	O
qdaily	O
,	O
now	O
tapered	O
to	O
0.5	O
mg	O
every	O
other	O
day	O
)	O
.	O
In	O
the	O
ED	O
,	O
initial	O
VS	O
were	O
:	O
97.7	O
10494/54	O
17	O
97	O
%	O
RA	O
.	O
Examination	O
was	O
notable	O
for	O
a	O
distended	O
,	O
tender	O
,	O
non-rigid	O
abdomen	O
with	O
guarding	O
.	O
Got	O
100	O
hydrocortisone	I-Drug
,	O
2L	O
NS	I-Drug
,	O
and	O
Albumin	I-Drug
5	O
%	O
(	O
12.5	O
g	O
/	O
250mL	O
)	O
x1	O
.	O
Dilaudid	I-Drug
1	O
mg	O
x3	O
given	O
for	O
pain	O
control	O
.	O
Bladder	O
scan	O
showed	O
>	O
800	O
cc	O
and	O
patient	O
unable	O
to	O
void	O
;	O
foley	O
placed	O
with	O
35	O
cc	O
UOP	O
,	O
likely	O
that	O
bladder	O
saw	O
ascites	O
not	O
urine	O
.	O
Foley	O
placement	O
verified	O
by	O
ultrasound	O
.	O
Diagnostic	O
paracentesis	O
performed	O
.	O
Patient	O
was	O
started	O
on	O
ceftriaxone	I-Drug
1g	O
,	O
vancomycin	I-Drug
1g	O
,	O
azithromycin	I-Drug
500	O
mg	O
and	O
blood	O
,	O
urine	O
,	O
ascites	O
cx	O
sent	O
.	O
On	O
transfer	O
,	O
VS	O
were	O
:	O
97.2	O
10387/57	O
20	O
99	O
%	O
4L	O
On	O
arrival	O
to	O
the	O
MICU	O
,	O
patient	O
's	O
VS.	O
98.1	O
,	O
100	O
,	O
96/59	O
,	O
18	O
,	O
98	O
%	O
RA	O
Review	O
of	O
systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
shortness	O
of	O
breath	O
,	O
cough	O
,	O
dyspnea	O
or	O
wheezing	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
.	O
Denies	O
diarrhea	O
,	O
dark	O
or	O
bloody	O
stools	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
Oncologic	O
History	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
59304	O
**	O
]	O
presented	O
to	O
his	O
PCP	O
in	O
[	O
**	O
2100-10-30	O
**	O
]	O
for	O
routine	O
physical	O
exam	O
and	O
reported	O
he	O
had	O
some	O
left	O
lower	O
quadrant	O
abdominal	O
discomfort	O
.	O
He	O
was	O
referred	O
to	O
a	O
surgeon	O
for	O
questionable	O
hernia	O
with	O
CT	O
scan	O
on	O
[	O
**	O
2100-11-18	O
**	O
]	O
revealing	O
a	O
left	O
kidney	O
mass	O
measuring	O
9	O
x	O
7.5	O
cm	O
,	O
with	O
a	O
larger	O
exophytic	O
component	O
measuring	O
approximately	O
12	O
cm	O
abutting	O
the	O
abdominal	O
wall	O
.	O
He	O
also	O
had	O
periaortic	O
lymphadenopathy	O
and	O
pulmonary	O
nodules	O
.	O
He	O
was	O
referred	O
here	O
for	O
further	O
management	O
.	O
Plain	O
film	O
of	O
the	O
left	O
femur	O
was	O
done	O
due	O
to	O
pain	O
,	O
revealing	O
a	O
lytic	O
lesion	O
.	O
He	O
was	O
referred	O
to	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
4223	O
**	O
]	O
in	O
orthopedics	O
with	O
plan	O
for	O
left	O
femur	O
surgery	O
in	O
the	O
future	O
.	O
She	O
obtained	O
plain	O
films	O
of	O
the	O
right	O
wrist	O
due	O
to	O
pain	O
and	O
another	O
lytic	O
lesion	O
was	O
noted	O
in	O
the	O
distal	O
ulna	O
.	O
Bone	O
scan	O
on	O
[	O
**	O
2100-12-6	O
**	O
]	O
revealed	O
widespread	B-Reason
bony	I-Reason
disease	I-Reason
.	O
Zometa	I-Drug
was	O
initiated	O
on	O
[	O
**	O
2100-12-7	O
**	O
]	O
.	O
He	O
underwent	O
open	O
radical	O
left	O
nephrectomy	O
on	O
[	O
**	O
2100-12-17	O
**	O
]	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3748	O
**	O
]	O
.	O
At	O
the	O
time	O
of	O
surgery	O
,	O
there	O
was	O
significant	O
progression	O
of	O
disease	O
with	O
extension	O
of	O
tumor	O
into	O
the	O
colon	O
and	O
mesentery	O
,	O
requiring	O
left	O
colectomy	O
and	O
small	O
bowel	O
resection	O
.	O
Pathology	O
confirmed	O
renal	O
cell	O
carcinoma	O
,	O
clear	O
cell	O
histology	O
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
19076	O
**	O
]	O
grade	O
2	O
with	O
lymphovascular	O
invasion	O
and	O
4	O
positive	O
lymph	O
nodes	O
.	O
He	O
underwent	O
excision	O
and	O
curettage	O
of	O
left	O
distal	O
femur	O
lesion	O
and	O
prophylactic	O
fixation	O
with	O
a	O
combination	O
of	O
cement	O
,	O
plate	O
,	O
and	O
screws	O
on	O
[	O
**	O
2101-1-5	O
**	O
]	O
by	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
4223	O
**	O
]	O
.	O
He	O
developed	O
increased	O
right	O
wrist	O
pain	O
and	O
was	O
found	O
to	O
have	O
a	O
pathologic	O
fracture	O
of	O
the	O
distal	O
ulna	O
on	O
[	O
**	O
2101-1-17	O
**	O
]	O
.	O
He	O
underwent	O
radiation	O
therapy	O
to	O
the	O
right	O
wrist	O
,	O
left	O
shoulder	O
and	O
left	O
femur	O
at	O
the	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
[	O
**	O
Hospital	O
5028	O
**	O
]	O
Cancer	O
Center	O
.	O
Right	O
heel	O
MRI	O
on	O
[	O
**	O
2101-2-28	O
**	O
]	O
demonstrated	O
a	O
metastatic	O
bony	O
lesion	O
and	O
he	O
received	O
radiation	O
to	O
that	O
site	O
,	O
completing	O
on	O
[	O
**	O
2101-3-18	O
**	O
]	O
.	O
He	O
also	O
had	O
radiation	O
to	O
the	O
left	O
tibia	O
and	O
L3	O
region	O
.	O
He	O
developed	O
a	O
pathologic	O
fracture	O
of	O
the	O
left	O
proximal	O
humerus	O
on	O
[	O
**	O
2101-4-25	O
**	O
]	O
,	O
managed	O
with	O
splinting	O
.	O
He	O
was	O
admitted	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
91600	O
**	O
]	O
with	O
anemia	O
,	O
ascites	O
and	O
disease	O
progression	O
noted	O
on	O
CT	O
including	O
lung	O
/	O
liver	O
/	O
peritoneam	O
metastases	O
.	O
1	O
.	O
RCC	O
-	O
as	O
above	O
2	O
.	O
Hypertension	O
.	O
3	O
.	O
Hypercholesterolemia	O
.	O
4	O
.	O
Anxiety	O
--	O
has	O
prior	O
history	O
of	O
panic	O
attacks	O
.	O
5	O
.	O
Migraines	O
.	O
6	O
.	O
Seasonal	O
allergies	O
.	O
7	O
.	O
s	O
/	O
p	O
XRT	O
to	O
L3	O
lesion	O
8	O
.	O
Right	O
humerus	O
pathologic	O
fracture	O
Social	O
History	O
:	O
Divorced	O
and	O
lives	O
in	O
[	O
**	O
Location	O
**	O
]	O
.	O
He	O
has	O
two	O
daughters	O
ages	O
8	O
and	O
11	O
.	O
He	O
works	O
as	O
a	O
firefighter	O
and	O
EMT	O
.	O
No	O
smoking	O
.	O
He	O
drinks	O
alcohol	O
socially	O
.	O
Denies	O
illicit	O
drug	O
use	O
.	O
Brother	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
is	O
HCP	O
.	O
Family	O
History	O
:	O
No	O
history	O
of	O
renal	O
cell	O
carcinoma	O
or	O
other	O
cancers	O
.	O
His	O
mother	O
died	O
of	O
a	O
cardiac	O
arrest	O
with	O
no	O
significant	O
cardiac	O
history	O
at	O
age	O
66	O
.	O
Grandmother	O
died	O
of	O
a	O
stroke	O
and	O
coronary	O
artery	O
disease	O
in	O
her	O
80s	O
.	O
He	O
has	O
a	O
brother	O
who	O
is	O
alive	O
and	O
well	O
.	O
His	O
biological	O
father	O
died	O
when	O
he	O
was	O
age	O
12	O
and	O
he	O
does	O
not	O
know	O
his	O
medical	O
history	O
.	O
Physical	O
Exam	O
:	O
ADMITTING	O
EXAM	O
97.2	O
10387/57	O
20	O
99	O
%	O
4L	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
EOMI	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
CV	O
:	O
tachycardic	O
regular	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
distended	O
,	O
flank	O
dullness	O
to	O
percusion	O
,	O
bowel	O
sounds	O
present	O
,	O
diffusely	O
tender	O
to	O
palpation	O
,	O
no	O
rebound	O
or	O
guarding	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
CNII	O
-	O
XII	O
intact	O
,	O
gait	O
deferred	O
,	O
no	O
asterixis	O
Pertinent	O
Results	O
:	O
ADMITTING	O
LABS	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
UREA	O
N	O
-	O
44	O
*	O
CREAT	O
-	O
2.9	O
*	O
#	O
SODIUM	O
-	O
132	O
*	O
POTASSIUM	O
-	O
5.8	O
*	O
CHLORIDE	O
-	O
91	O
*	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
23	O
*	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
17	O
AST	O
(	O
SGOT	O
)	O
-	O
19	O
LD	O
(	O
LDH	O
)	O
-	O
205	O
ALK	O
PHOS	O
-	O
162	O
*	O
TOT	O
BILI	O
-	O
0.3	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
LIPASE	O
-	O
7	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
ALBUMIN	O
-	O
2.5	O
*	O
CALCIUM	O
-	O
9.0	O
PHOSPHATE	O
-	O
5.4	O
*	O
#	O
MAGNESIUM	O
-	O
2.1	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
TSH	O
-	O
6.8	O
*	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
WBC	O
-	O
10.2	O
#	O
RBC	O
-	O
4.90	O
#	O
HGB	O
-	O
13.2	O
*	O
#	O
HCT	O
-	O
42.5	O
#	O
MCV	O
-	O
87	O
MCH	O
-	O
27.0	O
MCHC	O
-	O
31.1	O
RDW	O
-	O
17.0	O
*	O
[	O
**	O
2101-9-6	O
**	O
]	O
02:10	O
PM	O
NEUTS	O
-	O
78	O
*	O
BANDS	O
-	O
0	O
LYMPHS	O
-	O
18	O
MONOS	O
-	O
3	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
1	O
*	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
PERTINENT	O
LABS	O
[	O
**	O
2101-9-12	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
Glucose	O
-	O
146	O
*	O
UreaN	O
-	O
61	O
*	O
Creat	O
-	O
3.4	O
*	O
Na	O
-	O
137	O
K	O
-	O
4.8	O
Cl	O
-	O
103	O
HCO3	O
-	O
14	O
*	O
AnGap	O
-	O
25	O
*	O
[	O
**	O
2101-9-12	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
5.8	O
*	O
Mg	O
-	O
2.4	O
[	O
**	O
2101-9-12	O
**	O
]	O
01:25	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
87	O
pCO2	O
-	O
31	O
*	O
pH	O
-	O
7.26	O
*	O
calTCO2	O
-	O
15	O
*	O
Base	O
XS	O
--	O
11	O
Intubat	O
-	O
NOT	O
INTUBA	O
[	O
**	O
2101-9-12	O
**	O
]	O
11:11	O
AM	O
BLOOD	O
Lactate	O
-	O
3.7	O
*	O
MICRO	O
[	O
**	O
2101-9-10	O
**	O
]	O
1:36	O
pm	O
PERITONEAL	O
FLUID	O
PERITONEAL	O
FLUID	O
.	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2101-9-10	O
**	O
]	O
)	O
:	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
This	O
is	O
a	O
concentrated	O
smear	O
made	O
by	O
cytospin	O
method	O
,	O
please	O
refer	O
to	O
hematology	O
for	O
a	O
quantitative	O
white	O
blood	O
cell	O
count	O
.	O
.	O
FLUID	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
[	O
**	O
2101-9-7	O
**	O
]	O
2:23	O
pm	O
PERITONEAL	O
FLUID	O
PERITONEAL	O
FLUID	O
.	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2101-9-7	O
**	O
]	O
)	O
:	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
This	O
is	O
a	O
concentrated	O
smear	O
made	O
by	O
cytospin	O
method	O
,	O
please	O
refer	O
to	O
hematology	O
for	O
a	O
quantitative	O
white	O
blood	O
cell	O
count	O
.	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2101-9-10	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
IMAGING	O
.	O
Radiology	O
Report	O
RENAL	O
U.S.	O
Study	O
Date	O
of	O
[	O
**	O
2101-9-7	O
**	O
]	O
9:30	O
AM	O
IMPRESSION	O
:	O
1	O
.	O
Prior	O
left	O
nephrectomy	O
.	O
No	O
evidence	O
of	O
hydronephrosis	O
or	O
renal	O
vascular	O
occlusion	O
involving	O
the	O
right	O
kidney	O
to	O
explain	O
the	O
patient	O
's	O
acute	O
renal	O
failure	O
.	O
2	O
.	O
Large	O
amount	O
of	O
ascites	O
with	O
diffuse	O
intraperitoneal	O
metastatic	O
disease	O
.	O
.	O
ECHO	O
[	O
**	O
2101-9-8	O
**	O
]	O
at	O
9:30:00	O
AM	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
=	O
75	O
%	O
)	O
M	O
-	O
mode	O
analysis	O
of	O
the	O
aortic	O
valve	O
suggests	O
premature	O
systolic	O
closure	O
.	O
A	O
left	O
ventricular	O
outflow	O
tract	O
obstruction	O
can	O
not	O
be	O
excluded	O
with	O
certainty	O
due	O
to	O
the	O
technically	O
suboptimal	O
nature	O
of	O
this	O
study	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
a	O
normal	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
<	O
12mmHg	O
)	O
.	O
The	O
right	O
ventricular	O
free	O
wall	O
thickness	O
is	O
normal	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
with	O
depressed	O
free	O
wall	O
contractility	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
(	O
?	O
#	O
)	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
mild	O
posterior	O
leaflet	O
mitral	O
valve	O
prolapse	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
.	O
ECHO	O
Portable	O
TTE	O
(	O
Complete	O
)	O
Done	O
[	O
**	O
2101-9-12	O
**	O
]	O
at	O
2:20:00	O
PM	O
FINAL	O
Poor	O
image	O
quality.The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
>	O
75	O
%	O
)	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
probably	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis	O
or	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Tricuspid	O
regurgitation	O
is	O
present	O
but	O
can	O
not	O
be	O
quantified	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
.	O
CXR	O
8.9	O
As	O
compared	O
to	O
the	O
previous	O
radiograph	O
,	O
there	O
is	O
a	O
newly	O
appeared	O
moderate	O
left	O
pleural	O
effusion	O
.	O
There	O
is	O
unchanged	O
evidence	O
of	O
low	O
lung	O
volumes	O
and	O
known	O
nodular	O
opacities	O
in	O
both	O
lungs	O
.	O
No	O
evidence	O
of	O
pulmonary	O
edema	O
.	O
Unchanged	O
appearance	O
of	O
the	O
cardiac	O
silhouette	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
Shock	O
:	O
The	O
patient	O
presented	O
with	O
hypotension	I-Reason
with	O
systolics	O
in	O
the	O
70s	O
-	O
80s	O
compared	O
to	O
his	O
baseline	O
of	O
120s	O
-	O
130s	O
in	O
the	O
outpatient	O
setting	O
.	O
His	O
pressures	O
did	O
not	O
respond	O
adequately	O
to	O
fluid	I-Drug
boluses	O
.	O
A	O
PICC	O
line	O
was	O
placed	O
and	O
he	O
was	O
started	O
on	O
dopamine	I-Drug
initially	O
.	O
Dopamine	I-Drug
was	O
switched	O
to	O
vasopressin	I-Drug
given	O
concern	O
for	O
his	O
recurrent	O
ascites	I-Reason
.	O
His	O
shock	O
was	O
thought	O
to	O
be	O
due	O
to	O
a	O
combination	O
of	O
sepsis	O
and	O
intravascular	O
volume	O
depletion	O
[	O
**	O
3	O
-	O
3	O
**	O
]	O
recurrent	O
malignant	O
ascites	O
.	O
A	O
definitive	O
infectious	O
source	O
was	O
never	O
identified	O
,	O
though	O
SBP	O
was	O
excluded	O
with	O
2	O
large	O
volume	O
paracenteses	O
.	O
The	O
patient	O
was	O
placed	O
on	O
vancomycin	I-Drug
,	O
cefepime	I-Drug
,	O
and	O
flagyl	I-Drug
.	O
He	O
was	O
also	O
given	O
stress	O
dose	O
steroids	I-Drug
.	O
Fluid	B-Reason
resuscitation	I-Reason
was	O
performed	O
with	O
crystalloid	I-Drug
and	O
colloid	I-Drug
without	O
success	O
.	O
The	O
patient	O
continued	O
to	O
rapidly	O
reaccumulate	O
fluid	O
in	O
his	O
abdomen	O
.	O
The	O
patient	O
remained	O
oliguric	I-Reason
to	O
anuric	O
during	O
his	O
admission	O
.	O
Norepinephrine	I-Drug
was	O
added	O
on	O
the	O
day	O
of	O
intubation	O
added	O
without	O
improvement	O
in	O
urine	O
output	O
.	O
After	O
a	O
family	O
meeting	O
,	O
the	O
patient	O
was	O
made	O
CMO	O
and	O
vasoactive	I-Drug
medications	O
were	O
discontinued	O
.	O
The	O
patient	O
expired	O
shortly	O
thereafter	O
.	O
#	O
Respiratory	O
failure	O
:	O
The	O
patient	O
developed	O
tachypnea	O
and	O
increased	O
work	O
of	O
breathing	O
on	O
the	O
morning	O
of	O
his	O
expiration	O
while	O
undergoing	O
a	O
CT	O
head	O
.	O
He	O
was	O
intubated	O
for	O
respiratory	O
distress	O
,	O
self	O
-	O
extubated	O
,	O
and	O
was	O
reintubated	O
for	O
continuing	O
respiratory	O
distress	O
.	O
Versed	I-Drug
,	O
fentanyl	I-Drug
,	O
and	O
propofol	I-Drug
were	O
used	O
for	O
sedation	I-Reason
.	O
A	O
CXR	O
did	O
not	O
show	O
any	O
acute	O
intrapulmonary	O
process	O
.	O
Bilateral	O
LENIs	O
were	O
negative	O
for	O
DVTs	O
.	O
An	O
ECHO	O
did	O
not	O
show	O
any	O
RV	O
strain	O
.	O
Most	O
likely	O
etiology	O
was	O
worsening	O
lung	O
function	O
in	O
the	O
setting	O
of	O
extensive	O
RCC	O
lung	O
metastases	O
and	O
worsening	O
metabolic	O
acidoses	O
due	O
to	O
renal	O
failure	O
.	O
A	O
family	O
meeting	O
was	O
held	O
in	O
the	O
afternoon	O
and	O
the	O
decision	O
was	O
made	O
to	O
make	O
him	O
CMO	O
given	O
his	O
poor	O
prognosis	O
.	O
The	O
patient	O
was	O
terminally	O
extubated	O
on	O
the	O
afternoon	O
of	O
[	O
**	O
9	O
-	O
12	O
**	O
]	O
and	O
expired	O
shortly	O
thereafter	O
.	O
#	O
Acute	O
renal	O
failure	O
:	O
The	O
patient	O
was	O
oliguric	O
on	O
presentation	O
.	O
A	O
renal	O
ultrasound	O
did	O
not	O
show	O
impaired	O
renal	O
flow	O
.	O
Bladder	O
pressures	O
were	O
consistently	O
below	O
20	O
.	O
Etiology	O
was	O
likely	O
secondary	O
to	O
intraarterial	O
volume	O
depletion	O
due	O
to	O
massive	O
3rd	O
spacing	O
of	O
fluids	O
secondary	O
to	O
ascites	O
.	O
Urine	O
output	O
did	O
not	O
improve	O
after	O
large	O
volume	O
paracentesis	O
or	O
after	O
fluid	I-Reason
resuscitation	O
with	O
crystalloid	I-Drug
or	O
colloid	I-Drug
.	O
Patient	O
became	O
increasingly	O
acidemic	O
.	O
Dialysis	O
was	O
discussed	O
and	O
not	O
considered	O
appropriate	O
given	O
his	O
poor	O
prognosis	O
.	O
#	O
Metastatic	O
renal	O
cell	O
carcinoma	O
:	O
The	O
patient	O
required	O
2	O
large	O
volume	O
paracenteses	O
to	O
manage	O
his	O
malignant	O
ascites	O
.	O
His	O
pain	I-Reason
was	O
managed	O
with	O
a	O
dilaudid	I-Drug
PCA	O
.	O
Patient	O
's	O
outpatient	O
oncologist	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
and	O
informed	O
of	O
worsening	O
status	O
and	O
the	O
decision	O
was	O
made	O
to	O
not	O
be	O
aggressive	O
with	O
interventions	O
given	O
his	O
worsening	O
prognosis	O
and	O
lack	O
of	O
tumor	O
response	O
to	O
multiple	O
biologic	O
therapies	O
.	O
#	O
Comfort	O
care	O
:	O
Patient	O
's	O
Oncologist	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
regarding	O
transitioning	O
to	O
comfort	O
care	O
.	O
As	O
noted	O
above	O
,	O
his	O
prognosis	O
was	O
poor	O
given	O
his	O
lack	O
of	O
response	O
to	O
biologic	O
therapies	O
.	O
Palliative	O
care	O
service	O
was	O
consulted	O
.	O
Patient	O
's	O
family	O
was	O
called	O
on	O
the	O
day	O
of	O
intubation	O
and	O
arrived	O
in	O
the	O
afternoon	O
.	O
Discussion	O
was	O
had	O
with	O
the	O
family	O
as	O
well	O
as	O
Oncologist	O
NP	O
and	O
Palliative	O
care	O
and	O
decision	O
was	O
made	O
to	O
terminally	O
extubate	O
.	O
Patient	O
expired	O
peacefully	O
in	O
the	O
evening	O
.	O
Medications	O
on	O
Admission	O
:	O
Preadmission	O
medications	O
listed	O
are	O
correct	O
and	O
complete	O
.	O
Information	O
was	O
obtained	O
from	O
PatientwebOMR	O
.	O
1	O
.	O
Dexamethasone	I-Drug
0.5	O
mg	O
PO	O
EVERY	O
OTHER	O
DAY	O
2	O
.	O
Lisinopril	I-Drug
20	O
mg	O
PO	O
DAILY	O
3	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
PO	O
DAILY	O
PRN	O
SBP	O
>	O
110	O
4	O
.	O
HYDROmorphone	I-Drug
(	O
Dilaudid	O
)	O
2	O
-	O
6	O
mg	O
PO	O
Q3H	O
:	O
PRN	O
pain	I-Reason
hold	O
for	O
sedation	O
,	O
RR	O
<	O
10	O
5	O
.	O
Oxycodone	I-Drug
SR	O
(	O
OxyconTIN	O
)	O
60	O
mg	O
PO	O
Q8H	O
6	O
.	O
Sertraline	B-Drug
50	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications	O
:	O
expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Metastatic	O
renal	O
cell	O
carcinoma	O
Malignant	O
ascites	O
Respiratory	O
failure	O
Discharge	O
Condition	O
:	O
Expired	O
.	O
Discharge	O
Instructions	O
:	O
Expired	O
.	O
Followup	O
Instructions	O
:	O
Expired	O
.	O
Completed	O
by	O
:[	O
**	O
2101-9-13	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2139-1-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2139-1-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2068-2-28	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
898	O
**	O
]	O
Chief	O
Complaint	O
:	O
Melena	O
,	O
hypotension	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
EGD	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
70	O
year	O
old	O
gentleman	O
with	O
ischemic	O
cardiomyopathy	O
EF	O
20	O
%	O
,	O
atrial	B-Reason
fibrillation	I-Reason
on	O
coumadin	I-Drug
,	O
history	O
of	O
Barrett	O
's	O
esophagitis	O
,	O
colonic	O
polyps	O
,	O
asthma	O
,	O
hypothyroidism	O
,	O
and	O
depression	O
.	O
He	O
presents	O
with	O
black	O
loose	O
stools	O
for	O
one	O
day	O
.	O
Yesterday	O
morning	O
,	O
the	O
patient	O
woke	O
up	O
and	O
had	O
diarrhea	O
that	O
was	O
black	O
and	O
tarry	O
in	O
nature	O
.	O
He	O
proceeded	O
to	O
have	O
a	O
loose	O
stool	O
movement	O
every	O
15	O
minutes	O
over	O
the	O
day	O
.	O
Over	O
the	O
course	O
of	O
the	O
day	O
he	O
became	O
more	O
lightheaded	O
and	O
this	O
morning	O
felt	O
like	O
he	O
was	O
going	O
to	O
fall	O
down	O
prompting	O
him	O
to	O
seek	O
medical	O
attention	O
in	O
the	O
ED	O
.	O
He	O
did	O
not	O
notice	O
frank	O
blood	O
in	O
his	O
bowel	O
movements	O
.	O
He	O
also	O
has	O
had	O
some	O
nausea	O
with	O
poor	O
appetite	O
(	O
has	O
not	O
eaten	O
in	O
two	O
days	O
)	O
but	O
no	O
vomiting	O
or	O
hematemesis	O
.	O
No	O
abdominal	O
pain	O
.	O
No	O
coldness	O
in	O
extremities	O
.	O
.	O
The	O
patient	O
was	O
bought	O
in	O
by	O
his	O
wife	O
to	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
.	O
There	O
the	O
patient	O
was	O
noted	O
to	O
have	O
a	O
low	O
blood	O
pressure	O
in	O
the	O
high	O
80s	O
systolic	O
,	O
P	O
105	O
.	O
Hct	O
was	O
42	O
(	O
baseline	O
31	O
)	O
and	O
BUN	O
/	O
Cr	O
56/2	O
.4	O
(	O
baseline	O
cr	O
1.5	O
-	O
1.8	O
)	O
.	O
NG	O
lavage	O
negative	O
.	O
Believed	O
to	O
be	O
volume	I-Reason
depleted	O
.	O
He	O
received	O
3	O
L	O
NS	I-Drug
,	O
2	O
units	O
pRBC	I-Drug
,	O
and	O
1	O
unit	O
FFP	I-Drug
(	O
addtl	O
'	O
units	O
ordered	O
)	O
.	O
Given	O
IV	O
protonix	I-Drug
.	O
Transferred	O
to	O
MICU	O
,	O
on	O
transfer	O
pt	O
says	O
he	O
feels	O
somewhat	O
better	O
.	O
.	O
Of	O
note	O
,	O
he	O
is	O
known	O
to	O
have	O
Barrett	O
's	O
Esophagus	O
seen	O
on	O
[	O
**	O
2133	O
**	O
]	O
EGD	O
.	O
In	O
addition	O
,	O
he	O
is	O
s	O
/	O
p	O
removal	O
of	O
adenomatous	O
polyp	O
(	O
path	O
with	O
dysplasia	O
)	O
in	O
[	O
**	O
2134	O
**	O
]	O
,	O
no	O
polyps	O
seen	O
on	O
[	O
**	O
2135	O
**	O
]	O
colonoscopy	O
.	O
Past	O
Medical	O
History	O
:	O
11	O
.	O
CAD	O
,	O
s	O
/	O
p	O
1	O
-	O
vessel	O
CABG	O
and	O
ascending	O
aortic	O
arch	O
repair	O
.	O
Last	O
cath	O
in	O
[	O
**	O
8	O
-	O
/	O
2136	O
**	O
]	O
with	O
no	O
significant	O
CAD	O
,	O
patent	O
LIMA	O
to	O
LAD	O
.	O
P	O
-	O
MIBI	O
in	O
[	O
**	O
6	O
-	O
/	O
2137	O
**	O
]	O
with	O
slight	O
worsening	O
of	O
partially	O
reversible	O
,	O
moderate	O
perfusion	O
defects	O
in	O
the	O
basilar	O
anterolateral	O
,	O
mid	O
anterolateral	O
,	O
basilar	O
posterolateral	O
,	O
mid	O
posterolateral	O
,	O
and	O
lateral	O
walls	O
(	O
entire	O
lateral	O
portion	O
of	O
the	O
left	O
ventricle	O
)	O
.	O
2	O
.	O
Ischemic	O
cardiomyopathy	O
with	O
EF	O
15	O
-	O
20	O
%	O
,	O
NYHA	O
class	O
III	O
.	O
3	O
.	O
Chronic	O
renal	O
insufficiency	O
,	O
baseline	O
creatinine	O
around	O
1.5	O
-	O
1.7	O
4	O
.	O
Atrial	O
fibrillation	O
5	O
.	O
Hypothyroidism	O
6	O
.	O
Status	O
post	O
AICD	O
placement	O
,	O
multiple	O
firing	O
episodes	O
,	O
last	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
in	O
[	O
**	O
9	O
-	O
/	O
2137	O
**	O
]	O
in	O
setting	O
of	O
hypokalemia	O
.	O
7	O
.	O
Asthma	O
9	O
.	O
Hyperlipidemia	O
10	O
.	O
Depression	O
11	O
.	O
Dementia	O
12	O
.	O
Anemia	O
,	O
baseline	O
hct	O
around	O
30	O
.	O
13	O
.	O
Barrett	O
's	O
Esophagus	O
seen	O
on	O
[	O
**	O
2133	O
**	O
]	O
EGD	O
14	O
.	O
s	O
/	O
p	O
removal	O
of	O
adenomatous	O
polyp	O
(	O
path	O
with	O
dysplasia	O
)	O
in	O
[	O
**	O
2134	O
**	O
]	O
,	O
no	O
polyps	O
seen	O
on	O
[	O
**	O
2135	O
**	O
]	O
colonoscopy	O
.	O
Social	O
History	O
:	O
Married	O
,	O
lives	O
with	O
wife	O
,	O
has	O
five	O
children	O
.	O
Formerly	O
drank	O
alcohol	I-Drug
but	O
not	O
since	O
[	O
**	O
48	O
**	O
]	O
years	O
ago	O
.	O
No	O
smoking	O
or	O
illicit	O
drug	O
use	O
.	O
Retired	O
painter	O
.	O
Family	O
History	O
:	O
Non-contributory	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
97.6	O
P	O
77	O
BP	O
109/71	O
RR	O
22	O
O2	O
98	O
RA	O
Gen	O
:	O
WD	O
/	O
WN	O
male	O
Caucasian	O
,	O
NAD	O
.	O
Eyes	O
:	O
Sclerae	O
anicteric	O
,	O
PERRL	O
.	O
Mouth	O
:	O
No	O
bruising	O
,	O
no	O
petechiae	O
.	O
Neck	O
:	O
Obese	O
,	O
no	O
JVD	O
(	O
JVP	O
to	O
6	O
cm	O
)	O
Chest	O
:	O
Lungs	O
CTA	O
b	O
/	O
l	O
no	O
wheezes	O
,	O
fair	O
air	O
movement	O
Abd	O
:	O
Obese	O
,	O
non	O
tender	O
,	O
some	O
nausea	O
elicited	O
with	O
palpation	O
.	O
Ext	O
:	O
No	O
edema	O
,	O
faint	O
but	O
palpable	O
DP	O
pulses	O
Neurol	O
:	O
alert	O
and	O
oriented	O
to	O
time	O
,	O
place	O
,	O
and	O
person	O
Pertinent	O
Results	O
:	O
[	O
**	O
2139-1-6	O
**	O
]	O
08:01	O
PM	O
HCT	O
-	O
35.2	O
*	O
[	O
**	O
2139-1-6	O
**	O
]	O
02:56	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
UREA	O
N	O
-	O
361	O
CREAT	O
-	O
43	O
SODIUM	O
-	O
85	O
[	O
**	O
2139-1-6	O
**	O
]	O
02:19	O
PM	O
HCT	O
-	O
34.0	O
*	O
[	O
**	O
2139-1-6	O
**	O
]	O
12:15	O
PM	O
URINE	O
COLOR	O
-	O
Straw	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.008	O
[	O
**	O
2139-1-6	O
**	O
]	O
12:15	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
GLUCOSE	O
-	O
112	O
*	O
UREA	O
N	O
-	O
56	O
*	O
CREAT	O
-	O
2.4	O
*	O
SODIUM	O
-	O
137	O
POTASSIUM	O
-	O
4.3	O
CHLORIDE	O
-	O
101	O
TOTAL	O
CO2	O
-	O
25	O
ANION	O
GAP	O
-	O
15	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
CK	O
(	O
CPK	O
)	O
-	O
129	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
16	O
AST	O
(	O
SGOT	O
)	O
-	O
26	O
ALK	O
PHOS	O
-	O
79	O
AMYLASE	O
-	O
84	O
TOT	O
BILI	O
-	O
0.4	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
LIPASE	O
-	O
33	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
DIGOXIN	O
-	O
1.3	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
WBC	O
-	O
6.3	O
RBC	O
-	O
4.66	O
#	O
HGB	O
-	O
13.8	O
*	O
#	O
HCT	O
-	O
42.0	O
#	O
MCV	O
-	O
90	O
MCH	O
-	O
29.7	O
MCHC	O
-	O
32.9	O
RDW	O
-	O
14.1	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
NEUTS	O
-	O
77.1	O
*	O
LYMPHS	O
-	O
11.5	O
*	O
MONOS	O
-	O
9.0	O
EOS	O
-	O
1.9	O
BASOS	O
-	O
0.5	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
PLT	O
COUNT	O
-	O
160	O
[	O
**	O
2139-1-6	O
**	O
]	O
10:15	O
AM	O
PT	O
-	O
31.0	O
*	O
PTT	O
-	O
31.9	O
INR	O
(	O
PT	O
)	O
-	O
3.3	O
*	O
Brief	O
Hospital	O
Course	O
:	O
Upper	O
GI	O
bleed	O
:	O
Pt	O
.	O
initially	O
with	O
borderline	O
hypotension	O
and	O
tachycardia	O
.	O
Responded	O
well	O
to	O
fluid	O
resuscitation	O
.	O
Admitted	O
initially	O
to	O
ICU	O
,	O
where	O
an	O
EGD	O
was	O
performed	O
on	O
AM	O
of	O
hospital	O
day	O
2	O
.	O
EGD	O
revealed	O
duodenitis	O
,	O
no	O
active	O
bleed	O
,	O
no	O
ulcer	O
,	O
Barrett	O
's	O
esophagus	O
.	O
In	O
the	O
ICU	O
,	O
was	O
transfused	O
2	O
units	O
pRBC	I-Drug
,	O
1	O
unit	O
FFP	I-Drug
.	O
Given	O
initial	O
low	O
BP	O
and	O
GIB	O
,	O
all	O
antihypertensives	I-Drug
were	O
initially	O
held	O
,	O
as	O
was	O
coumadin.Throughout	B-Drug
the	O
rest	O
of	O
hospital	O
stay	O
,	O
pt	O
.	O
had	O
stable	O
vital	O
signs	O
,	O
no	O
further	O
GIB	O
.	O
Hct	O
responded	O
appropriately	O
to	O
transfusion	O
,	O
remained	O
stable	O
.	O
Antihypertensives	I-Drug
and	O
coumadin	I-Drug
were	O
restarted	O
on	O
HD	B-Drug
3	I-Drug
and	O
were	O
tolerated	O
well	O
.	O
Overall	O
,	O
continued	O
ASA	I-Drug
and	O
warfarin	I-Drug
,	O
but	O
stopped	O
plavix	I-Drug
after	O
consultation	O
with	O
Cardiology	O
.	O
.	O
Respiratory	O
distress	O
/	O
asthma	O
flare	O
:	O
On	O
Hospital	O
day	O
3	O
,	O
began	O
to	O
have	O
increasing	O
respiratory	O
distress	O
.	O
Exam	O
notable	O
for	O
marked	O
wheezing	I-Reason
.	O
CXR	O
with	O
no	O
definite	O
infiltrates	O
.	O
While	O
initially	O
volume	O
overloaded	O
after	O
MICU	O
stay	O
,	O
no	O
longer	O
had	O
evidence	O
of	O
CHF	O
.	O
Overall	O
,	O
he	O
was	O
treated	O
with	O
prednisone	I-Drug
and	O
nebs	O
for	O
asthma	B-Reason
flare	I-Reason
.	O
Also	O
empirically	O
treated	O
for	O
PNA	I-Reason
-	O
although	O
limited	O
evidence	O
for	O
this	O
on	O
cxr	O
-	O
with	O
rocephin	I-Drug
/	O
azithro	I-Drug
.	O
Will	O
be	O
d	O
/	O
c	O
with	O
levaquin	I-Drug
to	O
complete	O
7	O
day	O
course	O
.	O
.	O
Chest	O
pressure	O
:	O
On	O
the	O
night	O
of	O
HD	B-Drug
3	I-Drug
,	O
patient	O
had	O
an	O
episode	O
of	O
L	O
-	O
sided	O
chest	O
pain	O
that	O
was	O
ssociated	O
with	O
diaphoresis	O
and	O
an	O
increased	O
02	I-Drug
requirement	O
(	O
responded	O
to	O
2L	O
NC	O
)	O
.	O
Pain	O
resolved	O
quickly	O
with	O
3	O
SL	O
nitroglycerin	I-Drug
,	O
albuterol	I-Drug
neb	O
,	O
and	O
IV	O
lasix	I-Drug
.	O
Cardiac	O
enzymes	O
were	O
trended	O
and	O
over	O
the	O
following	O
day	O
climbed	O
from	O
0.05	O
to	O
a	O
peak	O
of	O
0.08	O
.	O
He	O
had	O
no	O
further	O
events	O
,	O
and	O
had	O
stress	O
MIBI	O
in	O
hospital	O
prior	O
to	O
discharge	O
,	O
which	O
again	O
demonstrated	O
his	O
severe	O
ischemic	O
dilated	O
cardiomyopathy	O
and	O
also	O
multiple	O
predominantly	O
fixed	O
perfusion	O
defects	O
-	O
previous	O
stress	O
in	O
[	O
**	O
2137	O
**	O
]	O
with	O
progressively	O
worse	O
reversible	O
perfusion	O
defects	O
.	O
Will	O
continue	O
medicla	O
management	O
.	O
.	O
ARF	O
on	O
CKD	O
:	O
Pt	O
.	O
had	O
briefly	O
elevated	O
Cr	O
,	O
which	O
returned	O
quickly	O
to	O
baseline	O
with	O
fluid	B-Drug
resuscitation	I-Drug
.	O
In	O
setting	O
of	O
GIB	O
,	O
seemed	O
c	O
/	O
w	O
prerenal	O
picture	O
.	O
ACEI	I-Drug
was	O
initially	O
held	O
,	O
but	O
restarted	O
without	O
adverse	O
effect	O
once	O
Cr	O
returned	O
to	O
baseline	O
.	O
Remained	O
at	O
baseline	O
thereafter	O
with	O
re-introduction	O
of	O
meds	O
.	O
.	O
Abdominal	O
pain	O
/	O
constipation	O
:	O
On	O
HD	B-Drug
3	I-Drug
,	O
pt	O
.	O
developed	O
bilateral	O
lower	O
quadrant	O
abdominal	O
pain	O
,	O
which	O
he	O
attributed	O
to	O
not	O
having	O
had	O
a	O
bowel	O
movement	O
since	O
admission	O
to	O
hospital	O
.	O
Abdominal	O
exam	O
was	O
benign	O
,	O
KUB	O
unremarkable	O
.	O
Had	O
relief	O
after	O
BM	O
.	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Lasix	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
Aldactone	I-Drug
25	O
mg	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
Metoprolol	I-Drug
Succinate	O
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
4	O
.	O
Digoxin	I-Drug
125	O
mcg	O
Tablet	O
Daily	O
5	O
.	O
Atorvastatin	B-Drug
20	O
mg	O
PO	O
DAILY	O
6	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
PO	O
Daily	O
7	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
PO	O
daily	O
.	O
8	O
.	O
Lisinopril	I-Drug
5	O
mg	O
PO	O
Daily	O
9	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
adjusted	O
accordingly	O
to	O
INR	O
.	O
10	O
.	O
Levothyroxine	I-Drug
112	O
mcg	O
PO	O
Daily	O
.	O
11	O
.	O
Citalopram	I-Drug
60	O
mg	O
PO	O
Daily	O
.	O
12	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
E.C.	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
13	O
.	O
Mexiletine	B-Drug
150	O
mg	O
PO	O
Q8H	O
.	O
14	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
PO	O
BID	O
.	O
15	O
.	O
Senna	I-Drug
8.6	O
mg	O
PO	O
BID	O
prn	O
.	O
16	O
.	O
Quetiapine	B-Drug
50	O
mg	O
Tablet	O
PO	O
QAM	O
,	O
25	O
mg	O
PO	O
QPM	O
,	O
225	O
mg	O
QHS	O
.	O
17	O
.	O
Clonazepam	B-Drug
0.5	O
mg	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
18	O
.	O
Fluticasone	I-Drug
-	O
Salmeterol	O
100	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
[	O
**	O
Hospital1	O
**	O
]	O
19	O
.	O
Trazodone	I-Drug
25	O
mg	O
Tablet	O
PO	O
HS	O
PRN	O
.	O
20	O
.	O
Donepezil	I-Drug
5	O
mg	O
PO	O
HS	O
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Atorvastatin	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Levothyroxine	I-Drug
112	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Donepezil	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Fluticasone	I-Drug
-	O
Salmeterol	O
100	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Clonazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O
8	O
.	O
Mexiletine	I-Drug
150	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
9	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
inh	O
Inhalation	O
Q3	O
-	O
4H	O
(	O
Every	O
3	O
to	O
4	O
Hours	O
)	O
as	O
needed	O
.	O
inh	O
10	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
11	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Digoxin	I-Drug
125	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
15	O
.	O
Furosemide	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
16	O
.	O
Nebulizer	O
Please	O
dispense	O
home	O
nebulizer	O
set	O
-	O
up	O
.	O
17	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
18	O
.	O
Levaquin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
3	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
19	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
180	O
neb	O
*	O
Refills	O
:	O
*	O
2	O
*	O
20	O
.	O
Prednisone	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
9	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
21	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
120	O
neb	O
*	O
Refills	O
:	O
*	O
2	O
*	O
22	O
.	O
Nitroglycerin	I-Drug
0.3	O
mg	O
Tablet	O
,	O
Sublingual	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Sublingual	O
Sublingual	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
23	O
.	O
Furosemide	B-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
24	O
.	O
Spironolactone	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
25	O
.	O
Quetiapine	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
4.5	O
Tablets	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
26	O
.	O
Quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)	O
)	O
.	O
27	O
.	O
Quetiapine	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QPM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
evening	O
)	O
)	O
.	O
28	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
119	O
**	O
]	O
Homecare	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
upper	O
GI	O
bleed	O
secondary	O
to	O
gastritis	O
,	O
duodenitis	O
Secondary	O
diagnoses	O
:	O
1	O
.	O
CAD	O
,	O
s	O
/	O
p	O
1	O
-	O
vessel	O
CABG	O
2	O
.	O
Ischemic	O
cardiomyopathy	O
with	O
EF	O
15	O
-	O
20	O
%	O
,	O
NYHA	O
class	O
III	O
.	O
3	O
.	O
Chronic	O
renal	O
insufficiency	O
,	O
baseline	O
creatinine	O
around	O
1.5	O
-	O
1.7	O
4	O
.	O
Atrial	O
fibrillation	O
5	O
.	O
Hypothyroidism	O
6	O
.	O
Status	O
post	O
AICD	O
placement	O
7	O
.	O
Asthma	O
9	O
.	O
Hyperlipidemia	O
10	O
.	O
Depression	O
11	O
.	O
Dementia	O
12	O
.	O
Anemia	O
,	O
baseline	O
hct	O
around	O
30	O
.	O
13	O
.	O
Barrett	O
's	O
Esophagus	O
seen	O
on	O
[	O
**	O
2133	O
**	O
]	O
EGD	O
14	O
.	O
s	O
/	O
p	O
removal	O
of	O
adenomatous	O
polyp	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Continue	O
all	O
previously	O
prescribed	O
medications	O
.	O
You	O
may	O
resume	O
your	O
usual	O
diet	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
gain	O
>	O
3	O
lbs	O
.	O
Adhere	O
to	O
2	O
gm	O
sodium	O
diet	O
Return	O
to	O
the	O
hospital	O
or	O
call	O
your	O
doctor	O
immediately	O
for	O
:	O
-	O
Any	O
further	O
very	O
dark	O
or	O
bloody	O
stools	O
-	O
Feeling	O
weak	O
or	O
dizzy	O
-	O
Fainting	O
or	O
feeling	O
that	O
you	O
might	O
faint	O
-	O
Any	O
trouble	O
breathing	O
-	O
Any	O
other	O
concerning	O
symptoms	O
Followup	O
Instructions	O
:	O
Please	O
call	O
your	O
primary	O
care	O
doctor	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
766	O
**	O
]	O
to	O
arrange	O
a	O
follow	O
-	O
up	O
appointment	O
.	O
You	O
will	O
also	O
need	O
a	O
repeat	O
endoscopy	O
to	O
monitor	O
your	O
[	O
**	O
Doctor	O
Last	O
Name	O
15532	O
**	O
]	O
esophagus	O
,	O
which	O
is	O
a	O
potentially	O
pre-cancerous	O
condition	O
.	O
Your	O
primary	O
care	O
doctor	O
can	O
arrange	O
the	O
appointment	O
with	O
gastroenterology	O
for	O
you	O
,	O
or	O
you	O
can	O
call	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
8892	O
**	O
]	O
to	O
schedule	O
an	O
appointment	O
.	O
You	O
should	O
see	O
them	O
within	O
the	O
next	O
4	O
weeks	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2124-12-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2124-12-26	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2062-12-13	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2297	O
**	O
]	O
Chief	O
Complaint	O
:	O
Shortness	O
of	O
Breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Intubation	O
and	O
Mechanical	O
Ventilation	O
Arterial	O
Line	O
Placement	O
Bronchoscopy	O
History	O
of	O
Present	O
Illness	O
:	O
61	O
yo	O
M	O
with	O
hypertension	O
,	O
COPD	O
,	O
alcoholism	O
(	O
unclear	O
if	O
active	O
)	O
,	O
possible	O
schizophrenia	O
was	O
admitted	O
overnight	O
through	O
the	O
ED	O
.	O
His	O
ability	O
to	O
relate	O
a	O
consistent	O
hx	O
is	O
currently	O
impaired	O
,	O
but	O
per	O
prior	O
notes	O
,	O
it	O
seems	O
that	O
he	O
was	O
told	O
by	O
his	O
neighbor	O
to	O
come	O
to	O
the	O
hospital	O
as	O
he	O
appeared	O
short	O
of	O
breath	O
.	O
The	O
initial	O
assessment	O
of	O
ED	O
staff	O
was	O
that	O
the	O
pt	O
was	O
massively	O
fluid	B-Reason
overloaded	I-Reason
in	O
the	O
setting	O
of	O
CHF	I-Reason
and	O
non-compliance	O
with	O
lasix	I-Drug
.	O
He	O
was	O
treated	O
with	O
Lasix	I-Drug
IV	O
40	O
mg	O
x	O
2	O
,	O
ASA	I-Drug
325	O
and	O
nitro	I-Drug
,	O
although	O
no	O
chest	O
pain	O
and	O
EKG	O
.	O
Further	O
review	O
of	O
OMR	O
reveals	O
that	O
the	O
pt	O
is	O
no	O
on	O
lasix	I-Drug
and	O
has	O
no	O
clinical	O
hx	O
of	O
CHF	O
,	O
last	O
echo	O
in	O
[	O
**	O
2119	O
**	O
]	O
showed	O
preserved	O
LVEF	O
of	O
55	O
with	O
only	O
mild	O
Ao	O
dilation	O
.	O
.	O
Initial	O
labs	O
were	O
notable	O
for	O
Na	O
of	O
116	O
with	O
K	O
of	O
6.6	O
(	O
initial	O
7.8	O
was	O
hemolyzed	O
)	O
and	O
CR	O
2.7	O
;	O
no	O
EKG	O
changes	O
.	O
LFTs	O
elevated	O
AST	O
120	O
,	O
ALT	O
50	O
,	O
with	O
bili	O
4.5	O
,	O
INR	O
1.6	O
,	O
albumin	O
2.6	O
.	O
With	O
one	O
dose	O
of	O
kayexalate	I-Drug
,	O
potassium	O
has	O
trended	O
down	O
to	O
5.3	O
.	O
Serial	O
troponins	O
0.04	O
.	O
Initial	O
CK	O
700	O
trending	O
down	O
with	O
minimal	O
MB	O
fraction	O
.	O
.	O
In	O
terms	O
of	O
his	O
mental	O
status	O
,	O
his	O
PCP	O
saw	O
him	O
one	O
month	O
ago	O
at	O
which	O
point	O
he	O
was	O
at	O
baseline	O
A&OX	O
3	O
,	O
independent	O
for	O
all	O
ADLs	O
.	O
MS	O
not	O
in	O
ED	O
not	O
clearly	O
documented	O
.	O
At	O
8AM	O
this	O
morning	O
,	O
he	O
trigerred	O
for	O
tachypnea	O
with	O
RR	O
close	O
to	O
30	O
and	O
worsened	O
MS	O
A&O	O
x1	O
only	O
to	O
self	O
.	O
[	O
**	O
Hospital	O
**	O
]	O
transferred	O
to	O
the	O
MICU	O
.	O
On	O
arrival	O
,	O
pt	O
was	O
on	O
2L	O
and	O
confused	O
/	O
somnolent	O
.	O
His	O
audible	I-Reason
wheezing	O
,	O
tachypnea	I-Reason
,	O
and	O
hypoxia	I-Reason
improved	O
rapidly	O
with	O
albuterol	I-Drug
.	O
MS	O
improved	O
slightly	O
when	O
taken	O
off	O
supplemental	O
O2	O
.	O
ABG	O
on	O
room	O
air	O
:	O
7.4	O
/	O
35/73	O
.	O
ROS	O
:	O
Denies	O
any	O
pain	O
but	O
unable	O
to	O
provide	O
detailed	O
ROS	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Multiple	O
ED	O
admissions	O
for	O
ETOH	O
intoxication	O
2	O
.	O
HTN	O
.	O
3	O
.	O
Emphysema	O
.	O
4	O
.	O
Prostate	O
hyperplasia	O
5	O
.	O
Nocturnal	O
leg	O
cramps	O
6	O
.	O
Finger	O
reconstructive	O
surgery	O
7	O
.	O
HIV	O
?	O
(	O
per	O
OMR	O
note	O
from	O
[	O
**	O
2119	O
**	O
]	O
)	O
no	O
ab	O
tx	O
in	O
system	O
Social	O
History	O
:	O
-	O
Tobacco	O
history	O
:	O
1ppd	O
x	O
42	O
years	O
-	O
ETOH	O
:	O
History	O
of	O
alcohol	O
abuse	O
but	O
he	O
claims	O
he	O
has	O
not	O
had	O
a	O
drink	O
in	O
2	O
years	O
-	O
Illicit	O
drugs	O
:	O
Patient	O
denies	O
,	O
admission	O
tox	O
negative	O
Family	O
History	O
:	O
uanble	O
to	O
elicit	O
Physical	O
Exam	O
:	O
General	O
Appearance	O
:	O
Overweight	O
/	O
Obese	O
,	O
total	O
body	O
anasarca	O
Eyes	O
/	O
Conjunctiva	O
:	O
PERRL	O
,	O
3	O
mm	O
pupils	O
reactive	O
Head	O
,	O
Ears	O
,	O
Nose	O
,	O
Throat	O
:	O
Normocephalic	O
,	O
Poor	O
dentition	O
Lymphatic	O
:	O
Cervical	O
WNL	O
,	O
Supraclavicular	O
WNL	O
,	O
No	O
(	O
t	O
)	O
Cervical	O
adenopathy	O
Cardiovascular	O
:	O
(	O
S1	O
:	O
Normal	O
)	O
,	O
(	O
S2	O
:	O
Normal	O
)	O
,	O
No	O
(	O
t	O
)	O
S3	O
,	O
No	O
(	O
t	O
)	O
S4	O
,	O
No	O
(	O
t	O
)	O
Rub	O
,	O
(	O
Murmur	O
:	O
No	O
(	O
t	O
)	O
Systolic	O
,	O
No	O
(	O
t	O
)	O
Diastolic	O
)	O
Peripheral	O
Vascular	O
:	O
(	O
Right	O
radial	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Left	O
radial	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Right	O
DP	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Left	O
DP	O
pulse	O
:	O
Present	O
)	O
Respiratory	O
/	O
Chest	O
:	O
(	O
Expansion	O
:	O
Symmetric	O
)	O
,	O
(	O
Percussion	O
:	O
No	O
(	O
t	O
)	O
Resonant	O
:	O
,	O
No	O
(	O
t	O
)	O
Hyperresonant	O
:	O
,	O
No	O
(	O
t	O
)	O
Dullness	O
:	O
)	O
,	O
(	O
Breath	O
Sounds	O
:	O
Clear	O
:	O
,	O
Wheezes	I-Reason
:	O
greatly	O
improved	O
with	O
albuterol	I-Drug
)	O
Abdominal	O
:	O
Soft	O
,	O
Distended	O
,	O
pitting	O
edema	O
over	O
entire	O
abdomen	O
Extremities	O
:	O
Right	O
lower	O
extremity	O
edema	O
:	O
4	O
+	O
,	O
Left	O
lower	O
extremity	O
edema	O
:	O
4	O
+	O
,	O
Clubbing	O
Skin	O
:	O
Cool	O
,	O
Rash	O
:	O
LE	O
venous	O
stasis	O
BL	O
Neurologic	O
:	O
No	O
(	O
t	O
)	O
Attentive	O
,	O
No	O
(	O
t	O
)	O
Follows	O
simple	O
commands	O
,	O
Responds	O
to	O
:	O
Not	O
assessed	O
,	O
Oriented	O
(	O
to	O
)	O
:	O
ONLY	O
SELF	O
,	O
Movement	O
:	O
Purposeful	O
,	O
Tone	O
:	O
Normal	O
Pertinent	O
Results	O
:	O
[	O
**	O
2124-12-4	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
WBC	O
-	O
11.4	O
*	O
#	O
RBC	O
-	O
3.27	O
*	O
Hgb	O
-	O
10.7	O
*	O
Hct	O
-	O
32.3	O
*	O
MCV	O
-	O
99	O
*	O
#	O
MCH	O
-	O
32.6	O
*	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
218	O
#	O
[	O
**	O
2124-12-11	O
**	O
]	O
04:26	O
AM	O
BLOOD	O
WBC	O
-	O
12.4	O
*	O
RBC	O
-	O
2.55	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
25.6	O
*	O
MCV	O
-	O
100	O
*	O
MCH	O
-	O
35.1	O
*	O
MCHC	O
-	O
35.0	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
88	O
*	O
[	O
**	O
2124-12-16	O
**	O
]	O
03:40	O
PM	O
BLOOD	O
WBC	O
-	O
36.4	O
*	O
RBC	O
-	O
2.91	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
29.0	O
*	O
MCV	O
-	O
100	O
*	O
MCH	O
-	O
33.8	O
*	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
17.7	O
*	O
Plt	O
Ct	O
-	O
45	O
*	O
[	O
**	O
2124-12-26	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
WBC	O
-	O
16.3	O
*	O
RBC	O
-	O
2.58	O
*	O
Hgb	O
-	O
8.9	O
*	O
Hct	O
-	O
28.0	O
*	O
MCV	O
-	O
109	O
*	O
MCH	O
-	O
34.6	O
*	O
MCHC	O
-	O
31.9	O
RDW	O
-	O
21.0	O
*	O
Plt	O
Ct	O
-	O
33	O
*	O
[	O
**	O
2124-12-4	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
PT	O
-	O
18.0	O
*	O
PTT	O
-	O
35.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.6	O
*	O
[	O
**	O
2124-12-10	O
**	O
]	O
01:02	O
PM	O
BLOOD	O
PT	O
-	O
26.0	O
*	O
PTT	O
-	O
54.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.5	O
*	O
[	O
**	O
2124-12-21	O
**	O
]	O
04:33	O
AM	O
BLOOD	O
PT	O
-	O
39.5	O
*	O
PTT	O
-	O
56.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.1	O
*	O
[	O
**	O
2124-12-22	O
**	O
]	O
10:16	O
AM	O
BLOOD	O
PT	O
-	O
64.8	O
*	O
PTT	O
-	O
81.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
7.4	O
*	O
[	O
**	O
2124-12-22	O
**	O
]	O
06:40	O
PM	O
BLOOD	O
PT	O
-	O
111.4	O
*	O
PTT	O
-	O
105.1	O
*	O
INR	O
(	O
PT	O
)	O
-	O
14.2	O
*	O
[	O
**	O
2124-12-23	O
**	O
]	O
03:52	O
PM	O
BLOOD	O
PT	O
-	O
105.0	O
*	O
PTT	O
-	O
96.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
13.2	O
*	O
[	O
**	O
2124-12-25	O
**	O
]	O
03:52	O
AM	O
BLOOD	O
PT	O
-	O
150	O
*	O
PTT	O
-	O
114.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
>	O
20.2	O
[	O
**	O
2124-12-25	O
**	O
]	O
10:45	O
AM	O
BLOOD	O
PT	O
-	O
150	O
*	O
PTT	O
-	O
150	O
*	O
INR	O
(	O
PT	O
)	O
-	O
>	O
20.2	O
*	O
[	O
**	O
2124-12-25	O
**	O
]	O
04:22	O
PM	O
BLOOD	O
PT	O
-	O
150	O
*	O
PTT	O
-	O
150	O
*	O
INR	O
(	O
PT	O
)	O
-	O
>	O
20.2	O
[	O
**	O
2124-12-26	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
PT	O
-	O
150	O
*	O
PTT	O
-	O
127.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
27.4	O
*	O
[	O
**	O
2124-12-4	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
Glucose	O
-	O
72	O
UreaN	O
-	O
66	O
*	O
Creat	O
-	O
2.8	O
*	O
#	O
Na	O
-	O
116	O
*	O
K	O
-	O
7.8	O
*	O
Cl	O
-	O
87	O
*	O
HCO3	O
-	O
24	O
AnGap	O
-	O
13	O
[	O
**	O
2124-12-18	O
**	O
]	O
04:24	O
AM	O
BLOOD	O
Glucose	O
-	O
112	O
*	O
UreaN	O
-	O
83	O
*	O
Creat	O
-	O
6.4	O
*	O
#	O
Na	O
-	O
138	O
K	O
-	O
3.3	O
Cl	O
-	O
99	O
HCO3	O
-	O
23	O
AnGap	O
-	O
19	O
[	O
**	O
2124-12-26	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Glucose	O
-	O
80	O
UreaN	O
-	O
8	O
Creat	O
-	O
0.9	O
Na	O
-	O
130	O
*	O
K	O
-	O
3.7	O
Cl	O
-	O
97	O
HCO3	O
-	O
20	O
*	O
AnGap	O
-	O
17	O
[	O
**	O
2124-12-26	O
**	O
]	O
09:41	O
AM	O
BLOOD	O
Glucose	O
-	O
48	O
*	O
Na	O
-	O
131	O
*	O
K	O
-	O
4.1	O
Cl	O
-	O
98	O
HCO3	O
-	O
17	O
*	O
AnGap	O
-	O
20	O
[	O
**	O
2124-12-4	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
693	O
*	O
[	O
**	O
2124-12-6	O
**	O
]	O
06:29	O
AM	O
BLOOD	O
ALT	O
-	O
35	O
AST	O
-	O
71	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
246	O
CK	O
(	O
CPK	O
)	O
-	O
225	O
*	O
AlkPhos	O
-	O
86	O
TotBili	O
-	O
4.0	O
*	O
[	O
**	O
2124-12-15	O
**	O
]	O
04:27	O
AM	O
BLOOD	O
ALT	O
-	O
84	O
*	O
AST	O
-	O
230	O
*	O
AlkPhos	O
-	O
87	O
TotBili	O
-	O
8.4	O
*	O
[	O
**	O
2124-12-17	O
**	O
]	O
04:21	O
AM	O
BLOOD	O
ALT	O
-	O
589	O
*	O
AST	O
-	O
1196	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
506	O
*	O
AlkPhos	O
-	O
151	O
*	O
TotBili	O
-	O
9.8	O
*	O
[	O
**	O
2124-12-20	O
**	O
]	O
06:21	O
PM	O
BLOOD	O
ALT	O
-	O
348	O
*	O
AST	O
-	O
387	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
14	O
*	O
AlkPhos	O
-	O
171	O
*	O
TotBili	O
-	O
14.9	O
*	O
[	O
**	O
2124-12-22	O
**	O
]	O
05:36	O
AM	O
BLOOD	O
ALT	O
-	O
271	O
*	O
AST	O
-	O
344	O
*	O
AlkPhos	O
-	O
162	O
*	O
TotBili	O
-	O
14.6	O
*	O
[	O
**	O
2124-12-23	O
**	O
]	O
12:30	O
AM	O
BLOOD	O
ALT	O
-	O
1307	O
*	O
AST	O
-	O
5023	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
2880	O
*	O
AlkPhos	O
-	O
246	O
*	O
TotBili	O
-	O
13.3	O
*	O
[	O
**	O
2124-12-23	O
**	O
]	O
03:52	O
PM	O
BLOOD	O
ALT	O
-	O
2172	O
*	O
AST	O
-	O
7388	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
2712	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
45	O
AlkPhos	O
-	O
412	O
*	O
TotBili	O
-	O
13.4	O
*	O
[	O
**	O
2124-12-24	O
**	O
]	O
05:11	O
AM	O
BLOOD	O
ALT	O
-	O
2203	O
*	O
AST	O
-	O
6404	O
*	O
AlkPhos	O
-	O
492	O
*	O
TotBili	O
-	O
14.6	O
*	O
[	O
**	O
2124-12-25	O
**	O
]	O
04:22	O
PM	O
BLOOD	O
ALT	O
-	O
1549	O
*	O
AST	O
-	O
2710	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
878	O
*	O
AlkPhos	O
-	O
564	O
*	O
TotBili	O
-	O
16.1	O
*	O
[	O
**	O
2124-12-26	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
ALT	O
-	O
1325	O
*	O
AST	O
-	O
[	O
**	O
2071	O
**	O
]	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
824	O
*	O
AlkPhos	O
-	O
589	O
*	O
TotBili	O
-	O
16.8	O
*	O
[	O
**	O
2124-12-4	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
ASA	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
[	O
**	O
2124-12-4	O
**	O
]	O
10:00	O
PM	O
BLOOD	O
Ethanol	O
-	O
NEG	O
[	O
**	O
2124-12-8	O
**	O
]	O
05:22	O
AM	O
BLOOD	O
C3	O
-	O
19	O
*	O
C4	O
-	O
6	O
*	O
[	O
**	O
2124-12-20	O
**	O
]	O
05:26	O
AM	O
BLOOD	O
IgG	O
-	O
2123	O
*	O
[	O
**	O
2124-12-5	O
**	O
]	O
06:08	O
PM	O
BLOOD	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
-	O
NEGATIVE	O
[	O
**	O
2124-12-5	O
**	O
]	O
06:08	O
PM	O
BLOOD	O
AMA	O
-	O
NEGATIVE	O
Smooth	O
-	O
POSITIVE	O
*	O
[	O
**	O
2124-12-8	O
**	O
]	O
04:16	O
PM	O
BLOOD	O
ANCA	O
-	O
NEGATIVE	O
B	O
[	O
**	O
2124-12-23	O
**	O
]	O
03:52	O
PM	O
BLOOD	O
Smooth	O
-	O
POSITIVE	O
A	O
[	O
**	O
2124-12-5	O
**	O
]	O
06:08	O
PM	O
BLOOD	O
HBsAg	O
-	O
NEGATIVE	O
HBsAb	O
-	O
NEGATIVE	O
HAV	O
Ab	O
-	O
POSITIVE	O
IgM	O
HBc	O
-	O
NEGATIVE	O
[	O
**	O
2124-12-12	O
**	O
]	O
02:34	O
PM	O
BLOOD	O
Cortsol	O
-	O
12.1	O
[	O
**	O
2124-12-12	O
**	O
]	O
03:15	O
PM	O
BLOOD	O
Cortsol	O
-	O
17.8	O
[	O
**	O
2124-12-5	O
**	O
]	O
06:08	O
PM	O
BLOOD	O
calTIBC	O
-	O
163	O
*	O
Hapto	O
-	O
<	O
20	O
*	O
Ferritn	O
-	O
1368	O
*	O
TRF	O
-	O
125	O
*	O
[	O
**	O
2124-12-5	O
**	O
]	O
10:29	O
AM	O
BLOOD	O
Lactate	O
-	O
1.7	O
K	O
-	O
5.0	O
[	O
**	O
2124-12-20	O
**	O
]	O
11:10	O
AM	O
BLOOD	O
Lactate	O
-	O
2.3	O
*	O
[	O
**	O
2124-12-21	O
**	O
]	O
04:58	O
AM	O
BLOOD	O
Lactate	O
-	O
3.0	O
*	O
[	O
**	O
2124-12-23	O
**	O
]	O
04:14	O
PM	O
BLOOD	O
Lactate	O
-	O
5.9	O
*	O
[	O
**	O
2124-12-23	O
**	O
]	O
11:27	O
PM	O
BLOOD	O
Lactate	O
-	O
7.7	O
*	O
[	O
**	O
2124-12-24	O
**	O
]	O
04:11	O
PM	O
BLOOD	O
Lactate	O
-	O
6.1	O
*	O
[	O
**	O
2124-12-25	O
**	O
]	O
04:01	O
AM	O
BLOOD	O
Lactate	O
-	O
7.2	O
*	O
[	O
**	O
2124-12-26	O
**	O
]	O
04:07	O
AM	O
BLOOD	O
Lactate	O
-	O
7.6	O
*	O
IMAGING	O
:	O
[	O
**	O
2124-12-5	O
**	O
]	O
:	O
PORTABLE	O
SEMI-UPRIGHT	O
CHEST	O
RADIOGRAPH	O
:	O
Low	O
lung	O
volumes	O
and	O
body	O
habitus	O
limits	O
the	O
film	O
.	O
Heart	O
size	O
is	O
probably	O
top	O
normal	O
.	O
There	O
is	O
right	O
hilar	O
fullness	O
and	O
a	O
prominent	O
azygous	O
vein	O
suggested	O
volume	O
overload	O
.	O
Retrocardiac	O
opacification	O
may	O
be	O
dud	O
to	O
suboptimal	O
film	O
.	O
No	O
pneumothorax	O
.	O
Recommend	O
convention	O
PA	O
and	O
lateral	O
with	O
encouraged	O
increased	O
respiratory	O
effort	O
.	O
[	O
**	O
2124-12-5	O
**	O
]	O
:	O
CT	O
Head	O
:	O
IMPRESSION	O
:	O
Limited	O
study	O
secondary	O
to	O
patient	O
motion	O
without	O
evidence	O
of	O
gross	O
acute	O
intracranial	O
abnormality	O
.	O
Global	O
diffuse	O
atrophy	O
[	O
**	O
2124-12-5	O
**	O
]	O
:	O
CT	O
Chest	O
Abd	O
/	O
Pelvis	O
:	O
IMPRESSION	O
:	O
Markedly	O
limited	O
examination	O
secondary	O
to	O
patient	O
body	O
habitus	O
and	O
lack	O
of	O
intravenous	O
contrast	O
.	O
1	O
.	O
Nodular	O
liver	O
suggestive	O
of	O
cirrhosis	O
.	O
Splenomegaly	O
,	O
likely	O
indicative	O
of	O
portal	O
hypertension	O
.	O
2	O
.	O
Mild	O
intra-abdominal	O
ascites	O
.	O
3	O
.	O
Mild	O
centrilobular	O
emphysema	O
.	O
4	O
.	O
Cholelithiasis	O
.	O
[	O
**	O
2124-12-11	O
**	O
]	O
:	O
CT	O
Chest	O
/	O
Abd	O
/	O
Pelvis	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Interval	O
development	O
of	O
bilateral	O
lower	O
lobe	O
consolidations	O
with	O
air	O
bronchograms	O
concerning	O
for	O
aspiration	O
pneumonia	O
.	O
Diffuse	O
ground	O
glass	O
opacity	O
throughout	O
both	O
lungs	O
is	O
also	O
identified	O
and	O
may	O
represent	O
superimposed	O
pulmonary	O
edema	O
.	O
2	O
.	O
Interval	O
development	O
of	O
mediastinal	O
and	O
axillary	O
lymph	O
nodes	O
which	O
may	O
be	O
reactive	O
.	O
3	O
.	O
Cirrhotic	O
-	O
appearing	O
liver	O
with	O
splenomegaly	O
,	O
unchanged	O
.	O
4	O
.	O
Interval	O
decrease	O
in	O
intra-abdominal	O
ascites	O
.	O
5	O
.	O
Cholelithiasis	O
with	O
gallbladder	O
distention	O
.	O
6	O
.	O
Emphysematous	O
changes	O
.	O
[	O
**	O
2124-12-20	O
**	O
]	O
:	O
Liver	O
U	O
/	O
S	O
:	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
acute	O
gallbladder	O
process	O
.	O
Gallstones	O
again	O
noted	O
.	O
[	O
**	O
2124-12-21	O
**	O
]	O
:	O
CT	O
Chest	O
/	O
Abd	O
/	O
Pelvis	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Interval	O
improvement	O
of	O
bilateral	O
lower	O
lobe	O
consolidations	O
,	O
with	O
remaining	O
basilar	O
consolidation	O
and	O
small	O
bilateral	O
pleural	O
effusions	O
.	O
2	O
.	O
Cirrhotic	O
-	O
appearing	O
liver	O
with	O
splenomegaly	O
,	O
unchanged	O
.	O
3	O
.	O
Interval	O
increase	O
in	O
intra-abdominal	O
ascites	O
.	O
4	O
.	O
Cholelithiasis	O
with	O
gallbladder	O
distention	O
.	O
5	O
.	O
Mild	O
fat	O
stranding	O
around	O
the	O
pancreas	O
.	O
Suboptimal	O
evaluation	O
due	O
to	O
lack	O
of	O
IV	O
contrast	I-Drug
.	O
6	O
.	O
Emphysema	O
.	O
7	O
.	O
Low	O
attenuation	O
right	O
renal	O
lesion	O
,	O
most	O
consistent	O
with	O
a	O
cyst	O
.	O
Pathology	O
:	O
Liver	O
Biopsy	O
[	O
**	O
2124-12-21	O
**	O
]	O
:	O
Liver	O
,	O
transjugular	O
needle	O
core	O
biopsy	O
:	O
Markedly	O
fragmented	O
biopsy	O
demonstrating	O
:	O
1	O
.	O
Predominantly	O
fragments	O
of	O
broad	O
,	O
fibrous	O
septa	O
with	O
mild	O
,	O
mixed	O
inflammation	O
and	O
focal	O
cholangiolar	O
proliferation	O
,	O
consistent	O
with	O
established	O
cirrhosis	O
(	O
confirmed	O
by	O
trichrome	O
stain	O
)	O
.	O
2	O
.	O
Scant	O
,	O
nodular	O
foci	O
of	O
hepatic	O
lobular	O
parenchyma	O
(	O
totaling	O
only	O
20	O
%	O
of	O
the	O
total	O
biopsy	O
volume	O
)	O
,	O
with	O
focal	O
microvesicular	O
steatosis	O
and	O
moderate	O
canalicular	O
cholestasis	O
.	O
3	O
.	O
No	O
central	O
veins	O
or	O
native	O
portal	O
tracts	O
present	O
for	O
evaluation	O
in	O
this	O
limited	O
sample	O
.	O
4	O
.	O
Iron	O
stain	O
shows	O
moderate	O
iron	O
deposition	O
within	O
hepatocytes	O
.	O
Note	O
:	O
The	O
biopsy	O
consists	O
almost	O
exclusively	O
of	O
fibrous	O
tissue	O
,	O
consistent	O
with	O
established	O
cirrhosis	O
.	O
The	O
scant	O
lobular	O
parenchyma	O
present	O
shows	O
only	O
minimal	O
,	O
non-specific	O
changes	O
of	O
end	O
stage	O
liver	O
disease	O
.	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
4370	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
was	O
notified	O
of	O
the	O
findings	O
on	O
[	O
**	O
2124-12-22	O
**	O
]	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
61	O
yom	O
with	O
hx	O
of	O
HTN	O
and	O
COPD	O
who	O
initially	O
presented	O
to	O
the	O
ED	O
c	O
/	O
o	O
SOB	O
and	O
noted	O
to	O
be	O
massively	O
fluid	O
overloaded	O
,	O
in	O
ARF	O
with	O
hyponatremia	O
/	O
hyperkalemia	O
,	O
with	O
transaminitis	O
and	O
synthetic	O
dysfunction	O
who	O
was	O
then	O
admitted	O
to	O
the	O
MICU	O
for	O
altered	O
mental	O
status	O
and	O
eventually	O
intubated	O
for	O
respiratory	O
distress	O
and	O
fluid	O
overload	O
.	O
#	O
Acute	O
on	O
Chronic	O
Liver	O
Failure	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
presented	O
with	O
total	O
body	O
fluid	O
overload	O
.	O
He	O
had	O
a	O
transaminitis	O
which	O
improved	O
and	O
worsened	O
several	O
times	O
throughout	O
his	O
hospital	O
stay	O
.	O
He	O
had	O
synthetic	O
dysfunction	O
of	O
the	O
liver	O
manifested	O
by	O
thrombocytopenia	O
and	O
coagulopathy	O
.	O
All	O
of	O
these	O
findings	O
were	O
consistent	O
with	O
cirrhosis	O
.	O
A	O
CT	O
scan	O
on	O
admission	O
confirmed	O
a	O
nodular	O
liver	O
.	O
He	O
slowly	O
developed	O
worsening	O
liver	O
failure	O
during	O
his	O
hospitalization	O
.	O
A	O
liver	O
biopsy	O
was	O
done	O
on	O
[	O
**	O
2124-12-21	O
**	O
]	O
which	O
confirmed	O
cirrhosis	O
.	O
Hepatitis	O
serologies	O
were	O
sent	O
and	O
were	O
negative	O
for	O
Hep	O
B	O
and	O
Hep	O
C.	O
Hep	O
A	O
antibody	O
was	O
positive	O
.	O
Hepatology	O
was	O
consulted	O
and	O
cirrhosis	O
was	O
thought	O
to	O
be	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
history	O
of	O
EtOH	O
abuse	O
.	O
Tranaminitis	O
in	O
the	O
hospital	O
was	O
unclear	O
but	O
possibly	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
shock	O
liver	O
in	O
the	O
setting	O
of	O
hypotension	O
.	O
INR	O
continued	O
to	O
rise	O
and	O
peaked	O
to	O
a	O
level	O
of	O
27	O
today	O
.	O
Family	O
was	O
involved	O
and	O
a	O
family	O
meeting	O
was	O
held	O
today	O
given	O
his	O
worsensing	O
liver	O
failure	O
and	O
shock	I-Reason
which	O
was	O
requiring	O
4	O
pressors	I-Drug
.	O
He	O
was	O
made	O
CMO	O
by	O
his	O
father	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
and	O
the	O
patient	O
passed	O
away	O
peacefully	O
today	O
at	O
225	O
pm	O
.	O
#	O
Hypoxic	O
respiratory	O
failure	O
/	O
Pneumonia	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
initially	O
intubated	O
for	O
respiraroty	O
distress	O
in	O
the	O
setting	O
of	O
hypoxemia	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
fluid	B-Reason
overload	I-Reason
.	O
He	O
was	O
treated	O
with	O
diuretics	I-Drug
with	O
minimal	O
urine	O
output	O
.	O
Renal	O
was	O
consulted	O
and	O
he	O
was	O
diagnosed	O
with	O
Hepatorenal	O
syndrome	O
and	O
required	O
dialysis	O
for	O
fluid	O
removal	O
.	O
He	O
was	O
placed	O
on	O
HD	O
with	O
good	O
removal	O
of	O
fluid	O
intitially	O
.	O
WBC	O
then	O
began	O
to	O
elevate	O
and	O
CXR	O
was	O
consistent	O
with	O
Pneumonia	O
so	O
he	O
was	O
started	O
on	O
Vanco	I-Drug
/	O
Zosyn	I-Drug
/	O
Levo	I-Drug
for	O
treament	O
of	O
hospital	B-Reason
acquired	I-Reason
pneumonia	I-Reason
.	O
He	O
completed	O
a	O
7	O
day	O
course	O
for	O
his	O
PNA	O
.	O
He	O
self	O
extubated	O
while	O
in	O
the	O
MICU	O
and	O
was	O
then	O
reintubated	O
for	O
respiratory	O
distress	O
.	O
He	O
then	O
developed	O
VAP	I-Reason
while	O
intubated	O
and	O
was	O
treated	O
with	O
Vanco	I-Drug
/	O
Zosyn	I-Drug
/	O
Cipro	I-Drug
.	O
#	O
Shock	O
:	O
Patient	O
had	O
acute	O
decompensated	O
liver	O
failure	O
along	O
with	O
pneumonia	O
which	O
were	O
likely	O
contributing	O
to	O
his	O
shock	O
.	O
Broead	O
infectious	O
workup	O
was	O
done	O
and	O
workup	O
remained	O
negative	O
while	O
in	O
the	O
hospital	O
.	O
He	O
was	O
treated	O
with	O
Vanco	I-Drug
/	O
Zosyn	I-Drug
/	O
Cipro	I-Drug
for	O
treatment	O
of	O
HAP	I-Reason
.	O
Flagyl	I-Drug
was	O
started	O
out	O
of	O
concern	O
for	O
c.diff	I-Reason
although	O
c.diff	O
cultures	O
remained	O
negative	O
.	O
#	O
Altered	B-Reason
mental	I-Reason
status	I-Reason
:	O
Thought	O
to	O
be	O
secondary	O
to	O
hepatic	I-Reason
encephalopathy	O
.	O
Initially	O
improved	O
with	O
lactulose	I-Drug
.	O
Patient	O
was	O
treated	O
with	O
lactulose	I-Drug
and	O
rifaximin	I-Drug
throughout	O
his	O
stay	O
.	O
#	O
Acute	O
Renal	O
Failure	O
:	O
Thought	O
to	O
be	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
hepatorenal	O
syndrome	O
.	O
He	O
developed	O
anuria	O
while	O
in	O
the	O
hospital	O
.	O
Given	O
his	O
fluid	O
overload	O
and	O
pulmonary	O
edema	O
requiring	O
intubation	O
,	O
renal	O
was	O
consulted	O
and	O
a	O
dialysis	O
line	O
was	O
placed	O
.	O
He	O
was	O
placed	O
on	O
HD	O
for	O
removal	O
of	O
fluid	O
.	O
This	O
was	O
changed	O
to	O
CVVH	O
when	O
he	O
became	O
hypotensive	O
to	O
allow	O
for	O
gentle	O
fluid	O
removal	O
.	O
#	O
Hyponatremia	O
:	O
Thought	O
to	O
be	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
fluid	O
overload	O
in	O
the	O
setting	O
of	O
cirrhosis	O
#	O
Coagulopathy	O
:	O
Likley	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
cirrhosis	O
and	O
liver	O
failure	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
COMBIVENT	I-Drug
INHALER	O
2	O
.	O
CYCLOBENZAPRINE	I-Drug
10	O
MG	O
TABLET	O
3	O
.	O
DOXAZOSIN	B-Drug
MESYLATE	I-Drug
8	O
MG	O
TAB	O
4	O
.	O
FINASTERIDE	B-Drug
5	O
MG	O
TABLET	O
5	O
.	O
FLUCONAZOLE	I-Drug
200	O
MG	O
TABLET	O
6	O
.	O
GABAPENTIN	I-Drug
100	O
MG	O
CAPSULE	O
7	O
.	O
HYDROCHLOROTHIAZIDE	I-Drug
25	O
MG	O
TAB	O
8	O
.	O
KETOCONAZOLE	I-Drug
2	O
%	O
CREAM	O
9	O
.	O
LACLOTION	I-Drug
12	O
%	O
LOTION	O
10	O
.	O
NYSTATIN	I-Drug
100,000	O
UNIT	O
/	O
GM	O
POWD	O
11	O
.	O
UREA	I-Drug
40	O
%	O
CREAM	O
Discharge	O
Medications	O
:	O
Expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Expired	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
Expired	O
Followup	O
Instructions	O
:	O
Expired	O

Admission	O
Date	O
:	O
[	O
**	O
2108-4-9	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2108-4-19	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
348	O
**	O
]	O
Chief	O
Complaint	O
:	O
weakness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
male	O
with	O
history	O
of	O
congestive	O
heart	O
failure	O
,	O
chronic	O
kidney	O
disease	O
,	O
gout	O
,	O
GERD	O
,	O
anemia	O
,	O
and	O
possible	O
MDS	O
was	O
admitted	O
from	O
the	O
ED	O
with	O
weakness	O
.	O
.	O
He	O
initially	O
presented	O
to	O
geriatrics	O
clinic	O
with	O
2	O
-	O
3	O
weeks	O
of	O
diarrhea	O
and	O
vomiting	O
.	O
Additional	O
review	O
of	O
systems	O
was	O
notable	O
for	O
the	O
following	O
:	O
poor	O
intake	O
,	O
decreased	O
appetite	O
.	O
He	O
denied	O
fevers	O
,	O
shaking	O
chills	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpitations	O
,	O
abdominal	O
pain	O
,	O
bright	O
red	O
blood	O
per	O
rectum	O
,	O
muscle	O
aches	O
,	O
and	O
pain	O
.	O
.	O
Upon	O
arrival	O
in	O
the	O
ED	O
,	O
temp	O
98.3	O
,	O
HR	O
70	O
,	O
BP	O
75/45	O
,	O
and	O
pulse	O
ox	O
97	O
%	O
.	O
His	O
exam	O
was	O
notable	O
for	O
dry	O
mucous	O
membranes	O
,	O
irregular	O
heart	O
rate	O
,	O
and	O
decreased	O
skin	O
turgor	O
.	O
His	O
abdominal	O
and	O
pulmonary	O
exams	O
were	O
unremarkable	O
.	O
He	O
received	O
levofloxacin	I-Drug
750	O
mg	O
IV	O
x	O
1	O
,	O
metronidazole	I-Drug
500	O
mg	O
IV	O
x	O
1	O
,	O
potassium	B-Drug
chloride	I-Drug
20mEq	O
IV	O
x	O
1	O
,	O
and	O
1L	O
NS	B-Drug
IVF	I-Drug
.	O
RUQ	O
US	O
demonstrated	O
unchanged	O
cholelithiasis	O
and	O
CXR	O
was	O
unremarkable	O
.	O
He	O
was	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
management	O
of	O
his	O
hypotension	O
and	O
weakness	O
.	O
Upon	O
arrival	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
he	O
reports	O
feeling	O
much	O
improved	O
with	O
improved	O
strength	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Congestive	O
Heart	O
Failure	O
-	O
[	O
**	O
8	O
-	O
21	O
**	O
]	O
EF	O
20	O
-	O
30	O
%	O
,	O
dilated	O
RV	O
,	O
[	O
**	O
12	O
-	O
16	O
**	O
]	O
+	O
MR	O
,	O
1	O
+	O
TR	O
,	O
dilated	O
and	O
hypokinetic	O
RV	O
-	O
follows	O
with	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
and	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
401	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
437	O
**	O
]	O
2	O
.	O
Atrial	B-Reason
Fibrillation	I-Reason
-	O
follows	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
-	O
s	O
/	O
p	O
BiV	O
ICD	O
-	O
NSR	O
on	O
amiodarone	I-Drug
therapy	O
3	O
.	O
Chronic	O
Kidney	O
Disease	O
-	O
Baseline	O
Creatinine	O
2.3	O
-	O
2.8	O
-	O
followed	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
4883	O
**	O
]	O
4	O
.	O
Gout	O
5	O
.	O
GERD	O
6	O
.	O
Osteoarthritis	O
7	O
.	O
Myelodysplastic	O
Syndrome	O
-	O
followed	O
with	O
Drs.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
449	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
410	O
**	O
]	O
and	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
4135	O
**	O
]	O
-	O
baseline	O
hematocrit	O
32	O
/	O
baseline	O
platelets	O
100	O
-	O
120	O
/	O
baseline	O
WBC	O
[	O
**	O
3	O
-	O
18	O
**	O
]	O
8	O
.	O
BPH	O
9	O
.	O
Hypertension	O
10	O
.	O
s	O
/	O
p	O
Appendectomy	O
Social	O
History	O
:	O
-	O
Home	O
:	O
lives	O
in	O
an	O
[	O
**	O
Hospital3	O
**	O
]	O
facility	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
583	O
**	O
]	O
;	O
supportive	O
family	O
with	O
1	O
daughter	O
in	O
CT	O
,	O
1	O
daughter	O
in	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
,	O
and	O
1	O
son	O
in	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
;	O
-	O
Occupation	O
:	O
high	O
school	O
graduate	O
and	O
retired	O
heating	O
engineer	O
-	O
EtOH	O
:	O
Denies	O
-	O
Drugs	O
:	O
Denies	O
-	O
Tobacco	O
:	O
Quit	O
smoking	O
20	O
years	O
ago	O
.	O
Family	O
History	O
:	O
Noncontributory	O
Physical	O
Exam	O
:	O
VS	O
:	O
T95	O
,	O
BP	O
104/46	O
,	O
HR	O
70	O
,	O
RR	O
23	O
,	O
O2sat	O
100	O
%	O
RA	O
Gen	O
:	O
Elderly	O
male	O
,	O
fatigued	O
,	O
no	O
acute	O
distress	O
,	O
resting	O
comfortably	O
in	O
bed	O
HEENT	O
:	O
Clear	O
OP	O
,	O
dry	O
mucous	O
membranes	O
NECK	O
:	O
Supple	O
,	O
No	O
LAD	O
,	O
JVP	O
elevated	O
to	O
8	O
cm	O
CV	O
:	O
RR	O
,	O
NL	O
rate	O
.	O
NL	O
S1	O
,	O
S2	O
.	O
No	O
murmurs	O
,	O
rubs	O
or	O
gallops	O
LUNGS	O
:	O
CTA	O
,	O
BS	O
BL	O
,	O
mild	O
rales	O
at	O
bases	O
b	O
/	O
l	O
,	O
no	O
wheezes	O
or	O
rhonchi	O
ABD	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
.	O
NL	O
BS	O
.	O
No	O
HSM	O
EXT	O
:	O
No	O
edema	O
.	O
2	O
+	O
DP	O
pulses	O
BL	O
SKIN	O
:	O
No	O
lesions	O
NEURO	O
:	O
A&O	O
x3	O
.	O
Appropriate	O
.	O
CN	O
2	O
-	O
12	O
intact	O
.	O
5/5	O
strength	O
throughout	O
.	O
Normal	O
coordination	O
.	O
Gait	O
assessment	O
deferred	O
PSYCH	O
:	O
Listens	O
and	O
responds	O
to	O
questions	O
appropriately	O
,	O
pleasant	O
.	O
On	O
transfer	O
:	O
VS	O
:	O
T96	O
.2	O
,	O
BP	O
89/62	O
,	O
HR	O
68	O
,	O
O2sat	O
97	O
%	O
RA	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
male	O
with	O
multiple	O
medical	O
problems	O
including	O
congestive	O
heart	O
failure	O
,	O
atrial	B-Reason
fibrillation	I-Reason
on	O
coumadin	I-Drug
,	O
chronic	O
kidney	O
disease	O
,	O
and	O
myelodysplastic	O
syndrome	O
was	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
with	O
hypotension	I-Reason
in	O
the	O
setting	O
of	O
two	O
weeks	O
of	O
diarrhea	I-Reason
,	O
treated	O
with	O
intravenous	O
fluids	I-Drug
.	O
His	O
course	O
was	O
notable	O
for	O
progressive	O
renal	O
failure	O
and	O
anuria	O
.	O
The	O
patient	O
and	O
his	O
family	O
elected	O
to	O
focus	O
on	O
comfort	O
;	O
he	O
was	O
seen	O
by	O
the	O
palliative	O
consult	O
team	O
.	O
His	O
family	O
spent	O
the	O
day	O
with	O
him	O
on	O
[	O
**	O
4	O
-	O
18	O
**	O
]	O
;	O
he	O
died	O
on	O
[	O
**	O
2108-4-19	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Allopurinol	I-Drug
100	O
mg	O
PO	O
qod	O
2	O
.	O
Amiodarone	I-Drug
200	O
mg	O
PO	O
daily	O
3	O
.	O
Betamethasone	I-Drug
cream	O
daily	O
4	O
.	O
Calcitriol	I-Drug
.25	O
mcg	O
PO	O
q	O
MWF	O
5	O
.	O
Colchicine	I-Drug
.6	O
mg	O
PO	O
qod	O
6	O
.	O
Aranesp	I-Drug
7	O
.	O
Furosemide	I-Drug
120	O
mg	O
PO	O
tid	O
8	O
.	O
Lidocaine	I-Drug
patch	O
daily	O
9	O
.	O
Lisinopril	I-Drug
2.5	O
mg	O
PO	O
daily	O
10	O
.	O
Lopressor	I-Drug
25	O
mg	O
PO	O
bid	O
11	O
.	O
Nasonex	I-Drug
50mcg	O
intranasally	O
daily	O
12	O
.	O
Warfarin	I-Drug
2.5	O
mg	O
PO	O
daily	O
13	O
.	O
Acetaminophen	I-Drug
prn	O
14	O
.	O
Sarna	I-Drug
15	O
.	O
Omeprazole	I-Drug
20	O
mg	O
PO	O
bid	O
Discharge	O
Medications	O
:	O
N	O
/	O
A	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Renal	O
failure	O
Discharge	O
Condition	O
:	O
Expired	O

Admission	O
Date	O
:	O
[	O
**	O
2175-6-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2175-6-20	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Sulfa	B-Drug
(	I-Drug
Sulfonamides	I-Drug
)	I-Drug
/	O
Ceftriaxone	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3507	O
**	O
]	O
Chief	O
Complaint	O
:	O
SOB	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
female	O
with	O
hx	O
of	O
HTN	O
,	O
afib	O
,	O
?	O
PE	O
,	O
multiinfarct	O
dementia	O
and	O
recurrent	O
UTI	O
who	O
presents	O
with	O
lethargy	O
,	O
hypoxia	O
,	O
and	O
LE	O
erythema	O
.	O
Pt	O
is	O
aphasic	O
at	O
baseline	O
.	O
Per	O
notes	O
from	O
ED	O
and	O
PCP	O
coverage	O
,	O
the	O
patient	O
was	O
being	O
treated	O
for	O
recurrent	B-Reason
UTI	I-Reason
with	O
a	O
course	O
of	O
levofloxacin	I-Drug
started	O
on	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
but	O
was	O
otherwise	O
doing	O
well	O
.	O
Last	O
night	O
she	O
was	O
noted	O
to	O
be	O
more	O
lethargic	O
than	O
normal	O
with	O
increasing	O
SOB	O
.	O
She	O
was	O
noted	O
to	O
be	O
hypoxic	O
with	O
O2	O
Sats	O
of	O
80	O
%	O
so	O
was	O
transferred	O
to	O
the	O
ED	O
.	O
In	O
the	O
ED	O
she	O
had	O
a	O
fever	O
to	O
101.8	O
with	O
intermittent	B-Reason
hypoxia	I-Reason
that	O
improved	O
to	O
98	O
%	O
with	O
4LNS	O
oxygen	I-Drug
.	O
She	O
was	O
given	O
Clindamycin	I-Drug
600	O
mg	O
IV	O
x1	O
for	O
LE	B-Reason
cellulitis	I-Reason
and	O
a	O
dose	O
of	O
Levofloxacin	I-Drug
500	O
mg	O
IV	O
for	O
possible	B-Reason
UTI	I-Reason
.	O
For	O
her	O
hypoxia	I-Reason
,	O
she	O
was	O
given	O
20	O
mg	O
IV	O
Lasix	I-Drug
and	O
a	O
combivent	I-Drug
neb	O
with	O
significant	O
improvement	O
with	O
CTA	O
neg	O
for	O
PE	O
and	O
LENI	O
neg	O
for	O
DVT	O
.	O
She	O
continued	O
to	O
have	O
intermittent	O
hypoxia	O
of	O
unclear	O
etiology	O
so	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
closer	O
monitoring	O
.	O
.	O
In	O
the	O
MICU	O
,	O
the	O
patient	O
was	O
treated	O
with	O
CTX	I-Drug
and	O
Vanc	I-Drug
for	O
UTI	I-Reason
/	O
cellulitis	I-Reason
.	O
Also	O
diuresed	O
.	O
Patient	O
improved	O
and	O
sent	O
to	O
floor	O
[	O
**	O
6	O
-	O
11	O
**	O
]	O
on	O
2L	O
NC	O
.	O
Patient	O
noted	O
to	O
have	O
increased	B-Ade
Eos	I-Ade
in	O
blood	O
and	O
urine	O
so	O
CTX	I-Drug
stopped	O
and	O
placed	O
on	O
levo	I-Drug
/	O
macrodantin	I-Drug
.	O
.	O
[	O
**	O
6	O
-	O
13	O
**	O
]	O
Patient	O
decompenstated	O
on	O
the	O
floor	O
.	O
Patient	O
desatted	O
to	O
80's	O
on	O
6L	O
NC	O
.	O
ABG	O
7.46	O
/	O
52/63	O
on	O
6L	O
NC	O
.	O
Patient	O
initially	O
with	O
HR	O
in	O
80's	O
.	O
Patient	O
given	O
lasix	I-Drug
20	O
mg	O
IV	O
x	O
1	O
and	O
an	O
alb	I-Drug
neb.	O
.	O
Then	O
went	O
into	O
afib	B-Reason
with	I-Reason
RVR	I-Reason
into	O
the	O
140	O
's	O
maintaining	O
her	O
pressure	O
.	O
Patient	O
given	O
5	O
mg	O
IV	O
lopressor	I-Drug
x	O
3	O
with	O
out	O
response	O
in	O
HR	O
.	O
Transferred	O
back	O
unit	O
for	O
further	O
mgt	O
of	O
HR	O
and	O
hypoxia	O
,	O
where	O
she	O
was	O
started	O
on	O
a	O
diltiazem	I-Drug
drip	O
;	O
CTA	O
was	O
without	O
evidence	O
of	O
PE	O
.	O
Course	O
complicated	O
by	O
persistent	O
hypotension	I-Ade
requiring	O
multiple	O
fluid	I-Drug
boluses	O
;	O
this	O
resolved	O
after	O
the	O
discontinuation	O
of	O
the	O
diltiazem	I-Drug
drip	O
.	O
She	O
was	O
started	O
on	O
an	O
amiodarone	I-Drug
load	O
with	O
conversion	B-Reason
into	I-Reason
NSR	I-Reason
.	O
Her	O
O2	O
sat	O
improved	O
with	O
diuresis	O
.	O
A	O
picc	O
line	O
was	O
placed	O
and	O
she	O
was	O
started	O
on	O
aztreonam	I-Drug
(	O
instead	O
of	O
macrobid	I-Drug
)	O
for	O
UTI	I-Reason
.	O
She	O
was	O
transferred	O
back	O
to	O
the	O
general	O
medical	O
floor	O
on	O
[	O
**	O
2175-6-16	O
**	O
]	O
.	O
Currently	O
,	O
she	O
has	O
a	O
new	O
rash	I-Ade
over	O
her	O
trunk	O
and	O
arms	O
bilaterally	O
--	O
thought	O
to	O
be	O
from	O
Ceftriaxone	I-Drug
.	O
Past	O
Medical	O
History	O
:	O
CVA	O
-	O
with	O
multiinfarct	O
dementia	O
-	O
aphasic	O
at	O
baseline	O
Afib	O
UTI	O
Zoster	O
-	O
L	O
thorax	O
Syncope	O
PE	O
Hypothyroidism	O
DJD	O
Social	O
History	O
:	O
Divorced	O
,	O
lived	O
alone	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
7349	O
**	O
]	O
until	O
fall	O
at	O
home	O
with	O
hip	O
fx	O
then	O
moved	O
to	O
NH	O
here	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
because	O
son	O
lives	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
392	O
**	O
]	O
,	O
had	O
CVA	O
at	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
never	O
smoker	O
,	O
no	O
ETOH	O
,	O
no	O
illicits	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
T	O
98	O
HR	O
93	O
BP	O
100/37	O
RR	O
24	O
O2Sat	O
99	O
(	O
3LNC	O
)	O
Gen	O
:	O
chronically	O
ill	O
,	O
in	O
bed	O
listing	O
to	O
left	O
side	O
,	O
NAD	O
HEENT	O
:	O
R	O
nasolabial	O
flattening	O
,	O
Edentulous	O
,	O
Dry	O
MM	O
,	O
Neck	O
:	O
JVP	O
to	O
mandible	O
Heart	O
:	O
regular	O
with	O
occasional	O
premature	O
beats	O
,	O
no	O
MRG	O
,	O
no	O
heave	O
,	O
not	O
parvus	O
et	O
tardus	O
Lungs	O
:	O
Marked	O
kyphosis	O
,	O
Bilateral	O
crackles	O
throughout	O
,	O
decreased	O
breath	O
sounds	O
at	O
R	O
base	O
-	O
not	O
dull	O
to	O
percussion	O
.	O
Abd	O
:	O
soft	O
,	O
NT	O
,	O
ND	O
,	O
BS	O
+	O
Extrem	O
:	O
2	O
+	O
LLE	O
with	O
erthema	O
to	O
midshin	O
,	O
1	O
+	O
RLE	O
,	O
1	O
+	O
DP	O
pulses	O
bilaterally	O
.	O
Neuro	O
:	O
expressive	O
aphasia	O
-	O
unintelligable	O
speech	O
,	O
follows	O
verbal	O
commands	O
"	O
close	O
your	O
eyes	O
"	O
"	O
wiggle	O
your	O
toes	O
"	O
Pupils	O
2	O
--	O
>	O
1	O
cm	O
bilaterally	O
,	O
arcus	O
senilis	O
,	O
moving	O
all	O
4	O
extremities	O
.	O
Skin	O
:	O
Large	O
3x4cm	O
SK	O
's	O
over	O
thorax	O
,	O
crusted	O
raised	O
lesions	O
in	O
T4	O
distribution	O
on	O
Left	O
back	O
and	O
chest	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2175-6-10	O
**	O
]	O
CT	O
CHEST	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
pulmonary	O
embolism	O
,	O
aortic	O
aneurysm	O
,	O
or	O
dissection	O
.	O
2	O
.	O
No	O
evidence	O
of	O
pneumonia	O
.	O
3	O
.	O
Midthoracic	O
vertebral	O
body	O
compression	O
fracture	O
likely	O
chronic	O
.	O
4	O
.	O
Calcified	O
left	O
lung	O
granuloma	O
and	O
mediastinal	O
lymph	O
node	O
consistent	O
with	O
old	O
granulomatous	O
disease	O
,	O
such	O
as	O
tuberculosis	O
.	O
5	O
.	O
Moderate	O
-	O
sized	O
hiatal	O
hernia	O
.	O
.	O
[	O
**	O
2175-6-10	O
**	O
]	O
BILAT	O
LOWER	O
EXT	O
VEINS	O
:	O
No	O
evidence	O
of	O
DVT	O
.	O
.	O
[	O
**	O
2175-6-10	O
**	O
]	O
CT	O
HEAD	O
:	O
Slightly	O
limited	O
study	O
by	O
patient	O
motion	O
,	O
but	O
no	O
intracranial	O
hemorrhage	O
is	O
identified	O
.	O
.	O
[	O
**	O
2175-6-10	O
**	O
]	O
CXR	O
:	O
No	O
evidence	O
of	O
pneumonia	O
or	O
CHF	O
.	O
.	O
[	O
**	O
2175-6-10	O
**	O
]	O
ECG	O
:	O
Technically	O
difficult	O
study	O
Sinus	O
tachycardia	O
Left	O
ventricular	O
hypertrophy	O
Early	O
R	O
wave	O
progression	O
Lateral	O
ST	O
-	O
T	O
changes	O
are	O
probably	O
due	O
to	O
ventricular	O
hypertrophy	O
Clinical	O
correlation	O
is	O
suggested	O
No	O
previous	O
tracing	O
available	O
for	O
comparison	O
.	O
[	O
**	O
2175-6-13	O
**	O
]	O
CTA	O
CHEST	O
:	O
1	O
.	O
No	O
pulmonary	O
embolism	O
.	O
2	O
.	O
Right	O
lower	O
lobe	O
atelectasis	O
/	O
consolidation	O
with	O
tiny	O
bilateral	O
pleural	O
effusions	O
.	O
3	O
.	O
Moderate	O
hiatal	O
hernia	O
.	O
4	O
.	O
Unchanged	O
calcified	O
mediastinal	O
lymph	O
node	O
.	O
.	O
[	O
**	O
2175-6-13	O
**	O
]	O
CXR	O
:	O
Small	O
bilateral	O
pleural	O
effusions	O
without	O
overt	O
CHF	O
/	O
pulmonary	O
edema	O
and	O
no	O
evidence	O
for	O
new	O
pneumonia	O
.	O
Calcified	O
granuloma	O
and	O
node	O
on	O
left	O
.	O
Osteoporosis	O
of	O
spine	O
with	O
compression	O
fractures	O
.	O
.	O
[	O
**	O
2175-6-13	O
**	O
]	O
ECG	O
:	O
Sinus	O
rhythm	O
@	O
78	O
with	O
atrial	O
premature	O
beats	O
.	O
Left	O
ventricular	O
hypertrophy	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2175-6-10	O
**	O
]	O
probably	O
no	O
significant	O
change	O
,	O
although	O
baseline	O
artifact	O
on	O
both	O
tracings	O
makes	O
comparison	O
difficult	O
.	O
TRACING	O
#	O
1	O
.	O
[	O
**	O
2175-6-13	O
**	O
]	O
ECG	O
:	O
Atrial	O
fibrillation	O
with	O
a	O
rapid	O
ventricular	O
response	O
.	O
Left	O
ventricular	O
hypertrophy	O
.	O
Non-specific	O
ST	O
-	O
T	O
wave	O
changes	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2175-6-13	O
**	O
]	O
atrial	O
fibrillation	O
and	O
ST	O
-	O
T	O
wave	O
changes	O
are	O
present	O
.	O
TRACING	O
#	O
2	O
.	O
[	O
**	O
2175-6-14	O
**	O
]	O
FLUORO	O
:	O
Successful	O
repositioning	O
of	O
the	O
right	O
-	O
sided	O
PICC	O
which	O
now	O
terminates	O
in	O
the	O
distal	O
SVC	O
.	O
Line	O
is	O
ready	O
for	O
use	O
.	O
.	O
[	O
**	O
2175-6-14	O
**	O
]	O
ECHO	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
16	O
-	O
20	O
mmHg	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
70	O
-	O
80	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Impression	O
:	O
hypertrophic	O
,	O
hyperdynamic	O
left	O
ventricle	O
.	O
[	O
**	O
2175-6-16	O
**	O
]	O
CXR	O
:	O
Lung	O
volumes	O
have	O
improved	O
,	O
borderline	O
interstitial	O
edema	O
decreased	O
,	O
heart	O
size	O
normal	O
,	O
but	O
left	O
atrium	O
likely	O
enlarged	O
.	O
Stable	O
pulmonary	O
vascular	O
congestion	O
.	O
Small	O
right	O
pleural	O
effusion	O
may	O
also	O
have	O
decreased	O
.	O
Leftward	O
tracheal	O
deviation	O
just	O
above	O
the	O
thoracic	O
inlet	O
is	O
due	O
to	O
tortuous	O
head	O
and	O
neck	O
vessels	O
.	O
.	O
[	O
**	O
2175-6-11	O
**	O
]	O
8:35	O
am	O
URINE	O
Source	O
:	O
Catheter	O
.	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2175-6-12	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
.	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
URINE	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.014	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
URINE	O
Blood	O
-	O
MOD	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
NEG	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.0	O
Leuks	O
-	O
MOD	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
URINE	O
RBC	O
-	O
[	O
**	O
7	O
-	O
23	O
**	O
]	O
*	O
WBC	O
-	O
>	O
50	O
Bacteri	O
-	O
RARE	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
[	O
**	O
4	O
-	O
17	O
**	O
]	O
[	O
**	O
2175-6-12	O
**	O
]	O
06:31	O
PM	O
URINE	O
Eos	O
-	O
POSITIVE	O
[	O
**	O
2175-6-11	O
**	O
]	O
08:35	O
AM	O
URINE	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.020	O
[	O
**	O
2175-6-11	O
**	O
]	O
08:35	O
AM	O
URINE	O
Blood	O
-	O
LGE	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
100	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
15	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
6.0	O
Leuks	O
-	O
NEG	O
[	O
**	O
2175-6-11	O
**	O
]	O
08:35	O
AM	O
URINE	O
RBC	O
-	O
88	O
*	O
WBC	O
-	O
2	O
Bacteri	O
-	O
FEW	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
0	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
WBC	O
-	O
17.6	O
*	O
RBC	O
-	O
3.73	O
*	O
Hgb	O
-	O
11.3	O
*	O
Hct	O
-	O
34.2	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
30.4	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
229	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
Neuts	O
-	O
84	O
*	O
Bands	O
-	O
9	O
*	O
Lymphs	O
-	O
2	O
*	O
Monos	O
-	O
2	O
Eos	O
-	O
3	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
Hypochr	O
-	O
1	O
+	O
Anisocy	O
-	O
1	O
+	O
Poiklo	O
-	O
1	O
+	O
Macrocy	O
-	O
1	O
+	O
Microcy	O
-	O
NORMAL	O
Polychr	O
-	O
1	O
+	O
Ovalocy	O
-	O
1	O
+	O
Stipple	O
-	O
OCCASIONAL	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
229	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
Glucose	O
-	O
144	O
*	O
UreaN	O
-	O
19	O
Creat	O
-	O
0.8	O
Na	O
-	O
138	O
K	O
-	O
4.5	O
Cl	O
-	O
99	O
HCO3	O
-	O
30	O
AnGap	O
-	O
14	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
ALT	O
-	O
11	O
AST	O
-	O
21	O
AlkPhos	O
-	O
101	O
Amylase	O
-	O
23	O
TotBili	O
-	O
0.4	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
Lipase	O
-	O
17	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
2	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2175-6-10	O
**	O
]	O
10:30	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
proBNP	O
-	O
1148	O
*	O
[	O
**	O
2175-6-10	O
**	O
]	O
10:30	O
AM	O
BLOOD	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2175-6-10	O
**	O
]	O
04:41	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
2	O
cTropnT	O
-	O
0.03	O
*	O
proBNP	O
-	O
1259	O
*	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:15	O
AM	O
BLOOD	O
Albumin	O
-	O
3.6	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.1	O
[	O
**	O
2175-6-10	O
**	O
]	O
11:55	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
101	O
pCO2	O
-	O
49	O
*	O
pH	O
-	O
7.43	O
calTCO2	O
-	O
34	O
*	O
Base	O
XS	O
-	O
6	O
Intubat	O
-	O
NOT	O
INTUBA	O
[	O
**	O
2175-6-10	O
**	O
]	O
03:34	O
AM	O
BLOOD	O
Lactate	O
-	O
1.9	O
.	O
[	O
**	O
2175-6-11	O
**	O
]	O
10:15	O
AM	O
BLOOD	O
WBC	O
-	O
10.2	O
RBC	O
-	O
3.35	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
31.9	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
32.8	O
RDW	O
-	O
13.1	O
Plt	O
Ct	O
-	O
211	O
[	O
**	O
2175-6-11	O
**	O
]	O
10:15	O
AM	O
BLOOD	O
Neuts	O
-	O
73.5	O
*	O
Lymphs	O
-	O
12.2	O
*	O
Monos	O
-	O
1.0	O
*	O
Eos	O
-	O
12.2	O
*	O
Baso	O
-	O
0	O
Atyps	O
-	O
1.0	O
*	O
[	O
**	O
2175-6-11	O
**	O
]	O
10:15	O
AM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
NORMAL	O
Poiklo	O
-	O
NORMAL	O
Macrocy	O
-	O
NORMAL	O
Microcy	O
-	O
NORMAL	O
Polychr	O
-	O
NORMAL	O
[	O
**	O
2175-6-11	O
**	O
]	O
10:15	O
AM	O
BLOOD	O
PT	O
-	O
14.3	O
*	O
PTT	O
-	O
32.3	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2175-6-11	O
**	O
]	O
10:15	O
AM	O
BLOOD	O
Plt	O
Smr	O
-	O
NORMAL	O
Plt	O
Ct	O
-	O
211	O
[	O
**	O
2175-6-11	O
**	O
]	O
05:54	O
AM	O
BLOOD	O
Glucose	O
-	O
95	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.6	O
Na	O
-	O
140	O
K	O
-	O
3.6	O
Cl	O
-	O
101	O
HCO3	O
-	O
31	O
AnGap	O
-	O
12	O
[	O
**	O
2175-6-11	O
**	O
]	O
05:54	O
AM	O
BLOOD	O
Calcium	O
-	O
8.6	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
2.2	O
.	O
CT	O
Head	O
FINDINGS	O
:	O
There	O
is	O
no	O
intracranial	O
hemorrhage	O
,	O
mass	O
effect	O
,	O
hydrocephalus	O
,	O
or	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
Ventricular	O
prominence	O
is	O
unchanged	O
,	O
consistent	O
with	O
moderate	O
cortical	O
atrophy	O
.	O
Focal	O
hypodensities	O
in	O
the	O
left	O
parietal	O
lobe	O
,	O
coronal	O
radiata	O
,	O
and	O
frontal	O
lobe	O
are	O
unchanged	O
,	O
representing	O
chronic	O
infarction	O
.	O
More	O
diffuse	O
hypodensities	O
in	O
the	O
periventricular	O
white	O
matter	O
are	O
unchanged	O
,	O
and	O
most	O
consistent	O
with	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
.	O
Surrounding	O
osseous	O
and	O
soft	O
tissue	O
structures	O
are	O
unremarkable	O
.	O
.	O
IMPRESSION	O
:	O
No	O
significant	O
change	O
since	O
[	O
**	O
2175-6-10	O
**	O
]	O
.	O
Unchanged	O
appearance	O
of	O
several	O
left	O
-	O
sided	O
chronic	O
infarcts	O
,	O
and	O
small	O
vessel	O
ischemic	O
disease	O
.	O
No	O
intracranial	O
hemorrhage	O
.	O
.	O
[	O
**	O
2175-6-20	O
**	O
]	O
06:10	O
AM	O
98	O
13	O
1.3	O
*	O
141	O
4.0	O
100	O
36	O
*	O
9	O
.	O
CXR	O
[	O
**	O
6	O
-	O
19	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Slight	O
interval	O
improvement	O
in	O
pulmonary	O
vascular	O
congestion	O
,	O
otherwise	O
no	O
significant	O
interval	O
change	O
.	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
female	O
with	O
hx	O
of	O
HTN	O
,	O
afib	O
,	O
PE	O
,	O
multinfarct	O
dementia	O
admitted	O
with	O
UTI	O
,	O
left	O
leg	O
cellulitis	O
,	O
and	O
diastolic	O
CHF	O
;	O
course	O
c	O
/	O
b	O
AF	O
with	O
RVR	O
.	O
.	O
#Diastolic	O
CHF	I-Reason
:	O
initially	O
due	O
to	O
infection	O
,	O
worsened	O
by	O
AF	O
with	O
RVR	O
and	O
fluid	O
resuscitation	O
,	O
was	O
continued	O
on	O
Lasix	I-Drug
with	O
good	O
diuresis	O
.	O
Needs	O
serial	O
assesments	O
of	O
volume	O
status	O
/	O
weights	O
at	O
her	O
nursing	O
home	O
with	O
her	O
lasix	I-Drug
titrated	O
accordingly	O
.	O
Low	O
dose	O
ACE	I-Drug
was	O
added	O
.	O
No	O
evidence	O
of	O
ACS	O
.	O
Lasix	I-Drug
held	O
on	O
day	O
of	O
d	O
/	O
c	O
secondary	O
to	O
bump	B-Ade
in	I-Ade
Cr	I-Ade
(	O
.8	O
--	O
>	O
1.3	O
)	O
.	O
Needs	O
serial	O
Chem	O
7	O
at	O
her	O
nursing	O
home	O
.	O
Currently	O
has	O
minimal	O
oxygen	O
requirements	O
.	O
.	O
#AF	O
:	O
Now	O
in	O
NSR	O
on	O
amiodarone	I-Drug
and	O
Lopressor	I-Drug
12.5	O
TID	O
.	O
Needs	O
one	O
more	O
week	O
of	O
Amio	I-Drug
200	O
[	O
**	O
Hospital1	O
**	O
]	O
then	O
200	O
mg	O
daily	O
.	O
Poor	O
anticoagulation	O
candidate	O
given	O
fall	O
risk	O
and	O
advanced	O
age	O
.	O
.	O
#UTI	O
:	O
Pt	O
has	O
received	O
7	O
days	O
of	O
treatment	O
(	O
CTX	I-Drug
,	O
macrodantin	I-Drug
,	O
aztreonam	I-Drug
)	O
for	O
E.	O
coli	O
UTI	O
;	O
d	O
/	O
c	O
'd	O
aztreonam	I-Drug
/	O
ctx	I-Drug
given	O
rash	I-Ade
.	O
.	O
#LLE	O
Cellulitis	I-Reason
:	O
resolved	O
with	O
10	O
days	O
of	O
vancomycin	I-Drug
.	O
.	O
#Rash	O
:	O
suspect	O
secondary	O
to	O
ceftriaxone	I-Drug
or	O
aztreonam	I-Drug
.	O
Resolving	O
.	O
.	O
#Dementia	O
:	O
pt	O
noted	O
to	O
be	O
more	O
somnolent	O
on	O
[	O
**	O
6	O
-	O
19	O
**	O
]	O
;	O
CT	O
head	O
/	O
ABG	O
/	O
toxic	O
-	O
metabolic	O
w	O
/	O
u	O
unrevealing	O
.	O
?	O
secondary	O
to	O
benadryl	I-Drug
(	O
from	O
rash	O
)	O
along	O
with	O
neurontin	I-Drug
.	O
Would	O
avoid	O
sedating	O
meds	O
until	O
MS	O
completely	O
back	O
to	O
baseline	O
.	O
No	O
evidence	O
of	O
recurrent	O
infection	O
.	O
Medications	O
on	O
Admission	O
:	O
Ciprofloxacin	I-Drug
250	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Amoxicillin	I-Drug
500	O
mg	O
PO	O
tid	O
?	O
d	O
/	O
c	O
'	O
ed	O
Lopressor	I-Drug
25	O
mg	O
tid	O
Lasix	I-Drug
40	O
mg	O
alt	O
20	O
mg	O
qd	O
held	O
Neurontin	I-Drug
100	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Levofloxacin	I-Drug
250	O
mg	O
qd	O
-	O
started	O
on	O
Tylenol	I-Drug
prn	O
Erythromycin	I-Drug
eye	O
ointment	O
Levalbuterol	I-Drug
Nebs	O
q6h	O
prn	O
Nortryptilline	I-Drug
25	O
mg	O
qhs	O
MVI	I-Drug
Digoxin	I-Drug
0.125	O
mg	O
qd	O
KCl	I-Drug
10	O
meq	O
qd	O
Celexa	I-Drug
10	O
mg	O
qd	O
Colace	I-Drug
Levothyroxine	I-Drug
50mcg	O
qd	O
Macrodantin	I-Drug
50	O
mg	O
qid	O
-	O
completed	O
Discharge	O
Medications	O
:	O
1	O
.	O
Citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Aspirin	B-Drug
325	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Levothyroxine	I-Drug
50	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Gabapentin	B-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
:	O
Pleaes	O
hold	O
for	O
somnolence	O
.	O
5	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
:	O
hold	O
for	O
SBP	O
<	O
110	O
or	O
HR	O
<	O
55	O
.	O
8	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
9	O
.	O
Lasix	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
alternate	O
with	O
20	O
mg	O
daily	O
to	O
start	O
[	O
**	O
6	O
-	O
21	O
**	O
]	O
.	O
10	O
.	O
Camphor	B-Drug
-	I-Drug
Menthol	I-Drug
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
11	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
for	O
1	O
weeks	O
.	O
12	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
to	O
begin	O
after	O
one	O
week	O
of	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
391	O
**	O
]	O
Bay	O
Skilled	O
Nursing	O
Facility	O
Discharge	O
Diagnosis	O
:	O
Left	O
Lower	O
Extremity	O
Cellulitis	O
Urinary	O
Tract	O
Infection	O
Diastolic	O
Dysfunction	O
/	O
Congestive	O
Heart	O
Failure	O
Atrial	O
Fibrillation	O
Drug	O
Rash	O
Secondary	O
Diagnoses	O
:	O
CVA	O
-	O
with	O
multiinfarct	O
dementia	O
-	O
aphasic	O
at	O
baseline	O
h	O
/	O
o	O
Zoster	O
-	O
L	O
thorax	O
Hypothyroidism	O
DJD	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
Please	O
come	O
back	O
to	O
the	O
emergency	O
room	O
should	O
you	O
develop	O
any	O
fevers	O
,	O
chills	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
difficulty	O
thinking	O
,	O
or	O
any	O
other	O
complaints	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
within	O
the	O
next	O
two	O
weeks	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2174-6-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2174-6-16	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2121-12-16	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Compazine	I-Drug
/	O
Reglan	I-Drug
/	O
Opioids	I-Drug
-	O
Morphine	I-Drug
&	O
Related	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
30	O
**	O
]	O
Chief	O
Complaint	O
:	O
Shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Intubation	O
Thoracentesis	O
(	O
multiple	O
)	O
Chest	O
Tube	O
History	O
of	O
Present	O
Illness	O
:	O
52	O
year	O
old	O
female	O
with	O
a	O
history	O
of	O
lone	O
atrial	O
fibrillation	O
and	O
Lyme	O
meningitis	O
presenting	O
with	O
progressive	O
shortness	O
of	O
breath	O
over	O
past	O
2	O
weeks	O
.	O
On	O
[	O
**	O
5	O
-	O
23	O
**	O
]	O
,	O
patient	O
awoke	O
with	O
10/10	O
pleuritic	B-Reason
pain	I-Reason
radiating	O
down	O
to	O
left	O
shoulder	O
to	O
left	O
arm	O
associated	O
with	O
SOB	O
and	O
diaphoresis	O
.	O
She	O
went	O
to	O
PCP	O
who	O
ordered	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
CTA	O
which	O
was	O
negative	O
for	O
PE	O
and	O
diagnosed	O
her	O
with	O
pleurisy	I-Reason
.	O
She	O
was	O
prescribed	O
motrin	I-Drug
800	O
mg	O
TID	O
.	O
.	O
Her	O
pain	I-Reason
was	O
mildy	O
improved	O
with	O
the	O
motrin	I-Drug
but	O
she	O
developed	O
DOE	O
which	O
progressed	O
to	O
dyspnea	O
at	O
rest	O
over	O
the	O
past	O
2	O
weeks	O
.	O
Also	O
endorsing	O
chest	O
heaviness	O
,	O
pleuritis	O
left	O
sided	O
/	O
LUQ	O
pain	O
,	O
orthopnea	O
and	O
PND	O
.	O
Her	O
pain	O
would	O
be	O
releived	O
sitting	O
forward	O
.	O
Denies	O
LE	O
edema	O
.	O
1	O
week	O
ago	O
she	O
experienced	O
1	O
day	O
of	O
vomiting	O
x5	O
episodes	O
NBNB	O
.	O
In	O
the	O
past	O
few	O
days	O
had	O
fevers	O
/	O
chills	O
and	O
abd	O
distention	O
associated	O
with	O
constipation	O
and	O
low	O
grade	O
headache	O
.	O
TMax	O
of	O
101.3	O
.	O
Also	O
had	O
dry	O
cough	O
.	O
Saw	O
PCP	O
who	O
took	O
CXR	O
which	O
showed	O
pna	O
with	O
b	O
/	O
l	O
pleural	O
effusions	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vitals	O
were	O
T	O
101	O
HR	O
120	O
BP	O
120/77	O
RR	O
18	O
Pox	O
89	O
%	O
RA	O
.	O
Resp	O
distress	O
.	O
CXR	O
L	O
>	O
R	O
effusion	O
and	O
pericardial	O
effusion	O
.	O
Triggered	O
in	O
the	O
ED	O
for	O
hypoxia	I-Reason
to	O
89	O
%	O
RA	O
,	O
placed	O
on	O
O2	I-Drug
by	O
N	O
/	O
C	O
+	O
abx	I-Drug
(	O
CTX	I-Drug
and	O
lev	I-Drug
)	O
,	O
2L	O
bolus	O
,	O
followed	O
by	O
150	O
/	O
hr	O
.	O
Cards	O
c	O
/	O
s	O
:	O
resolving	O
pericardial	O
effusion	O
,	O
decided	O
not	O
to	O
tap	O
.	O
Labs	O
notable	O
for	O
ALT	O
:	O
146	O
AP	O
:	O
483	O
Tbili	O
:	O
2.4	O
Alb	O
:	O
3.3	O
WBC	O
to	O
17	O
(	O
no	O
bands	O
)	O
.	O
Believe	O
that	O
pleural	O
effusion	O
may	O
be	O
bigger	O
issue	O
.	O
Had	O
thoracentesis	O
in	O
ED	O
1200cc	O
straw	O
colored	O
fluid	O
.	O
Prior	O
to	O
transfer	O
,	O
99.4	O
,	O
110	O
,	O
122/85	O
,	O
20	O
,	O
100	O
%	O
by	O
N	O
/	O
C	O
5L	O
.	O
.	O
Upon	O
arriving	O
to	O
the	O
ICU	O
,	O
patient	O
was	O
in	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
left	O
sided	O
pleuritic	O
chest	O
pain	O
.	O
She	O
felt	O
SOB	O
slightly	O
improved	O
.	O
Pain	O
worse	O
and	O
different	O
after	O
thoracentesis	O
.	O
Also	O
endorsed	O
"	O
contact	O
"	O
dermatitis	O
with	O
couple	O
blisters	O
on	O
lower	O
extremities	O
worse	O
2	O
weeks	O
ago	O
thought	O
to	O
be	O
a	O
nickel	O
allergy	O
.	O
She	O
has	O
been	O
drinking	O
POs	O
well	O
recently	O
but	O
appetite	O
poor	O
.	O
Endorsed	O
1	O
year	O
of	O
nightsweats	O
which	O
she	O
believes	O
are	O
postmenopausal	O
.	O
Of	O
note	O
,	O
she	O
missed	O
her	O
[	O
**	O
2173	O
**	O
]	O
mammogram	O
.	O
.	O
ROS	O
:	O
Review	O
of	O
Systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Review	O
of	O
Systems	O
:	O
GEN	O
:	O
No	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
HEENT	O
:	O
No	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
CV	O
:	O
No	O
palpitations	O
.	O
PULM	O
:	O
No	O
wheezing	O
.	O
GI	O
:	O
No	O
nausea	O
,	O
diarrhea	O
,	O
or	O
abdominal	O
pain	O
.	O
No	O
recent	O
change	O
in	O
bowel	O
habits	O
,	O
no	O
hematochezia	O
or	O
melena	O
.	O
GUI	O
:	O
No	O
dysuria	O
or	O
change	O
in	O
bladder	O
habits	O
.	O
MSK	O
:	O
No	O
arthritis	O
,	O
arthralgias	O
,	O
or	O
myalgias	O
.	O
NEURO	O
:	O
No	O
numbness	O
/	O
tingling	O
in	O
extremities	O
.	O
PSYCH	O
:	O
No	O
feelings	O
of	O
depression	O
or	O
anxiety	O
.	O
All	O
other	O
review	O
of	O
systems	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
SHOULDER	O
PAIN	O
,	O
LEFT	O
-	O
S	O
/	O
P	O
LABRAL	O
TEAR	O
REPAIR	O
AND	O
AC	O
REPAIR	O
FRACTURE	O
,	O
FINGER	O
OSTEOPENIA	O
MENOPAUSAL	O
STATE	O
LYME	B-Reason
DISEASE	I-Reason
meningitis	I-Reason
[	O
**	O
2170	O
**	O
]	O
s	O
/	O
p	O
3	O
years	O
of	O
abx	I-Drug
(	O
seasonal	O
plaquinel	I-Drug
plus	O
doxycycline	I-Drug
alternating	O
with	O
clarithromycin	I-Drug
,	O
finished	O
in	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
ATRIAL	O
FIBRILLATION	O
-	O
PAROXSYMAL	O
since	O
age	O
24	O
MIGRAINE	O
HERPES	O
SIMPLEX	O
COSTOCHONDRITIS	O
Social	O
History	O
:	O
She	O
has	O
one	O
dtr	O
age	O
8	O
.	O
She	O
is	O
a	O
landscape	O
designer	O
who	O
runs	O
her	O
own	O
business	O
.	O
She	O
does	O
not	O
smoke	O
.	O
Denies	O
recent	O
travel	O
.	O
Does	O
live	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
1514	O
**	O
]	O
and	O
has	O
hiked	O
recently	O
but	O
no	O
noted	O
ticks	O
.	O
Denies	O
ever	O
having	O
PPD	O
placed	O
ETOH	O
:	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
martinis	O
a	O
week	O
.	O
Tobacco	O
:	O
none	O
Illicits	O
:	O
none	O
Family	O
History	O
:	O
Mother	O
-	O
MI	O
[	O
**	O
95	O
**	O
]	O
but	O
survived	O
4	O
younger	O
siblings	O
healthy	O
father	O
died	O
of	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
18275	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
3711	O
**	O
]	O
at	O
54	O
,	O
grandfather	O
died	O
of	O
lung	O
ca	O
in	O
50s	O
,	O
a	O
smoker	O
,	O
paternal	O
aunt	O
had	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
18276	O
**	O
]	O
cancer	O
died	O
in	O
50s	O
Physical	O
Exam	O
:	O
VS	O
:	O
97.3	O
113122/76	O
93	O
%	O
3L	O
,	O
pulsus	O
12mmHg	O
GEN	O
:	O
pleasant	O
,	O
visibly	O
in	O
discomfort	O
from	O
L	O
sided	O
chest	O
pain	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
anicteric	O
,	O
MMM	O
,	O
op	O
without	O
lesions	O
,	O
no	O
supraclavicular	O
or	O
cervical	O
lymphadenopathy	O
,	O
JVP	O
to	O
jaw	O
,	O
no	O
carotid	O
bruits	O
,	O
no	O
thyromegaly	O
or	O
thyroid	O
nodules	O
RESP	O
:	O
decreased	O
bS	O
at	O
b	O
/	O
l	O
bases	O
with	O
poor	O
airmovement	O
[	O
**	O
2	O
-	O
23	O
**	O
]	O
effort	O
and	O
pain	O
CV	O
:	O
RR	O
,	O
S1	O
and	O
S2	O
wnl	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
ABD	O
:	O
mild	O
distension	O
,	O
+	O
b	O
/	O
s	O
,	O
soft	O
,	O
TTP	O
in	O
b	O
/	O
l	O
upper	O
quadrants	O
,	O
no	O
masses	O
or	O
hepatosplenomegaly	O
,	O
no	O
rebound	O
or	O
guarding	O
EXT	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
SKIN	O
:	O
no	O
jaundice	O
/	O
no	O
splinters	O
,	O
left	O
skin	O
with	O
1inch	O
diameter	O
round	O
erythematous	O
plaque	O
,	O
?	O
EN	O
,	O
right	O
posterior	O
LE	O
with	O
small	O
1	O
cm	O
erythmatous	O
bliser	O
NEURO	O
:	O
AAOx3	O
.	O
Cn	O
II	O
-	O
XII	O
intact	O
.	O
5/5	O
strength	O
throughout	O
.	O
No	O
sensory	O
deficits	O
to	O
light	O
touch	O
appreciated	O
.	O
No	O
pass	O
-	O
pointing	O
on	O
finger	O
to	O
nose	O
.	O
2	O
+	O
DTR	O
's	O
-	O
patellar	O
and	O
biceps	O
RECTAL	O
:	O
deffered	O
Pertinent	O
Results	O
:	O
EKG	O
:	O
sinus	O
tachycardia	O
at	O
a	O
rate	O
of	O
117	O
,	O
normal	O
axis	O
,	O
non-specific	O
ST	O
,	O
T	O
changes	O
,	O
diffusly	O
low	O
voltage	O
,	O
RBBB	O
pattern	O
.	O
right	O
bundeloid	O
.	O
ST	O
,	O
T	O
changes	O
are	O
new	O
since	O
[	O
**	O
2	O
-	O
1	O
**	O
]	O
.	O
.	O
2D	O
-	O
ECHOCARDIOGRAM	O
:	O
(	O
[	O
**	O
2174-6-6	O
**	O
]	O
)	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
diameters	O
of	O
aorta	O
at	O
the	O
sinus	O
,	O
ascending	O
and	O
arch	O
levels	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis	O
or	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
a	O
moderate	O
sized	O
pericardial	O
effusion	O
(	O
1.3	O
cm	O
anteriorly	O
and	O
1.8	O
cm	O
around	O
the	O
right	O
atrium	O
)	O
.	O
The	O
effusion	O
is	O
echo	O
dense	O
,	O
consistent	O
with	O
blood	O
,	O
inflammation	O
or	O
other	O
cellular	O
elements	O
.	O
Stranding	O
is	O
visualized	O
within	O
the	O
pericardial	O
space	O
c	O
/	O
w	O
organization	O
.	O
No	O
right	O
ventricular	O
diastolic	O
collapse	O
is	O
seen	O
.	O
There	O
is	O
brief	O
right	O
atrial	O
diastolic	O
invagination	O
.	O
There	O
is	O
significant	O
,	O
accentuated	O
respiratory	O
variation	O
in	O
mitral	O
/	O
tricuspid	O
valve	O
inflows	O
,	O
consistent	O
with	O
impaired	O
ventricular	O
filling	O
.	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2174-3-9	O
**	O
]	O
,	O
the	O
pericardial	O
effusion	O
is	O
new	O
.	O
No	O
overt	O
tamponade	O
is	O
seen	O
however	O
elevated	O
intrapericardial	O
pressure	O
is	O
suggested	O
.	O
.	O
Echo	O
:	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
small	O
pericardial	O
effusion	O
is	O
echo	O
dense	O
,	O
consistent	O
with	O
blood	O
,	O
inflammation	O
or	O
other	O
cellular	O
elements	O
and	O
appears	O
largely	O
organized	O
with	O
minimal	O
free	O
fluid	O
.	O
The	O
pericardium	O
may	O
be	O
thickened	O
.	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
/	O
201	O
,	O
the	O
pericardial	O
effusion	O
now	O
appears	O
slightly	O
smaller	O
.	O
LABORATORY	O
DATA	O
:	O
140	O
104	O
14	O
---	O
|	O
----	O
|	O
---	O
|	O
------	O
<	O
17.4	O
>	O
------	O
<	O
424	O
3.9	O
26	O
0.8	O
33	O
Troponin	O
<	O
0.01	O
ALT	O
:	O
146	O
AP	O
:	O
483	O
Tbili	O
:	O
2.4	O
Alb	O
:	O
3.3	O
AST	O
:	O
33	O
LDH	O
:	O
Dbili	O
:	O
TProt	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
:	O
Lip	O
:	O
17	O
PT	O
:	O
15.9	O
PTT	O
:	O
30.5	O
INR	O
:	O
1.4	O
.	O
Micro	O
:	O
Pleural	O
,	O
Blood	O
,	O
Urine	O
cultures	O
,	O
Urine	O
Legionella	O
negative	O
.	O
RUBEOLA	O
ANTIBODY	O
IgG	O
positive	O
.	O
.	O
CXR	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
:	O
Extensive	O
left	O
pleural	O
effusion	O
,	O
that	O
occupies	O
approximately	O
one	O
-	O
half	O
of	O
the	O
left	O
hemithorax	O
.	O
A	O
small	O
right	O
basal	O
pleural	O
effusion	O
.	O
Additional	O
mild	O
fluid	O
markings	O
of	O
the	O
fissures	O
and	O
slight	O
distention	O
of	O
the	O
vasculature	O
suggests	O
mild	O
pulmonary	O
edema	O
.	O
Subsequent	O
areas	O
of	O
bilateral	O
atelectasis	O
.	O
The	O
contour	O
of	O
the	O
cardiac	O
silhouette	O
can	O
not	O
be	O
reliably	O
determined	O
.	O
.	O
CXR	O
post	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
576	O
**	O
]	O
:	O
Infiltrate	O
worse	O
on	O
right	O
,	O
improved	O
on	O
left	O
,	O
no	O
PTX	O
.	O
[	O
**	O
5	O
-	O
23	O
**	O
]	O
CTA	O
Grossly	O
normal	O
study	O
,	O
specifically	O
no	O
evidence	O
of	O
pulmonary	O
embolism	O
.	O
.	O
CXR	O
:	O
[	O
**	O
2174-6-15	O
**	O
]	O
INDICATION	O
:	O
Bilateral	O
pleural	O
effusions	O
,	O
status	O
post	O
right	O
thoracocentesis	O
.	O
.	O
COMPARISON	O
:	O
[	O
**	O
2174-6-15	O
**	O
]	O
at	O
01:33	O
p.m.	O
(	O
approximately	O
three	O
hours	O
earlier	O
)	O
.	O
.	O
CHEST	O
RADIOGRAPH	O
,	O
PORTABLE	O
VIEW	O
:	O
Interval	O
removal	O
of	O
left	O
pigtail	O
catheter	O
.	O
When	O
compared	O
to	O
the	O
most	O
recent	O
study	O
,	O
there	O
has	O
been	O
decrease	O
in	O
bilateral	O
pleural	O
effusion	O
,	O
now	O
small	O
.	O
.	O
No	O
pneumothorax	O
is	O
noted	O
.	O
Bibasilar	O
atelectasis	O
is	O
again	O
noted	O
,	O
left	O
more	O
than	O
right	O
.	O
.	O
The	O
cardiomediastinal	O
and	O
hilar	O
silhouettes	O
appear	O
unchanged	O
.	O
.	O
Pleural	O
fluid	O
:	O
[	O
**	O
2174-6-15	O
**	O
]	O
ATYPICAL	O
.	O
Rare	O
atypical	O
epithelioid	O
cell	O
in	O
a	O
background	O
of	O
reactive	O
mesothelial	O
cells	O
,	O
histiocytes	O
,	O
and	O
lymphocytes	O
;	O
see	O
note	O
.	O
Note	O
:	O
One	O
hematology	O
slide	O
labeled	O
1556E	O
-	O
[	O
**	O
2174-6-15	O
**	O
]	O
was	O
reviewed	O
and	O
demonstrates	O
mesothelial	O
cells	O
;	O
no	O
atypical	O
cells	O
seen	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
52	O
year	O
old	O
female	O
with	O
a	O
history	O
of	O
lone	O
atrial	O
fibrillation	O
and	O
Lyme	O
meningitis	O
presenting	O
with	O
progressive	O
shortness	O
of	O
breath	O
and	O
DOE	O
over	O
past	O
2	O
weeks	O
admitted	O
to	O
the	O
MICU	O
with	O
pleural	O
effusions	O
and	O
a	O
pericardial	O
effusion	O
in	O
the	O
setting	O
of	O
presumed	O
viral	O
pleurisy	O
and	O
pericarditis	O
that	O
developed	O
into	O
an	O
effusion	I-Ade
after	O
chronic	O
NSAID	I-Drug
use	O
possible	O
aspiration	O
/	O
CAP	O
PNA	O
who	O
developed	O
AFIB	O
with	O
RVR	O
secondary	O
to	O
pain	O
and	O
pericardial	O
effusion	O
,	O
transaminitis	O
with	O
cholestasis	O
and	O
acute	B-Ade
renal	I-Ade
failure	I-Ade
in	O
the	O
setting	O
of	O
anemia	O
and	O
NSAID	I-Drug
use	O
who	O
has	O
a	O
persistent	O
O2	O
requirement	O
with	O
pleuritic	O
pain	O
and	O
resolving	O
pericardial	O
effusion	O
.	O
She	O
improved	O
clinically	O
prior	O
to	O
discharge	O
after	O
CT	O
placement	O
for	O
her	O
L	O
effusion	O
and	O
a	O
thoracentesis	O
to	O
remove	O
her	O
R	O
sided	O
pleural	O
effusion	O
.	O
.	O
#	O
SOB	O
/	O
CP	O
/	O
hypoxia	O
:	O
Likely	O
multifactorial	O
with	O
most	O
obvious	O
etiologies	O
being	O
pleural	O
,	O
pericardial	O
effusions	O
,	O
and	O
.	O
PE	O
was	O
less	O
likely	O
given	O
[	O
**	O
5	O
-	O
23	O
**	O
]	O
CTA	O
negative	O
.	O
Due	O
to	O
her	O
effusions	O
,	O
it	O
was	O
thought	O
she	O
may	O
have	O
an	O
underlying	O
PNA	O
and	O
she	O
was	O
started	O
on	O
levaquin	I-Drug
for	O
CAP	I-Reason
.	O
She	O
was	O
given	O
a	O
prolonged	O
course	O
due	O
to	O
concern	O
that	O
she	O
may	O
have	O
had	O
infection	O
in	O
her	O
pericardial	O
fluid	O
.	O
The	O
day	O
after	O
admission	O
(	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
)	O
she	O
was	O
intubated	O
for	O
hemodynamic	O
control	O
(	O
Afib	O
RVR	O
150s	O
)	O
,	O
pain	O
control	O
,	O
and	O
for	O
potential	O
procedure	O
for	O
a	O
possible	O
pericardial	O
window	O
.	O
From	O
a	O
respiratory	O
prospective	O
she	O
was	O
comfortable	O
prior	O
to	O
intubation	O
which	O
was	O
done	O
under	O
rapid	O
sequence	O
given	O
signs	O
of	O
early	O
tamponade	O
.	O
She	O
was	O
extubated	O
without	O
event	O
when	O
it	O
was	O
determined	O
that	O
cardiology	O
did	O
not	O
think	O
her	O
pericardal	O
effusion	O
needed	O
to	O
be	O
drained	O
.	O
Instead	O
,	O
cardiology	O
recommended	O
serial	O
Echo	O
's	O
to	O
follow	O
the	O
effusions	O
size	O
.	O
An	O
echo	O
on	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
showed	O
that	O
the	O
effusion	O
was	O
reduced	O
in	O
size	O
compared	O
to	O
prior	O
imaging	O
.	O
.	O
#Afib	O
with	I-Reason
RVR	I-Reason
:	O
The	O
Patient	O
has	O
a	O
history	O
of	O
lone	O
atrial	O
fibrillation	O
.	O
On	O
day	O
of	O
admission	O
patient	O
went	O
to	O
Afib	I-Reason
to	O
200s	O
briefly	O
sustaining	O
in	O
the	O
160s	O
.	O
This	O
was	O
thought	O
[	O
**	O
2	O
-	O
23	O
**	O
]	O
to	O
pain	O
and	O
infection	O
vs	O
tamponade	O
physiology	O
.	O
She	O
received	O
metroprolol	I-Drug
IV	O
and	O
dilt	I-Drug
drip	O
.	O
When	O
patient	O
was	O
intubated	O
,	O
she	O
converted	O
back	O
to	O
sinus	O
rhythm	O
and	O
maintained	O
in	O
sinus	O
rhythm	O
.	O
After	O
extubation	O
and	O
while	O
on	O
the	O
floor	O
the	O
patient	O
did	O
not	O
have	O
any	O
palpitations	O
or	O
further	O
episodes	O
of	O
Afib	O
wtih	O
RVR	O
.	O
-	O
She	O
will	O
need	O
to	O
discuss	O
with	O
her	O
outpatient	O
physician	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
**	O
]	O
with	O
aspirin	I-Drug
when	O
her	O
pericardial	O
effusion	O
resolves	O
.	O
.	O
#	O
Pleural	O
Effusions	O
:	O
She	O
presented	O
with	O
pleuritic	O
chest	O
pain	O
which	O
was	O
initially	O
attributed	O
to	O
her	O
pleural	O
effusions	O
.	O
Initially	O
,	O
the	O
DDx	O
was	O
broad	O
including	O
infectious	O
(	O
Lyme	O
/	O
parvo	O
negative	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
pending	O
)	O
,	O
malignant	O
(	O
cytology	O
ultimately	O
negative	O
)	O
,	O
and	O
rheumatologic	O
(	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
negative	O
and	O
C3	O
/	O
C4	O
normal	O
)	O
.	O
CHF	O
and	O
cirrhosis	O
unlikely	O
based	O
on	O
H+P	O
.	O
Lipase	O
normal	O
makes	O
pancreatits	O
unlikely	O
.	O
Thoracentesis	O
reveals	O
exudate	O
,	O
likely	O
parapneumonic	O
given	O
fevers	O
,	O
and	O
a	O
viral	O
pleuritis	O
was	O
also	O
considered	O
.	O
ID	O
was	O
consulted	O
who	O
recommended	O
empiric	O
coverage	O
for	O
CAP	I-Reason
with	O
a	O
prolonged	O
course	O
of	O
Levofloxacin	I-Drug
(	O
14	O
days	O
-	O
finish	O
on	O
[	O
**	O
6	O
-	O
20	O
**	O
]	O
)	O
due	O
to	O
a	O
concern	O
that	O
the	O
pericardial	O
fluid	O
could	O
[	O
**	O
Hospital1	O
**	O
]	O
infection	O
.	O
Cytology	O
negative	O
,	O
cultures	O
negative	O
.	O
Morphine	I-Drug
and	O
fentanyl	I-Drug
pleuritic	B-Reason
CP	I-Reason
.	O
The	O
most	O
likely	O
diagnosis	O
was	O
a	O
viral	O
infection	O
with	O
a	O
superimposed	O
bacterial	O
process	O
possibly	O
in	O
the	O
setting	O
of	O
aspiration	O
1	O
week	O
prior	O
.	O
Of	O
note	O
her	O
effusions	O
persisted	O
despite	O
antibiotic	I-Drug
therapy	O
and	O
NSAID	I-Drug
therapy	O
.	O
She	O
was	O
given	O
diuretics	I-Drug
with	O
lasix	I-Drug
which	O
did	O
not	O
reduced	O
the	O
size	O
of	O
her	O
effusion	I-Reason
.	O
Therefore	O
,	O
a	O
L	O
sided	O
chest	O
tube	O
placement	O
by	O
IP	O
in	O
addition	O
to	O
a	O
right	O
sided	O
thoracentesis	O
.	O
After	O
subsequent	O
removal	O
of	O
her	O
bilateral	O
pleural	O
effusions	O
,	O
her	O
symptoms	O
of	O
SOB	O
and	O
O2	O
requirement	O
resolved	O
.	O
.	O
#	O
Pericardial	O
Effusion	O
:	O
Initially	O
echo	O
concerning	O
for	O
early	O
but	O
not	O
overt	O
tamponade	O
physiology	O
and	O
exam	O
was	O
concerning	O
.	O
Patient	O
was	O
given	O
IVF	I-Drug
to	O
maintain	B-Reason
preload	I-Reason
.	O
Serologies	O
were	O
sent	O
as	O
above	O
.	O
Her	O
pulsus	O
was	O
monitored	O
closely	O
and	O
was	O
never	O
above	O
12mmHG	O
.	O
Cardiology	O
consult	O
followed	O
closely	O
and	O
serial	O
echos	O
showed	O
improvement	O
in	O
effusions	O
.	O
The	O
decision	O
was	O
made	O
not	O
to	O
drain	O
effusions	O
for	O
diagnostic	O
purposes	O
given	O
the	O
risks	O
involved	O
.	O
She	O
was	O
restarted	O
on	O
NSAID	I-Drug
therapy	O
for	O
viral	I-Reason
pericarditis	O
.	O
Of	O
note	O
,	O
her	O
effusion	O
improved	O
by	O
echo	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
CAP	I-Reason
:	O
Given	O
her	O
exudative	O
effusion	O
and	O
viral	O
pleuritis	O
there	O
was	O
concern	O
for	O
CAP	O
and	O
possible	O
aspiration	O
.	O
She	O
was	O
given	O
a	O
two	O
week	O
course	O
of	O
levofloxacin	I-Drug
to	O
finish	O
on	O
the	O
date	O
listed	O
above	O
.	O
.	O
#	O
Diarrhea	I-Ade
:	O
She	O
had	O
transient	O
episode	O
of	O
diarrhea	O
while	O
on	O
antibiotics	I-Drug
,	O
and	O
her	O
diarrhea	O
resolved	O
.	O
.	O
#	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
/	O
Low	O
UO	O
:	O
Dark	O
urine	O
and	O
poor	O
output	O
early	O
in	O
ICU	O
course	O
.	O
Thought	O
potentially	O
from	O
NSAIDs	I-Drug
.	O
Renal	O
spun	O
urine	O
and	O
it	O
was	O
not	O
active	O
.	O
She	O
had	O
low	B-Reason
UOP	I-Reason
,	O
which	O
improved	O
with	O
IVF	I-Drug
.	O
.	O
Cholestasis	O
and	O
Hepatitis	O
:	O
She	O
was	O
noted	O
to	O
have	O
to	O
have	O
abnormal	O
LFT	O
's	O
with	O
cholestatsis	O
in	O
addition	O
to	O
pleuritic	O
R	O
sided	O
abdominal	O
pain	O
.	O
There	O
was	O
concern	O
that	O
she	O
could	O
have	O
either	O
a	O
viral	O
induced	O
hepatitis	O
with	O
cholestasis	O
versus	O
a	O
congestive	O
hepatopathy	O
in	O
the	O
setting	O
of	O
mild	O
volume	O
overload	O
.	O
Cholecystitis	O
was	O
less	O
likely	O
given	O
the	O
absence	O
of	O
a	O
white	O
count	O
.	O
Her	O
LFT	O
's	O
trended	O
down	O
independent	O
of	O
diuresis	O
thereby	O
suggesting	O
/	O
confirming	O
a	O
possible	O
viral	O
etiology	O
for	O
her	O
hepatitis	O
and	O
cholestasis	O
.	O
Of	O
note	O
her	O
hepatitis	O
serologies	O
were	O
negative	O
.	O
.	O
#	O
Anemia	O
:	O
Baseline	O
hct	O
40s	O
most	O
recently	O
in	O
[	O
**	O
2171	O
**	O
]	O
.	O
No	O
signs	O
or	O
symptoms	O
of	O
bleeding	O
.	O
Likely	O
from	O
systemic	O
process	O
going	O
on	O
.	O
Normal	O
colonoscopy	O
in	O
[	O
**	O
2171	O
**	O
]	O
.	O
Of	O
note	O
,	O
she	O
is	O
currently	O
menopausal	O
,	O
and	O
has	O
iron	O
studies	O
that	O
suggest	O
she	O
has	O
anemia	O
of	O
chronic	O
disease	O
,	O
or	O
at	O
least	O
anemia	O
with	O
acute	O
inflammation	O
.	O
-	O
She	O
will	O
need	O
a	O
CBC	O
as	O
an	O
outpatient	O
.	O
Medications	O
on	O
Admission	O
:	O
-	O
ASPIRIN	I-Drug
TAB	O
81MG	O
EC	O
(	O
ASPIRIN	I-Drug
)	O
1	O
QD	O
Discharge	O
Medications	O
:	O
1	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
pack	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
30	O
packets	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
levofloxacin	I-Drug
750	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
4	O
days	O
.	O
Disp	O
:	O
*	O
4	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
5	O
Adhesive	O
Patch	O
,	O
Medicated	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
4	O
.	O
ibuprofen	I-Drug
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
5	O
.	O
Colace	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
6	O
.	O
Benadryl	I-Drug
25	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
Prior	O
to	O
Morphine	I-Drug
:	O
Please	O
take	O
before	O
Morphine	I-Drug
as	O
needed	O
for	O
itching	I-Ade
.	O
Please	O
do	O
not	O
drive	O
after	O
taking	O
this	O
medication	O
.	O
Disp	O
:	O
*	O
20	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
morphine	I-Drug
10	O
mg	O
Capsule	O
,	O
Ext	O
Release	O
Pellets	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Ext	O
Release	O
Pellets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
:	O
Please	O
do	O
not	O
drive	O
after	O
taking	O
this	O
medication	O
.	O
Disp	O
:	O
*	O
20	O
Capsule	O
,	O
Ext	O
Release	O
Pellets	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Pleuritis	O
with	O
Bilateral	O
Pleural	O
Effusion	O
and	O
Pericardial	O
Effusion	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
Discharge	O
Instructions	O
:	O
Dear	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
3271	O
**	O
]	O
,	O
You	O
were	O
admitted	O
for	O
worsening	O
shortness	O
of	O
breath	O
due	O
to	O
fluid	O
in	O
your	O
lungs	O
and	O
around	O
your	O
heart	O
.	O
The	O
exact	O
cause	O
of	O
this	O
is	O
unknown	O
.	O
Your	O
breathing	O
has	O
markedly	O
improved	O
and	O
you	O
are	O
presently	O
able	O
to	O
breathe	O
without	O
use	O
of	O
supplemental	O
oxygen	I-Drug
.	O
You	O
will	O
need	O
to	O
be	O
followed	O
by	O
your	O
primary	O
care	O
physician	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
were	O
started	O
on	O
an	O
antibiotics	I-Drug
and	O
ibuprofen	I-Drug
.	O
The	O
following	O
medicaiton	O
changes	O
were	O
made	O
:	O
ADDED	O
:	O
levaquin	I-Drug
,	O
ibuprofen	I-Drug
,	O
miralax	I-Drug
,	O
morphine	I-Drug
,	O
lidocaine	I-Drug
patch	O
,	O
benadryl	I-Drug
,	O
morphine	I-Drug
,	O
colace	I-Drug
STOPPED	O
:	O
aspirin	I-Drug
Followup	O
Instructions	O
:	O
Please	O
visit	O
your	O
primary	O
care	O
physician	O
for	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
702	O
**	O
]	O
bloodwork	O
and	O
to	O
determine	O
whether	O
you	O
will	O
need	O
to	O
take	O
more	O
Lasix	I-Drug
(	O
the	O
'	O
water	O
-	O
pill	O
'	O
that	O
you	O
during	O
your	O
stay	O
in	O
the	O
hopsital	O
)	O
.	O
Name	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
L.	O
Location	O
:	O
PERSONAL	O
[	O
**	O
Hospital	O
**	O
]	O
HEALTH	O
CARE	O
,	O
P.C.	O
Address	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
3881	O
**	O
]	O
,	O
[	O
**	O
Apartment	O
Address	O
(	O
1	O
)	O
1823	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
1700	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1408	O
**	O
]	O
Appt	O
:	O
[	O
**	O
6	O
-	O
21	O
**	O
]	O
at	O
4	O
pm	O
Completed	O
by	O
:[	O
**	O
2174-7-12	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2178-3-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2178-3-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2094-5-27	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3326	O
**	O
]	O
Chief	O
Complaint	O
:	O
altered	O
mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
83	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
tongue	B-Reason
cancer	I-Reason
on	O
chemoradiation	O
,	O
most	O
recent	O
cisplatin	I-Drug
dose	O
on	O
[	O
**	O
2178-3-13	O
**	O
]	O
,	O
presents	O
with	O
altered	B-Ade
mental	I-Ade
status	I-Ade
.	O
Per	O
his	O
wife	O
,	O
the	O
patient	O
took	O
his	O
oxycodone	I-Drug
-	O
acetaminophen	O
for	O
the	O
first	O
time	O
the	O
night	O
before	O
admission	O
,	O
[	O
**	O
2178-3-24	O
**	O
]	O
.	O
He	O
woke	O
up	O
the	O
morning	O
of	O
admission	O
,	O
[	O
**	O
2178-3-25	O
**	O
]	O
,	O
confused	I-Ade
and	O
somnolent	I-Ade
.	O
No	O
other	O
complaint	O
.	O
Patient	O
was	O
brought	O
to	O
the	O
ED	O
.	O
.	O
Of	O
note	O
,	O
patient	O
has	O
been	O
hyponatremic	O
lately	O
,	O
per	O
Atrius	O
records	O
:	O
.	O
Date	O
Na	O
[	O
**	O
2	O
-	O
20	O
**	O
]	O
115	O
[	O
**	O
2	O
-	O
22	O
**	O
]	O
126	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
133	O
[	O
**	O
3	O
-	O
5	O
**	O
]	O
130	O
[	O
**	O
3	O
-	O
19	O
**	O
]	O
124	O
.	O
In	O
the	O
ED	O
,	O
T	O
98.9	O
,	O
HR	O
95	O
,	O
BP	O
142/59	O
,	O
RR	O
18	O
,	O
97	O
%	O
RA	O
.	O
His	O
neuro	O
exam	O
was	O
nonfocal	O
.	O
Head	O
CT	O
showed	O
no	O
acute	O
abnormality	O
.	O
CXR	O
and	O
urinalysis	O
unremarkable	O
.	O
His	O
labs	O
were	O
notable	O
for	O
Na	O
117	O
,	O
Cr	O
0.8	O
,	O
WBC	O
2.3	O
with	O
66	O
%	O
neutrophils	O
,	O
Hct	O
22.0	O
,	O
plt	O
194	O
.	O
He	O
reportedly	O
became	O
more	O
awake	O
and	O
mental	O
status	O
almost	O
returned	O
to	O
baseline	O
after	O
some	O
hydration	O
in	O
the	O
ED	O
.	O
Admitted	O
for	O
further	O
management	O
.	O
.	O
On	O
the	O
floor	O
,	O
patient	O
was	O
oriented	O
to	O
name	O
,	O
date	O
,	O
and	O
US	O
president	O
,	O
but	O
not	O
location	O
.	O
He	O
was	O
unable	O
to	O
name	O
months	O
backwards	O
.	O
.	O
Review	O
of	O
Systems	O
:	O
not	O
obtainable	O
due	O
to	O
patient	O
's	O
mental	O
status	O
Past	O
Medical	O
History	O
:	O
ONCOLOGIC	O
HISTORY	O
:	O
#	O
Stage	O
[	O
**	O
Doctor	O
First	O
Name	O
690	O
**	O
]	O
T4aN2cM0	O
squamous	B-Reason
cell	I-Reason
carcinoma	I-Reason
of	I-Reason
the	I-Reason
tongue	I-Reason
:	O
diagnosed	O
in	O
[	O
**	O
2177-12-10	O
**	O
]	O
.	O
Started	O
on	O
radiation	O
and	O
chemotherapy	I-Drug
with	O
cisplatin	I-Drug
on	O
[	O
**	O
2178-2-12	O
**	O
]	O
.	O
.	O
OTHER	O
MEDICAL	O
HISTORY	O
:	O
HTN	O
DM2	O
Hyperlipidemia	O
BPH	O
Social	O
History	O
:	O
Quit	O
smoking	O
in	O
[	O
**	O
2155	O
**	O
]	O
after	O
20	O
pack	O
-	O
years	O
.	O
Rare	O
alcohol	O
.	O
used	O
to	O
work	O
in	O
the	O
gun	O
business	O
then	O
in	O
a	O
sporting	O
goods	O
store	O
.	O
Has	O
5	O
children	O
,	O
15	O
grandchildren	O
,	O
and	O
2	O
great	O
-	O
grandchildren	O
.	O
Family	O
History	O
:	O
Mother	O
had	O
a	O
[	O
**	O
Last	O
Name	O
**	O
]	O
problem	O
.	O
Father	O
had	O
alcoholism	O
.	O
Son	O
had	O
a	O
kidney	O
transplant	O
.	O
One	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
died	O
of	O
lung	O
cancer	O
.	O
A	O
maternal	O
uncle	O
had	O
leukemia	O
,	O
and	O
another	O
maternal	O
uncle	O
had	O
lung	O
cancer	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
99.8	O
,	O
BP	O
160/70	O
,	O
HR	O
102	O
,	O
RR	O
16	O
,	O
95	O
%	O
RA	O
GEN	O
:	O
Elderly	O
man	O
sleeping	O
in	O
bed	O
but	O
easily	O
arousable	O
,	O
in	O
NAD	O
HEENT	O
:	O
EOMI	O
,	O
sclera	O
anicteric	O
,	O
conjunctivae	O
clear	O
NECK	O
:	O
Supple	O
CV	O
:	O
Regular	O
,	O
slightly	O
tachycardic	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
CHEST	O
:	O
Resp	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
CTAB	O
,	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
ABD	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
,	O
no	O
HSM	O
,	O
bowel	O
sounds	O
present	O
MSK	O
:	O
normal	O
muscle	O
tone	O
and	O
bulk	O
EXT	O
:	O
No	O
c	O
/	O
c	O
/	O
e	O
,	O
2	O
+	O
DP	O
/	O
PT	O
bilaterally	O
SKIN	O
:	O
No	O
rash	O
,	O
warm	O
skin	O
NEURO	O
:	O
oriented	O
to	O
name	O
,	O
date	O
,	O
US	O
president	O
but	O
not	O
location	O
,	O
unable	O
to	O
name	O
months	O
backwards	O
.	O
CN	O
II	O
-	O
XII	O
intact	O
,	O
5/5	O
strength	O
throughout	O
,	O
intact	O
sensation	O
to	O
light	O
touch	O
Pertinent	O
Results	O
:	O
[	O
**	O
2178-3-25	O
**	O
]	O
01:12	O
PM	O
GLUCOSE	O
-	O
202	O
*	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
117	O
*	O
POTASSIUM	O
-	O
3.7	O
CHLORIDE	O
-	O
77	O
*	O
TOTAL	O
CO2	O
-	O
31	O
ANION	O
GAP	O
-	O
13	O
[	O
**	O
2178-3-25	O
**	O
]	O
01:12	O
PM	O
WBC	O
-	O
2.3	O
*	O
RBC	O
-	O
2.36	O
*	O
HGB	O
-	O
8.1	O
*	O
HCT	O
-	O
22.0	O
*	O
#	O
MCV	O
-	O
93	O
MCH	O
-	O
34.4	O
*	O
MCHC	O
-	O
37.0	O
*	O
RDW	O
-	O
15.4	O
[	O
**	O
2178-3-25	O
**	O
]	O
01:12	O
PM	O
NEUTS	O
-	O
66	O
BANDS	O
-	O
2	O
LYMPHS	O
-	O
11	O
*	O
MONOS	O
-	O
18	O
*	O
EOS	O
-	O
3	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2178-3-25	O
**	O
]	O
01:12	O
PM	O
PLT	O
SMR	O
-	O
NORMAL	O
PLT	O
COUNT	O
-	O
194	O
[	O
**	O
2178-3-25	O
**	O
]	O
01:12	O
PM	O
PT	O
-	O
12.9	O
PTT	O
-	O
24.2	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2178-3-27	O
**	O
]	O
06:28	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
86	O
pCO2	O
-	O
71	O
*	O
pH	O
-	O
7.31	O
*	O
calTCO2	O
-	O
37	O
*	O
Base	O
XS	O
-	O
5	O
IMAGING	O
:	O
Head	O
CT	O
[	O
**	O
2178-3-25	O
**	O
]	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
process	O
.	O
No	O
evidence	O
of	O
intracranial	O
hemorrhage	O
.	O
2	O
.	O
Small	O
vessel	O
ischemic	O
disease	O
.	O
Prominent	O
sulci	O
and	O
ventricles	O
,	O
most	O
likely	O
age	O
-	O
related	O
involutionary	O
changes	O
.	O
3	O
.	O
Sinus	O
disease	O
,	O
as	O
detailed	O
above	O
.	O
CXR	O
[	O
**	O
2178-3-25	O
**	O
]	O
:	O
1	O
.	O
Left	O
lower	O
lobe	O
opacity	O
could	O
be	O
atelectasis	O
;	O
however	O
,	O
can	O
not	O
exclude	O
superinfection	O
.	O
2	O
.	O
Possible	O
bilateral	O
small	O
pleural	O
effusions	O
.	O
3	O
.	O
Cardiac	O
silhouette	O
top	O
normal	O
.	O
CTA	O
chest	O
[	O
**	O
2178-3-27	O
**	O
]	O
:	O
(	O
prelim	O
)	O
1	O
.	O
No	O
PE	O
or	O
acute	O
aortic	O
pathology	O
.	O
2	O
.	O
Moderate	O
-	O
to	O
-	O
large	O
bilateral	O
pleural	O
effusions	O
,	O
with	O
subtotal	O
atelectasis	O
of	O
the	O
lower	O
lobes	O
.	O
3	O
.	O
No	O
PNA	O
.	O
4	O
.	O
Mild	O
septal	O
thickening	O
compatible	O
with	O
mild	O
pulmonary	O
edema	O
.	O
CXR	O
[	O
**	O
2178-3-27	O
**	O
]	O
:	O
(	O
prelim	O
)	O
Bilateral	O
moderate	O
sized	O
pleural	O
effusions	O
.	O
No	O
pneumothorax	O
.	O
Pulmonary	O
edema	O
,	O
cardiomegaly	O
.	O
Bibasal	O
atelectasis	O
.	O
Findings	O
similar	O
to	O
earlier	O
CT	O
chest	O
.	O
Brief	O
Hospital	O
Course	O
:	O
83	O
-	O
year	O
-	O
old	O
man	O
with	O
squamous	B-Reason
cell	I-Reason
carcinoma	I-Reason
of	I-Reason
the	I-Reason
tongue	I-Reason
,	O
ongoing	O
chemoradiation	I-Drug
,	O
presents	O
with	O
altered	O
mental	O
status	O
.	O
1	O
.	O
Hypoxic	B-Reason
respiratory	I-Reason
failure	I-Reason
:	O
Patient	O
had	O
been	O
in	O
sinus	O
tachycardia	O
to	O
~	O
120	O
since	O
admission	O
despite	O
2L	O
IVF	I-Drug
and	O
2	O
units	O
pRBC	I-Drug
.	O
Given	O
this	O
and	O
his	O
2L	O
O2	I-Drug
requirement	O
,	O
he	O
went	O
for	O
CTA	O
chest	O
,	O
which	O
showed	O
no	O
PE	O
,	O
but	O
large	O
bilateral	O
pleural	O
effusions	O
with	O
atelectasis	O
.	O
He	O
was	O
agitated	O
since	O
the	O
CTA	O
,	O
and	O
around	O
6	O
pm	O
,	O
he	O
looked	O
cyanotic	O
and	O
had	O
a	O
desaturation	O
to	O
60	O
%	O
on	O
2L	O
,	O
improved	O
to	O
93	O
%	O
on	O
NRB	O
.	O
He	O
was	O
given	O
20	O
mg	O
lasix	I-Drug
IV	O
with	O
brisk	O
urine	O
output	O
,	O
as	O
well	O
as	O
0.5	O
mg	O
IV	O
haloperidol	I-Drug
and	O
10	O
mg	O
IV	O
hydralazine	I-Drug
(	O
BP	B-Reason
~	I-Reason
180/90	I-Reason
)	O
and	O
transferred	O
to	O
the	O
ICU	O
.	O
Stat	O
CXR	O
showed	O
diffuse	O
pulmonary	O
edema	O
,	O
and	O
with	O
his	O
concurrent	O
hypertension	I-Reason
,	O
he	O
was	O
started	O
on	O
a	O
nitroglycerin	I-Drug
drip	O
.	O
His	O
BP	O
improved	O
and	O
overshot	O
transiently	O
down	O
to	O
70/30	O
,	O
but	O
rapidly	O
improved	O
to	O
~	O
130s	O
/	O
80s	O
with	O
cessation	O
of	O
drip	O
.	O
His	O
O2	O
sats	O
remained	O
in	O
the	O
90s	O
on	O
high	O
-	O
flow	O
oxygen	O
mask	O
.	O
He	O
was	O
sent	O
for	O
CT	O
head	O
given	O
his	O
altered	O
mental	O
status	O
and	O
possibly	O
new	O
anisocoria	O
.	O
While	O
being	O
transported	O
,	O
he	O
developed	O
bradycardia	O
down	O
to	O
20	O
,	O
desaturation	O
,	O
and	O
apnea	O
requiring	O
bag	O
ventilation	O
.	O
On	O
evaluation	O
,	O
there	O
were	O
no	O
palpable	O
pulses	O
and	O
no	O
obtainable	O
blood	O
pressure	O
.	O
Given	O
his	O
confirmed	O
DNR	O
status	O
,	O
he	O
was	O
not	O
resuscitated	O
and	O
expired	O
.	O
Post-mortem	O
exam	O
was	O
declined	O
.	O
2	O
.	O
Altered	B-Ade
mental	I-Ade
status	I-Ade
:	O
Cause	O
not	O
entirely	O
clear	O
,	O
but	O
possible	O
contribution	O
from	O
opioids	I-Drug
at	O
home	O
,	O
as	O
well	O
as	O
hyponatremia	O
.	O
He	O
was	O
also	O
treated	O
with	O
levofloxacin	I-Drug
for	O
a	O
possible	O
pneumonia	I-Reason
,	O
given	O
left	O
basilar	O
opacity	O
,	O
mild	O
hypoxia	O
(	O
93	O
%	O
RA	O
)	O
,	O
low	O
grade	O
temps	O
(	O
99.7	O
)	O
and	O
cough	O
.	O
When	O
the	O
patient	O
became	O
agitated	I-Reason
as	O
noted	O
in	O
the	O
events	O
described	O
above	O
,	O
he	O
was	O
treated	O
with	O
0.5	O
mg	O
IV	O
haloperidol	I-Drug
prn	O
(	O
total	O
1.5	O
mg	O
given	O
)	O
with	O
good	O
effect	O
.	O
CT	O
head	O
with	O
no	O
acute	O
process	O
on	O
admission	O
and	O
was	O
planned	O
to	O
be	O
repeated	O
given	O
anisocoria	O
,	O
but	O
aborted	O
given	O
above	O
events	O
.	O
3	O
.	O
Hyponatremia	I-Reason
:	O
Treated	O
with	O
IV	O
fluids	I-Drug
with	O
improvement	O
from	O
117	O
to	O
127	O
.	O
4	O
.	O
Tongue	B-Reason
cancer	I-Reason
:	O
On	O
cisplatin	I-Drug
and	O
radiation	O
,	O
with	O
radiation	O
received	O
during	O
this	O
admission	O
.	O
5	O
.	O
Anemia	I-Reason
:	O
Hct	O
22	O
on	O
admission	O
.	O
Transfused	O
2	O
units	O
PRBCs	I-Drug
with	O
improvement	O
to	O
30.7	O
.	O
Medications	O
on	O
Admission	O
:	O
terazosin	I-Drug
5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
omeprazole	B-Drug
20	O
mg	O
daily	O
morphine	I-Drug
10	O
mg	O
oral	O
solution	O
q3h	O
prn	O
pain	I-Reason
ondansetron	I-Drug
prn	O
prochlorperazine	I-Drug
prn	O
lorazepam	B-Drug
1	O
mg	O
q8h	O
prn	O
anxiety	I-Reason
/	O
insomnia	I-Reason
metformin	I-Drug
500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
glipizide	B-Drug
10	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
aspirin	B-Drug
325	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
Expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Expired	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
Expired	O
Followup	O
Instructions	O
:	O
Expired	O
Completed	O
by	O
:[	O
**	O
2178-3-28	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2182-12-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2182-12-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2151-12-6	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lamictal	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4765	O
**	O
]	O
Chief	O
Complaint	O
:	O
Pericardial	O
Effusion	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Pericardial	O
Window	O
Right	O
Heart	O
Catheterization	O
and	O
attempted	O
Pericardiocentesis	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
30	O
y	O
/	O
o	O
F	O
with	O
h	O
/	O
o	O
Depression	O
,	O
PTSD	O
,	O
bipolar	O
disorder	O
who	O
is	O
admitted	O
after	O
Echo	O
showed	O
early	O
sings	O
of	O
tamponade	O
.	O
.	O
Patient	O
was	O
seen	O
on	O
[	O
**	O
2182-11-29	O
**	O
]	O
at	O
[	O
**	O
Hospital	O
191	O
**	O
]	O
clinic	O
with	O
multiple	O
complains	O
,	O
including	O
disphagia	O
,	O
dysuria	O
and	O
abdominal	O
pain	O
.	O
A	O
Ct	O
scan	O
was	O
done	O
on	O
[	O
**	O
2182-12-2	O
**	O
]	O
that	O
did	O
not	O
reveal	O
any	O
intraabdominal	O
pathologies	O
,	O
but	O
it	O
showed	O
a	O
large	O
pericardial	O
effusion	O
.	O
She	O
had	O
an	O
Echocardiogram	O
on	O
[	O
**	O
2181-12-4	O
**	O
]	O
that	O
showed	O
+	O
RA	O
collapse	O
,	O
pulses	O
in	O
clinic	O
15	O
-	O
20	O
.	O
BP	O
100/60	O
,	O
HR	O
100	O
so	O
she	O
was	O
refered	O
for	O
pericardiocentesis	O
.	O
.	O
She	O
reports	O
that	O
over	O
last	O
6	O
weeks	O
,	O
she	O
had	O
join	O
aches	O
,	O
fatigue	O
,	O
sore	O
thorat	O
,	O
+	O
dry	O
ocugh	O
and	O
low	O
grade	O
fevers	O
.	O
Over	O
last	O
2	O
weeks	O
,	O
she	O
had	O
worsening	O
shortness	O
of	O
breath	O
on	O
exertion	O
,	O
feeling	O
more	O
fatigue	O
while	O
walking	O
or	O
going	O
up	O
stairs	O
.	O
Also	O
reports	O
,	O
increase	O
orthopnea	O
going	O
from	O
2	O
to	O
5	O
pillows	O
.	O
She	O
also	O
had	O
ongoing	O
episodic	O
abdominal	O
pain	O
over	O
last	O
month	O
.	O
Diffusse	O
,	O
not	O
nausea	O
of	O
vomit	O
.	O
Intermittent	O
loose	O
stools	O
.	O
.	O
In	O
the	O
cath	O
lab	O
,	O
multiple	O
attempts	O
to	O
acces	O
fluid	O
by	O
subxiphoid	O
approach	O
failed	O
.	O
Pressures	O
RA	O
7	O
,	O
RV	O
18	O
/	O
1/6	O
,	O
PA	O
14/7/10	O
,	O
PCW	O
3	O
.	O
Echo	O
post	O
procedure	O
showed	O
a	O
moderate	O
to	O
large	O
sized	O
pericardial	O
effusion	O
with	O
brief	O
right	O
atrial	O
diastolic	O
collapse	O
.	O
There	O
was	O
also	O
intermittent	O
,	O
localized	O
(	O
inferior	O
RV	O
free	O
wall	O
)	O
RV	O
compression	O
suggestive	O
of	O
elevated	O
intrapericardial	O
pressure	O
and	O
/	O
or	O
early	O
,	O
focal	O
tamponade	O
.	O
.	O
Patient	O
was	O
transfer	O
to	O
CCU	O
for	O
monitoring	O
.	O
.	O
On	O
review	O
of	O
symptoms	O
,	O
he	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
.	O
No	O
urinary	O
symptoms	O
.	O
.	O
***	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
+	O
chest	O
thitgness	O
,	O
dyspnea	O
on	O
exertion	O
,	O
orthopnea	O
.	O
No	O
ankle	O
edema	O
.	O
Past	O
Medical	O
History	O
:	O
Depression	O
Post	O
traumatic	O
disorder	O
Border	O
line	O
personality	O
disorder	O
Dissociative	O
identity	O
disorder	O
Sexual	O
aversion	O
disorder	O
Conversion	O
disorder	O
Anorexia	O
h	O
/	O
o	O
self	O
harm	O
and	O
suicidal	O
ideation	O
GERD	O
Premature	O
ovarian	O
failure	O
Migraines	O
Chornic	O
fatigue	O
syndrome	O
CKD	I-Ade
likely	O
secondary	O
to	O
lithium	I-Drug
Inflammatory	O
arthorpathy	O
-	O
likely	O
psoriatic	O
arthritis	O
Fibromyalgia	O
Osteopenia	O
Mitral	O
valve	O
prolapse	O
Pituitary	O
adenoma	O
.	O
Cardiac	O
Risk	O
Factors	O
:	O
Diabetes	O
(	O
-	O
)	O
,	O
Dyslipidemia	O
(	O
-	O
)	O
,	O
Hypertension	O
(	O
-	O
Social	O
History	O
:	O
Lives	O
in	O
a	O
group	O
home	O
.	O
Cambrige	O
.	O
works	O
partime	O
as	O
pharmacy	O
technician	O
.	O
NO	O
smoking	O
,	O
alcohol	O
or	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
,	O
grand	O
mother	O
,	O
and	O
grand	O
grand	O
mother	O
with	O
breast	O
cancer	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
97.3	O
,	O
BP	O
118/75	O
,	O
HR	O
68	O
,	O
RR17	O
,	O
O2	O
0	O
2L	O
Pulses	O
:	O
4mmHg	O
Gen	O
:	O
non	O
apparent	O
distress	O
,	O
pale	O
HEENT	O
:	O
Sclera	O
anicteric	O
.	O
Pale	O
conjuctiva	O
.	O
dry	O
oral	O
mucose	O
.	O
Neck	O
:	O
JVP	O
flat	O
.	O
CV	O
:	O
RRR	O
,	O
s1	O
-	O
s2	O
normal	O
,	O
no	O
murmurs	O
,	O
rubs	O
or	O
gallops	O
appreciated	O
.	O
Chest	O
:	O
Clear	O
to	O
auscultation	O
anteriorly	O
Abd	O
:	O
soft	O
,	O
mild	O
diffuse	O
tenderness	O
,	O
no	O
rebound	O
Ext	O
:	O
No	O
edema	O
.	O
distal	O
pulses	O
preserved	O
.	O
Skin	O
:	O
No	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
scars	O
,	O
or	O
xanthomas	O
.	O
Pulses	O
:	O
strong	O
distally	O
Skin	O
:	O
no	O
hematoma	O
on	O
groin	O
site	O
.	O
subxiphoid	O
incision	O
clean	O
.	O
Pertinent	O
Results	O
:	O
EKG	O
:	O
NSR	O
,	O
her	O
83	O
,	O
normal	O
axis	O
,	O
normal	O
intervals	O
,	O
no	O
t	O
wave	O
or	O
st	O
changes	O
[	O
**	O
2182-12-4	O
**	O
]	O
12:45	O
PM	O
WBC	O
-	O
5.1	O
RBC	O
-	O
3.68	O
*	O
HGB	O
-	O
12.1	O
HCT	O
-	O
34.2	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
32.8	O
*	O
MCHC	O
-	O
35.4	O
*	O
RDW	O
-	O
12.6	O
[	O
**	O
2182-12-4	O
**	O
]	O
12:45	O
PM	O
PLT	O
COUNT	O
-	O
178	O
[	O
**	O
2182-12-4	O
**	O
]	O
12:45	O
PM	O
GLUCOSE	O
-	O
115	O
*	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
1.6	O
*	O
SODIUM	O
-	O
142	O
POTASSIUM	O
-	O
4.8	O
CHLORIDE	O
-	O
108	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
15	O
[	O
**	O
2182-12-4	O
**	O
]	O
05:52	O
PM	O
WBC	O
-	O
4.6	O
RBC	O
-	O
3.73	O
*	O
HGB	O
-	O
11.7	O
*	O
HCT	O
-	O
35.3	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
12.6	O
[	O
**	O
2182-12-4	O
**	O
]	O
05:52	O
PM	O
NEUTS	O
-	O
81.2	O
*	O
LYMPHS	O
-	O
14.4	O
*	O
MONOS	O
-	O
3.2	O
EOS	O
-	O
0.9	O
BASOS	O
-	O
0.3	O
[	O
**	O
2182-12-4	O
**	O
]	O
05:52	O
PM	O
TSH	O
-	O
1.3	O
[	O
**	O
2182-12-4	O
**	O
]	O
05:52	O
PM	O
GLUCOSE	O
-	O
151	O
*	O
UREA	O
N	O
-	O
20	O
CREAT	O
-	O
1.5	O
*	O
SODIUM	O
-	O
142	O
POTASSIUM	O
-	O
4.3	O
CHLORIDE	O
-	O
109	O
*	O
TOTAL	O
CO2	O
-	O
25	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2182-12-4	O
**	O
]	O
05:52	O
PM	O
CALCIUM	O
-	O
9.3	O
PHOSPHATE	O
-	O
2.8	O
MAGNESIUM	O
-	O
2.3	O
[	O
**	O
2182-12-7	O
**	O
]	O
09:22	O
AM	O
BLOOD	O
WBC	O
-	O
2.5	O
*	O
RBC	O
-	O
3.39	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
32.3	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
31.9	O
MCHC	O
-	O
33.5	O
RDW	O
-	O
12.4	O
Plt	O
Ct	O
-	O
137	O
*	O
[	O
**	O
2182-12-10	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
WBC	O
-	O
4.3	O
RBC	O
-	O
3.68	O
*	O
Hgb	O
-	O
11.8	O
*	O
Hct	O
-	O
35.7	O
*	O
MCV	O
-	O
97	O
MCH	O
-	O
32.2	O
*	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
13.0	O
Plt	O
Ct	O
-	O
220	O
[	O
**	O
2182-12-10	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
Glucose	O
-	O
98	O
UreaN	O
-	O
17	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
142	O
K	O
-	O
3.8	O
Cl	O
-	O
111	O
*	O
HCO3	O
-	O
24	O
AnGap	O
-	O
11	O
[	O
**	O
2182-12-7	O
**	O
]	O
09:22	O
AM	O
BLOOD	O
TotProt	O
-	O
4.9	O
*	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
2.9	O
Mg	O
-	O
1.8	O
[	O
**	O
2182-12-7	O
**	O
]	O
09:22	O
AM	O
BLOOD	O
LD	O
(	O
LDH	O
)	O
-	O
124	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
Cryoglb	O
-	O
NO	O
CRYOGLO	O
[	O
**	O
2182-12-4	O
**	O
]	O
05:52	O
PM	O
BLOOD	O
TSH	O
-	O
1.3	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
ANCA	O
-	O
NEGATIVE	O
B	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
-	O
NEGATIVE	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
RheuFac	O
-	O
6	O
CRP	O
-	O
1.0	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
C3	O
-	O
88	O
*	O
C4	O
-	O
27	O
[	O
**	O
2182-12-9	O
**	O
]	O
04:40	O
AM	O
BLOOD	O
HIV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2182-12-9	O
**	O
]	O
03:55	O
AM	O
BLOOD	O
PARVOVIRUS	O
B19	O
ANTIBODIES	O
(	O
IGG	O
&	O
IGM	O
)	O
-	O
PND	O
[	O
**	O
2182-12-7	O
**	O
]	O
01:21	O
PM	O
BLOOD	O
DNA	O
AUTOANTIBODIES	O
,	O
SS	O
-	O
Test	O
[	O
**	O
2182-12-7	O
**	O
]	O
01:21	O
PM	O
BLOOD	O
SM	O
ANTIBODY	O
-	O
Test	O
[	O
**	O
2182-12-7	O
**	O
]	O
01:21	O
PM	O
BLOOD	O
RO	O
&	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
-	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
2182-12-7	O
**	O
]	O
01:21	O
PM	O
BLOOD	O
RNP	O
ANTIBODY	O
-	O
Test	O
[	O
**	O
2182-12-7	O
**	O
]	O
01:21	O
PM	O
BLOOD	O
ANTI-HISTONE	O
ANTIBODY	O
-	O
Test	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
SCLERODERMA	O
ANTIBODY	O
-	O
Test	O
[	O
**	O
2182-12-6	O
**	O
]	O
06:59	O
AM	O
BLOOD	O
CYCLIC	O
CITRULLINATED	O
PEPTIDE	O
(	O
CCP	O
)	O
ANTIBODY	O
,	O
IGG	O
-	O
Test	O
[	O
**	O
12	O
-	O
7	O
**	O
]	O
Pericardial	O
Fluid	O
:	O
[	O
**	O
2182-12-7	O
**	O
]	O
12:02	O
pm	O
FLUID	O
,	O
OTHER	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2182-12-7	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Final	O
[	O
**	O
2182-12-10	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
FUNGAL	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
FUNGUS	O
ISOLATED	O
.	O
ACID	O
FAST	O
SMEAR	O
(	O
Final	O
[	O
**	O
2182-12-9	O
**	O
]	O
)	O
:	O
NO	O
ACID	O
FAST	O
BACILLI	O
SEEN	O
ON	O
DIRECT	O
SMEAR	O
.	O
ACID	O
FAST	O
CULTURE	O
(	O
Pending	O
)	O
:	O
[	O
**	O
2182-12-7	O
**	O
]	O
12:02	O
PM	O
Report	O
Comment	O
:	O
PERICARDIAL	O
FLUID	O
ANALYSIS	O
WBC	O
,	O
Other	O
Fluid	O
130	O
*	O
#	O
/	O
uL	O
0	O
-	O
0	O
RBC	O
,	O
Other	O
Fluid	O
7760	O
*	O
#	O
/	O
uL	O
0	O
-	O
0	O
Polys	O
0	O
%	O
0	O
-	O
0	O
Lymphocytes	O
58	O
*	O
%	O
0	O
-	O
0	O
Monos	O
7	O
*	O
%	O
0	O
-	O
0	O
Macrophage	O
33	O
*	O
%	O
0	O
-	O
0	O
Other	O
Cell	O
2	O
*	O
%	O
0	O
-	O
0	O
Pericardial	O
Fluid	O
Adenosine	O
Deaminase	O
-	O
negative	O
[	O
**	O
2182-12-9	O
**	O
]	O
TTE	O
:	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2182-12-6	O
**	O
]	O
,	O
the	O
pericardial	O
effusion	O
has	O
resolved	O
.	O
.	O
[	O
**	O
2182-12-6	O
**	O
]	O
TTE	O
:	O
There	O
is	O
a	O
moderate	O
to	O
large	O
sized	O
pericardial	O
effusion	O
.	O
The	O
effusion	O
appears	O
circumferential	O
.	O
There	O
is	O
sustained	O
right	O
atrial	O
collapse	O
,	O
consistent	O
with	O
low	O
filling	O
pressures	O
or	O
early	O
tamponade	O
.	O
There	O
is	O
mild	O
right	O
ventricular	O
diastolic	O
collapse	O
,	O
consistent	O
with	O
impaired	O
fillling	O
/	O
tamponade	O
physiology	O
.	O
Compared	O
with	O
the	O
findings	O
of	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2181-12-4	O
**	O
]	O
,	O
the	O
pericardial	O
effusion	O
is	O
similar	O
in	O
size	O
;	O
however	O
,	O
left	O
atrial	O
chamber	O
invagination	O
is	O
now	O
present	O
.	O
In	O
addition	O
,	O
the	O
right	O
ventricvle	O
appears	O
somewhat	O
more	O
compressed	O
.	O
[	O
**	O
2182-12-4	O
**	O
]	O
Cath	O
:	O
.	O
Pericadial	O
effusion	O
without	O
clinical	O
signs	O
of	O
tamponade	O
and	O
with	O
normal	O
RA	O
pressure	O
.	O
2	O
.	O
Unsuccesful	O
pericardiocentesis	O
.	O
Multiple	O
attempts	O
to	O
access	O
the	O
pericardial	O
space	O
using	O
a	O
subxiphoid	O
approach	O
were	O
unsuccesful	O
.	O
TTE	O
obtained	O
during	O
the	O
procedure	O
showed	O
anterior	O
collection	O
but	O
not	O
at	O
apex	O
and	O
beneath	O
liver	O
edge	O
.	O
Despite	O
echo	O
guidance	O
,	O
the	O
operator	O
was	O
still	O
unable	O
to	O
enter	O
the	O
pericardial	O
space	O
.	O
The	O
patient	O
developed	O
left	O
shoulder	O
pain	O
during	O
the	O
procedure	O
attempts	O
that	O
resolved	O
with	O
removal	O
of	O
the	O
needle	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
1	O
.	O
No	O
clinical	O
signs	O
of	O
tamponade	O
,	O
normal	O
RA	O
pressure	O
.	O
2	O
.	O
Unsuccesful	O
pericardiocentesis	O
Brief	O
Hospital	O
Course	O
:	O
#	O
Pericardial	O
effusion	O
:	O
On	O
admission	O
the	O
patient	O
was	O
taken	O
to	O
cath	O
lab	O
for	O
pericardiocentesis	O
.	O
During	O
the	O
procedure	O
pericardial	O
fluid	O
was	O
failed	O
to	O
be	O
obtained	O
.	O
Hemodynamics	O
inconsistent	O
with	O
tamponade	O
physiology	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
CCU	O
for	O
continued	O
monitoring	O
.	O
Repeat	O
TTE	O
[	O
**	O
12	O
-	O
7	O
**	O
]	O
demonstrated	O
new	O
LA	O
and	O
RV	O
invagination	O
.	O
CT	O
surgery	O
was	O
consulted	O
and	O
the	O
patient	O
was	O
taken	O
for	O
pericardial	O
window	O
.	O
She	O
tolerated	O
the	O
procedure	O
well	O
with	O
no	O
complications	O
.	O
Drain	O
and	O
chest	O
tube	O
placed	O
during	O
procedure	O
.	O
Removed	O
on	O
[	O
**	O
12	O
-	O
10	O
**	O
]	O
after	O
repeat	O
TTE	O
on	O
[	O
**	O
12	O
-	O
10	O
**	O
]	O
demonstrated	O
a	O
normal	O
left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
normal	O
systolic	O
function	O
and	O
a	O
resolution	O
of	O
pericardial	O
fluid	O
.	O
Her	O
pericardial	O
fluid	O
was	O
of	O
unclear	O
etiology	O
.	O
Rheumatology	O
was	O
consulted	O
and	O
her	O
sulfasalazine	O
was	O
discontinued	O
for	O
concern	O
of	O
drug	O
induced	I-Ade
lupus	I-Ade
given	O
effusion	O
and	O
decreasing	O
WBC	O
.	O
WBC	O
did	O
stabalize	O
after	O
stopping	O
medication	O
.	O
Also	O
concern	O
for	O
collagen	O
vascular	O
disease	O
.	O
Panel	O
of	O
autoimmune	O
antibodies	O
pending	O
at	O
time	O
of	O
discharge	O
.	O
Cytology	O
and	O
pericardial	O
biopsy	O
also	O
pending	O
at	O
time	O
of	O
discharge	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
to	O
evaluate	O
for	O
TB	O
as	O
cause	O
pending	O
.	O
The	O
patient	O
did	O
report	O
recent	O
URI	O
symptoms	O
,	O
can	O
consider	O
pericarditis	O
as	O
cause	O
of	O
effusion	O
.	O
EBV	O
,	O
CMV	O
pending	O
.	O
HIV	O
negative	O
.	O
She	O
also	O
reports	O
a	O
family	O
history	O
of	O
breast	O
CA	O
-	O
recent	O
mamogram	O
WNL	O
.	O
The	O
patient	O
was	O
discharged	O
home	O
in	O
good	O
condition	O
to	O
follow	O
up	O
with	O
her	O
PCP	O
and	O
rheumatology	O
for	O
further	O
management	O
.	O
.	O
#	O
Hypotension	O
-	I-Reason
Pt	O
BP	O
range	O
80s	O
-	O
110	O
systolic	O
.	O
The	O
patient	O
does	O
have	O
low	O
BP	O
at	O
baseline	O
.	O
Reported	O
recent	O
poor	O
po	O
intake	O
and	O
history	O
of	O
eating	O
disorder	O
.	O
She	O
received	O
intermittent	O
fluid	O
bolus	O
,	O
likely	O
due	O
to	O
increased	O
insensible	O
losses	O
.	O
She	O
also	O
has	O
a	O
history	O
of	O
increased	O
urine	O
output	O
with	O
lithium	O
induced	O
CRI	O
.	I-Ade
.	O
#	O
Psych	O
:	I-Reason
continued	O
on	O
home	O
medications	O
Abilify	O
,	I-Drug
Quetiapine	O
.	I-Drug
#	O
Question	O
of	O
Psoriatic	O
arthiritis	I-Reason
:	I-Reason
continued	O
prednisone	O
per	O
Rheumatology	O
recommendation	O
.	O
Sulfasalazine	O
DC	O
'd	O
due	O
to	O
concern	O
for	O
drug	O
induced	I-Ade
lupus	I-Ade
.	I-Ade
#	O
Vaginal	O
Bleeding	O
-	O
During	O
her	O
hospitalization	O
the	O
patient	O
reported	O
scant	O
vaginal	O
bleeding	O
.	O
She	O
has	O
been	O
post-menopausal	O
for	O
many	O
years	O
.	O
She	O
was	O
advised	O
to	O
undergo	O
further	O
workup	O
for	O
this	O
bleeding	O
as	O
outpatient	O
.	O
Given	O
her	O
past	O
history	O
of	O
sexual	O
abuse	O
she	O
has	O
reported	O
refusing	O
previous	O
pelvic	O
examination	O
.	O
.	O
#	O
Fibromyalgia	O
:	I-Reason
continued	O
tizanidine	O
and	O
Ultram	O
#	O
CKD	O
:	O
creatinine	O
at	O
baseline	O
.	O
.	O
The	O
patient	O
is	O
scheduled	O
to	O
follow	O
up	O
with	O
Cardiology	O
,	O
CT	O
surgery	O
,	O
Rheumatology	O
and	O
her	O
PCP	O
for	O
further	O
management	O
.	O
Also	O
to	O
follow	O
up	O
on	O
outstanding	O
pericardial	O
fluid	O
cytology	O
and	O
biopsy	O
,	O
as	O
well	O
as	O
pending	O
Autoimmune	O
workup	O
.	O
Medications	O
on	O
Admission	O
:	O
Ativan	O
1	I-Drug
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Ativan	O
2	I-Drug
mg	O
qhs	O
Colace	O
Correctol	O
2	I-Drug
tab	O
once	O
a	O
day	O
(	O
not	O
taken	O
over	O
last	O
3	O
days	O
Cymbalta	O
120	O
qhs	O
Desmopresin	O
0,3	O
mg	O
qhs	O
fioricet	O
100	O
-	O
650	O
PRH	O
MVI	O
Naproxen	O
250	O
q4h	O
prn	O
Prednisone	O
10	O
mg	O
/	O
daily	O
Proair	O
HFA	I-Drug
2	I-Drug
puffs	O
inh	O
4	O
-	O
6h	O
seroquel	O
400	O
TID	O
and	O
800	O
qhs	O
Sulfasalazine	O
1500	O
[	O
**	O
Hospital1	O
**	O
]	O
Synthroid	O
50	O
mcg	O
/	O
daily	O
Topamax	O
75	O
[	O
**	O
Hospital1	O
**	O
]	O
100	O
mg	O
qhs	O
Ultram	O
EF	O
300	O
/	O
daily	O
Vistaril	O
50	O
mg	O
QID	O
PRN	O
Zanaflex	O
4	I-Drug
mg	O
qhs	O
Prilosec	O
40	O
[	O
**	O
Hospital1	O
**	O
]	O
Ranitidine	O
150	O
qhs	O
Abilify	O
30	O
mg	O
/	O
qhs	O
Hydroxizine	O
prazosin	O
Discharge	O
Medications	O
:	O
1	O
.	O
Lorazepam	O
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Lorazepam	O
1	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
3	O
.	O
Duloxetine	O
30	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Desmopressin	O
0.1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
5	O
.	O
Butalbital	O
-	I-Drug
Acetaminophen	I-Drug
-	I-Drug
Caff	I-Drug
50	O
-325-40	O
mg	O
Tablet	O
Sig	O
:	O
[	O
**	O
12	O
-	O
4	O
**	O
]	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
6	O
.	O
Hexavitamin	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Prednisone	O
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Quetiapine	O
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Quetiapine	O
200	O
mg	O
Tablet	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
10	O
.	O
Levothyroxine	O
50	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Topiramate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Topiramate	O
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
13	O
.	O
Hydroxyzine	O
HCl	O
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
14	O
.	O
Tizanidine	O
2	I-Drug
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
15	O
.	O
Pantoprazole	O
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
16	O
.	O
Ranitidine	O
HCl	O
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
17	O
.	O
Prazosin	O
1	I-Drug
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
18	O
.	O
Aripiprazole	O
10	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
19	O
.	O
Docusate	O
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
20	O
.	O
Ultram	O
ER	O
300	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
21	O
.	O
Albuterol	O
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
.	O
22	O
.	O
Correctol	O
5	I-Drug
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
1	O
.	O
Pericardial	O
Effusion	O
2	O
.	O
Pericarditis	O
-	O
Post	O
Viral	O
Secondary	O
:	O
1	O
.	O
Chronic	O
Renal	O
Insufficiency	O
2	O
.	O
Inflammatory	O
Arthropathy	O
Discharge	O
Condition	O
:	O
Good	O
,	O
Clinically	O
Improved	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
a	O
fluid	O
collection	O
around	O
your	O
heart	O
called	O
a	O
pericardial	O
effusion	O
.	O
You	O
underwent	O
a	O
catheterizaton	O
to	O
attempt	O
drainage	O
of	O
this	O
effusion	O
however	O
no	O
fluid	O
could	O
be	O
obtained	O
.	O
You	O
then	O
underwent	O
a	O
pericardial	O
window	O
by	O
cardiothoracic	O
surgery	O
to	O
open	O
your	O
pericardial	O
space	O
to	O
drain	O
the	O
fluid	O
.	O
.	O
Your	O
workup	O
from	O
your	O
pericardial	O
effusion	O
has	O
been	O
negative	O
to	O
date	O
.	O
The	O
cytology	O
and	O
biopsy	O
from	O
your	O
procedure	O
are	O
still	O
pending	O
as	O
well	O
as	O
viral	O
studies	O
.	O
You	O
will	O
follow	O
up	O
with	O
Cardiology	O
and	O
Rheumatology	O
for	O
further	O
workup	O
.	O
.	O
Your	O
medication	O
Sulfasalazine	O
has	O
been	O
discontinued	O
.	O
You	O
should	O
continue	O
to	O
take	O
your	O
medication	O
Prednisone	O
10	O
mg	O
daily	O
until	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
Rheumatology	O
.	O
.	O
You	O
continue	O
to	O
have	O
a	O
high	O
urine	O
output	O
related	O
to	O
your	O
kidney	O
disease	O
.	O
Please	O
continue	O
to	O
drink	O
plenty	O
of	O
caffeine	O
free	O
fluids	O
at	O
home	O
.	O
If	O
you	O
develop	O
lightheadedness	O
please	O
return	O
or	O
call	O
your	O
primary	O
care	O
physician	O
.	O
.	O
You	O
have	O
complained	O
of	O
occassional	O
vaginal	O
spotting	O
during	O
your	O
hospital	O
stay	O
.	O
You	O
should	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
for	O
further	O
workup	O
.	O
.	O
If	O
any	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
fevers	O
or	O
any	O
other	O
sympotms	O
that	O
may	O
concern	O
you	O
,	O
plaease	O
call	O
your	O
PCP	O
or	O
come	O
to	O
the	O
emergency	O
department	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
449	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
437	O
**	O
]	O
regarding	O
your	O
pericardial	O
effusion	O
,	O
in	O
the	O
cardiology	O
clinic	O
.	O
An	O
appointment	O
has	O
been	O
made	O
for	O
you	O
on	O
[	O
**	O
2183-1-1	O
**	O
]	O
@	O
10AM	O
,	O
in	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Center	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
.	O
Please	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
if	O
you	O
have	O
any	O
questions	O
or	O
concerns	O
about	O
this	O
appointment	O
.	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
1022	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
5808	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2182-12-26	O
**	O
]	O
10:20	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
Rheumatologist	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2226	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2182-12-19	O
**	O
]	O
8:30	O
.	O
Please	O
follow	O
up	O
with	O
Cardiothoracic	O
Surgery	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
72103	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
914	O
**	O
]	O
in	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
CARDIAC	O
SURGERY	O
LMOB	O
2A	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2182-12-25	O
**	O
]	O
2:00	O

Admission	O
Date	O
:	O
[	O
**	O
2141-4-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2141-4-11	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2145	O
**	O
]	O
Chief	O
Complaint	O
:	O
shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
86	O
yo	O
Iranian	O
(	O
farsi	O
speaking	O
)	O
male	O
with	O
h	O
/	O
o	O
COPD	I-Reason
(	O
on	O
home	O
o2	I-Drug
(	O
uses	O
2	O
-	O
3h	O
qdaily	O
of	O
home	O
o2	O
overall	O
)	O
,	O
HTN	O
,	O
restless	O
leg	O
syndrome	O
,	O
h	O
/	O
o	O
anemia	O
(	O
prior	O
studies	O
showing	O
thalesemia	O
)	O
and	O
BPH	O
presenting	O
today	O
with	O
2	O
days	O
symptoms	O
of	O
SOB	O
and	O
AMS	O
.	O
Per	O
daughter	O
and	O
pt	O
-	O
pt	O
was	O
in	O
his	O
USOH	O
till	O
2	O
days	O
prior	O
-	O
started	O
having	O
increasing	O
SOB	O
along	O
with	O
new	O
cough	O
with	O
increasing	O
sputum	O
production	O
,	O
no	O
f	O
/	O
c	O
,	O
no	O
cp	O
,	O
no	O
HA	O
,	O
ab	O
pain	O
,	O
n	O
/	O
v	O
,	O
but	O
+	O
constipation	O
-	O
along	O
with	O
sob	O
sx	O
-	O
pt	O
with	O
decreasing	O
po	O
intake	O
-	O
noted	O
decreased	O
urinary	O
production	O
yesterday	O
with	O
darker	O
urine	O
-	O
today	O
in	O
ED	O
with	O
increased	O
intake	O
has	O
finally	O
increased	O
production	O
.	O
Pt	O
denies	O
any	O
recent	O
changes	O
in	O
urination	O
prior	O
-	O
BPH	O
controlled	O
without	O
sx	O
of	O
dribbing	O
,	O
urgency	O
,	O
change	O
of	O
frequency	O
till	O
just	O
yesterday	O
.	O
In	O
terms	O
of	O
mentation	O
-	O
pt	O
also	O
has	O
been	O
having	O
mild	O
increased	O
confusion	O
-	O
usually	O
AA0x3	O
-	O
only	O
x2	O
now	O
with	O
process	O
as	O
above	O
.	O
<br>	O
In	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
pt	O
initially	O
91	O
%	O
on	O
RA	O
-	O
noted	O
pt	O
usually	O
uses	O
o2	I-Drug
3h	O
/	O
day	O
-	O
but	O
using	O
more	O
frequency	O
past	O
couple	O
days	O
without	O
response	O
.	O
Also	O
noted	O
pt	O
having	O
increased	O
fatigue	O
and	O
generalized	O
weakness	O
past	O
couple	O
days	O
without	O
ambulation	O
-	O
at	O
baseline	O
can	O
ambulate	O
(	O
+	O
/	O
-	O
can	O
/	O
walker	O
at	O
times	O
)	O
.	O
Pt	O
noted	O
afebrile	O
in	O
ED	O
-	O
given	O
nebs	I-Drug
,	O
IV	O
solumedrol	I-Drug
and	O
dose	O
of	O
levoquin	I-Drug
IV	O
and	O
admitted	O
for	O
copd	B-Reason
exacerbation	I-Reason
.	O
<br>	O
Review	O
of	O
systems	O
:	O
.	O
Constitutional	O
:	O
No	O
weight	O
loss	O
/	O
gain	O
,	O
+	O
fatigue	O
,	O
malaise	O
,	O
fevers	O
,	O
chills	O
,	O
rigors	O
,	O
night	O
sweats	O
,	O
anorexia	O
.	O
HEENT	O
:	O
+	O
chronic	O
loss	O
of	O
vision	O
,	O
no	O
photophobia	O
.	O
No	O
dry	O
motuh	O
,	O
oral	O
ulcers	O
,	O
bleeding	O
nose	O
or	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
**	O
]	O
,	O
tinnitus	O
,	O
or	O
sinus	O
pain	O
.	O
Cardiac	O
:	O
No	O
chest	O
pain	O
,	O
palpitations	O
,	O
LE	O
edema	O
,	O
orthopnea	O
,	O
PND	O
,	O
but	O
+	O
DOE	O
.	O
Respiratory	O
:	O
+	O
SOB	O
,	O
NO	O
pleuritic	O
pain	O
,	O
no	O
hemoptysis	O
,	O
+	O
cough	O
.	O
GI	O
:	O
No	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
abdominal	O
swelling	O
,	O
diarrhea	O
,	O
but	O
notable	O
for	O
+	O
constiatpion	O
,	O
no	O
hematemesis	O
,	O
hematochezia	O
,	O
or	O
melena	O
.	O
Heme	O
:	O
No	O
bleeding	O
,	O
bruising	O
.	O
Lymph	O
:	O
No	O
lymphadenopathy	O
.	O
GU	O
:	O
+	O
per	O
HPI	O
.	O
Skin	O
:	O
No	O
rashes	O
,	O
pruritius	O
.	O
Endocrine	O
:	O
No	O
change	O
in	O
skin	O
or	O
hair	O
,	O
no	O
heat	O
or	O
cold	O
intolerance	O
.	O
MS	O
:	O
No	O
myalgias	O
,	O
arthralgias	O
,	O
back	O
or	O
nec	O
pain	O
.	O
Neuro	O
:	O
No	O
numbness	O
,	O
weakness	O
or	O
parasthesias	O
.	O
No	O
dizziness	O
,	O
lightheadedness	O
,	O
vertigo	O
.	O
No	O
confusion	O
or	O
headache	O
.	O
but	O
positive	O
pains	O
in	O
LE	O
from	O
restless	O
leg	O
-	O
controlled	O
with	O
home	O
meds	O
Psychiatric	O
:	O
No	O
active	O
depression	O
or	O
anxiety	O
.	O
Past	O
Medical	O
History	O
:	O
COPD	I-Reason
-	O
uses	O
prn	O
home	O
o2	I-Drug
Restless	O
Leg	O
Syndrome	O
HTN	O
CKD	O
Stage	O
III	O
based	O
on	O
review	O
of	O
labs	O
this	O
admission	O
(	O
baseline	O
1.8	O
-	O
2.0	O
)	O
Depression	O
Knee	O
Replacement	O
Macular	O
Degeneration	O
BPH	O
Thalasemia	O
Social	O
History	O
:	O
Lives	O
at	O
home	O
with	O
wife	O
,	O
daughter	O
lives	O
on	O
floor	O
below	O
.	O
Heavy	O
Tobacco	O
history	O
,	O
70	O
years	O
smoking	O
,	O
quit	O
few	O
years	O
ago	O
.	O
no	O
etoh	O
,	O
no	O
drugs	O
Family	O
History	O
:	O
NC	O
-	O
no	O
CAD	O
,	O
but	O
+	O
h	O
/	O
o	O
COPD	O
in	O
family	O
.	O
Physical	O
Exam	O
:	O
Exam	O
VS	O
T	O
current	O
99.2	O
BP	O
120/59	O
HR	O
105	O
RR	O
20	O
O2sat	B-Drug
:	O
96	O
%	O
4L	O
o2nc	O
Gen	O
:	O
In	O
NAD	O
.	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
.	O
No	O
scleral	O
icterus	O
.	O
No	O
conjunctival	O
injection	O
.	O
Mucous	O
membranes	O
moist	O
.	O
No	O
oral	O
ulcers	O
.	O
Neck	O
:	O
Supple	O
,	O
no	O
LAD	O
,	O
no	O
JVP	O
elevation	O
.	O
Lungs	O
:	O
+	O
prolonged	O
exp	O
phase	O
with	O
end	O
exp	O
wheezing	O
-	O
mild	O
-	O
mod	O
tight	O
airflow	O
CV	O
:	O
RRR	O
,	O
+	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
HSM	O
at	O
apex	O
,	O
no	O
r	O
/	O
g	O
Abdomen	O
:	O
soft	O
,	O
NT	O
,	O
ND	O
,	O
NABS	O
Extremities	O
:	O
warm	O
and	O
well	O
perfused	O
,	O
no	O
cyanosis	O
,	O
clubbing	O
,	O
+	O
trace	O
pedal	O
edema	O
Neurological	O
:	O
alert	O
and	O
oriented	O
X	O
2	O
-	O
baseline	O
aa0x3	O
of	O
note	O
per	O
daughter	O
in	O
room	O
,	O
CN	O
[	O
**	O
Name	O
(	O
NI	O
)	O
12428	O
**	O
]	O
intact	O
.	O
Notable	O
that	O
pt	O
well	O
alert	O
-	O
no	O
evidence	O
of	O
somnulance	O
Psychiatric	O
:	O
Appropriate	O
.	O
GU	O
:	O
deferred	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2141-4-6	O
**	O
]	O
09:50	O
AM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
<br>	O
[	O
**	O
2141-4-6	O
**	O
]	O
10:00	O
AM	O
LACTATE	O
-	O
1.1	O
[	O
**	O
2141-4-6	O
**	O
]	O
09:50	O
AM	O
BLOOD	O
WBC	O
-	O
11.6	O
*	O
RBC	O
-	O
4.79	O
Hgb	O
-	O
9.1	O
*	O
Hct	O
-	O
32.0	O
*	O
MCV	O
-	O
67	O
*	O
MCH	O
-	O
19.1	O
*	O
MCHC	O
-	O
28.6	O
*	O
RDW	O
-	O
16.5	O
*	O
Plt	O
Ct	O
-	O
209	O
[	O
**	O
2141-4-6	O
**	O
]	O
09:50	O
AM	O
BLOOD	O
Neuts	O
-	O
79.6	O
*	O
Lymphs	O
-	O
13.3	O
*	O
Monos	O
-	O
5.1	O
Eos	O
-	O
1.8	O
Baso	O
-	O
0.2	O
[	O
**	O
2141-4-9	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
WBC	O
-	O
8.4	O
RBC	O
-	O
4.45	O
*	O
Hgb	O
-	O
8.9	O
*	O
Hct	O
-	O
28.8	O
*	O
MCV	O
-	O
65	O
*	O
MCH	O
-	O
20.0	O
*	O
MCHC	O
-	O
30.9	O
*	O
RDW	O
-	O
17.5	O
*	O
Plt	O
Ct	O
-	O
176	O
[	O
**	O
2141-4-7	O
**	O
]	O
02:00	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
69	O
*	O
pCO2	O
-	O
105	O
*	O
pH	O
-	O
7.16	O
*	O
calTCO2	O
-	O
40	O
*	O
Base	O
XS	O
-	O
4	O
Intubat	O
-	O
NOT	O
INTUBA	O
[	O
**	O
2141-4-8	O
**	O
]	O
12:15	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
69	O
*	O
pCO2	O
-	O
70	O
*	O
pH	O
-	O
7.31	O
*	O
calTCO2	O
-	O
37	O
*	O
Base	O
XS	O
-	O
5	O
Admisson	O
CXR	O
:	O
PA	O
AND	O
LATERAL	O
CHEST	O
RADIOGRAPH	O
:	O
Lungs	O
are	O
clear	O
.	O
There	O
is	O
no	O
consolidation	O
,	O
effusion	O
or	O
pneumothorax	O
.	O
Trace	O
pleural	O
thickening	O
is	O
seen	O
in	O
the	O
major	O
fissure	O
on	O
lateral	O
film	O
,	O
likely	O
right	O
sided	O
.	O
A	O
small	O
calcified	O
nodule	O
in	O
the	O
right	O
mid	O
lung	O
likely	O
reflects	O
a	O
granuloma	O
.	O
Hilar	O
and	O
cardiomediastinal	O
contours	O
are	O
unchanged	O
.	O
The	O
aorta	O
is	O
tortuous	O
.	O
There	O
is	O
no	O
evidence	O
for	O
volume	O
overload	O
.	O
There	O
is	O
degenerative	O
change	O
in	O
the	O
thoracic	O
spine	O
,	O
with	O
unchanged	O
wedge	O
deformity	O
of	O
a	O
mid	O
thoracic	O
vertebral	O
body	O
.	O
There	O
are	O
no	O
suspicious	O
lytic	O
or	O
sclerotic	O
osseous	O
lesions	O
.	O
.	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
cardiopulmonary	O
process	O
.	O
2	O
.	O
Unchanged	O
degenerative	O
change	O
with	O
wedge	O
deformity	O
of	O
a	O
mid	O
thoracic	O
vertebral	O
body	O
.	O
<br>	O
.	O
EKG	O
:	O
reviewed	O
-	O
sinus	O
tach	O
-	O
no	O
acute	O
ST	O
/	O
TW	O
changes	O
,	O
old	O
LAD	O
,	O
poor	O
r	O
-	O
wave	O
progression	O
,	O
possible	O
LAE	O
<br>	O
Brief	O
Hospital	O
Course	O
:	O
86	O
yo	O
Iranian	O
(	O
farsi	O
speaking	O
)	O
male	O
with	O
h	O
/	O
o	O
COPD	I-Reason
(	O
on	O
home	O
o2	I-Drug
(	O
uses	O
2	O
-	O
3h	O
qdaily	O
of	O
home	O
o2	I-Drug
overall	O
)	O
,	O
HTN	O
,	O
restless	O
leg	O
syndrome	O
,	O
BPH	O
transferred	O
for	O
hypercarbic	O
respiratory	O
failure	O
.	O
#	O
Acute	O
on	O
Chronic	O
Hypercarbic	O
repiratory	O
failure	O
:	O
#	O
Acute	O
COPD	O
exacerbation	O
He	O
presented	O
to	O
the	O
ED	O
with	O
shortness	O
of	O
breath	O
and	O
change	O
in	O
mental	O
status	O
.	O
He	O
was	O
admitted	O
to	O
the	O
floor	O
for	O
ARF	O
and	O
COPD	O
exacerbation	O
.	O
He	O
then	O
develooped	O
AMS	I-Ade
and	O
and	O
decreased	I-Ade
respiratory	O
rate	O
with	O
a	O
gas	O
of	O
7.16	O
/	O
105/69	O
.	O
This	O
was	O
thought	O
to	O
be	O
secondary	O
to	O
methadone	I-Drug
overdose	I-Ade
due	O
to	O
taking	O
30	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
rather	O
than	O
15	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
when	O
he	O
received	O
10	O
mg	O
tabs	O
rather	O
than	O
5	O
mg	O
tabs	O
from	O
his	O
pharmacy	O
.	O
He	O
required	O
BiPAP	O
the	O
first	O
day	O
in	O
the	O
ICU	O
given	O
that	O
his	O
PCO2	O
was	O
105	O
on	O
the	O
floor	O
.	O
He	O
was	O
started	O
on	O
a	O
narcan	I-Drug
gtt	O
with	O
improvement	O
of	O
his	O
respiratory	B-Reason
status	I-Reason
.	O
His	O
narcan	I-Drug
gtt	O
was	O
discontinued	O
on	O
[	O
**	O
4	O
-	O
8	O
**	O
]	O
in	O
the	O
AM	O
as	O
he	O
was	O
alert	O
and	O
speaking	O
farsi	O
.	O
He	O
was	O
given	O
fentanyl	I-Drug
boluses	O
and	O
ativan	I-Drug
while	O
in	O
the	O
ICU	O
to	O
help	O
with	O
withdrawal	I-Reason
and	O
to	O
tx	O
his	O
restless	I-Reason
leg	O
syndrome	O
.	O
He	O
was	O
started	O
on	O
Solumedrol	I-Drug
125	O
mg	O
IV	O
q6hrs	O
which	O
was	O
continued	O
x2	O
days	O
,	O
then	O
transitioned	O
to	O
prednisone	I-Drug
.	O
He	O
was	O
also	O
started	O
on	O
azithromycin	I-Drug
.	O
[	O
**	O
4	O
-	O
9	O
**	O
]	O
his	O
home	O
dose	O
of	O
methadone	I-Drug
was	O
restarted	O
15	O
mg	O
PO	O
BID	O
.	O
Pt	O
is	O
on	O
2L	O
oxygen	I-Drug
at	O
home	O
but	O
taken	O
off	O
oxygen	I-Drug
this	O
AM	O
with	O
goal	I-Reason
O2	O
sat	O
88	O
-	O
92	O
%	O
as	O
likely	O
is	O
chronic	O
CO2	O
retainer	O
.	O
Patient	O
??????	O
s	O
mental	O
status	O
is	O
at	O
baseline	O
now	O
oriented	O
to	O
self	O
and	O
yr	O
by	O
his	O
calendar	O
,	O
confirmed	O
with	O
family	O
that	O
his	O
mental	O
status	O
is	O
good	O
.	O
He	O
was	O
given	O
Rx	O
for	O
albuterol	I-Drug
MDI	O
and	O
is	O
to	O
continue	O
his	O
home	O
inhalers	O
as	O
well	O
.	O
#	O
Acute	B-Reason
on	I-Reason
Chronic	I-Reason
Renal	I-Reason
Failure	I-Reason
??????	O
appeared	O
pre	O
renal	O
in	O
etiology	O
,	O
now	O
resolved	O
.	O
He	O
is	O
to	O
continue	O
his	O
home	O
Tamsulosin	I-Drug
and	O
Finasteride	I-Drug
,	O
lasix	I-Drug
.	O
#	O
Restless	B-Ade
Leg	I-Ade
syndrome	I-Ade
??????	O
See	O
above	O
patient	O
may	O
have	O
accidentally	O
overdosed	I-Ade
on	O
his	O
methadone	I-Drug
.	O
His	O
mental	B-Reason
status	I-Reason
responded	O
to	O
a	O
narcan	I-Drug
gtt	O
.	O
He	O
was	O
given	O
prn	O
fentanyl	I-Drug
until	O
[	O
**	O
4	O
-	O
9	O
**	O
]	O
at	O
which	O
point	O
he	O
was	O
restarted	O
on	O
his	O
home	O
methadone	I-Drug
15	O
mg	O
PO	O
BID	O
.	O
Emphasized	O
appropriate	O
dosing	O
to	O
pt	O
,	O
family	O
,	O
and	O
have	O
set	O
up	O
VNA	O
services	O
to	O
ensure	O
he	O
understands	O
his	O
medication	O
.	O
#	O
Anemia	O
,	O
microcytic	O
-	O
has	O
h	O
/	O
o	O
thalessemia	O
.	O
HCT	O
stable	O
during	O
admission	O
.	O
#	O
Code	O
status	O
:	O
he	O
did	O
not	O
require	O
intubation	O
and	O
family	O
reports	O
he	O
does	O
not	O
have	O
any	O
history	O
of	O
COPD	O
hospitalizations	O
.	O
Code	O
status	O
is	O
full	O
,	O
but	O
his	O
providers	O
did	O
discuss	O
with	O
family	O
the	O
possibility	O
of	O
a	O
comfort	O
-	O
focused	O
,	O
noninvasive	O
approach	O
when	O
he	O
was	O
very	O
ill	O
in	O
the	O
unit	O
.	O
Recommend	O
that	O
further	O
goals	O
of	O
care	O
discussion	O
continue	O
with	O
his	O
PCP	O
.	O
Medications	O
on	O
Admission	O
:	O
Below	O
medications	O
confirmed	O
with	O
family	O
with	O
pill	O
boxes	O
:	O
.	O
lasix	I-Drug
40	O
mg	O
qdaily	O
atrovent	I-Drug
tid	O
methadone	I-Drug
15	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
flomax	I-Drug
0.4	O
mg	O
qdaily	O
finasteride	I-Drug
5	O
mg	O
qdaily	O
ocuvite	I-Drug
150	O
-30-6-150	O
cap	O
qdaily	O
vit	B-Drug
b12	I-Drug
1000mcg	O
[	O
**	O
Hospital1	O
**	O
]	O
cranberry	B-Drug
-	I-Drug
vit	I-Drug
c	I-Drug
-	I-Drug
vit	I-Drug
E	I-Drug
140	O
-100-3	O
-	O
cap	O
tid	O
Discharge	O
Medications	O
:	O
1	O
.	O
Finasteride	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Methadone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
one	O
and	O
a	O
half	O
Tablet	O
PO	O
twice	O
a	O
day	O
:	O
Please	O
look	O
carefully	O
at	O
your	O
bottle	O
at	O
home	O
.	O
Your	O
family	O
reports	O
that	O
the	O
pharmacy	O
recently	O
gave	O
you	O
10	O
mg	O
tablets	O
.	O
You	O
should	O
take	O
15	O
mg	O
per	O
dose	O
,	O
twice	O
a	O
day	O
.	O
3	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
puff	O
Inhalation	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
1	O
1	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Atrovent	I-Drug
HFA	O
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1	O
-	O
2	O
puffs	O
Inhalation	O
three	O
times	O
a	O
day	O
:	O
please	O
continue	O
to	O
take	O
this	O
medication	O
as	O
you	O
were	O
at	O
home	O
.	O
I	O
have	O
not	O
made	O
any	O
deliberate	O
changes	O
.	O
6	O
.	O
Cyanocobalamin	I-Drug
500	O
mcg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
Continue	O
taking	O
this	O
medication	O
(	O
vitamin	B-Drug
B12	I-Drug
)	O
as	O
you	O
were	O
at	O
home	O
.	O
7	O
.	O
Lasix	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
8	O
.	O
Ocuvite	I-Drug
150	O
-30-6-150	O
mg	O
-	O
unit	O
-	O
mg	O
-	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
daily	O
(	O
)	O
:	O
Continue	O
as	O
you	O
have	O
been	O
taking	O
at	O
home	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
119	O
**	O
]	O
Homecare	O
Discharge	O
Diagnosis	O
:	O
Hypercarbic	O
respiratory	O
failure	O
Acute	O
COPD	O
exacerbation	O
Restless	O
legs	O
syndrome	O
Chronic	O
kidney	O
disease	O
Anxiety	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
Please	O
seek	O
medical	O
attention	O
if	O
you	O
develop	O
new	O
shortness	O
of	O
breath	O
,	O
fever	O
,	O
coughing	O
Review	O
your	O
medication	O
list	O
carefully	O
and	O
compare	O
to	O
your	O
bottles	O
at	O
home	O
.	O
Your	O
methadone	I-Drug
should	O
be	O
15	O
mg	O
twice	O
daily	O
.	O
If	O
you	O
do	O
not	O
already	O
have	O
an	O
albuterol	I-Drug
inhaler	O
,	O
you	O
should	O
fill	O
out	O
the	O
prescription	O
we	O
have	O
given	O
you	O
.	O
If	O
you	O
already	O
have	O
one	O
at	O
home	O
,	O
you	O
can	O
continue	O
taking	O
it	O
as	O
prescribed	O
by	O
your	O
primary	O
care	O
physician	O
.	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
have	O
not	O
changed	O
any	O
of	O
your	O
other	O
medications	O
.	O
Followup	O
Instructions	O
:	O
Please	O
contact	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2903	O
**	O
]	O
for	O
a	O
follow	O
-	O
up	O
appointment	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
18651	O
**	O
]	O
in	O
the	O
next	O
1	O
-	O
2	O
weeks	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2158	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2141-4-11	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2120-6-16	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2120-7-1	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2065-9-5	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Diphenhydramine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1973	O
**	O
]	O
Chief	O
Complaint	O
:	O
etoh	O
withdrawal	O
,	O
vocal	O
cord	O
mass	O
or	O
selling	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
bronchoscopy	O
intubation	O
tracheostomy	O
PICC	O
History	O
of	O
Present	O
Illness	O
:	O
54	O
year	O
old	O
Male	O
with	O
a	O
PMH	O
of	O
HTN	O
and	O
etoh	O
abuse	O
who	O
presented	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
on	O
[	O
**	O
6	O
-	O
13	O
**	O
]	O
in	O
etoh	O
withdrawal	O
,	O
reporting	O
tachycardia	O
,	O
cough	O
,	O
and	O
chest	O
pain	O
.	O
He	O
drinks	O
1	O
quart	O
of	O
vodka	O
several	O
days	O
a	O
week	O
and	O
last	O
drink	O
was	O
around	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
or	O
[	O
**	O
6	O
-	O
13	O
**	O
]	O
.	O
He	O
ruled	O
out	O
with	O
2	O
sets	O
of	O
negative	O
cardiac	O
enzymes	O
and	O
a	O
non-ischemic	O
ekg	O
,	O
and	O
was	O
evaluated	O
by	O
cardiology	O
.	O
CXR	O
neg	O
for	O
acute	O
process	O
.	O
His	O
chest	O
pain	O
was	O
felt	O
likely	O
due	O
to	O
bronchitis	O
.	O
During	O
the	O
hospitalization	O
he	O
continued	O
to	O
exhibit	O
withdrawal	O
symptoms	O
so	O
was	O
started	O
on	O
CIWA	O
.	O
He	O
required	O
20	O
mg	O
IV	O
lorazepam	I-Drug
during	O
the	O
initial	O
6	O
hours	O
of	O
withdrawal	I-Reason
and	O
had	O
respiratory	O
distress	O
,	O
cyanosis	O
,	O
and	O
stridor	O
.	O
During	O
intubation	O
he	O
was	O
noted	O
to	O
have	O
a	O
vocal	O
cord	O
polypoid	O
mass	O
and	O
is	O
thus	O
being	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
evaluation	O
.	O
Over	O
the	O
past	O
24	O
hours	O
he	O
has	O
required	O
12	O
mg	O
IV	O
lorazepam	I-Drug
.	O
He	O
is	O
also	O
on	O
levofloxacin	I-Drug
for	O
unclear	O
reason	O
.	O
VS	O
prior	O
to	O
transfer	O
were	O
100.7	O
,	O
87	O
,	O
120/72	O
,	O
31	O
,	O
95	O
%	O
.	O
Upon	O
arrival	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
MICU	O
,	O
patient	O
is	O
intubated	I-Reason
,	O
on	O
propofol	I-Drug
,	O
and	O
mildly	O
agitated	O
.	O
Vent	O
settings	O
are	O
:	O
AC	O
,	O
TV	O
500	O
,	O
RR	O
16	O
,	O
PEEP	O
5	O
,	O
FiO2	O
40	O
%	O
.	O
He	O
failed	O
multiple	O
weaning	O
attempts	O
and	O
ultimately	O
underwent	O
tracheostomy	O
.	O
After	O
tracheostomy	O
he	O
was	O
discovered	O
to	O
have	O
a	O
pulmonary	O
embolism	O
on	O
[	O
**	O
6	O
-	O
21	O
**	O
]	O
.	O
Subsequent	O
laryngoscopy	O
showed	O
severe	O
laryngeal	O
edema	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
OSA	O
s	O
/	O
p	O
removal	O
of	O
adenoids	O
and	O
uvula	O
-	O
?	O
COPD	O
-	O
Hepatitis	O
C	O
-	O
ETOH	O
abuse	O
-	O
Nicotine	O
abuse	O
-	O
Anxiety	O
Social	O
History	O
:	O
Was	O
sober	O
for	O
7	O
years	O
but	O
relapsed	O
5	O
years	O
ago	O
and	O
has	O
been	O
drinking	O
a	O
quart	O
of	O
vodka	O
several	O
times	O
per	O
week	O
.	O
Desires	O
to	O
quit	O
and	O
has	O
been	O
through	O
20	O
rehabs	O
.	O
Smoked	O
for	O
over	O
30	O
years	O
but	O
recently	O
cut	O
down	O
to	O
1	O
pack	O
per	O
week	O
.	O
Lives	O
with	O
girlfriend	O
.	O
Family	O
History	O
:	O
No	O
history	O
of	O
head	O
and	O
neck	O
cancer	O
Physical	O
Exam	O
:	O
ADMISSION	O
EXAM	O
:	O
Vitals	O
:	O
97.2	O
,	O
106/67	O
,	O
88	O
,	O
27	O
,	O
98	O
%	O
on	O
vent	O
General	O
:	O
Intubated	O
,	O
agitated	I-Reason
but	O
calm	O
after	O
a	O
bolus	O
of	O
versed	I-Drug
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
pupils	O
pinpoint	O
but	O
equal	O
and	O
reactive	O
.	O
ET	O
tube	O
and	O
OG	O
tubes	O
in	O
place	O
.	O
Neck	O
:	O
Very	O
thick	O
neck	O
,	O
unable	O
to	O
assess	O
JVP	O
.	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
Soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
organomegaly	O
.	O
Well	O
healed	O
scar	O
over	O
LLQ	O
.	O
GU	O
:	O
+	O
foley	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
Moving	O
all	O
four	O
extremities	O
.	O
Lines	O
/	O
tubes	O
:	O
Left	O
subclavian	O
,	O
OG	O
tube	O
,	O
ET	O
tube	O
Pertinent	O
Results	O
:	O
IMAGING	O
:	O
[	O
**	O
2120-6-21	O
**	O
]	O
CTA	O
Chest	O
IMPRESSION	O
:	O
1	O
.	O
Acute	O
thromboembolus	O
in	O
the	O
right	O
upper	O
lobar	O
artery	O
and	O
several	O
main	O
segmental	O
branches	O
of	O
the	O
middle	O
lobar	O
artery	O
.	O
There	O
are	O
findings	O
suggestive	O
of	O
pulmonary	O
hypertension	O
,	O
but	O
no	O
lung	O
infarction	O
or	O
right	O
heart	O
strain	O
.	O
2	O
.	O
Stable	O
bilateral	O
small	O
pleural	O
effusions	O
and	O
stable	O
atelectasis	O
.	O
No	O
evidence	O
of	O
acute	O
infectious	O
process	O
.	O
.	O
[	O
**	O
2120-6-20	O
**	O
]	O
ECHO	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
No	O
atrial	O
septal	O
defect	O
or	O
patent	O
foramen	O
ovale	O
is	O
seen	O
by	O
2D	O
,	O
color	O
Doppler	O
or	O
saline	O
contrast	O
with	O
maneuvers	O
.	O
No	O
late	O
contrast	O
is	O
seen	O
in	O
the	O
left	O
heart	O
(	O
suggesting	O
absence	O
of	O
intrapulmonary	O
shunting	O
)	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
mildly	O
dilated	O
with	O
normal	O
free	O
wall	O
contractility	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis	O
or	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
prominent	O
fat	O
pad	O
.	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
intracardiac	O
or	O
cardiopulmonary	O
shunt	O
.	O
Normal	O
left	O
ventricular	O
cavity	O
size	O
and	O
wall	O
thickness	O
with	O
preserved	O
global	O
and	O
regional	O
left	O
ventricular	O
systolic	O
function	O
.	O
Mildly	O
dilated	O
right	O
ventricle	O
.	O
Mildly	O
dilated	O
aortic	O
root	O
and	O
ascending	O
aorta	O
.	O
Normal	O
pulmonary	O
artery	O
systolic	O
pressure	O
.	O
[	O
**	O
2120-6-29	O
**	O
]	O
10:38	O
AM	O
BLOOD	O
WBC	O
-	O
10.3	O
RBC	O
-	O
3.60	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
33.3	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
33.5	O
RDW	O
-	O
14.0	O
Plt	O
Ct	O
-	O
435	O
[	O
**	O
2120-6-26	O
**	O
]	O
05:31	O
AM	O
BLOOD	O
WBC	O
-	O
6.7	O
RBC	O
-	O
3.48	O
*	O
Hgb	O
-	O
10.5	O
*	O
Hct	O
-	O
32.2	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
32.6	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
332	O
[	O
**	O
2120-6-21	O
**	O
]	O
03:57	O
AM	O
BLOOD	O
WBC	O
-	O
7.9	O
#	O
RBC	O
-	O
3.18	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
30.3	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
30.9	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
13.7	O
Plt	O
Ct	O
-	O
275	O
[	O
**	O
2120-6-16	O
**	O
]	O
09:52	O
PM	O
BLOOD	O
WBC	O
-	O
11.1	O
*	O
RBC	O
-	O
3.76	O
*	O
Hgb	O
-	O
11.7	O
*	O
Hct	O
-	O
36.2	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
227	O
[	O
**	O
2120-6-16	O
**	O
]	O
09:52	O
PM	O
BLOOD	O
Neuts	O
-	O
77.0	O
*	O
Lymphs	O
-	O
14.6	O
*	O
Monos	O
-	O
4.6	O
Eos	O
-	O
3.2	O
Baso	O
-	O
0.5	O
[	O
**	O
2120-6-27	O
**	O
]	O
02:18	O
AM	O
BLOOD	O
PT	O
-	O
12.4	O
PTT	O
-	O
37.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2120-6-19	O
**	O
]	O
02:18	O
AM	O
BLOOD	O
PT	O
-	O
11.2	O
PTT	O
-	O
28.7	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2120-6-29	O
**	O
]	O
10:38	O
AM	O
BLOOD	O
Glucose	O
-	O
117	O
*	O
UreaN	O
-	O
14	O
Creat	O
-	O
0.7	O
Na	O
-	O
141	O
K	O
-	O
3.6	O
Cl	O
-	O
104	O
HCO3	O
-	O
28	O
AnGap	O
-	O
13	O
[	O
**	O
2120-6-24	O
**	O
]	O
09:40	O
PM	O
BLOOD	O
Glucose	O
-	O
117	O
*	O
UreaN	O
-	O
14	O
Creat	O
-	O
0.6	O
Na	O
-	O
140	O
K	O
-	O
4.0	O
Cl	O
-	O
102	O
HCO3	O
-	O
31	O
AnGap	O
-	O
11	O
[	O
**	O
2120-6-18	O
**	O
]	O
03:01	O
AM	O
BLOOD	O
Glucose	O
-	O
82	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.8	O
Na	O
-	O
141	O
K	O
-	O
3.8	O
Cl	O
-	O
109	O
*	O
HCO3	O
-	O
28	O
AnGap	O
-	O
8	O
[	O
**	O
2120-6-16	O
**	O
]	O
09:52	O
PM	O
BLOOD	O
Glucose	O
-	O
92	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.8	O
Na	O
-	O
142	O
K	O
-	O
4.2	O
Cl	O
-	O
107	O
HCO3	O
-	O
30	O
AnGap	O
-	O
9	O
[	O
**	O
2120-6-28	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
ALT	O
-	O
47	O
*	O
AST	O
-	O
33	O
LD	O
(	O
LDH	O
)	O
-	O
252	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
86	O
AlkPhos	O
-	O
55	O
TotBili	O
-	O
0.6	O
DirBili	O
-	O
0.3	O
IndBili	O
-	O
0.3	O
[	O
**	O
2120-6-19	O
**	O
]	O
02:18	O
AM	O
BLOOD	O
ALT	O
-	O
53	O
*	O
AST	O
-	O
62	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
185	O
CK	O
(	O
CPK	O
)	O
-	O
752	O
*	O
AlkPhos	O
-	O
44	O
TotBili	O
-	O
0.8	O
[	O
**	O
2120-6-20	O
**	O
]	O
04:02	O
AM	O
BLOOD	O
Lipase	O
-	O
11	O
[	O
**	O
2120-6-16	O
**	O
]	O
09:52	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2120-6-29	O
**	O
]	O
10:38	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
1.9	O
[	O
**	O
2120-6-28	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
Albumin	O
-	O
3.9	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
2.5	O
*	O
Mg	O
-	O
2.0	O
[	O
**	O
2120-6-19	O
**	O
]	O
02:18	O
AM	O
BLOOD	O
Albumin	O
-	O
3.2	O
*	O
Calcium	O
-	O
7.9	O
*	O
Phos	O
-	O
3.2	O
Mg	O
-	O
2.1	O
[	O
**	O
2120-6-16	O
**	O
]	O
09:52	O
PM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
4.3	O
Mg	O
-	O
2.2	O
[	O
**	O
2120-6-22	O
**	O
]	O
05:02	O
AM	O
BLOOD	O
Triglyc	O
-	O
109	O
[	O
**	O
2120-6-20	O
**	O
]	O
04:02	O
AM	O
BLOOD	O
Triglyc	O
-	O
78	O
[	O
**	O
2120-6-25	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
Vanco	O
-	O
4.0	O
*	O
[	O
**	O
2120-6-23	O
**	O
]	O
05:51	O
AM	O
BLOOD	O
Vanco	O
-	O
32.5	O
*	O
[	O
**	O
2120-6-21	O
**	O
]	O
03:57	O
AM	O
BLOOD	O
Vanco	O
-	O
9.6	O
*	O
[	O
**	O
2120-6-26	O
**	O
]	O
02:59	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
88	O
pCO2	O
-	O
49	O
*	O
pH	O
-	O
7.43	O
calTCO2	O
-	O
34	O
*	O
Base	O
XS	O
-	O
6	O
[	O
**	O
2120-6-26	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
107	O
*	O
pCO2	O
-	O
54	O
*	O
pH	O
-	O
7.41	O
calTCO2	O
-	O
35	O
*	O
Base	O
XS	O
-	O
7	O
[	O
**	O
2120-6-23	O
**	O
]	O
08:43	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
125	O
*	O
pCO2	O
-	O
44	O
pH	O
-	O
7.48	O
*	O
calTCO2	O
-	O
34	O
*	O
Base	O
XS	O
-	O
9	O
[	O
**	O
2120-6-21	O
**	O
]	O
09:15	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
Temp	O
-	O
36.9	O
Rates	O
-	O
24	O
/	O
Tidal	O
V	O
-	O
440	O
PEEP	O
-	O
12	O
FiO2	O
-	O
60	O
pO2	O
-	O
71	O
*	O
pCO2	O
-	O
49	O
*	O
pH	O
-	O
7.45	O
calTCO2	O
-	O
35	O
*	O
Base	O
XS	O
-	O
8	O
Intubat	O
-	O
INTUBATED	O
Vent	O
-	O
CONTROLLED	O
[	O
**	O
2120-6-16	O
**	O
]	O
11:54	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
Temp	O
-	O
37.2	O
Rates	O
-	O
16/5	O
Tidal	O
V	O
-	O
600	O
PEEP	O
-	O
5	O
FiO2	O
-	O
100	O
pO2	O
-	O
205	O
*	O
pCO2	O
-	O
66	O
*	O
pH	O
-	O
7.29	O
*	O
calTCO2	O
-	O
33	O
*	O
Base	O
XS	O
-	O
3	O
AADO2	O
-	O
442	O
REQ	O
O2	O
-	O
76	O
-	O
ASSIST	O
/	O
CON	O
Intubat	O
-	O
INTUBATED	O
[	O
**	O
2120-6-23	O
**	O
]	O
06:10	O
AM	O
BLOOD	O
freeCa	O
-	O
1.14	O
[	O
**	O
2120-6-20	O
**	O
]	O
05:04	O
AM	O
BLOOD	O
freeCa	O
-	O
1.10	O
*	O
[	O
**	O
2120-6-19	O
**	O
]	O
02:32	O
AM	O
BLOOD	O
freeCa	O
-	O
1.19	O
[	O
**	O
2120-6-18	O
**	O
]	O
03:11	O
AM	O
BLOOD	O
freeCa	O
-	O
1.14	O
Brief	O
Hospital	O
Course	O
:	O
54M	O
with	O
a	O
h	O
/	O
o	O
etoh	O
abuse	O
who	O
presented	O
to	O
an	O
OSH	O
on	O
[	O
**	O
6	O
-	O
13	O
**	O
]	O
for	O
chest	O
pain	O
,	O
felt	O
likely	O
secondary	O
to	O
bronchitis	O
.	O
Hospital	O
course	O
complicated	O
by	O
etoh	O
withdrawal	O
.	O
Patient	O
reportedly	O
developed	O
stridor	O
.	O
ENT	O
evaluated	O
patient	O
with	O
CT	O
scan	O
and	O
felt	O
he	O
may	O
have	O
had	O
a	O
mass	O
around	O
the	O
cords	O
.	O
He	O
was	O
sent	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
further	O
evaluation	O
.	O
ACTIVE	O
ISSUES	O
:	O
#	O
Respiratory	O
failure	O
/	O
Hypoxemia	O
/	O
Laryngeal	O
Edema	O
:	O
Patient	O
was	O
intubated	O
at	O
OSH	O
for	O
respiratory	O
distress	O
.	O
On	O
tubated	O
there	O
was	O
a	O
polypoid	O
lesion	O
on	O
his	O
vocal	O
cords	O
and	O
he	O
was	O
sent	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
evaluation	O
.	O
Here	O
,	O
ENT	O
performed	O
direct	O
laryngoscopy	O
which	O
revealed	O
edematous	B-Reason
cords	I-Reason
.	O
He	O
was	O
given	O
a	O
short	O
course	O
of	O
steroids	I-Drug
.	O
Extubation	O
was	O
attempted	O
however	O
resulted	O
in	O
recurrent	O
respiratory	O
distress	O
requiring	O
reintubation	O
.	O
ENT	O
felt	O
that	O
he	O
has	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
50614	O
**	O
]	O
edema	O
which	O
will	O
resolve	O
in	O
a	O
few	O
weeks	O
.	O
He	O
underwent	O
tracheostomy	O
placement	O
.	O
***	O
PATIENT	O
WILL	O
REQUIRE	O
DOWN	O
-	O
SIZING	O
OF	O
TRACH	O
DURING	O
WEEK	O
OF	O
[	O
**	O
7	O
-	O
8	O
**	O
]	O
PER	O
IP	O
RECOMMENDATIONS	O
.	O
***	O
He	O
was	O
also	O
need	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
ENT	O
.	O
#	O
Ventilator	B-Reason
Associated	I-Reason
Pneumonia	I-Reason
:	O
Patient	O
was	O
treated	O
with	O
7	O
days	O
of	O
antibiotics	I-Drug
while	O
in	O
patient	O
.	O
He	O
remained	O
afebrile	O
.	O
#	O
Pulmonary	B-Reason
Embolism	I-Reason
:	O
While	O
intubated	O
,	O
patient	O
was	O
difficult	O
to	O
ventilate	O
.	O
A	O
CT	O
was	O
performed	O
which	O
revealed	O
multiple	O
PEs	O
.	O
He	O
was	O
started	O
on	O
lovenox	I-Drug
.	O
After	O
all	O
procedures	O
are	O
completed	O
,	O
he	O
should	O
transition	O
to	O
Coumadin	I-Drug
for	O
at	O
least	O
a	O
6	O
month	O
course	O
unless	O
the	O
mass	O
is	O
found	O
to	O
be	O
a	O
solid	O
tumor	O
,	O
in	O
which	O
case	O
there	O
is	O
some	O
evidence	O
to	O
use	O
LMWH	I-Drug
for	O
solid	B-Reason
tumors	I-Reason
over	O
coumadin	I-Drug
.	O
#	O
Alcohol	B-Reason
Dependence	I-Reason
,	I-Reason
withdrawal	I-Reason
:	O
Given	O
thiamine	I-Drug
,	O
folic	B-Drug
acid	I-Drug
,	O
multivitamin	I-Drug
.	O
Ciwa	O
scale	O
was	O
maintained	O
while	O
in	O
the	O
ICU	O
#	O
Clostridium	B-Reason
difficile	I-Reason
Colitis	I-Reason
:	O
dx	O
made	O
on	O
[	O
**	O
2120-6-28	O
**	O
]	O
.	O
Was	O
started	O
for	O
10	O
day	O
course	O
of	O
PO	O
Flagyl	I-Drug
and	O
will	O
be	O
completed	O
on	O
[	O
**	O
2120-7-8	O
**	O
]	O
.	O
#	O
Anxiety	O
:	O
Patient	O
started	O
on	O
clonazepam	I-Drug
for	O
anxiety	I-Reason
.	O
Will	O
likely	O
need	O
to	O
wean	O
this	O
prior	O
to	O
discharge	O
from	O
facility	O
.	O
Transitions	O
of	O
care	O
:	O
-	O
will	O
need	O
outpatient	O
speech	O
and	O
swallow	O
appointment	O
to	O
discuss	O
advancing	O
his	O
diet	O
once	O
ENT	O
has	O
cleared	O
him	O
.	O
-	O
will	O
need	O
trach	O
changed	O
out	O
during	O
week	O
of	O
[	O
**	O
7	O
-	O
8	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
Home	O
Medications	O
:	O
Girlfriend	O
unable	O
to	O
recall	O
Transfer	O
Medications	O
:	O
1	O
.	O
pantoprazole	I-Drug
40	O
mg	O
daily	O
2	O
.	O
acetaminophen	I-Drug
650	O
mg	O
Q6h	O
prn	O
3	O
.	O
heparin	I-Drug
5000units	O
SC	O
Q8h	O
4	O
.	O
artificial	B-Drug
tears	I-Drug
5	O
.	O
chlorhexidine	I-Drug
15	O
ml	O
TID	O
6	O
.	O
propofol	I-Drug
100	O
ml	O
IV	O
Q4h	O
7	O
.	O
vecuronium	I-Drug
8	O
mg	O
Q6h	O
IV	O
prn	O
8	O
.	O
lorazepam	I-Drug
Q2h	O
IV	O
prn	O
CIWA	I-Reason
9	O
.	O
levofloxacin	I-Drug
100	O
ml	O
IV	O
Q24h	O
10	O
.	O
guaifenesin	I-Drug
200	O
mg	O
Q4h	O
prn	O
11	O
.	O
nitroglycerin	I-Drug
0.4	O
mg	O
SL	O
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
650	O
mg	O
PO	O
Q8H	O
:	O
PRN	O
pain	I-Reason
2	O
.	O
Clonazepam	I-Drug
1	O
mg	O
PO	O
BID	O
hold	O
for	O
rr	O
<	O
10	O
and	O
somnolence	O
3	O
.	O
FoLIC	B-Drug
Acid	I-Drug
1	O
mg	O
PO	O
DAILY	O
4	O
.	O
Pantoprazole	I-Drug
20	O
mg	O
PO	O
Q24H	O
5	O
.	O
Mirtazapine	I-Drug
7.5	O
mg	O
PO	O
HS	O
hold	O
for	O
rr	O
<	O
10	O
and	O
somnolence	O
6	O
.	O
Thiamine	I-Drug
100	O
mg	O
PO	O
DAILY	O
7	O
.	O
Multivitamins	I-Drug
1	O
TAB	O
PO	O
DAILY	O
8	O
.	O
Miconazole	B-Drug
Powder	I-Drug
2	O
%	O
1	O
Appl	O
TP	O
TID	O
:	O
PRN	O
rash	I-Reason
apply	O
to	O
affected	O
area	O
9	O
.	O
Enoxaparin	B-Drug
Sodium	I-Drug
110	O
mg	O
SC	O
Q12H	O
10	O
.	O
Clonazepam	I-Drug
0.5	O
mg	O
PO	O
QHS	O
:	O
PRN	O
anxiety	I-Reason
/	O
insomnia	I-Reason
11	O
.	O
MetRONIDAZOLE	I-Drug
(	O
FLagyl	I-Drug
)	O
500	O
mg	O
PO	O
Q8H	O
Duration	O
:	O
7	O
Days	O
D1	O
=	O
[	O
**	O
2120-6-28	O
**	O
]	O
.	O
12	O
.	O
Albuterol	B-Drug
-	I-Drug
Ipratropium	I-Drug
[	O
**	O
1	O
-	O
8	O
**	O
]	O
PUFF	O
IH	O
Q6H	O
:	O
PRN	O
sob	I-Reason
/	O
wheeze	I-Reason
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
for	O
Continuing	O
Medical	O
Care	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1121	O
**	O
]	O
(	O
[	O
**	O
Hospital3	O
1122	O
**	O
]	O
Center	O
)	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
ETOH	O
intoxication	O
airway	O
edema	O
and	O
possible	O
airway	O
mass	O
/	O
lesion	O
ventilator	O
associated	O
pneumonia	O
pulmonary	O
embolus	O
clostridium	O
difficile	O
oliguria	O
Secondary	O
:	O
GERD	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
It	O
was	O
a	O
pleasure	O
participating	O
in	O
your	O
care	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
alcoholic	O
detoxification	O
and	O
respiratory	O
distress	O
due	O
to	O
airway	O
compromise	O
from	O
swollen	O
vocal	O
cords	O
.	O
It	O
is	O
not	O
exactly	O
clear	O
why	O
there	O
was	O
swelling	O
around	O
your	O
vocal	O
cords	O
but	O
a	O
tracheostomy	O
was	O
needed	O
to	O
protect	O
your	O
airway	O
and	O
you	O
will	O
need	O
to	O
see	O
the	O
ENT	O
doctor	O
when	O
you	O
leave	O
the	O
hospital	O
to	O
assess	O
further	O
plans	O
to	O
manage	O
these	O
issues	O
.	O
After	O
you	O
see	O
the	O
ENT	O
doctor	O
,	O
you	O
should	O
following	O
up	O
with	O
a	O
speech	O
/	O
swallow	O
therapist	O
to	O
discuss	O
advancing	O
your	O
diet	O
.	O
While	O
in	O
the	O
hospital	O
,	O
you	O
developed	O
a	O
clot	I-Reason
in	O
your	O
lungs	O
which	O
you	O
will	O
need	O
to	O
been	O
on	O
blood	B-Drug
thinning	I-Drug
medications	I-Drug
for	O
.	O
You	O
also	O
have	O
an	O
infection	I-Reason
of	O
your	O
colon	O
for	O
which	O
you	O
will	O
need	O
to	O
take	O
a	O
course	O
of	O
antibiotics	I-Drug
.	O
Please	O
be	O
sure	O
to	O
complete	O
this	O
course	O
of	O
antibiotics	I-Drug
.	O
Otherwise	O
,	O
it	O
is	O
very	O
important	O
that	O
you	O
take	O
all	O
of	O
your	O
usual	O
home	O
medications	O
as	O
directed	O
in	O
your	O
discharge	O
paperwork	O
.	O
Please	O
followup	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
176	O
**	O
]	O
[	O
**	O
7	O
-	O
16	O
**	O
]	O
days	O
regarding	O
the	O
course	O
of	O
this	O
hospitalization	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
OTOLARYNGOLOGY	O
-	O
AUDIOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2120-7-4	O
**	O
]	O
at	O
9:45	O
AM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
15040	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
15041	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
41	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Bldg	O
(	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
895	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Completed	O
by	O
:[	O
**	O
2120-7-2	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2135-2-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2135-2-24	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Horse	O
Blood	O
Extract	O
Attending	O
:[	O
**	O
Doctor	O
First	O
Name	O
1402	O
**	O
]	O
Chief	O
Complaint	O
:	O
lightheadedness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
right	O
groin	O
hematoma	O
evacuation	O
and	O
repair	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
7518	O
**	O
]	O
is	O
an	O
85	O
y	O
/	O
o	O
male	O
with	O
COPD	O
,	O
HTN	O
,	O
AF	I-Reason
on	O
coumadin	I-Drug
admitted	O
to	O
NEBH	O
[	O
**	O
2	O
-	O
8	O
**	O
]	O
with	O
atrial	O
fibrillation	O
s	O
/	O
p	O
CV	O
developed	O
tachy	O
/	O
brady	O
syndrome	O
s	O
/	O
p	O
AF	O
ablation	O
on	O
[	O
**	O
2	O
-	O
14	O
**	O
]	O
discharged	O
on	O
CCB	I-Drug
,	O
metoprolol	I-Drug
and	O
dofetilide	I-Drug
now	O
presents	O
with	O
presyncope	O
and	O
sinus	O
bradycardia	O
.	O
On	O
[	O
**	O
2	O
-	O
14	O
**	O
]	O
patient	O
underwent	O
EP	O
study	O
which	O
showed	O
several	O
atrial	O
tachycardias	O
and	O
two	O
were	O
ablated	O
.	O
The	O
plan	O
was	O
for	O
cardioversion	O
following	O
ablation	O
but	O
patient	O
converted	O
to	O
NSR	O
and	O
remained	O
in	O
NSR	O
with	O
only	O
2	O
brief	O
episodes	O
of	O
AF	O
on	O
telemetry	O
.	O
Since	O
discharge	O
from	O
the	O
hospital	O
on	O
[	O
**	O
2	O
-	O
15	O
**	O
]	O
the	O
patient	O
has	O
been	O
feeling	O
well	O
.	O
He	O
has	O
not	O
had	O
any	O
chest	O
pain	O
,	O
lightheadedness	O
or	O
dizziness	O
until	O
this	O
morning	O
.	O
This	O
AM	O
had	O
minimal	O
appetite	O
at	O
breakfast	O
.	O
Then	O
attempted	O
to	O
have	O
a	O
bowel	O
movement	O
several	O
times	O
with	O
straining	O
and	O
each	O
time	O
felt	O
lightheaded	O
and	O
dizzy	O
with	O
associated	O
diaphoresis	O
.	O
He	O
has	O
been	O
constipated	O
over	O
the	O
past	O
four	O
days	O
.	O
His	O
children	O
were	O
with	O
him	O
,	O
helped	O
him	O
back	O
to	O
bed	O
and	O
called	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
who	O
referred	O
him	O
to	O
the	O
Emergency	O
Room	O
.	O
The	O
patient	O
did	O
not	O
ever	O
lose	O
consciousness	O
.	O
He	O
reports	O
that	O
he	O
has	O
been	O
complaint	O
with	O
all	O
of	O
his	O
medications	O
.	O
He	O
denies	O
any	O
associated	O
chest	O
pain	O
or	O
shortness	O
of	O
breath	O
.	O
Patient	O
has	O
history	O
of	O
bradycardia	I-Ade
in	O
past	O
when	O
on	O
metoprolol	I-Drug
and	O
cardizem	I-Drug
(	O
HR	O
ranging	O
from	O
40	O
-	O
100	O
bpm	O
)	O
.	O
.	O
During	O
the	O
patient	O
's	O
last	O
hospitalization	O
he	O
underwent	O
AF	O
ablation	O
however	O
according	O
to	O
d	O
/	O
c	O
summary	O
only	O
2	O
of	O
4	O
arrhythmias	O
were	O
ablated	O
.	O
He	O
was	O
in	O
sinus	O
rhythm	O
prior	O
to	O
discharge	O
and	O
was	O
discharged	O
on	O
lopressor	I-Drug
,	O
cardizem	I-Drug
and	O
dofetilide	I-Drug
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vitals	O
were	O
HR	O
:	O
45	O
-	O
55	O
BP	O
:	O
78/39	O
,	O
O2sat	O
96	O
%	O
on	O
RA	O
.	O
Exam	O
notable	O
for	O
patient	O
with	O
good	O
mentation	O
.	O
EKG	O
was	O
initially	O
sinus	O
bradycardia	O
.	O
Patient	O
received	O
2	O
g	O
Calcium	I-Drug
gluconate	O
and	O
1L	O
IVF	I-Drug
.	O
Symptoms	O
and	O
EKG	O
changes	O
felt	O
to	O
be	O
consistent	O
with	O
too	O
much	O
medication	O
.	O
.	O
On	O
arrival	O
to	O
the	O
CCU	O
,	O
the	O
patient	O
feels	O
"	O
better	O
"	O
.	O
He	O
is	O
fatigued	O
but	O
overall	O
improved	O
from	O
this	O
afternoon	O
.	O
HR	O
50s	O
.	O
BP	O
111/70	O
.	O
He	O
denies	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpitations	O
,	O
cough	O
,	O
abdominal	O
pain	O
,	O
orthopnea	O
,	O
ankle	O
edema	O
and	O
PND	O
.	O
He	O
does	O
report	O
some	O
persistent	O
groin	O
pain	O
,	O
R	O
>	O
L	O
which	O
has	O
improved	O
over	O
the	O
past	O
several	O
days	O
.	O
Past	O
Medical	O
History	O
:	O
Atrial	B-Reason
fibrillation	I-Reason
s	O
/	O
p	O
CV	O
[	O
**	O
2126	O
**	O
]	O
on	O
coumadin	I-Drug
hypertension	O
COPD	O
/	O
Bronchiectasis	O
congestive	O
heart	O
failure	O
(	O
unknown	O
ef	O
)	O
gastroesophageal	O
reflux	O
disease	O
,	O
benign	O
prostatic	O
hypertrophy	O
,	O
,	O
anemia	O
,	O
status	O
post	O
bilateral	O
total	O
knee	O
replacements	O
,	O
shoulder	O
arthroplasty	O
.	O
Cardiac	O
Risk	O
Factors	O
:	O
-	O
Diabetes	O
,	O
-	O
Dyslipidemia	O
,	O
+	O
Hypertension	O
Social	O
History	O
:	O
Social	O
history	O
is	O
significant	O
for	O
the	O
absence	O
of	O
current	O
tobacco	O
use	O
.	O
Former	O
smoker	O
but	O
quit	O
in	O
[	O
**	O
2095	O
**	O
]	O
with	O
40	O
pack	O
yr	O
hx	O
.	O
There	O
is	O
no	O
history	O
of	O
alcohol	O
abuse	O
.	O
No	O
illicit	O
drug	O
use	O
.	O
Widowed	O
.	O
Lives	O
alone	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
2312	O
**	O
]	O
and	O
completes	O
all	O
his	O
ADLs	O
.	O
Former	O
fire	O
-	O
fighter	O
but	O
retired	O
30	O
years	O
.	O
Has	O
4	O
children	O
and	O
4	O
grandkids	O
.	O
Family	O
History	O
:	O
Significant	O
for	O
heart	O
disease	O
in	O
father	O
(	O
mi	O
[	O
**	O
89	O
**	O
]	O
yo	O
)	O
,	O
mother	O
(	O
mi	O
[	O
**	O
08	O
**	O
]	O
yo	O
)	O
,	O
and	O
brother	O
(	O
mi	O
[	O
**	O
67	O
**	O
]	O
yo	O
)	O
.	O
No	O
diabetes	O
in	O
the	O
family	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
HR	O
56	O
,	O
BP	O
111/52	O
,	O
100	O
%	O
on	O
2L	O
Gen	O
:	O
Elderly	O
male	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Mood	O
,	O
affect	O
appropriate	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
No	O
xanthalesma	O
.	O
Neck	O
:	O
Supple	O
with	O
no	O
appreciable	O
JVP	O
.	O
CV	O
:	O
Bradycardic	O
.	O
s1	O
,	O
s2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
No	O
thrills	O
,	O
lifts	O
.	O
No	O
S3	O
or	O
S4	O
.	O
Soft	O
2/6	O
systolic	O
ejection	O
murmur	O
at	O
USB	O
.	O
Chest	O
:	O
No	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
CTAB	O
,	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
Resonant	O
to	O
percussion	O
.	O
Abd	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
Abd	O
aorta	O
not	O
enlarged	O
by	O
palpation	O
.	O
No	O
abdominial	O
bruits	O
.	O
Ext	O
:	O
Bilateral	O
groin	O
hematomas	O
,	O
right	O
side	O
is	O
firm	O
without	O
ooze	O
,	O
nontender	O
to	O
palpation	O
,	O
no	O
bruit	O
.	O
Left	O
side	O
is	O
soft	O
,	O
less	O
ecchymotic	O
.	O
Trace	O
edema	O
bilaterally	O
.	O
No	O
femoral	O
bruits	O
b	O
/	O
l.	O
.	O
Pulses	O
:	O
Right	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
Popliteal	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Left	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
Popliteal	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Pertinent	O
Results	O
:	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
GLUCOSE	O
-	O
194	O
*	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
1.0	O
SODIUM	O
-	O
137	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
103	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
11	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
139	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
cTropnT	O
-	O
0.09	O
*	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
CK	O
-	O
MB	O
-	O
3	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
WBC	O
-	O
6.9	O
RBC	O
-	O
2.77	O
*	O
HGB	O
-	O
8.2	O
*	O
HCT	O
-	O
23.8	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
29.4	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
15.2	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
NEUTS	O
-	O
92	O
*	O
BANDS	O
-	O
0	O
LYMPHS	O
-	O
6	O
*	O
MONOS	O
-	O
2	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
1	O
+	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
NORMAL	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
NORMAL	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
PLT	O
SMR	O
-	O
NORMAL	O
PLT	O
COUNT	O
-	O
197	O
[	O
**	O
2135-2-17	O
**	O
]	O
10:10	O
PM	O
PT	O
-	O
16.4	O
*	O
PTT	O
-	O
32.0	O
INR	O
(	O
PT	O
)	O
-	O
1.5	O
*	O
.	O
[	O
**	O
2	O
-	O
18	O
**	O
]	O
Large	O
bilateral	O
groin	O
hematomas	O
demonstrated	O
,	O
without	O
evidence	O
of	O
pseudoaneurysm	O
seen	O
.	O
.	O
[	O
**	O
2	O
-	O
20	O
**	O
]	O
Femoral	O
U	O
/	O
S	O
:	O
1	O
.	O
Increase	O
in	O
size	O
of	O
large	O
right	O
groin	O
hematoma	O
extending	O
into	O
the	O
medial	O
thigh	O
.	O
No	O
evidence	O
for	O
pseudoaneurysm	O
or	O
arteriovenous	O
fistula	O
.	O
2	O
.	O
Small	O
left	O
groin	O
hematoma	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
is	O
an	O
85	O
year	O
old	O
male	O
with	O
history	O
of	O
AF	O
s	O
/	O
p	O
CV	O
at	O
OSH	O
with	O
resultant	O
tachy	O
/	O
brady	O
s	O
/	O
p	O
AF	O
ablation	O
on	O
[	O
**	O
2	O
-	O
14	O
**	O
]	O
started	O
on	O
dofetilide	I-Drug
,	O
CCB	I-Drug
and	O
beta	B-Drug
blocker	I-Drug
now	O
presents	O
with	O
presyncope	I-Ade
and	O
bradycardia	I-Ade
likely	O
related	O
to	O
medication	O
.	O
Now	O
off	O
dilt	I-Drug
and	O
metoprolol	I-Drug
and	O
on	O
dofetilide	I-Drug
and	O
acebutolol	I-Drug
with	O
symptomatic	O
improvement	O
.	O
This	O
hospitalization	O
is	O
complicated	O
by	O
ongoing	O
fall	O
in	O
HCT	O
with	O
expansion	O
of	O
his	O
bilat	O
groin	O
hematomas	O
R	O
>	O
L	O
now	O
s	O
/	O
p	O
r	O
hematoma	O
evacuation	O
.	O
.	O
##	O
Bilateral	O
groin	O
hematomas	O
:	O
He	O
had	O
bilateral	O
groin	O
hematomas	O
,	O
and	O
had	O
a	O
hematocrit	O
drop	O
betwee	O
his	O
ablation	O
and	O
this	O
admission	O
from	O
about	O
30	O
--	O
>	O
24	O
.	O
He	O
had	O
groin	O
ultrasound	O
that	O
showed	O
bilateral	O
hematomas	O
but	O
no	O
pseudoaneurysm	O
.	O
S	O
/	O
p	O
drainage	O
and	O
hematoma	O
evacuation	O
by	O
vascular	O
surgery	O
[	O
**	O
2135-2-20	O
**	O
]	O
.	O
Now	O
with	O
one	O
JP	O
drain	O
in	O
place	O
.	O
Pt	O
denies	O
pain	O
.	O
No	O
transfusions	O
since	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
.	O
Following	O
vascular	O
recs	O
,	O
he	O
will	O
follow	O
up	O
in	O
2	O
weeks	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
HCT	O
remained	O
stable	O
at	O
time	O
of	O
discharge	O
.	O
.	O
##	O
Rhythm	O
:	O
He	O
does	O
have	O
AF	O
s	O
/	O
p	O
CV	O
c	O
/	O
b	O
bradycardia	O
and	O
tachycardia	O
recently	O
here	O
for	O
AF	O
ablation	O
on	O
[	O
**	O
2	O
-	O
14	O
**	O
]	O
with	O
2	O
of	O
4	O
atrial	O
arrhythmias	O
ablated	O
.	O
Discharged	O
on	O
[	O
**	O
2	O
-	O
15	O
**	O
]	O
on	O
Dofetelide	I-Drug
,	O
Cardizem	I-Drug
and	O
Metoprolol	I-Drug
in	O
normal	O
sinus	O
rhythm	O
.	O
Returns	O
with	O
near	O
syncopal	O
episodes	O
and	O
sinus	B-Ade
bradycardia	I-Ade
,	O
likely	O
medication	O
related	O
.	O
Symptoms	O
are	O
likely	O
exacerbated	O
in	O
setting	O
of	O
anemia	O
.	O
Cardizem	I-Drug
and	O
metoprolol	I-Drug
discontinued	O
and	O
he	O
was	O
discahrged	O
on	O
acebutolol	I-Drug
and	O
dofetilide	I-Drug
for	O
rate	B-Reason
and	I-Reason
rhythm	I-Reason
control	I-Reason
which	O
he	O
tolerated	O
.	O
HOLD	O
coumadin	I-Drug
with	O
lovenox	I-Drug
for	O
now	O
pending	O
HCT	O
stabilization	O
.	O
Should	O
be	O
restarted	O
at	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
of	O
vascular	O
surgery	O
.	O
He	O
was	O
monitored	O
on	O
telemetry	O
.	O
.	O
##	O
Pump	O
:	O
Patient	O
with	O
known	O
history	O
of	O
CHF	O
per	O
chart	O
.	O
Euvolemic	O
on	O
exam	O
.	O
Monitored	O
I	O
/	O
Os	O
,	O
goal	O
even	O
.	O
.	O
##	O
CAD	O
:	O
No	O
known	O
CAD	O
.	O
No	O
ischemic	O
sxs	O
currently	O
.	O
.	O
##	O
Cellulitis	I-Reason
:	O
Pt	O
had	O
mild	O
erythema	O
R	O
groin	O
near	O
well	O
-	O
healing	O
incision	O
.	O
had	O
low	O
grade	O
fever	O
with	O
pancultures	O
sent	O
.	O
He	O
was	O
started	O
on	O
cephalexin	I-Drug
to	O
complete	O
10	O
day	O
course	O
.	O
His	O
culture	O
data	O
had	O
no	O
growth	O
at	O
time	O
of	O
discharge	O
and	O
he	O
remained	O
afebrile	O
>	O
48	O
hours	O
prior	O
to	O
discharge	O
.	O
.	O
##	O
Anemia	O
:	O
Likely	O
related	O
to	O
blood	O
loss	O
in	O
groin	O
based	O
on	O
exam	O
findings	O
of	O
bilateral	O
hematomas	O
.	O
Baseline	O
approximately	O
30	O
.	O
Tranfused	O
total	O
6	O
units	O
.	O
Last	O
transfused	O
[	O
**	O
2135-2-21	O
**	O
]	O
.	O
Continue	O
iron	I-Drug
supplementation	O
,	O
B12	I-Drug
.	O
Mgmt	O
as	O
above	O
for	O
hematomas	O
.	O
.	O
##	O
GERD	I-Reason
:	O
Continued	O
ppi	I-Drug
.	O
##	O
COPD	O
:	O
Continued	O
inhalers	O
.	O
##	O
General	O
Care	O
:	O
pneumoboots	O
,	O
ppi	I-Drug
,	O
Code	O
status	O
:	O
FULL	O
CODE	O
confirmed	O
with	O
patient	O
,	O
Communication	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
(	O
son	O
)	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
111656	O
**	O
]	O
.	O
Discharged	O
when	O
cleared	O
by	O
PT	O
.	O
Medications	O
on	O
Admission	O
:	O
Dofetilide	I-Drug
500	O
mcg	O
PO	O
Q12H	O
Fluticasone	B-Drug
-	I-Drug
Salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
[	O
**	O
Hospital1	O
**	O
]	O
Fluticasone	I-Drug
50	O
mcg	O
/	O
Actuation	O
Spray	O
daily	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
PO	O
Q24H	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
daily	O
Cyanocobalamin	I-Drug
100	O
mcg	O
Tablet	O
5	O
Tablet	O
PO	O
DAILY	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4PM	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
PO	O
BID	O
Cardizem	B-Drug
CD	I-Drug
120	O
mg	O
1	O
capsule	O
daily	O
Lovenox	I-Drug
80	O
mg	O
/	O
0.8	O
mL	O
Discharge	O
Medications	O
:	O
1	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
Iron	O
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Fluticasone	B-Drug
-	I-Drug
Salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Fluticasone	I-Drug
50	O
mcg	O
/	O
Actuation	O
Spray	O
,	O
Suspension	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Spray	O
Nasal	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Cyanocobalamin	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Dofetilide	I-Drug
500	O
mcg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
7	O
.	O
Acebutolol	I-Drug
200	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
9	O
.	O
Cephalexin	I-Drug
250	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
three	O
times	O
a	O
day	O
for	O
8	O
days	O
.	O
Disp	O
:	O
*	O
24	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
10	O
.	O
Hydrocodone	B-Drug
-	I-Drug
Acetaminophen	I-Drug
5	O
-	O
500	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
119	O
**	O
]	O
Homecare	O
Discharge	O
Diagnosis	O
:	O
Acute	O
Blood	O
Loss	O
Anemia	O
Bilateral	O
groin	O
Hematomas	O
Chronic	O
Congestive	O
Heart	O
Failure	O
Atrial	O
Fibrillation	O
s	O
/	O
p	O
Ablation	O
Hypertension	O
Discharge	O
Condition	O
:	O
stable	O
.	O
Discharge	O
Instructions	O
:	O
You	O
had	O
bleeding	O
from	O
the	O
right	O
groin	O
site	O
that	O
required	O
surgery	O
and	O
evacuation	O
of	O
the	O
blood	O
.	O
A	O
drain	O
was	O
placed	O
and	O
will	O
stay	O
in	O
until	O
you	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3407	O
**	O
]	O
on	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
.	O
You	O
can	O
walk	O
with	O
this	O
drain	O
but	O
do	O
not	O
take	O
a	O
shower	O
or	O
bath	O
until	O
after	O
you	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3407	O
**	O
]	O
.	O
Please	O
keep	O
the	O
dressing	O
clean	O
and	O
dry	O
.	O
You	O
were	O
started	O
on	O
an	O
antibiotic	I-Drug
because	O
the	O
right	O
groin	O
site	O
was	O
warm	O
and	O
red	O
,	O
please	O
take	O
this	O
antibiotic	I-Drug
for	O
a	O
total	O
of	O
10	O
days	O
.	O
The	O
visiting	O
nurse	O
will	O
help	O
with	O
the	O
drain	O
.	O
New	O
medicines	O
:	O
1	O
.	O
Ceflexin	I-Drug
:	O
an	O
antibiotic	O
to	O
treat	O
the	O
local	B-Reason
skin	I-Reason
infection	I-Reason
near	O
the	O
surgery	O
site	O
.	O
2	O
.	O
Acebutalol	I-Drug
:	O
a	O
beta	B-Drug
blocker	I-Drug
to	O
take	O
instead	O
of	O
the	O
metoprolol	I-Drug
.	O
1	O
.	O
Do	O
not	O
take	O
any	O
coumadin	I-Drug
or	O
Lovenox	I-Drug
until	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3407	O
**	O
]	O
or	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
tells	O
you	O
it	O
is	O
OK	O
.	O
2	O
.	O
Stop	O
taking	O
Cartia	B-Drug
XT	I-Drug
and	O
metoprolol	I-Drug
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
>	O
3	O
lbs	O
.	O
Adhere	O
to	O
2	O
gm	O
sodium	O
diet	O
.	O
Please	O
call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
or	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3407	O
**	O
]	O
if	O
you	O
have	O
any	O
further	O
bleeding	O
,	O
increasing	O
swelling	O
,	O
pain	O
or	O
redness	O
,	O
fevers	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Vascular	O
Surgery	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1244	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1237	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2135-3-8	O
**	O
]	O
10:30	O
Cardiology	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
J.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
7960	O
**	O
]	O
Date	O
/	O
Time	O
:	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
V.	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
11193	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2122-4-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2122-8-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2075-12-28	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Benzocaine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2648	O
**	O
]	O
Addendum	O
:	O
He	O
remained	O
in	O
hospital	O
after	O
discovering	O
that	O
liver	B-Reason
abscesses	I-Reason
grew	O
sparse	O
mucor	O
.	O
ID	O
recommended	O
posoconazole	I-Drug
in	O
addition	O
to	O
ambisone	I-Drug
.	O
This	O
was	O
started	O
and	O
he	O
continued	O
on	O
this	O
for	O
the	O
remainder	O
of	O
hospital	O
course	O
.	O
The	O
decision	O
was	O
made	O
to	O
keep	O
him	O
hospitalized	O
until	O
re-transplanted	O
.	O
Psychiatry	O
was	O
consulted	O
for	O
depression	I-Reason
.	O
Dextroamphetamine	I-Drug
was	O
recommended	O
as	O
first	O
choice	O
with	O
zoloft	I-Drug
being	O
an	O
alternative	O
[	O
**	O
Doctor	O
Last	O
Name	O
932	O
**	O
]	O
.	O
Zoloft	I-Drug
was	O
started	O
and	O
dose	O
increase	O
during	O
remainder	O
of	O
hospital	O
stay	O
with	O
some	O
improvement	O
in	O
mood	O
.	O
2	O
units	O
of	O
PRBC	I-Drug
were	O
given	O
for	O
a	O
hct	B-Reason
of	I-Reason
22	I-Reason
on	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
.	O
Epogen	I-Drug
was	O
continued	O
.	O
On	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
an	O
abd	O
ct	O
revealed	O
mod	O
ascites	O
for	O
which	O
hepatology	O
was	O
consulted	O
.	O
A	O
paracentesis	O
was	O
performed	O
.	O
He	O
was	O
cultured	O
for	O
a	O
temp	O
of	O
101.7	O
on	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
for	O
which	O
the	O
c	O
-	O
line	O
was	O
changed	O
.	O
The	O
tip	O
was	O
neg	O
for	O
growth	O
as	O
well	O
as	O
urine	O
and	O
blood	O
.	O
On	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
he	O
grew	O
gram	B-Reason
+	I-Reason
cocci	I-Reason
(	I-Reason
VRE	I-Reason
-	I-Reason
enterococcus	I-Reason
faecium	I-Reason
)	I-Reason
only	I-Reason
sensitive	O
to	O
linezolid	I-Drug
.	O
Given	O
past	O
h	O
/	O
o	O
myelosuppression	I-Reason
,	O
he	O
was	O
started	O
on	O
Tigecycline	I-Drug
.	O
Tigecycline	I-Drug
continued	O
for	O
16	O
days	O
.	O
He	O
spiked	O
a	O
temp	O
on	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
and	O
again	O
the	O
c	O
-	O
line	O
was	O
changed	O
over	O
a	O
wire	O
.	O
A	O
rpt	O
ABD	O
CT	O
revealed	O
two	O
fluid	O
collections	O
within	O
the	O
left	O
and	O
right	O
lobes	O
of	O
the	O
liver	O
.	O
The	O
collection	O
within	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
appeared	O
to	O
have	O
increased	O
in	O
size	O
,	O
measuring	O
5.6	O
x	O
4.1	O
cm	O
.	O
The	O
left	O
liver	O
lobe	O
collection	O
was	O
essentially	O
unchanged	O
.	O
Bilateral	O
pleural	O
effusions	O
,	O
greater	O
on	O
the	O
left	O
,	O
were	O
decreased	O
slightly	O
and	O
a	O
large	O
amount	O
of	O
ascites	O
,	O
which	O
was	O
decreased	O
slightly	O
.	O
There	O
was	O
evidence	O
of	O
peritoneal	O
enhancement	O
.	O
The	O
fluid	O
extended	O
into	O
the	O
inguinal	O
canals	O
,	O
and	O
was	O
loculated	O
on	O
the	O
right	O
side	O
.	O
Ceftriaxone	I-Drug
which	O
was	O
used	O
for	O
E.coli	I-Reason
was	O
stopped	O
after	O
18	O
days	O
and	O
Meropenum	I-Drug
was	O
started	O
for	O
E.coli	I-Reason
&	O
Strep	B-Reason
veridins	I-Reason
to	O
broaden	O
coverage	O
.	O
Dapto	I-Drug
was	O
stopped	O
.	O
He	O
remained	O
on	O
meromenum	I-Drug
for	O
38	O
days	O
.	O
He	O
continued	O
to	O
spike	O
temps	O
.	O
Repeat	O
paracentesis	O
was	O
done	O
on	O
[	O
**	O
6	O
-	O
15	O
**	O
]	O
.	O
Cultures	O
were	O
negative	O
.	O
On	O
[	O
**	O
6	O
-	O
18	O
**	O
]	O
,	O
he	O
was	O
removed	O
from	O
the	O
Transplant	O
list	O
given	O
multidrug	O
resistant	O
multifocal	O
liver	O
abscesses	O
,	O
poor	O
nutritional	O
status	O
despite	O
J	O
tube	O
feedings	O
,	O
debilitation	O
and	O
poor	O
prior	O
outcomes	O
in	O
other	O
patients	O
with	O
similar	O
setting	O
.	O
On	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
blood	O
cultures	O
grew	O
yeast	O
.	O
Ambisone	I-Drug
was	O
started	O
[	O
**	O
6	O
-	O
19	O
**	O
]	O
.	O
Repeat	O
blood	O
and	O
drain	O
cultures	O
were	O
sent	O
.	O
A	O
TTE	O
was	O
done	O
to	O
r	O
/	O
o	O
vegetations	O
.	O
This	O
was	O
negative	O
.	O
An	O
Ophthalmology	O
exam	O
was	O
negative	O
as	O
well	O
.	O
On	O
[	O
**	O
6	O
-	O
23	O
**	O
]	O
a	O
repeat	O
abd	O
CT	O
revealed	O
two	O
large	O
fluid	O
collections	O
within	O
the	O
left	O
and	O
right	O
lobes	O
of	O
the	O
liver	O
.	O
The	O
left	O
lobe	O
fluid	O
collection	O
had	O
decreased	O
in	O
size	O
,	O
whereas	O
the	O
right	O
lobe	O
fluid	O
collection	O
had	O
increased	O
in	O
size	O
.	O
A	O
large	O
well	O
circumscribed	O
fluid	O
collection	O
extending	O
down	O
the	O
right	O
inguinal	O
canal	O
into	O
the	O
right	O
scrotum	O
was	O
seen	O
.	O
A	O
head	O
CT	O
was	O
done	O
to	O
r	O
/	O
o	O
infection	O
.	O
This	O
was	O
negative	O
.	O
On	O
[	O
**	O
6	O
-	O
24	O
**	O
]	O
an	O
8	O
Fr	O
catheter	O
was	O
repostitioned	O
in	O
RLQ	O
.	O
Culure	O
of	O
the	O
fluid	O
grew	O
ENTEROCOCCUS	O
SP	O
,	O
CITROBACTER	O
FREUNDII	O
COMPLEX	O
.	O
SPARSE	O
GROWTH	O
,	O
NON-FERMENTER	O
,	O
NOT	O
PSEUDOMONAS	O
AERUGINOSA	O
.	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
**	O
]	O
(	O
TORULOPSIS	O
)	O
GLABRATA.MODERATE	O
GROWTH	O
and	O
CITROBACTER	O
FREUNDII	O
COMPLEX	O
.	O
Blood	O
cultures	O
from	O
[	O
**	O
6	O
-	O
23	O
**	O
]	O
continued	O
to	O
grow	O
yeast	O
and	O
VRE	O
.	O
Blood	O
cultures	O
were	O
done	O
q	O
3	O
days	O
.	O
On	O
[	O
**	O
7	O
-	O
1	O
**	O
]	O
CT	O
findings	O
showed	O
new	O
area	O
of	O
decreased	O
enhancement	O
in	O
segment	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
of	O
the	O
liver	O
,	O
worrisome	O
for	O
a	O
new	O
area	O
of	O
ischemia	O
/	O
infarction	O
.	O
Internal	O
air	O
bubbles	O
were	O
present	O
,	O
and	O
superinfection	O
of	O
this	O
area	O
could	O
not	O
be	O
excluded	O
.	O
The	O
area	O
did	O
not	O
appear	O
to	O
have	O
adequate	O
liquification	O
for	O
percutaneous	O
catheter	O
drainage	O
.	O
Two	O
collections	O
in	O
left	O
lobe	O
of	O
the	O
liver	O
had	O
appropriately	O
positioned	O
drainage	O
catheters	O
appeared	O
slightly	O
smaller	O
and	O
a	O
collection	O
in	O
right	O
lobe	O
of	O
the	O
liver	O
,	O
which	O
contained	O
an	O
appropriately	O
positioned	O
catheter	O
was	O
unchanged	O
in	O
size	O
.	O
On	O
[	O
**	O
6	O
-	O
30	O
**	O
]	O
Dapto	I-Drug
was	O
restarted	O
as	O
well	O
as	O
gentamycin	I-Drug
for	O
synergy	O
to	O
attempt	O
to	O
clear	O
VRE	I-Reason
.	O
Ambisone	I-Drug
was	O
changed	O
to	O
Caspo	I-Drug
on	O
[	O
**	O
7	O
-	O
3	O
**	O
]	O
.	O
On	O
[	O
**	O
7	O
-	O
7	O
**	O
]	O
,	O
the	O
catheter	O
in	O
right	O
lobe	O
of	O
liver	O
was	O
advanced	O
several	O
centimeters	O
with	O
aspiration	O
of	O
approximately	O
20	O
cc	O
of	O
purulent	O
material	O
.	O
This	O
appeared	O
in	O
continuity	O
with	O
multiple	O
bilomas	O
/	O
dilated	O
ducts	O
,	O
which	O
were	O
slightly	O
more	O
prominent	O
than	O
on	O
the	O
previous	O
study	O
.	O
ID	O
recommended	O
a	O
TTE	O
to	O
r	O
/	O
o	O
vegetation	O
,	O
but	O
the	O
patient	O
refused	O
TTE	O
.	O
Synercid	I-Drug
was	O
started	O
perioperatively	O
for	O
VRE	B-Reason
coverage	I-Reason
.	O
On	O
[	O
**	O
7	O
-	O
17	O
**	O
]	O
he	O
was	O
taken	O
to	O
the	O
OR	O
for	O
irrigation	O
and	O
debridement	O
of	O
hepatic	O
abscess	O
,	O
right	O
lobe	O
by	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
40	O
-	O
50cc	O
of	O
purulent	O
,	O
bile	O
stained	O
drainage	O
was	O
removed	O
.	O
A	O
large	O
drain	O
was	O
left	O
in	O
place	O
and	O
placed	O
to	O
suction	O
.	O
He	O
tolerated	O
this	O
procedure	O
well	O
.	O
Blood	O
cultures	O
and	O
cline	O
tip	O
on	O
[	O
**	O
7	O
-	O
7	O
**	O
]	O
were	O
negative	O
.	O
Cultures	O
were	O
negative	O
until	O
[	O
**	O
7	O
-	O
14	O
**	O
]	O
.	O
He	O
was	O
relisted	O
for	O
liver	O
transplantation	O
.	O
Subsequent	O
cultures	O
grew	O
enterococcus	O
faeceum	O
.	O
Repeat	O
cultures	O
were	O
negative	O
,	O
but	O
then	O
reculture	O
grew	O
enterococcus	O
faeceum	O
and	O
presumed	O
torulopsis	O
glabrata	O
(	O
per	O
ID	O
)	O
.	O
Levaquin	I-Drug
was	O
added	O
for	O
additional	O
gram	B-Reason
negative	I-Reason
coverage	I-Reason
.	O
Repeat	O
Abd	O
CT	O
showed	O
interval	O
placement	O
of	O
JP	O
drain	O
into	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
with	O
associated	O
focal	O
subcutaneous	O
air	O
/	O
surgical	O
emphysema	O
.	O
Air	O
containing	O
abscess	O
in	O
the	O
right	O
lobe	O
superior	O
to	O
this	O
appeared	O
to	O
have	O
increased	O
in	O
size	O
.	O
Splenomegaly	O
and	O
ascites	O
were	O
again	O
noted	O
.	O
On	O
[	O
**	O
7	O
-	O
21	O
**	O
]	O
,	O
he	O
underwent	O
successful	O
CT	O
-	O
guided	O
pigtail	O
cath	O
placement	O
in	O
enlarging	O
fluid	O
collection	O
at	O
the	O
junction	O
of	O
segments	O
8	O
and	O
4A	O
.	O
On	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
abd	O
CT	O
revealed	O
1	O
)	O
S	O
/	O
p	O
multiple	O
drains	O
.	O
Confluent	O
biloma	O
/	O
abscess	O
involving	O
segment	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
and	O
VIII	O
of	O
the	O
liver	O
,	O
the	O
component	O
in	O
the	O
right	O
lobe	O
is	O
smaller	O
compared	O
to	O
the	O
CT	O
of	O
[	O
**	O
2122-7-21	O
**	O
]	O
.	O
2	O
)	O
Small	O
bilateral	O
pleural	O
effusions	O
.	O
3	O
)	O
Persisting	O
ascites	O
,	O
predominantly	O
left	O
-	O
sided	O
and	O
partially	O
loculated	O
.	O
4	O
)	O
Nonvisualized	O
proper	O
hepatic	O
artery	O
,	O
likely	O
occluded	O
.	O
Partial	O
SMV	O
occlusion	O
.	O
5	O
)	O
Prominent	O
right	O
-	O
sided	O
hydrocele	O
.	O
6	O
)	O
Splenomegaly	O
.	O
Abscess	O
cultures	O
persistently	O
grew	O
VRE	O
and	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
**	O
]	O
(	O
TORULOPSIS	O
)	O
GLABRATA	O
.	O
P.	O
On	O
[	O
**	O
7	O
-	O
31	O
**	O
]	O
Caspofungin	I-Drug
and	O
meropenum	I-Drug
was	O
stopped	O
.	O
The	O
2	O
drains	O
in	O
the	O
left	O
lobe	O
were	O
removed	O
.	O
A	O
repeat	O
CT	O
on	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
revealed	O
collection	O
in	O
left	O
lobe	O
and	O
a	O
drain	O
was	O
placed	O
into	O
this	O
site	O
and	O
10cc	O
was	O
sent	O
for	O
culture	O
.	O
Results	O
are	O
pending	O
.	O
On	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
the	O
capped	O
PTC	O
drain	O
fell	O
out	O
with	O
no	O
adverse	O
effects	O
.	O
Developed	O
diarrhea	O
after	O
tube	O
feed	O
formula	O
changed	O
.	O
Stool	O
was	O
sent	O
for	O
c.diff	O
.	O
Stool	O
neg	O
on	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
and	O
pending	O
for	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
On	O
[	O
**	O
8	O
-	O
14	O
**	O
]	O
the	O
right	O
liver	O
abscess	O
catheter	O
fell	O
out	O
.	O
This	O
area	O
was	O
then	O
loosely	O
packed	O
with	O
normal	B-Drug
saline	I-Drug
moist	O
gauze	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
Potassium	O
was	O
consistently	O
running	O
high	O
.	O
A	O
renal	O
consult	O
was	O
obtained	O
.	O
Bactrim	I-Drug
and	O
synercid	I-Drug
were	O
felt	O
to	O
be	O
contributing	O
to	O
hyperkalemia	I-Ade
.	O
Bactrim	I-Drug
SS	O
was	O
decreased	O
to	O
3x	O
/	O
week	O
and	O
the	O
tube	O
feeding	O
was	O
changed	O
back	O
to	O
1/2	O
strength	O
Nepro	I-Drug
.	O
Potassium	O
decreased	O
within	O
the	O
normal	O
range	O
.	O
In	O
summary	O
,	O
this	O
hospital	O
course	O
was	O
extremely	O
long	O
and	O
complicated	O
.	O
He	O
has	O
remained	O
afebrile	O
for	O
last	O
few	O
weeks	O
.	O
Posoconazole	I-Drug
,	O
Levaquin	I-Drug
,	O
Synercid	I-Drug
will	O
continue	O
.	O
Rifaximin	I-Drug
is	O
to	O
prevent	B-Reason
encephalopathy	I-Reason
.	O
Bactrim	I-Drug
is	O
for	O
pcp	I-Reason
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
2515	O
**	O
]	O
.	O
The	O
plan	O
is	O
to	O
send	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
Rehab	O
Hospital	O
with	O
the	O
hope	O
of	O
building	O
him	O
up	O
nutritionally	O
and	O
increasing	O
his	O
physical	O
strength	O
and	O
independence	O
with	O
the	O
hope	O
of	O
keeping	O
him	O
afebrile	O
while	O
awaiting	O
re-transplantation	O
of	O
a	O
second	O
liver	O
.	O
He	O
will	O
be	O
followed	O
by	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
(	O
Transplant	O
Surgeon	O
)	O
and	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
25	O
**	O
]	O
(	O
ID	O
)	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
polymicrobial	O
liver	O
abscesses	O
-	O
ecoli	O
,	O
mucor	O
,	O
yeast	O
,	O
vre	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
ischemic	O
biliary	O
ducts	O
Pertinent	O
Results	O
:	O
Hematology	O
COMPLETE	O
BLOOD	O
COUNT	O
WBC	O
RBC	O
Hgb	O
Hct	O
MCV	O
MCH	O
MCHC	O
RDW	O
Plt	O
Ct	O
[	O
**	O
2122-8-17	O
**	O
]	O
05:15	O
AM	O
2.4	O
*	O
3.14	O
*	O
9.0	O
*	O
26.4	O
*	O
84	O
28.7	O
34.2	O
20.7	O
*	O
68	O
*	O
DIFFERENTIAL	O
Neuts	O
Bands	O
Lymphs	O
Monos	O
Eos	O
Baso	O
Atyps	O
Metas	O
Myelos	O
[	O
**	O
2122-5-2	O
**	O
]	O
06:36	O
PM	O
87	O
*	O
3	O
3	O
*	O
4	O
1	O
0	O
1	O
*	O
1	O
*	O
0	O
RED	O
CELL	O
MORPHOLOGY	O
Hypochr	O
Anisocy	O
Poiklo	O
Macrocy	O
Microcy	O
Polychr	O
Ovalocy	O
Schisto	O
[	O
**	O
2122-5-2	O
**	O
]	O
06:36	O
PM	O
1	O
+1	O
1	O
+	O
OCCASIONAL	O
NORMAL	O
2	O
+	O
OCCASIONAL	O
1	O
1	O
+	O
MANUAL	O
BASIC	O
COAGULATION	O
(	O
PT	O
,	O
PTT	O
,	O
PLT	O
,	O
INR	O
)	O
PT	O
PTT	O
Plt	O
Smr	O
Plt	O
Ct	O
INR	O
(	O
PT	O
)	O
[	O
**	O
2122-8-17	O
**	O
]	O
05:15	O
AM	O
68	O
*	O
BASIC	O
COAGULATION	O
(	O
FIBRINOGEN	O
,	O
DD	O
,	O
TT	O
,	O
REPTILASE	O
,	O
BT	O
)	O
Fibrino	O
[	O
**	O
2122-5-17	O
**	O
]	O
04:17	O
AM	O
523	O
*	O
Chemistry	O
RENAL	O
&	O
GLUCOSE	O
Glucose	O
UreaN	O
Creat	O
Na	O
K	O
Cl	O
HCO3	O
AnGap	O
[	O
**	O
2122-8-17	O
**	O
]	O
05:15	O
AM	O
162	O
*	O
34	O
*	O
0.7	O
133	O
4.4	O
99	O
29	O
9	O
ENZYMES	O
&	O
BILIRUBIN	O
ALT	O
AST	O
LD	O
(	O
LDH	O
)	O
CK	O
(	O
CPK	O
)	O
AlkPhos	O
Amylase	O
TotBili	O
DirBili	O
[	O
**	O
2122-8-18	O
**	O
]	O
06:00	O
AM	O
18	O
*	O
1	O
1	O
VERIFIED	O
BY	O
REPLICATE	O
ANALYSIS	O
Discharge	O
Medications	O
:	O
1	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
.	O
3	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
4	O
.	O
Epoetin	B-Drug
Alfa	I-Drug
10,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
QMOWEFR	O
(	O
Monday	O
-	O
Wednesday	O
-	O
Friday	O
)	O
.	O
5	O
.	O
Posaconazole	I-Drug
Sig	O
:	O
Two	O
Hundred	O
(	O
200	O
)	O
mg	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Rifaximin	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Sertraline	B-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Nifedipine	B-Drug
10	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Furosemide	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Psyllium	I-Drug
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Packet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Sirolimus	B-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Trimethoprim	B-Drug
-	I-Drug
Sulfamethoxazole	O
80	O
-	O
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
3X	O
/	O
WEEK	O
(	O
MO	O
,	O
WE	O
,	O
FR	O
)	O
.	O
13	O
.	O
Heparin	I-Drug
Lock	O
Flush	O
(	O
Porcine	O
)	O
100	O
unit	O
/	O
mL	O
Syringe	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
ML	O
Intravenous	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
:	O
picc	B-Reason
line	I-Reason
care	I-Reason
.	O
14	O
.	O
Levofloxacin	I-Drug
in	O
D5W	O
500	O
mg	O
/	O
100	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
15	O
.	O
Quinupristin	B-Drug
-	I-Drug
Dalfopristin	O
500	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Recon	O
Soln	O
Intravenous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
16	O
.	O
Hydromorphone	I-Drug
2	O
mg	O
/	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
mg	O
Injection	O
prn	O
:	O
q4	O
-	O
6	O
.	O
17	O
.	O
Insulin	B-Drug
Glargine	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Twenty	O
One	O
(	O
21	O
)	O
units	O
Subcutaneous	O
once	O
a	O
day	O
.	O
18	O
.	O
Insulin	I-Drug
Regular	O
Human	O
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
follow	O
sliding	O
scale	O
Injection	O
four	O
times	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
14	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
15	O
**	O
]	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2649	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2650	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2122-8-19	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2112-2-16	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2112-2-23	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2042-4-10	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Thiazides	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2186	O
**	O
]	O
Chief	O
Complaint	O
:	O
Weakness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
69	O
year	O
-	O
old	O
woman	O
who	O
presented	O
with	O
a	O
week	O
-	O
long	O
history	O
of	O
malaise	O
.	O
The	O
pt	O
is	O
Mandarin	O
speaking	O
woman	O
who	O
was	O
in	O
her	O
USOH	O
until	O
last	O
week	O
when	O
developed	O
a	O
low	B-Reason
-	I-Reason
grade	I-Reason
fever	I-Reason
,	O
cough	I-Reason
,	O
lethargy	I-Reason
and	O
was	O
started	O
on	O
a	O
medication	O
amoxicillin	I-Drug
,	O
the	O
a	O
course	O
of	O
azithromycin	I-Drug
by	O
her	O
PCP	O
without	O
any	O
improvement	O
and	O
received	O
IVFs	I-Drug
by	O
PCP	O
without	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
65	O
**	O
]	O
improvement	O
.	O
She	O
continued	O
to	O
experience	O
malaise	O
and	O
lethargy	O
,	O
requiring	O
assistance	O
in	O
ambulating	O
for	O
generalized	O
weakness	O
(	O
baseline	O
is	O
self	O
ambulating	O
)	O
She	O
denied	O
focal	O
weakness	O
,	O
numbness	O
or	O
parasthesiae	O
.	O
There	O
is	O
no	O
history	O
of	O
back	O
pain	O
.	O
Pt	O
was	O
seen	O
again	O
by	O
PCP	O
on	O
day	O
of	O
presentation	O
to	O
the	O
ED	O
and	O
was	O
told	O
that	O
she	O
had	O
a	O
distended	O
abdomen	O
and	O
was	O
sent	O
to	O
the	O
ED	O
for	O
further	O
work	O
up	O
.	O
In	O
the	O
ED	O
,	O
a	O
foley	O
was	O
placed	O
and	O
1700cc	O
of	O
urine	O
was	O
cleared	O
.	O
The	O
patient	O
had	O
no	O
urge	O
to	O
urinate	O
and	O
last	O
urinated	O
the	O
AM	O
of	O
admission	O
.	O
She	O
stated	O
that	O
she	O
feels	O
that	O
she	O
was	O
able	O
to	O
appreciate	O
a	O
full	O
bladder	O
and	O
has	O
had	O
no	O
recent	O
difficulties	O
urinating	O
.	O
In	O
addition	O
,	O
she	O
denied	O
any	O
bowel	O
retention	O
or	O
incontinence	O
and	O
has	O
had	O
regular	O
bowel	O
movements	O
as	O
is	O
usual	O
.	O
She	O
denied	O
any	O
headache	O
,	O
loss	O
of	O
vision	O
,	O
blurred	O
vision	O
,	O
diplopia	O
.	O
Denied	O
dysarthria	O
,	O
dysphagia	O
.	O
Denied	O
lightheadedness	O
or	O
vertigo	O
.	O
Denied	O
any	O
difficulties	O
with	O
her	O
speech	O
.	O
Also	O
+	O
low	O
grade	O
fever	O
with	O
her	O
URI	O
,	O
no	O
chills	O
or	O
nightsweats	O
,	O
no	O
CP	O
or	O
SOB	O
,	O
no	O
palpitation	O
,	O
n	O
,	O
v	O
,	O
diarrhea	O
,	O
dysuria	O
or	O
abdominal	O
pain	O
,	O
myalgia	O
,	O
arthralgia	O
or	O
rash	O
.	O
Past	O
Medical	O
History	O
:	O
HTN	O
Hyperlipidemia	O
Social	O
History	O
:	O
The	O
pt	O
lives	O
with	O
her	O
husband	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
778	O
**	O
]	O
.	O
She	O
is	O
fully	O
independent	O
in	O
all	O
of	O
her	O
ADLs	O
.	O
There	O
is	O
no	O
history	O
of	O
tobacco	O
,	O
alcohol	O
or	O
illicit	O
drug	O
use	O
.	O
Immigrated	O
to	O
USA	O
in	O
'	O
[	O
**	O
97	O
**	O
]	O
,	O
has	O
not	O
worked	O
eversince	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
Gen	O
-	O
Appears	O
stated	O
age	O
,	O
pleasant	O
,	O
in	O
NAD	O
Vs	O
-	O
96.1	O
129/74	O
69	O
17	O
98RA	O
HEENT	O
-	O
NC	O
/	O
AT	O
PERRL	O
EOMI	O
,	O
Neck	O
-	O
supple	O
,	O
JVP	O
flat	O
,	O
no	O
thyromegaly	O
or	O
LAD	O
CV	O
-	O
rrr	O
,	O
normal	O
s1	O
,	O
s2	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
Pulm	O
-	O
good	O
air	O
movement	O
,	O
no	O
w	O
/	O
r	O
/	O
r	O
Back	O
-	O
no	O
spinal	O
or	O
CVAT	O
Abd	O
-	O
Soft	O
,	O
NT	O
,	O
ND	O
,	O
+	O
BS	O
Extr	O
-	O
no	O
C	O
/	O
C	O
/	O
E.	O
DP	O
and	O
PT	O
pulses	O
strong	O
b	O
/	O
l	O
Neuro	O
-	O
global	O
hyporeflexia	O
,	O
motor	O
strength	O
5/5	O
b	O
/	O
l	O
upper	O
and	O
lower	O
Pertinent	O
Results	O
:	O
RENAL	O
U.S.	O
[	O
**	O
2112-2-16	O
**	O
]	O
11:24	O
PM	O
:	O
The	O
right	O
kidney	O
measures	O
10.2	O
cm	O
and	O
contains	O
mild	O
hydronephrosis	O
.	O
No	O
stones	O
or	O
masses	O
are	O
visualized	O
.	O
The	O
left	O
kidney	O
measures	O
11	O
cm	O
,	O
and	O
has	O
minimal	O
fullness	O
of	O
the	O
collecting	O
system	O
.	O
There	O
are	O
no	O
renal	O
masses	O
or	O
stones	O
.	O
The	O
bladder	O
is	O
collapsed	O
with	O
a	O
Foley	O
catheter	O
within	O
it	O
.	O
IMPRESSION	O
:	O
Mild	O
hydronephrosis	O
,	O
right	O
greater	O
than	O
left	O
.	O
[	O
**	O
2112-2-23	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
WBC	O
-	O
7.4	O
RBC	O
-	O
3.83	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
33.8	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
29.2	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
652	O
*	O
[	O
**	O
2112-2-17	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
PT	O
-	O
11.9	O
PTT	O
-	O
27.9	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2112-2-16	O
**	O
]	O
06:40	O
PM	O
BLOOD	O
Glucose	O
-	O
173	O
*	O
UreaN	O
-	O
25	O
*	O
Creat	O
-	O
1.8	O
*	O
Na	O
-	O
104	O
*	O
K	O
-	O
3.3	O
Cl	O
-	O
67	O
*	O
HCO3	O
-	O
18	O
*	O
AnGap	O
-	O
22	O
*	O
[	O
**	O
2112-2-16	O
**	O
]	O
08:40	O
PM	O
BLOOD	O
Glucose	O
-	O
167	O
*	O
UreaN	O
-	O
24	O
*	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
107	O
*	O
K	O
-	O
2.9	O
*	O
Cl	O
-	O
70	O
*	O
HCO3	O
-	O
23	O
AnGap	O
-	O
17	O
[	O
**	O
2112-2-17	O
**	O
]	O
02:25	O
AM	O
BLOOD	O
Glucose	O
-	O
116	O
*	O
UreaN	O
-	O
20	O
Creat	O
-	O
1.2	O
*	O
Na	O
-	O
116	O
*	O
K	O
-	O
3.5	O
Cl	O
-	O
84	O
*	O
HCO3	O
-	O
23	O
AnGap	O
-	O
13	O
[	O
**	O
2112-2-17	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Glucose	O
-	O
104	O
UreaN	O
-	O
19	O
Creat	O
-	O
1.0	O
Na	O
-	O
121	O
*	O
K	O
-	O
3.1	O
*	O
Cl	O
-	O
87	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
15	O
[	O
**	O
2112-2-17	O
**	O
]	O
12:05	O
PM	O
BLOOD	O
Glucose	O
-	O
121	O
*	O
UreaN	O
-	O
19	O
Creat	O
-	O
1.0	O
Na	O
-	O
121	O
*	O
K	O
-	O
3.0	O
*	O
Cl	O
-	O
90	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
12	O
[	O
**	O
2112-2-18	O
**	O
]	O
05:32	O
AM	O
BLOOD	O
Glucose	O
-	O
88	O
UreaN	O
-	O
19	O
Creat	O
-	O
0.9	O
Na	O
-	O
127	O
*	O
K	O
-	O
3.6	O
Cl	O
-	O
95	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
14	O
[	O
**	O
2112-2-19	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
Glucose	O
-	O
91	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.8	O
Na	O
-	O
128	O
*	O
K	O
-	O
3.6	O
Cl	O
-	O
94	O
*	O
HCO3	O
-	O
24	O
AnGap	O
-	O
14	O
[	O
**	O
2112-2-22	O
**	O
]	O
07:30	O
AM	O
BLOOD	O
Glucose	O
-	O
146	O
*	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.9	O
Na	O
-	O
138	O
K	O
-	O
4.1	O
Cl	O
-	O
103	O
HCO3	O
-	O
25	O
AnGap	O
-	O
14	O
[	O
**	O
2112-2-23	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
Glucose	O
-	O
164	O
*	O
UreaN	O
-	O
17	O
Creat	O
-	O
0.9	O
Na	O
-	O
131	O
*	O
K	O
-	O
4.1	O
Cl	O
-	O
96	O
HCO3	O
-	O
25	O
AnGap	O
-	O
14	O
[	O
**	O
2112-2-17	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Cortsol	O
-	O
19.7	O
[	O
**	O
2112-2-16	O
**	O
]	O
08:40	O
PM	O
BLOOD	O
T4	O
-	O
8.4	O
[	O
**	O
2112-2-16	O
**	O
]	O
08:40	O
PM	O
BLOOD	O
TSH	O
-	O
0.68	O
[	O
**	O
2112-2-16	O
**	O
]	O
08:40	O
PM	O
BLOOD	O
Osmolal	O
-	O
234	O
*	O
[	O
**	O
2112-2-16	O
**	O
]	O
10:15	O
PM	O
URINE	O
Osmolal	O
-	O
102	O
[	O
**	O
2112-2-16	O
**	O
]	O
10:15	O
PM	O
URINE	O
Hours	O
-	O
RANDOM	O
Creat	O
-	O
8	O
Na	O
-	O
28	O
K	O
-	O
4	O
Cl	O
-	O
24	O
HCO3-LESS	O
THAN	O
.	O
MICROBIOLOGY	O
Urine	O
cx	O
(	O
-	O
)	O
x3	O
.	O
Blood	O
cx	O
x2	O
negative	O
at	O
time	O
of	O
d	O
/	O
c.	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
69	O
yo	O
Cantonse	O
speaking	O
female	O
who	O
presented	O
with	O
letargy	O
,	O
gait	O
abnormality	O
and	O
a	O
serum	O
sodium	O
of	O
104	O
.	O
In	O
ED	O
she	O
was	O
found	O
to	O
have	O
obstructive	O
uropathy	O
resolving	O
with	O
foley	O
placement	O
.	O
Of	O
note	O
she	O
has	O
been	O
of	O
HCTZ	B-Drug
/	I-Drug
Triamtrene	I-Drug
for	O
number	O
of	O
years	O
as	O
treatment	O
of	O
her	O
HTN	I-Reason
.	O
1	O
.	O
Hyponatremia	I-Ade
:	O
Pt	O
with	O
profound	O
hyponatremia	O
thought	O
likely	O
secondary	O
to	O
her	O
diuretic	I-Drug
use	O
.	O
In	O
the	O
ED	O
she	O
appeared	O
dry	O
on	O
exam	O
.	O
The	O
patient	O
had	O
an	O
initial	O
FeNa	O
of	O
4.91	O
and	O
a	O
urine	O
Na	O
of	O
26	O
which	O
was	O
consistent	O
with	O
renal	O
losses	O
and	O
inconsistent	O
with	O
SIADH	O
.	O
In	O
the	O
ED	O
she	O
received	O
one	O
liter	O
of	O
normal	B-Drug
saline	I-Drug
and	O
her	O
sodium	O
increased	O
from	O
the	O
nadir	O
of	O
104	O
to	O
121	O
by	O
the	O
time	O
of	O
arrival	O
to	O
the	O
ICU	O
.	O
She	O
was	O
not	O
given	O
any	O
more	O
saline	I-Drug
at	O
that	O
time	O
,	O
and	O
her	O
sodium	O
was	O
monitored	O
while	O
tolerating	O
a	O
regular	O
diet	O
.	O
It	O
slowly	O
increased	O
to	O
127	O
,	O
she	O
was	O
noted	O
to	O
have	O
global	O
hyporeflexia	O
but	O
no	O
other	O
neurological	O
deficits	O
at	O
time	O
of	O
transfer	O
to	O
the	O
floors	O
.	O
Pt	O
was	O
monitored	O
and	O
all	O
IVFs	I-Drug
were	O
held	O
,	O
as	O
her	O
sodium	O
level	O
slowly	O
increased	O
to	O
normal	O
on	O
HD	O
#	O
5	O
.	O
It	O
was	O
thought	O
that	O
her	O
neurogenic	O
bladder	O
caused	O
a	O
decrease	O
in	O
GFR	O
,	O
and	O
a	O
build	O
of	O
thiazide	B-Drug
diuretic	I-Drug
which	O
led	O
to	O
her	O
severe	I-Ade
hyponatremia	O
.	O
Once	O
a	O
Foley	O
was	O
placed	O
in	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
pt	O
was	O
able	O
to	O
urinate	O
and	O
auto	O
-	O
correct	O
,	O
and	O
her	O
sodium	O
drifted	O
to	O
normal	O
with	O
minimal	O
intervention	O
.	O
No	O
neurologic	O
sequelae	O
was	O
seen	O
due	O
to	O
the	O
correction	O
of	O
her	O
sodium	O
during	O
this	O
admission	O
.	O
Pt	O
was	O
instructed	O
at	O
discharge	O
to	O
never	O
restart	O
her	O
thiazide	B-Drug
diuretic	I-Drug
as	O
this	O
alone	O
may	O
have	O
precipitated	O
her	O
severe	B-Ade
hyponatremia	I-Ade
.	O
.	O
2	O
.	O
Urine	O
outflow	O
obstruction	O
:	O
It	O
remained	O
unclear	O
what	O
caused	O
her	O
initial	O
neurogenic	O
bladder	O
and	O
bladder	O
residual	O
of	O
1700cc	O
at	O
time	O
of	O
admission	O
.	O
It	O
was	O
thought	O
that	O
perhaps	O
a	O
medication	O
effect	O
,	O
whether	O
OTC	O
medication	O
or	O
anticholinergic	O
benadryl	I-Drug
in	O
cough	O
syrup	O
,	O
that	O
perhaps	O
contributed	O
to	O
her	O
neurogenic	B-Ade
bladder	I-Ade
.	O
Pt	O
was	O
attempted	O
multiple	O
voiding	O
trials	O
on	O
HD	O
#	O
5	O
and	O
HD	O
#	O
7	O
but	O
each	O
time	O
patient	O
had	O
PVR	O
of	O
>	O
700cc	O
,	O
and	O
the	O
Foley	O
was	O
reinserted	O
.	O
Urology	O
was	O
consulted	O
who	O
recommended	O
leaving	O
the	O
Foley	O
in	O
place	O
for	O
1	O
week	O
after	O
discharge	O
,	O
and	O
to	O
f	O
/	O
u	O
with	O
urology	O
in	O
1	O
week	O
for	O
voiding	O
trial	O
at	O
that	O
time	O
.	O
A	O
spinal	O
MRI	O
perfomed	O
at	O
this	O
admission	O
did	O
not	O
show	O
mass	O
or	O
any	O
cord	O
compression	O
that	O
would	O
lead	O
to	O
urinary	O
retention	O
.	O
.	O
3	O
.	O
Cough	O
:	O
She	O
developed	O
a	O
productive	O
cough	O
with	O
mild	O
hemoptysis	O
at	O
time	O
of	O
transfer	O
to	O
the	O
floors	O
,	O
this	O
was	O
associated	O
with	O
a	O
fever	O
of	O
101	O
the	O
night	O
prior	O
.	O
She	O
was	O
therefore	O
contained	O
on	O
precautions	O
and	O
ruled	O
out	O
for	O
TB	O
,	O
although	O
with	O
no	O
history	O
of	O
TB	O
and	O
no	O
evidence	O
of	O
opacities	O
on	O
chest	O
xray	O
.	O
4	O
.	O
Renal	O
Failure	O
:	O
ARF	O
on	O
admission	O
with	O
Cr	O
1.8	O
due	O
to	O
obstructive	O
uropathy	O
,	O
resolved	O
with	O
Foley	O
placement	O
,	O
returning	O
to	O
0.9	O
on	O
discharge	O
.	O
Renal	O
u	O
/	O
s	O
with	O
R	O
>	O
L	O
hydro	O
appears	O
to	O
be	O
resolving	O
.	O
.	O
5	O
.	O
HTN	I-Reason
:	O
normotensive	O
on	O
presentation	O
to	O
the	O
ED	O
.	O
Pt	O
's	O
previous	O
cardizem	I-Drug
and	O
dyazide	I-Drug
were	O
stopped	O
,	O
and	O
patient	O
was	O
started	O
on	O
Metoprolol	I-Drug
for	O
BP	B-Reason
control	I-Reason
.	O
Pt	O
was	O
instructed	O
to	O
never	O
restart	O
her	O
dyazide	B-Drug
diuretic	I-Drug
.	O
.	O
DISPO	O
:	O
Spoke	O
to	O
PCP	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
day	O
of	O
discharge	O
regarding	O
f	O
/	O
u	O
sodium	O
recheck	O
in	O
3	O
days	O
after	O
discharge	O
,	O
and	O
f	O
/	O
u	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
27479	O
**	O
]	O
from	O
urology	O
on	O
[	O
**	O
2112-3-1	O
**	O
]	O
.	O
Communications	O
:	O
Daughter	O
[	O
**	O
Name	O
(	O
NI	O
)	O
27480	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
22924	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
27481	O
**	O
]	O
(	O
mandarin	O
/	O
cantonese	O
speaking	O
)	O
[	O
**	O
Name	O
(	O
NI	O
)	O
27482	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
Granddaughter	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
27483	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
27484	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
22924	O
**	O
]	O
Granddaughter	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
27485	O
**	O
]	O
PCP	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Hospital1	O
27486	O
**	O
]	O
Basement	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
745	O
**	O
]	O
Ctr	O
,	O
MA	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
27487	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
cardizem	I-Drug
180	O
mg	O
dyazide	I-Drug
2tabs	O
day	O
xalatan	I-Drug
0.005	O
%	O
1	O
drop	O
qhs	O
saline	I-Drug
eye	O
drops	O
lipitor	I-Drug
10	O
mg	O
qd	O
ASA	I-Drug
81	O
mg	O
qd	O
Discharge	O
Medications	O
:	O
1	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Toprol	B-Drug
XL	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Latanoprost	I-Drug
0.005	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Outpatient	O
Lab	O
Work	O
Please	O
have	O
a	O
sodium	O
(	O
Na	O
)	O
level	O
drawn	O
,	O
Friday	O
,	O
[	O
**	O
2	O
-	O
26	O
**	O
]	O
,	O
and	O
fax	O
results	O
to	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
27488	O
**	O
]	O
office	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital6	O
1952	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnoses	O
:	O
1	O
)	O
hyponatremia	I-Ade
,	O
suspected	O
thiazide	I-Drug
induced	O
2	O
)	O
URI	O
3	O
)	O
urinary	O
retention	O
Discharge	O
Condition	O
:	O
Good	O
,	O
hyponatremia	O
resolved	O
,	O
foley	O
in	O
place	O
to	O
be	O
re-evaluated	O
by	O
urology	O
in	O
one	O
week	O
.	O
Discharge	O
Instructions	O
:	O
1	O
)	O
Please	O
take	O
your	O
medications	O
as	O
directed	O
.	O
Your	O
aspirin	I-Drug
has	O
been	O
held	O
because	O
you	O
coughed	O
up	O
blood	O
in	O
the	O
ICU	O
.	O
Please	O
discuss	O
with	O
your	O
primary	O
care	O
physician	O
whether	O
to	O
restart	O
this	O
medication	O
or	O
not	O
.	O
You	O
should	O
NEVER	O
take	O
any	O
THIAZIDE	I-Drug
medication	O
.	O
You	O
have	O
been	O
prescribed	O
a	O
new	O
blood	B-Reason
pressure	I-Reason
lowering	O
medication	O
,	O
Toprol	I-Drug
.	O
.	O
2	O
)	O
Please	O
attend	O
your	O
follow	O
-	O
up	O
appointments	O
.	O
.	O
3	O
)	O
Please	O
have	O
your	O
sodium	O
level	O
rechecked	O
on	O
Friday	O
,	O
[	O
**	O
2	O
-	O
26	O
**	O
]	O
.	O
Please	O
fax	O
results	O
to	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
27488	O
**	O
]	O
office	O
.	O
.	O
4	O
)	O
You	O
were	O
not	O
given	O
the	O
pneumococcal	B-Drug
vaccine	I-Drug
in	O
-	O
house	O
.	O
Please	O
discuss	O
this	O
with	O
your	O
primary	O
care	O
physician	O
.	O
Followup	O
Instructions	O
:	O
1	O
)	O
You	O
are	O
scheduled	O
to	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
4229	O
**	O
]	O
(	O
Urology	O
)	O
on	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
at	O
4	O
pm	O
to	O
have	O
your	O
Foley	O
removed	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
to	O
reschedule	O
that	O
appointment	O
.	O
.	O
2	O
)	O
Please	O
call	O
the	O
office	O
of	O
your	O
primary	O
care	O
physician	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2112-2-24	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2148-10-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2148-10-15	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2097-9-27	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
147	O
**	O
]	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
668	O
**	O
]	O
Chief	O
Complaint	O
:	O
Dislodged	O
Dophoff	O
feeding	O
tube	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Placement	O
of	O
dophoff	O
catheter	O
under	O
fluro	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
with	O
episode	O
of	O
hiccups	O
,	O
which	O
pt	O
had	O
c	O
/	O
o	O
for	O
many	O
months	O
,	O
resulting	O
in	O
the	O
dislodging	O
of	O
his	O
dophoff	O
feeding	O
tube	O
Past	O
Medical	O
History	O
:	O
anemia	O
Hepatitis	O
C	O
CHF	O
CRI	O
DVT	O
portal	O
hypertension	O
Depression	O
Social	O
History	O
:	O
Lives	O
at	O
[	O
**	O
Hospital	O
106240	O
**	O
]	O
Rehab	O
Centersmoking	O
15pack	O
year	O
hitoryno	O
etohremote	O
IVDformer	O
[	O
**	O
Company	O
2318	O
**	O
]	O
worker	O
Family	O
History	O
:	O
noncontributary	O
Physical	O
Exam	O
:	O
NAD	O
AAO	O
times	O
3	O
RRR	O
S1	O
+	O
S2	O
CTA	O
Bilat	O
Soft	O
NT	O
/	O
ND	O
,	O
incision	O
healing	O
well	O
Pertinent	O
Results	O
:	O
US	O
ABD	O
LIMIT	O
,	O
SINGLE	O
ORGAN	O
[	O
**	O
2148-10-14	O
**	O
]	O
2:33	O
PM	O
REPORT	O
:	O
There	O
is	O
a	O
dumb	O
-	O
bell	O
shaped	O
collection	O
in	O
the	O
gallbladder	O
fossa	O
which	O
contains	O
complex	O
internal	O
echoes	O
.	O
Each	O
of	O
the	O
limbs	O
of	O
the	O
collection	O
measure	O
approximately	O
4	O
cm	O
in	O
diameter	O
each	O
.	O
The	O
lesion	O
passes	O
close	O
to	O
the	O
stomach	O
posteriorly	O
but	O
is	O
extragastric	O
.	O
The	O
liver	O
parenchyma	O
appears	O
normal	O
throughout	O
.	O
No	O
focal	O
hepatic	O
mass	O
is	O
identified	O
otherwise	O
.	O
No	O
subcapsular	O
lesion	O
is	O
seen	O
.	O
Status	O
post	O
cholecystectomy	O
.	O
The	O
common	O
bile	O
duct	O
measures	O
7	O
mm	O
in	O
maximum	O
dimensions	O
.	O
The	O
right	O
kidney	O
appears	O
normal	O
in	O
size	O
shape	O
and	O
echotexture	O
.	O
Doppler	O
ultrasound	O
.	O
Doppler	O
ultrasound	O
was	O
performed	O
of	O
the	O
anastomosed	O
vessels	O
.	O
The	O
hepatic	O
veins	O
appear	O
normal	O
.	O
There	O
appears	O
to	O
be	O
a	O
clip	O
intimately	O
related	O
to	O
the	O
middle	O
hepatic	O
vein	O
which	O
appears	O
narrowed	O
at	O
this	O
point	O
.	O
Portal	O
vein	O
is	O
patent	O
with	O
centrifugal	O
flow	O
.	O
The	O
hepatic	O
arteries	O
have	O
not	O
been	O
examined	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Pt	O
admitted	O
on	O
[	O
**	O
10	O
-	O
13	O
**	O
]	O
after	O
dophoff	O
tube	O
was	O
accidentally	O
d	O
/	O
c	O
'd	O
after	O
a	O
episode	O
of	O
hiccups	O
.	O
A	O
NG	O
tube	O
was	O
placed	O
on	O
admission	O
.	O
Pt	O
had	O
an	O
episode	O
of	O
nausea	O
and	O
emesis	O
around	O
the	O
tube	O
.	O
A	O
dophoff	O
was	O
placed	O
on	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
and	O
the	O
nausea	O
and	O
emesis	O
resolved	O
.	O
A	O
RUQ	O
US	O
was	O
performed	O
which	O
showed	O
an	O
evolving	O
collection	O
in	O
the	O
gallbladder	O
fossa	O
but	O
was	O
otherwise	O
unremarkable	O
.	O
Pt	O
improved	O
and	O
was	O
D	O
/	O
C	O
'd	O
to	O
return	O
to	O
rehab	O
on	O
[	O
**	O
10	O
-	O
15	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
CellCept	I-Drug
[	O
**	O
Pager	O
number	O
**	O
]	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
2	O
.	O
Megestrol	I-Drug
Acetate	O
40	O
mg	O
/	O
mL	O
Suspension	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Lansoprazole	B-Drug
30	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
4	O
.	O
Methylphenidate	I-Drug
HCl	O
5	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
5	O
.	O
Hydralazine	I-Drug
HCl	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
6	O
.	O
Levothyroxine	B-Drug
Sodium	I-Drug
150	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
7	O
.	O
Mirtazapine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
8	O
.	O
Ribavirin	B-Drug
200	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
9	O
.	O
Metoprolol	I-Drug
Tartrate	O
50	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Valganciclovir	I-Drug
HCl	O
450	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Trimethoprim	B-Drug
-	I-Drug
Sulfamethoxazole	O
80	O
-	O
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
12	O
.	O
Interferon	B-Drug
alfacon	I-Drug
-	I-Drug
1	I-Drug
30	O
mcg	O
/	O
mL	O
Injectable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
TIW	O
(	O
)	O
.	O
13	O
.	O
Tacrolimus	B-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
14	O
.	O
Prednisone	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QD	O
(	O
once	O
a	O
day	O
)	O
.	O
15	O
.	O
Insulin	B-Drug
Lispro	I-Drug
(	I-Drug
Human	I-Drug
)	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Dislodged	O
Dophoff	O
feeding	O
tube	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
Please	O
return	O
for	O
all	O
follow	O
-	O
up	O
appointments	O
Take	O
all	O
medications	O
as	O
directed	O
,	O
and	O
resume	O
all	O
previous	O
medications	O
Return	O
to	O
the	O
ER	O
if	O
any	O
increased	O
pain	O
,	O
nausea	O
and	O
vomitting	O
,	O
fevers	O
,	O
diarrhea	O
,	O
chest	O
pain	O
,	O
or	O
shortness	O
of	O
breath	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
Where	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
5628	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2148-10-16	O
**	O
]	O
2:20	O
Completed	O
by	O
:[	O
**	O
2148-10-15	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2125-6-19	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2125-6-30	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2081-12-19	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Codeine	I-Drug
/	O
Haldol	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4691	O
**	O
]	O
Chief	O
Complaint	O
:	O
Motorcycle	O
Crash	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2125-6-19	O
**	O
]	O
PROCEDURES	O
:	O
1	O
.	O
Closed	O
reduction	O
right	O
supracondylar	O
femur	O
fracture	O
with	O
manipulation	O
.	O
2	O
.	O
Closed	O
reduction	O
right	O
tibia	O
fracture	O
with	O
manipulation	O
.	O
3	O
.	O
Application	O
multi	O
plantar	O
external	O
fixator	O
to	O
right	O
supracondylar	O
femur	O
fracture	O
.	O
4	O
.	O
Application	O
multiplanar	O
external	O
fixator	O
to	O
right	O
tibia	O
fracture	O
.	O
5	O
.	O
Washout	O
and	O
debridement	O
open	O
supracondylar	O
femur	O
fracture	O
down	O
to	O
and	O
inclusive	O
of	O
bone	O
.	O
6	O
.	O
Washout	O
and	O
debridement	O
open	O
tibia	O
fracture	O
down	O
to	O
and	O
inclusive	O
of	O
bone	O
.	O
7	O
.	O
Closed	O
treatment	O
right	O
great	O
toe	O
phalanx	O
fracture	O
.	O
8	O
.	O
Washout	O
and	O
debridement	O
open	O
great	O
toe	O
phalanx	O
fracture	O
to	O
bone	O
.	O
9	O
.	O
Washout	O
and	O
closure	O
complex	O
laceration	O
to	O
left	O
forearm	O
with	O
the	O
wound	O
being	O
approximately	O
30	O
cm	O
in	O
length	O
.	O
[	O
**	O
2125-6-21	O
**	O
]	O
PROCEDURE	O
:	O
1	O
.	O
Removal	O
of	O
external	O
fixator	O
from	O
tibia	O
and	O
femur	O
.	O
2	O
.	O
Irrigation	O
and	O
debridement	O
down	O
to	O
inclusive	O
of	O
bone	O
of	O
both	O
tibial	O
wounds	O
.	O
3	O
.	O
Open	O
reduction	O
internal	O
fixation	O
distal	O
femur	O
with	O
lateral	O
plating	O
via	O
an	O
open	O
lateral	O
exposure	O
(	O
modifier	O
22	O
)	O
.	O
4	O
.	O
Intramedullary	O
nailing	O
right	O
tibia	O
shaft	O
comminuted	O
fracture	O
.	O
5	O
.	O
Complex	O
wound	O
closure	O
open	O
tibia	O
wound	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
43	O
year	O
old	O
male	O
who	O
was	O
helmeted	O
riding	O
a	O
motorcycle	O
and	O
hit	O
a	O
car	O
.	O
Unclear	O
if	O
he	O
experienced	O
any	O
loss	O
of	O
conciousness	O
.	O
He	O
was	O
transferred	O
from	O
an	O
OSH	O
with	O
for	O
further	O
management	O
.	O
He	O
sustained	O
a	O
R	O
comminuted	O
midshaft	O
tibia	O
fracture	O
a	O
R	O
comminuted	O
distal	O
femur	O
fx	O
,	O
a	O
R	O
foot	O
second	O
and	O
third	O
metatarsal	O
shaft	O
fractures	O
,	O
comminuted	O
proximal	O
and	O
distal	O
phalanx	O
fractures	O
of	O
great	O
toe	O
and	O
a	O
large	O
lacerations	O
with	O
degloving	O
of	O
LUEx	O
-	O
no	O
fractures	O
on	O
films	O
.	O
Past	O
Medical	O
History	O
:	O
Fibromyalgia	O
Bipolar	O
disorder	O
Right	O
knee	O
"	O
fracture	O
"	O
s	O
/	O
p	O
bike	O
accident	O
as	O
youth	O
Left	O
wrist	O
fracture	O
and	O
repair	O
"	O
bleeding	O
problem	O
"	O
as	O
youth	O
which	O
resolved	O
Social	O
History	O
:	O
No	O
Etoh	O
Family	O
History	O
:	O
Noncontributory	O
Physical	O
Exam	O
:	O
HR	O
:	O
130	O
O	O
(	O
2	O
)	O
Sat	O
:	O
98	O
normal	O
Constitutional	O
:	O
Moderate	O
to	O
severe	O
pain	O
HEENT	O
:	O
Normocephalic	O
,	O
atraumatic	O
,	O
Pupils	O
equal	O
,	O
round	O
and	O
reactive	O
to	O
light	O
,	O
Extraocular	O
muscles	O
intact	O
Oropharynx	O
within	O
normal	O
limits	O
neck	O
nontender	O
Chest	O
:	O
Clear	O
to	O
auscultation	O
Cardiovascular	O
:	O
Regular	O
Rate	O
and	O
Rhythm	O
Abdominal	O
:	O
Soft	O
,	O
Nontender	O
abrasion	O
across	O
the	O
abdomen	O
Rectal	O
:	O
Heme	O
Negative	O
GU	O
/	O
Flank	O
:	O
No	O
costovertebral	O
angle	O
tenderness	O
Extr	O
/	O
Back	O
:	O
The	O
right	O
upper	O
extremity	O
which	O
wound	O
with	O
exposed	O
muscle	O
.	O
The	O
left	O
lower	O
extremity	O
and	O
multiple	O
large	O
wound	O
with	O
exposed	O
muscle	O
and	O
obvious	O
deformity	O
her	O
knee	O
vascular	O
exam	O
is	O
intact	O
both	O
in	O
the	O
upper	O
and	O
lower	O
extremities	O
Skin	O
:	O
No	O
rash	O
Neuro	O
:	O
Speech	O
fluent	O
Psych	O
:	O
Normal	O
mood	O
Heme	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
:	O
No	O
petechiae	O
Pertinent	O
Results	O
:	O
[	O
**	O
2125-6-19	O
**	O
]	O
09:46	O
PM	O
GLUCOSE	O
-	O
173	O
*	O
UREA	O
N	O
-	O
7	O
CREAT	O
-	O
1.3	O
*	O
SODIUM	O
-	O
144	O
POTASSIUM	O
-	O
3.2	O
*	O
CHLORIDE	O
-	O
113	O
*	O
TOTAL	O
CO2	O
-	O
23	O
ANION	O
GAP	O
-	O
11	O
[	O
**	O
2125-6-19	O
**	O
]	O
09:46	O
PM	O
CALCIUM	O
-	O
8.1	O
*	O
PHOSPHATE	O
-	O
3.8	O
MAGNESIUM	O
-	O
1.6	O
[	O
**	O
2125-6-19	O
**	O
]	O
09:46	O
PM	O
WBC	O
-	O
27.9	O
*	O
RBC	O
-	O
3.41	O
*	O
#	O
HGB	O
-	O
10.2	O
*	O
#	O
HCT	O
-	O
30.3	O
*	O
#	O
MCV	O
-	O
89	O
MCH	O
-	O
29.8	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
13.5	O
[	O
**	O
2125-6-19	O
**	O
]	O
09:46	O
PM	O
PLT	O
COUNT	O
-	O
310	O
[	O
**	O
2125-6-19	O
**	O
]	O
04:50	O
PM	O
ASA	O
-	O
NEG	O
ETHANOL	O
-	O
NEG	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2125-6-19	O
**	O
]	O
04:50	O
PM	O
WBC	O
-	O
41.8	O
*	O
RBC	O
-	O
4.76	O
HGB	O
-	O
14.0	O
HCT	O
-	O
42.2	O
MCV	O
-	O
89	O
MCH	O
-	O
29.3	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
13.2	O
[	O
**	O
2125-6-19	O
**	O
]	O
04:50	O
PM	O
PLT	O
COUNT	O
-	O
421	O
CXR	O
(	O
[	O
**	O
6	O
-	O
19	O
**	O
]	O
)	O
:	O
1	O
.	O
No	O
acute	O
cardiopulmonary	O
pathology	O
detected	O
.	O
2	O
.	O
Mild	O
widening	O
of	O
the	O
superior	O
mediastinum	O
likely	O
relates	O
to	O
the	O
low	O
lung	O
volumes	O
.	O
If	O
there	O
is	O
continued	O
clinical	O
concern	O
for	O
acute	O
aortic	O
injury	O
,	O
a	O
CT	O
of	O
the	O
chest	O
can	O
be	O
performed	O
.	O
CT	O
Torso	O
:	O
1	O
.	O
Non-displaced	O
left	O
fourth	O
and	O
sixth	O
rib	O
fractures	O
,	O
with	O
associated	O
ground	O
-	O
glass	O
opacity	O
in	O
the	O
left	O
upper	O
lobe	O
adjacent	O
to	O
the	O
fracture	O
.	O
This	O
is	O
non-specific	O
and	O
may	O
represent	O
contusion	O
versus	O
an	O
area	O
of	O
inflammation	O
.	O
No	O
pneumothorax	O
or	O
acute	O
vascular	O
injury	O
detected	O
.	O
2	O
.	O
No	O
acute	O
traumatic	O
injury	O
identified	O
in	O
the	O
abdomen	O
and	O
pelvis	O
.	O
3	O
.	O
No	O
acute	O
vascular	O
injury	O
detected	O
in	O
the	O
right	O
lower	O
extremity	O
runoff	O
.	O
4	O
.	O
Extensive	O
right	O
lower	O
extremity	O
fractures	O
,	O
without	O
evidence	O
of	O
vascular	O
injury	O
.	O
Open	O
comminuted	O
right	O
tibial	O
and	O
fibular	O
fracture	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Pt	O
was	O
seen	O
and	O
resuscitated	O
in	O
the	O
trauma	O
bay	O
.	O
His	O
primary	O
survey	O
was	O
unremarkable	O
and	O
secondary	O
survey	O
revealed	O
a	O
nearly	O
amputated	O
RLE	O
at	O
the	O
level	O
of	O
the	O
ankle	O
/	O
mid	O
tibia	O
,	O
as	O
well	O
as	O
two	O
lacerations	O
on	O
the	O
LUE	O
,	O
each	O
approx	O
5	O
-	O
6	O
cm	O
.	O
Orthopedics	O
and	O
Plastic	O
Surgery	O
were	O
consulted	O
to	O
the	O
trauma	O
bay	O
for	O
management	O
of	O
these	O
two	O
injuries	O
respectively	O
.	O
He	O
required	O
one	O
unit	O
pRBCs	I-Drug
during	O
his	O
resuscitation	O
.	O
The	O
patient	O
did	O
still	O
have	O
a	O
dopplerable	O
pulse	O
in	O
the	O
RLE	O
,	O
and	O
was	O
taken	O
immediately	O
to	O
the	O
OR	O
for	O
preliminary	O
stabilization	O
of	O
the	O
associated	O
fractures	O
in	O
an	O
attempt	O
to	O
salvage	O
this	O
extremity	O
.	O
His	O
forearm	O
lacerations	O
were	O
repaired	O
concurrently	O
.	O
The	O
patient	O
was	O
followed	O
for	O
these	O
injuries	O
and	O
admitted	O
to	O
the	O
trauma	O
service	O
for	O
management	O
.	O
He	O
was	O
progressing	O
well	O
with	O
an	O
open	O
right	O
tib	O
fib	O
injury	O
that	O
had	O
already	O
been	O
stabilized	O
,	O
but	O
continued	O
to	O
have	O
unstable	O
hematocrits	O
,	O
requiring	O
multiple	O
additional	O
transfusions	O
.	O
No	O
source	O
outside	O
of	O
the	O
RLE	O
could	O
be	O
identified	O
,	O
so	O
the	O
bleeding	O
was	O
assumed	O
to	O
be	O
from	O
his	O
lower	O
extremity	O
injuries	O
.	O
During	O
the	O
patients	O
recovery	O
on	O
the	O
floor	O
he	O
developed	O
acute	O
mental	O
status	O
changes	O
.	O
A	O
head	O
CT	O
was	O
obtained	O
with	O
no	O
acute	O
changes	O
.	O
He	O
was	O
given	O
Haldol	I-Drug
for	O
agitation	I-Reason
and	O
acutely	O
developed	O
fever	I-Ade
to	O
103F	O
.	O
A	O
diagnosis	O
of	O
Neuroleptic	B-Ade
Malignant	I-Ade
Syndrome	I-Ade
was	O
presumed	O
and	O
he	O
was	O
transferred	O
to	O
the	O
SICU	O
for	O
management	O
.	O
He	O
was	O
also	O
noted	O
with	O
high	O
urine	O
output	O
and	O
hypernatremia	O
;	O
of	O
note	O
he	O
has	O
a	O
history	O
of	O
bipolar	B-Reason
disorder	I-Reason
and	O
has	O
been	O
on	O
lithium	I-Drug
.	O
Psychiatry	O
became	O
involved	O
and	O
his	O
Lithium	I-Drug
and	O
other	O
psychiatric	O
meds	O
were	O
withheld	O
.	O
His	O
Na	O
did	O
normalize	O
and	O
was	O
141	O
at	O
time	O
of	O
discharge	O
.	O
His	O
psychiatric	O
meds	O
were	O
recommended	O
to	O
be	O
slowed	O
restarted	O
.	O
All	O
of	O
his	O
other	O
potentially	O
offending	O
medications	O
were	O
held	O
and	O
he	O
was	O
followed	O
in	O
the	O
ICU	O
until	O
his	O
fevers	O
resolved	O
and	O
his	O
mental	O
status	O
improved	O
.	O
Following	O
this	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
floor	O
for	O
further	O
management	O
.	O
He	O
was	O
evaluated	O
by	O
Psychiatry	O
for	O
recommendations	O
regarding	O
his	O
home	O
psych	O
meds	O
and	O
they	O
were	O
resumed	O
at	O
lower	O
doses	O
in	O
order	O
to	O
assess	O
his	O
response	O
.	O
At	O
time	O
of	O
this	O
dictation	O
he	O
is	O
tolerating	O
these	O
initial	O
doses	O
and	O
should	O
be	O
increased	O
to	O
his	O
home	O
dose	O
once	O
continued	O
stabilized	O
while	O
at	O
rehab	O
.	O
He	O
did	O
have	O
significant	O
pain	I-Reason
control	O
issues	O
requiring	O
initially	O
higher	O
doses	O
of	O
his	O
narcotics	I-Drug
.	O
He	O
was	O
started	O
on	O
Methadone	I-Drug
10	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
manage	O
his	O
acute	B-Reason
pain	I-Reason
issues	O
and	O
is	O
also	O
receiving	O
Dilaudid	I-Drug
po	O
prn	O
for	O
breakthrough	B-Reason
pain	I-Reason
.	O
He	O
was	O
evaluated	O
by	O
Physical	O
therapy	O
and	O
is	O
being	O
recommended	O
for	O
rehab	O
after	O
his	O
acute	O
hospital	O
stay	O
.	O
Medications	O
on	O
Admission	O
:	O
Lithium	I-Drug
Percocet	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
pain	I-Reason
:	O
apply	O
over	O
.	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Magnesium	B-Drug
Hydroxide	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
5	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
6	O
.	O
Silver	B-Drug
Sulfadiazine	I-Drug
1	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
:	O
apply	O
to	O
right	O
distal	O
tibil	O
region	O
.	O
7	O
.	O
Multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Thiamine	B-Drug
HCl	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
every	O
[	O
**	O
3	O
-	O
27	O
**	O
]	O
hours	O
as	O
needed	O
for	O
fever	B-Reason
or	I-Reason
pain	I-Reason
.	O
11	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
ML	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Methadone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
for	O
pain	B-Reason
control	I-Reason
.	O
13	O
.	O
Perphenazine	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
home	O
medication	O
.	O
14	O
.	O
Lithium	B-Drug
Carbonate	I-Drug
300	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
Lithium	B-Drug
Carbonate	I-Drug
300	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
:	O
home	O
medication	O
.	O
16	O
.	O
Amiloride	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
please	O
administer	O
with	O
a.m.	O
Lithium	I-Drug
dose	O
.	O
17	O
.	O
Hydromorphone	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
1	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
Tablet	O
PO	O
Q3H	O
(	O
every	O
3	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
18	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
19	O
.	O
Magnesium	B-Drug
Citrate	I-Drug
Solution	O
Sig	O
:	O
Three	O
Hundred	O
(	O
300	O
)	O
ML	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
Cape	O
&	O
Islands	O
Discharge	O
Diagnosis	O
:	O
s	O
/	O
p	O
Motorcycle	O
crash	O
Left	O
upper	O
extremity	O
open	O
lacerations	O
Non	O
-	O
displaced	O
left	O
4th	O
&	O
6th	O
rib	O
fractures	O
Right	O
Tibia	O
&	O
Fibula	O
fractures	O
Malignant	O
neuroleptic	O
syndrome	O
Diabetes	O
Insipidus	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
*	O
Followup	O
Instructions	O
:	O
Follow	O
up	O
next	O
week	O
in	O
Plastics	O
Hand	O
Clinic	O
,	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3009	O
**	O
]	O
for	O
an	O
appointment	O
.	O
Follow	O
up	O
in	O
2	O
weeks	O
with	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
85162	O
**	O
]	O
Trauma	O
,	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1228	O
**	O
]	O
for	O
an	O
appointment	O
.	O
Follow	O
up	O
in	O
2	O
weeks	O
in	O
[	O
**	O
Hospital	O
2536	O
**	O
]	O
clinic	O
for	O
evlaution	O
of	O
your	O
rib	O
fractures	O
;	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
600	O
**	O
]	O
for	O
an	O
appointment	O
.	O
Completed	O
by	O
:[	O
**	O
2125-7-4	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2180-5-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2180-6-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2117-1-6	O
**	O
]	O
Sex	O
:	O
M	O
DISCHARGE	O
MEDICATIONS	O
:	O
The	O
patient	O
's	O
discharge	O
medications	O
are	O
as	O
follows	O
:	O
1	O
.	O
Atenolol	I-Drug
25	O
milligrams	O
po	O
q	O
day	O
.	O
2	O
.	O
Zoloft	I-Drug
125	O
milligrams	O
po	O
q	O
day	O
.	O
4	O
.	O
Vancomycin	I-Drug
1	O
gram	O
IV	O
q	O
day	O
,	O
dose	O
only	O
for	O
a	O
trough	O
level	O
of	O
less	O
than	O
20	O
.	O
The	O
patient	O
will	O
receive	O
this	O
through	O
[	O
**	O
2180-8-14	O
**	O
]	O
.	O
5	O
.	O
Flomax	I-Drug
0.4	O
milligrams	O
po	O
q	O
day	O
.	O
6	O
.	O
Multi	B-Drug
vitamin	I-Drug
one	O
po	O
q	O
day	O
.	O
7	O
.	O
Reglan	I-Drug
10	O
milligrams	O
po	O
qid	O
.	O
8	O
.	O
Oxycodone	I-Drug
5	O
to	O
10	O
milligrams	O
po	O
q	O
four	O
to	O
six	O
hours	O
prn	O
.	O
deltoid	O
and	O
left	O
calf	O
.	O
10	O
.	O
Protonix	I-Drug
40	O
milligrams	O
po	O
q	O
day	O
.	O
DISCHARGE	O
CONDITION	O
:	O
Stable	O
.	O
Discharged	O
to	O
acute	O
rehabilitation	O
facility	O
.	O
DISCHARGE	O
FOLLOW	O
UP	O
:	O
The	O
patient	O
is	O
to	O
follow	O
up	O
with	O
his	O
primary	O
oncologist	O
,	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
12	O
-	O
438	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
11732	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2180-6-7	O
**	O
]	O
09:55	O
T	O
:	O
[	O
**	O
2180-6-7	O
**	O
]	O
10:10	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2141-10-24	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2141-10-26	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2070-7-11	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Trileptal	I-Drug
/	O
Hydrochlorothiazide	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2297	O
**	O
]	O
Chief	O
Complaint	O
:	O
hyponatremia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
72	O
y	O
/	O
o	O
with	O
h	O
/	O
o	O
HTN	O
,	O
L	O
MCA	O
CVa	O
in	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
with	O
resudual	O
language	O
impairment	O
and	O
seizures	O
presents	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
with	O
a	O
Na	O
of	O
114	O
.	O
Because	O
of	O
her	O
seizures	I-Reason
,	O
she	O
was	O
recently	O
started	O
on	O
Trileptal	I-Drug
[	O
**	O
2141-10-13	O
**	O
]	O
,	O
and	O
seen	O
by	O
Neuro	O
[	O
**	O
2141-10-20	O
**	O
]	O
.	O
On	O
[	O
**	O
2141-10-23	O
**	O
]	O
,	O
her	O
Na	O
was	O
noted	O
to	O
fall	O
from	O
139	O
on	O
[	O
**	O
2141-10-13	O
**	O
]	O
to	O
126	O
on	O
[	O
**	O
2141-10-21	O
**	O
]	O
.	O
Her	O
trileptal	I-Drug
was	O
tapered	O
and	O
she	O
received	O
her	O
last	O
dose	O
on	O
[	O
**	O
2141-10-23	O
**	O
]	O
and	O
she	O
was	O
started	O
keppra	I-Drug
.	O
For	O
hypertension	I-Reason
,	O
she	O
was	O
started	O
HCTz	I-Drug
5	O
days	O
ago	O
by	O
her	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
she	O
presents	O
with	O
being	O
very	O
fatigued	O
.	O
No	O
fevers	O
,	O
chills	O
,	O
no	O
nausea	O
or	O
vomiting	O
no	O
chest	O
pain	O
or	O
shortness	O
of	O
breath	O
.	O
Denied	O
any	O
headaches	O
,	O
blurred	O
vision	O
.	O
She	O
has	O
been	O
drinking	O
[	O
**	O
2	O
-	O
7	O
**	O
]	O
glasses	O
of	O
water	O
per	O
day	O
and	O
has	O
not	O
eaten	O
very	O
much	O
per	O
the	O
patient	O
.	O
per	O
her	O
son	O
in	O
law	O
,	O
she	O
been	O
urinating	O
very	O
much	O
.	O
Past	O
Medical	O
History	O
:	O
Ischemic	O
stroke	O
L	O
MCA	O
superior	O
division	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
-	O
mild	O
Broca	O
's	O
aphasia	O
but	O
no	O
weakness	O
on	O
discharge	O
,	O
in	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
he	O
describes	O
that	O
she	O
had	O
"	O
hesitant	O
,	O
broken	O
,	O
frustrated	O
speech	O
.	O
On	O
the	O
other	O
hand	O
,	O
she	O
can	O
string	O
together	O
at	O
least	O
six	O
words	O
,	O
and	O
she	O
is	O
coherent	O
.	O
She	O
can	O
follow	O
multiple	O
different	O
two	O
-	O
step	O
commands	O
.	O
She	O
can	O
salute	O
.	O
She	O
can	O
repeat	O
various	O
different	O
phrases	O
except	O
she	O
did	O
have	O
difficulties	O
saying	O
[	O
**	O
State	O
350	O
**	O
]	O
Institute	O
of	O
Technology	O
.	O
"	O
Work	O
up	O
showed	O
evidence	O
of	O
rheumatic	O
disease	O
on	O
mitral	O
valve	O
,	O
no	O
carotid	O
stenosis	O
,	O
no	O
arrhythmias	O
on	O
telemetry	O
-	O
CAD	O
s	O
/	O
p	O
MI	O
5	O
yrs	O
ago	O
s	O
/	O
p	O
stent	O
-	O
High	O
cholesterol	O
-	O
Hypertension	O
-	O
s	O
/	O
p	O
basal	O
cell	O
ca	O
resection	O
[	O
**	O
5	O
-	O
13	O
**	O
]	O
-	O
GERD	O
Social	O
History	O
:	O
Social	O
History	O
:	O
Lives	O
with	O
husband	O
,	O
very	O
physically	O
active	O
,	O
takes	O
care	O
of	O
4	O
horses	O
;	O
no	O
tob	O
,	O
etoh	O
,	O
drugs	O
.	O
Has	O
one	O
son	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
,	O
one	O
daughter	O
.	O
Family	O
History	O
:	O
Family	O
History	O
:	O
No	O
known	O
early	O
strokes	O
in	O
family	O
.	O
Physical	O
Exam	O
:	O
On	O
admission	O
:	O
T	O
-	O
96.3	O
BP	O
-	O
149/66	O
HR	O
-	O
56	O
RR	O
-	O
13	O
O2Sat	O
-	O
97	O
%	O
on	O
RA	O
Gen	O
:	O
Lying	O
in	O
bed	O
,	O
NAD	O
.	O
SLowed	O
speech	O
,	O
but	O
appropriately	O
answering	O
questions	O
.	O
HEENT	O
:	O
NC	O
/	O
AT	O
,	O
dry	O
mucosa	O
Neck	O
:	O
No	O
tenderness	O
to	O
palpation	O
,	O
normal	O
ROM	O
,	O
supple	O
CV	O
:	O
RRR	O
,	O
Nl	O
S1	O
and	O
S2	O
,	O
no	O
murmurs	O
/	O
gallops	O
/	O
rubs	O
Lung	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
.	O
No	O
RRW	O
aBd	O
:	O
+	O
BS	O
soft	O
,	O
nontender	O
,	O
nondistended	O
ext	O
:	O
no	O
edema	O
skin	O
:	O
dry	O
Pertinent	O
Results	O
:	O
Labs	O
on	O
Admission	O
:	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
WBC	O
-	O
5.1	O
RBC	O
-	O
4.48	O
Hgb	O
-	O
14.2	O
Hct	O
-	O
38.6	O
MCV	O
-	O
86	O
MCH	O
-	O
31.6	O
MCHC	O
-	O
36.7	O
*	O
RDW	O
-	O
12.2	O
Plt	O
Ct	O
-	O
258	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
Neuts	O
-	O
73.9	O
*	O
Lymphs	O
-	O
17.2	O
*	O
Monos	O
-	O
7.6	O
Eos	O
-	O
0.8	O
Baso	O
-	O
0.5	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
258	O
[	O
**	O
2141-10-25	O
**	O
]	O
03:40	O
AM	O
BLOOD	O
PT	O
-	O
11.3	O
PTT	O
-	O
26.7	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2141-10-24	O
**	O
]	O
03:59	O
PM	O
BLOOD	O
ESR	O
-	O
14	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
Glucose	O
-	O
116	O
*	O
UreaN	O
-	O
15	O
Creat	O
-	O
1.0	O
Na	O
-	O
114	O
*	O
K	O
-	O
4.5	O
Cl	O
-	O
78	O
*	O
HCO3	O
-	O
26	O
AnGap	O
-	O
15	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
93	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
Calcium	O
-	O
9.8	O
Phos	O
-	O
3.5	O
Mg	O
-	O
2.0	O
[	O
**	O
2141-10-24	O
**	O
]	O
09:40	O
PM	O
BLOOD	O
Osmolal	O
-	O
245	O
*	O
[	O
**	O
2141-10-24	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
TSH	O
-	O
1.3	O
Brief	O
Hospital	O
Course	O
:	O
72	O
y	O
/	O
o	O
with	O
h	O
/	O
o	O
HTN	O
,	O
L	O
MCA	O
CVa	O
in	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
with	O
resudual	O
language	O
impairment	O
and	O
seizures	O
presents	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
with	O
slowed	O
speech	O
and	O
fatigue	O
.	O
Because	O
of	O
her	O
seizures	I-Reason
,	O
she	O
was	O
recently	O
started	O
on	O
Trileptal	I-Drug
[	O
**	O
2141-10-13	O
**	O
]	O
.	O
On	O
[	O
**	O
2141-10-21	O
**	O
]	O
,	O
her	O
Na	O
was	O
noted	O
to	O
fall	O
from	O
139	O
on	O
[	O
**	O
2141-10-13	O
**	O
]	O
to	O
126	O
on	O
[	O
**	O
2141-10-21	O
**	O
]	O
.	O
Her	O
trileptal	I-Drug
was	O
tapered	O
and	O
she	O
received	O
her	O
last	O
dose	O
on	O
[	O
**	O
2141-10-23	O
**	O
]	O
and	O
she	O
was	O
started	O
keppra	I-Drug
.	O
For	O
hypertension	I-Reason
,	O
she	O
was	O
started	O
HCTz	I-Drug
5	O
days	O
ago	O
.	O
Today	I-Drug
,	O
she	O
presents	O
with	O
being	O
very	O
fatigued	O
with	O
slowed	O
speech	O
.	O
She	O
denied	O
fevers	O
,	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
chest	O
pain	O
or	O
shortness	O
of	O
breath	O
.	O
Denied	O
any	O
headaches	O
,	O
blurred	O
vision	O
.	O
She	O
has	O
been	O
drinking	O
[	O
**	O
2	O
-	O
7	O
**	O
]	O
glasses	O
of	O
water	O
per	O
day	O
and	O
has	O
not	O
eaten	O
very	O
much	O
-	O
per	O
the	O
patient	O
.	O
Per	O
her	O
son	O
in	O
law	O
,	O
she	O
been	O
experiencing	O
increased	O
urination	O
over	O
the	O
past	O
week	O
.	O
.	O
In	O
the	O
ED	O
:	O
-	O
80cc	O
/	O
hr	O
of	O
NS	I-Drug
for	O
a	O
total	O
of	O
500	O
cc	O
-	O
and	O
her	O
Na	O
increased	O
to	O
116	O
.	O
.	O
Her	O
Urine	O
Sodium	O
was	O
48	O
,	O
her	O
serum	O
Osm	O
was	O
248	O
and	O
her	O
Urine	O
Osm	O
was	O
in	O
the	O
432	O
consistent	O
with	O
SIADH	O
.	O
We	O
also	O
felt	O
that	O
she	O
was	O
slightly	O
hypovolemic	O
.	O
Hence	O
she	O
was	O
treated	O
with	O
hypertonic	I-Drug
saline	O
with	O
a	O
goal	O
of	O
increasing	B-Reason
her	I-Reason
Na	I-Reason
~	O
8MeQ	O
/	O
24	O
hours	O
.	O
She	O
also	O
received	O
NS	I-Drug
for	O
volume	B-Reason
repletion	I-Reason
.	O
Her	O
trileptal	I-Drug
was	O
tapered	O
off	O
by	O
the	O
Neurology	O
sevice	O
and	O
transitioned	O
over	O
to	O
keppra	I-Drug
for	O
antiseizure	B-Reason
prophylaxis	I-Reason
.	O
Also	O
,	O
her	O
HCTZ	I-Drug
was	O
discontinued	O
and	O
her	O
BP	O
remained	O
in	O
the	O
120s	O
-	O
130s	O
in	O
the	O
ICU	O
.	O
Her	O
Na	O
gradually	O
improved	O
to	O
134	O
by	O
the	O
morning	O
of	O
[	O
**	O
2141-10-26	O
**	O
]	O
.	O
The	O
pt	O
.	O
remained	O
stable	O
while	O
in	O
the	O
ICU	O
,	O
showing	O
no	O
evidence	O
of	O
seizure	O
activity	O
,	O
and	O
her	O
mental	O
status	O
gradually	O
improving	O
.	O
Per	O
request	O
of	O
the	O
Neurology	O
service	O
she	O
underwent	O
an	O
[	O
**	O
Date	O
Range	O
**	O
]	O
that	O
on	O
prelim	O
read	O
showed	O
slowing	O
in	O
the	O
region	O
of	O
your	O
old	O
stroke	O
-	O
however	O
,	O
the	O
final	O
read	O
is	O
pending	O
at	O
the	O
time	O
of	O
your	O
discharge	O
.	O
On	O
HD	O
3	O
the	O
pt	O
.	O
Na	O
had	O
reached	O
a	O
normal	O
level	O
,	O
she	O
was	O
tolerating	O
PO	O
intake	O
,	O
was	O
urinating	O
without	O
difficulty	O
,	O
was	O
ambulating	O
without	O
difficulty	O
,	O
and	O
was	O
ready	O
for	O
discharge	O
.	O
Moreover	O
,	O
the	O
pt	O
.	O
mental	O
status	O
was	O
at	O
baseline	O
at	O
the	O
time	O
of	O
discharge	O
-	O
A&O	O
x3	O
and	O
speaking	O
in	O
full	O
sentences	O
.	O
Medications	O
on	O
Admission	O
:	O
keppra	I-Drug
HCTZ	I-Drug
25	O
mg	O
daily	O
Atenolol	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Zetia	I-Drug
10	O
mg	O
qd	O
Nexium	I-Drug
40	O
mg	O
qd	O
Aspirin	I-Drug
325	O
mg	O
qd	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Zetia	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
4	O
.	O
Nexium	I-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Hyponatremia	I-Ade
due	O
to	O
trileptal	I-Drug
/	O
HCTZ	I-Drug
Discharge	O
Condition	O
:	O
AAO	O
x	O
3	O
.	O
Speaking	O
fluently	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
your	O
Sodium	B-Ade
level	I-Ade
was	I-Ade
low	O
.	O
This	O
was	O
most	O
likely	O
related	O
to	O
taking	O
Trileptal	I-Drug
and	O
Hydrochlorthiazide	I-Drug
,	O
both	O
of	O
which	O
can	O
lower	O
your	O
Sodium	O
levels	O
.	O
Please	O
STOP	O
taking	O
these	O
medications	O
.	O
.	O
Please	O
also	O
limit	O
your	O
fluid	O
intake	O
to	O
64	O
ounces	O
per	O
day	O
=	O
2	O
quarts	O
.	O
This	O
will	O
also	O
help	O
your	O
sodium	O
level	O
to	O
improve	O
.	O
.	O
Please	O
go	O
to	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
49335	O
**	O
]	O
office	O
on	O
Friday	O
to	O
have	O
your	O
sodium	O
level	O
checked	O
.	O
In	O
addition	O
,	O
you	O
will	O
follow	O
up	O
with	O
him	O
on	O
Monday	O
for	O
an	O
office	O
visit	O
.	O
Followup	O
Instructions	O
:	O
**	O
It	O
is	O
very	O
important	O
that	O
you	O
make	O
the	O
following	O
appointments	O
.	O
Please	O
call	O
to	O
confirm	O
appointments	O
**	O
.	O
You	O
have	O
an	O
appointment	O
at	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
office	O
on	O
Friday	O
for	O
a	O
blood	O
draw	O
for	O
your	O
Sodium	O
level	O
.	O
.	O
You	O
have	O
an	O
appointment	O
on	O
Monday	O
the	O
24th	O
at	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
49335	O
**	O
]	O
office	O
at	O
145	O
pm	O
for	O
a	O
follow	O
up	O
visit	O
.	O
Please	O
bring	O
a	O
copy	O
of	O
your	O
discharge	O
summary	O
which	O
we	O
will	O
provide	O
for	O
you	O
for	O
this	O
.	O
.	O
Please	O
call	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
17720	O
**	O
]	O
office	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2574	O
**	O
]	O
for	O
to	O
arrange	O
for	O
a	O
follow	O
up	O
appointment	O
.	O
.	O
You	O
have	O
an	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
test	O
which	O
is	O
scheduled	O
as	O
below	O
.	O
This	O
is	O
to	O
follow	O
up	O
your	O
stroke	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
LAB	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
19105	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2141-10-31	O
**	O
]	O
3:00	O

Admission	O
Date	O
:	O
[	O
**	O
2175-8-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2175-8-17	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2132-3-23	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Zosyn	I-Drug
Attending	O
:[	O
**	O
Known	O
firstname	O
30	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fever	O
of	O
103	O
on	O
HD	O
,	O
abd	O
pain	O
,	O
N	O
/	O
V	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
ERCP	O
on	O
[	O
**	O
2175-8-8	O
**	O
]	O
with	O
stent	O
placement	O
ET	O
Intubation	O
on	O
[	O
**	O
2175-8-8	O
**	O
]	O
ERCP	O
on	O
[	O
**	O
2175-8-14	O
**	O
]	O
with	O
stent	O
placement	O
Extubation	O
on	O
[	O
**	O
2175-8-14	O
**	O
]	O
Hemodialysis	O
Central	O
venous	O
catheter	O
-	O
RIJ	O
Arterial	O
line	O
Echocardiogram	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
43	O
yo	O
man	O
transferred	O
from	O
MICU	O
[	O
**	O
Location	O
(	O
un	O
)	O
2452	O
**	O
]	O
for	O
ERCP	O
in	O
the	O
setting	O
of	O
presumed	O
biliary	O
sepsis	O
.	O
Patient	O
was	O
transferred	O
on	O
[	O
**	O
2175-8-7	O
**	O
]	O
from	O
[	O
**	O
Hospital3	O
**	O
]	O
ED	O
with	O
fever	O
found	O
at	O
HD	O
[	O
**	O
2175-8-7	O
**	O
]	O
to	O
103	O
.	O
He	O
reports	O
symptoms	O
started	O
the	O
evening	O
of	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
with	O
sharp	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomitting	O
,	O
and	O
diarrhea	O
.	O
At	O
HD	O
he	O
was	O
febrile	B-Reason
with	I-Reason
rigors	I-Reason
to	I-Reason
temp	I-Reason
of	I-Reason
103	I-Reason
.	O
He	O
had	O
blood	O
cultures	O
and	O
was	O
given	O
vanco	I-Drug
/	O
ceftazidime	I-Drug
and	O
sent	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
.	O
At	O
[	O
**	O
Hospital3	O
3583	O
**	O
]	O
he	O
was	O
given	O
benedryl	I-Drug
25	O
mg	O
iv	O
,	O
reglan	I-Drug
10	O
mg	O
iv	O
,	O
morphine	I-Drug
6	O
mg	O
iv	O
,	O
zosyn	I-Drug
2.25	O
gm	O
iv	O
.	O
He	O
had	O
an	O
abdomen	O
/	O
pelvis	O
CT	O
that	O
preliminarily	O
showed	O
gall	O
bladder	O
hypodensity	O
without	O
signs	O
of	O
acute	O
cholecysitis	O
.	O
He	O
was	O
transferred	O
here	O
for	O
ERCP	O
given	O
elevated	O
amylase	O
,	O
lipase	O
and	O
transaminases	O
.	O
AT	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
he	O
was	O
given	O
3L	O
IVF	I-Drug
for	O
SBP	B-Reason
77	I-Reason
-	I-Reason
111	I-Reason
with	O
HR	B-Reason
100	I-Reason
's	I-Reason
with	O
Tm	B-Reason
101.5	I-Reason
.	O
He	O
was	O
given	O
tylenol	I-Drug
1gm	O
.	O
He	O
was	O
admitted	O
to	O
MICU	O
[	O
**	O
Location	O
(	O
un	O
)	O
2452	O
**	O
]	O
overnight	O
where	O
a	O
right	O
IJ	O
central	O
line	O
was	O
placed	O
and	O
he	O
received	O
2L	O
NS	I-Drug
,	O
IV	O
vancomycin	I-Drug
and	O
zosyn	I-Drug
.	O
Patient	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
planned	O
ERCP	O
intervention	O
on	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
s	O
/	O
p	O
stent	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
2177	O
**	O
]	O
in	O
the	O
setting	O
of	O
pna	O
HTN	O
gout	I-Reason
:	O
no	O
active	O
symptoms	O
for	O
several	O
years	O
,	O
does	O
not	O
take	O
ppx	I-Drug
ESRD	O
on	O
HD	O
x9	O
years	O
,	O
?	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
post-strep	O
infection	O
as	O
a	O
child	O
?	O
,	O
on	O
M	O
/	O
W	O
/	O
F	O
schedule	O
,	O
last	O
HD	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
,	O
at	O
Forsinius	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
3320	O
**	O
]	O
where	O
he	O
reportedly	O
normally	O
gets	O
5	O
kg	O
removed	O
OSA	O
on	O
CPAP	O
,	O
pressure	O
17mmHg	O
?	O
,	O
but	O
is	O
unable	O
to	O
tolerate	O
at	O
home	O
Social	O
History	O
:	O
Lives	O
with	O
children	O
(	O
age	O
19	O
,	O
22	O
)	O
,	O
denies	O
past	O
or	O
current	O
tobacco	O
,	O
drinks	O
etoh	O
only	O
on	O
special	O
occaisions	O
(	O
less	O
than	O
once	O
/	O
month	O
)	O
but	O
drank	O
more	O
heavily	O
prior	O
to	O
HD	O
,	O
occaisional	O
MJ	O
but	O
no	O
IVDU	O
or	O
cocaine	O
.	O
Family	O
History	O
:	O
Father	O
with	O
hypertension	O
,	O
mother	O
with	O
DM	O
,	O
sibs	O
healthy	O
,	O
children	O
healthy	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
99.5	O
HR	O
101	O
BP	O
117/75	O
RR	O
28	O
Sat	O
93	O
%	O
on	O
4L	O
NC	O
Gen	O
:	O
NAD	O
,	O
obese	O
man	O
,	O
speaking	O
in	O
full	O
sentances	O
,	O
mild	O
labored	O
breathing	O
,	O
drowsy	O
but	O
arousable	O
,	O
witnessed	O
apnic	O
episodes	O
while	O
sleeping	O
HEENT	O
:	O
PERRL	O
,	O
OP	O
clear	O
,	O
MM	O
dry	O
,	O
mild	O
scleral	O
icterus	O
Neck	O
:	O
Supple	O
,	O
Right	O
IJ	O
in	O
place	O
,	O
no	O
LAD	O
CV	O
:	O
Reg	O
,	O
Tachy	O
,	O
III	O
/	O
VI	O
SEM	O
best	O
at	O
RUSB	O
,	O
heard	O
throughout	O
,	O
no	O
r	O
/	O
g	O
Resp	O
:	O
Decreased	O
BS	O
at	O
both	O
bases	O
with	O
scattered	O
rales	O
R	O
base	O
Abdomen	O
:	O
Obese	O
,	O
distended	O
but	O
soft	O
,	O
NT	O
,	O
no	O
obvious	O
masses	O
but	O
very	O
protuberant	O
,	O
white	O
striae	O
,	O
no	O
fluid	O
wave	O
,	O
tympanic	O
to	O
percussion	O
throughout	O
,	O
unable	O
to	O
palpate	O
liver	O
or	O
spleen	O
;	O
no	O
periumbilical	O
ecchymosis	O
Ext	O
:	O
1	O
+	O
PE	O
to	O
thigh	O
bilaterally	O
;	O
2	O
+	O
DP	O
's	O
B	O
,	O
left	O
UE	O
fistula	O
+	O
palpable	O
thrill	O
Neuro	O
:	O
A&O	O
x3	O
,	O
CN	O
II	O
-	O
XII	O
intact	O
,	O
strength	O
5/5	O
B	O
UE	O
/	O
LE	O
,	O
sensation	O
intact	O
to	O
light	O
touch	O
Skin	O
:	O
no	O
rashes	O
,	O
lesions	O
or	O
ecchymoses	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2175-8-8	O
**	O
]	O
10:22	O
PM	O
TYPE	O
-	O
ART	O
TEMP	O
-	O
38.2	O
RATES	O
-	O
20/1	O
TIDAL	O
VOL	O
-	O
700	O
PEEP	O
-	O
5	O
O2	O
-	O
60	O
PO2	O
-	O
79	O
*	O
PCO2	O
-	O
41	O
PH	O
-	O
7.42	O
TOTAL	O
CO2	O
-	O
28	O
BASE	O
XS	O
-	O
1	O
INTUBATED	O
-	O
INTUBATED	O
VENT	O
-	O
CONTROLLED	O
[	O
**	O
2175-8-8	O
**	O
]	O
10:22	O
PM	O
LACTATE	O
-	O
1.2	O
[	O
**	O
2175-8-8	O
**	O
]	O
10:22	O
PM	O
O2	O
SAT	O
-	O
95	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:56	O
PM	O
TYPE	O
-	O
ART	O
TEMP	O
-	O
38.2	O
RATES	O
-	O
[	O
**	O
10	O
-	O
30	O
**	O
]	O
TIDAL	O
VOL	O
-	O
700	O
PEEP	O
-	O
5	O
O2	O
-	O
60	O
PO2	O
-	O
86	O
PCO2	O
-	O
63	O
*	O
PH	O
-	O
7.28	O
*	O
TOTAL	O
CO2	O
-	O
31	O
*	O
BASE	O
XS	O
-	O
0	O
INTUBATED	O
-	O
INTUBATED	O
VENT	O
-	O
CONTROLLED	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:56	O
PM	O
LACTATE	O
-	O
0.9	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:56	O
PM	O
freeCa	O
-	O
1.03	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:49	O
PM	O
GLUCOSE	O
-	O
101	O
UREA	O
N	O
-	O
45	O
*	O
CREAT	O
-	O
10.1	O
*	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
4.6	O
CHLORIDE	O
-	O
98	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
20	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:49	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
534	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:49	O
PM	O
CK	O
-	O
MB	O
-	O
5	O
cTropnT	O
-	O
0.29	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
08:49	O
PM	O
CALCIUM	O
-	O
7.6	O
*	O
PHOSPHATE	O
-	O
5.9	O
*	O
MAGNESIUM	O
-	O
2.1	O
[	O
**	O
2175-8-8	O
**	O
]	O
02:22	O
PM	O
TYPE	O
-	O
MIX	O
PO2	O
-	O
44	O
*	O
PCO2	O
-	O
54	O
*	O
PH	O
-	O
7.39	O
TOTAL	O
CO2	O
-	O
34	O
*	O
BASE	O
XS	O
-	O
5	O
[	O
**	O
2175-8-8	O
**	O
]	O
02:22	O
PM	O
LACTATE	O
-	O
1.4	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
GLUCOSE	O
-	O
125	O
*	O
UREA	O
N	O
-	O
38	O
*	O
CREAT	O
-	O
9.1	O
*	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
96	O
TOTAL	O
CO2	O
-	O
30	O
ANION	O
GAP	O
-	O
17	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
70	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
50	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
198	O
ALK	O
PHOS	O
-	O
200	O
*	O
AMYLASE	O
-	O
241	O
*	O
TOT	O
BILI	O
-	O
4.5	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
LIPASE	O
-	O
236	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
ALBUMIN	O
-	O
3.5	O
CALCIUM	O
-	O
7.8	O
*	O
PHOSPHATE	O
-	O
5.1	O
*	O
MAGNESIUM	O
-	O
2.1	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
WBC	O
-	O
6.9	O
RBC	O
-	O
3.60	O
*	O
HGB	O
-	O
11.2	O
*	O
HCT	O
-	O
33.2	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
14.2	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
NEUTS	O
-	O
92.5	O
*	O
LYMPHS	O
-	O
3.1	O
*	O
MONOS	O
-	O
4.0	O
EOS	O
-	O
0.2	O
BASOS	O
-	O
0.2	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:55	O
PM	O
PLT	O
COUNT	O
-	O
179	O
[	O
**	O
2175-8-8	O
**	O
]	O
01:21	O
PM	O
LACTATE	O
-	O
1.7	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
GLUCOSE	O
-	O
127	O
*	O
UREA	O
N	O
-	O
32	O
*	O
CREAT	O
-	O
8.8	O
*	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
4.8	O
CHLORIDE	O
-	O
92	O
*	O
TOTAL	O
CO2	O
-	O
32	O
ANION	O
GAP	O
-	O
21	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
87	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
66	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
80	O
ALK	O
PHOS	O
-	O
213	O
*	O
AMYLASE	O
-	O
376	O
*	O
TOT	O
BILI	O
-	O
3.7	O
*	O
DIR	O
BILI	O
-	O
2.3	O
*	O
INDIR	O
BIL	O
-	O
1.4	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
LIPASE	O
-	O
459	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.21	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
ALBUMIN	O
-	O
3.9	O
CALCIUM	O
-	O
7.6	O
*	O
PHOSPHATE	O
-	O
4.4	O
MAGNESIUM	O
-	O
1.2	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
TRIGLYCER	O
-	O
236	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
CORTISOL	O
-	O
34.3	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
VANCO	O
-	O
10.4	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
ASA	O
-	O
NEG	O
ACETMNPHN	O
-	O
7.0	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
WBC	O
-	O
10.3	O
RBC	O
-	O
3.63	O
*	O
HGB	O
-	O
11.2	O
*	O
HCT	O
-	O
32.5	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
30.9	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
14.7	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
NEUTS	O
-	O
94	O
*	O
BANDS	O
-	O
4	O
LYMPHS	O
-	O
1	O
*	O
MONOS	O
-	O
1	O
*	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
NORMAL	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
NORMAL	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
NORMAL	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
PLT	O
COUNT	O
-	O
240	O
[	O
**	O
2175-8-8	O
**	O
]	O
04:10	O
AM	O
PT	O
-	O
15.5	O
*	O
PTT	O
-	O
28.7	O
INR	O
(	O
PT	O
)	O
-	O
1.4	O
*	O
[	O
**	O
2175-8-8	O
**	O
]	O
ERCP	O
FINDINGS	O
:	O
The	O
common	O
bile	O
duct	O
was	O
adequately	O
opacified	O
with	O
contrast	O
medium	O
after	O
the	O
cannulation	O
of	O
the	O
biliary	O
duct	O
.	O
No	O
apparent	O
extrahepatic	O
or	O
intrahepatic	O
biliary	O
duct	O
dilatation	O
or	O
irregularity	O
is	O
seen	O
.	O
No	O
filling	O
defects	O
consistent	O
with	O
stones	O
were	O
noted	O
.	O
As	O
per	O
report	O
,	O
in	O
subsequent	O
images	O
,	O
biliary	O
stent	O
was	O
successfully	O
placed	O
.	O
IMPRESSION	O
:	O
Successful	O
placement	O
of	O
biliary	O
stent	O
.	O
[	O
**	O
2175-8-9	O
**	O
]	O
Transthoracic	O
Echo	O
:	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
There	O
is	O
moderate	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
70	O
%	O
)	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
Transmitral	O
Doppler	O
and	O
tissue	O
velocity	O
imaging	O
are	O
consistent	O
with	O
Grade	O
II	O
(	O
moderate	O
)	O
LV	O
diastolic	O
dysfunction	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
ascending	O
aorta	O
is	O
moderately	O
dilated	O
.	O
There	O
are	O
three	O
aortic	O
valve	O
leaflets	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
mild	O
aortic	O
valve	O
stenosis	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
[	O
**	O
2175-8-14	O
**	O
]	O
ERCP	O
FINDINGS	O
:	O
Comparison	O
is	O
made	O
with	O
CT	O
from	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
,	O
[	O
**	O
2174	O
**	O
]	O
and	O
prior	O
ERCP	O
from	O
[	O
**	O
2175-8-8	O
**	O
]	O
.	O
There	O
is	O
removal	O
of	O
a	O
plastic	O
stent	O
.	O
A	O
retrograde	O
cholangiogram	O
shows	O
multiple	O
filling	O
defects	O
,	O
some	O
of	O
which	O
likely	O
represent	O
stones	O
,	O
within	O
otherwise	O
normal	O
-	O
appearing	O
biliary	O
tree	O
.	O
A	O
biliary	O
stent	O
was	O
then	O
placed	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#Hypotension	O
/	O
Sepsis	O
:	O
On	O
admission	O
,	O
patient	O
met	O
SIRS	O
criteria	O
with	O
fever	O
,	O
tachypnea	O
,	O
tachycardia	O
and	O
lactate	O
of	O
2.5	O
consistent	O
with	O
sepsis	O
.	O
Infectious	O
source	O
was	O
likely	O
biliary	O
tract	O
vs.	O
HD	O
line	O
infection	O
,	O
however	O
also	O
considered	O
was	O
pulmonary	O
source	O
w	O
/	O
new	O
O2	O
requirements	O
although	O
more	O
likely	O
from	O
capillary	O
leak	O
/	O
CHF	O
.	O
Patient	O
has	O
remained	O
fluid	O
responsive	O
intially	O
without	O
need	O
for	O
pressors	I-Drug
.	O
The	O
underlying	O
infection	I-Reason
was	O
treated	O
with	O
IV	O
vancomycin	I-Drug
/	O
unasyn	I-Drug
/	O
gentamycin	I-Drug
for	O
synergy	I-Reason
until	O
cultures	O
at	O
OSH	O
grew	O
enterobacter	I-Reason
at	O
which	O
point	O
only	O
zosyn	I-Drug
was	O
continued	O
with	O
appropriate	O
coverage	O
.	O
The	O
patients	O
lactate	O
level	O
,	O
fevers	O
and	O
WBC	O
were	O
trended	O
and	O
returned	O
to	O
[	O
**	O
Location	O
213	O
**	O
]	O
.	O
Zosyn	I-Drug
was	O
switched	O
to	O
Ciprofloxacin	I-Drug
after	O
the	O
patient	O
developed	O
a	O
drug	B-Ade
rash	I-Ade
.	O
.	O
#Mechanical	O
ventilation	O
:	O
Patient	O
came	O
to	O
the	O
ICU	O
intubated	O
s	O
/	O
p	O
ERCP	O
,	O
on	O
a	O
propofol	I-Drug
drip	O
.	O
Initially	O
he	O
was	O
hypotensive	I-Ade
which	O
was	O
treated	O
with	O
IV	O
fluids	I-Drug
and	O
discontinued	O
propofol	I-Drug
,	O
switching	O
to	O
fentanyl	I-Drug
/	O
versed	I-Drug
for	O
sedation	I-Reason
.	O
Shortly	O
thereafter	O
the	O
patient	O
became	O
restless	O
,	O
agitated	O
and	O
continued	O
to	O
be	O
hypotensive	I-Ade
.	O
He	O
was	O
given	O
10	O
mg	O
vecuronium	I-Drug
and	O
paralyzed	B-Reason
for	I-Reason
arterial	I-Reason
line	I-Reason
placement	O
and	O
foley	O
placement	O
.	O
His	O
labile	O
blood	O
pressures	O
also	O
exacerbated	O
his	O
already	O
fluid	O
-	O
overloaded	O
state	O
,	O
making	O
it	O
difficult	O
to	O
wean	O
off	O
the	O
vent	O
.	O
The	O
initiation	O
of	O
hemodialysis	O
effectively	O
controlled	O
his	O
BP	O
and	O
fluid	O
status	O
,	O
and	O
on	O
day	O
7	O
,	O
after	O
his	O
second	O
ERCP	O
,	O
he	O
was	O
extubated	O
and	O
started	O
on	O
CPAP	O
overnight	O
.	O
.	O
#	O
Gallstone	O
Pancreatitis	O
:	O
On	O
admission	O
the	O
patient	O
had	O
elevated	O
LFTs	O
,	O
pancreatic	O
enzymes	O
,	O
bilirubin	O
and	O
alk	O
phos	O
.	O
His	O
levels	O
slowly	O
trended	O
down	O
post-ERCP	O
except	O
bilirubin	O
and	O
AP	O
,	O
which	O
continued	O
to	O
rise	O
.	O
The	O
patient	O
experienced	O
intermittent	O
epigastric	O
discomfort	O
which	O
prompted	O
a	O
RUQ	O
US	O
,	O
which	O
showed	O
a	O
fatty	O
liver	O
but	O
the	O
common	O
bile	O
duct	O
non-well	O
visualised	O
.	O
CT	O
scan	O
of	O
abdomen	O
showed	O
no	O
intrahepatic	O
biliary	O
dilatation	O
,	O
cholelithiasis	O
,	O
and	O
a	O
subtle	O
hypodensity	O
in	O
pancreatic	O
head	O
.	O
Hepatology	O
and	O
ERCP	O
were	O
consulted	O
prompting	O
a	O
second	O
-	O
look	O
ERCP	O
,	O
which	O
showed	O
sludge	O
drainage	O
in	O
the	O
major	O
papilla	O
,	O
stent	O
migrated	O
to	O
major	O
papilla	O
and	O
several	O
stones	O
in	O
the	O
cystic	O
duct	O
.	O
The	O
stent	B-Reason
was	I-Reason
replaced	I-Reason
,	O
antibiotics	I-Drug
were	O
continued	O
,	O
and	O
the	O
patient	O
's	O
enzymes	O
and	O
bilirubin	O
were	O
trended	O
.	O
.	O
#	O
ESRD	O
:	O
Initially	O
the	O
nephrology	O
service	O
felt	O
HD	O
was	O
not	O
appropriate	O
early	O
during	O
admission	O
,	O
in	O
setting	O
of	O
patient	O
becoming	O
hypertensive	I-Reason
to	O
200s	O
with	O
volume	O
resusitation	O
for	O
pancreatitis	O
.	O
Beta	B-Drug
-	I-Drug
blockers	I-Drug
were	O
started	O
however	O
the	O
patient	O
did	O
not	O
respond	O
and	O
O2	O
sats	O
started	O
trending	O
down	O
with	O
worsening	O
acidemia	O
and	O
low	O
PaO2	O
.	O
The	O
following	O
day	O
HD	O
was	O
initiated	O
with	O
good	O
response	O
in	O
blood	O
pressure	O
.	O
The	O
patient	O
received	O
HD	O
throughout	O
his	O
course	O
,	O
with	O
the	O
day	O
before	O
D	O
/	O
c	O
the	O
final	O
time	O
.	O
.	O
#	O
Hypoxia	I-Reason
:	O
Suspected	O
capillary	O
leak	O
in	O
the	O
setting	O
of	O
sepsis	O
vs.	O
CHF	O
as	O
pt	O
with	O
known	O
CAD	O
.	O
The	O
patient	O
was	O
weaned	O
off	O
his	O
O2	I-Drug
requirement	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
Drug	B-Ade
Rash	I-Ade
:	O
Patient	O
developed	O
a	O
diffuse	O
petticheal	B-Ade
/	I-Ade
macular	I-Ade
rash	I-Ade
on	O
his	O
chest	O
and	O
legs	O
which	O
was	O
pruritic	O
.	O
Dermatology	O
was	O
consulted	O
who	O
felt	O
consistent	O
with	O
a	O
drug	O
rash	O
.	O
Offending	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
was	O
felt	O
to	O
be	O
Zosyn	I-Drug
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
was	O
discontinued	O
and	O
rash	O
improved	O
.	O
He	O
will	O
continue	O
hydoxyzine	O
,	O
sarna	O
and	O
fluocinonide	O
.	O
.	O
#	O
CAD	I-Reason
:	O
An	O
echo	O
was	O
performed	O
to	O
rule	O
out	O
endocarditis	O
as	O
a	O
cause	O
of	O
fever	O
.	O
This	O
showed	O
extensive	O
calcification	O
of	O
cardiac	O
skeleton	O
,	O
mild	O
calcific	O
aortic	O
stenosis	O
,	O
and	O
no	O
definite	O
vegetations	O
.	O
His	O
ECG	O
had	O
some	O
ischemic	O
changes	O
of	O
unclear	O
duration	O
,	O
and	O
the	O
patient	O
had	O
no	O
active	O
symptoms	O
.	O
Cardiac	O
enzymes	O
were	O
stably	O
elevated	O
on	O
admission	O
and	O
,	O
in	O
the	O
setting	O
of	O
ESRD	O
,	O
this	O
was	O
unlikely	O
to	O
be	O
acute	O
event	O
.	O
His	O
aspirin	I-Drug
and	O
plavix	I-Drug
were	O
continued	O
and	O
the	O
patient	O
remained	O
on	O
telemetry	O
for	O
the	O
duration	O
of	O
his	O
stay	O
.	O
.	O
#	O
OSA	O
:	O
Witnessed	O
apneic	O
episodes	O
while	O
asleep	O
.	O
Known	O
history	O
of	O
OSA	O
on	O
CPAP	O
as	O
outpatient	O
but	O
has	O
not	O
been	O
tolerating	O
of	O
recent	O
.	O
Once	O
patient	O
was	O
extubated	O
he	O
was	O
started	O
on	O
CPAP	O
overnight	O
.	O
.	O
#	O
Anemia	O
:	O
Normocytic	O
with	O
normal	O
RDW	O
.	O
Unclear	O
baseline	O
.	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
be	O
low	O
related	O
to	O
ESRD	O
(	O
not	O
on	O
epo	O
as	O
outpatient	O
that	O
we	O
know	O
of	O
)	O
.	O
D.	O
bili	O
not	O
consistent	O
with	O
hemolysis	O
.	O
Hematocrit	O
was	O
trended	O
and	O
continued	O
to	O
improve	O
with	O
HD	O
and	O
management	O
.	O
Renal	O
recs	O
:	O
use	O
epo	O
during	O
HD	O
.	O
.	O
Medications	O
on	O
Admission	O
:	O
fish	B-Drug
oil	I-Drug
daily	O
sensipar	I-Drug
120	O
mg	O
daily	O
ativan	I-Drug
0.5	O
mg	O
prn	O
(	O
rare	O
)	O
percocet	I-Drug
prn	O
(	O
rare	O
)	O
nifedipineER	I-Drug
90	O
daily	O
(	O
last	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
)	O
minoxidil	I-Drug
-	O
dose	O
unable	O
to	O
verify	O
but	O
pt	O
states	O
rx	O
for	O
2	O
tabs	O
and	O
only	O
takes	O
1	O
renagel	I-Drug
2400	O
mg	O
tid	O
ac	O
phoslo	I-Drug
1334	O
mg	O
(	O
?	O
)	O
tid	O
ac	O
simvastatin	I-Drug
20	O
mg	O
daily	O
plavix	I-Drug
75	O
mg	O
daily	O
aspirin	I-Drug
325	O
mg	O
daily	O
toprolXL	I-Drug
50	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Clopidogrel	B-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Simvastatin	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Metoprolol	I-Drug
Succinate	O
50	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Camphor	B-Drug
-	I-Drug
Menthol	O
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
1	O
tube	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Ciprofloxacin	I-Drug
750	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
5	O
days	O
:	O
Take	O
this	O
at	O
least	O
one	O
hour	O
before	O
you	O
take	O
Renagel	I-Drug
.	O
Disp	O
:	O
*	O
5	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Hydroxyzine	I-Drug
HCl	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
itching	I-Reason
:	O
Only	O
take	O
this	O
as	O
long	O
as	O
your	O
rash	O
is	O
itching	O
.	O
Disp	O
:	O
*	O
21	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
Fluocinonide	I-Drug
0.05	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
rash	I-Reason
for	O
12	O
days	O
:	O
Only	O
use	O
while	O
you	O
have	O
the	O
rash	O
.	O
Disp	O
:	O
*	O
1	O
tube	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Cinacalcet	I-Drug
30	O
mg	O
Tablet	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Nifedipine	I-Drug
90	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Minoxidil	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Sevelamer	I-Drug
HCl	O
800	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
13	O
.	O
Calcium	I-Drug
Acetate	O
667	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnoses	O
:	O
Biliary	O
Sepsis	O
Gallstone	O
Pancreatitis	O
Secondary	O
Diagnoses	O
:	O
ESRD	O
with	O
hemodialysis	O
CAD	O
Drug	O
rash	O
OSA	O
HTN	O
Anemia	O
Discharge	O
Condition	O
:	O
Good	O
,	O
tolerating	O
regular	O
diet	O
,	O
ambulating	O
with	O
walker	O
for	O
deconditioning	O
,	O
able	O
to	O
climb	O
a	O
flight	O
of	O
stairs	O
,	O
no	O
oxygen	O
requirement	O
,	O
VSS	O
Discharge	O
Instructions	O
:	O
You	O
were	O
seen	O
and	O
treated	O
at	O
the	O
hopital	O
for	O
a	O
blockage	B-Reason
in	I-Reason
the	I-Reason
area	O
of	O
your	O
gallbladder	O
,	O
which	O
caused	O
you	O
to	O
become	O
infected	I-Reason
.	O
You	O
were	O
treated	O
with	O
intravenous	O
fluids	I-Drug
,	O
antibiotics	I-Drug
and	O
ERCP	O
(	O
Endoscopic	O
Retrograde	O
Cholangiopancreatography	O
)	O
twice	O
.	O
A	O
small	O
tube	O
called	O
a	O
stent	O
was	O
placed	O
near	O
your	O
gallbladder	O
so	O
that	O
it	O
will	O
drain	O
bile	O
into	O
your	O
intestine	O
.	O
Please	O
take	O
the	O
antibiotics	B-Drug
(	I-Drug
Ciprofloxacin	I-Drug
)	I-Drug
until	O
it	O
is	O
finished	O
.	O
You	O
may	O
also	O
use	O
the	O
skin	O
cream	O
for	O
your	O
rash	O
as	O
long	O
as	O
you	O
need	O
it	O
.	O
You	O
may	O
take	O
all	O
of	O
your	O
home	O
medications	O
,	O
and	O
none	O
of	O
the	O
dosages	O
were	O
changed	O
.	O
Call	O
your	O
doctor	O
or	O
come	O
to	O
the	O
Emergency	O
Department	O
right	O
away	O
if	O
any	O
of	O
the	O
following	O
problems	O
develop	O
:	O
*	O
If	O
you	O
are	O
vomitting	O
and	O
can	O
not	O
keep	O
in	O
fluids	O
or	O
your	O
medications	O
.	O
*	O
You	O
are	O
getting	O
dehydrated	O
due	O
to	O
continued	O
vomitting	O
,	O
diarrhea	O
or	O
other	O
reasons	O
.	O
Signs	O
of	O
dehydration	O
include	O
dry	O
mouth	O
,	O
rapid	O
heartbeat	O
or	O
feeling	O
dizzy	O
or	O
faint	O
when	O
standing	O
.	O
*	O
You	O
see	O
blood	O
or	O
dark	O
/	O
black	O
material	O
when	O
you	O
vomit	O
or	O
have	O
a	O
bowel	O
movement	O
.	O
*	O
Your	O
skin	O
,	O
or	O
the	O
whites	O
of	O
your	O
eyes	O
become	O
yellow	O
again	O
.	O
*	O
Your	O
pain	O
is	O
not	O
improving	O
within	O
8	O
-	O
12	O
hours	O
or	O
not	O
gone	O
within	O
24	O
hours	O
.	O
Call	O
or	O
return	O
immediately	O
if	O
your	O
pain	O
is	O
getting	O
worse	O
or	O
is	O
changing	O
location	O
or	O
moving	O
to	O
your	O
chest	O
or	O
back	O
.	O
*	O
You	O
have	O
shaking	O
chills	O
,	O
or	O
a	O
fever	O
greater	O
than	O
100.4	O
(	O
F	O
)	O
degrees	O
or	O
38	O
(	O
C	O
)	O
degrees	O
.	O
*	O
Any	O
serious	O
change	O
in	O
your	O
symptoms	O
,	O
or	O
any	O
new	O
symptoms	O
that	O
concern	O
you	O
.	O
Followup	O
Instructions	O
:	O
Please	O
make	O
an	O
appointment	O
to	O
follow	O
up	O
with	O
your	O
PCP	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
80088	O
**	O
]	O
in	O
the	O
next	O
week	O
or	O
two	O
to	O
further	O
evaluate	O
your	O
response	O
to	O
treatment	O
.	O
You	O
will	O
also	O
need	O
to	O
follow	O
-	O
up	O
with	O
the	O
Gastroenterology	O
team	O
to	O
have	O
a	O
repeat	O
ERCP	O
6	O
weeks	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
Please	O
call	O
his	O
office	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2306	O
**	O
]	O
M	O
-	O
F	O
8:30	O
am	O
-	O
4:30	O
pm	O
.	O
The	O
Dermatologists	O
would	O
also	O
like	O
you	O
to	O
make	O
an	O
appointment	O
for	O
some	O
areas	O
of	O
skin	O
that	O
require	O
follow	O
-	O
up	O
.	O
You	O
may	O
call	O
their	O
office	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
8132	O
**	O
]	O
to	O
schedule	O
the	O
appointment	O
.	O
Completed	O
by	O
:[	O
**	O
2175-8-17	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2194-7-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2194-7-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2122-2-12	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1257	O
**	O
]	O
Chief	O
Complaint	O
:	O
altered	O
mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
72	O
year	O
old	O
spanish	O
speaking	O
woman	O
with	O
a	O
history	O
of	O
a	O
hemorrhagic	O
CVA	O
in	O
[	O
**	O
2164	O
**	O
]	O
s	O
/	O
p	O
craniotomy	O
,	O
hypertension	O
,	O
hyperlipidemia	O
,	O
admitted	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
on	O
[	O
**	O
7	O
-	O
1	O
**	O
]	O
with	O
two	O
weeks	O
of	O
increased	O
confusion	O
at	O
home	O
,	O
slurred	O
speech	O
and	O
conversation	O
not	O
making	O
any	O
sense	O
,	O
unsteady	O
gait	O
,	O
weakness	O
,	O
and	O
substernal	O
chest	O
pain	O
.	O
.	O
First	O
presented	O
to	O
LGH	O
[	O
**	O
2194-6-30	O
**	O
]	O
where	O
she	O
was	O
141/80	O
p82	O
rr18	O
98	O
%	O
RA	O
.	O
She	O
had	O
a	O
positive	O
UA	O
for	O
infxn	I-Reason
(	O
Proteus	O
Vulgaris	O
,	O
per	O
report	O
)	O
and	O
she	O
was	O
given	O
either	O
Levaquin	I-Drug
,	O
Rocephin	I-Drug
,	O
or	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
(	O
unclear	O
)	O
.	O
CK	O
was	O
123	O
,	O
MB	O
2.3	O
,	O
and	O
TropI	O
0.03	O
,	O
subsequently	O
"	O
negative	O
x3	O
.	O
"	O
Other	O
labs	O
significant	O
for	O
hypercalcemia	O
at	O
10.4	O
,	O
WBC	O
7.9	O
,	O
Hct	O
30.8	O
(	O
normocytic	O
)	O
,	O
Plts	O
425k	O
.	O
Chemistry	O
unremarkable	O
,	O
Cr	O
1.1	O
.	O
EKG	O
was	O
non	O
specific	O
with	O
some	O
ST	O
changes	O
in	O
II	O
.	O
CT	O
of	O
head	O
negative	O
x2	O
for	O
acute	O
process	O
with	O
post-operative	O
changes	O
,	O
chronic	O
ischemic	O
changes	O
.	O
Carotid	O
duplex	O
study	O
pending	O
.	O
.	O
Stress	O
test	O
positive	O
for	O
inferior	O
ischemia	O
(	O
?	O
unclear	O
if	O
pt	O
got	O
the	O
stress	O
test	O
,	O
reports	O
indicate	O
that	O
she	O
was	O
too	O
agitated	O
to	O
sit	O
still	O
for	O
it	O
)	O
.	O
Cathed	O
today	O
and	O
found	O
to	O
have	O
a	O
tight	O
proximal	O
90	O
%	O
PDA	O
lesion	O
.	O
5	O
French	O
sheath	O
in	O
RFA	O
.	O
On	O
aspirin	I-Drug
only	O
,	O
has	O
not	O
been	O
prescribed	O
plavix	I-Drug
.	O
Daughter	O
speaks	O
english	O
and	O
has	O
signed	O
consent	O
,	O
will	O
come	O
with	O
patient	O
.	O
Past	O
Medical	O
History	O
:	O
Cerebral	O
aneurysm	O
s	O
/	O
p	O
cerebral	O
(	O
MCA	O
)	O
hemorrhage	O
in	O
[	O
**	O
2164	O
**	O
]	O
,	O
s	O
/	O
p	O
craniotomy	O
and	O
repair	O
(	O
clip	O
placement	O
)	O
--	O
>	O
anterior	O
temporal	O
frontal	O
encephalomalacia	O
Patchy	O
white	O
matter	O
disease	O
changes	O
in	O
the	O
periventricular	O
and	O
subcortical	O
white	O
matter	O
HTN	O
HL	O
Social	O
History	O
:	O
lives	O
with	O
her	O
daughter	O
.	O
non	O
-	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
1818	O
**	O
]	O
non-drinker	O
Family	O
History	O
:	O
N	O
/	O
C	O
Physical	O
Exam	O
:	O
On	O
admission	O
to	O
ICU	O
:	O
97.5	O
183/83	O
p98	O
19	O
98	O
%	O
RA	O
Large	O
hispanic	O
woman	O
in	O
no	O
distress	O
but	O
with	O
eyes	O
closed	O
and	O
moaning	O
.	O
Opens	O
her	O
eyes	O
to	O
voice	O
and	O
follows	O
simple	O
commands	O
but	O
moans	O
or	O
says	O
nonsensical	O
things	O
and	O
dozes	O
back	O
off	O
if	O
not	O
stimulated	O
.	O
Not	O
in	O
respiratory	O
distress	O
.	O
Corneas	O
with	O
bilateral	O
cataracts	O
,	O
pupils	O
are	O
constricted	O
,	O
but	O
EOMI	O
are	O
grossly	O
intact	O
and	O
sclera	O
normal	O
appearing	O
No	O
jugular	O
distention	O
noted	O
.	O
CTAB	O
no	O
w	O
/	O
c	O
/	O
r	O
/	O
r	O
noted	O
anteriorly	O
,	O
good	O
air	O
movement	O
Regular	O
rhythm	O
but	O
tachycardic	O
,	O
no	O
murmurs	O
or	O
gallops	O
are	O
heard	O
.	O
Bilateral	O
radial	O
and	O
DP	O
's	O
pulses	O
palpable	O
Abd	O
soft	O
,	O
NT	O
ND	O
,	O
BS	O
hyperactive	O
No	O
BLE	O
edema	O
No	O
rashes	O
noted	O
Pt	O
responsive	O
but	O
not	O
coherently	O
.	O
Opens	O
eyes	O
to	O
commands	O
but	O
does	O
n't	O
answer	O
questions	O
appropriately	O
.	O
Pupils	O
constricted	O
to	O
1	O
-	O
2	O
mm	O
,	O
EOMI	O
grossly	O
intact	O
.	O
No	O
facial	O
droop	O
noted	O
.	O
Dysarthria	O
unable	O
to	O
be	O
appropriately	O
tested	O
.	O
Spontaneously	O
moving	O
all	O
four	O
extremities	O
,	O
with	O
normal	O
tone	O
,	O
not	O
rigid	O
.	O
Pertinent	O
Results	O
:	O
OSH	O
:	O
-	O
UA	O
/	O
UCx	O
:	O
>	O
100k	O
Proteus	O
Vulgaris	O
:	O
resistant	O
--	O
amp	I-Drug
,	O
nitrofurantoin	I-Drug
,	O
tetracycline	I-Drug
,	O
cefuroxime	I-Drug
,	O
cefazolin	I-Drug
sensitive	O
--	O
ceftazadime	I-Drug
,	O
ceftriaxone	I-Drug
,	O
gent	I-Drug
,	O
levaquin	I-Drug
,	O
pip	B-Drug
-	I-Drug
tazo	I-Drug
,	O
tobra	I-Drug
,	O
bactrim	I-Drug
,	O
cefoxitin	I-Drug
,	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
9847	O
**	O
]	O
-	O
CARDIAC	O
CATH	O
performed	O
at	O
OSH	O
demonstrated	O
:	O
90	O
%	O
PDA	O
stenosis	O
AO	O
148/76	O
(	O
106	O
)	O
LV	O
156/4	O
,11	O
AO	O
157/71	O
(	O
107	O
)	O
LV	O
161/3	O
,10	O
.	O
[	O
**	O
2194-7-8	O
**	O
]	O
3:06	O
pm	O
URINE	O
Source	O
:	O
Catheter	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2194-7-9	O
**	O
]	O
**	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2194-7-9	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
Coronary	O
Artery	O
Disease	O
:	O
The	O
patient	O
was	O
transfered	O
for	O
cardiac	O
catheterization	O
.	O
Although	O
the	O
patient	O
was	O
found	O
to	O
have	O
90	O
%	O
PDA	O
lesion	O
,	O
her	O
symptoms	O
and	O
stress	O
test	O
were	O
unclear	O
.	O
It	O
was	O
thought	O
that	O
the	O
patient	O
could	O
benefit	O
from	O
medication	O
managment	O
of	O
CAD	I-Reason
with	O
ASA	I-Drug
,	O
increased	O
statin	I-Drug
and	O
addition	O
of	O
betablocker	I-Drug
.	O
Therefore	O
,	O
she	O
did	O
not	O
undergo	O
repeat	O
cardiac	O
catheterization	O
.	O
Plavix	I-Drug
was	O
stopped	O
.	O
If	O
she	O
does	O
develop	O
more	O
chest	O
pain	O
in	O
the	O
future	O
,	O
she	O
could	O
have	O
further	O
optimization	O
of	O
anti-anginal	O
medications	O
and	O
then	O
undergo	O
repeat	O
stress	O
testing	O
.	O
.	O
#	O
Agitation	I-Reason
/	O
Altered	B-Reason
Mental	I-Reason
Status	I-Reason
:	O
Patient	O
became	O
agitated	I-Reason
in	O
the	O
pre	O
cath	O
area	O
and	O
was	O
given	O
multiple	O
doses	O
of	O
haldol	I-Drug
.	O
This	O
agitation	O
was	O
attributed	O
to	O
delirium	O
[	O
**	O
3	O
-	O
11	O
**	O
]	O
UTI	O
.	O
She	O
was	O
transferred	O
from	O
the	O
CCU	O
to	O
the	O
medicine	O
service	O
on	O
[	O
**	O
2194-7-5	O
**	O
]	O
.	O
She	O
did	O
well	O
with	O
the	O
resolution	O
of	O
her	O
UTI	O
.	O
.	O
She	O
was	O
started	O
on	O
nighttime	O
Zyprexa	I-Drug
which	O
we	O
should	O
be	O
stopped	O
in	O
two	O
weeks	O
.	O
.	O
#HCT	O
Drop	O
:	O
Thought	O
to	O
be	O
[	O
**	O
3	O
-	O
11	O
**	O
]	O
Groin	O
oozing	O
into	O
her	O
leg	O
.	O
Bedside	O
doppler	O
was	O
negative	O
for	O
pseudoanneurysm	O
and	O
there	O
were	O
no	O
bruits	O
on	O
exam	O
.	O
Her	O
HCT	O
stabilized	O
.	O
This	O
was	O
complicated	O
by	O
iron	B-Reason
deficiency	I-Reason
anemia	I-Reason
,	O
for	O
which	O
she	O
was	O
started	O
on	O
iron	B-Drug
with	I-Drug
vitamin	O
C.	O
.	O
#	O
Urinary	O
Tract	O
Infection	O
:	O
At	O
the	O
outside	O
hospital	O
prior	O
to	O
transfer	O
,	O
she	O
was	O
noted	O
to	O
have	O
a	O
Proteus	B-Reason
UTI	I-Reason
,	O
and	O
was	O
started	O
on	O
levofloxacin	I-Drug
on	O
[	O
**	O
2194-6-30	O
**	O
]	O
,	O
switched	O
to	O
ceftriaxone	I-Drug
on	O
[	O
**	O
7	O
-	O
1	O
**	O
]	O
,	O
then	O
to	O
ciprofloxacin	I-Drug
on	O
[	O
**	O
7	O
-	O
3	O
**	O
]	O
,	O
based	O
on	O
culture	O
data	O
.	O
While	O
here	O
she	O
was	O
treated	O
with	O
ciprofloxacin	I-Drug
,	O
initially	O
IV	O
due	O
to	O
agitation	O
,	O
and	O
later	O
with	O
PO	O
.	O
She	O
completed	O
her	O
course	O
in	O
house	O
.	O
#	O
s	O
/	O
p	O
Arthroscopy	O
:	O
Patient	O
had	O
R	O
knee	O
arthroscopy	O
at	O
[	O
**	O
Hospital3	O
12748	O
**	O
]	O
in	O
[	O
**	O
4	O
-	O
16	O
**	O
]	O
per	O
her	O
daughters	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
right	O
knee	O
was	O
initially	O
noted	O
to	O
be	O
more	O
swollen	O
than	O
the	O
left	O
,	O
but	O
with	O
no	O
obvious	O
effusion	O
.	O
She	O
was	O
given	O
one	O
dose	O
of	O
vancomycin	I-Drug
,	O
ultimately	O
,	O
her	O
right	O
knee	O
did	O
not	O
appear	O
infected	O
w	O
/	O
o	O
small	O
amount	O
of	O
suprapatellar	O
swelling	O
but	O
no	O
effusion	O
,	O
warmth	O
or	O
pain	O
on	O
movement	O
.	O
Vancomycin	I-Drug
was	O
discontinued	O
.	O
Medications	O
on	O
Admission	O
:	O
Home	O
medications	O
:	O
Multivitamin	I-Drug
ASA	I-Drug
Lovaza	I-Drug
(	O
omega	B-Drug
3	I-Drug
fish	I-Drug
oils	I-Drug
)	O
.	O
MEDICATIONS	O
ON	O
TRANSFER	O
:	O
Simvastatin	I-Drug
asa	I-Drug
81	O
mg	O
Plavix	I-Drug
600	O
mg	O
prior	O
to	O
cardiac	B-Reason
catheterization	I-Reason
seroquel	I-Drug
Ancef	I-Drug
1g	O
given	O
at	O
8	O
am	O
(	O
[	O
**	O
7	O
-	O
4	O
**	O
]	O
?	O
)	O
vs	O
Ciprofloxacin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
15	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Adhesive	O
Patch	O
,	O
Medicated	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
300	O
mg	O
(	O
60	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
9	O
.	O
Olanzapine	I-Drug
5	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
0.5	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
for	O
2	O
weeks	O
.	O
Disp	O
:	O
*	O
7	O
Tablet	O
,	O
Rapid	O
Dissolve	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
10	O
.	O
Tylenol	B-Drug
Extra	I-Drug
Strength	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
All	O
Care	O
VNA	O
of	O
greater	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Urinary	O
Tract	O
Infection	O
Coronary	O
Artery	O
Disease	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
for	O
chest	O
pain	O
,	O
and	O
for	O
possible	O
coronary	O
catheterization	O
.	O
While	O
here	O
you	O
were	O
noted	O
to	O
be	O
confused	O
.	O
You	O
were	O
found	O
to	O
have	O
a	O
urinary	B-Reason
tract	I-Reason
infection	I-Reason
,	O
and	O
were	O
treated	O
with	O
the	O
antibiotic	I-Drug
ciprofloxacin	I-Drug
.	O
Followup	O
Instructions	O
:	O
Please	O
arrange	O
to	O
see	O
your	O
primary	O
care	O
doctor	O
within	O
one	O
week	O
of	O
discharge	O
.	O
.	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
648	O
**	O
]	O
:	O
Tuesday	O
,	O
[	O
**	O
2194-7-15	O
**	O
]	O
@	O
4:15	O
pm	O
With	O
:	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
1399	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Location	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
85714	O
**	O
]	O
,	O
#	O
204	O
-	O
[	O
**	O
Hospital1	O
487	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
85352	O
**	O
]	O
Phone	O
:	O
(	O
[	O
**	O
2194	O
**	O
]	O
Department	O
:	O
GASTROENTEROLOGY	O
When	O
:	O
FRIDAY	O
[	O
**	O
2194-7-25	O
**	O
]	O
at	O
1:45	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2837	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
463	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
858	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Completed	O
by	O
:[	O
**	O
2194-7-11	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2200-8-28	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2200-8-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2142-4-26	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
[	O
**	O
Hospital	O
Unit	O
Name	O
196	O
**	O
]	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Tetracyclines	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2704	O
**	O
]	O
Chief	O
Complaint	O
:	O
elective	O
catheterization	O
with	O
aspirin	I-Drug
desentization	I-Reason
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Cardiac	O
Catheterization	O
History	O
of	O
Present	O
Illness	O
:	O
58	O
yo	O
white	O
male	O
w	O
/	O
h	O
/	O
o	O
CAD	O
s	O
/	O
p	O
catheterization	O
in	O
3/99	O
who	O
now	O
presnts	O
for	O
aspirin	I-Drug
desentization	I-Reason
and	O
repeat	O
cath	O
s	O
/	O
p	O
positive	O
MIBI	O
study	O
.	O
Pt	O
presented	O
with	O
CP	O
in	O
3/99	O
and	O
had	O
angioplasty	O
of	O
80	O
%	O
stenosed	O
RCA	O
(	O
vessel	O
too	O
small	O
for	O
stents	O
)	O
and	O
states	O
6	O
months	O
afterwards	O
he	O
had	O
the	O
same	O
vessel	O
angioplastied	O
again	O
.	O
States	O
since	O
then	O
he	O
has	O
felt	O
well	O
up	O
until	O
6	O
months	O
ago	O
when	O
he	O
began	O
having	O
CP	O
again	O
.	O
C	O
/	O
o	O
SSCP	O
that	O
comes	O
on	O
when	O
he	O
walks	O
about	O
a	O
block	O
.	O
States	O
the	O
pain	O
only	O
lasts	O
a	O
few	O
minutes	O
and	O
accompanied	O
by	O
SOB	O
but	O
no	O
N	O
/	O
V	O
/	O
diaphoresis	O
.	O
No	O
radiation	O
.	O
Pain	O
resolves	O
if	O
he	O
stops	O
to	O
rest	O
.	O
States	O
he	O
does	O
not	O
take	O
SL	O
Nitro	I-Drug
b	O
/	O
c	O
the	O
pain	O
resolves	O
on	O
its	O
own	O
.	O
He	O
had	O
a	O
stress	O
test	O
[	O
**	O
2200-5-27	O
**	O
]	O
which	O
showed	O
mild	O
to	O
moderate	O
,	O
partially	O
reversible	O
myocardial	O
perfusion	O
defects	O
involving	O
the	O
anterior	O
wall	O
,	O
apex	O
,	O
and	O
septum	O
,	O
with	O
transient	O
ischemic	O
dilatation	O
of	O
the	O
LV	O
and	O
global	O
hypokinesis	O
(	O
LVEF	O
30	O
%	O
)	O
.	O
Pt	O
now	O
returns	O
for	O
repeat	O
cath	O
.	O
Pt	O
states	O
approx	O
25	O
years	O
ago	O
he	O
took	O
an	O
aspirin	I-Drug
and	O
shortly	O
after	O
developed	O
hives	I-Ade
and	O
profuse	B-Ade
vomiting	I-Ade
.	O
Since	O
then	O
he	O
has	O
not	O
tried	O
to	O
take	O
aspirin	I-Drug
again	O
.	O
He	O
is	O
now	O
admitted	O
for	O
aspirin	I-Drug
desensitization	I-Reason
before	O
catheterization	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
-	O
s	O
/	O
p	O
cath	O
[	O
**	O
2	O
-	O
/	O
2195	O
**	O
]	O
with	O
RCA	O
80	O
%	O
stenosed	O
-	O
angioplasty	O
but	O
too	O
small	O
for	O
stent	O
.	O
HYPERCHOLESTEROLEMIA	O
HYPOTHYROIDISM	O
ANEMIA	O
OSTEOARTHRITIS	O
TINEA	O
PEDIS	O
ONYCHOMYCOSIS	O
s	O
/	O
p	O
APPENDECTOMY	O
COLON	O
POLYPS	O
LEFT	O
BUNDLE	O
BRANCH	O
BLOCK	O
HYPERTENSION	O
Social	O
History	O
:	O
Lives	O
with	O
wife	O
.	O
Smoked	O
1	O
ppd	O
x	O
15	O
years	O
.	O
Quit	O
5	O
years	O
ago	O
.	O
EtOH	O
-	O
drinks	O
1	O
-	O
2	O
beers	O
qnight	O
.	O
Denies	O
withdrawal	O
symptoms	O
.	O
No	O
other	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
died	O
at	O
age	O
62	O
of	O
colon	O
cancer	O
.	O
Father	O
died	O
at	O
age	O
71	O
of	O
PNA	O
Sister	O
has	O
CAD	O
.	O
Physical	O
Exam	O
:	O
t	O
:	O
98.7	O
BP	O
:	O
157/66	O
HR	O
:	O
79	O
RR	O
:	O
20	O
O2sat	O
:	O
97	O
%	O
RA	O
Gen	O
:	O
in	O
NAD	O
HEENT	O
:	O
PERRLA	O
,	O
EOMI	O
,	O
no	O
sceral	O
icterus	O
Neck	O
:	O
supple	O
,	O
no	O
lymphadenopathy	O
CV	O
:	O
RRR	O
,	O
II	O
/	O
VI	O
holosystolic	O
murmur	O
heard	O
best	O
at	O
LLSB	O
.	O
Lungs	O
:	O
CTA	O
bilaterally	O
.	O
No	O
wheezes	O
or	O
crackles	O
Abd	O
:	O
obese	O
,	O
S	O
/	O
NT	O
/	O
ND	O
.	O
+	O
BS	O
.	O
No	O
HSM	O
Ext	O
:	O
no	O
c	O
/	O
c	O
/	O
e.	O
Pulses	O
2	O
+	O
bilaterally	O
DP	O
/	O
PT	O
.	O
R	O
femoral	O
2	O
+	O
.	O
L	O
femoral	O
not	O
palpated	O
.	O
Bruit	O
auscultated	O
in	O
L	O
groin	O
.	O
Neuro	O
:	O
A&O	O
x3	O
.	O
non-focal	O
.	O
strength	O
5/5	O
throughout	O
.	O
Sensation	O
in	O
tact	O
to	O
light	O
touch	O
.	O
Pertinent	O
Results	O
:	O
Cardiac	O
catheterization	O
(	O
[	O
**	O
2200-8-26	O
**	O
]	O
)	O
:	O
1	O
.	O
Selective	O
coronary	O
angiography	O
revealed	O
a	O
right	O
dominant	O
system	O
.	O
The	O
LMCA	O
was	O
angiographically	O
normal	O
.	O
The	O
LAD	O
had	O
a	O
50	O
%	O
lesion	O
after	O
the	O
takeoff	O
of	O
D1	O
.	O
The	O
D1	O
had	O
a	O
60	O
%	O
lesion	O
proximally	O
.	O
The	O
LCX	O
had	O
a	O
50	O
%	O
lesion	O
after	O
the	O
high	O
OM1	O
(	O
which	O
bifurcates	O
)	O
.	O
The	O
RCA	O
has	O
diffuse	O
irregularities	O
,	O
which	O
are	O
<	O
50	O
%	O
.	O
2	O
.	O
Limited	O
hemodynamics	O
on	O
entry	O
show	O
mildly	O
elevated	O
left	O
-	O
sided	O
filling	O
pressures	O
(	O
LVEDP	O
20	O
mm	O
Hg	O
)	O
.	O
3	O
.	O
Left	O
ventriculography	O
showed	O
a	O
globally	O
hypokinetic	O
ventricle	O
with	O
a	O
LVEF	O
of	O
26	O
%	O
.	O
There	O
was	O
no	O
gradient	O
across	O
the	O
LV	O
on	O
pullback	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
1	O
.	O
Two	O
vessel	O
coronary	O
artery	O
disease	O
.	O
2	O
.	O
Severe	O
systolic	O
ventricular	O
dysfunction	O
.	O
Mild	O
diastolic	O
ventricular	O
dysfunction	O
.	O
Brief	O
Hospital	O
Course	O
:	O
58	O
yo	O
M	O
with	O
h	O
/	O
o	O
CAD	O
s	O
/	O
p	O
angioplasty	O
in	O
'	O
[	O
**	O
94	O
**	O
]	O
who	O
now	O
returns	O
for	O
repeat	O
cath	O
and	O
aspirin	I-Drug
desentization	I-Reason
.	O
1	O
.	O
CV	O
:	O
A.	O
CAD	I-Reason
-	O
Continue	O
Plavix	I-Drug
,	O
Lipitor	I-Drug
,	O
Metoprolol	I-Drug
,	O
Lisinopril	I-Drug
.	O
H	O
/	O
o	O
aspirin	I-Drug
allergy	I-Ade
-	O
pt	O
underwent	O
aspirin	I-Drug
desensitization	I-Reason
the	O
night	O
before	O
his	O
catheterization	O
.	O
He	O
tolerated	O
the	O
protocol	O
well	O
with	O
no	O
complications	O
.	O
Similarly	O
,	O
his	O
catheterization	O
was	O
tolerated	O
well	O
with	O
no	O
complications	O
and	O
it	O
was	O
felt	O
that	O
the	O
pt	O
has	O
diffusely	O
mild	O
disease	O
that	O
did	O
not	O
require	O
intervention	O
at	O
this	O
time	O
.	O
After	O
the	O
procedure	O
the	O
pt	O
's	O
groin	O
had	O
good	O
hemostasis	O
.	O
No	O
hematomas	O
were	O
found	O
.	O
B.	O
HTN	I-Reason
-	O
continue	O
Imdur	I-Drug
,	O
Norvasc	I-Drug
,	O
Metoprolol	I-Drug
,	O
Lisinopril	I-Drug
.	O
2	O
.	O
Endo	I-Reason
:	O
continue	O
Levoxyl	I-Drug
.	O
3	O
.	O
PPX	I-Reason
:	O
on	O
protonix	I-Drug
.	O
4	O
.	O
Dispo	O
:	O
Pt	O
remained	O
in	O
the	O
MICU	O
the	O
night	O
before	O
his	O
catheterization	O
and	O
was	O
stable	O
after	O
the	O
procedure	O
and	O
was	O
sent	O
home	O
with	O
followup	O
instructions	O
.	O
FULL	O
CODE	O
.	O
Medications	O
on	O
Admission	O
:	O
IMDUR	I-Drug
60MG	O
--	O
One	O
by	O
mouth	O
every	O
day	O
LIPITOR	I-Drug
80MG	O
--	O
One	O
by	O
mouth	O
every	O
day	O
METOPROLOL	I-Drug
100MG	O
--	O
One	O
by	O
mouth	O
twice	O
a	O
day	O
NITROGLYCERIN	I-Drug
0.4	O
MG	O
--	O
Use	O
as	O
directed	O
NORVASC	I-Drug
5MG	O
--	O
One	O
by	O
mouth	O
every	O
day	O
OMEPRAZOLE	I-Drug
20MG	O
--	O
One	O
every	O
day	O
PLAVIX	I-Drug
75MG	O
--	O
One	O
by	O
mouth	O
every	O
day	O
PROTONIX	I-Drug
40MG	O
--	O
Take	O
one	O
by	O
mouth	O
every	O
day	O
ZESTRIL	I-Drug
20MG	O
--	O
One	O
by	O
mouth	O
twice	O
a	O
day	O
LEVOXYL	I-Drug
137	O
mcg	O
--	O
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Coronary	O
Artery	O
Disease	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Do	O
not	O
do	O
any	O
heavy	O
lifting	O
for	O
the	O
next	O
week	O
.	O
Avoid	O
injury	O
to	O
your	O
groin	O
site	O
--	O
do	O
not	O
bicycle	O
,	O
perform	O
squats	O
or	O
sharp	O
bending	O
at	O
the	O
groin	O
for	O
the	O
next	O
few	O
weeks	O
Followup	O
Instructions	O
:	O
Your	O
primary	O
care	O
physician	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
per	O
your	O
routine	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2110-12-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2110-12-19	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Aspirin	I-Drug
/	O
Codeine	I-Drug
/	O
Sulfa	B-Drug
(	I-Drug
Sulfonamides	I-Drug
)	I-Drug
/	O
Morphine	I-Drug
/	O
Dilaudid	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2901	O
**	O
]	O
Chief	O
Complaint	O
:	O
fever	O
,	O
decreased	O
PO	O
intake	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
Swan	O
Ganz	O
catheter	O
(	O
performed	O
at	O
outside	O
hospital	O
)	O
2	O
.	O
Percutaneous	O
coronary	O
intervention	O
History	O
of	O
Present	O
Illness	O
:	O
81	O
yof	O
admitted	O
to	O
OSH	O
[	O
**	O
2110-12-7	O
**	O
]	O
with	O
approximately	O
1	O
week	O
of	O
feeling	O
weak	O
with	O
decreased	O
po	O
intake	O
.	O
In	O
ER	O
,	O
temp	O
was	O
105	O
and	O
UA	O
grossly	O
positive	O
.	O
BC	O
grew	O
+	O
GNR	O
3/4	O
bottles	O
c	O
/	O
w	O
urosepsis	I-Reason
.	O
Received	O
levoquin	I-Drug
and	O
one	O
dose	O
each	O
of	O
ceftriaxone	I-Drug
and	O
ceftazadine	I-Drug
.	O
Patient	O
ruled	O
in	O
for	O
MI	O
with	O
tropI	O
of	O
12	O
,	O
25.3	O
,	O
13.5	O
.	O
Patient	O
became	O
hypotensive	I-Reason
and	O
was	O
started	O
on	O
dopamine	I-Drug
ggt	O
overnight	O
and	O
levophed	I-Drug
the	O
following	O
morning	O
.	O
PA	O
line	O
was	O
placed	O
with	O
wedge	O
16	O
mmHG	O
,	O
RA	O
11	O
.	O
Cardiac	O
index	O
started	O
to	O
drop	O
around	O
12	O
pm	O
(	O
1.8	O
)	O
-	O
dobutamine	I-Drug
was	O
started	O
.	O
.	O
She	O
had	O
also	O
been	O
on	O
heparin	I-Drug
overnight	O
,	O
platelets	O
started	O
to	O
drop	O
and	O
D	O
-	O
Dimer	O
+	O
at	O
5000	O
.	O
Heparin	I-Drug
was	O
changed	O
to	O
lovenox	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
.	O
.	O
Echo	O
[	O
**	O
2110-12-8	O
**	O
]	O
showed	O
EF	O
25	O
-	O
30	O
%	O
and	O
anteroapical	O
akinesis	O
.	O
About	O
4	O
pm	O
patient	O
began	O
to	O
develop	O
chest	B-Ade
discomfort	I-Ade
.	O
EKG	O
with	O
ST	O
elevation	O
in	O
anterior	O
leads	O
(	O
V2	O
-	O
V4	O
)	O
.	O
Dobutamine	I-Drug
was	O
stopped	O
at	O
this	O
point	O
and	O
IV	O
nitro	I-Drug
started	O
.	O
She	O
became	O
pain	O
free	O
and	O
was	O
subsequently	O
transferred	O
by	O
helicopter	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
.	O
Pt	O
cath	O
'd	O
with	O
LAD	O
60	O
%	O
occlusion	O
otherwise	O
patent	O
RCA	O
and	O
LCx	O
,	O
abnormal	O
LV	O
gram	O
.	O
.	O
On	O
review	O
of	O
systems	O
,	O
denies	O
headache	O
,	O
dizziness	O
,	O
cough	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
nausea	O
,	O
dysuria	O
,	O
urinary	O
frequency	O
,	O
back	O
pain	O
.	O
Per	O
patient	O
's	O
family	O
,	O
she	O
has	O
not	O
been	O
feeling	O
well	O
for	O
approximately	O
1	O
week	O
,	O
occasionally	O
vomitting	O
and	O
with	O
decreased	O
PO	O
intake	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
hypertension	O
2	O
.	O
rheumatoid	O
arthritis	O
3	O
.	O
anemia	O
4	O
.	O
s	O
/	O
p	O
fracture	O
of	O
clavicle	O
5	O
.	O
s	O
/	O
p	O
left	O
total	O
knee	O
replacement	O
6	O
.	O
s	O
/	O
p	O
hysterectomy	O
7	O
.	O
s	O
/	O
p	O
CCY	O
Social	O
History	O
:	O
No	O
tobacco	O
,	O
no	O
etoh	O
.	O
Lives	O
at	O
home	O
with	O
her	O
husband	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
adopted	O
older	O
daughter	O
who	O
lives	O
nearby	O
.	O
Retired	O
,	O
used	O
to	O
work	O
for	O
the	O
government	O
.	O
Family	O
History	O
:	O
denies	O
family	O
history	O
of	O
heart	O
disease	O
Physical	O
Exam	O
:	O
VS	O
T	O
96.6	O
BP	O
96/63	O
MAP	O
74	O
HR	O
78	O
RR	O
18	O
100	O
%	O
NC	O
6L	O
PAP	O
34/19	O
CVP	O
14	O
Ht	O
5	O
??????	O
2	O
??????	O
Weight	O
50	O
kg	O
.	O
GEN	O
:	O
elderly	O
,	O
NAD	O
,	O
lying	O
flat	O
HEENT	O
:	O
PERRL	O
2	O
mm	O
to	O
1	O
mm	O
,	O
EOMI	O
,	O
o	O
/	O
p	O
clear	O
,	O
dry	O
mm	O
NECK	O
:	O
supple	O
CV	O
:	O
RRR	O
S1S2	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
LUNG	O
:	O
decreased	O
BS	O
at	O
left	O
base	O
and	O
clear	O
on	O
right	O
ABD	O
:	O
soft	O
,	O
nt	O
,	O
bs	O
+	O
EXT	O
:	O
nonpitting	O
2	O
+	O
edema	O
in	O
ankles	O
b	O
/	O
l	O
and	O
1	O
+	O
nonpitting	O
edema	O
in	O
hands	O
b	O
/	O
l	O
,	O
DP	O
dopplerable	O
,	O
PT	O
1	O
+	O
,	O
right	O
groin	O
with	O
dressing	O
NEURO	O
:	O
alert	O
,	O
oriented	O
to	O
person	O
,	O
place	O
(	O
knew	O
city	O
but	O
not	O
hosp	O
)	O
,	O
time	O
(	O
knew	O
[	O
**	O
Holiday	O
**	O
]	O
was	O
near	O
but	O
not	O
year	O
was	O
[	O
**	O
2109	O
**	O
]	O
)	O
Pertinent	O
Results	O
:	O
U	O
/	O
A	O
leuk	O
tr	O
,	O
nitr	O
neg	O
,	O
WBC	O
[	O
**	O
6	O
-	O
27	O
**	O
]	O
,	O
bact	O
many	O
,	O
epi	O
[	O
**	O
3	O
-	O
22	O
**	O
]	O
Gluc	O
187	O
,	O
Na	O
136	O
,	O
K	O
3.8	O
,	O
Cl	O
108	O
,	O
HCO3	O
16	O
,	O
BUN	O
18	O
,	O
Cr	O
1.0	O
CK	O
538	O
MB	O
85	O
MBI	O
15.8	O
TropT	O
1.80	O
Ca	O
6.9	O
Mg	O
1.6	O
P	O
2.9	O
ALT	O
49	O
AST	O
132	O
AP	O
159	O
TB	O
0.9	O
Alb	O
2.2	O
WBC	O
45.5	O
HBG	O
9.8	O
Hct	O
29.1	O
Plat	O
122	O
N	O
56	O
Bands	O
39	O
L	O
1	O
M	O
2	O
E	O
0	O
Bas	O
0	O
Metas	O
2	O
PT	O
13.9	O
PTT	O
58.5	O
INR	O
1.3	O
ABG	O
7.34	O
/	O
26/83/15	O
[	O
**	O
2110-12-8	O
**	O
]	O
Plt	O
Ct	O
-	O
122	O
*	O
[	O
**	O
2110-12-11	O
**	O
]	O
Plt	O
Ct	O
-	O
62	O
*	O
[	O
**	O
2110-12-13	O
**	O
]	O
Plt	O
Ct	O
-	O
127	O
*	O
#	O
[	O
**	O
2110-12-18	O
**	O
]	O
Plt	O
Ct	O
-	O
333	O
[	O
**	O
2110-12-12	O
**	O
]	O
Fibrino	O
-	O
302	O
[	O
**	O
2110-12-12	O
**	O
]	O
%	O
HbA1c	O
-	O
6.1	O
*	O
[	O
**	O
2110-12-12	O
**	O
]	O
Triglyc	O
-	O
134	O
HDL	O
-	O
22	O
CHOL	O
/	O
HD	O
-	O
5.4	O
LDLcalc	O
-	O
70	O
[	O
**	O
2110-12-12	O
**	O
]	O
HIT	O
Ab	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
negative	O
[	O
**	O
2110-12-16	O
**	O
]	O
HIT	O
Ab	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
negative	O
[	O
**	O
2110-12-19	O
**	O
]	O
PT	O
-	O
19.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.6	O
Microbiology	O
:	O
urine	O
culture	O
at	O
outside	O
hospital	O
E	O
Coli	O
pansensitive	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
blood	O
culture	O
no	O
growth	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
urine	O
culture	O
no	O
growth	O
c	O
diff	O
negative	O
x3	O
.	O
EKG	O
:	O
NSR	O
79	O
bpm	O
,	O
left	O
axis	O
,	O
1.0	O
mm	O
ST	O
elevation	O
V1	O
,	O
2.0	O
mm	O
ST	O
elev	O
V2	O
,	O
.5	O
mm	O
depressions	O
in	O
V4	O
-	O
5	O
,	O
1.0	O
mm	O
depression	O
V6	O
,	O
TW	O
flattening	O
/	O
TWI	O
throughout	O
?	O
.	O
Cath	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
:	O
LAD	O
60	O
%	O
occlusion	O
,	O
nl	O
LCx	O
and	O
RCA	O
.	O
.	O
CXR	O
:	O
cardiomegaly	O
no	O
CHF	O
,	O
LLL	O
atelectasis	O
/	O
infiltrate	O
,	O
biapical	O
pleural	O
thickening	O
/	O
scarring	O
?	O
prior	O
granulomatous	O
disease	O
,	O
density	O
in	O
the	O
right	O
mid	O
zone	O
extending	O
to	O
the	O
right	O
hilum	O
,	O
osteopenia	O
.	O
.	O
CAROTID	O
SERIES	O
COMPLETE	O
[	O
**	O
2110-12-12	O
**	O
]	O
No	O
hemodynamically	O
significant	O
stenosis	O
was	O
identified	O
in	O
the	O
bilateral	O
extracranial	O
carotid	O
arteries	O
.	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
[	O
**	O
2110-12-11	O
**	O
]	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
acute	O
intracranial	O
hemorrhage	O
.	O
No	O
evidence	O
of	O
acute	O
infarction	O
.	O
MRI	O
is	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
acute	O
infarction	O
.	O
.	O
MR	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
[	O
**	O
2110-12-11	O
**	O
]	O
12:33	O
PM	O
CONCLUSION	O
:	O
Unremarkable	O
MRI	O
and	O
MRA	O
of	O
the	O
head	O
for	O
age	O
.	O
No	O
MR	O
features	O
of	O
acute	O
vascular	O
territorial	O
infarct	O
.	O
.	O
[	O
**	O
12	O
-	O
13	O
**	O
]	O
EEG	O
IMPRESSION	O
:	O
Probably	O
normal	O
awake	O
and	O
drowsy	O
EEG	O
without	O
focal	O
,	O
lateralizing	O
,	O
or	O
epileptiform	O
features	O
seen	O
.	O
A	O
senile	O
drowsy	O
pattern	O
is	O
considered	O
normal	O
for	O
this	O
age	O
although	O
deep	O
midline	O
dysfunction	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
.	O
UNILAT	O
LOWER	O
EXT	O
VEINS	O
RIGHT	O
[	O
**	O
2110-12-14	O
**	O
]	O
No	O
right	O
lower	O
extremity	O
DVT	O
Brief	O
Hospital	O
Course	O
:	O
81	O
year	O
old	O
woman	O
with	O
h	O
/	O
o	O
htn	O
and	O
rheumatoid	B-Reason
arthritis	I-Reason
(	O
on	O
chronic	O
steroids	I-Drug
)	O
admitted	O
with	O
urosepsis	O
and	O
found	O
to	O
have	O
stress	O
-	O
induced	O
cardiomyopathy	O
(	O
s	O
/	O
p	O
cath	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
)	O
.	O
Found	O
to	O
have	O
thrombocytopenia	O
consistent	O
with	O
HIT	O
and	O
may	O
have	O
suffered	O
a	O
TIA	O
with	O
negative	O
head	O
CT	O
and	O
MRI	O
/	O
MRA	O
.	O
Was	O
placed	O
on	O
argatroban	I-Drug
gtt	O
and	O
aggrenox	I-Drug
and	O
bridged	O
to	O
coumadin	I-Drug
while	O
HIT	O
Ab	O
test	O
was	O
pending	O
.	O
.	O
##	O
Thrombocytopenia	I-Ade
:	O
Patient	O
's	O
platelet	O
count	O
was	O
122K	O
on	O
admission	O
and	O
dropped	O
three	O
days	O
later	O
to	O
62K	O
.	O
Differential	O
diagnosis	O
included	O
sepsis	O
,	O
possible	O
HIT	O
I	O
or	O
II	O
.	O
SQ	O
heparin	I-Drug
and	O
all	O
flushes	O
stopped	O
.	O
Concurrently	O
,	O
patient	O
developed	O
facial	O
droop	O
,	O
ptosis	O
,	O
tongue	O
deviation	O
and	O
right	O
LE	O
swelling	O
concerning	O
for	O
arterial	O
and	O
venous	O
thrombi	O
.	O
US	O
of	O
right	O
LE	O
negative	O
for	O
DVT	O
.	O
While	O
HIT	O
Ab	O
was	O
pending	O
,	O
patient	O
was	O
started	O
on	O
argatroban	I-Drug
gtt	O
.	O
Hematology	O
/	O
oncology	O
was	O
consulted	O
and	O
recommended	O
bridging	O
patient	O
to	O
warfarin	I-Drug
.	O
First	O
HIT	O
Ab	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
test	O
returned	O
as	O
negative	O
.	O
Argatroban	I-Drug
ggt	O
was	O
discontinued	O
after	O
the	O
INR	O
was	O
>	O
3	O
after	O
a	O
3	O
hour	O
trial	O
off	O
argatroban	I-Drug
.	O
Second	O
HIT	O
Ab	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
was	O
negative	O
suggesting	O
no	O
HIT	O
Ab	O
.	O
Also	O
,	O
per	O
heme	O
/	O
onc	O
time	O
course	O
of	O
thrombocytopenia	O
was	O
shorter	O
than	O
expected	O
for	O
development	O
of	O
HIT	O
Ab	O
(	O
usually	O
5	O
-	O
6	O
days	O
)	O
however	O
in	O
the	O
setting	O
of	O
a	O
possible	O
TIA	O
,	O
patient	O
will	O
continue	O
warfarin	I-Drug
with	O
goal	O
INR	O
betw	O
[	O
**	O
2	O
-	O
20	O
**	O
]	O
until	O
follow	O
-	O
up	O
at	O
hematology	O
/	O
oncology	O
clinic	O
.	O
.	O
##	O
Neuro	O
:	O
Had	O
new	O
facial	O
droop	O
and	O
tongue	O
deviation	O
on	O
[	O
**	O
12	O
-	O
11	O
**	O
]	O
thought	O
be	O
a	O
TIA	O
likely	O
secondary	O
to	O
HIT	O
Ab	O
.	O
Head	O
CT	O
was	O
negative	O
for	O
bleed	O
.	O
Head	O
MRI	O
/	O
MRA	O
was	O
negative	O
for	O
acute	O
ischemia	O
.	O
Carotid	O
doppler	O
showed	O
no	O
significant	O
stenosis	O
.	O
HBAIC	O
6.0	O
and	O
lipid	O
panel	O
within	O
normal	O
limits	O
.	O
Stroke	O
team	O
was	O
consulted	O
and	O
recommended	O
starting	O
ASA	I-Drug
.	O
Patient	O
was	O
switched	O
from	O
salsalate	I-Drug
to	O
ASA	I-Drug
without	O
adverse	O
drug	O
rxn	O
(	O
hx	O
of	O
asa	I-Drug
allergy	O
)	O
,	O
and	O
then	O
switched	O
to	O
aggrenox	I-Drug
.	O
Patient	O
placed	O
on	O
baby	O
ASA	I-Drug
while	O
on	O
coumadin	I-Drug
.	O
Unclear	O
whether	O
facial	O
signs	O
were	O
TIA	O
or	O
twitching	O
so	O
EEG	O
was	O
performed	O
which	O
was	O
negative	O
for	O
epileptiform	O
activity	O
.	O
Per	O
stroke	O
,	O
continue	O
ASA	I-Drug
until	O
outpatient	O
follow	O
-	O
up	O
.	O
Recommended	O
increasing	O
ASA	I-Drug
dose	O
to	O
325	O
mg	O
once	O
off	O
warfarin	I-Drug
.	O
.	O
##	O
Cardiac	O
:	O
likely	O
stress	O
-	O
induced	O
cardiomyopathy	O
(	O
Takotsubo	O
)	O
versus	O
secondary	O
to	O
sepsis	O
.	O
#	O
Ischemia	O
:	O
patient	O
had	O
PTCA	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
revealing	O
an	O
LAD	O
60	O
%	O
occlus	O
,	O
patent	O
Lcx	O
&	O
RCA	O
.	O
Repeat	O
echo	O
[	O
**	O
12	O
-	O
9	O
**	O
]	O
EF	O
25	O
-	O
30	O
%	O
severe	O
LV	O
hypokinesis	O
and	O
LV	O
sys	O
fcn	O
depression	O
,	O
RV	O
sys	O
fcn	O
depression	O
,	O
no	O
endocarditis	O
.	O
TropI	O
peaked	O
at	O
25.3	O
at	O
outside	O
hospital	O
,	O
tropT	O
1.80	O
on	O
admission	O
.	O
Patient	O
started	O
on	O
toprol	I-Drug
XL	O
25	O
mg	O
QD	O
,	O
lisinopril	I-Drug
5	O
mg	O
PO	O
QD	O
and	O
baby	O
ASA	I-Drug
.	O
Nifedipine	I-Drug
was	O
held	O
.	O
#	O
Pump	O
:	O
Patient	O
with	O
low	O
EF	O
in	O
setting	O
of	O
sepsis	O
.	O
Initially	O
hypotensive	I-Ade
on	O
levophed	I-Drug
and	O
aggressively	O
fluid	I-Drug
resuscitated	O
.	O
Patient	O
was	O
on	O
also	O
hydrocortisone	I-Drug
and	O
fludrocortisone	I-Drug
for	O
1	O
week	O
course	O
and	O
then	O
resumed	O
on	O
her	O
outpatient	O
dose	O
of	O
prednisone	I-Drug
1	O
mg	O
PO	O
BID	O
.	O
Patient	O
was	O
gradually	O
weaned	O
off	O
pressors	I-Drug
.	O
Patient	O
became	O
hypotensive	O
again	O
secondary	O
to	O
excessive	O
diarrhea	O
which	O
improved	O
with	O
fluid	I-Drug
boluses	O
and	O
resolution	O
of	O
her	O
dairrhea	O
.	O
#	O
Rhythm	O
:	O
Sinus	O
with	O
PVCs	O
.	O
Cont	O
telemetry	O
.	O
.	O
#	O
.	O
Fever	O
/	O
Leukocytosis	O
:	O
Likely	O
[	O
**	O
2	O
-	O
19	O
**	O
]	O
E	O
coli	O
UTI	O
and	O
+	O
BC	O
GNR	O
,	O
has	O
been	O
afebrile	O
since	O
admission	O
,	O
leukocytosis	I-Ade
may	O
also	O
be	O
secondary	O
to	O
steroids	I-Drug
,	O
newly	O
diagnosed	O
lymphoma	O
.	O
OSH	O
cx	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
ICU	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
31585	O
**	O
]	O
)	O
-	O
>	O
E.	O
Coli	O
pansensitive	O
.	O
Possible	O
LLL	O
pna	O
on	O
CXR	O
however	O
sat	O
'	O
ing	O
well	O
on	O
room	O
air	O
and	O
asymptomatic	O
.	O
Repeat	O
U	O
/	O
A	O
+	O
for	O
UTI	O
&	O
urine	O
cxr	O
no	O
growth	O
.	O
C.	O
diff	O
negativex3	O
.	O
Patient	O
to	O
complete	O
a	O
2	O
week	O
course	O
of	O
levoquin	I-Drug
until	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
urosepsis	I-Reason
and	O
possible	B-Reason
LLL	I-Reason
pneumonia	I-Reason
.	O
C.	O
diff	O
negativex3	O
.	O
.	O
#	O
.	O
Acidosis	O
:	O
mixed	O
venous	O
pH	O
7.31	O
,	O
HCO3	O
15	O
,	O
AG	O
adj	O
for	O
hypoalb	O
=	O
13	O
HCO3	O
16	O
.	O
Likely	O
mixed	O
picture	O
,	O
nongap	O
and	O
gap	O
acidosis	O
.	O
Etiology	O
likely	O
secondary	O
to	O
septic	O
shock	O
,	O
decreased	O
PO	O
intake	O
and	O
fluid	B-Reason
resuscitation	I-Reason
with	O
NS	I-Drug
.	O
Her	O
1.5	O
days	O
of	O
diarrhea	O
likely	O
contributed	O
to	O
her	O
nongap	O
acidosis	O
.	O
HCO3	O
at	O
discharge	O
22	O
with	O
no	O
anion	O
gap	O
.	O
.	O
#	O
Aphthous	O
ulcer	O
:	O
likely	O
[	O
**	O
2	O
-	O
19	O
**	O
]	O
HSV	O
1	O
and	O
stress	O
.	O
-	O
topical	O
acyclovir	I-Drug
to	O
lip	O
-	O
magic	I-Drug
mouthwash	O
for	O
tongue	O
/	O
throat	O
-	O
pureed	O
diet	O
for	O
now	O
as	O
pt	O
's	O
dentures	O
do	O
n't	O
fit	O
-	O
consider	O
adding	O
sulcrafate	I-Drug
if	O
not	O
feeling	O
better	O
.	O
#	O
Diarrhea	O
:	O
likely	O
[	O
**	O
2	O
-	O
19	O
**	O
]	O
to	O
abx	O
v	O
c	O
diff	O
v	O
[	O
**	O
2	O
-	O
19	O
**	O
]	O
too	O
aggressive	O
bowel	O
regimen	O
.	O
Resolving	O
.	O
Changed	O
to	O
lactose	O
free	O
diet	O
.	O
-	O
cont	O
Imodium	I-Drug
-	O
Hold	O
bowel	O
regimen	O
-	O
C	O
diff	O
negative	O
x3	O
.	O
#	O
.	O
Rheumatoid	B-Reason
arthritis	I-Reason
:	O
initally	O
held	O
methotrexate	I-Drug
and	O
prednisone	I-Drug
.	O
Should	O
resume	O
outpatient	O
regimen	O
.	O
.	O
#	O
.	O
FEN	O
:	O
repleting	O
lytes	O
,	O
cardiac	O
healthy	O
diet	O
as	O
tolerated	O
.	O
Nutrition	O
was	O
consulted	O
given	O
history	O
of	O
decreased	O
intake	O
and	O
low	O
albumin	O
,	O
boost	O
breezes	O
with	O
meals	O
,	O
zinc	I-Drug
oxide	O
,	O
vitamin	B-Drug
C	I-Drug
for	O
wound	O
healing	O
(	B-Reason
sacral	I-Reason
irritation	I-Reason
)	I-Reason
and	O
calcium	I-Drug
vit	O
D	O
supplementation	O
for	O
chronic	B-Reason
steroid	I-Drug
use	O
.	O
.	O
#	O
.	O
Code	O
status	O
:	O
full	O
.	O
#	O
.	O
Communication	O
:	O
Husband	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
31586	O
**	O
]	O
,	O
Daughters	O
:	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
31587	O
**	O
]	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
31588	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
at	O
home	O
1	O
.	O
calcium	I-Drug
c	O
D	O
600U	O
[	O
**	O
Hospital1	O
**	O
]	O
2	O
.	O
folate	I-Drug
1	O
mg	O
qd	O
3	O
.	O
toprol	I-Drug
XL	O
37.5	O
mg	O
qd	O
(	O
?	O
)	O
4	O
.	O
nifedipine	I-Drug
60	O
mg	O
qd	O
5	O
.	O
salsalate	I-Drug
750	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
6	O
.	O
methotrexate	I-Drug
2.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
qFri	O
,	O
qSat	O
7	O
.	O
prednisone	I-Drug
1	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
at	O
OSH	O
1	O
.	O
ceftriaxone	I-Drug
1gm	O
IV	O
x1	O
2	O
.	O
ceftazadine	I-Drug
1gm	O
IV	O
x1	O
3	O
.	O
levoquin	I-Drug
250	O
mg	O
IV	O
x1	O
4	O
.	O
levophed	I-Drug
@	O
12mcg	O
/	O
min	O
5	O
.	O
IV	O
nitro	I-Drug
@	O
20mcg	O
/	O
min	O
6	O
.	O
dobutamine	I-Drug
(	O
now	O
off	O
)	O
7	O
.	O
NS	I-Drug
75	O
cc	O
/	O
hour	O
8	O
.	O
toprol	I-Drug
25	O
mg	O
QD	O
9	O
.	O
lovenox	I-Drug
50	O
mg	O
q12	O
(	O
10am	O
/	O
pm	O
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
Timolol	B-Drug
Maleate	I-Drug
0.5	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Cyclosporine	I-Drug
0.05	O
%	O
Dropperette	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Dropperette	O
Ophthalmic	O
OU	O
QD	O
.	O
3	O
.	O
Polyvinyl	B-Drug
Alcohol	I-Drug
-	I-Drug
Povidone	O
1.4	O
-	O
0.6	O
%	O
Dropperette	O
Sig	O
:	O
[	O
**	O
1	O
-	O
19	O
**	O
]	O
Drops	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
4	O
.	O
Prednisone	B-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Lisinopril	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Metoprolol	I-Drug
Succinate	O
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Lidocaine	B-Drug
HCl	I-Drug
2	O
%	O
Gel	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Urethral	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
8	O
.	O
Mineral	B-Drug
Oil	I-Drug
-	I-Drug
Hydrophil	I-Drug
Petrolat	I-Drug
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
9	O
.	O
Loperamide	I-Drug
2	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
diarrhea	I-Reason
.	O
10	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Zinc	I-Drug
Sulfate	O
220	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Levofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
2	O
days	O
:	O
Until	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
.	O
13	O
.	O
Acyclovir	I-Drug
5	O
%	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
6X	O
/	O
D	O
(	O
6	O
times	O
a	O
day	O
)	O
.	O
14	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
15	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
16	O
.	O
Lidocaine	B-Drug
Viscous	I-Drug
2	O
%	O
Solution	O
Sig	O
:	O
15	O
-	O
20	O
cc	O
Mucous	O
membrane	O
QACHS	O
as	O
needed	O
for	O
mouth	B-Reason
/	I-Reason
throat	I-Reason
discomfort	I-Reason
.	O
17	O
.	O
Aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
18	O
.	O
Tylenol	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
:	O
Not	O
to	O
exceed	O
4g	O
/	O
day	O
.	O
19	O
.	O
Ibuprofen	I-Drug
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
:	O
Please	O
take	O
with	O
food	O
.	O
20	O
.	O
Calcium	I-Drug
500	O
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
:	O
Please	O
give	O
before	O
meals	O
and	O
at	O
least	O
30	O
minutes	O
before	O
or	O
after	O
giving	O
levoquin	I-Drug
and	O
protonix	I-Drug
.	O
21	O
.	O
Vitamin	B-Drug
D	I-Drug
400	O
unit	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
:	O
Please	O
give	O
before	O
meals	O
.	O
22	O
.	O
Warfarin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
23	O
.	O
Methotrexate	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
:	O
Fridays	O
and	O
Saturdays	O
ONLY	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
25759	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
1	O
.	O
Urosepsis	O
2	O
.	O
Cardiomyopathy	O
3	O
.	O
Pneumonia	O
4	O
.	O
Thrombocytopenia	O
5	O
.	O
TIA	O
Secondary	O
Diagnosis	O
:	O
6	O
.	O
Hypertension	O
7	O
.	O
Rheumatoid	O
arthritis	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Please	O
take	O
the	O
medications	O
as	O
prescribed	O
.	O
Please	O
check	O
INR	O
level	O
tomorrow	O
Saturday	O
[	O
**	O
2110-12-20	O
**	O
]	O
and	O
adjust	O
warfarin	I-Drug
dose	O
as	O
needed	O
for	O
goal	O
INR	O
between	O
2	O
and	O
3	O
.	O
Please	O
keep	O
your	O
follow	O
-	O
up	O
appointments	O
.	O
If	O
you	O
have	O
any	O
chest	O
pain	O
,	O
fevers	O
/	O
chills	O
,	O
difficulty	O
breathing	O
or	O
any	O
other	O
worrying	O
symptoms	O
please	O
call	O
your	O
primary	O
care	O
physician	O
or	O
come	O
to	O
the	O
emergency	O
room	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
Please	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
17863	O
**	O
]	O
on	O
[	O
**	O
2111-1-2	O
**	O
]	O
3:30	O
pm	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
31589	O
**	O
]	O
.	O
.	O
2	O
.	O
Please	O
follow	O
-	O
up	O
in	O
Cardiology	O
clinic	O
with	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1445	O
**	O
]	O
on	O
[	O
**	O
2111-1-5	O
**	O
]	O
10:30	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Center	O
Floor	O
7	O
Phone	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
9490	O
**	O
]	O
.	O
.	O
3	O
.	O
Please	O
follow	O
-	O
up	O
in	O
Heme	O
/	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
with	O
Dr.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3060	O
**	O
]	O
on	O
[	O
**	O
2110-2-20	O
**	O
]	O
10:00	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Center	O
Floor	O
9	O
Phone	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
31590	O
**	O
]	O
.	O
.	O
4	O
.	O
Please	O
follow	O
-	O
up	O
in	O
[	O
**	O
Hospital	O
878	O
**	O
]	O
clinic	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
1104	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
4638	O
**	O
]	O
on	O
[	O
**	O
2110-3-24	O
**	O
]	O
3:00	O
pm	O
Location	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Center	O
Floor	O
8	O
Phone	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22692	O
**	O
]	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2908	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
2909	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2110-12-19	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2165-6-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2165-7-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2112-7-5	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
78	O
**	O
]	O
Chief	O
Complaint	O
:	O
SAH	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
6	O
-	O
3	O
**	O
]	O
:	O
Rt	O
EVD	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
:	O
Distal	O
L	O
ICA	O
aneurysm	O
coiling	O
[	O
**	O
6	O
-	O
26	O
**	O
]	O
:	O
PEG	O
placment	O
History	O
of	O
Present	O
Illness	O
:	O
52F	O
w	O
/	O
o	O
PMH	O
,	O
reportedly	O
collapsed	O
in	O
early	O
evening	O
of	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
;	O
transported	O
to	O
OSH	O
where	O
whe	O
was	O
intubated	O
;	O
head	O
CT	O
showed	O
diffuse	O
SAH	O
;	O
tx	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
definitive	O
treatment	O
Past	O
Medical	O
History	O
:	O
None	O
Social	O
History	O
:	O
unknown	O
Family	O
History	O
:	O
unknown	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
102/64	O
107	O
20	O
100	O
%	O
Intubated	O
,	O
not	O
sedated	O
.	O
Pupils	O
:	O
3	O
mm	O
,	O
trace	O
reactive	O
,	O
bilat	O
.	O
No	O
eye	O
opening	O
.	O
No	O
vocal	O
response	O
.	O
Motor	O
:	O
internal	O
rotation	O
/	O
flexion	O
of	O
UE	O
to	O
stim	O
,	O
symetrically	O
.	O
Min	O
.	O
withdrawal	O
LE	O
to	O
stim	O
,	O
symetrically	O
.	O
DTRs	O
2	O
+	O
throughout	O
and	O
symetric	O
;	O
toes	O
downgoing	O
;	O
tone	O
:	O
normal	O
;	O
On	O
Discharge	O
:	O
XXXXXXXXX	O
Pertinent	O
Results	O
:	O
Labs	O
on	O
Admission	O
:	O
[	O
**	O
2165-6-3	O
**	O
]	O
10:38	O
PM	O
BLOOD	O
WBC	O
-	O
14.9	O
*	O
RBC	O
-	O
3.83	O
*	O
Hgb	O
-	O
12.5	O
Hct	O
-	O
39.2	O
MCV	O
-	O
102	O
*	O
MCH	O
-	O
32.7	O
*	O
MCHC	O
-	O
31.9	O
RDW	O
-	O
12.8	O
Plt	O
Ct	O
-	O
258	O
[	O
**	O
2165-6-3	O
**	O
]	O
10:38	O
PM	O
BLOOD	O
Neuts	O
-	O
73.8	O
*	O
Lymphs	O
-	O
21.1	O
Monos	O
-	O
3.9	O
Eos	O
-	O
0.7	O
Baso	O
-	O
0.5	O
[	O
**	O
2165-6-4	O
**	O
]	O
04:28	O
AM	O
BLOOD	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
23.7	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2165-6-3	O
**	O
]	O
10:38	O
PM	O
BLOOD	O
Glucose	O
-	O
245	O
*	O
UreaN	O
-	O
22	O
*	O
Creat	O
-	O
0.9	O
Na	O
-	O
140	O
K	O
-	O
3.5	O
Cl	O
-	O
105	O
HCO3	O
-	O
20	O
*	O
AnGap	O
-	O
19	O
[	O
**	O
2165-6-4	O
**	O
]	O
04:28	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
304	O
*	O
[	O
**	O
2165-6-4	O
**	O
]	O
04:28	O
AM	O
BLOOD	O
cTropnT	O
-	O
0.96	O
*	O
[	O
**	O
2165-6-4	O
**	O
]	O
12:31	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
21	O
*	O
MB	O
Indx	O
-	O
6.2	O
*	O
cTropnT	O
-	O
0.51	O
*	O
[	O
**	O
2165-6-4	O
**	O
]	O
09:36	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
12	O
*	O
MB	O
Indx	O
-	O
4.5	O
cTropnT	O
-	O
0.31	O
*	O
[	O
**	O
2165-6-5	O
**	O
]	O
02:55	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.13	O
*	O
[	O
**	O
2165-6-3	O
**	O
]	O
10:38	O
PM	O
BLOOD	O
Calcium	O
-	O
7.5	O
*	O
Phos	O
-	O
5.2	O
*	O
Mg	O
-	O
2.0	O
Labs	O
on	O
Discharge	O
:	O
XXXXXXXXXXXXXX	O
Imaging	O
:	O
CTA	O
Head	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Diffuse	O
subarachnoid	O
hemorrhage	O
as	O
described	O
above	O
with	O
a	O
multilobulated	O
left	O
ICA	O
terminus	O
aneurysm	O
measuring	O
approximately	O
4	O
x	O
6	O
mm	O
as	O
the	O
presumed	O
source	O
.	O
Traditional	O
angiography	O
pending	O
.	O
Cardiac	O
Echo	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
:	O
Conclusions	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
(	O
LVEF	O
=	O
20	O
--	O
25	O
%	O
)	O
.	O
There	O
is	O
severe	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
akinesis	O
of	O
mid-to-apical	O
myocardioum	O
.	O
Basal	O
and	O
Apex	O
areas	O
are	O
spared	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
The	O
number	O
of	O
aortic	O
valve	O
leaflets	O
can	O
not	O
be	O
determined	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
No	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
Moderate	O
to	O
severe	O
[	O
3	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
IMPRESSION	O
:	O
Severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
(	O
EF	O
20	O
-	O
25	O
%	O
)	O
with	O
regionality	O
;	O
akinesis	O
of	O
mid-to-apical	O
walls	O
with	O
sparing	O
of	O
the	O
apex	O
.	O
Right	O
ventricular	O
systolic	O
function	O
and	O
size	O
is	O
normal	O
.	O
Moderate	O
to	O
severe	O
(	O
3	O
+	O
)	O
tricuspid	O
regurgitation	O
.	O
CT	O
C	O
-	O
spine	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
:	O
IMPRESSIONS	O
:	O
1	O
.	O
No	O
acute	O
traumatic	O
injury	O
seen	O
in	O
the	O
cervical	O
spine	O
.	O
2	O
.	O
Blood	O
in	O
the	O
basal	O
cisterns	O
tracking	O
inferiorly	O
and	O
anteriorly	O
along	O
the	O
brainstem	O
and	O
upper	O
spinal	O
cord	O
.	O
Thecal	O
sac	O
contents	O
are	O
not	O
adequately	O
assessed	O
on	O
the	O
present	O
study	O
.	O
MR	O
can	O
be	O
considered	O
if	O
there	O
is	O
concern	O
based	O
on	O
neurological	O
examination	O
.	O
3	O
.	O
Airspace	O
consolidation	O
in	O
the	O
posterior	O
lung	O
apices	O
with	O
smooth	O
septal	O
thickening	O
.	O
Findings	O
along	O
with	O
chest	O
radiograph	O
likely	O
represents	O
some	O
pulmonary	O
edema	O
,	O
although	O
aspiration	O
can	O
not	O
be	O
excluded	O
.	O
CT	O
Head	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
:	O
FINDINGS	O
:	O
The	O
diffuse	O
subarachnoid	O
hemorrhage	O
appears	O
stable	O
in	O
extent	O
.	O
Overall	O
,	O
ventricular	O
size	O
has	O
further	O
decreased	O
,	O
compared	O
to	O
the	O
prior	O
study	O
.	O
The	O
ventriculostomy	O
catheter	O
terminating	O
in	O
the	O
region	O
of	O
the	O
third	O
ventricle	O
remains	O
present	O
.	O
There	O
has	O
been	O
further	O
interval	O
progression	O
of	O
bilateral	O
regions	O
of	O
hypoattenuation	O
involving	O
the	O
medial	O
inferior	O
frontal	O
lobes	O
.	O
There	O
is	O
no	O
associated	O
parenchymal	O
hemorrhage	O
.	O
There	O
is	O
no	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
The	O
streak	O
artifact	O
produced	O
by	O
left	O
distal	O
internal	O
carotid	O
artery	O
coils	O
obscures	O
evaluation	O
in	O
area	O
.	O
The	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
is	O
preserved	O
.	O
Trace	O
intraventricular	O
hemorrhage	O
layering	O
posteriorly	O
in	O
the	O
occipital	O
horns	O
as	O
well	O
as	O
small	O
amount	O
in	O
the	O
third	O
ventricle	O
are	O
stable	O
.	O
The	O
mastoid	O
air	O
cells	O
and	O
imaged	O
paranasal	O
sinuses	O
remain	O
well	O
aerated	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Slight	O
decrease	O
in	O
ventricular	O
size	O
,	O
compared	O
to	O
the	O
prior	O
study	O
.	O
2	O
.	O
Further	O
evolution	O
of	O
bifrontal	O
hypoattenuation	O
,	O
which	O
may	O
represent	O
infarcts	O
rather	O
than	O
non-hemorrhagic	O
contusion	O
,	O
given	O
the	O
progression	O
.	O
No	O
parenchymal	O
hemorrhage	O
.	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
head	O
can	O
be	O
considered	O
,	O
if	O
necessary	O
to	O
assess	O
extent	O
and	O
vessels	O
as	O
recommended	O
earlier	O
.	O
3	O
.	O
Stable	O
extent	O
of	O
diffuse	O
subarachnoid	O
hemorrhage	O
.	O
CXR	O
[	O
**	O
2165-6-5	O
**	O
]	O
Final	O
Report	O
INDICATION	O
:	O
52	O
-	O
year	O
-	O
old	O
female	O
with	O
subarachnoid	O
hemorrhage	O
,	O
dilated	O
cardiomyopathy	O
.	O
Evaluate	O
for	O
pulmonary	O
edema	O
.	O
Single	O
AP	O
chest	O
radiographs	O
compared	O
to	O
13	O
hours	O
prior	O
shows	O
no	O
change	O
.	O
ET	O
tube	O
tip	O
is	O
2.3	O
cm	O
above	O
the	O
carina	O
.	O
Left	O
internal	O
jugular	O
central	O
venous	O
catheter	O
terminates	O
in	O
the	O
mid	O
SVC	O
.	O
The	O
NG	O
tube	O
tip	O
is	O
in	O
the	O
stomach	O
,	O
the	O
sidehole	O
slightly	O
below	O
the	O
gastroesophageal	O
junction	O
.	O
The	O
cardiomediastinal	O
silhouette	O
is	O
stable	O
.	O
Again	O
seen	O
are	O
bilateral	O
perihilar	O
opacities	O
consistent	O
with	O
pulmonary	O
edema	O
,	O
not	O
significantly	O
changed	O
from	O
prior	O
exam	O
.	O
There	O
is	O
no	O
pneumothorax	O
or	O
pleural	O
effusion	O
.	O
IMPRESSION	O
:	O
Compared	O
to	O
prior	O
exam	O
from	O
[	O
**	O
2165-6-5	O
**	O
]	O
,	O
there	O
is	O
no	O
change	O
in	O
the	O
extent	O
of	O
pulmonary	O
edema	O
.	O
Cardiac	O
Echo	O
:	O
[	O
**	O
2165-6-11	O
**	O
]	O
Conclusions	O
No	O
spontaneous	O
echo	O
contrast	O
or	O
thrombus	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
/	O
left	O
atrial	O
appendage	O
or	O
the	O
body	O
of	O
the	O
right	O
atrium	O
/	O
right	O
atrial	O
appendage	O
.	O
Right	O
atrial	O
appendage	O
ejection	O
velocity	O
is	O
good	O
(	O
>	O
20	O
cm	O
/	O
s	O
)	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
(	O
LVEF	O
=	O
20	O
-	O
25	O
%	O
)	O
.	O
with	O
mild	O
global	O
free	O
wall	O
hypokinesis	O
.	O
with	O
focal	O
hypokinesis	O
of	O
the	O
apical	O
free	O
wall	O
.	O
There	O
is	O
no	O
mass	O
/	O
thrombus	O
in	O
the	O
right	O
ventricle	O
.	O
The	O
ascending	O
,	O
transverse	O
and	O
descending	O
thoracic	O
aorta	O
are	O
normal	O
in	O
diameter	O
and	O
free	O
of	O
atherosclerotic	O
plaque	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
small	O
pericardial	O
effusion	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
Compared	O
with	O
the	O
findings	O
of	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2165-6-4	O
**	O
]	O
,	O
left	O
ventricular	O
systolic	O
function	O
has	O
improved	O
.	O
Akinesis	O
of	O
mid-to-apical	O
walls	O
with	O
sparing	O
of	O
the	O
apex	O
has	O
resolved	O
.	O
Final	O
Report	O
PORTABLE	O
CHEST	O
[	O
**	O
2165-6-19	O
**	O
]	O
:	O
COMPARISON	O
:	O
Study	O
of	O
earlier	O
the	O
same	O
date	O
.	O
INDICATION	O
:	O
Feeding	O
tube	O
assessment	O
.	O
FINDINGS	O
:	O
Feeding	O
tube	O
tip	O
is	O
directed	O
cephalad	O
in	O
region	O
of	O
gastroduodenal	O
junction	O
.	O
Appearance	O
of	O
the	O
chest	O
is	O
similar	O
to	O
the	O
recent	O
radiograph	O
of	O
about	O
2	O
hours	O
earlier	O
except	O
for	O
minimal	O
improved	O
aeration	O
in	O
the	O
left	O
retrocardiac	O
region	O
.	O
[	O
**	O
2165-6-25	O
**	O
]	O
12:25	O
PM	O
CT	O
HEAD	O
CT	O
:	O
Axial	O
imaging	O
was	O
performed	O
through	O
the	O
brain	O
without	O
IV	O
contrast	I-Drug
administration	O
.	O
COMPARISON	O
:	O
CT	O
head	O
[	O
**	O
2165-6-23	O
**	O
]	O
.	O
FINDINGS	O
:	O
There	O
is	O
a	O
tract	O
of	O
hypodensity	O
extending	O
along	O
the	O
course	O
of	O
the	O
prior	O
right	O
frontal	O
approach	O
ventriculostomy	O
catheter	O
(	O
2:13	O
)	O
.	O
There	O
is	O
no	O
hyperdensity	O
along	O
this	O
tract	O
to	O
suggest	O
the	O
presence	O
of	O
hemorrhage	O
.	O
The	O
ventricles	O
are	O
unchanged	O
in	O
size	O
and	O
configuration	O
.	O
There	O
is	O
streak	O
artifact	O
from	O
a	O
left	O
ICA	O
aneurysm	O
coil	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
remains	O
well	O
preserved	O
.	O
There	O
is	O
no	O
evidence	O
of	O
prior	O
subarachnoid	O
hemorrhage	O
.	O
There	O
is	O
no	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
There	O
is	O
hypodensity	O
in	O
the	O
territory	O
of	O
the	O
left	O
MCA	O
related	O
to	O
prior	O
infarct	O
(	O
2:15	O
)	O
,	O
which	O
appear	O
stable	O
without	O
evidence	O
for	O
hemorrhagic	O
transformation	O
.	O
There	O
is	O
a	O
right	O
frontal	O
burr	O
hole	O
otherwise	O
osseous	O
structures	O
are	O
intact	O
.	O
The	O
paranasal	O
sinuses	O
,	O
ethmoid	O
,	O
and	O
mastoid	O
air	O
cells	O
are	O
clear	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Post-right	O
frontal	O
approach	O
ventriculostomy	O
catheter	O
removal	O
without	O
evidence	O
for	O
hemorrhage	O
.	O
Stable	O
ventricular	O
size	O
.	O
2	O
.	O
Unchanged	O
appearance	O
to	O
region	O
of	O
infarction	O
in	O
the	O
left	O
MCA	O
distribution	O
without	O
hemorrhagic	O
transformation	O
.	O
SAT	O
[	O
**	O
2165-6-22	O
**	O
]	O
12:08	O
PM	O
Final	O
Report	O
INDICATION	O
:	O
52	O
-	O
year	O
-	O
old	O
female	O
with	O
transaminitis	O
and	O
fevers	O
.	O
Evaluate	O
right	O
upper	O
quadrant	O
.	O
COMPARISON	O
:	O
CT	O
chest	O
dated	O
[	O
**	O
2165-6-7	O
**	O
]	O
.	O
FINDINGS	O
:	O
The	O
liver	O
is	O
normal	O
in	O
contour	O
and	O
echotexture	O
.	O
There	O
is	O
a	O
single	O
1.2	O
-	O
cm	O
cyst	O
identified	O
in	O
the	O
periphery	O
of	O
the	O
right	O
dome	O
.	O
There	O
are	O
no	O
other	O
focal	O
liver	O
lesions	O
identified	O
.	O
There	O
is	O
no	O
intrahepatic	O
or	O
extrahepatic	O
biliary	O
ductal	O
dilatation	O
.	O
The	O
common	O
bile	O
duct	O
measures	O
5	O
mm	O
.	O
The	O
gallbladder	O
is	O
unremarkable	O
,	O
with	O
no	O
wall	O
thickening	O
,	O
no	O
pericholecystic	O
fluid	O
.	O
There	O
are	O
no	O
stones	O
or	O
sludge	O
identified	O
within	O
the	O
gallbladder	O
.	O
There	O
is	O
normal	O
antegrade	O
flow	O
identified	O
in	O
the	O
main	O
portal	O
vein	O
.	O
The	O
spleen	O
measures	O
8.7	O
cm	O
and	O
is	O
normal	O
in	O
appearance	O
.	O
There	O
is	O
no	O
free	O
fluid	O
in	O
the	O
abdomen	O
.	O
Small	O
right	O
pleural	O
effusion	O
is	O
noted	O
.	O
IMPRESSION	O
:	O
1	O
.	O
1.2	O
-	O
cm	O
cyst	O
in	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
,	O
as	O
appreciated	O
on	O
CT	O
of	O
the	O
chest	O
dated	O
[	O
**	O
2165-6-7	O
**	O
]	O
.	O
Liver	O
is	O
otherwise	O
unremarkable	O
.	O
2	O
.	O
No	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
493	O
**	O
]	O
evidence	O
for	O
acute	O
cholecystitis	O
.	O
No	O
cholelithiasis	O
.	O
Brief	O
Hospital	O
Course	O
:	O
52F	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
after	O
transfer	O
from	O
OSH	O
following	O
a	O
witnessed	O
syncopal	O
episode	O
.	O
Head	O
CT	O
performed	O
showing	O
diffuse	O
SAH	I-Reason
.	O
CTA	O
of	O
head	O
also	O
performed	O
with	O
preliminarily	O
identified	O
an	O
aneurysm	I-Reason
at	O
the	O
left	O
ICA	O
bifurcation	O
.	O
She	O
was	O
loaded	O
with	O
dilantin	I-Drug
,	O
and	O
started	O
on	O
nimodipine	I-Drug
,	O
and	O
emergent	O
bedside	O
external	O
ventricular	O
drain	O
was	O
placed	O
.	O
She	O
also	O
had	O
a	O
cardiac	O
echo	O
done	O
for	O
concerns	O
of	O
a	O
catacholamine	O
induced	O
cardiomyopathy	O
(	O
had	O
developed	O
pulmonary	O
edema	O
)	O
,	O
which	O
showed	O
significantly	O
depressed	O
cardic	O
function	O
.	O
She	O
was	O
placed	O
on	O
a	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
18821	O
**	O
]	O
monitor	O
to	O
more	O
closely	O
monitor	O
for	O
this	O
.	O
She	O
had	O
an	O
angiogram	O
done	O
on	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
,	O
when	O
the	O
left	O
distal	O
ICA	O
aneurysm	O
was	O
coiled	O
.	O
She	O
then	O
returned	O
to	O
the	O
ICU	O
postoperatively	O
.	O
On	O
[	O
**	O
6	O
-	O
5	O
**	O
]	O
(	O
overnight	O
)	O
she	O
had	O
a	O
ICP	O
elevation	O
to	O
50	O
and	O
the	O
drain	O
was	O
promplty	O
dropped	O
to	O
10	O
cm	O
,	O
and	O
ICP	O
normalized	O
.	O
Emergent	O
head	O
CT	O
was	O
done	O
which	O
showed	O
likely	O
evolving	O
brifrontal	O
hypoattenuations	O
/	O
possible	O
stroke	O
.	O
She	O
again	O
returned	O
to	O
angio	O
on	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
to	O
further	O
evaluate	O
vascualar	O
patency	O
given	O
this	O
new	O
CT	O
finding.The	O
patient	O
was	O
febrile	O
with	O
a	O
Tmax	O
101.6	O
and	O
was	O
pan	O
cultured	O
,	O
the	O
urine	O
and	O
cerebral	O
spinal	O
fluid	O
cultures	O
were	O
both	O
neagtive	O
.	O
On	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
The	O
Dobutamine	I-Drug
intravenous	O
drip	O
was	O
off	O
,	O
vasopressors	I-Drug
Levophed	I-Drug
and	O
neo	I-Drug
cont	O
.	O
The	O
Nimodipine	I-Drug
cut	O
in	O
[	O
**	O
12	O
-	O
21	O
**	O
]	O
to	B-Reason
maintain	I-Reason
goal	I-Reason
blood	I-Reason
pressures	I-Reason
.	O
The	O
patient	O
was	O
brought	O
to	O
angio	O
,	O
there	O
was	O
no	O
significant	O
spasm	O
and	O
given	O
5	O
mg	O
verapamil	I-Drug
-	O
aneurysm	I-Reason
stable	O
.	O
Blood	O
cultures	O
were	O
found	O
to	O
be	O
negative	O
.	O
The	O
sputum	O
culture	O
was	O
positive	O
for	O
rare	O
yeast.On	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
:	O
The	O
patient	O
had	O
an	O
acute	O
PaO2	O
decrease	O
to	O
50	O
%	O
.	O
There	O
was	O
a	O
concern	O
for	O
Pulmonary	O
embolusE	O
.	O
The	O
CTA	O
of	O
the	O
Chest	O
was	O
not	O
consistent	O
with	O
Pulmonary	O
embolus	O
.	O
The	O
CT	O
Head	O
was	O
unchanged	O
.	O
The	O
patient	O
was	O
moniotored	O
for	O
possible	O
Central	O
Diabetes	O
Insipidus	O
.	O
The	O
urine	O
and	O
sputum	O
cultures	O
were	O
both	O
negative	O
.	O
On	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
,	O
The	O
patient	O
was	O
pan-cultured	O
for	O
a	O
fever	O
to	O
102	O
.	O
A	O
head	O
CT	O
ordered	O
for	O
elevated	O
ICP	O
to	O
44	O
,	O
Mannitol	I-Drug
was	O
initiated	O
for	O
increased	B-Reason
ICPs	I-Reason
.	O
A	O
CTA	O
was	O
performed	O
which	O
was	O
consistent	O
with	O
a	O
slight	O
decrease	O
in	O
intercranial	O
vasospasm	O
.	O
On	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
,	O
The	O
patient	O
required	O
3	O
doses	O
of	O
mannitol	I-Drug
for	O
sustained	B-Reason
ICP	I-Reason
levels	I-Reason
of	I-Reason
23	I-Reason
.	O
There	O
were	O
no	O
changes	O
in	O
the	O
patients	O
mental	O
status	O
with	O
these	O
ICP	O
increases.On	O
exam	O
the	O
patient	O
was	O
intermitently	O
following	O
commands	O
in	O
the	O
right	O
upper	O
extremity	O
,	O
the	O
left	O
upper	O
extremity	O
moved	O
to	O
command	O
,	O
the	O
left	O
lower	O
extremity	O
and	O
Right	O
upper	O
extremity	O
withdrew	O
to	O
pain	O
,	O
the	O
patients	O
eyes	O
were	O
open	O
and	O
tracked	O
with	O
her	O
eyes	O
.	O
On	O
[	O
**	O
6	O
-	O
10	O
**	O
]	O
,	O
The	O
patient	O
was	O
back	O
on	O
a	O
dobutamine	I-Drug
gtt	O
continuously	O
to	O
maintain	O
a	O
goal	O
blood	O
pressure	O
,	O
The	O
patient	O
had	O
a	O
TEE	O
which	O
was	O
consistent	O
with	O
Ejection	O
F	O
of	O
20	O
%	O
.	O
The	O
LENIS	O
were	O
negative	O
for	O
deep	O
vein	O
thrombosis	O
,	O
The	O
CSF	O
and	O
sputum	O
cultures	O
were	O
negative	O
.	O
On	O
[	O
**	O
6	O
-	O
11	O
**	O
]	O
,	O
The	O
patient	O
underwent	O
an	O
angio	O
which	O
was	O
consistent	O
with	O
mild	O
to	O
mod	O
vasospasm	O
.	O
She	O
recieved	O
2	O
doses	O
of	O
verapamil.Nimodipine	B-Drug
at	O
15	O
mg	O
every	O
2	O
hours	O
was	O
restarted	O
.	O
On	O
[	O
**	O
6	O
-	O
12	O
**	O
]	O
,	O
The	O
patient	O
was	O
bolused	O
with	O
dilantin	I-Drug
300	O
mg	O
for	O
a	O
7.9	O
level	O
.	O
The	O
Head	O
CT	O
was	O
repeated	O
and	O
was	O
stable	O
.	O
The	O
patient	O
was	O
extubated	O
and	O
stopped	O
nimodpine	I-Drug
for	O
systolic	B-Ade
blood	I-Ade
pressure	I-Ade
in	I-Ade
60's	I-Ade
.	O
The	O
goal	B-Reason
MAP	I-Reason
>	I-Reason
100	I-Reason
and	O
dobutamine	I-Drug
was	O
restarted	O
.	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
CT	O
shows	O
:	O
new	O
stroke	O
in	O
the	O
posterior	O
left	O
MCA	O
distribution	O
CTA	O
shows	O
diffuse	O
,	O
severe	O
vasospasm	O
involving	O
the	O
bilateral	O
MCAs	O
(	O
left	O
worse	O
than	O
right	O
)	O
the	O
following	O
day	O
she	O
underwent	O
a	O
cerebral	O
angiogram	O
which	O
showed	O
Mild	O
to	O
moderate	O
spasm	O
Left	O
A1	O
,2	O
and	O
M1	O
,2	O
segments	O
though	O
her	O
exam	O
seemed	O
to	O
slightly	O
improve	O
with	O
brisk	O
localization	O
on	O
LUE	O
and	O
localization	O
on	O
RUE	O
though	O
not	O
as	O
brisk	O
as	O
left	O
.	O
She	O
had	O
some	O
intermittent	O
eye	O
opening	O
.	O
A	O
stroke	O
neurology	O
consult	O
was	O
obtained	O
and	O
they	O
agreed	O
with	O
our	O
continued	O
HHH	O
management	O
and	O
requested	O
starting	O
a	O
Statin	I-Drug
.	O
On	O
[	O
**	O
6	O
-	O
17	O
**	O
]	O
,	O
she	O
was	O
again	O
febrile	O
,	O
and	O
pan	O
cultured	O
.	O
CVL	O
access	O
was	O
changed	O
and	O
catheter	O
tip	O
sent	O
.	O
OR	O
was	O
cancelled	O
for	O
the	O
day	O
for	O
her	O
temperature	O
,	O
and	O
possibly	O
to	O
re-attempt	O
[	O
**	O
6	O
-	O
19	O
**	O
]	O
or	O
[	O
**	O
6	O
-	O
20	O
**	O
]	O
if	O
afebrile	O
and	O
no	O
positive	O
cultures	O
.	O
Positive	O
blood	O
cx	O
from	O
arterial	O
line	O
and	O
appearance	O
of	O
axillary	O
A	O
line	O
,	O
concerned	O
for	O
line	O
infection	O
and	O
she	O
was	O
treated	O
for	O
line	O
associated	O
bacteremia	O
for	O
7	O
day	O
course	O
.	O
PEG	O
placed	O
by	O
surgery	O
team	O
on	O
[	O
**	O
2165-6-26	O
**	O
]	O
without	O
event	O
.	O
Meds	O
and	O
diet	O
were	O
advanced	O
through	O
PEG	O
as	O
recommended	O
without	O
issue	O
.	O
On	O
discharge	O
her	O
neurological	O
exam	O
she	O
preferred	O
her	O
eyes	O
closed	O
would	O
open	O
to	O
voice	O
,	O
questionable	O
following	O
commands	O
with	O
left	O
side	O
.	O
She	O
is	O
essentially	O
plegic	O
on	O
right	O
side	O
but	O
will	O
withdraw	O
both	O
arm	O
and	O
leg	O
to	O
pain	O
.	O
Her	O
pupils	O
are	O
4	O
mm	O
and	O
reactive	O
,	O
her	O
incision	O
are	O
well	O
healed	O
.	O
She	O
was	O
tolerating	O
her	O
tube	O
feeds	O
without	O
difficulty	O
.	O
Speech	O
and	O
swallow	O
recommends	O
video	O
swallow	O
before	O
initiating	O
any	O
oral	O
feeds	O
.	O
Medications	O
on	O
Admission	O
:	O
Unknown	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fevers	I-Reason
.	O
2	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
3	O
.	O
Insulin	I-Drug
Regular	O
Human	O
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
4	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Ibuprofen	B-Drug
100	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
.	O
6	O
.	O
Famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
stridor	I-Reason
.	O
8	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
rash	I-Reason
.	O
9	O
.	O
Atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Levetiracetam	I-Drug
100	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
12	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
13	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
thrush	I-Reason
.	O
14	O
.	O
Bupropion	I-Drug
HCl	O
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
Aspirin	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
85	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
SAH	O
Left	O
ICA	O
bifurcation	O
aneurysm	O
dysphagia	O
pulmonary	O
edema	O
cerebral	O
vasospasm	O
cardiogenic	O
shock	O
d	O
/	O
t	O
sympathetic	O
surge	O
stroke	O
left	O
MCA	O
distribution	O
bifrontal	O
strokes	O
fever	O
/	O
central	O
bacteremia	O
/	O
coag	O
neg	O
staph	O
altered	O
mental	O
status	O
mutism	O
Discharge	O
Condition	O
:	O
Neurologically	O
with	O
right	O
sided	O
plegia	O
and	O
mutism	O
intermittently	O
follows	O
commands	O
Discharge	O
Instructions	O
:	O
Angiogram	O
with	O
Embolization	O
and	O
/	O
or	O
Stent	O
placement	O
Medications	O
:	O
??????	O
Take	O
Aspirin	I-Drug
325	O
mg	O
(	O
enteric	O
coated	O
)	O
once	O
daily	O
.	O
??????	O
Continue	O
all	O
other	O
medications	O
you	O
were	O
taking	O
before	O
surgery	O
,	O
unless	O
otherwise	O
directed	O
??????	O
You	O
make	O
take	O
Tylenol	I-Drug
or	O
prescribed	O
pain	B-Drug
medications	I-Drug
for	O
any	O
post	B-Reason
procedure	I-Reason
pain	I-Reason
or	I-Reason
discomfort	I-Reason
.	O
What	O
activities	O
you	O
can	O
and	O
can	O
not	O
do	O
:	O
??????	O
When	O
you	O
go	O
home	O
,	O
you	O
may	O
walk	O
and	O
go	O
up	O
and	O
down	O
stairs	O
.	O
??????	O
You	O
may	O
shower	O
(	O
let	O
the	O
soapy	O
water	O
run	O
over	O
groin	O
incision	O
,	O
rinse	O
and	O
pat	O
dry	O
)	O
??????	O
Your	O
incision	O
may	O
be	O
left	O
uncovered	O
,	O
unless	O
you	O
have	O
small	O
amounts	O
of	O
drainage	O
from	O
the	O
wound	O
,	O
then	O
place	O
a	O
dry	O
dressing	O
or	O
band	O
aid	O
over	O
the	O
area	O
that	O
is	O
draining	O
,	O
as	O
needed	O
??????	O
No	O
heavy	O
lifting	O
,	O
pushing	O
or	O
pulling	O
(	O
greater	O
than	O
5	O
lbs	O
)	O
for	O
1	O
week	O
(	O
to	O
allow	O
groin	O
puncture	O
to	O
heal	O
)	O
.	O
??????	O
After	O
1	O
week	O
,	O
you	O
may	O
resume	O
sexual	O
activity	O
.	O
??????	O
After	O
1	O
week	O
,	O
gradually	O
increase	O
your	O
activities	O
and	O
distance	O
walked	O
as	O
you	O
can	O
tolerate	O
.	O
??????	O
No	O
driving	O
until	O
you	O
are	O
no	O
longer	O
taking	O
pain	B-Drug
medications	I-Drug
What	O
to	O
report	O
to	O
office	O
:	O
??????	O
Changes	O
in	O
vision	O
(	O
loss	O
of	O
vision	O
,	O
blurring	O
,	O
double	O
vision	O
,	O
half	O
vision	O
)	O
??????	O
Slurring	O
of	O
speech	O
or	O
difficulty	O
finding	O
correct	O
words	O
to	O
use	O
??????	O
Severe	B-Reason
headache	I-Reason
or	O
worsening	B-Reason
headache	I-Reason
not	O
controlled	O
by	O
pain	I-Drug
medication	O
??????	O
A	O
sudden	O
change	O
in	O
the	O
ability	O
to	O
move	O
or	O
use	O
your	O
arm	O
or	O
leg	O
or	O
the	O
ability	O
to	O
feel	O
your	O
arm	O
or	O
leg	O
??????	O
Trouble	O
swallowing	O
,	O
breathing	O
,	O
or	O
talking	O
??????	O
Numbness	O
,	O
coldness	O
or	O
pain	O
in	O
lower	O
extremities	O
??????	O
Temperature	O
greater	O
than	O
101.5	O
F	O
for	O
24	O
hours	O
??????	O
New	O
or	O
increased	O
drainage	O
from	O
incision	O
or	O
white	O
,	O
yellow	O
or	O
green	O
drainage	O
from	O
incisions	O
??????	O
Bleeding	O
from	O
groin	O
puncture	O
site	O
*	O
SUDDEN	O
,	O
SEVERE	O
BLEEDING	O
OR	O
SWELLING	O
(	O
Groin	O
puncture	O
site	O
)	O
Lie	O
down	O
,	O
keep	O
leg	O
straight	O
and	O
have	O
someone	O
apply	O
firm	O
pressure	O
to	O
area	O
for	O
10	O
minutes	O
.	O
If	O
bleeding	O
stops	O
,	O
call	O
our	O
office	O
.	O
If	O
bleeding	O
does	O
not	O
stop	O
,	O
call	O
911	O
for	O
transfer	O
to	O
closest	O
Eme	O
Followup	O
Instructions	O
:	O
Please	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1669	O
**	O
]	O
to	O
schedule	O
an	O
appointment	O
to	O
be	O
seen	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
approx	O
4	O
weeks	O
after	O
your	O
discharge	O
.	O
You	O
will	O
need	O
to	O
have	O
a	O
CT	O
scan	O
of	O
the	O
head	O
without	O
contrast	O
at	O
that	O
time	O
Completed	O
by	O
:[	O
**	O
2165-7-3	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2118-4-18	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2118-4-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2088-12-21	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
358	O
**	O
]	O
Chief	O
Complaint	O
:	O
transfer	O
for	O
renal	O
failure	O
and	O
severe	O
hypertension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
tunnelled	O
HD	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
29	O
y	O
/	O
o	O
M	O
no	O
PMH	O
p	O
/	O
w	O
HTN	O
and	O
renal	O
failure	O
.	O
He	O
had	O
been	O
in	O
USOH	O
until	O
1	O
month	O
prior	O
to	O
admission	O
when	O
he	O
began	O
feeling	O
increased	O
fatigue	O
.	O
Then	O
,	O
1	O
week	O
prior	O
to	O
admission	O
he	O
began	O
feeling	O
worsening	O
malaise	O
and	O
decreased	O
PO	O
intake	O
.	O
He	O
denied	O
any	O
fever	O
,	O
chills	O
,	O
HA	O
,	O
chest	O
pain	O
.	O
Then	O
,	O
on	O
morning	O
of	O
admission	O
,	O
he	O
developed	O
acute	O
onset	O
severe	O
upper	O
abd	O
pain	O
which	O
radiated	O
to	O
his	O
back	O
and	O
lasted	O
for	O
5	O
hours	O
.	O
he	O
then	O
went	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
Hosp	O
ED	O
.	O
At	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
97.4	O
,	O
77	O
,	O
229/137	O
,	O
100	O
%	O
RA	O
.	O
Hct	O
22	O
and	O
creatinine	O
found	O
to	O
be	O
23	O
.	O
CXR	O
and	O
KUB	O
negative	O
by	O
report	O
.	O
He	O
was	O
started	O
on	O
labatalol	I-Drug
gtt	O
with	O
decrease	O
in	O
BP	O
to	O
170	O
's	O
and	O
received	O
dilaudid	I-Drug
and	O
zofran	I-Drug
.	O
He	O
was	O
sent	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
care	O
.	O
.	O
In	O
the	O
emergency	O
department	O
,	O
initial	O
vitals	O
:	O
98.5	O
,	O
151/90	O
,	O
55	O
,	O
18	O
,	O
100	O
%	O
RA	O
.	O
He	O
was	O
continued	O
on	O
labetalol	I-Drug
gtt	O
.	O
CTA	O
abd	O
/	O
pelvis	O
was	O
negative	O
for	O
dissection	O
.	O
He	O
had	O
guaiac	O
positive	O
brown	O
stool	O
in	O
ED	O
.	O
he	O
was	O
seen	O
by	O
renal	O
in	O
ED	O
.	O
.	O
Upon	O
arrival	O
to	O
ICU	O
,	O
he	O
currently	O
reports	O
only	O
fatigue	O
.	O
He	O
denies	O
any	O
pain	O
,	O
N	O
/	O
V	O
,	O
abd	O
discomfort	O
.	O
He	O
denies	O
any	O
chest	O
pain	O
,	O
palpitations	O
,	O
headache	O
,	O
vision	O
changes	O
.	O
He	O
had	O
been	O
taking	O
[	O
**	O
1	O
-	O
18	O
**	O
]	O
advil	I-Drug
every	O
other	O
day	O
X	O
1	O
month	O
,	O
but	O
stopped	O
last	O
week	O
.	O
Past	O
Medical	O
History	O
:	O
None	O
Social	O
History	O
:	O
Smoking	O
:	O
none	O
EtOH	O
:	O
none	O
IVDU	O
:	O
denies	O
Family	O
History	O
:	O
Denies	O
renal	O
dz	O
,	O
HTN	O
,	O
DM	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
97.2	O
BP	O
147/75	O
(	O
147-187/76	O
-	O
100	O
)	O
HR	O
67	O
-	O
79	O
RR	O
14	O
O2	O
98	O
%	O
RA	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
temp	O
HD	O
line	O
in	O
R	O
neck	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
Warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Pertinent	O
Results	O
:	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
WBC	O
-	O
9.7	O
RBC	O
-	O
2.73	O
*	O
HGB	O
-	O
7.7	O
*	O
HCT	O
-	O
22.4	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
28.4	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
14.6	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
HCV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
ASA	O
-	O
NEG	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
CRP	O
-	O
5.4	O
*	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
HBsAg	O
-	O
NEGATIVE	O
HBs	O
Ab	O
-	O
POSITIVE	O
HBc	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
TRIGLYCER	O
-	O
288	O
*	O
HDL	O
CHOL	O
-	O
25	O
CHOL	O
/	O
HDL	O
-	O
8.6	O
LDL	O
(	O
CALC	O
)	O
-	O
132	O
*	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
CK	O
-	O
MB	O
-	O
3	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
LIPASE	O
-	O
65	O
*	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:35	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
6	O
AST	O
(	O
SGOT	O
)	O
-	O
9	O
LD	O
(	O
LDH	O
)	O
-	O
470	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
681	O
*	O
ALK	O
PHOS	O
-	O
54	O
TOT	O
BILI	O
-	O
0.3	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:45	O
AM	O
URINE	O
EOS	O
-	O
NEGATIVE	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:45	O
AM	O
URINE	O
AMORPH	O
-	O
RARE	O
[	O
**	O
2118-4-18	O
**	O
]	O
04:45	O
AM	O
URINE	O
COLOR	O
-	O
Straw	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.011	O
[	O
**	O
2118-4-18	O
**	O
]	O
05:04	O
AM	O
URINE	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
opiates	O
-	O
NEG	O
cocaine	O
-	O
NEG	O
amphetmn	O
-	O
NEG	O
mthdone	O
-	O
NEG	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
negative	O
,	O
HIV	O
negative	O
,	O
C3	O
c4	O
normal	O
Brief	O
Hospital	O
Course	O
:	O
Mr	O
[	O
**	O
Known	O
lastname	O
82740	O
**	O
]	O
is	O
a	O
29	O
yo	O
M	O
,	O
with	O
acute	O
on	O
chronic	O
renal	O
failure	O
on	O
HD	O
and	O
HTN	I-Reason
controled	O
on	O
PO	O
meds	I-Drug
.	O
.	O
#	O
Acute	O
on	O
chronic	O
renal	O
failure	O
,	O
initiation	O
of	O
HD	O
-	O
His	O
renal	O
failure	O
appears	O
to	O
be	O
of	O
chronic	O
etiology	O
.	O
His	O
symptoms	O
,	O
including	O
had	O
leg	O
swelling	O
,	O
mental	O
status	O
,	O
and	O
abdominal	O
pain	O
/	O
nausea	O
have	O
worsened	O
over	O
months	O
to	O
two	O
years	O
.	O
The	O
urine	O
sediment	O
anaylsis	O
had	O
very	O
large	O
waxy	O
brown	O
muddy	O
casts	O
,	O
consistent	O
with	O
a	O
chronic	O
renal	O
failure	O
picture	O
in	O
addition	O
to	O
possible	O
ATN	I-Ade
that	O
could	O
have	O
been	O
induced	O
in	O
the	O
setting	O
of	O
NSAID	I-Drug
use	O
.	O
Despite	O
nephrotic	O
range	O
proteinuria	O
,	O
the	O
patient	O
does	O
not	O
have	O
clinically	O
overt	O
nephrotic	O
stigma	O
of	O
diffuse	O
edema	O
.	O
.	O
Definitive	O
diagnosis	O
is	O
to	O
be	O
made	O
upon	O
results	O
of	O
kindey	O
biopsy	O
that	O
was	O
done	O
the	O
day	O
prior	O
to	O
discharge	O
.	O
Prilimiary	O
differential	O
is	O
most	O
likely	O
for	O
focal	O
segmental	O
glomulonephritis	O
given	O
age	O
,	O
ethinithy	O
,	O
and	O
severity	O
of	O
disease	O
.	O
However	O
,	O
all	O
hepatic	O
and	O
HIV	O
serologies	O
were	O
negative	O
.	O
Second	O
most	O
likely	O
given	O
the	O
severity	O
of	O
the	O
hypertension	O
is	O
hypertensive	O
glomulerosclerosis	O
.	O
ANCA	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
,	O
HIV	O
,	O
hepatitis	O
serologies	O
negative	O
.	O
Normal	O
c3	O
c4	O
complement	O
levels	O
and	O
normal	O
SPEP	O
.	O
Urine	O
tox	O
screen	O
was	O
negative	O
.	O
.	O
Patient	O
was	O
receiving	O
daily	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
through	O
a	O
tunnelled	O
HD	O
line	O
at	O
the	O
time	O
of	O
discharge	O
and	O
was	O
clinically	O
stable	O
.	O
Patient	O
did	O
not	O
have	O
any	O
symptoms	O
consistent	O
with	O
uremia	O
-	O
no	O
more	O
vague	O
abdominal	O
symptoms	O
,	O
pericarditis	O
,	O
or	O
altered	O
mental	O
status	O
.	O
Patient	O
was	O
seen	O
by	O
nutrition	O
regarding	O
having	O
a	O
renal	O
diet	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
patient	O
was	O
making	O
urine	O
,	O
around	O
100	O
-	O
200	O
cc	O
/	O
hr	O
.	O
Patient	O
is	O
to	O
have	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
here	O
and	O
to	O
be	O
followed	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
until	O
outpatient	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2286	O
**	O
]	O
is	O
arranged	O
.	O
Hep	O
B	O
vaccine	O
was	O
administered	O
.	O
.	O
PPD	O
placed	O
LEFT	O
volar	O
forearm	O
on	O
[	O
**	O
909	O
-4-21	O
**	O
]	O
,	O
will	O
be	O
read	O
in	O
[	O
**	O
Month	O
Year	O
2286	O
**	O
]	O
on	O
[	O
**	O
4	O
-	O
23	O
**	O
]	O
.	O
.	O
#	O
HTN	O
-	O
The	O
chronological	O
relationship	O
to	O
renal	O
failure	O
unknown	O
,	O
but	O
clearly	O
made	O
worse	O
by	O
declining	O
renal	O
function	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
was	O
normotensive	O
with	O
pressures	O
of	O
121/65	O
on	O
labetalol	I-Drug
and	O
amlodipine	I-Drug
.	O
Upon	O
presentation	O
to	O
OSH	O
pressures	O
were	O
230/130	O
suggesting	O
a	O
chronic	O
hypertensive	O
picture	O
.	O
Patient	O
says	O
that	O
he	O
had	O
seen	O
a	O
physician	O
as	O
an	O
outpatient	O
within	O
the	O
past	O
year	O
,	O
and	O
was	O
found	O
to	O
be	O
hypertensive	I-Reason
and	O
was	O
started	O
on	O
presumably	O
HCTZ	I-Drug
,	O
which	O
the	O
patient	O
was	O
non-compliant	O
.	O
Once	O
the	O
results	O
of	O
the	O
renal	O
biopsy	O
are	O
obtained	O
,	O
will	O
consider	O
starting	O
ACEI	I-Drug
.	O
.	O
#	O
Hypertriglyergiemia	I-Reason
-	O
Could	O
be	O
elevated	O
in	O
the	O
setting	O
of	O
nephrotic	O
disease	O
.	O
LDL	O
was	O
130	O
and	O
trigs	O
288	O
.	O
Patient	O
was	O
started	O
on	O
simvastatin	I-Drug
10	O
mg	O
PO	O
daily	O
.	O
.	O
#	O
Secondary	O
Hyperparathyoidism	O
in	O
the	O
setting	O
of	O
renal	O
failure	O
-	O
PTH	O
elevated	O
561	O
suggesting	O
a	O
chronic	O
renal	O
failure	O
picture	O
.	O
The	O
corrected	O
calicium	O
was	O
7	O
and	O
the	O
phos	O
5.8	O
,	O
suggesting	O
that	O
the	O
patient	O
was	O
severely	O
nutritionally	O
deficient	O
.	O
Patient	O
was	O
started	O
on	O
Phos	B-Drug
-	I-Drug
Lo	I-Drug
calcium	I-Drug
acetate	I-Drug
with	O
meals	O
.	O
.	O
#Abdominal	O
pain	O
-	O
although	O
CTA	O
showed	O
jejunal	O
changes	O
,	O
benign	O
abdominal	O
exam	O
.	O
The	O
[	O
**	O
Doctor	O
First	O
Name	O
9189	O
**	O
]	O
mesentery	O
appears	O
to	O
be	O
non-specific	O
edema	O
in	O
the	O
setting	O
of	O
small	O
ascities	O
in	O
a	O
malnurished	O
,	O
hypoalbuminemic	O
,	O
uremic	O
patient	O
.	O
Uremia	O
leads	O
to	O
inflammation	O
and	O
can	O
worsen	O
the	O
edema	O
.	O
The	O
symptoms	O
have	O
resolved	O
with	O
the	O
initiation	O
of	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
and	O
the	O
patient	O
at	O
the	O
time	O
of	O
discharge	O
did	O
not	O
have	O
any	O
nausea	O
or	O
vomitting	O
.	O
Phorphria	O
was	O
negative	O
.	O
.	O
#Anemia	O
-	O
labs	O
consistent	O
with	O
anemia	O
of	O
chronic	O
disease	O
,	O
most	O
likely	O
secondary	O
to	O
chronic	O
renal	O
failure	O
.	O
EPO	I-Drug
being	O
administered	O
with	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
and	O
patient	O
being	O
started	O
on	O
folate	I-Drug
.	O
Normal	O
ferritin	O
levels	O
.	O
Red	O
cell	O
morphology	O
normal	O
,	O
normal	O
bili	O
.	O
No	O
evidence	O
of	O
hemolysis	O
but	O
elevated	O
LDH	O
.	O
.	O
#	O
Elevated	O
CK	O
-	O
appears	O
idiopathic	O
,	O
and	O
is	O
in	O
the	O
300	O
-	O
600	O
range	O
and	O
not	O
correlated	O
clinically	O
to	O
a	O
rhabdomylsis	O
picture	O
.	O
.	O
Medications	O
on	O
Admission	O
:	O
none	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Calcium	B-Drug
Acetate	I-Drug
667	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
Disp	O
:	O
*	O
180	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Labetalol	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
270	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Multi-Day	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
acute	O
on	O
chronic	O
renal	O
failure	O
requiring	O
HD	O
of	O
unknown	O
etiology	O
severe	O
hypertension	O
,	O
well	O
-	O
controlled	O
Secondary	O
:	O
hypertriglyeridemia	O
Discharge	O
Condition	O
:	O
stable	O
,	O
pressure	O
stable	O
,	O
not	O
dizzy	O
or	O
orthostatic	O
at	O
the	O
time	O
of	O
discharge	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
for	O
acute	O
on	O
chronic	O
renal	O
failure	O
and	O
severe	O
hypertension	O
.	O
You	O
were	O
started	O
on	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
for	O
your	O
renal	O
failure	O
and	O
are	O
to	O
continue	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
here	O
until	O
your	O
outpatient	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
is	O
arranged	O
.	O
You	O
hypertension	O
was	O
controlled	O
intially	O
with	O
IV	O
medications	O
and	O
you	O
were	O
stable	O
at	O
the	O
time	O
of	O
discharge	O
on	O
oral	O
medications	O
.	O
You	O
were	O
instructed	O
on	O
the	O
importance	O
of	O
a	O
renal	O
diet	O
and	O
to	O
take	O
Phos	B-Drug
-	I-Drug
Lo	I-Drug
calcium	I-Drug
acetate	I-Drug
with	O
meals	O
.	O
You	O
are	O
to	O
have	O
your	O
PPD	O
read	O
tomorrow	O
at	O
[	O
**	O
Doctor	O
First	O
Name	O
2286	O
**	O
]	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Please	O
keep	O
the	O
area	O
of	O
your	O
kidney	O
biopsy	O
site	O
clean	O
and	O
dry	O
.	O
Replace	O
the	O
bandaid	O
daily	O
for	O
the	O
next	O
four	O
days	O
.	O
Please	O
take	O
all	O
medications	O
as	O
prescribed	O
.	O
Please	O
contact	O
your	O
PCP	O
or	O
return	O
to	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
if	O
you	O
develop	O
altered	O
mental	O
status	O
,	O
significant	O
swelling	O
,	O
or	O
develop	O
an	O
infection	O
or	O
pain	O
around	O
the	O
kidney	O
biopsy	O
site	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
SCHEDULE	O
HEMODIALYSIS	O
UNIT	O
Date	O
/	O
Time	O
:[	O
**	O
2118-4-23	O
**	O
]	O
7:30	O
Completed	O
by	O
:[	O
**	O
2118-4-23	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2128-4-24	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2128-5-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2073-4-18	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
99	O
**	O
]	O
Chief	O
Complaint	O
:	O
L	O
SDH	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
55	O
y	O
/	O
o	O
M	O
with	O
history	O
of	O
liver	O
cirrhosis	O
presents	O
s	O
/	O
p	O
1	O
day	O
of	O
headache	O
and	O
unsteady	O
gait	O
per	O
friend	O
presents	O
to	O
OSH	O
.	O
Per	O
OSH	O
reports	O
,	O
patient	O
was	O
seen	O
in	O
ED	O
where	O
he	O
seized	O
3	O
times	O
and	O
was	O
found	O
to	O
have	O
L	B-Reason
SDH	I-Reason
on	O
CT	O
scan	O
of	O
head	O
.	O
He	O
was	O
loaded	O
with	O
dilantin	I-Drug
and	O
intubated	O
,	O
then	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
evaluation	O
and	O
management	O
.	O
Patient	O
is	O
sedated	O
on	O
propofol	I-Drug
with	O
a	O
platelet	O
count	O
of	O
48	O
upon	O
arrival	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
Past	O
Medical	O
History	O
:	O
liver	O
cirrhosis	O
,	O
bipolar	O
,	O
hepatitis	O
C	O
Social	O
History	O
:	O
ETOH	O
,	O
drink	O
beer	O
daily	O
Lives	O
with	O
friend	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
O	O
:	O
BP	O
:	O
125/73	O
HR	O
:	O
73	O
R	O
:	O
18	O
O2Sats	O
:	O
100	O
%	O
CMV	O
Gen	O
:	O
patient	O
is	O
intubated	I-Reason
on	O
propofol	I-Drug
HEENT	O
:	O
atraumatic	O
,	O
normocephalic	O
Pupils	O
:	O
4	O
-	O
3	O
mm	O
bilaterally	O
Neuro	O
:	O
Minimal	O
EO	O
to	O
stimuli	O
Pupils	O
4	O
-	O
3	O
mm	O
bilaterally	O
BUE	O
purposeful	O
BLE	O
w	O
/	O
d	O
to	O
noxious	O
L	O
>	O
R	O
Pertinent	O
Results	O
:	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2128-4-24	O
**	O
]	O
1	O
.	O
Bilateral	O
subdural	O
hematomas	O
,	O
as	O
above	O
,	O
left	O
greater	O
than	O
right	O
,	O
with	O
stable	O
rightward	O
shift	O
and	O
subfalcine	O
and	O
mild	O
/	O
early	O
uncal	O
herniation	O
.	O
2	O
.	O
Possible	O
retained	O
foreign	O
body	O
in	O
left	O
frontotemporal	O
soft	O
tissues	O
,	O
please	O
correlate	O
clinically	O
.	O
3	O
.	O
Comminuted	O
nasal	O
fractures	O
,	O
likely	O
chronic	O
.	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2128-4-25	O
**	O
]	O
1	O
.	O
Post-left	O
subdural	O
evacuation	O
changes	O
,	O
with	O
improved	O
moderate	O
left	O
pneumocephalus	O
and	O
overlying	O
subcutaneous	O
emphysema	O
.	O
2	O
.	O
Unchanged	O
blood	O
layering	O
along	O
the	O
tentorial	O
leaflets	O
.	O
3	O
.	O
Improved	O
rightward	O
subfalcine	O
herniation	O
.	O
4	O
.	O
No	O
new	O
hemorrhage	O
or	O
mass	O
effect	O
.	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Brief	O
Hospital	O
Course	O
:	O
55	O
y	O
/	O
o	O
M	O
with	O
hepatitis	O
C	O
andl	O
iver	O
cirrhosis	O
presents	O
to	O
OSH	O
after	O
1	O
day	O
of	O
headachae	O
and	O
unsteadiness	O
.	O
Head	O
CT	O
revealed	O
L	O
SDH	O
with	O
midline	O
shift	O
.	O
He	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
neurosurgical	O
intervention	O
.	O
His	O
platelet	O
count	O
at	O
the	O
OSH	O
was	O
48	O
,	O
repeat	O
head	O
CT	O
showed	O
no	O
increase	O
in	O
hemorrhage	O
,	O
he	O
was	O
taken	O
emergently	O
to	O
the	O
OR	O
for	O
a	O
L	O
craniotomy	O
for	O
evacuation	O
of	O
L	O
SDH	O
.	O
OR	O
was	O
uncomplicated	O
and	O
patient	O
was	O
transferred	O
to	O
the	O
ICU	O
for	O
monitoring	O
overnight	O
.	O
Post	O
op	O
head	O
CT	O
showed	O
pneumocephalus	O
with	O
good	O
evacuation	O
of	O
blood	O
.	O
On	O
post	O
op	O
examination	O
,	O
he	O
localized	O
bilateral	O
upper	O
extremities	O
and	O
moved	O
BLE	O
spontaneously	O
.	O
On	O
[	O
**	O
4	O
-	O
26	O
**	O
]	O
,	O
patient	O
was	O
slightly	O
lethargic	O
,	O
but	O
alert	O
and	O
moving	O
all	O
extremities	O
to	O
commands	O
.	O
He	O
was	O
transferred	O
to	O
step	O
down	O
unit	O
.	O
He	O
remained	O
stable	O
overnight	O
but	O
he	O
also	O
remained	O
hyponatremic	I-Reason
.	O
A	O
repeat	O
sodium	O
was	O
135	O
after	O
being	O
started	O
on	O
salt	I-Drug
tabs	O
.	O
A	O
repeat	O
urinalysis	O
was	O
also	O
checked	O
to	O
evaluate	O
the	O
UTI	O
that	O
was	O
treated	O
in	O
the	O
emergency	O
room	O
which	O
was	O
essentially	O
negative	O
.	O
On	O
the	O
evening	O
of	O
[	O
**	O
2128-4-27	O
**	O
]	O
,	O
patient	O
bacame	O
hypotensive	I-Reason
and	O
required	O
aggressive	O
crystalloid	I-Drug
resuscitation	O
.	O
He	O
responded	O
reasonably	O
but	O
continued	O
to	O
have	O
hypotension	I-Reason
in	O
the	O
AM	O
[	O
**	O
4	O
-	O
28	O
**	O
]	O
.	O
He	O
required	O
several	O
boluses	O
of	O
IVFs	I-Drug
.	O
NGT	O
was	O
placed	O
in	O
routine	O
fashion	O
and	O
a	O
CXR	O
confirmed	O
placement	O
in	O
the	O
bowel	O
.	O
Cardiac	O
enzymes	O
and	O
ECG	O
was	O
obtained	O
to	O
rule	O
out	O
cardiac	O
etiology	O
for	O
persistent	O
hypotension	O
.	O
In	O
addition	O
,	O
medicine	O
was	O
consulted	O
for	O
further	O
recommendations	O
and	O
assistance	O
in	O
management	O
of	O
hypotension	O
.	O
CK	O
was	O
elevated	O
at	O
1028	O
.	O
ECG	O
showed	O
low	O
voltage	O
and	O
thus	O
TTE	O
was	O
recommended	O
by	O
medicine	O
as	O
well	O
as	O
urine	O
studies	O
to	O
rule	O
out	O
rhabdomyolysis	O
.	O
Required	O
ventilation	O
support	O
for	O
hypoxia	O
.	O
Continued	O
to	O
become	O
progressively	O
more	O
hypotensive	O
despite	O
multiple	O
vasopressors	I-Drug
.	O
Decision	O
made	O
by	O
HCP	O
to	O
withdraw	O
treatment	O
and	O
make	O
patient	O
CMO	O
.	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Medications	O
on	O
Admission	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Discharge	O
Medications	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Discharge	O
Condition	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Discharge	O
Instructions	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O
Followup	O
Instructions	O
:	O
Patient	O
Passed	O
Away	O
on	O
[	O
**	O
2128-5-4	O
**	O
]	O
at	O
5:31	O
PM	O
after	O
being	O
made	O
CMO	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2145-8-24	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2145-8-27	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2111-6-30	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Enbrel	I-Drug
/	O
Latex	O
/	O
Hayfever	O
/	O
Sulfa	B-Drug
(	I-Drug
Sulfonamide	I-Drug
Antibiotics	I-Drug
)	I-Drug
/	O
Nafcillin	I-Drug
/	O
Ace	B-Drug
Inhibitors	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1990	O
**	O
]	O
Chief	O
Complaint	O
:	O
fever	O
and	O
lip	O
swelling	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
38758	O
**	O
]	O
is	O
a	O
34F	O
with	O
mixed	B-Reason
connective	I-Reason
tissue	I-Reason
disease	I-Reason
/	O
rheumatoid	B-Reason
arthritis	I-Reason
on	O
immunosuppression	I-Reason
with	O
leflunamide	I-Drug
and	O
prednisone	I-Drug
who	O
returns	O
with	O
fevers	O
x1	O
day	O
.	O
.	O
Of	O
note	O
,	O
she	O
was	O
recently	O
admitted	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
11069	O
**	O
]	O
treated	O
with	O
vancomycin	I-Drug
and	O
fluconazole	I-Drug
for	O
MSSA	I-Reason
and	O
C.	B-Reason
parapsilosis	I-Reason
osteomyelitis	O
of	O
the	O
fingers	O
and	O
hand	O
,	O
as	O
well	O
as	O
a	O
suspected	O
coagulase	B-Reason
-	I-Reason
negative	I-Reason
staph	I-Reason
line	I-Reason
infection	I-Reason
.	O
Her	O
hospital	O
course	O
was	O
notable	O
for	O
moderate	O
hypertension	I-Reason
to	O
130	O
-	O
150	O
's	O
systolic	O
and	O
she	O
was	O
discharged	O
on	O
lisinopril	I-Drug
.	O
.	O
She	O
reports	O
feeling	O
in	O
her	O
usual	O
state	O
of	O
health	O
following	O
discharge	O
.	O
The	O
day	O
prior	O
to	O
presentation	O
she	O
developed	O
some	O
subjective	O
chills	O
and	O
low	O
grade	O
temp	O
to	O
99F	O
.	O
Overnight	O
,	O
she	O
felt	O
like	O
she	O
"	O
bit	O
her	O
lip	O
.	O
"	O
When	O
she	O
woke	O
up	O
the	O
morning	O
of	O
presentation	O
,	O
her	O
husband	O
noticed	O
that	O
her	O
lip	O
was	O
swollen	O
.	O
Repeat	O
temperature	O
was	O
101F	O
leading	O
her	O
to	O
present	O
for	O
further	O
evaluation	O
in	O
the	O
ER	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
T102	O
.3	O
P	O
120	O
BP	O
146/100100	O
%	O
on	O
RA	O
.	O
Found	O
to	O
have	O
swelling	O
of	O
upper	O
lip	O
,	O
reported	O
tongue	O
tingling	O
.	O
Also	O
had	O
tenderness	O
over	O
her	O
port	O
.	O
Handling	O
secretions	O
and	O
in	O
no	O
respiratory	O
distress	O
.	O
She	O
was	O
given	O
methylprednisolone	I-Drug
125	O
mg	O
,	O
acetaminophen	I-Drug
,	O
benadryl	I-Drug
for	O
suspected	O
angioedema	I-Reason
.	O
Took	O
Pepcid	I-Drug
at	O
home	O
.	O
Vitals	O
T	O
99102137	O
/	O
95	O
20	O
100	O
%	O
on	O
RA	O
.	O
Has	O
PIV	O
x1	O
and	O
port	O
.	O
.	O
On	O
evaluation	O
in	O
the	O
ICU	O
,	O
she	O
has	O
no	O
major	O
complaints	O
.	O
Denies	O
dyspnea	O
,	O
dysphagia	O
or	O
odynophagia	O
,	O
rash	O
,	O
tearing	O
.	O
She	O
denies	O
ever	O
having	O
similar	O
swelling	O
before	O
.	O
Last	O
dose	O
of	O
lisinopril	I-Drug
was	O
the	O
evening	O
prior	O
to	O
presentation	O
.	O
Only	O
other	O
new	O
medication	O
was	O
MS	B-Drug
contin	I-Drug
,	O
which	O
she	O
also	O
started	O
the	O
day	O
prior	O
to	O
presentation	O
.	O
She	O
notes	O
mild	O
tenderness	O
around	O
her	O
port	O
over	O
the	O
last	O
week	O
,	O
without	O
any	O
erythema	O
or	O
discharge	O
.	O
Apparently	O
her	O
VNA	O
had	O
trouble	O
drawing	O
back	O
from	O
the	O
port	O
last	O
week	O
,	O
but	O
this	O
problem	O
did	O
not	O
persist	O
.	O
She	O
feels	O
that	O
her	O
fingers	O
are	O
healing	O
well	O
-	O
pain	O
is	O
at	O
baseline	O
,	O
no	O
drainage	O
or	O
swelling	O
.	O
.	O
On	O
review	O
of	O
systems	O
she	O
reports	O
mild	O
headache	O
the	O
evening	O
prior	O
to	O
admission	O
and	O
some	O
neck	B-Reason
and	I-Reason
back	I-Reason
discomfort	I-Reason
today	O
which	O
is	O
now	O
resolved	O
after	O
steroids	I-Drug
.	O
She	O
has	O
occasional	O
sensation	O
of	O
ear	O
"	O
popping	O
"	O
but	O
denies	O
sinus	O
or	O
throat	O
discomfort	O
.	O
Has	O
a	O
chronic	O
"	O
smokers	O
cough	O
"	O
productive	O
of	O
small	O
amounts	O
of	O
phlegm	O
.	O
She	O
denies	O
nausea	O
or	O
vomiting	O
,	O
but	O
has	O
had	O
mild	O
abdominal	O
discomfort	O
that	O
she	O
notices	O
only	O
when	O
pressing	O
on	O
her	O
abdomen	O
.	O
She	O
has	O
been	O
constipated	O
with	O
last	O
bowel	O
movement	O
the	O
day	O
prior	O
to	O
presentation	O
,	O
no	O
diarrhea	O
.	O
Also	O
denies	O
any	O
dysuria	O
or	O
urinary	O
frequency	O
.	O
Her	O
joint	O
pains	O
are	O
at	O
baseline	O
.	O
No	O
recent	O
travel	O
,	O
no	O
tick	O
bites	O
or	O
other	O
animal	O
contacts	O
.	O
Past	O
Medical	O
History	O
:	O
*	O
Mixed	O
connective	O
tissue	O
disease	O
*	O
Recurrent	O
finger	O
osteomyelitis	O
--	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
564	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
45290	O
**	O
]	O
[	O
**	O
10	O
-	O
7	O
**	O
]	O
s	O
/	O
p	O
fluconazole	I-Drug
x3	O
months	O
--	O
Enterococcus	O
species	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
debrided	O
[	O
**	O
4	O
-	O
8	O
**	O
]	O
and	O
treated	O
with	O
vancomycin	I-Drug
x6	O
weeks	O
--	O
MSSA	I-Reason
isolated	O
[	O
**	O
2145-7-29	O
**	O
]	O
treated	O
empirically	O
with	O
vancomycin	I-Drug
-	O
had	O
tongue	B-Ade
/	I-Ade
lip	I-Ade
numbness	I-Ade
with	O
test	O
dose	O
of	O
nafcillin	I-Drug
so	O
resumed	O
vancomycin	I-Drug
,	O
s	O
/	O
p	O
debridement	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
with	O
hardware	O
removal	O
from	O
3rd	O
digit	O
.	O
Returned	O
with	O
fevers	O
[	O
**	O
8	O
-	O
15	O
**	O
]	O
and	O
underwent	O
debridement	O
[	O
**	O
8	O
-	O
17	O
**	O
]	O
of	O
right	O
thumb	O
abscess	O
--	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
564	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
45290	O
**	O
]	O
again	O
isolated	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
,	O
treated	O
with	O
fluconazole	I-Drug
*	O
Coag	O
negative	O
staph	O
?	O
line	O
infection	O
versus	O
contaminant	O
[	O
**	O
8	O
-	O
15	O
**	O
]	O
*	O
Raynauds	O
*	O
Lupus	O
anticoagulant	O
*	O
GERD	O
Social	O
History	O
:	O
+	O
Smoking	O
,	O
occasional	O
EtoH	O
and	O
marijuana	O
.	O
Married	O
,	O
not	O
currently	O
employed	O
.	O
Family	O
History	O
:	O
no	O
similar	O
swelling	O
Physical	O
Exam	O
:	O
On	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
admission	O
:	O
Vitals	O
97.9	O
108137/92	O
18	O
97	O
%	O
on	O
RA	O
General	O
Pleasant	O
woman	O
in	O
no	O
distress	O
HEENT	O
Sclera	O
anicteric	O
,	O
conjunctiva	O
pale	O
,	O
MMM	O
.	O
Upper	O
lip	O
swollen	O
.	O
No	O
drooling	O
.	O
No	O
tongue	O
edema	O
.	O
Neck	O
Supple	O
,	O
no	O
adenopathy	O
or	O
mass	O
Pulm	O
Lungs	O
clear	O
bilaterally	O
,	O
no	O
wheezing	O
,	O
stridor	O
,	O
or	O
rhonchi	O
.	O
Talking	O
in	O
complete	O
sentences	O
.	O
Chest	O
minimal	O
tenderness	O
around	O
port	O
no	O
erythema	O
or	O
drainage	O
CV	O
Regular	O
S1	O
S2	O
no	O
m	O
/	O
r	O
/	O
g	O
Abd	O
Soft	O
+	O
bowel	O
sounds	O
mild	O
tenderness	O
RLQ	O
/	O
RUQ	O
without	O
rigidity	O
or	O
guarding	O
.	O
Extrem	O
Warm	O
no	O
edema	O
palpable	O
distal	O
pulses	O
.	O
R	O
finger	O
bandages	O
C	O
/	O
D	O
/	O
I.	O
Mild	O
tenderness	O
to	O
palpation	O
of	O
small	O
joints	O
of	O
hands	O
and	O
wrists	O
at	O
baseline	O
.	O
Neuro	O
Alert	O
awake	O
and	O
interactive	O
Derm	O
No	O
rash	O
or	O
jaundice	O
Pertinent	O
Results	O
:	O
On	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
admission	O
[	O
**	O
2145-8-24	O
**	O
]	O
:	O
WBC	O
-	O
10.3	O
#	O
RBC	O
-	O
3.44	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
32.1	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.3	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
13.5	O
Plt	O
Ct	O
-	O
204	O
Neuts	O
-	O
72	O
*	O
Bands	O
-	O
8	O
*	O
Lymphs	O
-	O
16	O
*	O
Monos	O
-	O
4	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
Glucose	O
-	O
94	O
UreaN	O
-	O
9	O
Creat	O
-	O
1.0	O
Na	O
-	O
138	O
K	O
-	O
3.6	O
Cl	O
-	O
104	O
HCO3	O
-	O
23	O
AnGap	O
-	O
15	O
ALT	O
-	O
20	O
AST	O
-	O
31	O
AlkPhos	O
-	O
71	O
TotBili	O
-	O
0.5	O
Lipase	O
-	O
22	O
ESR	O
-	O
55	O
*	O
CRP	O
-	O
38.0	O
*	O
C4	O
-	O
35	O
Vanco	O
-	O
19.9	O
[	O
**	O
8	O
-	O
24	O
**	O
]	O
CXR	O
:	O
No	O
acute	O
intrathoracic	O
abnormality	O
.	O
[	O
**	O
8	O
-	O
25	O
**	O
]	O
Port	O
ultrasound	O
(	O
wet	O
read	O
)	O
:	O
No	O
signs	O
of	O
abscess	O
Brief	O
Hospital	O
Course	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
38758	O
**	O
]	O
is	O
a	O
34F	O
with	O
mixed	B-Reason
connective	I-Reason
tissue	I-Reason
disease	I-Reason
on	O
medical	O
immunosuppression	I-Reason
with	O
prednisone	I-Drug
and	O
leflunamide	I-Drug
and	O
recurrent	O
digit	O
osteomyelitis	O
who	O
returns	O
with	O
fevers	O
and	O
lip	O
swelling	O
.	O
.	O
#Angioedema	O
:	O
The	O
patient	O
was	O
evaluated	O
by	O
Allergy	O
who	O
felt	O
the	O
most	O
likely	O
etiology	O
was	O
the	O
newly	O
started	O
ACEI	I-Drug
(	O
started	O
5d	O
prior	O
to	O
noted	O
symptoms	O
)	O
.	O
There	O
was	O
never	O
any	O
evidence	O
of	O
respiratory	O
compromise	O
,	O
hypotension	O
or	O
other	O
signs	O
concerning	O
for	O
anaphylaxis	O
.	O
Allergy	O
serologies	O
(	O
tryptase	O
,	O
C1	O
inhibitor	O
and	O
C2	O
)	O
are	O
pending	O
at	O
time	O
of	O
discharge	O
.	O
Steroids	I-Drug
were	O
transitioned	O
to	O
oral	O
.	O
On	O
discharge	O
patient	O
was	O
scheduled	O
to	O
complete	O
steroid	I-Drug
taper	O
over	O
3	O
days	O
(	O
20	O
mg	O
x1d	O
,	O
10	O
mg	O
x1d	O
,	O
7.5	O
mg	O
ongoing	O
as	O
home	O
dose	O
)	O
.	O
She	O
received	O
pepcid	I-Drug
and	O
benadryl	I-Drug
x48h	O
and	O
then	O
fexofenadine	I-Drug
x48h	O
.	O
The	O
presenting	O
lip	O
swelling	O
,	O
tingling	O
resolved	O
within	O
24h	O
and	O
remained	O
absent	O
during	O
her	O
admission	O
.	O
She	O
is	O
scheduled	O
for	O
follow	O
-	O
up	O
with	O
Allergy	O
within	O
1	O
week	O
of	O
discharge	O
.	O
She	O
was	O
instructed	O
to	O
avoid	O
ACEI	I-Drug
in	O
the	O
future	O
.	O
The	O
potential	O
use	O
of	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
in	O
this	O
setting	O
remains	O
controversial	O
and	O
formal	O
recommendations	O
regarding	O
future	O
use	O
of	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
was	O
deferred	O
to	O
the	O
Allergy	O
service	O
.	O
.	O
#Fever	O
:	O
Initial	O
fever	O
and	O
bandemia	O
were	O
concerning	O
for	O
infection	O
.	O
Patient	O
remained	O
afebrile	O
after	O
initial	O
T103F	O
on	O
admission	O
.	O
Of	O
note	O
,	O
there	O
was	O
consideration	O
for	O
prednisone	I-Drug
related	O
fever	O
suppression	O
and	O
the	O
patient	O
was	O
advised	O
to	O
continue	O
to	O
monitor	O
for	O
fever	O
during	O
prednisone	I-Drug
taper	O
following	O
discharge	O
.	O
.	O
Per	O
discussion	O
with	O
Allergy	O
,	O
ACE	I-Drug
related	O
angioedema	I-Ade
was	O
likely	O
not	O
an	O
etiology	O
in	O
fever	O
.	O
Most	O
likely	O
sources	O
were	O
felt	O
to	O
be	O
(	B-Reason
1	I-Reason
)	I-Reason
persistent	I-Reason
osteomyelitis	I-Reason
of	O
the	O
R	O
digits	O
versus	O
(	O
2	O
)	O
CVC	O
endovascular	O
infection	O
.	O
After	O
coordinated	O
discussion	O
with	O
the	O
patient	O
's	O
in	O
-	O
patient	O
and	O
out	O
-	O
patient	O
attendings	O
(	O
ID	O
,	O
Rheumatology	O
,	O
Surgery	O
,	O
Medicine	O
)	O
the	O
decision	O
was	O
made	O
to	O
remove	O
the	O
port	O
.	O
Rationale	O
included	O
(	O
a	O
)	O
prior	O
positive	O
CVC	O
culture	O
with	O
CoNS	O
in	O
the	O
setting	O
of	O
CoNS	O
growing	O
from	O
R	O
hand	O
OR	O
cultures	O
,	O
(	O
b	O
)	O
persistent	O
port	O
site	O
tenderness	O
,	O
(	O
c	O
)	O
limited	O
anticipated	O
use	O
of	O
Port	O
for	O
next	O
several	O
months	O
[	O
immunosuppressive	O
regimen	O
is	O
being	O
deferred	O
until	O
completion	O
of	O
Fluconazole	I-Drug
course	O
which	O
is	O
anticipated	O
to	O
end	O
in	O
[	O
**	O
2145-11-30	O
**	O
]	O
]	O
,	O
(	O
d	O
)	O
potential	O
future	O
risk	O
for	O
fungal	O
colonization	O
given	O
known	O
Candidal	B-Reason
osteomyelitis	I-Reason
.	O
There	O
was	O
low	O
concern	O
for	O
other	O
mechanisms	O
of	O
infection	O
including	O
resistant	O
organisms	O
(	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
noted	O
as	O
Fluc	O
sensitive	O
,	O
MSSA	O
,	O
CoNS	O
both	O
Vancomycin	I-Drug
sensitive	O
)	O
,	O
non	O
gram	O
positive	O
organisms	O
(	O
Bld	O
Cx	O
remained	O
negative	O
during	O
this	O
admission	O
;	O
Bld	O
/	O
Port	O
Cx	O
x2	O
)	O
,	O
metastatic	O
infection	O
(	O
recent	O
TTE	O
negative	O
for	O
vegetation	O
,	O
no	O
focal	O
si	O
/	O
sx	O
suggestive	O
of	O
other	O
metastatic	O
sites	O
including	O
spleen	O
/	O
abdomen	O
and	O
spine	O
)	O
.	O
.	O
She	O
will	O
be	O
scheduled	O
for	O
Port	O
removal	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
PA	O
is	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
8817	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
who	O
will	O
assist	O
in	O
coordination	O
of	O
PICC	O
placement	O
.	O
She	O
was	O
evaluated	O
by	O
the	O
IV	O
team	O
prior	O
to	O
discharge	O
who	O
felt	O
out	O
-	O
patient	O
PICC	O
placement	O
with	O
consideration	O
for	O
IR	O
guidance	O
was	O
an	O
appropriate	O
plan	O
.	O
Of	O
note	O
,	O
the	O
removed	O
Port	O
-	O
A-Cath	O
tip	O
should	O
be	O
sent	O
for	O
culture	O
(	O
bacterial	O
,	O
fungal	O
,	O
AFB	O
)	O
.	O
.	O
#HTN	O
:	O
Patient	O
's	O
blood	O
pressures	O
remained	O
130	O
-	O
150s	O
/	O
80s	O
-	O
110s	O
.	O
Metoprolol	I-Drug
was	O
increased	O
from	O
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
with	O
improvement	O
in	O
blood	O
pressures	O
.	O
Additional	O
regimen	O
changes	O
were	O
deferred	O
to	O
the	O
outpatient	O
setting	O
following	O
steroid	I-Drug
taper	O
,	O
given	O
potential	O
steroid	I-Drug
related	O
contribution	O
to	O
noted	O
hypertension	I-Ade
.	O
Patient	O
experienced	O
Metoprolol	I-Drug
related	O
GI	I-Ade
upset	O
/	O
dysphagia	I-Ade
which	O
resolved	O
with	O
administration	O
w	O
/	O
food	O
.	O
Patient	O
additionally	O
expressed	O
concern	O
re	O
:	O
potential	O
side	O
effects	O
re	O
:	O
Raynaud	B-Ade
's	I-Ade
and	O
beta	B-Ade
blockade	I-Ade
.	O
Of	O
note	O
,	O
prior	O
literature	O
supports	O
safety	O
of	O
use	O
of	O
metoprolol	I-Drug
specifically	O
in	O
the	O
setting	O
of	O
Raynaud	O
's	O
.	O
.	O
#	O
Mixed	O
connective	O
tissue	O
disease	O
:	O
Her	O
home	O
immunosuppressants	O
were	O
continued	O
and	O
she	O
is	O
to	O
follow	O
-	O
up	O
with	O
rheumatology	O
as	O
outpatient	O
.	O
She	O
was	O
instructed	O
to	O
hold	O
Mobic	I-Drug
(	O
an	O
NSAID	O
)	O
pending	O
surgical	O
Port	O
-	O
A-Cath	O
removal	O
.	O
.	O
#Post	O
-	I-Reason
operative	I-Reason
Pain	I-Reason
:	O
Patients	O
pain	O
regimen	O
was	O
continued	O
.	O
MS	I-Drug
Contin	O
was	O
increased	O
from	O
15	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
20	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
.	O
#	O
Anemia	O
:	O
Hematocrit	O
was	O
stably	O
30	O
-	O
32	O
during	O
admission	O
.	O
Iron	I-Drug
studies	O
were	O
suggestive	O
of	O
mixed	B-Reason
Fe	I-Reason
-	I-Reason
deficiency	I-Reason
anemia	I-Reason
and	O
anemia	I-Reason
of	O
chronic	O
disease	O
(	O
Fe	O
31	O
,	O
TIBC	O
328	O
,	O
Ferritin	O
66	O
)	O
.	O
She	O
was	O
written	O
for	O
FeSulfate	I-Drug
on	O
discharge	O
with	O
follow	O
-	O
up	O
Fe	O
studies	O
deferred	O
to	O
the	O
patient	O
's	O
primary	O
care	O
physician	O
.	O
Medications	O
on	O
Admission	O
:	O
fluconazole	I-Drug
400	O
mg	O
daily	O
vancomycin	I-Drug
1.25	O
g	O
IV	O
q8h	O
prednisone	I-Drug
7.5	O
mg	O
daily	O
leflunomide	I-Drug
30	O
mg	O
daily	O
amitriptyline	I-Drug
20	O
mg	O
qhs	O
gabapentin	I-Drug
400	O
mg	O
tid	O
meloxicam	I-Drug
15	O
mg	O
daily	O
oxycodone	I-Drug
10	O
mg	O
q3h	O
prn	O
morphine	I-Drug
15	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
fluticasone	I-Drug
[	O
**	O
1	O
-	O
1	O
**	O
]	O
sprays	O
nasl	O
daily	O
azelastine	I-Drug
[	O
**	O
1	O
-	O
1	O
**	O
]	O
sprays	O
[	O
**	O
Hospital1	O
**	O
]	O
pantoprazole	I-Drug
40	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Vancomycin	I-Drug
500	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
1250	O
(	O
1250	O
)	O
mg	O
Intravenous	O
Q	O
8H	O
(	O
Every	O
8	O
Hours	O
)	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
21	O
doses	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Fluconazole	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
3	O
.	O
Amitriptyline	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Gabapentin	I-Drug
400	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
5	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
7	O
.	O
Leflunomide	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
daily	O
(	O
)	O
.	O
8	O
.	O
Leflunomide	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
daily	O
(	O
)	O
.	O
9	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
10	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
11	O
.	O
Prochlorperazine	I-Drug
Maleate	O
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
12	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
13	O
.	O
Morphine	I-Drug
20	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
Pellets	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
Pellets	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
40	O
Capsule	O
,	O
Sust	O
.	O
Release	O
Pellets	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
14	O
.	O
Linezolid	B-Drug
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
for	O
3	O
days	O
:	O
Please	O
start	O
the	O
Linezolid	I-Drug
the	O
day	O
of	O
your	O
PORT	O
removal	O
and	O
continue	O
it	O
for	O
2	O
days	O
after	O
.	O
You	O
will	O
resume	O
Vancomycin	I-Drug
once	O
the	O
PICC	O
is	O
placed	O
.	O
.	O
Disp	O
:	O
*	O
6	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
15	O
.	O
Prednisone	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
take	O
4	O
tablets	O
on	O
[	O
**	O
2145-8-28	O
**	O
]	O
(	O
20	O
mg	O
)	O
.	O
Take	O
2	O
tablets	O
on	O
[	O
**	O
2145-8-29	O
**	O
]	O
(	O
10	O
mg	O
)	O
,	O
then	O
resume	O
your	O
home	O
dose	O
of	O
1.5	O
tablets	O
(	O
7.5	O
mg	O
)	O
daily	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Critical	O
Care	O
Systems	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
ACE	B-Drug
Inhibitor	I-Drug
associated	O
Angioedema	I-Ade
Secondary	O
Diagnoses	O
:	O
Mixed	O
Connective	O
Tissue	O
Disease	O
Hypertension	O
GERD	O
Rheumatoid	O
Arthritis	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
evaluation	O
of	O
fever	O
and	O
lip	O
swelling	O
.	O
It	O
was	O
felt	O
that	O
the	O
lip	B-Ade
swelling	I-Ade
was	O
most	O
likely	O
an	O
allergic	O
reaction	O
to	O
Lisinopril	I-Drug
(	O
and	O
to	O
the	O
broader	O
classes	O
of	O
medications	O
known	O
as	O
ACE	B-Drug
Inhibitors	I-Drug
)	O
.	O
You	O
should	O
avoid	O
taking	O
ACE	B-Drug
Inhibitors	I-Drug
and	O
Angiotensin	B-Drug
Receptor	I-Drug
Blockers	I-Drug
in	O
the	O
future	O
.	O
.	O
Your	O
fever	O
was	O
felt	O
to	O
be	O
most	O
likely	O
related	O
to	O
either	O
osteomyelitis	O
but	O
we	O
could	O
not	O
rule	O
out	O
the	O
possibility	O
of	O
a	O
Port	O
-	O
A-Cath	O
infection	O
.	O
The	O
plan	O
after	O
discussing	O
with	O
several	O
providers	O
involved	O
in	O
your	O
care	O
will	O
be	O
for	O
Port	O
-	O
A-Cath	O
removal	O
next	O
week	O
,	O
interval	O
Linezolid	I-Drug
x48h	O
,	O
followed	O
by	O
PICC	O
(	O
IV	O
)	O
placement	O
for	O
the	O
completion	O
of	O
Vancomycin	I-Drug
for	O
your	O
known	O
osteomyelitis	I-Reason
.	O
.	O
Your	O
blood	O
pressures	O
were	O
elevated	O
during	O
your	O
hospitalization	O
.	O
The	O
dose	O
of	O
Metoprolol	I-Drug
was	O
increased	O
from	O
25	O
mg	O
twice	O
a	O
day	O
to	O
50	O
mg	O
twice	O
a	O
day	O
.	O
You	O
will	O
need	O
to	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
for	O
potential	O
further	O
management	O
of	O
your	O
blood	O
pressure	O
.	O
You	O
may	O
also	O
benefit	O
from	O
purchasing	O
a	O
home	O
blood	O
pressure	O
machine	O
to	O
measure	O
your	O
BPs	O
intermittently	O
.	O
.	O
Please	O
do	O
not	O
take	O
your	O
Mobic	I-Drug
for	O
7	O
days	O
prior	O
to	O
anticipated	O
Port	O
removal	O
.	O
.	O
If	O
you	O
experience	O
new	O
fever	O
(	O
particularly	O
in	O
the	O
setting	O
of	O
prednisone	I-Drug
taper	O
)	O
,	O
worsening	O
headache	O
,	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
shortness	O
of	O
breath	O
,	O
abdominal	O
pain	O
,	O
diarrhea	O
,	O
back	O
pain	O
,	O
visual	O
changes	O
(	O
decreased	O
acuity	O
,	O
blurriness	O
)	O
,	O
or	O
any	O
symptom	O
that	O
concerns	O
you	O
please	O
contact	O
your	O
primary	O
care	O
physician	O
or	O
return	O
to	O
the	O
hospital	O
.	O
Followup	O
Instructions	O
:	O
#	O
Port	O
-	O
a-cath	O
removal	O
and	O
PICC	O
line	O
placement	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
8817	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
515	O
**	O
]	O
office	O
will	O
contact	O
you	O
regarding	O
the	O
exact	O
date	O
and	O
time	O
for	O
these	O
appointments	O
.	O
#	O
OB	O
/	O
GYN	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
45288	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
45289	O
**	O
]	O
on	O
[	O
**	O
2145-8-31	O
**	O
]	O
at	O
3:45	O
PM	O
.	O
#	O
ALLERGY	O
:	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
9316	O
**	O
]	O
on	O
[	O
**	O
8	O
-	O
30	O
**	O
]	O
at	O
9AM	O
.	O
#	O
ID	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
457	O
**	O
]	O
on	O
[	O
**	O
2145-9-10	O
**	O
]	O
at	O
11:00	O
AM	O
.	O
#	O
Rheumatology	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
14465	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2226	O
**	O
]	O
on	O
[	O
**	O
2145-10-19	O
**	O
]	O
at	O
12:00	O
PM	O
.	O
#	O
Primary	O
Care	O
:	O
Please	O
schedule	O
an	O
appointment	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
26455	O
**	O
]	O
within	O
the	O
next	O
2	O
-	O
3	O
weeks	O
for	O
evaluation	O
/	O
further	O
management	O
of	O
your	O
high	O
blood	O
pressure	O
.	O
Completed	O
by	O
:[	O
**	O
2145-8-27	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2135-2-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2135-2-14	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2052-1-30	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Bactrim	I-Drug
Attending	O
:[	O
**	O
Doctor	O
First	O
Name	O
2080	O
**	O
]	O
Chief	O
Complaint	O
:	O
shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
thoracentesis	O
History	O
of	O
Present	O
Illness	O
:	O
Reason	O
for	O
MICU	O
Admission	O
:	O
hypoxia	O
respiratory	O
distress	O
.	O
Primary	O
Care	O
Physician	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
585	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
586	O
**	O
]	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
589	O
**	O
]	O
.	O
CC	O
:	O
cough	O
,	O
shortness	O
of	O
breath	O
.	O
HPI	O
:	O
83yo	O
female	O
Russian	O
with	O
history	O
of	O
CLL	O
presenting	O
with	O
respiratory	O
distress	O
.	O
.	O
Per	O
patient	O
she	O
reports	O
6	O
days	O
of	O
productive	O
cough	O
and	O
progressive	O
dyspnea	O
.	O
She	O
reports	O
associated	O
fevers	O
up	O
to	O
100.2	O
and	O
sore	O
throat	O
.	O
Two	O
days	O
prior	O
to	O
admission	O
prescribed	O
bactrim	I-Drug
by	O
her	O
son	O
who	O
is	O
a	O
physician	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
3010	O
**	O
]	O
worsened	O
and	O
she	O
presented	O
to	O
her	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
3011	O
**	O
]	O
.	O
There	O
vital	O
signs	O
notable	O
for	O
O2	I-Drug
sat	O
89	O
%	O
RA	O
,	O
improved	O
to	O
92	O
%	O
on	O
2L	O
NC	O
.	O
CXR	O
with	O
right	O
increased	O
effusion	O
and	O
possible	O
left	O
sided	O
infiltrate	O
.	O
She	O
was	O
referred	O
to	O
ED	O
for	O
further	O
eval	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
VS	O
:	O
99.3	O
81118/46	O
20	O
96	O
%	O
NRB	O
.	O
Labs	O
notable	O
for	O
WBC	O
of	O
33.2	O
,	O
61	O
%	O
lymphocytes	O
;	O
K	O
:	O
5.2	O
,	O
creatinine	O
2.7	O
,	O
lactate	O
1.3	O
.	O
Blood	O
cultures	O
obtained	O
.	O
CXR	O
performed	O
which	O
demonstrated	O
interval	O
increase	O
in	O
moderate	O
-	O
large	O
right	O
pleural	I-Reason
effusion	O
as	O
well	O
as	O
opacity	B-Reason
lateral	I-Reason
to	I-Reason
left	I-Reason
hilum	I-Reason
.	O
Patient	O
received	O
PO	O
Tylenol	I-Drug
650	O
mg	O
x1	O
,	O
IV	O
Ceftriaxone	I-Drug
and	O
Levofloxacin	I-Drug
.	O
The	O
patient	O
was	O
attempted	O
to	O
be	O
weaned	O
to	O
NC	O
,	O
but	O
desated	O
to	O
90	O
%	O
.	O
She	O
was	O
placed	O
back	O
on	O
a	O
NRB	O
and	O
transferred	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
evaluation	O
and	O
management	O
.	O
.	O
In	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
the	O
patient	O
states	O
that	O
her	O
breathing	O
has	O
improved	O
.	O
.	O
ROS	O
:	O
+	O
:	O
as	O
per	O
HPI	O
-	O
:	O
denies	O
any	O
chills	O
,	O
weight	O
change	O
,	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
diarrhea	O
,	O
constipation	O
,	O
melena	O
,	O
hematochezia	O
,	O
chest	O
pain	O
,	O
orthopnea	O
,	O
PND	O
,	O
lower	O
extremity	O
edema	O
,	O
urinary	O
frequency	O
,	O
urgency	O
,	O
dysuria	O
,	O
lightheadedness	O
,	O
gait	O
unsteadiness	O
,	O
focal	O
weakness	O
,	O
vision	O
changes	O
,	O
headache	O
,	O
rash	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
Past	O
Medical	O
History	O
:	O
#	O
Oncologic	O
History	O
Chronic	B-Reason
Lymphocytic	I-Reason
Leukemia	I-Reason
-	O
Diagnosed	O
in	O
[	O
**	O
2125	O
**	O
]	O
:	O
Rai	O
stage	O
0	O
in	O
[	O
**	O
2125	O
**	O
]	O
-	O
s	O
/	O
p	O
5	O
cycles	O
of	O
fludarabine	I-Drug
ending	O
in	O
[	O
**	O
2130-5-29	O
**	O
]	O
.	O
-	O
recurrent	O
anemia	O
and	O
advancing	O
peripheral	O
blood	O
lymphocytosis	O
and	O
lymphadenopathy	O
,	O
prompted	O
4	O
additional	O
3	O
-	O
day	O
cycles	O
of	O
fludarabine	I-Drug
from	O
[	O
**	O
3	O
-	O
9	O
**	O
]	O
to	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
.	O
#	O
PMH	O
1	O
.	O
Macular	O
degeneration	O
;	O
legally	O
blind	O
.	O
2	O
.	O
Chronic	O
renal	O
failure	O
:	O
baseline	O
creatinine	O
1.5	O
3	O
.	O
Hypothyroidism	O
secondary	O
to	O
hemithyroidectomy	O
on	O
[	O
**	O
2121-2-26	O
**	O
]	O
4	O
.	O
Diabetes	O
:	O
last	O
HgA1c	O
:	O
7.0	O
5	O
.	O
Hypertension	O
.	O
6	O
.	O
In	O
[	O
**	O
2133-6-29	O
**	O
]	O
,	O
she	O
was	O
admitted	O
to	O
hospital	O
with	O
respiratory	O
infection	O
due	O
to	O
H1N1	B-Reason
influenza	I-Reason
A	I-Reason
.	O
She	O
received	O
6	O
days	O
of	O
Tamiflu	I-Drug
and	O
Levaquin	I-Drug
with	O
improvement	O
in	O
symptoms	O
.	O
Myelosuppression	O
during	O
her	O
viral	O
illness	O
improved	O
.	O
.	O
SURGICAL	O
HISTORY	O
:	O
Hysterectomy	O
at	O
age	O
43	O
.	O
Appendectomy	O
.	O
Right	O
thyroidectomy	O
Social	O
History	O
:	O
Lives	O
with	O
her	O
husband	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
two	O
children	O
.	O
Retired	O
teacher	O
.	O
Originally	O
from	O
[	O
**	O
Country	O
532	O
**	O
]	O
Tob	O
:	O
none	O
EtOH	O
:	O
none	O
Family	O
History	O
:	O
Father	O
-	O
h	O
/	O
o	O
esophageal	O
cancer	O
Mother	O
-	O
h	O
/	O
o	O
skin	O
cancer	O
Sister	O
-	O
h	O
/	O
o	O
breast	O
cancer	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
GEN	O
:	O
Well	O
-	O
appearing	O
,	O
well	O
-	O
nourished	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
sclera	O
anicteric	O
,	O
no	O
epistaxis	O
or	O
rhinorrhea	O
,	O
MMM	O
,	O
OP	O
Clear	O
NECK	O
:	O
No	O
JVD	O
,	O
carotid	O
pulses	O
brisk	O
,	O
no	O
bruits	O
,	O
no	O
cervical	O
lymphadenopathy	O
,	O
trachea	O
midline	O
COR	O
:	O
RRR	O
,	O
II	O
/	O
VI	O
SEM	O
,	O
no	O
M	O
/	O
G	O
/	O
R	O
,	O
normal	O
S1	O
S2	O
,	O
radial	O
pulses	O
+2	O
PULM	O
:	O
diminished	O
BS	O
at	O
the	O
right	O
base	O
,	O
otherwise	O
no	O
W	O
/	O
R	O
/	O
R	O
ABD	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
,	O
+	O
BS	O
,	O
no	O
HSM	O
,	O
no	O
masses	O
EXT	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
,	O
no	O
palpable	O
cords	O
NEURO	O
:	O
alert	O
,	O
oriented	O
to	O
person	O
,	O
place	O
,	O
and	O
time	O
.	O
CN	O
II	O
??????	O
XII	O
grossly	O
intact	O
.	O
Moves	O
all	O
4	O
extremities	O
.	O
Strength	O
5/5	O
in	O
upper	O
and	O
lower	O
extremities	O
.	O
Patellar	O
DTR	O
+1	O
.	O
Plantar	O
reflex	O
downgoing	O
.	O
No	O
gait	O
disturbance	O
.	O
No	O
cerebellar	O
dysfunction	O
.	O
SKIN	O
:	O
No	O
jaundice	O
,	O
cyanosis	O
,	O
or	O
gross	O
dermatitis	O
.	O
No	O
ecchymo	O
Pertinent	O
Results	O
:	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
WBC	O
-	O
33.2	O
*	O
RBC	O
-	O
4.31	O
HGB	O
-	O
12.5	O
HCT	O
-	O
36.5	O
MCV	O
-	O
85	O
MCH	O
-	O
29.1	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
15.9	O
*	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
PLT	O
SMR	O
-	O
NORMAL	O
PLT	O
COUNT	O
-	O
164	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
NEUTS	O
-	O
34	O
*	O
BANDS	O
-	O
0	O
LYMPHS	O
-	O
61	O
*	O
MONOS	O
-	O
5	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
NORMAL	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
NORMAL	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
NORMAL	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
GLUCOSE	O
-	O
134	O
*	O
UREA	O
N	O
-	O
48	O
*	O
CREAT	O
-	O
2.7	O
*	O
#	O
SODIUM	O
-	O
136	O
POTASSIUM	O
-	O
5.2	O
*	O
CHLORIDE	O
-	O
102	O
TOTAL	O
CO2	O
-	O
20	O
*	O
ANION	O
GAP	O
-	O
19	O
[	O
**	O
2135-2-8	O
**	O
]	O
10:28	O
PM	O
PT	O
-	O
13.6	O
*	O
PTT	O
-	O
28.0	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
89	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:35	O
PM	O
LACTATE	O
-	O
1.3	O
[	O
**	O
2135-2-8	O
**	O
]	O
10:28	O
PM	O
PT	O
-	O
13.6	O
*	O
PTT	O
-	O
28.0	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2135-2-8	O
**	O
]	O
05:30	O
PM	O
CK	O
-	O
MB	O
-	O
4	O
proBNP	O
-	O
1345	O
*	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
UREA	O
N	O
-	O
390	O
CREAT	O
-	O
52	O
SODIUM	O
-	O
37	O
POTASSIUM	O
-	O
30	O
CHLORIDE	O
-	O
16	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
OSMOLAL	O
-	O
270	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.008	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
RBC	O
-	O
<	O
1	O
WBC	O
-	O
1	O
BACTERIA	O
-	O
NONE	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
<	O
1	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
MUCOUS	O
-	O
RARE	O
[	O
**	O
2135-2-8	O
**	O
]	O
11:09	O
PM	O
URINE	O
EOS	O
-	O
NEGATIVE	O
.	O
IgG	O
IgA	O
IgM	O
[	O
**	O
2135-2-10	O
**	O
]	O
05:57	O
963	O
52	O
*	O
66	O
.	O
Micro	O
:	O
Legionella	O
Urinary	O
Antigen	O
(	O
Final	O
[	O
**	O
2135-2-9	O
**	O
]	O
)	O
:	O
NEGATIVE	O
FOR	O
LEGIONELLA	O
SEROGROUP	O
1	O
ANTIGEN	O
.	O
[	O
**	O
2135-2-9	O
**	O
]	O
2:33	O
pm	O
PLEURAL	O
FLUID	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2135-2-9	O
**	O
]	O
)	O
:	O
1	O
+	O
(	O
<	O
1	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
FLUID	O
CULTURE	O
(	O
Preliminary	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2135-2-11	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2135-2-10	O
**	O
]	O
)	O
:	O
<	O
10,000	O
organisms	O
/	O
ml	O
Pleural	O
Pathology	O
:	O
pending	O
CT	O
chest	O
:	O
FINDINGS	O
:	O
Bulky	O
lymphadenopathy	O
is	O
present	O
in	O
the	O
imaged	O
portion	O
of	O
the	O
lower	O
neck	O
,	O
superior	O
mediastinum	O
,	O
throughout	O
the	O
intrathoracic	O
mediastinum	O
,	O
bilateral	O
hila	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
within	O
the	O
axillary	O
regions	O
.	O
Large	O
right	O
pleural	O
effusion	O
is	O
dependent	O
in	O
location	O
and	O
measures	O
simple	O
fluid	O
density	O
.	O
A	O
small	O
amount	O
of	O
loculated	O
fluid	O
is	O
also	O
present	O
within	O
the	O
major	O
fissure	O
and	O
in	O
the	O
anterolateral	O
portion	O
of	O
the	O
right	O
lower	O
chest	O
.	O
Extensive	O
consolidation	O
is	O
present	O
within	O
the	O
right	O
lower	O
and	O
right	O
middle	O
lobes	O
.	O
Peribronchiolar	O
abnormalities	O
are	O
present	O
in	O
both	O
upper	O
lobes	O
with	O
a	O
combination	O
of	O
ground	O
glass	O
and	O
consolidation	O
accompanied	O
by	O
bronchial	O
wall	O
thickening	O
and	O
small	O
peribronchial	O
nodules	O
.	O
A	O
dominant	O
peribronchial	O
nodule	O
in	O
the	O
left	O
upper	O
lobe	O
measures	O
2.2	O
cm	O
and	O
is	O
surrounded	O
by	O
a	O
halo	O
of	O
ground	O
-	O
glass	O
opacity	O
(	O
26	O
,	O
series	O
3A	O
)	O
.	O
This	O
corresponds	O
to	O
a	O
rapidly	O
growing	O
focal	O
opacity	O
on	O
serial	O
chest	O
x-rays	O
between	O
[	O
**	O
2135-2-8	O
**	O
]	O
and	O
[	O
**	O
2135-2-10	O
**	O
]	O
.	O
Additional	O
peribronchiolar	O
abnormalities	O
are	O
present	O
to	O
a	O
lesser	O
extent	O
within	O
the	O
left	O
lower	O
lobe	O
.	O
Exam	O
was	O
not	O
tailored	O
to	O
evaluate	O
the	O
subdiaphragmatic	O
region	O
,	O
but	O
note	O
is	O
made	O
of	O
retroperitoneal	O
or	O
intra-abdominal	O
lymphadenopathy	O
as	O
well	O
as	O
incompletely	O
imaged	O
splenomegaly	O
.	O
Lucent	O
spine	O
lesions	O
within	O
the	O
lower	O
thoracic	O
spine	O
(	O
image	O
53	O
,	O
series	O
3A	O
and	O
image	O
48	O
,	O
series	O
3A	O
)	O
are	O
probably	O
hemangiomas	O
.	O
Degenerative	O
changes	O
are	O
also	O
noted	O
at	O
multiple	O
levels	O
throughout	O
the	O
spine	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Multifocal	O
lung	O
abnormalities	O
most	O
suggestive	O
of	O
a	O
widespread	O
infectious	O
process	O
.	O
Nodular	O
opacity	O
with	O
ground	O
-	O
glass	O
halo	O
in	O
left	O
upper	O
lobe	O
is	O
nonspecific	O
,	O
but	O
this	O
appearance	O
may	O
be	O
associated	O
with	O
angioinvasive	O
Aspergillus	O
infection	O
in	O
the	O
setting	O
of	O
neutropenic	O
fever	O
.	O
2	O
.	O
Large	O
simple	O
right	O
pleural	O
effusion	O
.	O
3	O
.	O
Extensive	O
lymphadenopathy	O
,	O
likely	O
related	O
to	O
the	O
provided	O
history	O
of	O
CLL	O
.	O
Splenomegaly	O
is	O
also	O
in	O
keeping	O
with	O
this	O
diagnosis	O
.	O
4	O
.	O
Two	O
lucent	O
thoracic	O
vertebral	O
body	O
lesions	O
in	O
the	O
lower	O
thoracic	O
spine	O
which	O
probably	O
reflect	O
hemangiomas	O
.	O
.	O
TTE	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
0	O
-	O
10mmHg	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
a	O
normal	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
<	O
12mmHg	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Normal	O
left	O
ventricular	O
cavity	O
size	O
and	O
wall	O
thickness	O
with	O
preserved	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function	O
.	O
No	O
clinically	O
significant	O
valvular	O
regurgitation	O
.	O
Borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
An	O
area	O
of	O
echodensity	O
measuring	O
7.4	O
cm	O
x	O
4.9	O
cm	O
(	O
clip	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
**	O
]	O
)	O
is	O
seen	O
that	O
appears	O
to	O
be	O
contained	O
within	O
a	O
small	O
right	O
pleural	O
effusion	O
.	O
Clinical	O
correlation	O
and	O
consideration	O
of	O
a	O
chest	O
CT	O
for	O
further	O
characterization	O
suggested	O
.	O
.	O
LENI	O
:	O
FINDINGS	O
:	O
Color	O
and	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
scale	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
was	O
performed	O
on	O
the	O
bilateral	O
lower	O
extremities	O
.	O
The	O
bilateral	O
common	O
femoral	O
,	O
superficial	O
femoral	O
and	O
popliteal	O
veins	O
are	O
normal	O
in	O
compressibility	O
,	O
augmentation	O
,	O
and	O
Doppler	O
waveforms	O
.	O
The	O
calf	O
veins	O
are	O
patent	O
and	O
compressible	O
.	O
There	O
is	O
no	O
deep	O
vein	O
thrombosis	O
in	O
either	O
lower	O
extremity	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
83	O
year	O
-	O
old	O
female	O
with	O
a	O
history	O
of	O
CLL	O
who	O
presents	O
with	O
respiratory	O
distress	O
.	O
.	O
#	O
Respiratory	O
Distress	O
.	O
Etiology	O
likely	O
secondary	O
to	O
worsening	O
effusion	O
as	O
well	O
as	O
new	O
infiltrates	O
concerning	O
for	O
multifocal	O
pneumonia	O
.	O
Patient	O
with	O
known	O
malignancy	O
and	O
therefore	O
at	O
risk	O
for	O
hypercoagulable	O
state	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
3012	O
**	O
]	O
score	O
appears	O
to	O
be	O
low	O
-1	O
(	O
+1	O
for	O
malignancy	O
,	O
-2	O
for	O
other	O
cause	O
of	O
dyspnea	O
)	O
.	O
LENIs	O
negative	O
.	O
Biomarkers	O
flat	O
.	O
TTE	O
with	O
normal	O
systolic	O
and	O
diastolic	O
function	O
.	O
Patient	O
underwent	O
uncomplicated	O
thoracentitis	O
on	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
,	O
500cc	O
was	O
removed	O
.	O
Fluid	O
largely	O
transudative	O
.	O
Gram	O
stain	O
with	O
no	O
growth	O
.	O
Cytology	O
pending	O
.	O
CXR	O
with	O
LUL	O
infiltrate	O
.	O
Urine	O
legionella	O
negative	O
.	O
Blood	O
cx	O
:	O
NGTD	O
.	O
CT	O
scan	O
consistent	O
with	O
multifocal	B-Reason
pneumonia	I-Reason
;	O
though	O
question	O
of	O
fungal	O
per	O
radiology	O
,	O
clinical	O
suspicion	O
higher	O
for	O
pneumococcal	I-Reason
pathogen	O
.	O
Patient	O
continued	O
on	O
Ceftriaxone	I-Drug
and	O
Levofloxacin	I-Drug
with	O
plan	O
for	O
8	O
-	O
10day	O
course	O
.	O
Patient	O
's	O
respiratory	O
status	O
improved	O
on	O
these	O
antibiotics	I-Drug
and	O
O2	I-Drug
was	O
weaned	O
as	O
tolerated	O
.	O
At	O
time	O
of	O
transfer	O
to	O
floor	O
on	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
,	O
oxygen	O
saturation	O
was	O
>	O
94	O
%	O
on	O
3L	O
NC	O
.	O
Narrowed	O
to	O
Levofloxacin	I-Drug
alone	O
prior	O
to	O
discharge	O
.	O
PENDING	O
CYTOLOGY	O
NEEDS	O
FOLLOW	O
UP	O
.	O
ALSO	O
RECOMMEND	O
CT	O
CHEST	O
AFTER	O
TREATMENT	O
COMPLETED	O
.	O
.	O
#	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
.	O
Patient	O
with	O
history	O
of	O
chronic	O
renal	O
insufficiency	O
with	O
baseline	O
creatinine	O
1.5	O
.	O
Creatinine	O
on	O
admission	O
2.7	O
.	O
Etiology	O
pre-renal	B-Ade
,	I-Ade
AIN	I-Ade
in	O
setting	O
of	O
recent	O
bactrim	I-Drug
usage	O
.	O
UA	O
and	O
urine	O
culture	O
without	O
sign	O
of	O
infection	O
.	O
Urine	O
eosinophils	O
negative	O
.	O
FeNa	O
:	O
1.3	O
.	O
Creatinine	I-Reason
slowly	O
improved	O
with	O
IVF	I-Drug
and	O
was	O
2.3	O
.	O
at	O
time	O
of	O
transfer	O
to	O
the	O
medical	O
floor	O
.	O
Trending	O
daily	O
.	O
It	O
was	O
lowered	O
to	O
1.7	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
CLL	I-Reason
.	O
Patient	O
diagnosed	O
in	O
[	O
**	O
2125	O
**	O
]	O
.	O
Patient	O
last	O
treated	O
with	O
fludarabine	I-Drug
in	O
[	O
**	O
2133-5-29	O
**	O
]	O
.	O
Labs	O
notable	O
for	O
elevated	O
WBC	O
>	O
20	O
since	O
4	O
/	O
[	O
**	O
2134	O
**	O
]	O
.	O
Patient	O
without	O
anemia	O
or	O
thrombocytopenia	O
.	O
IgG	O
levels	O
checked	O
.	O
IgG	O
level	O
wnl	O
.	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
followed	O
patient	O
closely	O
.	O
No	O
plan	O
for	O
IVIG	I-Drug
infusion	O
.	O
.	O
#	O
Diabetes	I-Reason
.	O
Last	O
HgA1c	O
:	O
9.0	O
.	O
Patient	O
states	O
she	O
does	O
not	O
take	O
any	O
meds	O
for	O
diabetes	O
and	O
her	O
daughter	O
said	O
she	O
eats	O
whatever	O
she	O
wants	O
.	O
Monitoring	O
QID	O
FS	O
,	O
ISS	I-Drug
.	O
.	O
#	O
Hypothyroid	I-Reason
.	O
Continued	O
Synthroid	I-Drug
.	O
#	O
FEN	I-Reason
:	O
IVF	I-Drug
,	O
replete	O
prn	O
,	O
diabetic	O
/	O
cardiac	O
diet	O
.	O
#	O
Access	O
:	O
PIV	O
.	O
#	O
PPx	I-Reason
:	O
subQ	O
heparin	I-Drug
,	O
home	O
PPI	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
See	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
admission	O
note	O
Discharge	O
Medications	O
:	O
1	O
.	O
omeprazole	B-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
2	O
.	O
tramadol	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
levothyroxine	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
lipase	I-Drug
-	O
protease	O
-	O
amylase	O
12,000	O
-	O
38,000	O
-60,000	O
unit	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
1	O
-	O
2	O
puffs	O
Inhalation	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	O
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
1	O
inhaler	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
levofloxacin	I-Drug
750	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q48H	O
(	O
every	O
48	O
hours	O
)	O
for	O
2	O
doses	O
.	O
Disp	O
:	O
*	O
2	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Home	O
Oxygen	I-Drug
2	O
liters	O
continuous	O
pulse	O
dose	O
for	O
portability	O
.	O
dx	O
:	O
pleural	B-Reason
effusion	I-Reason
8	O
.	O
metformin	I-Drug
500	O
mg	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
Family	O
&	O
[	O
**	O
Hospital1	O
1926	O
**	O
]	O
Services	O
Discharge	O
Diagnosis	O
:	O
Community	O
acquired	O
pneumonia	O
with	O
parapneumonic	O
effusion	O
Chronic	O
kidney	O
disease	O
stage	O
III	O
CLL	O
Hypothyroidism	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
for	O
treatment	O
for	O
severe	B-Reason
pneumonia	I-Reason
as	O
well	O
as	O
fluid	O
in	O
the	O
lung	O
.	O
The	O
fluid	O
in	O
the	O
lung	O
was	O
sampled	O
.	O
You	O
were	O
started	O
on	O
antibiotics	I-Drug
with	O
improvement	O
in	O
your	O
symptoms	O
.	O
Please	O
continue	O
your	O
antibiotics	I-Drug
to	O
complete	O
the	O
full	O
course	O
.	O
Please	O
take	O
all	O
other	O
medications	O
as	O
prescribed	O
.	O
You	O
need	O
to	O
see	O
you	O
PCP	O
in	O
close	O
follow	O
up	O
.	O
Lung	O
fluid	O
cytology	O
is	O
PENDING	O
at	O
discharge	O
and	O
will	O
need	O
to	O
be	O
followed	O
up	O
.	O
Also	O
,	O
we	O
recommend	O
a	O
follow	O
up	O
CT	O
scan	O
of	O
the	O
chest	O
once	O
your	O
symptoms	O
resolve	O
.	O
START	O
:	O
Levofloxacin	I-Drug
750	O
mg	O
every	O
48	O
hours	O
Albuterol	I-Drug
inhaler	O
as	O
needed	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
as	O
soon	O
as	O
possible	O
Department	O
:	O
[	O
**	O
Hospital3	O
1935	O
**	O
]	O
CENTER	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2135-2-23	O
**	O
]	O
at	O
8:20	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
354	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3013	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
253	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
TUESDAY	O
[	O
**	O
2135-3-22	O
**	O
]	O
at	O
1:30	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
3014	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
MEDICAL	O
SPECIALTIES	O
When	O
:	O
THURSDAY	O
[	O
**	O
2135-5-19	O
**	O
]	O
at	O
9:30	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
312	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3015	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1803	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O

Admission	O
Date	O
:	O
[	O
**	O
2132-8-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2132-8-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2065-10-3	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Atenolol	I-Drug
/	O
Ms	B-Drug
Contin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1253	O
**	O
]	O
Chief	O
Complaint	O
:	O
COPD	O
exacerbation	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
13621	O
**	O
]	O
is	O
a	O
66	O
-	O
year	O
-	O
old	O
smoker	O
with	O
a	O
history	O
of	O
COPD	O
,	O
recent	O
DVT	I-Reason
now	O
off	O
coumadin	I-Drug
,	O
AAA	O
,	O
and	O
multiple	O
admissions	O
for	O
pneumonia	O
who	O
presented	O
with	O
dyspnea	O
and	O
is	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
management	O
of	O
COPD	O
exacerbation	O
requiring	O
bipap	O
.	O
He	O
has	O
been	O
hospitalized	O
multiple	O
times	O
for	O
COPD	O
exacerbation	O
and	O
pneumonia	O
requiring	O
ICU	O
admission	O
and	O
intubation	O
on	O
a	O
single	O
occasion	O
in	O
[	O
**	O
2131-9-23	O
**	O
]	O
,	O
and	O
most	O
recently	O
was	O
discharged	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
[	O
**	O
2131	O
**	O
]	O
to	O
rehab	O
and	O
has	O
been	O
home	O
for	O
a	O
few	O
weeks	O
.	O
At	O
baseline	O
he	O
is	O
unable	O
to	O
walk	O
a	O
few	O
steps	O
without	O
getting	O
short	O
of	O
breath	O
and	O
he	O
is	O
not	O
on	O
supplemental	O
O2	I-Drug
at	O
home	O
.	O
He	O
was	O
in	O
his	O
usual	O
state	O
of	O
health	O
when	O
he	O
developed	O
worsening	O
of	O
his	O
chronic	O
,	O
productive	O
cough	O
of	O
white	O
sputum	O
,	O
worsening	O
dyspnea	O
,	O
and	O
tachypnea	O
last	O
night	O
.	O
His	O
symptoms	O
progressed	O
and	O
he	O
activated	O
EMS	O
.	O
Per	O
report	O
,	O
O2	O
sat	O
on	O
room	O
air	O
upon	O
their	O
arrival	O
was	O
81	O
%	O
.	O
Of	O
note	O
,	O
he	O
was	O
diagnosed	O
with	O
a	O
right	O
segmental	O
PE	O
and	O
LLE	O
DVT	O
in	O
[	O
**	O
2131-12-24	O
**	O
]	O
and	O
was	O
on	O
warfarin	I-Drug
until	O
[	O
**	O
2132-5-22	O
**	O
]	O
when	O
it	O
was	O
discontinued	O
because	O
of	O
concerns	O
of	O
medication	O
adherence	O
.	O
In	O
the	O
ED	O
initial	O
vital	O
signs	O
were	O
97.5	O
116158/94	O
28	O
95	O
%	O
O2	O
.	O
His	O
exam	O
was	O
notable	O
for	O
minimal	O
air	O
sounds	O
and	O
mild	O
wheezes	O
,	O
and	O
he	O
was	O
intermittently	O
tachypneic	O
to	O
the	O
high	O
30s	O
,	O
with	O
tachycardia	O
to	O
the	O
130s	O
.	O
A	O
CXR	O
demonstrated	O
left	O
sided	O
infiltrate	O
,	O
which	O
was	O
confirmed	O
on	O
a	O
chest	O
CTA	O
that	O
was	O
negative	O
for	O
PE	O
but	O
demonstrated	O
multifocal	O
pneumonia	O
.	O
He	O
was	O
placed	O
on	O
cpap	O
and	O
given	O
nebs	I-Drug
,	O
solumedrol	I-Drug
125	O
mg	O
iv	O
x1	O
,	O
ceftriaxone	I-Drug
,	O
and	O
levofloxacin	I-Drug
.	O
Review	O
of	O
Systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chest	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
rash	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Right	O
segmental	O
PE	I-Reason
and	O
LLE	B-Reason
DVT	I-Reason
in	O
[	O
**	O
12/2131	O
**	O
]	O
,	O
on	O
Coumadin	I-Drug
-	O
COPD	O
,	O
admission	O
to	O
[	O
**	O
Hospital1	O
2177	O
**	O
]	O
with	O
COPD	I-Reason
exacerbation	O
last	O
winter	O
,	O
not	O
on	O
home	O
O2	I-Drug
.	O
-	O
AAA	O
-	O
HTN	O
-	O
Hyperlipidemia	O
-	O
Gout	O
-	O
Osteoporosis	O
,	O
history	O
of	O
L1	O
burst	O
fracture	O
on	O
chronic	O
opioids	I-Drug
for	O
pain	B-Reason
relief	I-Reason
,	O
l3	O
compresion	O
fracture	O
Social	O
History	O
:	O
Home	O
:	O
lives	O
alone	O
,	O
son	O
very	O
involved	O
,	O
visits	O
daily	O
.	O
EtOH	I-Drug
:	O
4	O
beers	O
per	O
day	O
.	O
Drugs	O
:	O
Denies	O
.	O
Tobacco	O
:	O
currently	O
smoking	O
4	O
cigarrettes	O
daily	O
,	O
trying	O
to	O
cut	O
back	O
and	O
has	O
>	O
80	O
PPY	O
history	O
Family	O
History	O
:	O
No	O
history	O
of	O
CAD	O
.	O
No	O
history	O
of	O
clotting	O
disorder	O
.	O
Physical	O
Exam	O
:	O
GEN	O
:	O
NAD	O
,	O
cachectic	O
,	O
anxious	O
VS	O
:	O
113118/68	O
26	O
100	O
%	O
cpap	O
10/5	O
off	O
HEENT	O
:	O
MMM	O
,	O
no	O
OP	O
lesions	O
,	O
JVP	O
not	O
distended	O
CV	O
:	O
RR	O
,	O
NL	O
S1S2	O
no	O
S3S4	O
MRG	O
PULM	O
:	O
decreased	O
BS	O
b	O
/	O
l	O
ABD	O
:	O
BS	O
+	O
,	O
soft	O
,	O
NTND	O
,	O
no	O
masses	O
or	O
HSM	O
LIMBS	O
:	O
No	O
LE	O
edema	O
,	O
no	O
tremors	O
or	O
asterixis	O
,	O
no	O
clubbing	O
SKIN	O
:	O
No	O
rashes	O
or	O
skin	O
breakdown	O
NEURO	O
:	O
CNII	O
-	O
XII	O
nonfocal	O
,	O
strength	O
5/5	O
of	O
the	O
upper	O
and	O
lower	O
extremities	O
On	O
Discharge	O
:	O
Tm	O
:	O
97.7	O
T	O
:	O
97.7	O
BP	O
:	O
123/85	O
P	O
:	O
89	O
R	O
:	O
18	O
O2	O
:	O
96	O
%	O
RA	O
(	O
95	O
-	O
97	O
RA	O
)	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
.	O
Cachectic	O
appearing	O
.	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Minimal	O
air	O
entry	O
.	O
Inspiratory	O
wheezes	O
bilaterally	O
.	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
.	O
LEs	O
are	O
wasted	O
.	O
Pertinent	O
Results	O
:	O
Leukocytosis	O
on	O
admission	O
eventually	O
trended	O
down	O
:	O
(	O
On	O
admission	O
)	O
[	O
**	O
2132-8-3	O
**	O
]	O
03:10	O
AM	O
WBC	O
-	O
30.6	O
*	O
#	O
RBC	O
-	O
5.22	O
HGB	O
-	O
15.4	O
HCT	O
-	O
47.6	O
#	O
MCV	O
-	O
91	O
MCH	O
-	O
29.6	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
14.2	O
NEUTS	O
-	O
89	O
*	O
BANDS	O
-	O
2	O
LYMPHS	O
-	O
3	O
*	O
MONOS	O
-	O
5	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
1	O
*	O
MYELOS	O
-	O
0	O
(	O
-	O
)	O
UA	O
on	O
admission	O
BCx	O
had	O
NGTD	O
upon	O
discharge	O
.	O
[	O
**	O
2132-8-3	O
**	O
]	O
CXR	O
IMPRESSION	O
:	O
Interval	O
development	O
of	O
left	O
mid	O
lung	O
hazy	O
opacity	O
,	O
concerning	O
for	O
pneumonia	O
.	O
[	O
**	O
2132-8-4	O
**	O
]	O
Chest	O
X	O
ray	O
IMPRESSION	O
:	O
Unchanged	O
left	O
mid	O
lung	O
field	O
opacity	O
concerning	O
for	O
pneumonia	O
.	O
[	O
**	O
2132-8-3	O
**	O
]	O
CTA	O
CT	O
CHEST	O
WITH	O
AND	O
WITHOUT	O
CONTRAST	O
:	O
There	O
is	O
no	O
pulmonary	O
embolism	O
.	O
The	O
pulmonary	O
arterial	O
vasculature	O
is	O
patent	O
to	O
the	O
segmental	O
level	O
.	O
The	O
aorta	O
demonstrates	O
no	O
acute	O
pathology	O
.	O
The	O
remaining	O
great	O
mediastinal	O
vessels	O
are	O
unremarkable	O
.	O
The	O
heart	O
is	O
normal	O
in	O
size	O
without	O
pericardial	O
effusions	O
.	O
Moderate	O
coronary	O
calcifications	O
are	O
again	O
noted	O
.	O
Small	O
mediastinal	O
lymph	O
nodes	O
are	O
not	O
pathologically	O
enlarged	O
,	O
compatible	O
with	O
the	O
underlying	O
pneumonia	O
.	O
There	O
is	O
no	O
definitive	O
hilar	O
or	O
axillary	O
lymphadenopathy	O
.	O
Again	O
noted	O
are	O
severe	O
emphysematous	O
changes	O
of	O
the	O
lung	O
parenchyma	O
,	O
with	O
upper	O
lobe	O
predominance	O
and	O
also	O
parasagittal	O
bulla	O
in	O
the	O
anterior	O
lungs	O
.	O
There	O
is	O
interval	O
increase	O
of	O
honeycombing	O
opacity	O
in	O
the	O
left	O
upper	O
lobe	O
,	O
with	O
persistent	O
left	O
lower	O
lobe	O
consolidation	O
,	O
compatible	O
with	O
worsening	O
infectious	O
process	O
in	O
the	O
left	O
lung	O
.	O
The	O
right	O
lung	O
base	O
opacification	O
from	O
prior	O
pneumonia	O
appears	O
to	O
decrease	O
in	O
size	O
.	O
There	O
is	O
no	O
pneumothorax	O
or	O
pleural	O
effusion	O
.	O
The	O
central	O
tracheobronchial	O
tree	O
remains	O
patent	O
.	O
The	O
study	O
is	O
not	O
designed	O
for	O
subdiaphragmatic	O
diagnosis	O
.	O
An	O
abdominal	O
aortic	O
aneurysm	O
is	O
not	O
adequately	O
assessed	O
in	O
the	O
current	O
study	O
,	O
measuring	O
up	O
to	O
30	O
mm	O
in	O
diameter	O
(	O
image	O
3:127	O
)	O
.	O
BONE	O
WINDOW	O
:	O
Multilevel	O
degenerative	O
changes	O
are	O
mild	O
to	O
moderate	O
.	O
Left	O
-	O
lateral	O
spinal	O
fusion	O
rod	O
is	O
unchanged	O
in	O
position	O
.	O
Mild	O
-	O
to	O
-	O
moderate	O
loss	O
of	O
vertebral	O
heights	O
are	O
again	O
noted	O
.	O
There	O
are	O
no	O
suspicious	O
lytic	O
or	O
sclerotic	O
lesions	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Interval	O
worsening	O
of	O
left	O
-	O
sided	O
multifocal	O
pneumonia	O
.	O
Near	O
-	O
resolution	O
of	O
right	O
lower	O
lobe	O
pneumonia	O
.	O
2	O
.	O
No	O
PE	O
or	O
acute	O
aortic	O
dissection	O
.	O
Incidental	O
note	O
of	O
an	O
abdominal	O
aortic	O
aneurysm	O
.	O
3	O
.	O
Unchanged	O
severe	O
centrilobular	O
emphysema	O
.	O
Lower	O
extremity	O
ultrasound	O
[	O
**	O
2132-8-6	O
**	O
]	O
:	O
FINDINGS	O
:	O
There	O
is	O
normal	O
compressibility	O
,	O
color	O
Doppler	O
and	O
pulse	O
-	O
wave	O
Doppler	O
waveforms	O
of	O
the	O
left	O
common	O
femoral	O
vein	O
,	O
popliteal	O
vein	O
,	O
posterior	O
tibial	O
and	O
peroneal	O
veins	O
.	O
There	O
is	O
non-occlusive	O
thrombus	O
in	O
the	O
superficial	O
femoral	O
vein	O
on	O
the	O
left	O
.	O
Overall	O
,	O
this	O
represents	O
partial	O
resorption	O
of	O
clot	O
seen	O
on	O
the	O
prior	O
exam	O
[	O
**	O
2131-12-30	O
**	O
]	O
.	O
There	O
is	O
normal	O
compressibility	O
,	O
color	O
Doppler	O
and	O
pulse	O
-	O
wave	O
Doppler	O
of	O
the	O
right	O
common	O
femoral	O
,	O
superficial	O
femoral	O
,	O
popliteal	O
veins	O
.	O
There	O
is	O
thrombus	O
seen	O
within	O
the	O
duplicated	O
posterior	O
tibial	O
veins	O
.	O
The	O
right	O
peroneal	O
vein	O
was	O
not	O
seen	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Partially	O
resorbed	O
clot	O
in	O
the	O
left	O
popliteal	O
vein	O
with	O
persistent	O
thrombus	O
in	O
the	O
left	O
superficial	O
femoral	O
vein	O
.	O
2	O
.	O
New	O
thrombus	O
in	O
the	O
right	O
posterior	O
tibial	O
veins	O
.	O
Brief	O
Hospital	O
Course	O
:	O
66	O
yo	O
male	O
with	O
hx	O
of	O
severe	O
COPD	O
,	O
recent	O
DVT	I-Reason
now	O
off	O
coumadin	I-Drug
,	O
AAA	O
,	O
and	O
multiple	O
admissions	O
for	O
COPD	O
exacerbations	O
and	O
PNA	O
,	O
p	O
/	O
w	O
COPD	O
exacerbation	O
and	O
found	O
to	O
have	O
multifocal	O
PNA	O
on	O
CT.	O
.	O
Patient	O
was	O
admitted	O
with	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
,	O
treated	O
with	O
nebs	I-Drug
in	O
the	O
ER	O
,	O
and	O
ultimately	O
required	O
bipap	O
.	O
Patient	O
was	O
transferred	O
to	O
the	O
ICU	O
,	O
where	O
he	O
was	O
weaned	O
off	O
Bipap	O
and	O
eventually	O
tolerating	O
O2	I-Drug
via	O
NC	O
.	O
He	O
was	O
started	O
on	O
Solumedrol	I-Drug
and	O
Levaquin	I-Drug
/	O
Ceftriaxone	I-Drug
.	O
Patient	O
was	O
transferred	O
to	O
the	O
floor	O
on	O
O2	I-Drug
via	O
NC	O
and	O
converted	O
to	O
PO	O
Prednisone	I-Drug
.	O
We	O
also	O
stopped	O
the	O
ceftriaxone	I-Drug
and	O
continued	O
the	O
levaquin	I-Drug
.	O
Patient	O
eventually	O
was	O
tolerating	O
RA	O
and	O
was	O
discharged	O
home	O
with	O
VNA	O
services	O
.	O
Problem	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
:	O
1	O
.	O
COPD	B-Reason
Exacerbation	I-Reason
:	O
Patient	O
started	O
on	O
ceftriaxone	I-Drug
,	O
levaquin	I-Drug
,	O
and	O
IV	O
solumedrol	I-Drug
on	O
admission	O
and	O
required	O
bipap	O
.	O
He	O
was	O
quickly	O
weaned	O
off	O
bipap	O
and	O
continued	O
on	O
abx	I-Drug
and	O
steroids	I-Drug
.	O
He	O
rapidly	O
improved	O
clinically	O
and	O
was	O
saturating	O
well	O
on	O
RA	O
upon	O
discharge	O
.	O
He	O
was	O
discharged	O
and	O
instructed	O
to	O
take	O
50	O
mg	O
Prednisone	I-Drug
daily	O
x	O
3	O
days	O
,	O
and	O
taper	O
by	O
10	O
every	O
three	O
days	O
thereafter	O
.	O
2	O
.	O
Multifocal	O
PNA	O
:	O
Patient	O
had	O
leukocytosis	O
on	O
admission	O
and	O
found	O
to	O
have	O
evidence	O
of	O
multifocal	O
PNA	O
on	O
CT.	O
.	O
He	O
was	O
started	O
on	O
Levaquin	I-Drug
and	O
Ceftriaxone	I-Drug
.	O
Blood	O
cultures	O
were	O
negative	O
as	O
was	O
legionella	O
antigen	O
.	O
The	O
leukocytosis	O
quickly	O
resolved	O
over	O
the	O
hospitalization	O
and	O
the	O
ceftriaxone	I-Drug
was	O
discharged	O
once	O
patient	O
was	O
transferred	O
to	O
general	O
medicine	O
floor	O
.	O
Patient	O
was	O
discharged	O
after	O
completing	O
a	O
5	O
day	O
course	O
of	O
his	O
levaquin	I-Drug
.	O
3	O
.	O
Cavitary	O
Lung	O
Lesion	O
:	O
Seemed	O
to	O
have	O
decreased	O
based	O
on	O
CT	O
done	O
on	O
admission	O
.	O
Patient	O
was	O
intructed	O
to	O
follow	O
up	O
with	O
pulmonologist	O
and	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
was	O
read	O
as	O
negative	O
.	O
4	O
.	O
DVT	O
:	O
Patient	O
received	O
duplex	O
ultrasound	O
that	O
demonstrated	O
resolving	O
clot	O
in	O
Left	O
superficial	O
femoral	O
.	O
New	O
thrombus	O
found	O
in	O
posteriar	O
tibial	O
.	O
Patient	O
was	O
kept	O
on	O
prophylaxsis	I-Reason
heparin	I-Drug
dosing	O
.	O
5	O
.	O
Hyperglycemia	I-Reason
:	O
Patient	O
was	O
on	O
insulin	I-Drug
sliding	O
scale	O
secondary	O
to	O
steroid	I-Drug
use	O
.	O
Patient	O
was	O
also	O
started	O
on	O
basal	O
NPH	I-Drug
when	O
he	O
received	O
his	O
dose	O
of	O
steroids	I-Drug
.	O
He	O
was	O
instructed	O
to	O
use	O
the	O
NPH	I-Drug
at	O
home	O
,	O
starting	O
with	O
12	O
units	O
,	O
when	O
he	O
takes	O
his	O
steroid	I-Drug
dose	O
every	O
morning	O
.	O
He	O
was	O
instructed	O
to	O
check	O
his	O
glucose	O
via	O
glucometer	O
to	O
make	O
sure	O
sugars	O
were	O
stable	O
.	O
He	O
was	O
instructed	O
to	O
contact	O
PCP	O
with	O
results	O
so	O
that	O
he	O
can	O
taper	O
his	O
daily	O
insulin	I-Drug
shot	O
to	O
prevent	B-Ade
hypoglycemia	I-Ade
.	O
6	O
.	O
Hyperlipidemia	I-Reason
:	O
Stable	O
on	O
atorvastatin	I-Drug
.	O
7	O
.	O
Hypertension	O
:	O
Stable	O
.	O
No	O
medications	O
were	O
required	O
.	O
8	O
.	O
Osteoporosis	I-Reason
:	O
Patient	O
continued	O
on	O
Vitamin	B-Drug
D.	O
Patient	O
remained	O
DNR	O
,	O
but	O
not	O
DNI	O
during	O
this	O
hospitalization	O
.	O
Patient	O
was	O
also	O
advised	O
to	O
stop	B-Reason
smoking	I-Reason
.	O
He	O
was	O
given	O
scripts	O
for	O
nicotine	I-Drug
patches	O
and	O
gum	O
.	O
Medications	O
on	O
Admission	O
:	O
ALBUTEROL	B-Drug
SULFATE	I-Drug
-	O
0.63	O
mg	O
/	O
3	O
mL	O
Solution	O
for	O
Nebulization	O
-	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
Solution	O
(	O
s	O
)	O
inhaled	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	O
or	O
wheezing	I-Reason
ALBUTEROL	B-Drug
SULFATE	I-Drug
-	O
90	O
mcg	O
HFA	O
Aerosol	O
Inhaler	O
-	O
2	O
puffs	O
inh	O
4	O
times	O
a	O
day	O
prn	O
ALLOPURINOL	I-Drug
-	O
300	O
mg	O
Tablet	O
-	O
0.5	O
(	O
One	O
half	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
ATORVASTATIN	I-Drug
[	O
LIPITOR	I-Drug
]	O
-	O
10	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
CODEINE	B-Drug
-	I-Drug
GUAIFENESIN	I-Drug
-	O
100	O
mg	O
-	O
10	O
mg	O
/	O
5	O
mL	O
Liquid	O
-	O
[	O
**	O
3	O
-	O
31	O
**	O
]	O
mL	O
by	O
mouth	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
cough	I-Reason
FLUTICASONE	B-Drug
-	I-Drug
SALMETEROL	I-Drug
[	I-Drug
ADVAIR	I-Drug
DISKUS	I-Drug
]	I-Drug
-	O
250	O
mcg	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
-	O
1	O
puff	O
(	O
s	O
)	O
inhaled	O
twice	O
a	O
day	O
rinse	O
after	O
use	O
OXYCODONE	B-Drug
-	I-Drug
ACETAMINOPHEN	O
-	O
5	O
mg	O
-	O
325	O
mg	O
Tablet	O
-	O
1	O
to	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
four	O
times	O
a	O
day	O
as	O
needed	O
for	O
pain	I-Reason
RANITIDINE	I-Drug
HCL	O
-	O
150	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
RISEDRONATE	B-Drug
[	I-Drug
ACTONEL	I-Drug
]	I-Drug
-	O
35	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
weekly	O
with	O
full	O
glass	O
of	O
water	O
TIOTROPIUM	B-Drug
BROMIDE	I-Drug
[	O
SPIRIVA	O
WITH	O
HANDIHALER	O
]	O
-	O
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
-	O
contents	O
of	O
one	O
capsule	O
by	O
inhaler	O
once	O
daily	O
TRAZODONE	I-Drug
-	O
50	O
mg	O
Tablet	O
-	O
0.5	O
(	O
One	O
half	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
qhs	O
DOCUSATE	B-Drug
SODIUM	I-Drug
-	O
100	O
mg	O
Capsule	O
-	O
2	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
ERGOCALCIFEROL	B-Drug
(	I-Drug
VITAMIN	I-Drug
D2	I-Drug
)	I-Drug
[	I-Drug
VITAMIN	I-Drug
D	I-Drug
]	I-Drug
-	O
400	O
unit	O
Capsule	O
-	O
2	O
(	O
Two	O
)	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
(	O
total	O
of	O
800	O
units	O
)	O
FERROUS	B-Drug
SULFATE	I-Drug
-	O
325	O
mg	O
(	O
65	O
mg	O
Iron	O
)	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
FOOD	B-Drug
SUPPLEMENT	I-Drug
,	I-Drug
LACTOSE	I-Drug
-	I-Drug
FREE	I-Drug
[	I-Drug
ENSURE	I-Drug
]	I-Drug
-	O
Liquid	O
-	O
1	O
can	O
by	O
mouth	O
tid	O
with	O
each	O
meal	O
NICOTINE	I-Drug
-	O
21	O
mg	O
/	O
24	O
hour	O
Patch	O
24	O
hr	O
-	O
apply	O
to	O
skin	O
daily	O
SENNA	I-Drug
-	O
8.6	O
mg	O
Capsule	O
-	O
1	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
at	O
bedtime	O
as	O
needed	O
Discharge	O
Medications	O
:	O
1	O
.	O
NPH	B-Drug
Insulin	I-Drug
Human	I-Drug
Recomb	I-Drug
100	O
unit	O
/	O
mL	O
(	O
3	O
mL	O
)	O
Insulin	I-Drug
Pen	O
Sig	O
:	O
One	O
(	O
1	O
)	O
12	O
Units	O
Subcutaneous	O
QAM	O
.	O
Disp	O
:	O
*	O
1	O
Pens	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Lancets	I-Drug
Misc	O
Sig	O
:	O
One	O
(	O
1	O
)	O
lancet	O
Miscellaneous	O
four	O
times	O
a	O
day	O
for	O
2	O
weeks	O
.	O
Disp	O
:	O
*	O
1	O
Box	O
of	O
Lancets	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Blood	B-Drug
Glucose	I-Drug
Monitor	I-Drug
Kit	I-Drug
Kit	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Miscellaneous	O
four	O
times	O
a	O
day	O
:	O
Please	O
dispense	O
glucometer	O
and	O
testing	O
strips	O
.	O
Disp	O
:	O
*	O
1	O
Kit	O
*	O
Refills	O
:	O
*	O
0	O
*	O
4	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.63	O
mg	O
/	O
3	O
mL	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
solutions	O
Inhalation	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	I-Reason
of	O
breath	O
or	O
wheezing	I-Reason
.	O
5	O
.	O
Albuterol	I-Drug
Sulfate	O
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
puffs	O
Inhalation	O
four	O
times	O
a	O
day	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
6	O
.	O
Allopurinol	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Atorvastatin	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Codeine	B-Drug
-	I-Drug
Guaifenesin	O
10	O
-	O
100	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
[	O
**	O
3	O
-	O
31	O
**	O
]	O
ml	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
cough	I-Reason
.	O
9	O
.	O
Fluticasone	I-Drug
-	O
Salmeterol	O
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
puff	O
Inhalation	O
twice	O
a	O
day	O
.	O
10	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	O
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
11	O
.	O
Ranitidine	I-Drug
HCl	O
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
12	O
.	O
Risedronate	I-Drug
35	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
week	O
.	O
13	O
.	O
Tiotropium	B-Drug
Bromide	I-Drug
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
capsule	O
Inhalation	O
once	O
a	O
day	O
.	O
14	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
15	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
once	O
a	O
day	O
.	O
16	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
300	O
mg	O
(	O
60	O
mg	O
Iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
17	O
.	O
Ensure	I-Drug
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
can	O
PO	O
three	O
times	O
a	O
day	O
.	O
18	O
.	O
Nicotine	I-Drug
21	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
patch	O
Transdermal	O
once	O
a	O
day	O
:	O
Please	O
take	O
off	O
before	O
going	O
to	O
bed	O
.	O
Disp	O
:	O
*	O
30	O
patch	O
*	O
Refills	O
:	O
*	O
0	O
*	O
19	O
.	O
Senna	I-Drug
8.6	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
20	O
.	O
Nicotine	B-Drug
(	I-Drug
Polacrilex	I-Drug
)	I-Drug
2	O
mg	O
Gum	O
Sig	O
:	O
One	O
(	O
1	O
)	O
piece	O
of	O
gum	O
Buccal	O
Q1	O
-	O
2	O
Hours	O
.	O
Disp	O
:	O
*	O
48	O
Gum	O
Pieces	O
*	O
Refills	O
:	O
*	O
0	O
*	O
21	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
take	O
5	O
tabs	O
each	O
day	O
for	O
3	O
days	O
(	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
-	O
[	O
**	O
8	O
-	O
10	O
**	O
]	O
)	O
then	O
take	O
4	O
tabs	O
each	O
day	O
for	O
3	O
days	O
(	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
**	O
]	O
)	O
then	O
take	O
3	O
tabs	O
each	O
day	O
for	O
3	O
days	O
(	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
4215	O
**	O
]	O
)	O
then	O
take	O
2	O
tabs	O
each	O
day	O
for	O
3	O
days	O
(	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
17341	O
**	O
]	O
)	O
then	O
take	O
1	O
tab	O
each	O
day	O
for	O
3	O
days	O
(	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
17342	O
**	O
]	O
)	O
.	O
Disp	O
:	O
*	O
45	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
22	O
.	O
Ergocalciferol	I-Drug
(	O
Vitamin	O
D2	O
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
1	O
.	O
COPD	O
Exacerbation	O
2	O
.	O
Multifocal	O
Pneumonia	O
Secondary	O
Diagnoses	O
:	O
-	O
Lower	O
extremity	O
deep	O
vein	O
thrombosis	O
-	O
Abdominal	O
aortic	O
aneurysm	O
-	O
Hypertension	O
-	O
Hyperlipidemia	O
-	O
Gout	O
-	O
Osteoporosis	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
came	O
to	O
the	O
hospital	O
because	O
you	O
were	O
very	O
short	O
of	O
breath	O
.	O
You	O
were	O
found	O
to	O
have	O
pneumonia	I-Reason
and	O
a	O
COPD	B-Reason
flare	I-Reason
.	O
You	O
were	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
and	O
given	O
IV	O
steroids	I-Drug
and	O
antibiotics	I-Drug
as	O
well	O
as	O
started	O
on	O
a	O
breathing	O
machine	O
called	O
Bipap	O
.	O
Your	O
breathing	O
improved	O
and	O
you	O
were	O
discharged	O
home	O
in	O
good	O
condition	O
.	O
Medications	O
Added	O
This	O
Admission	O
:	O
1	O
.	O
Prednisone	I-Drug
50	O
mg	O
.	O
Please	O
take	O
50	O
mg	O
for	O
3	O
more	O
days	O
,	O
then	O
take	O
40	O
mg	O
for	O
3	O
more	O
days	O
,	O
then	O
take	O
30	O
mg	O
for	O
3	O
days	O
,	O
then	O
20	O
mg	O
for	O
3	O
days	O
,	O
then	O
10	O
mg	O
for	O
3	O
days	O
.	O
2	O
.	O
NPH	I-Drug
Insulin	O
-	O
12	O
units	O
Please	O
take	O
12	O
units	O
of	O
insulin	I-Drug
when	O
you	O
take	O
your	O
prednisone	I-Drug
and	O
check	O
your	O
glucose	O
in	O
the	O
morning	O
,	O
before	O
meals	O
,	O
and	O
before	O
going	O
to	O
bed	O
.	O
If	O
sugars	O
are	O
below	O
100	O
or	O
you	O
feel	O
lightheaded	O
/	O
dizzy	O
/	O
palpitations	O
/	O
sweating	O
please	O
notify	O
your	O
primary	O
care	O
physician	O
immediately	O
and	O
do	O
not	O
take	O
anymore	O
insulin	I-Drug
.	O
You	O
will	O
need	O
to	O
talk	O
to	O
your	O
primary	O
care	O
doctor	O
to	O
decide	O
when	O
to	O
stop	O
this	O
medication	O
3	O
.	O
Nicotine	I-Drug
patch	O
and	O
Nicotine	I-Drug
gum	O
Please	O
stop	O
smoking	O
.	O
Smoking	O
will	O
only	O
worsen	O
your	O
other	O
chronic	O
medical	O
issues	O
.	O
You	O
have	O
been	O
provided	O
with	O
a	O
prescription	O
for	O
smoking	B-Reason
cessation	I-Reason
aids	I-Reason
and	O
we	O
strongly	O
encourage	O
you	O
to	O
use	O
them	O
.	O
Followup	O
Instructions	O
:	O
You	O
have	O
the	O
following	O
scheduled	O
appointments	O
:	O
Primary	O
care	O
Nurse	O
Practitioner	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
1240	O
**	O
]	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
Tuesday	O
,	O
[	O
**	O
2132-8-12	O
**	O
]	O
:	O
00	O
am	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
building	O
,	O
North	O
Suite	O
Pulmonologist	O
:	O
Provider	O
:	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
Tuesday	O
,	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
at	O
10	O
am	O
(	O
please	O
arrive	O
at	O
9:40	O
for	O
your	O
breathing	O
tests	O
)	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
building	O
[	O
**	O
Location	O
(	O
un	O
)	O
436	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2119-2-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2119-2-21	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2079-5-29	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1145	O
**	O
]	O
Chief	O
Complaint	O
:	O
cardiac	O
arrest	O
;	O
transferred	O
for	O
cooling	O
protocol	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
ICD	O
(	O
defibrillator	O
)	O
placement	O
[	O
**	O
2119-2-17	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
39	O
yo	O
male	O
who	O
was	O
working	O
on	O
a	O
construction	O
site	O
and	O
was	O
witnessed	O
to	O
fall	O
from	O
a	O
standing	O
position	O
and	O
lose	O
consciousness	O
.	O
He	O
was	O
also	O
reported	O
to	O
have	O
?	O
seizure	O
activity	O
.	O
Bystanders	O
found	O
him	O
to	O
be	O
unresponsive	O
/	O
pulseless	O
and	O
initiated	O
CPR	O
for	O
10	O
minutes	O
.	O
EMS	O
arrived	O
and	O
found	O
him	O
to	O
be	O
in	O
VF	O
arrest	O
which	O
was	O
converted	O
to	O
sinus	O
with	O
1	O
shock	O
.	O
He	O
was	O
intubated	O
on	O
the	O
field	O
and	O
transferred	O
to	O
[	O
**	O
Hospital6	O
**	O
]	O
.	O
On	O
arrival	O
he	O
was	O
unresponsive	O
;	O
and	O
shortly	O
went	O
into	O
PEA	O
arrest	O
and	O
was	O
?	O
shocked	O
?	O
x	O
1	O
with	O
resolution	O
to	O
sinus	O
tach	O
with	O
LBBB	O
.	O
.	O
He	O
was	O
taken	O
to	O
the	O
cath	O
lab	O
which	O
showed	O
100	O
%	O
RCA	O
and	O
100	O
%	O
LCx	O
;	O
LAD	O
20	O
%	O
lesion	O
which	O
appeared	O
"	O
chronic	O
"	O
;	O
EF	O
15	O
%	O
.	O
When	O
they	O
tried	O
to	O
cross	O
1	O
lesion	O
his	O
HR	O
increased	O
to	O
180	O
's	O
?	O
VT	O
;	O
he	O
was	O
shocked	O
with	O
200J	O
x	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
70830	O
**	O
]	O
at	O
120	O
's	O
;	O
he	O
was	O
also	O
hypertensive	B-Reason
to	I-Reason
the	I-Reason
200	I-Reason
's	I-Reason
which	O
was	O
treated	O
with	O
?	O
nitro	I-Drug
drip	O
.	O
At	O
[	O
**	O
Hospital6	O
**	O
]	O
he	O
received	O
600cc	O
IVF	I-Drug
;	O
325cc	O
IV	O
contrast	I-Drug
;	O
10	O
mg	O
ativan	I-Drug
.	O
.	O
Post-cath	O
he	O
was	O
noted	O
again	O
to	O
have	O
seizure	B-Reason
-	I-Reason
like	I-Reason
activity	I-Reason
(	O
unsure	O
of	O
character	O
)	O
and	O
was	O
given	O
10	O
mg	O
ativan	I-Drug
and	O
taken	O
to	O
CT	O
scan	O
which	O
was	O
preliminarily	O
read	O
as	O
negative	O
(	O
although	O
on	O
review	O
here	O
may	O
be	O
c	O
/	O
w	O
sub-arachnoid	O
hemorrhage	O
)	O
.	O
On	O
[	O
**	O
Hospital	O
**	O
]	O
transfer	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
he	O
was	O
noted	O
to	O
have	O
decerebrate	O
posturing	O
and	O
L	O
-	O
turning	O
of	O
head	O
.	O
Past	O
Medical	O
History	O
:	O
HTN	O
heavy	O
alcohol	O
abuse	O
-	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
vodka	O
every	O
day	O
until	O
5	O
days	O
PTA	O
.	O
Social	O
History	O
:	O
very	O
heave	O
alcohol	O
abuse	O
.	O
In	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
started	O
to	O
drink	O
about	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
vodka	O
/	O
day	O
until	O
5	O
days	O
prior	O
to	O
admission	O
;	O
2ppd	O
smoker	O
;	O
+	O
MJ	O
,	O
?	O
cocaine	O
;	O
construction	O
worker	O
Family	O
History	O
:	O
no	O
early	O
CAD	O
in	O
family	O
Physical	O
Exam	O
:	O
T	O
98	O
HR	O
107	O
BP	O
127/76	O
RR	O
30	O
SaO2	O
100	O
%	O
Vent	O
settings	O
:	O
AC	O
12X	O
600	O
,	O
100	O
%	O
fiO2	O
,	O
15	O
peep	O
Gen	O
:	O
Intubated	O
,	O
sedated	O
HEENT	O
:	O
blood	O
in	O
mouth	O
;	O
poor	O
dentition	O
CV	O
:	O
tachy	O
,	O
no	O
m	O
/	O
r	O
/	O
?	O
S3	O
+4	O
?	O
,	O
no	O
murmurs	O
Pulm	O
:	O
CTA	O
B	O
Abd	O
:	O
s	O
/	O
nd	O
/	O
nt	O
;	O
no	O
BS	O
Ext	O
:	O
warm	O
,	O
trace	O
to	O
1	O
+	O
DP	O
pulses	O
;	O
no	O
edema	O
neuro	O
:	O
PERRL	O
3	O
-	O
2.5	O
mm	O
;	O
w	O
/	O
draws	O
all	O
extremities	O
to	O
pain	O
;	O
+	O
corneal	O
reflex	O
;	O
eyes	O
wander	O
(	O
conjugate	O
gaze	O
)	O
;	O
unable	O
to	O
assess	O
dolls	O
-	O
head	O
Pertinent	O
Results	O
:	O
[	O
**	O
2119-2-8	O
**	O
]	O
CT	O
head	O
:	O
IMPRESSION	O
:	O
Slightly	O
limited	O
study	O
due	O
to	O
patient	O
motion	O
.	O
Allowing	O
for	O
this	O
,	O
no	O
evidence	O
of	O
intra	O
-	O
or	O
extra-axial	O
hemorrhage	O
.	O
.	O
The	O
findings	O
were	O
discussed	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
1255	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
at	O
9:40	O
p.m.	O
on	O
[	O
**	O
2119-2-8	O
**	O
]	O
.	O
The	O
outside	O
hospital	O
CT	O
scan	O
was	O
obtained	O
on	O
hard	O
copy	O
,	O
and	O
will	O
be	O
brought	O
to	O
the	O
file	O
room	O
in	O
the	O
morning	O
.	O
Review	O
of	O
that	O
examination	O
at	O
the	O
time	O
of	O
attending	O
review	O
does	O
show	O
increased	O
density	O
of	O
the	O
tentorium	O
,	O
which	O
presumably	O
relates	O
to	O
the	O
large	O
volume	O
of	O
IV	O
contrast	I-Drug
used	O
for	O
what	O
apparently	O
was	O
a	O
cardiac	O
catheterization	O
at	O
that	O
facility	O
,	O
which	O
also	O
resulted	O
in	O
visualization	O
of	O
the	O
vascular	O
tributaries	O
of	O
the	O
circle	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
431	O
**	O
]	O
on	O
this	O
[	O
**	O
Hospital3	O
**	O
]	O
CT	O
scan	O
.	O
This	O
tentorial	O
enhancement	O
is	O
no	O
longer	O
seen	O
,	O
likely	O
due	O
to	O
the	O
renal	O
excretion	O
of	O
the	O
contrast	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
.	O
.	O
[	O
**	O
2119-2-8	O
**	O
]	O
CXR	O
:	O
1	O
.	O
Successful	O
intubation	O
.	O
2	O
.	O
Diffuse	O
bilateral	O
hazy	O
ground	O
-	O
glass	O
opacities	O
.	O
This	O
is	O
nonspecific	O
,	O
and	O
may	O
represent	O
diverse	O
etiologies	O
depending	O
on	O
the	O
patient	O
's	O
clinical	O
situation	O
,	O
e.g.	O
aspiration	O
,	O
hemorrhage	O
,	O
or	O
PCP	O
if	O
the	O
patient	O
is	O
immunocompromised	O
.	O
Followup	O
is	O
recommended	O
.	O
.	O
[	O
**	O
2119-2-10	O
**	O
]	O
CXR	O
:	O
Since	O
the	O
prior	O
chest	O
x-ray	O
,	O
the	O
endotracheal	O
tube	O
and	O
nasogastric	O
tube	O
have	O
been	O
removed	O
.	O
There	O
has	O
been	O
no	O
significant	O
change	O
since	O
the	O
prior	O
film	O
of	O
six	O
hours	O
previous	O
.	O
The	O
cardiomegaly	O
,	O
effusions	O
,	O
and	O
some	O
edema	O
are	O
still	O
present	O
.	O
.	O
IMPRESSION	O
:	O
Cardiac	O
failure	O
persists	O
.	O
.	O
[	O
**	O
2119-2-10	O
**	O
]	O
EKG	O
:	O
Sinus	O
rhythm	O
.	O
Left	O
axis	O
deviation	O
.	O
Left	O
bundle	O
-	O
branch	O
block	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
sinus	O
rhythm	O
is	O
now	O
present	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
)	O
VF	B-Reason
arrest	I-Reason
/	I-Reason
rhythm	I-Reason
:	O
Most	O
likely	O
a	O
primary	O
arrthymic	O
event	O
(	O
based	O
on	O
story	O
of	O
falling	O
,	O
pulseless	O
with	O
CPR	O
for	O
10	O
min	O
,	O
and	O
Vfib	O
when	O
EMS	O
arrived	O
)	O
and	O
secondary	O
to	O
ischemic	O
scar	O
from	O
old	O
infacts	O
.	O
Does	O
not	O
appear	O
to	O
be	O
ACS	O
(	O
low	O
level	O
CE	O
,	O
stenosis	O
on	O
cath	O
appeared	O
old	O
)	O
.	O
ECGs	O
during	O
hospitalization	O
showed	O
sinus	O
rhythm	O
/	O
sinus	O
tach	O
with	O
LBBB	O
(	O
no	O
old	O
ECGs	O
for	O
comparison	O
)	O
.	O
He	O
was	O
loaded	O
with	O
amiodarone	I-Drug
and	O
maintained	O
on	O
metoprolol	I-Drug
for	O
rate	I-Reason
control	O
.	O
He	O
was	O
monitored	O
on	O
telemetry	O
and	O
had	O
no	O
further	O
Vfib	O
events	O
;	O
rhythm	O
strips	O
obtained	O
from	O
EMS	O
and	O
the	O
outside	O
hospital	O
did	O
not	O
capture	O
any	O
v	O
-	O
fib	O
events	O
.	O
He	O
had	O
an	O
ICD	O
implanted	O
on	O
[	O
**	O
2119-2-17	O
**	O
]	O
and	O
tolerated	O
the	O
procedure	O
well	O
.	O
He	O
will	O
follow	O
up	O
in	O
device	O
clinic	O
on	O
[	O
**	O
2119-3-1	O
**	O
]	O
.	O
.	O
#	O
)	O
CAD	I-Reason
/	O
Ischaemia	I-Reason
:	O
He	O
was	O
taken	O
for	O
cardiac	O
catheterization	O
and	O
was	O
found	O
to	O
have	O
RCA	O
and	O
LCx	O
occlusion	O
which	O
was	O
thought	O
to	O
be	O
likely	O
chronic	O
.	O
CE	O
's	O
were	O
trended	O
and	O
peaked	O
at	O
low	O
level	O
(	O
likely	O
related	O
to	O
post-code	O
and	O
not	O
consistent	O
with	O
ACS	O
)	O
.	O
He	O
was	O
continued	O
on	O
aspirin	I-Drug
,	O
and	O
was	O
titrated	O
up	O
on	O
metoprolol	I-Drug
.	O
A	O
statin	I-Drug
was	O
not	O
started	O
right	O
away	O
given	O
his	O
elevated	O
LFTs	O
,	O
but	O
once	O
these	O
normalized	O
,	O
he	O
was	O
started	O
on	O
a	O
reduced	O
-	O
dose	O
statin	I-Drug
(	O
20	O
mg	O
atorvastatin	I-Drug
)	O
.	O
#	O
)	O
Pump	O
:	O
Cath	O
report	O
showed	O
an	O
EF	O
15	O
%	O
;	O
Multifactorial	O
;	O
?	O
acute	O
post	O
code	O
shock	O
,	O
ischemic	O
cardiomyopathy	O
,	O
?	O
alcoholic	O
cardiomyopathy	O
.	O
Hopefully	O
he	O
will	O
recover	O
some	O
function	O
.	O
A	O
repeat	O
echo	O
showed	O
an	O
EF	O
of	O
20	O
-	O
25	O
%	O
with	O
no	O
major	O
valvular	O
abnormalities	O
.	O
He	O
will	O
need	O
another	O
echo	O
in	O
approximately	O
one	O
month	O
to	O
assess	O
for	O
recovery	O
of	O
his	O
systolic	O
function	O
.	O
.	O
#	O
fevers	I-Reason
:	O
He	O
spiked	O
fevers	O
up	O
to	O
102	O
.	O
He	O
was	O
initially	O
started	O
on	O
levo	I-Drug
/	O
metronidazole	I-Drug
and	O
vanco	I-Drug
before	O
a	O
known	O
source	O
was	O
found	O
to	O
cover	O
for	O
likely	O
aspiration	B-Reason
pneumonia	I-Reason
and	O
line	B-Reason
infections	I-Reason
.	O
He	O
was	O
then	O
found	O
to	O
have	O
strep	B-Reason
pneumo	I-Reason
in	O
his	O
sputum	O
and	O
continued	O
to	O
spike	O
fevers	I-Reason
until	O
he	O
was	O
stabilized	O
on	O
an	O
antibiotic	O
regimen	O
of	O
ceftriaxone	I-Drug
/	O
azithromycin	I-Drug
.	O
There	O
was	O
also	O
concern	O
that	O
these	O
fevers	O
might	O
be	O
related	O
to	O
alcohol	O
withdrawl	O
and	O
/	O
or	O
drug	B-Ade
fever	I-Ade
(	O
from	O
phenytoin	I-Drug
,	O
which	O
was	O
stopped	O
on	O
[	O
**	O
2	O
-	O
13	O
**	O
]	O
)	O
.	O
He	O
completed	O
a	O
five	O
day	O
course	O
of	O
azithromycin	I-Drug
and	O
his	O
ceftriaxone	I-Drug
will	O
be	O
converted	O
to	O
cefpodoxime	I-Drug
to	O
complete	O
a	O
10	O
-	O
day	O
course	O
.	O
.	O
#	O
)	O
Altered	O
mental	O
status	O
/	O
EtOH	O
withdrawl	O
:	O
This	O
has	O
a	O
multifactorial	O
origin	O
:	O
VF	O
arrest	O
,	O
EtOH	O
,	O
sedation	O
now	O
.	O
Per	O
his	O
sister	O
(	O
whom	O
he	O
lives	O
with	O
)	O
that	O
he	O
drank	O
about	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
vodka	O
per	O
night	O
for	O
4	O
months	O
and	O
then	O
stopped	O
abruptly	O
~	O
4	O
days	O
prior	O
to	O
admission	O
.	O
Neurology	O
was	O
consulted	O
especially	O
given	O
question	O
of	O
seizure	O
activity	O
at	O
the	O
OSH	O
.	O
An	O
EEG	O
was	O
negative	O
for	O
seizures	O
and	O
an	O
LP	O
showed	O
normal	O
cell	O
count	O
,	O
protein	O
,	O
and	O
glucose	O
with	O
no	O
evidence	O
of	O
infection	O
.	O
A	O
psychiatry	O
consultation	O
was	O
obtained	O
and	O
they	O
believed	O
that	O
his	O
prolonged	O
delirium	I-Ade
may	O
have	O
been	O
benzodiazepine	I-Drug
intoxication	O
.	O
He	O
was	O
maintained	O
on	O
standing	O
Haldol	I-Drug
and	O
only	O
short	O
-	O
acting	O
benzo	B-Drug
's	I-Drug
(	O
lorazepam	I-Drug
)	O
were	O
used	O
for	O
his	O
CIWA	B-Reason
scale	I-Reason
and	O
his	O
mental	O
status	O
gradually	O
improved	O
.	O
He	O
worked	O
with	O
PT	O
/	O
OT	O
to	O
regain	O
strength	O
,	O
balance	O
,	O
and	O
functioning	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
)	O
Transaminitis	O
:	O
Patient	O
has	O
mildly	O
elevated	O
alt	O
>	O
ast	O
.	O
GGT	O
mildly	O
elevated	O
as	O
well	O
.	O
Most	O
likely	O
secondary	O
to	O
mild	O
shock	O
liver	O
in	O
setting	O
of	O
code	O
.	O
Underlying	O
liver	O
disease	O
from	O
h	O
/	O
o	O
recent	O
heavy	O
EtOH	O
use	O
,	O
high	O
triglycerides	O
(	O
150	O
)	O
could	O
put	O
him	O
at	O
risk	O
for	O
more	O
damage	O
.	O
His	O
acetaminophen	I-Drug
use	O
was	O
limited	O
to	O
2g	O
/	O
day	O
and	O
he	O
was	O
eventually	O
started	O
on	O
a	O
reduced	O
dose	O
of	O
atorvastatin	I-Drug
for	O
his	O
hyperlipidemia	I-Reason
.	O
.	O
#	O
)	O
Elevated	O
Cr	O
:	O
Initially	O
had	O
some	O
ARF	O
which	O
was	O
most	O
-	O
likely	O
ATN	O
/	O
hypoperfusion	O
from	O
cardiac	O
arrest	O
.	O
He	O
was	O
hydrated	O
and	O
received	O
mucomyst	I-Drug
for	O
cath	I-Reason
.	O
His	O
Cr	O
trended	O
down	O
and	O
recovered	O
.	O
.	O
#	O
)	O
FEN	O
/	O
GI	O
:	O
He	O
was	O
given	O
protonix	I-Drug
for	O
GI	B-Reason
ppx	I-Reason
given	O
alcohol	O
use	O
.	O
He	O
was	O
also	O
ordered	O
for	O
a	O
speech	O
and	O
swallow	O
eval	O
after	O
extubation	O
given	O
his	O
still	O
"	O
cloudy	O
"	O
mental	O
status	O
to	O
assess	O
risk	O
for	O
aspiration	O
.	O
He	O
eventually	O
passed	O
a	O
speech	O
and	O
swallow	O
study	O
,	O
though	O
was	O
recommeded	O
to	O
have	O
close	O
supervision	O
with	O
meals	O
given	O
his	O
distractability	O
.	O
Heart	O
healthy	O
low	O
sodium	O
diet	O
.	O
Medications	O
on	O
Admission	O
:	O
none	O
known	O
Discharge	O
Medications	O
:	O
1	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Fluticasone	I-Drug
-	O
Salmeterol	O
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Disk	O
with	O
Device	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Aspirin	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Hexavitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Cap	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Nicotine	I-Drug
21	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
24	O
HR	O
Transdermal	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Patch	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Ipratropium	I-Drug
Bromide	O
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
1	O
inhaler	O
*	O
Refills	O
:	O
*	O
2	O
*	O
9	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
diagnosis	O
:	O
cardiac	O
arrest	O
due	O
to	O
ventricular	O
fibrillation	O
Secondary	O
diagnoses	O
:	O
alcohol	O
abuse	O
,	O
ischemic	O
and	O
alcoholic	O
cardiomyopathy	O
,	O
coronary	O
artery	O
disease	O
Discharge	O
Condition	O
:	O
stable	O
,	O
alert	O
and	O
oriented	O
x3	O
,	O
ambulatory	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
a	O
cardiac	O
arrest	O
.	O
You	O
had	O
a	O
defibrillator	O
implanted	O
to	O
help	O
keep	O
your	O
heart	O
beating	O
properly	O
and	O
prevent	O
against	O
such	O
an	O
arrhythmia	O
.	O
You	O
were	O
found	O
to	O
have	O
severe	B-Reason
disease	I-Reason
of	I-Reason
your	I-Reason
coronary	I-Reason
arteries	I-Reason
(	O
the	O
arteries	O
that	O
supply	O
your	O
heart	O
with	O
oxygen	O
)	O
.	O
For	O
this	O
,	O
you	O
should	O
take	O
one	O
aspirin	I-Drug
daily	O
for	O
the	O
rest	O
of	O
your	O
life	O
.	O
You	O
were	O
also	O
started	O
on	O
medication	O
for	O
your	O
cholesterol	O
and	O
blood	O
pressure	O
.	O
You	O
are	O
also	O
finishing	O
a	O
course	O
of	O
antibiotics	I-Drug
(	O
cefpodoxime	I-Drug
)	O
for	O
a	B-Reason
possible	I-Reason
pneumonia	I-Reason
.	O
In	O
order	O
to	O
optimize	O
the	O
health	O
of	O
your	O
heart	O
,	O
you	O
should	O
completely	O
avoid	O
both	O
cigarettes	O
and	O
alcohol	O
.	O
In	O
order	O
to	O
help	O
you	O
decrease	O
your	O
craving	O
for	O
cigarretes	O
,	O
you	O
have	O
been	O
prescribed	O
the	O
nicotine	I-Drug
patch	O
.	O
Do	O
NOT	O
smoke	O
and	O
have	O
the	O
patch	O
on	O
at	O
the	O
same	O
time	O
.	O
You	O
will	O
be	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
by	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2411	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
51086	O
**	O
]	O
to	O
talk	O
with	O
you	O
about	O
support	O
systems	O
to	O
help	O
avoid	O
alcohol	O
.	O
If	O
you	O
experience	O
loss	O
of	O
consciousness	O
,	O
chest	O
pain	O
,	O
high	O
fevers	O
,	O
or	O
other	O
concerning	O
symptoms	O
,	O
you	O
should	O
seek	O
medical	O
attention	O
.	O
Followup	O
Instructions	O
:	O
DEVICE	O
CLINIC	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
59	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2119-3-1	O
**	O
]	O
11:30	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
of	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Building	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
)	O
.	O
You	O
have	O
a	O
follow	O
up	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
23651	O
**	O
]	O
,	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
70831	O
**	O
]	O
,	O
on	O
Feburary	O
12th	O
.	O
Have	O
your	O
primary	O
doctor	O
schedule	O
a	O
repeat	O
echo	O
in	O
4	O
weeks	O
to	O
assess	O
your	O
heart	O
function	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2158-1-31	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2158-2-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2111-2-7	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
ADMITTING	O
DIAGNOSIS	O
:	O
Pelvic	O
mass	O
.	O
POSTOPERATIVE	O
DIAGNOSIS	O
:	O
Ovarian	O
cancer	O
.	O
HISTORY	O
OF	O
THE	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
was	O
admitted	O
for	O
with	O
symptoms	O
of	O
bloating	O
.	O
The	O
patient	O
's	O
workup	O
revealed	O
a	O
large	O
pelvic	O
mass	O
that	O
was	O
suspicious	O
for	O
ovarian	O
cancer	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
Significant	O
for	O
migraines	O
.	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
Noncontributory	O
.	O
PAST	O
OBSTETRICAL	O
HISTORY	O
:	O
Noncontributory	O
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
was	O
admitted	O
for	O
an	O
exploratory	O
laparotomy	O
,	O
TAH	O
/	O
BSO	O
,	O
peritoneal	O
washings	O
,	O
omentectomy	O
,	O
and	O
debulking	O
,	O
and	O
pelvic	O
lymph	O
node	O
dissection	O
.	O
The	O
estimated	O
blood	O
loss	O
of	O
the	O
procedure	O
was	O
250	O
cc	O
.	O
The	O
procedure	O
was	O
uncomplicated	O
.	O
The	O
patient	O
's	O
postoperative	O
course	O
was	O
complicated	O
by	O
an	O
episode	O
of	O
respiratory	B-Ade
arrest	I-Ade
believed	O
to	O
be	O
related	O
to	O
narcotic	I-Drug
sensitivity	O
.	O
The	O
patient	O
had	O
received	O
in	O
total	O
3	O
mg	O
of	O
morphine	I-Drug
IV	O
and	O
4	O
mg	O
of	O
Dilaudid	I-Drug
IV	O
and	O
then	O
4	O
mg	O
of	O
Dilaudid	I-Drug
subcutaneously	O
.	O
A	O
code	O
was	O
called	O
.	O
The	O
patient	O
's	O
airway	O
was	O
immediately	O
secured	O
and	O
she	O
was	O
immediately	O
bagged	O
.	O
Narcan	I-Drug
was	O
given	O
IV	O
and	O
the	O
patient	O
responded	O
well	O
with	O
a	O
vigorous	O
respiratory	O
effort	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
closer	O
monitoring	O
and	O
at	O
that	O
time	O
was	O
started	O
on	O
a	O
Narcan	I-Drug
drip	O
.	O
The	O
patient	O
did	O
well	O
for	O
the	O
remainder	O
of	O
the	O
night	O
and	O
the	O
Narcan	I-Drug
drip	O
was	O
then	O
discontinued	O
in	O
the	O
early	O
morning	O
.	O
The	O
patient	O
's	O
pain	I-Reason
control	O
overnight	O
was	O
managed	O
with	O
a	O
dose	O
of	O
p.o.	O
Percocet	I-Drug
early	O
in	O
the	O
morning	O
.	O
The	O
patient	O
was	O
called	O
out	O
of	O
the	O
MICU	O
on	O
postoperative	O
day	O
number	O
one	O
and	O
transferred	O
to	O
the	O
regular	O
Postsurgical	O
Floor	O
.	O
The	O
patient	O
's	O
pain	B-Reason
control	I-Reason
was	O
initially	O
controlled	O
with	O
Percocet	I-Drug
and	O
then	O
transitioned	O
to	O
Toradol	I-Drug
and	O
then	O
finally	O
after	O
a	O
consultation	O
with	O
the	O
Pain	O
Service	O
was	O
transitioned	O
to	O
Flexeril	I-Drug
10	O
mg	O
t.i.d.	O
and	O
Motrin	I-Drug
600	O
mg	O
q.	O
six	O
hours	O
.	O
In	O
addition	O
,	O
Physical	O
Therapy	O
consult	O
was	O
obtained	O
to	O
provide	O
assistance	O
with	O
the	O
patient	O
in	O
ambulation	O
and	O
mobility	O
.	O
The	O
patient	O
's	O
urine	O
output	O
was	O
adequate	O
throughout	O
her	O
hospitalization	O
/	O
postoperative	O
course	O
.	O
She	O
began	O
tolerating	O
p.o.	O
on	O
postoperative	O
day	O
number	O
one	O
.	O
On	O
postoperative	O
day	O
number	O
one	O
,	O
she	O
also	O
began	O
ambulating	O
.	O
The	O
patient	O
's	O
Foley	O
was	O
discontinued	O
and	O
she	O
was	O
voiding	O
spontaneously	O
.	O
Her	O
vital	O
signs	O
remained	O
stable	O
for	O
the	O
remainder	O
of	O
the	O
hospitalization	O
.	O
Her	O
abdominal	O
examination	O
had	O
positive	O
bowel	O
sounds	O
and	O
was	O
appropriately	O
tender	O
.	O
Her	O
incision	O
remained	O
clean	O
,	O
dry	O
,	O
and	O
intact	O
.	O
The	O
patient	O
will	O
be	O
discharged	O
to	O
home	O
on	O
a	O
full	O
diet	O
with	O
Flexeril	I-Drug
10	O
mg	O
t.i.d.	O
and	O
600	O
mg	O
of	O
Motrin	I-Drug
q.	O
six	O
hours	O
,	O
simethicone	I-Drug
80	O
mg	O
q.	O
eight	O
hours	O
.	O
DISPOSITION	O
:	O
The	O
patient	O
will	O
be	O
discharged	O
to	O
home	O
.	O
CONDITION	O
ON	O
DISCHARGE	O
:	O
Good	O
.	O
The	O
patient	O
will	O
have	O
home	O
VNA	O
to	O
assess	O
her	O
postoperative	O
course	O
.	O
FOLLOW	O
-	O
UP	O
:	O
The	O
patient	O
will	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1022	O
**	O
]	O
in	O
approximately	O
one	O
months	O
time	O
.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
4871	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Name8	O
(	O
MD	O
)	O
4872	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2158-2-4	O
**	O
]	O
01:04	O
T	O
:	O
[	O
**	O
2158-2-6	O
**	O
]	O
12:56	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
4873	O
**	O
]	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
7045	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
1715	O
**	O
]	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
7046	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2112-10-23	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2112-11-25	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2045-8-3	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
7047	O
**	O
]	O
Addendum	O
:	O
Mrs	O
[	O
**	O
Known	O
lastname	O
7048	O
**	O
]	O
blood	O
pressure	O
was	O
consistently	O
in	O
the	O
range	O
of	O
90	O
-	O
100	O
systolic	O
and	O
did	O
not	O
require	O
anti-hypertensive	I-Drug
medications	O
.	O
.	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
7049	O
**	O
]	O
prescription	O
for	O
Megace	I-Drug
was	O
inadvertantly	O
omitted	O
from	O
her	O
discharge	O
planning	O
.	O
A	O
prescription	O
for	O
this	O
was	O
called	O
in	O
to	O
her	O
local	O
pharmacy	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Hospice	O
of	O
the	O
Good	O
[	O
**	O
Doctor	O
Last	O
Name	O
5548	O
**	O
]	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
499	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
7050	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
7051	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2112-11-25	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2120-12-23	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2120-12-27	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2053-8-26	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
NEUROLOGY	O
Allergies	O
:	O
Hydromorphone	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
65686	O
**	O
]	O
Chief	O
Complaint	O
:	O
headache	O
,	O
nausea	O
&	O
vomiting	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
Attempted	O
drainage	O
of	O
brain	O
cyst	O
with	O
neurosurgery	O
on	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
2	O
.	O
Brain	O
cyst	O
drainage	O
with	O
interventional	O
radiology	O
on	O
[	O
**	O
12	O
-	O
26	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
67	O
right	O
handed	O
female	O
with	O
a	O
history	O
of	O
Ovarian	O
CA	O
who	O
presented	O
with	O
imbalance	O
and	O
a	O
large	O
cerebellar	O
cystic	O
lesion	O
,	O
she	O
underwent	O
stereotactic	O
drainage	O
and	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
catheter	O
placement	O
on	O
[	O
**	O
2120-12-11	O
**	O
]	O
.	O
She	O
has	O
been	O
treated	O
with	O
Cyberknife	O
locally	O
,	O
and	O
recieved	O
her	O
last	O
treatment	O
This	O
past	O
Thursday	O
[	O
**	O
2120-12-19	O
**	O
]	O
.	O
She	O
States	O
that	O
she	O
had	O
a	O
headache	O
on	O
Friday	O
which	O
resolved	O
and	O
was	O
headache	O
free	O
over	O
the	O
weekend	O
,	O
but	O
then	O
again	O
developed	O
a	O
headache	O
accompanied	O
by	O
nausea	O
and	O
vomiting	O
this	O
morning	O
.	O
She	O
Called	O
her	O
oncologist	O
who	O
advised	O
her	O
to	O
take	O
an	O
extra	O
dose	O
of	O
Decadron	I-Drug
today	O
and	O
not	O
start	O
her	O
taper	O
and	O
to	O
come	O
to	O
the	O
emergency	O
department	O
.	O
She	O
has	O
taken	O
4	O
mg	O
of	O
Decadron	I-Drug
for	O
the	O
past	O
few	O
days	O
.	O
Past	O
Medical	O
History	O
:	O
Ovarian	O
CA	O
,	O
Hypertension	O
,	O
arthritis	O
,	O
seasonal	O
allergies	O
,	O
depression	O
,	O
hyperlipidemia	O
,	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
adenomas	O
,	O
asthma	O
and	O
TIA	O
Social	O
History	O
:	O
-	O
denies	O
tobacco	O
and	O
recreational	O
drug	O
use	O
-	O
rare	O
alcohol	O
use	O
Family	O
History	O
:	O
-	O
father	O
with	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
499	O
**	O
]	O
cancer	O
,	O
deceased	O
at	O
49	O
-	O
brother	O
with	O
prostate	O
cancer	O
Physical	O
Exam	O
:	O
Gen	O
:	O
WD	O
/	O
WN	O
,	O
comfortable	O
,	O
NAD	O
.	O
HEENT	O
:	O
Pupils	O
:	O
6	O
to	O
4	O
mm	O
EOMs	O
:	O
intact	O
Neck	O
:	O
Supple	O
.	O
Abd	O
:	O
Soft	O
,	O
NT	O
,	O
BS	O
+	O
Extrem	O
:	O
Warm	O
and	O
well	O
-	O
perfused	O
.	O
Neuro	O
:	O
Mental	O
status	O
:	O
Awake	O
and	O
alert	O
,	O
cooperative	O
with	O
exam	O
,	O
normal	O
affect	O
.	O
Orientation	O
:	O
Oriented	O
to	O
person	O
,	O
place	O
,	O
and	O
date	O
.	O
Language	O
:	O
slightly	O
dysarthric	O
with	O
thick	O
speech	O
,	O
good	O
comprehension	O
and	O
repetition	O
.	O
Cranial	O
Nerves	O
:	O
I	O
:	O
Not	O
tested	O
II	O
:	O
Pupils	O
equally	O
round	O
and	O
reactive	O
to	O
light	O
,6	O
to	O
4	O
mm	O
bilaterally	O
.	O
Visual	O
fields	O
are	O
full	O
to	O
confrontation	O
.	O
III	O
,	O
IV	O
,	O
VI	O
:	O
Extraocular	O
movements	O
intact	O
bilaterally	O
without	O
nystagmus	O
.	O
V	O
,	O
VII	O
:	O
Facial	O
strength	O
and	O
sensation	O
intact	O
and	O
symmetric	O
.	O
VIII	O
:	O
Hearing	O
intact	O
to	O
voice	O
.	O
IX	O
,	O
X	O
:	O
Palatal	O
elevation	O
symmetrical	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
Sternocleidomastoid	O
and	O
trapezius	O
normal	O
bilaterally	O
.	O
XII	O
:	O
Tongue	O
midline	O
without	O
fasciculations	O
.	O
Motor	O
:	O
Normal	O
bulk	O
and	O
tone	O
bilaterally	O
.	O
No	O
abnormal	O
movements	O
,	O
tremors	O
.	O
Strength	O
full	O
power	O
[	O
**	O
5	O
-	O
8	O
**	O
]	O
throughout	O
.	O
No	O
pronator	O
drift	O
Sensation	O
:	O
Intact	O
to	O
light	O
touch	O
,	O
propioception	O
,	O
pinprick	O
and	O
vibration	O
bilaterally	O
.	O
PHYSICAL	O
EXAM	O
UPON	O
DISCHARGE	O
:	O
*********	O
Pertinent	O
Results	O
:	O
[	O
**	O
2120-12-23	O
**	O
]	O
11:18	O
PM	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
11516	O
**	O
]	O
-	O
125	O
*	O
POTASSIUM	O
-	O
3.9	O
CHLORIDE	O
-	O
87	O
*	O
[	O
**	O
2120-12-23	O
**	O
]	O
07:30	O
PM	O
GLUCOSE	O
-	O
157	O
*	O
UREA	O
N	O
-	O
11	O
CREAT	O
-	O
0.5	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
11516	O
**	O
]	O
-	O
125	O
*	O
POTASSIUM	O
-	O
3.1	O
*	O
CHLORIDE	O
-	O
85	O
*	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
19	O
BIOPSY	O
of	O
cystic	O
lesion	O
drainage	O
:	O
pending	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
HEAD	O
CT	O
IMPRESSION	O
:	O
1	O
.	O
Left	O
cerebellar	O
hypodense	O
lesion	O
,	O
with	O
mild	O
interval	O
increase	O
in	O
size	O
since	O
the	O
prior	O
study	O
.	O
An	O
MRI	O
is	O
recommended	O
for	O
further	O
evaluation	O
.	O
2	O
.	O
No	O
evidence	O
of	O
acute	O
intracranial	O
hemorrhage	O
.	O
[	O
**	O
12	O
-	O
24	O
**	O
]	O
BRAIN	O
MRI	O
IMPRESSION	O
:	O
1	O
.	O
Enlargement	O
in	O
the	O
size	O
of	O
the	O
left	O
posterior	O
fossa	O
cystic	O
lesion	O
despite	O
drain	O
in	O
situ	O
.	O
Signal	O
characteristics	O
today	O
are	O
suggestive	O
of	O
subacute	O
blood	O
products	O
.	O
2	O
.	O
Increase	O
in	O
the	O
surrounding	O
vasogenic	O
edema	O
and	O
increased	O
mass	O
effect	O
on	O
the	O
fourth	O
ventricle	O
and	O
inferior	O
displacement	O
of	O
cerebellar	O
tonsils	O
without	O
new	O
hydrocephalus	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
67	O
yo	O
female	O
with	O
h	O
/	O
o	O
stage	O
IV	O
ovarian	O
ca	O
s	O
/	O
p	O
surgery	O
,	O
6	O
cycles	O
of	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
/	O
taxol	I-Drug
,	O
cyst	O
aspiration	O
of	O
a	O
cerebellar	O
lesion	O
and	O
Cyberknife	O
treatments	O
now	O
admitted	O
with	O
increased	O
HAs	O
,	O
n	O
/	O
v	O
,	O
dysarthria	O
likely	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
increased	O
edema	O
in	O
brain	O
lesion	O
.	O
.	O
#	O
N	O
/	O
V	O
/	O
dysarthria	O
:	O
Pt	O
was	O
initially	O
admitted	O
to	O
the	O
neurosurgical	O
service	O
in	O
the	O
ICU	O
for	O
close	O
observation	O
.	O
A	O
head	O
CT	O
was	O
performed	O
which	O
revealed	O
cerebellar	O
cyst	O
versus	O
edema	O
.	O
She	O
was	O
given	O
10	O
mg	O
decadron	I-Drug
,	O
IV	O
hydration	I-Drug
,	O
Decadron	I-Drug
4	O
mg	O
Q6h	O
.	O
She	O
underwent	O
an	O
MRI	O
w	O
and	O
w	O
/	O
o	O
contrast	O
which	O
showed	O
enlargement	O
in	O
the	O
size	O
of	O
the	O
left	O
posterior	O
fossa	O
cystic	O
lesion	O
and	O
increase	O
in	O
the	O
surrounding	O
vasogenic	O
edema	O
and	O
increased	O
mass	O
effect	O
on	O
the	O
fourth	O
ventricle	O
.	O
Overnight	O
,	O
she	O
neurologically	O
improved	O
.	O
Her	O
dysarthria	O
,	O
H	O
/	O
A	O
&	O
N	O
/	O
V	O
resolved	O
.	O
Pt	O
was	O
transferred	O
to	O
OMED	O
floor	O
,	O
where	O
she	O
continued	O
to	O
be	O
largely	O
aymptomatic	O
.	O
Neurosurg	O
attempted	O
to	O
drain	O
from	O
the	O
cystic	O
lesion	O
,	O
however	O
,	O
was	O
unsuccessful	O
.	O
The	O
drainage	O
was	O
then	O
planned	O
by	O
IR	O
the	O
next	O
day	O
and	O
approx	O
14cc	O
of	O
fluid	O
was	O
drained	O
.	O
The	O
fluid	O
was	O
sent	O
to	O
the	O
lab	O
for	O
analysis	O
.	O
likely	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
increased	O
edema	O
seen	O
on	O
imaging	O
.	O
Pt	O
was	O
continued	O
on	O
Reglan	I-Drug
PRN	O
,	O
Compazine	I-Drug
PRN	O
and	O
Zofran	I-Drug
PRN	O
for	O
nausea	I-Reason
.	O
At	O
discharge	O
,	O
Dexamethasone	I-Drug
was	O
started	O
to	O
be	O
tapered	O
.	O
Pt	O
was	O
also	O
initiated	O
on	O
Bactrim	I-Drug
for	O
PCP	I-Reason
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
.	O
.	O
#	O
Hyponatremia	O
:	O
Her	O
Na	O
was	O
initially	O
125	O
.	O
Likely	O
SIADH	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
brain	O
edema	O
.	O
Improved	O
with	O
fluid	O
restriction	O
and	O
salt	O
tabs	O
.	O
Na	O
133	O
on	O
day	O
of	O
discharge	O
.	O
.	O
#	O
Stage	O
IV	O
ovarian	O
cancer	O
:	O
Pt	O
was	O
continued	O
on	O
pain	B-Reason
control	I-Reason
with	O
home	O
Motrin	I-Drug
,	O
Oxycodone	I-Drug
PRN	O
.	O
Pt	O
has	O
f	O
/	O
u	O
MRI	O
and	O
appt	O
on	O
[	O
**	O
2120-1-28	O
**	O
]	O
with	O
Brain	O
[	O
**	O
Hospital	O
341	O
**	O
]	O
Clinic	O
.	O
Given	O
pt	O
's	O
unusual	O
metastatic	O
spread	O
of	O
her	O
ovarian	O
cancer	O
to	O
the	O
brain	O
and	O
history	O
of	O
prostate	O
cancer	O
in	O
the	O
family	O
at	O
a	O
young	O
age	O
,	O
it	O
can	O
be	O
considered	O
to	O
do	O
genetic	O
testing	O
(	O
incl	O
BRCA	O
)	O
as	O
outpt	O
.	O
.	O
#	O
Depression	I-Reason
/	O
Insomnia	I-Reason
:	O
Pt	O
was	O
continued	O
on	O
home	O
Citalopram	I-Drug
and	O
Ativan	I-Drug
qhs	O
PRN	O
.	O
.	O
#	O
HTN	B-Reason
/	I-Reason
HL	I-Reason
:	O
Pt	O
was	O
continued	O
on	O
home	O
HCTZ	I-Drug
,	O
Lisinopril	I-Drug
,	O
Verapamil	I-Drug
.	O
It	O
can	O
be	O
considered	O
as	O
outpt	O
to	O
discontinue	O
HCTZ	I-Drug
,	O
given	O
pt	O
's	O
persistent	O
hyponatremia	I-Ade
.	O
Pt	O
was	O
continued	O
on	O
home	O
Simvastatin	I-Drug
.	O
.	O
#	O
Pt	O
was	O
on	O
a	O
regular	O
diet	O
,	O
oncology	O
repletion	O
scales	O
.	O
Pain	I-Reason
control	O
was	O
with	O
Motrin	I-Drug
,	O
Oxycodone	I-Drug
PRN	O
.	O
Pt	O
was	O
on	O
a	O
bowel	O
regimen	O
and	O
a	O
PPI	I-Drug
.	O
Pt	O
was	O
on	O
DVT	B-Reason
PPx	I-Reason
with	O
SC	O
Heparin	I-Drug
.	O
Pt	O
was	O
full	O
code	O
.	O
Medications	O
on	O
Admission	O
:	O
DEXAMETHASONE	I-Drug
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
1	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
Taper	O
as	O
follows	O
:	O
take	O
2	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
on	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
,	O
take	O
2	O
mg	O
QAM	O
and	O
1	O
mg	O
QPM	O
on	O
[	O
**	O
2122-12-24	O
**	O
]	O
,	O
take	O
2	O
mg	O
once	O
daily	O
on	O
[	O
**	O
11	O
-	O
20	O
**	O
]	O
,	O
take	O
1	O
mg	O
once	O
daily	O
on	O
[	O
**	O
2123-1-1	O
**	O
]	O
.	O
Stop	O
taking	O
Decadron	I-Drug
after	O
your	O
dose	O
on	O
[	O
**	O
2121-1-3	O
**	O
]	O
.	O
HYDROCHLOROTHIAZIDE	I-Drug
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
12.5	O
mg	O
Capsule	O
-	O
2	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
DAILY	O
(	O
Daily	O
)	O
IBUPROFEN	I-Drug
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
600	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
pain	I-Reason
LISINOPRIL	I-Drug
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
5	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
DAILY	O
(	O
Daily	O
)	O
LORAZEPAM	I-Drug
-	O
0.5	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
at	O
bedtime	O
and	O
as	O
needed	O
METOCLOPRAMIDE	I-Drug
-	O
10	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
every	O
6	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
,	O
abdominal	B-Reason
bloating	I-Reason
take	O
30	O
min	O
before	O
meals	O
OMEPRAZOLE	I-Drug
-	O
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
-	O
1	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
DAILY	O
(	O
Daily	O
)	O
ONDANSETRON	B-Drug
HCL	I-Drug
-	O
8	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q8hr	O
as	O
needed	O
for	O
nausea	I-Reason
,	O
vomiting	I-Reason
OXYCODONE	I-Drug
-	O
5	O
mg	O
Tablet	O
-	O
[	O
**	O
1	O
-	O
6	O
**	O
]	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q4hr	O
as	O
needed	O
for	O
pain	I-Reason
PROCHLORPERAZINE	B-Drug
MALEATE	I-Drug
-	O
10	O
mg	O
Tablet	O
-	O
1/2	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q6hr	O
as	O
needed	O
for	O
nausea	I-Reason
,	O
vomiting	I-Reason
SCALP	O
PROSTHESIS	O
-	O
-	O
apply	O
to	O
head	O
SIMVASTATIN	I-Drug
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
10	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
DAILY	O
(	O
Daily	O
)	O
VERAPAMIL	I-Drug
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
240	O
mg	O
Tablet	O
Sustained	O
Release	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
every	O
twenty	O
-	O
four	O
(	O
24	O
)	O
hours	O
Discharge	O
Medications	O
:	O
1	O
.	O
citalopram	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
verapamil	I-Drug
120	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
4	O
.	O
oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
5	O
.	O
docusate	I-Drug
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
ondansetron	B-Drug
HCl	I-Drug
8	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
8	O
.	O
prochlorperazine	I-Drug
maleate	O
5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
four	O
times	O
a	O
day	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
9	O
.	O
simvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
11	O
.	O
metoclopramide	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
12	O
.	O
omeprazole	I-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
13	O
.	O
hydrochlorothiazide	I-Drug
12.5	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
chloride	I-Drug
1	O
gram	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
180	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
15	O
.	O
dexamethasone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
18	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
16	O
.	O
dexamethasone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
12	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
17	O
.	O
dexamethasone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)	O
)	O
.	O
Disp	O
:	O
*	O
36	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
18	O
.	O
oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
20	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
19	O
.	O
Bactrim	B-Drug
DS	I-Drug
800	O
-	O
160	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
MWF	O
.	O
Disp	O
:	O
*	O
12	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnoses	O
:	O
1	O
.	O
Cystic	O
brain	O
lesion	O
2	O
.	O
SIADH	O
,	O
low	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
3	O
.	O
Stage	O
IV	O
Ovarian	O
Cancer	O
Secondary	O
Diagnoses	O
:	O
1	O
.	O
Depression	O
2	O
.	O
Hypertension	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
It	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
during	O
this	O
admission	O
.	O
You	O
were	O
admitted	O
for	O
headaches	O
,	O
nausea	O
,	O
vomiting	O
,	O
and	O
difficulty	O
speaking	O
.	O
You	O
had	O
an	O
MRI	O
of	O
your	O
head	O
that	O
showed	O
increased	O
size	O
of	O
cystic	O
lesion	O
.	O
Neurosurgery	O
tried	O
to	O
drain	O
the	O
fluid	O
but	O
were	O
unable	O
to	O
.	O
You	O
had	O
a	O
second	O
procedure	O
with	O
interventional	O
radiology	O
,	O
who	O
was	O
able	O
to	O
remove	O
some	O
fluid	O
.	O
Your	O
headaches	O
improved	O
.	O
The	O
following	O
medications	O
were	O
changed	O
during	O
this	O
admission	O
:	O
START	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
chloride	I-Drug
1	O
mg	O
,	O
2	O
tablets	O
,	O
three	O
times	O
daily	O
(	O
this	O
is	O
to	O
maintain	O
your	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
levels	O
at	O
a	O
normal	O
level	O
)	O
START	O
Oxycodone	I-Drug
5	O
mg	O
1	O
-	O
2	O
tablets	O
every	O
four	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
**	O
This	O
medication	O
can	O
cause	O
sedation	I-Ade
,	O
do	O
not	O
take	O
this	O
medication	O
while	O
if	O
you	O
feel	O
sedated	O
or	O
confused	O
.	O
And	O
you	O
should	O
not	O
be	O
driving	O
while	O
on	O
this	O
medication	O
,	O
or	O
at	O
all	O
.	O
START	O
Bactrim	B-Drug
DS	I-Drug
(	O
Oral	O
)	O
800	O
-	O
160	O
mg	O
Tablet	O
,	O
1	O
tablet	O
on	O
Monday	O
,	O
Wednesday	O
and	O
Friday	O
(	O
this	O
is	O
an	O
antibiotic	O
that	O
prevents	O
an	O
infection	O
called	O
PCP	O
in	O
the	O
lungs	O
;	O
this	O
is	O
important	O
to	O
take	O
since	O
you	O
are	O
on	O
steroids	I-Drug
and	O
may	O
be	O
more	O
susceptible	O
to	O
infection	O
)	O
The	O
dose	O
of	O
Dexamethasone	I-Drug
was	O
changed	O
;	O
Please	O
follow	O
the	O
schedule	O
below	O
:	O
START	O
Dexamethasone	I-Drug
6	O
mg	O
by	O
mouth	O
twice	O
daily	O
for	O
3	O
days	O
,	O
then	O
take	O
4	O
mg	O
twice	O
daily	O
for	O
3	O
days	O
,	O
then	O
take	O
6	O
mg	O
daily	O
in	O
the	O
morning	O
.	O
You	O
should	O
see	O
your	O
doctor	O
in	O
the	O
interim	O
to	O
determine	O
how	O
long	O
you	O
need	O
to	O
be	O
on	O
the	O
dexamethasone	I-Drug
.	O
Continue	O
all	O
other	O
medications	O
you	O
were	O
on	O
prior	O
to	O
this	O
admission	O
.	O
**	O
You	O
have	O
been	O
continued	O
on	O
your	O
home	O
dose	O
of	O
hydrochlorathiazide	I-Drug
25	O
mg	O
daily	O
.	O
However	O
,	O
we	O
would	O
like	O
you	O
to	O
discuss	O
discontinuing	O
this	O
with	O
your	O
doctor	O
.	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
2172	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
has	O
been	O
low	O
during	O
this	O
admission	O
,	O
which	O
has	O
been	O
controlled	O
with	O
restriction	O
of	O
1L	O
of	O
fluid	O
and	O
salt	O
tabs	O
.	O
However	O
,	O
HCTZ	I-Drug
can	O
also	O
lower	O
the	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
.	O
Since	O
you	O
have	O
been	O
stable	O
on	O
this	O
medication	O
,	O
you	O
were	O
continued	O
on	O
it	O
.	O
Though	O
,	O
please	O
discuss	O
this	O
with	O
your	O
doctor	O
at	O
follow	O
-	O
up	O
.	O
**	O
In	O
terms	O
of	O
travel	O
,	O
it	O
is	O
safe	O
for	O
you	O
to	O
visit	O
you	O
family	O
.	O
However	O
,	O
you	O
should	O
NOT	O
drive	O
.	O
This	O
can	O
be	O
very	O
dangerous	O
,	O
especially	O
since	O
you	O
recently	O
had	O
a	O
procedure	O
.	O
??????	O
Take	O
your	O
pain	O
medicine	O
as	O
prescribed	O
.	O
??????	O
Exercise	O
should	O
be	O
limited	O
to	O
walking	O
;	O
no	O
lifting	O
,	O
straining	O
,	O
or	O
excessive	O
bending	O
.	O
??????	O
Increase	O
your	O
intake	O
of	O
fluids	O
and	O
fiber	I-Drug
,	O
as	O
narcotic	B-Drug
pain	I-Drug
medicine	O
can	O
cause	O
constipation	I-Ade
.	O
We	O
generally	O
recommend	O
taking	O
an	O
over	O
the	O
counter	O
stool	B-Drug
softener	I-Drug
,	O
such	O
as	O
Docusate	I-Drug
(	O
Colace	I-Drug
)	O
while	O
taking	O
narcotic	B-Drug
pain	I-Drug
medication	I-Drug
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
the	O
following	O
appointments	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
SCAN	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2121-1-10	O
**	O
]	O
11:15	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2121-1-13	O
**	O
]	O
11:00	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
3750	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3751	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2121-1-13	O
**	O
]	O
11:00	O
Department	O
:	O
RADIOLOGY	O
When	O
:	O
FRIDAY	O
[	O
**	O
2121-1-10	O
**	O
]	O
at	O
11:15	O
AM	O
With	O
:	O
CAT	O
SCAN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
861	O
**	O
]	O
Campus	O
:	O
EAST	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
MONDAY	O
[	O
**	O
2121-1-13	O
**	O
]	O
at	O
11:00	O
AM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
MONDAY	O
[	O
**	O
2121-1-13	O
**	O
]	O
at	O
11:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
3750	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3751	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
**	O
You	O
will	O
also	O
need	O
a	O
follow	O
-	O
up	O
brain	O
MRI	O
in	O
one	O
month	O
.	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
86075	O
**	O
]	O
office	O
will	O
be	O
in	O
contact	O
with	O
you	O
regarding	O
it	O
.	O
Completed	O
by	O
:[	O
**	O
2120-12-27	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2185-7-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2185-8-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2116-9-30	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Demerol	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4111	O
**	O
]	O
Chief	O
Complaint	O
:	O
small	O
bowel	O
obstruction	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Parastomal	O
hernia	O
repair	O
and	O
take	O
down	O
of	O
colostomy	O
with	O
re-siting	O
to	O
the	O
right	O
side	O
of	O
abdomen	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
patient	O
had	O
undergone	O
a	O
series	O
of	O
bouts	O
of	O
intestinal	O
obstruction	O
.	O
This	O
last	O
time	O
she	O
was	O
in	O
fact	O
given	O
an	O
upper	O
GI	O
series	O
and	O
small	O
bowel	O
follow	O
through	O
and	O
when	O
she	O
came	O
to	O
the	O
hospital	O
,	O
she	O
had	O
some	O
barium	O
and	O
a	O
nest	O
of	O
bowel	O
in	O
the	O
pelvis	O
.	O
It	O
was	O
not	O
clear	O
exactly	O
what	O
the	O
cause	O
of	O
obstruction	O
was	O
but	O
she	O
did	O
not	O
pass	O
much	O
gas	O
nor	O
was	O
she	O
able	O
to	O
get	O
rid	O
of	O
her	O
nasogastric	O
tube	O
.	O
The	O
colostomy	O
was	O
prolapsed	O
and	O
it	O
appeared	O
on	O
CT	O
scan	O
that	O
she	O
had	O
an	O
area	O
of	O
a	O
kink	O
in	O
the	O
small	O
bowel	O
which	O
was	O
a	O
transitional	O
point	O
.	O
This	O
in	O
fact	O
was	O
the	O
case	O
but	O
it	O
was	O
also	O
a	O
place	O
where	O
she	O
was	O
obstructed	O
with	O
barium	O
.	O
Past	O
Medical	O
History	O
:	O
rectal	O
CA	O
(	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
-	O
[	O
**	O
2170	O
**	O
]	O
)	O
diabetes	O
HTN	O
high	O
cholesterol	O
parastomal	O
hernia	O
(	O
[	O
**	O
2177	O
**	O
]	O
)	O
Social	O
History	O
:	O
Patient	O
lives	O
with	O
son	O
,	O
long	O
time	O
smoker	O
,	O
denies	O
alcohol	O
use	O
.	O
Family	O
History	O
:	O
noncontributory	O
Physical	O
Exam	O
:	O
afebrile	O
,	O
hemodynamically	O
stable	O
patient	O
in	O
mild	O
distress	O
at	O
presentation	O
Chest	O
-	O
CTAB	O
CV	O
-	O
RRR	O
,	O
-	O
MRG	O
Abd	O
:	O
soft	O
,	O
mildly	O
tender	O
to	O
palpation	O
,	O
no	O
stool	O
or	O
gas	O
at	O
ostomy	O
site	O
,	O
large	O
parastomal	O
hernia	O
on	O
the	O
left	O
,	O
decreased	O
bowel	O
sounds	O
Pertinent	O
Results	O
:	O
[	O
**	O
2185-7-26	O
**	O
]	O
08:00	O
PM	O
BLOOD	O
WBC	O
-	O
19.0	O
*	O
RBC	O
-	O
3.37	O
*	O
Hgb	O
-	O
10.9	O
*	O
Hct	O
-	O
31.7	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
16.1	O
*	O
Plt	O
Ct	O
-	O
397	O
[	O
**	O
2185-8-1	O
**	O
]	O
04:42	O
AM	O
BLOOD	O
WBC	O
-	O
9.3	O
RBC	O
-	O
2.92	O
*	O
Hgb	O
-	O
9.2	O
*	O
Hct	O
-	O
26.8	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
31.6	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
16.0	O
*	O
Plt	O
Ct	O
-	O
368	O
[	O
**	O
2185-7-20	O
**	O
]	O
04:33	O
AM	O
BLOOD	O
Glucose	O
-	O
264	O
*	O
UreaN	O
-	O
11	O
Creat	O
-	O
0.5	O
Na	O
-	O
135	O
K	O
-	O
3.8	O
Cl	O
-	O
104	O
HCO3	O
-	O
23	O
AnGap	O
-	O
12	O
[	O
**	O
2185-8-2	O
**	O
]	O
04:02	O
AM	O
BLOOD	O
Glucose	O
-	O
109	O
*	O
UreaN	O
-	O
13	O
Creat	O
-	O
0.9	O
Na	O
-	O
136	O
K	O
-	O
4.0	O
Cl	O
-	O
100	O
HCO3	O
-	O
26	O
AnGap	O
-	O
14	O
[	O
**	O
2185-7-31	O
**	O
]	O
02:06	O
AM	O
BLOOD	O
calTIBC	O
-	O
163	O
*	O
Ferritn	O
-	O
208	O
*	O
TRF	O
-	O
125	O
*	O
[	O
**	O
2185-7-24	O
**	O
]	O
03:46	O
AM	O
BLOOD	O
calTIBC	O
-	O
281	O
Ferritn	O
-	O
179	O
*	O
TRF	O
-	O
216	O
[	O
**	O
2185-7-17	O
**	O
]	O
04:04	O
AM	O
BLOOD	O
Folate	O
-	O
11.8	O
[	O
**	O
2185-7-15	O
**	O
]	O
09:21	O
PM	O
BLOOD	O
calTIBC	O
-	O
374	O
Ferritn	O
-	O
50	O
TRF	O
-	O
288	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
admitted	O
for	O
the	O
question	O
of	O
small	O
bowel	O
obstruction	O
.	O
On	O
CT	O
scan	O
she	O
had	O
an	O
area	O
of	O
twisted	O
bowel	O
along	O
with	O
her	O
large	O
parastomal	O
hernia	O
.	O
Her	O
ostomy	O
output	O
had	O
no	O
stool	O
or	O
gas	O
in	O
it	O
.	O
She	O
was	O
taken	O
to	O
the	O
OR	O
to	O
resolve	O
these	O
issues	O
.	O
In	O
the	O
OR	O
she	O
had	O
a	O
large	O
amount	O
of	O
barium	O
in	O
the	O
small	O
intestine	O
which	O
was	O
moved	O
into	O
the	O
cecum	O
.	O
She	O
had	O
a	O
hyperkalemia	I-Reason
directly	O
following	O
surgery	O
which	O
resolved	O
with	O
an	O
insulin	I-Drug
drip	O
.	O
She	O
was	O
admitted	O
to	O
the	O
ICU	O
for	O
this	O
purpose	O
.	O
Her	O
blood	O
sugars	O
were	O
difficult	O
to	O
control	O
post-operatively	O
and	O
she	O
was	O
maintained	O
on	O
the	O
insulin	I-Drug
drip	O
for	O
the	O
first	O
3	O
days	O
post-operatively	O
.	O
It	O
was	O
also	O
difficult	O
to	O
ween	O
her	O
from	O
her	O
O2	I-Drug
needs	O
post-op	O
(	O
this	O
was	O
most	O
likely	O
due	O
to	O
her	O
very	O
long	O
smoking	O
history	O
)	O
.	O
Eventually	O
she	O
was	O
restarted	O
on	O
her	O
home	O
metformin	I-Drug
and	O
was	O
able	O
to	O
come	O
off	O
of	O
oxygen	I-Drug
therapy	O
.	O
On	O
day	O
3	O
post-operatively	O
gas	O
and	O
stool	O
appeared	O
at	O
her	O
ostomy	O
following	O
a	O
bowel	B-Reason
regimen	I-Reason
of	O
colace	I-Drug
and	O
mineral	B-Drug
oil	I-Drug
.	O
She	O
was	O
discharged	O
home	O
to	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
957	O
**	O
]	O
in	O
clinic	O
.	O
She	O
was	O
tolerating	O
PO	O
intake	O
at	O
discharge	O
and	O
was	O
in	O
good	O
condition	O
.	O
Medications	O
on	O
Admission	O
:	O
atenolol	I-Drug
50	O
pravastatin	I-Drug
40	O
FeSO4	I-Drug
325	O
metformin	I-Drug
500	O
xanax	I-Drug
1	O
mg	O
HS	O
Discharge	O
Medications	O
:	O
1	O
.	O
Bactrim	I-Drug
DS	O
160	O
-	O
800	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
for	O
1	O
weeks	O
.	O
Disp	O
:	O
*	O
28	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Mineral	B-Drug
Oil	I-Drug
Oil	O
Sig	O
:	O
2.5	O
MLs	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
20	O
ML	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital3	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Small	O
Bowel	O
Obstruction	O
Discharge	O
Condition	O
:	O
stable	O
,	O
good	O
Discharge	O
Instructions	O
:	O
Please	O
return	O
if	O
:	O
1	O
.	O
fever	O
>	O
101	O
2	O
.	O
not	O
passing	O
stool	O
out	O
of	O
your	O
ostomy	O
site	O
3	O
.	O
abdominal	O
pain	O
4	O
.	O
inability	O
to	O
tolerate	O
oral	O
diet	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
957	O
**	O
]	O
in	O
his	O
clinic	O
next	O
Wednesday	O
,	O
[	O
**	O
8	O
-	O
10	O
**	O
]	O
at	O
10:00	O
AM	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2154-8-30	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2154-9-1	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2081-12-11	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Optiray	B-Drug
320	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2290	O
**	O
]	O
Chief	O
Complaint	O
:	O
Post-operative	O
hypoxia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Debridement	O
of	O
tracheal	O
nodule	O
with	O
interventional	O
pulmonology	O
History	O
of	O
Present	O
Illness	O
:	O
72	O
yo	O
F	O
with	O
poorly	O
differentiated	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
lung	O
who	O
underwent	O
rigid	O
bronch	O
[	O
**	O
2154-8-30	O
**	O
]	O
(	O
Friday	O
)	O
in	O
the	O
CDC	O
for	O
debridement	O
of	O
a	O
nodule	O
partially	O
occluding	O
the	O
trachea	O
(	O
CT	O
09	O
/	O
[	O
**	O
2153	O
**	O
]	O
)	O
.	O
Patient	O
was	O
apneic	I-Ade
post-operatively	O
attributed	O
to	O
paralytics	I-Drug
,	O
for	O
which	O
she	O
was	O
intubated	O
and	O
placed	O
on	O
AC	O
until	O
the	O
paralytic	I-Drug
wore	O
off	O
.	O
She	O
was	O
then	O
weaned	O
to	O
CPAP	O
and	O
extubated	O
to	O
high	O
flow	O
facemask	O
without	O
difficulty	O
.	O
She	O
was	O
later	O
switched	O
to	O
high	O
flow	O
face	O
tent	O
and	O
then	O
nasal	O
canula	O
4L	O
-	O
>	O
2L	O
and	O
was	O
comfortable	O
sating	O
92	O
%	O
.	O
On	O
the	O
floor	O
,	O
the	O
patient	O
was	O
comfortable	O
on	O
2L	O
nasal	O
cannula	O
,	O
sating	O
94	O
%	O
.	O
Complains	O
of	O
coughing	O
when	O
taking	O
deep	O
breaths	O
,	O
but	O
otherwise	O
stable	O
.	O
She	O
denies	O
CP	O
,	O
N	O
/	O
V	O
/	O
D	O
/	O
C	O
,	O
dysuria	O
,	O
HA	O
,	O
vision	O
changes	O
,	O
or	O
depressed	O
mood	O
.	O
Past	O
Medical	O
History	O
:	O
Poorly	O
differentiated	O
SCC	B-Reason
of	I-Reason
lung	I-Reason
:	O
-	O
s	O
/	O
p	O
right	O
upper	O
lobectomy	O
and	O
chemotherapy	I-Drug
[	O
**	O
2148	O
**	O
]	O
-	O
left	O
lower	O
lobe	O
nodule	O
1.4	O
cm	O
,	O
non-diagnostic	O
CT	O
-	O
guided	O
biopsy	O
,	O
s	O
/	O
p	O
CyberKnife	O
CAD	O
s	O
/	O
p	O
Coronary	O
angioplasty	O
[	O
**	O
2139	O
**	O
]	O
,	O
[	O
**	O
2151	O
**	O
]	O
,	O
CABG	O
x	O
3v	O
[	O
**	O
2151	O
**	O
]	O
H	O
/	O
o	O
Infectious	O
colitis	O
[	O
**	O
2152	O
**	O
]	O
HTN	O
IDDM	O
Hypercholesterolemia	O
Bladder	O
surgery	O
[	O
**	O
2123	O
**	O
]	O
Hernia	O
repair	O
[	O
**	O
2147	O
**	O
]	O
,	O
S	O
/	O
p	O
Cholecystectomy	O
[	O
**	O
2147	O
**	O
]	O
Social	O
History	O
:	O
Former	O
smoker	O
,	O
80	O
pack	O
year	O
history	O
.	O
No	O
EtOH	O
or	O
drugs	O
.	O
Married	O
.	O
Family	O
History	O
:	O
Father	O
with	O
lung	O
/	O
bone	O
cancer	O
,	O
mother	O
relatively	O
healthy	O
until	O
later	O
yrs	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
97.9	O
96.9	O
102/60	O
20	O
96	O
%	O
2LNC	O
GEN	O
:	O
Pleasant	O
,	O
comfortable	O
,	O
NAD	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
anicteric	O
,	O
dry	O
MM	O
RESP	O
:	O
Wheezing	O
throughout	O
with	O
Rhonchorous	O
breath	O
sounds	O
CV	O
:	O
RR	O
,	O
S1	O
and	O
S2	O
wnl	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
ABD	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
,	O
+	O
BS	O
,	O
no	O
masses	O
or	O
hepatosplenomegaly	O
EXT	O
:	O
Trace	O
edema	O
in	O
bilateral	O
lower	O
extremities	O
SKIN	O
:	O
No	O
rashes	O
,	O
fairly	O
dry	O
skin	O
,	O
surfaces	O
intact	O
NEURO	O
:	O
AOx3	O
.	O
CNII	O
-	O
XII	O
,	O
sensory	O
,	O
and	O
motor	O
grossly	O
intact	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2154-9-1	O
**	O
]	O
07:10	O
AM	O
BLOOD	O
WBC	O
-	O
5.9	O
RBC	O
-	O
4.15	O
*	O
Hgb	O
-	O
12.1	O
Hct	O
-	O
35.8	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
29.1	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
15.4	O
Plt	O
Ct	O
-	O
170	O
[	O
**	O
2154-8-30	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
WBC	O
-	O
8.8	O
RBC	O
-	O
5.04	O
Hgb	O
-	O
14.4	O
Hct	O
-	O
44.7	O
MCV	O
-	O
89	O
MCH	O
-	O
28.5	O
MCHC	O
-	O
32.2	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
230	O
[	O
**	O
2154-9-1	O
**	O
]	O
07:10	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
170	O
[	O
**	O
2154-8-30	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
230	O
[	O
**	O
2154-8-30	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
Glucose	O
-	O
269	O
*	O
UreaN	O
-	O
14	O
Creat	O
-	O
0.7	O
Na	O
-	O
142	O
K	O
-	O
4.3	O
Cl	O
-	O
104	O
HCO3	O
-	O
33	O
*	O
AnGap	O
-	O
9	O
[	O
**	O
2154-8-31	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
Glucose	O
-	O
136	O
*	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.6	O
Na	O
-	O
141	O
K	O
-	O
3.7	O
Cl	O
-	O
105	O
HCO3	O
-	O
29	O
AnGap	O
-	O
11	O
[	O
**	O
2154-8-31	O
**	O
]	O
04:08	O
AM	O
BLOOD	O
Calcium	O
-	O
8.2	O
*	O
Phos	O
-	O
3.0	O
Mg	O
-	O
1.8	O
[	O
**	O
2154-8-30	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
4.1	O
Mg	O
-	O
2.1	O
[	O
**	O
2154-8-30	O
**	O
]	O
02:09	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
97	O
pCO2	O
-	O
49	O
*	O
pH	O
-	O
7.37	O
calTCO2	O
-	O
29	O
Base	O
XS	O
-	O
1	O
[	O
**	O
2154-8-30	O
**	O
]	O
10:26	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
66	O
*	O
pCO2	O
-	O
55	O
*	O
pH	O
-	O
7.33	O
*	O
calTCO2	O
-	O
30	O
Base	O
XS	O
-	O
0	O
Intubat	O
-	O
INTUBATED	O
[	O
**	O
2154-8-30	O
**	O
]	O
10:26	O
AM	O
BLOOD	O
Glucose	O
-	O
239	O
*	O
Lactate	O
-	O
2.2	O
*	O
Na	O
-	O
141	O
K	O
-	O
4.4	O
Cl	O
-	O
102	O
[	O
**	O
2154-8-30	O
**	O
]	O
10:26	O
AM	O
BLOOD	O
Hgb	O
-	O
14.4	O
calcHCT	O
-	O
43	O
O2	O
Sat	O
-	O
89	O
COHgb	O
-	O
2.0	O
MetHgb	O
-	O
0	O
[	O
**	O
2154-8-30	O
**	O
]	O
10:26	O
AM	O
BLOOD	O
freeCa	O
-	O
1.13	O
[	O
**	O
2154-8-30	O
**	O
]	O
MRSA	O
SCREEN	O
MRSA	O
SCREEN	O
-	O
PENDING	O
[	O
**	O
2154-8-31	O
**	O
]	O
Radiology	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
Right	O
upper	O
,	O
right	O
perihilar	O
,	O
right	O
lower	O
lobe	O
opacities	O
consistent	O
with	O
improving	O
hemorrhage	O
or	O
aspiration	O
are	O
unchanged	O
.	O
A	O
left	O
lung	O
is	O
grossly	O
clear	O
.	O
There	O
is	O
no	O
evident	O
pneumothorax	O
.	O
Right	O
lung	O
peripheral	O
opacities	O
better	O
evaluated	O
in	O
prior	O
CT	O
[	O
**	O
8	O
-	O
5	O
**	O
]	O
and	O
are	O
unchanged	O
.	O
[	O
**	O
2154-8-31	O
**	O
]	O
Radiology	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
There	O
has	O
been	O
markedly	O
improved	O
in	O
right	O
upper	O
,	O
right	O
perihilar	O
and	O
right	O
lower	O
lobe	O
opacities	O
consistent	O
with	O
improving	O
hemorrhage	O
or	O
aspiration	O
.	O
Cardiomediastinal	O
contours	O
are	O
unchanged	O
with	O
mild	O
-	O
to	O
-	O
moderate	O
cardiomegaly	O
.	O
There	O
is	O
no	O
evident	O
pneumothorax	O
.	O
Of	O
note	O
,	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
hemithorax	O
was	O
not	O
included	O
on	O
the	O
film	O
.	O
There	O
are	O
no	O
increasing	O
right	O
pleural	O
effusions	O
.	O
Sternal	O
wires	O
are	O
aligned	O
with	O
fracture	O
of	O
the	O
first	O
wire	O
.	O
[	O
**	O
2154-8-30	O
**	O
]	O
Radiology	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
FINDINGS	O
:	O
In	O
comparison	O
with	O
the	O
earlier	O
study	O
of	O
this	O
date	O
,	O
the	O
endotracheal	O
tube	O
has	O
been	O
removed	O
.	O
The	O
diffuse	O
area	O
of	O
opacification	O
involving	O
the	O
perihilar	O
region	O
extending	O
into	O
both	O
the	O
apical	O
and	O
lower	O
zone	O
on	O
the	O
right	O
is	O
again	O
seen	O
.	O
Again	O
,	O
this	O
could	O
well	O
represent	O
post-procedure	O
hemorrhage	O
,	O
though	O
supervening	O
pneumonia	O
can	O
not	O
be	O
excluded	O
.	O
[	O
**	O
2154-8-30	O
**	O
]	O
Radiology	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
IMPRESSIONS	O
:	O
Extensive	O
right	O
central	O
and	O
upper	O
lung	O
airspace	O
opacity	O
,	O
which	O
may	O
reflect	O
hemorrhage	O
from	O
the	O
recent	O
procedure	O
,	O
or	O
asymmetric	O
pulmonary	O
edema	O
.	O
[	O
**	O
2154-8-30	O
**	O
]	O
Pathology	O
Tissue	O
:	O
Tracheal	O
tumor	O
Distal	O
,	O
[	O
**	O
2154-8-30	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
829	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
828	O
**	O
]	O
C.	O
Not	O
Finalized	O
Brief	O
Hospital	O
Course	O
:	O
#	O
Apnea	O
/	O
Hypoxia	O
:	O
The	O
patient	O
experienced	O
apnea	O
in	O
the	O
immediate	O
post-operative	O
period	O
following	O
debridement	O
of	O
a	O
tracheal	O
nodule	O
.	O
The	O
apnea	I-Ade
was	O
thought	O
to	O
be	O
attributed	O
to	O
paralytics	I-Drug
,	O
which	O
warranted	O
intubation	O
.	O
When	O
the	O
paralytic	O
agents	O
wore	O
off	O
,	O
the	O
patient	O
was	O
extubated	O
,	O
but	O
remained	O
hypoxia	O
.	O
The	O
prolonged	O
hypoxia	O
post-operatively	O
was	O
attributed	O
to	O
aspiration	O
pneumonitis	O
likely	O
with	O
an	O
element	O
of	O
post-operative	O
inflammation	O
from	O
the	O
procedure	O
itself	O
.	O
The	O
patient	O
remained	O
rhoncorous	O
with	O
course	O
upper	O
airway	O
breath	O
sounds	O
throughout	O
the	O
hospitalization	O
.	O
CXR	O
ruled	O
out	O
PNA	O
as	O
a	O
potentialy	O
source	O
of	O
hypoxia	O
,	O
and	O
the	O
patient	O
did	O
not	O
produce	O
significant	O
volumes	O
of	O
concentration	O
of	O
blood	O
in	O
the	O
sputum	O
concerning	O
for	O
tracheal	O
bleed	O
.	O
Other	O
possibilities	O
include	O
worsening	O
of	O
underlying	O
lung	O
cancer	O
which	O
is	O
unlikely	O
to	O
explain	O
acute	O
hypoxia	O
.	O
The	O
patient	O
was	O
eventually	O
transitioned	O
to	O
high	O
flow	O
face	O
mask	O
,	O
followed	O
by	O
high	O
-	O
flow	O
face	O
tent	O
,	O
followed	O
by	O
nasal	O
cannular	O
on	O
4L	O
.	O
The	O
patient	O
was	O
weaned	O
without	O
event	O
from	O
4L	O
to	O
2L	O
nasal	O
cannula	O
and	O
transferred	O
to	O
the	O
inpatient	O
medical	O
floor	O
,	O
where	O
she	O
continued	O
sat	O
'	O
ing	O
~	O
94	O
%	O
on	O
2L	O
.	O
Nebs	I-Drug
were	O
administered	O
on	O
an	O
as	O
needed	O
basis	O
throughout	O
the	O
duration	O
of	O
hospitalization	O
,	O
and	O
were	O
found	O
to	O
be	O
helpful	O
in	O
terms	O
of	O
coughing	B-Reason
up	I-Reason
phlegm	I-Reason
.	O
The	O
patient	O
was	O
taken	O
off	O
supplemental	O
oxygen	O
the	O
following	O
day	O
and	O
sat	O
'	O
ed	O
within	O
her	O
normal	O
baseline	O
range	O
88	O
-	O
92	O
%	O
on	O
room	O
air	O
without	O
any	O
problems	O
at	O
rest	O
.	O
However	O
,	O
patient	O
desaturated	O
with	O
physical	O
therapy	O
during	O
activity	O
.	O
They	O
recommended	O
home	O
oxygen	I-Drug
(	O
2L	O
with	O
activity	O
)	O
when	O
ambulating	O
with	O
a	O
walker	O
.	O
The	O
patient	O
will	O
be	O
discharged	O
with	O
home	O
oxygen	I-Drug
as	O
well	O
as	O
VNA	O
services	O
.	O
.	O
#	O
Hct	O
Drop	O
:	O
The	O
patient	O
presented	O
with	O
a	O
Hct	O
44.7	O
and	O
found	O
to	O
have	O
a	O
Hct	O
of	O
33.1	O
post-operatively	O
.	O
The	O
low	O
Hct	O
is	O
most	O
likely	O
attributable	O
to	O
fluids	O
received	O
during	O
procedure	O
and	O
minimal	O
blood	O
loss	O
,	O
however	O
given	O
the	O
12	O
point	O
drop	O
,	O
her	O
lab	O
values	O
were	O
followed	O
and	O
the	O
Hct	O
level	O
was	O
stable	O
and	O
began	O
to	O
rise	O
without	O
event	O
or	O
concern	O
for	O
chonic	O
blood	O
loss	O
.	O
Hct	O
34.0	O
-	O
>	O
35.8	O
this	O
AM	O
.	O
.	O
#	O
Non-Small	O
Cell	O
Lung	O
CA	O
:	O
A	O
new	O
tracheal	O
mass	O
identified	O
on	O
CT	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
was	O
highly	O
concerning	O
for	O
metastasis	O
and	O
likely	O
to	O
grow	O
to	O
occlude	O
airway	O
the	O
airway	O
,	O
so	O
surgical	O
debridement	O
was	O
warranted	O
with	O
interventional	O
pulmonology	O
without	O
intraoperative	O
complications	O
outside	O
of	O
apnea	O
/	O
hypoxia	O
as	O
elaborated	O
on	O
above	O
.	O
The	O
patient	O
is	O
now	O
POD	O
#	O
2	O
s	O
/	O
p	O
debridment	O
by	O
IP	O
.	O
Biopsy	O
results	O
are	O
pending	O
.	O
She	O
is	O
followed	O
by	O
interventional	O
pulmonology	O
for	O
continued	O
management	O
.	O
.	O
#	O
Goals	O
of	O
Care	O
:	O
Discussed	O
code	O
status	O
with	O
patient	O
,	O
daughter	O
and	O
sons	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
quite	O
clearly	O
does	O
not	O
desire	O
intubation	O
or	O
heroic	O
measures	O
.	O
Daughter	O
is	O
having	O
a	O
difficult	O
time	O
with	O
this	O
but	O
understands	O
and	O
respects	O
her	O
mother	O
's	O
wishes	O
.	O
The	O
DNR	O
/	O
DNI	O
status	O
was	O
confirmed	O
with	O
the	O
patient	O
and	O
her	O
health	O
care	O
proxy	O
.	O
.	O
#	O
IDDM	I-Reason
:	O
Continued	O
home	O
glargine	I-Drug
and	O
home	O
meds	O
.	O
.	O
#	O
HTN	I-Reason
:	O
Continued	O
amlodipine	I-Drug
,	O
lopressor	I-Drug
and	O
ASA	I-Drug
.	O
.	O
#	O
Hyperlipidemia	I-Reason
:	O
Continued	O
home	O
statin	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
AMLODIPINE	I-Drug
5	O
mg	O
daily	O
ESOMEPRAZOLE	I-Drug
40	O
mg	O
qd	O
GLARGINE	I-Drug
8	O
units	O
daily	O
@	O
night	O
LORAZEPAM	I-Drug
1	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
METOPROLOL	I-Drug
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
REPAGLINIDE	I-Drug
0.5	O
mg	O
tid	O
SIMVASTATIN	I-Drug
40	O
mg	O
qd	O
ASPIRIN	I-Drug
81	O
mg	O
daily	O
FAMOTIDINE	I-Drug
qd	O
Discharge	O
Medications	O
:	O
1	O
.	O
amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Tablet	O
(	O
s	O
)	O
2	O
.	O
pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
3	O
.	O
insulin	B-Drug
glargine	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Eight	O
(	O
8	O
)	O
units	O
Subcutaneous	O
at	O
bedtime	O
.	O
4	O
.	O
lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
5	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
repaglinide	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
8	O
.	O
Aspirin	I-Drug
Low	O
Dose	O
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
9	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
10	O
.	O
ipratropium	B-Drug
-	I-Drug
albuterol	I-Drug
18	O
-	O
103	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
puffs	O
Inhalation	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	O
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
1	O
IH	O
*	O
Refills	O
:	O
*	O
2	O
*	O
11	O
.	O
Oxygen	I-Drug
2L	O
nasal	O
canula	O
with	O
ambulation	O
12	O
.	O
famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
932	O
**	O
]	O
Area	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Aspiration	O
-	O
induced	O
hypoxia	O
Secondary	O
:	O
Poorly	O
differentiated	O
SCC	B-Reason
of	I-Reason
lung	I-Reason
:	O
-	O
right	O
upper	O
lobectomy	O
and	O
chemotherapy	I-Drug
[	O
**	O
2148	O
**	O
]	O
-	O
left	O
lower	O
lobe	O
nodule	O
1.4	O
cm	O
,	O
non-diagnostic	O
CT	O
-	O
guided	O
biopsy	O
,	O
s	O
/	O
p	O
CyberKnife	O
Coronary	O
artery	O
disease	O
:	O
Coronary	O
angioplasty	O
[	O
**	O
2139	O
**	O
]	O
,	O
[	O
**	O
2151	O
**	O
]	O
,	O
CABG	O
x	O
3v	O
[	O
**	O
2151	O
**	O
]	O
Infectious	O
colitis	O
[	O
**	O
2152	O
**	O
]	O
Hypertension	O
Insulin	I-Drug
-	O
dependent	O
diabetes	B-Reason
mellitus	I-Reason
Hypercholesterolemia	O
Bladder	O
surgery	O
[	O
**	O
2123	O
**	O
]	O
Hernia	O
repair	O
[	O
**	O
2147	O
**	O
]	O
Cholecystectomy	O
[	O
**	O
2147	O
**	O
]	O
Tracheal	O
nodule	O
debridement	O
[	O
**	O
8	O
-	O
/	O
2154	O
**	O
]	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
and	O
supplemental	O
oxygen	I-Drug
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
18	O
**	O
]	O
hospital	O
for	O
surgical	O
debridement	O
of	O
a	O
tracheal	O
nodule	O
that	O
was	O
contributing	O
to	O
your	O
difficulty	O
breathing	O
.	O
You	O
underwent	O
this	O
procedure	O
with	O
the	O
interventional	O
pulmonologists	O
.	O
After	O
surgery	O
you	O
were	O
found	O
to	O
have	O
difficulty	B-Ade
breathing	I-Ade
and	O
decreased	B-Ade
oxygen	I-Ade
levels	I-Ade
that	O
were	O
thought	O
to	O
be	O
a	O
result	O
of	O
both	O
the	O
paralytic	I-Drug
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
used	O
during	O
surgery	O
as	O
well	O
as	O
the	O
possibility	O
that	O
you	O
aspirated	O
fluids	O
into	O
your	O
trachea	O
/	O
lungs	O
during	O
surgery	O
.	O
As	O
such	O
,	O
you	O
were	O
intubated	O
and	O
transferred	O
to	O
the	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
for	O
respiratory	O
care	O
and	O
support	O
.	O
In	O
the	O
MICU	O
,	O
your	O
blood	O
oxygen	O
levels	O
improved	O
over	O
the	O
course	O
of	O
a	O
day	O
on	O
supplemental	O
oxygen	I-Drug
and	O
you	O
were	O
transitioned	O
from	O
a	O
face	O
-	O
mask	O
to	O
a	O
face	O
-	O
tent	O
to	O
a	O
nasal	O
cannula	O
on	O
supplementary	O
oxygen	I-Drug
.	O
When	O
your	O
oxygen	O
levels	O
stabilized	O
,	O
you	O
were	O
transferred	O
to	O
the	O
inpatient	O
floor	O
,	O
where	O
you	O
were	O
eventually	O
weaned	O
off	O
of	O
supplementary	O
oxygen	O
.	O
You	O
were	O
breathing	O
stable	O
at	O
your	O
baseline	O
blood	O
oxygen	O
levels	O
on	O
the	O
inpatient	O
floor	O
at	O
rest	O
,	O
but	O
were	O
found	O
to	O
be	O
significantly	O
short	O
of	O
breath	O
with	O
activity	O
.	O
As	O
such	O
,	O
physical	O
therapy	O
has	O
recommended	O
home	O
oxygen	I-Drug
,	O
as	O
well	O
as	O
instructed	O
you	O
to	O
walk	O
with	O
a	O
walker	O
.	O
We	O
have	O
set	O
up	O
visiting	O
nursing	O
to	O
assist	O
you	O
with	O
your	O
home	O
oxygen	I-Drug
,	O
as	O
well	O
as	O
evaluating	O
you	O
for	O
home	O
safety	O
and	O
continued	O
physical	O
therapy	O
.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
at	O
-	O
home	O
medications	O
:	O
1	O
)	O
Added	O
Home	O
oxygen	I-Drug
.	O
2	O
)	O
Added	O
Albuterol	B-Drug
-	I-Drug
Ipratropium	I-Drug
inhaler	O
.	O
Please	O
take	O
1	O
-	O
2	O
PUFFs	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
No	O
other	O
changes	O
were	O
made	O
to	O
your	O
at	O
-	O
home	O
medications	O
.	O
Please	O
continue	O
taking	O
them	O
as	O
instructed	O
.	O
3	O
)	O
Decreased	O
your	O
metoprolol	I-Drug
to	O
50	O
mg	O
twice	O
a	O
day	O
from	O
150	O
mg	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
7	O
-	O
10	O
days	O
following	O
discharge	O
.	O
Completed	O
by	O
:[	O
**	O
2154-9-1	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2143-1-7	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2143-1-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2074-4-30	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2145	O
**	O
]	O
Chief	O
Complaint	O
:	O
SOB	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
V	O
/	O
Q	O
scan	O
CT	O
scans	O
TTE	O
TEE	O
PICC	O
placement	O
Bedside	O
thoracentesis	O
CT	O
-	O
guided	O
thoracentesis	O
Persantine	I-Drug
cardiac	B-Reason
stress	I-Reason
test	I-Reason
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
.	O
is	O
a	O
68	O
yo	O
active	O
retired	O
man	O
with	O
hemochromatosis	O
,	O
cirrhosis	O
and	O
DM	O
,	O
who	O
had	O
a	O
mechanical	O
fall	O
2	O
weeks	O
prior	O
to	O
admission	O
while	O
at	O
his	O
winter	O
home	O
in	O
[	O
**	O
State	O
108	O
**	O
]	O
.	O
After	O
falling	O
,	O
he	O
developed	O
left	O
sided	O
rib	B-Reason
pain	I-Reason
(	O
later	O
found	O
to	O
be	O
due	O
to	O
rib	O
fracture	O
)	O
,	O
and	O
sought	O
care	O
at	O
the	O
local	O
ED	O
,	O
where	O
he	O
was	O
told	O
to	O
take	O
tylenol	I-Drug
.	O
After	O
continuing	O
to	O
have	O
pain	O
for	O
several	O
more	O
days	O
he	O
returned	O
to	O
the	O
ED	O
and	O
was	O
prescribed	O
motrin	I-Drug
for	O
the	O
rib	I-Reason
pain	O
.	O
He	O
reports	O
taking	O
600	O
mg	O
every	O
4	O
-	O
5	O
hrs	O
for	O
3	O
-	O
4	O
days	O
.	O
He	O
also	O
reports	O
having	O
very	O
diminished	O
appetite	O
and	O
eating	O
and	O
drinking	O
very	O
little	O
during	O
this	O
time	O
.	O
Three	O
days	O
PTA	O
,	O
he	O
developed	O
SOB	O
.	O
At	O
the	O
urging	O
of	O
his	O
children	O
,	O
he	O
flew	O
back	O
from	O
FL	O
to	O
be	O
seen	O
here	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
.	O
In	O
addition	O
to	O
decreased	O
PO	O
intake	O
,	O
he	O
reported	O
insomnia	O
and	O
nausea	O
/	O
dry	O
heaves	O
.	O
He	O
denied	O
abdominal	O
pain	O
,	O
fevers	O
,	O
chills	O
,	O
sick	O
contacts	O
,	O
or	O
travel	O
out	O
of	O
the	O
country	O
.	O
.	O
On	O
admission	O
,	O
EKG	O
showed	O
right	O
heart	O
strain	O
and	O
possible	O
lateral	O
ischemic	O
changes	O
.	O
Pulmonary	O
embolism	O
was	O
considered	O
;	O
V	O
/	O
Q	O
scan	O
was	O
read	O
as	O
low	O
probability	O
.	O
Acute	O
coronary	O
syndrome	O
was	O
also	O
considered	O
,	O
and	O
cardiac	O
enzymes	O
were	O
elevated	O
with	O
troponin	O
0.12	O
and	O
MB	O
index	O
14.8	O
.	O
Heparin	I-Drug
gtt	O
was	O
started	O
,	O
along	O
with	O
ASA	I-Drug
and	O
beta	B-Drug
blocker	I-Drug
.	O
Also	O
on	O
admission	O
,	O
he	O
was	O
found	O
to	O
have	O
lactic	O
acidosis	O
in	O
setting	O
of	O
ARF	O
(	O
creatinine	O
3.4	O
with	O
baseline	O
1.1	O
)	O
with	O
serum	O
lactate	O
3.9	O
--	O
>	O
6.7	O
and	O
Anion	O
Gap	O
of	O
25	O
.	O
Serum	O
potassium	O
was	O
6.0	O
and	O
bicarb	O
12	O
.	O
He	O
was	O
given	O
bicarb	I-Drug
gtt	O
for	O
acidosis	I-Reason
and	O
kayexelate	I-Drug
,	O
insulin	I-Drug
and	O
glucose	I-Drug
for	O
elevated	B-Reason
K.	O
.	O
Initial	O
temp	O
was	O
94.4	O
and	O
CXR	O
showed	O
vague	B-Reason
opacity	I-Reason
in	I-Reason
RML	I-Reason
.	O
Blood	O
cultures	O
were	O
drawn	O
and	O
levo	I-Drug
/	O
vanc	I-Drug
started	O
.	O
In	O
the	O
ED	O
,	O
patient	O
has	O
2	O
transient	O
episodes	O
of	O
hypotension	O
which	O
resolved	O
spontaneously	O
.	O
He	O
was	O
admitted	O
to	O
the	O
MICU	O
.	O
Past	O
Medical	O
History	O
:	O
PMH	O
:	O
*	O
Hemochromatosis	O
with	O
monthly	O
phlebotomy	O
;	O
dx	O
15	O
yrs	O
ago	O
*	O
Cardiac	O
involvement	O
from	O
hemochromatosis	O
*	O
DM	O
*	O
hx	O
of	O
colon	O
polyps	O
*	O
gallstones	O
(	O
asx	O
)	O
*	O
Hypothyroidism	O
*	O
ARF	I-Ade
in	O
setting	O
of	O
NSAID	I-Drug
use	O
13	O
years	O
ago	O
,	O
requiring	O
5	O
months	O
of	O
HD	O
.	O
Social	O
History	O
:	O
Widowed	O
,	O
occ	O
alcohol	O
,	O
no	O
cigarettes	O
Family	O
History	O
:	O
Parents	O
died	O
in	O
their	O
50s	O
,	O
unknown	O
cause	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
95.2	O
BP	O
132/43	O
HR	O
74	O
RR	O
15	O
O2sat	O
100	O
%	O
NRB	O
GEN	O
:	O
NAD	O
,	O
pleasant	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
no	O
scleral	O
icterus	O
,	O
MM	O
dry	O
NECK	O
:	O
JVP	O
flat	O
,	O
no	O
LAD	O
CHEST	O
:	O
gynecomastia	O
,	O
decreased	O
breath	O
sounds	O
at	O
the	O
bases	O
,	O
no	O
wheezes	O
,	O
no	O
crackles	O
CV	O
:	O
Distant	O
heart	O
sounds	O
,	O
RRR	O
,	O
No	O
m	O
/	O
r	O
/	O
g	O
ABD	O
:	O
Normal	O
bowel	O
sounds	O
,	O
soft	O
,	O
nontender	O
,	O
no	O
hepatomegaly	O
EXT	O
:	O
bilateral	O
2	O
+	O
pitting	O
edema	O
,	O
flat	O
maculopapular	O
rash	O
on	O
left	O
foot	O
,	O
2	O
+	O
DP	O
bilaterally	O
NRO	O
:	O
CN	O
2	O
-	O
12	O
intact	O
,	O
5/5	O
strength	O
throughout	O
Pertinent	O
Results	O
:	O
LABS	O
ON	O
ADMISSION	O
[	O
**	O
2143-1-7	O
**	O
]	O
:	O
.	O
WBC	O
-	O
16.3	O
*	O
#	O
RBC	O
-	O
4.63	O
HGB	O
-	O
13.8	O
*	O
HCT	O
-	O
39.5	O
*	O
PLT	O
COUNT	O
-	O
131	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
29.7	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
16.6	O
*	O
NEUTS	O
-	O
92.6	O
*	O
LYMPHS	O
-	O
4.4	O
*	O
MONOS	O
-	O
2.9	O
EOS	O
-	O
0	O
BASOS	O
-	O
0.1	O
.	O
SODIUM	O
-	O
130	O
*	O
CHLORIDE	O
-	O
92	O
*	O
TOTAL	O
CO2	O
-	O
13	O
*	O
GLUCOSE	O
-	O
291	O
*	O
UREA	O
N	O
-	O
52	O
*	O
CREAT	O
-	O
3.2	O
*	O
#	O
SODIUM	O
-	O
129	O
*	O
POTASSIUM	O
-	O
5.4	O
*	O
CHLORIDE	O
-	O
93	O
*	O
TOTAL	O
CO2	O
-	O
14	O
*	O
ANION	O
GAP	O
-	O
27	O
*	O
LACTATE	O
-	O
6.7	O
*	O
.	O
ALT	O
(	O
SGPT	O
)	O
-	O
21	O
AST	O
(	O
SGOT	O
)	O
-	O
37	O
CK	O
(	O
CPK	O
)	O
-	O
122	O
ALK	O
PHOS	O
-	O
156	O
*	O
AMYLASE	O
-	O
265	O
*	O
TOT	O
BILI	O
-	O
1.1	O
LIPASE	O
-	O
12	O
ALBUMIN	O
-	O
2.6	O
*	O
.	O
CK	O
-	O
MB	O
-	O
18	O
*	O
MB	O
INDX	O
-	O
14.8	O
*	O
cTropnT	O
-	O
0.12	O
*	O
.	O
URINE	O
BLOOD	O
-	O
LG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
500	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
7.0	O
LEUK	O
-	O
MOD	O
URINE	O
RBC	O
-0-2	O
WBC	O
-	O
[	O
**	O
5	O
-	O
25	O
**	O
]	O
*	O
BACTERIA	O
-	O
NONE	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
0	O
URINE	O
HOURS	O
-	O
RANDOM	O
UREA	O
N	O
-	O
247	O
CREAT	O
-	O
178	O
SODIUM	O
-	O
49	O
POTASSIUM	O
-	O
38	O
URINE	O
OSMOLAL	O
-	O
358	O
.	O
TYPE	O
-	O
ART	O
PO2	O
-	O
74	O
*	O
PCO2	O
-	O
29	O
*	O
PH	O
-	O
7.35	O
TOTAL	O
CO2	O
-	O
17	O
*	O
BASE	O
XS	O
--	O
7	O
.	O
.	O
STUDIES	O
:	O
.	O
#	O
.	O
V	O
/	O
Q	O
scan	O
[	O
**	O
2143-1-7	O
**	O
]	O
INTERPRETATION	O
:	O
Ventilation	O
images	O
obtained	O
with	O
Tc	O
-	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
m	O
aerosol	O
in	O
8	O
views	O
demonstrate	O
very	O
heterogenous	O
ventilation	O
with	O
numerous	O
subsegmental	O
defects	O
bilaterally	O
.	O
Perfusion	O
images	O
in	O
the	O
same	O
8	O
views	O
show	O
numerous	O
small	O
bilateral	O
non-segmental	O
defects	O
.	O
These	O
defects	O
are	O
in	O
the	O
same	O
areas	O
as	O
the	O
ventilation	O
defects	O
,	O
but	O
are	O
less	O
prominent	O
.	O
The	O
AP	O
dimension	O
is	O
enlarged	O
,	O
and	O
the	O
diaphgrams	O
are	O
flattened	O
.	O
The	O
chest	O
x-ray	O
is	O
clear	O
.	O
The	O
above	O
findings	O
are	O
consistent	O
with	O
a	O
low	O
probability	O
for	O
pulmonary	O
embolism	O
,	O
but	O
are	O
consistent	O
with	O
COPD	O
.	O
.	O
#	O
.	O
TTE	O
[	O
**	O
2143-1-8	O
**	O
]	O
Conclusions	O
:	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
with	O
severe	O
global	O
free	O
wall	O
hypokinesis	O
.	O
There	O
is	O
abnormal	O
septal	O
motion	O
/	O
position	O
consistent	O
with	O
right	O
ventricular	O
pressure	O
/	O
volume	O
overload	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
to	O
severe	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Right	O
ventricular	O
cavity	O
enlargement	O
with	O
free	O
wall	O
hypokinesis	O
and	O
moderate	O
-	O
severe	O
pulmonary	O
artery	O
systolic	O
hypertension	O
c	O
/	O
w	O
a	O
primary	O
pulmonary	O
process	O
.	O
.	O
#	O
.	O
ECG	O
[	O
**	O
2143-1-9	O
**	O
]	O
Sinus	O
rhythm	O
,	O
right	O
ventricular	O
hypertrophy	O
,	O
Diffuse	O
ST	O
-	O
T	O
wave	O
changes	O
with	O
borderline	O
prolonged	O
/	O
upper	O
limits	O
of	O
normal	O
Q	O
-	O
Tc	O
interval	O
-	O
could	O
be	O
due	O
in	O
part	O
to	O
right	O
ventricular	O
hypertrophy	O
but	O
clinical	O
correlation	O
is	O
suggested	O
Since	O
previous	O
tracing	O
of	O
[	O
**	O
2143-1-8	O
**	O
]	O
,	O
further	O
ST	O
-	O
T	O
wave	O
changes	O
present	O
and	O
Q	O
-	O
Tc	O
interval	O
appears	O
short	O
.	O
.	O
#	O
.	O
CT	O
chest	O
with	O
Contrast	O
[	O
**	O
2143-1-9	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Right	O
loculated	O
collection	O
which	O
has	O
high	O
CT	O
attenuation	O
value	O
and	O
may	O
represent	O
either	O
empyema	O
or	O
hemorrhage	O
within	O
pleural	O
effusion	O
.	O
2	O
.	O
Right	O
lower	O
lobe	O
opacity	O
with	O
bronchial	O
wall	O
thickening	O
which	O
may	O
represent	O
pneumonia	O
/	O
aspiration	O
.	O
3	O
.	O
Right	O
basilar	O
atelectasis	O
.	O
4	O
.	O
Small	O
left	O
pleural	O
effusion	O
.	O
5	O
.	O
Ground	O
-	O
glass	O
opacity	O
in	O
the	O
right	O
apex	O
.	O
This	O
should	O
be	O
followed	O
up	O
with	O
a	O
CT	O
in	O
three	O
months	O
.	O
6	O
.	O
Focal	O
ground	O
-	O
glass	O
opacity	O
in	O
the	O
right	O
middle	O
lobe	O
and	O
right	O
lower	O
lobe	O
may	O
represent	O
infectious	O
/	O
inflammatory	O
etiology	O
.	O
This	O
could	O
also	O
be	O
followed	O
up	O
on	O
the	O
CT	O
which	O
will	O
be	O
obtained	O
in	O
three	O
months	O
.	O
7	O
.	O
Atherosclerotic	O
coronary	O
calcifications	O
.	O
8	O
.	O
Gallstones	O
without	O
evidence	O
of	O
cholecystitis	O
.	O
9	O
.	O
Liver	O
granulomas	O
.	O
.	O
#	O
.	O
Renal	O
US	O
[	O
**	O
2143-1-10	O
**	O
]	O
:	O
FINDINGS	O
:	O
The	O
right	O
kidney	O
measures	O
9	O
cm	O
in	O
length	O
,	O
previously	O
measuring	O
9.5	O
cm	O
.	O
The	O
left	O
kidney	O
measures	O
10.2	O
cm	O
in	O
length	O
,	O
previously	O
measuring	O
10.7	O
cm	O
in	O
length	O
.	O
In	O
the	O
interpolar	O
region	O
of	O
the	O
right	O
kidney	O
,	O
there	O
is	O
an	O
area	O
with	O
lobulated	O
appearance	O
consistent	O
with	O
cortical	O
scarring	O
,	O
unchanged	O
from	O
the	O
prior	O
study	O
.	O
In	O
the	O
interpolar	O
region	O
of	O
the	O
left	O
kidney	O
,	O
there	O
is	O
a	O
tiny	O
cortical	O
crystal	O
.	O
There	O
is	O
no	O
hydronephrosis	O
,	O
stones	O
,	O
or	O
renal	O
masses	O
.	O
There	O
is	O
no	O
perirenal	O
fluid	O
.	O
The	O
bladder	O
is	O
unremarkable	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Slight	O
interval	O
decrease	O
in	O
size	O
in	O
both	O
kidneys	O
.	O
2	O
.	O
There	O
is	O
no	O
hydronephrosis	O
.	O
3	O
.	O
Stable	O
area	O
of	O
cortical	O
scarring	O
in	O
the	O
right	O
kidney	O
.	O
.	O
#	O
.	O
TEE	O
[	O
**	O
2143-1-15	O
**	O
]	O
Conclusions	O
:	O
1	O
.	O
The	O
left	O
atrium	O
is	O
dilated	O
.	O
2	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
difficult	O
to	O
assess	O
but	O
is	O
probably	O
normal	O
.	O
3	O
.	O
There	O
are	O
complex	O
(	O
>	O
4	O
mm	O
)	O
sessile	O
atheroma	O
in	O
the	O
aortic	O
arch	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
4	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
5	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
6	O
.	O
There	O
is	O
a	O
small	O
pericardial	O
effusion	O
.	O
7	O
.	O
No	O
evidence	O
of	O
endocarditis	O
seen	O
.	O
.	O
#	O
.	O
CTA	O
Chest	O
[	O
**	O
2143-1-16	O
**	O
]	O
:	O
1	O
.	O
No	O
evidence	O
of	O
pulmonary	O
embolism	O
.	O
2	O
.	O
Unchanged	O
right	O
loculated	O
collection	O
within	O
the	O
pleural	O
space	O
of	O
hyperattenuation	O
.	O
Given	O
the	O
appearance	O
with	O
increased	O
subpleural	O
fat	O
,	O
this	O
has	O
the	O
appearance	O
of	O
chronic	O
right	O
effusion	O
.	O
It	O
is	O
difficult	O
to	O
comment	O
on	O
possible	O
thickening	O
of	O
the	O
pleura	O
.	O
3	O
.	O
Small	O
left	O
simple	O
effusion	O
,	O
slightly	O
increased	O
from	O
the	O
prior	O
study	O
.	O
4	O
.	O
3	O
-	O
mm	O
nodule	O
in	O
the	O
right	O
middle	O
lobe	O
.	O
In	O
the	O
absence	O
of	O
known	O
malignancy	O
,	O
one	O
-	O
year	O
CT	O
followup	O
could	O
be	O
considered	O
.	O
5	O
.	O
Atherosclerotic	O
coronary	O
artery	O
calcifications	O
.	O
6	O
.	O
Cirrhosis	O
of	O
the	O
liver	O
,	O
with	O
low	O
-	O
attenuation	O
oval	O
lesion	O
near	O
the	O
dome	O
.	O
It	O
is	O
incompletely	O
characterized	O
on	O
the	O
study	O
.	O
7	O
.	O
Gallstones	O
without	O
evidence	O
of	O
cholecystitis	O
.	O
8	O
.	O
Left	O
lateral	O
fifth	O
and	O
seventh	O
rib	O
fractures	O
.	O
9	O
.	O
Cystic	O
structure	O
above	O
the	O
manubrial	O
notch	O
without	O
enhancement	O
,	O
incompletely	O
characterized	O
on	O
this	O
study	O
.	O
.	O
#	O
.	O
Core	O
biopsy	O
of	O
R	O
solid	O
pleural	O
effusion	O
[	O
**	O
2143-1-17	O
**	O
]	O
.	O
#	O
.	O
Stress	O
test	O
[	O
**	O
2143-1-21	O
**	O
]	O
Exercising	O
stress	O
test	O
:	O
No	O
anginal	O
symptoms	O
or	O
ECG	O
changes	O
from	O
baseline	O
.	O
N	O
Persantine	I-Drug
MIBI	I-Reason
:	O
Left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Resting	O
and	O
stress	O
perfusion	O
images	O
reveal	O
uniform	O
tracer	O
uptake	O
throughout	O
the	O
myocardium	O
.	O
Gated	O
images	O
reveal	O
normal	O
wall	O
motion	O
.	O
The	O
calculated	O
left	O
ventricular	O
ejection	O
fraction	O
is	O
71	O
%	O
.	O
No	O
prior	O
studies	O
are	O
available	O
for	O
comparison	O
.	O
IMPRESSION	O
:	O
Normal	O
myocardial	O
perfusion	O
.	O
EF	O
71	O
%	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
.	O
Anion	O
Gap	O
Acidosis	O
:	O
Was	O
likely	O
due	O
to	O
lactic	O
acidosis	O
given	O
his	O
high	O
lactate	O
on	O
admission	O
.	O
High	O
lactate	O
production	O
likely	O
occurred	O
[	O
**	O
1	O
-	O
17	O
**	O
]	O
sepsis	O
and	O
poor	O
perfusion	O
,	O
and	O
ARF	O
prevented	O
clearance	O
of	O
lactate	O
.	O
Was	O
treated	O
with	O
bicarb	O
in	O
the	O
ED	O
and	O
Gap	O
resolved	O
.	O
.	O
#	O
.	O
Hyperkalemia	I-Reason
:	O
resolved	O
after	O
receiving	O
kayexelate	I-Drug
,	O
insulin	I-Drug
and	O
glucose	I-Drug
in	O
ED	O
.	O
.	O
#	O
.	O
RV	O
strain	O
/	O
Pulmonary	O
Hypertension	O
:	O
On	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
TTE	O
was	O
obtained	O
and	O
showed	O
a	O
dilated	O
RV	O
with	O
severe	O
global	O
free	O
wall	O
hypokinesis	O
and	O
abnormal	O
septal	O
movement	O
.	O
He	O
was	O
also	O
noted	O
to	O
have	O
moderate	O
-	O
severe	O
pulmonary	O
artery	O
systolic	O
hypertension	O
consistent	O
with	O
a	O
primary	O
pulmonary	O
process	O
.	O
LVEF	O
was	O
>	O
55	O
%	O
.	O
Elevated	O
tropinins	O
measured	O
in	O
the	O
ED	O
were	O
thought	O
to	O
be	O
due	O
to	O
RV	O
strain	O
combined	O
with	O
decreased	O
renal	O
clearance	O
.	O
By	O
[	O
**	O
1	O
-	O
9	O
**	O
]	O
,	O
troponin	O
had	O
trended	O
down	O
and	O
heparin	I-Drug
gtt	O
was	O
discontinued	O
.	O
For	O
his	O
pulmonary	O
hypertension	O
observed	O
on	O
echo	O
,	O
a	O
pulmonary	O
consult	O
was	O
obtained	O
.	O
Acute	O
PE	O
was	O
thought	O
to	O
be	O
an	O
unlikely	O
cause	O
of	O
his	O
echo	O
findings	O
given	O
the	O
negative	O
V	O
/	O
Q	O
scan	O
on	O
admission	O
,	O
but	O
chronic	O
PE	O
was	O
thought	O
to	O
be	O
a	O
possibility	O
.	O
CTA	O
was	O
obtained	O
on	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
,	O
which	O
was	O
negative	O
.	O
Other	O
etiologies	O
were	O
considered	O
,	O
including	O
porto	O
-	O
pulmonary	O
hypertension	O
from	O
cirrhosis	O
.	O
HIV	O
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
and	O
RF	O
were	O
sent	O
and	O
found	O
to	O
be	O
negative	O
.	O
Scleroderma	O
antibody	O
test	O
is	O
pending	O
.	O
He	O
will	O
undergo	O
an	O
outpatient	O
work	O
-	O
up	O
for	O
pulmonary	O
hypertension	O
with	O
PFTs	O
,	O
sleep	O
study	O
,	O
and	O
outpatient	O
appointment	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
.	O
.	O
#	O
.	O
Hypoxia	I-Reason
:	O
The	O
patient	O
was	O
dyspneic	O
on	O
admission	O
,	O
and	O
was	O
maintained	O
on	O
supplemental	O
oxygen	I-Drug
for	O
oxygen	O
saturations	O
that	O
dropped	O
into	O
the	O
high	O
80's	O
at	O
rest	O
on	O
room	O
air	O
.	O
This	O
was	O
thought	O
to	O
be	O
related	O
to	O
a	O
presumed	O
RML	O
pneumonia	O
(	O
seen	O
as	O
opacity	O
on	O
admission	O
CXR	O
)	O
and	O
underlying	O
pulmonary	O
hypertension	O
seen	O
on	O
Echo	O
.	O
However	O
,	O
the	O
opacity	O
observed	O
on	O
CXR	O
was	O
not	O
seen	O
on	O
CT	O
from	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
,	O
so	O
it	O
is	O
unlikely	O
that	O
the	O
original	O
opacity	O
represented	O
a	O
pneumonia	O
as	O
originally	O
thought	O
.	O
His	O
dyspnea	O
slowly	O
improved	O
,	O
and	O
he	O
was	O
weaned	O
from	O
supplemental	O
oxygen	I-Drug
by	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
.	O
However	O
,	O
on	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
he	O
again	O
developed	O
an	O
oxygen	I-Drug
requirement	O
after	O
IV	O
fluids	I-Drug
were	O
initiated	O
in	O
preparation	O
for	O
receiving	O
IV	O
contrast	I-Drug
,	O
and	O
on	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
,	O
resting	O
oxygen	O
saturation	O
was	O
measured	O
at	O
89	O
%	O
on	O
room	O
air	O
at	O
rest	O
,	O
85	O
%	O
while	O
ambulating	O
.	O
CTA	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
showed	O
an	O
enlarged	O
left	O
-	O
sided	O
pleural	O
effusion	O
(	O
fluid	O
density	O
)	O
and	O
a	O
R	O
-	O
sided	O
pleural	O
effusion	O
that	O
was	O
determined	O
to	O
be	O
solid	O
on	O
thorocentesis	O
(	O
Path	O
result	O
is	O
pending	O
)	O
.	O
These	O
findings	O
,	O
in	O
combination	O
with	O
his	O
pulmonary	B-Reason
hypertension	I-Reason
and	O
deconditioning	O
were	O
thought	O
to	O
account	O
for	O
the	O
patient	O
's	O
continued	O
hypoxia	O
.	O
Diuresis	I-Drug
was	O
initiated	O
the	O
following	O
day	O
,	O
and	O
satrurations	O
improved	O
,	O
but	O
he	O
continued	O
to	O
have	O
an	O
oxygen	O
requirement	O
.	O
He	O
had	O
also	O
been	O
noted	O
to	O
have	O
worsened	O
dyspnea	O
while	O
ambulating	O
,	O
and	O
a	O
stress	O
test	O
was	O
performed	O
to	O
rule	O
-	O
out	O
an	O
anginal	O
component	O
.	O
Stress	O
test	O
was	O
normal	O
,	O
showing	O
no	O
ECG	O
changes	O
or	O
anginal	O
component	O
and	O
normal	O
myocardial	O
perfusion	O
with	O
Ejection	O
Fraction	O
of	O
71	O
%	O
.	O
By	O
discharge	O
,	O
oxygen	O
saturations	O
were	O
98	O
%	O
on	O
3L	O
,	O
and	O
he	O
was	O
discharged	O
home	O
on	O
2L	O
oxygen	I-Drug
via	O
nasal	O
cannula	O
.	O
.	O
#	O
.	O
Acute	O
Renal	O
Failure	O
:	O
On	O
admission	O
,	O
the	O
patient	O
had	O
a	O
creatinine	O
level	O
of	O
3.4	O
.	O
This	O
appeared	O
to	O
be	O
related	O
to	O
a	O
prerenal	O
state	O
,	O
as	O
supported	O
by	O
his	O
history	O
of	O
very	O
poor	O
PO	O
intake	O
x	O
10	O
days	O
and	O
FENa	O
<	O
1	O
%	O
.	O
The	O
possibility	O
of	O
ATN	I-Ade
from	O
NSAIDs	I-Drug
was	O
also	O
considered	O
given	O
his	O
recent	O
history	O
of	O
taking	O
Motrin	I-Drug
for	O
pain	I-Reason
,	O
and	O
renal	O
followed	O
the	O
patient	O
until	O
Cr	O
had	O
improved	O
.	O
Renal	O
ultrasound	O
showed	O
no	O
hydronephrosis	O
.	O
Creatinine	O
slowly	O
improved	O
with	O
IVF	I-Drug
and	O
time	O
,	O
and	O
had	O
decreased	O
to	O
1.2	O
by	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
(	O
most	O
recent	O
baseline	O
measurement	O
was	O
1.1	O
in	O
[	O
**	O
2140	O
**	O
]	O
)	O
.	O
When	O
the	O
patient	O
's	O
home	O
diuretics	I-Drug
were	O
subsequently	O
restarted	O
for	O
hyponatremia	I-Reason
and	O
fluid	B-Reason
overload	I-Reason
,	O
Cr	O
rose	O
again	O
to	O
1.6	O
.	O
By	O
discharge	O
,	O
the	O
patient	O
's	O
creatinine	O
was	O
1.4	O
.	O
.	O
#	O
.	O
Staph	B-Reason
Bacteremia	I-Reason
:	O
Blood	O
cultures	O
on	O
admission	O
grew	O
MSSA	O
(	O
4/4	O
bottles	O
from	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
)	O
.	O
Renally	O
-	O
dosed	O
vancomycin	I-Drug
was	O
started	O
on	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
,	O
then	O
switched	O
to	O
oxacillin	I-Drug
on	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
when	O
sensitivities	O
returned	O
.	O
2/2	O
blood	O
cultures	O
from	O
[	O
**	O
1	O
-	O
10	O
**	O
]	O
also	O
grew	O
staph	O
aureus	O
.	O
Surveillance	O
cultures	O
since	O
then	O
have	O
been	O
negative	O
.	O
TEE	O
done	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
not	O
show	O
any	O
valvular	O
abnormalities	O
.	O
A	O
PICC	O
line	O
was	O
placed	O
on	O
[	O
**	O
1	O
-	O
12	O
**	O
]	O
and	O
the	O
patient	O
completed	O
a	O
14	O
-	O
day	O
course	O
of	O
IV	O
antibiotics	I-Drug
on	O
[	O
**	O
2143-1-22	O
**	O
]	O
and	O
the	O
PICC	O
was	O
removed	O
prior	O
to	O
discharge	O
.	O
.	O
#	O
.	O
Hyponatremia	I-Reason
:	O
While	O
in	O
the	O
ICU	O
,	O
the	O
patient	O
had	O
one	O
set	O
of	O
serum	O
chemistries	O
with	O
serum	O
sodium	O
of	O
122	O
.	O
Remainder	O
of	O
values	O
were	O
in	O
130s	O
until	O
fluids	O
were	O
started	O
on	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
in	O
preparation	O
for	O
CTA	O
with	O
dye	O
load	O
.	O
Next	O
measured	O
Na	O
was	O
127	O
on	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
.	O
He	O
was	O
fluid	O
restricted	O
to	O
1500cc	O
/	O
day	O
and	O
encouraged	O
to	O
improve	O
his	O
food	O
intake	O
,	O
which	O
had	O
been	O
poor	O
throughout	O
his	O
admission	O
.	O
Given	O
that	O
he	O
also	O
had	O
evidence	O
of	O
total	B-Reason
body	I-Reason
fluid	I-Reason
overload	I-Reason
(	O
peripheral	O
and	O
abdominal	O
edema	O
)	O
,	O
he	O
was	O
restarted	O
on	O
his	O
home	O
diuretic	I-Drug
regimen	O
of	O
Lasix	I-Drug
20	O
mg	O
and	O
spironolactone	I-Drug
25	O
mg	O
.	O
By	O
[	O
**	O
1	O
-	O
22	O
**	O
]	O
,	O
Na	O
had	O
risen	O
to	O
131	O
.	O
.	O
#	O
.	O
UTI	I-Reason
:	O
Urine	O
labs	O
from	O
[	O
**	O
1	O
-	O
9	O
**	O
]	O
showed	O
UTI	O
,	O
for	O
which	O
the	O
patient	O
was	O
treated	O
with	O
a	O
7	O
day	O
course	O
of	O
Levofloxacin	I-Drug
that	O
finished	O
on	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
.	O
Urine	O
Cx	O
was	O
negative	O
,	O
but	O
was	O
sent	O
after	O
the	O
patient	O
had	O
started	O
Levofloxacin	I-Drug
and	O
Vancomycin	I-Drug
.	O
Fever	O
curve	O
remained	O
flat	O
.	O
.	O
#	O
.	O
Anxiety	I-Reason
:	O
The	O
patient	O
consistently	O
reported	O
having	O
a	O
"	O
nervous	O
stomach	O
"	O
that	O
felt	O
like	O
it	O
had	O
"	O
knots	O
in	O
it	O
.	O
"	O
He	O
has	O
had	O
these	O
sensations	O
for	O
many	O
years	O
,	O
and	O
reported	O
that	O
it	O
made	O
eating	O
difficult	O
because	O
it	O
caused	O
him	O
to	O
feel	O
nauseus	O
.	O
This	O
was	O
thought	O
to	O
be	O
a	O
manifestation	O
of	O
anxiety	I-Reason
,	O
and	O
the	O
patient	O
was	O
tried	O
on	O
0.5	O
mg	O
of	O
Ativan	I-Drug
.	O
This	O
was	O
subsequently	O
discontinued	O
when	O
he	O
was	O
found	O
to	O
be	O
excessively	B-Ade
somnolent	I-Ade
.	O
The	O
patient	O
agreed	O
to	O
start	O
Remeron	I-Drug
for	O
help	O
with	O
anxiety	I-Reason
and	O
appetite	I-Reason
stimulation	O
.	O
He	O
tolerated	O
it	O
well	O
and	O
was	O
discharged	O
on	O
15	O
mg	O
Remeron	I-Drug
QHS	O
.	O
.	O
#	O
.	O
DM	I-Reason
:	O
The	O
patient	O
recived	O
QID	O
finger	O
sticks	O
and	O
was	O
treated	O
with	O
bedtime	O
glargine	I-Drug
and	O
ISS	I-Drug
.	O
Blood	O
glucose	O
measurments	O
fluxuated	O
with	O
his	O
PO	O
intake	O
and	O
adjustments	O
were	O
made	O
as	O
appropriate	O
.	O
.	O
#	O
.	O
Hypertension	I-Reason
/	O
CAD	I-Reason
:	O
The	O
patient	O
was	O
treated	O
with	O
ASA	I-Drug
325	O
mg	O
and	O
Metoprolol	I-Drug
12.5	O
mg	O
TID	O
.	O
As	O
the	O
patient	O
had	O
no	O
apparent	O
indication	O
for	O
digoxin	I-Drug
,	O
this	O
was	O
held	O
during	O
his	O
hospitalization	O
.	O
He	O
was	O
discharged	O
on	O
atenolol	I-Drug
12.5	O
mg	O
daily	O
and	O
ASA	I-Drug
325	O
mg	O
daily	O
.	O
Stress	O
test	O
revealed	O
no	O
hypoperfusion	O
at	O
rest	O
or	O
with	O
persantine	I-Drug
stimulation	O
.	O
.	O
#	O
.	O
Nutrition	O
:	O
Albumin	O
was	O
2.6	O
on	O
admission	O
,	O
2.4	O
on	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
.	O
The	O
patient	O
reported	O
a	O
10	O
day	O
history	O
of	O
anorexia	O
on	O
admission	O
and	O
continued	O
to	O
have	O
poor	O
PO	O
intake	O
throughout	O
most	O
of	O
his	O
hospitalization	O
.	O
He	O
cited	O
lack	O
of	O
appetite	O
and	O
nausea	O
caused	O
by	O
his	O
"	O
nervous	O
stomach	O
"	O
as	O
reasons	O
for	O
his	O
poor	O
intake	O
.	O
The	O
patient	O
was	O
maintained	O
on	O
a	O
renal	O
diet	O
with	O
liquid	O
supplements	O
(	O
Boost	O
)	O
TID	O
.	O
He	O
had	O
poor	O
compliance	O
until	O
2	O
days	O
prior	O
to	O
discharge	O
,	O
when	O
he	O
reported	O
an	O
increase	O
in	O
appetite	O
and	O
improved	O
PO	O
intake	O
was	O
recorded	O
.	O
.	O
#	O
.	O
Hemochromatosis	O
/	O
cirrhosis	O
:	O
Remained	O
stable	O
during	O
this	O
hospitalization	O
.	O
.	O
#	O
.	O
Hypothyroidism	I-Reason
:	O
Remained	O
stable	O
.	O
He	O
was	O
treated	O
with	O
his	O
home	O
dose	O
of	O
Levothyroxine	I-Drug
100	O
mcg	O
daily	O
during	O
this	O
admission	O
.	O
.	O
#	O
Physical	O
Therapy	O
:	O
The	O
patient	O
was	O
evaluated	O
and	O
followed	O
by	O
PT	O
,	O
who	O
felt	O
he	O
was	O
safe	O
to	O
return	O
to	O
his	O
daugter	O
's	O
home	O
.	O
.	O
#	O
Prophylaxis	I-Reason
:	O
The	O
patient	O
was	O
treated	O
with	O
incentive	O
spirometry	O
,	O
H2	B-Drug
blocker	I-Drug
,	O
and	O
SC	O
heparin	I-Drug
(	O
which	O
was	O
discontinued	O
when	O
he	O
began	O
ambulating	O
)	O
.	O
#	O
.	O
Abnormal	O
tests	O
requiring	O
outpatient	O
follow	O
-	O
up	O
:	O
Seen	O
on	O
CTA	O
[	O
**	O
2143-1-16	O
**	O
]	O
:	O
1	O
.	O
3	O
mm	O
pulmonary	O
nodule	O
in	O
the	O
right	O
middle	O
lobe	O
.	O
2	O
.	O
hypodense	O
oval	O
lesion	O
approx	O
8	O
mm	O
at	O
the	O
liver	O
dome	O
.	O
Recommend	O
follow	O
-	O
up	O
CT	O
in	O
1	O
year	O
.	O
Medications	O
on	O
Admission	O
:	O
Meds	O
on	O
admission	O
:	O
*	O
Spironolactone	I-Drug
25	O
mg	O
daily	O
*	O
Lasix	I-Drug
20	O
mg	O
daily	O
*	O
Digoxin	I-Drug
0.125	O
mg	O
daily	O
*	O
Synthroid	I-Drug
0.1	O
mg	O
daily	O
*	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
daily	O
*	O
Diltiazem	I-Drug
30	O
mg	O
daily	O
*	O
insulin	I-Drug
Discharge	O
Medications	O
:	O
*	O
Spironolactone	I-Drug
25	O
mg	O
daily	O
*	O
Furosemide	I-Drug
20	O
mg	O
daily	O
*	O
Synthroid	I-Drug
0.1	O
mg	O
daily	O
*	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
daily	O
*	O
Diltiazem	I-Drug
30	O
mg	O
daily	O
*	O
Mirtazapine	I-Drug
15	O
mg	O
at	O
bedtime	O
*	O
Aspirin	I-Drug
81	O
mg	O
daily	O
*	O
Combivent	I-Drug
103	O
-	O
18	O
mcg	O
/	O
Actuation	O
Aerosol	O
1	O
puff	O
QID	O
*	O
Oxygen	I-Drug
2	O
-	O
3L	O
via	O
nasal	O
cannula	O
to	O
keep	O
O2	B-Reason
sat	I-Reason
>	I-Reason
94	I-Reason
%	O
*	O
insulin	I-Drug
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
2255	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2256	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Staph	O
aureus	O
bacteremia	O
2	O
.	O
Pulmonary	O
hypertension	O
3	O
.	O
Acute	O
renal	O
failure	O
4	O
.	O
Lactic	O
acidosis	O
5	O
.	O
Dibetes	O
mellitus	O
6	O
.	O
hemochromatosis	O
/	O
cirrhosis	O
Discharge	O
Condition	O
:	O
Stable	O
.	O
Requiring	O
supplemental	O
oxygen	I-Drug
at	O
2L	O
via	O
nasal	O
cannula	O
.	O
Discharge	O
Instructions	O
:	O
1	O
.	O
Call	O
your	O
doctor	O
or	O
go	O
to	O
the	O
ER	O
for	O
:	O
-	O
fever	O
>	O
101	O
-	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
weakness	O
-	O
other	O
concerns	O
2	O
.	O
Please	O
use	O
wear	O
your	O
oxygen	O
at	O
all	O
times	O
.	O
Avoid	O
smoking	O
or	O
open	O
flames	O
as	O
oxygen	I-Drug
is	O
flammable	O
.	O
3	O
.	O
Please	O
take	O
all	O
of	O
your	O
medications	O
as	O
prescribed	O
5	O
.	O
Take	O
the	O
Ensure	O
supplement	O
drinks	O
three	O
times	O
a	O
day	O
;	O
these	O
can	O
be	O
purchased	O
at	O
most	O
pharmacies	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
2143-1-24	O
**	O
]	O
at	O
9:15	O
AM	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1983	O
**	O
]	O
(	O
Please	O
call	O
before	O
appointment	O
to	O
update	O
your	O
registration	O
information	O
)	O
2	O
.	O
SLEEP	O
STUDY	O
-	O
Office	O
will	O
call	O
you	O
to	O
schedule	O
appointment	O
.	O
You	O
can	O
contact	O
them	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
16716	O
**	O
]	O
3	O
.	O
PULMONARY	O
FUNCTION	O
TESTS	O
:	O
[	O
**	O
2143-2-14	O
**	O
]	O
11:30	O
AM	O
(	O
Please	O
go	O
to	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
building	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
&	O
check	O
-	O
in	O
at	O
Rehab	O
Services	O
)	O
4	O
.	O
DR.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
(	O
PULMONARY	O
)	O
[	O
**	O
2143-2-14	O
**	O
]	O
1:10	O
PM	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
612	O
**	O
]	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
2158	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2163-6-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2163-6-14	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
invasive	O
sqamous	O
scalp	O
ca	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
PICC	O
line	O
placement	O
,	O
neurosurgical	O
intervention	O
cancelled	O
,	O
History	O
of	O
Present	O
Illness	O
:	O
Patient	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
old	O
female	O
with	O
afib	O
,	O
cad	O
,	O
dm	O
who	O
was	O
transferred	O
from	O
[	O
**	O
Hospital1	O
**	O
]	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
lesion	O
on	O
scalp	O
(	O
can	O
see	O
brain	O
matter	O
)	O
.	O
She	O
was	O
evaluated	O
as	O
an	O
outpatient	O
intially	O
by	O
dermatology	O
that	O
did	O
a	O
biopsy	O
of	O
the	O
scalp	O
mass	O
and	O
she	O
was	O
diagnosed	O
with	O
squamous	O
cell	O
carcinoma	O
.	O
The	O
ulcerative	O
lesion	O
eroding	O
skull	O
extending	O
intracranially	O
and	O
was	O
to	O
have	O
neurosurgical	O
intervention	O
but	O
the	O
patient	O
was	O
supertheraputic	I-Reason
INR	O
of	O
7.7	O
so	O
she	O
was	O
sent	O
to	O
the	O
MICU	O
.	O
She	O
was	O
reversed	O
with	O
reversed	O
with	O
10	O
IV	O
K	I-Drug
,	O
2u	O
FFP	I-Drug
.	O
She	O
was	O
also	O
noted	O
to	O
have	O
arf	O
with	O
cr	O
of	O
2	O
,	O
anuric	O
,	O
dry	B-Reason
on	I-Reason
exam	I-Reason
with	I-Reason
a	I-Reason
sodium	O
158	O
--	O
>	O
161	O
.	O
She	O
received	O
a	O
NS	I-Drug
bolus	O
and	O
then	O
D5W	I-Drug
and	O
avoiding	O
lasix	I-Drug
and	O
acei	I-Drug
given	O
renal	O
failure	O
,	O
renal	O
ultrasound	O
with	O
R	O
hydro	O
and	O
pelvic	O
mass	O
(	O
family	O
does	O
not	O
want	O
w	O
/	O
u	O
)	O
.	O
Patient	O
was	O
placed	O
on	O
vanc	I-Drug
and	O
cetriaxone	I-Drug
for	O
meningitis	B-Reason
proprolaxis	I-Reason
since	O
there	O
is	O
CSF	O
communicating	O
with	O
skin	O
secondary	O
to	O
scc	O
.	O
Patient	O
is	O
having	O
PICC	O
placed	O
in	O
the	O
AM	O
for	O
long	O
-	O
term	O
abx	O
and	O
fluids	I-Drug
.	O
Cultures	O
are	O
pending	O
.	O
Family	O
is	O
aware	O
of	O
poor	O
prognosis	O
and	O
she	O
is	O
dnr	O
/	O
dni	O
,	O
family	O
wants	O
conservative	O
med	O
management	O
.	O
Past	O
Medical	O
History	O
:	O
CHF	O
-	O
unknown	O
type	O
or	O
EF	O
.	O
bradycardia	O
s	O
/	O
p	O
pacemaker	O
afib	O
-	O
s	O
/	O
p	O
cardioversion	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
htn	O
hyperthyroidism	O
arthritis	O
hernia	O
repair	O
anxiety	O
h.o	O
SCC	O
of	O
the	O
scalp	O
year	O
ago	O
per	O
records	O
glaucoma	O
Social	O
History	O
:	O
Lives	O
in	O
[	O
**	O
Location	O
**	O
]	O
.	O
No	O
tobacco	O
,	O
EtOH	O
,	O
or	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
98.9	O
,	O
102/666	O
,	O
64	O
,	O
22	O
,	O
98	O
%	O
RA	O
,	O
FS140	O
General	O
:	O
Alert	O
,	O
trembling	O
,	O
cooperative	O
HEENT	O
:	O
PERRLA	O
,	O
3x3cm	O
irregular	O
discolored	O
raised	O
mass	O
,	O
EOMI	O
,	O
anicteric	O
,	O
MMM	O
neck	O
-	O
JVD	O
to	O
ear?positional	O
,	O
no	O
LAD	O
chest	O
-	O
b	O
/	O
l	O
ae	O
no	O
w	O
/	O
c	O
/	O
r	O
heart	O
-	O
s1s2	O
4/6	O
systolic	O
murmur	O
heard	O
throughout	O
precordium	O
abd	O
-	O
+	O
bs	O
,	O
soft	O
,	O
Nt	O
,	O
ND	O
ext	O
-	O
NO	O
c	O
/	O
c	O
/	O
e	O
1	O
+	O
puluses	O
,	O
cold	O
,	O
r	O
first	O
toe	O
ichemic	O
ulcer	O
neuro	O
-	O
aaox2	O
,	O
moves	O
all	O
extremities	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2163-6-6	O
**	O
]	O
05:35	O
PM	O
PT	O
-	O
63.8	O
*	O
PTT	O
-	O
41.1	O
*	O
INR	O
(	O
PT	O
)	O
-	O
7.7	O
*	O
[	O
**	O
2163-6-6	O
**	O
]	O
05:35	O
PM	O
WBC	O
-	O
13.1	O
*	O
#	O
RBC	O
-	O
3.65	O
*	O
HGB	O
-	O
10.8	O
*	O
HCT	O
-	O
35.6	O
*	O
MCV	O
-	O
98	O
MCH	O
-	O
29.7	O
#	O
MCHC	O
-	O
30.5	O
*	O
RDW	O
-	O
13.7	O
[	O
**	O
2163-6-6	O
**	O
]	O
05:35	O
PM	O
cTropnT	O
-	O
0.07	O
*	O
[	O
**	O
2163-6-6	O
**	O
]	O
05:35	O
PM	O
WBC	O
-	O
13.1	O
*	O
#	O
RBC	O
-	O
3.65	O
*	O
HGB	O
-	O
10.8	O
*	O
HCT	O
-	O
35.6	O
*	O
MCV	O
-	O
98	O
MCH	O
-	O
29.7	O
#	O
MCHC	O
-	O
30.5	O
*	O
RDW	O
-	O
13.7	O
[	O
**	O
2163-6-6	O
**	O
]	O
05:35	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
33	O
[	O
**	O
2163-6-6	O
**	O
]	O
05:55	O
PM	O
LACTATE	O
-	O
1.7	O
CT	O
head	O
:	O
TECHNIQUE	O
:	O
Axial	O
non-contrast	O
images	O
performed	O
in	O
an	O
outside	O
hospital	O
(	O
[	O
**	O
Hospital3	O
**	O
]	O
)	O
were	O
submitted	O
for	O
review	O
.	O
No	O
reconstructions	O
were	O
available	O
.	O
No	O
formal	O
report	O
was	O
provided	O
.	O
FINDINGS	O
:	O
Within	O
the	O
brain	O
parenchyma	O
,	O
there	O
is	O
global	O
parenchymal	O
atrophy	O
,	O
indicated	O
by	O
enlargement	O
of	O
the	O
ventricles	O
and	O
sulci	O
.	O
There	O
is	O
also	O
periventricular	O
and	O
subcortical	O
white	O
matter	O
hypodensity	O
,	O
consistent	O
with	O
small	O
vessel	O
ischemic	O
disease	O
.	O
A	O
right	O
cerebellar	O
lacunar	O
infarct	O
is	O
also	O
noted	O
.	O
There	O
is	O
no	O
hemorrhage	O
,	O
edema	O
,	O
or	O
mass	O
effect	O
.	O
There	O
is	O
no	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
The	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
appears	O
preserved	O
.	O
There	O
is	O
a	O
large	O
destructive	O
lesion	O
involving	O
the	O
vertex	O
of	O
the	O
calvarium	O
.	O
There	O
is	O
no	O
underlying	O
brain	O
mass	O
lesion	O
or	O
brain	O
abscess	O
,	O
although	O
there	O
is	O
an	O
extra	O
-	O
axial	O
,	O
likely	O
subdural	O
,	O
soft	O
tissue	O
/	O
fluid	O
component	O
to	O
this	O
lesion	O
,	O
although	O
this	O
is	O
difficult	O
to	O
evaluate	O
due	O
to	O
volume	O
averaging	O
at	O
the	O
vertex	O
and	O
the	O
lack	O
of	O
reconstructions	O
.	O
The	O
lesion	O
at	O
the	O
vertex	O
causes	O
significant	O
osseous	O
destruction	O
.	O
There	O
is	O
subcutaneous	O
gas	O
,	O
which	O
also	O
extends	O
intracranially	O
,	O
with	O
resultant	O
pneumocephalus	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Extensive	O
destructive	O
lesion	O
involving	O
the	O
calvarial	O
vertex	O
,	O
with	O
intracranial	O
extension	O
indicated	O
by	O
pneumocephalus	O
and	O
extra-axial	O
,	O
intracranial	O
soft	O
tissue	O
/	O
fluid	O
component	O
.	O
This	O
does	O
not	O
appear	O
to	O
be	O
of	O
primary	O
CNS	O
etiology	O
.	O
Differential	O
includes	O
infectious	O
process	O
or	O
a	O
subcutaneous	O
or	O
osseous	O
malignancy	O
.	O
Further	O
evaluation	O
with	O
contrast	O
-	O
enhanced	O
MRI	O
is	O
recommended	O
.	O
2	O
.	O
Small	O
vessel	O
ischemic	O
disease	O
,	O
lacunar	O
infarcts	O
,	O
and	O
global	O
parenchymal	O
atrophy	O
.	O
There	O
are	O
no	O
brain	O
mass	O
lesions	O
or	O
brain	O
abscesses	O
identified	O
.	O
Renal	O
ultrasound	O
[	O
**	O
2163-6-7	O
**	O
]	O
:	O
FINDINGS	O
:	O
The	O
left	O
kidney	O
measures	O
9	O
cm	O
in	O
length	O
.	O
There	O
is	O
no	O
left	O
-	O
sided	O
hydronephrosis	O
.	O
The	O
right	O
kidney	O
measures	O
9.5	O
cm	O
in	O
length	O
.	O
There	O
is	O
moderate	O
right	O
-	O
sided	O
hydronephrosis	O
.	O
There	O
is	O
no	O
renal	O
mass	O
or	O
stone	O
.	O
There	O
is	O
a	O
large	O
>	O
15	O
cm	O
cystic	O
pelvic	O
mass	O
,	O
which	O
can	O
not	O
be	O
further	O
characterized	O
.	O
Bladder	O
is	O
not	O
visualized	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Moderate	O
right	O
-	O
sided	O
hydronephrosis	O
.	O
2	O
.	O
Non-specific	O
,	O
large	O
cystic	O
pelvic	O
mass	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
was	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
old	O
female	O
with	O
h.o	O
CHF	O
,	O
DM	O
,	O
afib	O
,	O
who	O
presented	O
with	O
invasive	O
scalp	O
squamous	O
cell	O
carcinoma	O
with	O
intracranial	O
extension	O
who	O
died	O
after	O
code	O
status	O
was	O
CMO	O
.	O
.	O
#	O
CMO	O
-	O
Had	O
family	O
meeting	O
[	O
**	O
6	O
-	O
10	O
**	O
]	O
.	O
Discussed	O
to	O
stop	O
vital	O
signs	O
,	O
non-essential	O
medications	O
other	O
than	O
eye	B-Drug
drops	I-Drug
,	O
pain	B-Drug
meds	I-Drug
,	O
and	O
PO	O
antibiotics	I-Drug
.	O
Patient	O
was	O
continued	O
on	O
maintainance	O
IV	O
fluids	I-Drug
.	O
.	O
#	O
Pain	B-Reason
control	I-Reason
-	O
This	O
was	O
the	O
family	O
's	O
primary	O
goal	O
of	O
care	O
.	O
There	O
were	O
multiple	O
etiologies	O
of	O
the	O
pain	O
including	O
her	O
chonic	O
right	O
shoulder	O
pain	O
,	O
sacral	O
decubiti	O
with	O
possible	O
abcess	O
,	O
painful	O
scalp	O
leison	O
,	O
or	O
the	O
>	O
15	O
cm	O
pelvic	O
mass	O
.	O
Pain	O
control	O
was	O
transitioned	O
from	O
outpatient	O
oxycontin	I-Drug
pills	O
to	O
fenanyl	I-Drug
patch	O
and	O
oxycodone	I-Drug
liquid	O
.	O
Patient	O
was	O
comfortably	O
sedated	O
and	O
only	O
required	O
additional	O
pain	O
medication	O
when	O
she	O
was	O
moved	O
.	O
Palliative	O
care	O
was	O
involved	O
in	O
pain	O
management	O
.	O
.	O
#	O
Squamous	O
cell	O
ca	O
,	O
intracranial	O
-	O
The	O
carcinoma	O
developed	O
over	O
an	O
unknown	O
time	O
period	O
.	O
It	O
probably	O
developed	O
before	O
her	O
care	O
to	O
nursing	O
home	O
facility	O
given	O
that	O
there	O
was	O
a	O
rapid	O
decline	O
in	O
her	O
functional	O
status	O
and	O
intracraninal	O
involvement	O
of	O
the	O
tumor	O
.	O
She	O
was	O
evaluated	O
as	O
an	O
outpatient	O
by	O
dermatology	O
and	O
was	O
determined	O
to	O
have	O
a	O
squamous	O
cell	O
ca	O
as	O
per	O
biopsy	O
on	O
[	O
**	O
5	O
-	O
25	O
**	O
]	O
.	O
Initially	O
,	O
the	O
family	O
wanted	O
to	O
have	O
a	O
neurosurgical	O
intervention	O
,	O
but	O
the	O
patient	O
's	O
INR	O
was	O
7.7	O
so	O
she	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
reversal	O
.	O
Later	O
,	O
the	O
family	O
decided	O
not	O
to	O
have	O
surgery	O
once	O
it	O
became	O
apparent	O
that	O
the	O
morbity	O
was	O
high	O
.	O
Patient	O
was	O
started	O
on	O
vancomycin	I-Drug
and	O
ceftriaxone	I-Drug
for	O
meningitis	B-Reason
ppx	I-Reason
and	O
this	O
was	O
changed	O
to	O
PO	O
cefepoxidime	I-Drug
after	O
a	O
family	O
meeting	O
determining	O
that	O
she	O
would	O
not	O
want	O
IV	O
antibiotics	I-Drug
.	O
Wound	O
care	O
was	O
done	O
to	O
address	O
her	O
head	O
wound	O
.	O
.	O
#	O
Resolved	O
hypovolemia	O
/	O
acute	O
renal	O
failure	O
/	O
hypernatremia	O
-	O
secondary	O
to	O
dehydration	I-Ade
and	O
intravascular	B-Ade
hypovolemia	I-Ade
in	O
the	O
setting	O
of	O
diruetic	I-Drug
use	O
.	O
Cr	O
2.0	O
on	O
admission	O
,	O
most	O
recent	O
baseline	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
1.1	O
.	O
This	O
was	O
the	O
reason	O
for	O
the	O
PICC	O
line	O
placement	O
and	O
why	O
the	O
family	O
wanted	O
IVF	I-Drug
.	O
.	O
#	O
Pelvic	O
mass	O
-	O
There	O
is	O
a	O
large	O
>	O
15	O
cm	O
cystic	O
pelvic	O
mass	O
seen	O
on	O
renal	O
ultrasound	O
.	O
This	O
may	O
be	O
a	O
source	O
of	O
pain	O
.	O
.	O
#	O
afib	O
not	O
on	O
anticoagulation	O
-	O
Patient	O
has	O
a	O
history	O
of	O
atrial	O
fibrillation	O
but	O
was	O
placed	O
on	O
anticoagulation	O
for	O
a	O
recent	O
phelbiltis	O
.	O
Given	O
that	O
the	O
scalp	O
wound	O
oozes	O
blood	O
,	O
the	O
family	O
has	O
decided	O
that	O
they	O
do	O
not	O
want	O
anticoagulation	O
.	O
.	O
#	O
DM	O
-	O
HISS	O
.	O
COMFORT	O
MEASURES	O
ONLY	O
DISCHARGE	O
TO	O
DEATH	O
Medications	O
on	O
Admission	O
:	O
Medications	O
at	O
home	O
:	O
Lasix	I-Drug
40	O
mg	O
PO	O
daily	O
Lisinopril	I-Drug
40	O
mg	O
PO	O
daily	O
OxyContin	I-Drug
20	O
mg	O
PO	O
q12	O
,	O
10	O
mg	O
PO	O
qHS	O
Xalatan	I-Drug
0.005	O
%	O
Eye	O
Drops	O
1	O
Drops	O
(	O
s	O
)	O
Once	O
Daily	O
,	O
at	O
bedtime	O
Azopt	I-Drug
1	O
%	O
Eye	O
Drops	O
Ophthalmic	O
1	O
drop	O
daily	O
Tylenol	I-Drug
1g	O
PO	O
TID	O
Serax	I-Drug
10	O
mg	O
PO	O
BID	O
MVI	I-Drug
PO	O
daily	O
Pro-Stat	B-Drug
64	I-Drug
--	O
Unknown	O
Strength	O
,	O
Twice	O
Daily	O
Zinc	I-Drug
Chelated	O
50	O
mg	O
PO	O
daily	O
Vitamin	B-Drug
C	I-Drug
500	O
mg	O
SR	O
PO	O
daily	O
Simethicone	B-Drug
80	O
mg	O
chewable	O
tab	O
PO	O
prn	O
.	O
Medications	O
on	O
transfer	O
:	O
CeftriaXONE	I-Drug
1	O
gm	O
IV	O
Q24H	O
Vancomycin	I-Drug
1000	O
mg	O
IV	O
ONCE	O
(	O
dose	O
by	O
level	O
)	O
Oxycodone	B-Drug
SR	I-Drug
(	O
OxyconTIN	I-Drug
)	O
10	O
mg	O
PO	O
Q12H	O
Humalog	I-Drug
insulin	O
sliding	O
scale	O
Latanoprost	I-Drug
0.005	O
%	O
Ophth	O
.	O
Soln	O
.	O
1	O
DROP	O
BOTH	O
EYES	O
HS	O
Pantoprazole	B-Drug
40	O
mg	O
PO	O
Q24H	O
Docusate	I-Drug
Sodium	O
(	O
Liquid	O
)	O
100	O
mg	O
PO	O
BID	O
Multivitamins	I-Drug
1	O
TAB	O
PO	O
DAILY	O
Oxazepam	I-Drug
10	O
mg	O
PO	O
BID	O
:	O
PRN	O
anxiety	I-Reason
Acetaminophen	I-Drug
325	O
-	O
650	O
mg	O
PO	O
Q6H	O
:	O
PRN	O
pain	I-Reason
/	O
fever	I-Reason
Bisacodyl	B-Drug
10	O
mg	O
PO	O
/	O
PR	O
DAILY	O
:	O
PRN	O
Senna	I-Drug
1	O
TAB	O
PO	O
BID	O
:	O
PRN	O
Discharge	O
Medications	O
:	O
NONE	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
intracranial	O
extension	O
of	O
invasive	O
sqamous	O
cell	O
carcinoma	O
Secondary	O
:	O
resolved	O
acute	O
renal	O
failure	O
secondary	O
to	O
dehydration	O
pelvic	O
mass	O
of	O
unknown	O
etiology	O
atrial	O
fibrillation	O
,	O
chronic	O
hypertension	O
diabetes	O
mellitus	O
,	O
type	O
2	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
none	O
Followup	O
Instructions	O
:	O
none	O
Completed	O
by	O
:[	O
**	O
2163-6-15	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2195-6-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2195-6-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2125-8-26	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Azithromycin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
6780	O
**	O
]	O
Chief	O
Complaint	O
:	O
Shortness	O
of	O
breath	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
BiPap	O
Arterial	O
Line	O
Placement	O
Central	O
Line	O
Placement	O
PICC	O
Line	O
Placement	O
History	O
of	O
Present	O
Illness	O
:	O
69	O
F	O
c	O
hx	O
of	O
CAD	O
s	O
/	O
p	O
multiple	O
stents	O
,	O
ischemic	O
CM	O
EF	O
25	O
%	O
,	O
asthma	O
,	O
multiple	O
recent	O
admissions	O
(	O
most	O
recently	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
27916	O
**	O
]	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
fall	O
and	O
hypoglycemia	I-Ade
thought	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
insulin	I-Drug
use	O
in	O
the	O
setting	O
of	O
ARF	O
;	O
previously	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
107613	O
**	O
]	O
c	O
respiratory	O
failure	O
thought	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
COPD	O
and	O
CHF	O
.	O
As	O
per	O
ED	O
history	O
,	O
pt	O
found	O
by	O
VNA	O
to	O
hypoxic	O
to	O
80's	O
on	O
RA	O
.	O
ED	O
COURSE	O
:	O
She	O
was	O
found	O
to	O
be	O
86	O
%	O
on	O
ra	O
,	O
HR	O
100	O
,	O
BP	O
155/59	O
,	O
RR	O
32	O
.	O
She	O
was	O
treated	O
for	O
a	O
copd	O
flare	O
vs.	O
chf	O
.	O
She	O
has	O
a	O
h	O
/	O
o	O
of	O
dvt	O
,	O
not	O
anticoagulated	O
at	O
this	O
time	O
at	O
home	O
.	O
Her	O
O2	O
improved	O
on	O
bipap	O
,	O
could	O
not	O
lay	O
flat	O
for	O
CT	O
-	O
PE	O
could	O
not	O
be	O
ruled	O
out	O
.	O
She	O
had	O
significant	O
improvement	O
with	O
nitro	I-Drug
gtt	O
,	O
lasix	I-Drug
,	O
bipap	O
,	O
steroids	I-Drug
,	O
levofloxacin	I-Drug
.	O
When	O
pt	O
came	O
up	O
to	O
MICU	O
unable	O
to	O
get	O
complete	O
history	O
,	O
pt	O
denied	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
.	O
History	O
limited	O
by	O
use	O
of	O
BiPAP	O
mask	O
.	O
.	O
Past	O
Medical	O
History	O
:	O
#	O
CAD	O
s	O
/	O
p	O
MI	O
(	O
[	O
**	O
2190	O
**	O
]	O
)	O
-	O
known	O
total	O
occlusion	O
of	O
LAD	O
and	O
ramus	O
w	O
/	O
R	O
-	O
>	O
L	O
collaterals	O
-	O
aborted	O
CABG	O
(	O
[	O
**	O
2190	O
**	O
]	O
)	O
d	O
/	O
t	O
extensive	O
calcification	O
making	O
it	O
impossible	O
to	O
cross	O
clamp	O
aorta	O
-	O
s	O
/	O
p	O
stents	O
to	O
LAD	O
,	O
LCx	O
,	O
OM	O
,	O
D2	O
,	O
ramus	O
and	O
RCA	O
#	O
CHF	O
:	O
last	O
echo	O
[	O
**	O
3	O
-	O
28	O
**	O
]	O
with	O
EF	O
25	O
%	O
,	O
1	O
+	O
MR	O
,	O
infero	O
-	O
lateral	O
and	O
distal	O
LV	O
/	O
apical	O
akinesis	O
-	O
s	O
/	O
p	O
dual	O
chambered	O
ICD	O
[	O
**	O
2191-7-4	O
**	O
]	O
for	O
primary	O
prevention	O
(	O
[	O
**	O
Company	O
1543	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
24119	O
**	O
]	O
DR	O
)	O
#	O
Hypertension	O
#	O
Diabetes	O
type	O
2	O
#	O
Hyperlipidemia	O
#	O
COPD	O
(	O
has	O
been	O
labelled	O
as	O
asthma	O
,	O
however	O
CXR	O
and	O
ABGs	O
more	O
c	O
/	O
w	O
COPD	O
along	O
w	O
/	O
long	O
smoking	O
hx	O
)	O
#	O
Depression	O
#	O
h	O
/	O
o	O
LV	O
thrombus	O
#	O
Carotid	O
artery	O
disease	O
-	O
s	O
/	O
p	O
R	O
catorid	O
artery	O
stenting	O
[	O
**	O
2189	O
**	O
]	O
#	O
h	O
/	O
o	O
cerebral	O
infarction	O
by	O
MR	O
in	O
[	O
**	O
2190	O
**	O
]	O
#	O
s	O
/	O
p	O
ccy	O
#	O
Likely	O
dementia	O
(	O
?	O
-	O
Alzhemer	O
's	O
vs.	O
Vascular	O
)	O
Social	O
History	O
:	O
Originally	O
from	O
[	O
**	O
Location	O
(	O
un	O
)	O
4708	O
**	O
]	O
.	O
She	O
never	O
knew	O
her	O
father	O
and	O
her	O
mother	O
left	O
her	O
when	O
she	O
was	O
very	O
young	O
.	O
She	O
grew	O
up	O
with	O
a	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
family	O
.	O
She	O
immigrated	O
to	O
America	O
in	O
the	O
[	O
**	O
2157	O
**	O
]	O
.	O
She	O
has	O
7	O
children	O
and	O
13	O
grandchildren	O
used	O
to	O
live	O
with	O
many	O
of	O
them	O
in	O
a	O
large	O
3	O
-	O
family	O
house	O
,	O
but	O
most	O
recently	O
was	O
at	O
NH	O
.	O
She	O
used	O
to	O
smoke	O
about	O
1	O
/	O
2ppd	O
for	O
unclear	O
amount	O
of	O
time	O
and	O
currently	O
has	O
an	O
occassional	O
cigarette	O
.	O
She	O
does	O
n't	O
currently	O
use	O
alcohol	O
(	O
previously	O
used	O
to	O
only	O
when	O
"	O
partying	O
"	O
-	O
can	O
not	O
quantify	O
)	O
.	O
She	O
has	O
never	O
used	O
illicit	O
drugs	O
.	O
Family	O
History	O
:	O
Unknown	O
hx	O
of	O
parents	O
.	O
Physical	O
Exam	O
:	O
VS	O
-	O
T	O
97.9	O
,	O
108	O
,	O
120/97	O
,	O
RR22	O
,	O
SpO2	O
100	O
%	O
on	O
CPAP	O
5/5	O
GEN	O
-	O
elderly	O
woman	O
,	O
with	O
BiPAP	O
,	O
NAD	O
HEENT	O
-	O
NCAT	O
,	O
JVD	O
not	O
markedly	O
elevated	O
LUNGS	O
-	O
moderate	O
air	O
movement	O
,	O
no	O
wheezes	O
,	O
no	O
crackles	O
HEART	O
-	O
RRR	O
,	O
S1	O
,	O
S2	O
ABDOM	O
-	O
soft	O
,	O
NT	O
,	O
+	O
BS	O
EXTRE	O
-	O
trace	O
edema	O
bilaterally	O
NEURO	O
-	O
grossly	O
normal	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
================	O
9.8	O
5.5	O
>	O
------	O
<	O
304	O
31.0	O
133	O
99	O
20	O
-----	O
|	O
----	O
|	O
-----	O
<	O
147	O
4.9	O
28	O
0.8	O
Ca	O
8.3	O
Mg	O
2.1	O
Phos	O
2.8	O
PERTINENT	O
LABS	O
:	O
===============	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
BNP	O
[	O
**	O
Numeric	O
Identifier	O
107614	O
**	O
]	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
Cortisol	O
25.7	O
--	O
>	O
45.3	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
TSH	O
0.86	O
,	O
T3	O
52	O
,	O
FT4	O
1.0	O
Haptoglobin	O
trend	O
:	O
20	O
-	O
undectable	O
-	O
<	O
20	O
-	O
<	O
20	O
-	O
26	O
Lactate	O
trend	O
:	O
2.6	O
-	O
8.1	O
-	O
8.7	O
-	O
7.6	O
-	O
3.6	O
-	O
1.2	O
-	O
8.7	O
-	O
10.3	O
-	O
7.8	O
-	O
1.3	O
MICROBIOLOGY	O
:	O
============	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
BCx	O
x	O
2	O
:	O
negative	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
BCx	O
x	O
2	O
:	O
negative	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
UCx	O
:	O
Staph	O
species	O
~	O
3000	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
Legionella	O
Antigen	O
:	O
negative	O
STUDIES	O
:	O
==========	O
CXR	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
MPRESSION	O
:	O
Blunting	O
of	O
the	O
right	O
costophrenic	O
angle	O
may	O
indicate	O
small	O
pleural	O
effusion	O
or	O
basilar	O
atelectasis	O
.	O
A	O
faint	O
right	O
lower	O
lobe	O
opacity	O
may	O
be	O
due	O
to	O
bronchovascular	O
crowding	O
,	O
however	O
an	O
early	O
developing	O
pneumonia	O
can	O
not	O
be	O
excluded	O
.	O
RUQ	O
U	O
/	O
S	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
IMPRESSION	O
:	O
Patient	O
is	O
status	O
post	O
cholecystectomy	O
.	O
Study	O
is	O
otherwise	O
unremarkable	O
.	O
CTA	O
CHEST	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Very	O
small	O
subsegmental	O
left	O
apical	O
pulmonary	O
emboli	O
,	O
unlikely	O
to	O
account	O
for	O
the	O
patient	O
's	O
severe	O
hypotensive	O
episode	O
.	O
2	O
.	O
Bibasilar	O
pleural	O
effusions	O
,	O
right	O
greater	O
than	O
left	O
,	O
with	O
associated	O
airspace	O
disease	O
,	O
atelectasis	O
versus	O
aspiration	O
or	O
pneumonia	O
.	O
3	O
.	O
Cardiomegaly	O
and	O
dense	O
coronary	O
artery	O
calcifications	O
.	O
LENI	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
IMPRESSION	O
:	O
Limited	O
exam	O
due	O
to	O
patient	O
agitation	O
and	O
motion	O
.	O
No	O
definite	O
evidence	O
of	O
right	O
lower	O
extremity	O
DVT	O
.	O
Please	O
note	O
that	O
left	O
lower	O
extremity	O
venous	O
ultrasound	O
was	O
not	O
performed	O
due	O
to	O
patient	O
incooperation	O
.	O
CT	O
HEAD	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
IMPRESSION	O
:	O
No	O
change	O
in	O
subacute	O
to	O
chronic	O
infarctions	O
at	O
the	O
right	O
occipital	O
and	O
parietal	O
lobes	O
.	O
No	O
new	O
evidence	O
of	O
acute	O
ischemia	O
or	O
acute	O
hemorrhage	O
is	O
seen	O
.	O
ECHO	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
mildly	O
dilated	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
with	O
global	O
hypokinesis	O
and	O
inferior	O
and	O
apical	O
akinesis	O
(	O
LVEF	O
=	O
20	O
%	O
)	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
with	O
moderate	O
global	O
free	O
wall	O
hypokinesis	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
to	O
severe	O
[	O
3	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2195-4-7	O
**	O
]	O
,	O
the	O
degree	O
of	O
mitral	O
and	O
tricuspid	O
regurgitation	O
are	O
probabaly	O
similar	O
(	O
underestimated	O
on	O
prior	O
report	O
)	O
.	O
The	O
LVEF	O
is	O
similar	O
.	O
The	O
degree	O
of	O
pulmonary	O
hypertension	O
detected	O
has	O
increased	O
.	O
EEG	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
IMPRESSION	O
:	O
This	O
is	O
an	O
abnormal	O
portable	O
EEG	O
in	O
the	O
waking	O
and	O
sleeping	O
states	O
due	O
to	O
the	O
disorganized	O
,	O
low	O
voltage	O
,	O
and	O
slow	O
background	O
with	O
admixed	O
bursts	O
of	O
moderate	O
amplitude	O
generalized	O
mixed	O
frequency	O
slowing	O
.	O
This	O
constellation	O
of	O
findings	O
is	O
consistent	O
with	O
a	O
mild	O
global	O
encephalopathy	O
due	O
to	O
dysfunction	O
of	O
bilateral	O
subcortical	O
or	O
deep	O
midline	O
structures	O
.	O
Medications	O
,	O
metabolic	O
disturbances	O
,	O
infection	O
and	O
anoxia	O
are	O
among	O
the	O
common	O
causes	O
of	O
encephalopathy	O
but	O
there	O
are	O
others	O
.	O
There	O
were	O
no	O
areas	O
of	O
prominent	O
focal	O
slowing	O
.	O
There	O
were	O
no	O
epileptiform	O
features	O
.	O
Brief	O
Hospital	O
Course	O
:	O
69	O
y.o.	O
F	O
h	O
/	O
o	O
CAD	O
s	O
/	O
p	O
multiple	O
stents	O
,	O
ischemic	O
CM	O
EF	O
25	O
%	O
,	O
asthma	O
,	O
multiple	O
recent	O
admissions	O
(	O
most	O
recently	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
27916	O
**	O
]	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
fall	O
and	O
hypoglycemia	I-Ade
thought	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
insulin	I-Drug
use	O
in	O
the	O
setting	O
of	O
ARF	O
;	O
previously	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
107613	O
**	O
]	O
c	O
respiratory	O
failure	O
thought	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
COPD	O
and	O
CHF	O
.	O
found	O
by	O
her	O
VNA	O
to	O
hypoxic	O
to	O
80's	O
on	O
RA	O
.	O
Upon	O
arrival	O
to	O
the	O
ED	O
VS	O
=	O
86	O
%	O
on	O
ra	O
,	O
HR	O
100	O
,	O
BP	O
155/59	O
,	O
RR	O
32	O
.	O
She	O
was	O
treated	O
for	O
COPD	B-Reason
flare	I-Reason
(	O
steroids	I-Drug
)	O
,	O
CHF	I-Reason
(	O
bipap	O
,	O
lasix	I-Drug
,	O
nitro	I-Drug
gtt	O
)	O
,	O
and	O
PNA	I-Reason
(	O
levaquin	I-Drug
)	O
.	O
CTA	O
not	O
performed	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
inability	O
to	O
lie	O
flat	O
,	O
but	O
pt	O
empirically	O
started	O
on	O
heparin	I-Drug
gtt	O
.	O
Her	O
oxygen	O
status	O
improved	O
and	O
she	O
was	O
transferred	O
to	O
the	O
MICU	O
.	O
In	O
the	O
MICU	O
,	O
pt	O
's	O
antibiotic	I-Drug
coverage	O
was	O
broadened	O
to	O
CTX	I-Drug
/	O
vanco	I-Drug
and	O
azithromycin	I-Drug
.	O
In	O
the	O
setting	O
of	O
her	O
first	O
azithromycin	I-Drug
dose	O
on	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
,	O
pt	O
became	O
hypotensive	I-Ade
requiring	O
pressors	I-Drug
(	O
levo	I-Drug
,	O
neo	I-Drug
,	O
vaso	I-Drug
)	O
,	O
felt	O
to	O
be	O
an	O
allergic	B-Ade
reaction	I-Ade
to	O
the	O
azithromycin	I-Drug
.	O
Pressors	I-Drug
were	O
titrated	O
off	O
~	O
12	O
hrs	O
later	O
on	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
.	O
Her	O
respiratory	O
status	O
continued	O
to	O
improve	O
,	O
and	O
she	O
was	O
weaned	O
of	O
bipap	O
on	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
,	O
and	O
steroids	I-Drug
were	O
discontinued	O
as	O
COPD	O
was	O
felt	O
less	O
likely	O
.	O
On	O
[	O
**	O
6	O
-	O
7	O
**	O
]	O
pt	O
's	O
HCT	O
31	O
-	O
>	O
24	O
,	O
she	O
was	O
transfused	O
1U	O
PRBC	I-Drug
,	O
complicated	O
by	O
grand	O
mal	O
seizure	O
,	O
and	O
hypotension	I-Reason
,	O
again	O
requiring	O
pressors	I-Drug
(	O
levo	I-Drug
,	O
neo	I-Drug
,	O
vaso	I-Drug
)	O
for	O
~	O
12	O
hrs	O
.	O
Neuro	O
was	O
consulted	O
as	O
there	O
was	O
also	O
a	O
question	O
of	O
left	O
dilated	O
pupil	O
,	O
head	O
CT	O
showed	O
no	O
acute	O
bleeding	O
,	O
+	O
subacute	O
/	O
chronic	O
infarctions	O
,	O
EEG	O
c	O
/	O
w	O
toxic	O
/	O
metabolic	O
insult	O
,	O
heparin	I-Drug
gtt	O
was	O
held	O
.	O
CTA	O
was	O
obtained	O
which	O
showed	O
very	O
small	O
left	O
apical	O
PE	O
,	O
felt	O
unlikely	O
to	O
account	O
for	O
hypotension	O
.	O
TTE	O
revealed	O
EF	O
=	O
20	O
%	O
(	O
old	O
)	O
,	O
2	O
+	O
mr	O
,	O
3	O
+	O
tr	O
.	O
On	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
,	O
repeat	O
blood	O
transfusion	O
performed	O
without	O
complication	O
.	O
HCT	O
21	O
-	O
>	O
26	O
,	O
however	O
hemolysis	O
labs	O
revealed	O
hapto	O
<	O
20	O
,	O
LDH	O
760	O
-	O
>	O
468	O
,	O
smear	O
+	O
schistocytes	O
,	O
suggestive	O
of	O
hemolysis	O
,	O
DAT	O
negative	O
x	O
2	O
(	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
,	O
[	O
**	O
6	O
-	O
9	O
**	O
]	O
)	O
.	O
Per	O
report	O
,	O
pt	O
's	O
mental	O
status	O
(	O
which	O
waxes	O
and	O
wanes	O
)	O
,	O
is	O
not	O
far	O
from	O
her	O
baseline	O
.	O
She	O
responds	O
to	O
voice	O
,	O
but	O
is	O
a	O
&	O
ox1	O
(	O
name	O
)	O
only	O
.	O
On	O
[	O
**	O
6	O
-	O
10	O
**	O
]	O
O2	O
and	O
BP	O
were	O
stable	O
and	O
pt	O
was	O
transferred	O
to	O
the	O
floor	O
.	O
On	O
the	O
Floor	O
she	O
completed	O
her	O
course	O
of	O
Vanc	I-Drug
/	O
Cefepime	I-Drug
.	O
Her	O
BP	O
stabilized	O
and	O
she	O
was	O
restarted	O
on	O
home	O
antihypertensive	I-Drug
regimen	O
.	O
Fingersticks	O
remained	O
elevated	O
,	O
and	O
her	O
glargine	I-Drug
was	O
increased	O
for	O
better	B-Reason
glycemic	I-Reason
control	I-Reason
.	O
She	O
continued	O
on	O
albuterol	I-Drug
and	O
atrovent	I-Drug
prn	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
/	O
wheezing	I-Reason
.	O
Heme	O
/	O
onc	O
was	O
consulted	O
regarding	O
hemolysis	O
and	O
anticoagulation	I-Drug
.	O
Their	O
recommendations	O
stated	O
that	O
the	O
exact	O
cause	O
of	O
hemolysis	O
is	O
difficult	O
to	O
interpret	O
,	O
however	O
by	O
the	O
time	O
the	O
pt	O
was	O
on	O
the	O
floor	O
,	O
the	O
hct	O
was	O
rising	O
and	O
LDH	O
was	O
falling	O
suggesting	O
that	O
hemolysis	O
was	O
resolving	O
.	O
They	O
recommended	O
that	O
there	O
was	O
no	O
contraindication	O
to	O
anticoagulation	O
.	O
Given	O
her	O
multiple	O
indications	O
for	O
anticoagulation	I-Reason
,	O
decision	O
was	O
made	O
to	O
begin	O
coumadin	I-Drug
with	O
a	O
lovenox	I-Drug
bridge	O
.	O
Her	O
INR	O
was	O
1.9	O
on	O
discharge	O
,	O
and	O
she	O
will	O
continue	O
on	O
lovenox	I-Drug
SQ	O
until	O
INR	O
therapeutic	O
at	O
2	O
-	O
3	O
and	O
coumadin	I-Drug
10	O
mg	O
daily	O
.	O
The	O
lovenox	I-Drug
may	O
be	O
stopped	O
after	O
therapeutic	O
INR	O
.	O
INRs	O
should	O
be	O
followed	O
and	O
her	O
dose	O
adjusted	O
accordingly	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
daily	O
2	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
daily	O
3	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
20	O
mg	O
daily	O
4	O
.	O
Albuterol	I-Drug
INH	O
PRN	O
5	O
.	O
Ipratropium	I-Drug
INH	O
PRN	O
6	O
.	O
Toprol	I-Drug
25	O
mg	O
daily	O
7	O
.	O
Docusate	I-Drug
1	O
cap	O
[	O
**	O
Hospital1	O
**	O
]	O
8	O
.	O
Aspirin	I-Drug
325	O
mg	O
daily	O
9	O
.	O
Enoxaparin	I-Drug
90	O
[	O
**	O
Hospital1	O
**	O
]	O
until	O
therapeutic	O
INR	O
10	O
.	O
Warfarin5	B-Drug
mg	O
daily	O
11	O
.	O
Furosemide	I-Drug
40	O
mg	O
daily	O
12	O
.	O
Lisinopril	I-Drug
10	O
mg	O
daily	O
13	O
.	O
Insulin	B-Drug
Lispro	I-Drug
32	O
u	O
AM	O
,	O
10	O
u	O
PM	O
14	O
.	O
Insulin	B-Drug
Regular	I-Drug
sliding	O
scale	O
15	O
.	O
Fluticasone	I-Drug
220	O
INH	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
Clopidogrel	I-Drug
75	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
Solution	O
for	O
Nebulization	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Three	O
(	O
3	O
)	O
mL	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
5	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Three	O
(	O
3	O
)	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
6	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
3	O
*	O
8	O
.	O
Toprol	B-Drug
XL	I-Drug
25	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
9	O
.	O
Furosemide	I-Drug
40	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Lisinopril	I-Drug
10	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Enoxaparin	I-Drug
100	O
mg	O
/	O
mL	O
Syringe	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Ninety	O
(	O
90	O
)	O
mg	O
Subcutaneous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
:	O
Until	O
coumadin	I-Drug
therapuetic	O
.	O
12	O
.	O
Insulin	B-Drug
Glargine	I-Drug
100	O
unit	O
/	O
mL	O
Cartridge	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Thirty	O
Six	O
(	O
36	O
)	O
units	O
Subcutaneous	O
qAM	O
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
2	O
*	O
13	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
14	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
15	O
.	O
Digoxin	I-Drug
125	O
mcg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
0.5	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
15	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
16	O
.	O
Colace	I-Drug
100	O
mg	O
Capsule	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
17	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
.	O
Tablet	O
(	O
s	O
)	O
18	O
.	O
Insulin	I-Drug
Please	O
see	O
attached	O
sliding	O
scale	O
for	O
dosing	O
.	O
19	O
.	O
Dulcolax	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
11729	O
**	O
]	O
Home	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
Pneumonia	O
Sepsis	O
Pulmonary	O
Embolism	O
Atrial	O
Fibrillation	O
Congestive	O
Heart	O
Failure	O
Discharge	O
Condition	O
:	O
Oxygenation	O
stable	O
,	O
BP	O
stable	O
.	O
A+O	O
x1	O
(	O
at	O
baseline	O
)	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
low	O
oxygen	O
level	O
.	O
You	O
were	O
treated	O
for	O
pneumonia	O
,	O
COPD	O
,	O
and	O
blood	O
clot	O
in	O
the	O
lung	O
.	O
Your	O
blood	I-Ade
pressure	O
fell	O
after	O
recieving	O
azithromycin	I-Drug
,	O
and	O
this	O
was	O
thought	O
to	O
be	O
due	O
to	O
an	O
allergic	B-Ade
reaction	I-Ade
.	O
Your	O
blood	O
pressure	O
also	O
fell	O
after	O
receiving	O
a	O
blood	O
transfusion	O
and	O
you	O
had	O
a	O
seizure	O
.	O
Neurology	O
evaluated	O
you	O
and	O
felt	O
that	O
you	O
did	O
not	O
need	O
and	O
seizure	O
medications	O
.	O
With	O
antibiotics	I-Drug
,	O
your	O
oxygenation	O
improved	O
,	O
and	O
your	O
blood	O
pressure	O
stabilized	O
.	O
You	O
were	O
started	O
on	O
lovenox	I-Drug
and	O
then	O
coumadin	I-Drug
to	O
treat	O
the	O
clots	B-Reason
in	I-Reason
your	I-Reason
lung	I-Reason
.	O
.	O
Because	O
of	O
your	O
diagnosis	O
of	O
congestive	O
heart	O
failure	O
,	O
you	O
should	O
weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
>	O
3	O
lbs	O
.	O
Adhere	O
to	O
2	O
gm	O
sodium	O
diet	O
Fluid	O
Restriction	O
:	O
1500	O
cc	O
/	O
day	O
.	O
.	O
Take	O
all	O
of	O
your	O
medications	O
as	O
prescribed	O
below	O
.	O
Changes	O
include	O
:	O
1	O
.	O
Senna	I-Drug
1	O
tablet	O
twice	O
daily	O
as	O
needed	O
for	O
constipation	I-Reason
2	O
.	O
Colace	I-Drug
1	O
tablet	O
twice	O
daily	O
as	O
needed	O
for	O
constipation	I-Reason
3	O
.	O
Warfarin	I-Drug
10	O
mg	O
daily	O
4	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
tablet	O
daily	O
5	O
.	O
Digoxin	I-Drug
[	O
**	O
1	O
-	O
21	O
**	O
]	O
tablet	O
(	O
0.0625	O
mg	O
)	O
daily	O
6	O
.	O
Lovenox	I-Drug
90	O
mg	O
SQ	O
every	O
12	O
hours	O
(	O
until	O
therapeutic	O
INR	O
)	O
.	O
Keep	O
all	O
of	O
your	O
appointments	O
as	O
written	O
below	O
.	O
.	O
If	O
you	O
have	O
symptoms	O
of	O
shortness	O
of	O
breath	O
,	O
cough	O
,	O
chest	O
pain	O
,	O
fevers	O
,	O
or	O
anyother	O
concerning	O
symptoms	O
call	O
your	O
doctor	O
or	O
go	O
to	O
the	O
ER	O
.	O
Followup	O
Instructions	O
:	O
Primary	O
Care	O
:	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
1528	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3581	O
**	O
]	O
.	O
Appointment	O
on	O
[	O
**	O
2195-7-8	O
**	O
]	O
at	O
1:45	O
PM	O
.	O
You	O
should	O
have	O
your	O
INR	O
checked	O
daily	O
.	O
Goal	O
INR	O
[	O
**	O
2	O
-	O
22	O
**	O
]	O
.	O
Completed	O
by	O
:[	O
**	O
2195-6-23	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2116-11-9	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2116-11-14	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2033-7-28	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1234	O
**	O
]	O
Chief	O
Complaint	O
:	O
Known	O
Throacic	O
Aortic	O
Aneurysm	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2116-11-9	O
**	O
]	O
-	O
PROCEDURE	O
:	O
Endovascular	O
thoracic	O
aortic	O
aneurysm	O
repair	O
,	O
one	O
distal	O
extension	O
,	O
left	O
common	O
iliac	O
conduit	O
10	O
-	O
mm	O
Dacron	O
graft	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
4726	O
**	O
]	O
TAG	O
45	O
-	O
20	O
times	O
two	O
[	O
**	O
2116-11-9	O
**	O
]	O
-	O
PROCEDURES	O
:	O
1	O
.	O
Stent	O
graft	O
repair	O
of	O
thoracoabdominal	O
aortic	O
aneurysm	O
using	O
two	O
[	O
**	O
Doctor	O
Last	O
Name	O
4726	O
**	O
]	O
TAG	O
endoprostheses	O
.	O
The	O
TAG	O
graft	O
data	O
is	O
the	O
following	O
:	O
The	O
first	O
[	O
**	O
Doctor	O
Last	O
Name	O
4726	O
**	O
]	O
graft	O
is	O
catalog	O
number	O
[	O
**	O
Serial	O
Number	O
99640	O
**	O
]	O
,	O
lot	O
number	O
[	O
**	O
Serial	O
Number	O
99641	O
**	O
]	O
.	O
The	O
second	O
one	O
is	O
reference	O
catalog	O
number	O
[	O
**	O
Serial	O
Number	O
99640	O
**	O
]	O
,	O
lot	O
number	O
[	O
**	O
Serial	O
Number	O
99642	O
**	O
]	O
.	O
2	O
.	O
Thoracic	O
and	O
abdominal	O
aortography	O
.	O
3	O
.	O
Left	O
iliac	O
conduit	O
placement	O
performed	O
by	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
and	O
his	O
colleagues	O
for	O
stent	O
graft	O
deployment	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
The	O
patient	O
is	O
an	O
elderly	O
female	O
with	O
a	O
known	O
greater	O
than	O
8	O
-	O
cm	O
thoracic	O
aneurysm	O
.	O
She	O
has	O
been	O
worked	O
up	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
as	O
an	O
outpatient	O
and	O
presented	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
on	O
[	O
**	O
11	O
-	O
9	O
**	O
]	O
for	O
definitive	O
repair	O
and	O
magagement	O
of	O
her	O
aneurysm	O
.	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
dical	O
History	O
:	O
Coronary	O
artery	O
disease	O
,	O
hyperlipidemia	O
,	O
Hypertension	O
,	O
Diabetes	O
Mellitus	O
II	O
,	O
Chronic	O
renal	O
insuficiency	O
,	O
hearing	O
loss	O
,	O
macular	O
degeneration	O
,	O
thoracic	O
aneurysm	O
status	O
post	O
repair	O
in	O
[	O
**	O
2111-8-24	O
**	O
]	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
Le	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
sciatica	O
,	O
diverticulosis	O
,	O
colonic	O
polyps	O
,	O
cerebral	O
microvascular	O
disease	O
,	O
proteinuria	O
,	O
cholelithiasis	O
,	O
venous	O
stasis	O
disease	O
,	O
hemorrhoids	O
,	O
sciatica	O
,	O
and	O
peripheral	O
vascular	O
disease	O
.	O
Past	O
surgical	O
history	O
is	O
notable	O
for	O
hysterectomy	O
,	O
pilonidal	O
cyst	O
surgery	O
,	O
multiple	O
polypectomies	O
,	O
and	O
an	O
aortic	O
repair	O
in	O
[	O
**	O
2111-8-24	O
**	O
]	O
.	O
Social	O
History	O
:	O
Currently	O
,	O
she	O
is	O
retired	O
.	O
She	O
lives	O
in	O
[	O
**	O
Location	O
1456	O
**	O
]	O
with	O
her	O
daughter	O
.	O
She	O
is	O
an	O
active	O
smoker	O
for	O
greater	O
than	O
50	O
years	O
.	O
Her	O
last	O
dental	O
examination	O
was	O
oughly	O
a	O
year	O
ago	O
.	O
She	O
drinks	O
one	O
or	O
two	O
drinks	O
a	O
couple	O
of	O
evenings	O
per	O
week	O
.	O
Physical	O
Exam	O
:	O
On	O
Discharge	O
:	O
Temp	O
97.1	O
,	O
HR	O
66	O
,	O
BP	O
132/60	O
,	O
RR	O
20	O
,	O
O2	O
99	O
%	O
Gen	O
:	O
Well	O
,	O
NAD	O
,	O
Alert	O
and	O
oriented	O
CV	O
:	O
RRR	O
,	O
No	O
R	O
/	O
G	O
/	O
M	O
Resp	O
:	O
Lungs	O
clear	O
to	O
ausculation	O
bilaterally	O
ABD	O
:	O
Soft	O
,	O
Non-tender	O
,	O
non-distended	O
Ext	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
PT	O
and	O
DP	O
signals	O
in	O
bilateral	O
lower	O
extremity	O
Groin	O
:	O
puncture	O
site	O
C	O
/	O
D	O
/	O
i	O
with	O
no	O
erythema	O
,	O
hemotoma	O
,	O
or	O
swelling	O
Pertinent	O
Results	O
:	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ECHOCARDIOGRAPHY	O
REPORT	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
99643	O
**	O
]	O
(	O
Complete	O
)	O
Done	O
[	O
**	O
2116-11-9	O
**	O
]	O
at	O
9:20:00	O
AM	O
FINAL	O
1	O
.	O
The	O
left	O
atrium	O
and	O
right	O
atrium	O
are	O
normal	O
in	O
cavity	O
size	O
with	O
a	O
hypertrophied	O
septum	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
2	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
3	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
4	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
ascending	O
aorta	O
graft	O
material	O
is	O
seen	O
.	O
The	O
aortic	O
arch	O
is	O
mildly	O
dilated	O
.	O
The	O
descending	O
thoracic	O
aorta	O
is	O
moderately	O
dilated	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
There	O
is	O
spontaneous	O
echo	O
contrast	O
and	O
thrombus	O
along	O
the	O
wall	O
(	O
diameter	O
measures	O
4.5	O
x5cm	O
)	O
.	O
5	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
6	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
25	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
7	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
8	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
was	O
notified	O
in	O
person	O
of	O
the	O
results	O
on	O
[	O
**	O
2116-11-9	O
**	O
]	O
at	O
930	O
.	O
9	O
.	O
Surgeons	O
used	O
fluroscopy	O
to	O
check	O
for	O
endoleaks	O
rather	O
than	O
request	O
TEE	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Pt	O
was	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
on	O
[	O
**	O
2116-11-9	O
**	O
]	O
and	O
underwent	O
endovascular	O
repair	O
of	O
her	O
thoracic	O
aortic	O
aneurysm	O
.	O
Pt	O
tolerated	O
the	O
procedure	O
well	O
.	O
For	O
full	O
detail	O
please	O
see	O
operative	O
reports	O
.	O
Pt	O
went	O
to	O
the	O
ICU	O
post-operatively	O
and	O
remained	O
intubated	O
due	O
to	O
low	O
tidal	O
volumes	O
.	O
Pt	O
remained	O
on	O
a	O
fentanyl	I-Drug
drip	O
for	O
pain	I-Reason
control	O
and	O
was	O
placed	O
on	O
an	O
insulin	I-Drug
sliding	O
scale	O
for	O
tight	I-Reason
glycemic	O
control	O
post-operatively	O
.	O
Pt	O
was	O
extubated	O
the	O
morning	O
of	O
POD1	O
on	O
[	O
**	O
11	O
-	O
10	O
**	O
]	O
.	O
Pt	O
was	O
weaned	O
on	O
nitroglycerin	I-Drug
drip	O
.	O
On	O
[	O
**	O
11	O
-	O
11	O
**	O
]	O
diet	O
was	O
begun	O
and	O
advanced	O
to	O
clears	O
the	O
lumbar	O
drain	O
was	O
removed	O
.	O
The	O
pt	O
was	O
transferred	O
from	O
the	O
ICU	O
to	O
the	O
VICU	O
stepdown	O
unit	O
,	O
the	O
PA	O
catheter	O
and	O
arterial	O
line	O
were	O
removed	O
.	O
BP	I-Reason
was	O
controlled	O
with	O
lopressor	I-Drug
.	O
Pt	O
began	O
to	O
work	O
with	O
physical	O
therapy	O
on	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
.	O
BP	O
management	O
was	O
transitioned	O
to	O
her	O
home	O
medications	O
of	O
amlodipine	I-Drug
,	O
Atenolol	I-Drug
,	O
and	O
enalapril	I-Drug
.	O
Home	O
medications	O
were	O
restarted	O
.	O
Noted	O
on	O
telemetry	O
,	O
pt	O
had	O
several	O
asymptomatic	O
episodes	O
of	O
bradycardia	O
.	O
The	O
cardiology	O
service	O
was	O
consulted	O
who	O
recommended	O
changing	O
her	O
blood	B-Reason
pressure	I-Reason
management	I-Reason
to	O
Losartan	I-Drug
and	O
discontinuing	O
her	O
previous	O
home	O
medications	O
.	O
There	O
were	O
no	O
further	O
bradycardic	O
events	O
after	O
this	O
change	O
was	O
made	O
and	O
her	O
pressures	O
were	O
well	O
controlled	O
.	O
On	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
physical	O
therapy	O
continued	O
as	O
pt	O
was	O
still	O
quite	O
unsteady	O
.	O
Pt	O
was	O
discharged	O
home	O
on	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
with	O
home	O
physical	O
therapy	O
,	O
tolertating	O
a	O
regular	O
diet	O
.	O
Medications	O
on	O
Admission	O
:	O
Amlodipine	I-Drug
5	O
,	O
ASA	I-Drug
325	O
,	O
Atenolol	I-Drug
50	O
,	O
Diuril	I-Drug
250	O
,	O
Enalapril	I-Drug
20	O
"	O
,	O
Metformin	I-Drug
250	O
,	O
Glipizide	I-Drug
5	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Losartan	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Chlorothiazide	B-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Metformin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Glipizide	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
All	O
Care	O
VNA	O
of	O
Greater	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Thoracic	O
Aortic	O
Aneurysm	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Your	O
heart	O
rate	O
was	O
slow	O
bradycardic	I-Ade
seveal	O
times	O
while	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Per	O
Cardiology	O
recommendations	O
your	O
Amlodipine	I-Drug
,	O
Atenolol	I-Drug
and	O
enalapril	I-Drug
were	O
stopped	O
and	O
you	O
were	O
started	O
on	O
a	O
new	O
medication	O
,	O
Losartan	I-Drug
.	O
This	O
medication	O
may	O
need	O
to	O
be	O
increased	O
or	O
decreased	O
depending	O
on	O
your	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O
You	O
should	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
1	O
week	O
to	O
determine	O
if	O
this	O
medication	O
needs	O
to	O
be	O
adjusted	O
.	O
Division	O
of	O
Vascular	O
and	O
Endovascular	O
Surgery	O
Endovascular	O
Aortic	O
Aneurysm	O
Discharge	O
Instructions	O
Medications	O
:	O
??????	O
Take	O
Aspirin	I-Drug
325	O
mg	O
(	O
enteric	O
coated	O
)	O
once	O
daily	O
??????	O
Do	O
not	O
stop	O
Aspirin	I-Drug
unless	O
your	O
Vascular	O
Surgeon	O
instructs	O
you	O
to	O
do	O
so	O
.	O
??????	O
Continue	O
all	O
other	O
medications	O
you	O
were	O
taking	O
before	O
surgery	O
,	O
unless	O
otherwise	O
directed	O
??????	O
You	O
make	O
take	O
Tylenol	I-Drug
or	O
prescribed	O
pain	B-Drug
medications	I-Drug
for	O
any	O
post	B-Reason
procedure	I-Reason
pain	I-Reason
or	I-Reason
discomfort	I-Reason
What	O
to	O
expect	O
when	O
you	O
go	O
home	O
:	O
It	O
is	O
normal	O
to	O
have	O
slight	O
swelling	O
of	O
the	O
legs	O
:	O
??????	O
Elevate	O
your	O
leg	O
above	O
the	O
level	O
of	O
your	O
heart	O
(	O
use	O
[	O
**	O
1	O
-	O
26	O
**	O
]	O
pillows	O
or	O
a	O
recliner	O
)	O
every	O
2	O
-	O
3	O
hours	O
throughout	O
the	O
day	O
and	O
at	O
night	O
??????	O
Avoid	O
prolonged	O
periods	O
of	O
standing	O
or	O
sitting	O
without	O
your	O
legs	O
elevated	O
It	O
is	O
normal	O
to	O
feel	O
tired	O
and	O
have	O
a	O
decreased	O
appetite	O
,	O
your	O
appetite	O
will	O
return	O
with	O
time	O
??????	O
Drink	O
plenty	O
of	O
fluids	O
and	O
eat	O
small	O
frequent	O
meals	O
??????	O
It	O
is	O
important	O
to	O
eat	O
nutritious	O
food	O
options	O
(	O
high	O
fiber	O
,	O
lean	O
meats	O
,	O
vegetables	O
/	O
fruits	O
,	O
low	O
fat	O
,	O
low	O
cholesterol	O
)	O
to	O
maintain	O
your	O
strength	O
and	O
assist	O
in	O
wound	O
healing	O
??????	O
To	O
avoid	O
constipation	O
:	O
eat	O
a	O
high	O
fiber	O
diet	O
and	O
use	O
stool	I-Drug
softener	O
while	O
taking	O
pain	B-Drug
medication	I-Drug
What	O
activities	O
you	O
can	O
and	O
can	O
not	O
do	O
:	O
??????	O
When	O
you	O
go	O
home	O
,	O
you	O
may	O
walk	O
and	O
go	O
up	O
and	O
down	O
stairs	O
??????	O
You	O
may	O
shower	O
(	O
let	O
the	O
soapy	O
water	O
run	O
over	O
groin	O
incision	O
,	O
rinse	O
and	O
pat	O
dry	O
)	O
??????	O
Your	O
incision	O
may	O
be	O
left	O
uncovered	O
,	O
unless	O
you	O
have	O
small	O
amounts	O
of	O
drainage	O
from	O
the	O
wound	O
,	O
then	O
place	O
a	O
dry	O
dressing	O
or	O
band	O
aid	O
over	O
the	O
area	O
that	O
is	O
draining	O
,	O
as	O
needed	O
??????	O
No	O
heavy	O
lifting	O
,	O
pushing	O
or	O
pulling	O
(	O
greater	O
than	O
5	O
lbs	O
)	O
for	O
1	O
week	O
(	O
to	O
allow	O
groin	O
puncture	O
to	O
heal	O
)	O
??????	O
After	O
1	O
week	O
,	O
you	O
may	O
resume	O
sexual	O
activity	O
??????	O
After	O
1	O
week	O
,	O
gradually	O
increase	O
your	O
activities	O
and	O
distance	O
walked	O
as	O
you	O
can	O
tolerate	O
??????	O
No	O
driving	O
until	O
you	O
are	O
no	O
longer	O
taking	O
pain	O
medications	O
??????	O
Call	O
and	O
schedule	O
an	O
appointment	O
to	O
be	O
seen	O
in	O
[	O
**	O
3	O
-	O
29	O
**	O
]	O
weeks	O
for	O
post	O
procedure	O
check	O
and	O
CTA	O
What	O
to	O
report	O
to	O
office	O
:	O
??????	O
Numbness	O
,	O
coldness	O
or	O
pain	O
in	O
lower	O
extremities	O
??????	O
Temperature	O
greater	O
than	O
101.5	O
F	O
for	O
24	O
hours	O
??????	O
New	O
or	O
increased	O
drainage	O
from	O
incision	O
or	O
white	O
,	O
yellow	O
or	O
green	O
drainage	O
from	O
incisions	O
??????	O
Bleeding	O
from	O
groin	O
puncture	O
site	O
SUDDEN	O
,	O
SEVERE	O
BLEEDING	O
OR	O
SWELLING	O
(	O
Groin	O
puncture	O
site	O
or	O
incision	O
)	O
??????	O
Lie	O
down	O
,	O
keep	O
leg	O
straight	O
and	O
have	O
someone	O
apply	O
firm	O
pressure	O
to	O
area	O
for	O
10	O
minutes	O
.	O
If	O
bleeding	O
stops	O
,	O
call	O
vascular	O
office	O
.	O
If	O
bleeding	O
does	O
not	O
stop	O
,	O
call	O
911	O
for	O
transfer	O
to	O
closest	O
Emergency	O
Room	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1244	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1241	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2116-11-18	O
**	O
]	O
3:00	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
177	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2116-12-15	O
**	O
]	O
1:00	O
Please	O
follow	O
-	O
up	O
with	O
your	O
Primary	O
Care	O
Physician	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
1	O
week	O
to	O
address	O
your	O
recent	O
change	O
in	O
blood	O
pressure	O
medication	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2141-9-5	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2141-9-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2117-8-7	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Percocet	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
348	O
**	O
]	O
Chief	O
Complaint	O
:	O
right	O
leg	O
pain	O
,	O
hypertension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
blood	O
transfusion	O
x2	O
History	O
of	O
Present	O
Illness	O
:	O
Ms	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
24	O
year	O
old	O
woman	O
with	O
SLE	O
,	O
CKD	O
V	O
,	O
and	O
multiple	O
admissions	O
for	O
labile	O
hypertension	O
who	O
presented	O
to	O
the	O
ED	O
complaining	O
of	O
about	O
a	O
weeks	O
??????	O
worth	O
of	O
right	O
leg	O
pain	O
.	O
The	O
pain	O
is	O
worst	O
when	O
she	O
tried	O
to	O
bear	O
weight	O
on	O
the	O
leg	O
,	O
or	O
when	O
she	O
uses	O
it	O
to	O
roll	O
over	O
or	O
adjust	O
her	O
position	O
in	O
bed	O
.	O
The	O
pain	O
begins	O
in	O
her	O
buttock	O
and	O
travels	O
down	O
the	O
posterior	O
thigh	O
and	O
calf	O
but	O
stops	O
before	O
reaching	O
the	O
ankle	O
.	O
It	O
occasionally	O
feels	O
like	O
it	O
is	O
coming	O
from	O
her	O
low	O
back	O
.	O
She	O
denies	O
any	O
parasthesias	O
or	O
weakness	O
in	O
the	O
leg	O
,	O
and	O
she	O
denies	O
any	O
numbness	O
in	O
her	O
foot	O
or	O
groin	O
.	O
She	O
denies	O
any	O
fevers	O
or	O
incontinence	O
.	O
The	O
pain	I-Reason
was	O
unrelieved	O
by	O
Vicodin	I-Drug
that	O
she	O
had	O
at	O
home	O
,	O
so	O
she	O
scheduled	O
an	O
urgent	O
visit	O
with	O
her	O
nephrologist	O
yesterday	O
[	O
**	O
2141-9-4	O
**	O
]	O
.	O
At	O
her	O
nephrologist	O
??????	O
s	O
office	O
,	O
she	O
was	O
hypertensive	O
to	O
250/145	O
and	O
so	O
she	O
was	O
referred	O
to	O
the	O
ED	O
.	O
She	O
ended	O
up	O
leaving	O
the	O
ED	O
against	O
medical	O
advice	O
yesterday	O
,	O
but	O
returned	O
today	O
because	O
of	O
persistent	O
leg	O
pain	O
.	O
She	O
reports	O
that	O
she	O
took	O
all	O
of	O
her	O
morning	O
and	O
noon	O
BP	O
meds	O
.	O
She	O
denies	O
any	O
fevers	O
,	O
headaches	O
,	O
visual	O
changes	O
,	O
nausea	O
(	O
prior	O
to	O
coming	O
to	O
the	O
ED	O
)	O
,	O
or	O
leg	O
weakness	O
.	O
Upon	O
arrival	O
to	O
the	O
ED	O
today	O
,	O
she	O
was	O
afebrile	O
,	O
BP	O
237/146	O
,	O
HR	O
97	O
,	O
RR	O
16	O
,	O
Sat	O
100	O
%	O
on	O
room	O
air	O
.	O
She	O
received	O
a	O
total	O
of	O
90	O
mg	O
of	O
IV	O
labetalol	I-Drug
and	O
nitropaste	I-Drug
,	O
and	O
was	O
eventually	O
put	O
on	O
a	O
labetalol	I-Drug
drip	O
for	O
her	B-Reason
hypertension	I-Reason
.	O
With	O
these	O
interventions	O
,	O
her	O
SBP	O
dropped	O
to	O
the	O
180s	O
,	O
but	O
she	O
reported	O
feeling	O
nauseous	O
and	O
so	O
the	O
drip	O
was	O
discontinued	O
.	O
She	O
was	O
also	O
given	O
4	O
mg	O
of	O
IV	O
morphine	I-Drug
and	O
1	O
mg	O
of	O
IV	O
hydromorphone	I-Drug
for	O
her	O
leg	B-Reason
pain	I-Reason
with	O
decent	O
relief	O
.	O
Due	O
to	O
a	O
urinalysis	O
suggestive	O
of	O
infection	I-Reason
,	O
she	O
was	O
given	O
one	O
tablet	O
of	O
DS	B-Drug
TMP	I-Drug
/	I-Drug
SMX	I-Drug
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Systemic	B-Reason
lupus	I-Reason
erythematosus	I-Reason
:	O
-	O
Diagnosed	O
[	O
**	O
2134	O
**	O
]	O
(	O
16	O
years	O
old	O
)	O
when	O
she	O
had	O
swollen	O
fingers	O
,	O
arm	O
rash	O
and	O
arthralgias	O
-	O
Previous	O
treatment	O
with	O
cytoxan	I-Drug
,	O
cellcept	I-Drug
;	O
currently	O
on	O
prednisone	I-Drug
-	O
Complicated	O
by	O
uveitis	O
(	O
[	O
**	O
2139	O
**	O
]	O
)	O
and	O
ESRD	O
(	O
[	O
**	O
2135	O
**	O
]	O
)	O
2	O
.	O
CKD	O
/	O
ESRD	O
:	O
-	O
Diagosed	O
[	O
**	O
2135	O
**	O
]	O
-	O
Initiated	O
dialysis	O
[	O
**	O
2137	O
**	O
]	O
-	O
PD	O
catheter	O
placement	O
[	O
**	O
5	O
-	O
18	O
**	O
]	O
3	O
.	O
Malignant	O
hypertension	O
-	O
Baseline	O
BPs	O
180	O
's	O
-	O
120	O
's	O
-	O
History	O
of	O
hypertensive	O
crisis	O
with	O
seizures	O
-	O
History	O
of	O
two	O
intraparenchymal	O
hemorrhages	O
that	O
were	O
thought	O
to	O
be	O
due	O
to	O
the	O
posterior	O
reversible	O
leukoencephalopathy	O
syndrome	O
4	O
.	O
Thrombocytopenia	O
:	O
-	O
TTP	O
(	O
got	O
plasmapheresisis	O
)	O
versus	O
malignant	O
HTN	O
5	O
.	O
Thrombotic	O
events	O
:	O
-	O
SVC	O
thrombosis	O
(	O
[	O
**	O
2139	O
**	O
]	O
)	O
;	O
related	O
to	O
a	O
catheter	O
-	O
Negative	O
lupus	O
anticoagulant	O
(	O
[	O
**	O
4	O
-	O
/	O
2138	O
**	O
]	O
,	O
[	O
**	O
8	O
-	O
/	O
2138	O
**	O
]	O
,	O
[	O
**	O
9	O
-	O
/	O
2140	O
**	O
]	O
)	O
-	O
Negative	O
anticardiolipin	O
antibodies	O
IgG	O
and	O
IgM	O
x4	O
(	O
[	O
**	O
2137	O
**	O
]	O
-	O
[	O
**	O
2140	O
**	O
]	O
)	O
-	O
Negative	O
Beta	O
-	O
2	O
glycoprotein	O
antibody	O
(	O
[	O
**	O
4	O
-	O
/	O
2138	O
**	O
]	O
,	O
[	O
**	O
8	O
-	O
/	O
2140	O
**	O
]	O
)	O
6	O
.	O
HOCM	O
:	O
Last	O
noted	O
on	O
echo	O
[	O
**	O
8	O
-	O
17	O
**	O
]	O
7	O
.	O
Anemia	O
8	O
.	O
History	O
of	O
left	O
eye	O
enucleation	O
[	O
**	O
2139-4-20	O
**	O
]	O
for	O
fungal	O
infection	O
9	O
.	O
History	O
of	O
vaginal	O
bleeding	O
[	O
**	O
2139	O
**	O
]	O
lasting	O
2	O
months	O
s	O
/	O
p	O
DepoProvera	I-Drug
injection	O
requiring	O
transfusion	O
10	O
.	O
History	O
of	O
Coag	O
negative	O
Staph	O
bacteremia	O
and	O
HD	O
line	O
infection	O
-	O
[	O
**	O
6	O
-	O
16	O
**	O
]	O
and	O
[	O
**	O
5	O
-	O
17	O
**	O
]	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
1	O
.	O
Placement	O
of	O
multiple	O
catheters	O
including	O
dialysis	O
.	O
2	O
.	O
Tonsillectomy	O
.	O
3	O
.	O
Left	O
eye	O
enucleation	O
in	O
[	O
**	O
2140-4-10	O
**	O
]	O
.	O
4	O
.	O
PD	O
catheter	O
placement	O
in	O
[	O
**	O
2141-5-11	O
**	O
]	O
.	O
Social	O
History	O
:	O
Single	O
and	O
lives	O
with	O
her	O
mother	O
and	O
a	O
brother	O
.	O
She	O
graduated	O
from	O
high	O
school	O
.	O
The	O
patient	O
is	O
on	O
disability	O
.	O
The	O
patient	O
does	O
not	O
drink	O
alcohol	O
or	O
smoke	O
,	O
and	O
has	O
never	O
used	O
recreational	O
drugs	O
.	O
Family	O
History	O
:	O
Negative	O
for	O
autoimmune	O
diseases	O
,	O
thrombophilic	O
disorders	O
.	O
Maternal	O
grandfather	O
with	O
HTN	O
,	O
MI	O
,	O
stroke	O
in	O
70s	O
.	O
Physical	O
Exam	O
:	O
MICU	O
physical	O
:	O
Tmax	O
:	O
36.3	O
??????	O
C	O
(	O
97.4	O
??????	O
F	O
)	O
Tcurrent	O
:	O
36.3	O
??????	O
C	O
(	O
97.4	O
??????	O
F	O
)	O
HR	O
:	O
92	O
(	O
92	O
-	O
94	O
)	O
bpm	O
BP	O
:	O
209/138	O
(	O
152	O
)	O
{	O
201/134	O
(	O
151	O
)	O
-	O
209/138	O
(	O
152	O
)	O
}	O
mmHg	O
RR	O
:	O
19	O
(	O
19	O
-	O
30	O
)	O
insp	O
/	O
min	O
SpO2	O
:	O
91	O
%	O
Heart	O
rhythm	O
:	O
SR	O
(	O
Sinus	O
Rhythm	O
)	O
Height	O
:	O
59	O
Inch	O
General	O
:	O
well	O
-	O
appearing	O
young	O
woman	O
in	O
no	O
acute	O
distress	O
HEENT	O
:	O
no	O
scleral	O
icterus	O
;	O
prosthetic	O
right	O
eye	O
Neck	O
:	O
supple	O
Chest	O
:	O
clear	O
to	O
auscultation	O
throughout	O
,	O
no	O
wheezes	O
/	O
rales	O
/	O
ronchi	O
CV	O
:	O
regular	O
rate	O
/	O
rhythm	O
,	O
normal	O
s1s2	O
,	O
no	O
murmurs	O
Abdomen	O
:	O
soft	O
,	O
nontender	O
,	O
nondistended	O
,	O
PD	O
catheter	O
in	O
place	O
in	O
left	O
abdomen	O
Back	O
:	O
very	O
mild	O
spinal	O
tenderness	O
over	O
approx	O
L3	O
level	O
of	O
spine	O
Extremities	O
:	O
no	O
edema	O
,	O
1	O
+	O
PT	O
pulses	O
,	O
warm	O
Skin	O
:	O
no	O
rashes	O
or	O
jaundice	O
Neuro	O
:	O
alert	O
,	O
oriented	O
x3	O
,	O
5/5	O
strength	O
in	O
bilateral	O
deltoids	O
,	O
biceps	O
,	O
triceps	O
,	O
hip	O
flexors	O
/	O
extensors	O
,	O
ankle	O
flexors	O
/	O
extensors	O
;	O
unable	O
to	O
elicit	O
patellar	O
reflexes	O
bilaterally	O
;	O
negative	O
straight	O
leg	O
raise	O
bilaterally	O
Pertinent	O
Results	O
:	O
138	O
111	O
54	O
-----------------	O
<	O
83	O
5.4	O
14	O
8.2	O
.	O
WBC	O
:	O
3.7	O
HCT	O
:	O
19	O
PLT	O
:	O
101	O
N	O
:	O
69.3	O
L	O
:	O
23.4	O
M	O
:	O
5.5	O
E	O
:	O
1.7	O
Bas	O
:	O
0.1	O
PT	O
:	O
21.9	O
PTT	O
:	O
48.2	O
INR	O
:	O
2.1	O
.	O
Trends	O
:	O
HCT	O
:	O
19	O
-	O
>	O
22	O
w	O
1u	O
then	O
received	O
another	O
unit	O
.	O
INR	O
3.4	O
on	O
discharge	O
Discharge	O
chem	O
:	O
Glucose	O
-	O
104	O
UreaN	O
-	O
51	O
*	O
Creat	O
-	O
8.4	O
*	O
Na	O
-	O
136	O
K	O
-	O
5.3	O
*	O
Cl	O
-	O
106	O
HCO3	O
-	O
18	O
*	O
AnGap	O
-	O
17	O
.	O
[	O
**	O
2141-9-8	O
**	O
]	O
07:30	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
126	O
[	O
**	O
2141-9-5	O
**	O
]	O
02:50	O
PM	O
BLOOD	O
HCG	O
-	O
<	O
5	O
.	O
[	O
**	O
2141-9-8	O
**	O
]	O
1:37	O
pm	O
PERITONEAL	O
FLUID	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2141-9-8	O
**	O
]	O
)	O
:	O
NO	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
SEEN	O
.	O
NO	O
MICROORGANISMS	O
SEEN	O
.	O
This	O
is	O
a	O
concentrated	O
smear	O
made	O
by	O
cytospin	O
method	O
,	O
please	O
refer	O
to	O
hematology	O
for	O
a	O
quantitative	O
white	O
blood	O
cell	O
count	O
.	O
MRI	O
L	O
-	O
spine	O
:	O
IMPRESSION	O
:	O
Diffuse	O
low	O
-	O
signal	O
intensity	O
is	O
identified	O
in	O
the	O
bone	O
marrow	O
of	O
the	O
lumbar	O
and	O
lower	O
thoracic	O
spine	O
as	O
described	O
above	O
,	O
possibly	O
related	O
with	O
anemic	O
changes	O
,	O
please	O
correlate	O
clinically	O
.	O
There	O
is	O
no	O
evidence	O
of	O
spinal	O
canal	O
stenosis	O
or	O
neural	O
foraminal	O
narrowing	O
at	O
the	O
different	O
intervertebral	O
disc	O
spaces	O
.	O
.	O
CXR	O
admit	O
:	O
IMPRESSION	O
:	O
Moderate	O
cardiomegaly	O
,	O
bilateral	O
pleural	O
effusions	O
,	O
and	O
pulmonary	O
vascular	O
prominence	O
consistent	O
with	O
pulmonary	O
edema	O
.	O
.	O
Hip	O
film	O
:	O
FINDINGS	O
:	O
No	O
comparisons	O
.	O
No	O
acute	O
fracture	O
or	O
dislocation	O
is	O
seen	O
.	O
No	O
lucent	O
or	O
sclerotic	O
lesion	O
is	O
noted	O
.	O
There	O
is	O
a	O
distal	O
aspect	O
of	O
a	O
catheter	O
or	O
shunt	O
seen	O
in	O
the	O
pelvis	O
.	O
Soft	O
tissues	O
are	O
otherwise	O
unremarkable	O
.	O
There	O
is	O
minimal	O
degenerative	O
change	O
of	O
the	O
pubic	O
symphysis	O
.	O
IMPRESSION	O
:	O
No	O
acute	O
fracture	O
or	O
dislocation	O
.	O
.	O
Abdominal	O
film	O
:	O
FINDINGS	O
:	O
A	O
PD	O
catheter	O
is	O
seen	O
with	O
its	O
tip	O
coiled	O
in	O
the	O
pelvis	O
.	O
There	O
is	O
normal	O
bowel	O
gas	O
.	O
The	O
underlying	O
osseous	O
structures	O
are	O
unremarkable	O
.	O
IMPRESSION	O
:	O
PD	O
catheter	O
with	O
tip	O
coiled	O
in	O
the	O
pelvis	O
.	O
CXR	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Marked	O
cardiomegaly	O
,	O
unchanged	O
.	O
Interval	O
resolution	O
of	O
pulmonary	O
edema	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Ms	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
24	O
year	O
old	O
woman	O
with	O
SLE	O
,	O
CKD	O
V	O
,	O
and	O
multiple	O
admissions	O
for	O
labile	O
hypertension	O
who	O
presented	O
to	O
the	O
ED	O
complaining	O
of	O
about	O
a	O
weeks	O
??????	O
worth	O
of	O
right	O
leg	O
pain	O
.	O
She	O
was	O
initially	O
admitted	O
to	O
the	O
MICU	O
for	O
hypertensive	O
urgency	O
and	O
then	O
transfered	O
to	O
the	O
floor	O
after	O
a	O
day	O
.	O
#	O
Hypertensive	B-Reason
urgency	I-Reason
:	O
had	O
been	O
on	O
labetalol	I-Drug
drip	O
in	O
the	O
ED	O
,	O
but	O
this	O
was	O
stopped	O
due	O
to	O
nausea	I-Ade
(	O
presumed	O
that	O
her	O
BP	O
was	O
coming	O
down	O
too	O
fast	O
)	O
.	O
She	O
was	O
started	O
on	O
her	O
home	O
meds	O
and	O
tolerated	O
these	O
fairly	O
well	O
.	O
Transferred	O
to	O
the	O
floor	O
and	O
noted	O
to	O
have	O
SPBs	O
in	O
the	O
90s	O
.	O
She	O
required	O
1L	O
IVF	I-Drug
bolus	O
since	O
her	O
baseline	O
SBP	O
is	O
thought	O
to	O
run	O
in	O
the	O
130	O
-	O
170	O
range	O
.	O
She	O
also	O
had	O
transient	O
dizziness	O
during	O
this	O
episode	O
.	O
BP	O
meds	O
were	O
held	O
and	O
later	O
that	O
night	O
her	O
SBP	O
was	O
in	O
the	O
220s	O
.	O
BP	O
meds	O
restarted	O
.	O
She	O
remained	O
stable	O
thereafter	O
with	O
SBPs	O
in	O
the	O
130	O
-	O
170s	O
.	O
We	O
opted	O
to	O
discharge	O
her	O
on	O
her	O
home	O
regimen	O
(	O
without	O
decreasing	O
doses	O
)	O
since	O
she	O
is	O
more	O
often	O
having	O
issues	O
with	O
elevated	O
blood	O
pressures	O
.	O
.	O
#	O
Right	O
leg	O
pain	O
:	O
no	O
evidence	O
of	O
avascular	O
necrosis	O
or	O
fracture	O
on	O
plain	O
film	O
.	O
MRI	O
and	O
plain	O
films	O
were	O
ordered	O
and	O
showed	O
no	O
acute	O
pathology	O
.	O
The	O
pain	O
was	O
in	O
the	O
distribution	O
of	O
her	O
right	O
hamstring	O
and	O
was	O
worsened	O
when	O
it	O
was	O
stretched	O
thus	O
suggesting	O
a	O
muscle	O
injury	O
.	O
CK	O
was	O
normal	O
.	O
Pain	I-Reason
was	O
treated	O
with	O
dilaudid	I-Drug
initially	O
.	O
On	O
day	O
of	O
discharge	O
,	O
she	O
was	O
able	O
to	O
ambulate	O
without	O
gait	O
abnormality	O
or	O
pain	O
.	O
PT	O
saw	O
her	O
and	O
rec	O
outpt	O
PT	O
followup	O
.	O
.	O
#	O
CKD	O
V	O
:	O
PD	O
catheter	O
placement	O
in	O
place	O
.	O
Pt	O
was	O
tried	O
on	O
PD	O
on	O
a	O
number	O
of	O
occasions	O
but	O
did	O
not	O
tolerate	O
it	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
pain	O
.	O
KUB	O
confirmed	O
tip	O
in	O
place	O
.	O
Cx	O
of	O
peritoneal	O
fluid	O
not	O
suggestive	O
of	O
peritonitis	O
.	O
K	O
remained	O
mildly	O
elevated	O
.	O
Hyperpara	I-Reason
treated	O
with	O
sevelamer	I-Drug
(	O
although	O
patient	O
refused	O
)	O
then	O
tums	I-Drug
.	O
Pt	O
will	O
reconsider	O
PD	O
as	O
outpatient	O
.	O
.	O
#	O
Anemia	O
:	O
chronic	O
.	O
Received	O
2u	O
pRBC	I-Drug
while	O
inhouse	O
for	O
Hct	O
in	O
the	O
18	O
-	O
19	O
range	O
.	O
Had	O
appropriate	O
response	O
.	O
Not	O
on	O
Epo	I-Drug
given	O
hypertension	O
.	O
#	O
ID	O
:	O
Rx	O
with	O
cipro	I-Drug
for	O
?	O
UTI	I-Reason
although	O
urine	O
cx	O
neg	O
.	O
Also	O
had	O
temp	O
to	O
101	O
on	O
evening	O
prior	O
to	O
discharge	O
.	O
No	O
clear	O
source	O
.	O
PD	O
fluid	O
cultured	O
and	O
NGTD	O
.	O
Pt	O
remainded	O
HD	O
stable	O
on	O
day	O
of	O
discharge	O
.	O
.	O
#	O
Prior	O
SVC	B-Reason
thrombus	I-Reason
.	O
Continued	O
warfarin	I-Drug
with	O
appropriate	O
INR	O
checks	O
.	O
INR	O
elevated	O
on	O
day	O
of	O
discharge	O
.	O
Rec	O
holding	O
coumadin	I-Drug
for	O
2d	O
.	O
#	O
Systemic	B-Reason
lupus	I-Reason
erythematosus	I-Reason
:	O
cont	O
home	O
prednisone	I-Drug
dose	O
.	O
#	O
Dispo	O
status	O
:	O
ambulating	O
,	O
pain	O
free	O
,	O
BP	O
in	O
the	O
150/90	O
range	O
Medications	O
on	O
Admission	O
:	O
Nifedipine	I-Drug
60	O
mg	O
PO	O
qhs	O
Labetalol	I-Drug
900	O
mg	O
PO	O
tid	O
Hydralazine	I-Drug
50	O
mg	O
PO	O
tid	O
Clonidine	I-Drug
0.3	O
mg	O
/	O
hr	O
patch	O
qWED	O
Vitamin	B-Drug
D	I-Drug
once	O
weekly	O
Vicodin	I-Drug
prn	O
Aliskiren	I-Drug
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Prednisone	I-Drug
5	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Prednisone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Coumadin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
3	O
.	O
Nifedipine	I-Drug
30	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Hydralazine	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
5	O
.	O
Clonidine	I-Drug
0.3	O
mg	O
/	O
24	O
hr	O
Patch	O
Weekly	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
Weekly	O
Transdermal	O
QWED	O
(	O
every	O
Wednesday	O
)	O
.	O
6	O
.	O
Ergocalciferol	I-Drug
(	O
Vitamin	O
D2	O
)	O
50,000	O
unit	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
WEEKLY	O
(	O
)	O
.	O
7	O
.	O
Aliskiren	I-Drug
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
bid	O
(	O
)	O
.	O
8	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
20	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Outpatient	O
Physical	O
Therapy	O
Please	O
provide	O
PT	O
for	O
right	O
hamstring	O
injury	O
10	O
.	O
Labetalol	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
Disp	O
:	O
*	O
270	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Coumadin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
:	O
hold	O
dose	O
until	O
[	O
**	O
9	O
-	O
10	O
**	O
]	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
12	O
.	O
Lactulose	I-Drug
10	O
gram	O
/	O
15	O
mL	O
Solution	O
Sig	O
:	O
15	O
-	O
30	O
ml	O
PO	O
once	O
a	O
day	O
:	O
goal	O
is	O
[	O
**	O
1	O
-	O
11	O
**	O
]	O
soft	O
bowel	O
movements	O
per	O
day	O
.	O
Disp	O
:	O
*	O
500	O
ml	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
-	O
HTN	O
urgency	O
-	O
right	O
leg	O
pain	O
-	O
thought	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
hamstring	O
injury	O
-	O
chronic	O
kidney	O
disease	O
-	O
not	O
currently	O
on	O
dialysis	O
-	O
SLE	O
-	O
anemia	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
CKD	O
and	O
SLE	O
-	O
hx	O
of	O
SVC	B-Reason
thrombosis	I-Reason
on	O
coumadin	I-Drug
now	O
Secondary	O
:	O
-	O
hx	O
hypertrophic	O
obstructive	O
cardiomyopathy	O
-	O
chronic	O
thrombocytopenia	O
Discharge	O
Condition	O
:	O
ambulating	O
without	O
difficulty	O
.	O
tolerating	O
oral	O
diet	O
.	O
afebrile	O
and	O
SBP	O
in	O
the	O
130	O
-	O
150	O
range	O
.	O
Discharge	O
Instructions	O
:	O
You	O
came	O
in	O
with	O
right	O
leg	O
pain	O
and	O
poorly	O
controlled	O
hypertension	O
.	O
Your	O
blood	O
pressure	O
was	O
controlled	O
initially	O
with	O
IV	O
medications	O
then	O
your	O
home	O
medications	O
.	O
Since	O
your	O
blood	O
pressure	O
was	O
occasionally	O
low	O
,	O
we	O
recommend	O
that	O
you	O
hold	O
your	O
labetalol	I-Drug
if	O
you	O
are	O
feeling	O
lightheaded	O
or	O
have	O
dizziness	O
or	O
have	O
blood	O
pressure	O
less	O
than	O
110/60	O
.	O
In	O
terms	O
of	O
your	O
leg	O
pain	O
,	O
we	O
performed	O
xrays	O
,	O
ultrasound	O
,	O
and	O
MRI	O
without	O
finding	O
a	O
cause	O
.	O
We	O
suspect	O
a	O
hamstring	B-Reason
injury	I-Reason
given	O
its	O
location	O
.	O
Please	O
take	O
pain	B-Drug
medications	I-Drug
if	O
needed	O
.	O
We	O
recommend	O
followup	O
with	O
physical	O
therapy	O
.	O
You	O
also	O
had	O
a	O
fever	O
which	O
is	O
suggestive	O
of	O
infection	O
.	O
We	O
treated	O
you	O
with	O
cipro	I-Drug
in	O
case	O
you	O
had	O
a	O
UTI	I-Reason
.	O
Otherwise	O
,	O
your	O
cultures	O
were	O
unrevealing	O
.	O
We	O
attempted	O
peritoneal	O
dialysis	O
but	O
this	O
was	O
unsuccessful	O
.	O
Please	O
followup	O
with	O
your	O
nephrologist	O
.	O
Please	O
return	O
to	O
the	O
ED	O
if	O
you	O
experience	O
headache	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
high	O
fevers	O
,	O
or	O
worsening	O
leg	O
pain	O
.	O
Please	O
hold	O
your	O
coumadin	I-Drug
for	O
two	O
days	O
then	O
restart	O
as	O
per	O
previously	O
written	O
.	O
Please	O
take	O
lactulose	I-Drug
for	O
constipation	I-Reason
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
.	O
D.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2574	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2141-9-12	O
**	O
]	O
5:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
706	O
**	O
]	O
NURSE	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2141-9-14	O
**	O
]	O
2:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
7548	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
327	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2141-9-14	O
**	O
]	O
3:00	O
Please	O
followup	O
with	O
your	O
nephrologist	O
and	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
would	O
like	O
you	O
to	O
see	O
your	O
nephrologist	O
within	O
the	O
next	O
1	O
-	O
2	O
weeks	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2119-4-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2119-4-15	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Bactrim	I-Drug
Ds	O
/	O
Zyprexa	I-Drug
/	O
Lisinopril	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
552	O
**	O
]	O
Chief	O
Complaint	O
:	O
Altered	O
Mental	O
Status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
CT	O
head	O
MRI	O
/	O
MRA	O
LP	O
Larynoscopy	O
History	O
of	O
Present	O
Illness	O
:	O
HPI	O
:	O
The	O
patient	O
is	O
an	O
88	O
year	O
old	O
female	O
,	O
resident	O
at	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
553	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
554	O
**	O
]	O
[	O
**	O
Hospital3	O
**	O
]	O
,	O
with	O
medical	O
history	O
pertinent	O
for	O
Parkinson	O
's	O
disease	O
,	O
Diabetes	O
,	O
and	O
recent	O
cornea	O
transplant	O
who	O
now	O
presents	O
with	O
altered	O
mental	O
status	O
.	O
Per	O
last	O
progress	O
note	O
from	O
patient	O
's	O
PCP	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
patient	O
has	O
been	O
in	O
her	O
usual	O
state	O
of	O
health	O
with	O
exception	O
of	O
management	O
of	O
a	O
cervical	O
vertebral	O
fracture	O
secondary	O
to	O
fall	O
as	O
well	O
as	O
plans	O
for	O
a	O
repat	O
penetrating	O
keratoplasty	O
(	O
corneal	O
transplant	O
)	O
s	O
/	O
p	O
failed	O
prior	O
.	O
The	O
patient	O
was	O
at	O
that	O
time	O
apparently	O
at	O
her	O
baseline	O
and	O
cleared	O
for	O
surgery	O
.	O
The	O
patient	O
underwent	O
penetrating	O
keratoplasty	O
on	O
[	O
**	O
2119-3-30	O
**	O
]	O
for	O
indication	O
of	O
failed	O
graft	O
without	O
complication	O
.	O
The	O
patient	O
was	O
seen	O
by	O
her	O
ophthalmologist	O
on	O
[	O
**	O
2119-4-4	O
**	O
]	O
with	O
impression	O
that	O
there	O
was	O
moderate	O
lid	O
edema	O
present	O
suggestive	O
of	O
hypersensitivity	O
but	O
no	O
discharge	O
to	O
suggest	O
infection	O
.	O
Polysporin	I-Drug
was	O
discontinued	O
(	O
with	O
concern	O
for	O
hypersensitivty	I-Ade
per	O
discussion	O
with	O
daughter	O
)	O
and	O
other	O
meds	O
(	O
Pred	I-Drug
1	O
%	O
TID	O
OS	O
,	O
Timolol	I-Drug
0.5	O
%	O
[	O
**	O
Hospital1	O
**	O
]	O
OU	O
,	O
Xalatan	I-Drug
QHS	O
OS	O
,	O
Tobradex	I-Drug
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
OS	O
QHS	O
)	O
continued	O
.	O
The	O
patient	O
now	O
presents	O
form	O
her	O
[	O
**	O
Hospital3	O
**	O
]	O
with	O
concern	O
for	O
altered	O
mental	O
status	O
.	O
Only	O
limited	O
information	O
is	O
available	O
from	O
available	O
staff	O
at	O
[	O
**	O
Hospital3	O
400	O
**	O
]	O
,	O
with	O
report	O
only	O
that	O
patient	O
was	O
noted	O
tonight	O
to	O
be	O
acutely	O
confused	O
and	O
"	O
not	O
making	O
sense	O
"	O
.	O
Per	O
discussion	O
with	O
the	O
patient	O
's	O
daughter	O
,	O
the	O
patient	O
was	O
in	O
her	O
usual	O
state	O
of	O
health	O
as	O
early	O
as	O
yesterday	O
morning	O
,	O
looking	O
well	O
.	O
Later	O
in	O
the	O
day	O
,	O
the	O
patient	O
was	O
reported	O
to	O
be	O
walking	O
up	O
and	O
down	O
the	O
hallway	O
,	O
refusing	O
to	O
go	O
to	O
her	O
room	O
.	O
The	O
patient	O
was	O
noted	O
to	O
be	O
shivering	O
and	O
unsteady	O
on	O
her	O
feet	O
.	O
Recommendation	O
was	O
made	O
that	O
patient	O
be	O
sent	O
to	O
hospital	O
for	O
further	O
evaluation	O
.	O
Per	O
discussion	O
with	O
daughter	O
,	O
the	O
patient	O
has	O
had	O
prior	O
episodes	O
of	O
confusion	O
in	O
setting	O
of	O
underlying	O
infetion	O
,	O
usually	O
UTI	O
.	O
.	O
ED	O
Course	O
:	O
98.4	O
-	O
>	O
102.8	O
rectal	O
,	O
186/84	O
,	O
85	O
,	O
20	O
,	O
93	O
%	O
RA	O
.	O
Labs	O
notable	O
for	O
WBC	O
8.0	O
,	O
lactate	O
1.8	O
.	O
Not	O
signed	O
out	O
,	O
but	O
per	O
nursing	O
report	O
and	O
discussion	O
a	O
central	O
line	O
was	O
attempted	O
given	O
poor	O
PIV	O
access	O
for	O
which	O
the	O
patient	O
received	O
Haldol	I-Drug
.	O
No	O
documentation	O
of	O
dose	O
is	O
available	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
RN	O
to	O
RN	O
signout	O
this	O
was	O
5	O
mg	O
IV	O
.	O
Central	O
line	O
was	O
not	O
successfully	O
placed	O
and	O
ultimately	O
a	O
22	O
PIV	O
in	O
the	O
hand	O
was	O
obtained	O
.	O
The	O
patient	O
had	O
a	O
negative	O
UA	O
,	O
CXR	O
without	O
obvious	O
infiltrate	O
although	O
limited	O
.	O
Ophthalmology	O
was	O
not	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
as	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
impression	O
was	O
that	O
eye	O
was	O
not	O
infected	O
.	O
LP	O
was	O
recommended	O
by	O
ED	O
but	O
patients	O
'	O
daughter	O
declined	O
this	O
.	O
The	O
patient	O
was	O
given	O
Azithromycin	I-Drug
,	O
Vancomycin	I-Drug
,	O
and	O
Ceftriaxone	I-Drug
empirically	O
and	O
is	O
now	O
admitted	O
to	O
the	O
medical	O
service	O
for	O
ongoing	O
care	O
.	O
On	O
arrival	O
to	O
floor	O
patient	O
is	O
lethargic	O
but	O
wakes	O
to	O
voice	O
.	O
She	O
answers	O
questions	O
although	O
requires	O
repeat	O
questioning	O
at	O
times	O
to	O
wake	O
her	O
.	O
Patient	O
reports	O
mild	O
neck	O
pain	O
since	O
having	O
collar	O
removed	O
,	O
denies	O
headache	O
,	O
chest	O
pain	O
,	O
dyspnea	O
,	O
abdominal	O
pain	O
or	O
other	O
localizing	O
symptoms	O
.	O
Past	O
Medical	O
History	O
:	O
Parkinson	O
's	O
Disease	O
Dementia	O
,	O
mild	O
Hypertension	O
Hyperlipidemia	O
Hypothyroidism	O
Type	O
II	O
DM	O
,	O
diet	O
controlled	O
Pernicious	O
anemia	O
History	O
of	O
breast	O
cancer	O
Urge	O
incontinence	O
s	O
/	O
p	O
penetrating	O
keratoplasty	O
[	O
**	O
2119-3-30	O
**	O
]	O
Cervical	O
vertebral	O
fracture	O
Social	O
History	O
:	O
She	O
is	O
widowed	O
.	O
She	O
had	O
a	O
6	O
-	O
year	O
history	O
of	O
tobacco	O
use	O
but	O
quit	O
decades	O
ago	O
.	O
Her	O
daughter	O
is	O
in	O
her	O
50s	O
and	O
is	O
healthy	O
.	O
She	O
denies	O
alcohol	O
use	O
or	O
abuse	O
.	O
She	O
formerly	O
taught	O
English	O
in	O
[	O
**	O
Country	O
532	O
**	O
]	O
;	O
she	O
also	O
worked	O
as	O
an	O
interpreter	O
of	O
[	O
**	O
Doctor	O
First	O
Name	O
533	O
**	O
]	O
,	O
Japanese	O
,	O
and	O
English	O
.	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
On	O
admission	O
:	O
Vitals	O
:	O
98.3	O
,	O
136/74	O
,	O
76	O
,	O
20	O
,	O
94	O
%	O
RA	O
General	O
:	O
elderly	O
female	O
.	O
Lethargic	O
but	O
arousable	O
to	O
vocal	O
stimuli	O
.	O
Only	O
opens	O
eyes	O
after	O
extensive	O
coaching	O
.	O
Can	O
answer	O
questions	O
but	O
often	O
does	O
not	O
respond	O
the	O
first	O
time	O
.	O
HEENT	O
:	O
+	O
mild	O
erythema	O
,	O
yellow	O
bruising	O
,	O
and	O
mod	O
edema	O
periorbital	O
edema	O
surrounding	O
left	O
eye	O
.	O
PERRL	O
Mouth	O
:	O
Significant	O
tongue	O
swelling	O
and	O
swollen	O
lower	O
lip	O
.	O
Barely	O
able	O
to	O
visualize	O
uvula	O
when	O
using	O
a	O
tongue	O
depressor	O
.	O
No	O
erythema	O
of	O
the	O
mouth	O
.	O
Neck	O
:	O
No	O
LAD	O
Chest	O
:	O
Difficult	O
to	O
access	O
given	O
pt	O
intermittently	O
snoring	O
during	O
exam	O
despite	O
repeatedly	O
waking	O
her	O
up	O
.	O
No	O
obvious	O
crackles	O
.	O
Cardiac	O
:	O
RRR	O
,	O
III	O
/	O
VI	O
systolic	O
murmur	O
loudest	O
at	O
LLSB	O
Abdomen	O
:	O
+	O
bs	O
,	O
soft	O
,	O
NTND	O
,	O
no	O
HSM	O
Ext	O
:	O
erythema	O
bilaterally	O
at	O
ankles	O
with	O
no	O
skin	O
breakdown	O
,	O
DP	O
pulses	O
and	O
PT	O
pulses	O
+1	O
,	O
radial	O
pulses	O
+	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
.	O
No	O
c	O
/	O
c	O
/	O
e.	O
Neuro	O
:	O
oriented	O
to	O
name	O
only	O
.	O
States	O
she	O
is	O
in	O
her	O
apartment	O
.	O
UE	O
reflexes	O
+2	O
,	O
LE	O
reflexes	O
difficult	O
to	O
access	O
as	O
pt	O
not	O
relaxing	O
and	O
is	O
pulling	O
away	O
from	O
babinski	O
.	O
Motor	O
:	O
Due	O
to	O
lethargy	O
pt	O
has	O
poor	O
participation	O
in	O
exam	O
.	O
UE	O
strength	O
4	O
-	O
/	O
5	O
except	O
for	O
grip	O
[	O
**	O
5	O
-	O
2	O
**	O
]	O
bilaterally	O
.	O
LE	O
poor	O
effort	O
.	O
Sensation	O
:	O
Intact	O
in	O
face	O
,	O
UE	O
and	O
LE	O
to	O
touch	O
Pertinent	O
Results	O
:	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
GLUCOSE	O
-	O
145	O
*	O
UREA	O
N	O
-	O
24	O
*	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
104	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
15	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
16	O
AST	O
(	O
SGOT	O
)	O
-	O
27	O
LD	O
(	O
LDH	O
)	O
-	O
261	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
49	O
ALK	O
PHOS	O
-	O
129	O
*	O
AMYLASE	O
-	O
35	O
TOT	O
BILI	O
-	O
0.3	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
LIPASE	O
-	O
23	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
ALBUMIN	O
-	O
4.0	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
WBC	O
-	O
8.0	O
RBC	O
-	O
4.42	O
HGB	O
-	O
13.1	O
HCT	O
-	O
37.5	O
MCV	O
-	O
85	O
MCH	O
-	O
29.7	O
MCHC	O
-	O
35.0	O
RDW	O
-	O
15.1	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
NEUTS	O
-	O
75.4	O
*	O
LYMPHS	O
-	O
17.2	O
*	O
MONOS	O
-	O
6.0	O
EOS	O
-	O
1.3	O
BASOS	O
-	O
0.2	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
PLT	O
COUNT	O
-	O
152	O
[	O
**	O
2119-4-5	O
**	O
]	O
08:25	O
PM	O
PT	O
-	O
13.6	O
*	O
PTT	O
-	O
24.4	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
CT	O
head	O
[	O
**	O
4	O
-	O
5	O
**	O
]	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
hemorrhage	O
or	O
acute	O
fracture	O
.	O
2	O
.	O
Diffuse	O
cerebral	O
atrophy	O
with	O
moderate	O
sulcal	O
and	O
ventricular	O
prominence	O
.	O
3	O
.	O
Chronic	O
microvascular	O
infarcts	O
,	O
unchanged	O
.	O
4	O
.	O
Paranasal	O
sinus	O
disease	O
as	O
described	O
,	O
likely	O
acute	O
in	O
the	O
sphenoid	O
sinus	O
.	O
CT	O
neck	O
[	O
**	O
4	O
-	O
6	O
**	O
]	O
:	O
1	O
.	O
Significant	O
swelling	O
/	O
inflammation	O
of	O
the	O
soft	O
tissues	O
at	O
the	O
base	O
of	O
tongue	O
,	O
oropharynx	O
,	O
with	O
fullness	O
in	O
the	O
vallecula	O
and	O
the	O
piriform	O
sinuses	O
,	O
overall	O
resulting	O
in	O
moderate	O
to	O
marked	O
narrowing	O
of	O
the	O
oropharynx	O
.	O
The	O
etiology	O
of	O
this	O
finding	O
is	O
uncertain	O
from	O
the	O
present	O
study	O
.	O
To	O
correlate	O
with	O
direct	O
ENT	O
examination	O
.	O
2	O
.	O
Fullness	O
of	O
the	O
hypopharynx	O
and	O
adjacent	O
portions	O
of	O
esophagus	O
-	O
no	O
adequately	O
assessed	O
on	O
the	O
present	O
study	O
-	O
further	O
evaluation	O
recommended	O
.	O
3	O
.	O
Increased	O
attenuation	O
of	O
the	O
fat	O
in	O
the	O
carotid	O
space	O
,	O
with	O
soft	O
tissue	O
attenuation	O
opacity	O
,	O
with	O
heterogeneous	O
appearance	O
,	O
causing	O
indentation	O
on	O
the	O
right	O
internal	O
jugular	O
vein	O
extending	O
down	O
along	O
the	O
carotid	O
space	O
,	O
into	O
the	O
region	O
of	O
the	O
thoracic	O
inlet	O
.	O
This	O
may	O
relate	O
to	O
inflammation	O
,	O
phlegmon	O
,	O
and	O
radiation	O
-	O
related	O
changes	O
if	O
there	O
is	O
history	O
of	O
radiation	O
in	O
the	O
past	O
and	O
less	O
likely	O
neoplastic	O
.	O
Close	O
followup	O
evaluation	O
,	O
with	O
ultrasound	O
can	O
be	O
considered	O
to	O
evaluate	O
for	O
any	O
abscess	O
,	O
given	O
the	O
patient	O
's	O
symptoms	O
of	O
fever	O
.	O
CT	O
orbits	O
:	O
1	O
.	O
Increased	O
attenuation	O
of	O
the	O
preseptal	O
soft	O
tissues	O
with	O
some	O
enhancement	O
,	O
on	O
the	O
left	O
side	O
,	O
likely	O
due	O
to	O
inflamamtion	O
/	O
post-surgical	O
changes	O
-	O
correlate	O
with	O
clinical	O
examination	O
.	O
No	O
definite	O
abscess	O
on	O
the	O
present	O
set	O
of	O
images	O
.	O
No	O
intraconal	O
abnormality	O
.	O
F	O
/	O
u	O
as	O
clinically	O
indicated	O
.	O
2	O
.	O
Moderate	O
paranasal	O
sinus	O
disease	O
CT	O
head	O
[	O
**	O
4	O
-	O
9	O
**	O
]	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
process	O
.	O
2	O
.	O
Persistent	O
cerebral	O
atrophy	O
.	O
3	O
.	O
Chronic	O
microvascular	O
ischemic	O
changes	O
.	O
4	O
.	O
Paranasal	O
sinus	O
disease	O
.	O
MRI	O
/	O
MRA	O
brain	O
:	O
Final	O
Report	O
HISTORY	O
:	O
Parkinson	O
's	O
,	O
delirium	O
,	O
lethargy	O
,	O
right	O
facial	O
droop	O
and	O
dysarthria	O
.	O
Evaluate	O
for	O
signs	O
of	O
intracranial	O
hemorrhage	O
or	O
acute	O
stroke	O
.	O
Comparison	O
is	O
made	O
to	O
most	O
recent	O
head	O
CT	O
of	O
[	O
**	O
2119-4-9	O
**	O
]	O
TECHNIQUE	O
:	O
Multiplanar	O
T1	O
-	O
and	O
T2	O
-	O
weighted	O
sequences	O
were	O
obtained	O
through	O
the	O
brain	O
without	O
intravenous	O
gadolinium	O
.	O
3D	O
time	O
-	O
of	O
-	O
flight	O
MR	O
arteriography	O
was	O
also	O
performed	O
.	O
Volume	O
-	O
rendering	O
reconstructed	O
images	O
were	O
evaluated	O
.	O
MRI	O
OF	O
THE	O
BRAIN	O
AND	O
MRA	O
OF	O
THE	O
BRAIN	O
:	O
There	O
is	O
no	O
evidence	O
of	O
intracranial	O
hemorrhage	O
,	O
masses	O
,	O
mass	O
effect	O
,	O
or	O
regions	O
of	O
restricted	O
diffusion	O
to	O
suggest	O
acute	O
infarction	O
.	O
A	O
few	O
scattered	O
periventricular	O
T2	O
/	O
FLAIR	O
hyperintensities	O
are	O
noted	O
,	O
which	O
are	O
nonspecific	O
but	O
likely	O
suggest	O
chronic	O
small	O
vessel	O
ischemia	O
.	O
There	O
are	O
also	O
adjacent	O
prominent	O
Virchow	O
-	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
spaces	O
.	O
While	O
there	O
is	O
underlying	O
global	O
cerebral	O
atrophy	O
,	O
the	O
degree	O
of	O
dilatation	O
of	O
the	O
ventricular	O
system	O
may	O
be	O
somewhat	O
disproportionate	O
to	O
the	O
amount	O
of	O
central	O
atrophy	O
.	O
Small	O
amount	O
of	O
fluid	O
is	O
noted	O
in	O
the	O
mastoids	O
bilateral	O
.	O
MR	O
arteriography	O
of	O
the	O
circle	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
431	O
**	O
]	O
displays	O
no	O
aneurysmal	O
dilatation	O
.	O
Mild	O
atherosclerosis	O
is	O
noted	O
in	O
the	O
right	O
M1	O
segment	O
.	O
Posterior	O
circulation	O
is	O
left	O
dominant	O
.	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
infarction	O
.	O
Scattered	O
changes	O
likely	O
related	O
to	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
.	O
2	O
.	O
Question	O
slightly	O
disproportionate	O
degree	O
of	O
ventricular	O
dilatation	O
in	O
relation	O
to	O
the	O
amount	O
underlying	O
cerebral	O
atrophy	O
.	O
While	O
this	O
finding	O
is	O
nonspecific	O
,	O
in	O
the	O
appropriate	O
clinical	O
scenario	O
it	O
may	O
reflect	O
underlying	O
NPH	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
pt	O
is	O
a	O
88yo	O
female	O
w	O
h	O
/	O
o	O
Parkinson	O
's	O
disease	O
,	O
mild	O
dementia	O
and	O
recent	O
corneal	O
transplant	O
admitted	O
to	O
the	O
hospital	O
for	O
AMS	O
and	O
to	O
the	O
ICU	O
for	O
airway	O
narrowing	O
.	O
.	O
#	O
Airway	O
narrowing	O
:	O
She	O
was	O
noted	O
to	O
have	O
swelling	O
of	O
the	O
tongue	O
and	O
lower	O
lips	O
on	O
admission	O
.	O
A	O
CT	I-Reason
of	O
the	O
Head	O
and	O
Neck	O
with	O
IV	O
contrast	I-Drug
showed	O
no	O
clear	O
evidence	O
of	O
preseptal	O
cellulitis	O
and	O
?	O
of	O
soft	O
tissue	O
infection	O
/	O
edema	O
of	O
neck	O
and	O
throat	O
.	O
Over	O
course	O
of	O
day	O
,	O
noted	O
to	O
have	O
increased	O
audible	O
upper	O
airway	O
sounds	O
with	O
good	O
O2	O
sat	O
of	O
97	O
%	O
on	O
2L	O
which	O
has	O
been	O
stable	O
.	O
ENT	O
was	O
consulted	O
and	O
saw	O
extensive	O
edema	O
and	O
soft	O
tissue	O
swelling	O
in	O
oropharynx	O
with	O
patent	O
airway	O
.	O
Swelling	O
around	O
false	O
cords	O
,	O
tonsillar	B-Reason
edema	I-Reason
,	O
but	O
true	O
cords	O
without	O
edema	O
.	O
The	O
team	O
thought	O
the	O
swelling	I-Reason
to	O
be	O
secondary	O
to	O
possible	O
allergic	O
reaction	O
to	O
medications	O
.	O
She	O
was	O
started	O
on	O
solumedrol	I-Drug
60IV	O
and	O
famotidine	I-Drug
20	O
mg	O
.	O
She	O
was	O
given	O
one	O
dose	O
of	O
zosyn	I-Drug
and	O
then	O
switched	O
to	O
unasyn	I-Drug
to	O
cover	O
for	O
possible	O
soft	B-Reason
tissue	I-Reason
infection	I-Reason
.	O
Pt	O
without	O
leukocytosis	O
,	O
fever	O
(	O
was	O
102.8	O
in	O
the	O
ED	O
but	O
afebrile	O
since	O
)	O
,	O
or	O
abcess	O
.	O
ENT	O
and	O
anesthesia	O
recommended	O
transfer	O
to	O
ICU	O
for	O
further	O
monitoring	O
.	O
She	O
was	O
monitored	O
and	O
continued	O
on	O
Decadron	I-Drug
for	O
three	O
doses	O
.	O
During	O
successive	O
scopes	O
by	O
ENT	O
,	O
oropharyngeal	O
edema	O
and	O
some	O
secretions	O
were	O
seen	O
,	O
but	O
airway	O
remained	O
patent	O
.	O
Unclear	O
etiology	O
:	O
possible	O
allergic	O
reaction	O
vs	O
infectious	O
process	O
vs	O
both	O
given	O
tonsils	O
appear	O
possibly	O
infectious	O
and	O
lower	O
airway	O
appears	O
more	O
edematous	O
and	O
less	O
infectious	O
.	O
Lisinopril	I-Drug
was	O
stopped	O
,	O
and	O
her	O
laryngoscopic	O
exam	O
visibly	O
improved	O
by	O
the	O
time	O
she	O
was	O
called	O
out	O
to	O
the	O
floor	O
.	O
-	O
Pt	O
was	O
treated	O
for	O
10	O
days	O
for	O
?	O
soft	B-Reason
tissue	I-Reason
infection	I-Reason
and	O
switched	O
to	O
Augmentin	I-Drug
for	O
additional	O
5	O
days	O
at	O
dc	O
-	O
ENT	O
follow	O
up	O
appt	O
was	O
set	O
up	O
#	O
s	O
/	O
p	O
corneal	O
TP	O
:	O
lid	O
edema	O
on	O
exam	O
.	O
Ophtho	O
believes	O
likely	O
secondary	O
to	O
blockage	O
of	O
drainage	O
and	O
not	O
as	O
likely	O
due	O
to	O
allergy	O
.	O
Ophtho	O
felt	O
the	O
eye	O
was	O
improving	O
and	O
recommended	O
decreasing	O
doses	O
of	O
eye	B-Drug
drops	I-Drug
.	O
-	O
FU	O
appt	O
with	O
Optho	O
set	O
up	O
.	O
#	O
.	O
Altered	B-Ade
Mental	I-Ade
Status	I-Ade
:	O
On	O
admission	O
,	O
she	O
was	O
lethargic	I-Ade
,	O
possibly	O
from	O
the	O
Haldol	I-Drug
she	O
received	O
in	O
the	O
ED	O
.	O
By	O
the	O
time	O
she	O
was	O
called	O
out	O
of	O
the	O
ICU	O
,	O
she	O
was	O
likely	O
at	O
her	O
baseline	O
mental	O
status	O
,	O
pleasant	O
and	O
easily	O
conversant	O
.	O
Shortely	O
thereafter	O
,	O
however	O
,	O
she	O
became	O
agitated	I-Reason
and	O
combative	I-Reason
and	O
received	O
1.5	O
mg	O
Haldol	I-Drug
and	O
later	O
the	O
same	O
day	O
5	O
mg	O
of	O
Zyprexa	I-Drug
.	O
She	O
remained	O
agitated	O
for	O
about	O
36	O
hours	O
before	O
she	O
became	O
lethargic	O
and	O
barely	O
arousable	O
.	O
Head	O
CT	O
was	O
unchanged	O
from	O
before	O
.	O
She	O
had	O
not	O
had	O
any	O
new	O
fevers	O
or	O
new	O
signs	O
of	O
infection	O
.	O
She	O
had	O
a	O
lumbar	O
puncture	O
that	O
was	O
unremarkable	O
.	O
MRI	O
/	O
MRA	O
was	O
neg	O
except	O
for	O
some	O
ventriculomegaly	O
in	O
setting	O
of	O
global	O
atrophy	O
which	O
was	O
difficult	O
to	O
differentiate	O
from	O
NPH	O
.	O
Neurology	O
thought	O
it	O
was	O
unlikely	O
to	O
be	O
NPH	O
.	O
EEG	O
showed	O
some	O
focal	O
acitivity	O
concerning	O
for	O
sublinical	B-Reason
seizures	I-Reason
.	O
Pt	O
was	O
started	O
on	O
keppra	I-Drug
,	O
initially	O
continued	O
to	O
have	O
periods	O
of	O
somnolence	O
along	O
with	O
R	O
sided	O
facial	O
droop	O
(	O
which	O
was	O
thought	O
be	O
Neurology	O
to	O
represent	O
a	O
post-ictal	O
state	O
with	O
[	O
**	O
Doctor	O
Last	O
Name	O
555	O
**	O
]	O
paralysis	O
)	O
but	O
day	O
before	O
discharge	O
had	O
significant	O
improvement	O
in	O
mental	O
status	O
and	O
was	O
alert	O
and	O
conversive	O
.	O
Due	O
to	O
hx	O
of	O
dementia	O
and	O
also	O
ongoing	O
hypoactive	O
delirium	O
,	O
pt	O
was	O
not	O
fully	O
oriented	O
but	O
did	O
have	O
significant	O
improvement	O
in	O
level	O
of	O
alertness	O
.	O
-	O
Pt	O
curently	O
is	O
on	O
Keppra	I-Drug
1000	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
one	O
week	O
and	O
to	O
be	O
increased	O
to	O
1500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
later	O
and	O
kept	O
at	O
that	O
dose	O
.	O
-	O
Pt	O
should	O
be	O
followed	O
by	O
a	O
neurologist	O
at	O
[	O
**	O
Hospital	O
100	O
**	O
]	O
Rehab	O
-	O
Outpt	O
FU	O
w	O
neurology	O
is	O
already	O
set	O
up	O
.	O
#	O
.	O
UTI	I-Reason
:	O
grew	O
Enterococcus	I-Reason
in	O
UCx	O
.	O
She	O
was	O
continued	O
on	O
Unasyn	I-Drug
for	O
10	O
days	O
.	O
.	O
#	O
.	O
Positive	O
blood	O
cultures	O
:	O
1/4	O
bottles	O
growing	O
coag	O
negative	O
Staph	O
.	O
This	O
was	O
likely	O
a	O
contaminant	O
so	O
vancomycin	I-Drug
was	O
stopped	O
.	O
Repeat	O
blood	O
cultures	O
were	O
negative	O
.	O
#	O
.	O
Parkinson	B-Reason
's	I-Reason
Disease	I-Reason
:	O
continued	O
Sinemet	I-Drug
except	O
when	O
patient	O
was	O
too	O
lethargic	O
to	O
safely	O
take	O
meds	O
.	O
#	O
.	O
Hypertension	B-Reason
,	I-Reason
benign	I-Reason
:	O
Lisinopril	I-Drug
was	O
stopped	O
due	O
to	O
concern	O
of	O
angioedema	I-Ade
.	O
Atenolol	I-Drug
was	O
continued	O
.	O
.	O
#	O
.	O
Hyperlipidemia	I-Reason
:	O
continued	O
statin	I-Drug
.	O
#	O
.	O
Hypothyroidism	I-Reason
:	O
TSH	O
normal	O
on	O
[	O
**	O
2119-4-6	O
**	O
]	O
so	O
not	O
a	O
picture	O
of	O
myxedema	O
and	O
can	O
not	O
account	O
for	O
MS	O
change	O
.	O
Continued	O
levothyroxine	I-Drug
.	O
#	O
.	O
Diabetes	B-Reason
II	I-Reason
,	O
diet	O
controlled	O
without	O
complication	O
:	O
-	O
insulin	I-Drug
sliding	O
scale	O
while	O
inpatient	O
and	O
bs	O
were	O
wnl	O
.	O
Pt	O
can	O
have	O
[	O
**	O
Hospital1	O
**	O
]	O
finger	O
checks	O
to	O
Rehab	O
but	O
since	O
not	O
needing	O
insulin	I-Drug
,	O
does	O
not	O
have	O
to	O
be	O
on	O
sliding	O
scale	O
#	O
Deconditioning	O
:	O
per	O
PT	O
eval	O
,	O
pt	O
was	O
2	O
person	O
assist	O
and	O
will	O
need	O
significant	O
PT	O
therapy	O
to	O
get	O
back	O
to	O
baseline	O
where	O
she	O
was	O
walking	O
with	O
a	O
walker	O
Medications	O
on	O
Admission	O
:	O
Tylenol	I-Drug
1000	O
mg	O
PO	O
twice	O
daliy	O
Aspirin	I-Drug
81	O
mg	O
daily	O
Atenolol	I-Drug
25	O
mg	O
daily	O
Carbidopa	B-Drug
/	I-Drug
Levodopa	I-Drug
25	O
/	O
100	O
mg	O
three	O
times	O
daily	O
Enablex	I-Drug
7.5	O
mg	O
SR	O
daily	O
Fish	B-Drug
Oil	I-Drug
1000	O
mg	O
daily	O
Levothyroxin	I-Drug
125mcg	O
daily	O
Lisinopril	I-Drug
20	O
mg	O
daily	O
Simvastatin	I-Drug
10	O
mg	O
daily	O
Cyanocobalamin	I-Drug
1000mcg	O
daily	O
Docusate	I-Drug
100	O
mg	O
daily	O
Pred	I-Drug
1	O
%	O
TID	O
OS	O
Timolol	I-Drug
0.5	O
%	O
[	O
**	O
Hospital1	O
**	O
]	O
OU	O
Xalatan	I-Drug
QHS	O
OS	O
Tobradex	I-Drug
OS	O
QHS	O
Discharge	O
Medications	O
:	O
1	O
.	O
Latanoprost	I-Drug
0.005	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
2	O
.	O
Tobramycin	B-Drug
-	I-Drug
Dexamethasone	I-Drug
0.3	O
-	O
0.1	O
%	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Ophthalmic	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
3	O
.	O
Timolol	B-Drug
Maleate	I-Drug
0.5	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Prednisolone	B-Drug
Acetate	I-Drug
1	O
%	O
Drops	O
,	O
Suspension	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Atenolol	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Carbidopa	B-Drug
-	I-Drug
Levodopa	I-Drug
25	O
-	O
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Levothyroxine	I-Drug
125	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Simvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Bisacodyl	I-Drug
10	O
mg	O
Suppository	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
for	O
one	O
week	O
,	O
then	O
increase	O
to	O
1500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
14	O
.	O
Augmentin	I-Drug
875	O
-	O
125	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
for	O
5	O
days	O
.	O
Disp	O
:	O
*	O
10	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
459	O
**	O
]	O
for	O
the	O
Aged	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
550	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
oropharyngeal	O
swelling	O
,	O
delirium	O
,	O
urinary	O
tract	O
infection	O
Secondary	O
:	O
Parkinson	O
's	O
disease	O
,	O
diabetes	O
type	O
2	O
,	O
hypertension	O
,	O
hyperlipidemia	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
You	O
were	O
evaluated	O
for	O
confusion	O
and	O
found	O
to	O
have	O
swelling	O
of	O
your	O
tongue	O
and	O
throat	O
as	O
well	O
as	O
a	O
urinary	B-Reason
tract	I-Reason
infection	I-Reason
.	O
You	O
improved	O
with	O
antibiotics	I-Drug
.	O
You	O
became	O
delirious	O
in	O
the	O
hospital	O
but	O
improved	O
with	O
conservative	O
treatment	O
.	O
If	O
you	O
have	O
fevers	O
,	O
chills	O
,	O
confusion	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
,	O
call	O
your	O
doctor	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
PCP	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
ph	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
,	O
please	O
call	O
and	O
make	O
appt	O
for	O
fu	O
in	O
[	O
**	O
2	O
-	O
1	O
**	O
]	O
weeks	O
2	O
.	O
Ophtho	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
ph	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
556	O
**	O
]	O
,	O
Appt	O
is	O
on	O
[	O
**	O
2119-4-28	O
**	O
]	O
at	O
11:00	O
AM	O
3	O
.	O
ENT	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
ph	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
41	O
**	O
]	O
,	O
Appt	O
is	O
on	O
[	O
**	O
4	O
-	O
20	O
**	O
]	O
,	O
Thurs	O
,	O
12:00	O
/	O
noon	O
4	O
.	O
Neurology	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
557	O
**	O
]	O
,	O
ph	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
558	O
**	O
]	O
,	O
Appt	O
is	O
on	O
[	O
**	O
5	O
-	O
9	O
**	O
]	O
,	O
Tuesday	O
at	O
9:30	O
AM	O

Admission	O
Date	O
:	O
[	O
**	O
2134-8-12	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2134-8-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2053-11-6	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2297	O
**	O
]	O
Chief	O
Complaint	O
:	O
s	O
/	O
p	O
fall	O
-	O
SAH	O
,	O
L	O
acetabular	O
fx	O
,	O
L2	O
+	O
L3	O
transverse	O
process	O
fractures	O
,	O
question	O
of	O
T	O
and	O
L	O
spine	O
compression	O
fractures	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
80	O
year	O
-	O
old	O
man	O
with	O
history	O
of	O
CAD	O
s	O
/	O
p	O
IMI	O
,	O
afib	I-Reason
s	O
/	O
p	O
pacemaker	O
on	O
coumadin	I-Drug
,	O
COPD	O
,	O
laryngeal	O
CA	O
,	O
who	O
was	O
admitted	O
to	O
the	O
TICU	O
with	O
SAH	O
after	O
a	O
fall	O
,	O
and	O
is	O
now	O
transferred	O
to	O
the	O
MICU	O
for	O
management	O
of	O
respiratory	O
failure	O
.	O
Briefly	O
,	O
he	O
had	O
a	O
mechanical	O
fall	O
on	O
[	O
**	O
2134-8-12	O
**	O
]	O
and	O
subsequently	O
sustained	O
a	O
SAH	O
,	O
transverse	O
process	O
fracture	O
at	O
L2	O
/	O
L3	O
,	O
a	O
compression	O
fracture	O
of	O
T3	O
/	O
T12	O
/	O
L1	O
/	O
L4	O
,	O
and	O
a	O
left	O
acetabular	O
fracture	O
.	O
His	O
SAH	O
and	O
fractures	O
were	O
thought	O
to	O
be	O
non-operable	O
per	O
neurosurgery	O
and	O
ortho	O
,	O
respectively	O
.	O
His	O
course	O
in	O
the	O
TICU	O
was	O
also	O
remarkable	O
for	O
respiratory	B-Reason
distress	I-Reason
and	O
?	O
new	O
hypoxia	O
on	O
the	O
day	O
after	O
admission	O
(	O
he	O
was	O
98	O
%	O
2L	O
on	O
the	O
day	O
of	O
admission	O
per	O
review	O
of	O
the	O
notes	O
)	O
,	O
for	O
which	O
he	O
was	O
placed	O
on	O
a	O
face	O
mask	O
,	O
started	O
on	O
solumedrol	I-Drug
,	O
nebs	I-Drug
,	O
and	O
azithromycin	I-Drug
empirically	O
for	O
a	B-Reason
presumed	I-Reason
COPD	O
exacerbation	O
.	O
This	O
was	O
weaned	O
down	O
to	O
2L	O
NC	O
on	O
the	O
day	O
prior	O
to	O
transfer	O
and	O
he	O
was	O
satting	O
98	O
%	O
ra	O
on	O
the	O
morning	O
of	O
transfer	O
with	O
a	O
plan	O
to	O
go	O
to	O
rehab	O
today	O
.	O
.	O
Per	O
report	O
,	O
later	O
this	O
morning	O
around	O
11	O
a.m.	O
,	O
he	O
was	O
found	O
to	O
be	O
dyspneic	O
,	O
lethargic	O
and	O
breathing	O
at	O
a	O
rate	O
of	O
40	O
.	O
He	O
was	O
placed	O
on	O
a	O
nonrebreather	O
and	O
had	O
O2	O
satts	O
in	O
the	O
70s	O
,	O
HR	O
100s	O
(	O
afib	O
)	O
,	O
SBP	O
110	O
.	O
ABG	O
was	O
7.37	O
/	O
47/98/28	O
.	O
He	O
was	O
thought	O
to	O
have	O
aspirated	O
vs	O
flash	B-Reason
pulmonary	I-Reason
edema	I-Reason
and	O
given	O
lasix	I-Drug
40	O
mg	O
IV	O
x	O
1	O
with	O
good	O
UOP	O
.	O
Of	O
note	O
,	O
his	O
family	O
has	O
been	O
updated	O
and	O
he	O
agrees	O
to	O
BiPAP	O
but	O
would	O
want	O
to	O
be	O
comfortable	O
if	O
this	O
fails	O
(	O
after	O
many	O
conversations	O
with	O
patient	O
and	O
family	O
)	O
.	O
.	O
His	O
hospital	O
course	O
has	O
also	O
been	O
remarkable	O
for	O
delerium	I-Ade
thought	O
to	O
be	O
secondary	O
to	O
sundowning	O
and	O
narcotics	I-Drug
,	O
with	O
geriatrics	O
consulted	O
.	O
Past	O
Medical	O
History	O
:	O
AAA	O
repair	O
4	O
years	O
earlier	O
Thyroidectomy	O
3	O
years	O
earlier	O
Advanced	O
COPD	O
AFib	I-Reason
treated	O
with	O
coumadin	I-Drug
CAD	O
and	O
pacemaker	O
placement	O
Social	O
History	O
:	O
Lives	O
at	O
home	O
with	O
son	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
current	O
alcohol	O
or	O
tobacco	O
use	O
.	O
Family	O
History	O
:	O
Unknown	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
BP	O
:	O
P	O
:	O
R	O
:	O
18	O
O2	O
:	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
rhonchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
.	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
WBC	O
-	O
17.9	O
*	O
#	O
RBC	O
-	O
5.01	O
#	O
Hgb	O
-	O
14.6	O
#	O
Hct	O
-	O
44.8	O
#	O
MCV	O
-	O
89	O
MCH	O
-	O
29.1	O
MCHC	O
-	O
32.6	O
RDW	O
-	O
14.1	O
Plt	O
Ct	O
-	O
200	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
Neuts	O
-	O
93.8	O
*	O
Lymphs	O
-	O
3.5	O
*	O
Monos	O
-	O
2.5	O
Eos	O
-	O
0.1	O
Baso	O
-	O
0.1	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
PT	O
-	O
32.5	O
*	O
PTT	O
-	O
35.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.3	O
*	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
Glucose	O
-	O
150	O
*	O
UreaN	O
-	O
24	O
*	O
Creat	O
-	O
1.8	O
*	O
Na	O
-	O
137	O
K	O
-	O
4.8	O
Cl	O
-	O
102	O
HCO3	O
-	O
25	O
AnGap	O
-	O
15	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
88	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2134-8-12	O
**	O
]	O
09:01	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
3.5	O
Mg	O
-	O
2.0	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
[	O
**	O
2134-8-12	O
**	O
]	O
04:14	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
43	O
*	O
pCO2	O
-	O
35	O
pH	O
-	O
7.44	O
calTCO2	O
-	O
25	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2134-8-12	O
**	O
]	O
06:17	O
AM	O
BLOOD	O
Lactate	O
-	O
1.6	O
[	O
**	O
2134-8-12	O
**	O
]	O
04:14	O
PM	O
BLOOD	O
freeCa	O
-	O
1.12	O
.	O
.	O
PERTINENT	O
STUDIES	O
:	O
.	O
CT	O
Chest	O
(	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
)	O
:	O
1	O
.	O
Multiple	O
thoracolumbar	O
compression	O
deformities	O
as	O
described	O
above	O
.	O
2	O
.	O
Right	O
transverse	O
process	O
fracture	O
of	O
L3	O
and	O
L4	O
.	O
3	O
.	O
Emphysema	O
and	O
multiple	O
pulmonary	O
nodules	O
,	O
one	O
of	O
which	O
is	O
not	O
included	O
in	O
the	O
field	O
of	O
view	O
of	O
the	O
prior	O
examination	O
,	O
measuring	O
4	O
mm	O
.	O
Given	O
risk	O
factors	O
,	O
a	O
12	O
-	O
month	O
followup	O
is	O
recommended	O
.	O
4	O
.	O
Multiple	O
hepatic	O
cysts	O
.	O
5	O
.	O
Bilateral	O
renal	O
cysts	O
CT	O
Head	O
(	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
)	O
:	O
There	O
is	O
asymmetric	O
dense	O
appearance	O
of	O
the	O
right	O
side	O
of	O
the	O
tentorium	O
and	O
lateral	O
to	O
it	O
indicating	O
a	O
possible	O
suddural	O
hemorrhage	O
associated	O
.	O
Close	O
f	O
/	O
u	O
to	O
assess	O
the	O
stability	O
of	O
the	O
above	O
findings	O
is	O
recommended	O
.	O
CT	O
C	O
-	O
Spine	O
(	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
)	O
:	O
There	O
is	O
asymmetry	O
in	O
the	O
size	O
of	O
the	O
disc	O
space	O
at	O
C4	O
/	O
5	O
,	O
wider	O
anteriorly	O
.	O
(	O
series	O
400b	O
,	O
im	O
19	O
)	O
.	O
Though	O
this	O
can	O
relate	O
to	O
DJD	O
and	O
disc	O
bulge	O
,	O
ligamentous	O
injury	O
needs	O
to	O
be	O
excluded	O
given	O
the	O
history	O
of	O
trauma	O
and	O
no	O
prior	O
studies	O
.	O
MR	O
c	O
spine	O
can	O
be	O
performed	O
for	O
the	O
same	O
.	O
LENI	O
(	O
[	O
**	O
8	O
-	O
18	O
**	O
]	O
)	O
:	O
LLE	O
:	O
partially	O
occluded	O
clot	O
in	O
greater	O
saphenous	O
,	O
unchanged	O
from	O
prior	O
;	O
superficial	O
femoral	O
vein	O
proximal	O
thrombus	O
.	O
Possible	O
thrombus	O
.	O
RLE	O
:	O
interval	O
development	O
of	O
partially	O
occlusive	O
clot	O
in	O
greater	O
saphenous	O
at	O
junction	O
of	O
common	O
femoral	O
.	O
CT	O
Head	O
(	O
[	O
**	O
8	O
-	O
18	O
**	O
]	O
)	O
:	O
1	O
.	O
No	O
evidence	O
of	O
new	O
hemorrhage	O
2	O
.	O
Stable	O
appearance	O
of	O
bilateral	O
subdural	O
hemorrhage	O
layering	O
along	O
the	O
tentorium	O
cerebelli	O
.	O
Interval	O
resolution	O
of	O
subarachnoid	O
hemorrhage	O
seen	O
in	O
the	O
interpeduncular	O
cistern	O
.	O
3	O
.	O
Chronic	O
small	O
vessel	O
ischemic	O
changes	O
.	O
4	O
.	O
Prominent	O
ventricles	O
and	O
sulci	O
,	O
unchanged	O
.	O
TTE	O
(	O
[	O
**	O
8	O
-	O
18	O
**	O
]	O
)	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
was	O
admitted	O
to	O
T	O
/	O
SICU	O
from	O
ER	O
for	O
management	O
of	O
his	O
injuries	O
s	O
/	O
p	O
mechanical	O
fall	O
,	O
which	O
included	O
SAH	O
,	O
L	O
acetabular	O
fracture	O
,	O
L2L3	O
transverse	O
process	O
fractures	O
,	O
and	O
thoracolumbar	O
compression	O
injuries	O
.	O
Orthopaedics	O
and	O
Neurosurgery	O
were	O
consulted	O
for	O
these	O
injuries	O
.	O
Orthopaedics	O
recommended	O
non-operative	O
management	O
of	O
L	O
hip	O
fracture	O
.	O
Patient	O
was	O
to	O
be	O
touch	O
-	O
down	O
weight	O
-	O
bearing	O
for	O
6	O
weeks	O
and	O
to	O
follow	O
-	O
up	O
in	O
the	O
[	O
**	O
Hospital	O
13308	O
**	O
]	O
clinic	O
after	O
this	O
course	O
of	O
time	O
.	O
Neurosurgery	O
recommended	O
normalization	O
of	O
his	O
INR	O
and	O
repeat	O
imaging	O
of	O
his	O
head	O
in	O
6hours	O
and	O
24	O
hours	O
.	O
No	O
intervention	O
was	O
recommended	O
for	O
vertebral	O
fractures	O
.	O
His	O
repeat	O
head	O
CTs	O
revealed	O
no	O
change	O
.	O
Patient	O
had	O
unstable	O
respiratory	O
status	O
while	O
in	O
the	O
ICU	O
,	O
which	O
was	O
felt	O
to	O
be	O
d	O
/	O
t	O
COPD	B-Reason
flair	I-Reason
.	O
He	O
was	O
treated	O
with	O
steroids	I-Drug
,	O
CPAP	O
or	O
BiPAP	O
,	O
and	O
Azithromycin	I-Drug
.	O
He	O
experienced	O
some	O
delirium	I-Reason
and	O
sundowning	I-Reason
in	O
the	O
unit	O
and	O
geriatrics	O
was	O
consulted	O
and	O
recommended	O
afternoon	O
haldol	I-Drug
rather	O
than	O
standing	O
doses	O
and	O
tylenol	I-Drug
with	O
breakthrough	O
oxycodone	I-Drug
rather	O
than	O
morphine	I-Drug
standing	O
.	O
On	O
HD4	O
patient	O
had	O
discussion	O
with	O
team	O
regaring	O
desire	O
to	O
be	O
DNR	O
/	O
DNI	O
and	O
desire	O
for	O
care	O
not	O
to	O
be	O
escalated	O
.	O
Patient	O
was	O
weaned	O
to	O
2L	O
NC	O
and	O
transferred	O
to	O
floor	O
.	O
Physical	O
therapy	O
and	O
occupational	O
therapy	O
evaluated	O
the	O
patient	O
and	O
hospice	O
care	O
was	O
consulted	O
.	O
Patient	O
had	O
a	O
speech	O
and	O
swallow	O
consult	O
.	O
1:1	O
supervision	O
with	O
crushed	O
/	O
pureed	O
foods	O
was	O
recommended	O
.	O
On	O
HD5	O
patient	O
became	O
increasingly	O
tachypneic	O
and	O
was	O
transferred	O
back	O
to	O
the	O
T	O
/	O
SICU	O
for	O
BiPAP	O
.	O
The	O
decision	O
was	O
made	O
to	O
transfer	O
patient	O
from	O
surgical	O
intensive	O
care	O
unit	O
to	O
medical	O
intensive	O
care	O
unit	O
.	O
During	O
his	O
MICU	O
stay	O
,	O
the	O
patient	O
was	O
placed	O
on	O
Bipap	O
for	O
hypoxic	O
respiratory	O
failure	O
.	O
He	O
was	O
placed	O
empirically	O
on	O
antibiotics	I-Drug
and	O
was	O
given	O
IV	O
steroids	I-Drug
for	O
a	B-Reason
possible	I-Reason
COPD	I-Reason
exacerbation	O
.	O
He	O
remained	O
dyspneic	O
with	O
labored	O
work	O
of	O
breathing	O
while	O
on	O
Bipap	O
.	O
LENIs	O
were	O
performed	O
,	O
which	O
showed	O
a	O
new	O
DVT	I-Reason
in	O
his	O
lower	O
extremity	O
.	O
He	O
was	O
thus	O
placed	O
on	O
a	O
heparin	I-Drug
drip	O
.	O
He	O
went	O
into	O
AFib	B-Reason
with	I-Reason
RVR	I-Reason
and	O
was	O
started	O
on	O
a	O
diltiazem	I-Drug
drip	O
.	O
He	O
developed	O
increased	O
work	O
of	O
breathing	O
in	O
the	O
setting	O
of	O
AFib	B-Reason
with	I-Reason
RVR	I-Reason
and	O
eventually	O
expired	O
from	O
cardiopulmonary	O
arrest	O
.	O
Medications	O
on	O
Admission	O
:	O
Nitropatch	I-Drug
0.2	O
mg	O
per	O
hour	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
per	O
day	O
Toprol	B-Drug
-	I-Drug
XL	I-Drug
12.5	O
mg	O
per	O
day	O
Protonix	I-Drug
40	O
mg	O
per	O
day	O
Coumadin	I-Drug
2	O
mg	O
per	O
day	O
Mirtazapine	I-Drug
Levoxyl	I-Drug
50	O
mcg	O
per	O
day	O
Testosterone	I-Drug
Vytorin	I-Drug
20/10	O
,	O
Albuterol	I-Drug
inhaler	O
Combivent	I-Drug
inhaler	O
Fluticasone	I-Drug
inhaler	O
Calcium	B-Drug
/	I-Drug
vit	I-Drug
B	I-Drug
-	I-Drug
12	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Nitroglycerin	I-Drug
0.3	O
mg	O
Tablet	O
,	O
Sublingual	O
Sig	O
:	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
Tablet	O
,	O
Sublinguals	O
Sublingual	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
chest	B-Reason
pain	I-Reason
.	O
2	O
.	O
Cyanocobalamin	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Azithromycin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
1	O
days	O
.	O
Disp	O
:	O
*	O
2	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
4	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Milk	B-Drug
of	I-Drug
Magnesia	I-Drug
800	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
's	O
PO	O
twice	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
6	O
.	O
Levothyroxine	I-Drug
75	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
every	O
[	O
**	O
4	O
-	O
12	O
**	O
]	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
8	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
s	O
/	O
p	O
Fall	O
Subarachnoid	O
hemorrhage	O
Transverse	O
process	O
fractures	O
L2	O
,3	O
Compression	O
fracture	O
T3	O
,12	O
;	O
L1	O
,4	O
Left	O
acetabular	O
fracture	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
Expired	O
Followup	O
Instructions	O
:	O
Expired	O
Completed	O
by	O
:[	O
**	O
2134-11-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2154-3-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2154-3-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2112-11-25	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Nsaids	I-Drug
/	O
Peppermint	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
15237	O
**	O
]	O
Chief	O
Complaint	O
:	O
Anemia	O
.	O
Abdominal	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
99778	O
**	O
]	O
is	O
a	O
41	O
year	O
old	O
female	O
a	O
history	O
of	O
warm	O
autoantibody	O
hemolytic	O
anemia	O
diagnosed	O
in	O
[	O
**	O
2150	O
**	O
]	O
who	O
recently	O
underwent	O
laparoscopic	O
splenectomy	O
on	O
[	O
**	O
2154-2-20	O
**	O
]	O
for	O
disease	O
refractory	O
to	O
steroids	I-Drug
,	O
and	O
refractory	O
to	O
rituximab	I-Drug
and	O
cyclosporin	I-Drug
.	O
She	O
tolerated	O
the	O
procedure	O
well	O
but	O
has	O
been	O
fatigued	O
but	O
has	O
been	O
experiencing	O
abdominal	B-Reason
pain	I-Reason
since	O
surgery	O
which	O
is	O
poorly	O
controlled	O
with	O
Percocet	I-Drug
.	O
She	O
has	O
also	O
felt	O
fatigued	O
and	O
dyspneic	O
,	O
consistent	O
with	O
prior	O
episodes	O
of	O
hemolysis	O
.	O
Because	O
of	O
her	O
abdominal	O
pain	O
and	O
fatigue	O
she	O
has	O
not	O
been	O
eating	O
well	O
and	O
has	O
not	O
taken	O
her	O
cyclosporin	I-Drug
for	O
approximately	O
2	O
days	O
.	O
She	O
initially	O
presented	O
with	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
Hospital	O
with	O
abdominal	O
pain	O
.	O
She	O
was	O
found	O
to	O
have	O
a	O
WBC	O
count	O
of	O
30	O
and	O
a	O
hematocrit	O
of	O
10	O
.	O
On	O
[	O
**	O
2154-2-26	O
**	O
]	O
her	O
WBC	O
count	O
was	O
13.4	O
with	O
a	O
hematoctit	O
of	O
25.1	O
.	O
She	O
underwent	O
a	O
CT	O
scan	O
of	O
the	O
abdomen	O
which	O
showed	O
no	O
evidence	O
of	O
acute	B-Reason
bleeding	I-Reason
or	O
other	O
etiology	O
of	O
her	O
abdominal	O
pain	O
.	O
She	O
received	O
4	O
units	O
of	O
non-crossmatched	O
PRBCs	I-Drug
and	O
solumedrol	I-Drug
125	O
mg	O
IV	O
x	O
1	O
.	O
She	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
.	O
On	O
arrival	O
to	O
the	O
emergency	O
room	O
her	O
initial	O
vitals	O
were	O
T	O
:	O
98.1	O
BP	O
:	O
118/55	O
HR	O
:	O
97	O
RR	O
:	O
21	O
O2	O
:	O
99	O
%	O
RA	O
.	O
She	O
was	O
evaluated	O
by	O
the	O
surgical	O
service	O
who	O
reviewed	O
the	O
OSH	O
CT	O
scan	O
and	O
did	O
not	O
feel	O
that	O
there	O
was	O
a	O
surgical	O
cause	O
of	O
her	O
pain	O
.	O
She	O
received	O
6	O
mg	O
IV	O
Dilaudid	I-Drug
for	O
pain	I-Reason
and	O
4	O
mg	O
IV	O
zofran	I-Drug
.	O
On	O
review	O
of	O
systems	O
she	O
endorses	O
chills	O
at	O
home	O
but	O
did	O
not	O
take	O
her	O
temperature	O
.	O
She	O
denies	O
chest	O
pain	O
or	O
pressure	O
.	O
She	O
endorses	O
dyspnea	O
with	O
exertion	O
,	O
lightheadedness	O
,	O
and	O
fatigue	O
.	O
She	O
endorses	O
diffuse	O
severe	O
abdominal	O
pain	O
with	O
nauesa	O
,	O
no	O
vomiting	O
.	O
She	O
has	O
had	O
diarrhea	O
x	O
1	O
day	O
but	O
can	O
not	O
describe	O
stools	O
.	O
She	O
denies	O
melena	O
or	O
hematochezia	O
.	O
She	O
endorse	O
decreased	O
urine	O
output	O
and	O
dark	O
urine	O
.	O
She	O
has	O
worsening	O
jaundice	O
.	O
She	O
has	O
no	O
lower	O
extremity	O
edema	O
or	O
swelling	O
.	O
All	O
other	O
review	O
of	O
systems	O
negative	O
in	O
detail	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Idiopathic	O
autoimmune	O
hemolytic	O
anemia	O
:	O
Diagnosed	O
in	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
admitted	O
to	O
the	O
ICU	O
with	O
Hct	O
9.6	O
,	O
given	O
high	O
dose	O
steroids	I-Drug
and	O
6	O
units	O
pRBC	I-Drug
,	O
developed	O
steroid	B-Ade
psychosis	I-Ade
and	O
tapered	O
off	O
.	O
Refused	O
splenectomy	O
then	O
received	O
4	O
cycles	O
Rituximab	I-Drug
and	O
has	O
been	O
on	O
cyclosporin	I-Drug
since	O
[	O
**	O
9	O
-	O
/	O
2152	O
**	O
]	O
and	O
finally	O
unwent	O
splenectomy	O
on	O
[	O
**	O
2154-2-20	O
**	O
]	O
.	O
2	O
.	O
Anxiety	B-Reason
disorder	I-Reason
:	O
on	O
benzodiazepines	I-Drug
3	O
.	O
Psoriasis	O
with	O
psoriatic	O
arthritis	O
4	O
.	O
Crohn	O
's	O
disease	O
,	O
history	O
of	O
leukocytoclastic	O
vasculitis	O
by	O
biopsy	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
359	O
**	O
]	O
Per	O
pt	O
this	O
is	O
inactive	O
.	O
5	O
.	O
Basal	O
Cell	O
Carcinoma	O
of	O
Leg	O
6	O
.	O
Osgood	O
-	O
Schlatter	O
(	O
osteochondritis	O
of	O
the	O
tibial	O
tuberosity	O
)	O
Social	O
History	O
:	O
Occasional	O
ETOH	O
use	O
,	O
no	O
tobacco	O
or	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
with	O
hemolytic	O
anemia	O
at	O
6	O
mth	O
of	O
age	O
,	O
uncle	O
with	O
hemolytic	O
anemia	O
in	O
infancy	O
causing	O
his	O
demise	O
.	O
No	O
family	O
h	O
/	O
o	O
SLE	O
or	O
Crohn	O
's	O
.	O
Brother	O
has	O
new	O
onset	O
atrial	O
fibrillation	O
.	O
Physical	O
Exam	O
:	O
On	O
admission	O
:	O
Vitals	O
:	O
T	O
:	O
99.7	O
HR	O
:	O
85	O
BP	O
:	O
102/63	O
RR	O
:	O
20	O
O2	O
:	O
99	O
%	O
on	O
RA	O
General	O
:	O
Tan	O
,	O
jaundiced	O
,	O
tearful	O
and	O
easily	O
aggitated	O
Skin	O
:	O
Tanned	O
skin	O
,	O
mild	O
jaundice	O
,	O
no	O
petechiae	O
or	O
rashes	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
sclera	O
icteric	O
,	O
MM	O
moist	O
,	O
oropharynx	O
clear	O
Cardiac	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
s1	O
and	O
s2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezez	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
Soft	O
,	O
non-distended	O
,	O
+	O
BS	O
,	O
well	O
healing	O
LUQ	O
laparoscopic	O
sites	O
,	O
+	O
voluntary	O
guarding	O
,	O
no	O
rebound	O
Extremities	O
:	O
Warm	O
and	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
Alert	O
and	O
oriented	O
x	O
3	O
,	O
strength	O
5/5	O
in	O
upper	O
and	O
lower	O
extremities	O
,	O
sensation	O
intact	O
to	O
light	O
touch	O
=======================================	O
At	O
time	O
of	O
discharge	O
:	O
BP	O
=	O
160s	O
-	O
170s	O
/	O
80s	O
-	O
90s	O
,	O
HR	O
=	O
50	O
-	O
60	O
Abdomen	O
:	O
non-distended	O
,	O
soft	O
,	O
tolerating	O
deep	O
palpation	O
with	O
minimal	O
discomfort	O
,	O
normal	O
bowel	O
sounds	O
.	O
Remainder	O
of	O
physical	O
exam	O
unchanged	O
Pertinent	O
Results	O
:	O
Labs	O
on	O
admission	O
:	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
WBC	O
-	O
28.0	O
*	O
#	O
RBC	O
-	O
1.73	O
*	O
#	O
Hgb	O
-	O
5.3	O
*	O
#	O
Hct	O
-	O
15.8	O
*	O
#	O
MCV	O
-	O
91	O
#	O
MCH	O
-	O
30.9	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
19.5	O
*	O
Plt	O
Ct	O
-	O
1481	O
*	O
#	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Neuts	O
-	O
84	O
*	O
Bands	O
-	O
1	O
Lymphs	O
-	O
8	O
*	O
Monos	O
-	O
5	O
Eos	O
-	O
0	O
Baso	O
-	O
1	O
Atyps	O
-	O
0	O
Metas	O
-	O
1	O
*	O
Myelos	O
-	O
0	O
NRBC	O
-	O
5	O
*	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
PT	O
-	O
17.2	O
*	O
PTT	O
-	O
28.6	O
INR	O
(	O
PT	O
)	O
-	O
1.6	O
*	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Ret	O
Man	O
-	O
11.2	O
*	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Glucose	O
-	O
193	O
*	O
UreaN	O
-	O
39	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
135	O
K	O
-	O
5.5	O
*	O
Cl	O
-	O
105	O
HCO3	O
-	O
17	O
*	O
AnGap	O
-	O
19	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
ALT	O
-	O
33	O
AST	O
-	O
57	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
472	O
*	O
AlkPhos	O
-	O
254	O
*	O
TotBili	O
-	O
2.8	O
*	O
DirBili	O
-	O
1.4	O
*	O
IndBili	O
-	O
1.4	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Lipase	O
-	O
22	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
UricAcd	O
-	O
8.3	O
*	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Hapto	O
-	O
261	O
*	O
[	O
**	O
2154-3-4	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Cyclspr	O
-	O
128	O
CT	O
abdomen	O
/	O
pelvis	O
[	O
**	O
2154-3-3	O
**	O
]	O
:	O
1	O
.	O
Heterogeneous	O
perfusion	O
of	O
the	O
liver	O
related	O
to	O
thrombosis	O
of	O
the	O
right	O
portal	O
vein	O
,	O
main	O
portal	O
vein	O
,	O
splenic	O
vein	O
,	O
and	O
SMV	O
.	O
Note	O
is	O
made	O
of	O
thrombus	O
extending	O
into	O
extensive	O
retroperitoneal	O
collaterals	O
.	O
2	O
.	O
Abnormal	O
bowel	O
wall	O
thickening	O
involving	O
the	O
sigmoid	O
colon	O
,	O
which	O
may	O
relate	O
to	O
venous	O
congestion	O
.	O
3	O
.	O
Patent	O
hepatic	O
veins	O
,	O
in	O
arterial	O
system	O
.	O
No	O
IVC	O
thrombosis	O
.	O
4	O
.	O
Gas	O
in	O
the	O
soft	O
tissues	O
of	O
the	O
left	O
anterior	O
abdominal	O
wall	O
.	O
Recommend	O
clinical	O
correlation	O
with	O
recent	O
surgery	O
.	O
CXR	O
:	O
Bilateral	O
pleural	O
effusions	O
,	O
right	O
greater	O
than	O
left	O
,	O
are	O
new	O
,	O
are	O
associated	O
with	O
adjacent	O
atelectasis	O
.	O
The	O
upper	O
lungs	O
are	O
clear	O
.	O
Moderate	O
cardiomegaly	O
is	O
unchanged	O
.	O
Discharge	O
Labs	O
:	O
[	O
**	O
2154-3-8	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
WBC	O
-	O
17.5	O
*	O
RBC	O
-	O
3.88	O
*	O
Hgb	O
-	O
11.9	O
*	O
Hct	O
-	O
36.6	O
MCV	O
-	O
94	O
MCH	O
-	O
30.8	O
MCHC	O
-	O
32.6	O
RDW	O
-	O
18.8	O
*	O
Plt	O
Ct	O
-	O
985	O
*	O
[	O
**	O
2154-3-8	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
PT	O
-	O
20.7	O
*	O
PTT	O
-	O
96.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.9	O
*	O
[	O
**	O
2154-3-8	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
Glucose	O
-	O
140	O
*	O
UreaN	O
-	O
21	O
*	O
Creat	O
-	O
1.0	O
Na	O
-	O
144	O
K	O
-	O
4.6	O
Cl	O
-	O
104	O
HCO3	O
-	O
27	O
AnGap	O
-	O
18	O
[	O
**	O
2154-3-8	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
LD	O
(	O
LDH	O
)	O
-	O
346	O
*	O
[	O
**	O
2154-3-5	O
**	O
]	O
03:45	O
AM	O
BLOOD	O
Mg	O
-	O
2.1	O
[	O
**	O
2154-3-3	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Hapto	O
-	O
261	O
*	O
[	O
**	O
2154-3-3	O
**	O
]	O
08:17	O
PM	O
BLOOD	O
Hapto	O
-	O
239	O
*	O
[	O
**	O
2154-3-4	O
**	O
]	O
04:00	O
AM	O
BLOOD	O
Hapto	O
-	O
243	O
*	O
[	O
**	O
2154-3-5	O
**	O
]	O
03:45	O
AM	O
BLOOD	O
Hapto	O
-	O
233	O
*	O
Brief	O
Hospital	O
Course	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
99778	O
**	O
]	O
is	O
a	O
41	O
year	O
old	O
female	O
with	O
warm	O
autoimmune	O
hemolytic	O
anemia	O
who	O
presented	O
ten	O
days	O
status	O
-	O
post	O
splenectomy	O
with	O
abdominal	O
pain	O
and	O
dyspnea	O
with	O
a	O
hematocrit	O
of	O
11	O
and	O
some	O
evidence	O
of	O
hemolysis	O
.	O
Anemia	O
:	O
Her	O
laboratories	O
at	O
OSH	O
were	O
consistent	O
with	O
but	O
not	O
diagnostic	O
of	O
hemolysis	O
;	O
she	O
did	O
not	O
display	O
signs	O
of	O
active	O
bleeding	O
.	O
The	O
haptoglobin	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
was	O
elevated	O
pointing	O
against	O
hemolysis	O
.	O
Given	O
her	O
low	O
hematocrit	O
.	O
She	O
was	O
initially	O
managed	O
in	O
the	O
ICU	O
.	O
A	O
CT	O
scan	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
showed	O
extensive	O
clot	O
burden	O
in	O
her	O
portal	O
system	O
,	O
likely	O
related	O
to	O
her	O
prior	O
surgery	O
.	O
She	O
received	O
four	O
units	O
of	O
major	O
antibody	O
crossmatched	O
blood	O
,	O
and	O
additional	O
tubes	O
were	O
sent	O
to	O
the	O
Red	O
Cross	O
for	O
further	O
crossmatching	O
.	O
Hematology	O
saw	O
the	O
patient	O
in	O
the	O
emergency	O
room	O
,	O
and	O
recommended	O
treatment	O
with	O
steroids	I-Drug
and	O
cyclosporine	I-Drug
.	O
She	O
was	O
started	O
on	O
Solumedrol	I-Drug
80	O
mg	O
IV	O
daily	O
and	O
Cyclosporine	I-Drug
150	O
mg	O
PO	O
q12hours	O
.	O
Hemolysis	O
labs	O
were	O
monitored	O
as	O
well	O
as	O
Cyclosporine	I-Drug
levels	O
.	O
The	O
Surgical	O
team	O
also	O
followed	O
the	O
patient	O
in	O
the	O
ICU	O
.	O
After	O
transfer	O
to	O
the	O
medical	O
floor	O
,	O
Hct	O
gradually	O
rose	O
daily	O
to	O
36.6	O
at	O
time	O
of	O
discharge	O
.	O
Solumedrol	I-Drug
was	O
tapered	O
and	O
converted	O
to	O
prednisione	I-Drug
.	O
Cyclosporine	I-Drug
was	O
also	O
tapered	O
to	O
75	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
LDH	O
was	O
persistently	O
elevated	O
likely	O
secondary	O
to	O
abdominal	O
clot	O
process	O
.	O
F	O
/	O
u	O
was	O
scheduled	O
with	O
her	O
hemtologist	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2148	O
**	O
]	O
.	O
Abdominal	O
Pain	O
/	O
Portal	O
thrombus	O
:	O
The	O
pain	O
was	O
diffuse	O
,	O
severe	O
,	O
and	O
out	O
of	O
proportion	O
to	O
exam	O
.	O
CT	O
scan	O
of	O
abdomen	O
did	O
show	O
large	O
portal	O
clot	O
burden	O
.	O
Empiric	O
metronidazole	I-Drug
was	O
started	O
until	O
a	O
C.diff	I-Reason
could	O
be	O
obtained	O
,	O
but	O
as	O
pt	O
did	O
not	O
have	O
a	O
BM	O
,	O
it	O
was	O
continued	O
until	O
day	O
of	O
discharge	O
.	O
Her	O
pain	I-Reason
was	O
controlled	O
with	O
Dilaudid	I-Drug
as	O
needed	O
.	O
Her	O
diet	O
was	O
advanced	O
to	O
regular	O
,	O
but	O
on	O
the	O
day	O
of	O
discharge	O
(	O
against	O
medical	O
advice	O
)	O
,	O
she	O
did	O
not	O
tolerate	O
jello	O
without	O
IV	O
dilaudid	I-Drug
.	O
Plan	O
was	O
for	O
pt	O
to	O
remain	O
until	O
able	O
to	O
tolerate	O
clears	O
with	O
only	O
po	O
pain	B-Drug
meds	I-Drug
,	O
but	O
she	O
chose	O
to	O
leave	O
AMA	O
(	O
form	O
signed	O
)	O
.	O
She	O
has	O
f	O
/	O
u	O
scheduled	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
within	O
one	O
week	O
.	O
Expressed	O
understanding	O
of	O
need	O
to	O
return	O
if	O
abdominal	O
pain	O
increases	O
.	O
Given	O
5	O
days	O
worth	O
of	O
home	O
dose	O
of	O
percocet	I-Drug
.	O
Thrombocytosis	O
:	O
Likely	O
related	O
to	O
recent	O
splenectomy	O
,	O
improved	O
from	O
1.5	O
million	O
to	O
900K	O
at	O
time	O
of	O
d	O
/	O
c.	O
Leukocytosis	I-Ade
:	O
Likely	O
reactive	O
process	O
+	O
related	O
to	O
high	O
dose	O
steroids	I-Drug
.	O
No	O
fevers	O
.	O
No	O
localizing	O
sources	O
of	O
infection	O
with	O
the	O
exception	O
of	O
abdominal	O
pain	O
.	O
She	O
was	O
started	O
on	O
empiric	O
Flagyl	I-Drug
which	O
was	O
discontinued	O
at	O
time	O
of	O
discharge	O
.	O
White	O
count	O
peaked	O
at	O
36	O
and	O
fell	O
to	O
17.5	O
at	O
time	O
of	O
discharge	O
.	O
Acute	O
Kidney	O
Injury	O
:	O
Creatinine	O
1.3	O
from	O
baseline	O
<	O
1.0	O
.	O
The	O
was	O
felt	O
to	O
most	O
likely	O
be	O
prerenal	O
from	O
dehydration	O
.	O
This	O
returned	O
to	O
baseline	O
prior	O
to	O
d	O
/	O
c.	O
.	O
Hypertension	I-Ade
:	O
likely	O
secondary	O
to	O
steroids	I-Drug
and	O
cyclosporine	I-Drug
.	O
not	O
stating	O
anti-htn	O
at	O
this	O
time	O
,	O
continue	O
to	O
monitor	O
;	O
should	O
improve	O
with	O
taper	O
.	O
BPs	O
peaking	O
in	O
the	O
170/80	O
range	O
at	O
time	O
of	O
discharge	O
.	O
.	O
Anxiety	I-Ade
:	O
The	O
patient	O
was	O
noted	O
to	O
be	O
very	O
anxious	O
,	O
and	O
this	O
seemed	O
to	O
worsen	O
after	O
the	O
initiation	O
of	O
steroids	I-Drug
.	O
There	O
is	O
concern	O
that	O
the	O
steroid	I-Drug
is	O
causing	O
side	O
effects	O
,	O
including	O
psychosis	I-Ade
,	O
as	O
it	O
had	O
done	O
in	O
the	O
past	O
according	O
to	O
the	O
patient	O
.	O
She	O
was	O
continued	O
on	O
home	O
benzodiazepines	B-Drug
(	I-Drug
Klonopin	I-Drug
)	I-Drug
,	O
as	O
well	O
as	O
Haldol	I-Drug
PRN	O
.	O
Disscharged	O
on	O
home	O
klonopin	I-Drug
dose	O
.	O
***	O
PT	O
DISCHARGED	O
AMA	O
.	O
Our	O
recommendation	O
was	O
that	O
she	O
stay	O
until	O
being	O
able	O
to	O
tolerate	O
po	O
with	O
only	O
percocet	I-Drug
for	O
pain	I-Reason
control	O
.	O
She	O
signed	O
AMA	O
form	O
and	O
expressed	O
understanding	O
of	O
risks	O
.	O
Medications	O
on	O
Admission	O
:	O
Benzoyl	B-Drug
Peroxide	I-Drug
cleanser	O
Clobetasol	I-Drug
cream	O
Clonazepam	I-Drug
1	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
PRN	O
Cyclosporin	I-Drug
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Folic	B-Drug
Acid	I-Drug
6	O
mg	O
daily	O
Omeprazole	I-Drug
40	O
mg	O
daily	O
Percocet	I-Drug
7.5	O
-	O
325	O
mg	O
tablet	O
1	O
-	O
2	O
tabs	O
Q6H	O
:	O
PRN	O
Paroxetine	I-Drug
30	O
mg	O
daily	O
Calcium	B-Drug
-	I-Drug
Vitamin	I-Drug
D	I-Drug
Magnesium	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
Multivitamin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Bactrim	I-Drug
80	O
-	O
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
prophylaxis	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Cholecalciferol	I-Drug
(	O
Vitamin	O
D3	O
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
30	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
Six	O
(	O
6	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Cyclosporine	I-Drug
25	O
mg	O
Capsule	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
180	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Clobetasol	I-Drug
0.05	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Clonazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
11	O
.	O
Warfarin	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
12	O
.	O
Multivitamins	I-Drug
Oral	O
13	O
.	O
Percocet	I-Drug
7.5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
40	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
autoimmune	O
hemolytic	O
anemia	O
portal	O
vein	O
thrombosis	O
thrombocytosis	O
anxiety	O
Discharge	O
Condition	O
:	O
Discharged	O
against	O
medical	O
advice	O
.	O
Is	O
not	O
tolerating	O
solid	O
food	O
without	O
IV	O
dilaudid	I-Drug
at	O
the	O
time	O
of	O
discharge	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
You	O
were	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
with	O
severe	O
abdominal	O
pain	O
and	O
a	O
very	O
low	O
blood	O
count	O
.	O
You	O
received	O
a	O
blood	O
transfusion	O
at	O
an	O
outside	O
hospital	O
and	O
another	O
one	O
here	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
your	O
blood	O
counts	O
were	O
nearing	O
the	O
normal	O
range	O
.	O
A	O
scan	O
of	O
your	O
abdomen	O
showed	O
a	O
large	O
amount	O
of	O
blood	O
clots	O
in	O
the	O
vessels	O
that	O
drain	O
your	O
intestines	O
.	O
For	O
this	O
,	O
you	O
will	O
need	O
to	O
be	O
anticoagulated	O
for	O
some	O
time	O
.	O
You	O
are	O
being	O
discharged	O
against	O
medical	O
advice	O
.	O
We	O
strongly	O
advise	O
you	O
to	O
stay	O
until	O
you	O
were	O
able	O
to	O
tolerate	O
food	O
without	O
IV	O
pain	B-Drug
medication	I-Drug
.	O
There	O
is	O
a	O
risk	O
that	O
advancing	O
your	O
diet	O
without	O
medical	O
supervision	O
may	O
lead	O
to	O
an	O
acute	O
abdomen	O
process	O
requiring	O
urgent	O
intervention	O
.	O
Please	O
return	O
to	O
the	O
hospital	O
if	O
you	O
develop	O
:	O
severe	O
abdominal	O
pain	O
,	O
fevers	O
,	O
chills	O
,	O
sweats	O
,	O
dizziness	O
,	O
blood	O
in	O
your	O
stool	O
,	O
tarry	O
stools	O
,	O
any	O
other	O
form	O
of	O
bleeding	O
,	O
severe	O
headache	O
,	O
chenage	O
in	O
vision	O
,	O
or	O
any	O
other	O
symptom	O
which	O
seriously	O
concerns	O
you	O
.	O
Several	O
changes	O
were	O
made	O
to	O
your	O
medications	O
:	O
-	O
cyclosporin	I-Drug
has	O
been	O
reduced	O
to	O
75	O
mg	O
twice	O
daily	O
-	O
prednisone	I-Drug
30	O
mg	O
daily	O
has	O
been	O
started	O
-	O
warfarin	I-Drug
5	O
mg	O
daily	O
has	O
been	O
started	O
-	O
bactrim	I-Drug
(	O
single	O
strength	O
)	O
has	O
been	O
started	O
-	O
omeprazole	I-Drug
,	O
paroxeteine	I-Drug
,	O
clonazepam	I-Drug
,	O
calcium	I-Drug
/	O
vitamin	B-Drug
D	I-Drug
,	O
and	O
folic	B-Drug
acid	I-Drug
have	O
been	O
continued	O
at	O
previous	O
doses	O
.	O
Followup	O
Instructions	O
:	O
We	O
have	O
scheduled	O
you	O
an	O
appointment	O
with	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2359	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2154-3-14	O
**	O
]	O
at	O
11:45	O
am	O
Please	O
call	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
7750	O
**	O
]	O
office	O
today	O
and	O
make	O
an	O
appointment	O
for	O
Tuesday	O
[	O
**	O
3	O
-	O
12	O
**	O
]	O
.	O
It	O
is	O
very	O
important	O
that	O
you	O
make	O
this	O
appointment	O
,	O
you	O
will	O
need	O
to	O
have	O
your	O
INR	O
(	O
blood	O
thinning	O
)	O
checked	O
.	O
Completed	O
by	O
:[	O
**	O
2154-3-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2183-1-7	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2183-1-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2105-3-17	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Ace	B-Drug
Inhibitors	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
633	O
**	O
]	O
Chief	O
Complaint	O
:	O
lightheadiness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
77	O
yo	O
M	O
with	O
CHF	O
,	O
afib	O
and	O
HTN	O
presented	O
to	O
the	O
ED	O
from	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
for	O
hypotension	O
.	O
He	O
was	O
found	O
on	O
INR	O
check	O
today	O
to	O
have	O
a	O
blood	O
pressure	O
about	O
40s	O
on	O
palp	O
.	O
In	O
the	O
ED	O
,	O
found	O
to	O
have	O
a	O
blood	B-Reason
pressure	I-Reason
in	I-Reason
the	I-Reason
80s	I-Reason
.	O
Inital	O
vitals	O
were	O
97.2	O
5686/63	O
16	O
100	O
%	O
4L	O
.	O
Received	O
250cc	O
of	O
fluid	I-Drug
with	O
increase	O
to	O
110s	O
.	O
Hypotensive	O
again	O
to	O
the	O
80s	O
,	O
received	O
500cc	O
with	O
return	O
to	O
110s	O
.	O
He	O
reports	O
feeling	O
fatigued	O
and	O
lightheaded	O
over	O
the	O
last	O
couple	O
days	O
.	O
He	O
reports	O
drinking	O
a	O
glass	O
or	O
two	O
of	O
wine	O
daily	O
over	O
the	O
weekend	O
.	O
His	O
son	O
reports	O
that	O
he	O
sounded	O
drunk	O
on	O
Sunday	O
.	O
He	O
denies	O
any	O
sick	O
symptoms	O
or	O
contacts	O
.	O
On	O
arrival	O
to	O
the	O
ICU	O
,	O
patient	O
feels	O
well	O
and	O
has	O
no	O
complaints	O
.	O
Review	O
of	O
systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheezing	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
,	O
or	O
weakness	O
.	O
Denies	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
abdominal	O
pain	O
,	O
or	O
changes	O
in	O
bowel	O
habits	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
congestive	O
heart	O
failure	O
CAD	O
atrial	O
fibrillation	O
stroke	O
in	O
[	O
**	O
2162	O
**	O
]	O
hypertension	O
hyperlipidemia	O
dysphagia	O
Social	O
History	O
:	O
He	O
was	O
born	O
in	O
[	O
**	O
Country	O
3587	O
**	O
]	O
and	O
then	O
lived	O
in	O
[	O
**	O
Country	O
48229	O
**	O
]	O
.	O
Living	O
in	O
[	O
**	O
Hospital3	O
400	O
**	O
]	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
.	O
-	O
Tobacco	O
:	O
None	O
-	O
Alcohol	O
:	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
glass	O
wine	O
/	O
day	O
-	O
Illicits	O
:	O
None	O
Family	O
History	O
:	O
Non	O
contributory	O
.	O
Physical	O
Exam	O
:	O
Admission	O
Physical	O
Exam	O
:	O
VS	O
:	O
97.3	O
8390/70	O
97	O
%	O
16	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
MMM	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
rhonchi	O
CV	O
:	O
Irreg	O
irreg	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Pertinent	O
Results	O
:	O
Admission	O
Labs	O
:	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
WBC	O
-	O
7.7	O
RBC	O
-	O
4.83	O
Hgb	O
-	O
14.8	O
Hct	O
-	O
43.5	O
MCV	O
-	O
90	O
#	O
MCH	O
-	O
30.6	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
12.9	O
Plt	O
Ct	O
-	O
302	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
Neuts	O
-	O
71.2	O
*	O
Lymphs	O
-	O
18.9	O
Monos	O
-	O
8.5	O
Eos	O
-	O
0.9	O
Baso	O
-	O
0.5	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
PT	O
-	O
31.9	O
*	O
PTT	O
-	O
36.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.1	O
*	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
Glucose	O
-	O
77	O
UreaN	O
-	O
59	O
*	O
Creat	O
-	O
2.6	O
*	O
Na	O
-	O
130	O
*	O
K	O
-	O
4.0	O
Cl	O
-	O
88	O
*	O
HCO3	O
-	O
31	O
AnGap	O
-	O
15	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
proBNP	O
-	O
949	O
*	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
3.8	O
Mg	O
-	O
2.3	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:57	O
AM	O
BLOOD	O
Lactate	O
-	O
1.4	O
[	O
**	O
2183-1-7	O
**	O
]	O
01:30	O
PM	O
URINE	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.010	O
[	O
**	O
2183-1-7	O
**	O
]	O
01:30	O
PM	O
URINE	O
Blood	O
-	O
NEG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
NEG	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
0.2	O
pH	O
-	O
6.0	O
Leuks	O
-	O
NEG	O
[	O
**	O
2183-1-7	O
**	O
]	O
01:30	O
PM	O
URINE	O
Hours	O
-	O
RANDOM	O
Creat	O
-	O
52	O
Na	O
-	O
40	O
K	O
-	O
17	O
Cl	O
-	O
32	O
[	O
**	O
2183-1-7	O
**	O
]	O
01:30	O
PM	O
URINE	O
Osmolal	O
-	O
248	O
Micro	O
:	O
Blood	O
cultures	O
pending	O
x2	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
:	O
IMPRESSION	O
:	O
No	O
acute	O
cardiopulmonary	O
process	O
.	O
Stable	O
cardiomegaly	O
.	O
.	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
EKG	O
:	O
Atrial	O
fibrillation	O
with	O
controlled	O
ventricular	O
response	O
rate	O
.	O
Intraventricular	O
conduction	O
delay	O
of	O
left	O
bundle	O
-	O
branch	O
block	O
morphology	O
.	O
Probable	O
prior	O
inferior	O
myocardial	O
infarction	O
.	O
T	O
wave	O
inversions	O
in	O
the	O
lateral	O
and	O
high	O
lateral	O
leads	O
consistent	O
with	O
possible	O
ischemia	O
.	O
Clinical	O
correlation	O
is	O
suggested	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2183-1-7	O
**	O
]	O
the	O
findings	O
are	O
similar	O
.	O
.	O
EKG	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
:	O
Atrial	O
fibrillation	O
with	O
slow	O
ventricular	O
response	O
.	O
Left	O
axis	O
deviation	O
.	O
Intraventricular	O
conduction	O
delay	O
of	O
left	O
bundle	O
-	O
branch	O
block	O
type	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2176-6-6	O
**	O
]	O
the	O
rate	O
is	O
slower	O
.	O
QRS	O
voltage	O
is	O
more	O
prominent	O
in	O
the	O
limb	O
leads	O
.	O
ST	O
-	O
T	O
wave	O
abnormalities	O
may	O
be	O
more	O
prominent	O
.	O
Clinical	O
correlation	O
is	O
suggested	O
.	O
.	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
Study	O
Date	O
of	O
[	O
**	O
2183-1-7	O
**	O
]	O
1:41	O
PM	O
There	O
is	O
no	O
evidence	O
of	O
acute	O
hemorrhage	O
,	O
edema	O
,	O
mass	O
,	O
mass	O
effect	O
,	O
or	O
new	O
infarction	O
.	O
There	O
is	O
slit	O
-	O
like	O
encephalomalacia	O
in	O
the	O
region	O
of	O
the	O
right	O
basal	O
ganglia	O
suggesting	O
prior	O
hemorrhage	O
with	O
ex	O
vacuo	O
dilitation	O
of	O
the	O
rigth	O
lateral	O
ventricle	O
.	O
Prominent	O
periventricular	O
white	O
matter	O
hypodensities	O
are	O
seen	O
,	O
most	O
commonly	O
due	O
to	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
.	O
The	O
basal	O
cisterns	O
appear	O
patent	O
and	O
there	O
is	O
preservation	O
of	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
differentiation	O
elsewhere	O
.	O
No	O
fracture	O
is	O
identified	O
.	O
The	O
paranasal	O
sinuses	O
,	O
mastoid	O
air	O
cells	O
and	O
middle	O
ear	O
cavities	O
are	O
clear	O
.	O
No	O
facial	O
or	O
cranial	O
soft	O
tissue	O
abnormalities	O
are	O
present	O
.	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
intracranial	O
process	O
.	O
2	O
.	O
Slit	O
-	O
like	O
encephalomalacia	O
in	O
the	O
area	O
of	O
the	O
right	O
basal	O
ganglia	O
is	O
suggestive	O
of	O
prior	O
hemorrhage	O
.	O
3	O
.	O
White	O
matter	O
hypodensities	O
most	O
commonly	O
due	O
to	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
.	O
.	O
ECHO	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
severe	O
global	O
left	O
ventricular	O
hypokinesis	O
(	O
LVEF	O
=	O
20	O
-	O
25	O
%	O
)	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
(	O
LVEF	O
=	O
20	O
-	O
25	O
%	O
)	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
with	O
mild	O
global	O
free	O
wall	O
hypokinesis	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
normal	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Suboptimal	O
image	O
quality	O
.	O
Severe	O
global	O
left	O
ventricular	O
hypokinesis	O
with	O
severely	O
depressed	O
systolic	O
function	O
(	O
EF	O
20	O
-	O
25	O
%	O
)	O
.	O
Normal	O
right	O
ventricular	O
size	O
with	O
mild	O
right	O
ventricular	O
hypokinesis	O
.	O
Mildly	O
dilated	O
ascending	O
aorta	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
[	O
**	O
2183-1-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
WBC	O
-	O
6.8	O
RBC	O
-	O
4.71	O
Hgb	O
-	O
14.7	O
Hct	O
-	O
42.5	O
MCV	O
-	O
90	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
12.7	O
Plt	O
Ct	O
-	O
304	O
[	O
**	O
2183-1-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
WBC	O
-	O
7.2	O
RBC	O
-	O
4.54	O
*	O
Hgb	O
-	O
14.3	O
Hct	O
-	O
41.1	O
MCV	O
-	O
91	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
12.8	O
Plt	O
Ct	O
-	O
318	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
WBC	O
-	O
7.7	O
RBC	O
-	O
4.83	O
Hgb	O
-	O
14.8	O
Hct	O
-	O
43.5	O
MCV	O
-	O
90	O
#	O
MCH	O
-	O
30.6	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
12.9	O
Plt	O
Ct	O
-	O
302	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
Neuts	O
-	O
71.2	O
*	O
Lymphs	O
-	O
18.9	O
Monos	O
-	O
8.5	O
Eos	O
-	O
0.9	O
Baso	O
-	O
0.5	O
[	O
**	O
2183-1-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
304	O
[	O
**	O
2183-1-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
PT	O
-	O
23.1	O
*	O
PTT	O
-	O
31.8	O
INR	O
(	O
PT	O
)	O
-	O
2.2	O
*	O
[	O
**	O
2183-1-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
318	O
[	O
**	O
2183-1-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
PT	O
-	O
26.6	O
*	O
PTT	O
-	O
35.6	O
INR	O
(	O
PT	O
)	O
-	O
2.6	O
*	O
[	O
**	O
2183-1-8	O
**	O
]	O
09:05	O
AM	O
BLOOD	O
PT	O
-	O
30.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.0	O
*	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
302	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
PT	O
-	O
31.9	O
*	O
PTT	O
-	O
36.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.1	O
*	O
[	O
**	O
2183-1-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Glucose	O
-	O
82	O
UreaN	O
-	O
28	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
134	O
K	O
-	O
4.3	O
Cl	O
-	O
98	O
HCO3	O
-	O
29	O
AnGap	O
-	O
11	O
[	O
**	O
2183-1-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
Glucose	O
-	O
90	O
UreaN	O
-	O
34	O
*	O
Creat	O
-	O
1.4	O
*	O
Na	O
-	O
136	O
K	O
-	O
4.6	O
Cl	O
-	O
99	O
HCO3	O
-	O
31	O
AnGap	O
-	O
11	O
[	O
**	O
2183-1-8	O
**	O
]	O
05:38	O
AM	O
BLOOD	O
Glucose	O
-	O
90	O
UreaN	O
-	O
42	O
*	O
Creat	O
-	O
1.6	O
*	O
Na	O
-	O
134	O
K	O
-	O
4.1	O
Cl	O
-	O
99	O
HCO3	O
-	O
27	O
AnGap	O
-	O
12	O
[	O
**	O
2183-1-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
190	O
[	O
**	O
2183-1-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:50	O
AM	O
BLOOD	O
proBNP	O
-	O
949	O
*	O
[	O
**	O
2183-1-7	O
**	O
]	O
11:57	O
AM	O
BLOOD	O
Lactate	O
-	O
1.4	O
[	O
**	O
2183-1-10	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
2.8	O
Mg	O
-	O
1.8	O
Brief	O
Hospital	O
Course	O
:	O
A	O
/	O
P	O
:	O
77	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
history	O
of	O
systolic	O
CHF	O
with	O
EF	O
of	O
20	O
%	O
,	O
atrial	B-Reason
fibrillation	I-Reason
on	O
Coumadin	I-Drug
,	O
COPD	O
,	O
CAD	O
who	O
was	O
admitted	O
to	O
the	O
MICU	O
[	O
**	O
1	O
-	O
7	O
**	O
]	O
with	O
hypotension	I-Reason
thought	O
to	O
be	O
due	O
to	O
hypovolemia	I-Reason
now	O
resolved	O
after	O
iv	O
hydration	I-Drug
.	O
.	O
#Hypotension	O
:	O
likely	O
hypovolemia	I-Ade
due	O
to	O
dehydration	O
from	O
diuretic	I-Drug
use	O
and	O
drinking	O
of	O
ETOH	O
at	O
home	O
.	O
Pt	O
did	O
not	O
have	O
any	O
infectious	O
symptoms	O
such	O
as	O
fever	O
,	O
leukocytosis	O
or	O
other	O
localizing	O
symptoms	O
.	O
Hypotension	I-Reason
resolved	O
with	O
2L	O
IVF	I-Drug
.	O
EKG	O
not	O
suggestive	O
of	O
ischemia	O
and	O
cardiac	O
enzymes	O
were	O
negative	O
.	O
TSH	O
and	O
cortisol	O
not	O
pursued	O
as	O
pt	O
's	O
symptoms	O
resolved	O
after	O
IV	O
fluids	I-Drug
.	O
However	O
,	O
BP	O
still	O
ranged	O
at	O
times	O
from	O
high	O
90's	O
-	O
110	O
's	O
and	O
pt	O
was	O
asymptomatic	O
and	O
ambulating	O
without	O
dizziness	O
or	O
difficulty	O
.	O
Orthostatics	O
were	O
negative	O
after	O
IV	O
hydration	I-Drug
.	O
Pt	O
's	O
lasix	I-Drug
,	O
spironolactone	I-Drug
,	O
HCTZ	I-Drug
,	O
and	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
were	O
held	O
during	O
admission	O
as	O
well	O
as	O
tamsulosin	I-Drug
.	O
He	O
was	O
advised	O
to	O
continue	O
to	O
hold	O
these	O
medications	O
upon	O
discharge	O
.	O
Carvedilol	I-Drug
was	O
restarted	O
.	O
ECHO	O
was	O
repeated	O
to	O
ensure	O
that	O
cardiac	O
function	O
had	O
not	O
worsened	O
and	O
was	O
found	O
to	O
be	O
similiar	O
to	O
prior	O
with	O
EF	O
20	O
-	O
25	O
%	O
.	O
Pt	O
will	O
be	O
discharged	O
on	O
half	O
dose	O
of	O
his	O
valsartan	I-Drug
80	O
mg	O
daily	O
.	O
+	O
+	O
could	O
have	O
been	O
due	O
to	O
increased	O
ETOH	O
prior	O
to	O
admit	O
.	O
Pt	O
did	O
not	O
have	O
any	O
suggestion	O
of	O
ETOH	O
withdrawal	O
during	O
admission	O
and	O
it	O
did	O
not	O
appear	O
that	O
drinking	O
ETOH	O
is	O
the	O
norm	O
for	O
the	O
patient	O
,	O
but	O
that	O
he	O
had	O
more	O
drinks	O
than	O
normal	O
weekend	O
prior	O
to	O
admission	O
.	O
However	O
,	O
he	O
should	O
be	O
continually	O
advised	O
to	O
refrain	O
from	O
excess	O
ETOH	O
given	O
his	O
CHF	O
.	O
Pt	O
did	O
not	O
display	O
signs	O
of	O
clinical	O
CHF	O
during	O
admission	O
.	O
.	O
#acute	O
on	O
chronic	O
renal	O
failure	O
-	O
Presented	O
with	O
Cr	O
2.6	O
.	O
Baseline	O
1.2	O
-	O
1.5	O
.	O
Thought	O
to	O
be	O
due	O
to	O
hypovolemia	I-Ade
in	O
the	O
setting	O
of	O
diuretic	I-Drug
use	O
.	O
Improved	O
during	O
admission	O
to	O
baseline	O
of	O
1.3	O
with	O
IVF	I-Drug
and	O
holding	O
diuretics	I-Drug
.	O
Will	O
continue	O
to	O
hold	O
lasix	I-Drug
,	O
HCTZ	I-Drug
,	O
spironolactone	I-Drug
upon	O
DC	O
.	O
Resumed	O
valsartan	I-Drug
at	O
80	O
mg	O
(	O
1	O
/	O
2home	O
dose	O
)	O
upon	O
DC	O
.	O
Pt	O
should	O
have	O
repeat	O
labs	O
at	O
his	O
PCP	O
appointment	O
on	O
[	O
**	O
2183-1-16	O
**	O
]	O
to	O
ensure	O
stability	O
of	O
renal	O
function	O
.	O
.	O
#Systolic	O
heart	O
failure	O
:	O
EF	O
20	O
%	O
.	O
Pt	O
did	O
not	O
appear	O
to	O
have	O
acute	O
heart	O
failure	O
during	O
admission	O
.	O
Repeat	O
ECHO	O
was	O
unchanged	O
from	O
prior	O
.	O
Carvedilol	I-Drug
was	O
restarted	O
.	O
Pt	O
was	O
given	O
an	O
rx	O
for	O
valsartan	I-Drug
80	O
mg	O
daily	O
(	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
home	O
dose	O
)	O
upon	O
discharge	O
.	O
His	O
lasix	I-Drug
,	O
spironolactone	I-Drug
,	O
and	O
HCTZ	I-Drug
were	O
not	O
restarted	O
during	O
admission	O
.	O
He	O
was	O
set	O
up	O
with	O
VNA	O
services	O
upon	O
discharge	O
to	O
help	O
monitor	O
for	O
signs	O
of	O
clinical	O
heart	O
failure	O
in	O
this	O
setting	O
of	O
medication	O
adjustment	O
.	O
BP	O
range	O
high	O
90's	O
-	O
110s	O
during	O
admission	O
off	O
these	O
agents	O
.	O
Pt	O
should	O
follow	O
up	O
with	O
PCP	O
and	O
cardiology	O
(	O
appointments	O
listed	O
below	O
)	O
in	O
order	O
to	O
continue	O
further	O
titration	O
of	O
these	O
medications	O
prn	O
.	O
Pt	O
should	O
have	O
repeat	O
chemistry	O
panel	O
at	O
upcoming	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
648	O
**	O
]	O
.	O
Daily	O
weights	O
.	O
.	O
#Afib	O
:	O
rate	O
controlled	O
.	O
Continued	O
Carvedilol	I-Drug
.	O
INR	O
initially	O
slightly	O
supratherapeutic	O
,	O
but	O
then	O
starting	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
his	O
home	O
regimen	O
of	O
4	O
mg	O
alternating	O
with	O
2	O
mg	O
daily	O
was	O
started	O
.	O
Started	O
with	O
4	O
mg	O
daily	O
on	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
.	O
INR	O
can	O
be	O
rechecked	O
at	O
PCP	O
's	O
appointment	O
on	O
[	O
**	O
2183-1-16	O
**	O
]	O
.	O
INR	O
3.1	O
,	O
2	O
,	O
2.6	O
,	O
2.2	O
on	O
day	O
of	O
DC	O
.	O
.	O
#HLD	O
:	O
continued	O
pravastatin	I-Drug
.	O
#BPH	O
:	O
held	O
tamsulosin	I-Drug
for	O
now	O
.	O
Continued	O
finasteride	I-Drug
.	O
#Reactive	O
airways	O
,	O
?	O
COPD	O
-	O
continued	O
inhalers	O
,	O
no	O
sign	O
of	O
acute	O
exacerbation	O
.	O
.	O
#FEN	O
:	O
cardiac	O
diet	O
.	O
#PPX	O
:	O
--	O
therapeutic	O
INR	O
.	O
FULL	O
CODE	O
Emergency	O
contact	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
(	O
son	O
)	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
48232	O
**	O
]	O
.	O
Transitional	O
issues	O
-	O
close	O
monitoring	O
of	O
volume	O
status	O
with	O
lasix	I-Drug
,	O
HCTZ	I-Drug
,	O
and	O
spironolactone	I-Drug
being	O
held	O
.	O
Restart	O
prn	O
-	O
monitoring	O
of	O
chemistries	O
,	O
INR	O
on	O
[	O
**	O
2183-1-16	O
**	O
]	O
PCP	O
appointment	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
48233	O
**	O
]	O
further	O
discussion	O
about	O
ETOH	O
intake	O
-	O
consider	O
TSH	O
,	O
cortisol	O
should	O
low	O
grade	O
hypotension	O
continue	O
to	O
be	O
an	O
issue	O
Medications	O
on	O
Admission	O
:	O
Albuterol	I-Drug
2	O
puffs	O
q4	O
hours	O
SOB	I-Reason
Carvedilol	I-Drug
3.125	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Finasteride	I-Drug
5	O
mg	O
daily	O
Fluticasone	I-Drug
50mcg	O
per	O
nostril	O
[	O
**	O
Hospital1	O
**	O
]	O
runny	B-Reason
nose	I-Reason
Fluticaseone	I-Drug
110mcg	O
2	O
puffs	O
[	O
**	O
Hospital1	O
**	O
]	O
Furosemide	I-Drug
20	O
mg	O
daily	O
Combivent	I-Drug
2	O
puffs	O
PRB	O
dyspnea	I-Reason
Pravastatin	I-Drug
40	O
mg	O
daily	O
Sildenafil	I-Drug
25	O
mg	O
1/2	O
-	O
1	O
tab	O
PRN	O
Spironolactone	B-Drug
-	I-Drug
HCTZ	I-Drug
25	O
-	O
25	O
mg	O
daily	O
Tamsulosin	I-Drug
0.4	O
mg	O
qHS	O
Valsartan	I-Drug
320	O
mg	O
tab	O
,	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
tab	O
daily	O
Warfarin	I-Drug
4	O
mg	O
QOD	O
,	O
2	O
mg	O
QOD	O
Acetaminophen	I-Drug
650	O
mg	O
TID	O
Discharge	O
Medications	O
:	O
1	O
.	O
albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
dyspnea	I-Reason
.	O
2	O
.	O
carvedilol	I-Drug
3.125	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
finasteride	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
fluticasone	I-Drug
110	O
mcg	O
/	O
actuation	O
Aerosol	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Puff	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
fluticasone	I-Drug
110	O
mcg	O
/	O
actuation	O
Aerosol	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
twice	O
a	O
day	O
.	O
6	O
.	O
Combivent	I-Drug
18	O
-	O
103	O
mcg	O
/	O
actuation	O
Aerosol	O
Sig	O
:	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
Inhalation	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
7	O
.	O
pravastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
8	O
.	O
valsartan	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
warfarin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QOD	O
(	O
)	O
.	O
10	O
.	O
warfarin	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
other	O
day	O
.	O
11	O
.	O
acetaminophen	I-Drug
650	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Laboure	O
Center	O
VNS	O
Discharge	O
Diagnosis	O
:	O
hypotension	O
acute	O
renal	O
failure	O
chronic	O
systolic	O
heart	O
failure	O
atrial	O
fibrillation	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
low	B-Reason
blood	I-Reason
pressure	I-Reason
,	O
fatigue	O
,	O
and	O
kidney	O
injury	O
.	O
Your	O
symptoms	O
were	O
thought	O
to	O
be	O
due	O
to	O
dehydration	O
along	O
with	O
taking	O
your	O
medications	O
for	O
your	O
heart	O
.	O
Your	O
symptoms	O
improved	O
with	O
IV	O
fluids	I-Drug
and	O
stopping	O
some	O
of	O
your	O
heart	O
medications	O
.	O
You	O
did	O
not	O
have	O
any	O
signs	O
of	O
infection	O
.	O
Some	O
of	O
your	O
heart	O
medications	O
will	O
continue	O
to	O
be	O
held	O
upon	O
discharge	O
.	O
However	O
,	O
it	O
will	O
be	O
very	O
important	O
that	O
you	O
follow	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
8499	O
**	O
]	O
and	O
your	O
cardiologist	O
to	O
determine	O
when	O
you	O
may	O
resume	O
these	O
medications	O
.	O
.	O
Medication	O
changes	O
:	O
1	O
.	O
stop	O
lasix	I-Drug
for	O
now	O
2	O
.	O
stop	O
HCTZ	I-Drug
for	O
now	O
3	O
.	O
stop	O
spironolactone	I-Drug
for	O
now	O
4	O
.	O
DECREASE	O
VALSARTAN	I-Drug
TO	O
80MG	O
DAILY	O
,	O
stop	O
your	O
160	O
mg	O
dose	O
5	O
.	O
stop	O
tamsulosin	I-Drug
for	O
now	O
-	O
please	O
be	O
sure	O
to	O
keep	O
your	O
PCP	O
appointment	O
below	O
.	O
You	O
may	O
need	O
to	O
restart	O
some	O
of	O
these	O
medications	O
.	O
.	O
Please	O
take	O
all	O
of	O
your	O
medications	O
as	O
prescribed	O
and	O
follow	O
up	O
with	O
the	O
appointments	O
below	O
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
[	O
**	O
Hospital1	O
7975	O
**	O
]	O
ST	O
HLTH	O
CTR	O
-	O
KCSS	O
When	O
:	O
THURSDAY	O
[	O
**	O
2183-1-16	O
**	O
]	O
at	O
11:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
10134	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
7980	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital1	O
7977	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
,	O
MA	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
OFF	O
CAMPUS	O
Best	O
Parking	O
:	O
Free	O
Parking	O
on	O
Site	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
THURSDAY	O
[	O
**	O
2183-1-23	O
**	O
]	O
at	O
3:20	O
PM	O
With	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
900	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
901	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
[	O
**	O
Hospital1	O
7975	O
**	O
]	O
ST	O
HLTH	O
CTR	O
-	O
KCSS	O
When	O
:	O
FRIDAY	O
[	O
**	O
2183-2-28	O
**	O
]	O
at	O
9:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
10134	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
7980	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital1	O
7977	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
,	O
MA	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
OFF	O
CAMPUS	O
Best	O
Parking	O
:	O
Free	O
Parking	O
on	O
Site	O

Admission	O
Date	O
:	O
[	O
**	O
2119-4-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2119-4-8	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2297	O
**	O
]	O
Chief	O
Complaint	O
:	O
Unresponsive	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Pleurex	O
catheter	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
old	O
woman	O
with	O
PMH	O
of	O
stage	O
IV	O
NSCLC	O
,	O
CVA	O
,	O
and	O
a	O
recurrent	O
malignant	O
right	O
sided	O
pleural	O
effusion	O
who	O
presented	O
after	O
attempted	O
IP	O
procedure	O
on	O
day	O
of	O
admission	O
with	O
altered	O
mental	O
status	O
and	O
an	O
unresponsive	O
episode	O
.	O
Pt	O
was	O
scheduled	O
for	O
outpatient	O
pleuroscopy	O
,	O
pleurodesis	O
,	O
and	O
PleurX	O
Catheter	O
placement	O
today	O
.	O
She	O
was	O
prepped	O
and	O
received	O
75Mcg	O
of	O
Fentanyl	I-Drug
and	O
1.5	O
mg	O
total	O
of	O
Midazolam	I-Drug
.	O
An	O
incision	O
was	O
made	O
,	O
but	O
at	O
that	O
time	O
the	O
patient	O
became	O
unresponsive	O
with	O
bradycardia	O
into	O
the	O
30s	O
and	O
hypotension	O
with	O
SBPs	O
in	O
the	O
60s	O
.	O
She	O
required	O
ventilatory	B-Reason
support	I-Reason
with	O
a	O
BVM	O
briefly	O
,	O
got	O
Atropine	I-Drug
0.5	O
mg	O
x	O
2	O
and	O
the	O
procedure	O
was	O
aborted	O
(	O
and	O
small	O
incision	O
sutured	O
closed	O
)	O
.	O
She	O
was	O
given	O
flumazenil	I-Drug
0.5	O
mg	O
as	O
well	O
as	O
narcan	I-Drug
0.4	O
mg	O
with	O
minimal	O
response	O
.	O
She	O
was	O
not	O
responding	O
verbally	O
/	O
appropriately	O
.	O
She	O
was	O
withdrawing	O
to	O
painful	O
stimuli	O
and	O
moving	O
all	O
extremities	O
.	O
At	O
the	O
time	O
of	O
this	O
incident	O
,	O
an	O
EKG	O
was	O
performed	O
that	O
showed	O
atrial	O
fibrillation	O
and	O
ST	O
depressions	O
(	O
reportedly	O
in	O
V2	O
-	O
V3	O
)	O
.	O
Repeat	O
EKG	O
30	O
minutes	O
later	O
showed	O
normalization	O
of	O
these	O
abnormalities	O
.	O
Prior	O
to	O
the	O
procedure	O
she	O
reported	O
cough	O
,	O
dyspnea	O
,	O
and	O
weight	O
loss	O
.	O
She	O
specifically	O
denied	O
orthopnea	O
,	O
PND	O
or	O
leg	O
edema	O
.	O
Of	O
note	O
,	O
she	O
has	O
had	O
thoracentesis	O
x	O
2	O
on	O
[	O
**	O
1	O
-	O
26	O
**	O
]	O
and	O
[	O
**	O
2	O
-	O
27	O
**	O
]	O
draining	O
850	O
ml	O
and	O
1300	O
ml	O
respectively	O
.	O
Post	O
procedure	O
her	O
dyspnea	O
improved	O
and	O
there	O
was	O
complete	O
lung	O
expansion	O
.	O
On	O
the	O
floor	O
,	O
the	O
patient	O
is	O
responsive	O
to	O
painful	O
stimuli	O
only	O
.	O
Review	O
of	O
systems	O
:	O
Unable	O
to	O
obtain	O
due	O
to	O
patient	O
's	O
mental	O
status	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
CVA	O
2	O
.	O
Right	O
-	O
sided	O
breast	O
cancer	O
:	O
This	O
was	O
about	O
30	O
years	O
ago	O
and	O
treated	O
with	O
mastectomy	O
and	O
radiation	O
therapy	O
.	O
3	O
.	O
Type	O
2	O
diabetes	O
:	O
Diet	O
controlled	O
.	O
4	O
.	O
Hypertension	O
.	O
5	O
.	O
Atrial	O
fibrillation	O
.	O
6	O
.	O
Gout	O
.	O
7	O
.	O
Hypothyroidism	O
.	O
8	O
.	O
Osteopenia	O
/	O
osteoporosis	O
.	O
9	O
.	O
Glaucoma	O
.	O
10	O
.	O
NSCLC	O
as	O
below	O
:	O
-	O
[	O
**	O
10	O
-	O
7	O
**	O
]	O
CXR	O
for	O
cough	O
showed	O
R	O
-	O
sided	O
opacity	O
,	O
chest	O
CT	O
which	O
showed	O
a	O
nodular	O
lesions	O
in	O
superior	O
RLL	O
and	O
mod	O
/	O
large	O
R	O
pleural	O
effusion	O
-	O
[	O
**	O
2118-11-2	O
**	O
]	O
pleural	O
effusion	O
tapped	O
and	O
negative	O
for	O
malignancy	O
Pt	O
then	O
developed	O
hoarseness	O
and	O
was	O
seen	O
by	O
ENT	O
[	O
**	O
1	O
-	O
8	O
**	O
]	O
and	O
determined	O
to	O
have	O
recurrent	O
nerve	O
paralysis	O
,	O
highly	O
concerning	O
for	O
malignancy	O
.	O
-	O
[	O
**	O
2119-1-13	O
**	O
]	O
repeat	O
imaging	O
disclosed	O
a	O
smaller	O
LUL	O
nodule	O
and	O
paratracheal	O
mass	O
,	O
likely	O
a	O
lymph	O
node	O
conglomerage	O
-	O
[	O
**	O
2119-1-26	O
**	O
]	O
EBUS	O
with	O
FNA	O
sampled	O
paratracheal	O
mass	O
and	O
lymph	O
node	O
,	O
both	O
positive	O
for	O
poorly	O
differentiated	O
adenocarcinoma	O
.	O
Brochial	O
brushings	O
of	O
the	O
right	O
lobar	O
bronchi	O
were	O
atypical	O
-	O
[	O
**	O
2119-2-9	O
**	O
]	O
:	O
C1D1	O
09	O
-	O
018	O
:	O
irreversible	O
EGFR	O
/	O
ErbB2	O
TKI	O
PF	O
-	O
[	O
**	O
Numeric	O
Identifier	O
108198	O
**	O
]	O
Social	O
History	O
:	O
The	O
patient	O
currently	O
lives	O
with	O
her	O
family	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
2312	O
**	O
]	O
,	O
she	O
has	O
VNA	O
2X	O
/	O
week	O
.	O
She	O
is	O
originally	O
from	O
the	O
[	O
**	O
Country	O
31115	O
**	O
]	O
but	O
moved	O
here	O
in	O
[	O
**	O
2081	O
**	O
]	O
and	O
has	O
not	O
been	O
back	O
there	O
recently	O
.	O
She	O
previously	O
lived	O
in	O
[	O
**	O
Location	O
86	O
**	O
]	O
and	O
then	O
moved	O
to	O
[	O
**	O
State	O
108	O
**	O
]	O
and	O
has	O
now	O
been	O
back	O
up	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
for	O
the	O
last	O
2	O
years	O
.	O
She	O
denies	O
any	O
other	O
areas	O
of	O
residence	O
.	O
She	O
denies	O
any	O
alcohol	O
use	O
and	O
she	O
denies	O
any	O
past	O
or	O
present	O
cigarette	O
smoking	O
.	O
However	O
,	O
her	O
husband	O
was	O
a	O
significant	O
smoker	O
.	O
The	O
patient	O
previously	O
worked	O
for	O
the	O
Red	O
Cross	O
and	O
had	O
no	O
occupational	O
exposures	O
.	O
Family	O
very	O
involved	O
in	O
her	O
care	O
.	O
Family	O
History	O
:	O
No	O
family	O
history	O
of	O
lung	O
disease	O
.	O
However	O
,	O
note	O
that	O
her	O
husband	O
who	O
is	O
a	O
long	O
time	O
smoker	O
died	O
of	O
lung	O
cancer	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
95.6	O
(	O
axillary	O
)	O
BP	O
:	O
97/62	O
P	O
:	O
62	O
R	O
:	O
20	O
O2	O
:	O
99	O
%	O
2	O
L	O
General	O
:	O
Withdraws	O
to	O
painful	O
stimuli	O
only	O
,	O
no	O
posturing	O
.	O
HEENT	O
:	O
No	O
evidence	O
of	O
trauma	O
.	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
,	O
PERRL	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
limited	O
air	O
movement	O
at	O
apices	O
only	O
(	O
decreased	O
breath	O
sounds	O
bilateral	O
bases	O
)	O
CV	O
:	O
irregularly	O
irregular	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
withdraws	O
all	O
extremities	O
to	O
painful	O
stimuli	O
only	O
,	O
1	O
+	O
LE	O
reflexes	O
,	O
toes	O
downgoing	O
bilaterally	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2119-4-6	O
**	O
]	O
09:08	O
PM	O
TYPE	O
-	O
ART	O
TEMP	O
-	O
35.0	O
PO2	O
-	O
127	O
*	O
PCO2	O
-	O
65	O
*	O
PH	O
-	O
7.40	O
TOTAL	O
CO2	O
-	O
42	O
*	O
BASE	O
XS	O
-	O
12	O
INTUBATED	O
-	O
NOT	O
INTUBA	O
[	O
**	O
2119-4-6	O
**	O
]	O
09:08	O
PM	O
GLUCOSE	O
-	O
157	O
*	O
LACTATE	O
-	O
0.7	O
K	O
+	O
-	O
3.8	O
[	O
**	O
2119-4-6	O
**	O
]	O
09:08	O
PM	O
freeCa	O
-	O
1.13	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
GLUCOSE	O
-	O
219	O
*	O
UREA	O
N	O
-	O
50	O
*	O
CREAT	O
-	O
1.1	O
SODIUM	O
-	O
139	O
CHLORIDE	O
-	O
92	O
*	O
TOTAL	O
CO2	O
-	O
41	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
79	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
CALCIUM	O
-	O
8.9	O
PHOSPHATE	O
-	O
5.2	O
*	O
MAGNESIUM	O
-	O
2.4	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
TSH	O
-	O
7.8	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
FREE	O
T4	O
-	O
1.6	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
WBC	O
-	O
8.2	O
RBC	O
-	O
3.71	O
*	O
HGB	O
-	O
11.7	O
*	O
HCT	O
-	O
37.8	O
MCV	O
-	O
102	O
*	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
30.9	O
*	O
RDW	O
-	O
16.4	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:06	O
PM	O
PLT	O
COUNT	O
-	O
249	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:04	O
PM	O
TYPE	O
-	O
ART	O
RATES	O
-	O
/	O
18	O
PO2	O
-	O
413	O
*	O
PCO2	O
-	O
78	O
*	O
PH	O
-	O
7.34	O
*	O
TOTAL	O
CO2	O
-	O
44	O
*	O
BASE	O
XS	O
-	O
12	O
INTUBATED	O
-	O
NOT	O
INTUBA	O
VENT	O
-	O
SPONTANEOU	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:04	O
PM	O
GLUCOSE	O
-	O
266	O
*	O
LACTATE	O
-	O
2.3	O
*	O
NA	O
+	O
-	O
137	O
K	O
+	O
-	O
3.6	O
CL	O
--	O
85	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:04	O
PM	O
HGB	O
-	O
12.4	O
calcHCT	O
-	O
37	O
O2	O
SAT	O
-	O
98	O
[	O
**	O
2119-4-6	O
**	O
]	O
05:04	O
PM	O
freeCa	O
-	O
1.11	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
GLUCOSE	O
-	O
151	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
UREA	O
N	O
-	O
52	O
*	O
CREAT	O
-	O
1.1	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
3.2	O
*	O
CHLORIDE	O
-	O
90	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
27	O
AST	O
(	O
SGOT	O
)	O
-	O
32	O
LD	O
(	O
LDH	O
)	O
-	O
201	O
ALK	O
PHOS	O
-	O
86	O
TOT	O
BILI	O
-	O
0.7	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
TOT	O
PROT	O
-	O
6.7	O
ALBUMIN	O
-	O
3.7	O
GLOBULIN	O
-	O
3.0	O
CALCIUM	O
-	O
9.4	O
PHOSPHATE	O
-	O
3.7	O
MAGNESIUM	O
-	O
2.3	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
WBC	O
-	O
8.1	O
RBC	O
-	O
3.61	O
*	O
HGB	O
-	O
11.8	O
*	O
HCT	O
-	O
36.9	O
MCV	O
-	O
102	O
*	O
MCH	O
-	O
32.8	O
*	O
MCHC	O
-	O
32.1	O
RDW	O
-	O
15.9	O
*	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
NEUTS	O
-	O
71.9	O
*	O
LYMPHS	O
-	O
18.3	O
MONOS	O
-	O
6.2	O
EOS	O
-	O
3.3	O
BASOS	O
-	O
0.4	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
PLT	O
COUNT	O
-	O
217	O
[	O
**	O
2119-4-6	O
**	O
]	O
11:20	O
AM	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
24.6	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2119-4-8	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
WBC	O
-	O
8.7	O
RBC	O
-	O
3.54	O
*	O
Hgb	O
-	O
11.0	O
*	O
Hct	O
-	O
35.1	O
*	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
31.1	O
MCHC	O
-	O
31.3	O
RDW	O
-	O
17.3	O
*	O
Plt	O
Ct	O
-	O
183	O
[	O
**	O
2119-4-8	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
Glucose	O
-	O
139	O
*	O
UreaN	O
-	O
60	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
144	O
K	O
-	O
4.4	O
Cl	O
-	O
100	O
HCO3	O
-	O
39	O
*	O
AnGap	O
-	O
9	O
.	O
CXR	O
(	O
portable	O
)	O
:	O
[	O
**	O
2119-4-6	O
**	O
]	O
CHEST	O
,	O
AP	O
:	O
Lung	O
volumes	O
are	O
low	O
,	O
with	O
increased	O
left	O
lower	O
lobe	O
atelectasis	O
and	O
a	O
tiny	O
left	O
apical	O
pneumothorax	O
.	O
Right	O
lower	O
lobe	O
atelectasis	O
and	O
subpulmonic	O
effusion	O
persist	O
.	O
Hazy	O
opacity	O
in	O
the	O
right	O
upper	O
lobe	O
corresponds	O
to	O
known	O
primary	O
tumor	O
.	O
Left	O
upper	O
lobe	O
nodule	O
is	O
vaguely	O
seen	O
overlying	O
the	O
second	O
anterior	O
and	O
fourth	O
posterior	O
ribs	O
.	O
Mild	O
-	O
to	O
-	O
moderate	O
cardiomegaly	O
and	O
aortic	O
tortuosity	O
persist	O
.	O
The	O
stomach	O
is	O
markedly	O
distended	O
,	O
with	O
PEG	O
tube	O
in	O
place	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Bibasilar	O
atelectasis	O
,	O
tiny	O
left	O
pneumothorax	O
.	O
2	O
.	O
Distended	O
stomach	O
,	O
please	O
decompress	O
through	O
PEG	O
tube	O
.	O
CT	O
Head	O
w	O
/	O
o	O
Contrast	O
[	O
**	O
2119-4-6	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
process	O
.	O
2	O
.	O
1.4	O
cm	O
calcified	O
left	O
paraclinoid	O
lesion	O
most	O
consistent	O
with	O
meningioma	O
without	O
associated	O
edema	O
.	O
3	O
.	O
Areas	O
of	O
hypodensity	O
within	O
the	O
right	O
parietal	O
and	O
right	O
frontal	O
regions	O
corresponding	O
to	O
FLAIR	O
abnormalities	O
on	O
prior	O
MRI	O
and	O
consistent	O
with	O
remote	O
infarcts	O
.	O
.	O
MRI	O
Head	O
[	O
**	O
2119-4-7	O
**	O
]	O
:	O
No	O
acute	O
pathology	O
(	O
prelim	O
)	O
.	O
CXR	O
[	O
**	O
2119-4-7	O
**	O
]	O
(	O
post	O
Pleurex	O
)	O
:	O
No	O
evidence	O
of	O
residual	O
pneumothorax	O
.	O
Brief	O
Hospital	O
Course	O
:	O
#	O
Altered	B-Ade
Mental	I-Ade
Status	I-Ade
:	O
The	O
patient	O
's	O
unresponsiveness	O
/	O
altered	O
mental	O
status	O
was	O
possibly	O
due	O
to	O
versed	I-Drug
/	O
fentanyl	I-Drug
with	O
slow	O
metabolism	O
,	O
but	O
also	O
possibly	O
due	O
to	O
hypoxia	O
and	O
resultant	O
CNS	O
insult	O
that	O
occurred	O
as	O
a	O
result	O
of	O
her	O
hypoperfusion	O
with	O
low	O
HR	O
and	O
blood	O
pressure	O
.	O
Alternative	O
explanations	O
include	O
CVA	O
and	O
other	O
toxic	O
/	O
metabolic	O
abnormalities	O
.	O
Glucose	O
level	O
was	O
normal	O
.	O
As	O
this	O
change	O
in	O
level	O
of	O
consciousness	O
was	O
so	O
acute	O
,	O
less	O
likely	O
due	O
to	O
infection	O
/	O
sepsis	O
.	O
Patient	O
also	O
with	O
long	O
history	O
of	O
atrial	O
fibrillation	O
,	O
not	O
currently	O
on	O
anticoagulation	I-Drug
with	O
an	O
INR	O
of	O
1.2	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
SICU	O
under	O
the	O
care	O
of	O
the	O
MICU	O
team	O
.	O
Her	O
airway	O
was	O
monitored	O
closely	O
and	O
she	O
had	O
a	O
repeat	O
ABG	O
that	O
showed	O
7.4	O
/	O
65/127	O
.	O
She	O
did	O
not	O
receive	O
any	O
further	O
opiates	I-Drug
/	O
benzodiazepines	I-Drug
.	O
Her	O
mental	O
status	O
was	O
waxing	O
and	O
[	O
**	O
Doctor	O
Last	O
Name	O
688	O
**	O
]	O
,	O
and	O
she	O
would	O
have	O
periods	O
throughout	O
the	O
night	O
where	O
she	O
would	O
open	O
her	O
eyes	O
and	O
follow	O
simple	O
commands	O
(	O
squeeze	O
hands	O
)	O
.	O
Otherwise	O
,	O
she	O
was	O
responsive	O
only	O
to	O
painful	O
stimuli	O
.	O
An	O
MRI	O
of	O
her	O
brain	O
was	O
performed	O
due	O
to	O
concern	O
for	O
embolic	O
CVA	O
which	O
showed	O
no	O
acute	O
pathology	O
.	O
She	O
did	O
receive	O
flumazenil	I-Drug
0.5	O
mg	O
again	O
along	O
with	O
narcan	I-Drug
0.4	O
mg	O
.	O
Approximately	O
one	O
hour	O
after	O
the	O
administration	O
of	O
these	O
medicines	O
,	O
the	O
patient	O
was	O
fully	O
awake	O
,	O
alert	O
and	O
oriented	O
.	O
On	O
the	O
day	O
following	O
admission	O
,	O
she	O
was	O
able	O
to	O
converse	O
with	O
her	O
family	O
(	O
present	O
at	O
bedside	O
)	O
although	O
she	O
frequently	O
reported	O
feeling	O
"	O
tired	O
.	O
"	O
She	O
later	O
tolerated	O
her	O
IP	O
procedure	O
well	O
and	O
was	O
alert	O
on	O
discharge	O
.	O
#	O
Hypotension	I-Reason
:	O
When	O
the	O
patient	O
first	O
arrived	O
to	O
the	O
ICU	O
,	O
her	O
blood	O
pressures	O
were	O
in	O
the	O
high	O
90s	O
and	O
low	O
100s	O
systolic	O
.	O
Over	O
the	O
subsequent	O
several	O
hours	O
,	O
her	O
blood	O
pressures	O
drifted	O
down	O
to	O
a	O
nadir	O
of	O
70s	O
systolic	O
.	O
She	O
received	O
2	O
IV	O
fluid	I-Drug
boluses	O
of	O
500	O
ml	O
.	O
She	O
showed	O
improvement	O
in	O
her	O
blood	O
pressure	O
to	O
90s	O
-	O
100s	O
.	O
A	O
central	O
line	O
set	O
up	O
was	O
at	O
bed	O
side	O
in	O
case	O
pressors	I-Drug
were	O
needed	O
,	O
but	O
her	O
blood	O
pressure	O
remained	O
stable	O
and	O
then	O
increased	O
to	O
120s	O
systolic	O
when	O
she	O
became	O
fully	O
awake	O
.	O
During	O
this	O
time	O
her	O
UOP	O
remained	O
satisfactory	O
,	O
averaging	O
30ml	O
/	O
hour	O
.	O
#	O
EKG	O
changes	O
:	O
The	O
patient	O
had	O
EKG	O
changes	O
during	O
her	O
initial	O
bradycardic	O
/	O
hypotensive	O
episode	O
with	O
new	O
RBBB	O
and	O
minimal	O
ST	O
depressions	O
in	O
V2	O
-	O
V3	O
.	O
A	O
repeat	O
EKG	O
30	O
minutes	O
later	O
showed	O
resolution	O
of	O
these	O
findings	O
and	O
only	O
showed	O
atrial	O
fibrillation	O
with	O
no	O
ST	O
/	O
T	O
wave	O
abnormalities	O
.	O
The	O
patient	O
does	O
not	O
carry	O
the	O
diagnosis	O
of	O
CAD	O
,	O
but	O
is	O
a	O
diabetic	O
and	O
is	O
predisposed	O
to	O
vascular	O
abnormalities	O
.	O
As	O
a	O
result	O
cardiac	O
enzymes	O
were	O
cycled	O
.	O
A	O
second	O
set	O
did	O
show	O
a	O
small	O
increase	O
in	O
troponin	O
T	O
to	O
0.02	O
,	O
but	O
no	O
MB	O
component	O
.	O
Third	O
set	O
of	O
enzymes	O
was	O
negative	O
.	O
#	O
NSCLC	O
with	O
pleural	O
effusion	O
:	O
Patient	O
is	O
now	O
status	O
post	O
2	O
cycles	O
with	O
investigatory	O
drug	O
,	O
now	O
with	O
reaccumulation	O
of	O
pleural	O
effusion	O
.	O
The	O
reaccumulation	O
likely	O
represents	O
progression	O
of	O
tumor	O
.	O
On	O
the	O
day	O
following	O
admission	O
,	O
she	O
was	O
seen	O
by	O
IP	O
and	O
a	O
PleurX	O
catheter	O
was	O
placed	O
at	O
bedside	O
with	O
drainage	O
of	O
1100	O
cc	O
of	O
fluid	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
reported	O
feelling	O
"	O
much	O
better	O
.	O
"	O
F	O
/	O
U	O
chest	O
x-ray	O
showed	O
no	O
PTX	O
.	O
She	O
was	O
called	O
out	O
to	O
the	O
general	O
medical	O
wards	O
after	O
this	O
procedure	O
.	O
She	O
was	O
discharged	O
the	O
following	O
day	O
with	O
no	O
acute	O
issues	O
.	O
#	O
DM	O
2	O
:	O
The	O
patient	O
's	O
diabetes	O
was	O
generally	O
diet	O
controlled	O
,	O
here	O
with	O
glucose	O
range	O
150	O
-	O
250	O
.	O
She	O
was	O
maintained	O
on	O
a	O
RISS	I-Drug
.	O
#	O
Afib	I-Reason
:	O
Atenolol	I-Drug
was	O
discontinued	O
given	O
her	O
hypotension	I-Reason
.	O
Pt	O
's	O
heart	O
rate	O
was	O
stable	O
prior	O
to	O
discharge	O
.	O
#	O
Hypothyroidism	I-Reason
:	O
A	O
TSH	O
was	O
sent	O
and	O
was	O
elevated	O
at	O
7.8	O
,	O
however	O
,	O
a	O
free	O
T4	O
was	O
normal	O
at	O
1.6	O
.	O
Te	O
patient	O
was	O
maintained	O
on	O
her	O
home	O
dose	O
levothyroxine	I-Drug
via	O
PEG	O
daily	O
.	O
#	O
Code	O
status	O
:	O
The	O
patient	O
expressed	O
wishes	O
to	O
be	O
DNR	O
/	O
DNI	O
during	O
this	O
admission	O
.	O
This	O
decision	O
was	O
discussed	O
with	O
her	O
daughter	O
at	O
bedside	O
.	O
The	O
patient	O
was	O
provided	O
with	O
a	O
DNR	O
/	O
DNI	O
form	O
to	O
complete	O
should	O
she	O
require	O
future	O
documentation	O
of	O
this	O
decision	O
.	O
Patient	O
was	O
discharged	O
home	O
with	O
VNA	O
.	O
The	O
family	O
did	O
not	O
want	O
hospice	O
but	O
VNA	O
will	O
be	O
there	O
to	O
assist	O
them	O
and	O
help	O
make	O
the	O
patient	O
comfortable	O
.	O
Palliative	O
care	O
was	O
also	O
consulted	O
this	O
admission	O
to	O
help	O
with	O
planning	O
.	O
Medications	O
on	O
Admission	O
:	O
ALLKARE	O
PROTECTIVE	O
BARRIER	O
WIPES	O
-	O
-	O
use	O
to	O
cleanse	O
area	O
around	O
your	O
feeding	O
tube	O
twice	O
a	O
day	O
or	O
as	O
needed	O
Convatec	O
ALLOPURINOL	I-Drug
-	O
100	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
ATENOLOL	I-Drug
-	O
50	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
COLCHICINE	I-Drug
-	O
0.6	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
as	O
directed	O
take	O
only	O
with	O
gout	B-Reason
flare	I-Reason
.	O
do	O
not	O
take	O
on	O
regular	O
basis	O
FUROSEMIDE	I-Drug
-	O
40	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
as	O
needed	O
for	O
volume	B-Reason
overload	I-Reason
as	O
directed	O
HYDROCHLOROTHIAZIDE	I-Drug
-	O
12.5	O
mg	O
Capsule	O
-	O
1	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
qam	O
for	O
blood	B-Reason
pressure	I-Reason
IPRATROPIUM	B-Drug
-	I-Drug
ALBUTEROL	I-Drug
-	O
0.5	O
mg	O
-	O
2.5	O
mg	O
/	O
3	O
mL	O
Solution	O
for	O
Nebulization	O
-	O
1	O
neb	O
(	O
s	O
)	O
inh	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
wheeze	I-Reason
ICD9	O
:	O
496	O
LEVOTHYROXINE	I-Drug
-	O
75	O
mcg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
SALINE	B-Drug
BULLETS	I-Drug
-	O
-	O
1	O
neb	O
inh	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
wheeze	I-Reason
Use	O
with	O
nebulizer	O
machine	O
TIMOLOL	B-Drug
MALEATE	I-Drug
-	O
0.5	O
%	O
Drops	O
-	O
1	O
drop	O
(	O
s	O
)	O
both	O
eyes	O
twice	O
a	O
day	O
TRAZODONE	I-Drug
-	O
50	O
mg	O
Tablet	O
-	O
1.5	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
at	O
bedtime	O
Dose	O
=	O
75	O
mg	O
nightly	O
Medications	O
-	O
OTC	O
LACTOSE	B-Drug
-	I-Drug
FREE	I-Drug
FOOD	I-Drug
WITH	I-Drug
FIBER	I-Drug
[	O
ISOSOURCE	O
1.5	O
CAL	O
]	O
-	O
Liquid	O
-	O
4	O
can	O
via	O
feeding	O
tube	O
daily	O
Bolus	O
feedings	O
,	O
4	O
cans	O
daily	O
,	O
URGENT	O
delivery	O
please	O
LOPERAMIDE	I-Drug
-	O
2	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q3h	O
as	O
needed	O
for	O
diarrhea	I-Reason
Take	O
after	O
each	O
episode	O
of	O
diarrhea	O
,	O
maximum	O
8	O
pills	O
per	O
day	O
.	O
NUTRITIONAL	B-Drug
SUPPLEMENT	I-Drug
-	I-Drug
FIBER	I-Drug
[	O
FIBERSOURCE	O
HN	O
]	O
-	O
Liquid	O
-	O
50	O
mL	O
PEG	O
50	O
mL	O
/	O
hour	O
continuous	O
over	O
24	O
hours	O
modify	O
as	O
directed	O
by	O
Nutritionist	O
Discharge	O
Medications	O
:	O
1	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Levothyroxine	I-Drug
75	O
mcg	O
Tablet	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Ipratropium	B-Drug
-	I-Drug
Albuterol	I-Drug
0.5	O
-	O
2.5	O
mg	O
/	O
3	O
mL	O
Solution	O
for	O
Nebulization	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
four	O
times	O
a	O
day	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
5	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
1.5	O
Tablets	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
6	O
.	O
Loperamide	I-Drug
2	O
mg	O
Tablet	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
7	O
.	O
Nutritional	B-Drug
Supplement	I-Drug
-	I-Drug
Fiber	I-Drug
Liquid	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
Fifty	O
(	O
50	O
)	O
ml	O
/	O
hr	O
PO	O
once	O
a	O
day	O
:	O
ASDIR	O
BY	O
NUTRITIONIST	O
.	O
8	O
.	O
Morphine	B-Drug
Concentrate	I-Drug
20	O
mg	O
/	O
mL	O
Solution	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
5	O
-	O
10	O
mg	O
PO	O
q	O
15	O
min	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
20	O
ml	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Allopurinol	I-Drug
100	O
mg	O
Tablet	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
:	O
Five	O
(	O
5	O
)	O
ml	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
150	O
ml	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Caregroup	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
(	O
1	O
)	O
Unresponsiveness	O
(	O
2	O
)	O
Hypotension	O
Secondary	O
:	O
(	O
1	O
)	O
Non-Small	O
cell	O
lung	O
cancer	O
(	O
2	O
)	O
Diabetes	O
Mellitus	O
(	O
3	O
)	O
CVA	O
(	O
4	O
)	O
Hypothyroidism	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
108197	O
**	O
]	O
,	O
You	O
were	O
seen	O
and	O
evaluated	O
for	O
low	O
blood	O
pressure	O
and	O
a	O
period	O
of	O
unresponsiveness	O
in	O
the	O
hospital	O
after	O
a	O
planned	O
pulmonary	O
procedure	O
.	O
Your	O
unresponsiveness	O
was	O
likely	O
due	O
to	O
the	O
medications	O
you	O
received	O
for	O
sedation	O
in	O
the	O
procedure	O
,	O
and	O
you	O
are	O
probably	O
an	O
individual	O
who	O
breaks	O
down	O
these	O
medicines	O
very	O
slowly	O
.	O
You	O
were	O
monitored	O
closely	O
in	O
the	O
intensive	O
care	O
unit	O
and	O
received	O
fluid	O
resuscitation	O
for	O
your	O
low	O
blood	O
pressure	O
.	O
You	O
also	O
underwent	O
the	O
planned	O
procedure	O
,	O
which	O
involved	O
placing	O
a	O
tube	O
in	O
your	O
chest	O
to	O
drain	O
the	O
fluid	O
.	O
You	O
tolerated	O
the	O
procedure	O
well	O
.	O
As	O
you	O
may	O
be	O
aware	O
,	O
you	O
had	O
a	O
discussion	O
with	O
our	O
palliative	O
care	O
team	O
,	O
and	O
decided	O
that	O
you	O
did	O
not	O
want	O
to	O
be	O
recussitated	O
.	O
You	O
also	O
indicated	O
that	O
your	O
goals	O
of	O
care	O
were	O
geared	O
towards	O
comfort	O
,	O
but	O
did	O
not	O
want	O
to	O
be	O
set	O
up	O
with	O
home	O
hospice	O
care	O
.	O
We	O
made	O
the	O
following	O
changes	O
to	O
your	O
medication	O
regimen	O
:	O
We	O
stopped	O
you	O
blood	O
pressure	O
medications	O
,	O
including	O
atenolol	I-Drug
and	O
hydrochlorothiazide	I-Drug
,	O
since	O
you	O
had	O
low	O
blood	O
pressure	O
.	O
Should	O
your	O
blood	O
pressure	O
at	O
home	O
be	O
elevated	O
,	O
and	O
should	O
you	O
choose	O
to	O
treat	O
this	O
condition	O
,	O
you	O
may	O
contact	O
your	O
regular	O
doctor	O
to	O
restart	O
these	O
medications	O
.	O
We	O
also	O
are	O
giving	O
you	O
medication	O
in	O
case	O
you	O
develop	O
constipation	I-Reason
,	O
i.e.	O
loperamide	I-Drug
,	O
or	O
diarrhea	I-Reason
,	O
i.e.	O
colace	I-Drug
,	O
senna	I-Drug
,	O
bisacodyl	I-Drug
;	O
all	O
of	O
which	O
may	O
be	O
taken	O
on	O
an	O
as	O
needed	O
basis	O
.	O
Finally	O
we	O
are	O
giving	O
you	O
morphine	I-Drug
,	O
to	O
take	O
sublingually	O
,	O
in	O
case	O
you	O
have	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
pain	I-Reason
.	O
It	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
M.D.	O
Date	O
/	O
Time	O
:[	O
**	O
2119-4-13	O
**	O
]	O
11:20	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
251	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
252	O
**	O
]	O
,	O
M.D.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
253	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2119-5-31	O
**	O
]	O
10:00	O
Completed	O
by	O
:[	O
**	O
2119-4-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2108-11-12	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2108-11-20	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2042-12-3	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Lisinopril	I-Drug
/	O
Diovan	I-Drug
/	O
Opioid	B-Drug
Analgesics	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1505	O
**	O
]	O
Chief	O
Complaint	O
:	O
Coronary	O
artery	O
disease	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Cardiac	O
Catherization	O
[	O
**	O
2108-11-12	O
**	O
]	O
Coronary	O
Artery	O
Bypass	O
Graft	O
x4	O
(	O
left	O
internal	O
mammary	O
artery	O
>	O
left	O
anterior	O
descending	O
,	O
saphenous	O
vein	O
graft	O
>	O
diagonal	O
,	O
saphenous	O
vein	O
graft	O
>	O
obtuse	O
marginal	O
,	O
saphenous	O
vein	O
graft	O
>	O
posterior	O
descending	O
artery	O
)	O
[	O
**	O
2108-11-16	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
65	O
F	O
with	O
HTN	O
,	O
+	O
FH	O
of	O
early	O
CAD	O
,	O
+	O
smoker	O
and	O
little	O
recent	O
medical	O
care	O
transferred	O
from	O
CMI	O
service	O
following	O
cath	O
yesterday	O
.	O
Up	O
until	O
last	O
month	O
,	O
she	O
had	O
had	O
no	O
medical	O
followup	O
.	O
She	O
recently	O
decided	O
to	O
have	O
cataract	O
surgery	O
and	O
the	O
following	O
events	O
occurred	O
as	O
a	O
result	O
of	O
preop	O
workup	O
.	O
She	O
has	O
had	O
at	O
least	O
a	O
two	O
year	O
history	O
of	O
gradually	O
worsening	O
exertional	O
angina	O
and	O
dyspnea	O
on	O
exertion	O
but	O
never	O
sought	O
medical	O
attention	O
.	O
Symptoms	O
also	O
occured	O
with	O
times	O
of	O
emotional	O
stress	O
.	O
She	O
initially	O
attributed	O
her	O
symptoms	O
to	O
stress	O
and	O
anxiety	O
.	O
Over	O
the	O
last	O
couple	O
months	O
,	O
her	O
exertional	O
chest	O
pain	O
sometimes	O
took	O
hours	O
before	O
going	O
away	O
(	O
initially	O
responded	O
quickly	O
to	O
rest	O
)	O
.	O
Symptoms	O
(	O
CP	I-Reason
and	O
dyspnea	O
)	O
also	O
occurring	O
at	O
rest	O
with	O
minor	O
emotional	O
stressors	O
.	O
.	O
She	O
had	O
persantine	I-Drug
MIBI	I-Reason
on	O
[	O
**	O
2108-10-18	O
**	O
]	O
which	O
showed	O
possible	O
mild	O
lateral	O
wall	O
ischemia	O
.	O
She	O
also	O
developed	O
hypertension	B-Reason
to	I-Reason
210/120	O
during	O
stress	O
and	O
required	O
presentation	O
to	O
OSH	O
ED	O
.	O
She	O
was	O
started	O
on	O
an	O
antihypertensive	I-Drug
regimen	O
with	O
prn	O
SLNTG	I-Drug
.	O
In	O
the	O
two	O
weeks	O
PTA	O
she	O
has	O
taken	O
at	O
least	O
5	O
per	O
day	O
.	O
.	O
She	O
was	O
admitted	O
for	O
cath	O
yesterday	O
.	O
Found	O
to	O
have	O
99	O
%	O
LCx	O
lesion	O
that	O
could	O
not	O
be	O
stented	O
.	O
Also	O
had	O
disease	O
of	O
RCA	O
,	O
LAD	O
(	O
see	O
below	O
)	O
.	O
Got	O
Plavix	I-Drug
600	O
x	O
1	O
pre	O
cath	O
.	O
Cardiac	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
consulted	O
;	O
plan	O
for	O
CABG	O
after	O
Plavix	I-Drug
washout	O
.	O
.	O
Following	O
cath	O
started	O
on	O
heparin	I-Drug
gtt	O
(	O
since	O
continued	O
mild	O
CP	O
and	O
ST	B-Reason
depressions	I-Reason
/	I-Reason
TWI	I-Reason
in	I-Reason
lateral	I-Reason
leads	I-Reason
)	O
.	O
Also	O
has	O
been	O
on	O
nitro	I-Drug
gtt	O
for	O
CP	I-Reason
.	O
Reports	O
CP	O
during	O
cardiac	O
cath	O
;	O
following	O
this	O
has	O
had	O
intermittent	O
0.5	O
-	O
1/10	O
CP	O
with	O
one	O
increase	O
to	O
[	O
**	O
8	O
-	O
7	O
**	O
]	O
last	O
night	O
,	O
responsive	O
to	O
increase	O
in	O
nitro	I-Drug
gtt	O
.	O
Reports	O
severe	I-Reason
anxiety	O
,	O
relieved	O
by	O
benzos	I-Drug
.	O
.	O
On	O
review	O
of	O
systems	O
,	O
she	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
All	O
of	O
the	O
other	O
review	O
of	O
systems	O
were	O
negative	O
.	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
absence	O
of	O
paroxysmal	O
nocturnal	O
dyspnea	O
,	O
orthopnea	O
,	O
ankle	O
edema	O
,	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
HTN	O
-	O
Anxiety	O
with	O
panic	O
attacks	O
-	O
Depression	O
-	O
Discoid	O
lupus	O
(	O
diagnosed	O
by	O
biopsy	O
of	O
nonhealing	O
ulcers	O
15	O
yrs	O
ago	O
)	O
,	O
no	O
treatment	O
or	O
other	O
known	O
manifestations	O
of	O
SLE	O
-	O
TMJ	O
-	O
Cataracts	O
-	O
s	O
/	O
p	O
ovarian	O
cyst	O
removal	O
-	O
s	O
/	O
p	O
tonsillectomy	O
.	O
Cardiac	O
Risk	O
Factors	O
:	O
(	O
-	O
)	O
Diabetes	O
,	O
(	O
-	O
)	O
Dyslipidemia	O
,	O
(	O
+	O
)	O
Hypertension	O
.	O
Cardiac	O
History	O
:	O
None	O
previously	O
known	O
Social	O
History	O
:	O
Social	O
history	O
is	O
significant	O
for	O
the	O
current	O
tobacco	O
use	O
(	O
1	O
to	O
1-1/2	O
PPD	O
x	O
50	O
yrs	O
)	O
.	O
There	O
is	O
no	O
history	O
of	O
alcohol	O
abuse	O
.	O
Family	O
History	O
:	O
There	O
is	O
significant	O
family	O
history	O
of	O
premature	O
coronary	O
artery	O
disease	O
.	O
Sister	O
with	O
MI	O
at	O
32	O
and	O
CABG	O
at	O
34	O
;	O
other	O
sister	O
with	O
MI	O
at	O
48	O
and	O
cardiac	O
arrest	O
;	O
other	O
sister	O
with	O
hypertension	O
and	O
died	O
at	O
59	O
during	O
stress	O
test	O
.	O
Father	O
with	O
fatal	O
MI	O
at	O
56	O
.	O
Physical	O
Exam	O
:	O
VS	O
-	O
T	O
98.6	O
;	O
BP	O
99/63	O
(	O
range	O
99	O
-	O
133	O
)	O
;	O
P	O
82	O
(	O
range	O
66	O
-	O
82	O
)	O
;	O
R22	O
;	O
95	O
-	O
97	O
%	O
RA	O
Gen	O
:	O
WDWN	O
middle	O
aged	O
female	O
in	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Appears	O
slightly	O
anxious	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
Neck	O
:	O
Supple	O
with	O
no	O
noted	O
JVP	O
elevation	O
.	O
No	O
carotid	O
bruits	O
.	O
CV	O
:	O
RRR	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
No	O
thrills	O
,	O
lifts	O
.	O
No	O
S3	O
or	O
S4	O
.	O
Chest	O
:	O
No	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
CTAB	O
,	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
Abd	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
Ext	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
R	O
groin	O
with	O
moderate	O
ecchymoses	O
,	O
slightly	O
firm	O
over	O
pubis	O
.	O
No	O
active	O
ooze	O
or	O
obvious	O
hematoma	O
.	O
Skin	O
:	O
No	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
scars	O
,	O
or	O
xanthomas	O
.	O
.	O
Pulses	O
:	O
Right	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Left	O
:	O
Carotid	O
2	O
+	O
Femoral	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Pertinent	O
Results	O
:	O
Initial	O
EKG	O
(	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
AM	O
)	O
demonstrated	O
NSR	O
at	O
97	O
,	O
normal	O
axis	O
/	O
intervals	O
,	O
ST	O
depressions	O
V4	O
-	O
V6	O
,	O
I	O
;	O
TWI	O
aVL	O
.	O
ECG	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
AM	O
(	O
during	O
CP	O
)	O
also	O
with	O
NSR	O
at	O
76	O
,	O
lateral	O
ST	O
depressions	O
and	O
TWI	O
(	O
V5	O
,	O
V6	O
,	O
I	O
,	O
aVL	O
)	O
.	O
.	O
2D	O
-	O
ECHOCARDIOGRAM	O
performed	O
on	O
[	O
**	O
2108-11-13	O
**	O
]	O
demonstrated	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
hyperdynamic	O
(	O
EF	O
>	O
75	O
%	O
)	O
.	O
There	O
is	O
an	O
abnormal	O
systolic	O
flow	O
contour	O
at	O
rest	O
(	O
likely	O
due	O
to	O
a	O
hyperdynamic	O
LV	O
function	O
)	O
.	O
.	O
ETT	O
performed	O
on	O
[	O
**	O
2108-10-18	O
**	O
]	O
demonstrated	O
:	O
+	O
chest	O
and	O
jaw	O
pain	O
with	O
hypertension	O
to	O
210/120	O
;	O
imaging	O
showing	O
?	O
mild	O
lateral	O
wall	O
ischemia	O
vs.	O
artifact	O
.	O
.	O
CARDIAC	O
CATH	O
performed	O
on	O
[	O
**	O
2108-11-12	O
**	O
]	O
demonstrated	O
:	O
99	O
%	O
mid	O
LCx	O
lesion	O
(	O
failed	O
attempt	O
to	O
stent	O
)	O
,	O
100	O
%	O
OM1	O
and	O
90	O
%	O
OM2	O
;	O
50	O
%	O
mid	O
LAD	O
and	O
80	O
%	O
D1	O
(	O
also	O
aneurysmal	O
)	O
;	O
60	O
%	O
mid	O
RCA	O
.	O
Patent	O
renals	O
.	O
3	O
cm	O
infrarenal	O
AAA	O
.	O
.	O
[	O
**	O
2108-11-19	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
WBC	O
-	O
9.1	O
RBC	O
-	O
2.93	O
*	O
Hgb	O
-	O
9.4	O
*	O
Hct	O
-	O
27.3	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
32.1	O
*	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
14.3	O
Plt	O
Ct	O
-	O
311	O
[	O
**	O
2108-11-18	O
**	O
]	O
05:30	O
AM	O
BLOOD	O
WBC	O
-	O
11.3	O
*	O
RBC	O
-	O
2.69	O
*	O
Hgb	O
-	O
8.9	O
*	O
Hct	O
-	O
25.2	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
33.1	O
*	O
MCHC	O
-	O
35.4	O
*	O
RDW	O
-	O
14.0	O
Plt	O
Ct	O
-	O
234	O
[	O
**	O
2108-11-12	O
**	O
]	O
12:13	O
PM	O
BLOOD	O
WBC	O
-	O
7.4	O
RBC	O
-	O
3.77	O
*	O
Hgb	O
-	O
11.7	O
*	O
Hct	O
-	O
34.1	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
31.1	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
13.7	O
Plt	O
Ct	O
-	O
342	O
[	O
**	O
2108-11-19	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
311	O
[	O
**	O
2108-11-12	O
**	O
]	O
12:13	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
342	O
[	O
**	O
2108-11-12	O
**	O
]	O
12:13	O
PM	O
BLOOD	O
PT	O
-	O
14.1	O
*	O
PTT	O
-	O
150	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2108-11-19	O
**	O
]	O
11:05	O
AM	O
BLOOD	O
Glucose	O
-	O
107	O
*	O
UreaN	O
-	O
17	O
Creat	O
-	O
1.1	O
Na	O
-	O
140	O
K	O
-	O
4.2	O
Cl	O
-	O
105	O
HCO3	O
-	O
28	O
AnGap	O
-	O
11	O
[	O
**	O
2108-11-12	O
**	O
]	O
12:13	O
PM	O
BLOOD	O
Glucose	O
-	O
142	O
*	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.9	O
Na	O
-	O
135	O
K	O
-	O
2.8	O
*	O
Cl	O
-	O
99	O
HCO3	O
-	O
25	O
AnGap	O
-	O
14	O
[	O
**	O
2108-11-12	O
**	O
]	O
12:13	O
PM	O
BLOOD	O
ALT	O
-	O
19	O
AST	O
-	O
18	O
AlkPhos	O
-	O
80	O
TotBili	O
-	O
0.4	O
CHEST	O
(	O
PA	O
&	O
LAT	O
)	O
[	O
**	O
2108-11-20	O
**	O
]	O
12:21	O
PM	O
FINDINGS	O
:	O
In	O
comparison	O
with	O
study	O
of	O
[	O
**	O
11	O
-	O
18	O
**	O
]	O
,	O
the	O
small	O
apical	O
pneumothorax	O
appears	O
to	O
be	O
even	O
less	O
than	O
on	O
the	O
previous	O
study	O
.	O
Brief	O
Hospital	O
Course	O
:	O
She	O
was	O
taken	O
to	O
the	O
operating	O
room	O
on	O
[	O
**	O
11	O
-	O
16	O
**	O
]	O
where	O
she	O
underwent	O
a	O
CABG	O
x4	O
.	O
She	O
was	O
transferred	O
to	O
the	O
ICU	O
in	O
critical	O
but	O
stable	O
condition	O
.	O
She	O
was	O
extuabted	O
later	O
that	O
same	O
day	O
.	O
She	O
was	O
transferred	O
to	O
the	O
floor	O
on	O
POD	O
#	O
1	O
.	O
She	O
developed	O
a	O
small	O
left	O
apical	O
pneumothorax	O
after	O
her	O
chest	O
tubes	O
were	O
pulled	O
that	O
remained	O
stable	O
on	O
subsequent	O
chest	O
xray	O
.	O
She	O
also	O
developed	O
a	O
pruritic	B-Ade
generalized	I-Ade
rash	I-Ade
for	O
which	O
her	O
lasix	I-Drug
was	O
discontinued	O
and	O
she	O
was	O
treated	O
with	O
sarna	I-Drug
lotion	O
.	O
She	O
otherwise	O
did	O
well	O
postoperatively	O
and	O
was	O
ready	O
for	O
discharge	O
home	O
on	O
POD	O
#	O
4	O
.	O
Medications	O
on	O
Admission	O
:	O
Meds	O
at	O
home	O
:	O
hydralazine	I-Drug
25	O
[	O
**	O
Hospital1	O
**	O
]	O
HCTZ	I-Drug
25	O
mg	O
daily	O
Norvasc	I-Drug
10	O
mg	O
daily	O
Oxazepam	B-Drug
10	O
mg	O
TID	O
ASA	I-Drug
325	O
mg	O
(	O
or	O
?	O
650	O
mg	O
)	O
daily	O
Chantix	I-Drug
(	O
prescribed	O
,	O
not	O
started	O
)	O
SLNTG	I-Drug
prn	O
.	O
Currents	O
meds	O
here	O
:	O
Metoprolol	I-Drug
25	O
[	O
**	O
Hospital1	O
**	O
]	O
ASA	I-Drug
325	O
mg	O
daily	O
heparin	I-Drug
gtt	O
NTG	I-Drug
gtt	O
(	O
current	O
at	O
0.3	O
mcg	O
/	O
kg	O
/	O
min	O
)	O
Amlodipine	I-Drug
10	O
mg	O
daily	O
HCTZ	I-Drug
25	O
mg	O
daily	O
Hydralazine	I-Drug
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Diazepam	I-Drug
10	O
mg	O
Q6h	O
Lorazepam	I-Drug
0.5	O
-	O
1	O
prn	O
Nicotine	I-Drug
patch	O
Simethicone	I-Drug
,	O
maalox	I-Drug
Zolpidem	I-Drug
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Camphor	B-Drug
-	I-Drug
Menthol	O
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
itching	I-Reason
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Oxazepam	B-Drug
10	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Simvastatin	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Acetaminophen	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital3	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Coronary	O
artery	O
disease	O
s	O
/	O
p	O
CABG	O
Anxiety	O
Depression	O
Hypertension	O
TMJ	O
Discoid	O
lupus	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Please	O
shower	O
daily	O
including	O
washing	O
incisions	O
,	O
no	O
baths	O
or	O
swimming	O
Monitor	O
wounds	O
for	O
infection	O
-	O
redness	O
,	O
drainage	O
,	O
or	O
increased	O
pain	O
Report	O
any	O
fever	O
greater	O
than	O
101	O
Report	O
any	O
weight	O
gain	O
of	O
greater	O
than	O
2	O
pounds	O
in	O
24	O
hours	O
or	O
5	O
pounds	O
in	O
a	O
week	O
No	O
creams	O
,	O
lotions	O
,	O
powders	O
,	O
or	O
ointments	O
to	O
incisions	O
No	O
driving	O
for	O
approximately	O
one	O
month	O
No	O
lifting	O
more	O
than	O
10	O
pounds	O
for	O
10	O
weeks	O
Please	O
call	O
with	O
any	O
questions	O
or	O
concerns	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
Continue	O
to	O
use	O
sarna	I-Drug
lotion	O
for	O
rash	I-Reason
-	O
if	O
the	O
itching	O
increases	O
or	O
the	O
rash	O
does	O
not	O
continue	O
to	O
improve	O
please	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
Smoking	O
cessation	O
-	O
please	O
continue	O
to	O
refrain	O
from	O
smoking	O
if	O
you	O
are	O
having	O
difficulty	O
please	O
follow	O
up	O
with	O
PCP	O
Followup	O
Instructions	O
:	O
Please	O
call	O
to	O
schedule	O
all	O
appointments	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
4	O
weeks	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
170	O
**	O
]	O
)	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
10543	O
**	O
]	O
in	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
weeks	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
4475	O
**	O
]	O
)	O
Wound	O
check	O
appointment	O
[	O
**	O
Hospital	O
Ward	O
Name	O
121	O
**	O
]	O
2	O
as	O
instructed	O
by	O
nurse	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3633	O
**	O
]	O
)	O
Completed	O
by	O
:[	O
**	O
2108-11-20	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2181-9-5	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2181-9-14	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
A.C.E	B-Drug
Inhibitors	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2745	O
**	O
]	O
Chief	O
Complaint	O
:	O
Back	O
Pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
NA	O
History	O
of	O
Present	O
Illness	O
:	O
The	O
patient	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
-	O
year	O
-	O
old	O
female	O
with	O
past	O
medical	O
history	O
significant	O
for	O
stable	O
coronary	O
disease	O
,	O
PAF	O
,	O
and	O
a	O
six	O
-	O
month	O
history	O
of	O
low	O
back	O
pain	O
,	O
left	O
greater	O
than	O
right	O
with	O
radiation	O
down	O
her	O
left	O
lateral	O
thigh	O
to	O
her	O
left	O
calf	O
.	O
The	O
pain	O
is	O
intermittent	O
,	O
sharp	O
,	O
and	O
electric	O
radiating	O
down	O
her	O
left	O
lateral	O
thigh	O
to	O
her	O
left	O
lateral	O
calf	O
;	O
she	O
has	O
weakness	O
in	O
her	O
left	O
hip	O
flexor	O
.	O
She	O
recently	O
had	O
a	O
lumber	B-Reason
nerve	I-Reason
root	I-Reason
block	I-Reason
with	O
immediate	O
relief	O
from	O
the	O
bupivicaine	I-Drug
and	O
mild	O
improvement	O
with	O
the	O
steroid	I-Drug
injection	O
.	O
A	O
week	O
before	O
admission	O
she	O
developed	O
worsening	O
left	O
sciatic	O
pain	O
,	O
with	O
significant	O
limitation	O
in	O
ambulation	O
.	O
She	O
was	O
brought	O
in	O
by	O
her	O
daughter	O
for	O
uncontrolled	O
pain	O
and	O
inability	O
to	O
perform	O
activities	O
of	O
daily	O
living	O
.	O
She	O
reports	O
pain	O
,	O
denies	O
fever	O
,	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
loss	O
of	O
urine	O
or	O
stool	O
.	O
There	O
is	O
not	O
a	O
significant	O
change	O
in	O
the	O
quality	O
of	O
her	O
radiculopathy	O
,	O
rather	O
in	O
the	O
severity	O
.	O
It	O
is	O
worse	O
with	O
sitting	O
and	O
standing	O
for	O
a	O
prolonged	O
time	O
and	O
worse	O
when	O
getting	O
from	O
a	O
sitting	O
to	O
a	O
standing	O
position	O
.	O
She	O
states	O
that	O
the	O
pain	O
is	O
worse	O
when	O
she	O
lays	O
on	O
her	O
left	O
side	O
as	O
well	O
.	O
The	O
pain	O
is	O
slightly	O
better	O
with	O
rest	O
and	O
lying	O
on	O
her	O
right	O
side	O
.	O
The	O
patient	O
states	O
that	O
she	O
has	O
been	O
able	O
to	O
walk	O
with	O
only	O
a	O
cane	O
,	O
but	O
over	O
the	O
last	O
six	O
months	O
,	O
the	O
pain	O
has	O
gotten	O
so	O
bad	O
that	O
at	O
time	O
she	O
needs	O
to	O
walk	O
with	O
a	O
walker	O
and	O
this	O
has	O
stopped	O
her	O
from	O
going	O
to	O
church	O
.	O
She	O
denies	O
any	O
numbness	O
,	O
any	O
weakness	O
or	O
any	O
bowel	O
or	O
bladder	O
incontinence	O
.	O
Past	O
Medical	O
History	O
:	O
AF	O
since	O
[	O
**	O
2177-2-27	O
**	O
]	O
CVA	O
in	O
[	O
**	O
2150	O
**	O
]	O
,	O
TIA	O
(	O
no	O
residual	O
deficits	O
)	O
L	O
hip	O
OA	O
s	O
/	O
p	O
arthroplasty	O
[	O
**	O
10	O
-	O
2	O
**	O
]	O
H.	O
pylori	O
resulting	O
in	O
GIB	O
3	O
years	O
prior	O
with	O
transfusion	O
,	O
ICU	O
stay	O
:	O
NSTEMI	O
in	O
[	O
**	O
2170	O
**	O
]	O
,	O
s	O
/	O
p	O
RCA	O
stents	O
in	O
[	O
**	O
7	O
-	O
/	O
2177	O
**	O
]	O
for	O
positive	O
MIBI	O
CEA	O
on	O
R	O
and	O
L	O
carotid	O
for	O
symptomatic	O
TIA	O
s	O
/	O
p	O
pelvic	O
lift	O
,	O
C	O
-	O
sections	O
s	O
/	O
p	O
L	O
femur	O
surgery	O
for	O
osteomyelitis	O
[	O
**	O
2092	O
**	O
]	O
Eye	O
surgery	O
.	O
Colonoscopy	O
[	O
**	O
2173	O
**	O
]	O
:	O
Diverticulosis	O
of	O
the	O
colon	O
Grade	O
3	O
internal	O
hemorrhoids	O
Otherwise	O
normal	O
Colonoscopy	O
to	O
cecum	O
Social	O
History	O
:	O
Lives	O
independently	O
with	O
support	O
from	O
family	O
Family	O
History	O
:	O
NA	O
Physical	O
Exam	O
:	O
Physical	O
Exam	O
:	O
VS	O
:	O
Afebrile	O
,	O
normotensive	O
99	O
%	O
RA	O
GEN	O
:	O
The	O
patient	O
is	O
uncomfortable	O
,	O
but	O
pleasant	O
SKIN	O
:	O
No	O
rashes	O
or	O
skin	O
changes	O
noted	O
HEENT	O
:	O
WNL	O
.	O
CHEST	O
:	O
Lungs	O
are	O
clear	O
without	O
wheeze	O
,	O
rales	O
,	O
or	O
rhonchi	O
.	O
CARDIAC	O
:	O
Regular	O
rhythm	O
;	O
SEM	O
at	O
apex	O
ABDOMEN	O
:	O
Non-distended	O
,	O
and	O
soft	O
without	O
tenderness	O
EXTREMITIES	O
:	O
no	O
peripheral	O
edema	O
,	O
warm	O
without	O
cyanosis	O
NEUROLOGIC	O
:	O
Alert	O
and	O
appropriate	O
.	O
CN	O
II	O
-	O
XII	O
grossly	O
intact	O
.	O
BUE	O
[	O
**	O
4	O
-	O
2	O
**	O
]	O
,	O
and	O
LLE	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
hip	O
,	O
[	O
**	O
3	O
-	O
3	O
**	O
]	O
quad	O
and	O
hamstring	O
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
938	O
**	O
]	O
[	O
**	O
4	O
-	O
2	O
**	O
]	O
,	O
significant	O
pain	O
with	O
dorsiflexion	O
.	O
L	O
patellar	O
refex	O
1	O
,	O
Right	O
2	O
.	O
Both	O
toes	O
upgoing	O
,	O
Rectal	O
not	O
checked	O
.	O
CN	O
I	O
:	O
not	O
tested	O
CN	O
III	O
,	O
IV	O
,	O
VI	O
:	O
EOMI	O
CN	O
VII	O
:	O
full	O
facial	O
symmetry	O
and	O
strength	O
CN	O
IX	O
,	O
X	O
:	O
palate	O
rises	O
symmetrically	O
CN	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
shrug	O
[	O
**	O
4	O
-	O
2	O
**	O
]	O
and	O
symmetric	O
CN	O
XII	O
:	O
tongue	O
midline	O
and	O
agile	O
Pertinent	O
Results	O
:	O
[	O
**	O
2181-9-5	O
**	O
]	O
06:15	O
AM	O
URINE	O
HOURS	O
-	O
RANDOM	O
[	O
**	O
2181-9-5	O
**	O
]	O
06:15	O
AM	O
URINE	O
GR	O
HOLD	O
-	O
HOLD	O
[	O
**	O
2181-9-5	O
**	O
]	O
06:15	O
AM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.015	O
[	O
**	O
2181-9-5	O
**	O
]	O
06:15	O
AM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
7.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
GLUCOSE	O
-	O
118	O
*	O
UREA	O
N	O
-	O
21	O
*	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
127	O
*	O
POTASSIUM	O
-	O
4.1	O
CHLORIDE	O
-	O
95	O
*	O
TOTAL	O
CO2	O
-	O
22	O
ANION	O
GAP	O
-	O
14	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
CK	O
(	O
CPK	O
)	O
-	O
143	O
*	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
CK	O
-	O
MB	O
-	O
7	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
CALCIUM	O
-	O
8.8	O
PHOSPHATE	O
-	O
3.1	O
MAGNESIUM	O
-	O
1.7	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
WBC	O
-	O
10.5	O
#	O
RBC	O
-	O
3.30	O
*	O
HGB	O
-	O
9.9	O
*	O
HCT	O
-	O
28.7	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
14.6	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
NEUTS	O
-	O
90.1	O
*	O
LYMPHS	O
-	O
6.1	O
*	O
MONOS	O
-	O
3.6	O
EOS	O
-	O
0.2	O
BASOS	O
-	O
0	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
PLT	O
COUNT	O
-	O
266	O
[	O
**	O
2181-9-5	O
**	O
]	O
02:30	O
AM	O
PT	O
-	O
26.4	O
*	O
PTT	O
-	O
39.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.6	O
*	O
[	O
**	O
9	O
-	O
11	O
**	O
]	O
TTE	O
:	O
Conclusions	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
asymmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
unusually	O
small	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
70	O
%	O
)	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
Transmitral	O
Doppler	O
and	O
tissue	O
velocity	O
imaging	O
are	O
consistent	O
with	O
Grade	O
III	O
/	O
IV	O
(	O
severe	O
)	O
LV	O
diastolic	O
dysfunction	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
There	O
are	O
focal	O
calcifications	O
in	O
the	O
aortic	O
arch	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
There	O
is	O
severe	O
mitral	O
annular	O
calcification	O
.	O
There	O
is	O
moderate	O
thickening	O
of	O
the	O
mitral	O
valve	O
chordae	O
.	O
AT	O
LEAST	O
moderate	O
(	O
2	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
The	O
left	O
ventricular	O
inflow	O
pattern	O
suggests	O
a	O
restrictive	O
filling	O
abnormality	O
,	O
with	O
elevated	O
left	O
atrial	O
pressure	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
The	O
supporting	O
structures	O
of	O
the	O
tricuspid	O
valve	O
are	O
thickened	O
/	O
fibrotic	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
severe	O
asymmetric	O
left	O
ventricular	O
hypertrophy	O
;	O
small	O
left	O
ventricular	O
cavity	O
;	O
severe	O
left	O
ventricular	O
diastolic	O
dysfunction	O
;	O
at	O
least	O
moderate	O
(	O
and	O
probably	O
significantly	O
more	O
)	O
mitral	O
regurgitation	O
[	O
**	O
9	O
-	O
9	O
**	O
]	O
CT	O
abd	O
/	O
pelvis	O
with	O
IV	O
contrast	I-Drug
:	O
CT	O
OF	O
THE	O
ABDOMEN	O
WITH	O
IV	O
CONTRAST	I-Drug
:	O
A	O
left	O
pleural	O
effusion	O
with	O
associated	O
atelectasis	O
is	O
stable	O
.	O
The	O
lung	O
bases	O
are	O
otherwise	O
clear	O
.	O
The	O
liver	O
,	O
gallbladder	O
,	O
spleen	O
,	O
adrenal	O
glands	O
,	O
and	O
kidneys	O
appear	O
unremarkable	O
.	O
Note	O
is	O
again	O
made	O
of	O
a	O
small	O
right	O
renal	O
hypodensity	O
measuring	O
6	O
mm	O
,	O
likely	O
representing	O
a	O
renal	O
cyst	O
.	O
There	O
is	O
evidence	O
of	O
periportal	O
edema	O
and	O
anasarca	O
.	O
A	O
large	O
left	O
retroperitoneal	O
hematoma	O
,	O
now	O
measures	O
8	O
(	O
transverse	O
)	O
x	O
7	O
(	O
AP	O
)	O
x	O
13	O
(	O
coronal	O
)	O
cm	O
and	O
allowing	O
for	O
measurement	O
differences	O
,	O
has	O
not	O
changed	O
in	O
size	O
compared	O
to	O
the	O
prior	O
study	O
in	O
terms	O
of	O
size	O
.	O
No	O
areas	O
of	O
active	O
extravasation	O
are	O
noted	O
on	O
the	O
arterial	O
phase	O
imaging	O
and	O
the	O
density	O
of	O
the	O
retroperitoneal	O
hematoma	O
does	O
not	O
increase	O
with	O
delayed	O
imaging	O
.	O
No	O
new	O
hemorrhage	O
is	O
identified	O
.	O
The	O
abdominal	O
portions	O
of	O
the	O
large	O
and	O
small	O
bowel	O
are	O
unremarkable	O
.	O
Heavy	O
calcification	O
of	O
the	O
abdominal	O
aorta	O
is	O
noted	O
,	O
and	O
a	O
focal	O
area	O
of	O
stenosis	O
at	O
the	O
level	I-Drug
of	O
the	O
pancreas	O
is	O
additionally	O
noted	O
.	O
CT	O
OF	O
THE	O
PELVIS	O
WITH	O
IV	O
CONTRAST	I-Drug
:	O
Evaluation	O
of	O
the	O
pelvis	O
is	O
limited	O
secondary	O
to	O
streak	O
artifact	O
from	O
left	O
hip	O
prosthesis	O
.	O
A	O
Foley	O
balloon	O
is	O
present	O
within	O
the	O
bladder	O
.	O
The	O
rectum	O
and	O
sigmoid	O
colon	O
are	O
grossly	O
unremarkable	O
.	O
IMPRESSION	O
:	O
Large	O
left	O
retroperitoneal	O
hematoma	O
essentially	O
unchanged	O
in	O
size	O
compared	O
to	O
the	O
examination	O
of	O
nine	O
hours	O
prior	O
.	O
No	O
CT	O
evidence	O
of	O
active	O
extravasation	O
Brief	O
Hospital	O
Course	O
:	O
ACUTE	O
ON	O
CHRONIC	O
LUMBOSACRAL	O
RADICULOPATHY	O
:	O
Despite	O
multimodality	O
pain	O
regimen	O
,	O
the	O
patient	O
's	O
pain	I-Reason
remained	O
poorly	O
controlled	O
,	O
except	O
when	O
treated	O
with	O
ketorolac	I-Drug
.	O
Unfortunately	O
,	O
this	O
is	O
a	O
potentially	O
dangerous	O
medication	O
in	O
this	O
woman	O
with	O
advanced	O
age	O
,	O
mildly	O
reduced	O
renal	O
function	O
,	O
and	O
on	O
warfarin	I-Drug
and	O
plavix	I-Drug
.	O
A	O
pain	O
consult	O
was	O
obtained	O
,	O
but	O
they	O
did	O
not	O
add	O
much	O
to	O
the	O
present	O
management	O
.	O
MRI	O
of	O
LS	O
spine	O
showed	O
no	O
evidence	O
of	O
nerve	O
root	O
impingement	O
,	O
cauda	O
equina	O
or	O
canal	O
stenosis	O
,	O
but	O
incidental	O
note	O
was	O
made	O
of	O
a	O
possible	O
left	O
pelvic	O
mass	O
.	O
This	O
was	O
further	O
evaluated	O
by	O
CT.	O
...	O
...	O
It	O
is	O
possible	O
that	O
some	O
of	O
the	O
pain	O
and	O
weakness	O
may	O
be	O
related	O
to	O
an	O
iliopsoas	O
process	O
.	O
.	O
ACUTE	B-Ade
RENAL	I-Ade
FAILURE	I-Ade
:	O
related	O
to	O
NSAID	B-Drug
's	I-Drug
and	O
dehydration	O
.	O
.	O
PAROXYSMAL	B-Reason
ATRIAL	I-Reason
FIBRILLATION	I-Reason
:	O
Continue	O
warfarin	I-Drug
goal	O
INR	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
.	O
CORONARY	B-Reason
ARTERY	I-Reason
DISEASE	I-Reason
:	O
Stable	O
-	O
plavix	I-Drug
,	O
statin	I-Drug
,	O
toprol	I-Drug
.	O
OSTEOPOROSIS	I-Reason
:	O
Vitamin	B-Drug
D	I-Drug
,	O
q	O
month	O
Boniva	I-Drug
HYPERTENSION	O
:	O
Continue	O
outpatient	O
medications	O
____________________________________	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
Course	O
and	O
subsequent	O
medical	O
service	O
course	O
:	O
This	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
-	O
old	O
female	O
with	O
a	O
history	O
of	O
Afib	O
,	O
CVA	O
,	O
CAD	O
initially	O
admitted	O
on	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
with	O
worsening	O
low	O
back	O
pain	O
who	O
became	O
hypotensive	O
to	O
80's	O
systolic	O
this	O
evening	O
.	O
Of	O
note	O
,	O
this	O
morning	O
she	O
had	O
a	O
CT	O
scan	O
that	O
showed	O
an	O
RP	B-Ade
bleed	I-Ade
.	O
This	O
was	O
thought	O
to	O
be	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
increased	O
INR	O
and	O
she	O
was	O
given	O
1	O
mg	O
sc	O
vitamin	B-Drug
k	I-Drug
and	O
2	O
mg	O
po	O
vitamin	B-Drug
k.	O
No	O
recent	O
procedures	O
.	O
No	O
change	O
in	O
medications	O
.	O
Her	O
coumadin	I-Drug
was	O
given	O
on	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
but	O
held	O
since	O
[	O
**	O
9	O
-	O
6	O
**	O
]	O
because	O
of	O
increased	O
INR	O
.	O
She	O
also	O
is	O
hyponatremic	I-Ade
which	O
was	O
thought	O
to	O
be	O
iatrogenic	O
from	O
D51	B-Drug
/	I-Drug
2	I-Drug
NS	I-Drug
maintenance	O
fluids	O
given	O
continuously	O
despite	O
an	O
initial	O
sodium	O
of	O
128	O
on	O
admission	O
.	O
Her	O
urine	O
lytes	O
show	O
urine	O
na	O
<	O
10	O
and	O
osm	O
>	O
300	O
.	O
Her	O
sodium	O
is	O
up	O
from	O
117	O
--	O
>	O
121	O
with	O
NS	I-Drug
bolus	O
.	O
Patient	O
herself	O
feels	O
well	O
.	O
She	O
denies	O
LH	O
,	O
dizziness	O
,	O
cp	O
,	O
palp	O
,	O
sob	O
,	O
abd	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
back	O
pain	O
.	O
On	O
the	O
floor	O
,	O
she	O
was	O
given	O
2	O
u	O
ffp	I-Drug
,	O
1	O
u	O
prbcs	I-Drug
and	O
500	O
cc	O
normal	B-Drug
saline	I-Drug
bolus	O
.	O
She	O
initially	O
improved	O
with	O
SBP	O
high	O
90s	O
to	O
low	O
100s	O
.	O
BP	O
recheck	O
an	O
hour	O
later	O
was	O
in	O
the	O
80s	O
again	O
and	O
her	O
crit	O
prior	O
to	O
blood	I-Drug
transfusion	O
came	O
back	O
at	O
16	O
so	O
she	O
was	O
transferred	O
to	O
the	O
ICU	O
for	O
hypotension	O
and	O
bleed	O
.	O
.	O
In	O
the	O
ICU	O
,	O
her	O
initial	O
vs	O
were	O
:	O
T	O
96	O
BP	O
122/49	O
,	O
HR	O
79	O
,	O
O2	O
sat	O
96	O
%	O
RA	O
,	O
R	O
16	O
.	O
She	O
reported	O
feeling	O
well	O
.	O
Denied	O
LH	O
,	O
dizziness	O
,	O
cp	O
,	O
sob	O
,	O
abd	O
or	O
back	O
pain	O
.	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
year	O
-	O
old	O
female	O
with	O
a	O
history	O
of	O
CAD	O
,	O
CVA	O
,	O
afib	I-Reason
on	O
coumadin	I-Drug
with	O
supratherapeutic	B-Ade
INR	I-Ade
presented	O
with	O
hypotension	O
in	O
setting	O
of	O
RP	B-Ade
bleed	I-Ade
and	O
hematocrit	O
drop	O
.	O
#	O
.	O
RP	B-Reason
Bleed	I-Reason
:	O
Seen	O
on	O
CT	O
scan	O
.	O
Repeat	O
CT	O
-	O
scan	O
w	O
/	O
contrast	I-Drug
did	O
not	O
show	O
expansion	O
of	O
the	O
hematoma	O
or	O
evidence	O
of	O
active	O
bleed	O
.	O
Likely	O
in	O
setting	O
of	O
elevated	O
INR	O
??????	O
no	O
trauma	O
by	O
history	O
.	O
Given	O
2U	O
pRBCs	I-Drug
during	O
admission	O
.	O
Hematocrit	O
stable	O
over	O
rest	O
of	O
hospital	O
course	O
.	O
Conservative	O
management	O
.	O
-	O
*	O
Given	O
patient	O
's	O
significant	O
retroperitoneal	B-Ade
bleed	I-Ade
with	O
hct	O
drop	O
and	O
hypotension	O
,	O
the	O
patient	O
's	O
coumadin	I-Drug
,	O
aspirin	I-Drug
and	O
plavix	I-Drug
were	O
all	O
discontinued	O
.	O
I	O
recommend	O
that	O
patient	O
not	O
be	O
restarted	O
on	O
coumadin	I-Drug
in	O
the	O
future	O
.	O
In	O
my	O
opinion	O
,	O
the	O
risk	O
of	O
recurrent	O
significant	O
RP	O
bleed	O
outweighs	O
the	O
cardioembolic	O
benefits	O
in	O
the	O
setting	O
of	O
the	O
patient	O
's	O
a-fib	O
.	O
The	O
patient	O
can	O
be	O
restarted	O
on	O
aspirin	I-Drug
+	O
/	O
-	O
plavix	I-Drug
per	O
PCP	O
discretion	O
at	O
future	O
outpatient	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
.	O
*	O
#	O
.	O
Atrial	B-Reason
fibrillation	I-Reason
with	I-Reason
RVR	I-Reason
:	O
The	O
patient	O
converted	O
from	O
sinus	O
rhythm	O
to	O
a-fib	O
on	O
[	O
**	O
9	O
-	O
10	O
**	O
]	O
with	O
subsequent	O
RVR	O
up	O
to	O
the	O
140s	O
.	O
This	O
was	O
in	O
the	O
setting	O
of	O
RP	O
bleed	O
,	O
holding	O
of	O
her	O
beta	B-Drug
-	I-Drug
blocker	I-Drug
,	O
the	O
stress	O
of	O
medical	O
illness	O
.	O
Cardiology	O
was	O
consulted	O
to	O
assist	O
in	O
management	O
.	O
Metoprolol	I-Drug
was	O
uptitrated	O
to	O
75	O
mg	O
po	O
qid	O
after	O
which	O
the	O
patient	O
eventually	O
spontaneously	O
converted	O
to	O
sinus	O
rhythm	O
in	O
the	O
early	O
am	O
of	O
[	O
**	O
9	O
-	O
14	O
**	O
]	O
.	O
At	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
was	O
discharged	O
on	O
metoprolol	I-Drug
100	O
mg	O
po	O
bid	O
in	O
sinus	O
rhythm	O
.	O
-	O
Patient	O
will	O
require	O
further	O
downtitration	O
of	O
her	O
metoprolol	I-Drug
by	O
PCP	O
at	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
/	O
u	O
outpatient	O
visits	O
.	O
#	O
HTN	B-Reason
,	I-Reason
benign	I-Reason
:	O
*	O
Of	O
note	O
,	O
the	O
patient	O
's	O
amlodipine	I-Drug
,	O
aliskeren	I-Drug
,	O
and	O
valsartan	I-Drug
were	O
all	O
held	O
at	O
time	O
of	O
discharge	O
given	O
focus	O
on	O
maximizing	O
beta	B-Drug
-	I-Drug
blockade	I-Drug
for	O
rate	B-Reason
control	I-Reason
.	O
These	O
can	O
be	O
selectively	O
restarted	O
as	O
desired	O
by	O
the	O
patient	O
's	O
PCP	O
at	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
/	O
u	O
outpatient	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
.	O
*	O
#	O
.	O
Acute	B-Reason
Diastolic	I-Reason
heart	I-Reason
failure	I-Reason
/	O
pulmonary	B-Reason
edema	I-Reason
:	O
Occurred	O
twice	O
following	O
transfusion	O
of	O
blood	B-Drug
products	I-Drug
>	O
causing	O
flash	I-Ade
pulmonary	O
edema	O
.	O
Pt	O
again	O
became	O
SOB	I-Ade
after	O
blood	B-Drug
products	I-Drug
,	O
improved	O
with	O
lasix	I-Drug
and	O
morphine	I-Drug
.	O
Patient	O
's	O
also	O
a-fib	O
with	O
RVR	O
in	O
setting	O
of	O
diastolic	O
heart	O
failure	O
contributed	O
.	O
With	O
further	O
gentle	O
lasix	I-Drug
and	O
rate	O
-	O
control	O
,	O
the	O
patient	O
reached	O
euvolemia	O
.	O
The	O
patient	O
was	O
not	O
discharged	O
on	O
lasix	I-Drug
.	O
#	O
Low	O
back	O
pain	O
:	O
No	O
neurologic	O
defecits	O
on	O
exam	O
.	O
Her	O
low	O
back	O
pain	O
may	O
have	O
been	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
this	O
RP	O
bleed	O
as	O
her	O
L	O
spine	O
imaging	O
on	O
admission	O
showed	O
a	O
?	O
left	O
pelvic	O
mass	O
.	O
Has	O
history	O
of	O
chronic	O
low	O
back	O
pain	O
.	O
#	O
Coagulopathy	O
-	O
Patient	O
had	O
supratherapeutic	O
INR	O
during	O
admission	O
.	O
Coumadin	I-Drug
was	O
held	O
and	O
subsequently	O
discontinued	O
.	O
#	O
CAD	I-Reason
:	O
Admission	O
EKG	O
wnl	O
.	O
Continued	O
statin	I-Drug
on	O
d	O
/	O
c	O
,	O
d	O
/	O
'd	O
asa	I-Drug
and	O
plavix	I-Drug
until	O
PCP	O
f	O
/	O
u.	O
#	O
Hypothyroidism	I-Reason
:	O
Cont	O
levothyroxine	I-Drug
#	O
Code	O
:	O
Full	O
Code	O
,	O
confirmed	O
with	O
HCP	O
#	O
Comm	O
:	O
Daughter	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
24311	O
**	O
]	O
-	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
17	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
??????	O
Relationship	O
:	O
daughter	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
24312	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
Aliskiren	I-Drug
*	O
NF	O
*	O
150	O
mg	O
Oral	O
qd	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Warfarin	I-Drug
2.5	O
mg	O
PO	O
4X	O
/	O
WEEK	O
(	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
,	O
MO	O
,	O
WE	O
,	O
FR	O
)	O
Warfarin	I-Drug
2	O
mg	O
PO	O
DAYS	O
(	O
TU	O
,	O
TH	O
,	O
SA	O
)	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Amlodipine	I-Drug
2.5	O
mg	O
PO	O
DAILY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Atorvastatin	I-Drug
80	O
mg	O
PO	O
DAILY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Levothyroxine	B-Drug
Sodium	I-Drug
112	O
mcg	O
PO	O
DAILY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Clopidogrel	B-Drug
75	O
mg	O
PO	O
DAILY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
PO	O
BID	O
Duration	O
:	O
24	O
Hours	O
Metoprolol	B-Drug
Succinate	I-Drug
XL	O
50	O
mg	O
PO	O
DAILY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Valsartan	I-Drug
320	O
mg	O
PO	O
DAILY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Furosemide	I-Drug
20	O
mg	O
PO	O
Q	O
MON	O
/	O
WED	O
/	O
FRIDAY	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Lactulose	I-Drug
30	O
mL	O
PO	O
Q8H	O
:	O
PRN	O
[	O
**	O
9	O
-	O
5	O
**	O
]	O
@	O
1128	O
Lidocaine	I-Drug
5	O
%	O
Patch	O
1	O
PTCH	O
TD	O
DAILY	O
Start	O
:	O
[	O
**	O
2181-9-5	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Levothyroxine	I-Drug
112	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Ciprofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
5	O
days	O
.	O
Disp	O
:	O
*	O
10	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Valsartan	B-Drug
320	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
HOLD	O
THIS	O
MEDICATION	I-Drug
UNTIL	O
DISCUSSION	O
AT	O
F	O
/	O
U	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
.	O
7	O
.	O
aliskeren	I-Drug
Sig	O
:	O
One	O
[	O
**	O
Age	O
over	O
90	O
1230	O
**	O
]	O
y	O
(	O
150	O
)	O
mg	O
once	O
a	O
day	O
:	O
DO	O
NOT	O
TAKE	O
THIS	O
MEDICATION	I-Drug
UNTIL	O
DISCUSSION	O
WITH	O
AT	O
PCP	O
f	O
/	O
u	O
visit	O
.	O
8	O
.	O
Gabapentin	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
9	O
.	O
Tizanidine	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
45	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Tylenol	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
3	O
*	O
11	O
.	O
Methocarbamol	B-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
as	O
needed	O
for	O
pain	I-Reason
.	O
12	O
.	O
Boniva	I-Drug
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
2203	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
Retroperitoneal	O
Bleed	O
Atrial	O
fibrillation	O
with	O
RVR	O
Acute	O
Diastolic	O
Heart	O
Failure	O
UTI	O
Hyponatremia	O
Leukocytosis	O
CAD	O
,	O
native	O
vessel	O
Discharge	O
Condition	O
:	O
Vital	O
Signs	O
Stable	O
Discharge	O
Instructions	O
:	O
Return	O
to	O
emergency	O
room	O
if	O
patient	O
is	O
having	O
significant	O
worsening	O
of	O
her	O
left	O
back	O
/	O
flank	O
pain	O
,	O
light	O
-	O
headedness	O
,	O
confusion	O
,	O
somnolence	O
,	O
chest	O
pain	O
,	O
significant	O
shortness	O
of	O
breath	O
,	O
persistent	O
palpitations	O
,	O
sustained	O
fast	O
heart	O
rate	O
>	O
110	O
beats	O
per	O
minute	O
.	O
DO	O
NOT	O
TAKE	O
COUMADIN	I-Drug
,	O
PLAVIX	I-Drug
,	O
AND	O
ASPIRIN	I-Drug
FOR	O
NOW	O
.	O
AT	O
PCP	O
F	O
/	O
U	O
,	O
discuss	O
resumption	O
of	O
aspirin	I-Drug
(	O
consider	O
adult	O
dose	O
)	O
and	O
plavix	I-Drug
.	O
Would	O
permanently	O
discontinue	O
coumadin	I-Drug
.	O
Patient	O
will	O
need	O
further	O
outpatient	O
downtitration	O
of	O
her	O
metoprolol	I-Drug
at	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
.	O
Followup	O
Instructions	O
:	O
Patient	O
to	O
f	O
/	O
u	O
closely	O
with	O
her	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
7728	O
**	O
]	O
for	O
appointment	O
in	O
[	O
**	O
11	O
-	O
29	O
**	O
]	O
weeks	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2178-1-7	O
**	O
]	O
Discharge	O
Date	O
:	O
Service	O
:	O
GEN	O
SURGER	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
an	O
85	O
year	O
old	O
woman	O
who	O
presents	O
for	O
a	O
right	O
hemicolectomy	O
for	O
resection	O
of	O
carcinoma	O
of	O
the	O
cecum	O
.	O
The	O
patient	O
was	O
initially	O
found	O
to	O
be	O
anemic	O
on	O
routine	O
physical	O
examination	O
by	O
her	O
primary	O
care	O
physician	O
and	O
further	O
workup	O
included	O
a	O
colonoscopy	O
which	O
revealed	O
a	O
mass	O
in	O
the	O
cecum	O
as	O
well	O
as	O
diverticulosis	O
.	O
The	O
mass	O
was	O
biopsied	O
and	O
revealed	O
an	O
adenoma	O
with	O
high	O
grade	O
dysplasia	O
.	O
The	O
patient	O
admits	O
to	O
intermittent	O
melena	O
,	O
no	O
bright	O
red	O
blood	O
per	O
rectum	O
.	O
She	O
has	O
mild	O
constipation	O
,	O
no	O
diarrhea	O
,	O
no	O
weight	O
loss	O
,	O
no	O
fevers	O
or	O
chills	O
,	O
no	O
history	O
of	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
dizziness	O
,	O
syncope	O
,	O
nausea	O
or	O
vomiting	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Hypertension	O
.	O
2	O
.	O
Breast	O
cancer	O
in	O
the	O
past	O
which	O
was	O
resected	O
and	O
she	O
had	O
a	O
left	O
mastectomy	O
in	O
[	O
**	O
2152	O
**	O
]	O
,	O
and	O
a	O
right	O
lumpectomy	O
in	O
[	O
**	O
2168	O
**	O
]	O
.	O
ALLERGIES	O
:	O
No	O
known	O
drug	O
allergies	O
.	O
MEDICATIONS	O
ON	O
ADMISSION	O
:	O
1	O
.	O
Norvasc	I-Drug
5	O
mg	O
p.o.	O
q.d.	O
2	O
.	O
Butoptic	I-Drug
one	O
to	O
two	O
drops	O
to	O
each	O
eye	O
b.i.d.	O
for	O
prevention	B-Reason
of	I-Reason
glaucoma	I-Reason
.	O
3	O
.	O
Trusopt	I-Drug
2	O
%	O
one	O
drop	O
each	O
eye	O
for	O
prevention	B-Reason
of	I-Reason
glaucoma	I-Reason
which	O
runs	O
in	O
her	O
family	O
.	O
SOCIAL	O
HISTORY	O
:	O
Significant	O
for	O
thirty	O
pack	O
year	O
history	O
of	O
tobacco	O
.	O
She	O
quit	O
fifteen	O
years	O
ago	O
.	O
Socially	O
ETOH	O
,	O
less	O
than	O
two	O
drinks	O
per	O
week	O
.	O
She	O
lives	O
alone	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
.	O
REVIEW	O
OF	O
SYSTEMS	O
:	O
On	O
review	O
of	O
systems	O
,	O
she	O
does	O
get	O
short	O
of	O
breath	O
upon	O
walking	O
one	O
flight	O
of	O
stairs	O
.	O
Otherwise	O
,	O
the	O
review	O
of	O
systems	O
was	O
noncontributory	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
On	O
physical	O
examination	O
,	O
her	O
temperature	O
was	O
97.8	O
,	O
heart	O
rate	O
100	O
,	O
blood	O
pressure	O
128/78	O
,	O
respiratory	O
rate	O
16	O
,	O
and	O
she	O
was	O
saturating	O
96	O
%	O
in	O
room	O
air	O
.	O
She	O
is	O
mildly	O
obese	O
,	O
alert	O
,	O
oriented	O
times	O
three	O
,	O
pleasant	O
in	O
no	O
apparent	O
distress	O
.	O
The	O
pupils	O
are	O
equal	O
,	O
round	O
,	O
and	O
reactive	O
to	O
light	O
and	O
accommodation	O
.	O
Sclera	O
were	O
anicteric	O
.	O
Mucous	O
membranes	O
were	O
moist	O
.	O
No	O
lymphadenopathy	O
.	O
The	O
neck	O
was	O
supple	O
with	O
no	O
carotid	O
bruits	O
.	O
The	O
lungs	O
were	O
clear	O
to	O
auscultation	O
bilaterally	O
.	O
She	O
had	O
a	O
regular	O
rate	O
and	O
rhythm	O
.	O
The	O
abdomen	O
was	O
soft	O
,	O
nontender	O
,	O
protuberant	O
,	O
but	O
nondistended	O
,	O
positive	O
bowel	O
sounds	O
.	O
She	O
had	O
no	O
cyanosis	O
,	O
clubbing	O
or	O
edema	O
.	O
Her	O
pulses	O
were	O
palpable	O
bilaterally	O
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
plan	O
was	O
for	O
a	O
right	O
hemicolectomy	O
.	O
The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
,	O
however	O
,	O
on	O
transfer	O
to	O
the	O
floor	O
from	O
the	O
Post	O
Anesthesia	O
Care	O
Unit	O
,	O
the	O
patient	O
was	O
found	O
to	O
be	O
unresponsive	O
and	O
almost	O
apneic	O
.	O
On	O
workup	O
,	O
she	O
was	O
found	O
to	O
be	O
hypercarbic	I-Ade
which	O
was	O
presumed	O
to	O
be	O
most	O
likely	O
due	O
to	O
narcotics	I-Drug
from	O
her	O
epidural	O
.	O
The	O
epidural	O
was	O
immediately	O
capped	O
and	O
an	O
electrocardiogram	O
,	O
chest	O
x-ray	O
were	O
done	O
which	O
were	O
essentially	O
within	O
normal	O
limits	O
.	O
Once	O
the	O
epidural	O
was	O
capped	O
,	O
the	O
patient	O
's	O
respiratory	O
rate	O
increased	O
to	O
30	O
and	O
she	O
was	O
saturating	O
91	O
%	O
on	O
50	O
%	O
.	O
She	O
had	O
bilateral	O
crackles	O
at	O
the	O
bases	O
and	O
was	O
tachycardic	O
.	O
She	O
was	O
brought	O
to	O
the	O
Post	O
Anesthesia	O
Care	O
Unit	O
for	O
more	O
frequent	O
and	O
closer	O
monitoring	O
.	O
Her	O
narcotics	I-Drug
and	O
epidural	O
were	O
stopped	O
.	O
The	O
patient	O
was	O
closely	O
monitored	O
and	O
her	O
oxygen	O
saturations	O
came	O
up	O
,	O
however	O
,	O
she	O
continued	O
to	O
have	O
respiratory	O
difficulty	O
and	O
,	O
on	O
repeat	O
blood	O
gases	O
although	O
there	O
was	O
some	O
improvement	O
,	O
she	O
was	O
found	O
to	O
be	O
acidotic	O
and	O
still	O
hypercarbic	O
and	O
breathing	O
with	O
difficulty	O
.	O
Hence	O
,	O
after	O
supportive	O
therapy	O
was	O
maintained	O
for	O
a	O
couple	O
of	O
hours	O
,	O
the	O
decision	O
was	O
made	O
to	O
intubate	O
the	O
patient	O
and	O
transfer	O
to	O
the	O
Intensive	O
Care	O
Unit	O
.	O
She	O
was	O
extubated	O
on	O
the	O
following	O
day	O
,	O
postoperative	O
day	O
two	O
,	O
tolerated	O
extubation	O
well	O
.	O
She	O
had	O
a	O
slight	O
temperature	O
of	O
101.7	O
and	O
remained	O
slightly	O
tachycardic	O
but	O
that	O
was	O
her	O
baseline	O
and	O
her	O
oxygen	O
saturations	O
remained	O
within	O
normal	O
limits	O
in	O
the	O
mid	O
to	O
low	O
90s	O
which	O
was	O
around	O
her	O
baseline	O
.	O
Her	O
temperature	O
came	O
down	O
on	O
its	O
own	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
floor	O
on	O
postoperative	O
day	O
number	O
two	O
.	O
On	O
postoperative	O
day	O
number	O
three	O
,	O
the	O
patient	O
did	O
well	O
.	O
However	O
,	O
that	O
evening	O
she	O
awoke	O
short	O
of	O
breath	O
,	O
denied	O
any	O
chest	O
pain	O
,	O
tingling	O
in	O
her	O
arms	O
,	O
nausea	O
,	O
vomiting	O
or	O
dizziness	O
.	O
She	O
was	O
saturating	O
94	O
%	O
on	O
four	O
liters	O
.	O
She	O
did	O
have	O
crackles	O
at	O
the	O
bases	O
bilaterally	O
and	O
some	O
rhonchi	O
.	O
The	O
decision	O
was	O
made	O
to	O
give	O
her	O
some	O
Lasix	I-Drug
in	O
which	O
case	O
she	O
quickly	O
responded	O
and	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
dissipated	O
.	O
Another	O
electrocardiogram	O
was	O
done	O
which	O
again	O
was	O
within	O
normal	O
limits	O
.	O
The	O
patient	O
did	O
well	O
the	O
following	O
.	O
Vital	O
signs	O
were	O
all	O
stable	O
.	O
She	O
was	O
saturating	O
well	O
.	O
Her	O
nasogastric	O
tube	O
was	O
taken	O
out	O
and	O
she	O
was	O
started	O
on	O
sips	O
.	O
She	O
continued	O
to	O
do	O
well	O
.	O
On	O
postoperative	O
day	O
five	O
,	O
she	O
started	O
to	O
develop	O
some	O
burping	O
and	O
had	O
still	O
not	O
passed	O
any	O
flatus	O
.	O
Her	O
abdomen	O
became	O
slightly	O
distended	O
.	O
She	O
was	O
kept	O
NPO	O
.	O
However	O
,	O
on	O
postoperative	O
day	O
six	O
,	O
she	O
passed	O
large	O
amounts	O
of	O
stool	O
and	O
decision	O
was	O
made	O
to	O
start	O
her	O
again	O
on	O
clears	O
.	O
She	O
tolerated	O
clears	O
well	O
.	O
On	O
postoperative	O
day	O
seven	O
,	O
she	O
was	O
advanced	O
to	O
a	O
soft	O
regular	O
diet	O
and	O
was	O
discharged	O
to	O
rehabilitation	O
in	O
stable	O
condition	O
.	O
Her	O
vital	O
signs	O
were	O
all	O
stable	O
.	O
She	O
was	O
afebrile	O
.	O
A	O
Clostridium	O
difficile	O
had	O
been	O
sent	O
given	O
she	O
had	O
multiple	O
loose	O
bowel	O
movements	O
,	O
which	O
is	O
still	O
pending	O
.	O
She	O
will	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
957	O
**	O
]	O
.	O
DISCHARGE	O
DIAGNOSIS	O
:	O
Right	O
hemicolectomy	O
for	O
cecal	O
mass	O
.	O
MEDICATIONS	O
ON	O
DISCHARGE	O
:	O
1	O
.	O
Trusopt	I-Drug
2	O
%	O
one	O
drop	O
O.U.	O
t.i.d.	O
2	O
.	O
Butoptic	I-Drug
one	O
to	O
two	O
drops	O
O.U.	O
t.i.d.	O
3	O
.	O
Norvasc	I-Drug
5	O
mg	O
p.o.	O
q.d.	O
4	O
.	O
Tylenol	I-Drug
#	O
3	O
one	O
to	O
two	O
tablets	O
p.o.	O
q4	O
-	O
6hours	O
p.r.n.	O
pain	I-Reason
.	O
5	O
.	O
Zinc	I-Drug
220	O
mg	O
p.o.	O
q.d.	O
6	O
.	O
Multivitamin	I-Drug
.	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
4007	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2649	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2178-1-15	O
**	O
]	O
10:08	O
T	O
:	O
[	O
**	O
2178-1-15	O
**	O
]	O
10:19	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
24811	O
**	O
]	O
and	O
[	O
**	O
Numeric	O
Identifier	O
24812	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2174-6-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2174-6-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2099-9-12	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
Tachypnea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
74	O
year	O
old	O
male	O
with	O
h	O
/	O
o	O
DM	O
,	O
frequent	O
aspiration	O
,	O
CVA	O
(	O
left	O
weakness	O
,	O
at	O
baseline	O
unable	O
to	O
converse	O
)	O
,	O
presents	O
to	O
ED	O
for	O
tachypnea	O
.	O
Pt	O
found	O
at	O
facility	O
to	O
be	O
be	O
congested	O
,	O
with	O
difficulty	O
breathing	O
.	O
chief	O
complaint	O
of	O
lung	O
congestion	O
,	O
difficulty	O
breathing	O
.	O
Questionable	O
seizure	O
activity	O
prior	O
to	O
being	O
found	O
.	O
Confirmed	O
DNR	O
/	O
DNI	O
with	O
family	O
but	O
confirmed	O
otherwise	O
aggressive	O
care	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
98.4	O
105159/72	O
30s	O
-	O
40s	O
100	O
on	O
3	O
-	O
4L	O
,	O
with	O
eventual	O
spike	O
to	O
101	O
rectally	O
.	O
Although	O
CXR	O
neg	O
,	O
exam	O
revealed	O
diffuse	O
crackles	O
,	O
pt	O
was	O
treated	O
for	O
possible	O
aspiration	B-Reason
pneumonia	I-Reason
with	O
vanc	I-Drug
and	O
zosyn	I-Drug
(	O
levo	I-Drug
planned	O
but	O
not	O
yet	O
administered	O
)	O
.	O
Labs	O
sig	O
for	O
WBC	O
15.5	O
,	O
hyperglycemia	O
and	O
UA	O
with	O
SG	O
1	O
.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
59607	O
**	O
]	O
glucose	O
,	O
lactate	O
3.5	O
.	O
Head	O
CT	O
ucnhanged	O
except	O
newly	O
dislocated	O
lens	O
in	O
right	O
eye	O
.	O
Stage	O
2	O
sacral	O
decub	O
appeared	O
uninfected	O
.	O
EKG	O
without	O
ischemic	O
changes	O
.	O
.	O
VS	O
on	O
transfer	O
:	O
101.2	O
,	O
124/56	O
,	O
100	O
,	O
32	O
,	O
98	O
4L	O
Past	O
Medical	O
History	O
:	O
strokes	O
from	O
ruptured	O
intracerebral	O
aneurysms	O
in	O
[	O
**	O
2160	O
**	O
]	O
and	O
[	O
**	O
2162	O
**	O
]	O
or	O
[	O
**	O
2163	O
**	O
]	O
with	O
residual	O
left	O
sided	O
deficits	O
(	O
has	O
not	O
been	O
able	O
to	O
walk	O
since	O
the	O
stroke	O
in	O
'	O
[	O
**	O
63	O
**	O
]	O
)	O
and	O
aphasia	O
,	O
PEG	O
for	O
dysphagia	O
h	O
/	O
o	O
seizure	O
do	O
dementia	O
HTN	O
h	O
/	O
o	O
HepC	O
hepatitis	O
,	O
apparently	O
not	O
active	O
h	O
/	O
o	O
neurosyphilis	O
,	O
treated	O
in	O
[	O
**	O
2163	O
**	O
]	O
hypothyroidism	O
Social	O
History	O
:	O
Nursing	O
home	O
resident	O
(	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
)	O
since	O
[	O
**	O
2163	O
**	O
]	O
.	O
Sent	O
here	O
with	O
no	O
personal	O
belongings	O
.	O
Family	O
History	O
:	O
Noncontributory	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
afeb	O
BP	O
:	O
120/69	O
P	O
:	O
102	O
R	O
:	O
26	O
18	O
O2	O
:	O
General	O
:	O
NAD	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
PERRLA	O
,	O
MMM	O
Neck	O
:	O
supple	O
,	O
no	O
LAD	O
Lungs	O
:	O
Diffuse	O
ronchi	O
,	O
no	O
resp	O
distress	O
CV	O
:	O
Tachy	O
,	O
no	O
murmurs	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
,	O
G	O
tube	O
in	O
palce	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
Opens	O
eyes	O
slightly	O
to	O
command	O
,	O
withdraws	O
to	O
pain	O
on	O
right	O
,	O
no	O
movement	O
on	O
left	O
Pertinent	O
Results	O
:	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
WBC	O
-	O
15.5	O
*	O
RBC	O
-	O
4.19	O
*	O
HGB	O
-	O
12.4	O
*	O
HCT	O
-	O
38.3	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
29.6	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
15.0	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
NEUTS	O
-	O
76	O
*	O
BANDS	O
-	O
1	O
LYMPHS	O
-	O
12	O
*	O
MONOS	O
-	O
10	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
1	O
*	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
HYPOCHROM	O
-	O
1	O
+	O
ANISOCYT	O
-	O
1	O
+	O
POIKILOCY	O
-	O
NORMAL	O
MACROCYT	O
-	O
NORMAL	O
MICROCYT	O
-	O
NORMAL	O
POLYCHROM	O
-	O
NORMAL	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
PLT	O
SMR	O
-	O
NORMAL	O
PLT	O
COUNT	O
-	O
146	O
*	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
PTT	O
-	O
32.8	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:00	O
PM	O
GLUCOSE	O
-	O
327	O
*	O
UREA	O
N	O
-	O
23	O
*	O
CREAT	O
-	O
0.9	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
4.8	O
CHLORIDE	O
-	O
107	O
TOTAL	O
CO2	O
-	O
21	O
*	O
ANION	O
GAP	O
-	O
16	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:40	O
PM	O
URINE	O
COLOR	O
-	O
Amber	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.029	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:40	O
PM	O
URINE	O
BLOOD	O
-	O
NEG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
25	O
GLUCOSE	O
-	O
1000	O
KETONE	O
-	O
TR	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
4	O
*	O
PH	O
-	O
6.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:40	O
PM	O
URINE	O
RBC	O
-	O
0	O
WBC	O
-0-2	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
[	O
**	O
2174-6-3	O
**	O
]	O
12:40	O
PM	O
URINE	O
HYALINE	O
-	O
[	O
**	O
6	O
-	O
30	O
**	O
]	O
*	O
EEG	O
:	O
FINDINGS	O
:	O
ROUTINE	O
SAMPLING	O
:	O
The	O
background	O
activity	O
was	O
slow	O
reaching	O
a	O
maximum	O
of	O
about	O
6	O
Hz	O
biposteriorly	O
in	O
the	O
most	O
awake	O
parts	O
of	O
this	O
recording	O
.	O
In	O
addition	O
,	O
there	O
was	O
focal	O
slowing	O
in	O
the	O
delta	O
and	O
theta	O
range	O
seen	O
in	O
the	O
right	O
central	O
area	O
.	O
There	O
were	O
sharp	O
waves	O
seen	O
independently	O
in	O
the	O
right	O
frontal	O
,	O
right	O
central	O
parietal	O
,	O
as	O
well	O
as	O
left	O
fronto	O
-	O
temporal	O
areas	O
.	O
SPIKE	O
DETECTION	O
PROGRAMS	O
:	O
Showed	O
some	O
of	O
the	O
above	O
-	O
mentioned	O
right	O
and	O
left	O
sharp	O
waves	O
.	O
SEIZURE	O
DETECTION	O
PROGRAMS	O
:	O
Captured	O
periods	O
of	O
muscle	O
artifact	O
as	O
well	O
as	O
blinking	O
artifact	O
but	O
not	O
ongoing	O
seizure	O
activity	O
.	O
PUSHBUTTON	O
ACTIVATIONS	O
:	O
There	O
were	O
no	O
entries	O
in	O
these	O
files	O
.	O
SLEEP	O
:	O
The	O
patient	O
progressed	O
from	O
wakefulness	O
to	O
sleep	O
.	O
The	O
above	O
-	O
mentioned	O
sharp	O
waves	O
were	O
seen	O
more	O
frequently	O
in	O
sleep	O
.	O
CARDIAC	O
MONITOR	O
:	O
Showed	O
a	O
generally	O
regular	O
rhythm	O
.	O
IMPRESSION	O
:	O
This	O
telemetry	O
captured	O
no	O
ongoing	O
seizure	O
activity	O
.	O
Interictally	O
,	O
it	O
captured	O
epileptic	O
discharges	O
independently	O
in	O
the	O
right	O
frontal	O
,	O
right	O
central	O
parietal	O
,	O
and	O
left	O
fronto	O
-	O
temporal	O
areas	O
.	O
The	O
background	O
activity	O
was	O
slow	O
suggestive	O
of	O
diffuse	O
encephalopathy	O
with	O
additional	O
focal	O
slowing	O
seen	O
in	O
the	O
right	O
central	O
area	O
suggestive	O
of	O
subcortical	O
dysfunction	O
in	O
that	O
region	O
.	O
CT	O
Head	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
process	O
.	O
2	O
.	O
Chronic	O
left	O
pontine	O
lacunar	O
infarct	O
,	O
new	O
compared	O
to	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
[	O
**	O
2172	O
**	O
]	O
.	O
3	O
.	O
Posterior	O
dislocation	O
of	O
the	O
right	O
ocular	O
lens	O
,	O
new	O
since	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
[	O
**	O
2172	O
**	O
]	O
.	O
CTA	O
Chest	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
central	O
,	O
segmental	O
or	O
large	O
subsegmental	O
pulmonary	O
embolism	O
.	O
2	O
.	O
Bibasilar	O
consolidations	O
,	O
could	O
reflect	O
atelectasis	O
or	O
pneumonia	O
.	O
3	O
.	O
Left	O
thyroid	O
lobe	O
nodule	O
.	O
4	O
.	O
Coronary	O
artery	O
disease	O
.	O
5	O
.	O
Indeterminant	O
right	O
hepatic	O
lobe	O
lesion	O
most	O
likely	O
cyst	O
or	O
hemangioma	O
Micro	O
:	O
[	O
**	O
2174-6-5	O
**	O
]	O
URINE	O
URINE	O
CULTURE	O
negative	O
[	O
**	O
2174-6-5	O
**	O
]	O
URINE	O
Legionella	O
Urinary	O
Antigen	O
negative	O
[	O
**	O
2174-6-5	O
**	O
]	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST	O
negative	O
[	O
**	O
2174-6-4	O
**	O
]	O
MRSA	O
SCREEN	O
MRSA	O
SCREEN	O
-	O
positive	O
[	O
**	O
2174-6-3	O
**	O
]	O
BLOOD	O
CULTURE	O
Blood	O
Culture	O
,	O
pending	O
[	O
**	O
2174-6-3	O
**	O
]	O
BLOOD	O
CULTURE	O
Blood	O
Culture	O
,	O
pending	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
4587	O
**	O
]	O
is	O
a	O
74	O
yo	O
M	O
with	O
h	O
/	O
o	O
strokes	O
resultant	O
in	O
minimal	O
responsiveness	O
,	O
aphagia	O
,	O
frequent	O
aspiration	O
,	O
who	O
presented	O
from	O
[	O
**	O
Hospital3	O
**	O
]	O
with	O
tachypnea	O
and	O
question	O
of	O
seizure	O
-	O
like	O
activity	O
.	O
#	O
?	O
Aspiration	O
Pneumonia	O
:	O
Patient	O
presented	O
with	O
tachypnea	O
,	O
fever	O
,	O
tachycardia	O
,	O
elevated	O
WBC	O
and	O
was	O
admitted	O
to	O
the	O
MICU	O
.	O
He	O
was	O
started	O
empirically	O
on	O
Vancomycin	I-Drug
and	O
Zosyn	I-Drug
for	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
Chest	O
CT	O
-	O
A	O
ruled	O
out	O
PE	O
,	O
as	O
he	O
was	O
not	O
on	O
any	O
DVT	O
prophylaxis	O
at	O
the	O
nursing	O
facility	O
.	O
Chest	O
CT	O
also	O
showed	O
bibasilar	O
atelectasis	O
vs	O
consolidation	O
.	O
Patient	O
was	O
transitioned	O
to	O
azithromycin	I-Drug
and	O
transferred	O
to	O
floor	O
when	O
hemodynamically	O
stable	O
.	O
On	O
the	O
floor	O
,	O
he	O
was	O
restarted	O
on	O
Vancomycin	I-Drug
and	O
Zosyn	I-Drug
for	O
concern	O
of	O
aspiration	B-Reason
pneumonia	I-Reason
,	O
re-evaluating	O
bibasilar	O
consolidations	O
on	O
Chest	O
CT	O
,	O
likely	O
secondary	O
to	O
chronic	O
aspiration	O
from	O
tube	O
feeds	O
.	O
Pt	O
was	O
discharged	O
bac	O
kto	O
the	O
facility	O
to	O
continue	O
IV	O
antibiotics	I-Drug
for	O
a	O
total	O
of	O
7	O
days	O
.	O
Pt	O
was	O
without	O
fevers	O
or	O
leukocytosis	O
at	O
the	O
time	O
of	O
discharge	O
.	O
#	O
History	O
of	O
Seizures	I-Reason
:	O
Patient	O
was	O
reported	O
to	O
have	O
had	O
seizure	O
-	O
like	O
activity	O
prior	O
to	O
presentation	O
.	O
Corrected	O
Dilantin	I-Drug
level	O
was	O
within	O
therapeutic	O
range	O
.	O
Pt	O
was	O
continued	O
on	O
seizure	O
ppx	O
,	O
and	O
had	O
no	O
clinically	O
evident	O
seizure	O
activity	O
.	O
A	O
48	O
hr	O
EEG	O
was	O
performed	O
which	O
showed	O
no	O
seizure	O
activity	O
,	O
only	O
epileptic	O
interictal	O
discharges	O
,	O
consistent	O
with	O
past	O
stroke	O
.	O
#	O
Diabetes	B-Reason
Mellitus	I-Reason
:	O
Patient	O
was	O
continued	O
on	O
home	O
insulin	I-Drug
regimen	O
.	O
#	O
Hypertension	I-Reason
:	O
Patient	O
was	O
continued	O
on	O
BB	I-Drug
,	O
Hydralazine	I-Drug
and	O
Lisinopril	I-Drug
.	O
#	O
Anemia	O
:	O
Is	O
normocytic	O
,	O
likely	O
secondary	O
to	O
chronic	O
disease	O
.	O
Hct	O
was	O
stable	O
,	O
a	O
fecal	O
occult	O
blood	O
was	O
ordered	O
.	O
.	O
#	O
Patient	O
was	O
DNR	O
/	O
DNI	O
during	O
this	O
hospitalization	O
.	O
Pt	O
has	O
a	O
left	O
PICC	O
for	O
IV	O
access	O
.	O
Pt	O
was	O
maintained	O
on	O
SC	O
Heparin	I-Drug
for	O
DVT	I-Reason
ppx	O
.	O
Pt	O
was	O
on	O
tube	O
feeds	O
for	O
nutrition	O
.	O
Medications	O
on	O
Admission	O
:	O
Lisinopril	I-Drug
60	O
mg	O
via	O
G	O
tube	O
daily	O
KCL	I-Drug
elixir	O
20Meq	O
twice	O
daily	O
Novolin	I-Drug
4	O
SS	O
Lantus	I-Drug
26U	O
daily	O
Dilantin	I-Drug
25	O
mg	O
at	O
10	O
am	O
,	O
50	O
mg	O
50	O
mg	O
at	O
bedtime	O
Enulose	I-Drug
30	O
ml	O
via	O
G	O
tube	O
BIC	O
Docusate	I-Drug
liquid	O
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Metoprolol	I-Drug
10	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Hydralazine	I-Drug
40	O
mg	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
MOM	I-Drug
30	O
mg	O
NGT	O
TIW	O
Albuterol	I-Drug
nasal	O
neb	O
q6h	O
prn	O
SOB	I-Reason
Discharge	O
Medications	O
:	O
1	O
.	O
Lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Hydralazine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
4	O
.	O
Phenytoin	I-Drug
50	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
0.5	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
10	O
am	O
.	O
5	O
.	O
Phenytoin	I-Drug
50	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
6	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
.	O
7	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Lactulose	I-Drug
10	O
gram	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Vancomycin	B-Drug
in	I-Drug
D5W	I-Drug
1	O
gram	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
Q	O
12H	O
(	O
Every	O
12	O
Hours	O
)	O
for	O
5	O
days	O
.	O
10	O
.	O
Piperacillin	B-Drug
-	I-Drug
Tazobactam	I-Drug
-	I-Drug
Dextrs	I-Drug
4.5	O
gram	O
/	O
100	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
for	O
5	O
days	O
.	O
11	O
.	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
twice	O
a	O
day	O
.	O
12	O
.	O
Novolin	B-Drug
R	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
units	O
Injection	O
four	O
times	O
a	O
day	O
:	O
sliding	O
scale	O
.	O
13	O
.	O
Lantus	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Twenty	O
Six	O
(	O
26	O
)	O
units	O
Subcutaneous	O
once	O
a	O
day	O
.	O
14	O
.	O
Milk	B-Drug
of	I-Drug
Magnesia	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
mg	O
PO	O
three	O
times	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
2558	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Aspiration	O
Pneumonia	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
always	O
.	O
Level	O
of	O
Consciousness	O
:	O
Lethargic	O
but	O
arousable	O
.	O
Activity	O
Status	O
:	O
Bedbound	O
.	O
Discharge	O
Instructions	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
4587	O
**	O
]	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
was	O
having	O
difficulty	O
breathing	O
.	O
He	O
was	O
initially	O
in	O
the	O
ICU	O
,	O
where	O
he	O
was	O
started	O
on	O
IV	O
antibiotics	I-Drug
for	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
Pt	O
was	O
then	O
transferred	O
to	O
the	O
medicine	O
floor	O
.	O
An	O
EEG	O
was	O
performed	O
which	O
showed	O
no	O
seizure	O
activity	O
.	O
Pt	O
was	O
then	O
discharged	O
back	O
to	O
the	O
facility	O
.	O
He	O
needs	O
immediate	O
medical	O
attention	O
if	O
he	O
experiences	O
difficulty	O
breathing	O
,	O
has	O
fevers	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
Please	O
make	O
th	O
following	O
changes	O
to	O
his	O
medications	O
:	O
START	O
Piperacillin	B-Drug
-	I-Drug
Tazobactam	I-Drug
4.5	O
g	O
IV	O
every	O
8	O
hours	O
for	O
5	O
more	O
days	O
START	O
Vancomycin	I-Drug
1000	O
mg	O
IV	O
every	O
12	O
hours	O
for	O
5	O
more	O
days	O
You	O
will	O
need	O
to	O
have	O
your	O
thyroid	O
nodule	O
followed	O
up	O
.	O
Followup	O
Instructions	O
:	O
You	O
will	O
be	O
followed	O
by	O
doctors	O
at	O
the	O
facility	O
.	O
They	O
will	O
provide	O
you	O
with	O
a	O
follow	O
-	O
up	O
appointment	O
with	O
your	O
primary	O
care	O
doctor	O
in	O
the	O
future	O
.	O
Completed	O
by	O
:[	O
**	O
2174-6-7	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2156-4-26	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2156-5-1	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2086-12-6	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Niacin	I-Drug
/	O
aspirin	I-Drug
/	O
Codeine	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
290	O
**	O
]	O
Chief	O
Complaint	O
:	O
GI	O
Bleed	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
enteroscopy	O
[	O
**	O
2156-4-29	O
**	O
]	O
and	O
[	O
**	O
2156-4-30	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
HMED	O
ATTENDING	O
ADMISSION	O
NOTE	O
.	O
ADMIT	O
DATE	O
:	O
[	O
**	O
2156-4-26	O
**	O
]	O
ADMIT	O
TIME	O
:	O
2345	O
.	O
PCP	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
1575	O
**	O
]	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
.	O
Address	O
:	O
[	O
**	O
Doctor	O
Last	O
Name	O
32771	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
17464	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
8340	O
**	O
]	O
Fax	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
8341	O
**	O
]	O
.	O
Cardiology	O
:	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
2855	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
32772	O
**	O
]	O
Address	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
[	O
**	O
Apartment	O
Address	O
(	O
1	O
)	O
32773	O
**	O
]	O
.	O
[	O
**	O
Location	O
(	O
un	O
)	O
936	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
14967	O
**	O
]	O
.	O
69	O
yo	O
M	O
with	O
CAD	O
s	O
/	O
p	O
CABG	O
complicated	O
be	O
restenosis	O
requiring	O
multiple	O
stents	O
,	O
mechanical	B-Reason
aortic	I-Reason
valve	I-Reason
on	O
coumadin	I-Drug
,	O
recurrent	I-Ade
GI	O
bleeding	O
and	O
IDDM	O
who	O
is	O
transferred	O
from	O
[	O
**	O
Hospital3	O
**	O
]	O
for	O
advanced	O
endoscopy	O
for	O
management	O
of	O
active	O
upper	O
GI	O
bleed	O
.	O
.	O
Patient	O
was	O
admitted	O
to	O
[	O
**	O
Hospital6	O
33	O
**	O
]	O
approximately	O
one	O
week	O
ago	O
with	O
melena	O
and	O
hematocrit	O
of	O
22	O
,	O
found	O
to	O
have	O
a	O
NSTEMI	O
(	O
medical	O
management	O
per	O
cardiology	O
,	O
restarted	O
on	O
plavix	I-Drug
-	O
d	O
/	O
c	O
'	O
ed	O
in	O
[	O
**	O
2154	O
**	O
]	O
given	O
recurrent	B-Ade
gi	I-Ade
bleeds	I-Ade
,	O
1	O
month	O
after	O
BMS	O
placed	O
)	O
.	O
Upper	O
endoscopy	O
was	O
unrevealing	O
except	O
for	O
mild	O
gastritis	O
.	O
Colonoscopy	O
last	O
done	O
one	O
year	O
ago	O
which	O
was	O
unremarkable	O
except	O
for	O
benign	O
polyps	O
.	O
Patient	O
was	O
transfused	O
4	O
units	O
of	O
pRBCs	I-Drug
,	O
hematorcrit	O
increased	O
to	O
27	O
and	O
discharged	O
three	O
days	O
ago	O
.	O
Of	O
note	O
,	O
he	O
required	O
diuresis	O
for	O
decompensated	O
CHF	O
.	O
Was	O
seen	O
in	O
the	O
ED	O
on	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
for	O
chest	O
pain	O
,	O
no	O
EKG	O
changes	O
,	O
resolved	O
with	O
nitro	O
,	O
discharged	O
home	O
.	O
.	O
Patient	O
was	O
re-admitted	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
today	O
(	O
[	O
**	O
2156-4-26	O
**	O
]	O
)	O
with	O
recurrent	O
melena	O
.	O
Last	O
night	O
he	O
had	O
two	O
black	O
/	O
tarry	O
stools	O
.	O
He	O
also	O
endorsed	O
some	O
mild	O
chest	O
pain	O
.	O
His	O
hematocrit	O
on	O
admission	O
was	O
26.2	O
.	O
Patient	O
transfused	O
1	O
unit	O
of	O
packed	B-Drug
cells	I-Drug
.	O
He	O
ruled	O
out	O
for	O
ACS	O
by	O
three	O
sets	O
of	O
negative	O
cardiac	O
enzymes	O
and	O
non-ischemic	O
EKG	O
.	O
Patient	O
underwent	O
a	O
CT	O
angiogram	O
which	O
revealed	O
3	O
small	O
bowel	O
foci	O
of	O
hemorrhage	O
likely	O
in	O
the	O
proximal	O
ileum	O
.	O
Given	O
the	O
location	O
of	O
the	O
bleeding	O
decision	O
made	O
by	O
gastroenterologist	O
to	O
transfer	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
single	O
balloon	O
enteroscopy	O
.	O
Patient	O
has	O
been	O
continued	O
on	O
plavix	I-Drug
given	O
his	O
significant	O
cardiac	O
comorbidities	O
.	O
He	O
has	O
been	O
bridged	O
with	O
a	O
heparin	I-Drug
gtt	O
for	O
a	B-Reason
subtherapeutic	I-Reason
INR	I-Reason
of	I-Reason
1.9	I-Reason
.	O
.	O
Of	O
note	O
,	O
patient	O
had	O
recurrent	O
GI	O
bleeding	O
at	O
site	O
of	O
anastamosis	O
from	O
sigmoid	O
colectomy	O
in	O
[	O
**	O
2154	O
**	O
]	O
,	O
requiring	O
multiple	O
transfusions	O
.	O
Was	O
on	O
asa	I-Drug
/	O
plavix	I-Drug
/	O
coumadin	I-Drug
with	O
recent	O
BMS	O
placed	O
in	O
diagonal	O
.	O
ASA	I-Drug
stopped	O
and	O
plavix	I-Drug
discontinued	O
1	O
month	O
after	O
BMS	O
placement	O
given	O
recurrent	O
bleeding	O
.	O
He	O
had	O
no	O
further	O
bleeding	O
issues	O
until	O
this	O
past	O
week	O
.	O
.	O
Currently	O
patient	O
has	O
no	O
complaints	O
.	O
Denies	O
any	O
current	O
chest	O
pain	O
,	O
sob	O
,	O
lightheadedness	O
or	O
dizziness	O
.	O
No	O
nausea	O
,	O
vomiting	O
or	O
abdominal	O
pain	O
.	O
Reports	O
one	O
episode	O
of	O
black	O
stool	O
prior	O
to	O
transfer	O
.	O
.	O
ROS	O
as	O
per	O
HPI	O
,	O
10	O
pt	O
ROS	O
otherwise	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
CAD	O
s	O
/	O
p	O
CABG	O
2v	O
[	O
**	O
2135	O
**	O
]	O
,	O
restenosis	O
requiring	O
multiple	O
stents	O
,	O
[	O
**	O
2151	O
**	O
]	O
DES	O
for	O
RCA	O
stenosis	O
,	O
[	O
**	O
2152	O
**	O
]	O
NSTEMI	O
medically	O
managed	O
,	O
[	O
**	O
2154	O
**	O
]	O
BMS	O
diagonal	O
-	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
923	O
**	O
]	O
aortic	O
valve	O
replacement	O
[	O
**	O
2135	O
**	O
]	O
-	O
IDDM	O
-	O
COPD	O
-	O
Diverticulitis	O
s	O
/	O
p	O
sigmoid	O
colectomy	O
complicated	O
by	O
unstable	O
angina	O
,	O
s	O
/	O
p	O
cardiac	O
cath	O
and	O
BMS	O
to	O
diagonal	O
,	O
then	O
developed	O
recurrent	B-Ade
bleeding	I-Ade
on	O
asa	I-Drug
/	O
plavix	I-Drug
/	O
coumadin	I-Drug
therefore	O
plavix	I-Drug
d	O
/	O
c	O
'	O
ed	O
after	O
1	O
month	O
-	O
HTN	O
-	O
Hypothyroidism	O
-	O
CHF	O
-	O
Anxiety	O
-	O
S	O
/	O
p	O
knee	O
replacement	O
[	O
**	O
2152	O
**	O
]	O
complicated	O
NSTEMI	O
and	O
CHF	O
exacerbation	O
-	O
Hernia	O
repair	O
Social	O
History	O
:	O
Lives	O
with	O
wife	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
32774	O
**	O
]	O
and	O
grandson	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
32775	O
**	O
]	O
,	O
MA	O
.	O
Retired	O
heavy	O
lift	O
mechanic	O
.	O
+	O
tobacco	O
,	O
1	O
ppd	O
x	O
55	O
yrs	O
.	O
No	O
etoh	O
or	O
illicits	O
.	O
Family	O
History	O
:	O
+	O
CAD	O
and	O
DM	O
,	O
no	O
hx	O
of	O
gi	O
bleeds	O
Physical	O
Exam	O
:	O
ON	O
ADMISSION	O
:	O
VS	O
:	O
97.9	O
138/79	O
56	O
20	O
96	O
%	O
RA	O
Appearance	O
:	O
alert	O
,	O
NAD	O
,	O
obese	O
Eyes	O
:	O
eomi	O
,	O
perrl	O
,	O
anicteric	O
ENT	O
:	O
OP	O
clear	O
s	O
lesions	O
,	O
mmd	O
,	O
no	O
JVD	O
,	O
neck	O
supple	O
Cv	O
:	O
+	O
s1	O
,	O
s2	O
mechanical	O
aortic	O
click	O
,	O
no	O
peripheral	O
edema	O
,	O
2	O
+	O
dp	O
/	O
pt	O
bilaterally	O
Pulm	O
:	O
clear	O
bilaterally	O
,	O
diminished	O
at	O
bases	O
Abd	O
:	O
soft	O
,	O
obese	O
,	O
midline	O
scar	O
,	O
nt	O
,	O
nd	O
,	O
+	O
bs	O
Msk	O
:	O
5/5	O
strength	O
throughout	O
,	O
no	O
joint	O
swelling	O
,	O
no	O
cyanosis	O
or	O
clubbing	O
Neuro	O
:	O
cn	O
2	O
-	O
12	O
grossly	O
intact	O
,	O
no	O
focal	O
deficits	O
Skin	O
:	O
no	O
rashes	O
Psych	O
:	O
appropriate	O
,	O
pleasant	O
Heme	O
:	O
no	O
cervical	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
Pertinent	O
Results	O
:	O
[	O
**	O
Hospital6	O
33	O
**	O
]	O
labs	O
:	O
.	O
[	O
**	O
2156-4-26	O
**	O
]	O
.	O
6.3	O
>	O
[	O
**	O
10	O
-	O
20	O
**	O
]	O
<	O
148	O
.	O
138	O
100	O
18	O
------------	O
<	O
161	O
3.2	O
28	O
1.0	O
.	O
LFTs	O
wnl	O
.	O
[	O
**	O
Hospital6	O
33	O
**	O
]	O
Images	O
:	O
.	O
[	O
**	O
2156-4-26	O
**	O
]	O
CT	O
angio	O
a	O
/	O
p	O
:	O
three	O
small	O
foci	O
of	O
hemorrhage	O
,	O
located	O
in	O
proximal	O
ileum	O
with	O
extravasation	O
of	O
intraluminal	B-Drug
intravenous	I-Drug
contrast	I-Drug
may	O
be	O
due	O
to	O
angiodysplasia	O
,	O
no	O
evidence	O
for	O
underlying	O
mucosal	O
masses	O
;	O
colonic	O
diverticulosis	O
without	O
diverticulitis	O
,	O
mild	O
splenomegaly	O
.	O
[	O
**	O
2156-5-1	O
**	O
]	O
:	O
WBC	O
3.1	O
HCT	O
24.6	O
PLT	O
95	O
[	O
**	O
2156-4-30	O
**	O
]	O
HCT	O
25.7	O
PLT	O
105	O
[	O
**	O
2156-4-28	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
WBC	O
-	O
3.6	O
*	O
RBC	O
-	O
3.02	O
*	O
Hgb	O
-	O
10.1	O
*	O
Hct	O
-	O
29.2	O
*	O
MCV	O
-	O
97	O
MCH	O
-	O
33.6	O
*	O
MCHC	O
-	O
34.7	O
RDW	O
-	O
17.8	O
*	O
Plt	O
Ct	O
-	O
129	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
09:04	O
PM	O
BLOOD	O
Hct	O
-	O
29.9	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
03:16	O
PM	O
BLOOD	O
Hct	O
-	O
30.9	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
09:00	O
AM	O
BLOOD	O
Hct	O
-	O
28.5	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
05:15	O
AM	O
BLOOD	O
WBC	O
-	O
3.7	O
*	O
RBC	O
-	O
2.72	O
*	O
Hgb	O
-	O
9.5	O
*	O
Hct	O
-	O
26.8	O
*	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
34.8	O
*	O
MCHC	O
-	O
35.3	O
*	O
RDW	O
-	O
17.2	O
*	O
Plt	O
Ct	O
-	O
134	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
WBC	O
-	O
4.0	O
#	O
RBC	O
-	O
2.84	O
*	O
#	O
Hgb	O
-	O
9.5	O
*	O
#	O
Hct	O
-	O
27.7	O
*	O
MCV	O
-	O
98	O
#	O
MCH	O
-	O
33.4	O
*	O
#	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
17.1	O
*	O
Plt	O
Ct	O
-	O
134	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
Neuts	O
-	O
55	O
Bands	O
-	O
0	O
Lymphs	O
-	O
35	O
Monos	O
-	O
8	O
Eos	O
-	O
2	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
Hypochr	O
-	O
NORMAL	O
Anisocy	O
-	O
2	O
+	O
Poiklo	O
-	O
2	O
+	O
Macrocy	O
-	O
2	O
+	O
Microcy	O
-	O
NORMAL	O
Polychr	O
-	O
NORMAL	O
Ovalocy	O
-	O
1	O
+	O
Pencil	O
-	O
OCCASIONAL	O
Ellipto	O
-	O
OCCASIONAL	O
[	O
**	O
2156-5-1	O
**	O
]	O
:	O
INR	O
1.7	O
[	O
**	O
2156-4-28	O
**	O
]	O
06:40	O
PM	O
BLOOD	O
PT	O
-	O
19.7	O
*	O
PTT	O
-	O
75.3	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.9	O
*	O
[	O
**	O
2156-4-28	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
129	O
*	O
[	O
**	O
2156-4-28	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
PT	O
-	O
19.2	O
*	O
PTT	O
-	O
109.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.8	O
*	O
[	O
**	O
2156-4-28	O
**	O
]	O
02:48	O
AM	O
BLOOD	O
PT	O
-	O
19.0	O
*	O
PTT	O
-	O
112.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.8	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
08:55	O
PM	O
BLOOD	O
PT	O
-	O
18.9	O
*	O
PTT	O
-	O
56.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.8	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
01:00	O
PM	O
BLOOD	O
PT	O
-	O
20.7	O
*	O
PTT	O
-	O
42.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.0	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
05:15	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
134	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
05:15	O
AM	O
BLOOD	O
PT	O
-	O
22.3	O
*	O
PTT	O
-	O
150	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.1	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
Plt	O
Smr	O
-	O
LOW	O
Plt	O
Ct	O
-	O
134	O
*	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
PT	O
-	O
23.0	O
*	O
PTT	O
-	O
45.1	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.2	O
*	O
RENAL	O
&	O
GLUCOSE	O
Glucose	O
UreaN	O
Creat	O
Na	O
K	O
Cl	O
HCO3	O
AnGap	O
[	O
**	O
2156-5-1	O
**	O
]	O
02:22	O
glu131	O
*	O
urea	O
N9	O
cr0	O
.9	O
na140	O
k3	O
.5	O
cl108	O
hco3	O
24	O
AG12	O
[	O
**	O
2156-4-28	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
Glucose	O
-	O
85	O
UreaN	O
-	O
13	O
Creat	O
-	O
1.1	O
Na	O
-	O
141	O
K	O
-	O
3.9	O
Cl	O
-	O
105	O
HCO3	O
-	O
25	O
AnGap	O
-	O
15	O
[	O
**	O
2156-4-27	O
**	O
]	O
05:15	O
AM	O
BLOOD	O
Glucose	O
-	O
95	O
UreaN	O
-	O
11	O
Creat	O
-	O
0.9	O
Na	O
-	O
142	O
K	O
-	O
3.4	O
Cl	O
-	O
104	O
HCO3	O
-	O
26	O
AnGap	O
-	O
15	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
Glucose	O
-	O
80	O
UreaN	O
-	O
12	O
Creat	O
-	O
1.0	O
Na	O
-	O
143	O
K	O
-	O
3.7	O
Cl	O
-	O
105	O
HCO3	O
-	O
28	O
AnGap	O
-	O
14	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
Lipase	O
-	O
29	O
[	O
**	O
2156-5-1	O
**	O
]	O
ca8	O
.0	O
*	O
mg2	O
.4	O
*	O
phos1	O
.8	O
[	O
**	O
2156-4-28	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.2	O
Mg	O
-	O
2.3	O
[	O
**	O
2156-4-27	O
**	O
]	O
05:15	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.0	O
Mg	O
-	O
2.4	O
[	O
**	O
2156-4-27	O
**	O
]	O
12:40	O
AM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
3.1	O
Mg	O
-	O
1.0	O
*	O
.	O
[	O
**	O
4	O
-	O
28	O
**	O
]	O
ECHO	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
global	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
arch	O
is	O
mildly	O
dilated	O
.	O
A	O
mechanical	O
aortic	O
valve	O
prosthesis	O
is	O
present	O
.	O
The	O
transaortic	O
gradient	O
is	O
higher	O
than	O
expected	O
for	O
this	O
type	O
of	O
prosthesis	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
[	O
Normal	O
for	O
this	O
prosthesis	O
.	O
]	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
A	O
mitral	O
valve	O
annuloplasty	O
ring	O
is	O
present	O
.	O
The	O
gradient	O
across	O
the	O
mitral	O
valve	O
is	O
slightly	O
increased	O
(	O
mean	O
=	O
3	O
-	O
4	O
mmHg	O
)	O
resulting	O
in	O
trivial	O
/	O
minimal	O
mitral	O
stenosis	O
.	O
No	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
[	O
Due	O
to	O
acoustic	O
shadowing	O
,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
may	O
be	O
significantly	O
UNDERestimated	O
.	O
]	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Suboptimal	O
image	O
quality	O
.	O
Well	O
seated	O
mechanical	O
aortic	O
valve	O
but	O
with	O
increased	O
gradient	O
.	O
Well	O
seated	O
mitral	O
annuloplasty	O
ring	O
with	O
trivial	O
mitral	O
stenosis	O
.	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
biventricular	O
systolic	O
function	O
.	O
Pulmonary	O
artery	O
hypertension	O
.	O
Dilated	O
thoracic	O
aorta	O
.	O
Compared	O
with	O
the	O
report	O
of	O
the	O
prior	O
study	O
(	O
images	O
unavailable	O
for	O
review	O
)	O
of	O
[	O
**	O
2144-12-25	O
**	O
]	O
,	O
the	O
aortic	O
valve	O
gradient	O
is	O
increased	O
and	O
minimal	O
mitral	O
stenosis	O
is	O
now	O
identified	O
.	O
If	O
clinically	O
indicated	O
,	O
a	O
TEE	O
may	O
be	O
better	O
able	O
to	O
define	O
the	O
cause	O
of	O
the	O
increased	O
gradient	O
across	O
the	O
aortic	O
valve	O
.	O
.	O
[	O
**	O
2156-4-30	O
**	O
]	O
small	O
bowel	O
enteroscopy	O
report	O
:	O
(	O
from	O
above	O
)	O
Healthy	O
surgical	O
anastomosis	O
at	O
left	O
colon	O
corresponding	O
to	O
the	O
previous	O
colectomy	O
.	O
Moderate	O
to	O
severe	O
diverticulosis	O
in	O
the	O
entire	O
colon	O
.	O
The	O
terminal	O
ileum	O
was	O
entered	O
and	O
the	O
scope	O
was	O
advanced	O
to	O
the	O
proximal	O
/	O
mid	O
ileum	O
.	O
A	O
few	O
tiny	O
red	O
spots	O
were	O
seen	O
.	O
But	O
there	O
was	O
no	O
active	O
bleeding	O
.	O
No	O
AVM	O
or	O
mass	O
lesions	O
were	O
seen	O
.	O
Otherwise	O
normal	O
small	O
bowel	O
enteroscopy	O
to	O
third	O
part	O
of	O
the	O
duodenum	O
.	O
.	O
[	O
**	O
2156-4-29	O
**	O
]	O
small	O
bowel	O
enteroscopy	O
report	O
:	O
(	O
from	O
below	O
)	O
The	O
examined	O
proximal	O
ileum	O
was	O
normal	O
.	O
No	O
active	O
bleeding	O
or	O
AVM	O
or	O
mass	O
was	O
seen	O
.	O
Impression	O
:	O
Normal	O
esophagus	O
;	O
A	O
tiny	O
nonbleeding	O
erosion	O
seen	O
at	O
the	O
antrum	O
;	O
Mild	O
and	O
pathy	O
erythema	O
seen	O
at	O
duodenal	O
bulb	O
;	O
Normal	O
jejunum	O
.	O
No	O
active	O
bleeding	O
or	O
AVM	O
or	O
mass	O
seen	O
.	O
Itattooed	O
for	O
marking	O
;	O
Normal	O
proximal	O
ileum	O
.	O
No	O
active	O
bleeding	O
or	O
AVM	O
or	O
mass	O
seen	O
.	O
Otherwise	O
normal	O
small	O
bowel	O
enteroscopy	O
to	O
distal	O
jejunum	O
/	O
proximal	O
ileum	O
.	O
Brief	O
Hospital	O
Course	O
:	O
REASON	O
FOR	O
ICU	O
ADMISSION	O
:	O
Pt	O
is	O
a	O
69	O
y.o	O
male	O
with	O
h.o	O
CAD	O
s	O
/	O
p	O
CABG	O
complicated	O
by	O
restenosis	O
requiring	O
multiple	O
stents	O
and	O
recent	O
NSTEMI	O
,	O
mechanical	B-Reason
aortic	I-Reason
valve	I-Reason
on	O
coumadin	I-Drug
,	O
recurrent	B-Ade
GI	I-Ade
bleeds	I-Ade
and	O
IDDM	O
who	O
was	O
transferred	O
from	O
OSH	O
with	O
melena	O
and	O
CTA	O
showing	O
active	O
bleeding	O
in	O
proximal	O
ileum	O
.	O
.	O
#upper	O
GI	O
bleed	O
/	O
acute	O
blood	O
loss	O
/	O
anemia	O
-	O
CTA	O
per	O
OSH	O
report	O
showed	O
active	O
bleeding	O
in	O
the	O
proximal	O
ileum	O
.	O
Pt	O
with	O
recent	O
EGD	O
with	O
non-bleeding	O
gastritis	O
.	O
Last	O
colonoscopy	O
1	O
yr	O
ago	O
with	O
polyps	O
.	O
UGIB	I-Ade
in	O
the	O
setting	O
of	O
restarting	O
plavix	I-Drug
1	O
week	O
ago	O
for	O
NSTEMI	I-Reason
.	O
PT	O
also	O
on	O
couamdin	I-Drug
for	O
mechanical	B-Reason
valve	I-Reason
,	O
and	O
started	O
on	O
heparin	I-Drug
ggt	O
as	O
coumadin	I-Drug
was	O
held	O
in	O
setting	O
of	O
procedure	O
.	O
Hct	O
remained	O
stable	O
.	O
Pt	O
was	O
placed	O
on	O
a	O
protonix	I-Drug
gtt	O
.	O
Plavix	I-Drug
was	O
continued	O
up	O
until	O
transfer	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
,	O
then	O
restarted	O
.	O
Discussed	O
anticoagulation	I-Drug
with	O
patient	O
's	O
cardiologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
32772	O
**	O
]	O
who	O
felt	O
as	O
though	O
pt	O
should	O
be	O
on	O
heparin	I-Drug
gtt	O
as	O
long	O
as	O
deemed	O
safe	O
from	O
GI	O
procedure	O
prospective	O
.	O
Would	O
prefer	O
to	O
restart	O
ASAP	O
after	O
any	O
procedure	O
.	O
In	O
addition	O
,	O
outpt	O
cardiologist	O
felt	O
as	O
though	O
pt	O
should	O
be	O
on	O
plavix	I-Drug
unless	O
there	O
is	O
presence	O
of	O
hemodynamically	O
significant	O
GI	O
bleeding	O
.	O
He	O
agreed	O
that	O
pt	O
does	O
not	O
tolerate	O
dual	O
anti-platelet	B-Drug
therapy	I-Drug
(	O
per	O
pt	O
,	O
ASA	I-Drug
caused	O
bleeding	I-Ade
)	O
.	O
Enteroscopy	O
was	O
performed	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
2156-4-29	O
**	O
]	O
which	O
showed	O
no	O
evidence	O
of	O
bleeding	O
via	O
approach	O
from	O
above	O
.	O
Small	O
bowel	O
enteroscopy	O
/	O
colonoscopy	O
was	O
performed	O
[	O
**	O
2156-4-30	O
**	O
]	O
which	O
was	O
similarly	O
unremarkable	O
.	O
Pt	O
was	O
restarted	O
on	O
warfarin	I-Drug
and	O
heparin	I-Drug
gtt	O
.	O
Pt	O
went	O
home	O
[	O
**	O
2156-5-1	O
**	O
]	O
on	O
lovenox	I-Drug
as	O
bridge	O
,	O
with	O
INR	O
checks	O
planned	O
for	O
[	O
**	O
2156-5-3	O
**	O
]	O
and	O
[	O
**	O
2156-5-5	O
**	O
]	O
.	O
.	O
#CORONARY	O
ARTERY	O
DISEASE	O
:	O
s	O
/	O
p	O
CABG	O
and	O
PCI	O
x2	O
,	O
severe	O
CAD	O
with	O
chronic	O
angina	O
medically	O
managed	O
.	O
Recent	O
NSTEMI	I-Reason
with	O
decision	O
to	O
restart	O
plavix	I-Drug
after	O
being	O
held	O
x2	O
years	O
due	O
to	O
recurrent	B-Ade
GI	I-Ade
bleeds	O
.	O
At	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
plavix	I-Drug
was	O
held	O
initially	O
as	O
GI	O
team	O
was	O
uncomfortable	O
doing	O
procedure	O
on	O
plavix	I-Drug
as	O
interventions	O
for	O
bleeding	I-Ade
(	O
ex	O
.	O
clipping	O
,	O
cauterization	O
could	O
lead	O
to	O
more	O
bleeding	I-Ade
while	O
on	O
plavix	I-Drug
)	O
.	O
In	O
addition	O
,	O
it	O
was	O
felt	O
that	O
at	O
the	O
time	O
plavix	I-Drug
effects	O
would	O
still	O
be	O
in	O
his	O
system	O
as	O
there	O
was	O
no	O
complete	O
washout	O
period	O
.	O
As	O
above	O
,	O
discussed	O
case	O
with	O
pt	O
's	O
outpatient	O
cardiologist	O
who	O
felt	O
that	O
pt	O
would	O
need	O
to	O
remain	O
on	O
plavix	I-Drug
unless	O
life	O
hemodynamically	O
significant	O
GI	O
bleeding	O
.	O
Pt	O
was	O
continued	O
on	O
imdur	I-Drug
,	O
statin	I-Drug
,	O
beta	B-Drug
blocker	I-Drug
held	O
,	O
see	O
bradycardia	I-Ade
below	O
.	O
He	O
was	O
ruled	O
out	O
for	O
MI	O
at	O
OSH	O
prior	O
to	O
transfer	O
.	O
He	O
was	O
monitored	O
on	O
tele	O
.	O
Without	O
events	O
.	O
.	O
#	O
MECHANICAL	O
AORTIC	O
VALVE	O
:	O
placed	O
at	O
St.	O
[	O
**	O
Male	O
First	O
Name	O
(	O
un	O
)	O
1525	O
**	O
]	O
.	O
Patient	O
's	O
goal	O
INR	O
3.5	O
for	O
mechanical	B-Reason
valve	I-Reason
.	O
Was	O
switched	O
to	O
heparin	I-Drug
which	O
was	O
stopped	O
6	O
hours	O
prior	O
to	O
procedures	O
.	O
Given	O
significant	O
risk	B-Reason
of	I-Reason
thrombosis	O
,	O
heparin	I-Drug
was	O
restarted	O
after	O
procedures	O
,	O
despite	O
patient	O
's	O
known	O
GI	O
bleed	O
.	O
HCT	O
was	O
monitored	O
closely	O
and	O
remained	O
stable	O
.	O
Heparin	I-Drug
gtt	O
was	O
changed	O
to	O
lovenox	I-Drug
on	O
discharge	O
,	O
see	O
above	O
.	O
.	O
#	O
Bradycardia	I-Ade
:	O
Patient	O
noted	O
to	O
be	O
bradycardic	O
after	O
procedure	O
.	O
Thought	O
to	O
be	O
related	O
to	O
sedation	I-Drug
for	O
procedure	O
.	O
Improved	O
as	O
the	O
patient	O
woke	O
up	O
from	O
sedation	O
.	O
Still	O
,	O
HR	O
remained	O
in	O
the	O
50	O
-	O
60	O
range	O
throughout	O
hospitalization	O
.	O
Initially	O
home	O
beta	B-Drug
blocker	I-Drug
was	O
held	O
.	O
Pt	O
was	O
monitored	O
on	O
telemetry	O
without	O
events	O
.	O
He	O
was	O
asymptomatic	O
.	O
Home	O
atenolol	I-Drug
restarted	O
on	O
discharge	O
.	O
.	O
#DIABETES	O
MELLITUS	I-Reason
-	I-Reason
type	I-Reason
2	I-Reason
,	O
with	O
complications	O
,	O
peripheral	O
neuropathy	O
.	O
Placed	O
on	O
conservative	O
insulin	I-Drug
regimen	O
while	O
NPO	O
.	O
Pt	O
resumed	O
meformin	I-Drug
and	O
glyburide	I-Drug
upon	O
discharge	O
.	O
Continued	O
gabapentin	I-Drug
for	O
neuropathy	I-Reason
.	O
.	O
#HYPERTENSION	O
-	O
benign	O
;	O
initially	O
held	O
beta	B-Drug
blocker	I-Drug
in	O
setting	O
of	O
bradycardia	I-Ade
.	O
Continued	O
imdur	I-Drug
.	O
Held	O
lisinopril	I-Drug
while	O
NPO	O
.	O
On	O
the	O
morning	O
of	O
discharge	O
his	O
blood	O
pressure	O
was	O
elevated	O
in	O
the	O
170s	O
systolic	O
.	O
We	O
then	O
restarted	O
his	O
home	O
medications	O
(	O
atenolol	I-Drug
,	O
lisinopril	I-Drug
)	O
which	O
we	O
had	O
been	O
holding	O
and	O
felt	O
these	O
would	O
be	O
adequate	O
for	O
blood	B-Reason
pressure	I-Reason
control	I-Reason
.	O
.	O
#DIASTOLIC	O
HEART	I-Reason
FAILURE	I-Reason
-	O
chronic	O
,	O
but	O
with	O
recent	O
acute	O
exacerbation	O
.	O
Lasix	I-Drug
was	O
held	O
while	O
pt	O
was	O
NPO	O
,	O
and	O
also	O
was	O
given	O
with	O
1u	O
pRBCs	I-Drug
.	O
.	O
#hypothyroidism	O
-	O
continued	O
synthroid	I-Drug
.	O
#HL	O
-	O
continued	O
simvastatin	I-Drug
.	O
#GERD	O
-	O
on	O
PPI	I-Drug
ggt	O
for	O
c	O
/	O
f	O
GI	B-Reason
bleed	I-Reason
as	O
above	O
,	O
transitioned	O
to	O
PO	O
PPI	I-Drug
on	O
discharge	O
.	O
#leukopenia	O
/	O
thrombocytopenia	O
-	O
unclear	O
etiology	O
.	O
Could	O
be	O
due	O
to	O
acute	O
process	O
.	O
Thrombocytopenia	O
could	O
be	O
consumptive	O
.	O
PLT	O
count	O
was	O
monitored	O
closely	O
and	O
remained	O
stable	O
.	O
.	O
Pt	O
was	O
maintained	O
as	O
FULL	O
CODE	O
throughout	O
the	O
course	O
of	O
this	O
hospitalization	O
.	O
.	O
TRANSITIONAL	O
ISSUES	O
:	O
anticoagulation	I-Reason
:	O
pt	O
sent	O
home	O
on	O
warfarin	I-Drug
(	O
subtherapeutic	O
after	O
holding	O
for	O
procedures	O
)	O
and	O
lovenox	I-Drug
.	O
He	O
will	O
need	O
INR	O
checked	O
Monday	O
[	O
**	O
2156-5-3	O
**	O
]	O
and	O
Wednesday	O
[	O
**	O
2156-5-5	O
**	O
]	O
likely	O
to	O
DC	O
lovenox	I-Drug
[	O
**	O
2156-5-5	O
**	O
]	O
as	O
ideally	O
he	O
would	O
have	O
a	O
48	O
hour	O
therapeutic	O
overlap	O
.	O
Pt	O
was	O
instructed	O
to	O
follow	O
up	O
with	O
PCP	O
regarding	O
this	O
issue	O
.	O
Medications	O
on	O
Admission	O
:	O
Medications	O
on	O
Transfer	O
:	O
Vicodin	I-Drug
5/500	O
q6h	O
prn	O
Ativan	I-Drug
2	O
mg	O
po	O
TID	O
prn	O
Morphine	I-Drug
2	O
mg	O
iv	O
prn	O
NTG	I-Drug
0.4	O
q5	O
mins	O
prn	O
Protonix	I-Drug
gtt	O
Atenolol	I-Drug
25	O
mg	O
po	O
bid	O
Plavix	I-Drug
75	O
mg	O
daily	O
Ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Gabapentin	I-Drug
600	O
mg	O
QID	O
Humalog	I-Drug
sliding	O
scale	O
Synthroid	I-Drug
50mcg	O
daily	O
Kdur	I-Drug
?	O
dose	O
daily	O
Simvastatin	I-Drug
20	O
mg	O
daily	O
Heparin	I-Drug
gtt	O
Imdur	I-Drug
ER	O
60	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Lasix	I-Drug
40	O
mg	O
daily	O
Lantus	I-Drug
10	O
units	O
qam	O
Lisinopril	I-Drug
20	O
mg	O
daily	O
.	O
Outpatient	O
Medications	O
Lantus	I-Drug
20	O
units	O
qam	O
Metformin	I-Drug
850	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Glyburide	I-Drug
10	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Atenolol	I-Drug
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Plavix	I-Drug
75	O
mg	O
daily	O
Tylenol	I-Drug
prn	O
vicodin	I-Drug
1	O
tablet	O
q6h	O
prn	O
Ativan	I-Drug
2	O
mg	O
tid	O
prn	O
NTG	I-Drug
prn	O
Lasix	I-Drug
40	O
mg	O
daily	O
Gabapentin	I-Drug
600	O
mg	O
qid	O
Isosorbide	I-Drug
mononitrate	O
60	O
mg	O
daily	O
Levoxyl	I-Drug
50mcg	O
daily	O
Lisinopril	I-Drug
20	O
mg	O
daily	O
Simvastatin	I-Drug
20	O
mg	O
daily	O
Coumadin	I-Drug
5	O
mg	O
all	O
days	O
except	O
2.5	O
mg	O
on	O
M	O
or	O
F	O
Omeprazole	I-Drug
40	O
mg	O
daily	O
KCl	I-Drug
20	O
meq	O
daily	O
Ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
enoxaparin	I-Drug
40	O
mg	O
/	O
0.4	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Subcutaneous	O
once	O
a	O
day	O
for	O
5	O
days	O
:	O
Continue	O
until	O
INR	O
is	O
therepeutic	O
.	O
.	O
Disp	O
:	O
*	O
5	O
syringes	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
lorazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
3	O
.	O
gabapentin	B-Drug
300	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
insulin	B-Drug
glargine	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Twenty	O
(	O
20	O
)	O
Units	O
Subcutaneous	O
once	O
a	O
day	O
.	O
5	O
.	O
metformin	I-Drug
850	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
6	O
.	O
atenolol	B-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
7	O
.	O
clopidogrel	B-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
8	O
.	O
glyburide	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
9	O
.	O
Vicodin	I-Drug
5	O
-	O
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
10	O
.	O
Lasix	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
11	O
.	O
isosorbide	B-Drug
mononitrate	I-Drug
60	O
mg	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
12	O
.	O
Levoxyl	I-Drug
50	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
13	O
.	O
lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
14	O
.	O
simvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
15	O
.	O
omeprazole	B-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
16	O
.	O
potassium	I-Drug
chloride	O
20	O
mEq	O
Tablet	O
,	O
ER	O
Particles	O
/	O
Crystals	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
ER	O
Particles	O
/	O
Crystals	O
PO	O
once	O
a	O
day	O
.	O
17	O
.	O
ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
iron	I-Drug
)	O
Capsule	O
,	O
Extended	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Extended	O
Release	O
PO	O
twice	O
a	O
day	O
.	O
Capsule	O
,	O
Extended	O
Release	O
(	O
s	O
)	O
18	O
.	O
Outpatient	O
Lab	O
Work	O
please	O
have	O
INR	O
drawn	O
[	O
**	O
2156-5-3	O
**	O
]	O
and	O
[	O
**	O
2156-5-5	O
**	O
]	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Acute	O
blood	O
loss	O
anemia	O
from	O
gastrointestinal	O
bleeding	O
CAD	O
s	O
/	O
p	O
stenting	O
and	O
mechanical	O
aortic	O
valve	O
Recent	O
NSTEMI	O
HTN	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
32776	O
**	O
]	O
,	O
You	O
were	O
admitted	O
for	O
further	O
evaluation	O
of	O
gastrointestinal	O
bleeding	O
.	O
For	O
this	O
,	O
you	O
had	O
endoscopic	O
procedures	O
both	O
from	O
above	O
and	O
below	O
the	O
level	O
of	O
the	O
stomach	O
,	O
both	O
which	O
were	O
unrevealing	O
for	O
a	O
source	O
of	O
bleeding	O
.	O
This	O
likely	O
occurred	O
in	O
the	O
presence	O
of	O
multiple	O
blood	B-Drug
thinners	I-Drug
,	O
causing	O
leaking	B-Ade
of	I-Ade
a	I-Ade
vessel	O
which	O
stopped	O
once	O
we	O
held	O
your	O
blood	B-Drug
thinners	I-Drug
.	O
We	O
discussed	O
the	O
risks	O
and	O
benefits	O
of	O
being	O
on	O
blood	B-Drug
thinners	I-Drug
.	O
Given	O
your	O
cardiac	B-Reason
history	I-Reason
,	O
including	B-Reason
stents	I-Reason
and	O
mechanical	I-Reason
heart	O
valves	O
,	O
it	O
is	O
necessary	O
that	O
your	O
remain	O
on	O
warfarin	I-Drug
and	O
an	O
antiplatelet	I-Drug
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
(	O
such	O
as	O
aspirin	I-Drug
or	O
clopidogrel	B-Drug
AKA	I-Drug
Plavix	O
)	O
,	O
to	O
prevent	O
a	O
stroke	O
and	O
a	O
heart	O
attack	O
respectively	O
.	O
You	O
will	O
be	O
discharged	O
on	O
warfarin	I-Drug
at	O
your	O
usual	O
home	O
dose	O
as	O
well	O
as	O
clopidogrel	I-Drug
(	O
Plavix	O
)	O
.	O
Please	O
note	O
to	O
follow	O
up	O
with	O
your	O
cardiologest	O
within	O
the	O
week	O
to	O
assure	O
you	O
are	O
on	O
the	O
most	O
appropriate	O
therapy	O
for	O
your	O
cardiac	O
health	O
.	O
As	O
you	O
know	O
,	O
your	O
INR	O
was	O
below	O
goal	O
prior	O
to	O
discharge	O
(	O
goal	O
2.5	O
-	O
3.5	O
)	O
,	O
since	O
we	O
held	O
your	O
warfarin	I-Drug
in	O
the	O
hospital	O
so	O
you	O
could	O
have	O
procedures	O
.	O
You	O
will	O
be	O
going	O
home	O
on	O
enoxaparin	I-Drug
(	O
AKA	O
Lovenox	O
)	O
injections	O
to	O
keep	O
your	O
blood	O
thin	O
while	O
your	O
INR	O
becomes	O
therepeutic	O
.	O
Medication	O
changes	O
:	O
Please	O
START	O
taking	O
Clopidogrel	I-Drug
(	O
AKA	O
Plavix	O
)	O
75	O
mg	O
po	O
qday	O
Please	O
START	O
taking	O
Enoxaparin	I-Drug
subcutaneous	O
injections	O
until	O
your	O
INR	O
is	O
therepeutic	O
Please	O
continue	O
taking	O
the	O
rest	O
of	O
your	O
medications	O
as	O
prescribed	O
.	O
.	O
It	O
has	O
been	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
Mr.	O
[	O
**	O
Known	O
lastname	O
32776	O
**	O
]	O
!	O
Followup	O
Instructions	O
:	O
Please	O
arrange	O
follow	O
up	O
with	O
your	O
primary	O
care	O
doctor	O
and	O
your	O
cardiologist	O
within	O
1	O
week	O
of	O
discharge	O
.	O
You	O
will	O
need	O
to	O
have	O
your	O
INR	O
on	O
Monday	O
[	O
**	O
2156-5-3	O
**	O
]	O
and	O
Wednesday	O
[	O
**	O
2156-5-5	O
**	O
]	O
.	O
Speak	O
to	O
your	O
primary	O
care	O
physician	O
but	O
you	O
should	O
stop	O
lovenox	I-Drug
on	O
Wednesday	O
[	O
**	O
2156-5-5	O
**	O
]	O
if	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
26652	O
**	O
]	O
approves	O
.	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
292	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2153-9-18	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2153-10-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2079-3-29	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Percocet	I-Drug
/	O
Codeine	I-Drug
/	O
Demerol	I-Drug
/	O
Nafcillin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
Cellulitis	O
,	O
troponin	O
leak	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Bedside	O
debridement	O
of	O
eschar	O
on	O
right	O
foot	O
History	O
of	O
Present	O
Illness	O
:	O
74	O
yo	O
M	O
with	O
MM	O
including	O
PVD	O
,	O
DM	O
,	O
HTN	O
,	O
CAD	O
,	O
CRI	O
transferred	O
from	O
NWH	O
for	O
cellulitis	O
/	O
LE	O
pain	O
because	O
pt	O
's	O
podiatric	O
surgeon	O
is	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Initally	O
presented	O
to	O
NWH	O
because	O
of	O
increasing	O
right	O
foot	O
pain	O
and	O
redness	O
.	O
At	O
NWH	O
,	O
found	O
to	O
have	O
EKG	O
changes	O
with	O
STD	O
in	O
V2	O
-	O
V4	O
,	O
though	O
patient	O
was	O
asymptomatic	O
and	O
said	O
he	O
never	O
had	O
chest	O
pain	O
.	O
Unclear	O
if	O
he	O
received	O
abx	O
from	O
there	O
per	O
records	O
available	O
.	O
Patient	O
was	O
transferred	O
here	O
for	O
further	O
management	O
.	O
.	O
Of	O
note	O
,	O
patient	O
was	O
recently	O
hospitalized	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
91344	O
**	O
]	O
in	O
the	O
ICU	O
at	O
NWH	O
when	O
he	O
was	O
found	O
at	O
home	O
unresponsive	O
-	O
was	O
hypoglycemic	O
and	O
in	O
ARF	O
.	O
Patient	O
states	O
he	O
does	O
not	O
remember	O
'	O
anything	O
'	O
about	O
that	O
hospital	O
stay	O
,	O
the	O
medications	O
he	O
was	O
on	O
or	O
any	O
events	O
that	O
occurred	O
then	O
.	O
Per	O
report	O
,	O
he	O
was	O
discharged	O
on	O
lovenox	I-Drug
for	O
DVT	I-Reason
but	O
when	O
NWH	O
ED	O
was	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
,	O
records	O
there	O
indicated	O
that	O
he	O
was	O
started	O
on	O
Lovenox	I-Drug
ppx	I-Reason
because	O
he	O
was	O
immobile	O
and	O
was	O
supposed	O
to	O
continue	O
taking	O
it	O
until	O
he	O
was	O
able	O
to	O
consistently	O
walk	O
>	O
100	O
feet	O
.	O
Unclear	O
if	O
patient	O
has	O
been	O
administering	O
the	O
lovenox	I-Drug
himself	O
as	O
he	O
stated	O
that	O
he	O
no	O
longer	O
gives	O
himself	O
insulin	I-Drug
because	O
'	O
it	O
's	O
just	O
too	O
complicated	O
'	O
.	O
.	O
On	O
past	O
hospitalization	O
at	O
NWH	O
,	O
also	O
had	O
a	O
troponin	O
has	O
high	O
as	O
8.8	O
thought	O
be	O
due	O
to	O
demand	B-Reason
ischemia	I-Reason
in	I-Reason
the	I-Reason
setting	I-Reason
of	I-Reason
hypoglycemia	O
.	O
During	O
that	O
admission	O
,	O
he	O
never	O
had	O
chest	O
pain	O
and	O
a	O
stable	O
percent	O
MB	O
fraction	O
at	O
0.7	O
.	O
He	O
was	O
started	O
on	O
aspirin	I-Drug
,	O
beta	B-Drug
blocker	I-Drug
and	O
statin	I-Drug
.	O
An	O
ACEi	I-Drug
was	O
held	O
due	O
to	O
intolerance	I-Ade
in	O
the	O
past	O
.	O
.	O
In	O
the	O
ED	O
here	O
VS	O
:	O
AF	O
,	O
hr	O
:	O
67	O
,	O
bp	O
:	O
130/70	O
,	O
rr	O
:	O
16	O
98	O
%	O
on	O
RA	O
.	O
Received	O
fentanyl	I-Drug
for	O
pain	I-Reason
,	O
cards	O
and	O
vascular	O
were	O
c	O
/	O
s.	O
Blood	O
cx	O
were	O
drawn	O
.	O
Vascular	O
recommended	O
vanc	I-Drug
/	O
zosyn	I-Drug
given	O
their	O
concern	O
for	O
osteo	O
which	O
he	O
received	O
.	O
He	O
received	O
50	O
mg	O
iv	O
fentanyl	I-Drug
for	O
pain	I-Reason
.	O
.	O
Upon	O
transfer	O
to	O
the	O
floor	O
,	O
patient	O
c	O
/	O
o	O
of	O
persistent	O
right	O
foot	O
pain	O
.	O
Denies	O
fever	O
or	O
chills	O
,	O
CP	O
,	O
SOB	O
,	O
N	O
/	O
V	O
/	O
D	O
,	O
constipation	O
,	O
HA	O
or	O
vision	O
changes	O
.	O
.	O
The	O
patient	O
is	O
not	O
a	O
competent	O
historian	O
.	O
On	O
review	O
of	O
systems	O
,	O
he	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
,	O
myalgias	O
,	O
joint	O
pains	O
,	O
cough	O
,	O
hemoptysis	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
He	O
denies	O
recent	O
fevers	O
,	O
chills	O
or	O
rigors	O
.	O
He	O
denies	O
exertional	O
buttock	O
or	O
calf	O
pain	O
.	O
All	O
of	O
the	O
other	O
review	O
of	O
systems	O
per	O
HPI	O
.	O
.	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
absence	O
of	O
chest	O
pain	O
,	O
dyspnea	O
on	O
exertion	O
,	O
paroxysmal	O
nocturnal	O
dyspnea	O
,	O
orthopnea	O
,	O
ankle	O
edema	O
,	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
CARDIAC	O
RISK	O
FACTORS	O
:	O
(	O
+	O
)	O
Diabetes	O
,	O
(	O
+	O
)	O
Dyslipidemia	O
,	O
(	O
+	O
)	O
HTN	O
2	O
.	O
CARDIAC	O
HISTORY	O
:	O
-	O
CABG	O
:	O
[	O
**	O
2137	O
**	O
]	O
LIMA	O
-	O
>	O
LAD	O
.	O
SVG	O
-	O
>	O
dRCA	O
and	O
SVG	O
-	O
>	O
D1	O
/	O
OM	O
.	O
-	O
PERCUTANEOUS	O
CORONARY	O
INTERVENTIONS	O
:	O
[	O
**	O
2150	O
**	O
]	O
(	O
no	O
report	O
available	O
)	O
,	O
[	O
**	O
2147	O
**	O
]	O
:	O
3VD	O
,	O
patent	O
LIMA	O
--	O
>	O
LAD	O
,	O
patnet	O
SVG	O
--	O
>	O
dRCA	O
and	O
D1	O
/	O
OM	O
,	O
severe	O
native	O
vessel	O
disease	O
.	O
-	O
PACING	O
/	O
ICD	O
:	O
None	O
.	O
3	O
.	O
OTHER	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
Per	O
OMR	O
notes	O
,	O
patient	O
states	O
he	O
does	O
not	O
know	O
his	O
full	O
medical	O
history	O
PVD	O
CAD	O
s	O
/	O
p	O
MI	O
in	O
'	O
[	O
**	O
49	O
**	O
]	O
HTN	O
Hyperlipidemia	O
DM2	I-Reason
on	O
Insulin	I-Drug
Diastolic	O
CHF	O
CRI	O
(	O
baseline	O
1.8	O
-	O
2	O
)	O
h	O
/	O
o	O
GI	O
bleed	O
Bladder	O
carcinoma	O
Cervical	O
stenosis	O
Anemia	O
Gastroparesis	O
.	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
-	O
Debridement	O
of	O
osteomyelitis	O
with	O
L.	O
5th	O
metatarsal	O
head	O
resection	O
[	O
**	O
2153-4-19	O
**	O
]	O
-	O
L	O
CFA	O
to	O
BK	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
bypass	O
with	O
left	O
arm	O
vein	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
-	O
L4	O
-	O
5	O
laminectomies	O
bilat	O
w	O
/	O
resection	O
of	O
large	O
disk	O
herniation	O
[	O
**	O
4	O
-	O
24	O
**	O
]	O
-	O
R	O
2nd	O
second	O
toe	O
amp	O
[	O
**	O
5	O
-	O
24	O
**	O
]	O
-	O
R	O
CFA	O
to	O
AK	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
bypass	O
using	O
[	O
**	O
Doctor	O
Last	O
Name	O
4726	O
**	O
]	O
-	O
Tex	O
[	O
**	O
4	O
-	O
23	O
**	O
]	O
-	O
L	O
CEA	O
[	O
**	O
2	O
-	O
/	O
2140	O
**	O
]	O
,	O
4	O
vessel	O
CABG	O
[	O
**	O
1	O
-	O
/	O
2138	O
**	O
]	O
-	O
Aorta	O
-	O
bifemoral	O
bypass	O
at	O
NWH	O
in	O
[	O
**	O
2147	O
**	O
]	O
?	O
Social	O
History	O
:	O
HISTORY	O
:	O
Unwilling	O
to	O
give	O
.	O
Per	O
prior	O
records	O
,	O
married	O
twice	O
,	O
but	O
recently	O
separated	O
.	O
He	O
has	O
two	O
children	O
.	O
H	O
/	O
o	O
EtOH	O
abuse	O
in	O
AA	O
35	O
yrs	O
;	O
tobacco	O
45	O
pack	O
year	O
history	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
ADMISSION	O
PHYSICAL	O
EXAMINATION	O
:	O
VS	O
:	O
T	O
=	O
97.9	O
BP	O
=	O
140/60	O
HR	O
=	O
72	O
RR	O
=	O
20	O
O2	I-Drug
sat	O
=	O
93	O
on	O
2L	O
%	O
GENERAL	O
:	O
elderly	O
male	O
lying	O
in	O
bed	O
.	O
Oriented	O
x3	O
.	O
Mood	O
appropriate	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
dry	O
mmm	O
.	O
Poor	O
dentition	O
NECK	O
:	O
Supple	O
.	O
No	O
JVD	O
.	O
CARDIAC	O
:	O
RRR	O
.	O
s1	O
/	O
s2	O
.	O
III	O
/	O
VI	O
systolic	O
murmur	O
heard	O
best	O
at	O
LLSB	O
.	O
LUNGS	O
:	O
clear	O
anteriorly	O
.	O
patient	O
unwilling	O
to	O
fully	O
sit	O
up	O
for	O
posterior	O
thorax	O
exam	O
,	O
so	O
limited	O
.	O
Heard	O
scattered	O
wheezes	O
and	O
crackles	O
at	O
bases	O
posteriorly	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
+	O
bs	O
EXTREMITIES	O
:	O
chronic	O
venous	O
statis	O
changes	O
bilaterlly	O
.	O
warm	O
to	O
touch	O
,	O
DP	O
pulses	O
dopplerable	O
.	O
RLE	O
:	O
2	O
eshcars	O
-	O
one	O
on	O
medial	O
aspect	O
of	O
foot	O
and	O
one	O
on	O
plantar	O
aspect	O
of	O
foot	O
.	O
Area	O
of	O
erythema	O
on	O
anterior	O
/	O
medial	O
aspect	O
of	O
foot	O
with	O
increased	O
warmth	O
.	O
?	O
collection	O
under	O
foot	O
?	O
SKIN	O
:	O
as	O
above	O
Pertinent	O
Results	O
:	O
Admission	O
laboratories	O
:	O
COMPLETE	O
BLOOD	O
COUNT	O
(	O
[	O
**	O
9	O
-	O
18	O
**	O
]	O
)	O
WBC	O
:	O
9.2	O
RBC	O
:	O
3.45	O
*	O
Hgb	O
:	O
8.3	O
*	O
#	O
Hct	O
:	O
27.6	O
*	O
MCV	O
:	O
80	O
*	O
MCH	O
:	O
23.9	O
*	O
MCHC	O
:	O
30.0	O
*	O
RDW	O
:	O
24.4	O
*	O
Plt	O
Ct	O
:	O
300	O
DIFFERENTIAL	O
Neuts	O
87.1	O
*	O
Bands	O
Lymphs	O
6.3	O
*	O
Monos	O
4.8	O
Eos	O
1.4	O
Baso	O
0.5	O
[	O
**	O
2153-9-18	O
**	O
]	O
07:01	O
PM	O
BASIC	O
COAGULATION	O
(	O
PT	O
,	O
PTT	O
,	O
PLT	O
,	O
INR	O
)	O
PT	O
15.0	O
*	O
PTT	O
41.8	O
*	O
Plt	O
Ct	O
INR	O
(	O
PT	O
)	O
1.3	O
*	O
Chemistry	O
RENAL	O
&	O
GLUCOSE	O
Glucose	O
278	O
*	O
UreaN	O
69	O
*	O
Creat	O
2.0	O
*	O
Na	O
132	O
*	O
K	O
4.6	O
Cl	O
98	O
HCO3	O
22	O
EKG	O
(	O
[	O
**	O
9	O
-	O
20	O
**	O
]	O
)	O
:	O
Sinus	O
rhythm	O
.	O
Right	O
axis	O
deviation	O
.	O
Incomplete	O
right	O
bundle	O
branch	O
block	O
.	O
One	O
to	O
two	O
millimeter	O
downsloping	O
ST	O
segment	O
depression	O
in	O
the	O
anterior	O
leads	O
extending	O
from	O
leads	O
V3	O
-	O
V6	O
.	O
Consider	O
myocardial	O
ischemia	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2153-9-19	O
**	O
]	O
the	O
ST	O
-	O
T	O
wave	O
changes	O
are	O
pretty	O
similar	O
except	O
that	O
the	O
lead	O
placement	O
is	O
slightly	O
different	O
.	O
Rate	O
PR	O
QRS	O
QT	O
/	O
QTc	O
P	O
QRS	O
T	O
72126114440	O
/	O
46171121113	O
WOUND	O
CULTURE	O
(	O
Final	O
[	O
**	O
2153-9-25	O
**	O
]	O
)	O
:	O
KLEBSIELLA	O
OXYTOCA	O
.	O
SPARSE	O
GROWTH	O
.	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
SPARSE	O
GROWTH	O
.	O
Oxacillin	I-Drug
RESISTANT	O
Staphylococci	O
MUST	O
be	O
reported	O
as	O
also	O
RESISTANT	O
to	O
other	O
penicillins	I-Drug
,	O
cephalosporins	O
,	O
carbacephems	I-Drug
,	O
carbapenems	I-Drug
,	O
and	O
beta	B-Drug
-	I-Drug
lactamase	I-Drug
inhibitor	I-Drug
combinations	I-Drug
.	O
Rifampin	I-Drug
should	O
not	O
be	O
used	O
alone	O
for	O
therapy	O
.	O
Please	O
contact	O
the	O
Microbiology	O
Laboratory	O
(	O
[	O
**	O
6	O
-	O
/	O
2450	O
**	O
]	O
)	O
immediately	O
if	O
sensitivity	O
to	O
clindamycin	I-Drug
is	O
required	O
on	O
this	O
patient	O
's	O
isolate	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
KLEBSIELLA	O
OXYTOCA	O
|	O
STAPH	O
AUREUS	O
COAG	O
+	O
|	O
|	O
AMPICILLIN	I-Drug
/	O
SULBACTAM	I-Drug
--	O
8	O
S	O
CEFAZOLIN	I-Drug
-------------	O
8	O
S	O
CEFEPIME	I-Drug
--------------	O
<	O
=	O
1	O
S	O
CEFTAZIDIME	I-Drug
-----------	O
<	O
=	O
1	O
S	O
CEFTRIAXONE	I-Drug
-----------	O
<	O
=	O
1	O
S	O
CEFUROXIME	I-Drug
------------	O
4	O
S	O
CIPROFLOXACIN	I-Drug
---------	O
<	O
=	O
0.25	O
S	O
ERYTHROMYCIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
GENTAMICIN	O
------------	O
<	O
=	O
1	O
S	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
MEROPENEM	I-Drug
-------------	O
<	O
=	O
0.25	O
S	O
OXACILLIN	I-Drug
-------------	O
=	O
>	O
4	O
R	O
PIPERACILLIN	I-Drug
/	O
TAZO	O
-----	O
<	O
=	O
4	O
S	O
RIFAMPIN	I-Drug
--------------	O
<	O
=	O
0.5	O
S	O
TETRACYCLINE	I-Drug
----------	O
<	O
=	O
1	O
S	O
TOBRAMYCIN	I-Drug
------------	O
<	O
=	O
1	O
S	O
TRIMETHOPRIM	I-Drug
/	O
SULFA	O
----	O
<	O
=	O
1	O
S	O
<	O
=	O
0.5	O
S	O
VANCOMYCIN	I-Drug
------------	O
<	O
=	O
1	O
S	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2153-9-24	O
**	O
]	O
)	O
:	O
NO	O
ANAEROBES	O
ISOLATED	O
.	O
Imaging	O
:	O
Xray	O
of	O
right	O
foot	O
(	O
[	O
**	O
9	O
-	O
19	O
**	O
]	O
)	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Erosive	O
bony	O
destructions	O
at	O
the	O
first	O
distal	O
phalanx	O
and	O
at	O
the	O
stump	O
of	O
the	O
second	O
proximal	O
phalanx	O
consistent	O
with	O
osteomyelitis	O
.	O
2	O
.	O
Severe	O
degenerative	O
changes	O
in	O
the	O
tarsometatarsal	O
joints	O
and	O
fracture	O
at	O
the	O
3rd	O
metatarsal	O
,	O
suggesting	O
early	O
Charcot	O
joint	O
disease	O
.	O
3	O
.	O
Significant	O
small	O
vessel	O
disease	O
.	O
2D	O
-	O
ECHOCARDIOGRAM	O
(	O
[	O
**	O
9	O
-	O
20	O
**	O
]	O
)	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
markedly	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
There	O
is	O
no	O
left	O
ventricular	O
outflow	O
obstruction	O
at	O
rest	O
or	O
with	O
Valsalva	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
markedly	O
dilated	O
with	O
moderate	O
global	O
free	O
wall	O
hypokinesis	O
.	O
There	O
is	O
abnormal	O
septal	O
motion	O
/	O
position	O
consistent	O
with	O
right	O
ventricular	O
pressure	O
/	O
volume	O
overload	O
.	O
The	O
ascending	O
aorta	O
is	O
moderately	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
mild	O
aortic	O
valve	O
stenosis	O
(	O
valve	O
area	O
1.2	O
-	O
1.9	O
cm2	O
)	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
22	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
to	O
severe	O
[	O
3	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
severe	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2151-12-16	O
**	O
]	O
,	O
the	O
detected	O
pulmonary	O
hypertension	O
has	O
increased	O
.	O
There	O
is	O
no	O
change	O
in	O
the	O
left	O
ventricular	O
systolic	O
function	O
.	O
ETT	O
:	O
[	O
**	O
4	O
-	O
/	O
2151	O
**	O
]	O
:	O
This	O
72	O
yo	O
man	O
with	O
IDDM	O
,	O
mild	O
AS	O
s	O
/	O
p	O
multiple	O
cadiac	O
interventions	O
was	O
referred	O
to	O
the	O
lab	O
for	O
evaluation	O
as	O
a	O
part	O
of	O
the	O
Spinal	O
Cord	O
Stimulation	O
study	O
.	O
The	O
patient	O
exercised	O
for	O
2.5	O
minutes	O
on	O
a	O
modified	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
protocol	O
and	O
stopped	O
due	O
a	O
marked	O
drop	O
in	O
systolic	O
blood	O
pressure	O
.	O
This	O
represents	O
a	O
very	O
limited	O
exercise	O
tolerance	O
for	O
his	O
age	O
.	O
The	O
patient	O
denied	O
any	O
neck	O
,	O
chest	O
,	O
arm	O
or	O
back	O
discomfort	O
throughout	O
the	O
study	O
.	O
In	O
the	O
setting	O
of	O
baseline	O
abnormalities	O
,	O
an	O
additional	O
0.5	O
mm	O
of	O
ST	O
segment	O
depression	O
was	O
noted	O
in	O
V4	O
-	O
V5	O
at	O
peak	O
exercise	O
.	O
These	O
changes	O
returned	O
to	O
baseline	O
by	O
minute	O
3	O
post-exercise	O
.	O
The	O
rhythm	O
was	O
sinus	O
with	O
a	O
single	O
VPB	O
in	O
late	O
recovery	O
period	O
.	O
Marked	O
drop	O
in	O
blood	O
pressure	O
with	O
exercise	O
(	O
136	O
/	O
60mmHg	O
at	O
rest	O
to	O
98	O
/	O
50mmHg	O
at	O
peak	O
)	O
.	O
Post-exercise	O
hypertension	O
was	O
noted	O
(	O
172	O
/	O
60mmHg	O
at	O
10	O
minutes	O
of	O
recovery	O
)	O
.	O
.	O
IMPRESSION	O
:	O
Marked	O
drop	O
in	O
blood	O
pressure	O
with	O
exercise	O
.	O
Non-specific	O
EKG	O
changes	O
without	O
anginal	O
type	O
symptoms	O
.	O
.	O
CARDIAC	O
CATH	O
:	O
[	O
**	O
2147	O
**	O
]	O
:	O
COMMENTS	O
:	O
1	O
.	O
Coronary	O
angiography	O
of	O
this	O
right	O
dominant	O
circulation	O
revealed	O
severe	O
native	O
three	O
vessel	O
disease	O
.	O
The	O
LMCA	O
had	O
a	O
30	O
%	O
narrowing	O
.	O
The	O
LAD	O
had	O
diffuse	O
luminal	O
irregularities	O
and	O
a	O
70	O
%	O
proximal	O
stenosis	O
.	O
The	O
mid	O
vessel	O
was	O
diffusely	O
diseased	O
but	O
the	O
distal	O
vessel	O
filled	O
via	O
a	O
patent	O
LIMA	O
-	O
>	O
dLAD	O
.	O
The	O
LAD	O
supplied	O
a	O
large	O
S2	O
that	O
had	O
an	O
80	O
%	O
lesion	O
at	O
its	O
ostium	O
.	O
The	O
LAD	O
supplied	O
two	O
moderate	O
sized	O
diagonal	O
branches	O
which	O
had	O
diffuse	O
luminal	O
irregularities	O
.	O
The	O
LCX	O
tapered	O
quickly	O
and	O
was	O
totally	O
occluded	O
in	O
the	O
proximal	O
vessel	O
after	O
a	O
small	O
OM	O
branch	O
.	O
The	O
RCA	O
was	O
diffusely	O
diseased	O
and	O
totally	O
occluded	O
proximally	O
.	O
2	O
.	O
Selective	O
vein	O
graft	O
angiography	O
revealed	O
a	O
widely	O
patent	O
SVG	O
-	O
>	O
dRCA	O
and	O
a	O
widely	O
patent	O
SVG	O
-	O
>	O
D1	O
/	O
OM	O
.	O
3	O
.	O
Selective	O
arterial	O
conduit	O
arteriography	O
demonstrated	O
a	O
widely	O
patent	O
LIMA	O
-	O
>	O
LAD	O
.	O
4	O
.	O
Resting	O
hemodynamics	O
revealed	O
markedly	O
elevated	O
right	O
and	O
left	O
ventricular	O
filling	O
pressures	O
with	O
an	O
LVEDP	O
of	O
29	O
mmHg	O
and	O
a	O
mean	O
PCW	O
pressure	O
of	O
22	O
mmHg	O
.	O
In	O
addition	O
,	O
there	O
were	O
V	O
-	O
waves	O
to	O
50	O
mmHg	O
suggesting	O
significant	O
mitral	O
regurgitation	O
.	O
There	O
was	O
evidence	O
of	O
moderate	O
to	O
severe	O
pulmonary	O
hypertension	O
with	O
PA	O
pressures	O
of	O
62/21/39	O
mmHg	O
and	O
a	O
pulmonary	O
vascular	O
resistance	O
of	O
209	O
dynes	O
-	O
sec	O
/	O
cm5	O
.	O
The	O
cardiac	O
output	O
was	O
preserved	O
at	O
6.9	O
L	O
/	O
min	O
.	O
Note	O
was	O
made	O
of	O
a	O
10	O
mmHg	O
gradient	O
across	O
the	O
aortic	O
valve	O
.	O
5	O
.	O
Left	O
ventriculography	O
was	O
not	O
performed	O
due	O
to	O
the	O
patient	O
's	O
underlying	O
renal	O
insufficiency	O
and	O
recent	O
non-invasive	O
testing	O
documenting	O
a	O
preserved	O
LV	O
systolic	O
function	O
.	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
1	O
.	O
Severe	O
native	O
three	O
vessel	O
disease	O
.	O
2	O
.	O
Patent	O
LIMA	O
-	O
>	O
LAD	O
.	O
3	O
.	O
Patent	O
SVG	O
-	O
>	O
dRCA	O
and	O
SVG	O
-	O
>	O
D1	O
/	O
OM	O
.	O
4	O
.	O
Moderate	O
to	O
severe	O
left	O
ventricular	O
diastolic	O
dysfunction	O
.	O
5	O
.	O
Moderate	O
to	O
severe	O
pulmonary	O
hypertension	O
.	O
CT	O
head	O
(	O
[	O
**	O
9	O
-	O
24	O
**	O
]	O
)	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
process	O
.	O
2	O
.	O
Sequelae	O
of	O
chronic	O
infarction	O
involving	O
the	O
left	O
parieto	O
-	O
occipital	O
region	O
.	O
Renal	O
U	O
/	O
S	O
(	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
)	O
:	O
IMPRESSION	O
:	O
Absent	O
diastolic	O
flow	O
seen	O
in	O
the	O
bilateral	O
interlobar	O
arteries	O
of	O
the	O
kidneys	O
.	O
The	O
findings	O
are	O
nonspecific	O
,	O
but	O
indicate	O
renal	O
parenchymal	O
disease	O
.	O
There	O
is	O
limited	O
evaluation	O
of	O
the	O
main	O
renal	O
arteries	O
,	O
but	O
there	O
is	O
no	O
clear	O
evidence	O
of	O
renal	O
artery	O
stenosis	O
.	O
There	O
is	O
no	O
hydronephrosis	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Summary	O
:	O
74	O
yo	O
M	O
transferred	O
from	O
NWH	O
with	O
EKG	O
changes	O
,	O
trop	O
here	O
to	O
0.87	O
(	O
baseline	O
0.2	O
)	O
and	O
RLE	O
cellulitis	O
,	O
right	O
foot	O
osteomyelitis	O
,	O
worsening	O
acute	O
on	O
chronic	O
renal	O
failure	O
#	O
Right	O
lower	O
extremity	O
cellulitis	O
and	O
right	O
foot	O
osteomyelitis	O
:	O
The	O
patient	O
presented	O
with	O
right	O
lower	O
extremity	O
cellulitis	O
and	O
was	O
found	O
to	O
have	O
osteomyelitis	O
in	O
the	O
right	O
foot	O
.	O
Vascular	O
surgery	O
evaluated	O
the	O
patient	O
and	O
thought	O
that	O
treatment	O
for	O
the	O
infection	I-Reason
and	O
ischemia	O
would	O
be	O
a	O
below	O
the	O
knee	O
amputation	O
,	O
though	O
given	O
the	O
patient	O
's	O
poor	O
cardiac	O
status	O
,	O
he	O
would	O
not	O
be	O
a	O
good	O
candidate	O
for	O
surgery	O
.	O
The	O
patient	O
was	O
empirically	O
started	O
on	O
Vancomycin	I-Drug
and	O
Zosyn	I-Drug
.	O
A	O
wound	O
culture	O
grew	O
Klebsiella	O
oxytoca	O
and	O
MRSA	O
and	O
continued	O
on	O
those	O
antibiotics	O
.	O
Since	O
vascular	O
surgery	O
would	O
be	O
high	O
risk	O
,	O
podiatry	O
was	O
consulted	O
for	O
local	O
debridement	O
.	O
They	O
debrided	O
the	O
area	O
locally	O
,	O
yet	O
erythema	O
of	O
the	O
right	O
foot	O
existed	O
.	O
It	O
remained	O
unclear	O
whether	O
the	O
erythema	O
was	O
due	O
to	O
ischemia	O
vs.	O
a	O
subcutaneous	O
abscess	O
,	O
so	O
they	O
recommended	O
a	O
MRI	O
of	O
the	O
foot	O
.	O
The	O
MRI	O
was	O
never	O
performed	O
because	O
after	O
discussion	O
with	O
the	O
family	O
and	O
primary	O
care	O
physician	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
was	O
decided	O
for	O
the	O
patient	O
to	O
become	O
CMO	O
.	O
His	O
antibiotics	O
were	O
withdrawn	O
and	O
wound	O
care	O
applied	O
to	O
the	O
area	O
.	O
#	O
Acute	O
on	O
chronic	O
renal	O
failure	O
:	O
The	O
patient	O
presented	O
with	O
a	O
creatinine	O
close	O
to	O
his	O
baseline	O
,	O
however	O
,	O
after	O
periods	O
of	O
hypotension	O
,	O
likely	O
due	O
to	O
a	O
peri-septic	O
state	O
,	O
his	O
creatinine	O
starting	O
to	O
rise	O
.	O
He	O
was	O
given	O
fluid	O
boluses	O
of	O
500	O
cc	O
of	O
normal	I-Drug
saline	O
as	O
needed	O
because	O
his	O
urine	O
lytes	O
showed	O
a	O
FeUrea	O
~	O
20	O
-	O
25	O
%	O
.	O
Renal	O
was	O
consulted	O
and	O
thought	O
his	O
creatinine	O
rise	O
was	O
likely	O
due	O
to	O
acute	O
tubular	O
necrosis	O
secondary	O
to	O
a	O
pre-renal	O
state	O
.	O
The	O
patient	O
was	O
offered	O
aluminium	O
hydroxide	O
for	O
high	O
phosphate	O
levels	O
,	O
but	O
the	O
patient	O
refused	O
it	O
.	O
A	O
renal	O
ultrasound	O
showed	O
no	O
hydronephrosis	O
.	O
The	O
patient	O
became	O
progressively	O
oliguric	O
with	O
UOP	O
less	O
than	O
20	O
cc	O
/	O
hour	O
.	O
Renal	O
thought	O
his	O
kidneys	O
would	O
unlikely	O
recover	O
(	O
his	O
creatinine	O
rose	O
to	O
5.3	O
despite	O
interventions	O
)	O
.	O
The	O
patient	O
and	O
his	O
family	O
felt	O
that	O
they	O
did	O
not	O
want	O
to	O
pursue	O
dialysis	O
as	O
an	O
option	O
.	O
#Increased	O
troponins	O
:	O
The	O
patient	O
was	O
noted	O
to	O
have	O
high	O
troponins	O
and	O
excentuated	O
ST	O
wave	O
depressions	O
in	O
V3	O
-	O
V5	O
.	O
Cardiology	O
was	O
consulted	O
and	O
recommended	O
medical	O
management	O
with	O
a	O
beta	B-Drug
blocker	I-Drug
,	O
ACE	B-Drug
inhibitor	I-Drug
,	O
statin	O
,	O
and	O
aspirin	I-Drug
.	O
The	O
patient	O
was	O
started	O
on	O
these	O
medications	O
,	O
though	O
became	O
persistently	O
hyperkalemic	O
,	O
and	O
therefore	O
,	O
the	O
ACEi	O
was	O
discontinued	O
.	O
Also	O
,	O
his	O
CK	O
and	O
LFTs	O
were	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
28645	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
the	O
statin	O
dose	O
of	O
80	O
mg	O
was	O
lowered	O
to	O
20	O
mg	O
and	O
eventually	O
discontinued	O
due	O
to	O
persistently	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
28645	O
**	O
]	O
LFTs	O
.	O
An	O
echocardiogram	O
revealed	O
no	O
acute	O
wall	O
motion	O
abnormality	O
,	O
though	O
it	O
did	O
show	O
worsening	O
tricuspid	O
regurgitation	O
and	O
increased	O
pulmonary	O
artery	O
pressure	O
.	O
Throughout	O
his	O
stay	O
,	O
the	O
patient	O
did	O
not	O
have	O
any	O
chest	O
pain	O
.	O
#Increased	O
LFTs	O
:	O
The	O
patient	O
has	O
a	O
known	O
history	O
of	O
alcohol	O
abuse	O
and	O
increased	O
LFTs	O
in	O
the	O
past	O
.	O
During	O
his	O
peri-septic	O
period	O
,	O
the	O
patient	O
was	O
noted	O
to	O
have	O
increased	O
LFTs	O
,	O
likely	O
multifactorial	O
due	O
to	O
low	O
perfusion	O
to	O
the	O
liver	O
and	O
also	O
congestion	O
secondary	O
to	O
tricuspid	O
regurgitation	O
.	O
The	O
patient	O
did	O
not	O
have	O
any	O
complaints	O
of	O
abdominal	O
pain	O
,	O
though	O
,	O
he	O
had	O
hepatomegaly	O
on	O
exam	O
.	O
#Gastrointestinal	O
bleed	I-Ade
:	O
The	O
patient	O
has	O
a	O
history	O
of	O
a	O
GI	O
bleed	O
and	O
was	O
guiaic	O
positive	O
in	O
the	O
ER	O
.	O
In	O
addition	O
,	O
he	O
had	O
a	O
persistently	O
elevated	O
PT	O
/	O
PTT	O
,	O
likely	O
due	O
to	O
either	O
underlying	O
liver	O
or	O
hematologic	O
disease	O
.	O
The	O
patient	O
's	O
hematocrit	O
remained	O
stable	O
until	O
[	O
**	O
9	O
-	O
26	O
**	O
]	O
when	O
his	O
hematocrit	O
dropped	O
from	O
29.0	O
to	O
25.6	O
and	O
was	O
noted	O
to	O
have	O
melenic	O
stools	O
.	O
He	O
continued	O
to	O
have	O
melenic	O
stools	O
,	O
so	O
he	O
was	O
transfused	O
one	O
unit	O
of	O
blood	O
and	O
transferred	O
to	O
the	O
MICU	O
.	O
His	O
aspirin	I-Drug
was	O
discontinued	O
.	O
His	O
hematocrit	O
remained	O
stable	O
in	O
the	O
MICU	O
and	O
transferred	O
to	O
the	O
floors	O
where	O
there	O
were	O
no	O
signs	O
of	O
any	O
GI	O
bleeding	O
.	O
Altered	O
mental	O
status	O
:	O
The	O
patient	O
had	O
periods	O
where	O
he	O
had	O
altered	O
mental	O
status	O
,	O
mostly	O
at	O
night	O
.	O
His	O
AMS	O
was	O
likely	O
multifactorial	O
due	O
to	O
infection	O
,	O
pain	O
and	O
uremia	O
.	O
He	O
had	O
significant	O
altered	O
mental	O
status	O
on	O
one	O
day	O
when	O
he	O
appeared	O
more	O
somnolent	O
with	O
respirations	O
=	O
10	O
/	O
min	O
after	O
a	O
dose	O
of	O
Morphine	I-Drug
2	O
mg	O
IV	O
.	O
Narcane	O
was	O
given	O
with	O
some	O
effect	O
.	O
A	O
head	O
CT	O
showed	O
no	O
acute	O
pathology	O
.	O
He	O
continued	O
to	O
have	O
periods	O
of	O
delirium	O
mostly	O
at	O
night	O
.	O
#Pruritis	O
:	O
The	O
patient	O
has	O
been	O
complaining	O
of	O
pruritis	O
,	O
especially	O
on	O
his	O
back	O
,	O
since	O
admission	O
.	O
A	O
variety	O
of	O
remedies	O
were	O
tried	O
for	O
wound	O
care	O
.	O
According	O
to	O
his	O
son	O
,	O
the	O
pruritis	O
has	O
been	O
long	O
-	O
standing	O
.	O
It	O
might	O
be	O
exacerbated	O
by	O
his	O
renal	O
failure	O
.	O
A	O
side	O
effect	O
of	O
Morphine	I-Drug
is	O
a	O
possibility	O
,	O
but	O
he	O
still	O
had	O
the	O
itching	I-Reason
even	O
before	O
the	O
morphine	I-Drug
.	O
He	O
is	O
being	O
treated	O
with	O
skin	O
care	O
,	O
sarna	I-Drug
lotion	O
,	O
hydrocortisone	I-Drug
and	O
doxepin	I-Drug
.	O
Goals	O
of	O
care	O
:	O
The	O
patient	O
entered	O
the	O
hospital	O
as	O
full	O
code	O
.	O
After	O
the	O
renal	O
and	O
GI	O
bleeding	O
complications	O
from	O
his	O
illness	O
,	O
the	O
patient	O
and	O
his	O
family	O
decided	O
to	O
become	O
DNR	O
/	O
DNI	O
.	O
After	O
a	O
meeting	O
with	O
the	O
PCP	O
and	O
the	O
family	O
,	O
they	O
thought	O
the	O
best	O
route	O
would	O
be	O
to	O
become	O
comfort	O
measures	O
only	O
instead	O
of	O
pursuing	O
dialysis	O
and	O
being	O
chronically	O
cared	O
for	O
in	O
a	O
nursing	O
home	O
.	O
At	O
first	O
,	O
it	O
was	O
thought	O
that	O
his	O
beta	B-Drug
blocker	I-Drug
,	O
aspirin	I-Drug
,	O
and	O
antibiotics	I-Drug
would	O
be	O
continued	O
,	O
however	O
,	O
after	O
further	O
conversation	O
,	O
these	O
medications	O
were	O
discontinued	O
and	O
only	O
palliative	O
measures	O
for	O
insomnia	O
,	O
anxiety	O
,	O
pain	O
and	O
constipation	O
were	O
ordered	O
.	O
Medications	O
on	O
Admission	O
:	O
MEDICATIONS	O
(	O
from	O
NWH	O
D	O
/	O
C	O
summary	O
on	O
[	O
**	O
9	O
-	O
11	O
**	O
]	O
)	O
acetaminophen	I-Drug
1	O
g	O
q8hr	O
ASA	I-Drug
325	O
Daily	O
Erythropoietin	I-Drug
4000	O
units	O
SC	O
weekly	O
Ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
Daily	O
Furosemide	I-Drug
40	O
mg	O
daily	O
Lovenox	I-Drug
30	O
mg	O
SC	O
daily	O
until	O
ambulatory	O
NPH	I-Drug
(	O
8	O
units	O
before	O
breakfast	O
and	O
dinner	O
Regular	B-Drug
insulin	I-Drug
(	O
5	O
units	O
before	O
breakfast	O
and	O
dinner	O
Metoprolol	I-Drug
12.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
MVT	O
daily	O
Miralax	I-Drug
17	O
g	O
Daily	O
Nystain	B-Drug
triamcinolone	I-Drug
cream	O
topically	O
twice	O
daily	O
omeprazole	I-Drug
29	O
mg	O
daily	O
Sarna	I-Drug
lotion	O
to	O
affected	O
area	O
[	O
**	O
Hospital1	O
**	O
]	O
senokot	I-Drug
qHs	O
Sertraline	I-Drug
50	O
mg	O
daily	O
simvastatin	I-Drug
20	O
mg	O
daily	O
flomax	I-Drug
0.4	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Sertraline	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Camphor	B-Drug
-	I-Drug
Menthol	I-Drug
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
itching	I-Reason
.	O
3	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
,	O
pain	I-Reason
.	O
4	O
.	O
Quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
5	O
.	O
Trazodone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
6	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
7	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
8	O
.	O
Morphine	I-Drug
10	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
[	O
**	O
4	O
-	O
29	O
**	O
]	O
mL	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
,	O
respiratory	B-Reason
distress	I-Reason
.	O
9	O
.	O
Hydrocortisone	I-Drug
2.5	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Rectal	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
itching	I-Reason
.	O
10	O
.	O
Doxepin	I-Drug
25	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
12	O
.	O
Zofran	I-Drug
2	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
mg	O
Intravenous	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
Cape	O
Code	O
Nursing	O
&	O
Rehabilitation	O
Center	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
10072	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
-	O
cellulitis	O
of	O
lower	O
extremity	O
-	O
osteomyelitis	O
-	O
coronary	O
artery	O
disease	O
.	O
Secondary	O
-	O
Hypotension	O
-	O
Type	O
II	O
diabetes	O
Mellitus	O
Discharge	O
Condition	O
:	O
Stable	O
.	O
Patient	O
breathing	O
on	O
room	O
air	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
transferred	O
to	O
the	O
hospital	O
with	O
right	O
foot	O
cellulitis	O
and	O
osteomyelitis	O
.	O
You	O
were	O
started	O
on	O
antibiotics	O
.	O
Vascular	O
surgery	O
evaluated	O
the	O
foot	O
and	O
were	O
cautious	O
to	O
pursue	O
surgical	O
intervention	O
because	O
you	O
have	O
a	O
poor	O
cardiac	O
reserve	O
.	O
Podiatry	O
evaluated	O
you	O
and	O
they	O
....	O
.	O
You	O
should	O
come	O
back	O
to	O
the	O
hospital	O
or	O
call	O
your	O
primary	O
care	O
doctor	O
if	O
you	O
have	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
weight	O
gain	O
,	O
fevers	O
/	O
chills	O
or	O
increasing	O
pain	O
in	O
your	O
right	O
foot	O
.	O
Followup	O
Instructions	O
:	O
PRN	O

Admission	O
Date	O
:	O
[	O
**	O
2103-10-18	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2103-10-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2031-8-15	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Epinephrine	I-Drug
/	O
Lidocaine	I-Drug
/	O
Percocet	I-Drug
/	O
Imuran	I-Drug
/	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2297	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypercarbic	O
respiratory	O
failure	O
,	O
pneumothorax	O
,	O
mental	O
status	O
changes	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
Patient	O
is	O
a	O
72	O
yo	O
male	O
with	O
pmhx	O
Myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
x	O
10	O
yrs	O
,	O
diaphragmatic	O
weakness	O
,	O
Esophageal	O
CA	O
s	O
/	O
p	O
partial	O
partial	O
esophagectomy	O
,	O
TIA	O
s	O
/	O
p	O
R	O
CEA	O
,	O
CAD	O
w	O
/	O
MI	O
s	O
/	O
p	O
stent	O
[	O
**	O
7	O
-	O
4	O
**	O
]	O
w	O
/	O
nl	O
EF	O
who	O
p	O
/	O
w	O
hypercarbic	O
respiratory	O
failure	O
(	O
Co2	O
=	O
150	O
)	O
,	O
pneumothorax	O
,	O
mental	O
status	O
changes	O
.	O
Recently	O
discharged	O
from	O
[	O
**	O
Hospital1	O
**	O
]	O
in	O
early	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
with	O
myasthenia	O
crisis	O
after	O
surgery	O
.	O
Originally	O
presented	O
for	O
chest	O
pain	O
and	O
sob	O
.	O
He	O
went	O
to	O
surgery	O
for	O
baloon	O
dilation	O
of	O
pylorus	O
with	O
improvemtn	O
of	O
chest	O
pressure	O
and	O
tolerated	O
po	O
diet	O
.	O
Transferred	O
to	O
MICU	O
.	O
He	O
was	O
plasmapheresed	O
and	O
placed	O
on	O
Bipap	O
.	O
He	O
was	O
also	O
started	O
on	O
bipap	O
.	O
He	O
was	O
discharged	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
on	O
prednisone	I-Drug
125	O
mg	O
.	O
Tapered	O
too	O
quickly	O
at	O
rehab	O
.	O
Presents	O
today	O
with	O
increased	O
sob	O
and	O
weakness	O
starting	O
one	O
week	O
ago	O
.	O
He	O
was	O
diagnosed	O
with	O
a	O
UTI	I-Reason
earlier	O
in	O
the	O
week	O
and	O
treated	O
with	O
antibiotics	I-Drug
.	O
His	O
wife	O
also	O
reported	O
mental	O
status	O
changes	O
and	O
reported	O
that	O
he	O
had	O
"	O
difficulty	O
focusing	O
"	O
.	O
Also	O
notes	O
decreased	O
po	O
intake	O
in	O
the	O
last	O
week	O
.	O
ABG	O
in	O
ED	O
7.20	O
/	O
150/381	O
.	O
ED	O
vitals	O
:	O
T	O
97.8	O
HR	O
80	O
BP	O
136/65	O
RR	O
23	O
O2	O
sat	O
100	O
%	O
.	O
Past	O
Medical	O
History	O
:	O
Myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
dx	O
[	O
**	O
2092	O
**	O
]	O
and	O
started	O
with	O
diplopia	O
Bilateral	O
Diaphragmatic	O
weakness	O
Esophageal	B-Reason
cancer	I-Reason
s	O
/	O
p	O
partial	O
esophagectomy	O
,	O
XRT	O
,	O
chemo	I-Drug
Coronary	O
Artery	O
Disease	O
w	O
/	O
MI	O
s	O
/	O
p	O
cypher	O
stent	O
of	O
mid	O
RCA	O
[	O
**	O
6	O
-	O
/	O
2102	O
**	O
]	O
,	O
EF	O
60	O
%	O
9/06	O
TIA	O
hypercholesterolemia	O
sleep	O
apnea	O
on	O
night	O
bipap	O
15/5	O
and	O
O2	O
at	O
2	O
liters	O
malnutrition	O
s	O
/	O
p	O
j	O
tube	O
placemtn	O
and	O
removal	O
glaucoma	O
Social	O
History	O
:	O
Patient	O
currently	O
lives	O
at	O
[	O
**	O
Hospital	O
**	O
]	O
Rehab	O
,	O
but	O
prior	O
to	O
this	O
admission	O
he	O
was	O
living	O
at	O
home	O
with	O
his	O
wife	O
.	O
Retired	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
warehouse	O
worker	O
.	O
No	O
children	O
.	O
15	O
pk	O
/	O
yr	O
history	O
of	O
smoking	O
but	O
quit	O
25	O
years	O
ago	O
.	O
Denies	O
ETOH	O
or	O
drug	O
abuse	O
.	O
Uses	O
walker	O
at	O
baseline	O
,	O
but	O
more	O
weak	O
recently	O
.	O
O2	O
requirement	O
24	O
hours	O
per	O
day	O
.	O
Family	O
History	O
:	O
Notable	O
for	O
many	O
family	O
members	O
with	O
CAD	O
.	O
His	O
brother	O
had	O
lung	O
cancer	O
.	O
There	O
is	O
no	O
myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
or	O
other	O
neurological	O
problems	O
in	O
the	O
family	O
.	O
Physical	O
Exam	O
:	O
VS	O
T	O
94.8	O
ax	O
,	O
BP	O
113/64	O
P	O
108	O
RR	O
30	O
O2	O
sat	O
60	O
%	O
by	O
VM	O
Gen	O
-	O
elderly	O
man	O
in	O
acute	O
respiratory	O
distress	O
,	O
able	O
to	O
speak	O
a	O
few	O
words	O
at	O
a	O
time	O
HEENT	O
-	O
NCAT	O
,	O
PERRLA	O
,	O
anicteric	O
,	O
no	O
injections	O
,	O
OP	O
with	O
thrush	O
,	O
MM	O
dry	O
Neck	O
-	O
no	O
JVD	O
Cor	O
-	O
tacchycardic	O
,	O
normal	O
rythm	O
,	O
S1S2	O
no	O
MGR	O
Lungs	O
-	O
no	O
breath	O
sounds	O
appreciated	O
on	O
right	O
side	O
anteriorly	O
and	O
upper	O
posterior	O
lung	O
fields	O
.	O
Abd	O
-	O
+	O
bs	O
,	O
soft	O
,	O
nt	O
,	O
nd	O
,	O
no	O
masses	O
or	O
hsm	O
Extrem	O
-	O
no	O
CCE	O
,	O
cold	O
extremities	O
,	O
poor	O
peripheral	O
pulses	O
-	O
thready	O
Neuro	O
-	O
confused	O
,	O
disoriented	O
to	O
place	O
and	O
time	O
Pertinent	O
Results	O
:	O
pH	O
7.20	O
pCO2	O
150	O
pO2	O
381	O
HCO3	O
61	O
.	O
151	O
99	O
25	O
----------	O
<	O
224	O
4.6	O
>	O
50	O
0.5	O
.	O
wbc	O
10.2	O
hgb	O
11.2	O
hct	O
35.2	O
plt	O
218	O
MCV	O
106	O
CK	O
36	O
MB	O
not	O
done	O
Trop	O
0.07	O
PT	O
11.4	O
PTT	O
24.9	O
INR	O
1.0	O
.	O
CXR	O
-	O
right	O
apical	O
pneumothorax	O
,	O
no	O
evidence	O
of	O
tension	O
pneumothorax	O
by	O
CXR	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Pt	O
is	O
a	O
72	O
yo	O
man	O
with	O
pmhx	O
myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
w	O
/	O
last	O
crisis	O
3	O
weeks	O
ago	O
s	O
/	O
p	O
surgery	O
,	O
esophageal	O
cancer	O
s	O
/	O
p	O
resection	O
,	O
chemotherapy	I-Drug
and	O
XRT	O
,	O
CAD	O
who	O
presented	O
with	O
one	O
weak	O
of	O
increased	O
weakness	O
,	O
sob	O
and	O
pneumothorax	O
and	O
decreased	O
mental	O
status	O
.	O
Hypercarbic	O
respiratory	O
failure	O
probably	O
multifactorial	O
and	O
related	O
to	O
weakness	O
2/2	O
MG	O
,	O
diaphragmatic	O
weakness	O
which	O
would	O
not	O
allow	O
him	O
to	O
blow	O
off	O
CO2	O
.	O
He	O
was	O
also	O
found	O
to	O
have	O
a	O
new	O
right	O
apical	O
pnuemothorax	O
of	O
unclear	O
etiology	O
but	O
without	O
signs	O
of	O
tension	O
pneumothorax	O
on	O
imaging	O
or	O
exam	O
.	O
The	O
family	O
and	O
patient	O
declined	O
thoracocentesis	O
.	O
The	O
patient	O
was	O
dyspneic	O
and	O
did	O
not	O
tolerate	O
BiPAP	O
.	O
His	O
code	O
was	O
changed	O
from	O
DNR	O
/	O
DNI	O
to	O
comfort	O
measures	O
only	O
per	O
his	O
health	O
care	O
proxy	O
.	O
The	O
patient	O
died	O
on	O
[	O
**	O
2103-10-19	O
**	O
]	O
at	O
9:15	O
am	O
secondary	O
to	O
respiratory	O
failure	O
secondary	O
to	O
diaphragmatic	O
weakness	O
/	O
pneumothorax	O
secondary	O
to	O
[	O
**	O
First	O
Name9	O
(	O
NamePattern2	O
)	O
15917	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
.	O
The	O
family	O
was	O
present	O
at	O
the	O
time	O
of	O
death	O
.	O
They	O
declined	O
autopsy	O
.	O
Medications	O
on	O
Admission	O
:	O
albuterol	I-Drug
nebs	O
asa	I-Drug
81	O
mg	O
QD	O
plavix	I-Drug
75	O
mg	O
QD	O
Anzemet	I-Drug
12.5	O
mg	O
q8	O
bisacodyl	I-Drug
suppository	O
brimonidine	I-Drug
.15	O
%	O
1	O
drop	O
OU	O
q	O
12	O
hrs	O
celexa	I-Drug
20	O
mg	O
QD	O
cyanocobalamin	I-Drug
1,000	O
mcg	O
QD	O
Dorzolamide	I-Drug
-	O
timolol	O
2	O
-	O
0.5	O
%	O
1	O
gtt	O
OU	O
q	O
12	O
Fludrocortisone	I-Drug
0.1	O
mg	O
po	O
QD	O
insulin	I-Drug
sliding	O
scale	O
MOM	I-Drug
mupirocin	I-Drug
cream	O
QD	O
to	O
nose	O
Mycophenylate	I-Drug
1000	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Protonix	I-Drug
40	O
mg	O
IV	O
QD	O
Pyridostigmine	I-Drug
2	O
mg	O
injection	O
q	O
6	O
hours	O
Quetiapine	B-Drug
25	O
mg	O
QHS	O
Travatan	I-Drug
0.004	O
%	O
1	O
-	O
2	O
gtt	O
OU	O
q	O
MWF	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
n	O
/	O
a	O
Discharge	O
Condition	O
:	O
n	O
/	O
a	O
Discharge	O
Instructions	O
:	O
n	O
/	O
a	O
Followup	O
Instructions	O
:	O
n	O
/	O
a	O

Admission	O
Date	O
:	O
[	O
**	O
2178-10-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2178-11-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2120-5-31	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Sulfa	B-Drug
(	I-Drug
Sulfonamide	I-Drug
Antibiotics	I-Drug
)	I-Drug
/	O
Lamictal	I-Drug
/	O
Shellfish	O
Derived	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1990	O
**	O
]	O
Chief	O
Complaint	O
:	O
Weakness	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
For	O
full	O
H&P	O
please	O
refer	O
to	O
Nightfloat	O
admission	O
note	O
briefly	O
this	O
is	O
a	O
58	O
y.o.	O
Female	O
with	O
a	O
history	O
of	O
gastric	O
bypass	O
4	O
years	O
ago	O
w	O
/	O
multiple	O
recent	O
complications	O
including	O
spinal	O
abscess	O
,	O
osteomyelitis	O
,	O
intraabdominal	O
leak	O
,	O
spinal	O
osteomyelitis	O
with	O
abscess	O
,	O
sepsis	O
who	O
was	O
initially	O
admitted	O
for	O
weakness	O
.	O
.	O
On	O
review	O
of	O
her	O
initial	O
note	O
it	O
appears	O
she	O
was	O
discharged	O
following	O
the	O
aforementioned	O
complicated	O
course	O
on	O
a	O
course	O
of	O
first	O
Clindamycin	I-Drug
x	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
wks	O
which	O
was	O
changed	O
to	O
Levaquin	I-Drug
and	O
Vancomycin	I-Drug
.	O
On	O
the	O
day	O
of	O
her	O
admission	O
she	O
was	O
found	O
by	O
her	O
[	O
**	O
Month	O
/	O
Day	O
(	O
3	O
)	O
269	O
**	O
]	O
to	O
be	O
extremely	O
weak	O
specifically	O
with	O
lower	O
extremity	O
weakness	O
but	O
no	O
bladder	O
/	O
bowel	O
incontinence	O
or	O
anaesthesia	O
.	O
She	O
initially	O
was	O
seen	O
at	O
[	O
**	O
Hospital3	O
4107	O
**	O
]	O
and	O
then	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
as	O
pt	O
did	O
not	O
want	O
further	O
care	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
.	O
.	O
She	O
was	O
then	O
admitted	O
to	O
the	O
[	O
**	O
Hospital1	O
1516	O
**	O
]	O
service	O
where	O
she	O
was	O
noted	O
to	O
have	O
hypokalemia	O
due	O
to	O
increased	O
K	O
+	O
wasting	O
though	O
it	O
is	O
unclear	O
as	O
to	O
why	O
this	O
was	O
occuring	O
.	O
She	O
was	O
also	O
noted	O
to	O
be	O
in	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
thought	O
to	O
be	O
secondary	O
to	O
Vancomycin	I-Drug
toxicity	I-Ade
(	O
her	O
reported	O
Vancomycin	I-Drug
was	O
noted	O
to	O
be	O
80	O
?	O
)	O
.	O
An	O
MRI	O
was	O
obtained	O
given	O
her	O
lower	O
extremity	O
weakness	O
and	O
was	O
notable	O
for	O
worsening	O
L4	O
-	O
5	O
disco	O
-	O
osteomyelitis	O
.	O
Orthopaedics	O
were	O
consulted	O
and	O
pt	O
underwent	O
a	O
diskectomy	O
,	O
debridement	O
and	O
anterior	O
fusion	O
on	O
[	O
**	O
10	O
-	O
20	O
**	O
]	O
.	O
Following	O
induction	O
of	O
her	O
anaesthesia	O
she	O
was	O
noted	O
to	O
be	O
tachycardic	O
ranging	O
from	O
80s	O
-	O
110s	O
.	O
She	O
underwent	O
a	O
1.5	O
hour	O
surgery	O
which	O
was	O
uneventful	O
.	O
In	O
the	O
PACU	O
though	O
her	O
BP	O
was	O
noted	O
to	O
drop	O
from	O
110s	O
to	O
70s	O
,	O
though	O
she	O
was	O
mentating	O
well	O
.	O
BP	I-Reason
was	O
not	O
fluid	O
responsive	O
and	O
pt	O
was	O
started	O
on	O
Neo	I-Drug
ar	O
0.3	O
and	O
titrated	O
up	O
to	O
a	O
max	O
of	O
0.8	O
.	O
Following	O
IVF	I-Drug
resuscitation	I-Reason
2.8	O
L	O
as	O
well	O
as	O
1u	O
PRBC	I-Drug
post-op	O
(	O
she	O
received	O
2u	O
PRBC	I-Drug
prior	O
to	O
surgery	O
)	O
she	O
was	O
able	O
to	O
wean	O
off	O
pressors	I-Drug
and	O
have	O
an	O
increase	O
in	O
her	O
urine	O
output	O
.	O
For	O
work	O
-	O
up	O
of	O
her	O
hypotension	O
she	O
underwent	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
stim	O
testing	O
which	O
was	O
negative	O
for	O
adrenal	O
insufficiency	O
.	O
.	O
Her	O
ICU	O
course	O
has	O
also	O
been	O
notable	O
for	O
a	O
diffuse	O
morbilliform	O
rash	O
with	O
palm	O
and	O
sole	O
sparing	O
.	O
Dermatology	O
were	O
consulted	O
for	O
possible	O
SJS	O
.	O
Given	O
lack	O
of	O
mucosal	O
involvement	O
SJS	O
was	O
ruled	O
out	O
however	O
Dermatology	O
is	O
still	O
following	O
the	O
patient	O
.	O
The	O
rash	I-Ade
,	O
which	O
has	O
steadily	O
been	O
improving	O
,	O
was	O
thought	O
to	O
be	O
due	O
to	O
Lamotrigine	I-Drug
toxicity	I-Ade
given	O
her	O
progressively	O
poor	O
Creatinine	O
Clearance	O
.	O
Though	O
interestingly	O
enough	O
unclear	O
if	O
Lamotrigine	I-Drug
has	O
dose	O
adjustments	O
based	O
on	O
renal	O
clearance	O
.	O
.	O
With	O
regards	O
to	O
her	O
diskitis	O
,	O
her	O
blood	O
cultures	O
have	O
thus	O
far	O
been	O
negative	O
and	O
she	O
is	O
currently	O
on	O
Aztreonam	I-Drug
and	O
Vancomycin	I-Drug
per	O
ID	O
recs	O
.	O
She	O
is	O
still	O
being	O
followed	O
by	O
Ortho	O
who	O
will	O
take	O
her	O
to	O
the	O
OR	O
tomorrow	O
for	O
posterior	O
fusion	O
,	O
after	O
which	O
she	O
will	O
be	O
able	O
to	O
participate	O
in	O
PT	O
.	O
.	O
She	O
is	O
also	O
being	O
followed	O
by	O
Renal	O
for	O
her	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
which	O
is	O
thought	O
to	O
be	O
AIN	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
Vancomycin	I-Drug
toxicity	I-Ade
.	O
Renal	O
are	O
currently	O
considering	O
possible	O
biopsy	O
to	O
confirm	O
AIN	O
.	O
.	O
On	O
review	O
of	O
her	O
vitals	O
in	O
the	O
unit	O
over	O
the	O
past	O
few	O
hours	O
her	O
Tmax	O
has	O
been	O
100.2	O
,	O
Tc	O
98.6	O
,	O
HRs	O
109	O
-	O
118	O
,	O
SBP	O
114-149/59	O
-	O
70	O
,	O
RR	O
24	O
,	O
100	O
%	O
on	O
RA	O
.	O
.	O
ROS	O
per	O
HPI	O
.	O
Past	O
Medical	O
History	O
:	O
Gastric	O
Bypass	O
4	O
years	O
ago	O
with	O
multiple	O
complications	O
Spinal	O
Abscess	O
and	O
Osteo	O
Bipolar	O
disorder	O
requiring	O
hospitalization	O
in	O
the	O
[	O
**	O
2158	O
**	O
]	O
Congestive	O
heart	O
failure	O
-	O
apparently	O
this	O
resolved	O
after	O
her	O
bariatric	O
surgery	O
and	O
subsequent	O
weight	O
loss	O
(	O
EF	O
unknown	O
)	O
.	O
Social	O
History	O
:	O
Living	O
Situation	O
:	O
She	O
lives	O
with	O
daughter	O
and	O
granddaughter	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
269	O
**	O
]	O
at	O
her	O
house	O
Tobacco	O
:	O
denied	O
EtOH	O
:	O
denied	O
IVDU	O
:	O
denied	O
Family	O
History	O
:	O
FAMILY	O
HISTORY	O
:	O
Father	O
:	O
HTN	O
Mother	O
:	O
CHF	O
Brother	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
CA	O
Physical	O
Exam	O
:	O
PE	O
:	O
T	O
:	O
99.4	O
BP	O
:	O
142/67	O
HR	O
:	O
93	O
RR	O
:	O
18	O
O2	O
96	O
%	O
RA	O
Gen	O
:	O
NAD	O
/	O
ill	O
appearing	O
/	O
Comfortable	O
/	O
appears	O
stated	O
age	O
/	O
pleasant	O
HEENT	O
:	O
AT	O
/	O
NC	O
,	O
PERRLA	O
,	O
EOMI	O
,	O
anicteric	O
,	O
no	O
conjuctival	O
pallor	O
,	O
dryMM	O
,	O
clear	O
oropharynx	O
,	O
no	O
erythema	O
,	O
no	O
exudates	O
no	O
rhinorrhea	O
/	O
discharge	O
,	O
NECK	O
:	O
supple	O
,	O
trachea	O
midline	O
,	O
no	O
LAD	O
,	O
no	O
thyromegaly	O
LUNG	O
:	O
CTA	O
-	O
B	O
/	O
L	O
,	O
no	O
R	O
/	O
R	O
/	O
W	O
CV	O
:	O
S1	O
&	O
S2	O
,	O
RRR	O
,	O
II	O
/	O
VI	O
SEM	O
no	O
/	O
G	O
/	O
M	O
ABD	O
:	O
well	O
healed	O
surgical	O
scar	O
,	O
Soft	O
/	O
+	O
BS	O
/	O
mild	O
tenderness	O
in	O
the	O
RLQ	O
/	O
ND	O
/	O
no	O
rebound	O
/	O
no	O
guarding	O
/	O
EXT	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
+2	O
pulses	O
radial	O
,	O
DP	O
,	O
PT	O
b	O
/	O
l	O
&	O
symetrical	O
SKIN	O
:	O
No	O
lesions	O
,	O
rashes	O
,	O
bruises	O
BACK	O
:	O
tenderness	O
in	O
the	O
L4	O
-	O
L5	O
region	O
RECTAL	O
:	O
normal	O
tone	O
NEURO	O
:	O
AAOx3	O
CN	O
II	O
-	O
XII	O
grossly	O
intact	O
and	O
non-focal	O
b	O
/	O
l	O
5/5	O
strength	O
in	O
upper	O
ext	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
hip	O
flexors	O
,	O
[	O
**	O
3	O
-	O
31	O
**	O
]	O
in	O
the	O
rest	O
of	O
the	O
lower	O
ext	O
b	O
/	O
l	O
Sensation	O
to	O
pain	O
,	O
temp	O
,	O
position	O
intact	O
b	O
/	O
l	O
Reflexes	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
brachioradialis	O
,	O
biceps	O
,	O
triceps	O
,	O
Unable	O
to	O
elicit	O
in	O
the	O
lower	O
ext	O
patellar	O
,	O
Achilles	O
Toes	O
down	O
going	O
Unremarkable	O
finger	O
/	O
nose	O
,	O
unremarkable	O
rapid	O
/	O
alternating	O
PSYCH	O
:	O
Listens	O
and	O
responds	O
to	O
questions	O
appropriately	O
,	O
pleasant	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2178-10-14	O
**	O
]	O
08:21	O
PM	O
BLOOD	O
WBC	O
-	O
7.0	O
RBC	O
-	O
3.57	O
*	O
Hgb	O
-	O
8.1	O
*	O
Hct	O
-	O
25.7	O
*	O
MCV	O
-	O
72	O
*	O
MCH	O
-	O
22.7	O
*	O
MCHC	O
-	O
31.6	O
RDW	O
-	O
17.5	O
*	O
Plt	O
Ct	O
-	O
250	O
[	O
**	O
2178-10-14	O
**	O
]	O
08:21	O
PM	O
BLOOD	O
Neuts	O
-	O
84.2	O
*	O
Lymphs	O
-	O
9.6	O
*	O
Monos	O
-	O
3.6	O
Eos	O
-	O
2.1	O
Baso	O
-	O
0.5	O
[	O
**	O
2178-10-14	O
**	O
]	O
08:21	O
PM	O
BLOOD	O
Glucose	O
-	O
86	O
UreaN	O
-	O
16	O
Creat	O
-	O
2.8	O
*	O
Na	O
-	O
138	O
K	O
-	O
2.2	O
*	O
Cl	O
-	O
94	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
21	O
*	O
[	O
**	O
2178-10-14	O
**	O
]	O
08:31	O
PM	O
BLOOD	O
Lactate	O
-	O
0.7	O
K	O
-	O
2.2	O
*	O
Vancomycin	O
82.4	O
*	O
ug	O
/	O
mL	O
(	O
10	O
-	O
20	O
)	O
[	O
**	O
2178-10-15	O
**	O
]	O
07:20	O
AM	O
BLOOD	O
Vanco	O
-	O
78	O
*	O
---------------	O
DISCHARGE	O
LABS	O
:	O
[	O
**	O
2178-11-3	O
**	O
]	O
05:04	O
AM	O
BLOOD	O
WBC	O
-	O
10.2	O
RBC	O
-	O
3.16	O
*	O
Hgb	O
-	O
8.4	O
*	O
Hct	O
-	O
25.7	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
26.5	O
*	O
MCHC	O
-	O
32.6	O
RDW	O
-	O
18.2	O
*	O
Plt	O
Ct	O
-	O
253	O
[	O
**	O
2178-11-3	O
**	O
]	O
05:04	O
AM	O
BLOOD	O
Glucose	O
-	O
102	O
UreaN	O
-	O
10	O
Creat	O
-	O
0.9	O
Na	O
-	O
141	O
K	O
-	O
3.4	O
Cl	O
-	O
105	O
HCO3	O
-	O
29	O
AnGap	O
-	O
10	O
[	O
**	O
2178-11-3	O
**	O
]	O
05:04	O
AM	O
BLOOD	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
4.1	O
Mg	O
-	O
2.4	O
---------------	O
EKG	O
(	O
[	O
**	O
2178-10-14	O
**	O
]	O
20:35	O
)	O
:	O
NSR	O
,	O
rate	O
90	O
,	O
Left	O
axis	O
deviation	O
,	O
poor	O
R	O
-	O
wave	O
progression	O
,	O
LVH	O
---------------	O
IMAGING	O
STUDIES	O
:	O
CXR	O
(	O
[	O
**	O
2178-10-14	O
**	O
]	O
)	O
:	O
No	O
acute	O
cardiopulmonary	O
process	O
.	O
.	O
Renal	O
US	O
(	O
[	O
**	O
2178-10-15	O
**	O
]	O
)	O
:	O
Unremarkable	O
renal	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
hydronephrosis	O
.	O
.	O
CXR	O
(	O
[	O
**	O
2178-10-15	O
**	O
]	O
)	O
:	O
1	O
.	O
Right	O
PICC	O
catheter	O
terminates	O
at	O
the	O
junction	O
of	O
right	O
subclavian	O
and	O
right	O
internal	O
jugular	O
vein	O
,	O
without	O
evidence	O
of	O
pneumothorax	O
.	O
2	O
.	O
New	O
-	O
onset	O
small	O
right	O
pleural	O
effusion	O
.	O
.	O
MR	O
spine	O
(	O
[	O
**	O
2178-10-15	O
**	O
]	O
)	O
:	O
1	O
.	O
Signal	O
changes	O
at	O
L4	O
-	O
5	O
which	O
has	O
progressed	O
since	O
[	O
**	O
2178-9-17	O
**	O
]	O
and	O
is	O
concerning	O
for	O
disco	O
-	O
osteomyelitis	O
.	O
No	O
definite	O
epidural	O
extension	O
is	O
identified	O
,	O
although	O
the	O
lack	O
of	O
intravenous	O
contrast	O
does	O
decrease	O
sensitivity	O
.	O
Endplate	O
degenerative	O
changes	O
are	O
also	O
a	O
differential	O
consideration	O
(	O
type	O
1	O
)	O
,	O
but	O
considered	O
less	O
likely	O
given	O
the	O
progression	O
.	O
2	O
.	O
Transitional	O
anatomy	O
with	O
sacralization	O
of	O
the	O
L5	O
vertebral	O
body	O
.	O
3	O
.	O
Mild	O
degenerative	O
disc	O
disease	O
at	O
other	O
levels	O
as	O
detailed	O
above	O
,	O
most	O
significant	O
at	O
the	O
T7	O
-	O
8	O
level	O
,	O
where	O
there	O
is	O
mild	O
spinal	O
canal	O
narrowing	O
and	O
indentation	O
of	O
the	O
ventral	O
aspect	O
of	O
the	O
spinal	O
cord	O
.	O
.	O
CT	O
Abd	O
/	O
Pelvis	O
(	O
[	O
**	O
2178-10-16	O
**	O
]	O
)	O
:	O
1	O
.	O
Limited	O
examination	O
secondary	O
to	O
lack	O
of	O
intravenous	O
and	O
oral	O
contrast	O
.	O
2	O
.	O
Free	O
intra-abdominal	O
air	O
within	O
the	O
upper	O
abdomen	O
is	O
somewhat	O
less	O
in	O
amount	O
compared	O
to	O
the	O
outside	O
hospital	O
CT	O
exam	O
from	O
[	O
**	O
2178-9-18	O
**	O
]	O
.	O
Evidence	O
of	O
extensive	O
inflammatory	O
changes	O
in	O
the	O
upper	O
abdomen	O
,	O
not	O
well	O
assessed	O
on	O
this	O
non-contrast	O
examination	O
.	O
No	O
definte	O
intra-abdominal	O
collection	O
.	O
.	O
3	O
.	O
Mesenteric	O
adenopathy	O
.	O
4	O
.	O
Left	O
adrenal	O
myelolipoma	O
,	O
stable	O
.	O
5	O
.	O
Erosive	O
changes	O
involving	O
the	O
endplates	O
of	O
the	O
L5	O
vertebral	O
body	O
and	O
S1	O
portion	O
of	O
the	O
sacrum	O
concerning	O
for	O
osteomyelitis	O
,	O
better	O
delineated	O
on	O
the	O
recent	O
MRI	O
of	O
the	O
lumbar	O
spine	O
.	O
No	O
other	O
erosive	O
changes	O
evident	O
throughout	O
the	O
visualized	O
skeleton	O
.	O
6	O
.	O
Right	O
lower	O
lobe	O
consolidation	O
versus	O
atelectasis	O
.	O
.	O
Lumbar	O
Spine	O
Xray	O
(	O
[	O
**	O
2178-10-20	O
**	O
]	O
)	O
:	O
Single	O
intraoperative	O
cross-table	O
lateral	O
image	O
of	O
the	O
LS	O
spine	O
shows	O
placement	O
of	O
a	O
metallic	O
interbody	O
fusion	O
device	O
at	O
L4	O
-	O
5	O
.	O
Normal	O
vertebral	O
body	O
alignment	O
and	O
discs	O
.	O
We	O
have	O
no	O
preoperative	O
comparison	O
radiographs	O
.	O
.	O
CXR	O
(	O
[	O
**	O
2178-10-21	O
**	O
]	O
)	O
:	O
Lungs	O
are	O
fully	O
expanded	O
and	O
clear	O
.	O
Previous	O
mild	O
vascular	O
engorgement	O
has	O
resolved	O
and	O
may	O
reflect	O
hypovolemia	O
.	O
Heart	O
size	O
top	O
normal	O
,	O
unchanged	O
.	O
No	O
pleural	O
effusion	O
or	O
pneumothorax	O
.	O
Right	O
-	O
sided	O
central	O
venous	O
line	O
tip	O
projects	O
over	O
the	O
mid	O
SVC	O
.	O
[	O
**	O
2178-10-30	O
**	O
]	O
:	O
EGD	O
Impression	O
:	O
The	O
stomach	O
remnant	O
appeared	O
normal	O
Erythema	O
in	O
the	O
lower	O
third	O
of	O
the	O
esophagus	O
Large	O
small	O
bowel	O
ulcer	O
which	O
could	O
represent	O
the	O
site	O
of	O
bleeding	O
(	O
biopsy	O
)	O
Otherwise	O
normal	O
EGD	O
to	O
third	O
part	O
of	O
the	O
duodenum	O
Recommendations	O
:	O
Return	O
patient	O
to	O
floor	O
.	O
Continue	O
high	O
dose	O
ppi	O
.	O
Await	O
biopsy	O
report	O
Post	O
discharge	O
,	O
patient	O
needs	O
outpatient	O
GI	O
follow	O
up	O
in	O
fellow	O
clinic	O
[	O
**	O
2178-10-30	O
**	O
]	O
Colonoscopy	O
:	O
Impression	O
:	O
Stool	O
in	O
the	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
noted	O
.	O
Otherwise	O
normal	O
colonoscopy	O
to	O
hepatic	O
flexure	O
of	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
499	O
**	O
]	O
.	O
No	O
obvious	O
bleeding	O
source	O
was	O
noted	O
.	O
Recommendations	O
:	O
Return	O
patient	O
to	O
floor	O
Since	O
the	O
colonoscopy	O
was	O
aborted	O
at	O
the	O
level	O
of	O
hepatic	O
flexure	O
,	O
patient	O
will	O
need	O
a	O
colonoscopy	O
as	O
an	O
outpatient	O
.	O
Brief	O
Hospital	O
Course	O
:	O
ASSESSMENT	O
:	O
58	O
y.o.	O
Female	O
s	O
/	O
p	O
distant	O
gastric	O
bypass	O
complicated	O
by	O
recent	O
hospitalization	O
for	O
leak	O
s	O
/	O
p	O
repair	O
,	O
sepsis	O
initially	O
admitted	O
for	O
LE	O
weakness	O
,	O
hospitalization	O
c	O
/	O
b	O
diskitis	O
s	O
/	O
p	O
anterior	O
fusion	O
/	O
debridement	O
,	O
ICU	O
stay	O
for	O
hypotension	I-Reason
on	O
pressors	I-Drug
now	O
transferred	O
to	O
floor	O
awaiting	O
posterior	O
fusion	O
.	O
PLAN	O
:	O
##	O
Diskitis	O
:	O
Pt	O
was	O
initially	O
admitted	O
for	O
lower	O
extremity	O
weakness	O
with	O
mild	O
weakness	O
with	O
the	O
hip	O
flexors	O
,	O
normal	O
rectal	O
tone	O
.	O
MRI	O
work	O
up	O
was	O
notable	O
for	O
L4	O
-	O
L5	O
disco	O
-	O
osteomyelitis	O
.	O
Unclear	O
as	O
to	O
the	O
source	O
of	O
her	O
disco	O
-	O
osteomyelitis	O
though	O
given	O
her	O
recent	O
discharge	O
for	O
sepsis	O
it	O
is	O
possible	O
that	O
she	O
seeded	O
when	O
she	O
was	O
bacteremic	O
.	O
Pt	O
underwent	O
debridement	O
under	O
OR	O
and	O
anterior	O
fusion	O
and	O
later	O
posterior	O
fusion	O
.	O
Anterior	O
fusion	O
post-op	O
course	O
complicated	O
by	O
sepsis	O
(	O
discussed	O
below	O
)	O
.	O
OR	O
Swabs	O
and	O
multiple	O
subsequent	O
bld	O
cultures	O
have	O
been	O
negative	O
.	O
-	O
Continued	O
on	O
Aztreonam	I-Drug
and	O
Vancoymcin	I-Drug
per	O
ID	O
recs	O
,	O
switched	O
from	O
aztreonam	I-Drug
to	O
levofloxacin	I-Drug
.	O
Now	O
on	O
Levofloxacin	I-Drug
PO	O
Q24H	O
,	O
and	O
vancomycin	I-Drug
1gm	O
IV	O
Q24H	O
-	O
post-op	B-Reason
pain	I-Reason
control	I-Reason
:	O
PCA	O
switched	O
to	O
morphine	B-Drug
contin	I-Drug
15	O
mg	O
PO	O
Q12H	O
,	O
plus	O
morphine	I-Drug
5	O
-	O
15	O
mg	O
PO	O
Q6H	O
PRN	O
breakthrough	B-Reason
pain	I-Reason
(	O
has	O
had	O
little	O
pain	O
med	O
requirements	O
,	O
pain	O
well	O
controlled	O
)	O
-	O
Ortho	O
recommended	O
PT	O
-	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
need	O
a	O
vanc	I-Drug
trough	O
drawn	O
on	O
[	O
**	O
2178-11-4	O
**	O
]	O
and	O
dose	O
adjustement	O
accordingly	O
##	O
.	O
Rash	I-Ade
:	O
Pt	O
noted	O
to	O
have	O
diffuse	O
rash	O
over	O
entire	O
body	O
with	O
sparing	O
of	O
mucousal	O
membranes	O
,	O
feet	O
soles	O
and	O
palm	O
.	O
Dermatology	O
followed	O
and	O
concluded	O
this	O
was	O
due	O
to	O
lamictal	I-Drug
,	O
secondary	O
to	O
increased	O
levels	O
during	O
ARF	O
.	O
Pt	O
now	O
noted	O
to	O
have	O
lamictal	I-Drug
allergy	I-Ade
.	O
-	O
Held	O
lamictal	I-Drug
and	O
rash	I-Ade
resolved	O
without	O
signs	O
of	O
mucositis	O
-	O
Pt	O
to	O
continue	O
triamcinolone	I-Drug
cream	O
for	O
a	O
total	O
of	O
2	O
weeks	O
(	O
start	O
date	O
[	O
**	O
2178-10-23	O
**	O
]	O
)	O
##	O
Sepsis	O
:	O
Pt	O
admitted	O
to	O
the	O
unit	O
for	O
sepsis	I-Reason
.	O
Although	O
resolved	O
it	O
is	O
unclear	O
as	O
to	O
the	O
exact	O
cause	O
.	O
Pt	O
's	O
hypotensive	O
episode	O
occured	O
several	O
hours	O
after	O
anterior	O
fusion	O
surgery	O
so	O
unlikely	O
to	O
be	O
anaesthesia	O
induced	O
.	O
Given	O
requirement	O
of	O
pressors	O
following	O
surgery	O
in	O
an	O
area	O
complicated	O
by	O
infection	O
hypotensive	O
episode	O
may	O
be	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
transient	B-Reason
bacteremia	I-Reason
.	O
Vanc	I-Drug
and	O
levo	I-Drug
broadened	O
to	O
vanc	O
and	O
aztreonam	I-Drug
.	O
After	O
several	O
days	O
,	O
aztreonam	I-Drug
switched	O
back	O
to	O
levofloxacin	I-Drug
.	O
Bld	O
cultures	O
and	O
swabs	O
have	O
thus	O
far	O
been	O
negative	O
.	O
Sepsis	O
resolved	O
after	O
less	O
than	O
24	O
hours	O
and	O
pt	O
has	O
been	O
off	O
pressors	I-Drug
since	O
.	O
-	O
was	O
continued	O
on	O
Aztreonam	I-Drug
and	O
Vancomycin	I-Drug
per	O
ID	O
recs	O
and	O
later	O
switched	O
back	O
to	O
levofloxacin	I-Drug
-	O
To	O
rehab	O
facility	O
:	O
Pt	O
has	O
a	O
f	O
/	O
u	O
appointment	O
at	O
the	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
of	O
[	O
**	O
Hospital6	O
1708	O
**	O
]	O
with	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
402	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
on	O
[	O
**	O
2178-11-5	O
**	O
]	O
1000	O
am	O
.	O
#	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
39041	O
**	O
]	O
.	O
They	O
will	O
decide	O
the	O
stop	O
date	O
of	O
patient	O
's	O
antibiotics	O
.	O
.	O
##	O
ARF	O
:	O
Unclear	O
etiology	O
.	O
Creatinine	O
peaked	O
to	O
2.8	O
but	O
eventually	O
resolved	O
now	O
at	O
0.9	O
.	O
Per	O
renal	O
,	O
ARF	I-Ade
may	O
have	O
been	O
due	O
to	O
vancomycin	I-Drug
toxicity	I-Ade
from	O
too	O
high	O
dosing	O
.	O
(	O
vanc	I-Drug
level	O
80	O
at	O
one	O
point	O
)	O
.	O
No	O
signs	O
of	O
uremia	O
and	O
no	O
dialysis	O
was	O
employed	O
.	O
-	O
To	O
rehab	O
facility	O
:	O
Please	O
make	O
sure	O
to	O
f	O
/	O
u	O
vanc	I-Drug
troughs	O
every	O
three	O
days	O
,	O
as	O
pt	O
has	O
unstable	O
vancomycin	I-Drug
pharmacokinetics	O
##	O
Guiac	B-Reason
positive	I-Reason
stool	I-Reason
:	O
Pt	O
with	O
guiac	O
positive	O
melena	O
.	O
Hct	O
and	O
hemodynamics	O
remained	O
stable	O
.	O
Pt	O
underwent	O
EGD	O
which	O
showed	O
a	O
large	O
jejunal	O
ulcer	O
with	O
stigmata	O
of	O
bleeding	O
but	O
no	O
active	O
bleeding	O
.	O
This	O
may	O
have	O
been	O
due	O
to	O
the	O
stress	O
from	O
all	O
the	O
acute	O
illnesses	O
of	O
osteo	O
/	O
discitis	O
,	O
sepsis	O
,	O
etc.	O
.	O
No	O
intervention	O
done	O
.	O
Colonoscopy	O
non-diagnostic	O
due	O
to	O
poor	O
prep	O
.	O
Hct	O
stable	O
.	O
Pt	O
continued	O
on	O
pantoprazole	I-Drug
IV	O
Q12H	O
until	O
GI	O
follow	O
determines	O
when	O
to	O
discontinue	O
.	O
##	O
Malnutrition	O
:	O
Pt	O
malnourished	O
with	O
an	O
albumin	O
of	O
1.9	O
and	O
INR	O
of	O
1.4	O
secondary	O
to	O
vitamin	B-Drug
K	I-Drug
deficiency	O
thought	O
to	O
be	O
related	O
to	O
her	O
severe	O
illnesses	O
during	O
the	O
last	O
2	O
months	O
.	O
Pt	O
refusing	O
TPN	O
initially	O
,	O
calorie	O
count	O
initiated	O
,	O
only	O
200	O
-	O
300	O
calories	O
per	O
day	O
,	O
therefore	O
,	O
TPN	O
initiated	O
inhouse	O
started	O
[	O
**	O
2178-11-2	O
**	O
]	O
.	O
Patient	O
also	O
with	O
K	O
and	O
Mg	O
abnormalities	O
.	O
-	O
To	O
rehab	O
facility	O
:	O
Please	O
see	O
Page	O
2	O
for	O
nutrition	O
recs	O
.	O
-	O
To	O
rehab	O
facility	O
:	O
Please	O
check	O
daily	O
K	O
and	O
Mg	O
and	O
replete	O
lytes	O
as	O
necessary	O
.	O
Medications	O
on	O
Admission	O
:	O
MEDICATIONS	O
:	O
Vancomycin	I-Drug
1.5	O
g	O
Q12	O
Levaquin	I-Drug
500	O
mg	O
daily	O
Flexeril	I-Drug
10	O
mg	O
TID	O
Carvidilol	O
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Paxil	I-Drug
40	O
mg	O
daily	O
Lamictal	I-Drug
100	O
mg	O
daily	O
Seroquel	I-Drug
50	O
mg	O
daily	O
Klonopin	I-Drug
1	O
mg	O
TID	O
Dilaudid	I-Drug
2	O
mg	O
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Levofloxacin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q48H	O
(	O
every	O
48	O
hours	O
)	O
.	O
2	O
.	O
Carvedilol	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
3	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Lamotrigine	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
5	O
.	O
Quetiapine	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
6	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
SC	O
injection	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Clonazepam	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
:	O
Please	O
hold	O
for	O
sedation	I-Ade
and	O
RR	B-Ade
<	I-Ade
12	I-Ade
.	O
8	O
.	O
Cyclobenzaprine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
pain	I-Reason
:	O
hold	O
for	O
sedation	O
.	O
9	O
.	O
Hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
:	O
Please	O
hold	O
for	O
sedation	O
and	O
RR	O
<	O
12	O
.	O
10	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
hold	O
for	O
diarrhea	O
.	O
11	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
:	O
hold	O
for	O
diarrhea	O
.	O
12	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
/	O
fever	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
700	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
701	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Hypokalemia	O
Weakness	O
Osteomyelitis	O
/	O
Diskitis	O
S	O
/	O
p	O
gastric	O
bypass	O
revision	O
with	O
leakage	O
,	O
intra-abdominal	O
abscess	O
and	O
Spinal	O
abscess	O
Jejunal	O
ulcer	O
Acute	O
on	O
chronic	O
diastolic	O
congestive	O
heart	O
failure	O
Malnutrition	O
Secondary	O
:	O
HTN	O
Depression	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Vital	O
signs	O
stable	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
weakness	O
.	O
You	O
had	O
gastric	O
bypass	O
4	O
years	O
ago	O
and	O
a	O
recent	O
revision	O
in	O
[	O
**	O
2178-5-27	O
**	O
]	O
that	O
was	O
complicated	O
by	O
intra-abdominal	O
leakage	O
and	O
spinal	O
abscess	O
with	O
osteomyelitis	O
.	O
During	O
your	O
hospital	O
stay	O
your	O
surgery	O
to	O
debride	O
the	O
osteomyelitis	I-Reason
was	O
complicated	O
by	O
sepsis	I-Reason
,	O
which	O
promptly	O
resolved	O
after	O
IV	O
fluids	I-Drug
and	O
IV	O
antibiotics	I-Drug
.	O
You	O
also	O
developed	O
kidney	B-Ade
failure	I-Ade
,	O
possibly	O
due	O
to	O
vancomycin	I-Drug
toxicity	I-Ade
(	O
high	O
serum	O
levels	O
at	O
presentation	O
)	O
which	O
also	O
resolved	O
over	O
time	O
.	O
You	O
developed	O
a	O
rash	O
thought	O
to	O
be	O
related	O
to	O
a	O
lamictal	I-Drug
allergy	I-Ade
in	O
the	O
setting	O
of	O
increased	O
reduced	O
lamictal	I-Drug
clearance	O
given	O
kidney	O
failure	O
.	O
This	O
too	O
resolved	O
with	O
time	O
.	O
Also	O
,	O
you	O
developed	O
an	O
ulcer	O
which	O
bled	O
,	O
and	O
a	O
scope	O
showed	O
that	O
this	O
ulcer	O
remained	O
stable	O
.	O
You	O
will	O
follow	O
up	O
with	O
GI	O
regarding	O
the	O
ulcer	O
here	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
and	O
you	O
will	O
return	O
to	O
the	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
,	O
where	O
they	O
know	O
you	O
quite	O
well	O
.	O
You	O
also	O
developed	O
malnutrition	O
secondary	O
to	O
all	O
of	O
these	O
illnesses	O
,	O
which	O
is	O
requiring	O
total	O
parenteral	O
nutrition	O
.	O
Please	O
make	O
sure	O
to	O
follow	O
up	O
with	O
all	O
your	O
follow	O
up	O
appointments	O
.	O
Followup	O
Instructions	O
:	O
You	O
have	O
an	O
appointment	O
at	O
the	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
of	O
[	O
**	O
Hospital6	O
13185	O
**	O
]	O
with	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
402	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
already	O
an	O
appointment	O
on	O
[	O
**	O
2178-11-5	O
**	O
]	O
1000	O
am	O
.	O
#	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
39041	O
**	O
]	O
.	O
Date	O
/	O
Time	O
:[	O
**	O
2178-12-2	O
**	O
]	O
2:00	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
10314	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
463	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2178-11-17	O
**	O
]	O
1:30	O
Completed	O
by	O
:[	O
**	O
2178-11-5	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2142-7-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2142-8-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2084-1-25	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Heparin	B-Drug
Agents	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2777	O
**	O
]	O
Chief	O
Complaint	O
:	O
Left	O
lower	O
extemity	O
ischemia	O
,	O
transfered	O
from	O
OSH	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2142-8-20	O
**	O
]	O
:	O
Left	O
AKA	O
[	O
**	O
2142-8-2	O
**	O
]	O
:	O
Left	O
guillotine	O
amp	O
[	O
**	O
2142-7-30	O
**	O
]	O
:	O
LLE	O
angio	O
,	O
thrombectomy	O
of	O
vein	O
graft	O
and	O
tibial	O
vessles	O
,	O
patch	O
angioplasty	O
of	O
proximal	O
vein	O
graft	O
[	O
**	O
2142-7-28	O
**	O
]	O
:	O
LLE	O
angio	O
,	O
thrombectomy	O
via	O
graft	O
and	O
BKpop	O
,	O
Left	O
fem	O
-	O
BKpop	O
with	O
RT	O
GSV	O
,	O
fasciotomy	O
x4	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
58	O
year	O
old	O
gentleman	O
who	O
is	O
5	O
years	O
status	O
post	O
left	O
femoral	O
above	O
knee	O
popliteal	O
with	O
PTFE	O
.	O
The	O
day	O
prior	O
to	O
admission	O
he	O
experienced	O
acute	O
onset	O
of	O
left	O
calf	O
and	O
foot	O
pain	O
and	O
coolness	O
consistent	O
with	O
thrombosed	O
fem	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
graft	O
on	O
that	O
side	O
.	O
Evaluated	O
at	O
OSH	O
and	O
transfered	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
/	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
for	O
continued	O
care	O
.	O
Past	O
Medical	O
History	O
:	O
DM	O
2	O
,	O
HTN	O
,	O
COPD	O
,	O
ETOH	O
abuse	O
,	O
heavy	O
smoker	O
L	O
[	O
**	O
Doctor	O
Last	O
Name	O
69803	O
**	O
]	O
PTFE	O
graft	O
Social	O
History	O
:	O
Lives	O
at	O
home	O
with	O
family	O
.	O
Daily	O
ETOH	O
1	O
-	O
2ppd	O
Smoking	O
history	O
Family	O
History	O
:	O
n	O
/	O
c	O
Physical	O
Exam	O
:	O
Admission	O
H&P	O
PE	O
:	O
96.9	O
,	O
103	O
,	O
142/82	O
,	O
20	O
94	O
%	O
RA	O
General	O
:	O
NAD	O
,	O
pleasant	O
,	O
A&O	O
X3	O
cards	O
:	O
RRR	O
Lungs	O
:	O
CTA	O
Abd	O
:	O
soft	O
,	O
ND	O
,	O
+	O
BS	O
B	O
/	O
L	O
palp	O
fem	O
LLE	O
cool	O
below	O
knee	O
.	O
dop	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
-	O
DP	O
/	O
PT	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
palp	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
DP	O
-	O
PT	O
Pertinent	O
Results	O
:	O
[	O
**	O
2142-8-26	O
**	O
]	O
WBC	O
-	O
7.7	O
RBC	O
-	O
3.36	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
28.6	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
29.1	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
483	O
*	O
[	O
**	O
2142-8-28	O
**	O
]	O
PT	O
-	O
38.3	O
*	O
PTT	O
-	O
32.8	O
INR	O
(	O
PT	O
)	O
-	O
4.3	O
*	O
[	O
**	O
2142-8-26	O
**	O
]	O
Glucose	O
-	O
102	O
UreaN	O
-	O
11	O
Creat	O
-	O
0.5	O
Na	O
-	O
135	O
K	O
-	O
3.6	O
Cl	O
-	O
95	O
*	O
HCO3	O
-	O
30	O
AnGap	O
-	O
14	O
[	O
**	O
2142-8-26	O
**	O
]	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
4.3	O
Mg	O
-	O
1.9	O
[	O
**	O
2142-8-14	O
**	O
]	O
5:36	O
pm	O
SWAB	O
LEFT	O
BKA	O
STUMP	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2142-8-18	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2142-8-14	O
**	O
]	O
)	O
:	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
POLYMORPHONUCLEAR	O
LEUKOCYTES	O
.	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
.	O
IN	O
PAIRS	O
.	O
WOUND	O
CULTURE	O
(	O
Final	O
[	O
**	O
2142-8-17	O
**	O
]	O
)	O
:	O
ENTEROCOCCUS	O
SP.	O
.	O
MODERATE	O
GROWTH	O
.	O
ACINETOBACTER	O
BAUMANNII	O
.	O
SPARSE	O
GROWTH	O
.	O
"	O
Note	O
,	O
for	O
Amp	B-Drug
/	I-Drug
sulbactam	I-Drug
,	O
higher	O
-	O
than	O
-	O
standard	O
dosing	O
needs	O
to	O
be	O
used	O
,	O
since	O
therapeutic	O
efficacy	O
relies	O
on	O
intrinsic	O
activity	O
of	O
the	O
sulbactam	I-Drug
component	O
"	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
ENTEROCOCCUS	O
SP.	O
.	O
|	O
ACINETOBACTER	O
BAUMANNII	O
|	O
|	O
AMPICILLIN	O
------------	O
<	O
=	O
2	O
S	O
AMPICILLIN	O
/	O
SULBACTAM	O
--	O
=	O
>	O
32	O
R	O
CEFEPIME	O
--------------	O
32	O
R	O
CEFTAZIDIME	O
-----------	O
=	O
>	O
64	O
R	O
CIPROFLOXACIN	O
---------	O
=	O
>	O
4	O
R	O
GENTAMICIN	O
------------	O
2	O
S	O
IMIPENEM	O
--------------	O
8	O
I	O
LEVOFLOXACIN	O
----------	O
4	O
I	O
LINEZOLID	O
-------------	O
2	O
S	O
PENICILLIN	O
------------	O
8	O
S	O
TOBRAMYCIN	O
------------	O
<	O
=	O
1	O
S	O
TRIMETHOPRIM	O
/	O
SULFA	O
----	O
<	O
=	O
1	O
S	O
VANCOMYCIN	O
------------	O
=	O
>	O
32	O
R	O
ANAEROBIC	O
CULTURE	O
(	O
Final	O
[	O
**	O
2142-8-18	O
**	O
]	O
)	O
:	O
NO	O
ANAEROBES	O
ISOLATED	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
2142-7-28	O
**	O
]	O
Transferred	O
from	O
OSH	O
with	O
cold	O
,	O
ischemic	O
left	O
leg	O
and	O
taken	O
urgently	O
to	O
OR	O
.	O
UnderwentLeft	O
lower	O
extremity	O
angiography	O
,	O
mechanical	O
thrombectomy	O
of	O
left	O
femoral	O
popliteal	O
PTFE	O
graft	O
.	O
Thrombectomy	O
of	O
below	O
knee	O
popliteal	O
anterior	O
tibialis	O
and	O
peroneal	O
arteries	O
and	O
posterior	O
tibialis	O
arteries	O
,	O
right	O
greater	O
saphenous	O
vein	O
harvest	O
,	O
left	O
femoral	O
to	O
below	O
knee	O
popliteal	O
bypass	O
graft	O
with	O
right	O
greater	O
saphenous	O
vein	O
,	O
angioscopy	O
and	O
valve	O
lysis	O
and	O
fasciotomy	O
x4	O
.	O
Surgery	O
without	O
complications	O
and	O
was	O
extubated	O
in	O
OR	O
.	O
In	O
[	O
**	O
Name	O
(	O
NI	O
)	O
13042	O
**	O
]	O
,	O
pt	O
with	O
symptoms	O
of	O
DTs	I-Reason
.	O
CIWA	O
initiated	O
and	O
he	O
received	O
Haldol	I-Drug
and	O
Ativan	I-Drug
with	O
effect	O
.	O
Transferred	O
to	O
VICU	O
.	O
Heparin	I-Drug
gtt	O
and	O
ABX	I-Drug
continued	O
.	O
Patient	O
continued	O
to	O
have	O
tremors	O
/	O
DTs	O
.	O
[	O
**	O
2142-7-30	O
**	O
]	O
:	O
Postop	O
he	O
was	O
found	O
to	O
have	O
a	O
cooler	O
foot	O
and	O
loss	O
of	O
Doppler	O
signal	O
.	O
The	O
patient	O
had	O
already	O
been	O
systemically	O
heparinized	I-Drug
so	O
was	O
taken	O
urgently	O
back	O
to	O
the	O
operating	O
room	O
and	O
underwent	O
thrombectomy	O
and	O
revision	O
of	O
left	O
common	O
femoral	O
to	O
below	O
-	O
knee	O
popliteal	O
artery	O
bypass	O
graft	O
with	O
vein	O
patch	O
angioplasty	O
.	O
At	O
the	O
time	O
of	O
re-exploration	O
,	O
he	O
was	O
suspected	O
of	O
having	O
HIT	I-Reason
and	O
was	O
started	O
on	O
argatroban	I-Drug
.	O
HIT	O
specimen	O
positive	O
.	O
Due	O
to	O
witnessed	O
DT	O
's	O
preop	O
,	O
postop	O
he	O
remained	O
intubated	O
for	O
airway	O
protection	O
.	O
While	O
intubated	O
,	O
received	O
tube	O
feeds	O
.	O
Transfused	O
1uPRBCs	O
[	O
**	O
8	O
-	O
2	O
**	O
]	O
to	O
OR	O
for	O
L	O
guillotine	O
BKA	O
.	O
Continue	O
Vanco	I-Drug
/	O
Levo	I-Drug
/	O
Flagyl	I-Drug
ABX	I-Drug
.	O
NS	O
w	O
-	O
D	O
dressings	O
to	O
BKA	O
open	O
stump	O
.	O
Transfused	O
2uPRBCs	O
.	O
Remained	O
intubated	O
for	O
airway	O
protection	O
due	O
to	O
ETOH	O
withdrawal	O
until	O
[	O
**	O
2142-8-7	O
**	O
]	O
.	O
[	O
**	O
2142-8-7	O
**	O
]	O
Extubated	O
[	O
**	O
2142-8-8	O
**	O
]	O
Speech	O
and	O
swallow	O
evaluation	O
for	O
oral	O
and	O
pharyngeal	O
dysphagia	O
following	O
extubation	O
.	O
[	O
**	O
2142-8-10	O
**	O
]	O
Transferred	O
from	O
SICU	O
to	O
VICU	O
.	O
[	O
**	O
2142-8-14	O
**	O
]	O
Due	O
to	O
extensive	O
necrosis	O
of	O
the	O
patient	O
's	O
left	O
BKA	O
stump	O
,	O
taken	O
to	O
OR	O
for	O
debridement	O
.	O
Surgery	O
without	O
complication	O
.	O
Extubated	O
and	O
transferred	O
to	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
13042	O
**	O
]	O
.	O
Pain	I-Reason
controlled	O
with	O
Morphine	I-Drug
,	O
fentanyl	I-Drug
patch	O
.	O
Transfused	O
,	O
Electrolytes	O
repleted	O
.	O
[	O
**	O
2142-8-20	O
**	O
]	O
Underwent	O
Left	O
above	O
-	O
the	O
-	O
knee	O
amputation	O
for	O
infected	O
open	O
BKA	O
.	O
Surgery	O
without	O
complication	O
.	O
Extubated	O
and	O
transferred	O
to	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
13042	O
**	O
]	O
.	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
69804	O
**	O
]	O
Surgical	O
dressing	O
changed	O
.	O
VSS	O
.	O
Tolerating	O
po	O
and	O
urinating	O
qs	O
.	O
Antibiotics	I-Drug
changed	O
to	O
Linezolid	I-Drug
,	O
Vanco	I-Drug
d'ced	O
(	O
VRE	O
)	O
.	O
B	O
/	O
L	O
palpable	O
femoral	O
pulses	O
.	O
Amputation	O
site	O
healing	O
.	O
Coumadin	I-Drug
started	O
.	O
Continued	O
Argatroban	I-Drug
gtt	O
.	O
Daily	O
coags	I-Drug
.	O
Physical	O
therapy	O
initiated	O
.	O
Rehab	O
screened	O
.	O
Stable	O
for	O
transfer	O
to	O
acute	O
rehab	O
when	O
bed	O
available	O
and	O
INR	O
therapeutic	O
.	O
[	O
**	O
2142-8-27	O
**	O
]	O
Argatroban	I-Drug
discontinued	O
[	O
**	O
2142-8-28	O
**	O
]	O
INR	O
4.3	O
.	O
LT	O
AKA	O
stump	O
c	O
/	O
d	O
/	O
i.	O
VSS	O
.	O
Afebrile	O
.	O
Antibiotics	I-Drug
discontinued	O
.	O
B	O
/	O
L	O
fem	O
palpable	O
.	O
RT	O
PT	O
dopplerable	O
.	O
Continue	O
other	O
current	O
medications	O
including	O
Coumadin	I-Drug
5	O
mg	O
daily	O
(	O
adjust	O
to	O
keep	B-Reason
INR	I-Reason
2.0	I-Reason
-	I-Reason
3.0	I-Reason
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Simvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
.	O
4	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
17	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Puff	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
5	O
.	O
Acetaminophen	I-Drug
160	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
6	O
.	O
Famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
7	O
.	O
Quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Fentanyl	I-Drug
50	O
mcg	O
/	O
hr	O
Patch	O
72	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
HR	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
.	O
10	O
.	O
Gabapentin	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
q8hr	O
(	O
)	O
.	O
11	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Furosemide	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
13	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
:	O
Adjust	O
to	O
maintain	B-Reason
INR	I-Reason
of	I-Reason
2.0	I-Reason
-	I-Reason
3.0	I-Reason
.	O
14	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
15	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
16	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
17	O
.	O
Insulin	I-Drug
Breakfast	O
and	O
Bedtime	O
-	O
NPH	I-Drug
10	O
Units	O
Fingerstick	O
before	O
meals	O
and	O
bed	O
-	O
cover	O
with	O
regulsr	O
sliding	O
scale	O
Insulin	I-Drug
SC	O
Sliding	O
Scale	O
Breakfast	O
Lunch	O
Dinner	O
Bedtime	O
Q0H	O
Glucose	I-Drug
Insulin	I-Drug
Dose	O
Insulin	I-Drug
Dose	O
Insulin	I-Drug
Dose	O
Insulin	I-Drug
Dose	O
Insulin	I-Drug
Dose	O
0	O
-	O
60	O
mg	O
/	O
dL	O
[	O
**	O
1	O
-	O
15	O
**	O
]	O
amp	O
D50	O
61	O
-	O
120	O
mg	O
/	O
dL	O
0	O
Units	O
121	O
-	O
140	O
mg	O
/	O
dL	O
3	O
Units	O
141	O
-	O
160	O
mg	O
/	O
dL	O
6	O
Units	O
161	O
-	O
180	O
mg	O
/	O
dL	O
9	O
Units	O
181	O
-	O
200	O
mg	O
/	O
dL	O
12	O
Units	O
201	O
-	O
220	O
mg	O
/	O
dL	O
15	O
Units	O
221	O
-	O
240	O
mg	O
/	O
dL	O
18	O
Units	O
241	O
-	O
260	O
mg	O
/	O
dL	O
21	O
Units	O
261	O
-	O
280	O
mg	O
/	O
dL	O
24	O
Units	O
281	O
-	O
300	O
mg	O
/	O
dL	O
27	O
Units	O
301	O
-	O
320	O
mg	O
/	O
dL	O
30	O
Units	O
Notify	O
M.D.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7665	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Peripheral	O
arterial	O
disease	O
DM	O
2	O
,	O
HTN	O
,	O
COPD	O
,	O
ETOH	O
,	O
heavy	O
smoker	O
history	O
of	O
L	O
[	O
**	O
Doctor	O
Last	O
Name	O
69803	O
**	O
]	O
PTFE	O
graft	O
Discharge	O
Condition	O
:	O
Good	O
VSS	O
.	O
INR	O
4.3	O
.	O
Discharge	O
Instructions	O
:	O
DISCHARGE	O
INSTRUCTIONS	O
FOLLOWING	O
BELOW	O
OR	O
ABOVE	O
KNEE	O
AMPUTATION	O
This	O
information	O
is	O
designed	O
as	O
a	O
guideline	O
to	O
assist	O
you	O
in	O
a	O
speedy	O
recovery	O
from	O
your	O
surgery	O
.	O
Please	O
follow	O
these	O
guidelines	O
unless	O
your	O
physician	O
has	O
specifically	O
instructed	O
you	O
otherwise	O
.	O
Please	O
call	O
our	O
office	O
nurse	O
if	O
you	O
have	O
any	O
questions	O
.	O
Dial	O
911	O
if	O
you	O
have	O
any	O
medical	O
emergency	O
.	O
ACTIVITY	O
:	O
There	O
are	O
restrictions	O
on	O
activity	O
.	O
On	O
the	O
side	O
of	O
your	O
amputation	O
you	O
are	O
non	O
weight	O
bearing	O
until	O
cleared	O
by	O
your	O
Surgeon	O
.	O
You	O
should	O
keep	O
this	O
amputation	O
site	O
elevated	O
when	O
ever	O
possible	O
.	O
You	O
may	O
use	O
the	O
other	O
leg	O
to	O
assist	O
in	O
transferring	O
and	O
pivots	O
.	O
But	O
try	O
not	O
to	O
exert	O
to	O
much	O
pressure	O
on	O
the	O
amputation	O
site	O
when	O
transferring	O
and	O
or	O
pivoting	O
.	O
Please	O
keep	O
knee	O
immobilizer	O
on	O
at	O
all	O
times	O
to	O
help	O
keep	O
the	O
amputation	O
site	O
straight	O
.	O
No	O
driving	O
until	O
cleared	O
by	O
your	O
Surgeon	O
.	O
PLEASE	O
CALL	O
US	O
IMMEDIATELY	O
FOR	O
ANY	O
OF	O
THE	O
FOLLOWING	O
PROBLEMS	O
:	O
Redness	O
in	O
or	O
drainage	O
from	O
your	O
leg	O
wound	O
(	O
s	O
)	O
.	O
Watch	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
.	O
These	O
are	O
:	O
a	O
fever	O
greater	O
than	O
101	O
degrees	O
,	O
chills	O
,	O
increased	O
redness	O
,	O
or	O
pus	O
draining	O
from	O
the	O
incision	O
site	O
.	O
If	O
you	O
experience	O
any	O
of	O
these	O
or	O
bleeding	O
at	O
the	O
incision	O
site	O
,	O
CALL	O
THE	O
DOCTOR	O
.	O
Exercise	O
:	O
Limit	O
strenuous	O
activity	O
for	O
6	O
weeks	O
.	O
Do	O
not	O
drive	O
a	O
car	O
unless	O
cleared	O
by	O
your	O
Surgeon	O
.	O
Try	O
to	O
keep	O
leg	O
elevated	O
when	O
able	O
.	O
BATHING	O
/	O
SHOWERING	O
:	O
You	O
may	O
shower	O
immediately	O
upon	O
coming	O
home	O
.	O
No	O
bathing	O
.	O
A	O
dressing	O
may	O
cover	O
you	O
??????	O
re	O
amputation	O
site	O
and	O
this	O
should	O
be	O
left	O
in	O
place	O
for	O
three	O
(	O
3	O
)	O
days	O
.	O
Remove	O
it	O
after	O
this	O
time	O
and	O
wash	O
your	O
incision	O
(	O
s	O
)	O
gently	O
with	O
soap	O
and	O
water	O
.	O
You	O
will	O
have	O
sutures	O
,	O
which	O
are	O
usually	O
removed	O
in	O
4	O
weeks	O
.	O
This	O
will	O
be	O
done	O
by	O
the	O
Surgeon	O
on	O
your	O
follow	O
-	O
up	O
appointment	O
.	O
WOUND	O
CARE	O
:	O
Sutures	O
/	O
Staples	O
may	O
be	O
removed	O
before	O
discharge	O
.	O
If	O
they	O
are	O
not	O
,	O
an	O
appointment	O
will	O
be	O
made	O
for	O
you	O
to	O
return	O
for	O
staple	O
removal	O
.	O
When	O
the	O
sutures	O
are	O
removed	O
the	O
doctor	O
may	O
or	O
may	O
not	O
place	O
pieces	O
of	O
tape	O
called	O
steri	O
-	O
strips	O
over	O
the	O
incision	O
.	O
These	O
will	O
stay	O
on	O
about	O
a	O
week	O
and	O
you	O
may	O
shower	O
with	O
them	O
on	O
.	O
If	O
these	O
do	O
not	O
fall	O
off	O
after	O
10	O
days	O
,	O
you	O
may	O
peel	O
them	O
off	O
with	O
warm	O
water	O
and	O
soap	O
in	O
the	O
shower	O
.	O
Avoid	O
taking	O
a	O
tub	O
bath	O
,	O
swimming	O
,	O
or	O
soaking	O
in	O
a	O
hot	O
tub	O
for	O
four	O
weeks	O
after	O
surgery	O
.	O
MEDICATIONS	O
:	O
Unless	O
told	O
otherwise	O
you	O
should	O
resume	O
taking	O
all	O
of	O
the	O
medications	O
you	O
were	O
taking	O
before	O
surgery	O
.	O
You	O
will	O
be	O
given	O
a	O
new	O
prescription	O
for	O
pain	B-Drug
medication	I-Drug
,	O
which	O
can	O
be	O
taken	O
every	O
three	O
(	O
3	O
)	O
to	O
four	O
(	O
4	O
)	O
hours	O
only	O
if	O
necessary	O
.	O
Remember	O
that	O
narcotic	B-Drug
pain	I-Drug
meds	I-Drug
can	O
be	O
constipating	I-Ade
and	O
you	O
should	O
increase	O
the	O
fluid	O
and	O
bulk	O
foods	O
in	O
your	O
diet	O
.	O
(	O
Check	O
with	O
your	O
physician	O
if	O
you	O
have	O
fluid	O
restrictions	O
.	O
)	O
If	O
you	O
feel	O
that	O
you	O
are	O
constipated	I-Reason
,	O
do	O
not	O
strain	O
at	O
the	O
toilet	O
.	O
You	O
may	O
use	O
over	O
the	O
counter	O
Metamucil	I-Drug
or	O
Milk	B-Drug
of	I-Drug
Magnesia	I-Drug
.	O
Appetite	O
suppression	O
may	O
occur	O
;	O
this	O
will	O
improve	O
with	O
time	O
.	O
Eat	O
small	O
balanced	O
meals	O
throughout	O
the	O
day	O
.	O
CAUTIONS	O
:	O
NO	O
SMOKING	O
!	O
We	O
know	O
you	O
've	O
heard	O
this	O
before	O
,	O
but	O
it	O
really	O
is	O
an	O
important	O
step	O
to	O
your	O
recovery	O
.	O
Smoking	O
causes	O
narrowing	O
of	O
your	O
blood	O
vessels	O
which	O
in	O
turn	O
decreases	O
circulation	O
.	O
If	O
you	O
smoke	O
you	O
will	O
need	O
to	O
stop	O
as	O
soon	O
as	O
possible	O
.	O
Ask	O
your	O
nurse	O
or	O
doctor	O
for	O
information	O
on	O
smoking	O
cessation	O
.	O
Avoid	O
pressure	O
to	O
your	O
amputation	O
site	O
.	O
No	O
strenuous	O
activity	O
for	O
6	O
weeks	O
after	O
surgery	O
.	O
DIET	O
:	O
There	O
are	O
no	O
special	O
restrictions	O
on	O
your	O
diet	O
postoperatively	O
.	O
Poor	O
appetite	O
is	O
expected	O
for	O
several	O
weeks	O
and	O
small	O
,	O
frequent	O
meals	O
may	O
be	O
preferred	O
.	O
For	O
people	O
with	O
vascular	O
problems	O
we	O
would	O
recommend	O
a	O
cholesterol	O
lowering	O
diet	O
:	O
Follow	O
a	O
diet	O
low	O
in	O
total	O
fat	O
and	O
low	O
in	O
saturated	O
fat	O
and	O
in	O
cholesterol	O
to	O
improve	O
lipid	O
profile	O
in	O
your	O
blood	O
.	O
Additionally	O
,	O
some	O
people	O
see	O
a	O
reduction	O
in	O
serum	O
cholesterol	O
by	O
reducing	O
dietary	O
cholesterol	O
.	O
Since	O
a	O
reduction	O
in	O
dietary	O
cholesterol	O
is	O
not	O
harmful	O
,	O
we	O
suggest	O
that	O
most	O
people	O
reduce	O
dietary	O
fat	O
,	O
saturated	O
fat	O
and	O
cholesterol	O
to	O
decrease	O
total	O
cholesterol	O
and	O
LDL	O
(	O
Low	O
Density	O
Lipoprotein	O
-	O
the	O
bad	O
cholesterol	O
)	O
.	O
Exercise	O
will	O
increase	O
your	O
HDL	O
(	O
High	O
Density	O
Lipoprotein	O
-	O
the	O
good	O
cholesterol	O
)	O
and	O
with	O
your	O
doctor	O
's	O
permission	O
,	O
is	O
typically	O
recommended	O
.	O
You	O
may	O
be	O
self	O
-	O
referred	O
or	O
get	O
a	O
referral	O
from	O
your	O
doctor	O
.	O
If	O
you	O
are	O
overweight	O
,	O
you	O
need	O
to	O
think	O
about	O
starting	O
a	O
weight	O
management	O
program	O
.	O
Your	O
health	O
and	O
its	O
improvement	O
depend	O
on	O
it	O
.	O
We	O
know	O
that	O
making	O
changes	O
in	O
your	O
lifestyle	O
will	O
not	O
be	O
easy	O
,	O
and	O
it	O
will	O
require	O
a	O
whole	O
new	O
set	O
of	O
habits	O
and	O
a	O
new	O
attitude	O
.	O
If	O
interested	O
you	O
can	O
may	O
be	O
self	O
-	O
referred	O
or	O
can	O
get	O
a	O
referral	O
from	O
your	O
doctor	O
.	O
If	O
you	O
have	O
diabetes	O
and	O
would	O
like	O
additional	O
guidance	O
,	O
you	O
may	O
request	O
a	O
referral	O
from	O
your	O
doctor	O
.	O
FOLLOW	O
-	O
UP	O
APPOINTMENT	O
:	O
Be	O
sure	O
to	O
keep	O
your	O
medical	O
appointments	O
.	O
The	O
key	O
to	O
your	O
improving	O
health	O
will	O
be	O
to	O
keep	O
a	O
tight	O
reign	O
on	O
any	O
of	O
the	O
chronic	O
medical	O
conditions	O
that	O
you	O
have	O
.	O
Things	O
like	O
high	O
blood	O
pressure	O
,	O
diabetes	O
,	O
and	O
high	O
cholesterol	O
are	O
major	O
villains	O
to	O
the	O
blood	O
vessels	O
.	O
Do	O
n't	O
Please	O
call	O
the	O
office	O
on	O
the	O
first	O
working	O
day	O
after	O
your	O
discharge	O
from	O
the	O
hospital	O
to	O
schedule	O
a	O
follow	O
-	O
up	O
visit	O
.	O
This	O
should	O
be	O
scheduled	O
on	O
the	O
calendar	O
for	O
seven	O
to	O
fourteen	O
days	O
after	O
discharge	O
.	O
Normal	O
office	O
hours	O
are	O
8:30	O
-	O
5	O
Monday	O
through	O
Friday	O
.	O
.	O
PLEASE	O
FEEL	O
FREE	O
TO	O
CALL	O
THE	O
OFFICE	O
WITH	O
ANY	O
OTHER	O
CONCERNS	O
OR	O
QUESTIONS	O
THAT	O
MIGHT	O
ARISE	O
Followup	O
Instructions	O
:	O
Call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
office	O
for	O
follow	O
up	O
in	O
3	O
weeks	O
.	O
His	O
office	O
is	O
located	O
at	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
439	O
**	O
]	O
5B	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
718	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2142-8-28	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2127-2-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2127-2-12	O
**	O
]	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1556	O
**	O
]	O
Chief	O
Complaint	O
:	O
MVA	O
,	O
car	O
vs	O
tree	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
88	O
year	O
old	O
man	O
in	O
high	O
speed	O
motor	O
vehicle	O
collision	O
with	O
tree	O
,	O
unrestrained	O
.	O
+	O
bilat	O
airbag	O
deployment	O
,	O
large	O
front	O
end	O
damage	O
to	O
vehicle	O
.	O
+	O
LOC	O
with	O
Right	O
chest	O
and	O
sternal	O
pain	O
,	O
worse	O
with	O
movement	O
/	O
inspiration	O
Past	O
Medical	O
History	O
:	O
HTN	O
,	O
DM	O
,	O
?	O
afib	O
ex	O
lap	O
after	O
gsw	O
in	O
WWII	O
Social	O
History	O
:	O
Lives	O
alone	O
,	O
wife	O
and	O
sons	O
live	O
nearby	O
etoh	O
:	O
1	O
drink	O
per	O
day	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
-	O
99.7	O
HR	O
-	O
80	O
BP	O
-	O
120/60	O
RR	O
-	O
20	O
O2sat	O
:	O
100	O
%	O
on	O
4L	O
nc	O
HEENT	O
:	O
1	O
cm	O
bleeding	O
lac	O
to	O
left	O
temporal	O
scalp	O
Perrl	O
chest	O
:	O
decreased	O
breath	O
sounds	O
bilat	O
,	O
chest	O
and	O
sternum	O
tender	O
to	O
palpation	O
heart	O
:	O
irregularly	O
irregular	O
ABD	O
:	O
soft	O
,	O
non-tender	O
Rectal	O
:	O
normal	O
tone	O
,	O
no	O
gross	O
blood	O
,	O
trace	O
heme	O
+	O
ext	O
:	O
no	O
sign	O
of	O
trauma	O
Neuro	O
:	O
alert	O
,	O
agitated	O
sensation	O
grossly	O
intact	O
DTRs	O
normal	O
moving	O
all	O
extremities	O
Pertinent	O
Results	O
:	O
[	O
**	O
2127-2-6	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
WBC	O
-	O
5.3	O
RBC	O
-	O
3.01	O
*	O
Hgb	O
-	O
9.6	O
*	O
Hct	O
-	O
28.9	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
31.8	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
16.1	O
*	O
Plt	O
Ct	O
-	O
189	O
[	O
**	O
2127-2-6	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
PT	O
-	O
12.9	O
PTT	O
-	O
27.7	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2127-2-6	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
Fibrino	O
-	O
433	O
*	O
[	O
**	O
2127-2-6	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
UreaN	O
-	O
40	O
*	O
Creat	O
-	O
1.5	O
*	O
[	O
**	O
2127-2-6	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
96	O
Amylase	O
-	O
35	O
[	O
**	O
2127-2-7	O
**	O
]	O
03:30	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
18	O
*	O
MB	O
Indx	O
-	O
3.2	O
cTropnT	O
-	O
0.03	O
*	O
[	O
**	O
2127-2-7	O
**	O
]	O
03:30	O
AM	O
BLOOD	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
3.5	O
Mg	O
-	O
2.2	O
[	O
**	O
2127-2-6	O
**	O
]	O
09:39	O
PM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
CT	O
C	O
-	O
spine	O
:	O
C7	O
pedicle	O
fx	O
extending	O
from	O
spinolaminar	O
junction	O
into	O
spinous	O
process	O
as	O
well	O
and	O
right	O
inferior	O
and	O
left	O
superior	O
articular	O
facet	O
.	O
C6	O
/	O
C7	O
widening	O
,	O
C4	O
/	O
5	O
arthrolithesis	O
(	O
?	O
ligamentous	O
injury	O
)	O
.	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
CT	O
-	O
Chest	O
:	O
Transverse	O
manubrial	O
frx	O
.	O
RML	O
and	O
RLL	O
contusion	O
.	O
R	O
rib	O
frx	O
[	O
**	O
1	O
-	O
14	O
**	O
]	O
.	O
L	O
rib	O
frx	O
3,5,6	O
.	O
Scattered	O
opacities	O
?	O
aspiration	O
vs.	O
infection	O
vs.	O
contusions	O
.	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
CT	O
-	O
head	O
:	O
Soft	O
tissue	O
contusion	O
anterior	O
to	O
left	O
frontal	O
bone	O
with	O
single	O
focus	O
of	O
subcutaneous	O
emphysema	O
.	O
No	O
fx	O
.	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
CT	O
abdomen	O
:	O
?	O
jejunal	O
thickening	O
.	O
No	O
other	O
solid	O
organ	O
injury	O
[	O
**	O
2	O
-	O
10	O
**	O
]	O
chest	O
x-ray	O
:	O
Area	O
of	O
increased	O
density	O
is	O
seen	O
on	O
the	O
lateral	O
view	O
which	O
may	O
represent	O
lower	O
lobe	O
pneumonia	O
possibly	O
on	O
the	O
right	O
side	O
.	O
Overall	O
improvement	O
from	O
prior	O
x-ray	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
HD	O
#	O
1	O
Admitted	O
to	O
the	O
Trauma	O
service	O
.	O
His	O
scalp	O
laceration	O
was	O
sutured	O
.	O
He	O
underwent	O
CT	O
imaging	O
which	O
showed	O
bilateral	O
rib	O
fractures	O
,	O
sternal	O
fracture	O
,	O
pulmonary	O
contusion	O
and	O
C7	O
pedicle	O
fracture	O
with	O
possible	O
ligamentous	O
injury	O
at	O
C3	O
-	O
C4	O
.	O
Seen	O
and	O
evaluated	O
by	O
Neurosurgery	O
who	O
recommended	O
non	O
operative	O
intervention	O
with	O
use	O
of	O
a	O
c	O
-	O
collar	O
with	O
thoracic	O
extension	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
36323	O
**	O
]	O
brace	O
)	O
.	O
[	O
**	O
2	O
-	O
7	O
**	O
]	O
HD	O
#	O
2	O
Seen	O
by	O
the	O
acute	O
pain	O
service	O
because	O
of	O
his	O
rib	O
fractures	O
.	O
An	O
epidural	O
catheter	O
was	O
placed	O
(	O
Dilaudid	I-Drug
)	O
for	O
pain	I-Reason
control	O
.	O
His	O
diet	O
was	O
slowly	O
advanced	O
.	O
[	O
**	O
2	O
-	O
8	O
**	O
]	O
HD	O
#	O
3	O
He	O
was	O
transferred	O
to	O
the	O
floor	O
.	O
Tolerating	O
his	O
diabetic	O
diet	O
.	O
Pain	O
controlled	O
,	O
pulmonary	O
hygiene	O
continues	O
.	O
He	O
was	O
transfused	O
1	O
unit	O
of	O
PRBCs	I-Drug
for	O
low	O
Hct	O
;	O
post	O
transfusion	O
Hct	O
28.1	O
.	O
Seen	O
and	O
evaluated	O
by	O
PT	O
&	O
OT	O
,	O
they	O
have	O
recommended	O
short	O
term	O
rehab	O
to	O
improve	O
overall	O
functioning	O
.	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
HD	O
#	O
4	O
In	O
the	O
evening	O
,	O
when	O
the	O
RN	O
was	O
cleaning	O
under	O
the	O
brace	O
,	O
the	O
patient	O
refused	O
to	O
have	O
the	O
brace	O
replaced	O
.	O
He	O
became	O
increasingly	O
agitated	O
and	O
a	O
psych	O
emergency	O
was	O
called	O
.	O
Episode	O
was	O
felt	O
to	O
be	O
related	O
to	O
delirium	I-Ade
per	O
Psychiatry	O
who	O
was	O
consulted	O
,	O
caused	O
by	O
sedatives	I-Drug
that	O
patient	O
had	O
previously	O
received	O
during	O
the	O
acute	O
hospital	O
phase	O
.	O
He	O
subsequently	O
was	O
placed	O
on	O
sitters	O
;	O
sedatives	O
were	O
stopped	O
.	O
His	O
behavior	O
improved	O
significantly	O
and	O
the	O
sitters	O
were	O
able	O
to	O
be	O
discontinued	O
.	O
[	O
**	O
2	O
-	O
10	O
**	O
]	O
HD	O
#	O
5	O
His	O
brace	O
was	O
adjusted	O
by	O
the	O
Orthotics	O
company	O
for	O
a	O
more	O
comfortable	O
fit	O
.	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
Diabetes	O
Center	O
was	O
also	O
consulted	O
due	O
to	O
elevated	O
blood	O
sugars	O
;	O
glargine	I-Drug
added	O
and	O
his	O
sliding	O
scale	O
was	O
adjusted	O
.	O
Epidural	O
catheter	O
discontinued	O
and	O
he	O
was	O
transitioned	O
to	O
oral	O
pain	B-Drug
medications	I-Drug
.	O
Ho	O
pain	O
overall	O
was	O
in	O
much	O
better	O
control	O
at	O
this	O
time	O
.	O
[	O
**	O
2	O
-	O
11	O
**	O
]	O
HD	O
#	O
6	O
Pt	O
continu	O
ed	O
to	O
improve	O
,	O
pt	O
made	O
aware	O
of	O
importance	O
of	O
keeping	O
brace	O
on	O
,	O
and	O
patient	O
agreed	O
,	O
via	O
russian	O
translator	O
,	O
to	O
do	O
so	O
.	O
Sitter	O
d	O
/	O
c	O
'd	O
in	O
preparation	O
for	O
rehab	O
.	O
[	O
**	O
2	O
-	O
12	O
**	O
]	O
HD	O
#	O
7	O
Pt	O
cleared	O
for	O
discharge	O
to	O
rehab	O
with	O
brace	O
.	O
Follow	O
up	O
instructions	O
discussed	O
with	O
patient	O
.	O
Need	O
to	O
keep	O
brace	O
on	O
discussed	O
with	O
patient	O
.	O
Patient	O
agrees	O
to	O
plan	O
anf	O
follow	O
up	O
.	O
Medications	O
on	O
Admission	O
:	O
Detrol	I-Drug
4	O
,	O
Flomax	I-Drug
0.4	O
,	O
Flonase	I-Drug
50	O
,	O
iron	I-Drug
18	O
'	O
''	O
,	O
lisinopril	I-Drug
20	O
,	O
nifedipine	I-Drug
60	O
,	O
omeprazole	I-Drug
20	O
,	O
Paxil	I-Drug
20	O
mg	O
,	O
MVI	I-Drug
,	O
doxepin	I-Drug
cream	O
5	O
%	O
,	O
ASA	I-Drug
81	O
,	O
trazodone	I-Drug
50	O
,	O
Zyrtec	I-Drug
10	O
,	O
salsalate	I-Drug
750	O
'	O
''	O
Discharge	O
Medications	O
:	O
1	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Tolterodine	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Nifedipine	I-Drug
60	O
mg	O
Tablet	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
Sustained	O
Release	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
HR	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Ferrous	B-Drug
Sulfate	I-Drug
325	O
(	O
65	O
)	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Fluticasone	I-Drug
50	O
mcg	O
/	O
Actuation	O
Aerosol	O
,	O
Spray	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Spray	O
Nasal	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
1	O
bottle	O
*	O
Refills	O
:	O
*	O
2	O
*	O
9	O
.	O
Salsalate	I-Drug
750	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Bisacodyl	I-Drug
10	O
mg	O
Suppository	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
.	O
11	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
12	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
13	O
.	O
Oxycodone	B-Drug
-	I-Drug
Acetaminophen	I-Drug
5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
25	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
14	O
.	O
Timolol	B-Drug
Maleate	I-Drug
0.5	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
Brimonidine	I-Drug
0.15	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
16	O
.	O
Protonix	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
17	O
.	O
Dextromethorphan	B-Drug
-	I-Drug
Guaifenesin	I-Drug
10	O
-	O
100	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
cough	I-Reason
.	O
18	O
.	O
Cepacol	I-Drug
2	O
mg	O
Lozenge	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Lozenge	O
Mucous	O
membrane	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
sore	B-Reason
throat	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Lozenge	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
19	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
1643	O
**	O
]	O
Center	O
Discharge	O
Diagnosis	O
:	O
s	O
/	O
p	O
Motor	O
vehicle	O
crash	O
C7	O
-	O
pedicle	O
fracture	O
Pulmonary	O
contusion	O
Bilateral	O
multiple	O
rib	O
fractures	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
You	O
must	O
continue	O
to	O
wear	O
your	O
brace	O
as	O
instructed	O
by	O
Neurosurgery	O
.	O
Followup	O
Instructions	O
:	O
Follow	O
up	O
with	O
your	O
Primary	O
Physician	O
for	O
the	O
incidental	O
finding	O
of	O
a	O
nodule	O
in	O
your	O
chest	O
.	O
You	O
will	O
need	O
to	O
call	O
for	O
an	O
appointment	O
.	O
Follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
739	O
**	O
]	O
,	O
Neurosurgery	O
,	O
in	O
1	O
week	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
77038	O
**	O
]	O
for	O
an	O
appointment	O
.	O
Inform	O
the	O
office	O
that	O
you	O
will	O
need	O
a	O
repeat	O
CT	O
scan	O
of	O
your	O
spine	O
for	O
this	O
appointment	O
.	O
Additional	O
appointments	O
that	O
were	O
scehduled	O
prior	O
to	O
your	O
hospitalization	O
include	O
the	O
following	O
:	O
Provider	O
:	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
5376	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
463	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2127-3-10	O
**	O
]	O
1:30	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
11136	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
.	O
D.	O
Date	O
/	O
Time	O
:[	O
**	O
2127-3-18	O
**	O
]	O
10:30	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
11771	O
**	O
]	O
,	O
M.D.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
26488	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2127-3-18	O
**	O
]	O
2:30	O

Admission	O
Date	O
:	O
[	O
**	O
2107-9-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2107-9-30	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2027-2-6	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
99	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
On	O
pressor	I-Drug
support	O
Central	O
line	O
placement	O
PICC	O
line	O
placement	O
Post-pyloric	O
feeding	O
tube	O
placement	O
Transfusion	O
of	O
packed	B-Drug
RBC	I-Drug
History	O
of	O
Present	O
Illness	O
:	O
80	O
yo	O
male	O
with	O
hx	O
of	O
schizophrenia	O
,	O
dementia	O
was	O
admitted	O
to	O
MICU	O
from	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
after	O
being	O
found	O
to	O
be	O
septic	O
.	O
Patient	O
was	O
being	O
transported	O
to	O
[	O
**	O
Hospital1	O
336	O
**	O
]	O
/	O
[	O
**	O
Hospital1	O
**	O
]	O
for	O
evaluation	O
of	O
vomiting	O
x	O
few	O
days	O
(	O
2	O
or	O
4	O
days	O
,	O
depending	O
on	O
whose	O
report	O
you	O
read	O
)	O
.	O
He	O
was	O
only	O
responsive	O
to	O
verbal	O
stimuli	O
per	O
EMS	O
notes	O
.	O
and	O
per	O
evaluation	O
from	O
the	O
ambulance	O
,	O
his	O
BP	O
was	O
70/30	O
,	O
RR	O
30s	O
and	O
HR	O
60s	O
.	O
Of	O
note	O
,	O
patient	O
has	O
been	O
having	O
poor	O
appetite	O
x	O
4	O
days	O
.	O
KUB	O
was	O
apparently	O
negative	O
for	O
obstruction	O
.	O
.	O
From	O
his	O
RN	O
home	O
,	O
he	O
was	O
noted	O
to	O
have	O
:	O
-	O
Cr	O
of	O
2.9	O
BUN	O
of	O
65	O
on	O
[	O
**	O
2107-9-24	O
**	O
]	O
and	O
digoxin	I-Drug
level	O
of	O
1.5	O
-	O
INR	O
of	O
1.07	O
on	O
[	O
**	O
2107-9-24	O
**	O
]	O
and	O
Pt	O
of	O
11.6	O
.	O
In	O
the	O
ED	O
:	O
He	O
was	O
alert	O
and	O
following	O
commands	O
.	O
Initially	O
BP	O
responded	O
to	O
fluids	O
and	O
was	O
in	O
the	O
110s	O
,	O
then	O
dropped	O
to	O
67/59	O
-	O
started	O
on	O
dopamine	I-Drug
.	O
He	O
was	O
also	O
initially	O
bradycardic	O
to	O
the	O
40s	O
-	O
50s	O
(	O
but	O
then	O
110s	O
for	O
unclear	O
reasons	O
)	O
.	O
Dopamine	I-Drug
was	O
titrated	O
to	O
10mcg	O
/	O
kg	O
/	O
min	O
and	O
then	O
was	O
placed	O
on	O
levophed	I-Drug
at	O
0.5	O
mcg	O
/	O
kg	O
/	O
min	O
and	O
then	O
titrated	O
up	O
to	O
3mcg	O
/	O
kg	O
/	O
min	O
.	O
On	O
arrival	O
to	O
the	O
floor	O
,	O
he	O
was	O
on	O
only	O
Levophed	I-Drug
at	O
3mcg	O
/	O
kg	O
/	O
min	O
.	O
-	O
increased	O
pulmonary	O
congestion	O
and	O
BiPAP	O
was	O
applied	O
.	O
-	O
received	O
7L	O
NS	I-Drug
in	O
ED	O
-	O
got	O
Levo	I-Drug
/	O
Flagyl	I-Drug
/	O
Vanco	I-Drug
.	O
Access	O
:	O
A	O
L	O
groin	O
was	O
attempted	O
.	O
Then	O
a	O
R	O
IJ	O
was	O
attempted	O
-	O
which	O
led	O
to	O
guidewire	O
getting	O
stuck	O
in	O
the	O
IVC	O
filter	O
.	O
This	O
was	O
removed	O
by	O
Vascular	O
Surgery	O
.	O
Finally	O
,	O
a	O
R	O
femoral	O
line	O
was	O
placed	O
.	O
Past	O
Medical	O
History	O
:	O
CAD	O
CHF	O
PVD	O
Dementia	O
Schizophrenia	O
CRI	O
Cardiac	O
Dysrhythmias	O
Social	O
History	O
:	O
Lives	O
at	O
long	O
-	O
term	O
care	O
facility	O
.	O
Sister	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
976	O
**	O
]	O
,	O
is	O
his	O
[	O
**	O
Name	O
(	O
NI	O
)	O
5993	O
**	O
]	O
.	O
Family	O
History	O
:	O
Non-contributory	O
Physical	O
Exam	O
:	O
T	O
:	O
99.4	O
BP	O
:	O
109/62	O
P	O
:	O
112	O
RR	O
:	O
28	O
O2	O
sats	O
:	O
95	O
%	O
BiPAP	O
Gen	O
:	O
Elderly	O
man	O
with	O
nonsensical	O
speech	O
HEENT	O
:	O
CV	O
:	O
+	O
s1	O
+	O
s2	O
Quiet	O
heart	O
sounds	O
.	O
No	O
murmurs	O
appreciated	O
.	O
Resp	O
:	O
Mild	O
crackles	O
and	O
decreased	O
sounds	O
at	O
lung	O
bases	O
.	O
Abd	O
:	O
Soft	O
NT	O
ND	O
Skin	O
:	O
Warm	O
.	O
Perfused	O
.	O
Ext	O
:	O
RLE	O
with	O
cellulitis	O
from	O
area	O
below	O
knee	O
to	O
above	O
the	O
ankle	O
with	O
area	O
of	O
increased	O
erythema	O
around	O
R	O
medial	O
malleolus	O
.	O
-	O
+	O
DP	O
and	O
PT	O
pulses	O
B	O
/	O
L	O
-	O
need	O
doppler	O
to	O
identify	O
.	O
Neuro	O
:	O
Patient	O
moving	O
extremities	O
x	O
4	O
.	O
EKG	O
:	O
Tachycardia	O
w	O
/	O
RBBB	O
Pertinent	O
Results	O
:	O
Labs	O
on	O
admission	O
:	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
WBC	O
-	O
17.0	O
*	O
RBC	O
-	O
3.77	O
*	O
Hgb	O
-	O
11.8	O
*	O
Hct	O
-	O
35.4	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
31.3	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
15.9	O
*	O
Plt	O
Ct	O
-	O
180	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
Neuts	O
-	O
76	O
*	O
Bands	O
-	O
4	O
Lymphs	O
-	O
6	O
*	O
Monos	O
-	O
5	O
Eos	O
-	O
6	O
*	O
Baso	O
-	O
3	O
*	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
PT	O
-	O
16.8	O
*	O
PTT	O
-	O
27.4	O
INR	O
(	O
PT	O
)	O
-	O
1.6	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
02:05	O
AM	O
BLOOD	O
Fibrino	O
-	O
477	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
02:05	O
AM	O
BLOOD	O
D	O
-	O
Dimer	O
-	O
2929	O
*	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
Glucose	O
-	O
117	O
*	O
UreaN	O
-	O
81	O
*	O
Creat	O
-	O
5.6	O
*	O
Na	O
-	O
151	O
*	O
K	O
-	O
4.3	O
Cl	O
-	O
108	O
HCO3	O
-	O
25	O
AnGap	O
-	O
22	O
*	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
124	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.67	O
*	O
[	O
**	O
2107-9-25	O
**	O
]	O
08:59	O
PM	O
BLOOD	O
Calcium	O
-	O
9.1	O
Phos	O
-	O
4.0	O
Mg	O
-	O
3.6	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
03:47	O
AM	O
BLOOD	O
Cortsol	O
-	O
27.4	O
*	O
[	O
**	O
2107-9-25	O
**	O
]	O
11:25	O
PM	O
BLOOD	O
Digoxin	O
-	O
1.3	O
[	O
**	O
2107-9-25	O
**	O
]	O
11:40	O
PM	O
BLOOD	O
Type	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
pO2	O
-	O
140	O
*	O
pCO2	O
-	O
45	O
pH	O
-	O
7.28	O
*	O
calTCO2	O
-	O
22	O
Base	O
XS	O
--	O
5	O
[	O
**	O
2107-9-25	O
**	O
]	O
09:00	O
PM	O
BLOOD	O
Lactate	O
-	O
4.3	O
*	O
.	O
Pertinent	O
labs	O
during	O
hospital	O
course	O
:	O
[	O
**	O
2107-9-26	O
**	O
]	O
08:14	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
372	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
04:00	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
357	O
*	O
[	O
**	O
2107-9-27	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
242	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
08:14	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
14	O
*	O
MB	O
Indx	O
-	O
3.8	O
cTropnT	O
-	O
1.22	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
04:00	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
11	O
*	O
MB	O
Indx	O
-	O
3.1	O
cTropnT	O
-	O
0.90	O
*	O
[	O
**	O
2107-9-27	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
6	O
cTropnT	O
-	O
0.57	O
*	O
[	O
**	O
2107-9-28	O
**	O
]	O
08:40	O
AM	O
BLOOD	O
calTIBC	O
-	O
156	O
*	O
VitB12	O
-	O
1080	O
*	O
Folate	O
-	O
13.8	O
Ferritn	O
-	O
543	O
*	O
TRF	O
-	O
120	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
01:15	O
PM	O
BLOOD	O
Triglyc	O
-	O
125	O
HDL	O
-	O
28	O
CHOL	O
/	O
HD	O
-	O
3.9	O
LDLcalc	O
-	O
55	O
[	O
**	O
2107-9-25	O
**	O
]	O
11:40	O
PM	O
BLOOD	O
Glucose	O
-	O
113	O
*	O
Lactate	O
-	O
2.9	O
*	O
Na	O
-	O
149	O
*	O
K	O
-	O
4.0	O
Cl	O
-	O
118	O
*	O
[	O
**	O
2107-9-26	O
**	O
]	O
08:24	O
AM	O
BLOOD	O
Lactate	O
-	O
1.3	O
.	O
Labs	O
on	O
discharge	O
:	O
[	O
**	O
2107-9-30	O
**	O
]	O
02:57	O
AM	O
BLOOD	O
WBC	O
-	O
8.5	O
RBC	O
-	O
3.54	O
*	O
Hgb	O
-	O
10.6	O
*	O
Hct	O
-	O
32.3	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
32.9	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
203	O
[	O
**	O
2107-9-30	O
**	O
]	O
02:57	O
AM	O
BLOOD	O
Neuts	O
-	O
71.6	O
*	O
Lymphs	O
-	O
16.1	O
*	O
Monos	O
-	O
3.7	O
Eos	O
-	O
8.0	O
*	O
Baso	O
-	O
0.6	O
[	O
**	O
2107-9-30	O
**	O
]	O
02:57	O
AM	O
BLOOD	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
29.8	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2107-9-30	O
**	O
]	O
02:57	O
AM	O
BLOOD	O
Glucose	O
-	O
125	O
*	O
UreaN	O
-	O
14	O
Creat	O
-	O
1.1	O
Na	O
-	O
138	O
K	O
-	O
3.7	O
Cl	O
-	O
109	O
*	O
HCO3	O
-	O
19	O
*	O
AnGap	O
-	O
14	O
[	O
**	O
2107-9-28	O
**	O
]	O
04:12	O
AM	O
BLOOD	O
ALT	O
-	O
13	O
AST	O
-	O
27	O
AlkPhos	O
-	O
82	O
TotBili	O
-	O
0.4	O
[	O
**	O
2107-9-30	O
**	O
]	O
02:57	O
AM	O
BLOOD	O
Calcium	O
-	O
8.3	O
*	O
Phos	O
-	O
2.1	O
*	O
Mg	O
-	O
1.7	O
.	O
Microbiology	O
:	O
[	O
**	O
2107-9-25	O
**	O
]	O
Blood	O
cx	O
:	O
2/2	O
bottles	O
coag	O
neg	O
staph	O
[	O
**	O
2107-9-25	O
**	O
]	O
Urine	O
cx	O
:	O
mixed	O
flora	O
,	O
contaminant	O
[	O
**	O
2107-9-26	O
**	O
]	O
Blood	O
cx	O
:	O
NGTD	O
[	O
**	O
2107-9-26	O
**	O
]	O
Urine	O
legionella	O
:	O
negative	O
[	O
**	O
2107-9-27	O
**	O
]	O
Blood	O
cx	O
:	O
NGTD	O
[	O
**	O
2107-9-27	O
**	O
]	O
Sputum	O
cx	O
:	O
oropharyngeal	O
flora	O
[	O
**	O
2107-9-27	O
**	O
]	O
Catheter	O
tip	O
cx	O
:	O
Multimicrobial	O
bacteria	O
[	O
**	O
2107-9-28	O
**	O
]	O
Blood	O
cx	O
:	O
NGTD	O
[	O
**	O
2107-9-28	O
**	O
]	O
Urine	O
cx	O
:	O
Negative	O
[	O
**	O
2107-9-29	O
**	O
]	O
Urine	O
cx	O
:	O
Negative	O
.	O
Imaging	O
:	O
[	O
**	O
2107-9-25	O
**	O
]	O
CXR	O
:	O
CHEST	O
,	O
SINGLE	O
VIEW	O
:	O
No	O
prior	O
for	O
comparison	O
.	O
Lung	O
volumes	O
are	O
low	O
.	O
The	O
cardiac	O
shadow	O
is	O
slightly	O
enlarged	O
.	O
Aorta	O
is	O
ectatic	O
.	O
Considerable	O
right	O
lung	O
volume	O
loss	O
with	O
collapse	O
of	O
right	O
lower	O
lobe	O
and	O
partial	O
atelectasis	O
right	O
middle	O
lobe	O
with	O
questionable	O
cut	O
-	O
off	O
of	O
bronchus	O
intermedius	O
.	O
Although	O
possibly	O
due	O
to	O
secretions	O
,	O
an	O
obstructing	O
neoplastic	O
mass	O
should	O
be	O
considered	O
.	O
Initial	O
further	O
evaluation	O
with	O
PA	O
and	O
lateral	O
CXR	O
is	O
recommended	O
.	O
If	O
persistent	O
,	O
contrast	O
-	O
enhanced	O
CT	O
would	O
be	O
recommended	O
.	O
.	O
[	O
**	O
2107-9-26	O
**	O
]	O
ECHOCARDIOGRAM	O
:	O
Conclusions	O
:	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
Normal	O
left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
.	O
There	O
is	O
moderate	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
akinesis	O
of	O
the	O
distal	O
half	O
of	O
the	O
inferior	O
,	O
septal	O
,	O
and	O
anterior	O
walls	O
.	O
The	O
remaining	O
segments	O
are	O
mildly	O
hypokinetic	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
moderate	O
to	O
severe	O
aortic	O
valve	O
stenosis	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
13	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Normal	O
left	O
ventricular	O
cavity	O
size	O
with	O
extensive	O
regional	O
dysfunction	O
c	O
/	O
w	O
multivessel	O
coronary	O
disease	O
.	O
Moderate	O
to	O
severe	O
aortic	O
valve	O
stenosis	O
.	O
Mild	O
aortic	O
regurgitation	O
.	O
Pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
Based	O
on	O
[	O
**	O
2097	O
**	O
]	O
AHA	O
endocarditis	O
prophylaxis	O
recommendations	O
,	O
the	O
echo	O
findings	O
indicate	O
a	O
moderate	O
risk	O
(	O
prophylaxis	O
recommended	O
)	O
.	O
Clinical	O
decisions	O
regarding	O
the	O
need	O
for	O
prophylaxis	O
should	O
be	O
based	O
on	O
clinical	O
and	O
echocardiographic	O
data	O
.	O
.	O
[	O
**	O
2107-9-26	O
**	O
]	O
Bilateral	O
lower	O
extremity	O
ultrasound	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Right	O
deep	O
venous	O
thrombosis	O
of	O
indeterminate	O
age	O
(	O
old	O
clot	O
per	O
radiology	O
)	O
2	O
.	O
No	O
evidence	O
of	O
deep	O
venous	O
thrombosis	O
involving	O
the	O
left	O
lowerextremity	O
.	O
.	O
[	O
**	O
2107-9-27	O
**	O
]	O
CXR	O
:	O
CONCLUSION	O
:	O
Short	O
-	O
interval	O
improvement	O
in	O
the	O
aeration	O
of	O
the	O
right	O
lower	O
lung	O
field	O
,	O
with	O
some	O
residual	O
opacities	O
present	O
in	O
the	O
right	O
infrahilar	O
region	O
.	O
.	O
[	O
**	O
2107-9-30	O
**	O
]	O
PICC	O
line	O
placement	O
.	O
.	O
[	O
**	O
2107-9-30	O
**	O
]	O
nasogastric	O
tube	O
placement	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
is	O
an	O
80	O
year	O
old	O
male	O
with	O
history	O
of	O
CAD	O
,	O
CHF	O
,	O
dementia	O
,	O
schizophrenia	O
,	O
chronic	O
renal	O
insufficiency	O
,	O
cardiac	O
dysrythmia	O
who	O
was	O
admitted	O
for	O
sepsis	O
.	O
.	O
1	O
.	O
Septic	O
shock	O
/	O
infectious	O
disease	O
issues	O
:	O
Patient	O
presented	O
from	O
his	O
nursing	O
home	O
with	O
hypotension	O
,	O
leukocytosis	O
,	O
acute	O
on	O
chronic	O
renal	O
failure	O
,	O
indicating	O
sepsis	O
.	O
Initial	O
studies	O
demonstrated	O
CXR	O
with	O
right	O
lower	O
lobe	O
pneumonia	O
,	O
and	O
u	O
/	O
a	O
that	O
was	O
positive	O
.	O
Patient	O
also	O
with	O
some	O
cellulitis	O
in	O
left	O
lower	O
extremity	O
.	O
Therefore	O
,	O
intially	O
thought	O
source	O
of	O
sepsis	O
was	O
pneumonia	O
vs	O
UTI	O
vs	O
cellulitis	O
.	O
Cortisol	O
stimulation	O
test	O
was	O
negative	O
,	O
ruling	O
out	O
adrenal	O
insufficiency	O
on	O
admission	O
.	O
The	O
patient	O
was	O
fluid	O
rescusitated	O
and	O
initially	O
started	O
on	O
levaphed	I-Drug
for	O
pressor	B-Reason
support	I-Reason
.	O
He	O
was	O
maintained	O
on	O
vancomycin	I-Drug
and	O
zosyn	I-Drug
for	O
broad	B-Reason
spectrum	I-Reason
antibiotics	I-Reason
coverage	I-Reason
.	O
Shortly	O
after	O
admission	O
,	O
patient	O
had	O
improved	O
blood	O
pressure	O
and	O
levaphed	I-Drug
pressor	O
was	O
weaned	O
off	O
.	O
Blood	O
cultures	O
from	O
admission	O
grew	O
coag	O
negative	O
staph	O
,	O
2/2	O
bottles	O
,	O
likely	O
source	O
of	O
this	O
infection	O
being	O
his	O
left	O
lower	O
extremity	O
cellulitis	I-Reason
.	O
Therefore	O
he	O
was	O
maintained	O
on	O
vancomycin	I-Drug
to	O
complete	O
a	O
14	O
day	O
course	O
.	O
Wound	O
care	O
nursing	O
was	O
also	O
consulted	O
and	O
dressing	O
changes	O
were	O
applied	O
per	O
their	O
recommendations	O
.	O
For	O
his	O
pneumonia	I-Reason
,	O
sputum	O
culture	O
did	O
not	O
grow	O
any	O
bacteria	O
.	O
Urine	O
legionella	O
antigen	O
was	O
negative	O
.	O
Therefore	O
patient	O
was	O
empirically	O
treated	O
with	O
vancomycin	I-Drug
to	O
complete	O
a	O
14	O
day	O
course	O
,	O
as	O
above	O
,	O
and	O
zosyn	I-Drug
,	O
which	O
was	O
converted	O
to	O
levofloxacin	I-Drug
on	O
discharge	O
,	O
for	O
gram	B-Reason
negative	I-Reason
coverage	I-Reason
to	O
complete	O
a	O
7	O
day	O
course	O
.	O
For	O
his	O
presumed	O
UTI	I-Reason
,	O
the	O
patient	O
had	O
2	O
positive	O
U	O
/	O
A	O
's	O
during	O
the	O
hospital	O
course	O
,	O
with	O
negative	O
urine	O
cultures	O
.	O
The	O
3rd	O
u	O
/	O
a	O
prior	O
to	O
discharge	O
was	O
negative	O
,	O
with	O
a	O
corresponding	O
negative	O
culture	O
.	O
Therefore	O
,	O
upon	O
discharge	O
,	O
patient	O
had	O
a	O
very	O
stable	O
blood	O
pressure	O
,	O
stable	O
oxygenation	O
off	O
of	O
oxygen	O
,	O
and	O
was	O
discharged	O
on	O
vancomycin	I-Drug
to	O
complete	O
a	O
14	O
day	O
course	O
and	O
levofloxacin	I-Drug
to	O
complete	O
a	O
7	O
day	O
course	O
(	O
started	O
with	O
zosyn	I-Drug
)	O
.	O
He	O
had	O
a	O
PICC	O
line	O
placed	O
prior	O
to	O
discharge	O
.	O
.	O
2	O
.	O
Cardiac	O
:	O
A.	O
Ischemia	O
:	O
Patient	O
has	O
a	O
history	O
of	O
coronary	O
artery	O
disease	O
.	O
On	O
presentation	O
,	O
EKG	O
demonstrated	O
right	O
bundle	O
branch	O
block	O
(	O
last	O
EKG	O
in	O
our	O
system	O
is	O
from	O
[	O
**	O
2092	O
**	O
]	O
that	O
demonstrates	O
no	O
RBBB	O
-	O
however	O
,	O
obtained	O
outside	O
hospital	O
records	O
that	O
does	O
show	O
RBBB	O
,	O
so	O
not	O
new	O
)	O
.	O
On	O
admission	O
,	O
cardiac	O
enzymes	O
were	O
elevated	O
.	O
Cardiology	O
was	O
therefore	O
consulted	O
.	O
Patient	O
was	O
thought	O
to	O
be	O
having	O
a	O
demand	O
ischemic	B-Reason
event	I-Reason
,	O
and	O
therefore	O
was	O
started	O
on	O
heparin	I-Drug
drip	O
to	O
complete	O
48	O
hours	O
per	O
cardiology	O
recommendations	O
.	O
His	O
outpatient	O
aspirin	I-Drug
dose	O
was	O
increased	O
from	O
81	O
mg	O
to	O
325	O
mg	O
daily	O
.	O
He	O
initially	O
could	O
not	O
be	O
on	O
beta	B-Drug
blocker	I-Drug
therapy	O
given	O
his	O
hypotensive	O
sepsis	O
.	O
Upon	O
resolution	O
of	O
his	O
hypotension	O
,	O
his	O
outpatient	O
lopressor	I-Drug
was	O
re-started	O
and	O
titrated	O
up	O
to	O
his	O
outpatient	O
dose	O
of	O
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
His	O
CK	O
peaked	O
at	O
372	O
,	O
and	O
cardiac	O
enzymes	O
trended	O
down	O
throughout	O
remainder	O
of	O
hospital	O
course	O
.	O
No	O
plans	O
for	O
cardiac	O
catheterization	O
given	O
the	O
nature	O
of	O
his	O
MI	O
in	O
setting	O
of	O
sepsis	O
,	O
and	O
his	O
co-morbid	O
conditions	O
.	O
B.	O
Rhythm	O
:	O
Patient	O
had	O
a	O
known	O
history	O
of	O
some	O
cardiac	O
dysrhythmia	O
,	O
but	O
unknown	O
type	O
.	O
During	O
hospital	O
course	O
,	O
patient	O
was	O
noted	O
to	O
have	O
strange	O
rhythm	O
on	O
telemetry	O
and	O
EKG	O
.	O
The	O
electrophysiologist	O
cardiologists	O
were	O
curbsided	O
,	O
and	O
believed	O
the	O
patient	O
's	O
rhythm	O
to	O
be	O
due	O
to	O
wenkebach	B-Reason
rhythm	I-Reason
.	O
They	O
recommended	O
no	O
further	O
intervention	O
and	O
believed	O
that	O
the	O
patient	O
's	O
outpatient	O
digoxin	I-Drug
could	O
be	O
discontinued	O
.	O
Otherwise	O
patient	O
was	O
maintained	O
on	O
lipitor	I-Drug
,	O
as	O
above	O
.	O
C.	O
Pump	O
:	O
Patient	O
has	O
a	O
history	O
of	O
CHF	I-Reason
,	O
and	O
was	O
on	O
lisinopril	I-Drug
and	O
lasix	I-Drug
and	O
digoxin	I-Drug
as	O
and	O
outpatient	O
.	O
All	O
of	O
these	O
medications	O
were	O
held	O
on	O
admission	O
due	O
to	O
the	O
patient	O
's	O
renal	O
failure	O
and	O
sepsis	O
.	O
ECHO	O
on	O
admission	O
demonstrated	O
diffuse	O
disease	O
,	O
EF	O
20	O
-	O
25	O
%	O
,	O
mod	O
-	O
severe	O
aortic	O
stenosis	O
,	O
mild	O
aortic	O
regurgitation	O
,	O
mild	O
-	O
mod	O
mitral	O
regurgiation	O
.	O
Upon	O
resolution	O
of	O
the	O
patient	O
's	O
sepsis	O
/	O
hypotension	O
,	O
his	O
lisinopril	I-Drug
was	O
restarted	O
.	O
Digoxin	I-Drug
and	O
lasix	I-Drug
were	O
not	O
restarted	O
.	O
Spironolactone	I-Drug
was	O
initiated	O
given	O
the	O
patient	O
's	O
heart	B-Reason
failure	I-Reason
and	O
low	B-Reason
EF	I-Reason
.	O
He	O
remained	O
euvolemic	O
during	O
remainder	O
of	O
hospital	O
course	O
.	O
.	O
3	O
.	O
Acute	O
on	O
chronic	O
renal	O
failure	O
:	O
Patient	O
with	O
a	O
history	O
of	O
chronic	O
renal	O
insufficiency	O
with	O
baseline	O
creatnine	O
thought	O
to	O
be	O
2.0	O
.	O
On	O
day	O
of	O
admission	O
,	O
Cr	O
was	O
elevated	O
at	O
2.9	O
and	O
quickly	O
rose	O
to	O
peak	O
of	O
5.6	O
.	O
Patient	O
was	O
fluid	O
rescusitated	O
and	O
Cr	O
dropped	O
throughout	O
admission	O
and	O
was	O
down	O
to	O
1.1	O
at	O
time	O
of	O
discharge	O
.	O
During	O
hospital	O
course	O
,	O
the	O
patient	O
's	O
lisinopril	I-Drug
,	O
lasix	I-Drug
,	O
and	O
digoxin	I-Drug
were	O
held	O
due	O
to	O
the	O
patient	O
's	O
renal	O
failure	O
.	O
Only	O
his	O
lisinopril	I-Drug
was	O
restarted	O
,	O
as	O
above	O
.	O
His	O
antibiotics	I-Drug
were	O
renally	O
dosed	O
and	O
adjusted	O
throughout	O
hospital	O
course	O
.	O
.	O
4	O
.	O
Anemia	I-Reason
:	O
Patient	O
had	O
a	O
hematocrit	O
of	O
low	O
30's	O
on	O
admission	O
,	O
trended	O
down	O
to	O
low	O
of	O
26	O
during	O
hospital	O
course	O
.	O
Iron	O
studies	O
were	O
consistent	O
with	O
anemia	O
of	O
chronic	O
disease	O
.	O
Patient	O
was	O
transfused	O
1	O
unit	O
of	O
pRBC	I-Drug
for	O
Hct	B-Reason
of	I-Reason
26	I-Reason
,	O
given	O
his	O
history	O
of	O
CAD	O
,	O
and	O
Hct	O
bumped	O
appropriately	O
to	O
29	O
,	O
and	O
remained	O
stable	O
during	O
remainder	O
of	O
.	O
?	O
baseline	O
.	O
Hct	O
increased	O
to	O
29	O
w	O
/	O
1	O
unit	O
pRBC	I-Drug
.	O
Plan	O
to	O
:	O
-	O
will	O
f	O
/	O
u	O
iron	O
studies	O
-	O
guaiac	O
all	O
stools	O
-	O
tfs	O
to	O
keep	O
hct	O
>	O
28	O
-	O
moniter	O
.	O
5	O
.	O
Facial	B-Ade
eccymoses	I-Ade
and	O
erythema	I-Ade
:	O
Patient	O
had	O
noted	O
left	O
sided	O
peri-orbital	O
facial	O
erythema	O
and	O
eccymoses	O
on	O
exam	O
on	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
.	O
Radiology	O
and	O
opthalmology	O
were	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
as	O
this	O
was	O
thought	O
possibley	O
secondary	O
to	O
peri-orbital	O
cellulitis	O
.	O
MRI	O
scan	O
was	O
initially	O
considered	O
for	O
futher	O
evaluation	O
.	O
However	O
,	O
opthalmology	O
evaluated	O
the	O
patient	O
and	O
thought	O
it	O
was	O
unlikely	O
to	O
be	O
peri-orbital	B-Ade
cellulitis	I-Ade
,	O
and	O
therefore	O
no	O
imaging	O
was	O
necessary	O
.	O
This	O
exam	O
finding	O
was	O
thought	O
likely	O
secondary	O
to	O
the	O
heparin	I-Drug
drip	O
that	O
the	O
patient	O
was	O
on	O
for	O
his	O
cardiac	O
issues	O
,	O
and	O
continued	O
to	O
improve	O
throughout	O
remainder	O
of	O
hospital	O
course	O
once	O
heparin	I-Drug
was	O
discontinued	O
.	O
.	O
6	O
.	O
Guidewire	O
caught	O
on	O
IVC	O
filter	O
:	O
Patient	O
had	O
a	O
right	O
IJ	O
guidewire	O
get	O
caught	O
in	O
his	O
IVC	O
filter	O
during	O
his	O
ED	O
course	O
.	O
This	O
was	O
removed	O
by	O
vascular	O
surgery	O
.	O
Patient	O
was	O
given	O
1U	O
PRBC	I-Drug
in	O
ED	O
for	O
fear	B-Reason
of	I-Reason
bleed	I-Reason
.	O
Hematocrit	O
remained	O
stable	O
.	O
Nothing	O
further	O
was	O
done	O
.	O
.	O
7	O
.	O
Mental	O
status	O
:	O
Patient	O
was	O
somnolent	O
on	O
admission	O
,	O
likely	O
secondary	O
to	O
his	O
infectious	O
status	O
.	O
He	O
returned	O
quickly	O
to	O
his	O
baseline	O
mental	O
status	O
that	O
included	O
being	O
awake	O
,	O
alert	O
,	O
pleasant	O
,	O
responsive	O
,	O
oriented	O
only	O
x	O
1	O
to	O
person	O
.	O
He	O
was	O
written	O
for	O
zyprexa	I-Drug
5	O
mg	O
PRN	O
for	O
agitation	I-Reason
,	O
but	O
did	O
not	O
receive	O
any	O
during	O
hospital	O
course	O
.	O
.	O
8	O
.	O
Peripheral	O
vascular	O
disease	O
:	O
Patient	O
had	O
dopplerable	O
pulses	O
on	O
this	O
admission	O
.	O
.	O
9	O
.	O
Coagulopathy	I-Reason
:	O
Patient	O
on	O
coumadin	I-Drug
as	O
outpatient	O
for	O
dysrhythmias	I-Reason
and	O
lower	B-Reason
extremity	I-Reason
DVT	I-Reason
.	O
Coumadin	I-Drug
was	O
initially	O
held	O
given	O
the	O
patient	O
's	O
poor	O
clinical	O
condition	O
.	O
It	O
was	O
restarted	O
during	O
hospital	O
course	O
,	O
and	O
he	O
was	O
discharged	O
on	O
his	O
outpatient	O
dose	O
of	O
1	O
mg	O
qhs	O
,	O
with	O
a	O
subtherapeutic	O
INR	O
.	O
It	O
should	O
be	O
addressed	O
with	O
his	O
outpatient	O
primary	O
care	O
physician	O
whether	O
or	O
not	O
to	O
continue	O
his	O
coumadin	I-Drug
,	O
given	O
his	O
fall	O
risk	O
and	O
his	O
risk	O
vs	O
benefit	O
ratio	O
.	O
.	O
10	O
.	O
Hypernatremia	I-Reason
:	O
Patient	O
was	O
quite	O
hypernatremic	O
during	O
hospital	O
course	O
,	O
with	O
sodium	O
of	O
151	O
on	O
admission	O
.	O
This	O
was	O
thought	O
likely	O
a	O
hypovolemic	O
hypernatremia	O
.	O
His	O
hypernatremia	O
improved	O
slightly	O
with	O
initial	O
fluid	I-Drug
rescusitation	O
.	O
The	O
patient	O
then	O
proceded	O
to	O
get	O
free	O
water	O
boluses	O
per	O
his	O
NG	O
tube	O
,	O
which	O
continued	O
to	O
control	O
his	O
hypernatremia	O
.	O
.	O
11	O
.	O
Nutrition	O
:	O
Patient	O
underwent	O
speech	O
and	O
swallow	O
evaluation	O
early	O
in	O
hospital	O
course	O
which	O
he	O
failed	O
.	O
Therefore	O
he	O
had	O
an	O
NG	O
tube	O
placed	O
and	O
received	O
tube	O
feeds	O
and	O
medications	O
per	O
his	O
NG	O
tube	O
.	O
Upon	O
improved	O
alertness	O
,	O
patient	O
underwent	O
a	O
repeat	O
bedside	O
speech	O
and	O
swallow	O
evaluation	O
,	O
which	O
he	O
also	O
failed	O
.	O
Following	O
this	O
,	O
patient	O
lost	O
his	O
NG	O
tube	O
.	O
He	O
therefore	O
had	O
an	O
IR	O
placed	O
post-pyloric	O
feeding	O
tube	O
to	O
continue	O
his	O
tube	O
feeds	O
and	O
medications	O
.	O
He	O
was	O
discharged	O
with	O
this	O
tube	O
in	O
place	O
with	O
plans	O
for	O
a	O
repeat	O
speech	O
and	O
swallow	O
upon	O
improvement	O
at	O
rehab	O
.	O
If	O
he	O
fails	O
this	O
,	O
the	O
issue	O
of	O
PEG	O
tube	O
placement	O
should	O
be	O
brought	O
up	O
with	O
his	O
[	O
**	O
Name	O
(	O
NI	O
)	O
5993	O
**	O
]	O
,	O
his	O
sister	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
976	O
**	O
]	O
.	O
.	O
12	O
.	O
Prophylaxis	O
:	O
Patient	O
was	O
initially	O
maintained	O
on	O
heparin	I-Drug
drip	O
for	O
his	O
non	B-Reason
ST	I-Reason
elevation	I-Reason
MI	I-Reason
for	O
DVT	B-Reason
prophylaxis	I-Reason
,	O
which	O
was	O
changed	O
to	O
subcutaneous	O
heparin	I-Drug
after	O
48	O
hours	O
.	O
He	O
was	O
also	O
re-started	O
on	O
his	O
coumadin	I-Drug
as	O
above	O
.	O
He	O
was	O
also	O
maintained	O
on	O
a	O
PPI	I-Drug
.	O
.	O
13	O
.	O
Access	O
:	O
PICC	O
line	O
was	O
placed	O
prior	O
to	O
discharge	O
.	O
.	O
14	O
.	O
Code	O
:	O
DNR	O
/	O
DNI	O
-	O
per	O
nursing	O
home	O
records	O
and	O
confirmed	O
by	O
[	O
**	O
Name	O
(	O
NI	O
)	O
5993	O
**	O
]	O
,	O
his	O
sister	O
.	O
.	O
15	O
.	O
Contacts	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
976	O
**	O
]	O
(	O
sister	O
and	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
5993	O
**	O
]	O
)	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
94072	O
**	O
]	O
,	O
Nursing	O
home	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
3504	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
69555	O
**	O
]	O
,	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
68737	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
Meds	O
:	O
-	O
coumadin	I-Drug
:	O
1	O
mg	O
PO	O
QD	O
-	O
lopressor	I-Drug
:	O
50	O
mg	O
PO	O
BID	O
-	O
zyprexa	I-Drug
:	O
5	O
mg	O
QHS	O
-	O
vicodin	I-Drug
:	O
5/500	O
:	O
1	O
tab	O
PO	O
QD	O
1	O
hour	O
prior	O
to	O
dressing	O
change	O
-	O
lanoxin	B-Drug
-	I-Drug
digoxin	I-Drug
:	O
1	O
tab	O
PO	O
QD	O
-	O
omeprazole	I-Drug
:	O
1	O
tab	O
PO	O
BID	O
-	O
MVI	I-Drug
-	O
Lasix	I-Drug
:	O
40	O
mg	O
QD	O
-	O
Lisinopril	I-Drug
:	O
5	O
mg	O
PO	O
QD	O
-	O
ASA	I-Drug
:	O
81	O
mg	O
QD	O
-	O
Vitamin	B-Drug
C	I-Drug
-	O
MOM	I-Drug
:	O
PRN	O
-	O
Dulcolax	I-Drug
:	O
PRN	O
-	O
Fleet	B-Drug
Enema	I-Drug
:	O
PRN	O
-	O
Maalox	I-Drug
:	O
PRN	O
-	O
Tylenol	I-Drug
:	O
PRN	O
-	O
Robitussin	I-Drug
:	O
PRN	O
-	O
duonebs	I-Drug
PRN	O
-	O
cepacol	I-Drug
lozenges	O
Discharge	O
Medications	O
:	O
1	O
.	O
Olanzapine	I-Drug
5	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
as	O
needed	O
.	O
2	O
.	O
Ascorbic	B-Drug
Acid	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Magnesium	B-Drug
Hydroxide	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
4	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
5	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Erythromycin	I-Drug
5	O
mg	O
/	O
g	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
aplication	O
Ophthalmic	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
for	O
4	O
days	O
.	O
7	O
.	O
Artificial	B-Drug
Tear	I-Drug
with	I-Drug
Lanolin	I-Drug
0.1	O
-	O
0.1	O
%	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
8	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Please	O
adjust	O
dose	O
to	O
achieve	O
INR	O
of	O
2	O
.	O
9	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
Please	O
hold	O
for	O
SBP	O
<	O
100	O
,	O
HR	O
<	O
60	O
.	O
10	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Please	O
hold	O
for	O
SBP	O
<	O
100	O
.	O
11	O
.	O
Atorvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Thiamine	B-Drug
HCl	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
Lansoprazole	I-Drug
30	O
mg	O
Susp	O
,	O
Delayed	O
Release	O
for	O
Recon	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
mg	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Per	O
nasogastric	O
tube	O
.	O
15	O
.	O
Spironolactone	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
16	O
.	O
Levofloxacin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
2	O
days	O
.	O
17	O
.	O
Vancomycin	B-Drug
in	I-Drug
Dextrose	I-Drug
1	O
g	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
gram	O
Intravenous	O
Q	O
24H	O
(	O
Every	O
24	O
Hours	O
)	O
for	O
9	O
days	O
.	O
18	O
.	O
PICC	O
line	O
care	O
PICC	O
line	O
care	O
per	O
protocol	O
19	O
.	O
PICC	O
line	O
care	O
Please	O
flush	O
PICC	O
line	O
per	O
protocol	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
105	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Sepsis	O
Urinary	O
tract	O
infection	O
Pneumonia	O
Coag	O
negative	O
staph	O
bacteremia	O
Wenkebach	O
cardiac	O
dysrrhythmia	O
Non	O
ST	O
elevation	O
myocardial	O
infarction	O
acute	O
renal	O
failure	O
Discharge	O
Condition	O
:	O
Stable	O
.	O
Discharge	O
Instructions	O
:	O
Please	O
contact	O
physician	O
if	O
develop	O
worsening	O
cough	O
,	O
chest	O
pain	O
/	O
pressure	O
,	O
shortness	O
of	O
breath	O
,	O
fever	O
,	O
low	O
blood	O
pressure	O
,	O
any	O
other	O
questions	O
/	O
concerns	O
.	O
.	O
Please	O
take	O
medications	O
as	O
directed	O
.	O
.	O
Please	O
follow	O
up	O
with	O
physician	O
as	O
directed	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
primary	O
care	O
physician	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
the	O
next	O
1	O
-	O
2	O
weeks	O
.	O
Can	O
contact	O
him	O
at	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
68737	O
**	O
]	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2170-2-23	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2170-3-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2139-11-26	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
CARDIOTHORACIC	O
Allergies	O
:	O
Erythromycin	I-Drug
Base	O
/	O
Compazine	I-Drug
/	O
Morphine	I-Drug
/	O
Levaquin	I-Drug
/	O
Sulfa	I-Drug
(	O
Sulfonamides	O
)	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2969	O
**	O
]	O
Chief	O
Complaint	O
:	O
Esophageal	O
stricture	O
,	O
gastric	O
atony	O
and	O
duodenal	O
ulcer	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
s	O
/	O
p	O
distal	O
esophagectomy	O
/	O
total	O
gastrectomy	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
esophagojejunostomy	O
/	O
J	O
tube	O
placement	O
[	O
**	O
2	O
-	O
23	O
**	O
]	O
,	O
with	O
takeback	O
for	O
abdom	O
compartment	O
syndrome	O
,	O
oversewing	O
of	O
anastomoses	O
&	O
revision	O
of	O
J	O
tube	O
site	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
s	O
/	O
p	O
washout	O
on	O
[	O
**	O
3	O
-	O
5	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
30	O
F	O
with	O
ALL	I-Reason
s	O
/	O
p	O
BMT	O
/	O
chemo	I-Drug
/	O
XRT	O
,	O
esophagitis	O
,	O
GERD	O
,	O
Barrett	O
's	O
,	O
Esophageal	O
perf	O
with	O
ileal	O
patch	O
,	O
esophageal	O
dysmotility	O
with	O
multiple	O
dilations	O
;	O
Gastric	O
atony	O
,	O
hypergastrinemia	O
;	O
Duodenal	O
ulcer	O
.	O
Recurrent	O
esophogeal	O
stricture	O
requiring	O
dilitation	O
q2	O
-	O
3	O
weeks	O
x4	O
over	O
past	O
3	O
-	O
4	O
months	O
.	O
Limited	O
po	O
intake	O
,	O
High	O
gastrin	O
level	O
presents	O
for	O
total	O
gastrectomy	O
Past	O
Medical	O
History	O
:	O
ALL	O
,	O
status	O
post	O
BMT	O
[	O
**	O
2151	O
**	O
]	O
,	O
esophageal	O
strictures	O
and	O
ulcers	O
,	O
duodenal	O
ulcers	O
,	O
elevated	O
gastrin	O
levels	O
,	O
Ocreotide	I-Drug
scan	O
[	O
**	O
1	O
-	O
11	O
**	O
]	O
negative	O
for	O
gastronoma	O
,	O
MRSA	B-Reason
right	I-Reason
hip	I-Reason
on	O
chronic	O
doxycycline	I-Drug
,	O
hypothyroid	O
,	O
hypercholesterol	O
,	O
COPD	O
,	O
depression	O
,	O
seizure	O
disorder	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
Hx	O
:	O
esophageal	O
dilatation	O
,	O
perf	O
,	O
jejunal	O
patch	O
[	O
**	O
2158	O
**	O
]	O
,	O
CCY	O
,	O
Appy	O
Social	O
History	O
:	O
lives	O
with	O
parents	O
Physical	O
Exam	O
:	O
General	O
-	O
Sedated	O
,	O
intubated	O
,	O
edemetous	O
,	O
very	O
ill	O
appearing	O
female	O
lying	O
flat	O
in	O
ICU	O
bed	O
.	O
Neuro	O
-	O
Pupils	O
reactive	O
R	O
>	O
L	O
,	O
+	O
incteric	O
sclera	O
.	O
Sedated	O
HEENT	O
-	O
Bloody	O
packing	O
present	O
in	O
nares	O
,	O
+	O
oral	O
bleeding	O
,	O
ETT	O
in	O
place	O
.	O
generalized	O
cervical	O
edema	O
.	O
Cor	O
-	O
RRR	O
,	O
tachycardia	O
REsp	O
-	O
course	O
BS	O
bilat	O
,	O
diminished	O
ABD	O
-	O
Surgical	O
open	O
abd	O
,	O
clear	O
adhesive	O
barrier	O
in	O
place	O
,	O
+	O
+	O
distention	O
,	O
+	O
firm	O
,	O
+	O
edema	O
,	O
no	O
BS	O
.	O
Skin	O
-	O
+	O
edema	O
peripherally	O
,	O
+	O
jaundice	O
.	O
Extremities	O
-	O
+	O
edema	O
Pertinent	O
Results	O
:	O
[	O
**	O
2170-2-23	O
**	O
]	O
12:06	O
PM	O
GLUCOSE	O
-	O
154	O
*	O
LACTATE	O
-	O
4.2	O
*	O
NA	O
+	O
-	O
139	O
K	O
+	O
-	O
3.6	O
CL	O
--	O
102	O
[	O
**	O
2170-2-23	O
**	O
]	O
08:57	O
PM	O
LACTATE	O
-	O
5.0	O
*	O
[	O
**	O
2170-2-23	O
**	O
]	O
06:03	O
PM	O
HGB	O
-	O
8.0	O
*	O
calcHCT	O
-	O
24	O
[	O
**	O
2170-2-23	O
**	O
]	O
07:00	O
PM	O
HGB	O
-	O
10.7	O
*	O
calcHCT	O
-	O
32	O
COMPLETE	O
BLOOD	O
COUNT	O
WBC	O
RBC	O
Hgb	O
Hct	O
MCV	O
MCH	O
MCHC	O
RDW	O
Plt	O
Ct	O
[	O
**	O
2170-3-7	O
**	O
]	O
10:50	O
AM	O
27.5	O
*	O
1	O
3.18	O
*	O
9.9	O
*	O
27.5	O
*	O
86.5	O
31.3	O
36.2	O
*	O
18.5	O
*	O
53	O
*	O
2	O
[	O
**	O
2170-3-7	O
**	O
]	O
03:32	O
AM	O
26.0	O
*	O
1	O
3.15	O
*	O
10.2	O
*	O
27.3	O
*	O
87	O
32.2	O
*	O
37.3	O
*	O
18.8	O
*	O
59	O
*	O
2	O
1	O
CORRECTED	O
FOR	O
41	O
NRBC	O
2	O
VERIFIED	O
BY	O
SMEAR	O
[	O
**	O
2170-3-7	O
**	O
]	O
12:04	O
AM	O
38.8	O
*	O
3.33	O
*	O
10.6	O
*	O
28.6	O
*	O
86	O
31.7	O
37.0	O
*	O
17.9	O
*	O
43	O
*	O
DIFFERENTIAL	O
Neuts	O
Bands	O
Lymphs	O
Monos	O
Eos	O
Baso	O
Atyps	O
Metas	O
Myelos	O
Promyel	O
NRBC	O
Plasma	O
[	O
**	O
2170-3-7	O
**	O
]	O
10:50	O
AM	O
55	O
17	O
*	O
20	O
6	O
0	O
0	O
1	O
*	O
0	O
0	O
54	O
*	O
1	O
*	O
WHOLE	O
BLOOD	O
,	O
MISCELLANEOUS	O
CHEMISTRY	O
Glucose	O
Lactate	O
Na	O
K	O
Cl	O
calHCO3	O
[	O
**	O
2170-3-7	O
**	O
]	O
10:58	O
AM	O
4.3	O
*	O
1	O
RENAL	O
&	O
GLUCOSE	O
Glucose	O
UreaN	O
Creat	O
Na	O
K	O
Cl	O
HCO3	O
AnGap	O
[	O
**	O
2170-3-7	O
**	O
]	O
10:50	O
AM	O
121	O
*	O
93	O
*	O
1.2	O
*	O
1	O
133	O
6.6	O
*	O
2	O
99	O
19	O
*	O
22	O
*	O
SLIGHT	O
HEMOLYSIS	O
[	O
**	O
2170-3-7	O
**	O
]	O
03:32	O
AM	O
115	O
*	O
89	O
*	O
1.5	O
*	O
1	O
1362	O
5.8	O
*	O
2	O
1022	O
20	O
*	O
20	O
SPECIMEN	O
LIPEMIC	O
ENZYMES	O
&	O
BILIRUBIN	O
ALT	O
AST	O
LD	O
(	O
LDH	O
)	O
CK	O
(	O
CPK	O
)	O
AlkPhos	O
Amylase	O
TotBili	O
DirBili	O
IndBili	O
[	O
**	O
2170-3-7	O
**	O
]	O
10:50	O
AM	O
79	O
*	O
233	O
*	O
138	O
*	O
26.5	O
*	O
1	O
18.1	O
*	O
2	O
8.4	O
[	O
**	O
2170-3-7	O
**	O
]	O
03:32	O
AM	O
75	O
*	O
214	O
*	O
127	O
*	O
23.9	O
*	O
1	O
17.6	O
*	O
2	O
6.3	O
SPECIMEN	O
LIPEMIC	O
OTHER	O
ENZYMES	O
&	O
BILIRUBINS	O
Lipase	O
[	O
**	O
2170-3-2	O
**	O
]	O
04:07	O
AM	O
99	O
*	O
CPK	O
ISOENZYMES	O
CK	O
-	O
MB	O
cTropnT	O
[	O
**	O
2170-2-25	O
**	O
]	O
02:02	O
AM	O
4	O
0.12	O
*	O
1	O
1	O
CTROPNT	O
>	O
0.10	O
NG	O
/	O
ML	O
SUGGESTS	O
ACUTE	O
MI	O
CHEMISTRY	O
TotProt	O
Albumin	O
Globuln	O
Calcium	O
Phos	O
Mg	O
UricAcd	O
Iron	O
[	O
**	O
2170-3-7	O
**	O
]	O
10:50	O
AM	O
2.9	O
*	O
9.3	O
4.7	O
*	O
2.4	O
SLIGHT	O
HEMOLYSIS	O
[	O
**	O
2170-3-7	O
**	O
]	O
03:32	O
AM	O
3.3	O
*	O
9.5	O
4.6	O
*	O
2.4	O
SPECIMEN	O
LIPEMIC	O
HEMATOLOGIC	O
Hapto	O
[	O
**	O
2170-2-28	O
**	O
]	O
07:44	O
AM	O
160	O
LIPID	O
/	O
CHOLESTEROL	O
Triglyc	O
[	O
**	O
2170-2-24	O
**	O
]	O
10:15	O
AM	O
911	O
1	O
LDL	O
(	O
CALC	O
)	O
INVALID	O
IF	O
TRIG	O
>	O
400	O
OR	O
NON-FASTING	O
SAMPLE	O
OTHER	O
CHEMISTRY	O
Ammonia	O
[	O
**	O
2170-3-2	O
**	O
]	O
11:11	O
AM	O
44	O
HEPATITIS	O
HBsAg	O
HBsAb	O
HBcAb	O
HAV	O
Ab	O
[	O
**	O
2170-2-24	O
**	O
]	O
04:07	O
AM	O
NEGATIVE	O
POSITIVE	O
NEGATIVE	O
POSITIVE	O
GASTROINTESTINAL	O
Gastrin	O
[	O
**	O
2170-2-24	O
**	O
]	O
08:53	O
PM	O
[	O
**	O
2164	O
**	O
]	O
*	O
1	O
1	O
VERIFIED	O
BY	O
DILUTION	O
HEPATITIS	O
C	O
SEROLOGY	O
HCV	O
Ab	O
[	O
**	O
2170-2-24	O
**	O
]	O
04:07	O
AM	O
NEGATIVE	O
RADIOLOGY	O
Final	O
Report	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
[	O
**	O
2170-3-7	O
**	O
]	O
2:28	O
AM	O
Reason	O
:	O
please	O
eval	O
for	O
infiltrate	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
30F	O
with	O
esophageal	O
stricture	O
s	O
/	O
p	O
esophagogastrectomy	O
,	O
worsening	O
saturation	O
and	O
ventilation	O
INDICATION	O
:	O
Esophageal	O
stricture	O
status	O
post	O
esophagogastrectomy	O
.	O
COMPARISON	O
:	O
Radiograph	O
dated	O
[	O
**	O
2170-3-5	O
**	O
]	O
.	O
AP	O
SUPINE	O
VIEW	O
OF	O
THE	O
CHEST	O
:	O
The	O
lines	O
and	O
tubes	O
are	O
unchanged	O
.	O
There	O
are	O
low	O
lung	O
volumes	O
.	O
Pleural	O
-	O
based	O
right	O
apical	O
opacity	O
is	O
unchanged	O
.	O
There	O
is	O
persistent	O
left	O
lower	O
lobe	O
atelectasis	O
.	O
IMPRESSION	O
:	O
No	O
significant	O
interval	O
change	O
compared	O
to	O
the	O
study	O
of	O
2	O
days	O
prior	O
with	O
persistent	O
left	O
lower	O
lobe	O
atelectasis	O
and	O
right	O
apical	O
pleural	O
-	O
based	O
density	O
.	O
RADIOLOGY	O
Final	O
Report	O
ABDOMEN	O
U.S.	O
(	O
COMPLETE	O
STUDY	O
)	O
[	O
**	O
2170-2-28	O
**	O
]	O
8:16	O
AM	O
Reason	O
:	O
PT	O
WITH	O
[	O
**	O
Name	O
(	O
NI	O
)	O
39043	O
**	O
]	O
,	O
?	O
BILIARY	O
OBSTRUCTION	O
&	O
SIGNS	O
OF	O
SHOCK	O
LIVER	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
30F	O
s	O
/	O
p	O
ex	O
lap	O
x	O
2	O
,	O
with	O
gross	O
cirrhosis	O
,	O
who	O
is	O
now	O
developing	O
hyperbili	O
.	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
eval	O
for	O
biliary	O
obstruction	O
&	O
signs	O
of	O
shock	O
liver	O
.	O
ABDOMINAL	O
ULTRASOUND	O
:	O
INDICATION	O
:	O
Cirrhosis	O
,	O
hyperbilirubinemia	O
.	O
FINDINGS	O
:	O
A	O
bedside	O
portable	O
examination	O
was	O
performed	O
.	O
The	O
study	O
is	O
markedly	O
limited	O
due	O
to	O
body	O
habitus	O
.	O
Portal	O
vein	O
is	O
patent	O
,	O
but	O
demonstrates	O
reversal	O
of	O
flow	O
,	O
new	O
since	O
[	O
**	O
2168-10-11	O
**	O
]	O
,	O
probably	O
related	O
to	O
underlying	O
cirrhosi	O
.	O
No	O
gross	O
intrahepatic	O
biliary	O
ductal	O
dilatation	O
.	O
Spleen	O
is	O
slightly	O
enlarged	O
,	O
measuring	O
12.1	O
cm	O
in	O
length	O
.	O
Limited	O
examination	O
of	O
the	O
kidneys	O
shows	O
no	O
frank	O
evidence	O
of	O
hydronephrosis	O
.	O
IMPRESSION	O
:	O
1	O
)	O
Limited	O
examination	O
,	O
showing	O
reversal	O
of	O
portal	O
venous	O
blood	O
flow	O
,	O
new	O
since	O
[	O
**	O
2168-10-11	O
**	O
]	O
.	O
2	O
)	O
No	O
gross	O
evidence	O
of	O
hydronephrosis	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
underwent	O
esophagogastectomy	O
with	O
rou	O
-	O
en	O
-	O
y	O
reconstruction	O
for	O
longstangind	O
history	O
of	O
esophageal	O
stricture	O
and	O
gastric	O
atony	O
on	O
[	O
**	O
2170-2-22	O
**	O
]	O
.	O
Overnight	O
patient	O
develop	O
increase	O
in	O
need	O
for	O
fluid	O
to	O
support	O
blood	O
pressure	O
as	O
well	O
as	O
a	O
bile	O
leak	O
from	O
one	O
of	O
the	O
anastomosis	O
.	O
Then	O
patient	O
developed	O
increased	O
in	O
abdominal	O
bladder	O
pressure	O
.	O
She	O
was	O
taken	O
urgently	O
to	O
the	O
operating	O
room	O
for	O
the	O
revision	O
of	O
the	O
anastomosis	O
and	O
wash	O
out	O
.	O
Her	O
abdomin	O
was	O
unable	O
to	O
be	O
closed	O
so	O
bogata	O
bag	O
was	O
placed	O
.	O
After	O
the	O
operation	O
,	O
patient	O
continued	O
to	O
require	O
fluid	I-Drug
and	O
pressors	I-Drug
for	O
blood	O
pressure	O
support	O
.	O
Then	O
patient	O
became	O
septic	O
.	O
She	O
was	O
started	O
on	O
Xigris	I-Drug
for	O
treatment	O
of	O
septic	I-Reason
shock	O
.	O
She	O
improved	O
but	O
continued	O
to	O
require	O
full	O
ICU	O
care	O
.	O
Neurologically	O
,	O
she	O
moved	O
all	O
extremities	O
but	O
required	O
sedation	I-Drug
and	O
paralysis	I-Drug
to	O
help	B-Reason
with	I-Reason
oxygenation	I-Reason
.	O
Cadiovascularlly	O
,	O
she	O
was	O
started	O
on	O
Xigris	I-Drug
which	O
initally	O
helped	O
with	O
decreased	O
in	O
need	O
for	O
pressors	I-Drug
but	O
she	O
continued	O
to	O
need	O
pressors	I-Drug
for	O
blood	O
pressure	O
support	O
.	O
She	O
also	O
developed	O
atrial	B-Reason
fibrillation	I-Reason
which	O
lead	O
to	O
need	O
for	O
amiodarone	I-Drug
drip	O
for	O
a	O
period	O
of	O
time	O
.	O
She	O
continued	O
to	O
need	O
mechanical	O
support	O
and	O
the	O
need	O
for	O
supported	O
increased	O
for	O
both	O
oxygenation	O
and	O
ventilation	O
over	O
time	O
.	O
Patient	O
also	O
developed	O
renal	O
insuffiency	O
.	O
Patient	O
also	O
developed	O
shocked	O
liver	O
with	O
coagulation	O
parameters	O
not	O
responding	O
to	O
replacements	O
.	O
On	O
[	O
**	O
2170-3-5	O
**	O
]	O
,	O
she	O
developed	O
leukocytosis	O
to	O
40s	O
and	O
she	O
was	O
taken	O
to	O
the	O
operating	O
room	O
for	O
a	O
washout	O
.	O
Subsequently	O
she	O
developed	O
multi-organ	O
failure	O
.	O
After	O
a	O
discussion	O
with	O
family	O
patient	O
was	O
made	O
comfort	O
measures	O
only	O
and	O
she	O
died	O
after	O
withdrawing	O
her	O
ventilation	O
.	O
Medications	O
on	O
Admission	O
:	O
Metoprolol	I-Drug
,	O
levoxyl	I-Drug
,	O
amytriptyline	I-Drug
,	O
paxil	I-Drug
,	O
colace	I-Drug
,	O
sulcrafate	I-Drug
,	O
doxycycline	I-Drug
,	O
lantus	I-Drug
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Discharge	O
Diagnosis	O
:	O
Hypergastrinemia	O
Esophageal	O
Strictures	O
Esophageal	O
dysmotility	O
Gastric	O
Atony	O
Duodenal	O
ulcer	O
Asthma	O
COPD	O
Sinus	O
tachycardia	O
Gallstone	O
panreastitis	O
s	O
/	O
p	O
cholecystectomy	O
s	O
/	O
p	O
appendectomy	O
Right	O
hip	O
MRSA	O
s	O
/	O
p	O
gastrectomy	O
with	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
39044	O
**	O
]	O
and	O
J	O
tube	O
placement	O
Abdominal	O
compartment	O
syndrome	O
Multiorgan	O
failure	O
Discharge	O
Condition	O
:	O
Death	O
Completed	O
by	O
:[	O
**	O
2170-3-8	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2124-3-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2124-3-21	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2055-1-24	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Aspirin	I-Drug
/	O
lisinopril	I-Drug
/	O
Wellbutrin	I-Drug
/	O
Seroquel	I-Drug
Attending	O
:[	O
**	O
Doctor	O
First	O
Name	O
6807	O
**	O
]	O
Chief	O
Complaint	O
:	O
Palpitations	O
during	O
hemodialysis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Radioablation	O
(	O
via	O
right	O
femoral	O
access	O
)	O
Hemodialysis	O
History	O
of	O
Present	O
Illness	O
:	O
69F	O
with	O
history	O
of	O
SVT	O
/	O
AT	O
s	O
/	O
p	O
ablation	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
,	O
CAD	O
s	O
/	O
p	O
two	O
BMS	O
in	O
LAD	O
(	O
[	O
**	O
9	O
-	O
26	O
**	O
]	O
)	O
,	O
depressed	O
EF	O
35	O
%	O
(	O
[	O
**	O
9	O
-	O
/	O
2123	O
**	O
]	O
)	O
,	O
ESRD	O
(	O
HD	O
M	O
/	O
W	O
/	O
F	O
)	O
,	O
who	O
was	O
admited	O
after	O
developing	O
palpitations	O
during	O
hemodialysis	O
this	O
morning	O
.	O
She	O
was	O
able	O
to	O
complete	O
the	O
dialysis	O
.	O
She	O
denies	O
chest	O
pain	O
,	O
SOB	O
,	O
or	O
lightheadedness	O
during	O
the	O
episode	O
.	O
No	O
syncope	O
/	O
presyncope	O
.	O
She	O
has	O
a	O
long	O
history	O
of	O
becoming	O
tachycardic	O
during	O
HD	O
;	O
admitted	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
last	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
.	O
She	O
continues	O
to	O
breakthrough	O
despite	O
pharmacologic	O
therapy	O
with	O
metoprolol	I-Drug
,	O
and	O
failed	O
amiodarone	I-Drug
.	O
She	O
undewent	O
ablation	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
[	O
**	O
2124-3-2	O
**	O
]	O
.	O
.	O
She	O
had	O
been	O
discharged	O
yesterday	O
from	O
[	O
**	O
Hospital	O
882	O
**	O
]	O
hospital	O
after	O
admission	O
for	O
SOB	O
and	O
was	O
found	O
to	O
have	O
pulmonary	O
edema	O
.	O
She	O
uses	O
2	O
pillows	O
/	O
day	O
and	O
wakes	O
up	O
SOB	O
[	O
**	O
2	O
-	O
18	O
**	O
]	O
/	O
week	O
.	O
She	O
has	O
not	O
noticed	O
any	O
changes	O
in	O
her	O
functional	O
status	O
recently	O
.	O
She	O
lives	O
with	O
her	O
husband	O
and	O
is	O
able	O
to	O
perform	O
ADL	O
.	O
.	O
In	O
the	O
ED	O
,	O
VS	O
were	O
T	O
-	O
98.2	O
,	O
P	O
-	O
130	O
,	O
BP	O
-	O
98/65	O
,	O
RR	O
-	O
16	O
,	O
96	O
%	O
on	O
RA	O
;	O
triggerred	O
for	O
tachycardia	O
.	O
Received	O
500cc	O
NS	I-Drug
bolus	O
.	O
Labs	O
remarkable	O
for	O
troponin	O
of	O
0.18	O
in	O
the	O
setting	O
of	O
ARF	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Paroxysmal	O
SVT	O
/	O
AT	O
-	O
CAD	O
;	O
NSTEMI	O
(	O
[	O
**	O
9	O
-	O
26	O
**	O
]	O
)	O
BMS	O
to	O
LAD	O
,	O
RCA	O
100	O
%	O
occluded	O
-	O
chronic	O
systolic	O
HF	O
,	O
LVEF	O
35	O
%	O
-	O
DM2	O
-	O
Hypertension	O
-	O
Hyperlipidemia	O
-	O
CVA	O
(	O
residual	O
R	O
weakness	O
and	O
intermittent	O
R	O
facial	O
droop	O
)	O
-	O
PAD	O
-	O
ESRD	O
on	O
HD	O
3x	O
/	O
week	O
:	O
anuric	O
,	O
on	O
HD	O
for	O
>	O
5y	O
-	O
Sleep	O
apnea	O
(	O
not	O
using	O
CPAP	O
)	O
-	O
Seizure	B-Reason
disorder	I-Reason
since	O
[	O
**	O
3	O
-	O
/	O
2123	O
**	O
]	O
on	O
Keppra	I-Drug
:	O
one	O
seizure	O
per	O
pt	O
-	O
depression	O
with	O
psychosis	O
-	O
GERD	O
with	O
gastric	O
ulcer	O
causing	O
UGI	O
[	O
**	O
3	O
-	O
/	O
2123	O
**	O
]	O
-	O
Cervical	O
Disk	O
disease	O
-	O
Syncope	O
and	O
collapse	O
-	O
diabetic	O
retinopathy	O
-	O
gout	O
-	O
anemia	O
-	O
carotid	O
artery	O
stenosis	O
-	O
thyroid	O
cancer	O
(	O
vastly	O
fluctuating	O
TSH	O
)	O
.	O
PSHx	O
:	O
-	O
bariatric	O
surgery	O
-	O
cholecystectomy	O
-	O
C	O
section	O
x3	O
-	O
LUE	O
braciocephalic	O
AV	O
fistula	O
last	O
angioplasty	O
[	O
**	O
11	O
-	O
25	O
**	O
]	O
Social	O
History	O
:	O
Married	O
,	O
lives	O
with	O
husband	O
.	O
2	O
sons	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
and	O
[	O
**	O
Name	O
(	O
NI	O
)	O
74998	O
**	O
]	O
(	O
HCP	O
)	O
.	O
Able	O
to	O
perform	O
ADL	O
.	O
-	O
Tobacco	O
history	O
:	O
denies	O
-	O
ETOH	O
:	O
denies	O
-	O
Illicit	O
drugs	O
:	O
denies	O
Family	O
History	O
:	O
No	O
family	O
history	O
of	O
early	O
MI	O
,	O
arrhythmias	O
,	O
cardiomyopathies	O
,	O
or	O
sudden	O
cardiac	O
death	O
.	O
Mother	O
died	O
in	O
her	O
70's	O
of	O
cancer	O
.	O
Father	O
was	O
killed	O
.	O
Physical	O
Exam	O
:	O
ADMISSION	O
EXAM	O
:	O
VS	O
:	O
T	O
-	O
98.3	O
P	O
-	O
128	O
BP	O
-	O
107/70	O
97	O
%	O
Sat	O
on	O
RA	O
GENERAL	O
:	O
Thin	O
,	O
pleasant	O
elderly	O
woman	O
in	O
NAD	O
.	O
Lethargic	O
.	O
Alert	O
and	O
Oriented	O
x3	O
.	O
Mood	O
-	O
appropriate	O
.	O
Affect	O
-	O
flat	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
Mucous	O
membrane	O
moist	O
.	O
NECK	O
:	O
Supple	O
with	O
JVP	O
of	O
8	O
cm	O
.	O
Carotid	O
bruits	O
L	O
>	O
R.	O
+	O
Hepatojugular	O
reflex	O
CARDIAC	O
:	O
PMI	O
nondisplaced	O
,	O
tachy	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
Difficult	O
to	O
appreciate	O
murmurs	O
due	O
to	O
heart	O
-	O
rate	O
.	O
No	O
rubs	O
or	O
thrills	O
.	O
LUNGS	O
:	O
Unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
Crackles	O
in	O
mid-lower	O
lung	O
fields	O
b	O
/	O
l.	O
No	O
wheezes	O
or	O
rhonchi	O
.	O
Scoliosis	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
104848	O
**	O
]	O
bruit	O
over	O
L	O
brachiocephalic	O
fistula	O
.	O
SKIN	O
:	O
Xerosis	O
.	O
No	O
stasis	O
dermatitis	O
or	O
ulcers	O
.	O
PULSES	O
:	O
1	O
+	O
carotid	O
,	O
1	O
+	O
brachial	O
,	O
1	O
+	O
DP	O
and	O
PT	O
.	O
NEURO	O
:	O
CN	O
2	O
-	O
12	O
grossly	O
intact	O
,	O
motor	O
strength	O
and	O
sensation	O
grossly	O
intact	O
bilaterally	O
.	O
3/5	O
strength	O
symmetric	O
.	O
No	O
facial	O
droop	O
or	O
dysarthria	O
.	O
.	O
DISCHARGE	O
EXAM	O
:	O
VS.	O
98.3	O
BP	O
109/58	O
(	O
95-125/50	O
-	O
60	O
)	O
HR	O
87	O
18	O
100	O
/	O
RA	O
fasting	O
FS	O
111	O
Wt	O
55.4	O
kg	O
GENERAL	O
:	O
well	O
-	O
appearing	O
elderly	O
female	O
sitting	O
up	O
in	O
chair	O
,	O
pleasant	O
,	O
alert	O
and	O
conversational	O
,	O
NAD	O
.	O
NECK	O
:	O
supple	O
,	O
JVP	O
7	O
cm	O
.	O
Carotid	O
bruits	O
L	O
>	O
R.	O
CARDIAC	O
:	O
normal	O
S1	O
,	O
S2	O
.	O
high	O
-	O
pitched	O
holosystolic	O
[	O
**	O
Name	O
(	O
NI	O
)	O
9413	O
**	O
]	O
best	O
@LUSB	O
LUNGS	O
:	O
prominent	O
sternum	O
/	O
clavicle	O
.	O
respirations	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
bibasilar	O
crackles	O
,	O
no	O
wheezes	O
or	O
rhonchi	O
.	O
Scoliosis	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
Pulse	O
:	O
palpable	O
R	O
femoral	O
bruit	O
(	O
decreased	O
from	O
yesterday	O
's	O
exam	O
)	O
.	O
warm	O
,	O
well	O
-	O
perfused	O
RLE	O
and	O
LLE	O
,	O
warm	O
feet	O
,	O
palpable	O
distal	O
pulses	O
,	O
no	O
edema	O
NEURO	O
:	O
AOX3	O
,	O
face	O
symmetric	O
,	O
speech	O
fluent	O
but	O
slow	O
,	O
moves	O
all	O
extremities	O
spontaneously	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2124-3-15	O
**	O
]	O
Glucose	O
-	O
109	O
*	O
UreaN	O
-	O
22	O
*	O
Creat	O
-	O
4.1	O
*	O
#	O
Na	O
-	O
140	O
K	O
-	O
5.4	O
*	O
Cl	O
-	O
96	O
HCO3	O
-	O
32	O
AnGap	O
-	O
17	O
Calcium	O
-	O
9.3	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.0	O
[	O
**	O
2124-3-15	O
**	O
]	O
WBC	O
-	O
4.6	O
RBC	O
-	O
3.16	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
33.3	O
*	O
MCV	O
-	O
105	O
*	O
#	O
MCH	O
-	O
34.0	O
*	O
MCHC	O
-	O
32.3	O
RDW	O
-	O
13.7	O
Plt	O
Ct	O
-	O
182	O
Neuts	O
-	O
74.5	O
*	O
Lymphs	O
-	O
15.2	O
*	O
Monos	O
-	O
5.0	O
Eos	O
-	O
2.0	O
Baso	O
-	O
3.3	O
*	O
.	O
DISCHARGE	O
LABS	O
03	O
/	O
06	O
/	O
12Glucose	O
-	O
103	O
*	O
UreaN	O
-	O
48	O
*	O
Creat	O
-	O
6.7	O
*	O
#	O
Na	O
-	O
139	O
K	O
-	O
3.9	O
Cl	O
-	O
96	O
HCO3	O
-	O
26	O
AnGap	O
-	O
21	O
*	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
3.4	O
Mg	O
-	O
1.9	O
[	O
**	O
2124-3-21	O
**	O
]	O
WBC	O
-	O
5.0	O
RBC	O
-	O
2.91	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
29.9	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
33.8	O
*	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
14.9	O
Plt	O
Ct	O
-	O
146	O
*	O
.	O
OTHER	O
PERTINENT	O
LABS	O
[	O
**	O
2124-3-16	O
**	O
]	O
TSH	O
-	O
2.5	O
.	O
IMAGING	O
CXR	O
(	O
[	O
**	O
2124-3-15	O
**	O
]	O
)	O
:	O
FINDINGS	O
:	O
Single	O
frontal	O
view	O
of	O
the	O
chest	O
was	O
obtained	O
.	O
There	O
are	O
low	O
lung	O
volumes	O
,	O
accentuate	O
the	O
bronchovascular	O
markings	O
.	O
Fullness	O
of	O
the	O
hila	O
and	O
mild	O
perihilar	O
opacities	O
may	O
relate	O
to	O
mild	O
fluid	O
overload	O
and	O
/	O
or	O
crowding	O
of	O
vessels	O
.	O
No	O
definite	O
focal	O
consolidation	O
is	O
seen	O
.	O
No	O
large	O
pleural	O
effusion	O
or	O
pneumothorax	O
.	O
Cardiac	O
and	O
mediastinal	O
silhouettes	O
are	O
grossly	O
stable	O
.	O
IMPRESSION	O
:	O
Low	O
lung	O
volumes	O
with	O
possible	O
mild	O
fluid	O
overload	O
.	O
Consider	O
repeat	O
with	O
better	O
inspiration	O
when	O
patient	O
able	O
.	O
.	O
EKG	O
[	O
**	O
2124-3-15	O
**	O
]	O
:	O
HR	O
120	O
,	O
atrial	O
tachycardia	O
,	O
Nl	O
axis	O
,	O
normal	O
interval	O
,	O
nl	O
R	O
wave	O
progression	O
,	O
no	O
ST	O
-	O
changes	O
.	O
[	O
**	O
2124-3-19	O
**	O
]	O
:	O
NSR	O
84	O
.	O
Microbiology	O
:	O
[	O
**	O
2	O
-	O
/	O
2041	O
**	O
]	O
Blood	O
culture	O
(	O
FINAL	O
)	O
:	O
NO	O
growth	O
MRSA	O
screen	O
:	O
NO	O
MRSA	O
isolated	O
.	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
TTE	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
(	O
LVEF	O
=	O
20	O
%	O
)	O
secondary	O
to	O
extensive	O
apical	O
akinesis	O
and	O
severe	O
hypokinesis	O
of	O
the	O
rest	O
of	O
the	O
left	O
ventricle	O
with	O
the	O
exception	O
of	O
the	O
basal	O
posterior	O
and	O
lateral	O
walls	O
,	O
which	O
are	O
relatively	O
preserved	O
.	O
[	O
Intrinsic	O
left	O
ventricular	O
systolic	O
function	O
is	O
likely	O
more	O
depressed	O
given	O
the	O
severity	O
of	O
valvular	O
regurgitation	O
.	O
]	O
A	O
left	O
ventricular	O
apical	O
mass	O
/	O
thrombus	O
can	O
not	O
be	O
excluded	O
with	O
certainty	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
The	O
right	O
ventricular	O
free	O
wall	O
thickness	O
is	O
normal	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
dilated	O
with	O
depressed	O
free	O
wall	O
contractility	O
.	O
[	O
Intrinsic	O
right	O
ventricular	O
systolic	O
function	O
is	O
likely	O
more	O
depressed	O
given	O
the	O
severity	O
of	O
tricuspid	O
regurgitation	O
.	O
]	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
There	O
is	O
severe	O
mitral	O
annular	O
calcification	O
.	O
Severe	O
(	O
4	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Severe	O
[	O
4	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
[	O
In	O
the	O
setting	O
of	O
at	O
least	O
moderate	O
to	O
severe	O
tricuspid	O
regurgitation	O
,	O
the	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
may	O
be	O
underestimated	O
due	O
to	O
a	O
very	O
high	O
right	O
atrial	O
pressure	O
.	O
]	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
findings	O
of	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2123-10-7	O
**	O
]	O
,	O
there	O
has	O
been	O
marked	O
further	O
deterioration	O
of	O
left	O
ventricular	O
contractile	O
function	O
as	O
well	O
as	O
marked	O
increased	O
in	O
mitral	O
and	O
tricuspid	O
regurgitation	O
.	O
.	O
[	O
**	O
3	O
-	O
19	O
**	O
]	O
R	O
FEMORAL	O
ULTRASOUND	O
FINDINGS	O
:	O
Focused	O
vascular	O
ultrasound	O
of	O
the	O
right	O
groin	O
,	O
the	O
common	O
femoral	O
artery	O
and	O
vein	O
was	O
performed	O
with	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
scale	O
,	O
color	O
Doppler	O
,	O
and	O
spectral	O
analysis	O
.	O
Findings	O
are	O
concerning	O
for	O
an	O
AV	O
fistula	O
between	O
the	O
right	O
common	O
femoral	O
artery	O
and	O
vein	O
,	O
just	O
proximal	O
to	O
the	O
greater	O
saphenous	O
vein	O
takeoff	O
,	O
where	O
there	O
is	O
turbulent	O
,	O
mixed	O
broad	O
waveform	O
and	O
suggestion	O
of	O
connection	O
between	O
the	O
two	O
vessels	O
.	O
No	O
evidence	O
of	O
pseudoaneurysm	O
is	O
seen	O
.	O
No	O
evidence	O
of	O
hematoma	O
is	O
seen	O
in	O
the	O
right	O
groin	O
.	O
IMPRESSION	O
:	O
Findings	O
concerning	O
for	O
AV	O
fistula	O
between	O
the	O
right	O
common	O
femoral	O
artery	O
and	O
vein	O
.	O
No	O
evidence	O
of	O
pseudoaneurysm	O
.	O
Brief	O
Hospital	O
Course	O
:	O
69F	O
with	O
HX	O
SVT	O
,	O
ESRD	O
,	O
CAD	O
,	O
PAD	O
,	O
and	O
sCHF	O
p	O
/	O
w	O
symptomatic	O
atrial	O
tachycardia	O
to	O
the	O
130s	O
during	O
outpatient	O
dialysis	O
;	O
admitted	O
for	O
management	O
of	O
this	O
chronic	O
problem	O
,	O
previously	O
refractory	O
to	O
pharmacologic	O
therapy	O
and	O
a	O
1st	O
ablation	O
attempt	O
on	O
[	O
**	O
2124-3-2	O
**	O
]	O
;	O
during	O
this	O
admission	O
she	O
underwent	O
a	O
2nd	O
ablation	O
attempt	O
which	O
was	O
not	O
wholly	O
successful	O
(	O
some	O
intermittent	O
Atach	O
episodes	O
thereafter	O
)	O
,	O
and	O
which	O
was	O
c	O
/	O
b	O
a	O
post-procedure	O
R	O
femoral	O
AVF	O
.	O
.	O
#	O
ATRIAL	O
TACHYCARDIA	O
Admitted	O
from	O
HD	O
w	O
/	O
atrial	O
tachycardia	O
,	O
a	O
chronic	O
intermittent	O
issues	O
.	O
Usually	O
asymptomatic	O
;	O
now	O
symptomatic	O
w	O
/	O
lightheadedness	O
at	O
HD	O
.	O
Admission	O
EKG	O
here	O
documented	O
atrial	O
tachycardia	O
to	O
the	O
130s	O
,	O
no	O
ischemic	O
changes	O
.	O
Hemodynamically	O
stable	O
and	O
asymptomatic	O
despite	O
HR	O
intermittently	O
to	O
the	O
130s	O
.	O
Underwent	O
successful	O
ablation	O
here	O
on	O
[	O
**	O
2124-3-16	O
**	O
]	O
,	O
after	O
which	O
she	O
was	O
in	O
NSR	O
for	O
>	O
24h	O
.	O
However	O
,	O
she	O
did	O
flip	O
into	O
atrial	O
tachycardia	O
intermittently	O
thereafter	O
,	O
with	O
HR	O
max	O
120s	O
-	O
episodes	O
self	O
-	O
resolved	O
,	O
occurred	O
primarily	O
during	O
HD	O
,	O
and	O
were	O
asymptomatic	O
.	O
Attempts	O
to	O
increase	O
beta	B-Reason
-	I-Reason
blockade	I-Reason
beyond	O
Toprol	I-Drug
75	O
mg	O
PO	O
QD	O
were	O
limited	O
by	O
BP	O
.	O
Patient	O
will	O
see	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
(	O
electrophysiologist	O
)	O
in	O
outpatient	O
follow	O
-	O
up	O
in	O
~	O
1	O
week	O
to	O
discuss	O
any	O
possible	O
future	O
intervenion	O
.	O
In	O
the	O
interim	O
,	O
at	O
home	O
and	O
at	O
HD	O
,	O
her	O
inpatient	O
cardiologist	O
felt	O
comfortable	O
tolerating	O
asymptomatic	O
atrial	O
tachycardia	O
to	O
the	O
120s	O
-	O
130s	O
.	O
We	O
note	O
that	O
on	O
[	O
**	O
3	O
-	O
16	O
**	O
]	O
,	O
post-procedure	O
recovery	O
was	O
initially	O
complicated	O
by	O
anaesthesia	I-Drug
-	O
induced	O
hypotension	I-Ade
(	O
requiring	O
overnight	O
ICU	O
obs	O
)	O
and	O
later	O
by	O
the	O
slow	O
development	O
of	O
a	O
R	O
femoral	O
AVF	O
(	O
documented	O
by	O
ultrasound	O
,	O
see	O
results	O
)	O
.	O
For	O
the	O
R	O
femoral	O
AVF	O
,	O
vascular	O
surgery	O
consult	O
service	O
evaluated	O
her	O
daily	O
and	O
recommended	O
conservative	O
management	O
vascular	O
surgery	O
f	O
/	O
u	O
in	O
4	O
weeks	O
.	O
Expect	O
spontaneous	O
resolution	O
.	O
.	O
#	O
CHRONIC	O
SYSTOLIC	O
HEART	O
FAILURE	O
,	O
LVEF	O
20	O
%	O
TTE	O
during	O
this	O
admission	O
demonstrated	O
LVEF	O
20	O
%	O
,	O
MR	O
4	O
+	O
TR	O
4	O
+	O
,	O
all	O
worse	O
than	O
prior	O
.	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
9413	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
on	O
exam	O
.	O
Ischemic	O
vs.	O
tachycardia	O
-	O
induced	O
cardiomyopathy	O
suspected	O
as	O
underlying	O
cause	O
.	O
She	O
was	O
euvolemic	O
during	O
admission	O
;	O
volume	B-Reason
/	I-Reason
BP	I-Reason
control	I-Reason
primarily	O
via	O
BB	I-Drug
and	O
dialysis	O
.	O
Imdur	I-Drug
was	O
stopped	O
due	O
to	O
relative	O
hypotension	I-Ade
(	O
SBP	O
90s	O
-	O
110s	O
)	O
.	O
Metoprolol	I-Drug
dose	O
increased	O
to	O
Toprol	I-Drug
75	O
mg	O
QD	O
.	O
We	O
note	O
hx	O
lisinopril	I-Drug
allergy	O
;	O
considered	O
started	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
but	O
deferred	O
this	O
for	O
outpatient	O
f	O
/	O
u	O
in	O
setting	O
of	O
borderline	O
BPs	O
.	O
.	O
#	O
ORTHOSTATIC	O
HYPOTENSION	O
Patient	O
's	O
BP	O
fell	O
to	O
75	O
/	O
palp	O
when	O
working	O
w	O
/	O
PT	O
on	O
[	O
**	O
3	O
-	O
20	O
**	O
]	O
.	O
Family	O
confirmed	O
that	O
she	O
suffers	O
from	O
lightheadedness	O
when	O
she	O
first	O
rises	O
to	O
stand	O
,	O
especially	O
after	O
watching	O
television	O
(	O
she	O
like	O
Westerns	O
)	O
.	O
Imdur	I-Drug
had	O
already	O
been	O
stopped	O
prior	O
to	O
this	O
PT	O
eval	O
;	O
BB	I-Drug
was	O
subsequently	O
lowered	O
from	O
Toprol	I-Drug
100	O
QD	O
to	O
75	O
QD	O
(	O
further	O
decrease	O
thought	O
inappropriate	O
given	O
need	O
to	O
control	O
atrial	O
tachycardia	O
)	O
.	O
She	O
worked	O
with	O
PT	O
twice	O
more	O
and	O
was	O
instructed	O
on	O
techniques	O
to	O
decrease	O
orthostatic	O
symptoms	O
and	O
prevent	O
falls	O
.	O
Outpatient	O
PT	O
arranged	O
at	O
discharge	O
.	O
.	O
#	O
DM2	O
Patient	O
has	O
known	O
DM2	I-Reason
,	O
not	O
on	O
either	O
oral	O
hypoglycemics	I-Drug
or	O
insulin	I-Drug
.	O
Insulin	I-Drug
needs	O
here	O
ranged	O
from	O
8	O
-	O
12U	O
/	O
day	O
.	O
Discussed	O
initiating	O
insulin	I-Drug
w	O
/	O
pt	O
,	O
but	O
she	O
refused	O
.	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
require	O
ongoing	O
BS	O
evaluation	O
/	O
discussion	O
of	O
therapeutic	O
options	O
as	O
an	O
outpatient	O
.	O
.	O
INACTIVE	O
ISSUES	O
.	O
#	O
CAD	I-Reason
Patient	O
w	O
/	O
significant	O
2V	O
CAD	O
(	O
LAD	O
stented	O
w	O
/	O
BMS	O
x2	O
,	O
RCA	O
occluded	O
100	O
%	O
on	O
[	O
**	O
9	O
-	O
/	O
2123	O
**	O
]	O
cath	O
)	O
.	O
EKGs	O
negative	O
for	O
evidence	O
of	O
restenosis	O
or	O
ischemic	O
changes	O
.	O
No	O
chest	O
pain	O
or	O
dyspnea	O
.	O
Continued	O
Plavix	I-Drug
and	O
ASA	I-Drug
81	O
mg	O
.	O
.	O
#	O
CHRONIC	O
ANEMIA	O
Chronic	O
;	O
family	O
confirms	O
that	O
she	O
receives	O
Epo	O
at	O
outpatient	O
HD	O
.	O
Denies	O
h	O
/	O
o	O
melena	O
or	O
GI	O
bleeding	O
.	O
Hct	O
remained	O
stable	O
~	O
30	O
.	O
.	O
#	O
ESRD	O
:	O
Longstanding	O
,	O
on	O
qMWF	O
schedule	O
.	O
No	O
difficulty	O
w	O
/	O
LUE	O
AV	O
fistula	O
access	O
.	O
Atrial	O
tachycardia	O
episodes	O
occurred	O
primarily	O
during	O
HD	O
sessions	O
,	O
were	O
asymptomatic	O
and	O
self	O
-	O
resolved	O
within	O
minutes	O
.	O
See	O
above	O
for	O
cardiology	O
plan	O
re	O
:	O
any	O
future	O
asymptomatic	O
ATach	O
during	O
HD	O
.	O
.	O
#	O
Hx	O
Hypothyroidism	I-Reason
s	O
/	O
p	O
thyroidectomy	O
TSH	O
wnl	O
at	O
admission	O
.	O
Continued	O
home	O
dose	O
of	O
synthroid	I-Drug
.	O
.	O
#	O
Hx	O
HLD	I-Reason
Continued	O
home	O
statin	I-Drug
.	O
.	O
#	O
Hx	O
Seizure	B-Reason
disorder	I-Reason
One	O
seizure	O
in	O
the	O
past	O
per	O
patient	O
.	O
Continued	O
home	O
Keppra	I-Drug
.	O
No	O
seizure	O
activity	O
observed	O
.	O
.	O
TRANSITIONAL	O
ISSUES	O
1	O
.	O
EP	O
to	O
reassess	O
for	O
possible	O
future	O
repeat	O
ablation	O
attempt	O
2	O
.	O
DM2	I-Reason
-	O
Pt	O
refused	O
discussion	O
of	O
insulin	I-Drug
,	O
had	O
8	O
-	O
12U	O
/	O
day	O
insulin	I-Drug
requirement	O
.	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
need	O
further	O
discussion	O
/	O
education	O
about	O
risks	O
of	O
continuing	O
with	O
dietary	O
control	O
and	O
without	O
any	O
medical	O
management	O
.	O
3	O
.	O
Worsening	O
sCHF	O
(	O
35	O
%	O
-	O
>	O
20	O
%	O
)	O
.	O
Suspected	O
declining	O
LVEF	O
due	O
to	O
tachycardia	O
-	O
induced	O
crdiomyopathy	O
[	O
**	O
2	O
-	O
17	O
**	O
]	O
long	O
-	O
standing	O
Atrial	O
Tachycardia	O
.	O
Suggest	O
repeat	O
TTE	O
in	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
mos	O
to	O
reassess	O
LVEF	O
,	O
MR	O
and	O
TR	O
once	O
rate	O
better	O
controlled	O
.	O
4	O
.	O
Follow	O
-	O
up	O
HR	O
,	O
BP	O
,	O
orthostatic	O
VS.	O
Toprol	I-Drug
dose	O
increased	O
to	O
75	O
mg	O
po	O
DAILY	O
,	O
imdur	I-Drug
stopped	O
.	O
5	O
.	O
Follow	O
-	O
up	O
logistics	O
of	O
outpatient	O
PT	O
,	O
recommended	O
by	O
inpatient	O
PT	O
consult	O
6	O
.	O
Monitor	O
exam	O
for	O
changes	O
in	O
R	O
femoral	O
AVF	O
(	O
vascular	O
surgery	O
f	O
/	O
u	O
arranged	O
)	O
6	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Tablet	O
(	O
s	O
)	O
2	O
.	O
clopidogrel	B-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
isosorbide	I-Drug
mononitrate	O
60	O
mg	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
aripiprazole	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
B	B-Drug
complex	I-Drug
-	I-Drug
vitamin	I-Drug
C	I-Drug
-	I-Drug
folic	O
acid	O
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
calcium	I-Drug
acetate	O
667	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
7	O
.	O
citalopram	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
ONCE	O
(	O
Once	O
)	O
for	O
1	O
doses	O
.	O
9	O
.	O
levothyroxine	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
mirtazapine	B-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	I-Reason
insomnia	O
.	O
11	O
.	O
pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
12	O
.	O
aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
docusate	I-Drug
sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	I-Reason
pain	O
.	O
16	O
.	O
metoprolol	I-Drug
succinate	O
50	O
mg	O
po	O
qday	O
Discharge	O
Medications	O
:	O
1	O
.	O
atorvastatin	B-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
aripiprazole	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
B	B-Drug
complex	I-Drug
-	I-Drug
vitamin	I-Drug
C	I-Drug
-	I-Drug
folic	O
acid	O
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
calcium	I-Drug
acetate	O
667	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
6	O
.	O
citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
levothyroxine	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
mirtazapine	B-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	I-Reason
insomnia	O
.	O
10	O
.	O
pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
11	O
.	O
aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
docusate	I-Drug
sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	I-Reason
pain	O
.	O
15	O
.	O
Toprol	I-Drug
XL	O
25	O
mg	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
Extended	O
Release	O
24	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
VNA	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Atrial	O
tachycardia	O
2	O
.	O
Coronary	O
artery	O
disease	O
3	O
.	O
Depressed	O
ejection	O
fraction	O
4	O
.	O
End	O
-	O
stage	O
renal	O
disease	O
5	O
.	O
Hypothyroidism	O
6	O
.	O
Type	O
2	O
Diabetes	O
7	O
.	O
Hypertension	O
8	O
.	O
Sleep	O
Apnea	O
9	O
.	O
Seizure	O
disorder	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
.	O
It	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
when	O
you	O
were	O
admitted	O
for	O
rapid	O
heart	O
rate	O
during	O
dialysis	O
similar	O
to	O
the	O
episodes	O
you	O
have	O
experienced	O
in	O
the	O
past	O
.	O
.	O
During	O
this	O
hospital	O
stay	O
,	O
you	O
underwent	O
an	O
ablation	O
procedure	O
.	O
The	O
procedure	O
was	O
successful	O
-	O
you	O
developed	O
occasional	O
rapid	O
rates	O
but	O
eventually	O
returned	O
to	O
[	O
**	O
Location	O
213	O
**	O
]	O
sinus	O
rhythm	O
.	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
will	O
see	O
you	O
in	O
follow	O
-	O
up	O
to	O
discuss	O
whether	O
you	O
might	O
need	O
another	O
ablation	O
procedure	O
if	O
you	O
develop	O
rapid	O
heartrate	O
again	O
.	O
We	O
noticed	O
that	O
you	O
were	O
lightheaded	O
and	O
had	O
slightly	O
low	O
blood	O
pressures	O
when	O
you	O
first	O
stand	O
up	O
,	O
especially	O
on	O
dialysis	O
days	O
.	O
You	O
worked	O
with	O
a	O
physical	O
therapist	O
here	O
who	O
gave	O
recommendation	O
about	O
standing	O
up	O
slowly	O
to	O
avoid	O
lightheadedness	O
and	O
falls	O
.	O
We	O
also	O
adjusted	O
your	O
medications	O
to	O
minimize	O
symptoms	O
.	O
You	O
had	O
elevated	B-Reason
blood	I-Reason
sugars	I-Reason
here	O
,	O
to	O
>	O
300	O
on	O
more	O
than	O
1	O
occassion	O
.	O
On	O
average	O
,	O
you	O
received	O
12	O
units	O
of	O
insulin	I-Drug
/	O
day	O
to	O
control	O
your	O
blood	O
sugar	O
.	O
You	O
did	O
not	O
want	O
to	O
start	O
diabetes	O
medications	O
.	O
You	O
should	O
discuss	O
this	O
further	O
with	O
your	O
PCP	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
3	O
**	O
]	O
you	O
should	O
be	O
taking	O
medication	O
to	O
control	O
high	O
blood	O
sugar	O
at	O
home	O
.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
medications	O
:	O
CHANGED	O
METOPROLOL	I-Drug
FORMULATION	O
:	O
START	O
TAKING	O
TOPROL	I-Drug
XL	O
75	O
MG	O
PER	O
DAY	O
(	O
EXTENDED	O
RELEASE	O
)	O
.	O
DO	O
N'T	O
TAKE	O
YOUR	O
OLD	O
METOPROLOL	B-Drug
/	I-Drug
LOPRESSOR	O
PILLS	O
.	O
STOP	O
TAKING	O
IMDUR	I-Drug
Review	O
your	O
medication	O
list	O
with	O
your	O
PCP	O
and	O
cardiologist	O
at	O
your	O
next	O
appointment	O
.	O
Please	O
keep	O
your	O
follow	O
-	O
up	O
appointments	O
as	O
scheduled	O
below	O
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
Followup	O
Instructions	O
:	O
Name	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
M.	O
Location	O
:	O
[	O
**	O
Hospital1	O
641	O
**	O
]	O
Address	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
2260	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3530	O
**	O
]	O
Appointment	O
:	O
Tuesday	O
[	O
**	O
2124-3-28	O
**	O
]	O
11:00	O
am	O
Name	O
:	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
Location	O
:	O
[	O
**	O
Hospital1	O
641	O
**	O
]	O
Address	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
718	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2258	O
**	O
]	O
Appointment	O
:	O
Friday	O
[	O
**	O
2124-3-31	O
**	O
]	O
1:10	O
pm	O
Department	O
:	O
VASCULAR	O
SURGERY	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2124-4-19	O
**	O
]	O
at	O
2:45	O
PM	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1237	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Department	O
:	O
VASCULAR	O
SURGERY	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2124-4-19	O
**	O
]	O
at	O
3:30	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3469	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2625	O
**	O
]	O
Building	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
WEST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
Garage	O
Name	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name7	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Initial	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
Location	O
:	O
[	O
**	O
Hospital1	O
641	O
**	O
]	O
Address	O
:	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
34126	O
**	O
]	O
[	O
**	O
Location	O
1268	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
3883	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
38275	O
**	O
]	O
Appointment	O
:	O
Thursday	O
[	O
**	O
2124-4-27	O
**	O
]	O
2:10	O
pm	O
*	O
You	O
did	O
have	O
an	O
appointment	O
scheduled	O
for	O
tomorrow	O
which	O
has	O
been	O
cancelled	O
.	O
If	O
you	O
have	O
any	O
questions	O
or	O
concerns	O
please	O
call	O
the	O
office	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2154-7-12	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2154-7-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2110-6-3	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Nickel	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2186	O
**	O
]	O
Chief	O
Complaint	O
:	O
Dizziness	O
,	O
malaise	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
CC	O
:[	O
**	O
CC	O
Contact	O
Info	O
63737	O
**	O
]	O
.	O
HPI	O
:	O
44yo	O
man	O
with	O
h	O
/	O
o	O
hypertension	O
,	O
ESRD	O
on	O
hemodialysis	O
presenting	O
with	O
hypotension	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
63738	O
**	O
]	O
with	O
chest	O
pain	O
,	O
hypertensive	O
urgency	O
,	O
and	O
diastolic	O
CHF	O
.	O
Hospital	O
course	O
was	O
complicated	O
by	O
hematemesis	O
and	O
hemoptysis	O
.	O
He	O
was	O
discharged	O
on	O
five	O
new	O
antihypertensive	I-Drug
medications	O
,	O
which	O
he	O
reports	O
taking	O
regularly	O
for	O
the	O
past	O
week	O
.	O
He	O
was	O
dialyzed	O
today	O
with	O
4	O
kg	O
removed	O
,	O
and	O
then	O
took	O
all	O
his	O
medications	O
at	O
one	O
time	O
.	O
He	O
developed	O
a	O
posterior	O
headache	O
,	O
not	O
associated	O
with	O
dizziness	O
,	O
flashing	O
lights	O
,	O
nausea	O
,	O
or	O
visual	O
changes	O
,	O
and	O
presented	O
to	O
the	O
first	O
aide	O
booth	O
[	O
**	O
Hospital1	O
14630	O
**	O
]	O
where	O
he	O
works	O
.	O
Blood	O
pressure	O
on	O
evaluation	O
was	O
80/50	O
,	O
and	O
he	O
was	O
sent	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
for	O
further	O
evaluation	O
.	O
.	O
On	O
arrival	O
in	O
the	O
ED	O
T	O
97.5	O
HR	O
95	O
BP	O
81/50	O
RR	O
20	O
93	O
-	O
94	O
%	O
RA	O
.	O
He	O
was	O
mentating	O
normally	O
and	O
headache	O
had	O
improved	O
.	O
He	O
was	O
treated	O
with	O
2L	O
NS	I-Drug
,	O
and	O
BP	O
improved	O
to	O
91/52	O
(	O
MAP	O
60	O
)	O
.	O
He	O
denies	O
dizziness	O
,	O
vision	O
changes	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
fever	O
,	O
chills	O
,	O
abdominal	O
pain	O
,	O
nausea	O
,	O
diarrhea	O
,	O
dysuria	O
,	O
and	O
skin	O
rashes	O
.	O
.	O
PMH	O
:	O
Hypertension	O
ESRD	O
on	O
hemodialysis	O
(	O
M	O
,	O
W	O
,	O
F	O
)	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
HTN	O
disease	O
.	O
Meds	O
:	O
Renagel	I-Drug
800	O
mg	O
tid	O
Protonix	I-Drug
40	O
mg	O
daily	O
Aspirin	I-Drug
81	O
mg	O
daily	O
Calcium	I-Drug
acetate	O
667	O
mg	O
tid	O
Lisinopril	I-Drug
40	O
mg	O
daily	O
Imdur	I-Drug
60	O
mg	O
daily	O
Amlodipine	I-Drug
10	O
mg	O
daily	O
Diltiazem	I-Drug
480	O
mg	O
daily	O
.	O
All	O
:	O
nickel	O
-	O
rash	O
.	O
SHx	O
:	O
Patient	O
lives	O
at	O
[	O
**	O
Location	O
63739	O
**	O
]	O
shelter	O
.	O
He	O
works	O
as	O
a	O
cook	O
[	O
**	O
Hospital1	O
63740	O
**	O
]	O
.	O
Tob	O
:	O
[	O
**	O
12	O
-	O
16	O
**	O
]	O
ppd	O
x	O
15	O
yrs	O
EtOH	O
:	O
2	O
drinks	O
/	O
day	O
Illicits	O
:	O
occasional	O
crack	O
cocaine	O
.	O
FHx	O
:	O
Mother	O
with	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
,	O
diabetes	O
Father	O
d.	O
lung	O
ca	O
.	O
ROS	O
:	O
no	O
fever	O
,	O
chills	O
,	O
sweats	O
,	O
change	O
in	O
appetite	O
,	O
vision	O
changes	O
,	O
palpitations	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
cough	O
,	O
hemoptysis	O
,	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
dysuria	O
,	O
hematuria	O
,	O
skin	O
rashes	O
.	O
.	O
PE	O
:	O
T	O
97.5	O
HR	O
78	O
BP	O
92/52	O
RR	O
14	O
97	O
%	O
RA	O
GEN	O
:	O
comfortable	O
,	O
NAD	O
HEENT	O
:	O
PERRL	O
,	O
anicteric	O
,	O
MMM	O
,	O
OP	O
clear	O
Neck	O
:	O
JVP	O
nondistended	O
,	O
no	O
LAD	O
,	O
4	O
cm	O
lipoma	O
on	O
posterior	O
neck	O
CV	O
:	O
RRR	O
,	O
no	O
mrg	O
Resp	O
:	O
CTAB	O
Abd	O
:	O
+	O
BS	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
,	O
no	O
masses	O
,	O
no	O
HSM	O
Back	O
:	O
nontender	O
,	O
5	O
cm	O
lipoma	O
over	O
right	O
scapula	O
Ext	O
:	O
no	O
edema	O
,	O
1	O
+	O
DP	O
pulses	O
,	O
left	O
arm	O
fistula	O
Neuro	O
:	O
A&O	O
x3	O
,	O
strength	O
5/5	O
throughout	O
,	O
sensation	O
intact	O
grossly	O
.	O
Labs	O
:	O
see	O
end	O
of	O
record	O
CXR	O
:	O
pending	O
.	O
A	O
/	O
P	O
:	O
44yo	O
man	O
with	O
h	O
/	O
o	O
HTN	O
,	O
ESRD	O
on	O
HD	O
presenting	O
with	O
hypotension	O
.	O
#	O
.	O
Hypotension	I-Reason
:	O
This	O
episode	O
of	O
hypotension	O
is	O
most	O
likely	O
due	O
to	O
hypovolemia	O
c	O
/	O
b	O
medication	O
effect	O
as	O
it	O
occurred	O
after	O
the	O
patient	O
was	O
dialyzed	O
and	O
then	O
took	O
five	O
new	O
medications	O
simultaneously	O
at	O
max	O
dose	O
.	O
If	O
hypotension	O
persists	O
,	O
would	O
need	O
to	O
consider	O
cardiac	O
ischemia	O
,	O
CHF	O
,	O
sepsis	O
,	O
adrenal	O
insufficiency	O
,	O
but	O
these	O
seem	O
less	O
likely	O
.	O
Echo	O
done	O
during	O
the	O
last	O
hospitalization	O
showed	O
mild	O
LVH	O
,	O
dilated	O
LA	O
,	O
nml	O
EF	O
>	O
55	O
%	O
.	O
-	O
hold	O
all	O
antihypertensives	I-Drug
;	O
plan	O
to	O
add	O
back	O
slowly	O
at	O
reduced	O
doses	O
and	O
varying	O
schedule	O
-	O
rule	O
out	O
MI	O
-	O
bolus	O
NS	I-Drug
to	O
maintain	B-Reason
MAP	I-Reason
>	I-Reason
60	I-Reason
with	O
caution	O
given	O
ESRD	O
and	O
oliguric	O
.	O
#	O
.	O
ESRD	I-Reason
:	O
M	O
,	O
W	O
,	O
F	O
hemodialysis	O
.	O
-	O
will	O
notify	O
Renal	O
team	O
-	O
continue	O
Renagel	I-Drug
,	O
calcium	B-Drug
acetate	I-Drug
.	O
#	O
.	O
Metabolic	O
alkalosis	O
:	O
There	O
is	O
no	O
history	O
of	O
vomiting	O
or	O
diuretic	O
use	O
.	O
He	O
does	O
not	O
have	O
decreased	O
ventiliation	O
causing	O
hypercapnia	O
,	O
and	O
thus	O
this	O
is	O
not	O
likely	O
compensatory	O
.	O
-	O
recheck	O
chemistries	O
;	O
consider	O
ABG	O
if	O
persists	O
.	O
#	O
.	O
Hyperkalemia	I-Reason
:	O
Patient	O
was	O
dialyzed	O
today	O
.	O
monitor	O
closely	O
and	O
give	O
kayexelate	I-Drug
if	O
K	O
+	O
rises	O
further	O
.	O
#	O
.	O
FEN	O
:	O
renal	O
,	O
low	O
sodium	O
diet	O
.	O
#	O
.	O
PPx	I-Reason
:	O
pneumoboots	O
,	O
Protonix	I-Drug
.	O
#	O
.	O
Full	O
Code	O
Past	O
Medical	O
History	O
:	O
PMHx	O
:	O
denies	O
cardiac	O
history	O
1	O
)	O
ESRD	O
[	O
**	O
1	O
-	O
16	O
**	O
]	O
HTN	O
,	O
on	O
HD	O
MWF	O
.	O
On	O
HD	O
x	O
4	O
yrs	O
.	O
LUE	O
AVF	O
.	O
dry	O
wt	O
210	O
lbs	O
.	O
2	O
)	O
HTN	O
:	O
Social	O
History	O
:	O
SHx	O
:	O
smokes	O
<	O
[	O
**	O
12	O
-	O
16	O
**	O
]	O
ppd	O
X	O
15	O
yrs	O
.	O
He	O
drinks	O
2	O
alcoholic	O
beverages	O
daily	O
.	O
Crack	O
/	O
cocaine	O
use	O
a	O
few	O
times	O
per	O
month	O
.	O
Works	O
as	O
vendor	O
in	O
local	O
stadium	O
.	O
Family	O
History	O
:	O
FHx	O
:	O
Maternal	O
GM	O
and	O
GF	O
with	O
hypertension	O
.	O
Mother	O
with	O
diabetes	O
.	O
No	O
family	O
history	O
of	O
CAD	O
or	O
cancer	O
.	O
.	O
Physical	O
Exam	O
:	O
S	O
:	O
Pt	O
comfortable	O
,	O
denies	O
chest	O
pain	O
;	O
denies	O
dizziness	O
,	O
denies	O
swelling	O
or	O
shortness	O
of	O
breath	O
.	O
No	O
fevers	O
,	O
chills	O
,	O
sweats	O
.	O
Pt	O
would	O
like	O
to	O
go	O
home	O
today	O
.	O
PE	O
:	O
T	O
98.1	O
;	O
HR	O
87	O
,	O
(	O
76	O
-	O
87	O
)	O
;	O
BP	O
100/64	O
(	O
111-100/62	O
-	O
70	O
)	O
;	O
RR	O
18	O
;	O
O2	O
sat	O
99	O
%	O
RA	O
GEN	O
:	O
comfortable	O
,	O
NAD	O
HEENT	O
:	O
anicteric	O
,	O
MMM	O
Neck	O
:	O
JVP	O
nondistended	O
,	O
lipoma	O
on	O
neck	O
unchanged	O
CV	O
:	O
RR	O
,	O
no	O
murmur	O
or	O
rub	O
or	O
gallop	O
Resp	O
:	O
CTAB	O
Abd	O
:	O
Soft	O
,	O
NT	O
,	O
ND	O
.	O
Ext	O
:	O
no	O
edema	O
,	O
left	O
arm	O
fistula	O
Neuro	O
:	O
A&O	O
x3	O
.	O
Pertinent	O
Results	O
:	O
Admission	O
laboratories	O
:	O
[	O
**	O
2154-7-12	O
**	O
]	O
09:44	O
PM	O
BLOOD	O
Glucose	O
-	O
78	O
UreaN	O
-	O
24	O
*	O
Creat	O
-	O
6.1	O
*	O
#	O
Na	O
-	O
144	O
K	O
-	O
5.4	O
*	O
Cl	O
-	O
97	O
HCO3	O
-	O
33	O
*	O
AnGap	O
-	O
19	O
[	O
**	O
2154-7-12	O
**	O
]	O
09:44	O
PM	O
BLOOD	O
WBC	O
-	O
8.8	O
RBC	O
-	O
4.13	O
*	O
#	O
Hgb	O
-	O
12.9	O
*	O
#	O
Hct	O
-	O
40.8	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
31.3	O
MCHC	O
-	O
31.7	O
RDW	O
-	O
15.4	O
Plt	O
Ct	O
-	O
271	O
[	O
**	O
2154-7-12	O
**	O
]	O
09:44	O
PM	O
BLOOD	O
PT	O
-	O
13.0	O
PTT	O
-	O
28.3	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2154-7-12	O
**	O
]	O
09:44	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
271	O
Cardiac	O
enzyme	O
cycle	O
:	O
[	O
**	O
2154-7-12	O
**	O
]	O
09:44	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
0.11	O
*	O
[	O
**	O
2154-7-13	O
**	O
]	O
06:15	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.10	O
*	O
[	O
**	O
2154-7-13	O
**	O
]	O
01:30	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.11	O
*	O
HD	O
#	O
2	O
[	O
**	O
2154-7-13	O
**	O
]	O
06:15	O
AM	O
BLOOD	O
Glucose	O
-	O
112	O
*	O
UreaN	O
-	O
33	O
*	O
Creat	O
-	O
7.5	O
*	O
#	O
Na	O
-	O
139	O
K	O
-	O
4.2	O
Cl	O
-	O
97	O
HCO3	O
-	O
29	O
AnGap	O
-	O
17	O
[	O
**	O
2154-7-13	O
**	O
]	O
06:15	O
AM	O
BLOOD	O
Calcium	O
-	O
10.0	O
Phos	O
-	O
4.6	O
*	O
Mg	O
-	O
1.8	O
Brief	O
Hospital	O
Course	O
:	O
This	O
44	O
year	O
-	O
old	O
gentleman	O
with	O
a	O
history	O
of	O
hypertension	O
,	O
end	O
-	O
stage	O
renal	O
disease	O
on	O
hemodialysis	O
,	O
and	O
illicit	O
drug	O
abuse	O
.	O
He	O
had	O
had	O
a	O
recent	O
admission	O
to	O
this	O
hospital	O
for	O
hypertensive	O
urgency	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
hypotension	I-Ade
after	O
taking	O
his	O
5	O
BP	B-Drug
medication	I-Drug
just	O
subsequent	O
to	O
his	O
dialysis	O
yesterday	O
.	O
His	O
blood	O
pressure	O
normalized	O
after	O
administration	O
of	O
2	O
boluses	O
of	O
1L	O
normal	B-Drug
saline	I-Drug
.	O
He	O
was	O
admitted	O
to	O
the	O
medicine	O
service	O
.	O
Throughout	O
his	O
brief	O
stay	O
,	O
he	O
remained	O
hemodynamically	O
stable	O
with	O
blood	O
pressure	O
in	O
the	O
normotensive	O
range	O
.	O
At	O
no	O
time	O
did	O
he	O
exhibit	O
signs	O
of	O
cardiogenic	O
shock	O
or	O
sepsis	O
.	O
It	O
was	O
felt	O
that	O
his	O
symptomatology	O
and	O
hypotension	O
was	O
related	O
to	O
his	O
taking	O
blood	B-Drug
pressure	I-Drug
medications	I-Drug
to	O
soon	O
after	O
his	O
dialysis	O
session	O
.	O
It	O
was	O
felt	O
that	O
it	O
was	O
safe	O
for	O
the	O
patient	O
to	O
go	O
home	O
.	O
He	O
was	O
advised	O
to	O
not	O
take	O
any	O
of	O
his	O
blood	B-Drug
pressure	I-Drug
medications	I-Drug
in	O
the	O
4	O
-6	O
hour	O
time	O
period	O
after	O
each	O
dialysis	O
session	O
and	O
given	O
a	O
prescription	O
and	O
schedule	O
to	O
take	O
two	O
of	O
his	O
antihypertensive	I-Drug
medications	O
in	O
the	O
morning	O
,	O
and	O
two	O
at	O
night	O
.	O
This	O
was	O
also	O
communicated	O
to	O
the	O
attending	O
physician	O
that	O
day	O
,	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
4154	O
**	O
]	O
who	O
agreed	O
with	O
this	O
.	O
Discharge	O
of	O
patient	O
was	O
to	O
be	O
arranged	O
pending	O
final	O
evaluation	O
from	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
4154	O
**	O
]	O
.	O
The	O
patient	O
,	O
however	O
,	O
grew	O
impatient	O
saying	O
he	O
needed	O
to	O
be	O
at	O
work	O
soon	O
.	O
He	O
was	O
given	O
a	O
letter	O
excusing	O
him	O
from	O
work	O
and	O
he	O
seemed	O
satisfied	O
with	O
this	O
and	O
said	O
he	O
would	O
wait	O
for	O
the	O
attending	O
.	O
The	O
patient	O
,	O
however	O
,	O
did	O
not	O
wait	O
for	O
the	O
attending	O
's	O
final	O
evaluation	O
and	O
subsequently	O
left	O
AMA	O
soon	O
thereafter	O
.	O
Attending	O
was	O
notified	O
.	O
In	O
summary	O
this	O
is	O
a	O
44	O
year	O
-	O
old	O
gentleman	O
with	O
hypertension	O
and	O
end	O
stage	O
renal	O
disease	O
on	O
hemodialysiswho	O
presented	O
with	O
hypotension	O
after	O
taking	O
all	O
four	O
blood	B-Drug
pressure	I-Drug
medications	I-Drug
shorly	O
after	O
a	O
hemodialysis	O
session	O
.	O
His	O
hypotension	O
resolved	O
and	O
was	O
hemodynamically	O
stable	O
upon	O
leaving	O
AMA	O
.	O
Reasons	O
for	O
leaving	O
AMA	O
,	O
not	O
entirely	O
clear	O
.	O
Issues	O
and	O
plan	O
as	O
follows	O
:	O
.	O
1	O
)	O
Hypotension	O
:	O
Likely	O
from	O
taking	O
BP	B-Drug
medications	I-Drug
too	O
soon	O
after	O
HD	O
.	O
Given	O
schedule	O
for	O
taking	O
2	O
medications	O
in	O
morning	O
,	O
two	O
at	O
night	O
.	O
Advised	O
not	O
to	O
take	O
antihypertensive	B-Drug
medications	I-Drug
at	O
least	O
4	O
-	O
6	O
hours	O
after	O
hemodialysis	O
.	O
-	O
ruled	O
out	O
for	O
MI	O
.	O
2	O
)	O
ESRD	I-Reason
:	O
M	O
,	O
W	O
,	O
F	O
hemodialysis	O
.	O
-	O
continue	O
Renagel	I-Drug
,	O
calcium	I-Drug
acetate	O
-	O
Renal	O
service	O
notified	O
.	O
.	O
3	O
)	O
Metabolic	O
abnormalities	O
:	O
Alkalosis	O
/	O
hyperkalemia	O
:	O
K	O
Trended	O
down	O
to	O
normal	O
range	O
,	O
alkalosis	O
resolved	O
,	O
long	O
term	O
managment	O
with	O
dialysis	O
.	O
4	O
)	O
FEN	O
:	O
renal	O
,	O
low	O
sodium	O
diet	O
.	O
5	O
)	O
PPx	I-Reason
:	O
pneumoboots	O
,	O
Protonix	I-Drug
.	O
6	O
)	O
Full	O
Code	O
7	O
)	O
Left	O
AMA	O
,	O
reasons	O
unclear	O
.	O
It	O
was	O
safe	O
for	O
him	O
to	O
leave	O
although	O
attending	O
physician	O
needed	O
to	O
see	O
him	O
for	O
final	O
clearance	O
.	O
Claimed	O
he	O
needed	O
to	O
return	O
to	O
work	O
so	O
given	O
note	O
excusing	O
him	O
from	O
work	O
.	O
This	O
did	O
not	O
prevent	O
him	O
from	O
leaving	O
AMA	O
.	O
Medications	O
on	O
Admission	O
:	O
Renagel	I-Drug
800	O
mg	O
tid	O
Protonix	I-Drug
40	O
mg	O
daily	O
Aspirin	I-Drug
81	O
mg	O
daily	O
Calcium	I-Drug
acetate	O
667	O
mg	O
tid	O
Lisinopril	I-Drug
40	O
mg	O
daily	O
Imdur	I-Drug
60	O
mg	O
daily	O
Amlodipine	I-Drug
10	O
mg	O
daily	O
Diltiazem	I-Drug
480	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Sevelamer	I-Drug
800	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Pantoprazole	I-Drug
Sodium	O
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
3	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Calcium	B-Drug
Acetate	I-Drug
667	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
5	O
.	O
Lisinopril	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
morning	O
.	O
6	O
.	O
Imdur	I-Drug
60	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
at	O
bedtime	O
.	O
7	O
.	O
Amlodipine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
8	O
.	O
Diltiazem	I-Drug
HCl	O
240	O
mg	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
Every	O
morning	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Hypotension	I-Ade
from	O
overdose	O
of	O
antihypertensive	B-Drug
medications	I-Drug
.	O
End	O
stage	O
renal	O
disease	O
,	O
on	O
hemodialysis	O
.	O
Discharge	O
Condition	O
:	O
Good	O
.	O
Blood	O
pressure	O
in	O
normal	O
range	O
.	O
No	O
dizziness	O
or	O
lightheadedness	O
.	O
No	O
chest	O
pain	O
.	O
Discharge	O
Instructions	O
:	O
Please	O
wait	O
at	O
least	O
4	O
hours	O
after	O
your	O
hemodialysis	O
before	O
taking	O
any	O
of	O
your	O
medications	O
.	O
Please	O
return	O
if	O
you	O
feel	O
dizzy	O
or	O
lightheaded	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
at	O
the	O
[	O
**	O
Hospital	O
3501	O
**	O
]	O
Medical	O
Foundation	O

Admission	O
Date	O
:	O
[	O
**	O
2173-11-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2173-11-18	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2112-8-6	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3021	O
**	O
]	O
Chief	O
Complaint	O
:	O
Dyspnea	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
ONCO	O
-	O
MED	O
HOSPITALIST	O
ADMISSION	O
NOTE	O
.	O
61	O
year	O
old	O
gentleman	O
with	O
COPD	O
,	O
stage	O
IV	O
NSCLC	O
mucinous	O
adenocarcinoma	O
and	O
recent	O
PE	O
who	O
presents	O
with	O
dyspnea	O
.	O
He	O
reports	O
sudden	O
-	O
onset	O
worsening	O
of	O
respiratory	O
status	O
on	O
the	O
morning	O
of	O
admission	O
without	O
associated	O
productive	O
cough	O
,	O
fevers	O
/	O
chills	O
,	O
CP	O
,	O
or	O
other	O
symptoms	O
.	O
.	O
Of	O
note	O
,	O
patient	O
was	O
recently	O
readmitted	O
in	O
early	O
[	O
**	O
2173-10-28	O
**	O
]	O
for	O
SOB	O
/	O
dyspnea	O
,	O
at	O
which	O
time	O
a	O
new	O
LLL	B-Reason
consolidation	I-Reason
was	O
seen	O
.	O
He	O
was	O
provided	O
with	O
one	O
dose	O
of	O
Vanc	I-Drug
/	O
Cefepime	I-Drug
,	O
and	O
started	O
on	O
a	O
morphine	I-Drug
drip	O
in	O
concert	O
with	O
patient	O
's	O
HCP	I-Reason
as	O
well	O
as	O
patient	O
wishes	O
.	O
Improvement	O
in	O
clinical	O
status	O
was	O
noted	O
overnight	O
and	O
his	O
morphine	I-Drug
drip	O
was	O
discontinued	O
.	O
His	O
acute	B-Reason
respiratory	I-Reason
decompensation	O
was	O
attributed	O
to	O
a	O
mucus	O
plug	O
,	O
aspiration	O
,	O
perhaps	O
with	O
contributing	O
atalectasis	O
.	O
He	O
was	O
continued	O
albuterol	I-Drug
/	O
ipratropium	I-Drug
nebulizers	O
,	O
as	O
well	O
as	O
enoxaparin	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
for	O
his	O
recent	B-Reason
PE	I-Reason
's	I-Reason
.	O
Antibiotics	I-Drug
were	O
not	O
resumed	O
at	O
time	O
of	O
discharge	O
.	O
After	O
discharge	O
,	O
blood	O
cultures	O
from	O
[	O
**	O
2173-11-3	O
**	O
]	O
grew	O
Fusobacterium	O
Nucleatum	O
in	O
one	O
out	O
of	O
two	O
bottles	O
.	O
The	O
patient	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
on	O
[	O
**	O
2173-11-6	O
**	O
]	O
regarding	O
this	O
lab	O
result	O
,	O
and	O
did	O
not	O
feel	O
any	O
different	O
since	O
discharge	O
from	O
the	O
hospital	O
.	O
Repeat	O
blood	O
cultures	O
at	O
his	O
outpatient	O
oncologist	O
failed	O
to	O
reveal	O
positive	O
cultures	O
.	O
Since	O
his	O
recent	O
discharge	O
,	O
discussion	O
regarding	O
hospice	O
care	O
has	O
been	O
continued	O
with	O
his	O
oncologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
45322	O
**	O
]	O
,	O
given	O
the	O
patient	O
's	O
poor	O
prognosis	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vitals	O
recorded	O
were	O
a	O
RR	O
of	O
32	O
.	O
Labs	O
showed	O
hyponatremia	O
with	O
a	O
sodium	O
of	O
129	O
,	O
otherwise	O
unremarkable	O
CMP	O
.	O
CBC	O
with	O
WBC	O
count	O
of	O
16.0	O
with	O
97.3	O
PMN	O
's	O
and	O
2.4	O
%	O
lymphocytes	O
.	O
HCT	O
of	O
30.6	O
,	O
platelets	O
of	O
508	O
.	O
Coags	O
showed	O
INR	O
of	O
1.2	O
,	O
PTT	O
of	O
31.8	O
.	O
CXR	O
showed	O
Stable	O
right	O
-	O
sided	O
pleural	O
effusion	O
and	O
post-obstructive	O
consolidation	O
,	O
increasing	O
left	B-Reason
pleural	I-Reason
effusion	O
with	O
basal	B-Reason
atelectasis	I-Reason
.	O
Patient	O
had	O
his	O
pleurex	O
catheter	O
drained	O
with	O
300	O
cc	O
's	O
of	O
straw	O
colored	O
fluid	O
aspirated	O
.	O
He	O
was	O
administered	O
albuterol	B-Drug
/	I-Drug
ipratropium	I-Drug
nebs	O
,	O
vancomycin	I-Drug
/	O
zosyn	I-Drug
,	O
as	O
well	O
as	O
lorazepam	I-Drug
and	O
methylprednisolone	I-Drug
.	O
.	O
In	O
MICU	O
,	O
VS	O
:	O
96.9	O
103131/74	O
14	O
90	O
%	O
4L	O
NC	O
.	O
He	O
endorsed	O
feeling	O
hungry	O
.	O
His	O
respiratory	O
status	O
stabilized	O
after	O
clearing	O
mucous	O
plug	O
,	O
but	O
still	O
requiring	O
4	O
-	O
5L	O
NRB	O
.	O
No	O
antibiotics	I-Drug
were	O
given	O
as	O
low	O
suspicion	O
for	O
acute	O
infection	O
.	O
He	O
improved	O
with	O
time	O
,	O
albuterol	I-Drug
/	O
ipratropium	I-Drug
nebs	O
.	O
He	O
was	O
continued	O
on	O
lovenox	I-Drug
for	O
recent	B-Reason
PE	I-Reason
.	O
In	O
addition	O
,	O
as	O
a	O
large	O
component	O
of	O
dyspnea	O
was	O
anxiety	I-Reason
,	O
patient	O
was	O
placed	O
on	O
standing	O
clonazepam	I-Drug
1	O
mg	O
TID	O
.	O
Palliative	O
care	O
was	O
consulted	O
for	O
assistance	O
with	O
pain	O
control	O
and	O
was	O
made	O
DNR	O
/	O
DNI	O
.	O
Of	O
note	O
,	O
he	O
was	O
found	O
to	O
be	O
growing	O
G	B-Reason
+	I-Reason
cocci	O
in	O
1	O
of	O
2	O
Bcx	O
bottles	O
,	O
was	O
started	O
on	O
IV	O
vancomycin	I-Drug
and	O
was	O
transferred	O
out	O
of	O
ICU	O
.	O
.	O
ROS	O
:	O
He	O
denies	O
F	O
/	O
C	O
/	O
S	O
,	O
N	O
/	O
V	O
,	O
headache	O
,	O
dizziness	O
,	O
chest	O
pain	O
,	O
abdominal	O
pain	O
,	O
back	O
pain	O
,	O
constipation	O
,	O
diarrhea	O
,	O
hematochezia	O
,	O
urinary	O
symptoms	O
,	O
or	O
rash	O
.	O
All	O
other	O
ROS	O
were	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Metastatic	B-Reason
NSCLC	I-Reason
to	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
500	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
,	O
with	O
malignant	O
effusion	O
,	O
Pleurex	O
placed	O
[	O
**	O
2173-9-16	O
**	O
]	O
,	O
s	O
/	O
p	O
carboplatin	I-Drug
/	O
paclitaxel	I-Drug
x2	O
cycles	O
,	O
then	O
pemetrexad	I-Drug
x2	O
cycles	O
(	O
last	O
given	O
[	O
**	O
2173-11-11	O
**	O
]	O
)	O
.	O
2	O
.	O
PE	O
,	O
9	O
/	O
[	O
**	O
2172	O
**	O
]	O
.	O
3	O
.	O
CVA	O
.	O
4	O
.	O
Carotid	O
stenosis	O
s	O
/	O
p	O
CEA	O
[	O
**	O
2173-7-31	O
**	O
]	O
.	O
5	O
.	O
Hypertension	O
.	O
6	O
.	O
Ocular	O
migraine	O
.	O
7	O
.	O
Alcohol	O
abuse	O
.	O
8	O
.	O
Hyperlipidemia	O
.	O
Social	O
History	O
:	O
-	O
Tobacco	O
:	O
Smoked	O
2	O
PPD	O
age	O
20	O
to	O
61	O
.	O
-	O
Alcohol	O
:	O
Former	O
heavy	O
drinker	O
,	O
drinks	O
[	O
**	O
11	O
-	O
29	O
**	O
]	O
bottle	O
of	O
wine	O
per	O
night	O
.	O
-	O
Illicits	O
:	O
Denies	O
.	O
-	O
Occupation	O
:	O
ECG	O
engineer	O
.	O
-	O
Exposures	O
:	O
Denies	O
.	O
Family	O
History	O
:	O
Mother	O
-	O
colon	O
cancer	O
at	O
83	O
s	O
/	O
p	O
resection	O
,	O
still	O
alive	O
at	O
88	O
,	O
hypertension	O
.	O
Father	O
-	O
died	O
of	O
multiple	O
myeloma	O
at	O
age	O
80	O
,	O
high	O
cholesterol	O
.	O
Sister	O
1	O
-	O
died	O
of	O
malignant	O
brain	O
tumor	O
at	O
age	O
24	O
.	O
Sister	O
2	O
-	O
hypertension	O
.	O
No	O
FH	O
of	O
stroke	O
,	O
diabetes	O
.	O
Physical	O
Exam	O
:	O
Admission	O
to	O
Floor	O
Physical	O
Exam	O
Vitals	O
:	O
97.8	O
108/62	O
111	O
21	O
97	O
%	O
NC	O
5L	O
,	O
0/10	O
pain	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
,	O
dyspnia	O
occasionally	O
interferes	O
with	O
his	O
ability	O
to	O
complete	O
sentences	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
Lungs	O
:	O
Diminished	O
BS	O
at	O
bases	O
b	O
/	O
l	O
,	O
R	O
>	O
L	O
CV	O
:	O
Tachycardic	O
~	O
110	O
,	O
regular	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2173-11-15	O
**	O
]	O
11:30	O
AM	O
WBC	O
-	O
16.0	O
*	O
#	O
RBC	O
-	O
3.16	O
*	O
HGB	O
-	O
9.3	O
*	O
HCT	O
-	O
30.6	O
*	O
MCV	O
-	O
97	O
MCH	O
-	O
29.6	O
MCHC	O
-	O
30.5	O
*	O
RDW	O
-	O
17.8	O
*	O
[	O
**	O
2173-11-15	O
**	O
]	O
11:30	O
AM	O
NEUTS	O
-	O
97.3	O
*	O
LYMPHS	O
-	O
2.4	O
*	O
MONOS	O
-	O
0.2	O
*	O
EOS	O
-	O
0.1	O
BASOS	O
-	O
0	O
[	O
**	O
2173-11-15	O
**	O
]	O
11:30	O
AM	O
PLT	O
COUNT	O
-	O
508	O
*	O
[	O
**	O
2173-11-15	O
**	O
]	O
11:30	O
AM	O
PT	O
-	O
12.9	O
*	O
PTT	O
-	O
31.8	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2173-11-15	O
**	O
]	O
11:30	O
AM	O
GLUCOSE	O
-	O
124	O
*	O
UREA	O
N	O
-	O
12	O
CREAT	O
-	O
0.4	O
*	O
SODIUM	O
-	O
129	O
*	O
POTASSIUM	O
-	O
4.4	O
CHLORIDE	O
-	O
92	O
*	O
TOTAL	O
CO2	O
-	O
31	O
ANION	O
GAP	O
-	O
10	O
.	O
Thoracentesis	O
Fluid	O
[	O
**	O
2173-11-15	O
**	O
]	O
12:00	O
PM	O
PLEURAL	O
WBC	O
-	O
50	O
*	O
RBC	O
-	O
2725	O
*	O
POLYS	O
-	O
67	O
*	O
LYMPHS	O
-	O
24	O
*	O
MONOS	O
-	O
7	O
*	O
MESOTHELI	O
-	O
2	O
*	O
.	O
[	O
**	O
2173-11-15	O
**	O
]	O
CTA	O
CHEST	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Extensive	O
right	O
lung	O
mass	O
with	O
post	O
obstructive	O
collapse	O
of	O
the	O
right	O
upper	O
and	O
middle	O
lobes	O
.	O
2	O
.	O
No	O
pulmonary	O
emboli	O
.	O
The	O
right	O
upper	O
and	O
middle	O
lobe	O
pulmonary	O
arteries	O
are	O
attenuated	O
by	O
the	O
mass	O
.	O
3	O
.	O
Pleural	O
effusions	O
increased	O
since	O
the	O
preceding	O
exam	O
14	O
days	O
ago	O
.	O
4	O
.	O
Extensive	O
sclerotic	O
metastases	O
to	O
the	O
spine	O
and	O
sternum	O
.	O
5	O
.	O
Ground	O
glass	O
opacity	O
in	O
left	O
apex	O
is	O
non-specific	O
but	O
could	O
represent	O
infectious	O
process	O
.	O
.	O
[	O
**	O
2173-11-15	O
**	O
]	O
CXR	O
:	O
IMPRESSION	O
:	O
Stable	O
appearance	O
of	O
right	O
-	O
sided	O
pleural	O
effusion	O
and	O
post-obstructive	O
consolidation	O
in	O
the	O
setting	O
of	O
a	O
known	O
right	O
chest	O
mass	O
;	O
increasing	O
left	O
pleural	O
effusion	O
with	O
basal	O
atelectasis	O
.	O
.	O
[	O
**	O
2173-11-15	O
**	O
]	O
CXR	O
:	O
IMPRESSION	O
:	O
Interval	O
decrease	O
in	O
left	O
pleural	O
effusion	O
with	O
associated	O
atelectasis	O
and	O
no	O
pneumothorax	O
.	O
.	O
DISCHARGE	O
LABS	O
:	O
[	O
**	O
2173-11-17	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
WBC	O
-	O
10.0	O
RBC	O
-	O
2.87	O
*	O
Hgb	O
-	O
8.9	O
*	O
Hct	O
-	O
28.7	O
*	O
MCV	O
-	O
100	O
*	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
31.2	O
RDW	O
-	O
17.6	O
*	O
Plt	O
Ct	O
-	O
382	O
[	O
**	O
2173-11-16	O
**	O
]	O
06:36	O
AM	O
BLOOD	O
Neuts	O
-	O
96.7	O
*	O
Lymphs	O
-	O
2.3	O
*	O
Monos	O
-	O
0.6	O
*	O
Eos	O
-	O
0.2	O
Baso	O
-	O
0.1	O
[	O
**	O
2173-11-17	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
PT	O
-	O
12.2	O
PTT	O
-	O
27.8	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2173-11-17	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
Glucose	O
-	O
93	O
UreaN	O
-	O
9	O
Creat	O
-	O
0.2	O
*	O
Na	O
-	O
129	O
*	O
K	O
-	O
4.0	O
Cl	O
-	O
92	O
*	O
HCO3	O
-	O
31	O
AnGap	O
-	O
10	O
[	O
**	O
2173-11-17	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
3.6	O
Mg	O
-	O
1.5	O
*	O
Brief	O
Hospital	O
Course	O
:	O
61yo	O
man	O
with	O
metastatic	O
NSCLC	O
to	O
ribs	O
,	O
malignant	O
effusion	O
,	O
and	O
encasement	O
of	O
right	O
hilum	O
,	O
on	O
enoxaparin	I-Drug
for	O
PE	I-Reason
,	O
Pleurex	O
catheter	O
for	O
malignant	O
effusion	O
,	O
hx	O
of	O
CVA	O
admitted	O
to	O
the	O
ICU	O
for	O
acute	O
dyspnea	O
.	O
He	O
initially	O
required	O
non-rebreather	O
O2m	B-Drug
byt	O
after	O
expectorating	O
a	O
mucous	O
plug	O
,	O
his	O
O2	I-Drug
requirement	O
decreased	O
to	O
5L	O
.	O
Palliative	O
care	O
consulted	O
.	O
Clonazepam	I-Drug
added	O
for	O
anxiety	I-Reason
.	O
Code	O
status	O
changed	O
to	O
DNR	O
/	O
DNI	O
.	O
Blood	B-Reason
cultures	I-Reason
grew	I-Reason
GPC	O
in	O
clusters	O
and	O
GPC	O
in	O
chains	O
,	O
two	O
separate	O
species	O
.	O
Started	O
on	O
vancomycin	I-Drug
.	O
He	O
continued	O
to	O
decline	O
requiring	O
more	O
oxygen	I-Drug
again	O
despite	O
suctioning	O
.	O
He	O
was	O
placed	O
on	O
a	O
morphine	I-Drug
gtt	O
for	O
comfort	I-Reason
and	O
died	O
[	O
**	O
2173-11-18	O
**	O
]	O
at	O
16:20	O
PM	O
.	O
.	O
#	O
Dyspnea	O
/	O
hypoxia	O
:	O
Due	O
to	O
malignancy	O
and	O
malignant	O
effusion	O
+	O
/	O
-	O
post-obstructive	O
pneumonia	O
.	O
Required	O
non-rebreather	O
in	O
ICU	O
,	O
but	O
improved	O
after	O
mucous	O
plug	O
expectorated	O
.	O
Blood	O
cultures	O
growing	O
GPC	O
in	O
clusters	O
and	O
GPCs	O
in	O
chains	O
.	O
Started	O
vancomycin	I-Drug
[	O
**	O
2173-11-16	O
**	O
]	O
for	O
GPC	B-Reason
bacteremia	I-Reason
,	O
leukocytosis	O
,	O
increased	O
mucous	O
production	O
,	O
leukocytosis	O
,	O
tachycardia	O
,	O
and	O
tachypnea	O
--	O
>	O
sepsis	I-Reason
.	O
Continued	O
albuterol	I-Drug
prn	O
,	O
fluticasone	I-Drug
-	O
salmeterol	O
.	O
Tiotropium	I-Drug
changed	O
to	O
ipratropium	I-Drug
nebs	O
.	O
Continued	O
guaifenesin	B-Drug
/	I-Drug
codeine	I-Drug
and	O
benzonatate	I-Drug
for	O
cough	I-Reason
.	O
O2	I-Drug
support	O
as	O
needed	O
.	O
Morphine	I-Drug
for	O
dyspnea	I-Reason
.	O
Lorazepam	I-Drug
for	O
respiratory	B-Reason
distress	I-Reason
.	O
Suctioned	O
for	O
worsening	O
hypoxia	O
,	O
but	O
no	O
improvement	O
.	O
Trigger	O
for	O
hypoxia	O
88	O
%	O
on	O
6L	O
[	O
**	O
2173-11-18	O
**	O
]	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
and	O
his	O
girlfriend	O
agreed	O
to	O
comfort	O
care	O
only	O
and	O
inpatient	O
hospice	O
.	O
He	O
was	O
placed	O
on	O
a	O
morphine	I-Drug
gtt	O
for	O
comfort	I-Reason
and	O
died	O
[	O
**	O
2173-11-18	O
**	O
]	O
at	O
16:20	O
PM	O
.	O
.	O
#	O
Metastatic	B-Reason
NSCLC	I-Reason
:	O
Last	O
given	O
pemetrexad	I-Drug
[	O
**	O
2173-11-11	O
**	O
]	O
.	O
Palliative	O
care	O
consulted	O
.	O
Stopped	O
folate	I-Drug
considering	O
goals	O
of	O
care	O
.	O
.	O
#	O
Leukocytosis	O
:	O
Due	O
to	O
sepsis	O
.	O
No	O
labs	O
considering	O
goals	O
of	O
care	O
.	O
.	O
#	O
Anemia	I-Ade
:	O
Likely	O
chemo	I-Drug
induced	O
and	O
anemia	O
of	O
inflammation	O
.	O
No	O
labs	O
.	O
.	O
#	O
Chronic	B-Reason
PE	I-Reason
:	O
Stopped	O
enoxaparin	I-Drug
for	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3225	O
**	O
]	O
.	O
.	O
#	O
HTN	I-Reason
:	O
Held	O
metoprolol	I-Drug
and	O
hydralazine	I-Drug
due	O
to	O
hypotension	I-Ade
.	O
.	O
#	O
Anxiety	I-Reason
:	O
Added	O
clonazepam	I-Drug
.	O
.	O
#	O
Pain	B-Reason
(	I-Reason
rib	I-Reason
)	I-Reason
:	O
Continue	O
MSContin	I-Drug
.	O
Increased	O
morphine	I-Drug
IV	O
PRN	O
for	O
pain	I-Reason
and	O
dyspnea	I-Reason
.	O
.	O
#	O
FEN	O
:	O
Regular	O
diet	O
.	O
Hyponatremia	O
possibly	O
SIADH	O
stable	O
.	O
Repleted	O
hypomagnesemia	O
.	O
.	O
#	O
GI	B-Reason
PPx	I-Reason
:	O
PPI	I-Drug
and	O
bowel	O
regimen	O
.	O
.	O
#	O
DVT	B-Reason
PPx	I-Reason
:	O
Enoxaparin	I-Drug
for	O
PE	O
stopped	O
for	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3225	O
**	O
]	O
.	O
.	O
#	O
Precautions	O
:	O
None	O
.	O
.	O
#	O
Lines	O
:	O
Peripheral	O
.	O
.	O
#	O
CODE	O
:	O
DNR	O
/	O
DNI	O
,	O
[	O
**	O
Month	O
/	O
Day	O
/	O
Year	O
3225	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
Benzonatate	B-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
[	O
**	O
11	O
-	O
29	O
**	O
]	O
Capsules	O
PO	O
TID	O
prn	O
Metoprolol	B-Drug
succinate	I-Drug
50	O
mg	O
Tablet	O
Extended	O
Release	O
1	O
tab	O
po	O
BID	O
Morphine	I-Drug
30	O
mg	O
Tablet	O
Extended	O
Release	O
1	O
po	O
q12hrs	O
Docusate	I-Drug
sodium	O
100	O
mg	O
Capsule	O
1	O
po	O
BID	O
Tiotropium	I-Drug
bromide	O
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
Sig	O
:	O
1	O
cap	O
qday	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
1	O
po	O
q6hrs	O
prn	O
Folic	B-Drug
acid	I-Drug
1	O
mg	O
Tablet	O
1	O
po	O
qday	O
Fluticasone	I-Drug
-	O
salmeterol	O
100	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
1	O
inh	O
[	O
**	O
Hospital1	O
**	O
]	O
Enoxaparin	I-Drug
80	O
mg	O
/	O
0.8	O
mL	O
Syringe	O
1	O
SC	O
q12	O
hrs	O
Albuterol	B-Drug
sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
PRN	O
SOB	I-Reason
Dexamethasone	I-Drug
4	O
mg	O
Tablet	O
daily	O
Lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
1	O
po	O
q4	O
hours	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
Hydralazine	I-Drug
50	O
mg	O
Tablet	O
1	O
PO	O
TID	O
Megestrol	I-Drug
20	O
mg	O
1	O
po	O
qday	O
Ondansetron	B-Drug
8	O
mg	O
Tablet	O
ODT	O
PO	O
three	O
times	O
a	O
day	O
PRN	O
Prochlorperazine	I-Drug
maleate	O
10	O
mg	O
Tablet	O
1	O
PO	O
three	O
times	O
PRN	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
1	O
tab	O
PO	O
twice	O
a	O
day	O
.	O
Nicotine	I-Drug
7	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Transdermal	O
qday	O
Discharge	O
Medications	O
:	O
N	O
/	O
A.	O
Discharge	O
Disposition	O
:	O
Home	O
with	O
Service	O
Discharge	O
Diagnosis	O
:	O
Sepsis	O
(	O
severe	O
blood	O
infection	O
)	O
Hypoxia	O
(	O
low	O
oxygen	O
levels	O
)	O
Shortness	O
of	O
breath	O
Non-small	O
cell	O
lung	O
cancer	O
Malignant	O
effusion	O
(	O
fluid	O
in	O
the	O
lungs	O
from	O
cancer	O
)	O
Anxiety	O
Death	O
Discharge	O
Condition	O
:	O
Deceased	O
.	O
Discharge	O
Instructions	O
:	O
N	O
/	O
A.	O
Deceased	O
.	O
Followup	O
Instructions	O
:	O
N	O
/	O
A.	O
Deceased	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2186-10-11	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2186-12-19	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Wellbutrin	I-Drug
/	O
Kaopectate	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4052	O
**	O
]	O
Chief	O
Complaint	O
:	O
Non-responsiveness	O
and	O
hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
T	O
tube	O
placement	O
and	O
cholangiogram	O
EGD	O
x	O
4	O
History	O
of	O
Present	O
Illness	O
:	O
Patient	O
is	O
an	O
84	O
year	O
old	O
female	O
with	O
history	O
of	O
dementia	O
,	O
hypertension	O
,	O
type	O
two	O
diabetes	O
mellitus	O
,	O
bipolar	O
disease	O
who	O
presents	O
with	O
two	O
weeks	O
of	O
declining	O
social	O
functioning	O
and	O
PO	O
intake	O
,	O
usually	O
able	O
to	O
walk	O
with	O
walker	O
and	O
perform	O
ADL	O
.	O
CT	O
scan	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
showed	O
(	O
-	O
)	O
CT	O
and	O
(	O
-	O
)	O
troponins	O
.	O
Admitted	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
10	O
-	O
12	O
**	O
]	O
,	O
tox	O
screen	O
(	O
-	O
)	O
,	O
CEs	O
(	O
-	O
)	O
,	O
primary	O
team	O
managing	O
BP	I-Drug
meds	O
and	O
psyche	I-Drug
meds	O
.	O
Was	O
being	O
worked	O
up	O
on	O
[	O
**	O
Wardname	O
836	O
**	O
]	O
for	O
renal	O
failure	O
and	O
balancing	O
HTN	I-Drug
meds	O
,	O
when	O
found	O
by	O
NSG	O
staff	O
to	O
be	O
'	O
unresponsive	O
'	O
with	O
no	O
breathing	O
or	O
radial	O
pulse	O
for	O
20	O
seconds	O
.	O
Code	O
blue	O
called	O
,	O
initial	O
blood	O
pressure	O
80/50	O
with	O
improvement	O
in	O
mentation	O
to	O
baseline	O
.	O
Two	O
hours	O
after	O
event	O
,	O
noted	O
to	O
have	O
decreasing	O
BPs	O
to	O
60s	O
with	O
concurrent	O
mental	O
status	O
changes	O
.	O
Repeat	O
BPs	O
in	O
trendelenburg	O
resolved	O
to	O
110	O
with	O
return	O
of	O
mentation	O
.	O
She	O
was	O
transferred	O
to	O
the	O
MICU	O
on	O
[	O
**	O
2186-10-15	O
**	O
]	O
for	O
NSG	O
concern	O
of	O
hypotension	O
.	O
.	O
In	O
the	O
MICU	O
she	O
had	O
three	O
more	O
episodes	O
.	O
These	O
were	O
characterized	O
by	O
unresponsiveness	O
,	O
lack	O
of	O
a	O
radial	O
pulse	O
(	O
no	O
femoral	O
pulse	O
was	O
taken	O
)	O
,	O
and	O
a	O
post-ictal	O
confusional	O
state	O
most	O
consistent	O
with	O
seizures	O
.	O
Her	O
EKG	O
during	O
these	O
episodes	O
was	O
unremarkable	O
,	O
although	O
she	O
does	O
have	O
a	O
baseline	O
RBBB	O
.	O
Hence	O
,	O
heart	O
block	O
was	O
deemed	O
unlikely	O
.	O
MICU	O
team	O
was	O
suspicious	O
of	O
seizure	O
activity	O
,	O
given	O
complete	O
unresponsiveness	O
to	O
verbal	O
and	O
tactile	O
stimuli	O
,	O
then	O
confusion	O
and	O
return	O
to	O
baseline	O
after	O
episode	O
.	O
Further	O
,	O
given	O
her	O
diabetes	O
and	O
her	O
labile	O
blood	O
pressure	O
,	O
autonomic	O
seizures	O
were	O
of	O
particular	O
concern	O
.	O
She	O
was	O
worked	O
up	O
by	O
multiple	O
teams	O
,	O
including	O
Neurology	O
.	O
Per	O
neurology	O
a	O
head	O
CT	O
was	O
obtained	O
which	O
indicated	O
atrophy	O
w	O
/	O
mild	O
microangiopathic	O
changes	O
.	O
She	O
was	O
put	O
on	O
EEG	O
monitoring	O
to	O
capture	O
seizure	O
activity	O
however	O
she	O
did	O
not	O
have	O
an	O
episode	O
during	O
monitoring	O
.	O
Other	O
considerations	O
were	O
her	O
baseline	O
psyciatric	O
disorder	O
or	O
medication	O
regimen	O
.	O
She	O
was	O
seen	O
by	O
Psychiatry	O
who	O
do	O
not	O
feel	O
her	O
episodes	O
of	O
hypotension	O
are	O
entirely	O
explained	O
by	O
her	O
bipolar	O
disorder	O
.	O
Finally	O
nephrology	O
was	O
consulted	O
to	O
evaluate	O
a	O
renal	O
source	O
of	O
her	O
labile	O
BP	O
and	O
possible	O
source	O
of	O
hypotensive	B-Ade
episodes	I-Ade
.	O
Nephrology	O
determined	O
she	O
did	O
not	O
have	O
RAS	O
by	O
US	O
and	O
Captopril	I-Drug
study	O
and	O
did	O
not	O
feel	O
that	O
her	O
labile	O
BP	O
was	O
renal	O
in	O
origin	O
.	O
Ultimately	O
,	O
it	O
was	O
felt	O
that	O
a	O
polypharmacy	O
of	O
her	O
BP	B-Drug
and	I-Drug
anti-psychotic	I-Drug
medications	O
were	O
responsible	O
for	O
these	O
episodes	O
.	O
Her	O
BP	B-Drug
/	I-Drug
Psych	I-Drug
med	I-Drug
regimen	O
were	O
tapered	O
and	O
she	O
has	O
been	O
stable	O
for	O
3	O
days	O
.	O
She	O
was	O
transferred	O
to	O
[	O
**	O
Wardname	O
**	O
]	O
[	O
**	O
2186-10-17	O
**	O
]	O
for	O
further	O
workup	O
of	O
an	O
anion	O
gap	O
and	O
elevated	O
WBC	O
prior	O
to	O
anticipated	O
discharge	O
to	O
a	O
rehab	O
facility	O
.	O
.	O
Of	O
note	O
,	O
recently	O
hospitalized	O
@QuincyMC	O
for	O
mania	O
,	O
had	O
episode	O
of	O
syncope	O
;	O
workup	O
head	O
CT	O
,	O
head	O
MRI	O
,	O
neck	O
MRA	O
,	O
carotid	O
doppler	O
studies	O
,	O
EEG	O
,	O
CXR	O
,	O
and	O
echocardiogram	O
.	O
Head	O
MRI	O
notable	O
for	O
periventricular	O
white	O
matter	O
changes	O
suggesting	O
small	O
vessel	O
disease	O
.	O
TTE	O
showed	O
normal	O
sized	O
LV	O
with	O
hyperdynamic	O
systolic	O
function	O
and	O
EF	O
of	O
75	O
%	O
.	O
EEG	O
normal	O
.	O
MRA	O
of	O
neck	O
showed	O
65	O
-	O
70	O
%	O
stenosis	O
of	O
internal	O
carotids	O
bilaterally	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Bipolar	O
d	O
/	O
o	O
(	O
recent	O
hospitalization	O
at	O
[	O
**	O
Hospital1	O
392	O
**	O
]	O
for	O
manic	O
episode	O
:	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
39296	O
**	O
]	O
;	O
peridiocally	O
on	O
medical	O
floor	O
for	O
syncope	O
eval	O
)	O
2	O
.	O
Mild	O
dementia	O
3	O
.	O
Refractory	O
HTN	O
4	O
.	O
DM	O
type	O
II	O
5	O
.	O
Hypothyroidism	O
6	O
.	O
Chronic	O
Kidney	O
Disease	O
7	O
.	O
Bilateral	O
hearing	O
loss	O
8	O
.	O
Arthritis	O
9	O
.	O
Bilateral	O
carotid	O
stenosis	O
Social	O
History	O
:	O
Lives	O
at	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
house	O
,	O
Has	O
4	O
kids	O
all	O
living	O
locally	O
,	O
widowed	O
.	O
Distant	O
smoking	O
history	O
,	O
distant	O
social	O
EtOH	O
.	O
Family	O
History	O
:	O
Mother	O
had	O
psychiatric	O
disease	O
with	O
multiple	O
psychiatric	O
admissions	O
,	O
died	O
in	O
a	O
state	O
hospital	O
.	O
Physical	O
Exam	O
:	O
ON	O
ADMISSION	O
:	O
Vitals	O
-	O
T	O
97.6	O
,	O
BP	O
175/57	O
,	O
HR	O
69	O
,	O
RR	O
20	O
,	O
O2	O
sat	O
96	O
%	O
3L	O
NC	O
General	O
-	O
elderly	O
female	O
,	O
pleasant	O
,	O
NAD	O
HEENT	O
-	O
PERRL	O
,	O
OP	O
clr	O
,	O
MMM	O
,	O
JVP	O
flat	O
CV	O
-	O
RRR	O
,	O
[	O
**	O
1	O
-	O
17	O
**	O
]	O
syst	O
mur	O
at	O
apex	O
Chest	O
-	O
coarse	O
R	O
basilar	O
crackles	O
Abdomen	O
-	O
NABS	O
,	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
no	O
g	O
/	O
r	O
;	O
soft	O
abdominal	O
bruit	O
Ext	O
-	O
trace	O
bilat	O
edema	O
.	O
ON	O
TRANSFER	O
to	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
7	O
:	O
Physical	O
Examination	O
Vitals	O
-	O
T	O
96.9	O
,	O
BP	O
160/60	O
,	O
HR	O
68	O
,	O
RR	O
20	O
,	O
O2	O
sat	O
99	O
%	O
RA	O
General	O
-	O
elderly	O
female	O
,	O
pleasant	O
,	O
NAD	O
HEENT	O
-	O
PERRL	O
,	O
sclera	O
are	O
erythematous	O
,	O
OP	O
clr	O
,	O
MMM	O
,	O
JVP	O
flat	O
CV	O
-	O
RRR	O
,	O
[	O
**	O
1	O
-	O
17	O
**	O
]	O
syst	O
mur	O
at	O
apex	O
Chest	O
-	O
clear	O
to	O
ascultation	O
bilaterally	O
Abdomen	O
-	O
NABS	O
,	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
no	O
g	O
/	O
r	O
;	O
soft	O
abdominal	O
bruit	O
Ext	O
-	O
bilat	O
edema	O
4	O
+	O
on	O
hands	O
,	O
2	O
+	O
on	O
LE	O
,	O
WWP	O
Neuro	O
-	O
AOx3	O
,	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
bl	O
UE	O
and	O
LE	O
strenght	O
bl	O
.	O
sensation	O
intact	O
throughout	O
symmetrically	O
.	O
Pertinent	O
Results	O
:	O
LABS	O
ON	O
ADMISSION	O
[	O
**	O
2186-10-11	O
**	O
]	O
:	O
[	O
**	O
2186-10-11	O
**	O
]	O
04:45	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.016	O
[	O
**	O
2186-10-11	O
**	O
]	O
04:45	O
PM	O
URINE	O
BLOOD	O
-	O
LG	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
30	O
GLUCOSE	O
-	O
250	O
KETONE	O
-	O
15	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
6.5	O
LEUK	O
-	O
NEG	O
[	O
**	O
2186-10-11	O
**	O
]	O
04:45	O
PM	O
URINE	O
RBC	O
-	O
>	O
50	O
WBC	O
-0-2	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
[	O
**	O
2186-10-11	O
**	O
]	O
04:45	O
PM	O
URINE	O
HYALINE	O
-0-2	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
GLUCOSE	O
-	O
209	O
*	O
UREA	O
N	O
-	O
36	O
*	O
CREAT	O
-	O
1.6	O
*	O
SODIUM	O
-	O
144	O
POTASSIUM	O
-	O
3.5	O
CHLORIDE	O
-	O
104	O
TOTAL	O
CO2	O
-	O
28	O
ANION	O
GAP	O
-	O
16	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
16	O
AST	O
(	O
SGOT	O
)	O
-	O
23	O
LD	O
(	O
LDH	O
)	O
-	O
196	O
ALK	O
PHOS	O
-	O
67	O
TOT	O
BILI	O
-	O
0.5	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
ALBUMIN	O
-	O
3.6	O
CALCIUM	O
-	O
8.4	O
PHOSPHATE	O
-	O
3.7	O
MAGNESIUM	O
-	O
2.5	O
IRON	O
-	O
40	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
calTIBC	O
-	O
263	O
VIT	O
B12	O
-	O
609	O
FOLATE	O
-	O
16.5	O
FERRITIN	O
-	O
102	O
TRF	O
-	O
202	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
TSH	O
-	O
0.089	O
*	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
CRP	O
-	O
9.1	O
*	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
WBC	O
-	O
9.4	O
RBC	O
-	O
3.66	O
*	O
HGB	O
-	O
11.4	O
*	O
HCT	O
-	O
34.1	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.1	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
13.9	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
PLT	O
COUNT	O
-	O
273	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
PT	O
-	O
11.3	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:55	O
PM	O
SED	O
RATE	O
-	O
46	O
*	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
GLUCOSE	O
-	O
170	O
*	O
UREA	O
N	O
-	O
41	O
*	O
CREAT	O
-	O
1.7	O
*	O
SODIUM	O
-	O
145	O
POTASSIUM	O
-	O
3.4	O
CHLORIDE	O
-	O
105	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
16	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
CK	O
(	O
CPK	O
)	O
-	O
314	O
*	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
CK	O
-	O
MB	O
-	O
3	O
cTropnT	O
-	O
0.02	O
*	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
ASA	O
-	O
NEG	O
ETHANOL	O
-	O
NEG	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
WBC	O
-	O
10.9	O
RBC	O
-	O
3.61	O
*	O
HGB	O
-	O
11.4	O
*	O
HCT	O
-	O
33.6	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.6	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
13.6	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
NEUTS	O
-	O
80.1	O
*	O
LYMPHS	O
-	O
14.7	O
*	O
MONOS	O
-	O
3.4	O
EOS	O
-	O
0.8	O
BASOS	O
-	O
0.9	O
[	O
**	O
2186-10-11	O
**	O
]	O
12:10	O
AM	O
PLT	O
COUNT	O
-	O
298	O
.	O
.	O
Laboratory	O
Studies	O
(	O
on	O
transfer	O
to	O
[	O
**	O
Wardname	O
**	O
]	O
)	O
:	O
ABG	O
:	O
94	O
,	O
28	O
,	O
7.42	O
,	O
19	O
,	O
base	O
-4	O
CBC	O
:	O
17.4	O
,	O
38.8	O
,	O
315	O
Chem7	O
:	O
139	O
,	O
3.8	O
,	O
102	O
,	O
19	O
,	O
43	O
,	O
1.2	O
,	O
243	O
CK	O
18	O
,	O
Ca	O
8.9	O
,	O
Mg	O
2.4	O
,	O
P	O
3.4	O
PT	O
11.5	O
,	O
PTT	O
26.3	O
,	O
INR	O
1.0	O
UA	O
:	O
straw	O
,	O
clear	O
,	O
1.017	O
,	O
5.0	O
,	O
bld	O
large	O
,	O
prot	O
30	O
,	O
gluc	O
1000	O
,	O
ket	O
50	O
,	O
RBC	O
84	O
,	O
WBC	O
0	O
,	O
Bact	O
none	O
,	O
Yest	O
none	O
,	O
epi	O
<	O
1	O
,	O
(	O
negative	O
for	O
Urobbil	O
,	O
Bili	O
,	O
Leuk	O
,	O
Nitr	O
)	O
Urine	O
Cre	O
77	O
,	O
Prot	O
51	O
,	O
Prot	O
/	O
Cre	O
0.7	O
.	O
Radiographic	O
Studies	O
:	O
Chest	O
AP	O
(	O
prelim	O
)	O
-	O
Allowing	O
for	O
difference	O
in	O
technique	O
,	O
cardiomediastinal	O
silhouette	O
is	O
unchanged	O
with	O
mild	O
cardiomegaly	O
.	O
There	O
is	O
no	O
pneumothorax	O
or	O
pleural	O
effusion	O
.	O
The	O
lungs	O
are	O
clear	O
.	O
.	O
(	O
[	O
**	O
2186-10-13	O
**	O
]	O
)	O
ECG	O
:	O
NSR	O
,	O
RBBB	O
,	O
LAFB	O
,	O
LVH	O
.	O
unchanged	O
from	O
prior	O
.	O
(	O
[	O
**	O
2186-10-16	O
**	O
]	O
)	O
EEG	O
IMPRESSION	O
:	O
This	O
telemetry	O
captured	O
no	O
pushbutton	O
activations	O
for	O
symptoms	O
.	O
Routine	O
sampling	O
and	O
automated	O
detection	O
programs	O
recorded	O
no	O
epileptiform	O
features	O
or	O
electrographic	O
seizures	O
.	O
There	O
was	O
some	O
multifocal	O
slowing	O
admixed	O
to	O
the	O
waking	O
background	O
,	O
but	O
this	O
would	O
be	O
assessed	O
better	O
through	O
routine	O
EEG	O
tracings	O
.	O
There	O
were	O
no	O
areas	O
of	O
fixed	O
focal	O
slowing	O
,	O
and	O
there	O
were	O
no	O
epileptiform	O
features	O
.	O
.	O
(	O
[	O
**	O
2186-10-14	O
**	O
]	O
)	O
EEG	O
IMPRESSION	O
:	O
This	O
is	O
an	O
abnormal	O
portable	O
EEG	O
in	O
the	O
waking	O
and	O
drowsy	O
states	O
due	O
to	O
intermittent	O
brief	O
bursts	O
of	O
mixed	O
frequency	O
slowing	O
seen	O
in	O
the	O
temporal	O
regions	O
bilaterally	O
,	O
independently	O
and	O
asynchronously	O
.	O
The	O
findings	O
suggest	O
underlying	O
subcortical	O
dysfunction	O
in	O
those	O
regions	O
.	O
In	O
a	O
patient	O
of	O
this	O
age	O
,	O
vascular	O
disease	O
would	O
be	O
among	O
the	O
common	O
causes	O
.	O
In	O
addition	O
,	O
there	O
were	O
brief	O
bursts	O
of	O
generalized	O
mixed	O
frequency	O
slowing	O
,	O
more	O
non-specific	O
in	O
etiology	O
.	O
There	O
were	O
no	O
clearly	O
epileptiform	O
features	O
.	O
No	O
electrographic	O
seizures	O
were	O
noted	O
.	O
.	O
(	O
[	O
**	O
2186-10-13	O
**	O
]	O
)	O
CT	O
HEAD	O
IMPRESSION	O
:	O
Moderate	O
degree	O
of	O
atrophy	O
with	O
mild	O
microangiopathic	O
changes	O
.	O
.	O
(	O
[	O
**	O
2186-10-13	O
**	O
]	O
)	O
RENAL	O
US	O
IMPRESSION	O
:	O
Study	O
limited	O
by	O
patient	O
factors	O
:	O
blood	O
flow	O
to	O
both	O
kidneys	O
,	O
there	O
is	O
no	O
hydronephrosis	O
,	O
nephrolithiasis	O
,	O
simple	O
cysts	O
in	O
both	O
kidneys	O
.	O
(	O
[	O
**	O
2186-10-16	O
**	O
]	O
)	O
RENAL	O
CAPTOPRIL	I-Drug
SCAN	O
IMPRESSION	O
:	O
Essentially	O
normal	O
captopril	I-Drug
renal	O
scan	O
.	O
Specifically	O
,	O
no	O
evidence	O
of	O
renal	O
artery	O
stenosis	O
.	O
.	O
(	O
[	O
**	O
10	O
-	O
17	O
**	O
]	O
and	O
[	O
**	O
2186-10-17	O
**	O
]	O
)	O
EEG	O
:	O
IMPRESSION	O
:	O
This	O
telemetry	O
captured	O
no	O
pushbutton	O
activations	O
for	O
symptoms	O
.	O
Routine	O
sampling	O
and	O
automated	O
detection	O
programs	O
recorded	O
no	O
epileptiform	O
features	O
or	O
electrographic	O
seizures	O
.	O
There	O
was	O
some	O
multifocal	O
slowing	O
admixed	O
to	O
the	O
waking	O
background	O
,	O
but	O
this	O
would	O
be	O
assessed	O
better	O
through	O
routine	O
EEG	O
tracings	O
.	O
There	O
were	O
no	O
areas	O
of	O
fixed	O
focal	O
slowing	O
,	O
and	O
there	O
were	O
no	O
epileptiform	O
features	O
.	O
.	O
(	O
[	O
**	O
2186-10-20	O
**	O
]	O
)	O
:	O
Chest	O
X-ray	O
IMPRESSION	O
:	O
Improving	O
right	O
lower	O
lobe	O
opacity	O
.	O
.	O
(	O
[	O
**	O
2186-10-20	O
**	O
]	O
)	O
:	O
Transthoracic	O
Echo	O
:	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
and	O
regional	O
systolic	O
function	O
.	O
.	O
(	O
[	O
**	O
2186-10-22	O
**	O
]	O
)	O
:	O
EKG	O
:	O
Artifact	O
is	O
present	O
.	O
Probable	O
sinus	O
rhythm	O
.	O
Left	O
axis	O
deviation	O
.	O
Left	O
anterior	O
fascicular	O
block	O
.	O
There	O
is	O
an	O
early	O
transition	O
which	O
is	O
non-specific	O
with	O
subsequent	O
loss	O
of	O
anterolateral	O
R	O
waves	O
associated	O
with	O
anterior	O
and	O
anterolateral	O
ST	O
-	O
T	O
wave	O
changes	O
consistent	O
with	O
probable	O
myocardial	O
infarction	O
.	O
Left	O
ventricular	O
hypertrophy	O
with	O
associated	O
ST	O
-	O
T	O
wave	O
changes	O
.	O
Incomplete	O
right	O
bundle	O
-	O
branch	O
block	O
.	O
Compared	O
to	O
the	O
prior	O
tracing	O
right	O
bundle	O
-	O
branch	O
block	O
is	O
now	O
incomplete	O
.	O
.	O
(	O
[	O
**	O
2186-10-26	O
**	O
]	O
)	O
:	O
Liver	O
Ultrasound	O
IMPRESSION	O
:	O
1	O
.	O
Findings	O
are	O
suspicious	O
for	O
acute	O
cholecystitis	O
and	O
possible	O
focal	O
necrosis	O
and	O
perforation	O
of	O
the	O
gallbladder	O
wall	O
.	O
2	O
.	O
Right	O
renal	O
cysts	O
.	O
.	O
(	O
[	O
**	O
2186-10-26	O
**	O
]	O
)	O
:	O
CT	O
Pelvis	O
/	O
Abdomen	O
/	O
Chest	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Small	O
amount	O
of	O
free	O
fluid	O
in	O
deep	O
pelvis	O
posterior	O
to	O
the	O
rectum	O
and	O
anterior	O
to	O
the	O
sacrum	O
,	O
without	O
fluid	O
collection	O
or	O
free	O
air	O
.	O
Diverticulosis	O
,	O
without	O
evidence	O
of	O
diverticulitis	O
.	O
Atelectasis	O
and	O
patchy	O
opacities	O
in	O
the	O
lungs	O
,	O
without	O
discrete	O
consolidation	O
suggestive	O
of	O
pneumonia	O
.	O
2	O
.	O
Renal	O
cysts	O
.	O
3	O
.	O
Nonspecific	O
fluid	O
-	O
filled	O
distended	O
second	O
portion	O
of	O
duodenum	O
surrounded	O
by	O
mild	O
fat	O
stranding	O
,	O
with	O
slight	O
fat	O
stranding	O
surrounding	O
the	O
pancreatic	O
head	O
.	O
The	O
finding	O
is	O
nonspecific	O
;	O
however	O
,	O
in	O
this	O
patient	O
with	O
elevated	O
white	O
blood	O
cell	O
,	O
duodenitis	O
or	O
early	O
pancreatitis	O
can	O
not	O
be	O
excluded	O
.	O
Please	O
correlate	O
with	O
laboratory	O
values	O
.	O
4	O
.	O
Small	O
amount	O
of	O
pericholecystic	O
fluid	O
with	O
questionable	O
sludge	O
.	O
If	O
indicated	O
,	O
please	O
consider	O
gallbladder	O
ultrasound	O
.	O
.	O
(	O
[	O
**	O
2186-10-28	O
**	O
]	O
)	O
:	O
CT	O
Abdomen	O
/	O
Pelvis	O
:	O
IMPRESSION	O
:	O
Percutaneous	O
gallbladder	O
drain	O
contained	O
within	O
the	O
gallbladder	O
.	O
The	O
gallbladder	O
is	O
decompressed	O
.	O
No	O
perihepatic	O
or	O
intra-abdominal	O
fluid	O
or	O
hemorrhage	O
is	O
identified	O
.	O
Stable	O
stranding	O
surrounding	O
the	O
second	O
and	O
third	O
portions	O
of	O
the	O
duodenum	O
and	O
pancreatic	O
head	O
.	O
(	O
[	O
**	O
2186-10-30	O
**	O
]	O
)	O
:	O
Ultrasound	O
of	O
lower	O
extremities	O
:	O
IMPRESSION	O
:	O
No	O
evidence	O
for	O
deep	O
venous	O
thrombus	O
in	O
bilateral	O
lower	O
extremities	O
.	O
.	O
(	O
[	O
**	O
2186-10-30	O
**	O
]	O
)	O
:	O
Head	O
CT	O
w	O
/	O
out	O
contrast	O
:	O
IMPRESSION	O
:	O
Aerosolized	O
secretions	O
in	O
the	O
sphenoid	O
sinus	O
and	O
increased	O
opacity	O
in	O
the	O
right	O
frontoethmoid	O
recess	O
.	O
Please	O
correlate	O
clinically	O
.	O
Otherwise	O
,	O
no	O
significant	O
change	O
,	O
including	O
no	O
evidence	O
of	O
intracranial	O
hemorrhage	O
or	O
large	O
recent	O
infarction	O
.	O
.	O
(	O
[	O
**	O
2186-11-3	O
**	O
]	O
)	O
:	O
Gallbladder	O
scan	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Prompt	O
filling	O
of	O
the	O
gallbladder	O
and	O
exit	O
into	O
the	O
duodenum	O
.	O
2	O
.	O
Patent	O
cholecystostomy	O
drainage	O
tube	O
.	O
3	O
.	O
No	O
evidence	O
of	O
leak	O
outside	O
of	O
the	O
gallbladder	O
.	O
.	O
(	O
[	O
**	O
2186-11-5	O
**	O
]	O
)	O
:	O
Ultrasound	O
of	O
abdomen	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
main	O
portal	O
vein	O
thrombosis	O
.	O
The	O
more	O
distal	O
branches	O
of	O
the	O
portal	O
vein	O
were	O
not	O
interrogated	O
.	O
If	O
there	O
is	O
further	O
clinical	O
concern	O
,	O
additional	O
dedicated	O
views	O
of	O
the	O
portal	O
vein	O
vasculature	O
can	O
be	O
performed	O
.	O
2	O
.	O
Nonvisualization	O
of	O
the	O
gallbladder	O
,	O
likley	O
due	O
to	O
collapsed	O
state	O
.	O
3	O
.	O
Stable	O
simple	O
-	O
appearing	O
right	O
renal	O
cysts	O
.	O
.	O
(	O
[	O
**	O
2186-11-27	O
**	O
]	O
)	O
Ultrasound	O
of	O
thyroid	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Completely	O
absent	O
right	O
lobe	O
of	O
the	O
thyroid	O
.	O
Small	O
remnant	O
of	O
the	O
left	O
thyroid	O
lobe	O
is	O
unchanged	O
compared	O
to	O
the	O
prior	O
study	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
is	O
an	O
84	O
year	O
old	O
female	O
with	O
mild	O
dementia	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
type	O
two	O
,	O
and	O
bipolar	O
disease	O
,	O
who	O
presented	O
on	O
[	O
**	O
2186-10-11	O
**	O
]	O
from	O
[	O
**	O
Hospital3	O
**	O
]	O
with	O
failure	O
to	O
thrive	O
,	O
and	O
was	O
being	O
worked	O
up	O
for	O
renal	O
failure	O
and	O
balancing	O
hypertension	I-Drug
medications	O
,	O
who	O
was	O
found	O
by	O
nursing	O
staff	O
to	O
be	O
'	O
unresponsive	I-Ade
'	O
with	O
no	B-Ade
breathing	I-Ade
or	I-Ade
radial	I-Ade
pulse	I-Ade
for	I-Ade
20	I-Ade
seconds	I-Ade
and	O
transferred	O
to	O
intensive	O
care	O
unit	O
.	O
.	O
#	O
Unresponsive	O
episodes	O
-	O
Patient	O
had	O
initial	O
episode	O
of	O
unresponsiveness	O
,	O
and	O
additional	O
episodes	O
witnessed	O
by	O
the	O
intensive	O
care	O
team	O
.	O
There	O
was	O
concern	O
for	O
seizure	O
activity	O
,	O
given	O
complete	O
unresponsiveness	O
to	O
verbal	O
and	O
tactile	O
stimuli	O
,	O
then	O
confusion	O
and	O
return	O
to	O
baseline	O
after	O
episode	O
.	O
Given	O
her	O
diabetes	O
and	O
her	O
labile	O
blood	O
pressure	O
,	O
autonomic	O
seizures	O
were	O
of	O
particular	O
concern	O
,	O
as	O
was	O
complete	O
heart	O
block	O
(	O
given	O
known	O
RBBB	O
with	O
LAFB	O
)	O
however	O
telemetry	O
tracings	O
remained	O
within	O
normal	O
limits	O
.	O
It	O
was	O
also	O
concerning	O
that	O
her	O
medications	O
could	O
be	O
playing	O
role	O
.	O
She	O
was	O
monitored	O
on	O
telemetry	O
which	O
was	O
unrevealing	O
for	O
a	O
cause	O
,	O
a	O
transthoracic	O
echo	O
did	O
not	O
reveal	O
clear	O
cause	O
,	O
nor	O
did	O
continuous	O
EEG	O
monitoring	O
.	O
Several	O
of	O
her	O
blood	B-Drug
pressure	I-Drug
medications	O
were	O
held	O
to	O
avoid	O
hypotensive	B-Ade
episodes	I-Ade
,	O
which	O
ultimately	O
felt	O
to	O
be	O
the	O
a	O
large	O
part	O
of	O
the	O
cause	O
.	O
She	O
had	O
no	O
further	O
episodes	O
after	O
her	O
first	O
transfer	O
out	O
of	O
the	O
intensive	O
care	O
unit	O
on	O
[	O
**	O
2186-10-17	O
**	O
]	O
.	O
.	O
#	O
Hypertension	O
-	O
Patient	O
has	O
historically	O
difficult	O
to	O
control	O
blood	O
pressure	O
,	O
with	O
typical	O
systolic	O
blood	O
pressure	O
of	O
180	O
's	O
as	O
an	O
outpatient	O
.	O
An	O
abdominal	O
bruit	O
was	O
appreciated	O
on	O
exam	O
.	O
A	O
renal	O
ultarsound	O
showed	O
bilateral	O
flow	O
with	O
doplers	O
.	O
Imaging	O
with	O
captopril	I-Drug
was	O
obtained	O
to	O
further	O
evaluate	O
for	O
renal	O
artery	O
stenosis	O
,	O
and	O
was	O
within	O
normal	O
limits	O
.	O
A	O
work	O
up	O
for	O
other	O
secondary	O
causes	O
was	O
initiated	O
,	O
including	O
hyperaldosterone	O
,	O
hyper	O
-	O
renin	O
,	O
hyper	O
-	O
ACTH	O
,	O
and	O
pheochromocytoma	O
.	O
Her	O
work	O
up	O
revealed	O
slightly	O
elevated	O
normetanephrine	O
in	O
serum	O
and	O
urine	O
,	O
as	O
well	O
as	O
very	O
mildly	O
elevated	O
epinephrine	I-Drug
,	O
norepinephrine	I-Drug
,	O
dopamine	I-Drug
,	O
and	O
catecholamines	O
;	O
it	O
was	O
not	O
felt	O
that	O
these	O
were	O
consistent	O
with	O
a	O
pheochromocytoma	O
.	O
An	O
AM	B-Ade
cortisol	I-Ade
was	I-Ade
found	I-Ade
to	I-Ade
be	O
elevated	O
and	O
resistant	O
to	O
supression	O
by	O
1	O
mg	O
dexamethasone	I-Drug
overnight	O
.	O
Because	O
of	O
that	O
,	O
a	O
CT	O
abdomen	O
/	O
pelvis	O
was	O
obtained	O
on	O
[	O
**	O
2186-10-26	O
**	O
]	O
to	O
look	O
for	O
source	O
of	O
Cushings	O
syndrome	O
or	O
ectopic	O
ACTH	O
secretion	O
--	O
it	O
showed	O
inflammation	O
around	O
the	O
duodenum	O
and	O
head	O
of	O
the	O
pancreas	O
but	O
no	O
adrenal	O
masses	O
.	O
.	O
Her	O
blood	B-Drug
pressure	I-Drug
medications	I-Drug
were	O
slowly	O
re-introduced	O
,	O
to	O
avoid	O
hypotension	O
,	O
with	O
goal	O
systolic	O
blood	O
pressure	O
greater	O
than	O
130	O
's	O
to	O
140	O
's	O
.	O
.	O
At	O
time	O
of	O
discharge	O
,	O
her	O
blood	B-Drug
pressure	I-Drug
medications	I-Drug
were	O
:	O
-	O
Metoprolol	I-Drug
100	O
mg	O
q8	O
hours	O
-	O
Clonidine	I-Drug
TTS	O
2	O
patch	O
weekly	O
-	O
Captopril	I-Drug
75	O
mg	O
q8	O
hours	O
.	O
#	O
Arrythmias	I-Reason
:	O
Cardiology	O
was	O
consulted	O
early	O
in	O
her	O
stay	O
after	O
episodes	O
of	O
V	O
-	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
,	O
and	O
PVCs	O
.	O
It	O
was	O
recommended	O
to	O
continue	O
rate	B-Reason
control	I-Reason
metoprolol	I-Drug
,	O
as	O
well	O
as	O
continue	O
her	O
ACE	B-Drug
-	I-Drug
I.	O
Electrophysiology	O
was	O
asked	O
to	O
see	O
patient	O
again	O
on	O
[	O
**	O
2186-10-22	O
**	O
]	O
for	O
repeated	O
episodes	O
of	O
V	O
-	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
**	O
]	O
.	O
At	O
that	O
time	O
,	O
amiodarone	I-Drug
was	O
initiated	O
at	O
200	O
TID	O
,	O
tapered	O
to	O
200	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
on	O
[	O
**	O
11	O
-	O
1	O
**	O
]	O
,	O
and	O
finally	O
continued	O
at	O
200	O
mg	O
daily	O
since	O
[	O
**	O
2186-11-14	O
**	O
]	O
.	O
She	O
had	O
no	O
further	O
arrythmias	O
noted	O
.	O
.	O
#	O
Renal	O
insufficiency	O
-	O
Upon	O
admission	O
,	O
she	O
had	O
worsening	O
of	O
her	O
renal	O
function	O
with	O
a	O
creatinine	O
to	O
1.7	O
.	O
It	O
was	O
felt	O
that	O
her	O
renal	B-Reason
insufficiency	I-Reason
was	O
pre-renal	O
in	O
nature	O
,	O
and	O
she	O
was	O
given	O
gentle	O
intravenous	O
fluids	I-Drug
.	O
It	O
was	O
thought	O
she	O
had	O
an	O
element	O
of	O
diabetic	O
nephropathy	O
as	O
well	O
.	O
The	O
renal	O
team	O
was	O
consulted	O
and	O
assisted	O
with	O
management	O
of	O
her	O
care	O
.	O
Her	O
creatinine	O
rose	O
to	O
2.0	O
at	O
its	O
peak	O
,	O
coinciding	O
with	O
her	O
hypotensive	O
episodes	O
.	O
At	O
time	O
of	O
discharge	O
,	O
her	O
renal	O
function	O
was	O
stable	O
at	O
0.8	O
-	O
1.2	O
,	O
and	O
she	O
continued	O
to	O
put	O
out	O
good	O
amounts	O
of	O
urine	O
.	O
.	O
.	O
#	O
Type	B-Reason
two	I-Reason
diabetes	I-Reason
mellitus	I-Reason
-	O
Patient	O
was	O
on	O
glipizide	I-Drug
at	O
home	O
,	O
however	O
with	O
her	O
worsening	O
renal	O
function	O
and	O
very	O
little	O
PO	O
intake	O
,	O
a	O
sliding	O
scale	O
of	O
insulin	I-Drug
was	O
started	O
,	O
and	O
basal	I-Drug
insulin	O
was	O
added	O
as	O
needed	O
.	O
At	O
time	O
of	O
discharge	O
,	O
she	O
was	O
on	O
30	O
units	O
of	O
lantus	I-Drug
in	O
addition	O
to	O
a	O
humalong	I-Drug
sliding	O
scale	O
.	O
.	O
#	O
Hypothyroidism	I-Reason
-	O
Patient	O
has	O
history	O
of	O
thyroid	O
carcinoma	O
and	O
is	O
status	O
-	O
post	O
thyroidectomy	O
.	O
At	O
time	O
of	O
admission	O
,	O
her	O
TSH	O
was	O
very	O
suppressed	O
,	O
but	O
her	O
free	O
T4	O
level	O
was	O
within	O
normal	O
limits	O
.	O
Her	O
TSH	O
rose	O
during	O
her	O
stay	O
,	O
peaking	O
at	O
32	O
.	O
Her	O
T4	O
studies	O
were	O
found	O
to	O
be	O
low	O
.	O
Endocrine	O
consultation	O
was	O
obtained	O
to	O
assist	O
with	O
management	O
of	O
her	O
thyroid	O
disease	O
,	O
especially	O
with	O
concurrent	O
use	O
of	O
amiodarone	I-Drug
and	O
lithium	I-Drug
.	O
Her	O
dose	O
of	O
levothyroxine	I-Drug
was	O
increased	O
to	O
300	O
mcg	O
for	O
several	O
days	O
,	O
then	O
brought	O
down	O
to	O
175	O
mcg	O
prior	O
to	O
discharge	O
.	O
Her	O
TSH	O
remained	O
elevated	O
(	O
15	O
)	O
on	O
a	O
subsequent	O
check	O
on	O
[	O
**	O
12	O
-	O
13	O
**	O
]	O
.	O
This	O
was	O
associated	O
with	O
a	O
normal	O
free	O
T4	O
(	O
1.5	O
)	O
.	O
After	O
discussion	O
with	O
endocrinology	O
,	O
it	O
was	O
felt	O
that	O
she	O
may	O
not	O
be	O
absorbing	O
well	O
and	O
may	O
be	O
becoming	O
progressively	O
more	O
hypothyroid	O
.	O
Her	O
tube	O
feeds	O
should	O
be	O
held	O
30	O
minutes	O
before	O
and	O
after	O
administering	O
synthroid	I-Drug
;	O
she	O
should	O
have	O
her	O
levels	O
followed	O
to	O
ensure	O
that	O
this	O
is	O
effective	O
.	O
If	O
she	O
is	O
still	O
underreplaced	O
,	O
she	O
may	O
need	O
to	O
have	O
IV	O
levothyroxine	I-Drug
.	O
-	O
Her	O
thyroid	O
function	O
tests	O
should	O
be	O
checked	O
and	O
followed	O
up	O
1	O
-	O
2	O
weeks	O
after	O
discharge	O
.	O
-	O
An	O
ultrasound	O
of	O
her	O
thyroid	O
was	O
checked	O
to	O
assess	O
for	O
any	O
thyroid	O
disease	O
or	O
cancer	O
recurrence	O
in	O
light	O
of	O
her	O
elevated	O
TSH	O
.	O
The	O
ultrasound	O
was	O
unchanged	O
from	O
prior	O
studies	O
.	O
.	O
#	O
Upper	O
gastrointestinal	O
bleed	O
:	O
On	O
[	O
**	O
2186-11-4	O
**	O
]	O
patient	O
developed	O
a	O
decline	O
in	O
her	O
hematocrit	O
to	O
19	O
,	O
with	O
guaiac	O
positive	O
stools	O
,	O
then	O
melena	O
and	O
bright	O
red	O
blood	O
per	O
rectum	O
.	O
She	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
and	O
gastroenterology	O
was	O
consulted	O
.	O
An	O
upper	O
endoscopy	O
revealed	O
bleeding	B-Reason
duodenal	I-Reason
ulcers	I-Reason
that	O
were	O
injected	O
and	O
cauterized	O
.	O
She	O
required	O
a	O
total	O
of	O
9	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
during	O
her	O
intensive	O
care	O
stay	O
.	O
Her	O
hematocrit	O
remained	O
relatively	O
stable	O
after	O
her	O
transfer	O
back	O
to	O
the	O
general	O
floors	O
on	O
[	O
**	O
2186-11-8	O
**	O
]	O
,	O
until	O
[	O
**	O
2186-11-15	O
**	O
]	O
,	O
at	O
which	O
time	O
her	O
hematocrit	O
continued	O
to	O
drift	O
downward	O
and	O
her	O
stools	O
were	O
guaiac	O
positive	O
.	O
Plans	O
were	O
made	O
for	O
a	O
colonoscopy	O
,	O
however	O
,	O
in	O
light	O
of	O
an	O
additional	O
hematocrit	O
drop	O
to	O
20	O
,	O
a	O
repeat	O
endoscopy	O
was	O
completed	O
on	O
[	O
**	O
2186-11-17	O
**	O
]	O
,	O
and	O
a	O
new	O
third	O
duodenal	O
ulcer	O
was	O
noted	O
which	O
was	O
also	O
treated	O
.	O
She	O
received	O
two	O
additional	O
units	O
of	O
red	B-Drug
blood	I-Drug
cells	I-Drug
.	O
.	O
Testing	O
for	O
h.	O
pylori	O
was	O
negative	O
,	O
and	O
gastrin	O
levels	O
were	O
elevated	O
;	O
the	O
elevated	B-Ade
gastrin	I-Ade
levels	I-Ade
were	O
expected	O
in	O
setting	O
of	O
PPI	I-Drug
use	O
,	O
and	O
endocrine	O
consultation	O
did	O
not	O
feel	O
there	O
was	O
any	O
additional	O
pathology	O
contributing	O
to	O
the	O
elevated	B-Ade
gastrin	I-Ade
levels	O
.	O
-	O
[	O
**	O
Hospital1	O
**	O
]	O
PPI	I-Drug
was	O
initiated	O
and	O
should	O
be	O
continued	O
for	O
at	O
least	O
4	O
additional	O
weeks	O
,	O
then	O
continued	O
daily	O
.	O
-	O
Patient	O
will	O
need	O
follow	O
up	O
with	O
gastroenterology	O
after	O
discharge	O
,	O
for	O
possible	O
further	O
evaluation	O
of	O
nodules	O
seen	O
during	O
her	O
first	O
endoscopy	O
.	O
.	O
#	O
C.	B-Reason
Difficile	I-Reason
Colitis	I-Reason
:	O
Patient	O
developed	O
diarrhea	O
on	O
[	O
**	O
2186-11-24	O
**	O
]	O
,	O
and	O
stool	O
samples	O
revealed	O
c.	B-Reason
difficile	I-Reason
.	O
She	O
was	O
initiated	O
on	O
treatment	O
with	O
flagyl	I-Drug
on	O
[	O
**	O
2186-11-25	O
**	O
]	O
,	O
however	O
was	O
refusing	O
oral	O
medications	O
,	O
so	O
intravenous	O
flagyl	I-Drug
was	O
administered	O
until	O
[	O
**	O
2186-12-2	O
**	O
]	O
at	O
which	O
time	O
she	O
could	O
receive	O
oral	O
medications	O
via	O
her	O
PEG	O
.	O
She	O
did	O
not	O
have	O
any	O
abdominal	O
pain	O
or	O
distention	O
.	O
Her	O
white	O
blood	O
cell	O
count	O
bumped	O
to	O
>	O
20	O
at	O
the	O
time	O
of	O
her	B-Reason
c.	I-Reason
difficile	O
infection	O
.	O
Then	O
improved	O
.	O
Around	O
[	O
**	O
12	O
-	O
5	O
**	O
]	O
her	O
WBC	O
count	O
again	O
increased	O
,	O
with	O
no	O
other	O
clear	O
etiology	O
found	O
.	O
It	O
was	O
decided	O
to	O
change	O
flagyl	I-Drug
back	O
to	O
IV	O
,	O
and	O
to	O
add	O
PO	O
vanco	I-Drug
.	O
The	O
plan	O
is	O
to	O
continue	O
IV	O
flagyl	I-Drug
and	O
PO	O
vanco	I-Drug
until	O
about	O
a	O
week	O
after	O
WBC	O
stopping	O
other	O
antibiotics	I-Drug
(	O
cipro	I-Drug
for	O
UTI	I-Reason
)	O
.	O
.	O
#	O
Bipolar	O
Disorder	O
:	O
Patient	O
had	O
recent	O
hospitalization	O
for	O
manic	O
episode	O
at	O
outside	O
hospital	O
.	O
She	O
has	O
long	O
standing	O
history	O
of	O
depression	I-Reason
and	O
manic	I-Reason
episodes	O
,	O
with	O
numerous	O
prior	O
psychiatric	O
admissions	O
.	O
Her	O
family	O
gave	O
history	O
that	O
many	O
of	O
her	O
prior	O
depressive	O
episodes	O
had	O
started	O
with	O
refusal	O
to	O
eat	O
.	O
.	O
Psychiatry	O
team	O
was	O
consulted	O
at	O
the	O
start	O
of	O
her	O
stay	O
and	O
followed	O
along	O
the	O
entire	O
time	O
.	O
Therapeutic	O
options	O
for	O
her	O
bipolar	B-Reason
disease	I-Reason
were	O
limited	O
given	O
her	O
multiple	O
serious	O
medical	O
co-morbidities	O
.	O
There	O
was	O
concern	O
during	O
her	O
stay	O
for	O
seizures	O
and	O
serotonin	O
syndrome	O
,	O
however	O
neither	O
was	O
felt	O
to	O
have	O
taken	O
place	O
.	O
She	O
was	O
titrated	O
upward	O
on	O
citalopram	I-Drug
to	O
40	O
mg	O
(	O
increased	O
from	O
20	O
mg	O
on	O
[	O
**	O
2186-11-24	O
**	O
]	O
and	O
increased	O
from	O
30	O
mg	O
on	O
[	O
**	O
2186-12-11	O
**	O
]	O
)	O
.	O
Given	O
her	O
prior	O
success	O
on	O
lithium	I-Drug
,	O
which	O
had	O
been	O
stopped	O
due	O
to	O
"	B-Ade
toxicity	I-Ade
"	I-Ade
of	O
unclear	O
etiology	O
,	O
the	O
decision	O
was	O
made	O
to	O
re-introduce	O
lithium	I-Drug
while	O
in	O
the	O
inpatient	O
setting	O
where	O
the	O
patient	O
could	O
be	O
carefully	O
monitored	O
.	O
150	O
mg	O
qHS	O
was	O
started	O
on	O
[	O
**	O
2186-11-8	O
**	O
]	O
,	O
and	O
levels	O
were	O
closely	O
followed	O
,	O
with	O
goal	O
level	O
about	O
0.5	O
.	O
.	O
ECT	O
:	O
Psychiatry	O
felt	O
that	O
one	O
of	O
the	O
best	O
options	O
would	O
be	O
ECT	O
,	O
however	O
the	O
patient	O
continued	O
to	O
adamantly	O
voice	O
her	O
refusal	O
.	O
Several	O
family	O
meetings	O
took	O
place	O
with	O
her	O
primary	O
care	O
physician	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
primary	O
medical	O
,	O
and	O
psychiatric	O
teams	O
to	O
discuss	O
various	O
options	O
for	O
her	O
severe	O
depression	I-Reason
,	O
which	O
was	O
felt	O
to	O
be	O
the	O
main	O
reason	O
for	O
her	O
failure	O
to	O
thrive	O
and	O
poor	O
PO	O
intake	O
.	O
Given	O
her	O
refusal	O
to	O
ECT	O
,	O
legal	O
guardianship	O
would	O
need	O
to	O
be	O
pursued	O
if	O
the	O
patient	O
's	O
family	O
desired	O
to	O
pursue	O
ECT	O
and	O
it	O
was	O
necessary	O
to	O
deem	O
the	O
patient	O
incompetent	O
to	O
make	O
a	O
decision	O
regarding	O
ECT	O
due	O
to	O
her	O
depression	I-Reason
.	O
-	O
Remeron	I-Drug
was	O
considered	O
,	O
but	O
contraindicated	O
with	O
use	O
of	O
clonidine	I-Drug
.	O
-	O
Rilatin	I-Drug
was	O
also	O
considered	O
,	O
but	O
contraindicated	O
with	O
her	O
cardiac	O
arrhythmias	O
.	O
-	O
Patient	O
will	O
need	O
continued	O
follow	O
up	O
with	O
psychiatry	O
as	O
an	O
outpatient	O
.	O
.	O
At	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
's	O
mood	O
and	O
affect	O
had	O
improved	O
greatly	O
since	O
her	O
initial	O
presentation	O
,	O
and	O
she	O
appeared	O
much	O
less	O
flat	O
.	O
She	O
was	O
answering	O
questions	O
with	O
complete	O
sentences	O
with	O
improved	O
,	O
though	O
still	O
limited	O
,	O
range	O
of	O
emotions	O
.	O
.	O
#	O
Failure	O
to	O
thrive	O
/	O
Anorexia	O
-	O
Patient	O
continued	O
to	O
refuse	O
to	O
eat	O
and	O
take	O
her	O
medications	O
during	O
most	O
of	O
her	O
stay	O
.	O
As	O
her	O
medical	O
problems	O
cleared	O
,	O
she	O
became	O
more	O
interactive	O
and	O
started	O
to	O
eat	O
small	O
amounts	O
and	O
take	O
her	O
medications	O
.	O
After	O
much	O
discussion	O
and	O
a	O
trial	O
of	O
one	O
week	O
once	O
medically	O
stable	O
to	O
improve	O
PO	O
intake	O
,	O
decision	O
was	O
made	O
to	O
place	O
PEG	O
tube	O
,	O
which	O
was	O
completed	O
on	O
[	O
**	O
2186-12-1	O
**	O
]	O
.	O
-	O
Physical	O
therapy	O
and	O
occupational	O
therapy	O
were	O
consulted	O
and	O
followed	O
along	O
during	O
the	O
patient	O
's	O
stay	O
.	O
-	O
Thyroid	O
management	O
as	O
detailed	O
above	O
.	O
.	O
#	O
Dementia	I-Reason
:	O
Patient	O
has	O
history	O
of	O
mild	O
dementia	O
.	O
She	O
was	O
initially	O
on	O
Namenda	I-Drug
,	O
however	O
it	O
was	O
held	O
due	O
to	O
her	O
unresponsive	B-Ade
episodes	I-Ade
,	O
contribution	O
to	O
hypertension	I-Ade
,	O
and	O
possible	O
serotonin	B-Ade
syndrome	I-Ade
.	O
.	O
#	O
Tachypnea	O
:	O
Patient	O
had	O
intermittent	O
episodes	O
of	O
increased	O
respiratory	O
rate	O
,	O
ranging	O
25	O
-	O
30	O
.	O
Her	O
oxygenation	O
remained	O
normal	O
,	O
and	O
her	O
lungs	O
were	O
clear	O
,	O
and	O
she	O
denied	O
any	O
complaints	O
.	O
Several	O
chest	O
x-rays	O
were	O
unrevealing	O
.	O
Her	O
tachypnea	O
improved	O
overall	O
,	O
but	O
she	O
would	O
occasionally	O
have	O
episodes	O
of	O
increased	O
respiratory	O
rate	O
when	O
aroused	O
,	O
agitated	O
(	O
eg	O
by	O
asking	O
several	O
questions	O
)	O
.	O
.	O
#	O
Acalculus	B-Reason
Cholecystitis	I-Reason
:	O
A	O
RUQ	O
US	O
showed	O
possible	O
GB	O
wall	O
necrosis	O
and	O
microperforation	O
.	O
Surgery	O
was	O
consulted	O
and	O
recommended	O
a	O
percutaneous	O
GB	O
tube	O
,	O
which	O
was	O
placed	O
on	O
[	O
**	O
2186-10-27	O
**	O
]	O
.	O
It	O
was	O
assumed	O
that	O
this	O
was	O
the	O
source	O
of	O
her	O
persistent	B-Reason
leukocytosis	I-Reason
,	O
since	O
her	O
WBC	O
fell	O
to	O
15	O
after	O
placement	O
of	O
the	O
tube	O
,	O
but	O
the	O
WBC	O
has	O
since	O
increased	O
.	O
On	O
[	O
**	O
10	O
-	O
28	O
**	O
]	O
after	O
the	O
procedure	O
,	O
levo	I-Drug
/	O
flagyl	I-Drug
was	O
switched	O
to	O
zosyn	I-Drug
for	O
better	O
gram	B-Reason
negative	I-Reason
coverage	I-Reason
.	O
Vanco	I-Drug
was	O
continued	O
.	O
Throughout	O
all	O
this	O
,	O
she	O
has	O
had	O
no	O
fevers	O
,	O
denies	O
abdominal	O
pain	O
and	O
has	O
a	O
relatively	O
benign	O
abd	O
exam	O
w	O
/	O
no	O
guarding	O
,	O
rebound	O
or	O
RUQ	O
tenderness	O
.	O
Surgery	O
strongly	O
feels	O
that	O
she	O
does	O
not	O
have	O
an	O
"	O
acute	O
abdmonial	O
process	O
"	O
and	O
they	O
want	O
to	O
revisit	O
the	O
idea	O
of	O
an	O
elective	O
cholecystectomy	O
in	O
[	O
**	O
3	O
-	O
18	O
**	O
]	O
weeks	O
.	O
However	O
,	O
it	O
seems	O
most	O
likely	O
that	O
the	O
necrotic	O
GB	O
was	O
the	O
course	O
of	O
the	O
persistent	O
leukocytosis	O
.	O
-	O
Her	O
drain	O
site	O
remained	O
clean	O
,	O
dry	O
,	O
and	O
intact	O
.	O
-	O
Several	O
cultures	O
from	O
her	O
bile	O
drain	O
were	O
without	O
growth	O
except	O
for	O
one	O
that	O
haad	O
coagulase	O
negative	O
staph	O
,	O
felt	O
to	O
be	O
a	O
contaminant	O
.	O
-	O
Patient	O
's	O
percutaneous	O
gall	O
bladder	O
drain	O
was	O
clamped	O
on	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
and	O
removed	O
on	O
[	O
**	O
2186-12-11	O
**	O
]	O
.	O
.	O
#	O
Conjunctivitis	I-Reason
:	O
Patient	O
completed	O
course	O
of	O
treatment	O
with	O
erythromycin	I-Drug
eye	O
drops	O
.	O
.	O
#	O
Oral	O
Thrush	O
:	O
Patient	O
occasionally	O
had	O
evidence	O
of	O
white	O
exudate	O
on	O
her	O
tongue	O
,	O
which	O
was	O
possibly	O
thrush	O
given	O
her	O
very	O
poor	O
PO	O
intake	O
and	O
refusal	O
of	O
mouth	O
care	O
ans	O
swabs	O
.	O
It	O
was	O
possible	O
that	O
thrush	I-Reason
was	O
also	O
contributing	O
to	O
her	O
lack	O
of	O
appetite	O
.	O
-	O
Nystatin	I-Drug
S+S	O
was	O
initiated	O
.	O
It	O
can	O
be	O
given	O
on	O
a	O
prn	O
basis	O
for	O
recurrence	O
.	O
.	O
#	O
Elevated	O
Cardiac	O
Enzymes	O
:	O
Patient	O
's	O
cardiac	O
enzymes	O
bumped	O
slightly	O
in	O
setting	O
of	O
her	O
gastrointestinal	O
bleed	O
and	O
relative	O
hypotension	O
.	O
She	O
had	O
no	O
chest	O
pain	O
or	O
EKG	O
changes	O
,	O
and	O
it	O
was	O
felt	O
that	O
she	O
had	O
an	O
episode	O
of	O
demand	O
ischemia	O
.	O
.	O
#	O
Tranaminitis	O
:	O
Patient	O
's	O
transaminases	O
were	O
elevated	O
into	O
the	O
[	O
**	O
2178	O
**	O
]	O
,	O
which	O
occurred	O
following	O
her	O
gastrointestinal	O
bleed	O
and	O
episode	O
of	O
relative	O
hypotension	O
when	O
her	O
systolic	O
blood	O
pressure	O
was	O
into	O
the	O
100s	O
in	O
setting	O
of	O
bleed	O
.	O
It	O
was	O
suspected	O
that	O
she	O
suffered	O
from	O
ischemic	O
process	O
(	O
CEs	O
also	O
bumped	O
)	O
due	O
to	O
hypotension	O
.	O
She	O
had	O
also	O
been	O
getting	O
tylenol	I-Drug
during	O
her	O
during	O
intensive	O
care	O
stay	O
,	O
but	O
not	O
greater	O
than	O
2	O
grams	O
per	O
day	O
.	O
-	O
A	O
RUQ	O
US	O
was	O
obtained	O
to	O
rule	O
out	O
thrombosis	O
or	O
other	O
process	O
was	O
completed	O
without	O
any	O
apparent	O
new	O
pathology	O
.	O
.	O
#	O
Thrombocytopenia	O
-	O
Patient	O
developed	O
thrombocytopenia	O
down	O
to	O
127	O
at	O
the	O
lowest	O
.	O
This	O
resolved	O
during	O
her	O
stay	O
,	O
and	O
it	O
was	O
thought	O
to	O
be	O
due	O
to	O
her	O
poor	O
nutritional	O
status	O
.	O
-	O
There	O
were	O
no	O
clear	O
offending	O
medications	O
on	O
her	O
medication	O
list	O
.	O
-	O
HIT	O
testing	O
was	O
negative	O
.	O
.	O
#	O
Leukocytosis	O
,	O
fevers	O
:	O
Patient	O
had	O
fevers	O
and	O
leukocytosis	O
intermittently	O
during	O
her	O
stay	O
.	O
Patient	O
's	O
fevers	O
have	O
resolved	O
,	O
but	O
she	O
has	O
had	O
continued	O
leukocytosis	O
.	O
Patient	O
had	O
definite	O
spike	O
to	O
>	O
20	O
with	O
c.	O
difficle	O
infection	O
.	O
-	O
Patient	O
had	O
multiple	O
sets	O
of	O
blood	O
,	O
urine	O
,	O
stool	O
,	O
and	O
bile	O
cultures	O
drawn	O
;	O
her	O
chest	O
x-ray	O
was	O
unchanged	O
.	O
.	O
#	O
Anemia	O
:	O
As	O
discussed	O
above	O
in	O
regards	O
to	O
GIB	O
.	O
Her	O
hematocrit	O
remained	O
stable	O
at	O
26	O
-	O
28	O
range	O
prior	O
to	O
discharge	O
.	O
Her	O
anemia	O
was	O
that	O
of	O
chronic	O
disease	O
as	O
well	O
as	O
losses	O
from	O
GI	O
tract	O
.	O
.	O
#	O
Urinary	O
retention	O
:	O
Patient	O
had	O
several	O
voiding	O
trials	O
with	O
removal	O
of	O
her	O
foley	O
with	O
persistent	O
urinary	O
retention	O
.	O
There	O
were	O
no	O
clear	O
offending	O
medications	O
.	O
-	O
Foley	O
replaced	O
.	O
-	O
Patient	O
may	O
need	O
follow	O
up	O
with	O
urology	O
to	O
further	O
management	O
of	O
her	O
foley	O
and	O
retention	O
.	O
She	O
will	O
be	O
discharged	O
with	O
foley	O
in	O
place	O
.	O
.	O
#	O
Tremor	O
:	O
Patient	O
had	O
intermittent	O
tremor	O
of	O
her	O
left	O
arm	O
and	O
bilateral	O
feet	O
,	O
which	O
was	O
stable	O
.	O
It	O
was	O
not	O
present	O
except	O
when	O
asked	O
several	O
questions	O
and	O
stimulated	O
.	O
Does	O
not	O
cause	O
patient	O
any	O
distress	O
.	O
Tremor	O
only	O
present	O
when	O
patient	O
stimulated	O
or	O
agitated	O
,	O
not	O
present	O
in	O
sleep	O
or	O
when	O
calm	O
.	O
No	O
other	O
evidence	O
of	O
toxicity	O
or	O
increased	O
tone	O
.	O
.	O
Medications	O
on	O
Admission	O
:	O
Home	O
Medications	O
:	O
risperdal	I-Drug
2	O
mg	O
qhs	O
trazodone	I-Drug
25	O
mg	O
qhs	O
Atorvastatin	B-Drug
10	O
mg	O
PO	O
HS	O
CloniDINE	I-Drug
0.3	O
mg	O
PO	O
BID	O
Diltiazem	B-Drug
Extended	I-Drug
-	I-Drug
Release	I-Drug
120	O
mg	O
PO	O
DAILY	O
GlipiZIDE	B-Drug
2.5	O
mg	O
PO	O
DAILY	O
Hydrochlorothiazide	B-Drug
25	O
mg	O
PO	O
DAILY	O
Isosorbide	B-Drug
Mononitrate	I-Drug
(	O
Extended	O
Release	O
)	O
30	O
mg	O
PO	O
DAILY	O
Metoprolol	B-Drug
XL	I-Drug
(	I-Drug
Toprol	I-Drug
XL	I-Drug
)	I-Drug
200	O
mg	O
PO	O
DAILY	O
Sertraline	B-Drug
50	O
mg	O
PO	O
DAILY	O
Levothyroxine	B-Drug
Sodium	I-Drug
150	O
mcg	O
PO	O
DAILY	O
.	O
Medications	O
(	O
on	O
transfer	O
)	O
:	O
Atorvastatin	B-Drug
10	O
mg	O
PO	O
HS	O
CloniDINE	I-Drug
0.3	O
mg	O
PO	O
BID	O
Namenda	I-Drug
*	O
NF	O
*	O
5	O
mg	O
Oral	O
[	O
**	O
Hospital1	O
**	O
]	O
Levothyroxine	B-Drug
Sodium	I-Drug
150	O
mcg	O
PO	O
DAILY	O
Metoprolol	I-Drug
XL	O
(	O
Toprol	O
XL	O
)	O
200	O
mg	O
PO	O
DAILY	O
Isosorbide	B-Drug
Mononitrate	I-Drug
(	O
Extended	O
Release	O
)	O
30	O
mg	O
PO	O
DAILY	O
Diltiazem	I-Drug
Extended	O
-	O
Release	O
120	O
mg	O
PO	O
DAILY	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
PO	O
BID	O
GlipiZIDE	I-Drug
2.5	O
mg	O
PO	O
DAILY	O
Heparin	I-Drug
5000	O
UNIT	O
SC	O
TID	O
Hydrochlorothiazide	B-Drug
25	O
mg	O
PO	O
DAILY	O
traZODONE	I-Drug
25	O
mg	O
PO	O
HS	O
Senna	I-Drug
2	O
TAB	O
PO	O
DAILY	O
Sertraline	B-Drug
50	O
mg	O
PO	O
DAILY	O
Risperidone	I-Drug
2	O
mg	O
PO	O
HS	O
.	O
Allergies	O
:	O
Wellbutrin	I-Drug
-	O
nausea	I-Ade
and	O
vomiting	I-Ade
Kaopectate	I-Drug
-	O
loss	B-Ade
of	I-Ade
balance	I-Ade
and	O
alopecia	I-Ade
Discharge	O
Medications	O
:	O
1	O
.	O
Levothyroxine	I-Drug
175	O
mcg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
hold	O
tube	O
feeds	O
30	O
minutes	O
before	O
and	O
30	O
minutes	O
after	O
administration	O
.	O
Do	O
not	O
given	O
within	O
30	O
minutes	O
of	O
any	O
other	O
medication	O
.	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Atorvastatin	B-Drug
10	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Polyvinyl	B-Drug
Alcohol	I-Drug
-	O
Povidone	O
1.4	O
-	O
0.6	O
%	O
Dropperette	O
[	O
**	O
Hospital1	O
**	O
]	O
:	O
[	O
**	O
12	O
-	O
13	O
**	O
]	O
Drops	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
.	O
6	O
.	O
Lithium	I-Drug
Carbonate	O
150	O
mg	O
Capsule	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
7	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Calcium	I-Drug
Carbonate	O
500	O
mg	O
Tablet	O
,	O
Chewable	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Sucralfate	I-Drug
1	O
gram	O
Tablet	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Lansoprazole	B-Drug
30	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
,	O
DR	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Clonidine	I-Drug
0.2	O
mg	O
/	O
24	O
hr	O
Patch	O
Weekly	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Patch	O
Weekly	O
Transdermal	O
QTHUR	O
(	O
every	O
Thursday	O
)	O
.	O
12	O
.	O
Citalopram	B-Drug
40	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
13	O
.	O
Captopril	I-Drug
25	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
14	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
15	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
16	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
thrush	I-Reason
.	O
17	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
rash	I-Reason
.	O
18	O
.	O
Sodium	B-Drug
Chloride	I-Drug
0.65	O
%	O
Aerosol	O
,	O
Spray	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
:	O
[	O
**	O
12	O
-	O
13	O
**	O
]	O
Sprays	O
Nasal	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
19	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
20	O
.	O
Vancomycin	B-Drug
250	O
mg	O
Capsule	O
[	O
**	O
Month	O
/	O
Day	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
for	O
5	O
days	O
.	O
21	O
.	O
Insulin	I-Drug
Insulin	I-Drug
therapy	O
as	O
per	O
sliding	O
scale	O
22	O
.	O
Outpatient	O
Lab	O
Work	O
TSH	O
,	O
free	O
T4	O
to	O
be	O
checked	O
on	O
or	O
around	O
[	O
**	O
2186-12-26	O
**	O
]	O
.	O
To	O
be	O
followed	O
by	O
[	O
**	O
Location	O
(	O
un	O
)	O
583	O
**	O
]	O
House	O
and	O
/	O
or	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1266	O
**	O
]	O
.	O
23	O
.	O
Outpatient	O
Lab	O
Work	O
CBC	O
,	O
chem	O
7	O
to	O
be	O
checked	O
on	O
or	O
around	O
[	O
**	O
2186-12-22	O
**	O
]	O
;	O
to	O
be	O
followed	O
by	O
[	O
**	O
Location	O
(	O
un	O
)	O
583	O
**	O
]	O
House	O
and	O
/	O
or	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1266	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
583	O
**	O
]	O
House	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
depression	O
new	O
mulifocial	O
atrial	O
tachycardia	O
,	O
ventricular	O
tachycardia	O
on	O
EKG	O
Secondary	O
Diagnosis	O
:	O
failure	O
to	O
thrive	O
labile	O
hypertension	O
poorly	O
controlled	O
diabetes	O
mellitus	O
Discharge	O
Condition	O
:	O
improved	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hosptial	O
for	O
depression	O
and	O
failure	O
to	O
thrive	O
.	O
For	O
your	O
depression	I-Reason
and	O
failure	B-Reason
to	I-Reason
thrive	I-Reason
,	O
you	O
were	O
evaluated	O
by	O
our	O
psychiatrists	O
who	O
started	O
you	O
on	O
two	O
new	O
medications	O
called	O
celexa	I-Drug
and	O
lithium	I-Drug
.	O
These	O
medications	O
seemed	O
to	O
help	O
your	O
mood	O
and	O
improved	O
your	O
communication	O
.	O
While	O
you	O
were	O
here	O
,	O
you	O
also	O
had	O
several	O
other	O
medical	O
problems	O
including	O
labile	O
hypertension	O
,	O
uncontrolled	O
blood	O
sugars	O
,	O
gastrointestinal	O
bleeding	O
,	O
episodes	O
of	O
unresponsiveness	O
,	O
and	O
infection	O
of	O
your	O
gall	O
bladder	O
.	O
.	O
Your	O
blood	O
pressure	O
and	O
blood	O
sugars	O
were	O
controlled	O
.	O
You	O
were	O
given	O
nutrition	I-Drug
via	O
intravenous	O
administration	O
and	O
via	O
a	O
tube	O
going	O
from	O
your	O
nose	O
to	O
your	O
stomach	O
.	O
You	O
were	O
also	O
found	O
to	O
have	O
a	O
new	O
heart	O
arrythmia	O
and	O
transient	O
renal	O
failure	O
.	O
You	O
were	O
seen	O
by	O
psychiatry	O
and	O
treated	O
daily	O
for	O
your	O
depression	O
as	O
we	O
stabilized	O
you	O
medically	O
.	O
.	O
You	O
also	O
developed	O
a	O
bleed	B-Reason
from	I-Reason
your	I-Reason
gastrointestinal	I-Reason
tract	I-Reason
,	O
and	O
required	O
blood	I-Drug
transfusions	O
.	O
.	O
The	O
medicines	O
we	O
stopped	O
were	O
:	O
risperdal	I-Drug
,	O
trazodone	I-Drug
,	O
diltiazem	I-Drug
,	O
glipizide	I-Drug
,	O
HCTZ	I-Drug
,	O
Imdur	I-Drug
,	O
sertraline	I-Drug
.	O
The	O
medicines	O
we	O
started	O
were	O
:	O
amiodarone	I-Drug
,	O
lansoprazole	I-Drug
,	O
insulin	I-Drug
,	O
captopril	I-Drug
,	O
citalopram	I-Drug
,	O
calcium	I-Drug
,	O
colace	I-Drug
,	O
sucralfate	I-Drug
,	O
senna	I-Drug
,	O
lithium	I-Drug
,	O
vancomycin	I-Drug
oral	O
liquid	O
(	O
thru	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
)	O
.	O
The	O
medications	O
we	O
changed	O
were	O
:	O
clonidine	I-Drug
(	O
now	O
taking	O
as	O
a	O
patch	O
)	O
,	O
levothyroxine	I-Drug
(	O
increased	O
to	O
175	O
mcg	O
per	O
day	O
)	O
,	O
metoprolol	I-Drug
(	O
increased	O
to	O
300	O
per	O
day	O
)	O
.	O
Please	O
take	O
all	O
of	O
your	O
medications	O
as	O
directed	O
.	O
Followup	O
Instructions	O
:	O
Please	O
continue	O
your	O
stay	O
at	O
the	O
rehabilitation	O
facility	O
until	O
you	O
are	O
deemed	O
ready	O
to	O
leave	O
.	O
Please	O
follow	O
-	O
up	O
closely	O
with	O
an	O
outside	O
hosptial	O
psychiatrist	O
.	O
.	O
Once	O
you	O
are	O
discharged	O
from	O
you	O
rehabilitation	O
facility	O
please	O
follow	O
-	O
up	O
with	O
a	O
cardiologist	O
of	O
your	O
choice	O
to	O
address	O
your	O
new	O
heart	O
arrhythmia	O
.	O
.	O
Please	O
call	O
your	O
primary	O
care	O
physician	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1266	O
**	O
]	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
608	O
**	O
]	O
to	O
schedule	O
an	O
appointment	O
for	O
2	O
weeks	O
after	O
discharge	O
.	O
.	O
You	O
will	O
need	O
to	O
have	O
your	O
thyroid	O
function	O
tests	O
checked	O
in	O
[	O
**	O
12	O
-	O
13	O
**	O
]	O
weeks	O
.	O
You	O
should	O
also	O
have	O
your	O
blood	O
counts	O
and	O
electrolytes	O
checked	O
on	O
Friday	O
,	O
[	O
**	O
12	O
-	O
22	O
**	O
]	O
.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
4055	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2196-10-26	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2196-11-30	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2118-7-15	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3043	O
**	O
]	O
Chief	O
Complaint	O
:	O
Cellulitis	O
/	O
DVT	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Thoracentesis	O
(	O
x2	O
)	O
Placement	O
of	O
Chest	O
Tube	O
Pleurodesis	O
Abdominal	O
paracentesis	O
(	O
x4	O
)	O
PICC	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
78	O
year	O
old	O
man	O
with	O
history	O
notable	O
for	O
extensive	O
pulmonary	O
asbestosis	O
,	O
atrial	O
fibrillation	O
,	O
and	O
RP	O
fibrosis	O
s	O
/	O
p	O
ureterolysis	O
and	O
omental	O
wrap	O
who	O
presented	O
to	O
an	O
outside	O
hospital	O
on	O
[	O
**	O
2196-10-26	O
**	O
]	O
for	O
elective	O
hernia	O
repair	O
.	O
The	O
patient	O
has	O
long	O
been	O
awaiting	O
repair	O
of	O
a	O
large	O
inguinal	O
hernia	O
and	O
ventral	O
hernia	O
and	O
had	O
stopped	O
taking	O
his	O
coumadin	I-Drug
10	O
days	O
prior	O
to	O
presentation	O
(	O
he	O
is	O
on	O
this	O
for	O
atrial	B-Reason
fibrillation	I-Reason
)	O
in	O
order	O
to	O
get	O
these	O
procedures	O
completed	O
.	O
Over	O
the	O
week	O
prior	O
to	O
presentation	O
he	O
had	O
also	O
noted	O
worsening	O
left	O
lower	O
extremity	O
edema	O
and	O
increasing	O
abdominal	O
girth	O
with	O
worsening	O
of	O
his	O
preexisting	O
vental	O
hernia	O
.	O
Other	O
review	O
of	O
systems	O
notable	O
for	O
some	O
nonproductive	O
cough	O
as	O
well	O
as	O
general	O
fatigue	O
and	O
decreased	O
mobility	O
for	O
the	O
past	O
month	O
,	O
which	O
he	O
largely	O
attributed	O
to	O
his	O
impressive	O
hydrocele	O
.	O
He	O
denied	O
any	O
fevers	O
,	O
chest	O
pain	O
,	O
orthopnea	O
,	O
or	O
PND	O
.	O
At	O
the	O
outside	O
hospital	O
initial	O
evaluation	O
revealed	O
abdominal	O
wall	O
erythema	O
concerning	O
for	O
cellulitis	O
as	O
well	O
as	O
a	O
swollen	O
left	O
lower	O
extremity	O
.	O
Ultrasound	O
showed	O
left	O
common	O
femoral	O
vein	O
DVT	O
.	O
He	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
.	O
On	O
arrival	O
he	O
complained	O
of	O
fatigue	O
and	O
discomfort	O
from	O
his	O
large	O
hernias	O
.	O
No	O
other	O
issues	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
asbestosis	O
-	O
atrial	O
fibrillation	O
-	O
ureterolysis	O
-	O
RP	O
fibrosis	O
(	O
presumed	O
idiopathic	O
)	O
-	O
omental	O
wrap	O
Social	O
History	O
:	O
The	O
patient	O
worked	O
as	O
a	O
steam	O
engineer	O
for	O
over	O
40	O
years	O
.	O
He	O
reports	O
significant	O
asbestos	O
exposure	O
over	O
a	O
period	O
of	O
several	O
years	O
.	O
He	O
lives	O
with	O
his	O
wife	O
of	O
58	O
years	O
.	O
He	O
denies	O
TOB	O
or	O
drug	O
use	O
and	O
says	O
he	O
drinks	O
alcohol	O
only	O
very	O
occasionally	O
.	O
Family	O
History	O
:	O
Father	O
died	O
of	O
complications	O
of	O
pernicious	O
anemia	O
,	O
mother	O
died	O
at	O
age	O
66	O
of	O
??????	O
heart	O
problems	O
??????	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
brother	O
died	O
of	O
an	O
MI	O
at	O
age	O
53	O
,	O
both	O
younger	O
brothers	O
died	O
of	O
CVD	O
in	O
their	O
40	O
??????	O
s	O
.	O
One	O
sister	O
died	O
of	O
complications	O
of	O
alcoholism	O
at	O
66	O
,	O
another	O
sister	O
died	O
at	O
age	O
68	O
of	O
cerebral	O
hemorrhage	O
.	O
His	O
one	O
remaining	O
sibling	O
,	O
a	O
sister	O
,	O
is	O
77	O
and	O
well	O
.	O
Physical	O
Exam	O
:	O
On	O
Presentation	O
:	O
T	O
=	O
94.7	O
HR	O
60	O
BP	O
153/56	O
RR30	O
93	O
%	O
NRB	O
PHYSICAL	O
EXAM	O
GENERAL	O
:	O
Pleasant	O
,	O
speaking	O
in	O
full	O
sentences	O
HEENT	O
:	O
Normocephalic	O
,	O
atraumatic	O
.	O
No	O
conjunctival	O
pallor	O
.	O
No	O
scleral	O
icterus	O
.	O
PERRLA	O
.	O
dry	O
mmm	O
.	O
OP	O
clear	O
.	O
Neck	O
Supple	O
,	O
No	O
LAD	O
.	O
CARDIAC	O
:	O
Regular	O
rhythm	O
,	O
normal	O
rate	O
.	O
Normal	O
S1	O
,	O
S2	O
.	O
No	O
murmurs	O
,	O
rubs	O
or	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
549	O
**	O
]	O
.	O
no	O
elevation	O
of	O
JVD	O
LUNGS	O
:	O
decreased	O
breath	O
sounds	O
in	O
lower	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
of	O
right	O
lung	O
and	O
poor	O
air	O
movement	O
with	O
crackles	O
in	O
the	O
rest	O
of	O
the	O
lung	O
.	O
ABDOMEN	O
:	O
large	O
ventral	O
hernia	O
,	O
multiple	O
large	O
other	O
hernias	O
.	O
NT	O
,	O
ND	O
.	O
+	O
bs	O
EXTREMITIES	O
:	O
+2	O
edema	O
to	O
the	O
sacrum	O
.	O
1	O
+	O
dorsalis	O
pedis	O
pulses	O
bilaterally	O
GU	O
:	O
very	O
large	O
scrotal	O
hernia	O
and	O
scrotal	O
edema	O
SKIN	O
:	O
macular	O
rash	O
on	O
abdomen	O
and	O
back	O
NEURO	O
:	O
A&O	O
x3	O
.	O
Appropriate	O
.	O
CN	O
2	O
-	O
12	O
intact	O
.	O
UE	O
and	O
LE	O
strength	O
[	O
**	O
5	O
-	O
10	O
**	O
]	O
.	O
PSYCH	O
:	O
Listens	O
and	O
responds	O
to	O
questions	O
appropriately	O
,	O
pleasant	O
,	O
tangential	O
speech	O
.	O
Pertinent	O
Results	O
:	O
=====================	O
LABORATORY	O
RESULTS	O
=====================	O
BLOOD	O
------	O
On	O
Presentation	O
:	O
WBC	O
-	O
11.5	O
*	O
RBC	O
-	O
4.20	O
*	O
Hgb	O
-	O
11.4	O
*	O
Hct	O
-	O
34.5	O
*	O
MCV	O
-	O
82	O
RDW	O
-	O
15.3	O
Plt	O
Ct	O
-	O
452	O
*	O
---	O
Neuts	O
-	O
84.8	O
*	O
Lymphs	O
-	O
5.1	O
*	O
Monos	O
-	O
8.7	O
Eos	O
-	O
1.0	O
Baso	O
-	O
0.4	O
PT	O
-	O
14.2	O
*	O
PTT	O
-	O
25.5	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
Glucose	O
-	O
105	O
UreaN	O
-	O
37	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
140	O
K	O
-	O
5.5	O
*	O
Cl	O
-	O
107	O
HCO3	O
-	O
24	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
4.1	O
Mg	O
-	O
1.8	O
Last	O
Full	O
Labs	O
:	O
WBC	O
-	O
16.1	O
*	O
RBC	O
-	O
3.82	O
*	O
Hgb	O
-	O
10.4	O
*	O
Hct	O
-	O
32.0	O
*	O
MCV	O
-	O
84	O
RDW	O
-	O
15.9	O
*	O
Plt	O
Ct	O
-	O
649	O
*	O
---	O
Neuts	O
-	O
86.8	O
*	O
Lymphs	O
-	O
3.4	O
*	O
Monos	O
-	O
8.6	O
Eos	O
-	O
0.8	O
Baso	O
-	O
0.4	O
PT	O
-	O
15.2	O
*	O
PTT	O
-	O
37.0	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
Glucose	O
-	O
121	O
*	O
UreaN	O
-	O
102	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
136	O
K	O
-	O
4.2	O
Cl	O
-	O
104	O
HCO3	O
-	O
21	O
*	O
Other	O
Important	O
Labs	O
:	O
[	O
**	O
2196-11-4	O
**	O
]	O
07:50	O
AM	O
BLOOD	O
ALT	O
-	O
10	O
AST	O
-	O
20	O
AlkPhos	O
-	O
60	O
TotBili	O
-	O
0.2	O
[	O
**	O
2196-11-5	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
Triglyc	O
-	O
135	O
HDL	O
-	O
29	O
CHOL	O
/	O
HD	O
-	O
4.2	O
LDLcalc	O
-	O
67	O
[	O
**	O
2196-11-18	O
**	O
]	O
03:50	O
AM	O
BLOOD	O
TSH	O
-	O
4.1	O
[	O
**	O
2196-11-18	O
**	O
]	O
03:50	O
AM	O
BLOOD	O
Cortsol	O
-	O
15.9	O
[	O
**	O
2196-11-8	O
**	O
]	O
12:52	O
PM	O
BLOOD	O
PSA	O
-	O
0.8	O
[	O
**	O
2196-11-9	O
**	O
]	O
07:25	O
AM	O
BLOOD	O
PEP	O
-	O
NO	O
SPECIFIC	O
PEAK	O
ID	O
's	O
Protein	O
/	O
Albumins	O
:	O
[	O
**	O
2196-11-4	O
**	O
]	O
07:50	O
AM	O
Albumin	O
-	O
2.7	O
*	O
[	O
**	O
2196-11-5	O
**	O
]	O
07:15	O
AM	O
TotProt	O
-	O
6.4	O
Albumin	O
-	O
3.5	O
[	O
**	O
2196-11-9	O
**	O
]	O
07:25	O
AM	O
TotProt	O
-	O
6.2	O
*	O
[	O
**	O
2196-11-11	O
**	O
]	O
05:00	O
AM	O
TotProt	O
-	O
5.9	O
*	O
Albumin	O
-	O
3.2	O
*	O
[	O
**	O
2196-11-12	O
**	O
]	O
05:37	O
AM	O
Albumin	O
-	O
3.3	O
*	O
[	O
**	O
2196-11-18	O
**	O
]	O
03:50	O
AM	O
Albumin	O
-	O
2.5	O
*	O
[	O
**	O
2196-11-22	O
**	O
]	O
05:56	O
AM	O
TotProt	O
-	O
4.3	O
*	O
Albumin	O
-	O
2.2	O
*	O
Urine	O
------	O
[	O
**	O
2196-11-25	O
**	O
]	O
:	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Hazy	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.017	O
Blood	O
-	O
TR	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
30	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.5	O
Leuks	O
-	O
NEG	O
RBC	O
-	O
2	O
WBC	O
-	O
1	O
Bacteri	O
-	O
NONE	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
1	O
TransE	O
-	O
<	O
1	O
CastGr	O
-	O
18	O
*	O
Pleural	O
Fluid	O
---------------	O
[	O
**	O
2196-11-13	O
**	O
]	O
WBC	O
-	O
190	O
*	O
RBC	O
-	O
5875	O
*	O
Polys	O
-	O
11	O
*	O
Lymphs	O
-	O
59	O
*	O
Monos	O
-	O
18	O
*	O
Eos	O
-	O
1	O
*	O
Meso	O
-	O
11	O
*	O
TotProt	O
-	O
3.6	O
Glucose	O
-	O
129	O
LD	O
(	O
LDH	O
)	O
-	O
116	O
Cholest	O
-	O
75	O
Triglyc	O
-	O
1120	O
[	O
**	O
2196-11-15	O
**	O
]	O
WBC	O
-	O
1000	O
*	O
RBC	O
-	O
9333	O
*	O
Polys	O
-	O
19	O
*	O
Lymphs	O
-	O
55	O
*	O
Monos	O
-	O
15	O
*	O
Eos	O
-	O
1	O
*	O
Meso	O
-	O
10	O
*	O
TotProt	O
-	O
3.5	O
LD	O
(	O
LDH	O
)	O
-	O
116	O
Amylase	O
-	O
28	O
Albumin	O
-	O
2.0	O
Peritoneal	O
Fluid	O
-----------------	O
[	O
**	O
2196-11-5	O
**	O
]	O
WBC	O
-	O
1875	O
*	O
RBC	O
-	O
[	O
**	O
Numeric	O
Identifier	O
**	O
]	O
*	O
Polys	O
-	O
22	O
*	O
Bands	O
-	O
1	O
*	O
Lymphs	O
-	O
40	O
*	O
Monos	O
-	O
0	O
Macroph	O
-	O
37	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
120	O
Albumin	O
-	O
2.0	O
Triglyc	O
-	O
1304	O
Adenosine	O
Deaminase	O
:	O
6.4	O
(	O
Normal	O
)	O
[	O
**	O
2196-11-10	O
**	O
]	O
WBC	O
-	O
740	O
*	O
RBC	O
-	O
3150	O
*	O
Polys	O
-	O
8	O
*	O
Lymphs	O
-	O
57	O
*	O
Monos	O
-	O
33	O
*	O
Mesothe	O
-	O
2	O
*	O
TotPro	O
-	O
3.6	O
LD	O
(	O
LDH	O
)	O
-	O
114	O
Albumin	O
-	O
2.1	O
Triglyc	O
-	O
815	O
[	O
**	O
2196-1-24	O
**	O
]	O
WBC	O
-	O
570	O
*	O
RBC	O
-	O
720	O
*	O
Polys	O
-	O
58	O
*	O
Lymphs	O
-	O
27	O
*	O
Monos	O
-	O
0	O
Eos	O
-	O
1	O
*	O
Plasma	O
-	O
2	O
*	O
Mesothe	O
-	O
1	O
*	O
Macroph	O
-	O
11	O
*	O
TotPro	O
-	O
2.4	O
Glucose	O
-	O
133	O
LD	O
(	O
LDH	O
)	O
-	O
139	O
Amylase	O
-	O
16	O
Albumin	O
-	O
1.4	O
===============	O
MICROBIOLOGY	O
===============	O
Blood	O
Cultures	O
*	O
6	O
:	O
No	O
growth	O
Urine	O
Cultures	O
*	O
4	O
:	O
No	O
Growth	O
Stool	O
for	O
C	O
diff	O
:	O
Negative	O
Peritoneal	O
Fluid	O
Culture	O
*	O
4	O
:	O
No	O
growth	O
Pleural	O
Fluid	O
Culture	O
*	O
3	O
:	O
No	O
Growth	O
===========	O
PATHOLOGY	O
===========	O
Pleural	O
Fluid	O
Cytology	O
from	O
[	O
**	O
11	O
-	O
10	O
**	O
]	O
,	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
,	O
and	O
[	O
**	O
11	O
-	O
15	O
**	O
]	O
:	O
Negative	O
for	O
Malignant	O
Cells	O
Peritoneal	O
Fluid	O
Cytology	O
from	O
[	O
**	O
11	O
-	O
5	O
**	O
]	O
and	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
:	O
Negative	O
for	O
malignant	O
cells	O
Pleural	O
Fluid	O
Immunophenotyping	O
:	O
NTERPRETATION	O
Non-specific	O
T	O
cell	O
dominant	O
lymphoid	O
profile	O
;	O
diagnostic	O
immunophenotypic	O
features	O
of	O
involvement	O
by	O
lymphoma	O
are	O
not	O
seen	O
in	O
specimen	O
.	O
Correlation	O
with	O
clinical	O
findings	O
and	O
morphology	O
(	O
see	O
C09	O
-	O
[	O
**	O
Numeric	O
Identifier	O
**	O
]	O
)	O
is	O
recommended	O
.	O
Flow	O
cytometry	O
immunophenotyping	O
may	O
not	O
detect	O
all	O
lymphomas	O
as	O
due	O
to	O
topography	O
,	O
sampling	O
or	O
artifacts	O
of	O
sample	O
preparation	O
.	O
===============	O
OTHER	O
STUDIES	O
===============	O
ECG	O
[	O
**	O
2196-10-26	O
**	O
]	O
:	O
Sinus	O
bradycardia	O
.	O
Otherwise	O
,	O
tracing	O
is	O
within	O
normal	O
limits	O
CT	O
Abdomen	O
and	O
Pelvis	O
W	O
/	O
O	O
Contrast	I-Drug
[	O
**	O
2196-10-26	O
**	O
]	O
:	O
IMPRESSION	O
AND	O
PLAN	O
:	O
1	O
.	O
Abnormal	O
soft	O
tissue	O
encasing	O
the	O
retroperitoneal	O
structures	O
,	O
surrounding	O
the	O
aorta	O
and	O
IVC	O
,	O
extending	O
inferiorly	O
along	O
the	O
presacral	O
space	O
.	O
These	O
findings	O
are	O
incompletely	O
characterized	O
without	O
intravenous	O
contrast	I-Drug
.	O
Findings	O
could	O
reflect	O
retroperitoneal	O
fibrosis	O
,	O
though	O
correlation	O
with	O
prior	O
history	O
or	O
any	O
prior	O
imaging	O
would	O
be	O
helpful	O
.	O
The	O
attenuation	O
of	O
this	O
material	O
is	O
not	O
compatible	O
with	O
hemorrhage	O
2	O
.	O
Complex	O
ventral	O
abdominal	O
wall	O
hernia	O
containing	O
fat	O
,	O
fluid	O
and	O
small	O
bowel	O
,	O
without	O
evidence	O
of	O
obstruction	O
.	O
3	O
.	O
Large	O
left	O
inguinal	O
hernia	O
,	O
with	O
herniation	O
of	O
fluid	O
and	O
sigmoid	O
colon	O
to	O
the	O
left	O
scrotal	O
sac	O
.	O
4	O
.	O
Large	O
amount	O
of	O
ascites	O
.	O
5	O
.	O
Left	O
external	O
iliac	O
,	O
common	O
femoral	O
,	O
and	O
superficial	O
femoral	O
venous	O
thrombosis	O
.	O
Chest	O
Radiograph	O
[	O
**	O
2196-11-1	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Marked	O
cardiac	O
enlargement	O
predominantly	O
involving	O
the	O
left	O
heart	O
.	O
Extensive	O
bilateral	O
pleural	O
changes	O
including	O
calcifications	O
consistent	O
with	O
previous	O
asbestos	O
exposure	O
.	O
Pulmonary	O
vasculature	O
demonstrates	O
upper	O
zone	O
re-distribution	O
pattern	O
but	O
no	O
conclusive	O
evidence	O
for	O
acute	O
infiltrates	O
.	O
Bilateral	O
Lower	O
Extremity	O
Ultrasounds	O
[	O
**	O
2196-11-3	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Occlusive	O
deep	O
venous	O
thrombosis	O
in	O
the	O
common	O
femoral	O
vein	O
extending	O
into	O
the	O
greater	O
saphenous	O
and	O
deep	O
femoral	O
veins	O
.	O
Of	O
note	O
,	O
the	O
proximal	O
extent	O
of	O
thrombus	O
is	O
not	O
defined	O
.	O
2	O
.	O
No	O
right	O
lower	O
extremity	O
deep	O
venous	O
thrombosis	O
.	O
Spirometry	O
[	O
**	O
2196-11-4	O
**	O
]	O
:	O
Impression	O
:	O
Marked	O
restrictive	O
ventilatory	O
defect	O
with	O
a	O
marked	O
gas	O
exchange	O
defect	O
.	O
The	O
reduced	O
DLCO	O
suggests	O
an	O
interstitial	O
process	O
.	O
There	O
are	O
no	O
prior	O
studies	O
available	O
for	O
comparison	O
.	O
TTE	O
[	O
**	O
2196-11-4	O
**	O
]	O
:	O
Conclusions	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
and	O
regional	O
/	O
global	O
systolic	O
function	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
There	O
is	O
no	O
VSD	O
seen	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
arch	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
a	O
minimally	O
increased	O
gradient	O
consistent	O
with	O
minimal	O
aortic	O
valve	O
stenosis	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
mild	O
mitral	O
valve	O
prolapse	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Abdominal	O
Ultrasound	O
w	O
/	O
Dopplers	O
[	O
**	O
2196-11-4	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Normal	O
portal	O
venous	O
,	O
hepatic	O
venous	O
,	O
and	O
hepatic	O
arterial	O
flow	O
to	O
the	O
liver	O
.	O
2	O
.	O
Large	O
amount	O
of	O
ascites	O
CT	O
Chest	O
W	O
/	O
O	O
Contrast	O
[	O
**	O
2196-11-7	O
**	O
]	O
:	O
IMPRESSION	O
:	O
The	O
constellation	O
of	O
findings	O
including	O
an	O
increasing	O
right	O
pleural	O
effusion	O
which	O
is	O
moderately	O
large	O
,	O
massive	O
hiatal	O
hernia	O
,	O
diffuse	O
ground	O
-	O
glass	O
opacities	O
throughout	O
the	O
lungs	O
probably	O
infective	O
or	O
inflammatory	O
,	O
extensive	O
calcification	O
in	O
multiple	O
pleural	O
plaques	O
with	O
extensive	O
intra	O
-	O
abdominal	O
ascites	O
all	O
contribute	O
to	O
the	O
worsening	O
respiratory	O
status	O
.	O
The	O
presence	O
of	O
an	O
increasing	O
pleural	O
effusion	O
with	O
calcified	O
and	O
noncalcified	O
pleural	O
plaques	O
in	O
the	O
setting	O
of	O
asbestos	O
-	O
related	O
disease	O
raises	O
the	O
remote	O
possibility	O
of	O
mesothelioma	O
.	O
TTE	O
[	O
**	O
2196-11-8	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Mild	O
concentric	O
hypertrophy	O
with	O
normal	O
biventricular	O
regional	O
and	O
global	O
systolic	O
function	O
.	O
Moderate	O
diastolic	O
dysfunction	O
with	O
elevated	O
PCWP	O
.	O
Mild	O
aortic	O
regurgitation	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2196-11-4	O
**	O
]	O
,	O
the	O
findings	O
are	O
similar	O
.	O
A	O
paramembranous	O
VSD	O
is	O
not	O
seen	O
on	O
either	O
study	O
(	O
mentioned	O
in	O
initial	O
report	O
)	O
.	O
The	O
velocity	O
across	O
the	O
aortic	O
valve	O
is	O
now	O
lower	O
CT	O
Chest	O
[	O
**	O
2196-11-12	O
**	O
]	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Large	O
right	O
-	O
sided	O
pleural	O
effusion	O
which	O
has	O
increased	O
in	O
size	O
since	O
the	O
study	O
performed	O
five	O
days	O
prior	O
.	O
Associated	O
compressive	O
atelectasis	O
of	O
the	O
right	O
lung	O
base	O
.	O
Also	O
compressive	O
atelectasis	O
of	O
the	O
left	O
lung	O
base	O
due	O
to	O
large	O
hiatal	O
hernia	O
which	O
is	O
unchanged	O
.	O
2	O
.	O
Scattered	O
ground	O
-	O
glass	O
opacities	O
throughout	O
both	O
lungs	O
,	O
stable	O
,	O
likely	O
infectious	O
or	O
inflammatory	O
in	O
nature	O
.	O
No	O
focal	O
consolidations	O
.	O
No	O
other	O
significant	O
changes	O
since	O
the	O
prior	O
study	O
.	O
Renal	O
Ultrasound	O
[	O
**	O
2196-11-12	O
**	O
]	O
:	O
IMPRESSION	O
:	O
No	O
hydronephrosis	O
.	O
Non-diagnostic	O
Doppler	O
evaluation	O
due	O
to	O
patient	O
's	O
inability	O
to	O
hold	O
breath	O
.	O
CT	O
Chest	O
w	O
/	O
o	O
Contast	O
[	O
**	O
2196-11-14	O
**	O
]	O
:	O
FINDINGS	O
:	O
There	O
has	O
been	O
a	O
slight	O
decrease	O
in	O
size	O
of	O
the	O
large	O
right	O
pleural	O
effusion	O
since	O
the	O
previous	O
CT	O
on	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
with	O
no	O
pneumothorax	O
.	O
The	O
right	O
lower	O
lobe	O
compressive	O
atelectasis	O
remains	O
similar	O
and	O
the	O
large	O
intrathoracic	O
hiatal	O
hernia	O
now	O
contains	O
peripheral	O
fluid	O
tracking	O
up	O
from	O
the	O
extensive	O
ascites	O
.	O
Otherwise	O
,	O
no	O
change	O
since	O
the	O
CT	O
torso	O
on	O
[	O
**	O
2196-11-12	O
**	O
]	O
,	O
and	O
reference	O
to	O
the	O
previous	O
CT	O
report	O
is	O
recommended	O
for	O
complete	O
description	O
of	O
findings	O
.	O
KUB	O
[	O
**	O
2196-11-25	O
**	O
]	O
:	O
FINDINGS	O
:	O
In	O
the	O
left	O
anterior	O
mid	O
abdomen	O
in	O
the	O
expected	O
location	O
of	O
the	O
patients	O
known	O
ventral	O
abdominal	O
hernia	O
,	O
multiple	O
air	O
-	O
filled	O
and	O
dilated	O
bowel	O
loops	O
are	O
seen	O
,	O
likely	O
involving	O
both	O
small	O
and	O
large	O
bowel	O
.	O
Air	O
is	O
visualized	O
in	O
the	O
rectum	O
.	O
CT	O
is	O
recommended	O
to	O
rule	O
out	O
large	O
or	O
small	O
bowel	O
obstruction	O
.	O
Chest	O
Radiograph	O
[	O
**	O
2196-11-26	O
**	O
]	O
:	O
FINDINGS	O
:	O
Portable	O
AP	O
upright	O
chest	O
radiograph	O
is	O
compared	O
with	O
[	O
**	O
11	O
-	O
22	O
**	O
]	O
and	O
[	O
**	O
2196-11-25	O
**	O
]	O
.	O
There	O
is	O
a	O
large	O
hiatal	O
hernia	O
.	O
There	O
is	O
increase	O
in	O
the	O
right	O
mid	O
lung	O
opacification	O
,	O
which	O
may	O
be	O
atelectasis	O
or	O
pneumonia	O
.	O
There	O
is	O
left	O
basal	O
atelectasis	O
with	O
increasing	O
pleural	O
effusion	O
.	O
Within	O
the	O
left	O
upper	O
lung	O
there	O
is	O
increased	O
opacification	O
,	O
which	O
may	O
be	O
secondary	O
to	O
infection	O
.	O
The	O
right	O
pigtail	O
catheter	O
is	O
unchanged	O
in	O
position	O
.	O
There	O
is	O
atherosclerotic	O
disease	O
of	O
the	O
thoracic	O
aorta	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
78	O
year	O
old	O
male	O
with	O
history	O
of	O
paradoxical	O
atrial	O
fibrillation	O
,	O
pulmonary	O
asbestosis	O
,	O
and	O
idiopathic	O
RP	O
fibrosis	O
presenting	O
with	O
cellulitis	O
and	O
increased	O
abdominal	O
distension	O
found	O
to	O
have	O
DVT	O
and	O
with	O
progressive	O
chylous	O
ascites	O
.	O
1	O
)	O
Chylous	O
Ascites	O
:	O
The	O
patient	O
was	O
noted	O
to	O
have	O
a	O
distended	O
abdomen	O
on	O
presentation	O
and	O
imaging	O
revealed	O
a	O
large	O
amount	O
of	O
ascites	O
.	O
As	O
the	O
patient	O
had	O
not	O
had	O
a	O
previous	O
history	O
of	O
ascites	O
this	O
was	O
worked	O
up	O
with	O
liver	O
ultrasound	O
that	O
revealed	O
no	O
parenchymal	O
or	O
vascular	O
dysfunction	O
.	O
Diagnostic	O
paracentesis	O
was	O
obtained	O
on	O
[	O
**	O
2196-11-5	O
**	O
]	O
that	O
showed	O
chylous	O
ascites	O
.	O
This	O
paracentesis	O
also	O
revealed	O
>	B-Reason
250	I-Reason
neutrophils	I-Reason
so	O
the	O
patient	O
was	O
empirically	O
started	O
on	O
a	O
five	O
day	O
course	O
of	O
ceftriaxone	I-Drug
though	O
he	O
remained	O
afebrile	O
and	O
had	O
no	O
abdominal	O
pain	O
.	O
After	O
the	O
chylous	O
ascites	O
was	O
discovered	O
primary	O
concern	O
was	O
for	O
a	O
malignancy	O
given	O
the	O
lack	O
of	O
liver	O
disease	O
.	O
Multiple	O
imaging	O
studies	O
failed	O
to	O
show	O
a	O
mass	O
,	O
however	O
,	O
multiple	O
fluid	O
cytologies	O
were	O
negative	O
,	O
and	O
the	O
patient	O
's	O
LDH	O
was	O
within	O
normal	O
limits	O
making	O
lymphoma	O
quite	O
unlikely	O
.	O
Therefore	O
,	O
most	O
likely	O
etiology	O
of	O
the	O
development	O
of	O
chylous	O
ascites	O
was	O
thought	O
to	O
be	O
progressive	O
lymphatic	O
obstruction	O
from	O
RP	O
fibrosis	O
leading	O
to	O
increased	O
hydrostatic	O
pressure	O
and	O
leak	O
into	O
the	O
peritoneal	O
cavity	O
.	O
The	O
patient	O
had	O
three	O
therapeutic	O
paracentesis	O
on	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
,	O
and	O
[	O
**	O
11	O
-	O
29	O
**	O
]	O
respectively	O
removing	O
900	O
cc	O
,	O
3L	O
and	O
1	O
L	O
of	O
chylous	O
fluid	O
respectively	O
.	O
The	O
second	O
of	O
these	O
revealed	O
a	O
neutrophil	B-Reason
count	I-Reason
of	I-Reason
280	I-Reason
so	O
led	O
to	O
a	O
second	O
course	O
of	O
five	O
days	O
of	O
antibiotics	I-Drug
with	O
ciprofloxacin	I-Drug
(	O
as	O
the	O
patient	O
was	O
on	O
cefepime	I-Drug
/	O
vanc	I-Drug
when	O
the	O
paracentesis	O
occured	O
)	O
which	O
completed	O
on	O
[	O
**	O
2196-11-29	O
**	O
]	O
.	O
All	O
cultures	O
remained	O
negative	O
.	O
Unfortunately	O
,	O
the	O
patient	O
developed	O
secondary	O
chylothorax	O
from	O
fluid	O
tracking	O
up	O
into	O
the	O
pleural	O
space	O
causing	O
respiratory	O
distress	O
.	O
Attempts	O
were	O
made	O
to	O
slow	B-Reason
accumulation	I-Reason
of	I-Reason
fluid	I-Reason
with	O
medical	O
therapies	O
including	O
octreotide	I-Drug
and	O
low	O
fat	O
diet	O
then	O
low	O
fat	O
TPN	O
but	O
these	O
were	O
unsuccessful	O
.	O
General	O
surgery	O
was	O
consulted	O
twice	O
and	O
both	O
times	O
said	O
that	O
surgery	O
to	O
attempt	O
to	O
improve	O
lymph	O
drainage	O
would	O
be	O
unsuccessful	O
as	O
structures	O
are	O
very	O
small	O
and	O
diffuse	O
and	O
post-surgical	O
scarring	O
would	O
likely	O
be	O
as	O
damaging	O
as	O
initial	O
insult	O
.	O
Case	O
was	O
discussed	O
with	O
thoracic	O
surgery	O
who	O
thought	O
that	O
without	O
clear	O
damage	O
to	O
thoracic	O
duct	O
there	O
was	O
no	O
indication	O
for	O
procedural	O
management	O
.	O
Finally	O
,	O
the	O
possibility	O
of	O
lymphangiogram	O
was	O
discussed	O
extensively	O
with	O
a	O
possible	O
intervention	O
and	O
balloon	O
dilation	O
of	O
cisterna	O
chyli	O
.	O
Unfortunately	O
,	O
planning	O
MRI	O
would	O
have	O
been	O
required	O
and	O
given	O
patient	O
's	O
progressively	O
poor	O
respiratory	O
status	O
this	O
would	O
have	O
required	O
intubation	O
.	O
As	O
lymphangiogram	O
and	O
balloon	O
dilation	O
are	O
extremely	O
uncommon	O
procedures	O
,	O
odds	O
of	O
success	O
were	O
not	O
considered	O
high	O
and	O
risk	O
of	O
intubation	O
and	O
likely	O
difficulty	O
extubation	O
was	O
discussed	O
with	O
the	O
family	O
and	O
patient	O
and	O
they	O
elected	O
to	O
pursue	O
comfort	O
focused	O
care	O
.	O
The	O
possibility	O
of	O
disease	O
modifying	O
therapy	O
for	O
RP	O
fibrosis	O
was	O
discussed	O
with	O
rheumatology	O
,	O
but	O
they	O
said	O
there	O
would	O
be	O
no	O
role	O
for	O
the	O
agents	O
used	O
(	O
almost	O
all	O
of	O
which	O
are	O
immune	O
suppressants	O
)	O
in	O
this	O
acutely	O
sick	O
individual	O
and	O
these	O
things	O
would	O
be	O
unlikely	O
to	O
lead	O
to	O
quick	O
turn	O
-	O
around	O
.	O
2	O
)	O
Chylothorax	O
/	O
Hypoxic	O
Respiratory	O
Failure	O
:	O
The	O
patient	O
was	O
initially	O
noted	O
to	O
be	O
hypoxic	O
soon	O
after	O
admission	O
with	O
desats	O
to	O
the	O
low	O
90's	O
on	O
room	O
air	O
.	O
He	O
was	O
seen	O
by	O
pulmonary	O
who	O
attributed	O
this	O
to	O
ascites	O
and	O
his	O
large	O
abdomen	O
causing	O
restrictive	O
pathology	O
in	O
the	O
setting	O
of	O
his	O
underlying	O
pulmonary	O
asbestosis	O
and	O
plaques	O
.	O
This	O
was	O
supported	O
by	O
his	O
initial	O
PFT	O
's	O
that	O
showed	O
a	O
restrictive	O
pattern	O
.	O
The	O
patient	O
then	O
became	O
progressively	O
more	O
hypoxic	O
in	O
the	O
setting	O
of	O
an	O
expanding	O
right	O
sided	O
pleural	O
effusion	O
and	O
a	O
large	O
amount	O
of	O
compressive	O
atelectasis	O
.	O
He	O
was	O
desatting	O
to	O
the	O
low	O
90's	O
on	O
4L	O
O2	I-Drug
by	O
nasal	O
cannula	O
when	O
he	O
had	O
his	O
first	O
thoracentesis	O
on	O
[	O
**	O
2196-11-10	O
**	O
]	O
with	O
considerable	O
improvement	O
after	O
the	O
procedure	O
.	O
By	O
[	O
**	O
11	O
-	O
12	O
**	O
]	O
,	O
however	O
,	O
he	O
had	O
reaccumulated	O
almost	O
completely	O
and	O
by	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
was	O
desaturating	O
again	O
so	O
that	O
an	O
ABG	O
showed	O
of	O
O2	O
of	O
around	O
53	O
.	O
Therefore	O
,	O
he	O
was	O
transferred	O
to	O
the	O
unit	O
while	O
he	O
awaited	O
a	O
second	O
thoracentesis	O
.	O
As	O
he	O
reaccumulated	O
quickly	O
again	O
after	O
that	O
thoracentesis	O
decision	O
was	O
made	O
to	O
place	O
a	O
pigtail	O
catheter	O
,	O
which	O
was	O
placed	O
on	O
[	O
**	O
2196-11-15	O
**	O
]	O
.	O
Over	O
the	O
ensuing	O
days	O
the	O
patient	O
continued	O
to	O
put	O
out	O
greater	O
than	O
one	O
liter	O
of	O
chylous	O
fluid	O
per	O
24	O
hour	O
period	O
despite	O
the	O
various	O
interventions	O
meant	O
to	O
reduce	B-Reason
chylous	I-Reason
ascites	I-Reason
mentioned	O
(	O
low	O
fat	O
diets	O
,	O
octreotide	I-Drug
,	O
etc.	O
.	O
.	O
)	O
.	O
On	O
[	O
**	O
2196-11-29	O
**	O
]	O
a	O
pleurodesis	O
was	O
attempted	O
in	O
hopes	O
of	O
allowing	O
eventual	O
removal	O
of	O
the	O
chest	O
tube	O
though	O
interventional	O
pulmonology	O
thought	O
this	O
had	O
a	O
very	O
low	O
probability	O
of	O
being	O
successful	O
.	O
After	O
the	O
second	O
thoracentesis	O
the	O
patient	O
remained	O
dependent	O
on	O
at	O
least	O
4L	O
of	O
oxygen	I-Drug
by	O
nasal	O
cannula	O
to	O
keep	O
sats	O
>	O
90	O
%	O
.	O
On	O
[	O
**	O
11	O
-	O
26	O
**	O
]	O
he	O
desaturated	O
to	O
the	O
80's	O
on	O
6L	O
in	O
the	O
context	O
of	O
worsening	O
infiltrates	O
bilaterally	O
but	O
this	O
seemed	O
to	O
improve	O
with	O
holding	O
TPN	O
and	O
was	O
ultimately	O
thought	O
most	O
likely	O
due	O
to	O
volume	O
overload	O
.	O
However	O
,	O
on	O
the	O
day	O
of	O
expected	O
discharge	O
(	O
[	O
**	O
11	O
-	O
30	O
**	O
]	O
)	O
,	O
his	O
respiratory	O
status	O
worsened	O
(	O
oxygen	O
saturation	O
of	O
90	O
-	O
92	O
%	O
on	O
non-rebreather	O
)	O
and	O
he	O
did	O
not	O
wish	O
to	O
use	O
the	O
mask	O
.	O
Given	O
that	O
comfort	O
was	O
the	O
goal	O
,	O
he	O
was	O
transitioned	O
back	O
to	O
nasal	O
cannula	O
,	O
and	O
oxygen	O
saturations	O
were	O
no	O
longer	O
followed	O
.	O
3	O
)	O
Nutrition	O
/	O
Protein	O
Loss	O
:	O
Initially	O
the	O
patient	O
was	O
allowed	O
to	O
eat	O
a	O
regular	O
diet	O
but	O
in	O
attempts	O
at	O
medical	O
management	O
he	O
was	O
converted	O
to	O
a	O
low	O
fat	O
,	O
high	O
protein	O
diet	O
and	O
then	O
made	O
NPO	O
with	O
TPN	O
.	O
Despite	O
TPN	O
his	O
protein	O
and	O
albumin	O
continued	O
to	O
fall	O
presumably	O
due	O
to	O
losses	O
in	O
the	O
chest	O
tube	O
.	O
After	O
he	O
became	O
quite	O
volume	O
overloaded	O
on	O
[	O
**	O
2196-11-27	O
**	O
]	O
and	O
given	O
the	O
minimal	O
reduction	O
in	O
fluid	O
output	O
seen	O
even	O
with	O
the	O
TPN	O
modifications	O
TPN	O
was	O
stopped	O
as	O
of	O
[	O
**	O
11	O
-	O
27	O
**	O
]	O
and	O
he	O
was	O
allowed	O
to	O
eat	O
for	O
comfort	O
.	O
He	O
and	O
his	O
family	O
understand	O
he	O
will	O
ultimately	O
continue	O
to	O
become	O
malnourished	O
and	O
weaker	O
but	O
given	O
poor	O
toleration	O
of	O
TPN	O
and	O
comfort	O
focused	O
care	O
this	O
was	O
considered	O
acceptable	O
by	O
them	O
.	O
4	O
)	O
Health	B-Reason
Care	I-Reason
Associated	I-Reason
Pneumonia	I-Reason
:	O
The	O
patient	O
was	O
noted	O
to	O
have	O
intermittently	O
elevated	O
white	O
counts	O
and	O
on	O
[	O
**	O
2196-11-19	O
**	O
]	O
had	O
a	O
right	O
upper	O
lobe	O
infiltrate	O
on	O
chest	O
radiograph	O
and	O
had	O
purulent	O
sputum	O
.	O
Therefore	O
,	O
he	O
received	O
9	O
days	O
of	O
cefepime	I-Drug
/	O
vancomycin	I-Drug
with	O
some	O
improvement	O
in	O
his	O
sputum	O
production	O
and	O
stable	O
chest	O
radiograph	O
findings	O
.	O
White	O
count	O
failed	O
to	O
trend	O
reliably	O
.	O
He	O
was	O
never	O
febrile	O
.	O
5	O
)	O
LLE	B-Reason
DVT	I-Reason
:	O
He	O
was	O
initially	O
on	O
heparin	I-Drug
gtt	O
then	O
transitioned	O
to	O
be	O
therapeutic	O
on	O
coumadin	I-Drug
.	O
He	O
was	O
transferred	O
back	O
to	O
heparin	I-Drug
gtt	O
once	O
on	O
the	O
medical	O
service	O
and	O
continued	O
on	O
this	O
throughout	O
his	O
course	O
there	O
to	O
make	O
procedures	O
feasible	O
without	O
needing	O
a	O
long	O
warfarin	I-Drug
wash	O
-	O
out	O
.	O
Anticoagulation	I-Reason
with	O
medications	O
other	O
than	O
unfractionated	I-Drug
heparin	O
(	O
enoxaparin	O
,	O
warfarin	O
)	O
was	O
not	O
optimal	O
given	O
his	O
renal	O
failure	O
and	O
poor	O
nutritional	O
status	O
.	O
6	O
)	O
Cellulitis	I-Reason
:	O
The	O
patient	O
initially	O
received	O
a	O
dose	O
of	O
penicillin	I-Drug
then	O
a	O
few	O
days	O
of	O
cefazolin	I-Drug
with	O
minimal	O
improvement	O
in	O
his	O
abdominal	B-Reason
rash	I-Reason
.	O
He	O
then	O
received	O
10	O
days	O
of	O
vancomycin	I-Drug
as	O
well	O
as	O
steroid	I-Drug
cream	O
after	O
dermatology	O
thought	O
the	O
abdominal	I-Reason
rash	O
could	O
be	O
a	O
contact	B-Reason
dermatitis	I-Reason
.	O
This	O
led	O
to	O
resolution	O
of	O
his	O
abdominal	O
rash	O
.	O
7	O
)	O
Likely	O
drug	O
rash	O
:	O
Later	O
in	O
his	O
hospitalization	O
(	O
around	O
[	O
**	O
11	O
-	O
19	O
**	O
]	O
-	O
15th	O
)	O
he	O
developed	O
a	O
morbilliform	B-Ade
eruption	I-Ade
on	O
his	O
trunk	O
in	O
the	O
context	O
of	O
receiving	O
a	O
dose	O
of	O
piperacillin	I-Drug
-	O
tazobactam	O
in	O
the	O
ICU	O
.	O
This	O
medication	O
was	O
stopped	O
an	O
his	O
rash	I-Ade
resolved	O
.	O
8	O
)	O
Hypotension	O
:	O
The	O
patient	O
developed	O
relative	O
hypotension	O
in	O
the	O
hospital	O
.	O
Multiple	O
blood	O
cultures	O
were	O
negative	O
and	O
this	O
seemed	O
stable	O
without	O
mental	O
status	O
changes	O
or	O
end	O
organ	O
dysfunction	O
(	O
except	O
some	O
worsening	O
of	O
his	O
CKD	O
)	O
.	O
This	O
was	O
thought	O
likely	O
due	O
to	O
poor	O
cardiac	O
return	O
due	O
to	O
massive	O
third	O
spacing	O
from	O
his	O
protein	O
losses	O
and	O
perhaps	O
external	O
compression	O
of	O
the	O
IVC	O
by	O
his	O
abdomen	O
.	O
9	O
)	O
Acute	O
Kidney	O
Injury	O
:	O
The	O
patient	O
's	O
baseline	O
Cr	O
is	O
unclear	O
.	O
At	O
presentation	O
Cr	O
was	O
2	O
then	O
trended	O
down	O
to	O
1.5	O
before	O
trending	O
up	O
again	O
in	O
the	O
setting	O
of	O
worsening	O
ascites	O
and	O
his	O
general	O
deterioration	O
.	O
Renal	O
was	O
consulted	O
twice	O
and	O
ultimately	O
concluded	O
this	O
was	O
likely	O
due	O
to	O
poor	O
preload	O
and	O
forward	O
flow	O
from	O
the	O
heart	O
in	O
the	O
context	O
of	O
his	O
third	O
spacing	O
and	O
massive	O
abdominal	O
distension	O
.	O
He	O
never	O
became	O
oliguric	O
or	O
anuric	O
.	O
10	O
)	O
Atrial	B-Reason
fibrillation	I-Reason
:	O
The	O
patient	O
developed	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
while	O
his	O
nodal	O
agents	O
were	O
being	O
held	O
.	O
This	O
broke	O
with	O
diltiazem	I-Drug
and	O
he	O
was	O
restarted	O
on	O
this	O
medication	O
with	O
good	O
rate	B-Reason
control	I-Reason
.	O
11	O
)	O
Goals	O
of	O
Care	O
:	O
After	O
extensive	O
discussion	O
with	O
the	O
family	O
and	O
patient	O
about	O
the	O
lack	O
of	O
options	O
for	O
reversing	O
the	O
patient	O
's	O
chylous	O
ascites	O
accumulation	O
and	O
subsequent	O
respiratory	O
compromise	O
and	O
progressive	O
protein	O
wasting	O
they	O
elected	O
to	O
pursue	O
comfort	O
focused	O
care	O
.	O
Reasonably	O
benign	O
interventions	O
(	O
i.e.	O
antibiotics	I-Drug
,	O
pleurodesis	O
through	O
a	O
preexisting	O
chest	O
tube	O
)	O
were	O
pursued	O
but	O
other	O
aggressive	O
cares	O
were	O
not	O
.	O
Similarly	O
oral	O
feeds	O
were	O
pursued	O
even	O
in	O
the	O
face	O
of	O
a	O
possible	O
SBO	O
for	O
the	O
patient	O
's	O
comfort	O
and	O
happiness	O
.	O
His	O
major	O
goal	O
was	O
comfort	O
and	O
the	O
family	O
and	O
patient	O
understood	O
his	O
poor	O
prognosis	O
.	O
When	O
his	O
respiratory	O
status	O
deteriorated	O
on	O
[	O
**	O
11	O
-	O
30	O
**	O
]	O
(	O
as	O
above	O
)	O
,	O
further	O
diagnostics	O
and	O
interventions	O
were	O
not	O
pursued	O
,	O
and	O
he	O
was	O
given	O
morphine	I-Drug
.	O
He	O
passed	O
away	O
in	O
the	O
evening	O
of	O
[	O
**	O
11	O
-	O
30	O
**	O
]	O
,	O
and	O
his	O
family	O
was	O
notified	O
.	O
Autopsy	O
was	O
requested	O
and	O
will	O
be	O
performed	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
2	O
.	O
Diltiazem	I-Drug
HCl	O
300	O
mg	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Metoprolol	I-Drug
Tartrate	O
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Lisinopril	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Furosemide	B-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Simvastatin	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Medications	O
:	O
Expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnoses	O
==================	O
Chylous	O
Ascites	O
Presumed	O
Secondary	O
to	O
Retroperitoneal	O
Fibrosis	O
Secondary	O
Chylothorax	O
Hypoxic	O
respiratory	O
distress	O
due	O
to	O
external	O
compression	O
Hospital	O
Acquired	O
Pneumonia	O
Spontaneous	O
Bacterial	O
Peritonitis	O
Acute	O
Kidney	O
Injury	O
Cellulitis	O
Left	O
Lower	O
Extremity	O
DVT	O
Secondary	O
Diagnoses	O
=====================	O
Paroxysmal	O
Atrial	O
Fibrillation	O
Pulmonary	O
Asbestosis	O
Large	O
inguinal	O
and	O
ventral	O
hernias	O
Discharge	O
Condition	O
:	O
Expired	O
Discharge	O
Instructions	O
:	O
Expired	O
Followup	O
Instructions	O
:	O
Expired	O

Admission	O
Date	O
:	O
[	O
**	O
2122-7-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2122-7-31	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2063-10-26	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Dilaudid	I-Drug
/	O
Chlorhexidine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
7333	O
**	O
]	O
Chief	O
Complaint	O
:	O
Ventricular	O
Tachycardia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Electrophysiology	O
Study	O
for	O
attempted	O
Ventricular	O
Tachycardia	O
Ablation	O
Cardiac	O
Catheterization	O
History	O
of	O
Present	O
Illness	O
:	O
58	O
year	O
old	O
male	O
with	O
a	O
PMH	O
of	O
a-fib	O
,	O
OSA	O
,	O
PVD	O
secondary	O
to	O
a	O
gunshot	O
wound	O
to	O
his	O
right	O
lower	O
leg	O
,	O
and	O
non-ischemic	O
cardiomyopathy	O
with	O
a	O
reported	O
EF	O
of	O
15	O
-	O
20	O
%	O
in	O
the	O
past	O
and	O
a	O
recent	O
EF	O
of	O
40	O
%	O
.	O
He	O
had	O
an	O
AICD	O
placed	O
in	O
[	O
**	O
5	O
-	O
30	O
**	O
]	O
,	O
and	O
he	O
has	O
had	O
4	O
episodes	O
of	O
syncope	O
in	O
the	O
past	O
2	O
months	O
.	O
He	O
has	O
been	O
shocked	O
8x	O
in	O
total	O
,	O
with	O
one	O
episode	O
shocking	O
him	O
four	O
times	O
consecutively	O
.	O
His	O
history	O
of	O
cardiomyopathy	O
(	O
best	O
attributed	O
to	O
a	O
possible	O
viral	O
illness	O
,	O
per	O
patient	O
report	O
)	O
,	O
dates	O
back	O
8	O
years	O
.	O
He	O
has	O
also	O
had	O
long	O
standing	O
a-fib	O
,	O
and	O
it	O
is	O
unclear	O
whether	O
he	O
had	O
the	O
cardiomyopathy	O
or	O
a-fib	O
first	O
as	O
he	O
has	O
never	O
been	O
symptomatic	O
until	O
[	O
**	O
Month	O
(	O
only	O
)	O
205	O
**	O
]	O
.	O
.	O
He	O
has	O
had	O
3	O
hospitalizations	O
for	O
syncope	O
since	O
[	O
**	O
2122-5-21	O
**	O
]	O
.	O
The	O
first	O
of	O
which	O
was	O
[	O
**	O
5	O
-	O
24	O
**	O
]	O
weekend	O
,	O
when	O
his	O
wife	O
reports	O
witnessing	O
him	O
lose	O
consciousness	O
for	O
a	O
few	O
seconds	O
and	O
falling	O
out	O
of	O
a	O
chair	O
.	O
He	O
was	O
evaluated	O
at	O
[	O
**	O
Hospital	O
107	O
**	O
]	O
Hospital	O
,	O
was	O
found	O
to	O
have	O
VT	I-Reason
,	O
and	O
had	O
an	O
AICD	O
placed	O
on	O
[	O
**	O
2122-5-26	O
**	O
]	O
.	O
.	O
0n	O
[	O
**	O
7	O
-	O
9	O
**	O
]	O
he	O
woke	O
up	O
from	O
sleep	O
,	O
his	O
AICD	O
fired	O
and	O
15	O
minutes	O
later	O
it	O
fired	O
again	O
.	O
He	O
was	O
asymptomatic	O
at	O
the	O
time	O
,	O
he	O
was	O
then	O
taken	O
to	O
[	O
**	O
Hospital3	O
8544	O
**	O
]	O
and	O
transferred	O
to	O
[	O
**	O
Hospital	O
107	O
**	O
]	O
hospital	O
.	O
He	O
was	O
given	O
a	O
loading	O
dose	O
of	O
amiodarone	I-Drug
,	O
and	O
converted	O
to	O
lower	O
dose	O
because	O
of	O
dizziness	O
.	O
He	O
was	O
discharged	O
home	O
and	O
on	O
[	O
**	O
7	O
-	O
17	O
**	O
]	O
,	O
he	O
was	O
feeding	O
his	O
horses	O
and	O
felt	O
dizzy	O
and	O
lightheaded	O
,	O
fell	O
to	O
the	O
ground	O
had	O
a	O
jerking	O
motion	O
,	O
his	O
family	O
again	O
witnessed	O
the	O
event	O
.	O
He	O
did	O
n't	O
feel	O
like	O
he	O
was	O
shocked	O
,	O
and	O
had	O
no	O
palpitations	O
at	O
the	O
time	O
.	O
He	O
lost	O
consciousness	O
and	O
his	O
wife	O
was	O
able	O
to	O
get	O
him	O
into	O
the	O
car	O
and	O
take	O
him	O
to	O
the	O
hospital	O
.	O
He	O
was	O
initially	O
treated	O
for	O
what	O
was	O
thought	O
to	O
be	O
ischemic	O
chest	O
pain	O
.	O
At	O
[	O
**	O
Hospital3	O
**	O
]	O
they	O
gave	O
him	O
dilaudid	I-Drug
for	O
chest	B-Reason
discomfort	I-Reason
which	O
caused	O
him	O
to	O
flush	I-Ade
and	O
have	O
diaphoresis	I-Ade
.	O
He	O
was	O
transferred	O
to	O
[	O
**	O
Location	O
(	O
un	O
)	O
796	O
**	O
]	O
and	O
they	O
gave	O
him	O
nitroglycerin	I-Drug
,	O
which	O
caused	O
his	O
blood	B-Ade
pressure	I-Ade
to	I-Ade
drop	I-Ade
.	O
This	O
entire	O
course	O
he	O
was	O
kept	O
on	O
amiodarone	I-Drug
of	O
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
He	O
had	O
several	O
6	O
-	O
7	O
beat	O
runs	O
of	O
NSVT	I-Reason
while	O
there	O
and	O
on	O
Monday	O
[	O
**	O
7	O
-	O
20	O
**	O
]	O
he	O
was	O
intially	O
increased	O
to	O
400	O
mg	O
TID	O
of	O
amio	I-Drug
,	O
then	O
due	O
to	O
persistent	O
episodes	O
of	O
NSVT	I-Reason
he	O
was	O
put	O
on	O
IV	O
amio	I-Drug
at	O
1mg	O
/	O
min	O
and	O
transitioned	O
today	O
to	O
0.5	O
mg	O
/	O
min	O
.	O
.	O
His	O
outpatient	O
cardiologist	O
was	O
concerned	O
for	O
AICD	O
lead	O
migration	O
and	O
on	O
[	O
**	O
7	O
-	O
21	O
**	O
]	O
he	O
was	O
taken	O
to	O
the	O
cath	O
lab	O
for	O
lead	O
replacement	O
.	O
Subsequently	O
he	O
developed	O
20	O
beats	O
of	O
VT	I-Reason
,	O
at	O
which	O
time	O
the	O
aforementioned	O
amio	I-Drug
drip	O
was	O
started	O
at	O
1mg	O
/	O
minute	O
.	O
Since	O
that	O
time	O
his	O
EKG	O
and	O
tele	O
has	O
shown	O
paced	O
beats	O
and	O
ectopy	O
.	O
.	O
Of	O
note	O
at	O
the	O
OSH	O
his	O
creatinine	O
was	O
1.1	O
,	O
CE	O
negative	O
x	O
3	O
,	O
electrolytes	O
WNL	O
,	O
Vanc	I-Drug
ppx	I-Reason
for	O
lead	O
placement	O
,	O
Coreg	I-Drug
was	O
decreased	O
to	O
25	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
Coumadin	I-Drug
was	O
held	O
,	O
mag	B-Drug
oxide	I-Drug
added	O
to	O
keep	O
a-fib	B-Reason
better	I-Reason
controlled	I-Reason
.	O
He	O
was	O
continued	O
on	O
digoxin	I-Drug
and	O
lisinopril	I-Drug
.	O
BPs	O
ranged	O
86-126/46	O
-	O
60	O
.	O
.	O
On	O
review	O
of	O
systems	O
,	O
he	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
,	O
myalgias	O
,	O
joint	O
pains	O
,	O
cough	O
,	O
hemoptysis	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
S	O
/	O
he	O
denies	O
recent	O
fevers	O
,	O
chills	O
or	O
rigors	O
.	O
S	O
/	O
he	O
denies	O
exertional	O
buttock	O
or	O
calf	O
pain	O
.	O
All	O
of	O
the	O
other	O
review	O
of	O
systems	O
were	O
negative	O
.	O
.	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
syncope	O
,	O
orthopnea	O
(	O
chronic	O
)	O
,	O
and	O
lower	O
extremity	O
edema	O
right	O
greater	O
than	O
left	O
,	O
as	O
well	O
as	O
absence	O
of	O
chest	O
pain	O
,	O
dyspnea	O
on	O
exertion	O
,	O
paroxysmal	O
nocturnal	O
dyspnea	O
,	O
palpitations	O
.	O
.	O
On	O
the	O
floor	O
,	O
initial	O
vitals	O
were	O
T	O
:	O
96.5	O
,	O
BP	O
:	O
98/72	O
,	O
HR	O
:	O
93	O
,	O
RR	O
:	O
23	O
,	O
SaO2	O
95	O
%	O
on	O
RA	O
,	O
resting	O
comfortably	O
in	O
bed	O
,	O
asymptomatic	O
with	O
his	O
wife	O
and	O
son	O
at	O
the	O
bedside	O
.	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
CARDIAC	O
RISK	O
FACTORS	O
:	O
None	O
2	O
.	O
CARDIAC	O
HISTORY	O
:	O
Ventricular	O
tachycardia	O
Chronic	O
a-fib	O
nonischemic	O
cardiomyopathy	O
with	O
(	O
?	O
)	O
EF	O
of	O
20	O
-	O
25	O
%	O
-	O
CABG	O
:	O
-	O
PERCUTANEOUS	O
CORONARY	O
INTERVENTIONS	O
:	O
-	O
PACING	O
/	O
ICD	O
:	O
AICD	O
placed	O
in	O
[	O
**	O
2122-5-26	O
**	O
]	O
3	O
.	O
OTHER	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
.	O
OSA	O
on	O
nasal	O
CPAP	O
.	O
PVD	O
secondary	O
to	O
gunshot	O
wound	O
at	O
17	O
.	O
Colecystectomy	O
Social	O
History	O
:	O
Former	O
boxer	O
,	O
asymptomatic	O
with	O
activity	O
.	O
Currently	O
a	O
farmer	O
.	O
-	O
Tobacco	O
history	O
:	O
denies	O
-	O
ETOH	O
:	O
rare	O
alcohol	O
use	O
-	O
Illicit	O
drugs	O
:	O
denies	O
Family	O
History	O
:	O
2	O
sisters	O
died	O
from	O
acute	O
myocardial	O
infarction	O
.	O
One	O
sister	O
was	O
33	O
at	O
the	O
time	O
of	O
her	O
death	O
,	O
and	O
his	O
other	O
sister	O
was	O
50	O
when	O
she	O
died	O
of	O
myocardial	O
infarction	O
.	O
He	O
states	O
they	O
do	O
n't	O
know	O
what	O
caused	O
the	O
heart	O
attacks	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
:	O
96.5	O
,	O
BP	O
:	O
98/72	O
,	O
HR	O
:	O
93	O
,	O
RR	O
:	O
23	O
,	O
SaO2	O
95	O
%	O
on	O
RA	O
GENERAL	O
:	O
Well	O
appearing	O
man	O
in	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Mood	O
,	O
affect	O
appropriate	O
.	O
Appears	O
his	O
stated	O
age	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
No	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
NECK	O
:	O
Supple	O
with	O
JVP	O
of	O
~	O
7	O
cm	O
.	O
CARDIAC	O
:	O
Irregular	O
rate	O
with	O
frequent	O
extra	O
beats	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
LUNGS	O
:	O
No	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
Sparse	O
end	O
inspiratory	O
wheezes	O
,	O
but	O
in	O
all	O
lung	O
fields	O
.	O
Mild	O
scattered	O
expiratory	O
rhonchi	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
Abd	O
aorta	O
not	O
enlarged	O
by	O
palpation	O
.	O
No	O
abdominial	O
bruits	O
.	O
Scar	O
on	O
the	O
umbilicus	O
from	O
prior	O
cholecystectomy	O
.	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
Well	O
healed	O
scar	O
,	O
and	O
considerable	O
indentation	O
close	O
to	O
the	O
medial	O
tibial	O
plateau	O
with	O
scar	O
vs	O
skin	O
graft	O
well	O
healed	O
x	O
many	O
years	O
on	O
the	O
right	O
lower	O
extremity	O
SKIN	O
:	O
No	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
or	O
scars	O
.	O
PULSES	O
:	O
Right	O
:	O
Carotid	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Left	O
:	O
Carotid	O
2	O
+	O
DP	O
2	O
+	O
PT	O
2	O
+	O
.	O
Exam	O
on	O
Discharge	O
:	O
VS	O
:	O
Tmax	O
:	O
98.9	O
T	O
current	O
:	O
98.1	O
BP	O
:	O
100-125/50	O
-	O
71	O
HR	O
:	O
69	O
-	O
85	O
RR	O
:	O
18	O
SaO2	O
98	O
%	O
on	O
RA	O
24	O
hours	O
:	O
I	O
=	O
1040	O
O	O
=	O
1440	O
8	O
hours	O
:	O
I	O
=	O
180	O
O	O
=	O
750	O
GENERAL	O
:	O
Well	O
appearing	O
man	O
in	O
NAD	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
NECK	O
:	O
Supple	O
,	O
no	O
JVD	O
.	O
CARDIAC	O
:	O
irregular	O
rate	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
LUNGS	O
:	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
Wheezes	O
posteriorly	O
.	O
No	O
cough	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
Right	O
groin	O
sites	O
with	O
minimal	O
ecchymosis	O
and	O
no	O
hematoma	O
.	O
SKIN	O
:	O
Rash	O
improving	O
,	O
few	O
patchy	O
areas	O
around	O
pacer	O
site	O
,	O
none	O
on	O
neck	O
now	O
.	O
Has	O
peeling	O
skin	O
on	O
left	O
hand	O
only	O
,	O
pt	O
states	O
this	O
is	O
chronic	O
.	O
PULSES	O
:	O
Right	O
:	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Left	O
:	O
DP	O
2	O
+	O
PT	O
2	O
+	O
Pertinent	O
Results	O
:	O
[	O
**	O
2122-7-21	O
**	O
]	O
08:42	O
PM	O
BLOOD	O
WBC	O
-	O
8.3	O
RBC	O
-	O
3.95	O
*	O
Hgb	O
-	O
12.1	O
*	O
Hct	O
-	O
34.4	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
30.7	O
MCHC	O
-	O
35.3	O
*	O
RDW	O
-	O
13.7	O
Plt	O
Ct	O
-	O
218	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
WBC	O
-	O
8.4	O
RBC	O
-	O
4.13	O
*	O
Hgb	O
-	O
12.7	O
*	O
Hct	O
-	O
36.2	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
30.7	O
MCHC	O
-	O
35.1	O
*	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
219	O
[	O
**	O
2122-7-23	O
**	O
]	O
06:13	O
AM	O
BLOOD	O
WBC	O
-	O
8.9	O
RBC	O
-	O
4.19	O
*	O
Hgb	O
-	O
12.6	O
*	O
Hct	O
-	O
37.2	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
13.8	O
Plt	O
Ct	O
-	O
226	O
[	O
**	O
2122-7-24	O
**	O
]	O
02:28	O
AM	O
BLOOD	O
WBC	O
-	O
10.0	O
RBC	O
-	O
4.20	O
*	O
Hgb	O
-	O
12.8	O
*	O
Hct	O
-	O
36.4	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
30.4	O
MCHC	O
-	O
35.1	O
*	O
RDW	O
-	O
13.6	O
Plt	O
Ct	O
-	O
234	O
[	O
**	O
2122-7-21	O
**	O
]	O
08:42	O
PM	O
BLOOD	O
Neuts	O
-	O
78.7	O
*	O
Lymphs	O
-	O
14.1	O
*	O
Monos	O
-	O
4.7	O
Eos	O
-	O
2.2	O
Baso	O
-	O
0.3	O
[	O
**	O
2122-7-21	O
**	O
]	O
08:42	O
PM	O
BLOOD	O
PT	O
-	O
17.2	O
*	O
PTT	O
-	O
25.1	O
INR	O
(	O
PT	O
)	O
-	O
1.5	O
*	O
[	O
**	O
2122-7-21	O
**	O
]	O
08:42	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
218	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
PT	O
-	O
17.6	O
*	O
PTT	O
-	O
40.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.6	O
*	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
219	O
[	O
**	O
2122-7-23	O
**	O
]	O
06:13	O
AM	O
BLOOD	O
PT	O
-	O
15.8	O
*	O
PTT	O
-	O
53.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.4	O
*	O
[	O
**	O
2122-7-24	O
**	O
]	O
02:28	O
AM	O
BLOOD	O
PT	O
-	O
14.7	O
*	O
PTT	O
-	O
23.9	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2122-7-24	O
**	O
]	O
02:28	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
234	O
[	O
**	O
2122-7-24	O
**	O
]	O
08:36	O
AM	O
BLOOD	O
PTT	O
-	O
58.3	O
*	O
[	O
**	O
2122-7-21	O
**	O
]	O
08:42	O
PM	O
BLOOD	O
Glucose	O
-	O
114	O
*	O
UreaN	O
-	O
18	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
137	O
K	O
-	O
4.2	O
Cl	O
-	O
103	O
HCO3	O
-	O
26	O
AnGap	O
-	O
12	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
Glucose	O
-	O
115	O
*	O
UreaN	O
-	O
18	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
139	O
K	O
-	O
4.2	O
Cl	O
-	O
103	O
HCO3	O
-	O
27	O
AnGap	O
-	O
13	O
[	O
**	O
2122-7-23	O
**	O
]	O
06:13	O
AM	O
BLOOD	O
Glucose	O
-	O
109	O
*	O
UreaN	O
-	O
22	O
*	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
136	O
K	O
-	O
4.3	O
Cl	O
-	O
101	O
HCO3	O
-	O
27	O
AnGap	O
-	O
12	O
[	O
**	O
2122-7-24	O
**	O
]	O
02:28	O
AM	O
BLOOD	O
Glucose	O
-	O
100	O
UreaN	O
-	O
26	O
*	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
137	O
K	O
-	O
4.1	O
Cl	O
-	O
100	O
HCO3	O
-	O
27	O
AnGap	O
-	O
14	O
[	O
**	O
2122-7-24	O
**	O
]	O
08:36	O
AM	O
BLOOD	O
Na	O
-	O
136	O
K	O
-	O
4.4	O
Cl	O
-	O
100	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
ALT	O
-	O
51	O
*	O
AST	O
-	O
29	O
AlkPhos	O
-	O
98	O
[	O
**	O
2122-7-23	O
**	O
]	O
06:13	O
AM	O
BLOOD	O
Calcium	O
-	O
8.6	O
Phos	O
-	O
4.3	O
Mg	O
-	O
2.7	O
*	O
[	O
**	O
2122-7-24	O
**	O
]	O
02:28	O
AM	O
BLOOD	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
4.0	O
Mg	O
-	O
2.9	O
*	O
[	O
**	O
2122-7-24	O
**	O
]	O
08:36	O
AM	O
BLOOD	O
Mg	O
-	O
2.5	O
[	O
**	O
2122-7-21	O
**	O
]	O
08:42	O
PM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
3.3	O
Mg	O
-	O
2.4	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
Triglyc	O
-	O
115	O
HDL	O
-	O
40	O
CHOL	O
/	O
HD	O
-	O
2.8	O
LDLcalc	O
-	O
48	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
TSH	O
-	O
4.3	O
*	O
[	O
**	O
2122-7-22	O
**	O
]	O
04:36	O
AM	O
BLOOD	O
Digoxin	O
-	O
0.9	O
.	O
ECHO	O
:	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
markedly	O
dilated	O
.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
10	O
-	O
20mmHg	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
appears	O
severely	O
depressed	O
(	O
LVEF	O
=	O
20	O
-	O
25	O
%	O
)	O
but	O
is	O
difficult	O
to	O
assess	O
due	O
to	O
poor	O
image	O
quality	O
and	O
frequent	O
ventricular	O
ectopy	O
.	O
Relative	O
preservation	O
of	O
basal	O
inferolateral	O
wall	O
function	O
.	O
There	O
is	O
considerable	O
beat	O
-	O
to	O
-	O
beat	O
variability	O
of	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
due	O
to	O
an	O
irregular	O
rhythm	O
/	O
premature	O
beats	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
with	O
depressed	O
free	O
wall	O
contractility	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis	O
.	O
Trace	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
structurally	O
normal	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
prominent	O
fat	O
pad	O
.	O
.	O
IMPRESSION	O
:	O
Suboptimal	O
image	O
quality	O
.	O
Dilated	O
left	O
ventricle	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
Right	O
ventricular	O
dilation	O
and	O
dysfunction	O
.	O
.	O
Cardiac	O
Cath	O
Study	O
Date	O
of	O
[	O
**	O
2122-7-28	O
**	O
]	O
COMMENTS	O
:	O
1	O
.	O
Coronary	O
angiography	O
in	O
this	O
right	O
dominant	O
system	O
demonstrated	O
no	O
angiongraphically	O
apparent	O
disease	O
.	O
The	O
LMCA	O
,	O
LAD	O
,	O
LCx	O
and	O
RCA	O
had	O
no	O
evidence	O
of	O
angiographically	O
apparent	O
disease	O
.	O
2	O
.	O
Resting	O
hemodyanamics	O
revealed	O
slightly	O
elevated	O
right	O
sided	O
filling	O
pressures	O
with	O
RVEDP	O
of	O
15mmHg	O
.	O
Cardiac	O
output	O
was	O
preserved	O
at	O
7	O
l	O
/	O
min	O
.	O
FINAL	O
DIAGNOSIS	O
:	O
1	O
.	O
Coronary	O
arteries	O
are	O
normal	O
.	O
2	O
.	O
Normal	O
ventricular	O
function	O
.	O
.	O
TTE	O
(	O
Complete	O
)	O
Done	O
[	O
**	O
2122-7-29	O
**	O
]	O
Conclusions	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
No	O
atrial	O
septal	O
defect	O
is	O
seen	O
by	O
2D	O
or	O
color	O
Doppler	O
.	O
There	O
is	O
moderate	O
global	O
left	O
ventricular	O
hypokinesis	O
(	O
LVEF	O
=	O
30	O
-	O
35	O
%	O
)	O
.	O
The	O
estimated	O
cardiac	O
index	O
is	O
normal	O
(	O
>	O
=	O
2.5	O
L	O
/	O
min	O
/	O
m2	O
)	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
mildly	O
dilated	O
with	O
borderline	O
normal	O
free	O
wall	O
function	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
There	O
is	O
no	O
aortic	O
valve	O
stenosis	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2122-7-22	O
**	O
]	O
,	O
biventricular	O
systolic	O
cavity	O
sizes	O
are	O
smaller	O
and	O
systolic	O
function	O
is	O
slightly	O
improved	O
.	O
.	O
Brief	O
Hospital	O
Course	O
:	O
58	O
year	O
old	O
with	O
a	O
PMH	O
significant	O
for	O
non-ischemic	O
cardiomyopathy	O
,	O
chronic	O
a-fib	O
,	O
and	O
ventricullar	O
tachycardia	O
s	O
/	O
p	O
AICD	O
placement	O
on	O
[	O
**	O
2122-5-26	O
**	O
]	O
,	O
that	O
was	O
transferred	O
from	O
[	O
**	O
Hospital	O
107	O
**	O
]	O
Hospital	O
in	O
RI	O
for	O
treatment	O
of	O
ventricular	O
tachycardia	O
with	O
ablation	O
.	O
.	O
#	O
Ventricular	O
tachycardia	O
/	O
dialated	O
cardiomyopathy	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
has	O
ventricular	O
tachycardia	O
in	O
the	O
setting	O
of	O
non-ischemic	O
cardiomyopathy	O
.	O
These	O
episodes	O
of	O
ventricular	O
tachycardia	O
started	O
in	O
[	O
**	O
2122-5-21	O
**	O
]	O
,	O
he	O
is	O
s	O
/	O
p	O
AICD	O
placement	O
and	O
has	O
had	O
several	O
instances	O
recently	O
of	O
firing	O
of	O
his	O
AICD	O
.	O
Etiology	O
of	O
his	O
v	O
-	O
tach	O
is	O
likely	O
cardiomyopathy	O
resulting	O
in	O
ectopy	O
.	O
An	O
initial	O
echo	O
was	O
done	O
the	O
morning	O
after	O
admission	O
and	O
showed	O
dilated	O
left	O
ventricle	O
with	O
severe	O
systolic	O
dysfunction	O
,	O
also	O
right	O
ventricular	O
dilation	O
and	O
dysfunction	O
.	O
Hemodynamically	O
stable	O
and	O
asymptomatic	O
.	O
He	O
was	O
conitnued	O
on	O
an	O
amiodarone	I-Drug
drip	O
of	O
0.5	O
mg	O
/	O
min	O
until	O
he	O
was	O
taken	O
for	O
EP	O
procedure	O
on	O
[	O
**	O
2122-7-23	O
**	O
]	O
.	O
During	O
the	O
study	O
,	O
they	O
were	O
beginning	O
to	O
warm	O
a	O
site	O
for	O
ablation	O
,	O
and	O
he	O
went	O
into	O
fast	O
VT	O
,	O
so	O
the	O
study	O
was	O
aborted	O
.	O
He	O
converted	O
back	O
to	O
his	O
normal	O
rhythm	O
.	O
His	O
amiodarone	I-Drug
was	O
converted	O
to	O
200	O
mg	O
PO	O
TID	O
and	O
he	O
still	O
had	O
VT	I-Reason
with	O
walking	O
minimal	O
distances	O
,	O
therefore	O
loading	O
dose	O
was	O
increased	O
to	O
400	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
with	O
plan	O
to	O
transition	O
to	O
200	O
mg	O
PO	O
BID	O
in	O
one	O
week	O
(	O
starting	O
[	O
**	O
2122-8-1	O
**	O
]	O
)	O
.	O
Now	O
currently	O
undergoing	O
workup	O
for	O
heart	O
transplant	O
.	O
CT	O
chest	O
completed	O
which	O
showed	O
multifocal	O
small	O
ground	O
-	O
glass	O
nodules	O
predominantly	O
involving	O
the	O
upper	O
lobes	O
,	O
requiring	O
a	O
follow	O
up	O
repeat	O
CT	O
in	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
weeks	O
as	O
an	O
outpatient	O
.	O
CT	O
abd	O
/	O
pelvis	O
showed	O
hypoattenuating	O
left	O
upper	O
pole	O
renal	O
lesion	O
,	O
most	O
likely	O
benign	O
,	O
but	O
a	O
renal	O
US	O
could	O
be	O
considered	O
as	O
an	O
outpatient	O
.	O
Hepatitis	O
A	O
,	O
B	O
,	O
C	O
,	O
CMV	O
and	O
HIV	O
serologies	O
were	O
negative	O
.	O
While	O
on	O
the	O
floor	O
[	O
**	O
2122-7-27	O
**	O
]	O
and	O
[	O
**	O
2122-7-28	O
**	O
]	O
he	O
had	O
increased	O
runs	O
of	O
VTach	O
resulting	O
in	O
AICD	O
firing	O
.	O
The	O
device	O
fired	O
once	O
on	O
[	O
**	O
2122-7-27	O
**	O
]	O
at	O
9:30	O
in	O
the	O
morning	O
when	O
he	O
was	O
walking	O
with	O
the	O
EP	O
team	O
to	O
reproduce	O
symptoms	O
.	O
On	O
the	O
7th	O
,	O
he	O
was	O
washing	O
his	O
hair	O
sitting	O
at	O
the	O
sink	O
and	O
he	O
became	O
symptomatic	O
with	O
lightheadedness	O
and	O
flushing	O
.	O
He	O
had	O
2	O
runs	O
of	O
VTach	O
that	O
both	O
resulted	O
in	O
ICD	O
firings	O
at	O
8:09	O
and	O
8:10	O
in	O
the	O
morning	O
.	O
He	O
was	O
taken	O
to	O
cath	O
immediately	O
following	O
,	O
and	O
then	O
he	O
was	O
taken	O
to	O
the	O
EP	O
lab	O
for	O
readjustment	O
of	O
his	O
leads	O
.	O
The	O
lead	O
wires	O
were	O
adjusted	O
to	O
remove	O
slack	O
from	O
the	O
wires	O
.	O
He	O
tolerated	O
the	O
procedure	O
well	O
and	O
has	O
been	O
without	O
any	O
runs	O
of	O
VTach	O
since	O
.	O
He	O
received	O
a	O
TTE	O
on	O
[	O
**	O
2122-7-29	O
**	O
]	O
when	O
compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2122-7-22	O
**	O
]	O
,	O
biventricular	O
systolic	O
cavity	O
sizes	O
are	O
smaller	O
and	O
systolic	O
function	O
is	O
slightly	O
improved	O
to	O
30	O
-	O
35	O
%	O
.	O
A	O
right	O
/	O
left	O
heart	O
cardiac	O
catheterization	O
that	O
showed	O
:	O
right	O
dominant	O
system	O
that	O
demonstrated	O
no	O
angiongraphically	O
apparent	O
disease	O
.	O
The	O
LMCA	O
,	O
LAD	O
,	O
LCx	O
and	O
RCA	O
had	O
no	O
evidence	O
of	O
angiographically	O
apparent	O
disease	O
.	O
Resting	O
hemodyanamics	O
revealed	O
slightly	O
elevated	O
right	O
sided	O
filling	O
pressures	O
with	O
RVEDP	O
of	O
15mmHg	O
.	O
Cardiac	O
output	O
was	O
preserved	O
at	O
7	O
l	O
/	O
min	O
.	O
His	O
volume	B-Reason
status	I-Reason
was	O
medically	O
managed	O
and	O
he	O
was	O
transitioned	O
back	O
to	O
his	O
home	O
PO	O
Lasix	I-Drug
of	O
20	O
mg	O
daily	O
.	O
.	O
#	O
Contact	O
dermatitis	O
/	O
cellulitis	O
:	O
He	O
developed	O
a	O
likely	O
contact	O
dermatitis	O
after	O
lead	O
replacement	O
at	O
OSH	O
.	O
The	O
contact	I-Ade
dermatitis	O
may	O
have	O
been	O
from	O
the	O
chlorhexadine	I-Drug
prep	O
during	O
the	O
procedure	O
as	O
the	O
patient	O
reported	O
that	O
this	O
happened	O
in	O
the	O
past	O
during	O
a	O
prior	O
cath	O
.	O
The	O
contact	O
dermatitis	O
likely	O
became	O
super-infected	O
and	O
he	O
developed	O
erispelas	I-Reason
which	O
was	O
treated	O
successfully	O
with	O
doxycyline	I-Drug
for	O
7	O
days	O
last	O
dose	O
[	O
**	O
2122-7-28	O
**	O
]	O
.	O
.	O
#	O
Atrial	B-Reason
fibrillation	I-Reason
:	O
His	O
atrial	O
fibrillation	O
was	O
rate	O
controlled	O
and	O
medically	O
managed	O
.	O
His	O
coumadin	I-Drug
was	O
held	O
secondary	O
to	O
need	O
for	O
cardiac	B-Reason
catheterization	I-Reason
and	O
he	O
was	O
placed	O
on	O
a	O
heparin	I-Drug
drip	O
throughout	O
his	O
admission	O
.	O
.	O
#	O
Sleep	O
apnea	O
:	O
His	O
sleep	O
apnea	O
was	O
medically	O
managed	O
with	O
his	O
CPAP	O
mask	O
at	O
night	O
without	O
complications	O
.	O
.	O
The	O
patient	O
was	O
full	O
code	O
for	O
this	O
admission	O
.	O
Pt	O
was	O
discharged	O
home	O
with	O
further	O
outpt	O
follow	O
-	O
up	O
planned	O
.	O
Medications	O
on	O
Admission	O
:	O
On	O
Transfer	O
from	O
OSH	O
:	O
.	O
Coumadin	I-Drug
last	O
dose	O
8/28	O
for	O
a-fib	I-Reason
.	O
Digoxin	I-Drug
0.25	O
mg	O
PO	O
Q24	O
.	O
Lisinopril	I-Drug
40	O
mg	O
PO	O
Q24	O
.	O
Coreg	I-Drug
25	O
mg	O
PO	O
Q12	O
.	O
Mag	B-Drug
Oxide	I-Drug
400	O
mg	O
PO	O
Q24	O
.	O
Lovastatin	I-Drug
20	O
mg	O
PO	O
Q24	O
.	O
Aldactone	I-Drug
12.5	O
mg	O
PO	O
Q24	O
.	O
Amiodarone	I-Drug
0.5	O
mg	O
/	O
min	O
IV	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Ventricular	O
Tachycardia	O
Non-ischemic	O
Cardiomyopathy	O
Acute	O
Renal	O
Failure	O
Discharge	O
Condition	O
:	O
Alert	O
and	O
Oriented	O
x3	O
Independent	O
Ambulation	O
Discharge	O
Instructions	O
:	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
You	O
were	O
initially	O
admitted	O
to	O
the	O
hospital	O
for	O
loss	O
of	O
consciousness	O
,	O
and	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
heart	O
rhythm	O
called	O
ventricular	O
tachycardia	O
.	O
You	O
were	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
of	O
your	O
ventricular	O
tachycardia	O
and	O
evaluation	O
for	O
potential	O
ablation	O
.	O
Unfortunately	O
,	O
the	O
site	O
of	O
the	O
abnormal	O
heart	O
rhythm	O
could	O
not	O
be	O
localized	O
for	O
ablation	O
on	O
this	O
attempt	O
.	O
Your	O
pacemaker	O
/	O
defibrillator	O
settings	O
were	O
adjusted	O
to	O
optimize	O
your	O
own	O
normal	O
heart	O
rhythm	O
and	O
conduction	O
.	O
You	O
felt	O
significantly	O
improved	O
following	O
the	O
adjustment	O
,	O
and	O
it	O
was	O
decided	O
that	O
your	O
irregular	O
heart	O
rhythm	O
would	O
be	O
controlled	O
with	O
medications	O
.	O
We	O
required	O
you	O
to	O
stay	O
in	O
the	O
hospital	O
for	O
a	O
few	O
days	O
to	O
best	O
optimize	O
your	O
medications	O
for	O
rhythm	O
control	O
.	O
During	O
this	O
hospitalization	O
,	O
we	O
also	O
began	O
the	O
evaluation	O
for	O
a	O
heart	O
transplant	O
in	O
case	O
this	O
is	O
something	O
that	O
might	O
benefit	O
you	O
in	O
the	O
future	O
.	O
Other	O
issues	O
on	O
this	O
hospitalization	O
included	O
a	O
rash	O
involving	O
your	O
chest	O
,	O
shoulders	O
and	O
neck	O
.	O
It	O
was	O
believed	O
to	O
be	O
related	O
to	O
contact	B-Ade
allergy	I-Ade
to	O
"	O
chlorhexidine	I-Drug
"	O
,	O
a	O
cleaning	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
we	O
commonly	O
use	O
before	O
procedures	O
.	O
We	O
also	O
believe	O
this	O
skin	B-Ade
rash	I-Ade
became	O
secondarily	O
infected	O
,	O
for	O
which	O
we	O
treated	O
you	O
with	O
antibiotics	I-Drug
.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
home	O
medications	O
:	O
-	O
Amiodarone	I-Drug
was	O
continued	O
at	O
400	O
mg	O
TWICE	O
daily	O
for	O
3	O
more	O
days	O
,	O
then	O
decrease	O
to	O
400	O
mg	O
once	O
daily	O
on	O
[	O
**	O
2122-9-2	O
**	O
]	O
.	O
Please	O
continue	O
that	O
dose	O
until	O
you	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
-	O
Start	O
Metoprolol	B-Drug
Succinate	I-Drug
to	O
control	O
your	O
ventricular	I-Reason
tachycardia	O
-	O
STOP	O
taking	O
Carvedilol	I-Drug
,	O
Magnesium	I-Drug
and	O
Digoxin	I-Drug
-	O
DECREASE	O
the	O
dose	O
of	O
Warfarin	I-Drug
to	O
4	O
mg	O
daily	O
.	O
Please	O
check	O
your	O
INR	O
on	O
Monday	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
with	O
results	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
-	O
Start	O
taking	O
clindamycin	I-Drug
,	O
an	O
antibiotic	I-Drug
,	O
to	O
prevent	B-Reason
infection	I-Reason
at	O
the	O
ICD	O
site	O
-	O
Start	O
taking	O
Tylenol	I-Drug
as	O
needed	O
for	O
pain	I-Reason
at	O
the	O
ICD	O
site	O
-	O
Start	O
taking	O
Lorazepam	I-Drug
if	O
you	O
need	O
for	O
anxiety	I-Reason
or	O
sleep	I-Reason
.	O
Please	O
weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
in	O
1	O
day	O
or	O
6	O
pounds	O
in	O
3	O
days	O
.	O
Check	O
your	O
INR	O
at	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
87185	O
**	O
]	O
office	O
on	O
Monday	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
.	O
You	O
should	O
have	O
the	O
INR	O
followed	O
closely	O
now	O
that	O
you	O
are	O
on	O
amiodarone	I-Drug
.	O
Please	O
be	O
sure	O
to	O
have	O
your	O
blood	O
drawn	O
at	O
your	O
doctor	O
's	O
office	O
in	O
[	O
**	O
11	O
-	O
22	O
**	O
]	O
months	O
to	O
check	O
your	O
thyroid	O
and	O
liver	O
function	O
tests	O
because	O
amiodarone	I-Drug
can	O
sometimes	O
affect	O
these	O
with	O
time	O
.	O
You	O
will	O
also	O
need	O
to	O
have	O
pulmonary	O
function	O
tests	O
done	O
to	O
make	O
sure	O
the	O
amiodarone	I-Drug
is	O
not	O
affecting	O
your	O
lungs	O
.	O
Your	O
initial	O
CT	O
scan	O
of	O
your	O
chest	O
here	O
showed	O
that	O
you	O
have	O
some	O
non-specific	O
nodules	O
that	O
may	O
be	O
due	O
to	O
an	O
infection	O
,	O
inflammatory	O
disease	O
,	O
or	O
even	O
cancer	O
.	O
Please	O
talk	O
to	O
your	O
primary	O
care	O
doctor	O
and	O
cardiologist	O
regarding	O
ordering	O
a	O
follow	O
up	O
CT	O
of	O
your	O
chest	O
in	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
weeks	O
to	O
evaluate	O
whether	O
there	O
is	O
any	O
change	O
.	O
Followup	O
Instructions	O
:	O
Please	O
be	O
sure	O
to	O
keep	O
all	O
of	O
your	O
followup	O
appointments	O
,	O
as	O
listed	O
below	O
:	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
MONDAY	O
[	O
**	O
2123-1-25	O
**	O
]	O
at	O
1:30	O
PM	O
With	O
:	O
DR.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
.	O
Department	O
:	O
Primary	O
Care	O
Name	O
:	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
335	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
When	O
:	O
Monday	O
[	O
**	O
2122-8-17	O
**	O
]	O
at	O
2	O
PM	O
Location	O
:	O
PRIMARY	O
CARE	O
CENTER	O
OF	O
[	O
**	O
Location	O
**	O
]	O
Address	O
:	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
87186	O
**	O
]	O
,	O
[	O
**	O
Location	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
87187	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
87188	O
**	O
]	O
Department	O
:	O
Interventional	O
Cardiology	O
Name	O
:	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
Hordes	O
When	O
:	O
Friday	O
[	O
**	O
2122-8-7	O
**	O
]	O
at	O
3	O
PM	O
.	O
Please	O
call	O
the	O
office	O
on	O
[	O
**	O
2122-8-7	O
**	O
]	O
after	O
1	O
PM	O
to	O
verify	O
this	O
appointment	O
.	O
Location	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
CARDIOLOGY	O
Address	O
:	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
51165	O
**	O
]	O
[	O
**	O
Apartment	O
Address	O
(	O
1	O
)	O
51166	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
51167	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
51168	O
**	O
]	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
MONDAY	O
[	O
**	O
2122-8-24	O
**	O
]	O
at	O
12:30	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
539	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
13861	O
**	O
]	O
,	O
NP	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
CARDIAC	O
SERVICES	O
When	O
:	O
MONDAY	O
[	O
**	O
2122-8-24	O
**	O
]	O
at	O
1	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Completed	O
by	O
:[	O
**	O
2122-7-31	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2123-1-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2123-1-31	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2061-9-28	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1936	O
**	O
]	O
Chief	O
Complaint	O
:	O
SOB	O
;	O
Transfer	O
from	O
OSH	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Intubation	O
A-line	O
History	O
of	O
Present	O
Illness	O
:	O
61	O
year	O
old	O
female	O
with	O
history	O
of	O
COPD	I-Reason
on	O
3L	O
home	O
O2	I-Drug
(	O
FEV1	O
/	O
FVC	O
33	O
FEV1	O
41	O
%	O
predicted	O
)	O
,	O
and	O
newly	O
diagnosed	O
LUL	O
mass	O
with	O
negative	O
cytology	O
on	O
trans	O
-	O
bronch	O
bx	O
,	O
brushing	O
,	O
and	O
BAL	O
[	O
**	O
2122-12-9	O
**	O
]	O
recently	O
admitted	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
82788	O
**	O
]	O
for	O
COPD	B-Reason
exacerbation	I-Reason
presents	O
with	O
SOB	O
.	O
She	O
has	O
had	O
trouble	O
breathing	O
over	O
past	O
3	O
days	O
but	O
then	O
acutely	O
worse	O
at	O
3	O
am	O
when	O
she	O
reports	O
the	O
coughing	O
began	O
and	O
persisted	O
for	O
14	O
hours	O
staright	O
.	O
She	O
went	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
,	O
gave	O
her	O
nebs	I-Drug
,	O
Solumedrol	I-Drug
and	O
Toradol	I-Drug
and	O
transferred	O
here	O
.	O
She	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
given	O
her	O
care	O
has	O
been	O
here	O
.	O
On	O
arrival	O
to	O
ED	O
,	O
vitals	O
:	O
96.5	O
HR	O
82	O
BP	O
108/58	O
RR	O
18	O
98	O
%	O
2L	O
.	O
She	O
was	O
oxygenating	O
fine	O
but	O
uncomfortable	O
per	O
their	O
report	O
.	O
CXR	O
showed	O
no	O
new	O
infiltrate	O
,	O
stable	O
LUL	O
mass	O
.	O
ABG	O
7.39	O
/	O
57/189	O
.	O
She	O
was	O
given	O
nebs	I-Drug
and	O
azithromycin	I-Drug
;	O
but	O
due	O
to	O
her	O
discomfort	O
she	O
was	O
started	O
on	O
BIPAP	O
which	O
she	O
did	O
not	O
tolerate	O
well	O
.	O
She	O
was	O
given	O
ativan	I-Drug
which	O
improved	O
her	O
coughing	I-Reason
/	O
discomfort	I-Reason
and	O
was	O
able	O
to	O
remain	O
on	O
NC	O
alone	O
.	O
She	O
was	O
subsequently	O
transferred	O
to	O
the	O
MICU	O
.	O
.	O
On	O
arrival	O
to	O
the	O
unit	O
,	O
Patient	O
was	O
in	O
mild	O
distress	O
with	O
coughing	O
and	O
increased	O
work	O
of	O
breathing	O
,	O
she	O
was	O
given	O
albuterol	I-Drug
nebs	O
and	O
0.5	O
mg	O
ativan	I-Drug
wtih	O
marked	O
improvement	O
.	O
She	O
reports	O
as	O
above	O
,	O
worsening	O
SOB	O
over	O
past	O
3	O
-	O
4	O
days	O
that	O
worsened	O
this	O
AM	O
.	O
She	O
denies	O
fevers	O
/	O
chills	O
,	O
N	O
/	O
V	O
,	O
CP	O
,	O
or	O
increased	O
sputum	O
production	O
.	O
Denies	O
new	O
myalgias	O
(	O
has	O
h	O
/	O
o	O
fibromyalgia	O
and	O
reports	O
close	O
to	O
baseline	O
pain	O
)	O
.	O
Denies	O
sick	O
contacts	O
.	O
.	O
.	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
recent	O
weight	O
loss	O
or	O
gain	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
,	O
or	O
weakness	O
.	O
Denies	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
abdominal	O
pain	O
,	O
or	O
changes	O
in	O
bowel	O
habits	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
LUL	O
Lung	O
Mass	O
--	O
s	O
/	O
p	O
bronch	O
w	O
/	O
brushings	O
,	O
BAL	O
,	O
and	O
lymph	O
nodes	O
EBUS	O
TBNA	O
(	O
neg	O
for	O
malignancy	O
)	O
2	O
.	O
Severe	O
emphysema	O
on	O
3L	O
home	O
O2	I-Drug
;	O
FEV1	O
/	O
FVC	O
33	O
,	O
FEV1	O
41	O
%	O
predicted	O
3	O
.	O
Recent	O
Pneumonia	I-Reason
-	O
treated	O
with	O
azithromycin	I-Drug
4	O
.	O
Diastolic	O
heart	O
failure	O
5	O
.	O
Fibromyalgia	O
6	O
.	O
Tobacco	O
Abuse	O
.	O
Past	O
Surgical	O
History	O
[	O
**	O
2122-12-9	O
**	O
]	O
:	O
Status	O
post	O
electromagnetic	O
navigational	O
bronchoscopy	O
with	O
radial	O
endobronchial	O
ultrasound	O
,	O
transbronchial	O
biopsy	O
,	O
bronchoalveolar	O
lavage	O
,	O
and	O
brushing	O
of	O
the	O
left	O
upper	O
lobe	O
mass	O
as	O
well	O
as	O
placement	O
of	O
fiducials	O
x4	O
into	O
the	O
left	O
upper	O
lobe	O
lung	O
mass	O
.	O
Social	O
History	O
:	O
lives	O
home	O
alone	O
,	O
has	O
two	O
daughters	O
,	O
widowed	O
x	O
2	O
.	O
Quit	O
smoking	O
last	O
month	O
when	O
diagnosed	O
with	O
new	O
lung	O
mass	O
,	O
prior	O
smoked	O
for	O
50	O
years	O
.	O
Retired	O
.	O
No	O
ETOH	O
in	O
17	O
years	O
,	O
no	O
drug	O
use	O
.	O
Family	O
History	O
:	O
brother	O
with	O
lung	O
CA	O
Physical	O
Exam	O
:	O
Temp	O
96.0	O
141/72	O
80	O
29	O
96	O
%	O
NRB	O
@	O
15L	O
General	O
Appearance	O
:	O
Anxious	O
,	O
slight	O
respiratory	O
distress	O
coughing	O
Eyes	O
/	O
Conjunctiva	O
:	O
PERRL	O
,	O
Pupils	O
dilated	O
Head	O
,	O
Ears	O
,	O
Nose	O
,	O
Throat	O
:	O
Normocephalic	O
Lymphatic	O
:	O
Cervical	O
WNL	O
,	O
Supraclavicular	O
WNL	O
Cardiovascular	O
:	O
(	O
S1	O
:	O
Normal	O
)	O
,	O
(	O
S2	O
:	O
Normal	O
)	O
Peripheral	O
Vascular	O
:	O
(	O
Right	O
radial	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Left	O
radial	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Right	O
DP	O
pulse	O
:	O
Present	O
)	O
,	O
(	O
Left	O
DP	O
pulse	O
:	O
Present	O
)	O
Respiratory	O
/	O
Chest	O
:	O
(	O
Expansion	O
:	O
Symmetric	O
)	O
,	O
(	O
Breath	O
Sounds	O
:	O
Bronchial	O
:	O
,	O
Wheezes	O
:	O
,	O
Diminished	O
:	O
)	O
,	O
poor	O
air	O
movement	O
throughout	O
Abdominal	O
:	O
Soft	O
,	O
Non-tender	O
,	O
Bowel	O
sounds	O
present	O
Extremities	O
:	O
Right	O
lower	O
extremity	O
edema	O
:	O
Absent	O
,	O
Left	O
lower	O
extremity	O
edema	O
:	O
Absent	O
Skin	O
:	O
Not	O
assessed	O
Neurologic	O
:	O
Responds	O
to	O
:	O
Not	O
assessed	O
,	O
Movement	O
:	O
Not	O
assessed	O
,	O
Tone	O
:	O
Not	O
assessed	O
Pertinent	O
Results	O
:	O
Admission	O
:	O
[	O
**	O
2123-1-25	O
**	O
]	O
03:15	O
PM	O
BLOOD	O
WBC	O
-	O
10.3	O
RBC	O
-	O
3.54	O
*	O
Hgb	O
-	O
10.4	O
*	O
Hct	O
-	O
31.4	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
29.3	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
14.1	O
Plt	O
Ct	O
-	O
189	O
[	O
**	O
2123-1-25	O
**	O
]	O
03:15	O
PM	O
BLOOD	O
Glucose	O
-	O
157	O
*	O
UreaN	O
-	O
21	O
*	O
Creat	O
-	O
0.7	O
Na	O
-	O
138	O
K	O
-	O
4.8	O
Cl	O
-	O
98	O
HCO3	O
-	O
30	O
AnGap	O
-	O
15	O
[	O
**	O
2123-1-25	O
**	O
]	O
03:15	O
PM	O
BLOOD	O
proBNP	O
-	O
89	O
[	O
**	O
2123-1-25	O
**	O
]	O
03:15	O
PM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
3.2	O
Mg	O
-	O
2.2	O
[	O
**	O
2123-1-25	O
**	O
]	O
04:29	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
PEEP	O
-	O
6	O
O2	O
Flow	O
-	O
50	O
pO2	O
-	O
198	O
*	O
pCO2	O
-	O
57	O
*	O
pH	O
-	O
7.39	O
calTCO2	O
-	O
36	O
*	O
Base	O
XS	O
-	O
8	O
CXR	O
:	O
[	O
**	O
1	O
-	O
25	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
cardiopulmonary	O
process	O
.	O
2	O
.	O
Unchanged	O
left	O
upper	O
lobe	O
spiculated	O
mass	O
.	O
CT	O
CHEST	O
:	O
[	O
**	O
1	O
-	O
26	O
**	O
]	O
FINDINGS	O
:	O
6.6	O
x	O
1.6	O
cm	O
left	O
upper	O
lobe	O
lesion	O
is	O
less	O
dense	O
and	O
has	O
slightly	O
decreased	O
in	O
size	O
since	O
[	O
**	O
2122-12-2	O
**	O
]	O
when	O
it	O
measured	O
6.6	O
x	O
3	O
cm	O
.	O
There	O
is	O
stable	O
mild	O
left	O
upper	O
lung	O
traction	O
bronchiectasis	O
.	O
There	O
is	O
near	O
complete	O
resolution	O
of	O
a	O
right	O
middle	O
lobe	O
(	O
4:106	O
)	O
opacity	O
measuring	O
under	O
5	O
mm	O
.	O
2.8	O
x	O
5	O
mm	O
consolidation	O
near	O
the	O
left	O
upper	O
lobe	O
fissure	O
is	O
unchanged	O
since	O
[	O
**	O
2122-12-2	O
**	O
]	O
.	O
Severe	O
centrilobular	O
emphysema	O
is	O
unchanged	O
since	O
[	O
**	O
2122-12-2	O
**	O
]	O
.	O
There	O
is	O
no	O
pleural	O
effusion	O
.	O
ET	O
tube	O
tip	O
is	O
1	O
cm	O
above	O
the	O
carina	O
.	O
An	O
NG	O
tube	O
courses	O
through	O
the	O
esophagus	O
and	O
stomach	O
with	O
its	O
tip	O
outside	O
the	O
plane	O
of	O
imaging	O
.	O
Heart	O
size	O
is	O
normal	O
.	O
The	O
main	O
pulmonary	O
artery	O
measures	O
3.2	O
cm	O
in	O
diameter	O
.	O
Scattered	O
enlarged	O
mediastinal	O
nodes	O
measuring	O
up	O
to	O
1.2	O
cm	O
in	O
diameter	O
are	O
little	O
change	O
since	O
[	O
**	O
2122-12-2	O
**	O
]	O
.	O
Although	O
this	O
exam	O
was	O
not	O
tailored	O
for	O
subdiaphragmatic	O
diagnosis	O
,	O
the	O
imaged	O
intra-abdominal	O
organs	O
are	O
unremarkable	O
.	O
Bone	O
windows	O
demonstrate	O
no	O
lesion	O
concerning	O
for	O
metastasis	O
or	O
infection	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Given	O
minimal	O
improvement	O
and	O
benign	O
histology	O
of	O
spiculated	O
left	O
upper	O
lobe	O
mass	O
followup	O
in	O
6	O
months	O
can	O
be	O
obtained	O
.	O
2	O
.	O
Resolution	O
of	O
opacity	O
in	O
the	O
right	O
lung	O
at	O
the	O
junction	O
of	O
the	O
major	O
and	O
minor	O
fissure	O
.	O
3	O
.	O
Stable	O
severe	O
centrilobular	O
emphysema	O
.	O
4	O
.	O
ET	O
tube	O
tip	O
is	O
just	O
above	O
the	O
carina	O
in	O
this	O
study	O
,	O
but	O
is	O
in	O
satisfactory	O
position	O
on	O
chest	O
radiograph	O
performed	O
6	O
hours	O
after	O
and	O
thus	O
does	O
not	O
need	O
to	O
be	O
repositioned	O
.	O
Brief	O
Hospital	O
Course	O
:	O
61	O
year	O
old	O
female	O
with	O
COPD	I-Reason
on	O
3L	O
home	O
O2	I-Drug
s	O
/	O
p	O
recent	O
admission	O
[	O
**	O
12	O
-	O
2	O
**	O
]	O
for	O
COPD	O
exacerbation	O
and	O
newly	O
diganosed	O
LUL	O
mass	O
now	O
admitted	O
with	O
respiratory	O
distress	O
.	O
.	O
#	O
.	O
Acute	O
hypercarbic	O
respiratory	O
distress	O
/	O
Cough	O
:	O
On	O
admission	O
,	O
the	O
patient	O
was	O
complaining	O
of	O
3	O
days	O
of	O
cough	O
and	O
SOB	O
that	O
acutely	O
worsened	O
overnight	O
.	O
She	O
presented	O
to	O
an	O
OSH	O
and	O
was	O
transferred	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
for	O
further	O
managment	O
.	O
She	O
was	O
placed	O
on	O
BiPAP	O
in	O
the	O
ED	O
and	O
transferred	O
to	O
the	O
MICU	O
.	O
She	O
had	O
hypercapneia	O
with	O
a	O
PCO2	O
of	O
57	O
initially	O
,	O
and	O
was	O
placed	O
on	O
non	O
rebreather	O
mask	O
with	O
little	O
improvement	O
,	O
and	O
was	O
then	O
started	O
on	O
non	O
invasive	O
positive	O
pressure	O
ventilation	O
.	O
Patient	O
however	O
tolerated	O
this	O
poorly	O
and	O
required	O
intubation	O
for	O
severe	O
respiratory	O
distress	O
.	O
During	O
acute	O
decompensation	O
,	O
It	O
was	O
noted	O
that	O
patient	O
was	O
taking	O
very	O
high	O
frequency	O
shallow	O
breaths	O
with	O
a	O
constant	O
cough	O
like	O
sound	O
generated	O
in	O
the	O
upper	O
airway	O
.	O
Patient	O
was	O
relatively	O
easy	O
to	O
ventilate	O
and	O
this	O
raised	O
question	O
of	O
paradoxycal	O
vocal	O
cord	O
dysfunction	O
,	O
phrenic	O
nerve	O
injury	O
,	O
etc.	O
.	O
During	O
intubation	O
however	O
,	O
vocal	O
cords	O
were	O
noted	O
to	O
be	O
normal	O
in	O
appearance	O
and	O
during	O
serial	O
imaging	O
diaphragms	O
remained	O
symmetrical	O
.	O
Patient	O
was	O
treated	O
with	O
pulse	O
dose	O
steroids	I-Drug
and	O
started	O
on	O
Azithromicyn	I-Drug
.	O
Given	O
known	O
left	O
upper	O
lobe	O
nodule	O
,	O
a	O
CT	O
scan	O
of	O
the	O
chest	O
was	O
performed	O
and	O
did	O
not	O
show	O
any	O
significant	O
interval	O
change	O
.	O
Patient	O
was	O
sucessfully	O
extubated	O
on	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
with	O
short	O
NIVPPV	O
bridge	O
.	O
Patient	O
was	O
transfered	O
to	O
medical	O
floor	O
on	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
.	O
She	O
had	O
an	O
uneventful	O
course	O
and	O
was	O
discharged	O
in	O
stable	O
condition	O
.	O
Pt	O
has	O
been	O
having	O
financial	O
problems	O
and	O
has	O
not	O
been	O
able	O
to	O
afford	O
Tiotropium	I-Drug
(	O
Spiriva	O
)	O
.	O
Social	O
work	O
was	O
consulted	O
and	O
she	O
was	O
given	O
Ipratropium	I-Drug
instead	O
.	O
Patient	O
was	O
slowly	O
weaned	O
off	O
steroids	I-Drug
with	O
taper	O
over	O
the	O
next	O
2	O
-	O
3	O
weeks	O
.	O
#	O
.	O
Fibromyalgia	I-Reason
:	O
Difficult	O
to	O
control	O
,	O
with	O
overt	O
anxiety	O
in	O
spite	O
of	O
[	O
**	O
Hospital	O
17073	O
**	O
]	O
medical	O
regimen	O
.	O
We	O
continued	O
regimen	O
with	O
fentanyl	I-Drug
patch	O
,	O
gabapentin	I-Drug
,	O
SOMA	I-Drug
,	O
darvocet	I-Drug
,	O
amitryptline	I-Drug
and	O
Propoxyphene	I-Drug
#	O
.	O
Anxiety	O
:	O
Patient	O
with	O
many	O
social	O
stressors	O
and	O
difficult	O
to	O
control	O
anxiety	O
.	O
Given	O
progression	O
of	O
symptoms	O
inspite	O
of	O
agressive	O
therapy	O
,	O
she	O
was	O
to	O
follow	O
up	O
her	O
outpatient	O
psychiatrist	O
to	O
address	O
her	O
anxiety	O
.	O
#	O
Anemia	O
:	O
During	O
admission	O
noted	O
to	O
be	O
near	O
baseline	O
of	O
31	O
.	O
There	O
was	O
no	O
overt	O
bleeding	O
or	O
hemolysis	O
.	O
Medications	O
on	O
Admission	O
:	O
Amitriptyline	I-Drug
150	O
mg	O
qhs	O
aspirin	I-Drug
81	O
daily	O
Darvocet	I-Drug
A	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
3	O
)	O
**	O
]	O
q6	O
prn	O
duonebs	I-Drug
valium	I-Drug
5	O
mg	O
TID	O
fentanyl	I-Drug
patch	O
25mcg	O
q72	O
hr	O
flurbiprofen	I-Drug
100	O
mg	O
TID	O
lasix	I-Drug
80	O
mg	O
daily	O
gabapentin	I-Drug
900	O
mg	O
TID	O
hydrocodone	I-Drug
-	O
acetaminophen	O
5	O
-	O
500	O
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
pain	I-Reason
Potassium	B-Drug
Chloride	I-Drug
8mEQ	O
QID	O
Pulmicort	I-Drug
Soma	I-Drug
350	O
mg	O
TID	O
MVI	I-Drug
Omega	B-Drug
3	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Carisoprodol	B-Drug
350	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
3	O
.	O
Diazepam	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Amitriptyline	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
5	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Darvocet	I-Drug
A	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
3	O
)	O
**	O
]	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
.	O
7	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
.	O
8	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
SOB	I-Reason
.	O
9	O
.	O
Fentanyl	I-Drug
50	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
.	O
10	O
.	O
Furosemide	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Gabapentin	I-Drug
300	O
mg	O
Capsule	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Pulmicort	I-Drug
Inhalation	O
13	O
.	O
Omega	B-Drug
-	I-Drug
3	I-Drug
Fatty	I-Drug
Acids	I-Drug
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
Multivitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
Flurbiprofen	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
16	O
.	O
Azithromycin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
3	O
days	O
.	O
Disp	O
:	O
*	O
6	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
17	O
.	O
Prednisone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
see	O
directions	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
2	O
weeks	O
:	O
take	O
8	O
pills	O
on	O
[	O
**	O
2123-1-31	O
**	O
]	O
,	O
then	O
take	O
6	O
pills	O
on	O
[	O
**	O
2	O
-	O
26	O
**	O
]	O
,	O
then	O
take	O
4	O
pills	O
on	O
[	O
**	O
2123-2-7	O
**	O
]	O
,	O
then	O
take	O
2	O
pills	O
on	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
,	O
then	O
take	O
1	O
pills	O
on	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
.	O
Disp	O
:	O
*	O
84	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Company	O
1519	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
COPD	O
exacerbation	O
Fibromyalgia	O
Lung	O
mass	O
Possible	O
h	O
/	O
o	O
diastolic	O
heart	O
failure	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
Discharge	O
Instructions	O
:	O
You	O
came	O
to	O
the	O
hospital	O
with	O
shortness	O
of	O
breath	O
that	O
is	O
likely	O
due	O
to	O
COPD	O
exacerbation	O
.	O
As	O
you	O
were	O
tiring	O
out	O
,	O
we	O
put	O
you	O
temporarily	O
on	O
a	O
ventilator	O
to	O
help	O
you	O
breath	O
.	O
You	O
recovered	O
after	O
one	O
day	O
and	O
returned	O
to	O
your	O
baseline	O
functional	O
status	O
.	O
We	O
found	O
on	O
CT	O
scan	O
a	O
lung	O
nodule	O
that	O
needs	O
to	O
be	O
followed	O
up	O
.	O
Please	O
see	O
f	O
/	O
u	O
appointments	O
.	O
You	O
were	O
discharged	O
in	O
stable	O
condition	O
.	O
.	O
Please	O
follow	O
up	O
with	O
your	O
doctors	O
,	O
see	O
below	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
Chest	O
CT	O
scan	O
for	O
the	O
lung	O
nodule	O
in	O
6	O
month	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
83672	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2664	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2123-2-19	O
**	O
]	O
10:30	O

Admission	O
Date	O
:	O
[	O
**	O
2165-5-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2165-5-25	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2093-12-17	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lisinopril	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
290	O
**	O
]	O
Chief	O
Complaint	O
:	O
transfer	O
from	O
outside	O
hospital	O
for	O
respiratory	O
failure	O
and	O
shock	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Mechanical	O
ventilation	O
Central	O
venous	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
75	O
year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
COPD	O
,	O
CAD	O
,	O
CHF	O
who	O
presents	O
with	O
respiratory	O
failure	O
,	O
transferred	O
from	O
an	O
OSH	O
.	O
.	O
Per	O
the	O
OSH	O
records	O
,	O
patient	O
had	O
a	O
gradual	O
onset	O
of	O
shortness	O
of	O
breath	O
over	O
the	O
24	O
hours	O
prior	O
to	O
admission	O
.	O
Also	O
with	O
cough	O
;	O
no	O
reported	O
fevers	O
or	O
chills	O
.	O
.	O
Per	O
EMS	O
report	O
,	O
"	O
pt	O
had	O
been	O
having	O
difficulty	O
breathing	O
and	O
chest	O
pain	O
since	O
yesterday	O
which	O
worsened	O
this	O
morning	O
...	O
Pt	O
states	O
pain	O
and	O
difficulty	O
breathing	O
began	O
at	O
the	O
same	O
time	O
...	O
he	O
points	O
just	O
to	O
the	O
(	O
R	O
)	O
of	O
his	O
sternum	O
and	O
on	O
his	O
sternum	O
mid-chest	O
when	O
asked	O
for	O
the	O
location	O
of	O
the	O
pain	O
.	O
O2	O
sat	O
97	O
%	O
on	O
NRB	O
.	O
"	O
.	O
Vitals	O
at	O
the	O
OSH	O
showed	O
a	O
temparature	O
of	O
97.2	O
,	O
BP	O
of	O
114/90	O
,	O
HR	O
90	O
,	O
RR	O
35	O
and	O
an	O
oxygen	O
saturation	O
of	O
88	O
%	O
on	O
room	O
air	O
.	O
Lungs	O
were	O
reported	O
as	O
"	O
diminished	O
but	O
clear	O
"	O
.	O
The	O
O2	I-Drug
deteriorated	O
to	O
the	O
50s	O
on	O
3	O
liters	O
and	O
the	O
patient	O
was	O
intubated	O
with	O
a	O
#	O
8	O
ETT	O
.	O
Subsequently	O
,	O
blood	B-Reason
pressure	I-Reason
fell	I-Reason
and	O
dopamine	I-Drug
was	O
started	O
.	O
Past	O
Medical	O
History	O
:	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Coronary	O
artery	O
disease	O
2	O
.	O
Congestive	O
heart	O
failure	O
3	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
on	O
1	O
liter	O
home	O
O2	I-Drug
4	O
.	O
Hypetension	O
5	O
.	O
History	O
of	O
DVT	O
6	O
.	O
Atrial	O
fibrillation	O
7	O
.	O
s	O
/	O
p	O
PPM	O
.	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
1	O
.	O
s	O
/	O
p	O
Total	O
hip	O
replacement	O
(	O
[	O
**	O
6	O
-	O
/	O
2153	O
**	O
]	O
)	O
2	O
.	O
s	O
/	O
p	O
Breast	O
mass	O
biopsy	O
(	O
[	O
**	O
12/2162	O
**	O
]	O
)	O
3	O
.	O
s	O
/	O
p	O
Umbilical	O
hernia	O
repair	O
(	O
[	O
**	O
4	O
-	O
/	O
2161	O
**	O
]	O
)	O
4	O
.	O
s	O
/	O
p	O
Vasectomy	O
(	O
[	O
**	O
11/2143	O
**	O
]	O
)	O
5	O
.	O
s	O
/	O
p	O
Ankle	O
(	O
left	O
)	O
fracture	O
/	O
repair	O
with	O
screws	O
(	O
[	O
**	O
12/2132	O
**	O
]	O
)	O
Social	O
History	O
:	O
Until	O
most	O
recent	O
admission	O
,	O
was	O
still	O
smoking	O
and	O
drinking	O
.	O
Lives	O
at	O
home	O
.	O
Family	O
History	O
:	O
not	O
obtained	O
Physical	O
Exam	O
:	O
Vitals	O
-	O
T	O
99.4	O
,	O
BP	O
106/39	O
,	O
HR	O
123	O
GEN	O
-	O
Intubated	O
.	O
Not	O
responsive	O
.	O
HEENT	O
-	O
Sclera	O
anicteric	O
.	O
No	O
palor	O
.	O
Prominent	O
jugular	O
pulsations	O
.	O
CV	O
-	O
Irregular	O
and	O
tachycardic	O
.	O
No	O
obvious	O
murmurs	O
.	O
PULM	O
-	O
Moving	O
air	O
without	O
rales	O
/	O
rhonchi	O
.	O
ABD	O
-	O
Soft	O
.	O
Non-distended	O
.	O
No	O
apparent	O
tenderness	O
.	O
RLQ	O
scar	O
and	O
midline	O
herniation	O
noted	O
.	O
EXT	O
-	O
Warm	O
.	O
Venous	O
stasis	O
changes	O
.	O
+	O
edema	O
.	O
Scar	O
from	O
prior	O
ankle	O
surgery	O
noted	O
on	O
left	O
.	O
NEURO	O
-	O
Pupils	O
3	O
mm	O
--	O
>	O
2	O
mm	O
and	O
equal	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2165-5-4	O
**	O
]	O
01:54	O
PM	O
BLOOD	O
WBC	O
-	O
4.1	O
RBC	O
-	O
4.18	O
*	O
Hgb	O
-	O
13.0	O
*	O
Hct	O
-	O
44.0	O
MCV	O
-	O
105	O
*	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
29.6	O
*	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
192	O
[	O
**	O
2165-5-7	O
**	O
]	O
02:12	O
AM	O
BLOOD	O
WBC	O
-	O
13.2	O
*	O
RBC	O
-	O
3.56	O
*	O
Hgb	O
-	O
11.1	O
*	O
Hct	O
-	O
35.2	O
*	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
31.6	O
RDW	O
-	O
15.3	O
Plt	O
Ct	O
-	O
124	O
*	O
[	O
**	O
2165-5-13	O
**	O
]	O
03:06	O
AM	O
BLOOD	O
WBC	O
-	O
9.7	O
RBC	O
-	O
3.15	O
*	O
Hgb	O
-	O
9.9	O
*	O
Hct	O
-	O
32.4	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
31.4	O
MCHC	O
-	O
30.5	O
*	O
RDW	O
-	O
15.8	O
*	O
Plt	O
Ct	O
-	O
162	O
[	O
**	O
2165-5-22	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
WBC	O
-	O
6.5	O
RBC	O
-	O
2.71	O
*	O
Hgb	O
-	O
8.5	O
*	O
Hct	O
-	O
26.4	O
*	O
MCV	O
-	O
98	O
MCH	O
-	O
31.3	O
MCHC	O
-	O
32.1	O
RDW	O
-	O
17.3	O
*	O
Plt	O
Ct	O
-	O
232	O
[	O
**	O
2165-5-23	O
**	O
]	O
03:37	O
AM	O
BLOOD	O
WBC	O
-	O
6.3	O
RBC	O
-	O
2.76	O
*	O
Hgb	O
-	O
8.8	O
*	O
Hct	O
-	O
26.3	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
31.8	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
17.6	O
*	O
Plt	O
Ct	O
-	O
247	O
[	O
**	O
2165-5-4	O
**	O
]	O
01:54	O
PM	O
BLOOD	O
PT	O
-	O
68.9	O
*	O
PTT	O
-	O
56.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
8.4	O
*	O
[	O
**	O
2165-5-11	O
**	O
]	O
03:33	O
AM	O
BLOOD	O
PT	O
-	O
39.8	O
*	O
PTT	O
-	O
43.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
4.3	O
*	O
[	O
**	O
2165-5-22	O
**	O
]	O
03:07	O
AM	O
BLOOD	O
PT	O
-	O
14.2	O
*	O
PTT	O
-	O
96.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2165-5-23	O
**	O
]	O
03:37	O
AM	O
BLOOD	O
PT	O
-	O
15.0	O
*	O
PTT	O
-	O
64.6	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2165-5-4	O
**	O
]	O
01:54	O
PM	O
BLOOD	O
Glucose	O
-	O
86	O
UreaN	O
-	O
60	O
*	O
Creat	O
-	O
1.9	O
*	O
Na	O
-	O
137	O
K	O
-	O
4.2	O
Cl	O
-	O
94	O
*	O
HCO3	O
-	O
34	O
*	O
AnGap	O
-	O
13	O
[	O
**	O
2165-5-13	O
**	O
]	O
04:40	O
PM	O
BLOOD	O
Glucose	O
-	O
105	O
UreaN	O
-	O
75	O
*	O
Creat	O
-	O
2.0	O
*	O
Na	O
-	O
146	O
*	O
K	O
-	O
5.0	O
Cl	O
-	O
118	O
*	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
12	O
[	O
**	O
2165-5-15	O
**	O
]	O
05:18	O
PM	O
BLOOD	O
Glucose	O
-	O
84	O
UreaN	O
-	O
87	O
*	O
Creat	O
-	O
2.4	O
*	O
Na	O
-	O
149	O
*	O
K	O
-	O
3.1	O
*	O
Cl	O
-	O
115	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
15	O
[	O
**	O
2165-5-17	O
**	O
]	O
06:28	O
PM	O
BLOOD	O
Glucose	O
-	O
146	O
*	O
UreaN	O
-	O
84	O
*	O
Creat	O
-	O
2.3	O
*	O
Na	O
-	O
145	O
K	O
-	O
3.8	O
Cl	O
-	O
112	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2165-5-19	O
**	O
]	O
02:52	O
AM	O
BLOOD	O
Glucose	O
-	O
173	O
*	O
UreaN	O
-	O
60	O
*	O
Creat	O
-	O
1.7	O
*	O
Na	O
-	O
148	O
*	O
K	O
-	O
3.9	O
Cl	O
-	O
114	O
*	O
HCO3	O
-	O
27	O
AnGap	O
-	O
11	O
[	O
**	O
2165-5-21	O
**	O
]	O
03:30	O
AM	O
BLOOD	O
Glucose	O
-	O
146	O
*	O
UreaN	O
-	O
35	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
142	O
K	O
-	O
4.0	O
Cl	O
-	O
107	O
HCO3	O
-	O
31	O
AnGap	O
-	O
8	O
[	O
**	O
2165-5-4	O
**	O
]	O
01:54	O
PM	O
BLOOD	O
ALT	O
-	O
14	O
AST	O
-	O
17	O
LD	O
(	O
LDH	O
)	O
-	O
210	O
CK	O
(	O
CPK	O
)	O
-	O
20	O
*	O
AlkPhos	O
-	O
65	O
TotBili	O
-	O
0.8	O
[	O
**	O
2165-5-7	O
**	O
]	O
05:30	O
PM	O
BLOOD	O
Fibrino	O
-	O
1773	O
*	O
[	O
**	O
2165-5-7	O
**	O
]	O
06:02	O
AM	O
BLOOD	O
Hapto	O
-	O
417	O
*	O
[	O
**	O
2165-5-12	O
**	O
]	O
02:30	O
AM	O
BLOOD	O
TSH	O
-	O
2.5	O
[	O
**	O
2165-5-12	O
**	O
]	O
09:29	O
AM	O
BLOOD	O
Cortsol	O
-	O
18.1	O
[	O
**	O
2165-5-12	O
**	O
]	O
10:35	O
AM	O
BLOOD	O
Cortsol	O
-	O
25.1	O
*	O
[	O
**	O
2165-5-4	O
**	O
]	O
04:30	O
PM	O
URINE	O
Blood	O
-	O
LG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
100	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.0	O
Leuks	O
-	O
NEG	O
[	O
**	O
2165-5-10	O
**	O
]	O
04:30	O
PM	O
PLEURAL	O
TotProt	O
-	O
1.4	O
Glucose	O
-	O
186	O
LD	O
(	O
LDH	O
)	O
-	O
414	O
Albumin-LESS	O
THAN	O
[	O
**	O
2165-5-10	O
**	O
]	O
04:30	O
PM	O
PLEURAL	O
WBC	O
-	O
2250	O
*	O
RBC	O
-	O
[	O
**	O
Numeric	O
Identifier	O
36575	O
**	O
]	O
*	O
Polys	O
-	O
88	O
*	O
Lymphs	O
-	O
9	O
*	O
Monos	O
-	O
3	O
*	O
[	O
**	O
2165-5-4	O
**	O
]	O
1:55	O
pm	O
SPUTUM	O
Source	O
:	O
Endotracheal	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2165-5-8	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2165-5-4	O
**	O
]	O
)	O
:	O
>	O
25	O
PMNs	O
and	O
<	O
10	O
epithelial	O
cells	O
/	O
100X	O
field	O
.	O
2	O
+	O
(	O
1	O
-	O
5	O
per	O
1000X	O
FIELD	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
IN	O
PAIRS	O
.	O
RESPIRATORY	O
CULTURE	O
(	O
Final	O
[	O
**	O
2165-5-8	O
**	O
]	O
)	O
:	O
RARE	O
GROWTH	O
OROPHARYNGEAL	O
FLORA	O
.	O
YEAST	O
.	O
RARE	O
GROWTH	O
.	O
STREPTOCOCCUS	O
PNEUMONIAE	O
.	O
SPARSE	O
GROWTH	O
.	O
[	O
**	O
2165-5-12	O
**	O
]	O
2:20	O
am	O
BLOOD	O
CULTURE	O
Source	O
:	O
Line	O
-	O
aline	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2165-5-18	O
**	O
]	O
**	O
Blood	O
Culture	O
,	O
Routine	O
(	O
Final	O
[	O
**	O
2165-5-18	O
**	O
]	O
)	O
:	O
STAPHYLOCOCCUS	O
,	O
COAGULASE	O
NEGATIVE	O
.	O
ISOLATED	O
FROM	O
ONE	O
SET	O
ONLY	O
.	O
SENSITIVITIES	O
PERFORMED	O
ON	O
REQUEST	O
.	O
.	O
Anaerobic	O
Bottle	O
Gram	O
Stain	O
(	O
Final	O
[	O
**	O
2165-5-15	O
**	O
]	O
)	O
:	O
REPORTED	O
BY	O
PHONE	O
TO	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
77738	O
**	O
]	O
@	O
0315	O
ON	O
[	O
**	O
2165-5-15	O
**	O
]	O
-	O
CC6D	O
-	O
[	O
**	O
Numeric	O
Identifier	O
19457	O
**	O
]	O
.	O
GRAM	O
POSITIVE	O
COCCI	O
IN	O
PAIRS	O
AND	O
CLUSTERS	O
.	O
All	O
other	O
Cx	O
including	O
blood	O
,	O
sputum	O
,	O
urine	O
,	O
pleural	O
fluid	O
were	O
negative	O
CXR	O
[	O
**	O
5	O
-	O
4	O
**	O
]	O
There	O
is	O
new	O
right	O
IJ	O
line	O
with	O
tip	O
in	O
the	O
SVC	O
.	O
The	O
pacemaker	O
is	O
unchanged	O
.	O
ET	O
tube	O
tip	O
is	O
6.9	O
cm	O
above	O
the	O
carina	O
.	O
The	O
NG	O
tube	O
tip	O
is	O
not	O
well	O
visualized	O
.	O
The	O
right	O
-	O
sided	O
airspace	O
opacities	O
are	O
again	O
visualized	O
as	O
is	O
volume	O
loss	O
/	O
infiltrate	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
The	O
CP	O
angles	O
are	O
off	O
the	O
film	O
,	O
and	O
thus	O
difficult	O
to	O
assess	O
for	O
effusion	O
on	O
this	O
film	O
.	O
Overall	O
with	O
exception	O
of	O
a	O
new	O
line	O
,	O
there	O
has	O
been	O
no	O
significant	O
interval	O
change	O
EKG	O
on	O
admission	O
:	O
Atrial	O
fibrillation	O
with	O
a	O
ventricular	O
premature	O
beat	O
and	O
probably	O
two	O
ventricular	O
paced	O
beats	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2165-5-5	O
**	O
]	O
ventricular	O
pacing	O
is	O
new	O
.	O
The	O
first	O
paced	O
beat	O
appears	O
early	O
and	O
may	O
be	O
related	O
to	O
a	O
non-sensed	O
ventricular	O
premature	O
beat	O
.	O
Clinical	O
correlation	O
is	O
suggested	O
.	O
Portable	O
TTE	O
(	O
Complete	O
)	O
Done	O
[	O
**	O
2165-5-7	O
**	O
]	O
at	O
3:05:11	O
PM	O
The	O
left	O
atrium	O
is	O
markedly	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
markedly	O
dilated	O
.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
10	O
-	O
15mmHg	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
There	O
is	O
mild	O
global	O
left	O
ventricular	O
hypokinesis	O
(	O
LVEF	O
=	O
40	O
-	O
50	O
%	O
)	O
,	O
most	O
likely	O
due	O
in	O
part	O
to	O
the	O
presence	O
of	O
reduced	O
ventricular	O
filling	O
secondary	O
to	O
atrial	O
fibrillation	O
with	O
relatively	O
rapid	O
ventricular	O
rate	O
.	O
There	O
is	O
no	O
ventricular	O
septal	O
defect	O
.	O
The	O
right	O
ventricular	O
free	O
wall	O
is	O
hypertrophied	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
dilated	O
with	O
depressed	O
free	O
wall	O
contractility	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Trivial	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
tricuspid	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
LIVER	O
OR	O
GALLBLADDER	O
US	O
(	O
SINGLE	O
ORGAN	O
)	O
[	O
**	O
2165-5-12	O
**	O
]	O
2:49	O
PM	O
Cholelithiasis	O
,	O
and	O
mild	O
gallbladder	O
wall	O
thickening	O
without	O
significant	O
gallbladder	O
distention	O
.	O
Wall	O
thickening	O
may	O
be	O
secondary	O
to	O
underdistention	O
of	O
the	O
gallbladder	O
,	O
or	O
third	O
spacing	O
.	O
Given	O
the	O
minimal	O
gallbladder	O
distention	O
,	O
this	O
is	O
less	O
likely	O
secondary	O
to	O
acute	O
cholecystitis	O
.	O
Evaluation	O
of	O
the	O
common	O
duct	O
in	O
the	O
region	O
of	O
the	O
pancreatic	O
head	O
is	O
limited	O
by	O
ultrasound	O
technique	O
.	O
US	O
EXTREMITY	O
NONVASCULAR	O
RIGHT	O
[	O
**	O
2165-5-12	O
**	O
]	O
2:09	O
PM	O
Focused	O
ultrasound	O
scanning	O
was	O
performed	O
in	O
the	O
area	O
of	O
the	O
patient	O
's	O
pacemaker	O
in	O
the	O
right	O
upper	O
chest	O
.	O
Pacemaker	O
leads	O
are	O
identified	O
in	O
the	O
subcutaneous	O
tissues	O
,	O
and	O
there	O
is	O
no	O
evidence	O
of	O
surrounding	O
fluid	O
collection	O
or	O
abscess	O
.	O
CT	O
SINUS	O
/	O
MANDIBLE	O
/	O
MAXILLOFACIAL	O
W	O
/	O
O	O
CONTRAST	I-Drug
[	O
**	O
2165-5-12	O
**	O
]	O
11:55	O
AM	O
No	O
evidence	O
of	O
acute	O
sinusitis	O
CT	O
CHEST	O
/	O
ABD	O
W	O
/	O
CONTRAST	I-Drug
[	O
**	O
2165-5-12	O
**	O
]	O
11:56	O
AM	O
1	O
.	O
There	O
is	O
no	O
CT	O
evidence	O
of	O
an	O
inflammatory	O
collection	O
or	O
an	O
inflammatory	O
process	O
in	O
the	O
chest	O
,	O
abdomen	O
,	O
or	O
pelvis	O
to	O
explain	O
the	O
patient	O
's	O
symptoms	O
.	O
2	O
.	O
Bilateral	O
bibasilar	O
mild	O
-	O
to	O
-	O
moderate	O
pleural	O
effusion	O
with	O
adjacent	O
bibasilar	O
atelectasis	O
.	O
No	O
radiographic	O
evidence	O
of	O
pneumonia	O
.	O
3	O
.	O
Ascites	O
confined	O
to	O
the	O
right	O
upper	O
quadrant	O
with	O
no	O
enhancing	O
wall	O
septations	O
or	O
loculations	O
.	O
4	O
.	O
Sludge	O
/	O
stones	O
in	O
the	O
gallbladder	O
.	O
5	O
.	O
Cluster	O
of	O
calcification	O
and	O
hypodensity	O
seen	O
in	O
the	O
head	O
and	O
uncinate	O
process	O
of	O
the	O
pancreas	O
in	O
close	O
proximity	O
may	O
represent	O
a	O
focus	O
of	O
chronic	O
pancreatitis	O
.	O
6	O
.	O
Equivocal	O
filling	O
defect	O
in	O
the	O
lower	O
CBD	O
and	O
prominant	O
appearance	O
of	O
the	O
region	O
of	O
the	O
papilla	O
.	O
As	O
the	O
patient	O
has	O
a	O
pacemaker	O
,	O
MR	O
evaluation	O
is	O
precluded	O
.	O
ERCP	O
may	O
be	O
useful	O
for	O
further	O
assessment	O
/	O
diagnosis	O
as	O
clinically	O
dictated	O
.	O
7	O
.	O
A	O
complex	O
cystic	O
mass	O
with	O
solid	O
enhancing	O
rim	O
is	O
seen	O
arising	O
from	O
the	O
left	O
kidney	O
suspecious	O
for	O
a	O
renal	O
cell	O
carcinoma	O
.	O
A	O
targeted	O
renal	O
US	O
should	O
be	O
confirmatory	O
.	O
Brief	O
Hospital	O
Course	O
:	O
NEURO	O
:	O
The	O
patient	O
was	O
transferred	O
intubated	O
and	O
sedated	O
on	O
the	O
ventilator	O
.	O
Throughout	O
his	O
hospital	O
course	O
,	O
he	O
had	O
daily	O
wake	O
-	O
ups	O
through	O
the	O
sedation	O
and	O
pain	B-Drug
medication	I-Drug
.	O
Early	O
in	O
his	O
course	O
,	O
he	O
awoke	O
very	O
agitated	O
and	O
not	O
following	O
commands	O
,	O
though	O
was	O
alert	O
,	O
looking	O
around	O
the	O
room	O
and	O
moving	O
all	O
extremities	O
with	O
equal	O
and	O
reactive	O
pupils	O
.	O
He	O
had	O
a	O
history	O
of	O
alcohol	O
use	O
,	O
and	O
had	O
experienced	O
DT	O
's	O
in	O
the	O
past	O
with	O
withdrawal	O
.	O
Consequently	O
,	O
he	O
was	O
maintained	O
on	O
a	O
versed	I-Drug
drip	O
and	O
much	O
of	O
the	O
confusion	O
was	O
attributed	O
to	O
possible	O
withdrawal	O
in	O
addition	O
to	O
delerium	O
.	O
With	O
re-evaluation	O
by	O
wake	O
-	O
ups	O
,	O
the	O
patient	O
slowly	O
became	O
more	O
attentive	O
and	O
did	O
not	O
have	O
tremors	O
/	O
shakes	O
,	O
was	O
following	O
commands	O
and	O
communicated	O
that	O
he	O
was	O
not	O
in	O
any	O
discomfort	O
.	O
After	O
extubation	O
,	O
a	O
full	O
neuro	O
exam	O
was	O
normal	O
including	O
strength	O
/	O
sensation	O
,	O
cranial	O
nerves	O
,	O
DTRs	O
,	O
cerebellar	O
exam	O
and	O
speech	O
/	O
memory	O
.	O
HEENT	O
:	O
The	O
patient	O
was	O
noted	O
to	O
have	O
poor	O
dentition	O
,	O
but	O
no	O
signs	O
of	O
abscess	O
/	O
infection	O
on	O
oral	O
exam	O
.	O
In	O
addition	O
,	O
a	O
CT	O
scan	O
of	O
his	O
head	O
was	O
normal	O
and	O
showed	O
no	O
signs	O
of	O
sinusitis	O
.	O
PULMONARY	O
:	O
His	O
active	O
problems	O
during	O
this	O
admission	O
were	O
respiratory	O
failure	O
,	O
pneumonia	O
,	O
pleural	O
effusion	O
.	O
The	O
main	O
concern	O
for	O
this	O
patient	O
was	O
that	O
of	O
pneumonia	O
,	O
and	O
strep	O
pneumonia	O
grew	O
in	O
the	O
first	O
sputum	O
culture	O
on	O
admission	O
.	O
He	O
was	O
noted	O
to	O
have	O
a	O
large	O
R	O
pleural	O
effusion	O
,	O
which	O
was	O
tapped	O
,	O
but	O
did	O
not	O
show	O
evidence	O
of	O
empyema	O
.	O
He	O
remained	O
on	O
the	O
ventilator	O
for	O
17	O
days	O
.	O
Upon	O
extubation	O
,	O
he	O
did	O
well	O
,	O
had	O
minimal	O
secretions	O
and	O
strong	O
cough	O
,	O
O2	O
sats	O
in	O
the	O
90's	O
,	O
work	O
of	O
breathing	O
was	O
easy	O
.	O
CARDIAC	O
:	O
Active	O
issues	O
during	O
this	O
admission	O
included	O
hypotension	O
and	O
atrial	O
fibrillation	O
,	O
with	O
a	O
history	O
of	O
CAD	O
and	O
CHF	O
.	O
The	O
hypotension	I-Reason
was	O
not	O
fluid	O
responsive	O
and	O
he	O
required	O
levophed	I-Drug
pressor	B-Reason
support	I-Reason
for	O
the	O
first	O
15	O
days	O
of	O
hospitalization	O
.	O
This	O
was	O
weened	O
off	O
and	O
he	O
was	O
eventually	O
restarted	O
on	O
all	O
of	O
his	O
home	O
HTN	B-Drug
medication	I-Drug
.	O
The	O
hypotension	O
was	O
felt	O
to	O
be	O
sepsis	O
physiology	O
,	O
without	O
evidence	O
of	O
new	O
mycardial	O
injury	O
.	O
The	O
atrial	O
fibrillation	O
remained	O
rate	O
controlled	O
,	O
and	O
at	O
first	O
anticoagulation	I-Drug
was	O
held	O
[	O
**	O
3	O
-	O
9	O
**	O
]	O
a	O
supratherapeutic	O
INR	O
.	O
This	O
came	O
down	O
to	O
normal	O
levels	O
,	O
and	O
a	O
heparin	I-Drug
drip	O
was	O
started	O
and	O
he	O
is	O
being	O
bridged	O
back	O
onto	O
coumadin	I-Drug
.	O
In	O
terms	O
of	O
his	O
CHF	O
,	O
an	O
echo	O
revealed	O
only	O
mildly	O
depressed	O
LVEF	O
at	O
40	O
-	O
50	O
%	O
,	O
and	O
specifics	O
are	O
listed	O
in	O
the	O
report	O
above	O
.	O
GI	O
/	O
FEN	O
:	O
patient	O
was	O
aggressively	O
volume	O
resuscitated	O
early	O
on	O
,	O
being	O
at	O
the	O
highest	O
27	O
liters	O
positive	O
on	O
his	O
i	O
/	O
o	O
's	O
.	O
This	O
eventually	O
was	O
diuresed	O
to	O
a	O
slightly	O
positive	O
volume	O
status	O
,	O
and	O
he	O
will	O
go	O
to	O
rehab	O
with	O
continued	O
diureses	O
.	O
He	O
was	O
started	O
on	O
tube	O
feeds	O
with	O
help	O
from	O
the	O
nutritionists	O
,	O
and	O
will	O
be	O
going	O
to	O
rehab	O
taking	O
PO	O
.	O
RENAL	O
/	O
GU	O
:	O
The	O
patient	O
came	O
to	O
the	O
service	O
with	O
mildly	O
reduced	O
renal	O
function	O
.	O
Upon	O
receiving	O
his	O
CT	O
his	O
renl	O
function	O
deteriorated	O
and	O
was	O
felt	O
to	O
have	O
contrast	I-Drug
nephropathy	I-Ade
.	O
Over	O
the	O
next	O
week	O
this	O
resolved	O
to	O
his	O
baseline.He	O
responded	O
well	O
to	O
Lasix	I-Drug
and	O
metolazone	I-Drug
diuresis	I-Reason
as	O
described	O
above	O
.	O
HEME	O
/	O
ID	O
:	O
Active	O
issues	O
included	O
elevated	O
INR	O
(	O
as	O
described	O
above	O
)	O
,	O
and	O
positive	O
cultures	O
included	O
strep	O
pneumonia	O
on	O
sputum	O
and	O
1/2	O
bottles	O
of	O
GPC	B-Reason
bacteremia	I-Reason
.	O
His	O
antibiotic	I-Drug
course	O
intially	O
was	O
broad	O
,	O
including	O
levaquin	I-Drug
,	O
ceftriaxone	I-Drug
,	O
vancomycin	I-Drug
and	O
zosyn	I-Drug
(	O
broad	O
plus	O
double	O
coverage	O
)	O
.	O
This	O
was	O
tailored	O
down	O
to	O
ceftriaxone	I-Drug
to	O
cover	O
the	O
strep	B-Reason
pneumonia	I-Reason
that	O
was	O
speciated	O
from	O
the	O
sputum	O
.	O
The	O
patient	O
started	O
requiring	O
slightly	O
higher	O
pressor	O
support	O
1.5	O
weeks	O
into	O
admission	O
,	O
started	O
spiking	O
nocturnal	O
fevers	O
,	O
and	O
subsequently	O
grew	O
the	O
coag	O
negative	O
staph	O
.	O
He	O
was	O
broadened	O
again	O
for	O
this	O
,	O
though	O
was	O
felt	O
this	O
was	O
likely	O
contaminant	O
.	O
His	O
fever	O
curve	O
and	O
white	O
count	O
normalized	O
and	O
the	O
course	O
of	O
antibiotics	O
was	O
d	O
/	O
c	O
'd	O
.	O
He	O
also	O
developes	O
some	O
diarrhea	O
,	O
but	O
c.diff	O
was	O
negative	O
x	O
3	O
(	O
got	O
PO	O
flagyl	I-Drug
until	O
negative	O
cx	O
came	O
back	O
)	O
Prophylaxis	I-Reason
:	O
remained	O
on	O
sch	I-Drug
,	O
then	O
hep	I-Drug
gtt	O
/	O
coumadin	I-Drug
,	O
pneumoboots	O
and	O
PPi	I-Drug
Code	O
:	O
remained	O
full	O
code	O
throughout	O
Dispo	O
:	O
discharge	O
to	O
rehab	O
facility	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
Atenolol	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
2	O
.	O
Diamox	I-Drug
500	O
mg	O
daily	O
3	O
.	O
Torsemide	I-Drug
100	O
mg	O
daily	O
4	O
.	O
Digoxin	I-Drug
0.25	O
mg	O
daily	O
5	O
.	O
Coumadin	I-Drug
5	O
mg	O
daily	O
6	O
.	O
Duoneb	I-Drug
QID	O
7	O
.	O
Theophylline	I-Drug
200	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
8	O
.	O
Floridil	I-Drug
x1	O
month	O
9	O
.	O
Flovent	I-Drug
110mcg	O
[	O
**	O
Hospital1	O
**	O
]	O
10	O
.	O
Spiriva	I-Drug
daily	O
11	O
.	O
Tylenol	I-Drug
PRN	O
12	O
.	O
Mucinex	I-Drug
400	O
mg	O
PRN	O
13	O
.	O
Viagra	I-Drug
100	O
mg	O
PRN	O
14	O
.	O
Chantix	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
2	O
.	O
Docusate	I-Drug
Sodium	O
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
hold	O
for	O
loose	O
stool	O
.	O
3	O
.	O
Bisacodyl	B-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
4	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
Famotidine	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Olanzapine	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
agitation	I-Reason
or	O
anxiety	I-Reason
.	O
7	O
.	O
Aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Titrate	O
to	O
INR	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
.	O
9	O
.	O
Heparin	I-Drug
Drip	O
Titrate	O
to	O
goal	O
PTT	O
60	O
-	O
80	O
.	O
Discontinue	O
once	O
INR	O
=	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
.	O
10	O
.	O
Digoxin	I-Drug
250	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Check	O
digoxin	I-Drug
level	O
qweek	O
.	O
.	O
11	O
.	O
Atenolol	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
12	O
.	O
Diamox	I-Drug
Sequels	O
500	O
mg	O
Capsule	O
,	O
Sustained	O
Release	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sustained	O
Release	O
PO	O
once	O
a	O
day	O
.	O
13	O
.	O
Torsemide	B-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
14	O
.	O
Flovent	I-Drug
HFA	O
110	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
puffs	O
Inhalation	O
twice	O
a	O
day	O
.	O
15	O
.	O
Spiriva	I-Drug
with	O
HandiHaler	O
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
Sig	O
:	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
capsule	O
Inhalation	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
ne	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
/	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Sepsis	O
Streptococcal	O
Pneumonia	O
respiratory	O
failure	O
Acute	O
renal	O
failure	O
congestive	O
heart	O
failure	O
COPD	O
Atrial	O
fibillation	O
with	O
rapid	O
ventricular	O
response	O
kidney	O
cystic	O
lesion	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
During	O
this	O
admission	O
you	O
were	O
treated	O
for	O
a	O
severe	O
pneumonia	O
,	O
requiring	O
intubation	O
and	O
life	O
support	O
.	O
You	O
will	O
be	O
discharged	O
to	O
a	O
rehab	O
facility	O
.	O
Please	O
continue	O
to	O
take	O
all	O
medications	O
as	O
prescribed	O
,	O
and	O
follow	O
up	O
with	O
your	O
PCP	O
within	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
few	O
days	O
of	O
leaving	O
rehab	O
.	O
On	O
the	O
CT	O
scan	O
of	O
your	O
abdomen	O
,	O
there	O
was	O
a	O
cystic	O
lesion	O
found	O
on	O
your	O
left	O
kidney	O
.	O
This	O
was	O
an	O
incidental	O
finding	O
and	O
not	O
associated	O
with	O
your	O
problems	O
during	O
this	O
hospitalization	O
,	O
however	O
,	O
this	O
should	O
be	O
followed	O
up	O
with	O
your	O
primary	O
care	O
doctor	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
6349	O
**	O
]	O
,	O
as	O
it	O
is	O
possible	O
this	O
may	O
represent	O
carcinoma	O
.	O
Followup	O
Instructions	O
:	O
follow	O
up	O
with	O
your	O
PCP	O
within	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
few	O
days	O
of	O
leaving	O
rehab	O
.	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
16826	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
W.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
33980	O
**	O
]	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
292	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2165-5-23	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2196-11-14	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2196-11-19	O
**	O
]	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
Sulfonamides	I-Drug
/	O
Epinephrine	I-Drug
/	O
Diltiazem	I-Drug
/	O
Pletal	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
78	O
**	O
]	O
Chief	O
Complaint	O
:	O
Depressed	O
Mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Left	O
Craniotomy	O
for	O
SDH	O
evacuation	O
History	O
of	O
Present	O
Illness	O
:	O
86	O
y	O
/	O
o	O
female	O
with	O
history	O
of	O
afib	I-Reason
on	O
Coumadin	I-Drug
.	O
Ms	O
[	O
**	O
Known	O
lastname	O
97533	O
**	O
]	O
was	O
with	O
her	O
son	O
yesterday	O
and	O
fell	O
getting	O
bundles	O
out	O
of	O
her	O
car	O
.	O
She	O
hit	O
her	O
head	O
on	O
the	O
pavement	O
and	O
did	O
not	O
have	O
a	O
loss	O
of	O
consciousness	O
.	O
She	O
was	O
able	O
to	O
do	O
her	O
normal	O
activities	O
she	O
went	O
to	O
bed	O
last	O
night	O
and	O
her	O
son	O
attempted	O
to	O
arrouse	O
her	O
at	O
2	O
am	O
for	O
which	O
he	O
stated	O
"	O
she	O
did	O
not	O
fully	O
awake	O
"	O
this	O
morning	O
when	O
his	O
mother	O
did	O
not	O
wake	O
up	O
he	O
found	O
her	O
in	O
her	O
room	O
and	O
was	O
able	O
to	O
minimally	O
arrouse	O
her	O
.	O
She	O
was	O
brought	O
by	O
ambulance	O
here	O
.	O
Past	O
Medical	O
History	O
:	O
Atrial	O
fibrillation	O
,	O
Diabetes	O
,	O
HTN	O
,	O
Menieres	O
Disease	O
,	O
S	O
/	O
P	O
multiple	O
falls	O
recent	O
radius	O
/	O
humeral	O
fractures	O
.	O
Social	O
History	O
:	O
Retired	O
nurse	O
,	O
lives	O
with	O
son	O
,	O
non	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
1818	O
**	O
]	O
,	O
no	O
alcohol	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
O	O
:	O
T	O
:	O
BP	O
:	O
169/78	O
HR	O
:	O
80	O
R17	O
O2Sats	O
100	O
%	O
Gen	O
:	O
Seen	O
prior	O
to	O
intubation	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
91248	O
**	O
]	O
respirations	O
,	O
no	O
commands	O
HEENT	O
:	O
Pupils	O
:	O
surgical	O
bilateral	O
2	O
mm	O
Neck	O
:	O
In	O
collar	O
Neuro	O
:	O
Does	O
not	O
follow	O
commands	O
Does	O
not	O
open	O
eyes	O
Extensor	O
postures	O
in	O
upper	O
extremities	O
will	O
slightly	O
withdraw	O
legs	O
left	O
greater	O
than	O
right	O
Face	O
symmetric	O
Toes	O
mute	O
Normal	O
tone	O
Difficult	O
to	O
obtain	O
any	O
reflexes	O
most	O
likely	O
hyporeflexic	O
and	O
symmetric	O
Pertinent	O
Results	O
:	O
[	O
**	O
Hospital1	O
69	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
15701	O
**	O
]	O
Pathology	O
Examination	O
Name	O
Birthdate	O
Age	O
Sex	O
Pathology	O
#	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
97534	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
2109-12-5	O
**	O
]	O
86	O
Female	O
[	O
**	O
-	O
8/4553	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
97535	O
**	O
]	O
Report	O
to	O
:	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2093	O
**	O
]	O
Description	O
by	O
:	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
/	O
mtd	O
SPECIMEN	O
SUBMITTED	O
:	O
left	O
subdural	O
hematoma	O
,	O
left	O
subdural	O
hematoma	O
.	O
Procedure	O
date	O
Tissue	O
received	O
Report	O
Date	O
Diagnosed	O
by	O
[	O
**	O
2196-11-14	O
**	O
]	O
[	O
**	O
2196-11-14	O
**	O
]	O
[	O
**	O
2196-11-17	O
**	O
]	O
DR.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
/	O
ttl	O
Previous	O
biopsies	O
:	O
[	O
**	O
Numeric	O
Identifier	O
97536	O
**	O
]	O
EGD	O
(	O
3	O
)	O
.	O
[	O
**	O
Numeric	O
Identifier	O
97537	O
**	O
]	O
(	O
Not	O
on	O
file	O
)	O
DIAGNOSIS	O
:	O
Left	O
subdural	O
hematoma	O
:	O
Blood	O
clot	O
.	O
Clinical	O
:	O
Left	O
subdural	O
hematoma	O
.	O
Gross	O
:	O
The	O
specimen	O
is	O
received	O
fresh	O
in	O
a	O
container	O
labeled	O
with	O
the	O
patient	O
's	O
name	O
,	O
"	O
[	O
**	O
Known	O
lastname	O
97533	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
"	O
,	O
and	O
the	O
medical	O
record	O
number	O
and	O
additionally	O
labeled	O
"	O
left	O
subdural	O
hematoma	O
"	O
.	O
It	O
consists	O
of	O
a	O
blood	O
clot	O
measuring	O
6	O
x	O
2	O
x	O
0.2	O
cm	O
.	O
Representative	O
sections	O
are	O
submitted	O
in	O
cassette	O
A.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
97538	O
**	O
]	O
F	O
86	O
[	O
**	O
2109-12-5	O
**	O
]	O
Cardiology	O
Report	O
ECG	O
Study	O
Date	O
of	O
[	O
**	O
2196-11-14	O
**	O
]	O
9:15:36	O
AM	O
Sinus	O
rhythm	O
.	O
Left	O
atrial	O
abnormality	O
.	O
Left	O
ventricular	O
hypertrophy	O
with	O
ST	O
-	O
T	O
wave	O
abnormalities	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2196-5-4	O
**	O
]	O
further	O
ST	O
-	O
T	O
wave	O
changes	O
are	O
present	O
.	O
Read	O
by	O
:	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
177	O
**	O
]	O
W.	O
Intervals	O
Axes	O
Rate	O
PR	O
QRS	O
QT	O
/	O
QTc	O
P	O
QRS	O
T	O
76	O
180	O
78	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
2	O
)	O
97539	O
**	O
]	O
0	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
97538	O
**	O
]	O
F	O
86	O
[	O
**	O
2109-12-5	O
**	O
]	O
Radiology	O
Report	O
CT	O
C	O
-	O
SPINE	O
W	O
/	O
O	O
CONTRAST	I-Drug
Study	O
Date	O
of	O
[	O
**	O
2196-11-14	O
**	O
]	O
9:22	O
AM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
EU	O
[	O
**	O
2196-11-14	O
**	O
]	O
9:22	O
AM	O
CT	O
C	O
-	O
SPINE	O
W	O
/	O
O	O
CONTRAST	I-Drug
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
97540	O
**	O
]	O
Reason	O
:	O
fx	O
,	O
dislocation	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
86	O
year	O
old	O
woman	O
with	O
s	O
/	O
p	O
fall	O
and	O
ams	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
fx	O
,	O
dislocation	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Wet	O
Read	O
:	O
LLTc	O
MON	O
[	O
**	O
2196-11-14	O
**	O
]	O
10:47	O
AM	O
NO	O
acute	O
fx	O
or	O
malalignment	O
.	O
Final	O
Report	O
INDICATION	O
:	O
86	O
-	O
year	O
-	O
old	O
female	O
status	O
post	O
fall	O
with	O
acute	O
mental	O
status	O
changes	O
.	O
TECHNIQUE	O
:	O
CT	O
of	O
the	O
C	O
-	O
spine	O
without	O
IV	O
contrast	I-Drug
.	O
COMPARISON	O
:	O
MR	O
of	O
the	O
C	O
-	O
spine	O
available	O
from	O
[	O
**	O
2191-6-5	O
**	O
]	O
.	O
FINDINGS	O
:	O
There	O
are	O
no	O
acute	O
fractures	O
or	O
traumatic	O
malalignment	O
.	O
There	O
is	O
mild	O
straightening	O
of	O
lordosis	O
,	O
consistent	O
with	O
the	O
presence	O
of	O
cervical	O
collar	O
.	O
There	O
are	O
moderate	O
to	O
severe	O
degenerative	O
changes	O
throughout	O
the	O
cervical	O
spine	O
,	O
including	O
severe	O
facet	O
arthropathy	O
,	O
and	O
loss	O
of	O
intervertebral	O
disc	O
space	O
,	O
most	O
severely	O
at	O
C5	O
through	O
T1	O
.	O
There	O
is	O
grade	O
1	O
anterolisthesis	O
of	O
C4	O
over	O
C5	O
.	O
Diffuse	O
disc	O
bulging	O
is	O
present	O
at	O
C5	O
-	O
C6	O
and	O
C6	O
-	O
C7	O
,	O
resulting	O
in	O
moderate	O
spinal	O
canal	O
stenosis	O
,	O
most	O
severely	O
at	O
C5	O
-	O
C6	O
.	O
There	O
is	O
no	O
prevertebral	O
hematoma	O
or	O
adjacent	O
soft	O
tissue	O
abnormalities	O
.	O
Included	O
views	O
of	O
the	O
lungs	O
demonstrate	O
mild	O
dependent	O
atelectasis	O
bilaterally	O
.	O
There	O
are	O
multiple	O
nodules	O
within	O
the	O
slightly	O
enlarged	O
right	O
thyroid	O
lobe	O
.	O
IMPRESSION	O
:	O
1	O
.	O
No	O
acute	O
fractures	O
or	O
traumatic	O
malalignment	O
.	O
2	O
.	O
Moderate	O
-	O
to	O
-	O
severe	O
degenerative	O
changes	O
throughout	O
the	O
cervical	O
spine	O
,	O
most	O
severely	O
at	O
C5	O
-	O
C6	O
,	O
with	O
associated	O
moderate	O
spinal	O
canal	O
stenosis	O
.	O
3	O
.	O
Multiple	O
right	O
thyroid	O
nodules	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
97538	O
**	O
]	O
F	O
86	O
[	O
**	O
2109-12-5	O
**	O
]	O
Radiology	O
Report	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
Study	O
Date	O
of	O
[	O
**	O
2196-11-14	O
**	O
]	O
9:22	O
AM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
EU	O
[	O
**	O
2196-11-14	O
**	O
]	O
9:22	O
AM	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
97541	O
**	O
]	O
Reason	O
:	O
ICH	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
86	O
year	O
old	O
woman	O
with	O
s	O
/	O
p	O
fall	O
and	O
AMS	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
ICH	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Wet	O
Read	O
:	O
LLTc	O
MON	O
[	O
**	O
2196-11-14	O
**	O
]	O
10:44	O
AM	O
Left	O
subdural	O
hematoma	O
with	O
mixed	O
hyperdensity	O
,	O
concerning	O
for	O
active	O
bleed	O
,	O
tracking	O
along	O
the	O
left	O
convexivity	O
and	O
left	O
tentorium	O
.	O
Rightward	O
shift	O
of	O
midline	O
structures	O
up	O
to	O
17	O
mm	O
,	O
with	O
significant	O
effacement	O
of	O
the	O
left	O
lateral	O
ventricle	O
.	O
Dilated	O
temporal	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
of	O
right	O
lateral	O
ventricle	O
concerning	O
for	O
early	O
hydrocephalus	O
.	O
Rightward	O
subfaclcine	O
herniation	O
.	O
Early	O
righward	O
uncal	O
herniation	O
.	O
Final	O
Report	O
INDICATION	O
:	O
86	O
-	O
year	O
-	O
old	O
female	O
status	O
post	O
fall	O
and	O
acute	O
mental	O
status	O
changes	O
.	O
TECHNIQUE	O
:	O
CT	O
of	O
the	O
head	O
without	O
IV	O
contrast	I-Drug
.	O
COMPARISON	O
:	O
CT	O
of	O
the	O
head	O
available	O
from	O
[	O
**	O
2193-12-12	O
**	O
]	O
.	O
FINDINGS	O
:	O
There	O
is	O
a	O
large	O
left	O
cerebral	O
subdural	O
hematoma	O
,	O
measuring	O
up	O
to	O
17	O
mm	O
in	O
thickness	O
,	O
with	O
blood	O
tracking	O
along	O
the	O
left	O
tentorium	O
.	O
There	O
is	O
significant	O
neighboring	O
mass	O
effect	O
on	O
left	O
cerebral	O
sulci	O
and	O
the	O
left	O
lateral	O
ventricle	O
with	O
subfalcine	O
herniation	O
and	O
17	O
-	O
mm	O
rightward	O
shift	O
of	O
normally	O
midline	O
structures	O
.	O
The	O
hematoma	O
has	O
mixed	O
hyper	O
and	O
hypoattenuating	O
components	O
,	O
consistent	O
with	O
an	O
acute	O
on	O
chronic	O
bleeding	O
.	O
There	O
is	O
slight	O
effacement	O
of	O
the	O
suprasellar	O
cistern	O
,	O
concerning	O
for	O
an	O
early	O
rightward	O
uncal	O
herniation	O
.	O
Slight	O
hyperattenuation	O
along	O
the	O
suprasellar	O
cistern	O
borders	O
may	O
represent	O
trace	O
subarachnoid	O
blood	O
.	O
The	O
quadrigeminal	O
cistern	O
is	O
preserved	O
but	O
slightly	O
asymmetric	O
.	O
The	O
right	O
lateral	O
ventricle	O
is	O
slightly	O
effaced	O
,	O
and	O
the	O
temporal	O
[	O
**	O
Doctor	O
Last	O
Name	O
534	O
**	O
]	O
is	O
slightly	O
dilated	O
in	O
comparison	O
to	O
the	O
prior	O
CT	O
exam	O
from	O
[	O
**	O
2193-12-12	O
**	O
]	O
,	O
concerning	O
for	O
possible	O
early	O
hydrocephalus	O
.	O
Again	O
,	O
there	O
is	O
significant	O
hypoattenuation	O
of	O
the	O
periventricular	O
white	O
matter	O
,	O
consistent	O
with	O
chronic	O
microvascular	O
ischemic	O
disease	O
.	O
There	O
are	O
no	O
acute	O
fractures	O
.	O
There	O
is	O
a	O
large	O
subgaleal	O
hematoma	O
overlying	O
the	O
left	O
parietal	O
and	O
occipital	O
regions	O
,	O
with	O
a	O
more	O
focal	O
hyperattenuating	O
region	O
representing	O
a	O
more	O
focal	O
hematoma	O
.	O
The	O
middle	O
ear	O
cavities	O
and	O
included	O
portions	O
of	O
the	O
mastoid	O
air	O
cells	O
and	O
paranasal	O
sinuses	O
are	O
clear	O
.	O
The	O
orbits	O
are	O
symmetrical	O
and	O
intact	O
.	O
IMPRESSION	O
:	O
Large	O
acute	O
left	O
subdural	O
hematoma	O
with	O
associated	O
mass	O
effect	O
,	O
subfalcine	O
herniation	O
and	O
left	O
uncal	O
herniation	O
.	O
Findings	O
were	O
communicated	O
with	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
at	O
10:45	O
a.m.	O
on	O
[	O
**	O
2196-11-14	O
**	O
]	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Medical	O
Record	O
Number	O
97538	O
**	O
]	O
F	O
86	O
[	O
**	O
2109-12-5	O
**	O
]	O
Radiology	O
Report	O
MR	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
Study	O
Date	O
of	O
[	O
**	O
2196-11-15	O
**	O
]	O
2:09	O
PM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
J.	O
NSURG	O
SICU	O
-	O
A	O
[	O
**	O
2196-11-15	O
**	O
]	O
2:09	O
PM	O
MR	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
**	O
]	O
Reason	O
:	O
86	O
year	O
old	O
woman	O
with	O
SDH	O
,	O
on	O
coumadin	I-Drug
.	O
Eval	O
for	O
interval	O
c	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
86	O
year	O
old	O
woman	O
with	O
SDH	O
,	O
on	O
coumadin	I-Drug
.	O
Eval	O
for	O
interval	O
change	O
.	O
***	O
PLEASE	O
INCLUDE	O
DWI	O
***	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
86	O
year	O
old	O
woman	O
with	O
SDH	O
,	O
on	O
coumadin	I-Drug
.	O
Eval	O
for	O
interval	O
change	O
.	O
***	O
PLEASE	O
INCLUDE	O
DWI	O
***	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Final	O
Addendum	O
Dedicated	O
imaging	O
of	O
the	O
intracranial	O
arteries	O
can	O
be	O
considered	O
with	O
MRA	O
.	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
10627	O
**	O
]	O
PERI	O
Approved	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
2196-11-17	O
**	O
]	O
11:04	O
AM	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
J.	O
NSURG	O
SICU	O
-	O
A	O
[	O
**	O
2196-11-15	O
**	O
]	O
2:09	O
PM	O
MR	O
HEAD	O
W	O
/	O
O	O
CONTRAST	I-Drug
Clip	O
#	O
[	O
**	O
Clip	O
Number	O
(	O
Radiology	O
)	O
**	O
]	O
Reason	O
:	O
86	O
year	O
old	O
woman	O
with	O
SDH	O
,	O
on	O
coumadin	I-Drug
.	O
Eval	O
for	O
interval	O
c	O
[	O
**	O
Hospital	O
93	O
**	O
]	O
MEDICAL	O
CONDITION	O
:	O
86	O
year	O
old	O
woman	O
with	O
SDH	O
,	O
on	O
coumadin	I-Drug
.	O
Eval	O
for	O
interval	O
change	O
.	O
***	O
PLEASE	O
INCLUDE	O
DWI	O
***	O
REASON	O
FOR	O
THIS	O
EXAMINATION	O
:	O
86	O
year	O
old	O
woman	O
with	O
SDH	O
,	O
on	O
coumadin	I-Drug
.	O
Eval	O
for	O
interval	O
change	O
.	O
***	O
PLEASE	O
INCLUDE	O
DWI	O
***	O
CONTRAINDICATIONS	O
FOR	O
IV	O
CONTRAST	I-Drug
:	O
None	O
.	O
Final	O
Report	O
INDICATION	O
:	O
86	O
-	O
year	O
-	O
old	O
woman	O
with	O
subdural	O
hematoma	O
on	O
Coumadin	I-Drug
,	O
status	O
post	O
evacuation	O
.	O
Evaluate	O
for	O
interval	O
change	O
.	O
COMPARISON	O
:	O
Multiple	O
head	O
CTs	O
most	O
recent	O
of	O
[	O
**	O
2196-11-14	O
**	O
]	O
.	O
TECHNIQUE	O
:	O
Sagittal	O
T1	O
and	O
axial	O
fat	O
-	O
saturated	O
T2	O
,	O
FLAIR	O
,	O
gradient	O
echo	O
,	O
and	O
diffusion	O
-	O
weighted	O
images	O
were	O
obtained	O
of	O
the	O
head	O
.	O
FINDINGS	O
:	O
Multiple	O
areas	O
of	O
restricted	O
diffusion	O
are	O
noted	O
,	O
consistent	O
with	O
acute	O
infarcts	O
in	O
the	O
left	O
anterior	O
,	O
middle	O
,	O
and	O
posterior	O
cerebral	O
artery	O
vascular	O
territories	O
.	O
In	O
addition	O
,	O
areas	O
of	O
acute	O
infarct	O
are	O
noted	O
in	O
the	O
right	O
anterior	O
and	O
posterior	O
cerebral	O
artery	O
vascular	O
territories	O
,	O
involving	O
the	O
right	O
thalamus	O
.	O
There	O
is	O
no	O
evidence	O
of	O
hemorrhagic	O
transformation	O
of	O
these	O
infarcts	O
.	O
There	O
is	O
persistent	O
rightward	O
shift	O
of	O
midline	O
structures	O
which	O
has	O
improved	O
since	O
the	O
previous	O
study	O
,	O
now	O
measuring	O
approximately	O
6	O
mm	O
down	O
from	O
10	O
mm	O
.	O
Previously	O
noted	O
pneumocephalus	O
is	O
resolving	O
.	O
Residual	O
left	O
subdural	O
hemorrhage	O
and	O
intraparenchymal	O
hemorrhage	O
are	O
again	O
seen	O
,	O
unchanged	O
.	O
The	O
ventricles	O
remain	O
unchanged	O
in	O
size	O
.	O
The	O
major	O
vascular	O
flow	O
voids	O
appear	O
patent	O
.	O
IMPRESSION	O
:	O
Acute	O
multi	O
vascular	O
territorial	O
infarcts	O
most	O
pronounced	O
in	O
the	O
left	O
hemisphere	O
,	O
as	O
described	O
above	O
.	O
While	O
these	O
can	O
relate	O
to	O
compression	O
of	O
the	O
arteries	O
from	O
the	O
extensive	O
SDH	O
and	O
mass	O
effect	O
,	O
embolic	O
etiology	O
is	O
also	O
in	O
the	O
differential	O
diagnosis	O
.	O
Findings	O
were	O
discussed	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
shortly	O
after	O
review	O
on	O
[	O
**	O
2196-11-15	O
**	O
]	O
.	O
The	O
study	O
and	O
the	O
report	O
were	O
reviewed	O
by	O
the	O
staff	O
radiologist	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
97533	O
**	O
]	O
arrived	O
to	O
the	O
ED	O
intubated	O
for	O
airway	O
protection	O
.	O
She	O
recieved	O
Profiline	O
9	O
and	O
several	O
units	O
of	O
FFp	O
to	O
reverse	O
her	O
coagulopathy	O
and	O
went	O
emergently	O
for	O
a	O
left	O
sided	O
craniotomy	O
for	O
SDH	O
evacuation	O
.	O
Post	O
operatively	O
she	O
was	O
left	O
intubated	O
and	O
transferred	O
to	O
the	O
Surgical	O
intensive	O
care	O
unit	O
.	O
Her	O
exam	O
never	O
improved	O
.	O
She	O
was	O
followed	O
clinically	O
for	O
the	O
next	O
few	O
days	O
.	O
An	O
MRI	O
was	O
performed	O
for	O
prognostics	O
.	O
She	O
was	O
made	O
CMO	O
after	O
a	O
family	O
meeting	O
.	O
She	O
later	O
expired	O
.	O
Medications	O
on	O
Admission	O
:	O
Medications	O
prior	O
to	O
admission	O
:	O
Amiodarone	I-Drug
200	O
QD	O
,	O
Carvedilol	I-Drug
25	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
Metformin	I-Drug
500	O
mg	O
tid	O
,	O
pravastatin	I-Drug
10	O
at	O
HS	O
,	O
Januvia	I-Drug
100	O
QD	O
,	O
and	O
Coumadin	I-Drug
Discharge	O
Medications	O
:	O
none	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Left	O
sided	O
Acute	O
on	O
Chronic	O
SDH	O
Hyperglycemia	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
none	O
Followup	O
Instructions	O
:	O
none	O
Completed	O
by	O
:[	O
**	O
2196-11-28	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2195-4-1	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2195-4-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2115-11-6	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Erythromycin	I-Drug
Base	O
/	O
Sulfa	I-Drug
(	O
Sulfonamide	B-Drug
Antibiotics	I-Drug
)	O
/	O
clindamycin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3918	O
**	O
]	O
Chief	O
Complaint	O
:	O
chills	O
,	O
rigors	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
2195-4-3	O
**	O
]	O
-	O
Colonoscopy	O
[	O
**	O
2195-4-13	O
**	O
]	O
-	O
Colonoscopy	O
History	O
of	O
Present	O
Illness	O
:	O
EAST	O
HOSPITAL	O
MEDICINE	O
ATTENDING	O
ADMISSION	O
NOTE	O
.	O
Date	O
:	O
[	O
**	O
2195-4-2	O
**	O
]	O
Time	O
:	O
0130	O
___________________________________________________	O
PCP	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
1158	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
679	O
**	O
]	O
.	O
Onc	O
:	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
.	O
CC	O
:[	O
**	O
CC	O
Contact	O
Info	O
93625	O
**	O
]	O
___________________________________________________	O
HPI	O
:	O
79	O
yo	O
F	O
with	O
MDS	O
--	O
>	O
AML	O
,	O
HTN	O
,	O
hyperlipidemia	O
,	O
diverticulosis	O
,	O
h	O
/	O
o	O
anal	O
fissure	O
,	O
AVM	O
s	O
/	O
p	O
recent	O
cauterization	O
who	O
was	O
recently	O
admitted	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
93626	O
**	O
]	O
for	O
decitabine	I-Drug
and	O
was	O
in	O
outpatient	O
center	O
today	O
for	O
platelet	O
transfusion	O
for	O
dropping	O
plt	O
count	O
(	O
22	O
)	O
and	O
nosebleeds	O
.	O
She	O
tolerated	O
the	O
infusion	O
but	O
on	O
her	O
way	O
home	O
,	O
she	O
developed	O
rigors	O
,	O
chills	O
and	O
she	O
returned	O
to	O
the	O
outpatient	O
unit	O
.	O
Upon	O
arrival	O
,	O
she	O
was	O
hypertensive	O
and	O
had	O
a	O
temp	O
to	O
99.8	O
.	O
She	O
was	O
given	O
benadryl	I-Drug
,	O
demerol	I-Drug
,	O
tylenol	I-Drug
,	O
hydrocortisone	I-Drug
.	O
She	O
subsequently	O
became	O
hypotensive	I-Reason
to	O
90/40	O
and	O
received	O
IVF	I-Drug
bolus	O
.	O
She	O
had	O
intermittent	O
,	O
mild	O
hypoxia	O
93	O
-	O
96	O
%	O
.	O
She	O
was	O
thought	O
to	O
have	O
a	O
transfusion	O
reaction	O
(	O
work	O
-	O
up	O
ordered	O
)	O
but	O
her	O
labs	O
were	O
notable	O
for	O
neutropenia	O
and	O
she	O
was	O
referred	O
to	O
the	O
ED	O
for	O
admission	O
.	O
In	O
ER	O
:	O
(	O
Triage	O
Vitals	O
:	O
99.1	O
85118/50	O
18	O
93	O
%	O
RA	O
)	O
CBC	O
notable	O
for	O
hct	O
19.6	O
from	O
24.9	O
earlier	O
in	O
the	O
day	O
.	O
hemolysis	O
labs	O
negative	O
.	O
CXR	O
revealed	O
mild	O
interstitial	O
edema	O
.	O
CT	O
scan	O
was	O
performed	O
to	O
r	O
/	O
o	O
a	O
RP	O
bleed	O
.	O
Currently	O
,	O
she	O
feels	O
completely	O
well	O
.	O
She	O
reports	O
that	O
she	O
felt	O
while	O
prior	O
to	O
the	O
platelet	O
infusion	O
and	O
denies	O
any	O
fever	O
,	O
chills	O
,	O
abd	O
pain	O
,	O
N	O
/	O
V	O
/	O
D	O
,	O
cough	O
,	O
headache	O
.	O
Her	O
only	O
concern	O
is	O
a	O
bruise	O
/	O
canker	O
sore	O
in	O
her	O
L	O
mouth	O
which	O
is	O
mildly	O
tender	O
.	O
.	O
PAIN	O
SCALE	O
:	O
none	O
___________________________________________________	O
REVIEW	O
OF	O
SYSTEMS	O
:	O
CONSTITUTIONAL	O
:	O
[	O
]	O
All	O
Normal	O
[	O
]	O
Fever	O
[	O
x	O
]	O
Chills	O
[	O
]	O
Sweats	O
[	O
]	O
Fatigue	O
[	O
]	O
Malaise	O
[	O
]	O
Anorexia	O
[	O
]	O
Night	O
sweats	O
[	O
]	O
_____	O
lbs	O
.	O
weight	O
loss	O
/	O
gain	O
over	O
_____	O
months	O
HEENT	O
:	O
[	O
]	O
All	O
Normal	O
[	O
]	O
Blurred	O
vision	O
[	O
]	O
Blindness	O
[	O
]	O
Photophobia	O
[	O
]	O
Decreased	O
acuity	O
[	O
]	O
Dry	O
mouth	O
[	O
x	O
]	O
Bleeding	O
gums	O
[	O
]	O
Oral	O
ulcers	O
[	O
]	O
Sore	O
throat	O
[	O
x	O
]	O
Epistaxis	O
[	O
]	O
Tinnitus	O
[	O
]	O
Decreased	O
hearing	O
[	O
]	O
Tinnitus	O
[	O
]	O
Other	O
:	O
RESPIRATORY	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
SOB	O
[	O
]	O
DOE	O
[	O
]	O
Ca	O
n't	O
walk	O
2	O
flights	O
[	O
]	O
Cough	O
[	O
]	O
Wheeze	O
[	O
]	O
Purulent	O
sputum	O
[	O
]	O
Hemoptysis	O
[	O
]	O
Pleuritic	O
pain	O
[	O
]	O
Other	O
:	O
CARDIAC	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Angina	O
[	O
]	O
Palpitations	O
[	O
]	O
Edema	O
[	O
]	O
PND	O
[	O
]	O
Orthopnea	O
[	O
]	O
Chest	O
Pain	O
[	O
]	O
Other	O
:	O
GI	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Blood	O
in	O
stool	O
[	O
]	O
Hematemesis	O
[	O
]	O
Odynophagia	O
[	O
]	O
Dysphagia	O
:	O
[	O
]	O
Solids	O
[	O
]	O
Liquids	O
[	O
]	O
Anorexia	O
[	O
]	O
Nausea	O
[	O
]	O
Vomiting	O
[	O
]	O
Reflux	O
[	O
]	O
Diarrhea	O
[	O
]	O
Constipation	O
[	O
]	O
Abd	O
pain	O
[	O
]	O
Other	O
:	O
GU	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Dysuria	O
[	O
]	O
Frequency	O
[	O
]	O
Hematuria	O
[	O
]	O
Discharge	O
[	O
]	O
Menorrhagia	O
SKIN	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Rash	O
[	O
]	O
Pruritus	O
MS	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Joint	O
pain	O
[	O
]	O
Jt	O
swelling	O
[	O
]	O
Back	O
pain	O
[	O
]	O
Bony	O
pain	O
NEURO	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Headache	O
[	O
]	O
Visual	O
changes	O
[	O
]	O
Sensory	O
change	O
[	O
]	O
Confusion	O
[	O
]	O
Numbness	O
of	O
extremities	O
[	O
]	O
Seizures	O
[	O
]	O
Weakness	O
[	O
]	O
Dizziness	O
/	O
Lightheaded	O
[	O
]	O
Vertigo	O
[	O
]	O
Headache	O
ENDOCRINE	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Skin	O
changes	O
[	O
]	O
Hair	O
changes	O
[	O
]	O
Temp	O
subjectivity	O
HEME	O
/	O
LYMPH	O
:	O
[	O
]	O
All	O
Normal	O
[	O
]	O
Easy	O
bruising	O
[	O
x	O
]	O
Easy	O
bleeding	O
[	O
]	O
Adenopathy	O
PSYCH	O
:	O
[	O
x	O
]	O
All	O
Normal	O
[	O
]	O
Mood	O
change	O
[	O
]	O
Suicidal	O
Ideation	O
[	O
]	O
Other	O
:	O
[	O
x	O
]	O
all	O
other	O
systems	O
negative	O
except	O
as	O
noted	O
above	O
Past	O
Medical	O
History	O
:	O
Past	O
Oncologic	O
history	O
:	O
-	O
MDS	O
initially	O
diagnosed	O
in	O
[	O
**	O
8	O
-	O
/	O
2194	O
**	O
]	O
during	O
workup	O
for	O
anemia	O
.	O
Initial	O
BM	O
biopsy	O
with	O
e	O
/	O
o	O
hypercellular	O
marrow	O
with	O
peripheral	O
blasts	O
.	O
The	O
patient	O
was	O
maintained	O
with	O
transfusion	O
as	O
needed	O
and	O
aranesp	I-Drug
qweek	O
.	O
In	O
winter	O
[	O
**	O
2194	O
**	O
]	O
,	O
pt	O
was	O
also	O
found	O
to	O
have	O
increasing	O
white	O
count	O
,	O
as	O
high	O
as	O
143K	O
on	O
most	O
recent	O
BMT	O
admission	O
,	O
at	O
which	O
point	O
repeat	O
biopsy	O
revealed	O
blasts	O
consistent	O
with	O
acute	O
myeloiod	O
transformation	O
.	O
.	O
PMH	O
:	O
-	O
diverticulosis	O
complicated	O
by	O
bleeding	O
-	O
bleeding	O
anal	O
fissures	O
-	O
bleeding	O
AVMs	O
(	O
[	O
**	O
2	O
-	O
/	O
2195	O
**	O
]	O
)	O
-	O
GERD	O
-	O
emphysema	O
(	O
mild	O
)	O
-	O
dental	O
extraction	O
-	O
myelodysplastic	O
syndrome	O
dx	O
[	O
**	O
8	O
-	O
/	O
2194	O
**	O
]	O
with	O
persistent	O
blastemia	O
-	O
hysterectomy	O
at	O
age	O
39	O
-	O
hemorrhoidectomy	O
x	O
4	O
-	O
colon	O
polyps	O
,	O
AVM	O
-	O
bilateral	O
bunion	O
surgery	O
-	O
hypertension	O
-	O
hyperlipidemia	O
-	O
proctalgia	O
fugax	O
-	O
TMJD	O
Social	O
History	O
:	O
The	O
patient	O
is	O
married	O
and	O
lives	O
with	O
her	O
husband	O
.	O
She	O
has	O
three	O
grown	O
children	O
.	O
Has	O
a	O
twin	O
sister	O
.	O
Ex	O
-	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
1818	O
**	O
]	O
,	O
quit	O
14	O
year	O
ago	O
;	O
has	O
35	O
pack	O
year	O
history	O
.	O
Denies	O
any	O
illicit	O
drug	O
use	O
.	O
Reports	O
having	O
a	O
glass	O
of	O
wine	O
nightly	O
.	O
Family	O
History	O
:	O
No	O
known	O
fhx	O
of	O
MDS	O
or	O
leukemia	O
.	O
Physical	O
Exam	O
:	O
Admission	O
physical	O
exam	O
:	O
T	O
95.9	O
P	O
82	O
BP	O
98/56	O
RR	O
20	O
O2Sat	O
96	O
%	O
RA	O
GENERAL	O
:	O
non-toxic	O
,	O
well	O
-	O
appearing	O
,	O
mentating	O
clearly	O
Eyes	O
:	O
NC	O
/	O
AT	O
,	O
post-surgical	O
pupils	O
(	O
cataracts	O
)	O
,	O
EOMI	O
,	O
no	O
scleral	O
icterus	O
noted	O
Ears	O
/	O
Nose	O
/	O
Mouth	O
/	O
Throat	O
:	O
MMM	O
,	O
small	O
purplish	O
nodule	O
on	O
tongue	O
,	O
bruising	O
on	O
inside	O
of	O
her	O
mouth	O
on	O
left	O
side	O
Neck	O
:	O
supple	O
,	O
no	O
JVD	O
Respiratory	O
:	O
Lungs	O
CTA	O
bilaterally	O
without	O
R	O
/	O
R	O
/	O
W	O
Cardiovascular	O
:	O
Reg	O
S1S2	O
,	O
no	O
M	O
/	O
R	O
/	O
G	O
noted	O
Gastrointestinal	O
:	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
+	O
bowel	O
sounds	O
Genitourinary	O
:	O
no	O
flank	O
tenderness	O
Skin	O
:	O
no	O
rashes	O
or	O
lesions	O
noted	O
.	O
Extremities	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
bilaterally	O
,	O
2	O
+	O
radial	O
,	O
DP	O
and	O
PT	O
pulses	O
b	O
/	O
l.	O
Lymphatics	O
/	O
Heme	O
/	O
Immun	O
:	O
No	O
cervical	O
,	O
supraclavicular	O
lymphadenopathy	O
noted	O
.	O
Neurologic	O
:	O
-	O
mental	O
status	O
:	O
Alert	O
,	O
oriented	O
x	O
3	O
.	O
Able	O
to	O
relate	O
history	O
without	O
difficulty	O
.	O
-	O
cranial	O
nerves	O
:	O
II	O
-	O
XII	O
intact	O
-	O
motor	O
:	O
normal	O
bulk	O
,	O
strength	O
and	O
tone	O
throughout	O
.	O
No	O
abnormal	O
movements	O
noted	O
.	O
-	O
sensory	O
:	O
No	O
deficits	O
to	O
light	O
touch	O
throughout	O
.	O
No	O
foley	O
catheter	O
/	O
tracheostomy	O
/	O
PEG	O
/	O
ventilator	O
support	O
/	O
chest	O
tube	O
/	O
colostomy	O
Psychiatric	O
:	O
pleasant	O
and	O
interactive	O
ACCESS	O
:	O
[	O
x	O
]	O
PIV	O
.	O
Discharge	O
PE	O
:	O
VS	O
:	O
Tc	O
97.2	O
Tmax	O
97.8	O
BP	O
118/68	O
(	O
110	O
-	O
130	O
'	O
/	O
60	O
-	O
80	O
'	O
)	O
HR	O
76	O
(	O
70	O
-	O
80	O
'	O
)	O
RR	O
18	O
Sat	O
99	O
RA	O
General	O
:	O
pleasant	O
,	O
well	O
appearing	O
elderly	O
female	O
,	O
sitting	O
comforably	O
in	O
chair	O
,	O
NAD	O
,	O
HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
OP	O
clear	O
,	O
MM	O
moist	O
neck	O
:	O
supple	O
CV	O
:	O
3/6	O
SEM	O
loudest	O
at	O
RUSB	O
,	O
normal	O
S1	O
,	O
S2	O
lungs	O
:	O
clear	O
to	O
auscultation	O
b	O
/	O
l	O
,	O
no	O
wheezes	O
/	O
rhonchi	O
/	O
crackles	O
abdomen	O
:	O
soft	O
,	O
mild	O
tenderness	O
at	O
left	O
lower	O
quadrant	O
and	O
minimal	O
tenderness	O
at	O
right	O
upper	O
quadrant	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
nondistended	O
,	O
+	O
BS	O
extremities	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
no	O
LE	O
edema	O
,	O
2	O
+	O
DP	O
pulses	O
Neuro	O
:	O
CN2	O
-	O
12	O
grossly	O
intact	O
,	O
normal	O
muscle	O
strength	O
and	O
sensation	O
throughout	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
===============	O
[	O
**	O
2195-4-1	O
**	O
]	O
WBC	O
-	O
2.2	O
*	O
RBC	O
-	O
2.67	O
*	O
HGB	O
-	O
8.4	O
*	O
HCT	O
-	O
24.9	O
*	O
MCV	O
-	O
94	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
18.4	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
NEUTS	O
-	O
30	O
*	O
BANDS	O
-	O
0	O
LYMPHS	O
-	O
42	O
MONOS	O
-	O
8	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
1	O
*	O
METAS	O
-	O
1	O
*	O
MYELOS	O
-	O
1	O
*	O
BLASTS	O
-	O
17	O
*	O
NUC	O
RBCS	O
-	O
2	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
PLT	O
SMR	O
-	O
VERY	O
LOW	O
PLT	O
COUNT	O
-	O
22	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
GRAN	O
CT	O
-	O
704	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
WBC	O
-	O
3.7	O
*	O
#	O
RBC	O
-	O
2.21	O
*	O
HGB	O
-	O
6.8	O
*	O
HCT	O
-	O
19.6	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.8	O
MCHC	O
-	O
34.7	O
RDW	O
-	O
19.6	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
NEUTS	O
-	O
87	O
*	O
BANDS	O
-	O
0	O
LYMPHS	O
-	O
2	O
*	O
MONOS	O
-	O
1	O
*	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
BLASTS	O
-	O
10	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
PLT	O
SMR	O
-	O
VERY	O
LOW	O
PLT	O
COUNT	O
-	O
21	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
PLT	O
COUNT	O
-	O
31	O
*	O
[	O
**	O
2195-4-1	O
**	O
]	O
ALT	O
(	O
SGPT	O
)	O
-	O
12	O
AST	O
(	O
SGOT	O
)	O
-	O
27	O
LD	O
(	O
LDH	O
)	O
-	O
274	O
*	O
ALK	O
PHOS	O
-	O
67	O
TOT	O
BILI	O
-	O
1.8	O
*	O
DIR	O
BILI	O
-	O
0.6	O
*	O
INDIR	O
BIL	O
-	O
1.2	O
[	O
**	O
2195-4-1	O
**	O
]	O
HAPTOGLOB	O
-	O
197	O
[	O
**	O
2195-4-1	O
**	O
]	O
GLUCOSE	O
-	O
116	O
*	O
UREA	O
N	O
-	O
25	O
*	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
4.3	O
CHLORIDE	O
-	O
103	O
TOTAL	O
CO2	O
-	O
26	O
ANION	O
GAP	O
-	O
13	O
[	O
**	O
2195-4-1	O
**	O
]	O
URINE	O
BLOOD	O
-	O
SM	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
TR	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2195-4-1	O
**	O
]	O
URINE	O
RBC	O
-	O
1	O
WBC	O
-	O
3	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
2	O
TRANS	O
EPI	O
-	O
<	O
1	O
.	O
Discharge	O
labs	O
:	O
===============	O
[	O
**	O
2195-4-19	O
**	O
]	O
BLOOD	O
ALT	O
-	O
8	O
AST	O
-	O
22	O
LD	O
(	O
LDH	O
)	O
-	O
222	O
AlkPhos	O
-	O
51	O
TotBili	O
-	O
1.1	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
WBC	O
-	O
1.8	O
*	O
RBC	O
-	O
2.94	O
*	O
Hgb	O
-	O
9.1	O
*	O
Hct	O
-	O
27.3	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
19.1	O
*	O
Plt	O
Ct	O
-	O
84	O
*	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
Neuts	O
-	O
53	O
Bands	O
-	O
0	O
Lymphs	O
-	O
33	O
Monos	O
-	O
0	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
2	O
*	O
Blasts	O
-	O
12	O
*	O
NRBC	O
-	O
1	O
*	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
Plt	O
Smr	O
-	O
LOW	O
Plt	O
Ct	O
-	O
84	O
*	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
PT	O
-	O
15.4	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.4	O
*	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
Gran	O
Ct	O
-	O
979	O
*	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
Glucose	O
-	O
101	O
*	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.8	O
Na	O
-	O
137	O
K	O
-	O
3.8	O
Cl	O
-	O
99	O
HCO3	O
-	O
29	O
AnGap	O
-	O
13	O
[	O
**	O
2195-4-22	O
**	O
]	O
BLOOD	O
Calcium	O
-	O
8.6	O
Phos	O
-	O
4.0	O
Mg	O
-	O
1.9	O
.	O
Microbiology	O
:	O
=============	O
Urine	O
culture	O
:	O
mixed	O
flora	O
Blood	O
culture	O
:	O
no	O
growth	O
MRSA	O
screen	O
:	O
negative	O
.	O
Imaging	O
:	O
========	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
CHEST	O
(	O
PA	O
&	O
LAT	O
)	O
-	O
Calcified	O
pleural	O
plaque	O
is	O
better	O
assessed	O
on	O
the	O
prior	O
CT.	O
.	O
There	O
is	O
mild	O
interstitial	O
edema	O
with	O
no	O
large	O
effusions	O
or	O
pneumothorax	O
.	O
No	O
signs	O
of	O
pneumonia	O
.	O
Cardiomediastinal	O
silhouette	O
is	O
stable	O
.	O
Calcified	O
tracheobronchial	O
tree	O
noted	O
.	O
Bony	O
structures	O
are	O
intact	O
.	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
CT	O
ABD	O
&	O
PELVIS	O
WITH	O
CO	O
-	O
No	O
acute	O
intra-abdominal	O
or	O
pelvic	O
process	O
.	O
No	O
evidence	O
of	O
retroperitoneal	O
hemorrhage	O
.	O
Stable	O
gallbladder	O
polyp	O
.	O
Stable	O
gallbladder	O
polyps	O
versus	O
a	O
focus	O
of	O
adenomyomatosis	O
within	O
the	O
gallbladder	O
fundus	O
.	O
Sigmoid	O
diverticulosis	O
.	O
Patchy	O
bibasilar	O
opacities	O
within	O
the	O
lung	O
bases	O
,	O
with	O
subpleural	O
scar	O
formations	O
and	O
bronchiectasis	O
within	O
the	O
lung	O
bases	O
.	O
.	O
[	O
**	O
2195-4-8	O
**	O
]	O
CT	O
head	O
without	O
contrast	O
:	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
intracranial	O
hemorrhage	O
or	O
mass	O
effect	O
.	O
Slightly	O
dense	O
appearance	O
of	O
the	O
cortex	O
lateral	O
to	O
the	O
Sylvian	O
fissure	O
(	O
se	O
2	O
,	O
im	O
12	O
)	O
is	O
likely	O
related	O
to	O
volume	O
averaging	O
rather	O
than	O
hemorrhage	O
;	O
a	O
follow	O
up	O
can	O
be	O
considered	O
if	O
necessary	O
.	O
No	O
prior	O
CT	O
studies	O
are	O
available	O
.	O
2	O
.	O
Bilateral	O
mastoid	O
opacification	O
from	O
fluid	O
/	O
mucosal	O
thickening	O
.	O
CTA	O
[	O
**	O
2195-4-18	O
**	O
]	O
Abd	O
-	O
Pelvis	O
IMPRESSION	O
:	O
1	O
.	O
No	O
contrast	O
extravasation	O
to	O
suggest	O
GI	O
bleeding	O
.	O
2	O
.	O
Stable	O
gallbladder	O
polyp	O
and	O
fundal	O
adenomyomatosis	O
.	O
3	O
.	O
Colonic	O
diverticulosis	O
without	O
evidence	O
of	O
diverticulitis	O
.	O
4	O
.	O
Small	O
left	O
adrenal	O
adenoma	O
.	O
5	O
.	O
Unchanged	O
Focal	O
celiac	O
artery	O
and	O
aortic	O
dilation	O
as	O
described	O
above	O
.	O
.	O
Colonoscopy	O
:	O
============	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
Colonoscopy	O
prior	O
to	O
this	O
admission	O
:	O
Abnormal	O
mucosa	O
in	O
the	O
colon	O
.	O
Diverticulosis	O
of	O
the	O
sigmoid	O
colon	O
.	O
A	O
small	O
posterior	O
rectal	O
fissure	O
was	O
noted	O
in	O
the	O
anal	O
canal	O
.	O
This	O
was	O
not	O
bleeding	O
.	O
Blood	O
was	O
noted	O
throughout	O
the	O
entire	O
colon	O
.	O
Otherwise	O
normal	O
colonoscopy	O
to	O
cecum	O
.	O
.	O
[	O
**	O
2195-4-3	O
**	O
]	O
colonoscopy	O
:	O
Non	O
bleediong	O
diverticulosis	O
of	O
the	O
whole	O
colon	O
.	O
Bleeding	O
angioectasias	O
in	O
the	O
cecum	O
treated	O
with	O
APC	O
.	O
Polyp	O
in	O
the	O
transverse	O
colon	O
.	O
Blood	O
and	O
stool	O
throughout	O
colon	O
.	O
Non	O
bleeding	O
posterior	O
anal	O
fissure	O
.	O
.	O
[	O
**	O
2195-4-13	O
**	O
]	O
colonoscopy	O
:	O
Blood	O
in	O
the	O
whole	O
colon	O
.	O
Diverticulosis	O
of	O
the	O
sigmoid	O
colon	O
and	O
descending	O
colon	O
.	O
Ulcers	O
in	O
the	O
cecum	O
.	O
A	O
large	O
adherent	O
blood	O
clot	O
was	O
found	O
in	O
the	O
cecum	O
with	O
surrounding	O
oozing	O
of	O
bright	O
red	O
blood	O
.	O
Given	O
the	O
risk	O
of	O
uncontrollable	O
bleeding	O
in	O
the	O
setting	O
of	O
low	O
platelets	O
,	O
the	O
clot	O
was	O
not	O
removed	O
.	O
Otherwise	O
normal	O
colonoscopy	O
to	O
cecum	O
Brief	O
Hospital	O
Course	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
73078	O
**	O
]	O
is	O
79	O
year	O
old	O
pleasant	O
woman	O
with	O
a	O
Past	O
medical	O
history	O
significant	O
for	O
MDS	O
with	O
AML	I-Reason
transformation	O
on	O
Dacogen	I-Drug
,	O
diverticulosis	O
,	O
known	O
cecal	O
AVMs	O
admitted	O
from	O
clinic	O
on	O
[	O
**	O
2195-4-1	O
**	O
]	O
in	O
the	O
setting	O
of	O
a	O
transfusion	O
reaction	O
to	O
platelets	I-Drug
with	O
thrombocytopenia	I-Ade
who	O
was	O
noted	O
to	O
develop	O
bright	O
red	O
blood	O
per	O
rectum	O
with	O
acute	O
hematocrit	O
drop	O
who	O
underwent	O
repeat	O
colonoscopy	O
showing	O
non-bleeding	O
diverticulosis	O
of	O
the	O
entire	O
colon	O
and	O
bleeding	O
angioectasias	O
of	O
the	O
cecum	O
treated	O
with	O
Argon	O
Plasma	O
coagulation	O
.	O
She	O
required	O
a	O
second	O
colonoscopy	O
for	O
repeated	O
bloody	O
bowel	O
movements	O
which	O
showed	O
a	O
clot	O
adherent	O
to	O
the	O
cecum	O
.	O
She	O
remained	O
stable	O
for	O
a	O
while	O
then	O
had	O
frequent	O
bloody	B-Reason
bowel	I-Reason
movements	I-Reason
again	O
which	O
was	O
controlled	O
by	O
amicar	I-Drug
drip	O
for	O
8	O
hours	O
.	O
Gradually	O
her	O
platelets	O
started	O
to	O
increase	O
.	O
After	O
these	O
events	O
,	O
she	O
remained	O
stable	O
and	O
was	O
discharged	O
home	O
in	O
stable	O
condition	O
.	O
She	O
will	O
require	O
HLA	O
matched	O
platelet	O
transfusions	O
in	O
the	O
future	O
if	O
needed	O
.	O
.	O
#	O
cecal	O
AVMs	O
:	O
She	O
was	O
transferred	O
to	O
the	O
ICU	O
twice	O
for	O
bright	O
red	O
blood	O
per	O
rectum	O
.	O
The	O
patient	O
developed	O
BRBPR	O
,	O
and	O
was	O
found	O
to	O
have	O
cecal	O
AVMs	O
on	O
colonoscopy	O
s	O
/	O
p	O
APC	O
.	O
Specifically	O
,	O
repeat	O
colonoscopy	O
demonstrated	O
cecal	O
angioectasias	O
that	O
were	O
actively	O
bleeding	O
,	O
non-bleeding	O
colonic	O
diverticula	O
and	O
small	O
polyp	O
.	O
Hemostasis	O
achieved	O
with	O
Argon	O
Plasma	O
coagulation	O
therapy	O
on	O
[	O
**	O
2195-4-3	O
**	O
]	O
.	O
During	O
her	O
stay	O
she	O
required	O
several	O
units	O
of	O
PRBC	I-Drug
and	O
platelets	I-Drug
.	O
After	O
remaining	O
stable	O
,	O
she	O
was	O
transferred	O
back	O
to	O
the	O
floor	O
however	O
she	O
had	O
the	O
same	O
situation	O
again	O
and	O
was	O
transferred	O
back	O
to	O
the	O
ICU	O
where	O
she	O
had	O
her	O
second	O
colonoscopy	O
which	O
showed	O
a	O
clot	O
adherent	O
to	O
the	O
cecum	O
with	O
oozing	O
around	O
the	O
clot	O
.	O
The	O
clot	O
was	O
not	O
removed	O
(	O
not	O
amenable	O
to	O
endoscopic	O
management	O
)	O
.	O
GI	O
recommended	O
surgical	O
consult	O
for	O
possible	O
resection	O
however	O
given	O
her	O
underlying	O
disease	O
and	O
low	O
platelet	O
counts	O
,	O
they	O
felt	O
this	O
will	O
not	O
be	O
a	O
favorable	O
management	O
.	O
After	O
having	O
stable	O
H	O
/	O
H	O
,	O
she	O
was	O
transferred	O
back	O
to	O
the	O
floor	O
.	O
While	O
on	O
the	O
floor	O
,	O
she	O
had	O
a	O
few	O
bloody	O
bowel	O
movements	O
however	O
the	O
night	O
of	O
[	O
**	O
4	O
-	O
17	O
**	O
]	O
she	O
had	O
total	O
of	O
450	O
cc	O
bloody	B-Reason
watery	I-Reason
stools	I-Reason
which	O
required	O
amicar	I-Drug
drip	O
for	O
8	O
hours	O
(	O
her	O
platelets	O
were	O
in	O
the	O
40	O
-	O
50's	O
)	O
.	O
CTA	O
was	O
negative	O
.	O
Following	O
this	O
,	O
she	O
did	O
not	O
have	O
any	O
further	O
significant	O
bloody	O
stools	O
.	O
She	O
remained	O
vitally	O
stable	O
with	O
stable	O
H	O
/	O
H	O
and	O
gradually	O
rising	O
platelet	O
count	O
.	O
.	O
#	O
thrombocytopenia	I-Ade
:	O
Secondary	O
to	O
chemotherapy	I-Drug
and	O
MDS	O
/	O
AML	O
concerns	O
.	O
Concern	O
for	O
consumptive	O
process	O
following	O
transfusion	O
of	O
platelets	I-Drug
in	O
the	O
setting	O
of	O
possible	O
ITP	O
vs.	O
TTP	O
however	O
Hematologic	O
smear	O
was	O
without	O
schistocytes	O
and	O
there	O
was	O
no	O
evidence	O
of	O
renal	O
failure	O
or	O
neurologic	O
concerns	O
;	O
no	O
fevers	O
.	O
The	O
patient	O
also	O
had	O
two	B-Ade
transfusion	I-Ade
reactions	I-Ade
to	O
platelets	I-Drug
when	O
first	O
admitted	O
.	O
She	O
was	O
premedicated	O
with	O
anti-histamines	I-Drug
.	O
While	O
the	O
patient	O
was	O
actively	O
bleeding	O
,	O
she	O
was	O
also	O
given	O
Amicar	I-Drug
(	O
2	O
grams	O
IV	O
with	O
1gram	O
/	O
hour	O
IV	O
infusion	O
overnight	O
on	O
[	O
**	O
2195-4-2	O
**	O
]	O
)	O
.	O
This	O
was	O
repeated	O
over	O
the	O
night	O
of	O
[	O
**	O
4	O
-	O
17	O
**	O
]	O
as	O
above	O
.	O
She	O
was	O
found	O
to	O
have	O
a	O
positive	B-Reason
PRA	I-Reason
and	O
required	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
for	O
all	O
subsequent	O
transfusions	O
.	O
Her	O
twin	O
sister	O
was	O
tested	O
at	O
Red	O
Cross	O
for	O
potential	O
candidate	O
to	O
donate	O
platelets	O
for	O
her	O
sister	O
however	O
since	O
she	O
takes	O
aspirin	I-Drug
and	O
plavix	I-Drug
,	O
this	O
was	O
not	O
a	O
suitable	O
option	O
.	O
Of	O
note	O
,	O
her	O
platelet	O
count	O
was	O
improving	O
already	O
and	O
did	O
not	O
require	O
further	O
platelet	I-Drug
transfusions	O
.	O
Platelet	O
count	O
was	O
in	O
the	O
90's	O
upon	O
discharge	O
.	O
.	O
#	O
transfusion	B-Ade
reaction	I-Ade
/	O
PRA	B-Ade
positive	I-Ade
:	O
The	O
patient	O
had	O
transfusion	O
reaction	O
to	O
platelet	I-Drug
transfusion	O
(	O
once	O
in	O
clinic	O
,	O
and	O
once	O
while	O
on	O
the	O
floor	O
)	O
.	O
She	O
was	O
premedicated	O
with	O
famotidine	I-Drug
,	O
benadryl	I-Drug
,	O
and	O
hydrocortisone	I-Drug
.	O
A	O
blood	O
bank	O
work	O
up	O
was	O
initiated	O
,	O
and	O
the	O
patient	O
was	O
given	O
group	O
specific	O
platelets	I-Drug
.	O
She	O
was	O
found	O
to	O
be	O
PRA	B-Reason
positive	I-Reason
and	O
requires	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
.	O
However	O
,	O
during	O
her	O
second	O
episode	O
of	O
BRBPR	O
on	O
[	O
**	O
4	O
-	O
12	O
**	O
]	O
,	O
it	O
was	O
found	O
that	O
there	O
was	O
no	O
more	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
available	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
area	O
.	O
Red	O
Cross	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
for	O
more	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
.	O
Sister	O
was	O
a	O
potential	O
donor	O
however	O
it	O
was	O
n't	O
suitable	O
given	O
her	O
anti-platelet	O
therapy	O
as	O
above	O
.	O
She	O
did	O
not	O
require	O
further	O
platelet	I-Drug
transfusions	O
once	O
her	O
platelet	O
count	O
started	O
to	O
increase	O
.	O
.	O
#	O
MDS	B-Reason
with	I-Reason
AML	I-Reason
transformation	I-Reason
:	O
While	O
the	O
patient	O
was	O
on	O
the	O
floor	O
,	O
it	O
was	O
noticed	O
that	O
her	O
blast	O
count	O
was	O
trending	O
up	O
and	O
her	O
neutrophil	O
count	O
was	O
trending	O
down	O
.	O
It	O
was	O
then	O
decided	O
to	O
start	O
her	O
on	O
second	O
cycle	O
of	O
Dacogen	I-Drug
(	O
day	O
1	O
=	O
[	O
**	O
2195-4-8	O
**	O
]	O
)	O
.	O
The	O
patient	O
tolerated	O
the	O
Dacogen	I-Drug
well	O
,	O
with	O
little	O
side	O
effects	O
.	O
12	O
%	O
blast	O
cells	O
on	O
peripheral	O
blood	O
upon	O
discharge	O
.	O
.	O
#	O
GERD	I-Reason
:	O
The	O
patient	O
was	O
continued	O
on	O
her	O
home	O
PPI	I-Drug
.	O
.	O
#	O
constipation	O
:	O
The	O
patient	O
has	O
a	O
history	O
of	O
severe	O
constipation	O
,	O
however	O
,	O
her	O
home	O
medications	O
were	O
held	O
in	O
the	O
setting	O
of	O
her	O
BRBPR	O
and	O
then	O
restarted	O
upon	O
discharge	O
given	O
resolution	O
of	O
bloody	O
bowel	O
movements	O
.	O
.	O
Transitional	O
Issues	O
:	O
-	O
The	O
patient	O
had	O
transfusion	B-Ade
reaction	I-Ade
to	O
platelets	I-Drug
;	O
a	O
blood	O
bank	O
work	O
up	O
was	O
initiated	O
and	O
she	O
was	O
found	O
to	O
be	O
PRA	B-Reason
positive	I-Reason
;	O
she	O
will	O
require	O
HLA	B-Drug
matched	I-Drug
platelets	I-Drug
for	O
all	O
subsequent	O
transfusions	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
loratadine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
daily	O
(	O
)	O
.	O
2	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
Powder	O
in	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Powder	O
in	O
Packet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
4	O
.	O
magnesium	B-Drug
hydroxide	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
5	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
allopurinol	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Medications	O
:	O
1	O
.	O
loratadine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
daily	O
(	O
)	O
.	O
2	O
.	O
omeprazole	I-Drug
40	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
Miralax	I-Drug
17	O
gram	O
Powder	O
in	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
4	O
.	O
Milk	B-Drug
of	I-Drug
Magnesia	I-Drug
400	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ml	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
5	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
myelodysplastic	O
syndrome	O
/	O
acute	O
myloid	O
leukemia	O
cecal	O
atriovenous	O
malformations	O
Lower	O
GI	O
bleed	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
73078	O
**	O
]	O
,	O
It	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
while	O
you	O
were	O
hospitalized	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
you	O
had	O
a	O
transfusion	B-Ade
reaction	I-Ade
after	O
getting	O
platelets	I-Drug
at	O
clinic	O
.	O
We	O
did	O
some	O
tests	O
and	O
found	O
that	O
you	O
will	O
need	O
specially	O
screened	O
platelets	O
from	O
now	O
on	O
because	O
your	O
body	O
reacts	O
to	O
normal	O
platelets	O
.	O
While	O
you	O
were	O
here	O
,	O
you	O
also	O
developed	O
some	O
bleeding	O
from	O
your	O
rectum	O
.	O
You	O
were	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
and	O
they	O
gastrointestinal	O
doctors	O
looked	O
into	O
your	O
intestines	O
with	O
a	O
camera	O
and	O
found	O
some	O
areas	O
of	O
bleeding	O
called	O
AV	O
malformations	O
that	O
were	O
clipped	O
.	O
After	O
this	O
,	O
you	O
were	O
sent	O
to	O
the	O
floor	O
then	O
sent	O
back	O
to	O
the	O
ICU	O
when	O
you	O
had	O
further	O
bleeding	O
.	O
Second	O
colonoscopy	O
was	O
done	O
which	O
showed	O
a	O
large	O
clot	O
attached	O
to	O
your	O
colon	O
in	O
the	O
same	O
area	O
where	O
the	O
AVM	O
's	O
were	O
clipped	O
.	O
Your	O
blood	O
level	O
was	O
stable	O
as	O
well	O
as	O
your	O
blood	O
pressure	O
and	O
you	O
were	O
transferred	O
to	O
the	O
floor	O
.	O
While	O
on	O
the	O
floor	O
,	O
you	O
had	O
a	O
few	O
loose	O
bloody	O
stools	O
that	O
subsequently	O
resolved	O
.	O
Your	O
diet	O
was	O
gradually	O
advanced	O
and	O
you	O
tolerated	O
it	O
well	O
prior	O
to	O
discharge	O
.	O
Your	O
platelets	O
gradually	O
increased	O
and	O
it	O
was	O
in	O
the	O
80's	O
on	O
your	O
discharge	O
day	O
.	O
The	O
surgeons	O
evaluated	O
you	O
for	O
possible	O
surgical	O
removal	O
of	O
part	O
of	O
your	O
colon	O
,	O
however	O
they	O
felt	O
it	O
is	O
unsafe	O
to	O
do	O
surgery	O
for	O
the	O
moment	O
.	O
We	O
did	O
not	O
discharge	O
you	O
on	O
Amicar	I-Drug
which	O
is	O
a	O
clot	I-Reason
stabilizer	O
medication	O
since	O
you	O
did	O
not	O
have	O
further	O
bloody	O
stools	O
,	O
your	O
blood	O
level	O
was	O
stable	O
and	O
your	O
platelets	O
were	O
gradually	O
increasing	O
.	O
We	O
also	O
noticed	O
some	O
changes	O
in	O
your	O
blood	O
work	O
that	O
made	O
us	O
think	O
that	O
your	O
leukemia	O
was	O
acting	O
up	O
again	O
;	O
because	O
of	O
that	O
we	O
started	O
you	O
on	O
another	O
five	O
day	O
cycle	O
of	O
chemotherapy	I-Drug
.	O
You	O
tolerated	O
the	O
chemo	I-Drug
well	O
.	O
.	O
While	O
in	O
the	O
hosiptal	O
,	O
it	O
was	O
noted	O
that	O
occasionally	O
your	O
blood	O
pressure	O
was	O
high	O
and	O
you	O
were	O
started	O
on	O
a	O
medication	O
for	O
brief	O
time	O
.	O
However	O
,	O
given	O
your	O
GI	O
bleeds	O
,	O
this	O
was	O
held	O
.	O
We	O
will	O
not	O
discharge	O
you	O
at	O
the	O
moment	O
with	O
anti-hypertensive	B-Drug
medication	I-Drug
.	O
We	O
did	O
the	O
following	O
changes	O
in	O
your	O
medication	O
list	O
:	O
-	O
Please	O
stop	O
allopurinol	I-Drug
Please	O
continue	O
the	O
rest	O
of	O
your	O
home	O
medications	O
the	O
same	O
way	O
you	O
were	O
taking	O
them	O
at	O
home	O
prior	O
to	O
admission	O
.	O
Your	O
PICC	O
line	O
was	O
removed	O
prior	O
to	O
discharge	O
.	O
It	O
will	O
be	O
important	O
for	O
you	O
to	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Please	O
follow	O
with	O
your	O
appointments	O
as	O
illustrated	O
below	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
MONDAY	O
[	O
**	O
2195-4-27	O
**	O
]	O
at	O
12:30	O
PM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
MONDAY	O
[	O
**	O
2195-4-27	O
**	O
]	O
at	O
12:30	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
2747	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
3983	O
**	O
]	O
,	O
NP	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3237	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
HEMATOLOGY	O
/	O
BMT	O
When	O
:	O
MONDAY	O
[	O
**	O
2195-4-27	O
**	O
]	O
at	O
1	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
539	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
9816	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3241	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
3922	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2117-10-6	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2117-10-9	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2058-12-19	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Iodine	I-Drug
;	O
Iodine	B-Drug
Containing	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
12	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fever	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Portacath	O
removal	O
(	O
[	O
**	O
2117-10-7	O
**	O
]	O
)	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
58	O
year	O
-	O
old	O
male	O
with	O
a	O
history	O
of	O
pancreatic	O
cancer	O
diagnosed	O
[	O
**	O
11	O
-	O
5	O
**	O
]	O
s	O
/	O
p	O
whipple	O
[	O
**	O
11	O
-	O
5	O
**	O
]	O
who	O
presents	O
with	O
fever	I-Reason
to	O
102.8	O
.	O
Patient	O
had	O
a	O
similar	O
admission	O
in	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
here	O
for	O
similar	O
reasons	O
.	O
Both	O
times	O
,	O
the	O
fever	O
started	O
shortly	O
after	O
port	O
access	O
.	O
During	O
his	O
admission	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
,	O
no	O
positive	O
blood	O
cultures	O
,	O
negative	O
urine	O
cx	O
,	O
negative	O
cxr	O
,	O
negative	O
echo	O
.	O
Was	O
diagnosed	O
with	O
supraventricular	B-Reason
tacchycardia	I-Reason
and	O
was	O
given	O
adenosine	I-Drug
and	O
then	O
lopressor	I-Drug
to	O
take	O
at	O
home	O
.	O
He	O
was	O
treated	O
with	O
vanc	I-Drug
and	O
ceftriaxone	I-Drug
and	O
then	O
ciprofloxacin	I-Drug
and	O
improved	O
.	O
He	O
usually	O
feels	O
ill	O
about	O
48	O
hours	O
after	O
port	O
access	O
for	O
chemotherapy	I-Drug
but	O
it	O
is	O
unclear	O
if	O
this	O
is	O
the	O
chemotherapy	I-Drug
or	O
infection	O
.	O
The	O
port	O
was	O
placed	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
.	O
On	O
Monday	O
,	O
he	O
had	O
his	O
port	O
accessed	O
for	O
labs	O
and	O
he	O
began	O
to	O
feel	O
like	O
he	O
was	O
"	O
coming	O
down	O
with	O
a	O
cold	O
"	O
on	O
tuesday	O
afternoon	O
.	O
He	O
went	O
to	O
work	O
today	O
and	O
around	O
noon	O
felt	O
weak	O
,	O
developed	O
abdominal	O
pain	O
radiating	O
to	O
his	O
left	O
shoulder	O
,	O
one	O
episode	O
of	O
vomiting	O
and	O
low	O
grade	O
temp	O
to	O
99	O
.	O
He	O
went	O
to	O
the	O
ED	O
where	O
his	O
temp	O
rose	O
to	O
102.9	O
and	O
he	O
experienced	O
rigors	O
.	O
He	O
denies	O
headache	O
,	O
meningismus	O
,	O
cp	O
,	O
sob	O
,	O
cough	O
,	O
change	O
in	O
abd	O
pain	O
from	O
baseline	O
,	O
diarrhea	O
,	O
change	O
in	O
bowel	O
habits	O
,	O
dysuria	O
,	O
rash	O
,	O
joint	O
pain	O
,	O
hematochezia	O
or	O
melena	O
.	O
No	O
sick	O
contacts	O
.	O
Traveled	O
to	O
[	O
**	O
State	O
**	O
]	O
this	O
weekend	O
for	O
a	O
conference	O
but	O
was	O
only	O
in	O
hotels	O
/	O
airport	O
.	O
No	O
hiking	O
or	O
outdoor	O
activities	O
.	O
Of	O
note	O
,	O
his	O
labs	O
on	O
monday	O
for	O
tumor	O
lysis	O
,	O
lfts	O
were	O
normal	O
and	O
crit	O
was	O
34	O
per	O
patient	O
.	O
.	O
In	O
the	O
ED	O
,	O
vs	O
were	O
:	O
99.4	O
111117/70	O
16	O
96	O
%	O
RA	O
initially	O
.	O
Mild	O
epigastric	O
tenderness	O
.	O
Guaic	O
negative	O
stool	O
.	O
Prostate	O
exam	O
normal	O
.	O
UA	O
negative	O
.	O
He	O
received	O
4	O
liters	O
IVF	I-Drug
.	O
CXR	O
negative	O
.	O
HR	O
130s	O
.	O
EKG	O
showed	O
sinus	O
tacchycardia	O
.	O
Received	O
lovenox	I-Drug
for	O
?	O
PE	I-Reason
since	O
he	O
couldnt	O
get	O
CTA	O
because	O
of	O
contrast	O
allergy	O
.	O
Temp	O
rose	O
to	O
102.8	O
,	O
gave	O
tylenol	I-Drug
.	O
Received	O
vanc	I-Drug
and	O
levaquin	I-Drug
.	O
Shortly	O
after	O
receiving	O
the	O
abx	I-Drug
,	O
his	O
lips	B-Ade
swelled	I-Ade
and	O
he	O
developed	O
hives	I-Ade
.	O
He	O
received	O
benadryl	I-Drug
and	O
pepcid	I-Drug
and	O
this	O
resolved	O
.	O
He	O
has	O
received	O
those	O
antibiotics	I-Drug
multiple	O
times	O
in	O
the	O
past	O
and	O
has	O
never	O
had	O
a	O
reaction	O
.	O
Of	O
note	O
,	O
per	O
wife	O
,	O
the	O
vanco	I-Drug
was	O
given	O
slowly	O
so	O
red	B-Ade
man	I-Ade
syndrome	I-Ade
less	O
likely	O
.	O
.	O
In	O
the	O
ICU	O
,	O
initial	O
vs	O
were	O
:	O
99.6	O
103125/78	O
90	O
20	O
93	O
%	O
RA	O
.	O
Patient	O
reported	O
feeling	O
better	O
.	O
Denied	O
ha	O
,	O
dizziness	O
,	O
cp	O
,	O
palp	O
,	O
sob	O
,	O
cough	O
,	O
abd	O
pain	O
,	O
nausea	O
,	O
etc.	O
.	O
ROS	O
:	O
see	O
hpi	O
Past	O
Medical	O
History	O
:	O
Past	O
Oncologic	O
History	O
:	O
-	O
developed	O
painless	O
jaundice	O
in	O
[	O
**	O
11	O
-	O
5	O
**	O
]	O
-	O
diagnosed	O
with	O
pancreatic	O
adenocarcinoma	O
-	O
underwent	O
Whipple	O
in	O
[	O
**	O
11	O
-	O
5	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
-	O
>	O
had	O
clear	O
margins	O
,	O
but	O
?	O
of	O
2	O
positive	O
lymph	O
nodes	O
-	O
complicated	O
by	O
intra-abdominal	O
hemorrhage	O
,	O
hematoma	O
/	O
abscess	O
formation	O
and	O
sepsis	I-Reason
which	O
required	O
multiple	O
drainages	O
-	O
treated	O
with	O
gemcitabine	I-Drug
-	O
then	O
5FU	I-Drug
continuous	O
infusion	O
,	O
XRT	O
(	O
6	O
weeks	O
)	O
and	O
low	O
dose	O
gemcitabine	I-Drug
-	O
XRT	O
completed	O
in	O
[	O
**	O
5	O
-	O
6	O
**	O
]	O
-	O
last	O
dose	O
of	O
gemcitabine	I-Drug
was	O
the	O
second	O
week	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
462	O
**	O
]	O
(	O
receives	O
this	O
with	O
decadron	O
)	O
.	O
Other	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
-	O
SVT	O
-	O
restless	O
leg	O
syndrome	O
-	O
BPH	O
s	O
/	O
p	O
TURP	O
in	O
end	O
[	O
**	O
6	O
-	O
6	O
**	O
]	O
-	O
>	O
had	O
urinary	O
obstruction	O
/	O
hydro	O
prior	O
-	O
HTN	O
Social	O
History	O
:	O
Dr.	O
[	O
**	O
Known	O
lastname	O
94286	O
**	O
]	O
is	O
a	O
faculty	O
member	O
here	O
who	O
specializes	O
in	O
HIV	O
vaccine	O
research	O
.	O
He	O
is	O
married	O
and	O
his	O
wife	O
is	O
also	O
on	O
faculty	O
here	O
(	O
neurology	O
)	O
.	O
No	O
tobacco	O
,	O
etoh	O
,	O
drug	O
use	O
.	O
Recent	O
travel	O
to	O
[	O
**	O
State	O
**	O
]	O
without	O
outdoor	O
activities	O
.	O
No	O
recent	O
sick	O
contacts	O
.	O
Family	O
History	O
:	O
Father	O
had	O
CABG	O
in	O
his	O
60s	O
,	O
died	O
of	O
CAD	O
at	O
age	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
No	O
family	O
history	O
of	O
DM	O
,	O
lung	O
disease	O
,	O
kidney	O
disease	O
No	O
family	O
history	O
of	O
bleeding	O
,	O
clotting	O
,	O
cancer	O
Physical	O
Exam	O
:	O
Tmax	O
:	O
37.7	O
??????	O
C	O
(	O
99.8	O
??????	O
F	O
)	O
Tcurrent	O
:	O
36.8	O
??????	O
C	O
(	O
98.2	O
??????	O
F	O
)	O
HR	O
:	O
100	O
(	O
100	O
-	O
115	O
)	O
bpm	O
BP	O
:	O
138/88	O
(	O
100	O
)	O
{	O
122/77	O
(	O
87	O
)	O
-	O
138/88	O
(	O
100	O
)	O
}	O
mmHg	O
RR	O
:	O
17	O
(	O
17	O
-	O
23	O
)	O
insp	O
/	O
min	O
SpO2	O
:	O
93	O
%	O
Heart	O
rhythm	O
:	O
SR	O
(	O
Sinus	O
Rhythm	O
)	O
Height	O
:	O
63	O
Inch	O
GEN	O
:	O
Well	O
-	O
appearing	O
,	O
thin	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
NCAT	O
,	O
EOMI	O
,	O
PERRL	O
,	O
sclera	O
anicteric	O
,	O
no	O
epistaxis	O
or	O
rhinorrhea	O
,	O
MM	O
dry	O
,	O
OP	O
Clear	O
,	O
no	O
thrush	O
or	O
oral	O
lesions	O
NECK	O
:	O
No	O
JVD	O
,	O
carotid	O
pulses	O
brisk	O
,	O
no	O
bruits	O
,	O
no	O
cervical	O
lymphadenopathy	O
,	O
trachea	O
midline	O
,	O
no	O
meningismus	O
COR	O
:	O
tacchy	O
,	O
RR	O
,	O
no	O
M	O
/	O
G	O
/	O
R	O
,	O
normal	O
S1	O
S2	O
,	O
radial	O
pulses	O
+2	O
PULM	O
:	O
Lungs	O
dullness	O
at	O
the	O
R	O
lung	O
base	O
,	O
no	O
W	O
/	O
R	O
/	O
R	O
ABD	O
:	O
Soft	O
,	O
mild	O
tenderness	O
in	O
epigastrium	O
,	O
ND	O
,	O
+	O
BS	O
,	O
no	O
HSM	O
,	O
no	O
masses	O
,	O
no	O
rebound	O
or	O
guarding	O
,	O
well	O
-	O
healed	O
scar	O
from	O
whipple	O
EXT	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
,	O
no	O
palpable	O
cords	O
NEURO	O
:	O
alert	O
,	O
oriented	O
to	O
person	O
,	O
place	O
,	O
and	O
time	O
.	O
CN	O
II	O
??????	O
XII	O
grossly	O
intact	O
.	O
Moves	O
all	O
4	O
extremities	O
.	O
Strength	O
5/5	O
in	O
upper	O
and	O
lower	O
extremities	O
.	O
Patellar	O
DTR	O
+1	O
.	O
SKIN	O
:	O
No	O
jaundice	O
,	O
cyanosis	O
,	O
or	O
gross	O
dermatitis	O
.	O
No	O
ecchymoses	O
.	O
BACK	O
:	O
no	O
spinal	O
tenderness	O
Pertinent	O
Results	O
:	O
.	O
[	O
**	O
2117-10-8	O
**	O
]	O
MRI	O
Abdomen	O
FINDINGS	O
:	O
The	O
patient	O
is	O
status	O
post	O
Whipple	O
with	O
expected	O
postoperative	O
anatomy	O
and	O
anastomoses	O
.	O
There	O
is	O
expected	O
pneumobilia	O
.	O
In	O
addition	O
,	O
there	O
is	O
mild	O
intrahepatic	O
biliary	O
ductal	O
dilation	O
,	O
preferentially	O
within	O
the	O
left	O
system	O
,	O
and	O
also	O
involving	O
the	O
posterior	O
right	O
biliary	O
duct	O
which	O
arises	O
from	O
the	O
left	O
system	O
,	O
an	O
anatomic	O
variant	O
.	O
The	O
pre-contrast	O
study	O
demonstrates	O
even	O
more	O
prominent	O
left	O
ductal	O
dilation	O
.	O
There	O
are	O
equivocal	O
areas	O
of	O
stenosis	O
in	O
the	O
peripheral	O
left	O
system	O
without	O
evidence	O
of	O
central	O
stenosis	O
,	O
although	O
the	O
evaluation	O
of	O
stenosis	O
is	O
limited	O
by	O
the	O
presence	O
of	O
pneumobilia	O
.	O
In	O
the	O
left	O
lobe	O
of	O
the	O
liver	O
,	O
there	O
is	O
subtle	O
hyperemia	O
in	O
the	O
arterial	O
phase	O
without	O
evidence	O
of	O
abnormality	O
in	O
signal	O
on	O
the	O
T2	O
-	O
weighted	O
images	O
suggestive	O
of	O
edema	O
.	O
No	O
enhancing	O
liver	O
lesions	O
are	O
identified	O
.	O
The	O
gallbladder	O
is	O
surgically	O
absent	O
.	O
Nodularity	O
of	O
the	O
right	O
adrenal	O
gland	O
is	O
stable	O
compared	O
to	O
the	O
preoperative	O
study	O
.	O
The	O
left	O
adrenal	O
gland	O
and	O
spleen	O
appear	O
unremarkable	O
.	O
The	O
pancreatic	O
parenchyma	O
enhances	O
homogeneously	O
.	O
The	O
pancreatic	O
duct	O
is	O
not	O
dilated	O
.	O
The	O
kidneys	O
enhance	O
and	O
excrete	O
contrast	O
symmetrically	O
without	O
hydronephrosis	O
.	O
There	O
are	O
bilateral	O
nonenhancing	O
renal	O
cysts	O
.	O
There	O
is	O
mild	O
perinephric	O
fluid	O
bilaterally	O
,	O
right	O
greater	O
than	O
left	O
.	O
There	O
is	O
mild	O
thickening	O
of	O
the	O
right	O
lateral	O
conal	O
fascia	O
which	O
is	O
probably	O
postoperative	O
.	O
Small	O
foci	O
of	O
blooming	O
artifact	O
on	O
the	O
gradient	O
-	O
echo	O
sequences	O
within	O
the	O
mesentery	O
near	O
the	O
area	O
of	O
surgery	O
are	O
likely	O
related	O
to	O
hemosiderin	O
and	O
postoperative	O
change	O
.	O
No	O
evidence	O
of	O
new	O
mass	O
or	O
lymphadenopathy	O
is	O
appreciated	O
.	O
The	O
signal	O
within	O
the	O
bone	O
marrow	O
appeared	O
to	O
be	O
normal	O
limits	O
.	O
The	O
lung	O
bases	O
demonstrate	O
small	O
bilateral	O
pleural	O
effusions	O
and	O
associated	O
atelectasis	O
,	O
right	O
greater	O
than	O
left	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Subtle	O
hyperemia	O
in	O
the	O
left	O
lobe	O
of	O
the	O
liver	O
without	O
evidence	O
of	O
edema	O
,	O
fluid	O
collection	O
,	O
or	O
central	O
biliary	O
stenosis	O
.	O
Equivocal	O
stenosis	O
in	O
the	O
periphery	O
of	O
the	O
left	O
biliary	O
system	O
is	O
difficult	O
to	O
evaluate	O
given	O
the	O
presence	O
of	O
pneumobilia	O
.	O
Findings	O
could	O
represent	O
subclinical	O
cholangitis	O
,	O
given	O
biliary	O
anastomoses	O
.	O
2	O
.	O
Bilateral	O
small	O
pleural	O
effusions	O
,	O
right	O
greater	O
than	O
left	O
,	O
with	O
associated	O
atelectasis	O
.	O
3	O
.	O
Stable	O
nodularity	O
in	O
the	O
right	O
adrenal	O
gland	O
,	O
unchanged	O
from	O
preoperative	O
study	O
.	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
GLUCOSE	O
-	O
125	O
*	O
UREA	O
N	O
-	O
16	O
CREAT	O
-	O
1.2	O
SODIUM	O
-	O
140	O
POTASSIUM	O
-	O
4.6	O
CHLORIDE	O
-	O
113	O
*	O
TOTAL	O
CO2	O
-	O
17	O
*	O
ANION	O
GAP	O
-	O
15	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
CALCIUM	O
-	O
7.7	O
*	O
PHOSPHATE	O
-	O
3.2	O
MAGNESIUM	O
-	O
1.4	O
*	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
TSH	O
-	O
2.4	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
WBC	O
-	O
12.2	O
*	O
#	O
RBC	O
-	O
3.37	O
*	O
HGB	O
-	O
10.6	O
*	O
HCT	O
-	O
31.9	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
14.1	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
NEUTS	O
-	O
73	O
*	O
BANDS	O
-	O
22	O
*	O
LYMPHS	O
-	O
3	O
*	O
MONOS	O
-	O
2	O
EOS	O
-	O
0	O
BASOS	O
-	O
0	O
ATYPS	O
-	O
0	O
METAS	O
-	O
0	O
MYELOS	O
-	O
0	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
HYPOCHROM	O
-	O
NORMAL	O
ANISOCYT	O
-	O
1	O
+	O
POIKILOCY	O
-	O
1	O
+	O
MACROCYT	O
-	O
1	O
+	O
MICROCYT	O
-	O
1	O
+	O
POLYCHROM	O
-	O
OCCASIONAL	O
OVALOCYT	O
-	O
1	O
+	O
SCHISTOCY	O
-	O
OCCASIONAL	O
[	O
**	O
2117-10-6	O
**	O
]	O
11:37	O
PM	O
PLT	O
COUNT	O
-	O
197	O
[	O
**	O
2117-10-6	O
**	O
]	O
06:12	O
PM	O
COMMENTS	O
-	O
GREEN	O
TOP	O
[	O
**	O
2117-10-6	O
**	O
]	O
06:12	O
PM	O
LACTATE	O
-	O
1.6	O
[	O
**	O
2117-10-6	O
**	O
]	O
02:40	O
PM	O
URINE	O
COLOR	O
-	O
Straw	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.015	O
[	O
**	O
2117-10-6	O
**	O
]	O
02:40	O
PM	O
URINE	O
BLOOD	O
-	O
TR	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
7.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2117-10-6	O
**	O
]	O
02:40	O
PM	O
URINE	O
RBC	O
-0-2	O
WBC	O
-0-2	O
BACTERIA	O
-	O
OCC	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
<	O
1	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:53	O
PM	O
COMMENTS	O
-	O
GREEN	O
TOP	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:53	O
PM	O
LACTATE	O
-	O
3.1	O
*	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
GLUCOSE	O
-	O
144	O
*	O
UREA	O
N	O
-	O
23	O
*	O
CREAT	O
-	O
1.5	O
*	O
SODIUM	O
-	O
137	O
POTASSIUM	O
-	O
4.8	O
CHLORIDE	O
-	O
101	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
14	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
ALT	O
(	O
SGPT	O
)	O
-	O
57	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
98	O
*	O
ALK	O
PHOS	O
-	O
173	O
*	O
TOT	O
BILI	O
-	O
0.7	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
LIPASE	O
-	O
10	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
ALBUMIN	O
-	O
4.3	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
WBC	O
-	O
7.4	O
#	O
RBC	O
-	O
3.89	O
*	O
#	O
HGB	O
-	O
12.5	O
*	O
#	O
HCT	O
-	O
36.9	O
*	O
#	O
MCV	O
-	O
95	O
MCH	O
-	O
32.2	O
*	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
14.1	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
NEUTS	O
-	O
93.6	O
*	O
LYMPHS	O
-	O
3.5	O
*	O
MONOS	O
-	O
0.6	O
*	O
EOS	O
-	O
2.2	O
BASOS	O
-	O
0.1	O
[	O
**	O
2117-10-6	O
**	O
]	O
01:40	O
PM	O
PLT	O
COUNT	O
-	O
254	O
Brief	O
Hospital	O
Course	O
:	O
58	O
year	O
-	O
old	O
male	O
with	O
a	O
history	O
of	O
pancreatic	O
cancer	O
who	O
presents	O
with	O
fever	O
and	O
tachycardia	O
.	O
#	O
Fever	O
:	O
Patient	O
with	O
fever	O
to	O
102	O
and	O
leukocytosis	O
.	O
This	O
is	O
most	O
likely	O
an	O
infectious	O
in	O
etiology	O
.	O
The	O
differential	O
includes	O
portacath	O
infection	O
given	O
recent	O
manipulation	O
and	O
timing	O
of	O
the	O
onset	O
.	O
The	O
port	O
was	O
last	O
accessed	O
on	O
monday	O
.	O
Blood	O
cultures	O
drawn	O
peripherally	O
but	O
not	O
from	O
port	O
.	O
The	O
patient	O
also	O
report	O
abdominal	O
pain	O
and	O
has	O
h	O
/	O
o	O
abdominal	O
abscess	O
,	O
but	O
patient	O
has	O
had	O
pain	O
at	O
baseline	O
.	O
CXR	O
today	O
showed	O
haziness	O
in	O
R	O
lower	O
base	O
concerning	O
for	O
early	O
pna	O
vs	O
pulmonary	O
edema	O
.	O
UA	O
negative	O
making	O
pna	O
and	O
UTI	O
unlikely	O
.	O
Pt	O
has	O
elevated	O
liver	O
enzymes	O
that	O
were	O
normal	O
on	O
monday	O
per	O
patient	O
.	O
Could	O
be	O
elevated	O
in	O
setting	O
of	O
sepsis	O
.	O
No	O
change	O
in	O
bowel	O
habit	O
,	O
no	O
signs	O
of	O
menigitis	O
,	O
no	O
murmur	O
on	O
exam	O
to	O
suggest	O
endocarditis	O
.	O
Tick	O
borne	O
disease	O
unlikely	O
as	O
pt	O
does	O
not	O
have	O
any	O
pets	O
and	O
does	O
not	O
do	O
outdoor	O
activities	O
at	O
all	O
.	O
No	O
new	O
drugs	O
to	O
suggest	O
drug	O
fever	O
.	O
Empiric	I-Drug
broad	O
spectrum	O
antibiotics	O
for	O
possible	O
line	I-Reason
infection	O
/	O
intrabdominal	O
process	O
:	O
linezolid	I-Drug
,	O
cefepime	I-Drug
and	O
flagyl	I-Drug
given	O
possible	O
allergy	O
to	O
vanc	I-Drug
and	O
levaquin	I-Drug
?	O
MRI	O
of	O
abdomen	O
was	O
performed	O
and	O
found	O
no	O
intrabdominal	O
abscess	O
but	O
subclinic	O
cholangisit	O
.	O
ID	O
was	O
consulted	O
and	O
thought	O
it	O
was	O
ok	O
to	O
discharge	O
him	O
on	O
PO	O
Augmetin	I-Drug
for	O
one	O
week	O
to	O
follow	O
up	O
with	O
primary	O
providers	O
.	O
.	O
#	O
Tacchycardia	O
:	O
Patient	O
's	O
HR	O
was	O
consistently	O
110	O
-	O
120s	O
here	O
.	O
Patient	O
's	O
ekg	O
was	O
c	O
/	O
w	O
sinus	O
tacchycardia	O
.	O
He	O
is	O
mildly	O
fluid	O
responsive	O
.	O
This	O
could	O
be	O
due	O
to	O
sepsis	O
as	O
above	O
.	O
Pt	O
high	O
risk	O
for	O
PE	O
given	O
onc	O
hx	O
,	O
but	O
no	O
other	O
signs	O
of	O
PE	O
.	O
Not	O
anemic	O
,	O
anxious	O
or	O
in	O
pain	O
.	O
His	O
BB	I-Drug
was	O
held	O
.	O
.	O
#	O
H	O
/	O
O	O
SVT	O
,	O
currently	O
sinus	O
tacchycardia	O
on	O
ekg	O
.	O
Held	O
metoprolol	I-Drug
given	O
patient	O
is	O
febrile	O
and	O
may	O
be	O
peri-septic	O
.	O
Held	O
BB	I-Drug
at	O
discharge	O
per	O
patient	O
request	O
.	O
.	O
#	O
ARF	O
:	O
likely	O
prerenal	O
in	O
setting	O
of	O
possible	O
sepsis	O
.	O
#	O
Transaminitis	O
:	O
likely	O
related	O
to	O
volume	O
depletion	O
and	O
sepsis	O
.	O
Since	O
lfts	O
were	O
normal	O
2	O
days	O
ago	O
,	O
liver	O
abscess	O
unlikely	O
.	O
Tbili	O
normal	O
.	O
Trended	O
down	O
.	O
.	O
#	O
Anemia	O
:	O
crit	O
at	O
baseline	O
to	O
slightly	O
higher	O
.	O
He	O
is	O
most	O
likely	O
hemoconcentrated	O
.	O
.	O
#	O
Pancreatic	O
cancer	O
:	O
defer	O
to	O
primary	O
onc	O
team	O
.	O
#	O
Restless	B-Reason
leg	I-Reason
:	O
cont	O
mirapex	I-Drug
.	O
#	O
HTN	I-Reason
:	O
hold	O
lopressor	I-Drug
.	O
#	O
GERD	I-Reason
:	O
cont	O
prilosec	I-Drug
.	O
#	O
General	O
Care	O
:	O
replete	O
lytes	O
prn	O
,	O
IVF	I-Drug
boluses	O
prn	O
MAP	O
<	O
65	O
,	O
npo	O
given	O
possible	O
port	O
removal	O
in	O
am	O
,	O
Access	O
:	O
portacath	O
,	O
one	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
place	O
another	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
,	O
PPx	O
:	O
prilosec	I-Drug
,	O
sub	O
q	O
heparin	I-Drug
,	O
bowel	O
regimen	O
,	O
Code	O
:	O
Full	O
-	O
confirmed	O
,	O
Discharged	O
in	O
good	O
condition	O
.	O
Comm	O
:	O
wife	O
is	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Numeric	O
Identifier	O
94287	O
**	O
]	O
pager	O
.	O
Medications	O
on	O
Admission	O
:	O
Mirapex	I-Drug
0.125	O
mg	O
qhs	O
Prilosec	I-Drug
20	O
mg	O
qhs	O
Lopressor	I-Drug
12.5	O
mg	O
PO	O
BID	O
pancrease	I-Drug
2	O
-	O
3	O
tabs	O
with	O
meals	O
Discharge	O
Medications	O
:	O
1	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Amylase	B-Drug
-	I-Drug
Lipase	I-Drug
-	I-Drug
Protease	I-Drug
20,000	O
-	O
4,500	O
-	O
25,000	O
unit	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Cap	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
3	O
.	O
Pramipexole	I-Drug
0.125	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
qhs	O
(	O
)	O
.	O
4	O
.	O
Augmentin	B-Drug
XR	I-Drug
1,000	O
-	O
62.5	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
PO	O
twice	O
a	O
day	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
14	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
Diagnosis	O
:	O
Sepsis	O
from	O
Port	O
infection	O
.	O
Secondary	O
Diagnosis	O
:	O
Pancreatic	O
Cancer	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
fevers	O
a	O
couple	O
of	O
days	O
after	O
having	O
your	O
port	O
accessed	O
.	O
Because	O
of	O
the	O
concern	O
of	O
sepsis	I-Reason
,	O
you	O
were	O
admitted	O
to	O
ICU	O
were	O
you	O
were	O
given	O
broad	B-Drug
spectrum	I-Drug
antibiotics	I-Drug
.	O
An	O
MRI	O
of	O
your	O
abdomen	O
was	O
peformed	O
which	O
ruled	O
out	O
a	O
fluid	O
collection	O
.	O
You	O
were	O
seen	O
by	O
the	O
ID	O
specialists	O
who	O
feel	O
it	O
is	O
safe	O
to	O
send	O
you	O
home	O
on	O
oral	O
antibiotics	I-Drug
.	O
.	O
Your	O
medication	O
regimen	O
remains	O
the	O
same	O
except	O
for	O
we	O
started	O
you	O
on	O
Augmentin	I-Drug
XR	O
twice	O
a	O
day	O
for	O
7	O
days	O
.	O
.	O
Please	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
your	O
oncologist	O
.	O
.	O
If	O
you	O
develope	O
any	O
of	O
the	O
following	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
palpatations	O
,	O
worsening	O
of	O
you	O
abdominal	O
pain	O
,	O
worsening	O
diarrhea	O
,	O
fevers	O
or	O
chills	O
,	O
or	O
nausea	O
and	O
vomiting	O
,	O
please	O
call	O
your	O
doctor	O
or	O
go	O
to	O
your	O
local	O
emergency	O
room	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
your	O
oncologist	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2093	O
**	O
]	O
your	O
primary	O
care	O
doctor	O
.	O
Completed	O
by	O
:[	O
**	O
2117-10-9	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2145-9-7	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2145-9-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2090-7-16	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Cefepime	I-Drug
/	O
Cipro	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3913	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypotension	O
,	O
cough	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
47367	O
**	O
]	O
is	O
a	O
55	O
yo	O
male	O
s	O
/	O
p	O
allogeneic	O
stem	O
cell	O
transplant	O
for	O
AML	O
[	O
**	O
6	O
-	O
/	O
2143	O
**	O
]	O
with	O
chronic	B-Reason
GVHD	I-Reason
on	O
long	O
-	O
term	O
steroids	I-Drug
,	O
DM	O
,	O
hx	I-Reason
of	O
PE	O
on	O
coumadin	I-Drug
.	O
.	O
He	O
presents	O
to	O
his	O
[	O
**	O
Hospital	O
3242	O
**	O
]	O
clinic	O
with	O
fatigue	O
for	O
several	O
days	O
,	O
and	O
anorexia	O
,	O
with	O
about	O
12	O
-	O
16	O
hours	O
of	O
worsening	O
shortness	O
of	O
breath	O
.	O
.	O
Endorses	O
increased	O
cough	O
with	O
yellow	O
sputum	O
production	O
and	O
chills	O
,	O
but	O
no	O
fever	O
.	O
This	O
morning	O
,	O
he	O
reported	O
an	O
acute	O
episode	O
of	O
dyspnea	O
that	O
did	O
not	O
rapidly	O
improved	O
,	O
and	O
occured	O
with	O
little	O
amounts	O
of	O
activity	O
and	O
somewhat	O
improved	O
with	O
rest	O
.	O
No	O
PND	O
/	O
orthopnea	O
.	O
No	O
hemoptysis	O
.	O
.	O
He	O
has	O
had	O
no	O
new	O
rashes	O
,	O
and	O
has	O
not	O
had	O
documented	O
fevers	O
.	O
He	O
has	O
no	O
diarrhea	O
,	O
but	O
has	O
been	O
nauseated	O
without	O
vomiting	O
.	O
He	O
reports	O
mild	O
epigastric	O
pain	O
.	O
He	O
has	O
a	O
mild	O
headache	O
made	O
somewhat	O
worse	O
with	O
light	O
,	O
but	O
he	O
feels	O
that	O
this	O
is	O
very	O
consistent	O
with	O
flares	O
of	O
GVH	O
and	O
not	O
different	O
(	O
has	O
occured	O
he	O
estimates	O
about	O
8	O
times	O
)	O
.	O
.	O
In	O
clinic	O
SBP	O
70's	O
,	O
and	O
he	O
was	O
given	O
saline	O
with	O
improvement	O
,	O
but	O
then	O
the	O
BP	O
decreased	O
down	O
to	O
the	O
80's	O
.	O
Labs	O
from	O
clinic	O
showed	O
that	O
Cr	O
increased	O
to	O
2.9	O
(	O
baseline	O
1.1	O
)	O
.	O
WBC	O
increased	O
somewhat	O
.	O
He	O
was	O
transferred	O
to	O
the	O
ED	O
for	O
further	O
evaluation	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
4	O
97.6	O
72105/73	O
18	O
99	O
%	O
He	O
was	O
given	O
total	O
of	O
3L	O
of	O
saline	O
,	O
and	O
recent	O
vital	O
signs	O
were	O
98.8	O
129/85	O
80	O
16	O
96	O
%	O
on	O
2L	O
at	O
time	O
of	O
transfer	O
.	O
A	O
bedside	O
"	O
shock	O
"	O
ultrasound	O
US	O
in	O
ED	O
showed	O
no	O
cardiac	O
effusion	O
,	O
no	O
evidence	O
of	O
gross	O
RV	O
overload	O
.	O
EKG	O
was	O
not	O
significantly	O
changed	O
.	O
Her	O
INR	O
was	O
3.0	O
.	O
Of	O
note	O
,	O
he	O
was	O
also	O
complaining	O
of	O
left	O
sided	O
shoulder	O
/	O
neck	O
pain	O
associated	O
with	O
shortness	O
of	O
breath	O
and	O
diaphoresis	O
.	O
.	O
For	O
interventions	O
,	O
he	O
received	O
1	O
gm	O
vanc	I-Drug
and	O
1gm	O
aztreonam	I-Drug
,	O
40	O
mg	O
medrol	I-Drug
,	O
and	O
2	O
L	O
IVF	I-Drug
in	O
clinic	O
,	O
and	O
another	O
liter	O
in	O
the	O
ED	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
AML	O
-	O
M7	O
:	O
s	O
/	O
p	O
matched	O
unrelated	O
allogenic	O
transplant	O
on	O
[	O
**	O
2143-6-24	O
**	O
]	O
-	O
Chronic	O
extensive	O
GVHD	O
of	O
skin	O
and	O
liver	O
,	O
liver	O
biopsy	O
[	O
**	O
4	O
-	O
23	O
**	O
]	O
consistent	O
with	O
GVHD	I-Reason
,	O
managed	O
with	O
cyclosporine	I-Drug
,	O
steroids	I-Drug
,	O
periodic	O
CellCept	I-Drug
,	O
and	O
has	O
received	O
1	O
cycle	O
of	O
Rituxan	I-Drug
.	O
-	O
Type	O
2	O
DM	O
-	O
Hyperlipidemia	O
-	O
H	O
/	O
o	O
AVN	O
bilateral	O
hips	O
-	O
HTN	O
-	O
H	O
/	O
o	O
nephrolithiasis	O
,	O
lithotripsy	O
and	O
previous	O
nephrostomy	O
tube	O
and	O
emergent	O
surgery	O
to	O
repair	O
ureteral	O
damage	O
-	O
h	O
/	O
o	O
left	O
interpolar	O
renal	O
lesion	O
,	O
followed	O
with	O
MRs	O
-	O
h	O
/	O
o	O
BCC	O
s	O
/	O
p	O
excision	O
-	O
h	O
/	O
o	O
SCC	O
left	O
cheek	O
,	O
s	O
/	O
p	O
Mohs	O
'	O
[	O
**	O
5	O
-	O
/	O
2144	O
**	O
]	O
-	O
h	O
/	O
o	O
multiple	O
back	O
surgeries	O
:	O
Lumbar	O
L5	O
-	O
S1	O
surgery	O
x	O
3	O
,	O
and	O
cervical	O
spine	O
fusion	O
(	O
bone	O
graft	O
,	O
no	O
hardware	O
)	O
-	O
h	O
/	O
o	O
anterior	O
cervical	O
diskectomy	O
and	O
instrument	O
arthrodesis	O
at	O
C5	O
-	O
C6	O
and	O
C6	O
-	O
C7	O
for	O
degenerative	O
cervical	O
spondylitic	O
disease	O
with	O
spinal	O
cord	O
compression	O
and	O
foraminal	O
stenosis	O
at	O
C5	O
-	O
C6	O
and	O
C6	O
-	O
C7	O
[	O
**	O
2	O
-	O
/	O
2144	O
**	O
]	O
-	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
548	O
**	O
]	O
-	O
Chronic	O
numbness	O
,	O
neuropathic	O
pain	O
in	O
left	O
upper	O
extremity	O
.	O
-	O
Multilevel	O
compression	O
fractures	O
T11	O
,	O
T12	O
,	O
L1	O
and	O
mild	O
compression	O
L3	O
and	O
L4	O
.	O
-	O
h	O
/	O
o	O
pulmonary	O
embolism	O
[	O
**	O
11/2144	O
**	O
]	O
on	O
anticoagulated	O
from	O
[	O
**	O
11/2144	O
**	O
]	O
-	O
present	O
-	O
h	O
/	O
o	O
RSV	O
[	O
**	O
11/2144	O
**	O
]	O
requiring	O
ICU	O
admission	O
-	O
h	O
/	O
o	O
OSA	O
,	O
planned	O
BIPAP	O
,	O
followed	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
4507	O
**	O
]	O
Social	O
History	O
:	O
Lives	O
with	O
his	O
wife	O
,	O
and	O
one	O
of	O
children	O
,	O
worked	O
as	O
a	O
[	O
**	O
Company	O
22957	O
**	O
]	O
technician	O
until	O
[	O
**	O
Month	O
(	O
only	O
)	O
547	O
**	O
]	O
when	O
he	O
took	O
early	O
retirement	O
and	O
he	O
is	O
no	O
longer	O
working	O
.	O
Tob	O
:	O
previously	O
smoked	O
1ppd	O
for	O
many	O
years	O
but	O
quit	O
2.5	O
years	O
ago	O
EtOH	O
:	O
h	O
/	O
o	O
social	O
use	O
;	O
none	O
recently	O
Family	O
History	O
:	O
Mother	O
died	O
suddenly	O
in	O
her	O
70s	O
.	O
Father	O
died	O
of	O
unknown	O
cancer	O
with	O
tumors	O
visible	O
across	O
body	O
.	O
One	O
sister	O
has	O
thyroid	O
cancer	O
.	O
One	O
brother	O
has	O
diabetes	O
and	O
kidney	O
stones	O
.	O
One	O
sister	O
has	O
[	O
**	O
Name	O
(	O
NI	O
)	O
5895	O
**	O
]	O
.	O
Physical	O
Exam	O
:	O
Tmax	O
:	O
36.7	O
??????	O
C	O
(	O
98.1	O
??????	O
F	O
)	O
Tcurrent	O
:	O
36.7	O
??????	O
C	O
(	O
98.1	O
??????	O
F	O
)	O
HR	O
:	O
85	O
(	O
85	O
-	O
85	O
)	O
bpm	O
BP	O
:	O
101/66	O
(	O
75	O
)	O
{	O
101/66	O
(	O
75	O
)	O
-	O
101/66	O
(	O
75	O
)	O
}	O
mmHg	O
RR	O
:	O
11	O
(	O
11	O
-	O
11	O
)	O
insp	O
/	O
min	O
SpO2	O
:	O
97	O
%	O
Heart	O
rhythm	O
:	O
SR	O
(	O
Sinus	O
Rhythm	O
)	O
.	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
mild	O
RUQ	O
-	O
>	O
mid	O
epigastrium	O
tenderness	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
.	O
No	O
calf	O
or	O
thigh	O
tenderness	O
.	O
Skin	O
:	O
depigmentation	O
on	O
hands	O
,	O
redness	O
of	O
neck	O
,	O
but	O
no	O
notable	O
skin	O
changes	O
otherwise	O
.	O
No	O
rashes	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
9	O
-	O
9	O
**	O
]	O
CT	O
chest	O
without	O
contrast	O
IMPRESSION	O
:	O
1	O
.	O
Mostly	O
resolved	O
parenchymal	O
opacities	O
,	O
leaving	O
several	O
parenchymal	O
bands	O
which	O
are	O
felt	O
most	O
likely	O
to	O
represent	O
residua	O
of	O
a	O
prior	O
infectious	O
or	O
inflammatory	O
process	O
.	O
2	O
.	O
Subacute	O
to	O
chronic	O
rib	O
fractures	O
,	O
including	O
along	O
the	O
right	O
posterior	O
seventh	O
rib	O
,	O
where	O
there	O
is	O
faint	O
but	O
suspicious	O
sclerosis	O
extending	O
further	O
laterally	O
than	O
would	O
usually	O
be	O
expected	O
in	O
the	O
setting	O
of	O
an	O
uncomplicated	O
rib	O
fracture	O
.	O
In	O
the	O
setting	O
of	O
prior	O
treated	O
hematological	O
malignancy	O
,	O
the	O
finding	O
of	O
vague	O
sclerosis	O
raises	O
concern	O
for	O
a	O
bone	O
marrow	O
abnormality	O
such	O
as	O
myelofibrosis	O
or	O
potentially	O
a	O
form	O
of	O
disease	O
recurrence	O
.	O
Mostly	O
,	O
however	O
,	O
the	O
bones	O
appear	O
within	O
normal	O
limits	O
.	O
.	O
[	O
**	O
9	O
-	O
9	O
**	O
]	O
PFT	O
's	O
SPIROMETRY	O
Pre	O
drug	O
Post	O
drug	O
Actual	O
Pred	O
%	O
Pred	O
Actual	O
%	O
Pred	O
%	O
chg	O
FVC	O
3.86	O
5.05	O
76	O
3.83	O
76	O
-1	O
FEV1	O
2.83	O
3.60	O
79	O
2.69	O
75	O
-5	O
FEV1	O
/	O
FVC	O
73	O
71	O
103	O
70	O
98	O
-4	O
.	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
RUQ	O
US	O
IMPRESSION	O
:	O
1	O
.	O
Polyp	O
at	O
neck	O
of	O
gallbladder	O
(	O
1.2	O
cm	O
)	O
,	O
which	O
was	O
also	O
seen	O
on	O
prior	O
ultrasound	O
scan	O
[	O
**	O
2145-2-9	O
**	O
]	O
.	O
This	O
has	O
not	O
changed	O
significantly	O
since	O
prior	O
ultrasound	O
scan	O
,	O
but	O
followup	O
imaging	O
is	O
advised	O
.	O
.	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
Echo	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
global	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
a	O
normal	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
<	O
12mmHg	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
There	O
is	O
borderline	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
an	O
anterior	O
space	O
which	O
most	O
likely	O
represents	O
a	O
fat	O
pad	O
.	O
.	O
Micro	O
:	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
CMV	O
VL	O
negative	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
sputum	O
:	O
oropharyngeal	O
flora	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
urine	O
cx	O
negative	O
[	O
**	O
9	O
-	O
8	O
**	O
]	O
viral	O
screen	O
and	O
cx	O
negative	O
[	O
**	O
9	O
-	O
7	O
**	O
]	O
blood	O
cx	O
negative	O
.	O
ON	O
ADMISSION	O
:	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
WBC	O
-	O
11.1	O
*	O
RBC	O
-	O
4.39	O
*	O
Hgb	O
-	O
16.0	O
Hct	O
-	O
49.0	O
MCV	O
-	O
112	O
*	O
MCH	O
-	O
36.5	O
*	O
MCHC	O
-	O
32.7	O
RDW	O
-	O
14.9	O
Plt	O
Ct	O
-	O
264	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
Neuts	O
-	O
85.1	O
*	O
Lymphs	O
-	O
7.0	O
*	O
Monos	O
-	O
5.2	O
Eos	O
-	O
2.5	O
Baso	O
-	O
0.3	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
PT	O
-	O
30.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.0	O
*	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
UreaN	O
-	O
28	O
*	O
Creat	O
-	O
2.9	O
*	O
#	O
Na	O
-	O
140	O
K	O
-	O
4.4	O
Cl	O
-	O
101	O
HCO3	O
-	O
29	O
AnGap	O
-	O
14	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
ALT	O
-	O
24	O
AST	O
-	O
20	O
LD	O
(	O
LDH	O
)	O
-	O
201	O
CK	O
(	O
CPK	O
)	O
-	O
37	O
*	O
AlkPhos	O
-	O
155	O
*	O
TotBili	O
-	O
0.3	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.05	O
*	O
[	O
**	O
2145-9-7	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
Albumin	O
-	O
4.2	O
Calcium	O
-	O
9.3	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
2.4	O
[	O
**	O
2145-9-7	O
**	O
]	O
08:13	O
PM	O
BLOOD	O
Lactate	O
-	O
1.9	O
.	O
ON	O
DISCHARGE	O
:	O
[	O
**	O
2145-9-12	O
**	O
]	O
05:40	O
AM	O
BLOOD	O
WBC	O
-	O
7.2	O
RBC	O
-	O
3.45	O
*	O
Hgb	O
-	O
12.5	O
*	O
Hct	O
-	O
38.3	O
*	O
MCV	O
-	O
111	O
*	O
MCH	O
-	O
36.2	O
*	O
MCHC	O
-	O
32.7	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
211	O
[	O
**	O
2145-9-12	O
**	O
]	O
05:40	O
AM	O
BLOOD	O
Neuts	O
-	O
68.8	O
Lymphs	O
-	O
17.2	O
*	O
Monos	O
-	O
7.9	O
Eos	O
-	O
5.7	O
*	O
Baso	O
-	O
0.4	O
[	O
**	O
2145-9-12	O
**	O
]	O
05:40	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
211	O
[	O
**	O
2145-9-12	O
**	O
]	O
05:40	O
AM	O
BLOOD	O
Glucose	O
-	O
80	O
UreaN	O
-	O
18	O
Creat	O
-	O
0.9	O
Na	O
-	O
143	O
K	O
-	O
3.7	O
Cl	O
-	O
104	O
HCO3	O
-	O
30	O
AnGap	O
-	O
13	O
[	O
**	O
2145-9-12	O
**	O
]	O
05:40	O
AM	O
BLOOD	O
ALT	O
-	O
25	O
AST	O
-	O
18	O
LD	O
(	O
LDH	O
)	O
-	O
181	O
AlkPhos	O
-	O
112	O
TotBili	O
-	O
0.2	O
[	O
**	O
2145-9-12	O
**	O
]	O
05:40	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
2.8	O
Mg	O
-	O
2.1	O
UricAcd	O
-	O
4.6	O
Brief	O
Hospital	O
Course	O
:	O
55	O
y	O
/	O
o	O
male	O
with	O
?	O
viral	O
syndrome	O
vs.	O
other	O
atypical	O
infection	O
with	O
hypotension	O
that	O
is	O
suspected	O
to	O
be	O
hypovolemia	O
or	O
adrenal	O
insufficiency	O
,	O
with	O
acute	O
renal	O
failure	O
.	O
.	O
#	O
Lethargy	O
:	O
concern	O
for	O
viral	O
syndrome	O
,	O
including	O
activation	O
of	O
CMV	O
,	O
or	O
a	O
respiratory	O
virus	O
.	O
He	O
has	O
been	O
known	O
EBV	O
+	O
in	O
the	O
past	O
.	O
This	O
could	O
also	O
be	O
related	O
to	O
sensation	O
of	O
dyspnea	O
that	O
he	O
has	O
been	O
having	O
,	O
and	O
warranted	O
further	O
cardiovascular	O
and	O
pulmonary	O
work	O
-	O
up	O
in	O
parallel	O
with	O
the	O
infectious	O
work	O
-	O
up	O
.	O
In	O
the	O
ICU	O
,	O
continued	O
broad	O
spectrum	O
antibiotics	I-Drug
of	O
vancomycin	I-Drug
and	O
aztreonam	I-Drug
(	O
given	O
allergy	O
)	O
.	O
Infectious	O
workup	O
largely	O
negative	O
including	O
CMV	O
VL	O
,	O
respiratory	O
panel	O
,	O
EBV	O
VL	O
,	O
fungal	O
markers	O
,	O
blood	O
cultures	O
,	O
urine	O
cultures	O
,	O
CT	O
chest	O
.	O
Pt	O
's	O
lethargy	O
improved	O
with	O
IVFs	I-Drug
,	O
antibiotics	I-Drug
,	O
and	O
stress	O
dose	O
steroids	I-Drug
.	O
Did	O
not	O
ever	O
need	O
pressors	I-Drug
.	O
.	O
#	O
Dyspnea	O
/	O
Cough	O
:	O
Concern	O
for	O
infectious	O
process	O
.	O
Regarding	O
VTE	O
,	O
his	O
risk	O
should	O
be	O
reduced	O
with	O
therapeutic	O
INR	O
,	O
though	O
the	O
concern	O
for	O
coumadin	I-Drug
failure	O
merits	O
consideration	O
,	O
though	O
would	O
be	O
unlikely	O
and	O
he	O
has	O
no	O
other	O
signs	O
and	O
symptoms	O
of	O
DVT	O
.	O
PFTs	O
completed	O
[	O
**	O
9	O
-	O
9	O
**	O
]	O
,	O
with	O
official	O
report	O
pending	O
at	O
time	O
of	O
this	O
summary	O
.	O
CT	O
chest	O
showing	O
resolving	O
parenchymal	O
processes	O
,	O
resolving	O
infectious	O
/	O
inflammatory	O
process	O
.	O
Continued	O
broad	O
spectrum	O
antibiotics	I-Drug
initially	O
.	O
When	O
no	O
infiltrate	O
noted	O
on	O
CXR	O
,	O
decreased	O
ABX	I-Drug
to	O
5	O
days	O
of	O
azithromycin	I-Drug
for	O
treatment	O
of	O
bronchitis	I-Reason
.	O
.	O
#	O
Hypotension	I-Reason
:	O
A	O
bedside	O
"	O
shock	O
"	O
ultrasound	O
US	O
in	O
ED	O
showed	O
no	O
cardiac	O
effusion	O
,	O
no	O
evidence	O
of	O
gross	O
RV	O
overload	O
.	O
EKG	O
unchanged	O
.	O
Patient	O
's	O
hypotension	O
was	O
fluid	O
/	O
stress	O
dose	O
steroids	I-Drug
responsive	O
.	O
Initially	O
given	O
stress	O
dose	O
steroids	I-Drug
with	O
plans	O
to	O
resume	O
home	O
dose	O
.	O
Also	O
given	O
IVF	I-Drug
repletion	O
.	O
BPs	O
normalized	O
.	O
Likely	O
etiology	O
was	O
slight	O
adrenal	O
insufficiency	O
in	O
setting	O
of	O
viral	O
syndrome	O
despite	O
negative	O
infectious	O
workup	O
.	O
Patient	O
discharged	O
with	O
prednisone	I-Drug
7.5	O
mg	O
daily	O
.	O
.	O
#	O
Acute	B-Reason
Renal	I-Reason
Failure	I-Reason
:	O
Likely	O
pre-renal	O
azotemia	O
.	O
Improved	O
with	O
IVFs	I-Drug
.	O
Cr	O
0.9	O
on	O
discharge	O
.	O
.	O
#	O
Mild	O
epigastric	O
/	O
RUQ	O
tenderness	O
:	O
No	O
laboratory	O
e	O
/	O
o	O
hepatitis	O
.	O
RUQ	O
US	O
showing	O
polyp	O
at	O
neck	O
of	O
gallbladder	O
(	O
1.2	O
cm	O
)	O
,	O
which	O
was	O
also	O
seen	O
on	O
prior	O
ultrasound	O
scan	O
[	O
**	O
2145-2-9	O
**	O
]	O
.	O
No	O
other	O
findings	O
to	O
explain	O
epigastric	O
pain	O
.	O
This	O
pain	O
has	O
resolved	O
on	O
discharge	O
.	O
.	O
#	O
Pulmonary	B-Reason
Embolism	I-Reason
[	O
**	O
11	O
-	O
23	O
**	O
]	O
:	O
continued	O
coumadin	I-Drug
with	O
INR	O
goal	O
[	O
**	O
1	O
-	O
19	O
**	O
]	O
.	O
#	O
Diabetes	I-Reason
:	O
Continued	O
NPH	I-Drug
12	O
units	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
with	O
close	O
sugar	O
monitoring	O
and	O
diabetic	O
diet	O
.	O
Medications	O
on	O
Admission	O
:	O
ACYCLOVIR	I-Drug
-	O
400	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
three	O
times	O
a	O
day	O
BUDESONIDE	I-Drug
[	O
ENTOCORT	B-Drug
EC	I-Drug
]	O
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
3	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
-	O
1	O
(	O
One	O
)	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
FOLIC	B-Drug
ACID	I-Drug
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
1	O
mg	O
Tablet	O
-	O
1	O
(	O
One	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
HYDROMORPHONE	I-Drug
-	O
2	O
mg	O
Tablet	O
-	O
[	O
**	O
12	O
-	O
18	O
**	O
]	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
every	O
[	O
**	O
3	O
-	O
22	O
**	O
]	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
INSULIN	B-Drug
LISPRO	I-Drug
[	O
HUMALOG	I-Drug
]	O
-	O
SS	O
LISINOPRIL	I-Drug
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
5	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
METOPROLOL	I-Drug
TARTRATE	O
-	O
25	O
mg	O
Tablet	O
-	O
1	O
(	O
One	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
OXYCODONE	I-Drug
-	O
20	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
-	O
3	O
(	O
Three	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
every	O
morning	O
(	O
60	O
mg	O
)	O
,	O
1	O
tablet	O
every	O
2	O
pm	O
(	O
20	O
mg	O
)	O
and	O
3	O
tablets	O
every	O
evening	O
(	O
60	O
mg	O
)	O
PANTOPRAZOLE	I-Drug
[	O
PROTONIX	I-Drug
]	O
-	O
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
day	O
PREDNISONE	I-Drug
-	O
2.5	O
mg	O
Tablet	O
-	O
2	O
(	O
Two	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
RISEDRONATE	I-Drug
[	O
ACTONEL	I-Drug
]	O
-	O
35	O
mg	O
Tablet	O
q	O
Saturday	O
TESTOSTERONE	I-Drug
[	O
ANDROGEL	I-Drug
]	O
-	O
50	O
mg	O
/	O
5	O
gram	O
(	O
1	O
%	O
)	O
Gel	O
in	O
Packet	O
-	O
Apply	O
to	O
upper	O
torso	O
once	O
daily	O
WARFARIN	I-Drug
[	O
COUMADIN	I-Drug
]	O
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
2.5	O
mg	O
Tablet	O
-	O
2	O
(	O
Two	O
)	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
or	O
as	O
directed	O
CHOLECALCIFEROL	I-Drug
(	O
VITAMIN	B-Drug
D3	I-Drug
)	O
[	O
DELTA	B-Drug
D3	I-Drug
]	O
-	O
(	O
Dose	O
adjustment	O
-	O
no	O
new	O
Rx	O
)	O
-	O
400	O
unit	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
DAILY	O
(	O
Daily	O
)	O
INSULIN	I-Drug
NPH	O
HUMAN	O
RECOMB	O
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
100	O
unit	O
/	O
mL	O
Suspension	O
-	O
12	O
units	O
twice	O
a	O
day	O
Please	O
take	O
first	O
dose	O
in	O
the	O
morning	O
and	O
the	O
second	O
dose	O
at	O
bedtime	O
Discharge	O
Medications	O
:	O
1	O
.	O
Azithromycin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
2	O
days	O
.	O
Disp	O
:	O
*	O
2	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Acyclovir	I-Drug
200	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
3	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Hydromorphone	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
5	O
.	O
OxyContin	I-Drug
60	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
PO	O
twice	O
a	O
day	O
:	O
QAM	O
and	O
QPM	O
.	O
6	O
.	O
OxyContin	I-Drug
20	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12	O
hr	O
PO	O
once	O
a	O
day	O
:	O
at	O
1400	O
every	O
day	O
.	O
7	O
.	O
Warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
8	O
.	O
Budesonide	I-Drug
3	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
twice	O
a	O
day	O
.	O
9	O
.	O
Prednisone	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
For	O
total	O
7.5	O
mg	O
daily	O
.	O
10	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
11	O
.	O
Cholecalciferol	I-Drug
(	O
Vitamin	B-Drug
D3	I-Drug
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Actonel	I-Drug
35	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
week	O
:	O
On	O
Saturdays	O
.	O
13	O
.	O
AndroGel	I-Drug
1	O
%	O
(	O
50	O
mg	O
/	O
5	O
gram	O
)	O
Gel	O
in	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
packet	O
Transdermal	O
once	O
a	O
day	O
:	O
Apply	O
to	O
upper	O
torso	O
once	O
daily	O
as	O
directed	O
.	O
14	O
.	O
Insulin	I-Drug
NPH	O
Human	O
Recomb	O
100	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Twelve	O
(	O
12	O
)	O
units	O
Subcutaneous	O
twice	O
a	O
day	O
.	O
15	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Varied	O
units	O
Subcutaneous	O
four	O
times	O
a	O
day	O
:	O
As	O
per	O
home	O
sliding	O
scale	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
diagnosis	O
:	O
Hypotension	O
/	O
adrenal	O
insufficiency	O
Bronchitis	O
Acute	O
renal	O
failure	O
.	O
Secondary	O
diagnosis	O
:	O
AML	O
s	O
/	O
p	O
MUD	O
allogeneic	O
SCT	O
[	O
**	O
6	O
-	O
/	O
2143	O
**	O
]	O
Chronic	O
GVHD	O
of	O
skin	O
/	O
liver	O
h	O
/	O
o	O
PE	O
Diabetes	O
mellitus	O
Discharge	O
Condition	O
:	O
Stable	O
,	O
afebrile	O
,	O
BP	O
113/76	O
,	O
RR	O
16	O
,	O
sats	O
96	O
%	O
on	O
RA	O
,	O
INR	O
1.8	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
fatigue	O
,	O
shortness	O
of	O
breath	O
,	O
cough	O
,	O
low	O
blood	O
pressure	O
and	O
acute	O
renal	O
failure	O
.	O
We	O
were	O
concerned	O
for	O
early	O
sepsis	I-Reason
and	O
you	O
were	O
in	O
the	O
ICU	O
initially	O
.	O
You	O
received	O
broad	O
spectrum	O
antibiotics	I-Drug
and	O
stress	O
dose	O
steroids	I-Drug
,	O
but	O
a	O
full	O
workup	O
(	O
including	O
viral	O
swabs	O
,	O
cultures	O
,	O
ECHO	O
,	O
and	O
CT	O
chest	O
)	O
were	O
unrevealing	O
.	O
CT	O
chest	O
showed	O
resolving	O
infiltrates	O
and	O
your	O
symptoms	O
improved	O
so	O
the	O
antibiotics	I-Drug
were	O
switched	O
to	O
azithromycin	I-Drug
for	O
presumed	B-Reason
bronchitis	I-Reason
.	O
Your	O
prednisone	I-Drug
was	O
increased	O
due	O
to	O
presumed	O
mild	B-Reason
adrenal	I-Reason
insufficiency	I-Reason
.	O
.	O
The	O
following	O
medication	O
changes	O
were	O
made	O
:	O
1	O
)	O
Prednisone	I-Drug
increased	O
to	O
7.5	O
mg	O
daily	O
2	O
)	O
Azithromycin	I-Drug
(	O
antibiotic	O
)	O
started	O
,	O
to	O
be	O
completed	O
as	O
outpatient	O
3	O
)	O
Your	O
lisinopril	I-Drug
(	O
blood	B-Drug
pressure	I-Drug
medication	I-Drug
)	O
and	O
metoprolol	I-Drug
were	O
discontinued	O
.	O
Do	O
NOT	O
resume	O
these	O
medications	O
until	O
speaking	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
.	O
You	O
need	O
to	O
have	O
your	O
INR	O
checked	O
on	O
Tuesday	O
,	O
[	O
**	O
2145-9-14	O
**	O
]	O
.	O
You	O
also	O
need	O
to	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
3235	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
3236	O
**	O
]	O
within	O
the	O
next	O
week	O
.	O
Please	O
call	O
their	O
office	O
tomorrow	O
to	O
make	O
this	O
appointment	O
.	O
.	O
of	O
the	O
following	O
symptoms	O
:	O
fever	O
,	O
chills	O
,	O
shortness	O
of	O
breath	O
,	O
difficulty	O
breathing	O
,	O
abdominal	O
pain	O
,	O
cough	O
,	O
flu	O
symptoms	O
,	O
or	O
any	O
other	O
worrisome	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
You	O
need	O
to	O
have	O
your	O
INR	O
checked	O
on	O
Tuesday	O
,	O
[	O
**	O
2145-9-14	O
**	O
]	O
.	O
.	O
Please	O
call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
3235	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
72254	O
**	O
]	O
office	O
to	O
make	O
an	O
appointment	O
to	O
be	O
seen	O
later	O
this	O
week	O
.	O
They	O
can	O
be	O
reached	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3241	O
**	O
]	O
.	O
Completed	O
by	O
:[	O
**	O
2145-9-17	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2121-11-3	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2121-11-17	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2048-1-11	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
ADMISSION	O
DIAGNOSIS	O
:	O
Incarcerated	O
parastomal	O
hernia	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
Incarcerated	O
parastomal	O
hernia	O
.	O
Status	O
post	O
reduction	O
of	O
hernia	O
,	O
re-siting	O
of	O
colostomy	O
.	O
Aspiration	O
pneumonia	O
.	O
ETOH	O
withdrawal	O
.	O
Respiratory	O
failure	O
.	O
Status	O
post	O
tracheostomy	O
.	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
a	O
73	O
-	O
year	O
-	O
old	O
woman	O
who	O
has	O
a	O
history	O
of	O
parastomal	O
hernias	O
and	O
has	O
had	O
these	O
hernias	O
repaired	O
times	O
four	O
or	O
five	O
.	O
She	O
now	O
presents	O
with	O
acute	O
onset	O
of	O
abdominal	O
distention	O
,	O
nausea	O
and	O
vomiting	O
,	O
as	O
well	O
as	O
a	O
mass	O
in	O
the	O
parastomal	O
region	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
ETOH	O
(	O
one	O
bottle	O
of	O
wine	O
per	O
day	O
)	O
.	O
Hypertension	O
.	O
Gastroesophageal	O
reflux	O
disease	O
.	O
Hepatitis	O
C.	O
Anxiety	O
.	O
Depression	O
.	O
Etiopathic	O
splenomegaly	O
.	O
Etiopathic	O
thrombocytopenia	O
.	O
Heparin	I-Drug
induced	O
thrombocytopenia	O
negative	O
.	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
Status	O
post	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
.	O
Parastomal	O
hernia	O
repair	O
times	O
four	O
or	O
five	O
.	O
Total	O
abdominal	O
hysterectomy	O
.	O
Breast	O
biopsy	O
.	O
Cataract	O
surgery	O
.	O
MEDICATIONS	O
AT	O
HOME	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
once	O
daily	O
.	O
2	O
.	O
Hydrochlorothiazide	I-Drug
25	O
mg	O
once	O
daily	O
.	O
3	O
.	O
Zoloft	I-Drug
50	O
mg	O
once	O
daily	O
.	O
4	O
.	O
Lisinopril	I-Drug
10	O
mg	O
once	O
daily	O
.	O
5	O
.	O
Ibuprofen	I-Drug
600	O
mg	O
once	O
daily	O
p.r.n.	O
6	O
.	O
Serax	I-Drug
15	O
mg	O
t.i.d.	O
ALLERGIES	O
:	O
No	O
known	O
drug	O
allergies	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
On	O
admission	O
,	O
the	O
patient	O
is	O
afebrile	O
.	O
Vital	O
signs	O
are	O
stable	O
.	O
Generally	O
,	O
she	O
is	O
in	O
some	O
distress	O
.	O
Chest	O
is	O
clear	O
to	O
auscultation	O
bilaterally	O
.	O
Cardiovascular	O
is	O
regular	O
rate	O
and	O
rhythm	O
without	O
murmur	O
,	O
rub	O
or	O
gallop	O
.	O
Abdomen	O
is	O
soft	O
,	O
mildly	O
distended	O
and	O
tender	O
to	O
palpation	O
.	O
Tenderness	O
is	O
localized	O
to	O
the	O
lower	O
abdomen	O
and	O
more	O
so	O
in	O
the	O
parastomal	O
region	O
.	O
There	O
is	O
a	O
large	O
bulge	O
around	O
the	O
ostomy	O
.	O
Stoma	O
itself	O
is	O
fairly	O
pink	O
and	O
healthy	O
.	O
Extremities	O
are	O
warm	O
and	O
well	O
perfused	O
with	O
minimal	O
edema	O
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
was	O
admitted	O
for	O
repair	O
of	O
her	O
incarcerated	O
parastomal	O
hernia	O
.	O
She	O
was	O
taken	O
to	O
the	O
Operating	O
Room	O
on	O
[	O
**	O
2121-11-3	O
**	O
]	O
for	O
reduction	O
,	O
as	O
well	O
as	O
colostomy	O
re-siting	O
into	O
the	O
left	O
upper	O
quadrant	O
.	O
For	O
details	O
of	O
this	O
,	O
please	O
see	O
the	O
previously	O
dictated	O
operative	O
note	O
.	O
Postoperatively	O
,	O
the	O
patient	O
's	O
course	O
was	O
complicated	O
by	O
what	O
was	O
thought	O
to	O
be	O
an	O
aspiration	O
event	O
on	O
the	O
evening	O
of	O
postoperative	O
day	O
number	O
two	O
.	O
She	O
had	O
acute	O
respiratory	O
distress	O
,	O
as	O
well	O
as	O
change	O
in	O
mental	O
status	O
,	O
which	O
is	O
different	O
from	O
her	O
baseline	O
.	O
She	O
was	O
maintained	O
with	O
Lasix	I-Drug
diuresis	I-Reason
and	O
face	O
mask	O
for	O
approximately	O
8	O
-	O
12	O
hours	O
but	O
then	O
was	O
subsequently	O
intubated	O
and	O
transferred	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
worsening	O
respiratory	O
status	O
.	O
She	O
was	O
initially	O
only	O
intubated	O
for	O
about	O
24	O
hours	O
and	O
met	O
all	O
criteria	O
for	O
extubation	O
.	O
Chest	O
x-ray	O
did	O
confirm	O
that	O
she	O
had	O
bilateral	O
upper	O
zone	O
infiltrates	O
and	O
the	O
patient	O
was	O
empirically	O
treated	O
with	O
a	O
seven	O
day	O
course	O
of	O
vancomycin	I-Drug
and	O
Levaquin	I-Drug
.	O
After	O
the	O
patient	O
met	O
her	O
respiratory	O
extubation	O
criteria	O
,	O
she	O
was	O
extubated	O
.	O
She	O
continued	O
to	O
do	O
fairly	O
well	O
but	O
had	O
change	O
in	O
mental	O
status	O
,	O
which	O
could	O
not	O
be	O
attributed	O
to	O
anything	O
other	O
than	O
alcohol	O
withdrawal	O
.	O
TSH	O
,	O
B	O
-	O
12	O
and	O
folate	O
levels	O
were	O
checked	O
,	O
which	O
were	O
normal	O
.	O
CT	O
scan	O
of	O
the	O
head	O
was	O
obtained	O
on	O
[	O
**	O
2121-11-10	O
**	O
]	O
,	O
which	O
did	O
not	O
show	O
any	O
evidence	O
of	O
acute	O
injury	O
.	O
There	O
was	O
some	O
evidence	O
of	O
old	O
lacunar	O
infarcts	O
.	O
MR	O
of	O
the	O
head	O
was	O
completed	O
on	O
[	O
**	O
2121-11-12	O
**	O
]	O
,	O
which	O
confirmed	O
the	O
above	O
.	O
In	O
addition	O
,	O
the	O
Neurology	O
service	O
was	O
consulted	O
for	O
her	O
change	B-Ade
in	I-Ade
mental	I-Ade
status	I-Ade
and	O
they	O
felt	O
it	O
was	O
best	O
attributed	O
also	O
to	O
her	O
alcohol	O
withdrawal	O
,	O
as	O
well	O
as	O
withdrawal	O
from	O
her	O
Serax	I-Drug
.	O
These	O
were	O
restarted	O
per	O
their	O
recommendations	O
and	O
the	O
patient	O
gradually	O
improved	O
some	O
of	O
her	O
mental	O
status	O
.	O
On	O
[	O
**	O
2121-11-10	O
**	O
]	O
,	O
the	O
patient	O
was	O
re-intubated	O
(	O
postoperative	O
day	O
number	O
seven	O
)	O
for	O
worsening	O
respiratory	O
status	O
.	O
She	O
was	O
maintained	O
and	O
ventilated	O
during	O
this	O
time	O
and	O
had	O
a	O
bronchoscopy	O
performed	O
on	O
[	O
**	O
2121-11-13	O
**	O
]	O
,	O
which	O
proved	O
to	O
be	O
negative	O
for	O
any	O
significant	O
pluggings	O
or	O
other	O
bronchial	O
disease	O
.	O
The	O
patient	O
was	O
extubated	O
later	O
that	O
day	O
on	O
[	O
**	O
2121-11-13	O
**	O
]	O
,	O
but	O
then	O
quickly	O
failed	O
her	O
extubation	O
trial	O
within	O
approximately	O
six	O
hours	O
.	O
She	O
was	O
emergently	O
re	O
-	O
intubated	O
and	O
there	O
was	O
seen	O
to	O
be	O
a	O
fair	O
amount	O
of	O
tracheal	O
and	O
laryngeal	O
edema	O
at	O
that	O
time	O
.	O
The	O
decision	O
was	O
then	O
made	O
to	O
give	O
the	O
patient	O
a	O
surgical	O
airway	O
and	O
percutaneous	O
tracheostomy	O
was	O
performed	O
on	O
[	O
**	O
2121-11-14	O
**	O
]	O
.	O
This	O
was	O
done	O
in	O
accordance	O
and	O
consent	O
with	O
her	O
son	O
,	O
who	O
was	O
the	O
healthcare	O
proxy	O
during	O
her	O
change	O
in	O
mental	O
status	O
.	O
Ultimately	O
,	O
the	O
patient	O
was	O
discharged	O
on	O
postoperative	O
day	O
number	O
fourteen	O
to	O
a	O
[	O
**	O
Hospital	O
4820	O
**	O
]	O
rehabilitation	O
facility	O
for	O
ventilatory	O
weaning	O
,	O
as	O
well	O
as	O
allowing	O
clearance	O
of	O
her	O
mental	O
status	O
.	O
The	O
Neurology	O
service	O
had	O
seen	O
the	O
patient	O
on	O
the	O
day	O
of	O
discharge	O
and	O
agreed	O
with	O
the	O
above	O
and	O
to	O
continue	O
present	O
management	O
.	O
The	O
patient	O
had	O
a	O
post-pyloric	O
feeding	O
tube	O
placed	O
in	O
Interventional	O
Radiology	O
on	O
the	O
day	O
of	O
discharge	O
in	O
order	O
to	O
decrease	O
the	O
risk	O
of	O
aspiration	O
pneumonia	O
.	O
The	O
patient	O
was	O
tolerating	O
tube	O
feeds	O
adequate	O
and	O
had	O
good	O
function	O
with	O
occasional	O
tracheostomy	O
mask	O
trials	O
from	O
the	O
vent	O
.	O
DISPOSITION	O
:	O
To	O
[	O
**	O
Hospital	O
4820	O
**	O
]	O
rehabilitation	O
facility	O
.	O
DIET	O
:	O
Tube	O
feedings	O
:	O
Impact	O
with	O
fiber	O
(	O
or	O
other	O
immunogenic	O
tube	O
feed	O
formulation	O
)	O
at	O
75	O
cc	O
/	O
hr	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
1	O
.	O
Albuterol	I-Drug
nebulizers	O
q	O
6	O
hours	O
p.r.n.	O
2	O
.	O
Lopressor	I-Drug
5	O
mg	O
intravenously	O
q	O
6	O
hours	O
,	O
hold	O
for	O
heart	O
rate	O
less	O
than	O
60	O
or	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
100	O
.	O
3	O
.	O
Zyprexa	I-Drug
5	O
mg	O
p.o.	O
or	O
per	O
nasogastric	O
tube	O
daily	O
.	O
4	O
.	O
Roxicet	I-Drug
elixir	O
5	O
-	O
10	O
cc	O
p.o.	O
or	O
nasogastric	O
tube	O
q	O
4	O
hours	O
p.r.n.	O
for	O
pain	I-Reason
.	O
5	O
.	O
Serax	I-Drug
15	O
mg	O
p.o.	O
or	O
per	O
nasogastric	O
tube	O
t.i.d.	O
6	O
.	O
Heparin	I-Drug
5,000	O
units	O
subcutaneously	O
t.i.d.	O
7	O
.	O
Dilaudid	I-Drug
0.5	O
-	O
2.0	O
mg	O
intravenously	O
or	O
subcutaneously	O
q	O
4	O
hours	O
p.r.n.	O
for	O
pain	I-Reason
.	O
8	O
.	O
Insulin	I-Drug
sliding	O
scale	O
to	O
cover	O
blood	B-Reason
sugars	I-Reason
.	O
This	O
should	O
begin	O
at	O
120	O
and	O
advance	O
every	O
40	O
points	O
of	O
a	O
blood	O
sugar	O
.	O
The	O
beginning	O
scale	O
should	O
start	O
at	O
two	O
and	O
increase	O
two	O
units	O
of	O
insulin	I-Drug
per	O
40	O
points	O
of	O
blood	O
sugar	O
.	O
9	O
.	O
Atrovent	I-Drug
nebulizers	O
inhaled	O
q	O
6	O
hours	O
p.r.n.	O
10	O
.	O
Ativan	I-Drug
0.5	O
-	O
1.0	O
mg	O
intravenously	O
q	O
6	O
hours	O
p.r.n.	O
11	O
.	O
Prevacid	I-Drug
30	O
mg	O
per	O
nasogastric	O
tube	O
q	O
24	O
hours	O
.	O
12	O
.	O
Zoloft	I-Drug
100	O
mg	O
p.o.	O
or	O
per	O
nasogastric	O
tube	O
daily	O
.	O
DISCHARGE	O
INSTRUCTIONS	O
:	O
The	O
patient	O
is	O
to	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
four	O
weeks	O
'	O
time	O
.	O
The	O
patient	O
should	O
continue	O
receiving	O
tube	O
feeds	O
of	O
an	O
immunogenic	O
formula	O
at	O
approximately	O
75	O
cc	O
/	O
hour	O
.	O
The	O
patient	O
should	O
continue	O
all	O
of	O
her	O
medications	O
as	O
described	O
above	O
.	O
In	O
particular	O
,	O
it	O
is	O
important	O
to	O
continue	O
the	O
Serax	I-Drug
and	O
give	O
Ativan	I-Drug
p.r.n.	O
for	O
withdrawal	B-Reason
symptoms	I-Reason
.	O
The	O
patient	O
should	O
have	O
ventilatory	O
weaning	O
with	O
tracheostomy	O
mask	O
trials	O
everyday	O
until	O
the	O
patient	O
can	O
be	O
weaned	O
off	O
of	O
mechanical	O
ventilation	O
.	O
The	O
patient	O
should	O
have	O
ostomy	O
care	O
per	O
standard	O
protocol	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1286	O
**	O
]	O
,	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
11126	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
23688	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2121-11-17	O
**	O
]	O
14:48:09	O
T	O
:	O
[	O
**	O
2121-11-17	O
**	O
]	O
15:25:35	O
Job	O
#	O
:	O
[	O
**	O
Job	O
Number	O
111143	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2142-7-20	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2142-7-27	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2065-8-22	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
783	O
**	O
]	O
Chief	O
Complaint	O
:	O
altered	O
mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Bronchoscopy	O
Intubation	O
(	O
prior	O
to	O
admission	O
)	O
Intensive	O
care	O
unit	O
monitoring	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
76	O
yr	O
old	O
woman	O
with	O
h	O
/	O
o	O
HTN	O
,	O
DM	O
,	O
CHF	I-Reason
on	O
digoxin	I-Drug
,	O
Afib	I-Reason
on	O
coumadin	I-Drug
,	O
who	O
presented	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
for	O
altered	O
mental	O
status	O
.	O
Pt	O
was	O
last	O
seen	O
acting	O
normally	O
at	O
4:30	O
pm	O
,	O
at	O
which	O
time	O
she	O
reported	O
feeling	O
dizzy	O
and	O
went	O
to	O
lay	O
down	O
.	O
Around	O
7	O
pm	O
,	O
she	O
was	O
found	O
by	O
her	O
husband	O
laying	O
on	O
her	O
right	O
side	O
,	O
moaning	O
and	O
unresponsive	O
.	O
No	O
tremors	O
or	O
bladder	O
or	O
bowel	O
incontinence	O
noted	O
.	O
She	O
was	O
brought	O
by	O
EMS	O
into	O
the	O
OSH	O
ED	O
for	O
evaluation	O
.	O
There	O
she	O
was	O
reportedly	O
nonverbal	O
but	O
combative	I-Reason
and	O
received	O
ativan	I-Drug
2	O
mg	O
IV	O
x	O
2	O
.	O
CT	O
head	O
was	O
negative	O
for	O
intracranial	O
hemorrhage	O
.	O
CXR	O
was	O
significant	O
for	O
a	O
RLQ	B-Reason
pneumonia	I-Reason
and	O
pt	O
was	O
given	O
levofloxacin	I-Drug
750	O
mg	O
IV	O
.	O
A	O
digoxin	I-Drug
level	O
was	O
checked	O
which	O
was	O
elevated	O
to	O
2.8	O
;	O
K	O
was	O
5.7	O
.	O
She	O
was	O
given	O
2	O
vials	O
of	O
digibind	I-Drug
and	O
intubated	O
under	O
succinylcholine	I-Drug
with	O
propofol	I-Drug
for	O
sedation	I-Reason
prior	O
to	O
transport	O
for	O
airway	O
protection	O
due	O
to	O
diminished	O
gag	O
reflex	O
in	O
the	O
setting	O
of	O
altered	O
mental	O
status	O
.	O
ABG	O
7.4	O
/	O
41/111	O
on	O
AC	O
500	O
/	O
12/70	O
%	O
/	O
5	O
.	O
In	O
our	O
ED	O
,	O
VS	O
:	O
T	O
97.3	O
,	O
HR	O
41	O
,	O
BP	O
154/49	O
,	O
O2sat	O
99	O
%	O
on	O
AC	O
at	O
TV	O
500	O
,	O
rate	O
14	O
,	O
PEEP	O
5	O
,	O
and	O
FiO2	O
100	O
%	O
.	O
Her	O
CXR	O
showed	O
a	O
sizeable	O
RML	B-Reason
infiltrate	I-Reason
,	O
and	O
vanco	I-Drug
dose	O
given	O
with	O
500cc	O
NS	I-Drug
.	O
EKG	O
showed	O
HR	O
in	O
low	O
40s	O
.	O
3	O
vials	O
of	O
digibind	I-Drug
drawn	O
up	O
.	O
Toxicology	O
was	O
consulted	O
and	O
recommended	O
holding	O
further	O
digibind	I-Drug
at	O
this	O
time	O
unless	O
pt	O
drops	O
blood	O
pressure	O
as	O
may	O
overcompensate	O
and	O
affect	O
her	O
baseline	O
therapeutic	O
level	O
of	O
digoxin	I-Drug
.	O
She	O
was	O
transferred	O
to	O
MICU	O
for	O
monitoring	O
.	O
On	O
the	O
MICU	O
floor	O
,	O
pt	O
report	O
is	O
intubated	O
and	O
sedated	O
.	O
Per	O
her	O
husband	O
,	O
she	O
had	O
no	O
fevers	O
,	O
chills	O
,	O
cough	O
,	O
or	O
shortness	O
of	O
breath	O
suggestive	O
of	O
pneumonia	O
;	O
no	O
choking	O
or	O
coughing	O
with	O
po	O
intake	O
;	O
no	O
recent	O
sick	O
contacts	O
or	O
hospitalizations	O
.	O
Pt	O
eats	O
small	O
meals	O
throughout	O
day	O
;	O
husband	O
did	O
not	O
note	O
any	O
recent	O
change	O
in	O
po	O
intake	O
.	O
She	O
did	O
not	O
complain	O
of	O
any	O
vision	O
changes	O
,	O
N	O
/	O
V	O
,	O
abd	O
pain	O
,	O
diarrhea	O
,	O
headache	O
,	O
confusion	O
,	O
or	O
hallucinations	O
.	O
Of	O
note	O
,	O
was	O
seen	O
in	O
Cardiology	O
clinic	O
the	O
day	O
prior	O
with	O
discontinuation	O
of	O
propanalol	I-Drug
and	O
clonidine	I-Drug
.	O
Past	O
Medical	O
History	O
:	O
A	B-Reason
fib	I-Reason
on	O
coumadin	I-Drug
Diabetes	O
mellitus	O
Hypertension	O
Congestive	O
heart	O
failiure	O
H	O
/	O
o	O
TIA	O
15	O
years	O
ago	O
with	O
sx	O
described	O
as	O
a	O
weak	O
arm	O
and	O
slurred	O
speech	O
.	O
Gout	O
GERD	O
L	O
-	O
TKR	O
Social	O
History	O
:	O
Patient	O
lives	O
with	O
her	O
husband	O
.	O
She	O
is	O
a	O
former	O
manager	O
with	O
[	O
**	O
Location	O
(	O
un	O
)	O
23944	O
**	O
]	O
Farms	O
,	O
now	O
retired	O
.	O
H	O
/	O
o	O
2	O
cigarettes	O
/	O
wk	O
for	O
"	O
years	O
"	O
but	O
quit	O
years	O
ago	O
.	O
Occasional	O
EtOH	O
.	O
Denies	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
with	O
possible	O
CAD	O
Physical	O
Exam	O
:	O
ON	O
ADMISSION	O
GEN	O
:	O
Sedated	O
,	O
occasionally	O
agitated	O
HEENT	O
:	O
NCAT	O
,	O
intubated	O
,	O
mucous	O
membranes	O
dry	O
LUNGS	O
:	O
CTA	O
anteriorly	O
HEART	O
:	O
RRR	O
,	O
S1	O
-	O
S2	O
nl	O
,	O
II	O
/	O
VI	O
SEM	O
radiating	O
to	O
carotids	O
ABD	O
:	O
BS	O
+	O
,	O
soft	O
,	O
ND	O
,	O
hepatomegaly	O
EXTREM	O
:	O
No	O
edema	O
,	O
pulses	O
2	O
+	O
b	O
/	O
l	O
NEURO	O
:	O
PERRL	O
,	O
opens	O
eyes	O
,	O
moves	O
all	O
extremities	O
,	O
withdraws	O
to	O
noxious	O
stimuli	O
.	O
ON	O
DISCHARGE	O
GEN	O
:	O
NAD	O
,	O
pleasant	O
,	O
alert	O
and	O
orientedx4	O
HEENT	O
:	O
NCAT	O
,	O
PERRL	O
,	O
EOMI	O
LUNGS	O
:	O
CTAB	O
except	O
crackles	O
in	O
right	O
middle	O
lobe	O
,	O
much	O
imporved	O
HEART	O
:	O
RRR	O
,	O
S1	O
-	O
S2	O
nl	O
,	O
II	O
/	O
VI	O
SEM	O
radiating	O
to	O
carotids	O
,	O
also	O
II	O
/	O
VI	O
systolic	O
murmur	O
at	O
apex	O
ABD	O
:	O
BS	O
+	O
,	O
soft	O
,	O
ND	O
,	O
EXTREM	O
:	O
No	O
edema	O
,	O
pulses	O
2	O
+	O
b	O
/	O
l	O
Pertinent	O
Results	O
:	O
Outside	O
Hosptial	O
prior	O
to	O
admission	O
:	O
WBC	O
17	O
,	O
Plt	O
264	O
N	O
86.7	O
,	O
L	O
6.8	O
,	O
M	O
5.1	O
,	O
E	O
1	O
,	O
Bas	O
0.4	O
Na	O
134	O
,	O
K	O
5.7	O
,	O
Cl	O
100	O
,	O
Bicarb	O
25	O
,	O
BUN	O
49	O
,	O
Cr	O
1.9	O
,	O
Gluc	O
208	O
AST	O
55	O
,	O
ALT	O
46	O
,	O
AP	O
84	O
,	O
TB	O
0.6	O
,	O
DB	O
0.1	O
,	O
TP	O
9	O
,	O
Alb	O
4.2	O
CK	O
106	O
Trop	O
T	O
0.03	O
ProBNP	O
2664	O
TSH	O
3.61	O
Ferritin	O
86.6	O
Vit	O
B12	O
1219	O
Dig	O
2.83	O
.	O
[	O
**	O
2142-7-20	O
**	O
]	O
WBC	O
-	O
14.8	O
*	O
#	O
RBC	O
-	O
3.62	O
*	O
Hgb	O
-	O
12.1	O
Hct	O
-	O
34.7	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
33.4	O
*	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
14.2	O
Plt	O
Ct	O
-	O
258	O
Neuts	O
-	O
87.3	O
*	O
Lymphs	O
-	O
8.5	O
*	O
Monos	O
-	O
3.8	O
Eos	O
-	O
0.2	O
Baso	O
-	O
0.2	O
PT	O
-	O
38.2	O
*	O
PTT	O
-	O
34.7	O
INR	O
(	O
PT	O
)	O
-	O
4.0	O
*	O
Glucose	O
-	O
165	O
*	O
UreaN	O
-	O
49	O
*	O
Creat	O
-	O
1.9	O
*	O
Na	O
-	O
140	O
K	O
-	O
4.6	O
Cl	O
-	O
103	O
HCO3	O
-	O
25	O
AnGap	O
-	O
17	O
ALT	O
-	O
40	O
AST	O
-	O
43	O
*	O
Calcium	O
-	O
9.7	O
Phos	O
-	O
3.4	O
Mg	O
-	O
2.3	O
CK	O
(	O
CPK	O
)	O
-	O
96	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.02	O
*	O
Lactate	O
-	O
2.8	O
*	O
URINE	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.011	O
Blood	O
-	O
TR	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
30	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
7.0	O
Leuks	O
-	O
NEG	O
RBC	O
-	O
[	O
**	O
4	O
-	O
5	O
**	O
]	O
*	O
WBC	O
-0-2	O
Bacteri	O
-	O
FEW	O
Yeast	O
-	O
NONE	O
Epi	O
-0-2	O
Eos	O
-	O
NEGATIVE	O
UreaN	O
-	O
557	O
Creat	O
-	O
38	O
Na	O
-	O
86	O
DISCHARGE	O
LABS	O
[	O
**	O
2142-7-27	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
WBC	O
-	O
7.9	O
RBC	O
-	O
2.87	O
*	O
Hgb	O
-	O
9.3	O
*	O
Hct	O
-	O
27.5	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
32.4	O
*	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
14.2	O
Plt	O
Ct	O
-	O
335	O
[	O
**	O
2142-7-27	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
Glucose	O
-	O
98	O
UreaN	O
-	O
31	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
140	O
K	O
-	O
3.8	O
Cl	O
-	O
108	O
HCO3	O
-	O
23	O
AnGap	O
-	O
13	O
[	O
**	O
2142-7-24	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
proBNP	O
-	O
[	O
**	O
Numeric	O
Identifier	O
23945	O
**	O
]	O
*	O
[	O
**	O
2142-7-26	O
**	O
]	O
06:34	O
AM	O
BLOOD	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
3.1	O
Mg	O
-	O
2.4	O
[	O
**	O
2142-7-24	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
T3	O
-	O
74	O
*	O
Free	O
T4	O
-	O
1.1	O
[	O
**	O
2142-7-23	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
TSH	O
-	O
8.9	O
*	O
[	O
**	O
2142-7-23	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
VitB12	O
-	O
GREATER	O
TH	O
.	O
[	O
**	O
2142-7-20	O
**	O
]	O
10:47	O
am	O
Influenza	O
A	O
/	O
B	O
by	O
DFA	O
Source	O
:	O
Nasal	O
swab	O
.	O
DIRECT	O
INFLUENZA	O
A	O
ANTIGEN	O
TEST	O
(	O
Final	O
[	O
**	O
2142-7-20	O
**	O
]	O
)	O
:	O
Negative	O
for	O
Influenza	O
A	O
viral	O
antigen	O
.	O
DIRECT	O
INFLUENZA	O
B	O
ANTIGEN	O
TEST	O
(	O
Final	O
[	O
**	O
2142-7-20	O
**	O
]	O
)	O
:	O
NEGATIVE	O
FOR	O
INFLUENZA	O
B	O
VIRAL	O
ANTIGEN	O
.	O
URINE	O
NEGATIVE	O
FOR	O
LEGIONELLA	O
SEROGROUP	O
1	O
ANTIGEN	O
EKG	O
:	O
Sinus	O
bradycardia	O
with	O
first	O
degree	O
atrio	O
-	O
ventricular	O
conduction	O
delay	O
.	O
Non-specific	O
QRS	O
widening	O
with	O
left	O
axis	O
deviation	O
and	O
diffuse	O
repolarization	O
abnormalities	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2141-12-23	O
**	O
]	O
cardiac	O
rhythm	O
is	O
now	O
sinus	O
mechanism	O
with	O
A-V	O
conduction	O
delay	O
.	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
Study	O
Date	O
of	O
[	O
**	O
2142-7-20	O
**	O
]	O
12:52	O
AM	O
1	O
.	O
Right	O
perihilar	O
pneumonia	O
or	O
hemorrhage	O
.	O
2	O
.	O
Left	O
retrocardiac	O
atelectasis	O
or	O
aspiration	O
.	O
3	O
.	O
Moderate	O
cardiomegaly	O
,	O
without	O
pulmonary	O
edema	O
.	O
KNEE	O
(	O
AP	O
,	O
LAT	O
&	O
OBLIQUE	O
)	O
RIGHT	O
Study	O
Date	O
of	O
[	O
**	O
2142-7-22	O
**	O
]	O
2:46	O
PM	O
The	O
bones	O
are	O
diffusely	O
demineralized	O
.	O
Degenerative	O
changes	O
are	O
present	O
predominantly	O
in	O
the	O
medial	O
compartment	O
where	O
there	O
is	O
joint	O
space	O
narrowing	O
and	O
subchondral	O
sclerosis	O
.	O
Minimal	O
osteophyte	O
formation	O
is	O
also	O
noted	O
in	O
the	O
patellofemoral	O
compartment	O
.	O
No	O
discrete	O
fracture	O
is	O
evident	O
and	O
there	O
is	O
no	O
evidence	O
of	O
dislocation	O
.	O
An	O
equivocal	O
small	O
suprapatellar	O
joint	O
effusion	O
is	O
demonstrated	O
as	O
well	O
as	O
extensive	O
vascular	O
calcifications	O
within	O
the	O
soft	O
tissues	O
.	O
CTA	O
CHEST	O
W&W	O
/	O
O	O
C&RECONS	O
,	O
NON-CORONARY	O
Study	O
Date	O
of	O
[	O
**	O
2142-7-24	O
**	O
]	O
1:09	O
AM	O
1	O
.	O
No	O
PE	O
.	O
2	O
.	O
Diffuse	O
septal	O
thickening	O
,	O
small	O
bilateral	O
pleural	O
effusions	O
,	O
cardiomegaly	O
,	O
and	O
ground	O
-	O
glass	O
opacities	O
in	O
the	O
dependent	O
portion	O
of	O
the	O
upper	O
and	O
lower	O
lobes	O
.	O
The	O
constellation	O
of	O
findings	O
is	O
most	O
compatible	O
with	O
CHF	O
.	O
3	O
.	O
Subcentimeter	O
hypodensity	O
in	O
the	O
right	O
lobe	O
of	O
the	O
thyroid	O
,	O
for	O
which	O
further	O
evaluation	O
with	O
ultrasound	O
can	O
be	O
performed	O
on	O
a	O
non-emergent	O
basis	O
.	O
TTE	O
(	O
Complete	O
)	O
Done	O
[	O
**	O
2142-7-25	O
**	O
]	O
at	O
1:51:57	O
PM	O
FINAL	O
The	O
left	O
atrium	O
is	O
moderately	O
dilated	O
.	O
The	O
right	O
atrial	O
pressure	O
is	O
indeterminate	O
.	O
There	O
is	O
mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
normal	O
cavity	O
size	O
.	O
There	O
is	O
moderate	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
hypokinesis	O
of	O
the	O
septum	O
and	O
inferior	O
walls	O
.	O
The	O
remaining	O
segments	O
contract	O
well	O
(	O
LVEF	O
=	O
30	O
-	O
35	O
%	O
)	O
.	O
Tissue	O
Doppler	O
imaging	O
suggests	O
an	O
increased	O
left	O
ventricular	O
filling	O
pressure	O
(	O
PCWP	O
>	O
18mmHg	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
with	O
mild	O
global	O
free	O
wall	O
hypokinesis	O
.	O
The	O
ascending	O
aorta	O
and	O
arch	O
are	O
normal	O
in	O
diameter	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
severe	O
aortic	O
valve	O
stenosis	O
(	O
valve	O
area	O
0.8	O
cm2	O
)	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
is	O
high	O
normal	O
.	O
There	O
is	O
a	O
no	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Mild	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
regional	O
systolic	O
dysfunction	O
c	O
/	O
w	O
CAD	O
.	O
Severe	O
aortic	O
valve	O
stenosis	O
.	O
Mild	O
-	O
moderate	O
mitral	O
regurgitation	O
.	O
Brief	O
Hospital	O
Course	O
:	O
76	O
yo	O
female	O
with	O
PMH	O
of	O
atrial	O
fibrillation	O
admitted	O
with	O
confusion	O
and	O
found	O
to	O
have	O
digoxin	I-Drug
toxicity	I-Ade
,	O
pneumonia	O
and	O
acute	O
renal	O
failure	O
.	O
#	O
Digoxin	I-Drug
toxicity	I-Ade
:	O
Digoxin	I-Drug
levels	O
elevated	O
in	O
toxic	O
range	O
with	O
bradycardia	I-Ade
and	O
PR	B-Ade
prolongation	I-Ade
.	O
Likely	O
in	O
setting	O
of	O
hyperkalemia	O
from	O
acute	O
renal	O
failure	O
from	O
dehydration	O
,	O
possibly	O
secondary	O
to	O
pneumonia	O
.	O
No	O
recent	O
medication	O
changes	O
other	O
than	O
discontinuation	O
of	O
propanolol	I-Drug
and	O
clonidine	I-Drug
,	O
which	O
do	O
not	O
affect	O
the	O
metabolization	O
of	O
digoxin	I-Drug
.	O
Patient	O
was	O
monitored	O
on	O
telemetry	O
with	O
frequent	O
EKGs	O
and	O
labs	O
for	O
hyperkalemia	O
.	O
Her	O
EKGs	O
remained	O
stable	O
.	O
She	O
remained	O
hemodynamically	O
stable	O
with	O
gradually	O
improving	O
HRs	O
.	O
Toxicology	O
was	O
consulted	O
and	O
recommended	O
holding	O
off	O
on	O
digibind	I-Drug
unless	O
HD	O
unstable	O
or	O
EKGs	O
worsened	O
.	O
This	O
did	O
not	O
occur	O
and	O
no	O
further	O
digibind	I-Drug
was	O
given	O
.	O
Digoxin	I-Drug
was	O
1.0	O
on	O
[	O
**	O
7	O
-	O
24	O
**	O
]	O
and	O
mental	O
status	O
resolved	O
to	O
baseline	O
.	O
Will	O
defer	O
to	O
outpatient	O
provider	O
regarding	O
restarting	O
digoxin	I-Drug
.	O
Once	O
bradycardia	O
resolved	O
patient	O
was	O
restarted	O
on	O
Metoprolol	I-Drug
without	O
any	O
unstable	O
hemodynamics	O
.	O
#Hypoxemia	O
.	O
The	O
patients	O
oxygen	I-Drug
requirements	O
increased	O
to	O
using	O
a	O
non-rebreather	O
mask	O
on	O
[	O
**	O
7	O
-	O
23	O
**	O
]	O
.	O
It	O
is	O
likely	O
that	O
this	O
was	O
due	O
to	O
CHF	O
exacerbation	O
(	O
supported	O
by	O
BNP	O
>	O
[	O
**	O
Numeric	O
Identifier	O
389	O
**	O
]	O
and	O
findings	O
on	O
CT	O
)	O
as	O
furosemide	I-Drug
was	O
being	O
held	O
vs	O
effusions	O
present	O
on	O
CT	O
likely	O
secondary	O
to	O
the	O
pneumonia	O
.	O
PE	O
was	O
initially	O
considered	O
and	O
ruled	O
out	O
by	O
CT	O
angiogram	O
.	O
The	O
patient	O
was	O
gradually	O
diuresed	O
and	O
her	O
respiratory	O
status	O
improved	O
,	O
though	O
this	O
was	O
also	O
likely	O
contributed	O
to	O
by	O
treatment	O
of	O
pneumonia	O
.	O
Discharged	O
on	O
2	O
-	O
3L	O
/	O
min	O
NC	O
with	O
stable	O
oxygen	O
status	O
to	O
be	O
weaned	O
at	O
nursing	O
facility	O
.	O
#	O
Altered	B-Ade
Mental	I-Ade
Status	I-Ade
:	O
Likely	O
[	O
**	O
3	O
-	O
5	O
**	O
]	O
digoxin	I-Drug
toxicity	O
although	O
may	O
also	O
have	O
delirium	O
in	O
setting	O
of	O
infection	O
.	O
Was	O
intubated	O
at	O
OSH	O
for	O
airway	O
protection	O
,	O
however	O
,	O
after	O
bronchoscopy	O
here	O
(	O
See	O
below	O
)	O
she	O
was	O
extubated	O
without	O
difficulty	O
.	O
CXR	O
notable	O
for	O
large	O
right	O
middle	O
lobe	O
infiltrate	O
concerning	O
for	O
pneumonia	O
.	O
Less	O
likely	O
neuro	O
process	O
;	O
no	O
h	O
/	O
o	O
of	O
seizures	O
,	O
CT	O
head	O
negative	O
for	O
acute	O
changes	O
.	O
Digoxin	I-Drug
toxicity	I-Ade
and	O
pneumonia	O
were	O
treated	O
as	O
described	O
elsewhere	O
and	O
mental	O
status	O
improved	O
to	O
baseline	O
.	O
#	O
Pneumonia	I-Reason
:	O
Large	O
RML	O
(	O
right	O
middle	O
lobe	O
)	O
infiltrate	O
and	O
leukocytosis	O
suggestive	O
of	O
infectious	O
process	O
although	O
patient	O
was	O
afebrile	O
and	O
asymptomatic	O
per	O
husband	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
likely	O
ventilator	O
-	O
acquired	O
pneumonia	O
vs	O
aspiration	O
from	O
altered	O
mental	O
status	O
.	O
Received	O
levofloxacin	I-Drug
and	O
vanco	I-Drug
prior	O
to	O
arrival	O
on	O
floor	O
.	O
In	O
setting	O
of	O
digoxin	I-Drug
toxicity	I-Ade
concern	O
for	O
QT	O
prolongation	O
,	O
she	O
was	O
changed	O
to	O
Azithromycin	I-Drug
/	O
Clindamycin	I-Drug
due	O
to	O
a	O
PCN	I-Drug
allergy	O
.	O
After	O
legionella	O
antigen	O
returned	O
negative	O
,	O
azithro	I-Drug
was	O
discontinued	O
.	O
She	O
underwent	O
bronchoscopy	O
and	O
cultures	O
which	O
grew	O
oropharyngeal	O
flora	O
.	O
Blood	O
cultures	O
were	O
negative	O
.	O
On	O
[	O
**	O
7	O
-	O
21	O
**	O
]	O
,	O
she	O
spiked	O
a	O
fever	O
and	O
antibiotics	I-Drug
were	O
changed	O
to	O
ceftriaxone	I-Drug
.	O
She	O
again	O
spiked	O
on	O
[	O
**	O
7	O
-	O
23	O
**	O
]	O
and	O
coverage	O
broadened	O
by	O
changing	O
antibiotics	I-Drug
to	O
cefipime	I-Drug
and	O
vancomycin	I-Drug
.	O
She	O
should	O
complete	O
a	O
8	O
day	O
course	O
for	O
ventilator	B-Reason
associate	I-Reason
pneumonia	O
.	O
Vancomycin	I-Drug
is	O
being	O
dosed	O
Q24	O
hours	O
for	O
renal	O
insufficiency	O
but	O
will	O
be	O
monitored	O
at	O
her	O
nursing	O
facility	O
should	O
her	O
renal	O
function	O
improve	O
.	O
#	O
Acute	B-Reason
renal	I-Reason
failure	I-Reason
:	O
Cr	O
elevated	O
above	O
baseline	O
here	O
1	O
year	O
ago	O
of	O
0.9	O
.	O
BUN	O
/	O
Cr	O
ratio	O
suggested	O
prerenal	O
etiology	O
,	O
likely	O
in	O
setting	O
of	O
pneumonia	O
.	O
Creatinine	O
improved	O
with	O
IVF	I-Drug
.	O
Renally	O
dosed	O
meds	I-Drug
.	O
Held	O
ACE	B-Drug
-	I-Drug
I.	O
On	O
[	O
**	O
7	O
-	O
23	O
**	O
]	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
increased	O
oxygen	I-Drug
requirments	O
and	O
was	O
placed	O
on	O
a	O
non-rebreather	O
mask	O
.	O
In	O
the	O
setting	O
of	O
respiratory	O
distress	O
and	O
concern	O
for	O
PE	O
vs	O
decompensated	O
heart	O
failure	O
,	O
the	O
risks	O
of	O
renal	O
insult	O
were	O
outweighed	O
by	O
the	O
need	O
for	O
CT	O
-	O
angio	O
with	O
IV	O
contrast	I-Drug
and	O
diuresis	I-Drug
.	O
Pt	O
received	O
N	B-Drug
-	I-Drug
acetylcysteine	I-Drug
course	O
and	O
cautious	O
fluid	O
resusitation	O
.	O
Upon	O
discharge	O
,	O
Cr	O
1.3	O
and	O
Lisinopril	I-Drug
continuing	O
to	O
be	O
held	O
with	O
possible	O
restart	O
at	O
her	O
nursing	O
facility	O
.	O
#	O
CHF	O
-	O
acute	O
on	O
chronic	O
,	O
systolic	O
:	O
Prior	O
TTEs	O
not	O
in	O
system	O
;	O
EF	O
unknown	O
prior	O
to	O
admission	O
but	O
appeared	O
dry	O
here	O
when	O
first	O
admitted	O
and	O
received	O
gentle	O
IVF	I-Drug
.	O
Held	O
lasix	I-Drug
in	O
setting	O
of	O
dehydration	O
.	O
Also	O
initially	O
held	O
beta	B-Drug
blocker	I-Drug
and	O
ACE	B-Drug
inhibitor	I-Drug
as	O
PR	O
prolongation	O
and	O
ARF	O
.	O
When	O
patient	O
developed	O
new	O
O2	I-Drug
requirment	O
,	O
Lasix	I-Drug
was	O
restarted	O
for	O
diuresis	I-Reason
.	O
TTE	O
obtained	O
at	O
that	O
time	O
revealed	O
AS	O
and	O
EF	O
=	O
30	O
-	O
35	O
%	O
.	O
Continued	O
to	O
hold	O
ACE	I-Drug
inhibitor	O
for	O
hospitalization	O
but	O
beta	B-Drug
blocker	I-Drug
was	O
restarted	O
and	O
patient	O
was	O
continued	O
on	O
statin	I-Drug
,	O
fish	B-Drug
oil	I-Drug
and	O
ASA	I-Drug
.	O
#	O
Atrial	O
Fibrillation	O
:	O
Held	O
digoxin	I-Drug
,	O
metoprolol	I-Drug
and	O
amiodarone	I-Drug
in	O
setting	O
of	O
digoxin	I-Drug
toxicity	I-Ade
as	O
did	O
not	O
want	O
to	O
contribute	O
to	O
nodal	O
blockade	O
given	O
bradycardia	O
.	O
INR	O
was	O
supratherapeutic	O
on	O
admission	O
and	O
coumadin	I-Drug
was	O
held	O
.	O
Warfarin	I-Drug
restarted	O
on	O
[	O
**	O
7	O
-	O
22	O
**	O
]	O
and	O
INR	O
has	O
been	O
therapeutic	O
.	O
Metoprolol	I-Drug
was	O
restarted	O
and	O
she	O
remained	O
rate	O
controlled	O
during	O
the	O
rest	O
of	O
her	O
admission	O
.	O
Amiodarone	I-Drug
and	O
Digoxin	I-Drug
were	O
not	O
restarted	O
.	O
#	O
Hypertension	O
:	O
Held	O
metoprolol	I-Drug
and	O
lisinopril	I-Drug
as	O
above	O
.	O
Continued	O
amlodipine	I-Drug
for	O
BP	B-Reason
control	I-Reason
.	O
Restarted	O
metoprolol	I-Drug
,	O
but	O
contiue	O
to	O
hold	O
lisinopril	I-Drug
for	O
ARF	O
.	O
#Aortic	O
stenosis	O
:	O
classified	O
as	O
severe	O
on	O
echocardiogram	O
.	O
Diuresed	O
gently	O
as	O
patient	O
was	O
preload	O
-	O
dependent	O
.	O
Remained	O
hemodynamically	O
stable	O
.	O
Advised	O
to	O
manage	O
as	O
outpatient	O
#	O
Swollen	O
righ	O
knee	O
:	O
Seen	O
by	O
rheumatology	O
,	O
whose	O
assessment	O
was	O
polyarticular	O
gout	O
flare	O
.	O
The	O
joint	O
was	O
aspirated	O
and	O
crystals	O
were	O
noted	O
by	O
Rheum	O
fellow	O
but	O
not	O
in	O
final	O
report	O
.	O
Synovial	O
fluid	O
with	O
neutrophilic	O
infiltrate	O
.	O
Cultures	O
negative	O
.	O
Acute	I-Reason
gout	O
flare	O
was	O
treated	O
with	O
indomethacin	I-Drug
and	O
colchicine	I-Drug
.	O
Indomethacin	I-Drug
was	O
discontinued	O
the	O
following	O
day	O
given	O
ARF	O
.	O
The	O
patinet	O
improved	O
and	O
has	O
not	O
complained	O
of	O
joint	O
pain	O
since	O
[	O
**	O
7	O
-	O
24	O
**	O
]	O
.	O
Colchicine	I-Drug
discontinued	O
on	O
[	O
**	O
7	O
-	O
27	O
**	O
]	O
.	O
Continued	O
home	O
dose	O
of	O
Allopurinol	I-Drug
.	O
#	O
Urinary	B-Reason
incontinence	I-Reason
:	O
Detrol	I-Drug
and	O
oxybutynin	I-Drug
were	O
discontinued	O
on	O
suspicion	O
that	O
they	O
might	O
contribute	O
to	O
AMS	I-Ade
.	O
The	O
patient	O
now	O
reports	O
feeling	O
that	O
she	O
is	O
able	O
to	O
adequately	O
control	O
her	O
bladder	O
,	O
and	O
we	O
will	O
defer	O
to	O
outpatient	O
provider	O
regarding	O
these	O
medications	O
.	O
#	O
History	B-Reason
of	I-Reason
TIA	I-Reason
:	O
No	O
evidence	O
of	O
bleed	O
on	O
OSH	O
CT	O
head	O
.	O
Continued	O
ASA	I-Drug
.	O
Therapeutic	O
on	O
warfarin	I-Drug
and	O
statin	I-Drug
therapy	O
.	O
#	O
Hypothyroid	O
-	O
elevated	O
TSH	O
,	O
T3	O
low	O
.	O
Patient	O
without	O
clinical	O
signs	O
or	O
symptoms	O
of	O
hypothyroidism	O
.	O
Difficult	O
to	O
evaluate	O
laboratory	O
abnormalities	O
in	O
setting	O
of	O
acute	O
illness	O
and	O
will	O
defer	O
treatment	O
for	O
now	O
and	O
recommend	O
evaluation	O
by	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
supplemental	O
medication	O
started	O
.	O
#	O
Thyroid	O
hypodensity	O
:	O
Noted	O
on	O
imaging	O
as	O
described	O
above	O
.	O
This	O
should	O
be	O
followed	O
by	O
PCP	O
for	O
further	O
evaluation	O
and	O
management	O
post-discharge	O
.	O
#Diabetes	O
mellitus	I-Reason
type	I-Reason
2	I-Reason
.	O
Managed	O
on	O
sliding	O
scale	O
insulin	I-Drug
with	O
basal	B-Drug
glarigne	I-Drug
while	O
holding	O
Metformin	I-Drug
.	O
Started	O
home	O
medication	O
metformin	I-Drug
the	O
day	O
of	O
discharge	O
as	O
patient	O
was	O
72	O
hours	O
after	O
her	O
contrast	I-Drug
load	O
.	O
Additionally	O
,	O
should	O
patient	O
Cr	O
worsen	O
to	O
>	O
1.5	O
would	O
stop	O
as	O
will	O
poorly	O
cleared	O
.	O
#	O
Code	O
:	O
FULL	O
#	O
Communication	O
:	O
With	O
husband	O
[	O
**	O
Name	O
(	O
NI	O
)	O
401	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
23946	O
**	O
]	O
)	O
and	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
4648	O
**	O
]	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
23947	O
**	O
]	O
)	O
Medications	O
on	O
Admission	O
:	O
ASA	I-Drug
81	O
mg	O
daily	O
Allopurinol	I-Drug
100	O
mg	O
daily	O
Amiodarone	I-Drug
200	O
mg	O
daily	O
Amlodipine	I-Drug
10	O
mg	O
daily	O
Atorvastatin	I-Drug
5	O
mg	O
daily	O
Darvocet	I-Drug
prn	O
pain	I-Reason
Detrol	B-Drug
LA	I-Drug
2	O
mg	O
daily	O
Digoxin	I-Drug
125	O
mcg	O
Tablet	O
daily	O
Diphenoxylate	I-Drug
as	O
needed	O
Fish	B-Drug
oil	I-Drug
1g	O
daily	O
Furosemide	I-Drug
80	O
mg	O
daily	O
Lisinopril	I-Drug
40	O
mg	O
daily	O
Metformin	I-Drug
500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Metoprolol	I-Drug
100	O
mg	O
daily	O
Oxybutynin	I-Drug
5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Zaroulyn	I-Drug
5	O
mg	O
prn	O
30	O
min	O
before	O
lasix	I-Drug
Warfarin	I-Drug
2	O
mg	O
qhs	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Allopurinol	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Amlodipine	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
/	O
pain	I-Reason
:	O
This	O
is	O
a	O
new	O
medication	O
since	O
admission	O
.	O
6	O
.	O
Warfarin	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
.	O
7	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
for	O
1	O
doses	O
:	O
This	O
medication	O
to	O
be	O
given	O
[	O
**	O
2142-7-27	O
**	O
]	O
PM	O
.	O
On	O
[	O
**	O
2142-7-28	O
**	O
]	O
AM	O
patient	O
should	O
start	O
Metoprolol	I-Drug
Succinate	O
100	O
mg	O
daily	O
.	O
8	O
.	O
Hydrocortisone	I-Drug
1	O
%	O
Ointment	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
pruritis	I-Reason
:	O
This	O
is	O
a	O
new	O
medication	O
since	O
admission	O
.	O
9	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
dermatitis	I-Reason
:	O
This	O
is	O
a	O
new	O
medication	O
since	O
admission	O
.	O
10	O
.	O
Furosemide	B-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Fexofenadine	I-Drug
60	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
itching	I-Reason
:	O
This	O
is	O
a	O
new	O
medication	O
since	O
admission	O
.	O
12	O
.	O
Heparin	I-Drug
Flush	O
(	O
10	O
units	O
/	O
ml	O
)	O
2	O
mL	O
IV	O
PRN	O
line	O
flush	O
Mid-line	O
,	O
heparin	I-Drug
dependent	O
:	O
Flush	O
with	O
10	O
mL	O
Normal	B-Drug
Saline	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
,	O
daily	O
and	O
PRN	O
per	O
lumen	O
.	O
13	O
.	O
Cefepime	I-Drug
2	O
gram	O
Recon	O
Soln	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
gram	O
Injection	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
4	O
days	O
.	O
14	O
.	O
Vancomycin	I-Drug
1,000	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
gram	O
Intravenous	O
Q	O
24H	O
(	O
Every	O
24	O
Hours	O
)	O
for	O
4	O
days	O
.	O
15	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Start	O
[	O
**	O
2142-7-28	O
**	O
]	O
AM	O
.	O
16	O
.	O
Metformin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
17	O
.	O
Fish	B-Drug
Oil	I-Drug
1,000	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
18	O
.	O
Insulin	I-Drug
Sliding	O
Scale	O
Please	O
see	O
attached	O
insulin	I-Drug
sliding	O
scale	O
.	O
Patient	O
was	O
on	O
insulin	I-Drug
sliding	O
scale	O
while	O
inpatient	O
while	O
Metformin	I-Drug
was	O
being	O
held	O
after	O
a	O
CT	O
scan	O
with	O
contrast	I-Drug
.	O
If	O
patient	O
does	O
not	O
require	O
insulin	I-Drug
after	O
resumption	O
of	O
her	O
Metformin	I-Drug
,	O
this	O
may	O
be	O
discontinued	O
.	O
19	O
.	O
Supplemental	B-Drug
oxygen	I-Drug
Patient	O
should	O
have	O
supplemental	B-Drug
oxygen	I-Drug
via	O
nasal	O
cannula	O
at	O
2	O
-	O
3L	O
/	O
min	O
or	O
at	O
rate	O
as	O
needed	O
to	B-Reason
keep	I-Reason
O2	I-Reason
saturation	I-Reason
>	I-Reason
92	I-Reason
%	I-Reason
.	O
Wean	O
as	O
tolerated	O
to	O
room	O
air	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
Lifecare	O
Center	O
of	O
Attelboro	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Digoxin	I-Drug
toxicity	I-Ade
,	O
congestive	O
heart	O
failure	O
(	O
acute	O
on	O
chronic	O
)	O
,	O
Pneumonia	O
likely	O
due	O
to	O
aspiration	O
,	O
Acute	O
renal	O
failure	O
,	O
Acute	O
gout	O
flare	O
,	O
altered	O
mental	O
status	O
,	O
delirium	O
,	O
aortic	O
stenosis	O
Secondary	O
:	O
Atrial	O
fibrillation	O
Chronic	O
heart	O
failure	O
(	O
EF	O
30	O
%	O
to	O
35	O
%	O
)	O
Discharge	O
Condition	O
:	O
Good	O
.	O
Hemodynamically	O
stable	O
and	O
afebrile	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
confusion	O
and	O
were	O
found	O
to	O
have	O
an	O
elevated	O
digoxin	I-Drug
level	O
in	O
your	O
blood	O
.	O
You	O
were	O
also	O
unable	O
to	O
get	O
enough	O
oxygen	I-Drug
to	O
your	O
blood	O
and	O
needed	O
to	O
wear	O
a	O
mask	O
.	O
The	O
following	O
changes	O
were	O
made	O
to	O
your	O
medications	O
:	O
1	O
)	O
STOP	O
digoxin	I-Drug
2	O
)	O
HOLD	O
amiodarone	I-Drug
,	O
please	O
discuss	O
with	O
your	O
cardiologist	O
whether	O
to	O
restart	O
this	O
medication	O
3	O
)	O
START	O
vancomycin	I-Drug
and	O
cefepime	I-Drug
,	O
to	O
be	O
continued	O
for	O
4	O
additional	O
days	O
4	O
)	O
HOLD	O
lisinopril	I-Drug
,	O
this	O
may	O
be	O
restarted	O
while	O
in	O
your	O
nursing	O
facility	O
depending	O
on	O
whether	O
your	O
kidney	O
function	O
returns	O
to	O
baseline	O
5	O
)	O
Hold	O
Darvocet	I-Drug
,	O
Detrol	B-Drug
LA	I-Drug
2	O
mg	O
,	O
Diphenoxylate	I-Drug
,	O
Oxybutynin	I-Drug
until	O
advised	O
to	O
restart	O
them	O
by	O
a	O
physician	O
.	O
Followup	O
Instructions	O
:	O
Please	O
contact	O
your	O
primary	O
care	O
physician	O
and	O
your	O
Cardiologist	O
upon	O
discharge	O
from	O
the	O
skilled	O
nursing	O
facility	O
to	O
schedule	O
follow	O
-	O
up	O
appointments	O
to	O
discuss	O
your	O
recent	O
hospitalization	O
.	O
At	O
these	O
appointments	O
please	O
bring	O
your	O
medication	O
list	O
to	O
discuss	O
any	O
changes	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
734	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
735	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
799	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2183-10-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2183-10-15	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2103-6-11	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Codeine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
11040	O
**	O
]	O
Chief	O
Complaint	O
:	O
shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
intubation	O
,	O
arterial	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
an	O
80	O
year	O
old	O
female	O
with	O
history	O
of	O
bronchiectasis	O
and	O
COPD	O
as	O
well	O
as	O
cardiomyopathy	O
secondary	O
to	O
cardiac	O
contusion	O
and	O
atrial	O
fibrillation	O
who	O
was	O
transferred	O
for	O
persistent	O
hypoxic	O
respiratory	O
failure	O
after	O
an	O
admission	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
.	O
The	O
patient	O
's	O
history	O
this	O
year	O
has	O
been	O
marked	O
for	O
starting	O
amioadarone	I-Drug
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
958	O
**	O
]	O
for	O
persistent	B-Reason
atrial	I-Reason
fibrilllation	I-Reason
(	O
also	O
had	O
TEE	O
and	O
cardioversion	O
)	O
and	O
had	O
stayed	O
in	O
sinus	O
rhythm	O
.	O
Unfortunately	O
,	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
the	O
patient	O
developed	O
worsening	O
cough	O
and	O
dyspnea	O
and	O
her	O
amiodarone	I-Drug
was	O
stopped	O
due	O
to	O
concern	O
for	O
early	O
pulmonary	B-Ade
toxicity	I-Ade
.	O
On	O
[	O
**	O
9	O
-	O
23	O
**	O
]	O
the	O
patient	O
was	O
admitted	O
to	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Hospial	O
with	O
worsening	O
respiratory	O
symptoms	O
,	O
including	O
dyspnea	O
,	O
cough	O
,	O
and	O
hypoxia	O
.	O
She	O
had	O
a	O
chest	O
CT	O
on	O
[	O
**	O
9	O
-	O
25	O
**	O
]	O
that	O
revealed	O
diffuse	O
GGO	O
on	O
a	O
background	O
of	O
bronchiectasis	I-Reason
and	O
emphysema	I-Reason
.	O
She	O
started	O
empiric	O
treatment	O
with	O
abx	I-Drug
and	O
steroids	I-Drug
for	O
concern	O
of	O
AIP	I-Reason
.	O
Given	O
progressive	O
respiratory	O
failure	O
she	O
was	O
intubated	O
.	O
At	O
the	O
time	O
of	O
bronchoscopy	O
she	O
had	O
bloody	O
secretions	O
and	O
there	O
was	O
concern	O
for	O
pulmonary	B-Ade
hemorrhage	I-Ade
.	O
Therefore	O
she	O
was	O
taken	O
off	O
anticoagulation	I-Drug
.	O
She	O
was	O
continued	O
on	O
antibiotics	I-Drug
(	O
amp	B-Drug
-	I-Drug
sublactam	I-Drug
and	O
azithromycin	I-Drug
)	O
and	O
steroids	I-Drug
,	O
her	O
anticoagulation	I-Drug
was	O
stopped	O
,	O
and	O
she	O
was	O
also	O
diuresed	O
gently	O
to	O
keep	O
steadily	O
negative	O
fluid	O
balances	O
.	O
She	O
had	O
mild	O
improvements	O
and	O
was	O
extubated	O
on	O
[	O
**	O
10	O
-	O
2	O
**	O
]	O
.	O
Unfortunately	O
,	O
since	O
extubation	O
she	O
had	O
progressive	O
supplementary	O
O2	I-Drug
requirements	O
and	O
spent	O
the	O
last	O
few	O
days	O
prior	O
to	O
transfer	O
bouncing	O
between	O
100	O
%	O
NRB	O
mask	O
and	O
CPAP	O
.	O
She	O
has	O
had	O
no	O
positive	O
cultures	O
and	O
bronchoscopy	O
revealed	O
no	O
organisms	O
and	O
no	O
pathognomonic	O
findings	O
for	O
a	O
particular	O
diagnosis	O
.	O
OSH	O
course	O
was	O
also	O
notable	O
for	O
persistent	O
and	O
difficult	O
to	O
control	O
afib	I-Reason
with	O
RVR	O
so	O
that	O
on	O
transfer	O
she	O
was	O
on	O
high	O
doses	O
of	O
diltiazem	I-Drug
,	O
metoprolol	I-Drug
,	O
and	O
digoxin	I-Drug
.	O
Given	O
her	O
?	O
pulmonary	O
hemorrhage	O
the	O
patient	O
's	O
primary	O
pulmonologist	O
strongly	O
felt	O
she	O
should	O
not	O
be	O
anticoagulated	I-Drug
again	O
and	O
wanted	O
transfer	O
partially	O
to	O
pursue	O
AV	O
nodal	O
ablation	O
or	O
other	O
more	O
advanced	O
RVR	O
management	O
by	O
our	O
EP	O
service	O
.	O
On	O
arrival	O
,	O
vital	O
signs	O
were	O
96.1	O
(	O
axillary	O
)	O
,	O
HR	O
88	O
(	O
afib	O
)	O
,	O
131/65	O
,	O
and	O
satting	O
95	O
%	O
on	O
non-rebreather	O
.	O
The	O
patient	O
was	O
awake	O
,	O
alert	O
,	O
responding	O
appropriately	O
to	O
questioning	O
.	O
Reports	O
that	O
her	O
breathing	O
is	O
"	O
a	O
little	O
labored	O
,	O
"	O
but	O
feels	O
better	O
than	O
she	O
had	O
at	O
the	O
OSH	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Cardiomyopathy	O
after	O
chest	O
contusion	O
with	O
former	O
EF	O
30	O
%	O
,	O
now	O
normalized	O
at	O
55	O
%	O
-	O
CAD	O
,	O
s	O
/	O
p	O
BMS	O
to	O
RCA	O
in	O
[	O
**	O
10/2181	O
**	O
]	O
-	O
Upper	O
lobe	O
bronchiectasis	O
attributed	O
to	O
severe	O
pneumonias	O
in	O
the	O
[	O
**	O
2132	O
**	O
]	O
.	O
Typically	O
has	O
2	O
-	O
3	O
episodes	O
of	O
exacerbation	O
bronchiectasis	O
each	O
year	O
.	O
-	O
COPD	O
with	O
moderately	O
severe	O
centrilobular	O
emphysema	O
on	O
CT	O
-	O
Hypertension	O
-	O
T2DM	O
-	O
Mitral	O
Valve	O
Prolapse	O
-	O
R	O
breast	O
nodularites	O
(	O
stable	O
on	O
subsequent	O
mammograms	O
)	O
-	O
Plantar	O
Fasciitis	O
-	O
s	O
/	O
p	O
partial	O
hysterectomy	O
in	O
[	O
**	O
2142	O
**	O
]	O
-	O
Bladder	O
suspension	O
-	O
GERD	O
-	O
Multinodular	O
goiter	O
Social	O
History	O
:	O
Former	O
smoker	O
,	O
x	O
30	O
years	O
at	O
about	O
two	O
packs	O
/	O
day	O
.	O
Stopped	O
seven	O
years	O
ago	O
.	O
Occasional	O
social	O
alcohol	O
.	O
Lives	O
at	O
home	O
alone	O
,	O
is	O
independent	O
in	O
ADLs	O
.	O
Two	O
children	O
are	O
involved	O
in	O
her	O
health	O
care	O
.	O
Family	O
History	O
:	O
There	O
is	O
a	O
family	O
history	O
of	O
premature	O
coronary	O
artery	O
disease	O
or	O
sudden	O
death	O
(	O
three	O
brothers	O
who	O
died	O
of	O
CAD	O
and	O
one	O
sister	O
with	O
CHF	O
)	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
Temp	O
:	O
96.1	O
BP	O
:	O
131/65	O
HR	O
:	O
88	O
(	O
afib	O
)	O
RR	O
:	O
28	O
O2sat	O
:	O
95	O
%	O
on	O
NRB	O
GEN	O
:	O
pleasant	O
,	O
speaking	O
in	O
[	O
**	O
3	O
-	O
17	O
**	O
]	O
word	O
sentences	O
with	O
NRB	O
in	O
place	O
.	O
Not	O
using	O
accessory	O
neck	O
muscles	O
.	O
Awake	O
,	O
alert	O
,	O
oriented	O
,	O
responding	O
appropriately	O
.	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
anicteric	O
,	O
MMM	O
,	O
op	O
without	O
lesions	O
,	O
no	O
supraclavicular	O
or	O
cervical	O
lymphadenopathy	O
,	O
no	O
jvd	O
,	O
+	O
mild	O
thyromegaly	O
RESP	O
:	O
Bibasilar	O
crackles	O
bilaterally	O
,	O
no	O
wheeze	O
CV	O
:	O
RR	O
,	O
S1	O
and	O
S2	O
wnl	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
ABD	O
:	O
nd	O
,	O
+	O
b	O
/	O
s	O
,	O
soft	O
,	O
nt	O
,	O
no	O
masses	O
or	O
hepatosplenomegaly	O
EXT	O
:	O
no	O
c	O
/	O
c	O
/	O
e	O
SKIN	O
:	O
no	O
rashes	O
/	O
no	O
jaundice	O
/	O
no	O
splinters	O
NEURO	O
:	O
AAOx3	O
.	O
4/5	O
strength	O
throughout	O
,	O
with	O
limited	O
effort	O
.	O
No	O
sensory	O
deficits	O
to	O
light	O
touch	O
appreciated	O
Pertinent	O
Results	O
:	O
====================	O
LABORATORY	O
RESULTS	O
====================	O
On	O
Admission	O
:	O
WBC	O
-	O
12.0	O
*	O
RBC	O
-	O
5.29	O
#	O
Hgb	O
-	O
13.3	O
Hct	O
-	O
39.4	O
MCV	O
-	O
75	O
*	O
RDW	O
-	O
17.7	O
*	O
Plt	O
Ct	O
-	O
274	O
---	O
Neuts	O
-	O
91.0	O
*	O
Lymphs	O
-	O
6.8	O
*	O
Monos	O
-	O
1.1	O
*	O
Eos	O
-	O
0.7	O
Baso	O
-	O
0.4	O
PT	O
-	O
11.8	O
PTT	O
-	O
23.9	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
Glucose	O
-	O
150	O
*	O
UreaN	O
-	O
33	O
*	O
Creat	O
-	O
0.5	O
Na	O
-	O
139	O
K	O
-	O
5.9	O
*	O
Cl	O
-	O
103	O
HCO3	O
-	O
27	O
Calcium	O
-	O
8.5	O
Phos	O
-	O
3.5	O
Mg	O
-	O
2.4	O
ABG	O
:	O
7.49	O
/	O
38	O
/	O
61	O
=================	O
OTHER	O
STUDIES	O
=================	O
Admission	O
ECG	O
:	O
Chest	O
Radiograph	O
[	O
**	O
2183-10-10	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Dense	O
bilateral	O
reticular	O
opacities	O
.	O
This	O
may	O
represent	O
an	O
acute	O
process	O
superimposed	O
on	O
background	O
chronic	O
changes	O
.	O
The	O
differential	O
diagnosis	O
includes	O
drug	O
-	O
related	O
pneumonitis	I-Ade
(	O
by	O
report	O
,	O
the	O
patient	O
is	O
on	O
amiodarone	I-Drug
)	O
,	O
interstitial	O
edema	O
,	O
and	O
interstitial	O
infection	O
.	O
Edema	O
is	O
considered	O
less	O
likely	O
given	O
the	O
absence	O
of	O
effusions	O
.	O
Bilateral	O
Lower	O
Extremity	O
Ultrasounds	O
[	O
**	O
2183-10-11	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Bilateral	O
lower	O
extremity	O
DVTs	O
,	O
more	O
extensive	O
on	O
the	O
right	O
involving	O
the	O
common	O
femoral	O
vein	O
,	O
proximal	O
and	O
distal	O
superficial	O
femoral	O
veins	O
and	O
posterior	O
tibial	O
and	O
peroneal	O
veins	O
.	O
Partially	O
occlusive	O
thrombus	O
within	O
the	O
distal	O
left	O
superficial	O
femoral	O
vein	O
.	O
Brief	O
Hospital	O
Course	O
:	O
80	O
y	O
/	O
o	O
F	O
with	O
likely	O
emphysema	O
and	O
bronchiectasis	O
as	O
well	O
as	O
Afib	O
w	O
/	O
RVR	O
and	O
history	O
of	O
cardiomyopathy	O
presenting	O
with	O
worsening	O
respiratory	O
symptoms	O
and	O
hypoxia	O
in	O
the	O
context	O
of	O
bilateral	O
ground	O
glass	O
infiltrates	O
of	O
uncertain	O
etiology	O
.	O
Hypoxic	B-Reason
respiratory	I-Reason
failure	I-Reason
:	O
The	O
patient	O
presented	O
with	O
very	O
high	O
oxygen	I-Drug
requirements	O
and	O
desatting	O
with	O
minimal	O
exertion	O
or	O
very	O
short	O
periods	O
off	O
the	O
high	O
flow	O
oxygen	I-Drug
masks	O
.	O
Unclear	O
ultimate	O
etiology	O
though	O
diffuse	O
findings	O
on	O
CT	O
were	O
thought	O
to	O
be	O
concerning	O
for	O
AIP	O
on	O
baseline	O
lung	O
disease	O
with	O
pulmonary	O
hemorrhage	O
thought	O
much	O
less	O
likely	O
given	O
reports	O
of	O
bleeding	O
.	O
Patient	O
had	O
already	O
received	O
a	O
fairly	O
high	O
pulse	O
of	O
steroids	I-Drug
leaving	O
the	O
benefit	O
of	O
another	O
course	O
questionable	O
but	O
given	O
tenuous	O
respiratory	O
status	O
limiting	O
ability	O
to	O
perform	O
further	O
diagnostic	O
work	O
-	O
up	O
(	O
particular	O
any	O
attempts	O
to	O
pursue	O
tissue	O
diagnosis	O
)	O
a	O
dose	O
of	O
1	O
gram	O
methylprednisolone	I-Drug
daily	O
was	O
initiated	O
for	O
three	O
days	O
followed	O
by	O
1	O
mg	O
/	O
kg	O
daily	O
.	O
She	O
was	O
also	O
started	O
on	O
vancomycin	I-Drug
and	O
cefepime	I-Drug
given	O
neither	O
vancomycin	I-Drug
nor	O
psuedomonas	O
had	O
been	O
covered	O
by	O
here	O
previous	O
antibiotics	I-Drug
and	O
those	O
could	O
be	O
established	O
in	O
her	O
altered	O
airways	O
as	O
a	O
not	O
uncommon	O
cause	O
of	O
pneumonia	I-Reason
.	O
Also	O
patient	O
was	O
found	O
to	O
have	O
DVT	O
's	O
as	O
described	O
elsewhere	O
,	O
which	O
were	O
treated	O
in	O
hopes	O
of	O
helping	O
hypoxia	I-Reason
.	O
Patient	O
received	O
levalbuterol	I-Drug
and	O
ipratroprium	I-Drug
nebulizers	O
.	O
Eventually	O
a	O
bronchoscopy	O
was	O
done	O
and	O
did	O
not	O
show	O
evidence	O
of	O
pulmonary	O
hemorrhage	O
.	O
However	O
,	O
the	O
patient	O
's	O
oxygenation	O
became	O
more	O
and	O
more	O
problem	O
[	O
**	O
Name	O
(	O
NI	O
)	O
115	O
**	O
]	O
and	O
she	O
was	O
intubated	O
for	O
hypoxemic	O
respiratory	O
failure	O
.	O
Her	O
ventilator	O
requirements	O
continued	O
to	O
escalate	O
.	O
Intracranial	B-Ade
hemorrage	I-Ade
:	O
While	O
on	O
a	O
heparin	I-Drug
drip	O
for	O
DVT	I-Reason
,	O
the	O
patient	O
was	O
noted	O
to	O
have	O
anisocoria	O
.	O
Head	O
CT	O
revealed	O
large	O
parenchymal	O
hemorrhage	O
apparently	O
centered	O
in	O
the	O
right	O
corona	O
radiata	O
or	O
that	O
caudate	O
nucleus	O
,	O
with	O
transependymal	O
dissection	O
into	O
both	O
lateral	O
ventricles	O
,	O
and	O
the	O
third	O
and	O
fourth	O
ventricles	O
.	O
The	O
patient	O
's	O
poor	O
prognosis	O
was	O
explained	O
to	O
her	O
family	O
.	O
The	O
decision	O
was	O
made	O
to	O
pursue	O
comfort	O
measures	O
only	O
.	O
Deep	O
Vein	O
Thromboses	O
:	O
On	O
presentation	O
given	O
patient	O
's	O
refractory	O
hypoxia	O
an	O
lack	O
of	O
good	O
options	O
decision	O
was	O
made	O
to	O
pursue	O
some	O
work	O
up	O
for	O
VTE	O
given	O
she	O
was	O
thought	O
to	O
be	O
too	O
unstable	O
for	O
CT	O
Scan	O
but	O
this	O
could	O
contribute	O
to	O
hypoxia	O
.	O
Lower	O
extremity	O
ultrasounds	O
revealed	O
DVT	I-Reason
and	O
she	O
was	O
started	O
on	O
heparin	I-Drug
gtt	O
.	O
Presumably	O
,	O
DVT	O
's	O
were	O
developed	O
during	O
OSH	O
course	O
after	O
warfarin	I-Drug
was	O
stopped	O
.	O
Atrial	B-Reason
fibrillation	I-Reason
:	O
Patient	O
was	O
well	O
rate	O
controlled	O
at	O
arrival	O
on	O
dilt	I-Drug
90	O
QID	O
,	O
metoprolol	I-Drug
tartrate	O
50	O
TID	O
and	O
dig	I-Drug
,	O
given	O
some	O
pauses	O
(	O
2	O
-	O
2.5	O
seconds	O
)	O
on	O
the	O
night	O
after	O
admission	O
and	O
generally	O
good	O
rate	O
control	O
.	O
Later	O
in	O
her	O
course	O
her	O
rate	B-Reason
became	I-Reason
more	O
rapid	O
and	O
she	O
briefly	O
requiring	O
diltiazem	I-Drug
gtt	O
.	O
Heparin	I-Drug
drip	O
was	O
continued	O
as	O
above	O
.	O
CAD	I-Reason
,	O
Cardiomyopathy	O
:	O
Patient	O
had	O
an	O
EF	O
of	O
30	O
with	O
a	O
cardiac	O
contusion	O
per	O
past	O
reports	O
but	O
now	O
normalized	O
to	O
55	O
.	O
Echo	O
showed	O
normal	O
biventricular	O
cavity	O
sizes	O
with	O
preserved	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function	O
and	O
biatrial	O
enlargement	O
.	O
Pulmonary	O
artery	O
systolic	O
hypertensionShe	O
was	O
continued	O
on	O
her	O
aspirin	I-Drug
,	O
simvastatin	I-Drug
,	O
and	O
beta	B-Drug
blocker	I-Drug
for	O
her	O
history	O
of	O
CAD	I-Reason
.	O
.	O
Hypotension	I-Reason
:	O
Initially	O
normotensive	O
on	O
rate	B-Drug
control	I-Drug
agents	I-Drug
.	O
Also	O
on	O
daily	O
furosemide	I-Drug
.	O
On	O
the	O
day	O
of	O
intubation	O
,	O
she	O
also	O
became	O
hypotensive	I-Ade
requiring	O
initiation	O
of	O
norepinephrine	I-Drug
.	O
Diabetes	B-Reason
Mellitus	I-Reason
Type	I-Reason
II	I-Reason
:	O
Mildly	O
hyperglycemic	I-Reason
on	O
arrival	O
.	O
On	O
oral	O
agents	O
at	O
home	O
,	O
fingersticks	O
with	O
ISS	I-Drug
at	O
OSH	O
.	O
SS	O
insulin	I-Drug
was	O
continued	O
.	O
.	O
Code	O
status	O
:	O
initially	O
full	O
,	O
later	O
comfort	O
measures	O
only	O
Medications	O
on	O
Admission	O
:	O
-	O
Metformin	I-Drug
1000	O
mg	O
PO	O
BID	O
-	O
Zocor	I-Drug
10	O
mg	O
PO	O
QHS	O
-	O
Aspirin	I-Drug
81	O
mg	O
PO	O
daily	O
-	O
Amiodarone	I-Drug
200	O
mg	O
PO	O
daily	O
-	O
Warfarin	I-Drug
3	O
mg	O
alternating	O
with	O
6	O
mg	O
PO	O
daily	O
-	O
Amlodipine	I-Drug
10	O
mg	O
PO	O
daily	O
-	O
Ca	B-Drug
+	I-Drug
+	I-Drug
/	I-Drug
Vit	I-Drug
D	I-Drug
-	O
HCTZ	I-Drug
25	O
mg	O
PO	O
daily	O
-	O
Glimepiride	I-Drug
2	O
mg	O
PO	O
daily	O
-	O
Metoprolol	I-Drug
50	O
mg	O
PO	O
BID	O
-	O
Prilosec	I-Drug
20	O
mg	O
PO	O
BID	O
.	O
Meds	O
on	O
transfer	O
:	O
simvastatin	I-Drug
10	O
mg	O
PO	O
QHS	O
senna	I-Drug
10	O
ml	O
PO	O
QHS	O
Aspirin	I-Drug
325	O
po	O
daily	O
docusate	I-Drug
100	O
mg	O
po	O
BID	O
guaifenesin	I-Drug
1200	O
mg	O
PO	O
BID	O
omeprazole	B-Drug
40	O
mg	O
PO	O
BID	O
digoxin	I-Drug
0.25	O
po	O
daily	O
diltiazem	I-Drug
90	O
po	O
q6H	O
metoprolol	I-Drug
50	O
mg	O
po	O
tid	O
SCH	I-Drug
5000	O
units	O
Q8	O
insulin	B-Drug
glargine	I-Drug
10	O
units	O
daily	O
&	O
SS	O
levalbuterol	I-Drug
NEB	O
QID	O
methylprednisolone	I-Drug
40	O
mg	O
IV	O
daily	O
ipratropium	I-Drug
neb	O
QID	O
furosemide	B-Drug
40	O
mg	O
iv	O
daily	O
acetaminophen	I-Drug
650	O
mg	O
PO	O
Q4H	O
prn	O
polyethylene	B-Drug
glycol	I-Drug
po	O
daily	O
diphenhydramine	B-Drug
25	O
mg	O
PO	O
HS	O
MR1	O
PRN	O
metoclopramide	I-Drug
10	O
mg	O
IV	O
Q6H	O
PRN	O
ondansetron	B-Drug
4	O
mg	O
IV	O
Q6H	O
PRN	O
metoprolol	I-Drug
5	O
mg	O
IV	O
Q6H	O
PRN	O
bisacodyl	B-Drug
10	O
mg	O
PR	O
daily	O
PRN	O
lorazepam	I-Drug
1	O
mg	O
IV	O
Q6H	O
PRN	O
morphine	I-Drug
2	O
mg	O
IV	O
Q4H	O
PRN	O
miconazole	I-Drug
topical	O
TID	O
PRN	O
Discharge	O
Medications	O
:	O
expired	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
respiratory	O
failure	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
expired	O
Followup	O
Instructions	O
:	O
expired	O
Completed	O
by	O
:[	O
**	O
2183-10-17	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2167-10-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2167-11-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2101-2-24	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Chromium	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2777	O
**	O
]	O
Chief	O
Complaint	O
:	O
AAA	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
[	O
**	O
10	O
-	O
27	O
**	O
]	O
:	O
OPERATION	O
PERFORMED	O
:	O
Open	O
repair	O
of	O
abdominal	O
aortic	O
aneurysm	O
and	O
bilateral	O
common	O
iliac	O
artery	O
aneurysms	O
with	O
a	O
Dacron	O
20	O
x	O
10	O
bifurcated	O
graft	O
as	O
well	O
as	O
a	O
bypass	O
to	O
the	O
left	O
renal	O
artery	O
.	O
[	O
**	O
10	O
-	O
29	O
**	O
]	O
:	O
Operation	O
Performed	O
:	O
Flexible	O
colonoscopy	O
to	O
60	O
cm	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
66	O
-	O
year	O
-	O
old	O
gentleman	O
who	O
has	O
a	O
known	O
large	O
abdominal	O
aortic	O
aneurysm	O
.	O
It	O
has	O
now	O
grown	O
to	O
8	O
cm	O
in	O
size	O
.	O
He	O
has	O
multiple	O
comorbidities	O
;	O
however	O
,	O
he	O
has	O
been	O
cleared	O
for	O
surgery	O
by	O
cardiology	O
after	O
cardiac	O
catheterization	O
.	O
He	O
has	O
a	O
suprarenal	O
abdominal	O
aortic	O
aneurysm	O
which	O
is	O
notamenable	O
to	O
endovascular	O
repair	O
.	O
he	O
has	O
a	O
single	O
kidney	O
(	O
left	O
)	O
with	O
a	O
stent	O
in	O
the	O
origin	O
which	O
comes	O
off	O
the	O
aneurysm	O
and	O
will	O
require	O
bypass	O
.	O
In	O
addition	O
,	O
he	O
has	O
bilateral	O
common	O
iliac	O
artery	O
aneurysms	O
with	O
a	O
very	O
large	O
(	O
5	O
cm	O
)	O
right	O
common	O
iliac	O
aneurysm	O
which	O
will	O
require	O
extension	O
of	O
the	O
graft	O
into	O
the	O
iliac	O
bifurcation	O
.	O
Given	O
his	O
risk	O
for	O
rupture	O
,	O
the	O
patient	O
was	O
consented	O
for	O
an	O
open	O
aneurysm	O
repair	O
Past	O
Medical	O
History	O
:	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
CAD	O
RISK	O
FACTORS	O
:	O
DM2	O
,	O
HTN	O
,	O
dyslipidemia	O
,	O
CAD	O
,	O
smoking	O
2	O
.	O
CARDIAC	O
HISTORY	O
:	O
-	O
CABG	O
:	O
none	O
-	O
PERCUTANEOUS	O
CORONARY	O
INTERVENTIONS	O
:	O
none	O
-	O
PACING	O
/	O
ICD	O
:	O
none	O
3	O
.	O
OTHER	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
-	O
50	O
+	O
pack	O
year	O
history	O
of	O
smoking	O
-	O
CRI	O
-	O
RAS	O
s	O
/	O
p	O
L	O
stenting	O
07	O
,	O
right	O
kidney	O
atretic	O
-	O
severe	O
COPD	O
-	O
obesity	O
-	O
back	O
surgery	O
-	O
abdominal	O
aneurysm	O
-	O
CT	O
angiogram	O
performed	O
in	O
[	O
**	O
2167-9-20	O
**	O
]	O
showed	O
the	O
size	O
to	O
be	O
8	O
cm	O
.	O
His	O
descending	O
thoracic	O
aort	O
is	O
also	O
enlarged	O
(	O
less	O
than	O
5	O
cm	O
)	O
,	O
and	O
the	O
right	O
common	O
iliac	O
artery	O
was	O
aneurysmal	O
(	O
5	O
cm	O
)	O
with	O
left	O
common	O
iliac	O
smaller	O
(	O
3	O
cm	O
)	O
aneurysm	O
.	O
Of	O
note	O
,	O
the	O
abdominal	O
aortic	O
aneurysm	O
is	O
pararenal	O
and	O
extends	O
to	O
the	O
left	O
renal	O
artery	O
(	O
which	O
had	O
been	O
stented	O
in	O
[	O
**	O
2165-2-17	O
**	O
]	O
)	O
.	O
Social	O
History	O
:	O
The	O
patient	O
in	O
married	O
and	O
lives	O
with	O
his	O
wife	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
is	O
retired	O
.	O
Smokes	O
1	O
ppd	O
and	O
has	O
done	O
so	O
for	O
over	O
50	O
years	O
.	O
He	O
denies	O
alcohol	O
or	O
recreational	O
drugs	O
.	O
He	O
does	O
not	O
exercise	O
and	O
has	O
no	O
dietary	O
restrictions	O
.	O
Family	O
History	O
:	O
significant	O
for	O
heart	O
disease	O
.	O
Negative	O
for	O
stroke	O
and	O
diabetes	O
Physical	O
Exam	O
:	O
PE	O
:	O
AFVSS	O
NEURO	O
:	O
PERRL	O
/	O
EOMI	O
MAE	O
equally	O
Answers	O
simple	O
commands	O
Neg	O
pronator	O
drift	O
Sensation	O
intact	O
to	O
ST	O
2	O
plus	O
DTR	O
Neg	O
Babinski	O
HEENT	O
:	O
NCAT	O
Neg	O
lesions	O
nares	O
,	O
oral	O
pharnyx	O
,	O
auditory	O
Supple	O
/	O
FAROM	O
neg	O
lyphandopathy	O
,	O
supra	O
clavicular	O
nodes	O
LUNGS	O
:	O
CTA	O
b	O
/	O
l	O
CARDIAC	O
:	O
RRR	O
without	O
murmers	O
ABDOMEN	O
:	O
Obese	O
,	O
Soft	O
,	O
NTTP	O
,	O
ND	O
,	O
pos	O
BS	O
,	O
neg	O
CVA	O
tenderness	O
EXT	O
:	O
rle	O
-	O
palp	O
fem	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
pt	O
,	O
dp	O
lle	O
-	O
palp	O
fem	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
pt	O
,	O
dp	O
Pertinent	O
Results	O
:	O
[	O
**	O
2167-11-8	O
**	O
]	O
04:07	O
AM	O
BLOOD	O
WBC	O
-	O
9.6	O
RBC	O
-	O
3.48	O
*	O
Hgb	O
-	O
10.1	O
*	O
Hct	O
-	O
29.3	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
29.1	O
MCHC	O
-	O
34.6	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
388	O
[	O
**	O
2167-11-6	O
**	O
]	O
05:42	O
AM	O
BLOOD	O
PT	O
-	O
14.5	O
*	O
PTT	O
-	O
26.2	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2167-11-10	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
Glucose	O
-	O
95	O
UreaN	O
-	O
42	O
*	O
Creat	O
-	O
2.1	O
*	O
Na	O
-	O
139	O
K	O
-	O
3.3	O
Cl	O
-	O
101	O
HCO3	O
-	O
24	O
AnGap	O
-	O
17	O
[	O
**	O
2167-11-10	O
**	O
]	O
06:05	O
AM	O
BLOOD	O
Calcium	O
-	O
7.9	O
*	O
Phos	O
-	O
3.3	O
Mg	O
-	O
1.7	O
[	O
**	O
2167-10-30	O
**	O
]	O
12:47	O
PM	O
URINE	O
Hours	O
-	O
RANDOM	O
UreaN	O
-	O
340	O
Creat	O
-	O
47	O
Na	O
-	O
89	O
URINE	O
Hours	O
-	O
RANDOM	O
URINE	O
Osmolal	O
-	O
380	O
URINE	O
Uhold	O
-	O
HOLD	O
RENAL	O
US	O
:	O
FINDINGS	O
:	O
The	O
right	O
kidney	O
is	O
noted	O
to	O
be	O
atrophic	O
measuring	O
only	O
8.0	O
cm	O
.	O
No	O
vascular	O
flow	O
is	O
identified	O
in	O
the	O
right	O
kidney	O
and	O
color	O
Doppler	O
imaging	O
.	O
The	O
left	O
kidney	O
measures	O
15.2	O
cm	O
.	O
There	O
is	O
no	O
hydronephrosis	O
.	O
No	O
cyst	O
or	O
stone	O
or	O
solid	O
mass	O
is	O
seen	O
in	O
the	O
left	O
kidney	O
.	O
DOPPLER	O
EXAMINATION	O
:	O
Color	O
Doppler	O
and	O
pulse	O
-	O
wave	O
Doppler	O
images	O
were	O
obtained	O
from	O
the	O
left	O
kidney	O
only	O
.	O
Note	O
is	O
made	O
that	O
this	O
is	O
a	O
limited	O
Doppler	O
study	O
due	O
to	O
the	O
portable	O
technique	O
and	O
the	O
patient	O
's	O
body	O
habitus	O
.	O
Arterial	O
flow	O
is	O
documented	O
within	O
the	O
left	O
main	O
renal	O
artery	O
,	O
but	O
can	O
not	O
be	O
further	O
assessed	O
.	O
Venous	O
flow	O
is	O
seen	O
in	O
the	O
main	O
renal	O
vein	O
.	O
Resistive	O
indices	O
are	O
mildly	O
elevated	O
measuring	O
80	O
,	O
79	O
,	O
and	O
73	O
.	O
IMPRESSION	O
:	O
1	O
.	O
Arterial	O
and	O
venous	O
flow	O
identified	O
within	O
the	O
left	O
kidney	O
with	O
mildly	O
elevated	O
resistive	O
indices	O
in	O
the	O
intraparenchymal	O
arteries	O
.	O
No	O
further	O
assessment	O
can	O
be	O
made	O
at	O
the	O
main	O
renal	O
artery	O
due	O
to	O
the	O
limited	O
nature	O
of	O
this	O
portable	O
technique	O
and	O
the	O
patient	O
's	O
body	O
habitus	O
.	O
2	O
.	O
Atrophic	O
right	O
kidney	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
17353	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
was	O
admitted	O
on	O
[	O
**	O
10	O
-	O
27	O
**	O
]	O
with	O
AAA	O
.	O
He	O
agreed	O
to	O
have	O
an	O
elective	O
surgery	O
.	O
Pre-operatively	O
,	O
he	O
was	O
consented	O
.	O
A	O
CXR	O
,	O
EKG	O
,	O
UA	O
,	O
CBC	O
,	O
Electrolytes	O
,	O
T	O
/	O
S	O
-	O
were	O
obtained	O
,	O
all	O
other	O
preparations	O
were	O
made	O
.	O
It	O
was	O
decided	O
that	O
she	O
would	O
undergo	O
a	O
:	O
Open	O
repair	O
of	O
abdominal	O
aortic	O
aneurysm	O
and	O
bilateral	O
common	O
iliac	O
artery	O
aneurysms	O
with	O
a	O
Dacron	O
20	O
x	O
10	O
bifurcated	O
graft	O
as	O
well	O
as	O
a	O
bypass	O
to	O
the	O
left	O
renal	O
artery	O
.	O
He	O
was	O
prepped	O
,	O
and	O
brought	O
down	O
to	O
the	O
operating	O
room	O
for	O
surgery	O
.	O
Intra-operatively	O
,	O
he	O
was	O
closely	O
monitored	O
and	O
remained	O
hemodynamically	O
stable	O
.	O
He	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
difficulty	O
or	O
complication	O
.	O
He	O
was	O
transferred	O
to	O
the	O
CVICU	O
for	O
further	O
care	O
.	O
He	O
had	O
a	O
prolong	O
intubation	O
.	O
[	O
**	O
2167-10-27	O
**	O
]	O
-	O
[	O
**	O
2167-11-5	O
**	O
]	O
.	O
He	O
received	O
mo	O
niter	O
care	O
and	O
pressure	O
support	O
.	O
During	O
this	O
time	O
frame	O
pt	O
had	O
ATN	O
.	O
His	O
nephrotoxic	B-Drug
drugs	I-Drug
were	O
held	O
.	O
He	O
received	O
PRBC	I-Drug
for	O
hypotension	I-Reason
and	O
volume	B-Reason
support	I-Reason
.	O
His	O
baseline	O
creatinine	O
was	O
1.6	O
,	O
High	O
4.6	O
,	O
now	O
2.1	O
.	O
All	O
his	O
home	O
meds	O
were	O
restarted	O
.	O
He	O
always	O
maintained	O
good	O
urine	O
output	O
.	O
Pr	O
also	O
had	O
Bowel	O
movements	O
in	O
the	O
immediate	O
post	O
operative	O
period	O
.	O
transplant	O
was	O
called	O
.	O
Had	O
mucosal	O
sloughing	O
.	O
His	O
lactate	O
was	O
normal	O
.	O
This	O
is	O
assumed	O
resolved	O
.	O
Pt	O
had	O
hypernatremia	O
to	O
147	O
.	O
This	O
resolved	O
with	O
fluids	I-Drug
.	O
After	O
he	O
was	O
extubated	O
he	O
was	O
then	O
transferred	O
to	O
the	O
VICU	O
for	O
further	O
recovery	O
.	O
While	O
in	O
the	O
VICU	O
he	O
received	O
monitored	O
care	O
.	O
When	O
stable	O
he	O
was	O
delined	O
.	O
His	O
diet	O
was	O
advanced	O
.	O
A	O
PT	O
consult	O
was	O
obtained	O
.	O
When	O
he	O
was	O
stabilized	O
from	O
the	O
acute	O
setting	O
of	O
post	O
operative	O
care	O
,	O
he	O
was	O
transferred	O
to	O
floor	O
status	O
On	O
the	O
floor	O
,	O
he	O
remained	O
hemodynamically	O
stable	O
with	O
his	O
pain	O
controlled	O
.	O
He	O
progressed	O
with	O
physical	O
therapy	O
to	O
improve	O
her	O
strength	O
and	O
mobility	O
.	O
He	O
continues	O
to	O
make	O
steady	O
progress	O
without	O
any	O
incidents	O
.	O
He	O
was	O
discharged	O
to	O
a	O
rehabilitation	O
facility	O
in	O
stable	O
condition	O
.	O
To	O
note	O
his	O
staples	O
were	O
removed	O
on	O
DC	O
.	O
Steri	O
strips	O
are	O
in	O
place	O
.	O
PT	O
HAS	O
RUL	O
OPACITY	O
ON	O
CXR	O
.	O
HE	O
NEEDS	O
TO	O
HAVE	O
THIS	O
WORKED	O
UP	O
.	O
HE	O
NEEDS	O
A	O
CT	O
SCAN	O
OF	O
CHEST	O
.	O
THIS	O
SHOULD	O
BE	O
DONE	O
BY	O
HIS	O
PCP	O
.	O
Medications	O
on	O
Admission	O
:	O
ATENOLOL	I-Drug
25	O
'	O
,	O
FUROSEMIDE	I-Drug
20	O
'	O
,	O
LISINOPRIL	I-Drug
10	O
'	O
,	O
LORAZEPAM	I-Drug
1	O
'	O
,	O
METFORMIN	I-Drug
850	O
"	O
,	O
PAROXETINE	I-Drug
20	O
'	O
,	O
CRESTOR	I-Drug
20	O
'	O
,	O
ASPIRIN	I-Drug
81	O
'	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Rosuvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
4	O
.	O
Furosemide	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Lisinopril	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
6	O
.	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Metformin	I-Drug
850	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
8	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
9	O
.	O
Potassium	B-Drug
Chloride	I-Drug
20	O
mEq	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
please	O
hold	O
for	O
k	O
greater	O
then	O
4.5	O
.	O
10	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
:	O
prn	O
.	O
11	O
.	O
Paroxetine	I-Drug
HCl	O
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Insulin	I-Drug
Insulin	I-Drug
SC	O
Sliding	O
Scale	O
Fingerstick	O
QACHS	O
Insulin	I-Drug
SC	O
Sliding	O
Scale	O
Breakfast	O
Lunch	O
Dinner	O
Bedtime	O
Regular	O
Glucose	O
Insulin	I-Drug
Dose	O
0	O
-	O
70	O
mg	O
/	O
dL	O
Proceed	O
with	O
hypoglycemia	O
protocol	O
71	O
-	O
150	O
mg	O
/	O
dL	O
0	O
Units	O
0	O
Units	O
0	O
Units	O
0	O
Units	O
151	O
-	O
200	O
mg	O
/	O
dL	O
2	O
Units	O
2	O
Units	O
2	O
Units	O
2	O
Units	O
201	O
-	O
250	O
mg	O
/	O
dL	O
4	O
Units	O
4	O
Units	O
4	O
Units	O
4	O
Units	O
251	O
-	O
300	O
mg	O
/	O
dL	O
6	O
Units	O
6	O
Units	O
6	O
Units	O
6	O
Units	O
301	O
-	O
350	O
mg	O
/	O
dL	O
8	O
Units	O
8	O
Units	O
8	O
Units	O
8	O
Units	O
351	O
-	O
400	O
mg	O
/	O
dL	O
10	O
Units	O
10	O
Units	O
10	O
Units	O
10	O
Units	O
>	O
400	O
mg	O
/	O
dL	O
Notify	O
M.D.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7665	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
AAA	O
Acute	O
Renal	O
failure	O
secondary	O
to	O
blood	O
loss	O
and	O
hypotension	O
Mucosal	O
sloughing	O
,	O
flex	O
sig	O
RUL	O
mass	O
,	O
Needs	O
outpt	O
CT	O
scan	O
from	O
PCP	O
hypotension	B-Reason
from	I-Reason
blood	I-Reason
loss	I-Reason
requiring	O
PRBC	I-Drug
Hypernatremia	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
Discharge	O
Instructions	O
:	O
Division	O
of	O
Vascular	O
and	O
Endovascular	O
Surgery	O
Abdominal	O
Aortic	O
Aneurysm	O
(	O
AAA	O
)	O
Surgery	O
Discharge	O
Instructions	O
What	O
to	O
expect	O
when	O
you	O
go	O
home	O
or	O
Rehab	O
:	O
1	O
.	O
It	O
is	O
normal	O
to	O
feel	O
weak	O
and	O
tired	O
,	O
this	O
will	O
last	O
for	O
[	O
**	O
4	O
-	O
27	O
**	O
]	O
weeks	O
??????	O
You	O
should	O
get	O
up	O
out	O
of	O
bed	O
every	O
day	O
and	O
gradually	O
increase	O
your	O
activity	O
each	O
day	O
??????	O
You	O
may	O
walk	O
and	O
you	O
may	O
go	O
up	O
and	O
down	O
stairs	O
??????	O
Increase	O
your	O
activities	O
as	O
you	O
can	O
tolerate	O
-	O
do	O
not	O
do	O
too	O
much	O
right	O
away	O
!	O
2	O
.	O
It	O
is	O
normal	O
to	O
have	O
incisional	O
and	O
leg	O
swelling	O
:	O
??????	O
Wear	O
loose	O
fitting	O
pants	O
/	O
clothing	O
(	O
this	O
will	O
be	O
less	O
irritating	O
to	O
incision	O
)	O
??????	O
Elevate	O
your	O
legs	O
above	O
the	O
level	O
of	O
your	O
heart	O
(	O
use	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
pillows	O
or	O
a	O
recliner	O
)	O
every	O
2	O
-	O
3	O
hours	O
throughout	O
the	O
day	O
and	O
at	O
night	O
??????	O
Avoid	O
prolonged	O
periods	O
of	O
standing	O
or	O
sitting	O
without	O
your	O
legs	O
elevated	O
3	O
.	O
It	O
is	O
normal	O
to	O
have	O
a	O
decreased	O
appetite	O
,	O
your	O
appetite	O
will	O
return	O
with	O
time	O
??????	O
You	O
will	O
probably	O
lose	O
your	O
taste	O
for	O
food	O
and	O
lose	O
some	O
weight	O
??????	O
Eat	O
small	O
frequent	O
meals	O
??????	O
It	O
is	O
important	O
to	O
eat	O
nutritious	O
food	O
options	O
(	O
high	O
fiber	O
,	O
lean	O
meats	O
,	O
vegetables	O
/	O
fruits	O
,	O
low	O
fat	O
,	O
low	O
cholesterol	O
)	O
to	O
maintain	O
your	O
strength	O
and	O
assist	O
in	O
wound	O
healing	O
??????	O
To	O
avoid	O
constipation	O
:	O
eat	O
a	O
high	O
fiber	O
diet	O
and	O
use	O
stool	O
softener	O
while	O
taking	O
pain	O
medication	O
What	O
activities	O
you	O
can	O
and	O
can	O
not	O
do	O
:	O
??????	O
No	O
driving	O
until	O
post-op	O
visit	O
and	O
you	O
are	O
no	O
longer	O
taking	O
pain	B-Drug
medications	I-Drug
??????	O
You	O
should	O
get	O
up	O
every	O
day	O
,	O
get	O
dressed	O
and	O
walk	O
,	O
gradually	O
increasing	O
your	O
activity	O
??????	O
You	O
may	O
up	O
and	O
down	O
stairs	O
,	O
go	O
outside	O
and	O
/	O
or	O
ride	O
in	O
a	O
car	O
??????	O
Increase	O
your	O
activities	O
as	O
you	O
can	O
tolerate	O
-	O
do	O
not	O
do	O
too	O
much	O
right	O
away	O
!	O
??????	O
No	O
heavy	O
lifting	O
,	O
pushing	O
or	O
pulling	O
(	O
greater	O
than	O
5	O
pounds	O
)	O
until	O
your	O
post	O
op	O
visit	O
??????	O
You	O
may	O
shower	O
(	O
let	O
the	O
soapy	O
water	O
run	O
over	O
incision	O
,	O
rinse	O
and	O
pat	O
dry	O
)	O
??????	O
Your	O
incision	O
may	O
be	O
left	O
uncovered	O
,	O
unless	O
you	O
have	O
small	O
amounts	O
of	O
drainage	O
from	O
the	O
wound	O
,	O
then	O
place	O
a	O
dry	O
dressing	O
over	O
the	O
area	O
that	O
is	O
draining	O
,	O
as	O
needed	O
??????	O
Take	O
all	O
the	O
medications	O
you	O
were	O
taking	O
before	O
surgery	O
,	O
unless	O
otherwise	O
directed	O
??????	O
Take	O
one	O
full	O
strength	O
(	O
325	O
mg	O
)	O
enteric	I-Drug
coated	O
aspirin	O
daily	O
,	O
unless	O
otherwise	O
directed	O
??????	O
Call	O
and	O
schedule	O
an	O
appointment	O
to	O
be	O
seen	O
in	O
2	O
weeks	O
for	O
staple	O
/	O
suture	O
removal	O
What	O
to	O
report	O
to	O
office	O
:	O
??????	O
Redness	O
that	O
extends	O
away	O
from	O
your	O
incision	O
??????	O
A	O
sudden	O
increase	O
in	O
pain	O
that	O
is	O
not	O
controlled	O
with	O
pain	I-Drug
medication	O
??????	O
A	O
sudden	O
change	O
in	O
the	O
ability	O
to	O
move	O
or	O
use	O
your	O
leg	O
or	O
the	O
ability	O
to	O
feel	O
your	O
leg	O
??????	O
Temperature	O
greater	O
than	O
101.5	O
F	O
for	O
24	O
hours	O
??????	O
Bleeding	O
from	O
incision	O
??????	O
New	O
or	O
increased	O
drainage	O
from	O
incision	O
or	O
white	O
,	O
yellow	O
or	O
green	O
drainage	O
from	O
incisions	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3469	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2625	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2167-11-25	O
**	O
]	O
2:15	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2908	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2168-7-28	O
**	O
]	O
4:00	O
PCP	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
17354	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
17355	O
**	O
]	O
.	O
You	O
should	O
mnake	O
an	O
appointment	O
with	O
her	O
ASAP	O
.	O
You	O
need	O
a	O
ct	O
scan	O
of	O
your	O
chest	O
to	O
follow	O
-	O
up	O
on	O
a	O
lung	O
mass	O
.	O
This	O
was	O
a	O
incidental	O
finding	O
.	O
Completed	O
by	O
:[	O
**	O
2167-11-10	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2153-7-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2153-8-1	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2074-11-10	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1481	O
**	O
]	O
Chief	O
Complaint	O
:	O
Abdominal	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
78	O
y	O
/	O
o	O
F	O
with	O
h	O
/	O
o	O
atrial	B-Reason
fibrillation	I-Reason
on	O
coumadin	I-Drug
and	O
h	O
/	O
o	O
of	O
GIST	O
s	O
/	O
p	O
excision	O
and	O
partial	O
gastrectomy	O
in	O
[	O
**	O
2143	O
**	O
]	O
who	O
later	O
developed	O
local	O
recurrence	O
and	O
omental	O
metastasis	O
s	O
/	O
p	O
resection	O
of	O
omental	O
mass	O
in	O
[	O
**	O
3	O
-	O
/	O
2153	O
**	O
]	O
and	O
now	O
presents	O
today	O
with	O
3	O
day	O
history	O
of	O
dull	O
epigastric	O
abdominal	O
pain	O
.	O
Pt	O
had	O
CT	O
scan	O
at	O
OSH	O
showing	O
intraperitoneal	O
bleeding	O
and	O
pt	O
was	O
subsequently	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
.	O
At	O
OSH	O
,	O
pt	O
had	O
BP	O
in	O
90s	O
,	O
hct	O
23.5	O
and	O
inr	O
4.0	O
.	O
Pt	O
denies	O
fevers	O
,	O
chills	O
,	O
nausea	O
/	O
vomiting	O
,	O
or	O
diarrhea	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
CARDIAC	O
RISK	O
FACTORS	O
:	O
Diabetes	O
,	O
Dyslipidemia	O
,	O
Hypertension	O
2	O
.	O
CARDIAC	O
HISTORY	O
:	O
-	O
.	O
Paroxysmal	B-Reason
Atrial	I-Reason
Fibrillation	I-Reason
on	O
coumadin	I-Drug
-	O
.	O
Heart	O
Failure	O
with	O
preserved	O
EF	O
-	O
CABG	O
:	O
none	O
-	O
PERCUTANEOUS	O
CORONARY	O
INTERVENTIONS	O
:	O
none	O
-	O
PACING	O
/	O
ICD	O
:	O
none	O
3	O
.	O
OTHER	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
.	O
1	O
.	O
CVA	O
in	O
[	O
**	O
2136	O
**	O
]	O
2	O
.	O
TIA	O
in	O
[	O
**	O
2138	O
**	O
]	O
3	O
.	O
Hypertension	O
4	O
.	O
Hypothyroidism	O
5	O
.	O
Abdominal	O
mass	O
-	O
GIST	I-Reason
(	O
diagnosed	O
[	O
**	O
2143	O
**	O
]	O
)	O
s	O
/	O
p	O
surgery	O
,	O
on	O
Gleevec	I-Drug
therapy	O
,	O
follows	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
13754	O
**	O
]	O
in	O
Heme	O
/	O
Onc	O
.	O
.	O
PAST	O
ONCOLOGIC	O
HISTORY	O
:	O
-	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
13755	O
**	O
]	O
initially	O
presented	O
[	O
**	O
2143-9-2	O
**	O
]	O
with	O
abdominal	O
pain	O
.	O
At	O
that	O
time	O
,	O
she	O
was	O
found	O
to	O
have	O
a	O
large	O
mass	O
in	O
her	O
abdomen	O
.	O
-	O
On	O
[	O
**	O
2143-9-6	O
**	O
]	O
,	O
she	O
underwent	O
an	O
incomplete	O
resection	O
of	O
this	O
tumor	I-Reason
.	O
It	O
was	O
found	O
to	O
be	O
increasing	O
in	O
size	O
and	O
she	O
was	O
treated	O
on	O
Gleevec	I-Drug
from	O
[	O
**	O
1	O
-	O
/	O
2145	O
**	O
]	O
to	O
12	O
/	O
[	O
**	O
2146	O
**	O
]	O
.	O
At	O
that	O
time	O
,	O
she	O
stopped	O
it	O
as	O
she	O
was	O
having	O
some	O
side	O
effects	O
from	O
this	O
therapy	O
,	O
most	O
notably	O
severe	B-Ade
cramping	I-Ade
.	O
On	O
the	O
Gleevec	I-Drug
,	O
her	O
tumor	I-Reason
had	O
decreased	O
in	O
size	O
.	O
However	O
,	O
the	O
mass	I-Reason
grew	O
while	O
she	O
was	O
off	O
the	O
Gleevec	I-Drug
and	O
she	O
was	O
restarted	O
on	O
it	O
again	O
in	O
07	O
/	O
[	O
**	O
2149	O
**	O
]	O
.	O
She	O
was	O
restarted	O
at	O
200	O
mg	O
daily	O
to	O
avoid	O
issues	O
with	O
cramping	I-Ade
.	O
-	O
On	O
[	O
**	O
2151-6-29	O
**	O
]	O
she	O
had	O
a	O
CT	O
scan	O
which	O
showed	O
new	O
liver	O
lesions	O
which	O
were	O
concerning	O
.	O
An	O
ultrasound	O
was	O
obtained	O
[	O
**	O
2151-7-13	O
**	O
]	O
which	O
showed	O
these	O
lesions	O
and	O
raised	O
concern	O
for	O
metastatic	B-Reason
disease	I-Reason
.	O
-	O
She	O
was	O
increased	O
from	O
Gleevec	I-Drug
200	O
mg	O
daily	O
to	O
400	O
mg	O
daily	O
on	O
[	O
**	O
2151-9-8	O
**	O
]	O
.	O
-	O
She	O
had	O
stable	O
CT	O
scans	O
and	O
the	O
liver	O
lesions	O
were	O
determined	O
to	O
be	O
cysts	O
,	O
she	O
was	O
decreased	O
from	O
400	O
mg	O
daily	O
to	O
200	O
mg	O
daily	O
due	O
to	O
nausea	O
on	O
[	O
**	O
2152-4-5	O
**	O
]	O
.	O
-	O
CT	O
scan	O
[	O
**	O
10/2152	O
**	O
]	O
there	O
was	O
increase	O
in	O
size	O
of	O
a	O
right	O
upper	O
mesenteric	O
nodule	O
with	O
no	O
other	O
enlarging	O
disease	O
.	O
Her	O
case	O
was	O
discussed	O
previously	O
and	O
surgery	O
is	O
an	O
option	O
.	O
At	O
this	O
time	O
she	O
is	O
interested	O
in	O
trying	O
400	O
mg	O
Gleevec	I-Drug
to	O
see	O
if	O
this	O
controls	O
/	O
shrinks	O
this	O
mass	O
.	O
If	O
the	O
mass	O
continues	O
to	O
enlarge	O
she	O
would	O
consider	O
surgery	O
.	O
Social	O
History	O
:	O
Lives	O
alone	O
.	O
Has	O
2	O
daughters	O
.	O
Moved	O
from	O
[	O
**	O
Country	O
**	O
]	O
in	O
[	O
**	O
2137	O
**	O
]	O
.	O
Has	O
grandchildren	O
who	O
visit	O
her	O
.	O
-	O
Tobacco	O
history	O
:	O
negative	O
-	O
ETOH	O
:	O
negative	O
-	O
Illicit	O
drugs	O
:	O
negative	O
Family	O
History	O
:	O
No	O
family	O
history	O
of	O
cancer	O
,	O
lung	O
disease	O
or	O
heart	O
disease	O
.	O
+	O
for	O
DM	O
.	O
Physical	O
Exam	O
:	O
T	O
98	O
P	O
70	O
BP	O
112/64	O
R	O
20	O
SaO2	O
98	O
%	O
RA	O
Gen	O
:	O
no	O
acute	O
distress	O
heent	O
:	O
no	O
scleral	O
icterus	O
neck	O
:	O
supple	O
Lungs	O
:	O
clear	O
heart	O
:	O
regular	O
rate	O
and	O
rhythm	O
abd	O
:	O
soft	O
,	O
no	O
tender	O
,	O
nondistended	O
,	O
no	O
guarding	O
,	O
nonrigid	O
Extrem	O
:	O
no	O
edema	O
Pertinent	O
Results	O
:	O
[	O
**	O
2153-7-29	O
**	O
]	O
03:20	O
PM	O
BLOOD	O
WBC	O
-	O
5.9	O
RBC	O
-	O
2.63	O
*	O
#	O
Hgb	O
-	O
7.8	O
*	O
#	O
Hct	O
-	O
23.5	O
*	O
#	O
MCV	O
-	O
90	O
MCH	O
-	O
29.9	O
MCHC	O
-	O
33.4	O
RDW	O
-	O
16.6	O
*	O
Plt	O
Ct	O
-	O
215	O
[	O
**	O
2153-7-29	O
**	O
]	O
03:20	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
215	O
[	O
**	O
2153-7-29	O
**	O
]	O
03:33	O
PM	O
BLOOD	O
Hgb	O
-	O
8.1	O
*	O
calcHCT	O
-	O
24	O
[	O
**	O
2153-7-30	O
**	O
]	O
02:30	O
AM	O
BLOOD	O
Glucose	O
-	O
109	O
*	O
UreaN	O
-	O
24	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
143	O
K	O
-	O
3.6	O
Cl	O
-	O
106	O
HCO3	O
-	O
27	O
AnGap	O
-	O
14	O
[	O
**	O
2153-7-30	O
**	O
]	O
02:30	O
AM	O
BLOOD	O
WBC	O
-	O
5.6	O
RBC	O
-	O
3.03	O
*	O
Hgb	O
-	O
9.1	O
*	O
Hct	O
-	O
26.8	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
17.1	O
*	O
Plt	O
Ct	O
-	O
214	O
[	O
**	O
2153-7-30	O
**	O
]	O
06:02	O
AM	O
BLOOD	O
Hct	O
-	O
27.4	O
*	O
[	O
**	O
2153-7-31	O
**	O
]	O
03:57	O
AM	O
BLOOD	O
WBC	O
-	O
5.4	O
RBC	O
-	O
3.42	O
*	O
Hgb	O
-	O
9.9	O
*	O
Hct	O
-	O
29.8	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
16.9	O
*	O
Plt	O
Ct	O
-	O
206	O
[	O
**	O
2153-7-31	O
**	O
]	O
11:52	O
AM	O
BLOOD	O
Hct	O
-	O
25.1	O
*	O
[	O
**	O
2153-7-31	O
**	O
]	O
04:10	O
PM	O
BLOOD	O
Hct	O
-	O
28.8	O
*	O
[	O
**	O
2153-8-1	O
**	O
]	O
06:35	O
AM	O
BLOOD	O
WBC	O
-	O
4.6	O
RBC	O
-	O
3.35	O
*	O
Hgb	O
-	O
10.0	O
*	O
Hct	O
-	O
30.2	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
30.0	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
16.8	O
*	O
Plt	O
Ct	O
-	O
252	O
Brief	O
Hospital	O
Course	O
:	O
78	O
years	O
old	O
female	O
with	O
dx	O
of	O
GIST	O
tumor	O
,	O
anticoagulated	O
for	O
Afib	O
admitted	O
wth	O
intraabdominal	O
bleeding	O
on	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
Patient	O
was	O
admitted	O
to	O
SICU	O
.	O
Transfused	O
2u	O
PRBC	I-Drug
and	O
1u	O
FFP	I-Drug
.	O
Neurologic	O
:	O
-	O
Intact	O
,	O
mentating	O
well	O
.	O
Continue	O
to	O
follow	O
-	O
Adequate	O
pain	B-Reason
control	I-Reason
with	O
dilaudid	I-Drug
IV	O
PRN	O
Then	O
switched	O
to	O
Po	O
pain	B-Drug
medication	I-Drug
.	O
Cardiovascular	O
:	O
-	O
Clinically	O
stable	O
-	O
Maintain	O
SBP	O
>	O
90	O
,	O
Continous	O
monitoring	O
showed	O
heart	O
rate	O
control	O
.	O
-	O
continue	O
to	O
follow	O
Hct	O
and	O
coags	O
Pulmonary	O
:	O
-	O
Clinically	O
stable	O
,	O
breathing	O
room	O
air	O
-	O
No	O
respiratory	O
distress	O
.	O
Gastrointestinal	O
/	O
Abdomen	O
:	O
-	O
GIST	O
tumor	O
s	O
/	O
p	O
multiple	O
resections	O
with	O
blood	O
collection	O
in	O
abdomen	O
-	O
No	O
surgical	O
intervention	O
at	O
this	O
time	O
unless	O
change	O
in	O
clinical	O
picture	O
Nutrition	O
:	O
-	O
NPO	O
during	O
HD	O
1	O
and	O
2	O
.	O
The	O
restarted	O
on	O
Clears	O
on	O
HD3	O
advanced	O
to	O
regular	O
cardiac	O
healthy	O
diet	O
on	O
HD4	O
.	O
Patient	O
tolerate	O
the	O
diet	O
,	O
no	O
abdominal	O
pain	O
or	O
distention	O
.	O
Renal	O
:	O
-	O
Stable	O
.	O
Urine	O
out	O
up	O
was	O
monitored	O
with	O
foley	O
.	O
On	O
HD	O
4	O
foley	O
was	O
d	O
/	O
c	O
and	O
patient	O
voided	O
.	O
Hematology	O
:	O
-	O
Anemia	O
secondary	O
to	O
likely	O
bleeding	O
in	O
abdomen	O
-	O
INR	B-Reason
4.0	I-Reason
,	O
2uFFP	O
and	O
10	O
mg	O
vit	B-Drug
K	I-Drug
was	O
given	O
on	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
-	O
Transfused	O
2uPRBC	O
,	O
and	O
follow	O
Hct	O
which	O
remined	O
stable	O
for	O
the	O
rest	O
of	O
her	O
hospitalization	O
.	O
Endocrine	O
:	O
Insuline	I-Drug
SS	O
,	O
f	O
/	O
u	O
blood	O
sugars	O
DVT	O
profilaxis	O
with	O
pneumatic	O
boots	O
Medications	O
on	O
Admission	O
:	O
Coumadin	I-Drug
4	O
mg	O
Mon	O
Coumadin	I-Drug
3	O
mg	O
TueWedFriSatSun	O
Coumadin	I-Drug
5	O
mg	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
Metoprolol	I-Drug
25	O
mg	O
daily	O
amiodarone	I-Drug
200	O
mg	O
daily	O
levothyroxine	I-Drug
200	O
mcg	O
daily	O
istalol	I-Drug
0.5	O
%	O
1	O
drop	O
each	O
eye	O
[	O
**	O
Hospital1	O
**	O
]	O
lumigan	I-Drug
0.03	O
%	O
1	O
drop	O
each	O
eye	O
daily	O
furosemide	B-Drug
80	O
mg	O
daily	O
gleevec	I-Drug
200	O
mg	O
daily	O
CaCO3	I-Drug
650	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
cholecalciferol	I-Drug
1000	O
units	O
daily	O
januvia	I-Drug
100	O
mg	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
timolol	I-Drug
maleate	O
0.5	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
latanoprost	I-Drug
0.005	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
3	O
.	O
levothyroxine	I-Drug
100	O
mcg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Lumigan	I-Drug
0.03	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Ophthalmic	O
once	O
a	O
day	O
:	O
1	O
drop	O
.	O
5	O
.	O
furosemide	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
6	O
.	O
cholecalciferol	B-Drug
(	I-Drug
vitamin	I-Drug
D3	I-Drug
)	I-Drug
1,000	O
unit	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
once	O
a	O
day	O
.	O
7	O
.	O
sitagliptin	B-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
History	O
of	O
Atrial	B-Reason
Fibrilation	I-Reason
on	O
coumadin	I-Drug
presents	O
with	O
intraperitoneal	B-Ade
bleeding	I-Ade
from	I-Ade
GIST	I-Ade
tumors	I-Ade
in	O
setting	O
of	O
anticoagulation	I-Drug
Heart	O
Failure	O
with	O
preserved	O
EF	O
Diabetes	O
Mellitus	O
Hypercholesterolemia	O
Hypertension	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
Please	O
schedule	O
an	O
appointment	O
with	O
your	O
PCP	O
within	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
week	O
to	O
restart	O
medications	O
(	O
Coumadin	I-Drug
and	O
Gleevec	I-Drug
)	O
and	O
f	O
/	O
u	O
INR	O
.	O
Please	O
take	O
any	O
new	O
medications	O
as	O
prescribed	O
.	O
Please	O
take	O
the	O
prescribed	O
analgesic	B-Drug
medications	I-Drug
as	O
needed	O
.	O
You	O
may	O
not	O
drive	O
or	O
heavy	O
machinery	O
while	O
taking	O
narcotic	B-Drug
analgesic	I-Drug
medications	O
.	O
You	O
may	O
also	O
take	O
acetaminophen	B-Drug
(	I-Drug
Tylenol	I-Drug
)	I-Drug
as	O
directed	O
,	O
but	O
do	O
not	O
exceed	O
4000	O
mg	O
in	O
one	O
day	O
.	O
Please	O
get	O
plenty	O
of	O
rest	O
,	O
continue	O
to	O
walk	O
several	O
times	O
per	O
day	O
,	O
and	O
drink	O
adequate	O
amounts	O
of	O
fluids	O
.	O
Avoid	O
strenuous	O
physical	O
activity	O
and	O
refrain	O
from	O
heavy	O
lifting	O
greater	O
than	O
10	O
lbs.	O
,	O
until	O
you	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
,	O
who	O
will	O
instruct	O
you	O
further	O
regarding	O
activity	O
restrictions	O
.	O
Please	O
also	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
.	O
Followup	O
Instructions	O
:	O
PLease	O
schedule	O
a	O
follow	O
up	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Phone	O
number	O
:	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1483	O
**	O
]	O
Please	O
schedule	O
an	O
appointment	O
with	O
PCP	O
within	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
week	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
DENSITY	O
TESTING	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
4586	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2153-8-3	O
**	O
]	O
1:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
3150	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
11133	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2153-8-24	O
**	O
]	O
3:00	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
62	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2153-10-31	O
**	O
]	O
11:20	O
Completed	O
by	O
:[	O
**	O
2153-8-1	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2184-10-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2184-11-9	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2120-5-4	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
6169	O
**	O
]	O
Chief	O
Complaint	O
:	O
Word	O
finding	O
difficulty	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Craniotomy	O
and	O
drainage	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
a	O
64	O
y	O
/	O
o	O
male	O
with	O
a	O
h	O
/	O
o	O
AML	O
/	O
MDS	O
,	O
DM2	O
,	O
and	O
COPD	O
who	O
presented	O
to	O
clinic	O
today	O
for	O
a	O
routine	O
visit	O
with	O
a	O
complaint	O
of	O
a	O
difficulty	O
finding	O
words	O
over	O
the	O
past	O
week	O
.	O
He	O
states	O
this	O
came	O
on	O
suddenly	O
.	O
The	O
primary	O
trouble	O
is	O
with	O
finding	O
words	O
to	O
describe	O
what	O
he	O
wants	O
to	O
say	O
,	O
not	O
actually	O
articulating	O
the	O
words	O
.	O
He	O
denies	O
any	O
other	O
neurologic	O
symptoms	O
,	O
including	O
weakness	O
(	O
no	O
stumbling	O
,	O
dropping	O
items	O
)	O
,	O
loss	O
of	O
sensation	O
,	O
or	O
other	O
confusion	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
displays	O
understanding	O
of	O
his	O
current	O
situation	O
and	O
location	O
.	O
He	O
denies	O
any	O
specific	O
symptoms	O
,	O
including	O
fever	O
/	O
chills	O
,	O
headache	O
,	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
/	O
pressure	O
,	O
nausea	O
/	O
vomiting	O
,	O
diarrhea	O
/	O
constipation	O
,	O
melena	O
/	O
hematochezia	O
,	O
dysuria	O
/	O
hematuria	O
,	O
nosebleeds	O
,	O
and	O
rashes	O
.	O
Hhis	O
speech	O
prompted	O
the	O
team	O
in	O
the	O
clinic	O
to	O
investigate	O
these	O
symptoms	O
,	O
and	O
an	O
MRI	O
/	O
MRA	O
demonstrated	O
a	O
left	O
parietal	O
fluid	O
collection	O
.	O
In	O
terms	O
of	O
his	O
AML	I-Reason
,	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
treated	O
with	O
LODAC	O
in	O
[	O
**	O
2182	O
**	O
]	O
and	O
subsequent	O
to	O
that	O
has	O
been	O
on	O
hydrea	I-Drug
and	O
donazol	I-Drug
and	O
has	O
been	O
transfusion	O
dependant	O
.	O
He	O
is	O
currently	O
on	O
hydroxyurea	I-Drug
only	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
)	O
AML	O
,	O
converted	O
from	O
MDS	O
2	O
.	O
)	O
DM	O
-	O
2	O
3	O
.	O
)	O
COPD	O
Social	O
History	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
lives	O
alone	O
.	O
His	O
sister	O
lives	O
about	O
one	O
block	O
from	O
him	O
and	O
is	O
very	O
supportive	O
.	O
He	O
uses	O
[	O
**	O
Company	O
107361	O
**	O
]	O
the	O
ride	O
to	O
get	O
to	O
his	O
[	O
**	O
Hospital1	O
107362	O
**	O
]	O
clinic	O
visits	O
.	O
He	O
lived	O
in	O
[	O
**	O
State	O
15946	O
**	O
]	O
for	O
many	O
years	O
where	O
he	O
worked	O
at	O
a	O
VA.	O
.	O
He	O
also	O
has	O
worked	O
as	O
a	O
taxi	O
driver	O
.	O
He	O
smoked	O
for	O
many	O
years	O
but	O
quit	O
around	O
30	O
years	O
ago	O
.	O
Family	O
History	O
:	O
Non-contributory	O
.	O
Physical	O
Exam	O
:	O
t	O
98.4	O
,	O
bp	O
114/68	O
,	O
hr	O
88	O
,	O
rr	O
14	O
,	O
spo2	O
95	O
%	O
ra	O
gen	O
-	O
thin	O
older	O
male	O
,	O
appears	O
frustrated	O
and	O
slightly	O
confused	O
heent	O
-	O
anicteric	O
sclera	O
,	O
op	O
clear	O
with	O
mmm	O
neck	O
-	O
no	O
jvd	O
,	O
no	O
lad	O
,	O
no	O
thyromegaly	O
cv	O
-	O
rrr	O
,	O
s1s2	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
pul	O
-	O
moves	O
air	O
well	O
,	O
occasional	O
wheeze	O
,	O
no	O
rales	O
/	O
rhonchi	O
abd	O
-	O
soft	O
,	O
nt	O
,	O
nad	O
,	O
nabs	O
,	O
no	O
organomegaly	O
extrm	O
-	O
decreased	O
bulk	O
/	O
normal	O
tone	O
,	O
no	O
c	O
/	O
c	O
/	O
e	O
,	O
warm	O
dry	O
neuro	O
-	O
a	O
&	O
ox3	O
(	O
knows	O
situation	O
,	O
knows	O
having	O
trouble	O
finding	O
words	O
)	O
;	O
language	O
:	O
pt	O
has	O
naming	O
difficulties	O
,	O
can	O
not	O
find	O
name	O
for	O
pen	O
,	O
chair	O
;	O
affect	O
:	O
approriately	O
frustrated	O
;	O
cn	O
:	O
eomi	O
,	O
perrl	O
,	O
facial	O
motion	O
/	O
sensation	O
intact	O
/	O
symmetric	O
,	O
tongue	O
midline	O
and	O
without	O
fasiculations	O
;	O
motor	O
:	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
distal	O
strength	O
all	O
extrm	O
,	O
4	O
+	O
/	O
5	O
in	O
le	O
with	O
hip	O
flexion	O
,	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
LE	O
knee	O
flexion	O
/	O
extension	O
,	O
ue	O
[	O
**	O
3	O
-	O
22	O
**	O
]	O
proximal	O
strenght	O
,	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
distal	O
,	O
no	O
pronator	O
drift	O
;	O
sensation	O
intact	O
to	O
light	O
touch	O
throughout	O
;	O
reflexes	O
+2	O
and	O
symmetric	O
patellar	O
,	O
ankle	O
,	O
biceps	O
;	O
finger	O
to	O
nose	O
normal	O
,	O
rapid	O
alternating	O
movements	O
normal	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2184-10-22	O
**	O
]	O
09:05	O
AM	O
BLOOD	O
WBC	O
-	O
22.4	O
*	O
RBC	O
-	O
3.40	O
*	O
Hgb	O
-	O
10.3	O
*	O
Hct	O
-	O
30.0	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
14.1	O
Plt	O
Ct	O
-	O
6	O
*	O
#	O
[	O
**	O
2184-10-29	O
**	O
]	O
12:30	O
AM	O
BLOOD	O
WBC	O
-	O
15.5	O
*	O
RBC	O
-	O
3.20	O
*	O
Hgb	O
-	O
9.8	O
*	O
Hct	O
-	O
28.9	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
30.6	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
14.4	O
Plt	O
Ct	O
-	O
82	O
*	O
[	O
**	O
2184-11-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
WBC	O
-	O
14.9	O
*	O
RBC	O
-	O
2.87	O
*	O
Hgb	O
-	O
8.7	O
*	O
Hct	O
-	O
25.9	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
30.5	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
27	O
*	O
#	O
[	O
**	O
2184-11-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
Glucose	O
-	O
83	O
UreaN	O
-	O
29	O
*	O
Creat	O
-	O
0.5	O
Na	O
-	O
140	O
K	O
-	O
4.2	O
Cl	O
-	O
100	O
HCO3	O
-	O
34	O
*	O
AnGap	O
-	O
10	O
[	O
**	O
2184-11-9	O
**	O
]	O
05:45	O
AM	O
BLOOD	O
Calcium	O
-	O
10.2	O
Phos	O
-	O
4.6	O
*	O
Mg	O
-	O
2.3	O
Brief	O
Hospital	O
Course	O
:	O
64	O
y	O
/	O
o	O
male	O
with	O
AML	I-Reason
progressed	O
from	O
MDS	O
currently	O
being	O
treated	O
with	O
hydroxyurea	I-Drug
who	O
was	O
admitted	O
for	O
a	O
word	O
finding	O
difficulty	O
and	O
was	O
found	O
to	O
have	O
a	O
subdural	O
bleed	O
in	O
the	O
setting	O
of	O
platelets	O
of	O
six	O
.	O
1	O
.	O
)	O
Subdural	O
bleed	O
--	O
The	O
patient	O
was	O
initially	O
brought	O
up	O
to	O
a	O
platelet	O
level	O
of	O
50	O
and	O
observed	O
in	O
the	O
bone	O
marrow	O
unit	O
.	O
On	O
the	O
second	O
day	O
of	O
admission	O
,	O
he	O
experienced	O
a	O
sudden	O
,	O
severe	O
headache	O
and	O
had	O
a	O
stat	O
head	O
CT	O
,	O
showing	O
no	O
definite	O
change	O
in	O
the	O
size	O
of	O
the	O
lesion	O
or	O
the	O
degree	O
of	O
midline	O
shift	O
,	O
yet	O
due	O
to	O
his	O
symptoms	O
,	O
neurosurgery	O
was	O
consulted	O
.	O
They	O
felt	O
it	O
appropriate	O
to	O
take	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
to	O
the	O
OR	O
where	O
the	O
subdural	O
bleed	O
was	O
drained	O
;	O
subsequent	O
pathology	O
demonstrated	O
clotted	O
blood	O
.	O
He	O
was	O
kept	O
in	O
the	O
neurosurgical	O
ICU	O
for	O
two	O
days	O
where	O
he	O
did	O
well	O
with	O
no	O
post-operative	O
complications	O
and	O
was	O
then	O
sent	O
back	O
to	O
the	O
bone	O
marrow	O
unit	O
for	O
further	O
care	O
.	O
By	O
his	O
return	O
to	O
BMT	O
,	O
his	O
speech	O
and	O
confusion	O
had	O
greatly	O
improved	O
,	O
and	O
his	O
family	O
members	O
agreed	O
that	O
he	O
was	O
back	O
to	O
his	O
baseline	O
.	O
Throughout	O
the	O
remainder	O
of	O
the	O
admission	O
,	O
he	O
continued	O
to	O
experience	O
a	O
slight	O
headache	I-Reason
,	O
much	O
improved	O
from	O
admission	O
,	O
that	O
was	O
well	O
relieved	O
by	O
5	O
mg	O
of	O
oxycodone	I-Drug
.	O
His	O
word	O
-	O
finding	O
symptoms	O
did	O
not	O
recur	O
.	O
The	O
main	O
challenge	O
was	O
maintaining	O
his	O
platelets	O
at	O
a	O
an	O
appropriate	O
level	O
due	O
to	O
his	O
underlying	O
myelodysplastic	O
syndrome	O
.	O
Per	O
the	O
neurosurgery	O
team	O
,	O
his	O
goal	O
for	O
platelets	O
was	O
around	O
50	O
for	O
three	O
weeks	O
;	O
at	O
the	O
time	O
of	O
discharge	O
,	O
he	O
will	O
require	O
an	O
additional	O
week	O
of	O
platelets	O
at	O
this	O
level	O
,	O
usually	O
achievable	O
by	O
giving	O
two	O
bags	O
of	O
platelets	O
each	O
morning	O
,	O
checking	O
a	O
post	O
transfusion	O
count	O
30	O
-	O
60	O
minutes	O
thereafter	O
.	O
After	O
this	O
week	O
has	O
finished	O
,	O
he	O
will	O
be	O
maintained	O
at	O
his	O
prior	O
level	O
,	O
getting	O
transfusion	O
two	O
to	O
three	O
times	O
per	O
week	O
at	O
[	O
**	O
Hospital1	O
1388	O
**	O
]	O
hematology	O
clinic	O
under	O
the	O
care	O
of	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1557	O
**	O
]	O
.	O
He	O
will	O
follow	O
-	O
up	O
with	O
his	O
hematologist	O
,	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1557	O
**	O
]	O
,	O
for	O
his	O
AML	O
in	O
one	O
week	O
and	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
739	O
**	O
]	O
,	O
a	O
neurosurgeon	O
,	O
in	O
two	O
weeks	O
(	O
he	O
will	O
get	O
a	O
repeat	O
CT	O
scan	O
at	O
that	O
time	O
)	O
.	O
2	O
.	O
)	O
AML	I-Reason
--	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
being	O
treated	O
with	O
hydroxyurea	I-Drug
and	O
transfusions	O
as	O
needed	O
.	O
His	O
WBC	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ranged	O
between	O
12	O
and	O
28	O
,	O
generally	O
around	O
14	O
.	O
His	O
goal	O
hematocrit	O
was	O
over	O
25	O
,	O
and	O
he	O
generally	O
required	O
one	O
unit	O
of	O
packed	B-Drug
RBC	I-Drug
's	I-Drug
every	O
three	O
to	O
four	O
days	O
.	O
Platelet	O
requirements	O
have	O
been	O
described	O
above	O
.	O
3	O
.	O
)	O
Type	B-Reason
two	I-Reason
diabetes	I-Reason
--	O
The	O
prednisone	I-Drug
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
takes	O
makes	O
his	O
blood	O
sugars	O
somewhat	O
difficult	O
to	O
control	O
,	O
however	O
,	O
a	O
regimen	O
of	O
Humalog	I-Drug
75/25	O
with	O
45	O
units	O
every	O
morning	O
and	O
25	O
units	O
at	O
night	O
seemed	O
to	O
work	O
the	O
best	O
.	O
He	O
was	O
also	O
covered	O
with	O
a	O
routine	O
regular	B-Drug
insulin	I-Drug
sliding	O
scale	O
for	O
excessively	O
high	O
values	O
(	O
usually	O
starting	O
at	O
2	O
units	O
of	O
regular	I-Drug
insulin	O
for	O
a	O
glucose	O
of	O
150	O
-	O
200	O
,	O
and	O
going	O
up	O
by	O
two	O
units	O
of	O
insulin	I-Drug
for	O
every	O
50mg	O
/	O
dl	O
of	O
blood	O
glucose	O
increase	O
)	O
.	O
4	O
.	O
)	O
COPD	I-Reason
--	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
was	O
maintained	O
on	O
Advair	I-Drug
250/50	O
,	O
one	O
puff	O
twice	O
a	O
day	O
.	O
He	O
was	O
also	O
given	O
an	O
albuterol	I-Drug
inhaler	O
for	O
shortness	B-Reason
of	I-Reason
breath	O
/	O
wheezing	I-Reason
that	O
he	O
rarely	O
needed	O
.	O
He	O
became	O
wheezier	O
in	O
the	O
middle	O
of	O
the	O
admission	O
,	O
and	O
was	O
given	O
twice	O
daily	O
scheduled	O
albuterol	I-Drug
nebs	O
to	O
which	O
he	O
responded	O
well	O
.	O
We	O
would	O
recommend	O
continuing	O
these	O
for	O
two	O
more	O
days	O
,	O
then	O
stopping	O
them	O
,	O
leaving	O
him	O
on	O
only	O
Advair	I-Drug
and	O
as	O
needed	O
albuterol	I-Drug
inhalers	O
.	O
5	O
.	O
)	O
Fever	O
--	O
One	O
week	O
prior	O
to	O
discharge	O
,	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
had	O
a	O
temperature	O
to	O
101	O
.	O
His	O
blood	O
and	O
urine	O
cultures	O
were	O
negative	O
.	O
Clinically	O
and	O
radiographically	O
,	O
his	O
most	O
likely	O
source	O
was	O
pulmonary	O
,	O
although	O
the	O
chest	O
x-ray	O
did	O
not	O
demonstrate	O
an	O
obvious	O
pneumonia	I-Reason
.	O
He	O
was	O
treated	O
with	O
levofloxacin	I-Drug
,	O
and	O
will	O
finish	O
his	O
course	O
with	O
seven	O
more	O
days	O
of	O
antibiotics	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
Humalog	I-Drug
75/25	O
40	O
units	O
sc	O
every	O
AM	O
and	O
PM	O
Furosemide	I-Drug
20	O
mg	O
po	O
daily	O
Advair	I-Drug
250/50	O
one	O
puff	O
twice	O
daily	O
Hydroxyurea	I-Drug
1000	O
mg	O
po	O
once	O
daily	O
Pantoprazole	I-Drug
40	O
mg	O
po	O
daily	O
Prednisone	I-Drug
15	O
mg	O
po	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Humalog	I-Drug
Mix	O
75	O
-	O
25	O
75	O
-	O
25	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Forty	O
Five	O
(	O
45	O
)	O
Units	O
Subcutaneous	O
qAM	O
.	O
2	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Neb	O
Inhalation	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Fexofenadine	B-Drug
HCl	I-Drug
60	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Levofloxacin	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
7	O
days	O
.	O
5	O
.	O
Furosemide	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Fluticasone	B-Drug
-	I-Drug
Salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Puff	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Hydroxyurea	I-Drug
500	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
9	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Oxycodone	B-Drug
HCl	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
11	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
12	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Heparin	B-Drug
Lock	I-Drug
Flush	I-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
100	O
unit	O
/	O
mL	O
Syringe	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Ml	O
Intravenous	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
Ml	O
14	O
.	O
Humalog	B-Drug
Mix	I-Drug
75	O
-	O
25	O
75	O
-	O
25	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Twenty	O
(	O
20	O
)	O
Units	O
Subcutaneous	O
qPM	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital1	O
700	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
701	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Subdural	O
hematomoa	O
Secondary	O
:	O
Acute	O
Myelogenous	O
leukemia	O
/	O
Myelodysplastic	O
syndrome	O
Diabetes	O
--	O
type	O
two	O
COPD	O
Discharge	O
Condition	O
:	O
Fair	O
,	O
with	O
improved	O
sx	O
,	O
stable	O
hematoma	O
,	O
requiring	O
frequent	O
platelet	O
transfusions	O
.	O
Discharge	O
Instructions	O
:	O
Please	O
return	O
to	O
the	O
emergency	O
department	O
for	O
fevers	O
/	O
chills	O
,	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
severe	O
headaches	O
,	O
confusion	O
,	O
speech	O
difficulties	O
.	O
Follow	O
up	O
as	O
below	O
.	O
Take	O
medications	O
as	O
prescribed	O
.	O
Followup	O
Instructions	O
:	O
You	O
have	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
[	O
**	O
11	O
-	O
19	O
**	O
]	O
at	O
11:30	O
.	O
Please	O
call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
107363	O
**	O
]	O
for	O
questions	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
1730	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
6175	O
**	O
]	O
,	O
MD	O
Where	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
HEMATOLOGY	O
/	O
BMT	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3237	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2184-11-15	O
**	O
]	O
12:30	O
Please	O
call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
739	O
**	O
]	O
,	O
your	O
neurosurgeon	O
,	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1669	O
**	O
]	O
to	O
be	O
seen	O
in	O
two	O
weeks	O
.	O
When	O
you	O
call	O
,	O
please	O
remind	O
them	O
you	O
will	O
need	O
another	O
CT	O
-	O
scan	O
of	O
your	O
head	O
prior	O
to	O
the	O
visit	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2118-10-30	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2118-11-25	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2072-7-27	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3507	O
**	O
]	O
Chief	O
Complaint	O
:	O
Fever	O
,	O
pancytopenia	O
,	O
RUQ	O
pain	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Bone	O
Marrow	O
Biopsy	O
ERCP	O
with	O
CBD	O
stent	O
placement	O
Central	O
Line	O
/	O
HD	O
Line	O
placement	O
Intubation	O
Lumbar	O
Puncture	O
Bronchoscopy	O
History	O
of	O
Present	O
Illness	O
:	O
HPI	O
:	O
46	O
yo	O
M	O
with	O
h	O
/	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2905	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
s	B-Reason
/	I-Reason
p	I-Reason
thymectomy	I-Reason
on	O
Imuran	I-Drug
who	O
initially	O
presented	O
to	O
his	O
PCP	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
151	O
**	O
]	O
T103	O
and	O
dry	B-Reason
cough	I-Reason
treated	O
with	O
Amoxicillin	I-Drug
and	O
Augmentin	I-Drug
without	O
improvement	O
.	O
He	O
was	O
then	O
admitted	O
to	O
an	O
OSH	O
on	O
[	O
**	O
2118-10-25	O
**	O
]	O
for	O
pancytopenia	O
(	O
WBC	O
2.6	O
,	O
18	O
%	O
bands	O
,	O
plt	O
104	O
)	O
and	O
elevated	O
LFTS	O
c	O
/	O
w	O
cholestasis	O
.	O
He	O
was	O
treated	O
with	O
Azythromycin	I-Drug
and	O
Atovaquone	I-Drug
for	O
suspected	B-Reason
tick	I-Reason
borne	O
illness	O
.	O
He	O
had	O
a	O
positive	O
monospot	O
test	O
.	O
Hepatitis	O
serologies	O
were	O
negative	O
.	O
.	O
Patient	O
was	O
admitted	O
to	O
the	O
surgical	O
service	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
on	O
[	O
**	O
2118-10-30	O
**	O
]	O
for	O
persisitent	O
fever	O
and	O
an	O
elevated	O
direct	O
Tbili	O
thought	O
to	O
be	O
secondary	O
to	O
cholangitis	I-Reason
.	O
He	O
was	O
started	O
on	O
Unasyn	I-Drug
.	O
He	O
underwent	O
an	O
ERCP	O
on	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
which	O
did	O
not	O
show	O
biliary	O
tract	O
obstruction	O
,	O
however	O
,	O
a	O
CBD	O
stent	O
was	O
placed	O
.	O
He	O
was	O
transfused	O
1	O
Unit	O
of	O
PRBC	B-Drug
's	I-Drug
,	O
3	O
bags	O
of	O
FFP	I-Drug
,	O
and	O
3	O
bags	O
of	O
plts	I-Drug
.	O
.	O
Prior	O
to	O
the	O
ERCP	O
he	O
developed	O
repsiratory	O
distress	O
and	O
was	O
intubated	O
.	O
CXR	O
revealed	O
bilateral	B-Reason
patchy	I-Reason
pulmonary	I-Reason
infiltrates	I-Reason
.	O
He	O
became	O
hemodynamically	B-Reason
unstable	I-Reason
and	O
he	O
was	O
started	O
on	O
Norepi	I-Drug
gtt	O
.	O
ID	O
was	O
consulted	O
and	O
Ceftriaxone	I-Drug
/	O
Doxycyclin	I-Drug
were	O
added	O
;	O
Zosyn	I-Drug
was	O
d	O
/	O
c	O
'	O
ed	O
.	O
He	O
spiked	O
a	O
temp	O
to	O
105.3	O
.	O
He	O
was	O
transfered	O
to	O
the	O
MICU	O
on	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
for	O
further	O
managament	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
for	O
19	O
years	O
s	O
/	O
p	O
thymectomy	O
[	O
**	O
2103	O
**	O
]	O
-	O
Migraines	O
-	O
Prednisone	I-Drug
induced	O
osteoporosis	I-Ade
-	O
Low	O
back	O
Pain	O
Social	O
History	O
:	O
Has	O
a	O
girlfriend	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
a	O
14	O
yo	O
son	O
who	O
recently	O
had	O
a	O
cold	O
.	O
Lives	O
with	O
girlfirend	O
and	O
step	O
children	O
.	O
Smokes	O
and	O
drinks	O
EtOH	O
occassionally	O
.	O
No	O
hx	O
of	O
IVDU	O
.	O
Lives	O
in	O
[	O
**	O
Location	O
4310	O
**	O
]	O
near	O
a	O
swamp	O
.	O
Breakheart	O
reservation	O
is	O
2	O
miles	O
away	O
.	O
No	O
hx	O
of	O
tick	O
bites	O
.	O
Family	O
History	O
:	O
Mother	O
has	O
HTN	O
.	O
Physical	O
Exam	O
:	O
Upon	O
transfer	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
:	O
Tm	O
102.2	O
Tc	O
97.6	O
BP	O
175/92	O
(	O
108-175/52	O
-	O
92	O
)	O
HR	O
89	O
(	O
71	O
-	O
111	O
)	O
PS	O
5/0	O
FiO2	O
35	O
%	O
Vt	O
850	O
(	O
700	O
-	O
850	O
)	O
RR	O
16	O
;	O
ABG	O
7.44	O
/	O
33	O
/	O
173/23	O
Fentanyl	I-Drug
125	O
;	O
Off	O
Midaz	I-Drug
since	O
[	O
**	O
11	O
-	O
6	O
**	O
]	O
Gen	O
:	O
Sedated	O
/	O
intubated	O
,	O
appears	O
comfortable	O
on	O
ventilator	O
,	O
occasional	O
hiccups	O
HEENT	O
:	O
ET	O
tube	O
in	O
place	O
,	O
Eyes	O
with	O
lubricant	O
,	O
PERRL	O
,	O
pupils	O
pinpoint	O
CV	O
:	O
distant	O
heart	O
sounds	O
.	O
No	O
murmurs	O
appreciated	O
.	O
Resp	O
:	O
anteriorly	O
-	O
crackles	O
throughout	O
Abd	O
:	O
Soft	O
,	O
distended	O
,	O
decreased	O
BM	O
,	O
unable	O
to	O
appreciate	O
HSM	O
Skin	O
:	O
Warm	O
.	O
Well	O
Perfused	O
.	O
Ext	O
:	O
hyperreflexic	O
,	O
Spastic	O
,	O
5	O
beats	O
of	O
myoclonus	O
,	O
Toes	O
upgoing	O
,	O
strong	O
DP	O
/	O
PT	O
pulses	O
Access	O
:	O
Right	O
IJ	O
triple	O
lumen	O
placed	O
[	O
**	O
11	O
-	O
6	O
**	O
]	O
,	O
Left	O
IJ	O
temp	O
dialysis	O
cath	O
placed	O
[	O
**	O
11	O
-	O
3	O
**	O
]	O
by	O
IR	O
Pertinent	O
Results	O
:	O
Liver	O
US	O
[	O
**	O
10	O
-	O
30	O
**	O
]	O
:	O
1	O
.	O
Marked	O
gallbladder	O
wall	O
edema	O
with	O
an	O
effaced	O
,	O
non-distended	O
gallbladder	O
lumen	O
is	O
noted	O
,	O
without	O
intrahepatic	O
biliary	O
ductal	O
dilatation	O
.	O
There	O
is	O
minimal	O
pericholecystic	O
fluid	O
.	O
2	O
.	O
Dilatation	O
of	O
the	O
proximal	O
CBD	O
.	O
3	O
.	O
Prominent	O
periportal	O
lymphadenopathy	O
,	O
nonspecific	O
.	O
.	O
CxR	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
:	O
New	O
perihilar	O
pulmonary	O
edema	O
and	O
bilateral	O
pleural	O
effusions	O
.	O
.	O
ERCP	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
:	O
Ccannulation	O
of	O
the	O
common	O
bile	O
duct	O
.	O
Cholangiogram	O
demonstrates	O
a	O
normal	O
caliber	O
of	O
the	O
common	O
bile	O
duct	O
and	O
intrahepatic	O
ducts	O
.	O
The	O
cystic	O
duct	O
is	O
also	O
filled	O
with	O
contrast	O
,	O
partially	O
opacifying	O
the	O
gallbladder	O
.	O
No	O
strictures	O
or	O
filling	O
defects	O
are	O
identified	O
.	O
Following	O
cholangiogram	O
,	O
there	O
is	O
placement	O
of	O
a	O
plastic	O
stent	O
within	O
the	O
common	O
bile	O
duct	O
.	O
.	O
CT	O
Chest	O
/	O
Abd	O
/	O
Pelvis	O
[	O
**	O
10	O
-	O
31	O
**	O
]	O
:	O
1	O
.	O
Multifocal	O
pulmonary	O
opacities	O
,	O
which	O
could	O
represent	O
an	O
infectious	O
process	O
.	O
2	O
.	O
Bilateral	O
axillary	O
and	O
right	O
hilar	O
lymphadenopathy	O
,	O
all	O
could	O
be	O
related	O
to	O
the	O
underlying	O
infectious	O
process	O
.	O
3	O
.	O
Moderate	O
bilateral	O
pleural	O
effusions	O
.	O
4	O
.	O
Although	O
there	O
is	O
ascites	O
,	O
fluid	O
within	O
the	O
lesser	O
sac	O
and	O
adjacent	O
to	O
the	O
pancreatic	O
head	O
raises	O
the	O
suspicion	O
of	O
pancreatitis	O
.	O
5	O
.	O
Splenomegaly	O
.	O
6	O
.	O
Periportal	O
lymphadenopathy	O
.	O
.	O
Echo	O
[	O
**	O
11	O
-	O
1	O
**	O
]	O
:	O
No	O
evidence	O
of	O
endocarditis	O
.	O
Normal	O
global	O
and	O
regional	O
biventricular	O
systolic	O
function	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
.	O
Immunophenotyping	O
[	O
**	O
11	O
-	O
2	O
**	O
]	O
:	O
Pending	O
.	O
Bronchial	O
washings	O
[	O
**	O
11	O
-	O
2	O
**	O
]	O
:	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS	O
.	O
Pulmonary	O
macrophages	O
.	O
No	O
viral	O
cytopathic	O
changes	O
or	O
microorganisms	O
seen	O
.	O
.	O
R	O
LENI	O
[	O
**	O
11	O
-	O
6	O
**	O
]	O
:	O
No	O
evidence	O
of	O
right	O
lower	O
extremity	O
DVT	O
.	O
.	O
CXR	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
:	O
Pulmonary	O
edema	O
,	O
now	O
mild	O
,	O
has	O
improved	O
substantially	O
since	O
[	O
**	O
11	O
-	O
5	O
**	O
]	O
.	O
A	O
relatively	O
rapid	O
onset	O
between	O
[	O
**	O
10	O
-	O
30	O
**	O
]	O
and	O
16	O
and	O
pace	O
of	O
improvement	O
suggests	O
the	O
diagnosis	O
is	O
cardiogenic	O
rather	O
than	O
noncardiac	O
edema	O
.	O
Heart	O
is	O
normal	O
size	O
.	O
There	O
is	O
no	O
mediastinal	O
or	O
pulmonary	O
vascular	O
engorgement	O
.	O
Lungs	O
are	O
clear	O
aside	O
from	O
bands	O
of	O
atelectasis	O
.	O
Other	O
pleural	O
surfaces	O
are	O
normal	O
except	O
for	O
mild	O
thickening	O
associated	O
with	O
fractures	O
of	O
left	O
ribs	O
at	O
least	O
the	O
fifth	O
,	O
which	O
may	O
have	O
developed	O
between	O
[	O
**	O
11	O
-	O
2	O
**	O
]	O
and	O
21	O
.	O
Tip	O
of	O
the	O
right	O
jugular	O
line	O
projects	O
over	O
the	O
junction	O
of	O
the	O
brachiocephalic	O
veins	O
and	O
a	O
left	O
internal	O
jugular	O
line	O
ends	O
in	O
the	O
upper	O
SVC	O
.	O
.	O
CT	O
abd	O
/	O
pelvis	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
:	O
1	O
.	O
Slightly	O
increased	O
amount	O
of	O
intraabdominal	O
simple	O
free	O
fluid	O
.	O
2	O
.	O
Interval	O
placement	O
of	O
CBD	O
stent	O
with	O
collapsed	O
,	O
edematous	O
gallbladder	O
.	O
3	O
.	O
Pancreas	O
appears	O
similar	O
to	O
previous	O
exam	O
.	O
.	O
CT	O
Head	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
:	O
1	O
.	O
No	O
acute	O
intracranial	O
hemorrhage	O
or	O
mass	O
effect	O
.	O
2	O
.	O
Interval	O
opacification	O
of	O
multiple	O
mastoid	O
air	O
cells	O
.	O
.	O
[	O
**	O
2118-10-30	O
**	O
]	O
09:46	O
PM	O
BLOOD	O
HCV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2118-10-31	O
**	O
]	O
10:21	O
PM	O
BLOOD	O
HIV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2118-10-30	O
**	O
]	O
09:46	O
PM	O
BLOOD	O
HBsAg	O
-	O
NEGATIVE	O
HBsAb	O
-	O
NEGATIVE	O
IgM	O
HAV	O
-	O
NEGATIVE	O
[	O
**	O
2118-11-21	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
TSH	O
-	O
2.9	O
[	O
**	O
2118-10-31	O
**	O
]	O
10:21	O
PM	O
BLOOD	O
calTIBC	O
-	O
156	O
*	O
VitB12	O
-	O
1420	O
*	O
Folate	O
-	O
14.4	O
Hapto	O
-	O
65	O
Ferritn	O
-	O
6065	O
*	O
TRF	O
-	O
120	O
*	O
[	O
**	O
2118-11-5	O
**	O
]	O
02:36	O
AM	O
BLOOD	O
Lipase	O
-	O
760	O
*	O
[	O
**	O
2118-11-23	O
**	O
]	O
06:25	O
AM	O
BLOOD	O
Lipase	O
-	O
242	O
*	O
[	O
**	O
2118-10-30	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
ALT	O
-	O
81	O
*	O
AST	O
-	O
240	O
*	O
AlkPhos	O
-	O
294	O
*	O
Amylase	O
-	O
147	O
*	O
TotBili	O
-	O
8.9	O
*	O
DirBili	O
-	O
7.4	O
*	O
IndBili	O
-	O
1.5	O
[	O
**	O
2118-11-1	O
**	O
]	O
11:35	O
PM	O
BLOOD	O
ALT	O
-	O
90	O
*	O
AST	O
-	O
361	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
665	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
725	O
*	O
AlkPhos	O
-	O
217	O
*	O
Amylase	O
-	O
203	O
*	O
TotBili	O
-	O
7.5	O
*	O
[	O
**	O
2118-11-24	O
**	O
]	O
06:20	O
AM	O
BLOOD	O
ALT	O
-	O
85	O
*	O
AST	O
-	O
21	O
AlkPhos	O
-	O
136	O
*	O
TotBili	O
-	O
1.7	O
*	O
[	O
**	O
2118-10-30	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
UreaN	O
-	O
16	O
Creat	O
-	O
1.0	O
Na	O
-	O
131	O
*	O
K	O
-	O
4.1	O
Cl	O
-	O
98	O
HCO3	O
-	O
24	O
AnGap	O
-	O
13	O
[	O
**	O
2118-11-4	O
**	O
]	O
06:30	O
PM	O
BLOOD	O
Glucose	O
-	O
111	O
*	O
UreaN	O
-	O
88	O
*	O
Creat	O
-	O
7.1	O
*	O
Na	O
-	O
130	O
*	O
K	O
-	O
4.9	O
Cl	O
-	O
98	O
HCO3	O
-	O
18	O
*	O
AnGap	O
-	O
19	O
[	O
**	O
2118-11-25	O
**	O
]	O
07:40	O
AM	O
BLOOD	O
Glucose	O
-	O
87	O
UreaN	O
-	O
30	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
138	O
K	O
-	O
3.8	O
Cl	O
-	O
105	O
HCO3	O
-	O
25	O
AnGap	O
-	O
12	O
[	O
**	O
2118-11-2	O
**	O
]	O
03:23	O
AM	O
BLOOD	O
WBC	O
-	O
3.5	O
*	O
Lymph	O
-	O
17	O
*	O
Abs	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
595	O
CD3	O
%	O
-	O
97	O
Abs	O
CD3	O
-	O
580	O
CD4	O
%	O
-	O
89	O
Abs	O
CD4	O
-	O
532	O
CD8	O
%	O
-	O
8.5	O
Abs	O
CD8	O
-	O
51	O
*	O
CD4	O
/	O
CD8	O
-	O
9.9	O
*	O
[	O
**	O
2118-11-25	O
**	O
]	O
07:40	O
AM	O
BLOOD	O
Gran	O
Ct	O
-	O
70	O
*	O
[	O
**	O
2118-10-30	O
**	O
]	O
01:20	O
PM	O
BLOOD	O
WBC	O
-	O
2.0	O
*	O
RBC	O
-	O
3.50	O
*	O
Hgb	O
-	O
11.5	O
*	O
Hct	O
-	O
33.5	O
*	O
MCV	O
-	O
96	O
MCH	O
-	O
32.8	O
*	O
MCHC	O
-	O
34.3	O
RDW	O
-	O
15.6	O
*	O
[	O
**	O
2118-11-25	O
**	O
]	O
07:40	O
AM	O
BLOOD	O
WBC	O
-	O
0.4	O
*	O
RBC	O
-	O
2.72	O
*	O
Hgb	O
-	O
8.1	O
*	O
Hct	O
-	O
22.6	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
29.9	O
MCHC	O
-	O
35.9	O
*	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
81	O
*	O
#	O
[	O
**	O
2118-11-17	O
**	O
]	O
02:14	O
PM	O
CEREBROSPINAL	O
FLUID	O
(	O
CSF	O
)	O
WBC	O
-	O
2	O
RBC	O
-	O
0	O
Polys	O
-	O
0	O
Lymphs	O
-	O
87	O
Monos	O
-	O
13	O
[	O
**	O
2118-11-1	O
**	O
]	O
11:34	O
PM	O
CEREBROSPINAL	O
FLUID	O
(	O
CSF	O
)	O
WBC	O
-	O
13	O
RBC	O
-	O
3	O
*	O
Polys	O
-	O
0	O
Lymphs	O
-	O
95	O
Monos	O
-	O
0	O
Macroph	O
-	O
5	O
[	O
**	O
2118-11-1	O
**	O
]	O
11:34	O
PM	O
CEREBROSPINAL	O
FLUID	O
(	O
CSF	O
)	O
WBC	O
-	O
13	O
RBC	O
-	O
32	O
*	O
Polys	O
-	O
0	O
Lymphs	O
-	O
67	O
Monos	O
-	O
0	O
Macroph	O
-	O
33	O
[	O
**	O
2118-11-17	O
**	O
]	O
02:13	O
PM	O
CEREBROSPINAL	O
FLUID	O
(	O
CSF	O
)	O
TotProt	O
-	O
34	O
Glucose	O
-	O
61	O
[	O
**	O
2118-11-1	O
**	O
]	O
11:34	O
PM	O
CEREBROSPINAL	O
FLUID	O
(	O
CSF	O
)	O
TotProt	O
-	O
19	O
Glucose	O
-	O
63	O
.	O
BM	O
Bx	O
ERYTHROID	O
-	O
DOMINANT	O
MARROW	O
WITH	O
INCREASED	O
HEMOPHAGOCYTIC	O
HISTIOCYTES	O
,	O
DECREASED	O
CELLULAR	O
DENSITY	O
,	O
AND	O
INCREASED	O
BACKGROUND	O
EOSINOPHILIC	O
CELL	O
DEBRIS	O
,	O
CONSISTENT	O
WITH	O
HEMOPHAGOCYTIC	O
SYNDROME	O
(	O
HEMOPHAGOCYTIC	O
LYMPHOHISTIOCYTOSIS	O
Brief	O
Hospital	O
Course	O
:	O
Hospital	O
Course	O
:	O
.	O
#	O
Fever	O
/	O
Pancytopenia	O
/	O
ID	O
/	O
Hemophagocytic	O
Lymphohistiocytosis	O
:	O
Pt	O
had	O
been	O
afebrile	O
since	O
[	O
**	O
11	O
-	O
4	O
**	O
]	O
and	O
all	O
ABX	O
d	O
/	O
c	O
'	O
ed	O
on	O
[	O
**	O
11	O
-	O
6	O
**	O
]	O
,	O
however	O
,	O
Vanco	I-Drug
/	O
Ceftaz	I-Drug
were	O
restarted	O
on	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
for	O
Tm	B-Reason
of	I-Reason
102.2	I-Reason
.	O
Concern	O
was	O
for	O
VAP	O
given	O
increased	O
respiratory	O
secretions	O
vs	O
recurrent	O
pancreatitis	O
with	O
pseudocyst	O
as	O
pancreas	O
enzymes	O
were	O
rising	O
after	O
recently	O
having	O
restarted	O
TF	O
.	O
CT	O
Abd	O
/	O
pelvis	O
was	O
without	O
evidence	O
of	O
worsening	O
radiographic	O
pancreatitis	O
.	O
Other	O
sources	O
considered	O
included	O
line	O
infections	O
(	O
Right	O
IJ	O
recently	O
replaced	O
in	O
same	O
site	O
)	O
or	O
C.	B-Ade
diff	I-Ade
given	O
prolonged	O
ABX	I-Drug
course	O
.	O
.	O
Extensive	O
prior	O
infectious	O
workup	O
had	O
revealed	O
a	O
positive	O
EBV	O
IgM	O
,	O
EBV	O
PCR	O
,	O
and	O
EBV	O
PCR	O
in	O
CSF	O
.	O
Given	O
pancyotpenia	O
,	O
splenomegaly	O
,	O
and	O
EBV	O
infection	O
Heme	O
/	O
Onc	O
and	O
ID	O
were	O
considered	O
the	O
diagnosis	O
of	O
Hemophagocytic	B-Reason
Lymphohistiocytosis	I-Reason
,	O
which	O
was	O
confirmed	O
by	O
repeat	O
bone	O
marrow	O
biopsy	O
(	O
first	O
biopsy	O
unremarkable	O
)	O
.	O
Pt	O
was	O
begun	O
on	O
etoposode	I-Drug
,	O
IVIG	I-Drug
and	O
decadron	I-Drug
on	O
~	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
.	O
His	O
pancytopenia	I-Reason
was	O
also	O
treated	O
with	O
epogen	I-Drug
and	O
neupogen	I-Drug
.	O
.	O
Per	O
HEME	O
,	O
HLH	O
likely	O
triggered	O
by	O
underlying	O
EBV	O
infection	O
.	O
While	O
there	O
was	O
evidence	O
of	O
EBV	O
in	O
the	O
CSF	O
;	O
because	O
of	O
normal	O
Protein	O
no	O
need	O
for	O
IT	O
-	O
MTX	I-Drug
.	O
The	O
patient	O
was	O
started	O
on	O
a	O
steroid	I-Drug
taper	O
(	O
currently	O
on	O
10	O
mg	O
Decadron	I-Drug
)	O
and	O
will	O
need	O
8	O
weeks	O
total	O
of	O
Etoposide	I-Drug
.	O
Renal	O
failure	O
,	O
pancreatic	O
abnormalities	O
,	O
and	O
elevated	O
LFTs	O
all	O
thought	O
to	O
be	O
d	O
/	O
t	O
underlying	O
HLH	O
.	O
In	O
addition	O
,	O
ID	O
consults	O
did	O
not	O
recommend	O
treating	O
EBV	B-Reason
viremia	I-Reason
with	O
anti-virals	I-Drug
.	O
.	O
On	O
[	O
**	O
11	O
-	O
9	O
**	O
]	O
,	O
pt	O
was	O
noted	O
to	O
have	O
EBSL	B-Reason
klebsiella	I-Reason
in	O
a	O
sputum	O
and	O
BAL	O
sample	O
,	O
and	O
was	O
begun	O
on	O
meropenem	I-Drug
for	O
14	O
day	O
course	O
.	O
He	O
continued	O
to	O
develop	O
low	O
grade	O
temperature	O
(	O
100.0	O
-	O
100.6	O
)	O
,	O
which	O
were	O
attributed	O
to	O
his	O
HLH	O
,	O
IVIG	O
,	O
and	O
CVVHD	O
.	O
.	O
#	O
Respiratory	O
Failure	O
:	O
Pt	O
intubated	O
on	O
[	O
**	O
2118-10-30	O
**	O
]	O
for	O
impending	O
respiratory	O
distress	O
at	O
time	O
of	O
his	O
ERCP	O
.	O
Upon	O
admission	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
on	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
,	O
his	O
respiratory	O
mechanics	O
had	O
improved	O
considerably	O
,	O
and	O
he	O
was	O
oxygenating	O
and	O
ventilating	O
well	O
on	O
PS	O
5/0	O
.	O
Initially	O
unable	O
to	O
extubate	O
secondary	O
to	O
altered	O
mental	O
status	O
and	O
increased	O
secretions	O
.	O
Pt	O
was	O
often	O
desyncrhonous	O
on	O
vent	O
secondary	O
to	O
hiccups	O
when	O
sedation	O
weaned	O
.	O
As	O
mental	O
status	O
improved	O
gradually	O
,	O
pt	O
was	O
extubated	O
on	O
[	O
**	O
11	O
-	O
10	O
**	O
]	O
.	O
His	O
respiratory	O
status	O
continued	O
to	O
improve	O
slowly	O
,	O
despite	O
+	O
BAL	O
for	O
EBSL	O
klebsiella	O
and	O
total	O
body	O
fluid	O
overload	O
,	O
and	O
on	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
pt	O
was	O
sat	O
'	O
ing	O
>	O
95	O
%	O
on	O
RA	O
.	O
.	O
#	O
Mental	O
Status	O
-	O
pt	O
presented	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
alert	O
&	O
oriented	O
,	O
however	O
his	O
mental	O
status	O
subsequently	O
declined	O
.	O
After	O
intubation	O
on	O
[	O
**	O
10	O
-	O
30	O
**	O
]	O
,	O
pt	O
remained	O
largely	O
sedated	O
until	O
just	O
prior	O
to	O
admission	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
on	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
.	O
Attempts	O
to	O
wean	O
sedation	O
were	O
limited	O
by	O
hiccups	O
which	O
resulted	O
in	O
dysynchrony	O
the	O
mechanical	O
ventilation	O
,	O
breif	O
neuro	O
exam	O
at	O
time	O
of	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
admission	O
with	O
sedation	O
weaned	O
revealed	O
pt	O
responsive	O
only	O
to	O
deep	O
painful	O
stimulus	O
(	O
sternal	O
rub	O
)	O
,	O
pupils	O
minimally	O
reactive	O
to	O
light	O
bilaterally	O
,	O
gag	O
was	O
present	O
,	O
with	O
slow	O
corneal	O
reflex	O
.	O
+	O
hyperreflexia	O
,	O
though	O
tone	O
was	O
flacid	O
,	O
and	O
5	O
-	O
10	O
beat	O
clonus	O
of	O
both	O
feet	O
was	O
noted	O
which	O
initially	O
worsened	O
to	O
20	O
beat	O
clonus	O
on	O
[	O
**	O
11	O
-	O
11	O
**	O
]	O
before	O
slowly	O
improving	O
.	O
.	O
Was	O
seen	O
by	O
the	O
neurology	O
/	O
psychiatry	O
services	O
given	O
his	O
new	O
neurological	O
findings	O
and	O
h	O
/	O
o	O
myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
(	O
which	O
predominantly	O
was	O
ocular	O
per	O
pt	O
's	O
family	O
)	O
.	O
EEG	O
was	O
obtained	O
which	O
showed	O
diffuse	O
slowing	O
,	O
but	O
no	O
focus	O
of	O
seizure	O
activity	O
.	O
CT	O
head	O
on	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
unremarkable	O
.	O
Over	O
the	O
course	O
of	O
his	O
first	O
week	O
in	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
153	O
**	O
]	O
,	O
pt	O
's	O
mental	O
status	O
improved	O
dramatically	O
,	O
presumably	O
with	O
chemotherapy	I-Drug
.	O
By	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
pt	O
was	O
alert	O
,	O
pleasantly	O
conversive	O
,	O
and	O
following	O
all	O
commands	O
.	O
His	O
imuran	I-Drug
for	O
myasthenia	I-Reason
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2902	O
**	O
]	O
has	O
been	O
held	O
since	O
admission	O
.	O
Neuro	O
also	O
noted	O
proximal	O
weakness	O
of	O
his	O
arms	O
,	O
which	O
improved	O
during	O
his	O
hospital	O
course	O
.	O
Per	O
Neruo	O
,	O
he	O
should	O
hold	O
Imuran	I-Drug
until	O
he	O
follows	O
up	O
with	O
Neuro	O
as	O
an	O
outpatient	O
.	O
.	O
#	O
Renal	O
-	O
pt	O
without	O
h	O
/	O
o	O
CRI	O
,	O
developed	O
ARF	O
likely	O
secondary	O
to	O
ATN	O
from	O
hypotension	O
and	O
underlying	O
HLH	O
on	O
[	O
**	O
11	O
-	O
1	O
**	O
]	O
.	O
Pt	O
was	O
started	O
on	O
CVVHD	O
at	O
that	O
time	O
for	O
volume	O
overload	O
[	O
**	O
2	O
-	O
17	O
**	O
]	O
anuria	O
,	O
however	O
,	O
UOP	O
gradually	O
improved	O
,	O
and	O
on	O
[	O
**	O
11	O
-	O
15	O
**	O
]	O
pt	O
was	O
discontinued	O
from	O
HD	O
.	O
Creatinine	O
normal	O
on	O
discharge	O
.	O
.	O
#	O
Cholestasis	O
/	O
hepatitis	O
/	O
pancreatitis	O
-	O
pt	O
presented	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
from	O
OSH	O
with	O
RUQ	O
pain	O
,	O
fever	O
,	O
and	O
elevated	O
LFTs	O
(	O
Tbil	O
7	O
's	O
)	O
,	O
for	O
which	O
he	O
underwent	O
ERCP	O
with	O
CBD	O
stent	O
on	O
[	O
**	O
11	O
-	O
2	O
**	O
]	O
.	O
LFTs	O
have	O
since	O
trended	O
down	O
,	O
though	O
amylase	O
/	O
lipase	O
(	O
peak	O
in	O
1000s	O
)	O
were	O
starting	O
to	O
plateau	O
at	O
500s	O
on	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
.	O
CT	O
abdomen	O
showed	O
pancreatic	O
fluid	O
collection	O
,	O
but	O
not	O
psuedocyst	O
or	O
necrosis	O
.	O
On	O
[	O
**	O
11	O
-	O
13	O
**	O
]	O
pt	O
denied	O
abdominal	O
pain	O
,	O
and	O
was	O
hungry	O
,	O
thus	O
was	O
transitioned	O
from	O
TPN	O
to	O
TF	O
cautiously	O
,	O
as	O
prior	O
attempt	O
to	O
restart	O
tube	O
feeds	O
was	O
limited	O
by	O
bump	O
in	O
amylase	O
/	O
lipase	O
.	O
On	O
[	O
**	O
11	O
-	O
14	O
**	O
]	O
,	O
pt	O
was	O
tolerating	O
TF	O
without	O
difficulty	O
,	O
in	O
addition	O
to	O
sips	O
of	O
clear	O
liquids	O
,	O
thus	O
he	O
was	O
advanced	O
to	O
a	O
regular	O
diet	O
after	O
a	O
speech	O
&	O
consult	O
was	O
obtained	O
.	O
On	O
the	O
floor	O
,	O
he	O
tolerated	O
his	O
diet	O
without	O
other	O
clinical	O
s	O
/	O
sx	O
of	O
pancreatitis	O
.	O
.	O
Psych	O
:	O
thought	O
the	O
patient	O
had	O
a	O
mild	O
encephalopathy	O
that	O
was	O
slowly	O
resolving	O
.	O
Recommeded	O
Haldol	I-Drug
/	O
Seroquel	I-Drug
for	O
sleep	I-Reason
;	O
however	O
,	O
this	O
made	B-Ade
the	I-Ade
patient	I-Ade
feel	I-Ade
strage	I-Ade
.	O
Given	O
resolution	O
of	O
MS	O
changes	O
,	O
ok	O
for	O
patient	O
to	O
receive	O
ambien	I-Drug
at	O
rehab	O
prn	O
.	O
.	O
HTN	I-Reason
:	O
kept	O
on	O
Lopressor	I-Drug
100	O
mg	O
TID	O
with	O
excellent	O
results	O
.	O
Medications	O
on	O
Admission	O
:	O
Imuran	I-Drug
,	O
Imitrex	I-Drug
,	O
Amoxicillin	I-Drug
,	O
Augmentin	I-Drug
,	O
Atovaquone	I-Drug
,	O
Azithromax	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
180	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Meropenem	I-Drug
500	O
mg	O
Recon	O
Soln	O
Sig	O
:	O
Five	O
Hundred	O
(	O
500	O
)	O
mg	O
Intravenous	O
every	O
eight	O
(	O
8	O
)	O
hours	O
:	O
please	O
continue	O
until	O
ANC	O
>	O
500	O
.	O
Disp	O
:	O
*	O
qs	O
mg	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Dexamethasone	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
2.5	O
Tablets	O
PO	O
once	O
a	O
day	O
:	O
Please	O
give	O
10	O
mg	O
PO	O
daily	O
until	O
[	O
**	O
12	O
-	O
5	O
**	O
]	O
;	O
then	O
begin	O
5	O
mg	O
po	O
daily	O
.	O
Disp	O
:	O
*	O
qs	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
for	O
fever	I-Reason
.	O
Disp	O
:	O
*	O
qs	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
:	O
while	B-Reason
on	I-Reason
steroids	I-Drug
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Miconazole	B-Drug
Nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Nystatin	I-Drug
100,000	O
unit	O
/	O
g	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
qs	O
qs	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Ambien	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Fluconazole	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
continue	O
until	O
ANC	O
>	O
500	O
.	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Hemophagocytic	O
lymphohistiocytosis	O
2	O
.	O
Acute	O
Renal	O
Failure	O
,	O
resolved	O
3	O
.	O
Elevated	O
LFTs	O
secondary	O
to	O
Obstruction	O
/	O
HLH	O
4	O
.	O
Elevated	O
amylase	O
/	O
lipase	O
,	O
likely	O
secondary	O
to	O
HLH	O
5	O
.	O
Myasthenia	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
,	O
stable	O
6	O
.	O
Hospital	O
Acquired	O
PNA	O
(	O
Klebsiella	O
)	O
7	O
.	O
Pancytopenia	O
/	O
Febrile	O
Neutropenia	O
8	O
.	O
Sepsis	O
9	O
.	O
Respiratory	O
Failure	O
10	O
.	O
Hypertension	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
Please	O
contact	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
3588	O
**	O
]	O
office	O
or	O
your	O
PCP	O
should	O
you	O
develop	O
any	O
fevers	O
,	O
chills	O
,	O
sweats	O
,	O
abodminal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
or	O
any	O
other	O
complaints	O
.	O
Please	O
make	O
an	O
appointment	O
to	O
see	O
your	O
outpatient	O
Neurologist	O
as	O
soon	O
as	O
possible	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
5026	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3237	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2118-11-30	O
**	O
]	O
11:00	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2118-11-30	O
**	O
]	O
11:00	O
Someone	O
from	O
the	O
Gastroenterology	O
Team	O
will	O
be	O
calling	O
you	O
at	O
Rehab	O
regarding	O
pulling	O
the	O
stent	O
from	O
your	O
liver	O
.	O
Please	O
f	O
/	O
u	O
with	O
your	O
neurologist	O
as	O
an	O
outpt	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2113-3-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2113-3-28	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2036-1-16	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1390	O
**	O
]	O
Chief	O
Complaint	O
:	O
right	O
hemopneumothorax	O
,	O
bilateral	O
pulmonary	O
contusions	O
,	O
right	O
rib	O
fractures	O
,	O
multiple	O
facial	O
fractures	O
,	O
degloving	O
injury	O
to	O
ear	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
right	O
chest	O
tube	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
74M	O
was	O
struck	O
by	O
his	O
car	O
after	O
attempting	O
to	O
do	O
some	O
mechanical	O
work	O
on	O
it	O
.	O
Car	O
rolled	O
over	O
him	O
and	O
dragged	O
him	O
several	O
feet	O
.	O
He	O
was	O
brought	O
to	O
the	O
ED	O
by	O
ambulance	O
.	O
He	O
had	O
concerns	O
of	O
RUQ	O
pain	O
,	O
chest	O
pain	O
and	O
a	O
laceration	O
to	O
the	O
head	O
.	O
He	O
denied	O
loss	O
of	O
consciousness	O
.	O
A	O
chest	O
tube	O
was	O
placed	O
in	O
the	O
ED	O
for	O
hemopneumothorax	O
.	O
Following	O
the	O
chest	O
tube	O
placement	O
,	O
the	O
patient	O
had	O
an	O
episode	O
of	O
hematemesis	O
and	O
hypotension	O
,	O
but	O
this	O
resolved	O
spontaneously	O
.	O
At	O
baseline	O
the	O
patient	O
is	O
functional	O
at	O
home	O
and	O
take	O
no	O
anticoagulant	B-Drug
medications	I-Drug
.	O
He	O
suffered	O
multiple	O
facial	O
fractures	O
,	O
an	O
ear	O
laceration	O
,	O
bilateral	O
pulmonary	O
contusions	O
,	O
multiple	O
right	O
sided	O
rib	O
fractures	O
and	O
a	O
dens	O
fracture	O
.	O
Past	O
Medical	O
History	O
:	O
Hypertension	O
Social	O
History	O
:	O
Patient	O
lives	O
in	O
[	O
**	O
Location	O
1411	O
**	O
]	O
with	O
his	O
wife	O
.	O
Denies	O
tobacco	O
or	O
IVDA	O
,	O
drinks	O
2	O
glasses	O
wine	O
nightly	O
.	O
Family	O
History	O
:	O
Non-contributory	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
97.6	O
90138/77	O
18	O
98	O
%	O
RA	O
GA	O
:	O
alert	O
and	O
oriented	O
x	O
3	O
,	O
no	O
acute	O
distress	O
CVS	O
:	O
normal	O
S1	O
,	O
S2	O
,	O
no	O
murmurs	O
Resp	O
:	O
mild	O
bibasilar	O
crackles	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
:	O
soft	O
,	O
nontender	O
,	O
nondistended	O
Ext	O
:	O
warm	O
,	O
no	O
edema	O
,	O
well	O
perfused	O
Pertinent	O
Results	O
:	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:25	O
PM	O
GLUCOSE	O
-	O
107	O
*	O
LACTATE	O
-	O
2.6	O
*	O
NA	O
+	O
-	O
143	O
K	O
+	O
-	O
4.6	O
CL	O
--	O
95	O
*	O
TCO2	O
-	O
31	O
*	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:28	O
PM	O
PT	O
-	O
13.1	O
PTT	O
-	O
24.1	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:28	O
PM	O
PLT	O
COUNT	O
-	O
201	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:28	O
PM	O
WBC	O
-	O
9.1	O
RBC	O
-	O
4.44	O
*	O
HGB	O
-	O
15.4	O
HCT	O
-	O
43.1	O
MCV	O
-	O
97	O
MCH	O
-	O
34.7	O
*	O
MCHC	O
-	O
35.8	O
*	O
RDW	O
-	O
13.1	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:28	O
PM	O
ASA	O
-	O
NEG	O
ETHANOL	O
-	O
NEG	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
tricyclic	O
-	O
NEG	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:28	O
PM	O
LIPASE	O
-	O
74	O
*	O
[	O
**	O
2113-3-22	O
**	O
]	O
01:28	O
PM	O
UREA	O
N	O
-	O
17	O
CREAT	O
-	O
1.1	O
[	O
**	O
2113-3-26	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
WBC	O
-	O
6.4	O
RBC	O
-	O
2.59	O
*	O
Hgb	O
-	O
9.0	O
*	O
Hct	O
-	O
24.6	O
*	O
MCV	O
-	O
95	O
MCH	O
-	O
34.8	O
*	O
MCHC	O
-	O
36.7	O
*	O
RDW	O
-	O
14.8	O
Plt	O
Ct	O
-	O
135	O
*	O
[	O
**	O
2113-3-26	O
**	O
]	O
05:00	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
135	O
*	O
[	O
**	O
2113-3-25	O
**	O
]	O
05:10	O
AM	O
BLOOD	O
Glucose	O
-	O
84	O
UreaN	O
-	O
11	O
Creat	O
-	O
0.8	O
Na	O
-	O
137	O
K	O
-	O
4.0	O
Cl	O
-	O
102	O
HCO3	O
-	O
29	O
AnGap	O
-	O
10	O
[	O
**	O
2113-3-25	O
**	O
]	O
05:10	O
AM	O
BLOOD	O
Calcium	O
-	O
8.1	O
*	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
2.1	O
[	O
**	O
2113-3-22	O
**	O
]	O
CT	O
SINUS	O
/	O
MANDIBLE	O
/	O
MAXIL	O
:	O
1	O
.	O
Numerous	O
facial	O
fractures	O
as	O
enumerated	O
before	O
corresponding	O
most	O
closely	O
to	O
a	O
Le	O
Fort	O
type	O
III	O
on	O
the	O
left	O
and	O
anterior	O
,	O
lateral	O
and	O
superior	O
walls	O
of	O
the	O
maxillary	O
sinus	O
on	O
the	O
right	O
including	O
the	O
inferior	O
orbital	O
rim	O
.	O
2	O
.	O
Hemorrhage	O
contained	O
within	O
the	O
maxillary	O
sinuses	O
.	O
3	O
.	O
Chronic	O
non-displaced	O
fracture	O
of	O
the	O
tip	O
of	O
the	O
dens	O
.	O
[	O
**	O
2113-3-27	O
**	O
]	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
:	O
Small	O
right	O
apical	O
pneumothorax	O
at	O
the	O
level	O
of	O
the	O
second	O
posterior	O
interspace	O
,	O
slightly	O
smaller	O
than	O
on	O
[	O
**	O
3	O
-	O
26	O
**	O
]	O
.	O
Small	O
right	O
pleural	O
effusion	O
has	O
probably	O
developed	O
.	O
Lungs	O
low	O
in	O
volume	O
but	O
clear	O
.	O
Moderate	O
cardiomegaly	O
unchanged	O
.	O
Healed	O
right	O
lower	O
and	O
lateral	O
rib	O
fractures	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Summary	O
of	O
Injuries	O
sustained	O
:	O
anterior	O
right	O
2	O
-	O
7th	O
rib	O
fractures	O
,	O
right	O
hemopneumothorax	O
,	O
bilateral	O
pulmonary	O
contusions	O
,	O
L	O
zygomatic	O
arch	O
fracture	O
,	O
left	O
lateral	O
pterygoid	O
plate	O
fractures	O
,	O
left	O
lateral	O
orbital	O
wall	O
fractures	O
,	O
left	O
minimally	O
displaced	O
orbital	O
fractures	O
,	O
nondisplaced	O
lamina	O
papyrica	O
fracture	O
,	O
right	O
orbital	O
floor	O
fracture	O
,	O
bilateral	O
lateral	O
wall	O
maxillary	O
sinus	O
fracture	O
,	O
right	O
ear	O
skin	O
avulsion	O
.	O
Review	O
of	O
Systems	O
:	O
Neurologic	O
:	O
Patient	O
was	O
neurologically	O
intact	O
.	O
He	O
recieved	O
dilaudid	I-Drug
IV	O
prn	O
during	O
his	O
ICU	O
stay	O
,	O
he	O
was	O
then	O
transitioned	O
to	O
PO	O
pain	B-Drug
medication	I-Drug
.	O
At	O
discharge	O
he	O
was	O
not	O
requiring	O
pain	I-Drug
medication	O
.	O
Opthalmology	O
assessed	O
patient	O
to	O
assess	O
visual	O
status	O
following	O
displaced	O
orbital	O
fractures	O
.	O
Plastic	O
surgery	O
assessed	O
facial	O
fractures	O
and	O
as	O
patient	O
is	O
refusing	O
surgery	O
,	O
they	O
will	O
follow	O
up	O
with	O
him	O
as	O
an	O
outpatient	O
.	O
For	O
his	O
facial	O
fractures	O
he	O
was	O
placed	O
under	O
sinus	O
precautions	O
and	O
is	O
restricted	O
to	O
a	O
soft	O
diet.Neurosurgery	O
assessed	O
patient	O
for	O
his	O
dens	O
fracture	O
and	O
it	O
was	O
determined	O
that	O
his	O
fracture	O
resulted	O
from	O
an	O
injury	O
20	O
years	O
ago	O
when	O
he	O
dove	O
into	O
a	O
pool	O
.	O
On	O
hospital	O
day	O
6	O
he	O
was	O
triggered	O
for	O
altered	B-Ade
mental	I-Ade
status	I-Ade
after	O
receiving	O
valium	I-Drug
.	O
Standing	O
zyprexa	I-Drug
was	O
administered	O
with	O
return	O
to	O
baseline	O
mental	O
status	O
without	O
further	O
incidient	O
.	O
He	O
requires	O
no	O
further	O
neurosurgical	O
follow	O
-	O
up	O
for	O
his	O
dens	O
fracture	O
.	O
Cardiovascular	O
:	O
Following	O
transfer	O
to	O
the	O
ICU	O
patient	O
remained	O
hemodynamically	O
stable	O
.	O
He	O
suffered	O
an	O
intial	O
period	O
of	O
hypotension	O
in	O
the	O
emergency	O
room	O
but	O
after	O
resuscitation	O
he	O
was	O
hemodynamically	O
stable	O
.	O
Pulmonary	O
:	O
A	O
chest	O
tube	O
was	O
placed	O
for	O
hemopneumothorax	O
in	O
the	O
ED	O
.	O
The	O
chest	O
tube	O
was	O
discontinued	O
on	O
HD6	O
.	O
There	O
was	O
a	O
small	O
increase	O
in	O
pneumothorax	O
upon	O
discontinuation	O
,	O
however	O
follow	O
up	O
CXR	O
revealed	O
this	O
change	O
to	O
be	O
stable	O
.	O
His	O
respiratory	O
status	O
was	O
stable	O
.	O
While	O
in	O
the	O
ICU	O
,	O
he	O
was	O
monitored	O
for	O
respiratory	O
decompensation	O
due	O
to	O
splinting	O
from	O
his	O
rib	O
fractures	O
,	O
however	O
his	O
respiratory	O
status	O
remained	O
stable	O
and	O
he	O
did	O
not	O
require	O
an	O
epidural	O
for	O
pain	O
control	O
.	O
GI	O
:	O
Patient	O
suffered	O
no	O
intraabdominal	O
injury	O
.	O
He	O
tolerated	O
a	O
soft	O
diet	O
without	O
issue	O
.	O
He	O
was	O
restricted	O
to	O
a	O
soft	O
diet	O
due	O
to	O
his	O
facial	O
fractures	O
.	O
GU	O
/	O
Renal	O
:	O
Patient	O
has	O
a	O
foley	O
catheter	O
placed	O
while	O
in	O
the	O
ICU	O
but	O
it	O
was	O
discontinued	O
when	O
he	O
was	O
transferred	O
to	O
the	O
floor	O
.	O
His	O
electrolytes	O
were	O
repleted	O
as	O
necessary	O
.	O
His	O
creatinine	O
remained	O
stable	O
.	O
Endocrine	O
:	O
He	O
was	O
placed	O
on	O
insulin	I-Drug
sliding	O
scale	O
while	O
in	O
the	O
ICU	O
.	O
At	O
discharge	O
sliding	O
scale	O
had	O
be	O
discontinued	O
and	O
patient	O
was	O
no	O
longer	O
requiring	O
insulin	I-Drug
.	O
A	O
right	O
thyroid	O
nodule	O
was	O
noted	O
on	O
CT	O
and	O
needs	O
to	O
be	O
followed	O
up	O
with	O
ultrasound	O
as	O
an	O
outpatient	O
,	O
Heme	O
:	O
Patient	O
underwent	O
serial	O
hematocrit	O
checks	O
which	O
trended	O
down	O
slowly	O
.	O
He	O
received	O
one	O
blood	I-Drug
transfusion	O
while	O
in	O
hospital	O
,	O
after	O
which	O
he	O
required	O
no	O
further	O
transfusions	O
as	O
his	O
hematocrit	O
was	O
stable	O
.	O
He	O
was	O
placed	O
on	O
SQH	I-Drug
for	O
DVT	I-Reason
prophylaxis	O
.	O
Skin	O
:	O
Patient	O
right	O
ear	O
laceration	O
was	O
repaired	O
primarily	O
by	O
plastic	O
surgery	O
.	O
He	O
was	O
placed	O
on	O
levofloxacin	I-Drug
,	O
which	O
following	O
treatment	O
course	O
,	O
was	O
discontinued	O
.	O
Medications	O
on	O
Admission	O
:	O
lopressor	I-Drug
(	O
unknown	O
dosage	O
)	O
,	O
timolol	I-Drug
Discharge	O
Medications	O
:	O
Metoprolol	B-Drug
Tartrate	I-Drug
12.5	O
mg	O
PO	O
/	O
NG	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
Timolol	B-Drug
Maleate	I-Drug
0.5	O
%	O
1	O
DROP	O
BOTH	O
EYES	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
Levofloxacin	I-Drug
500	O
mg	O
PO	O
Q24H	O
x	O
4	O
days	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Location	O
(	O
un	O
)	O
932	O
**	O
]	O
vna	O
Discharge	O
Diagnosis	O
:	O
Anterior	O
right	O
rib	O
fractures	O
[	O
**	O
2	O
-	O
6	O
**	O
]	O
Right	O
pneumothorax	O
Bilateral	O
pulmonary	O
contusions	O
Left	O
zygomatic	O
arch	O
fracture	O
Left	O
lateral	O
pterygoid	O
plate	O
fracture	O
Left	O
lateral	O
orbital	O
wall	O
fracture	O
Left	O
minimally	O
displaced	O
orbital	O
floor	O
fracture	O
Bilateral	O
lateral	O
wall	O
maxillary	O
sinus	O
fractures	O
Right	O
ear	O
skin	O
avulsion	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Please	O
call	O
your	O
doctor	O
or	O
nurse	O
practitioner	O
if	O
you	O
experience	O
the	O
following	O
:	O
*	O
You	O
experience	O
new	O
chest	O
pain	O
,	O
pressure	O
,	O
squeezing	O
or	O
tightness	O
.	O
*	O
New	O
or	O
worsening	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheeze	O
.	O
*	O
If	O
you	O
are	O
vomiting	O
and	O
can	O
not	O
keep	O
down	O
fluids	O
or	O
your	O
medications	O
.	O
*	O
You	O
are	O
getting	O
dehydrated	O
due	O
to	O
continued	O
vomiting	O
,	O
diarrhea	O
,	O
or	O
other	O
reasons	O
.	O
Signs	O
of	O
dehydration	O
include	O
dry	O
mouth	O
,	O
rapid	O
heartbeat	O
,	O
or	O
feeling	O
dizzy	O
or	O
faint	O
when	O
standing	O
.	O
*	O
You	O
see	O
blood	O
or	O
dark	O
/	O
black	O
material	O
when	O
you	O
vomit	O
or	O
have	O
a	O
bowel	O
movement	O
.	O
*	O
You	O
experience	O
burning	O
when	O
you	O
urinate	O
,	O
have	O
blood	O
in	O
your	O
urine	O
,	O
or	O
experience	O
a	O
discharge	O
.	O
*	O
Your	O
pain	O
is	O
not	O
improving	O
within	O
8	O
-	O
12	O
hours	O
or	O
is	O
not	O
gone	O
within	O
24	O
hours	O
.	O
Call	O
or	O
return	O
immediately	O
if	O
your	O
pain	O
is	O
getting	O
worse	O
or	O
changes	O
location	O
or	O
moving	O
to	O
your	O
chest	O
or	O
back	O
.	O
*	O
You	O
have	O
shaking	O
chills	O
,	O
or	O
fever	O
greater	O
than	O
101.5	O
degrees	O
Fahrenheit	O
or	O
38	O
degrees	O
Celsius	O
.	O
*	O
Any	O
change	O
in	O
your	O
symptoms	O
,	O
or	O
any	O
new	O
symptoms	O
that	O
concern	O
you	O
.	O
.	O
General	O
Discharge	O
Instructions	O
:	O
Please	O
resume	O
all	O
regular	O
home	O
medications	O
,	O
unless	O
specifically	O
advised	O
not	O
to	O
take	O
a	O
particular	O
medication	O
.	O
Also	O
,	O
please	O
take	O
any	O
new	O
medications	O
as	O
prescribed	O
.	O
Please	O
get	O
plenty	O
of	O
rest	O
,	O
continue	O
to	O
ambulate	O
several	O
times	O
per	O
day	O
,	O
and	O
drink	O
adequate	O
amounts	O
of	O
fluids	O
.	O
Avoid	O
lifting	O
weights	O
greater	O
than	O
[	O
**	O
5	O
-	O
9	O
**	O
]	O
lbs	O
until	O
you	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
,	O
who	O
will	O
instruct	O
you	O
further	O
regarding	O
activity	O
restrictions	O
.	O
Avoid	O
driving	O
or	O
operating	O
heavy	O
machinery	O
while	O
taking	O
pain	I-Drug
medications	O
.	O
Please	O
follow	O
-	O
up	O
with	O
your	O
surgeon	O
and	O
Primary	O
Care	O
Provider	O
(	O
PCP	O
)	O
as	O
advised	O
.	O
Incision	O
Care	O
:	O
*	O
Please	O
call	O
your	O
doctor	O
or	O
nurse	O
practitioner	O
if	O
you	O
have	O
increased	O
pain	O
,	O
swelling	O
,	O
redness	O
,	O
or	O
drainage	O
from	O
the	O
incision	O
site	O
.	O
*	O
Avoid	O
swimming	O
and	O
baths	O
until	O
your	O
follow	O
-	O
up	O
appointment	O
.	O
*	O
You	O
may	O
shower	O
,	O
and	O
wash	O
surgical	O
incisions	O
with	O
a	O
mild	O
soap	O
and	O
warm	O
water	O
.	O
Gently	O
pat	O
the	O
area	O
dry	O
.	O
*	O
If	O
you	O
have	O
staples	O
,	O
they	O
will	O
be	O
removed	O
at	O
your	O
follow	O
-	O
up	O
appointment	O
.	O
*	O
If	O
you	O
have	O
steri	O
-	O
strips	O
,	O
they	O
will	O
fall	O
off	O
on	O
their	O
own	O
.	O
Please	O
remove	O
any	O
remaining	O
strips	O
7	O
-	O
10	O
days	O
after	O
surgery	O
.	O
Followup	O
Instructions	O
:	O
Please	O
call	O
ACS	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
600	O
**	O
]	O
to	O
make	O
a	O
follow	O
-	O
up	O
appointment	O
within	O
2	O
-	O
3	O
weeks	O
Please	O
contact	O
the	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
90000	O
**	O
]	O
at	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
5343	O
**	O
]	O
with	O
Plastic	O
Surgery	O
to	O
make	O
a	O
follow	O
-	O
up	O
appointment	O
for	O
1	O
week	O
from	O
discharge	O
.	O
Please	O
contact	O
your	O
primary	O
care	O
provider	O
and	O
make	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
**	O
]	O
follow	O
-	O
up	O
appointment	O
within	O
2	O
weeks	O
.	O
You	O
will	O
need	O
to	O
have	O
an	O
ultrasound	O
of	O
your	O
thyroid	O
as	O
well	O
as	O
work	O
-	O
up	O
of	O
an	O
inguinal	O
hernia	O
.	O
Completed	O
by	O
:[	O
**	O
2113-3-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2171-3-26	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2171-3-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
Sex	O
:	O
F	O
Service	O
:	O
GYN	O
/	O
ONCOLOGY	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
a	O
58	O
year	O
-	O
old	O
P3	O
who	O
presented	O
to	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1022	O
**	O
]	O
with	O
a	O
large	O
pelvic	O
mass	O
.	O
She	O
had	O
a	O
history	O
of	O
undergoing	O
exploratory	O
laparotomy	O
for	O
appendicitis	O
in	O
[	O
**	O
2170-5-28	O
**	O
]	O
.	O
At	O
that	O
time	O
a	O
necrotic	O
right	O
fallopian	O
tube	O
was	O
excised	O
and	O
the	O
patient	O
was	O
noted	O
to	O
have	O
a	O
pelvic	O
mass	O
.	O
No	O
further	O
follow	O
up	O
until	O
recently	O
when	O
she	O
presented	O
to	O
[	O
**	O
Hospital6	O
1597	O
**	O
]	O
with	O
severe	O
anemia	O
and	O
a	O
gastrointestinal	O
bleed	O
.	O
She	O
had	O
a	O
transfusion	O
with	O
7	O
units	O
of	O
whole	O
blood	O
.	O
She	O
had	O
a	O
CT	O
during	O
her	O
hospitalization	O
,	O
which	O
revealed	O
a	O
large	O
abdominal	O
and	O
pelvic	O
mass	O
.	O
She	O
had	O
a	O
full	O
gastrointestinal	O
evaluation	O
,	O
which	O
included	O
an	O
upper	O
endoscopy	O
,	O
colonoscopy	O
and	O
small	O
bowel	O
follow	O
through	O
all	O
of	O
which	O
were	O
negative	O
.	O
The	O
patient	O
states	O
that	O
during	O
colonoscopy	O
the	O
right	O
side	O
of	O
the	O
colon	O
could	O
not	O
be	O
visualized	O
due	O
to	O
the	O
presence	O
of	O
the	O
mass	O
.	O
The	O
patient	O
complains	O
of	O
nausea	O
and	O
increased	O
abdominal	O
girth	O
.	O
She	O
has	O
chronic	O
constipation	O
and	O
there	O
is	O
nothing	O
new	O
.	O
There	O
is	O
no	O
other	O
change	O
in	O
bowel	O
or	O
urinary	O
habits	O
.	O
She	O
denies	O
any	O
vaginal	O
bleeding	O
and	O
any	O
weight	O
loss	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Hypertension	O
.	O
2	O
.	O
Psoriasis	O
.	O
3	O
.	O
Chronic	O
pain	O
syndrome	O
.	O
PAST	O
SURGICAL	O
HISTORY	O
:	O
Uterine	O
embolization	O
[	O
**	O
2169-11-28	O
**	O
]	O
.	O
Tubal	O
ligation	O
in	O
[	O
**	O
2143	O
**	O
]	O
.	O
Decompression	O
and	O
fusion	O
[	O
**	O
2169	O
**	O
]	O
.	O
Appendectomy	O
[	O
**	O
2169	O
**	O
]	O
.	O
Multiple	O
breast	O
adenoma	O
excisions	O
.	O
ALLERGIES	O
:	O
No	O
known	O
drug	O
allergies	O
.	O
MEDICATIONS	O
:	O
1	O
.	O
Tylenol	I-Drug
.	O
2	O
.	O
Lasix	I-Drug
.	O
3	O
.	O
Ativan	I-Drug
.	O
4	O
.	O
OxyContin	I-Drug
.	O
5	O
.	O
Celexa	I-Drug
.	O
6	O
.	O
Atarax	I-Drug
.	O
7	O
.	O
Neurontin	I-Drug
.	O
OB	O
HISTORY	O
:	O
Vaginal	O
delivery	O
times	O
three	O
.	O
GYN	O
HISTORY	O
:	O
Last	O
pap	O
smear	O
several	O
years	O
ago	O
normal	O
.	O
Last	O
mammogram	O
[	O
**	O
2171-1-26	O
**	O
]	O
normal	O
.	O
FAMILY	O
HISTORY	O
:	O
Significant	O
for	O
mother	O
with	O
breast	O
cancer	O
.	O
Sister	O
with	O
anal	O
cancer	O
and	O
a	O
brother	O
with	O
skin	O
cancer	O
.	O
SOCIAL	O
HISTORY	O
:	O
The	O
patient	O
does	O
not	O
smoke	O
or	O
drink	O
.	O
She	O
is	O
a	O
retired	O
nurse	O
.	O
REVIEW	O
OF	O
SYSTEMS	O
:	O
As	O
above	O
and	O
otherwise	O
noncontributory	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
General	O
appearance	O
,	O
well	O
developed	O
,	O
well	O
nourished	O
,	O
thin	O
.	O
HEENT	O
lymph	O
node	O
survey	O
was	O
negative	O
.	O
Lungs	O
were	O
clear	O
to	O
auscultation	O
.	O
Heart	O
was	O
regular	O
rate	O
and	O
rhythm	O
without	O
murmurs	O
.	O
Breasts	O
were	O
without	O
masses	O
.	O
Abdomen	O
was	O
soft	O
and	O
moderately	O
distended	O
.	O
There	O
was	O
a	O
large	O
palpable	O
mass	O
in	O
both	O
the	O
upper	O
and	O
lower	O
abdomen	O
.	O
There	O
was	O
no	O
evidence	O
of	O
ascites	O
.	O
Extremities	O
were	O
without	O
edema	O
.	O
On	O
bimanual	O
examination	O
vulva	O
and	O
vagina	O
were	O
normal	O
.	O
The	O
cervix	O
was	O
normal	O
.	O
Bimanual	O
rectovaginal	O
examination	O
revealed	O
a	O
large	O
pelvic	O
mass	O
,	O
which	O
was	O
somewhat	O
ill	O
-	O
defined	O
.	O
There	O
was	O
no	O
cul	O
-	O
de-sac	O
nodularity	O
and	O
the	O
rectum	O
was	O
intrinsically	O
normal	O
.	O
It	O
was	O
explained	O
to	O
the	O
patient	O
that	O
this	O
mass	O
could	O
be	O
benign	O
or	O
malignant	O
and	O
it	O
was	O
recommended	O
to	O
undergo	O
surgical	O
excision	O
including	O
exploratory	O
laparotomy	O
,	O
TAH	O
/	O
BSO	O
and	O
resection	O
of	O
the	O
mass	O
.	O
The	O
risks	O
and	O
benefits	O
were	O
discussed	O
.	O
Surgical	O
consent	O
was	O
signed	O
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
underwent	O
an	O
examination	O
under	O
anesthesia	O
,	O
exploratory	O
laparotomy	O
,	O
TAH	O
/	O
BSO	O
and	O
resection	O
of	O
a	O
pelvic	O
mass	O
on	O
[	O
**	O
2171-3-26	O
**	O
]	O
.	O
Intraoperative	O
findings	O
include	O
an	O
enlarged	O
uterus	O
with	O
a	O
subserosal	O
fibroid	O
and	O
evidence	O
of	O
tumor	O
extending	O
to	O
the	O
right	O
lateral	O
rectoperitoneum	O
as	O
well	O
as	O
centrally	O
and	O
left	O
into	O
the	O
sigmoid	O
and	O
small	O
bowel	O
mesentery	O
up	O
to	O
the	O
splenic	O
flexure	O
of	O
the	O
colon	O
.	O
The	O
anatomic	O
survey	O
was	O
otherwise	O
unremarkable	O
.	O
There	O
was	O
subcentimeter	O
periaortic	O
lymph	O
nodes	O
and	O
normal	O
ovaries	O
bilaterally	O
with	O
2	O
liters	O
of	O
bloody	O
ascites	O
in	O
the	O
abdomen	O
.	O
Estimated	O
blood	O
loss	O
3	O
liters	O
.	O
Secondary	O
to	O
the	O
patient	O
's	O
blood	O
loss	O
,	O
large	O
amount	O
of	O
ascites	O
and	O
extensive	O
surgery	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
critical	O
care	O
.	O
On	O
postoperative	O
day	O
zero	O
her	O
vital	O
signs	O
were	O
stable	O
.	O
Her	O
abdomen	O
was	O
nondistended	O
with	O
only	O
a	O
small	O
amount	O
of	O
drainage	O
from	O
the	O
inferior	O
aspect	O
of	O
the	O
incision	O
.	O
The	O
patient	O
's	O
hematocrit	O
was	O
27.2	O
,	O
INR	O
1.2	O
,	O
PTT	O
28.3	O
,	O
electrolytes	O
were	O
within	O
normal	O
limits	O
.	O
The	O
patient	O
at	O
this	O
time	O
had	O
been	O
transferred	O
to	O
the	O
unit	O
for	O
further	O
monitoring	O
.	O
She	O
had	O
been	O
given	O
7	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
.	O
She	O
was	O
in	O
stable	O
condition	O
.	O
Postoperative	O
day	O
one	O
the	O
patient	O
's	O
vital	O
signs	O
continued	O
to	O
be	O
stable	O
with	O
adequate	O
urine	O
output	O
overnight	O
.	O
Her	O
examination	O
was	O
appropriate	O
postoperatively	O
.	O
On	O
postoperative	O
day	O
one	O
hemodynamically	O
yesterday	O
's	O
hematocrit	O
was	O
27	O
,	O
which	O
improved	O
to	O
34	O
after	O
2	O
more	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
.	O
There	O
is	O
no	O
evidence	O
of	O
ongoing	O
intraabdominal	O
bleeding	O
.	O
Fluids	O
,	O
electrolytes	O
and	O
nutrition	O
:	O
the	O
patient	O
had	O
adequate	O
urine	O
output	O
with	O
no	O
evidence	O
of	O
fluid	O
overload	O
.	O
Pain	O
,	O
the	O
patient	O
was	O
on	O
a	O
Dilaudid	I-Drug
PCA	O
.	O
On	O
postoperative	O
day	O
two	O
the	O
patient	O
was	O
extubated	O
.	O
Her	O
pain	O
was	O
controlled	O
.	O
She	O
was	O
tolerating	O
clears	O
.	O
No	O
nausea	O
or	O
vomiting	O
.	O
No	O
chest	O
pain	O
or	O
shortness	O
of	O
breath	O
.	O
She	O
was	O
afebrile	O
.	O
Her	O
vital	O
signs	O
were	O
stable	O
.	O
She	O
had	O
adequate	O
urine	O
output	O
.	O
Her	O
most	O
recent	O
hematocrit	O
was	O
34.5	O
.	O
Her	O
electrolytes	O
were	O
within	O
normal	O
limits	O
.	O
Her	O
abdomen	O
was	O
appropriately	O
tender	O
and	O
nondistended	O
.	O
Renal	O
:	O
her	O
urine	O
output	O
was	O
normal	O
.	O
Her	O
Foley	O
catheter	O
was	O
discontinued	O
.	O
Her	O
creatinine	O
was	O
0.6	O
.	O
The	O
patient	O
was	O
encouraged	O
to	O
ambulate	O
.	O
Her	O
diet	O
was	O
advanced	O
.	O
Hematology	O
:	O
patient	O
had	O
9	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
,	O
4	O
units	O
of	O
fresh	I-Drug
frozen	O
platelets	O
.	O
Her	O
blood	O
pressure	O
was	O
stable	O
.	O
Her	O
hematocrit	O
was	O
34.5	O
.	O
Coumadinization	I-Drug
was	O
started	O
on	O
postoperative	O
day	O
two	O
.	O
Pulmonary	O
,	O
the	O
patient	O
's	O
supplemental	O
oxygen	I-Drug
was	O
weaned	O
for	O
oxygenation	O
of	O
greater	O
then	O
93	O
%	O
.	O
On	O
postoperative	O
day	O
three	O
the	O
patient	O
was	O
without	O
complaints	O
.	O
She	O
was	O
tolerating	O
clears	O
.	O
The	O
pain	I-Reason
was	O
adequately	O
controlled	O
on	O
40	O
mg	O
of	O
OxyContin	I-Drug
t.i.d.	O
and	O
Percocet	I-Drug
for	O
breakthrough	B-Reason
pain	I-Reason
.	O
Cardiovascularly	O
the	O
patient	O
has	O
a	O
history	O
of	O
hypertension	O
,	O
which	O
was	O
controlled	O
with	O
Lasix	I-Drug
40	O
mg	O
q	O
day	O
.	O
The	O
patient	O
was	O
deemed	O
stable	O
enough	O
for	O
discharge	O
to	O
home	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Pelvic	O
mass	O
status	O
post	O
exploratory	O
laparotomy	O
,	O
pelvic	O
washings	O
,	O
TAH	O
/	O
BSO	O
,	O
pelvic	O
mass	O
resection	O
.	O
2	O
.	O
Blood	O
loss	O
anemia	O
requiring	O
blood	O
transfusion	O
.	O
3	O
.	O
Hypertension	O
.	O
4	O
.	O
Chronic	O
pain	O
syndrome	O
.	O
DISCHARGE	O
CONDITION	O
:	O
Good	O
.	O
DISCHARGE	O
STATUS	O
:	O
The	O
patient	O
was	O
discharged	O
to	O
home	O
without	O
services	O
.	O
She	O
will	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
1022	O
**	O
]	O
as	O
an	O
outpatient	O
in	O
approximately	O
two	O
weeks	O
for	O
postoperative	O
visit	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
1	O
.	O
Percocet	I-Drug
.	O
2	O
.	O
Motrin	I-Drug
.	O
3	O
.	O
Celexa	I-Drug
.	O
4	O
.	O
Lasix	I-Drug
.	O
DR.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
16	O
-	O
314	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
6763	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2171-9-30	O
**	O
]	O
02:41	O
T	O
:	O
[	O
**	O
2171-10-1	O
**	O
]	O
08:23	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
49231	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2181-7-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2181-8-5	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2100-11-15	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1711	O
**	O
]	O
Chief	O
Complaint	O
:	O
Transferred	O
for	O
management	O
of	O
STEMI	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
temporary	O
dialysis	O
line	O
placement	O
cordis	O
placement	O
arterial	O
line	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
80	O
year	O
old	O
woman	O
(	O
DNR	O
)	O
with	O
two	O
recent	O
MI	O
's	O
,	O
known	O
severe	O
CAD	O
with	O
a	O
95	O
%	O
LM	O
stenosis	O
(	O
felt	O
not	O
to	O
be	O
a	O
candidate	O
for	O
CABG	O
)	O
,	O
cardiomyopathy	O
with	O
an	O
LVEF	O
of	O
15	O
-	O
20	O
%	O
,	O
moderate	O
aortic	O
stenosis	O
,	O
HTN	O
,	O
AF	O
,	O
hepatitis	O
C	O
with	O
thrombocytopenia	O
,	O
s	O
/	O
p	O
recent	O
cath	O
/	O
admission	O
at	O
[	O
**	O
Hospital1	O
**	O
]	O
where	O
PCI	O
was	O
not	O
an	O
option	O
and	O
CABG	O
is	O
too	O
high	O
risk	O
.	O
Patient	O
has	O
continued	O
to	O
have	O
ischemic	O
events	O
since	O
then	O
with	O
recent	O
presentation	O
with	O
new	O
onset	O
AF	O
,	O
echo	O
revealing	O
wall	O
motion	O
abnormality	O
involving	O
the	O
anterior	O
wall	O
and	O
apex	O
with	O
possible	O
thrombus	O
in	O
the	O
LV	O
apex	O
.	O
Medical	O
management	O
continued	O
with	O
eventual	O
discharge	O
to	O
home	O
earlier	O
this	O
week	O
.	O
She	O
did	O
okay	O
initially	O
and	O
then	O
represented	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
on	O
[	O
**	O
2181-7-26	O
**	O
]	O
evening	O
with	O
chest	O
pain	O
[	O
**	O
11	O
-	O
24	O
**	O
]	O
radiating	O
to	O
the	O
left	O
arm	O
and	O
back	O
,	O
associated	O
with	O
diaphoresis	O
,	O
lightheadedness	O
,	O
shortness	O
of	O
breath	O
and	O
ST	O
elevation	O
.	O
Family	O
refused	O
TPA	I-Drug
due	O
to	O
hx	O
of	O
thrombocytopenia	O
.	O
IV	O
nitro	I-Drug
inititated	O
,	O
heparin	I-Drug
,	O
aspirin	I-Drug
initiated	O
and	O
now	O
painfree	O
.	O
Troponin	O
last	O
drawn	O
was	O
13	O
(	O
still	O
rising	O
)	O
although	O
there	O
's	O
no	O
lab	O
sent	O
with	O
her	O
.	O
Currently	O
with	O
minimal	O
chest	O
discomfort	O
.	O
EKG	O
demonstrated	O
ST	O
elevation	O
inferiorly	O
at	O
tuft	O
's	O
.	O
Plans	O
are	O
for	O
evaluation	O
here	O
for	O
further	O
treatment	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
to	O
consult	O
.	O
On	O
arrival	O
here	O
pt	O
's	O
pain	O
free	O
and	O
without	O
complaint	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
CARDIAC	O
RISK	O
FACTORS	O
:	O
htn	O
,	O
hl	O
2	O
.	O
CARDIAC	O
HISTORY	O
:	O
-	O
CABG	O
:	O
n	O
/	O
a	O
-	O
PERCUTANEOUS	O
CORONARY	O
INTERVENTIONS	O
:	O
n	O
/	O
a	O
-	O
PACING	O
/	O
ICD	O
:	O
n	O
/	O
a	O
3	O
.	O
Others	O
:	O
hepatitis	O
C	O
multiple	O
hepatic	O
nodules	O
with	O
multiple	O
biopsies	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O
severe	O
diffuse	O
coronary	O
artery	O
disease	O
severe	O
cardiomyopathy	O
with	O
ef	O
of	O
15	O
-	O
20	O
%	O
severe	O
tricuspid	O
regurgitation	O
with	O
estimated	O
pa	O
pressure	O
of	O
53mmHg	O
moderate	O
aortic	O
stenosis	O
hypertension	O
hyperlipidemia	O
atrial	O
fibrillation	O
thrombocytopenia	O
Social	O
History	O
:	O
Patient	O
lives	O
with	O
daughters	O
.	O
she	O
denies	O
tobacco	O
,	O
alcohol	O
or	O
iv	O
drug	O
use	O
Family	O
History	O
:	O
Non-contibutory	O
Physical	O
Exam	O
:	O
temp	O
97.6	O
,	O
hr	O
62	O
/	O
min	O
,	O
bp	O
110/62	O
,	O
sats	O
97	O
%	O
on	O
ra	O
GENERAL	O
:	O
In	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Mood	O
,	O
affect	O
appropriate	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
No	O
xanthalesma	O
.	O
NECK	O
:	O
Supple	O
with	O
no	O
JVD	O
.	O
CARDIAC	O
:	O
rrr	O
,	O
nl	O
s1	O
,	O
faint	O
s2	O
,	O
[	O
**	O
4	O
-	O
20	O
**	O
]	O
ESM	O
as	O
well	O
as	O
[	O
**	O
4	O
-	O
20	O
**	O
]	O
PSM	O
.	O
LUNGS	O
:	O
No	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
CTAB	O
,	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
Abd	O
aorta	O
not	O
enlarged	O
by	O
palpation	O
.	O
No	O
abdominial	O
bruits	O
.	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
No	O
femoral	O
bruits	O
.	O
SKIN	O
:	O
No	O
stasis	O
dermatitis	O
,	O
ulcers	O
,	O
scars	O
,	O
or	O
xanthomas	O
.	O
PULSES	O
:	O
1	O
+	O
dp	O
and	O
pt	O
pulses	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2181-7-27	O
**	O
]	O
11:48	O
PM	O
BLOOD	O
WBC	O
-	O
7.7	O
RBC	O
-	O
3.83	O
*	O
Hgb	O
-	O
12.9	O
Hct	O
-	O
37.4	O
MCV	O
-	O
98	O
MCH	O
-	O
33.6	O
*	O
MCHC	O
-	O
34.4	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
112	O
*	O
[	O
**	O
2181-7-27	O
**	O
]	O
11:48	O
PM	O
BLOOD	O
Glucose	O
-	O
147	O
*	O
UreaN	O
-	O
34	O
*	O
Creat	O
-	O
1.4	O
*	O
Na	O
-	O
138	O
K	O
-	O
3.8	O
Cl	O
-	O
98	O
HCO3	O
-	O
28	O
AnGap	O
-	O
16	O
[	O
**	O
2181-7-27	O
**	O
]	O
11:48	O
PM	O
BLOOD	O
ALT	O
-	O
115	O
*	O
AST	O
-	O
303	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
1379	O
*	O
AlkPhos	O
-	O
99	O
TotBili	O
-	O
0.6	O
[	O
**	O
2181-7-27	O
**	O
]	O
11:48	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
250	O
*	O
MB	O
Indx	O
-	O
18.1	O
*	O
cTropnT	O
-	O
3.03	O
*	O
[	O
**	O
2181-7-28	O
**	O
]	O
06:18	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
217	O
*	O
MB	O
Indx	O
-	O
16.2	O
*	O
[	O
**	O
2181-7-28	O
**	O
]	O
03:44	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
122	O
*	O
MB	O
Indx	O
-	O
12.6	O
*	O
cTropnT	O
-	O
4.02	O
*	O
[	O
**	O
2181-7-30	O
**	O
]	O
05:22	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
22	O
*	O
cTropnT	O
-	O
4.05	O
*	O
MICROBIOLOGY	O
Urine	O
Cx	O
:	O
[	O
**	O
7	O
-	O
31	O
**	O
]	O
,	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
negative	O
IMAGING	O
:	O
ECHO	O
[	O
**	O
2181-7-28	O
**	O
]	O
:	O
Symmetric	O
left	O
ventricular	O
hypertrophy	O
.	O
Mild	O
regional	O
dysfunction	O
consistent	O
with	O
CAD	O
.	O
Moderately	O
dilated	O
right	O
ventricle	O
with	O
borderline	O
normal	O
function	O
.	O
Tricuspid	O
leaflets	O
do	O
not	O
coapt	O
and	O
there	O
is	O
corresponding	O
moderate	O
to	O
severe	O
tricuspid	O
regurgitation	O
.	O
Pulmonary	O
pressures	O
can	O
not	O
be	O
accurately	O
determined	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
Moderate	O
aortic	O
stenosis	O
.	O
ECG	O
[	O
**	O
2181-7-28	O
**	O
]	O
:	O
Sinus	O
rhythm	O
with	O
PACs	O
Prolonged	O
QT	O
interval	O
Inferior	O
infarct	O
-	O
age	O
undetermined	O
Anteroseptal	O
infarct	O
-	O
age	O
undetermined	O
ST	O
-	O
T	O
changes	O
may	O
be	O
due	O
to	O
myocardial	O
ischemia	O
No	O
previous	O
tracing	O
available	O
for	O
comparison	O
Brief	O
Hospital	O
Course	O
:	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
55334	O
**	O
]	O
is	O
an	O
80	O
year	O
old	O
female	O
with	O
a	O
history	O
of	O
LMain	O
and	O
3VD	O
,	O
moderate	O
aortic	O
stenosis	O
and	O
with	O
status	O
post	O
cardiac	O
cath	O
for	O
STEMI	O
back	O
on	O
[	O
**	O
2181-7-17	O
**	O
]	O
at	O
OSH	O
that	O
was	O
not	O
intervened	O
upon	O
by	O
PCI	O
or	O
CABG	O
who	O
then	O
presented	O
to	O
another	O
OSH	O
with	O
an	O
inferior	O
STEMI	O
on	O
[	O
**	O
2181-7-26	O
**	O
]	O
and	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
and	O
a	O
second	O
opinion	O
regarding	O
options	O
for	O
revascularization	O
.	O
CABG	O
versus	O
high	O
risk	O
PCI	O
were	O
considered	O
and	O
CT	O
surgery	O
was	O
consulted	O
.	O
Patient	O
remained	O
chest	O
pain	O
free	O
on	O
medical	O
management	O
of	O
her	O
CAD	O
,	O
however	O
,	O
the	O
acute	O
renal	O
failure	O
she	O
presented	O
with	O
evolved	O
rapidly	O
from	O
the	O
beginning	O
of	O
her	O
course	O
,	O
making	O
either	O
surgical	O
or	O
PCI	O
less	O
of	O
an	O
option	O
.	O
Renal	O
was	O
consulted	O
and	O
felt	O
her	O
renal	O
failure	O
was	O
likely	O
attributable	O
to	O
evolving	O
ATN	O
in	O
the	O
setting	O
of	O
poor	O
forward	O
flow	O
related	O
to	O
her	O
recent	O
MI	O
and	O
possibly	O
due	O
to	O
contrast	O
nephropathy	O
given	O
a	O
recent	O
catheterization	O
.	O
The	O
patient	O
became	O
oliguric	O
and	O
subsequently	O
volume	O
overloaded	O
and	O
hypoxic	O
.	O
Aggressive	O
diuresis	I-Reason
with	O
IV	O
lasix	I-Drug
and	O
diuril	I-Drug
were	O
unsuccessful	O
so	O
CVVH	O
was	O
initiated	O
.	O
At	O
this	O
point	O
she	O
had	O
become	O
hemodynamically	B-Reason
unstable	I-Reason
requiring	O
pressor	O
support	O
with	O
dopamine	I-Drug
.	O
Hemodynamic	O
instability	O
was	O
likely	O
also	O
affected	O
by	O
patient	O
's	O
development	O
of	O
slow	O
atrial	O
fibrillation	O
which	O
requried	O
placement	O
of	O
a	O
trancutaneous	O
pacer	O
.	O
Her	O
dopamine	I-Drug
requirement	O
increased	O
significantly	O
with	O
CVVH	O
which	O
likely	O
contributed	O
to	O
the	O
development	O
of	O
metabolic	B-Ade
acidosis	I-Ade
.	O
On	O
[	O
**	O
8	O
-	O
4	O
**	O
]	O
the	O
patient	O
was	O
found	O
to	O
have	O
a	O
lactate	O
of	O
11	O
and	O
had	O
developed	O
agonal	O
respirations	O
.	O
She	O
underwent	O
intubation	O
which	O
did	O
not	O
help	O
to	O
improve	O
her	O
worsening	O
acidemia	O
.	O
The	O
patient	O
's	O
family	O
decided	O
to	O
change	O
her	O
code	O
status	O
to	O
DNR	O
/	O
DNI	O
and	O
soon	O
after	O
to	O
CMO	O
when	O
it	O
was	O
clear	O
that	O
her	O
prognosis	O
had	O
become	O
very	O
poor	O
.	O
She	O
was	O
pronounced	O
dead	O
on	O
[	O
**	O
2181-8-5	O
**	O
]	O
at	O
0313	O
.	O
Her	O
three	O
daughters	O
were	O
at	O
her	O
bedside	O
and	O
agreed	O
in	O
declining	O
an	O
autopsy	O
.	O
Medications	O
on	O
Admission	O
:	O
Outpatient	O
Meds	O
:	O
lipitor	I-Drug
80	O
mg	O
daily	O
plavix	I-Drug
75	O
mg	O
daily	O
toprol	B-Drug
xl	I-Drug
50	O
mg	O
daily	O
zestril	I-Drug
5	O
mg	O
daily	O
alsix	I-Drug
80	O
mg	O
daily	O
aspirin	I-Drug
81	O
mg	O
daily	O
Meds	O
On	O
Transfer	O
:	O
IV	O
heparin	I-Drug
at	O
600u	O
/	O
hour	O
IV	O
nitro	I-Drug
at	O
30mcg	O
/	O
min	O
asa	I-Drug
325	O
mg	O
,	O
lipitor	I-Drug
20	O
mg	O
daily	O
lasix	I-Drug
80	O
mg	O
po	O
plavix	I-Drug
75	O
mg	O
zestril	I-Drug
5	O
mg	O
Discharge	O
Medications	O
:	O
NA	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Status	O
post	O
ST	O
elevation	O
myocardial	O
infarction	O
,	O
acute	O
heart	O
failure	O
,	O
renal	O
failure	O
,	O
metabolic	O
acidosis	O
,	O
respiratory	O
failure	O
Secondary	O
:	O
Aortic	O
stenosis	O
,	O
hepatitis	O
C	O
Discharge	O
Condition	O
:	O
expired	O
Discharge	O
Instructions	O
:	O
Patient	O
admitted	O
for	O
further	O
management	O
of	O
STEMI	O
.	O
Her	O
course	O
was	O
complicated	O
by	O
acute	O
renal	O
failure	O
,	O
acute	O
heart	O
failure	O
which	O
ultimately	O
led	O
to	O
pressor	I-Drug
support	O
.	O
Patient	O
developed	O
metabolic	O
acidosis	O
and	O
subsequent	O
respiratory	O
failure	O
requiring	O
intubation	O
.	O
Her	O
family	O
ultimately	O
decidied	O
to	O
make	O
her	O
DNR	O
/	O
DNI	O
and	O
soon	O
after	O
CMO	O
given	O
her	O
critical	O
condition	O
and	O
poor	O
prognosis	O
.	O
She	O
died	O
on	O
[	O
**	O
2181-8-5	O
**	O
]	O
at	O
0313	O
with	O
her	O
family	O
at	O
her	O
bedside	O
.	O
An	O
autopsy	O
was	O
declined	O
.	O
Followup	O
Instructions	O
:	O
NA	O
Completed	O
by	O
:[	O
**	O
2181-8-5	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2121-11-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2121-12-2	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2052-6-12	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
a	O
68	O
year	O
old	O
man	O
who	O
was	O
admitted	O
to	O
an	O
outside	O
hospital	O
after	O
pulling	O
his	O
chronic	O
Foley	O
catheter	O
out	O
at	O
[	O
**	O
Hospital3	O
24509	O
**	O
]	O
Home	O
.	O
The	O
patient	O
had	O
a	O
urinary	O
tract	O
infection	O
with	O
probable	O
urosepsis	O
and	O
he	O
is	O
chronically	O
treated	O
with	O
Foley	O
catheter	O
as	O
a	O
result	O
of	O
his	O
atonic	O
bladder	O
which	O
was	O
thought	O
to	O
be	O
related	O
to	O
his	O
systemic	O
amyloidosis	O
which	O
he	O
has	O
been	O
diagnosed	O
with	O
for	O
some	O
time	O
.	O
The	O
patient	O
developed	O
urosepsis	O
,	O
took	O
out	O
his	O
Foley	O
catheter	O
with	O
the	O
balloon	O
inflated	O
and	O
was	O
taken	O
to	O
an	O
outside	O
hospital	O
for	O
reinsertion	O
of	O
the	O
Foley	O
catheter	O
and	O
evaluation	O
of	O
hematuria	O
.	O
The	O
patient	O
had	O
significant	O
pain	O
with	O
reinsertion	O
of	O
the	O
Foley	O
catheter	O
and	O
was	O
resisting	O
significantly	O
in	O
the	O
Emergency	O
Room	O
and	O
was	O
given	O
multiple	O
pain	B-Drug
medications	I-Drug
,	O
most	O
notably	O
Versed	I-Drug
for	O
sedation	I-Reason
and	O
pain	B-Reason
control	I-Reason
in	O
order	O
to	O
place	O
the	O
Foley	O
catheter	O
.	O
Unfortunately	O
the	O
patient	O
became	O
apneic	O
and	O
went	O
into	O
respiratory	O
failure	O
and	O
was	O
intubated	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
[	O
**	O
Hospital6	O
256	O
**	O
]	O
intubated	O
and	O
directly	O
transferred	O
to	O
the	O
Fenard	O
Intensive	O
Care	O
Unit	O
.	O
The	O
patient	O
was	O
monitored	O
for	O
one	O
night	O
in	O
the	O
Intensive	O
Care	O
Unit	O
on	O
mechanical	O
ventilation	O
.	O
He	O
was	O
doing	O
fine	O
and	O
had	O
no	O
signs	O
of	O
pulmonary	O
function	O
outside	O
of	O
a	O
possible	O
pneumonia	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
The	O
patient	O
took	O
out	O
his	O
own	O
endotracheal	O
tube	O
on	O
the	O
second	O
day	O
of	O
admission	O
and	O
did	O
very	O
well	O
with	O
no	O
further	O
evidence	O
of	O
respiratory	I-Ade
failure	O
over-sedation	O
from	O
the	O
Versed	I-Drug
that	O
he	O
received	O
the	O
day	O
prior	O
.	O
The	O
patient	O
was	O
then	O
transferred	O
to	O
the	O
[	O
**	O
Company	O
191	O
**	O
]	O
Medicine	O
Service	O
on	O
[	O
**	O
11	O
-	O
29	O
**	O
]	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
Cardiac	O
amyloidosis	O
echocardiogram	O
from	O
[	O
**	O
2119-11-22	O
**	O
]	O
showing	O
diffusely	O
hypokinetic	O
left	O
ventricle	O
with	O
ejection	O
fraction	O
of	O
40	O
%	O
,	O
diffusely	O
hypokinetic	O
right	O
ventricle	O
,	O
amyloidosis	O
on	O
a	O
lung	O
basis	O
.	O
Left	O
lower	O
lobectomy	O
,	O
status	O
post	O
limited	O
stage	O
lung	O
cancer	O
.	O
Cervical	O
and	O
spinal	O
lumbar	O
stenosis	O
,	O
status	O
post	O
multiple	O
back	O
surgeries	O
and	O
complicated	O
by	O
atonic	O
bladder	O
,	O
peripheral	O
neuropathy	O
,	O
bilateral	O
ulnar	O
neuropathy	O
,	O
status	O
post	O
carpal	O
tunnel	O
surgery	O
on	O
the	O
right	O
,	O
depression	O
with	O
question	O
of	O
bipolar	O
disorder	O
and	O
recurrent	O
urinary	O
tract	O
infections	O
secondary	O
to	O
chronic	O
Foley	O
catheterization	O
.	O
HOSPITAL	O
COURSE	O
:	O
Shortness	O
of	O
breath	O
-	O
The	O
patient	O
continued	O
to	O
improve	O
from	O
a	O
respiratory	O
standpoint	O
and	O
required	O
no	O
oxygen	O
.	O
After	O
being	O
extubated	O
there	O
were	O
no	O
signs	O
of	O
congestive	B-Reason
heart	I-Reason
failure	I-Reason
and	O
was	O
maintained	O
on	O
1.5	O
liter	O
fluid	O
restriction	O
q.	O
day	O
and	O
his	O
outpatient	O
Lasix	I-Drug
regimen	O
.	O
Urinary	B-Reason
tract	I-Reason
infection	I-Reason
-	O
Foley	O
catheterization	O
,	O
the	O
patient	O
tolerated	O
his	O
Foley	O
catheter	O
and	O
was	O
treated	O
with	O
Levaquin	I-Drug
for	O
urinary	B-Reason
tract	I-Reason
infection	I-Reason
and	O
possible	B-Reason
left	I-Reason
lower	I-Reason
lobe	I-Reason
pneumonia	O
,	O
all	O
of	O
this	O
was	O
felt	O
to	O
be	O
atelectasis	O
upon	O
further	O
review	O
of	O
the	O
chest	O
radiographs	O
.	O
The	O
patient	O
was	O
to	O
complete	O
a	O
seven	O
day	O
course	O
of	O
Levaquin	I-Drug
,	O
500	O
mg	O
q.	O
day	O
.	O
He	O
had	O
no	O
urinary	O
symptoms	O
on	O
discharge	O
.	O
DISPOSITION	O
:	O
The	O
patient	O
was	O
discharged	O
to	O
[	O
**	O
Location	O
(	O
un	O
)	O
2716	O
**	O
]	O
Point	O
.	O
CONDITION	O
ON	O
DISCHARGE	O
:	O
The	O
patient	O
was	O
discharged	O
in	O
condition	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
1	O
.	O
Colace	I-Drug
100	O
mg	O
p.o.	O
b.i.d.	O
2	O
.	O
Lisinopril	I-Drug
40	O
mg	O
p.o.	O
q.	O
day	O
3	O
.	O
Levaquin	I-Drug
500	O
mg	O
p.o.	O
q.	O
day	O
to	O
complete	O
a	O
seven	O
day	O
course	O
4	O
.	O
Norvasc	I-Drug
5	O
mg	O
p.o.	O
q.	O
day	O
5	O
.	O
Toprol	I-Drug
100	O
mg	O
p.o.	O
q.	O
day	O
6	O
.	O
Detrol	I-Drug
discontinued	O
due	O
to	O
anticholinergic	B-Ade
side	I-Ade
effects	I-Ade
causing	O
mental	B-Ade
status	I-Ade
changes	I-Ade
7	O
.	O
Lasix	I-Drug
80	O
mg	O
p.o.	O
q.	O
day	O
8	O
.	O
Lamictal	I-Drug
200	O
mg	O
p.o.	O
q.h.s.	O
for	O
bipolar	B-Reason
disorder	I-Reason
9	O
.	O
Depakote	I-Drug
1500	O
mg	O
p.o.	O
q.h.s.	O
for	O
bipolar	B-Reason
disorder	I-Reason
10	O
.	O
Celexa	I-Drug
20	O
mg	O
p.o.	O
q.	O
day	O
for	O
depression	I-Reason
DISCHARGE	O
DIAGNOSIS	O
:	O
1	O
.	O
Respiratory	B-Ade
failure	I-Ade
secondary	O
to	O
Versed	I-Drug
overdose	O
2	O
.	O
Systemic	O
amyloidosis	O
3	O
.	O
Pulmonary	O
amyloidosis	O
4	O
.	O
Cardiac	O
amyloidosis	O
5	O
.	O
Atonic	O
bladder	O
6	O
.	O
Urinary	O
tract	O
infection	O
7	O
.	O
Urosepsis	O
ADDENDUM	O
-	O
PHYSICAL	O
EXAMINATION	O
:	O
The	O
patient	O
was	O
afebrile	O
,	O
vital	O
signs	O
stable	O
.	O
His	O
blood	O
pressure	O
was	O
150/65	O
,	O
sating	O
98	O
%	O
on	O
room	O
air	O
.	O
The	O
patient	O
was	O
in	O
no	O
acute	O
distress	O
,	O
was	O
alert	O
and	O
oriented	O
times	O
three	O
.	O
Pupils	O
equal	O
,	O
round	O
and	O
reactive	O
to	O
light	O
.	O
His	O
oropharynx	O
was	O
clear	O
,	O
no	O
signs	O
of	O
oropharyngeal	O
trauma	O
.	O
Neck	O
was	O
supple	O
with	O
occasional	O
pain	O
from	O
his	O
chronic	O
neck	O
pain	O
problems	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
lymphadenopathy	O
.	O
Lungs	O
were	O
clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
or	O
rhonchi	O
.	O
There	O
was	O
a	O
regular	O
rate	O
with	O
a	O
III	O
/	O
VI	O
systolic	O
murmur	O
at	O
the	O
right	O
sternal	O
border	O
which	O
was	O
old	O
.	O
Abdomen	O
was	O
soft	O
,	O
nontender	O
,	O
nondistended	O
,	O
bowel	O
sounds	O
were	O
active	O
.	O
Pulses	O
were	O
2	O
+	O
in	O
the	O
lower	O
extremities	O
and	O
upper	O
extremities	O
bilaterally	O
.	O
The	O
patient	O
had	O
1	O
+	O
deep	O
tendon	O
reflexes	O
in	O
the	O
upper	O
extremities	O
,	O
lower	O
extremities	O
bilaterally	O
,	O
5/5	O
strength	O
in	O
the	O
upper	O
extremities	O
,	O
lower	O
extremities	O
bilaterally	O
.	O
No	O
rashes	O
.	O
No	O
edema	O
.	O
LABORATORY	O
DATA	O
:	O
White	O
count	O
was	O
1.6	O
,	O
hemoglobin	O
12.3	O
,	O
hematocrit	O
39.1	O
,	O
MCV	O
87	O
,	O
platelets	O
150	O
.	O
Cerebrospinal	O
fluid	O
analysis	O
showed	O
1	O
white	O
blood	O
cell	O
,	O
4	O
red	O
blood	O
cells	O
,	O
100	O
%	O
lymphocytes	O
in	O
Tube	O
4	O
.	O
Chem	O
-	O
7	O
glucose	O
was	O
95	O
,	O
BUN	O
20	O
,	O
creatinine	O
.8	O
,	O
sodium	O
139	O
,	O
potassium	O
4.1	O
,	O
chloride	O
104	O
,	O
bicarbonate	O
23	O
,	O
calcium	O
8.4	O
,	O
phosphate	O
3.0	O
,	O
magnesium	O
1.7	O
.	O
Cerebrospinal	O
fluid	O
protein	O
was	O
47	O
and	O
glucose	O
was	O
54	O
,	O
both	O
were	O
normal	O
.	O
Urine	O
culture	O
was	O
negative	O
.	O
Cerebrospinal	O
fluid	O
culture	O
was	O
negative	O
with	O
no	O
polymorphonuclear	O
leukocytes	O
and	O
no	O
microorganisms	O
seen	O
,	O
no	O
growth	O
on	O
culture	O
.	O
Chest	O
x-ray	O
was	O
as	O
above	O
.	O
Electrocardiogram	O
was	O
sinus	O
rhythm	O
,	O
left	O
anterior	O
vesicular	O
block	O
,	O
left	O
bundle	O
branch	O
block	O
,	O
old	O
inferior	O
infarct	O
,	O
no	O
significant	O
change	O
from	O
the	O
last	O
electrocardiogram	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
5712	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
7942	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2121-12-2	O
**	O
]	O
11:24	O
T	O
:	O
[	O
**	O
2121-12-2	O
**	O
]	O
11:36	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
101513	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2112-11-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2112-12-16	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2049-3-2	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4358	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypoglycemia	O
;	O
seizure	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Tunneled	O
dialysis	O
line	O
placement	O
Central	O
venous	O
line	O
placement	O
and	O
removal	O
Peripherally	O
-	O
inserted	O
central	O
catheter	O
placement	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
63	O
year	O
-	O
old	O
man	O
with	O
a	O
PMH	O
notable	O
for	O
ESRD	O
on	O
HD	O
(	O
MWF	O
)	O
,	O
chronic	O
aspiration	O
,	O
seizure	B-Reason
disorder	I-Reason
,	O
history	O
of	O
CVA	O
with	O
residual	O
left	O
-	O
sided	O
weakness	O
and	O
dysarthria	O
,	O
who	O
presented	O
to	O
the	O
ED	O
s	O
/	O
p	O
seizure	O
.	O
Patient	O
denies	O
having	O
seizure	O
activity	O
though	O
brought	O
in	O
after	O
[	O
**	O
2	O
-	O
25	O
**	O
]	O
witnessed	O
seizures	O
at	O
his	O
day	O
program	O
.	O
Unclear	O
what	O
day	O
nurses	O
saw	O
at	O
the	O
rehab	O
or	O
if	O
he	O
fell	O
.	O
Patient	O
denies	O
headache	O
,	O
blurry	O
vision	O
,	O
numbness	O
,	O
tingling	O
,	O
weakness	O
of	O
his	O
extremities	O
.	O
He	O
is	O
a	O
poor	O
historian	O
as	O
he	O
does	O
not	O
speak	O
much	O
at	O
baseline	O
.	O
Patient	O
states	O
he	O
's	O
been	O
taking	O
his	O
Keppra	I-Drug
as	O
prescribed	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
VS	O
:	O
97.5	O
58131/78	O
18	O
100	O
%	O
.	O
Exam	O
notable	O
for	O
left	O
sided	O
deficits	O
,	O
speech	O
slow	O
and	O
minimal	O
(	O
reported	O
baseline	O
)	O
.	O
EKG	O
:	O
NSR	O
at	O
58	O
,	O
LAD	O
,	O
TWI	O
II	O
,	O
[	O
**	O
Month	O
/	O
Day	O
(	O
3	O
)	O
1105	O
**	O
]	O
,	O
AVF	O
,	O
V4	O
-	O
V6	O
,	O
c	O
/	O
w	O
prior	O
.	O
Lytes	O
showed	O
K	O
5.4	O
,	O
Cr	O
8.4	O
,	O
lactate	O
0.9	O
.	O
CBC	O
with	O
WBC	O
3.0	O
(	O
mildly	O
decreased	O
from	O
baseline	O
)	O
,	O
Hct	O
38	O
(	O
up	O
from	O
baseline	O
mid	O
30s	O
)	O
plts	O
104	O
(	O
at	O
baseline	O
)	O
.	O
A	O
left	O
central	O
line	O
was	O
placed	O
for	O
access	O
.	O
In	O
the	O
ED	O
,	O
line	O
was	O
placed	O
given	O
BG	O
dropped	O
to	O
35	O
,	O
given	O
1	O
amp	O
dextrose	O
,	O
and	O
BG	O
improved	O
to	O
130	O
.	O
Per	O
ED	O
d	O
/	O
w	O
daughter	O
,	O
pt	O
has	O
no	O
h	O
/	O
o	O
diabetes	O
and	O
has	O
multiple	O
episodes	O
of	O
hypoglycemia	O
in	O
the	O
past	O
that	O
has	O
reportedly	O
been	O
worked	O
up	O
by	O
endocrinology	O
without	O
known	O
etiology	O
.	O
CXR	O
showed	O
no	O
acute	O
process	O
,	O
and	O
CT	O
head	O
without	O
acute	O
process	O
.	O
Per	O
Epilepsy	I-Reason
attending	O
,	O
recommended	O
change	O
Keppra	I-Drug
to	O
1500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
abd	O
500	O
mg	O
after	O
HD	O
,	O
and	O
recommended	O
sending	O
a	O
Keppra	I-Drug
level	O
.	O
Blood	O
cultures	O
were	O
sent	O
x1	O
,	O
no	O
urine	O
sent	O
as	O
pt	O
does	O
not	O
make	O
urine	O
.	O
VS	O
prior	O
to	O
transfer	O
97.9	O
,	O
59	O
,	O
118/61	O
,	O
16	O
,	O
96	O
%	O
r	O
/	O
a.	O
.	O
On	O
the	O
floors	O
,	O
pt	O
triggered	O
for	O
hypoglycemia	O
with	O
FS	O
47	O
.	O
Please	O
see	O
trigger	O
note	O
for	O
further	O
details	O
.	O
Pt	O
denies	O
lightheadedness	O
,	O
nausea	O
,	O
vomiting	O
,	O
diaphoresis	O
.	O
He	O
denies	O
having	O
a	O
seizure	O
today	O
and	O
can	O
not	O
recall	O
and	O
falls	O
or	O
shaking	O
episodes	O
.	O
He	O
says	O
that	O
he	O
has	O
been	O
feeling	O
well	O
.	O
He	O
is	O
unsure	O
of	O
the	O
last	O
time	O
he	O
ate	O
,	O
but	O
knows	O
he	O
did	O
not	O
have	O
dinner	O
.	O
He	O
says	O
his	O
daughter	O
helps	O
him	O
eat	O
at	O
home	O
.	O
.	O
Attempted	O
to	O
call	O
daughter	O
,	O
but	O
no	O
answer	O
initially	O
.	O
Eventually	O
able	O
to	O
contact	O
her	O
,	O
and	O
reportedly	O
had	O
seizure	O
today	O
per	O
daycare	O
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
35689	O
**	O
]	O
House	O
in	O
Endleson	O
Day	O
care	O
.	O
Unsure	O
if	O
they	O
checked	O
his	O
BG	O
there	O
.	O
On	O
no	O
hypoglycemics	O
.	O
She	O
recalls	O
that	O
all	O
his	O
food	O
is	O
pureed	O
given	O
his	O
dysphagia	O
.	O
.	O
Pt	O
had	O
a	O
recent	O
admission	O
from	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
63593	O
**	O
]	O
for	O
possible	O
seizure	O
and	O
found	O
to	O
have	O
RLL	I-Reason
,	O
discharged	O
on	O
Levofloxacin	I-Drug
.	O
.	O
ROS	O
:	O
Per	O
HPI	O
.	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
headache	O
,	O
vision	O
changes	O
,	O
rhinorrhea	O
,	O
congestion	O
,	O
sore	O
throat	O
,	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
BRBPR	O
,	O
melena	O
,	O
hematochezia	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
ESRD	O
on	O
HD	O
(	O
M	O
/	O
W	O
/	O
F	O
at	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
)	O
-	O
h	O
/	O
o	O
multiple	O
prior	O
CVAs	O
-	O
per	O
last	O
dc	O
summary	O
ambulates	O
at	O
home	O
,	O
has	O
residual	O
left	O
-	O
sided	O
weakness	O
-	O
Seizure	O
disorder	O
-	O
Chronic	O
hepatitis	O
B	O
-	O
Chronic	O
aspiration	O
with	O
failed	O
speech	O
and	O
swallow	O
eval	O
-	O
family	O
wants	O
him	O
to	O
continue	O
eating	O
despite	O
risks	O
-	O
HTN	O
-	O
CAD	O
-	O
h	O
/	O
o	O
MSSA	O
bacteremia	O
after	O
manipulation	O
of	O
fistula	O
-	O
hospitalization	O
in	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
for	O
incarcerated	O
inguinal	O
hernia	O
complicated	O
by	O
ESBL	O
Klebsiella	O
bacteremia	O
and	O
PNA	O
-	O
Hyperlipidemia	O
-	O
GERD	O
-	O
S	O
/	O
p	O
SBO	O
[	O
**	O
2109	O
**	O
]	O
-	O
Hernia	O
repair	O
-	O
Hypoglycemia	O
Social	O
History	O
:	O
Patient	O
lives	O
in	O
[	O
**	O
Location	O
**	O
]	O
with	O
his	O
daughter	O
,	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
,	O
who	O
is	O
a	O
former	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
employee	O
.	O
He	O
denies	O
any	O
recent	O
use	O
of	O
alcohol	O
,	O
tobacco	O
,	O
illicit	O
drugs	O
,	O
or	O
herbal	O
medications	O
.	O
He	O
has	O
a	O
distant	O
,	O
but	O
considerable	O
smoking	O
history	O
per	O
his	O
daughter	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
uses	O
the	O
toilet	O
himself	O
,	O
but	O
needs	O
help	O
cleaning	O
himself	O
,	O
and	O
does	O
not	O
cook	O
or	O
manage	O
his	O
finances	O
.	O
He	O
is	O
at	O
HD	O
on	O
MWF	O
and	O
spends	O
TU	O
and	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
in	O
an	O
adult	O
day	O
program	O
.	O
His	O
daughter	O
does	O
not	O
leave	O
him	O
alone	O
by	O
himself	O
.	O
Family	O
History	O
:	O
Mother	O
died	O
at	O
45	O
with	O
hypertension	O
.	O
Father	O
died	O
at	O
60	O
of	O
unknown	O
causes	O
.	O
He	O
has	O
eight	O
living	O
siblings	O
,	O
many	O
of	O
whom	O
have	O
hypertension	O
.	O
He	O
has	O
six	O
children	O
who	O
are	O
all	O
healthy	O
.	O
Physical	O
Exam	O
:	O
ADMISSION	O
EXAM	O
VS	O
-	O
Temp	O
97.8	O
F	O
,	O
BP	O
140/83	O
,	O
HR	O
60	O
,	O
R	O
18	O
,	O
O2	O
-	O
sat	O
100	O
%	O
RA	O
FS	O
47	O
GENERAL	O
-	O
pleasant	O
male	O
,	O
appears	O
comfortable	O
,	O
NAD	O
[	O
**	O
Doctor	O
First	O
Name	O
4459	O
**	O
]	O
-	O
NC	O
/	O
AT	O
,	O
left	O
-	O
sided	O
facial	O
droop	O
(	O
old	O
per	O
pt	O
)	O
,	O
EOMI	O
,	O
sclerae	O
anicteric	O
,	O
MMM	O
,	O
OP	O
clear	O
NECK	O
-	O
supple	O
,	O
no	O
thyromegaly	O
,	O
no	O
JVD	O
,	O
left	O
IJ	O
with	O
dried	O
blood	O
on	O
gauze	O
LUNGS	O
-	O
no	O
use	O
access	O
mm	O
,	O
fair	O
air	O
movement	O
due	O
to	O
effort	O
,	O
no	O
wheezes	O
or	O
crackles	O
HEART	O
-	O
RRR	O
,	O
no	O
MRG	O
,	O
nl	O
S1	O
-	O
S2	O
ABDOMEN	O
-	O
NABS	O
,	O
soft	O
/	O
NT	O
/	O
ND	O
,	O
no	O
masses	O
or	O
HSM	O
,	O
no	O
rebound	O
/	O
guarding	O
EXTREMITIES	O
-	O
right	O
upper	O
extremity	O
with	O
AVG	O
+	O
thrill	O
,	O
LE	O
's	O
dry	O
without	O
edema	O
,	O
2	O
+	O
DP	O
pulses	O
NEURO	O
-	O
awake	O
,	O
oriented	O
to	O
person	O
,	O
states	O
"	O
hospital	O
"	O
,	O
"	O
[	O
**	O
Month	O
(	O
only	O
)	O
359	O
**	O
]	O
[	O
**	O
2112	O
**	O
]	O
"	O
,	O
answers	O
questions	O
appropriately	O
in	O
few	O
words	O
,	O
CNs	O
II	O
-	O
XII	O
grossly	O
intact	O
with	O
left	O
-	O
sided	O
facial	O
droop	O
,	O
5/5	O
strength	O
in	O
UE	O
's	O
,	O
4	O
+	O
/	O
5	O
bilaterally	O
in	O
lower	O
extermities	O
,	O
gait	O
not	O
assessed	O
.	O
DISCHARGE	O
EXAM	O
:	O
More	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
3584	O
**	O
]	O
,	O
able	O
to	O
eat	O
breakfast	O
and	O
drink	O
milk	O
with	O
supervision	O
.	O
RUE	O
AVG	O
thrombosed	O
and	O
no	O
longer	O
functional	O
.	O
Still	O
minimally	O
conversant	O
.	O
RRR	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
,	O
CTAB	O
.	O
Line	O
sites	O
:	O
Tunneled	O
dialysis	O
line	O
with	O
some	O
oozing	O
;	O
PICC	O
line	O
with	O
improving	O
oozing	O
as	O
well	O
,	O
due	O
to	O
elevated	O
PTT	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
[	O
**	O
2112-11-10	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
WBC	O
-	O
3.0	O
*	O
RBC	O
-	O
3.53	O
*	O
Hgb	O
-	O
12.8	O
*	O
Hct	O
-	O
38.5	O
*	O
MCV	O
-	O
109	O
*	O
MCH	O
-	O
36.2	O
*	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
104	O
*	O
[	O
**	O
2112-11-10	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
Neuts	O
-	O
46.4	O
*	O
Lymphs	O
-	O
38.0	O
Monos	O
-	O
8.9	O
Eos	O
-	O
6.2	O
*	O
Baso	O
-	O
0.6	O
[	O
**	O
2112-11-10	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
PT	O
-	O
22.6	O
*	O
PTT	O
-	O
38.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.1	O
*	O
[	O
**	O
2112-11-9	O
**	O
]	O
08:40	O
AM	O
BLOOD	O
Na	O
-	O
141	O
K	O
-	O
3.8	O
Cl	O
-	O
99	O
[	O
**	O
2112-11-10	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
Glucose	O
-	O
130	O
*	O
UreaN	O
-	O
35	O
*	O
Creat	O
-	O
8.4	O
*	O
#	O
Na	O
-	O
135	O
K	O
-	O
5.4	O
*	O
Cl	O
-	O
95	O
*	O
HCO3	O
-	O
30	O
AnGap	O
-	O
15	O
[	O
**	O
2112-11-11	O
**	O
]	O
06:31	O
AM	O
BLOOD	O
Calcium	O
-	O
9.2	O
Phos	O
-	O
3.5	O
Mg	O
-	O
1.8	O
[	O
**	O
2112-11-13	O
**	O
]	O
06:09	O
AM	O
BLOOD	O
VitB12	O
-	O
1735	O
*	O
Folate	O
-	O
GREATER	O
TH	O
[	O
**	O
2112-11-10	O
**	O
]	O
05:48	O
PM	O
BLOOD	O
Lactate	O
-	O
0.9	O
.	O
PERTINENT	O
LABS	O
AND	O
STUDIES	O
:	O
.	O
[	O
**	O
2112-11-16	O
**	O
]	O
05:21	O
AM	O
BLOOD	O
WBC	O
-	O
5.3	O
RBC	O
-	O
3.05	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
32.5	O
*	O
MCV	O
-	O
106	O
*	O
MCH	O
-	O
35.4	O
*	O
MCHC	O
-	O
33.3	O
RDW	O
-	O
14.1	O
Plt	O
Ct	O
-	O
118	O
*	O
[	O
**	O
2112-11-18	O
**	O
]	O
04:35	O
AM	O
BLOOD	O
WBC	O
-	O
8.1	O
RBC	O
-	O
3.37	O
*	O
#	O
Hgb	O
-	O
10.9	O
*	O
#	O
Hct	O
-	O
29.8	O
*	O
MCV	O
-	O
89	O
#	O
MCH	O
-	O
32.3	O
*	O
MCHC	O
-	O
36.5	O
*	O
RDW	O
-	O
18.5	O
*	O
Plt	O
Ct	O
-	O
110	O
*	O
[	O
**	O
2112-12-1	O
**	O
]	O
01:48	O
PM	O
BLOOD	O
WBC	O
-	O
11.5	O
*	O
RBC	O
-	O
2.61	O
*	O
Hgb	O
-	O
8.4	O
*	O
Hct	O
-	O
24.1	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
32.2	O
*	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
15.6	O
*	O
Plt	O
Ct	O
-	O
408	O
[	O
**	O
2112-12-12	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
WBC	O
-	O
6.5	O
RBC	O
-	O
2.31	O
*	O
Hgb	O
-	O
7.0	O
*	O
Hct	O
-	O
21.1	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
30.4	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
15.2	O
Plt	O
Ct	O
-	O
197	O
[	O
**	O
2112-12-14	O
**	O
]	O
05:06	O
AM	O
BLOOD	O
WBC	O
-	O
6.8	O
RBC	O
-	O
2.16	O
*	O
Hgb	O
-	O
6.6	O
*	O
Hct	O
-	O
19.9	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
30.4	O
MCHC	O
-	O
33.0	O
RDW	O
-	O
15.4	O
Plt	O
Ct	O
-	O
184	O
[	O
**	O
2112-12-16	O
**	O
]	O
01:34	O
PM	O
BLOOD	O
WBC	O
-	O
6.8	O
RBC	O
-	O
2.88	O
*	O
Hgb	O
-	O
8.6	O
*	O
Hct	O
-	O
26.0	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
29.8	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
16.3	O
*	O
Plt	O
Ct	O
-	O
147	O
*	O
[	O
**	O
2112-12-14	O
**	O
]	O
05:06	O
AM	O
BLOOD	O
PT	O
-	O
15.2	O
*	O
PTT	O
-	O
119.9	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
*	O
[	O
**	O
2112-12-15	O
**	O
]	O
03:40	O
AM	O
BLOOD	O
PT	O
-	O
19.9	O
*	O
PTT	O
-	O
150	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.8	O
*	O
[	O
**	O
2112-12-16	O
**	O
]	O
06:44	O
AM	O
BLOOD	O
PT	O
-	O
13.8	O
*	O
PTT	O
-	O
53.2	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2112-11-14	O
**	O
]	O
06:24	O
AM	O
BLOOD	O
Glucose	O
-	O
113	O
*	O
UreaN	O
-	O
56	O
*	O
Creat	O
-	O
10.9	O
*	O
#	O
Na	O
-	O
130	O
*	O
K	O
-	O
7.3	O
*	O
Cl	O
-	O
90	O
*	O
HCO3	O
-	O
28	O
AnGap	O
-	O
19	O
[	O
**	O
2112-11-17	O
**	O
]	O
01:08	O
AM	O
BLOOD	O
Glucose	O
-	O
170	O
*	O
UreaN	O
-	O
23	O
*	O
Creat	O
-	O
6.7	O
*	O
#	O
Na	O
-	O
142	O
K	O
-	O
4.5	O
Cl	O
-	O
99	O
HCO3	O
-	O
29	O
AnGap	O
-	O
19	O
[	O
**	O
2112-11-23	O
**	O
]	O
03:00	O
AM	O
BLOOD	O
Glucose	O
-	O
122	O
*	O
UreaN	O
-	O
52	O
*	O
Creat	O
-	O
8.4	O
*	O
#	O
Na	O
-	O
137	O
K	O
-	O
4.8	O
Cl	O
-	O
92	O
*	O
HCO3	O
-	O
32	O
AnGap	O
-	O
18	O
[	O
**	O
2112-12-13	O
**	O
]	O
02:07	O
PM	O
BLOOD	O
Glucose	O
-	O
161	O
*	O
UreaN	O
-	O
29	O
*	O
Creat	O
-	O
7.1	O
*	O
#	O
Na	O
-	O
137	O
K	O
-	O
3.9	O
Cl	O
-	O
96	O
HCO3	O
-	O
27	O
AnGap	O
-	O
18	O
[	O
**	O
2112-12-16	O
**	O
]	O
06:44	O
AM	O
BLOOD	O
Glucose	O
-	O
87	O
UreaN	O
-	O
38	O
*	O
Creat	O
-	O
8.4	O
*	O
#	O
Na	O
-	O
137	O
K	O
-	O
5.3	O
*	O
Cl	O
-	O
98	O
HCO3	O
-	O
28	O
AnGap	O
-	O
16	O
[	O
**	O
2112-11-28	O
**	O
]	O
11:51	O
AM	O
BLOOD	O
ALT	O
-	O
81	O
*	O
AST	O
-	O
62	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
473	O
*	O
AlkPhos	O
-	O
130	O
TotBili	O
-	O
0.7	O
[	O
**	O
2112-12-1	O
**	O
]	O
04:10	O
AM	O
BLOOD	O
ALT	O
-	O
40	O
AST	O
-	O
34	O
AlkPhos	O
-	O
121	O
TotBili	O
-	O
0.8	O
[	O
**	O
2112-11-16	O
**	O
]	O
05:21	O
AM	O
BLOOD	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
3.1	O
Mg	O
-	O
1.9	O
[	O
**	O
2112-11-22	O
**	O
]	O
03:10	O
AM	O
BLOOD	O
Calcium	O
-	O
9.1	O
Phos	O
-	O
2.5	O
*	O
Mg	O
-	O
1.9	O
[	O
**	O
2112-12-3	O
**	O
]	O
05:48	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
4.1	O
#	O
Mg	O
-	O
2.2	O
[	O
**	O
2112-12-14	O
**	O
]	O
05:06	O
AM	O
BLOOD	O
Calcium	O
-	O
9.5	O
Phos	O
-	O
5.4	O
*	O
Mg	O
-	O
1.7	O
[	O
**	O
2112-11-13	O
**	O
]	O
06:09	O
AM	O
BLOOD	O
VitB12	O
-	O
1735	O
*	O
Folate	O
-	O
GREATER	O
TH	O
[	O
**	O
2112-11-17	O
**	O
]	O
04:14	O
AM	O
BLOOD	O
Hapto	O
-	O
169	O
[	O
**	O
2112-11-25	O
**	O
]	O
05:19	O
AM	O
BLOOD	O
Cortsol	O
-	O
21.8	O
*	O
[	O
**	O
2112-11-12	O
**	O
]	O
02:36	O
PM	O
BLOOD	O
C	O
-	O
PEPTIDE	O
-	O
3.12	O
H	O
[	O
**	O
2112-11-12	O
**	O
]	O
02:36	O
PM	O
BLOOD	O
SULFONAMIDES	O
-	O
normal	O
[	O
**	O
2112-11-12	O
**	O
]	O
02:36	O
PM	O
BLOOD	O
INSULIN	O
,	O
FREE	O
(	O
BIOACTIVE	O
)	O
-	O
normal	O
[	O
**	O
2112-11-12	O
**	O
]	O
02:36	O
PM	O
BLOOD	O
INSULIN	O
-	O
normal	O
[	O
**	O
2112-11-12	O
**	O
]	O
02:36	O
PM	O
BLOOD	O
BETA	O
-	O
HYDROXYBUTYRATE	O
-	O
high	O
[	O
**	O
2112-11-11	O
**	O
]	O
06:31	O
AM	O
BLOOD	O
LEVETIRACETAM	B-Drug
(	I-Drug
KEPPRA	I-Drug
)	O
-	O
69.8	O
(	O
normal	O
)	O
MICROBIOLOGY	O
:	O
[	O
**	O
2112-12-7	O
**	O
]	O
4:29	O
pm	O
CATHETER	O
TIP	O
-	O
IV	O
Source	O
:	O
right	O
IJ	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2112-12-10	O
**	O
]	O
**	O
WOUND	O
CULTURE	O
(	O
Final	O
[	O
**	O
2112-12-10	O
**	O
]	O
)	O
:	O
KLEBSIELLA	O
PNEUMONIAE	O
.	O
>	O
15	O
colonies	O
.	O
IDENTIFICATION	O
AND	O
SENSITIVITIES	O
PERFORMED	O
ON	O
CULTURE	O
#	O
[	O
**	O
Numeric	O
Identifier	O
63594	O
**	O
]	O
,	O
[	O
**	O
2112-12-7	O
**	O
]	O
.	O
STAPHYLOCOCCUS	O
,	O
COAGULASE	O
NEGATIVE	O
.	O
<	O
15	O
colonies	O
.	O
COAG	O
NEG	O
STAPH	O
does	O
NOT	O
require	O
contact	O
precautions	O
,	O
regardless	O
of	O
resistance	O
.	O
Oxacillin	I-Drug
RESISTANT	O
Staphylococci	O
MUST	O
be	O
reported	O
as	O
also	O
RESISTANT	O
to	O
other	O
penicillins	I-Drug
,	O
cephalosporins	I-Drug
,	O
carbacephems	I-Drug
,	O
carbapenems	I-Drug
,	O
and	O
beta	B-Drug
-	I-Drug
lactamase	I-Drug
inhibitor	I-Drug
combinations	I-Drug
.	O
Rifampin	I-Drug
should	O
not	O
be	O
used	O
alone	O
for	O
therapy	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
STAPHYLOCOCCUS	O
,	O
COAGULASE	O
NEGATIVE	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
=	O
>	O
8	O
R	O
ERYTHROMYCIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
GENTAMICIN	I-Drug
------------	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
=	O
>	O
8	O
R	O
OXACILLIN	I-Drug
-------------	O
R	O
RIFAMPIN	I-Drug
--------------	O
<	O
=	O
0.5	O
S	O
TETRACYCLINE	I-Drug
----------	O
=	O
>	O
16	O
R	O
VANCOMYCIN	I-Drug
------------	O
1	O
S	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
KLEBSIELLA	O
PNEUMONIAE	O
|	O
AMIKACIN	I-Drug
--------------	O
=	O
>	O
64	O
R	O
AMPICILLIN	B-Drug
/	I-Drug
SULBACTAM	I-Drug
--	O
=	O
>	O
32	O
R	O
CEFAZOLIN	I-Drug
-------------	O
=	O
>	O
64	O
R	O
CEFEPIME	I-Drug
--------------	O
2	O
S	O
CEFTAZIDIME	I-Drug
-----------	O
=	O
>	O
64	O
R	O
CEFTRIAXONE	I-Drug
-----------	O
16	O
R	O
CIPROFLOXACIN	I-Drug
---------	O
=	O
>	O
4	O
R	O
GENTAMICIN	I-Drug
------------	O
=	O
>	O
16	O
R	O
MEROPENEM	I-Drug
-------------	O
<	O
=	O
0.25	O
S	O
TOBRAMYCIN	I-Drug
------------	O
=	O
>	O
16	O
R	O
TRIMETHOPRIM	B-Drug
/	I-Drug
SULFA	I-Drug
----	O
<	O
=	O
1	O
S	O
[	O
**	O
2112-12-8	O
**	O
]	O
4:50	O
pm	O
BLOOD	O
CULTURE	O
-	O
same	O
2	O
organisms	O
as	O
above	O
All	O
other	O
cultures	O
-	O
negative	O
IMAGING	O
:	O
CT	O
head	O
w	O
/	O
o	O
[	O
**	O
2112-11-10	O
**	O
]	O
:	O
No	O
acute	O
intracranial	O
process	O
.	O
Stable	O
bilateral	O
encephalomalacia	O
.	O
.	O
CT	O
Neck	O
[	O
**	O
2112-11-10	O
**	O
]	O
1	O
.	O
No	O
fracture	O
or	O
subluxation	O
.	O
2	O
.	O
Apparent	O
degenerative	O
changes	O
at	O
C5	O
-	O
6	O
with	O
probable	O
endplate	O
Schmorl	O
's	O
nodes	O
which	O
appear	O
similar	O
,	O
although	O
somewhat	O
progressed	O
since	O
the	O
prior	O
MR	O
study	O
.	O
Posterior	O
disc	O
osteophyte	O
complex	O
at	O
C5	O
-	O
6	O
and	O
disc	O
bulge	O
at	O
C6	O
-	O
7	O
slightly	O
indent	O
the	O
thecal	O
sac	O
.	O
Anterior	O
disc	O
space	O
widening	O
at	O
C6	O
-	O
7	O
is	O
chronic	O
.	O
3	O
.	O
Right	O
thyroid	O
enlargement	O
which	O
slightly	O
indents	O
the	O
trachea	O
.	O
.	O
CXR	O
[	O
**	O
2112-11-10	O
**	O
]	O
:	O
FINDINGS	O
:	O
AP	O
and	O
lateral	O
upright	O
radiographs	O
of	O
the	O
chest	O
were	O
obtained	O
.	O
There	O
are	O
moderately	O
low	O
lung	O
volumes	O
.	O
The	O
previously	O
seen	O
right	O
lower	O
lung	O
opacity	O
has	O
improved	O
,	O
but	O
not	O
completely	O
resolved	O
and	O
may	O
reflect	O
residual	O
atelectasis	O
or	O
infection	O
.	O
The	O
previously	O
described	O
right	O
paratracheal	O
fullness	O
is	O
stable	O
and	O
is	O
attributable	O
to	O
tortuous	O
vessels	O
as	O
seen	O
on	O
prior	O
CT	O
studies	O
.	O
Trachea	O
is	O
stably	O
narrowed	O
at	O
the	O
level	O
of	O
the	O
thoracic	O
inlet	O
and	O
is	O
attributable	O
to	O
tortuous	O
vessels	O
as	O
noted	O
on	O
CT	O
torso	O
.	O
There	O
is	O
stable	O
cardiomegaly	O
.	O
There	O
is	O
no	O
pleural	O
effusion	O
or	O
pneumothorax	O
.	O
IMPRESSION	O
:	O
Improvement	O
in	O
right	O
lower	O
lung	O
opacity	O
which	O
has	O
not	O
completely	O
resolved	O
and	O
may	O
reflect	O
residual	O
atelectasis	O
or	O
infection	O
.	O
.	O
CXR	O
line	O
placement	O
[	O
**	O
2112-11-10	O
**	O
]	O
:	O
FINDINGS	O
:	O
There	O
is	O
a	O
newly	O
placed	O
left	O
internal	O
jugular	O
catheter	O
with	O
the	O
tip	O
positioned	O
in	O
the	O
upper	O
SVC	O
.	O
No	O
pneumothorax	O
is	O
present	O
.	O
Bibasilar	O
atelectasis	O
is	O
present	O
.	O
The	O
cardiac	O
silhouette	O
,	O
hilar	O
,	O
and	O
mediastinal	O
contours	O
appear	O
stable	O
.	O
.	O
IMPRESSION	O
:	O
Satisfactory	O
central	O
line	O
position	O
without	O
pneumothorax	O
.	O
Bibasilar	O
atelectasis	O
.	O
.	O
CT	O
-	O
torso	O
(	O
[	O
**	O
2112-11-22	O
**	O
]	O
)	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Unchanged	O
right	O
perinephric	O
and	O
retroperitoneal	O
hematoma	O
.	O
2	O
.	O
Small	O
right	O
pleural	O
effusion	O
with	O
consolidated	O
portions	O
of	O
the	O
right	O
middle	O
and	O
lower	O
lobes	O
containing	O
hyperdense	O
material	O
suggesting	O
aspiration	O
as	O
a	O
possible	O
etiology	O
.	O
.	O
CT	O
-	O
head	O
(	O
[	O
**	O
2112-11-24	O
**	O
]	O
)	O
:	O
FINDINGS	O
:	O
There	O
is	O
no	O
evidence	O
of	O
acute	O
intracranial	O
hemorrhage	O
.	O
Again	O
noted	O
are	O
large	O
,	O
bilateral	O
ares	O
of	O
encephalomalacia	O
in	O
the	O
MCA	O
territory	O
is	O
present	O
since	O
[	O
**	O
2107	O
**	O
]	O
,	O
likely	O
due	O
to	O
old	O
infarcts	O
.	O
A	O
small	O
right	O
cerebellar	O
hypodensity	O
is	O
again	O
noted	O
.	O
The	O
ventricles	O
and	O
sulci	O
are	O
enlarged	O
,	O
likely	O
due	O
to	O
a	O
combination	O
of	O
age	O
-	O
related	O
atrophy	O
and	O
prior	O
infarctions	O
.	O
No	O
fractures	O
are	O
identified	O
.	O
Line	O
placements	O
by	O
IR	O
(	O
[	O
**	O
2112-12-15	O
**	O
]	O
)	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Successful	O
placement	O
of	O
a	O
4	O
French	O
single	O
-	O
lumen	O
PICC	O
via	O
the	O
left	O
basilica	O
vein	O
approach	O
,	O
terminating	O
at	O
the	O
cavoatrial	O
junction	O
.	O
The	O
line	O
is	O
ready	O
for	O
use	O
.	O
2	O
.	O
Successful	O
conversion	O
of	O
a	O
temporary	O
catheter	O
for	O
a	O
tunneled	O
15.5	O
French	O
dual	O
-	O
lumen	O
hemodialysis	O
catheter	O
via	O
the	O
left	O
IJ	O
approach	O
,	O
with	O
the	O
tip	O
terminating	O
within	O
the	O
right	O
atrium	O
.	O
The	O
line	O
is	O
ready	O
for	O
use	O
.	O
3	O
.	O
Left	O
arm	O
venogram	O
demonstrating	O
marked	O
tortuosity	O
at	O
the	O
basillic	O
-	O
axillary	O
junction	O
and	O
a	O
diminutive	O
cephalic	O
vein	O
.	O
All	O
visualized	O
veins	O
are	O
patent	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
63	O
year	O
-	O
old	O
man	O
with	O
a	O
PMH	O
notable	O
for	O
ESRD	O
on	O
HD	O
(	O
MWF	O
)	O
,	O
chronic	O
aspiration	O
,	O
seizure	O
disorder	O
,	O
history	O
of	O
CVA	O
with	O
residual	O
left	O
-	O
sided	O
weakness	O
and	O
dysarthria	O
,	O
who	O
presented	O
to	O
the	O
ED	O
s	O
/	O
p	O
seizure	O
and	O
hypoglycemia	O
.	O
Course	O
was	O
complicated	O
by	O
RP	O
bleed	O
,	O
s	O
/	O
p	O
IR	O
embolization	O
of	O
R	O
renal	O
artery	O
[	O
**	O
2112-11-17	O
**	O
]	O
,	O
PNA	I-Reason
s	O
/	O
p	O
course	O
of	O
Vanc	I-Drug
/	O
Zosyn	I-Drug
/	O
Tobra	I-Drug
,	O
and	O
inability	O
to	O
clear	O
his	O
own	O
secretions	O
with	O
subsequent	O
recurrent	O
mucus	O
plugging	O
and	O
chronic	O
aspiration	O
,	O
leading	O
to	O
episodes	O
of	O
hypoxic	O
respiratory	O
distress	O
.	O
.	O
#	O
Seizures	O
:	O
The	O
patient	O
had	O
a	O
witnessed	O
event	O
in	O
which	O
he	O
had	O
whole	O
-	O
body	O
shaking	O
and	O
was	O
non-responsive	O
.	O
DDx	O
for	O
seizure	O
precipitant	O
includes	O
metabolic	O
etiology	O
such	O
as	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
hypoglycemia	O
vs.	O
infection	O
vs.	O
medication	O
non-compliance	O
.	O
Not	O
likely	O
acute	O
intracranial	O
process	O
as	O
no	O
changed	O
on	O
CT	O
head	O
w	O
/	O
o.	O
No	O
reason	O
to	O
believe	O
that	O
the	O
patient	O
has	O
been	O
missing	O
his	O
medications	O
,	O
per	O
family	O
and	O
daycare	O
.	O
He	O
has	O
no	O
complaints	O
,	O
and	O
no	O
s	O
/	O
s	O
of	O
infection	O
(	O
no	O
fever	O
,	O
symptoms	O
,	O
and	O
CXR	O
w	O
/	O
no	O
focal	O
infiltrate	O
)	O
,	O
which	O
could	O
also	O
precipitate	O
seizures	O
.	O
Per	O
reviewing	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
pt	O
has	O
been	O
admitted	O
frequently	O
for	O
these	O
seizures	I-Reason
every	O
few	O
months	O
.	O
The	O
ED	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
pt	O
's	O
outpt	O
Neurologist	O
who	O
recommended	O
increasing	O
Keppra	I-Drug
dose	O
to	O
1500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
and	O
continuing	O
500	O
mg	O
after	O
HD	O
and	O
checking	O
a	O
level	O
.	O
Keppra	I-Drug
level	O
was	O
obtained	O
but	O
pending	O
as	O
it	O
is	O
a	O
send	O
out	O
.	O
Oxcarbazepine	I-Drug
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
continued	O
.	O
Treatment	O
of	O
hypoglycemia	O
as	O
below	O
.	O
.	O
#	O
Hypoglycemia	O
:	O
Pt	O
presented	O
with	O
significant	O
hypoglycemia	O
of	O
unknown	O
etiology	O
.	O
There	O
is	O
no	O
evidence	O
of	O
iatrogenic	O
cause	O
of	O
hypoglycemia	O
.	O
Workup	O
included	O
fasting	O
C	O
-	O
peptide	O
and	O
insulin	I-Drug
level	O
,	O
which	O
were	O
non-diagnostic	O
given	O
the	O
venous	O
glucose	O
for	O
the	O
specimen	O
was	O
not	O
less	O
than	O
50	O
.	O
There	O
was	O
no	O
evidence	O
of	O
adrenal	O
insufficiency	O
.	O
His	O
hypoglycemia	O
resolved	O
after	O
RP	O
bleed	O
for	O
unclear	O
reasons	O
.	O
.	O
#	O
Aspiration	O
:	O
Pt	O
has	O
a	O
documented	O
history	O
of	O
chronic	O
aspiration	O
likely	O
secondary	O
to	O
his	O
CVA	O
,	O
and	O
has	O
been	O
evaluated	O
by	O
speech	O
and	O
swallow	O
multiple	O
times	O
in	O
the	O
past	O
.	O
Pt	O
was	O
found	O
to	O
be	O
at	O
increased	O
risk	O
for	O
aspiration	O
.	O
However	O
,	O
family	O
in	O
the	O
past	O
had	O
insisted	O
on	O
continued	O
feeding	O
,	O
regardless	O
of	O
aspiration	O
risk	O
.	O
In	O
[	O
**	O
Month	O
(	O
only	O
)	O
**	O
]	O
,	O
speech	O
and	O
swallow	O
commented	O
that	O
"	O
As	O
aspiration	O
risks	O
are	O
similar	O
across	O
consistencies	O
,	O
pt	O
comfort	O
should	O
be	O
deciding	O
factor	O
in	O
diet	O
order	O
"	O
.	O
Pt	O
was	O
placed	O
on	O
mechanical	O
soft	O
diet	O
/	O
dysphagia	O
diet	O
on	O
admission	O
,	O
as	O
quality	O
of	O
life	O
was	O
considered	O
to	O
be	O
the	O
number	O
one	O
priority	O
by	O
the	O
family	O
.	O
During	O
this	O
admission	O
,	O
pt	O
was	O
found	O
to	O
have	O
significant	O
worsening	O
aspiration	O
,	O
manifested	O
by	O
copious	O
secretions	O
in	O
airway	O
.	O
He	O
had	O
multiple	O
episodes	O
of	O
desatting	O
both	O
in	O
the	O
MICU	O
and	O
on	O
the	O
regular	O
floor	O
.	O
He	O
collapsed	O
his	O
right	O
lung	O
several	O
times	O
in	O
the	O
setting	O
of	O
mucus	O
plugging	O
.	O
For	O
all	O
these	O
episodes	O
,	O
he	O
responded	O
well	O
with	O
suction	O
and	O
chest	O
PT	O
.	O
After	O
lengthy	O
discussion	O
with	O
family	O
,	O
decision	O
was	O
made	O
to	O
feed	O
the	O
patient	O
despite	O
the	O
aspiration	O
risk	O
.	O
A	O
PEG	O
tube	O
was	O
deferred	O
given	O
successful	O
eating	O
without	O
obvious	O
aspiration	O
.	O
.	O
#	O
Fistula	B-Reason
thrombosis	I-Reason
/	O
Access	O
:	O
Following	O
his	O
stay	O
in	O
the	O
ICU	O
the	O
patient	O
had	O
a	O
thrombosed	O
fistula	O
.	O
The	O
level	O
of	O
thrombosis	O
was	O
too	O
much	O
for	O
vascular	O
or	O
for	O
IR	O
to	O
open	O
the	O
fistula	O
.	O
He	O
had	O
a	O
temporary	O
line	O
placed	O
that	O
was	O
converted	O
to	O
a	O
tunneled	O
catheter	O
for	O
dialysis	O
and	O
IR	O
was	O
able	O
to	O
place	O
a	O
PICC	O
for	O
further	O
access	O
via	O
venogram	O
.	O
He	O
will	O
be	O
discharged	O
on	O
a	O
heparin	I-Drug
drip	O
-	O
to	O
-	O
warfarin	I-Drug
bridge	O
for	O
this	O
thrombosis	I-Reason
and	O
a	O
catheter	O
-	O
associated	O
thrombus	O
in	O
the	O
right	O
IJ	O
.	O
.	O
#	O
Line	B-Reason
infection	I-Reason
:	O
The	O
patient	O
had	O
pus	O
noted	O
around	O
his	O
right	O
IJ	O
following	O
his	O
time	O
in	O
the	O
ICU	O
.	O
Cultures	O
subsequently	O
grew	O
resistant	O
Klebsiella	O
and	O
coagulase	O
negative	O
gram	O
positive	O
cocci	O
,	O
along	O
with	O
confirmation	O
from	O
1	O
subsequent	O
blood	O
culture	O
.	O
He	O
will	O
be	O
treated	O
for	O
a	O
total	O
of	O
two	O
weeks	O
with	O
vancomycin	I-Drug
and	O
cefepime	I-Drug
,	O
to	O
be	O
completed	O
on	O
[	O
**	O
2112-12-20	O
**	O
]	O
.	O
#	O
Retroperitoneal	B-Reason
bleed	I-Reason
with	I-Reason
subsequent	I-Reason
anemia	I-Reason
:	O
Pt	O
was	O
found	O
to	O
have	O
tachycardia	O
and	O
hypotension	O
on	O
HD	O
#	O
7	O
,	O
with	O
a	O
9	O
-	O
point	O
HCT	O
drop	O
.	O
He	O
underwent	O
CTA	O
,	O
and	O
was	O
found	O
to	O
have	O
multifocal	O
retroperitoneal	O
bleed	O
in	O
the	O
right	O
kidney	O
.	O
He	O
was	O
admitted	O
to	O
MICU	O
and	O
intubated	O
for	O
airway	O
protection	O
.	O
Pt	O
had	O
a	O
total	O
of	O
9	O
units	O
pRBC	I-Drug
.	O
Transcatheter	O
embolization	O
of	O
the	O
right	O
kidney	O
was	O
performed	O
and	O
hemodynamic	O
stability	O
was	O
achieved	O
.	O
Subsequently	O
,	O
his	O
hematocrit	O
continued	O
to	O
run	O
low	O
,	O
requiring	O
intermittent	O
transfusions	O
of	O
RBCs	O
at	O
dialysis	O
,	O
with	O
a	O
nadir	O
of	O
19.9	O
.	O
Nephrology	O
will	O
be	O
assessing	O
whether	O
he	O
should	O
be	O
started	O
on	O
Epogen	I-Drug
at	O
dialysis	O
.	O
.	O
#	O
Pneumonia	I-Reason
:	O
Pt	O
was	O
found	O
to	O
have	O
pneumonia	O
on	O
MICU	O
day	O
4	O
,	O
with	O
leukocytosis	O
and	O
fever	O
.	O
The	O
etiology	O
of	O
pneumonia	O
was	O
HCAP	O
vs	O
VAP	O
.	O
He	O
was	O
treated	O
with	O
vanco	I-Drug
,	O
zosyn	I-Drug
and	O
tobra	I-Drug
for	O
a	O
total	O
of	O
9	O
days	O
.	O
His	O
WBC	O
and	O
fever	O
resolved	O
s	O
/	O
p	O
antibiotics	I-Drug
treatment	O
.	O
.	O
CHRONIC	O
ISSUES	O
:	O
#	O
ESRD	I-Reason
on	O
HD	O
:	O
MWF	O
,	O
received	O
dialysis	O
on	O
schedule	O
.	O
Access	O
is	O
now	O
a	O
tunneled	O
line	O
,	O
given	O
AVG	O
thrombosis	O
and	O
he	O
should	O
be	O
continued	O
on	O
sevelamer	I-Drug
and	O
nephrocaps	I-Drug
.	O
.	O
#	O
Pancytopenia	O
:	O
Pt	O
with	O
macroycytic	O
anemia	O
and	O
thrombocytopenia	O
prior	O
.	O
However	O
,	O
WBC	O
mildly	O
decreased	O
at	O
presentation	O
to	O
3.0	O
,	O
which	O
is	O
a	O
change	O
from	O
prior	O
.	O
No	O
s	O
/	O
s	O
infection	O
,	O
CXR	O
without	O
focal	O
infiltrate	O
as	O
above	O
.	O
B12	O
and	O
folate	O
were	O
high	O
.	O
.	O
#	O
CAD	I-Reason
/	O
CVA	I-Reason
history	O
:	O
ECG	O
unchanged	O
from	O
prior	O
.	O
We	O
initially	O
continued	O
home	O
aspirin	I-Drug
,	O
statin	I-Drug
,	O
metoprolol	I-Drug
,	O
and	O
coumadin	I-Drug
,	O
but	O
the	O
RP	O
bleed	O
complicated	O
this	O
regimen	O
.	O
Once	O
embolization	O
was	O
done	O
and	O
hematocrit	O
was	O
deemed	O
stable	O
,	O
multiple	B-Reason
thromboses	I-Reason
were	O
discovered	O
in	O
right	O
IJ	O
and	O
RUE	O
AVG	O
.	O
Therefore	O
,	O
a	O
heparin	I-Drug
drip	O
was	O
started	O
and	O
he	O
was	O
bridged	O
to	O
coumadin	I-Drug
.	O
.	O
#	O
Depression	I-Reason
:	O
on	O
fluoxetine	I-Drug
as	O
listed	O
discharge	O
med	O
but	O
held	O
on	O
discharge	O
as	O
it	O
causes	O
hypoglycemia	I-Ade
and	O
it	O
can	O
lower	B-Ade
the	I-Ade
seizure	I-Ade
threshold	O
.	O
.	O
ISSUES	O
OF	O
TRANSITIONS	O
IN	O
CARE	O
:	O
#	O
CODE	O
:	O
FULL	O
-	O
confirmed	O
HCP	O
daughter	O
#	O
CONTACT	O
:	O
patient	O
;	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
63591	O
**	O
]	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
/	O
Daughter	O
's	O
cell	O
:	O
(	O
h	O
)	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
63580	O
**	O
]	O
.	O
Adult	O
Day	O
Care	O
Program	O
is	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
35689	O
**	O
]	O
House	O
in	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
63595	O
**	O
]	O
#	O
PENDING	O
STUDIES	O
AT	O
TIME	O
OF	O
DISCHARGE	O
:	O
none	O
#	O
ISSUES	O
TO	O
ADDRESS	O
AT	O
FOLLOW	O
UP	O
:	O
please	O
see	O
page	O
1	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
/	O
fever	I-Reason
.	O
3	O
.	O
B	B-Drug
complex	I-Drug
-	I-Drug
vitamin	I-Drug
C	I-Drug
-	I-Drug
folic	I-Drug
acid	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
fluoxetine	I-Drug
20	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
levetiracetam	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HD	O
(	O
)	O
:	O
M	O
W	O
Fri	O
after	O
HD	O
.	O
8	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
oxcarbazepine	I-Drug
150	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
11	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
12	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
13	O
.	O
sevelamer	B-Drug
carbonate	I-Drug
800	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
14	O
.	O
simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
16	O
.	O
Coumadin	I-Drug
3	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Until	O
you	O
get	O
your	O
INR	O
checked	O
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
.	O
2	O
.	O
B	B-Drug
complex	I-Drug
-	I-Drug
vitamin	I-Drug
C	I-Drug
-	I-Drug
folic	I-Drug
acid	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
4	O
.	O
levetiracetam	I-Drug
500	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
1500	O
(	O
1500	O
)	O
mg	O
Intravenous	O
twice	O
a	O
day	O
.	O
5	O
.	O
LeVETiracetam	I-Drug
500	O
mg	O
IV	O
MWF	O
Dose	O
after	O
HD	O
6	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
:	O
hold	O
if	O
SBP	O
<	O
90	O
,	O
HR	O
<	O
55	O
.	O
7	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
Powder	O
in	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
8	O
.	O
senna	I-Drug
8.6	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
9	O
.	O
sevelamer	B-Drug
carbonate	I-Drug
800	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
10	O
.	O
simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
11	O
.	O
heparin	B-Drug
(	I-Drug
porcine	I-Drug
)	I-Drug
1,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
see	O
below	O
Injection	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
line	B-Reason
flush	I-Reason
:	O
4000	O
-	O
[	O
**	O
Numeric	O
Identifier	O
2249	O
**	O
]	O
UNIT	O
DWELL	O
PRN	O
line	O
flush	O
Dialysis	O
Catheter	O
(	O
Temporary	O
3	O
-	O
Lumen	O
)	O
:	O
DIALYSIS	O
Lumens	O
/	O
DIALYSIS	O
NURSE	O
ONLY	O
:	O
Withdraw	O
4	O
mL	O
prior	O
to	O
flushing	O
with	O
10	O
mL	O
NS	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
according	O
to	O
volume	O
per	O
lumen	O
.	O
12	O
.	O
warfarin	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Once	O
Daily	O
at	O
4	O
PM	O
:	O
please	O
titrate	O
to	O
INR	O
,	O
goal	O
[	O
**	O
2	O
-	O
25	O
**	O
]	O
.	O
13	O
.	O
heparin	B-Drug
(	I-Drug
porcine	I-Drug
)	I-Drug
1,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
see	O
below	O
Injection	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
dialysis	I-Reason
:	O
Heparin	B-Drug
Dwell	I-Drug
(	O
1000	O
Units	O
/	O
mL	O
)	O
[	O
**	O
2101	O
**	O
]	O
-	O
8000	O
UNIT	O
DWELL	O
PRN	O
dialysis	I-Reason
Dwell	O
to	O
catheter	O
volume	O
.	O
14	O
.	O
lacosamide	I-Drug
200	O
mg	O
/	O
20	O
mL	O
Solution	O
Sig	O
:	O
Fifty	O
(	O
50	O
)	O
mg	O
Intravenous	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
vancomycin	B-Drug
in	I-Drug
D5W	I-Drug
1	O
gram	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
g	O
Intravenous	O
HD	O
PROTOCOL	O
(	O
HD	O
Protochol	O
)	O
for	O
4	O
days	O
.	O
16	O
.	O
cefepime	I-Drug
1	O
gram	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Recon	O
Soln	O
Injection	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
4	O
days	O
.	O
17	O
.	O
heparin	B-Drug
(	I-Drug
porcine	I-Drug
)	I-Drug
in	I-Drug
NS	I-Drug
Intravenous	O
18	O
.	O
pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
-	O
[	O
**	O
Hospital1	O
8	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
primary	O
diagnosis	O
:	O
hypoglycemia	O
,	O
seizure	O
disorder	O
,	O
end	O
stage	O
renal	O
disease	O
secondary	O
diagnosis	O
:	O
hypertension	O
,	O
coronary	O
artery	O
disease	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
You	O
were	O
admitted	O
for	O
seizure	O
,	O
which	O
was	O
likely	O
in	O
the	O
setting	O
of	O
hypoglycemia	O
.	O
You	O
have	O
often	O
become	O
hypoglycemic	O
in	O
the	O
past	O
and	O
it	O
is	O
unclear	O
why	O
this	O
keeps	O
happening	O
.	O
You	O
were	O
evaluated	O
for	O
this	O
but	O
the	O
results	O
of	O
the	O
studies	O
can	O
be	O
discussed	O
in	O
outpatient	O
follow	O
up	O
.	O
Because	O
you	O
continue	O
to	O
be	O
hypoglycemic	O
,	O
it	O
was	O
felt	O
that	O
you	O
might	O
be	O
best	O
served	O
by	O
placement	O
in	O
a	O
long	O
term	O
care	O
facility	O
.	O
While	O
in	O
the	O
hospital	O
,	O
you	O
received	O
hemodialysis	O
per	O
your	O
normal	O
schedule	O
.	O
You	O
will	O
continue	O
to	O
get	O
hemodialysis	O
as	O
an	O
outpatient	O
while	O
you	O
are	O
in	O
the	O
long	O
term	O
care	O
facility	O
.	O
Please	O
note	O
the	O
following	O
changes	O
to	O
your	O
medications	O
:	O
STOP	O
aspirin	I-Drug
,	O
since	O
you	O
will	O
be	O
on	O
coumadin	I-Drug
STOP	O
fluoxetine	I-Drug
,	O
as	O
it	O
can	O
contribute	O
to	O
hypoglycemia	I-Ade
START	O
coumadin	I-Drug
,	O
with	O
dosing	O
to	O
be	O
adjusted	O
per	O
your	O
MDs	O
START	O
heparin	I-Drug
IV	O
,	O
dosing	O
to	O
be	O
adjusted	O
per	O
your	O
MDs	O
START	O
cefepime	I-Drug
and	O
vancomycin	I-Drug
to	O
help	B-Reason
fight	I-Reason
bacteria	I-Reason
in	I-Reason
your	I-Reason
blood	O
Please	O
be	O
sure	O
to	O
follow	O
up	O
with	O
your	O
physicians	O
as	O
below	O
.	O
Followup	O
Instructions	O
:	O
You	O
will	O
be	O
seen	O
by	O
the	O
doctors	O
at	O
the	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
-	O
term	O
care	O
facility	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
your	O
primary	O
care	O
doctor	O
,	O
will	O
see	O
you	O
if	O
you	O
are	O
discharged	O
from	O
this	O
facility	O
.	O
Please	O
feel	O
free	O
to	O
call	O
him	O
with	O
any	O
questions	O
-	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
250	O
**	O
]	O
.	O
You	O
should	O
see	O
your	O
outpatient	O
neurologist	O
to	O
continue	O
managing	O
your	O
anti-seizure	O
medications	O
.	O
Appointment	O
information	O
is	O
below	O
:	O
Department	O
:	O
NEUROLOGY	O
When	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
**	O
]	O
[	O
**	O
2113-1-6	O
**	O
]	O
at	O
2:00	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
7025	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3294	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
858	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
You	O
will	O
continue	O
getting	O
dialysis	O
at	O
your	O
regular	O
location	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2154-2-1	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2154-2-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2079-6-23	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
613	O
**	O
]	O
Chief	O
Complaint	O
:	O
AMS	O
,	O
intubated	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Extubation	O
History	O
of	O
Present	O
Illness	O
:	O
Patient	O
is	O
a	O
66	O
yo	O
F	O
with	O
a	O
history	O
of	O
CVA	O
,	O
HTN	O
,	O
HLD	O
who	O
was	O
transferred	O
from	O
an	O
OSH	O
with	O
altered	O
mental	O
status	O
.	O
Per	O
report	O
,	O
the	O
patient	O
had	O
a	O
fall	O
2	O
days	O
ago	O
after	O
slipping	O
on	O
ice	O
after	O
the	O
snowstorm	O
and	O
falling	O
on	O
her	O
right	O
side	O
.	O
She	O
was	O
diagnosed	O
with	O
R	O
sided	O
rib	O
fractures	O
during	O
an	O
urgent	O
care	O
visit	O
at	O
the	O
[	O
**	O
Hospital	O
6598	O
**	O
]	O
[	O
**	O
Hospital	O
**	O
]	O
Clinic	O
the	O
next	O
day	O
.	O
She	O
was	O
prescribed	O
vicodin	I-Drug
and	O
asked	O
to	O
come	O
back	O
for	O
CT	O
scan	O
.	O
Family	O
states	O
the	O
patient	O
took	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
a	O
tablet	O
of	O
vicodin	I-Drug
last	O
night	O
,	O
but	O
did	O
not	O
become	O
altered	O
until	O
this	O
morning	O
.	O
When	O
they	O
came	O
to	O
see	O
her	O
at	O
home	O
,	O
they	O
found	O
she	O
was	O
more	O
altered	O
;	O
she	O
was	O
lying	O
on	O
the	O
couch	O
,	O
more	O
lethargic	O
,	O
not	O
taking	O
good	O
POs	O
or	O
any	O
of	O
her	O
medications	O
,	O
and	O
complaining	O
of	O
a	O
headache	O
.	O
She	O
was	O
brought	O
into	O
the	O
OSH	O
(	O
[	O
**	O
Hospital1	O
**	O
]	O
/	O
[	O
**	O
Hospital1	O
6136	O
**	O
]	O
)	O
for	O
further	O
evaluation	O
.	O
There	O
,	O
the	O
patient	O
was	O
given	O
Narcan	I-Drug
without	O
good	O
effect	O
.	O
She	O
was	O
reportedly	O
intubated	O
for	O
a	O
GCS	O
of	O
6	O
and	O
for	O
airway	O
protection	O
in	O
the	O
setting	O
of	O
vomiting	O
.	O
Labs	O
at	O
the	O
OSH	O
significant	O
for	O
Hct	O
of	O
42.9	O
,	O
Plts	O
221	O
,	O
INR	O
of	O
1.0	O
,	O
Na	O
139	O
K	O
3.9	O
,	O
Cre	O
:	O
1.3	O
,	O
negative	O
EtOH	O
,	O
tylenol	I-Drug
,	O
and	O
ASA	I-Drug
levels	O
.	O
Pt	O
was	O
guaiac	O
negative	O
,	O
and	O
gastric	O
occult	O
negative	O
.	O
Head	O
CT	O
at	O
OSH	O
was	O
also	O
negative	O
for	O
acute	B-Reason
new	I-Reason
infarct	I-Reason
.	O
Received	O
Zosyn	I-Drug
3.25	O
mg	O
IV	O
x1	O
.	O
She	O
was	O
placed	O
on	O
propofol	I-Drug
for	O
sedation	I-Reason
,	O
but	O
subsequently	O
noted	O
post-intubation	O
to	O
become	O
hypotensive	I-Reason
,	O
required	O
1	O
L	O
IVFs	I-Drug
and	O
was	O
started	O
on	O
peripheral	O
dopamine	I-Drug
and	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
evaluaton	O
.	O
.	O
In	O
the	O
ED	O
,	O
admission	O
VS	O
were	O
88141/78	O
(	O
dopa	O
)	O
20	O
100	O
%	O
(	O
PS	O
[	O
**	O
10	O
-	O
28	O
**	O
]	O
PEEP	O
of	O
5	O
)	O
.	O
Pt	O
received	O
a	O
fentanyl	I-Drug
boluses	O
with	O
midazolam	I-Drug
gtt	O
.	O
Her	O
dopamine	I-Drug
was	O
quickly	O
weaned	O
with	O
2	O
L	O
of	O
IVFs	I-Drug
.	O
Labs	O
sig	O
for	O
Cre	O
of	O
1.3	O
,	O
WBC	O
of	O
15.8	O
,	O
Hct	O
of	O
32.9	O
,	O
and	O
urine	O
toxicology	O
screen	O
positive	O
for	O
benzos	I-Drug
and	O
methadone	I-Drug
.	O
Vancomycin	I-Drug
1	O
gram	O
IV	O
x1	O
given	O
.	O
Patient	O
noted	O
to	O
be	O
interacting	O
appropriately	O
on	O
minimal	O
sedation	O
.	O
Trauma	O
series	O
was	O
performed	O
(	O
CT	O
Head	O
,	O
CT	O
C	O
-	O
spine	O
,	O
CT	O
Torso	O
)	O
which	O
showed	O
a	O
LLL	O
consolidation	O
and	O
rib	O
fractures	O
but	O
no	O
obvious	O
bleed	O
or	O
C	O
-	O
spine	O
fractures	O
.	O
Head	O
CT	O
negative	O
for	O
acute	O
intracranial	O
process	O
but	O
does	O
show	O
old	O
MCA	O
-	O
PCA	O
watershed	O
infarct	O
.	O
C	O
-	O
collar	O
was	O
placed	O
.	O
Trauma	O
Surgery	O
was	O
consulted	O
and	O
will	O
be	O
following	O
for	O
tertiary	O
survey	O
in	O
AM	O
and	O
clearance	O
of	O
C	O
-	O
spine	O
in	O
AM	O
.	O
.	O
On	O
the	O
floor	O
,	O
patient	O
was	O
alert	O
and	O
interactive	O
.	O
Able	O
to	O
indicate	O
pain	O
from	O
her	O
rib	O
fractures	O
.	O
REVIEW	O
OF	O
SYSTEMS	O
:	O
(	O
+	O
)	O
ve	O
:	O
(	O
-	O
)	O
ve	O
:	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
,	O
loss	O
of	O
appetite	O
,	O
fatigue	O
,	O
chest	O
pain	O
,	O
palpitations	O
,	O
rhinorrhea	O
,	O
nasal	O
congestion	O
,	O
cough	O
,	O
sputum	O
production	O
,	O
hemoptysis	O
,	O
dyspnea	O
,	O
orthopnea	O
,	O
paroxysmal	O
nocturnal	O
dyspnea	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
hematochezia	O
,	O
melena	O
,	O
dysuria	O
,	O
urinary	O
frequency	O
,	O
urinary	O
urgency	O
,	O
focal	O
numbness	O
,	O
focal	O
weakness	O
,	O
myalgias	O
,	O
arthralgias	O
Past	O
Medical	O
History	O
:	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
h	O
/	O
o	O
CVA	O
in	O
[	O
**	O
2151	O
**	O
]	O
Hypertension	O
Hyperlipidemia	O
.	O
Past	O
Surgical	O
History	O
:	O
s	O
/	O
p	O
hysterectomy	O
s	O
/	O
p	O
carotid	O
endarterectomy	O
Social	O
History	O
:	O
Lives	O
alone	O
.	O
Ambulates	O
independently	O
without	O
a	O
walker	O
but	O
has	O
had	O
some	O
difficulty	O
walking	O
recently	O
after	O
her	O
stroke	O
.	O
+	O
tobacco	O
(	O
1	O
ppd	O
)	O
;	O
occasional	O
EtOH	O
use	O
;	O
no	O
illegal	O
drugs	O
or	O
IVDU	O
(	O
per	O
sister	O
)	O
Family	O
History	O
:	O
unknown	O
Physical	O
Exam	O
:	O
Exam	O
:	O
97.6	O
,	O
HR	O
73	O
,	O
BP	O
126/55	O
,	O
94	O
%	O
(	O
88	O
-	O
94	O
%	O
)	O
on	O
4Lnc	O
GEN	O
:	O
elderly	O
F	O
looking	O
younger	O
than	O
stated	O
age	O
HEENT	O
:	O
PERRLA	O
.	O
pinpoint	O
pupils	O
,	O
~	O
1	O
mm	O
in	O
diameter	O
,	O
MMM	O
.	O
NECK	O
:	O
neck	O
supple	O
PULM	O
:	O
bibasilar	O
rales	O
CARD	O
:	O
RRR	O
S1	O
/	O
S2	O
present	O
.	O
no	O
m	O
/	O
g	O
/	O
r.	O
ABD	O
:	O
soft	O
NT	O
+	O
BS	O
EXT	O
:	O
wwp	O
no	O
edema	O
NEURO	O
:	O
AAOX3	O
but	O
in	O
and	O
out	O
of	O
responsiveness	O
,	O
could	O
not	O
say	O
months	O
of	O
year	O
backwards	O
Pertinent	O
Results	O
:	O
[	O
**	O
2154-2-1	O
**	O
]	O
08:41	O
PM	O
TYPE	O
-	O
ART	O
PO2	O
-	O
86	O
PCO2	O
-	O
49	O
*	O
PH	O
-	O
7.32	O
*	O
TOTAL	O
CO2	O
-	O
26	O
BASE	O
XS	O
--	O
1	O
[	O
**	O
2154-2-1	O
**	O
]	O
08:41	O
PM	O
LACTATE	O
-	O
0.8	O
[	O
**	O
2154-2-1	O
**	O
]	O
08:19	O
PM	O
TYPE	O
-	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
TEMP	O
-	O
36.7	O
PEEP	O
-	O
5	O
PO2	O
-	O
35	O
*	O
PCO2	O
-	O
57	O
*	O
PH	O
-	O
7.28	O
*	O
TOTAL	O
CO2	O
-	O
28	O
BASE	O
XS	O
--	O
1	O
INTUBATED	O
-	O
INTUBATED	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:49	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
>	O
1.050	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:49	O
PM	O
URINE	O
BLOOD	O
-	O
TR	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
30	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.5	O
LEUK	O
-	O
NEG	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:49	O
PM	O
URINE	O
RBC	O
-	O
3	O
*	O
WBC	O
-	O
<	O
1	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
0	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:48	O
PM	O
GLUCOSE	O
-	O
122	O
*	O
UREA	O
N	O
-	O
26	O
*	O
CREAT	O
-	O
1.2	O
*	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
3.8	O
CHLORIDE	O
-	O
103	O
TOTAL	O
CO2	O
-	O
27	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:48	O
PM	O
CK	O
(	O
CPK	O
)	O
-	O
291	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:48	O
PM	O
CK	O
-	O
MB	O
-	O
5	O
cTropnT	O
-	O
0.04	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:48	O
PM	O
CALCIUM	O
-	O
7.7	O
*	O
PHOSPHATE	O
-	O
4.1	O
MAGNESIUM	O
-	O
1.9	O
IRON	O
-	O
14	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:48	O
PM	O
calTIBC	O
-	O
278	O
VIT	O
B12	O
-	O
516	O
FOLATE	O
-	O
GREATER	O
TH	O
FERRITIN	O
-	O
170	O
*	O
TRF	O
-	O
214	O
[	O
**	O
2154-2-1	O
**	O
]	O
07:48	O
PM	O
WBC	O
-	O
ERROR	O
DISR	O
RBC	O
-	O
ERROR	O
DISR	O
HGB	O
-	O
ERROR	O
DISR	O
HCT	O
-	O
ERROR	O
DISR	O
MCV	O
-	O
ERROR	O
DISR	O
MCH	O
-	O
ERROR	O
DISR	O
MCHC	O
-	O
ERROR	O
DISR	O
RDW	O
-	O
ERROR	O
DISR	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
UREA	O
N	O
-	O
30	O
*	O
CREAT	O
-	O
1.3	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
estGFR	O
-	O
Using	O
this	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
LIPASE	O
-	O
22	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
GR	O
HOLD	O
-	O
HOLD	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
bnzodzpn	O
-	O
POS	O
barbitrt	O
-	O
NEG	O
opiates	O
-	O
NEG	O
cocaine	O
-	O
NEG	O
amphetmn	O
-	O
NEG	O
mthdone	O
-	O
POS	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
WBC	O
-	O
15.8	O
*	O
RBC	O
-	O
3.73	O
*	O
HGB	O
-	O
11.6	O
*	O
HCT	O
-	O
32.9	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
31.2	O
MCHC	O
-	O
35.5	O
*	O
RDW	O
-	O
14.1	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
PLT	O
COUNT	O
-	O
195	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
PT	O
-	O
12.9	O
PTT	O
-	O
23.1	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
FIBRINOGE	O
-	O
512	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.016	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
BLOOD	O
-	O
MOD	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
75	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
RBC	O
-0-2	O
WBC	O
-0-2	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
[	O
**	O
12	O
-	O
8	O
**	O
]	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
GRANULAR	O
-0-2	O
HYALINE	O
-	O
[	O
**	O
6	O
-	O
28	O
**	O
]	O
*	O
[	O
**	O
2154-2-1	O
**	O
]	O
02:30	O
PM	O
URINE	O
AMORPH	O
-	O
FEW	O
Brief	O
Hospital	O
Course	O
:	O
#	O
.	O
Altered	O
mental	O
status	O
:	O
Patient	O
was	O
initially	O
found	O
to	O
have	O
altered	O
mental	O
status	O
after	O
slip	O
and	O
fall	O
on	O
ice	O
.	O
She	O
sustained	O
R	B-Reason
sided	I-Reason
rib	I-Reason
fractures	I-Reason
which	O
were	O
treated	O
with	O
vicodin	I-Drug
.	O
She	O
was	O
found	O
by	O
family	O
to	O
be	O
altered	O
and	O
brought	O
to	O
OSH	O
where	O
she	O
was	O
intubated	O
for	O
GCS	O
6	O
.	O
She	O
had	O
also	O
had	O
a	O
URI	O
prior	O
to	O
OSH	O
presentation	O
.	O
Initial	O
AMS	I-Ade
was	O
likely	O
multifactorial	O
due	O
to	O
infection	O
(	O
pneumonia	O
,	O
likely	O
acquired	O
in	O
setting	O
of	O
splinting	O
from	O
rib	O
pain	O
[	O
**	O
2	O
-	O
20	O
**	O
]	O
fractures	O
)	O
,	O
medication	O
induced	O
from	O
narcotics	I-Drug
(	O
received	O
vicodin	I-Drug
for	O
pain	B-Reason
control	I-Reason
)	O
but	O
urine	O
toxicology	O
screen	O
also	O
positive	O
for	O
methadone	I-Drug
,	O
and	O
ABG	O
showed	O
an	O
acute	O
respiratory	O
acidosis	O
concerning	O
for	O
respiratory	O
depression	O
.	O
Toxicology	O
screen	O
negative	O
at	O
OSH	O
for	O
EtOH	O
,	O
APAP	I-Drug
,	O
and	O
ASA	I-Drug
.	O
No	O
evidence	O
of	O
new	O
ICH	O
or	O
stroke	O
on	O
head	O
CT.	O
.	O
No	O
evidence	O
of	O
UTI	O
on	O
urine	O
analysis	O
.	O
Cardiac	O
etiology	O
was	O
ruled	O
out	O
with	O
cardiac	O
enzymes	O
negative	O
x	O
2	O
.	O
Patient	O
was	O
extubated	O
with	O
good	O
mental	O
status	O
but	O
subsequently	O
became	O
increasingly	O
altered	I-Ade
,	O
thought	O
to	O
be	O
associated	O
with	O
morphine	I-Drug
use	O
for	O
pain	B-Reason
control	I-Reason
.	O
This	O
delirium	I-Ade
resolved	O
upon	O
avoiding	O
opioid	B-Drug
medications	I-Drug
such	O
as	O
morphine	I-Drug
and	O
oxycodone	I-Drug
.	O
.	O
#	O
Respiratory	B-Reason
Failure	I-Reason
:	O
Pt	O
initially	O
hypoxic	O
with	O
pna	O
and	O
splinting	O
from	O
pain	O
,	O
intubated	O
[	O
**	O
2	O
-	O
20	O
**	O
]	O
altered	O
mental	O
status	O
.	O
The	O
pt	O
was	O
extubated	O
after	O
transfer	O
from	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
,	O
with	O
decreasing	O
O2	I-Drug
requirement	O
.	O
She	O
was	O
found	O
to	O
have	O
a	O
pneumonia	I-Reason
and	O
was	O
started	O
on	O
Levaquin	I-Drug
for	O
presumed	I-Reason
CAP	O
.	O
However	O
,	O
patient	O
continued	O
spiking	O
despite	O
abx	I-Drug
.	O
Given	O
sputum	O
cx	O
stained	O
2	O
+	O
GPC	O
in	O
pairs	O
and	O
chains	O
,	O
2	O
+	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
,	O
pt	O
was	O
broadened	O
to	O
Vanc	I-Drug
/	O
Zosyn	I-Drug
(	O
pt	O
is	O
allergic	I-Ade
to	O
penicillins	I-Drug
but	O
has	O
tolerated	O
zosyn	I-Drug
in	O
the	O
past	O
)	O
.	O
Abx	I-Drug
were	O
continued	O
for	O
an	O
eight	O
day	O
course	O
(	O
last	O
day	O
[	O
**	O
2	O
-	O
9	O
**	O
]	O
)	O
.	O
She	O
was	O
also	O
encouraged	O
to	O
use	O
incentive	O
spirometer	O
and	O
pain	O
was	O
controlled	O
as	O
below	O
.	O
.	O
#	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
,	O
prerenal	O
,	O
hypovolemic	O
:	O
pt	O
??????	O
s	O
cr	O
increased	O
from	O
nadir	O
1.0	O
to	O
1.5	O
.	O
Cr	O
improved	O
with	O
ivf	I-Drug
hydration	I-Reason
.	O
Cr	O
was	O
1.2	O
by	O
next	O
day	O
.	O
.	O
#	O
normocytic	O
anemia	O
:	O
Hct	O
down	O
to	O
32.9	O
from	O
42	O
at	O
OSH	O
.	O
HCT	O
slowly	O
trending	O
down	O
.	O
No	O
evidence	O
of	O
intra-abdominal	O
bleed	O
on	O
CT	O
scans	O
.	O
Iron	I-Drug
studies	O
[	O
**	O
Location	O
(	O
un	O
)	O
381	O
**	O
]	O
levels	O
,	O
showing	O
element	O
of	O
iron	I-Drug
deficiency	O
,	O
likely	O
mixed	O
with	O
anemia	O
of	O
chronic	O
disease	O
.	O
no	O
colonoscopy	O
in	O
system	O
.	O
B12	O
and	O
folate	I-Drug
nl	O
.	O
.	O
#	O
.	O
Rib	O
fractures	O
:	O
s	O
/	O
p	O
fall	O
with	O
R	O
sided	O
rib	O
fractures	O
from	O
T3	O
-	O
T7	O
.	O
Pain	B-Reason
control	I-Reason
with	O
standing	O
tylenol	I-Drug
,	O
lidocaine	I-Drug
patch	O
x3	O
for	O
rib	O
fractures	O
,	O
oxycodone	I-Drug
prn	O
pain	I-Reason
.	O
Patient	O
initially	O
treated	O
with	O
morphine	I-Drug
however	O
it	O
was	O
felt	O
to	O
contribute	O
to	O
here	O
AMS	I-Ade
.	O
Patient	O
's	O
pain	I-Reason
controlled	O
with	O
around	O
the	O
clock	O
Tylenol	I-Drug
and	O
lidocaine	I-Drug
patches	O
.	O
.	O
#	O
Mediastinal	O
Lymphadenopathy	O
:	O
CT	O
scan	O
showed	O
areas	O
of	O
mediastinal	O
lymphadenopathy	O
thought	O
to	O
be	O
less	O
consistent	O
with	O
reactive	O
process	O
.	O
Could	O
be	O
sarcoid	O
vs.	O
malignancy	O
.	O
Should	O
be	O
followed	O
up	O
with	O
an	O
outpatient	O
biopsy	O
to	O
assess	O
for	O
malignancy	O
.	O
Patient	O
scheduled	O
for	O
Interventional	O
Pulmonology	O
clinic	O
on	O
[	O
**	O
2	O
-	O
18	O
**	O
]	O
at	O
noon	O
.	O
MD	O
made	O
aware	O
at	O
facility	O
.	O
.	O
#	O
Adrenal	O
nodule	O
:	O
Incompletely	O
visualized	O
.	O
Should	O
be	O
followed	O
up	O
outpt	O
with	O
a	O
dedicated	O
adrenal	O
MR	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
.	O
.	O
#	O
.	O
Clearing	O
C	O
-	O
spine	O
:	O
clinically	O
cleared	O
per	O
trauma	O
.	O
#	O
.	O
Hypertension	I-Reason
:	O
home	O
antihypertensives	I-Drug
.	O
#	O
.	O
Hyperlipidemia	I-Reason
:	O
continue	O
statin	I-Drug
.	O
#	O
Anxiety	I-Reason
:	O
held	O
ativan	I-Drug
for	O
protection	O
of	O
respiratory	O
status	O
Medications	O
on	O
Admission	O
:	O
(	O
per	O
[	O
**	O
Hospital3	O
**	O
]	O
Records	O
and	O
confirmed	O
with	O
pt	O
's	O
pharmacy	O
(	O
Stop	O
and	O
Shop	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
6598	O
**	O
]	O
#	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
88247	O
**	O
]	O
)	O
Folic	B-Drug
Acid	I-Drug
Aspirin	B-Drug
81	O
mg	O
PO	O
daily	O
Amlodipine	B-Drug
5	O
mg	O
PO	O
daiy	O
Metoprolol	I-Drug
Tartrate	O
50	O
mg	O
PO	O
BID	O
Vicodin	I-Drug
5	O
-	O
500	O
mg	O
1	O
tablet	O
prn	O
:	O
pain	I-Reason
HCTZ	I-Drug
12.5	O
mg	O
PO	O
daily	O
Ativan	I-Drug
0.5	O
mg	O
PO	O
QHS	O
Trazadone	I-Drug
150	O
mg	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
tablet	O
PO	O
QHS	O
Mevacor	I-Drug
20	O
mg	O
PO	O
daily	O
.	O
OLD	O
MEDS	O
:	O
Buspirone	I-Drug
(	O
old	O
,	O
filled	O
last	O
back	O
in	O
[	O
**	O
2152	O
**	O
]	O
)	O
Combivent	I-Drug
Inhaler	O
(	O
filled	O
last	O
back	O
in	O
[	O
**	O
2152-3-19	O
**	O
]	O
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
acetaminophen	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
2	O
.	O
heparin	I-Drug
(	O
porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
simvastatin	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Adhesive	O
Patch	O
,	O
Medicated	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
6	O
.	O
metoprolol	I-Drug
tartrate	O
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
docusate	I-Drug
sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
nicotine	I-Drug
14	O
mg	O
/	O
24	O
hr	O
Patch	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
24	O
hr	O
Transdermal	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
tramadol	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
1	O
*	O
11	O
.	O
vancomycin	I-Drug
in	O
D5W	O
1	O
gram	O
/	O
200	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
Q	O
24H	O
(	O
Every	O
24	O
Hours	O
)	O
:	O
Please	O
complete	O
on	O
[	O
**	O
2154-2-9	O
**	O
]	O
.	O
12	O
.	O
piperacillin	B-Drug
-	I-Drug
tazobactam	O
2.25	O
gram	O
Recon	O
Soln	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Recon	O
Soln	O
Intravenous	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
:	O
Please	O
complete	O
on	O
[	O
**	O
2154-2-9	O
**	O
]	O
.	O
13	O
.	O
hydrochlorothiazide	B-Drug
12.5	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
85	O
**	O
]	O
-	O
[	O
**	O
Hospital3	O
**	O
]	O
(	O
[	O
**	O
Hospital	O
**	O
]	O
Hospital	O
of	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
and	O
Islands	O
)	O
Discharge	O
Diagnosis	O
:	O
metabolic	O
encephalopathy	O
community	O
-	O
acquired	O
pneumonia	O
Rib	O
fractures	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	I-Drug
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
88248	O
**	O
]	O
,	O
You	O
were	O
transferred	O
to	O
our	O
hospital	O
to	O
care	O
for	O
a	O
pneumonia	O
that	O
was	O
the	O
result	O
of	O
a	O
probable	O
aspiration	O
event	O
during	O
a	O
state	O
of	O
altered	B-Ade
mental	I-Ade
status	I-Ade
.	O
We	O
believe	O
the	O
pain	B-Drug
medications	I-Drug
in	O
the	O
opioid	O
class	O
(	O
including	O
morphine	I-Drug
,	O
vicodin	I-Drug
,	O
codeine	I-Drug
)	O
worsen	O
your	O
mental	O
status	O
and	O
make	O
you	O
delirious	I-Ade
.	O
Please	O
AVOID	O
TAKING	O
THESE	O
MEDICATIONS	O
.	O
We	O
treated	O
your	O
probable	O
pneumonia	I-Reason
with	O
antibiotics	I-Drug
,	O
that	O
should	O
be	O
completed	O
on	O
[	O
**	O
2154-2-9	O
**	O
]	O
.	O
We	O
placed	O
a	O
special	O
i.v.	O
into	O
your	O
arm	O
that	O
can	O
be	O
used	O
for	O
these	O
medications	O
.	O
Also	O
of	O
note	O
,	O
a	O
CAT	O
scan	O
at	O
the	O
beginning	O
of	O
your	O
visit	O
here	O
showed	O
a	O
left	O
lower	O
lobe	O
infiltrate	O
consistent	O
with	O
pneumonia	O
.	O
However	O
,	O
it	O
also	O
showed	O
a	O
couple	O
abnormalities	O
that	O
will	O
require	O
followup	O
.	O
This	O
includes	O
:	O
1	O
)	O
Mediastinal	O
lymphadenopathy	O
-	O
size	O
is	O
less	O
compatible	O
with	O
reactive	O
nodes	O
,	O
and	O
may	O
be	O
compatible	O
with	O
metastatic	O
nodes	O
or	O
sarcoidosis	O
.	O
2	O
)	O
Left	O
adrenal	O
nodule	O
,	O
incompletely	O
characterized	O
-	O
a	O
dedicated	O
adrenal	O
CT	O
Please	O
follow	O
up	O
with	O
our	O
pulmonologists	O
and	O
your	O
primary	O
doctor	O
to	O
set	O
up	O
these	O
examinations	O
to	O
further	O
evaluate	O
these	O
findings	O
.	O
We	O
controlled	O
your	O
pain	I-Reason
from	O
your	O
rib	O
fractures	O
with	O
Tylenol	I-Drug
and	O
lidocaine	I-Drug
patches	O
,	O
since	O
other	O
medications	O
worsened	O
your	O
mental	O
state	O
.	O
Please	O
continue	O
to	O
take	O
these	O
as	O
needed	O
for	O
your	B-Reason
pain	I-Reason
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
as	O
soon	O
as	O
you	O
can	O
after	O
discharge	O
Please	O
also	O
follow	O
up	O
with	O
our	O
pulmonary	O
clinic	O
to	O
follow	O
up	O
on	O
the	O
abnormal	O
CAT	O
scan	O
findings	O
.	O
You	O
have	O
an	O
appointment	O
with	O
the	O
interventional	O
pulmonology	O
clinic	O
here	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Hospital	O
Ward	O
Name	O
**	O
]	O
at	O
12	O
PM	O
on	O
[	O
**	O
2154-2-18	O
**	O
]	O
.	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
617	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2159-8-9	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2159-8-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2090-5-18	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Adult	O
Low	O
Dose	O
Aspirin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1899	O
**	O
]	O
Chief	O
Complaint	O
:	O
CHIEF	O
COMPLAINT	O
:	O
Pericardial	O
effusion	O
REASON	O
FOR	O
CCU	O
ADMISSION	O
:	O
Monitoring	O
post	O
pericardial	O
drain	O
placement	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Pericardial	O
drain	O
placement	O
[	O
**	O
2159-8-9	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
90050	O
**	O
]	O
is	O
a	O
69F	O
with	O
a	O
history	O
of	O
recently	O
diagnosed	O
synchronous	O
stage	O
IIIB	O
non-small	O
cell	O
lung	O
cancer	O
(	O
adenocarcinoma	O
by	O
bronchial	O
brushings	O
)	O
and	O
renal	O
cell	O
carcinoma	O
,	O
currently	O
s	O
/	O
p	O
left	O
nephrectomy	O
and	O
undergoing	O
chemotherapy	O
and	O
radiation	O
.	O
She	O
underwent	O
CT	O
scan	O
of	O
her	O
chest	O
for	O
re-staging	O
of	O
her	O
lung	O
cancer	O
on	O
[	O
**	O
2159-8-6	O
**	O
]	O
,	O
which	O
demonstrated	O
an	O
increasingly	O
large	O
pericardial	O
effusion	O
(	O
had	O
been	O
previously	O
noted	O
on	O
PET	O
scan	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
)	O
.	O
She	O
has	O
recently	O
been	O
experiencing	O
worsening	O
shortness	O
of	O
breath	O
at	O
home	O
,	O
which	O
she	O
notices	O
only	O
with	O
exertion	O
such	O
as	O
carrying	O
a	O
full	O
basket	O
of	O
laundry	O
.	O
She	O
has	O
had	O
some	O
associated	O
cough	O
,	O
but	O
no	O
sputum	O
production	O
.	O
In	O
addition	O
,	O
about	O
3	O
weeks	O
ago	O
she	O
was	O
seen	O
at	O
[	O
**	O
Hospital3	O
1443	O
**	O
]	O
hospital	O
for	O
chest	O
pain	O
;	O
she	O
was	O
ruled	O
out	O
for	O
MI	O
and	O
planned	O
for	O
outpatient	O
echocardiogram	O
,	O
which	O
would	O
have	O
been	O
today	O
but	O
she	O
cancelled	O
given	O
her	O
oncology	O
appointments	O
.	O
She	O
has	O
not	O
had	O
a	O
recurrence	O
of	O
the	O
chest	O
pain	O
.	O
She	O
was	O
seen	O
today	O
in	O
clinic	O
today	O
by	O
her	O
oncologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
who	O
noted	O
her	O
complaints	O
of	O
worsening	O
dyspnea	O
on	O
exertion	O
and	O
referred	O
her	O
to	O
the	O
ED	O
for	O
echocardiogram	O
to	O
evaluate	O
for	O
possible	O
tamponade	O
.	O
In	O
the	O
ED	O
,	O
echocardiogram	O
showed	O
brief	O
right	O
atrial	O
collapse	O
and	O
impaired	O
filling	O
of	O
the	O
right	O
ventricle	O
consistent	O
with	O
early	O
tamponade	O
physiology	O
.	O
She	O
was	O
evaluated	O
by	O
interventional	O
cardiology	O
and	O
taken	O
to	O
the	O
catheterization	O
lab	O
for	O
pericardial	O
fluid	O
removal	O
.	O
.	O
She	O
underwent	O
pericardial	O
drain	O
placement	O
with	O
~	O
400	O
cc	O
of	O
bloody	O
fluid	O
removed	O
,	O
followed	O
by	O
rapid	O
drainage	O
of	O
another	O
~	O
150cc	O
into	O
the	O
drainage	O
bag	O
.	O
She	O
tolerated	O
the	O
procedure	O
well	O
.	O
Immediate	O
post-procedure	O
echo	O
showed	O
small	O
residual	O
pericardial	O
effusion	O
with	O
no	O
Fluid	O
was	O
sent	O
for	O
cytology	O
.	O
Her	O
oncologist	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
and	O
updated	O
with	O
the	O
events	O
of	O
the	O
procedure	O
.	O
He	O
requested	O
transfusion	O
of	O
2	O
units	O
pRBCs	I-Drug
for	O
anemia	I-Reason
.	O
.	O
On	O
the	O
floor	O
,	O
she	O
reports	O
feeling	O
well	O
.	O
No	O
current	O
SOB	O
at	O
rest	O
or	O
chest	O
pain	O
(	O
only	O
very	O
mild	O
site	O
tenderness	O
with	O
drain	O
placement	O
)	O
.	O
.	O
Of	O
note	O
,	O
her	O
cancer	O
history	O
is	O
well	O
-	O
documented	O
in	O
OMR	O
note	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
dated	O
[	O
**	O
2159-8-9	O
**	O
]	O
.	O
Briefly	O
,	O
she	O
initially	O
presented	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
404	O
**	O
]	O
with	O
hematuria	O
,	O
and	O
further	O
work	O
up	O
revealed	O
both	O
a	O
large	O
9	O
-	O
cm	O
renal	O
mass	O
and	O
a	O
RUL	O
9	O
-	O
cm	O
mass	O
with	O
mediastinal	O
nodes	O
.	O
Based	O
on	O
renal	O
biopsy	O
(	O
RCC	O
,	O
clear	O
cell	O
type	O
)	O
and	O
bronchial	O
brushings	O
(	O
likely	O
adenocarcinoma	O
)	O
these	O
are	O
two	O
separate	O
cancers	I-Reason
.	O
She	O
has	O
been	O
treated	O
with	O
chemotherapy	I-Reason
with	O
cysplatin	I-Drug
and	O
paclitaxel	I-Drug
(	O
start	O
date	O
[	O
**	O
2159-7-12	O
**	O
]	O
)	O
and	O
radiation	O
therapy	O
to	O
the	O
chest	O
,	O
in	O
addition	O
to	O
unilateral	O
nephrectomy	O
in	O
4	O
/	O
[	O
**	O
2159	O
**	O
]	O
.	O
.	O
On	O
review	O
of	O
systems	O
,	O
she	O
endorses	O
bilateral	O
chronic	O
hip	O
pain	O
with	O
walking	O
(	O
not	O
new	O
or	O
changed	O
)	O
,	O
and	O
dark	B-Ade
stool	I-Ade
secondary	O
to	O
iron	I-Drug
use	O
.	O
She	O
denies	O
any	O
prior	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
(	O
though	O
had	O
one	O
GI	B-Ade
bleed	I-Ade
on	O
aspirin	I-Drug
in	O
[	O
**	O
2154	O
**	O
]	O
)	O
,	O
myalgias	O
,	O
hemoptysis	O
,	O
black	O
stools	O
or	O
red	O
stools	O
.	O
She	O
denies	O
recent	O
fevers	O
,	O
chills	O
,	O
nightsweats	O
or	O
rigors	O
.	O
No	O
recent	O
cold	O
or	O
flu	O
symptoms	O
.	O
She	O
denies	O
exertional	O
buttock	O
or	O
calf	O
pain	O
.	O
She	O
denies	O
dysuria	O
or	O
other	O
urinary	O
symptoms	O
.	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
absence	O
of	O
chest	O
pain	O
,	O
paroxysmal	O
nocturnal	O
dyspnea	O
,	O
orthopnea	O
(	O
sleeps	O
with	O
one	O
flat	O
pillow	O
)	O
,	O
ankle	O
edema	O
,	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
.	O
All	O
of	O
the	O
other	O
review	O
of	O
systems	O
were	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Renal	O
cell	O
carcinoma	O
(	O
clear	O
cell	O
type	O
by	O
biopsy	O
)	O
s	O
/	O
p	O
unilateral	O
left	O
nephrectomy	O
[	O
**	O
4	O
-	O
/	O
2158	O
**	O
]	O
-	O
Non-small	B-Reason
cell	I-Reason
lung	I-Reason
cancer	I-Reason
(	O
likely	O
adenocarcinoma	O
by	O
bronchial	O
brushings	O
)	O
stage	O
IIIB	O
s	O
/	O
p	O
cisplatin	I-Drug
/	O
paclitaxel	I-Drug
(	O
day	O
#	O
1	O
=	O
[	O
**	O
2159-7-12	O
**	O
]	O
)	O
and	O
radiation	O
(	O
ongoing	O
)	O
-	O
Esophagitis	I-Ade
secondary	O
to	O
chemo	I-Drug
/	O
radiation	O
-	O
Hypertension	O
diagnosed	O
>	O
30	O
years	O
ago	O
-	O
Depression	O
-	O
Status	O
post	O
gastrointestinal	B-Ade
bleed	I-Ade
from	O
GI	B-Ade
ulceration	I-Ade
from	O
aspirin	I-Drug
in	O
[	O
**	O
2154	O
**	O
]	O
-	O
History	O
of	O
iron	O
deficiency	O
anemia	O
-	O
Status	O
post	O
rotator	O
cuff	O
repair	O
in	O
[	O
**	O
2156	O
**	O
]	O
-	O
History	O
of	O
sinusitis	O
Social	O
History	O
:	O
Lives	O
at	O
home	O
with	O
her	O
husband	O
.	O
Continues	O
to	O
work	O
part	O
time	O
at	O
her	O
husband	O
's	O
business	O
(	O
he	O
owns	O
an	O
automotive	O
parts	O
supply	O
shop	O
)	O
.	O
-	O
Tobacco	O
history	O
:	O
Former	O
smoker	O
of	O
[	O
**	O
1	O
-	O
28	O
**	O
]	O
packs	O
per	O
day	O
until	O
age	O
65	O
(	O
~	O
75	O
pack	O
-	O
year	O
history	O
)	O
-	O
ETOH	O
:	O
Recreational	O
in	O
past	O
,	O
none	O
recent	O
-	O
Illicit	O
drugs	O
:	O
None	O
Family	O
History	O
:	O
Mother	O
died	O
of	O
stroke	O
;	O
father	O
died	O
of	O
heart	O
disease	O
.	O
No	O
family	O
history	O
of	O
early	O
MI	O
,	O
arrhythmia	O
,	O
cardiomyopathies	O
,	O
or	O
sudden	O
cardiac	O
death	O
;	O
no	O
family	O
history	O
of	O
lung	O
or	O
renal	O
cancer	O
;	O
one	O
maternal	O
aunt	O
had	O
cancer	O
of	O
an	O
unknown	O
type	O
.	O
Otherwise	O
non-contributory	O
.	O
Physical	O
Exam	O
:	O
ADMISSION	O
EXAM	O
:	O
VS	O
:	O
T	O
=	O
98.7	O
BP	O
=	O
100/69	O
HR	O
=	O
RR	O
=	O
16	O
O2	I-Drug
sat	O
=	O
97	O
%	O
on	O
4L	O
GENERAL	O
:	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Mood	O
,	O
affect	O
appropriate	O
.	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
PERRL	O
,	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
No	O
xanthalesma	O
.	O
NECK	O
:	O
Supple	O
with	O
no	O
JVD	O
.	O
No	O
carotid	O
bruits	O
noted	O
.	O
CARDIAC	O
:	O
Distant	O
S1S2	O
,	O
no	O
distinct	O
murmurs	O
,	O
rubs	O
or	O
gallops	O
.	O
Pericardial	O
drain	O
in	O
place	O
with	O
~	O
150	O
cc	O
of	O
sanguinous	O
fluid	O
in	O
bag	O
.	O
LUNGS	O
:	O
No	O
chest	O
wall	O
deformities	O
,	O
scoliosis	O
or	O
kyphosis	O
.	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
CTAB	O
,	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
2	O
+	O
DP	O
pulses	O
SKIN	O
:	O
Erythematous	O
rash	O
over	O
central	O
anterior	O
chest	O
secondary	O
to	O
recent	O
radiation	O
treatment	O
.	O
DISCHARGE	O
EXAM	O
:	O
GENERAL	O
:	O
NAD	O
.	O
Oriented	O
x3	O
.	O
Mood	O
,	O
affect	O
appropriate	O
.	O
CARDIAC	O
:	O
Distant	O
S1S2	O
,	O
no	O
distinct	O
murmurs	O
,	O
rubs	O
or	O
gallops	O
.	O
Dressing	O
in	O
place	O
at	O
the	O
site	O
of	O
pericardial	O
drain	O
,	O
c	O
/	O
d	O
/	O
i	O
LUNGS	O
:	O
CTAB	O
,	O
no	O
crackles	O
,	O
wheezes	O
or	O
rhonchi	O
.	O
ABDOMEN	O
:	O
Soft	O
,	O
NTND	O
.	O
No	O
HSM	O
or	O
tenderness	O
.	O
EXTREMITIES	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
2	O
+	O
DP	O
pulses	O
SKIN	O
:	O
Erythematous	O
rash	O
over	O
central	O
anterior	O
chest	O
secondary	O
to	O
recent	O
radiation	O
treatment	O
Pertinent	O
Results	O
:	O
LABS	O
ON	O
ADMISSION	O
:	O
[	O
**	O
2159-8-9	O
**	O
]	O
07:35	O
AM	O
WBC	O
-	O
14.5	O
*	O
RBC	O
-	O
2.93	O
*	O
HGB	O
-	O
7.8	O
*	O
HCT	O
-	O
24.1	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
26.7	O
*	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
18.3	O
*	O
[	O
**	O
2159-8-9	O
**	O
]	O
07:35	O
AM	O
PLT	O
COUNT	O
-	O
486	O
*	O
[	O
**	O
2159-8-9	O
**	O
]	O
12:20	O
PM	O
GLUCOSE	O
-	O
97	O
UREA	O
N	O
-	O
27	O
*	O
CREAT	O
-	O
1.3	O
*	O
SODIUM	O
-	O
131	O
*	O
POTASSIUM	O
-	O
5.1	O
CHLORIDE	O
-	O
94	O
*	O
TOTAL	O
CO2	O
-	O
24	O
ANION	O
GAP	O
-	O
18	O
[	O
**	O
2159-8-9	O
**	O
]	O
12:38	O
PM	O
GLUCOSE	O
-	O
104	O
LACTATE	O
-	O
1.1	O
NA	O
+	O
-	O
131	O
*	O
K	O
+	O
-	O
5.0	O
CL	O
--	O
95	O
*	O
TCO2	O
-	O
25	O
[	O
**	O
2159-8-9	O
**	O
]	O
02:45	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.050	O
*	O
[	O
**	O
2159-8-9	O
**	O
]	O
02:45	O
PM	O
URINE	O
BLOOD	O
-	O
MOD	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
30	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.5	O
LEUK	O
-	O
SM	O
[	O
**	O
2159-8-9	O
**	O
]	O
02:45	O
PM	O
URINE	O
RBC	O
-	O
15	O
*	O
WBC	O
-	O
6	O
*	O
BACTERIA	O
-	O
NONE	O
YEAST	O
-	O
NONE	O
EPI	O
-	O
2	O
TRANS	O
EPI	O
-	O
<	O
1	O
OTHER	O
SIGNIFICANT	O
LABS	O
:	O
.	O
MICROBIOLOGY	O
:	O
-	O
Pericardial	O
fluid	O
[	O
**	O
2159-8-9	O
**	O
]	O
:	O
Gram	O
stain	O
negative	O
for	O
organisms	O
or	O
PMNs	O
.	O
-	O
Pericardial	O
fluid	O
culture	O
[	O
**	O
2159-8-9	O
**	O
]	O
(	O
blood	O
culture	O
bottles	O
)	O
:	O
NO	O
GROWTH	O
-	O
MRSA	O
screen	O
[	O
**	O
2159-8-9	O
**	O
]	O
:	O
PENDING	O
IMAGING	O
:	O
.	O
-	O
ECHO	O
[	O
**	O
2159-8-9	O
**	O
]	O
(	O
pre-procedure	O
)	O
:	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
low	O
normal	O
(	O
LVEF	O
50	O
-	O
55	O
%	O
)	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
unusually	O
small	O
.	O
with	O
normal	O
free	O
wall	O
contractility	O
.	O
There	O
is	O
a	O
moderate	O
sized	O
pericardial	O
effusion	O
.	O
The	O
effusion	O
appears	O
circumferential	O
.	O
Stranding	O
is	O
visualized	O
within	O
the	O
pericardial	O
space	O
c	O
/	O
w	O
organization	O
.	O
There	O
is	O
brief	O
right	O
atrial	O
diastolic	O
collapse	O
.	O
There	O
is	O
significant	O
,	O
accentuated	O
respiratory	O
variation	O
in	O
tricuspid	O
valve	O
inflows	O
,	O
consistent	O
with	O
impaired	O
ventricular	O
filling	O
.	O
IMPRESSION	O
:	O
Moderate	O
circumferential	O
pericardial	O
effusion	O
with	O
most	O
of	O
the	O
fluid	O
located	O
over	O
the	O
right	O
atrium	O
and	O
inferolateral	O
wall	O
.	O
There	O
is	O
relatively	O
little	O
fluid	O
over	O
the	O
right	O
ventricular	O
free	O
wall	O
.	O
There	O
is	O
variation	O
in	O
tricuspid	O
inflows	O
,	O
along	O
with	O
brief	O
right	O
atrial	O
collapse	O
and	O
impaired	O
filling	O
of	O
the	O
right	O
ventricle	O
consistent	O
with	O
early	O
tamponade	O
physiology	O
.	O
.	O
-	O
ECHO	O
[	O
**	O
2159-8-9	O
**	O
]	O
(	O
post-procedure	O
)	O
:	O
Effusion	O
is	O
loculated	O
.	O
No	O
significant	O
respiratory	O
variation	O
in	O
mitral	O
/	O
tricuspid	O
valve	O
flows	O
.	O
IMPRESSION	O
:	O
Limited	O
study	O
,	O
Doppler	O
images	O
only	O
.	O
No	O
significant	O
variation	O
in	O
mitral	O
inflows	O
.	O
Pericardial	O
fluid	O
amount	O
is	O
reduced	O
.	O
.	O
-	O
ECHO	O
[	O
**	O
2159-8-11	O
**	O
]	O
(	O
post-procedure	O
)	O
:	O
Focused	O
views	O
s	O
/	O
p	O
pericardial	O
drainage	O
.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
0	O
-	O
5	O
mmHg	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
There	O
is	O
a	O
residual	O
small	O
pericardial	O
effusion	O
along	O
the	O
infero	O
-	O
lateral	O
wall	O
and	O
right	O
atrium	O
.	O
The	O
effusion	O
is	O
very	O
small	O
anterior	O
to	O
the	O
right	O
ventricle	O
and	O
significantly	O
improved	O
compared	O
to	O
the	O
prior	O
study	O
dated	O
[	O
**	O
2159-8-9	O
**	O
]	O
.	O
There	O
are	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
LABS	O
ON	O
DISCHARGE	O
:	O
Pericardial	O
Effusion	O
Fluid	O
:	O
[	O
**	O
2159-8-9	O
**	O
]	O
04:45	O
PM	O
OTHER	O
BODY	O
FLUID	O
WBC	O
-	O
1175	O
*	O
Hct,Fl	O
-	O
8.5	O
*	O
Polys	O
-	O
35	O
*	O
Lymphs	O
-	O
39	O
*	O
Monos	O
-	O
16	O
*	O
Eos	O
-	O
1	O
*	O
Macro-9	O
*	O
[	O
**	O
2159-8-9	O
**	O
]	O
04:45	O
PM	O
OTHER	O
BODY	O
FLUID	O
TotProt	O
-	O
5.3	O
Glucose	O
-	O
85	O
LD	O
(	O
LDH	O
)	O
-	O
996	O
Amylase	O
-	O
23	O
Albumin	O
-	O
3.4	O
CYTOLOGY	O
:	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS	O
.	O
Lymphocytes	O
,	O
red	O
blood	O
cells	O
,	O
hemosiderin	O
-	O
laden	O
histiocytes	O
,	O
and	O
rare	O
mesothelial	O
cells	O
.	O
.	O
[	O
**	O
2159-8-11	O
**	O
]	O
06:15	O
AM	O
BLOOD	O
WBC	O
-	O
11.4	O
*	O
RBC	O
-	O
3.65	O
*	O
Hgb	O
-	O
10.1	O
*	O
Hct	O
-	O
30.5	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
27.7	O
MCHC	O
-	O
33.2	O
RDW	O
-	O
18.4	O
*	O
Plt	O
Ct	O
-	O
411	O
[	O
**	O
2159-8-11	O
**	O
]	O
06:15	O
AM	O
BLOOD	O
Glucose	O
-	O
144	O
*	O
UreaN	O
-	O
19	O
Creat	O
-	O
1.0	O
Na	O
-	O
138	O
K	O
-	O
4.9	O
Cl	O
-	O
103	O
HCO3	O
-	O
25	O
AnGap	O
-	O
15	O
Brief	O
Hospital	O
Course	O
:	O
PRIMARY	O
REASON	O
FOR	O
ADMISSION	O
:	O
69	O
y	O
/	O
o	O
woman	O
with	O
renal	O
cell	O
carcinoma	O
and	O
non-small	O
cell	O
lung	O
cancer	O
diagnosed	O
early	O
[	O
**	O
2159	O
**	O
]	O
,	O
undergoing	O
chemotherapy	O
and	O
radiation	O
,	O
who	O
presents	O
with	O
DOE	O
and	O
worsening	O
pericardial	O
effusion	O
with	O
evidence	O
of	O
early	O
tamponade	O
by	O
echocardiogram	O
.	O
Admitted	O
to	O
CCU	O
for	O
monitoring	O
s	O
/	O
p	O
pericardial	O
drain	O
placement	O
.	O
ACTIVE	O
ISSUES	O
:	O
.	O
#	O
PERICARDIAL	O
EFFUSION	O
:	O
Pericardiocentesis	O
was	O
performed	O
with	O
immediate	O
drainage	O
of	O
400cc	O
sanguinous	O
fluid	O
.	O
Overnight	O
,	O
another	O
~	O
450cc	O
sanguinous	O
fluid	O
drained	O
,	O
and	O
samples	O
were	O
sent	O
for	O
gram	O
stain	O
,	O
protein	O
content	O
,	O
culture	O
,	O
electroyltes	O
and	O
cytology	O
.	O
Post-procedure	O
echo	O
showed	O
a	O
small	O
loculated	O
residual	O
effusion	O
with	O
no	O
evidence	O
of	O
tamponade	O
physiology	O
.	O
Cytology	O
was	O
negative	O
for	O
malignacy	O
,	O
but	O
suspicion	O
remains	O
high	O
for	O
a	O
malignant	O
etiology	O
.	O
Pulsus	O
was	O
followed	O
throughout	O
her	O
hospital	O
course	O
,	O
and	O
at	O
the	O
time	O
of	O
post-procedure	O
echo	O
pulses	O
was	O
12	O
by	O
doppler	O
.	O
Pt	O
was	O
asymptomatic	O
at	O
the	O
time	O
of	O
discahrge	O
and	O
specifically	O
denied	O
CP	O
/	O
SOB	O
/	O
DOE	O
,	O
palpitations	O
or	O
lightheadedness	O
.	O
If	O
pericardial	O
effusion	O
reaccumulates	O
,	O
would	O
consider	O
CT	O
surgery	O
consult	O
for	O
pericardial	O
window	O
.	O
.	O
#	O
RENAL	O
CELL	O
CARCINOMA	O
,	O
NON-SMALL	O
CELL	O
LUNG	O
CANCER	O
:	O
No	O
treatments	O
were	O
undertaken	O
during	O
this	O
hosptial	O
course	O
.	O
Pt	O
was	O
discahrged	O
with	O
Heme	O
/	O
Onc	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
.	O
#	O
TACHYCARDIA	I-Reason
-	O
Pt	O
remained	O
tachycardic	O
to	O
the	O
100	O
-	O
120s	O
throughout	O
her	O
course	O
.	O
Initially	O
it	O
was	O
felt	O
this	O
may	O
have	O
been	O
[	O
**	O
2	O
-	O
28	O
**	O
]	O
tamponade	O
physiology	O
,	O
but	O
tachycardia	O
persisted	O
s	O
/	O
p	O
pericardiocentesis	O
.	O
She	O
was	O
then	O
transfused	O
2U	O
pRBCs	I-Drug
at	O
the	O
request	O
of	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
bolused	O
1L	O
NS	I-Drug
due	O
to	O
concern	O
for	O
anemia	I-Reason
/	O
hypovolemia	I-Reason
,	O
but	O
tachycardia	O
persisted	O
.	O
Review	O
of	O
clinic	O
visits	O
revealed	O
that	O
she	O
has	O
been	O
persistently	O
tachycardic	O
for	O
several	O
months	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
small	O
loculated	O
effusion	O
that	O
was	O
not	O
accessed	O
by	O
the	O
tap	O
.	O
The	O
patient	O
denied	O
pain	O
throughout	O
her	O
course	O
and	O
refused	O
any	O
pain	O
medicaitons	O
.	O
Orthostatics	O
were	O
checked	O
at	O
discahrge	O
and	O
were	O
normal	O
.	O
.	O
#	O
ANEMIA	I-Reason
:	O
Her	O
Hct	O
has	O
trended	O
down	O
over	O
the	O
past	O
6	O
months	O
.	O
This	O
is	O
likely	O
related	O
to	O
chonric	O
disease	O
,	O
and	O
pt	O
was	O
transfused	O
2U	O
pRBCs	I-Drug
during	O
this	O
admission	O
.	O
She	O
is	O
taking	O
Fe	I-Drug
supplementation	O
,	O
which	O
was	O
continued	O
during	O
her	O
hospitalization	O
.	O
.	O
#	O
LEUKOCYTOSIS	O
:	O
She	O
had	O
a	O
low	O
grade	O
leukocytosis	O
throughout	O
her	O
admission	O
,	O
which	O
is	O
consistent	O
with	O
her	O
baseline	O
.	O
Suspect	O
this	O
is	O
related	O
to	O
her	O
malignancies	O
.	O
She	O
remained	O
afebrile	O
and	O
normotensive	O
throughout	O
her	O
course	O
,	O
pericardial	O
and	O
urine	O
cultures	O
were	O
negative	O
and	O
CXR	O
showed	O
no	O
evidence	O
of	O
pulmonary	O
process	O
.	O
.	O
CHRONIC	O
ISSUES	O
:	O
.	O
#	O
HYPERTENSION	I-Reason
:	O
Generally	O
normotensive	O
.	O
Continued	O
home	O
meds	O
(	O
amlodipine	I-Drug
10	O
mg	O
PO	O
daily	O
,	O
HCTZ	I-Drug
25	O
mg	O
PO	O
daily	O
)	O
with	O
holding	O
parameters	O
.	O
.	O
#	O
HYPERLIPIDEMIA	I-Reason
:	O
Continued	O
rosuvastatin	I-Drug
10	O
mg	O
PO	O
QHS	O
.	O
.	O
#	O
DEPRESSION	I-Reason
/	O
ANXIETY	I-Reason
:	O
Denies	O
current	O
depression	O
.	O
States	O
she	O
takes	O
Xanax	I-Drug
once	O
daily	O
in	O
the	O
mornings	O
.	O
Continued	O
Effexor	B-Drug
XR	I-Drug
150	O
mg	O
PO	O
daily	O
.	O
Continued	O
Xanax	I-Drug
0.5	O
mg	O
PO	O
daily	O
(	O
in	O
AM	O
)	O
.	O
.	O
#	O
OSTEOPOROSIS	I-Reason
:	O
Continued	O
alendronate	I-Drug
70	O
mg	O
PO	O
Q	O
week	O
(	O
Mondays	O
)	O
.	O
.	O
TRANSITION	O
OF	O
CARE	O
:	O
Pt	O
was	O
discharged	O
home	O
with	O
Heme	O
/	O
Onc	O
follow	O
up	O
.	O
She	O
was	O
also	O
scheduled	O
for	O
an	O
outpatient	O
echo	O
that	O
should	O
be	O
followed	O
up	O
by	O
her	O
PCP	O
/	O
Oncologist	O
.	O
She	O
was	O
instructed	O
to	O
return	O
to	O
the	O
ER	O
if	O
she	O
experiecned	O
worsening	O
SOB	O
/	O
CP	O
,	O
as	O
this	O
may	O
represet	O
reaccumulation	O
of	O
pericardial	O
fluid	O
.	O
Medications	O
on	O
Admission	O
:	O
-	O
Alendronate	I-Drug
70	O
mg	O
PO	O
Q	O
week	O
on	O
Mondays	O
-	O
Alprazolam	I-Drug
0.5	O
mg	O
PO	O
PRN	O
(	O
takes	O
once	O
daily	O
in	O
AM	O
)	O
-	O
Amlodipine	I-Drug
10	O
mg	O
PO	O
daily	O
-	O
Hydrochlorothiazide	I-Drug
25	O
mg	O
PO	O
daily	O
-	O
Maalox	B-Drug
:	I-Drug
Benadryl	I-Drug
:	I-Drug
2	I-Drug
%	I-Drug
Lidocaine	I-Drug
Mixture	O
1:1:1	O
15	O
minutes	O
before	O
meals	O
and	O
at	O
bedtime	O
PRN	O
(	O
no	O
recent	O
use	O
)	O
-	O
Olmesartan	I-Drug
40	O
mg	O
PO	O
daily	O
-	O
Odansetron	I-Drug
8	O
mg	O
PO	O
Q8H	O
PRN	O
nausea	I-Reason
(	O
no	O
recent	O
use	O
)	O
-	O
Prochlorperazine	I-Drug
10	O
mg	O
PO	O
Q8H	O
PRN	O
nausea	I-Reason
(	O
no	O
recent	O
use	O
)	O
-	O
Rosuvastatin	I-Drug
10	O
mg	O
PO	O
QHS	O
-	O
Venlafaxine	I-Drug
ER	O
-	O
24	O
hr	O
150	O
mg	O
PO	O
daily	O
-	O
Acetaminophen	I-Drug
325	O
-	O
650	O
mg	O
PO	O
30	O
minutes	O
before	O
meals	O
PRN	O
odynophagia	I-Reason
(	O
no	O
recent	O
use	O
)	O
-	O
Ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
PO	O
daily	O
-	O
Fish	B-Drug
oil	I-Drug
DHA	I-Drug
EPA	I-Drug
1,200	O
mg	O
-	O
144	O
mg	O
PO	O
daily	O
-	O
Magnesium	B-Drug
oxide	I-Drug
400	O
mg	O
PO	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
(	O
65	O
mg	O
iron	I-Drug
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
prochlorperazine	B-Drug
maleate	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
3	O
.	O
rosuvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
at	O
bedtime	O
.	O
4	O
.	O
alendronate	I-Drug
70	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QMON	O
(	O
every	O
Monday	O
)	O
.	O
5	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
6	O
.	O
halobetasol	B-Drug
propionate	I-Drug
0.05	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Topical	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Dry	O
skin	O
.	O
7	O
.	O
Maalox	B-Drug
:	I-Drug
Benadryl	I-Drug
:	I-Drug
2	I-Drug
%	I-Drug
Lidocaine	I-Drug
Mixture	O
Sig	O
:	O
One	O
(	O
1	O
)	O
15	O
minutes	O
before	O
meals	O
and	O
at	O
bedtime	O
.	O
8	O
.	O
Fish	B-Drug
Oil	I-Drug
1,200	O
-144-216	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
once	O
a	O
day	O
.	O
9	O
.	O
magnesium	B-Drug
oxide	I-Drug
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
alprazolam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
anxiety	I-Reason
.	O
11	O
.	O
amlodipine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
12	O
.	O
hydrochlorothiazide	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
13	O
.	O
olmesartan	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
14	O
.	O
venlafaxine	I-Drug
150	O
mg	O
Capsule	O
,	O
Ext	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Ext	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
15	O
.	O
ondansetron	I-Drug
8	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
DIAGNOSIS	O
Cardiac	O
Tamponade	O
SECONDARY	O
DIAGNOSIS	O
Lung	O
Cancer	O
Renal	O
Cancer	O
Anemia	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms	O
[	O
**	O
Known	O
lastname	O
90050	O
**	O
]	O
,	O
It	O
was	O
a	O
pleasure	O
caring	O
for	O
you	O
at	O
the	O
[	O
**	O
Hospital1	O
827	O
**	O
]	O
.	O
You	O
were	O
admitted	O
for	O
a	O
condition	O
called	O
pericardial	O
tamponade	O
.	O
This	O
is	O
caused	O
by	O
fluid	O
surrounding	O
the	O
heart	O
,	O
and	O
it	O
can	O
cause	O
the	O
heart	O
to	O
not	O
beat	O
effectively	O
.	O
For	O
this	O
you	O
underwent	O
pericardiocentesis	O
,	O
a	O
procedure	O
where	O
a	O
doctor	O
drains	O
the	O
fluid	O
with	O
a	O
needle	O
to	O
restore	O
the	O
normal	O
functioning	O
of	O
the	O
heart	O
.	O
After	O
this	O
procedure	O
we	O
performed	O
another	O
Echocardiogram	O
to	O
confirm	O
that	O
the	O
fluid	O
had	O
not	O
reaccumulated	O
and	O
felt	O
you	O
were	O
safe	O
to	O
return	O
home	O
.	O
During	O
this	O
hospitalization	O
,	O
we	O
made	O
NO	O
CHANGES	O
to	O
your	O
medicatios	O
.	O
It	O
will	O
be	O
important	O
for	O
you	O
to	O
follow	O
up	O
the	O
results	O
of	O
the	O
cytology	O
from	O
your	O
pericardial	O
fluid	O
analysis	O
with	O
you	O
oncologist	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
THURSDAY	O
[	O
**	O
2159-8-16	O
**	O
]	O
at	O
12:00	O
PM	O
With	O
:	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
8111	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
8112	O
**	O
]	O
,	O
RN	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
1905	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2179-3-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2179-3-14	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2110-3-4	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Naproxen	I-Drug
/	O
Codeine	I-Drug
/	O
Aspirin	I-Drug
/	O
Oxycontin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4373	O
**	O
]	O
Chief	O
Complaint	O
:	O
dyspnea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Patient	O
expired	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
10220	O
**	O
]	O
is	O
a	O
69	O
yo	O
F	O
with	O
breast	B-Reason
cancer	I-Reason
with	O
mets	O
to	O
peritoneum	O
on	O
complicated	O
by	O
acites	O
requiring	O
14	O
paracenteci	O
since	O
[	O
**	O
9	O
-	O
2	O
**	O
]	O
,	O
on	O
navelbine	I-Drug
/	O
avastin	I-Drug
C2D13	O
now	O
presents	O
wtih	O
dyspnea	O
and	O
poor	O
po	O
intake	O
.	O
Patient	O
noticed	O
increased	O
DOE	O
over	O
the	O
last	O
36	O
hours	O
with	O
increased	O
labored	O
breathing	O
while	O
walking	O
around	O
the	O
house	O
and	O
requiring	O
assistance	O
to	O
even	O
walk	O
around	O
the	O
living	O
room	O
.	O
Patient	O
also	O
reports	O
increased	O
nausea	O
with	O
vomitting	O
7	O
-	O
10	O
times	O
over	O
the	O
last	O
2	O
days	O
.	O
Vomitius	O
is	O
nonbilious	O
,	O
and	O
patient	O
has	O
been	O
unable	O
to	O
tolerate	O
po	O
intake	O
.	O
Patient	O
often	O
has	O
diarrhea	I-Ade
related	O
to	O
Chemo	I-Drug
,	O
but	O
reportedly	O
no	O
diarrhea	O
since	O
Tuesday	O
.	O
Patient	O
was	O
seen	O
by	O
VNA	O
today	O
and	O
BP	O
was	O
60	O
/	O
p.	O
EMS	O
was	O
called	O
and	O
on	O
arrival	O
BP	O
was	O
80	O
/	O
p.	O
.	O
In	O
the	O
ED	O
,	O
patient	O
was	O
noted	O
to	O
be	O
hypotensive	I-Reason
on	O
arrival	O
but	O
improved	O
with	O
3	O
L	O
NS	I-Drug
.	O
Inital	O
resident	O
echo	O
was	O
concerning	O
for	O
pericardial	O
effusion	O
with	O
collapse	O
of	O
RV	O
,	O
but	O
formal	O
TTE	O
by	O
Cardiology	O
fellow	O
showed	O
no	O
evidence	O
of	O
tamponade	O
.	O
LENIS	O
were	O
negative	O
for	O
DVT	O
.	O
CT	O
head	O
was	O
negative	O
.	O
CXR	O
was	O
unremarkable	O
.	O
Vanco	I-Drug
/	O
Zosyn	I-Drug
was	O
given	O
for	O
initial	O
concern	O
of	O
sepsis	I-Reason
.	O
Lytes	O
were	O
noteable	O
for	O
Na	O
117	O
down	O
from	O
122	O
earlier	O
in	O
the	O
month	O
and	O
Cr	O
2.2	O
from	O
0.8	O
.	O
Also	O
noted	O
to	O
be	O
neutropenic	O
.	O
Patient	O
refused	O
central	O
line	O
and	O
code	O
status	O
was	O
reportedly	O
DNR	O
/	O
I.	O
.	O
On	O
the	O
floor	O
,	O
patient	O
reports	O
chronic	O
low	O
back	O
pain	O
,	O
and	O
feels	O
weak	O
and	O
fatigued	O
,	O
but	O
otherwise	O
feels	O
well	O
.	O
.	O
Review	O
of	O
systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheezing	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
,	O
or	O
weakness	O
.	O
Denies	O
constipation	O
,	O
abdominal	O
pain	O
,	O
or	O
changes	O
in	O
bowel	O
habits	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
Past	O
Medical	O
History	O
:	O
Breast	O
cancer	O
-	O
Diagnosed	O
in	O
[	O
**	O
2174	O
**	O
]	O
with	O
an	O
infiltrating	O
lobular	O
carcinoma	O
grade	O
II	O
,	O
1.7	O
cm	O
,	O
multifocal	O
,	O
with	O
13	O
out	O
of	O
29	O
lymph	O
nodes	O
positive	O
.	O
The	O
tumor	O
was	O
ER	O
positive	O
,	O
PR	O
positive	O
,	O
and	O
HER	O
-	O
2	O
/	O
neu	O
negative	O
by	O
both	O
IHC	O
and	O
FISH	O
.	O
She	O
underwent	O
adjuvant	O
chemotherapy	I-Drug
after	O
completion	O
of	O
surgery	O
with	O
Adriamycin	I-Drug
and	O
Cytoxan	I-Drug
followed	O
by	O
10	O
weekly	O
doses	O
of	O
Taxol	I-Drug
.	O
She	O
received	O
and	O
completed	O
chest	O
wall	O
radiation	O
.	O
She	O
was	O
then	O
started	O
on	O
adjuvant	O
Arimidex	I-Drug
therapy	O
.	O
In	O
[	O
**	O
2178-1-25	O
**	O
]	O
she	O
developed	O
right	O
shoulder	O
pain	O
and	O
pain	O
in	O
her	O
upper	O
abdomen	O
.	O
The	O
abdominal	O
pain	O
prompted	O
workup	O
and	O
apparently	O
blood	O
work	O
showed	O
a	O
CA	O
[	O
**	O
95	O
**	O
]	O
-	O
29	O
level	O
of	O
203	O
.	O
A	O
PET	O
scan	O
revealed	O
nodularity	O
in	O
her	O
omentum	O
consistent	O
with	O
metastatic	O
disease	O
.	O
A	O
bone	O
scan	O
reportedly	O
was	O
negative	O
.	O
She	O
was	O
started	O
on	O
high	O
-	O
dose	O
Faslodex	I-Drug
hormone	O
treatment	O
[	O
**	O
2178-3-12	O
**	O
]	O
and	O
progressed	O
on	O
this	O
in	O
[	O
**	O
2178-7-25	O
**	O
]	O
.	O
She	O
was	O
started	O
on	O
Xeloda	I-Drug
in	O
[	O
**	O
8	O
-	O
/	O
2178	O
**	O
]	O
and	O
continued	O
and	O
recently	O
progressed	O
with	O
her	O
last	O
dose	O
of	O
Xeloda	I-Drug
on	O
[	O
**	O
2178-12-5	O
**	O
]	O
.	O
-	O
S	O
/	O
p	O
Fulvestrant	I-Drug
x7	O
last	O
given	O
[	O
**	O
2178-9-16	O
**	O
]	O
-	O
Temodar	I-Drug
PARP	O
Phase	O
II	O
Trial	O
:	O
Cycle	O
#	O
:	O
1	O
Day	O
1	O
:	O
[	O
**	O
2179-1-13	O
**	O
]	O
,	O
went	O
off	O
trial	O
for	O
for	O
toxicity	I-Ade
-	O
VinORELbine	I-Drug
(	O
Navelbine	O
)	O
40	O
mg	O
IV	O
day	O
1	O
(	O
[	O
**	O
2179-1-21	O
**	O
]	O
)	O
,	O
held	O
day	O
8	O
and	O
15	O
due	O
to	O
neutropenia	I-Ade
.	O
(	O
30	O
mg	O
/	O
m2	O
-	O
dose	O
reduced	O
by	O
17	O
%	O
to	O
25	O
mg	O
/	O
m2	O
)	O
.	O
Other	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Breast	O
cancer	O
as	O
above	O
2	O
.	O
Bladder	O
suspension	O
.	O
3	O
.	O
GERD	O
4	O
.	O
Osteoporosis	O
.	O
5	O
.	O
Left	O
frozen	O
shoulder	O
.	O
6	O
.	O
Depression	O
and	O
anxiety	O
.	O
7	O
.	O
Laparoscopic	O
cholecystectomy	O
.	O
8	O
.	O
Rosacea	O
.	O
9	O
.	O
Hypothyroidism	O
.	O
10	O
.	O
Sleep	O
apnea	O
.	O
11	O
.	O
Rheumatic	O
fever	O
with	O
subsequent	O
dental	O
prophylaxis	O
.	O
12	O
.	O
Left	O
eye	O
surgery	O
.	O
Social	O
History	O
:	O
She	O
is	O
divorced	O
.	O
She	O
is	O
a	O
nonsmoker	O
and	O
drinks	O
alcohol	O
socially	O
.	O
She	O
is	O
retired	O
and	O
former	O
employee	O
of	O
the	O
Federal	O
government	O
.	O
She	O
is	O
of	O
Lithuanian	O
origin	O
.	O
Family	O
History	O
:	O
Her	O
mother	O
had	O
breast	O
cancer	O
at	O
age	O
75	O
and	O
underwent	O
lumpectomy	O
and	O
radiation	O
therapy	O
.	O
Her	O
maternal	O
aunt	O
had	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
499	O
**	O
]	O
cancer	O
in	O
her	O
70s	O
.	O
The	O
patient	O
's	O
sister	O
had	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
499	O
**	O
]	O
cancer	O
at	O
55	O
and	O
two	O
paternal	O
aunts	O
with	O
breast	O
cancer	O
at	O
age	O
52	O
and	O
70	O
,	O
a	O
paternal	O
first	O
cousin	O
had	O
renal	O
cancer	O
.	O
She	O
has	O
not	O
undergone	O
genetic	O
testing	O
.	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
:	O
96.5	O
BP	O
:	O
100/58	O
P	O
:	O
116	O
R	O
:	O
18	O
O2	I-Drug
:	O
97	O
%	O
2L	O
NC	O
General	O
:	O
Markedly	O
cachectic	O
,	O
tired	O
appearing	O
,	O
pale	O
,	O
but	O
NAD	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
dry	O
MM	O
,	O
oropharynx	O
clear	O
without	O
thrush	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
1	O
+	O
edema	O
of	O
ankles	O
bilaterally	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
Pertinent	O
Results	O
:	O
[	O
**	O
2179-3-8	O
**	O
]	O
04:20	O
PM	O
BLOOD	O
WBC	O
-	O
1.1	O
*	O
#	O
RBC	O
-	O
3.85	O
*	O
Hgb	O
-	O
12.3	O
Hct	O
-	O
34.8	O
*	O
MCV	O
-	O
91	O
MCH	O
-	O
32.0	O
MCHC	O
-	O
35.4	O
*	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
270	O
[	O
**	O
2179-3-9	O
**	O
]	O
12:28	O
AM	O
BLOOD	O
WBC	O
-	O
1.0	O
*	O
RBC	O
-	O
3.46	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
32.3	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
32.4	O
*	O
MCHC	O
-	O
34.7	O
RDW	O
-	O
14.4	O
Plt	O
Ct	O
-	O
292	O
[	O
**	O
2179-3-9	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
WBC	O
-	O
1.0	O
*	O
RBC	O
-	O
3.40	O
*	O
Hgb	O
-	O
10.8	O
*	O
Hct	O
-	O
31.3	O
*	O
MCV	O
-	O
92	O
MCH	O
-	O
31.9	O
MCHC	O
-	O
34.6	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
268	O
[	O
**	O
2179-3-10	O
**	O
]	O
03:04	O
AM	O
BLOOD	O
WBC	O
-	O
1.2	O
*	O
RBC	O
-	O
3.30	O
*	O
Hgb	O
-	O
10.2	O
*	O
Hct	O
-	O
30.7	O
*	O
MCV	O
-	O
93	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
33.4	O
RDW	O
-	O
14.8	O
Plt	O
Ct	O
-	O
311	O
[	O
**	O
2179-3-9	O
**	O
]	O
12:28	O
AM	O
BLOOD	O
PT	O
-	O
11.3	O
PTT	O
-	O
34.4	O
INR	O
(	O
PT	O
)	O
-	O
0.9	O
[	O
**	O
2179-3-8	O
**	O
]	O
04:20	O
PM	O
BLOOD	O
Glucose	O
-	O
100	O
UreaN	O
-	O
115	O
*	O
Creat	O
-	O
2.2	O
*	O
#	O
Na	O
-	O
117	O
*	O
K	O
-	O
4.3	O
Cl	O
-	O
71	O
*	O
HCO3	O
-	O
30	O
AnGap	O
-	O
20	O
[	O
**	O
2179-3-9	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
Glucose	O
-	O
95	O
UreaN	O
-	O
88	O
*	O
Creat	O
-	O
1.5	O
*	O
Na	O
-	O
126	O
*	O
K	O
-	O
3.6	O
Cl	O
-	O
86	O
*	O
HCO3	O
-	O
29	O
AnGap	O
-	O
15	O
[	O
**	O
2179-3-10	O
**	O
]	O
03:04	O
AM	O
BLOOD	O
Glucose	O
-	O
96	O
UreaN	O
-	O
71	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
130	O
*	O
K	O
-	O
3.4	O
Cl	O
-	O
93	O
*	O
HCO3	O
-	O
27	O
AnGap	O
-	O
13	O
[	O
**	O
2179-3-9	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
18	O
*	O
[	O
**	O
2179-3-9	O
**	O
]	O
02:37	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
18	O
*	O
[	O
**	O
2179-3-10	O
**	O
]	O
03:04	O
AM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
16	O
*	O
[	O
**	O
2179-3-9	O
**	O
]	O
04:20	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
2	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2179-3-9	O
**	O
]	O
02:37	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2179-3-10	O
**	O
]	O
03:04	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2179-3-8	O
**	O
]	O
04:20	O
PM	O
BLOOD	O
proBNP	O
-	O
4631	O
*	O
.	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
Echo	O
:	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Due	O
to	O
suboptimal	O
image	O
quality	O
and	O
focused	O
views	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
excluded	O
.	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
is	O
not	O
well	O
seen	O
.	O
The	O
mitral	O
valve	O
appears	O
structurally	O
normal	O
with	O
trivial	O
mitral	O
regurgitation	O
.	O
There	O
is	O
a	O
very	O
small	O
pericardial	O
effusion	O
,	O
primarily	O
around	O
the	O
right	O
atrium	O
and	O
basal	O
right	O
ventricle	O
with	O
no	O
echocardiographic	O
signs	O
of	O
tamponade	O
.	O
.	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
CXR	O
:	O
(	O
pending	O
final	O
read	O
)	O
.	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
LENIs	O
:	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
DVT	O
of	O
either	O
lower	O
extremity	O
.	O
.	O
[	O
**	O
3	O
-	O
8	O
**	O
]	O
Head	O
CT	O
:	O
IMPRESSIONS	O
:	O
No	O
acute	O
intracranial	O
abnormality	O
.	O
No	O
evidence	O
of	O
intracranial	O
mass	O
,	O
but	O
MRI	O
is	O
more	O
sensitive	O
for	O
the	O
detection	O
of	O
intracranial	O
lesions	O
and	O
should	O
be	O
considered	O
.	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
:	O
KUB	O
Moderate	O
amount	O
of	O
ascites	O
with	O
largest	O
pocket	O
seen	O
within	O
the	O
right	O
lower	O
quadrant	O
.	O
Multiple	O
septations	O
are	O
noted	O
compatible	O
with	O
component	O
of	O
loculation	O
of	O
the	O
fluid	O
.	O
[	O
**	O
3	O
-	O
12	O
**	O
]	O
:	O
Request	O
for	O
Pleurx	O
catheterization	O
for	O
palliative	O
peritoneal	O
ascites	O
drainage	O
.	O
1	O
.	O
Successful	O
placement	O
of	O
Pleurx	O
catheter	O
in	O
the	O
right	O
abdomen	O
,	O
with	O
the	O
tip	O
terminating	O
in	O
the	O
lower	O
pelvis	O
.	O
2	O
.	O
Removal	O
of	O
one	O
liter	O
of	O
yellow	O
ascites	O
fluid	O
.	O
.	O
[	O
**	O
2179-3-13	O
**	O
]	O
05:23	O
PM	O
BLOOD	O
WBC	O
-	O
5.4	O
RBC	O
-	O
3.37	O
*	O
#	O
Hgb	O
-	O
10.6	O
*	O
#	O
Hct	O
-	O
33.4	O
*	O
#	O
MCV	O
-	O
99	O
*	O
MCH	O
-	O
31.4	O
MCHC	O
-	O
31.8	O
RDW	O
-	O
14.5	O
Plt	O
Ct	O
-	O
434	O
[	O
**	O
2179-3-13	O
**	O
]	O
05:12	O
AM	O
BLOOD	O
Glucose	O
-	O
86	O
UreaN	O
-	O
73	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
145	O
K	O
-	O
4.1	O
Cl	O
-	O
114	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
13	O
[	O
**	O
2179-3-13	O
**	O
]	O
05:23	O
PM	O
BLOOD	O
LD	O
(	O
LDH	O
)	O
-	O
132	O
TotBili	O
-	O
1.0	O
DirBili	O
-	O
0.4	O
*	O
IndBili	O
-	O
0.6	O
[	O
**	O
2179-3-13	O
**	O
]	O
05:12	O
AM	O
BLOOD	O
Calcium	O
-	O
10.2	O
Phos	O
-	O
3.5	O
Mg	O
-	O
1.9	O
[	O
**	O
2179-3-11	O
**	O
]	O
02:48	O
PM	O
BLOOD	O
CA27.29	O
-	O
744	O
*	O
[	O
**	O
2179-3-8	O
**	O
]	O
04:32	O
PM	O
BLOOD	O
Lactate	O
-	O
1.6	O
K	O
-	O
4.1	O
Brief	O
Hospital	O
Course	O
:	O
Patient	O
expired	O
.	O
69	O
yo	O
F	O
with	O
metastatic	O
breast	O
cancer	O
prsents	O
with	O
vomitting	O
,	O
poor	O
po	O
intake	O
and	O
dyspnea	O
and	O
to	O
be	O
in	O
acute	O
renal	O
failure	O
with	O
hyponatremia	O
.	O
Was	O
tachycardic	O
and	O
complaining	O
of	O
mild	O
chest	O
tightness	O
.	O
Admitted	O
to	O
the	O
ICU	O
for	O
tachycardia	O
and	O
hyponatremia	O
,	O
then	O
to	O
the	O
oncology	O
floor	O
.	O
See	O
below	O
for	O
discussion	O
of	O
each	O
issue	O
.	O
.	O
Goals	O
of	O
care	O
:	O
meeting	O
in	O
ICU	O
regarding	O
goals	O
of	O
care	O
and	O
poor	O
prognosis	O
,	O
then	O
reiterated	O
on	O
the	O
oncology	O
medicine	O
floor	O
:	O
Code	O
:	O
DNR	O
/	O
I	O
(	O
discussed	O
with	O
patient	O
and	O
HCP	O
)	O
,	O
and	O
daughter	O
HCP	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
80568	O
**	O
]	O
.	O
Focus	O
on	O
comfort	O
with	O
symptom	O
management	O
.	O
Avoidance	O
of	O
invasive	O
procedures	O
,	O
per	O
family	O
(	O
son	O
,	O
daughter	O
,	O
sister	O
)	O
.	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
**	O
]	O
died	O
the	O
morning	O
after	O
being	O
transferred	O
to	O
the	O
ICU	O
.	O
.	O
#	O
Altered	O
mental	O
status	O
:	O
Patient	O
does	O
not	O
respond	O
to	O
verbal	O
or	O
visual	O
stimuli	O
on	O
the	O
floor	O
.	O
Likely	O
d	O
/	O
t	O
progressive	O
metastatic	O
disease	O
,	O
combined	O
with	O
renal	O
failure	O
,	O
hypotension	O
,	O
pain	O
,	O
SBP	O
infection	O
,	O
delirium	O
.	O
Pain	I-Reason
controlled	O
with	O
IV	O
morphine	I-Drug
prn	O
,	O
treated	O
SBP	I-Reason
with	O
ceftriaxone	I-Drug
,	O
palliative	O
care	O
following	O
.	O
.	O
#	O
Chest	O
Pain	O
:	O
unclear	O
etiology	O
,	O
seemed	O
to	O
be	O
costrochondritis	O
related	O
as	O
the	O
pain	O
was	O
reproducible	O
.	O
Ruled	O
out	O
for	O
MI	O
with	O
three	O
sets	O
of	O
negative	O
cardiac	O
enzymes	O
.	O
A	O
V	O
/	O
Q	O
of	O
her	O
chest	O
was	O
ordered	O
to	O
rule	O
out	O
PE	O
,	O
but	O
the	O
patient	O
was	O
unable	O
to	O
lie	O
flat	O
and	O
complete	O
the	O
exam	O
so	O
it	O
was	O
aborted	O
.	O
Held	O
anticoagulation	O
d	O
/	O
t	O
goals	O
of	O
care	O
,	O
no	O
CTA	O
given	O
ARF	O
,	O
could	O
not	O
tolerate	O
V	O
/	O
Q	O
scan	O
.	O
On	O
the	O
floor	O
,	O
patient	O
unable	O
to	O
verbalize	O
whether	O
chest	O
pain	O
still	O
present	O
.	O
Pain	O
medications	O
provided	O
.	O
.	O
#	O
Hypotenion	O
/	O
Tachycardia	O
:	O
likely	O
was	O
related	O
to	O
underlying	O
cancer	O
and	O
hypovolemia	O
.	O
Was	O
volume	O
resuccitated	O
with	O
NS	I-Drug
and	O
the	O
LR	I-Drug
while	O
in	O
the	O
ICU	O
for	O
the	O
first	O
two	O
days	O
.	O
She	O
was	O
offerred	O
a	O
CVL	O
in	O
the	O
ED	O
and	O
declined	O
.	O
Her	O
BP	O
improved	O
to	O
SBPs	O
in	O
the	O
90s	O
,	O
then	O
100s	O
with	O
IVFs	I-Drug
and	O
remained	O
stable	O
.	O
Initially	O
she	O
seemed	O
fluid	O
responsive	O
with	O
a	O
decrease	O
in	O
rate	O
from	O
130s	O
to	O
110s	O
(	O
which	O
seemed	O
to	O
be	O
her	O
baseline	O
)	O
.	O
She	O
remained	O
tachycardic	O
on	O
day	O
two	O
of	O
admission	O
without	O
an	O
obvious	O
cause	O
as	O
she	O
seemed	O
mostly	O
fluid	O
repleted	O
.	O
We	O
continued	O
to	O
bolus	O
her	O
and	O
pursued	O
a	O
further	O
workup	O
for	O
PE	O
.	O
Initially	O
she	O
had	O
negative	O
LENIs	O
and	O
a	O
CT	O
was	O
deferred	O
because	O
of	O
ARF	O
.	O
A	O
V	O
/	O
Q	O
scan	O
was	O
performed	O
on	O
[	O
**	O
2179-3-10	O
**	O
]	O
,	O
but	O
she	O
was	O
unable	O
to	O
lie	O
flat	O
for	O
the	O
test	O
and	O
the	O
test	O
could	O
not	O
be	O
completed	O
.	O
She	O
was	O
bolused	O
periodically	O
overnight	O
to	O
maintain	O
MAP	O
of	O
over	O
65	O
.	O
Her	O
tachycardia	O
improved	O
with	O
IVF	I-Drug
boluses	O
prn	O
.	O
.	O
#	O
Hyponatremia	O
/	O
Acute	O
renal	O
failure	O
:	O
Based	O
on	O
exam	O
and	O
history	O
,	O
likely	O
hypovolemic	O
hyponatremia	O
.	O
Most	O
likely	O
Gi	O
losses	O
combined	O
with	O
third	O
spacing	O
in	O
the	O
setting	O
of	O
ascites	O
.	O
With	O
fluid	O
resuccitation	O
,	O
she	O
corrected	O
and	O
normalized	O
very	O
quickly	O
but	O
did	O
not	O
have	O
any	O
neurological	O
changes	O
.	O
She	O
did	O
have	O
a	O
CT	O
head	O
in	O
the	O
ED	O
that	O
showed	O
no	O
intracranial	O
lesions	O
to	O
explain	O
this	O
.	O
Her	O
ARF	I-Reason
also	O
improved	O
with	O
IVFs	I-Drug
and	O
her	O
urine	O
output	O
remained	O
brisk	O
throughout	O
her	O
hospitalization	O
.	O
.	O
#	O
Thrush	O
:	O
Likely	O
due	O
to	O
poor	O
po	O
intake	O
and	O
nausea	O
/	O
vomitting	O
.	O
Started	O
swish	O
and	O
swallow	O
for	O
her	O
comfort	O
.	O
.	O
#	O
Breast	B-Reason
Cancer	I-Reason
:	O
mid-cycle	O
in	O
her	O
avastin	I-Drug
and	O
navelbine	I-Drug
.	O
Is	O
metastatic	O
and	O
has	O
recurrent	O
ascites	O
requiring	O
taps	O
.	O
On	O
presentation	O
,	O
her	O
abdomen	O
was	O
soft	O
and	O
a	O
therapeutic	O
paracentesis	O
was	O
deferred	O
because	O
of	O
her	O
hypovolemia	O
,	O
moderate	O
hypotension	O
and	O
neutropenia	O
.	O
Oncology	O
was	O
consulted	O
and	O
followed	O
along	O
.	O
Patient	O
to	O
oncology	O
floor	O
,	O
outpatient	O
oncology	O
attending	O
described	O
poor	O
prognosis	O
.	O
Family	O
meeting	O
regarding	O
poor	O
prognosis	O
and	O
goals	O
of	O
care	O
;	O
patient	O
not	O
to	O
have	O
further	O
chemotherapy	I-Drug
or	O
interventions	O
/	O
invasive	O
procedures	O
.	O
.	O
#	O
Leukopenia	I-Ade
:	O
Likely	O
chemo	I-Drug
related	O
,	O
as	O
last	O
dose	O
was	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
.	O
ANC	O
600	O
so	O
not	O
yet	O
neutropenic	O
and	O
never	O
needed	O
to	O
be	O
on	O
neutropenic	O
precautions	O
.	O
On	O
3	O
18	O
,	O
her	O
WBC	O
began	O
to	O
recover	O
.	O
.	O
#	O
Pleurex	O
catheter	O
placed	O
to	O
help	O
with	O
paracentesis	O
/	O
ascites	O
drainage	O
.	O
SBP	I-Reason
treated	O
with	O
ceftriaxone	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
#	O
Octreotide	I-Drug
Acetate	O
100	O
mcg	O
SQ	O
[	O
**	O
Hospital1	O
**	O
]	O
#	O
Morphine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
#	O
Levothyroxine	I-Drug
50	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
#	O
Multivitamin	I-Drug
po	O
daily	O
#	O
Lorazepam	I-Drug
0.5	O
mg	O
PO	O
Q4H	O
prn	O
nausea	I-Reason
#	O
Loperamide	I-Drug
2	O
mg	O
po	O
QID	O
prn	O
#	O
Diphenoxylate	B-Drug
-	I-Drug
Atropine	O
2.5	O
-	O
0.025	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
prn	O
#	O
Nexium	I-Drug
20	O
mg	O
daily	O
#	O
Ondansetron	B-Drug
8	O
mg	O
Q8H	O
prn	O
#	O
Compazine	I-Drug
10	O
mg	O
po	O
Q6H	O
prn	O
#	O
Lidocaine	I-Drug
5	O
%	O
(	O
700	O
mg	O
/	O
patch	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Adhesive	O
Patch	O
,	O
Medicated	O
Topical	O
DAILY	O
(	O
Daily	O
#	O
NYSTATIN	I-Drug
-	O
100,000	O
unit	O
/	O
mL	O
Suspension	O
-	O
4	O
mL	O
by	O
mouth	O
four	O
times	O
daily	O
as	O
needed	O
for	O
thrush	I-Reason
swish	O
and	O
swallow	O
#	O
SUCRALFATE	I-Drug
-	O
1	O
gram	O
/	O
10	O
mL	O
Suspension	O
-	O
10	O
ml	O
by	O
mouth	O
as	O
needed	O
Discharge	O
Medications	O
:	O
n	O
/	O
a	O
Discharge	O
Disposition	O
:	O
Expired	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Spontaneous	O
bacterial	O
peritonitis	O
Secondary	O
:	O
Metastatic	O
breast	O
cancer	O
Discharge	O
Condition	O
:	O
Patient	O
expired	O
.	O
Discharge	O
Instructions	O
:	O
Patient	O
expired	O
.	O
Followup	O
Instructions	O
:	O
Patient	O
expired	O
.	O
Completed	O
by	O
:[	O
**	O
2179-3-20	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2192-3-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2192-3-19	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Lisinopril	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2108	O
**	O
]	O
Chief	O
Complaint	O
:	O
angioedema	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
87	O
year	O
-	O
old	O
[	O
**	O
Location	O
7972	O
**	O
]	O
male	O
with	O
a	O
history	O
of	O
afib	O
who	O
presents	O
with	O
fall	O
2	O
days	O
ago	O
in	O
BR	O
that	O
was	O
unwitnessed	O
.	O
Per	O
nephew	O
who	O
lives	O
with	O
the	O
pt	O
,	O
he	O
got	O
up	O
from	O
bed	O
and	O
in	O
the	O
BR	O
became	O
dizzy	O
and	O
had	O
a	O
LCO	O
.	O
He	O
was	O
recent	O
admitted	O
for	O
a	O
LGI	O
bleed	O
on	O
[	O
**	O
2192-3-8	O
**	O
]	O
thought	O
to	O
be	O
from	O
diverticulosis	O
.	O
He	O
was	O
started	O
on	O
lisinopril	I-Drug
5	O
mg	O
and	O
flomax	I-Drug
during	O
that	O
admission	O
.	O
In	O
his	O
fall	O
he	O
hit	O
his	O
left	O
face	O
and	O
sinc	O
then	O
has	O
been	O
having	O
increaseing	O
swelling	O
.	O
He	O
did	O
not	O
want	O
to	O
seek	O
care	O
at	O
that	O
time	O
.	O
He	O
has	O
no	O
SOB	O
.	O
No	O
diffictuly	O
swallowing	O
.	O
He	O
has	O
pain	O
along	O
his	O
right	O
cheek	O
and	O
left	O
eye	O
and	O
inner	O
lower	O
lip	O
.	O
He	O
thinks	O
he	O
is	O
starting	O
to	O
feel	O
better	O
since	O
his	O
ER	O
presentation	O
.	O
He	O
also	O
feels	O
like	O
he	O
has	O
something	O
in	O
the	O
back	O
of	O
his	O
throat	O
that	O
he	O
can	O
not	O
clear	O
.	O
.	O
In	O
the	O
ED	O
,	O
10	O
97.5	O
72133/61	O
16	O
96	O
%	O
.	O
He	O
had	O
edema	O
of	O
face	O
on	O
exam	O
with	O
concern	O
for	O
angioedema	I-Reason
.	O
Pt	O
was	O
given	O
solumederol	I-Drug
125	O
,	O
benadryl	I-Drug
25	O
,	O
famotidine	I-Drug
.	O
CT	O
head	O
and	O
neck	O
with	O
small	O
fx	O
,	O
unclear	O
age	O
.	O
ENT	O
not	O
consulted	O
in	O
ER	O
.	O
Pt	O
was	O
admitted	O
to	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
airway	O
monitoring	O
.	O
On	O
transfer	O
VS	O
were0	O
HR	O
70146/62	O
12	O
97	O
%	O
RA	O
.	O
Pt	O
has	O
PIV	O
18	O
and	O
20	O
G.	O
.	O
ROS	O
:	O
no	O
CP	O
,	O
no	O
SOB	O
,	O
no	O
cough	O
.	O
Chronic	O
RUQ	O
pain	O
for	O
2	O
months	O
,	O
not	O
associated	O
with	O
meals	O
,	O
no	O
hematuria	O
.	O
no	O
dysuria	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Rectal	O
bleeding	O
,	O
from	O
diverticulosis	O
-	O
Adenomas	O
on	O
colonoscopy	O
[	O
**	O
2	O
-	O
21	O
**	O
]	O
-	O
CAD	O
s	O
/	O
p	O
BMS	O
LAD	O
and	O
RPDA	O
-	O
Hypertension	O
-	O
Dyslipidemia	O
-	O
Paroxysmal	O
atrial	O
fibrillation	O
-	O
s	O
/	O
p	O
CVA	O
-	O
Asthma	O
/	O
COPD	O
-	O
Urinary	O
retention	O
-	O
Orthostatic	O
hypotension	O
:	O
admit	O
for	O
syncope	O
in	O
[	O
**	O
5	O
-	O
19	O
**	O
]	O
and	O
for	O
hypotension	O
in	O
[	O
**	O
10	O
-	O
19	O
**	O
]	O
.	O
Initial	O
work	O
-	O
up	O
consistent	O
with	O
medication	O
induced	O
orthostasis	O
,	O
also	O
had	O
formal	O
autonomic	O
testing	O
and	O
in	O
[	O
**	O
10	O
-	O
19	O
**	O
]	O
was	O
started	O
on	O
florinef	I-Drug
and	O
midodrine	I-Drug
(	O
see	O
d'	O
c	O
summary	O
from	O
[	O
**	O
10	O
-	O
19	O
**	O
]	O
for	O
details	O
)	O
.	O
These	O
medications	O
were	O
subsequently	O
stopped	O
by	O
pcp	O
due	O
to	O
hypertension	I-Ade
-	O
Paranoid	B-Reason
schizophrenia	I-Reason
:	O
diagnosed	O
5	O
-	O
10	O
years	O
ago	O
admitted	O
[	O
**	O
12	O
-	O
19	O
**	O
]	O
x	O
2	O
weeks	O
at	O
[	O
**	O
Hospital	O
1263	O
**	O
]	O
hospital	O
;	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
24050	O
**	O
]	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
admit	O
for	O
psychosis	I-Reason
after	O
stopping	O
risperidone	I-Drug
for	O
orthostatic	I-Ade
hypotension	O
-	O
Outpt	O
Psychiatrist	O
:	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
24051	O
**	O
]	O
at	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
Impaired	O
glucose	O
tolerance	O
Social	O
History	O
:	O
Tob	O
:	O
2ppd	O
,	O
quit	O
[	O
**	O
2186	O
**	O
]	O
No	O
alcohol	O
in	O
[	O
**	O
7	O
-	O
17	O
**	O
]	O
years	O
No	O
other	O
drug	O
use	O
.	O
Born	O
and	O
raised	O
in	O
[	O
**	O
Country	O
3587	O
**	O
]	O
.	O
Previously	O
worked	O
on	O
his	O
father	O
's	O
farm	O
,	O
states	O
he	O
did	O
not	O
attend	O
school	O
.	O
Emigrated	O
to	O
US	O
in	O
[	O
**	O
2168	O
**	O
]	O
,	O
3	O
children	O
and	O
2	O
brothers	O
in	O
[	O
**	O
Name	O
(	O
NI	O
)	O
86	O
**	O
]	O
area	O
.	O
Never	O
married	O
.	O
Worked	O
in	O
housekeeping	O
in	O
US	O
.	O
Lives	O
with	O
his	O
nephew	O
.	O
Family	O
History	O
:	O
Mother	O
-	O
Schizophrenia	O
Brother	O
-	O
Depression	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
96.9	O
79143/73	O
10	O
96	O
%	O
RA	O
GEN	O
:	O
[	O
**	O
Location	O
7972	O
**	O
]	O
speaking	O
,	O
Well	O
-	O
appearing	O
,	O
well	O
-	O
nourished	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
EOMI	O
,	O
PERRL	O
,	O
sclera	O
anicteric	O
,	O
swelling	O
of	O
right	O
lower	O
jaw	O
and	O
lips	O
,	O
bruising	O
around	O
left	O
eye	O
,	O
cut	O
on	O
inner	O
lower	O
lip	O
,	O
tongue	O
not	O
swollen	O
,	O
OP	O
visible	O
,	O
MMM	O
NECK	O
:	O
No	O
JVD	O
,	O
carotid	O
pulses	O
brisk	O
,	O
no	O
bruits	O
,	O
no	O
cervical	O
lymphadenopathy	O
,	O
trachea	O
midline	O
,	O
no	O
stridor	O
COR	O
:	O
RRR	O
,	O
no	O
M	O
/	O
G	O
/	O
R	O
,	O
normal	O
S1	O
S2	O
,	O
radial	O
pulses	O
+2	O
PULM	O
:	O
some	O
mild	O
wheezes	O
,	O
intermitent	O
ABD	O
:	O
Soft	O
,	O
mild	O
RUQ	O
pain	O
,	O
ND	O
,	O
+	O
BS	O
,	O
no	O
HSM	O
,	O
no	O
masses	O
EXT	O
:	O
No	O
C	O
/	O
C	O
/	O
E	O
,	O
no	O
palpable	O
cords	O
NEURO	O
:	O
alert	O
,	O
CN	O
II	O
??????	O
XII	O
grossly	O
intact	O
.	O
Moves	O
all	O
4	O
extremities	O
.	O
SKIN	O
:	O
No	O
jaundice	O
,	O
cyanosis	O
,	O
or	O
gross	O
dermatitis	O
.	O
Facial	O
ecchymoses	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2192-3-16	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
WBC	O
-	O
18.3	O
*	O
#	O
RBC	O
-	O
3.77	O
*	O
Hgb	O
-	O
10.2	O
*	O
Hct	O
-	O
30.4	O
*	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
27.1	O
MCHC	O
-	O
33.7	O
RDW	O
-	O
13.0	O
Plt	O
Ct	O
-	O
240	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
WBC	O
-	O
9.2	O
RBC	O
-	O
4.08	O
*	O
Hgb	O
-	O
11.2	O
*	O
Hct	O
-	O
32.8	O
*	O
MCV	O
-	O
80	O
*	O
MCH	O
-	O
27.4	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
13.3	O
Plt	O
Ct	O
-	O
249	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
Neuts	O
-	O
58.6	O
Lymphs	O
-	O
26.3	O
Monos	O
-	O
6.5	O
Eos	O
-	O
8.0	O
*	O
Baso	O
-	O
0.7	O
[	O
**	O
2192-3-16	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
PT	O
-	O
12.4	O
PTT	O
-	O
23.6	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
ESR	O
-	O
11	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
Glucose	O
-	O
106	O
*	O
UreaN	O
-	O
14	O
Creat	O
-	O
1.2	O
Na	O
-	O
129	O
*	O
K	O
-	O
4.4	O
Cl	O
-	O
94	O
*	O
HCO3	O
-	O
28	O
AnGap	O
-	O
11	O
[	O
**	O
2192-3-16	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Glucose	O
-	O
111	O
*	O
UreaN	O
-	O
17	O
Creat	O
-	O
1.1	O
Na	O
-	O
132	O
*	O
K	O
-	O
4.8	O
Cl	O
-	O
102	O
HCO3	O
-	O
22	O
AnGap	O
-	O
13	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
ALT	O
-	O
27	O
AST	O
-	O
28	O
LD	O
(	O
LDH	O
)	O
-	O
155	O
AlkPhos	O
-	O
88	O
TotBili	O
-	O
0.3	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2192-3-16	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
3.0	O
Mg	O
-	O
2.3	O
[	O
**	O
2192-3-16	O
**	O
]	O
04:30	O
AM	O
BLOOD	O
VitB12	O
-	O
437	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
CRP	O
-	O
1.2	O
[	O
**	O
2192-3-15	O
**	O
]	O
05:25	O
AM	O
BLOOD	O
C3	O
-	O
107	O
C4	O
-	O
23	O
RPR	O
non	O
reactive	O
cxr	O
[	O
**	O
2192-3-15	O
**	O
]	O
:	O
FINDINGS	O
:	O
There	O
is	O
suggestion	O
of	O
COPD	O
.	O
There	O
is	O
a	O
linear	O
opacity	O
at	O
the	O
left	O
mid	O
lung	O
likely	O
small	O
atelectasis	O
.	O
There	O
are	O
bibasilar	O
atelectasis	O
.	O
There	O
is	O
probable	O
RML	O
atelectasis	O
.	O
There	O
is	O
no	O
pneumonia	O
.	O
There	O
is	O
no	O
pleural	O
effusion	O
or	O
pneumothorax	O
.	O
Hilar	O
silhouette	O
is	O
normal	O
.	O
There	O
is	O
tortuosity	O
of	O
thoracic	O
aorta	O
.	O
Mild	O
cardiomegaly	O
with	O
a	O
left	O
ventricular	O
configuration	O
.	O
IMPRESSION	O
:	O
No	O
pneumonia	O
.	O
No	O
pneumothorax	O
.	O
[	O
**	O
2192-3-15	O
**	O
]	O
ct	O
c	O
spine	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Multilevel	O
degenerative	O
changes	O
in	O
the	O
cervical	O
spine	O
with	O
fusion	O
of	O
C3	O
-	O
C4	O
and	O
posterior	O
osteophytes	O
at	O
C4	O
-	O
C5	O
and	O
C6	O
-	O
C7	O
impinging	O
on	O
the	O
thecal	O
sac	O
anteriorly	O
and	O
placing	O
the	O
cord	O
for	O
higher	O
risk	O
of	O
injury	O
in	O
appropriate	O
mechanism	O
.	O
2	O
.	O
Small	O
osseous	O
fragment	O
superior	O
and	O
posterior	O
of	O
C3	O
vertebral	O
body	O
could	O
be	O
a	O
small	O
fracture	O
fragment	O
of	O
uncertain	O
chronicity	O
.	O
Correlate	O
with	O
point	O
tenderness	O
.	O
Comparison	O
with	O
prior	O
imaging	O
,	O
if	O
available	O
,	O
would	O
be	O
beneficial	O
.	O
If	O
clinical	O
concern	O
,	O
MRI	O
of	O
the	O
spine	O
can	O
be	O
done	O
for	O
evaluation	O
.	O
[	O
**	O
2192-3-15	O
**	O
]	O
ct	O
sinus	O
:	O
1	O
.	O
No	O
evidence	O
of	O
fracture	O
.	O
2	O
.	O
Mild	O
mucosal	O
thickening	O
in	O
bilateral	O
maxillary	O
sinuses	O
and	O
sphenoid	O
sinus	O
.	O
3	O
.	O
Left	O
preseptal	O
small	O
hematoma	O
.	O
[	O
**	O
2192-3-15	O
**	O
]	O
ct	O
head	O
without	O
contrast	O
:	O
FINDINGS	O
:	O
There	O
is	O
no	O
evidence	O
of	O
hemorrhage	O
,	O
infarction	O
,	O
or	O
masses	O
.	O
There	O
is	O
no	O
shift	O
of	O
midline	O
structures	O
.	O
Ventricles	O
and	O
sulci	O
are	O
normal	O
in	O
size	O
and	O
configuration	O
.	O
There	O
is	O
no	O
evidence	O
of	O
fracture	O
.	O
There	O
is	O
a	O
left	O
preseptal	O
hematoma	O
.	O
IMPRESSION	O
:	O
No	O
acute	O
intracranial	O
process	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
87	O
year	O
-	O
old	O
male	O
with	O
a	O
history	O
of	O
orthostatic	O
hypotension	O
and	O
recent	O
fall	O
c	O
/	O
b	O
trauma	O
to	O
face	O
who	O
presents	O
with	O
facial	O
swelling	O
and	O
?	O
angioedema	O
.	O
Facial	O
swelling	O
:	O
possibly	O
angioedema	I-Ade
given	O
recent	O
initiation	O
of	O
ACEi	I-Drug
but	O
also	O
possibly	O
related	O
to	O
the	O
fall	O
and	O
trauma	O
.	O
At	O
this	O
point	O
will	O
avoid	O
ACEi	I-Drug
or	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
and	O
have	O
placed	O
lisinopril	I-Drug
on	O
his	O
allergy	O
list	O
.	O
SYNCOPE	O
/	O
AUTNOMIC	O
DYSFUNCTION	O
:	O
symptoms	O
of	O
presyncope	O
chronically	O
(	O
for	O
2	O
years	O
)	O
and	O
a	O
formal	O
diagnosis	O
of	O
autnomic	O
dysfunction	O
has	O
been	O
made	O
with	O
tilt	O
table	O
testing	O
here	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
in	O
[	O
**	O
2190	O
**	O
]	O
.	O
He	O
had	O
previously	O
been	O
on	O
midodrine	I-Drug
and	O
florinef	I-Drug
but	O
was	O
hypertensive	I-Ade
so	O
these	O
were	O
discontinued	O
.	O
He	O
has	O
most	O
recently	O
been	O
on	O
flomax	I-Drug
and	O
lisinopril	I-Drug
and	O
was	O
more	O
orthostatic	I-Ade
.	O
For	O
now	O
I	O
have	O
changed	O
his	O
regimen	O
to	O
norvasc	I-Drug
2.5	O
mg	O
po	O
daily	O
and	O
thigh	O
high	O
TEDS	O
stockings	O
.	O
In	O
addition	O
given	O
his	O
CT	O
C	O
spine	O
findings	O
and	O
his	O
recurrent	O
falls	O
I	O
feel	O
that	O
it	O
would	O
be	O
dangerous	O
for	O
him	O
to	O
ambulate	O
without	O
an	O
assist	O
device	O
.	O
I	O
have	O
recommended	O
a	O
walker	O
with	O
a	O
seat	O
so	O
that	O
he	O
can	O
sit	O
down	O
immediately	O
should	O
he	O
feel	O
lightheaded	O
,	O
I	O
have	O
strongly	O
urged	O
he	O
use	O
this	O
at	O
all	O
times	O
given	O
his	O
high	O
risk	O
to	O
fall	O
,	O
and	O
have	O
suggested	O
if	O
this	O
is	O
ineffective	O
he	O
may	O
at	O
somepoint	O
be	O
committed	O
to	O
a	O
wheelchair	O
given	O
his	O
severe	O
autnomic	O
dysfunction	O
.	O
In	O
addition	O
he	O
will	O
have	O
a	O
home	O
safety	O
evaluation	O
by	O
VNA	O
.	O
He	O
had	O
no	O
acute	O
fractures	O
as	O
a	O
result	O
of	O
his	O
fall	O
.	O
I	O
have	O
also	O
checked	O
a	O
B12	O
which	O
was	O
400	O
and	O
an	O
RPR	O
which	O
was	O
non	O
reactive	O
given	O
that	O
he	O
had	O
a	O
+	O
romberg	O
sign	O
suggestive	O
of	O
posterior	O
column	O
spinal	O
cord	O
disease	O
.	O
Medications	O
on	O
Admission	O
:	O
1.fluticasone	O
-	O
salmeterol	O
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
[	O
**	O
Hospital1	O
**	O
]	O
2	O
.	O
haloperidol	I-Drug
2.5	O
mg	O
Tablet	O
PO	O
HS	O
3	O
.	O
tamsulosin	I-Drug
SR	O
0.4	O
mg	O
PO	O
HS	O
(	O
nephew	O
thinks	O
this	O
is	O
new	O
for	O
last	O
3	O
days	O
,	O
but	O
it	O
was	O
on	O
his	O
older	O
non-confimed	O
med	O
list	O
)	O
4	O
.	O
tiotropium	I-Drug
bromide	O
18	O
mcg	O
DAILY	O
5	O
.	O
atorvastatin	B-Drug
80	O
mg	O
PO	O
HS	O
6	O
.	O
lisinopril	I-Drug
5	O
mg	O
PO	O
DAILY	O
7	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
PO	O
twice	O
a	O
day	O
prn	O
8	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
PO	O
once	O
a	O
day	O
.	O
9	O
.	O
aspirin	B-Drug
325	O
mg	O
Tablet	O
,	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
citalopram	B-Drug
10	O
mg	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
ROLLATER	O
WALKER	O
one	O
rollater	O
walker	O
(	O
walker	O
with	O
seat	O
)	O
2	O
.	O
fluticasone	I-Drug
-	O
salmeterol	O
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
haloperidol	B-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
tiotropium	I-Drug
bromide	O
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
Inhalation	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
atorvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
6	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
7	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
8	O
.	O
aspirin	B-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
amlodipine	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
TEDS	O
STOCKINGS	O
SMALL	O
TEDS	O
STOCKINGS	O
,	O
ABOVE	O
THE	O
KNEE	O
11	O
.	O
citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Multicultural	O
VNA	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
DIAGNOSIS	O
:	O
angioedema	I-Ade
from	O
lisinopril	I-Drug
autonomic	O
dysfunction	O
complicated	O
by	O
falls	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
after	O
a	O
fall	O
and	O
had	O
lip	O
swelling	O
.	O
Your	O
fall	O
was	O
likely	O
related	O
to	O
your	O
chronic	O
lightheadedness	O
.	O
You	O
will	O
need	O
to	O
wear	O
the	O
TEDS	O
stockings	O
and	O
use	O
a	O
rolling	O
walker	O
with	O
a	O
seat	O
,	O
if	O
you	O
feel	O
lightheaded	O
please	O
sit	O
down	O
immediately	O
.	O
MEDICATION	O
CHANGES	O
:	O
STOP	O
taking	O
LISINOPRIL	I-Drug
(	O
you	O
may	O
be	O
allergic	O
to	O
this	O
medication	O
)	O
STOP	O
taking	O
FLOMAX	I-Drug
(	O
prostate	O
medication	O
)	O
START	O
taking	O
NORVASC	I-Drug
(	O
AMLODIPINE	O
)	O
Followup	O
Instructions	O
:	O
Department	O
:	O
SURGICAL	O
SPECIALTIES	O
When	O
:	O
THURSDAY	O
[	O
**	O
2192-3-29	O
**	O
]	O
at	O
9:00	O
AM	O
With	O
:	O
PELVIC	O
FLOOR	O
UNIT	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
274	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Department	O
:	O
[	O
**	O
Hospital1	O
7975	O
**	O
]	O
INTERNAL	O
MEDICINE	O
When	O
:	O
MONDAY	O
[	O
**	O
2192-4-9	O
**	O
]	O
at	O
10:45	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
7978	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
7976	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital1	O
7977	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
,	O
MA	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
OFF	O
CAMPUS	O
Best	O
Parking	O
:	O
Free	O
Parking	O
on	O
Site	O

Admission	O
Date	O
:	O
[	O
**	O
2134-4-19	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2134-5-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2061-11-2	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
12131	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hypotension	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Endoscopy	O
Sigmoidoscopy	O
Portacath	O
removal	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
catheter	O
placement	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
72M	O
with	O
pmh	O
significant	O
for	O
metastatic	O
rectal	O
cancer	O
was	O
at	O
radiology	O
clinic	O
receiving	O
scheduled	O
imaging	O
when	O
blood	B-Reason
pressure	I-Reason
at	O
triage	O
recorded	O
60/40	O
.	O
Recheck	O
was	O
70/40	O
.	O
His	O
port	O
was	O
accessed	O
and	O
he	O
was	O
bolused	O
with	O
300cc	O
of	O
IVF	I-Drug
and	O
transferred	O
to	O
the	O
ED	O
.	O
He	O
denied	O
syncope	O
or	O
lightheadedness	O
but	O
reported	O
mild	O
SOB	O
and	O
fatigue	O
.	O
He	O
reports	O
having	O
several	O
days	O
of	O
diahrrea	O
,	O
which	O
began	O
last	O
wednesday	O
[	O
**	O
4	O
-	O
14	O
**	O
]	O
.	O
His	O
last	O
dose	O
of	O
irinotecan	I-Drug
and	O
panitumab	I-Drug
chemotherapy	I-Drug
was	O
Monday	O
[	O
**	O
2134-3-29	O
**	O
]	O
(	O
patient	O
reports	O
was	O
[	O
**	O
4	O
-	O
12	O
**	O
]	O
but	O
not	O
recorded	O
in	O
OMR	O
)	O
,	O
and	O
he	O
reports	O
always	O
getting	O
diahrrea	I-Ade
with	O
his	O
chemotherapy	I-Drug
.	O
He	O
reports	O
haveing	O
watery	B-Reason
bowel	I-Reason
movements	O
roughly	O
every	O
45	O
minutes	O
since	O
wednesday	O
.	O
HIs	O
bowel	O
movements	O
are	O
not	O
bloody	O
or	O
melanaic	O
.	O
He	O
has	O
been	O
taking	O
immodium	I-Drug
and	O
diphenoxylate	B-Drug
-	I-Drug
atropine	I-Drug
without	O
improvement	O
.	O
Sunday	O
night	O
,	O
he	O
reports	O
acute	O
worsening	O
of	O
his	O
diahrrea	O
,	O
which	O
continued	O
through	O
Monday	O
.	O
EMS	O
gave	O
him	O
another	O
500cc	O
of	O
NS	I-Drug
prior	O
to	O
arrival	O
to	O
the	O
ED	O
.	O
.	O
On	O
arrival	O
to	O
the	O
ED	O
his	O
vitals	O
were	O
98.0	O
100/50	O
83	O
18	O
100	O
%	O
RA	O
.	O
Cr	O
was	O
1.3	O
from	O
1.1	O
.	O
Hct	O
was	O
27.3	O
.	O
Mg	O
was	O
0.8	O
mg	O
.	O
He	O
was	O
guaiac	O
negative	O
.	O
CT	O
torso	O
was	O
without	O
PE	O
or	O
dissection	O
,	O
but	O
did	O
have	O
multiple	O
stable	O
pulmonary	O
nodules	O
,	O
and	O
a	O
small	O
right	O
pleural	O
effusion	O
.	O
He	O
also	O
had	O
stable	O
metastatic	O
disease	O
.	O
EKG	O
was	O
sinus	O
in	O
the	O
70's	O
.	O
He	O
was	O
given	O
3L	O
of	O
NS	I-Drug
and	O
4	O
grams	O
of	O
Mg	I-Drug
.	O
.	O
Review	O
of	O
Systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
.	O
He	O
is	O
denying	O
fevers	O
,	O
abdominal	O
pain	O
,	O
chest	O
pain	O
,	O
hematochezia	O
,	O
melena	O
.	O
Past	O
Medical	O
History	O
:	O
Past	O
Oncologic	O
History	O
:	O
Adenocarcinoma	O
of	O
the	O
rectum	O
-	O
[	O
**	O
6	O
-	O
/	O
2131	O
**	O
]	O
:	O
The	O
patient	O
presented	O
with	O
a	O
change	O
in	O
bowel	O
habits	O
and	O
was	O
noted	O
to	O
have	O
an	O
abnormal	O
rectal	O
exam	O
by	O
his	O
primary	O
care	O
physician	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
39262	O
**	O
]	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
gastrointestinal	O
evaluation	O
.	O
-	O
[	O
**	O
2131-7-23	O
**	O
]	O
colonoscopy	O
:	O
Exophytic	O
cancer	O
of	O
the	O
rectum	O
[	O
**	O
9	O
-	O
9	O
**	O
]	O
cm	O
above	O
the	O
anal	O
margin	O
.	O
Polyp	O
noted	O
at	O
the	O
anorectal	O
junction	O
.	O
Biopsy	O
:	O
Invasive	O
,	O
moderately	O
differentiated	O
adenocarcinoma	O
arising	O
in	O
association	O
with	O
adenoma	O
.	O
Polyp	O
:	O
Adenoma	O
with	O
high	O
-	O
grade	O
dysplasia	O
.	O
-	O
[	O
**	O
2131-7-25	O
**	O
]	O
rectal	O
ultrasound	O
:	O
T3	O
posterior	O
midline	O
tumor	O
with	O
luminal	O
narrowing	O
of	O
the	O
rectum	O
.	O
-	O
[	O
**	O
2131-8-2	O
**	O
]	O
CT	O
scan	O
of	O
the	O
torso	O
:	O
Irregular	O
,	O
polypoid	O
lesion	O
seen	O
within	O
the	O
rectum	O
,	O
with	O
multiple	O
subcentimeter	O
presacral	O
and	O
pericolic	O
lymph	O
nodes	O
identified	O
.	O
Two	O
pulmonary	O
nodules	O
seen	O
in	O
the	O
left	O
lower	O
lobe	O
,	O
the	O
largest	O
measuring	O
2.9	O
x	O
2.2	O
cm	O
.	O
Multiple	O
low	O
-	O
attenuation	O
lesions	O
seen	O
within	O
the	O
liver	O
,	O
the	O
largest	O
of	O
which	O
may	O
represent	O
cyst	O
,	O
smaller	O
lesions	O
are	O
not	O
fully	O
characterized	O
.	O
Low	O
-	O
attenuation	O
lesions	O
seen	O
within	O
the	O
left	O
kidney	O
,	O
possibly	O
a	O
cyst	O
,	O
although	O
too	O
small	O
to	O
characterize	O
.	O
Per	O
report	O
,	O
a	O
CT	O
PET	O
performed	O
elsewhere	O
demonstrated	O
uptake	O
in	O
the	O
left	O
base	O
of	O
the	O
lung	O
.	O
-	O
[	O
**	O
2131-8-14	O
**	O
]	O
to	O
[	O
**	O
2131-9-25	O
**	O
]	O
:	O
Neoadjuvant	O
chemoradiation	O
with	O
continuous	O
5	O
-	O
FU	O
at	O
225	O
mg	O
/	O
m2	O
/	O
day	O
and	O
radiation	O
therapy	O
five	O
days	O
weekly	O
.	O
-	O
[	O
**	O
2131-12-10	O
**	O
]	O
:	O
Proctosigmoidectomy	O
with	O
stapled	O
coloanal	O
anastomosis	O
and	O
diverting	O
loop	O
ileostomy	O
.	O
Pathology	O
revealed	O
adenocarcinoma	O
of	O
the	O
rectum	O
,	O
low	O
-	O
grade	O
,	O
with	O
invasion	O
into	O
the	O
perirectal	O
adipose	O
tissue	O
and	O
metastasis	O
to	O
7	O
of	O
13	O
regional	O
lymph	O
nodes	O
(	O
T3N2	O
)	O
.	O
The	O
resection	O
margins	O
were	O
uninvolved	O
.	O
-	O
[	O
**	O
2132-1-28	O
**	O
]	O
PET	O
Scan	O
:	O
Interval	O
progression	O
of	O
disease	O
with	O
an	O
increase	O
in	O
the	O
size	O
of	O
the	O
previously	O
identified	O
lung	O
metastasis	O
.	O
There	O
is	O
a	O
new	O
FDG	O
-	O
avid	O
focus	O
in	O
segment	O
4A	O
of	O
the	O
liver	O
which	O
most	O
likely	O
represents	O
metastasis	O
.	O
-	O
[	O
**	O
2132-2-13	O
**	O
]	O
:	O
Ileostomy	O
takedown	O
with	O
simultaneous	O
flexible	O
bronchoscopy	O
and	O
VATS	O
with	O
left	O
lower	O
lobe	O
resection	O
.	O
Pathology	O
from	O
the	O
ileostomy	O
stoma	O
demonstrated	O
no	O
evidence	O
of	O
malignancy	O
.	O
The	O
left	O
lower	O
lobe	O
wedge	O
resection	O
demonstrated	O
an	O
adenocarcinoma	O
,	O
4.1	O
cm	O
,	O
consistent	O
with	O
metastasis	O
of	O
rectal	O
origin	O
.	O
The	O
pleural	O
and	O
apparent	O
stapled	O
margins	O
were	O
free	O
of	O
malignancy	O
.	O
-	O
[	O
**	O
2132-2-14	O
**	O
]	O
:	O
Evaluation	O
by	O
the	O
hepatobiliary	O
surgery	O
consult	O
team	O
due	O
to	O
the	O
finding	O
on	O
his	O
recent	O
PET	O
scan	O
of	O
a	O
likely	O
liver	O
metastasis	O
.	O
It	O
was	O
felt	O
that	O
the	O
lesion	O
was	O
amenable	O
to	O
surgical	O
resection	O
,	O
and	O
it	O
was	O
planned	O
that	O
the	O
patient	O
would	O
undergo	O
two	O
cycles	O
of	O
chemotherapy	O
prior	O
to	O
proceeding	O
with	O
hepatic	O
resection	O
.	O
-	O
[	O
**	O
2132-4-9	O
**	O
]	O
:	O
FOLFOX	B-Drug
chemotherapy	I-Drug
initiated	O
.	O
The	O
patient	O
completed	O
two	O
cycles	O
of	O
therapy	O
on	O
[	O
**	O
2132-6-3	O
**	O
]	O
.	O
-	O
[	O
**	O
2132-7-11	O
**	O
]	O
:	O
Hepatic	O
resection	O
of	O
a	O
1.7	O
cm	O
segment	O
4a	O
metastatic	O
lesion	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
-	O
[	O
**	O
2132-10-22	O
**	O
]	O
:	O
Cycle	O
1	O
Day	O
1	O
5FU	B-Drug
/	I-Drug
LV	I-Drug
for	O
further	O
adjuvant	O
chemotherapy	I-Drug
.	O
Oxaliplatin	I-Drug
eliminated	O
due	O
to	O
neuropathy	I-Ade
.	O
The	O
patient	O
completed	O
therapy	O
in	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
.	O
-	O
[	O
**	O
2132-11-26	O
**	O
]	O
:	O
Hospital	O
admission	O
for	O
SVC	B-Reason
syndrome	I-Reason
secondary	O
to	O
a	O
catheter	O
-	O
associated	O
thrombus	O
causing	O
occlusion	O
of	O
the	O
SVC	O
and	O
bilateral	O
brachiocephalic	O
veins	O
.	O
The	O
patient	O
underwent	O
TPA	O
infusion	O
followed	O
by	O
venous	O
angioplasty	O
with	O
balloon	O
dilation	O
with	O
resolution	O
of	O
symptoms	O
.	O
He	O
was	O
discharged	O
on	O
enoxaparin	I-Drug
.	O
-	O
[	O
**	O
2133-8-3	O
**	O
]	O
:	O
Initiation	O
of	O
ininotecan	I-Drug
for	O
recurrent	B-Reason
disease	I-Reason
.	O
-	O
[	O
**	O
2134-2-8	O
**	O
]	O
:	O
Due	O
to	O
laboratory	O
and	O
radiographic	O
evidence	O
of	O
disease	O
progression	O
,	O
cetuximab	I-Drug
was	O
added	O
to	O
ininotecan	I-Drug
;	O
due	O
to	O
an	O
allergic	B-Reason
reaction	I-Reason
,	O
cetuximab	I-Drug
was	O
changed	O
to	O
panitumumab	I-Drug
on	O
[	O
**	O
2134-2-16	O
**	O
]	O
.	O
.	O
Other	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Hypertension	O
.	O
2	O
.	O
Hyperlipidemia	O
.	O
3	O
.	O
ASCVD	O
,	O
status	O
post	O
MI	O
in	O
[	O
**	O
2111	O
**	O
]	O
.	O
4	O
.	O
Status	O
post	O
appendectomy	O
.	O
5	O
.	O
Diabetes	O
Social	O
History	O
:	O
The	O
patient	O
lives	O
alone	O
and	O
is	O
divorced	O
.	O
He	O
has	O
three	O
sons	O
in	O
their	O
40s	O
.	O
He	O
is	O
a	O
construction	O
inspector	O
.	O
He	O
denies	O
alcohol	O
use	O
and	O
drug	O
use	O
.	O
He	O
smoked	O
one	O
pack	O
of	O
cigarettes	O
daily	O
for	O
30	O
years	O
before	O
quitting	O
.	O
Family	O
History	O
:	O
The	O
patient	O
's	O
paternal	O
uncle	O
had	O
an	O
abdominal	O
cancer	O
,	O
details	O
unknown	O
.	O
His	O
father	O
died	O
of	O
an	O
MI	O
.	O
His	O
mother	O
died	O
of	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2481	O
**	O
]	O
disease	O
.	O
He	O
has	O
two	O
brothers	O
who	O
are	O
well	O
.	O
Physical	O
Exam	O
:	O
Admission	O
:	O
GEN	O
:	O
awake	O
,	O
alert	O
,	O
NAD	O
VS	O
:	O
97.6	O
110/46	O
88	O
19	O
100	O
%	O
2L	O
HEENT	O
:	O
EOMI	O
,	O
MMM	O
CV	O
:	O
irregularly	O
irregular	O
,	O
no	O
m	O
/	O
g	O
/	O
r	O
PULM	O
:	O
crackles	O
at	O
RLL	O
ABD	O
:	O
well	O
healed	O
scars	O
on	O
abdomen	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
LIMBS	O
:	O
no	O
edema	O
SKIN	O
:	O
erythema	O
and	O
excoriation	O
over	O
left	O
antecubital	O
fossa	O
.	O
Discharge	O
:	O
GEN	O
:	O
NAD	O
,	O
aaox3	O
HEENT	O
:	O
MMM	O
,	O
oropharynx	O
clear	O
.	O
CV	O
:	O
RRR	O
,	O
No	O
m	O
/	O
r	O
/	O
g	O
PULM	O
:	O
CTAB	O
,	O
decreased	O
breath	O
sounds	O
at	O
bases	O
.	O
Tunneled	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2286	O
**	O
]	O
catheter	O
noted	O
on	O
right	O
chest	O
,	O
c	O
/	O
d	O
/	O
i	O
ABD	O
:	O
Soft	O
,	O
distended	O
,	O
NT	O
,	O
+	O
BS	O
.	O
EXTR	O
:	O
2	O
+	O
bilateral	O
lower	O
extremity	O
edema	O
,	O
2	O
+	O
bilateral	O
upper	O
extremity	O
edema	O
,	O
left	O
>	O
right	O
2	O
+	O
DP	O
pulses	O
bilaterally	O
.	O
SKIN	O
:	O
blanching	O
macules	O
noted	O
scattered	O
across	O
forearms	O
and	O
upper	O
back	O
.	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
[	O
**	O
2134-4-19	O
**	O
]	O
11:35	O
AM	O
BLOOD	O
WBC	O
-	O
2.8	O
*	O
RBC	O
-	O
3.30	O
*	O
Hgb	O
-	O
9.3	O
*	O
Hct	O
-	O
27.3	O
*	O
MCV	O
-	O
83	O
MCH	O
-	O
28.3	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
20.0	O
*	O
Plt	O
Ct	O
-	O
283	O
[	O
**	O
2134-4-19	O
**	O
]	O
11:35	O
AM	O
BLOOD	O
PT	O
-	O
14.0	O
*	O
PTT	O
-	O
35.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2134-4-19	O
**	O
]	O
11:35	O
AM	O
BLOOD	O
Glucose	O
-	O
199	O
*	O
UreaN	O
-	O
23	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
139	O
K	O
-	O
4.0	O
Cl	O
-	O
106	O
HCO3	O
-	O
22	O
AnGap	O
-	O
15	O
[	O
**	O
2134-4-19	O
**	O
]	O
11:35	O
AM	O
BLOOD	O
Calcium	O
-	O
8.3	O
*	O
Phos	O
-	O
2.4	O
*	O
Mg	O
-	O
0.8	O
*	O
.	O
Discharge	O
labs	O
:	O
Micro	O
:	O
[	O
**	O
4	O
-	O
20	O
**	O
]	O
:	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST	O
(	O
Final	O
[	O
**	O
2134-4-21	O
**	O
]	O
)	O
:	O
Feces	O
negative	O
for	O
C.difficile	O
toxin	O
A	O
&	O
B	O
by	O
EIA	O
.	O
(	O
Reference	O
Range	O
-	O
Negative	O
)	O
.	O
FECAL	O
CULTURE	O
(	O
Final	O
[	O
**	O
2134-4-22	O
**	O
]	O
)	O
:	O
NO	O
SALMONELLA	O
OR	O
SHIGELLA	O
FOUND	O
.	O
CAMPYLOBACTER	O
CULTURE	O
(	O
Final	O
[	O
**	O
2134-4-22	O
**	O
]	O
)	O
:	O
NO	O
CAMPYLOBACTER	O
FOUND	O
.	O
.	O
[	O
**	O
2134-5-4	O
**	O
]	O
12:58	O
am	O
STOOL	O
CONSISTENCY	O
:	O
SOFT	O
Source	O
:	O
Stool	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2134-5-4	O
**	O
]	O
**	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST	O
(	O
Final	O
[	O
**	O
2134-5-4	O
**	O
]	O
)	O
:	O
Feces	O
negative	O
for	O
C.difficile	O
toxin	O
A	O
&	O
B	O
by	O
EIA	O
.	O
(	O
Reference	O
Range	O
-	O
Negative	O
)	O
.	O
[	O
**	O
2134-4-27	O
**	O
]	O
11:47	O
am	O
CATHETER	O
TIP	O
-	O
IV	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2134-4-29	O
**	O
]	O
**	O
GRAM	O
STAIN	O
(	O
Final	O
[	O
**	O
2134-4-27	O
**	O
]	O
)	O
:	O
TEST	O
CANCELLED	O
,	O
PATIENT	O
CREDITED	O
.	O
INAPPROPRIATE	O
SPECIMEN	O
FOR	O
GRAM	O
STAIN	O
.	O
WOUND	O
CULTURE	O
(	O
Final	O
[	O
**	O
2134-4-29	O
**	O
]	O
)	O
:	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
>	O
15	O
colonies	O
.	O
Staphylococcus	O
species	O
may	O
develop	O
resistance	O
during	O
prolonged	O
therapy	O
with	O
quinolones	O
.	O
Therefore	O
,	O
isolates	O
that	O
are	O
initially	O
susceptible	O
may	O
become	O
resistant	O
within	O
three	O
to	O
four	O
days	O
after	O
initiation	O
of	O
therapy	O
.	O
Testing	O
of	O
repeat	O
isolates	O
may	O
be	O
warranted	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
STAPH	O
AUREUS	O
COAG	O
+	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
<	O
=	O
0.25	O
S	O
ERYTHROMYCIN	I-Drug
----------	O
<	O
=	O
0.25	O
S	O
GENTAMICIN	I-Drug
------------	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
<	O
=	O
0.12	O
S	O
OXACILLIN	I-Drug
-------------	O
0.5	O
S	O
TRIMETHOPRIM	B-Drug
/	I-Drug
SULFA	I-Drug
----	O
<	O
=	O
0.5	O
S	O
[	O
**	O
2134-4-24	O
**	O
]	O
2:47	O
pm	O
BLOOD	O
CULTURE	O
Source	O
:	O
Line	O
-	O
PICC	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2134-4-29	O
**	O
]	O
**	O
Blood	O
Culture	O
,	O
Routine	O
(	O
Final	O
[	O
**	O
2134-4-29	O
**	O
]	O
)	O
:	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
SENSITIVITIES	O
PERFORMED	O
ON	O
CULTURE	O
#	O
294	O
-	O
1510A	O
[	O
**	O
2134-4-23	O
**	O
]	O
.	O
Consultations	O
with	O
ID	O
are	O
recommended	O
for	O
all	O
blood	O
cultures	O
positive	O
for	O
Staphylococcus	O
aureus	O
and	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
species	O
.	O
STAPH	O
AUREUS	O
COAG	O
+	O
.	O
SECOND	O
MORPHOLOGY	O
.	O
Consultations	O
with	O
ID	O
are	O
recommended	O
for	O
all	O
blood	O
cultures	O
positive	O
for	O
Staphylococcus	O
aureus	O
and	O
[	O
**	O
Female	O
First	O
Name	O
(	O
un	O
)	O
564	O
**	O
]	O
species	O
.	O
Staphylococcus	O
species	O
may	O
develop	O
resistance	O
during	O
prolonged	O
therapy	O
with	O
quinolones	O
.	O
Therefore	O
,	O
isolates	O
that	O
are	O
initially	O
susceptible	O
may	O
become	O
resistant	O
within	O
three	O
to	O
four	O
days	O
after	O
initiation	O
of	O
therapy	O
.	O
Testing	O
of	O
repeat	O
isolates	O
may	O
be	O
warranted	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
STAPH	O
AUREUS	O
COAG	O
+	O
|	O
CLINDAMYCIN	I-Drug
-----------	O
<	O
=	O
0.25	O
S	O
ERYTHROMYCIN	I-Drug
----------	O
<	O
=	O
0.25	O
S	O
GENTAMICIN	I-Drug
------------	O
<	O
=	O
0.5	O
S	O
LEVOFLOXACIN	I-Drug
----------	O
0.25	O
S	O
OXACILLIN	I-Drug
-------------	O
1	O
S	O
TRIMETHOPRIM	B-Drug
/	I-Drug
SULFA	I-Drug
----	O
<	O
=	O
0.5	O
S	O
Anaerobic	O
Bottle	O
Gram	O
Stain	O
(	O
Final	O
[	O
**	O
2134-4-26	O
**	O
]	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
IN	O
PAIRS	O
AND	O
CLUSTERS	O
.	O
Aerobic	O
Bottle	O
Gram	O
Stain	O
(	O
Final	O
[	O
**	O
2134-4-26	O
**	O
]	O
)	O
:	O
GRAM	O
POSITIVE	O
COCCI	O
IN	O
CLUSTERS	O
.	O
[	O
**	O
4	O
-	O
19	O
**	O
]	O
ECG	O
:	O
Sinus	O
rhythm	O
with	O
ventricular	O
premature	O
beat	O
.	O
Right	O
bundle	O
-	O
branch	O
block	O
.	O
Since	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2132-11-27	O
**	O
]	O
inferior	O
lead	O
Q	O
waves	O
are	O
less	O
prominent	O
.	O
.	O
[	O
**	O
4	O
-	O
19	O
**	O
]	O
CT	O
torso	O
:	O
1	O
.	O
No	O
evidence	O
of	O
pulmonary	O
embolism	O
or	O
dissection	O
.	O
Multiple	O
small	O
pulmonary	O
nodules	O
are	O
overall	O
stable	O
in	O
size	O
.	O
Stable	O
small	O
right	O
-	O
sided	O
pleural	O
effusion	O
.	O
2	O
.	O
Stable	O
extent	O
of	O
metastatic	O
disease	O
in	O
the	O
abdomen	O
.	O
3	O
.	O
Two	O
small	O
ventral	O
wall	O
hernias	O
containing	O
loops	O
of	O
small	O
bowel	O
,	O
but	O
no	O
evidence	O
of	O
obstruction	O
with	O
oral	O
contrast	O
seen	O
to	O
the	O
colon	O
.	O
4	O
.	O
Cholelithiasis	O
.	O
.	O
[	O
**	O
2134-4-26	O
**	O
]	O
RUE	O
ultrasound	O
.	O
INDICATION	O
:	O
72	O
-	O
year	O
-	O
old	O
man	O
with	O
swollen	O
left	O
arm	O
and	O
left	O
-	O
sided	O
Port	O
-	O
A-Cath	O
.	O
COMPARISON	O
:	O
None	O
.	O
TECHNIQUE	O
:	O
Grayscale	O
and	O
Doppler	O
evaluation	O
of	O
left	O
upper	O
extremity	O
.	O
FINDINGS	O
:	O
Grayscale	O
and	O
Doppler	O
evaluation	O
of	O
the	O
left	O
internal	O
jugular	O
,	O
subclavian	O
,	O
axillary	O
,	O
basilic	O
,	O
and	O
brachial	O
veins	O
demonstrate	O
normal	O
flow	O
,	O
compressibility	O
,	O
and	O
response	O
to	O
augmentation	O
wherever	O
applicable	O
.	O
No	O
intraluminal	O
thrombus	O
was	O
identified	O
.	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
DVT	O
in	O
the	O
left	O
upper	O
extremity	O
.	O
[	O
**	O
2134-4-27	O
**	O
]	O
renal	O
ultrasound	O
:	O
INDICATION	O
:	O
72	O
year	O
old	O
man	O
with	O
acute	O
kidney	O
failure	O
and	O
sepsis	O
.	O
COMPARISON	O
:	O
CTA	O
chest	O
performed	O
[	O
**	O
2134-4-19	O
**	O
]	O
.	O
RENAL	O
ULTRASOUND	O
:	O
The	O
left	O
kidney	O
measures	O
10.9	O
cm	O
.	O
The	O
right	O
kidney	O
measures	O
10.7	O
cm	O
.	O
There	O
is	O
no	O
hydronephrosis	O
,	O
stone	O
or	O
mass	O
in	O
either	O
kidney	O
.	O
The	O
bladder	O
is	O
unremarkable	O
.	O
IMPRESSION	O
:	O
Unremarkable	O
renal	O
ultrasound	O
without	O
evidence	O
of	O
hydronephrosis	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1683	O
**	O
]	O
is	O
a	O
72	O
yo	O
M	O
with	O
h	O
/	O
o	O
metastatic	O
rectal	O
CA	O
and	O
SVC	I-Reason
syndrome	O
,	O
now	O
resolved	O
on	O
lovenox	I-Drug
tx	O
,	O
who	O
was	O
admitted	O
to	O
OMED	O
on	O
[	O
**	O
4	O
-	O
19	O
**	O
]	O
with	O
intractable	B-Ade
diarrhea	I-Ade
thought	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
chemo	I-Drug
and	O
transferred	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
on	O
[	O
**	O
4	O
-	O
24	O
**	O
]	O
with	O
BRBPR	O
and	O
hematemesis	O
.	O
GI	O
was	O
consulted	O
and	O
an	O
EGD	O
was	O
performed	O
on	O
[	O
**	O
4	O
-	O
24	O
**	O
]	O
which	O
showed	O
diffuse	B-Reason
erythema	I-Reason
/	I-Reason
ulceration	I-Reason
,	I-Reason
in	I-Reason
esophagus	I-Reason
,	I-Reason
stomach	I-Reason
,	I-Reason
duodenum	I-Reason
.	O
This	O
was	O
thought	O
due	O
to	O
irinotecan	I-Drug
induced	O
GI	B-Ade
toxicity	I-Ade
.	O
They	O
recommended	O
PPI	I-Drug
and	O
carafate	I-Drug
slurry	O
.	O
They	O
were	O
concerned	O
that	O
patient	O
's	O
whole	O
GI	O
tract	O
was	O
diffusely	O
inflamed	O
as	O
was	O
seen	O
on	O
EGD	O
and	O
that	O
the	O
anastamotic	O
site	O
from	O
his	O
colectomy	O
might	O
be	O
a	O
bleeding	O
source	O
;	O
a	O
flex	O
sigmoidoscopy	O
was	O
done	O
on	O
as	O
well	O
and	O
showed	O
as	O
well	O
diffuse	O
ulceration	O
and	O
inflammation	I-Reason
.	O
HCTs	O
and	O
q6H	O
hemodynamics	O
remained	O
stable	O
throughout	O
his	O
hospital	O
course	O
.	O
The	O
patient	O
was	O
started	O
on	O
steroid	I-Drug
enemas	O
and	O
mesalamine	I-Drug
suppositories	O
to	O
decrease	O
inflammation	I-Reason
.	O
The	O
steroid	I-Drug
enemas	O
were	O
discontinued	O
,	O
but	O
the	O
mesalamine	I-Drug
suppositories	O
were	O
continued	O
through	O
to	O
discharge	O
.	O
In	O
total	O
,	O
he	O
received	O
3	O
units	O
PRBCs	I-Drug
and	O
2	O
units	O
of	O
FFP	I-Drug
.	O
Stool	O
cultures	O
revealed	O
no	O
evidence	O
of	O
infection	O
.	O
.	O
On	O
[	O
**	O
4	O
-	O
24	O
**	O
]	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
that	O
2/2	O
bottles	O
of	O
his	O
blood	O
cultures	O
drawn	O
from	O
his	O
portacath	O
were	O
growing	O
GPCs	O
,	O
speciation	O
showed	O
MSSA	O
.	O
He	O
was	O
treated	O
for	O
this	O
with	O
IV	O
vancomycin	I-Drug
,	O
leaving	O
the	O
portacath	O
and	O
PICC	O
in	O
place	O
.	O
Daily	O
surveillance	O
blood	O
cultures	O
were	O
performed	O
and	O
he	O
was	O
noted	O
to	O
clear	O
his	O
bacteremia	I-Reason
on	O
[	O
**	O
4	O
-	O
26	O
**	O
]	O
.	O
Infectious	O
diseases	O
was	O
consulted	O
and	O
the	O
patient	O
was	O
switched	O
to	O
nafcillin	I-Drug
with	O
confirmation	O
of	O
MSSA	I-Reason
.	O
The	O
port	O
-	O
a-cath	O
was	O
removed	O
which	O
was	O
the	O
source	O
of	O
infection	O
.	O
The	O
patient	O
however	O
despite	O
aggressive	O
crystalloid	I-Drug
and	O
colloid	I-Drug
(	O
albumin	I-Drug
,	O
a	O
further	O
2	O
units	O
of	O
blood	I-Drug
)	O
resuscitation	I-Reason
then	O
developed	O
sepsis	O
related	O
acute	O
tubular	O
necrosis	O
.	O
The	O
patient	O
became	O
anuric	O
and	O
nephrology	O
was	O
consulted	O
.	O
Hemodialysis	O
was	O
initiated	O
which	O
the	O
patient	O
tolerated	O
well	O
,	O
and	O
a	O
permanent	O
tunneled	O
catheter	O
line	O
was	O
placed	O
on	O
[	O
**	O
2134-5-7	O
**	O
]	O
.	O
The	O
patient	O
was	O
started	O
on	O
phosphate	B-Drug
binders	I-Drug
,	O
nephrocaps	I-Drug
and	O
erythropoeitin	I-Drug
dosed	O
at	O
hemodialysis	O
.	O
The	O
carafate	I-Drug
was	O
discontinued	O
due	O
to	O
risk	O
of	O
aluminum	B-Ade
toxicity	I-Ade
.	O
The	O
nafcillin	I-Drug
was	O
also	O
changed	O
to	O
Cefazolin	I-Drug
dosed	O
2	O
mg	O
at	O
each	O
[	O
**	O
Date	O
Range	O
2286	O
**	O
]	O
session	O
for	O
ease	B-Reason
of	I-Reason
administration	O
and	O
avoiding	B-Reason
extra	I-Reason
volume	I-Reason
loading	I-Reason
.	O
Should	O
the	O
patient	O
miss	O
[	O
**	O
Initials	O
(	O
NamePattern4	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
2286	O
**	O
]	O
session	O
,	O
extra	O
doses	O
of	O
cefazolin	I-Drug
should	O
be	O
administered	O
as	O
needed	O
.	O
The	O
patient	O
was	O
planned	O
for	O
a	O
28	O
day	O
course	O
of	O
cefazolin	I-Drug
to	O
be	O
finished	O
on	O
[	O
**	O
2134-5-22	O
**	O
]	O
.	O
.	O
Other	O
parts	O
of	O
his	O
hospitalization	O
are	O
outlined	O
by	O
problem	O
below	O
:	O
.	O
#Hypotension	O
/	O
Tachycardia	O
:	O
In	O
setting	O
of	O
extensive	O
diahrrea	O
.	O
Ct	O
torso	O
is	O
without	O
PE	O
or	O
dissection	O
.	O
His	O
BP	O
initally	O
recovered	O
with	O
500cc	O
NS	I-Drug
bolus	O
.	O
Once	O
he	O
had	O
an	O
episode	O
of	O
BRBPR	O
,	O
he	O
became	O
tacycardic	B-Reason
to	I-Reason
the	I-Reason
140s	I-Reason
,	O
with	O
BP	B-Reason
90s	I-Reason
/	I-Reason
60s	I-Reason
.	O
He	O
was	O
bolused	O
NS	I-Drug
and	O
given	O
PRBC	I-Drug
with	O
improved	O
HR	O
to	O
the	O
110s	O
,	O
and	O
BP	O
to	O
120s	O
/	O
80s	O
.	O
.	O
#SVC	O
syndrome	O
:	O
occurred	O
in	O
[	O
**	O
2132	O
**	O
]	O
.	O
s	O
/	O
p	O
TPA	O
infusion	O
followed	O
by	O
venous	O
angioplasty	O
with	O
balloon	O
dilation	O
with	O
resolution	O
of	O
symptoms	O
.	O
He	O
was	O
initially	O
treated	O
with	O
lovenox	I-Drug
(	O
dose	O
recalculated	O
this	O
admission	O
,	O
should	O
be	O
lower	O
than	O
his	O
admission	O
dose	O
)	O
,	O
but	O
this	O
was	O
held	O
secondary	O
to	O
GI	O
bleed	O
.	O
This	O
was	O
not	O
restarted	O
at	O
discharge	O
given	O
the	O
patient	O
's	O
renal	O
failure	O
.	O
.	O
#Diarrhea	O
-	O
the	O
patient	O
continued	O
to	O
have	O
diarrhea	O
that	O
was	O
controlled	O
with	O
titration	O
of	O
his	O
anti-diarrheal	B-Drug
medications	I-Drug
.	O
Infectious	O
sources	O
were	O
ruled	O
out	O
and	O
the	O
cause	O
was	O
likely	O
irinotecan	I-Drug
-	O
induced	O
GI	B-Ade
toxicity	I-Ade
and	O
radiation	B-Ade
proctitis	I-Ade
.	O
#Generalized	O
anasarca	O
-	O
The	O
patient	O
was	O
noted	O
to	O
have	O
an	O
extremely	O
low	O
albumin	O
on	O
admission	O
,	O
likely	O
related	O
to	O
poor	O
nutrition	O
due	O
to	O
his	O
GI	O
pathology	O
.	O
Albumins	O
ranged	O
between	O
2.7	O
and	O
1.9	O
.	O
During	O
volume	O
resuscitation	O
the	O
patient	O
became	O
grossly	O
edematous	O
,	O
and	O
albumin	O
was	O
administered	O
to	O
little	O
effect	O
.	O
His	O
left	O
upper	O
extremity	O
was	O
noted	O
to	O
be	O
more	O
edematous	O
than	O
the	O
rest	O
of	O
his	O
body	O
,	O
and	O
a	O
LUE	O
ultrasound	O
was	O
acquired	O
.	O
This	O
demonstrated	O
no	O
evidence	O
of	O
clot	O
.	O
The	O
patient	O
slowly	O
became	O
less	O
edematous	O
when	O
[	O
**	O
Year	O
(	O
4	O
digits	O
)	O
2286	O
**	O
]	O
was	O
initiated	O
and	O
ultrafiltration	O
was	O
started	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1683	O
**	O
]	O
'	O
code	O
status	O
was	O
confirmed	O
as	O
FULL	O
CODE	O
this	O
hospital	O
admission	O
.	O
Medications	O
on	O
Admission	O
:	O
DIPHENOXYLATE	B-Drug
-	I-Drug
ATROPINE	I-Drug
-	O
2.5	O
mg	O
-	O
0.025	O
mg	O
Tablet	O
-	O
[	O
**	O
1	O
-	O
30	O
**	O
]	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q6hr	O
as	O
needed	O
for	O
diarrhea	I-Reason
ENOXAPARIN	I-Drug
[	O
LOVENOX	I-Drug
]	O
-	O
150	O
mg	O
/	O
mL	O
Syringe	O
-	O
Inject	O
150	O
mg	O
once	O
a	O
day	O
LISINOPRIL	I-Drug
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
10	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
METOPROLOL	B-Drug
SUCCINATE	I-Drug
[	O
TOPROL	B-Drug
XL	I-Drug
]	O
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
METRONIDAZOLE	I-Drug
[	O
METROGEL	I-Drug
]	O
-	O
1	O
%	O
Gel	O
-	O
apply	O
to	O
rash	I-Reason
twice	O
a	O
day	O
PROCHLORPERAZINE	B-Drug
MALEATE	I-Drug
-	O
10	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q6hr	O
as	O
needed	O
for	O
nausea	I-Reason
SIMVASTATIN	I-Drug
-	O
(	O
Prescribed	O
by	O
Other	O
Provider	O
)	O
-	O
20	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
LOPERAMIDE	I-Drug
[	O
IMODIUM	B-Drug
A-D	I-Drug
]	O
-	O
2	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
q4he	O
as	O
needed	O
for	O
diarrhea	I-Reason
PYRIDOXINE	I-Drug
-	O
(	O
OTC	O
)	O
-	O
50	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
once	O
a	O
day	O
Discharge	O
Medications	O
:	O
1	O
.	O
Diphenoxylate	B-Drug
-	I-Drug
Atropine	I-Drug
2.5	O
-	O
0.025	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
diarrhea	I-Reason
.	O
2	O
.	O
Compazine	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
3	O
.	O
Simvastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
4	O
.	O
Loperamide	I-Drug
2	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
diarrhea	I-Reason
.	O
5	O
.	O
Pyridoxine	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
8	O
.	O
Simethicone	I-Drug
80	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
bloating	I-Reason
,	O
gas	I-Reason
.	O
9	O
.	O
Heparin	I-Drug
Flush	O
(	O
10	O
units	O
/	O
ml	O
)	O
2	O
mL	O
IV	O
PRN	O
line	O
flush	O
PICC	O
,	O
heparin	I-Drug
dependent	O
:	O
Flush	O
with	O
10mL	O
Normal	B-Drug
Saline	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
daily	O
and	O
PRN	O
per	O
lumen	O
.	O
10	O
.	O
Ondansetron	I-Drug
4	O
mg	O
IV	O
Q8H	O
:	O
PRN	O
nausea	I-Reason
11	O
.	O
Prochlorperazine	I-Drug
10	O
mg	O
IV	O
Q6H	O
:	O
PRN	O
nausea	I-Reason
12	O
.	O
CefazoLIN	I-Drug
2	O
g	O
IV	O
HD	O
PROTOCOL	O
HD	O
protocol	O
,	O
to	O
be	O
given	O
during	O
hemodialysis	O
13	O
.	O
Diphenoxylate	B-Drug
-	I-Drug
Atropine	I-Drug
2.5	O
-	O
0.025	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
diarrhea	I-Reason
.	O
14	O
.	O
Calcium	B-Drug
Acetate	I-Drug
667	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
W	O
/	O
MEALS	O
(	O
3	O
TIMES	O
A	O
DAY	O
WITH	O
MEALS	O
)	O
.	O
15	O
.	O
B	B-Drug
Complex	I-Drug
-	I-Drug
Vitamin	I-Drug
C	I-Drug
-	I-Drug
Folic	I-Drug
Acid	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
16	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
1,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
4000	O
-	O
[	O
**	O
Numeric	O
Identifier	O
2249	O
**	O
]	O
Unit	O
Injection	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
line	B-Reason
flush	I-Reason
:	O
DWELL	O
PRN	O
line	B-Reason
flush	I-Reason
[	O
**	O
Numeric	O
Identifier	O
**	O
]	O
Catheter	O
(	O
Tunneled	O
2	O
-	O
Lumen	O
)	O
:	O
[	O
**	O
Numeric	O
Identifier	O
**	O
]	O
NURSE	O
ONLY	O
:	O
Withdraw	O
4	O
mL	O
prior	O
to	O
flushing	O
with	O
10	O
mL	O
NS	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
according	O
to	O
volume	O
per	O
lumen	O
.	O
.	O
17	O
.	O
Insulin	B-Drug
Lispro	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Sliding	O
scale	O
units	O
Subcutaneous	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
:	O
2	O
units	O
for	O
101	O
-	O
150	O
4	O
units	O
for	O
151	O
-	O
200	O
6	O
units	O
for	O
201	O
-	O
250	O
8	O
units	O
for	O
251	O
-	O
300	O
10	O
units	O
for	O
301	O
-	O
350	O
12	O
units	O
for	O
351	O
-	O
400	O
.	O
18	O
.	O
Mesalamine	I-Drug
1,000	O
mg	O
Suppository	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
DAILY	O
(	O
Daily	O
)	O
.	O
19	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
20	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
nebulizer	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
dyspnea	I-Reason
.	O
21	O
.	O
Epogen	I-Drug
10,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Hemodialysis	O
Protocol	O
Injection	O
with	O
each	O
[	O
**	O
Numeric	O
Identifier	O
2286	O
**	O
]	O
session	O
.	O
22	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
mL	O
Injection	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
979	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
246	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Rectal	O
cancer	O
Diarrhea	O
Sepsis	O
Acute	O
Renal	O
Failure	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
diarrhea	O
.	O
We	O
believe	O
the	O
diarrhea	I-Ade
was	O
a	O
side	O
effect	O
of	O
the	O
chemotherapy	I-Drug
you	O
had	O
received	O
;	O
it	O
was	O
treated	O
with	O
3	O
anti-diarrheal	B-Drug
medications	I-Drug
.	O
You	O
also	O
have	O
a	O
low	O
blood	O
pressure	O
on	O
admission	O
,	O
this	O
was	O
likely	O
due	O
to	O
dehydration	O
in	O
the	O
setting	O
of	O
diarrhea	O
,	O
and	O
it	O
improved	O
with	O
rehydration	I-Reason
with	O
IV	O
fluids	I-Drug
.	O
Your	O
diarrhea	O
then	O
became	O
bloody	O
,	O
and	O
you	O
also	O
had	O
an	O
episode	O
of	O
vomit	O
with	O
blood	O
in	O
it	O
.	O
As	O
a	O
result	O
,	O
you	O
were	O
transferred	O
to	O
the	O
ICU	O
.	O
You	O
had	O
an	O
upper	O
endoscopy	O
and	O
a	O
sigmoidoscopy	O
,	O
which	O
showed	O
ulceration	B-Ade
in	I-Ade
your	I-Ade
esophagus	O
,	O
stomach	O
and	O
colon	O
.	O
This	O
was	O
thought	O
to	O
be	O
due	O
to	O
the	O
chemotherapy	I-Drug
and	O
radiation	O
that	O
you	O
have	O
been	O
receiving	O
for	O
your	O
colon	B-Reason
cancer	I-Reason
.	O
.	O
While	O
admitted	O
,	O
you	O
also	O
had	O
a	O
severe	O
bacterial	O
infection	O
that	O
got	O
into	O
your	O
blood	O
.	O
This	O
severely	O
damaged	O
your	O
kidneys	O
,	O
requiring	O
you	O
to	O
be	O
started	O
on	O
hemodialysis	O
.	O
You	O
had	O
a	O
permanent	O
[	O
**	O
Location	O
(	O
un	O
)	O
2286	O
**	O
]	O
catheter	O
placed	O
and	O
you	O
will	O
need	O
to	O
continue	O
getting	O
[	O
**	O
Location	O
(	O
un	O
)	O
2286	O
**	O
]	O
3	O
times	O
a	O
week	O
.	O
You	O
were	O
started	O
on	O
several	O
new	O
medications	O
when	O
you	O
were	O
admitted	O
.	O
Nephrocaps	I-Drug
1	O
capsule	O
daily	O
Phos	B-Drug
-	I-Drug
lo	I-Drug
667	O
mg	O
three	O
times	O
a	O
day	O
mesalamine	I-Drug
1000	O
mg	O
suppositories	O
once	O
a	O
day	O
Cefazolin	I-Drug
2g	O
given	O
with	O
hemodialysis	O
pantoprazole	I-Drug
40	O
mg	O
daily	O
Erythropoetin	I-Drug
given	O
with	O
hemodialysis	O
Your	O
metoprolol	I-Drug
was	O
changed	O
from	O
100	O
mg	O
once	O
a	O
day	O
to	O
25	O
mg	O
three	O
times	O
a	O
day	O
Your	O
lisinopril	I-Drug
and	O
enoxaparin	I-Drug
have	O
been	O
discontinued	O
.	O
Followup	O
Instructions	O
:	O
You	O
need	O
to	O
follow	O
up	O
with	O
your	O
outpatient	O
oncologists	O
,	O
Drs.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
discuss	O
any	O
further	O
treatment	O
for	O
you	O
rectal	O
cancer	O
.	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
636	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
Colorectal	O
Cancer	O
Clinic	O
on	O
[	O
**	O
5	O
-	O
31	O
**	O
]	O
at	O
10	O
AM	O
.	O
You	O
can	O
reach	O
the	O
office	O
by	O
calling	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22249	O
**	O
]	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
2747	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
5780	O
**	O
]	O
,	O
RN	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2134-5-24	O
**	O
]	O
10:00	O
Completed	O
by	O
:[	O
**	O
2134-5-12	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2139-10-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2139-11-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2104-1-15	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Ativan	I-Drug
/	O
Keflex	I-Drug
/	O
Sunscreen	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2108	O
**	O
]	O
Chief	O
Complaint	O
:	O
hypothermia	O
,	O
behavioral	O
changes	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
35	O
year	O
-	O
old	O
woman	O
with	O
microcephaly	O
,	O
psychosis	O
,	O
and	O
mental	O
retardation	O
who	O
has	O
been	O
noted	O
by	O
group	O
home	O
members	O
to	O
have	O
increased	O
somnolence	O
,	O
unsteady	O
gait	O
and	O
poor	O
PO	O
intake	O
over	O
the	O
past	O
month	O
in	O
the	O
setting	O
of	O
multiple	O
medication	O
changes	O
.	O
This	O
has	O
prompted	O
consideration	O
for	O
admission	O
to	O
a	O
psychiatric	O
facility	O
in	O
order	O
to	O
change	O
medications	O
,	O
and	O
she	O
was	O
brought	O
to	O
the	O
ED	O
for	O
medical	O
clearance	O
but	O
was	O
found	O
to	O
be	O
hypothermic	O
with	O
a	O
temp	O
of	O
32	O
.	O
At	O
her	O
baseline	O
,	O
she	O
can	O
feed	O
herself	O
and	O
dress	O
herself	O
if	O
given	O
clothes	O
,	O
but	O
she	O
is	O
dependent	O
on	O
others	O
for	O
all	O
other	O
ADLs	O
.	O
She	O
occasionally	O
mutters	O
phrases	O
and	O
most	O
of	O
the	O
time	O
replies	O
to	O
questions	O
with	O
"	O
yes	O
"	O
or	O
"	O
no	O
.	O
"	O
usually	O
she	O
has	O
violent	O
outbursts	O
,	O
and	O
staff	O
has	O
been	O
getting	O
concerned	O
that	O
she	O
seems	O
more	O
sluggish	O
recently	O
.	O
She	O
has	O
had	O
poor	O
urine	O
output	O
over	O
the	O
past	O
week	O
.	O
Has	O
been	O
constipated	O
.	O
She	O
has	O
had	O
a	O
rash	I-Reason
for	O
over	O
a	O
year	O
that	O
was	O
recently	O
biopsied	O
by	O
her	O
PCP	O
and	O
is	O
currently	O
on	O
Fluconazole	I-Drug
.	O
In	O
addition	O
,	O
she	O
has	O
had	O
insomnia	O
,	O
poor	O
oral	O
intake	O
,	O
and	O
has	O
been	O
stumbling	O
/	O
falling	O
to	O
one	O
side	O
when	O
walking	O
.	O
In	O
the	O
past	O
,	O
she	O
has	O
been	O
sent	O
to	O
a	O
psychiatric	O
facility	O
for	O
changes	O
to	O
her	O
medication	O
regimen	O
;	O
she	O
was	O
sent	O
to	O
the	O
ED	O
for	O
medical	O
clearance	O
.	O
In	O
the	O
ED	O
initial	O
vital	O
signs	O
were	O
remarkable	O
for	O
a	O
temperature	O
of	O
32	O
,	O
TSH	O
7.7	O
but	O
otherwise	O
normal	O
labs	O
with	O
lactate	O
,	O
negative	O
UA	O
,	O
CXR	O
and	O
head	O
CT	O
after	O
receiving	O
a	O
total	O
of	O
20	O
mg	O
PO	O
Haldol	I-Drug
.	O
She	O
was	O
placed	O
on	O
a	O
Bair	O
hugger	O
and	O
received	O
2	O
liters	O
of	O
warm	O
NS	I-Drug
with	O
improvement	O
of	O
her	O
temperature	O
to	O
32.9	O
.	O
No	O
nuchal	O
rigidity	O
or	O
signs	O
of	O
infection	O
.	O
She	O
was	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
monitoring	O
and	O
rewarming	O
.	O
At	O
transfer	O
,	O
vitals	O
were	O
32.9	O
(	O
91.2	O
)	O
,	O
71	O
,	O
99/67	O
,	O
13	O
,	O
94	O
%	O
RA	O
.	O
In	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
,	O
the	O
patient	O
was	O
alert	O
,	O
but	O
not	O
responding	O
to	O
questions	O
or	O
commands	O
.	O
The	O
patient	O
was	O
brought	O
back	O
to	O
normal	O
body	O
temperature	O
and	O
then	O
transferred	O
to	O
the	O
floor	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Mental	O
retardation	O
/	O
microcephaly	O
-	O
Mood	O
disorder	O
/	O
bipolar	O
d	O
/	O
o	O
?	O
,	O
last	O
psych	O
hospitalization	O
in	O
[	O
**	O
2129	O
**	O
]	O
-	O
Skin	O
rash	O
since	O
[	O
**	O
2138-5-30	O
**	O
]	O
-	O
Cortical	O
blindness	O
Social	O
History	O
:	O
Has	O
lived	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
511	O
**	O
]	O
Villages	O
group	O
home	O
for	O
>	O
10	O
years	O
.	O
No	O
smoking	O
,	O
drugs	O
.	O
Family	O
History	O
:	O
-	O
Grandfather	O
:	O
heart	O
disease	O
-	O
Brother	O
:	O
asthma	O
-	O
Skin	O
cancer	O
on	O
Mother	O
's	O
side	O
of	O
the	O
family	O
Physical	O
Exam	O
:	O
VS	O
:	O
T	O
93.7	O
rectal	O
,	O
BP	O
119/84	O
,	O
HR	O
78	O
,	O
RR	O
15	O
,	O
SaO2	O
96	O
%	O
RA	O
GEN	O
:	O
Obese	O
lady	O
with	O
shield	O
chest	O
,	O
NAD	O
HEENT	O
:	O
MMM	O
,	O
micrognathia	O
,	O
neck	O
obese	O
,	O
no	O
LAD	O
,	O
lower	O
lip	O
swelling	O
,	O
tongue	O
swelling	O
,	O
no	O
signs	O
of	O
thrush	O
.	O
SKIN	O
:	O
Erythematous	O
patches	O
in	O
pannus	O
and	O
intertriginous	O
areas	O
of	O
the	O
breast	O
,	O
with	O
satellite	O
lesions	O
throughout	O
entire	O
trunk	O
as	O
well	O
as	O
arms	O
,	O
with	O
signs	O
of	O
excoriation	O
CV	O
:	O
RRR	O
,	O
NL	O
S1S2	O
no	O
S3S4	O
MRG	O
PULM	O
:	O
Clear	O
to	O
auscultation	O
anteriorly	O
;	O
unable	O
to	O
auscultate	O
posteriorly	O
as	O
patient	O
does	O
not	O
comply	O
with	O
exam	O
ABD	O
:	O
BS	O
+	O
,	O
soft	O
,	O
NTND	O
,	O
no	O
masses	O
or	O
HSM	O
LIMBS	O
:	O
Trace	O
LE	O
edema	O
,	O
no	O
tremors	O
or	O
asterixis	O
,	O
no	O
clubbing	O
NEURO	O
:	O
Alert	O
,	O
does	O
not	O
comply	O
with	O
exam	O
but	O
face	O
is	O
symmetric	O
,	O
has	O
normal	O
bulk	O
and	O
tone	O
;	O
did	O
not	O
assess	O
gait	O
Pertinent	O
Results	O
:	O
CXR	O
[	O
**	O
2139-10-21	O
**	O
]	O
:	O
IMPRESSION	O
:	O
Low	O
lung	O
volumes	O
with	O
atelectasis	O
.	O
CT	O
HEAD	O
[	O
**	O
2139-10-22	O
**	O
]	O
:	O
Slightly	O
limited	O
by	O
motion	O
,	O
but	O
no	O
acute	O
intracranial	O
hemorrhage	O
.	O
The	O
etiology	O
of	O
mild	O
prominence	O
of	O
the	O
ventricles	O
including	O
temporal	O
horns	O
is	O
not	O
clear	O
.	O
MR	O
can	O
be	O
considered	O
for	O
assessment	O
of	O
parenchymal	O
changes	O
and	O
aqueduct	O
size	O
,	O
if	O
not	O
contra	O
-	O
indicated	O
.	O
[	O
**	O
2139-10-24	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
WBC	O
-	O
6.7	O
RBC	O
-	O
4.22	O
Hgb	O
-	O
12.2	O
Hct	O
-	O
37.1	O
MCV	O
-	O
88	O
MCH	O
-	O
28.9	O
MCHC	O
-	O
32.9	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
94	O
*	O
[	O
**	O
2139-10-21	O
**	O
]	O
03:25	O
PM	O
BLOOD	O
WBC	O
-	O
5.8	O
RBC	O
-	O
4.52	O
Hgb	O
-	O
13.0	O
Hct	O
-	O
38.7	O
MCV	O
-	O
86	O
MCH	O
-	O
28.7	O
MCHC	O
-	O
33.6	O
RDW	O
-	O
15.0	O
Plt	O
Ct	O
-	O
104	O
*	O
[	O
**	O
2139-10-31	O
**	O
]	O
08:00	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
281	O
#	O
[	O
**	O
2139-10-23	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
ESR	O
-	O
49	O
*	O
[	O
**	O
2139-11-2	O
**	O
]	O
09:05	O
PM	O
BLOOD	O
UreaN	O
-	O
12	O
Creat	O
-	O
0.7	O
[	O
**	O
2139-10-21	O
**	O
]	O
03:25	O
PM	O
BLOOD	O
Glucose	O
-	O
80	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.8	O
Na	O
-	O
143	O
K	O
-	O
4.8	O
Cl	O
-	O
107	O
HCO3	O
-	O
28	O
AnGap	O
-	O
13	O
[	O
**	O
2139-10-26	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
ALT	O
-	O
56	O
*	O
AST	O
-	O
59	O
*	O
AlkPhos	O
-	O
173	O
*	O
TotBili	O
-	O
0.3	O
[	O
**	O
2139-10-21	O
**	O
]	O
03:25	O
PM	O
BLOOD	O
ALT	O
-	O
62	O
*	O
AST	O
-	O
44	O
*	O
AlkPhos	O
-	O
156	O
*	O
TotBili	O
-	O
0.2	O
[	O
**	O
2139-10-26	O
**	O
]	O
11:25	O
AM	O
BLOOD	O
TotProt	O
-	O
6.9	O
Calcium	O
-	O
9.9	O
Phos	O
-	O
4.7	O
*	O
Mg	O
-	O
2.2	O
[	O
**	O
2139-10-22	O
**	O
]	O
06:17	O
AM	O
BLOOD	O
Albumin	O
-	O
3.2	O
*	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
2.7	O
Mg	O
-	O
1.8	O
[	O
**	O
2139-10-21	O
**	O
]	O
03:25	O
PM	O
BLOOD	O
TSH	O
-	O
7.7	O
*	O
[	O
**	O
2139-10-22	O
**	O
]	O
06:17	O
AM	O
BLOOD	O
Free	O
T4	O
-	O
1.0	O
[	O
**	O
2139-10-23	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
CRP	O
-	O
53.8	O
*	O
[	O
**	O
2139-10-23	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
C3	O
-	O
148	O
C4	O
-	O
33	O
[	O
**	O
2139-10-23	O
**	O
]	O
05:35	O
PM	O
BLOOD	O
HCV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2139-10-21	O
**	O
]	O
03:31	O
PM	O
BLOOD	O
Lactate	O
-	O
1.4	O
C3D	O
IMMUNE	O
COMPLEX	O
<	O
9	O
0	O
-	O
8	O
mcg	O
/	O
mL	O
[	O
**	O
2139-10-23	O
**	O
]	O
5:47	O
pm	O
URINE	O
Source	O
:	O
Catheter	O
.	O
**	O
FINAL	O
REPORT	O
[	O
**	O
2139-10-25	O
**	O
]	O
**	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2139-10-25	O
**	O
]	O
)	O
:	O
ENTEROCOCCUS	O
SP.	O
.	O
>	O
100,000	O
ORGANISMS	O
/	O
ML	O
.	O
.	O
SENSITIVITIES	O
:	O
MIC	O
expressed	O
in	O
MCG	O
/	O
ML	O
_________________________________________________________	O
ENTEROCOCCUS	O
SP.	O
.	O
|	O
AMPICILLIN	O
------------	O
<	O
=	O
2	O
S	O
NITROFURANTOIN	O
--------	O
<	O
=	O
16	O
S	O
TETRACYCLINE	O
----------	O
=	O
>	O
16	O
R	O
VANCOMYCIN	O
------------	O
1	O
S	O
[	O
**	O
2139-10-28	O
**	O
]	O
RENAL	O
ULTRASOUND	O
:	O
IMPRESSION	O
:	O
No	O
renal	O
or	O
urinary	O
bladder	O
abnormalities	O
.	O
Brief	O
Hospital	O
Course	O
:	O
35	O
year	O
-	O
old	O
woman	O
with	O
mental	O
retardation	O
since	O
childhood	O
presenting	O
with	O
mental	O
status	O
changes	O
,	O
ataxia	O
,	O
poor	O
PO	O
intake	O
,	O
and	O
thrombocytopenia	O
admitted	O
with	O
hypothermia	O
,	O
temperature	O
32C	O
.	O
She	O
was	O
initially	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
where	O
she	O
was	O
warmed	O
up	O
to	O
euthermia	O
and	O
subsequently	O
transferred	O
to	O
the	O
floor	O
.	O
Surveillance	O
for	O
infections	O
was	O
negative	O
.	O
Psychiatry	O
was	O
consulted	O
to	O
assess	O
for	O
possible	O
medication	O
related	O
symptoms	O
.	O
A	O
swollen	O
lower	O
lip	O
and	O
swollen	O
tongue	O
and	O
shortness	O
of	O
breath	O
prompted	O
an	O
eval	O
by	O
ENT	O
to	O
r	O
/	O
o	O
vocal	O
cord	O
edema	O
.	O
Workup	O
for	O
angioedema	O
was	O
initiated	O
.	O
Hypothermia	O
:	O
The	O
duration	O
of	O
her	O
hypothermia	O
is	O
unclear	O
as	O
she	O
previously	O
refused	O
vital	O
signs	O
for	O
weeks	O
.	O
Her	O
hypothermia	O
could	O
have	O
been	O
related	O
to	O
underlying	O
mental	O
retardation	O
and	O
inability	O
to	O
seek	O
warmth	O
or	O
side	O
effect	O
from	O
her	O
antipsychotic	O
medications	O
.	O
Her	O
core	O
temperature	O
increased	O
to	O
the	O
lower	O
range	O
of	O
normal	O
after	O
warming	O
with	O
Bair	O
hugger	O
and	O
receiving	O
2	O
liters	O
of	O
warmed	O
saline	I-Drug
in	O
the	O
ER	O
.	O
SHe	O
did	O
not	O
show	O
evidence	O
of	O
septic	O
physiology	O
.	O
slightly	O
elevated	O
TSH	O
but	O
normal	O
T4	O
indicating	O
sick	O
euthyroid	O
but	O
this	O
is	O
not	O
the	O
cause	O
of	O
the	O
patients	O
hypothermia	O
.	O
Ataxia	O
:	O
She	O
has	O
had	O
ataxia	O
for	O
approximately	O
one	O
month	O
which	O
could	O
be	O
an	O
effect	O
of	O
hypothermia	O
or	O
related	O
to	O
her	O
underlying	O
neurologic	O
disease	O
.	O
She	O
had	O
a	O
head	O
CT	O
that	O
did	O
not	O
show	O
any	O
acute	O
findings	O
.	O
She	O
continued	O
to	O
improve	O
as	O
an	O
inpatient	O
and	O
was	O
walking	O
independently	O
(	O
at	O
her	O
baseline	O
)	O
on	O
her	O
own	O
prior	O
to	O
discharge	O
Poor	O
oral	O
intake	O
:	O
She	O
had	O
poor	O
PO	O
intake	O
at	O
her	O
group	O
home	O
and	O
was	O
seen	O
by	O
speech	O
and	O
swallow	O
who	O
recommended	O
soft	O
solids	O
and	O
thin	O
liquids	O
with	O
meds	O
whole	O
or	O
crushed	O
in	O
puree	O
.	O
Her	O
mental	O
status	O
improved	O
and	O
she	O
was	O
able	O
to	O
take	O
regular	O
diet	O
.	O
Poor	B-Ade
urine	I-Ade
output	I-Ade
:	O
She	O
had	O
poor	O
urine	O
output	O
at	O
group	O
home	O
,	O
but	O
after	O
foley	O
placement	O
she	O
had	O
1200cc	O
urine	O
output	O
.	O
This	O
may	O
be	O
due	O
to	O
a	O
medication	O
side	O
effect	O
(	O
she	O
is	O
on	O
anticholinergics	I-Drug
to	O
prevent	O
side	O
effects	O
from	O
antipsychotics	I-Drug
)	O
.	O
Also	O
has	O
had	O
poor	O
oral	O
intake	O
recently	O
.	O
After	O
her	O
foley	O
was	O
discontinued	O
and	O
she	O
had	O
ongoing	O
urinary	O
retention	O
that	O
required	O
intermittent	O
catheterization	O
.	O
Urology	O
was	O
consulted	O
and	O
recommended	O
scheduled	O
intermittent	O
catheterization	O
and	O
Cystex	I-Drug
tid	O
.	O
Patient	O
frequently	O
refuses	O
catheterization	O
,	O
nurses	O
have	O
had	O
better	O
luck	O
with	O
the	O
catheterization	O
about	O
1	O
-	O
2	O
hours	O
after	O
antipsychotics	I-Drug
given	O
.	O
All	O
anticholinergics	I-Drug
were	O
stopped	O
,	O
including	O
Cogentin	I-Drug
,	O
with	O
some	O
improvement	O
in	O
her	O
bladder	O
volumes	O
.	O
It	O
is	O
unclear	O
if	O
there	O
is	O
a	O
behavioral	O
component	O
to	O
her	O
urinary	B-Ade
retention	I-Ade
.	O
Her	O
urinary	O
retention	O
was	O
of	O
moderate	O
volume	O
and	O
a	O
BUN	O
/	O
Cr	O
were	O
stable	O
(	O
Creatinine	O
0.7	O
)	O
on	O
[	O
**	O
11	O
-	O
2	O
**	O
]	O
,	O
she	O
has	O
outpt	O
urology	O
appt	O
scheduled	O
.	O
Given	O
the	O
urinary	O
retention	O
she	O
is	O
at	O
risk	O
for	O
urinary	O
tract	O
infections	O
,	O
the	O
patient	O
's	O
group	O
home	O
staff	O
was	O
informed	O
of	O
signs	O
of	O
a	O
UTI	O
such	O
as	O
delerium	O
/	O
agitation	O
/	O
other	O
behavioral	O
changes	O
or	O
urinary	O
changes	O
(	O
frequency	O
/	O
odor	O
)	O
which	O
should	O
prompt	O
referral	O
to	O
a	O
physician	O
for	O
workup	O
of	O
UTI	O
.	O
Rash	I-Reason
:	O
She	O
was	O
seen	O
by	O
dermatology	O
who	O
confirmed	O
with	O
scrapings	O
that	O
it	O
was	O
fungal	O
.	O
Patient	O
has	O
been	O
on	O
fluconazole	I-Drug
for	O
this	O
and	O
dermatology	O
recommended	O
swithcing	O
to	O
topical	O
terbinafine	I-Drug
which	O
improved	O
her	O
tinea	O
corporis	O
significantly	O
.	O
She	O
will	O
follow	O
up	O
with	O
dermatology	O
in	O
[	O
**	O
2139-12-30	O
**	O
]	O
.	O
Mental	O
Retardation	O
and	O
agitation	O
:	O
Her	O
home	O
psychiatric	O
medications	O
were	O
continued	O
including	O
a	O
slightly	O
lower	O
dose	O
risperdal	I-Drug
,	O
at	O
5	O
mg	O
po	O
bid	O
.	O
The	O
psychiatric	O
consultants	O
felt	O
that	O
given	O
the	O
patient	O
's	O
behavior	O
has	O
returned	O
to	O
baseline	O
it	O
may	O
be	O
best	O
to	O
avoid	O
transition	O
to	O
clozaril	I-Drug
as	O
previously	O
discussed	O
given	O
the	O
greater	O
propensity	O
for	O
anticholinergic	O
side	O
effects	O
and	O
that	O
if	O
behavioral	O
issues	O
and	O
agitation	O
issues	O
do	O
arise	O
perhaps	O
increasing	O
the	O
dose	O
of	O
risperdal	I-Drug
should	O
be	O
the	O
first	O
step	O
in	O
management	O
rather	O
than	O
an	O
alternative	O
anti-psychotic	I-Reason
.	O
Sick	O
euthyroid	O
:	O
Mild	O
TSH	O
elevation	O
to	O
7.7	O
with	O
normal	O
free	O
T4	O
.	O
This	O
should	O
be	O
repeated	O
as	O
an	O
outpatient	O
to	O
screen	O
for	O
hypothyroidism	O
.	O
Thrombocytopenia	I-Ade
:	O
This	O
could	O
be	O
a	O
side	O
effect	O
of	O
her	O
numerous	O
psychiatric	B-Drug
medications	I-Drug
or	O
fluconazole	I-Drug
.	O
This	O
remained	O
stable	O
during	O
her	O
hospital	O
stay	O
and	O
subsequently	O
improved	O
to	O
normal	O
.	O
Inflammation	O
:	O
she	O
had	O
an	O
elevated	O
ESR	O
and	O
CRP	O
of	O
unclear	O
etiology	O
,	O
very	O
non-specific	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
was	O
negative	O
.	O
Consider	O
repeating	O
these	O
in	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
months	O
after	O
discharge	O
.	O
In	O
regards	O
to	O
returning	O
to	O
normal	O
activity	O
she	O
is	O
cleared	O
to	O
return	O
to	O
her	O
workshop	O
and	O
other	O
normal	O
daily	O
activities	O
as	O
of	O
date	O
of	O
discharge	O
,	O
[	O
**	O
2139-11-3	O
**	O
]	O
.	O
Medications	O
on	O
Admission	O
:	O
-	O
Minerin	I-Drug
dry	O
skin	O
cream	O
-	O
Multivitamin	I-Drug
daily	O
-	O
Zyrtec	I-Drug
10	O
mg	O
qAM	O
-	O
Hydroxyzine	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
-	O
Fluconazole	I-Drug
150	O
mg	O
daily	O
-	O
Risperidone	I-Drug
5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
-	O
Benztropine	I-Drug
1	O
mg	O
TID	O
-	O
Inderal	I-Drug
30	O
mg	O
TID	O
-	O
Ambien	I-Drug
5	O
mg	O
qHS	O
(	O
started	O
[	O
**	O
2139-10-16	O
**	O
]	O
)	O
-	O
Luvox	I-Drug
was	O
discontinued	O
in	O
[	O
**	O
Month	O
(	O
only	O
)	O
216	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
miconazole	B-Drug
nitrate	I-Drug
2	O
%	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
fungal	B-Reason
infection	I-Reason
:	O
apply	O
to	O
under	O
breasts	O
,	O
until	O
rash	O
resolves	O
.	O
2	O
.	O
terbinafine	I-Drug
1	O
%	O
Cream	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Appl	O
Topical	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
apply	O
until	O
rash	I-Reason
resolves	O
,	O
then	O
for	O
an	O
additional	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
weeks	O
.	O
Disp	O
:	O
*	O
qs	O
tube	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
propranolol	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
bisacodyl	I-Drug
10	O
mg	O
Suppository	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Suppository	O
Rectal	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
constipation	I-Reason
:	O
use	O
if	O
colace	I-Drug
and	O
senna	I-Drug
are	O
ineffective	O
.	O
Disp	O
:	O
*	O
10	O
Suppository	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Risperidone	B-Drug
M	I-Drug
-	I-Drug
Tab	I-Drug
1	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
please	O
dispense	O
5	O
mg	O
tabs	O
if	O
available	O
or	O
equivalent	O
dosing	O
.	O
Disp	O
:	O
*	O
300	O
Tablet	O
,	O
Rapid	O
Dissolve	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Hypothermia	O
Agitation	O
Urinary	O
retention	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
low	B-Ade
body	I-Ade
temperature	I-Ade
.	O
This	O
improved	O
with	O
warming	O
in	O
the	O
ICU	O
.	O
This	O
may	O
have	O
been	O
due	O
to	O
your	O
antipsychotic	B-Drug
medications	I-Drug
.	O
You	O
also	O
developed	O
some	O
agitation	O
in	O
the	O
hospital	O
and	O
it	O
was	O
felt	O
that	O
you	O
may	O
benefit	O
from	O
an	O
adjustment	O
in	O
your	O
psychiatric	B-Drug
medications	I-Drug
.	O
You	O
had	O
some	B-Ade
urinary	I-Ade
retention	O
,	O
also	O
likely	O
due	O
to	O
medications	B-Drug
which	I-Drug
required	I-Drug
intermittent	O
catheterization	O
.	O
This	O
problem	O
has	O
improved	O
somewhat	O
but	O
you	O
should	O
still	O
see	O
a	O
urologist	O
,	O
this	O
appointment	O
has	O
been	O
made	O
for	O
you	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
SURGICAL	O
SPECIALTIES	O
When	O
:	O
WEDNESDAY	O
[	O
**	O
2139-12-2	O
**	O
]	O
at	O
2:30	O
PM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
161	O
**	O
]	O
[	O
**	O
Name6	O
(	O
MD	O
)	O
162	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
163	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
921	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Please	O
follow	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
176	O
**	O
]	O
4	O
weeks	O
of	O
your	O
discharge	O
from	O
the	O
hospital	O
.	O
Please	O
follow	O
up	O
with	O
your	O
psychiatrist	O
within	O
4	O
weeks	O
of	O
your	O
discharge	O
from	O
the	O
hospital	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2189-7-21	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2189-7-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2162-11-4	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Bactrim	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
783	O
**	O
]	O
Chief	O
Complaint	O
:	O
Right	O
arm	O
pain	O
and	O
swelling	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Incision	O
and	O
drainage	O
of	O
right	O
forearm	O
abscess	O
on	O
[	O
**	O
2189-7-21	O
**	O
]	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
26	O
yo	O
male	O
with	O
HIV	I-Reason
(	O
CD4	O
11	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
)	O
non	O
compliant	O
with	O
HAART	I-Drug
,	O
with	O
recent	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
admission	O
with	O
purigo	B-Reason
nodularis	I-Reason
and	O
treated	O
with	O
sarna	I-Drug
and	O
benadryl	I-Drug
,	O
now	O
c	O
/	O
o	O
3	O
-	O
days	O
of	O
increased	O
right	B-Reason
arm	I-Reason
pain	I-Reason
and	O
swelling	O
.	O
No	O
history	O
of	O
trauma	O
to	O
the	O
area	O
.	O
Pt	O
.	O
denied	O
scratching	O
area	O
or	O
IVDU	O
.	O
In	O
ED	O
,	O
afebrile	O
,	O
I&D	O
'd	O
,	O
started	O
on	O
vanco	I-Drug
and	O
levofloxacin	I-Drug
.	O
Past	O
Medical	O
History	O
:	O
1	O
)	O
HIV	O
diagnosed	O
in	O
[	O
**	O
2183	O
**	O
]	O
last	O
CD4	O
count	O
11	O
and	O
HIV	O
VL	O
4320	O
in	O
5	O
/	O
[	O
**	O
2189	O
**	O
]	O
.	O
2	O
)	O
History	O
of	O
Secondary	O
Syphillis	O
in	O
[	O
**	O
2187	O
**	O
]	O
treated	O
with	O
PCN	O
3	O
)	O
s	O
/	O
p	O
tonsillectomy	O
4	O
)	O
H	O
/	O
O	O
staph	O
skin	O
infections	O
5	O
)	O
Depression	O
Social	O
History	O
:	O
Patient	O
living	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
4398	O
**	O
]	O
with	O
friend	O
(	O
sleeps	O
on	O
the	O
couch	O
)	O
.	O
He	O
smokes	O
about	O
1ppd	O
since	O
[	O
**	O
01	O
**	O
]	O
years	O
old	O
.	O
He	O
admits	O
to	O
marijuana	O
use	O
,	O
and	O
history	O
of	O
crystal	O
meth	O
use	O
.	O
He	O
denies	O
any	O
IVDU	O
.	O
He	O
states	O
that	O
he	O
is	O
currently	O
not	O
sexually	O
active	O
.	O
He	O
denies	O
any	O
etoh	O
use	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
T	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
F	O
P	O
:	O
88	O
R	O
:	O
16	O
BP	O
:	O
118/78	O
SaO2	O
:	O
99	O
%	O
RA	O
General	O
:	O
awake	O
,	O
alert	O
,	O
NAD	O
HEENT	O
:	O
MMM	O
Neck	O
:	O
supple	O
Pulmonary	O
:	O
lungs	O
CTA	O
Cardiac	O
:	O
RRR	O
,	O
S1S2	O
,	O
no	O
murmur	O
Abdomen	O
:	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
active	O
BS	O
Extremities	O
:	O
1.5	O
well	O
-	O
circumscribed	O
lesion	O
over	O
dorsal	O
aspect	O
of	O
right	O
forearm	O
with	O
surrounding	O
erythema	O
,	O
tenderness	O
halfway	O
up	O
arm	O
proximally	O
and	O
wrist	O
distally	O
.	O
Full	O
strength	O
of	O
wrist	O
and	O
finger	O
flexors	O
and	O
extensors	O
on	O
right	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2189-7-21	O
**	O
]	O
09:00	O
PM	O
WBC	O
-	O
4.9	O
RBC	O
-	O
4.14	O
*	O
HGB	O
-	O
13.1	O
*	O
HCT	O
-	O
37.2	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
31.7	O
MCHC	O
-	O
35.3	O
*	O
RDW	O
-	O
14.7	O
[	O
**	O
2189-7-21	O
**	O
]	O
09:00	O
PM	O
PLT	O
COUNT	O
-	O
155	O
[	O
**	O
2189-7-21	O
**	O
]	O
09:00	O
PM	O
NEUTS	O
-	O
69.9	O
LYMPHS	O
-	O
17.1	O
*	O
MONOS	O
-	O
11.6	O
*	O
EOS	O
-	O
1.2	O
BASOS	O
-	O
0.2	O
[	O
**	O
2189-7-21	O
**	O
]	O
09:00	O
PM	O
GLUCOSE	O
-	O
95	O
UREA	O
N	O
-	O
12	O
CREAT	O
-	O
0.8	O
SODIUM	O
-	O
139	O
POTASSIUM	O
-	O
4.3	O
CHLORIDE	O
-	O
102	O
TOTAL	O
CO2	O
-	O
29	O
ANION	O
GAP	O
-	O
12	O
[	O
**	O
2189-7-21	O
**	O
]	O
10:21	O
PM	O
LACTATE	O
-	O
0.8	O
CMV	O
Viral	O
Load	O
(	O
Final	O
[	O
**	O
2189-7-27	O
**	O
]	O
)	O
:	O
CMV	O
DNA	O
not	O
detected	O
.	O
[	O
**	O
2189-7-22	O
**	O
]	O
5:15	O
pm	O
BLOOD	O
CULTURE	O
AEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2189-7-28	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2189-7-28	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
.	O
[	O
**	O
2189-7-22	O
**	O
]	O
1:15	O
pm	O
BLOOD	O
CULTURE	O
AEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2189-7-28	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2189-7-28	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
Brief	O
Hospital	O
Course	O
:	O
1	O
.	O
ANAPHYLAXIS	I-Ade
TO	O
BACTRIM	I-Drug
:	O
Patient	O
developed	O
fever	I-Ade
/	O
tachycardia	I-Ade
/	O
hypotension	I-Ade
on	O
hospital	O
day	O
#	O
2	O
;	O
initial	O
suspicion	O
for	O
sepsis	O
syndrome	O
,	O
however	O
blood	O
cultures	O
remained	O
negative	O
and	O
hemodynamic	O
recovery	O
achieved	O
with	O
massive	O
fluid	O
resuscitation	O
in	O
the	O
ICU	O
-	O
of	O
note	O
,	O
patient	O
had	O
received	O
dose	O
of	O
Bactrim	I-Drug
for	O
PCP	B-Reason
prophylaxis	I-Reason
preceding	O
his	O
hypotension	I-Ade
.	O
A	O
diffuse	B-Ade
rash	I-Ade
was	O
transiently	O
noted	O
in	O
the	O
ICU	O
.	O
Upon	O
return	O
to	O
the	O
floor	O
,	O
he	O
received	O
an	O
additional	O
dose	O
of	O
Bactrim	I-Drug
-	O
with	O
recurrence	O
of	O
fever	I-Ade
/	O
tachycardia	I-Ade
/	O
hypotension	I-Ade
,	O
again	O
requiring	O
ICU	O
stay	O
for	O
massive	O
fluid	O
resuscitation	O
.	O
Although	O
no	O
airway	O
compromise	O
was	O
noted	O
in	O
either	O
case	O
,	O
there	O
is	O
certainty	O
based	O
on	O
stereotyped	O
reaction	O
immediately	O
following	O
Bactrim	I-Drug
exposure	O
that	O
patient	O
experiences	O
anaphylactic	B-Ade
-	I-Ade
type	I-Ade
reaction	O
to	O
Bactrim	I-Drug
,	O
which	O
has	O
since	O
been	O
listed	O
as	O
a	O
serious	O
allergy	O
.	O
.	O
2	O
.	O
cellulitis	I-Reason
/	O
abscess	I-Reason
-	O
R	O
forearm	O
wound	O
culture	O
grew	O
MSSA	I-Reason
.	O
Pt	O
was	O
initially	O
started	O
on	O
vanco	I-Drug
and	O
linezolid	I-Drug
in	O
MICU	O
to	O
empirically	O
cover	O
MRSA	I-Reason
and	O
toxin	O
production	O
,	O
changed	O
to	O
oxacillin	I-Drug
and	O
clindamycin	I-Drug
per	O
ID	O
recs	O
after	O
sensitivy	O
inforamation	O
available	O
.	O
Surgery	O
drained	O
the	O
wound	O
and	O
packed	O
with	O
wet	O
to	O
dry	O
dressings	O
changed	O
tid	O
.	O
Erythema	O
over	O
R	O
forearm	O
decreased	O
over	O
stay	O
in	O
MICU	O
.	O
Pain	I-Reason
controlled	O
with	O
prn	O
morphine	I-Drug
in	O
MICU	O
.	O
-	O
on	O
the	O
floor	O
,	O
pt	O
's	O
erythema	O
around	O
the	O
site	O
improved	O
slowly	O
.	O
Surgery	O
removed	O
the	O
wick	O
.	O
and	O
started	O
wet	O
to	O
dry	O
dressings	O
.	O
-	O
per	O
ID	O
,	O
Use	O
Oxacillin	I-Drug
for	O
MSSA	B-Reason
coverage	I-Reason
and	O
Clinda	I-Drug
,	O
which	O
is	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
for	O
prevention	B-Reason
of	I-Reason
toxin	I-Reason
production	I-Reason
,	O
initially	O
.	O
After	O
5	O
days	O
clinda	I-Drug
was	O
stopped	O
and	O
pt	O
was	O
switched	O
over	O
to	O
Diclox	I-Drug
PO	O
and	O
sent	O
home	O
with	O
PO	O
antibiotics	I-Drug
.	O
-	O
Pt	O
will	O
f	O
/	O
u	O
with	O
Surgery	O
in	O
1	O
wk	O
of	O
discharge	O
.	O
-	O
ID	O
will	O
f	O
/	O
u	O
on	O
TSST	O
toxin	O
.	O
.	O
3	O
.	O
"	O
rash	I-Ade
"	O
-	O
in	O
MICU	O
pt	O
became	O
pink	O
throughout	O
the	O
body	O
/	O
face	O
.	O
?	O
drug	O
reaction	O
versus	O
bacterial	O
toxin	O
.	O
We	O
infused	O
vanco	I-Drug
slowly	O
(	O
over	O
2	O
hours	O
)	O
in	O
case	O
of	O
red	B-Ade
man	I-Ade
syndrome	I-Ade
.	O
Also	O
decided	O
to	O
hold	O
Bactrim	I-Drug
in	O
case	O
allergy	O
.	O
The	O
following	O
day	O
the	O
pt	O
appeared	O
less	O
pink	O
and	O
it	O
the	O
etiology	O
thus	O
remains	O
unclear	O
.	O
-	O
Once	O
stable	O
pt	O
was	O
given	O
bactrim	I-Drug
1000	O
mg	O
SS	O
.	O
Pt	O
became	O
hypotensive	I-Ade
and	O
needed	O
to	O
be	O
admitted	O
the	O
ICU	O
again	O
,	O
so	O
this	O
likely	O
anaphylactic	B-Ade
reaction	I-Ade
.	O
.	O
4	O
.	O
HIV	B-Reason
/	I-Reason
AIDS	I-Reason
-	O
CD4	O
11	O
as	O
of	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
,	O
viral	O
load	O
4320	O
as	O
of	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
.	O
pt	O
not	O
on	O
HAART	I-Drug
because	O
of	O
non-compliance	O
.	O
Per	O
ID	O
recs	O
did	O
NOT	O
start	O
on	O
HAART	I-Drug
in	O
hospital	O
but	O
will	O
recommend	O
follow	O
up	O
as	O
outpatient	O
to	O
do	O
so	O
.	O
Had	O
started	O
pt	O
on	O
Bactrim	I-Drug
as	O
prophylaxis	I-Reason
but	O
stopped	O
after	O
two	O
days	O
after	O
pt	O
's	O
skin	B-Ade
became	I-Ade
pink	I-Ade
all	I-Ade
over	I-Ade
in	O
case	O
of	O
allergic	O
rx	O
.	O
-	O
Would	O
not	O
use	O
Bactrim	I-Drug
for	O
PCP	B-Reason
prophylaxis	I-Reason
in	O
this	O
pt	O
.	O
Per	O
ID	O
may	O
use	O
dapsone	B-Drug
100	O
mg	O
po	O
Daily	O
after	O
G6PD	O
results	O
come	O
back	O
negative	O
-	O
No	O
azithromycin	I-Drug
for	O
now	O
for	O
MAC	B-Reason
prophylaxis	I-Reason
as	O
ID	O
concerned	O
that	O
he	O
may	O
already	O
have	O
disseminated	O
MAC	O
.	O
-	O
f	O
/	O
u	O
Mycolytic	B-Reason
cultures	I-Reason
in	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
and	O
if	O
neg	O
can	O
start	O
on	O
azithromycin	I-Drug
-	O
Pt	O
.	O
will	O
f	O
/	O
u	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
[	O
**	O
Hospital	O
**	O
]	O
clinic	O
.	O
Medications	O
on	O
Admission	O
:	O
None	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
MSSA	B-Reason
Cellulitis	I-Reason
ANAPHYLAXIS	I-Ade
TO	O
BACTRIM	I-Drug
Discharge	O
Condition	O
:	O
To	O
home	O
in	O
stable	O
condition	O
on	O
oral	O
antibotics	I-Drug
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
734	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
735	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
799	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2189-7-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2122-9-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2122-9-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2059-1-8	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Percocet	I-Drug
/	O
Motrin	I-Drug
/	O
Nsaids	I-Drug
/	O
Aspirin	I-Drug
/	O
Dilantin	I-Drug
/	O
Ativan	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1973	O
**	O
]	O
Chief	O
Complaint	O
:	O
Altered	O
mental	O
status	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Intubation	O
History	O
of	O
Present	O
Illness	O
:	O
63F	O
with	O
multiple	O
medical	O
problems	O
and	O
multiple	O
admissions	O
for	O
altered	O
mental	O
status	O
presenting	O
with	O
abdominal	O
pain	O
and	O
altered	O
mental	O
status	O
.	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
1834	O
**	O
]	O
exploratory	O
laparotomy	O
on	O
[	O
**	O
2122-9-11	O
**	O
]	O
and	O
was	O
found	O
to	O
have	O
benign	O
cecal	O
pneumatosis	O
.	O
The	O
patient	O
presents	O
now	O
for	O
progressive	O
confusion	O
and	O
decreased	O
mental	O
acuity	O
.	O
The	O
family	O
is	O
not	O
available	O
to	O
discuss	O
their	O
concerns	O
and	O
the	O
patient	O
complains	O
of	O
unchanged	O
abdominal	O
pain	O
.	O
In	O
the	O
ED	O
her	O
vitals	O
were	O
98.2	O
99123/39	O
17	O
99	O
%	O
RA	O
.	O
FSG	O
was	O
86	O
on	O
arrival	O
.	O
Exam	O
showed	O
A+O	O
x	O
1	O
.	O
Labs	O
were	O
c	O
/	O
w	O
ESRD	O
,	O
with	O
AG	O
acidosis	O
,	O
but	O
no	O
hyperkalemia	O
.	O
Neurology	O
was	O
consulted	O
given	O
the	O
AMS	O
,	O
and	O
felt	O
it	O
was	O
due	O
to	O
a	O
toxic	O
-	O
metabolic	O
encephalopathy	O
and	O
not	O
a	O
central	O
insult	O
or	O
seizure	O
.	O
CXR	O
was	O
unrevealing	O
except	O
for	O
LLL	O
atelectasis	O
.	O
No	O
urine	O
able	O
to	O
be	O
obtained	O
but	O
blood	O
cultures	O
were	O
sent	O
.	O
A	O
CT	O
head	O
was	O
negative	O
.	O
A	O
CT	O
abdomen	O
and	O
pelvis	O
was	O
obtained	O
which	O
showed	O
no	O
acute	O
process	O
or	O
abscess	O
,	O
but	O
a	O
small	O
hematoma	O
/	O
stranding	O
in	O
the	O
anterior	O
subcutaneous	O
tissues	O
and	O
likely	O
also	O
left	O
rectus	O
,	O
c	O
/	O
w	O
recent	O
surgery	O
.	O
Her	O
HR	B-Reason
did	I-Reason
increase	I-Reason
to	O
the	O
140s	O
in	O
the	O
ED	O
,	O
responded	O
to	O
IV	O
labetolol	I-Drug
,	O
but	O
pressure	I-Ade
dropped	O
.	O
This	O
responded	O
to	O
IVF	I-Drug
.	O
She	O
was	O
given	O
250	O
mg	O
of	O
levetiracetam	I-Drug
and	O
admitted	O
to	O
medicine	O
for	O
further	O
workup	O
of	O
AMS	O
and	O
correction	O
of	O
electrolytes	O
.	O
Past	O
Medical	O
History	O
:	O
PMH	O
:	O
1	O
.	O
Multiple	O
admission	O
with	O
altered	O
MS	O
recently	O
(	O
[	O
**	O
10	O
-	O
13	O
**	O
]	O
)	O
-	O
with	O
recent	O
extensive	O
neurological	O
workup	O
revealing	O
multifocal	O
etiology	O
likely	O
due	O
to	O
HD	O
fluid	O
/	O
electrolyte	O
shifts	O
,	O
?	O
uremia	O
prior	O
to	O
HD	O
,	O
also	O
component	O
of	O
vascular	O
dementia	O
.	O
Started	O
on	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
13401	O
**	O
]	O
[	O
**	O
9	O
-	O
14	O
**	O
]	O
.	O
2	O
.	O
Diabetes	O
mellitus	O
.	O
3	O
End	O
-	O
stage	O
renal	O
disease	O
secondary	O
to	O
diabetes	O
mellitus	O
s	O
/	O
p	O
failed	O
dual	O
extended	O
-	O
criteria	O
donor	O
renal	O
transplant	O
(	O
BK	O
virus	O
nephropathy	O
)	O
4	O
.	O
Hemodialysis	O
.	O
5	O
.	O
Hypertension	O
.	O
6	O
.	O
Hyperlipidemia	O
.	O
7	O
.	O
Thrombosis	O
of	O
bilateral	O
IVJ	O
(	O
catheter	O
placement	O
)	O
--	O
DVT	I-Reason
associated	O
with	O
HD	O
catheter	O
RUE	O
on	O
anticoagulation	B-Drug
(	I-Drug
Coumadin	I-Drug
)	I-Drug
--	O
balloon	O
angioplasty	O
performed	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
.	O
8	O
.	O
Osteoarthritis	O
.	O
9	O
.	O
PER	O
OMR	O
NOTES	O
(	O
?	O
)	O
-	O
Arthritis	O
of	O
the	O
left	O
knee	O
at	O
age	O
nine	O
,	O
treated	O
with	O
ACTH	O
resulting	O
in	O
secondary	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
.	O
She	O
was	O
diagnosed	O
with	O
rheumatic	O
fever	O
.	O
10	O
.	O
h	O
/	O
o	O
Trach	O
and	O
PEG	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
(	O
reversed	O
[	O
**	O
2	O
-	O
13	O
**	O
]	O
)	O
.	O
11	O
.	O
h	O
/	O
o	O
L	O
tension	O
pneumothorax	O
[	O
**	O
2	O
-	O
7	O
**	O
]	O
intubation	O
.	O
Past	O
Surgical	O
History	O
:	O
1	O
.	O
Kidney	O
transplant	O
in	O
[	O
**	O
2119	O
**	O
]	O
b	O
/	O
l	O
in	O
RLQ	O
2	O
.	O
Left	O
arm	O
AV	O
fistula	O
for	O
dialysis	O
.	O
3	O
.	O
Removal	O
of	O
remnant	O
of	O
AV	O
fistula	O
,	O
left	O
arm	O
.	O
4	O
.	O
Catheter	O
placement	O
for	O
hemodialysis	O
.	O
5	O
.	O
Low	O
back	O
surgery	O
(	O
unspecified	O
)	O
Social	O
History	O
:	O
The	O
patient	O
smokes	O
half	O
a	O
pack	O
of	O
cigarettes	O
a	O
day	O
for	O
the	O
last	O
20	O
years	O
.	O
She	O
does	O
not	O
drink	O
alcohol	O
or	O
has	O
ever	O
experienced	O
with	O
recreational	O
drugs	O
,	O
has	O
no	O
tattoos	O
.	O
The	O
patient	O
has	O
had	O
transfusions	O
in	O
[	O
**	O
2119	O
**	O
]	O
and	O
[	O
**	O
2120	O
**	O
]	O
.	O
The	O
patient	O
is	O
a	O
homemaker	O
.	O
The	O
patient	O
has	O
experienced	O
economic	O
problems	O
lately	O
.	O
.	O
Family	O
History	O
:	O
Family	O
History	O
:	O
From	O
prior	O
d	O
/	O
c	O
summary	O
Mother	O
and	O
sister	O
with	O
diabetic	O
mellitus	O
.	O
Kidney	O
failure	O
in	O
mother	O
,	O
sister	O
Physical	O
Exam	O
:	O
On	O
admission	O
to	O
ICU	O
PE	O
:	O
intubated	O
,	O
sedated	O
,	O
NAD	O
VS	O
:	O
T	O
98.0	O
BP	O
157/64	O
--	O
>	O
80s	O
/	O
40s	O
with	O
propofol	O
HR	O
96	O
RR	O
12	O
,	O
100	O
%	O
AC	O
100	O
%	O
500	O
x	O
20	O
5	O
General	O
:	O
intubated	O
,	O
sedated	O
HEENT	O
:	O
tongue	O
is	O
swollen	O
and	O
protruding	O
from	O
her	O
mouth	O
,	O
blood	O
visible	O
around	O
ET	O
tube	O
,	O
lips	O
swollen	O
.	O
L	O
pupil	O
briskly	O
reactive	O
to	O
light	O
from	O
3	O
mm	O
--	O
>	O
1	O
mm	O
;	O
R	O
pupil	O
is	O
sluggish	O
,	O
3	O
mm	O
--	O
>	O
2	O
mm	O
.	O
anicteric	O
.	O
NECK	O
:	O
no	O
JVD	O
,	O
supple	O
CV	O
:	O
+	O
s1s2	O
RRR	O
2/6	O
systolic	O
murmur	O
,	O
no	O
R	O
/	O
G.	O
+	O
L.sided	O
tunnel	O
cath	O
no	O
erythema	O
,	O
C	O
/	O
D	O
/	O
I	O
,	O
currently	O
accessed	O
/	O
receiveing	O
IVF	O
.	O
PULM	O
:	O
CTA	O
B	O
/	O
L	O
ABD	O
:	O
+	O
bs	O
,	O
midline	O
inscision	O
c	O
/	O
d	O
/	O
i	O
,	O
staples	O
in	O
place	O
,	O
soft	O
,	O
ND	O
.	O
EXT	O
:	O
no	O
C	O
/	O
C	O
/	O
edema	O
2	O
+	O
pulses	O
b	O
/	O
l	O
NEURO	O
:	O
intubated	O
/	O
sedated	O
.	O
moves	O
all	O
4	O
.	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:00	O
PM	O
PLT	O
COUNT	O
-	O
415	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:00	O
PM	O
NEUTS	O
-	O
67.4	O
LYMPHS	O
-	O
20.1	O
MONOS	O
-	O
9.8	O
EOS	O
-	O
2.6	O
BASOS	O
-	O
0.1	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:00	O
PM	O
WBC	O
-	O
8.3	O
RBC	O
-	O
2.72	O
*	O
HGB	O
-	O
9.1	O
*	O
HCT	O
-	O
27.7	O
*	O
MCV	O
-	O
102	O
*	O
MCH	O
-	O
33.3	O
*	O
MCHC	O
-	O
32.7	O
RDW	O
-	O
16.1	O
*	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:00	O
PM	O
ACETMNPHN	O
-	O
NEG	O
bnzodzpn	O
-	O
NEG	O
barbitrt	O
-	O
NEG	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:00	O
PM	O
CALCIUM	O
-	O
9.7	O
PHOSPHATE	O
-	O
8.0	O
*	O
#	O
MAGNESIUM	O
-	O
2.5	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:00	O
PM	O
GLUCOSE	O
-	O
58	O
*	O
UREA	O
N	O
-	O
49	O
*	O
CREAT	O
-	O
13.8	O
*	O
#	O
SODIUM	O
-	O
136	O
POTASSIUM	O
-	O
6.8	O
*	O
CHLORIDE	O
-	O
99	O
TOTAL	O
CO2	O
-	O
21	O
*	O
ANION	O
GAP	O
-	O
23	O
*	O
[	O
**	O
2122-9-21	O
**	O
]	O
04:09	O
PM	O
LACTATE	O
-	O
1.4	O
K	O
+	O
-	O
4.6	O
[	O
**	O
2122-9-21	O
**	O
]	O
05:24	O
PM	O
PT	O
-	O
18.3	O
*	O
PTT	O
-	O
29.2	O
INR	O
(	O
PT	O
)	O
-	O
1.7	O
*	O
[	O
**	O
2122-9-22	O
**	O
]	O
06:50	O
AM	O
PLT	O
COUNT	O
-	O
421	O
[	O
**	O
2122-9-22	O
**	O
]	O
06:50	O
AM	O
WBC	O
-	O
8.5	O
RBC	O
-	O
2.83	O
*	O
HGB	O
-	O
9.2	O
*	O
HCT	O
-	O
29.4	O
*	O
MCV	O
-	O
104	O
*	O
MCH	O
-	O
32.7	O
*	O
MCHC	O
-	O
31.4	O
RDW	O
-	O
15.5	O
[	O
**	O
9	O
-	O
21	O
**	O
]	O
CT	O
ABD	O
/	O
PELVIS	O
:	O
no	O
acute	O
process	O
,	O
diverticulosis	O
,	O
extensive	O
atherosclerotic	O
changes	O
,	O
left	O
anterior	O
subcutaneous	O
tissue	O
stranding	O
with	O
hematoma	O
-	O
post	O
surgical	O
,	O
extensive	O
collateral	O
circulation	O
,	O
suggestive	O
of	O
an	O
upper	O
extremity	O
thrombus	O
.	O
CT	O
HEAD	O
(	O
noncontrast	O
)	O
[	O
**	O
9	O
-	O
21	O
**	O
]	O
:	O
no	O
acute	O
intracranial	O
process	O
,	O
multiple	O
lacunar	O
infarcts	O
,	O
chronic	O
small	O
vessel	O
ischemic	O
disease	O
(	O
unchanged	O
)	O
EEG	O
:	O
This	O
is	O
an	O
abnormal	O
24	O
-	O
hour	O
video	O
EEG	O
telemetry	O
in	O
the	O
waking	O
and	O
sleeping	O
states	O
due	O
to	O
the	O
occasional	O
left	O
mid-temporal	O
sharp	O
waves	O
suggestive	O
of	O
a	O
potential	O
focus	O
of	O
epileptogenesis	O
.	O
In	O
addition	O
,	O
there	O
were	O
bursts	O
of	O
generalized	O
delta	O
frequency	O
slowing	O
suggestive	O
of	O
midline	O
subcortical	O
dysfunction	O
.	O
Nonetheless	O
,	O
there	O
were	O
no	O
electrographic	O
seizures	O
and	O
no	O
pushbutton	O
activations	O
noted	O
.	O
[	O
**	O
2122-9-29	O
**	O
]	O
01:30	O
PM	O
BLOOD	O
WBC	O
-	O
6.4	O
RBC	O
-	O
3.28	O
*	O
Hgb	O
-	O
10.9	O
*	O
Hct	O
-	O
33.7	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
33.3	O
*	O
MCHC	O
-	O
32.4	O
RDW	O
-	O
16.6	O
*	O
Plt	O
Ct	O
-	O
470	O
*	O
[	O
**	O
2122-9-29	O
**	O
]	O
01:30	O
PM	O
BLOOD	O
Plt	O
Ct	O
-	O
470	O
*	O
[	O
**	O
2122-9-29	O
**	O
]	O
01:30	O
PM	O
BLOOD	O
PT	O
-	O
27.6	O
*	O
PTT	O
-	O
131.8	O
*	O
INR	O
(	O
PT	O
)	O
-	O
2.8	O
*	O
[	O
**	O
2122-9-29	O
**	O
]	O
01:30	O
PM	O
BLOOD	O
Glucose	O
-	O
134	O
*	O
UreaN	O
-	O
36	O
*	O
Creat	O
-	O
9.5	O
*	O
#	O
Na	O
-	O
136	O
K	O
-	O
3.7	O
Cl	O
-	O
97	O
HCO3	O
-	O
26	O
AnGap	O
-	O
17	O
[	O
**	O
2122-9-29	O
**	O
]	O
01:30	O
PM	O
BLOOD	O
Calcium	O
-	O
8.6	O
Phos	O
-	O
5.8	O
*	O
Mg	O
-	O
2.2	O
Brief	O
Hospital	O
Course	O
:	O
1	O
.	O
Altered	B-Ade
mental	I-Ade
status	I-Ade
/	O
seizure	O
/	O
intubation	O
:	O
most	O
likely	O
etiology	O
is	O
multiple	O
missed	O
hemodialysis	O
sessions	O
/	O
uremia	O
.	O
It	O
is	O
possible	O
the	O
Tylenol	I-Drug
with	O
codeine	O
she	O
was	O
taking	O
for	O
post	I-Reason
operative	O
pain	O
control	O
contributed	O
.	O
The	O
morning	O
following	O
admission	O
she	O
had	O
an	O
episode	O
of	O
decreased	O
responsiveness	O
,	O
clonic	O
jerks	O
,	O
lip	O
smacking	O
and	O
hand	O
automatisms	O
.	O
She	O
was	O
evaluated	O
by	O
neurology	O
and	O
was	O
given	O
Ativan	I-Drug
and	O
Depakote	I-Drug
for	O
complex	B-Reason
partial	I-Reason
seizure	O
.	O
Approximately	O
1	O
hour	O
after	O
this	O
she	O
became	O
unresponsive	O
and	O
her	O
tongue	O
was	O
swollen	O
.	O
She	O
was	O
intubated	O
for	O
airway	O
protection	O
due	O
to	O
angioedema	O
.	O
Her	O
mental	O
status	O
normalized	O
(	O
thought	O
to	O
be	O
related	O
to	O
post-ictal	O
state	O
and	O
medications	O
)	O
,	O
EEG	O
was	O
negative	O
for	O
status	O
epilepticus	O
,	O
head	O
CT	O
and	O
toxicology	O
screens	O
were	O
negative	O
.	O
The	O
patient	O
required	O
daily	O
dialysis	O
from	O
[	O
**	O
Date	O
range	O
(	O
3	O
)	O
45315	O
**	O
]	O
and	O
her	O
mental	O
status	O
normalized	O
and	O
was	O
stable	O
for	O
several	O
days	O
at	O
discharge	O
.	O
2	O
.	O
Angioedema	O
/	O
respiratory	O
failure	O
:	O
Her	O
tongue	O
was	O
noted	O
to	O
be	O
swollen	O
prior	O
to	O
the	O
administration	O
of	O
Depakote	I-Drug
during	O
suctioning	O
prior	O
to	O
intubation	O
.	O
The	O
angioedema	I-Ade
seemed	O
to	O
correlate	O
with	O
the	O
Ativan	I-Drug
administration	O
.	O
There	O
is	O
a	O
report	O
of	O
angioedema	I-Ade
in	O
the	O
past	O
,	O
attributed	O
to	O
Dilantin	I-Drug
--	O
but	O
she	O
received	O
Ativan	I-Drug
at	O
that	O
time	O
as	O
well	O
.	O
She	O
was	O
treated	O
for	O
24	O
hours	O
with	O
steroids	I-Drug
with	O
remarkable	O
improvement	O
.	O
Her	O
lisinopril	I-Drug
was	O
also	O
discontinued	O
.	O
Her	O
intubation	O
was	O
for	O
airway	O
protection	O
in	O
the	O
setting	O
of	O
altered	O
mental	O
status	O
and	O
angioedema	O
.	O
She	O
had	O
persistent	O
apneic	O
episodes	O
on	O
the	O
ventilator	O
and	O
never	O
developed	O
a	O
cuff	O
leak	O
.	O
She	O
has	O
presumed	O
tracheal	O
stenosis	O
from	O
prior	O
tracheostomy	O
.	O
She	O
was	O
successfully	O
extubated	O
in	O
the	O
presence	O
of	O
anesthesia	I-Drug
on	O
[	O
**	O
2122-9-25	O
**	O
]	O
.	O
It	O
is	O
recommended	O
she	O
have	O
an	O
outpatient	O
sleep	O
study	O
to	O
evaluate	O
for	O
obstructive	O
sleep	O
apnea	O
as	O
well	O
as	O
an	O
outpatient	O
allergy	O
evaluation	O
.	O
3	O
.	O
Seizures	I-Reason
:	O
The	O
patient	O
suffered	O
a	O
partial	O
complex	O
seizure	O
on	O
the	O
morning	O
after	O
admission	O
.	O
The	O
neurology	O
team	O
followed	O
the	O
patient	O
throughout	O
her	O
admission	O
.	O
She	O
was	O
initially	O
loaded	O
with	O
depakote	I-Drug
,	O
however	O
,	O
this	O
was	O
then	O
tapered	O
off	O
and	O
her	O
[	O
**	O
Date	O
Range	O
13401	O
**	O
]	O
dosing	O
was	O
increased	O
to	O
500	O
mg	O
twice	O
daily	O
and	O
an	O
additional	O
dose	O
following	O
hemodialysis	O
.	O
She	O
will	O
follow	O
up	O
with	O
Neurology	O
as	O
an	O
outpatient	O
.	O
4	O
.	O
ESRD	O
on	O
HD	O
:	O
She	O
missed	O
two	O
outpatient	O
HD	O
sessions	O
prior	O
to	O
admission	O
.	O
She	O
was	O
dialyzed	O
daily	O
in	O
the	O
MICU	O
from	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
45316	O
**	O
]	O
then	O
returned	O
to	O
her	O
scheduled	O
of	O
T	O
/	O
T	O
/	O
Saturday	O
.	O
5	O
.	O
Atrial	B-Reason
fibrillation	I-Reason
:	O
Rate	B-Reason
control	I-Reason
with	O
metoprolol	I-Drug
.	O
She	O
had	O
a	O
single	O
episode	O
of	O
RVR	I-Reason
in	O
the	O
ED	O
prior	O
to	O
admission	O
which	O
responded	O
to	O
labetalol	I-Drug
,	O
otherwise	O
,	O
she	O
was	O
effectively	O
rate	O
controlled	O
.	O
Her	O
INR	O
was	O
subtherapeutic	O
at	O
admission	O
,	O
but	O
was	O
therapeutic	O
at	O
discharge	O
.	O
Her	O
INR	O
will	O
need	O
to	O
be	O
followed	O
in	O
rehabilitation	O
and	O
outpatient	O
monitoring	O
set	O
up	O
prior	O
to	O
discharge	O
home	O
.	O
6	O
.	O
Abdominal	B-Reason
Pain	I-Reason
:	O
likely	O
post	O
operative	O
,	O
waxed	O
and	O
waned	O
on	O
this	O
admission	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
pain	I-Reason
was	O
controlled	O
by	O
Tylenol	I-Drug
.	O
Her	O
staples	O
were	O
removed	O
by	O
the	O
surgical	O
team	O
during	O
this	O
hospitalization	O
.	O
She	O
had	O
increased	O
discharge	O
from	O
her	O
abdominal	O
wound	O
noted	O
on	O
[	O
**	O
2122-9-28	O
**	O
]	O
.	O
The	O
surgery	O
team	O
evaluated	O
and	O
felt	O
the	O
wound	O
was	O
healing	O
well	O
and	O
there	O
was	O
no	O
evidence	O
of	O
a	O
wound	O
infection	O
.	O
They	O
recommended	O
daily	O
dry	O
dressing	O
changes	O
.	O
7	O
.	O
Benign	B-Reason
Hypertension	I-Reason
:	O
continued	O
on	O
amlodipine	I-Drug
and	O
metoprolol	I-Drug
.	O
Lisinopril	I-Drug
discontinued	O
in	O
the	O
setting	O
of	O
angioedema	I-Ade
and	O
not	O
restarted	O
.	O
The	O
amlodipine	I-Drug
was	O
started	O
in	O
its	O
place	O
.	O
Her	O
blood	O
pressure	O
ranged	O
110	O
-	O
140s	O
/	O
50	O
-	O
70s	O
prior	O
to	O
discharge	O
.	O
8	O
.	O
Disposition	O
:	O
the	O
patient	O
was	O
discharged	O
to	O
a	O
rehabilitation	O
facility	O
.	O
She	O
will	O
benefit	O
from	O
a	O
home	O
safety	O
evaluation	O
and	O
visiting	O
nurses	O
to	O
evaluate	O
medication	O
understanding	O
/	O
compliance	O
.	O
She	O
requires	O
INR	O
monitoring	O
.	O
As	O
an	O
outpatient	O
,	O
she	O
should	O
have	O
an	O
allergy	O
evaluation	O
for	O
the	O
recurrent	O
angioedema	O
as	O
well	O
as	O
a	O
sleep	O
study	O
to	O
evaluate	O
sleep	O
apnea	O
.	O
Medications	O
on	O
Admission	O
:	O
MEDS	O
:	O
1	O
.	O
Metoprolol	B-Drug
Succinate	I-Drug
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
2	O
.	O
Atorvastatin	B-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
3	O
.	O
B	B-Drug
Complex	I-Drug
-	I-Drug
Vitamin	I-Drug
C	I-Drug
-	I-Drug
Folic	O
Acid	O
1	O
mg	O
Capsule	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Cinacalcet	B-Drug
90	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
5	O
.	O
Sertraline	I-Drug
100	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
6	O
.	O
Lisinopril	I-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Acetaminophen	B-Drug
-	I-Drug
Codeine	O
300	O
-	O
30	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
20	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
[	O
**	O
Date	O
Range	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Please	O
restart	O
[	O
**	O
2122-9-18	O
**	O
]	O
.	O
Do	O
NOT	O
dose	O
on	O
[	O
**	O
9	O
-	O
17	O
**	O
]	O
.	O
9	O
.	O
Levetiracetam	B-Drug
250	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
:	O
Started	O
with	O
previous	O
admission	O
10	O
.	O
Levetiracetam	B-Drug
250	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
following	O
HD	O
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Atorvastatin	I-Drug
20	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
B	B-Drug
Complex	I-Drug
-	I-Drug
Vitamin	I-Drug
C	I-Drug
-	I-Drug
Folic	O
Acid	O
1	O
mg	O
Capsule	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Cinacalcet	I-Drug
30	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Sertraline	B-Drug
100	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Warfarin	I-Drug
1	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Levetiracetam	B-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Levetiracetam	I-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HD	O
PROTOCOL	O
(	O
HD	O
Protochol	O
)	O
.	O
9	O
.	O
Amlodipine	B-Drug
5	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Acetaminophen	I-Drug
500	O
mg	O
Tablet	O
[	O
**	O
Month	O
/	O
Year	O
(	O
2	O
)	O
**	O
]	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
:	O
not	O
to	O
exceed	O
4	O
grams	O
/	O
24	O
hours	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
1186	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
538	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Altered	O
mental	O
status	O
Uremia	O
Angioedema	O
Respiratory	O
failure	O
Complex	O
partial	O
seizure	O
Secondary	O
Hypertension	O
End	O
stage	O
renal	O
disease	O
on	O
hemodialysis	O
Atrial	O
fibrillation	O
Seizure	O
Disorder	O
Failed	O
renal	O
transplant	O
X	O
2	O
Hyperlipidemia	O
Discharge	O
Condition	O
:	O
At	O
mental	O
status	O
baseline	O
,	O
pain	O
controlled	O
,	O
tolerating	O
diet	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
with	O
confusion	O
in	O
the	O
setting	O
of	O
missed	O
hemodialysis	O
sessions	O
.	O
In	O
the	O
hospital	O
,	O
you	O
had	O
a	O
seizure	O
and	O
a	O
reaction	O
to	O
a	O
medication	O
which	O
caused	O
your	O
tongue	O
to	O
swell	O
and	O
necessitated	O
a	O
breathing	O
tube	O
.	O
You	O
had	O
several	O
daily	O
dialysis	O
sessions	O
and	O
your	O
confusion	O
resolved	O
.	O
You	O
had	O
abdominal	B-Reason
pain	I-Reason
which	O
was	O
controlled	O
with	O
Tylenol	I-Drug
.	O
Surgery	O
evaluated	O
your	O
wound	O
and	O
thought	O
you	O
were	O
healing	O
well	O
.	O
You	O
are	O
being	O
discharged	O
to	O
a	O
rehabilitation	O
facility	O
to	O
regain	O
your	O
strength	O
after	O
the	O
long	O
hospitalization	O
.	O
Followup	O
Instructions	O
:	O
Please	O
call	O
your	O
primary	O
provider	O
,	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
45317	O
**	O
]	O
for	O
an	O
appointment	O
within	O
1	O
week	O
of	O
rehabilitation	O
discharge	O
.	O
Surgery	O
Follow	O
Up	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1330	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2122-10-16	O
**	O
]	O
2:00	O
Neurology	O
Follow	O
Up	O
:	O
Provider	O
:	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
1220	O
**	O
]	O
.	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
540	O
**	O
]	O
&	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
44	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2122-11-10	O
**	O
]	O
4:30	O
Renal	O
Transplant	O
Appointment	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
2105	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
2106	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2123-1-15	O
**	O
]	O
9:00	O
Completed	O
by	O
:[	O
**	O
2122-9-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2128-2-13	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2128-2-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2054-3-20	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
30	O
**	O
]	O
Chief	O
Complaint	O
:	O
s	O
/	O
p	O
fall	O
with	O
right	O
hip	O
pain	O
and	O
fracture	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Open	O
reduction	O
internal	O
fixation	O
right	O
valgus	O
impacted	O
femoral	O
neck	O
fracture	O
with	O
7.3	O
mm	O
screws	O
x3	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
73	O
year	O
old	O
woman	O
with	O
past	O
medical	O
history	O
of	O
IDDM	O
,	O
seizure	O
disorder	O
and	O
breast	O
cancer	O
who	O
lives	O
alone	O
presenting	O
with	O
right	O
-	O
sided	O
hip	O
,	O
leg	O
and	O
low	O
back	O
pain	O
after	O
slipping	O
off	O
her	O
toilet	O
this	O
morning	O
.	O
Patient	O
does	O
not	O
remember	O
any	O
other	O
details	O
at	O
this	O
time	O
.	O
There	O
were	O
no	O
witnesses	O
,	O
and	O
it	O
is	O
not	O
clear	O
how	O
long	O
she	O
was	O
down	O
for	O
.	O
.	O
In	O
the	O
ED	O
,	O
the	O
intitial	O
VS	O
t	O
96.6	O
hr	O
109	O
bp	O
138/83	O
rr	O
15	O
and	O
pain	O
was	O
[	O
**	O
9	O
-	O
19	O
**	O
]	O
.	O
Physical	O
exam	O
showed	O
pain	I-Reason
with	O
active	O
and	O
passive	O
R	O
hip	O
rotation	O
.	O
She	O
was	O
given	O
1g	O
tylenol	I-Drug
,	O
2	O
mg	O
IV	O
morphine	I-Drug
and	O
2L	O
NS	I-Drug
.	O
Evaluated	O
by	O
ortho	O
.	O
Imaging	O
showed	O
subcapital	O
femoral	O
neck	O
fx	O
.	O
Guaiac	O
negative	O
,	O
cr	O
1.8	O
from	O
b	O
/	O
l	O
of	O
1.3	O
.	O
K	O
+	O
5.8	O
-	O
>	O
5.6	O
,	O
EKG	O
notable	O
for	O
new	O
T	O
wave	O
inversions	O
in	O
V1	O
-	O
V4	O
.	O
A	O
CT	O
abdomen	O
and	O
pelvis	O
showed	O
urinary	O
retention	O
and	O
a	O
foley	O
catheter	O
was	O
placed	O
.	O
Perceived	O
to	O
have	O
a	O
somewhat	O
altered	O
mental	O
status	O
although	O
unclear	O
baseline	O
.	O
Past	O
Medical	O
History	O
:	O
Seizure	O
disorder	O
(	O
developed	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
DKA	O
in	O
[	O
**	O
2095	O
**	O
]	O
)	O
breast	O
CA	O
s	O
/	O
p	O
mastectomy	O
with	O
prosthetic	O
reconstruction	O
(	O
[	O
**	O
2107	O
**	O
]	O
)	O
IDDM	O
RA	O
HTN	O
glaucoma	O
bilat	O
TKRs	O
.	O
Of	O
note	O
,	O
neuropsych	O
evaluation	O
in	O
[	O
**	O
2125	O
**	O
]	O
commented	O
that	O
"	O
her	O
marked	O
attentional	O
impairments	O
raises	O
concerns	O
around	O
her	O
safety	O
,	O
medication	O
compliance	O
,	O
and	O
other	O
areas	O
of	O
functional	O
vulnerability	O
.	O
"	O
Social	O
History	O
:	O
Social	O
History	O
:	O
Lives	O
alone	O
.	O
Ambulatory	O
at	O
baseline	O
.	O
-	O
Tobacco	O
:	O
none	O
-	O
Alcohol	O
:	O
none	O
-	O
Illicits	O
:	O
none	O
Family	O
History	O
:	O
Family	O
History	O
:	O
mother	O
died	O
at	O
47	O
in	O
surgery	O
(	O
possibly	O
during	O
a	O
hysterectomy	O
)	O
.	O
No	O
information	O
was	O
available	O
to	O
her	O
regarding	O
her	O
birth	O
father	O
.	O
She	O
has	O
several	O
step	O
siblings	O
.	O
Her	O
daughter	O
is	O
healthy	O
.	O
Physical	O
Exam	O
:	O
PE	O
on	O
Admission	O
to	O
MICU	O
:	O
Vitals	O
:	O
T	O
96.8	O
BP	O
111/50	O
P	O
84	O
RR	O
16	O
O2	O
99ra	O
General	O
:	O
Alert	O
,	O
oriented	O
to	O
place	O
,	O
year	O
and	O
ethnicity	O
but	O
not	O
name	O
of	O
the	O
current	O
president	O
;	O
calm	O
but	O
in	O
visible	O
pain	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
dry	O
MM	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Chest	O
:	O
right	O
prosthetic	O
breast	O
GU	O
:	O
foley	O
Ext	O
:	O
cold	O
and	O
pale	O
bilaterally	O
with	O
weak	O
but	O
palpable	O
distal	O
pulses	O
bilaterally	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
[	O
**	O
2128-2-14	O
**	O
]	O
12:40	O
PM	O
BLOOD	O
WBC	O
-	O
3.1	O
*	O
RBC	O
-	O
3.70	O
*	O
Hgb	O
-	O
11.5	O
*	O
Hct	O
-	O
32.8	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
31.1	O
MCHC	O
-	O
35.2	O
*	O
RDW	O
-	O
19.1	O
*	O
Plt	O
Ct	O
-	O
66	O
*	O
[	O
**	O
2128-2-13	O
**	O
]	O
06:45	O
PM	O
BLOOD	O
Neuts	O
-	O
72.0	O
*	O
Lymphs	O
-	O
20.1	O
Monos	O
-	O
6.4	O
Eos	O
-	O
0.9	O
Baso	O
-	O
0.7	O
[	O
**	O
2128-2-14	O
**	O
]	O
01:50	O
AM	O
BLOOD	O
PT	O
-	O
12.9	O
PTT	O
-	O
25.7	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2128-2-14	O
**	O
]	O
12:40	O
PM	O
BLOOD	O
Glucose	O
-	O
90	O
UreaN	O
-	O
47	O
*	O
Creat	O
-	O
1.8	O
*	O
Na	O
-	O
143	O
K	O
-	O
4.6	O
Cl	O
-	O
112	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
14	O
.	O
DISCHARGE	O
LABS	O
:	O
[	O
**	O
2128-2-18	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
WBC	O
-	O
5.5	O
#	O
RBC	O
-	O
4.50	O
Hgb	O
-	O
14.1	O
Hct	O
-	O
41.6	O
MCV	O
-	O
93	O
MCH	O
-	O
31.3	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
18.7	O
*	O
Plt	O
Ct	O
-	O
222	O
[	O
**	O
2128-2-18	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
Glucose	O
-	O
155	O
*	O
UreaN	O
-	O
37	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
138	O
K	O
-	O
4.9	O
Cl	O
-	O
108	O
HCO3	O
-	O
21	O
*	O
AnGap	O
-	O
14	O
[	O
**	O
2128-2-18	O
**	O
]	O
06:50	O
AM	O
BLOOD	O
ALT	O
-	O
30	O
AST	O
-	O
31	O
LD	O
(	O
LDH	O
)	O
-	O
597	O
*	O
AlkPhos	O
-	O
147	O
*	O
TotBili	O
-	O
0.5	O
.	O
CARDIAC	O
ENZYME	O
TREND	O
:	O
[	O
**	O
2128-2-13	O
**	O
]	O
12:00	O
PM	O
BLOOD	O
CK	O
108	O
CK	O
-	O
MB	O
-	O
10	O
MB	O
Indx	O
-	O
9.3	O
*	O
cTropnT	O
-	O
0.16	O
*	O
[	O
**	O
2128-2-13	O
**	O
]	O
06:45	O
PM	O
BLOOD	O
CK	O
147	O
CK	O
-	O
MB	O
-	O
13	O
*	O
MB	O
Indx	O
-	O
8.8	O
*	O
cTropnT	O
-	O
0.22	O
*	O
[	O
**	O
2128-2-14	O
**	O
]	O
01:50	O
AM	O
BLOOD	O
CK	O
119	O
CK	O
-	O
MB	O
-	O
10	O
MB	O
Indx	O
-	O
8.4	O
*	O
cTropnT	O
-	O
0.22	O
*	O
[	O
**	O
2128-2-16	O
**	O
]	O
06:37	O
PM	O
BLOOD	O
CK	O
72	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.18	O
*	O
[	O
**	O
2128-2-16	O
**	O
]	O
11:45	O
PM	O
BLOOD	O
CK	O
49	O
CK	O
-	O
MB	O
-	O
NotDone	O
cTropnT	O
-	O
0.16	O
*	O
.	O
RADIOLOGY	O
:	O
R	O
Hip	O
Films	O
:	O
[	O
**	O
2128-2-13	O
**	O
]	O
FINDINGS	O
:	O
There	O
is	O
a	O
nondisplaced	O
,	O
slightly	O
impacted	O
right	O
subcapital	O
hip	O
fracture	O
.	O
No	O
other	O
fractures	O
are	O
identified	O
.	O
Mild	O
degenerative	O
changes	O
involving	O
the	O
SI	O
joints	O
and	O
lumbar	O
spine	O
are	O
noted	O
.	O
There	O
is	O
a	O
normal	O
bowel	O
gas	O
pattern	O
.	O
IMPRESSION	O
:	O
Right	O
subcapital	O
hip	O
fracture	O
as	O
described	O
above	O
.	O
.	O
CT	O
ABD	O
/	O
PELVIS	O
[	O
**	O
2128-2-13	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Right	O
subcapital	O
hip	O
fracture	O
.	O
2	O
.	O
Fibroid	O
uterus	O
.	O
3	O
.	O
Distended	O
bladder	O
with	O
mild	O
left	O
pelvic	O
fullness	O
.	O
4	O
.	O
Bilateral	O
adrenal	O
gland	O
thickening	O
,	O
left	O
greater	O
than	O
right	O
.	O
.	O
CT	O
HEAD	O
[	O
**	O
2128-2-13	O
**	O
]	O
IMPRESSION	O
:	O
No	O
acute	O
intracranial	O
hemorrhage	O
.	O
.	O
CT	O
C	O
-	O
SPINE	O
[	O
**	O
2128-2-13	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
No	O
evidence	O
of	O
acute	O
fracture	O
.	O
2	O
.	O
Multilevel	O
degenerative	O
changes	O
as	O
described	O
above	O
.	O
3	O
.	O
Lung	O
apices	O
suggestive	O
of	O
edema	O
,	O
inflammatory	O
,	O
or	O
small	O
airways	O
disease	O
,	O
vs	O
infectious	O
process	O
.	O
4	O
.	O
6	O
mm	O
peripherally	O
calcified	O
right	O
thyroid	O
nodule	O
for	O
which	O
further	O
evaluation	O
with	O
ultrasound	O
.	O
.	O
EKG	O
[	O
**	O
2128-2-13	O
**	O
]	O
Sinus	O
rhythm	O
.	O
The	O
P	O
-	O
R	O
interval	O
is	O
prolonged	O
.	O
There	O
is	O
a	O
late	O
transition	O
with	O
Q	O
waves	O
and	O
ST	O
-	O
T	O
wave	O
changes	O
in	O
the	O
anterior	O
leads	O
consistent	O
with	O
probable	O
prior	O
anterior	O
myocardial	O
infarction	O
.	O
There	O
are	O
tiny	O
R	O
waves	O
in	O
the	O
inferior	O
leads	O
consistent	O
with	O
possible	O
prior	O
inferior	O
myocardial	O
infarction	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
ST	O
segment	O
changes	O
are	O
new	O
.	O
.	O
CXR	O
[	O
**	O
2128-2-13	O
**	O
]	O
IMPRESSION	O
:	O
No	O
acute	O
cardiopulmonary	O
process	O
.	O
.	O
R	O
HIP	O
FILMS	O
[	O
**	O
2128-2-16	O
**	O
]	O
FINDINGS	O
:	O
In	O
comparison	O
with	O
study	O
of	O
[	O
**	O
2	O
-	O
13	O
**	O
]	O
,	O
views	O
from	O
the	O
operating	O
suite	O
show	O
placement	O
of	O
three	O
metallic	O
screws	O
across	O
the	O
previously	O
described	O
fracture	O
of	O
the	O
femur	O
.	O
.	O
[	O
**	O
2128-2-16	O
**	O
]	O
ECHO	O
:	O
The	O
left	O
atrium	O
is	O
normal	O
in	O
size	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
unusually	O
small	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
The	O
right	O
ventricular	O
cavity	O
is	O
markedly	O
dilated	O
with	O
severe	O
global	O
free	O
wall	O
hypokinesis	O
.	O
There	O
is	O
abnormal	O
diastolic	O
septal	O
motion	O
/	O
position	O
consistent	O
with	O
right	O
ventricular	O
volume	O
overload	O
.	O
The	O
diameters	O
of	O
aorta	O
at	O
the	O
sinus	O
,	O
ascending	O
and	O
arch	O
levels	O
are	O
normal	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
but	O
aortic	O
stenosis	O
is	O
not	O
present	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
No	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Markedly	O
dilated	O
right	O
ventricle	O
with	O
severe	O
global	O
hypokinesis	O
.	O
At	O
least	O
moderate	O
pulmonary	O
hypertension	O
.	O
Small	O
left	O
ventricular	O
cavity	O
size	O
with	O
preserved	O
systolic	O
function	O
.	O
.	O
[	O
**	O
2038-2-16	O
**	O
]	O
CAROTID	O
ULTRASOUNDS	O
IMPRESSION	O
:	O
There	O
is	O
less	O
than	O
40	O
%	O
stenosis	O
within	O
the	O
internal	O
carotid	O
arteries	O
bilaterally	O
.	O
.	O
[	O
**	O
2128-2-17	O
**	O
]	O
CXR	O
FINDINGS	O
:	O
In	O
comparison	O
with	O
the	O
study	O
of	O
[	O
**	O
2	O
-	O
16	O
**	O
]	O
,	O
there	O
has	O
been	O
a	O
substantial	O
decrease	O
in	O
the	O
bilateral	O
opacification	O
,	O
which	O
had	O
been	O
more	O
prominent	O
on	O
the	O
left	O
and	O
could	O
have	O
represented	O
either	O
asymmetric	O
pulmonary	O
edema	O
or	O
diffuse	O
aspiration	O
.	O
Some	O
residual	O
areas	O
of	O
opacification	O
are	O
seen	O
at	O
the	O
right	O
base	O
laterally	O
and	O
at	O
the	O
left	O
base	O
.	O
These	O
most	O
likely	O
represent	O
residual	O
aspiration	O
or	O
possible	O
atelectasis	O
.	O
.	O
[	O
**	O
2128-2-18	O
**	O
]	O
EKG	O
Normal	O
sinus	O
rhythm	O
with	O
Q	O
waves	O
in	O
the	O
right	O
precordial	O
leads	O
consistent	O
with	O
anterior	O
wall	O
myocardial	O
infarction	O
.	O
Q	O
waves	O
in	O
the	O
inferior	O
leads	O
consistent	O
with	O
inferior	O
myocardial	O
infarction	O
.	O
Compared	O
to	O
tracing	O
#	O
2	O
there	O
is	O
no	O
change	O
.	O
Brief	O
Hospital	O
Course	O
:	O
73F	O
PMHx	O
of	O
DM	O
,	O
seizure	O
disorder	O
and	O
breast	O
cancer	O
,	O
found	O
down	O
on	O
her	O
floor	O
with	O
R	O
hip	O
fx	O
s	O
/	O
p	O
fall	O
,	O
admitted	O
to	O
the	O
ICU	O
with	O
hip	O
fx	O
,	O
ARF	O
,	O
NSTEMI	O
,	O
and	O
hypoxia	O
.	O
Hospital	O
course	O
by	O
problem	O
:	O
#	O
Elevated	O
Cardiac	O
Enzymes	O
and	O
EKG	O
Changes	O
:	O
Had	O
elevated	O
troponins	O
in	O
the	O
setting	O
of	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
and	O
new	O
TWI	O
both	O
in	O
the	O
setting	O
of	O
anemia	O
.	O
[	O
**	O
Hospital	O
**	O
]	O
medical	O
regimen	O
included	O
ASA	I-Drug
81	O
mg	O
,	O
statin	I-Drug
80	O
mg	O
daily	O
,	O
and	O
beta	B-Drug
blocker	I-Drug
.	O
ACE	B-Drug
-	I-Drug
I	I-Drug
was	O
held	O
given	O
recent	O
acute	O
on	O
chronic	O
renal	O
failure	O
and	O
preserved	O
EF	O
as	O
seen	O
on	O
echo	O
(	O
see	O
below	O
)	O
.	O
.	O
#	O
Right	O
Hip	O
Fracture	O
s	O
/	O
p	O
Fall	O
.	O
Pt	O
was	O
evaluated	O
by	O
orthopedics	O
who	O
planned	O
for	O
minimally	O
invasive	O
pinning	O
procedure	O
pending	O
medical	O
clearance	O
,	O
which	O
was	O
provided	O
by	O
daughter	O
,	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1785	O
**	O
]	O
,	O
as	O
pt	O
was	O
delirious	O
.	O
Went	O
to	O
OR	O
on	O
[	O
**	O
2128-2-16	O
**	O
]	O
,	O
no	O
complications	O
intra-op	O
,	O
but	O
did	O
go	O
back	O
ot	O
the	O
ICU	O
for	O
overnight	O
monitoring	O
as	O
she	O
had	O
some	O
hypoxia	I-Ade
postoperatively	O
(	O
had	O
received	O
a	O
larga	O
amount	O
of	O
morphine	I-Drug
)	O
.	O
She	O
commenced	O
PT	O
POD	O
#	O
1	O
,	O
and	O
was	O
significantly	O
limited	O
by	O
pain	I-Reason
,	O
but	O
this	O
improved	O
by	O
POD	O
#	O
3	O
(	O
ay	O
of	O
d	O
/	O
c	O
)	O
.	O
She	O
did	O
receive	O
narcotics	I-Drug
around	O
the	O
time	O
of	O
PT	O
to	O
aid	O
in	O
progress	O
.	O
Pain	I-Reason
was	O
also	O
managed	O
with	O
tylenol	I-Drug
.	O
She	O
was	O
discharged	O
on	O
lovenox	I-Drug
40	O
mg	O
sQ	O
daily	O
for	O
DVT	B-Reason
ppx	I-Reason
,	O
and	O
with	O
orthopedic	O
followup	O
.	O
#	O
Pancyopenia	I-Ade
:	O
Presented	O
with	O
acute	O
on	O
chronic	O
anemia	O
with	O
baseline	O
in	O
low	O
30s	O
,	O
as	O
well	O
as	O
thrombocytopenia	O
with	O
nadir	O
platelets	O
in	O
the	O
40s	O
,	O
and	O
leukopenia	O
to	O
a	O
nadir	O
of	O
2.1	O
Felt	O
likely	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
methotrexate	I-Drug
use	O
with	O
questionable	O
use	O
of	O
folate	I-Drug
(	O
marrow	O
suppressive	O
process	O
)	O
.	O
She	O
was	O
transfused	O
3	O
units	O
in	O
the	O
ICU	O
and	O
on	O
HD	O
#	O
2	O
had	O
a	O
stable	O
Hct	O
to	O
32.8	O
.	O
DDAVP	I-Drug
was	O
given	O
for	O
low	B-Reason
platelets	I-Reason
.	O
Her	O
methotrexate	I-Drug
was	O
held	O
,	O
she	O
received	O
supplemental	O
folic	B-Drug
acid	I-Drug
,	O
and	O
all	O
cell	O
lines	O
recovered	O
to	O
normal	O
by	O
discharge	O
.	O
She	O
will	O
followup	O
with	O
erh	O
rheumatologist	O
for	O
?	O
resumption	O
of	O
methotrexate	I-Drug
.	O
#	O
Acute	O
Kidney	O
Injury	O
:	O
Baseline	O
creatinine	O
=	O
1.3	O
,	O
but	O
she	O
presented	O
with	O
creatinine	O
1.8	O
-	O
>	O
max	O
of	O
2.2	O
in	O
setting	O
of	O
fall	O
.	O
Normal	O
CKs	O
made	O
rhabdo	O
unlikely	O
.	O
Felt	O
likely	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
hypoperfusion	O
and	O
prerenal	O
state	O
.	O
Pt	O
.	O
was	O
given	O
IVF	I-Drug
boluses	O
and	O
Cr	O
decreased	O
to	O
1.3	O
by	O
discharge	O
.	O
#	O
Transaminitis	O
:	O
Had	O
elevations	O
of	O
ALT	O
,	O
AST	O
and	O
Alk	O
Phos	O
without	O
elevation	O
in	O
bilis	O
.	O
Unclear	O
etiology	O
,	O
felt	O
[	O
**	O
1	O
-	O
13	O
**	O
]	O
mild	O
ischemic	O
liver	O
in	O
setting	O
of	O
hypotension	O
.	O
Her	O
methotrexate	I-Drug
was	O
also	O
held	O
.	O
LFTs	O
had	O
entirely	O
normalized	O
by	O
discharge	O
.	O
#	O
IDDM	O
:	O
well	O
-	O
controlled	O
by	O
A1c	O
.	O
FS	O
were	O
checked	O
every	O
4	O
hours	O
and	O
she	O
was	O
placed	O
on	O
an	O
insuling	I-Drug
sliding	O
scale	O
.	O
Her	O
lisinopril	I-Drug
was	O
held	O
.	O
On	O
discharge	O
,	O
her	O
metformin	I-Drug
was	O
continued	O
,	O
but	O
lisinopril	I-Drug
was	O
still	O
held	O
in	O
setting	O
of	O
recent	O
acute	O
renal	O
failure	O
.	O
#	O
Fall	O
:	O
unclear	O
etiology	O
in	O
pt	O
with	O
h	O
/	O
o	O
seizure	O
d	O
/	O
o	O
and	O
multiple	O
CAD	O
risk	O
factors	O
.	O
Her	O
cardiac	O
enzymes	O
were	O
followed	O
and	O
Trop	O
was	O
trended	O
from	O
0.16	O
--	O
>	O
0.22	O
--	O
>	O
0.22	O
,	O
so	O
an	O
MI	O
could	O
be	O
the	O
etiology	O
but	O
this	O
could	O
also	O
have	O
been	O
a	O
conseqeunce	O
of	O
her	O
fall	O
.	O
Further	O
syncope	O
workup	O
included	O
monitoring	O
on	O
telemetry	O
without	O
significant	O
arryhtmia	O
,	O
sending	O
a	O
tegretol	I-Drug
level	O
(	O
normal	O
)	O
,	O
repeating	O
EKGs	O
(	O
developed	O
signs	O
of	O
MI	O
)	O
,	O
and	O
carotid	O
ultrasounds	O
which	O
were	O
normal	O
.	O
Head	O
CT	O
and	O
Cspine	O
Ct	O
in	O
ED	O
were	O
negative	O
.	O
#	O
Hypoxia	O
-	O
pt	O
still	O
had	O
minimal	O
O2	O
requirement	O
on	O
d	O
/	O
c.	O
Has	O
known	O
OSA	O
per	O
prior	O
sleep	O
evaluations	O
.	O
Also	O
received	O
many	O
liters	O
of	O
IVF	I-Drug
and	O
3	O
units	O
of	O
blood	I-Drug
during	O
her	O
hospital	O
course	O
,	O
so	O
?	O
some	O
element	O
of	O
hypervolemia	O
,	O
but	O
phsical	O
exam	O
did	O
not	O
support	O
this	O
.	O
Echo	O
performed	O
this	O
admission	O
revealed	O
preserved	O
EF	O
of	O
60	O
-	O
65	O
%	O
but	O
markedly	O
dilated	O
RV	O
with	O
severe	O
global	O
free	O
wall	O
hypokinesis	O
.	O
There	O
was	O
abnormal	O
diastolic	O
septal	O
motion	O
/	O
position	O
consistent	O
with	O
right	O
ventricular	O
volume	O
overload	O
.	O
There	O
was	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
This	O
was	O
thought	O
to	O
possible	O
represent	O
sequelae	O
from	O
her	O
MI	O
.	O
Pulmonary	O
embolism	O
was	O
on	O
the	O
differential	O
but	O
given	O
her	O
acute	O
on	O
chronic	O
renal	O
failure	O
,	O
a	O
CT	O
-	O
A	O
was	O
deferred	O
,	O
and	O
the	O
patient	O
was	O
allowed	O
to	O
autodiurese	O
and	O
recover	O
from	O
the	O
imediate	O
postoperative	O
period	O
and	O
wean	O
off	O
of	O
narcotics	I-Drug
.	O
If	O
persistent	O
,	O
this	O
could	O
be	O
further	O
worked	O
up	O
as	O
an	O
outpatient	O
.	O
#	O
RA	I-Reason
:	O
methotrexate	I-Drug
was	O
held	O
during	O
admission	O
given	O
pancytopenia	I-Ade
above	O
.	O
#	O
Depression	I-Reason
:	O
dx	O
with	O
mild	O
depression	O
-	O
Effexor	I-Drug
therapy	O
was	O
continued	O
#	O
Dementia	I-Reason
/	O
Delerium	I-Reason
:	O
unclear	O
circumstances	O
of	O
diagnosis	O
,	O
per	O
record	O
patient	O
reporting	O
forgetfulness	O
,	O
psych	O
testing	O
showing	O
mild	O
attention	O
deficits	O
.	O
She	O
was	O
continued	O
on	O
Aricept	I-Drug
.	O
She	O
did	O
experience	O
significant	O
delirium	O
during	O
her	O
hospitalization	O
which	O
had	O
improved	O
by	O
her	O
discharge	O
,	O
but	O
was	O
still	O
present	O
in	O
a	O
waxing	O
and	O
[	O
**	O
Doctor	O
Last	O
Name	O
688	O
**	O
]	O
nature	O
but	O
easily	O
treated	O
with	O
reorientation	O
and	O
discontinuation	O
of	O
foley	O
catheter	O
,	O
telemetry	O
,	O
and	O
hydration	O
.	O
She	O
does	O
have	O
followup	O
scheduled	O
with	O
her	O
cognitive	O
neurologist	O
.	O
#	O
FEN	O
:	O
pt	O
was	O
seen	O
by	O
speech	O
and	O
swallow	O
who	O
recommended	O
:	O
1	O
.	O
Continue	O
current	O
diet	O
of	O
thin	O
liquids	O
and	O
puree	O
.	O
2	O
.	O
Pills	O
whole	O
or	O
crushed	O
with	O
puree	O
.	O
3	O
.	O
1:1	O
supervision	O
for	O
all	O
POs	O
.	O
4	O
.	O
Give	O
POs	O
ONLY	O
when	O
patient	O
is	O
most	O
awake	O
and	O
alert	O
.	O
5	O
.	O
Nutrition	O
consult	O
.	O
6	O
.	O
Recommend	O
repeat	O
swallowing	O
evaluation	O
at	O
rehab	O
prior	O
to	O
upgrading	O
diet	O
.	O
#	O
Prophylaxis	O
:	O
will	O
be	O
on	O
lovenox	I-Drug
40	O
mg	O
sQ	O
daily	O
until	O
ealry	O
[	O
**	O
Month	O
(	O
only	O
)	O
547	O
**	O
]	O
for	O
DVT	B-Reason
ppx	I-Reason
,	O
also	O
d	O
/	O
c	O
'	O
ed	O
on	O
bowel	O
regimen	O
#	O
Communication	O
:	O
with	O
patient	O
and	O
daughter	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
HCP	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1785	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1356	O
**	O
]	O
[	O
**	O
PO	O
Box	O
103136	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
2268	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
103137	O
**	O
]	O
Home	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
103138	O
**	O
]	O
Cell	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
103139	O
**	O
]	O
Work	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
103140	O
**	O
]	O
#	O
Code	O
:	O
Full	O
#	O
Dispo	O
:	O
To	O
[	O
**	O
Hospital3	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
Lipitor	I-Drug
20	O
mg	O
daily	O
Tegretol	I-Drug
200	O
mg	O
TID	O
Aricept	I-Drug
10	O
mg	O
daily	O
Lisinopril	I-Drug
5	O
mg	O
daily	O
Meloxicam	I-Drug
15	O
mg	O
daily	O
Metformin	I-Drug
500	O
mg	O
daily	O
Methotrexate	I-Drug
12.5	O
mg	O
weekly	O
Effexor	I-Drug
150	O
mg	O
Daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
2	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Carbamazepine	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Enoxaparin	I-Drug
40	O
mg	O
/	O
0.4	O
mL	O
Syringe	O
Sig	O
:	O
Forty	O
(	O
40	O
)	O
mg	O
Subcutaneous	O
DAILY	O
(	O
Daily	O
)	O
for	O
25	O
days	O
:	O
LAST	O
DAY	O
OF	O
THERAPY	O
IS	O
[	O
**	O
2128-3-14	O
**	O
]	O
.	O
5	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Vitamin	B-Drug
D	I-Drug
400	O
unit	O
Tablet	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Venlafaxine	I-Drug
75	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Atorvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Donepezil	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
11	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
12	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
13	O
.	O
Metformin	I-Drug
500	O
mg	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
PO	O
once	O
a	O
day	O
.	O
14	O
.	O
Percocet	I-Drug
2.5	O
-	O
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
[	O
**	O
5	O
-	O
18	O
**	O
]	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
:	O
HOLD	O
for	O
any	O
CNS	O
or	O
respiratory	O
depression	O
(	O
RR	O
<	O
12	O
)	O
.	O
Can	O
be	O
given	O
prior	O
to	O
physical	O
therapy	O
sessions	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
537	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
538	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
-	O
Right	O
valgus	O
impacted	O
femoral	O
neck	O
fracture	O
.	O
-	O
NSTEMI	O
vs.	O
demand	O
ischemia	O
-	O
shock	O
liver	O
-	O
Pancytopenia	I-Ade
likely	O
due	O
to	O
methotrexate	I-Drug
-	O
Right	O
heart	O
failure	O
Secondary	O
:	O
-	O
Rheumatoid	O
arthritis	O
-	O
Hypertension	O
-	O
Depression	O
-	O
Seizure	O
disorder	O
-	O
Diabetes	O
mellitus	O
type	O
II	O
-	O
Obstructive	O
sleep	O
apnea	O
-	O
Dementia	O
-	O
H	O
/	O
O	O
breast	O
cancer	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
Discharge	O
Instructions	O
:	O
Dear	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
after	O
falling	O
at	O
home	O
.	O
You	O
were	O
found	O
after	O
being	O
down	O
on	O
the	O
floor	O
for	O
a	O
prolonged	O
time	O
.	O
As	O
a	O
result	O
of	O
the	O
fall	O
,	O
you	O
suffered	O
a	O
fractured	O
right	O
hip	O
,	O
as	O
well	O
as	O
low	O
blood	O
pressure	O
which	O
caused	O
major	O
stress	O
to	O
your	O
heart	O
and	O
liver	O
.	O
Your	O
hip	O
fracture	O
was	O
surgically	O
repaired	O
,	O
and	O
as	O
you	O
were	O
given	O
IV	O
fluids	I-Drug
,	O
the	O
damage	O
to	O
your	O
heart	O
and	O
liver	O
improved	O
substantially	O
.	O
You	O
will	O
need	O
a	O
course	O
of	O
rehabilitation	O
and	O
aggressive	O
physical	O
therapy	O
to	O
regain	O
your	O
previous	O
level	O
of	O
function	O
.	O
.	O
We	O
also	O
discovered	O
that	O
the	O
right	O
side	O
of	O
your	O
heart	O
is	O
not	O
working	O
well	O
,	O
which	O
will	O
need	O
to	O
be	O
worked	O
up	O
further	O
by	O
your	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
the	O
meantime	O
we	O
did	O
discharge	O
you	O
with	O
some	O
supplemental	O
oxygen	I-Drug
to	O
keep	O
your	O
oxygen	O
levels	O
at	O
a	O
healthy	O
level	O
.	O
.	O
Some	O
changes	O
were	O
made	O
to	O
your	O
medications	O
,	O
as	O
follows	O
:	O
1	O
)	O
Your	O
methotrexate	I-Drug
was	O
STOPPED	O
,	O
since	O
it	O
might	O
have	O
been	O
lowering	O
your	O
blood	O
cell	O
counts	O
when	O
you	O
came	O
to	O
the	O
hospital	O
.	O
The	O
blood	O
counts	O
revcovered	O
nicely	O
when	O
you	O
were	O
taken	O
off	O
methotrexate	I-Drug
.	O
You	O
can	O
determine	O
when	O
to	O
restart	O
this	O
when	O
you	O
see	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
6426	O
**	O
]	O
in	O
followup	O
.	O
2	O
)	O
Your	O
lipitor	I-Drug
was	O
increased	O
to	O
80	O
mg	O
daily	O
3	O
)	O
You	O
will	O
be	O
receiving	O
daily	O
injections	O
of	O
lovenox	I-Drug
,	O
a	O
blood	O
thinner	O
,	O
to	O
prevent	B-Reason
blood	I-Reason
clots	I-Reason
after	O
your	O
hip	O
surgery	O
,	O
for	O
the	O
next	O
25	O
days	O
4	O
)	O
START	O
calcium	I-Drug
and	O
vitamin	B-Drug
D	I-Drug
supplements	O
to	O
help	O
with	O
bone	I-Reason
healing	O
5	O
)	O
START	O
metoprolol	I-Drug
12.5	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
protect	B-Reason
the	I-Reason
heart	I-Reason
6	O
)	O
START	O
a	O
baby	O
aspirin	I-Drug
every	O
day	O
to	O
protect	B-Reason
the	I-Reason
heart	I-Reason
Followup	O
Instructions	O
:	O
Orthopedics	O
:	O
Tuesday	O
[	O
**	O
3	O
-	O
2	O
**	O
]	O
at	O
11:20	O
with	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
8661	O
**	O
]	O
Building	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
)	O
.	O
Cognitive	O
Neurology	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
20751	O
**	O
]	O
,	O
M.D.	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1682	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2128-3-2	O
**	O
]	O
10:30	O
.	O
Primary	O
Care	O
:	O
Thursday	O
,	O
[	O
**	O
2130-4-9	O
**	O
]	O
:	O
20	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
.	O
Rheumatology	O
:	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
14465	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
2226	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2128-3-4	O
**	O
]	O
11:30	O

Admission	O
Date	O
:	O
[	O
**	O
2202-10-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2202-10-22	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2143-12-3	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
NEUROLOGY	O
Allergies	O
:	O
Vicodin	I-Drug
/	O
Roxicet	I-Drug
/	O
Sirolimus	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1032	O
**	O
]	O
Chief	O
Complaint	O
:	O
Mental	O
status	O
changes	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Endotracheal	O
intubation	O
Lumbar	O
puncture	O
with	O
moderate	O
sedation	O
Radial	O
arterial	O
line	O
insertion	O
History	O
of	O
Present	O
Illness	O
:	O
58y	O
/	O
o	O
RHM	O
with	O
history	O
of	O
liver	O
transplant	O
,	O
Hepatitis	O
C	O
,	O
chronic	O
renal	O
disease	O
and	O
multiple	O
asymptomatic	O
strokes	O
,	O
presented	O
with	O
sudden	O
decline	O
in	O
his	O
mental	O
status	O
.	O
His	O
wife	O
witnessed	O
him	O
be	O
struggling	O
get	O
out	O
from	O
bed	O
,	O
decline	O
in	O
his	O
awareness	O
.	O
His	O
wife	O
spoke	O
to	O
him	O
with	O
appropriate	O
condition	O
around	O
6:05	O
PM	O
.	O
Around	O
6:25	O
PM	O
,	O
she	O
heard	O
that	O
the	O
patient	O
started	O
to	O
say	O
non-sence	O
,	O
act	O
inappropriately	O
,	O
unable	O
to	O
exchange	O
conversation	O
.	O
His	O
wife	O
recalled	O
some	O
"	O
shaking	O
"	O
at	O
the	O
right	O
arm	O
.	O
He	O
was	O
brought	O
into	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
above	O
time	O
and	O
Neurology	O
was	O
consulted	O
for	O
code	O
stroke	O
.	O
In	O
ED	O
,	O
while	O
Neurology	O
was	O
examining	O
patient	O
,	O
he	O
developed	O
right	O
arm	O
,	O
leg	O
clonic	O
seizure	O
with	O
head	O
deviation	O
and	O
gaze	O
deviation	O
toward	O
to	O
left	O
.	O
He	O
responded	O
with	O
moan	O
when	O
his	O
name	O
was	O
called	O
,	O
then	O
developed	O
left	O
arm	O
clonic	B-Reason
seizure	I-Reason
(	O
secondary	O
generalization	O
)	O
and	O
became	O
unresponsive	O
.	O
Ativan	I-Drug
2	O
mg	O
IV	O
was	O
given	O
to	O
stop	O
.	O
Patient	O
was	O
intubated	O
subsequently	O
to	O
have	O
further	O
neuroradiological	O
evaluation	O
.	O
HPI	O
ADDENDUM	O
:	O
Further	O
history	O
was	O
obtained	O
from	O
the	O
patient	O
's	O
wife	O
the	O
morning	O
following	O
his	O
admission	O
.	O
She	O
reports	O
the	O
patient	O
was	O
well	O
until	O
returning	O
from	O
a	O
same	O
-	O
day	O
-	O
surgical	O
procedure	O
on	O
[	O
**	O
10	O
-	O
14	O
**	O
]	O
for	O
repair	O
of	O
left	O
eye	O
retinal	O
detachment	O
.	O
The	O
patient	O
was	O
vague	O
with	O
his	O
reported	O
symptoms	O
,	O
but	O
complained	O
of	O
"	O
feeling	O
lousy	O
"	O
with	O
poor	O
appetite	O
and	O
fatigue	O
.	O
He	O
did	O
not	O
eat	O
or	O
drink	O
very	O
much	O
Friday	O
or	O
Saturday	O
following	O
.	O
On	O
Saturday	O
evening	O
he	O
began	O
to	O
vomit	O
quite	O
frequently	O
.	O
They	O
had	O
a	O
small	O
breakfast	O
Sunday	O
morning	O
and	O
the	O
patient	O
was	O
still	O
feeling	O
unwell	O
,	O
but	O
altogether	O
normal	O
per	O
his	O
wife	O
.	O
She	O
left	O
for	O
a	O
few	O
hours	O
during	O
the	O
day	O
,	O
returned	O
home	O
and	O
heard	O
him	O
yelling	O
out	O
of	O
frustration	O
after	O
having	O
dropped	O
something	O
in	O
his	O
room	O
,	O
however	O
the	O
yelling	O
continued	O
and	O
she	O
went	O
to	O
see	O
him	O
and	O
noted	O
that	O
he	O
had	O
a	O
great	O
amount	O
of	O
difficulty	O
getting	O
himself	O
upright	O
to	O
the	O
edge	O
of	O
his	O
bed	O
.	O
She	O
then	O
noted	O
his	O
right	O
arm	O
was	O
shaking	O
.	O
He	O
was	O
brought	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
where	O
the	O
above	O
described	O
event	O
occurred	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
ETOH	O
/	O
HCV	O
cirrhosis	O
s	O
/	O
p	O
Liver	O
Transplant	O
[	O
**	O
2195	O
**	O
]	O
on	O
immunosuppression	O
.	O
Course	O
c	O
/	O
b	O
recurrent	O
hep	O
C	O
viremia	O
,	O
CRI	O
,	O
LFT	O
abnl	O
,	O
acute	O
rejection	O
and	O
hepatic	O
artery	O
thrombosis	O
(	O
[	O
**	O
2196	O
**	O
]	O
)	O
-	O
Polymyositis	O
-	O
diagnosed	O
in	O
[	O
**	O
2196	O
**	O
]	O
after	O
hepatic	O
artery	O
thrombosis	O
,	O
Bx	O
showed	O
inflammatory	O
myositis	O
-	O
HTN	O
-	O
CRI	O
(	O
baseline	O
2.0	O
)	O
-	O
DM	I-Ade
on	O
insulin	I-Drug
-	O
post-transplant	O
,	O
related	O
to	O
steroid	I-Drug
treatment	O
-	O
IVDU	O
-	O
Multiple	O
strokes	O
-	O
[	O
**	O
2195	O
**	O
]	O
prior	O
to	O
transplant	O
left	O
corona	O
radiata	O
and	O
posterior	O
putaminal	O
infarct	O
,	O
periventricular	O
white	O
matter	O
disease	O
.	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
MRI	O
with	O
evidence	O
of	O
chronic	O
cerebellar	O
infarcts	O
.	O
-	O
Seizure	O
-	O
single	O
event	O
3	O
days	O
prior	O
to	O
transplant	O
while	O
in	O
hospital	O
.	O
However	O
chart	O
review	O
reveals	O
pt	O
may	O
have	O
had	O
seizures	O
associated	O
with	O
prior	O
infarcts	O
in	O
[	O
**	O
2195	O
**	O
]	O
.	O
Social	O
History	O
:	O
Lives	O
with	O
his	O
wife	O
.	O
Does	O
not	O
smoke	O
.	O
Quit	O
ETOH	O
use	O
several	O
years	O
prior	O
to	O
transplant	O
.	O
Family	O
History	O
:	O
No	O
FH	O
of	O
stroke	O
or	O
neurological	O
disease	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
?	O
HR	O
64	O
,	O
reg	O
BP	O
243/123	O
RR	O
17	O
SO2	O
97	O
%	O
r	O
/	O
a	O
Gen	O
:	O
NAD	O
.	O
HEENT	O
:	O
MMM	O
.	O
Sclera	O
clear	O
.	O
OP	O
clear	O
.	O
Extra	O
ear	O
canals	O
,	O
ear	O
drums	O
clear	O
.	O
Neck	O
:	O
No	O
Carotid	O
bruits	O
CV	O
:	O
RRR	O
,	O
Nl	O
S1	O
and	O
S2	O
,	O
no	O
murmurs	O
/	O
gallops	O
/	O
rubs	O
Lung	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
Abd	O
:	O
Horizontal	O
surgical	O
scar	O
.	O
Soft	O
,	O
flat	O
,	O
no	O
tenderness	O
Ext	O
:	O
No	O
arthralgia	O
,	O
no	O
deformities	O
,	O
no	O
edema	O
Neurologic	O
examination	O
:	O
MS	O
-	O
Opening	O
eyes	O
to	O
voice	O
.	O
Non-verbal	O
.	O
Vocalize	O
non	O
identifiable	O
sound	O
.	O
No	O
following	O
command	O
.	O
CN	O
-	O
Pupils	O
left	O
sclera	O
injected	O
,	O
surgical	O
.	O
Right	O
pupil	O
also	O
surgical	O
.	O
Left	O
gaze	O
preference	O
.	O
Left	O
head	O
turning	O
.	O
No	O
facial	O
droop	O
with	O
grimacing	O
.	O
Gag	O
+	O
.	O
Cough	O
+	O
.	O
Motor	O
/	O
Sensory	O
-	O
Normal	O
bulk	O
.	O
R	O
foot	O
clonus	O
x7	O
-	O
9	O
beats	O
.	O
Left	O
negative	O
.	O
No	O
withdrawal	O
at	O
R	O
arm	O
,	O
leg	O
,	O
L	O
leg	O
.	O
Withdrawal	O
at	O
R	O
arm	O
.	O
Response	O
to	O
the	O
noxious	O
stimuli	O
at	O
left	O
arm	O
.	O
None	O
at	O
right	O
arm	O
,	O
leg	O
and	O
left	O
leg	O
.	O
Reflexes	O
:	O
B	O
T	O
Br	O
Pa	O
Ankle	O
Right	O
2	O
2	O
2	O
3	O
3	O
Left	O
2	O
2	O
2	O
2	O
2	O
Toes	O
were	O
upgoing	O
at	O
the	O
right	O
,	O
down	O
at	O
the	O
left	O
.	O
Coordination	O
:	O
Unable	O
to	O
examine	O
due	O
to	O
inattention	O
.	O
Meningeal	O
sign	O
:	O
Negative	O
Brudzinski	O
sign	O
.	O
No	O
nuchal	O
rigidity	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
:	O
138	O
99	O
42	O
AGap	O
=	O
18	O
------------	O
<	O
140	O
3.9	O
25	O
2.3	O
estGFR	O
:	O
29/36	O
(	O
click	O
for	O
details	O
)	O
11.2	O
>	O
15.9	O
/	O
46.6	O
<	O
127	O
N	O
:	O
64.7	O
L	O
:	O
24.7	O
M	O
:	O
9.9	O
E	O
:	O
0.6	O
Bas	O
:	O
0.2	O
PT	O
:	O
11.7	O
PTT	O
:	O
31.0	O
INR	O
:	O
1.0	O
Head	O
CT	O
:	O
No	O
hemorrhage	O
.	O
Head	O
MRI	O
/	O
MRA	O
:	O
MRA	O
:	O
The	O
intracranial	O
vertebral	O
and	O
internal	O
carotid	O
arteries	O
and	O
their	O
major	O
branches	O
appear	O
normal	O
with	O
no	O
evidence	O
of	O
significant	O
stenosis	O
,	O
occlusion	O
,	O
or	O
aneurysms	O
.	O
MRI	O
:	O
Unchanged	O
appearance	O
of	O
punctate	O
hemorrhagic	O
areas	O
in	O
bilateral	O
cerebral	O
hemispheres	O
and	O
brainstem	O
suggestive	O
of	O
chronic	O
process	O
.	O
Amyloid	O
angiopathy	O
is	O
one	O
of	O
the	O
conditions	O
that	O
can	O
predispose	O
to	O
tiny	O
punctate	O
hemorrhages	O
.	O
No	O
acute	O
hemorrhage	O
,	O
masses	O
,	O
infarct	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
2809	O
**	O
]	O
is	O
a	O
58	O
year	O
old	O
gentleman	O
s	O
/	O
p	O
liver	O
transplant	O
related	O
to	O
chronic	O
HCV	O
infection	O
,	O
myopathy	I-Ade
(	O
?	O
steroid	I-Drug
induced	O
)	O
,	O
history	O
of	O
prior	O
multiple	O
asymptomatic	O
embolic	O
infarcts	O
prior	O
to	O
transplantation	O
,	O
who	O
presents	O
with	O
three	O
day	O
prodrome	O
of	O
general	O
malaise	O
,	O
poor	O
appetite	O
,	O
nausea	O
/	O
vomiting	O
,	O
followed	O
by	O
acute	O
change	O
in	O
mental	O
status	O
with	O
witnessed	O
partial	O
complex	O
seizure	O
in	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
.	O
1	O
)	O
Neuro	O
:	O
*	O
SEIZURE	O
-	O
Initially	O
a	O
code	O
stroke	O
was	O
called	O
in	O
the	O
ED	O
,	O
but	O
CT	O
imaging	O
and	O
later	O
,	O
MRI	O
,	O
showed	O
no	O
evidence	O
of	O
acute	O
infarction	O
.	O
Initial	O
labs	O
notable	O
for	O
presence	O
of	O
only	O
serum	O
benzodiazepines	I-Drug
on	O
tox	O
screening	O
and	O
acute	O
on	O
chronic	O
renal	O
failure	O
.	O
Etiology	O
of	O
seizure	O
was	O
thought	O
to	O
be	O
areas	O
of	O
prior	O
cortical	O
infarcts	O
in	O
setting	O
of	O
gastrointestinal	O
illness	O
.	O
The	O
patient	O
was	O
intubated	O
in	O
the	O
emergency	O
department	O
and	O
promptly	O
extubated	O
at	O
2	O
am	O
in	O
the	O
Neuro	O
ICU	O
the	O
same	O
evening	O
.	O
The	O
morning	O
following	O
admission	O
the	O
patient	O
's	O
examination	O
was	O
notable	O
for	O
marked	O
encephalopathy	O
.	O
He	O
was	O
changed	O
from	O
phenytoin	I-Drug
to	O
oxcarbazepine	I-Drug
(	O
Trileptal	I-Drug
)	O
given	O
multiple	O
long	O
term	O
side	O
effects	O
of	O
phenytoin	I-Drug
,	O
and	O
with	O
normal	O
hepatic	O
function	O
,	O
but	O
renal	O
impairment	O
and	O
keppra	I-Drug
did	O
not	O
seem	O
a	O
wise	O
choice	O
.	O
Lumbar	O
puncture	O
was	O
attempted	O
with	O
light	O
sedation	O
without	O
success	O
.	O
It	O
was	O
re-attempted	O
with	O
fentanyl	I-Drug
and	O
midazolam	I-Drug
for	O
monitored	B-Reason
conscious	I-Reason
sedation	I-Reason
and	O
revealed	O
1	O
WBC	O
,	O
0	O
RBC	O
,	O
normal	O
protein	O
and	O
glucose	O
.	O
He	O
was	O
transferred	O
to	O
the	O
floor	O
after	O
an	O
EEG	O
done	O
on	O
the	O
[	O
**	O
7	O
-	O
18	O
**	O
]	O
revealed	O
no	O
abnormalities	O
and	O
showed	O
a	O
normal	O
background	O
.	O
*	O
ENCEPHALOPATHY	O
-	O
On	O
the	O
floor	O
,	O
the	O
patient	O
's	O
exam	O
was	O
notable	O
for	O
continued	O
encephalopathy	O
,	O
but	O
he	O
was	O
evidently	O
not	O
delerious	O
.	O
His	O
main	O
abnormalities	O
were	O
frontal	O
dysfunction	O
(	O
as	O
exhibited	O
by	O
impulsiveness	O
,	O
stimulus	O
-	O
bound	O
behaviors	O
,	O
desinhibition	O
,	O
bilateral	O
grasp	O
and	O
palmomental	O
reflexes	O
,	O
a	O
marked	O
inability	O
to	O
switch	O
mindset	O
)	O
and	O
memory	O
(	O
as	O
exhibited	O
by	O
anososgnosia	O
,	O
orientation	O
to	O
place	O
and	O
time	O
,	O
as	O
well	O
as	O
not	O
imprinting	O
new	O
information	O
,	O
and	O
working	O
memory	O
(	O
the	O
patient	O
stayed	O
in	O
-	O
task	O
,	O
and	O
had	O
sufficent	O
attention	O
to	O
perform	O
,	O
but	O
could	O
n't	O
complete	O
the	O
tasks	O
)	O
.	O
Clinically	O
he	O
continued	O
to	O
improve	O
slowly	O
but	O
surely	O
,	O
an	O
EEG	O
done	O
on	O
[	O
**	O
10	O
-	O
21	O
**	O
]	O
showed	O
7	O
Hz	O
background	O
,	O
but	O
otherwise	O
normal	O
.	O
Per	O
his	O
wife	O
,	O
his	O
level	O
of	O
cognitive	O
functioning	O
at	O
home	O
was	O
high	O
,	O
as	O
for	O
example	O
he	O
was	O
able	O
to	O
discuss	O
politics	O
.	O
2	O
)	O
Cardio	O
:	O
*	O
NSTEMI	I-Reason
-	O
Patient	O
was	O
noted	O
to	O
have	O
elevated	O
troponin	O
enzymes	O
to	O
0.31	O
with	O
EKG	O
without	O
ischemic	O
changes	O
.	O
He	O
was	O
started	O
on	O
aspirin	I-Drug
,	O
beta	B-Drug
blocker	I-Drug
,	O
atorvastatin	I-Drug
.	O
Cardiology	O
consultation	O
was	O
obtained	O
and	O
additionally	O
recommended	O
echocardiogram	O
which	O
revealed	O
moderate	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
,	O
no	O
focal	O
wall	O
motion	O
abnormalities	O
(	O
poor	O
data	O
quality	O
though	O
)	O
,	O
LVEF	O
>	O
55	O
%	O
,	O
mild	O
aortic	O
valve	O
stenosis	O
.	O
His	O
NSTEMI	O
was	O
thought	O
related	O
to	O
demand	O
related	O
ischemia	O
in	O
the	O
setting	O
of	O
catecholamine	O
surge	O
associated	O
with	O
seizure	O
.	O
He	O
should	O
be	O
scheduled	O
for	O
an	O
exercise	O
stress	O
test	O
as	O
an	O
outpatient	O
.	O
3	O
)	O
FEN	O
*	O
Acute	B-Reason
Renal	I-Reason
Failure	I-Reason
-	O
Patient	O
's	O
has	O
prior	O
hepato	O
-	O
renal	O
syndrome	O
now	O
with	O
baseline	O
creatinine	O
of	O
1.9	O
-	O
2	O
.	O
Admission	O
creatinine	O
notable	O
for	O
2.4	O
.	O
He	O
was	O
noted	O
to	O
have	O
low	O
urine	O
output	O
.	O
He	O
received	O
vigorous	O
IV	O
hydration	I-Drug
with	O
improved	O
Cr	O
to	O
1.6	O
,	O
however	O
this	O
was	O
likely	O
a	O
sampling	O
error	O
because	O
all	O
the	O
lines	O
of	O
his	O
cellcount	O
were	O
down	O
on	O
this	O
blooddraw	O
as	O
well	O
,	O
repeat	O
labs	O
showed	O
a	O
creat	O
of	O
2.0	O
and	O
his	O
[	O
**	O
Hospital1	O
**	O
]	O
back	O
to	O
the	O
old	O
values	O
.	O
His	O
medications	O
were	O
renally	O
dosed	O
.	O
He	O
was	O
started	O
on	O
Thiamine	I-Drug
,	O
Folate	I-Drug
and	O
MVI	I-Drug
.	O
4	O
)	O
Liver	B-Reason
transplantation	I-Reason
Transaminase	O
levels	O
on	O
admission	O
were	O
WNL	O
.	O
Hepatology	O
consultation	O
was	O
obtained	O
and	O
recommended	O
continuing	O
with	O
his	O
prior	O
regimen	O
of	O
immunosuppressive	B-Drug
agents	I-Drug
.	O
No	O
changes	O
were	O
made	O
.	O
5	O
)	O
ID	O
A	O
broad	O
spectrum	O
of	O
CSF	O
studies	O
were	O
sent	O
despite	O
the	O
normal	O
cell	O
count	O
.	O
Varicella	O
PCR	O
and	O
CMV	O
PCR	O
negative	O
,	O
remainder	O
pending	O
.	O
MRSA	O
isolation	O
negative	O
.	O
VRE	O
swab	O
negative	O
.	O
Cryptococcal	O
antigen	O
GRAM	O
STAIN	O
,	O
FLUID	O
CULTURE	O
,	O
FUNGAL	O
CULTURE	O
-	O
PRELIMINARY	O
,	O
ACID	O
FAST	O
CULTURE	O
,	O
VIRAL	O
CULTURE	O
were	O
all	O
(	O
preliminary	O
)	O
negative	O
.	O
6	O
)	O
PPx	O
,	O
reactivation	O
and	O
reconditioning	O
For	O
prophylaxis	I-Reason
,	O
he	O
was	O
put	O
on	O
Heparin	I-Drug
,	O
pneumoboots	O
,	O
TEDs	O
,	O
and	O
PT	O
and	O
OT	O
were	O
consulted	O
to	O
evaluate	O
and	O
treat	O
him	O
.	O
Medications	O
on	O
Admission	O
:	O
Prograf	I-Drug
1	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Imuran	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Cellcept	I-Drug
(	O
mycophenidate	B-Drug
mofetil	I-Drug
)	O
1000	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
bactrim	I-Drug
metoprolol	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Clindagel	I-Drug
asa	I-Drug
81	O
mg	O
daily	O
fosamax	I-Drug
35	O
mg	O
q	O
fri	O
marinol	I-Drug
5	O
mg	O
qpm	O
and	O
qhs	O
simethicone	I-Drug
80	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
calcum	B-Drug
500	I-Drug
mg	I-Drug
+	I-Drug
D	I-Drug
[	O
**	O
Hospital1	O
**	O
]	O
Ambien	I-Drug
(	O
zolpidem	I-Drug
)	O
5	O
mg	O
qhs	O
doxazosin	I-Drug
1.5	O
mg	O
qhs	O
hydroxyzine	I-Drug
hcl	O
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
ritalin	I-Drug
15	O
mg	O
qam	O
remeron	I-Drug
7.5	O
qhs	O
prilosec	I-Drug
20	O
mg	O
daily	O
Effexor	I-Drug
37.5	O
mg	O
daily	O
Florinef	I-Drug
0.1	O
mg	O
daily	O
Lasix	I-Drug
20	O
mg	O
daily	O
Kayexylate	I-Drug
Lipitor	I-Drug
10	O
mg	O
daily	O
Lisinopril	I-Drug
5	O
mg	O
daily	O
Percocet	I-Drug
one	O
tab	O
qid	O
prn	O
Cosopt	I-Drug
one	O
drop	O
to	O
left	O
eye	O
[	O
**	O
Hospital1	O
**	O
]	O
Alphagan	I-Drug
0.15	O
%	O
to	O
left	O
eye	O
[	O
**	O
Hospital1	O
**	O
]	O
Ofloxacin	I-Drug
0.3	O
%	O
eye	O
drop	O
to	O
left	O
eye	O
qid	O
Prednisolone	I-Drug
1	O
%	O
eye	O
drop	O
to	O
left	O
eye	O
qid	O
Homatropine	I-Drug
5	O
%	O
eye	O
drop	O
to	O
left	O
eye	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Medications	O
:	O
1	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
3	O
.	O
Tacrolimus	I-Drug
1	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Mycophenolate	B-Drug
Mofetil	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
5	O
.	O
Colace	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
twice	O
a	O
day	O
.	O
6	O
.	O
Alendronate	I-Drug
35	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QFRI	O
(	O
every	O
Friday	O
)	O
.	O
7	O
.	O
Doxazosin	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
8	O
.	O
Hydroxyzine	I-Drug
HCl	O
25	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Venlafaxine	I-Drug
37.5	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Fludrocortisone	B-Drug
0.1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Heparin	I-Drug
(	O
Porcine	O
)	O
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Trimethoprim	B-Drug
-	I-Drug
Sulfamethoxazole	O
160	O
-	O
800	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
MWF	O
(	O
Monday	O
-	O
Wednesday	O
-	O
Friday	O
)	O
as	O
needed	O
for	O
ppx	I-Reason
.	O
13	O
.	O
Oxcarbazepine	B-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
14	O
.	O
Dorzolamide	B-Drug
-	I-Drug
Timolol	O
2	O
-	O
0.5	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
15	O
.	O
Brimonidine	I-Drug
0.15	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
Q	O
12H	O
(	O
Every	O
12	O
Hours	O
)	O
.	O
16	O
.	O
Ofloxacin	I-Drug
0.3	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Ophthalmic	O
four	O
times	O
daily	O
(	O
)	O
.	O
17	O
.	O
Prednisolone	B-Drug
Acetate	I-Drug
1	O
%	O
Drops	O
,	O
Suspension	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
18	O
.	O
Homatropine	I-Drug
HBr	O
5	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Ophthalmic	O
twice	O
daily	O
(	O
)	O
.	O
19	O
.	O
Famotidine	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
20	O
.	O
Metoprolol	I-Drug
Tartrate	O
25	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
21	O
.	O
Atorvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
22	O
.	O
Hexavitamin	I-Drug
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
23	O
.	O
Thiamine	I-Drug
HCl	O
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
24	O
.	O
Folic	B-Drug
Acid	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
1107	O
**	O
]	O
[	O
**	O
Hospital	O
**	O
]	O
[	O
**	O
Hospital	O
1108	O
**	O
]	O
Rehab	O
Unit	O
at	O
[	O
**	O
Hospital6	O
1109	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
1110	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Complex	O
partial	O
seizure	O
with	O
secondary	O
generalization	O
.	O
Discharge	O
Condition	O
:	O
Stable	O
,	O
improving	O
cognitively	O
.	O
Discharge	O
Instructions	O
:	O
You	O
have	O
been	O
admitted	O
with	O
an	O
epileptic	O
seizure	O
,	O
most	O
likely	O
related	O
to	O
small	O
scars	O
in	O
your	O
brain	O
from	O
old	O
small	O
strokes	O
,	O
possibly	O
in	O
the	O
setting	O
mild	O
dehydration	O
.	O
After	O
this	O
you	O
have	O
been	O
confused	O
for	O
a	O
while	O
,	O
which	O
is	O
not	O
unusual	O
with	O
a	O
fragile	O
brain	O
,	O
a	O
post-seizure	O
state	O
and	O
a	O
lot	O
of	O
medications	O
on	O
board	O
.	O
Your	O
medications	O
such	O
as	O
Remeron	I-Drug
and	O
Methylphenidate	I-Drug
have	O
been	O
temporarily	O
discontinued	O
-	O
please	O
follow	O
up	O
with	O
your	O
doctor	O
to	O
perhaps	O
reverse	O
these	O
changes	O
when	O
you	O
are	O
back	O
to	O
your	O
baseline	O
.	O
Please	O
take	O
all	O
medications	O
as	O
directed	O
,	O
and	O
attend	O
all	O
your	O
follow	O
-	O
up	O
appointments	O
.	O
If	O
you	O
experience	O
any	O
signs	O
or	O
symptoms	O
of	O
concern	O
,	O
please	O
contact	O
your	O
doctor	O
immediately	O
,	O
or	O
in	O
case	O
of	O
urgency	O
go	O
directly	O
to	O
the	O
emergency	O
room	O
-	O
for	O
example	O
in	O
case	O
of	O
recurrence	O
of	O
seizures	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2202-11-17	O
**	O
]	O
8:40	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
XRAY	O
(	O
SCC	O
2	O
)	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1228	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2202-12-14	O
**	O
]	O
4:10	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
8741	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1228	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2202-12-14	O
**	O
]	O
4:30	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
539	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
540	O
**	O
]	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
541	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2202-11-17	O
**	O
]	O
2:30	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
1041	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2188-2-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2188-2-11	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
12	O
**	O
]	O
Chief	O
Complaint	O
:	O
Hematemesis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
Endoscopy	O
with	O
clips	O
,	O
epinephrine	I-Drug
injection	O
,	O
and	O
Bicap	O
thermal	O
therapy	O
to	O
site	O
of	O
bleeding	O
gastric	O
ulcers	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
84M	O
with	O
lymphoma	I-Reason
s	O
/	O
p	O
CHOP	I-Drug
last	O
week	O
,	O
h	O
/	O
o	O
GIB	O
,	O
dilated	O
CMP	O
,	O
who	O
originally	O
presented	O
from	O
home	O
with	O
hematemesis	B-Ade
x2	I-Ade
,	O
after	O
taking	O
high	O
dose	O
prednisone	I-Drug
during	O
chemotherapy	I-Drug
as	O
well	O
as	O
Bufrin	I-Drug
for	O
arthritis	I-Reason
.	O
Patient	O
denied	O
melena	O
,	O
abdominal	O
pain	O
,	O
hematochezia	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
fever	O
,	O
chills	O
or	O
chest	O
pain	O
.	O
Patient	O
has	O
had	O
UGIB	I-Ade
in	O
past	O
with	O
NSAID	I-Drug
use	O
.	O
Patient	O
came	O
to	O
ED	O
,	O
with	O
VS	O
96.8	O
,	O
100	O
,	O
119/65	O
,	O
18	O
,	O
100	O
%	O
RA	O
and	O
A	O
and	O
O	O
times	O
3	O
.	O
At	O
home	O
,	O
patient	O
is	O
functional	O
in	O
his	O
ADLs	O
,	O
grocery	O
shopping	O
and	O
driving	O
on	O
his	O
own	O
,	O
and	O
taking	O
care	O
of	O
his	O
wife	O
with	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2481	O
**	O
]	O
disease	O
.	O
Patient	O
is	O
very	O
noncompliant	O
at	O
home	O
.	O
He	O
was	O
given	O
PPI	I-Drug
,	O
received	O
NGT	O
lavage	I-Drug
,	O
which	O
did	O
not	O
clear	O
after	O
1L	O
,	O
and	O
patient	O
was	O
fluid	I-Drug
resuscitated	I-Reason
prior	O
to	O
transfer	O
to	O
the	O
MICU	O
for	O
emergent	O
endoscopy	O
.	O
In	O
the	O
MICU	O
,	O
patient	O
had	O
endoscopy	O
showing	O
multiple	B-Reason
gastric	I-Reason
ulcers	I-Reason
,	O
which	O
were	O
clipped	O
,	O
injected	O
with	O
epinephrine	I-Drug
,	O
and	O
Bicapped	O
.	O
He	O
remained	O
hemodynamically	O
stable	O
.	O
Patient	O
was	O
also	O
found	O
to	O
have	O
an	O
evolving	O
STEMI	I-Reason
,	O
with	O
isolated	O
ST	O
elevation	O
in	O
V3	O
,	O
as	O
well	O
as	O
CE	O
with	O
peak	O
troponin	O
of	O
1.48	O
on	O
[	O
**	O
2188-2-6	O
**	O
]	O
.	O
Patient	O
remained	O
chest	O
pain	O
free	O
.	O
Cardiology	O
was	O
consulted	O
,	O
and	O
patient	O
was	O
medically	O
managed	O
with	O
a	O
beta	I-Drug
blocker	O
,	O
ACE	B-Drug
inhibitor	I-Drug
,	O
and	O
advised	O
to	O
follow	O
up	O
for	O
an	O
outpatient	O
stress	O
test	O
.	O
Patient	O
was	O
taken	O
off	O
his	O
home	O
digoxin	I-Drug
and	O
amlodipine	I-Drug
.	O
Patient	O
is	O
transferred	O
to	O
OMED	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Lymphoma	I-Reason
-	O
Biopsy	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
showing	O
B	O
-	O
cell	O
non	O
Hodgkins	O
lymphoma	O
c	O
difficult	O
subclassification	O
.	O
Originally	O
felt	O
to	O
be	O
a	O
small	O
lymphocytic	O
lymphoma	O
but	O
new	O
,	O
more	O
aggressive	O
behavior	O
is	O
suggestive	O
of	O
NHL	O
.	O
Tx	O
c	O
XRT	O
[	O
**	O
8	O
-	O
26	O
**	O
]	O
-	O
on	O
CHOP	B-Drug
-	I-Drug
R	I-Drug
-	O
last	O
chemo	I-Drug
last	O
Friday	O
2	O
.	O
Dilated	O
cardiomyopathy	O
,	O
EF	O
20	O
%	O
3	O
.	O
Chronic	O
afib	I-Reason
,	O
has	O
refused	O
coumadin	I-Drug
in	O
past	O
for	O
side	O
effects	O
4	O
.	O
HTN	O
5	O
.	O
Migraines	O
6	O
.	O
Arthritis	O
7	O
.	O
question	O
OSA	O
8	O
.	O
GI	B-Ade
bleed	I-Ade
-	O
[	O
**	O
2184	O
**	O
]	O
c	O
hgb	O
7.7	O
[	O
**	O
1	O
-	O
24	O
**	O
]	O
NSAID	I-Drug
/	O
aspirin	I-Drug
use	O
,	O
EGD	O
showing	O
gastritis	O
/	O
ulcers	O
in	O
fundus	O
.	O
9	O
.	O
Hearing	O
loss	O
10	O
.	O
ARF	O
from	O
hydronephrosis	O
due	O
to	O
lymphoma	O
Social	O
History	O
:	O
No	O
smoking	O
,	O
rare	O
ETOH	O
,	O
married	O
,	O
lives	O
in	O
[	O
**	O
Location	O
**	O
]	O
,	O
former	O
prof.	O
chemistry	O
c	O
hx	O
exposure	O
to	O
organic	O
compounds	O
.	O
Lives	O
at	O
home	O
with	O
his	O
wife	O
who	O
has	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2481	O
**	O
]	O
disease	O
.	O
Family	O
History	O
:	O
Mother	O
c	O
asthma	O
,	O
CHF	O
,	O
daughter	O
died	O
in	O
childhood	O
[	O
**	O
1	O
-	O
24	O
**	O
]	O
neuroblastoma	O
Physical	O
Exam	O
:	O
Tc	O
97.5	O
BP	O
120/70	O
HR	O
73	O
O2sat	O
99	O
%	O
RA	O
.	O
Gen	O
:	O
NAD	O
.	O
HEENT	O
:	O
NCAT	O
,	O
EOMI	O
.	O
No	O
cervical	O
LAD	O
.	O
No	O
oral	O
ulcers	O
or	O
exudates	O
.	O
CV	O
:	O
Irregularly	O
irregular	O
.	O
2/6	O
SEM	O
.	O
Lungs	O
:	O
CTAB	O
.	O
Decreased	O
BS	O
at	O
bases	O
/	O
Abd	O
:	O
+	O
BS	O
,	O
soft	O
,	O
NT	O
,	O
ND	O
.	O
Guaiac	O
positive	O
in	O
the	O
ED	O
.	O
Ext	O
:	O
WWP	O
.	O
No	O
CCE	O
.	O
Neuro	O
:	O
CN	O
II	O
-	O
XII	O
intact	O
,	O
strength	O
5/5	O
bilat	O
Pertinent	O
Results	O
:	O
132	O
97	O
52	O
/	O
186	O
AGap	O
=	O
14	O
------------	O
4.4	O
25	O
1.0	O
.	O
CK	O
:	O
38	O
MB	O
:	O
Notdone	O
Trop	O
-	O
*	O
T	O
*	O
:	O
0.02	O
Ca	O
:	O
8.3	O
Mg	O
:	O
2.0	O
P	O
:	O
4.1	O
ALT	O
:	O
10	O
AP	O
:	O
98	O
Tbili	O
:	O
0.5	O
Alb	O
:	O
3.1	O
AST	O
:	O
12	O
LDH	O
:	O
151	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
:	O
33	O
Lip	O
:	O
18	O
Dig	O
:	O
0.3	O
.	O
86	O
10.5	O
7.1	O
/	O
339	O
-------	O
20.8	O
D	O
N	O
:	O
96.9	O
Band	O
:	O
0	O
L	O
:	O
2.0	O
M	O
:	O
0.9	O
E	O
:	O
0.2	O
Bas	O
:	O
0.1	O
.	O
Conclusions	O
:	O
The	O
left	O
atrium	O
is	O
dilated	O
.	O
The	O
right	O
atrium	O
is	O
moderately	O
dilated	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
is	O
moderately	O
dilated	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
moderately	O
depressed	O
.	O
Resting	O
regional	O
wall	O
motion	O
abnormalities	O
include	O
mid	O
to	O
distal	O
anteroseptal	O
and	O
anterior	O
akinesis	O
/	O
hypokinesis	O
and	O
basal	O
to	O
mid	O
inferior	O
/	O
inferolateral	O
hypokinesis	O
akinesis	O
.	O
The	O
apex	O
is	O
not	O
fully	O
visualized	O
but	O
appears	O
hypokinetic	O
/	O
akinetic	O
.	O
Right	O
ventricular	O
chamber	O
size	O
and	O
free	O
wall	O
motion	O
are	O
normal	O
.	O
The	O
ascending	O
aorta	O
is	O
moderately	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
a	O
minimally	O
increased	O
gradient	O
consistent	O
with	O
minimal	O
aortic	O
valve	O
stenosis	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
moderately	O
thickened	O
.	O
There	O
is	O
moderate	O
thickening	O
of	O
the	O
mitral	O
valve	O
chordae	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
Moderate	O
to	O
severe	O
[	O
3	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
Significant	O
pulmonic	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2187-12-21	O
**	O
]	O
,	O
left	O
ventricular	O
systolic	O
function	O
is	O
now	O
significantly	O
worse	O
with	O
new	O
anteroseptal	O
and	O
anterior	O
akinesis	O
/	O
hypokinesis	O
.	O
.	O
EKG	O
[	O
**	O
2188-2-6	O
**	O
]	O
:	O
Atrial	O
fibrillation	O
Ventricular	O
premature	O
complex	O
Modest	O
nonspecific	O
intraventricular	O
conduction	O
delay	O
Left	O
ventricular	O
hypertrophy	O
with	O
ST	O
-	O
T	O
abnormalities	O
Anteroseptal	O
myocardial	O
infarct	O
,	O
age	O
indeterminate	O
-	O
possible	O
acute	O
/	O
recent	O
/	O
in	O
evolution	O
Diffuse	O
ST	O
-	O
T	O
wave	O
abnormalities	O
Since	O
previous	O
tracing	O
of	O
[	O
**	O
2188-2-5	O
**	O
]	O
,	O
further	O
ST	O
-	O
T	O
wave	O
abnormalities	O
present	O
.	O
Endoscopy	O
:	O
Findings	O
:	O
Esophagus	O
:	O
Lumen	O
:	O
A	O
sliding	O
small	O
size	O
hiatal	O
hernia	O
was	O
seen	O
.	O
Mucosa	O
:	O
A	O
salmon	O
colored	O
mucosa	O
suggestive	O
of	O
Barrett	O
's	O
Esophagus	O
was	O
found	O
.	O
Biopsy	O
not	O
performed	O
due	O
to	O
bleeding	O
.	O
Stomach	O
:	O
Excavated	O
Lesions	O
Multiple	O
ulcers	O
were	O
found	O
in	O
the	O
antrum	O
and	O
stomach	O
body	O
.	O
A	O
large	O
3	O
-	O
4	O
cm	O
cratered	O
ulcer	O
with	O
a	O
necrotic	O
center	O
and	O
adherent	O
clot	O
on	O
the	O
incisura	O
was	O
seen	O
.	O
There	O
was	O
a	O
pulsating	O
vessel	O
seen	O
after	O
the	O
clot	O
was	O
removed	O
.	O
Two	O
resolution	O
clips	O
were	O
applied	O
to	O
the	O
vessel	O
with	O
persistent	O
oozing	O
.	O
9cc	O
of	O
1:10,000	O
epinephrine	I-Drug
was	O
injected	O
with	O
successful	O
hemostasis	O
.	O
Bicap	O
thermal	O
therapy	O
was	O
then	O
applied	O
to	O
the	O
area	O
at	O
the	O
setting	O
of	O
28	O
.	O
No	O
bleeding	O
was	O
seen	O
at	O
the	O
completion	O
of	O
therapy	O
.	O
Much	O
of	O
the	O
body	O
and	O
fundus	O
was	O
not	O
well	O
-	O
visualized	O
due	O
to	O
blood	O
and	O
clot	O
obscuring	O
the	O
view	O
.	O
Duodenum	O
:	O
Other	O
lymphoid	O
hyperplasia	O
in	O
the	O
duodenal	O
bulb	O
.	O
Other	O
findings	O
:	O
An	O
opening	O
that	O
is	O
either	O
a	O
diverticulum	O
or	O
accessory	O
duct	O
was	O
seen	O
in	O
the	O
second	O
portion	O
of	O
the	O
duodenum	O
.	O
Impression	O
:	O
Ulcers	O
in	O
the	O
antrum	O
and	O
stomach	O
body	O
Lymphoid	O
hyperplasia	O
in	O
the	O
duodenal	O
bulb	O
.	O
Small	O
hiatal	O
hernia	O
An	O
opening	O
that	O
is	O
either	O
a	O
diverticulum	O
or	O
accessory	O
duct	O
was	O
seen	O
in	O
the	O
second	O
portion	O
of	O
the	O
duodenum	O
.	O
Mucosa	O
suggestive	O
of	O
Barrett	O
's	O
esophagus	O
Brief	O
Hospital	O
Course	O
:	O
84	O
yo	O
male	O
with	O
PMHx	O
sx	O
for	O
lymphoma	O
,	O
upper	O
GIB	O
,	O
cardiomyopathy	O
,	O
who	O
presented	O
with	O
an	O
upper	B-Ade
GI	I-Ade
bleed	I-Ade
with	O
multiple	B-Ade
gastric	I-Ade
ulcers	O
seen	O
on	O
endoscopy	O
,	O
likely	O
secondary	O
to	O
NSAID	I-Drug
use	O
and	O
recent	O
high	O
dose	O
prednisone	I-Drug
with	O
CHOP	I-Drug
therapy	O
for	O
lymphoma	I-Reason
.	O
Patient	O
was	O
also	O
found	O
to	O
have	O
a	O
silent	O
STEMI	O
,	O
with	O
V3	O
elevation	O
and	O
elevated	O
CE	O
.	O
.	O
Upper	B-Ade
GI	I-Ade
bleed	I-Ade
:	O
Patient	O
's	O
UGI	O
bleed	O
was	O
likely	O
[	O
**	O
1	O
-	O
24	O
**	O
]	O
NSAID	I-Drug
use	O
combined	O
with	O
recent	O
prednisone	I-Drug
for	O
CHOP	I-Drug
.	O
Patient	O
was	O
transfused	O
several	O
units	O
while	O
in	O
the	O
MICU	O
for	O
hematocrit	O
drop	O
from	O
29.9	O
to	O
20.8	O
on	O
presentation	O
.	O
Patient	O
had	O
an	O
NG	O
lavage	O
performed	O
,	O
which	O
did	O
not	O
clear	O
after	O
1000cc	O
NS	I-Drug
were	O
infused	O
.	O
An	O
emergent	O
upper	O
endoscopy	O
demonstrated	O
ulcers	O
in	O
the	O
antrum	O
and	O
stomach	O
body	O
,	O
lymphoid	O
hyperplasia	O
in	O
the	O
duodenal	O
bulb	O
,	O
and	O
mucosa	O
suggestive	O
of	O
Barrett	O
's	O
esophagus	O
.	O
Patient	O
's	O
ulcers	I-Reason
were	O
clipped	O
,	O
injected	O
with	O
epinephrine	I-Drug
,	O
and	O
had	O
thermal	O
therapy	O
which	O
stopped	O
the	O
bleeding	O
.	O
Biopsy	O
was	O
n't	O
performed	O
at	O
the	O
time	O
due	O
to	O
concern	O
for	O
increased	O
bleeding	O
.	O
On	O
transfer	O
to	O
OMED	O
,	O
patient	O
was	O
hemodynamically	O
stable	O
,	O
but	O
then	O
began	O
to	O
have	O
drop	B-Reason
in	I-Reason
hematocrit	O
.	O
He	O
received	O
three	O
units	O
of	O
blood	I-Drug
,	O
without	O
an	O
appropriate	O
increase	O
in	O
hematocrit	O
.	O
He	O
remained	O
guaiac	O
positive	O
,	O
had	O
two	O
large	O
bore	O
pIVs	O
for	O
access	O
,	O
and	O
continued	O
on	O
[	O
**	O
Hospital1	O
**	O
]	O
pantoprazole	I-Drug
.	O
He	O
had	O
serial	O
hematocrits	O
checked	O
,	O
and	O
was	O
stable	O
for	O
48	O
hours	O
prior	O
to	O
discharge	O
.	O
Patient	O
was	O
scheduled	O
for	O
outpatient	O
endoscopy	O
to	O
reassess	O
the	O
ulcers	O
,	O
and	O
for	O
biopsy	O
of	O
the	O
lymphoid	O
hyperplasia	O
.	O
Patient	O
was	O
advised	O
to	O
avoid	O
all	O
NSAIDs	I-Drug
.	O
He	O
will	O
have	O
serial	O
hematocrits	O
checked	O
by	O
home	O
VNA	O
.	O
.	O
STEMI	I-Reason
:	O
Patient	O
was	O
admitted	O
with	O
initial	O
STE	O
in	O
V3	O
,	O
but	O
with	O
a	O
progressive	O
rise	O
in	O
cardiac	O
enzymes	O
.	O
He	O
was	O
noted	O
to	O
have	O
evolving	O
ST	O
changes	O
since	O
admission	O
with	O
peak	O
troponin	O
,	O
and	O
was	O
diagnosed	O
as	O
having	O
a	O
STEMI	O
.	O
A	O
cardiology	O
consult	O
was	O
obtained	O
,	O
and	O
recommended	O
stopping	O
patient	O
's	O
amlodipine	I-Drug
and	O
digoxin	I-Drug
,	O
and	O
starting	O
atorvastatin	I-Drug
,	O
lisinopril	I-Drug
and	O
metoprolol	I-Drug
,	O
which	O
were	O
started	O
when	O
patient	O
was	O
hemodynamically	O
stable	O
from	O
a	O
GI	O
bleed	O
perspective	O
.	O
Patient	O
's	O
cardiac	O
enzymes	O
were	O
trended	O
,	O
and	O
he	O
was	O
found	O
to	O
have	O
continued	O
upward	O
trend	O
in	O
troponin	O
to	O
peak	O
2.24	O
,	O
with	O
gradual	O
decrease	O
in	O
CK	O
and	O
CKMB	O
.	O
Cardiology	O
was	O
reconsulted	O
,	O
and	O
felt	O
that	O
elevation	O
in	O
troponin	O
was	O
not	O
an	O
indication	O
for	O
cardiac	O
catheterization	O
,	O
and	O
opted	O
for	O
medical	O
management	O
.	O
Patient	O
was	O
not	O
placed	O
on	O
heparin	I-Drug
due	O
to	O
bleeding	O
risk	O
.	O
He	O
was	O
not	O
anticoagulated	I-Drug
for	O
his	O
atrial	B-Reason
fibrillation	I-Reason
due	O
to	O
bleeding	O
risk	O
,	O
and	O
due	O
to	O
concern	O
for	O
poor	O
compliance	O
as	O
an	O
outpatient	O
.	O
A	O
repeat	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
global	O
hypokinesis	O
and	O
a	O
depressed	O
EF	O
from	O
40	O
%	O
to	O
30	O
-	O
35	O
%	O
,	O
possibly	O
from	O
stunned	O
myocardium	O
.	O
He	O
will	O
need	O
to	O
have	O
follow	O
up	O
with	O
his	O
outpatient	O
cardiologist	O
.	O
He	O
remained	O
on	O
telemetry	O
with	O
no	O
events	O
.	O
He	O
will	O
need	O
a	O
stress	O
test	O
as	O
an	O
outpatient	O
.	O
He	O
remained	O
chest	O
pain	O
free	O
through	O
his	O
admission	O
.	O
.	O
Lymphoma	I-Reason
:	O
Patient	O
's	O
lymphoma	O
was	O
stable	O
.	O
He	O
received	O
one	O
dose	O
of	O
neupogen	I-Drug
as	O
an	O
inpatient	O
,	O
but	O
had	O
a	O
leukocytosis	I-Ade
.	O
He	O
will	O
be	O
seen	O
in	O
[	O
**	O
Hospital	O
20722	O
**	O
]	O
clinic	O
for	O
consideration	O
of	O
further	O
chemotherapy	I-Drug
.	O
Patient	O
will	O
be	O
seen	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
5565	O
**	O
]	O
as	O
an	O
outpatient	O
.	O
.	O
Patient	O
remained	O
full	O
code	O
.	O
His	O
diet	O
was	O
advanced	O
as	O
tolerated	O
.	O
His	O
electrolytes	I-Drug
were	O
monitored	O
carefully	O
and	O
repleted	O
.	O
Communication	O
was	O
with	O
patient	O
,	O
and	O
son	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2578	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
.	O
C	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
21950	O
**	O
]	O
H	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
21951	O
**	O
]	O
.	O
Patient	O
was	O
seen	O
by	O
physical	O
and	O
occupational	O
therapy	O
.	O
He	O
will	O
be	O
seen	O
by	O
physical	O
therapy	O
at	O
home	O
for	O
services	O
.	O
Medications	O
on	O
Admission	O
:	O
Amlodipine	I-Drug
Digoxin	I-Drug
Bufferin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
56	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Atorvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
28	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
28	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Company	O
1519	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
1	O
.	O
Upper	O
gastrointestinal	O
bleeding	O
2	O
.	O
Gastric	O
ulcers	O
3	O
.	O
ST	O
elevation	O
MI	O
4	O
.	O
Lymphoma	I-Reason
s	O
/	O
p	O
R	B-Drug
-	I-Drug
CHOP	I-Drug
5	O
.	O
Leukopenia	O
6	O
.	O
Lymphoid	O
hyperplasia	O
in	O
duodenal	O
bulb	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
If	O
you	O
develop	O
nausea	O
,	O
vomiting	O
,	O
shortness	O
of	O
breath	O
,	O
blood	O
in	O
your	O
stool	O
,	O
vomiting	O
blood	O
,	O
dizziness	O
on	O
standing	O
,	O
black	O
stools	O
,	O
chest	O
pain	O
,	O
please	O
call	O
your	O
primary	O
care	O
doctor	O
or	O
go	O
to	O
the	O
emergency	O
room	O
.	O
Followup	O
Instructions	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
5566	O
**	O
]	O
[	O
**	O
Name	O
Initial	O
(	O
NameIs	O
)	O
**	O
]	O
.	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
-	O
CC9	O
Date	O
/	O
Time	O
:[	O
**	O
2188-3-6	O
**	O
]	O
2:30	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
647	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2188-3-6	O
**	O
]	O
2:30	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
2788	O
**	O
]	O
CARDIOLOGY	O
-	O
PRIVATE	O
Date	O
/	O
Time	O
:[	O
**	O
2188-5-6	O
**	O
]	O
11:30	O
Please	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
21952	O
**	O
]	O
,	O
your	O
primary	O
care	O
doctor	O
,	O
in	O
the	O
next	O
1	O
-	O
2	O
weeks	O
.	O
The	O
number	O
to	O
call	O
is	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
4775	O
**	O
]	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2172-4-19	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2172-5-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2143-7-2	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Vancomycin	I-Drug
/	O
Gleevec	I-Drug
/	O
Cefepime	B-Drug
Hcl	I-Drug
/	O
Clindamycin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3913	O
**	O
]	O
Chief	O
Complaint	O
:	O
chest	O
and	O
neck	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
16368	O
**	O
]	O
is	O
a	O
28	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
history	O
of	O
biclonal	O
leukemia	O
,	O
diagnosed	O
in	O
[	O
**	O
2169-12-20	O
**	O
]	O
status	O
post	O
chemo	O
initially	O
and	O
then	O
after	O
a	O
relapse	O
of	O
his	O
ALL	O
,	O
he	O
underwent	O
allo	O
BMT	O
transplant	O
on	O
[	O
**	O
2170-5-3	O
**	O
]	O
,	O
but	O
his	O
ALL	O
relapsed	O
in	O
[	O
**	O
2171-7-21	O
**	O
]	O
and	O
was	O
treated	O
with	O
vincristine	I-Drug
,	O
prednisone	I-Drug
,	O
and	O
Gleevec	I-Drug
.	O
The	O
Gleevec	I-Drug
was	O
discontinued	O
because	O
of	O
a	O
reaction	O
to	O
it	O
.	O
Most	O
recently	O
he	O
has	O
received	O
Clofarabine	I-Drug
after	O
which	O
he	O
had	O
an	O
aplastic	O
-	O
looking	O
marrow	O
and	O
received	O
a	O
stem	O
cell	O
boost	O
.	O
His	O
most	O
recent	O
hospitalization	O
was	O
[	O
**	O
10	O
-	O
23	O
**	O
]	O
until	O
[	O
**	O
2172-3-26	O
**	O
]	O
during	O
which	O
he	O
was	O
noted	O
to	O
have	O
pulmonary	O
nodules	O
,	O
and	O
was	O
treated	O
empirically	O
with	O
ambisome	I-Drug
,	O
voriconazole	I-Drug
,	O
and	O
initially	O
capsofungin	I-Drug
and	O
was	O
sent	O
home	O
on	O
ambisome	I-Drug
and	O
voriconazole	I-Drug
.	O
Last	O
dose	O
of	O
ambisome	I-Drug
was	O
[	O
**	O
3	O
-	O
31	O
**	O
]	O
,	O
and	O
he	O
was	O
continued	O
on	O
voriconazole	I-Drug
alone	O
with	O
his	O
last	O
dose	O
on	O
[	O
**	O
4	O
-	O
16	O
**	O
]	O
because	O
the	O
the	O
medication	O
.	O
He	O
was	O
last	O
seen	O
in	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
??????	O
s	O
clinic	O
on	O
[	O
**	O
2172-4-16	O
**	O
]	O
and	O
had	O
been	O
doing	O
well	O
.	O
He	O
had	O
a	O
bone	O
marrow	O
biopsy	O
performed	O
on	O
that	O
day	O
as	O
well	O
.	O
The	O
bone	O
marrow	O
biopsy	O
is	O
pending	O
at	O
this	O
time	O
.	O
The	O
patient	O
presented	O
to	O
the	O
ED	O
on	O
[	O
**	O
4	O
-	O
19	O
**	O
]	O
at	O
04:30	O
complaining	O
of	O
chest	O
and	O
neck	O
pain	O
.	O
The	O
patient	O
states	O
that	O
he	O
was	O
in	O
his	O
usual	O
state	O
of	O
good	O
health	O
until	O
last	O
night	O
when	O
he	O
had	O
gradual	O
onset	O
left	O
neck	O
to	O
substernal	O
chest	O
pain	O
described	O
as	O
"	O
something	O
squeezing	O
in	O
from	O
my	O
lungs	O
,	O
"	O
"	O
pressure	O
,	O
"	O
15/10	O
and	O
pleurtic	O
.	O
He	O
also	O
complains	O
of	O
neck	O
pain	O
which	O
is	O
worse	O
with	O
movement	O
.	O
No	O
associated	O
SOB	O
or	O
diaphoresis	O
.	O
Has	O
had	O
mild	O
nausea	O
since	O
his	O
discharge	O
without	O
emesis	O
.	O
Patient	O
denies	O
f	O
/	O
c	O
,	O
cough	O
,	O
abdominal	O
pain	O
,	O
rash	O
.	O
This	O
pain	O
is	O
similar	O
to	O
pulmonary	O
nodule	O
pain	O
he	O
has	O
had	O
in	O
the	O
past	O
.	O
In	O
the	O
ED	O
,	O
his	O
initial	O
VS	O
were	O
99.2	O
,	O
HR	O
121	O
BP	O
126/78	O
RR	O
16	O
100	O
%	O
on	O
RA	O
.	O
He	O
was	O
given	O
Morphine	I-Drug
8	O
mg	O
iv	O
and	O
dilaudid	I-Drug
8	O
mg	O
iv	O
for	O
pain	B-Reason
control	I-Reason
and	O
became	O
hypotensive	O
with	O
VS	O
116	O
,	O
78/44	O
while	O
in	O
the	O
ED	O
.	O
He	O
recieved	O
6	O
L	O
NS	I-Drug
with	O
only	O
500	O
cc	O
of	O
dark	O
urine	O
output	O
over	O
several	O
hours	O
and	O
was	O
then	O
started	O
on	O
Levophed	I-Drug
for	O
pressure	I-Reason
support	O
.	O
Seen	O
by	O
cardiology	O
consult	O
who	O
felt	O
not	O
consistent	O
with	O
cardiogenic	O
shock	O
.	O
He	O
was	O
admitted	O
to	O
the	O
MICU	O
for	O
further	O
work	O
up	O
and	O
management	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Biclonal	O
leukemia	O
:	O
-	O
Diagnosed	O
[	O
**	O
12	O
-	O
23	O
**	O
]	O
--	O
Presenting	O
with	O
sore	O
throat	O
,	O
severe	O
upper	O
airway	O
inflammation	O
requiring	O
intubation	O
,	O
and	O
a	O
WBC	O
of	O
130,000	O
.	O
Examination	O
of	O
the	O
marrow	O
demonstrated	O
nearly	O
100	O
%	O
blasts	O
,	O
and	O
cytogenetic	O
examination	O
showed	O
t9	O
;	O
22	O
and	O
q341.	O
-	O
q11	O
.2	O
.	O
He	O
was	O
initially	O
treated	O
with	O
emergent	O
pheresis	O
,	O
steroids	I-Drug
,	O
and	O
hydroxyurea	I-Drug
,	O
then	O
was	O
started	O
on	O
regimens	O
to	O
address	O
both	O
ALL	O
and	O
the	O
AML	O
component	O
.	O
He	O
underwent	O
hyperCVAD	O
regimen	O
without	O
complete	O
remission	O
.	O
-	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
--	O
Pt	O
had	O
matched	O
unrelated	O
donor	O
allo	O
-	O
BMT	O
with	O
preceding	O
total	O
body	O
radiation	O
and	O
cytoxan	I-Drug
conditioning	O
regimen	O
.	O
Following	O
this	O
,	O
he	O
exeperienced	O
grade	O
1	O
GvHD	O
with	O
rash	O
,	O
treated	O
with	O
steroid	I-Drug
taper	O
.	O
He	O
had	O
a	O
transaminitis	O
at	O
the	O
time	O
,	O
but	O
bx	O
excluded	O
hepatic	O
GvHD	O
involvement	O
.	O
-	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
46485	O
**	O
]	O
--	O
Marrow	O
bx	O
indicated	O
remission	O
-	O
[	O
**	O
7	O
-	O
23	O
**	O
]	O
--	O
Pt	O
developed	O
petechiae	O
,	O
WBC	O
found	O
to	O
be	O
18.4	O
,	O
platelets	O
of	O
19	O
,	O
18	O
%	O
blasts	O
,	O
and	O
a	O
marrow	O
bx	O
indicated	O
ALL	I-Reason
recurrence	O
.	O
He	O
was	O
treated	O
with	O
vincristine	I-Drug
and	O
prednisone	I-Drug
.	O
-	O
[	O
**	O
2171-8-29	O
**	O
]	O
--	O
A	O
repeat	O
marrow	O
bx	O
indicated	O
residual	O
leukemia	O
,	O
though	O
improved	O
from	O
previous	O
.	O
-	O
[	O
**	O
2171-9-4	O
**	O
]	O
--	O
Pt	O
underwent	O
donor	O
lymphocyte	O
infusion	O
-	O
[	O
**	O
2171-10-14	O
**	O
]	O
--	O
Marrow	O
biopsy	O
shows	O
leukemia	O
with	O
80	O
%	O
involvement	O
,	O
and	O
pt	O
is	O
admitted	O
for	O
hyperCVAD	O
,	O
discharged	O
[	O
**	O
10	O
-	O
17	O
**	O
]	O
.	O
-	O
[	O
**	O
10	O
-	O
23	O
**	O
]	O
-	O
Received	O
Clofarabine	I-Drug
after	O
which	O
he	O
had	O
an	O
aplastic	O
-	O
looking	O
marrow	O
and	O
received	O
a	O
stem	O
cell	O
boost	O
.	O
2	O
.	O
Prolonged	O
Febrile	O
Neutropenia	O
complicated	O
by	O
severe	O
infections	O
including	O
probable	O
fungal	O
infection	O
with	O
pulmonary	O
nodules	O
and	O
mesenteric	O
mass	O
.	O
3	O
.	O
Transaminitis	O
--	O
Liver	O
bx	O
with	O
focal	O
pmn	O
aggregates	O
,	O
no	O
evidence	O
of	O
GvHD	O
[	O
**	O
6	O
-	O
21	O
**	O
]	O
.	O
4	O
.	O
Typhilitis	O
5	O
.	O
Line	O
infection	O
Social	O
History	O
:	O
Lives	O
in	O
[	O
**	O
Location	O
86	O
**	O
]	O
and	O
works	O
as	O
a	O
mechanical	O
engineer	O
.	O
Has	O
a	O
girlfriend	O
.	O
Family	O
is	O
supportive	O
.	O
No	O
tobacco	O
use	O
.	O
Previous	O
occasional	O
etoh	O
use	O
,	O
none	O
currently	O
.	O
No	O
illicit	O
drug	O
use	O
.	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
PE	O
:	O
T	O
100.5	O
HR	O
115	O
BP	O
76/32	O
-	O
106/58	O
(	O
current	O
)	O
R	O
16	O
%	O
Sat	O
99	O
RA	O
Pulsus	O
[	O
**	O
7	O
-	O
29	O
**	O
]	O
Gen	O
:	O
Fatigued	O
,	O
A&O	O
x	O
3	O
,	O
appears	O
mildly	O
uncomfortable	O
HEENT	O
:	O
ATNC	O
,	O
PERRLA	O
,	O
anicteric	O
,	O
OP	O
clear	O
,	O
MMM	O
Neck	O
:	O
Supple	O
,	O
no	O
LAD	O
,	O
Chest	O
:	O
CTA	O
bilat	O
,	O
no	O
egophany	O
or	O
fremitus	O
,	O
resonant	O
Cor	O
:	O
Tachy	O
,	O
nl	O
S1	O
S2	O
no	O
m	O
/	O
r	O
,	O
JVP	O
flat	O
Abd	O
:	O
Soft	O
,	O
nt	O
/	O
nd	O
,	O
no	O
HSM	O
/	O
M	O
hypoactive	O
BS	O
Ext	O
:	O
Warm	O
,	O
Skin	O
:	O
No	O
rashes	O
,	O
petechiae	O
.	O
Flat	O
smooth	O
1.3	O
cm	O
eschar	O
on	O
L	O
medial	O
shin	O
[	O
burn	O
site	O
]	O
Pertinent	O
Results	O
:	O
CXR	O
:	O
[	O
**	O
4	O
-	O
20	O
**	O
]	O
There	O
has	O
been	O
interval	O
development	O
of	O
patchy	O
opacification	O
at	O
the	O
left	O
lung	O
base	O
peripherally	O
.	O
Cardiac	O
and	O
mediastinal	O
contours	O
are	O
normal	O
.	O
Pulmonary	O
vasculature	O
remains	O
normal	O
.	O
The	O
osseous	O
structures	O
are	O
unremarkable	O
.	O
The	O
right	O
-	O
sided	O
central	O
venous	O
catheter	O
is	O
stable	O
in	O
position	O
.	O
IMPRESSION	O
:	O
Interval	O
development	O
of	O
new	O
left	O
-	O
sided	O
patchy	O
opacification	O
,	O
left	O
lung	O
base	O
.	O
Given	O
the	O
patient	O
's	O
history	O
of	O
ALL	O
,	O
this	O
is	O
concerning	O
for	O
developing	O
pnemonia	O
.	O
Chest	O
/	O
Abd	O
/	O
pelvis	O
CT	O
[	O
**	O
2172-4-19	O
**	O
]	O
:	O
1	O
)	O
Hazy	O
opacity	O
within	O
the	O
right	O
lower	O
lobe	O
,	O
a	O
finding	O
that	O
could	O
partly	O
related	O
to	O
atelectasis	O
,	O
although	O
is	O
suspicious	O
for	O
pneumonia	O
given	O
its	O
asymmetry	O
.	O
2	O
)	O
No	O
evidence	O
of	O
pulmonary	O
embolus	O
or	O
aortic	O
dissection	O
.	O
3	O
)	O
Stable	O
small	O
to	O
moderate	O
pericardial	O
effusion	O
.	O
4	O
)	O
Decreased	O
size	O
of	O
mesenteric	O
mass	O
,	O
which	O
is	O
now	O
not	O
measurable	O
,	O
with	O
minimal	O
residual	O
haziness	O
in	O
the	O
mesentery	O
.	O
[	O
**	O
2172-4-21	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
WBC	O
-	O
3.3	O
*	O
#	O
RBC	O
-	O
3.18	O
*	O
Hgb	O
-	O
10.2	O
*	O
Hct	O
-	O
28.6	O
*	O
MCV	O
-	O
90	O
MCH	O
-	O
32.1	O
*	O
MCHC	O
-	O
35.7	O
*	O
RDW	O
-	O
18.3	O
*	O
Plt	O
Ct	O
-	O
118	O
*	O
[	O
**	O
2172-4-20	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
WBC	O
-	O
8.2	O
RBC	O
-	O
3.91	O
*	O
#	O
Hgb	O
-	O
12.1	O
*	O
#	O
Hct	O
-	O
34.4	O
*	O
#	O
MCV	O
-	O
88	O
MCH	O
-	O
31.0	O
MCHC	O
-	O
35.2	O
*	O
RDW	O
-	O
16.9	O
*	O
Plt	O
Ct	O
-	O
130	O
*	O
[	O
**	O
2172-4-19	O
**	O
]	O
08:05	O
AM	O
BLOOD	O
WBC	O
-	O
7.1	O
RBC	O
-	O
2.68	O
*	O
#	O
Hgb	O
-	O
8.4	O
*	O
#	O
Hct	O
-	O
24.4	O
*	O
#	O
MCV	O
-	O
91	O
MCH	O
-	O
31.5	O
MCHC	O
-	O
34.5	O
RDW	O
-	O
17.5	O
*	O
Plt	O
Ct	O
-	O
145	O
*	O
[	O
**	O
2172-4-19	O
**	O
]	O
02:20	O
AM	O
BLOOD	O
Neuts	O
-	O
84.2	O
*	O
Lymphs	O
-	O
9.7	O
*	O
Monos	O
-	O
4.2	O
Eos	O
-	O
1.6	O
Baso	O
-	O
0.3	O
[	O
**	O
2172-4-20	O
**	O
]	O
05:05	O
AM	O
BLOOD	O
Neuts	O
-	O
94	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
3	O
*	O
Monos	O
-	O
2	O
Eos	O
-	O
1	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2172-4-21	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
PT	O
-	O
14.1	O
*	O
PTT	O
-	O
31.8	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
[	O
**	O
2172-4-21	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
Glucose	O
-	O
108	O
*	O
UreaN	O
-	O
17	O
Creat	O
-	O
1.2	O
Na	O
-	O
141	O
K	O
-	O
3.9	O
Cl	O
-	O
113	O
*	O
HCO3	O
-	O
22	O
AnGap	O
-	O
10	O
[	O
**	O
2172-4-19	O
**	O
]	O
02:20	O
AM	O
BLOOD	O
LD	O
(	O
LDH	O
)	O
-	O
152	O
CK	O
(	O
CPK	O
)	O
-	O
26	O
*	O
[	O
**	O
2172-4-19	O
**	O
]	O
08:05	O
AM	O
BLOOD	O
LD	O
(	O
LDH	O
)	O
-	O
83	O
*	O
CK	O
(	O
CPK	O
)	O
-	O
15	O
*	O
TotBili	O
-	O
0.8	O
DirBili	O
-	O
0.2	O
IndBili	O
-	O
0.6	O
[	O
**	O
2172-4-19	O
**	O
]	O
04:12	O
PM	O
BLOOD	O
CK	O
(	O
CPK	O
)	O
-	O
23	O
*	O
[	O
**	O
2172-4-19	O
**	O
]	O
02:20	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2172-4-19	O
**	O
]	O
08:05	O
AM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2172-4-19	O
**	O
]	O
04:12	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
1	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2172-4-21	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
Calcium	O
-	O
8.2	O
*	O
Phos	O
-	O
2.3	O
*	O
Mg	O
-	O
2.0	O
[	O
**	O
2172-4-19	O
**	O
]	O
08:05	O
AM	O
BLOOD	O
Hapto	O
-	O
72	O
[	O
**	O
2172-4-21	O
**	O
]	O
05:50	O
AM	O
BLOOD	O
ASPERGILLUS	O
GALACTOMANNAN	O
ANTIGEN	O
-	O
PND	O
Brief	O
Hospital	O
Course	O
:	O
#Hypotension	O
:	O
Original	O
ddx	O
was	O
early	O
sepsis	O
vs.	O
narcotics	I-Drug
related	O
vs.	O
cardiogenic	O
vs	O
adrenal	O
insufficiency	O
.	O
He	O
required	O
levophed	I-Drug
and	O
aggressive	O
fluid	O
hydration	O
to	O
maintain	O
SBP	O
>	O
100	O
and	O
was	O
started	O
on	O
fludrocotisone	I-Drug
for	O
possible	O
adrenal	I-Reason
insufficiency	O
.	O
Pt	O
had	O
flat	O
JVP	O
and	O
warm	O
extremities	O
,	O
no	O
evidence	O
of	O
tamponade	O
.	O
He	O
was	O
ruled	O
out	O
for	O
MI	O
by	O
enzymes	O
,	O
and	O
cardiology	O
consult	O
did	O
not	O
not	O
think	O
picture	O
was	O
c	O
/	O
w	O
cardiogenic	O
shock	O
.	O
A	O
cortasyn	O
stim	O
test	O
was	O
performed	O
and	O
he	O
was	O
seen	O
to	O
respond	O
,	O
so	O
we	O
discontinued	O
fludrocortisone	I-Drug
and	O
hydrocortisone	I-Drug
.	O
Sepsis	O
was	O
considered	O
and	O
he	O
was	O
broadly	O
covered	O
on	O
admission	O
with	O
ambisome	I-Drug
,	O
imipenem	I-Drug
,	O
voriconazole	I-Drug
.	O
He	O
was	O
weaned	O
off	O
vasopressors	I-Drug
and	O
IVF	I-Drug
on	O
HD3	O
and	O
SBP	O
's	O
remained	O
in	O
the	O
90's	O
but	O
he	O
was	O
asymptomatic	O
,	O
making	O
urine	O
,	O
and	O
had	O
normal	O
lactate	O
so	O
no	O
further	O
intervention	O
was	O
made	O
.	O
.	O
#ID	O
:	O
a	O
)	O
Pulmonary	O
nodules	O
:	O
Pt	O
had	O
history	O
of	O
pulmonary	O
nodules	O
thought	O
to	O
be	O
of	O
fungal	O
origin	O
without	O
positive	O
cultures	O
data	O
.	O
He	O
had	O
been	O
on	O
empiric	O
treatment	O
for	O
fungal	B-Reason
process	I-Reason
with	O
ambisome	I-Drug
and	O
vorinazole	I-Drug
for	O
3	O
months	O
,	O
then	O
voriconazole	I-Drug
alone	O
since	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
,	O
but	O
was	O
off	O
this	O
for	O
four	O
days	O
before	O
admission	O
.	O
Chest	O
CT	O
revealed	O
no	O
nodular	O
infection	O
but	O
a	O
RLL	O
infiltrate	O
concerning	O
for	O
CAP	I-Reason
and	O
on	O
HD2	O
was	O
started	O
on	O
levofloxacin	I-Drug
.	O
At	O
that	O
same	O
time	O
he	O
was	O
started	O
on	O
Vancomycin	I-Drug
since	O
his	O
allergy	O
was	O
questionable	O
and	O
he	O
had	O
a	O
permanent	O
tunneled	O
line	O
.	O
He	O
developed	O
periorbital	B-Ade
edema	I-Ade
and	O
diffuse	B-Ade
skin	I-Ade
etyhema	I-Ade
,	O
elevated	B-Ade
LFT	I-Ade
's	I-Ade
and	O
eosinophilia	I-Ade
thought	O
initially	O
due	O
to	O
vancomycin	I-Drug
so	O
this	O
was	O
stopped	O
.	O
Vancomycin	I-Drug
was	O
changed	O
to	O
daptomycin	I-Drug
which	O
was	O
stopped	O
[	O
**	O
4	O
-	O
21	O
**	O
]	O
given	O
blood	O
cultures	O
remained	O
negative	O
x	O
48	O
hours	O
.	O
Infectious	O
workup	O
in	O
looking	O
for	O
source	O
of	O
sepsis	O
included	O
urine	O
,	O
blood	O
and	O
sputum	O
culture	O
,	O
fungal	O
,	O
AFB	O
,	O
PCP	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
14616	O
**	O
]	O
,	O
mycoplasma	O
,	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
14616	O
**	O
]	O
urine	O
Ag	O
,	O
galatomannan	O
all	O
of	O
which	O
were	O
negative	O
.	O
Pt	O
's	O
LFT	O
's	O
continued	O
to	O
rise	O
off	O
of	O
the	O
vancomycin	I-Drug
so	O
the	O
levofloxacin	I-Drug
was	O
changed	O
to	O
azithromycin	I-Drug
which	O
he	O
completed	O
a	O
10	O
day	O
course	O
of	O
.	O
He	O
was	O
then	O
started	O
on	O
voriconazole	I-Drug
as	O
below	O
for	O
risk	O
of	O
recurrence	O
of	O
fungal	B-Reason
infection	I-Reason
with	O
immunosuppressive	O
treatment	O
for	O
GVHD	O
as	O
below	O
.	O
Elevated	O
LFT	O
's	O
-	O
Pt	O
continued	O
to	O
have	O
climbing	O
LFT	O
with	O
a	O
cholestatic	O
picture	O
initially	O
thought	O
to	O
be	O
due	O
to	O
drug	O
reaction	O
by	O
both	O
ID	O
and	O
dermatology	O
.	O
Skin	O
biopsy	O
showed	O
complete	O
separation	O
of	O
dermis	O
and	O
epidermis	O
consistent	O
with	O
drug	O
rash	O
.	O
Alkaline	O
phosphatase	O
continued	O
to	O
rise	O
despite	O
rash	O
improving	O
so	O
then	O
arose	O
concern	O
for	O
GVHD	O
as	O
had	O
occured	O
in	O
the	O
past	O
.	O
At	O
this	O
point	O
he	O
was	O
started	O
on	O
cyclosporine	I-Drug
dosed	O
to	O
trough	O
>	O
100	O
and	O
a	O
day	O
later	O
Mycofenolate	I-Drug
was	O
added	O
.	O
Liver	O
team	O
was	O
consulted	O
and	O
felt	O
this	O
was	O
most	O
likely	O
GVHD	O
and	O
got	O
a	O
liver	O
biopsy	O
.	O
Biopsy	O
revealed	O
diffuse	O
biliary	O
destruction	O
consistent	O
with	O
GVHD	O
although	O
it	O
was	O
unclear	O
if	O
this	O
was	O
old	O
or	O
new	O
.	O
He	O
was	O
continued	O
on	O
immunosuppressive	O
therapy	O
as	O
above	O
and	O
on	O
[	O
**	O
5	O
-	O
3	O
**	O
]	O
was	O
feeling	O
well	O
so	O
plan	O
was	O
made	O
for	O
further	O
workup	O
and	O
treatment	O
of	O
elevated	O
LFT	O
's	O
as	O
an	O
outpt	O
.	O
.	O
#Chest	O
/	O
Neck	O
pain	O
:	O
T	O
wave	O
changes	O
on	O
EKG	O
were	O
non-diagnostic	O
.	O
It	O
did	O
n't	O
appear	O
to	O
be	O
due	O
to	O
ischemia	O
given	O
he	O
was	O
ruled	O
out	O
for	O
MI	O
with	O
serial	O
enzymes	O
and	O
had	O
no	O
events	O
on	O
telemetry	O
.	O
CTA	O
showed	O
no	O
PE	O
/	O
aortic	O
dissection	O
.	O
Most	O
likely	O
cause	O
of	O
pain	O
is	O
pleuritic	B-Reason
chest	I-Reason
pain	I-Reason
from	O
pneumonia	O
.	O
He	O
was	O
treated	O
with	O
his	O
outpatient	O
dose	O
of	O
oxycontin	I-Drug
in	O
hospital	O
which	O
he	O
responded	O
well	O
to	O
.	O
.	O
#Anemia	O
:	O
baseline	O
hct	O
was	O
around	O
28	O
thought	O
to	O
be	O
anemia	O
of	O
chronic	O
diseae	O
.	O
Hemolysis	O
labs	O
were	O
negative	O
Medications	O
on	O
Admission	O
:	O
Acyclovir	I-Drug
400	O
mg	O
po	O
bid	O
(	O
For	O
Zoster	O
ppx	O
)	O
Voriconazole	I-Drug
200	O
mg	O
po	O
bid	O
(	O
unable	O
to	O
fill	O
for	O
last	O
three	O
days	O
)	O
Imipenenem	I-Drug
500	O
mg	O
q	O
6	O
hour	O
Aerosolized	O
pentamidine	I-Drug
qmonth	O
(	O
For	O
PCP	O
[	O
**	O
Name9	O
(	O
PRE	O
)	O
**	O
]	O
last	O
dose4	O
/	O
19	O
)	O
Diphenhydramine	I-Drug
prn	O
Oxycodone	B-Drug
SR	I-Drug
60	O
mg	O
po	O
bid	O
Oxycodone	I-Drug
5	O
-	O
10	O
mg	O
po	O
q6h	O
breakthrough	O
Lorazepam	I-Drug
2	O
mg	O
po	O
q4	O
-	O
6h	O
prn	O
Discharge	O
Medications	O
:	O
1	O
.	O
Oxycodone	B-Drug
HCl	I-Drug
20	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
2	O
.	O
Voriconazole	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
28	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Acyclovir	I-Drug
200	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Mycophenolate	B-Drug
Mofetil	I-Drug
250	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
5	O
.	O
Prednisone	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
21	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
30	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
qhs	O
/	O
prn	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
Oxycodone	B-Drug
HCl	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q4	O
-	O
6	O
hous	O
/	O
prn	O
as	O
needed	O
for	O
pain	I-Reason
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
Oxycodone	B-Drug
HCl	I-Drug
10	O
mg	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
Sustained	O
Release	O
12	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Mycophenolate	B-Drug
Mofetil	I-Drug
500	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Critical	O
Care	O
Systems	O
Discharge	O
Diagnosis	O
:	O
GVHD	O
CAP	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
daily	O
on	O
[	O
**	O
Hospital	O
Ward	O
Name	O
1826	O
**	O
]	O
7	O
for	O
measurement	O
of	O
your	O
LFT	O
's	O
and	O
to	O
continue	O
following	O
your	O
rash	O
.	O
Followup	O
Instructions	O
:	O
Needs	O
ECHO	O
in	O
2	O
weeks	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2137-1-31	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2137-2-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2091-1-5	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Codeine	I-Drug
/	O
Percocet	I-Drug
/	O
Demerol	I-Drug
/	O
Ceftin	I-Drug
/	O
Toradol	I-Drug
/	O
Naprosyn	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3984	O
**	O
]	O
Chief	O
Complaint	O
:	O
Abdominal	O
/	O
back	O
pain	O
s	O
/	O
p	O
nephrostomy	O
tube	O
replacement	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
,	O
also	O
fever	O
/	O
chills	O
.	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
45	O
yo	O
woman	O
with	O
recurrent	O
Stage	O
III	O
papillary	O
serous	O
Ovarian	O
CA	O
s	O
/	O
p	O
TAH	O
/	O
BSO	O
,	O
two	O
subsequent	O
tumor	O
debulkings	O
,	O
chemotherapy	O
,	O
RT	O
,	O
now	O
receiving	O
home	O
hospice	O
,	O
who	O
is	O
referred	O
s	O
/	O
p	O
nephrostogram	O
/	O
tube	O
replacement	O
with	O
RLQ	O
pain	O
,	O
R	O
flank	O
pain	O
,	O
fever	O
/	O
chills	O
since	O
day	O
prior	O
to	O
yesterday	O
.	O
She	O
also	O
reports	O
diarrhea	O
that	O
has	O
since	O
resolved	O
.	O
She	O
denies	O
nausea	O
/	O
vomiting	O
.	O
The	O
remainder	O
of	O
her	O
ROS	O
is	O
negative	O
.	O
Past	O
Medical	O
History	O
:	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
-	O
Stage	O
III	O
papillary	O
serous	O
ovarian	O
cancer	O
s	O
/	O
p	O
chemotherapy	O
currently	O
receiving	O
RT	O
-	O
recurrent	O
UTI	O
with	O
e.	O
coli	O
and	O
enterococcus	O
-	O
Recent	O
hospitalization	O
for	O
pyelonephritis	O
-	O
migraine	O
headaches	O
-	O
atrophic	O
left	O
kidney	O
-	O
congenitally	O
atrophic	O
right	O
arm	O
below	O
the	O
elbow	O
-	O
seasonal	O
asthma	O
-	O
HTN	O
PAST	O
SURGICAL	O
HISTORY	O
1	O
.	O
Cholecystectomy	O
2	O
.	O
Ovarian	O
cancer	O
cytoreduction	O
s	O
/	O
p	O
TAH	O
-	O
BSO	O
&	O
omentectomy	O
in	O
'	O
[	O
**	O
25	O
**	O
]	O
,	O
then	O
2	O
debulking	O
surgeries	O
in	O
'	O
[	O
**	O
31	O
**	O
]	O
and	O
'	O
[	O
**	O
35	O
**	O
]	O
;	O
3	O
.	O
R	O
ureteral	O
stent	O
[	O
**	O
2136-5-18	O
**	O
]	O
for	O
right	O
-	O
sided	O
hydronephrosis	O
secondary	O
to	O
extrinsic	O
ureteric	O
compression	O
from	O
advanced	O
ovarian	O
cancer	O
,	O
R	O
percutaneous	O
nephrostomy	O
on	O
[	O
**	O
2136-6-8	O
**	O
]	O
,	O
with	O
replacement	O
by	O
IR	O
[	O
**	O
2137-1-31	O
**	O
]	O
(	O
pyelogram	O
revealed	O
distal	O
obstruction	O
)	O
Social	O
History	O
:	O
Lives	O
with	O
:	O
27	O
year	O
old	O
daughter	O
(	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
)	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
2251	O
**	O
]	O
Occupation	O
:	O
previously	O
worked	O
in	O
medical	O
billing	O
at	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
Tobacco	O
:	O
Smoked	O
1	O
pack	O
per	O
month	O
x15	O
years	O
;	O
quit	O
several	O
yeas	O
ago	O
EtOH	O
:	O
Denies	O
Drugs	O
:	O
Denies	O
Mood	O
:	O
Depressed	O
Support	O
system	O
:	O
Feels	O
support	O
from	O
daughter	O
/	O
friends	O
"	O
sometimes	O
"	O
Family	O
History	O
:	O
Mother	O
:	O
Recurrent	O
lung	O
CA	O
;	O
DM	O
Father	O
:	O
HTN	O
,	O
CVA	O
at	O
age	O
48	O
Sister	O
:	O
Cervical	O
CA	O
Physical	O
Exam	O
:	O
T	O
98.9	O
8492/44	O
15	O
98	O
NAD	O
RRR	O
CTAB	O
Abd	O
soft	O
+	O
TTP	O
RLQ	O
no	O
g	O
/	O
r	O
+	O
R	O
CVAT	O
Nephrostomy	O
tube	O
in	O
place	O
,	O
site	O
intact	O
with	O
no	O
erythema	O
/	O
exudate	O
Pelvic	O
deferred	O
Pertinent	O
Results	O
:	O
Labs	O
:	O
WBC	O
6.3	O
(	O
68	O
%	O
PMNs	O
,	O
0	O
bands	O
)	O
,	O
HCT	O
26.3	O
(	O
baseline	O
27	O
-	O
31	O
)	O
,	O
PLT	O
492	O
(	O
baseline	O
200	O
)	O
PT	O
12.9	O
INR	O
1.1	O
PTT	O
31.0	O
Creatinine	O
1.1	O
(	O
baseline	O
1.3	O
)	O
Na	O
142	O
,	O
K	O
4.1	O
,	O
Cl	O
107	O
,	O
HCO3	O
27	O
,	O
BUN11	O
,	O
Gluc	O
92	O
Brief	O
Hospital	O
Course	O
:	O
45	O
yo	O
woman	O
with	O
recurrent	O
Stage	O
III	O
papillary	O
serous	O
Ovarian	O
CA	O
s	O
/	O
p	O
TAH	O
/	O
BSO	O
,	O
two	O
subsequent	O
tumor	O
debulkings	O
,	O
chemotherapy	O
,	O
RT	O
,	O
now	O
receiving	O
home	O
hospice	O
,	O
who	O
is	O
referred	O
s	O
/	O
p	O
nephrostogram	O
/	O
tube	O
replacement	O
with	O
RLQ	O
pain	O
,	O
R	O
flank	O
pain	O
,	O
fever	O
/	O
chills	O
since	O
[	O
**	O
1	O
-	O
29	O
**	O
]	O
.	O
At	O
presentation	O
on	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
,	O
there	O
was	O
no	O
clear	O
evidence	O
of	O
infection	O
given	O
that	O
her	O
WBC	O
was	O
normal	O
and	O
she	O
was	O
afebrile	O
.	O
Her	O
nephrostomy	O
pigtail	O
was	O
replaced	O
and	O
antegrade	O
pyelogram	O
indicated	O
functional	O
nephrostomy	O
tube	O
and	O
persistent	O
distal	O
ureteral	O
obstruction	O
.	O
On	O
CXR	O
,	O
the	O
lungs	O
were	O
clear	O
.	O
She	O
was	O
admitted	O
for	O
pain	O
control	O
.	O
However	O
,	O
her	O
UA	O
revealed	O
>	O
100K	O
WBCs	O
and	O
,	O
on	O
[	O
**	O
2	O
-	O
1	O
**	O
]	O
,	O
she	O
mounted	O
a	O
fever	I-Reason
to	O
100.7	O
F	O
.	O
She	O
was	O
placed	O
on	O
zosyn	I-Drug
and	O
vancomycin	I-Drug
was	O
added	O
when	O
she	O
was	O
persistently	B-Reason
febrile	I-Reason
.	O
Despite	O
urine	O
WBC	O
count	O
as	O
above	O
,	O
urine	O
cultures	O
revealed	O
only	O
yeast	O
10	O
-	O
100K	O
.	O
A	O
pain	O
consult	O
was	O
requested	O
and	O
they	O
recommended	O
dilaudid	I-Drug
PCA	O
.	O
She	O
was	O
started	O
on	O
the	O
dilaudid	I-Drug
PCA	O
,	O
but	O
had	O
several	O
episodes	O
of	O
hypotension	I-Ade
while	O
on	O
increased	O
narcotics	I-Drug
for	O
her	O
pain	I-Reason
requiring	O
transfer	O
to	O
the	O
ICU	O
for	O
monitoring	O
.	O
Her	O
PCA	O
was	O
discontinued	O
and	O
her	O
fentanyl	I-Drug
patch	O
was	O
restarted	O
.	O
Psychiatry	O
was	O
consulted	O
for	O
management	O
of	O
depression	I-Reason
and	O
affective	O
instability	O
and	O
recommendations	O
regarding	O
her	O
multiple	O
medications	O
including	O
clonazepam	I-Drug
,	O
lorazepam	I-Drug
,	O
mirtazapine	I-Drug
and	O
narcotics	I-Drug
.	O
During	O
her	O
stay	O
,	O
she	O
was	O
showing	O
signs	O
of	O
mild	O
delirium	O
with	O
decreased	O
attention	O
and	O
concentration	O
.	O
Thus	O
psychiatry	O
recommended	O
continuing	O
her	O
mirtazapine	I-Drug
and	O
clonazepam	I-Drug
,	O
but	O
suggested	O
limiting	O
prn	O
ativan	I-Drug
and	O
narcotics	I-Drug
as	O
possible	O
,	O
recognizing	O
the	O
difficulty	O
in	O
this	O
given	O
her	O
chronic	O
pain	I-Reason
.	O
They	O
also	O
suggested	O
using	O
seroquel	I-Drug
for	O
anxiety	I-Reason
and	O
insomnia	I-Reason
.	O
In	O
the	O
setting	O
of	O
increased	O
pain	B-Drug
medication	I-Drug
,	O
specifically	O
narcotics	I-Drug
,	O
she	O
became	O
hypotensive	I-Ade
to	O
70s	O
systolic	O
.	O
She	O
was	O
mildly	O
lightheaded	O
at	O
this	O
time	O
.	O
She	O
was	O
transferred	O
to	O
the	O
ICU	O
where	O
she	O
received	O
IV	O
fluids	I-Drug
to	O
which	O
her	O
BP	O
responded	O
with	O
systolics	O
returning	O
to	O
the	O
low	O
100s	O
mmHg	O
.	O
Her	O
hypotension	I-Ade
was	O
thought	O
more	O
likely	O
[	O
**	O
2	O
-	O
8	O
**	O
]	O
to	O
her	O
pain	B-Drug
medication	I-Drug
regimen	O
and	O
poor	O
PO	O
rather	O
than	O
hypotension	O
[	O
**	O
2	O
-	O
8	O
**	O
]	O
to	O
sepsis	O
.	O
During	O
her	O
stay	O
,	O
multiple	O
family	O
meetings	O
including	O
her	O
pastor	O
were	O
had	O
to	O
evaluate	O
code	O
status	O
.	O
She	O
had	O
previously	O
been	O
in	O
the	O
care	O
of	O
hospice	O
prior	O
to	O
this	O
admission	O
.	O
During	O
her	O
stay	O
in	O
the	O
setting	O
of	O
hypotension	O
,	O
code	O
status	O
was	O
readdressed	O
and	O
she	O
decided	O
that	O
she	O
no	O
longer	O
wished	O
DNR	O
/	O
DNI	O
,	O
but	O
wanted	O
full	O
code	O
.	O
While	O
in	O
the	O
ICU	O
,	O
this	O
was	O
again	O
readdressed	O
with	O
her	O
family	O
,	O
pastor	O
,	O
and	O
patient	O
,	O
and	O
code	O
status	O
was	O
changed	O
to	O
CMO	O
.	O
She	O
requested	O
transfer	O
back	O
to	O
her	O
home	O
hospice	O
care	O
.	O
Medications	O
on	O
Admission	O
:	O
Fentanyl	I-Drug
150	O
mcg	O
/	O
hr	O
Patch	O
Lorazepam	I-Drug
1	O
mg	O
prn	O
Clonazepam	I-Drug
0.5	O
mg	O
HS	O
Hydromorphone	I-Drug
10	O
mg	O
PRN	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
po	O
bid	O
Senna	I-Drug
QD	O
Reglan	I-Drug
PRN	O
Mirtazapine	I-Drug
30	O
mg	O
HS	O
Omeprazole	I-Drug
20	O
mg	O
QD	O
Discharge	O
Medications	O
:	O
1	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
3	O
.	O
Clonazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
4	O
.	O
Mirtazapine	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
as	O
needed	O
.	O
5	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
6	O
.	O
Metoclopramide	I-Drug
10	O
mg	O
IV	O
Q6H	O
:	O
PRN	O
7	O
.	O
Zyprexa	B-Drug
Zydis	I-Drug
5	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
at	O
bedtime	O
:	O
Please	O
give	O
at	O
10	O
pm	O
.	O
8	O
.	O
Ibuprofen	I-Drug
600	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
.	O
9	O
.	O
Ativan	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
-	O
1	O
Tablet	O
PO	O
every	O
4	O
-	O
6	O
hours	O
as	O
needed	O
for	O
agitation	I-Reason
.	O
10	O
.	O
Ativan	I-Drug
2	O
mg	O
/	O
mL	O
Syringe	O
Sig	O
:	O
0.5	O
-	O
1	O
mg	O
Injection	O
every	O
[	O
**	O
6	O
-	O
14	O
**	O
]	O
hours	O
as	O
needed	O
for	O
agitation	I-Reason
:	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
give	O
IV	O
or	O
SC	O
.	O
11	O
.	O
Quetiapine	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
Q4H	O
PRN	O
AND	O
HS	O
PRN	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
12	O
.	O
Clonidine	I-Drug
0.1	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
twice	O
a	O
day	O
.	O
13	O
.	O
Fentanyl	I-Drug
100	O
mcg	O
/	O
hr	O
Patch	O
72	O
HR	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
patches	O
Transdermal	O
every	O
seventy	O
-	O
two	O
(	O
72	O
)	O
hours	O
.	O
14	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
15	O
.	O
Morphine	I-Drug
10	O
mg	O
/	O
5	O
mL	O
Solution	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ml	O
PO	O
q4hrs	O
:	O
prn	O
as	O
needed	O
for	O
pain	I-Reason
.	O
16	O
.	O
Haloperidol	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
:	O
prn	O
as	O
needed	O
for	O
agitation	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital	O
2255	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
2256	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
ovarian	O
cancer	O
abdominal	O
pain	O
depression	O
anxiety	O
renal	O
insufficiency	O
urinary	O
tract	O
infection	O
hypertension	O
Discharge	O
Condition	O
:	O
Good	O
Discharge	O
Instructions	O
:	O
Call	O
if	O
fever	O
,	O
worsening	O
pain	O
,	O
other	O
concerns	O
/	O
questions	O
Followup	O
Instructions	O
:	O
Home	O
Hospice	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2437	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
2438	O
**	O
]	O

Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
18458	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2133-9-8	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2133-9-10	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2064-8-27	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
VSU	O
CHIEF	O
COMPLAINT	O
:	O
Thoracoabdominal	O
aortic	O
aneurysm	O
.	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
This	O
is	O
a	O
69	O
-	O
year	O
-	O
old	O
female	O
who	O
was	O
transferred	O
from	O
[	O
**	O
Hospital	O
8	O
**	O
]	O
Hospital	O
with	O
a	O
known	O
TAA	O
who	O
presented	O
with	O
a	O
heart	O
rate	O
in	O
the	O
40s	O
,	O
blood	O
pressures	O
in	O
the	O
70s	O
.	O
A	O
CT	O
was	O
done	O
which	O
showed	O
fusiform	O
TAA	O
with	O
contained	O
rupture	O
at	O
the	O
SMA	O
.	O
Creatinine	O
was	O
elevated	O
at	O
1.9	O
,	O
baseline	O
0.9	O
.	O
The	O
patient	O
denied	O
any	O
symptoms	O
.	O
The	O
patient	O
was	O
transferred	O
here	O
for	O
further	O
treatment	O
and	O
evaluation	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
COPD	I-Reason
O2	I-Drug
dependent	O
,	O
pulmonary	O
hypertension	O
with	O
a	O
pulmonary	O
artery	O
pressure	O
of	O
77	O
,	O
steroid	I-Drug
dependent	O
COPD	I-Reason
,	O
current	O
tobacco	O
user	O
,	O
history	O
of	O
coronary	O
artery	O
disease	O
status	O
post	O
myocardial	O
infarction	O
,	O
history	O
of	O
transitional	O
cell	O
renal	O
cell	O
carcinoma	O
status	O
post	O
left	O
nephrectomy	O
,	O
history	O
of	O
spinal	O
canal	O
surgery	O
status	O
post	O
lumbar	O
surgery	O
,	O
history	O
of	O
GERD	O
,	O
history	O
of	O
depression	O
,	O
history	O
of	O
steroid	I-Drug
myopathy	I-Ade
,	O
history	O
of	O
anal	B-Reason
squamous	I-Reason
cell	I-Reason
carcinoma	O
status	O
post	O
chemotherapy	I-Drug
and	O
radiation	O
,	O
history	O
of	O
type	O
2	O
diabetes	O
controlled	O
,	O
history	O
of	O
carotid	O
disease	O
status	O
post	O
left	O
CEA	O
,	O
status	O
post	O
total	O
abdominal	O
hysterectomy	O
.	O
Aortic	O
aneurysm	O
,	O
carotid	O
stenosis	O
status	O
post	O
left	O
carotid	O
endarterectomy	O
,	O
osteoarthritis	O
status	O
post	O
right	O
hip	O
replacement	O
,	O
squamous	O
cell	O
carcinoma	O
anal	O
status	O
post	O
radiation	O
and	O
chemotherapy	O
,	O
status	O
post	O
transitional	O
cell	O
carcinoma	O
status	O
post	O
left	O
nephrectomy	O
radical	O
.	O
History	O
of	O
COPD	I-Reason
with	O
pulmonary	O
hypertension	O
,	O
O2	I-Drug
dependent	O
,	O
steroid	I-Drug
dependent	O
.	O
Right	O
middle	O
lobe	O
pulmonary	O
nodule	O
.	O
Current	O
smoker	O
.	O
Type	O
2	O
diabetes	O
noninsulin	O
-	O
dependent	O
controlled	O
.	O
History	O
of	O
spinal	O
canal	O
stenosis	O
status	O
post	O
lumbar	O
surgery	O
.	O
History	O
of	O
GERD	O
.	O
History	O
of	O
coronary	O
artery	O
disease	O
status	O
post	O
myocardial	O
infarction	O
.	O
History	O
of	O
steroid	I-Drug
myopathy	I-Ade
.	O
History	O
of	O
pulmonary	O
hypertension	O
.	O
Status	O
post	O
total	O
abdominal	O
hysterectomy	O
,	O
status	O
post	O
appendectomy	O
.	O
MEDICATIONS	O
:	O
On	O
admission	O
Lipitor	I-Drug
10	O
mg	O
daily	O
,	O
sertraline	I-Drug
100	O
mg	O
daily	O
,	O
tizanidine	I-Drug
4	O
mg	O
q.i.d.	O
,	O
Spirolactone	I-Drug
25	O
mg	O
daily	O
,	O
Toprol	B-Drug
XL	I-Drug
50	O
mg	O
daily	O
,	O
lisinopril	I-Drug
10	O
mg	O
daily	O
,	O
magnesium	B-Drug
oxide	I-Drug
400	O
mg	O
daily	O
,	O
Protonix	I-Drug
40	O
mg	O
daily	O
,	O
Plavix	I-Drug
75	O
mg	O
daily	O
,	O
Mirapex	I-Drug
0.125	O
mg	O
t.i.d.	O
,	O
gabapentin	I-Drug
300	O
mg	O
in	O
the	O
a.m.	O
and	O
afternoon	O
and	O
600	O
mg	O
at	O
bedtime	O
,	O
trazodone	I-Drug
300	O
mg	O
at	O
h.s.	O
,	O
calcium	I-Drug
600	O
mg	O
t.i.d.	O
,	O
aspirin	I-Drug
325	O
mg	O
daily	O
,	O
Advair	I-Drug
[	O
**	O
5	O
-	O
/	O
2076	O
**	O
]	O
1	O
puff	O
b.i.d.	O
,	O
DuoNeb	I-Drug
treatments	O
4	O
times	O
a	O
day	O
.	O
SOCIAL	O
HISTORY	O
:	O
Current	O
smoker	O
of	O
a	O
pack	O
per	O
day	O
.	O
The	O
patient	O
lives	O
alone	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
Vital	O
signs	O
:	O
Pulse	O
59	O
,	O
respirations	O
17	O
,	O
O2	I-Drug
sat	O
91	O
%	O
on	O
6	O
liters	O
nasal	O
cannula	O
,	O
blood	O
pressure	O
154/76	O
.	O
General	O
appearance	O
:	O
In	O
no	O
acute	O
distress	O
;	O
oriented	O
x3	O
.	O
Heart	O
is	O
regular	O
rate	O
and	O
rhythm	O
without	O
murmur	O
,	O
gallop	O
or	O
rub	O
.	O
Breath	O
sounds	O
are	O
diminished	O
at	O
the	O
bases	O
bilaterally	O
.	O
Abdomen	O
is	O
soft	O
,	O
nontender	O
and	O
nondistended	O
.	O
A	O
well	O
-	O
healed	O
left	O
flank	O
incision	O
.	O
Abdominal	O
aorta	O
not	O
prominent	O
.	O
Pulse	O
exam	O
shows	O
palpable	O
femoral	O
and	O
pedal	O
pulses	O
bilaterally	O
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
CT	O
surgery	O
was	O
requested	O
to	O
see	O
the	O
patient	O
.	O
The	O
patient	O
underwent	O
CT	O
chest	O
,	O
abdomen	O
and	O
pelvis	O
with	O
reconstruction	O
and	O
3	O
-	O
D	O
imaging	O
.	O
The	O
chest	O
portion	O
showed	O
extensive	O
emphysema	O
changes	O
throughout	O
both	O
lungs	O
.	O
There	O
was	O
an	O
8.2	O
x	O
6.7	O
mm	O
nodular	O
density	O
in	O
the	O
right	O
upper	O
lobe	O
.	O
There	O
is	O
atelectasis	O
present	O
in	O
the	O
base	O
.	O
There	O
were	O
several	O
large	O
intrathoracic	O
mediastinal	O
nodes	O
.	O
There	O
were	O
several	O
scattered	O
sub	O
centimeter	O
mediastinal	O
lymph	O
nodes	O
.	O
CT	O
of	O
the	O
abdomen	O
with	O
and	O
without	O
contrast	O
revealed	O
the	O
left	O
kidney	O
was	O
absent	O
.	O
There	O
is	O
free	O
fluid	O
in	O
the	O
upper	O
abdomen	O
surrounding	O
liver	O
and	O
spleen	O
.	O
The	O
pancreas	O
is	O
atrophic	O
.	O
The	O
right	O
renal	O
gland	O
and	O
right	O
renal	O
kidney	O
appear	O
unremarkable	O
.	O
The	O
pelvis	O
CT	O
with	O
and	O
without	O
contrast	O
revealed	O
streaked	O
artifacts	O
and	O
bilateral	O
hip	O
replacements	O
.	O
Diverticular	O
disease	O
in	O
the	O
sigmoid	O
colon	O
without	O
evidence	O
of	O
diverticulitis	O
.	O
There	O
is	O
no	O
significant	O
pelvic	O
lymphadenopathy	O
.	O
Musculoskeletal	O
shows	O
degenerative	O
changes	O
present	O
in	O
the	O
lumbar	O
spine	O
as	O
well	O
as	O
a	O
well	O
defined	O
sclerotic	O
focus	O
in	O
the	O
left	O
iliac	O
bone	O
most	O
likely	O
a	O
bone	O
island	O
.	O
CT	O
of	O
the	O
abdomen	O
with	O
extensive	O
atherosclerotic	O
disease	O
of	O
the	O
aorta	O
and	O
its	O
branches	O
.	O
The	O
right	O
and	O
left	O
coronary	O
arteries	O
arise	O
from	O
a	O
normal	O
expected	O
anatomical	O
location	O
.	O
The	O
descending	O
aorta	O
at	O
the	O
level	O
of	O
the	O
right	O
main	O
pulmonary	O
artery	O
is	O
38	O
x	O
38	O
mm	O
.	O
There	O
is	O
extensive	O
concentric	O
noncalcification	O
plaque	O
present	O
in	O
the	O
descending	O
thoracic	O
and	O
abdominal	O
aortas	O
.	O
There	O
are	O
multiple	O
ulcerative	O
plaques	O
throughout	O
the	O
entire	O
course	O
of	O
the	O
descending	O
aorta	O
.	O
The	O
descending	O
aorta	O
at	O
the	O
level	O
of	O
the	O
left	O
inferior	O
pulmonary	O
vein	O
measures	O
42.2	O
x	O
37.4	O
mm	O
.	O
The	O
abdominal	O
aorta	O
in	O
the	O
upper	O
abdomen	O
above	O
the	O
celiac	O
access	O
measures	O
37.3	O
x	O
49.3	O
mm	O
.	O
The	O
celiac	O
access	O
,	O
superior	O
mesenteric	O
artery	O
are	O
widely	O
patent	O
.	O
Inferior	O
mesenteric	O
artery	O
was	O
not	O
clear	O
to	O
visualize	O
.	O
There	O
is	O
an	O
abdominal	O
aortic	O
aneurysm	O
that	O
measures	O
63.5	O
x	O
65.1	O
mm	O
in	O
maximum	O
transverse	O
diameter	O
.	O
There	O
is	O
a	O
24	O
x	O
24.6	O
mm	O
right	O
common	O
iliac	O
aneurysm	O
which	O
contains	O
concentric	O
mural	O
thrombus	O
.	O
CT	O
surgery	O
was	O
consulted	O
after	O
review	O
of	O
the	O
CT	O
scan	O
.	O
In	O
discussion	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
1391	O
**	O
]	O
and	O
CT	O
surgery	O
Dr.	O
__________	O
it	O
was	O
determined	O
the	O
patient	O
was	O
not	O
a	O
surgical	O
candidate	O
because	O
of	O
extensive	O
medical	O
problems	O
,	O
respiratory	O
problems	O
.	O
The	O
patient	O
was	O
made	O
DNR	O
,	O
DNI	O
.	O
Blood	O
pressure	O
medications	O
were	O
adjusted	O
to	O
stabilize	O
blood	O
pressure	O
.	O
The	O
patient	O
was	O
transferred	O
out	O
of	O
the	O
ICU	O
to	O
the	O
regular	O
nursing	O
floor	O
on	O
[	O
**	O
2133-9-9	O
**	O
]	O
.	O
The	O
patient	O
was	O
discharged	O
to	O
home	O
with	O
well	O
controlled	O
blood	O
pressure	O
without	O
any	O
symptoms	O
.	O
The	O
patient	O
's	O
creatinine	O
at	O
discharge	O
was	O
1.1	O
.	O
The	O
patient	O
should	O
follow	O
up	O
with	O
the	O
primary	O
care	O
physician	O
for	O
continued	O
blood	O
pressure	O
monitoring	O
and	O
blood	O
pressure	O
medication	O
adjustment	O
.	O
She	O
should	O
call	O
primary	O
care	O
if	O
she	O
develops	O
any	O
chest	O
,	O
back	O
,	O
abdominal	O
pain	O
or	O
near	O
syncopal	O
episodes	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Thoracoabdominal	O
aneurysm	O
.	O
2	O
.	O
History	O
of	O
chronic	B-Reason
obstructive	I-Reason
pulmonary	I-Reason
disease	I-Reason
,	O
O2	I-Drug
dependent	O
,	O
steroid	I-Drug
dependent	O
.	O
3	O
.	O
History	O
of	O
coronary	O
artery	O
disease	O
status	O
post	O
myocardial	O
infarction	O
.	O
4	O
.	O
History	O
of	O
pulmonary	O
hypertension	O
secondary	O
to	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O
5	O
.	O
History	O
of	O
transitional	O
cell	O
renal	O
cell	O
carcinoma	O
status	O
post	O
radical	O
nephrectomy	O
.	O
6	O
.	O
History	O
of	O
spinal	O
canal	O
stenosis	O
status	O
post	O
lumbar	O
surgery	O
.	O
7	O
.	O
History	O
of	O
gastroesophageal	O
reflux	O
disease	O
.	O
8	O
.	O
History	O
of	O
depression	O
.	O
9	O
.	O
History	O
of	O
steroid	I-Drug
myopathy	I-Ade
.	O
10	O
.	O
History	O
of	O
carotid	O
stenosis	O
status	O
post	O
left	O
carotid	O
endarterectomy	O
.	O
11	O
.	O
History	O
of	O
squamous	O
cell	O
anal	O
cancer	O
status	O
post	O
chemotherapy	O
and	O
radiation	O
therapy	O
.	O
12	O
.	O
Status	O
post	O
total	O
abdominal	O
hysterectomy	O
.	O
13	O
.	O
Status	O
post	O
appendectomy	O
.	O
14	O
.	O
History	O
of	O
hypertension	O
.	O
15	O
.	O
History	O
of	O
type	O
2	O
diabetes	O
noninsulin	O
-	O
dependent	O
,	O
controlled	O
.	O
16	O
.	O
History	O
of	O
osteoarthritis	O
status	O
post	O
bilateral	O
total	O
hip	O
replacements	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
Fluticasone	B-Drug
Solu	I-Drug
-	I-Drug
Medrol	I-Drug
250/50	O
mcg	O
disk	O
b.i.d.	O
,	O
tiotropium	B-Drug
bromide	I-Drug
18	O
mcg	O
capsule	O
with	O
inhalation	O
device	O
daily	O
,	O
__________	O
10	O
mg	O
daily	O
,	O
sertraline	I-Drug
100	O
mg	O
daily	O
,	O
trazodone	I-Drug
300	O
mg	O
at	O
bedtime	O
,	O
propofol	B-Drug
sustained	I-Drug
release	O
50	O
mg	O
daily	O
,	O
prednisone	I-Drug
10	O
mg	O
daily	O
,	O
gabapentin	I-Drug
300	O
mg	O
b.i.d.	O
,	O
gabapentin	I-Drug
600	O
mg	O
at	O
bedtime	O
,	O
lisinopril	I-Drug
20	O
mg	O
daily	O
,	O
spirolactone	I-Drug
25	O
mg	O
daily	O
,	O
hydralazine	I-Drug
20	O
mg	O
q.	O
6	O
h	O
,	O
Ativan	I-Drug
0.5	O
mg	O
tablets	O
q.	O
8	O
h	O
p.r.n.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2380	O
**	O
]	O
,	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
2381	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
2382	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2133-9-10	O
**	O
]	O
08:56:47	O
T	O
:	O
[	O
**	O
2133-9-10	O
**	O
]	O
10:05:24	O
Job	O
#	O
:	O
[	O
**	O
Job	O
Number	O
18459	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2124-9-25	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2124-9-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2047-2-17	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
NEUROSURGERY	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3227	O
**	O
]	O
Chief	O
Complaint	O
:	O
:	O
"	O
s	O
/	O
p	O
unwitnessed	O
fall	O
on	O
coumadin	I-Drug
"	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
77	O
year	O
old	O
female	O
with	O
history	O
of	O
dementia	O
,	O
hypertension	O
,	O
and	O
atrial	B-Reason
fibrilation	I-Reason
on	O
coumadin	I-Drug
who	O
is	O
status	O
post	O
unwitnessed	O
fall	O
at	O
home	O
.	O
There	O
was	O
unknown	O
loss	O
of	O
consiousness	O
.	O
The	O
report	O
from	O
[	O
**	O
Hospital6	O
17032	O
**	O
]	O
states	O
that	O
the	O
patient	O
was	O
seen	O
on	O
[	O
**	O
9	O
-	O
24	O
**	O
]	O
at	O
920	O
pm	O
and	O
had	O
fallen	O
at	O
home	O
24	O
hours	O
prior	O
.	O
The	O
patients	O
husband	O
is	O
not	O
present	O
for	O
interview	O
but	O
reportedly	O
heard	O
a	O
"	O
thud	O
"	O
and	O
found	O
the	O
patient	O
on	O
the	O
floor	O
.	O
She	O
was	O
able	O
to	O
get	O
up	O
,	O
ambulate	O
into	O
a	O
chair	O
and	O
then	O
into	O
bed	O
.	O
The	O
patient	O
is	O
non	O
verbal	O
at	O
the	O
time	O
of	O
this	O
exam	O
and	O
there	O
is	O
no	O
family	O
to	O
provide	O
history	O
.	O
The	O
husband	O
was	O
called	O
at	O
home	O
by	O
Neurosurgery	O
Service	O
x	O
2	O
and	O
was	O
not	O
successfully	O
reached	O
.	O
At	O
baseline	O
,	O
the	O
patient	O
is	O
alert	O
x2	O
.	O
Past	O
Medical	O
History	O
:	O
dementia	O
,	O
HTN	O
,	O
afib	O
Social	O
History	O
:	O
lives	O
at	O
home	O
with	O
husband	O
Family	O
History	O
:	O
unknown	O
Physical	O
Exam	O
:	O
O	O
:	O
T	O
:	O
97.8	O
BP	O
:	O
148/62	O
HR	O
:	O
66	O
R	O
:	O
20	O
O2Sats	O
:	O
97	O
%	O
Gen	O
:	O
comfortable	O
,	O
NAD	O
.	O
HEENT	O
:	O
hard	O
cervical	O
collar	O
on	O
Pupils	O
:	O
EOMs	O
:	O
patient	O
does	O
not	O
participate	O
,	O
appears	O
grossly	O
intact	O
Neck	O
:	O
hard	O
cervical	O
collar	O
on	O
Extrem	O
:	O
Warm	O
and	O
well	O
-	O
perfused	O
.	O
Neuro	O
:	O
Mental	O
status	O
:	O
Awake	O
and	O
alert	O
,	O
cooperative	O
with	O
exam	O
,	O
normal	O
affect	O
.	O
Orientation	O
:	O
not	O
oriented	O
to	O
person	O
,	O
place	O
,	O
and	O
date	O
.	O
Recall	O
/	O
Language	O
:	O
non	O
verbal	O
Cranial	O
Nerves	O
:	O
I	O
:	O
Not	O
tested	O
II	O
:	O
Pupils	O
equally	O
round	O
and	O
reactive	O
to	O
light	O
,	O
3	O
to	O
2	O
mm	O
bilaterally	O
.	O
Visual	O
fields	O
unable	O
to	O
test	O
III	O
,	O
IV	O
,	O
VI	O
:	O
Extraocular	O
movements	O
unable	O
to	O
test	O
V	O
,	O
VII	O
:	O
Facial	O
strength	O
and	O
sensation	O
intact	O
and	O
symmetric	O
.	O
VIII	O
:	O
Hearing	O
grossly	O
intact	O
IX	O
,	O
X	O
:	O
Palatal	O
elevation	O
-	O
patient	O
does	O
not	O
participate	O
[	O
**	O
Doctor	O
First	O
Name	O
81	O
**	O
]	O
:	O
Sternocleidomastoid	O
and	O
trapezius	O
normal	O
bilaterally	O
.	O
XII	O
:	O
Tongue	O
midline	O
without	O
fasciculations	O
.	O
Motor	O
:	O
Normal	O
bulk	O
and	O
tone	O
bilaterally	O
.	O
No	O
abnormal	O
movements	O
,	O
tremors	O
.	O
Strength	O
full	O
power	O
[	O
**	O
5	O
-	O
3	O
**	O
]	O
throughout	O
.	O
No	O
pronator	O
drift	O
Sensation	O
:	O
patient	O
unable	O
to	O
participate	O
in	O
exam	O
Toes	O
downgoing	O
bilaterally	O
Coordination	O
:	O
patient	O
unable	O
to	O
participate	O
DISCHARGE	O
EXAM	O
:	O
Confused	O
but	O
interactive	O
.	O
Non-focal	O
.	O
Moves	O
all	O
extremities	O
x	O
4	O
Pertinent	O
Results	O
:	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2124-9-25	O
**	O
]	O
Bifrontal	O
intraparenchymal	O
hemorrhage	O
,	O
left	O
greater	O
than	O
right	O
with	O
extension	O
into	O
the	O
subarachnoid	O
and	O
subdural	O
spaces	O
.	O
Small	O
amount	O
of	O
blood	O
seen	O
layering	O
posteriorly	O
within	O
the	O
ventricles	O
.	O
No	O
midline	O
shift	O
or	O
herniation	O
.	O
[	O
**	O
9	O
-	O
25	O
**	O
]	O
CT	O
Head	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Unchanged	O
foci	O
of	O
hemorrhage	O
in	O
the	O
bifrontal	O
parenchymal	O
region	O
,	O
left	O
greater	O
than	O
the	O
right	O
,	O
with	O
extension	O
into	O
the	O
subarachnoid	O
,	O
subdural	O
,	O
and	O
intraventricular	O
spaces	O
.	O
2	O
.	O
No	O
new	O
shift	O
of	O
the	O
normally	O
midline	O
structures	O
or	O
herniation	O
.	O
[	O
**	O
9	O
-	O
28	O
**	O
]	O
CT	O
Head	O
:	O
Impression	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Unchanged	O
large	O
bifrontal	O
hemorrhagic	O
contusions	O
,	O
subarachnoid	O
hemorrhage	O
,	O
parafalcine	O
subdural	O
hemorrhage	O
,	O
and	O
intraventricular	O
hemorrhage	O
.	O
2	O
.	O
Right	O
occipital	O
fracture	O
extending	O
into	O
the	O
foramen	O
magnum	O
.	O
If	O
there	O
is	O
a	O
clinical	O
concern	O
for	O
transverse	O
sinus	O
injury	O
,	O
CTV	O
could	O
be	O
performed	O
Brief	O
Hospital	O
Course	O
:	O
77	O
y	O
/	O
o	O
F	O
with	O
baseline	O
dementia	O
and	O
on	O
coumadin	I-Drug
for	O
a-fib	I-Reason
is	O
s	O
/	O
p	O
unwitnessed	O
fall	O
with	O
unknown	O
LOC	O
presents	O
to	O
OSH	O
.	O
She	O
presented	O
with	O
an	O
INR	O
of	O
4.3	O
and	O
was	O
given	O
one	O
dose	O
of	O
vitamin	B-Drug
K	I-Drug
and	O
a	O
dilantin	I-Drug
load	O
.	O
Head	O
CT	O
showed	O
bilateral	O
frontal	O
IPH	O
and	O
SAH	O
.	O
She	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
neurosurgical	O
workup	O
.	O
Upon	O
arrival	O
to	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
patient	O
was	O
given	O
2	O
units	O
of	O
FFP	I-Drug
and	O
profiline	I-Drug
in	O
the	O
ED	O
for	O
an	O
INR	O
of	O
5	O
.	O
She	O
was	O
admitted	O
to	O
the	O
ICU	O
for	O
neurosurgical	O
observation	O
.	O
Her	O
exam	O
was	O
nonverbal	O
and	O
confused	O
,	O
but	O
full	O
strength	O
.	O
She	O
was	O
cleared	O
by	O
the	O
trauma	O
service	O
of	O
further	O
injuries	O
.	O
On	O
[	O
**	O
9	O
-	O
25	O
**	O
]	O
,	O
patient	O
's	O
exam	O
much	O
improved	O
,	O
she	O
is	O
alert	O
to	O
self	O
and	O
full	O
strength	O
.	O
Repeat	O
head	O
CT	O
stable	O
and	O
patient	O
's	O
INR	O
was	O
1.3	O
.	O
While	O
in	O
the	O
ICU	O
she	O
went	O
in	O
to	O
rapid	O
afib	O
with	O
heart	O
rate	O
in	O
the	O
140	O
's	O
and	O
she	O
was	O
started	O
on	O
a	O
diltiazem	I-Drug
iv	O
drip	O
with	O
plan	O
to	O
wean	O
to	O
PO	O
diltiazem	I-Drug
.	O
On	O
[	O
**	O
9	O
-	O
26	O
**	O
]	O
pt	O
had	O
a	O
repeat	O
CT	O
head	O
that	O
showed	O
no	O
change	O
from	O
her	O
previous	O
scan	O
.	O
Her	O
INR	O
remained	O
below	O
1.3	O
.	O
She	O
remained	O
in	O
the	O
ICU	O
to	O
continue	O
her	O
diltiazem	I-Drug
IV	O
drip	O
for	O
treatment	O
of	O
her	O
atrial	B-Reason
fibrilation	I-Reason
.	O
Cardiology	O
was	O
consulted	O
for	O
further	O
management	O
and	O
felt	O
it	O
was	O
safe	O
to	O
discontinue	O
her	O
IV	O
and	O
PO	O
diltiazem	I-Drug
and	O
remain	O
on	O
her	O
amiodarone	I-Drug
PO	O
.	O
Her	O
lopressor	I-Drug
was	O
increased	O
per	O
their	O
recommendations	O
to	O
50	O
mg	O
twice	O
daily	O
.	O
Her	O
heart	O
rate	O
remained	O
stable	O
and	O
had	O
no	O
further	O
episodes	O
of	O
rapid	O
atrial	O
fibrilation	O
.	O
[	O
**	O
Date	O
range	O
(	O
1	O
)	O
80149	O
**	O
]	O
Pt	O
transfered	O
to	O
the	O
floor	O
in	O
stable	O
condition	O
.	O
Repeat	O
head	O
ct	O
showed	O
no	O
change	O
in	O
size	O
of	O
contusions	O
and	O
was	O
stable	O
when	O
compared	O
to	O
previous	O
exams	O
.	O
Her	O
blood	O
pressure	O
was	O
noted	O
to	O
be	O
in	O
the	O
170s	O
,	O
and	O
cardiology	O
recommended	O
adding	O
HCTZ	I-Drug
to	O
her	O
current	O
regimen	O
.	O
She	O
was	O
seen	O
by	O
physical	O
therapy	O
and	O
plan	O
was	O
for	O
discharge	O
to	O
her	O
extended	O
care	O
facility	O
.	O
The	O
patient	O
's	O
neurologic	O
examination	O
remained	O
unchanged	O
throughout	O
the	O
entire	O
hospitalization	O
.	O
Medications	O
on	O
Admission	O
:	O
metformin	I-Drug
500	O
mg	O
po	O
BID	O
,	O
amiodarone	I-Drug
(	O
pacerone	I-Drug
)	O
100	O
mg	O
po	O
qd	O
,	O
diltiazem	B-Drug
hcl	I-Drug
ext	O
-	O
release	O
(	O
cartia	B-Drug
XT	I-Drug
)	O
120	O
mg	O
poqd	O
,	O
simvastatin	I-Drug
4	O
-	O
mg	O
po	O
qd	O
,	O
zetia	I-Drug
10	O
po	O
qd	O
,	O
lopressor	I-Drug
25	O
mg	O
po	O
bid	O
,	O
coumadin	I-Drug
4	O
mg	O
po	O
qd	O
,	O
aricept	I-Drug
5	O
mg	O
po	O
qd	O
,	O
celexa	I-Drug
10	O
mg	O
po	O
qd	O
,	O
pravachol	I-Drug
80	O
po	O
qd	O
,	O
zestril	I-Drug
40	O
po	O
qd	O
,	O
ciprofloxacin	I-Drug
250	O
po	O
bid	O
,	O
ativan	I-Drug
1	O
mg	O
po	O
PRN	O
Discharge	O
Medications	O
:	O
1	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
/	O
fever	I-Reason
.	O
2	O
.	O
Amiodarone	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Donepezil	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Pravastatin	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
Lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
(	O
1	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Insulin	B-Drug
Regular	I-Drug
Human	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
ASDIR	O
(	O
AS	O
DIRECTED	O
)	O
.	O
12	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
13	O
.	O
Hydrochlorothiazide	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
14	O
.	O
Metoprolol	B-Drug
Tartrate	I-Drug
5	O
mg	O
IV	O
Q4H	O
:	O
PRN	O
for	O
hear	B-Reason
rate	I-Reason
>	I-Reason
100	I-Reason
15	O
.	O
Famotidine	I-Drug
(	O
PF	O
)	O
in	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
(	O
Iso	O
-	O
os	O
)	O
20	O
mg	O
/	O
50	O
mL	O
Piggyback	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Intravenous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
16	O
.	O
Hydralazine	I-Drug
20	O
mg	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
SBP	B-Reason
>	I-Reason
160	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
25759	O
**	O
]	O
&	O
Rehab	O
Center	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
b	O
/	O
l	O
frontal	O
IPH	O
,	O
IVH	O
,	O
SAH	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
always	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Discharge	O
Instructions	O
:	O
??????	O
Take	O
your	O
pain	B-Drug
medicine	I-Drug
as	O
prescribed	O
.	O
??????	O
Exercise	O
should	O
be	O
limited	O
to	O
walking	O
;	O
no	O
lifting	O
,	O
straining	O
,	O
or	O
excessive	O
bending	O
.	O
??????	O
Increase	O
your	O
intake	O
of	O
fluids	O
and	O
fiber	O
,	O
as	O
narcotic	B-Drug
pain	I-Drug
medicine	O
can	O
cause	O
constipation	I-Ade
.	O
We	O
generally	O
recommend	O
taking	O
an	O
over	O
the	O
counter	O
stool	B-Reason
softener	I-Reason
,	O
such	O
as	O
Docusate	I-Drug
(	O
Colace	O
)	O
while	O
taking	O
narcotic	O
pain	O
medication	O
.	O
??????	O
Unless	O
directed	O
by	O
your	O
doctor	O
,	O
do	O
not	O
take	O
any	O
anti-inflammatory	I-Reason
medicines	O
such	O
as	O
Motrin	I-Drug
,	O
Aspirin	I-Drug
,	O
Advil	I-Drug
,	O
or	O
Ibuprofen	I-Drug
etc.	O
??????	O
If	O
you	O
were	O
on	O
a	O
medication	O
such	O
as	O
Coumadin	I-Drug
(	O
Warfarin	O
)	O
,	O
or	O
Plavix	I-Drug
(	O
clopidogrel	O
)	O
prior	O
to	O
your	O
injury	O
,	O
you	O
may	O
safely	O
resume	O
taking	O
this	O
in	O
4	O
weeks	O
??????	O
If	O
you	O
have	O
been	O
prescribed	O
Dilantin	I-Drug
(	O
Phenytoin	O
)	O
for	O
anti-seizure	B-Reason
medicine	I-Reason
,	O
take	O
it	O
as	O
prescribed	O
and	O
follow	O
up	O
with	O
laboratory	O
blood	O
drawing	O
in	O
one	O
week	O
.	O
This	O
can	O
be	O
drawn	O
at	O
your	O
PCP	O
??????	O
s	O
office	O
,	O
but	O
please	O
have	O
the	O
results	O
faxed	O
to	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
87	O
**	O
]	O
.	O
If	O
you	O
haven	O
been	O
discharged	O
on	O
Keppra	I-Drug
(	O
Levetiracetam	O
)	O
,	O
you	O
will	O
not	O
require	O
blood	O
work	O
monitoring	O
.	O
CALL	O
YOUR	O
SURGEON	O
IMMEDIATELY	O
IF	O
YOU	O
EXPERIENCE	O
ANY	O
OF	O
THE	O
FOLLOWING	O
??????	O
New	O
onset	O
of	O
tremors	O
or	O
seizures	O
.	O
??????	O
Any	O
confusion	O
,	O
lethargy	O
or	O
change	O
in	O
mental	O
status	O
.	O
??????	O
Any	O
numbness	O
,	O
tingling	O
,	O
weakness	O
in	O
your	O
extremities	O
.	O
??????	O
Pain	O
or	O
headache	O
that	O
is	O
continually	O
increasing	O
,	O
or	O
not	O
relieved	O
by	O
pain	O
medication	O
.	O
??????	O
New	O
onset	O
of	O
the	O
loss	O
of	O
function	O
,	O
or	O
decrease	O
of	O
function	O
on	O
one	O
whole	O
side	O
of	O
your	O
body	O
.	O
Followup	O
Instructions	O
:	O
Follow	O
-	O
Up	O
Appointment	O
Instructions	O
??????	O
Please	O
call	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
88	O
**	O
]	O
to	O
schedule	O
an	O
appointment	O
with	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
to	O
be	O
seen	O
in	O
4	O
weeks	O
.	O
??????	O
You	O
will	O
need	O
a	O
CT	O
scan	O
of	O
the	O
brain	O
without	O
contrast	O
prior	O
to	O
your	O
appointment	O
.	O
This	O
can	O
be	O
scheduled	O
when	O
you	O
call	O
to	O
make	O
your	O
office	O
visit	O
appointment	O
.	O
Completed	O
by	O
:[	O
**	O
2124-9-29	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2148-9-19	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2148-10-4	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2082-7-19	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
4377	O
**	O
]	O
Chief	O
Complaint	O
:	O
Chest	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
intubation	O
s	O
/	O
p	O
extubation	O
central	O
line	O
placement	O
PICC	O
arterial	O
line	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
104371	O
**	O
]	O
is	O
a	O
66yo	O
M	O
with	O
history	O
of	O
COPD	I-Reason
on	O
2L	O
home	O
O2	I-Drug
and	O
hypertension	O
who	O
presented	O
to	O
his	O
PCP	O
's	O
office	O
with	O
12	O
days	O
of	O
non-radiating	O
substernal	O
chest	O
pain	O
and	O
worsening	O
shortness	O
of	O
breath	O
.	O
He	O
felt	O
this	O
pain	O
may	O
have	O
been	O
his	O
GERD	I-Reason
but	O
did	O
not	O
improve	O
with	O
tums	I-Drug
.	O
At	O
[	O
**	O
Company	O
191	O
**	O
]	O
(	O
his	O
PCP	O
's	O
office	O
)	O
,	O
he	O
was	O
noted	O
to	O
be	O
look	O
weak	O
and	O
an	O
EKG	O
was	O
concerning	O
for	O
?	O
new	O
anterior	O
-	O
lateral	O
changes	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
98	O
,	O
84	O
,	O
136/88	O
,	O
18	O
,	O
96	O
%	O
2L	O
.	O
On	O
arrival	O
to	O
ER	O
,	O
EKG	O
was	O
NSR	O
without	O
ST	O
changes	O
,	O
and	O
labs	O
were	O
significant	O
for	O
trop	O
of	O
0.31	O
,	O
platelets	O
of	O
9	O
,	O
leukocytosis	O
to	O
35	O
with	O
88	O
%	O
"	O
other	O
"	O
cell	O
types	O
and	O
hematocrit	O
of	O
21	O
.	O
Repeat	O
EKG	O
was	O
still	O
non-ischemic	O
and	O
cardiology	O
felt	O
his	O
troponins	O
were	O
not	O
due	O
to	O
active	O
ischemia	O
.	O
Given	O
his	O
platelets	O
,	O
there	O
were	O
no	O
plans	O
for	O
intervention	O
.	O
Heme	O
/	O
onc	O
was	O
consulted	O
to	O
review	O
his	O
smear	O
given	O
concern	O
for	O
acute	O
leukemia	O
.	O
Patient	O
was	O
given	O
one	O
sublingual	O
nitro	I-Drug
and	O
started	O
on	O
morphine	I-Drug
for	O
pain	B-Reason
control	I-Reason
.	O
He	O
was	O
moving	O
very	O
little	O
air	O
on	O
exam	O
and	O
felt	O
to	O
be	O
having	O
a	O
COPD	I-Reason
exacerbation	O
.	O
He	O
was	O
given	O
solumedrol	I-Drug
,	O
ceftriaxone	I-Drug
,	O
azithromyin	I-Drug
,	O
cefepime	I-Drug
and	O
albuterol	I-Drug
/	O
ipratropium	I-Drug
nebs	O
.	O
Patient	O
was	O
transferred	O
to	O
the	O
ICU	O
for	O
further	O
management	O
.	O
At	O
time	O
of	O
transfer	O
,	O
vitals	O
were	O
98.7	O
,	O
93	O
,	O
150/68	O
,	O
20	O
,	O
94	O
%	O
3L	O
NC	O
.	O
In	O
the	O
ICU	O
,	O
he	O
endorses	O
having	O
had	O
chest	O
pain	O
for	O
the	O
past	O
couple	O
weeks	O
that	O
he	O
felt	O
was	O
heartburn	O
and	O
epigrastric	O
pain	O
.	O
Over	O
this	O
time	O
period	O
,	O
he	O
has	O
also	O
had	O
some	O
generalized	O
weakness	O
and	O
cough	O
productive	O
of	O
blood	O
tinged	O
sputum	O
.	O
He	O
feels	O
his	O
scattered	O
arm	O
bruises	O
are	O
related	O
to	O
tripping	O
and	O
falling	O
a	O
few	O
days	O
ago	O
.	O
Past	O
Medical	O
History	O
:	O
#	O
Pneumonia	I-Reason
that	O
was	O
slow	O
to	O
resolve	O
,	O
requiring	O
2	O
-	O
3	O
months	O
of	O
ABX	I-Drug
[	O
**	O
9	O
-	O
21	O
**	O
]	O
#	O
COPD	I-Reason
with	O
2L	O
home	O
O2	I-Drug
#	O
History	O
of	O
asbestos	O
exposure	O
#	O
psoriasis	O
#	O
hyperlipidemia	O
#	O
arthritis	O
#	O
hypertension	O
#	O
depression	O
#	O
venous	O
insufficiency	O
Social	O
History	O
:	O
He	O
is	O
married	O
and	O
has	O
a	O
daughter	O
who	O
is	O
his	O
HCP	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
previously	O
smoked	O
but	O
quit	O
a	O
number	O
of	O
years	O
ago	O
.	O
He	O
occasionally	O
drinks	O
alcohol	O
but	O
denies	O
IV	O
drug	O
use	O
.	O
Family	O
History	O
:	O
Mother	O
had	O
unspecified	O
mental	O
illness	O
and	O
had	O
a	O
coronary	O
artery	O
bypass	O
.	O
His	O
father	O
with	O
unknown	O
cancer	O
died	O
at	O
the	O
age	O
of	O
83	O
.	O
Physical	O
Exam	O
:	O
ICU	O
Exam	O
on	O
Admission	O
-	O
Vitals	O
:	O
T	O
:	O
97.6	O
BP	O
:	O
130/71	O
P	O
:	O
102	O
R	O
:	O
14	O
O2	O
:	O
92	O
%	O
4L	O
NC	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Very	O
limited	O
air	O
movement	O
bilaterally	O
but	O
clear	O
to	O
auscultation	O
without	O
wheezes	O
,	O
rales	O
,	O
or	O
rhonchi	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
distant	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
obese	O
,	O
soft	O
,	O
non-tender	O
,	O
mildly	O
distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
appreciated	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
scattered	O
upper	O
extremity	O
ecchymoses	O
,	O
R	O
>	O
L	O
mild	O
,	O
1	O
+	O
pitting	O
edema	O
,	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
or	O
cyanosis	O
ICU	O
Exam	O
on	O
Transfer	O
-	O
General	O
:	O
very	O
somnolent	O
but	O
arousable	O
(	O
RN	O
&	O
daughter	O
state	O
not	O
a	O
change	O
from	O
baseline	O
)	O
,	O
A+O	O
x	O
2	O
(	O
name	O
,	O
[	O
**	O
Hospital	O
**	O
]	O
hospital	O
)	O
HEENT	O
:	O
Sclerae	O
anicteric	O
,	O
PERRL	O
,	O
EOMI	O
Neck	O
:	O
supple	O
Lungs	O
:	O
scattered	O
bibasilar	O
crackles	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
distant	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abdomen	O
:	O
obese	O
,	O
soft	O
,	O
non-tender	O
,	O
distended	O
,	O
normal	O
bowel	O
sounds	O
no	O
HSM	O
.	O
Right	O
sided	O
abd	O
ecchymosis	O
which	O
is	O
stable	O
from	O
prior	O
exam	O
GU	O
:	O
foley	O
in	O
place	O
Ext	O
:	O
L	O
>	O
R	O
upper	O
extremity	O
edema	O
,	O
scattered	O
upper	O
extremity	O
ecchymoses	O
,	O
trace	O
pitting	O
edema	O
,	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
Neuro	O
:	O
L	O
sided	O
hemiparesis	O
from	O
known	O
IPH	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
WBC	O
-	O
38.9	O
*	O
RBC	O
-	O
2.49	O
*	O
HGB	O
-	O
7.5	O
*	O
HCT	O
-	O
20.3	O
*	O
MCV	O
-	O
82	O
MCH	O
-	O
30.3	O
MCHC	O
-	O
37.1	O
*	O
RDW	O
-	O
15.8	O
*	O
GLUCOSE	O
-	O
214	O
*	O
UREA	O
N	O
-	O
22	O
*	O
CREAT	O
-	O
0.6	O
SODIUM	O
-	O
131	O
*	O
POTASSIUM	O
-	O
3.8	O
CHLORIDE	O
-	O
91	O
*	O
TOTAL	O
CO2	O
-	O
28	O
ANION	O
GAP	O
-	O
16	O
ALT	O
(	O
SGPT	O
)	O
-	O
52	O
*	O
AST	O
(	O
SGOT	O
)	O
-	O
70	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
661	O
*	O
ALK	O
PHOS	O
-	O
85	O
TOT	O
BILI	O
-	O
0.9	O
LACTATE	O
-	O
1.3	O
CK	O
(	O
CPK	O
)	O
-	O
739	O
*	O
CK	O
-	O
MB	O
-	O
70	O
*	O
MB	O
INDX	O
-	O
9.5	O
*	O
cTropnT	O
-	O
0.55	O
*	O
FIBRINOGE	O
-	O
158	O
D	O
-	O
DIMER	O
-	O
8889	O
*	O
LIPASE	O
-	O
25	O
Discharge	O
labs	O
:	O
[	O
**	O
2148-10-4	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
WBC	O
-	O
3.2	O
*	O
RBC	O
-	O
3.65	O
*	O
Hgb	O
-	O
10.9	O
*	O
Hct	O
-	O
30.8	O
*	O
MCV	O
-	O
84	O
MCH	O
-	O
29.9	O
MCHC	O
-	O
35.5	O
*	O
RDW	O
-	O
15.9	O
*	O
Plt	O
Ct	O
-	O
79	O
*	O
[	O
**	O
2148-10-4	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Neuts	O
-	O
25	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
40	O
Monos	O
-	O
6	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
Other	O
-	O
29	O
*	O
[	O
**	O
2148-10-4	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
PT	O
-	O
14.3	O
*	O
PTT	O
-	O
31.2	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2148-10-4	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
105	O
*	O
[	O
**	O
2148-10-4	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Gran	O
Ct	O
-	O
810	O
*	O
[	O
**	O
2148-10-4	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Glucose	O
-	O
138	O
*	O
UreaN	O
-	O
19	O
Creat	O
-	O
0.5	O
Na	O
-	O
134	O
K	O
-	O
3.7	O
Cl	O
-	O
99	O
HCO3	O
-	O
23	O
AnGap	O
-	O
16	O
[	O
**	O
2148-10-4	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
ALT	O
-	O
29	O
AST	O
-	O
24	O
LD	O
(	O
LDH	O
)	O
-	O
353	O
*	O
AlkPhos	O
-	O
82	O
TotBili	O
-	O
1.4	O
[	O
**	O
2148-10-4	O
**	O
]	O
12:00	O
AM	O
BLOOD	O
Albumin	O
-	O
3.6	O
Calcium	O
-	O
8.7	O
Phos	O
-	O
3.6	O
Mg	O
-	O
1.8	O
UricAcd	O
-	O
3.3	O
*	O
STUDIES	O
:	O
NEOPLASTIC	O
BLOOD	O
Date	O
of	O
[	O
**	O
2148-9-19	O
**	O
]	O
Karyotype	O
:	O
47	O
,	O
XY	O
,	O
+8	O
,	O
t	O
(	O
15	O
;	O
17	O
)	O
(	O
q22	O
;	O
q21	O
.1	O
)	O
[	O
2	O
]	O
Only	O
two	O
metaphase	O
cells	O
were	O
obtained	O
and	O
analyzed	O
from	O
this	O
specimen	O
.	O
This	O
limited	O
/	O
incomplete	O
study	O
may	O
not	O
rule	O
out	O
mosaicism	O
at	O
a	O
level	O
that	O
is	O
standard	O
for	O
such	O
an	O
analysis	O
.	O
Two	O
cells	O
contained	O
an	O
extra	O
copy	O
of	O
chromosome	O
8	O
(	O
TRISOMY	O
8	O
)	O
and	O
a	O
TRANSLOCATION	O
of	O
chromosomes	O
15	O
and	O
17	O
.	O
This	O
translocation	O
is	O
associated	O
with	O
PML	O
-	O
RARA	O
fusion	O
and	O
is	O
a	O
characteristic	O
finding	O
in	O
acute	O
promyelocytic	O
(	O
M3	O
)	O
leukemia	O
.	O
----------------	O
INTERPHASE	O
FISH	O
ANALYSIS	O
,	O
100	O
-	O
300	O
CELLS	O
-------------------	O
nuc	O
ish	O
(	O
PML	O
,	O
RARA	O
)	O
x3	O
(	O
PML	O
con	O
RARAx2	O
)	O
[	O
89/100	O
]	O
FISH	O
evaluation	O
for	O
a	O
PML	O
-	O
RARA	O
rearrangement	O
was	O
performed	O
on	O
nuclei	O
with	O
the	O
LSI	O
PML	O
/	O
RARA	O
Dual	O
Color	O
,	O
Dual	O
Fusion	O
Translocation	O
Probe	O
(	O
[	O
**	O
Doctor	O
Last	O
Name	O
7594	O
**	O
]	O
Molecular	O
)	O
for	O
PML	O
at	O
15q22	O
and	O
RARA	O
at	O
17q21	O
.1	O
and	O
is	O
interpreted	O
as	O
ABNORMAL	O
.	O
Rearrangement	O
was	O
observed	O
in	O
89/100	O
nuclei	O
,	O
which	O
exceeds	O
the	O
normal	O
range	O
(	O
up	O
to	O
1	O
%	O
dual	O
rearrangement	O
)	O
for	O
this	O
probe	O
in	O
our	O
laboratory	O
.	O
A	O
PML	O
-	O
RARA	O
rearrangement	O
is	O
found	O
in	O
most	O
acute	O
promyelocytic	O
leukemias	O
(	O
FAB	O
M3	O
)	O
.	O
This	O
test	O
was	O
developed	O
and	O
its	O
performance	O
determined	O
by	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
Cytogenetics	O
Laboratory	O
as	O
required	O
by	O
the	O
CLIA	O
'	O
[	O
**	O
25	O
**	O
]	O
regulations	O
.	O
It	O
has	O
not	O
been	O
cleared	O
or	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
.	O
This	O
test	O
is	O
used	O
for	O
clinical	O
purposes	O
.	O
FLOW	O
CYTOMETRY	O
:	O
RESULTS	O
:	O
Three	O
color	O
gating	O
is	O
performed	O
(	O
light	O
scatter	O
vs.	O
CD45	O
)	O
to	O
optimize	O
blast	O
yield	O
.	O
Abnormal	O
cells	O
comprise	O
82	O
%	O
of	O
total	O
gated	O
events	O
.	O
B	O
-	O
cells	O
comprise	O
6	O
%	O
of	O
lymphoid-gated	O
events	O
,	O
are	O
polyclonal	O
,	O
and	O
do	O
not	O
express	O
aberrant	O
antigens	O
.	O
T	O
-	O
cells	O
comprise	O
57	O
%	O
of	O
lymphoid-gated	O
events	O
,	O
express	O
mature	O
lineage	O
antigens	O
,	O
and	O
have	O
a	O
normal	O
helper	O
-	O
cytotoxic	O
ratio	O
of	O
1.04	O
(	O
usual	O
range	O
in	O
blood	O
0.7	O
-	O
3.0	O
)	O
.	O
Cell	O
marker	O
analysis	O
demonstrates	O
that	O
the	O
majority	O
of	O
the	O
cells	O
isolated	O
from	O
this	O
peripheral	O
blood	O
express	O
myeloid	O
associated	O
antigens	O
(	O
CD13	O
,	O
CD33	O
(	O
bright	O
)	O
,	O
CD15	O
(	O
bright	O
,	O
subset	O
)	O
,	O
express	O
CD64	O
,	O
CD71	O
,	O
lack	O
B	O
and	O
T	O
cell	O
associated	O
antigens	O
,	O
are	O
CD10	O
(	O
cALLAa	O
)	O
negative	O
,	O
and	O
are	O
negative	O
for	O
CD34	O
,	O
HLA	O
-	O
DR	O
,	O
CD14	O
,	O
CD41	O
,	O
CD11C	O
,	O
CD56	O
and	O
Glycophorin	O
A.	O
Immunophenotypic	O
findings	O
consistent	O
with	O
involvement	O
by	O
acute	O
myeloid	O
leukemia	O
.	O
Lack	O
of	O
CD34	O
and	O
HLA	O
-	O
DR	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
promyelocytic	O
differentiation	O
.	O
However	O
,	O
correlation	O
with	O
concurrent	O
cytogenetic	O
findings	O
is	O
recommended	O
for	O
further	O
characterization	O
.	O
.	O
IMAGING	O
:	O
ECHOCARDIOGRAM	O
[	O
**	O
2148-9-20	O
**	O
]	O
Conclusions	O
The	O
left	O
atrium	O
is	O
elongated	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
are	O
normal	O
.	O
The	O
left	O
ventricular	O
cavity	O
size	O
is	O
normal	O
.	O
Due	O
to	O
suboptimal	O
technical	O
quality	O
,	O
a	O
focal	O
wall	O
motion	O
abnormality	O
can	O
not	O
be	O
fully	O
excluded	O
.	O
There	O
is	O
moderate	O
to	O
severe	O
global	O
left	O
ventricular	O
hypokinesis	O
,	O
with	O
some	O
regional	O
variation	O
(	O
the	O
anterior	O
septum	O
,	O
anterior	O
free	O
wall	O
,	O
and	O
apex	O
appearing	O
more	O
hypokinetic	O
than	O
the	O
other	O
walls	O
)	O
(	O
LVEF	O
=	O
30	O
%	O
)	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
with	O
severe	O
global	O
free	O
wall	O
hypokinesis	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
at	O
the	O
sinus	O
level	O
.	O
The	O
ascending	O
aorta	O
is	O
moderately	O
dilated	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
regurgitation	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
Mild	O
(	O
1	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
pulmonary	O
artery	O
systolic	O
pressure	O
could	O
not	O
be	O
determined	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Compared	O
with	O
the	O
findings	O
of	O
the	O
prior	O
study	O
(	O
images	O
reviewed	O
)	O
of	O
[	O
**	O
2146-5-26	O
**	O
]	O
,	O
contractile	O
function	O
of	O
both	O
ventricles	O
is	O
now	O
significantly	O
reduced	O
.	O
CT	O
HEAD	O
W	O
/	O
O	O
CONTRAST	O
[	O
**	O
2148-9-23	O
**	O
]	O
6:31	O
PM	O
IMPRESSION	O
:	O
Large	O
intraparenchymal	O
hemorrhage	O
in	O
the	O
right	O
frontal	O
lobe	O
,	O
with	O
surrounding	O
vasogenic	O
edema	O
and	O
local	O
mass	O
effect	O
.	O
A	O
hypodense	O
lesion	O
with	O
smaller	O
hemorrhagic	O
component	O
is	O
also	O
seen	O
in	O
the	O
right	O
occipital	O
lobe	O
,	O
with	O
two	O
additional	O
non-hemorrhagic	O
hypodense	O
lesions	O
seen	O
in	O
the	O
left	O
cerebellar	O
hemisphere	O
and	O
the	O
right	O
parieto	O
-	O
occipital	O
cortex	O
.	O
Given	O
the	O
multifocality	O
of	O
these	O
lesions	O
,	O
and	O
history	O
of	O
malignancy	O
,	O
these	O
may	O
represent	O
metastases	O
with	O
associated	O
hemorrhage	O
.	O
An	O
alternate	O
consideration	O
is	O
multiple	O
infarctions	O
,	O
some	O
hemorrhagic	O
,	O
likely	O
embolic	O
.	O
MRI	O
with	O
and	O
without	O
contrast	O
would	O
be	O
helpful	O
for	O
further	O
evaluation	O
.	O
MRI	O
BRAIN	O
[	O
**	O
2148-9-24	O
**	O
]	O
3:27	O
PM	O
CONCLUSION	O
:	O
Multiple	O
acute	O
areas	O
of	O
infarction	O
,	O
many	O
with	O
hemorrhage	O
.	O
The	O
distribution	O
suggests	O
emboli	O
from	O
a	O
proximal	O
source	O
,	O
most	O
likely	O
cardiac	O
.	O
5	O
-	O
6	O
mm	O
anterior	O
communicating	O
artery	O
aneurysm	O
.	O
The	O
location	O
of	O
the	O
hemorrhages	O
does	O
not	O
imply	O
prior	O
bleeding	O
from	O
this	O
aneurysm	O
.	O
Within	O
the	O
limits	O
of	O
an	O
adequate	O
but	O
not	O
optimal	O
MRA	O
examination	O
,	O
no	O
other	O
intracranial	O
vascular	O
abnormalities	O
are	O
detected	O
.	O
ECHOCARDIOGRAM	O
[	O
**	O
2148-9-25	O
**	O
]	O
at	O
1:30:32	O
PM	O
Conclusions	O
:	O
No	O
spontaneous	O
echo	O
contrast	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
No	O
mass	O
/	O
thrombus	O
is	O
seen	O
in	O
the	O
left	O
atrium	O
or	O
left	O
atrial	O
appendage	O
.	O
No	O
spontaneous	O
echo	O
contrast	O
is	O
seen	O
in	O
the	O
body	O
of	O
the	O
right	O
atrium	O
.	O
No	O
atrial	O
septal	O
defect	O
or	O
patent	O
foramen	O
ovale	O
is	O
seen	O
by	O
2D	O
,	O
color	O
Doppler	O
or	O
saline	O
contrast	O
with	O
maneuvers	O
.	O
Left	O
ventricular	O
wall	O
thicknesses	O
and	O
cavity	O
size	O
are	O
normal	O
.	O
There	O
is	O
mild	O
regional	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
anterior	O
hypokinesis	O
.	O
No	O
masses	O
or	O
thrombi	O
are	O
seen	O
in	O
the	O
left	O
ventricle	O
.	O
RV	O
hypokinesis	O
is	O
seen	O
.	O
There	O
are	O
complex	O
(	O
>	O
4	O
mm	O
)	O
atheroma	O
in	O
the	O
aortic	O
arch	O
.	O
There	O
are	O
simple	O
atheroma	O
in	O
the	O
descending	O
thoracic	O
aorta	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
are	O
mildly	O
thickened	O
.	O
No	O
masses	O
or	O
vegetations	O
are	O
seen	O
on	O
the	O
aortic	O
valve	O
.	O
No	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
prolapse	O
.	O
There	O
is	O
small	O
vegetation	O
(	O
4	O
mm	O
)	O
on	O
the	O
mitral	O
valve	O
attached	O
to	O
the	O
posterior	O
leaflet	O
on	O
the	O
[	O
**	O
Name	O
Prefix	O
(	O
Prefixes	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
16	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Small	O
vegetation	O
of	O
the	O
mitral	O
valve	O
.	O
Complex	O
,	O
non-mobile	O
atheroma	O
of	O
the	O
aortic	O
arch	O
.	O
Mild	O
regional	O
LV	O
systolic	O
dysfunction	O
.	O
CT	O
HEAD	O
[	O
**	O
2148-10-1	O
**	O
]	O
8:28	O
PM	O
IMPRESSION	O
:	O
1	O
.	O
No	O
interval	O
change	O
since	O
[	O
**	O
2148-9-24	O
**	O
]	O
,	O
with	O
unchanged	O
appearance	O
of	O
right	O
frontal	O
parenchymal	O
hematoma	O
with	O
associated	O
edema	O
,	O
local	O
mass	O
effect	O
and	O
stable	O
degree	O
of	O
leftward	O
shift	O
of	O
normally	O
-	O
midline	O
structures	O
.	O
2	O
.	O
Hypodense	O
lesions	O
in	O
the	O
right	O
occipital	O
and	O
parietal	O
occipital	O
cortex	O
appear	O
grossly	O
unchanged	O
but	O
are	O
not	O
further	O
characterized	O
on	O
this	O
motion	O
-	O
degraded	O
study	O
.	O
LEFT	O
UPPER	O
EXTREMITY	O
ULTRASOUND	O
:	O
[	O
**	O
2148-10-3	O
**	O
]	O
1:45	O
PM	O
Findings	O
:	O
Grayscale	O
and	O
Doppler	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
of	O
right	O
subclavian	O
vein	O
was	O
performed	O
and	O
shows	O
normal	O
compressibility	O
,	O
flow	O
,	O
and	O
augmentation	O
.	O
Grayscale	O
and	O
Doppler	O
son	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
of	O
left	O
subclavian	O
,	O
left	O
internal	O
jugular	O
,	O
left	O
axillary	O
,	O
left	O
brachial	O
,	O
left	O
basilic	O
,	O
and	O
left	O
cephalic	O
veins	O
were	O
performed	O
.	O
The	O
left	O
internal	O
jugular	O
vein	O
shows	O
normal	O
flow	O
and	O
augmentation	O
.	O
There	O
is	O
abnormal	O
flow	O
in	O
the	O
left	O
subclavian	O
vein	O
,	O
left	O
axillary	O
vein	O
,	O
and	O
left	O
basilic	O
vein	O
.	O
Hypoechoic	O
foci	O
consistent	O
with	O
clots	O
are	O
also	O
clearly	O
visualized	O
in	O
the	O
left	O
basilic	O
and	O
left	O
axillary	O
veins	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
an	O
upper	O
extremity	O
thrombus	O
in	O
the	O
left	O
subclavian	O
vein	O
,	O
left	O
axillary	O
vein	O
,	O
and	O
left	O
basilic	O
vein	O
.	O
Brief	O
Hospital	O
Course	O
:	O
66	O
yo	O
man	O
h	O
/	O
o	O
severe	O
emphysema	O
who	O
presented	O
with	O
a	O
new	O
diagnosis	O
of	O
APML	O
and	O
NSTEMI	O
with	O
EF	O
30	O
%	O
,	O
s	O
/	O
p	O
intubation	O
[	O
**	O
9	O
-	O
20	O
**	O
]	O
with	O
extubation	O
on	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
,	O
found	O
to	O
have	O
large	O
IPH	O
,	O
multiple	O
strokes	O
,	O
and	O
endocarditis	O
.	O
#	O
APML	I-Reason
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
104371	O
**	O
]	O
was	O
diagnosed	O
with	O
APML	O
by	O
peripheral	O
smear	O
,	O
flow	O
cytometry	O
,	O
and	O
PCR	O
of	O
the	O
blood	O
.	O
He	O
was	O
treated	O
with	O
ATRA	I-Drug
and	O
hydroxyurea	I-Drug
initially	O
and	O
when	O
his	O
WBC	O
was	O
<	O
10K	O
,	O
his	O
hydroxyurea	I-Drug
was	O
stopped	O
.	O
He	O
also	O
received	O
steroids	I-Drug
initially	O
for	O
prophylaxis	B-Reason
of	I-Reason
ATRA	I-Reason
syndrome	I-Reason
and	O
this	O
was	O
gradually	O
weaned	O
.	O
He	O
was	O
monitored	O
for	O
tumor	O
lysis	O
and	O
DIC	O
and	O
transfused	O
blood	O
products	O
prn	O
to	O
keep	O
his	O
fibrinogen	O
>	O
100	O
and	O
INR	O
<	O
1.5	O
.	O
His	O
platelet	O
goal	O
was	O
initially	O
20K	O
but	O
this	O
was	O
increased	O
to	O
100K	O
after	O
his	O
intraparenchymal	O
hemorrhage	O
.	O
#	O
NSTEMI	I-Reason
with	O
new	O
heart	B-Reason
failure	I-Reason
(	O
EF	O
35	O
%	O
)	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
104371	O
**	O
]	O
initially	O
presented	O
to	O
his	O
PCP	O
's	O
office	O
with	O
chest	O
pain	O
.	O
He	O
had	O
elevated	O
troponins	O
on	O
admission	O
with	O
no	O
ST	O
or	O
T	O
wave	O
changes	O
on	O
EKG	O
,	O
c	O
/	O
w	O
NSTEMI	O
.	O
We	O
trended	O
his	O
troponins	O
which	O
plateaued	O
at	O
3.50	O
.	O
His	O
first	O
ECHO	O
showed	O
moderate	O
to	O
severe	O
global	O
left	O
ventricular	O
hypokinesis	O
,	O
with	O
some	O
regional	O
variation	O
(	O
the	O
anterior	O
septum	O
,	O
anterior	O
free	O
wall	O
,	O
and	O
apex	O
appearing	O
more	O
hypokinetic	O
than	O
the	O
other	O
walls	O
)	O
and	O
LVEF	O
=	O
30	O
%	O
.	O
He	O
was	O
monitored	O
on	O
telemetry	O
and	O
had	O
no	O
significant	O
arrhythmias	O
.	O
Given	O
his	O
concurrent	O
IPH	O
(	O
see	O
below	O
)	O
,	O
antiplatelet	O
&	O
anticoagulant	O
agents	O
are	O
contraindicated	O
and	O
he	O
was	O
medically	O
managed	O
with	O
nitrates	I-Drug
,	O
beta	B-Drug
-	I-Drug
blockers	I-Drug
,	O
low	O
-	O
dose	O
ACE	B-Drug
-	I-Drug
i	I-Drug
and	O
a	O
statin	I-Drug
.	O
Repeat	O
ECHO	O
on	O
[	O
**	O
2148-9-25	O
**	O
]	O
showed	O
a	O
persistent	O
small	O
vegetation	O
of	O
the	O
mitral	O
valve	O
,	O
complex	O
,	O
non-mobile	O
atheroma	O
of	O
the	O
aortic	O
arch	O
,	O
and	O
mild	O
regional	O
LV	O
systolic	O
dysfunction	O
(	O
EF	O
45	O
%	O
)	O
.	O
#	O
Intraparenchymal	O
hemorrhage	O
:	O
On	O
the	O
morning	O
of	O
[	O
**	O
2148-9-23	O
**	O
]	O
,	O
it	O
was	O
noted	O
that	O
Mr.	O
[	O
**	O
Known	O
lastname	O
104371	O
**	O
]	O
was	O
not	O
moving	O
his	O
L	O
arm	O
.	O
CT	O
head	O
showed	O
a	O
large	O
intraparenchymal	O
hemorrhage	O
in	O
the	O
right	O
frontal	O
lobe	O
,	O
with	O
surrounding	O
vasogenic	O
edema	O
and	O
local	O
mass	O
effect	O
.	O
A	O
hypodense	O
lesion	O
with	O
smaller	O
hemorrhagic	O
component	O
was	O
also	O
seen	O
in	O
the	O
right	O
occipital	O
lobe	O
,	O
with	O
two	O
additional	O
non-hemorrhagic	O
hypodense	O
lesions	O
seen	O
in	O
the	O
left	O
cerebellar	O
hemisphere	O
and	O
the	O
right	O
parieto	O
-	O
occipital	O
cortex	O
.	O
MRI	O
/	O
A	O
on	O
[	O
**	O
2148-9-24	O
**	O
]	O
revealed	O
multiple	O
areas	O
of	O
acute	O
infarction	O
,	O
many	O
with	O
hemorrhage	O
,	O
with	O
a	O
distribution	O
that	O
suggests	O
emboli	O
from	O
a	O
proximal	O
source	O
,	O
likely	O
cardiac	O
.	O
Unclear	O
etiology	O
for	O
embolism	O
??????	O
blood	O
cultures	O
are	O
negative	O
to	O
date	O
to	O
assess	O
for	O
bacteremia	O
.	O
TEE	O
showed	O
aortic	O
plaque	O
that	O
could	O
be	O
potential	O
embolic	O
source	O
.	O
MRA	O
showed	O
a	O
5	O
-	O
6	O
mm	O
communicating	O
artery	O
aneurysm	O
as	O
well	O
.	O
Neurosurgery	O
had	O
no	O
plans	O
for	O
intervention	O
.	O
Neurology	O
was	O
consulted	O
&	O
recommended	O
EEG	O
which	O
showed	O
a	O
diffuse	O
encephalopathy	O
pattern	O
and	O
a	O
focal	O
area	O
with	O
epileptogenic	O
potential	O
,	O
but	O
no	O
electrographic	O
seizures	O
.	O
All	O
antiplatelet	O
/	O
anticoagulant	O
agents	O
were	O
held	O
.	O
DIC	O
labs	O
were	O
stable	O
,	O
with	O
a	O
platelet	O
count	O
goal	O
of	O
>	O
100K	O
.	O
He	O
was	O
able	O
to	O
be	O
extubated	O
on	O
[	O
**	O
2148-9-27	O
**	O
]	O
and	O
PT	O
/	O
OT	O
was	O
consulted	O
for	O
help	O
managing	O
/	O
recovering	O
from	O
his	O
stroke	O
.	O
He	O
continued	O
to	O
suffer	O
from	O
mood	O
lability	O
on	O
the	O
floor	O
and	O
intermittently	O
refused	O
his	O
medications	O
.	O
Neurology	O
continued	O
to	O
follow	O
him	O
.	O
EEG	O
was	O
repeated	O
and	O
did	O
not	O
show	O
any	O
seizure	O
activity	O
,	O
just	O
a	O
diffuse	O
encephalopathy	O
.	O
Haldol	I-Drug
0.5	O
mg	O
IV	O
was	O
used	O
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
for	O
mood	I-Reason
stabilization	O
as	O
he	O
refused	O
.	O
#	O
Respiratory	O
Distress	O
/	O
Hypoxia	O
:	O
On	O
presentation	O
,	O
he	O
was	O
hypoxic	I-Reason
and	O
required	O
oxygen	I-Drug
support	O
by	O
nasal	O
cannula	O
(	O
up	O
to	O
6L	O
)	O
.	O
It	O
was	O
felt	O
to	O
be	O
multifactorial	O
,	O
with	O
his	O
underlying	O
emphysema	O
,	O
acute	O
systolic	O
heart	O
failure	O
,	O
pulmonary	O
edema	O
,	O
and	O
pneumonia	O
contributing	O
.	O
Following	O
his	O
IPH	O
,	O
he	O
was	O
intubated	O
for	O
airway	O
protection	O
on	O
[	O
**	O
2148-9-20	O
**	O
]	O
with	O
successful	O
extubation	O
on	O
[	O
**	O
2148-9-27	O
**	O
]	O
.	O
Bronchoscopy	O
on	O
[	O
**	O
2148-9-26	O
**	O
]	O
showed	O
edematous	O
airways	O
with	O
friability	O
but	O
no	O
frank	O
blood	O
.	O
BAL	O
grew	O
yeast	O
(	O
it	O
was	O
initially	O
reported	O
as	O
mold	O
,	O
concerning	O
for	O
Aspergillus	O
,	O
but	O
galactomannan	O
/	O
glucan	O
were	O
normal	O
and	O
it	O
was	O
re-read	O
as	O
yeast	O
)	O
.	O
He	O
is	O
s	O
/	O
p	O
8	O
day	O
course	O
of	O
cefepime	I-Drug
and	O
levofloxacin	I-Drug
for	O
his	O
pneumonia	I-Reason
.	O
Following	O
extubation	O
,	O
he	O
was	O
maintained	O
on	O
his	O
home	O
COPD	O
medications	O
and	O
was	O
maintaining	O
stable	O
O2	O
sats	O
on	O
room	O
air	O
.	O
#	O
Culture	O
-	O
negative	O
endocarditis	O
:	O
ECHO	O
on	O
[	O
**	O
2148-9-25	O
**	O
]	O
showed	O
a	O
small	O
vegetation	O
on	O
mitral	O
valve	O
.	O
Unclear	O
if	O
this	O
is	O
infectious	O
versus	O
malignant	O
.	O
Added	O
vancomycin	I-Drug
(	O
d1	O
=[	O
**	O
9	O
-	O
25	O
**	O
]	O
)	O
for	O
MRSA	I-Reason
endocarditis	O
coverage	O
and	O
started	O
ceftriaxone	I-Drug
(	O
d1	O
=[	O
**	O
9	O
-	O
27	O
**	O
]	O
)	O
.	O
Had	O
abdominal	O
CT	O
[	O
**	O
2148-9-26	O
**	O
]	O
which	O
did	O
not	O
show	O
any	O
infectious	O
source	O
.	O
Per	O
ID	O
,	O
6	O
week	O
course	O
of	O
antibiotics	I-Drug
recommended	O
.	O
#	O
LUE	O
edema	O
:	O
LUE	O
>	O
RUE	O
edema	O
,	O
of	O
hand	O
and	O
arm	O
.	O
Patient	O
had	O
PICC	O
placed	O
in	O
left	O
arm	O
[	O
**	O
2148-9-27	O
**	O
]	O
and	O
his	O
edema	O
was	O
concerning	O
for	O
DVT	O
.	O
Given	O
his	O
recent	O
IPH	O
,	O
anticoagulation	I-Drug
was	O
not	O
an	O
option	O
.	O
Left	O
upper	O
extremity	O
U	O
/	O
S	O
done	O
on	O
[	O
**	O
2148-9-27	O
**	O
]	O
to	O
r	O
/	O
o	O
DVT	O
was	O
negative	O
.	O
Edema	O
and	O
pain	O
persisted	O
,	O
so	O
a	O
repeat	O
LUE	O
U	O
/	O
S	O
was	O
done	O
on	O
[	O
**	O
2148-10-3	O
**	O
]	O
and	O
showed	O
extensive	O
DVT	O
of	O
the	O
L	O
subclavian	O
,	O
axillary	O
and	O
basilic	O
vein	O
.	O
The	O
PICC	O
line	O
was	O
removed	O
on	O
[	O
**	O
2148-10-3	O
**	O
]	O
and	O
a	O
peripheral	O
IV	O
was	O
placed	O
.	O
On	O
[	O
**	O
2148-10-4	O
**	O
]	O
,	O
the	O
family	O
expressed	O
a	O
desire	O
to	O
transfer	O
his	O
care	O
to	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
.	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
the	O
inpatient	O
hematologic	O
malignancy	O
team	O
who	O
accepted	O
the	O
patient	O
in	O
transfer	O
.	O
Medications	O
on	O
Admission	O
:	O
ALBUTEROL	B-Drug
SULFATE	I-Drug
-	O
90	O
mcg	O
HFA	O
Aerosol	O
Inhaler	O
-	O
2	O
puffs	O
inhaled	O
four	O
times	O
daily	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
BUPROPION	B-Drug
HCL	I-Drug
150	O
mg	O
Tablet	O
Sustained	O
Release	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
CLOBETASOL	I-Drug
-	O
0.05	O
%	O
Ointment	O
-	O
Apply	O
[	O
**	O
Hospital1	O
**	O
]	O
to	O
affected	O
areas	O
x	O
up	O
to	O
2	O
weeks	O
per	O
month	O
:	O
AVOID	O
face	O
and	O
folds	O
[	O
**	O
Hospital1	O
**	O
]	O
;	O
may	O
wrap	O
with	O
saran	O
to	O
areas	O
as	O
directed	O
DIAZEPAM	I-Drug
[	O
VALIUM	O
]	O
-	O
5	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
as	O
needed	O
FLUTICASONE	B-Drug
-	I-Drug
SALMETEROL	I-Drug
[	O
ADVAIR	O
DISKUS	O
]	O
-	O
250	O
mcg	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
-	O
1	O
puff	O
inhaled	O
Every	O
12	O
hours	O
;	O
Rinse	O
mouth	O
well	O
after	O
each	O
use	O
FUROSEMIDE	I-Drug
-	O
40	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
HYDROCHLOROTHIAZIDE	I-Drug
-	O
25	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
OXYGEN	I-Drug
-	O
-	O
2L	O
by	O
nasal	O
cannula	O
continuously	O
during	O
sleep	O
and	O
with	O
any	O
exertion	O
Room	O
air	O
sat	O
87	O
%	O
with	O
minimal	O
exertion	O
documented	O
[	O
**	O
2146-10-25	O
**	O
]	O
POTASSIUM	B-Drug
CHLORIDE	I-Drug
-	O
10	O
mEq	O
Capsule	O
,	O
Sustained	O
Release	O
-	O
1	O
Capsule	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
SILDENAFIL	I-Drug
[	O
VIAGRA	O
]	O
-	O
(	O
Not	O
Taking	O
as	O
Prescribed	O
)	O
-	O
100	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
as	O
needed	O
SIMVASTATIN	I-Drug
-	O
40	O
mg	O
Tablet	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
TIOTROPIUM	B-Drug
BROMIDE	I-Drug
[	O
SPIRIVA	O
WITH	O
HANDIHALER	O
]	O
-	O
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
-	O
1	O
puff	O
inh	O
daily	O
VERAPAMIL	I-Drug
-	O
240	O
mg	O
Cap	O
,24	O
hr	O
Sust	O
Release	O
Pellets	O
-	O
1	O
Cap	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
ACETAMINOPHEN	I-Drug
[	O
TYLENOL	O
EXTRA	O
STRENGTH	O
]	O
-	O
(	O
OTC	O
)	O
-	O
500	O
mg	O
Tablet	O
-	O
2	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
twice	O
a	O
day	O
as	O
needed	O
ASPIRIN	I-Drug
[	O
ENTERIC	O
COATED	O
ASPIRIN	O
]	O
-	O
81	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
-	O
1	O
Tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
.	O
2	O
.	O
allopurinol	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
4	O
.	O
docusate	B-Drug
sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
One	O
Hundred	O
(	O
100	O
)	O
mg	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
senna	I-Drug
8.8	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
polyethylene	B-Drug
glycol	I-Drug
3350	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
packet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
packet	O
7	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
isosorbide	B-Drug
mononitrate	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
9	O
.	O
fluticasone	I-Drug
110	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Puff	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
lisinopril	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
tretinoin	I-Drug
(	O
chemotherapy	O
)	O
10	O
mg	O
Capsule	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
ipratropium	B-Drug
bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
inhalation	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
13	O
.	O
albuterol	B-Drug
sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q2H	O
(	O
every	O
2	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
14	O
.	O
albuterol	B-Drug
sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
.	O
15	O
.	O
nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
thrush	I-Reason
.	O
16	O
.	O
bupropion	B-Drug
HCl	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
17	O
.	O
CeftriaXONE	I-Drug
2	O
gm	O
IV	O
Q24H	O
Start	O
:	O
In	O
am	O
START	O
ON	O
MORNING	O
OF	O
[	O
**	O
9	O
-	O
27	O
**	O
]	O
18	O
.	O
Vancomycin	I-Drug
1000	O
mg	O
IV	O
Q	O
8H	O
d1	O
=[	O
**	O
9	O
-	O
25	O
**	O
]	O
19	O
.	O
Haloperidol	I-Drug
0.5	O
mg	O
IV	O
BID	O
:	O
PRN	O
agitation	I-Reason
20	O
.	O
Sodium	B-Drug
Chloride	I-Drug
0.9	O
%	O
Flush	O
3	O
mL	O
IV	O
Q8H	O
:	O
PRN	O
line	O
flush	O
Peripheral	O
line	O
:	O
Flush	O
with	O
3	O
mL	O
Normal	B-Drug
Saline	I-Drug
every	O
8	O
hours	O
and	O
PRN	O
.	O
21	O
.	O
Heparin	I-Drug
Flush	O
(	O
10	O
units	O
/	O
ml	O
)	O
2	O
mL	O
IV	O
PRN	O
line	O
flush	O
PICC	O
,	O
heparin	I-Drug
dependent	O
:	O
Flush	O
with	O
10mL	O
Normal	B-Drug
Saline	I-Drug
followed	O
by	O
Heparin	I-Drug
as	O
above	O
daily	O
and	O
PRN	O
per	O
lumen	O
.	O
22	O
.	O
Lantus	I-Drug
100	O
unit	O
/	O
mL	O
Cartridge	O
Sig	O
:	O
Eighteen	O
(	O
18	O
)	O
units	O
Subcutaneous	O
at	O
bedtime	O
.	O
23	O
.	O
Humalog	I-Drug
100	O
unit	O
/	O
mL	O
Cartridge	O
Sig	O
:	O
2	O
-	O
10	O
units	O
Subcutaneous	O
QACHS	O
:	O
According	O
to	O
sliding	O
scale	O
.	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Acute	O
Promyelocytic	O
Leukemia	O
Stroke	O
with	O
intracranial	O
hemorrhage	O
Non	O
ST	O
elevation	O
MI	O
Endocarditis	O
,	O
culture	O
negative	O
Delerium	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
always	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
104371	O
**	O
]	O
,	O
You	O
were	O
admitted	O
with	O
an	O
NSTEMI	O
,	O
new	O
diagnosis	O
of	O
APML	O
,	O
Stroke	O
with	O
ICH	O
and	O
endocarditis	O
.	O
You	O
were	O
treated	O
with	O
ATRA	I-Drug
and	O
antibiotics	I-Drug
.	O
You	O
are	O
being	O
transferred	O
to	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
for	O
further	O
care	O
per	O
your	O
request	O
.	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
104371	O
**	O
]	O
,	O
You	O
were	O
admitted	O
with	O
an	O
NSTEMI	O
,	O
new	O
diagnosis	O
of	O
APML	O
,	O
Stroke	O
with	O
ICH	O
and	O
endocarditis	O
.	O
You	O
were	O
treated	O
with	O
ATRA	I-Drug
and	O
antibiotics	I-Drug
.	O
You	O
are	O
being	O
transferred	O
to	O
[	O
**	O
Hospital1	O
2025	O
**	O
]	O
for	O
further	O
care	O
per	O
your	O
request	O
.	O
Followup	O
Instructions	O
:	O
You	O
will	O
need	O
to	O
follow	O
up	O
with	O
a	O
hematologist	O
on	O
discharge	O
.	O
Completed	O
by	O
:[	O
**	O
2148-10-4	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2172-1-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2172-2-5	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2092-2-13	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
SURGERY	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Cephalosporins	I-Drug
/	O
Carbapenem	I-Drug
/	O
A.C.E	B-Drug
Inhibitors	I-Drug
/	O
Angiotensin	B-Drug
Receptor	I-Drug
Antagonist	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
148	O
**	O
]	O
Chief	O
Complaint	O
:	O
Small	O
bowel	O
obstruction	O
Abdominal	O
Pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
Exploratory	O
laparotomy	O
.	O
2	O
.	O
Extended	O
adhesiolysis	O
.	O
3	O
.	O
Small	O
-	O
bowel	O
resection	O
with	O
primary	O
anastomosis	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
79	O
-	O
year	O
-	O
old	O
gentleman	O
has	O
had	O
a	O
previous	O
total	O
abdominal	O
colectomy	O
here	O
at	O
this	O
institution	O
5	O
years	O
ago	O
for	O
C	O
difficile	O
colitis	O
.	O
He	O
has	O
been	O
fine	O
in	O
this	O
period	O
of	O
time	O
but	O
has	O
recently	O
presented	O
with	O
a	O
bowel	O
obstruction	O
for	O
the	O
first	O
time	O
about	O
5	O
days	O
ago	O
.	O
We	O
treated	O
him	O
with	O
conservative	O
care	O
and	O
found	O
that	O
over	O
the	O
next	O
5	O
days	O
he	O
did	O
not	O
open	O
up	O
a	O
known	O
transition	O
point	O
on	O
a	O
CAT	O
scan	O
.	O
His	O
white	O
blood	O
cell	O
count	O
came	O
down	O
and	O
he	O
was	O
stable	O
throughout	O
this	O
period	O
.	O
NG	O
tube	O
suction	O
care	O
did	O
improve	O
his	O
abdominal	O
distention	O
.	O
However	O
,	O
a	O
follow	O
-	O
up	O
CAT	O
scan	O
showed	O
that	O
the	O
transition	O
point	O
in	O
the	O
right	O
lower	O
quadrant	O
near	O
the	O
ileostomy	O
site	O
did	O
not	O
change	O
significantly	O
.	O
With	O
these	O
findings	O
,	O
I	O
proposed	O
an	O
exploratory	O
laparotomy	O
for	O
adhesiolysis	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
CAD	O
,	O
s	O
/	O
p	O
MI	O
in	O
[	O
**	O
2166	O
**	O
]	O
(	O
intraoperative	O
MI	O
during	O
nephrectomy	O
)	O
,	O
s	O
/	O
p	O
LAD	O
stent	O
in	O
[	O
**	O
11/2167	O
**	O
]	O
and	O
OM1	O
stent	O
in	O
[	O
**	O
12/2167	O
**	O
]	O
(	O
c	O
/	O
b	O
in	O
-	O
stent	O
restenosis	O
of	O
OM1	O
s	O
/	O
p	O
balloon	O
angio	O
in	O
1	O
/	O
[	O
**	O
2169	O
**	O
]	O
)	O
.	O
-	O
Type	O
II	O
DM	O
-	O
c	O
/	O
b	O
peripheral	O
neuropathy	O
and	O
nephropathy	O
-	O
Chronic	O
Kidney	O
Disease	O
-	O
baseline	O
creatinine	O
2	O
-	O
2.5	O
;	O
s	O
/	O
p	O
partial	O
R	O
nephrectomy	O
for	O
RCC	O
in	O
[	O
**	O
2166	O
**	O
]	O
-	O
Systolic	O
CHF	O
-	O
prior	O
LVEF	O
(	O
[	O
**	O
6	O
-	O
/	O
2170	O
**	O
]	O
)	O
of	O
35	O
%	O
;	O
Most	O
recent	O
ECHO	O
in	O
[	O
**	O
6	O
-	O
27	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
shows	O
EF	O
of	O
45	O
-	O
50	O
%	O
-	O
Hypertension	O
-	O
Hypercholesterolemia	O
-	O
H	O
/	O
o	O
Renal	O
cell	O
carcinoma	O
,	O
s	O
/	O
p	O
partial	O
R	O
nephrectomy	O
[	O
**	O
2	O
-	O
/	O
2166	O
**	O
]	O
-	O
H	O
/	O
o	O
prostate	O
CA	O
,	O
s	O
/	O
p	O
XRT	O
-	O
Type	O
1	O
RTA	O
-	O
Hypoaldosteronism	O
-	O
H	O
/	O
o	O
hyperkalemia	O
-	O
Anemia	O
-	O
baseline	O
hematocrit	O
30	O
-	O
Fulminant	O
C.	O
diff	O
colitis	O
(	O
[	O
**	O
2167	O
**	O
]	O
)	O
,	O
s	O
/	O
p	O
total	O
colectomy	O
w	O
/	O
ileostomy	O
-	O
H	O
/	O
o	O
multiple	O
falls	O
,	O
s	O
/	O
p	O
mid-shaft	O
and	O
surgical	O
neck	O
humerus	O
fracture	O
(	O
[	O
**	O
7	O
-	O
/	O
2169	O
**	O
]	O
)	O
-	O
BiPap	O
at	O
home	O
for	O
?	O
OSA	O
-	O
Major	O
depression	O
Social	O
History	O
:	O
Retired	O
attorney	O
(	O
once	O
argued	O
before	O
the	O
supreme	O
court	O
)	O
.	O
Lives	O
alone	O
.	O
H	O
/	O
o	O
tobacco	O
,	O
quit	O
55	O
years	O
ago	O
.	O
Denies	O
EtOH	O
.	O
Uses	O
a	O
scooter	O
to	O
get	O
around	O
,	O
but	O
can	O
walk	O
with	O
a	O
walker	O
.	O
Family	O
History	O
:	O
Father	O
--	O
CVA	O
,	O
fatal	O
,	O
49	O
yo	O
Mother	O
--	O
MI	O
,	O
fatal	O
,	O
80s	O
Sister	O
--	O
breast	O
cancer	O
,	O
81	O
yo	O
Physical	O
Exam	O
:	O
99.1	O
,	O
83	O
,	O
141/65	O
,	O
18	O
,	O
96	O
%	O
RA	O
Gen	O
:	O
A+O	O
x	O
3	O
,	O
drowsy	O
,	O
uncomfortable	O
appearing	O
HEENT	O
:	O
anicteric	O
sclera	O
Chest	O
:	O
decreased	O
breath	O
sounds	O
CV	O
:	O
RRR	O
GI	O
/	O
Abd	O
:	O
grossly	O
distended	O
,	O
absent	O
BS	O
,	O
vomits	O
brown	O
/	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
fluid	O
when	O
push	O
lightly	O
on	O
belly	O
,	O
no	O
peritoneal	O
signs	O
Ext	O
:	O
trace	O
LE	O
edema	O
Pertinent	O
Results	O
:	O
[	O
**	O
2172-1-22	O
**	O
]	O
07:55	O
AM	O
BLOOD	O
WBC	O
-	O
11.6	O
*	O
RBC	O
-	O
4.55	O
*	O
Hgb	O
-	O
12.8	O
*	O
Hct	O
-	O
38.7	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
28.1	O
MCHC	O
-	O
33.1	O
RDW	O
-	O
16.3	O
*	O
Plt	O
Ct	O
-	O
283	O
[	O
**	O
2172-1-30	O
**	O
]	O
01:59	O
AM	O
BLOOD	O
WBC	O
-	O
14.6	O
*	O
RBC	O
-	O
3.79	O
*	O
Hgb	O
-	O
10.6	O
*	O
Hct	O
-	O
32.9	O
*	O
MCV	O
-	O
87	O
MCH	O
-	O
27.9	O
MCHC	O
-	O
32.1	O
RDW	O
-	O
14.8	O
Plt	O
Ct	O
-	O
156	O
[	O
**	O
2172-2-4	O
**	O
]	O
05:30	O
AM	O
BLOOD	O
WBC	O
-	O
14.0	O
*	O
RBC	O
-	O
3.44	O
*	O
Hgb	O
-	O
9.6	O
*	O
Hct	O
-	O
29.1	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
27.8	O
MCHC	O
-	O
32.9	O
RDW	O
-	O
14.7	O
Plt	O
Ct	O
-	O
319	O
[	O
**	O
2172-1-24	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
Glucose	O
-	O
155	O
*	O
UreaN	O
-	O
49	O
*	O
Creat	O
-	O
3.3	O
*	O
Na	O
-	O
150	O
*	O
K	O
-	O
4.1	O
Cl	O
-	O
113	O
*	O
HCO3	O
-	O
25	O
AnGap	O
-	O
16	O
[	O
**	O
2172-2-4	O
**	O
]	O
05:30	O
AM	O
BLOOD	O
Glucose	O
-	O
100	O
UreaN	O
-	O
34	O
*	O
Creat	O
-	O
2.1	O
*	O
Na	O
-	O
141	O
K	O
-	O
3.6	O
Cl	O
-	O
105	O
HCO3	O
-	O
27	O
AnGap	O
-	O
13	O
[	O
**	O
2172-2-4	O
**	O
]	O
05:30	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
3.8	O
Mg	O
-	O
1.9	O
[	O
**	O
2172-1-28	O
**	O
]	O
11:41	O
AM	O
BLOOD	O
Cortsol	O
-	O
33.9	O
*	O
[	O
**	O
2172-1-28	O
**	O
]	O
12:29	O
PM	O
BLOOD	O
Cortsol	O
-	O
51.2	O
*	O
[	O
**	O
2172-1-28	O
**	O
]	O
12:44	O
PM	O
BLOOD	O
Cortsol	O
-	O
52.4	O
*	O
.	O
CT	O
ABDOMEN	O
W	O
/	O
O	O
CONTRAST	I-Drug
[	O
**	O
2172-1-22	O
**	O
]	O
12:34	O
PM	O
IMPRESSION	O
:	O
Distal	O
ileal	O
small	O
-	O
bowel	O
obstruction	O
with	O
discrete	O
transition	O
point	O
identified	O
in	O
the	O
right	O
lateral	O
mid	O
abdomen	O
.	O
Given	O
the	O
traction	O
on	O
multiple	O
adjoining	O
small	O
bowel	O
loops	O
,	O
adhesion	O
is	O
highly	O
suspect	O
.	O
Incidental	O
findings	O
are	O
detailed	O
above	O
.	O
.	O
CT	O
ABDOMEN	O
W	O
/	O
O	O
CONTRAST	I-Drug
[	O
**	O
2172-1-26	O
**	O
]	O
3:14	O
PM	O
IMPRESSION	O
:	O
No	O
significant	O
change	O
in	O
findings	O
consistent	O
with	O
small	O
-	O
bowel	O
obstruction	O
.	O
.	O
CHEST	O
(	O
PORTABLE	O
AP	O
)	O
[	O
**	O
2172-1-29	O
**	O
]	O
11:05	O
AM	O
IMPRESSION	O
:	O
Status	O
post	O
extubation	O
with	O
lingular	O
atelectasis	O
and	O
left	O
lung	O
volume	O
loss	O
.	O
Please	O
note	O
the	O
nasogastric	O
tube	O
is	O
likely	O
in	O
the	O
post-pyloric	O
position	O
and	O
retraction	O
should	O
be	O
considered	O
for	O
more	O
optimal	O
placement	O
.	O
Brief	O
Hospital	O
Course	O
:	O
This	O
is	O
a	O
79	O
year	O
old	O
male	O
who	O
presented	O
with	O
a	O
small	O
bowel	O
obstruction	O
.	O
He	O
noted	O
decreased	O
ostomy	O
output	O
and	O
has	O
had	O
nausea	O
and	O
vomiting	O
and	O
abdominal	O
distention	O
.	O
Small	B-Reason
bowel	I-Reason
obstruction	I-Reason
:	O
He	O
was	O
NPO	O
,	O
with	O
IVF	I-Drug
and	O
a	O
NGT	O
.	O
We	O
noted	O
no	O
gas	O
or	O
stool	O
in	O
his	O
ostomy	O
bag	O
.	O
we	O
attempted	O
to	O
manage	O
him	O
conservatively	O
,	O
but	O
a	O
repeat	O
CT	O
on	O
[	O
**	O
2172-1-26	O
**	O
]	O
showed	O
no	O
improvement	O
in	O
his	O
distal	O
ileal	O
small	O
-	O
bowel	O
obstruction	O
with	O
discrete	O
transition	O
point	O
identified	O
in	O
the	O
right	O
lateral	O
mid	O
abdomen	O
.	O
He	O
went	O
to	O
the	O
OR	O
on	O
[	O
**	O
2172-1-27	O
**	O
]	O
for	O
:	O
1	O
.	O
Exploratory	O
laparotomy	O
.	O
2	O
.	O
Extended	O
adhesiolysis	O
.	O
3	O
.	O
Small	O
-	O
bowel	O
resection	O
with	O
primary	O
anastomosis	O
.	O
He	O
was	O
NPO	O
,	O
with	O
IVF	I-Drug
and	O
a	O
NGT	O
.	O
The	O
NGT	O
was	O
removed	O
on	O
POD	O
4	O
.	O
We	O
slowly	O
advanced	O
his	O
diet	O
as	O
he	O
had	O
return	O
of	O
bowel	O
function	O
.	O
He	O
was	O
on	O
TPN	O
while	O
we	O
awaited	O
return	O
of	O
bowel	O
function	O
.	O
He	O
was	O
tolerating	O
fulls	O
on	O
POD	O
7	O
and	O
regular	O
diet	O
POD	O
8	O
and	O
the	O
TPN	O
was	O
weaned	O
off	O
.	O
His	O
incision	O
was	O
C	O
/	O
D	O
/	O
I	O
with	O
a	O
small	O
amount	O
of	O
redness	O
along	O
the	O
distal	O
part	O
of	O
the	O
incision	O
.	O
The	O
staples	O
were	O
left	O
in	O
place	O
and	O
should	O
be	O
removed	O
on	O
Monday	O
/	O
Tuesday	O
next	O
week	O
with	O
steri	O
strips	O
applied	O
.	O
CHF	O
:	O
He	O
has	O
chronic	O
diastolic	O
documented	O
heart	O
failure	O
.	O
We	O
monitored	O
his	O
cardiac	O
function	O
and	O
he	O
received	O
his	O
home	O
meds	O
when	O
appropriate	O
along	O
with	O
diuretics	I-Drug
as	O
described	O
below	O
.	O
Resp	O
:	O
He	O
remained	O
intubated	O
post-operatively	O
and	O
was	O
transferred	O
to	O
the	O
ICU	O
.	O
He	O
was	O
extubated	O
on	O
POD	O
2	O
and	O
did	O
well	O
.	O
He	O
was	O
on	O
a	O
50	O
%	O
face	O
tent	O
in	O
the	O
ICU	O
.	O
Good	O
pulmonary	O
toilet	O
was	O
encouraged	O
,	O
including	O
ambulation	O
and	O
IS	O
.	O
We	O
assess	O
his	O
respiratory	O
status	O
and	O
he	O
received	O
diuresis	I-Drug
when	O
appropriate	O
.	O
He	O
continued	O
on	O
O2	I-Drug
by	O
nasal	O
cannula	O
once	O
out	O
on	O
the	O
floor	O
.	O
GU	O
:	O
He	O
was	O
receiving	O
fluid	B-Drug
resuscitation	I-Drug
and	O
albumin	I-Drug
initially	O
for	O
hypovolemia	I-Reason
.	O
and	O
then	O
diuresis	I-Drug
when	O
appropriate	O
.	O
His	O
BUN	O
/	O
Cr	O
remained	O
slightly	O
elevated	O
and	O
stable	O
.	O
He	O
was	O
having	O
urinary	O
incontinence	O
.	O
Hypernatremia	O
:	O
He	O
is	O
on	O
chronic	O
Torsemide	I-Drug
treatment	O
for	O
his	O
CHF	I-Reason
.	O
His	O
sodium	O
was	O
elevated	O
since	O
admission	O
.	O
His	O
fluids	O
were	O
changed	O
to	O
D5W	I-Drug
.	O
Hypernatremia	I-Ade
likely	O
due	O
to	O
diuretics	I-Drug
and	O
NGT	O
suction	O
.	O
His	O
torsemide	I-Drug
was	O
held	O
,	O
as	O
he	O
did	O
not	O
appear	O
fluid	O
overloaded	O
and	O
he	O
was	O
gently	O
hydrated	I-Reason
with	O
D5W	I-Drug
.	O
His	O
sodium	O
slowly	O
recovered	O
and	O
was	O
stable	O
.	O
Endo	O
:	O
He	O
was	O
followed	O
by	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
for	O
blood	B-Reason
glucose	I-Reason
control	I-Reason
.	O
He	O
was	O
taking	O
Lantus	I-Drug
and	O
a	O
Humalog	I-Drug
sliding	O
scale	O
.	O
A	O
cortisol	O
stimulation	O
test	O
was	O
negative	O
.	O
Medications	O
on	O
Admission	O
:	O
asa	I-Drug
81	O
mg	O
'	O
,	O
calcitriol	I-Drug
.25	O
mcg	O
'	O
,	O
lantus	I-Drug
46	O
'	O
,	O
neurontin	I-Drug
300	O
mg	O
'	O
''	O
,	O
paxil	I-Drug
30	O
mg	O
'	O
,	O
Zocor	I-Drug
10	O
mg	O
'	O
Discharge	O
Medications	O
:	O
1	O
.	O
Heparin	B-Drug
(	I-Drug
Porcine	I-Drug
)	I-Drug
5,000	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Injection	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
Paroxetine	B-Drug
HCl	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
Aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
5	O
.	O
Acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
.	O
6	O
.	O
Pantoprazole	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
7	O
.	O
Simvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
Torsemide	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
10	O
.	O
Carvedilol	I-Drug
12.5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
11	O
.	O
Insulin	B-Drug
Glargine	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
Forty	O
Five	O
(	O
45	O
)	O
Units	O
Subcutaneous	O
at	O
bedtime	O
:	O
and	O
see	O
sliding	O
Humalog	I-Drug
scale	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital3	O
7	O
**	O
]	O
and	O
Rehab	O
Center	O
Discharge	O
Diagnosis	O
:	O
Small	O
Bowel	O
Obstruction	O
Incontinence	O
Deconditioning	O
Discharge	O
Condition	O
:	O
Good	O
Ostomy	O
functioning	O
well	O
Fair	O
Appetite	O
Pain	O
well	O
controlled	O
Discharge	O
Instructions	O
:	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
>	O
3	O
lbs	O
.	O
Adhere	O
to	O
2	O
gm	O
sodium	O
diet	O
Fluid	O
Restriction	O
Incision	O
Care	O
:	O
Keep	O
clean	O
and	O
dry	O
.	O
The	O
staples	O
were	O
left	O
in	O
place	O
at	O
this	O
time	O
.	O
Please	O
removed	O
staples	O
on	O
Monday	O
or	O
Tuesday	O
next	O
week	O
and	O
place	O
steri	O
strip	O
across	O
incision	O
.	O
-	O
You	O
may	O
shower	O
,	O
and	O
wash	O
surgical	O
incisions	O
.	O
-	O
Avoid	O
swimming	O
and	O
baths	O
until	O
your	O
follow	O
-	O
up	O
appointment	O
.	O
-	O
Please	O
call	O
the	O
doctor	O
if	O
you	O
have	O
increased	O
pain	O
,	O
swelling	O
,	O
redness	O
,	O
or	O
drainage	O
from	O
the	O
incision	O
sites	O
.	O
.	O
Please	O
call	O
your	O
doctor	O
or	O
return	O
to	O
the	O
ER	O
for	O
any	O
of	O
the	O
following	O
:	O
*	O
You	O
experience	O
new	O
chest	O
pain	O
,	O
pressure	O
,	O
squeezing	O
or	O
tightness	O
.	O
*	O
New	O
or	O
worsening	O
cough	O
or	O
wheezing	O
.	O
*	O
If	O
you	O
are	O
vomiting	O
and	O
can	O
not	O
keep	O
in	O
fluids	O
or	O
your	O
medications	O
.	O
*	O
You	O
are	O
getting	O
dehydrated	O
due	O
to	O
continued	O
vomiting	O
,	O
diarrhea	O
or	O
other	O
reasons	O
.	O
*	O
Signs	O
of	O
dehydration	O
include	O
dry	O
mouth	O
,	O
rapid	O
heartbeat	O
or	O
feeling	O
dizzy	O
or	O
faint	O
when	O
standing	O
.	O
*	O
You	O
see	O
blood	O
or	O
dark	O
/	O
black	O
material	O
when	O
you	O
vomit	O
or	O
have	O
a	O
bowel	O
movement	O
.	O
*	O
Your	O
skin	O
,	O
or	O
the	O
whites	O
of	O
your	O
eyes	O
become	O
yellow	O
.	O
*	O
Your	O
pain	O
is	O
not	O
improving	O
within	O
8	O
-	O
12	O
hours	O
or	O
not	O
gone	O
within	O
24	O
hours	O
.	O
Call	O
or	O
return	O
immediately	O
if	O
your	O
pain	O
is	O
getting	O
worse	O
or	O
is	O
changing	O
location	O
or	O
moving	O
to	O
your	O
chest	O
or	O
back	O
.	O
*	O
You	O
have	O
shaking	O
chills	O
,	O
or	O
a	O
fever	O
greater	O
than	O
101.5	O
(	O
F	O
)	O
degrees	O
or	O
38	O
(	O
C	O
)	O
degrees	O
.	O
*	O
Any	O
serious	O
change	O
in	O
your	O
symptoms	O
,	O
or	O
any	O
new	O
symptoms	O
that	O
concern	O
you	O
.	O
.	O
*	O
Please	O
resume	O
all	O
regular	O
home	O
medications	O
and	O
take	O
any	O
new	O
meds	O
as	O
ordered	O
.	O
*	O
Do	O
not	O
drive	O
or	O
operate	O
heavy	O
machinery	O
while	O
taking	O
any	O
narcotic	O
pain	O
medication	O
.	O
You	O
may	O
have	O
constipation	I-Ade
when	O
taking	O
narcotic	B-Drug
pain	I-Drug
medications	I-Drug
(	O
oxycodone	I-Drug
,	O
percocet	I-Drug
,	O
vicodin	I-Drug
,	O
hydrocodone	I-Drug
,	O
dilaudid	I-Drug
,	O
etc.	O
)	O
;	O
you	O
should	O
continue	O
drinking	O
fluids	O
,	O
you	O
may	O
take	O
stool	B-Drug
softeners	I-Drug
,	O
and	O
should	O
eat	O
foods	O
that	O
are	O
high	O
in	O
fiber	O
.	O
*	O
Continue	O
to	O
ambulate	O
several	O
times	O
per	O
day	O
.	O
*	O
No	O
heavy	O
lifting	O
(	O
>	O
[	O
**	O
11	O
-	O
4	O
**	O
]	O
lbs	O
)	O
until	O
your	O
follow	O
up	O
appointment	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
Febuary	O
8	O
,	O
[	O
**	O
2172	O
**	O
]	O
at	O
8:30	O
am	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1231	O
**	O
]	O
with	O
questions	O
or	O
concerns	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
20430	O
**	O
]	O
,	O
MD	O
Date	O
/	O
Time	O
:[	O
**	O
2172-2-13	O
**	O
]	O
2:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1248	O
**	O
]	O
,	O
CHAIR	O
ONE	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1248	O
**	O
]	O
ROOMS	O
Date	O
/	O
Time	O
:[	O
**	O
2172-2-13	O
**	O
]	O
3:00	O
Provider	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
20430	O
**	O
]	O
,	O
MD	O
Date	O
/	O
Time	O
:[	O
**	O
2172-2-27	O
**	O
]	O
2:00	O
Completed	O
by	O
:[	O
**	O
2172-2-5	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2169-7-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2169-8-3	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2141-5-5	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Latex	O
/	O
Biaxin	I-Drug
/	O
Protonix	I-Drug
/	O
Sulfa	B-Drug
(	I-Drug
Sulfonamides	I-Drug
)	I-Drug
/	O
Risperidone	I-Drug
/	O
Linezolid	I-Drug
/	O
Clindamycin	I-Drug
/	O
Rifampin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
800	O
**	O
]	O
Chief	O
Complaint	O
:	O
Shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Pt	O
is	O
a	O
28	O
yo	O
F	O
with	O
h	O
/	O
o	O
asthma	O
,	O
bipolar	O
d	O
/	O
o	O
,	O
and	O
hypothyroidism	O
who	O
presents	O
with	O
SOB	O
X	O
4	O
days	O
.	O
Was	O
in	O
USOH	O
when	O
began	O
to	O
have	O
a	O
sore	B-Reason
throat	I-Reason
on	O
Tuesday	O
which	O
she	O
treated	O
with	O
nystatin	I-Drug
.	O
The	O
following	O
day	O
she	O
began	O
to	O
have	O
a	O
productive	O
cough	O
of	O
green	O
sputum	O
,	O
worsening	B-Reason
SOB	I-Reason
,	O
and	O
wheezing	I-Reason
.	O
Took	O
albuterol	I-Drug
>	O
10	O
times	O
a	O
day	O
and	O
woken	O
up	O
at	O
night	O
due	O
to	O
symptoms	O
.	O
Went	O
to	O
PCP	O
's	O
office	O
where	O
peak	O
flow	O
280	O
(	O
baseline	O
450	O
)	O
.	O
Referred	O
to	O
ED	O
.	O
Per	O
pt	O
,	O
has	O
had	O
multiple	O
admissions	O
for	O
asthma	O
exacerbations	O
and	O
had	O
been	O
intubated	O
once	O
at	O
OSH	O
in	O
[	O
**	O
3	O
-	O
10	O
**	O
]	O
in	O
setting	O
of	O
MRSA	O
PNA	O
and	O
asthma	O
exacerbation	O
.	O
Takes	O
oral	O
prednisone	I-Drug
4	O
-	O
5	O
times	O
a	O
year	O
for	O
asthma	I-Reason
flares	O
.	O
Denies	O
any	O
recent	O
sick	O
contacts	O
.	O
Feels	O
that	O
stress	O
,	O
allergies	O
,	O
and	O
heat	O
can	O
exacerbate	O
her	O
asthma	O
and	O
she	O
has	O
been	O
stressed	O
recently	O
by	O
her	O
new	O
job	O
which	O
involves	O
taking	O
care	O
of	O
a	O
disabled	O
child	O
.	O
.	O
In	O
the	O
ED	O
her	O
vitals	O
were	O
T	O
97.6	O
,	O
BP	O
143/75	O
,	O
P	O
108	O
,	O
RR	O
20	O
,	O
O2	O
Sat	O
100	O
%	O
on	O
RA	O
.	O
She	O
was	O
given	O
albuteral	I-Drug
nebs	O
,	O
methylprednisolone	B-Drug
,	I-Drug
magnesium	I-Drug
,	O
ipratropium	I-Drug
,	O
and	O
levofloxacin	I-Drug
for	O
a	O
suspected	O
lingular	B-Reason
PNA	I-Reason
and	O
admitted	O
to	O
the	O
floor	O
.	O
Past	O
Medical	O
History	O
:	O
Asthma	O
-	O
multiple	O
hospitalizations	O
and	O
intubation	O
Bipolar	O
disorder	O
B12	O
deficiency	O
Dysmenorrhea	O
Hypothyroidism	O
Dermatitis	O
Mitral	O
valve	O
prolapse	O
Chronic	O
diarrhea	O
,	O
followed	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
GI	O
PTSD	O
Depression	O
Bulimia	O
Nervosa	O
per	O
pt	O
report	O
s	O
/	O
p	O
appendectomy	O
and	O
cholecystectomy	O
Social	O
History	O
:	O
Lives	O
in	O
a	O
respite	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
.	O
Recently	O
lived	O
with	O
her	O
mother	O
by	O
her	O
report	O
.	O
Patient	O
denies	O
h	O
/	O
o	O
tobacco	O
or	O
illicit	O
drug	O
use	O
.	O
She	O
also	O
denies	O
current	O
etoh	O
and	O
denies	O
h	O
/	O
o	O
daily	O
or	O
excessive	O
drinking	O
.	O
She	O
has	O
had	O
>	O
15	O
jobs	O
since	O
she	O
was	O
18	O
;	O
she	O
loses	O
them	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
feeling	O
overwhelmed	O
.	O
Her	O
current	O
job	O
involves	O
taking	O
care	O
of	O
a	O
disabled	O
child	O
.	O
She	O
would	O
like	O
to	O
become	O
a	O
mid-wife	O
.	O
Family	O
History	O
:	O
Father	O
has	O
MS	O
Mother	O
has	O
depression	O
Aunt	O
has	O
schizophrenia	O
Aunt	O
has	O
asthma	O
Cousin	O
has	O
asthma	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
98.2	O
BP	O
102-134/48	O
-	O
79	O
HR	O
117	O
RR	O
20	O
97	O
%	O
RA	O
General	O
:	O
sitting	O
up	O
in	O
bed	O
,	O
no	O
signs	O
of	O
accessory	O
muscle	O
use	O
HEENT	O
:	O
PERRL	O
,	O
EOMI	O
,	O
white	O
coating	O
present	O
on	O
the	O
tongue	O
,	O
no	O
clear	O
thrush	O
over	O
OP	O
Neck	O
:	O
no	O
LAD	O
,	O
no	O
JVD	O
Heart	O
:	O
sinus	O
tachycardia	O
,	O
no	O
murmurs	O
/	O
rubs	O
/	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
549	O
**	O
]	O
Lungs	O
:	O
tight	O
air	O
mvmt	O
b	O
/	O
l	O
with	O
no	O
appreciable	O
wheezing	O
,	O
decreased	O
BS	O
over	O
bases	O
Abd	O
:	O
+	O
BS	O
,	O
soft	O
,	O
ND	O
,	O
NT	O
Ext	O
:	O
WWP	O
,	O
no	O
C	O
/	O
C	O
/	O
E	O
Skin	O
:	O
no	O
rashes	O
Neuro	O
:	O
AOX3	O
,	O
CN	O
III	O
-	O
XII	O
intact	O
,	O
motor	O
/	O
sensation	O
grossly	O
intact	O
Psych	O
:	O
anxious	O
Pertinent	O
Results	O
:	O
[	O
**	O
2169-8-3	O
**	O
]	O
05:55	O
AM	O
BLOOD	O
WBC	O
-	O
6.0	O
RBC	O
-	O
4.27	O
Hgb	O
-	O
12.5	O
Hct	O
-	O
36.9	O
MCV	O
-	O
86	O
MCH	O
-	O
29.3	O
MCHC	O
-	O
33.9	O
RDW	O
-	O
13.1	O
Plt	O
Ct	O
-	O
208	O
[	O
**	O
2169-8-3	O
**	O
]	O
05:55	O
AM	O
BLOOD	O
Glucose	O
-	O
94	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.7	O
Na	O
-	O
140	O
K	O
-	O
3.9	O
Cl	O
-	O
102	O
HCO3	O
-	O
30	O
AnGap	O
-	O
12	O
[	O
**	O
2169-8-2	O
**	O
]	O
08:50	O
AM	O
BLOOD	O
WBC	O
-	O
6.1	O
RBC	O
-	O
4.24	O
Hgb	O
-	O
12.6	O
Hct	O
-	O
37.0	O
MCV	O
-	O
87	O
MCH	O
-	O
29.8	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
13.2	O
Plt	O
Ct	O
-	O
188	O
[	O
**	O
2169-7-29	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
WBC	O
-	O
9.9	O
#	O
RBC	O
-	O
4.68	O
Hgb	O
-	O
13.7	O
Hct	O
-	O
40.4	O
MCV	O
-	O
87	O
MCH	O
-	O
29.3	O
MCHC	O
-	O
33.8	O
RDW	O
-	O
13.5	O
Plt	O
Ct	O
-	O
195	O
[	O
**	O
2169-7-29	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
Neuts	O
-	O
91	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
8	O
*	O
Monos	O
-	O
1	O
*	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2169-8-2	O
**	O
]	O
08:50	O
AM	O
BLOOD	O
Glucose	O
-	O
95	O
UreaN	O
-	O
17	O
Creat	O
-	O
0.9	O
Na	O
-	O
141	O
K	O
-	O
3.1	O
*	O
Cl	O
-	O
104	O
HCO3	O
-	O
29	O
AnGap	O
-	O
11	O
[	O
**	O
2169-7-29	O
**	O
]	O
10:25	O
AM	O
BLOOD	O
Glucose	O
-	O
108	O
*	O
UreaN	O
-	O
14	O
Creat	O
-	O
0.7	O
Na	O
-	O
140	O
K	O
-	O
3.8	O
Cl	O
-	O
105	O
HCO3	O
-	O
24	O
AnGap	O
-	O
15	O
[	O
**	O
2169-7-31	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
83	O
*	O
pCO2	O
-	O
39	O
pH	O
-	O
7.44	O
calTCO2	O
-	O
27	O
Base	O
XS	O
-	O
1	O
[	O
**	O
2169-7-30	O
**	O
]	O
05:34	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
103	O
pCO2	O
-	O
37	O
pH	O
-	O
7.43	O
calTCO2	O
-	O
25	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2169-7-30	O
**	O
]	O
03:12	O
AM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
159	O
*	O
pCO2	O
-	O
39	O
pH	O
-	O
7.42	O
calTCO2	O
-	O
26	O
Base	O
XS	O
-	O
1	O
[	O
**	O
2169-7-29	O
**	O
]	O
11:59	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
197	O
*	O
pCO2	O
-	O
35	O
pH	O
-	O
7.44	O
calTCO2	O
-	O
25	O
Base	O
XS	O
-	O
0	O
[	O
**	O
2169-7-29	O
**	O
]	O
10:28	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
123	O
*	O
pCO2	O
-	O
39	O
pH	O
-	O
7.40	O
calTCO2	O
-	O
25	O
Base	O
XS	O
-	O
0	O
Intubat	O
-	O
NOT	O
INTUBA	O
[	O
**	O
2169-7-29	O
**	O
]	O
10:31	O
AM	O
BLOOD	O
Lactate	O
-	O
1.9	O
[	O
**	O
2169-7-31	O
**	O
]	O
CXR	O
:	O
The	O
lung	O
volumes	O
are	O
markedly	O
reduced	O
.	O
Bibasilar	O
opacities	O
likely	O
represent	O
atelectasis	O
.	O
Right	O
infrahilar	O
opacity	O
has	O
improved	O
.	O
There	O
is	O
no	O
pneumothorax	O
or	O
pleural	O
effusion	O
[	O
**	O
2169-7-30	O
**	O
]	O
CXR	O
:	O
There	O
has	O
been	O
interval	O
worsening	O
in	O
the	O
appearance	O
of	O
the	O
chest	O
,	O
with	O
increased	O
plate	O
-	O
like	O
atelectasis	O
at	O
both	O
lung	O
bases	O
.	O
There	O
are	O
low	O
lung	O
volumes	O
.	O
Heart	O
and	O
mediastinum	O
are	O
within	O
normal	O
limits	O
.	O
There	O
is	O
a	O
new	O
patchy	O
focus	O
of	O
consolidation	O
in	O
the	O
right	O
perihilar	O
region	O
.	O
[	O
**	O
2169-7-29	O
**	O
]	O
CXR	O
:	O
PA	O
and	O
lateral	O
views	O
of	O
the	O
chest	O
demonstrate	O
low	O
lung	O
volumes	O
.	O
There	O
is	O
plate	O
-	O
like	O
atelectasis	O
at	O
the	O
left	O
lung	O
base	O
.	O
There	O
is	O
minimal	O
atelectasis	O
at	O
the	O
right	O
lung	O
base	O
as	O
well	O
.	O
Heart	O
and	O
mediastinum	O
are	O
within	O
normal	O
limits	O
.	O
Brief	O
Hospital	O
Course	O
:	O
When	O
the	O
pt	O
arrived	O
on	O
the	O
floor	O
she	O
was	O
placed	O
on	O
standing	O
nebs	I-Drug
and	O
prednisone	I-Drug
.	O
During	O
the	O
night	O
,	O
pt	O
felt	O
more	O
SOB	I-Reason
and	O
tachypneic	O
.	O
MICU	O
team	O
called	O
for	O
evaluation	O
and	O
the	O
pt	O
was	O
found	O
to	O
have	O
accessory	O
muscle	O
use	O
while	O
sitting	O
up	O
in	O
bed	O
,	O
tachypnea	I-Reason
to	O
upper	O
20s	O
,	O
O2	O
sat	O
99	O
%	O
RA	O
.	O
Pt	O
placed	O
on	O
continuous	O
albuterol	I-Drug
neb	O
but	O
subjectively	O
felt	O
her	O
breathing	O
was	O
worse	O
.	O
ABG	O
at	O
that	O
time	O
was	O
7.4	O
/	O
39	O
/	O
123/25	O
.	O
Pt	O
was	O
transferred	O
to	O
the	O
MICU	O
for	O
further	O
care	O
.	O
.	O
In	O
the	O
MICU	O
she	O
was	O
started	O
on	O
IV	O
solumedrol	I-Drug
,	O
continuous	O
nebulized	O
albuterol	I-Drug
and	O
heliox	I-Drug
for	O
her	O
asthma	B-Reason
exacerbation	I-Reason
.	O
Pt	O
was	O
also	O
placed	O
on	O
levaquin	I-Drug
for	O
possible	O
pneumonia	I-Reason
.	O
Pt	O
's	O
respiratory	O
status	O
improved	O
with	O
increased	O
air	O
entry	O
and	O
was	O
transitioned	O
to	O
albuterol	I-Drug
q1h	O
.	O
Intubation	O
was	O
not	O
required	O
.	O
Serial	O
ABGs	O
with	O
pH	O
7.40	O
-	O
7.46	O
.	O
Pt	O
experienced	O
sinus	B-Ade
tachycardia	I-Ade
in	O
the	O
120s	O
,	O
BP	O
adequate	O
100-130/50	O
-	O
80	O
.	O
Thought	O
to	O
be	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
continuous	O
albuterol	I-Drug
-	O
>	O
pt	O
switched	O
to	O
xoponex	I-Drug
q1h	O
and	O
ipratroprium	I-Drug
q4h	O
.	O
Pt	O
was	O
able	O
to	O
speak	O
in	O
full	O
sentences	O
and	O
did	O
not	O
show	O
any	O
signs	O
of	O
accessory	O
muscle	O
use	O
.	O
PEFR	O
was	O
250	O
(	O
baseline	O
450	O
)	O
.	O
Pt	O
was	O
transferred	O
back	O
to	O
the	O
floor	O
.	O
.	O
#	O
Asthma	B-Reason
exacerbation	I-Reason
:	O
No	O
clear	O
exacebating	O
factors	O
on	O
history	O
beyond	O
increased	O
stress	O
at	O
work	O
.	O
CXR	O
did	O
not	O
show	O
obvious	O
PNA	O
but	O
there	O
was	O
an	O
increased	O
R	O
perihilar	O
density	O
.	O
Pt	O
was	O
transitioned	O
from	O
IV	O
solumedrol	I-Drug
125	O
mg	O
q8h	O
in	O
the	O
MICU	O
to	O
PO	O
prednisone	I-Drug
50	O
mg	O
on	O
the	O
floor	O
.	O
Pt	O
was	O
also	O
continued	O
on	O
ipratroprium	I-Drug
q4h	O
with	O
xoponex	I-Drug
nebs	O
q1h	O
prn	O
.	O
The	O
pt	O
's	O
advair	I-Drug
was	O
held	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
systemic	B-Drug
steroid	I-Drug
use	O
.	O
Pt	O
did	O
well	O
with	O
this	O
therapy	O
for	O
about	O
a	O
day	O
and	O
then	O
became	O
acutely	O
short	B-Reason
of	I-Reason
breath	I-Reason
with	O
RR	O
in	O
the	O
high	O
20's	O
,	O
O2	O
sat	O
91	O
%	O
on	O
RA	O
,	O
PEFR	O
125	O
and	O
sinus	O
tachycardia	O
to	O
the	O
150s	O
.	O
Pt	O
responded	O
well	O
to	O
4L	O
O2	I-Drug
by	O
NC	O
,	O
IV	O
solumedrol	I-Drug
125	O
mg	O
x1	O
,	O
Combivent	I-Drug
and	O
IV	O
Ativan	I-Drug
2	O
mg	O
(	O
it	O
was	O
felt	O
that	O
there	O
was	O
a	O
large	O
component	O
of	O
anxiety	I-Reason
contributing	O
to	O
the	O
pt	O
's	O
respiratory	O
distress	O
)	O
.	O
Pt	O
did	O
well	O
with	O
this	O
episode	O
and	O
did	O
not	O
require	O
further	O
IV	O
steroids	I-Drug
.	O
Pt	O
continued	O
to	O
do	O
well	O
on	O
ipratroprium	I-Drug
q4h	O
and	O
xoponex	I-Drug
nebs	O
q1h	O
prn	O
(	O
pt	O
received	O
roughly	O
q4h	O
)	O
.	O
Outpatient	O
loratidine	I-Drug
and	O
flonase	I-Drug
were	O
continued	O
to	O
control	O
her	O
allergies	I-Reason
,	O
which	O
could	O
contribute	O
to	O
her	O
exacerbation	O
.	O
Pt	O
was	O
able	O
to	O
ambulate	O
with	O
RA	O
O2	O
sats	O
from	O
91	O
-	O
93	O
%	O
on	O
[	O
**	O
8	O
-	O
2	O
**	O
]	O
.	O
On	O
the	O
day	O
of	O
discharge	O
pt	O
felt	O
much	O
better	O
,	O
was	O
ambulating	O
without	O
supplemental	B-Drug
O2	I-Drug
.	O
O2	O
sat	O
on	O
RA	O
was	O
98	O
%	O
.	O
PEFR	O
increased	O
to	O
250	O
.	O
Minimal	B-Reason
upper	I-Reason
-	I-Reason
airway	I-Reason
wheezing	I-Reason
.	O
Pt	O
will	O
be	O
discharged	O
with	O
a	O
steroid	I-Drug
taper	O
,	O
50	O
mg	O
qdaily	O
x	O
5days	O
,	O
40	O
mg	O
qdaily	O
x	O
5days	O
,	O
30	O
mg	O
qdaily	O
x	O
5days	O
,	O
20	O
mg	O
qdaily	O
x	O
5days	O
and	O
10	O
mg	O
qdaily	O
until	O
she	O
sees	O
her	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
will	O
be	O
sent	O
home	O
with	O
Atrovent	I-Drug
nebs	O
q6h	O
prn	O
.	O
.	O
#	O
Pneumonia	I-Reason
:	O
CXR	O
was	O
suggestive	O
of	O
pneumonia	O
and	O
pt	O
was	O
treated	O
with	O
Levaquin	I-Drug
750	O
mg	O
IV	O
for	O
5	O
days	O
.	O
Pt	O
had	O
?	O
history	O
of	O
MRSA	O
pneumonia	O
although	O
there	O
were	O
no	O
records	O
of	O
this	O
.	O
WBC	O
trended	O
down	O
after	O
treatment	O
with	O
ABX	I-Drug
.	O
Sputum	O
cultures	O
showed	O
3	O
+	O
gram	O
+	O
cocci	O
in	O
pairs	O
/	O
cluster	O
and	O
2	O
+	O
gram	O
+	O
rods	O
.	O
This	O
expectorated	O
sample	O
was	O
adequate	O
(	O
<	O
10	O
sq	O
epis	O
)	O
,	O
however	O
it	O
was	O
collected	O
after	O
multiple	O
doses	O
of	O
Levaquin	I-Drug
.	O
Clinically	O
pt	O
improved	O
,	O
using	O
incentive	O
spirometry	O
and	O
ambulating	O
as	O
tolerated	O
with	O
RA	O
O2	O
sats	O
from	O
91	O
-	O
93	O
%	O
on	O
[	O
**	O
8	O
-	O
2	O
**	O
]	O
.	O
RA	O
O2	O
sats	O
98	O
%	O
on	O
the	O
day	O
of	O
discharge	O
.	O
Final	O
sputum	O
culture	O
revealed	O
growth	O
of	O
oropharyngeal	O
flora	O
.	O
.	O
#	O
Tachycardia	I-Ade
:	O
Pt	O
had	O
sinus	O
tachycardia	O
in	O
the	O
MICU	O
to	O
the	O
120s	O
and	O
on	O
the	O
floor	O
peaked	O
to	O
the	O
150s	O
.	O
There	O
were	O
multiple	O
causes	O
of	O
her	O
tachycardia	I-Ade
-	O
hypoxemia	O
,	O
continuous	O
albuterol	I-Drug
nebs	O
in	O
the	O
MICU	O
,	O
anxiety	O
,	O
pain	O
and	O
possible	O
infection	O
.	O
Pt	O
was	O
not	O
anemic	O
or	O
febrile	O
(	O
on	O
steroids	I-Drug
)	O
and	O
clinically	O
she	O
did	O
not	O
appear	O
hypovolemic	O
.	O
No	O
EKG	O
changes	O
were	O
noted	O
.	O
Pt	O
was	O
monitored	O
on	O
telemetry	O
.	O
Pt	O
's	O
tachycardia	I-Ade
improved	O
after	O
d	O
/	O
c	O
of	O
albuterol	I-Drug
and	O
as	O
her	O
exacerbation	I-Reason
was	O
treated	O
with	O
steroids	I-Drug
and	O
nebulizers	I-Drug
.	O
.	O
#	O
Bipolar	B-Reason
Disease	I-Reason
:	O
Pt	O
not	O
currently	O
manic	O
or	O
depressed	O
.	O
Pt	O
was	O
continued	O
on	O
her	O
outpatient	O
fluoxetine	I-Drug
,	O
trazodone	I-Drug
,	O
thorazine	I-Drug
,	O
and	O
carbamazepine	I-Drug
.	O
.	O
#	O
Bulimia	I-Reason
:	O
Pt	O
had	O
poor	O
PO	O
intake	O
[	O
**	O
3	O
-	O
4	O
**	O
]	O
pain	O
and	O
SOB	O
according	O
to	O
the	O
pt	O
.	O
She	O
was	O
continued	O
on	O
her	O
outpatient	O
naltrexone	I-Drug
.	O
.	O
#	O
Thrush	I-Reason
:	O
Treated	O
with	O
nystatin	I-Drug
.	O
.	O
#	O
Hypothyroidism	I-Reason
:	O
On	O
[	O
**	O
5	O
-	O
9	O
**	O
]	O
TSH	O
was	O
3.9	O
.	O
Outpatient	O
levothyroxine	I-Drug
was	O
continued	O
.	O
.	O
#	O
B12	B-Reason
Deficiency	I-Reason
:	O
Pt	O
receives	O
vit	B-Drug
B12	I-Drug
monthly	O
inj	O
.	O
.	O
#	O
FEN	O
/	O
GI	O
:	O
Pt	O
was	O
started	O
on	O
Vitamin	B-Drug
D	I-Drug
and	O
Calcium	I-Drug
given	O
her	O
recurrent	B-Reason
use	I-Reason
of	I-Reason
systemic	I-Reason
steroids	I-Drug
.	O
Pt	O
should	O
continue	O
vitamin	B-Drug
D	I-Drug
and	O
calcium	I-Drug
as	O
an	O
outpatient	O
,	O
if	O
she	O
needs	O
a	O
prescription	O
she	O
can	O
follow	O
with	O
her	O
PCP	O
.	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
tolerated	O
a	O
regular	O
diet	O
,	O
K	O
was	O
repleted	O
once	O
(	O
K	O
3.3	O
)	O
with	O
40meq	O
KCl	I-Drug
x1	O
,	O
continued	O
on	O
outpatient	O
ranitidine	I-Drug
.	O
.	O
#	O
PPx	I-Reason
:	O
Maintained	O
on	O
heparin	I-Drug
sc	O
,	O
bowel	O
regimen	O
,	O
ranitidine	I-Drug
.	O
.	O
#	O
Access	O
-	O
PIV	O
.	O
#	O
Code	O
-	O
Full	O
.	O
Medications	O
on	O
Admission	O
:	O
Albuterol	I-Drug
INH	O
2	O
puffs	O
qid	O
prn	O
Flonase	I-Drug
daily	O
Flovent	I-Drug
110	O
mcg	O
1	O
puff	O
[	O
**	O
Hospital1	O
**	O
]	O
prn	O
to	O
be	O
combined	O
with	O
Advair	I-Drug
Advair	I-Drug
500	O
/	O
50mcg	O
1	O
puff	O
[	O
**	O
Hospital1	O
**	O
]	O
Loratadine	B-Drug
10	O
mg	O
daily	O
Levothyroxine	I-Drug
50	O
mcg	O
daily	O
Carbamazepine	I-Drug
200	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Fluoxetine	B-Drug
20	O
mg	O
daily	O
Naltrexone	I-Drug
50	O
mg	O
qhs	O
Thorazine	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Trazodone	I-Drug
200	O
mg	O
qhs	O
VitB12	I-Drug
1000	O
mcg	O
monthly	O
Ranitidine	I-Drug
150	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Asthma	O
exacerbation	O
Pneumonia	O
Secondary	O
:	O
Bipolar	O
disorder	O
Hypothyroidism	O
Bulemia	O
Discharge	O
Condition	O
:	O
Stable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
treated	O
in	O
the	O
hospital	O
for	O
an	O
asthma	O
exacerbation	O
.	O
You	O
were	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
early	O
in	O
your	O
admission	O
because	O
you	O
were	O
having	O
difficulty	O
breathing	O
.	O
You	O
did	O
not	O
need	O
a	O
tube	O
to	O
help	O
you	O
breath	O
,	O
but	O
you	O
were	O
treated	O
with	O
steroids	I-Drug
and	O
nebulizer	O
treatments	O
.	O
You	O
also	O
had	O
a	O
probable	I-Reason
pneumonia	O
for	O
which	O
you	O
were	O
given	O
antibiotics	I-Drug
.	O
You	O
will	O
go	O
home	O
with	O
steroids	I-Drug
and	O
will	O
gradually	O
stop	O
taking	O
them	O
.	O
You	O
were	O
also	O
given	O
an	O
additional	O
nebulized	O
medication	O
called	O
Atrovent	I-Drug
.	O
You	O
should	O
continue	O
to	O
take	O
calcium	I-Drug
and	O
vitamin	B-Drug
D	I-Drug
supplements	O
because	O
of	O
the	O
risk	B-Ade
of	I-Ade
osteoporosis	I-Ade
from	O
long	O
-	O
term	O
steroid	I-Drug
use	O
.	O
You	O
should	O
talk	O
to	O
your	O
PCP	O
if	O
you	O
need	O
a	O
prescription	O
for	O
these	O
supplements	I-Drug
.	O
There	O
were	O
no	O
other	O
changes	O
made	O
to	O
your	O
medications	O
.	O
You	O
should	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
as	O
an	O
outpatient	O
.	O
You	O
should	O
call	O
your	O
doctor	O
or	O
return	O
to	O
the	O
ED	O
if	O
you	O
experience	O
any	O
worsening	O
symptoms	O
including	O
wheezing	O
,	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
palpitations	O
,	O
fever	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
Followup	O
Instructions	O
:	O
Please	O
follow	O
-	O
up	O
with	O
your	O
PCP	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
on	O
Friday	O
,	O
[	O
**	O
8	O
-	O
11	O
**	O
]	O
at	O
11:00	O
AM	O
.	O
Please	O
call	O
(	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3346	O
**	O
]	O
for	O
any	O
questions	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
810	O
**	O
]	O
MD	O
,	O
[	O
**	O
MD	O
Number	O
(	O
3	O
)	O
811	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2169-8-3	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2114-8-1	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2114-8-7	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2068-6-21	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1491	O
**	O
]	O
Chief	O
Complaint	O
:	O
Abdominal	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
EGD	O
with	O
banding	O
History	O
of	O
Present	O
Illness	O
:	O
46	O
yo	O
F	O
s	O
/	O
p	O
liver	O
transplant	O
'	O
[	O
**	O
05	O
**	O
]	O
for	O
acute	O
Hep	O
A	O
who	O
is	O
undergoing	O
liver	O
/	O
kidney	O
transplant	O
eval	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
had	O
colonoscopy	O
and	O
EGD	O
on	O
[	O
**	O
7	O
-	O
31	O
**	O
]	O
which	O
was	O
notable	O
for	O
grade	O
3	O
varices	O
which	O
were	O
banded	O
and	O
an	O
unremarkable	O
colonoscopy	O
.	O
However	O
,	O
she	O
developed	O
abd	O
pain	O
after	O
the	O
colonoscopy	O
.	O
She	O
went	O
home	O
,	O
noted	O
severe	O
abd	O
pain	O
and	O
presented	O
to	O
[	O
**	O
Hospital3	O
**	O
]	O
hospital	O
.	O
Presented	O
with	O
mildly	O
increased	O
distension	O
of	O
abdomen	O
-	O
KUB	O
and	O
CT	O
showed	O
no	O
free	O
air	O
,	O
but	O
did	O
show	O
increased	O
air	O
in	O
colon	O
which	O
could	O
have	O
resulted	O
from	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
.	O
[	O
**	O
Hospital3	O
**	O
]	O
spoke	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
497	O
**	O
]	O
who	O
recommended	O
paracentesis	O
,	O
but	O
they	O
did	O
not	O
feel	O
comfortable	O
doing	O
this	O
.	O
Therefore	O
,	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
497	O
**	O
]	O
requested	O
she	O
receive	O
a	O
dose	O
of	O
ceftriaxone	I-Drug
and	O
be	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
.	O
In	O
the	O
ED	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
,	O
the	O
patient	O
had	O
a	O
diagnostic	O
and	O
therapeutic	O
paracentesis	O
which	O
drained	O
2.7	O
L	O
of	O
amber	O
liquid	O
.	O
Peritoneal	O
fluid	O
was	O
negative	O
for	O
SBP	O
with	O
31	O
WBC	O
,	O
culture	O
pending	O
.	O
She	O
also	O
received	O
phenergan	I-Drug
,	O
morphine	I-Drug
,	O
and	O
1000cc	O
NS	I-Drug
.	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
medicine	O
for	O
further	O
evaluation	O
of	O
abdominal	O
pain	O
.	O
Upon	O
arrival	O
to	O
the	O
floor	O
,	O
the	O
patient	O
had	O
3	O
episodes	O
of	O
coffee	B-Reason
ground	I-Reason
emesis	I-Reason
(	O
approx	O
350cc	O
total	O
)	O
with	O
a	O
6	O
point	O
drop	O
in	O
Hct	O
.	O
Liver	O
fellow	O
was	O
contact	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
who	O
recommended	O
IV	O
protonix	I-Drug
,	O
octreotide	I-Drug
,	O
and	O
transfer	O
to	O
MICU	O
for	O
emergent	O
EGD	O
and	O
monitoring	O
.	O
In	O
the	O
MICU	O
an	O
EGD	O
was	O
performed	O
which	O
showed	O
grade	O
III	O
varices	O
which	O
were	O
banded	O
.	O
Following	O
this	O
procedure	O
and	O
multiple	O
blood	O
transfusion	O
,	O
her	O
Hct	O
has	O
stabilized	O
at	O
34	O
.	O
Given	O
persistent	O
complaints	O
of	O
tense	O
abdomen	O
and	O
pain	O
,	O
have	O
made	O
multiple	O
attempts	O
to	O
repeat	O
paracentesis	O
-	O
hindered	O
by	O
dilated	O
loops	O
of	O
bowel	O
.	O
As	O
her	O
HCT	O
remains	O
stable	O
she	O
was	O
transfered	O
back	O
to	O
medicine	O
for	O
further	O
care	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
liver	O
transplant	O
'	O
[	O
**	O
05	O
**	O
]	O
for	O
acute	O
hep	O
A	O
(	O
obtained	O
after	O
eating	O
chinese	O
food	O
)	O
now	O
complicated	O
by	O
cirrhosis	O
documented	O
by	O
bx	O
[	O
**	O
10	O
-	O
26	O
**	O
]	O
.	O
-	O
h	O
/	O
o	O
variceal	O
bleeding	O
s	O
/	O
p	O
banding	O
-	O
osteopenia	O
-	O
h	O
/	O
o	O
scarlet	O
fever	O
Social	O
History	O
:	O
no	O
etoh	O
,	O
drugs	O
,	O
or	O
tobacco	O
.	O
Lives	O
with	O
parents	O
.	O
From	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
.	O
Family	O
History	O
:	O
noncontributory	O
Physical	O
Exam	O
:	O
PE	O
:	O
98.7	O
151/80	O
116	O
18	O
94	O
%	O
RA	O
Gen	O
:	O
appears	O
uncomfortable	O
,	O
lying	O
still	O
HEENT	O
:	O
anicteric	O
,	O
MM	O
slightly	O
dry	O
.	O
Neck	O
:	O
supple	O
,	O
no	O
JVD	O
CV	O
:	O
tachy	O
,	O
possible	O
+	O
S4	O
/	O
split	O
S1	O
Back	O
:	O
no	O
CVA	O
tenderness	O
Abd	O
:	O
+	O
BS	O
,	O
tense	O
,	O
diffuse	O
tenderness	O
to	O
palpation	O
;	O
previous	O
transplant	O
scars	O
;	O
+	O
caput	O
;	O
no	O
obvious	O
rebound	O
,	O
+	O
ventral	O
hernia	O
easily	O
reducable	O
.	O
Ext	O
:	O
no	O
LE	O
edema	O
Skin	O
:	O
+	O
spider	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
61458	O
**	O
]	O
,	O
[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
**	O
]	O
erythema	O
Neuro	O
:	O
somnolent	O
but	O
interactive	O
.	O
A&O	O
x3	O
.	O
MAEW	O
.	O
strenght	O
[	O
**	O
4	O
-	O
26	O
**	O
]	O
throughout	O
.	O
sensation	O
in	O
tact	O
to	O
LT.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2114-8-1	O
**	O
]	O
09:20	O
PM	O
HCT	O
-	O
33.1	O
*	O
[	O
**	O
2114-8-1	O
**	O
]	O
08:43	O
PM	O
URINE	O
HOURS	O
-	O
RANDOM	O
UREA	O
N	O
-	O
470	O
CREAT	O
-	O
89	O
SODIUM	O
-	O
<	O
10	O
[	O
**	O
2114-8-1	O
**	O
]	O
08:43	O
PM	O
URINE	O
OSMOLAL	O
-	O
349	O
[	O
**	O
2114-8-1	O
**	O
]	O
08:43	O
PM	O
URINE	O
COLOR	O
-	O
Yellow	O
APPEAR	O
-	O
Clear	O
SP	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
155	O
**	O
]	O
-	O
1.013	O
[	O
**	O
2114-8-1	O
**	O
]	O
08:43	O
PM	O
URINE	O
BLOOD	O
-	O
TR	O
NITRITE	O
-	O
NEG	O
PROTEIN	O
-	O
NEG	O
GLUCOSE	O
-	O
NEG	O
KETONE	O
-	O
NEG	O
BILIRUBIN	O
-	O
NEG	O
UROBILNGN	O
-	O
NEG	O
PH	O
-	O
5.0	O
LEUK	O
-	O
NEG	O
[	O
**	O
2114-8-1	O
**	O
]	O
08:43	O
PM	O
URINE	O
RBC	O
-	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
*	O
WBC	O
-	O
[	O
**	O
2	O
-	O
24	O
**	O
]	O
BACTERIA	O
-	O
FEW	O
YEAST	O
-	O
NONE	O
EPI	O
-0-2	O
TRANS	O
EPI	O
-0-2	O
[	O
**	O
2114-8-1	O
**	O
]	O
08:43	O
PM	O
URINE	O
HYALINE	O
-	O
<	O
1	O
[	O
**	O
2114-8-1	O
**	O
]	O
04:00	O
PM	O
GLUCOSE	O
-	O
153	O
*	O
UREA	O
N	O
-	O
47	O
*	O
CREAT	O
-	O
2.3	O
*	O
SODIUM	O
-	O
135	O
POTASSIUM	O
-	O
5.0	O
CHLORIDE	O
-	O
101	O
TOTAL	O
CO2	O
-	O
20	O
*	O
ANION	O
GAP	O
-	O
19	O
[	O
**	O
2114-8-1	O
**	O
]	O
04:00	O
PM	O
CALCIUM	O
-	O
8.2	O
*	O
PHOSPHATE	O
-	O
6.1	O
*	O
MAGNESIUM	O
-	O
1.7	O
[	O
**	O
2114-8-1	O
**	O
]	O
04:00	O
PM	O
WBC	O
-	O
18.6	O
*	O
RBC	O
-	O
3.74	O
*	O
HGB	O
-	O
9.5	O
*	O
HCT	O
-	O
30.0	O
*	O
MCV	O
-	O
80	O
*	O
MCH	O
-	O
25.5	O
*	O
MCHC	O
-	O
31.8	O
RDW	O
-	O
20.3	O
*	O
[	O
**	O
2114-8-1	O
**	O
]	O
04:00	O
PM	O
PLT	O
COUNT	O
-	O
113	O
*	O
[	O
**	O
2114-8-1	O
**	O
]	O
04:00	O
PM	O
PT	O
-	O
13.8	O
*	O
PTT	O
-	O
27.5	O
INR	O
(	O
PT	O
)	O
-	O
1.3	O
[	O
**	O
2114-8-1	O
**	O
]	O
01:04	O
PM	O
HCT	O
-	O
30.6	O
*	O
[	O
**	O
2114-8-1	O
**	O
]	O
01:04	O
PM	O
PT	O
-	O
13.5	O
*	O
PTT	O
-	O
27.8	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
[	O
**	O
2114-8-1	O
**	O
]	O
05:45	O
AM	O
ASCITES	O
WBC	O
-	O
31	O
*	O
RBC	O
-	O
9800	O
*	O
POLYS	O
-	O
45	O
*	O
LYMPHS	O
-	O
5	O
*	O
MONOS	O
-	O
0	O
MESOTHELI	O
-	O
10	O
*	O
MACROPHAG	O
-	O
40	O
*	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
GLUCOSE	O
-	O
123	O
*	O
UREA	O
N	O
-	O
37	O
*	O
CREAT	O
-	O
2.2	O
*	O
SODIUM	O
-	O
138	O
POTASSIUM	O
-	O
3.7	O
CHLORIDE	O
-	O
104	O
TOTAL	O
CO2	O
-	O
21	O
*	O
ANION	O
GAP	O
-	O
17	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
ALT	O
(	O
SGPT	O
)	O
-	O
34	O
AST	O
(	O
SGOT	O
)	O
-	O
27	O
ALK	O
PHOS	O
-	O
200	O
*	O
TOT	O
BILI	O
-	O
0.8	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
ALBUMIN	O
-	O
3.9	O
CALCIUM	O
-	O
9.2	O
PHOSPHATE	O
-	O
5.7	O
*	O
MAGNESIUM	O
-	O
1.8	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
ALBUMIN	O
-	O
3.9	O
CALCIUM	O
-	O
9.2	O
PHOSPHATE	O
-	O
5.7	O
*	O
MAGNESIUM	O
-	O
1.8	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
WBC	O
-	O
12.6	O
*	O
#	O
RBC	O
-	O
4.48	O
#	O
HGB	O
-	O
11.0	O
*	O
#	O
HCT	O
-	O
36.1	O
#	O
MCV	O
-	O
81	O
*	O
MCH	O
-	O
24.6	O
*	O
MCHC	O
-	O
30.5	O
*	O
RDW	O
-	O
20.9	O
*	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
NEUTS	O
-	O
88.2	O
*	O
LYMPHS	O
-	O
6.3	O
*	O
MONOS	O
-	O
4.0	O
EOS	O
-	O
1.3	O
BASOS	O
-	O
0.2	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
HYPOCHROM	O
-	O
3	O
+	O
ANISOCYT	O
-	O
2	O
+	O
MICROCYT	O
-	O
3	O
+	O
[	O
**	O
2114-8-1	O
**	O
]	O
03:40	O
AM	O
PLT	O
COUNT	O
-	O
150	O
[	O
**	O
2114-7-31	O
**	O
]	O
08:20	O
AM	O
CYCLSPRN	O
-	O
80	O
*	O
Brief	O
Hospital	O
Course	O
:	O
46	O
y	O
/	O
o	O
female	O
w	O
/	O
h	O
/	O
o	O
liver	O
transplant	O
for	O
Hep	O
A	O
c	O
/	O
b	O
cirrhosis	O
,	O
and	O
grade	O
3	O
esophageal	O
varices	O
,	O
originally	O
admitted	O
with	O
diffuse	O
abdominal	O
pain	O
after	O
colonscopy	O
,	O
now	O
with	O
coffee	O
ground	O
emesis	O
x	O
3	O
s	O
/	O
p	O
EGD	O
with	O
banding	O
of	O
varices	O
and	O
persisting	O
ascites	O
.	O
.	O
1	O
)	O
UPPER	B-Reason
GI	I-Reason
BLEED	I-Reason
:	O
pt	O
w	O
/	O
coffee	O
ground	O
emesis	O
on	O
[	O
**	O
8	O
-	O
1	O
**	O
]	O
had	O
grade	O
3	O
varices	O
on	O
EGD	O
[	O
**	O
8	O
-	O
1	O
**	O
]	O
,	O
banded	O
.	O
She	O
received	O
a	O
total	O
of	O
3	O
U	O
PRBC	I-Drug
during	O
MICU	O
course	O
.	O
She	O
is	O
now	O
hemodynamically	O
stable	O
and	O
her	O
HCT	O
has	O
remained	O
stable	O
since	O
transfusions	O
.	O
Patient	O
recieved	O
Octreotide	I-Drug
for	O
total	O
of	O
5	O
days	O
Patient	O
continued	O
on	O
Protonix	I-Drug
40	O
mg	O
po	O
BID	O
.	O
Patient	O
given	O
sucralfate	I-Drug
.	O
Nadolol	I-Drug
was	O
held	O
.	O
.	O
2	O
)	O
ABDOMINAL	O
PAIN	O
-	O
There	O
was	O
concern	B-Reason
for	I-Reason
perforation	I-Reason
given	O
recent	O
colonoscopy	O
;	O
however	O
,	O
X-ray	O
and	O
Abd	O
CT	O
@	O
OSH	O
did	O
not	O
show	O
evidence	O
of	O
free	O
air	O
,	O
and	O
repeat	O
upright	O
CXR	O
@	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
shows	O
no	O
free	O
air	O
.	O
Also	O
considered	O
was	O
SBP	I-Reason
from	O
bacterial	O
translocation	O
from	O
colonoscopy	O
.	O
Pt	O
received	O
ceftriaxone	I-Drug
at	O
OSH	O
,	O
but	O
pt	O
only	O
had	O
31	O
WBC	O
by	O
paracentesis	O
.	O
Abdominal	O
pain	O
improved	O
since	O
initial	O
paracentesis	O
in	O
ED	O
;	O
now	O
ascites	O
redeveloped	O
and	O
pain	O
has	O
returned	O
.	O
Ceftriaxone	I-Drug
/	O
Rifaximin	I-Drug
was	O
given	O
immunosuppression	I-Drug
and	O
elevated	B-Reason
WBC	I-Reason
.	O
She	O
recieved	O
morphine	I-Drug
prn	O
for	O
pain	I-Reason
.	O
.	O
A	O
second	O
paracentesis	O
was	O
attempted	O
;	O
however	O
only	O
10	O
cc	O
of	O
fluid	O
was	O
removed	O
.	O
She	O
was	O
then	O
taken	O
to	O
have	O
U	O
/	O
S	O
-	O
guided	O
paracentesis	O
,	O
but	O
found	O
to	O
have	O
significantly	O
dilated	O
loops	O
of	O
bowel	O
which	O
hindered	O
further	O
attempts	O
.	O
On	O
repeat	O
US	O
guided	O
paracentesis	O
for	O
[	O
**	O
8	O
-	O
6	O
**	O
]	O
for	O
symptomatic	O
relieve	O
was	O
successful	O
.	O
Her	O
abdominal	O
pain	O
resolved	O
prior	O
to	O
discharge	O
.	O
.	O
3	O
)	O
RENAL	B-Ade
FAILURE	I-Ade
-	O
likely	O
[	O
**	O
1	O
-	O
24	O
**	O
]	O
to	O
nephrotoxity	I-Ade
from	O
cyclosporin	I-Drug
;	O
appears	O
to	O
have	O
resolved	O
as	O
pt	O
's	O
creatinine	O
at	O
baseline	O
of	O
2.2	O
.	O
She	O
was	O
given	O
25	O
grams	O
of	O
Albumin	I-Drug
after	O
her	O
paracentesis	O
.	O
Her	O
medications	O
were	O
renally	O
dosed	O
.	O
4	O
)	O
CIRRHOSIS	O
-	O
Cirrhosis	O
of	O
transplanted	O
liver	O
is	O
thought	O
to	O
be	O
[	O
**	O
1	O
-	O
24	O
**	O
]	O
to	O
prior	O
noncompliance	O
with	O
immunosuppressive	B-Drug
meds	I-Drug
.	O
Patient	O
being	O
evaluated	O
for	O
a	O
re-transplant	O
by	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
28609	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
pt	O
intially	O
w	O
/	O
varices	O
and	O
now	O
w	O
/	O
asterixis	O
.	O
possibly	O
enephalopathic	O
due	O
to	O
increased	O
urea	O
load	O
w	O
/	O
GIB	O
.	O
Her	O
encephalopathy	O
resolved	O
.	O
Decreased	O
cyclosporin	I-Drug
to	O
50	O
qd	O
and	O
started	O
sirolimus	I-Drug
4	O
mg	O
qd	O
on	O
[	O
**	O
8	O
-	O
3	O
**	O
]	O
.	O
She	O
continued	O
Lactulose	I-Drug
and	O
rifamixin	I-Drug
for	O
encephalopathy	B-Reason
ppx	I-Reason
.	O
Diuretics	I-Drug
were	O
held	O
given	O
GIB	O
and	O
renal	O
dysfunction	O
.	O
She	O
continued	O
prednisone	I-Drug
.	O
Her	O
cyclosporin	I-Drug
and	O
sirolimus	I-Drug
levels	O
were	O
checked	O
.	O
.	O
5	O
)	O
DIARRHEA	I-Ade
-	O
likely	O
related	O
to	O
Lactulose	I-Drug
,	O
resolved	O
prior	O
to	O
discharge	O
.	O
Medications	O
on	O
Admission	O
:	O
1	O
.	O
levaquin	I-Drug
250	O
po	O
qd	O
2	O
.	O
Lactulose	I-Drug
prn	O
3	O
.	O
Lasix	I-Drug
40	O
mg	O
po	O
qd	O
4	O
.	O
Aldactone	I-Drug
50	O
mg	O
po	O
qd	O
5	O
.	O
Rifaximib	I-Drug
6	O
.	O
Iron	I-Drug
sulfate	O
7	O
.	O
Protonix	I-Drug
40	O
mg	O
po	O
qd	O
8	O
.	O
Neoral	I-Drug
100	O
mg	O
po	O
qd	O
9	O
.	O
Morphine	I-Drug
SR	O
60	O
mg	O
po	O
prn	O
10	O
.	O
Prednisone	I-Drug
10	O
mg	O
po	O
qd	O
11	O
.	O
Calcium	I-Drug
supplements	O
Discharge	O
Medications	O
:	O
1	O
.	O
Lactulose	I-Drug
10	O
g	O
/	O
15	O
mL	O
Syrup	O
Sig	O
:	O
Thirty	O
(	O
30	O
)	O
ML	O
PO	O
tid	O
-	O
qid	O
:	O
Tritrate	O
to	O
3	O
bowel	O
movement	O
a	O
day	O
.	O
Disp	O
:	O
*	O
q	O
/	O
s	O
ml	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Prednisone	B-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Sirolimus	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
Do	O
not	O
take	O
on	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
and	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
.	O
Restart	O
on	O
[	O
**	O
8	O
-	O
10	O
**	O
]	O
(	O
Friday	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Rifaximin	I-Drug
200	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Levofloxacin	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
for	O
10	O
days	O
.	O
Disp	O
:	O
*	O
10	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
6	O
.	O
Sucralfate	I-Drug
1	O
g	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
8	O
.	O
Oxycodone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q4	O
-	O
6H	O
(	O
every	O
4	O
to	O
6	O
hours	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
20	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Midodrine	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
10	O
.	O
Lasix	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
11	O
.	O
Spironolactone	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
SBP	O
,	O
Upper	O
GI	O
bleed	O
Discharge	O
Condition	O
:	O
stable	O
Discharge	O
Instructions	O
:	O
Please	O
call	O
primary	O
care	O
provider	O
or	O
come	O
to	O
emergency	O
room	O
if	O
have	O
increased	O
abdominal	O
pain	O
,	O
vomiting	O
of	O
blood	O
,	O
lightheadedness	O
or	O
any	O
other	O
concerning	O
symptoms	O
.	O
**	O
Do	O
not	O
take	O
Rapamune	I-Drug
for	O
next	O
2	O
days	O
(	O
[	O
**	O
8	O
-	O
8	O
**	O
]	O
and	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
,	O
then	O
restart	O
om	O
[	O
**	O
8	O
-	O
10	O
**	O
]	O
Friday	O
at	O
2	O
mg	O
daily	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
497	O
**	O
]	O
on	O
Monday	O
,	O
transplant	O
coordinator	O
will	O
call	O
2	O
.	O
Transplant	O
coordinatro	O
will	O
call	O
with	O
appointment	O
Completed	O
by	O
:[	O
**	O
2114-8-13	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2104-4-10	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2104-4-15	O
**	O
]	O
Service	O
:	O
NOTE	O
:	O
Day	O
of	O
discharge	O
to	O
be	O
decided	O
;	O
possibly	O
[	O
**	O
2104-4-15	O
**	O
]	O
.	O
CHIEF	O
COMPLAINT	O
:	O
Melena	O
.	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
The	O
patient	O
is	O
an	O
88	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
history	O
coronary	O
artery	O
disease	O
and	O
previous	O
colonoscopy	O
in	O
[	O
**	O
2101	O
**	O
]	O
with	O
multiple	O
polyps	O
presenting	O
with	O
melena	O
and	O
hematemesis	O
.	O
The	O
patient	O
presented	O
to	O
the	O
Emergency	O
Department	O
for	O
evaluation	O
of	O
lower	O
back	O
and	O
leg	O
pain	O
.	O
While	O
there	O
,	O
she	O
developed	O
melena	O
and	O
hematemesis	O
.	O
The	O
patient	O
was	O
recently	O
treated	O
for	O
a	O
zoster	B-Reason
infection	I-Reason
with	O
Motrin	I-Drug
times	O
two	O
weeks	O
per	O
Emergency	O
Department	O
documentation	O
.	O
Currently	O
,	O
she	O
denies	O
any	O
fevers	O
,	O
chills	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
abdominal	O
pain	O
.	O
She	O
reports	O
diarrhea	O
today	O
times	O
five	O
times	O
.	O
She	O
had	O
not	O
looked	O
at	O
her	O
previous	O
stools	O
.	O
The	O
patient	O
was	O
hemodynamically	O
stable	O
in	O
the	O
Emergency	O
Department	O
.	O
In	O
the	O
Emergency	O
Department	O
,	O
a	O
nasogastric	O
tube	O
was	O
placed	O
and	O
lavage	O
did	O
not	O
clear	O
with	O
2	O
liters	O
of	O
lavage	I-Drug
.	O
She	O
received	O
Kayexalate	I-Drug
for	O
a	O
potassium	B-Reason
of	I-Reason
6	I-Reason
,	O
calcium	B-Drug
,	I-Drug
insulin	B-Drug
,	I-Drug
and	O
D	B-Drug
-	I-Drug
50	I-Drug
.	O
Her	O
electrocardiogram	O
also	O
showed	O
peaked	O
T	O
waves	O
consistent	O
with	O
hyperkalemia	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Coronary	O
artery	O
disease	O
;	O
status	O
post	O
coronary	O
artery	O
bypass	O
graft	O
in	O
[	O
**	O
2097	O
**	O
]	O
with	O
saphenous	O
vein	O
graft	O
to	O
the	O
first	O
obtuse	O
marginal	O
,	O
saphenous	O
vein	O
graft	O
to	O
posterior	O
descending	O
artery	O
,	O
and	O
saphenous	O
vein	O
graft	O
to	O
the	O
left	O
anterior	O
descending	O
artery	O
.	O
She	O
is	O
status	O
post	O
multiple	O
percutaneous	O
transluminal	O
coronary	O
angioplasties	O
with	O
brachy	O
therapy	O
.	O
2	O
.	O
Gastroesophageal	O
reflux	O
disease	O
.	O
3	O
.	O
Depression	O
.	O
4	O
.	O
Degenerative	O
joint	O
disease	O
.	O
5	O
.	O
Irritable	O
bowel	O
syndrome	O
.	O
6	O
.	O
B12	O
deficiency	O
(	O
pernicious	O
anemia	O
)	O
.	O
7	O
.	O
Chronic	O
renal	O
insufficiency	O
(	O
with	O
a	O
baseline	O
creatinine	O
of	O
1.2	O
)	O
.	O
8	O
.	O
Anemia	O
(	O
with	O
a	O
baseline	O
hematocrit	O
of	O
26	O
to	O
32	O
)	O
.	O
9	O
.	O
Recent	O
urinary	O
tract	O
infections	O
.	O
10	O
.	O
Status	O
post	O
total	O
abdominal	O
hysterectomy	O
and	O
small	O
-	O
bowel	O
obstruction	O
.	O
11	O
.	O
A	O
2	O
-	O
D	O
echocardiogram	O
in	O
[	O
**	O
2102-9-26	O
**	O
]	O
showing	O
an	O
ejection	O
fraction	O
of	O
greater	O
than	O
70	O
%	O
,	O
moderate	O
left	O
ventricular	O
hypertrophy	O
,	O
normal	O
right	O
wall	O
motion	O
,	O
1	O
+	O
aortic	O
insufficiency	O
,	O
and	O
1	O
+	O
mitral	O
regurgitation	O
,	O
and	O
diastolic	O
dysfunction	O
.	O
12	O
.	O
History	O
of	O
Kaposi	O
sarcoma	O
resected	O
in	O
[	O
**	O
2103-5-27	O
**	O
]	O
.	O
ALLERGIES	O
:	O
BACTRIM	B-Drug
,	I-Drug
CIPROFLOXACIN	B-Drug
,	I-Drug
and	O
AMPICILLIN	B-Drug
.	I-Drug
MEDICATIONS	O
ON	O
ADMISSION	O
:	O
1	O
.	O
Lisinopril	I-Drug
10	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
2	O
.	O
Lipitor	I-Drug
20	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
3	O
.	O
Imdur	I-Drug
45	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
4	O
.	O
Metoprolol	I-Drug
50	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
.	O
5	O
.	O
Plavix	I-Drug
75	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
6	O
.	O
Aspirin	B-Drug
325	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
7	O
.	O
Prilosec	I-Drug
20	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
8	O
.	O
Remeron	I-Drug
30	O
mg	O
by	O
mouth	O
at	O
hour	O
of	O
sleep	O
.	O
9	O
.	O
Ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
10	O
.	O
BuSpar	I-Drug
5	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
.	O
FAMILY	O
HISTORY	O
:	O
Sister	O
with	O
heart	O
disease	O
.	O
SOCIAL	O
HISTORY	O
:	O
Lives	O
at	O
the	O
[	O
**	O
Hospital3	O
537	O
**	O
]	O
.	O
She	O
denies	O
tobacco	O
or	O
alcohol	O
use	O
.	O
She	O
is	O
a	O
widow	O
.	O
PHYSICAL	O
EXAMINATION	O
ON	O
PRESENTATION	O
:	O
Temperature	O
was	O
98.7	O
degrees	O
Fahrenheit	O
,	O
her	O
blood	O
pressure	O
was	O
136/70	O
,	O
her	O
pulse	O
was	O
90	O
,	O
her	O
respiratory	O
rate	O
was	O
16	O
,	O
and	O
she	O
was	O
saturating	O
98	O
%	O
on	O
room	O
air	O
.	O
In	O
general	O
,	O
the	O
patient	O
is	O
an	O
elderly	O
female	O
in	O
no	O
apparent	O
distress	O
.	O
She	O
appeared	O
pale	O
and	O
fatigued	O
.	O
Head	O
,	O
eyes	O
,	O
ears	O
,	O
nose	O
,	O
and	O
throat	O
examination	O
the	O
oropharynx	O
was	O
clear	O
.	O
The	O
mucous	O
membranes	O
were	O
dry	O
.	O
Nasogastric	O
tube	O
with	O
blood	O
.	O
The	O
neck	O
was	O
supple	O
.	O
The	O
lungs	O
were	O
clear	O
to	O
auscultation	O
bilaterally	O
.	O
Heart	O
was	O
regular	O
in	O
rate	O
and	O
rhythm	O
plus	O
a	O
2/6	O
systolic	O
ejection	O
murmur	O
at	O
the	O
right	O
upper	O
sternal	O
border	O
.	O
The	O
abdomen	O
was	O
soft	O
,	O
nontender	O
,	O
and	O
nondistended	O
.	O
There	O
were	O
good	O
bowel	O
sounds	O
.	O
Maroon	O
-	O
tinged	O
stool	O
.	O
Guaiac	O
-	O
positive	O
.	O
No	O
melena	O
.	O
Extremities	O
revealed	O
needed	O
.	O
Multiple	O
bruise	O
-	O
like	O
lesions	O
with	O
central	O
hardness	O
on	O
arms	O
and	O
legs	O
.	O
No	O
evidence	O
of	O
rashes	O
.	O
Neurologically	O
,	O
cranial	O
nerves	O
II	O
through	O
XII	O
were	O
intact	O
.	O
She	O
followed	O
commands	O
.	O
PERTINENT	O
LABORATORY	O
VALUES	O
ON	O
PRESENTATION	O
:	O
White	O
blood	O
cell	O
count	O
was	O
5.8	O
(	O
with	O
a	O
differential	O
of	O
76	O
%	O
neutrophils	O
,	O
21	O
%	O
lymphocytes	O
,	O
2	O
%	O
monocytes	O
,	O
and	O
1	O
%	O
eosinophils	O
)	O
,	O
her	O
hematocrit	O
was	O
27.4	O
(	O
down	O
from	O
30	O
on	O
admission	O
to	O
the	O
Emergency	O
Department	O
)	O
,	O
and	O
her	O
platelets	O
were	O
127	O
.	O
Her	O
INR	O
was	O
1.1	O
,	O
her	O
partial	O
thromboplastin	O
time	O
was	O
24.9	O
.	O
Chemistry	O
-	O
7	O
revealed	O
her	O
sodium	O
was	O
137	O
,	O
potassium	O
was	O
6	O
(	O
repeat	O
4.9	O
)	O
,	O
chloride	O
was	O
108	O
,	O
bicarbonate	O
was	O
20	O
,	O
blood	O
urea	O
nitrogen	O
was	O
51	O
,	O
creatinine	O
was	O
1.2	O
,	O
and	O
her	O
blood	O
glucose	O
was	O
115	O
.	O
Urinalysis	O
was	O
straw	O
colored	O
,	O
specific	O
gravity	O
of	O
0.018	O
,	O
trace	O
leukocyte	O
esterase	O
,	O
pH	O
of	O
5	O
.	O
PERTINENT	O
RADIOLOGY	O
/	O
IMAGING	O
:	O
An	O
electrocardiogram	O
showed	O
a	O
normal	O
sinus	O
rhythm	O
at	O
79	O
beats	O
per	O
minute	O
,	O
and	O
primary	O
atrioventricular	O
block	O
.	O
Q	O
wave	O
in	O
II	O
,	O
III	O
,	O
and	O
F.	O
Normal	O
axis	O
.	O
Peaked	O
T	O
waves	O
in	O
precordium	O
.	O
ASSESSMENT	O
:	O
The	O
patient	O
is	O
an	O
88	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
gastrointestinal	B-Reason
bleed	I-Reason
after	O
taking	O
nonsteroidal	I-Drug
antiinflammatory	O
drugs	O
for	O
the	O
last	O
two	O
weeks	O
for	O
left	O
leg	O
pain	O
.	O
BRIEF	O
SUMMARY	O
OF	O
HOSPITAL	O
COURSE	O
BY	O
ISSUE	O
/	O
SYSTEM	O
:	O
1	O
.	O
GASTROINTESTINAL	O
BLEED	O
ISSUES	O
:	O
The	O
patient	O
had	O
an	O
initial	O
esophagogastroduodenoscopy	O
on	O
[	O
**	O
4	O
-	O
11	O
**	O
]	O
which	O
showed	O
a	O
big	O
clot	O
adherent	O
to	O
a	O
large	O
-	O
sized	O
hiatal	O
hernia	O
.	O
The	O
clot	O
was	O
too	O
large	O
to	O
safely	O
irrigate	O
off	O
.	O
Underneath	O
the	O
clot	O
could	O
have	O
been	O
an	O
ulcer	O
erosion	O
or	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
tear	O
.	O
In	O
the	O
stomach	O
,	O
there	O
was	O
diffuse	O
atrophy	O
of	O
the	O
mucosa	O
with	O
no	O
bleeding	O
noted	O
;	O
compatible	O
with	O
chronic	O
atrophic	O
gastritis	O
.	O
There	O
was	O
no	O
bleeding	O
in	O
the	O
duodenum	O
.	O
The	O
patient	O
was	O
kept	O
on	O
strict	O
nothing	O
by	O
mouth	O
and	O
intravenous	O
fluids	I-Drug
,	O
and	O
her	O
hematocrit	O
levels	O
were	O
followed	O
to	O
keep	O
her	O
hematocrit	O
above	O
30	O
.	O
Her	O
hematocrit	O
dropped	O
initially	O
from	O
30.3	O
to	O
27.4	O
and	O
then	O
to	O
22.6	O
.	O
She	O
was	O
transfused	O
2	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
,	O
and	O
her	O
hematocrit	O
has	O
been	O
stable	O
since	O
,	O
ranging	O
from	O
30	O
to	O
32	O
,	O
with	O
no	O
further	O
episodes	O
of	O
bleeding	O
since	O
[	O
**	O
4	O
-	O
12	O
**	O
]	O
.	O
She	O
has	O
remained	O
on	O
a	B-Drug
proton	I-Drug
pump	I-Drug
inhibitor	I-Drug
(	I-Drug
Protonix	I-Drug
)	I-Drug
twice	O
per	O
day	O
.	O
A	O
repeat	O
esophagogastroduodenoscopy	O
performed	O
on	O
[	O
**	O
4	O
-	O
14	O
**	O
]	O
showed	O
still	O
adherent	O
clot	O
about	O
8	O
cm	O
in	O
length	O
and	O
2	O
cm	O
in	O
width	O
,	O
adherent	O
to	O
a	O
2	O
-	O
cm	O
length	O
mucosa	O
within	O
the	O
large	O
hiatal	O
hernia	O
.	O
There	O
were	O
no	O
signs	O
of	O
active	O
bleeding	O
.	O
Electrocautery	O
was	O
applied	O
to	O
the	O
base	O
of	O
the	O
clot	O
in	O
an	O
attempt	O
to	O
dislodge	O
it	O
from	O
the	O
esophageal	O
mucosa	O
and	O
for	O
hemostasis	O
;	O
however	O
,	O
despite	O
the	O
clot	O
still	O
remained	O
adherent	O
to	O
the	O
esophageal	O
mucosa	O
.	O
It	O
appeared	O
that	O
there	O
may	O
be	O
an	O
ulceration	O
and	O
mucous	O
in	O
the	O
area	O
of	O
the	O
esophagus	O
to	O
which	O
the	O
clot	O
was	O
adherent	O
.	O
Otherwise	O
,	O
the	O
stomach	O
and	O
the	O
duodenum	O
were	O
normal	O
on	O
the	O
repeat	O
esophagogastroduodenoscopy	O
.	O
The	O
patient	O
was	O
kept	O
nothing	O
by	O
mouth	O
for	O
the	O
remaining	O
portion	O
of	O
[	O
**	O
Last	O
Name	O
(	O
LF	O
)	O
766	O
**	O
]	O
,	O
[	O
**	O
4	O
-	O
14	O
**	O
]	O
,	O
and	O
was	O
continued	O
on	O
intravenous	O
fluids	I-Drug
.	O
Since	O
her	O
hematocrit	O
remained	O
stable	O
on	O
the	O
following	O
day	O
(	O
[	O
**	O
4	O
-	O
15	O
**	O
]	O
)	O
,	O
she	O
was	O
started	O
on	O
clear	O
liquids	O
in	O
the	O
morning	O
,	O
and	O
diet	O
may	O
be	O
advanced	O
to	O
soft	O
solids	O
until	O
her	O
repeat	O
upper	O
endoscopy	O
next	O
week	O
which	O
has	O
already	O
been	O
scheduled	O
.	O
Since	O
her	O
hematocrit	O
has	O
been	O
stable	O
for	O
the	O
last	O
several	O
days	O
,	O
the	O
patient	O
is	O
safe	O
to	O
be	O
discharged	O
to	O
home	O
or	O
to	O
rehabilitation	O
.	O
An	O
upper	O
endoscopy	O
followup	O
has	O
been	O
scheduled	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
21140	O
**	O
]	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2161	O
**	O
]	O
at	O
the	O
Endoscopy	O
Unit	O
on	O
the	O
[	O
**	O
Location	O
(	O
un	O
)	O
448	O
**	O
]	O
of	O
[	O
**	O
Hospital	O
Ward	O
Name	O
1950	O
**	O
]	O
One	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
Building	O
on	O
[	O
**	O
2104-5-8	O
**	O
]	O
at	O
9:30	O
a.m.	O
.	O
The	O
patient	O
should	O
not	O
have	O
anything	O
to	O
eat	O
after	O
midnight	O
on	O
[	O
**	O
2104-5-7	O
**	O
]	O
and	O
should	O
not	O
eat	O
breakfast	O
on	O
the	O
morning	O
of	O
[	O
**	O
2104-5-8	O
**	O
]	O
(	O
on	O
the	O
morning	O
of	O
the	O
esophagogastroduodenoscopy	O
)	O
.	O
Her	O
aspirin	I-Drug
and	O
Plavix	I-Drug
should	O
be	O
held	O
considering	O
her	O
gastrointestinal	O
bleed	O
,	O
and	O
restarting	O
of	O
these	O
two	O
medications	O
will	O
be	O
made	O
after	O
her	O
repeat	O
endoscopy	O
on	O
[	O
**	O
5	O
-	O
8	O
**	O
]	O
.	O
The	O
patient	O
should	O
remain	O
on	O
Protonix	I-Drug
40	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
until	O
her	O
repeat	O
endoscopy	O
,	O
and	O
she	O
should	O
avoid	O
nonsteroidal	B-Drug
antiinflammatory	I-Drug
drugs	I-Drug
until	O
her	O
procedure	O
.	O
The	O
patient	O
will	O
also	O
probably	O
benefit	O
from	O
a	O
colonoscopy	O
as	O
an	O
outpatient	O
.	O
Helicobacter	O
pylori	O
antibody	O
was	O
still	O
pending	O
.	O
2	O
.	O
THROMBOCYTOPENIA	I-Ade
ISSUES	O
:	O
Heparin	I-Drug
-	O
induced	O
thrombocytopenia	I-Ade
antibody	O
was	O
positive	O
,	O
so	O
the	O
patient	O
should	O
not	O
receive	O
any	O
heparin	B-Drug
.	I-Drug
The	O
patient	O
has	O
a	O
history	O
of	O
a	O
mild	O
pancytopenia	O
in	O
the	O
past	O
,	O
and	O
this	O
issue	O
was	O
discussed	O
between	O
the	O
patient	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
410	O
**	O
]	O
of	O
Hematology	O
/	O
Oncology	O
,	O
and	O
it	O
was	O
decided	O
that	O
no	O
bone	O
marrow	O
biopsy	O
would	O
be	O
performed	O
.	O
The	O
patient	O
should	O
follow	O
up	O
as	O
an	O
outpatient	O
with	O
her	O
primary	O
care	O
physician	O
to	O
insure	O
that	O
she	O
has	O
a	O
rise	O
in	O
her	O
platelets	O
.	O
3	O
.	O
HYPERKALEMIA	O
ISSUES	O
:	O
The	O
patient	O
had	O
an	O
initial	O
potassium	O
value	O
of	O
6	O
with	O
peaked	O
T	O
waves	O
on	O
electrocardiogram	O
.	O
This	O
was	O
thought	O
to	O
likely	O
be	O
due	O
to	O
dehydration	O
,	O
and	O
the	O
blood	O
sample	O
was	O
also	O
moderately	O
hemolyzed	O
.	O
Otherwise	O
,	O
her	O
potassium	O
has	O
remained	O
stable	O
.	O
4	O
.	O
CONGESTIVE	O
HEART	O
FAILURE	O
ISSUES	O
:	O
The	O
patient	O
does	O
have	O
an	O
element	O
of	O
diastolic	O
dysfunction	O
,	O
and	O
so	O
her	O
fluid	O
status	O
was	O
carefully	O
monitored	O
a	O
she	O
was	O
getting	O
significant	O
amounts	O
of	O
fluids	I-Drug
and	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
.	O
She	O
has	O
maintained	O
stable	O
oxygenation	O
,	O
and	O
good	O
oxygen	O
saturations	O
,	O
as	O
well	O
as	O
good	O
urine	O
output	O
.	O
5	O
.	O
COAGULOPATHY	O
ISSUES	O
:	O
The	O
patient	O
developed	O
an	O
INR	O
of	O
1.4	O
;	O
likely	O
secondary	O
to	O
being	O
nothing	O
by	O
mouth	O
for	O
many	O
days	O
and	O
deficiency	O
in	O
vitamin	O
K	O
.	O
She	O
has	O
been	O
given	O
by	O
mouth	O
vitamin	B-Drug
K	I-Drug
and	O
should	O
continue	O
this	O
for	O
two	O
more	O
days	O
.	O
Her	O
INR	O
will	O
likely	O
decrease	O
when	O
she	O
receives	O
adequate	O
nutrition	O
.	O
6	O
.	O
CORONARY	O
ARTERY	O
DISEASE	O
ISSUES	O
:	O
As	O
mentioned	O
above	O
,	O
aspirin	I-Drug
and	O
Plavix	I-Drug
were	O
being	O
held	O
secondary	O
to	O
a	O
large	O
gastrointestinal	O
bleed	O
.	O
The	O
patient	O
should	O
continue	O
to	O
hold	O
these	O
two	O
medications	O
until	O
her	O
repeat	O
endoscopy	O
on	O
[	O
**	O
5	O
-	O
8	O
**	O
]	O
;	O
at	O
which	O
time	O
the	O
decision	O
as	O
to	O
whether	O
to	O
restart	O
these	O
medications	O
can	O
be	O
made	O
.	O
The	O
patient	O
has	O
been	O
restarted	O
on	O
her	O
beta	B-Drug
blocker	I-Drug
.	O
She	O
will	O
continue	O
with	O
her	O
statin	I-Drug
,	O
Imdur	I-Drug
beta	B-Drug
blocker	I-Drug
,	O
and	O
ACE	B-Drug
inhibitor	I-Drug
.	O
7	O
.	O
CHRONIC	O
RENAL	O
INSUFFICIENCY	O
ISSUES	O
:	O
The	O
patient	O
's	O
creatinine	O
is	O
at	O
baseline	O
.	O
Her	O
blood	O
urea	O
nitrogen	O
was	O
likely	O
increased	O
secondary	O
to	O
bleeding	O
and	O
has	O
now	O
returned	O
to	O
[	O
**	O
Location	O
213	O
**	O
]	O
.	O
8	O
.	O
LEFT	O
LEG	O
PAIN	O
ISSUES	O
:	O
The	O
patient	O
had	O
a	O
previous	O
zoster	I-Reason
infection	O
that	O
was	O
treated	O
with	O
Valtrex	B-Drug
.	I-Drug
On	O
admission	O
,	O
she	O
had	O
no	O
evidence	O
of	O
a	O
zoster	O
infection	O
with	O
no	O
rashes	O
apparent	O
.	O
The	O
patient	O
has	O
multiple	O
musculoskeletal	O
complaints	O
that	O
have	O
been	O
chronic	O
.	O
She	O
was	O
continued	O
on	O
her	O
Neurontin	I-Drug
for	O
neuropathic	B-Reason
pain	I-Reason
.	O
The	O
patient	O
was	O
also	O
given	O
Tylenol	I-Drug
for	O
pain	B-Reason
control	I-Reason
.	O
She	O
does	O
not	O
have	O
an	O
active	O
zoster	O
infection	O
.	O
9	O
.	O
PSYCHIATRIC	O
ISSUES	O
:	O
The	O
patient	O
was	O
continued	O
on	O
her	O
BuSpar	B-Drug
.	I-Drug
She	O
has	O
multiple	O
somatic	O
complaints	O
;	O
likely	O
anxiety	I-Reason
related	O
.	O
10	O
.	O
ACIDOSIS	O
/	O
FLUIDS	O
/	O
ELECTROLYTES	O
/	O
NUTRITION	O
ISSUES	O
:	O
The	O
patient	O
's	O
acidosis	O
was	O
improving	O
as	O
her	O
diarrhea	O
improved	O
.	O
It	O
will	O
likely	O
continue	O
to	O
improve	O
as	O
she	O
maintains	O
a	O
normal	O
diet	O
and	O
her	O
diarrhea	O
continues	O
to	O
decrease	O
.	O
She	O
was	O
started	O
on	O
a	O
clear	O
diet	O
on	O
[	O
**	O
4	O
-	O
15	O
**	O
]	O
following	O
her	O
esophagogastroduodenoscopy	O
since	O
her	O
hematocrit	O
has	O
been	O
stable	O
.	O
11	O
.	O
PROPHYLAXIS	O
ISSUES	O
:	O
The	O
patient	O
was	O
maintained	O
on	O
pneumatic	O
boots	O
and	O
a	B-Drug
proton	I-Drug
pump	I-Drug
inhibitor	I-Drug
.	O
The	O
patient	O
should	O
not	O
receive	O
any	O
heparin	I-Drug
secondary	O
to	O
positive	O
heparin	I-Drug
-	O
induced	O
thrombocytopenia	I-Ade
antibody	O
.	O
12	O
.	O
ACCESS	O
ISSUES	O
:	O
The	O
patient	O
has	O
difficult	O
access	O
issues	O
and	O
two	O
peripheral	O
intravenous	O
lines	O
through	O
most	O
of	O
her	O
stay	O
.	O
13	O
.	O
CODE	O
STATUS	O
ISSUES	O
:	O
The	O
patient	O
is	O
a	O
full	O
code	O
.	O
14	O
.	O
DISPOSITION	O
ISSUES	O
:	O
At	O
the	O
time	O
of	O
this	O
dictation	O
,	O
a	O
Physical	O
Therapy	O
consultation	O
has	O
recommended	O
benefit	O
from	O
rehabilitation	O
for	O
maximum	O
safety	O
.	O
The	O
patient	O
is	O
being	O
screened	O
for	O
rehabilitation	O
at	O
the	O
time	O
of	O
this	O
dictation	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
1	O
.	O
Gastrointestinal	O
bleed	O
.	O
2	O
.	O
Anemia	O
.	O
3	O
.	O
Chronic	O
renal	O
insufficiency	O
.	O
4	O
.	O
Coronary	O
artery	O
disease	O
.	O
5	O
.	O
Anxiety	O
/	O
depression	O
.	O
DISCHARGE	O
STATUS	O
:	O
To	O
rehabilitation	O
.	O
CONDITION	O
AT	O
DISCHARGE	O
:	O
Stable	O
.	O
MEDICATIONS	O
ON	O
DISCHARGE	O
:	O
1	O
.	O
Protonix	I-Drug
40	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
.	O
2	O
.	O
Metoprolol	I-Drug
25	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
.	O
3	O
.	O
Nystatin	I-Drug
5	O
mg	O
by	O
mouth	O
four	O
times	O
per	O
day	O
as	O
needed	O
(	O
for	O
thrush	I-Reason
)	O
.	O
4	O
.	O
Gabapentin	B-Drug
300	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
.	O
5	O
.	O
Cepacol	I-Drug
one	O
lozenge	O
by	O
mouth	O
as	O
needed	O
.	O
6	O
.	O
Oxycodone	I-Drug
2.5	O
mg	O
to	O
5	O
mg	O
by	O
mouth	O
q.4	O
-	O
6h	O
.	O
as	O
needed	O
.	O
7	O
.	O
Tylenol	I-Drug
1000	O
mg	O
by	O
mouth	O
three	O
times	O
per	O
day	O
.	O
8	O
.	O
Ferrous	B-Drug
sulfate	I-Drug
325	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
9	O
.	O
BuSpar	I-Drug
5	O
mg	O
by	O
mouth	O
twice	O
per	O
day	O
.	O
10	O
.	O
Mirtazapine	I-Drug
30	O
mg	O
by	O
mouth	O
at	O
hour	O
of	O
sleep	O
.	O
11	O
.	O
Isosorbide	I-Drug
mononitrate	O
extended	O
release	O
45	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
12	O
.	O
Atorvastatin	B-Drug
20	O
mg	O
by	O
mouth	O
once	O
per	O
day	O
.	O
DISCHARGE	O
INSTRUCTIONS	O
/	O
FOLLOWUP	O
:	O
1	O
.	O
The	O
patient	O
was	O
instructed	O
to	O
follow	O
up	O
with	O
her	O
primary	O
care	O
physician	O
in	O
one	O
to	O
two	O
weeks	O
.	O
2	O
.	O
The	O
patient	O
has	O
a	O
follow	O
-	O
up	O
esophagogastroduodenoscopy	O
scheduled	O
for	O
[	O
**	O
5	O
-	O
8	O
**	O
]	O
at	O
9:30	O
a.m.	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
21140	O
**	O
]	O
and	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
2161	O
**	O
]	O
at	O
the	O
Endoscopy	O
Unit	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
448	O
**	O
]	O
of	O
[	O
**	O
Hospital	O
Ward	O
Name	O
1950	O
**	O
]	O
One	O
,	O
[	O
**	O
Hospital	O
Ward	O
Name	O
516	O
**	O
]	O
Building	O
.	O
The	O
patient	O
should	O
register	O
in	O
the	O
lobby	O
of	O
the	O
[	O
**	O
Hospital	O
Ward	O
Name	O
1826	O
**	O
]	O
Building	O
at	O
8:30	O
a.m.	O
and	O
should	O
not	O
have	O
anything	O
to	O
eat	O
after	O
midnight	O
on	O
[	O
**	O
2104-5-7	O
**	O
]	O
.	O
She	O
should	O
not	O
eat	O
breakfast	O
on	O
the	O
morning	O
of	O
[	O
**	O
2104-5-8	O
**	O
]	O
.	O
3	O
.	O
Esophagogastroduodenoscopy	O
reports	O
have	O
been	O
sent	O
with	O
the	O
patient	O
to	O
rehabilitation	O
,	O
and	O
the	O
patient	O
should	O
bring	O
these	O
papers	O
with	O
her	O
to	O
her	O
esophagogastroduodenoscopy	O
appointment	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
1019	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Name8	O
(	O
MD	O
)	O
10397	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2104-4-15	O
**	O
]	O
13:01	O
T	O
:	O
[	O
**	O
2104-4-15	O
**	O
]	O
14:36	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
101481	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2171-4-15	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2171-4-21	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2101-5-28	O
**	O
]	O
Sex	O
:	O
F	O
CHIEF	O
COMPLAINT	O
:	O
1	O
.	O
Non-ST	O
elevation	O
myocardial	O
infarction	O
.	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
69	O
year	O
-	O
old	O
outside	O
hospital	O
for	O
cardiac	O
catheterization	O
after	O
ruling	O
in	O
for	O
non-ST	O
elevation	O
MI	O
.	O
The	O
patient	O
was	O
in	O
her	O
usual	O
state	O
of	O
health	O
until	O
five	O
days	O
prior	O
to	O
arrival	O
.	O
She	O
had	O
an	O
episode	O
of	O
chest	O
tightness	O
around	O
two	O
hours	O
of	O
duration	O
while	O
at	O
rest	O
.	O
Relieved	O
spontaneously	O
,	O
no	O
sublingual	O
nitroglycerin	I-Drug
at	O
home	O
.	O
Two	O
days	O
pain	O
radiating	O
to	O
the	O
right	O
shoulder	O
and	O
neck	O
.	O
This	O
persisted	O
two	O
to	O
three	O
hours	O
.	O
The	O
patient	O
presented	O
to	O
outside	O
hospital	O
chest	O
pain	O
free	O
.	O
Ruled	O
in	O
for	O
non-ST	O
elevation	O
MI	O
.	O
She	O
was	O
given	O
Nitro	I-Drug
Paste	O
and	O
beta	B-Drug
blocker	I-Drug
and	O
aspirin	I-Drug
.	O
The	O
patient	O
with	O
peak	O
CK	O
MB	O
index	O
of	O
4.3	O
,	O
peak	O
CK	O
of	O
189	O
.	O
She	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
1444	O
**	O
]	O
on	O
Heparin	I-Drug
and	O
Aggrastat	I-Drug
started	O
on	O
the	O
evening	O
of	O
[	O
**	O
2171-4-14	O
**	O
]	O
after	O
receiving	O
enoxaparin	I-Drug
for	O
cardiac	B-Reason
catheterization	I-Reason
.	O
At	O
presentation	O
at	O
[	O
**	O
Hospital1	O
69	O
**	O
]	O
no	O
chest	O
pain	O
times	O
three	O
days	O
.	O
Denies	O
fever	O
,	O
chills	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
or	O
constipation	O
.	O
Positive	O
melena	O
times	O
two	O
days	O
,	O
no	O
bright	O
red	O
blood	O
per	O
rectum	O
,	O
no	O
urinary	O
symptoms	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Coronary	O
artery	O
disease	O
status	O
post	O
RCA	O
stent	O
and	O
PTCA	O
of	O
the	O
left	O
circumflex	O
on	O
[	O
**	O
3	O
-	O
/	O
2165	O
**	O
]	O
.	O
Restenosis	O
/	O
PTCA	O
of	O
left	O
circumflex	O
branch	O
in	O
08/96	O
.	O
Both	O
of	O
these	O
procedures	O
were	O
done	O
at	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Hospital	O
in	O
[	O
**	O
Location	O
(	O
un	O
)	O
86	O
**	O
]	O
.	O
2	O
.	O
Hypertension	O
.	O
3	O
.	O
Hypercholesterolemia	O
.	O
4	O
.	O
Status	O
post	O
myocardial	O
infarction	O
in	O
[	O
**	O
2165	O
**	O
]	O
.	O
OUTPATIENT	O
MEDICATIONS	O
:	O
1	O
.	O
Gemfibrozil	I-Drug
600	O
milligrams	O
po	O
bid	O
.	O
2	O
.	O
Plendil	I-Drug
5	O
milligrams	O
po	O
q	O
day	O
.	O
3	O
.	O
Hygroton	I-Drug
.	O
4	O
.	O
Naprosyn	I-Drug
.	O
5	O
.	O
Aspirin	I-Drug
325	O
milligrams	O
.	O
6	O
.	O
Vitamin	B-Drug
C.	O
7	O
.	O
Fluvastatin	I-Drug
MEDICATIONS	O
AT	O
TRANSFER	O
:	O
1	O
.	O
Metoprolol	I-Drug
25	O
milligrams	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
2	O
.	O
Aggrastat	I-Drug
.	O
3	O
.	O
Heparin	I-Drug
.	O
4	O
.	O
Aspirin	I-Drug
325	O
milligrams	O
po	O
bid	O
.	O
5	O
.	O
Nitro	I-Drug
Paste	O
one	O
inch	O
q	O
six	O
.	O
6	O
.	O
Plendil	I-Drug
5	O
milligrams	O
po	O
q	O
day	O
.	O
7	O
.	O
Gemfibrozil	I-Drug
600	O
milligrams	O
po	O
bid	O
.	O
8	O
.	O
Prevacid	I-Drug
15	O
milligrams	O
po	O
q	O
day	O
.	O
ALLERGIES	O
:	O
1	O
.	O
Lipitor	I-Drug
causes	O
arthralgias	I-Ade
.	O
SOCIAL	O
HISTORY	O
:	O
The	O
patient	O
lives	O
in	O
[	O
**	O
Location	O
701	O
**	O
]	O
with	O
husband	O
.	O
Habits	O
-	O
no	O
tobacco	O
,	O
rare	O
alcohol	O
.	O
FAMILY	O
HISTORY	O
:	O
Father	O
died	O
of	O
CAD	O
at	O
age	O
67	O
.	O
Mother	O
with	O
CAD	O
.	O
PHYSICAL	O
EXAMINATION	O
:	O
On	O
admission	O
temperature	O
98.7	O
F	O
,	O
blood	O
pressure	O
156/55	O
,	O
pulse	O
57	O
,	O
respiratory	O
rate	O
93	O
on	O
room	O
air	O
.	O
Weight	O
200	O
lbs	O
.	O
In	O
general	O
pleasant	O
,	O
in	O
no	O
acute	O
distress	O
.	O
HEENT	O
-	O
anicteric	O
.	O
OP	O
clear	O
.	O
Neck	O
-	O
2	O
+	O
carotids	O
,	O
no	O
thyromegaly	O
.	O
Cardiovascular	O
-	O
Regular	O
rate	O
and	O
rhythm	O
,	O
S1	O
,	O
S2	O
.	O
II	O
/	O
VI	O
systolic	O
ejection	O
murmur	O
at	O
right	O
upper	O
sternal	O
border	O
without	O
radiation	O
.	O
Pulmonary	O
-	O
clear	O
bilaterally	O
.	O
Abdomen	O
-	O
soft	O
,	O
nontender	O
,	O
nondistended	O
,	O
positive	O
bowel	O
sounds	O
,	O
obese	O
.	O
Extremities	O
-	O
trace	O
edema	O
bilaterally	O
.	O
Neuro	O
-	O
alert	O
and	O
oriented	O
times	O
3	O
,	O
mentating	O
well	O
.	O
Cranial	O
nerves	O
II	O
through	O
XII	O
intact	O
grossly	O
.	O
Rectal	O
exam	O
-	O
brown	O
stool	O
guaiac	O
positive	O
.	O
LABORATORY	O
DATA	O
:	O
From	O
outside	O
hospital	O
first	O
CK	O
was	O
189	O
with	O
an	O
MB	O
of	O
5.5	O
,	O
index	O
of	O
2.9	O
,	O
Troponin	O
I	O
2.8	O
.	O
CK	O
#	O
2	O
at	O
outside	O
hospital	O
CK	O
137	O
,	O
MB	O
5.3	O
,	O
index	O
3.9	O
and	O
Troponin	O
I	O
of	O
4.2	O
.	O
[	O
**	O
2171-4-15	O
**	O
]	O
in	O
A.M.	O
at	O
outside	O
hospital	O
white	O
count	O
5.4	O
,	O
hematocrit	O
35.9	O
,	O
platelet	O
count	O
243,000	O
.	O
PTT	O
70.9	O
,	O
sodium	O
140	O
,	O
potassium	O
3.2	O
,	O
chloride	O
102	O
,	O
CO2	O
24	O
,	O
BUN	O
20	O
,	O
creatinine	O
0.7	O
,	O
glucose	O
134	O
,	O
calcium	O
9.2	O
.	O
[	O
**	O
2171-4-14	O
**	O
]	O
in	O
the	O
afternoon	O
chloride	O
164	O
,	O
triglycerides	O
231	O
,	O
HDL	O
31	O
,	O
LDL	O
77	O
,	O
total	O
protein	O
7.7	O
,	O
albumin	O
4.4	O
,	O
Tbili	O
0.6	O
,	O
alkaline	O
phosphatase	O
79	O
,	O
AST	O
32	O
,	O
ALT	O
35	O
.	O
EKG	O
[	O
**	O
2171-4-13	O
**	O
]	O
no	O
prior	O
comparisons	O
,	O
normal	O
sinus	O
rhythm	O
at	O
100	O
beats	O
per	O
minute	O
,	O
axis	O
0	O
degrees	O
,	O
ST	O
depressions	O
in	O
I	O
,	O
V2	O
,	O
V3	O
,	O
V4	O
,	O
V5	O
.	O
ST	O
elevation	O
1	O
mm	O
in	O
III	O
,	O
biphasic	O
Ts	O
in	O
V4	O
and	O
V5	O
,	O
small	O
Q	O
wave	O
in	O
I.	O
BRIEF	O
SUMMARY	O
OF	O
HOSPITAL	O
COURSE	O
:	O
ASSESSMENT	O
AND	O
PLAN	O
:	O
A	O
69	O
year	O
-	O
old	O
female	O
with	O
past	O
medical	O
history	O
of	O
coronary	O
artery	O
disease	O
status	O
post	O
MI	O
with	O
stent	O
to	O
RCA	O
in	O
[	O
**	O
2165	O
**	O
]	O
presents	O
from	O
outside	O
hospital	O
after	O
ruling	O
in	O
for	O
myocardial	O
infarction	O
.	O
The	O
patient	O
transferred	O
here	O
for	O
cardiac	O
catheterization	O
.	O
1	O
.	O
Cardiac	O
-	O
Coronaries	O
the	O
patient	O
with	O
known	O
disease	O
,	O
increased	O
Troponin	O
and	O
index	O
at	O
outside	O
hospital	O
with	O
EKG	O
changes	O
all	O
suggestive	O
of	O
acute	O
coronary	O
syndrome	O
.	O
At	O
presentation	O
the	O
patient	O
was	O
chest	O
pain	O
free	O
times	O
three	O
days	O
.	O
The	O
patient	O
was	O
originally	O
continued	O
on	O
Heparin	I-Drug
,	O
Aggrastat	I-Drug
,	O
beta	B-Drug
blocker	I-Drug
,	O
aspirin	I-Drug
,	O
statin	I-Drug
and	O
Gemfibrozil	I-Drug
.	O
Plendil	I-Drug
was	O
discontinued	O
in	O
favor	O
of	O
starting	O
an	O
Ace	I-Drug
inhibitor	O
.	O
The	O
patient	O
underwent	O
cardiac	O
catheterization	O
on	O
[	O
**	O
2171-4-16	O
**	O
]	O
and	O
this	O
showed	O
one	O
vessel	O
coronary	O
artery	O
disease	O
.	O
The	O
patient	O
underwent	O
successful	O
stenting	O
of	O
95	O
%	O
mid	O
RCA	O
stenosis	O
.	O
Ejection	O
fraction	O
was	O
preserved	O
.	O
The	O
patient	O
suffered	O
from	O
no	O
flow	O
phenomenon	O
requiring	O
Diltiazem	I-Drug
and	O
Nitroglycerin	I-Drug
secondary	O
to	O
chest	B-Reason
pain	I-Reason
and	O
ST	B-Reason
elevations	I-Reason
with	O
stent	O
deployment	O
.	O
The	O
patient	O
also	O
suffered	O
complete	B-Ade
heart	I-Ade
block	I-Ade
secondary	O
to	O
Diltiazem	I-Drug
in	O
cath	O
lab	O
requiring	O
transient	O
pacer	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
CCU	O
with	O
chest	O
pain	O
and	O
persistent	O
ST	O
elevations	O
.	O
Aggrastat	I-Drug
was	O
stopped	O
prior	O
to	O
catheterization	O
secondary	O
to	O
epistasis	I-Ade
and	O
guaiac	B-Ade
positive	I-Ade
stools	I-Ade
.	O
In	O
the	O
cath	O
lab	O
the	O
patient	O
stabilized	O
on	O
Nitro	I-Drug
drip	O
.	O
Complete	O
heart	O
block	O
resolved	O
and	O
pacing	O
wire	O
was	O
taken	O
out	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
floor	O
without	O
chest	O
pain	O
and	O
with	O
complete	O
resolution	O
of	O
EKG	O
changes	O
to	O
continue	O
medical	O
management	O
.	O
The	O
patient	O
had	O
no	O
further	O
episodes	O
of	O
chest	O
pain	O
throughout	O
her	O
hospital	O
stay	O
.	O
The	O
patient	O
's	O
Ace	B-Drug
inhibitor	I-Drug
was	O
changed	O
to	O
Lisinopril	I-Drug
for	O
two	O
day	O
dosing	O
.	O
The	O
patient	O
continued	O
on	O
Gemfibrozil	I-Drug
and	O
Fluvastatin	I-Drug
for	O
cholesterol	I-Reason
and	O
was	O
to	O
complete	O
a	O
30	O
day	O
course	O
of	O
Plavix	I-Drug
.	O
Estimated	O
ejection	O
fraction	O
at	O
cardiac	O
catheterization	O
was	O
60	O
%	O
.	O
2	O
.	O
Hematocrit	O
-	O
The	O
patient	O
with	O
a	O
hematocrit	O
drop	O
peri	O
catheterization	O
thought	O
to	O
be	O
secondary	O
to	O
anticoagulation	O
.	O
The	O
patient	O
received	O
three	O
units	O
of	O
packed	B-Drug
red	I-Drug
blood	I-Drug
cells	I-Drug
.	O
The	O
patient	O
hematocrit	O
low	O
was	O
26	O
.	O
[	O
**	O
4	O
-	O
22	O
**	O
]	O
.	O
ON	O
day	O
of	O
discharge	O
[	O
**	O
2171-4-21	O
**	O
]	O
the	O
patient	O
's	O
hematocrit	O
bumped	O
to	O
39.1	O
.	O
3	O
.	O
Infectious	O
Disease	O
-	O
The	O
patient	O
had	O
a	O
temperature	O
spike	O
to	O
101.2	O
F	O
the	O
evening	O
of	O
[	O
**	O
4	O
-	O
18	O
**	O
]	O
.	O
The	O
patient	O
was	O
started	O
on	O
Bactrim	I-Drug
for	O
mildly	B-Reason
positive	I-Reason
urinalysis	I-Reason
which	O
consisted	O
of	O
large	O
blood	O
,	O
small	O
leukocytes	O
,	O
negative	O
nitrites	O
,	O
5	O
whites	O
,	O
moderate	O
bacteria	O
,	O
one	O
squamous	O
epithelial	O
cell	O
.	O
The	O
patient	O
had	O
received	O
temporary	O
Foley	O
catheter	O
in	O
the	O
CCU	O
and	O
complained	O
of	O
mild	O
urinary	O
burning	O
after	O
its	O
being	O
taken	O
out	O
.	O
The	O
patient	O
defervesced	O
over	O
the	O
next	O
few	O
days	O
but	O
had	O
a	O
low	O
grade	O
temperature	O
on	O
the	O
evening	O
of	O
[	O
**	O
2171-4-19	O
**	O
]	O
.	O
The	O
patient	O
was	O
changed	O
to	O
Ciprofloxacin	I-Drug
and	O
chest	O
x-ray	O
was	O
unrevealing	O
.	O
Blood	O
cultures	O
were	O
drawn	O
which	O
showed	O
no	O
growth	O
to	O
date	O
at	O
the	O
time	O
of	O
discharge	O
.	O
The	O
patient	O
to	O
be	O
followed	O
as	O
an	O
outpatient	O
and	O
instructed	O
to	O
take	O
her	O
temperature	O
and	O
if	O
over	O
100	O
to	O
seek	O
medical	O
attention	O
.	O
The	O
patient	O
to	O
complete	O
a	O
seven	O
day	O
course	O
for	O
UTI	I-Reason
.	O
Urine	O
culture	O
was	O
uninterpretable	O
due	O
to	O
fecal	O
contamination	O
.	O
DISCHARGE	O
FOLLOW	O
UP	O
:	O
The	O
patient	O
to	O
follow	O
up	O
with	O
PCP	O
next	O
week	O
as	O
well	O
as	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
7047	O
**	O
]	O
for	O
primary	O
cardiologist	O
.	O
DISCHARGE	O
CONDITION	O
:	O
Stable	O
.	O
DISCHARGE	O
STATUS	O
:	O
To	O
home	O
.	O
DISCHARGE	O
DIAGNOSIS	O
:	O
1	O
.	O
Coronary	O
artery	O
disease	O
.	O
2	O
.	O
Hypercholesterolemia	O
.	O
3	O
.	O
UTI	O
.	O
DISCHARGE	O
MEDICATIONS	O
:	O
1	O
.	O
Atenolol	I-Drug
25	O
milligrams	O
po	O
q	O
day	O
.	O
2	O
.	O
Aspirin	I-Drug
325	O
milligrams	O
po	O
q	O
day	O
.	O
3	O
.	O
Lisinopril	I-Drug
20	O
milligrams	O
po	O
q	O
day	O
.	O
4	O
.	O
Gemfibrozil	I-Drug
600	O
milligrams	O
po	O
bid	O
.	O
5	O
.	O
Protonix	I-Drug
40	O
milligrams	O
po	O
q	O
day	O
.	O
6	O
.	O
Fluvastatin	I-Drug
20	O
milligrams	O
po	O
q	O
day	O
.	O
7	O
.	O
Plavix	I-Drug
75	O
milligrams	O
po	O
q	O
day	O
times	O
28	O
days	O
.	O
8	O
.	O
Ciprofloxacin	I-Drug
250	O
milligrams	O
po	O
bid	O
times	O
six	O
days	O
.	O
CODE	O
STATUS	O
:	O
The	O
patient	O
is	O
full	O
code	O
.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
21044	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
21045	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
1324	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2171-4-21	O
**	O
]	O
11:05	O
T	O
:	O
[	O
**	O
2171-4-22	O
**	O
]	O
13:18	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
41392	O
**	O
]	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
7047	O
**	O
]	O
,	O
MD	O

Admission	O
Date	O
:	O
[	O
**	O
2116-8-11	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2116-8-14	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2057-7-21	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1973	O
**	O
]	O
Chief	O
Complaint	O
:	O
alcohol	O
withdrawal	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
59M	O
known	O
for	O
EtOH	O
abuse	O
and	O
HTN	O
initially	O
presented	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
morning	O
of	O
[	O
**	O
8	O
-	O
11	O
**	O
]	O
from	O
[	O
**	O
Hospital	O
1680	O
**	O
]	O
rehab	O
for	O
EtOH	O
withdrawal	O
,	O
was	O
discharged	O
back	O
to	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
and	O
then	O
represented	O
to	O
ED	O
in	O
PM	O
of	O
[	O
**	O
8	O
-	O
11	O
**	O
]	O
for	O
concern	O
for	O
delerium	O
tremens	O
.	O
Per	O
[	O
**	O
Hospital	O
**	O
]	O
rehab	O
records	O
,	O
pt	O
's	O
last	O
drink	O
was	O
reportedly	O
on	O
Sunday	O
,	O
[	O
**	O
8	O
-	O
9	O
**	O
]	O
.	O
He	O
was	O
sectioned	O
to	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
on	O
[	O
**	O
8	O
-	O
10	O
**	O
]	O
for	O
rehab	O
.	O
Initial	O
ED	O
course	O
:	O
98.6	O
HR	O
:	O
67	O
BP	O
:	O
104/70	O
Resp	O
:	O
18	O
O	O
(	O
2	O
)	O
Sat	O
:	O
96	O
%	O
RA	O
.	O
He	O
complained	O
of	O
confusion	O
,	O
tremulousness	O
,	O
unsteady	O
gait	O
and	O
visual	O
hallucinations	O
which	O
he	O
could	O
bring	O
on	O
by	O
closing	O
his	O
eyes	O
.	O
Labs	O
significant	O
for	O
cr	O
of	O
1.8	O
,	O
K	O
2.9	O
,	O
AG	O
15	O
,	O
CBC	O
with	O
crit	O
32.4	O
,	O
wbc	O
5.9	O
,	O
plt	O
111	O
.	O
He	O
was	O
given	O
60mEq	O
of	O
K	B-Drug
+	I-Drug
and	O
given	O
valium	I-Drug
.	O
As	O
per	O
ED	O
attending	O
discharge	O
,	O
"	O
The	O
patient	O
is	O
not	O
actively	O
withdrawing	O
from	O
alcohol	O
the	O
emergency	O
department	O
as	O
he	O
has	O
a	O
CIWA	O
scale	O
less	O
than	O
10	O
.	O
"	O
He	O
was	O
discharged	O
back	O
to	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
detox	O
.	O
This	O
afternoon	O
,	O
while	O
back	O
at	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
,	O
he	O
became	O
more	O
ataxic	O
,	O
confused	O
and	O
aggressive	O
and	O
combative	O
towards	O
staff	O
and	O
was	O
subsequently	O
brought	O
back	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
for	O
re-evaluation	O
of	O
etoh	O
w	O
/	O
drawal	O
.	O
While	O
at	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
,	O
he	O
apparently	O
had	O
two	O
witnessed	O
falls	O
without	O
head	O
trauma	O
or	O
LOC	O
.	O
Per	O
nurse	O
manager	O
at	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
,	O
he	O
also	O
urinated	O
on	O
the	O
floor	O
and	O
had	O
one	O
episode	O
of	O
NBNB	O
vomiting	O
24	O
hrs	O
prior	O
to	O
presentation	O
in	O
ED	O
.	O
Second	O
ED	O
course	O
:	O
T97	O
.8	O
P98	O
BP110	O
/	O
75	O
RR18	O
O2	O
:	O
98	O
%	O
RA	O
.	O
As	O
per	O
EMS	O
,	O
orthostatics	O
were	O
checked	O
and	O
negative	O
.	O
He	O
was	O
reportedly	O
combative	O
and	O
confused	O
but	O
PE	O
was	O
unremarkable	O
for	O
any	O
focal	O
neurologic	O
findings	O
with	O
the	O
exception	O
of	O
ataxia	O
.	O
He	O
had	O
no	O
stigmata	O
of	O
chronic	O
liver	O
disease	O
and	O
per	O
hx	O
obtained	O
through	O
staff	O
at	O
[	O
**	O
Name	O
(	O
NI	O
)	O
1680	O
**	O
]	O
,	O
pt	O
did	O
not	O
have	O
any	O
complaints	O
of	O
abdominal	O
pain	O
,	O
diarrhea	O
,	O
cough	O
,	O
headache	O
,	O
fever	O
,	O
chills	O
.	O
Pt	O
was	O
given	O
5	O
mg	O
haldol	I-Drug
and	O
2	O
mg	O
IV	O
ativan	I-Drug
.	O
Labs	O
were	O
significant	O
for	O
improved	O
chem	O
7	O
with	O
K	O
now	O
3.5	O
,	O
and	O
cr	O
now	O
1.0	O
.	O
AG	O
had	O
resolved	O
.	O
Mg	O
was	O
1.3	O
and	O
Ca	O
8.3	O
.	O
CBC	O
grossly	O
unchanged	O
from	O
earlier	O
in	O
the	O
day	O
.	O
Head	O
CT	O
without	O
any	O
acute	O
findings	O
.	O
EKG	O
x2	O
revealed	O
leftward	O
axis	O
deviation	O
but	O
otherwise	O
unremarkable	O
.	O
While	O
in	O
the	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
pt	O
did	O
not	O
have	O
any	O
significant	O
acid	O
-	O
base	O
or	O
electrolyte	O
disturbances	O
,	O
no	O
hemodynamic	O
or	O
respiratory	O
instability	O
,	O
hyperthermia	O
,	O
tremors	O
or	O
tachycardia	O
.	O
As	O
per	O
nursing	O
signout	O
,	O
his	O
CIWA	O
score	O
was	O
5	O
at	O
time	O
of	O
transfer	O
.	O
Past	O
Medical	O
History	O
:	O
HTN	O
EtOH	O
abuse	O
with	O
h	O
/	O
o	O
DTs	O
depression	O
IBS	O
Social	O
History	O
:	O
divorced	O
-	O
Tobacco	O
:	O
no	O
-	O
Alcohol	O
:	O
yes	O
-	O
Illicits	O
:	O
?	O
Family	O
History	O
:	O
Noncontributory	O
Physical	O
Exam	O
:	O
VS	O
:	O
Afebrile	O
,	O
82	O
,	O
118/68	O
,	O
RR	O
121	O
94	O
%	O
RA	O
General	O
:	O
sleeping	O
,	O
combative	O
when	O
awoken	O
HEENT	O
:	O
Refused	O
this	O
part	O
of	O
the	O
exam	O
Neck	O
:	O
CV	O
:	O
Regular	O
rate	O
and	O
rhythm	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
no	O
clubbing	O
,	O
cyanosis	O
or	O
edema	O
Neuro	O
:	O
alseep	O
,	O
slightly	O
combative	O
,	O
moving	O
all	O
extremities	O
Pertinent	O
Results	O
:	O
Admission	O
Labs	O
:	O
[	O
**	O
2116-8-11	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
WBC	O
-	O
5.9	O
RBC	O
-	O
3.22	O
*	O
Hgb	O
-	O
11.3	O
*	O
Hct	O
-	O
32.4	O
*	O
MCV	O
-	O
101	O
*	O
MCH	O
-	O
35.1	O
*	O
MCHC	O
-	O
34.9	O
RDW	O
-	O
20.7	O
*	O
Plt	O
Ct	O
-	O
114	O
*	O
[	O
**	O
2116-8-11	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
Neuts	O
-	O
65.3	O
Lymphs	O
-	O
23.5	O
Monos	O
-	O
9.1	O
Eos	O
-	O
1.8	O
Baso	O
-	O
0.3	O
[	O
**	O
2116-8-11	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
Glucose	O
-	O
85	O
UreaN	O
-	O
20	O
Creat	O
-	O
1.8	O
*	O
Na	O
-	O
142	O
K	O
-	O
2.9	O
*	O
Cl	O
-	O
100	O
HCO3	O
-	O
27	O
AnGap	O
-	O
18	O
[	O
**	O
2116-8-11	O
**	O
]	O
11:00	O
PM	O
BLOOD	O
Calcium	O
-	O
8.3	O
*	O
Phos	O
-	O
2.8	O
Mg	O
-	O
1.3	O
*	O
[	O
**	O
2116-8-11	O
**	O
]	O
12:30	O
PM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
POS	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
[	O
**	O
2116-8-11	O
**	O
]	O
01:45	O
PM	O
URINE	O
bnzodzp	O
-	O
POS	O
barbitr	O
-	O
NEG	O
opiates	O
-	O
NEG	O
cocaine	O
-	O
NEG	O
amphetm	O
-	O
NEG	O
mthdone	O
-	O
NEG	O
Relevant	O
labs	O
:	O
[	O
**	O
2116-8-12	O
**	O
]	O
04:38	O
AM	O
URINE	O
Color	O
-	O
Straw	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.008	O
[	O
**	O
2116-8-12	O
**	O
]	O
04:38	O
AM	O
URINE	O
Blood	O
-	O
TR	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
NEG	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
7.0	O
Leuks	O
-	O
NEG	O
[	O
**	O
2116-8-12	O
**	O
]	O
04:38	O
AM	O
URINE	O
RBC	O
-	O
4	O
*	O
WBC	O
-	O
<	O
1	O
Bacteri	O
-	O
FEW	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
0	O
Discharge	O
labs	O
:	O
[	O
**	O
2116-8-13	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
WBC	O
-	O
4.6	O
RBC	O
-	O
3.48	O
*	O
Hgb	O
-	O
12.2	O
*	O
Hct	O
-	O
35.6	O
*	O
MCV	O
-	O
103	O
*	O
MCH	O
-	O
35.1	O
*	O
MCHC	O
-	O
34.2	O
RDW	O
-	O
20.8	O
*	O
Plt	O
Ct	O
-	O
153	O
[	O
**	O
2116-8-13	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
PT	O
-	O
10.1	O
PTT	O
-	O
30.9	O
INR	O
(	O
PT	O
)	O
-	O
0.9	O
[	O
**	O
2116-8-13	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
Glucose	O
-	O
100	O
UreaN	O
-	O
20	O
Creat	O
-	O
1.0	O
Na	O
-	O
141	O
K	O
-	O
3.5	O
Cl	O
-	O
104	O
HCO3	O
-	O
25	O
AnGap	O
-	O
16	O
[	O
**	O
2116-8-13	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
Calcium	O
-	O
9.0	O
Phos	O
-	O
3.1	O
Mg	O
-	O
1.6	O
[	O
**	O
2116-8-13	O
**	O
]	O
07:15	O
AM	O
BLOOD	O
VitB12	O
-	O
484	O
Folate	O
-	O
8.6	O
Imaging	O
:	O
[	O
**	O
2116-8-11	O
**	O
]	O
CXR	O
PA	O
/	O
lat	O
:	O
Bilateral	O
low	O
lung	O
volumes	O
are	O
noted	O
with	O
crowding	O
of	O
bronchovascular	O
markings	O
.	O
Cardiac	O
silhouette	O
is	O
accentuated	O
by	O
low	O
lung	O
volumes	O
.	O
Thoracic	O
aorta	O
is	O
quite	O
tortuous	O
and	O
may	O
be	O
enlarged	O
in	O
ascending	O
or	O
descending	O
portions	O
.	O
Clinical	O
correlation	O
is	O
indicated	O
to	O
see	O
if	O
imaging	O
is	O
indicated	O
.	O
No	O
acute	O
focal	O
consolidation	O
,	O
pleural	O
effusion	O
or	O
pneumothorax	O
.	O
[	O
**	O
2116-8-11	O
**	O
]	O
non-contrast	O
CT	O
head	O
:	O
There	O
is	O
no	O
evidence	O
for	O
acute	O
intracranial	O
hemorrhage	O
,	O
large	O
mass	O
,	O
mass	O
effect	O
,	O
edema	O
,	O
or	O
hydrocephalus	O
.	O
There	O
is	O
preservation	O
of	O
[	O
**	O
Doctor	O
Last	O
Name	O
352	O
**	O
]	O
-	O
white	O
matter	O
differentiation	O
.	O
The	O
basal	O
cisterns	O
appear	O
patent	O
.	O
Prominent	O
ventricles	O
and	O
sulci	O
suggest	O
age	O
-	O
related	O
involutional	O
changes	O
.	O
Note	O
is	O
made	O
of	O
a	O
persistent	O
cavum	O
septum	O
pellucidum	O
.	O
The	O
visualized	O
portions	O
of	O
the	O
paranasal	O
sinuses	O
and	O
mastoid	O
air	O
cells	O
appear	O
well	O
aerated	O
.	O
No	O
acute	O
bony	O
abnormality	O
is	O
detected	O
.	O
IMPRESSION	O
:	O
No	O
CT	O
evidence	O
for	O
acute	O
intracranial	O
process	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
is	O
a	O
59	O
M	O
with	O
PMH	O
EtOH	O
abuse	O
,	O
IBS	O
and	O
depression	O
,	O
admitted	O
from	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
for	O
management	O
of	O
EtOH	O
withdrawal	O
and	O
concern	O
for	O
[	O
**	O
Hospital	O
90022	O
**	O
]	O
hospital	O
course	O
complicated	O
by	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
.	O
ACTIVE	O
ISSUES	O
:	O
#	O
Alcohol	O
withdrawal	O
,	O
concern	O
for	O
DTs	O
,	O
Adverse	O
Drug	O
Reaction	O
-	O
Patient	O
was	O
agitated	O
on	O
arrival	O
and	O
ataxic	O
and	O
there	O
was	O
concern	O
that	O
he	O
was	O
going	O
into	O
DTs	O
,	O
despite	O
being	O
on	O
librium	I-Drug
at	O
the	O
detox	O
facility	O
.	O
In	O
the	O
ED	O
he	O
received	O
5	O
mg	O
Haldol	I-Drug
for	O
acute	I-Reason
agitation	O
.	O
He	O
was	O
admitted	O
to	O
the	O
MICU	O
for	O
management	O
of	O
withdrawal	O
and	O
close	O
monitoring	O
.	O
He	O
was	O
not	O
tachycardic	O
or	O
hypertensive	O
.	O
In	O
the	O
MICU	O
,	O
he	O
was	O
treated	O
with	O
diazepam	I-Drug
per	O
CIWA	O
scale	O
(	O
most	O
recently	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
~	O
5	O
)	O
,	O
as	O
well	O
as	O
thiamine	I-Drug
and	O
folate	I-Drug
(	O
recently	O
transitioned	O
to	O
PO	O
)	O
.	O
Non-contrast	O
head	O
CT	O
(	O
for	O
eval	O
given	O
falls	O
)	O
showed	O
no	O
ICH	O
.	O
After	O
transfer	O
to	O
the	O
floor	O
,	O
patient	O
was	O
calm	O
and	O
appropriate	O
,	O
with	O
little	O
memory	O
of	O
what	O
had	O
brought	O
him	O
to	O
the	O
hospital	O
;	O
he	O
felt	O
that	O
his	O
what	O
had	O
been	O
described	O
to	O
him	O
was	O
not	O
consistent	O
with	O
his	O
character	O
.	O
Psychiatry	O
was	O
consulted	O
to	O
evaluate	O
whether	O
bizarre	O
behavior	O
at	O
[	O
**	O
Hospital1	O
1680	O
**	O
]	O
may	O
have	O
had	O
an	O
alternative	O
explanation	O
.	O
Consult	O
theorized	O
that	O
patient	O
's	O
presentation	O
was	O
more	O
consistent	O
with	O
benzodiazepene	I-Drug
intoxication	I-Ade
than	O
alcohol	O
withdrawal	O
.	O
#	O
Acute	O
Renal	O
Failure	O
due	O
to	O
Dehydration	O
:	O
Initial	O
Cr	O
was	O
1.8	O
,	O
but	O
improved	O
to	O
1.0	O
on	O
second	O
chem	O
panel	O
without	O
any	O
intervention	O
.	O
CHRONIC	O
:	O
#	O
Depression	O
:	O
Patient	O
reported	O
history	O
of	O
depression	O
,	O
which	O
was	O
impetus	O
for	O
him	O
to	O
resume	O
excess	O
alcohol	O
consumption	O
.	O
He	O
denied	O
depression	O
during	O
this	O
admission	O
.	O
He	O
was	O
provided	O
with	O
resources	O
by	O
SW	O
.	O
Psychiatry	O
evaluation	O
was	O
performed	O
who	O
felt	O
he	O
was	O
completely	O
safe	O
to	O
discharge	O
,	O
and	O
was	O
not	O
particularly	O
depressed	O
at	O
this	O
time	O
.	O
No	O
SI	O
/	O
HI	O
.	O
#	O
thrombocytopenia	O
/	O
Anemia	O
:	O
likely	O
EtOH	O
induced	O
marrow	O
suppression	O
given	O
h	O
/	O
o	O
etoh	O
abuse	O
,	O
elevated	O
MCV	O
.	O
Stable	O
throughout	O
admission	O
#	O
Benign	B-Reason
Hypertension	I-Reason
:	O
No	O
acute	O
exacerbation	O
of	O
chronic	O
issue	O
,	O
pt	O
.	O
was	O
continued	O
on	O
home	O
dose	O
of	O
amlodipine	I-Drug
.	O
TRANSITIONAL	O
ISSUES	O
:	O
#	O
Caution	O
with	O
benzodiazepenes	I-Drug
during	O
withdrawal	O
.	O
#	O
Recommended	O
to	O
have	O
close	O
follow	O
up	O
for	O
depression	O
.	O
Medications	O
on	O
Admission	O
:	O
Preadmission	O
medications	O
listed	O
are	O
correct	O
and	O
complete	O
.	O
Information	O
was	O
obtained	O
from	O
Patient	O
.	O
1	O
.	O
Amlodipine	I-Drug
5	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications	O
:	O
1	O
.	O
FoLIC	B-Drug
Acid	I-Drug
1	O
mg	O
PO	O
DAILY	O
start	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
RX	O
*	O
folic	B-Drug
acid	I-Drug
1	O
mg	O
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Disp	O
#	O
*	O
30	O
Tablet	O
Refills	O
:	O
*	O
0	O
2	O
.	O
Multivitamins	B-Drug
W	I-Drug
/	I-Drug
minerals	I-Drug
1	O
TAB	O
PO	O
DAILY	O
start	O
on	O
[	O
**	O
8	O
-	O
12	O
**	O
]	O
RX	O
*	O
multivitamin,tx	B-Drug
-	I-Drug
minerals	I-Drug
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Disp	O
#	O
*	O
30	O
Tablet	O
Refills	O
:	O
*	O
0	O
3	O
.	O
Thiamine	B-Drug
500	O
mg	O
IV	O
DAILY	O
Duration	O
:	O
3	O
Days	O
RX	O
*	O
thiamine	I-Drug
HCl	O
50	O
mg	O
1	O
tablet	O
(	O
s	O
)	O
by	O
mouth	O
daily	O
Disp	O
#	O
*	O
30	O
Tablet	O
Refills	O
:	O
*	O
0	O
4	O
.	O
Amlodipine	B-Drug
5	O
mg	O
PO	O
DAILY	O
5	O
.	O
Lorazepam	B-Drug
0.5	O
mg	O
PO	O
Q8H	O
:	O
PRN	O
anxiety	I-Reason
RX	O
*	O
lorazepam	I-Drug
0.5	O
mg	O
1	O
tablet	O
by	O
mouth	O
every	O
eight	O
hours	O
Disp	O
#	O
*	O
15	O
Tablet	O
Refills	O
:	O
*	O
0	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
DIAGNOSES	O
:	O
alcohol	O
withdarawal	O
benzodiazepine	I-Drug
intoxication	I-Ade
SECONDARY	O
DIAGNOSES	O
:	O
HTN	O
depression	O
/	O
anxiety	O
IBS	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
You	O
were	O
transferred	O
to	O
[	O
**	O
Hospital1	O
69	O
**	O
]	O
from	O
[	O
**	O
Hospital	O
1680	O
**	O
]	O
Hospital	O
for	O
concern	O
that	O
you	O
were	O
behaving	O
abnormally	O
.	O
You	O
were	O
treated	O
for	O
alcohol	B-Reason
withdrawal	I-Reason
,	O
which	O
may	O
have	O
contributed	O
to	O
your	O
symptoms	O
.	O
You	O
were	O
given	O
benzodiazepines	I-Drug
,	O
intravenous	O
fluid	I-Drug
and	O
vitamin	B-Drug
supplementation	I-Drug
.	O
During	O
this	O
hospitalization	O
,	O
you	O
returned	O
to	O
behaving	O
like	O
your	O
normal	O
self	O
.	O
You	O
were	O
seen	O
by	O
the	O
psychiatry	O
team	O
who	O
believe	O
that	O
your	O
abnormal	O
behavior	O
may	O
also	O
have	O
been	O
in	O
part	O
due	O
to	O
side	O
effects	O
from	O
the	O
medication	O
used	O
to	O
treat	O
your	O
alcohol	O
withdrawal	O
.	O
You	O
complained	O
of	O
anxiety	I-Reason
while	O
in	O
the	O
hospital	O
.	O
We	O
have	O
given	O
you	O
a	O
3	O
day	O
prescription	O
for	O
an	O
anti-anxiety	B-Drug
medication	I-Drug
to	O
treat	O
your	O
symptoms	O
until	O
you	O
can	O
see	O
your	O
primary	O
care	O
physician	O
who	O
will	O
take	O
over	O
management	O
of	O
your	O
anxiety	O
.	O
MEDICATION	O
CHANGES	O
:	O
START	O
-	O
lorazepam	I-Drug
(	O
Ativan	O
)	O
0.5	O
mg	O
by	O
mouth	O
as	O
needed	O
for	O
anxiety	I-Reason
,	O
up	O
to	O
one	O
every	O
8	O
hours	O
.	O
Followup	O
Instructions	O
:	O
Name	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
11182	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
NP	O
Location	O
:	O
[	O
**	O
Hospital1	O
**	O
]	O
FAMILY	O
PHYSICIANS	O
Address	O
:	O
[	O
**	O
Street	O
Address	O
(	O
2	O
)	O
89231	O
**	O
]	O
,	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
[	O
**	O
Numeric	O
Identifier	O
89232	O
**	O
]	O
Phone	O
:	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
39393	O
**	O
]	O
Appt	O
:	O
[	O
**	O
8	O
-	O
18	O
**	O
]	O
at	O
11:20	O
am	O
NOTE	O
:	O
This	O
appointment	O
is	O
with	O
a	O
member	O
of	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
??????	O
s	O
team	O
as	O
part	O
of	O
your	O
transition	O
from	O
the	O
hospital	O
back	O
to	O
your	O
primary	O
care	O
provider	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2185-5-11	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2185-5-25	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2120-1-12	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Heparin	I-Drug
Agents	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
613	O
**	O
]	O
Chief	O
Complaint	O
:	O
Right	O
lower	O
extremity	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1794	O
**	O
]	O
is	O
a	O
65	O
year	O
-	O
old	O
male	O
with	O
history	O
of	O
recent	O
hospitalization	O
for	O
bilateral	O
pulmonary	O
emboli	O
,	O
DVTs	O
,	O
and	O
spontaneous	O
intra-hepatic	O
hematoma	O
requiring	O
massive	O
transfusion	O
protocal	O
activation	O
sent	O
today	O
from	O
PCP	O
's	O
office	O
after	O
four	O
days	O
of	O
right	O
lower	O
extremity	O
pain	O
.	O
Patient	O
found	O
to	O
have	O
ultrasound	O
evidence	O
of	O
a	O
full	O
length	O
right	O
lower	O
extremtiy	O
DVT	O
.	O
.	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1794	O
**	O
]	O
was	O
admitted	O
from	O
[	O
**	O
2185-4-23	O
**	O
]	O
-	O
[	O
**	O
2185-5-1	O
**	O
]	O
for	O
left	O
sided	O
chest	O
pain	O
and	O
was	O
found	O
to	O
have	O
bilateral	B-Reason
PEs	I-Reason
.	O
Patient	O
was	O
initially	O
anticoagulated	I-Reason
with	O
heparin	I-Drug
,	O
which	O
was	O
transitioned	O
to	O
lovenox	I-Drug
and	O
warfarin	I-Drug
.	O
Patient	O
developed	O
abdominal	O
pain	O
and	O
was	O
found	O
on	O
CT	O
scan	O
to	O
have	O
an	O
intrahepatic	B-Reason
hematoma	I-Reason
with	I-Reason
extravasation	O
.	O
He	O
was	O
taken	O
to	O
IR	O
,	O
but	O
no	O
active	O
extravasation	O
was	O
discovered	O
and	O
nothing	O
was	O
embolized	O
.	O
He	O
received	O
4	O
units	O
PRBC	I-Drug
with	O
massive	O
transfusion	O
protocol	O
and	O
1	O
unit	O
platelets	I-Drug
.	O
He	O
received	O
additional	O
2	O
units	O
of	O
PRBC	I-Drug
on	O
day	O
1	O
of	O
MICU	O
stay	O
because	O
of	O
hypotension	I-Reason
,	O
which	O
was	O
attributed	O
to	O
hemorrhage	O
.	O
Transplant	O
surgery	O
was	O
consulted	O
and	O
recommended	O
conservative	O
management	O
of	O
intrahepatic	O
hematoma	O
.	O
MICU	O
course	O
was	O
complicated	O
by	O
hypoxic	O
respiratory	O
failure	O
requiring	O
intubation	O
.	O
As	O
anticoagulation	I-Drug
was	O
contra	O
-	O
indicated	O
given	O
bleed	O
,	O
IR	O
placed	O
IVC	O
filter	O
on	O
[	O
**	O
2185-4-25	O
**	O
]	O
.	O
Patient	O
was	O
discharged	O
on	O
no	O
anticoagulation	I-Drug
.	O
.	O
Today	O
patient	O
presented	O
to	O
his	O
primary	O
care	O
doctor	O
's	O
office	O
complaining	O
of	O
4	O
days	O
of	O
right	O
lower	O
extremity	O
pain	O
with	O
numbness	O
in	O
his	O
leg	O
and	O
loss	O
of	O
sensation	O
in	O
his	O
right	O
foot	O
.	O
The	O
pain	O
is	O
exacerbated	O
by	O
direct	O
pressure	O
on	O
his	O
foot	O
.	O
He	O
notes	O
pain	O
extending	O
from	O
his	O
mid	O
calf	O
until	O
the	O
top	O
of	O
his	O
thigh	O
.	O
.	O
Patient	O
was	O
sent	O
to	O
the	O
emergency	O
department	O
.	O
Initial	O
vitals	O
were	O
T	O
97.9	O
,	O
HR	O
116	O
,	O
BP	O
124/85	O
,	O
R	O
20	O
,	O
O2	I-Drug
Sat	O
98	O
%	O
on	O
4L	O
.	O
He	O
triggered	O
on	O
arrival	O
for	O
a	O
pulseless	O
right	O
foot	O
.	O
Initially	O
the	O
emergency	O
department	O
was	O
concerned	O
for	O
arterial	O
compromise	O
.	O
An	O
ultrasound	O
of	O
the	O
RLE	O
showed	O
evidence	O
of	O
a	O
full	B-Reason
RLE	I-Reason
DVT	I-Reason
.	O
Vascular	O
surgery	O
was	O
consulted	O
and	O
felt	O
that	O
the	O
limb	O
was	O
non-threatened	O
as	O
patient	O
had	O
palpable	O
right	O
femoral	O
,	O
popliteal	O
,	O
and	O
DP	O
pulses	O
and	O
recommended	O
anticoagulation	I-Drug
when	O
safe	O
,	O
elevation	O
of	O
RLE	O
,	O
and	O
ACE	O
wrap	O
.	O
.	O
In	O
ED	O
patient	O
also	O
complained	O
intermittent	O
,	O
vague	O
abdominal	O
pain	O
.	O
He	O
had	O
a	O
CT	O
Abdomen	O
/	O
Pelvis	O
showing	O
a	O
stable	O
liver	O
hematoma	O
.	O
The	O
CT	O
also	O
showed	O
the	O
IVC	O
filter	O
with	O
clot	O
extending	O
2.2	O
cm	O
above	O
the	O
filter	O
in	O
the	O
IVC	O
.	O
Patient	O
was	O
evaluated	O
by	O
transplant	O
surgery	O
who	O
felt	O
there	O
was	O
no	O
role	O
for	O
surgical	O
intervenstion	O
adn	O
the	O
risk	O
/	O
benefit	O
of	O
anticoagulation	I-Drug
in	O
the	O
setting	O
of	O
liver	O
hematoma	O
should	O
be	O
made	O
by	O
primary	O
team	O
.	O
Patient	O
received	O
no	O
medications	O
or	O
blood	I-Drug
.	O
He	O
received	O
1.5	O
L	O
of	O
IVF	I-Drug
.	O
On	O
transfer	O
vitals	O
were	O
T	O
100.1	O
,	O
HR	O
124	O
,	O
BP	O
138/98	O
,	O
RR	O
27	O
,	O
O2	O
sat	O
98RA	O
.	O
.	O
On	O
the	O
floor	O
,	O
patient	O
reports	O
that	O
he	O
has	O
leg	O
pain	O
from	O
his	O
right	O
mid-posterior	O
calf	O
extending	O
up	O
though	O
thigh	O
to	O
his	O
right	O
groin	O
.	O
He	O
has	O
some	O
mild	O
numbness	O
and	O
tingling	O
on	O
the	O
back	O
of	O
his	O
right	O
calf	O
.	O
He	O
denies	O
abdominal	O
pain	O
unless	O
someone	O
presses	O
down	O
on	O
his	O
abdomen	O
.	O
He	O
denies	O
chest	O
pain	O
,	O
dyspnea	O
,	O
lightheadedness	O
,	O
syncope	O
.	O
His	O
abdominal	O
pain	O
is	O
improved	O
from	O
his	O
last	O
admission	O
.	O
Patient	O
has	O
noted	O
recent	O
weight	O
loss	O
and	O
decreased	O
appetite	O
recently	O
.	O
Endorses	O
fatigue	O
and	O
weakness	O
.	O
.	O
Review	O
of	O
systems	O
:	O
(	O
+	O
)	O
Per	O
HPI	O
(	O
-	O
)	O
Denies	O
fever	O
,	O
chills	O
,	O
night	O
sweats	O
.	O
Denies	O
headache	O
,	O
sinus	O
tenderness	O
,	O
rhinorrhea	O
or	O
congestion	O
.	O
Denies	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
or	O
wheezing	O
.	O
Denies	O
chest	O
pain	O
,	O
chest	O
pressure	O
,	O
palpitations	O
.	O
Denies	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
abdominal	O
pain	O
,	O
or	O
changes	O
in	O
bowel	O
habits	O
.	O
Denies	O
BRBPR	O
,	O
melena	O
.	O
Denies	O
dysuria	O
,	O
frequency	O
,	O
or	O
urgency	O
.	O
Denies	O
arthralgias	O
or	O
myalgias	O
.	O
Denies	O
rashes	O
or	O
skin	O
changes	O
.	O
Past	O
Medical	O
History	O
:	O
b	O
/	O
l	O
Pulmonary	O
Emboli	O
Intra-hepatic	O
hematoma	O
[	O
**	O
Doctor	O
Last	O
Name	O
933	O
**	O
]	O
Disease	O
Dyslipidemia	O
Hypertension	O
Social	O
History	O
:	O
Married	O
,	O
lives	O
with	O
wife	O
.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
involved	O
in	O
care	O
Occupation	O
:	O
Retired	O
;	O
previously	O
worked	O
with	O
animals	O
and	O
livestock	O
;	O
denies	O
h	O
/	O
o	O
pesticide	O
exposure	O
or	O
factory	O
work	O
Tobacco	O
:	O
Denies	O
EtoH	O
:	O
Denies	O
Drugs	O
:	O
Denies	O
Family	O
History	O
:	O
No	O
history	O
of	O
clotting	O
disorders	O
No	O
history	O
malignancy	O
Physical	O
Exam	O
:	O
On	O
Admission	O
:	O
Vitals	O
:	O
T	O
:	O
99.6	O
BP	O
:	O
152/76	O
P	O
:	O
112	O
R	O
:	O
20	O
O2	O
:	O
96	O
%	O
on	O
RA	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
rales	O
,	O
ronchi	O
CV	O
:	O
Tachycardiac	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
,	O
no	O
heaves	O
or	O
lifts	O
Abdomen	O
:	O
soft	O
,	O
mild	O
right	O
upper	O
quadrant	O
and	O
right	O
lower	O
quadradant	O
tenderness	O
to	O
palpation	O
,	O
non-distended	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
,	O
?	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
no	O
foley	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
right	O
calf	O
larger	O
than	O
left	O
calf	O
,	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
+	O
DP	O
pulses	O
on	O
right	O
and	O
left	O
,	O
1	O
+	O
PT	O
pulses	O
,	O
no	O
palpable	O
cords	O
,	O
lower	O
extremity	O
sensation	O
intact	O
to	O
pinprick	O
and	O
light	O
touch	O
On	O
Discharge	O
:	O
Tc	O
+	O
Tm	O
99.6	O
,	O
BP	O
108/86	O
(	O
108-120/70	O
-	O
86	O
)	O
,	O
HR	O
107	O
(	O
96	O
-	O
112	O
)	O
,	O
98	O
%	O
RA	O
(	O
98	O
-	O
100	O
%	O
RA	O
)	O
General	O
:	O
Alert	O
,	O
oriented	O
,	O
no	O
acute	O
distress	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
MMM	O
,	O
oropharynx	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
not	O
elevated	O
,	O
no	O
LAD	O
Lungs	O
:	O
Clear	O
to	O
auscultation	O
bilaterally	O
,	O
no	O
wheezes	O
,	O
few	O
basilar	O
rales	O
,	O
ronchi	O
CV	O
:	O
Tachycardiac	O
,	O
normal	O
S1	O
+	O
S2	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
,	O
no	O
heaves	O
or	O
lifts	O
Abdomen	O
:	O
no	O
TTP	O
in	O
RUQ	O
or	O
throughout	O
abdomen	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
right	O
calf	O
in	O
ace	O
bandage	O
,	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
+	O
DP	O
pulses	O
on	O
right	O
and	O
left	O
,	O
1	O
+	O
PT	O
pulses	O
,	O
no	O
palpable	O
cords	O
,	O
lower	O
extremity	O
sensation	O
intact	O
to	O
light	O
touch	O
Pertinent	O
Results	O
:	O
Admission	O
labs	O
:	O
[	O
**	O
2185-5-11	O
**	O
]	O
07:30	O
PM	O
BLOOD	O
WBC	O
-	O
10.8	O
RBC	O
-	O
3.79	O
*	O
Hgb	O
-	O
11.6	O
*	O
Hct	O
-	O
32.4	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
30.6	O
MCHC	O
-	O
35.9	O
*	O
RDW	O
-	O
14.4	O
Plt	O
Ct	O
-	O
247	O
[	O
**	O
2185-5-11	O
**	O
]	O
07:30	O
PM	O
BLOOD	O
Neuts	O
-	O
88.4	O
*	O
Lymphs	O
-	O
7.2	O
*	O
Monos	O
-	O
3.9	O
Eos	O
-	O
0.2	O
Baso	O
-	O
0.3	O
[	O
**	O
2185-5-11	O
**	O
]	O
07:30	O
PM	O
BLOOD	O
PT	O
-	O
13.9	O
*	O
PTT	O
-	O
24.7	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2185-5-11	O
**	O
]	O
07:30	O
PM	O
BLOOD	O
Glucose	O
-	O
122	O
*	O
UreaN	O
-	O
20	O
Creat	O
-	O
1.0	O
Na	O
-	O
133	O
K	O
-	O
4.5	O
Cl	O
-	O
99	O
HCO3	O
-	O
22	O
AnGap	O
-	O
17	O
RLE	O
Ultrasound	O
:	O
IMPRESSION	O
:	O
Vein	O
thrombosis	O
seen	O
throughout	O
the	O
entire	O
extent	O
of	O
the	O
right	O
lower	O
extremity	O
.	O
Dampened	O
waveforms	O
in	O
contralateral	O
left	O
common	O
femoral	O
vein	O
are	O
suggestive	O
of	O
more	O
proximal	O
thrombosis	O
.	O
CTA	O
Aorta	O
,	O
Bifem	O
,	O
Iliac	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Patent	O
three	O
-	O
vessel	O
runoff	O
.	O
2	O
.	O
Findings	O
in	O
the	O
abdomen	O
and	O
pelvis	O
,	O
including	O
subcapsular	O
liver	O
hematoma	O
and	O
IVC	O
thrombus	O
extending	O
into	O
the	O
right	O
common	O
iliac	O
,	O
external	O
iliac	O
,	O
and	O
likely	O
common	O
femoral	O
veins	O
as	O
well	O
as	O
possibly	O
into	O
the	O
left	O
common	O
iliac	O
vein	O
,	O
better	O
assessed	O
on	O
CT	O
abdomen	O
/	O
pelvis	O
performed	O
just	O
prior	O
to	O
this	O
,	O
on	O
[	O
**	O
2185-5-11	O
**	O
]	O
at	O
21:50	O
,	O
see	O
that	O
report	O
.	O
3	O
.	O
Apparent	O
diffuse	O
wall	O
thickening	O
of	O
the	O
urinary	O
bladder	O
may	O
relate	O
to	O
its	O
underdistension	O
,	O
however	O
,	O
recommend	O
correlation	O
with	O
urinalysis	O
to	O
exclude	O
underlying	O
infection	O
.	O
4	O
.	O
Enlarged	O
prostate	O
gland	O
;	O
recommend	O
correlation	O
with	O
serum	O
PSA	O
if	O
this	O
has	O
not	O
already	O
been	O
performed	O
.	O
CT	O
Abdomen	O
/	O
Pelvis	O
:	O
IMPRESSION	O
:	O
1	O
.	O
17	O
x	O
19	O
x	O
6	O
cm	O
subcapsular	O
liver	O
hematoma	O
,	O
which	O
appears	O
stable	O
compared	O
to	O
the	O
[	O
**	O
Month	O
(	O
only	O
)	O
547	O
**	O
]	O
examination	O
.	O
Active	O
extravasation	O
does	O
not	O
appear	O
present	O
,	O
but	O
is	O
limited	O
on	O
this	O
single	O
-	O
phase	O
study	O
.	O
2	O
.	O
IVC	O
filter	O
with	O
a	O
clot	O
extending	O
cephalad	O
2.2	O
cm	O
above	O
the	O
top	O
of	O
the	O
filter	O
.	O
However	O
,	O
thrombus	O
does	O
not	O
extend	O
into	O
the	O
renal	O
veins	O
.	O
Occlusive	O
thrombus	O
into	O
the	O
right	O
common	O
iliac	O
internal	O
and	O
external	O
iliacs	O
and	O
common	O
femoral	O
vein	O
.	O
There	O
may	O
be	O
partially	O
occlusive	O
thrombus	O
in	O
the	O
left	O
common	O
iliac	O
.	O
Labs	O
on	O
Discharge	O
:	O
[	O
**	O
2185-5-25	O
**	O
]	O
08:32	O
AM	O
BLOOD	O
WBC	O
-	O
8.6	O
RBC	O
-	O
4.02	O
*	O
Hgb	O
-	O
11.1	O
*	O
Hct	O
-	O
34.0	O
*	O
MCV	O
-	O
85	O
MCH	O
-	O
27.7	O
MCHC	O
-	O
32.7	O
RDW	O
-	O
15.5	O
Plt	O
Ct	O
-	O
460	O
*	O
[	O
**	O
2185-5-19	O
**	O
]	O
06:35	O
AM	O
BLOOD	O
Glucose	O
-	O
87	O
UreaN	O
-	O
19	O
Creat	O
-	O
1.1	O
Na	O
-	O
135	O
K	O
-	O
4.9	O
Cl	O
-	O
101	O
HCO3	O
-	O
24	O
AnGap	O
-	O
15	O
[	O
**	O
2185-5-20	O
**	O
]	O
06:30	O
AM	O
BLOOD	O
LD	O
(	O
LDH	O
)	O
-	O
798	O
*	O
[	O
**	O
2185-5-19	O
**	O
]	O
06:35	O
AM	O
BLOOD	O
Calcium	O
-	O
8.4	O
Phos	O
-	O
2.7	O
Mg	O
-	O
2.4	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1794	O
**	O
]	O
is	O
a	O
65	O
year	O
-	O
old	O
man	O
with	O
h	O
/	O
o	O
recent	O
hospitalization	O
and	O
MICU	O
stay	O
for	O
bilateral	O
pulmonary	O
embolism	O
complicated	O
by	O
spontaneous	O
intra-hepatic	O
hemorrhage	O
presenting	O
on	O
this	O
admission	O
with	O
RLE	O
pain	O
and	O
numbness	O
found	O
to	O
have	O
full	O
length	O
RLE	O
DVT	O
.	O
.	O
#	O
Right	B-Reason
Lower	I-Reason
Extremity	I-Reason
DVT	I-Reason
:	O
Patient	O
with	O
history	O
of	O
recent	O
b	O
/	O
l	O
PE	O
,	O
complicated	O
by	O
intra-hepatic	O
hematoma	O
on	O
anticoagulation	I-Drug
.	O
Patient	O
discharged	O
home	O
on	O
recent	O
prior	O
admission	O
with	O
IVC	O
filter	O
,	O
not	O
on	O
anticoagulation	O
.	O
On	O
this	O
admission	O
,	O
patient	O
found	O
to	O
have	O
a	O
large	O
RLE	O
DVT	O
.	O
Patient	O
with	O
palpable	O
peripheral	O
pulses	O
bilaterally	O
.	O
Evaluated	O
by	O
vascular	O
surgery	O
in	O
ED	O
,	O
who	O
felt	O
that	O
his	O
RLE	O
was	O
non-threatened	O
and	O
no	O
surgical	O
intervention	O
was	O
required	O
.	O
Given	O
the	O
risk	O
of	O
extension	O
of	O
DVT	I-Reason
to	O
the	O
point	O
where	O
vascular	O
compromise	O
could	O
be	O
reached	O
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
further	O
extending	O
PEs	O
,	O
we	O
cautiously	O
anticoagulated	I-Drug
the	O
patient	O
with	O
careful	O
monitoring	O
for	O
fear	O
that	O
the	O
pt	O
would	O
patient	O
have	O
another	O
hepatic	O
bleed	O
.	O
Patient	O
was	O
admitted	O
to	O
ICU	O
and	O
anticoagulation	I-Reason
was	O
started	O
with	O
heparin	I-Drug
gtt	O
with	O
goal	O
of	O
60	O
-	O
80	O
.	O
Patient	O
reached	O
the	O
therapeutic	O
level	O
and	O
his	O
HCT	O
remained	O
stable	O
.	O
Serial	O
vascular	O
exams	O
were	O
stable	O
.	O
The	O
RLE	O
was	O
elevated	O
and	O
wrapped	O
in	O
ACE	O
.	O
He	O
was	O
then	O
sent	O
to	O
the	O
regular	O
medicine	O
floor	O
.	O
However	O
,	O
unfortunately	O
he	O
then	O
had	O
his	O
platelets	O
drop	O
,	O
and	O
was	O
found	O
to	O
have	O
heparin	I-Drug
induced	O
thrombocytopenia	I-Ade
(	O
see	O
below	O
)	O
,	O
and	O
was	O
transitioned	O
to	O
argatroban	I-Drug
for	O
his	O
DVT	I-Reason
.	O
He	O
was	O
then	O
transitioned	O
to	O
coumadin	I-Drug
prior	O
to	O
D	O
/	O
C.	O
His	O
INR	O
was	O
4.0	O
on	O
day	O
of	O
discharge	O
,	O
and	O
he	O
was	O
instructed	O
to	O
follow	O
up	O
with	O
his	O
PCP	O
for	O
further	O
monitoring	O
of	O
his	O
INR	O
with	O
a	O
goal	O
of	O
between	O
[	O
**	O
2	O
-	O
3	O
**	O
]	O
.	O
.	O
#	O
Heparin	I-Drug
Induced	O
Thrombocytopenia	I-Ade
:	O
Patient	O
's	O
platelets	O
dropped	O
from	O
247	O
on	O
[	O
**	O
5	O
-	O
11	O
**	O
]	O
to	O
118	O
on	O
[	O
**	O
2185-5-14	O
**	O
]	O
,	O
which	O
normally	O
would	O
not	O
fit	O
with	O
the	O
traditional	O
window	O
for	O
HIT	I-Ade
,	O
but	O
pt	O
had	O
received	O
heparin	I-Drug
on	O
his	O
prior	O
admission	O
also	O
.	O
Hematology	O
was	O
consulted	O
,	O
and	O
recommended	O
switching	O
to	O
argatroban	I-Drug
,	O
which	O
we	O
did	O
.	O
Patient	O
's	O
PF4	O
test	O
was	O
sent	O
,	O
and	O
returned	O
with	O
an	O
optical	O
density	O
of	O
2.7	O
,	O
so	O
the	O
lab	O
cancelled	O
our	O
serotonin	O
release	O
assay	O
as	O
the	O
PF4	O
was	O
considered	O
positive	O
enough	O
.	O
Patient	O
was	O
instructed	O
to	O
get	O
a	O
heparin	I-Drug
allergy	O
bracelet	O
with	O
help	O
from	O
his	O
PCP	O
.	O
.	O
#	O
Recent	O
subcapsular	O
hepatic	O
bleed	O
:	O
Patient	O
with	O
recent	O
ICU	O
stay	O
requiring	O
massive	O
transfusion	O
protocol	O
following	O
spontaneous	O
subcapsular	B-Ade
hepatic	I-Ade
bleed	I-Ade
while	O
on	O
anticoagulation	I-Drug
.	O
Patient	O
discharged	O
home	O
from	O
prior	O
admission	O
on	O
no	O
anti-coagulation	O
.	O
For	O
this	O
admission	O
,	O
imaging	O
showed	O
that	O
his	O
liver	O
hematoma	O
had	O
a	O
stable	O
appearance	O
.	O
Surgery	O
was	O
consulted	O
in	O
the	O
ED	O
and	O
recommended	O
no	O
surgical	O
intervention	O
at	O
this	O
time	O
.	O
Surgery	O
recommended	O
supportive	O
care	O
should	O
the	O
bleed	O
recur	O
,	O
but	O
patient	O
remained	O
with	O
stable	O
VSs	O
and	O
no	O
RUQ	O
abdominal	O
pain	O
.	O
.	O
#	O
Bilateral	O
pulmonary	O
embolism	O
:	O
Patient	O
initially	O
presented	O
with	O
left	O
sided	O
chest	O
and	O
flank	O
pain	O
when	O
admitted	O
in	O
[	O
**	O
2185-4-1	O
**	O
]	O
.	O
The	O
etiology	O
of	O
emboli	O
is	O
unclear	O
-	O
patient	O
was	O
discharged	O
with	O
plan	O
for	O
outpatient	O
hypercoagulable	O
work	O
-	O
up	O
.	O
Patient	O
discharged	O
with	O
IVC	O
filter	O
,	O
not	O
on	O
anti-coagulation	I-Drug
.	O
Concern	O
for	O
extension	O
of	O
pulmonary	O
embolism	O
on	O
this	O
admission	O
as	O
clot	O
extended	O
proximally	O
above	O
IVC	O
filter	O
.	O
Patient	O
remained	O
mildly	O
tachycardiac	O
throughout	O
the	O
admission	O
,	O
but	O
not	O
hypoxic	O
,	O
dyspnic	O
,	O
and	O
did	O
not	O
have	O
chest	O
pain	O
.	O
Patient	O
's	O
PE	B-Reason
's	I-Reason
were	O
treated	O
with	O
argatroban	I-Drug
when	O
his	O
DVT	I-Reason
was	O
treated	O
with	O
argatroban	I-Drug
.	O
HIT	O
may	O
have	O
contributed	O
to	O
extension	O
of	O
clots	O
above	O
IVC	O
filter	O
.	O
Patient	O
will	O
need	O
outpatient	O
anticoagulation	I-Drug
w	O
/	O
u	O
,	O
but	O
this	O
is	O
complicated	O
by	O
the	O
fact	O
that	O
he	O
is	O
now	O
on	O
coumadin	I-Drug
for	O
at	O
least	O
6	O
months	O
.	O
.	O
#	O
h	O
/	O
o	O
[	O
**	O
Doctor	O
Last	O
Name	O
933	O
**	O
]	O
disease	O
:	O
Previously	O
followed	O
by	O
Endocrine	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
Per	O
patient	O
not	O
receiving	O
any	O
treatment	O
.	O
Denies	O
symptoms	O
or	O
hyper	O
/	O
hypothyroid	O
at	O
this	O
time	O
.	O
TSH	O
was	O
wnl	O
therefore	O
no	O
intervention	O
undertaken	O
.	O
.	O
#	O
Hypertension	I-Reason
:	O
Patient	O
with	O
history	O
of	O
hypertension	O
,	O
and	O
was	O
hypertensive	O
on	O
admission	O
.	O
Patient	O
had	O
not	O
been	O
taking	O
lisinopril	I-Drug
since	O
discharge	O
.	O
Lisinopril	I-Drug
was	O
held	O
in	O
the	O
ICU	O
while	O
anticoagulating	I-Drug
given	O
bleeding	O
risk	O
,	O
and	O
patient	O
remained	O
normotensive	O
there	O
as	O
well	O
as	O
when	O
transferred	O
to	O
the	O
floor	O
.	O
Therefore	O
,	O
we	O
did	O
not	O
restart	O
pt	O
's	O
lisinopril	I-Drug
at	O
dispo	O
and	O
instructed	O
him	O
to	O
f	O
/	O
u	O
with	O
his	O
PCP	O
.	O
.	O
#	O
Dyslipidemia	I-Reason
:	O
Simvastatin	I-Drug
10	O
mg	O
qhs	O
held	O
after	O
last	O
admission	O
as	O
patient	O
had	O
transaminitis	O
likely	O
[	O
**	O
2	O
-	O
2	O
**	O
]	O
subcapsular	O
liver	O
bleed	O
.	O
LFTs	O
were	O
wnl	O
.	O
Therefore	O
we	O
restarted	O
simvastatin	I-Drug
on	O
this	O
admission	O
.	O
.	O
#	O
Code	O
:	O
Full	O
(	O
discussed	O
with	O
patient	O
)	O
PENDING	O
LABS	O
:	O
None	O
TRANSITIONAL	O
CARE	O
ISSUES	O
:	O
Patient	O
will	O
need	O
his	O
INR	O
monitored	O
frequently	O
until	O
he	O
is	O
stably	O
threapeutic	O
between	O
2	O
and	O
3	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
,	O
his	O
new	O
PCP	O
was	O
[	O
**	O
Name	O
(	O
NI	O
)	O
653	O
**	O
]	O
and	O
his	O
office	O
agreed	O
to	O
follow	O
pt	O
's	O
INR	O
.	O
Medications	O
on	O
Admission	O
:	O
None	O
per	O
pt	O
Discharge	O
Medications	O
:	O
1	O
.	O
docusate	I-Drug
sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
2	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
3	O
.	O
warfarin	I-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
Four	O
(	O
4	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
:	O
On	O
[	O
**	O
5	O
-	O
25	O
**	O
]	O
ONLY	O
take	O
7.5	O
mg	O
(	O
3	O
tabs	O
)	O
,	O
then	O
start	O
this	O
medication	O
dose	O
(	O
10	O
mg	O
per	O
day	O
)	O
on	O
[	O
**	O
5	O
-	O
26	O
**	O
]	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
simvastatin	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
Uphams	O
Corner	O
Home	O
Care	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
right	B-Reason
lower	I-Reason
extremity	I-Reason
DVT	I-Reason
,	O
heparin	I-Drug
-	O
induced	O
thrombocytopenia	I-Ade
Secondary	O
:	O
Pulmonay	O
embolism	O
,	O
Hypertension	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
Independent	O
.	O
Discharge	O
Instructions	O
:	O
Dear	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1794	O
**	O
]	O
,	O
You	O
were	O
seen	O
in	O
the	O
hospital	O
for	O
a	O
blood	B-Reason
clot	I-Reason
in	I-Reason
your	I-Reason
leg	I-Reason
.	O
While	O
you	O
were	O
here	O
,	O
it	O
was	O
determined	O
that	O
you	O
have	O
an	O
allergy	O
to	O
heparin	I-Drug
.	O
You	O
should	O
never	O
be	O
given	O
heparin	I-Drug
in	O
the	O
future	O
.	O
Please	O
arrange	O
with	O
your	O
PCP	O
to	O
have	O
an	O
allergy	O
bracelet	O
made	O
so	O
that	O
you	O
are	O
n't	O
given	O
heparin	I-Drug
.	O
You	O
were	O
put	O
on	O
an	O
oral	O
blood	I-Reason
thinner	O
called	O
coumadin	I-Drug
,	O
that	O
you	O
will	O
have	O
to	O
continue	O
to	O
take	O
once	O
a	O
day	O
until	O
your	O
doctors	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
[	O
**	O
Name5	O
(	O
PTitle	O
)	O
**	O
]	O
to	O
stop	O
taking	O
it	O
.	O
We	O
made	O
the	O
following	O
changes	O
to	O
your	O
medications	O
:	O
1	O
)	O
We	O
STARTED	O
you	O
on	O
COUMADIN	I-Drug
(	O
WARFARIN	O
)	O
.	O
You	O
will	O
take	O
7.5	O
mg	O
on	O
[	O
**	O
5	O
-	O
25	O
**	O
]	O
,	O
then	O
take	O
10	O
mg	O
once	O
per	O
day	O
starting	O
on	O
[	O
**	O
5	O
-	O
26	O
**	O
]	O
until	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
tells	O
you	O
to	O
change	O
to	O
a	O
different	O
dose	O
.	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
will	O
follow	O
your	O
coumadin	I-Drug
levels	O
and	O
adjust	O
your	O
dose	O
of	O
coumadin	I-Drug
as	O
needed	O
.	O
If	O
you	O
have	O
any	O
questions	O
,	O
you	O
should	O
call	O
him	O
.	O
2	O
)	O
We	O
STOPPED	O
your	O
LISINOPRIL	I-Drug
because	O
your	O
blood	O
pressure	O
is	O
already	O
well	O
controlled	O
on	O
no	O
anti-hypertensive	B-Drug
medications	I-Drug
.	O
Your	O
PCP	O
may	O
tell	O
you	O
to	O
restart	O
this	O
medication	O
at	O
some	O
point	O
.	O
If	O
you	O
experience	O
any	O
of	O
the	O
below	O
listed	O
Danger	O
Signs	O
,	O
or	O
any	O
other	O
new	O
symptom	O
,	O
please	O
call	O
your	O
doctor	O
or	O
go	O
to	O
the	O
nearest	O
Emergency	O
Room	O
.	O
It	O
was	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
[	O
**	O
Hospital1	O
7975	O
**	O
]	O
INTERNAL	O
MEDICINE	O
When	O
:	O
FRIDAY	O
[	O
**	O
2185-5-27	O
**	O
]	O
at	O
11:15	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
7978	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
7976	O
**	O
]	O
Building	O
:	O
[	O
**	O
Hospital1	O
7977	O
**	O
]	O
(	O
[	O
**	O
Location	O
(	O
un	O
)	O
686	O
**	O
]	O
,	O
MA	O
)	O
[	O
**	O
Location	O
(	O
un	O
)	O
**	O
]	O
Campus	O
:	O
OFF	O
CAMPUS	O
Best	O
Parking	O
:	O
Free	O
Parking	O
on	O
Site	O
Department	O
:	O
HEMATOLOGY	O
/	O
ONCOLOGY	O
When	O
:	O
FRIDAY	O
[	O
**	O
2185-7-8	O
**	O
]	O
at	O
10:00	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
1730	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
5056	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
22	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
24	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
[	O
**	O
First	O
Name5	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
617	O
**	O
]	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
1156	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
[	O
**	O
Doctor	O
First	O
Name	O
1157	O
**	O
]	O
Unit	O
No	O
:	O
[	O
**	O
Numeric	O
Identifier	O
1158	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2128-6-22	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2128-6-25	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2046-8-19	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MED	O
Allergies	O
:	O
Patient	O
recorded	O
as	O
having	O
No	O
Known	O
Allergies	O
to	O
Drugs	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1159	O
**	O
]	O
Chief	O
Complaint	O
:	O
see	O
original	O
note	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
see	O
original	O
note	O
History	O
of	O
Present	O
Illness	O
:	O
see	O
original	O
note	O
Past	O
Medical	O
History	O
:	O
see	O
original	O
note	O
Social	O
History	O
:	O
see	O
original	O
note	O
Family	O
History	O
:	O
see	O
original	O
note	O
Physical	O
Exam	O
:	O
see	O
original	O
note	O
Pertinent	O
Results	O
:	O
see	O
original	O
note	O
Brief	O
Hospital	O
Course	O
:	O
The	O
patient	O
was	O
discharged	O
with	O
12	O
more	O
days	O
of	O
amoxcillin	I-Drug
/	O
clarithromycin	I-Drug
/	O
protonix	I-Drug
for	O
total	O
course	O
of	O
14	O
days	O
for	O
treatment	B-Reason
of	I-Reason
positive	I-Reason
H.	I-Reason
pylori	I-Reason
.	O
Medications	O
on	O
Admission	O
:	O
see	O
original	O
note	O
Discharge	O
Medications	O
:	O
see	O
original	O
note	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Hospital6	O
313	O
**	O
]	O
,	O
[	O
**	O
Location	O
(	O
un	O
)	O
42	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
GI	O
ulcer	O
/	O
bleed	O
glaucoma	O
Discharge	O
Condition	O
:	O
stable	O
and	O
recovering	O
Discharge	O
Instructions	O
:	O
Please	O
be	O
sure	O
to	O
take	O
your	O
full	O
course	O
of	O
medications	O
as	O
directed	O
.	O
You	O
should	O
call	O
911	O
or	O
return	O
to	O
emergency	O
room	O
if	O
you	O
experience	O
dizziness	O
,	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
black	O
/	O
bloody	O
stool	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1160	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
1161	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2128-6-25	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2148-8-16	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2148-8-21	O
**	O
]	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Dicloxacillin	I-Drug
/	O
Beta	B-Drug
-	I-Drug
Blockers	I-Drug
(	I-Drug
Beta	I-Drug
-	I-Drug
Adrenergic	I-Drug
Blocking	I-Drug
Agts	I-Drug
)	I-Drug
/	O
Shellfish	O
/	O
Aspirin	I-Drug
/	O
Epinephrine	I-Drug
/	O
Cefaclor	I-Drug
/	O
Neomycin	I-Drug
/	O
clindamycin	I-Drug
/	O
Bacitracin	I-Drug
/	O
Clavulanic	B-Drug
Acid	I-Drug
/	O
Latex	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2712	O
**	O
]	O
Chief	O
Complaint	O
:	O
Chief	O
Complaint	O
:	O
s	O
/	O
p	O
fall	O
,	O
hypoxia	O
,	O
agitation	O
.	O
Reason	O
for	O
MICU	O
Admission	O
:	O
hypoxia	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
staples	O
to	O
repair	O
right	O
forehead	O
laceration	O
History	O
of	O
Present	O
Illness	O
:	O
This	O
is	O
a	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
female	O
with	O
history	O
of	O
diastolic	O
CHF	O
,	O
COPD	O
,	O
?	O
dementia	O
who	O
presents	O
from	O
[	O
**	O
Hospital1	O
1501	O
**	O
]	O
s	O
/	O
p	O
fall	O
.	O
Patient	O
was	O
overtly	O
delirious	O
on	O
admission	O
and	O
unable	O
to	O
provide	O
history	O
.	O
Information	O
was	O
obtained	O
from	O
records	O
provided	O
.	O
.	O
Apparently	O
patient	O
was	O
found	O
on	O
floor	O
today	O
with	O
head	O
laceration	O
,	O
and	O
it	O
is	O
unknown	O
if	O
LOC	O
occurred	O
.	O
She	O
was	O
noted	O
to	O
be	O
anxious	O
and	O
agitated	O
.	O
According	O
to	O
HCP	O
,	O
patient	O
[	O
**	O
Name2	O
(	O
NI	O
)	O
102738	O
**	O
]	O
becomes	O
hypoxic	O
when	O
she	O
becomes	O
agitated	O
.	O
Given	O
fall	O
patient	O
was	O
sent	O
to	O
ED	O
for	O
further	O
evaluation	O
.	O
.	O
In	O
the	O
ED	O
,	O
initial	O
vs	O
were	O
:	O
90152/90	O
24	O
92	O
%	O
4L	O
Nasal	O
Cannula	O
.	O
Pt	O
initially	O
was	O
very	O
agitated	I-Reason
and	O
was	O
given	O
haldol	I-Drug
5	O
mg	O
x	O
2	O
,	O
as	O
well	O
as	O
lorazepam	I-Drug
2	O
mg	O
x	O
1	O
.	O
Primary	O
trauma	O
survey	O
was	O
unremarkable	O
.	O
CXR	O
was	O
significant	O
for	O
bilateral	O
pleural	O
effusions	O
and	O
possible	O
evidence	O
of	O
pneumonia	O
.	O
CT	O
of	O
head	O
and	O
C	O
-	O
spine	O
was	O
limited	O
,	O
but	O
patient	O
was	O
cleared	O
.	O
Patient	O
was	O
given	O
vancomycin	I-Drug
and	O
levofloxacin	I-Drug
for	O
HCAP	B-Reason
coverage	I-Reason
and	O
was	O
also	O
given	O
methylprednisolone	I-Drug
125	O
mg	O
x1	O
for	O
COPD	B-Reason
exacerbation	I-Reason
.	O
She	O
also	O
received	O
lasix	I-Drug
40	O
mg	O
IV	O
x	O
1	O
,	O
producing	O
about	O
250	O
mL	O
urine	O
.	O
The	O
patient	O
's	O
laceration	O
was	O
repaired	O
.	O
Tetanus	O
shot	O
was	O
given	O
to	O
patient	O
.	O
According	O
to	O
ED	O
signout	O
,	O
patient	O
became	O
more	O
hypoxic	O
to	O
70s	O
while	O
agitated	O
and	O
was	O
placed	O
on	O
NRB	O
with	O
recovery	O
of	O
sats	O
to	O
low	O
90s	O
.	O
Attempts	O
were	O
made	O
to	O
place	O
patient	O
on	O
BiPAP	O
however	O
the	O
patient	O
did	O
not	O
tolerate	O
this	O
intervention	O
.	O
VS	O
prior	O
to	O
transfer	O
were	O
VS	O
:	O
96.5	O
,	O
91	O
,	O
157/114	O
,	O
30	O
,	O
100	O
%	O
NRB	O
.	O
Patient	O
was	O
placed	O
on	O
4	O
point	O
restraints	O
prior	O
to	O
transfer	O
.	O
.	O
On	O
arrival	O
to	O
the	O
ICU	O
,	O
patient	O
continued	O
to	O
be	O
agitated	O
and	O
immediately	O
required	O
another	O
0.5	O
mg	O
lorazepam	I-Drug
IV	O
x	O
2	O
.	O
She	O
presented	O
on	O
non-rebreather	O
and	O
was	O
unable	O
to	O
answer	O
questions	O
.	O
.	O
Review	O
of	O
systems	O
:	O
Unable	O
to	O
obtain	O
due	O
to	O
agitation	O
Past	O
Medical	O
History	O
:	O
COPD	O
Diastolic	O
congestive	O
heart	O
failure	O
Hypertension	O
Hyperlipidemia	O
Obstructive	O
sleep	O
apnea	O
GERD	O
Anemia	O
Monoclonal	O
gammopathy	O
Gait	O
disturbance	O
Atrial	O
fibrillation	O
(	O
not	O
on	O
anticoagulation	O
)	O
h	O
/	O
o	O
Subdural	O
hematoma	O
s	O
/	O
p	O
fall	O
Restless	O
leg	O
syndrome	O
Hypothyroidism	O
Depression	O
/	O
anxiety	O
Basal	O
cell	O
carcinoma	O
of	O
bilateral	O
lower	O
legs	O
s	O
/	O
p	O
radiation	O
therapy	O
Dry	O
macular	O
degeneration	O
Multiple	O
falls	O
c	O
/	O
b	O
fractured	O
nose	O
,	O
left	O
rib	O
fractures	O
Umbilical	O
hernia	O
s	O
/	O
p	O
Appendectomy	O
s	O
/	O
p	O
TAH	O
/	O
BSO	O
Social	O
History	O
:	O
Ambulates	O
with	O
walker	O
with	O
assitance	O
.	O
Family	O
History	O
:	O
unable	O
to	O
obtain	O
Physical	O
Exam	O
:	O
Admission	O
Exam	O
:	O
Vitals	O
:	O
T	O
96.9	O
P	O
90	O
BP	O
144/60	O
R	O
30	O
Sat	O
99	O
%	O
on	O
NRB	O
General	O
:	O
Elderly	O
woman	O
,	O
agitated	O
,	O
appears	O
uncomfortable	O
,	O
using	O
accessory	O
muscles	O
to	O
breathe	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
left	O
eye	O
with	O
edema	O
and	O
conjunctivae	O
diffusely	O
erythematous	O
,	O
MMM	O
,	O
oropharynx	O
appears	O
clear	O
Neck	O
:	O
supple	O
,	O
JVP	O
difficult	O
to	O
assess	O
given	O
agitation	O
and	O
use	O
of	O
accessory	O
muscles	O
to	O
breathe	O
,	O
no	O
LAD	O
Lungs	O
:	O
rhonchorous	O
sounds	O
and	O
rales	O
bilaterally	O
on	O
anterior	O
exam	O
,	O
no	O
wheezes	O
audible	O
,	O
using	O
neck	O
and	O
abdominal	O
muscles	O
to	O
breathe	O
CV	O
:	O
irregular	O
rhythm	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
audible	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
umbilical	O
hernia	O
present	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
GU	O
:	O
foley	O
catheter	O
in	O
place	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
trace	O
edema	O
bilaterally	O
.	O
Discharge	O
Exam	O
T	O
98.7	O
,	O
HR	O
92	O
,	O
BP	O
122/52	O
,	O
RR	O
24	O
,	O
sat	O
89	O
%	O
on	O
2L	O
General	O
:	O
Elderly	O
woman	O
,	O
sitting	O
up	O
in	O
chair	O
.	O
Alert	O
,	O
talkative	O
,	O
appropriate	O
HEENT	O
:	O
Sclera	O
anicteric	O
,	O
left	O
eye	O
with	O
edema	O
and	O
conjunctivae	O
diffusely	O
erythematous	O
,	O
MMM	O
,	O
oropharynx	O
appears	O
clear	O
Lungs	O
:	O
Bibasilar	O
crackles	O
,	O
no	O
wheezes	O
audible	O
CV	O
:	O
irregular	O
rhythm	O
,	O
no	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
audible	O
Abdomen	O
:	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
umbilical	O
hernia	O
present	O
,	O
bowel	O
sounds	O
present	O
,	O
no	O
rebound	O
tenderness	O
or	O
guarding	O
,	O
no	O
organomegaly	O
Ext	O
:	O
warm	O
,	O
well	O
perfused	O
,	O
2	O
+	O
pulses	O
,	O
trace	O
edema	O
bilaterally	O
Pertinent	O
Results	O
:	O
Admission	O
Labs	O
:	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
WBC	O
-	O
8.7	O
#	O
RBC	O
-	O
3.19	O
*	O
Hgb	O
-	O
10.9	O
*	O
Hct	O
-	O
33.8	O
*	O
MCV	O
-	O
106	O
*	O
MCH	O
-	O
34.2	O
*	O
MCHC	O
-	O
32.3	O
RDW	O
-	O
19.4	O
*	O
Plt	O
Ct	O
-	O
326	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
Neuts	O
-	O
86.8	O
*	O
Lymphs	O
-	O
7.2	O
*	O
Monos	O
-	O
3.3	O
Eos	O
-	O
1.4	O
Baso	O
-	O
1.3	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
PT	O
-	O
12.6	O
PTT	O
-	O
22.7	O
INR	O
(	O
PT	O
)	O
-	O
1.1	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
Fibrino	O
-	O
342	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
Glucose	O
-	O
110	O
*	O
UreaN	O
-	O
33	O
*	O
Creat	O
-	O
0.9	O
Na	O
-	O
144	O
K	O
-	O
5.2	O
*	O
Cl	O
-	O
102	O
HCO3	O
-	O
36	O
*	O
AnGap	O
-	O
11	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
3	O
proBNP	O
-	O
5091	O
*	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
cTropnT	O
-	O
0.02	O
*	O
[	O
**	O
2148-8-16	O
**	O
]	O
06:18	O
PM	O
BLOOD	O
ASA	O
-	O
NEG	O
Ethanol	O
-	O
NEG	O
Acetmnp	O
-	O
NEG	O
Bnzodzp	O
-	O
NEG	O
Barbitr	O
-	O
NEG	O
Tricycl	O
-	O
NEG	O
.	O
CT	O
Head	O
[	O
**	O
2148-8-16	O
**	O
]	O
:	O
No	O
acute	O
intracranial	O
process	O
.	O
Moderate	O
-	O
sized	O
hematoma	O
overlying	O
the	O
left	O
frontal	O
bone	O
.	O
Evidence	O
of	O
prior	O
right	O
frontoparietal	O
craniotomy	O
.	O
CT	O
CAP	O
[	O
**	O
2148-8-16	O
**	O
]	O
:	O
1	O
.	O
Exam	O
is	O
severely	O
limited	O
by	O
motion	O
.	O
No	O
evidence	O
of	O
acute	O
trauma	O
.	O
Multiple	O
left	O
-	O
sided	O
rib	O
and	O
transverse	O
process	O
fractures	O
identified	O
with	O
varying	O
degrees	O
of	O
healing	O
.	O
No	O
acute	O
fracture	O
identified	O
.	O
Correlate	O
with	O
exam	O
and	O
mechanism	O
.	O
2	O
.	O
Small	O
right	O
pleural	O
effusion	O
.	O
3	O
.	O
Cardiomegaly	O
.	O
4	O
.	O
Bilateral	O
adrenal	O
gland	O
hyperplasia	O
.	O
.	O
CT	O
C	O
-	O
spine	O
[	O
**	O
2148-8-16	O
**	O
]	O
:	O
1	O
.	O
Severely	O
limited	O
exam	O
.	O
No	O
evidence	O
of	O
gross	O
acute	O
fracture	O
or	O
malalignment	O
.	O
2	O
.	O
T2	O
compression	O
deformity	O
with	O
morphology	O
suggests	O
chronicity	O
but	O
no	O
prior	O
studies	O
available	O
for	O
comparison	O
.	O
.	O
CXR	O
[	O
**	O
2148-8-16	O
**	O
]	O
Marked	O
volume	O
overload	O
evident	O
by	O
moderate	O
pulmonary	O
edema	O
,	O
likely	O
cardiogenic	O
in	O
etiology	O
.	O
Recommend	O
appropriate	O
diuresis	O
and	O
repeat	O
radiography	O
to	O
assess	O
for	O
underlying	O
infection	O
.	O
There	O
are	O
at	O
least	O
fractures	O
involving	O
the	O
left	O
third	O
,	O
fourth	O
,	O
and	O
fifth	O
ribs	O
.	O
No	O
pneumothorax	O
is	O
seen	O
.	O
.	O
Discharge	O
Labs	O
:	O
[	O
**	O
2148-8-21	O
**	O
]	O
05:24	O
AM	O
BLOOD	O
Glucose	O
-	O
138	O
*	O
UreaN	O
-	O
38	O
*	O
Creat	O
-	O
1.0	O
Na	O
-	O
150	O
*	O
K	O
-	O
4.5	O
Cl	O
-	O
102	O
HCO3	O
-	O
43	O
*	O
AnGap	O
-	O
10	O
[	O
**	O
2148-8-21	O
**	O
]	O
05:24	O
AM	O
BLOOD	O
Calcium	O
-	O
8.0	O
*	O
Phos	O
-	O
2.2	O
*	O
Mg	O
-	O
2.4	O
Brief	O
Hospital	O
Course	O
:	O
[	O
**	O
Age	O
over	O
90	O
**	O
]	O
yo	O
female	O
with	O
history	O
of	O
diastolic	O
CHF	O
and	O
COPD	O
who	O
presented	O
with	O
hypoxia	O
and	O
agitation	O
.	O
.	O
#	O
Hypoxemic	O
Respiratory	O
Distress	O
:	O
Her	O
admission	O
CT	O
chest	O
was	O
fairly	O
unremarkable	O
.	O
However	O
,	O
she	O
spiked	O
a	O
fever	O
and	O
developed	O
bilateral	O
infiltrates	O
;	O
she	O
was	O
started	O
on	O
Vanc	I-Drug
,	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
2830	O
**	O
]	O
,	O
levo	I-Drug
for	O
HCAP	I-Reason
.	O
Cultures	O
were	O
sent	O
,	O
but	O
did	O
not	O
grow	O
an	O
organism	O
.	O
Her	O
antibiotics	I-Drug
were	O
tapered	O
to	O
levofloxacin	I-Drug
only	O
with	O
the	O
plan	O
to	O
continue	O
for	O
an	O
8	O
day	O
course	O
for	O
HCAP	I-Reason
.	O
She	O
improved	O
clinically	O
and	O
had	O
resolution	O
of	O
fevers	I-Reason
on	O
levofloxacin	I-Drug
alone	O
.	O
.	O
#Hypercarbic	O
respiratory	I-Ade
failure	I-Ade
:	O
Pt	O
became	O
somnolent	I-Ade
in	O
setting	O
of	O
antipsychotics	I-Drug
/	O
benzos	I-Drug
.	O
Per	O
discussion	O
with	O
her	O
family	O
and	O
her	O
MD	O
at	O
rehab	O
,	O
there	O
is	O
a	O
very	O
narrow	O
therapeutic	O
window	O
which	O
such	O
medications	O
in	O
this	O
patient	O
.	O
PCO2	O
was	O
grossly	O
elevated	O
indicating	O
hypoventilation	O
.	O
She	O
was	O
placed	O
on	O
BiPAP	O
with	O
improvement	O
in	O
mental	O
status	O
.	O
Ativan	I-Drug
was	O
d	O
/	O
ced	O
and	O
only	O
risperidone	I-Drug
(	O
home	O
med	O
)	O
was	O
used	O
to	O
manage	O
her	O
anxiety	I-Reason
.	O
This	O
a	O
uptitrated	O
to	O
1.5	O
mg	O
nightly	O
.	O
.	O
#	O
Hypernatremia	I-Ade
:	O
Likely	O
hypovolemia	B-Ade
hyponatremia	I-Ade
after	O
Lasix	I-Drug
given	O
concentrated	O
appearance	O
of	O
urine	O
.	O
Pt	O
is	O
taking	O
good	O
po	O
free	O
water	O
,	O
and	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
3646	O
**	O
]	O
at	O
rehab	O
will	O
be	O
monitoring	O
lytes	O
.	O
She	O
appears	O
euvolemic	O
on	O
exam	O
and	O
is	O
at	O
baseline	O
mental	O
status	O
.	O
.	O
#	O
S	O
/	O
P	O
Fall	O
with	O
Head	O
Laceration	O
:	O
Initial	O
trauma	O
survey	O
negative	O
.	O
Unremarkable	O
CT	O
head	O
on	O
admission	O
.	O
Head	O
laceration	O
was	O
repaired	O
in	O
the	O
ED	O
.	O
Will	O
need	O
staples	O
removed	O
7	O
days	O
from	O
placement	O
(	O
placed	O
[	O
**	O
2148-8-16	O
**	O
]	O
)	O
.	O
.	O
#	O
Atrial	O
fibrillation	O
:	O
patient	O
not	O
on	O
anticoagulation	O
given	O
past	O
history	O
of	O
subdural	O
hematoma	O
.	O
She	O
is	O
also	O
not	O
currently	O
on	O
rate	O
control	O
.	O
Heart	O
rate	O
was	O
<	O
100	O
throughout	O
her	O
hospital	O
stay	O
.	O
.	O
Code	O
status	O
:	O
DNR	O
/	O
DNI	O
.	O
The	O
patient	O
and	O
her	O
family	O
would	O
prefer	O
she	O
stay	O
at	O
[	O
**	O
Hospital	O
100	O
**	O
]	O
Rehab	O
and	O
not	O
come	O
to	O
the	O
hospital	O
.	O
If	O
there	O
is	O
some	O
issue	O
that	O
can	O
not	O
be	O
managed	O
at	O
[	O
**	O
Hospital	O
100	O
**	O
]	O
Rehab	O
and	O
the	O
pt	O
is	O
brought	O
to	O
the	O
ED	O
,	O
they	O
request	O
she	O
not	O
be	O
admitted	O
to	O
the	O
ICU	O
in	O
the	O
future	O
.	O
Medications	O
on	O
Admission	O
:	O
Furosemide	I-Drug
60	O
mg	O
PO	O
daily	O
Sunday	O
,	O
Tuesday	O
,	O
Thursday	O
,	O
Saturday	O
Furosemide	I-Drug
80	O
mg	O
PO	O
daily	O
Monday	O
,	O
Wednesday	O
,	O
Friday	O
Fluticasone	I-Drug
50	O
mcg	O
actuation	O
spray	O
1	O
spray	O
nasal	O
daily	O
Sertraline	I-Drug
125	O
mg	O
PO	O
daily	O
Risperidone	I-Drug
1	O
mg	O
PO	O
daily	O
Albuterol	B-Drug
sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
solution	O
for	O
neb	O
1	O
IH	O
q2h	O
PRN	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
Lorazepam	I-Drug
0.5	O
mg	O
PO	O
q6h	O
PRN	O
Tylenol	I-Drug
650	O
mg	O
PO	O
q4	O
-	O
6h	O
PRN	O
pain	I-Reason
Ergocalciferol	I-Drug
50,000	O
units	O
1	O
capsule	O
PO	O
monthly	O
Sodium	B-Drug
chloride	I-Drug
0.65	O
%	O
aerosol	O
spray	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
sprays	O
QID	O
PRN	O
dry	B-Reason
nose	I-Reason
Phenylephrine	B-Drug
HCl	I-Drug
0.5	O
%	O
spray	O
non-aerosol	O
1	O
spray	O
q4h	O
PRN	O
dry	I-Reason
nose	O
Polyethylene	B-Drug
glycol	I-Drug
1	O
dose	O
PO	O
daily	O
PRN	O
constipation	I-Reason
Aluminum	B-Drug
-	I-Drug
magnesium	I-Drug
hydroxide	I-Drug
-	I-Drug
simethicone	I-Drug
200	O
-200-20	O
mg	O
/	O
5	O
mL	O
suspension	O
15	O
-	O
30	O
mL	O
PO	O
QID	O
PRN	O
upset	B-Reason
stomach	I-Reason
Fluticasone	B-Drug
-	I-Drug
salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
with	O
device	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
IH	O
[	O
**	O
Hospital1	O
**	O
]	O
Levothyroxine	I-Drug
112	O
mcg	O
PO	O
daily	O
Ipratropium	B-Drug
bromide	I-Drug
0.02	O
%	O
solution	O
1	O
IH	O
q6h	O
PRN	O
wheezing	I-Reason
Guaifenesin	B-Drug
/	I-Drug
dextromethorphan	I-Drug
100	O
mg	O
/	O
5	O
mL	O
syrup	O
[	O
**	O
5	O
-	O
7	O
**	O
]	O
mL	O
PO	O
q6h	O
PRN	O
cough	I-Reason
Pramixpexole	I-Drug
1.25	O
mg	O
PO	O
daily	O
Camphor	B-Drug
-	I-Drug
menthol	I-Drug
0.5	O
-	O
0.5	O
%	O
lotion	O
1	O
appl	O
topical	O
QID	O
PRN	O
itching	I-Reason
Artificial	B-Drug
tears	I-Drug
1	O
drop	O
each	O
eye	O
apply	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
sertraline	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
2.5	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
fluticasone	I-Drug
50	O
mcg	O
/	O
Actuation	O
Spray	O
,	O
Suspension	O
Sig	O
:	O
One	O
(	O
1	O
)	O
spray	O
/	O
nostril	O
Nasal	O
once	O
a	O
day	O
.	O
3	O
.	O
risperidone	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
At	O
8	O
pm	O
.	O
4	O
.	O
albuterol	B-Drug
sulfate	I-Drug
2.5	O
mg	O
/	O
3	O
mL	O
(	O
0.083	O
%	O
)	O
Solution	O
for	O
Nebulization	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
q2	O
hours	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
5	O
.	O
lorazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
anxiety	I-Reason
:	O
.	O
6	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
[	O
**	O
4	O
-	O
3	O
**	O
]	O
hours	O
as	O
needed	O
for	O
fever	I-Reason
or	O
pain	I-Reason
.	O
7	O
.	O
ergocalciferol	B-Drug
(	I-Drug
vitamin	I-Drug
D2	I-Drug
)	I-Drug
50,000	O
unit	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
once	O
a	O
month	O
.	O
8	O
.	O
sodium	B-Drug
chloride	I-Drug
0.65	O
%	O
Aerosol	O
,	O
Spray	O
Sig	O
:	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
Sprays	O
Nasal	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
nasal	B-Reason
dryness	I-Reason
.	O
9	O
.	O
phenylephrine	B-Drug
HCl	I-Drug
0.5	O
%	O
Spray	O
,	O
Non-Aerosol	O
Sig	O
:	O
One	O
(	O
1	O
)	O
spray	O
Nasal	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
nasal	B-Reason
dryness	I-Reason
.	O
10	O
.	O
Miralax	I-Drug
17	O
gram	O
/	O
dose	O
Powder	O
Sig	O
:	O
One	O
(	O
1	O
)	O
dose	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
11	O
.	O
alum	B-Drug
-	I-Drug
mag	I-Drug
hydroxide	I-Drug
-	I-Drug
simeth	I-Drug
200	O
-200-20	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15	O
-	O
30	O
mL	O
PO	O
four	O
times	O
a	O
day	O
as	O
needed	O
for	O
indigestion	I-Reason
.	O
12	O
.	O
Advair	B-Drug
Diskus	I-Drug
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
inhalation	O
Inhalation	O
twice	O
a	O
day	O
.	O
13	O
.	O
levothyroxine	I-Drug
112	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
14	O
.	O
ipratropium	B-Drug
bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
neb	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
15	O
.	O
dextromethorphan	B-Drug
-	I-Drug
guaifenesin	I-Drug
10	O
-	O
100	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
[	O
**	O
5	O
-	O
7	O
**	O
]	O
mL	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
cough	I-Reason
.	O
16	O
.	O
pramipexole	I-Drug
1	O
mg	O
Tablet	O
Sig	O
:	O
1.25	O
mg	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
17	O
.	O
polyvinyl	B-Drug
alcohol	I-Drug
1.4	O
%	O
Drops	O
Sig	O
:	O
1	O
-	O
2	O
Drops	O
Ophthalmic	O
PRN	O
(	O
as	O
needed	O
)	O
as	O
needed	O
for	O
eye	B-Reason
dryness	I-Reason
.	O
18	O
.	O
camphor	B-Drug
-	I-Drug
menthol	I-Drug
0.5	O
-	O
0.5	O
%	O
Lotion	O
Sig	O
:	O
One	O
(	O
1	O
)	O
application	O
Topical	O
once	O
a	O
day	O
as	O
needed	O
for	O
itching	I-Reason
.	O
19	O
.	O
levofloxacin	I-Drug
750	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
2	O
doses	O
:	O
To	O
finish	O
[	O
**	O
2148-8-23	O
**	O
]	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
459	O
**	O
]	O
for	O
the	O
Aged	O
-	O
MACU	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
s	O
/	O
p	O
fall	O
head	O
lacteration	O
altered	O
mental	O
status	O
health	O
-	O
care	O
associated	O
pneumonia	O
.	O
Secondary	O
:	O
anxiety	O
COPD	O
sleep	O
apnea	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
**	O
]	O
,	O
.	O
It	O
has	O
been	O
a	O
pleasure	O
taking	O
care	O
of	O
you	O
here	O
at	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
64579	O
**	O
]	O
.	O
You	O
came	O
to	O
the	O
hospital	O
after	O
a	O
fall	O
.	O
There	O
was	O
no	O
break	O
in	O
your	O
skull	O
or	O
spine	O
,	O
and	O
you	O
had	O
a	O
laceration	O
stapled	O
.	O
You	O
were	O
admitted	O
to	O
the	O
ICU	O
because	O
you	O
were	O
confused	O
and	O
your	O
oxygen	O
was	O
low	O
.	O
Some	O
of	O
this	O
may	O
have	O
been	O
related	O
to	O
medication	O
you	O
recieved	O
.	O
You	O
are	O
much	O
more	O
yourself	O
and	O
will	O
be	O
going	O
back	O
to	O
[	O
**	O
Hospital	O
100	O
**	O
]	O
Rehab	O
.	O
.	O
We	O
made	O
the	O
following	O
changes	O
to	O
your	O
medications	O
:	O
-	O
Please	O
increase	O
your	O
risperidone	I-Drug
to	O
1.5	O
mg	O
daily	O
,	O
to	O
be	O
taken	O
at	O
8	O
pm	O
(	O
instead	O
of	O
6	O
pm	O
)	O
.	O
This	O
should	O
help	O
you	O
sleep	I-Reason
.	O
-	O
Please	O
STOP	O
taking	O
Lasix	I-Drug
for	O
now	O
.	O
You	O
are	O
a	O
bit	O
dehydrated	I-Ade
.	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
3646	O
**	O
]	O
will	O
watch	O
you	O
closely	O
and	O
decide	O
when	O
to	O
restart	O
this	O
medicine	O
.	O
-	O
Please	O
tale	O
levofloxacin	I-Drug
750	O
mg	O
once	O
daily	O
for	O
2	O
days	O
to	O
finish	O
treatment	O
for	O
pneumonia	I-Reason
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
Followup	O
Instructions	O
:	O
Pt	O
to	O
be	O
follwed	O
closely	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
3646	O
**	O
]	O
at	O
rehab	O
.	O

Admission	O
Date	O
:	O
[	O
**	O
2119-1-23	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2119-2-11	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2067-8-9	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Levofloxacin	I-Drug
/	O
Penicillins	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
transfer	O
from	O
outside	O
hospital	O
with	O
lung	O
mass	O
/	O
lymphadenopathy	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
VATS	O
Chest	O
tube	O
s	O
/	O
p	O
VATS	O
History	O
of	O
Present	O
Illness	O
:	O
50	O
yoM	O
w	O
/	O
h	O
/	O
o	O
chronic	O
pain	O
syndrome	O
,	O
history	O
of	O
testicular	O
cancer	O
,	O
and	O
recent	O
PNA	O
presented	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
[	O
**	O
Location	O
(	O
un	O
)	O
620	O
**	O
]	O
[	O
**	O
2119-1-20	O
**	O
]	O
with	O
chough	O
X	O
2	O
days	O
productive	O
of	O
yellow	O
mucus	O
and	O
subjective	O
fever	O
without	O
chills	O
.	O
(	O
+	O
)	O
occasional	O
pleuritic	O
left	O
flank	O
pain	O
.	O
In	O
the	O
ED	O
,	O
CXR	O
with	O
consolidation	O
vs	O
mass	O
at	O
RLL	O
.	O
He	O
was	O
thought	O
to	O
have	O
right	B-Reason
lower	I-Reason
lobe	I-Reason
PNA	I-Reason
and	O
?	O
RAD	O
exacerbation	O
.	O
He	O
was	O
treated	O
with	O
antibiotics	I-Drug
(	O
Ceftriaxone	I-Drug
)	O
,	O
nebulizers	I-Drug
,	O
and	O
admitted	O
to	O
medical	O
service	O
for	O
further	O
evaluation	O
.	O
Given	O
concern	O
for	O
mass	O
on	O
initial	O
CXR	O
,	O
he	O
had	O
a	O
Chest	O
CT	O
[	O
**	O
2119-1-20	O
**	O
]	O
that	O
showed	O
extensive	O
lymphadenopathy	O
.	O
w	O
/	O
lymphadenopathy	O
of	O
left	O
axilla	O
,	O
mediastinum	O
,	O
and	O
right	O
hilum	O
and	O
celiac	O
axis	O
(	O
worrisome	O
for	O
lymphoma	O
)	O
.	O
Course	O
c	O
/	O
b	O
fever	O
to	O
101.4	O
,	O
leukocytosis	O
with	O
bandemia	O
.	O
Given	O
concern	O
for	O
aspiration	I-Reason
and	O
history	B-Reason
of	I-Reason
MRSA	I-Reason
,	O
his	O
antibiotic	I-Drug
coverage	O
was	O
changed	O
to	O
Flagyl	I-Drug
,	O
Ceftazidime	I-Drug
,	O
Azithromycin	I-Drug
,	O
and	O
vancomycin	I-Drug
.	O
On	O
hospital	O
day	O
four	O
,	O
due	O
to	O
the	O
patient	O
's	O
worsening	O
shortness	O
of	O
breath	O
,	O
there	O
was	O
concern	O
for	O
superimpsosed	B-Reason
congestive	I-Reason
heart	I-Reason
failure	O
,	O
and	O
the	O
patient	O
received	O
40	O
mg	O
IV	O
lasix	I-Drug
and	O
nitropaste	I-Drug
.	O
However	O
a	O
CXR	O
was	O
without	O
CHF	O
findings	O
and	O
a	O
BNP	O
was	O
normal	O
at	O
73	O
.	O
A	O
pulmonary	O
consult	O
was	O
obtained	O
,	O
who	O
recommended	O
lung	O
biopsy	O
/	O
lymph	O
node	O
biopsy	O
via	O
VATS	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
management	O
Currently	O
,	O
the	O
patient	O
reports	O
mild	O
shortness	O
of	O
breath	O
,	O
only	O
with	O
coughing	O
.	O
(	O
+	O
)	O
diffuse	O
chest	O
pain	O
only	O
with	O
coughing	O
.	O
(	O
+	O
)	O
intermittent	O
subjective	O
fevers	O
/	O
chills	O
.	O
(	O
+	O
)	O
sputum	O
yellow	O
/	O
green	O
with	O
occasional	O
streaks	O
of	O
blood	O
.	O
(	O
+	O
)	O
wheezing	O
ROS	O
:	O
Mild	O
intermittent	O
frontal	O
headache	O
.	O
No	O
rhinorrhea	O
,	O
sore	O
throat	O
,	O
ear	O
pain	O
,	O
stiff	O
neck	O
,	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
dysuria	O
,	O
or	O
diarrhea	O
.	O
(	O
+	O
)	O
history	O
of	O
IVDU	O
(	O
quit	O
[	O
**	O
2094	O
**	O
]	O
)	O
.	O
Last	O
HIV	O
test	O
1	O
yr	O
ago	O
(	O
per	O
pt	O
at	O
[	O
**	O
Hospital1	O
112	O
**	O
]	O
)	O
negative	O
.	O
No	O
history	O
of	O
TB	O
,	O
although	O
pt	O
has	O
been	O
incarcerated	O
in	O
the	O
past	O
.	O
No	O
recent	O
travel	O
.	O
(	O
+	O
)	O
daughter	O
with	O
pneumonia	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
)	O
s	O
/	O
p	O
MVA	O
with	O
spleen	O
rupture	O
,	O
bilateral	O
open	O
tibial	O
fractures	O
,	O
and	O
head	O
trauma	O
2	O
)	O
Chronic	O
pain	O
syndrome	O
3	O
)	O
Recurrent	O
lower	O
extremity	O
ulcers	O
4	O
)	O
sinus	O
tachycardia	O
of	O
unclear	O
etiology	O
--	O
reflex	O
sympathetic	O
dystrophy	O
PNA	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
5	O
)	O
LLL	O
PNA	O
[	O
**	O
11	O
-	O
7	O
**	O
]	O
6	O
)	O
Remote	O
history	O
of	O
testicular	O
cancer	O
:	O
dx	O
[	O
**	O
2092	O
**	O
]	O
with	O
recurrence	O
in	O
[	O
**	O
2101	O
**	O
]	O
--	O
received	O
treatment	O
at	O
JP	O
[	O
**	O
Hospital	O
**	O
]	O
hospital	O
;	O
reports	O
he	O
had	O
an	O
orchiectomy	O
in	O
[	O
**	O
2092	O
**	O
]	O
followed	O
by	O
radiation	O
and	O
lymph	O
node	O
dissection	O
in	O
[	O
**	O
2101	O
**	O
]	O
.	O
7	O
)	O
GERD	O
8	O
)	O
h	O
/	O
o	O
MRSA	O
Social	O
History	O
:	O
1	O
ppd	O
X	O
30	O
yrs	O
.	O
(	O
+	O
)	O
history	O
of	O
IVDU	O
,	O
quit	O
in	O
[	O
**	O
2094	O
**	O
]	O
.	O
No	O
ethanol	O
use	O
.	O
Lives	O
with	O
his	O
wife	O
.	O
Currently	O
unemployed	O
Family	O
History	O
:	O
Grandfather	O
s	O
/	O
p	O
MI	O
in	O
70s	O
.	O
Grandmother	O
died	O
in	O
her	O
sleep	O
of	O
unknown	O
cause	O
in	O
her	O
70s	O
.	O
No	O
family	O
history	O
of	O
cancer	O
.	O
Physical	O
Exam	O
:	O
PE	O
:	O
Tc	O
100	O
,	O
HR	O
118	O
,	O
bpc	O
132/82	O
,	O
resp	O
22	O
,	O
95	O
%	O
50	O
%	O
FM	O
Gen	O
:	O
chronically	O
ill	O
-	O
appearing	O
middle	O
-	O
aged	O
male	O
,	O
A&OX	O
3	O
,	O
intermittently	O
coughing	O
,	O
no	O
acute	O
respiratory	O
distress	O
HEENT	O
:	O
pupils	O
1.5	O
mm	O
and	O
nonreactive	O
,	O
EOMI	O
,	O
anicteric	O
,	O
normal	O
conjunctiva	O
,	O
OMMM	O
slightly	O
dry	O
,	O
OP	O
clear	O
,	O
neck	O
supple	O
,	O
shotty	O
cervical	O
LAD	O
,	O
no	O
JVD	O
Cardiac	O
:	O
tachycardic	O
,	O
regular	O
,	O
no	O
M	O
/	O
R	O
/	O
G	O
appreciated	O
Pulm	O
:	O
Diffuse	O
course	O
ronchi	O
with	O
wheezes	O
.	O
Abd	O
:	O
NABS	O
,	O
soft	O
,	O
NT	O
/	O
ND	O
,	O
no	O
masses	O
,	O
no	O
hepatomegaly	O
Ext	O
:	O
chronic	O
LE	O
-	O
scarring	O
with	O
superficial	O
eschar	O
left	O
mid-tibia	O
.	O
No	O
discharge	O
,	O
erythema	O
or	O
edema	O
,	O
warm	O
with	O
1	O
+	O
DP	O
bilaterally	O
.	O
(	O
+	O
)	O
shiny	O
skin	O
.	O
Neuro	O
:	O
CN	O
II	O
-	O
XII	O
grossly	O
intact	O
and	O
symmetric	O
bilaterally	O
,	O
[	O
**	O
6	O
-	O
8	O
**	O
]	O
upper	O
extremities	O
bilaterally	O
,	O
4/5	O
strength	O
lower	O
extremities	O
bilaterally	O
.	O
Contracture	O
of	O
right	O
ankle	O
.	O
Decreased	O
sensation	O
to	O
light	O
touch	O
of	O
lower	O
extremities	O
to	O
ankle	O
bilaterally	O
.	O
Pertinent	O
Results	O
:	O
OSH	O
[	O
**	O
2119-1-23	O
**	O
]	O
wbc	O
21.1	O
(	O
from	O
19.2	O
)	O
,	O
HCT	O
42.1	O
,	O
MCV	O
75.8	O
,	O
RDW	O
18.2	O
,	O
Plt	O
577	O
--	O
PMN	O
78	O
,	O
bands	O
7	O
,	O
lymph	O
7	O
,	O
mono	O
7	O
,	O
eos	O
1	O
Na	O
136	O
,	O
K	O
4.0	O
,	O
Cl	O
96	O
,	O
HCO3	O
29	O
,	O
BUN	O
5	O
,	O
Cr	O
0.9	O
,	O
AG	O
11	O
BNP	O
73.7	O
ABG	O
10L	O
FM	O
7.5	O
/	O
41/47	O
87	O
%	O
Micro	O
:	O
bcx	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
pending	O
,	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
pending	O
,	O
spcx	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
>	O
25	O
PMN	O
,	O
rare	O
GPC	O
cocci	O
in	O
pair	O
;	O
spcx	O
rare	O
growth	O
normal	O
flora	O
[	O
**	O
1	O
-	O
23	O
**	O
]	O
HIV	O
Ab	O
pending	O
[	O
**	O
1	O
-	O
20	O
**	O
]	O
Chest	O
CT	O
w	O
/	O
contrast	O
:	O
left	O
axillary	O
,	O
mediastinal	O
,	O
right	O
hilar	O
,	O
retrocrural	O
and	O
celiac	O
LAD	O
(	O
worrisome	O
for	O
lymphoma	O
or	O
testicular	O
metastases	O
)	O
.	O
Calcified	O
subcarinal	O
lymph	O
nodes	O
may	O
be	O
sequelae	O
of	O
previously	O
treated	O
lymph	O
nodes	O
or	O
granulomatous	O
exposure	O
.	O
Nonspecific	O
consolidation	O
and	O
ground	O
-	O
glass	O
opacities	O
in	O
right	O
apex	O
and	O
bowth	O
lower	O
lobes	O
,	O
likely	O
of	O
infectious	O
etiology	O
.	O
Surgical	O
clips	O
in	O
RML	O
.	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
Abd	O
/	O
pelvis	O
CT	O
with	O
contrast	O
:	O
celiac	O
and	O
portal	O
lymphadenopathy	O
,	O
bibasilar	O
nonspecific	O
ground	O
glass	O
and	O
consolidative	O
opacities	O
most	O
likely	O
infectious	O
in	O
etiology	O
,	O
no	O
retroperitoneal	O
lymphadenopathy	O
[	O
**	O
2119-1-23	O
**	O
]	O
EKG	O
:	O
ST	O
@	O
120	O
,	O
nl	O
intervals	O
,	O
TWF	O
II	O
,	O
II	O
,	O
avF	O
Brief	O
Hospital	O
Course	O
:	O
1	O
)	O
Pulmonary	O
:	O
Given	O
the	O
patient	O
's	O
leukocytosis	O
/	O
bandemia	O
,	O
fever	O
,	O
hypoxia	O
,	O
the	O
differential	O
diagnosis	O
includes	O
CAP	O
(	O
typicals	O
and	O
atypicals	O
)	O
,	O
PCP	O
(	O
multiple	O
HIV	O
risk	O
factors	O
)	O
,	O
aspiration	I-Ade
pneumonia	O
(	O
given	O
history	O
of	O
narcotic	I-Drug
overuse	O
)	O
,	O
malignancy	O
(	O
lymphoma	O
,	O
testicular	O
CA	O
,	O
other	O
)	O
,	O
or	O
TB	O
.	O
The	O
patient	O
was	O
broadly	O
covered	O
with	O
ceftriaxone	I-Drug
,	O
azithromycin	I-Drug
,	O
flagyl	I-Drug
,	O
and	O
vancomycin	I-Drug
.	O
A	O
CT	O
was	O
obtained	O
[	O
**	O
2119-1-24	O
**	O
]	O
that	O
showed	O
diffuse	O
centrilobular	O
opacities	O
and	O
apical	O
ground	O
glass	O
attenuation	O
with	O
bilateral	O
axillary	O
and	O
mediastinal	O
lymphadenopathy	O
.	O
The	O
patient	O
's	O
eosinophils	O
rose	O
to	O
13	O
%	O
,	O
raising	O
concern	O
for	O
hypersensitivity	O
pneumonitis	O
,	O
eosinophilic	O
pneumonia	O
,	O
or	O
bronchopulmonary	O
aspergillosis	O
.	O
Legionella	O
urinary	O
antigen	O
and	O
HIV	O
Ab	O
tests	O
were	O
negative	O
.	O
LDH	O
was	O
elevated	O
,	O
which	O
could	O
be	O
suggestive	O
of	O
PCP	O
or	O
lymphoma	O
.	O
PCP	O
smear	O
was	O
negative	O
X1	O
and	O
sputum	O
cultures	O
grew	O
only	O
oropharyngeal	O
flora	O
.	O
Pulmonary	O
and	O
thoracic	O
surgery	O
were	O
consulted	O
,	O
and	O
the	O
patient	O
underwent	O
VATS	O
on	O
[	O
**	O
2119-1-26	O
**	O
]	O
with	O
biopsies	O
of	O
left	O
upper	O
and	O
lower	O
lung	O
and	O
left	O
axillary	O
lymph	O
node	O
.	O
A	O
PPD	O
was	O
placed	O
,	O
and	O
was	O
negative	O
.	O
ANCA	O
and	O
RF	O
were	O
negative	O
.	O
The	O
patient	O
developed	O
worsening	O
hypoxia	O
and	O
shortness	O
of	O
breath	O
and	O
required	O
a	O
MICU	O
stay	O
,	O
though	O
no	O
intubation	O
.	O
He	O
was	O
started	O
on	O
IV	O
steroids	I-Drug
for	O
his	O
lymphadenopathy	I-Reason
and	O
worsening	B-Reason
pneumonia	I-Reason
.	O
He	O
was	O
also	O
continued	O
on	O
his	O
Vanco	I-Drug
,	O
CTX	I-Drug
,	O
and	O
Azithromycin	I-Drug
.	O
He	O
had	O
a	O
CT	O
scan	O
to	O
look	O
for	O
a	O
PE	O
and	O
this	O
found	O
large	O
b	B-Reason
/	I-Reason
lateral	I-Reason
pulmonary	O
emboli	O
.	O
A	O
heparin	I-Drug
gtt	O
was	O
started	O
.	O
In	O
this	O
CT	O
scan	O
,	O
it	O
was	O
also	O
noted	O
that	O
his	O
infiltrates	I-Reason
and	O
lymphadenopathy	I-Reason
improved	O
,	O
so	O
steroids	I-Drug
,	O
abx	I-Drug
were	O
also	O
continued	O
.	O
The	O
patient	O
improved	O
his	O
oxygen	O
saturations	O
and	O
breathing	O
and	O
was	O
transferred	O
back	O
to	O
the	O
floor	O
.	O
His	O
chest	O
tube	O
had	O
been	O
removed	O
without	O
complication	O
,	O
including	O
no	O
pneumothorax	O
,	O
while	O
he	O
was	O
in	O
the	O
MICU	O
and	O
2	O
nylon	O
sutures	O
were	O
removed	O
from	O
the	O
site	O
on	O
[	O
**	O
1	O
-	O
31	O
**	O
]	O
.	O
After	O
coming	O
back	O
to	O
the	O
floor	O
,	O
the	O
patient	O
did	O
well	O
and	O
was	O
on	O
room	O
air	O
at	O
discharge	O
.	O
His	O
cultures	O
from	O
a	O
BAL	O
were	O
all	O
negative	O
and	O
after	O
discussion	O
with	O
pulmonary	O
team	O
antibiotics	I-Drug
were	O
discontinued	O
after	O
9	O
days	O
of	O
vanc	I-Drug
,	O
ctx	I-Drug
,	O
azithro	I-Drug
.	O
He	O
was	O
afebrile	O
and	O
his	O
wbc	O
was	O
elevated	O
(	O
thought	O
to	O
be	O
related	O
to	O
high	O
dose	O
steroids	I-Drug
)	O
.	O
Diff	O
was	O
normal	O
.	O
--	O
tapering	O
CCST	O
His	O
VATS	O
pathology	O
came	O
back	O
and	O
demonstrated	O
2	O
discrete	O
morphologies	O
affecting	O
upper	O
and	O
lower	O
lobes	O
.	O
In	O
the	O
upper	O
lobes	O
,	O
the	O
process	O
appeared	O
to	O
be	O
infiltrative	O
dz	O
of	O
the	O
alveoli	O
,	O
while	O
lower	O
lungs	O
demonstrated	O
bronchiocentric	O
inflammation	O
.	O
Path	O
was	O
read	O
as	O
acute	O
organizing	O
PNA	O
with	O
neutrophilic	O
predominence	O
,	O
likley	O
viral	O
/	O
bacterial	O
etiology	O
.	O
Pt	O
's	O
steroids	I-Drug
were	O
tapered	O
down	O
to	O
20	O
mg	O
QD	O
,	O
which	O
he	O
will	O
cont	O
for	O
3	O
days	O
,	O
then	O
will	O
switch	O
to	O
10	O
mg	O
QD	O
for	O
5	O
days	O
and	O
then	O
off	O
.	O
He	O
will	O
follow	O
-	O
up	O
in	O
pulmonary	O
clinic	O
on	O
[	O
**	O
3	O
-	O
6	O
**	O
]	O
.	O
2	O
)	O
Chest	B-Ade
wall	I-Ade
hematoma	I-Ade
-	O
Pt	O
c	O
/	O
o	O
pain	O
over	O
LN	O
bx	O
site	O
with	O
tender	O
mass	O
and	O
expansion	O
over	O
a	O
24	O
hr	O
period	O
.	O
U	O
/	O
S	O
showed	O
hematoma	O
.	O
His	O
anticoagulation	I-Drug
proceeded	O
cautiously	O
with	O
heparin	I-Drug
(	O
goal	O
PTT	O
50	O
-	O
70	O
)	O
.	O
His	O
HCT	O
remained	O
stable	O
and	O
there	O
was	O
no	O
significant	O
expansion	O
of	O
the	O
lesion	O
,	O
so	O
he	O
was	O
bridged	O
to	O
coumadin	I-Drug
(	O
goal	O
INR	O
[	O
**	O
3	O
-	O
9	O
**	O
]	O
)	O
.	O
Thoracics	O
recommended	O
supportive	O
and	O
preventive	O
interventions	O
including	O
elevation	O
of	O
the	O
arm	O
,	O
ROM	O
training	O
,	O
radial	O
pulses	O
,	O
warm	O
compresses	O
,	O
but	O
felt	O
there	O
was	O
no	O
need	O
to	O
evacuate	O
the	O
hematoma	O
.	O
...	O
Pt	O
may	O
need	O
IVC	O
filter	O
if	O
conts	O
to	O
expand	O
while	O
on	O
anticoags	O
pt	O
c	O
/	O
o	O
of	O
pain	O
over	O
the	O
bx	O
site	O
.	O
Pain	I-Reason
was	O
well	O
controlled	O
with	O
IV	O
dilaudid	I-Drug
.	O
2	O
)	O
Chronic	B-Reason
pain	I-Reason
syndrome	I-Reason
/	O
LE	B-Reason
neuropathy	I-Reason
/	O
LE	B-Reason
ulcers	I-Reason
:	O
The	O
patient	O
was	O
maintained	O
on	O
MS	B-Drug
contin	I-Drug
,	O
hydromorphone	I-Drug
,	O
Neurontin	I-Drug
,	O
Flexeril	I-Drug
.	O
His	O
ulcers	O
appeared	O
noninfected	O
and	O
superficial	O
while	O
the	O
patient	O
was	O
in	O
the	O
hospital	O
.	O
These	O
are	O
chronic	O
.	O
3	O
)	O
GI	O
:	O
The	O
patient	O
was	O
continued	O
on	O
protonix	I-Drug
throughout	O
his	O
hospital	O
course	O
for	O
GERD	I-Reason
.	O
HepBSag	O
and	O
Sab	O
were	O
negative	O
,	O
HCV	O
and	O
HepB	O
&	O
C	O
Ab	O
were	O
pending	O
on	O
discharge	O
.	O
Patient	O
's	O
LFTs	O
were	O
normal	O
.	O
4	O
)	O
Hypothyroidism	I-Reason
:	O
Although	O
the	O
patient	O
has	O
no	O
previous	O
diagnosis	O
of	O
hyporthyroidism	O
,	O
TSH	O
11	O
and	O
free	O
T4	O
0.7	O
.	O
Levothyroxine	I-Drug
50	O
mcg	O
PO	O
daily	O
was	O
initiated	O
.	O
The	O
patient	O
will	O
require	O
follow	O
-	O
up	O
TSH	O
within	O
6	O
weeks	O
following	O
discharge	O
.	O
5	O
)	O
Diabetes	I-Reason
:	O
The	O
patient	O
's	O
fingersticks	B-Ade
were	I-Ade
very	I-Ade
elevated	I-Ade
after	O
starting	O
on	O
IV	O
steroids	I-Drug
.	O
He	O
was	O
started	O
on	O
insulin	I-Drug
and	O
then	O
required	O
some	O
long	O
acting	O
for	O
severe	O
hyperglycemia	O
.	O
The	O
patient	O
had	O
a	O
Hgb	O
A1C	O
of	O
7.1	O
.	O
His	O
glucose	O
should	O
come	O
down	O
as	O
his	O
steroids	I-Drug
are	O
tapered	O
but	O
he	O
will	O
have	O
to	O
be	O
followed	O
closely	O
.	O
He	O
was	O
maintained	O
on	O
RISS	I-Drug
with	O
QID	O
fingersticks	O
while	O
in	O
-	O
house	O
,	O
but	O
#######	O
6	O
)	O
PEs	I-Reason
:	O
Patient	O
had	O
bilateral	O
PEs	O
as	O
discussed	O
above	O
.	O
He	O
was	O
started	O
on	O
heparin	I-Drug
gtt	O
and	O
bridged	O
to	O
coumadin	I-Drug
once	O
his	O
chest	O
wall	O
hematoma	O
was	O
stable	O
.	O
Bilateral	O
LENIs	O
were	O
negative	O
for	O
DVT	O
and	O
echo	O
showed	O
#####	O
7	O
)	O
Dispo	O
:	O
Pt	O
will	O
be	O
going	O
home	O
with	O
services	O
,	O
rather	O
than	O
to	O
rehab	O
,	O
as	O
he	O
has	O
used	O
up	O
all	O
of	O
his	O
[	O
**	O
Hospital	O
103876	O
**	O
]	O
rehab	O
days	O
.	O
Prior	O
to	O
dispo	O
,	O
pt	O
's	O
PCP	O
was	O
updated	O
on	O
[	O
**	O
Hospital	O
**	O
]	O
hospital	O
course	O
and	O
need	O
for	O
close	O
follow	O
-	O
up	O
care	O
.	O
Medications	O
on	O
Admission	O
:	O
Meds	O
on	O
transfer	O
:	O
combivent	I-Drug
nebs	O
q4hr	O
neurontin	I-Drug
800	O
mg	O
TID	O
protonix	I-Drug
40	O
PO	O
QD	O
Trileptal	I-Drug
150	O
PO	O
TID	O
Colace	I-Drug
100	O
mg	O
PO	O
BID	O
[	O
**	O
Doctor	O
Last	O
Name	O
18928	O
**	O
]	O
130	O
mg	O
PO	O
qAM	O
/	O
qPM	O
vanco	I-Drug
1	O
mg	O
IV	O
BID	O
flagyl	I-Drug
500	O
mg	O
OP	O
TID	O
ceftazidine	I-Drug
2g	O
TID	O
azithromycin	I-Drug
500	O
mg	O
PO	O
QD	O
tylenol	I-Drug
PRN	O
oxycodone	I-Drug
10	O
mg	O
PO	O
q4hr	O
ronbitussin	I-Drug
PRN	O
hydroxyzine	I-Drug
PRN	O
flexeril	I-Drug
PRN	O
Discharge	O
Medications	O
:	O
1	O
.	O
Gabapentin	I-Drug
400	O
mg	O
Capsule	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
180	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Ipratropium	B-Drug
Bromide	I-Drug
0.02	O
%	O
Solution	O
Sig	O
:	O
[	O
**	O
2	O
-	O
5	O
**	O
]	O
puff	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
1	O
INH	O
*	O
Refills	O
:	O
*	O
0	O
*	O
3	O
.	O
Pantoprazole	B-Drug
Sodium	I-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Oxcarbazepine	I-Drug
300	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Docusate	B-Drug
Sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Cyclobenzaprine	B-Drug
HCl	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
7	O
.	O
Levothyroxine	B-Drug
Sodium	I-Drug
50	O
mcg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
8	O
.	O
Clonazepam	I-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
9	O
.	O
Warfarin	B-Drug
Sodium	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
:	O
Should	O
be	O
adjusted	O
for	O
INR	O
[	O
**	O
3	O
-	O
9	O
**	O
]	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
10	O
.	O
Benzonatate	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
90	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
11	O
.	O
Insulin	I-Drug
Glargine	O
10	O
units	O
HS	O
ISS	I-Drug
:	O
FS	O
120	O
-	O
180	O
0	O
units	O
200	O
-	O
250	O
2	O
units	O
251	O
-	O
300	O
4	O
units	O
301	O
-	O
350	O
6	O
units	O
351	O
-	O
400	O
8	O
units	O
This	O
should	O
be	O
adjusted	O
as	O
patient	O
's	O
steroids	I-Drug
are	O
tapered	O
.	O
12	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
0.083	O
%	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
puff	O
Inhalation	O
Q4H	O
(	O
every	O
4	O
hours	O
)	O
as	O
needed	O
for	O
shortness	B-Reason
of	I-Reason
breath	I-Reason
or	O
wheezing	I-Reason
.	O
Disp	O
:	O
*	O
1	O
INH	O
*	O
Refills	O
:	O
*	O
0	O
*	O
13	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
14	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
15	O
.	O
Hydromorphone	B-Drug
HCl	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
4	O
-	O
8	O
Tablets	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
:	O
Can	O
decrease	O
as	O
tolerated	O
.	O
16	O
.	O
Prednisone	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
for	O
4	O
days	O
.	O
Disp	O
:	O
*	O
34	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
17	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
16	O
days	O
:	O
Please	O
start	O
on	O
[	O
**	O
2119-2-19	O
**	O
]	O
and	O
continue	O
through	O
[	O
**	O
2119-3-6	O
**	O
]	O
.	O
Disp	O
:	O
*	O
48	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
18	O
.	O
glucometer	O
Please	O
instruct	O
pt	O
on	O
usage	O
19	O
.	O
glucometer	O
test	O
strips	O
Please	O
instruct	O
on	O
usage	O
.	O
20	O
.	O
Glucose	I-Drug
4	O
g	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
PRN	O
hypoglycemia	I-Reason
as	O
needed	O
for	O
hypoglycemia	I-Reason
:	O
Please	O
take	O
2	O
tabs	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
,	O
and	O
recheck	O
blood	O
glucose	O
.	O
.	O
Disp	O
:	O
*	O
50	O
Tablet	O
,	O
Chewable	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
21	O
.	O
Enoxaparin	B-Drug
Sodium	I-Drug
80	O
mg	O
/	O
0.8	O
mL	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
injection	O
injection	O
Subcutaneous	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
14	O
injectioninjection	O
*	O
Refills	O
:	O
*	O
0	O
*	O
22	O
.	O
Albuterol	I-Drug
90	O
mcg	O
/	O
Actuation	O
Aerosol	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
Q2H	O
(	O
every	O
2	O
hours	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
1	O
inhaler	O
*	O
Refills	O
:	O
*	O
0	O
*	O
23	O
.	O
Warfarin	B-Drug
Sodium	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
24	O
.	O
Fluticasone	B-Drug
-	I-Drug
Salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
1	O
Disk	O
with	O
Device	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
25	O
.	O
Diltiazem	B-Drug
HCl	I-Drug
30	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
120	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
26	O
.	O
Prednisone	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
for	O
5	O
days	O
.	O
Disp	O
:	O
*	O
5	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
27	O
.	O
Oxycodone	B-Drug
HCl	I-Drug
15	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
every	O
four	O
(	O
4	O
)	O
hours	O
for	O
7	O
days	O
.	O
Disp	O
:	O
*	O
50	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
0	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
[	O
**	O
Company	O
1519	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Pulmonary	O
infection	O
of	O
unknown	O
etiology	O
steroid	O
-	O
induced	O
DM	O
Bilateral	O
PEs	O
Axillary	O
hematoma	O
chronic	O
pain	O
syndrome	O
remote	O
h	O
/	O
o	O
testicular	O
CA	O
sinus	O
tachycardia	O
with	O
unclear	O
etiology	O
Discharge	O
Condition	O
:	O
Fair	O
Discharge	O
Instructions	O
:	O
Continue	O
to	O
take	O
all	O
medications	O
as	O
directed	O
.	O
Please	O
call	O
your	O
doctor	O
and	O
come	O
to	O
the	O
hospital	O
you	O
experience	O
worsening	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
fever	O
/	O
chills	O
,	O
or	O
any	O
other	O
concerning	O
symptoms	O
you	O
may	O
have	O
.	O
Please	O
note	O
that	O
your	O
prednisone	I-Drug
is	O
being	O
tapered	O
.	O
Please	O
check	O
your	O
fingerstick	O
daily	O
and	O
keep	O
a	O
record	O
of	O
these	O
values	O
for	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
103877	O
**	O
]	O
,	O
as	O
you	O
may	O
need	O
an	O
oral	O
hypoglycemic	B-Drug
medication	I-Drug
.	O
Followup	O
Instructions	O
:	O
1	O
)	O
Primary	O
care	O
:	O
Please	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Name	O
Initial	O
(	O
PRE	O
)	O
176	O
**	O
]	O
1	O
week	O
following	O
discharge	O
.	O
Please	O
call	O
for	O
appointment	O
.	O
Hep	O
B	O
&	O
C	O
serologies	O
should	O
be	O
followed	O
up	O
on	O
and	O
TSH	O
should	O
be	O
checked	O
in	O
approximately	O
5	O
weeks	O
.	O
2	O
)	O
Pulmonary	O
follow	O
-	O
up	O
(	O
very	O
important	O
)	O
:	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
&	O
DR	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
Where	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
MEDICAL	O
SPECIALTIES	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
612	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2119-3-6	O
**	O
]	O
1:30	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1571	O
**	O
]	O
EXAM	O
ROOM	O
IS	O
(	O
NO	O
CHARGE	O
)	O
Where	O
:	O
IS	O
(	O
NO	O
CHARGE	O
)	O
Date	O
/	O
Time	O
:[	O
**	O
2119-3-6	O
**	O
]	O
1:30	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1571	O
**	O
]	O
BREATHING	O
TESTS	O
Where	O
:	O
[	O
**	O
Hospital6	O
29	O
**	O
]	O
PULMONARY	O
FUNCTION	O
LAB	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
612	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2119-3-6	O
**	O
]	O
1:15	O

Admission	O
Date	O
:	O
[	O
**	O
2108-12-29	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2109-1-9	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2058-6-13	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Azithromycin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
943	O
**	O
]	O
Chief	O
Complaint	O
:	O
Transfer	O
from	O
outside	O
hospital	O
with	O
acute	O
hepatitis	O
and	O
liver	O
failure	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
IJ	O
line	O
insertion	O
[	O
**	O
2108-12-31	O
**	O
]	O
Liver	O
biopsy	O
[	O
**	O
2108-12-31	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
59022	O
**	O
]	O
is	O
a	O
50	O
year	O
old	O
female	O
with	O
questionable	O
history	O
of	O
alcohol	O
abuse	O
in	O
the	O
past	O
,	O
HTN	O
,	O
CRI	O
with	O
baseline	O
2.8	O
,	O
and	O
nephrolithiasis	O
,	O
who	O
was	O
transfered	O
from	O
an	O
outside	O
hospital	O
with	O
fulminant	O
liver	O
and	O
renal	O
failure	O
.	O
Her	O
current	O
illness	O
began	O
3	O
weeks	O
ago	O
at	O
which	O
time	O
she	O
presented	O
to	O
an	O
ED	O
with	O
URI	I-Reason
symptoms	O
and	O
was	O
given	O
cough	B-Drug
medicine	I-Drug
.	O
She	O
saw	O
her	O
PCP	O
one	O
week	O
later	O
with	O
continued	O
URI	B-Reason
symptoms	I-Reason
,	O
and	O
orthopnea	I-Reason
,	O
and	O
was	O
prescribed	O
zithromax	I-Drug
,	O
prednisone	I-Drug
,	O
and	O
flonase	I-Drug
.	O
She	O
began	O
to	O
note	O
hematuria	O
and	O
numbness	O
and	O
weakness	O
of	O
her	O
extremities	O
.	O
Over	O
the	O
next	O
week	O
she	O
developed	O
abdominal	O
pain	O
,	O
bloating	O
,	O
decreased	O
urine	O
output	O
,	O
fever	I-Reason
,	O
and	O
chills	I-Reason
,	O
at	O
which	O
time	O
she	O
presented	O
again	O
to	O
the	O
outside	O
hospital	O
.	O
There	O
,	O
she	O
was	O
found	O
to	O
have	O
markedly	O
elevated	O
transaminases	O
,	O
liver	O
failure	O
,	O
and	O
acute	O
renal	O
failure	O
.	O
She	O
denied	O
nausea	O
,	O
vomiting	O
,	O
dysuria	O
,	O
though	O
has	O
had	O
decreased	O
apetite	O
.	O
She	O
has	O
had	O
a	O
cough	O
productive	O
of	O
sputum	O
.	O
No	O
hematochezia	O
or	O
melena	O
.	O
No	O
sick	O
contacts	O
.	O
She	O
has	O
been	O
using	O
[	O
**	O
1	O
-	O
4	O
**	O
]	O
325	O
mg	O
tylenol	I-Drug
tabs	O
a	O
day	O
.	O
She	O
denied	O
mushroom	O
exposure	O
.	O
LABS	O
AT	O
OSH	O
:	O
wbc	O
14.3	O
,	O
no	O
eos	O
hct	O
31	O
plt	O
458	O
Na	O
134	O
K	O
7.2	O
CL	O
102	O
HCO3	O
10	O
BUN	O
94	O
CR	O
6.2	O
Gluc	O
95	O
Alb	O
3	O
Ca	O
8.6	O
TB	O
4.8	O
,	O
DB	O
3.9	O
TP	O
6.4	O
ALP	O
1344	O
AST	O
5476	O
ALT	O
3419	O
PT	O
27	O
,	O
INR	O
5.6	O
,	O
PTT	O
33.3	O
EKG	O
unchanged	O
from	O
baseline	O
.	O
No	O
ST	O
/	O
T	O
changes	O
.	O
She	O
was	O
treated	O
for	O
hyperkalemia	I-Reason
with	O
kayexalate	I-Drug
,	O
ca	I-Drug
gluconate	O
.	O
She	O
was	O
given	O
mucomyst	I-Drug
for	O
possible	B-Reason
tylenol	I-Drug
OD	I-Reason
,	O
though	O
tylenol	I-Drug
levels	O
were	O
found	O
to	O
be	O
normal	O
.	O
Abdominal	O
CT	O
scan	O
showed	O
:	O
No	O
evidence	O
of	O
apendicitis	O
.	O
Marked	O
thickening	O
of	O
GB	O
wall	O
,	O
which	O
could	O
be	O
related	O
to	O
ascites	O
,	O
however	O
acute	O
cholecystitis	O
ca	O
n't	O
be	O
ruled	O
out	O
.	O
Underdistension	O
/	O
thickening	O
of	O
the	O
ascending	O
colon	O
.	O
LLL	O
consolidation	O
with	O
b	O
/	O
l	O
small	O
pleural	O
effusions	O
.	O
She	O
was	O
then	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
further	O
care	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
)	O
HTN	O
2	O
)	O
chronic	O
renal	O
failure	O
,	O
w	O
/	O
baseline	O
Cr	O
2.8	O
in	O
[	O
**	O
8	O
-	O
4	O
**	O
]	O
:	O
Limited	O
medical	O
care	O
,	O
admitted	O
to	O
[	O
**	O
Hospital	O
**	O
]	O
[	O
**	O
Hospital3	O
**	O
]	O
in	O
[	O
**	O
8	O
-	O
4	O
**	O
]	O
with	O
renal	O
failure	O
.	O
UA	O
[	O
**	O
8	O
-	O
4	O
**	O
]	O
with	O
2	O
+	O
protein	O
,	O
2	O
+	O
blood	O
,	O
BUN	O
/	O
cr	O
38/2	O
.8	O
at	O
that	O
time	O
.	O
PTH	O
15.9	O
.	O
Pt	O
.	O
apparently	O
did	O
not	O
follow	O
up	O
for	O
outpatient	O
evaluation	O
.	O
3	O
)	O
Nephrolithiasis	O
4	O
)	O
Alcohol	O
use	O
/	O
abuse	O
,	O
but	O
not	O
for	O
few	O
months	O
prior	O
to	O
admission	O
Social	O
History	O
:	O
Married	O
with	O
5	O
children	O
.	O
She	O
moved	O
from	O
[	O
**	O
Country	O
5737	O
**	O
]	O
10	O
years	O
ago	O
.	O
She	O
denies	O
any	O
cigarette	O
use	O
,	O
and	O
quit	O
alcohol	O
,	O
though	O
she	O
used	O
to	O
abuse	O
alcohol	O
.	O
No	O
IVDU	O
.	O
Family	O
History	O
:	O
No	O
history	O
of	O
liver	O
or	O
renal	O
disease	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
97	O
,	O
138/84	O
,	O
70	O
,	O
18	O
,	O
97	O
%	O
RA	O
Gen	O
:	O
Overweight	O
african	O
-	O
american	O
female	O
,	O
sitting	O
in	O
bed	O
,	O
getting	O
ready	O
to	O
eat	O
dinner	O
,	O
appearing	O
well	O
,	O
obviously	O
jaundiced	O
.	O
HEENT	O
:	O
Icteric	O
sclerae	O
,	O
hyperpigmentation	O
on	O
face	O
.	O
Neck	O
:	O
JVP	O
not	O
elevated	O
.	O
CVS	O
:	O
RR	O
,	O
normal	O
rate	O
,	O
no	O
m	O
/	O
r	O
/	O
g	O
lungs	O
:	O
CTA	O
b	O
/	O
l	O
,	O
no	O
w	O
/	O
r	O
/	O
r	O
Abd	O
:	O
NABS	O
,	O
soft	O
,	O
NT	O
,	O
mild	O
distention	O
without	O
rebound	O
or	O
guarding	O
,	O
mild	O
fluid	O
wave	O
.	O
Extr	O
:	O
No	O
asterixis	O
,	O
2	O
+	O
bipedal	O
edema	O
,	O
edema	O
of	O
upper	O
extremities	O
Neuro	O
:	O
CN	O
II	O
-	O
XII	O
intact	O
,	O
strength	O
5/5	O
bilaterally	O
.	O
AT	O
OSH	O
:	O
AF	O
,	O
74	O
,	O
169/65	O
,	O
100	O
%	O
on	O
2L	O
Gen	O
:	O
Moderately	O
chronically	O
ill	O
appearing	O
female	O
lying	O
40	O
degrees	O
in	O
bed	O
with	O
mild	O
respiratory	O
discomfort	O
.	O
HEENT	O
:	O
Moist	O
mucous	O
membranes	O
.	O
Icterus	O
.	O
Neck	O
:	O
JVD	O
noted	O
to	O
ear	O
.	O
No	O
LAD	O
or	O
thyromegaly	O
.	O
Chest	O
:	O
Bronchial	O
breath	O
sounds	O
at	O
L	O
mid	O
lung	O
Heart	O
:	O
RR	O
,	O
normal	O
rate	O
,	O
no	O
rub	O
,	O
[	O
**	O
2	O
-	O
3	O
**	O
]	O
holosystolic	O
murmur	O
at	O
apex	O
.	O
Abdomen	O
:	O
Soft	O
,	O
mildly	O
distended	O
.	O
Diffusely	O
tender	O
,	O
without	O
rebound	O
or	O
guarding	O
.	O
Liver	O
edge	O
palpable	O
3	O
cm	O
below	O
costal	O
margin	O
.	O
Bladder	O
not	O
clearly	O
percussed	O
.	O
Extr	O
:	O
1	O
+	O
lower	O
extremity	O
edema	O
,	O
no	O
rash	O
.	O
Pertinent	O
Results	O
:	O
[	O
**	O
2108-12-29	O
**	O
]	O
WBC	O
-	O
23.2	O
*	O
RBC	O
-	O
3.69	O
*	O
Hgb	O
-	O
11.3	O
*	O
Hct	O
-	O
32.5	O
*	O
MCV	O
-	O
88	O
MCH	O
-	O
30.6	O
MCHC	O
-	O
34.7	O
RDW	O
-	O
17.5	O
*	O
Plt	O
Ct	O
-	O
133	O
*	O
[	O
**	O
2109-1-9	O
**	O
]	O
WBC	O
-	O
12.0	O
*	O
RBC	O
-	O
3.65	O
*	O
Hgb	O
-	O
10.6	O
*	O
Hct	O
-	O
32.3	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
32.8	O
RDW	O
-	O
18.7	O
*	O
Plt	O
Ct	O
-	O
233	O
[	O
**	O
2108-12-29	O
**	O
]	O
Neuts	O
-	O
82	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
15	O
*	O
Monos	O
-	O
3	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
NRBC	O
-	O
25	O
*	O
[	O
**	O
2109-1-4	O
**	O
]	O
Neuts	O
-	O
78	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
8	O
*	O
Monos	O
-	O
10	O
Eos	O
-	O
4	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2108-12-29	O
**	O
]	O
PT	O
-	O
24.5	O
*	O
PTT	O
-	O
36.7	O
*	O
INR	O
(	O
PT	O
)	O
-	O
3.8	O
[	O
**	O
2109-1-9	O
**	O
]	O
PT	O
-	O
13.8	O
*	O
PTT	O
-	O
25.5	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
[	O
**	O
2108-12-31	O
**	O
]	O
Fibrino	O
-	O
175	O
[	O
**	O
2109-1-5	O
**	O
]	O
Fibrino	O
-	O
410	O
*	O
#	O
[	O
**	O
2108-12-29	O
**	O
]	O
Glucose	O
-	O
63	O
*	O
UreaN	O
-	O
80	O
*	O
Creat	O
-	O
5.7	O
*	O
Na	O
-	O
140	O
K	O
-	O
3.5	O
Cl	O
-	O
96	O
HCO3	O
-	O
20	O
*	O
[	O
**	O
2109-1-9	O
**	O
]	O
Glucose	O
-	O
106	O
*	O
UreaN	O
-	O
96	O
*	O
Creat	O
-	O
6.1	O
*	O
Na	O
-	O
145	O
K	O
-	O
4.5	O
Cl	O
-	O
100	O
HCO3	O
-	O
30	O
*	O
[	O
**	O
2108-12-29	O
**	O
]	O
Lipase	O
-	O
268	O
*	O
[	O
**	O
2109-1-7	O
**	O
]	O
Lipase	O
-	O
289	O
*	O
[	O
**	O
2108-12-29	O
**	O
]	O
Albumin	O
-	O
3.3	O
*	O
Calcium	O
-	O
6.9	O
*	O
Phos	O
-	O
8.0	O
*	O
Mg	O
-	O
2.1	O
[	O
**	O
2109-1-9	O
**	O
]	O
Albumin	O
-	O
3.4	O
Calcium	O
-	O
9.1	O
Phos	O
-	O
4.9	O
*	O
Mg	O
-	O
2.0	O
[	O
**	O
2108-12-31	O
**	O
]	O
Hapto	O
-	O
<	O
20	O
*	O
[	O
**	O
2108-12-31	O
**	O
]	O
Ret	O
Man	O
-	O
6.5	O
*	O
[	O
**	O
2108-12-31	O
**	O
]	O
VitB12	O
-	O
GREATER	O
TH	O
Folate	O
-	O
7.6	O
[	O
**	O
2109-1-9	O
**	O
]	O
PTH	O
-	O
369	O
*	O
Liver	O
studies	O
:	O
[	O
**	O
2108-12-29	O
**	O
]	O
ALT	O
-	O
4890	O
*	O
AST	O
-	O
8950	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
[	O
**	O
Numeric	O
Identifier	O
59023	O
**	O
]	O
*	O
AlkPhos	O
-	O
1024	O
*	O
Amylase	O
-	O
212	O
*	O
TotBili	O
-	O
9.2	O
*	O
[	O
**	O
2108-12-31	O
**	O
]	O
ALT	O
-	O
1273	O
*	O
AST	O
-	O
787	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
2720	O
*	O
AlkPhos	O
-	O
529	O
*	O
TotBili	O
-	O
32.6	O
*	O
DirBili	O
-	O
30.0	O
*	O
IndBili	O
-	O
2.6	O
[	O
**	O
2109-1-9	O
**	O
]	O
ALT	O
-	O
111	O
*	O
AST	O
-	O
41	O
*	O
LD	O
(	O
LDH	O
)	O
-	O
379	O
*	O
AlkPhos	O
-	O
429	O
*	O
TotBili	O
-	O
5.9	O
*	O
[	O
**	O
2109-1-2	O
**	O
]	O
HBcAb	O
-	O
POSITIVE	O
[	O
**	O
2108-12-31	O
**	O
]	O
IgM	O
HAV	O
-	O
NEGATIVE	O
[	O
**	O
2108-12-31	O
**	O
]	O
HBcAb	O
-	O
POSITIVE	O
[	O
**	O
2108-12-30	O
**	O
]	O
HBsAg	O
-	O
NEGATIVE	O
HBsAb	O
-	O
POSITIVE	O
HAV	O
Ab	O
-	O
POSITIVE	O
[	O
**	O
2108-12-30	O
**	O
]	O
HCV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2108-12-30	O
**	O
]	O
ANCA	O
-	O
NEGATIVE	O
B	O
[	O
**	O
2108-12-30	O
**	O
]	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
-	O
POSITIVE	O
Titer	O
-	O
1:40	O
[	O
**	O
2108-12-31	O
**	O
]	O
BLOOD	O
IgG	O
-	O
1132	O
IgA	O
-	O
504	O
*	O
IgM	O
-	O
121	O
[	O
**	O
2109-1-4	O
**	O
]	O
C3	O
-	O
52	O
*	O
C4	O
-	O
11	O
[	O
**	O
2108-12-30	O
**	O
]	O
C3	O
-	O
49	O
*	O
C4	O
-	O
8	O
*	O
[	O
**	O
2108-12-31	O
**	O
]	O
HIV	O
Ab	O
-	O
NEGATIVE	O
[	O
**	O
2108-12-29	O
**	O
]	O
Acetmnp	O
-	O
NEG	O
Urine	O
Studies	O
:	O
[	O
**	O
2109-1-1	O
**	O
]	O
05:10	O
PM	O
URINE	O
Color	O
-	O
Amber	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.012	O
Blood	O
-	O
LG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
100	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
MOD	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
6.5	O
Leuks	O
-	O
NEG	O
[	O
**	O
2108-12-30	O
**	O
]	O
03:57	O
AM	O
URINE	O
Color	O
-	O
LtAmb	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.015	O
Blood	O
-	O
LGE	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
100	O
Glucose	O
-	O
NEG	O
Ketone	O
-	O
NEG	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
5.0	O
Leuks	O
-	O
NEG	O
RBC	O
-	O
12	O
*	O
WBC	O
-	O
0	O
Bacteri	O
-	O
FEW	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
0	O
[	O
**	O
2108-12-30	O
**	O
]	O
03:57	O
AM	O
URINE	O
Hours	O
-	O
RANDOM	O
UreaN	O
-	O
257	O
Creat	O
-	O
56	O
Na	O
-	O
91	O
TotProt	O
-	O
132	O
Prot	O
/	O
Cr	O
-	O
2.4	O
*	O
Albumin	O
-	O
80.1	O
Alb	O
/	O
Cre	O
-	O
1430.4	O
*	O
[	O
**	O
2109-1-3	O
**	O
]	O
07:56	O
PM	O
URINE	O
pH	O
-	O
5	O
Hours	O
-	O
24	O
Volume	O
-	O
1500	O
Creat	O
-	O
42	O
[	O
**	O
2109-1-1	O
**	O
]	O
08:00	O
PM	O
URINE	O
Porphob	O
-	O
NEGATIVE	O
[	O
**	O
2109-1-3	O
**	O
]	O
07:56	O
PM	O
URINE	O
Porphob	O
-	O
NEGATIVE	O
AEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2109-1-4	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2109-1-4	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
AEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2109-1-6	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
ANAEROBIC	O
BOTTLE	O
(	O
Final	O
[	O
**	O
2109-1-6	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
URINE	O
CULTURE	O
(	O
Final	O
[	O
**	O
2108-12-31	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
RAPID	O
PLASMA	O
REAGIN	O
TEST	O
(	O
Final	O
[	O
**	O
2109-1-1	O
**	O
]	O
)	O
:	O
NONREACTIVE	O
.	O
Reference	O
Range	O
:	O
Non-Reactive	O
.	O
CMV	O
IgG	O
ANTIBODY	O
(	O
Final	O
[	O
**	O
2109-1-1	O
**	O
]	O
)	O
:	O
NEGATIVE	O
FOR	O
CMV	O
IgG	O
ANTIBODY	O
BY	O
EIA	O
.	O
<	O
4	O
AU	O
/	O
ML	O
.	O
Reference	O
Range	O
:	O
Negative	O
<	O
4	O
AU	O
/	O
ml	O
,	O
Positive	O
>	O
=	O
6	O
AU	O
/	O
ml	O
.	O
CMV	O
IgM	O
ANTIBODY	O
(	O
Final	O
[	O
**	O
2109-1-1	O
**	O
]	O
)	O
:	O
NEGATIVE	O
FOR	O
CMV	O
IgM	O
ANTIBODY	O
BY	O
EIA	O
.	O
INTERPRETATION	O
:	O
NO	O
ANTIBODY	O
DETECTED	O
.	O
Greatly	O
elevated	O
serum	O
protein	O
with	O
IgG	O
levels	O
>	O
[	O
**	O
2103	O
**	O
]	O
mg	O
/	O
dl	O
may	O
cause	O
interference	O
with	O
CMV	O
IgM	O
results	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
VIRUS	O
VCA	O
-	O
IgG	O
AB	O
(	O
Final	O
[	O
**	O
2109-1-3	O
**	O
]	O
)	O
:	O
POSITIVE	O
BY	O
EIA	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
VIRUS	O
EBNA	O
IgG	O
AB	O
(	O
Final	O
[	O
**	O
2109-1-3	O
**	O
]	O
)	O
:	O
POSITIVE	O
BY	O
EIA	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
-	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
VIRUS	O
VCA	O
-	O
IgM	O
AB	O
(	O
Final	O
[	O
**	O
2109-1-3	O
**	O
]	O
)	O
:	O
NEGATIVE	O
<	O
1:10	O
BY	O
IFA	O
.	O
INTERPRETATION	O
:	O
RESULTS	O
INDICATIVE	O
OF	O
PAST	O
EBV	O
INFECTION	O
.	O
In	O
most	O
populations	O
,	O
90	O
%	O
of	O
adults	O
have	O
been	O
infected	O
at	O
sometime	O
with	O
EBV	O
and	O
will	O
have	O
measurable	O
VCA	O
IgG	O
and	O
EBNA	O
antibodies	O
.	O
Antibodies	O
to	O
EBNA	O
develop	O
6	O
-	O
8	O
weeks	O
after	O
primary	O
infection	O
and	O
remain	O
present	O
for	O
life	O
.	O
Presence	O
of	O
VCA	O
IgM	O
antibodies	O
indicates	O
recent	O
primary	O
infection	O
.	O
TOXOPLASMA	O
IgG	O
ANTIBODY	O
(	O
Final	O
[	O
**	O
2109-1-1	O
**	O
]	O
)	O
:	O
NEGATIVE	O
FOR	O
TOXOPLASMA	O
IgG	O
ANTIBODY	O
BY	O
EIA	O
.	O
0.0	O
IU	O
/	O
ML	O
.	O
Reference	O
Range	O
:	O
Negative	O
<	O
4	O
IU	O
/	O
ml	O
,	O
Positive	O
>	O
=	O
8	O
IU	O
/	O
ml	O
.	O
TOXOPLASMA	O
IgM	O
ANTIBODY	O
(	O
Final	O
[	O
**	O
2109-1-1	O
**	O
]	O
)	O
:	O
NEGATIVE	O
FOR	O
TOXOPLASMA	O
IgM	O
ANTIBODY	O
BY	O
EIA	O
.	O
INTERPRETATION	O
:	O
NO	O
ANTIBODY	O
DETECTED	O
.	O
The	O
FDA	O
is	O
advising	O
that	O
the	O
result	O
from	O
any	O
one	O
toxoplasma	O
IgM	O
commercial	O
test	O
kit	O
should	O
not	O
be	O
used	O
as	O
the	O
sole	O
determinant	O
of	O
recent	O
toxoplasma	O
infection	O
when	O
screening	O
a	O
pregnant	O
patient	O
.	O
CXR	O
[	O
**	O
12	O
-	O
29	O
**	O
]	O
:	O
There	O
are	O
bilateral	O
pulmonary	O
opacities	O
in	O
the	O
perihilar	O
regions	O
,	O
left	O
worse	O
than	O
right	O
.	O
This	O
may	O
represent	O
some	O
failure	O
,	O
bilateral	O
infiltrates	O
can	O
not	O
be	O
excluded	O
.	O
ABD	O
US	O
[	O
**	O
12	O
-	O
30	O
**	O
]	O
:	O
Right	O
liver	O
lobe	O
hemangioma	O
.	O
Normal	O
hepatic	O
blood	O
flow	O
.	O
Echogenic	O
kidneys	O
representing	O
parenchymal	O
disease	O
.	O
CXR	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
:	O
1	O
.	O
No	O
evidence	O
of	O
pneumothorax	O
.	O
2	O
.	O
Worsening	O
asymmetrical	O
perihilar	O
haziness	O
,	O
left	O
greater	O
than	O
right	O
,	O
most	O
likely	O
due	O
to	O
worsening	O
perihilar	O
edema	O
.	O
CT	O
ABD	O
/	O
PELVIS	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
:	O
1	O
.	O
No	O
evidence	O
of	O
a	O
retroperitoneal	O
hematoma	O
.	O
Small	O
amount	O
of	O
simple	O
free	O
fluid	O
in	O
the	O
pelvis	O
.	O
2	O
.	O
Small	O
bilateral	O
pleural	O
effusions	O
.	O
3	O
.	O
Patchy	O
consolidation	O
in	O
the	O
left	O
lower	O
lobe	O
could	O
represent	O
pneumonia	O
.	O
4	O
.	O
Small	O
pericardial	O
effusion	O
.	O
5	O
.	O
Probable	O
small	O
hemorrhage	O
in	O
the	O
liver	O
,	O
consistent	O
with	O
recent	O
biopsy	O
.	O
[	O
**	O
12	O
-	O
31	O
**	O
]	O
Liver	O
transjugular	O
biopsy	O
:	O
1	O
.	O
Acute	O
submassive	O
hepatic	O
necrosis	O
,	O
centrolobular	O
and	O
mid-zonal	O
areas	O
(	O
zones	O
[	O
**	O
1	O
-	O
3	O
**	O
]	O
)	O
.	O
About	O
50	O
%	O
of	O
liver	O
is	O
involved	O
.	O
2	O
.	O
Moderate	O
lobular	O
mononuclear	O
cell	O
inflammation	O
with	O
scattered	O
neutrophils	O
,	O
and	O
minimal	O
portal	O
inflammation	O
.	O
3	O
.	O
Mild	O
cholestasis	O
.	O
4	O
.	O
Trichrome	O
stain	O
:	O
No	O
increased	O
fibrosis	O
.	O
5	O
.	O
Iron	O
stain	O
:	O
No	O
stainable	O
iron	O
.	O
Note	O
:	O
Probable	O
causes	O
include	O
drug	O
/	O
toxic	O
and	O
ischemic	O
disease	O
.	O
Transthoracic	O
echo	O
[	O
**	O
1	O
-	O
1	O
**	O
]	O
:	O
Conclusions	O
:	O
1	O
.	O
No	O
atrial	O
septal	O
defect	O
or	O
patent	O
foramen	O
ovale	O
is	O
seen	O
by	O
2D	O
,	O
color	O
Doppler	O
or	O
saline	B-Drug
contrast	I-Drug
with	O
maneuvers	O
.	O
2	O
.	O
Left	O
ventricular	O
wall	O
thickness	O
,	O
cavity	O
size	O
,	O
and	O
systolic	O
function	O
are	O
normal	O
(	O
LVEF	O
>	O
55	O
%	O
)	O
.	O
Regional	O
left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
3	O
.	O
The	O
aortic	O
root	O
is	O
mildly	O
dilated	O
.	O
The	O
ascending	O
aorta	O
is	O
mildly	O
dilated	O
.	O
4	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Mild	O
to	O
moderate	O
(	O
[	O
**	O
12	O
-	O
2	O
**	O
]	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
5	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
Renal	O
biopsy	O
[	O
**	O
2109-1-4	O
**	O
]	O
:	O
DIAGNOSIS	O
:	O
Renal	O
Biopsy	O
,	O
needle	O
:	O
Advanced	O
Global	O
Glomerulosclerosis	O
,	O
Interstitial	O
Fibrosis	O
,	O
and	O
Tubular	O
Atrophy	O
,	O
see	O
note	O
.	O
Note	O
:	O
Light	O
Microscopy	O
:	O
The	O
specimen	O
consists	O
of	O
renal	O
cortex	O
and	O
medulla	O
,	O
containing	O
approximately	O
6	O
glomeruli	O
,	O
all	O
of	O
which	O
show	O
advanced	O
injury	O
or	O
global	O
sclerosis	O
.	O
There	O
is	O
moderate	O
to	O
marked	O
interstitial	O
fibrosis	O
and	O
tubular	O
atrophy	O
.	O
Patchy	O
chronic	O
inflammation	O
accompanies	O
the	O
scarring	O
.	O
Arteries	O
show	O
moderate	O
intimal	O
fibroplasia	O
.	O
Arterioles	O
show	O
moderate	O
-	O
marked	O
mural	O
thickening	O
,	O
with	O
hyaline	O
change	O
.	O
Immunofluorescence	O
:	O
Not	O
done	O
,	O
as	O
the	O
tissue	O
did	O
not	O
contain	O
glomeruli	O
(	O
block	O
exhausted	O
)	O
.	O
Electron	O
Microscopy	O
(	O
C4047	O
)	O
:	O
Fine	O
structural	O
studies	O
of	O
a	O
single	O
glomerular	O
tuft	O
with	O
advanced	O
injury	O
reveal	O
that	O
most	O
capillaries	O
show	O
obsolescence	O
with	O
loss	O
of	O
cellular	O
elements	O
.	O
Extensive	O
foot	O
process	O
effacement	O
with	O
areas	O
of	O
total	O
podocyte	O
loss	O
are	O
seen	O
.	O
Mesangial	O
matrix	O
is	O
increased	O
with	O
occasional	O
granular	O
electron	O
dense	O
deposits	O
.	O
One	O
loop	O
is	O
more	O
preserved	O
,	O
and	O
shows	O
endocapillary	O
cells	O
with	O
subendothelial	O
electron	O
dense	O
deposits	O
.	O
No	O
subepithelial	O
deposits	O
are	O
noted	O
.	O
Comment	O
:	O
Sample	O
size	O
is	O
limited	O
.	O
Clinical	O
correlation	O
is	O
indicated	O
to	O
determine	O
if	O
this	O
small	O
sample	O
size	O
is	O
representative	O
of	O
the	O
kidneys	O
.	O
The	O
findings	O
are	O
that	O
of	O
advanced	O
injury	O
that	O
can	O
not	O
be	O
specifically	O
categorized	O
.	O
.	O
CT	O
ABD	O
/	O
PELVIS	O
[	O
**	O
1	O
-	O
5	O
**	O
]	O
:	O
1	O
.	O
Interval	O
development	O
of	O
moderate	O
-	O
size	O
perinephric	O
hematoma	O
as	O
above	O
.	O
These	O
findings	O
were	O
communicated	O
to	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
5716	O
**	O
]	O
at	O
the	O
time	O
of	O
interpretation	O
.	O
2	O
.	O
Stable	O
appearance	O
of	O
small	O
,	O
bilateral	O
pleural	O
effusions	O
.	O
3	O
.	O
Small	O
amount	O
of	O
fluid	O
surrounding	O
the	O
liver	O
.	O
Previously	O
evident	O
capsular	O
hematoma	O
is	O
not	O
well	O
seen	O
.	O
4	O
.	O
Moderate	O
amount	O
of	O
free	O
fluid	O
is	O
in	O
the	O
pelvis	O
.	O
5	O
.	O
Marked	O
circumferential	O
edema	O
of	O
the	O
gallbladder	O
wall	O
in	O
the	O
setting	O
of	O
luminal	O
contraction	O
,	O
secondary	O
to	O
known	O
underlying	O
liver	O
disease	O
.	O
Brief	O
Hospital	O
Course	O
:	O
50	O
year	O
old	O
female	O
with	O
history	O
of	O
HTN	O
and	O
nephrolithiasis	O
,	O
transferred	O
from	O
outside	O
hospital	O
with	O
fulminant	B-Ade
liver	I-Ade
failure	I-Ade
and	O
acute	O
on	O
chronic	O
renal	O
failure	O
,	O
admitted	O
to	O
the	O
MICU	O
.	O
Briefly	O
,	O
her	O
liver	O
failure	O
had	O
almost	O
resolved	O
by	O
the	O
time	O
of	O
discharge	O
.	O
The	O
etiology	O
still	O
remains	O
unclear	O
,	O
though	O
zithromax	I-Drug
was	O
felt	O
to	O
be	O
the	O
most	O
likely	O
cause	O
.	O
Her	O
renal	O
failure	O
continued	O
,	O
and	O
she	O
was	O
discharged	O
with	O
anticipation	O
of	O
dialysis	O
in	O
the	O
near	O
future	O
.	O
The	O
cause	O
of	O
her	O
renal	O
failure	O
also	O
remains	O
unclear	O
.	O
1	O
)	O
Liver	O
failure	O
:	O
On	O
admission	O
,	O
she	O
was	O
found	O
to	O
have	O
transaminases	O
in	O
the	O
8000	O
range	O
,	O
as	O
well	O
as	O
INR	O
3.8	O
,	O
PT	O
24.5	O
,	O
albumin	O
3.0	O
,	O
Total	O
bili	O
9.2	O
,	O
and	O
LDH	O
12,610	O
.	O
She	O
was	O
admitted	O
to	O
the	O
MICU	O
and	O
followed	O
by	O
the	O
hepatology	O
team	O
.	O
A	O
number	O
of	O
blood	O
tests	O
were	O
sent	O
off	O
to	O
ascertain	O
the	O
etiology	O
of	O
her	O
liver	O
failure	O
,	O
however	O
they	O
were	O
uniformly	O
negative	O
(	O
these	O
included	O
tylenol	I-Drug
,	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
,	O
CMV	O
,	O
EBV	O
,	O
toxoplasma	O
,	O
Hepatitis	O
serologies	O
,	O
leptospirosis	O
,	O
and	O
porphyria	O
)	O
.	O
She	O
underwent	O
a	O
transjugular	O
liver	O
biopsy	O
on	O
the	O
3rd	O
day	O
of	O
the	O
admission	O
,	O
which	O
showed	O
a	O
non-specific	O
pattern	O
of	O
injury	O
consistent	O
with	O
drug	O
/	O
toxic	O
or	O
ischemic	O
disease	O
.	O
She	O
unfortunately	O
developed	O
a	O
subcapsular	B-Reason
liver	I-Reason
hematoma	I-Reason
during	O
the	O
procedure	O
,	O
however	O
this	O
was	O
stabilized	O
with	O
FFP	I-Drug
and	O
Vitamin	O
K	O
which	O
the	O
patient	O
had	O
already	O
been	O
receiving	O
.	O
She	O
also	O
received	O
2	O
U	O
PRBC	I-Drug
,	O
and	O
hematocrit	O
was	O
subsequently	O
stable	O
.	O
A	O
repeat	O
abdominal	O
CT	O
scan	O
later	O
in	O
the	O
course	O
demonstrated	O
resolution	O
of	O
the	O
hematoma	O
.	O
She	O
was	O
followed	O
by	O
the	O
transplant	O
service	O
,	O
however	O
she	O
never	O
met	O
criteria	O
for	O
liver	O
transplant	O
(	O
no	O
encephalopathy	O
)	O
,	O
and	O
liver	O
function	O
began	O
to	O
improve	O
remarkably	O
(	O
see	O
below	O
)	O
.	O
During	O
her	O
hospitalization	O
she	O
received	O
more	O
than	O
14	O
units	O
of	O
FFP	I-Drug
to	B-Reason
keep	I-Reason
her	I-Reason
INR	I-Reason
<	I-Reason
1.5	I-Reason
,	O
as	O
well	O
as	O
DDAVP	I-Drug
x	O
5	O
,	O
and	O
multiple	O
dosese	O
of	O
vitamin	B-Drug
K.	O
Prior	O
to	O
discharge	O
,	O
her	O
INR	O
had	O
remained	O
<	O
1.5	O
on	O
it	O
's	O
own	O
for	O
>	O
48	O
hours	O
.	O
Her	O
transaminases	O
had	O
trended	O
down	O
almost	O
into	O
the	O
normal	O
range	O
(	O
111	O
and	O
41	O
for	O
ALT	O
and	O
AST	O
respectively	O
)	O
,	O
and	O
her	O
total	O
bilirubin	O
had	O
trended	O
down	O
to	O
5.9	O
from	O
a	O
peak	O
of	O
40.3	O
.	O
The	O
etiology	O
of	O
the	O
liver	B-Ade
insult	I-Ade
remains	O
unclear	O
,	O
however	O
the	O
zithromax	I-Drug
course	O
that	O
she	O
had	O
received	O
is	O
a	O
potential	O
[	O
**	O
Doctor	O
Last	O
Name	O
360	O
**	O
]	O
,	O
and	O
she	O
should	O
therefore	O
not	O
receive	O
zithromax	I-Drug
in	O
the	O
future	O
.	O
The	O
hepatology	O
team	O
felt	O
that	O
she	O
would	O
likely	O
return	O
to	O
completely	O
normal	O
liver	O
function	O
.	O
2	O
)	O
Acute	O
on	O
chronic	O
renal	O
failure	O
:	O
On	O
admission	O
she	O
was	O
also	O
in	O
acute	O
renal	O
failure	O
with	O
creatinine	O
of	O
5.7	O
.	O
By	O
report	O
from	O
the	O
outside	O
hospital	O
,	O
her	O
recent	O
baseline	O
Cr	O
was	O
2.8	O
in	O
[	O
**	O
8	O
-	O
4	O
**	O
]	O
.	O
Hepatorenal	O
syndrome	O
was	O
in	O
the	O
differential	O
,	O
however	O
her	O
urine	O
sodium	O
was	O
elevated	O
,	O
therefore	O
this	O
diagnosis	O
could	O
not	O
be	O
made	O
.	O
Initial	O
urine	O
sediment	O
was	O
felt	O
to	O
be	O
consistent	O
with	O
ATN	O
or	O
AIN	O
(	O
RBCs	O
,	O
no	O
acanthocytes	O
,	O
occasional	O
WBC	O
,	O
hyaline	O
casts	O
,	O
occasional	O
renal	O
tubular	O
epithelial	O
cells	O
,	O
granular	O
casts	O
,	O
no	O
muddy	O
brown	O
casts	O
or	O
rbc	O
casts	O
)	O
.	O
A	O
renal	O
US	O
revealed	O
echogenic	O
kidneys	O
consistent	O
with	O
parenchymal	O
disease	O
.	O
A	O
later	O
urine	O
sediment	O
showed	O
many	O
acanthocytic	O
and	O
dysmorphic	O
rbcs	O
,	O
many	O
casts	O
,	O
granular	O
and	O
bite	O
stained	O
,	O
no	O
WBCs	O
,	O
no	O
RBC	O
casts	O
,	O
occasional	O
RTE	O
cells	O
,	O
and	O
100	O
mg	O
/	O
dl	O
protein	O
.	O
The	O
nephrology	O
team	O
felt	O
that	O
her	O
acute	O
insult	O
had	O
resolved	O
,	O
and	O
the	O
new	O
sediment	O
was	O
suggestive	O
of	O
underlying	O
glomerular	O
injury	O
,	O
the	O
possibilities	O
for	O
which	O
included	O
cryoglobulinemia	O
,	O
lupus	O
,	O
endocarditis	O
,	O
idiopathic	O
MPGN	O
,	O
and	O
post-infectious	O
GN	O
.	O
A	O
renal	O
biopsy	O
was	O
recommended	O
.	O
Ms.	O
[	O
**	O
Known	O
lastname	O
59022	O
**	O
]	O
had	O
a	O
renal	O
biopsy	O
on	O
day	O
6	O
of	O
her	O
admission	O
.	O
Unfortunately	O
there	O
were	O
only	O
5	O
glomeruli	O
in	O
the	O
specimen	O
,	O
all	O
globally	O
sclerosed	O
.	O
The	O
interstitium	O
was	O
severely	O
fibrosed	O
,	O
and	O
there	O
was	O
tubular	O
atrophy	O
,	O
all	O
consistent	O
with	O
advanced	O
injury	O
that	O
could	O
not	O
be	O
specified	O
.	O
Post-biopsy	O
she	O
developed	O
flank	O
pain	O
,	O
and	O
was	O
noted	O
to	O
have	O
a	O
hematocrit	O
drop	O
from	O
31	O
to	O
25	O
.	O
A	O
CT	O
of	O
the	O
abdomen	O
demonstrated	O
a	O
moderate	O
-	O
sized	O
perinephric	B-Reason
hematoma	I-Reason
.	O
She	O
again	O
received	O
FFP	I-Drug
,	O
DDAVP	I-Drug
,	O
and	O
2	O
U	O
PRBC	I-Drug
.	O
Her	O
hematocrit	O
stabilized	O
and	O
she	O
had	O
no	O
further	O
flank	O
pain	O
prior	O
to	O
discharge	O
.	O
Her	O
creatinine	O
on	O
discharge	O
was	O
still	O
markedly	O
above	O
baseline	O
at	O
6.1	O
,	O
and	O
she	O
was	O
exhibiting	O
mild	O
signs	O
of	O
volume	O
overload	O
(	O
orthopnea	O
,	O
peripheral	O
edema	O
)	O
.	O
The	O
renal	O
team	O
did	O
not	O
feel	O
that	O
she	O
met	O
criteria	O
for	O
urgent	O
hemodialysis	O
,	O
however	O
,	O
and	O
she	O
was	O
therefore	O
seen	O
by	O
the	O
dialysis	O
team	O
and	O
set	O
up	O
with	O
outpatient	O
follow	O
up	O
for	O
probable	O
need	O
for	O
dialysis	O
in	O
the	O
near	O
future	O
.	O
Of	O
note	O
,	O
her	O
PTH	O
prior	O
to	O
discharge	O
was	O
369	O
(	O
up	O
from	O
15	O
only	O
a	O
few	O
months	O
prior	O
)	O
.	O
She	O
was	O
also	O
started	O
on	O
lasix	I-Drug
at	O
the	O
recommendation	O
of	O
the	O
renal	O
team	O
,	O
with	O
the	O
hopes	B-Reason
of	I-Reason
improving	I-Reason
her	O
fluid	O
balance	O
and	O
controlling	B-Reason
her	I-Reason
hypertension	I-Reason
(	O
see	O
below	O
)	O
.	O
3	O
)	O
Pneumonia	I-Reason
:	O
At	O
the	O
outside	O
hospital	O
she	O
had	O
been	O
found	O
to	O
have	O
a	O
LLL	B-Reason
PNA	I-Reason
and	O
was	O
therefore	O
already	O
on	O
levo	I-Drug
/	O
flagyl	I-Drug
on	O
transfer	O
.	O
These	O
were	O
continued	O
to	O
complete	O
a	O
7	O
day	O
course	O
.	O
She	O
remained	O
afebrile	O
throughout	O
her	O
course	O
.	O
Her	O
wbc	O
was	O
elevated	O
on	O
admission	O
,	O
however	O
this	O
was	O
felt	O
to	O
be	O
related	O
to	O
the	O
acute	O
liver	O
injury	O
,	O
and	O
trended	O
down	O
throughout	O
the	O
admission	O
.	O
She	O
felt	O
well	O
throughout	O
,	O
and	O
had	O
no	O
shortness	O
of	O
breath	O
other	O
than	O
orthopnea	O
from	O
her	O
fluid	O
overload	O
.	O
Her	O
oxygen	O
saturation	O
was	O
consistenly	O
>	O
95	O
%	O
.	O
4	O
)	O
Hypertension	I-Reason
:	O
She	O
has	O
a	O
history	B-Reason
of	I-Reason
hypertension	I-Reason
,	I-Reason
and	O
had	O
been	O
taking	O
toprol	I-Drug
XL	O
25	O
mg	O
daily	O
.	O
In	O
the	O
MICU	O
she	O
had	O
very	O
difficult	B-Reason
to	I-Reason
control	I-Reason
hypertension	I-Reason
,	O
and	O
was	O
given	O
metoprolol	I-Drug
,	O
hydralazine	I-Drug
,	O
and	O
amlodipine	I-Drug
.	O
A	O
labetalol	I-Drug
drip	O
was	O
started	O
very	O
briefly	O
,	O
for	O
only	O
a	O
few	O
hours	O
.	O
On	O
the	O
floors	O
,	O
Mrs.	O
[	O
**	O
Known	O
lastname	O
59024	O
**	O
]	O
blood	B-Reason
pressure	I-Reason
was	O
moderately	O
well	O
controlled	O
on	O
metoprolol	I-Drug
50	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
and	O
amlodipine	I-Drug
10	O
mg	O
daily	O
.	O
She	O
was	O
given	O
lasix	I-Drug
40	O
mg	O
PO	O
once	O
prior	O
to	O
discharge	O
,	O
and	O
discharged	O
on	O
80	O
mg	O
PO	O
daily	O
,	O
per	O
renal	O
,	O
plus	O
toprol	I-Drug
XL	O
100	O
mg	O
daily	O
,	O
and	O
amlodipine	I-Drug
10	O
mg	O
daily	O
.	O
5	O
)	O
Anemia	O
:	O
The	O
patient	O
had	O
a	O
persistently	O
low	O
hematocrit	O
during	O
the	O
admission	O
,	O
however	O
she	O
also	O
had	O
an	O
elevated	O
LDH	O
and	O
persistent	O
nucleated	O
RBCs	O
,	O
therefore	O
hematology	O
/	O
oncology	O
was	O
called	O
.	O
Review	O
of	O
peripheral	O
smear	O
was	O
consistent	O
with	O
stress	O
hematopoesis	O
due	O
to	O
acute	O
liver	O
failure	O
and	O
not	O
autoimmune	O
hemolytic	O
anemia	O
.	O
They	O
felt	O
that	O
her	O
elevated	O
LDH	O
and	O
bili	O
,	O
as	O
well	O
as	O
low	O
haptoglobin	O
,	O
were	O
all	O
a	O
result	O
of	O
her	O
liver	O
disease	O
.	O
She	O
likely	O
has	O
an	O
underlying	O
anemia	O
of	O
chronic	O
disease	O
from	O
her	O
renal	O
failure	O
.	O
Her	O
hematocrit	O
was	O
stable	O
between	O
30	O
and	O
32	O
prior	O
to	O
discharge	O
.	O
Medications	O
on	O
Admission	O
:	O
Toprol	I-Drug
XL	O
25	O
mg	O
daily	O
Prednisone	I-Drug
x	O
2	O
days	O
Flonase	I-Drug
Robitussin	I-Drug
Discharge	O
Medications	O
:	O
1	O
.	O
Calcium	B-Drug
Carbonate	I-Drug
500	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
180	O
Tablet	O
,	O
Chewable	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
2	O
.	O
Amlodipine	I-Drug
Besylate	O
5	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
3	O
.	O
Toprol	I-Drug
XL	O
100	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
90	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
4	O
.	O
Lasix	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Acute	O
liver	O
failure	O
,	O
resolving	O
Acute	O
on	O
chronic	O
renal	O
failure	O
Hypertension	I-Reason
Discharge	O
Condition	O
:	O
Good	O
,	O
stable	O
.	O
Discharge	O
Instructions	O
:	O
We	O
have	O
increased	O
your	O
dose	O
of	O
Toprol	I-Drug
XL	O
to	O
300	O
mg	O
daily	O
.	O
We	O
have	O
also	O
started	O
you	O
on	O
a	O
new	O
medication	O
for	O
your	B-Reason
blood	I-Reason
pressure	O
called	O
amlodipine	I-Drug
,	O
10	O
mg	O
daily	O
.	O
We	O
have	O
also	O
started	O
furosemide	I-Drug
(	O
Lasix	O
)	O
80	O
mg	O
daily	O
to	B-Reason
help	I-Reason
remove	I-Reason
fluid	I-Reason
.	O
Call	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
if	O
you	O
stop	O
urinating	O
,	O
or	O
get	O
short	O
of	O
breath	O
.	O
You	O
have	O
a	O
number	O
of	O
follow	O
up	O
appointments	O
,	O
listed	O
below	O
.	O
Followup	O
Instructions	O
:	O
Someone	O
from	O
the	O
kidney	O
doctor	O
's	O
office	O
(	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
will	O
be	O
calling	O
you	O
to	O
make	O
an	O
appointment	O
for	O
you	O
with	O
them	O
.	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1344	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
3125	O
**	O
]	O
,	O
MD	O
Where	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
3126	O
**	O
]	O
CENTER	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2109-1-24	O
**	O
]	O
1:00	O
Provider	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
971	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
970	O
**	O
]	O
,	O
MD	O
Where	O
:	O
LM	O
[	O
**	O
Hospital	O
Unit	O
Name	O
3126	O
**	O
]	O
CENTER	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
673	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2109-3-12	O
**	O
]	O
9:30	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
TRANSPLANT	O
SOCIAL	O
WORK	O
Where	O
:	O
TRANSPLANT	O
SOCIAL	O
WORK	O
Date	O
/	O
Time	O
:[	O
**	O
2109-3-12	O
**	O
]	O
11:00	O
You	O
have	O
an	O
appointment	O
with	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
at	O
[	O
**	O
Hospital1	O
189	O
**	O
]	O
Community	O
Health	O
Center	O
on	O
[	O
**	O
2109-1-16	O
**	O
]	O
at	O
1:15	O
p.m.	O

Admission	O
Date	O
:	O
[	O
**	O
2174-7-26	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2174-7-29	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2095-8-17	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Coumadin	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
3276	O
**	O
]	O
Chief	O
Complaint	O
:	O
chest	O
pain	O
,	O
lactic	O
acidosis	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
none	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
100424	O
**	O
]	O
is	O
a	O
78	O
year	O
old	O
gentleman	O
with	O
metastatic	O
NSCLC	O
admitted	O
for	O
elevated	O
lactate	O
.	O
The	O
patient	O
presented	O
to	O
Radiation	O
Oncology	O
today	O
for	O
WBXRT	O
(	O
session	O
[	O
**	O
5	O
-	O
3	O
**	O
]	O
today	O
)	O
,	O
and	O
while	O
at	O
clinic	O
developed	O
2	O
-	O
3	O
minutes	O
of	O
chest	O
pain	O
described	O
as	O
sternal	O
chest	O
pressure	O
rated	O
as	O
[	O
**	O
4	O
-	O
29	O
**	O
]	O
that	O
resolved	O
with	O
supplemental	O
oxygen	O
.	O
The	O
patient	O
denied	O
any	O
associated	O
SOB	O
,	O
n	O
/	O
v	O
,	O
palpitations	O
,	O
pain	O
radiating	O
to	O
jaw	O
,	O
arm	O
,	O
or	O
back	O
that	O
resolved	O
with	O
supplmental	O
oxygen	I-Drug
.	O
He	O
was	O
then	O
sent	O
to	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
for	O
further	O
evaluation	O
.	O
.	O
In	O
the	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
ED	O
,	O
VS	O
97.9	O
143/89	O
68	O
16	O
100	O
%	O
RA	O
.	O
The	O
patient	O
received	O
vanco	I-Drug
and	O
levofloxacin	I-Drug
over	O
concern	O
for	O
pneumonia	I-Reason
as	O
well	O
as	O
3L	O
IVF	I-Drug
with	O
an	O
increase	O
in	O
his	O
lactate	O
from	O
4.1	O
to	O
4.7	O
.	O
A	O
CTA	O
was	O
negative	O
for	O
PE	O
,	O
but	O
demonstrated	O
diffuse	O
ground	O
glass	O
opacities	O
,	O
right	O
base	O
consolidation	O
,	O
and	O
persistent	O
infiltrates	O
largely	O
unchanged	O
from	O
a	O
recent	O
PET	O
-	O
CT.	O
.	O
The	O
patient	O
was	O
then	O
admitted	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
for	O
further	O
evaluation	O
.	O
.	O
On	O
admission	O
to	O
the	O
[	O
**	O
Hospital	O
Unit	O
Name	O
153	O
**	O
]	O
,	O
the	O
patient	O
was	O
resting	O
comfortably	O
without	O
complaints	O
.	O
Denies	O
any	O
f	O
/	O
c	O
/	O
s	O
,	O
n	O
/	O
v	O
/	O
d	O
,	O
CP	O
/	O
SOB	O
,	O
palpitations	O
,	O
cough	O
,	O
orthopnea	O
,	O
PND	O
,	O
or	O
hemoptysis	O
.	O
Past	O
Medical	O
History	O
:	O
1	O
.	O
Recurrent	O
adenocarcinoma	O
s	O
/	O
p	O
RLL	O
(	O
[	O
**	O
2168	O
**	O
]	O
)	O
and	O
RML	O
(	O
[	O
**	O
2170	O
**	O
]	O
)	O
resection	O
,	O
and	O
CyberKnife	O
therapy	O
(	O
[	O
**	O
2172	O
**	O
]	O
)	O
2	O
.	O
Hypertension	O
3	O
.	O
DMII	O
4	O
.	O
COPD	O
5	O
.	O
Hypercholesterolemia	O
6	O
.	O
CAD	O
s	O
/	O
p	O
MI	O
(	O
"	O
several	O
years	O
ago	O
)	O
7	O
.	O
Psoriasis	O
8	O
.	O
TIA	O
(	O
[	O
**	O
2156	O
**	O
]	O
)	O
PSH	O
:	O
1	O
.	O
Carotid	O
endarterectomy	O
in	O
[	O
**	O
2161	O
**	O
]	O
.	O
2	O
.	O
Bilateral	O
cataracts	O
.	O
3	O
.	O
Ischiorectal	O
surgery	O
in	O
the	O
[	O
**	O
2115	O
**	O
]	O
.	O
4	O
.	O
Appendectomy	O
.	O
5	O
.	O
RLL	O
(	O
[	O
**	O
2168	O
**	O
]	O
)	O
and	O
RML	O
(	O
[	O
**	O
2170	O
**	O
]	O
)	O
resection	O
Social	O
History	O
:	O
Retired	O
electronic	O
store	O
owner	O
.	O
Splits	O
time	O
between	O
MA	O
and	O
FL	O
with	O
wife	O
.	O
Social	O
alcohol	O
use	O
(	O
[	O
**	O
2	O
-	O
22	O
**	O
]	O
drinks	O
/	O
week	O
)	O
.	O
Smoked	O
1	O
-	O
2ppd	O
x	O
58	O
yrs	O
,	O
quit	O
in	O
[	O
**	O
2168	O
**	O
]	O
.	O
Family	O
History	O
:	O
No	O
history	O
of	O
lung	O
cancer	O
.	O
Physical	O
Exam	O
:	O
VS	O
:	O
98.1	O
67145/71	O
88	O
19	O
97	O
%	O
RA	O
Gen	O
:	O
Age	O
appropriate	O
male	O
in	O
NAD	O
HEENT	O
:	O
Perrl	O
,	O
eomi	O
,	O
sclerae	O
anicteric	O
.	O
MMM	O
,	O
OP	O
clear	O
without	O
lesions	O
,	O
exudate	O
or	O
erythema	O
.	O
Neck	O
supple	O
.	O
CV	O
:	O
Nl	O
S1	O
+	O
S2	O
,	O
no	O
m	O
/	O
r	O
/	O
g.	O
JVP	O
<	O
10	O
cm	O
.	O
No	O
pre-cordial	O
heave	O
or	O
laterally	O
displaced	O
PMI	O
.	O
Pulm	O
:	O
Diffuse	O
expiratory	O
wheezes	O
.	O
Decreased	O
breaths	O
sounds	O
on	O
right	O
with	O
dullness	O
to	O
percussion	O
and	O
vocal	O
fremitus	O
.	O
Abd	O
:	O
S	O
/	O
NT	O
/	O
ND	O
+	O
bs	O
Ext	O
:	O
No	O
c	O
/	O
c	O
/	O
e.	O
Neuro	O
:	O
AO	O
x3	O
,	O
CN	O
II	O
-	O
XII	O
intact	O
Pertinent	O
Results	O
:	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
WBC	O
-	O
14.8	O
*	O
RBC	O
-	O
5.22	O
Hgb	O
-	O
16.5	O
Hct	O
-	O
47.5	O
MCV	O
-	O
91	O
MCH	O
-	O
31.6	O
MCHC	O
-	O
34.7	O
RDW	O
-	O
14.1	O
Plt	O
Ct	O
-	O
ERROR	O
[	O
**	O
2174-7-29	O
**	O
]	O
06:40	O
AM	O
BLOOD	O
WBC	O
-	O
13.7	O
*	O
RBC	O
-	O
5.05	O
Hgb	O
-	O
16.0	O
Hct	O
-	O
45.9	O
MCV	O
-	O
91	O
MCH	O
-	O
31.7	O
MCHC	O
-	O
34.9	O
RDW	O
-	O
14.2	O
Plt	O
Ct	O
-	O
95	O
*	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
Neuts	O
-	O
85	O
*	O
Bands	O
-	O
0	O
Lymphs	O
-	O
12	O
*	O
Monos	O
-	O
3	O
Eos	O
-	O
0	O
Baso	O
-	O
0	O
Atyps	O
-	O
0	O
Metas	O
-	O
0	O
Myelos	O
-	O
0	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
PT	O
-	O
11.8	O
PTT	O
-	O
20.5	O
*	O
INR	O
(	O
PT	O
)	O
-	O
1.0	O
[	O
**	O
2174-7-29	O
**	O
]	O
06:40	O
AM	O
BLOOD	O
Plt	O
Smr	O
-	O
LOW	O
Plt	O
Ct	O
-	O
95	O
*	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
Glucose	O
-	O
285	O
*	O
UreaN	O
-	O
41	O
*	O
Creat	O
-	O
0.9	O
Na	O
-	O
138	O
K	O
-	O
4.7	O
Cl	O
-	O
98	O
HCO3	O
-	O
25	O
AnGap	O
-	O
20	O
[	O
**	O
2174-7-29	O
**	O
]	O
06:40	O
AM	O
BLOOD	O
Glucose	O
-	O
177	O
*	O
UreaN	O
-	O
31	O
*	O
Creat	O
-	O
0.8	O
Na	O
-	O
140	O
K	O
-	O
4.7	O
Cl	O
-	O
102	O
HCO3	O
-	O
27	O
AnGap	O
-	O
16	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
ALT	O
-	O
68	O
*	O
AST	O
-	O
28	O
CK	O
(	O
CPK	O
)	O
-	O
38	O
AlkPhos	O
-	O
51	O
TotBili	O
-	O
0.5	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
Lipase	O
-	O
71	O
*	O
[	O
**	O
2174-7-26	O
**	O
]	O
01:05	O
PM	O
BLOOD	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2174-7-27	O
**	O
]	O
04:47	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
4	O
cTropnT	O
-	O
<	O
0.01	O
[	O
**	O
2174-7-29	O
**	O
]	O
06:40	O
AM	O
BLOOD	O
Calcium	O
-	O
8.9	O
Phos	O
-	O
3.5	O
Mg	O
-	O
2.2	O
[	O
**	O
2174-7-29	O
**	O
]	O
07:35	O
AM	O
BLOOD	O
Lactate	O
-	O
2.7	O
*	O
[	O
**	O
2174-7-26	O
**	O
]	O
03:51	O
PM	O
BLOOD	O
Lactate	O
-	O
4.1	O
*	O
[	O
**	O
2174-7-26	O
**	O
]	O
05:17	O
PM	O
URINE	O
Color	O
-	O
Yellow	O
Appear	O
-	O
Clear	O
Sp	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
-	O
1.048	O
*	O
[	O
**	O
2174-7-26	O
**	O
]	O
05:17	O
PM	O
URINE	O
Blood	O
-	O
NEG	O
Nitrite	O
-	O
NEG	O
Protein	O
-	O
TR	O
Glucose	O
-	O
1000	O
Ketone	O
-	O
TR	O
Bilirub	O
-	O
NEG	O
Urobiln	O
-	O
NEG	O
pH	O
-	O
6.5	O
Leuks	O
-	O
NEG	O
[	O
**	O
2174-7-26	O
**	O
]	O
05:17	O
PM	O
URINE	O
RBC	O
-	O
0	O
WBC	O
-0-2	O
Bacteri	O
-	O
NONE	O
Yeast	O
-	O
NONE	O
Epi	O
-	O
0	O
Blood	O
Culture	O
,	O
Routine	O
(	O
Final	O
[	O
**	O
2174-8-1	O
**	O
]	O
)	O
:	O
NO	O
GROWTH	O
.	O
CTA	O
1	O
.	O
Innumerable	O
ground	O
-	O
glass	O
nodules	O
and	O
peribronchial	O
lesions	O
in	O
both	O
lungs	O
,	O
right	O
greater	O
than	O
left	O
.	O
Consolidation	O
in	O
the	O
posterior	O
segment	O
of	O
the	O
right	O
upper	O
lobe	O
.	O
Changes	O
appear	O
stable	O
compared	O
to	O
[	O
**	O
2174-7-15	O
**	O
]	O
PET	O
CT.	O
2	O
.	O
No	O
evidence	O
of	O
acute	O
pulmonary	O
emboli	O
.	O
No	O
dissection	O
in	O
the	O
thoracic	O
aorta	O
.	O
3	O
.	O
Fatty	O
liver	O
.	O
Calcifications	O
within	O
the	O
spleen	O
and	O
liver	O
,	O
likely	O
from	O
remote	O
granulomatous	O
infection	O
.	O
4	O
.	O
Old	O
right	O
sixth	O
rib	O
fracture	O
and	O
eighth	O
rib	O
sclerosis	O
.	O
5	O
.	O
Scattered	O
lung	O
nodules	O
.	O
CXR	O
Interval	O
worsening	O
in	O
size	O
of	O
right	O
pleural	O
effusion	O
with	O
associated	O
atelectasis	O
and	O
overall	O
decreasing	O
right	O
upper	O
lobe	O
aeration	O
compared	O
to	O
radiograph	O
of	O
[	O
**	O
2173-8-14	O
**	O
]	O
.	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
100424	O
**	O
]	O
is	O
a	O
78	O
year	O
old	O
gentleman	O
with	O
stage	O
IV	O
NSCLC	O
admitted	O
for	O
lactic	O
acidosis	O
.	O
.	O
#	O
Lactic	O
acidosis	O
:	O
Anion	O
gap	O
of	O
15	O
on	O
admission	O
.	O
During	O
recent	O
admission	O
(	O
[	O
**	O
6	O
-	O
28	O
**	O
]	O
)	O
,	O
no	O
lactate	O
was	O
measured	O
although	O
AG	O
ranged	O
from	O
[	O
**	O
1	O
-	O
2	O
**	O
]	O
and	O
bicarb	O
24	O
-	O
26	O
during	O
admission	O
with	O
albumin	O
>	O
4	O
.	O
Differential	O
includes	O
type	O
A	O
lactic	O
acidosis	O
(	O
hypoperfusion	O
)	O
from	O
SIRS	O
in	O
setting	O
of	O
pneumonia	O
or	O
cardiogenic	O
shock	O
from	O
ACS	O
versus	O
type	B-Ade
B	I-Ade
lactic	I-Ade
acidosis	I-Ade
from	O
metformin	I-Drug
/	O
diabetes	O
or	O
active	O
malignancy	O
.	O
No	O
evidence	O
of	O
liver	O
mets	O
or	O
decreased	O
synthetic	O
function	O
to	O
suggest	O
inability	O
to	O
clear	O
lactate	O
.	O
While	O
in	O
the	O
ICU	O
,	O
the	O
patient	O
's	O
metformin	I-Drug
was	O
held	O
,	O
venous	O
lactate	O
levels	O
and	O
anion	O
gap	O
were	O
followed	O
.	O
He	O
received	O
maintenence	O
fluids	I-Drug
.	O
His	O
lactate	O
was	O
downtrending	O
on	O
transfer	O
to	O
the	O
floor	O
.	O
.	O
#	O
Chest	O
pain	O
/	O
CAD	O
:	O
Low	O
suspicion	O
for	O
ACS	O
given	O
ECG	O
in	O
ED	O
unchanged	O
without	O
ST	O
-	O
T	O
wave	O
abnormalities	O
.	O
CTA	O
negative	O
for	O
PE	O
and	O
patient	O
was	O
CP	O
free	O
throughout	O
his	O
stay	O
in	O
the	O
ICU	O
.	O
His	O
home	O
meds	O
including	O
ASA	I-Drug
,	O
statin	I-Drug
,	O
lisinopril	I-Drug
,	O
and	O
nadolol	I-Drug
were	O
continued	O
.	O
.	O
#	O
Leukocytosis	I-Ade
:	O
likely	O
secondary	O
to	O
dexamethasone	I-Drug
,	O
WBC	O
and	O
fever	O
curve	O
were	O
stable	O
in	O
ICU	O
.	O
.	O
#	O
Lung	B-Reason
CA	I-Reason
:	O
Per	O
primary	O
oncologist	O
,	O
Dr	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
3274	O
**	O
]	O
,	O
Decadron	I-Drug
was	O
continued	O
.	O
The	O
patient	O
received	O
whole	O
brain	O
XRT	O
while	O
in	O
the	O
ICU	O
,	O
with	O
plans	O
to	O
receive	O
another	O
dose	O
the	O
day	O
after	O
ICU	O
discharge	O
.	O
#	O
Ground	O
glass	O
opacities	O
:	O
Patchy	O
ground	O
glass	O
opacities	O
on	O
CT	O
present	O
in	O
6	O
/	O
[	O
**	O
2174	O
**	O
]	O
.	O
Given	O
heteregenous	O
nature	O
,	O
unlikely	O
to	O
be	O
edema	O
.	O
Less	O
likely	O
to	O
be	O
blood	O
,	O
and	O
low	O
likelihood	O
given	O
clinical	O
presentation	O
for	O
bacterial	O
infection	O
.	O
Given	O
recent	O
dexamethasone	I-Drug
therapy	O
,	O
concern	O
for	O
PCP	O
given	O
lack	O
of	O
prophylaxis	O
,	O
although	O
ground	O
glass	O
present	O
prior	O
to	O
initiation	O
of	O
dexamethasone	I-Drug
makes	O
this	O
less	O
likely	O
.	O
Pt	O
was	O
started	O
on	O
PCP	I-Reason
prophylaxis	O
with	O
Bactrim	I-Drug
.	O
#	O
COPD	I-Reason
:	O
Advair	I-Drug
,	O
tiotropium	I-Drug
,	O
and	O
albuterol	I-Drug
were	O
continued	O
.	O
.	O
#	O
HTN	I-Reason
:	O
Home	O
regimen	O
of	O
amlodipine	I-Drug
and	O
lisinopril	I-Drug
was	O
continued	O
.	O
.	O
#	O
Diabetes	B-Reason
,	I-Reason
type	I-Reason
2	I-Reason
:	O
Metformin	I-Drug
given	O
lactic	O
acidosis	O
and	O
contrast	I-Drug
load	O
,	O
pt	O
was	O
covered	O
with	O
ISS	I-Drug
with	O
accuchecks	O
.	O
.	O
#	O
Hypercholesterolemia	I-Reason
:	O
Statin	I-Drug
was	O
continued	O
,	O
ezetimibe	I-Drug
held	O
given	O
lack	O
of	O
data	O
regarding	O
benefit	O
.	O
.	O
#	O
GERD	I-Reason
:	O
PPI	I-Drug
Continued	O
Medications	O
on	O
Admission	O
:	O
Tylenol	I-Drug
#	O
3	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
tab	O
PO	O
Q6	O
-	O
8	O
hours	O
prn	O
Albuterol	I-Drug
INH	O
Amlodipine	I-Drug
5	O
mg	O
PO	O
daily	O
Brimonidine	I-Drug
0.1	O
%	O
drops	O
1	O
drop	O
each	O
eye	O
daily	O
Escitalopram	I-Drug
20	O
mg	O
PO	O
daily	O
Ezetimibe	I-Drug
10	O
mg	O
PO	O
daily	O
Fenofibrate	I-Drug
145	O
mg	O
PO	O
daily	O
Fexofenadine	B-Drug
-	I-Drug
pseudoephedrine	I-Drug
120	O
/	O
60	O
mg	O
PO	O
Q12	O
hours	O
Fluticasone	B-Drug
-	I-Drug
Salmeterol	I-Drug
500/50	O
1	O
puff	O
[	O
**	O
Hospital1	O
**	O
]	O
Ipratroprium	I-Drug
INH	O
2	O
squirts	O
daily	O
Lisinopril	I-Drug
40	O
mg	O
PO	O
BID	O
Metformin	I-Drug
1000	O
mg	O
PO	O
BID	O
Nadolol	I-Drug
5	O
mg	O
PO	O
daily	O
Dexamthasone	I-Drug
4	O
mg	O
PO	O
Q6H	O
Simvastatin	I-Drug
60	O
mg	O
PO	O
daily	O
Tamsulosin	I-Drug
0.4	O
mg	O
PO	O
daily	O
Tiotropium	I-Drug
18mcg	O
PO	O
daily	O
ASA	I-Drug
81	O
mg	O
PO	O
daily	O
Omeprazole	I-Drug
20	O
mg	O
PO	O
daily	O
Discharge	O
Medications	O
:	O
1	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
2	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
Constipation	I-Reason
.	O
3	O
.	O
Docusate	B-Drug
Sodium	I-Drug
50	O
mg	O
/	O
5	O
mL	O
Liquid	O
Sig	O
:	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
5	O
ml	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
Albuterol	B-Drug
Sulfate	I-Drug
90	O
mcg	O
/	O
Actuation	O
HFA	O
Aerosol	O
Inhaler	O
Sig	O
:	O
1	O
-	O
2	O
Puffs	O
Inhalation	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
wheezing	I-Reason
.	O
5	O
.	O
Fexofenadine	I-Drug
60	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
6	O
.	O
Nadolol	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.25	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
7	O
.	O
Lisinopril	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
8	O
.	O
Amlodipine	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Brimonidine	I-Drug
0.15	O
%	O
Drops	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Drop	O
Ophthalmic	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
10	O
.	O
Escitalopram	I-Drug
10	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
Fluticasone	B-Drug
-	I-Drug
Salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
Dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Disk	O
with	O
Device	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
12	O
.	O
Simvastatin	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
1.5	O
Tablets	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
13	O
.	O
Tamsulosin	I-Drug
0.4	O
mg	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Sust	O
.	O
Release	O
24	O
hr	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
14	O
.	O
Tiotropium	B-Drug
Bromide	I-Drug
18	O
mcg	O
Capsule	O
,	O
w	O
/	O
Inhalation	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Cap	O
Inhalation	O
DAILY	O
(	O
Daily	O
)	O
.	O
15	O
.	O
Aspirin	I-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
16	O
.	O
Omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
17	O
.	O
Trimethoprim	B-Drug
-	I-Drug
Sulfamethoxazole	I-Drug
80	O
-	O
400	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
18	O
.	O
Acetaminophen	B-Drug
-	I-Drug
Codeine	I-Drug
300	O
-	O
30	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
headache	I-Reason
.	O
19	O
.	O
Dexamethasone	I-Drug
4	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q8H	O
(	O
every	O
8	O
hours	O
)	O
.	O
Disp	O
:	O
*	O
qs	O
30	O
days	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
20	O
.	O
Glipizide	I-Drug
5	O
mg	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
(	O
2	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
(	O
2	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Tablet	O
Extended	O
Rel	O
24	O
hr	O
(	O
2	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
21	O
.	O
Lantus	I-Drug
100	O
unit	O
/	O
mL	O
Solution	O
Sig	O
:	O
One	O
(	O
1	O
)	O
30	O
units	O
Subcutaneous	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
qs	O
30	O
days	O
*	O
Refills	O
:	O
*	O
3	O
*	O
22	O
.	O
Easy	O
Comfort	O
Insulin	I-Drug
Syringe	O
1	O
mL	O
30	O
x	O
[	O
**	O
6	O
-	O
4	O
**	O
]	O
Syringe	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Syringe	O
Miscellaneous	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Syringe	O
*	O
Refills	O
:	O
*	O
2	O
*	O
Discharge	O
Disposition	O
:	O
Home	O
With	O
Service	O
Facility	O
:	O
VNA	O
[	O
**	O
Location	O
(	O
un	O
)	O
270	O
**	O
]	O
East	O
Discharge	O
Diagnosis	O
:	O
Primary	O
:	O
Metastatic	O
Lung	O
Cancer	O
Secondary	O
:	O
Superficial	O
bladder	O
cancer	O
-	O
Hypertension	O
-	O
Diabetes	O
Mellitus	O
-	O
COPD	I-Reason
,	O
last	O
exacerbation	O
[	O
**	O
2174-5-20	O
**	O
]	O
,	O
treated	O
with	O
prednisone	I-Drug
-	O
Hypercholesterolemia	O
-	O
CAD	O
s	O
/	O
p	O
MI	O
(	O
"	O
several	O
years	O
ago	O
"	O
)	O
-	O
Psoriasis	O
-	O
TIA	O
(	O
[	O
**	O
2156	O
**	O
]	O
)	O
-	O
BPH	O
-	O
glaucoma	O
-	O
GERD	O
-	O
adenoma	O
of	O
the	O
descending	O
colon	O
Discharge	O
Condition	O
:	O
afebrile	O
,	O
tolerating	O
diet	O
,	O
comfortable	O
Discharge	O
Instructions	O
:	O
You	O
were	O
admitted	O
because	O
you	O
were	O
found	O
in	O
clinic	O
to	O
be	O
short	O
of	O
breath	O
with	O
chest	O
pain	O
.	O
A	O
heart	O
related	O
cause	O
was	O
ruled	O
out	O
with	O
testing	O
,	O
however	O
another	O
test	O
showed	O
that	O
you	O
had	O
too	O
much	O
lactic	B-Drug
acid	I-Drug
.	O
This	O
is	O
usually	O
a	O
seroius	O
sign	O
that	O
your	O
body	O
is	O
not	O
getting	O
enough	O
oxygen	O
.	O
Thus	O
,	O
you	O
spent	O
a	O
night	O
in	O
the	O
ICU	O
.	O
It	O
was	O
discovered	O
also	O
that	O
your	O
blood	O
sugar	O
was	O
far	O
too	O
high	O
.	O
Accordingly	O
,	O
your	O
lactic	B-Ade
acid	I-Ade
may	O
be	O
the	O
result	O
of	O
uncontrolled	O
diabetes	O
and	O
the	O
pill	O
(	O
metformin	I-Drug
)	O
you	O
were	O
using	O
to	O
treat	O
it	O
.	O
We	O
followed	O
your	O
labs	O
and	O
you	O
gradually	O
improved	O
.	O
At	O
the	O
same	O
time	O
,	O
you	O
were	O
able	O
to	O
receive	O
radiation	O
therapy	O
.	O
.	O
You	O
were	O
discharged	O
with	O
a	O
new	O
diabetes	O
treatment	O
regimen	O
:	O
NEW	O
Lantus	I-Drug
20	O
units	O
in	O
the	O
morning	O
NEW	O
Glypizide	I-Drug
5	O
mg	O
twice	O
a	O
day	O
NEW	O
Bactrim	I-Drug
-	O
to	B-Reason
prevent	I-Reason
a	I-Reason
lung	I-Reason
infection	I-Reason
when	O
on	O
steroids	I-Drug
STOP	O
Metformin	I-Drug
HOLD	O
Ezetimibe	I-Drug
,	O
Fenofibrate	I-Drug
-	O
discuss	O
instead	O
starting	O
a	O
statin	I-Drug
(	O
such	O
as	O
simvastatin	I-Drug
)	O
with	O
your	O
primary	O
care	O
doctor	O
.	O
Your	O
sugars	B-Ade
are	I-Ade
elevated	I-Ade
due	O
to	O
your	O
steroids	I-Drug
-	O
once	O
your	O
steroids	I-Drug
are	O
decreased	O
this	O
diabetes	O
regimen	O
will	O
need	O
to	O
be	O
adjusted	O
.	O
Therefore	O
it	O
is	O
very	O
important	O
to	O
follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
doctor	O
.	O
Call	O
your	O
primary	O
care	O
doctor	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
S.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
14148	O
**	O
]	O
,	O
for	O
an	O
appointment	O
in	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
weeks	O
for	O
diabetes	O
management	O
.	O
Take	O
your	O
blood	O
sugar	O
as	O
directed	O
by	O
your	O
primary	O
doctor	O
.	O
If	O
you	O
have	O
low	O
blood	O
sugar	O
drink	O
apple	O
juice	O
and	O
crackers	O
and	O
call	O
your	O
primary	O
care	O
doctor	O
.	O
.	O
Return	O
to	O
the	O
hospital	O
if	O
you	O
have	O
chest	O
pain	O
,	O
high	O
fevers	O
,	O
dizziness	O
,	O
weakness	O
or	O
any	O
other	O
symptoms	O
that	O
concern	O
you	O
.	O
.	O
Call	O
your	O
primary	O
care	O
doctor	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
S.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
14148	O
**	O
]	O
,	O
for	O
an	O
appointment	O
in	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
weeks	O
for	O
diabetes	O
management	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
251	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
0	O
-	O
0	O
-	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2174-8-23	O
**	O
]	O
10:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1571	O
**	O
]	O
FUNCTION	O
LAB	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
609	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2174-9-28	O
**	O
]	O
1:40	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1570	O
**	O
]	O
,	O
INTERPRET	O
W	O
/	O
LAB	O
NO	O
CHECK	O
-	O
IN	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1570	O
**	O
]	O
INTEPRETATION	O
BILLING	O
Date	O
/	O
Time	O
:[	O
**	O
2174-9-28	O
**	O
]	O
2:00	O
Followup	O
Instructions	O
:	O
Call	O
your	O
primary	O
care	O
doctor	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
,	O
[	O
**	O
Doctor	O
Last	O
Name	O
**	O
]	O
S.	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
14148	O
**	O
]	O
,	O
for	O
an	O
appointment	O
in	O
[	O
**	O
1	O
-	O
21	O
**	O
]	O
weeks	O
for	O
diabetes	O
management	O
.	O
RADIATION	O
-	O
in	O
[	O
**	O
Hospital1	O
**	O
]	O
at	O
12:15	O
pm	O
Provider	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
251	O
**	O
]	O
[	O
**	O
Name11	O
(	O
NameIs	O
)	O
**	O
]	O
,	O
MD	O
Phone	O
:[	O
**	O
0	O
-	O
0	O
-	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2174-8-23	O
**	O
]	O
10:00	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1571	O
**	O
]	O
FUNCTION	O
LAB	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
609	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2174-9-28	O
**	O
]	O
1:40	O
Provider	O
:	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1570	O
**	O
]	O
,	O
INTERPRET	O
W	O
/	O
LAB	O
NO	O
CHECK	O
-	O
IN	O
[	O
**	O
Name10	O
(	O
NameIs	O
)	O
1570	O
**	O
]	O
INTEPRETATION	O
BILLING	O
Date	O
/	O
Time	O
:[	O
**	O
2174-9-28	O
**	O
]	O
2:00	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
251	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
3282	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2174-12-2	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2200-10-16	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2200-11-8	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2142-1-23	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Chlohexadine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
4616	O
**	O
]	O
Chief	O
Complaint	O
:	O
metastatic	O
melanoma	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
1	O
.	O
Right	O
frontal	O
craniotomy	O
.	O
2	O
.	O
Excision	O
of	O
tumor	O
with	O
stereotactic	O
navigation	O
.	O
History	O
of	O
Present	O
Illness	O
:	O
HPI	O
:	O
Patient	O
is	O
a	O
58	O
year	O
old	O
gentleman	O
with	O
a	O
history	O
of	O
malignant	O
melanoma	O
who	O
presented	O
to	O
an	O
outside	O
hospital	O
complaining	O
of	O
nausea	O
and	O
headaches	O
.	O
He	O
was	O
previously	O
on	O
hospice	O
care	O
but	O
had	O
a	O
change	O
of	O
heart	O
.	O
His	O
melanoma	O
had	O
previously	O
metastasized	O
to	O
his	O
lungs	O
,	O
brain	O
,	O
and	O
bowels	O
,	O
which	O
required	O
surgical	O
intervention	O
.	O
CT	O
scan	O
recently	O
at	O
OSH	O
showed	O
new	O
lesions	O
in	O
the	O
head	O
necrosis	O
vs.	O
new	O
mets	O
.	O
The	O
patient	O
changed	O
his	O
mind	O
RE	O
hospice	O
care	O
and	O
would	O
like	O
this	O
treated	O
.	O
An	O
MRI	O
today	O
at	O
the	O
OSH	O
showed	O
edema	O
concerning	O
for	O
metastatic	O
disease	O
at	O
R	O
frontal	O
parietal	O
.	O
There	O
was	O
also	O
increase	O
vasogenic	O
edema	O
,	O
and	O
5	O
mm	O
osseous	O
neoplastic	O
disease	O
.	O
Was	O
transfered	O
here	O
to	O
get	O
Thallium	O
PET	O
.	O
[	O
**	O
Month	O
(	O
only	O
)	O
116	O
**	O
]	O
get	O
cyberknife	O
vs	O
resection	O
.	O
Past	O
Medical	O
History	O
:	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
HTN	O
(	O
?	O
)	O
Atrial	O
fibrillation	O
,	O
[	O
**	O
2195	O
**	O
]	O
,	O
resolved	O
Depression	O
Bradycardia	O
Social	O
History	O
:	O
Lived	O
with	O
his	O
brother	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
.	O
Was	O
a	O
Polaroid	O
technician	O
.	O
Never	O
smoked	O
tobacco	O
,	O
rare	O
EtOH	O
use	O
.	O
Family	O
History	O
:	O
Mom	O
and	O
dad	O
with	O
diabetes	O
.	O
Aunt	O
with	O
unknown	O
malignancy	O
,	O
cousin	O
with	O
breast	O
ca	O
.	O
Physical	O
Exam	O
:	O
On	O
Admission	O
Vitals	O
-	O
T	O
:	O
97.6	O
BP	O
:	O
116/64	O
HR	O
:	O
74	O
RR	O
:	O
18	O
02	O
sat	O
:	O
94	O
GENERAL	O
:	O
slow	O
to	O
respond	O
,	O
but	O
AAOx3	O
SKIN	O
:	O
warm	O
and	O
well	O
perfused	O
,	O
no	O
excoriations	O
or	O
lesions	O
,	O
no	O
rashes	O
,	O
some	O
hemangiomas	O
throughout	O
body	O
.	O
HEENT	O
:	O
AT	O
/	O
NC	O
,	O
EOMI	O
,	O
PERRLA	O
,	O
anicteric	O
sclera	O
,	O
pink	O
conjunctiva	O
,	O
patent	O
nares	O
,	O
MMM	O
,	O
good	O
dentition	O
,	O
nontender	O
supple	O
neck	O
,	O
no	O
LAD	O
,	O
no	O
JVD	O
.	O
Eyes	O
dysconjugate	O
.	O
CARDIAC	O
:	O
RRR	O
,	O
S1	O
/	O
S2	O
,	O
no	O
mrg	O
LUNG	O
:	O
CTAB	O
ABDOMEN	O
:	O
nondistended	O
,	O
+	O
BS	O
,	O
nontender	O
in	O
all	O
quadrants	O
,	O
no	O
rebound	O
/	O
guarding	O
,	O
no	O
hepatosplenomegaly	O
M	O
/	O
S	O
:	O
moving	O
all	O
extremities	O
well	O
,	O
no	O
cyanosis	O
,	O
clubbing	O
or	O
edema	O
,	O
no	O
obvious	O
deformities	O
PULSES	O
:	O
2	O
+	O
DP	O
pulses	O
bilaterally	O
NEURO	O
:	O
CN	O
II	O
-	O
XII	O
intact	O
.	O
On	O
Discharge	O
:	O
Vitals	O
-	O
96.6	O
,	O
122/70	O
,	O
87	O
,	O
16	O
,	O
95RA	O
GENERAL	O
:	O
lying	O
in	O
bed	O
SKIN	O
:	O
warm	O
and	O
well	O
perfused	O
,	O
no	O
excoriations	O
or	O
lesions	O
,	O
no	O
rashes	O
,	O
some	O
hemangiomas	O
throughout	O
body	O
.	O
HEENT	O
:	O
AT	O
/	O
NC	O
,	O
EOMI	O
,	O
anicteric	O
sclera	O
,	O
MMM	O
,	O
nontender	O
supple	O
neck	O
,	O
no	O
LAD	O
,	O
no	O
JVD	O
.	O
CARDIAC	O
:	O
RRR	O
,	O
S1	O
/	O
S2	O
,	O
no	O
mrg	O
LUNG	O
:	O
CTAB	O
ABDOMEN	O
:	O
nondistended	O
,	O
+	O
BS	O
,	O
nontender	O
in	O
all	O
quadrants	O
,	O
no	O
rebound	O
/	O
guarding	O
,	O
no	O
hepatosplenomegaly	O
M	O
/	O
S	O
:	O
moving	O
all	O
extremities	O
well	O
,	O
no	O
cyanosis	O
,	O
clubbing	O
or	O
edema	O
,	O
no	O
obvious	O
deformities	O
PULSES	O
:	O
2	O
+	O
DP	O
pulses	O
bilaterally	O
NEURO	O
:	O
CN	O
II	O
-	O
XII	O
intact	O
Pertinent	O
Results	O
:	O
On	O
Admission	O
:	O
[	O
**	O
2200-10-17	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
WBC	O
-	O
8.0	O
RBC	O
-	O
4.87	O
Hgb	O
-	O
14.1	O
Hct	O
-	O
43.5	O
MCV	O
-	O
89	O
MCH	O
-	O
29.0	O
MCHC	O
-	O
32.5	O
RDW	O
-	O
12.4	O
Plt	O
Ct	O
-	O
260	O
[	O
**	O
2200-10-17	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
Plt	O
Ct	O
-	O
260	O
[	O
**	O
2200-10-17	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
Glucose	O
-	O
83	O
UreaN	O
-	O
16	O
Creat	O
-	O
0.8	O
Na	O
-	O
138	O
K	O
-	O
4.0	O
Cl	O
-	O
101	O
HCO3	O
-	O
29	O
AnGap	O
-	O
12	O
[	O
**	O
2200-10-21	O
**	O
]	O
06:00	O
AM	O
BLOOD	O
ALT	O
-	O
21	O
AST	O
-	O
13	O
LD	O
(	O
LDH	O
)	O
-	O
170	O
AlkPhos	O
-	O
87	O
TotBili	O
-	O
0.2	O
[	O
**	O
2200-10-17	O
**	O
]	O
05:35	O
AM	O
BLOOD	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
2.9	O
Mg	O
-	O
2.0	O
[	O
**	O
2200-10-31	O
**	O
]	O
02:09	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
174	O
*	O
pCO2	O
-	O
24	O
*	O
pH	O
-	O
7.61	O
*	O
calTCO2	O
-	O
25	O
Base	O
XS	O
-	O
4	O
[	O
**	O
2200-10-31	O
**	O
]	O
02:09	O
PM	O
BLOOD	O
Glucose	O
-	O
98	O
Lactate	O
-	O
1.1	O
Na	O
-	O
135	O
K	O
-	O
2.8	O
*	O
Cl	O
-	O
107	O
[	O
**	O
2200-10-31	O
**	O
]	O
02:09	O
PM	O
BLOOD	O
freeCa	O
-	O
0.99	O
*	O
.	O
Pertinent	O
Results	O
:	O
.	O
CT	O
head	O
[	O
**	O
2200-11-7	O
**	O
]	O
IMPRESSION	O
:	O
No	O
acute	O
hemorrhage	O
or	O
mass	O
effect	O
.	O
Expected	O
post-surgical	O
changes	O
.	O
.	O
CXR	O
[	O
**	O
2200-11-2	O
**	O
]	O
FINDINGS	O
:	O
Right	O
internal	O
jugular	O
vascular	O
catheter	O
has	O
been	O
repositioned	O
,	O
now	O
terminating	O
in	O
the	O
mid	O
superior	O
vena	O
cava	O
,	O
with	O
no	O
visible	O
pneumothorax	O
.	O
Endotracheal	O
tube	O
and	O
nasogastric	O
tube	O
have	O
been	O
removed	O
.	O
Cardiomediastinal	O
contours	O
are	O
stable	O
in	O
appearance	O
.	O
Persistent	O
right	O
lower	O
lobe	O
scarring	O
versus	O
atelectasis	O
adjacent	O
to	O
surgical	O
chain	O
sutures	O
as	O
well	O
as	O
a	O
small	O
right	O
pleural	O
effusion	O
versus	O
pleural	O
thickening	O
.	O
No	O
new	O
or	O
worsening	O
lung	O
or	O
pleural	O
abnormalities	O
.	O
.	O
ECG	O
[	O
**	O
2200-11-2	O
**	O
]	O
Sinus	O
tachycardia	O
,	O
rate	O
107	O
with	O
frequent	O
ventricular	O
premature	O
beats	O
.	O
There	O
is	O
moderate	O
baseline	O
artifact	O
.	O
Left	O
atrial	O
abnormality	O
.	O
Compared	O
to	O
the	O
previous	O
tracing	O
of	O
[	O
**	O
2200-10-28	O
**	O
]	O
,	O
except	O
for	O
the	O
change	O
in	O
rate	O
and	O
the	O
presence	O
of	O
frequent	O
ventricular	O
premature	O
beats	O
,	O
no	O
diagnostic	O
interval	O
change	O
.	O
.	O
Brain	O
Tissue	O
Biopsy	O
DIAGNOSIS	O
:	O
I.	O
Brain	O
,	O
right	O
craniotomy	O
:	O
Necrosis	O
and	O
changes	O
consistent	O
with	O
radiation	O
changes	O
.	O
See	O
note	O
.	O
II	O
.	O
Brain	O
,	O
right	O
craniotomy	O
:	O
Necrosis	O
and	O
changes	O
consistent	O
with	O
radiation	O
changes	O
.	O
See	O
note	O
.	O
.	O
MRI	O
BRAIN	O
[	O
**	O
2200-10-28	O
**	O
]	O
IMPRESSION	O
:	O
1	O
.	O
Right	O
frontal	O
enhancing	O
mass	O
from	O
tumor	O
/	O
radiation	O
necrosis	O
at	O
the	O
resection	O
site	O
with	O
associated	O
significant	O
perilesional	O
edema	O
/	O
radiation	O
induced	O
changes	O
.	O
There	O
is	O
extensive	O
perilesional	O
FLAIR	O
and	O
T2	O
hyperintensity	O
surrounding	O
this	O
mass	O
.	O
There	O
is	O
mild	O
decrease	O
in	O
enhancement	O
as	O
compared	O
to	O
the	O
previous	O
MRIS	O
with	O
no	O
change	O
in	O
the	O
perilesional	O
hyperintensity	O
.	O
This	O
mass	O
is	O
likely	O
to	O
represent	O
radiation	O
induced	O
necrosis	O
rather	O
than	O
residual	O
/	O
recurrent	O
neoplasm	O
.	O
For	O
surgical	O
planning	O
.	O
2	O
.	O
No	O
evidence	O
of	O
new	O
enhancing	O
lesion	O
.	O
.	O
Discharge	O
Labs	O
:	O
.	O
[	O
**	O
2200-11-7	O
**	O
]	O
01:45	O
PM	O
BLOOD	O
WBC	O
-	O
8.5	O
RBC	O
-	O
4.32	O
*	O
Hgb	O
-	O
13.1	O
*	O
Hct	O
-	O
37.1	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
35.2	O
*	O
RDW	O
-	O
12.9	O
Plt	O
Ct	O
-	O
227	O
[	O
**	O
2200-10-30	O
**	O
]	O
07:45	O
AM	O
BLOOD	O
WBC	O
-	O
12.0	O
*	O
RBC	O
-	O
4.84	O
Hgb	O
-	O
14.7	O
Hct	O
-	O
41.6	O
MCV	O
-	O
86	O
MCH	O
-	O
30.3	O
MCHC	O
-	O
35.3	O
*	O
RDW	O
-	O
12.7	O
Plt	O
Ct	O
-	O
270	O
[	O
**	O
2200-11-7	O
**	O
]	O
01:45	O
PM	O
BLOOD	O
Glucose	O
-	O
91	O
UreaN	O
-	O
15	O
Creat	O
-	O
0.5	O
Na	O
-	O
134	O
K	O
-	O
3.7	O
Cl	O
-	O
97	O
HCO3	O
-	O
27	O
AnGap	O
-	O
14	O
[	O
**	O
2200-11-7	O
**	O
]	O
01:45	O
PM	O
BLOOD	O
ALT	O
-	O
24	O
AST	O
-	O
20	O
AlkPhos	O
-	O
95	O
TotBili	O
-	O
1.2	O
[	O
**	O
2200-11-7	O
**	O
]	O
01:45	O
PM	O
BLOOD	O
Albumin	O
-	O
3.5	O
Calcium	O
-	O
8.6	O
Phos	O
-	O
2.6	O
*	O
Mg	O
-	O
1.6	O
[	O
**	O
2200-11-1	O
**	O
]	O
08:01	O
PM	O
BLOOD	O
Type	O
-	O
ART	O
pO2	O
-	O
147	O
*	O
pCO2	O
-	O
40	O
pH	O
-	O
7.45	O
calTCO2	O
-	O
29	O
Base	O
XS	O
-	O
4	O
Brief	O
Hospital	O
Course	O
:	O
Mr.	O
[	O
**	O
Name14	O
(	O
STitle	O
)	O
102120	O
**	O
]	O
presented	O
from	O
an	O
outside	O
hospital	O
with	O
severe	O
headaches	O
and	O
nausea	O
.	O
Thallium	O
scan	O
that	O
was	O
inconclusive	O
.	O
The	O
neurosurgical	O
team	O
saw	O
the	O
patient	O
and	O
agreed	O
to	O
do	O
a	O
craniotomy	O
and	O
biopsy	O
.	O
Following	O
the	O
surgery	O
,	O
was	O
cared	O
for	O
by	O
the	O
neurosurgical	O
team	O
for	O
several	O
days	O
.	O
The	O
patient	O
had	O
some	O
relief	O
to	O
nausea	O
and	O
headache	O
,	O
but	O
symptoms	O
were	O
not	O
completely	O
resolved	O
.	O
The	O
pathology	O
shows	O
necrosis	O
and	O
arrangements	O
were	O
made	O
for	O
an	O
outpatient	O
family	O
meeting	O
with	O
neuroncology	O
next	O
week	O
.	O
In	O
the	O
meantime	O
,	O
he	O
will	O
go	O
to	O
a	O
living	O
facility	O
.	O
During	O
his	O
stay	O
,	O
Mr.	O
[	O
**	O
Known	O
lastname	O
76901	O
**	O
]	O
received	O
PT	O
for	O
general	O
weakness	O
.	O
Palliative	O
care	O
provided	O
significant	O
input	O
regarding	O
medication	O
for	O
pain	O
and	O
anxiety	O
.	O
Medications	O
on	O
Admission	O
:	O
Scopolamine	I-Drug
patch	O
1.5	O
mg	O
TD	O
q3days	O
(	O
next	O
change	O
[	O
**	O
2200-10-17	O
**	O
]	O
)	O
Dilaudid	I-Drug
4	O
mg	O
PO	O
q4h	O
prn	O
pain	I-Reason
[	O
**	O
1	O
-	O
22	O
**	O
]	O
Dilaudid	I-Drug
6	O
mg	O
PO	O
q4h	O
prn	O
pain	I-Reason
[	O
**	O
6	O
-	O
27	O
**	O
]	O
Senna	I-Drug
2tabs	O
PO	O
qhs	O
Bisacodyl	I-Drug
10	O
mg	O
PR	O
qod	O
Fentanyl	I-Drug
25mcg	O
TD	O
q3days	O
(	O
next	O
change	O
[	O
**	O
2200-10-16	O
**	O
]	O
)	O
Dilaudid	I-Drug
6	O
mg	O
PO	O
q4h	O
Decadron	I-Drug
4	O
mg	O
PO	O
q6h	O
Ativan	I-Drug
1	O
mg	O
PO	O
q6h	O
prn	O
Compazine	I-Drug
10	O
mg	O
PO	O
q6h	O
prn	O
Keppra	I-Drug
750	O
mg	O
PO	O
BID	O
MVI	I-Drug
1tab	O
PO	O
daily	O
Miralax	I-Drug
17g	O
PO	O
daily	O
Fioricet	I-Drug
2tab	O
PO	O
daily	O
Haldol	I-Drug
2	O
mg	O
PO	O
daily	O
Valium	I-Drug
10	O
mg	O
PR	O
prn	O
q15min	O
x	O
4	O
doses	O
until	O
seizure	B-Reason
activity	I-Reason
subsides	O
Maalox	I-Drug
15mL	O
q4h	O
prn	O
Baclofen	I-Drug
5	O
mg	O
PO	O
TID	O
prn	O
Effexor	I-Drug
37.5	O
mg	O
PO	O
daily	O
Zofran	I-Drug
4	O
mg	O
PO	O
q6h	O
prn	O
Levsin	I-Drug
0.125	O
mg	O
PO	O
daily	O
QIDACHS	O
Levsin	I-Drug
0.125	O
mg	O
PO	O
q6h	O
prn	O
secretions	I-Reason
Reglan	I-Drug
10	O
mg	O
PO	O
QIDACHS	O
Colace	I-Drug
100	O
mg	O
PO	O
BID	O
Discharge	O
Medications	O
:	O
1	O
.	O
venlafaxine	I-Drug
37.5	O
mg	O
Capsule	O
,	O
Ext	O
Release	O
24	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Ext	O
Release	O
24	O
hr	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
3	O
.	O
docusate	B-Drug
sodium	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
4	O
.	O
labetalol	I-Drug
100	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
.	O
5	O
.	O
dexamethasone	B-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q	O
12h	O
(	O
)	O
for	O
4	O
days	O
.	O
6	O
.	O
levetiracetam	B-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
7	O
.	O
acetaminophen	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
pain	I-Reason
/	O
fever	I-Reason
.	O
8	O
.	O
fentanyl	I-Drug
12	O
mcg	O
/	O
hr	O
Patch	O
72	O
hr	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Patch	O
72	O
hr	O
Transdermal	O
Q72H	O
(	O
every	O
72	O
hours	O
)	O
.	O
9	O
.	O
lorazepam	B-Drug
0.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
nausea	I-Reason
or	O
anxiety	I-Reason
.	O
10	O
.	O
pantoprazole	B-Drug
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
11	O
.	O
nystatin	I-Drug
100,000	O
unit	O
/	O
mL	O
Suspension	O
Sig	O
:	O
Five	O
(	O
5	O
)	O
ML	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
thrush	I-Reason
.	O
12	O
.	O
olanzapine	B-Drug
2.5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
13	O
.	O
ZOFRAN	I-Drug
ODT	O
4	O
mg	O
Tablet	O
,	O
Rapid	O
Dissolve	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Rapid	O
Dissolve	O
PO	O
every	O
eight	O
(	O
8	O
)	O
hours	O
as	O
needed	O
for	O
nausea	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
**	O
]	O
Rehabilitation	O
and	O
Nursing	O
Center	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
701	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Metastatic	O
Malignant	O
Melanoma	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Confused	O
-	O
sometimes	O
.	O
Level	O
of	O
Consciousness	O
:	O
Lethargic	O
but	O
arousable	O
.	O
Activity	O
Status	O
:	O
Out	O
of	O
Bed	O
with	O
assistance	O
to	O
chair	O
or	O
wheelchair	O
.	O
Discharge	O
Instructions	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
76901	O
**	O
]	O
,	O
you	O
presented	O
to	O
us	O
with	O
severe	O
headaches	O
and	O
nausea	O
and	O
were	O
to	O
be	O
worked	O
up	O
for	O
possible	O
new	O
brain	O
metastasis	O
of	O
your	O
pre-existing	O
cancer	O
.	O
While	O
with	O
us	O
,	O
you	O
underwent	O
several	O
imaging	O
studies	O
of	O
your	O
brain	O
,	O
and	O
had	O
neurosurgical	O
intervention	O
to	O
remove	O
the	O
mass	O
from	O
your	O
head	O
.	O
We	O
have	O
changed	O
several	O
of	O
your	O
medications	O
.	O
Please	O
only	O
take	O
the	O
medications	O
listed	O
below	O
.	O
Do	O
not	O
take	O
any	O
medications	O
not	O
listed	O
below	O
.	O
Followup	O
Instructions	O
:	O
Department	O
:	O
NEUROLOGY	O
When	O
:	O
TUESDAY	O
[	O
**	O
2200-11-11	O
**	O
]	O
at	O
9:30	O
AM	O
With	O
:	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
12567	O
**	O
]	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
**	O
]	O
,	O
MD	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
1844	O
**	O
]	O
Building	O
:	O
SC	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Clinical	O
Ctr	O
[	O
**	O
Location	O
(	O
un	O
)	O
858	O
**	O
]	O
Campus	O
:	O
EAST	O
Best	O
Parking	O
:	O
[	O
**	O
Hospital	O
Ward	O
Name	O
23	O
**	O
]	O
Garage	O
Completed	O
by	O
:[	O
**	O
2200-11-9	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2106-7-4	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2106-7-13	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2056-12-21	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
Cardiothoracic	O
Surgery	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS	O
:	O
This	O
is	O
a	O
49	O
-	O
year	O
-	O
old	O
gentleman	O
with	O
a	O
known	O
history	O
of	O
ischemic	O
cardiomyopathy	O
with	O
an	O
estimated	O
ejection	O
fraction	O
of	O
approximately	O
20	O
%	O
.	O
He	O
had	O
been	O
accepted	O
by	O
the	O
[	O
**	O
Hospital	O
4415	O
**	O
]	O
heart	O
transplant	O
service	O
and	O
was	O
at	O
home	O
listed	O
as	O
a	O
status	O
2	O
awaiting	O
cardiac	O
transplantation	O
.	O
On	O
[	O
**	O
2106-7-4	O
**	O
]	O
the	O
patient	O
had	O
new	O
onset	O
chest	O
pain	O
and	O
was	O
admitted	O
to	O
the	O
hospital	O
where	O
he	O
ruled	O
in	O
for	O
myocardial	O
infarction	O
.	O
PAST	O
MEDICAL	O
HISTORY	O
:	O
1	O
.	O
Type	O
1	O
diabetes	O
.	O
2	O
.	O
Known	O
coronary	O
artery	O
disease	O
status	O
post	O
multiple	O
cardiac	O
catheterizations	O
.	O
He	O
is	O
status	O
post	O
automatic	O
implantable	O
cardioverter	O
-	O
defibrillator	O
placement	O
.	O
He	O
has	O
ischemic	O
cardiomyopathy	O
.	O
3	O
.	O
Hypothyroidism	O
.	O
MEDICATIONS	O
ON	O
ADMISSION	O
:	O
1	O
.	O
Coreg	I-Drug
25	O
mg	O
p.o.	O
q.d.	O
2	O
.	O
Toprol	I-Drug
25	O
mg	O
p.o.	O
q.d.	O
3	O
.	O
Plavix	I-Drug
75	O
mg	O
p.o.	O
q.d.	O
4	O
.	O
Aspirin	I-Drug
325	O
mg	O
p.o.	O
q.d.	O
5	O
.	O
Aldactone	I-Drug
12	O
mg	O
p.o.	O
q.d.	O
6	O
.	O
Synthroid	I-Drug
0.125	O
p.o.	O
q.d.	O
7	O
.	O
Lantus	B-Drug
insulin	I-Drug
25	O
q.d.	O
8	O
.	O
Humalog	I-Drug
sliding	O
scale	O
subcutaneous	O
insulin	I-Drug
coverage	O
.	O
ALLERGIES	O
:	O
ACE	B-Drug
inhibitor	I-Drug
cause	O
a	O
cough	I-Ade
.	O
HOSPITAL	O
COURSE	O
:	O
The	O
patient	O
was	O
taken	O
to	O
the	O
cardiac	O
catheterization	O
laboratory	O
where	O
he	O
was	O
found	O
to	O
have	O
significant	O
multivessel	O
coronary	O
artery	O
disease	O
including	O
a	O
30	O
%	O
left	O
main	O
and	O
99	O
%	O
left	O
anterior	O
descending	O
coronary	O
artery	O
,	O
totally	O
occluded	O
left	O
circumflex	O
and	O
totally	O
occluded	O
right	O
coronary	O
.	O
His	O
left	O
ventricular	O
ejection	O
fraction	O
was	O
estimated	O
at	O
13	O
%	O
at	O
cardiac	O
catheterization	O
.	O
The	O
patient	O
was	O
then	O
referred	O
to	O
the	O
cardiothoracic	O
surgery	O
service	O
for	O
assessment	O
for	O
coronary	O
artery	O
bypass	O
grafting	O
.	O
The	O
patient	O
subsequently	O
preoperatively	O
was	O
managed	O
on	O
the	O
cardiology	O
service	O
approximately	O
[	O
**	O
2106-7-8	O
**	O
]	O
,	O
was	O
noted	O
to	O
have	O
a	O
dropping	O
hematocrit	O
and	O
was	O
sent	O
for	O
an	O
urgent	O
CT	O
scan	O
of	O
his	O
abdomen	O
and	O
pelvis	O
to	O
rule	O
out	O
a	O
source	O
of	O
hematocrit	O
drop	O
.	O
He	O
was	O
found	O
to	O
have	O
no	O
intra-abdominal	O
nor	O
retroperitoneal	O
hematoma	O
at	O
that	O
time	O
however	O
it	O
was	O
noted	O
that	O
he	O
had	O
a	O
pericardial	O
effusion	O
.	O
The	O
patient	O
also	O
on	O
[	O
**	O
2106-7-8	O
**	O
]	O
underwent	O
a	O
myocardial	O
viability	O
study	O
which	O
showed	O
diffuse	O
uptake	O
consistent	O
with	O
diffuse	O
viability	O
of	O
left	O
ventricular	O
wall	O
.	O
The	O
patient	O
remained	O
on	O
the	O
cardiology	O
service	O
and	O
was	O
taken	O
to	O
the	O
operating	O
room	O
on	O
[	O
**	O
2106-7-12	O
**	O
]	O
where	O
he	O
underwent	O
coronary	O
artery	O
bypass	O
grafting	O
x	O
4	O
by	O
Dr.	O
[	O
**	O
First	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
**	O
]	O
.	O
He	O
had	O
a	O
LIMA	O
to	O
the	O
LAD	O
,	O
saphenous	O
vein	O
to	O
the	O
RPL	O
,	O
saphenous	O
vein	O
to	O
the	O
D1	O
,	O
to	O
the	O
OM	O
.	O
The	O
patient	O
had	O
a	O
preoperative	O
intra-aortic	O
balloon	O
pump	O
placed	O
at	O
the	O
beginning	O
of	O
the	O
case	O
prophylactically	O
due	O
to	O
his	O
poor	O
ejection	O
fraction	O
.	O
The	O
patient	O
did	O
wean	O
from	O
cardiopulmonary	O
bypass	O
and	O
his	O
chest	O
was	O
being	O
closed	O
when	O
he	O
was	O
noted	O
to	O
have	O
significant	O
problems	O
with	O
hypotension	O
.	O
At	O
that	O
time	O
it	O
was	O
felt	O
appropriate	O
to	O
place	O
him	O
on	O
a	O
left	O
ventricular	O
assist	O
device	O
.	O
He	O
was	O
also	O
placed	O
on	O
vasopressin	I-Drug
,	O
epinephrine	I-Drug
,	O
Levophed	I-Drug
,	O
and	O
milrinone	I-Drug
drips	O
.	O
With	O
the	O
support	O
of	O
the	O
left	O
ventricular	O
assist	O
device	O
and	O
the	O
pressors	I-Drug
and	O
inotropic	B-Drug
agents	I-Drug
the	O
patient	O
was	O
successfully	O
transported	O
from	O
the	O
operating	O
room	O
to	O
the	O
cardiac	B-Reason
surgery	I-Reason
recovery	O
unit	O
in	O
the	O
evening	O
of	O
[	O
**	O
2106-7-12	O
**	O
]	O
where	O
he	O
proceeded	O
to	O
wake	O
up	O
from	O
general	B-Drug
anesthesia	I-Drug
.	O
He	O
required	O
some	O
fluid	O
resuscitation	O
with	O
blood	B-Drug
products	I-Drug
over	O
the	O
course	O
of	O
the	O
first	O
few	O
postoperative	O
hours	O
and	O
remained	O
relatively	O
stable	O
on	O
the	O
support	O
.	O
On	O
physical	O
examination	O
at	O
this	O
time	O
,	O
neurologically	O
the	O
patient	O
is	O
sedated	I-Reason
on	O
propofol	I-Drug
but	O
is	O
easily	O
awoken	O
,	O
follows	O
commands	O
,	O
nods	O
his	O
head	O
appropriately	O
and	O
moves	O
all	O
extremities	O
.	O
From	O
a	O
cardiac	O
standpoint	O
the	O
patient	O
has	O
a	O
blood	O
pressure	O
from	O
90	O
to	O
110s	O
systolic	O
with	O
a	O
mean	O
arterial	O
pressure	O
of	O
65	O
to	O
70	O
,	O
presently	O
on	O
vasopressin	I-Drug
,	O
epinephrine	I-Drug
,	O
Levophed	I-Drug
and	O
milrinone	I-Drug
drips	O
.	O
He	O
is	O
on	O
an	O
left	O
ventricular	O
assist	O
device	O
,	O
Abiomed	O
BVAD	O
5000	O
I	O
,	O
with	O
liter	O
flows	O
between	O
5	O
and	O
5.6	O
liters	O
per	O
minute	O
.	O
His	O
thermodilution	O
cardiac	O
output	O
has	O
also	O
been	O
in	O
the	O
5	O
to	O
6	O
liter	O
per	O
minute	O
range	O
with	O
an	O
SvO2	O
of	O
approximately	O
70	O
%	O
.	O
The	O
patient	O
's	O
lungs	O
are	O
rhonchorous	O
.	O
The	O
patient	O
has	O
adequate	O
oxygenation	O
at	O
this	O
time	O
.	O
His	O
abdomen	O
is	O
soft	O
,	O
nontender	O
.	O
His	O
extremities	O
are	O
warm	O
with	O
minimal	O
edema	O
and	O
he	O
has	O
positive	O
Doppler	O
signals	O
in	O
both	O
of	O
his	O
feet	O
.	O
Immediately	O
postoperatively	O
the	O
patient	O
's	O
intra-aortic	O
balloon	O
pump	O
was	O
removed	O
at	O
the	O
bedside	O
.	O
Manual	O
pressure	O
was	O
held	O
for	O
35	O
minutes	O
.	O
The	O
groin	O
looks	O
good	O
without	O
signs	O
of	O
bleeding	O
or	O
hematoma	O
and	O
the	O
pulse	O
remains	O
audible	O
by	O
Doppler	O
in	O
his	O
balloon	O
foot	O
,	O
which	O
is	O
the	O
right	O
.	O
CURRENT	O
MEDICATIONS	O
:	O
1	O
.	O
IV	O
vasopressin	I-Drug
drip	O
at	O
0.8	O
units	O
per	O
minute	O
.	O
2	O
.	O
Epinephrine	I-Drug
0.025	O
mcg	O
per	O
kg	O
per	O
minute	O
.	O
3	O
.	O
Levophed	I-Drug
0.02	O
mcg	O
per	O
kg	O
per	O
minute	O
.	O
4	O
.	O
Milrinone	I-Drug
0.5	O
mcg	O
per	O
kg	O
per	O
minute	O
.	O
5	O
.	O
Propofol	I-Drug
30	O
.	O
6	O
.	O
Vancomycin	I-Drug
1	O
gram	O
q.	O
12	O
hours	O
.	O
7	O
.	O
Carafate	I-Drug
1	O
gram	O
q.	O
6	O
hours	O
.	O
8	O
.	O
Aspirin	I-Drug
325	O
mg	O
q.d.	O
9	O
.	O
Ranitidine	I-Drug
150	O
mg	O
b.i.d.	O
10	O
.	O
Insulin	I-Drug
drip	O
at	O
29	O
units	O
per	O
hour	O
,	O
maintaining	B-Reason
a	I-Reason
blood	I-Reason
sugar	I-Reason
in	I-Reason
the	I-Reason
120	I-Reason
-	I-Reason
140	I-Reason
range	O
at	O
this	O
time	O
.	O
MOST	O
RECENT	O
LABORATORY	O
DATA	O
:	O
White	O
blood	O
cell	O
count	O
10.4	O
,	O
hematocrit	O
30.6	O
,	O
platelet	O
count	O
167	O
.	O
Sodium	O
138	O
,	O
potassium	O
3.7	O
,	O
chloride	O
103	O
,	O
CO2	O
17	O
,	O
BUN	O
16	O
,	O
creatinine	O
0.9	O
,	O
glucose	O
131	O
.	O
His	O
most	O
recent	O
prothrombin	O
time	O
is	O
15.1	O
with	O
an	O
INR	O
of	O
1.5	O
,	O
PTT	O
is	O
42.6	O
.	O
Blood	O
gas	O
from	O
this	O
morning	O
is	O
pH	O
7.42	O
,	O
PaCO2	O
32	O
,	O
PaO2	O
116	O
,	O
bicarbonate	O
21	O
,	O
base	O
deficit	O
-2	O
.	O
Initially	O
postoperatively	O
the	O
patient	O
had	O
a	O
significant	O
metabolic	B-Reason
acidosis	I-Reason
which	O
resolved	O
with	O
a	O
total	O
of	O
[	O
**	O
3	O
-	O
1	O
**	O
]	O
amps	O
of	O
bicarbonate	I-Drug
over	O
the	O
course	O
of	O
the	O
night	O
,	O
blood	O
products	O
and	O
fluid	O
resuscitation	O
.	O
DISCHARGE	O
DIAGNOSES	O
:	O
Ischemic	O
cardiomyopathy	O
with	O
left	O
ventricular	O
assist	O
device	O
placement	O
status	O
post	O
coronary	O
artery	O
bypass	O
grafting	O
x	O
4	O
.	O
CONDITION	O
:	O
His	O
condition	O
remains	O
critical	O
.	O
DISPOSITION	O
:	O
He	O
is	O
being	O
transported	O
to	O
the	O
[	O
**	O
Hospital	O
8503	O
**	O
]	O
under	O
the	O
care	O
of	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
36737	O
**	O
]	O
for	O
assessment	O
for	O
heart	O
transplant	O
as	O
well	O
as	O
possible	O
HeartMate	O
left	O
ventricular	O
assist	O
device	O
placement	O
in	O
the	O
next	O
few	O
days	O
.	O
[	O
**	O
Doctor	O
Last	O
Name	O
412	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Prefixes	O
)	O
413	O
**	O
]	O
,	O
M.D.	O
[	O
**	O
MD	O
Number	O
(	O
1	O
)	O
414	O
**	O
]	O
Dictated	O
By	O
:[	O
**	O
Name8	O
(	O
MD	O
)	O
964	O
**	O
]	O
MEDQUIST36	O
D	O
:	O
[	O
**	O
2106-7-13	O
**	O
]	O
09:36	O
T	O
:	O
[	O
**	O
2106-7-13	O
**	O
]	O
10:06	O
JOB	O
#	O
:	O
[	O
**	O
Job	O
Number	O
36738	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2145-3-27	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2145-4-12	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2106-12-1	O
**	O
]	O
Sex	O
:	O
M	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Penicillins	I-Drug
/	O
Keflex	I-Drug
/	O
Ciprofloxacin	I-Drug
/	O
Sulfa	I-Drug
(	O
Sulfonamides	O
)	O
/	O
Clarithromycin	I-Drug
/	O
Demerol	I-Drug
/	O
Red	O
Dye	O
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
689	O
**	O
]	O
Chief	O
Complaint	O
:	O
fevers	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
None	O
History	O
of	O
Present	O
Illness	O
:	O
Mr.	O
[	O
**	O
Known	O
lastname	O
1968	O
**	O
]	O
is	O
a	O
38	O
year	O
old	O
male	O
with	O
history	O
of	O
cerebral	O
palsy	O
who	O
lives	O
at	O
home	O
with	O
his	O
parents	O
.	O
Yesterday	O
the	O
patient	O
developed	O
a	O
constellation	O
of	O
symptoms	O
including	O
increased	O
agitation	O
,	O
cough	O
,	O
nausea	O
/	O
vomiting	O
and	O
headache	O
.	O
He	O
has	O
not	O
been	O
experiencing	O
diarrhea	O
.	O
The	O
patient	O
is	O
at	O
baseline	O
non-communicative	O
but	O
is	O
reportedly	O
able	O
to	O
communicate	O
through	O
translation	O
with	O
his	O
mother	O
with	O
gesturing	O
of	O
his	O
eyes	O
.	O
He	O
will	O
look	O
upward	O
to	O
answer	O
yes	O
.	O
Given	O
the	O
patient	O
's	O
symptoms	O
his	O
temperature	O
was	O
taken	O
with	O
reported	O
Tmax	O
of	O
102	O
.	O
The	O
patient	O
's	O
mother	O
reports	O
that	O
a	O
number	O
of	O
family	O
members	O
have	O
recently	O
had	O
a	O
viral	O
syndrome	O
including	O
fever	O
and	O
cough	O
.	O
The	O
patient	O
has	O
not	O
been	O
noted	O
during	O
this	O
time	O
to	O
have	O
any	O
seizures	O
.	O
Given	O
concern	O
,	O
the	O
patient	O
was	O
brought	O
to	O
the	O
ED	O
for	O
further	O
evaluation	O
.	O
ED	O
COURSE	O
:	O
Vitals	O
:	O
T	O
-	O
99.5	O
(	O
102.7	O
highest	O
documented	O
)	O
.	O
128/100	O
,	O
114	O
,	O
22	O
,	O
96	O
%	O
on	O
2L	O
(	O
room	O
air	O
not	O
documented	O
)	O
In	O
the	O
ED	O
the	O
patient	O
had	O
a	O
UA	O
which	O
was	O
negative	O
for	O
UTI	O
and	O
a	O
CXR	O
which	O
did	O
not	O
reveal	O
pneumonia	O
.	O
The	O
patient	O
received	O
1gm	O
Vancomycin	I-Drug
,	O
2g	O
Aztreonam	I-Drug
,	O
500	O
mg	O
Flagyl	I-Drug
with	O
plan	O
for	O
potential	O
intubation	O
and	O
LP	O
if	O
ID	O
eval	O
negative	O
.	O
A	O
CT	O
Abd	O
/	O
Pelvis	O
was	O
obtained	O
which	O
revealed	O
no	O
intraabdominal	O
infection	O
but	O
evidence	O
of	O
bibasilar	O
infiltrates	O
concerning	O
for	O
organizing	O
pneumonia	O
.	O
Diazepam	I-Drug
,	O
Phenobarb	I-Drug
,	O
Tylenol	I-Drug
and	O
Ondansetron	I-Drug
.	O
He	O
received	O
3L	O
NS	I-Drug
prior	O
to	O
transfer	O
.	O
Past	O
Medical	O
History	O
:	O
#	O
.	O
Cerebral	O
Palsy	O
-	O
wheelchair	O
bound	O
at	O
baseline	O
#	O
.	O
Seizure	O
Disorder	O
#	O
.	O
Ulcerative	O
Colitis	O
#	O
.	O
History	O
of	O
Aspiration	O
Pneumonia	O
#	O
.	O
GERD	O
#	O
.	O
s	O
/	O
p	O
feeding	O
tube	O
placement	O
Social	O
History	O
:	O
The	O
patient	O
currently	O
lives	O
at	O
home	O
with	O
his	O
parents	O
who	O
provide	O
his	O
care	O
.	O
He	O
is	O
at	O
baseline	O
wheelchair	O
bound	O
,	O
dependent	O
on	O
family	O
for	O
all	O
ADL	O
.	O
He	O
received	O
his	O
care	O
previously	O
at	O
[	O
**	O
Hospital3	O
1810	O
**	O
]	O
but	O
currently	O
transitioning	O
to	O
adult	O
medicine	O
.	O
Receives	O
nutrition	O
predominantly	O
through	O
G	O
-	O
tube	O
but	O
is	O
allowed	O
minimal	O
solid	O
PO	O
intake	O
,	O
no	O
liquids	O
.	O
Personal	O
care	O
assistant	O
at	O
home	O
100	O
hours	O
a	O
week	O
,	O
patient	O
's	O
mother	O
with	O
him	O
24	O
-	O
7	O
,	O
very	O
involved	O
in	O
his	O
care	O
.	O
Tobacco	O
:	O
None	O
ETOH	O
:	O
None	O
Illicits	O
:	O
None	O
Family	O
History	O
:	O
NC	O
Physical	O
Exam	O
:	O
Vitals	O
:	O
T	O
-	O
100.8	O
BP	O
-	O
104/60	O
HR	O
-	O
116	O
RR	O
-	O
24	O
O2	I-Drug
-	O
86	O
%	O
RA	O
95	O
%	O
4L	O
.	O
General	O
:	O
Patient	O
is	O
a	O
young	O
male	O
,	O
non-communicative	O
,	O
moderately	O
agitated	O
with	O
many	O
gutteral	O
upper	O
airway	O
sounds	O
.	O
HEENT	O
:	O
NCAT	O
,	O
PEERL	O
.	O
Sclera	O
anicteric	O
,	O
conjunctiva	O
WNL	O
.	O
Per	O
interviewed	O
with	O
mother	O
,	O
patient	O
reports	O
headache	O
but	O
denies	O
neck	O
pain	O
with	O
forced	O
flexion	O
Skin	O
:	O
No	O
petechiae	O
,	O
no	O
rashes	O
OP	O
:	O
Limited	O
exam	O
secondary	O
to	O
participation	O
.	O
+	O
Dental	O
work	O
,	O
mucous	O
membranes	O
relatively	O
moist	O
appearing	O
Chest	O
:	O
Course	O
transmitted	O
upper	O
airway	O
sounds	O
on	O
expiration	O
,	O
few	O
crackles	O
appreciated	O
at	O
left	O
base	O
as	O
well	O
Cor	O
:	O
Limited	O
by	O
loud	O
pulmonary	O
sounds	O
,	O
regular	O
,	O
no	O
obvious	O
murmurs	O
,	O
rubs	O
,	O
gallops	O
Abd	O
:	O
+	O
G	O
-	O
tube	O
,	O
surrounding	O
skin	O
appears	O
intact	O
without	O
erythema	O
or	O
induration	O
.	O
Mildly	O
distended	O
,	O
no	O
guarding	O
with	O
exam	O
.	O
No	O
pain	O
on	O
exam	O
per	O
mother	O
's	O
report	O
Back	O
:	O
Small	O
scar	O
over	O
sacrum	O
s	O
/	O
p	O
mole	O
removal	O
,	O
no	O
sacral	O
decubitus	O
ulcers	O
Ext	O
:	O
Hands	O
and	O
legs	O
contracted	O
.	O
No	O
cyanosis	O
,	O
no	O
edema	O
Neuro	O
:	O
Limited	O
secondary	O
to	O
cooperation	O
CNII	O
-	O
XII	O
:	O
Appears	O
symmetric	O
,	O
tracks	O
in	O
all	O
directions	O
Motor	O
:	O
Moves	O
all	O
limbs	O
relativley	O
equally	O
Pertinent	O
Results	O
:	O
WBC	O
8.7	O
(	O
N	O
:	O
88	O
Band	O
:	O
4	O
L	O
:	O
5	O
M	O
:	O
2	O
E	O
:	O
0	O
Bas	O
:	O
0	O
Atyps	O
:	O
1	O
)	O
Hct	O
:	O
40.2	O
Phenobarb	O
:	O
16.3	O
[	O
**	O
Doctor	O
First	O
Name	O
**	O
]	O
:	O
63	O
Lip	O
:	O
17	O
Alk	O
Phos	O
:	O
176	O
(	O
181	O
[	O
**	O
2143-11-3	O
**	O
]	O
)	O
LDH	O
:	O
261	O
Tb	O
:	O
0.5	O
Alb	O
:	O
4.9	O
Cr	O
:	O
1.0	O
.	O
Microbiology	O
:	O
UA	O
:	O
Leuk	O
Neg	O
,	O
Nitr	O
Neg	O
,	O
Trace	O
Ket	O
Ucx	O
:	O
Pending	O
.	O
Blood	O
Cultures	O
x	O
2	O
:	O
Pending	O
.	O
.	O
Imaging	O
:	O
.	O
[	O
**	O
2145-3-27	O
**	O
]	O
:	O
Portable	O
CXR	O
IMPRESSION	O
:	O
No	O
acute	O
cardiopulmonary	O
abnormality	O
.	O
[	O
**	O
2145-3-27	O
**	O
]	O
:	O
Portable	O
Abdomen	O
IMPRESSION	O
:	O
No	O
evidence	O
of	O
obstruction	O
.	O
[	O
**	O
2145-3-27	O
**	O
]	O
:	O
CT	O
Abd	O
/	O
Pelvis	O
:	O
Wet	O
read	O
-	O
Bibasilar	O
aveolar	O
infiltrates	O
likely	O
indicate	O
pneumonia	O
,	O
possibly	O
aspiration	O
pneumonia	O
.	O
Brief	O
Hospital	O
Course	O
:	O
38	O
year	O
old	O
male	O
with	O
history	O
of	O
cerebral	O
palsy	O
,	O
ulcerative	O
colitis	O
,	O
previous	O
aspiration	O
pneumonias	O
,	O
here	O
with	O
influenza	O
,	O
aspiration	O
pneumonia	O
,	O
and	O
antibiotic	O
-	O
associated	O
diarrhea	O
.	O
***	O
FOLLOWUP	O
:	O
1	O
.	O
Cdiff	O
toxin	O
B	O
pending	O
.	O
Cdiff	O
x2	O
negative	O
on	O
stool	O
culture	O
.	O
Was	O
treated	O
with	O
10	O
day	O
course	O
of	O
Flagyl	I-Drug
IV	O
during	O
admission	O
,	O
and	O
diarrhea	I-Reason
did	O
not	O
change	O
in	O
frequency	O
or	O
quantity	O
.	O
#	O
Influenza	O
/	O
aspiration	O
pneumonia	O
:	O
The	O
patient	O
presented	O
with	O
nausea	O
and	O
vomiting	O
from	O
influenza	O
,	O
and	O
likely	O
aspirated	O
during	O
this	O
admission	O
in	O
this	O
setting	O
.	O
On	O
[	O
**	O
3	O
-	O
28	O
**	O
]	O
,	O
he	O
had	O
an	O
aspiration	O
event	O
and	O
hypoxemia	O
,	O
and	O
CXR	O
showed	O
LLL	O
infiltrate	O
from	O
aspiration	B-Reason
pneumonia	I-Reason
.	O
He	O
was	O
treated	O
with	O
Clindamycin	I-Drug
and	O
Levofloxacin	I-Drug
,	O
but	O
he	O
developed	O
diarrhea	I-Ade
.	O
The	O
patient	O
has	O
a	O
history	O
of	O
colitis	I-Ade
with	O
Ciprofloxacin	I-Drug
in	O
the	O
past	O
per	O
his	O
mother	O
,	O
and	O
Levofloxacin	I-Drug
was	O
stopped	O
on	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
,	O
and	O
Azithromycin	I-Drug
was	O
started	O
.	O
On	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
,	O
the	O
patient	O
developed	O
stridor	O
and	O
worsening	O
O2	O
saturation	O
to	O
the	O
low	O
80s	O
with	O
minimal	O
improvement	O
on	O
NRB	O
.	O
Although	O
ENT	O
found	O
no	O
airway	O
edema	O
,	O
obstruction	O
or	O
tracheomalacia	O
,	O
the	O
patient	O
's	O
respiratory	O
status	O
continued	O
to	O
worsen	O
and	O
he	O
was	O
transferred	O
to	O
the	O
MICU	O
and	O
intubated	O
.	O
He	O
remained	O
intubated	O
for	O
two	O
days	O
,	O
on	O
aztreonam	I-Drug
and	O
vancomycin	I-Drug
(	O
both	O
started	O
[	O
**	O
4	O
-	O
1	O
**	O
]	O
)	O
.	O
His	O
weaning	O
was	O
complicated	O
by	O
agitation	O
and	O
tachycardia	O
,	O
which	O
improved	O
as	O
lines	O
/	O
tubes	O
were	O
minimized	O
.	O
He	O
was	O
extubated	O
successfully	O
2	O
days	O
prior	O
to	O
transfer	O
to	O
the	O
floor	O
.	O
#	O
Diarrhea	O
:	O
On	O
[	O
**	O
3	O
-	O
31	O
**	O
]	O
,	O
the	O
patient	O
spiked	O
a	O
new	O
fever	O
and	O
developed	O
antibiotic	I-Drug
-	O
associated	O
diarrhea	I-Ade
.	O
His	O
diarrhea	I-Reason
continued	O
,	O
despite	O
being	O
maintained	O
on	O
flagyl	I-Drug
x	O
6	O
days	O
and	O
cdiff	O
negative	O
x	O
2	O
.	O
Cdiff	O
toxin	O
B	O
was	O
still	O
pending	O
on	O
the	O
day	O
of	O
discharge	O
.	O
#	O
Dystonic	B-Ade
reaction	I-Ade
to	O
Haldol	I-Drug
:	O
When	O
he	O
arrived	O
to	O
the	O
floor	O
after	O
being	O
in	O
the	O
MICU	O
,	O
he	O
developed	O
dystonia	O
and	O
partially	O
fixing	O
of	O
his	O
head	O
turned	O
to	O
the	O
left	O
side	O
,	O
tongue	O
thrusting	O
movements	O
,	O
toe	O
curling	O
,	O
arm	O
and	O
wrist	O
bending	O
.	O
He	O
had	O
been	O
given	O
haldol	I-Drug
2.5	O
IV	O
daily	O
because	O
he	O
had	O
been	O
very	O
agitated	I-Reason
in	O
the	O
MICU	O
.	O
When	O
he	O
clinically	O
improved	O
,	O
his	O
signs	O
did	O
not	O
change	O
.	O
He	O
responded	O
well	O
to	O
Benadryl	I-Drug
50	O
IV	O
and	O
Ativan	I-Drug
1	O
IV	O
TID	O
prn	O
,	O
with	O
relief	O
of	O
dystonia	I-Reason
within	O
minutes	O
.	O
Benztropine	I-Drug
was	O
never	O
given	O
because	O
of	O
concern	O
of	O
exacerbating	O
sinus	O
tachycardia	O
with	O
HR	O
100	O
-	O
105	O
due	O
to	O
infection	O
.	O
#	O
Sinus	O
tachycardia	O
:	O
His	O
baseline	O
HR	O
is	O
80s	O
per	O
his	O
mother	O
,	O
who	O
is	O
very	O
involved	O
in	O
his	O
care	O
.	O
His	O
HR	O
was	O
consistently	O
100	O
-	O
105	O
during	O
admission	O
,	O
despite	O
fluid	O
repletion	O
and	O
running	O
of	O
tube	O
feeds	O
and	O
water	O
flushes	O
at	O
home	O
rate	O
for	O
3	O
days	O
before	O
discharge	O
.	O
His	O
HR	O
should	O
be	O
rechecked	O
as	O
an	O
outpatient	O
,	O
discussed	O
with	O
his	O
mother	O
.	O
His	O
mother	O
stated	O
that	O
she	O
was	O
cancelling	O
the	O
patient	O
's	O
appointment	O
with	O
GI	O
tomorrow	O
because	O
the	O
patient	O
greatly	O
wanted	O
to	O
be	O
home	O
and	O
away	O
from	O
hospitals	O
,	O
but	O
she	O
lives	O
near	O
a	O
pediatrician	O
friend	O
who	O
agreed	O
to	O
check	O
the	O
patient	O
's	O
vitals	O
at	O
his	O
house	O
this	O
week	O
.	O
VNA	O
was	O
offered	O
to	O
the	O
patient	O
's	O
mother	O
and	O
family	O
,	O
but	O
they	O
agreed	O
to	O
have	O
the	O
pediatrician	O
see	O
the	O
patient	O
in	O
3	O
days	O
after	O
discharge	O
.	O
#	O
Seizure	B-Reason
Disorder	I-Reason
:	O
The	O
patient	O
was	O
continued	O
on	O
Phenobarbital	I-Drug
,	O
level	O
was	O
therapeutic	O
during	O
admission	O
.	O
#	O
Cerebral	O
Palsy	O
:	O
The	O
patient	O
was	O
continued	O
on	O
Valium	I-Drug
QHS	O
for	O
spasms	I-Reason
.	O
#	O
Ulcerative	B-Reason
Colitis	I-Reason
:	O
He	O
was	O
continued	O
on	O
Asacol	I-Drug
per	O
outpatient	O
regimen	O
.	O
#	O
GERD	I-Reason
:	O
He	O
was	O
continued	O
on	O
home	O
regimen	O
of	O
PPI	I-Drug
and	O
H2	B-Drug
-	I-Drug
Blocker	I-Drug
.	O
Medications	O
on	O
Admission	O
:	O
Famotidine	I-Drug
20	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Glycolax	I-Drug
1	O
cap	O
daily	O
Asacol	I-Drug
1200	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
Celexa	I-Drug
20	O
mg	O
daily	O
Prevacid	I-Drug
30	O
mg	O
daily	O
Phenobarbital	I-Drug
96.12	O
mg	O
(	O
3	O
x	O
32.4	O
)	O
qhs	O
Diazepam	I-Drug
6	O
mg	O
qhs	O
Discharge	O
Medications	O
:	O
1	O
.	O
Famotidine	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
Q12H	O
(	O
every	O
12	O
hours	O
)	O
.	O
2	O
.	O
Citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Phenobarbital	I-Drug
30	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
.	O
4	O
.	O
Prevacid	I-Drug
30	O
mg	O
Susp	O
,	O
Delayed	O
Release	O
for	O
Recon	O
Sig	O
:	O
One	O
(	O
1	O
)	O
tablet	O
PO	O
once	O
a	O
day	O
.	O
5	O
.	O
Diazepam	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
QHS	O
(	O
once	O
a	O
day	O
(	O
at	O
bedtime	O
)	O
)	O
.	O
6	O
.	O
Mesalamine	I-Drug
400	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
180	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
7	O
.	O
GlycoLax	I-Drug
17	O
gram	O
(	O
100	O
%	O
)	O
Powder	O
in	O
Packet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
caplet	O
PO	O
once	O
a	O
day	O
as	O
needed	O
for	O
constipation	I-Reason
.	O
Discharge	O
Disposition	O
:	O
Home	O
Discharge	O
Diagnosis	O
:	O
Primary	O
diagnosis	O
:	O
Pneumonia	O
,	O
antibiotic	O
-	O
associated	O
diarrhea	O
Secondary	O
diagnosis	O
:	O
Cerebral	O
palsy	O
Discharge	O
Condition	O
:	O
HR	O
95	O
-	O
105	O
,	O
tube	O
feeds	O
at	O
home	O
rate	O
,	O
smiling	O
,	O
communicating	O
that	O
he	O
feels	O
better	O
.	O
Discharge	O
Instructions	O
:	O
Please	O
return	O
to	O
the	O
emergency	O
room	O
if	O
you	O
experience	O
increased	O
shortness	O
of	O
breath	O
,	O
cough	O
,	O
diarrhea	O
,	O
fever	O
,	O
other	O
concerning	O
symptoms	O
.	O
Please	O
keep	O
all	O
appointments	O
with	O
your	O
physicians	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
Provider	O
:	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
6925	O
**	O
]	O
Phone	O
:[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
463	O
**	O
]	O
Date	O
/	O
Time	O
:[	O
**	O
2145-4-13	O
**	O
]	O
1:00	O
2	O
.	O
Dr.	O
[	O
**	O
First	O
Name8	O
(	O
NamePattern2	O
)	O
333	O
**	O
]	O
[	O
**	O
Known	O
lastname	O
1968	O
**	O
]	O
,	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
3329	O
**	O
]	O
,	O
primary	O
care	O
.	O
Since	O
Dr.	O
[	O
**	O
Known	O
lastname	O
1968	O
**	O
]	O
is	O
out	O
for	O
the	O
next	O
few	O
months	O
,	O
please	O
followup	O
with	O
the	O
primary	O
care	O
physician	O
covering	O
for	O
Dr.	O
[	O
**	O
Known	O
lastname	O
1968	O
**	O
]	O
per	O
our	O
conversation	O
.	O
Completed	O
by	O
:[	O
**	O
2145-4-12	O
**	O
]	O

Name	O
:	O
[	O
**	O
Known	O
lastname	O
17394	O
**	O
]	O
,	O
[	O
**	O
Known	O
firstname	O
**	O
]	O
/	O
SISTER	O
Unit	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
:	O
[	O
**	O
Numeric	O
Identifier	O
17395	O
**	O
]	O
Admission	O
Date	O
:	O
[	O
**	O
2111-1-17	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2111-1-27	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2030-2-21	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Sulfa	B-Drug
(	I-Drug
Sulfonamides	I-Drug
)	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
1513	O
**	O
]	O
Addendum	O
:	O
Re	O
:	O
Medication	O
changes	O
made	O
prior	O
to	O
discharge	O
Brief	O
Hospital	O
Course	O
:	O
#	O
A.fib	I-Reason
-	O
Here	O
digoxin	I-Drug
level	O
continued	O
to	O
trend	O
down	O
.	O
On	O
discharge	O
,	O
digoxin	I-Drug
level	O
was	O
1.3	O
however	O
we	O
elected	O
not	O
to	O
restart	O
given	O
her	O
recent	O
toxicity	O
and	O
development	O
of	O
nausea	I-Ade
/	O
retching	I-Ade
.	O
For	O
now	O
we	O
will	O
continue	O
with	O
beta	B-Drug
blocker	I-Drug
for	O
rate	B-Reason
control	I-Reason
.	O
The	O
metoprolol	I-Drug
will	O
be	O
swicthed	O
to	O
Toprol	I-Drug
XL	O
.	O
#	O
CHF	I-Reason
-	O
Added	O
imdur	I-Drug
30	O
mg	O
qday	O
given	O
BP	O
's	O
still	O
in	O
the	O
140	O
-	O
160	O
range	O
.	O
Also	O
will	O
change	O
metoprolol	I-Drug
50	O
mg	O
tid	O
to	O
Toprol	I-Drug
XL	O
150	O
mg	O
qday	O
.	O
#	O
[	O
**	O
Name	O
(	O
NI	O
)	O
16357	O
**	O
]	O
Pt	O
has	O
been	O
on	O
lipitor	I-Drug
prior	O
to	O
admission	O
.	O
Her	O
AST	B-Ade
/	I-Ade
ALT	I-Ade
were	O
mildy	O
elevated	O
at	O
50/56	O
.	O
These	O
should	O
be	O
recheck	O
as	O
an	O
outpatient	O
.	O
For	O
now	O
continued	O
her	O
lipitor	I-Drug
.	O
Discharge	O
Medications	O
:	O
1	O
.	O
Atorvastatin	I-Drug
Calcium	O
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
Aspirin	B-Drug
81	O
mg	O
Tablet	O
,	O
Chewable	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Chewable	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
Pantoprazole	I-Drug
Sodium	O
40	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
Q24H	O
(	O
every	O
24	O
hours	O
)	O
.	O
4	O
.	O
Docusate	I-Drug
Sodium	O
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
60	O
Capsule	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
5	O
.	O
Senna	I-Drug
8.6	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
6	O
.	O
Bisacodyl	I-Drug
5	O
mg	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
DAILY	O
(	O
Daily	O
)	O
as	O
needed	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
5	O
*	O
7	O
.	O
Aluminum	B-Drug
-	I-Drug
Magnesium	I-Drug
Hydroxide	I-Drug
225	O
-	O
200	O
mg	O
/	O
5	O
mL	O
Suspension	O
Sig	O
:	O
15	O
-	O
30	O
MLs	O
PO	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
.	O
8	O
.	O
Spironolactone	I-Drug
25	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
9	O
.	O
Lisinopril	B-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
10	O
.	O
Bumetanide	I-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
Two	O
(	O
2	O
)	O
Tablet	O
PO	O
QAM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
morning	O
)	O
)	O
.	O
11	O
.	O
Bumetanide	B-Drug
2	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
QPM	O
(	O
once	O
a	O
day	O
(	O
in	O
the	O
evening	O
)	O
)	O
.	O
12	O
.	O
Zolpidem	B-Drug
Tartrate	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
insomnia	I-Reason
.	O
13	O
.	O
Imdur	I-Drug
30	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
once	O
a	O
day	O
.	O
Disp	O
:	O
*	O
30	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
(	O
s	O
)	O
*	O
Refills	O
:	O
*	O
2	O
*	O
14	O
.	O
Toprol	I-Drug
XL	O
50	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
Sustained	O
Release	O
24	O
HR	O
PO	O
once	O
a	O
day	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital6	O
3465	O
**	O
]	O
-	O
[	O
**	O
Location	O
(	O
un	O
)	O
824	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
Left	O
Frontal	O
Lobe	O
Contusion	O
CHF	O
CAD	O
Hyperlipidemia	O
A.fib	O
Discharge	O
Condition	O
:	O
Stable	O
,	O
no	O
SOB	O
,	O
ambulating	O
without	O
dyspnea	O
,	O
no	O
neuro	O
deficits	O
Discharge	O
Instructions	O
:	O
Please	O
take	O
all	O
medications	O
as	O
instructed	O
.	O
Please	O
do	O
not	O
restart	O
your	O
digoxin	I-Drug
and	O
follow	O
up	O
with	O
your	O
doctors	O
regarding	O
controlling	B-Reason
your	I-Reason
heart	I-Reason
rate	I-Reason
with	O
other	O
medications	O
.	O
Do	O
not	O
start	O
taking	O
your	O
coumadin	I-Drug
until	O
told	O
to	O
do	O
so	O
by	O
your	O
doctors	O
,	O
this	O
should	O
be	O
restarted	O
about	O
[	O
**	O
2111-2-8	O
**	O
]	O
but	O
check	O
with	O
your	O
doctors	O
[	O
**	O
First	O
Name	O
(	O
Titles	O
)	O
17396	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
Titles	O
)	O
17397	O
**	O
]	O
.	O
If	O
you	O
experience	O
any	O
chest	O
pain	O
,	O
shortness	O
of	O
breath	O
,	O
lower	O
extremity	O
swelling	O
,	O
weight	O
gain	O
,	O
lightheadedness	O
you	O
should	O
seek	O
medical	O
attention	O
.	O
Followup	O
Instructions	O
:	O
1	O
.	O
Follow	O
-	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
[	O
**	O
1	O
-	O
11	O
**	O
]	O
wks	O
.	O
Call	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
8659	O
**	O
]	O
for	O
an	O
appointment	O
.	O
Please	O
inform	O
the	O
office	O
that	O
you	O
need	O
a	O
Head	O
CT	O
scan	O
prior	O
to	O
your	O
appointment	O
.	O
2	O
.	O
Follow	O
-	O
up	O
with	O
your	O
outpatient	O
ophthalmologist	O
in	O
4	O
wks	O
.	O
3	O
.	O
Follow	O
-	O
up	O
with	O
your	O
primary	O
care	O
physician	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
**	O
]	O
.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
to	O
evaluate	O
a	O
L	O
thyroid	O
calcification	O
noted	O
on	O
the	O
CT	O
scan	O
.	O
Also	O
you	O
need	O
to	O
follow	O
up	O
with	O
Dr.	O
[	O
**	O
Last	O
Name	O
(	O
STitle	O
)	O
**	O
]	O
in	O
regards	O
to	O
your	O
heart	O
failure	O
and	O
atrial	O
fibrillation	O
.	O
It	O
has	O
been	O
recommended	O
that	O
your	O
coumadin	I-Drug
be	O
held	O
for	O
3	O
weeks	O
until	O
[	O
**	O
2	O
-	O
8	O
**	O
]	O
.	O
Also	O
need	O
to	O
have	O
your	O
LFTs	O
closely	O
followed	O
given	O
mild	O
elevation	O
and	O
patient	O
on	O
lipitor	I-Drug
.	O
4	O
.	O
You	O
should	O
follow	O
up	O
with	O
your	O
cardiologist	O
about	O
CHF	O
and	O
a.fib	O
management	O
.	O
[	O
**	O
First	O
Name11	O
(	O
Name	O
Pattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern4	O
)	O
1514	O
**	O
]	O
MD	O
[	O
**	O
MD	O
Number	O
(	O
2	O
)	O
1515	O
**	O
]	O
Completed	O
by	O
:[	O
**	O
2111-1-27	O
**	O
]	O

Admission	O
Date	O
:	O
[	O
**	O
2123-1-12	O
**	O
]	O
Discharge	O
Date	O
:	O
[	O
**	O
2123-1-19	O
**	O
]	O
Date	O
of	O
Birth	O
:	O
[	O
**	O
2047-9-27	O
**	O
]	O
Sex	O
:	O
F	O
Service	O
:	O
MEDICINE	O
Allergies	O
:	O
Tape	O
[	O
**	O
12	O
-	O
14	O
**	O
]	O
"	O
X10YD	O
/	O
Morphine	I-Drug
Attending	O
:[	O
**	O
First	O
Name3	O
(	O
LF	O
)	O
2387	O
**	O
]	O
Chief	O
Complaint	O
:	O
Shortness	O
of	O
breath	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure	O
:	O
-	O
Cardiac	O
catheterization	O
[	O
**	O
2123-1-14	O
**	O
]	O
History	O
of	O
Present	O
Illness	O
:	O
75	O
F	O
with	O
CAD	O
s	O
/	O
p	O
to	O
stent	O
to	O
RCA	O
[	O
**	O
2116	O
**	O
]	O
,	O
COPD	O
recently	O
started	O
on	O
home	O
oxygen	O
,	O
HTN	O
,	O
PVD	O
who	O
inititally	O
presented	O
to	O
[	O
**	O
Hospital	O
1474	O
**	O
]	O
Hospital	O
after	O
for	O
ongoing	O
SOB	O
since	O
the	O
beginning	O
of	O
[	O
**	O
Month	O
(	O
only	O
)	O
404	O
**	O
]	O
.	O
Pt	O
states	O
that	O
since	O
early	O
[	O
**	O
Month	O
(	O
only	O
)	O
404	O
**	O
]	O
,	O
she	O
has	O
been	O
experiencing	O
worsening	O
shortness	O
of	O
breath	O
that	O
has	O
occurred	O
on	O
exercise	O
&	O
at	O
rest	O
.	O
She	O
has	O
been	O
unable	O
to	O
sleep	O
or	O
tolerate	O
recumbency	O
.	O
She	O
has	O
had	O
an	O
ongoing	O
cough	O
productive	O
of	O
clear	O
-	O
white	O
sputum	O
without	O
hemoptysis	O
.	O
She	O
experienced	O
one	O
episode	O
of	O
chest	O
thightness	O
/	O
sharp	O
chest	O
pain	O
roughly	O
3	O
weeks	O
ago	O
.	O
This	O
pain	O
was	O
non-radiation	O
;	O
it	O
was	O
not	O
associated	O
with	O
diaphoresis	O
,	O
nausea	O
,	O
vomiting	O
.	O
.	O
She	O
was	O
seen	O
by	O
her	O
PCP	O
and	O
started	O
on	O
inhalers	O
for	O
concern	O
regarding	O
possible	O
URI	O
.	O
On	O
Monday	O
,	O
she	O
was	O
started	O
on	O
azithromycin	I-Drug
yesterday	O
as	O
well	O
as	O
home	O
oxygen	I-Drug
with	O
a	O
plan	O
to	O
increase	O
her	O
prednisone	I-Drug
.	O
.	O
Early	O
on	O
the	O
morning	O
of	O
admission	O
,	O
she	O
had	O
worsening	O
SOB	O
/	O
DOE	O
so	O
she	O
called	O
911	O
&	O
was	O
brought	O
to	O
[	O
**	O
Hospital	O
1474	O
**	O
]	O
Hospital	O
.	O
There	O
was	O
iniital	O
concern	O
for	O
a	O
COPD	B-Reason
exacerbation	I-Reason
;	O
she	O
was	O
given	O
250	O
mg	O
azithro	I-Drug
,	O
1	O
gm	O
cftx	I-Drug
,	O
albuterol	B-Drug
/	I-Drug
ipratropium	I-Drug
nebs	O
,	O
IV	O
solumedrol	I-Drug
125	O
mg	O
IV	O
.	O
CXR	O
showed	O
bilateral	O
effusions	O
.	O
CTA	O
was	O
negative	O
for	O
PE	O
.	O
.	O
Pt	O
ruled	O
in	O
for	O
NSTEMI	I-Reason
(	O
trop	O
2.76	O
-	O
>	O
4.02	O
)	O
.	O
She	O
was	O
given	O
325	O
mg	O
ASA	I-Drug
,	O
plavix	I-Drug
75	O
mg	O
,	O
&	O
she	O
was	O
started	O
on	O
heparin	I-Drug
gtt	O
.	O
She	O
was	O
also	O
given	O
40	O
mg	O
IV	O
lasix	I-Drug
and	O
subsequently	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
possible	O
cath	O
.	O
.	O
REVIEW	O
OF	O
SYSTEMS	O
:	O
As	O
per	O
HPI	O
.	O
No	O
headache	O
,	O
dizziness	O
,	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
constipation	O
,	O
melena	O
,	O
hematochezia	O
,	O
dysuria	O
,	O
myalgias	O
,	O
or	O
arthralgias	O
.	O
No	O
history	O
of	O
stroke	O
,	O
TIA	O
,	O
deep	O
venous	O
thrombosis	O
,	O
pulmonary	O
embolism	O
,	O
bleeding	O
at	O
the	O
time	O
of	O
surgery	O
.	O
No	O
recent	O
fevers	O
,	O
chills	O
or	O
rigors	O
.	O
All	O
of	O
the	O
other	O
review	O
of	O
systems	O
were	O
negative	O
.	O
.	O
Cardiac	O
review	O
of	O
systems	O
is	O
notable	O
for	O
absence	O
of	O
chest	O
pain	O
,	O
PND	O
,	O
ankle	O
edema	O
,	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
.	O
Past	O
Medical	O
History	O
:	O
-	O
Hypertension	O
-	O
CAD	O
s	O
/	O
p	O
RCA	O
stenting	O
in	O
[	O
**	O
2117-9-12	O
**	O
]	O
-	O
COPD	O
/	O
emphysema	O
-	O
PVD	O
/	O
LE	O
claudication	O
---	O
>	O
Fem	O
-	O
fem	O
bypass	O
graft	O
---	O
>	O
Left	O
fem	O
-	O
SFA	O
profunda	O
bypass	O
-	O
Carotid	O
artery	O
disease	O
-	O
Prior	O
head	O
trauma	O
---	O
>	O
Fractured	O
skull	O
at	O
age	O
14	O
months	O
after	O
falling	O
out	O
of	O
a	O
second	O
story	O
window	O
---	O
>	O
Age	O
9	O
:	O
hit	O
in	O
the	O
head	O
with	O
an	O
axe	O
by	O
brother	O
-	O
History	O
of	O
fainting	O
spells	O
since	O
childhood	O
-	O
Seizure	O
disorder	O
diagnosed	O
in	O
[	O
**	O
2112	O
**	O
]	O
-	O
last	O
seizure	O
[	O
**	O
12/2120	O
**	O
]	O
-	O
Rheumatoid	O
arthritis	O
on	O
chronic	O
steroids	O
-	O
Osteopenia	O
-	O
Glaucoma	O
-	O
Macular	O
degeneration	O
-	O
Cataract	O
surgery	O
,	O
left	O
eye	O
-	O
Raynaud	O
's	O
phenomenon	O
-	O
s	O
/	O
p	O
cholecystectomy	O
-	O
s	O
/	O
p	O
Appendectomy	O
-	O
Pernicious	O
anemia	O
-	O
Vit	O
B	O
12	O
injections	O
monthly	O
-	O
Diverticulosis	O
Social	O
History	O
:	O
-	O
Lives	O
with	O
daughter	O
.	O
-	O
Previous	O
40	O
-	O
50	O
year	O
smoking	O
history	O
;	O
quit	O
[	O
**	O
2109	O
**	O
]	O
.	O
-	O
No	O
EtOH	O
or	O
illicits	O
.	O
Family	O
History	O
:	O
No	O
family	O
history	O
of	O
early	O
MI	O
,	O
arrhythmias	O
,	O
cardiomyopathies	O
,	O
or	O
sudden	O
cardiac	O
death	O
.	O
Mother	O
had	O
angina	O
.	O
Physical	O
Exam	O
:	O
ADMISSION	O
PHYSICAL	O
EXAM	O
:	O
VS	O
:	O
T	O
=	O
95.6	O
BP	O
=	O
135/69	O
HR	O
=	O
105	O
RR	O
=	O
18	O
O2	O
sat	O
=	O
95	O
%	O
RA	O
GENERAL	O
:	O
thin	O
elderly	O
female	O
,	O
resting	O
comfortably	O
but	O
fatigued	O
appearing	O
,	O
NAD	O
HEENT	O
:	O
NCAT	O
.	O
Sclera	O
anicteric	O
.	O
Pupils	O
equal	O
,	O
EOMI	O
.	O
Conjunctiva	O
were	O
pink	O
,	O
no	O
pallor	O
or	O
cyanosis	O
of	O
the	O
oral	O
mucosa	O
.	O
No	O
xanthalesma	O
.	O
Slightly	O
dry	O
mucous	O
membranes	O
/	O
NECK	O
:	O
Supple	O
with	O
JVD	O
to	O
mandible	O
.	O
CARDIAC	O
:	O
RRR	O
,	O
normal	O
S1	O
,	O
S2	O
.	O
No	O
m	O
/	O
r	O
/	O
g.	O
Distant	O
heart	O
sounds	O
.	O
LUNGS	O
:	O
Resp	O
were	O
unlabored	O
,	O
no	O
accessory	O
muscle	O
use	O
.	O
Decreased	O
breath	O
sounds	O
with	O
bibasilar	O
crackles	O
,	O
no	O
wheezing	O
or	O
rhonchi	O
.	O
ABDOMEN	O
:	O
Bowel	O
sounds	O
present	O
,	O
soft	O
,	O
non-tender	O
,	O
non-distended	O
,	O
no	O
organomegaly	O
,	O
no	O
guarding	O
or	O
rebound	O
tenderness	O
.	O
EXTREMITIES	O
:	O
Warm	O
,	O
DPs	O
2	O
+	O
bilaterally	O
,	O
no	O
edema	O
SKIN	O
:	O
No	O
stasis	O
dermatitis	O
or	O
other	O
rashes	O
.	O
NEURO	O
:	O
AAOx3	O
,	O
CN	O
2	O
-	O
12	O
grossly	O
intact	O
,	O
strength	O
5/5	O
throughout	O
,	O
sensation	O
grossly	O
intact	O
to	O
light	O
touch	O
PSYCH	O
:	O
Calm	O
,	O
appropriate	O
DISCHARGE	O
PHYSICAL	O
EXAM	O
:	O
Tm	O
:	O
98.5	O
100	O
(	O
70	O
-	O
100	O
)	O
97/50	O
(	O
80-120/40	O
-	O
80	O
)	O
18	O
98	O
/	O
2L	O
24	O
I	O
/	O
O	O
:	O
1170/1100	O
GEN	O
:	O
Appears	O
frail	O
.	O
HEENT	O
:	O
NCAT	O
.	O
NECK	O
:	O
No	O
JVD	O
COR	O
:	O
+	O
S1S2	O
,	O
RRR	O
,	O
no	O
m	O
/	O
g	O
/	O
r.	O
PULM	O
:	O
Crackles	O
at	O
bases	O
,	O
do	O
not	O
clear	O
with	O
cough	O
.	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
**	O
]	O
:	O
+	O
NABS	O
in	O
4Q	O
.	O
Soft	O
,	O
NTND	O
.	O
EXT	O
:	O
WWP	O
,	O
no	O
leg	O
edema	O
.	O
R	O
groin	O
with	O
hematoma	O
stable	O
.	O
NEURO	O
:	O
MAEE	O
,	O
weak	O
.	O
Pertinent	O
Results	O
:	O
ADMISSION	O
LABS	O
&	O
STUDIES	O
:	O
[	O
**	O
2123-1-13	O
**	O
]	O
06:55	O
AM	O
BLOOD	O
PT	O
-	O
13.2	O
*	O
PTT	O
-	O
VERIFIED	O
B	O
INR	O
(	O
PT	O
)	O
-	O
1.2	O
*	O
[	O
**	O
2123-1-13	O
**	O
]	O
06:55	O
AM	O
BLOOD	O
WBC	O
-	O
9.4	O
RBC	O
-	O
3.95	O
*	O
Hgb	O
-	O
11.8	O
*	O
Hct	O
-	O
33.9	O
*	O
MCV	O
-	O
86	O
MCH	O
-	O
29.9	O
MCHC	O
-	O
34.8	O
RDW	O
-	O
14.2	O
Plt	O
Ct	O
-	O
290	O
[	O
**	O
2123-1-13	O
**	O
]	O
06:55	O
AM	O
BLOOD	O
Glucose	O
-	O
100	O
UreaN	O
-	O
23	O
*	O
Creat	O
-	O
1.3	O
*	O
Na	O
-	O
140	O
K	O
-	O
3.6	O
Cl	O
-	O
100	O
HCO3	O
-	O
26	O
AnGap	O
-	O
18	O
[	O
**	O
2123-1-13	O
**	O
]	O
12:34	O
AM	O
BLOOD	O
CK	O
-	O
MB	O
-	O
9	O
cTropnT	O
-	O
0.33	O
*	O
[	O
**	O
2123-1-13	O
**	O
]	O
06:55	O
AM	O
BLOOD	O
Calcium	O
-	O
8.8	O
Phos	O
-	O
5.8	O
*	O
#	O
Mg	O
-	O
2.1	O
CXR	O
(	O
[	O
**	O
2123-1-14	O
**	O
]	O
)	O
:	O
FINDINGS	O
:	O
Comparison	O
is	O
made	O
with	O
the	O
most	O
recent	O
study	O
at	O
this	O
institution	O
of	O
[	O
**	O
2118-6-16	O
**	O
]	O
.	O
The	O
cardiac	O
silhouette	O
remains	O
somewhat	O
enlarged	O
and	O
there	O
is	O
increased	O
opacification	O
at	O
the	O
bases	O
consistent	O
with	O
small	O
pleural	O
effusions	O
and	O
associated	O
compressive	O
atelectasis	O
.	O
There	O
is	O
engorgement	O
of	O
ill	O
-	O
defined	O
pulmonary	O
vessels	O
,	O
consistent	O
with	O
elevated	O
pulmonary	O
venous	O
pressure	O
,	O
as	O
suggested	O
in	O
the	O
clinical	O
history	O
CT	O
ABDOMEN	O
&	O
PELVIS	O
(	O
[	O
**	O
2123-1-14	O
**	O
]	O
)	O
:	O
IMPRESSION	O
:	O
1	O
.	O
Left	O
groin	O
hematoma	O
,	O
deep	O
to	O
the	O
left	O
common	O
femoral	O
artery	O
.	O
There	O
is	O
mild	O
stranding	O
surrounding	O
the	O
right	O
common	O
femoral	O
artery	O
,	O
though	O
no	O
evidence	O
of	O
hematoma	O
.	O
2	O
.	O
Diverticulosis	O
.	O
3	O
.	O
New	O
bilateral	O
pleural	O
effusions	O
and	O
smooth	O
intralobular	O
septal	O
thickening	O
,	O
likely	O
indicating	O
volume	O
overload	O
.	O
4	O
.	O
Extensive	O
atherosclerosis	O
.	O
5	O
.	O
Calcified	O
granulomata	O
in	O
the	O
liver	O
and	O
spleen	O
.	O
DISCHARGE	O
LABS	O
&	O
STUDIES	O
:	O
[	O
**	O
2123-1-19	O
**	O
]	O
08:55	O
AM	O
BLOOD	O
Glucose	O
-	O
104	O
*	O
UreaN	O
-	O
25	O
*	O
Creat	O
-	O
1.1	O
Na	O
-	O
139	O
K	O
-	O
4.2	O
Cl	O
-	O
100	O
HCO3	O
-	O
28	O
AnGap	O
-	O
15	O
[	O
**	O
2123-1-18	O
**	O
]	O
07:05	O
AM	O
BLOOD	O
proBNP	O
-	O
9710	O
*	O
[	O
**	O
2123-1-19	O
**	O
]	O
08:55	O
AM	O
BLOOD	O
WBC	O
-	O
8.0	O
RBC	O
-	O
3.28	O
*	O
Hgb	O
-	O
9.9	O
*	O
Hct	O
-	O
29.1	O
*	O
MCV	O
-	O
89	O
MCH	O
-	O
30.2	O
MCHC	O
-	O
34.0	O
RDW	O
-	O
14.4	O
Plt	O
Ct	O
-	O
291	O
TTE	O
(	O
[	O
**	O
2123-1-13	O
**	O
]	O
)	O
:	O
The	O
left	O
atrium	O
is	O
mildly	O
dilated	O
.	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
depressed	O
(	O
LVEF	O
=	O
25	O
-	O
30	O
%	O
)	O
secondary	O
to	O
akinesis	O
of	O
the	O
entire	O
septum	O
and	O
apex	O
,	O
and	O
moderate	O
global	O
hypokinesis	O
of	O
the	O
remaining	O
segments	O
.	O
The	O
basal	O
-	O
mid	O
lateral	O
wall	O
contracts	O
best	O
.	O
Right	O
ventricular	O
chamber	O
size	O
is	O
normal	O
.	O
with	O
focal	O
hypokinesis	O
of	O
the	O
apical	O
free	O
wall	O
.	O
The	O
aortic	O
valve	O
leaflets	O
(	O
3	O
)	O
appear	O
structurally	O
normal	O
with	O
good	O
leaflet	O
excursion	O
and	O
no	O
aortic	O
stenosis	O
.	O
Mild	O
(	O
1	O
+	O
)	O
aortic	O
regurgitation	O
is	O
seen	O
.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
.	O
Moderate	O
(	O
2	O
+	O
)	O
mitral	O
regurgitation	O
is	O
seen	O
.	O
The	O
left	O
ventricular	O
inflow	O
pattern	O
suggests	O
a	O
restrictive	O
filling	O
abnormality	O
,	O
with	O
elevated	O
left	O
atrial	O
pressure	O
.	O
Moderate	O
[	O
2	O
+	O
]	O
tricuspid	O
regurgitation	O
is	O
seen	O
.	O
There	O
is	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
There	O
is	O
a	O
trivial	O
/	O
physiologic	O
pericardial	O
effusion	O
.	O
IMPRESSION	O
:	O
Severe	O
global	O
left	O
ventricular	O
systolic	O
dysfunction	O
c	O
/	O
w	O
multivessel	O
CAD	O
.	O
Moderate	O
mitral	O
and	O
tricuspid	O
regurgitation	O
with	O
moderate	O
pulmonary	O
artery	O
systolic	O
hypertension	O
.	O
Brief	O
Hospital	O
Course	O
:	O
REASON	O
FOR	O
HOSPITALIZATION	O
:	O
75	O
F	O
w	O
CAD	O
s	O
/	O
p	O
RCA	O
stent	O
[	O
**	O
2116	O
**	O
]	O
,	O
COPD	O
,	O
RA	O
,	O
seizure	O
disorder	O
,	O
HTN	O
,	O
PVD	O
,	O
p	O
/	O
w	O
several	O
weeks	O
of	O
worsening	O
SOB	O
.	O
Ruled	O
in	O
for	O
STEMI	O
at	O
OSH	O
&	O
subsequently	O
transferred	O
to	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
for	O
cath	O
.	O
ACUTE	O
DIAGNOSES	O
:	O
#	O
NSTEMI	I-Reason
:	O
Found	O
to	O
have	O
peak	O
troponin	O
to	O
2.76	O
at	O
OSH	O
with	O
T	O
wave	O
changes	O
in	O
V2	O
-	O
V5	O
.	O
Transferred	O
on	O
heparin	I-Drug
gtt	O
.	O
Pt	O
was	O
continued	O
on	O
metoprolol	I-Drug
,	O
statin	I-Drug
,	O
ASA	I-Drug
.	O
Loaded	O
with	O
plavix	I-Drug
prior	O
to	O
cath	O
on	O
[	O
**	O
2123-1-14	O
**	O
]	O
which	O
showed	O
minimal	O
in	O
-	O
stent	O
restenosis	O
of	O
RCA	O
stent	O
,	O
as	O
well	O
as	O
a	O
tight	O
ostial	O
LAD	O
on	O
which	O
PCI	O
could	O
not	O
be	O
performed	O
(	O
too	O
difficult	O
)	O
.	O
Pt	O
had	O
radial	O
access	O
for	O
arterial	O
cath	O
;	O
venous	O
access	O
in	O
groin	O
difficult	O
to	O
obtain	O
.	O
Patient	O
hypotensive	O
during	O
case	O
,	O
requiring	O
dopamine	I-Drug
gtt	O
temporarily	O
(	O
now	O
off	O
pressors	O
)	O
.	O
Afterward	O
,	O
patient	O
developed	O
rapidly	O
expanding	O
left	O
groin	O
hematoma	O
.	O
She	O
was	O
given	O
protamine	I-Drug
.	O
Hematoma	O
now	O
stable	O
,	O
hematocrit	O
29	O
on	O
discharge	O
(	O
stable	O
for	O
days	O
)	O
.	O
Patient	O
also	O
dyspnea	I-Reason
,	O
requiring	O
O2	I-Drug
4L	O
per	O
NC	O
,	O
and	O
appears	O
somewhat	O
volume	O
overloaded	O
.	O
Patient	O
admitted	O
to	O
CCU	O
for	O
diuresis	O
and	O
observation	O
overnight	O
.	O
B	O
/	O
L	O
LE	O
US	O
were	O
negative	O
for	O
hematoma	O
,	O
non-contrast	O
CT	O
abdomen	O
and	O
pelvis	O
were	O
negative	O
for	O
RP	O
bleed	O
.	O
In	O
the	O
CCU	O
,	O
patient	O
was	O
continued	O
on	O
ASA	I-Drug
325	O
mg	O
PO	O
,	O
Atorvastatin	I-Drug
80	O
mg	O
PO	O
daily	O
,	O
Metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
PO	O
BID	O
,	O
plavix	I-Drug
.	O
Amlodipine	I-Drug
was	O
discontinued	O
and	O
lisinopril	I-Drug
was	O
held	O
due	O
to	O
hypotension	I-Ade
/	O
low	I-Ade
urine	O
output	O
.	O
On	O
the	O
floor	O
,	O
patient	O
started	O
on	O
diovan	I-Drug
40	O
mg	O
,	O
which	O
should	O
be	O
held	O
if	O
her	O
blood	O
pressure	O
is	O
less	O
than	O
100	O
.	O
Discharged	O
on	O
full	O
ASA	I-Drug
,	O
plavix	I-Drug
,	O
metoprolol	B-Drug
succinate	I-Drug
100	O
mg	O
QD	O
.	O
#	O
LEFT	B-Reason
GROIN	I-Reason
HEMATOMA	I-Reason
:	O
Developed	O
apparent	O
right	O
groin	O
hematoma	O
which	O
was	O
treated	O
with	O
protamine	I-Drug
.	O
CT	O
[	O
**	O
Last	O
Name	O
(	O
un	O
)	O
103	O
**	O
]	O
showed	O
pt	O
actually	O
had	O
left	O
groin	O
hematoma	O
,	O
none	O
on	O
right	O
.	O
No	O
pseudoaneurysm	O
/	O
RP	O
bleed	O
.	O
Hematoma	O
and	O
hematocrit	O
remained	O
stable	O
throughout	O
CCU	O
&	O
floor	O
course	O
.	O
DPs	O
dopplerable	O
BL	O
.	O
Patient	O
was	O
maintained	O
on	O
pneumoboots	O
instead	O
of	O
heparin	I-Drug
sq	O
prophylaxis	I-Reason
.	O
#	O
Acute	O
on	O
Chronic	O
Systolic	O
CHF	O
:	O
CXR	O
showed	O
pulmonary	O
engorgement	O
&	O
bilateral	O
effusions	O
with	O
compressive	O
atelectasis	O
.	O
Pt	O
was	O
given	O
IV	O
lasix	I-Drug
prior	O
to	O
going	O
to	O
the	O
cath	O
lab	O
.	O
A	O
TTE	O
was	O
performed	O
that	O
showed	O
severe	O
global	O
hypokinesis	O
&	O
akinesis	O
of	O
entire	O
septum	O
&	O
apex	O
.	O
LVEF	O
25	O
-	O
30	O
%	O
.	O
Prior	O
ECHO	O
shows	O
EF	O
40	O
-	O
45	O
%	O
in	O
[	O
**	O
2116	O
**	O
]	O
.	O
During	O
catheterization	O
,	O
pt	O
was	O
hypotensive	I-Reason
&	O
required	O
dopamine	I-Drug
gtt	O
.	O
She	O
was	O
transferred	O
to	O
the	O
CCU	O
for	O
transient	I-Reason
hypotension	O
requiring	O
dopamine	I-Drug
in	O
the	O
catheterization	O
lab	O
.	O
Ms.	O
[	O
**	O
Known	O
lastname	O
13143	O
**	O
]	O
was	O
normotensive	O
on	O
the	O
floor	O
.	O
Diovan	I-Drug
was	O
started	O
on	O
the	O
floor	O
as	O
above	O
.	O
Lasix	I-Drug
will	O
not	O
be	O
reinitiated	O
on	O
discharge	O
.	O
CHRONIC	O
DIAGNOSES	O
:	O
#	O
COPD	I-Reason
/	O
Emphysema	I-Reason
:	O
Pt	O
was	O
continued	O
on	O
her	O
course	O
of	O
azithromycin	I-Drug
.	O
There	O
was	O
no	O
concern	O
for	O
acute	O
exacerbatin	O
given	O
good	O
air	O
movement	O
&	O
lack	O
of	O
wheeze	O
.	O
#	O
PVD	I-Reason
:	O
continued	O
on	O
aspirin	I-Drug
&	O
plavix	I-Drug
.	O
#	O
Seizure	B-Reason
disorder	I-Reason
:	O
Last	O
seizure	O
was	O
on	O
[	O
**	O
2120	O
**	O
]	O
.	O
He	O
was	O
continued	O
on	O
home	O
keppra	I-Drug
1500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
,	O
but	O
pharmacy	O
recommended	O
switching	O
her	O
dose	O
based	O
on	O
her	O
renal	O
function	O
.	O
The	O
recommended	O
dose	O
(	O
based	O
on	O
creatinine	O
clearance	O
)	O
is	O
750	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
.	O
This	O
was	O
explained	O
to	O
the	O
patient	O
as	O
she	O
was	O
nervous	O
about	O
the	O
change	O
in	O
dose	O
.	O
#	O
Rheumatoid	B-Reason
arthritis	I-Reason
:	O
He	O
was	O
continued	O
on	O
prednisone	I-Drug
5	O
mg	O
PO	O
daily	O
.	O
Her	O
celebrex	I-Drug
was	O
held	O
due	O
to	O
NSTEMI	O
.	O
#	O
Osteopenia	I-Reason
:	O
He	O
was	O
continued	O
on	O
calcium	I-Drug
,	O
vitamin	B-Drug
D.	O
TRANSITIONAL	O
ISSUES	O
:	O
#	O
Follow	O
-	O
Up	O
:	O
Upon	O
leaving	O
rehab	O
,	O
the	O
patient	O
should	O
schedule	O
follow	O
up	O
appointments	O
with	O
her	O
cardiologist	O
(	O
Dr.	O
[	O
**	O
First	O
Name4	O
(	O
NamePattern1	O
)	O
**	O
]	O
[	O
**	O
Last	O
Name	O
(	O
NamePattern1	O
)	O
**	O
]	O
)	O
and	O
her	O
primary	O
care	O
doctor	O
.	O
#	O
Code	O
Status	O
:	O
DNR	O
/	O
DNI	O
.	O
Daughter	O
is	O
HCP	O
:	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Name	O
(	O
NI	O
)	O
**	O
]	O
[	O
**	O
Telephone	O
/	O
Fax	O
(	O
1	O
)	O
28220	O
**	O
]	O
Medications	O
on	O
Admission	O
:	O
Aspirin	I-Drug
81	O
mg	O
daily	O
Celebrex	I-Drug
100	O
mg	O
daily	O
Simvastatin	I-Drug
20	O
mg	O
nightly	O
Prednisone	I-Drug
5	O
mg	O
daily	O
Metoprolol	I-Drug
25	O
mg	O
daily	O
Omeprazole	I-Drug
20	O
mg	O
daily	O
Amlodipine	I-Drug
5	O
mg	O
daily	O
Vitamin	B-Drug
D	I-Drug
400	O
units	O
daily	O
Calcium	B-Drug
carbonate	I-Drug
-	O
6	O
tabs	O
daily	O
Keppra	I-Drug
1500	O
mg	O
[	O
**	O
Hospital1	O
**	O
]	O
B12	I-Drug
injection	O
once	O
per	O
month	O
Timolol	I-Drug
0.5	O
%	O
one	O
drop	O
to	O
each	O
eye	O
daily	O
in	O
AM	O
(	O
not	O
recently	O
taking	O
)	O
Brimodidine	I-Drug
0.15	O
%	O
one	O
drop	O
left	O
eye	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
not	O
recently	O
taking	O
)	O
Optive	B-Drug
dry	I-Drug
eye	I-Drug
solution	O
,	O
both	O
eyes	O
TID	O
(	O
not	O
recently	O
taking	O
)	O
Discharge	O
Medications	O
:	O
1	O
.	O
prednisone	I-Drug
5	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
2	O
.	O
clopidogrel	I-Drug
75	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
3	O
.	O
atorvastatin	I-Drug
80	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
4	O
.	O
sodium	B-Drug
chloride	I-Drug
0.65	O
%	O
Aerosol	O
,	O
Spray	O
Sig	O
:	O
[	O
**	O
12	O
-	O
14	O
**	O
]	O
Sprays	O
Nasal	O
QID	O
(	O
4	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
dry	B-Reason
nose	I-Reason
.	O
5	O
.	O
aspirin	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
6	O
.	O
metoprolol	B-Drug
tartrate	I-Drug
50	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
:	O
Please	O
hold	O
for	O
sBP	O
<	O
100	O
or	O
HR	O
<	O
60	O
.	O
7	O
.	O
citalopram	I-Drug
20	O
mg	O
Tablet	O
Sig	O
:	O
0.5	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
8	O
.	O
valsartan	I-Drug
40	O
mg	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
:	O
Please	O
hold	O
for	O
sBP	O
<	O
100	O
.	O
9	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
10	O
.	O
cholecalciferol	I-Drug
(	O
vitamin	O
D3	O
)	O
400	O
unit	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
DAILY	O
(	O
Daily	O
)	O
.	O
11	O
.	O
benzonatate	I-Drug
100	O
mg	O
Capsule	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
PO	O
TID	O
(	O
3	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
cough	I-Reason
for	O
2	O
weeks	O
.	O
12	O
.	O
Cepacol	B-Drug
Sore	I-Drug
Throat	I-Drug
15	O
-	O
2.6	O
mg	O
Lozenge	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Mucous	O
membrane	O
five	O
times	O
a	O
day	O
as	O
needed	O
for	O
sore	B-Reason
throat	I-Reason
for	O
1	O
weeks	O
.	O
13	O
.	O
Tylenol	I-Drug
325	O
mg	O
Tablet	O
Sig	O
:	O
1	O
-	O
2	O
Tablets	O
PO	O
every	O
six	O
(	O
6	O
)	O
hours	O
as	O
needed	O
for	O
pain	I-Reason
.	O
14	O
.	O
omeprazole	I-Drug
20	O
mg	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Capsule	O
,	O
Delayed	O
Release	O
(	O
E.C.	O
)	O
PO	O
once	O
a	O
day	O
.	O
15	O
.	O
calcium	B-Drug
citrate	I-Drug
200	O
mg	O
(	O
950	O
mg	O
)	O
Tablet	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Tablet	O
PO	O
three	O
times	O
a	O
day	O
.	O
16	O
.	O
Medication	O
B12	I-Drug
injections	O
one	O
per	O
month	O
17	O
.	O
timolol	B-Drug
maleate	I-Drug
(	I-Drug
PF	I-Drug
)	I-Drug
0.5	O
%	O
Dropperette	O
Sig	O
:	O
One	O
(	O
1	O
)	O
drop	O
Ophthalmic	O
QAM	O
.	O
18	O
.	O
levetiracetam	I-Drug
250	O
mg	O
Tablet	O
Sig	O
:	O
Three	O
(	O
3	O
)	O
Tablet	O
PO	O
BID	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
19	O
.	O
guaifenesin	I-Drug
100	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
5	O
-	O
10	O
MLs	O
PO	O
Q6H	O
(	O
every	O
6	O
hours	O
)	O
as	O
needed	O
for	O
cough	I-Reason
.	O
20	O
.	O
codeine	B-Drug
-	I-Drug
guaifenesin	I-Drug
10	O
-	O
100	O
mg	O
/	O
5	O
mL	O
Syrup	O
Sig	O
:	O
5	O
-	O
10	O
MLs	O
PO	O
HS	O
(	O
at	O
bedtime	O
)	O
as	O
needed	O
for	O
cough	I-Reason
for	O
1	O
weeks	O
:	O
Do	O
not	O
administer	O
this	O
medication	O
if	O
patient	O
sedated	O
.	O
21	O
.	O
oxymetazoline	I-Drug
0.05	O
%	O
Aerosol	O
,	O
Spray	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Spray	O
Nasal	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
as	O
needed	O
for	O
congestion	I-Reason
for	O
2	O
days	O
.	O
22	O
.	O
fluticasone	B-Drug
-	I-Drug
salmeterol	I-Drug
250	O
-	O
50	O
mcg	O
/	O
dose	O
Disk	O
with	O
Device	O
Sig	O
:	O
One	O
(	O
1	O
)	O
Inhalation	O
Inhalation	O
[	O
**	O
Hospital1	O
**	O
]	O
(	O
2	O
times	O
a	O
day	O
)	O
.	O
Discharge	O
Disposition	O
:	O
Extended	O
Care	O
Facility	O
:	O
[	O
**	O
Hospital	O
27838	O
**	O
]	O
Rehabilitation	O
&	O
[	O
**	O
Hospital	O
**	O
]	O
Care	O
Center	O
-	O
[	O
**	O
Hospital1	O
1474	O
**	O
]	O
Discharge	O
Diagnosis	O
:	O
PRIMARY	O
DIAGNOSIS	O
:	O
-	O
Non-ST	O
Elevation	O
Myocardial	O
Infarction	O
SECONDARY	O
DIAGNOSES	O
:	O
-	O
Congestive	O
Heart	O
Failure	O
-	O
Coronary	O
Artery	O
Disease	O
Discharge	O
Condition	O
:	O
Mental	O
Status	O
:	O
Clear	O
and	O
coherent	O
.	O
Level	O
of	O
Consciousness	O
:	O
Alert	O
and	O
interactive	O
.	O
Activity	O
Status	O
:	O
Ambulatory	O
-	O
requires	O
assistance	O
or	O
aid	O
(	O
walker	O
or	O
cane	O
)	O
.	O
Discharge	O
Instructions	O
:	O
Ms.	O
[	O
**	O
Known	O
lastname	O
13143	O
**	O
]	O
,	O
it	O
was	O
a	O
pleasure	O
to	O
participate	O
in	O
your	O
care	O
while	O
you	O
were	O
at	O
[	O
**	O
Hospital1	O
18	O
**	O
]	O
.	O
You	O
came	O
to	O
the	O
hospital	O
for	O
shortness	O
of	O
breath	O
over	O
hte	O
past	O
month	O
.	O
You	O
were	O
transferred	O
from	O
[	O
**	O
Hospital	O
1474	O
**	O
]	O
Hospital	O
after	O
it	O
was	O
found	O
that	O
you	O
had	O
a	O
small	O
heart	O
attack	O
.	O
While	O
you	O
were	O
here	O
,	O
you	O
had	O
a	O
cardiac	O
catheterization	O
which	O
showed	O
a	O
blockage	O
.	O
We	O
were	O
unable	O
to	O
treat	O
the	O
blockage	O
because	O
your	O
blood	O
pressure	O
was	O
low	O
during	O
the	O
procedure	O
and	O
you	O
need	O
to	O
go	O
to	O
the	O
cardiac	O
intensive	O
care	O
unit	O
.	O
While	O
you	O
were	O
there	O
,	O
you	O
were	O
treated	O
with	O
some	O
intravenous	O
diuretics	I-Drug
.	O
Your	O
urine	O
output	O
temporarily	O
dropped	O
,	O
but	O
by	O
the	O
time	O
you	O
were	O
transferred	O
back	O
to	O
the	O
medical	O
floor	O
,	O
your	O
urine	O
production	O
improved	O
.	O
You	O
had	O
an	O
ultrasound	O
of	O
your	O
heart	O
that	O
showed	O
slight	O
worsening	O
of	O
your	O
heart	O
failure	O
.	O
Weigh	O
yourself	O
every	O
morning	O
,	O
[	O
**	O
Name8	O
(	O
MD	O
)	O
138	O
**	O
]	O
MD	O
if	O
weight	O
goes	O
up	O
more	O
than	O
3	O
lbs	O
.	O
MEDICATION	O
INSTRUCTIONS	O
:	O
-	O
Medications	O
STARTED	O
:	O
---	O
>	O
Please	O
start	O
taking	O
celexa	I-Drug
10	O
mg	O
daily	O
---	O
>	O
Please	O
start	O
taking	O
diovan	I-Drug
40	O
mg	O
daily	O
---	O
>	O
Please	O
start	O
taking	O
atorvastatin	I-Drug
80	O
mg	O
daily	O
---	O
>	O
Please	O
start	O
taking	O
plavix	I-Drug
75	O
mg	O
daily	O
---	O
>	O
Please	O
start	O
taking	O
nasal	O
saline	I-Drug
spray	O
as	O
needed	O
for	O
dry	I-Reason
nose	O
---	O
>	O
Please	O
start	O
taking	O
calcium	B-Drug
citrate	I-Drug
(	O
instead	O
of	O
calcium	I-Drug
carbonate	O
)	O
---	O
>	O
Please	O
start	O
taking	O
your	O
inhaler	O
as	O
indicated	O
-	O
Medications	O
STOPPED	O
:	O
---	O
>	O
Please	O
stop	O
taking	O
lisinopril	I-Drug
---	O
>	O
Please	O
stop	O
taking	O
amlodipine	I-Drug
---	O
>	O
Please	O
stop	O
taking	O
simvastatin	I-Drug
---	O
>	O
Please	O
stop	O
taking	O
calcium	B-Drug
carbonate	I-Drug
-	O
Medications	O
CHANGED	O
:	O
---	O
>	O
Please	O
decrease	O
your	O
dose	O
of	O
Keppra	I-Drug
from	O
1500	O
mg	O
twice	O
a	O
day	O
to	O
750	O
mg	O
twice	O
a	O
day	O
(	O
this	O
medication	O
is	O
now	O
dosed	O
safely	O
according	O
to	O
your	O
kidney	O
function	O
)	O
---	O
>	O
Please	O
increase	O
your	O
dose	O
of	O
aspirin	I-Drug
from	O
81	O
mg	O
to	O
325	O
mg	O
daily	O
---	O
>	O
Please	O
increase	O
your	O
dose	O
of	O
metoprolol	I-Drug
from	O
25	O
mg	O
daily	O
to	O
100	O
mg	O
daily	O
Followup	O
Instructions	O
:	O
After	O
you	O
leave	O
rehab	O
,	O
please	O
call	O
Dr.	O
[	O
**	O
Name	O
(	O
NI	O
)	O
5452	O
**	O
]	O
office	O
to	O
schedule	O
a	O
follow	O
-	O
up	O
appointment	O
.	O

